(lp0
(dp1
S'line'
p2
VOur results demonstrated that hsa-miR-483-5p, hsa-miR-675, hsa-miR-139-3p, hsa-miR-598, hsa-miR-625 and hsa-miR-187 could serve as prognostic and predictive markers for survival of BDC patients and could potentially be provided as targets for future therapy.
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I104
sS'name'
p8
Vhsa-miR-187
p9
sS'lengthInChars'
p10
I11
sS'uniprot'
p11
S''
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I75
sg8
Vhsa-miR-598
p15
sg10
I11
sg11
g12
sg13
I1
sa(dp16
g7
I46
sg8
Vhsa-miR-675
p17
sg10
I11
sg11
g12
sg13
I1
sa(dp18
g7
I30
sg8
Vhsa-miR-483-5p
p19
sg10
I14
sg11
g12
sg13
I1
sa(dp20
g7
I88
sg8
Vhsa-miR-625
p21
sg10
I11
sg11
g12
sg13
I1
sa(dp22
g7
I59
sg8
Vhsa-miR-139-3p
p23
sg10
I14
sg11
g12
sg13
I1
sasS'diseases'
p24
(lp25
(dp26
g7
I30
sg8
Vhsa
p27
sg10
I3
sS'cui'
p28
VC0393754
p29
sg13
I1
sa(dp30
g7
I30
sg8
Vhsa
p31
sg10
I3
sg28
VC0393754
p32
sg13
I1
sa(dp33
g7
I30
sg8
Vhsa
p34
sg10
I3
sg28
VC0393754
p35
sg13
I1
sa(dp36
g7
I181
sg8
VBDC
p37
sg10
I3
sg28
VC1266044
p38
sg13
I1
sa(dp39
g7
I30
sg8
Vhsa
p40
sg10
I3
sg28
VC0393754
p41
sg13
I1
sa(dp42
g7
I30
sg8
Vhsa
p43
sg10
I3
sg28
VC0393754
p44
sg13
I1
sa(dp45
g7
I30
sg8
Vhsa
p46
sg10
I3
sg28
VC0393754
p47
sg13
I1
sasa(dp48
g2
VTargeting the centromeres of chromosomes 3, 7, 17 (CEP3, 7, 17) and the 9p21-locus (LSI9p21) for diagnosing bladder cancer (BC) is time- and cost-intensive and requires a manual investigation of the sample by a well-trained investigator thus overall limiting its use in clinical diagnostics and large-scaled epidemiological studies.
p49
sg4
(lp50
sg24
(lp51
(dp52
g7
I108
sg8
Vbladder cancer
p53
sg10
I14
sg28
VC0699885
p54
sg13
I2
sa(dp55
g7
I124
sg8
VBC
p56
sg10
I2
sg28
VC0699885
p57
sg13
I1
sasa(dp58
g2
VOssification of the ligamentum flavum (OLF) causing compressive cervical myelopathy or radiculopathy is rare.
p59
sg4
(lp60
sg24
(lp61
(dp62
g7
I87
sg8
Vradiculopathy
p63
sg10
I13
sg28
VC0700594
p64
sg13
I1
sa(dp65
g7
I64
sg8
Vcervical myelopathy
p66
sg10
I19
sg28
VC0149645
p67
sg13
I2
sasa(dp68
g2
VHowever, thoracic OLF rarely causes radiculopathy.
p69
sg4
(lp70
sg24
(lp71
(dp72
g7
I36
sg8
Vradiculopathy
p73
sg10
I13
sg28
VC0700594
p74
sg13
I1
sa(dp75
g7
I9
sg8
Vthoracic
p76
sg10
I8
sg28
VC0729233
p77
sg13
I1
sasa(dp78
g2
VWe report a rare case of thoracic radiculopathy caused by OLF.
p79
sg4
(lp80
sg24
(lp81
(dp82
g7
I25
sg8
Vthoracic radiculopathy
p83
sg10
I22
sg28
VC0154737
p84
sg13
I2
sasa(dp85
g2
VThoracic radiculopathy caused by OLF was suspected.
p86
sg4
(lp87
sg24
(lp88
(dp89
g7
I0
sg8
VThoracic radiculopathy
p90
sg10
I22
sg28
VC0154737
p91
sg13
I2
sasa(dp92
g2
VThoracic OLF rarely causes radiculopathy, but it should be considered as a differential diagnosis of thoracic radicular pain.
p93
sg4
(lp94
sg24
(lp95
(dp96
g7
I101
sg8
Vthoracic
p97
sg10
I8
sg28
VC0729233
p98
sg13
I1
sa(dp99
g7
I0
sg8
VThoracic
p100
sg10
I8
sg28
VC0729233
p101
sg13
I1
sa(dp102
g7
I27
sg8
Vradiculopathy
p103
sg10
I13
sg28
VC0700594
p104
sg13
I1
sa(dp105
g7
I110
sg8
Vradicular pain
p106
sg10
I14
sg28
VC0278147
p107
sg13
I2
sasa(dp108
g2
VOLF should be kept in mind if a patient presents with radiculopathy, particularly in the cervical region, for which surgical intervention is contemplated.
p109
sg4
(lp110
(dp111
g7
I0
sg8
VOLF
p112
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp113
(dp114
g7
I54
sg8
Vradiculopathy
p115
sg10
I13
sg28
VC0700594
p116
sg13
I1
sasa(dp117
g2
VRadiculopathy resulting from ossification of the ligamentum flavum (OLF) is extremely rare and concerns only intercostal neuralgias.
p118
sg4
(lp119
sg24
(lp120
(dp121
g7
I121
sg8
Vneuralgias
p122
sg10
I10
sg28
VC0027796
p123
sg13
I1
sa(dp124
g7
I0
sg8
VRadiculopathy
p125
sg10
I13
sg28
VC0700594
p126
sg13
I1
sasa(dp127
g2
VWe describe a 37-year-old Caucasian woman with a lumbar radiculopathy revealing an OLF.
p128
sg4
(lp129
sg24
(lp130
(dp131
g7
I49
sg8
Vlumbar radiculopathy
p132
sg10
I20
sg28
VC1263855
p133
sg13
I2
sasa(dp134
S'labels'
p135
(dp136
(Vcathepsin L
p137
VPancreatitis
p138
tp139
I01
ssg2
VPancreatitis was induced in C57Bl/6 wild-type (control), cathepsin B-knockout, and cathepsin L-knockout mice by partial pancreatic duct ligation with supramaximal caerulein injection, or by repetitive supramaximal caerulein injections alone.
p140
sg4
(lp141
(dp142
g7
I57
sg8
Vcathepsin B
p143
sg10
I11
sg11
VP07858
p144
sg13
I2
sa(dp145
g7
I83
sg8
g137
sg10
I11
sg11
VP07711
p146
sg13
I2
sasg24
(lp147
(dp148
g7
I0
sg8
g138
sg10
I12
sg28
VC0030305
p149
sg13
I1
sasa(dp150
g135
(dp151
(VTrypsinogen
p152
Vpancreatitis
p153
tp154
I00
ssg2
VTrypsinogen became activated in macrophages cultured with purified trypsinogen or co-cultured with pancreatic acini and in pancreata of mice with pancreatitis; trypsinogen activation required macrophage endocytosis and expression and activity of cathepsin B, and was sensitive to pH.
p155
sg4
(lp156
(dp157
g7
I67
sg8
Vtrypsinogen
p158
sg10
I11
sg11
VP07478
p159
sg13
I1
sa(dp160
g7
I246
sg8
Vcathepsin B
p161
sg10
I11
sg11
VP07858
p162
sg13
I2
sa(dp163
g7
I67
sg8
Vtrypsinogen
p164
sg10
I11
sg11
VP07478
p165
sg13
I1
sa(dp166
g7
I0
sg8
g152
sg10
I11
sg11
VP07478
p167
sg13
I1
sasg24
(lp168
(dp169
g7
I146
sg8
g153
sg10
I12
sg28
VC0030305
p170
sg13
I1
sasa(dp171
g135
(dp172
(Vcathepsin B
p173
Vpancreatitis
p174
tp175
I00
ssg2
VActivation of trypsinogen in macrophages resulted in translocation of NF-kB and production of inflammatory cytokines; mice without trypsinogen activation (cathepsin B-knockout mice) in macrophages developed less severe pancreatitis compared with control mice.
p176
sg4
(lp177
(dp178
g7
I131
sg8
Vtrypsinogen activation
p179
sg10
I22
sg11
VP07478
p180
sg13
I2
sa(dp181
g7
I14
sg8
Vtrypsinogen
p182
sg10
I11
sg11
VP07478
p183
sg13
I1
sa(dp184
g7
I155
sg8
g173
sg10
I11
sg11
VP07858
p185
sg13
I2
sasg24
(lp186
(dp187
g7
I53
sg8
Vtranslocation
p188
sg10
I13
sg28
VC0040715
p189
sg13
I1
sa(dp190
g7
I219
sg8
g174
sg10
I12
sg28
VC0030305
p191
sg13
I1
sasa(dp192
g135
(dp193
(Vcathepsin B
p194
Vpancreatitis
p195
tp196
I00
ssg2
VTransfer of macrophage from control mice to cathepsin B-knockout mice increased the severity of pancreatitis.
p197
sg4
(lp198
(dp199
g7
I44
sg8
g194
sg10
I11
sg11
VP07858
p200
sg13
I2
sasg24
(lp201
(dp202
g7
I96
sg8
g195
sg10
I12
sg28
VC0030305
p203
sg13
I1
sasa(dp204
g135
(dp205
(Vtrypsin
p206
Vacute pancreatitis
p207
tp208
I01
ssg2
VExperimental studies in acute pancreatitis (AP) suggest a strong association of acinar cell injury with cathepsin B-dependent intracellular activation of trypsin.
p209
sg4
(lp210
(dp211
g7
I154
sg8
g206
sg10
I7
sg11
VP35030
p212
sg13
I1
sasg24
(lp213
(dp214
g7
I44
sg8
VAP
p215
sg10
I2
sg28
VC0001339
p216
sg13
I1
sa(dp217
g7
I87
sg8
Vcell injury
p218
sg10
I11
sg28
VC0599732
p219
sg13
I2
sa(dp220
g7
I24
sg8
g207
sg10
I18
sg28
VC0001339
p221
sg13
I2
sasa(dp222
g135
(dp223
(Vtrypsin
p224
Vpancreatitis
p225
tp226
I00
ssg2
VPancreas, lung, and serum was harvested up to 48 h after pancreatitis induction and used for histopathology, amylase, lipase, cathepsin B, trypsin, and elastase activity measurements, myeloperoxidase (MPO) content and cytokine concentrations.
p227
sg4
(lp228
(dp229
g7
I126
sg8
Vcathepsin B
p230
sg10
I11
sg11
VP07858
p231
sg13
I2
sa(dp232
g7
I152
sg8
Velastase
p233
sg10
I8
sg11
VP30740
p234
sg13
I1
sa(dp235
g7
I184
sg8
Vmyeloperoxidase
p236
sg10
I15
sg11
VP05164
p237
sg13
I1
sa(dp238
g7
I118
sg8
Vlipase
p239
sg10
I6
sg11
VP04118
p240
sg13
I1
sa(dp241
g7
I201
sg8
VMPO
p242
sg10
I3
sg11
VP05164
p243
sg13
I1
sa(dp244
g7
I109
sg8
Vamylase
p245
sg10
I7
sg11
VP04746
p246
sg13
I1
sa(dp247
g7
I139
sg8
g224
sg10
I7
sg11
VP35030
p248
sg13
I1
sasg24
(lp249
(dp250
g7
I57
sg8
g225
sg10
I12
sg28
VC0030305
p251
sg13
I1
sasa(dp252
g135
(dp253
(VMPO
p254
Vpancreatitis
p255
tp256
I01
ssg2
VIn taurocholate-pancreatitis AZD8309 reduced cathepsin B activity and MPO.
p257
sg4
(lp258
(dp259
g7
I45
sg8
Vcathepsin B
p260
sg10
I11
sg11
VP07858
p261
sg13
I2
sa(dp262
g7
I70
sg8
g254
sg10
I3
sg11
VP05164
p263
sg13
I1
sasg24
(lp264
(dp265
g7
I16
sg8
g255
sg10
I12
sg28
VC0030305
p266
sg13
I1
sasa(dp267
g135
(dp268
(Vtrypsinogen
p269
Vpancreatitis
p270
tp271
I00
ssg2
VThe lysosomal hydrolase cathepsin B (CTSB) is a known activator of trypsinogen, and its deletion reduces disease severity in experimental pancreatitis.
p272
sg4
(lp273
(dp274
g7
I4
sg8
Vlysosomal hydrolase cathepsin B
p275
sg10
I31
sg11
VP07858
p276
sg13
I4
sa(dp277
g7
I37
sg8
VCTSB
p278
sg10
I4
sg11
VP07858
p279
sg13
I1
sa(dp280
g7
I67
sg8
g269
sg10
I11
sg11
VP07478
p281
sg13
I1
sasg24
(lp282
(dp283
g7
I138
sg8
g270
sg10
I12
sg28
VC0030305
p284
sg13
I1
sasa(dp285
g135
(dp286
(Vtrypsinogen
p287
Vpancreatitis
p288
tp289
I00
ssg2
VIn summary, CTSB in pancreatitis undergoes activation in a secretory, vesicular, and acidic compartment where it activates trypsinogen.
p290
sg4
(lp291
(dp292
g7
I123
sg8
g287
sg10
I11
sg11
VP07478
p293
sg13
I1
sasg24
(lp294
(dp295
g7
I20
sg8
g288
sg10
I12
sg28
VC0030305
p296
sg13
I1
sasa(dp297
g2
VC3F was also significantly increased in 20 chronic renal failure (CRF) patients as compared to 196 controls; this would support the existence of functional differences between C3F and C3S alleles.
p298
sg4
(lp299
(dp300
g7
I0
sg8
VC3F
p301
sg10
I3
sg11
g12
sg13
I1
sa(dp302
g7
I0
sg8
VC3F
p303
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp304
(dp305
g7
I66
sg8
VCRF
p306
sg10
I3
sg28
VC0022661
p307
sg13
I1
sa(dp308
g7
I43
sg8
Vchronic renal failure
p309
sg10
I21
sg28
VC0022661
p310
sg13
I3
sasa(dp311
g2
VEctopic expression of Fgfr2c, a gene implicated in craniosynostosis in mice and humans, and that of Runx2 was detected within the affected sutures of Bcl11b(-/-) mice.
p312
sg4
(lp313
(dp314
g7
I150
sg8
VBcl11b(-/-)
p315
sg10
I11
sg11
g12
sg13
I1
sa(dp316
g7
I100
sg8
VRunx2
p317
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp318
(dp319
g7
I51
sg8
Vcraniosynostosis
p320
sg10
I16
sg28
VC0010278
p321
sg13
I1
sasa(dp322
g2
VThese data suggest that ectopic expression of Fgfr2c in the sutural mesenchyme, without concomitant changes in the expression of FGF ligands, appears to induce the RUNX2-dependent osteogenic program and craniosynostosis in Bcl11b(-/-) mice.
p323
sg4
(lp324
(dp325
g7
I223
sg8
VBcl11b(-/-)
p326
sg10
I11
sg11
g12
sg13
I1
sa(dp327
g7
I129
sg8
VFGF ligands
p328
sg10
I11
sg11
g12
sg13
I2
sa(dp329
g7
I164
sg8
VRUNX2
p330
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp331
(dp332
g7
I203
sg8
Vcraniosynostosis
p333
sg10
I16
sg28
VC0010278
p334
sg13
I1
sasa(dp335
g2
V(2) An analysis of all published HLA data for patients of European origin indicated a weak association of pernicious anemia with HLA-B7.
p336
sg4
(lp337
(dp338
g7
I129
sg8
VHLA-B7
p339
sg10
I6
sg11
VP30486
p340
sg13
I1
sa(dp341
g7
I33
sg8
VHLA
p342
sg10
I3
sg11
VP30486
p343
sg13
I1
sasg24
(lp344
(dp345
g7
I106
sg8
Vpernicious anemia
p346
sg10
I17
sg28
VC0002892
p347
sg13
I2
sasa(dp348
g2
VSpecifically, studies have demonstrated miR-221/-222 function as oncogenes, and promote PCa cell proliferation and the development of castration-resistant prostate cancer (CRPC).
p349
sg4
(lp350
sg24
(lp351
(dp352
g7
I88
sg8
VPCa
p353
sg10
I3
sg28
VC0268398
p354
sg13
I1
sa(dp355
g7
I155
sg8
Vprostate cancer
p356
sg10
I15
sg28
VC0600139
p357
sg13
I2
sa(dp358
g7
I97
sg8
Vproliferation
p359
sg10
I13
sg28
VC0334094
p360
sg13
I1
sasa(dp361
g2
VSOCS3 was found significantly declined, while microRNA-221 (miR-221) obviously up-regulated in bladder cancer tissue.
p362
sg4
(lp363
(dp364
g7
I0
sg8
VSOCS3
p365
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp366
(dp367
g7
I95
sg8
Vbladder cancer
p368
sg10
I14
sg28
VC0699885
p369
sg13
I2
sasa(dp370
g135
(dp371
(VSTAT3
p372
Vbladder cancer
p373
tp374
I00
ssg2
VThis study investigated the role of miR-221 in regulating SOCS3/JAK-STAT3 signaling pathway and bladder cancer cell proliferation and apoptosis.
p375
sg4
(lp376
(dp377
g7
I68
sg8
g372
sg10
I5
sg11
VP40763
p378
sg13
I1
sa(dp379
g7
I58
sg8
VSOCS3
p380
sg10
I5
sg11
g12
sg13
I1
sa(dp381
g7
I36
sg8
VmiR-221
p382
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp383
(dp384
g7
I96
sg8
g373
sg10
I14
sg28
VC0699885
p385
sg13
I2
sa(dp386
g7
I116
sg8
Vproliferation
p387
sg10
I13
sg28
VC0334094
p388
sg13
I1
sasa(dp389
g2
VBladder cancer tumor tissue and para-carcinoma tissue were collected from patients to test miR-221 and SOCS3 expressions.
p390
sg4
(lp391
(dp392
g7
I91
sg8
VmiR-221
p393
sg10
I7
sg11
g12
sg13
I1
sa(dp394
g7
I103
sg8
VSOCS3
p395
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp396
(dp397
g7
I0
sg8
VBladder cancer
p398
sg10
I14
sg28
VC0699885
p399
sg13
I2
sa(dp400
g7
I15
sg8
Vtumor
p401
sg10
I5
sg28
VC0027651
p402
sg13
I1
sa(dp403
g7
I37
sg8
Vcarcinoma
p404
sg10
I9
sg28
VC0007097
p405
sg13
I1
sasa(dp406
g2
VMiR-221 significantly increased, while SOCS3 obviously reduced in bladder cancer tissue compared with para-carcinoma tissue.
p407
sg4
(lp408
(dp409
g7
I0
sg8
VMiR-221
p410
sg10
I7
sg11
g12
sg13
I1
sa(dp411
g7
I39
sg8
VSOCS3
p412
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp413
(dp414
g7
I107
sg8
Vcarcinoma
p415
sg10
I9
sg28
VC0007097
p416
sg13
I1
sa(dp417
g7
I66
sg8
Vbladder cancer
p418
sg10
I14
sg28
VC0699885
p419
sg13
I2
sasa(dp420
g2
VMiR-221 elevated, while SOCS3 reduced in bladder cancer tissue.
p421
sg4
(lp422
(dp423
g7
I0
sg8
VMiR-221 elevated, while SOCS3
p424
sg10
I29
sg11
g12
sg13
I4
sasg24
(lp425
(dp426
g7
I41
sg8
Vbladder cancer
p427
sg10
I14
sg28
VC0699885
p428
sg13
I2
sasa(dp429
g135
(dp430
(VPI3K
p431
Vprostate cancer
p432
tp433
I00
ssg2
VAs miR-221 targets several regulators of the PI3K-AKT-mTOR pathway and a link between this pathway and CD44 has been previously shown in prostate cancer, we considered miR-221 regulation of CD44 may be through this pathway.
p434
sg4
(lp435
(dp436
g7
I54
sg8
VmTOR
p437
sg10
I4
sg11
VP42345
p438
sg13
I1
sa(dp439
g7
I50
sg8
VAKT
p440
sg10
I3
sg11
g12
sg13
I1
sa(dp441
g7
I45
sg8
g431
sg10
I4
sg11
VP42336
p442
sg13
I1
sasg24
(lp443
(dp444
g7
I137
sg8
g432
sg10
I15
sg28
VC0600139
p445
sg13
I2
sasa(dp446
g135
(dp447
(Vtumor tissue prostate-specific antigen
p448
VPSA
p449
tp450
I00
ssg2
VThe aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy.
p451
sg4
(lp452
(dp453
g7
I249
sg8
Vserum PSA
p454
sg10
I9
sg11
VP55786
p455
sg13
I2
sa(dp456
g7
I190
sg8
VmiR-221
p457
sg10
I7
sg11
g12
sg13
I1
sa(dp458
g7
I65
sg8
VERG
p459
sg10
I3
sg11
VP11308
p460
sg13
I1
sa(dp461
g7
I162
sg8
VPCA3
p462
sg10
I4
sg11
VP78358
p463
sg13
I1
sa(dp464
g7
I129
sg8
VPSA
p465
sg10
I3
sg11
VP55786
p466
sg13
I1
sa(dp467
g7
I89
sg8
g448
sg10
I38
sg11
VP07288
p468
sg13
I4
sa(dp469
g7
I135
sg8
Vprostate cancer antigen 3
p470
sg10
I25
sg11
VP78358
p471
sg13
I4
sa(dp472
g7
I178
sg8
VmiR-26a
p473
sg10
I7
sg11
g12
sg13
I1
sa(dp474
g7
I57
sg8
VTMPRSS2
p475
sg10
I7
sg11
g12
sg13
I1
sa(dp476
g7
I169
sg8
VmiR-23b
p477
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp478
(dp479
g7
I280
sg8
VPCa
p480
sg10
I3
sg28
VC0268398
p481
sg13
I1
sa(dp482
g7
I89
sg8
Vtumor
p483
sg10
I5
sg28
VC0027651
p484
sg13
I1
sa(dp485
g7
I284
sg8
Vrecurrence
p486
sg10
I10
sg28
VC1458156
p487
sg13
I1
sa(dp488
g7
I135
sg8
Vprostate cancer
p489
sg10
I15
sg28
VC0600139
p490
sg13
I2
sa(dp491
g7
I129
sg8
VPSA
p492
sg10
I3
sg28
VC1519176
p493
sg13
I1
sa(dp494
g7
I102
sg8
Vprostate-specific antigen
p495
sg10
I25
sg28
VC1519176
p496
sg13
I2
sa(dp497
g7
I129
sg8
g449
sg10
I3
sg28
VC1519176
p498
sg13
I1
sasa(dp499
g2
VOnly 5 genes were significantly up-regulated in MS patients vs control subjects; namely TNF-AIP6, IL-1RA, OASL, CLC and DOCK4 (p &lt; 0.05).
p500
sg4
(lp501
(dp502
g7
I88
sg8
VTNF-AIP6
p503
sg10
I8
sg11
VP01375
p504
sg13
I1
sa(dp505
g7
I120
sg8
VDOCK4
p506
sg10
I5
sg11
g12
sg13
I1
sa(dp507
g7
I106
sg8
VOASL
p508
sg10
I4
sg11
g12
sg13
I1
sa(dp509
g7
I112
sg8
VCLC
p510
sg10
I3
sg11
g12
sg13
I1
sa(dp511
g7
I98
sg8
VIL-1RA
p512
sg10
I6
sg11
VP18510
p513
sg13
I1
sasg24
(lp514
sa(dp515
g2
VAnalysis of the effector molecules of the up-regulated genes revealed that 83 MS patients had positive serum level of OASL, 87 MS patients had positive serum levels of IL-1RA, and none of the 88 MS patients showed detectable serum levels of TNF-AIP6, CLC or DOCK4.
p516
sg4
(lp517
(dp518
g7
I258
sg8
VDOCK4
p519
sg10
I5
sg11
g12
sg13
I1
sa(dp520
g7
I168
sg8
VIL-1RA
p521
sg10
I6
sg11
VP18510
p522
sg13
I1
sa(dp523
g7
I241
sg8
VTNF
p524
sg10
I3
sg11
VP01375
p525
sg13
I1
sa(dp526
g7
I251
sg8
VCLC
p527
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp528
sa(dp529
g2
VOASL and IL-1RA genes were strongly expressed in MS patients and that their effector molecules may be considered as biomarkers associated with the inflammatory process of the disease and possibly treatment response.
p530
sg4
(lp531
(dp532
g7
I0
sg8
VOASL
p533
sg10
I4
sg11
g12
sg13
I1
sa(dp534
g7
I9
sg8
VIL-1RA genes
p535
sg10
I12
sg11
VP18510
p536
sg13
I2
sasg24
(lp537
sa(dp538
g2
VHowever, IRF1, IFNK and viral restriction factors (IFIT1, 2, 3, 5, OASL, CD74, RTP4) were up-regulated.
p539
sg4
(lp540
(dp541
g7
I73
sg8
VCD74
p542
sg10
I4
sg11
VP04233
p543
sg13
I1
sa(dp544
g7
I51
sg8
VIFIT1
p545
sg10
I5
sg11
VP09914
p546
sg13
I1
sa(dp547
g7
I9
sg8
VIRF1
p548
sg10
I4
sg11
VP10914
p549
sg13
I1
sa(dp550
g7
I79
sg8
VRTP4
p551
sg10
I4
sg11
g12
sg13
I1
sa(dp552
g7
I67
sg8
VOASL
p553
sg10
I4
sg11
g12
sg13
I1
sa(dp554
g7
I24
sg8
Vviral restriction factors
p555
sg10
I25
sg11
VP19883
p556
sg13
I3
sa(dp557
g7
I15
sg8
VIFNK
p558
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp559
sa(dp560
g135
(dp561
(VISG15
p562
VAdhesion
p563
tp564
I00
ssg2
VThe signature's genes are: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 (IL16), 2',5'-Oligoadenylate Synthetase Like (OASL), and Adhesion G Protein Coupled Receptor E5 (ADGRE5).
p565
sg4
(lp566
(dp567
g7
I127
sg8
VOASL
p568
sg10
I4
sg11
g12
sg13
I1
sa(dp569
g7
I66
sg8
VInterleukin 16
p570
sg10
I14
sg11
g12
sg13
I2
sa(dp571
g7
I89
sg8
V2',5'-Oligoadenylate Synthetase Like
p572
sg10
I36
sg11
g12
sg13
I3
sa(dp573
g7
I82
sg8
VIL16
p574
sg10
I4
sg11
g12
sg13
I1
sa(dp575
g7
I27
sg8
VInterferon Stimulated Gene 15
p576
sg10
I29
sg11
g12
sg13
I4
sa(dp577
g7
I58
sg8
g562
sg10
I5
sg11
VP05161
p578
sg13
I1
sasg24
(lp579
(dp580
g7
I138
sg8
g563
sg10
I8
sg28
VC0001511
p581
sg13
I1
sasa(dp582
g135
(dp583
(VOAS2
p584
Vviral infection
p585
tp586
I01
ssg2
VPrevious work has identified that following viral infection, type I IFN signaling induces the production of the 2'-5'-oligoadenylate synthetase (OAS) family, which include OAS1, OAS2, OAS3, and OAS-like (OASL) protein.
p587
sg4
(lp588
(dp589
g7
I68
sg8
VIFN
p590
sg10
I3
sg11
VP01562
p591
sg13
I1
sa(dp592
g7
I194
sg8
VOAS-like
p593
sg10
I8
sg11
g12
sg13
I1
sa(dp594
g7
I112
sg8
V2'-5'-oligoadenylate synthetase
p595
sg10
I31
sg11
g12
sg13
I2
sa(dp596
g7
I204
sg8
VOASL
p597
sg10
I4
sg11
g12
sg13
I1
sa(dp598
g7
I184
sg8
VOAS3
p599
sg10
I4
sg11
g12
sg13
I1
sa(dp600
g7
I178
sg8
g584
sg10
I4
sg11
VP29728
p601
sg13
I1
sa(dp602
g7
I145
sg8
VOAS
p603
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp604
(dp605
g7
I145
sg8
VOAS
p606
sg10
I3
sg28
VC0599973
p607
sg13
I1
sa(dp608
g7
I112
sg8
V2'-5'-oligoadenylate synthetase
p609
sg10
I31
sg28
VC0599973
p610
sg13
I2
sa(dp611
g7
I145
sg8
VOAS
p612
sg10
I3
sg28
VC0599973
p613
sg13
I1
sa(dp614
g7
I44
sg8
g585
sg10
I15
sg28
VC0042769
p615
sg13
I2
sasa(dp616
g2
VOASL was identified to be strongly induced following viral infection through engaging the RNA sensor RIG-I and increasing signaling through this pathway to enhance the anti-viral type I IFN response.
p617
sg4
(lp618
(dp619
g7
I0
sg8
VOASL
p620
sg10
I4
sg11
g12
sg13
I1
sa(dp621
g7
I101
sg8
VRIG-I
p622
sg10
I5
sg11
g12
sg13
I1
sa(dp623
g7
I186
sg8
VIFN
p624
sg10
I3
sg11
VP01562
p625
sg13
I1
sasg24
(lp626
(dp627
g7
I53
sg8
Vviral infection
p628
sg10
I15
sg28
VC0042769
p629
sg13
I2
sasa(dp630
g2
VSurprisingly, infection with viral dsDNA revealed an IFN inhibitory role and therefore pro-viral function of OASL through the inhibition of the cGAS cytosolic DNA sensing mechanism.
p631
sg4
(lp632
(dp633
g7
I53
sg8
VIFN
p634
sg10
I3
sg11
VP01562
p635
sg13
I1
sa(dp636
g7
I109
sg8
VOASL
p637
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp638
(dp639
g7
I14
sg8
Vinfection
p640
sg10
I9
sg28
VC0009450
p641
sg13
I1
sasa(dp642
g2
VIntracellular bacteria are able to activate the cytosolic DNA sensing pathway, however the role of OASL during bacterial infection is largely unknown.
p643
sg4
(lp644
(dp645
g7
I99
sg8
VOASL
p646
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp647
(dp648
g7
I111
sg8
Vbacterial infection
p649
sg10
I19
sg28
VC0004623
p650
sg13
I2
sasa(dp651
g2
VVacuolar pathogenic microbes such as mycobacteria induce OASL early post infection, where it functions in a prosurvival fashion by inhibiting autophagic mechanisms and antimicrobial peptide expression.
p652
sg4
(lp653
(dp654
g7
I57
sg8
VOASL
p655
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp656
(dp657
g7
I73
sg8
Vinfection
p658
sg10
I9
sg28
VC0009450
p659
sg13
I1
sasa(dp660
g2
VThis suggests an underestimated role of OASL in the innate immune response to infection with a variety of pathogens and points to OASL-associated modulation of the type I IFN response.
p661
sg4
(lp662
(dp663
g7
I40
sg8
VOASL
p664
sg10
I4
sg11
g12
sg13
I1
sa(dp665
g7
I40
sg8
VOASL
p666
sg10
I4
sg11
g12
sg13
I1
sa(dp667
g7
I164
sg8
Vtype I IFN
p668
sg10
I10
sg11
VP01562
p669
sg13
I3
sasg24
(lp670
(dp671
g7
I78
sg8
Vinfection
p672
sg10
I9
sg28
VC0009450
p673
sg13
I1
sa(dp674
g7
I52
sg8
Vinnate immune response
p675
sg10
I22
sg28
VC1155265
p676
sg13
I3
sasa(dp677
g2
VOASL may therefore play a critical role in defining the outcome of infection.
p678
sg4
(lp679
(dp680
g7
I0
sg8
VOASL
p681
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp682
(dp683
g7
I67
sg8
Vinfection
p684
sg10
I9
sg28
VC0009450
p685
sg13
I1
sasa(dp686
g2
VWe earlier nominated 16 genes (IRF7, IFIT1, IFIT5, OASL, CLC, GBP-1, PSMB9, HERC5, CCR1, CD36, MS4A4A, BIRC4BP, PLSCR1, DEFA1/DEFA3, DEFA4, and COL9A2) as predictors of response to remission induction therapy against MPA.
p687
sg4
(lp688
(dp689
g7
I120
sg8
VDEFA1
p690
sg10
I5
sg11
VP59665
p691
sg13
I1
sa(dp692
g7
I31
sg8
VIRF7
p693
sg10
I4
sg11
g12
sg13
I1
sa(dp694
g7
I57
sg8
VCLC
p695
sg10
I3
sg11
g12
sg13
I1
sa(dp696
g7
I83
sg8
VCCR1
p697
sg10
I4
sg11
VP32246
p698
sg13
I1
sa(dp699
g7
I144
sg8
VCOL9A2
p700
sg10
I6
sg11
g12
sg13
I1
sa(dp701
g7
I112
sg8
VPLSCR1
p702
sg10
I6
sg11
g12
sg13
I1
sa(dp703
g7
I133
sg8
VDEFA4
p704
sg10
I5
sg11
VP12838
p705
sg13
I1
sa(dp706
g7
I103
sg8
VBIRC4BP
p707
sg10
I7
sg11
g12
sg13
I1
sa(dp708
g7
I126
sg8
VDEFA3
p709
sg10
I5
sg11
VP59665
p710
sg13
I1
sa(dp711
g7
I76
sg8
VHERC5
p712
sg10
I5
sg11
g12
sg13
I1
sa(dp713
g7
I37
sg8
VIFIT1
p714
sg10
I5
sg11
VP09914
p715
sg13
I1
sa(dp716
g7
I51
sg8
VOASL
p717
sg10
I4
sg11
g12
sg13
I1
sa(dp718
g7
I44
sg8
VIFIT5
p719
sg10
I5
sg11
g12
sg13
I1
sa(dp720
g7
I69
sg8
VPSMB9
p721
sg10
I5
sg11
VP28065
p722
sg13
I1
sa(dp723
g7
I62
sg8
VGBP-1
p724
sg10
I5
sg11
VP32455
p725
sg13
I1
sa(dp726
g7
I95
sg8
VMS4A4A
p727
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp728
(dp729
g7
I181
sg8
Vremission
p730
sg10
I9
sg28
VC0687702
p731
sg13
I1
sasa(dp732
g135
(dp733
(VOAS2
p734
VOAS
p735
tp736
I00
ssg2
VThe 2'5'-oligoadenylate synthetase (OAS) is an interferon (IFN)-induced protein that plays an important role in the antiviral action of IFN, with OAS3 being one of the four OAS classes (OAS1, OAS2, OAS3, OASL).
p737
sg4
(lp738
(dp739
g7
I146
sg8
VOAS3
p740
sg10
I4
sg11
g12
sg13
I1
sa(dp741
g7
I4
sg8
V2'5'-oligoadenylate synthetase
p742
sg10
I30
sg11
g12
sg13
I2
sa(dp743
g7
I47
sg8
Vinterferon
p744
sg10
I10
sg11
VP01563
p745
sg13
I1
sa(dp746
g7
I59
sg8
VIFN
p747
sg10
I3
sg11
VP01562
p748
sg13
I1
sa(dp749
g7
I146
sg8
VOAS3
p750
sg10
I4
sg11
g12
sg13
I1
sa(dp751
g7
I204
sg8
VOASL
p752
sg10
I4
sg11
g12
sg13
I1
sa(dp753
g7
I36
sg8
VOAS
p754
sg10
I3
sg11
g12
sg13
I1
sa(dp755
g7
I192
sg8
g734
sg10
I4
sg11
VP29728
p756
sg13
I1
sa(dp757
g7
I59
sg8
VIFN
p758
sg10
I3
sg11
VP01562
p759
sg13
I1
sa(dp760
g7
I36
sg8
VOAS
p761
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp762
(dp763
g7
I36
sg8
VOAS
p764
sg10
I3
sg28
VC0599973
p765
sg13
I1
sa(dp766
g7
I4
sg8
V2'5'-oligoadenylate synthetase
p767
sg10
I30
sg28
VC0599973
p768
sg13
I2
sa(dp769
g7
I36
sg8
g735
sg10
I3
sg28
VC0599973
p770
sg13
I1
sasa(dp771
g2
VIn a pooled analysis of 105 candidate genes and two genome-wide association studies, we observed associations of single nucleotide polymorphisms from nine genes (EIF2AK2, IFNAR2, ITPA, MBL2, MX1, OASL, SPP1, TGFB1, TNK2) with response to interferon-based therapy.
p772
sg4
(lp773
(dp774
g7
I191
sg8
VMX1
p775
sg10
I3
sg11
VP20591
p776
sg13
I1
sa(dp777
g7
I196
sg8
VOASL
p778
sg10
I4
sg11
g12
sg13
I1
sa(dp779
g7
I208
sg8
VTGFB1
p780
sg10
I5
sg11
VP01137
p781
sg13
I1
sa(dp782
g7
I202
sg8
VSPP1
p783
sg10
I4
sg11
VP10451
p784
sg13
I1
sa(dp785
g7
I215
sg8
VTNK2
p786
sg10
I4
sg11
g12
sg13
I1
sa(dp787
g7
I162
sg8
VEIF2AK2
p788
sg10
I7
sg11
VP19525
p789
sg13
I1
sa(dp790
g7
I185
sg8
VMBL2
p791
sg10
I4
sg11
VP11226
p792
sg13
I1
sa(dp793
g7
I179
sg8
VITPA
p794
sg10
I4
sg11
g12
sg13
I1
sa(dp795
g7
I171
sg8
VIFNAR2
p796
sg10
I6
sg11
VP48551
p797
sg13
I1
sa(dp798
g7
I238
sg8
Vinterferon
p799
sg10
I10
sg11
VP01563
p800
sg13
I1
sasg24
(lp801
sa(dp802
g2
VSingle nucleotide polymorphisms in the OAS1 (rs1131476), OAS2 (rs1293747), OAS3 (rs2072136), OASL (rs10849829) and IL28B (rs12979860, rs12980275 and rs8099917) genes were studied to examine their associations with responses to IFN treatment in paediatric patients.
p803
sg4
(lp804
(dp805
g7
I93
sg8
VOASL (rs10849829)
p806
sg10
I17
sg11
g12
sg13
I2
sa(dp807
g7
I57
sg8
VOAS2
p808
sg10
I4
sg11
VP29728
p809
sg13
I1
sa(dp810
g7
I75
sg8
VOAS3
p811
sg10
I4
sg11
g12
sg13
I1
sa(dp812
g7
I227
sg8
VIFN
p813
sg10
I3
sg11
VP01562
p814
sg13
I1
sa(dp815
g7
I115
sg8
VIL28B
p816
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp817
sa(dp818
g2
VThe association analysis for CR showed that the TT genotype of IL28B rs12979860 was present only in the no-CR group (P = 0.033) and the AA genotype of OASL rs10849829 was significantly more frequent in the no-CR group (P = 0.044, OR = 0.26, 95%CI: 0.07-0.88).
p819
sg4
(lp820
(dp821
g7
I151
sg8
VOASL rs10849829
p822
sg10
I15
sg11
g12
sg13
I2
sa(dp823
g7
I63
sg8
VIL28B rs12979860
p824
sg10
I16
sg11
g12
sg13
I2
sasg24
(lp825
sa(dp826
g2
VThe aim of the present study was to evaluate agreement between three pairs formed by one of three mania scales (Young Mania Rating Scale [YMRS], Bech-Rafaelsen Mania Scale [BRMS], or the Clinician-Administered Rating Scale for Mania [CARS-M]) and a single depression scale (21-item Hamilton Depression Rating Scale [21-HAM-D]) for evaluation of response to mood stabilizers in patients with mixed bipolar disorder.
p827
sg4
(lp828
sg24
(lp829
(dp830
g7
I118
sg8
VMania
p831
sg10
I5
sg28
VC0338831
p832
sg13
I1
sa(dp833
g7
I118
sg8
VMania
p834
sg10
I5
sg28
VC0338831
p835
sg13
I1
sa(dp836
g7
I391
sg8
Vmixed bipolar disorder
p837
sg10
I22
sg28
VC2937260
p838
sg13
I3
sa(dp839
g7
I319
sg8
VHAM
p840
sg10
I3
sg28
VC0030481
p841
sg13
I1
sa(dp842
g7
I256
sg8
Vdepression
p843
sg10
I10
sg28
VC0011581
p844
sg13
I1
sa(dp845
g7
I291
sg8
VDepression
p846
sg10
I10
sg28
VC0011581
p847
sg13
I1
sa(dp848
g7
I98
sg8
Vmania
p849
sg10
I5
sg28
VC0338831
p850
sg13
I1
sa(dp851
g7
I118
sg8
VMania
p852
sg10
I5
sg28
VC0338831
p853
sg13
I1
sasa(dp854
g135
(dp855
(VCARS-M
p856
Vmania
p857
tp858
I00
ssg2
VThe present study suggests that any one of the three tested mania rating scales (YMRS, BRMS, and CARS-M) can be combined with the 21-HAM-D to assess treatment response in patients with mixed bipolar disorder.
p859
sg4
(lp860
(dp861
g7
I97
sg8
g856
sg10
I6
sg11
VP49589
p862
sg13
I1
sasg24
(lp863
(dp864
g7
I133
sg8
VHAM
p865
sg10
I3
sg28
VC0030481
p866
sg13
I1
sa(dp867
g7
I60
sg8
g857
sg10
I5
sg28
VC0338831
p868
sg13
I1
sa(dp869
g7
I185
sg8
Vmixed bipolar disorder
p870
sg10
I22
sg28
VC2937260
p871
sg13
I3
sasa(dp872
g2
VOlder adults and patients with dementia often have disrupted circadian activity rhythms (CARs).
p873
sg4
(lp874
sg24
(lp875
(dp876
g7
I31
sg8
Vdementia
p877
sg10
I8
sg28
VC0497327
p878
sg13
I1
sasa(dp879
g135
(dp880
(VcGAS
p881
Vbreast cancer
p882
tp883
I00
ssg2
VClinically, decreased levels of cGAS are associated with poor prognosis for patients with breast cancer harbouring high levels of miR-25/93.
p884
sg4
(lp885
(dp886
g7
I130
sg8
VmiR-25
p887
sg10
I6
sg11
g12
sg13
I1
sa(dp888
g7
I32
sg8
g881
sg10
I4
sg11
VP10645
p889
sg13
I1
sasg24
(lp890
(dp891
g7
I90
sg8
g882
sg10
I13
sg28
VC0678222
p892
sg13
I2
sasa(dp893
g2
VIn our analysis, we found that increased expression of 12 mature miRNAs-hsa-miR-320a, hsa-miR-361-5p, hsa-miR-103a-3p, hsa-miR-21-5p, hsa-miR-374b-5p, hsa-miR-140-3p, hsa-miR-25-3p, hsa-miR-651-5p, hsa-miR-200c-3p, hsa-miR-30a-5p, hsa-miR-30c-5p, and hsa-let-7i-5p -each predicted improved breast cancer survival.
p894
sg4
(lp895
(dp896
g7
I134
sg8
Vhsa-miR-374b-5p
p897
sg10
I15
sg11
g12
sg13
I1
sa(dp898
g7
I151
sg8
Vhsa-miR-140-3p
p899
sg10
I14
sg11
g12
sg13
I1
sa(dp900
g7
I86
sg8
Vhsa-miR-361-5p
p901
sg10
I14
sg11
g12
sg13
I1
sa(dp902
g7
I182
sg8
Vhsa-miR-651-5p
p903
sg10
I14
sg11
g12
sg13
I1
sa(dp904
g7
I215
sg8
Vhsa-miR-30a-5p
p905
sg10
I14
sg11
g12
sg13
I1
sa(dp906
g7
I102
sg8
Vhsa-miR-103a-3p
p907
sg10
I15
sg11
g12
sg13
I1
sa(dp908
g7
I198
sg8
Vhsa-miR-200c-3p
p909
sg10
I15
sg11
g12
sg13
I1
sa(dp910
g7
I119
sg8
Vhsa-miR-21-5p
p911
sg10
I13
sg11
g12
sg13
I1
sa(dp912
g7
I65
sg8
VmiR
p913
sg10
I3
sg11
g12
sg13
I1
sa(dp914
g7
I251
sg8
Vhsa-let-7i-5p
p915
sg10
I13
sg11
g12
sg13
I1
sa(dp916
g7
I231
sg8
Vhsa-miR-30c-5p
p917
sg10
I14
sg11
g12
sg13
I1
sa(dp918
g7
I167
sg8
Vhsa-miR-25-3p
p919
sg10
I13
sg11
g12
sg13
I1
sa(dp920
g7
I72
sg8
Vhsa
p921
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp922
(dp923
g7
I72
sg8
Vhsa
p924
sg10
I3
sg28
VC0393754
p925
sg13
I1
sa(dp926
g7
I72
sg8
Vhsa
p927
sg10
I3
sg28
VC0393754
p928
sg13
I1
sa(dp929
g7
I72
sg8
Vhsa
p930
sg10
I3
sg28
VC0393754
p931
sg13
I1
sa(dp932
g7
I72
sg8
Vhsa
p933
sg10
I3
sg28
VC0393754
p934
sg13
I1
sa(dp935
g7
I290
sg8
Vbreast cancer
p936
sg10
I13
sg28
VC0678222
p937
sg13
I2
sa(dp938
g7
I72
sg8
Vhsa
p939
sg10
I3
sg28
VC0393754
p940
sg13
I1
sa(dp941
g7
I72
sg8
Vhsa
p942
sg10
I3
sg28
VC0393754
p943
sg13
I1
sa(dp944
g7
I72
sg8
Vhsa
p945
sg10
I3
sg28
VC0393754
p946
sg13
I1
sa(dp947
g7
I72
sg8
Vhsa
p948
sg10
I3
sg28
VC0393754
p949
sg13
I1
sa(dp950
g7
I72
sg8
Vhsa
p951
sg10
I3
sg28
VC0393754
p952
sg13
I1
sa(dp953
g7
I72
sg8
Vhsa
p954
sg10
I3
sg28
VC0393754
p955
sg13
I1
sa(dp956
g7
I72
sg8
Vhsa
p957
sg10
I3
sg28
VC0393754
p958
sg13
I1
sa(dp959
g7
I72
sg8
Vhsa
p960
sg10
I3
sg28
VC0393754
p961
sg13
I1
sasa(dp962
g2
VHere, we report a novel function of isoliquiritigenin (ISL) as a natural inhibitor of autophagy-related miR-25 in killing drug-resistant breast cancer cells.
p963
sg4
(lp964
(dp965
g7
I104
sg8
VmiR-25
p966
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp967
(dp968
g7
I137
sg8
Vbreast cancer
p969
sg10
I13
sg28
VC0678222
p970
sg13
I2
sasa(dp971
g2
VOverall, our results not only indicate that ISL acts as a natural autophagy inducer to increase breast cancer chemosensitivity, but also reveal that miR-25 functions as a novel regulator of autophagy by targeting ULK1.
p972
sg4
(lp973
(dp974
g7
I149
sg8
VmiR-25
p975
sg10
I6
sg11
g12
sg13
I1
sa(dp976
g7
I213
sg8
VULK1
p977
sg10
I4
sg11
g12
sg13
I1
sa(dp978
g7
I44
sg8
VISL
p979
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp980
(dp981
g7
I96
sg8
Vbreast cancer
p982
sg10
I13
sg28
VC0678222
p983
sg13
I2
sasa(dp984
g135
(dp985
(VWNT5A
p986
Vhsa
p987
tp988
I00
ssg2
VExpression of a panel of seven microRNAs (hsa-miR-34a, hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, hsa-miR-326, and hsa-miR-375) and seven target genes ( E2F3, PI3KCA, TOM34, WNT5A, PDCD4, DFFA, and EGFR) in 43 glioblastoma multiforme specimens were profiled compared to non-cancer tissues via quantitative reverse transcription-polymerase chain reaction.
p989
sg4
(lp990
(dp991
g7
I67
sg8
Vhsa-miR-17
p992
sg10
I10
sg11
g12
sg13
I1
sa(dp993
g7
I42
sg8
Vhsa
p994
sg10
I3
sg11
g12
sg13
I1
sa(dp995
g7
I194
sg8
VDFFA, and EGFR
p996
sg10
I14
sg11
g12
sg13
I3
sa(dp997
g7
I46
sg8
VmiR
p998
sg10
I3
sg11
g12
sg13
I1
sa(dp999
g7
I91
sg8
Vhsa-miR-221
p1000
sg10
I11
sg11
g12
sg13
I1
sa(dp1001
g7
I187
sg8
VPDCD4
p1002
sg10
I5
sg11
g12
sg13
I1
sa(dp1003
g7
I180
sg8
g986
sg10
I5
sg11
VP41221
p1004
sg13
I1
sa(dp1005
g7
I55
sg8
Vhsa-miR-16
p1006
sg10
I10
sg11
g12
sg13
I1
sa(dp1007
g7
I42
sg8
Vhsa
p1008
sg10
I3
sg11
g12
sg13
I1
sa(dp1009
g7
I104
sg8
Vhsa-miR-326
p1010
sg10
I11
sg11
g12
sg13
I1
sa(dp1011
g7
I42
sg8
Vhsa
p1012
sg10
I3
sg11
g12
sg13
I1
sa(dp1013
g7
I173
sg8
VTOM34
p1014
sg10
I5
sg11
g12
sg13
I1
sa(dp1015
g7
I159
sg8
VE2F3
p1016
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp1017
(dp1018
g7
I42
sg8
Vhsa
p1019
sg10
I3
sg28
VC0393754
p1020
sg13
I1
sa(dp1021
g7
I280
sg8
Vcancer
p1022
sg10
I6
sg28
VC0006826
p1023
sg13
I1
sa(dp1024
g7
I42
sg8
Vhsa
p1025
sg10
I3
sg28
VC0393754
p1026
sg13
I1
sa(dp1027
g7
I216
sg8
Vglioblastoma multiforme
p1028
sg10
I23
sg28
VC1621958
p1029
sg13
I2
sa(dp1030
g7
I42
sg8
Vhsa
p1031
sg10
I3
sg28
VC0393754
p1032
sg13
I1
sa(dp1033
g7
I42
sg8
Vhsa
p1034
sg10
I3
sg28
VC0393754
p1035
sg13
I1
sa(dp1036
g7
I42
sg8
Vhsa
p1037
sg10
I3
sg28
VC0393754
p1038
sg13
I1
sa(dp1039
g7
I42
sg8
Vhsa
p1040
sg10
I3
sg28
VC0393754
p1041
sg13
I1
sa(dp1042
g7
I42
sg8
g987
sg10
I3
sg28
VC0393754
p1043
sg13
I1
sasa(dp1044
g2
VThe present study examined whether it could be possible to quantify the expression of TOMM34 and RNF43 in colorectal cancer and liver metastasis samples prepared from paraffin blocks.
p1045
sg4
(lp1046
(dp1047
g7
I97
sg8
VRNF43
p1048
sg10
I5
sg11
g12
sg13
I1
sa(dp1049
g7
I86
sg8
VTOMM34
p1050
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp1051
(dp1052
g7
I106
sg8
Vcolorectal cancer
p1053
sg10
I17
sg28
VC1527249
p1054
sg13
I2
sa(dp1055
g7
I128
sg8
Vliver metastasis
p1056
sg10
I16
sg28
VC0494165
p1057
sg13
I2
sasa(dp1058
g2
VQuantification of TOMM34 and RNF43 gene expression in several-year-old paraffin-embedded colorectal cancer specimens was possible by qPCR using the Universal ProbeLibrary.
p1059
sg4
(lp1060
(dp1061
g7
I18
sg8
VTOMM34
p1062
sg10
I6
sg11
g12
sg13
I1
sa(dp1063
g7
I29
sg8
VRNF43 gene
p1064
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp1065
(dp1066
g7
I89
sg8
Vcolorectal cancer
p1067
sg10
I17
sg28
VC1527249
p1068
sg13
I2
sasa(dp1069
g135
(dp1070
(Vring finger protein-43
p1071
VWT1
p1072
tp1073
I00
ssg2
VThe mRNA levels of seven TAAs, Wilms' tumor gene (WT1), kinetochore associated-2 (KNTC2), cell division cycle associated-1 (CDCA1), M phase phosphoprotein-1 (MPHOSPH1), DEP domain-containing 1 (DEPDC1), 34-kDa translocase of the outer mitochondrial membrane (TOMM34) and ring finger protein-43 (RNF43), were analyzed using quantitative real-time reverse transcription-polymerase chain reaction, and their relationships with clinicopathological factors and the cell cycle were analyzed.
p1074
sg4
(lp1075
(dp1076
g7
I82
sg8
VKNTC2
p1077
sg10
I5
sg11
g12
sg13
I1
sa(dp1078
g7
I203
sg8
V34-kDa translocase of the outer mitochondrial membrane (TOMM34)
p1079
sg10
I63
sg11
g12
sg13
I8
sa(dp1080
g7
I132
sg8
VM phase phosphoprotein-1
p1081
sg10
I24
sg11
g12
sg13
I3
sa(dp1082
g7
I169
sg8
VDEP domain-containing 1
p1083
sg10
I23
sg11
g12
sg13
I3
sa(dp1084
g7
I271
sg8
g1071
sg10
I22
sg11
VP62877
p1085
sg13
I3
sa(dp1086
g7
I194
sg8
VDEPDC1
p1087
sg10
I6
sg11
g12
sg13
I1
sa(dp1088
g7
I295
sg8
VRNF43
p1089
sg10
I5
sg11
g12
sg13
I1
sa(dp1090
g7
I158
sg8
VMPHOSPH1
p1091
sg10
I8
sg11
g12
sg13
I1
sa(dp1092
g7
I31
sg8
VWilms' tumor gene (WT1), kinetochore associated-2
p1093
sg10
I49
sg11
g12
sg13
I6
sasg24
(lp1094
(dp1095
g7
I31
sg8
VWilms' tumor
p1096
sg10
I12
sg28
VC0027708
p1097
sg13
I2
sa(dp1098
g7
I50
sg8
g1072
sg10
I3
sg28
VC0027708
p1099
sg13
I1
sasa(dp1100
g2
VThese antigenic peptides were derived from 5 proteins identified as cancer-testis antigens(ring finger protein 43 [RNF43], translocase of outer mitochondrial membrane 34[TOMM34], maternal embryonic leucine zipper kinase[MELK], forkhead box M1[FOXM1], and holliday junction recognition protein[HJURP])and 2 vascular endothelial growth factor receptors(VEGFR1 and VEGFR2).
p1101
sg4
(lp1102
(dp1103
g7
I255
sg8
Vholliday junction recognition protein
p1104
sg10
I37
sg11
g12
sg13
I4
sa(dp1105
g7
I293
sg8
VHJURP
p1106
sg10
I5
sg11
g12
sg13
I1
sa(dp1107
g7
I240
sg8
VM1[FOXM1]
p1108
sg10
I9
sg11
g12
sg13
I1
sa(dp1109
g7
I351
sg8
VVEGFR1
p1110
sg10
I6
sg11
VP17948
p1111
sg13
I1
sa(dp1112
g7
I306
sg8
Vvascular endothelial growth factor receptors
p1113
sg10
I44
sg11
g12
sg13
I5
sa(dp1114
g7
I220
sg8
VMELK
p1115
sg10
I4
sg11
g12
sg13
I1
sa(dp1116
g7
I362
sg8
VVEGFR2
p1117
sg10
I6
sg11
VP35968
p1118
sg13
I1
sa(dp1119
g7
I91
sg8
Vring finger protein 43
p1120
sg10
I22
sg11
g12
sg13
I4
sa(dp1121
g7
I179
sg8
Vmaternal embryonic leucine zipper kinase
p1122
sg10
I40
sg11
VP30740
p1123
sg13
I5
sa(dp1124
g7
I68
sg8
Vcancer-testis antigens
p1125
sg10
I22
sg11
VP15735
p1126
sg13
I2
sasg24
(lp1127
(dp1128
g7
I68
sg8
Vcancer
p1129
sg10
I6
sg28
VC0006826
p1130
sg13
I1
sasa(dp1131
g135
(dp1132
(VVEGFR2
p1133
Vcolorectal cancer
p1134
tp1135
I00
ssg2
VTo evaluate the safety of combination vaccine treatment of multiple peptides, phase I clinical trial was conducted for patients with advanced colorectal cancer using five novel HLA-A*2402-restricted peptides, three peptides derived from oncoantigens, ring finger protein 43 (RNF43), 34 kDa-translocase of the outer mitochondrial membrane (TOMM34), and insulin-like growth factor-II mRNA binding protein 3 (KOC1), and the remaining two from angiogenesis factors, vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.
p1136
sg4
(lp1137
(dp1138
g7
I406
sg8
VKOC1
p1139
sg10
I4
sg11
g12
sg13
I1
sa(dp1140
g7
I251
sg8
Vring finger protein 43
p1141
sg10
I22
sg11
g12
sg13
I4
sa(dp1142
g7
I352
sg8
Vinsulin-like growth factor-II mRNA binding protein 3
p1143
sg10
I52
sg11
VP01308
p1144
sg13
I7
sa(dp1145
g7
I339
sg8
VTOMM34
p1146
sg10
I6
sg11
g12
sg13
I1
sa(dp1147
g7
I509
sg8
VVEGFR1
p1148
sg10
I6
sg11
VP17948
p1149
sg13
I1
sa(dp1150
g7
I177
sg8
VHLA-A*2402
p1151
sg10
I10
sg11
VP30447
p1152
sg13
I1
sa(dp1153
g7
I462
sg8
Vvascular endothelial growth factor receptor 1
p1154
sg10
I45
sg11
VP17948
p1155
sg13
I6
sa(dp1156
g7
I275
sg8
VRNF43
p1157
sg10
I5
sg11
g12
sg13
I1
sa(dp1158
g7
I521
sg8
g1133
sg10
I6
sg11
VP35968
p1159
sg13
I1
sasg24
(lp1160
(dp1161
g7
I142
sg8
g1134
sg10
I17
sg28
VC1527249
p1162
sg13
I2
sasa(dp1163
g2
VThese antigenic peptides were derived from 2 different cancer-testis antigens, ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34( TOMM34).
p1164
sg4
(lp1165
(dp1166
g7
I114
sg8
Vtranslocase of outer mitochondrial membrane 34
p1167
sg10
I46
sg11
g12
sg13
I6
sa(dp1168
g7
I55
sg8
Vcancer-testis antigens
p1169
sg10
I22
sg11
VP15735
p1170
sg13
I2
sa(dp1171
g7
I79
sg8
Vring finger protein 43
p1172
sg10
I22
sg11
g12
sg13
I4
sa(dp1173
g7
I103
sg8
VRNF43
p1174
sg10
I5
sg11
g12
sg13
I1
sa(dp1175
g7
I162
sg8
VTOMM34
p1176
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp1177
(dp1178
g7
I55
sg8
Vcancer
p1179
sg10
I6
sg28
VC0006826
p1180
sg13
I1
sasa(dp1181
g135
(dp1182
(Vcolorectal cancer-specific peptide
p1183
Vcolorectal cancer
p1184
tp1185
I00
ssg2
VWe conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer.
p1186
sg4
(lp1187
(dp1188
g7
I69
sg8
VRNF43
p1189
sg10
I5
sg11
g12
sg13
I1
sa(dp1190
g7
I33
sg8
g1183
sg10
I34
sg11
VP31749
p1191
sg13
I3
sa(dp1192
g7
I76
sg8
VTOMM34
p1193
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp1194
(dp1195
g7
I168
sg8
Vrecurrent colorectal cancer
p1196
sg10
I27
sg28
VC0854750
p1197
sg13
I3
sa(dp1198
g7
I33
sg8
g1184
sg10
I17
sg28
VC1527249
p1199
sg13
I2
sasa(dp1200
g135
(dp1201
(Vmaternal embryonic leucine zipper kinase
p1202
Vrecurrent colorectal cancer
p1203
tp1204
I00
ssg2
VWe started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.
p1205
sg4
(lp1206
(dp1207
g7
I164
sg8
Vholliday junction recognition protein
p1208
sg10
I37
sg11
g12
sg13
I4
sa(dp1209
g7
I82
sg8
Vforkhead box protein M1 [FOXM1]
p1210
sg10
I31
sg11
g12
sg13
I5
sa(dp1211
g7
I157
sg8
VMELK
p1212
sg10
I4
sg11
g12
sg13
I1
sa(dp1213
g7
I202
sg8
VHJURP
p1214
sg10
I5
sg11
g12
sg13
I1
sa(dp1215
g7
I210
sg8
Vvascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2
p1216
sg10
I65
sg11
VP17948
p1217
sg13
I8
sa(dp1218
g7
I67
sg8
VRNF43
p1219
sg10
I5
sg11
g12
sg13
I1
sa(dp1220
g7
I74
sg8
VTOMM34
p1221
sg10
I6
sg11
g12
sg13
I1
sa(dp1222
g7
I115
sg8
g1202
sg10
I40
sg11
VP30740
p1223
sg13
I5
sasg24
(lp1224
(dp1225
g7
I310
sg8
g1203
sg10
I27
sg28
VC0854750
p1226
sg13
I3
sasa(dp1227
g135
(dp1228
(Vvascular endothelial growth factor             receptors VEGFR1 and VEGFR2
p1229
Vcolorectal cancer
p1230
tp1231
I00
ssg2
VRecently, analysis of tumor antigens using micro-arrays has revealed upregulation             of cancer-testis antigens RNF43 and TOMM34 and vascular endothelial growth factor             receptors VEGFR1 and VEGFR2 in colorectal cancer.
p1232
sg4
(lp1233
(dp1234
g7
I130
sg8
VTOMM34
p1235
sg10
I6
sg11
g12
sg13
I1
sa(dp1236
g7
I120
sg8
VRNF43
p1237
sg10
I5
sg11
g12
sg13
I1
sa(dp1238
g7
I141
sg8
g1229
sg10
I74
sg11
VP17948
p1239
sg13
I20
sasg24
(lp1240
(dp1241
g7
I97
sg8
Vcancer
p1242
sg10
I6
sg28
VC0006826
p1243
sg13
I1
sa(dp1244
g7
I22
sg8
Vtumor
p1245
sg10
I5
sg28
VC0027651
p1246
sg13
I1
sa(dp1247
g7
I219
sg8
g1230
sg10
I17
sg28
VC1527249
p1248
sg13
I2
sasa(dp1249
g2
VOur aim was to analyze the dynamic modulation, determined by ADT, of the expression of selected genes involved in the pathogenesis and progression of prostate cancer (TMPRSS2:ERG, WNT11, SPINK1, CHGA, AR, and SPDEF) using real-time polymerase chain reaction in a series of 59 surgical samples of prostate carcinomas, including 37 cases preoperatively treated with ADT and 22 untreated cases, and in 43 corresponding biopsies.
p1250
sg4
(lp1251
(dp1252
g7
I187
sg8
VSPINK1
p1253
sg10
I6
sg11
VP00995
p1254
sg13
I1
sa(dp1255
g7
I209
sg8
VSPDEF
p1256
sg10
I5
sg11
g12
sg13
I1
sa(dp1257
g7
I175
sg8
VERG
p1258
sg10
I3
sg11
VP11308
p1259
sg13
I1
sa(dp1260
g7
I195
sg8
VCHGA
p1261
sg10
I4
sg11
VP10645
p1262
sg13
I1
sa(dp1263
g7
I180
sg8
VWNT11
p1264
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp1265
(dp1266
g7
I305
sg8
Vcarcinomas
p1267
sg10
I10
sg28
VC0007097
p1268
sg13
I1
sa(dp1269
g7
I118
sg8
Vpathogenesis
p1270
sg10
I12
sg28
VC0699748
p1271
sg13
I1
sa(dp1272
g7
I135
sg8
Vprogression of prostate cancer
p1273
sg10
I30
sg28
VC1739135
p1274
sg13
I4
sasa(dp1275
g2
VHowever, Wnt-11 expression in cervical cancer has not been well investigated.
p1276
sg4
(lp1277
sg24
(lp1278
(dp1279
g7
I30
sg8
Vcervical cancer
p1280
sg10
I15
sg28
VC0302592
p1281
sg13
I2
sasa(dp1282
g2
VWnt-11 and HR-HPV E6 expression increased in a manner that corresponded with the progression of cervical cancer and was significantly correlated with the International Federation of Gynecology and Obstetrics cancer stage, lymph node metastasis, tumor size, and HPV infection.
p1283
sg4
(lp1284
sg24
(lp1285
(dp1286
g7
I96
sg8
Vcervical cancer
p1287
sg10
I15
sg28
VC0302592
p1288
sg13
I2
sa(dp1289
g7
I245
sg8
Vtumor
p1290
sg10
I5
sg28
VC0027651
p1291
sg13
I1
sa(dp1292
g7
I222
sg8
Vlymph node metastasis
p1293
sg10
I21
sg28
VC0686619
p1294
sg13
I3
sa(dp1295
g7
I105
sg8
Vcancer
p1296
sg10
I6
sg28
VC0006826
p1297
sg13
I1
sa(dp1298
g7
I265
sg8
Vinfection
p1299
sg10
I9
sg28
VC0009450
p1300
sg13
I1
sasa(dp1301
g2
VWnt-11 protein expression was positively associated with HR-HPV E6 protein expression in all 78 cervical cancer samples (P &lt; 0.001).
p1302
sg4
(lp1303
sg24
(lp1304
(dp1305
g7
I96
sg8
Vcervical cancer
p1306
sg10
I15
sg28
VC0302592
p1307
sg13
I2
sasa(dp1308
g135
(dp1309
(VJNK1
p1310
Vcervical cancer
p1311
tp1312
I01
ssg2
VFurthermore, Wnt-11 was positively associated with P-JNK1 expression and promoted cervical cancer cell proliferation and invasion.
p1313
sg4
(lp1314
(dp1315
g7
I53
sg8
g1310
sg10
I4
sg11
VP45983
p1316
sg13
I1
sasg24
(lp1317
(dp1318
g7
I103
sg8
Vproliferation
p1319
sg10
I13
sg28
VC0334094
p1320
sg13
I1
sa(dp1321
g7
I121
sg8
Vinvasion
p1322
sg10
I8
sg28
VC2699153
p1323
sg13
I1
sa(dp1324
g7
I82
sg8
g1311
sg10
I15
sg28
VC0302592
p1325
sg13
I2
sasa(dp1326
g135
(dp1327
(VJNK
p1328
Vcervical cancer
p1329
tp1330
I00
ssg2
VThese observations suggest that the increased Wnt-11 expression observed in cervical cancer cells may lead to the phosphorylation and activation of JNK-1 and significantly promote tumor cell proliferation and cell migration/invasion through activation of the Wnt/JNK pathway.
p1331
sg4
(lp1332
(dp1333
g7
I148
sg8
VJNK-1
p1334
sg10
I5
sg11
VP53779
p1335
sg13
I1
sa(dp1336
g7
I148
sg8
g1328
sg10
I3
sg11
VP53779
p1337
sg13
I1
sasg24
(lp1338
(dp1339
g7
I191
sg8
Vproliferation
p1340
sg10
I13
sg28
VC0334094
p1341
sg13
I1
sa(dp1342
g7
I180
sg8
Vtumor
p1343
sg10
I5
sg28
VC0027651
p1344
sg13
I1
sa(dp1345
g7
I76
sg8
g1329
sg10
I15
sg28
VC0302592
p1346
sg13
I2
sa(dp1347
g7
I224
sg8
Vinvasion
p1348
sg10
I8
sg28
VC2699153
p1349
sg13
I1
sasa(dp1350
g2
VConsequently, Wnt-11 may serve as a novel target for cervical cancer therapy.
p1351
sg4
(lp1352
sg24
(lp1353
(dp1354
g7
I53
sg8
Vcervical cancer
p1355
sg10
I15
sg28
VC0302592
p1356
sg13
I2
sasa(dp1357
g135
(dp1358
(Vinterleukin-10
p1359
Vtumor necrosis
p1360
tp1361
I01
ssg2
VIn this study, we aimed to explore the association among gene variants of five cytokines, tumor necrosis factor alpha (TNF-Alfa), transforming growth factor beta-1 (TGF-Beta1), interferon gamma (IFN-Gamma), interleukin-6 (IL-6), and interleukin-10 (IL-10), and clinical parameters and prognosis in patients with multiple myeloma (MM) treated with novel therapeutic drugs in Turkish population for the first time except TNF-Alfa.
p1362
sg4
(lp1363
(dp1364
g7
I249
sg8
VIL-10
p1365
sg10
I5
sg11
VP22301
p1366
sg13
I1
sa(dp1367
g7
I207
sg8
Vinterleukin-6
p1368
sg10
I13
sg11
VP05231
p1369
sg13
I1
sa(dp1370
g7
I130
sg8
Vtransforming growth factor beta-1
p1371
sg10
I33
sg11
VP01137
p1372
sg13
I4
sa(dp1373
g7
I119
sg8
VTNF-Alfa
p1374
sg10
I8
sg11
VP01375
p1375
sg13
I1
sa(dp1376
g7
I90
sg8
Vtumor necrosis factor alpha
p1377
sg10
I27
sg11
VP01375
p1378
sg13
I4
sa(dp1379
g7
I165
sg8
VTGF-Beta1
p1380
sg10
I9
sg11
VP01137
p1381
sg13
I1
sa(dp1382
g7
I195
sg8
VIFN-Gamma
p1383
sg10
I9
sg11
VP01579
p1384
sg13
I1
sa(dp1385
g7
I177
sg8
Vinterferon gamma
p1386
sg10
I16
sg11
VP01579
p1387
sg13
I2
sa(dp1388
g7
I222
sg8
VIL-6
p1389
sg10
I4
sg11
VP05231
p1390
sg13
I1
sa(dp1391
g7
I233
sg8
g1359
sg10
I14
sg11
VP22301
p1392
sg13
I1
sasg24
(lp1393
(dp1394
g7
I312
sg8
Vmultiple myeloma
p1395
sg10
I16
sg28
VC0026764
p1396
sg13
I2
sa(dp1397
g7
I90
sg8
g1360
sg10
I14
sg28
VC0333516
p1398
sg13
I2
sasa(dp1399
g135
(dp1400
(VPLA2G2A
p1401
Vheart failure
p1402
tp1403
I00
ssg2
VUsing absolute value of log2 fold-change &gt; 2 or extremely small P value (10-20) as a criterion, we identified nine significant genes (HBA1, HBB, HIST1H2AC, GSTT1, MYL7, NPPA, NPPB, PDK4, PLA2G2A) in LVH, also found in published data set for ischemic and dilated cardiomyopathy in heart failure.
p1404
sg4
(lp1405
(dp1406
g7
I166
sg8
VMYL7
p1407
sg10
I4
sg11
g12
sg13
I1
sa(dp1408
g7
I159
sg8
VGSTT1
p1409
sg10
I5
sg11
VP30711
p1410
sg13
I1
sa(dp1411
g7
I137
sg8
VHBA1
p1412
sg10
I4
sg11
VP69905
p1413
sg13
I1
sa(dp1414
g7
I143
sg8
VHBB
p1415
sg10
I3
sg11
VP02042
p1416
sg13
I1
sa(dp1417
g7
I172
sg8
VNPPA
p1418
sg10
I4
sg11
VP01160
p1419
sg13
I1
sa(dp1420
g7
I178
sg8
VNPPB
p1421
sg10
I4
sg11
VP16860
p1422
sg13
I1
sa(dp1423
g7
I148
sg8
VHIST1H2AC
p1424
sg10
I9
sg11
g12
sg13
I1
sa(dp1425
g7
I184
sg8
VPDK4
p1426
sg10
I4
sg11
g12
sg13
I1
sa(dp1427
g7
I190
sg8
g1401
sg10
I7
sg11
VP14555
p1428
sg13
I1
sasg24
(lp1429
(dp1430
g7
I257
sg8
Vdilated cardiomyopathy
p1431
sg10
I22
sg28
VC0007193
p1432
sg13
I2
sa(dp1433
g7
I202
sg8
VLVH
p1434
sg10
I3
sg28
VC0149721
p1435
sg13
I1
sa(dp1436
g7
I283
sg8
g1402
sg10
I13
sg28
VC0018802
p1437
sg13
I2
sasa(dp1438
g135
(dp1439
(Vkappa-casein-specific IgG(1)
p1440
Vatopic dermatitis
p1441
tp1442
I00
ssg2
VTolerized cow's milk protein (CMP)-sensitive atopic dermatitis had, in particular, decreased kappa-casein-specific IgG(1) levels, compared with clinically reactive patients.
p1443
sg4
(lp1444
(dp1445
g7
I93
sg8
g1440
sg10
I28
sg11
VP07498
p1446
sg13
I2
sasg24
(lp1447
(dp1448
g7
I45
sg8
g1441
sg10
I17
sg28
VC0011615
p1449
sg13
I2
sasa(dp1450
g135
(dp1451
(Vkappa-casein
p1452
Vatopic dermatitis
p1453
tp1454
I00
ssg2
VTolerised patients, particularly those with atopic dermatitis, had decreased responses to kappa-casein which were restored after Treg depletion.
p1455
sg4
(lp1456
(dp1457
g7
I90
sg8
g1452
sg10
I12
sg11
VP07498
p1458
sg13
I1
sasg24
(lp1459
(dp1460
g7
I44
sg8
g1453
sg10
I17
sg28
VC0011615
p1461
sg13
I2
sasa(dp1462
g135
(dp1463
(Vkappa-casein
p1464
Vatopic dermatitis
p1465
tp1466
I00
ssg2
VA markedly decreased proliferative response to kappa-casein in tolerised IgE-mediated CMA patients with atopic dermatitis, which was abrogated by Treg depletion, suggested a role for kappa-casein in tolerance induction.
p1467
sg4
(lp1468
(dp1469
g7
I47
sg8
Vkappa-casein
p1470
sg10
I12
sg11
VP07498
p1471
sg13
I1
sa(dp1472
g7
I73
sg8
VIgE
p1473
sg10
I3
sg11
VP01854
p1474
sg13
I1
sa(dp1475
g7
I47
sg8
g1464
sg10
I12
sg11
VP07498
p1476
sg13
I1
sasg24
(lp1477
(dp1478
g7
I21
sg8
Vproliferative
p1479
sg10
I13
sg28
VC0334094
p1480
sg13
I1
sa(dp1481
g7
I73
sg8
VIgE
p1482
sg10
I3
sg28
VC0270850
p1483
sg13
I1
sa(dp1484
g7
I104
sg8
g1465
sg10
I17
sg28
VC0011615
p1485
sg13
I2
sa(dp1486
g7
I199
sg8
Vtolerance
p1487
sg10
I9
sg28
VC0020963
p1488
sg13
I1
sasa(dp1489
g135
(dp1490
(VIgE
p1491
VIgE
p1492
tp1493
I01
ssg2
VIn order to investigate the role of food antigen-specific T cells circulating in the blood of patients with food allergy, we compared T cell response to three casein components (alpha s-, beta- and, kappa-casein) with specificities of IgG and IgE binding to the casein components in four milk-allergic patients (P1-4) with atopic dermatitis.
p1494
sg4
(lp1495
(dp1496
g7
I243
sg8
g1491
sg10
I3
sg11
VP01854
p1497
sg13
I1
sasg24
(lp1498
(dp1499
g7
I323
sg8
Vatopic dermatitis
p1500
sg10
I17
sg28
VC0011615
p1501
sg13
I2
sa(dp1502
g7
I108
sg8
Vfood allergy
p1503
sg10
I12
sg28
VC0016470
p1504
sg13
I2
sa(dp1505
g7
I243
sg8
g1492
sg10
I3
sg28
VC0270850
p1506
sg13
I1
sasa(dp1507
g135
(dp1508
(Vinsulin
p1509
Vglucose intolerance
p1510
tp1511
I00
ssg2
VStudies have identified that PKM2 is related to the development of glucose intolerance and insulin resistance in rodents and humans.
p1512
sg4
(lp1513
(dp1514
g7
I91
sg8
g1509
sg10
I7
sg11
VP01308
p1515
sg13
I1
sasg24
(lp1516
(dp1517
g7
I91
sg8
Vinsulin resistance
p1518
sg10
I18
sg28
VC0021655
p1519
sg13
I2
sa(dp1520
g7
I67
sg8
g1510
sg10
I19
sg28
VC0271650
p1521
sg13
I2
sasa(dp1522
g2
VMechanistically, we showed that hyperglycemia and diabetes decreased PKM2 tetramer formation and activity by sulfenylation in mouse glomeruli and cultured podocytes.
p1523
sg4
(lp1524
sg24
(lp1525
(dp1526
g7
I50
sg8
Vdiabetes
p1527
sg10
I8
sg28
VC0011849
p1528
sg13
I1
sa(dp1529
g7
I32
sg8
Vhyperglycemia
p1530
sg10
I13
sg28
VC0020456
p1531
sg13
I1
sasa(dp1532
g2
VPodocyte-specific Pkm2-knockout (KO) mice with diabetes developed worse albuminuria and glomerular pathology.
p1533
sg4
(lp1534
sg24
(lp1535
(dp1536
g7
I47
sg8
Vdiabetes
p1537
sg10
I8
sg28
VC0011849
p1538
sg13
I1
sa(dp1539
g7
I99
sg8
Vpathology
p1540
sg10
I9
sg28
VC0677042
p1541
sg13
I1
sasa(dp1542
g135
(dp1543
(Vsmall-molecule PKM2 activator
p1544
Vhyperglycemia
p1545
tp1546
I00
ssg2
VConversely, we found that pharmacological activation of PKM2 by a small-molecule PKM2 activator, TEPP-46, reversed hyperglycemia-induced elevation in toxic glucose metabolites and mitochondrial dysfunction, partially by increasing glycolytic flux and PGC-1Alfa mRNA in cultured podocytes.
p1547
sg4
(lp1548
(dp1549
g7
I251
sg8
VPGC-1Alfa mRNA
p1550
sg10
I14
sg11
VP20142
p1551
sg13
I2
sa(dp1552
g7
I97
sg8
VTEPP-46
p1553
sg10
I7
sg11
g12
sg13
I1
sa(dp1554
g7
I66
sg8
g1544
sg10
I29
sg11
VP05154
p1555
sg13
I3
sasg24
(lp1556
(dp1557
g7
I115
sg8
g1545
sg10
I13
sg28
VC0020456
p1558
sg13
I1
sasa(dp1559
g2
VTo identify the miR-155 targets relevant for B-cell lymphoma, we performed RNA immunoprecipitation of Argonaute 2 in Hodgkin lymphoma (HL) cells upon miR-155 inhibition and in BL cells upon ectopic expression of miR-155.
p1560
sg4
(lp1561
(dp1562
g7
I16
sg8
VmiR-155
p1563
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp1564
(dp1565
g7
I117
sg8
VHodgkin lymphoma
p1566
sg10
I16
sg28
VC0019829
p1567
sg13
I2
sa(dp1568
g7
I45
sg8
VB-cell lymphoma
p1569
sg10
I15
sg28
VC0079731
p1570
sg13
I2
sa(dp1571
g7
I135
sg8
VHL
p1572
sg10
I2
sg28
VC0019829
p1573
sg13
I1
sasa(dp1574
g135
(dp1575
(VCDK4
p1576
Vbladder cancer
p1577
tp1578
I00
ssg2
VFurther research suggested that METTL13 negatively regulates cell proliferation in bladder cancer and reinstates G1/S checkpoint via the coordinated downregulation of CDK6, CDK4 and CCND1, decreased phosphorylation of Rb and subsequent delayed cell cycle progression.
p1579
sg4
(lp1580
(dp1581
g7
I182
sg8
VCCND1
p1582
sg10
I5
sg11
VP24385
p1583
sg13
I1
sa(dp1584
g7
I173
sg8
g1576
sg10
I4
sg11
VP11802
p1585
sg13
I1
sa(dp1586
g7
I167
sg8
VCDK6
p1587
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp1588
(dp1589
g7
I66
sg8
Vproliferation
p1590
sg10
I13
sg28
VC0334094
p1591
sg13
I1
sa(dp1592
g7
I83
sg8
g1577
sg10
I14
sg28
VC0699885
p1593
sg13
I2
sasa(dp1594
g2
VmiR-29c could inhibit the proliferation, migration and invasion of bladder cancer cells via regulating CDK6.
p1595
sg4
(lp1596
(dp1597
g7
I103
sg8
VCDK6
p1598
sg10
I4
sg11
g12
sg13
I1
sa(dp1599
g7
I0
sg8
VmiR-29c
p1600
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp1601
(dp1602
g7
I67
sg8
Vbladder cancer
p1603
sg10
I14
sg28
VC0699885
p1604
sg13
I2
sa(dp1605
g7
I55
sg8
Vinvasion
p1606
sg10
I8
sg28
VC2699153
p1607
sg13
I1
sa(dp1608
g7
I26
sg8
Vproliferation
p1609
sg10
I13
sg28
VC0334094
p1610
sg13
I1
sasa(dp1611
g135
(dp1612
(Vp34cdc2
p1613
VSEGA
p1614
tp1615
I01
ssg2
Vp34cdc2, collapsin response mediator protein 4 (CRMP4), doublecortin (DCX), HuD, and NeuN expression was assessed in tuber (n = 16) and subependymal giant cell astrocytoma (SEGA; n = 6) specimens in tuberous sclerosis complex to define the developmental phenotype and lineage of giant cells (CGs) in these lesions.
p1616
sg4
(lp1617
(dp1618
g7
I85
sg8
VNeuN
p1619
sg10
I4
sg11
g12
sg13
I1
sa(dp1620
g7
I48
sg8
VCRMP4
p1621
sg10
I5
sg11
g12
sg13
I1
sa(dp1622
g7
I70
sg8
VDCX
p1623
sg10
I3
sg11
g12
sg13
I1
sa(dp1624
g7
I9
sg8
Vcollapsin response mediator protein 4
p1625
sg10
I37
sg11
g12
sg13
I5
sa(dp1626
g7
I76
sg8
VHuD
p1627
sg10
I3
sg11
VP26378
p1628
sg13
I1
sa(dp1629
g7
I0
sg8
g1613
sg10
I7
sg11
VP06493
p1630
sg13
I1
sa(dp1631
g7
I56
sg8
Vdoublecortin
p1632
sg10
I12
sg11
g12
sg13
I1
sasg24
(lp1633
(dp1634
g7
I199
sg8
Vtuberous sclerosis complex
p1635
sg10
I26
sg28
VC0041341
p1636
sg13
I3
sa(dp1637
g7
I136
sg8
Vsubependymal giant cell astrocytoma
p1638
sg10
I35
sg28
VC0205768
p1639
sg13
I4
sa(dp1640
g7
I149
sg8
Vgiant
p1641
sg10
I5
sg28
VC0017547
p1642
sg13
I1
sa(dp1643
g7
I173
sg8
g1614
sg10
I4
sg28
VC0205768
p1644
sg13
I1
sasa(dp1645
g135
(dp1646
(VITGAX
p1647
Vaggressive
p1648
tp1649
I00
ssg2
VFirst, logistic regression analysis in two human prostate gene expression datasets revealed that expression levels of five genes (CXCL14, ITGAX, LPCAT2, RNASEH2A, and ZNF322) were positively correlated with aggressive prostate cancer and two genes (CCL19 and HIST1H1A) were protective for aggressive prostate cancer.
p1650
sg4
(lp1651
(dp1652
g7
I153
sg8
VRNASEH2A
p1653
sg10
I8
sg11
g12
sg13
I1
sa(dp1654
g7
I130
sg8
VCXCL14
p1655
sg10
I6
sg11
g12
sg13
I1
sa(dp1656
g7
I167
sg8
VZNF322
p1657
sg10
I6
sg11
g12
sg13
I1
sa(dp1658
g7
I138
sg8
g1647
sg10
I5
sg11
VP20702
p1659
sg13
I1
sa(dp1660
g7
I145
sg8
VLPCAT2
p1661
sg10
I6
sg11
g12
sg13
I1
sa(dp1662
g7
I259
sg8
VHIST1H1A
p1663
sg10
I8
sg11
g12
sg13
I1
sa(dp1664
g7
I249
sg8
VCCL19
p1665
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp1666
(dp1667
g7
I218
sg8
Vprostate cancer
p1668
sg10
I15
sg28
VC0600139
p1669
sg13
I2
sa(dp1670
g7
I207
sg8
Vaggressive
p1671
sg10
I10
sg28
VC0001807
p1672
sg13
I1
sa(dp1673
g7
I218
sg8
Vprostate cancer
p1674
sg10
I15
sg28
VC0600139
p1675
sg13
I2
sa(dp1676
g7
I207
sg8
g1648
sg10
I10
sg28
VC0001807
p1677
sg13
I1
sasa(dp1678
g135
(dp1679
(VH1 antihistamines
p1680
Vallergic rhinitis
p1681
tp1682
I00
ssg2
VSecond generation H1 antihistamines (H1A) are currently recommended as first choice medications for allergic rhinitis and rhinoconjunctivitis.
p1683
sg4
(lp1684
(dp1685
g7
I18
sg8
g1680
sg10
I17
sg11
VP08620
p1686
sg13
I2
sa(dp1687
g7
I37
sg8
VH1A
p1688
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp1689
(dp1690
g7
I122
sg8
Vrhinoconjunctivitis
p1691
sg10
I19
sg28
VC0861155
p1692
sg13
I1
sa(dp1693
g7
I100
sg8
g1681
sg10
I17
sg28
VC2607914
p1694
sg13
I2
sasa(dp1695
g2
VConsecutive patients suffering from allergic rhinitis or rhinoconjunctivitis were included and followed prospectively for 30 days from the prescription of a second generation H1A in monotherapy.
p1696
sg4
(lp1697
(dp1698
g7
I175
sg8
VH1A
p1699
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp1700
(dp1701
g7
I57
sg8
Vrhinoconjunctivitis
p1702
sg10
I19
sg28
VC0861155
p1703
sg13
I1
sa(dp1704
g7
I21
sg8
Vsuffering
p1705
sg10
I9
sg28
VC0683278
p1706
sg13
I1
sa(dp1707
g7
I36
sg8
Vallergic rhinitis
p1708
sg10
I17
sg28
VC2607914
p1709
sg13
I2
sasa(dp1710
g135
(dp1711
(VH1b
p1712
Vinfluenza
p1713
tp1714
I00
ssg2
VAntibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e., H1, H2, H5, H6) but has little neutralizing activity against the H1b clade.
p1715
sg4
(lp1716
(dp1717
g7
I143
sg8
g1712
sg10
I3
sg11
VP16401
p1718
sg13
I1
sasg24
(lp1719
(dp1720
g7
I34
sg8
g1713
sg10
I9
sg28
VC0021400
p1721
sg13
I1
sasa(dp1722
g135
(dp1723
(VOTX2
p1724
Vretinitis pigmentosa
p1725
tp1726
I01
ssg2
VWe have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells.
p1727
sg4
(lp1728
(dp1729
g7
I22
sg8
g1724
sg10
I4
sg11
VP32243
p1730
sg13
I1
sa(dp1731
g7
I163
sg8
VMertk
p1732
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp1733
(dp1734
g7
I119
sg8
g1725
sg10
I20
sg28
VC0035334
p1735
sg13
I2
sasa(dp1736
g135
(dp1737
(VOTX2
p1738
Vage-related macular degeneration
p1739
tp1740
I00
ssg2
VTransplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.
p1741
sg4
(lp1742
(dp1743
g7
I19
sg8
g1738
sg10
I4
sg11
VP32243
p1744
sg13
I1
sasg24
(lp1745
(dp1746
g7
I88
sg8
Vretinal diseases
p1747
sg10
I16
sg28
VC0035309
p1748
sg13
I2
sa(dp1749
g7
I151
sg8
g1739
sg10
I32
sg28
VC0242383
p1750
sg13
I3
sasa(dp1751
g135
(dp1752
(VOTX2
p1753
VAMD
p1754
tp1755
I00
ssg2
VTherapeutic restoration of OTX2 expression might help revive RPE and visual function in retinal diseases such as AMD.
p1756
sg4
(lp1757
(dp1758
g7
I27
sg8
g1753
sg10
I4
sg11
VP32243
p1759
sg13
I1
sasg24
(lp1760
(dp1761
g7
I88
sg8
Vretinal diseases
p1762
sg10
I16
sg28
VC0035309
p1763
sg13
I2
sa(dp1764
g7
I113
sg8
g1754
sg10
I3
sg28
VC0242383
p1765
sg13
I1
sasa(dp1766
g135
(dp1767
(VOtx2
p1768
Vphotoreceptor degeneration
p1769
tp1770
I00
ssg2
VThe retinal disease resembles conditional mice models that show slow photoreceptor degeneration secondary to loss of Otx2 function in the adult RPE.
p1771
sg4
(lp1772
(dp1773
g7
I117
sg8
g1768
sg10
I4
sg11
VP32243
p1774
sg13
I1
sasg24
(lp1775
(dp1776
g7
I83
sg8
Vdegeneration secondary
p1777
sg10
I22
sg28
VC0043020
p1778
sg13
I2
sa(dp1779
g7
I4
sg8
Vretinal disease
p1780
sg10
I15
sg28
VC0035309
p1781
sg13
I2
sa(dp1782
g7
I69
sg8
g1769
sg10
I26
sg28
VC1998028
p1783
sg13
I2
sasa(dp1784
g135
(dp1785
(VSox9
p1786
VRP59
p1787
tp1788
I00
ssg2
VWhen the beads were coated with amelogenin gene splice products (A+4 or A-4), the expression of osteo-chondrogenic markers (RP59, Sox9, or BSP) was also observed.
p1789
sg4
(lp1790
(dp1791
g7
I32
sg8
Vamelogenin gene splice products
p1792
sg10
I31
sg11
g12
sg13
I4
sa(dp1793
g7
I130
sg8
g1786
sg10
I4
sg11
VP48436
p1794
sg13
I1
sasg24
(lp1795
(dp1796
g7
I124
sg8
g1787
sg10
I4
sg28
VC3151227
p1797
sg13
I1
sasa(dp1798
g2
VThis study has provided evidence that the regulation of the SVCT2 transporter plays an important role not only in T1D osteoporosis but also in other oxidative stress-related musculoskeletal complications.
p1799
sg4
(lp1800
(dp1801
g7
I60
sg8
VSVCT2 transporter
p1802
sg10
I17
sg11
g12
sg13
I2
sasg24
(lp1803
(dp1804
g7
I118
sg8
Vosteoporosis
p1805
sg10
I12
sg28
VC0029456
p1806
sg13
I1
sa(dp1807
g7
I149
sg8
Voxidative stress
p1808
sg10
I16
sg28
VC0242606
p1809
sg13
I2
sasa(dp1810
g135
(dp1811
(VHMG-CoA synthase
p1812
Vlethargy
p1813
tp1814
I00
ssg2
VAutosomal recessive HMG-CoA synthase deficiency (HMGCS2D) is characterized by hypoketotic hypoglycemia, vomiting, lethargy, and hepatomegaly after periods of prolonged fasting or illness.
p1815
sg4
(lp1816
(dp1817
g7
I20
sg8
g1812
sg10
I16
sg11
VP54868
p1818
sg13
I2
sasg24
(lp1819
(dp1820
g7
I90
sg8
Vhypoglycemia
p1821
sg10
I12
sg28
VC0020615
p1822
sg13
I1
sa(dp1823
g7
I104
sg8
Vvomiting
p1824
sg10
I8
sg28
VC0042963
p1825
sg13
I1
sa(dp1826
g7
I128
sg8
Vhepatomegaly
p1827
sg10
I12
sg28
VC0019209
p1828
sg13
I1
sa(dp1829
g7
I24
sg8
VCoA
p1830
sg10
I3
sg28
VC2678439
p1831
sg13
I1
sa(dp1832
g7
I114
sg8
g1813
sg10
I8
sg28
VC0023380
p1833
sg13
I1
sasa(dp1834
g2
VMost frequent disease presentation in our patients was characterized with early and prominent oromandibular dystonia (OMD), followed by severe generalized dystonia and early loss of mobility within the first five years of prolonged disease duration (18.7 +/- 10.0 years).
p1835
sg4
(lp1836
sg24
(lp1837
(dp1838
g7
I94
sg8
Voromandibular dystonia
p1839
sg10
I22
sg28
VC2242577
p1840
sg13
I2
sa(dp1841
g7
I118
sg8
VOMD
p1842
sg10
I3
sg28
VC3150833
p1843
sg13
I1
sa(dp1844
g7
I143
sg8
Vgeneralized dystonia
p1845
sg10
I20
sg28
VC1848954
p1846
sg13
I2
sasa(dp1847
g2
VEight out of 9 patients reached 7 significant clinical milestones (OMD, generalized dystonia, dysarthria, dysphagia, postural instability, gait difficulties, ADL dependency) in the first 4.6 years of disease course.
p1848
sg4
(lp1849
sg24
(lp1850
(dp1851
g7
I72
sg8
Vgeneralized dystonia
p1852
sg10
I20
sg28
VC1848954
p1853
sg13
I2
sa(dp1854
g7
I139
sg8
Vgait difficulties
p1855
sg10
I17
sg28
VC0575081
p1856
sg13
I2
sa(dp1857
g7
I67
sg8
VOMD
p1858
sg10
I3
sg28
VC3150833
p1859
sg13
I1
sa(dp1860
g7
I106
sg8
Vdysphagia
p1861
sg10
I9
sg28
VC0011168
p1862
sg13
I1
sa(dp1863
g7
I94
sg8
Vdysarthria
p1864
sg10
I10
sg28
VC0013362
p1865
sg13
I1
sasa(dp1866
g2
VA smoothelin-deficient mouse model may help to establish the role of smoothelin-A in intestinal contraction and provide a model for myogenic chronic intestinal pseudo-obstruction.
p1867
sg4
(lp1868
sg24
(lp1869
(dp1870
g7
I96
sg8
Vcontraction
p1871
sg10
I11
sg28
VC1140999
p1872
sg13
I1
sa(dp1873
g7
I141
sg8
Vchronic intestinal pseudo-obstruction
p1874
sg10
I37
sg28
VC0238062
p1875
sg13
I3
sasa(dp1876
g2
VThe pathology of mice lacking smoothelin-A is reminiscent of that seen in patients with chronic intestinal pseudo-obstruction.
p1877
sg4
(lp1878
sg24
(lp1879
(dp1880
g7
I4
sg8
Vpathology
p1881
sg10
I9
sg28
VC0677042
p1882
sg13
I1
sa(dp1883
g7
I88
sg8
Vchronic intestinal pseudo-obstruction
p1884
sg10
I37
sg28
VC0238062
p1885
sg13
I3
sasa(dp1886
g2
VHereditary tyrosinemia type 1 (HT1) is characterized by severe progressive liver disease and renal tubular dysfunction.
p1887
sg4
(lp1888
sg24
(lp1889
(dp1890
g7
I0
sg8
VHereditary tyrosinemia
p1891
sg10
I22
sg28
VC0268483
p1892
sg13
I2
sa(dp1893
g7
I93
sg8
Vrenal tubular dysfunction
p1894
sg10
I25
sg28
VC0151747
p1895
sg13
I3
sa(dp1896
g7
I75
sg8
Vliver disease
p1897
sg10
I13
sg28
VC0023895
p1898
sg13
I2
sasa(dp1899
g135
(dp1900
(VFAH
p1901
Vkidney dysfunction
p1902
tp1903
I00
ssg2
VIf left untreated this deficiency of functional FAH leads to a buildup of toxic metabolites that can cause liver disease, kidney dysfunction and high mortality.
p1904
sg4
(lp1905
(dp1906
g7
I48
sg8
g1901
sg10
I3
sg11
VP16930
p1907
sg13
I1
sasg24
(lp1908
(dp1909
g7
I113
sg8
Vdisease, kidney
p1910
sg10
I15
sg28
VC0022658
p1911
sg13
I2
sa(dp1912
g7
I122
sg8
g1902
sg10
I18
sg28
VC0151746
p1913
sg13
I2
sasa(dp1914
g135
(dp1915
(Vfumarylacetoacetate hydrolase
p1916
Vfibrosis
p1917
tp1918
I00
ssg2
VIn this study, we investigated whether fumarylacetoacetate hydrolase deficient (FAH-/-) pigs, a novel large-animal model of HT1, develop fibrosis and cirrhosis characteristic of the human disease.
p1919
sg4
(lp1920
(dp1921
g7
I39
sg8
g1916
sg10
I29
sg11
VP16930
p1922
sg13
I2
sasg24
(lp1923
(dp1924
g7
I150
sg8
Vcirrhosis
p1925
sg10
I9
sg28
VC0023890
p1926
sg13
I1
sa(dp1927
g7
I137
sg8
g1917
sg10
I8
sg28
VC0016059
p1928
sg13
I1
sasa(dp1929
g2
VUnder conditions of low-dose NTBC, FAH-/- pigs developed liver fibrosis and portal hypertension, and thus may serve as a large-animal model of chronic liver disease.
p1930
sg4
(lp1931
sg24
(lp1932
(dp1933
g7
I57
sg8
Vliver fibrosis
p1934
sg10
I14
sg28
VC0239946
p1935
sg13
I2
sa(dp1936
g7
I76
sg8
Vportal hypertension
p1937
sg10
I19
sg28
VC0020541
p1938
sg13
I2
sa(dp1939
g7
I143
sg8
Vchronic liver disease
p1940
sg10
I21
sg28
VC0341439
p1941
sg13
I3
sasa(dp1942
g135
(dp1943
(VFah
p1944
Vcirrhosis
p1945
tp1946
I00
ssg2
VFah-deficient mice and pigs are phenotypically analogous to human HT1, but do not recapitulate all the chronic features of the human disorder, especially liver fibrosis and cirrhosis.
p1947
sg4
(lp1948
(dp1949
g7
I0
sg8
g1944
sg10
I3
sg11
VP16930
p1950
sg13
I1
sasg24
(lp1951
(dp1952
g7
I154
sg8
Vliver fibrosis
p1953
sg10
I14
sg28
VC0239946
p1954
sg13
I2
sa(dp1955
g7
I173
sg8
g1945
sg10
I9
sg28
VC0023890
p1956
sg13
I1
sasa(dp1957
g135
(dp1958
(VFah mutant
p1959
Vcirrhosis
p1960
tp1961
I00
ssg2
VMore importantly, the Fah(-/-) rats developed remarkable liver fibrosis and cirrhosis, which have not been observed in Fah mutant mice or pigs.
p1962
sg4
(lp1963
(dp1964
g7
I22
sg8
VFah(-/-)
p1965
sg10
I8
sg11
VP16930
p1966
sg13
I1
sa(dp1967
g7
I119
sg8
g1959
sg10
I10
sg11
VP16930
p1968
sg13
I2
sasg24
(lp1969
(dp1970
g7
I57
sg8
Vliver fibrosis
p1971
sg10
I14
sg28
VC0239946
p1972
sg13
I2
sa(dp1973
g7
I76
sg8
g1960
sg10
I9
sg28
VC0023890
p1974
sg13
I1
sa(dp1975
g7
I123
sg8
Vmutant
p1976
sg10
I6
sg28
VC0596988
p1977
sg13
I1
sasa(dp1978
g135
(dp1979
(VFah(-/-)
p1980
Vliver fibrosis
p1981
tp1982
I00
ssg2
VMoreover, the highly efficient repopulation of hepatocytes in Fah(-/-) livers prevented the progression of liver fibrosis to cirrhosis and in turn restored liver architecture.
p1983
sg4
(lp1984
(dp1985
g7
I62
sg8
g1980
sg10
I8
sg11
VP16930
p1986
sg13
I1
sasg24
(lp1987
(dp1988
g7
I125
sg8
Vcirrhosis
p1989
sg10
I9
sg28
VC0023890
p1990
sg13
I1
sa(dp1991
g7
I107
sg8
g1981
sg10
I14
sg28
VC0239946
p1992
sg13
I2
sasa(dp1993
g135
(dp1994
(VFah
p1995
Vliver cirrhosis
p1996
tp1997
I00
ssg2
VThese results indicate that Fah(-/-) rats may be used as an animal model of HT1 with liver cirrhosis.
p1998
sg4
(lp1999
(dp2000
g7
I28
sg8
g1995
sg10
I3
sg11
VP16930
p2001
sg13
I1
sasg24
(lp2002
(dp2003
g7
I85
sg8
g1996
sg10
I15
sg28
VC0023890
p2004
sg13
I2
sasa(dp2005
g135
(dp2006
(VCHAT
p2007
Vglaucoma
p2008
tp2009
I00
ssg2
VRecent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).
p2010
sg4
(lp2011
(dp2012
g7
I178
sg8
VARHGEF12
p2013
sg10
I8
sg11
g12
sg13
I1
sa(dp2014
g7
I268
sg8
VGLIS3
p2015
sg10
I5
sg11
g12
sg13
I1
sa(dp2016
g7
I201
sg8
VATXN2
p2017
sg10
I5
sg11
g12
sg13
I1
sa(dp2018
g7
I150
sg8
VGMDS
p2019
sg10
I4
sg11
g12
sg13
I1
sa(dp2020
g7
I255
sg8
VEPDR1
p2021
sg10
I5
sg11
g12
sg13
I1
sa(dp2022
g7
I194
sg8
VFOXC1
p2023
sg10
I5
sg11
g12
sg13
I1
sa(dp2024
g7
I162
sg8
VTGFBR3
p2025
sg10
I6
sg11
g12
sg13
I1
sa(dp2026
g7
I283
sg8
VDPM2-FAM102
p2027
sg10
I11
sg11
g12
sg13
I1
sa(dp2028
g7
I275
sg8
VFERMT2
p2029
sg10
I6
sg11
g12
sg13
I1
sa(dp2030
g7
I156
sg8
VPMM2
p2031
sg10
I4
sg11
g12
sg13
I1
sa(dp2032
g7
I188
sg8
VGAS7
p2033
sg10
I4
sg11
g12
sg13
I1
sa(dp2034
g7
I262
sg8
g2007
sg10
I4
sg11
VP28329
p2035
sg13
I1
sa(dp2036
g7
I143
sg8
VAFAP1
p2037
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp2038
(dp2039
g7
I60
sg8
Vglaucoma
p2040
sg10
I8
sg28
VC0017601
p2041
sg13
I1
sa(dp2042
g7
I114
sg8
Vopen-angle glaucoma
p2043
sg10
I19
sg28
VC0017612
p2044
sg13
I2
sa(dp2045
g7
I323
sg8
VXFS
p2046
sg10
I3
sg28
VC0206368
p2047
sg13
I1
sa(dp2048
g7
I100
sg8
VPOAG
p2049
sg10
I4
sg28
VC0339573
p2050
sg13
I1
sa(dp2051
g7
I301
sg8
Vexfoliation syndrome
p2052
sg10
I20
sg28
VC0206368
p2053
sg13
I2
sa(dp2054
g7
I223
sg8
Vprimary angle-closure glaucoma
p2055
sg10
I30
sg28
VC0017606
p2056
sg13
I3
sa(dp2057
g7
I60
sg8
g2008
sg10
I8
sg28
VC0017601
p2058
sg13
I1
sasa(dp2059
g135
(dp2060
(VITGA4
p2061
Vautoimmune diseases
p2062
tp2063
I00
ssg2
VRecently, a genome-wide association study identified genetic variations in ITGA4 and HLA-DRB1 that affect the LMR levels and were widely believed to be susceptibility genes for autoimmune diseases, including rheumatoid arthritis (RA).
p2064
sg4
(lp2065
(dp2066
g7
I85
sg8
VHLA
p2067
sg10
I3
sg11
VP30486
p2068
sg13
I1
sa(dp2069
g7
I89
sg8
VDRB1
p2070
sg10
I4
sg11
g12
sg13
I1
sa(dp2071
g7
I75
sg8
g2061
sg10
I5
sg11
VP13612
p2072
sg13
I1
sasg24
(lp2073
(dp2074
g7
I208
sg8
Vrheumatoid arthritis
p2075
sg10
I20
sg28
VC0003873
p2076
sg13
I2
sa(dp2077
g7
I230
sg8
VRA
p2078
sg10
I2
sg28
VC0003873
p2079
sg13
I1
sa(dp2080
g7
I177
sg8
g2062
sg10
I19
sg28
VC0004364
p2081
sg13
I2
sasa(dp2082
g135
(dp2083
(VC-reactive protein
p2084
Vsystemic sclerosis
p2085
tp2086
I00
ssg2
VTo evaluate serum levels of fractalkine (FKN), a mediator of leukocyte transmigration, C-reactive protein (CRP) and expression of integrins CD11a and CD49d on peripheral blood lymphocytes in systemic sclerosis (SSc) and to investigate whether they are modulated by intravenous prostaglandin E1 (PGE1).
p2087
sg4
(lp2088
(dp2089
g7
I140
sg8
VCD11a
p2090
sg10
I5
sg11
VP20701
p2091
sg13
I1
sa(dp2092
g7
I150
sg8
VCD49d
p2093
sg10
I5
sg11
VP13612
p2094
sg13
I1
sa(dp2095
g7
I107
sg8
VCRP
p2096
sg10
I3
sg11
VP02741
p2097
sg13
I1
sa(dp2098
g7
I87
sg8
g2084
sg10
I18
sg11
VP02741
p2099
sg13
I2
sasg24
(lp2100
(dp2101
g7
I211
sg8
VSSc
p2102
sg10
I3
sg28
VC0036421
p2103
sg13
I1
sa(dp2104
g7
I191
sg8
g2085
sg10
I18
sg28
VC0036421
p2105
sg13
I2
sasa(dp2106
g135
(dp2107
(VCD11a
p2108
Vsystemic sclerosis
p2109
tp2110
I01
ssg2
VProstaglandin E1 down-regulates serum fractalkine level, as well as CD11a and CD49d expression on peripheral blood lymphocytes, which suggests additional mechanisms in which this vasodilatatory agent exerts its efficacy in systemic sclerosis.
p2111
sg4
(lp2112
(dp2113
g7
I78
sg8
VCD49d
p2114
sg10
I5
sg11
VP13612
p2115
sg13
I1
sa(dp2116
g7
I68
sg8
g2108
sg10
I5
sg11
VP20701
p2117
sg13
I1
sasg24
(lp2118
(dp2119
g7
I223
sg8
g2109
sg10
I18
sg28
VC0036421
p2120
sg13
I2
sasa(dp2121
g135
(dp2122
(VRSK
p2123
Vmetastasis
p2124
tp2125
I00
ssg2
VMR-1S directly phosphorylates and activates the MEK-ERK-RSK pathway to accelerate cancer growth and facilitates metastasis by activating the MLC2-FAK-AKT pathway.
p2126
sg4
(lp2127
(dp2128
g7
I141
sg8
VMLC2
p2129
sg10
I4
sg11
VP24844
p2130
sg13
I1
sa(dp2131
g7
I150
sg8
VAKT
p2132
sg10
I3
sg11
g12
sg13
I1
sa(dp2133
g7
I48
sg8
VMEK
p2134
sg10
I3
sg11
VP45985
p2135
sg13
I1
sa(dp2136
g7
I52
sg8
VERK
p2137
sg10
I3
sg11
VP29323
p2138
sg13
I1
sa(dp2139
g7
I146
sg8
VFAK
p2140
sg10
I3
sg11
g12
sg13
I1
sa(dp2141
g7
I0
sg8
VMR-1S
p2142
sg10
I5
sg11
VP08235
p2143
sg13
I1
sa(dp2144
g7
I56
sg8
g2123
sg10
I3
sg11
VP51812
p2145
sg13
I1
sasg24
(lp2146
(dp2147
g7
I112
sg8
g2124
sg10
I10
sg28
VC0027627
p2148
sg13
I1
sa(dp2149
g7
I82
sg8
Vcancer
p2150
sg10
I6
sg28
VC0006826
p2151
sg13
I1
sasa(dp2152
g135
(dp2153
(VERK
p2154
Vlung cancer
p2155
tp2156
I00
ssg2
VAfter overexpressing TMEM17, levels of p-ERK and its downstream molecules, p-P90RSK and Snail, were down-regulated, while levels of Occludin and Zo-1 were up-regulated, which result in the inhibition of invasion and migration ability of lung cancer cells.
p2157
sg4
(lp2158
(dp2159
g7
I132
sg8
VOccludin
p2160
sg10
I8
sg11
g12
sg13
I1
sa(dp2161
g7
I41
sg8
g2154
sg10
I3
sg11
VP29323
p2162
sg13
I1
sa(dp2163
g7
I145
sg8
VZo-1
p2164
sg10
I4
sg11
g12
sg13
I1
sa(dp2165
g7
I21
sg8
VTMEM17
p2166
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp2167
(dp2168
g7
I203
sg8
Vinvasion
p2169
sg10
I8
sg28
VC2699153
p2170
sg13
I1
sa(dp2171
g7
I237
sg8
g2155
sg10
I11
sg28
VC0684249
p2172
sg13
I2
sasa(dp2173
g135
(dp2174
(VsPLA2-IIA
p2175
Vobesity
p2176
tp2177
I00
ssg2
VHerein, to understand the underlying relationship between obesity and brain tumors, we investigated the effect of leptin, alone or in combination with sPLA2-IIA on astrocytoma cell functions.
p2178
sg4
(lp2179
(dp2180
g7
I114
sg8
Vleptin
p2181
sg10
I6
sg11
VP41159
p2182
sg13
I1
sa(dp2183
g7
I151
sg8
g2175
sg10
I9
sg11
VP14555
p2184
sg13
I1
sasg24
(lp2185
(dp2186
g7
I164
sg8
Vastrocytoma
p2187
sg10
I11
sg28
VC0004114
p2188
sg13
I1
sa(dp2189
g7
I70
sg8
Vbrain tumors
p2190
sg10
I12
sg28
VC0006118
p2191
sg13
I2
sa(dp2192
g7
I58
sg8
g2176
sg10
I7
sg28
VC0028754
p2193
sg13
I1
sasa(dp2194
g135
(dp2195
(VPLA2g2a
p2196
Vobesity
p2197
tp2198
I00
ssg2
VPLA2g2a was elevated with hypothyroidism and high fat diets which may contribute to the low grade inflammation associated with hypothyroidism and diet induced obesity.
p2199
sg4
(lp2200
(dp2201
g7
I0
sg8
g2196
sg10
I7
sg11
VP14555
p2202
sg13
I1
sasg24
(lp2203
(dp2204
g7
I26
sg8
Vhypothyroidism
p2205
sg10
I14
sg28
VC0020676
p2206
sg13
I1
sa(dp2207
g7
I26
sg8
Vhypothyroidism
p2208
sg10
I14
sg28
VC0020676
p2209
sg13
I1
sa(dp2210
g7
I98
sg8
Vinflammation
p2211
sg10
I12
sg28
VC0021368
p2212
sg13
I1
sa(dp2213
g7
I159
sg8
g2197
sg10
I7
sg28
VC0028754
p2214
sg13
I1
sasa(dp2215
g135
(dp2216
(VsPLA2
p2217
Vvisceral obesity
p2218
tp2219
I00
ssg2
VThere were significant correlations between age, visceral obesity, MPO, sPLA2, and SAA (r = 0.43; p = 0.00; r = 0.30; p = 0.00; r = 0.28; p = 0.00 and r = 0.53; p = 0.00).
p2220
sg4
(lp2221
(dp2222
g7
I67
sg8
VMPO
p2223
sg10
I3
sg11
VP05164
p2224
sg13
I1
sa(dp2225
g7
I72
sg8
g2217
sg10
I5
sg11
VP14555
p2226
sg13
I1
sasg24
(lp2227
(dp2228
g7
I49
sg8
g2218
sg10
I16
sg28
VC2936179
p2229
sg13
I2
sasa(dp2230
g135
(dp2231
(Vpla2g2a
p2232
Vmetabolic syndrome
p2233
tp2234
I00
ssg2
VWe suggest that pla2g2a may have a causal relationship with chronic adiposity and metabolic syndrome and that its inhibition in vivo may be a valuable new approach to treat obesity, type 2 diabetes, and metabolic dysfunction in humans.
p2235
sg4
(lp2236
(dp2237
g7
I16
sg8
g2232
sg10
I7
sg11
VP14555
p2238
sg13
I1
sasg24
(lp2239
(dp2240
g7
I182
sg8
Vtype 2 diabetes
p2241
sg10
I15
sg28
VC0011860
p2242
sg13
I3
sa(dp2243
g7
I68
sg8
Vadiposity
p2244
sg10
I9
sg28
VC0028754
p2245
sg13
I1
sa(dp2246
g7
I173
sg8
Vobesity
p2247
sg10
I7
sg28
VC0028754
p2248
sg13
I1
sa(dp2249
g7
I82
sg8
g2233
sg10
I18
sg28
VC0524620
p2250
sg13
I2
sasa(dp2251
g135
(dp2252
(VODC
p2253
VAfrican trypanosomiasis
p2254
tp2255
I00
ssg2
VTrypanosoma brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and metabolism by ornithine decarboxylase (ODC) for survival.
p2256
sg4
(lp2257
(dp2258
g7
I133
sg8
Vornithine decarboxylase
p2259
sg10
I23
sg11
VP11926
p2260
sg13
I2
sa(dp2261
g7
I158
sg8
g2253
sg10
I3
sg11
VP11926
p2262
sg13
I1
sa(dp2263
g7
I82
sg8
VHAT
p2264
sg10
I3
sg11
g12
sg13
I1
sa(dp2265
g7
I51
sg8
Vhuman African trypanosomiasis
p2266
sg10
I29
sg11
g12
sg13
I3
sasg24
(lp2267
(dp2268
g7
I57
sg8
g2254
sg10
I23
sg28
VC0041228
p2269
sg13
I2
sasa(dp2270
g2
VFurthermore, the molecular dynamics simulation work reveals that ZINC67909154 could be a potent inhibitor and this compound can be used to combat VL disease Conclusion: This study concludes that ZINC67909154 has the great potential to inhibit L. donovani ODC and would add to the drug discovery process against visceral leishmaniasis.
p2271
sg4
(lp2272
sg24
(lp2273
(dp2274
g7
I311
sg8
Vvisceral leishmaniasis
p2275
sg10
I22
sg28
VC0023290
p2276
sg13
I2
sa(dp2277
g7
I269
sg8
Vadd
p2278
sg10
I3
sg28
VC0004269
p2279
sg13
I1
sasa(dp2280
g135
(dp2281
(Vdeoxyhypusine synthase
p2282
Vleishmaniasis
p2283
tp2284
I00
ssg2
Varginase (ARG), ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase (AdoMetDC), spermidine synthase (SpdS), trypanothione synthetase (TryS or TSA), trypanothione reductase (TryR or TR), tryparedoxin peroxidase (TXNPx), deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) are promising targets for the development of new drugs against leishmaniasis.
p2285
sg4
(lp2286
(dp2287
g7
I0
sg8
Varginase (ARG), ornithine decarboxylase
p2288
sg10
I39
sg11
VP11926
p2289
sg13
I4
sa(dp2290
g7
I266
sg8
Vdeoxyhypusine hydroxylase
p2291
sg10
I25
sg11
g12
sg13
I2
sa(dp2292
g7
I115
sg8
VSpdS
p2293
sg10
I4
sg11
VP35453
p2294
sg13
I1
sa(dp2295
g7
I225
sg8
VTXNPx
p2296
sg10
I5
sg11
VP30041
p2297
sg13
I1
sa(dp2298
g7
I83
sg8
VAdoMetDC
p2299
sg10
I8
sg11
VP17707
p2300
sg13
I1
sa(dp2301
g7
I156
sg8
VTSA
p2302
sg10
I3
sg11
VP32119
p2303
sg13
I1
sa(dp2304
g7
I94
sg8
Vspermidine synthase
p2305
sg10
I19
sg11
VP19623
p2306
sg13
I2
sa(dp2307
g7
I257
sg8
VDHS
p2308
sg10
I3
sg11
VP49366
p2309
sg13
I1
sa(dp2310
g7
I41
sg8
VODC
p2311
sg10
I3
sg11
VP11926
p2312
sg13
I1
sa(dp2313
g7
I162
sg8
Vtrypanothione reductase
p2314
sg10
I23
sg11
g12
sg13
I2
sa(dp2315
g7
I200
sg8
Vtryparedoxin peroxidase
p2316
sg10
I23
sg11
VP30041
p2317
sg13
I2
sa(dp2318
g7
I293
sg8
VDOHH
p2319
sg10
I4
sg11
g12
sg13
I1
sa(dp2320
g7
I47
sg8
VS-adenosylmethionine decarboxylase
p2321
sg10
I34
sg11
VP17707
p2322
sg13
I2
sa(dp2323
g7
I233
sg8
g2282
sg10
I22
sg11
VP49366
p2324
sg13
I2
sasg24
(lp2325
(dp2326
g7
I257
sg8
VDHS
p2327
sg10
I3
sg28
VC0272051
p2328
sg13
I1
sa(dp2329
g7
I362
sg8
g2283
sg10
I13
sg28
VC0023281
p2330
sg13
I1
sasa(dp2331
g135
(dp2332
(VTGF-Beta
p2333
Vcutaneous leishmaniasis
p2334
tp2335
I00
ssg2
VThe plasma levels of arginase I, ornithine decarboxylase (ODC), transforming growth factor Beta (TGF-Beta), and prostaglandin E2 (PGE2) were higher in patients with DCL, compared with patients with localized cutaneous leishmaniasis (LCL) or with controls from an area of endemicity.
p2336
sg4
(lp2337
(dp2338
g7
I33
sg8
Vornithine decarboxylase
p2339
sg10
I23
sg11
VP11926
p2340
sg13
I2
sa(dp2341
g7
I21
sg8
Varginase I
p2342
sg10
I10
sg11
VP05089
p2343
sg13
I2
sa(dp2344
g7
I64
sg8
Vtransforming growth factor Beta
p2345
sg10
I31
sg11
VP18075
p2346
sg13
I4
sa(dp2347
g7
I58
sg8
VODC
p2348
sg10
I3
sg11
VP11926
p2349
sg13
I1
sa(dp2350
g7
I97
sg8
g2333
sg10
I8
sg11
VP18075
p2351
sg13
I1
sasg24
(lp2352
(dp2353
g7
I208
sg8
g2334
sg10
I23
sg28
VC0023283
p2354
sg13
I2
sasa(dp2355
g2
VImmunohistochemistry confirmed that arginase I, ODC, and cyclooxygenase2 expression was higher in lesion biopsy specimens from patients with DCL than in those from patients with LCL.
p2356
sg4
(lp2357
(dp2358
g7
I48
sg8
VODC
p2359
sg10
I3
sg11
VP11926
p2360
sg13
I1
sa(dp2361
g7
I36
sg8
Varginase I
p2362
sg10
I10
sg11
VP05089
p2363
sg13
I2
sasg24
(lp2364
sa(dp2365
g2
VOur data implicate arginase I, ODC, PGE2, and TGF-Beta in the failure to mount an efficient immune response and suggest perspectives in the development of new strategies for therapeutic intervention for patients with DCL.
p2366
sg4
(lp2367
(dp2368
g7
I31
sg8
VODC
p2369
sg10
I3
sg11
VP11926
p2370
sg13
I1
sa(dp2371
g7
I19
sg8
Varginase I
p2372
sg10
I10
sg11
VP05089
p2373
sg13
I2
sa(dp2374
g7
I46
sg8
VTGF-Beta
p2375
sg10
I8
sg11
VP18075
p2376
sg13
I1
sasg24
(lp2377
sa(dp2378
g135
(dp2379
(VSHMT
p2380
Vmalaria
p2381
tp2382
I00
ssg2
VThe active form of vitamin B6, pyridoxal 5-phosphate, is, besides its antioxidative properties, a cofactor for a variety of essential enzymes present in the malaria parasite which includes the ornithine decarboxylase (ODC, synthesis of polyamines), the aspartate aminotransferase (AspAT, involved in the protein biosynthesis), and the serine hydroxymethyltransferase (SHMT, a key enzyme within the folate metabolism).
p2383
sg4
(lp2384
(dp2385
g7
I335
sg8
Vserine hydroxymethyltransferase
p2386
sg10
I31
sg11
VP34896
p2387
sg13
I2
sa(dp2388
g7
I281
sg8
VAspAT
p2389
sg10
I5
sg11
VP17174
p2390
sg13
I1
sa(dp2391
g7
I218
sg8
VODC
p2392
sg10
I3
sg11
VP11926
p2393
sg13
I1
sa(dp2394
g7
I193
sg8
Vornithine decarboxylase
p2395
sg10
I23
sg11
VP11926
p2396
sg13
I2
sa(dp2397
g7
I253
sg8
Vaspartate aminotransferase
p2398
sg10
I26
sg11
VP17174
p2399
sg13
I2
sa(dp2400
g7
I368
sg8
g2380
sg10
I4
sg11
VP34896
p2401
sg13
I1
sasg24
(lp2402
(dp2403
g7
I157
sg8
g2381
sg10
I7
sg28
VC0024530
p2404
sg13
I1
sasa(dp2405
g135
(dp2406
(VODC
p2407
VAfrican sleeping sickness
p2408
tp2409
I00
ssg2
VAlfa-Difluoromethylornithine (DFMO), a potent drug used for the treatment of African sleeping sickness is an irreversible inhibitor of ornithine decarboxylase (ODC), the first rate limiting enzyme of polyamine biosynthesis.
p2410
sg4
(lp2411
(dp2412
g7
I135
sg8
Vornithine decarboxylase
p2413
sg10
I23
sg11
VP11926
p2414
sg13
I2
sa(dp2415
g7
I160
sg8
g2407
sg10
I3
sg11
VP11926
p2416
sg13
I1
sasg24
(lp2417
(dp2418
g7
I77
sg8
g2408
sg10
I25
sg28
VC0041228
p2419
sg13
I3
sasa(dp2420
g2
VThis is the first study from north India reporting CYP1B1 mutations in Axenfeld-Rieger syndrome with bilateral buphthalmos and early onset glaucoma.
p2421
sg4
(lp2422
(dp2423
g7
I35
sg8
VIndia reporting CYP1B1
p2424
sg10
I22
sg11
g12
sg13
I3
sasg24
(lp2425
(dp2426
g7
I71
sg8
VAxenfeld-Rieger syndrome
p2427
sg10
I24
sg28
VC0265341
p2428
sg13
I2
sa(dp2429
g7
I139
sg8
Vglaucoma
p2430
sg10
I8
sg28
VC0017601
p2431
sg13
I1
sa(dp2432
g7
I111
sg8
Vbuphthalmos
p2433
sg10
I11
sg28
VC0020302
p2434
sg13
I1
sasa(dp2435
g2
VPurported BS2 cases may be divided into: (1) Bardet-Biedl syndrome with fortuitous coloboma or aniridia, (2) BS2 sensu stricto, a recessively inherited syndrome of sexual infantilism, short stature, coloboma, and preaxial polydactyly without obesity, only known from the original report, (3) a "new" dominantly inherited form of colobomatous microphthalmia occasionally associated with obesity, hypogonadism, and mental retardation, to which our observations belong.
p2436
sg4
(lp2437
sg24
(lp2438
(dp2439
g7
I58
sg8
Vsyndrome
p2440
sg10
I8
sg28
VC0039082
p2441
sg13
I1
sa(dp2442
g7
I213
sg8
Vpreaxial polydactyly
p2443
sg10
I20
sg28
VC0345354
p2444
sg13
I2
sa(dp2445
g7
I184
sg8
Vshort stature
p2446
sg10
I13
sg28
VC0013336
p2447
sg13
I2
sa(dp2448
g7
I164
sg8
Vsexual infantilism
p2449
sg10
I18
sg28
VC0242341
p2450
sg13
I2
sa(dp2451
g7
I45
sg8
VBardet-Biedl syndrome
p2452
sg10
I21
sg28
VC0752166
p2453
sg13
I2
sa(dp2454
g7
I95
sg8
Vaniridia
p2455
sg10
I8
sg28
VC0003076
p2456
sg13
I1
sa(dp2457
g7
I413
sg8
Vmental retardation
p2458
sg10
I18
sg28
VC0025362
p2459
sg13
I2
sa(dp2460
g7
I83
sg8
Vcoloboma
p2461
sg10
I8
sg28
VC0009363
p2462
sg13
I1
sa(dp2463
g7
I83
sg8
Vcoloboma
p2464
sg10
I8
sg28
VC0009363
p2465
sg13
I1
sa(dp2466
g7
I242
sg8
Vobesity
p2467
sg10
I7
sg28
VC0028754
p2468
sg13
I1
sa(dp2469
g7
I329
sg8
Vcolobomatous microphthalmia
p2470
sg10
I27
sg28
VC2931500
p2471
sg13
I2
sa(dp2472
g7
I395
sg8
Vhypogonadism
p2473
sg10
I12
sg28
VC0020619
p2474
sg13
I1
sa(dp2475
g7
I242
sg8
Vobesity
p2476
sg10
I7
sg28
VC0028754
p2477
sg13
I1
sasa(dp2478
g2
VGanglioneuromas (GNs) are benign tumors resulting from neural crest tissue.
p2479
sg4
(lp2480
sg24
(lp2481
(dp2482
g7
I17
sg8
VGNs
p2483
sg10
I3
sg28
VC0017075
p2484
sg13
I1
sa(dp2485
g7
I26
sg8
Vbenign tumors
p2486
sg10
I13
sg28
VC0086692
p2487
sg13
I2
sa(dp2488
g7
I0
sg8
VGanglioneuromas
p2489
sg10
I15
sg28
VC0017075
p2490
sg13
I1
sa(dp2491
g7
I62
sg8
Vcrest
p2492
sg10
I5
sg28
VC0206138
p2493
sg13
I1
sasa(dp2494
g2
VAdrenal ganglioneuromas (GNs) constitute rare, differentiated tumors which originate from neural crest cells.
p2495
sg4
(lp2496
sg24
(lp2497
(dp2498
g7
I62
sg8
Vtumors
p2499
sg10
I6
sg28
VC0027651
p2500
sg13
I1
sa(dp2501
g7
I97
sg8
Vcrest
p2502
sg10
I5
sg28
VC0206138
p2503
sg13
I1
sa(dp2504
g7
I8
sg8
Vganglioneuromas
p2505
sg10
I15
sg28
VC0017075
p2506
sg13
I1
sa(dp2507
g7
I25
sg8
VGNs
p2508
sg10
I3
sg28
VC0017075
p2509
sg13
I1
sasa(dp2510
g2
VGanglioneuromas (GNs) are hamartomatous tumors derived from the autonomic nervous system.
p2511
sg4
(lp2512
sg24
(lp2513
(dp2514
g7
I74
sg8
Vnervous
p2515
sg10
I7
sg28
VC0027769
p2516
sg13
I1
sa(dp2517
g7
I17
sg8
VGNs
p2518
sg10
I3
sg28
VC0017075
p2519
sg13
I1
sa(dp2520
g7
I0
sg8
VGanglioneuromas
p2521
sg10
I15
sg28
VC0017075
p2522
sg13
I1
sa(dp2523
g7
I40
sg8
Vtumors
p2524
sg10
I6
sg28
VC0027651
p2525
sg13
I1
sa(dp2526
g7
I26
sg8
Vhamartomatous
p2527
sg10
I13
sg28
VC0018552
p2528
sg13
I1
sasa(dp2529
g135
(dp2530
(VGNs
p2531
Vganglioneuromatosis
p2532
tp2533
I00
ssg2
VGNs are categorized into three different morphological subtypes, namely, polypoid GN, ganglioneuromatous polyposis, and diffuse ganglioneuromatosis.
p2534
sg4
(lp2535
(dp2536
g7
I0
sg8
g2531
sg10
I3
sg11
VP15586
p2537
sg13
I1
sasg24
(lp2538
(dp2539
g7
I105
sg8
Vpolyposis
p2540
sg10
I9
sg28
VC0334108
p2541
sg13
I1
sa(dp2542
g7
I128
sg8
g2532
sg10
I19
sg28
VC0334595
p2543
sg13
I1
sasa(dp2544
g2
VGanglioneuromas (GNs) arising from neural crest sympathogonia are rare benign neurogenic tumors.
p2545
sg4
(lp2546
sg24
(lp2547
(dp2548
g7
I89
sg8
Vtumors
p2549
sg10
I6
sg28
VC0027651
p2550
sg13
I1
sa(dp2551
g7
I17
sg8
VGNs
p2552
sg10
I3
sg28
VC0017075
p2553
sg13
I1
sa(dp2554
g7
I0
sg8
VGanglioneuromas
p2555
sg10
I15
sg28
VC0017075
p2556
sg13
I1
sa(dp2557
g7
I42
sg8
Vcrest
p2558
sg10
I5
sg28
VC0206138
p2559
sg13
I1
sasa(dp2560
g2
VGanglioneuromas (GNs) are neural crest cell-derived tumors and rarely occur in the adrenal gland.
p2561
sg4
(lp2562
sg24
(lp2563
(dp2564
g7
I17
sg8
VGNs
p2565
sg10
I3
sg28
VC0017075
p2566
sg13
I1
sa(dp2567
g7
I0
sg8
VGanglioneuromas
p2568
sg10
I15
sg28
VC0017075
p2569
sg13
I1
sa(dp2570
g7
I52
sg8
Vtumors
p2571
sg10
I6
sg28
VC0027651
p2572
sg13
I1
sa(dp2573
g7
I33
sg8
Vcrest
p2574
sg10
I5
sg28
VC0206138
p2575
sg13
I1
sasa(dp2576
g2
VGanglioneuromas (GNs) are the rarest and most benign of the neuroblastic tumors.
p2577
sg4
(lp2578
sg24
(lp2579
(dp2580
g7
I17
sg8
VGNs
p2581
sg10
I3
sg28
VC0017075
p2582
sg13
I1
sa(dp2583
g7
I0
sg8
VGanglioneuromas
p2584
sg10
I15
sg28
VC0017075
p2585
sg13
I1
sa(dp2586
g7
I73
sg8
Vtumors
p2587
sg10
I6
sg28
VC0027651
p2588
sg13
I1
sasa(dp2589
g135
(dp2590
(VNF-1
p2591
VGanglioneuromas
p2592
tp2593
I00
ssg2
VGanglioneuromas (GNs) are rare benign tumors and their association with neurofibromatosis type 1 (NF-1) is especially uncommon.
p2594
sg4
(lp2595
(dp2596
g7
I72
sg8
Vneurofibromatosis type 1
p2597
sg10
I24
sg11
VP21359
p2598
sg13
I3
sa(dp2599
g7
I98
sg8
g2591
sg10
I4
sg11
VP21359
p2600
sg13
I1
sasg24
(lp2601
(dp2602
g7
I72
sg8
Vneurofibromatosis type 1
p2603
sg10
I24
sg28
VC0027831
p2604
sg13
I3
sa(dp2605
g7
I17
sg8
VGNs
p2606
sg10
I3
sg28
VC0017075
p2607
sg13
I1
sa(dp2608
g7
I98
sg8
VNF-1
p2609
sg10
I4
sg28
VC0027831
p2610
sg13
I1
sa(dp2611
g7
I31
sg8
Vbenign tumors
p2612
sg10
I13
sg28
VC0086692
p2613
sg13
I2
sa(dp2614
g7
I0
sg8
g2592
sg10
I15
sg28
VC0017075
p2615
sg13
I1
sasa(dp2616
g135
(dp2617
(VBCAR1
p2618
Vtype 2 diabetes
p2619
tp2620
I00
ssg2
VFour of eight T1D-specific regions contained known type 2 diabetes (T2D) candidate genes (COBL, GLIS3, RNLS and BCAR1), suggesting a shared cellular etiology.
p2621
sg4
(lp2622
(dp2623
g7
I103
sg8
VRNLS
p2624
sg10
I4
sg11
g12
sg13
I1
sa(dp2625
g7
I90
sg8
VCOBL
p2626
sg10
I4
sg11
g12
sg13
I1
sa(dp2627
g7
I96
sg8
VGLIS3
p2628
sg10
I5
sg11
g12
sg13
I1
sa(dp2629
g7
I112
sg8
g2618
sg10
I5
sg11
VP56945
p2630
sg13
I1
sasg24
(lp2631
(dp2632
g7
I68
sg8
VT2D
p2633
sg10
I3
sg28
VC0011860
p2634
sg13
I1
sa(dp2635
g7
I51
sg8
g2619
sg10
I15
sg28
VC0011860
p2636
sg13
I3
sasa(dp2637
g135
(dp2638
(Vinsulin
p2639
Vtype 1 diabetes
p2640
tp2641
I00
ssg2
VAutoantibodies to insulin (IAA), GAD (GADA), insulinoma-associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured in follow-up sera, and genotyping for type 1 diabetes susceptibility genes (HLA-DR/HLA-DQ, INS variable number of tandem repeats [VNTR] and single nucleotide polymorphisms at PTPN22, PTPN2, ERBB3, IL2, SH2B3, CTLA4, IFIH1, KIAA0350 [also known as CLEC16A], CD25, IL18RAP, IL10, COBL) was performed on the DNA samples of children born to a parent with type 1 diabetes and prospectively followed from birth for up to 22 years.
p2642
sg4
(lp2643
(dp2644
g7
I353
sg8
VKIAA0350
p2645
sg10
I8
sg11
g12
sg13
I1
sa(dp2646
g7
I206
sg8
VHLA-DR
p2647
sg10
I6
sg11
VP30486
p2648
sg13
I1
sa(dp2649
g7
I393
sg8
VIL18RAP
p2650
sg10
I7
sg11
g12
sg13
I1
sa(dp2651
g7
I320
sg8
VERBB3
p2652
sg10
I5
sg11
VP21860
p2653
sg13
I1
sa(dp2654
g7
I89
sg8
Vzinc transporter 8
p2655
sg10
I18
sg11
g12
sg13
I3
sa(dp2656
g7
I305
sg8
VPTPN2
p2657
sg10
I5
sg11
VP17706
p2658
sg13
I1
sa(dp2659
g7
I206
sg8
VHLA
p2660
sg10
I3
sg11
VP30486
p2661
sg13
I1
sa(dp2662
g7
I305
sg8
VPTPN22
p2663
sg10
I6
sg11
g12
sg13
I1
sa(dp2664
g7
I377
sg8
VCLEC16A
p2665
sg10
I7
sg11
g12
sg13
I1
sa(dp2666
g7
I339
sg8
VCTLA4
p2667
sg10
I5
sg11
VP16410
p2668
sg13
I1
sa(dp2669
g7
I402
sg8
VIL10
p2670
sg10
I4
sg11
VP22301
p2671
sg13
I1
sa(dp2672
g7
I408
sg8
VCOBL
p2673
sg10
I4
sg11
g12
sg13
I1
sa(dp2674
g7
I332
sg8
VSH2B3
p2675
sg10
I5
sg11
g12
sg13
I1
sa(dp2676
g7
I346
sg8
VIFIH1
p2677
sg10
I5
sg11
g12
sg13
I1
sa(dp2678
g7
I387
sg8
VCD25
p2679
sg10
I4
sg11
VP01589
p2680
sg13
I1
sa(dp2681
g7
I327
sg8
VIL2
p2682
sg10
I3
sg11
VP60568
p2683
sg13
I1
sa(dp2684
g7
I18
sg8
g2639
sg10
I7
sg11
VP01308
p2685
sg13
I1
sasg24
(lp2686
(dp2687
g7
I33
sg8
VGAD
p2688
sg10
I3
sg28
VC0270549
p2689
sg13
I1
sa(dp2690
g7
I45
sg8
Vinsulinoma
p2691
sg10
I10
sg28
VC0021670
p2692
sg13
I1
sa(dp2693
g7
I221
sg8
VINS
p2694
sg10
I3
sg28
VC1533172
p2695
sg13
I1
sa(dp2696
g7
I168
sg8
Vtype 1 diabetes
p2697
sg10
I15
sg28
VC0011854
p2698
sg13
I3
sa(dp2699
g7
I168
sg8
g2640
sg10
I15
sg28
VC0011854
p2700
sg13
I3
sasa(dp2701
g135
(dp2702
(VIL10
p2703
Vdiabetes
p2704
tp2705
I00
ssg2
VChildren of parents with type 1 diabetes and prospectively followed from birth for the development of islet autoantibodies and diabetes were genotyped for single-nucleotide polymorphisms at 12 type 1 diabetes susceptibility genes (ERBB3, PTPN2, IFIH1, PTPN22, KIAA0350, CD25, CTLA4, SH2B3, IL2, IL18RAP, IL10 and COBL).
p2706
sg4
(lp2707
(dp2708
g7
I290
sg8
VIL2
p2709
sg10
I3
sg11
VP60568
p2710
sg13
I1
sa(dp2711
g7
I260
sg8
VKIAA0350
p2712
sg10
I8
sg11
g12
sg13
I1
sa(dp2713
g7
I231
sg8
VERBB3
p2714
sg10
I5
sg11
VP21860
p2715
sg13
I1
sa(dp2716
g7
I313
sg8
VCOBL
p2717
sg10
I4
sg11
g12
sg13
I1
sa(dp2718
g7
I276
sg8
VCTLA4
p2719
sg10
I5
sg11
VP16410
p2720
sg13
I1
sa(dp2721
g7
I295
sg8
VIL18RAP
p2722
sg10
I7
sg11
g12
sg13
I1
sa(dp2723
g7
I252
sg8
VPTPN22
p2724
sg10
I6
sg11
g12
sg13
I1
sa(dp2725
g7
I245
sg8
VIFIH1
p2726
sg10
I5
sg11
g12
sg13
I1
sa(dp2727
g7
I283
sg8
VSH2B3
p2728
sg10
I5
sg11
g12
sg13
I1
sa(dp2729
g7
I238
sg8
VPTPN2
p2730
sg10
I5
sg11
VP17706
p2731
sg13
I1
sa(dp2732
g7
I270
sg8
VCD25
p2733
sg10
I4
sg11
VP01589
p2734
sg13
I1
sa(dp2735
g7
I304
sg8
g2703
sg10
I4
sg11
VP22301
p2736
sg13
I1
sasg24
(lp2737
(dp2738
g7
I25
sg8
Vtype 1 diabetes
p2739
sg10
I15
sg28
VC0011854
p2740
sg13
I3
sa(dp2741
g7
I25
sg8
Vtype 1 diabetes
p2742
sg10
I15
sg28
VC0011854
p2743
sg13
I3
sa(dp2744
g7
I32
sg8
g2704
sg10
I8
sg28
VC0011849
p2745
sg13
I1
sasa(dp2746
g135
(dp2747
(VERBB3
p2748
Vdiabetes
p2749
tp2750
I00
ssg2
VThe greatest diabetes discrimination was obtained by the sum of risk alleles for eight genes (IFIH1, CTLA4, PTPN22, IL18RAP, SH2B3, KIAA0350, COBL and ERBB3) in the HLA-risk children.
p2751
sg4
(lp2752
(dp2753
g7
I165
sg8
VHLA
p2754
sg10
I3
sg11
VP30486
p2755
sg13
I1
sa(dp2756
g7
I101
sg8
VCTLA4
p2757
sg10
I5
sg11
VP16410
p2758
sg13
I1
sa(dp2759
g7
I116
sg8
VIL18RAP
p2760
sg10
I7
sg11
g12
sg13
I1
sa(dp2761
g7
I108
sg8
VPTPN22
p2762
sg10
I6
sg11
g12
sg13
I1
sa(dp2763
g7
I142
sg8
VCOBL
p2764
sg10
I4
sg11
g12
sg13
I1
sa(dp2765
g7
I94
sg8
VIFIH1
p2766
sg10
I5
sg11
g12
sg13
I1
sa(dp2767
g7
I125
sg8
VSH2B3
p2768
sg10
I5
sg11
g12
sg13
I1
sa(dp2769
g7
I132
sg8
VKIAA0350
p2770
sg10
I8
sg11
g12
sg13
I1
sa(dp2771
g7
I151
sg8
g2748
sg10
I5
sg11
VP21860
p2772
sg13
I1
sasg24
(lp2773
(dp2774
g7
I13
sg8
g2749
sg10
I8
sg28
VC0011849
p2775
sg13
I1
sasa(dp2776
g135
(dp2777
(VGM-CSF
p2778
Vatopic
p2779
tp2780
I01
ssg2
VHowever, all of the eosinophil-activating cytokines, such as IL-5, IL-3, and GM-CSF, are typically present in atopic diseases, including allergic asthma.
p2781
sg4
(lp2782
(dp2783
g7
I61
sg8
VIL-5
p2784
sg10
I4
sg11
VP05113
p2785
sg13
I1
sa(dp2786
g7
I67
sg8
VIL-3
p2787
sg10
I4
sg11
VP08700
p2788
sg13
I1
sa(dp2789
g7
I77
sg8
g2778
sg10
I6
sg11
VP04141
p2790
sg13
I1
sasg24
(lp2791
(dp2792
g7
I137
sg8
Vallergic asthma
p2793
sg10
I15
sg28
VC0155877
p2794
sg13
I2
sa(dp2795
g7
I110
sg8
g2779
sg10
I6
sg28
VC0392707
p2796
sg13
I1
sasa(dp2797
g135
(dp2798
(VIL-13
p2799
Vasthmatic
p2800
tp2801
I00
ssg2
VIn a murine model of allergic asthma, we found that Tyk-2((-/-)) asthmatic mice have induced peribronchial collagen deposition, mucosal type mast cells in the lung, IRF4 and hyperproliferative lung Th2 CD4(+) effector T cells over-expressing IL-3, IL-4, IL-5, IL-10 and IL-13.
p2802
sg4
(lp2803
(dp2804
g7
I254
sg8
VIL-5
p2805
sg10
I4
sg11
VP05113
p2806
sg13
I1
sa(dp2807
g7
I165
sg8
VIRF4
p2808
sg10
I4
sg11
g12
sg13
I1
sa(dp2809
g7
I242
sg8
VIL-3
p2810
sg10
I4
sg11
VP08700
p2811
sg13
I1
sa(dp2812
g7
I248
sg8
VIL-4
p2813
sg10
I4
sg11
VP05112
p2814
sg13
I1
sa(dp2815
g7
I174
sg8
Vhyperproliferative lung Th2 CD4
p2816
sg10
I31
sg11
VP01730
p2817
sg13
I4
sa(dp2818
g7
I270
sg8
g2799
sg10
I5
sg11
VP35225
p2819
sg13
I1
sasg24
(lp2820
(dp2821
g7
I21
sg8
Vallergic asthma
p2822
sg10
I15
sg28
VC0155877
p2823
sg13
I2
sa(dp2824
g7
I65
sg8
g2800
sg10
I9
sg28
VC0004096
p2825
sg13
I1
sasa(dp2826
g2
VHeterologous or homologous Nrf2 deletion (Nrf2+/- or Nrf2-/-) rescued the pancreatic phenotypes, weight loss and hypoglycemia in KC::Keap1 mice, suggesting that Nrf2 is a major downstream target of Keap1.
p2827
sg4
(lp2828
(dp2829
g7
I27
sg8
VNrf2
p2830
sg10
I4
sg11
g12
sg13
I1
sa(dp2831
g7
I27
sg8
VNrf2
p2832
sg10
I4
sg11
g12
sg13
I1
sa(dp2833
g7
I133
sg8
VKeap1
p2834
sg10
I5
sg11
g12
sg13
I1
sa(dp2835
g7
I133
sg8
VKeap1
p2836
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp2837
(dp2838
g7
I113
sg8
Vhypoglycemia
p2839
sg10
I12
sg28
VC0020615
p2840
sg13
I1
sasa(dp2841
g2
VDisrupting the Keap1-Nrf2 pathway enhances Nrf2 activity, which has been identified as an important approach for the prevention of different chronic diseases in which oxidative stress and inflammation are present, such as cancer, diabetes, Alzheimer's and Parkinson's.
p2842
sg4
(lp2843
(dp2844
g7
I21
sg8
VNrf2
p2845
sg10
I4
sg11
g12
sg13
I1
sa(dp2846
g7
I21
sg8
VNrf2
p2847
sg10
I4
sg11
g12
sg13
I1
sa(dp2848
g7
I15
sg8
VKeap1
p2849
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp2850
(dp2851
g7
I222
sg8
Vcancer
p2852
sg10
I6
sg28
VC0006826
p2853
sg13
I1
sa(dp2854
g7
I230
sg8
Vdiabetes
p2855
sg10
I8
sg28
VC0011849
p2856
sg13
I1
sa(dp2857
g7
I167
sg8
Voxidative stress
p2858
sg10
I16
sg28
VC0242606
p2859
sg13
I2
sa(dp2860
g7
I188
sg8
Vinflammation
p2861
sg10
I12
sg28
VC0021368
p2862
sg13
I1
sa(dp2863
g7
I141
sg8
Vchronic diseases
p2864
sg10
I16
sg28
VC0008679
p2865
sg13
I2
sasa(dp2866
g2
VThis study investigates the role of ACSVL3 in the maintenance of glioblastoma multiforme (GBM) stem cell self-renewal and the capacity of GBM stem cells to initiate tumor xenograft formation.
p2867
sg4
(lp2868
sg24
(lp2869
(dp2870
g7
I90
sg8
VGBM
p2871
sg10
I3
sg28
VC1621958
p2872
sg13
I1
sa(dp2873
g7
I90
sg8
VGBM
p2874
sg10
I3
sg28
VC1621958
p2875
sg13
I1
sa(dp2876
g7
I65
sg8
Vglioblastoma multiforme
p2877
sg10
I23
sg28
VC1621958
p2878
sg13
I2
sa(dp2879
g7
I165
sg8
Vtumor
p2880
sg10
I5
sg28
VC0027651
p2881
sg13
I1
sasa(dp2882
g2
VWe examined ACSVL3 expression during differentiation of several GBM stem cell enriched neurosphere cultures.
p2883
sg4
(lp2884
sg24
(lp2885
(dp2886
g7
I64
sg8
VGBM
p2887
sg10
I3
sg28
VC0017636
p2888
sg13
I1
sasa(dp2889
g2
VACSVL3 expression levels were substantially increased in GBM stem cell enriched neurosphere cultures and decreased after differentiation of the neurospheres.
p2890
sg4
(lp2891
sg24
(lp2892
(dp2893
g7
I57
sg8
VGBM
p2894
sg10
I3
sg28
VC0017636
p2895
sg13
I1
sasa(dp2896
g2
VFurthermore, ACSVL3 knockdown reduced anchorage-independent neurosphere cell growth, neurosphere-forming capacity as well as self-renewal of these GBM stem cell enriched neurosphere cultures.
p2897
sg4
(lp2898
sg24
(lp2899
(dp2900
g7
I147
sg8
VGBM
p2901
sg10
I3
sg28
VC0017636
p2902
sg13
I1
sasa(dp2903
g135
(dp2904
(VHGF
p2905
Vtumor initiation
p2906
tp2907
I00
ssg2
VA link between ACSVL3 and cancer stem cell phenotype was further established by the findings that ACSVL3 expression was regulated by receptor tyrosine kinase pathways that support GBM stem cell self-renewal and tumor initiation, including EGFR and HGF/c-Met pathways.
p2908
sg4
(lp2909
(dp2910
g7
I133
sg8
Vreceptor tyrosine kinase
p2911
sg10
I24
sg11
VP29401
p2912
sg13
I3
sa(dp2913
g7
I252
sg8
Vc-Met
p2914
sg10
I5
sg11
VP08581
p2915
sg13
I1
sa(dp2916
g7
I248
sg8
g2905
sg10
I3
sg11
VP05231
p2917
sg13
I1
sasg24
(lp2918
(dp2919
g7
I180
sg8
VGBM
p2920
sg10
I3
sg28
VC0017636
p2921
sg13
I1
sa(dp2922
g7
I26
sg8
Vcancer
p2923
sg10
I6
sg28
VC0006826
p2924
sg13
I1
sa(dp2925
g7
I248
sg8
VHGF
p2926
sg10
I3
sg28
VC0399440
p2927
sg13
I1
sa(dp2928
g7
I211
sg8
g2906
sg10
I16
sg28
VC0598935
p2929
sg13
I2
sasa(dp2930
g2
VOur findings indicate that the lipid metabolism enzyme ACSVL3 is involved in GBM stem cell maintenance and the tumor-initiating capacity of GBM stem cell enriched-neurospheres in animals.
p2931
sg4
(lp2932
sg24
(lp2933
(dp2934
g7
I77
sg8
VGBM
p2935
sg10
I3
sg28
VC0017636
p2936
sg13
I1
sa(dp2937
g7
I111
sg8
Vtumor
p2938
sg10
I5
sg28
VC0027651
p2939
sg13
I1
sa(dp2940
g7
I77
sg8
VGBM
p2941
sg10
I3
sg28
VC0017636
p2942
sg13
I1
sasa(dp2943
g2
VA significant association was detected between TLR9 genotypes and some of the disease manifestations as myositis (p = 0.032), psychosis (p = 0.014), photosensitivity (p = 0.002), and pleurisy (p = &lt;0.001).
p2944
sg4
(lp2945
(dp2946
g7
I47
sg8
VTLR9 genotypes
p2947
sg10
I14
sg11
g12
sg13
I2
sasg24
(lp2948
(dp2949
g7
I149
sg8
Vphotosensitivity
p2950
sg10
I16
sg28
VC0393720
p2951
sg13
I1
sa(dp2952
g7
I183
sg8
Vpleurisy
p2953
sg10
I8
sg28
VC0497354
p2954
sg13
I1
sa(dp2955
g7
I104
sg8
Vmyositis
p2956
sg10
I8
sg28
VC0027121
p2957
sg13
I1
sa(dp2958
g7
I126
sg8
Vpsychosis
p2959
sg10
I9
sg28
VC0349204
p2960
sg13
I1
sasa(dp2961
g135
(dp2962
(VLj-HMGB2
p2963
Vacute monocytic leukemia
p2964
tp2965
I00
ssg2
VIn addition, rLj-HMGB2 could induce the generation of proinflammatory mediators in the activated human acute monocytic leukemia cell line (THP1), which suggested that Lj-HMGB2 may participate in the immune response of the lampreys.
p2966
sg4
(lp2967
(dp2968
g7
I139
sg8
VTHP1
p2969
sg10
I4
sg11
VP10070
p2970
sg13
I1
sa(dp2971
g7
I13
sg8
VrLj-HMGB2
p2972
sg10
I9
sg11
VP26583
p2973
sg13
I1
sa(dp2974
g7
I14
sg8
g2963
sg10
I8
sg11
VP26583
p2975
sg13
I1
sasg24
(lp2976
(dp2977
g7
I103
sg8
g2964
sg10
I24
sg28
VC1318544
p2978
sg13
I3
sasa(dp2979
g2
VNut consumption was independently associated with a decreased risk of overall and vascular-disease mortality, particularly in women.
p2980
sg4
(lp2981
(dp2982
g7
I0
sg8
VNut
p2983
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp2984
sa(dp2985
g2
VNut consumption has been inconsistently associated with risk of stroke.
p2986
sg4
(lp2987
(dp2988
g7
I0
sg8
VNut
p2989
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp2990
(dp2991
g7
I64
sg8
Vstroke
p2992
sg10
I6
sg28
VC0038454
p2993
sg13
I1
sasa(dp2994
g135
(dp2995
(Vtumour necrosis factor [TNF]-Alfa
p2996
Vtumour necrosis
p2997
tp2998
I00
ssg2
VUlcerative colitis patients display increased numbers of circulating pro-inflammatory monocyte human leukocyte antigen-DR [HLA-DRhi] monocytes expressing high levels of the gut-homing C-C chemokine receptor 9 [CCR9] and tumour necrosis factor [TNF]-Alfa.
p2999
sg4
(lp3000
(dp3001
g7
I86
sg8
Vmonocyte human leukocyte antigen-DR
p3002
sg10
I35
sg11
VP05534
p3003
sg13
I4
sa(dp3004
g7
I123
sg8
VHLA
p3005
sg10
I3
sg11
VP30486
p3006
sg13
I1
sa(dp3007
g7
I220
sg8
g2996
sg10
I33
sg11
VP01375
p3008
sg13
I4
sa(dp3009
g7
I173
sg8
Vgut-homing C-C chemokine receptor 9 [CCR9]
p3010
sg10
I42
sg11
g12
sg13
I6
sasg24
(lp3011
(dp3012
g7
I0
sg8
VUlcerative colitis
p3013
sg10
I18
sg28
VC0009324
p3014
sg13
I2
sa(dp3015
g7
I220
sg8
g2997
sg10
I15
sg28
VC0333516
p3016
sg13
I2
sasa(dp3017
g135
(dp3018
(VCCR9
p3019
Vblind
p3020
tp3021
I00
ssg2
VThe aim of this first-in-human, double-blind, randomised, placebo-controlled trial was to evaluate selective removal of circulating CCR9-expressing monocytes by leukapheresis in patients with moderate to severe ulcerative colitis, with regards to safety, tolerability, and immunological response.
p3022
sg4
(lp3023
(dp3024
g7
I132
sg8
g3019
sg10
I4
sg11
VP51686
p3025
sg13
I1
sasg24
(lp3026
(dp3027
g7
I211
sg8
Vulcerative colitis
p3028
sg10
I18
sg28
VC0009324
p3029
sg13
I2
sa(dp3030
g7
I39
sg8
g3020
sg10
I5
sg28
VC0456909
p3031
sg13
I1
sasa(dp3032
g135
(dp3033
(VCCR9
p3034
Vulcerative colitis
p3035
tp3036
I00
ssg2
VPatients with ulcerative colitis were treated every second day with leukapheresis during five sessions with a C-C chemokine ligand 25 [CCL25; CCR9 ligand] column or a placebo column.
p3037
sg4
(lp3038
(dp3039
g7
I110
sg8
VC-C chemokine ligand 25
p3040
sg10
I23
sg11
VP55773
p3041
sg13
I4
sa(dp3042
g7
I142
sg8
g3034
sg10
I4
sg11
VP51686
p3043
sg13
I1
sa(dp3044
g7
I135
sg8
VCCL25
p3045
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp3046
(dp3047
g7
I14
sg8
g3035
sg10
I18
sg28
VC0009324
p3048
sg13
I2
sasa(dp3049
g135
(dp3050
(VCCR9
p3051
Vinflammatory bowel disease
p3052
tp3053
I00
ssg2
VCC chemokine receptor type 9 (CCR9) activation by CCL25 plays a key role in leukocyte recruitment to the gut and represents a therapeutic target in inflammatory bowel disease.
p3054
sg4
(lp3055
(dp3056
g7
I0
sg8
VCC chemokine receptor type 9
p3057
sg10
I28
sg11
g12
sg13
I5
sa(dp3058
g7
I30
sg8
g3051
sg10
I4
sg11
VP51686
p3059
sg13
I1
sa(dp3060
g7
I50
sg8
VCCL25
p3061
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp3062
(dp3063
g7
I148
sg8
g3052
sg10
I26
sg28
VC0021390
p3064
sg13
I3
sa(dp3065
g7
I86
sg8
Vrecruitment
p3066
sg10
I11
sg28
VC0271510
p3067
sg13
I1
sasa(dp3068
g135
(dp3069
(VCCR9
p3070
VCrohn's disease
p3071
tp3072
I01
ssg2
VThe selective CCR9 antagonist vercirnon progressed to phase 3 clinical trials in Crohn's disease but efficacy was limited, with the need for very high doses to block receptor activation.
p3073
sg4
(lp3074
(dp3075
g7
I14
sg8
g3070
sg10
I4
sg11
VP51686
p3076
sg13
I1
sasg24
(lp3077
(dp3078
g7
I81
sg8
g3071
sg10
I15
sg28
VC0010346
p3079
sg13
I2
sasa(dp3080
g135
(dp3081
(VIFN-Beta
p3082
Vinflammation
p3083
tp3084
I00
ssg2
VTo investigate whether Imiquimod (IMQ) as TLR7 ligand protects mice from colonic inflammation and the mechanisms underlying in such immunoregulatory conditions.#\u3000METHODS: Murine colitis was induced to Balb/c mice by administration of trinitrobenzene sulfonic acid (TNBS) with or without daily intraperitoneal administration of IMQ.#\u3000Colitis was evaluated by body weight decreases and by histological score.#\u3000Also colonic mRNA expression was measured by RT-PCR.#\u3000To confirm the induction of Regulatory T cells (Tregs) by type-1 IFN from pDCs, we generated mouse bone marrow-derived pDCs and co-cultured these with CD4+ T cells isolated from mouse spleen with or without IMQ stimulation.#\u3000Cytokine production in the culture supernatant was measured by ELISA and the number of Tregs were analyzed by flow cytometry.#\u3000Spleen and mesenteric lymph nodes (MLN) from IMQ-treated mice were collected, and mRNA expressions of cytokine were measured by RT-PCR and cytokine productions were measured by ELISA.#\u3000Tregs and chemokine expressions were analyzed in colon of TNBS-induced colitis mouse by immunohistochemistry.#\u3000RESULTS: Administration of IMQ significantly suppressed colonic inflammation of TNBS-induced colitis.#\u3000In the colons of IMQ-treated mice, mRNA expression of TNF-Alfa was decreased, and strong expressions of IL-6, IFN-Beta and TGF-Beta were detected.#\u3000IL-10 and TGF-Beta productions were increased in the supernatant of co-cultured cells stimulated with IMQ, although we were unable to detect Treg differentiaton in IMQ-stimulated co-cultured cells.#\u3000In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-Beta, TGF-Beta and Foxp3 mRNA were detected.#\u3000IL-10 production from MLN cells was also increased in the IMQ-treated group.#\u3000Finally, Tregs in the inflamed colon and CCR9 in MLN of IMQ-treated mice were detected.#\u3000CONCLUSION: These results suggest that IMQ protects mice from TNBS colitis through induction of CCR9, which regulates accumulation of Tregs in the inflamed colon.
p3085
sg4
(lp3086
(dp3087
g7
I613
sg8
VCD4+
p3088
sg10
I4
sg11
VP01730
p3089
sg13
I1
sa(dp3090
g7
I1267
sg8
VTNF-Alfa
p3091
sg10
I8
sg11
VP01375
p3092
sg13
I1
sa(dp3093
g7
I849
sg8
VMLN
p3094
sg10
I3
sg11
VP12872
p3095
sg13
I1
sa(dp3096
g7
I520
sg8
Vtype-1 IFN
p3097
sg10
I10
sg11
VP01562
p3098
sg13
I2
sa(dp3099
g7
I1336
sg8
VTGF-Beta
p3100
sg10
I8
sg11
VP18075
p3101
sg13
I1
sa(dp3102
g7
I1785
sg8
VCCR9
p3103
sg10
I4
sg11
VP51686
p3104
sg13
I1
sa(dp3105
g7
I1323
sg8
VIFN-Beta
p3106
sg10
I8
sg11
VP01574
p3107
sg13
I1
sa(dp3108
g7
I1639
sg8
VFoxp3 mRNA
p3109
sg10
I10
sg11
g12
sg13
I2
sa(dp3110
g7
I1317
sg8
VIL-6
p3111
sg10
I4
sg11
VP05231
p3112
sg13
I1
sa(dp3113
g7
I42
sg8
VTLR7 ligand
p3114
sg10
I11
sg11
g12
sg13
I2
sa(dp3115
g7
I825
sg8
Vmesenteric lymph nodes
p3116
sg10
I22
sg11
VP12872
p3117
sg13
I3
sa(dp3118
g7
I1336
sg8
VTGF-Beta
p3119
sg10
I8
sg11
VP18075
p3120
sg13
I1
sa(dp3121
g7
I1336
sg8
VTGF-Beta
p3122
sg10
I8
sg11
VP18075
p3123
sg13
I1
sa(dp3124
g7
I1785
sg8
VCCR9
p3125
sg10
I4
sg11
VP51686
p3126
sg13
I1
sa(dp3127
g7
I42
sg8
VTLR7
p3128
sg10
I4
sg11
g12
sg13
I1
sa(dp3129
g7
I1323
sg8
g3082
sg10
I8
sg11
VP01574
p3130
sg13
I1
sasg24
(lp3131
(dp3132
g7
I178
sg8
Vcolitis
p3133
sg10
I7
sg28
VC0009319
p3134
sg13
I1
sa(dp3135
g7
I178
sg8
Vcolitis
p3136
sg10
I7
sg28
VC0009319
p3137
sg13
I1
sa(dp3138
g7
I81
sg8
Vinflammation
p3139
sg10
I12
sg28
VC0021368
p3140
sg13
I1
sa(dp3141
g7
I332
sg8
V\u3000Colitis
p3142
sg10
I8
sg28
VC0009319
p3143
sg13
I1
sa(dp3144
g7
I178
sg8
Vcolitis
p3145
sg10
I7
sg28
VC0009319
p3146
sg13
I1
sa(dp3147
g7
I178
sg8
Vcolitis
p3148
sg10
I7
sg28
VC0009319
p3149
sg13
I1
sa(dp3150
g7
I81
sg8
g3083
sg10
I12
sg28
VC0021368
p3151
sg13
I1
sasa(dp3152
g135
(dp3153
(VCCR9+ CD11b+
p3154
Vacute hepatitis
p3155
tp3156
I00
ssg2
VWe here showed that CCR9+ CD11b+ macrophages play an important role during the course of Concanavalin A-induced murine acute liver injury as well as human acute hepatitis via the production of inflammatory cytokines and the Th1 induction.
p3157
sg4
(lp3158
(dp3159
g7
I20
sg8
g3154
sg10
I12
sg11
VP51686
p3160
sg13
I2
sasg24
(lp3161
(dp3162
g7
I155
sg8
g3155
sg10
I15
sg28
VC0267797
p3163
sg13
I2
sasa(dp3164
g135
(dp3165
(VPLEK
p3166
Vceliac disease
p3167
tp3168
I00
ssg2
VWe found 54 single-nucleotide polymorphisms (SNPs) in 5 genes associated with celiac disease (TAGAP, IL18R1, RGS21, PLEK, and CCR9) in time to celiac disease analyses (10-4&gt;P&gt;5.8x10-6).
p3169
sg4
(lp3170
(dp3171
g7
I126
sg8
VCCR9
p3172
sg10
I4
sg11
VP51686
p3173
sg13
I1
sa(dp3174
g7
I109
sg8
VRGS21
p3175
sg10
I5
sg11
g12
sg13
I1
sa(dp3176
g7
I116
sg8
g3166
sg10
I4
sg11
VP08567
p3177
sg13
I1
sa(dp3178
g7
I101
sg8
VIL18R1
p3179
sg10
I6
sg11
g12
sg13
I1
sa(dp3180
g7
I94
sg8
VTAGAP
p3181
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp3182
(dp3183
g7
I78
sg8
Vceliac disease
p3184
sg10
I14
sg28
VC0007570
p3185
sg13
I2
sa(dp3186
g7
I78
sg8
g3167
sg10
I14
sg28
VC0007570
p3187
sg13
I2
sasa(dp3188
g135
(dp3189
(VCCL20
p3190
Vtumor necrosis
p3191
tp3192
I00
ssg2
VIncluding chemokines [C-C motif ligand (CCL) 19, CCL20, CCL21, C-X-C motif ligand (CXCL) 6, CXCL10, and CXCL11] and soluble cytokine and chemokine receptors [soluble (s) interleukin (IL) 6 receptor (R), soluble tumor necrosis factor receptor (sTNFR) 1, sTNFR2, and sIL-R2], ten inflammation-related markers, were nominally associated with diabetes (P&lt;0.05).
p3193
sg4
(lp3194
(dp3195
g7
I56
sg8
VCCL21
p3196
sg10
I5
sg11
g12
sg13
I1
sa(dp3197
g7
I92
sg8
VCXCL10
p3198
sg10
I6
sg11
VP02778
p3199
sg13
I1
sa(dp3200
g7
I211
sg8
Vtumor necrosis factor receptor (sTNFR) 1
p3201
sg10
I40
sg11
VP01375
p3202
sg13
I6
sa(dp3203
g7
I265
sg8
VsIL-R2
p3204
sg10
I6
sg11
VP40967
p3205
sg13
I1
sa(dp3206
g7
I104
sg8
VCXCL11
p3207
sg10
I6
sg11
g12
sg13
I1
sa(dp3208
g7
I49
sg8
g3190
sg10
I5
sg11
VP78556
p3209
sg13
I1
sasg24
(lp3210
(dp3211
g7
I339
sg8
Vdiabetes
p3212
sg10
I8
sg28
VC0011849
p3213
sg13
I1
sa(dp3214
g7
I21
sg8
V[C-C motif ligand
p3215
sg10
I17
sg28
VC1852438
p3216
sg13
I3
sa(dp3217
g7
I40
sg8
VCCL
p3218
sg10
I3
sg28
VC1852438
p3219
sg13
I1
sa(dp3220
g7
I265
sg8
VsIL
p3221
sg10
I3
sg28
VC0333873
p3222
sg13
I1
sa(dp3223
g7
I278
sg8
Vinflammation
p3224
sg10
I12
sg28
VC0021368
p3225
sg13
I1
sa(dp3226
g7
I211
sg8
g3191
sg10
I14
sg28
VC0333516
p3227
sg13
I2
sasa(dp3228
g2
VWe identified mutations in melanoma-associated antigen D2 in all study participants and showed, in vivo and in vitro, reduced expression of the furosemide and thiazide sensitive transporters sodium-potassium-2-chloride cotransporter and sodium chloride cotransporter, respectively.
p3229
sg4
(lp3230
(dp3231
g7
I27
sg8
Vmelanoma-associated antigen D2
p3232
sg10
I30
sg11
g12
sg13
I3
sasg24
(lp3233
(dp3234
g7
I27
sg8
Vmelanoma
p3235
sg10
I8
sg28
VC0025202
p3236
sg13
I1
sasa(dp3237
g2
VMAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.We distinguish two types of hereditary NDI: a 'pure' type with loss of water only and a complex type with loss of water and ions.
p3238
sg4
(lp3239
(dp3240
g7
I0
sg8
VMAGED2
p3241
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp3242
(dp3243
g7
I33
sg8
Vpolyhydramnios
p3244
sg10
I14
sg28
VC0020224
p3245
sg13
I1
sa(dp3246
g7
I168
sg8
VNDI
p3247
sg10
I3
sg28
VC1563705
p3248
sg13
I1
sa(dp3249
g7
I110
sg8
VBartter's syndrome
p3250
sg10
I18
sg28
VC0004775
p3251
sg13
I2
sasa(dp3252
g135
(dp3253
(Vvasopressin V2 receptor
p3254
VBartter's syndrome
p3255
tp3256
I00
ssg2
VA new variant of this was recently identified: seven families were described with transient antenatal Bartter's syndrome, polyhydramnios and MAGED2 mutations.Multiple compounds have been identified experimentally that may stimulate urinary concentration independently of the vasopressin V2 receptor.
p3257
sg4
(lp3258
(dp3259
g7
I275
sg8
g3254
sg10
I23
sg11
VP30518
p3260
sg13
I3
sa(dp3261
g7
I141
sg8
VMAGED2
p3262
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp3263
(dp3264
g7
I122
sg8
Vpolyhydramnios
p3265
sg10
I14
sg28
VC0020224
p3266
sg13
I1
sa(dp3267
g7
I102
sg8
g3255
sg10
I18
sg28
VC0004775
p3268
sg13
I2
sasa(dp3269
g2
VFluorescent and radio conjugates of 11B6, an antibody targeting free hK2, are internalized and noninvasively report AR pathway activity in metastatic and genetically engineered models of cancer development and treatment.
p3270
sg4
(lp3271
(dp3272
g7
I69
sg8
VhK2
p3273
sg10
I3
sg11
VP20151
p3274
sg13
I1
sasg24
(lp3275
(dp3276
g7
I187
sg8
Vcancer
p3277
sg10
I6
sg28
VC0006826
p3278
sg13
I1
sasa(dp3279
g2
VHumanized 11B6, which has undergone toxicological tests in nonhuman primates, has the potential to improve patient management in these cancers.
p3280
sg4
(lp3281
(dp3282
g7
I0
sg8
VHumanized 11B6
p3283
sg10
I14
sg11
g12
sg13
I2
sasg24
(lp3284
(dp3285
g7
I135
sg8
Vcancers
p3286
sg10
I7
sg28
VC0006826
p3287
sg13
I1
sasa(dp3288
g2
VMAGE-D2 is new gene found to cause severe polyhydramnios and transient postnatal Bartter-like syndrome.
p3289
sg4
(lp3290
(dp3291
g7
I0
sg8
VMAGE-D2
p3292
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp3293
(dp3294
g7
I42
sg8
Vpolyhydramnios
p3295
sg10
I14
sg28
VC0020224
p3296
sg13
I1
sa(dp3297
g7
I94
sg8
Vsyndrome
p3298
sg10
I8
sg28
VC0039082
p3299
sg13
I1
sasa(dp3300
g2
VThese women were divided into two after breast cancer groups (BCG1 and BCG2) and a control group (CG).
p3301
sg4
(lp3302
(dp3303
g7
I62
sg8
VBCG1
p3304
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp3305
(dp3306
g7
I40
sg8
Vbreast cancer
p3307
sg10
I13
sg28
VC0678222
p3308
sg13
I2
sasa(dp3309
g2
VGroup BCG1 consisted of women who had undergone breast cancer surgery within the last 18months and BCG2 those whose postoperative periods were more than 18months.
p3310
sg4
(lp3311
sg24
(lp3312
(dp3313
g7
I48
sg8
Vbreast cancer
p3314
sg10
I13
sg28
VC0678222
p3315
sg13
I2
sasa(dp3316
g2
VThe indices in millisecond, RMSSD (BCG1=19.83; BCG2=14.99; CG=31.46), SD1 (BCG1=14.03; BCG2=10.61; CG=22.27), SD2 (BCG1=39.17; BCG2=35.28; CG=61.16), SDNN (BCG1=29.58; BCG2=26.12; CG=46.36) and HF in milliseconds squared (BCG1=194.2; BCG2=91.07; CG=449.4) showed statistically significant reductions in the breast cancer groups compared to the CG (p&lt;=0.0001).
p3317
sg4
(lp3318
sg24
(lp3319
(dp3320
g7
I307
sg8
Vbreast cancer
p3321
sg10
I13
sg28
VC0678222
p3322
sg13
I2
sa(dp3323
g7
I70
sg8
VSD1
p3324
sg10
I3
sg28
VC1861380
p3325
sg13
I1
sasa(dp3326
g2
VThe discovery that mutations in MAGED2 cause a rare and transient form of antenatal Bartter's Syndrome may have implications beyond the very small number of affected families.
p3327
sg4
(lp3328
(dp3329
g7
I32
sg8
VMAGED2
p3330
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp3331
(dp3332
g7
I84
sg8
VBartter's Syndrome
p3333
sg10
I18
sg28
VC0004775
p3334
sg13
I2
sasa(dp3335
g2
VWe identified a mutation in MAGED2 in each of the 13 infants in our analysis who had transient antenatal Bartter's syndrome.
p3336
sg4
(lp3337
(dp3338
g7
I28
sg8
VMAGED2
p3339
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp3340
(dp3341
g7
I105
sg8
VBartter's syndrome
p3342
sg10
I18
sg28
VC0004775
p3343
sg13
I2
sasa(dp3344
g2
VMAGED2 encodes melanoma-associated antigen D2 (MAGE-D2) and maps to the X chromosome.
p3345
sg4
(lp3346
(dp3347
g7
I0
sg8
VMAGED2
p3348
sg10
I6
sg11
g12
sg13
I1
sa(dp3349
g7
I47
sg8
VMAGE-D2
p3350
sg10
I7
sg11
g12
sg13
I1
sa(dp3351
g7
I15
sg8
Vmelanoma-associated antigen D2
p3352
sg10
I30
sg11
g12
sg13
I3
sasg24
(lp3353
(dp3354
g7
I15
sg8
Vmelanoma
p3355
sg10
I8
sg28
VC0025202
p3356
sg13
I1
sasa(dp3357
g2
VWe also identified two different MAGED2 mutations in two families with idiopathic polyhydramnios.
p3358
sg4
(lp3359
(dp3360
g7
I33
sg8
VMAGED2 mutations
p3361
sg10
I16
sg11
g12
sg13
I2
sasg24
(lp3362
(dp3363
g7
I82
sg8
Vpolyhydramnios
p3364
sg10
I14
sg28
VC0020224
p3365
sg13
I1
sasa(dp3366
g2
VWe found that MAGED2 mutations caused X-linked polyhydramnios with prematurity and a severe but transient form of antenatal Bartter's syndrome.
p3367
sg4
(lp3368
(dp3369
g7
I14
sg8
VMAGED2
p3370
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp3371
(dp3372
g7
I124
sg8
VBartter's syndrome
p3373
sg10
I18
sg28
VC0004775
p3374
sg13
I2
sa(dp3375
g7
I47
sg8
Vpolyhydramnios
p3376
sg10
I14
sg28
VC0020224
p3377
sg13
I1
sasa(dp3378
g2
VVirulence factors profiling showed that most of MRSA isolates in our center carried the virulence factor pattern of cna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld (214/239, 89.54%).
p3379
sg4
(lp3380
(dp3381
g7
I116
sg8
Vcna-clfA-clfB-eno-fib-icaA-icaD-sea-psmAlfa-lukED-hlg-hlgv-hla-hld
p3382
sg10
I66
sg11
g12
sg13
I1
sasg24
(lp3383
(dp3384
g7
I48
sg8
VMRSA
p3385
sg10
I4
sg28
VC0343401
p3386
sg13
I1
sasa(dp3387
g2
VThe main virulence genes in these strains were hlg (33.3%), scn (23.3%), cna (20%), hlb (20%), and clfA (18.3%), others including icaA, fnbA, tst, seb, hld, eta and sea.
p3388
sg4
(lp3389
(dp3390
g7
I152
sg8
Vhld
p3391
sg10
I3
sg11
VP35670
p3392
sg13
I1
sa(dp3393
g7
I142
sg8
Vtst
p3394
sg10
I3
sg11
g12
sg13
I1
sa(dp3395
g7
I157
sg8
Veta
p3396
sg10
I3
sg11
VP25101
p3397
sg13
I1
sa(dp3398
g7
I147
sg8
Vseb
p3399
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp3400
sa(dp3401
g2
VOther virulence genes detected were (number of strains): tsst-1 (6), hla (15), hlb (9), hld (15), hlg (6), hlgv (9), cna (2), aur (14), and egc-like cluster (3).
p3402
sg4
(lp3403
sg24
(lp3404
sa(dp3405
g2
VSearch terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases: CENTRAL (2007, Issue 1); MEDLINE via PUBMED (1966 to March 2007); EMBASE (2005 to April 2007); CINAHL (1982 to March 2007); LILACS (1982 to March 2007); PsycINFO (1887 to March 2007); ERIC (1966 to March 2007); CCT (March 2007); Academic Search Elite (to March 2007), C2- SPECTR (to March 2007 ), NRR (2007 Issue 1), ClinicalTrials.gov (accessed March 2007) and within supplements of Medicine and Science in Sports and Exercise.
p3406
sg4
(lp3407
sg24
(lp3408
(dp3409
g7
I322
sg8
VCCT
p3410
sg10
I3
sg28
VC2752078
p3411
sg13
I1
sa(dp3412
g7
I54
sg8
VDown syndrome
p3413
sg10
I13
sg28
VC0013080
p3414
sg13
I2
sasa(dp3415
g2
VSearch terms and synonyms for "aerobic exercise" and "Down syndrome" were used within the following databases:CENTRAL (2005, Issue 2); MEDLINE (1966 to March 2005); EMBASE (2005 to April 2005); CINAHL (1982 to March 2005); LILACS (1982 to March 2005); PsycINFO (1887 to March 2005); ERIC (1966 to March 2005); CCT (March 2005); Academic Search Elite (to March 2005), C2- SPECTR (to March 2005 ), NRR (2005 Issue 1), ClinicalTrials.gov (accessed March 2005)and within supplements of Medicine and Science in Sports and Exercise.
p3416
sg4
(lp3417
sg24
(lp3418
(dp3419
g7
I54
sg8
VDown syndrome
p3420
sg10
I13
sg28
VC0013080
p3421
sg13
I2
sa(dp3422
g7
I310
sg8
VCCT
p3423
sg10
I3
sg28
VC2752078
p3424
sg13
I1
sasa(dp3425
g2
VFMT in inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS) and metabolic syndrome should only be performed in research settings.
p3426
sg4
(lp3427
(dp3428
g7
I0
sg8
VFMT
p3429
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp3430
(dp3431
g7
I36
sg8
VIBD
p3432
sg10
I3
sg28
VC0021390
p3433
sg13
I1
sa(dp3434
g7
I68
sg8
VIBS
p3435
sg10
I3
sg28
VC0022104
p3436
sg13
I1
sa(dp3437
g7
I42
sg8
Virritable bowel syndrome
p3438
sg10
I24
sg28
VC0022104
p3439
sg13
I3
sa(dp3440
g7
I77
sg8
Vmetabolic syndrome
p3441
sg10
I18
sg28
VC0524620
p3442
sg13
I2
sa(dp3443
g7
I7
sg8
Vinflammatory bowel diseases
p3444
sg10
I27
sg28
VC0021390
p3445
sg13
I3
sasa(dp3446
g135
(dp3447
(VMyl9
p3448
Vinflammation
p3449
tp3450
I00
ssg2
VBlockade of CD69-Myl9/12 interaction ameliorates allergic airway inflammation in ovalbumin-induced and house dust mite-induced mouse models of asthma.
p3451
sg4
(lp3452
(dp3453
g7
I12
sg8
VCD69
p3454
sg10
I4
sg11
g12
sg13
I1
sa(dp3455
g7
I17
sg8
g3448
sg10
I4
sg11
VP24844
p3456
sg13
I1
sasg24
(lp3457
(dp3458
g7
I143
sg8
Vasthma
p3459
sg10
I6
sg28
VC0004096
p3460
sg13
I1
sa(dp3461
g7
I65
sg8
g3449
sg10
I12
sg28
VC0021368
p3462
sg13
I1
sasa(dp3463
g135
(dp3464
(Vmyosin
p3465
Vasthmatic
p3466
tp3467
I00
ssg2
VA greater activation of myosin, via increased phosphorylation of its regulatory light chain (LC20) by myosin light chain kinase, correlates with an increased Vmax in models of AH and in human asthmatic bronchial SM cells.
p3468
sg4
(lp3469
(dp3470
g7
I24
sg8
g3465
sg10
I6
sg11
VP13535
p3471
sg13
I1
sa(dp3472
g7
I102
sg8
Vmyosin light chain kinase
p3473
sg10
I25
sg11
g12
sg13
I4
sasg24
(lp3474
(dp3475
g7
I192
sg8
g3466
sg10
I9
sg28
VC0004096
p3476
sg13
I1
sasa(dp3477
g135
(dp3478
(Vnc-HOXD12-3
p3479
VRP11
p3480
tp3481
I00
ssg2
VSome of the differentially expressed lncRNAs that were upregulated, such as AK124776, lincRNA-RAB12-1, KRT8P25, RP11-474J18.4, AC000110.1, KRT8P13, KRT8P10, BC072678, and downregulated, such as nc-HOXB9-206, RP11-160A10.2, nc-HOXA11-86, nc-HOXD10-7, nc-HOXB9-205, CES4, nc-HOXD12-3, systematic research on these lncRNAs will help clarify the mechanisms of urothelial carcinoma of the bladder and guide the early diagnosis and treatment of this cancer in the future.
p3482
sg4
(lp3483
(dp3484
g7
I223
sg8
Vnc-HOXA11-86
p3485
sg10
I12
sg11
VP31270
p3486
sg13
I1
sa(dp3487
g7
I112
sg8
VRP11-474J18.4, AC000110.1
p3488
sg10
I25
sg11
g12
sg13
I2
sa(dp3489
g7
I250
sg8
Vnc-HOXB9-205
p3490
sg10
I12
sg11
VP17482
p3491
sg13
I1
sa(dp3492
g7
I197
sg8
VHOXB9-206
p3493
sg10
I9
sg11
VP17482
p3494
sg13
I1
sa(dp3495
g7
I86
sg8
VlincRNA-RAB12-1
p3496
sg10
I15
sg11
g12
sg13
I1
sa(dp3497
g7
I208
sg8
VRP11-160A10.2
p3498
sg10
I13
sg11
g12
sg13
I1
sa(dp3499
g7
I237
sg8
Vnc-HOXD10-7
p3500
sg10
I11
sg11
VP28358
p3501
sg13
I1
sa(dp3502
g7
I270
sg8
g3479
sg10
I11
sg11
VP35452
p3503
sg13
I1
sa(dp3504
g7
I264
sg8
VCES4
p3505
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp3506
(dp3507
g7
I112
sg8
VRP11
p3508
sg10
I4
sg28
VC1838601
p3509
sg13
I1
sa(dp3510
g7
I367
sg8
Vcarcinoma of the bladder
p3511
sg10
I24
sg28
VC0699885
p3512
sg13
I4
sa(dp3513
g7
I444
sg8
Vcancer
p3514
sg10
I6
sg28
VC0006826
p3515
sg13
I1
sa(dp3516
g7
I112
sg8
g3480
sg10
I4
sg28
VC1838601
p3517
sg13
I1
sasa(dp3518
g135
(dp3519
(VRab-3
p3520
VLCA
p3521
tp3522
I00
ssg2
VProteins labeled with LCA were Rab-3, Rab-12, Rab-16, and M-Ras.
p3523
sg4
(lp3524
(dp3525
g7
I46
sg8
VRab-16
p3526
sg10
I6
sg11
VP52594
p3527
sg13
I1
sa(dp3528
g7
I38
sg8
VRab-12
p3529
sg10
I6
sg11
VP52594
p3530
sg13
I1
sa(dp3531
g7
I31
sg8
g3520
sg10
I5
sg11
VP52594
p3532
sg13
I1
sa(dp3533
g7
I58
sg8
VM-Ras
p3534
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp3535
(dp3536
g7
I22
sg8
g3521
sg10
I3
sg28
VC0339527
p3537
sg13
I1
sasa(dp3538
g135
(dp3539
(VANT2 precursors
p3540
Voncocytomas
p3541
tp3542
I00
ssg2
VMoreover, the ANT2 precursors were observed to change in oncocytomas.
p3543
sg4
(lp3544
(dp3545
g7
I14
sg8
g3540
sg10
I15
sg11
VP05141
p3546
sg13
I2
sasg24
(lp3547
(dp3548
g7
I57
sg8
g3541
sg10
I11
sg28
VC0949541
p3549
sg13
I1
sasa(dp3550
g135
(dp3551
(VANT2
p3552
Vrenal tumor
p3553
tp3554
I01
ssg2
VIn particular, a high transcript level for the adenine nucleotide translocator isoform 2(ANT2) gene, which is usually not expressed in differentiated cells, was observed in oncocytoma and malignant urothelial renal tumor.
p3555
sg4
(lp3556
(dp3557
g7
I89
sg8
g3552
sg10
I4
sg11
VP05141
p3558
sg13
I1
sa(dp3559
g7
I47
sg8
Vadenine nucleotide translocator isoform 2
p3560
sg10
I41
sg11
g12
sg13
I5
sasg24
(lp3561
(dp3562
g7
I173
sg8
Voncocytoma
p3563
sg10
I10
sg28
VC0949541
p3564
sg13
I1
sa(dp3565
g7
I209
sg8
g3553
sg10
I11
sg28
VC0022665
p3566
sg13
I2
sasa(dp3567
g2
VThis study aimed to assess inflammatory, cardiac, renal and hematological markers in 56 breast cancer patients (BCP) before, during and after termination of chemotherapy with CYP and DOX.
p3568
sg4
(lp3569
sg24
(lp3570
(dp3571
g7
I88
sg8
Vbreast cancer
p3572
sg10
I13
sg28
VC0678222
p3573
sg13
I2
sasa(dp3574
g2
VBased on the results, we conclude that breast cancer and co-treatment of CYP and DOX interfere with various biological markers, thereby, showing the physiological imbalance.
p3575
sg4
(lp3576
sg24
(lp3577
(dp3578
g7
I39
sg8
Vbreast cancer
p3579
sg10
I13
sg28
VC0678222
p3580
sg13
I2
sa(dp3581
g7
I163
sg8
Vimbalance
p3582
sg10
I9
sg28
VC1397014
p3583
sg13
I1
sasa(dp3584
g135
(dp3585
(VCYP
p3586
Vbreast cancer
p3587
tp3588
I00
ssg2
VEpoxyeicosatrienoic acid (EET) production via cytochrome P450 (CYP) epoxygenases closely correlates with the progression of breast cancer.
p3589
sg4
(lp3590
(dp3591
g7
I46
sg8
Vcytochrome P450
p3592
sg10
I15
sg11
VP20853
p3593
sg13
I2
sa(dp3594
g7
I63
sg8
g3586
sg10
I3
sg11
VP20853
p3595
sg13
I1
sasg24
(lp3596
(dp3597
g7
I124
sg8
g3587
sg10
I13
sg28
VC0678222
p3598
sg13
I2
sasa(dp3599
g135
(dp3600
(VCYP3A4
p3601
Vtamoxifen
p3602
tp3603
I00
ssg2
VHere, we found that CYP3A4 expression and its epoxy-product, 11,12-epoxyeicosatrienoic acid (11,12-EET) was enhanced in tamoxifen (TAM)-resistant MCF-7 (TAMR-MCF-7) breast cancer cells compared to control MCF-7 cells.
p3604
sg4
(lp3605
(dp3606
g7
I20
sg8
g3601
sg10
I6
sg11
VP08684
p3607
sg13
I1
sasg24
(lp3608
(dp3609
g7
I165
sg8
Vbreast cancer
p3610
sg10
I13
sg28
VC0678222
p3611
sg13
I2
sa(dp3612
g7
I131
sg8
VTAM
p3613
sg10
I3
sg28
VC1834582
p3614
sg13
I1
sa(dp3615
g7
I120
sg8
g3602
sg10
I9
sg28
VC1834582
p3616
sg13
I1
sasa(dp3617
g135
(dp3618
(VCYP3A4
p3619
Vbreast cancer
p3620
tp3621
I00
ssg2
VOur findings suggest that the CYP3A4-mediated EET pathway represents a potential therapeutic target for the treatment of tamoxifen-resistant breast cancer.
p3622
sg4
(lp3623
(dp3624
g7
I30
sg8
g3619
sg10
I6
sg11
VP08684
p3625
sg13
I1
sasg24
(lp3626
(dp3627
g7
I141
sg8
g3620
sg10
I13
sg28
VC0678222
p3628
sg13
I2
sasa(dp3629
g135
(dp3630
(VCYP3A4
p3631
Vbreast cancer
p3632
tp3633
I00
ssg2
VCYP3A4 was unexpectedly associated with breast cancer mitochondria and synthesized arachidonic acid (AA)-derived epoxyeicosatrienoic acids (EETs), which promoted the electron transport chain/respiration and inhibited AMPKAlfa.
p3634
sg4
(lp3635
(dp3636
g7
I0
sg8
g3631
sg10
I6
sg11
VP08684
p3637
sg13
I1
sasg24
(lp3638
(dp3639
g7
I40
sg8
g3632
sg10
I13
sg28
VC0678222
p3640
sg13
I2
sasa(dp3641
g135
(dp3642
(VCYP3A4
p3643
Vmammary tumor
p3644
tp3645
I00
ssg2
VCYP3A4 knockdown activated AMPKAlfa, promoted autophagy, and prevented mammary tumor formation.
p3646
sg4
(lp3647
(dp3648
g7
I0
sg8
g3643
sg10
I6
sg11
VP08684
p3649
sg13
I1
sasg24
(lp3650
(dp3651
g7
I71
sg8
g3644
sg10
I13
sg28
VC1458155
p3652
sg13
I2
sasa(dp3653
g2
VComprehensive genotyping of CYP enzymes and transporters was performed using the iPLEX ADME PGx Pro Panel in 302 tamoxifen-treated breast cancer patients.
p3654
sg4
(lp3655
(dp3656
g7
I28
sg8
VCYP enzymes
p3657
sg10
I11
sg11
g12
sg13
I2
sasg24
(lp3658
(dp3659
g7
I131
sg8
Vbreast cancer
p3660
sg10
I13
sg28
VC0678222
p3661
sg13
I2
sasa(dp3662
g135
(dp3663
(VCD38
p3664
Vobese
p3665
tp3666
I01
ssg2
VIt has been recently reported that CD38 was highly expressed in adipose tissues from obese people and CD38-deficient mice were resistant to high-fat diet (HFD)-induced obesity.
p3667
sg4
(lp3668
(dp3669
g7
I35
sg8
VCD38
p3670
sg10
I4
sg11
VP28907
p3671
sg13
I1
sa(dp3672
g7
I35
sg8
g3664
sg10
I4
sg11
VP28907
p3673
sg13
I1
sasg24
(lp3674
(dp3675
g7
I168
sg8
Vobesity
p3676
sg10
I7
sg28
VC0028754
p3677
sg13
I1
sa(dp3678
g7
I85
sg8
g3665
sg10
I5
sg28
VC0028754
p3679
sg13
I1
sasa(dp3680
g135
(dp3681
(VCD38
p3682
Vobesity
p3683
tp3684
I01
ssg2
VIn this study, to explore the roles of CD38 in adipogenesis and lipogenesis in vivo and in vitro, obesity models were generated with male CD38-/- and WT mice fed with HFD.
p3685
sg4
(lp3686
(dp3687
g7
I39
sg8
VCD38
p3688
sg10
I4
sg11
VP28907
p3689
sg13
I1
sa(dp3690
g7
I39
sg8
g3682
sg10
I4
sg11
VP28907
p3691
sg13
I1
sasg24
(lp3692
(dp3693
g7
I98
sg8
g3683
sg10
I7
sg28
VC0028754
p3694
sg13
I1
sasa(dp3695
g135
(dp3696
(VCD38
p3697
Vobesity
p3698
tp3699
I01
ssg2
VThe results showed that CD38-/- male mice were significantly resistant to HFD-induced obesity.
p3700
sg4
(lp3701
(dp3702
g7
I24
sg8
g3697
sg10
I4
sg11
VP28907
p3703
sg13
I1
sasg24
(lp3704
(dp3705
g7
I86
sg8
g3698
sg10
I7
sg28
VC0028754
p3706
sg13
I1
sasa(dp3707
g135
(dp3708
(VCD38
p3709
Vobesity
p3710
tp3711
I01
ssg2
VThese results suggest that CD38 deficiency impairs adipogenesis and lipogenesis through activating Sirt1/PPARGamma-FASN signalling pathway during the development of obesity.
p3712
sg4
(lp3713
(dp3714
g7
I27
sg8
g3709
sg10
I4
sg11
VP28907
p3715
sg13
I1
sa(dp3716
g7
I99
sg8
VSirt1
p3717
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp3718
(dp3719
g7
I165
sg8
g3710
sg10
I7
sg28
VC0028754
p3720
sg13
I1
sasa(dp3721
g135
(dp3722
(VCD38+
p3723
Vobesity
p3724
tp3725
I01
ssg2
VWe also found that obesity development was associated with an increase in the number of CD38+ adipose progenitors, this effect being more pronounced in intra-abdominal than in subcutaneous fat, suggesting a higher rate of adipocyte commitment in visceral depots.
p3726
sg4
(lp3727
(dp3728
g7
I88
sg8
g3723
sg10
I5
sg11
VP28907
p3729
sg13
I1
sasg24
(lp3730
(dp3731
g7
I19
sg8
g3724
sg10
I7
sg28
VC0028754
p3732
sg13
I1
sasa(dp3733
g135
(dp3734
(VCD4+
p3735
Vtype 1 diabetes
p3736
tp3737
I00
ssg2
VIn this study, we show that CD45RO+CD38+ Beta cell Ag-specific CD4+ T cells were present at higher frequencies in type 1 diabetes subjects compared with those in healthy subjects.
p3738
sg4
(lp3739
(dp3740
g7
I28
sg8
VCD45RO+CD38+ Beta cell Ag
p3741
sg10
I25
sg11
VP28907
p3742
sg13
I4
sa(dp3743
g7
I63
sg8
g3735
sg10
I4
sg11
VP01730
p3744
sg13
I1
sasg24
(lp3745
(dp3746
g7
I114
sg8
g3736
sg10
I15
sg28
VC0011854
p3747
sg13
I3
sasa(dp3748
g135
(dp3749
(VCD38
p3750
VNAD
p3751
tp3752
I00
ssg2
VRegulation of the SIRT/NAD system was associated with early (SIRT4, SIRT7, NAPRT1 and NMNAT2) and late phases (NMNAT3, NMRK2, ABCA1 and CD38) of glucose intolerance.
p3753
sg4
(lp3754
(dp3755
g7
I86
sg8
VNMNAT2
p3756
sg10
I6
sg11
g12
sg13
I1
sa(dp3757
g7
I68
sg8
VSIRT7
p3758
sg10
I5
sg11
g12
sg13
I1
sa(dp3759
g7
I136
sg8
g3750
sg10
I4
sg11
VP28907
p3760
sg13
I1
sa(dp3761
g7
I61
sg8
VSIRT4
p3762
sg10
I5
sg11
g12
sg13
I1
sa(dp3763
g7
I111
sg8
VNMNAT3
p3764
sg10
I6
sg11
g12
sg13
I1
sa(dp3765
g7
I75
sg8
VNAPRT1
p3766
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp3767
(dp3768
g7
I145
sg8
Vglucose intolerance
p3769
sg10
I19
sg28
VC0271650
p3770
sg13
I2
sa(dp3771
g7
I23
sg8
g3751
sg10
I3
sg28
VC1850380
p3772
sg13
I1
sasa(dp3773
g135
(dp3774
(VSELL
p3775
Vanorexia nervosa
p3776
tp3777
I00
ssg2
VA total of eleven of genes were differently expressed in celiac patients compared with disease controls of which CD36, CD38, FOXP1, SELL, PPARA, PPARG, AGT previously associated with type 2 diabetes and AKAP6, NTNG1 with anorexia nervosa remained significant after correction for multiple testing.
p3778
sg4
(lp3779
(dp3780
g7
I152
sg8
VAGT
p3781
sg10
I3
sg11
VP21549
p3782
sg13
I1
sa(dp3783
g7
I119
sg8
VCD38
p3784
sg10
I4
sg11
VP28907
p3785
sg13
I1
sa(dp3786
g7
I145
sg8
VPPARG
p3787
sg10
I5
sg11
g12
sg13
I1
sa(dp3788
g7
I132
sg8
g3775
sg10
I4
sg11
VP14151
p3789
sg13
I1
sa(dp3790
g7
I138
sg8
VPPARA
p3791
sg10
I5
sg11
g12
sg13
I1
sa(dp3792
g7
I210
sg8
VNTNG1
p3793
sg10
I5
sg11
g12
sg13
I1
sa(dp3794
g7
I125
sg8
VFOXP1
p3795
sg10
I5
sg11
g12
sg13
I1
sa(dp3796
g7
I203
sg8
VAKAP6
p3797
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp3798
(dp3799
g7
I183
sg8
Vtype 2 diabetes
p3800
sg10
I15
sg28
VC0011860
p3801
sg13
I3
sa(dp3802
g7
I221
sg8
g3776
sg10
I16
sg28
VC0003125
p3803
sg13
I2
sasa(dp3804
g135
(dp3805
(VNF-YA
p3806
VSBMA
p3807
tp3808
I00
ssg2
VPF significantly increased the expression of nuclear factor-YA (NF-YA), which strongly upregulated the molecules involved in the proteolytic machinery [molecular chaperones, carboxyl terminus of Hsc70-interacting protein and transcription factor EB], which thus mitigated the behavioral and pathological impairments in an SBMA mouse model through the upregulation of pathogenic androgen receptor protein clearance in motor neurons and muscles.
p3809
sg4
(lp3810
(dp3811
g7
I195
sg8
VHsc70-interacting protein
p3812
sg10
I25
sg11
VP50502
p3813
sg13
I2
sa(dp3814
g7
I378
sg8
Vandrogen receptor protein
p3815
sg10
I25
sg11
VP10275
p3816
sg13
I3
sa(dp3817
g7
I45
sg8
Vnuclear factor-YA
p3818
sg10
I17
sg11
VP01160
p3819
sg13
I2
sa(dp3820
g7
I225
sg8
Vtranscription factor EB
p3821
sg10
I23
sg11
VP19484
p3822
sg13
I3
sa(dp3823
g7
I64
sg8
g3806
sg10
I5
sg11
VP23511
p3824
sg13
I1
sasg24
(lp3825
(dp3826
g7
I322
sg8
g3807
sg10
I4
sg28
VC1839259
p3827
sg13
I1
sasa(dp3828
g2
VOne hundred and seven patients (49.3%) had no significant change in BP; 30.9% had intradialytic hypertension (IDHT) while 19.8% had intradialytic hypotension (IDH).
p3829
sg4
(lp3830
sg24
(lp3831
(dp3832
g7
I96
sg8
Vhypertension
p3833
sg10
I12
sg28
VC0020538
p3834
sg13
I1
sasa(dp3835
g2
VThis week's articles describe ways to treat arthritis caused by chikungunya virus, IDH-mutant cancers, and hypertension.
p3836
sg4
(lp3837
sg24
(lp3838
(dp3839
g7
I94
sg8
Vcancers
p3840
sg10
I7
sg28
VC0006826
p3841
sg13
I1
sa(dp3842
g7
I107
sg8
Vhypertension
p3843
sg10
I12
sg28
VC0020538
p3844
sg13
I1
sa(dp3845
g7
I64
sg8
Vchikungunya
p3846
sg10
I11
sg28
VC0008055
p3847
sg13
I1
sa(dp3848
g7
I87
sg8
Vmutant
p3849
sg10
I6
sg28
VC0596988
p3850
sg13
I1
sa(dp3851
g7
I44
sg8
Varthritis
p3852
sg10
I9
sg28
VC0003864
p3853
sg13
I1
sasa(dp3854
g135
(dp3855
(VIDH
p3856
VCVA
p3857
tp3858
I00
ssg2
VOn univariate analysis, diabetes mellitus, hypertension (HTN), cerebrovascular accident (CVA), left ventricular dysfunction (LVD), peripheral vascular disease (PVD), smoking, hepatitis C, inadequate dialysis, intradialytic hypotension (IDH), interdialytic weight gain, low serum creatinine &lt;4 mg/dL, and anemia (Hb &lt;10 g/dL) were found to be statistically significantly different between frail and nonfrail groups On multivariate regression analysis, only HTN, PVD, CVA, anemia, smoking, and IDH were found to be significant.
p3859
sg4
(lp3860
(dp3861
g7
I57
sg8
VHTN
p3862
sg10
I3
sg11
VP24821
p3863
sg13
I1
sa(dp3864
g7
I209
sg8
Vintradialytic hypotension
p3865
sg10
I25
sg11
VP48735
p3866
sg13
I2
sa(dp3867
g7
I43
sg8
Vhypertension
p3868
sg10
I12
sg11
VP24821
p3869
sg13
I1
sa(dp3870
g7
I236
sg8
g3856
sg10
I3
sg11
VP48735
p3871
sg13
I1
sasg24
(lp3872
(dp3873
g7
I160
sg8
VPVD
p3874
sg10
I3
sg28
VC0085096
p3875
sg13
I1
sa(dp3876
g7
I43
sg8
Vhypertension
p3877
sg10
I12
sg28
VC0020538
p3878
sg13
I1
sa(dp3879
g7
I89
sg8
VCVA
p3880
sg10
I3
sg28
VC0038454
p3881
sg13
I1
sa(dp3882
g7
I57
sg8
VHTN
p3883
sg10
I3
sg28
VC0020538
p3884
sg13
I1
sa(dp3885
g7
I125
sg8
VLVD
p3886
sg10
I3
sg28
VC0242698
p3887
sg13
I1
sa(dp3888
g7
I95
sg8
Vleft ventricular dysfunction
p3889
sg10
I28
sg28
VC0242698
p3890
sg13
I3
sa(dp3891
g7
I160
sg8
VPVD
p3892
sg10
I3
sg28
VC0085096
p3893
sg13
I1
sa(dp3894
g7
I307
sg8
Vanemia
p3895
sg10
I6
sg28
VC0002871
p3896
sg13
I1
sa(dp3897
g7
I63
sg8
Vcerebrovascular accident
p3898
sg10
I24
sg28
VC0038454
p3899
sg13
I2
sa(dp3900
g7
I307
sg8
Vanemia
p3901
sg10
I6
sg28
VC0002871
p3902
sg13
I1
sa(dp3903
g7
I57
sg8
VHTN
p3904
sg10
I3
sg28
VC0020538
p3905
sg13
I1
sa(dp3906
g7
I24
sg8
Vdiabetes mellitus
p3907
sg10
I17
sg28
VC0011849
p3908
sg13
I2
sa(dp3909
g7
I131
sg8
Vperipheral vascular disease
p3910
sg10
I27
sg28
VC0085096
p3911
sg13
I3
sa(dp3912
g7
I175
sg8
Vhepatitis C
p3913
sg10
I11
sg28
VC0019196
p3914
sg13
I2
sa(dp3915
g7
I89
sg8
g3857
sg10
I3
sg28
VC0038454
p3916
sg13
I1
sasa(dp3917
g135
(dp3918
(VIDH
p3919
VPVD
p3920
tp3921
I00
ssg2
VFactors predicting frailty include HTN, smoking, LVD, PVD, CVA, smoking, anemia, and IDH.
p3922
sg4
(lp3923
(dp3924
g7
I85
sg8
g3919
sg10
I3
sg11
VP48735
p3925
sg13
I1
sasg24
(lp3926
(dp3927
g7
I59
sg8
VCVA
p3928
sg10
I3
sg28
VC0038454
p3929
sg13
I1
sa(dp3930
g7
I73
sg8
Vanemia
p3931
sg10
I6
sg28
VC0002871
p3932
sg13
I1
sa(dp3933
g7
I35
sg8
VHTN
p3934
sg10
I3
sg28
VC0020538
p3935
sg13
I1
sa(dp3936
g7
I54
sg8
g3920
sg10
I3
sg28
VC0085096
p3937
sg13
I1
sasa(dp3938
g2
VIntradialytic hypertension (IDH) increases morbidity and mortality.
p3939
sg4
(lp3940
sg24
(lp3941
(dp3942
g7
I14
sg8
Vhypertension
p3943
sg10
I12
sg28
VC0020538
p3944
sg13
I1
sasa(dp3945
g2
VIntradialytic hypertension (ID-HTN) is an increasingly recognized phenomenon and although less common than IDH, portends poor cardiovascular prognosis as well as reflects higher hypertension burden in the dialysis population.
p3946
sg4
(lp3947
sg24
(lp3948
(dp3949
g7
I31
sg8
VHTN
p3950
sg10
I3
sg28
VC0020538
p3951
sg13
I1
sa(dp3952
g7
I14
sg8
Vhypertension
p3953
sg10
I12
sg28
VC0020538
p3954
sg13
I1
sa(dp3955
g7
I14
sg8
Vhypertension
p3956
sg10
I12
sg28
VC0020538
p3957
sg13
I1
sasa(dp3958
g2
VDry weight, hypertension, and phosphorus levels are modifiable risk factors to possibly reduce the rate of IDH episodes.
p3959
sg4
(lp3960
sg24
(lp3961
(dp3962
g7
I12
sg8
Vhypertension
p3963
sg10
I12
sg28
VC0020538
p3964
sg13
I1
sasa(dp3965
g2
VWe believe that all hypertension guidelines should follow the National Institute for Health and Excellence (NICE) and make IDP and CTD first choice 'thiazide-like diuretics.'
p3966
sg4
(lp3967
sg24
(lp3968
(dp3969
g7
I20
sg8
Vhypertension
p3970
sg10
I12
sg28
VC0020538
p3971
sg13
I1
sasa(dp3972
g135
(dp3973
(VSOX6
p3974
Vanaplastic astrocytomas
p3975
tp3976
I00
ssg2
VImmunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analyzed (14 glioblastomas, 14 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas, 5 diffuse astrocytomas, 1 oligodendroglioma, and 1 pilocytic astrocytoma) expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in nonneoplastic tissues from the cerebral cortex.
p3977
sg4
(lp3978
(dp3979
g7
I43
sg8
VSOX6
p3980
sg10
I4
sg11
VP35712
p3981
sg13
I1
sa(dp3982
g7
I38
sg8
Vanti-SOX6 antibody
p3983
sg10
I18
sg11
VP35712
p3984
sg13
I2
sa(dp3985
g7
I43
sg8
g3974
sg10
I4
sg11
VP35712
p3986
sg13
I1
sasg24
(lp3987
(dp3988
g7
I134
sg8
Vastrocytomas
p3989
sg10
I12
sg28
VC0004114
p3990
sg13
I1
sa(dp3991
g7
I77
sg8
Vglioma
p3992
sg10
I6
sg28
VC0017638
p3993
sg13
I1
sa(dp3994
g7
I272
sg8
Vtumor
p3995
sg10
I5
sg28
VC0027651
p3996
sg13
I1
sa(dp3997
g7
I105
sg8
Vglioblastomas
p3998
sg10
I13
sg28
VC0017636
p3999
sg13
I1
sa(dp4000
g7
I231
sg8
Vpilocytic astrocytoma
p4001
sg10
I21
sg28
VC0334583
p4002
sg13
I2
sa(dp4003
g7
I206
sg8
Voligodendroglioma
p4004
sg10
I17
sg28
VC0028945
p4005
sg13
I1
sa(dp4006
g7
I123
sg8
g3975
sg10
I23
sg28
VC0334579
p4007
sg13
I2
sasa(dp4008
g135
(dp4009
(VIl1beta
p4010
VRP3
p4011
tp4012
I00
ssg2
VTo address these issues, we analyzed the production of proinflammatory mediators in mouse thyroid organs and demonstrate consistency with in vitro studies performed previously that Il1alpha, Il1beta, Il6, and Tnfalpha and the enzyme Cox2 are produced by RP3-transgenic thyroid tissue, but absent from nontransgenic thyroids.
p4013
sg4
(lp4014
(dp4015
g7
I200
sg8
VIl6
p4016
sg10
I3
sg11
VP05231
p4017
sg13
I1
sa(dp4018
g7
I233
sg8
VCox2
p4019
sg10
I4
sg11
VP35354
p4020
sg13
I1
sa(dp4021
g7
I209
sg8
VTnfalpha
p4022
sg10
I8
sg11
VP01375
p4023
sg13
I1
sa(dp4024
g7
I181
sg8
VIl1alpha
p4025
sg10
I8
sg11
VP01583
p4026
sg13
I1
sa(dp4027
g7
I254
sg8
VRP3
p4028
sg10
I3
sg11
VP51808
p4029
sg13
I1
sa(dp4030
g7
I191
sg8
g4010
sg10
I7
sg11
VP01584
p4031
sg13
I1
sasg24
(lp4032
(dp4033
g7
I254
sg8
g4011
sg10
I3
sg28
VC1845667
p4034
sg13
I1
sasa(dp4035
g2
VWith a few exceptions, higher circulating levels of endostatin seem to reflect vascular and myocardial damage, and a worsened prognosis for cardiovascular events or mortality in individuals with hypertension, diabetes, kidney disease, cardiovascular disease, as well as in the general population.
p4036
sg4
(lp4037
sg24
(lp4038
(dp4039
g7
I226
sg8
Vdisease, cardiovascular
p4040
sg10
I23
sg28
VC0007222
p4041
sg13
I2
sa(dp4042
g7
I209
sg8
Vdiabetes
p4043
sg10
I8
sg28
VC0011849
p4044
sg13
I1
sa(dp4045
g7
I195
sg8
Vhypertension
p4046
sg10
I12
sg28
VC0020538
p4047
sg13
I1
sasa(dp4048
g2
VEndostatin is one of the main angiostatic mediators, and inhibits angiogenesis and prevents progression of atherosclerosis.
p4049
sg4
(lp4050
sg24
(lp4051
(dp4052
g7
I107
sg8
Vatherosclerosis
p4053
sg10
I15
sg28
VC0004153
p4054
sg13
I1
sasa(dp4055
g2
VFor ischemic versus hemorrhagic strokes comparison, NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) &gt;4.9 (odds ratio, 2.40; 95% confidence interval, 1.55-3.71; P&lt;0.0001) and endostatin &gt;4.7 (odds ratio, 2.02; 95% confidence interval, 1.19-3.45; P=0.010), together with age, sex, blood pressure, stroke severity, atrial fibrillation, and hypertension, were included in the model.
p4056
sg4
(lp4057
sg24
(lp4058
(dp4059
g7
I20
sg8
Vhemorrhagic strokes
p4060
sg10
I19
sg28
VC0553692
p4061
sg13
I2
sa(dp4062
g7
I32
sg8
Vstroke
p4063
sg10
I6
sg28
VC0038454
p4064
sg13
I1
sa(dp4065
g7
I352
sg8
Vhypertension
p4066
sg10
I12
sg28
VC0020538
p4067
sg13
I1
sa(dp4068
g7
I327
sg8
Vatrial fibrillation
p4069
sg10
I19
sg28
VC0004238
p4070
sg13
I2
sasa(dp4071
g2
VIn patients with coronary heart disease, the count of endothelial progenitor cells was lower by 4 times, the level of VEGF was higher by 52%, and the level of endostatin was lower by 13% than in healthy volunteers.
p4072
sg4
(lp4073
sg24
(lp4074
(dp4075
g7
I17
sg8
Vcoronary heart disease
p4076
sg10
I22
sg28
VC0010054
p4077
sg13
I3
sasa(dp4078
g135
(dp4079
(Vserum endostatin
p4080
Vatherosclerosis
p4081
tp4082
I01
ssg2
VTo examine the association between the serum endostatin levels and subclinical atherosclerosis independent of traditional risk factors in a healthy Japanese population.
p4083
sg4
(lp4084
(dp4085
g7
I39
sg8
g4080
sg10
I16
sg11
VP39059
p4086
sg13
I2
sasg24
(lp4087
(dp4088
g7
I79
sg8
g4081
sg10
I15
sg28
VC0004153
p4089
sg13
I1
sasa(dp4090
g2
VA higher serum endostatin level reflected subclinical atherosclerosis in this Japanese population.
p4091
sg4
(lp4092
sg24
(lp4093
(dp4094
g7
I54
sg8
Vatherosclerosis
p4095
sg10
I15
sg28
VC0004153
p4096
sg13
I1
sasa(dp4097
g2
VThe most common diseases among humanitarian cases were benign tumors (29%, 5/17), cranioplasty (23%, 4/17), obstructive hydrocephalus (11%, 2/17), nonobstructive hydrocephalus (11%, 2/17), hemifacial spasm (11%, 2/17), and cerebral angiography (11%, 2/17).
p4098
sg4
(lp4099
sg24
(lp4100
(dp4101
g7
I200
sg8
Vspasm
p4102
sg10
I5
sg28
VC0037763
p4103
sg13
I1
sa(dp4104
g7
I108
sg8
Vobstructive hydrocephalus
p4105
sg10
I25
sg28
VC0549423
p4106
sg13
I2
sa(dp4107
g7
I55
sg8
Vbenign tumors
p4108
sg10
I13
sg28
VC0086692
p4109
sg13
I2
sa(dp4110
g7
I120
sg8
Vhydrocephalus
p4111
sg10
I13
sg28
VC0020255
p4112
sg13
I1
sasa(dp4113
g2
VTwenty-seven (33.8%) patients developed ARE, 5 (6%) developed hydrocephalus, 10 (12.5%) reported new ataxia, 17 (21%) developed trigeminal dysfunction, 3 (3.75%) had facial weakness, and 1 patient developed hemifacial spasm.
p4114
sg4
(lp4115
sg24
(lp4116
(dp4117
g7
I101
sg8
Vataxia
p4118
sg10
I6
sg28
VC0004134
p4119
sg13
I1
sa(dp4120
g7
I166
sg8
Vfacial weakness
p4121
sg10
I15
sg28
VC0427055
p4122
sg13
I2
sa(dp4123
g7
I62
sg8
Vhydrocephalus
p4124
sg10
I13
sg28
VC0020255
p4125
sg13
I1
sa(dp4126
g7
I218
sg8
Vspasm
p4127
sg10
I5
sg28
VC0037763
p4128
sg13
I1
sasa(dp4129
g2
VTwelve factors, including gender, hypertension, intracranial aneurysm, cerebral vascular spasm, hydrocephalus and conscious disturbance during hospitalization, smoking, age, WFNS (World Federation of Neurological Surgeons) scale, Fisher grade, white blood cell count and blood glucose level at admission, were analyzed by using Chi-square test, t test, and Logistic multiple regression analysis.
p4130
sg4
(lp4131
sg24
(lp4132
(dp4133
g7
I61
sg8
Vaneurysm, cerebral
p4134
sg10
I18
sg28
VC0917996
p4135
sg13
I2
sa(dp4136
g7
I34
sg8
Vhypertension, intracranial
p4137
sg10
I26
sg28
VC0151740
p4138
sg13
I2
sa(dp4139
g7
I96
sg8
Vhydrocephalus
p4140
sg10
I13
sg28
VC0020255
p4141
sg13
I1
sa(dp4142
g7
I80
sg8
Vvascular spasm
p4143
sg10
I14
sg28
VC0085616
p4144
sg13
I2
sasa(dp4145
g2
VWe studied 37 patients with spasm, trisomy 21, prematurity, epilepsy, psychomotor retardation, and/or hydrocephalus (study group) and 67 control patients, all between 14 months and 14 years of age.
p4146
sg4
(lp4147
sg24
(lp4148
(dp4149
g7
I60
sg8
Vepilepsy, psychomotor
p4150
sg10
I21
sg28
VC0085417
p4151
sg13
I2
sa(dp4152
g7
I102
sg8
Vhydrocephalus
p4153
sg10
I13
sg28
VC0020255
p4154
sg13
I1
sa(dp4155
g7
I28
sg8
Vspasm
p4156
sg10
I5
sg28
VC0037763
p4157
sg13
I1
sa(dp4158
g7
I35
sg8
Vtrisomy 21
p4159
sg10
I10
sg28
VC0013080
p4160
sg13
I2
sasa(dp4161
g2
VSurgical treatment after radiosurgery or radiotherapy may be necessary for tumors that continue to grow, or for patients who develop brainstem compressive symptoms, disabling hemifacial spasm, or hydrocephalus.
p4162
sg4
(lp4163
sg24
(lp4164
(dp4165
g7
I186
sg8
Vspasm
p4166
sg10
I5
sg28
VC0037763
p4167
sg13
I1
sa(dp4168
g7
I75
sg8
Vtumors
p4169
sg10
I6
sg28
VC0027651
p4170
sg13
I1
sa(dp4171
g7
I196
sg8
Vhydrocephalus
p4172
sg10
I13
sg28
VC0020255
p4173
sg13
I1
sasa(dp4174
g135
(dp4175
(Vbrain homeobox 2,5-hydroxytryptamine receptor 1D
p4176
Vcervical cancer
p4177
tp4178
I00
ssg2
VAmong these, 236 differentially expressed genes (DEGs) were statistically significant, including many DEGs that were novel in cervical cancer, including gastrulation brain homeobox 2,5-hydroxytryptamine receptor 1D and endothelin 3.
p4179
sg4
(lp4180
(dp4181
g7
I49
sg8
VDEGs
p4182
sg10
I4
sg11
g12
sg13
I1
sa(dp4183
g7
I219
sg8
Vendothelin 3
p4184
sg10
I12
sg11
VP14138
p4185
sg13
I2
sa(dp4186
g7
I166
sg8
g4176
sg10
I48
sg11
VP52954
p4187
sg13
I5
sa(dp4188
g7
I17
sg8
Vdifferentially expressed genes
p4189
sg10
I30
sg11
g12
sg13
I3
sasg24
(lp4190
(dp4191
g7
I126
sg8
g4177
sg10
I15
sg28
VC0302592
p4192
sg13
I2
sasa(dp4193
g135
(dp4194
(VEDN3
p4195
Vcervical cancer
p4196
tp4197
I00
ssg2
VA total of 5 overlapping genes [dipeptidyl peptidase 4 (DPP4); endothelin 3 (EDN3); fibroblast growth factor 14 (FGF14); tachykinin, precursor 1 (TAC1); and wingless-type MMTV integration site family, member 16 (WNT16)] between the 561 overlapping differentially methylated genes and the 242 DEGs were identified, which were downregulated and hypermethylated simultaneously in cervical cancer samples.
p4198
sg4
(lp4199
(dp4200
g7
I121
sg8
Vtachykinin, precursor 1
p4201
sg10
I23
sg11
VP29401
p4202
sg13
I3
sa(dp4203
g7
I157
sg8
Vwingless-type MMTV integration site family, member 16
p4204
sg10
I53
sg11
g12
sg13
I7
sa(dp4205
g7
I31
sg8
V[dipeptidyl peptidase 4
p4206
sg10
I23
sg11
VP27487
p4207
sg13
I3
sa(dp4208
g7
I56
sg8
VDPP4
p4209
sg10
I4
sg11
VP27487
p4210
sg13
I1
sa(dp4211
g7
I84
sg8
Vfibroblast growth factor 14
p4212
sg10
I27
sg11
g12
sg13
I4
sa(dp4213
g7
I212
sg8
VWNT16
p4214
sg10
I5
sg11
g12
sg13
I1
sa(dp4215
g7
I113
sg8
VFGF14
p4216
sg10
I5
sg11
g12
sg13
I1
sa(dp4217
g7
I63
sg8
Vendothelin 3
p4218
sg10
I12
sg11
VP14138
p4219
sg13
I2
sa(dp4220
g7
I77
sg8
g4195
sg10
I4
sg11
VP14138
p4221
sg13
I1
sasg24
(lp4222
(dp4223
g7
I377
sg8
g4196
sg10
I15
sg28
VC0302592
p4224
sg13
I2
sasa(dp4225
g2
VEmploying functions of several bioinformatics tools, we selected 143 differentially expressed genes (DEGs) associated with the cervical cancer.
p4226
sg4
(lp4227
(dp4228
g7
I101
sg8
VDEGs
p4229
sg10
I4
sg11
g12
sg13
I1
sa(dp4230
g7
I69
sg8
Vdifferentially expressed genes
p4231
sg10
I30
sg11
g12
sg13
I3
sasg24
(lp4232
(dp4233
g7
I127
sg8
Vcervical cancer
p4234
sg10
I15
sg28
VC0302592
p4235
sg13
I2
sasa(dp4236
g2
VThe results of bioinformatics analysis show that these DEGs play important roles in the development of cervical cancer.
p4237
sg4
(lp4238
(dp4239
g7
I55
sg8
VDEGs
p4240
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp4241
(dp4242
g7
I103
sg8
Vcervical cancer
p4243
sg10
I15
sg28
VC0302592
p4244
sg13
I2
sasa(dp4245
g2
VA total of 1,160 and 756 DEGs were identified in the pre-invasive and invasive stages of cervical cancer, respectively.
p4246
sg4
(lp4247
sg24
(lp4248
(dp4249
g7
I89
sg8
Vcervical cancer
p4250
sg10
I15
sg28
VC0302592
p4251
sg13
I2
sasa(dp4252
g2
VSurvival analysis then revealed a five-PcG gene signature one protective gene (enhancer of zeste homolog 1) and four risky genes (EZH2, PHD finger protein 19, DNMT3A and DNMT3B), which may identify patients with high risk of poor prognosis of glioma.
p4253
sg4
(lp4254
(dp4255
g7
I170
sg8
VDNMT3B
p4256
sg10
I6
sg11
g12
sg13
I1
sa(dp4257
g7
I91
sg8
Vzeste homolog 1
p4258
sg10
I15
sg11
g12
sg13
I3
sa(dp4259
g7
I159
sg8
VDNMT3A
p4260
sg10
I6
sg11
g12
sg13
I1
sa(dp4261
g7
I136
sg8
VPHD finger protein 19
p4262
sg10
I21
sg11
g12
sg13
I4
sa(dp4263
g7
I130
sg8
VEZH2
p4264
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp4265
(dp4266
g7
I243
sg8
Vglioma
p4267
sg10
I6
sg28
VC0017638
p4268
sg13
I1
sasa(dp4269
g2
VIn this study, we exploited this platform to evaluate the behavior of two biodegradable formulations, poly-Epsilon-caprolactone (PCL3) and poly lactic-acid (PLA8), respectively, in cellular and animal models of triple-negative breast cancer (TNBC).
p4270
sg4
(lp4271
(dp4272
g7
I129
sg8
VPCL3
p4273
sg10
I4
sg11
g12
sg13
I1
sa(dp4274
g7
I102
sg8
Vpoly-Epsilon-caprolactone
p4275
sg10
I25
sg11
g12
sg13
I1
sasg24
(lp4276
(dp4277
g7
I227
sg8
Vbreast cancer
p4278
sg10
I13
sg28
VC0678222
p4279
sg13
I2
sasa(dp4280
g2
VInterestingly, changes in EZH2, PHF19, CBX7, CBX6 and EZH1 occurred progressively as astrocytoma grade increased.
p4281
sg4
(lp4282
(dp4283
g7
I26
sg8
VEZH2
p4284
sg10
I4
sg11
g12
sg13
I1
sa(dp4285
g7
I39
sg8
VCBX7
p4286
sg10
I4
sg11
g12
sg13
I1
sa(dp4287
g7
I54
sg8
VEZH1
p4288
sg10
I4
sg11
g12
sg13
I1
sa(dp4289
g7
I45
sg8
VCBX6
p4290
sg10
I4
sg11
g12
sg13
I1
sa(dp4291
g7
I32
sg8
VPHF19
p4292
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp4293
(dp4294
g7
I85
sg8
Vastrocytoma
p4295
sg10
I11
sg28
VC0004114
p4296
sg13
I1
sasa(dp4297
g2
VIn this report, we show that PHF19 silencing reduces the cell proliferation rate and increases the transendothelial migration capacities of melanoma cell lines.
p4298
sg4
(lp4299
(dp4300
g7
I29
sg8
VPHF19
p4301
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp4302
(dp4303
g7
I140
sg8
Vmelanoma
p4304
sg10
I8
sg28
VC0025202
p4305
sg13
I1
sa(dp4306
g7
I62
sg8
Vproliferation
p4307
sg10
I13
sg28
VC0334094
p4308
sg13
I1
sasa(dp4309
g2
VOur data therefore indicate the role of PHF19 and its upstream regulator, Akt, in the phenotype switch of melanoma cells from proliferative to invasive states.
p4310
sg4
(lp4311
(dp4312
g7
I40
sg8
VPHF19
p4313
sg10
I5
sg11
g12
sg13
I1
sa(dp4314
g7
I74
sg8
VAkt
p4315
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp4316
(dp4317
g7
I106
sg8
Vmelanoma
p4318
sg10
I8
sg28
VC0025202
p4319
sg13
I1
sa(dp4320
g7
I126
sg8
Vproliferative
p4321
sg10
I13
sg28
VC0334094
p4322
sg13
I1
sasa(dp4323
g2
VInterestingly, the products of the hPCL3 gene, particularly the short form, hPCL3S, are markedly overexpressed in many types of cancers, including colon, skin, lung, rectal, cervical, uterus, and liver cancers.
p4324
sg4
(lp4325
(dp4326
g7
I76
sg8
VhPCL3S
p4327
sg10
I6
sg11
g12
sg13
I1
sa(dp4328
g7
I35
sg8
VhPCL3 gene
p4329
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp4330
(dp4331
g7
I128
sg8
Vcancers
p4332
sg10
I7
sg28
VC0006826
p4333
sg13
I1
sa(dp4334
g7
I196
sg8
Vliver cancers
p4335
sg10
I13
sg28
VC0345904
p4336
sg13
I2
sasa(dp4337
g2
VBoth hPCL3S and hPCL3L messages were increased dramatically in most cell lines derived from various stages of melanoma and glioma tumor progression.
p4338
sg4
(lp4339
(dp4340
g7
I5
sg8
VhPCL3S
p4341
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp4342
(dp4343
g7
I123
sg8
Vglioma
p4344
sg10
I6
sg28
VC0017638
p4345
sg13
I1
sa(dp4346
g7
I110
sg8
Vmelanoma
p4347
sg10
I8
sg28
VC0025202
p4348
sg13
I1
sa(dp4349
g7
I130
sg8
Vtumor progression
p4350
sg10
I17
sg28
VC0178874
p4351
sg13
I2
sasa(dp4352
g2
VFifty patients (19 males and 31 females, mean age 52.4 y) showed sagging posterior layer TLF, and 32 of them developed &gt;=1 junctional problems, such as retrolistheses (n=25), compression fractures (n=5), spondylolistheses (n=4), progressive scoliosis (n=4), and segmental instability with bone marrow change (n=2).
p4353
sg4
(lp4354
sg24
(lp4355
(dp4356
g7
I244
sg8
Vscoliosis
p4357
sg10
I9
sg28
VC0700208
p4358
sg13
I1
sa(dp4359
g7
I178
sg8
Vcompression fractures
p4360
sg10
I21
sg28
VC0521169
p4361
sg13
I2
sa(dp4362
g7
I207
sg8
Vspondylolistheses
p4363
sg10
I17
sg28
VC0038016
p4364
sg13
I1
sasa(dp4365
g2
VHowever, the patients with thoracolumbar fracture (TLF) had significantly more MSCs than those with degenerative disc disease (DDD), but not for NCs.
p4366
sg4
(lp4367
sg24
(lp4368
(dp4369
g7
I127
sg8
VDDD
p4370
sg10
I3
sg28
VC0406811
p4371
sg13
I1
sa(dp4372
g7
I100
sg8
Vdegenerative disc disease
p4373
sg10
I25
sg28
VC0158266
p4374
sg13
I3
sasa(dp4375
g2
VCommon physiological pathways are involved in several ARCA, such as DNA repair deficiency (AOA1, ataxia telangiectasia [AT]...), RNA termination disorder (AOA2), mitochondrial defect (FRDA, sensory ataxic neuropathy with dysarthria and ophthalmoplegia [Sando]...), lipoprotein assembly defects (AVED, abetalipoproteinemia [ABL]), chaperon protein disorders (ARSACS, Marinesco-Sjoegren syndrome [MSS]) or peroxysomal diseases (Refsum disease [RD]).
p4376
sg4
(lp4377
(dp4378
g7
I184
sg8
VFRDA
p4379
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp4380
(dp4381
g7
I236
sg8
Vophthalmoplegia
p4382
sg10
I15
sg28
VC0029089
p4383
sg13
I1
sa(dp4384
g7
I323
sg8
VABL
p4385
sg10
I3
sg28
VC0000744
p4386
sg13
I1
sa(dp4387
g7
I385
sg8
Vsyndrome
p4388
sg10
I8
sg28
VC0039082
p4389
sg13
I1
sa(dp4390
g7
I301
sg8
Vabetalipoproteinemia
p4391
sg10
I20
sg28
VC0000744
p4392
sg13
I1
sa(dp4393
g7
I184
sg8
VFRDA
p4394
sg10
I4
sg28
VC1856689
p4395
sg13
I1
sa(dp4396
g7
I221
sg8
Vdysarthria
p4397
sg10
I10
sg28
VC0013362
p4398
sg13
I1
sa(dp4399
g7
I155
sg8
VAOA2
p4400
sg10
I4
sg28
VC1853761
p4401
sg13
I1
sa(dp4402
g7
I253
sg8
VSando
p4403
sg10
I5
sg28
VC1843851
p4404
sg13
I1
sa(dp4405
g7
I205
sg8
Vneuropathy
p4406
sg10
I10
sg28
VC0442874
p4407
sg13
I1
sa(dp4408
g7
I358
sg8
VARSACS
p4409
sg10
I6
sg28
VC1849140
p4410
sg13
I1
sa(dp4411
g7
I97
sg8
Vataxia telangiectasia
p4412
sg10
I21
sg28
VC0004135
p4413
sg13
I2
sa(dp4414
g7
I198
sg8
Vataxic
p4415
sg10
I6
sg28
VC0234366
p4416
sg13
I1
sa(dp4417
g7
I91
sg8
VAOA1
p4418
sg10
I4
sg28
VC1859598
p4419
sg13
I1
sa(dp4420
g7
I426
sg8
VRefsum disease
p4421
sg10
I14
sg28
VC0034960
p4422
sg13
I2
sa(dp4423
g7
I68
sg8
VDNA repair deficiency
p4424
sg10
I21
sg28
VC0268134
p4425
sg13
I3
sa(dp4426
g7
I295
sg8
VAVED
p4427
sg10
I4
sg28
VC1848533
p4428
sg13
I1
sa(dp4429
g7
I395
sg8
VMSS
p4430
sg10
I3
sg28
VC0024814
p4431
sg13
I1
sasa(dp4432
g2
VWhile Friedreich's ataxia (FRDA) and ataxia telangiectasia (AT) are known to be the two most frequent forms of autosomal recessive cerebellar ataxia (ARCA), knowledge on the other forms of ARCA has been obtained only recently, and they appear to be rarer.
p4433
sg4
(lp4434
sg24
(lp4435
(dp4436
g7
I60
sg8
VAT
p4437
sg10
I2
sg28
VC0004135
p4438
sg13
I1
sa(dp4439
g7
I37
sg8
Vataxia telangiectasia
p4440
sg10
I21
sg28
VC0004135
p4441
sg13
I2
sa(dp4442
g7
I6
sg8
VFriedreich's ataxia
p4443
sg10
I19
sg28
VC0016719
p4444
sg13
I2
sa(dp4445
g7
I111
sg8
Vautosomal recessive cerebellar ataxia
p4446
sg10
I37
sg28
VC0007758
p4447
sg13
I4
sa(dp4448
g7
I27
sg8
VFRDA
p4449
sg10
I4
sg28
VC1856689
p4450
sg13
I1
sa(dp4451
g7
I150
sg8
VARCA
p4452
sg10
I4
sg28
VC0007758
p4453
sg13
I1
sa(dp4454
g7
I150
sg8
VARCA
p4455
sg10
I4
sg28
VC0007758
p4456
sg13
I1
sasa(dp4457
g135
(dp4458
(VTranscription factor MEF2C
p4459
Vautism spectrum disorder
p4460
tp4461
I01
ssg2
VTranscription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy.
p4462
sg4
(lp4463
(dp4464
g7
I0
sg8
g4459
sg10
I26
sg11
VP35398
p4465
sg13
I3
sa(dp4466
g7
I98
sg8
Vhuman MEF2C
p4467
sg10
I11
sg11
g12
sg13
I2
sasg24
(lp4468
(dp4469
g7
I174
sg8
Vepilepsy
p4470
sg10
I8
sg28
VC0014544
p4471
sg13
I1
sa(dp4472
g7
I88
sg8
VASD
p4473
sg10
I3
sg28
VC1510586
p4474
sg13
I1
sa(dp4475
g7
I145
sg8
Vintellectual disability
p4476
sg10
I23
sg28
VC0025362
p4477
sg13
I2
sa(dp4478
g7
I88
sg8
VASD
p4479
sg10
I3
sg28
VC1510586
p4480
sg13
I1
sa(dp4481
g7
I62
sg8
g4460
sg10
I24
sg28
VC1510586
p4482
sg13
I3
sasa(dp4483
g135
(dp4484
(VSYT1
p4485
Vepilepsy
p4486
tp4487
I01
ssg2
VThe microRNAs target a group of genes enriched for synaptic signaling and epilepsy risk, including SLC12A5, SYT1, GRIN2A, GRIN2B, KCNB1, SCN2A, TSC1, and MEF2C.
p4488
sg4
(lp4489
(dp4490
g7
I108
sg8
g4485
sg10
I4
sg11
VP21579
p4491
sg13
I1
sa(dp4492
g7
I122
sg8
VGRIN2B
p4493
sg10
I6
sg11
g12
sg13
I1
sa(dp4494
g7
I99
sg8
VSLC12A5
p4495
sg10
I7
sg11
g12
sg13
I1
sa(dp4496
g7
I137
sg8
VSCN2A
p4497
sg10
I5
sg11
g12
sg13
I1
sa(dp4498
g7
I154
sg8
VMEF2C
p4499
sg10
I5
sg11
g12
sg13
I1
sa(dp4500
g7
I114
sg8
VGRIN2A
p4501
sg10
I6
sg11
g12
sg13
I1
sa(dp4502
g7
I130
sg8
VKCNB1
p4503
sg10
I5
sg11
g12
sg13
I1
sa(dp4504
g7
I144
sg8
VTSC1
p4505
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp4506
(dp4507
g7
I144
sg8
VTSC1
p4508
sg10
I4
sg28
VC1854465
p4509
sg13
I1
sa(dp4510
g7
I74
sg8
g4486
sg10
I8
sg28
VC0014544
p4511
sg13
I1
sasa(dp4512
g135
(dp4513
(VCR1
p4514
VAD
p4515
tp4516
I00
ssg2
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p4517
sg4
(lp4518
(dp4519
g7
I292
sg8
VPICALM
p4520
sg10
I6
sg11
g12
sg13
I1
sa(dp4521
g7
I176
sg8
VCD2AP
p4522
sg10
I5
sg11
g12
sg13
I1
sa(dp4523
g7
I270
sg8
VMS4A4E
p4524
sg10
I6
sg11
g12
sg13
I1
sa(dp4525
g7
I255
sg8
VMEF2C
p4526
sg10
I5
sg11
g12
sg13
I1
sa(dp4527
g7
I227
sg8
VHLA
p4528
sg10
I3
sg11
VP30486
p4529
sg13
I1
sa(dp4530
g7
I206
sg8
VDSG2
p4531
sg10
I4
sg11
g12
sg13
I1
sa(dp4532
g7
I189
sg8
VCELF1
p4533
sg10
I5
sg11
g12
sg13
I1
sa(dp4534
g7
I157
sg8
VAPOE
p4535
sg10
I4
sg11
VP02649
p4536
sg13
I1
sa(dp4537
g7
I150
sg8
VABCA7
p4538
sg10
I5
sg11
g12
sg13
I1
sa(dp4539
g7
I313
sg8
VRIN3
p4540
sg10
I4
sg11
g12
sg13
I1
sa(dp4541
g7
I328
sg8
VSORL1
p4542
sg10
I5
sg11
g12
sg13
I1
sa(dp4543
g7
I319
sg8
VSLC24A4
p4544
sg10
I7
sg11
g12
sg13
I1
sa(dp4545
g7
I247
sg8
VINPP5D
p4546
sg10
I6
sg11
g12
sg13
I1
sa(dp4547
g7
I262
sg8
VMS4A4A
p4548
sg10
I6
sg11
g12
sg13
I1
sa(dp4549
g7
I183
sg8
VCD33
p4550
sg10
I4
sg11
VP20138
p4551
sg13
I1
sa(dp4552
g7
I300
sg8
VPLD3
p4553
sg10
I4
sg11
g12
sg13
I1
sa(dp4554
g7
I219
sg8
VFERMT2
p4555
sg10
I6
sg11
g12
sg13
I1
sa(dp4556
g7
I169
sg8
VCASS4
p4557
sg10
I5
sg11
g12
sg13
I1
sa(dp4558
g7
I196
sg8
VCLU
p4559
sg10
I3
sg11
VP10909
p4560
sg13
I1
sa(dp4561
g7
I306
sg8
VPTK2B
p4562
sg10
I5
sg11
g12
sg13
I1
sa(dp4563
g7
I212
sg8
VEPHA1
p4564
sg10
I5
sg11
VP21709
p4565
sg13
I1
sa(dp4566
g7
I278
sg8
VMS4A6E
p4567
sg10
I6
sg11
g12
sg13
I1
sa(dp4568
g7
I227
sg8
VHLA
p4569
sg10
I3
sg11
VP30486
p4570
sg13
I1
sa(dp4571
g7
I201
sg8
g4514
sg10
I3
sg11
VP17927
p4572
sg13
I1
sa(dp4573
g7
I339
sg8
VZCWPW1 genes
p4574
sg10
I12
sg11
g12
sg13
I2
sa(dp4575
g7
I286
sg8
VNME8
p4576
sg10
I4
sg11
g12
sg13
I1
sa(dp4577
g7
I231
sg8
VDRB1
p4578
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp4579
(dp4580
g7
I95
sg8
VAlzheimer's diseases
p4581
sg10
I20
sg28
VC0002395
p4582
sg13
I2
sa(dp4583
g7
I117
sg8
g4515
sg10
I2
sg28
VC0002395
p4584
sg13
I1
sasa(dp4585
g2
VEpilepsy-causing SIK1 sequence variations resulted in abnormalities in the MEF2C-ARC pathway of neuronal development and synapse activity response.
p4586
sg4
(lp4587
(dp4588
g7
I17
sg8
VSIK1 sequence
p4589
sg10
I13
sg11
VP57059
p4590
sg13
I2
sa(dp4591
g7
I81
sg8
VARC
p4592
sg10
I3
sg11
g12
sg13
I1
sa(dp4593
g7
I75
sg8
VMEF2C
p4594
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp4595
(dp4596
g7
I81
sg8
VARC
p4597
sg10
I3
sg28
VC0001857
p4598
sg13
I1
sa(dp4599
g7
I0
sg8
VEpilepsy
p4600
sg10
I8
sg28
VC0014544
p4601
sg13
I1
sasa(dp4602
g2
VThis work provides the first insights into the mechanisms of pathogenesis in SIK1 syndrome, and extends the ARX-MEF2C pathway in the pathogenesis of developmental epilepsy.
p4603
sg4
(lp4604
(dp4605
g7
I112
sg8
VMEF2C
p4606
sg10
I5
sg11
g12
sg13
I1
sa(dp4607
g7
I108
sg8
VARX
p4608
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp4609
(dp4610
g7
I61
sg8
Vpathogenesis
p4611
sg10
I12
sg28
VC0699748
p4612
sg13
I1
sa(dp4613
g7
I82
sg8
Vsyndrome
p4614
sg10
I8
sg28
VC0039082
p4615
sg13
I1
sa(dp4616
g7
I163
sg8
Vepilepsy
p4617
sg10
I8
sg28
VC0014544
p4618
sg13
I1
sa(dp4619
g7
I61
sg8
Vpathogenesis
p4620
sg10
I12
sg28
VC0699748
p4621
sg13
I1
sasa(dp4622
g2
VA common single nucleotide polymorphism (SNP, rs190982) in MEF2C gene was identified to be related to late-onset Alzheimer's disease (LOAD) in Caucasians in a large meta-analysis of genome-wide association studies (GWAS).
p4623
sg4
(lp4624
(dp4625
g7
I59
sg8
VMEF2C gene
p4626
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp4627
(dp4628
g7
I113
sg8
VAlzheimer's disease
p4629
sg10
I19
sg28
VC1521724
p4630
sg13
I2
sasa(dp4631
g135
(dp4632
(Vparaoxonase-1
p4633
Vtype 2 diabetes
p4634
tp4635
I00
ssg2
VA key factor protecting from oxidative stress in gestational diabetes mellitus (GDM) and in type 2 diabetes (T2D) is paraoxonase-1 (PON1).
p4636
sg4
(lp4637
(dp4638
g7
I132
sg8
VPON1
p4639
sg10
I4
sg11
VP27169
p4640
sg13
I1
sa(dp4641
g7
I117
sg8
g4633
sg10
I13
sg11
VP14222
p4642
sg13
I1
sasg24
(lp4643
(dp4644
g7
I49
sg8
Vgestational diabetes mellitus
p4645
sg10
I29
sg28
VC0085207
p4646
sg13
I3
sa(dp4647
g7
I80
sg8
VGDM
p4648
sg10
I3
sg28
VC0085207
p4649
sg13
I1
sa(dp4650
g7
I109
sg8
VT2D
p4651
sg10
I3
sg28
VC0011860
p4652
sg13
I1
sa(dp4653
g7
I29
sg8
Voxidative stress
p4654
sg10
I16
sg28
VC0242606
p4655
sg13
I2
sa(dp4656
g7
I92
sg8
g4634
sg10
I15
sg28
VC0011860
p4657
sg13
I3
sasa(dp4658
g135
(dp4659
(VPON1
p4660
VGDM
p4661
tp4662
I00
ssg2
VIn this study our aim was to evaluate paraoxonase (PON1) activity and free sulfhydryl groups (-SH) as antioxidative parameters and lipid hydroperoxide (LOOH) as oxidative parameter in the serum of women with gestational diabetes mellitus (GDM) and determine their relation with the degree of subclinical atherosclerosis.
p4663
sg4
(lp4664
(dp4665
g7
I38
sg8
Vparaoxonase
p4666
sg10
I11
sg11
VP14222
p4667
sg13
I1
sa(dp4668
g7
I51
sg8
g4660
sg10
I4
sg11
VP27169
p4669
sg13
I1
sasg24
(lp4670
(dp4671
g7
I304
sg8
Vatherosclerosis
p4672
sg10
I15
sg28
VC0004153
p4673
sg13
I1
sa(dp4674
g7
I208
sg8
Vgestational diabetes mellitus
p4675
sg10
I29
sg28
VC0085207
p4676
sg13
I3
sa(dp4677
g7
I239
sg8
g4661
sg10
I3
sg28
VC0085207
p4678
sg13
I1
sasa(dp4679
g135
(dp4680
(VPON-1
p4681
VPCO
p4682
tp4683
I00
ssg2
VTo clarify the levels of protein oxidation markers such as protein carbonyl (PCO), protein hydroperoxides (P-OOH), advanced oxidation protein products (AOPP) and nitrotyrosine (NT), as well as antioxidative enzymes such as paraoxonase (PON-1) in women with and without gestational diabetes mellitus (GDM).
p4684
sg4
(lp4685
(dp4686
g7
I223
sg8
Vparaoxonase
p4687
sg10
I11
sg11
VP14222
p4688
sg13
I1
sa(dp4689
g7
I236
sg8
g4681
sg10
I5
sg11
VP27169
p4690
sg13
I1
sasg24
(lp4691
(dp4692
g7
I269
sg8
Vgestational diabetes mellitus
p4693
sg10
I29
sg28
VC0085207
p4694
sg13
I3
sa(dp4695
g7
I59
sg8
Vprotein carbonyl
p4696
sg10
I16
sg28
VC0032460
p4697
sg13
I2
sa(dp4698
g7
I300
sg8
VGDM
p4699
sg10
I3
sg28
VC0085207
p4700
sg13
I1
sa(dp4701
g7
I77
sg8
g4682
sg10
I3
sg28
VC0032460
p4702
sg13
I1
sasa(dp4703
g2
VRecently, numerous new antibodies defining the characteristic clinical phenotype have been described as anti-MDA5 antibodies associated with interstitial lung disease and amyopathic dermatomyositis or anti-TIF1Gamma antibodies as markers for paraneoplastic dermatomyositis.
p4704
sg4
(lp4705
(dp4706
g7
I104
sg8
Vanti-MDA5 antibodies
p4707
sg10
I20
sg11
g12
sg13
I2
sa(dp4708
g7
I201
sg8
Vanti-TIF1Gamma antibodies
p4709
sg10
I25
sg11
g12
sg13
I2
sasg24
(lp4710
(dp4711
g7
I242
sg8
Vparaneoplastic dermatomyositis
p4712
sg10
I30
sg28
VC1735598
p4713
sg13
I2
sa(dp4714
g7
I171
sg8
Vamyopathic dermatomyositis
p4715
sg10
I26
sg28
VC0406645
p4716
sg13
I2
sa(dp4717
g7
I141
sg8
Vinterstitial lung disease
p4718
sg10
I25
sg28
VC0206062
p4719
sg13
I3
sasa(dp4720
g2
VPM is associated with anti-synthetase antibodies (anti-Jo-1, PL-7, PL-12, OJ, and EJ) and DM with anti-Mi-2, anti-SAE, anti-TIF-1-Gamma and anti-NXP2 (both associated with cancer) or anti-MDA5 antibodies (associated with interstitial lung disease).
p4721
sg4
(lp4722
(dp4723
g7
I98
sg8
Vanti-Mi-2
p4724
sg10
I9
sg11
g12
sg13
I1
sa(dp4725
g7
I140
sg8
Vanti-NXP2
p4726
sg10
I9
sg11
g12
sg13
I1
sa(dp4727
g7
I183
sg8
Vanti-MDA5 antibodies
p4728
sg10
I20
sg11
g12
sg13
I2
sa(dp4729
g7
I119
sg8
Vanti-TIF-1-Gamma
p4730
sg10
I16
sg11
g12
sg13
I1
sasg24
(lp4731
(dp4732
g7
I172
sg8
Vcancer
p4733
sg10
I6
sg28
VC0006826
p4734
sg13
I1
sa(dp4735
g7
I221
sg8
Vinterstitial lung disease
p4736
sg10
I25
sg28
VC0206062
p4737
sg13
I3
sasa(dp4738
g135
(dp4739
(Vanti-signal recognition particle antibody
p4740
VMSA
p4741
tp4742
I00
ssg2
VTwenty-six (43.3%) PM/DM-ILD patients were anti-aminoacyl tRNA-synthetase antibody-positive (anti-ARS-positive), 15 (25.0%) were anti-melanoma differentiation-associated gene 5 antibody-positive (anti-MDA5-positive), 3 (5%) were anti-signal recognition particle antibody-positive, 1 (1.7%) was anti-transcriptional intermediary factor 1-gamma antibody-positive, and 15 (25%) were MSA-negative.
p4743
sg4
(lp4744
(dp4745
g7
I196
sg8
Vanti-MDA5
p4746
sg10
I9
sg11
g12
sg13
I1
sa(dp4747
g7
I129
sg8
Vanti-melanoma differentiation-associated gene 5 antibody
p4748
sg10
I56
sg11
g12
sg13
I5
sa(dp4749
g7
I229
sg8
g4740
sg10
I41
sg11
VP61011
p4750
sg13
I4
sa(dp4751
g7
I294
sg8
Vanti-transcriptional intermediary factor 1-gamma antibody
p4752
sg10
I57
sg11
g12
sg13
I5
sasg24
(lp4753
(dp4754
g7
I134
sg8
Vmelanoma
p4755
sg10
I8
sg28
VC0025202
p4756
sg13
I1
sa(dp4757
g7
I380
sg8
g4741
sg10
I3
sg28
VC0393571
p4758
sg13
I1
sasa(dp4759
g2
VAntibodies to transcription intermediary factor 1Gamma/Alfa (TIF1Gamma/Alfa, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD.
p4760
sg4
(lp4761
(dp4762
g7
I61
sg8
VTIF1Gamma
p4763
sg10
I9
sg11
g12
sg13
I1
sa(dp4764
g7
I147
sg8
Vanti-melanoma differentiation-associated gene 5
p4765
sg10
I47
sg11
g12
sg13
I4
sa(dp4766
g7
I14
sg8
Vtranscription intermediary factor 1Gamma
p4767
sg10
I40
sg11
g12
sg13
I4
sa(dp4768
g7
I77
sg8
Vp155/140
p4769
sg10
I8
sg11
g12
sg13
I1
sa(dp4770
g7
I196
sg8
VMDA5
p4771
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp4772
(dp4773
g7
I130
sg8
Vmalignancy
p4774
sg10
I10
sg28
VC0006826
p4775
sg13
I1
sa(dp4776
g7
I152
sg8
Vmelanoma
p4777
sg10
I8
sg28
VC0025202
p4778
sg13
I1
sasa(dp4779
g2
VAnti-TIF-1Gamma positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia.
p4780
sg4
(lp4781
(dp4782
g7
I0
sg8
VAnti-TIF-1Gamma
p4783
sg10
I15
sg11
g12
sg13
I1
sasg24
(lp4784
(dp4785
g7
I114
sg8
VRaynaud phenomenon
p4786
sg10
I18
sg28
VC0034735
p4787
sg13
I2
sa(dp4788
g7
I148
sg8
Varthralgia
p4789
sg10
I10
sg28
VC0003862
p4790
sg13
I1
sa(dp4791
g7
I138
sg8
Varthritis
p4792
sg10
I9
sg28
VC0003864
p4793
sg13
I1
sa(dp4794
g7
I87
sg8
Vinterstitial lung disease
p4795
sg10
I25
sg28
VC0206062
p4796
sg13
I3
sasa(dp4797
g2
VThe frequency of pulmonary fibrosis during the disease progression was 2/12, 1/4 and 1/4 in anti-TIF1Gamma, anti-NXP2 and anti-SAE, respectively.
p4798
sg4
(lp4799
(dp4800
g7
I108
sg8
Vanti-NXP2
p4801
sg10
I9
sg11
g12
sg13
I1
sa(dp4802
g7
I92
sg8
Vanti-TIF1Gamma
p4803
sg10
I14
sg11
g12
sg13
I1
sasg24
(lp4804
(dp4805
g7
I47
sg8
Vdisease progression
p4806
sg10
I19
sg28
VC0242656
p4807
sg13
I2
sa(dp4808
g7
I17
sg8
Vpulmonary fibrosis
p4809
sg10
I18
sg28
VC0034069
p4810
sg13
I2
sasa(dp4811
g135
(dp4812
(VGR
p4813
VSRs
p4814
tp4815
I00
ssg2
VEach of the identified mutations altered the equilibrium between alternative GR conformations distinctively, indicating that the Hsp90 dependence of SRs may correlate with differences in the conformational dynamics of these receptors.
p4816
sg4
(lp4817
(dp4818
g7
I129
sg8
VHsp90
p4819
sg10
I5
sg11
VP07900
p4820
sg13
I1
sa(dp4821
g7
I149
sg8
VSRs
p4822
sg10
I3
sg11
VP35270
p4823
sg13
I1
sa(dp4824
g7
I77
sg8
g4813
sg10
I2
sg11
VP00390
p4825
sg13
I1
sasg24
(lp4826
(dp4827
g7
I135
sg8
Vdependence
p4828
sg10
I10
sg28
VC0439857
p4829
sg13
I1
sa(dp4830
g7
I149
sg8
g4814
sg10
I3
sg28
VC0175693
p4831
sg13
I1
sasa(dp4832
g135
(dp4833
(VSRs
p4834
VSRs
p4835
tp4836
I00
ssg2
VThe ubiquitous heat shock protein 90 (hsp90) has been shown to participate directly in the function of a wide variety of cellular signal transduction components, including steroid receptors (SRs).
p4837
sg4
(lp4838
(dp4839
g7
I172
sg8
Vsteroid receptors
p4840
sg10
I17
sg11
VP52788
p4841
sg13
I2
sa(dp4842
g7
I15
sg8
Vheat shock protein 90
p4843
sg10
I21
sg11
VP07900
p4844
sg13
I4
sa(dp4845
g7
I38
sg8
Vhsp90
p4846
sg10
I5
sg11
VP07900
p4847
sg13
I1
sa(dp4848
g7
I191
sg8
g4834
sg10
I3
sg11
VP35270
p4849
sg13
I1
sasg24
(lp4850
(dp4851
g7
I172
sg8
Vsteroid receptors
p4852
sg10
I17
sg28
VC0175693
p4853
sg13
I2
sa(dp4854
g7
I191
sg8
g4835
sg10
I3
sg28
VC0175693
p4855
sg13
I1
sasa(dp4856
g135
(dp4857
(VSRs
p4858
VSRs
p4859
tp4860
I00
ssg2
VHowever, there is still no direct evidence for an in vivo association of SRs with hsp90.
p4861
sg4
(lp4862
(dp4863
g7
I82
sg8
Vhsp90
p4864
sg10
I5
sg11
VP07900
p4865
sg13
I1
sa(dp4866
g7
I73
sg8
g4858
sg10
I3
sg11
VP35270
p4867
sg13
I1
sasg24
(lp4868
(dp4869
g7
I73
sg8
g4859
sg10
I3
sg28
VC0175693
p4870
sg13
I1
sasa(dp4871
g135
(dp4872
(VSRs
p4873
VSRs
p4874
tp4875
I00
ssg2
VThe results suggest that the interaction of SRs with the hsp90 is minimal when compared to a bona fide type of interaction with the co-factors.
p4876
sg4
(lp4877
(dp4878
g7
I57
sg8
Vhsp90
p4879
sg10
I5
sg11
VP07900
p4880
sg13
I1
sa(dp4881
g7
I44
sg8
g4873
sg10
I3
sg11
VP35270
p4882
sg13
I1
sasg24
(lp4883
(dp4884
g7
I44
sg8
g4874
sg10
I3
sg28
VC0175693
p4885
sg13
I1
sasa(dp4886
g135
(dp4887
(VCx43
p4888
Vprostate cancer
p4889
tp4890
I00
ssg2
VTo address the role of endothelial Cx43 in this process, we analyzed Cx43 regulation in human umbilical vein endothelial cells in the proximity of Cx43high (DU-145 and MAT-LyLu) and Cx43low prostate cancer cells (PC-3 and AT-2).
p4891
sg4
(lp4892
(dp4893
g7
I168
sg8
VMAT-LyLu
p4894
sg10
I8
sg11
VP24752
p4895
sg13
I1
sa(dp4896
g7
I35
sg8
VCx43
p4897
sg10
I4
sg11
VP17302
p4898
sg13
I1
sa(dp4899
g7
I35
sg8
g4888
sg10
I4
sg11
VP17302
p4900
sg13
I1
sa(dp4901
g7
I213
sg8
VPC-3
p4902
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp4903
(dp4904
g7
I190
sg8
g4889
sg10
I15
sg28
VC0600139
p4905
sg13
I2
sasa(dp4906
g135
(dp4907
(VAT2-R
p4908
Vprostate cancer
p4909
tp4910
I01
ssg2
VThe data on the nature of AT2-R expression in prostate tissue of prostate cancer patients may be considered as a tool for predicting biochemical recurrence after combined hormone and radiation therapy.
p4911
sg4
(lp4912
(dp4913
g7
I26
sg8
g4908
sg10
I5
sg11
VP50052
p4914
sg13
I1
sasg24
(lp4915
(dp4916
g7
I145
sg8
Vrecurrence
p4917
sg10
I10
sg28
VC1458156
p4918
sg13
I1
sa(dp4919
g7
I65
sg8
g4909
sg10
I15
sg28
VC0600139
p4920
sg13
I2
sasa(dp4921
g135
(dp4922
(VMat
p4923
Vprostate cancer
p4924
tp4925
I00
ssg2
VThe present study found that, similarly to 5-fluorouracil, low concentrations (1-10 myM) of 9-aminoacridine (9-AAA) inhibited the growth of the two rat prostate cancer AT-2 and Mat-LyLu cell lines and the human melanoma A375 cell line.
p4926
sg4
(lp4927
(dp4928
g7
I177
sg8
g4923
sg10
I3
sg11
VP24752
p4929
sg13
I1
sa(dp4930
g7
I148
sg8
Vrat prostate cancer AT-2
p4931
sg10
I24
sg11
g12
sg13
I4
sasg24
(lp4932
(dp4933
g7
I211
sg8
Vmelanoma
p4934
sg10
I8
sg28
VC0025202
p4935
sg13
I1
sa(dp4936
g7
I111
sg8
VAAA
p4937
sg10
I3
sg28
VC0162871
p4938
sg13
I1
sa(dp4939
g7
I152
sg8
g4924
sg10
I15
sg28
VC0600139
p4940
sg13
I2
sasa(dp4941
g135
(dp4942
(VAT2R
p4943
Vprostate cancer
p4944
tp4945
I01
ssg2
VFurthermore, our previous studies indicate that increased expression of Ang II type 2 receptor (AT2R) alone induced apoptosis in human prostate cancer lines, an effect that did not require Ang II.
p4946
sg4
(lp4947
(dp4948
g7
I72
sg8
VAng II type 2 receptor
p4949
sg10
I22
sg11
VP01019
p4950
sg13
I5
sa(dp4951
g7
I72
sg8
VAng II
p4952
sg10
I6
sg11
VP01019
p4953
sg13
I2
sa(dp4954
g7
I96
sg8
g4943
sg10
I4
sg11
VP50052
p4955
sg13
I1
sasg24
(lp4956
(dp4957
g7
I135
sg8
g4944
sg10
I15
sg28
VC0600139
p4958
sg13
I2
sasa(dp4959
g135
(dp4960
(VAT2R
p4961
Vprostate cancer
p4962
tp4963
I01
ssg2
VHuman prostate cancer DU145 xenograft mouse model was used to assess the effect of AT2R on tumor growth in vivo.
p4964
sg4
(lp4965
(dp4966
g7
I83
sg8
g4961
sg10
I4
sg11
VP50052
p4967
sg13
I1
sasg24
(lp4968
(dp4969
g7
I91
sg8
Vtumor growth
p4970
sg10
I12
sg28
VC0598934
p4971
sg13
I2
sa(dp4972
g7
I6
sg8
g4962
sg10
I15
sg28
VC0600139
p4973
sg13
I2
sasa(dp4974
g135
(dp4975
(VAT2R
p4976
Vprostate cancer
p4977
tp4978
I01
ssg2
VThe results showed that AT2R overexpression can inhibit tumor growth of prostate cancer in vivo by inhibiting proliferation and inducing apoptosis of tumor cells.
p4979
sg4
(lp4980
(dp4981
g7
I24
sg8
g4976
sg10
I4
sg11
VP50052
p4982
sg13
I1
sasg24
(lp4983
(dp4984
g7
I56
sg8
Vtumor growth
p4985
sg10
I12
sg28
VC0598934
p4986
sg13
I2
sa(dp4987
g7
I110
sg8
Vproliferation
p4988
sg10
I13
sg28
VC0334094
p4989
sg13
I1
sa(dp4990
g7
I72
sg8
g4977
sg10
I15
sg28
VC0600139
p4991
sg13
I2
sa(dp4992
g7
I56
sg8
Vtumor
p4993
sg10
I5
sg28
VC0027651
p4994
sg13
I1
sasa(dp4995
g135
(dp4996
(VAT2
p4997
Vprostate cancers
p4998
tp4999
I01
ssg2
VThe aim of the present study was the evaluation of AT1 and AT2 expressions in human prostate cancers.
p5000
sg4
(lp5001
(dp5002
g7
I51
sg8
VAT1
p5003
sg10
I3
sg11
VP30556
p5004
sg13
I1
sa(dp5005
g7
I59
sg8
g4997
sg10
I3
sg11
VP50052
p5006
sg13
I1
sasg24
(lp5007
(dp5008
g7
I51
sg8
VAT1
p5009
sg10
I3
sg28
VC0004135
p5010
sg13
I1
sa(dp5011
g7
I84
sg8
g4998
sg10
I16
sg28
VC0376358
p5012
sg13
I2
sasa(dp5013
g135
(dp5014
(VAT1
p5015
VAT1
p5016
tp5017
I00
ssg2
VThe data on AT1 and AT2 receptor expressions may suggest the involvement of RAS in prostate cancerogenesis.
p5018
sg4
(lp5019
(dp5020
g7
I76
sg8
VRAS
p5021
sg10
I3
sg11
VP01116
p5022
sg13
I1
sa(dp5023
g7
I20
sg8
VAT2 receptor
p5024
sg10
I12
sg11
VP50052
p5025
sg13
I2
sa(dp5026
g7
I12
sg8
g5015
sg10
I3
sg11
VP30556
p5027
sg13
I1
sasg24
(lp5028
(dp5029
g7
I12
sg8
g5016
sg10
I3
sg28
VC0004135
p5030
sg13
I1
sasa(dp5031
g2
Vsartanes) and/or AT2 agonists in prostate cancer prophylaxis and/or treatment.
p5032
sg4
(lp5033
sg24
(lp5034
(dp5035
g7
I33
sg8
Vprostate cancer
p5036
sg10
I15
sg28
VC0600139
p5037
sg13
I2
sasa(dp5038
g2
VThe results indicate that CEGA using the new circular stapling device in surgery of the esophageal carcinoma is a very effective procedure to improve the anastomotic technique from a traditional hand-sewn anastomosis to a stapled anastomosis and can reduce the incidence of complications.
p5039
sg4
(lp5040
sg24
(lp5041
(dp5042
g7
I205
sg8
Vanastomosis
p5043
sg10
I11
sg28
VC0332853
p5044
sg13
I1
sa(dp5045
g7
I88
sg8
Vesophageal carcinoma
p5046
sg10
I20
sg28
VC0152018
p5047
sg13
I2
sa(dp5048
g7
I205
sg8
Vanastomosis
p5049
sg10
I11
sg28
VC0332853
p5050
sg13
I1
sasa(dp5051
g2
VAn unusual retinal pigment epitheliopathy resembling ophthalmomyiasis interna posterior (OMI) is endemic to Guam.
p5052
sg4
(lp5053
sg24
(lp5054
(dp5055
g7
I11
sg8
Vretinal pigment epitheliopathy
p5056
sg10
I30
sg28
VC0860552
p5057
sg13
I3
sa(dp5058
g7
I53
sg8
Vophthalmomyiasis
p5059
sg10
I16
sg28
VC0027034
p5060
sg13
I1
sasa(dp5061
g2
VToxicity, such as mucositis, leukocytopenia and neutropenia, was higher in ConcCRTx than in CTx followed by RTx.
p5062
sg4
(lp5063
sg24
(lp5064
(dp5065
g7
I92
sg8
VCTx
p5066
sg10
I3
sg28
VC0238052
p5067
sg13
I1
sa(dp5068
g7
I29
sg8
Vleukocytopenia
p5069
sg10
I14
sg28
VC0023530
p5070
sg13
I1
sa(dp5071
g7
I18
sg8
Vmucositis
p5072
sg10
I9
sg28
VC0333355
p5073
sg13
I1
sasa(dp5074
g2
VAt the 4th dose level (Ctx 1400 mg/m2, Epidx 100 mg/m2, 5-Fu 600 mg/m2), two patients had dose-limiting mucositis and one patient developed dose-limiting neutropenia.
p5075
sg4
(lp5076
sg24
(lp5077
(dp5078
g7
I104
sg8
Vmucositis
p5079
sg10
I9
sg28
VC0333355
p5080
sg13
I1
sa(dp5081
g7
I23
sg8
VCtx
p5082
sg10
I3
sg28
VC0238052
p5083
sg13
I1
sasa(dp5084
g2
VTherefore, the effect of CKD on the disposition of CYP1A2-metabolized, CYP2C8-metabolized, CYP2C9-metabolized, CYP2C19-metabolized, and organic anion-transporting polypeptide (OATP)-transported drugs was investigated.
p5085
sg4
(lp5086
(dp5087
g7
I91
sg8
VCYP2C9
p5088
sg10
I6
sg11
VP11712
p5089
sg13
I1
sa(dp5090
g7
I111
sg8
VCYP2C19
p5091
sg10
I7
sg11
VP33261
p5092
sg13
I1
sa(dp5093
g7
I71
sg8
VCYP2C8
p5094
sg10
I6
sg11
VP10632
p5095
sg13
I1
sa(dp5096
g7
I51
sg8
VCYP1A2
p5097
sg10
I6
sg11
VP05177
p5098
sg13
I1
sasg24
(lp5099
sa(dp5100
g2
VWe identified dedicated CKD studies with 6, 5, 6, 4, and 12 "model" substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP, respectively.
p5101
sg4
(lp5102
(dp5103
g7
I99
sg8
VCYP2C9
p5104
sg10
I6
sg11
VP11712
p5105
sg13
I1
sa(dp5106
g7
I83
sg8
VCYP1A2
p5107
sg10
I6
sg11
VP05177
p5108
sg13
I1
sa(dp5109
g7
I107
sg8
VCYP2C19
p5110
sg10
I7
sg11
VP33261
p5111
sg13
I1
sa(dp5112
g7
I91
sg8
VCYP2C8
p5113
sg10
I6
sg11
VP10632
p5114
sg13
I1
sasg24
(lp5115
sa(dp5116
g2
VIn contrast, the effect of CKD on CYP1A2, CYP2C9, and CYP2C19 was variable and modest compared to CYP2C8 and OATP.
p5117
sg4
(lp5118
(dp5119
g7
I54
sg8
VCYP2C19
p5120
sg10
I7
sg11
VP33261
p5121
sg13
I1
sa(dp5122
g7
I42
sg8
VCYP2C9
p5123
sg10
I6
sg11
VP11712
p5124
sg13
I1
sa(dp5125
g7
I109
sg8
VOATP
p5126
sg10
I4
sg11
VP46721
p5127
sg13
I1
sa(dp5128
g7
I34
sg8
VCYP1A2
p5129
sg10
I6
sg11
VP05177
p5130
sg13
I1
sa(dp5131
g7
I98
sg8
VCYP2C8
p5132
sg10
I6
sg11
VP10632
p5133
sg13
I1
sasg24
(lp5134
sa(dp5135
g135
(dp5136
(VCYP3A4
p5137
Vlupus nephritis
p5138
tp5139
I01
ssg2
VTo investigate the impact of genetic variants in CYP2C9, CYP2C19, CYP3A4, GSTT1, GSTM1 and GSTP1 on the efficacy of cyclophosphamide (CYC) therapy in patients with lupus nephritis.
p5140
sg4
(lp5141
(dp5142
g7
I74
sg8
VGSTT1
p5143
sg10
I5
sg11
VP30711
p5144
sg13
I1
sa(dp5145
g7
I81
sg8
VGSTM1
p5146
sg10
I5
sg11
VP09488
p5147
sg13
I1
sa(dp5148
g7
I49
sg8
VCYP2C9
p5149
sg10
I6
sg11
VP11712
p5150
sg13
I1
sa(dp5151
g7
I91
sg8
VGSTP1
p5152
sg10
I5
sg11
VP09211
p5153
sg13
I1
sa(dp5154
g7
I57
sg8
VCYP2C19
p5155
sg10
I7
sg11
VP33261
p5156
sg13
I1
sa(dp5157
g7
I66
sg8
g5137
sg10
I6
sg11
VP08684
p5158
sg13
I1
sasg24
(lp5159
(dp5160
g7
I164
sg8
g5138
sg10
I15
sg28
VC0024143
p5161
sg13
I2
sasa(dp5162
g135
(dp5163
(VCYP2C9
p5164
VCKD
p5165
tp5166
I00
ssg2
VChronic kidney disease (CKD) complicates warfarin anticoagulation partially through its effect on CYP2C9 activity.
p5167
sg4
(lp5168
(dp5169
g7
I98
sg8
g5164
sg10
I6
sg11
VP11712
p5170
sg13
I1
sasg24
(lp5171
(dp5172
g7
I0
sg8
VChronic kidney disease
p5173
sg10
I22
sg28
VC1561643
p5174
sg13
I3
sa(dp5175
g7
I24
sg8
g5165
sg10
I3
sg28
VC1561643
p5176
sg13
I1
sasa(dp5177
g2
VCKD increased the effect of CYP2C9 genetic variation on (S)-warfarin and (R,S)-warfarin metabolism.
p5178
sg4
(lp5179
(dp5180
g7
I28
sg8
VCYP2C9
p5181
sg10
I6
sg11
VP11712
p5182
sg13
I1
sasg24
(lp5183
sa(dp5184
g2
VTecarfarin exposure was similar between the HVs and the CKD subjects regardless of CYP2C9 genotype.
p5185
sg4
(lp5186
(dp5187
g7
I83
sg8
VCYP2C9 genotype
p5188
sg10
I15
sg11
VP11712
p5189
sg13
I2
sasg24
(lp5190
sa(dp5191
g135
(dp5192
(VCYP2C9
p5193
Vend-stage renal disease
p5194
tp5195
I01
ssg2
VThe CYP2C9 pathway (4-hydroxyflurbiprofen formation clearance) was similar in all the patients with CKD and was concordant with previous reports of patients with end-stage renal disease (ESRD) and healthy controls.
p5196
sg4
(lp5197
(dp5198
g7
I4
sg8
g5193
sg10
I6
sg11
VP11712
p5199
sg13
I1
sasg24
(lp5200
(dp5201
g7
I187
sg8
VESRD
p5202
sg10
I4
sg28
VC0022661
p5203
sg13
I1
sa(dp5204
g7
I162
sg8
g5194
sg10
I23
sg28
VC0022661
p5205
sg13
I3
sasa(dp5206
g135
(dp5207
(VCYP2C9
p5208
Vglomerulonephritis
p5209
tp5210
I00
ssg2
VFor flurbiprofen, patients with glomerulonephritis had higher oral clearance than those with nonglomerular CKD, suggesting higher unbound fraction and enhanced metabolism through other (non-CYP2C9) routes.
p5211
sg4
(lp5212
(dp5213
g7
I190
sg8
g5208
sg10
I6
sg11
VP11712
p5214
sg13
I1
sasg24
(lp5215
(dp5216
g7
I32
sg8
g5209
sg10
I18
sg28
VC0017658
p5217
sg13
I1
sasa(dp5218
g135
(dp5219
(VCYP2C9 and CYP3A4
p5220
Vglomerulonephritis
p5221
tp5222
I00
ssg2
VThe current study suggests no statistically significant differences in the in vivo activity of CYP2C9 and CYP3A4 in patients with either glomerulonephritis or nonglomerular CKD.
p5223
sg4
(lp5224
(dp5225
g7
I95
sg8
g5220
sg10
I17
sg11
VP08684
p5226
sg13
I3
sasg24
(lp5227
(dp5228
g7
I137
sg8
g5221
sg10
I18
sg28
VC0017658
p5229
sg13
I1
sasa(dp5230
g135
(dp5231
(VACE
p5232
Vnon-proliferative diabetic retinopathy
p5233
tp5234
I01
ssg2
VWe examined whether the renin inhibitor, aliskiren, provides similar or greater protection than ACE inhibition from non-proliferative diabetic retinopathy and from the proliferative neoangiogenesis of oxygen-induced retinopathy.
p5235
sg4
(lp5236
(dp5237
g7
I24
sg8
Vrenin
p5238
sg10
I5
sg11
VP00797
p5239
sg13
I1
sa(dp5240
g7
I96
sg8
g5232
sg10
I3
sg11
VP12821
p5241
sg13
I1
sasg24
(lp5242
(dp5243
g7
I182
sg8
Vneoangiogenesis
p5244
sg10
I15
sg28
VC0027686
p5245
sg13
I1
sa(dp5246
g7
I143
sg8
Vretinopathy
p5247
sg10
I11
sg28
VC0035309
p5248
sg13
I1
sa(dp5249
g7
I120
sg8
Vproliferative
p5250
sg10
I13
sg28
VC0334094
p5251
sg13
I1
sa(dp5252
g7
I116
sg8
g5233
sg10
I38
sg28
VC0004606
p5253
sg13
I3
sasa(dp5254
g135
(dp5255
(Vangiotensin-converting enzyme
p5256
Vproliferative diabetic retinopathy
p5257
tp5258
I00
ssg2
VTo assess angiotensin-converting enzyme (ACE) levels in aqueous humor and plasma of patients with nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) as another potent ischemia-induced angiogenic factor.
p5259
sg4
(lp5260
(dp5261
g7
I41
sg8
VACE
p5262
sg10
I3
sg11
VP12821
p5263
sg13
I1
sa(dp5264
g7
I223
sg8
Vangiogenic factor
p5265
sg10
I17
sg11
g12
sg13
I2
sa(dp5266
g7
I10
sg8
g5256
sg10
I29
sg11
VP12821
p5267
sg13
I2
sasg24
(lp5268
(dp5269
g7
I98
sg8
Vnonproliferative diabetic retinopathy
p5270
sg10
I37
sg28
VC0004606
p5271
sg13
I3
sa(dp5272
g7
I56
sg8
Vaqueous humor
p5273
sg10
I13
sg28
VC0595936
p5274
sg13
I2
sa(dp5275
g7
I137
sg8
VNPDR
p5276
sg10
I4
sg28
VC0004606
p5277
sg13
I1
sa(dp5278
g7
I138
sg8
VPDR
p5279
sg10
I3
sg28
VC0154830
p5280
sg13
I1
sa(dp5281
g7
I206
sg8
Vischemia
p5282
sg10
I8
sg28
VC0022116
p5283
sg13
I1
sa(dp5284
g7
I101
sg8
g5257
sg10
I34
sg28
VC0154830
p5285
sg13
I3
sasa(dp5286
g135
(dp5287
(VACE
p5288
Vaqueous humor
p5289
tp5290
I00
ssg2
VWe observed significantly elevated ACE level in aqueous humor of patients with PDR compared with the patients with NPDR and normal subjects (P = 0.023), but no significant difference was detected between nonproliferative diabetics and control group (P = 0.239).
p5291
sg4
(lp5292
(dp5293
g7
I35
sg8
g5288
sg10
I3
sg11
VP12821
p5294
sg13
I1
sasg24
(lp5295
(dp5296
g7
I79
sg8
VPDR
p5297
sg10
I3
sg28
VC1845050
p5298
sg13
I1
sa(dp5299
g7
I48
sg8
g5289
sg10
I13
sg28
VC0595936
p5300
sg13
I2
sasa(dp5301
g135
(dp5302
(VACE I/D
p5303
VPDR
p5304
tp5305
I01
ssg2
VStudies exploring the association between ACE I/D polymorphism and BDR or PDR may help us better understand the genetics of DR.
p5306
sg4
(lp5307
(dp5308
g7
I42
sg8
g5303
sg10
I7
sg11
VP12821
p5309
sg13
I2
sasg24
(lp5310
(dp5311
g7
I74
sg8
g5304
sg10
I3
sg28
VC1845050
p5312
sg13
I1
sasa(dp5313
g135
(dp5314
(Vangiotensin-converting enzyme inhibitors
p5315
VNPDR
p5316
tp5317
I01
ssg2
VTo evaluate the effects of angiotensin-converting enzyme inhibitors (ACE-I) in retarding progression of severe non-proliferative diabetic retinopathy (NPDR) in normotensive type 2 diabetic patients.
p5318
sg4
(lp5319
(dp5320
g7
I69
sg8
VACE-I
p5321
sg10
I5
sg11
VP12821
p5322
sg13
I1
sa(dp5323
g7
I27
sg8
g5315
sg10
I40
sg11
VP12821
p5324
sg13
I3
sasg24
(lp5325
(dp5326
g7
I111
sg8
Vnon-proliferative diabetic retinopathy
p5327
sg10
I38
sg28
VC0004606
p5328
sg13
I3
sa(dp5329
g7
I151
sg8
g5316
sg10
I4
sg28
VC0004606
p5330
sg13
I1
sasa(dp5331
g135
(dp5332
(VACE-I
p5333
Vsevere NPDR
p5334
tp5335
I00
ssg2
VThis was a retrospective case control study of 128 patients with normotensive type 2 diabetes with lower than +1 dipstick proteinuria and severe NPDR who were classified into either an ACE-I treated group (Enalapril maleate 10 mg, n=12 , Ramipril 5 mg, n=17) or an ACE-I untreated group (n=99).
p5336
sg4
(lp5337
(dp5338
g7
I185
sg8
VACE-I
p5339
sg10
I5
sg11
VP12821
p5340
sg13
I1
sa(dp5341
g7
I185
sg8
g5333
sg10
I5
sg11
VP12821
p5342
sg13
I1
sasg24
(lp5343
(dp5344
g7
I78
sg8
Vtype 2 diabetes
p5345
sg10
I15
sg28
VC0011860
p5346
sg13
I3
sa(dp5347
g7
I138
sg8
g5334
sg10
I11
sg28
VC0730278
p5348
sg13
I2
sasa(dp5349
g135
(dp5350
(VACE-I
p5351
Vsevere NPDR
p5352
tp5353
I00
ssg2
VSmall doses of ACE-I did not yield any beneficial effects in retarding the progression of severe NPDR.
p5354
sg4
(lp5355
(dp5356
g7
I15
sg8
g5351
sg10
I5
sg11
VP12821
p5357
sg13
I1
sasg24
(lp5358
(dp5359
g7
I90
sg8
g5352
sg10
I11
sg28
VC0730278
p5360
sg13
I2
sasa(dp5361
g2
VA7730C variant which showed a high mutation frequency in cervical cancer was predicted to be a binding site for the cellular transcription factor PHOX2A.
p5362
sg4
(lp5363
(dp5364
g7
I146
sg8
VPHOX2A
p5365
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp5366
(dp5367
g7
I57
sg8
Vcervical cancer
p5368
sg10
I15
sg28
VC0302592
p5369
sg13
I2
sasa(dp5370
g2
VmiR-326 regulates cell proliferation and migration in lung cancer by targeting Phox2a and is regulated by HOTAIR.
p5371
sg4
(lp5372
(dp5373
g7
I0
sg8
VmiR
p5374
sg10
I3
sg11
g12
sg13
I1
sa(dp5375
g7
I79
sg8
VPhox2a
p5376
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp5377
(dp5378
g7
I54
sg8
Vlung cancer
p5379
sg10
I11
sg28
VC0684249
p5380
sg13
I2
sa(dp5381
g7
I23
sg8
Vproliferation
p5382
sg10
I13
sg28
VC0334094
p5383
sg13
I1
sasa(dp5384
g2
VPHOX2B and its paralogue gene PHOX2A are two homeodomain proteins in the network regulating the development of autonomic ganglia that have been associated with the pathogenesis of neuroblastoma (NB), because of their over-expression in different NB cell lines and tumour samples.
p5385
sg4
(lp5386
(dp5387
g7
I0
sg8
VPHOX2B
p5388
sg10
I6
sg11
g12
sg13
I1
sa(dp5389
g7
I30
sg8
VPHOX2A
p5390
sg10
I6
sg11
g12
sg13
I1
sa(dp5391
g7
I45
sg8
Vhomeodomain proteins
p5392
sg10
I20
sg11
g12
sg13
I2
sasg24
(lp5393
(dp5394
g7
I195
sg8
VNB
p5395
sg10
I2
sg28
VC0027819
p5396
sg13
I1
sa(dp5397
g7
I195
sg8
VNB
p5398
sg10
I2
sg28
VC0027819
p5399
sg13
I1
sa(dp5400
g7
I264
sg8
Vtumour
p5401
sg10
I6
sg28
VC0027651
p5402
sg13
I1
sa(dp5403
g7
I164
sg8
Vpathogenesis
p5404
sg10
I12
sg28
VC0699748
p5405
sg13
I1
sa(dp5406
g7
I180
sg8
Vneuroblastoma
p5407
sg10
I13
sg28
VC0027819
p5408
sg13
I1
sasa(dp5409
g135
(dp5410
(VFOXL2
p5411
Vstage I NSCLC
p5412
tp5413
I00
ssg2
VTo identify novel abnormally methylated genes in early stage non-small cell lung cancer (NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1, MYF6, OC2, PDGFRA, PHOX2A, PITX2, RARB, SIX6, SMPD3 and SOX1) in cancer tissues from 101 cases of stage I NSCLC patients and lung tissues from 30 cases of non-cancerous lung disease controls, using methylation-specific PCR (MSP).
p5414
sg4
(lp5415
(dp5416
g7
I189
sg8
VPHOX2A
p5417
sg10
I6
sg11
g12
sg13
I1
sa(dp5418
g7
I176
sg8
VOC2
p5419
sg10
I3
sg11
VP43235
p5420
sg13
I1
sa(dp5421
g7
I197
sg8
VPITX2
p5422
sg10
I5
sg11
g12
sg13
I1
sa(dp5423
g7
I170
sg8
VMYF6
p5424
sg10
I4
sg11
VP23409
p5425
sg13
I1
sa(dp5426
g7
I181
sg8
VPDGFRA
p5427
sg10
I6
sg11
VP16234
p5428
sg13
I1
sa(dp5429
g7
I226
sg8
VSOX1
p5430
sg10
I4
sg11
g12
sg13
I1
sa(dp5431
g7
I216
sg8
VSMPD3
p5432
sg10
I5
sg11
g12
sg13
I1
sa(dp5433
g7
I204
sg8
VRARB
p5434
sg10
I4
sg11
VP10826
p5435
sg13
I1
sa(dp5436
g7
I164
sg8
VHPP1
p5437
sg10
I4
sg11
g12
sg13
I1
sa(dp5438
g7
I145
sg8
VALX1
p5439
sg10
I4
sg11
g12
sg13
I1
sa(dp5440
g7
I210
sg8
VSIX6
p5441
sg10
I4
sg11
g12
sg13
I1
sa(dp5442
g7
I151
sg8
VBCL2
p5443
sg10
I4
sg11
VP10415
p5444
sg13
I1
sa(dp5445
g7
I157
sg8
g5411
sg10
I5
sg11
VP58012
p5446
sg13
I1
sasg24
(lp5447
(dp5448
g7
I89
sg8
VNSCLC
p5449
sg10
I5
sg28
VC0007131
p5450
sg13
I1
sa(dp5451
g7
I81
sg8
Vcancer
p5452
sg10
I6
sg28
VC0006826
p5453
sg13
I1
sa(dp5454
g7
I61
sg8
Vnon-small cell lung cancer
p5455
sg10
I26
sg28
VC0007131
p5456
sg13
I4
sa(dp5457
g7
I339
sg8
Vlung disease
p5458
sg10
I12
sg28
VC0024115
p5459
sg13
I2
sa(dp5460
g7
I268
sg8
g5412
sg10
I13
sg28
VC0278504
p5461
sg13
I3
sasa(dp5462
g135
(dp5463
(VRARB
p5464
Vlung disease
p5465
tp5466
I00
ssg2
VThe methylation frequencies (29.70-64.36%) of 7 genes (MYF6, SIX6, SOX1, RARB, BCL2, PHOX2A and FOLX2) in stage I NSCLC were significantly higher compared with those in non-cancerous lung disease controls (P&lt;0.05).
p5467
sg4
(lp5468
(dp5469
g7
I85
sg8
VPHOX2A
p5470
sg10
I6
sg11
g12
sg13
I1
sa(dp5471
g7
I55
sg8
VMYF6
p5472
sg10
I4
sg11
VP23409
p5473
sg13
I1
sa(dp5474
g7
I61
sg8
VSIX6
p5475
sg10
I4
sg11
g12
sg13
I1
sa(dp5476
g7
I79
sg8
VBCL2
p5477
sg10
I4
sg11
VP10415
p5478
sg13
I1
sa(dp5479
g7
I67
sg8
VSOX1
p5480
sg10
I4
sg11
g12
sg13
I1
sa(dp5481
g7
I73
sg8
g5464
sg10
I4
sg11
VP10826
p5482
sg13
I1
sasg24
(lp5483
(dp5484
g7
I106
sg8
Vstage I NSCLC
p5485
sg10
I13
sg28
VC0278504
p5486
sg13
I3
sa(dp5487
g7
I183
sg8
g5465
sg10
I12
sg28
VC0024115
p5488
sg13
I2
sasa(dp5489
g135
(dp5490
(VEMA
p5491
VEMA
p5492
tp5493
I00
ssg2
VFurthermore, we also detected the expression of 8 pathological markers (VEGF, HER-2, P53, P21, EGFR, CHGA, SYN and EMA) in cancer tissues of stage I NSCLC by immunohistochemistry, and found that high expression levels of p53 and CHGA were associated with the methylation of BCL2 (P=0.025) and PHOX2A (P=0.023), respectively.
p5494
sg4
(lp5495
(dp5496
g7
I90
sg8
VP21
p5497
sg10
I3
sg11
VP42857
p5498
sg13
I1
sa(dp5499
g7
I101
sg8
VCHGA
p5500
sg10
I4
sg11
VP10645
p5501
sg13
I1
sa(dp5502
g7
I274
sg8
VBCL2
p5503
sg10
I4
sg11
VP10415
p5504
sg13
I1
sa(dp5505
g7
I101
sg8
VCHGA
p5506
sg10
I4
sg11
VP10645
p5507
sg13
I1
sa(dp5508
g7
I107
sg8
VSYN
p5509
sg10
I3
sg11
VP17600
p5510
sg13
I1
sa(dp5511
g7
I293
sg8
VPHOX2A
p5512
sg10
I6
sg11
g12
sg13
I1
sa(dp5513
g7
I221
sg8
Vp53
p5514
sg10
I3
sg11
VP42771
p5515
sg13
I1
sa(dp5516
g7
I85
sg8
VP53
p5517
sg10
I3
sg11
VP42771
p5518
sg13
I1
sa(dp5519
g7
I78
sg8
VHER-2
p5520
sg10
I5
sg11
VP04626
p5521
sg13
I1
sa(dp5522
g7
I115
sg8
g5491
sg10
I3
sg11
VP13804
p5523
sg13
I1
sasg24
(lp5524
(dp5525
g7
I141
sg8
Vstage I NSCLC
p5526
sg10
I13
sg28
VC0278504
p5527
sg13
I3
sa(dp5528
g7
I123
sg8
Vcancer
p5529
sg10
I6
sg28
VC0006826
p5530
sg13
I1
sa(dp5531
g7
I115
sg8
g5492
sg10
I3
sg28
VC0268596
p5532
sg13
I1
sasa(dp5533
g135
(dp5534
(VMYF6
p5535
VNSCLC
p5536
tp5537
I00
ssg2
VIn this study, among the 7 genes which demonstrated hypermethylation in stage I NSCLC compared with non-cancerous lung diseases, 5 genes (MYF6, SIX6, PHOX2A, FOLX2 and SOX1) were found for the first time to be abonormally methylated in NSCLC.
p5538
sg4
(lp5539
(dp5540
g7
I168
sg8
VSOX1
p5541
sg10
I4
sg11
g12
sg13
I1
sa(dp5542
g7
I138
sg8
g5535
sg10
I4
sg11
VP23409
p5543
sg13
I1
sa(dp5544
g7
I144
sg8
VSIX6
p5545
sg10
I4
sg11
g12
sg13
I1
sa(dp5546
g7
I150
sg8
VPHOX2A
p5547
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp5548
(dp5549
g7
I72
sg8
Vstage I NSCLC
p5550
sg10
I13
sg28
VC0278504
p5551
sg13
I3
sa(dp5552
g7
I114
sg8
Vlung diseases
p5553
sg10
I13
sg28
VC0024115
p5554
sg13
I2
sa(dp5555
g7
I80
sg8
g5536
sg10
I5
sg28
VC0007131
p5556
sg13
I1
sasa(dp5557
g2
VHeteroplasmic m.3697G&gt;A has been reported in patients with Leber's hereditary optic neuropathy, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes and Stuve-Wiedemann syndrome.
p5558
sg4
(lp5559
sg24
(lp5560
(dp5561
g7
I132
sg8
Vlactic acidosis
p5562
sg10
I15
sg28
VC0001125
p5563
sg13
I2
sa(dp5564
g7
I177
sg8
VStuve-Wiedemann syndrome
p5565
sg10
I24
sg28
VC0796176
p5566
sg13
I2
sa(dp5567
g7
I99
sg8
Vmitochondrial encephalomyopathy
p5568
sg10
I31
sg28
VC0162666
p5569
sg13
I2
sa(dp5570
g7
I152
sg8
Vstroke
p5571
sg10
I6
sg28
VC0038454
p5572
sg13
I1
sa(dp5573
g7
I62
sg8
VLeber's hereditary optic neuropathy
p5574
sg10
I35
sg28
VC0917796
p5575
sg13
I4
sasa(dp5576
g2
VThese can be grouped into disorders with reduced papillae (Machado-Joseph disease, Stuve-Wiedemann syndrome, familial dysautonomia, dystonia musculorum, and Behcet's disease) and those with taste defects only (Alzheimer's disease, Huntington's disease, hereditary sensory and autonomic neuropathy type IV, and diabetes mellitus).
p5577
sg4
(lp5578
sg24
(lp5579
(dp5580
g7
I310
sg8
Vdiabetes mellitus
p5581
sg10
I17
sg28
VC0011849
p5582
sg13
I2
sa(dp5583
g7
I132
sg8
Vdystonia
p5584
sg10
I8
sg28
VC0393593
p5585
sg13
I1
sa(dp5586
g7
I210
sg8
VAlzheimer's disease
p5587
sg10
I19
sg28
VC1521724
p5588
sg13
I2
sa(dp5589
g7
I253
sg8
Vhereditary sensory and autonomic neuropathy type IV
p5590
sg10
I51
sg28
VC0020074
p5591
sg13
I7
sa(dp5592
g7
I109
sg8
Vfamilial dysautonomia
p5593
sg10
I21
sg28
VC0013364
p5594
sg13
I2
sa(dp5595
g7
I59
sg8
VMachado-Joseph disease
p5596
sg10
I22
sg28
VC0024408
p5597
sg13
I2
sa(dp5598
g7
I231
sg8
VHuntington's disease
p5599
sg10
I20
sg28
VC0020179
p5600
sg13
I2
sa(dp5601
g7
I83
sg8
VStuve-Wiedemann syndrome
p5602
sg10
I24
sg28
VC0796176
p5603
sg13
I2
sa(dp5604
g7
I157
sg8
VBehcet's disease
p5605
sg10
I16
sg28
VC0004943
p5606
sg13
I2
sasa(dp5607
g2
VWe used in-situ hybridization to analyze the expression patterns of three known members (a, b and c) of the RGM ("repulsive guidance molecule") gene family and of the RGMa receptor neogenin in a glaucoma mouse model (DBA/2J strain) and the C57BL/6J strain, which served as a control.
p5608
sg4
(lp5609
(dp5610
g7
I167
sg8
VRGMa receptor neogenin
p5611
sg10
I22
sg11
g12
sg13
I3
sasg24
(lp5612
(dp5613
g7
I195
sg8
Vglaucoma
p5614
sg10
I8
sg28
VC0017601
p5615
sg13
I1
sa(dp5616
g7
I217
sg8
VDBA
p5617
sg10
I3
sg28
VC0398550
p5618
sg13
I1
sasa(dp5619
g2
VIn order to understand the role of the RGMs and neogenin in glaucoma, we characterized their expression patterns in the developing and mature mouse retina and in the optic nerve.
p5620
sg4
(lp5621
(dp5622
g7
I39
sg8
VRGMs and neogenin
p5623
sg10
I17
sg11
g12
sg13
I3
sasg24
(lp5624
(dp5625
g7
I60
sg8
Vglaucoma
p5626
sg10
I8
sg28
VC0017601
p5627
sg13
I1
sasa(dp5628
g2
VInterestingly, we found a higher expression of RGMa, RGMb and neogenin in the retinas of all glaucoma-affected mice than in the age-matched control strain.
p5629
sg4
(lp5630
(dp5631
g7
I53
sg8
VRGMb and neogenin
p5632
sg10
I17
sg11
g12
sg13
I3
sa(dp5633
g7
I47
sg8
VRGMa
p5634
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp5635
(dp5636
g7
I93
sg8
Vglaucoma
p5637
sg10
I8
sg28
VC0017601
p5638
sg13
I1
sasa(dp5639
g2
VA tool developed for their use--DeAR GP (Dementia Assessment Referral to GP)--empowers care home staff, makes more efficient use of GPs' and specialist memory nurses' time, and improves diagnosis of dementia.
p5640
sg4
(lp5641
(dp5642
g7
I132
sg8
VGPs
p5643
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp5644
(dp5645
g7
I41
sg8
VDementia
p5646
sg10
I8
sg28
VC0497327
p5647
sg13
I1
sa(dp5648
g7
I199
sg8
Vdementia
p5649
sg10
I8
sg28
VC0497327
p5650
sg13
I1
sa(dp5651
g7
I132
sg8
VGPs
p5652
sg10
I3
sg28
VC0272302
p5653
sg13
I1
sasa(dp5654
g135
(dp5655
(VPTH
p5656
Vautosomal dominant hypophosphatemic rickets
p5657
tp5658
I00
ssg2
VUsing homozygous mice for an autosomal dominant hypophosphatemic rickets-FGF23 mutation or animals treated with a furin inhibitor, we showed that cFGF23 and iFGF23 levels increased equivalently after PTH injection.
p5659
sg4
(lp5660
(dp5661
g7
I114
sg8
Vfurin
p5662
sg10
I5
sg11
VP09958
p5663
sg13
I1
sa(dp5664
g7
I73
sg8
VFGF23
p5665
sg10
I5
sg11
g12
sg13
I1
sa(dp5666
g7
I200
sg8
g5656
sg10
I3
sg11
VP01270
p5667
sg13
I1
sasg24
(lp5668
(dp5669
g7
I29
sg8
g5657
sg10
I43
sg28
VC0342642
p5670
sg13
I4
sasa(dp5671
g2
VWe discuss in this review the current implications of GRx and/or glutathionylation in the inflammatory response and in diseases associated with chronic inflammation, namely diabetes, atherosclerosis, inflammatory lung disease, cancer, and Alzheimer's disease, and in viral infections.
p5672
sg4
(lp5673
sg24
(lp5674
(dp5675
g7
I239
sg8
VAlzheimer's disease
p5676
sg10
I19
sg28
VC1521724
p5677
sg13
I2
sa(dp5678
g7
I90
sg8
Vinflammatory response
p5679
sg10
I21
sg28
VC1155266
p5680
sg13
I2
sa(dp5681
g7
I144
sg8
Vchronic inflammation
p5682
sg10
I20
sg28
VC0021376
p5683
sg13
I2
sa(dp5684
g7
I183
sg8
Vatherosclerosis
p5685
sg10
I15
sg28
VC0004153
p5686
sg13
I1
sa(dp5687
g7
I213
sg8
Vlung disease
p5688
sg10
I12
sg28
VC0024115
p5689
sg13
I2
sa(dp5690
g7
I267
sg8
Vviral infections
p5691
sg10
I16
sg28
VC0042769
p5692
sg13
I2
sa(dp5693
g7
I173
sg8
Vdiabetes
p5694
sg10
I8
sg28
VC0011849
p5695
sg13
I1
sa(dp5696
g7
I227
sg8
Vcancer
p5697
sg10
I6
sg28
VC0006826
p5698
sg13
I1
sasa(dp5699
g2
VIn addition to arising from the procedure per se, a genetic or cytogenetic abnormality in offspring of an ICSI pregnancy could arise as result of offspring inheriting the mutant gene or chromosomal abnormality conferring paternal infertility: Y deletions (DAZ) in oligospermia males, cystic fibrosis in offspring of males with congenital bilateral absence vas deferens (CBAVD), and sex chromosomal abnormalities in offspring of Klinefelter syndrome (47,XXY) males.
p5700
sg4
(lp5701
sg24
(lp5702
(dp5703
g7
I284
sg8
Vcystic fibrosis
p5704
sg10
I15
sg28
VC0010674
p5705
sg13
I2
sa(dp5706
g7
I186
sg8
Vchromosomal abnormality
p5707
sg10
I23
sg28
VC0008625
p5708
sg13
I2
sa(dp5709
g7
I428
sg8
VKlinefelter syndrome
p5710
sg10
I20
sg28
VC0022735
p5711
sg13
I2
sa(dp5712
g7
I382
sg8
Vsex chromosomal abnormalities
p5713
sg10
I29
sg28
VC0036868
p5714
sg13
I3
sa(dp5715
g7
I370
sg8
VCBAVD
p5716
sg10
I5
sg28
VC0403814
p5717
sg13
I1
sa(dp5718
g7
I230
sg8
Vinfertility
p5719
sg10
I11
sg28
VC0021359
p5720
sg13
I1
sa(dp5721
g7
I171
sg8
Vmutant
p5722
sg10
I6
sg28
VC0596988
p5723
sg13
I1
sa(dp5724
g7
I327
sg8
Vcongenital bilateral absence vas deferens
p5725
sg10
I41
sg28
VC0403814
p5726
sg13
I5
sa(dp5727
g7
I264
sg8
Voligospermia
p5728
sg10
I12
sg28
VC0028960
p5729
sg13
I1
sa(dp5730
g7
I63
sg8
Vcytogenetic abnormality
p5731
sg10
I23
sg28
VC0008625
p5732
sg13
I2
sasa(dp5733
g135
(dp5734
(VFgfr1
p5735
Vdepressive state
p5736
tp5737
I00
ssg2
VTwo recent candidate genes, ErbB3 and Fgfr1, are growth factors whose mRNA levels have been found to be altered in the leukocytes of patients that are affected by bipolar disorder in a depressive state.
p5738
sg4
(lp5739
(dp5740
g7
I28
sg8
VErbB3
p5741
sg10
I5
sg11
VP21860
p5742
sg13
I1
sa(dp5743
g7
I38
sg8
g5735
sg10
I5
sg11
VP20930
p5744
sg13
I1
sasg24
(lp5745
(dp5746
g7
I163
sg8
Vbipolar disorder
p5747
sg10
I16
sg28
VC0005586
p5748
sg13
I2
sa(dp5749
g7
I185
sg8
g5736
sg10
I16
sg28
VC0011570
p5750
sg13
I2
sasa(dp5751
g135
(dp5752
(VFGFR1
p5753
Vdepression
p5754
tp5755
I00
ssg2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p5756
sg4
(lp5757
(dp5758
g7
I94
sg8
VARHGEF10
p5759
sg10
I8
sg11
g12
sg13
I1
sa(dp5760
g7
I186
sg8
VNEF3
p5761
sg10
I4
sg11
VP07197
p5762
sg13
I1
sa(dp5763
g7
I210
sg8
VPPP3CC
p5764
sg10
I6
sg11
VP48454
p5765
sg13
I1
sa(dp5766
g7
I142
sg8
VEGR3
p5767
sg10
I4
sg11
g12
sg13
I1
sa(dp5768
g7
I120
sg8
VCHRNB3
p5769
sg10
I6
sg11
g12
sg13
I1
sa(dp5770
g7
I86
sg8
VADRA1A
p5771
sg10
I6
sg11
VP25100
p5772
sg13
I1
sa(dp5773
g7
I234
sg8
VSLC18A1
p5774
sg10
I7
sg11
VP54219
p5775
sg13
I1
sa(dp5776
g7
I228
sg8
VVMAT1
p5777
sg10
I5
sg11
VP54219
p5778
sg13
I1
sa(dp5779
g7
I180
sg8
VNAT2
p5780
sg10
I4
sg11
VP18440
p5781
sg13
I1
sa(dp5782
g7
I128
sg8
VDKK4
p5783
sg10
I4
sg11
g12
sg13
I1
sa(dp5784
g7
I162
sg8
g5753
sg10
I5
sg11
VP20930
p5785
sg13
I1
sa(dp5786
g7
I104
sg8
VCHRNA2
p5787
sg10
I6
sg11
g12
sg13
I1
sa(dp5788
g7
I134
sg8
VDPYSL2
p5789
sg10
I6
sg11
g12
sg13
I1
sa(dp5790
g7
I169
sg8
VFZD3
p5791
sg10
I4
sg11
g12
sg13
I1
sa(dp5792
g7
I148
sg8
VFGF17
p5793
sg10
I5
sg11
g12
sg13
I1
sa(dp5794
g7
I155
sg8
VFGF20
p5795
sg10
I5
sg11
g12
sg13
I1
sa(dp5796
g7
I218
sg8
VSFRP1
p5797
sg10
I5
sg11
g12
sg13
I1
sa(dp5798
g7
I198
sg8
VPCM1
p5799
sg10
I4
sg11
g12
sg13
I1
sa(dp5800
g7
I112
sg8
VCHRNA6
p5801
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp5802
(dp5803
g7
I436
sg8
Vcancer
p5804
sg10
I6
sg28
VC0006826
p5805
sg13
I1
sa(dp5806
g7
I309
sg8
Vschizophrenia
p5807
sg10
I13
sg28
VC0036341
p5808
sg13
I1
sa(dp5809
g7
I332
sg8
Vbipolar disorder
p5810
sg10
I16
sg28
VC0005586
p5811
sg13
I2
sa(dp5812
g7
I324
sg8
Vautism
p5813
sg10
I6
sg28
VC0004352
p5814
sg13
I1
sa(dp5815
g7
I366
sg8
Vneurodegenerative disorders
p5816
sg10
I27
sg28
VC0524851
p5817
sg13
I2
sa(dp5818
g7
I353
sg8
g5754
sg10
I10
sg28
VC0011581
p5819
sg13
I1
sa(dp5820
g7
I411
sg8
VAlzheimer's disease
p5821
sg10
I19
sg28
VC1521724
p5822
sg13
I2
sasa(dp5823
g135
(dp5824
(Vp14
p5825
Vchromosomal translocation
p5826
tp5827
I00
ssg2
VThe region on chromosome 3p13-p14 known to contain several chromosomal translocation breakpoints in families with "pure familial renal cell carcinoma" is quite proximal to the VHL locus in 3p25-p26 we have identified.
p5828
sg4
(lp5829
(dp5830
g7
I176
sg8
VVHL locus
p5831
sg10
I9
sg11
VP40337
p5832
sg13
I2
sa(dp5833
g7
I30
sg8
g5825
sg10
I3
sg11
VP03971
p5834
sg13
I1
sasg24
(lp5835
(dp5836
g7
I176
sg8
VVHL
p5837
sg10
I3
sg28
VC0019562
p5838
sg13
I1
sa(dp5839
g7
I120
sg8
Vfamilial renal cell carcinoma
p5840
sg10
I29
sg28
VC2931352
p5841
sg13
I4
sa(dp5842
g7
I59
sg8
g5826
sg10
I25
sg28
VC0040715
p5843
sg13
I2
sasa(dp5844
g2
VImmunohistochemical studies and TCR gamma gene rearrangement analysis using a polymerase chain reaction with primers specific for V gamma 1-8 and V gamma 9 gene segments in combination with denaturing gradient gel electrophoresis (PCR/ DGGE) were performed on frozen material of 11 pseudo-T-cell lymphomas and 17 CTCLs, including 9 cases of mycosis fungoides (MF) and 8 pleomorphic CTCLs.
p5845
sg4
(lp5846
(dp5847
g7
I130
sg8
VV gamma 1-8 and V gamma 9 gene segments
p5848
sg10
I39
sg11
g12
sg13
I9
sasg24
(lp5849
(dp5850
g7
I341
sg8
Vmycosis fungoides
p5851
sg10
I17
sg28
VC0026948
p5852
sg13
I2
sa(dp5853
g7
I289
sg8
VT-cell lymphomas
p5854
sg10
I16
sg28
VC0079772
p5855
sg13
I2
sa(dp5856
g7
I360
sg8
VMF
p5857
sg10
I2
sg28
VC0026948
p5858
sg13
I1
sasa(dp5859
g2
VUnclassifiable cutaneous T-cell lymphoma was also diagnosed in the second patient: it was associated with a monoclonal proliferation of T-cell receptor V gamma 9, delta + large granular T lymphocytes and finally developed into frank, acute pre-T lymphatic leukemia.
p5860
sg4
(lp5861
(dp5862
g7
I136
sg8
VT-cell receptor V gamma 9, delta
p5863
sg10
I32
sg11
g12
sg13
I6
sasg24
(lp5864
(dp5865
g7
I119
sg8
Vproliferation
p5866
sg10
I13
sg28
VC0334094
p5867
sg13
I1
sa(dp5868
g7
I15
sg8
Vcutaneous T-cell lymphoma
p5869
sg10
I25
sg28
VC0079773
p5870
sg13
I3
sa(dp5871
g7
I246
sg8
Vlymphatic leukemia
p5872
sg10
I18
sg28
VC0023448
p5873
sg13
I2
sasa(dp5874
g2
VIn addition to providing insight into Pol I transcription and ES control, Pol I transcription inhibitors potentially also provide new approaches to treat trypanosomiasis.
p5875
sg4
(lp5876
(dp5877
g7
I38
sg8
VPol I
p5878
sg10
I5
sg11
VP10266
p5879
sg13
I2
sa(dp5880
g7
I38
sg8
VPol I
p5881
sg10
I5
sg11
VP10266
p5882
sg13
I2
sasg24
(lp5883
(dp5884
g7
I154
sg8
Vtrypanosomiasis
p5885
sg10
I15
sg28
VC0041227
p5886
sg13
I1
sasa(dp5887
g135
(dp5888
(VRNA polymerase I
p5889
VAfrican sleeping sickness
p5890
tp5891
I00
ssg2
VIn the unicellular parasite Trypanosoma brucei, which causes African sleeping sickness, TbISWI down-regulates RNA polymerase I (Pol I)-transcribed variant surface glycoprotein (VSG) gene expression sites (ESs), which are monoallelically expressed.
p5892
sg4
(lp5893
(dp5894
g7
I110
sg8
g5889
sg10
I16
sg11
VP24928
p5895
sg13
I3
sa(dp5896
g7
I128
sg8
VPol I
p5897
sg10
I5
sg11
VP10266
p5898
sg13
I2
sasg24
(lp5899
(dp5900
g7
I61
sg8
g5890
sg10
I25
sg28
VC0041228
p5901
sg13
I3
sasa(dp5902
g2
VA significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.
p5903
sg4
(lp5904
(dp5905
g7
I48
sg8
Vperilipin rs1052700
p5906
sg10
I19
sg11
g12
sg13
I2
sasg24
(lp5907
(dp5908
g7
I85
sg8
VT2D
p5909
sg10
I3
sg28
VC0011860
p5910
sg13
I1
sa(dp5911
g7
I85
sg8
VT2D
p5912
sg10
I3
sg28
VC0011860
p5913
sg13
I1
sa(dp5914
g7
I137
sg8
Vobesity
p5915
sg10
I7
sg28
VC0028754
p5916
sg13
I1
sasa(dp5917
g2
VThe perilipin rs1052700 polymorphism is related to T2D but not obesity.
p5918
sg4
(lp5919
(dp5920
g7
I51
sg8
VT2D
p5921
sg10
I3
sg11
g12
sg13
I1
sa(dp5922
g7
I4
sg8
Vperilipin rs1052700
p5923
sg10
I19
sg11
g12
sg13
I2
sasg24
(lp5924
(dp5925
g7
I51
sg8
VT2D
p5926
sg10
I3
sg28
VC0011860
p5927
sg13
I1
sa(dp5928
g7
I63
sg8
Vobesity
p5929
sg10
I7
sg28
VC0028754
p5930
sg13
I1
sasa(dp5931
g135
(dp5932
(VCYP3A5*1 allele
p5933
VESRD
p5934
tp5935
I00
ssg2
VThis prospective study recruited 22 patients with ESRD who underwent a first living kidney allograft transplantation, comprising 12 patients with CYP3A5*1 allele (CYP3A5*1/*1 or *1/*3) and 10 patients without CYP3A5*1 allele (CYP3A5*3/*3).
p5936
sg4
(lp5937
(dp5938
g7
I146
sg8
VCYP3A5*1
p5939
sg10
I8
sg11
VP20815
p5940
sg13
I1
sa(dp5941
g7
I226
sg8
VCYP3A5*3/*3
p5942
sg10
I11
sg11
VP20815
p5943
sg13
I1
sa(dp5944
g7
I146
sg8
VCYP3A5*1 allele
p5945
sg10
I15
sg11
VP20815
p5946
sg13
I2
sa(dp5947
g7
I146
sg8
g5933
sg10
I15
sg11
VP20815
p5948
sg13
I2
sasg24
(lp5949
(dp5950
g7
I50
sg8
g5934
sg10
I4
sg28
VC0022661
p5951
sg13
I1
sasa(dp5952
g135
(dp5953
(VABCB1
p5954
Vnephrolithiasis
p5955
tp5956
I00
ssg2
VNineteen SNPs in the ABCB1, NR1I2, UGT1A1, SLCO1B1 and CYP3A5 genes were examined in case patients with atazanavir/ritonavir-induced nephrolithiasis (n = 31) and controls (n = 47).
p5957
sg4
(lp5958
(dp5959
g7
I35
sg8
VUGT1A1
p5960
sg10
I6
sg11
VP35504
p5961
sg13
I1
sa(dp5962
g7
I55
sg8
VCYP3A5 genes
p5963
sg10
I12
sg11
VP20815
p5964
sg13
I2
sa(dp5965
g7
I21
sg8
g5954
sg10
I5
sg11
VP08183
p5966
sg13
I1
sa(dp5967
g7
I43
sg8
VSLCO1B1
p5968
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp5969
(dp5970
g7
I133
sg8
g5955
sg10
I15
sg28
VC0392525
p5971
sg13
I1
sasa(dp5972
g2
VCalcineurin inhibitor (CNI) use is considered to play a major role in the development of CKD after LT. We studied the influence of single-nucleotide polymorphisms (SNPs) in the genes of the donor and recipient CNI-metabolizing enzyme CYP3A5 and the CNI-transporting ABCB1 on the development of CKD after LT. Tacrolimus (Tac) predose concentrations at different time-points after transplantation and the CYP3A5 6986A&gt;G and ABCB1 3435C&gt;T SNPs were determined in 125 LT recipients and their respective donors to study the influence of Tac predose levels and genetics on the development of CKD.
p5973
sg4
(lp5974
(dp5975
g7
I425
sg8
VABCB1 3435C
p5976
sg10
I11
sg11
VP08183
p5977
sg13
I2
sa(dp5978
g7
I249
sg8
VCNI-transporting ABCB1
p5979
sg10
I22
sg11
g12
sg13
I2
sa(dp5980
g7
I210
sg8
VCNI-metabolizing enzyme CYP3A5
p5981
sg10
I30
sg11
g12
sg13
I3
sa(dp5982
g7
I23
sg8
VCNI
p5983
sg10
I3
sg11
g12
sg13
I1
sa(dp5984
g7
I0
sg8
VCalcineurin inhibitor
p5985
sg10
I21
sg11
g12
sg13
I2
sa(dp5986
g7
I440
sg8
VT SNPs
p5987
sg10
I6
sg11
g12
sg13
I2
sa(dp5988
g7
I403
sg8
VCYP3A5 6986A
p5989
sg10
I12
sg11
VP20815
p5990
sg13
I2
sasg24
(lp5991
sa(dp5992
g2
VNeither did we find a correlation between the investigated SNPs in either donor or recipient ABCB1 and CYP3A5 genes (or combinations thereof) and the development of CKD.
p5993
sg4
(lp5994
(dp5995
g7
I93
sg8
VABCB1
p5996
sg10
I5
sg11
VP08183
p5997
sg13
I1
sa(dp5998
g7
I103
sg8
VCYP3A5 genes
p5999
sg10
I12
sg11
VP20815
p6000
sg13
I2
sasg24
(lp6001
sa(dp6002
g2
VAn individual's risk of developing CKD after LT is not associated with genetic variation in either recipient or donor CYP3A5 or ABCB1 genotype status.
p6003
sg4
(lp6004
(dp6005
g7
I118
sg8
VCYP3A5
p6006
sg10
I6
sg11
VP20815
p6007
sg13
I1
sa(dp6008
g7
I128
sg8
VABCB1 genotype
p6009
sg10
I14
sg11
VP08183
p6010
sg13
I2
sasg24
(lp6011
sa(dp6012
g135
(dp6013
(VCYP3A
p6014
Vrenal failure
p6015
tp6016
I00
ssg2
VIn conclusion, these results suggest that CYP3A5 polymorphism and plasma concentration of 3-INDS may account for the interindividual variability of CYP3A activity, and that plasma concentration of 3-INDS may partially explain the gap in CYP3A activity that cannot be explained by genetic contribution in patients with renal failure.
p6017
sg4
(lp6018
(dp6019
g7
I42
sg8
VCYP3A
p6020
sg10
I5
sg11
VP08684
p6021
sg13
I1
sa(dp6022
g7
I42
sg8
VCYP3A5
p6023
sg10
I6
sg11
VP20815
p6024
sg13
I1
sa(dp6025
g7
I42
sg8
g6014
sg10
I5
sg11
VP08684
p6026
sg13
I1
sasg24
(lp6027
(dp6028
g7
I318
sg8
g6015
sg10
I13
sg28
VC0035078
p6029
sg13
I2
sasa(dp6030
g135
(dp6031
(V\u3001AFP
p6032
Vfaciogenital dysplasia
p6033
tp6034
I00
ssg2
V#\u76ee#\u7684#\uff1a #\u63a2#\u8ba8FGD6  (faciogenital dysplasia) #\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u7684#\u4f5c#\u7528#\u3002 #\u65b9#\u6cd5#\uff1a #\u9009#\u53d6FGD6#\u57fa#\u56e0#\u5e72#\u6270#\u9776#\u5e8f#\u5217, #\u4f7f#\u7528AdEasy#\u7cfb#\u7edf#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53, #\u5305#\u88c5#\u5e76#\u6269#\u589e#\u91cd#\u7ec4#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA, #\u611f#\u67d3HP14.5#\u7ec6#\u80de#\u3002#\u7ec6#\u80de#\u514d#\u75ab#\u8367#\u5149#\u68c0#\u6d4bFGD6#\u86cb#\u767d#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe#\u6c34#\u5e73, #\u5b9e#\u65f6#\u8367#\u5149#\u5b9a#\u91cfPCR#\u68c0#\u6d4bFGD6#\u3001#\u7532#\u80ce#\u86cb#\u767d (AFP) #\u53ca#\u767d#\u86cb#\u767d (Alb) #\u7684mRNA#\u6c34#\u5e73, Western blot#\u68c0#\u6d4bFGD6#\u3001AFP#\u53caAlb#\u7684#\u86cb#\u767d#\u8868#\u8fbe#\u6c34#\u5e73#\u3002#\u6bcf#\u7ec4#\u7ec6#\u80de#\u5747#\u8bbe#\u7f6epSES-Ad-RFP#\u817a#\u75c5#\u6bd2#\u7a7a#\u8f7d#\u4f53#\u611f#\u67d3#\u8fdb#\u884c#\u5bf9#\u7167#\u3002#\u6240#\u6709#\u6570#\u636e#\u7528#\u5747#\u6570+/-#\u6807#\u51c6#\u5dee (x+/-s) #\u8868#\u793a, #\u91c7#\u7528#\u5355#\u56e0#\u7d20#\u65b9#\u5dee#\u5206#\u6790#\u3002 #\u7ed3#\u679c#\uff1a FGD6#\u86cb#\u767d#\u4e3b#\u8981#\u8868#\u8fbe#\u4e8eHP14.5#\u7ec6#\u80de#\u80de#\u6838#\u4e2d#\u3002#\u6210#\u529f#\u6784#\u5efa#\u817a#\u75c5#\u6bd2#\u8f7d#\u4f53pSES-FGD6-siRNA#\u3002#\u4e0b#\u8c03FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u964d#\u4f4eAFP#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe, #\u800c#\u5347#\u9ad8Alb#\u7684mRNA#\u53ca#\u86cb#\u767d#\u7684#\u8868#\u8fbe (P&lt;0.01) #\u3002 #\u7ed3#\u8bba#\uff1a #\u6291#\u5236FGD6#\u57fa#\u56e0#\u5728HP14.5#\u7ec6#\u80de#\u4e2d#\u7684#\u8868#\u8fbe, #\u53ef#\u4f7fHP14.5#\u7ec6#\u80de#\u5411#\u809d#\u7ec6#\u80de#\u65b9#\u5411#\u5206#\u5316, #\u56e0#\u6b64, FGD6#\u57fa#\u56e0#\u5bf9#\u809d#\u5e72#\u7ec6#\u80de#\u5206#\u5316#\u8c03#\u63a7#\u53ef#\u80fd#\u8d77#\u7740#\u91cd#\u8981#\u4f5c#\u7528#\u3002.
p6035
sg4
(lp6036
(dp6037
g7
I11
sg8
VFGD6
p6038
sg10
I4
sg11
g12
sg13
I1
sa(dp6039
g7
I376
sg8
VRFP
p6040
sg10
I3
sg11
VP25090
p6041
sg13
I1
sa(dp6042
g7
I11
sg8
VFGD6
p6043
sg10
I4
sg11
g12
sg13
I1
sa(dp6044
g7
I329
sg8
g6032
sg10
I4
sg11
VP02771
p6045
sg13
I1
sa(dp6046
g7
I11
sg8
VFGD6
p6047
sg10
I4
sg11
g12
sg13
I1
sa(dp6048
g7
I11
sg8
VFGD6
p6049
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6050
(dp6051
g7
I18
sg8
g6033
sg10
I22
sg28
VC0175701
p6052
sg13
I2
sasa(dp6053
g135
(dp6054
(Valbumin
p6055
VAlport syndrome
p6056
tp6057
I00
ssg2
VFiltered albumin has been suggested to be a cause of the glomerular and tubular injuries observed at advanced stages of Alport syndrome.
p6058
sg4
(lp6059
(dp6060
g7
I9
sg8
g6055
sg10
I7
sg11
VP00441
p6061
sg13
I1
sasg24
(lp6062
(dp6063
g7
I120
sg8
g6056
sg10
I15
sg28
VC1567741
p6064
sg13
I2
sasa(dp6065
g135
(dp6066
(Valbumin
p6067
Vkidney disease
p6068
tp6069
I00
ssg2
VTo directly investigate the role that albumin plays in the progression of disease in Alport syndrome, we generated albumin knockout (Alb(-/-)) mice to use as a tool for removing albuminuria as a component of kidney disease.
p6070
sg4
(lp6071
(dp6072
g7
I38
sg8
Valbumin
p6073
sg10
I7
sg11
VP00441
p6074
sg13
I1
sa(dp6075
g7
I38
sg8
g6067
sg10
I7
sg11
VP00441
p6076
sg13
I1
sa(dp6077
g7
I133
sg8
VAlb
p6078
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp6079
(dp6080
g7
I85
sg8
VAlport syndrome
p6081
sg10
I15
sg28
VC1567741
p6082
sg13
I2
sa(dp6083
g7
I208
sg8
g6068
sg10
I14
sg28
VC0022658
p6084
sg13
I2
sasa(dp6085
g2
VAlb mutant mice were bred to collagen-Alfa3(IV) knockout (Col4a3(-/-)) mice, which are a model for human Alport syndrome.
p6086
sg4
(lp6087
(dp6088
g7
I0
sg8
VAlb
p6089
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp6090
(dp6091
g7
I105
sg8
VAlport syndrome
p6092
sg10
I15
sg28
VC1567741
p6093
sg13
I2
sa(dp6094
g7
I4
sg8
Vmutant
p6095
sg10
I6
sg28
VC0596988
p6096
sg13
I1
sasa(dp6097
g135
(dp6098
(Valbumin
p6099
VAlport syndrome
p6100
tp6101
I00
ssg2
VWe conclude that filtered albumin is injurious to kidney cells in Alport syndrome and perhaps in other proteinuric kidney diseases, including diabetic nephropathy.
p6102
sg4
(lp6103
(dp6104
g7
I26
sg8
g6099
sg10
I7
sg11
VP00441
p6105
sg13
I1
sasg24
(lp6106
(dp6107
g7
I142
sg8
Vdiabetic nephropathy
p6108
sg10
I20
sg28
VC0011881
p6109
sg13
I2
sa(dp6110
g7
I115
sg8
Vkidney diseases
p6111
sg10
I15
sg28
VC0022658
p6112
sg13
I2
sa(dp6113
g7
I66
sg8
g6100
sg10
I15
sg28
VC1567741
p6114
sg13
I2
sasa(dp6115
g135
(dp6116
(VVEGF-C
p6117
Vtongue cancer
p6118
tp6119
I00
ssg2
VOn the other hand, we believe that tumor depth of invasion (&gt;=4 mm), POI, and VEGF-C expression all need to be considered in the preoperative and postoperative planning stages for tongue cancer treatment.
p6120
sg4
(lp6121
(dp6122
g7
I81
sg8
g6117
sg10
I6
sg11
VP49767
p6123
sg13
I1
sasg24
(lp6124
(dp6125
g7
I183
sg8
g6118
sg10
I13
sg28
VC0558353
p6126
sg13
I2
sa(dp6127
g7
I35
sg8
Vtumor
p6128
sg10
I5
sg28
VC0027651
p6129
sg13
I1
sa(dp6130
g7
I50
sg8
Vinvasion
p6131
sg10
I8
sg28
VC2699153
p6132
sg13
I1
sasa(dp6133
g135
(dp6134
(VVEGF-C
p6135
Vtongue cancer
p6136
tp6137
I00
ssg2
VThe use of a therapeutic approach which blocks lymphangiogenic factors, such as VEGF-C and VEGF-D, may be beneficial in suppressing the lymphatic spread of tongue cancer with intense intranodal lymphangiogenesis.
p6138
sg4
(lp6139
(dp6140
g7
I80
sg8
g6135
sg10
I6
sg11
VP49767
p6141
sg13
I1
sa(dp6142
g7
I91
sg8
VVEGF-D
p6143
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp6144
(dp6145
g7
I156
sg8
g6136
sg10
I13
sg28
VC0558353
p6146
sg13
I2
sasa(dp6147
g135
(dp6148
(VVEGF-C
p6149
Vtongue cancer
p6150
tp6151
I00
ssg2
VVEGF, VEGF-C, VEGF-D and MIA expression levels of metastatic tongue cancer HSC-3 cells were higher than those with no metastatic HSC-4 cells, and VEGF, VEGF-C and VEGF-D expression levels were decreased by MIA siRNA treatment in both cells.
p6152
sg4
(lp6153
(dp6154
g7
I14
sg8
VVEGF-D
p6155
sg10
I6
sg11
g12
sg13
I1
sa(dp6156
g7
I6
sg8
VVEGF-C
p6157
sg10
I6
sg11
VP49767
p6158
sg13
I1
sa(dp6159
g7
I206
sg8
VMIA siRNA
p6160
sg10
I9
sg11
g12
sg13
I2
sa(dp6161
g7
I25
sg8
VMIA
p6162
sg10
I3
sg11
g12
sg13
I1
sa(dp6163
g7
I14
sg8
VVEGF-D
p6164
sg10
I6
sg11
g12
sg13
I1
sa(dp6165
g7
I6
sg8
g6149
sg10
I6
sg11
VP49767
p6166
sg13
I1
sasg24
(lp6167
(dp6168
g7
I61
sg8
g6150
sg10
I13
sg28
VC0558353
p6169
sg13
I2
sasa(dp6170
g135
(dp6171
(VNotch1
p6172
Vtongue cancer
p6173
tp6174
I01
ssg2
VVascular endothelial growth factor and Notch1 expression are significantly related to cervical lymph node metastasis and depth of invasion in tongue cancer patients.
p6175
sg4
(lp6176
(dp6177
g7
I0
sg8
VVascular endothelial growth factor
p6178
sg10
I34
sg11
g12
sg13
I4
sa(dp6179
g7
I39
sg8
g6172
sg10
I6
sg11
VP46531
p6180
sg13
I1
sasg24
(lp6181
(dp6182
g7
I130
sg8
Vinvasion
p6183
sg10
I8
sg28
VC2699153
p6184
sg13
I1
sa(dp6185
g7
I95
sg8
Vlymph node metastasis
p6186
sg10
I21
sg28
VC0686619
p6187
sg13
I3
sa(dp6188
g7
I142
sg8
g6173
sg10
I13
sg28
VC0558353
p6189
sg13
I2
sasa(dp6190
g2
VMutant-type p53 and VEGF are known to be related to angiogenesis, and maspin is a potent angiogenic inhibitor but its role in tongue cancer has scarcely been examined.
p6191
sg4
(lp6192
(dp6193
g7
I12
sg8
Vp53
p6194
sg10
I3
sg11
VP42771
p6195
sg13
I1
sasg24
(lp6196
(dp6197
g7
I0
sg8
VMutant
p6198
sg10
I6
sg28
VC0596988
p6199
sg13
I1
sa(dp6200
g7
I126
sg8
Vtongue cancer
p6201
sg10
I13
sg28
VC0558353
p6202
sg13
I2
sasa(dp6203
g135
(dp6204
(Vmaspin
p6205
Vtongue cancer
p6206
tp6207
I00
ssg2
VWe observed the expression of maspin, mutant-type p53 and VEGF by immunohistochemistry in 33 patients with stages I and II oral tongue cancer.
p6208
sg4
(lp6209
(dp6210
g7
I30
sg8
g6205
sg10
I6
sg11
VP36952
p6211
sg13
I1
sa(dp6212
g7
I38
sg8
Vmutant-type p53
p6213
sg10
I15
sg11
VP42771
p6214
sg13
I2
sasg24
(lp6215
(dp6216
g7
I128
sg8
g6206
sg10
I13
sg28
VC0558353
p6217
sg13
I2
sa(dp6218
g7
I38
sg8
Vmutant
p6219
sg10
I6
sg28
VC0596988
p6220
sg13
I1
sasa(dp6221
g135
(dp6222
(Vcytidine deaminase
p6223
Vautoimmunity
p6224
tp6225
I00
ssg2
VIn an experimental autoimmune encephalomyelitis model of CNS autoimmunity, we found activation-induced cytidine deaminase, a GC-defining enzyme, in meningeal ELT (mELT) densely populated by B and T cells.
p6226
sg4
(lp6227
(dp6228
g7
I103
sg8
g6223
sg10
I18
sg11
VP32320
p6229
sg13
I2
sasg24
(lp6230
(dp6231
g7
I30
sg8
Vencephalomyelitis
p6232
sg10
I17
sg28
VC0014070
p6233
sg13
I1
sa(dp6234
g7
I61
sg8
g6224
sg10
I12
sg28
VC0004368
p6235
sg13
I1
sa(dp6236
g7
I19
sg8
Vautoimmune
p6237
sg10
I10
sg28
VC0443146
p6238
sg13
I1
sasa(dp6239
g2
VA prospective randomized survey of 113 abortions carried out by 1 operator using a single technique among women in the 7th-10th week of amenorrhea was undertaken to test the effectiveness of systemically administered oxytocins to reduce bleeding during therapeutic abortion by suction.
p6240
sg4
(lp6241
sg24
(lp6242
(dp6243
g7
I136
sg8
Vamenorrhea
p6244
sg10
I10
sg28
VC0002453
p6245
sg13
I1
sa(dp6246
g7
I237
sg8
Vbleeding
p6247
sg10
I8
sg28
VC0019080
p6248
sg13
I1
sasa(dp6249
g2
VThis cross-sectional study includes 304 patients with type 2 diabetes treated with oral antidiabetic drugs (ADOs) and a glomerular filtration rate (estimated GFR) &amp;lt;60ml/min/1.73m2.
p6250
sg4
(lp6251
sg24
(lp6252
(dp6253
g7
I54
sg8
Vtype 2 diabetes
p6254
sg10
I15
sg28
VC0011860
p6255
sg13
I3
sasa(dp6256
g2
VThe purpose of this study was to evaluate the hypothesis that acute hyperglycaemia in hearts of rats without diabetes alters coronary vascular responses to nitric oxide (NO), adenosine (ADO) and phenylephrine (PHE).
p6257
sg4
(lp6258
sg24
(lp6259
(dp6260
g7
I62
sg8
Vacute hyperglycaemia
p6261
sg10
I20
sg28
VC0342301
p6262
sg13
I2
sa(dp6263
g7
I109
sg8
Vdiabetes
p6264
sg10
I8
sg28
VC0011849
p6265
sg13
I1
sasa(dp6266
g2
VIn conclusion, STZ-diabetes mellitus enhances the antiphosphaturic effect of ADO by mechanisms unrelated to ADO A1 receptor stimulation.
p6267
sg4
(lp6268
(dp6269
g7
I108
sg8
VADO A1 receptor
p6270
sg10
I15
sg11
g12
sg13
I3
sasg24
(lp6271
(dp6272
g7
I19
sg8
Vdiabetes mellitus
p6273
sg10
I17
sg28
VC0011849
p6274
sg13
I2
sasa(dp6275
g135
(dp6276
(Vinsulin
p6277
VT2D
p6278
tp6279
I00
ssg2
VBradykinin type 1 receptor antagonism could represent a promising therapeutic tool in combination with TZD for the treatment of T2D, obesity and insulin resistance.
p6280
sg4
(lp6281
(dp6282
g7
I0
sg8
VBradykinin type 1 receptor
p6283
sg10
I26
sg11
VP01042
p6284
sg13
I4
sa(dp6285
g7
I145
sg8
g6277
sg10
I7
sg11
VP01308
p6286
sg13
I1
sasg24
(lp6287
(dp6288
g7
I133
sg8
Vobesity
p6289
sg10
I7
sg28
VC0028754
p6290
sg13
I1
sa(dp6291
g7
I145
sg8
Vinsulin resistance
p6292
sg10
I18
sg28
VC0021655
p6293
sg13
I2
sa(dp6294
g7
I128
sg8
g6278
sg10
I3
sg28
VC0011860
p6295
sg13
I1
sasa(dp6296
g135
(dp6297
(Vinsulin
p6298
VT2D
p6299
tp6300
I00
ssg2
VThe aim of this study was to analyze the acute responses of bradykinin, insulin, and glycemia to exercise performed above and below lactate threshold (LT) in individuals with type 2 diabetes mellitus (T2D).
p6301
sg4
(lp6302
(dp6303
g7
I60
sg8
Vbradykinin
p6304
sg10
I10
sg11
VP01042
p6305
sg13
I1
sa(dp6306
g7
I72
sg8
g6298
sg10
I7
sg11
VP01308
p6307
sg13
I1
sasg24
(lp6308
(dp6309
g7
I175
sg8
Vtype 2 diabetes mellitus
p6310
sg10
I24
sg28
VC0011860
p6311
sg13
I4
sa(dp6312
g7
I201
sg8
g6299
sg10
I3
sg28
VC0011860
p6313
sg13
I1
sasa(dp6314
g135
(dp6315
(VAngiotensin
p6316
Vtype 1 diabetes
p6317
tp6318
I00
ssg2
VTo examine the association of bradykinin and related peptides with the development of diabetic nephropathy lesions in 243 participants with type 1 diabetes (T1D) from the Renin-Angiotensin System Study who, at baseline, were normoalbuminuric, normotensive and had normal or increased glomerular filtration rate (GFR).
p6319
sg4
(lp6320
(dp6321
g7
I30
sg8
Vbradykinin
p6322
sg10
I10
sg11
VP01042
p6323
sg13
I1
sa(dp6324
g7
I171
sg8
VRenin
p6325
sg10
I5
sg11
VP00797
p6326
sg13
I1
sa(dp6327
g7
I177
sg8
g6316
sg10
I11
sg11
VP21549
p6328
sg13
I1
sasg24
(lp6329
(dp6330
g7
I86
sg8
Vdiabetic nephropathy
p6331
sg10
I20
sg28
VC0011881
p6332
sg13
I2
sa(dp6333
g7
I157
sg8
VT1D
p6334
sg10
I3
sg28
VC0011854
p6335
sg13
I1
sa(dp6336
g7
I140
sg8
g6317
sg10
I15
sg28
VC0011854
p6337
sg13
I3
sasa(dp6338
g135
(dp6339
(Vcongenital generalized lipodystrophy type 2
p6340
Vintellectual impairment
p6341
tp6342
I00
ssg2
VHeterozygosity for missense mutations in Seipin, namely N88S and S90L, leads to a broad spectrum of motor neuropathy, while a number of loss-of-function mutations in Seipin are associated with the Berardinelli-Seip congenital generalized lipodystrophy type 2 (CGL2, BSCL2), a condition that is characterized by severe lipoatrophy, insulin resistance, and intellectual impairment.
p6343
sg4
(lp6344
(dp6345
g7
I331
sg8
Vinsulin
p6346
sg10
I7
sg11
VP01308
p6347
sg13
I1
sa(dp6348
g7
I266
sg8
VBSCL2
p6349
sg10
I5
sg11
g12
sg13
I1
sa(dp6350
g7
I260
sg8
VCGL2
p6351
sg10
I4
sg11
VP20718
p6352
sg13
I1
sa(dp6353
g7
I41
sg8
VSeipin
p6354
sg10
I6
sg11
g12
sg13
I1
sa(dp6355
g7
I215
sg8
g6340
sg10
I43
sg11
VP20718
p6356
sg13
I5
sa(dp6357
g7
I41
sg8
VSeipin
p6358
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp6359
(dp6360
g7
I318
sg8
Vlipoatrophy
p6361
sg10
I11
sg28
VC1280433
p6362
sg13
I1
sa(dp6363
g7
I331
sg8
Vinsulin resistance
p6364
sg10
I18
sg28
VC0021655
p6365
sg13
I2
sa(dp6366
g7
I276
sg8
Vcondition
p6367
sg10
I9
sg28
VC0012634
p6368
sg13
I1
sa(dp6369
g7
I100
sg8
Vmotor neuropathy
p6370
sg10
I16
sg28
VC0235025
p6371
sg13
I2
sa(dp6372
g7
I260
sg8
VCGL2
p6373
sg10
I4
sg28
VC1720863
p6374
sg13
I1
sa(dp6375
g7
I215
sg8
Vcongenital generalized lipodystrophy type 2
p6376
sg10
I43
sg28
VC1720863
p6377
sg13
I5
sa(dp6378
g7
I355
sg8
g6341
sg10
I23
sg28
VC0683322
p6379
sg13
I2
sasa(dp6380
g2
VIn comparison to liver biopsies of patients with non-viral liver disease, liver biopsies of patients with HCV showed significantly increased mRNA expression of IL-28A and IL-29.
p6381
sg4
(lp6382
(dp6383
g7
I171
sg8
VIL-29
p6384
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp6385
(dp6386
g7
I65
sg8
Vdisease, liver
p6387
sg10
I14
sg28
VC0023895
p6388
sg13
I2
sasa(dp6389
g2
VHere, we demonstrate a key regulatory role of IL-28A in T-cell-mediated hepatitis.
p6390
sg4
(lp6391
sg24
(lp6392
(dp6393
g7
I72
sg8
Vhepatitis
p6394
sg10
I9
sg28
VC0019159
p6395
sg13
I1
sasa(dp6396
g135
(dp6397
(VCD4+
p6398
Vhepatitis
p6399
tp6400
I01
ssg2
VIL-28A induced TH1 cytokine production by CD4+ T lymphocytes in a T-bet-dependent manner and was up-regulated in a murine model of T-cell-mediated hepatitis upon Con A administration.
p6401
sg4
(lp6402
(dp6403
g7
I42
sg8
g6398
sg10
I4
sg11
VP01730
p6404
sg13
I1
sa(dp6405
g7
I15
sg8
VTH1 cytokine
p6406
sg10
I12
sg11
VP13236
p6407
sg13
I2
sasg24
(lp6408
(dp6409
g7
I147
sg8
g6399
sg10
I9
sg28
VC0019159
p6410
sg13
I1
sasa(dp6411
g135
(dp6412
(Vinterferon-gamma
p6413
Vhepatitis
p6414
tp6415
I00
ssg2
VIn addition, IL-28A-transgenic mice showed markedly augmented Con A-induced hepatitis with up-regulated interferon-gamma cytokine production, as compared with wild-type mice.
p6416
sg4
(lp6417
(dp6418
g7
I104
sg8
g6413
sg10
I16
sg11
VP01579
p6419
sg13
I1
sasg24
(lp6420
(dp6421
g7
I76
sg8
g6414
sg10
I9
sg28
VC0019159
p6422
sg13
I1
sasa(dp6423
g135
(dp6424
(Vinterferon-gamma
p6425
Vhepatitis
p6426
tp6427
I00
ssg2
VIn addition, in vivo blockade of interferon-gamma but not IL-4 suppressed augmented liver inflammation in transgenic mice, suggesting that IL-28A induces the T-bet signaling pathway in T-cell-induced hepatitis.
p6428
sg4
(lp6429
(dp6430
g7
I58
sg8
VIL-4
p6431
sg10
I4
sg11
VP05112
p6432
sg13
I1
sa(dp6433
g7
I158
sg8
VT-bet
p6434
sg10
I5
sg11
g12
sg13
I1
sa(dp6435
g7
I33
sg8
g6425
sg10
I16
sg11
VP01579
p6436
sg13
I1
sasg24
(lp6437
(dp6438
g7
I90
sg8
Vinflammation
p6439
sg10
I12
sg28
VC0021368
p6440
sg13
I1
sa(dp6441
g7
I200
sg8
g6426
sg10
I9
sg28
VC0019159
p6442
sg13
I1
sasa(dp6443
g2
VThus, targeting of IL-28A represents a potential novel approach for therapy of Th1-mediated inflammatory diseases such as T-cell-mediated hepatitis.
p6444
sg4
(lp6445
sg24
(lp6446
(dp6447
g7
I138
sg8
Vhepatitis
p6448
sg10
I9
sg28
VC0019159
p6449
sg13
I1
sasa(dp6450
g135
(dp6451
(VNOD receptor
p6452
VNOD
p6453
tp6454
I00
ssg2
VThe present study therefore indicated that NOD receptor and TLR9 may modulate the inflammatory response and further impact upon intestinal injury of SAP, via the regulation of NF-KB expression and the oxidation/antioxidation balance, suggesting therapeutically targeting NOD receptor and TLR9 might be a useful approach for the treatment of severe acute pancreatitis.
p6455
sg4
(lp6456
(dp6457
g7
I60
sg8
VTLR9
p6458
sg10
I4
sg11
g12
sg13
I1
sa(dp6459
g7
I60
sg8
VTLR9
p6460
sg10
I4
sg11
g12
sg13
I1
sa(dp6461
g7
I43
sg8
VNOD receptor
p6462
sg10
I12
sg11
VP54259
p6463
sg13
I2
sa(dp6464
g7
I43
sg8
g6452
sg10
I12
sg11
VP54259
p6465
sg13
I2
sasg24
(lp6466
(dp6467
g7
I82
sg8
Vinflammatory response
p6468
sg10
I21
sg28
VC1155266
p6469
sg13
I2
sa(dp6470
g7
I43
sg8
VNOD
p6471
sg10
I3
sg28
VC0751781
p6472
sg13
I1
sa(dp6473
g7
I348
sg8
Vacute pancreatitis
p6474
sg10
I18
sg28
VC0001339
p6475
sg13
I2
sa(dp6476
g7
I43
sg8
g6453
sg10
I3
sg28
VC0751781
p6477
sg13
I1
sasa(dp6478
g2
VIt also has efficacy in limiting TLR9-mediated sterile inflammation in in vivo models of acute liver injury and acute pancreatitis.
p6479
sg4
(lp6480
(dp6481
g7
I33
sg8
VTLR9
p6482
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6483
(dp6484
g7
I47
sg8
Vsterile
p6485
sg10
I7
sg28
VC0678108
p6486
sg13
I1
sa(dp6487
g7
I55
sg8
Vinflammation
p6488
sg10
I12
sg28
VC0021368
p6489
sg13
I1
sa(dp6490
g7
I112
sg8
Vacute pancreatitis
p6491
sg10
I18
sg28
VC0001339
p6492
sg13
I2
sasa(dp6493
g2
VGenetic deletion and pharmacologic antagonism demonstrate that specific DAMP receptors, including Toll-like receptor (TLR) 4, TLR9, and P2X7, are also required for inflammation in experimental acute pancreatitis.
p6494
sg4
(lp6495
(dp6496
g7
I63
sg8
Vspecific DAMP receptors
p6497
sg10
I23
sg11
g12
sg13
I3
sa(dp6498
g7
I98
sg8
VToll-like receptor (TLR) 4
p6499
sg10
I26
sg11
g12
sg13
I4
sa(dp6500
g7
I126
sg8
VTLR9
p6501
sg10
I4
sg11
g12
sg13
I1
sa(dp6502
g7
I136
sg8
VP2X7
p6503
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6504
(dp6505
g7
I164
sg8
Vinflammation
p6506
sg10
I12
sg28
VC0021368
p6507
sg13
I1
sa(dp6508
g7
I193
sg8
Vacute pancreatitis
p6509
sg10
I18
sg28
VC0001339
p6510
sg13
I2
sasa(dp6511
g135
(dp6512
(Vcaspase-1
p6513
VAcute pancreatitis
p6514
tp6515
I00
ssg2
VAcute pancreatitis was induced by caerulein stimulation in wild-type mice and mice deficient in components of the inflammasome (apoptosis-associated speck-like protein containing a caspase recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor P2X(7).
p6516
sg4
(lp6517
(dp6518
g7
I256
sg8
VTLR9
p6519
sg10
I4
sg11
g12
sg13
I1
sa(dp6520
g7
I270
sg8
Vpurinergic receptor P2X(7)
p6521
sg10
I26
sg11
VP51575
p6522
sg13
I3
sa(dp6523
g7
I234
sg8
VToll-like receptor 9
p6524
sg10
I20
sg11
g12
sg13
I3
sa(dp6525
g7
I181
sg8
Vcaspase
p6526
sg10
I7
sg11
VP39880
p6527
sg13
I1
sa(dp6528
g7
I222
sg8
g6513
sg10
I9
sg11
VP29466
p6529
sg13
I1
sasg24
(lp6530
(dp6531
g7
I189
sg8
Vrecruitment
p6532
sg10
I11
sg28
VC0271510
p6533
sg13
I1
sa(dp6534
g7
I0
sg8
g6514
sg10
I18
sg28
VC0001339
p6535
sg13
I2
sasa(dp6536
g2
VAdditionally, wild-type mice were pretreated with a TLR9 antagonist before induction of acute pancreatitis by caerulein or retrograde bile duct infusion of taurolithocholic acid 3-sulfate.
p6537
sg4
(lp6538
(dp6539
g7
I52
sg8
VTLR9
p6540
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6541
(dp6542
g7
I88
sg8
Vacute pancreatitis
p6543
sg10
I18
sg28
VC0001339
p6544
sg13
I2
sasa(dp6545
g135
(dp6546
(VP2X(7)
p6547
Vacute pancreatitis
p6548
tp6549
I00
ssg2
VTLR9 and P2X(7) are important DAMP receptors upstream of inflammasome activation, and their antagonism could provide a new therapeutic strategy for treating acute pancreatitis.
p6550
sg4
(lp6551
(dp6552
g7
I0
sg8
VTLR9
p6553
sg10
I4
sg11
g12
sg13
I1
sa(dp6554
g7
I9
sg8
g6547
sg10
I6
sg11
VP51575
p6555
sg13
I1
sasg24
(lp6556
(dp6557
g7
I157
sg8
g6548
sg10
I18
sg28
VC0001339
p6558
sg13
I2
sasa(dp6559
g135
(dp6560
(VPTGDS
p6561
VDFNB79
p6562
tp6563
I00
ssg2
VWe are currently screening the 113 candidate DFNB79 genes for mutations and have excluded CACNA1B, EDF1, PTGDS, EHMT1, QSOX2, NOTCH1, MIR126 and MIR602.
p6564
sg4
(lp6565
(dp6566
g7
I112
sg8
VEHMT1
p6567
sg10
I5
sg11
g12
sg13
I1
sa(dp6568
g7
I90
sg8
VCACNA1B
p6569
sg10
I7
sg11
g12
sg13
I1
sa(dp6570
g7
I119
sg8
VQSOX2
p6571
sg10
I5
sg11
g12
sg13
I1
sa(dp6572
g7
I99
sg8
VEDF1
p6573
sg10
I4
sg11
g12
sg13
I1
sa(dp6574
g7
I45
sg8
VDFNB79 genes
p6575
sg10
I12
sg11
g12
sg13
I2
sa(dp6576
g7
I126
sg8
VNOTCH1
p6577
sg10
I6
sg11
VP46531
p6578
sg13
I1
sa(dp6579
g7
I105
sg8
g6561
sg10
I5
sg11
VP41222
p6580
sg13
I1
sasg24
(lp6581
(dp6582
g7
I45
sg8
g6562
sg10
I6
sg28
VC2750082
p6583
sg13
I1
sasa(dp6584
g135
(dp6585
(VCD184
p6586
Vneuroblastoma
p6587
tp6588
I00
ssg2
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p6589
sg4
(lp6590
(dp6591
g7
I79
sg8
VCD15
p6592
sg10
I4
sg11
VP22083
p6593
sg13
I1
sa(dp6594
g7
I194
sg8
VNMYC protein
p6595
sg10
I12
sg11
VP04198
p6596
sg13
I2
sa(dp6597
g7
I17
sg8
Vmorphogenetic protein (BMP)-4
p6598
sg10
I29
sg11
VP18075
p6599
sg13
I3
sa(dp6600
g7
I85
sg8
g6586
sg10
I5
sg11
VP61073
p6601
sg13
I1
sasg24
(lp6602
(dp6603
g7
I92
sg8
g6587
sg10
I13
sg28
VC0027819
p6604
sg13
I1
sasa(dp6605
g135
(dp6606
(VCyclin D1
p6607
VMPNST
p6608
tp6609
I00
ssg2
VRecent studies indicate that C-X-C motif chemokine receptor 4 (CXCR4) and its ligand, C-X-C motif chemokine ligand 12 (CXCL12), stimulate expression of the cell cycle regulatory protein Cyclin D1 in neurofibromatosis 1-associated malignant peripheral nerve sheath tumor (MPNST) cells and promote their proliferation.
p6610
sg4
(lp6611
(dp6612
g7
I29
sg8
VC-X-C motif chemokine receptor 4
p6613
sg10
I32
sg11
VP51679
p6614
sg13
I5
sa(dp6615
g7
I119
sg8
VCXCL12
p6616
sg10
I6
sg11
VP48061
p6617
sg13
I1
sa(dp6618
g7
I63
sg8
VCXCR4
p6619
sg10
I5
sg11
VP61073
p6620
sg13
I1
sa(dp6621
g7
I86
sg8
VC-X-C motif chemokine ligand 12
p6622
sg10
I31
sg11
VP55773
p6623
sg13
I5
sa(dp6624
g7
I186
sg8
g6607
sg10
I9
sg11
VP24385
p6625
sg13
I2
sasg24
(lp6626
(dp6627
g7
I230
sg8
Vmalignant peripheral nerve sheath tumor
p6628
sg10
I39
sg28
VC0751690
p6629
sg13
I5
sa(dp6630
g7
I199
sg8
Vneurofibromatosis 1
p6631
sg10
I19
sg28
VC0027831
p6632
sg13
I2
sa(dp6633
g7
I302
sg8
Vproliferation
p6634
sg10
I13
sg28
VC0334094
p6635
sg13
I1
sa(dp6636
g7
I271
sg8
g6608
sg10
I5
sg28
VC0751690
p6637
sg13
I1
sasa(dp6638
g135
(dp6639
(VCXCR4 isoforms
p6640
Vneuroblastoma
p6641
tp6642
I00
ssg2
VWestern blot analysis revealed the expression of multiple CXCR4 isoforms in neuroblastoma cells.
p6643
sg4
(lp6644
(dp6645
g7
I58
sg8
g6640
sg10
I14
sg11
VP61073
p6646
sg13
I2
sasg24
(lp6647
(dp6648
g7
I76
sg8
g6641
sg10
I13
sg28
VC0027819
p6649
sg13
I1
sasa(dp6650
g135
(dp6651
(V47 kDa CXCR4 isoform
p6652
Vneuroblastoma
p6653
tp6654
I00
ssg2
VOur data suggest a modulatory role of the MSC secretome on the expression of the 47 kDa CXCR4 isoform and invasion potential of the neuroblastoma cells to the bone marrow.
p6655
sg4
(lp6656
(dp6657
g7
I81
sg8
g6652
sg10
I20
sg11
VP61073
p6658
sg13
I4
sasg24
(lp6659
(dp6660
g7
I132
sg8
g6653
sg10
I13
sg28
VC0027819
p6661
sg13
I1
sa(dp6662
g7
I106
sg8
Vinvasion
p6663
sg10
I8
sg28
VC2699153
p6664
sg13
I1
sasa(dp6665
g135
(dp6666
(VCXC chemokine receptor-4
p6667
Vmetastasis
p6668
tp6669
I00
ssg2
VIn this study, we investigated the role of NF-KB signaling pathway in the regulation of CXC chemokine receptor-4 (CXCR4) in neuroblastoma metastasis.
p6670
sg4
(lp6671
(dp6672
g7
I114
sg8
VCXCR4
p6673
sg10
I5
sg11
VP61073
p6674
sg13
I1
sa(dp6675
g7
I88
sg8
g6667
sg10
I24
sg11
VP61073
p6676
sg13
I3
sasg24
(lp6677
(dp6678
g7
I124
sg8
Vneuroblastoma
p6679
sg10
I13
sg28
VC0027819
p6680
sg13
I1
sa(dp6681
g7
I138
sg8
g6668
sg10
I10
sg28
VC0027627
p6682
sg13
I1
sasa(dp6683
g135
(dp6684
(VCXCR4
p6685
Vneuroblastoma
p6686
tp6687
I00
ssg2
VTargeting NF-KB signalling pathways and ultimately CXCR4 could be a strategy in neuroblastoma therapy.
p6688
sg4
(lp6689
(dp6690
g7
I51
sg8
g6685
sg10
I5
sg11
VP61073
p6691
sg13
I1
sasg24
(lp6692
(dp6693
g7
I80
sg8
g6686
sg10
I13
sg28
VC0027819
p6694
sg13
I1
sasa(dp6695
g135
(dp6696
(Vinterleukin-like
p6697
Vmetastasis
p6698
tp6699
I00
ssg2
VThe FAM3C interleukin-like epithelial-to-mesenchymal-transition (EMT) inducer (ILEI) has been shown to be strongly up-regulated in several cancers and to be essential for tumor formation and metastasis in epithelial cells, correlating with a significant decrease in overall survival in colon and breast cancer patients.
p6700
sg4
(lp6701
(dp6702
g7
I79
sg8
VILEI
p6703
sg10
I4
sg11
g12
sg13
I1
sa(dp6704
g7
I4
sg8
VFAM3C
p6705
sg10
I5
sg11
g12
sg13
I1
sa(dp6706
g7
I10
sg8
g6697
sg10
I16
sg11
VP60568
p6707
sg13
I1
sasg24
(lp6708
(dp6709
g7
I139
sg8
Vcancers
p6710
sg10
I7
sg28
VC0006826
p6711
sg13
I1
sa(dp6712
g7
I296
sg8
Vbreast cancer
p6713
sg10
I13
sg28
VC0678222
p6714
sg13
I2
sa(dp6715
g7
I171
sg8
Vtumor
p6716
sg10
I5
sg28
VC0027651
p6717
sg13
I1
sa(dp6718
g7
I53
sg8
Vtransition
p6719
sg10
I10
sg28
VC0599156
p6720
sg13
I1
sa(dp6721
g7
I191
sg8
g6698
sg10
I10
sg28
VC0027627
p6722
sg13
I1
sasa(dp6723
g135
(dp6724
(VInterleukin-like
p6725
Vtumor progression
p6726
tp6727
I01
ssg2
VInterleukin-like epithelial-to-mesenchymal transition inducer (ILEI) is an essential cytokine in tumor progression that is upregulated in several cancers, and its altered subcellular localization is a predictor of poor survival in human breast cancer.
p6728
sg4
(lp6729
(dp6730
g7
I0
sg8
g6725
sg10
I16
sg11
VP60568
p6731
sg13
I1
sasg24
(lp6732
(dp6733
g7
I237
sg8
Vbreast cancer
p6734
sg10
I13
sg28
VC0678222
p6735
sg13
I2
sa(dp6736
g7
I97
sg8
g6726
sg10
I17
sg28
VC0178874
p6737
sg13
I2
sa(dp6738
g7
I43
sg8
Vtransition
p6739
sg10
I10
sg28
VC0599156
p6740
sg13
I1
sa(dp6741
g7
I146
sg8
Vcancers
p6742
sg10
I7
sg28
VC0006826
p6743
sg13
I1
sasa(dp6744
g2
VMurine mammary tumor and metastasis models of EpC40 and 4T1 cells overexpressing different mutant forms of ILEI were used-extended with in vivo aprotinin treatment for the inhibition of ILEI-processing proteases-to test the in vivo relevance of proteolytic cleavage.
p6745
sg4
(lp6746
(dp6747
g7
I107
sg8
VILEI
p6748
sg10
I4
sg11
g12
sg13
I1
sa(dp6749
g7
I107
sg8
VILEI
p6750
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6751
(dp6752
g7
I25
sg8
Vmetastasis
p6753
sg10
I10
sg28
VC0027627
p6754
sg13
I1
sa(dp6755
g7
I91
sg8
Vmutant
p6756
sg10
I6
sg28
VC0596988
p6757
sg13
I1
sa(dp6758
g7
I7
sg8
Vmammary tumor
p6759
sg10
I13
sg28
VC1458155
p6760
sg13
I2
sasa(dp6761
g2
VImmunohistochemistry for ILEI localization and uPAR expression was performed on two human breast cancer arrays, and ILEI and uPAR scores were correlated with the metastasis-free survival of patients.
p6762
sg4
(lp6763
(dp6764
g7
I25
sg8
VILEI
p6765
sg10
I4
sg11
g12
sg13
I1
sa(dp6766
g7
I25
sg8
VILEI
p6767
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6768
(dp6769
g7
I162
sg8
Vmetastasis
p6770
sg10
I10
sg28
VC0027627
p6771
sg13
I1
sa(dp6772
g7
I90
sg8
Vbreast cancer
p6773
sg10
I13
sg28
VC0678222
p6774
sg13
I2
sasa(dp6775
g2
VMoreover, altered subcellular ILEI localization strongly correlates with high tumor cell-associated uPAR protein expression, as well as with poor survival, in human breast cancer.
p6776
sg4
(lp6777
sg24
(lp6778
(dp6779
g7
I78
sg8
Vtumor
p6780
sg10
I5
sg28
VC0027651
p6781
sg13
I1
sa(dp6782
g7
I165
sg8
Vbreast cancer
p6783
sg10
I13
sg28
VC0678222
p6784
sg13
I2
sasa(dp6785
g135
(dp6786
(Vplasmin
p6787
Vbreast cancer
p6788
tp6789
I00
ssg2
VOur findings point out extracellular serine proteases, in particular plasmin, and uPAR as valuable therapeutic targets against ILEI-driven tumor progression and emphasize the prognostic relevance of ILEI localization and a combined ILEI-uPAR marker analysis in human breast cancer.
p6790
sg4
(lp6791
(dp6792
g7
I127
sg8
VILEI
p6793
sg10
I4
sg11
g12
sg13
I1
sa(dp6794
g7
I23
sg8
Vextracellular serine proteases
p6795
sg10
I30
sg11
VP30740
p6796
sg13
I3
sa(dp6797
g7
I69
sg8
g6787
sg10
I7
sg11
VP00747
p6798
sg13
I1
sa(dp6799
g7
I127
sg8
VILEI
p6800
sg10
I4
sg11
g12
sg13
I1
sa(dp6801
g7
I127
sg8
VILEI
p6802
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6803
(dp6804
g7
I139
sg8
Vtumor progression
p6805
sg10
I17
sg28
VC0178874
p6806
sg13
I2
sa(dp6807
g7
I267
sg8
g6788
sg10
I13
sg28
VC0678222
p6808
sg13
I2
sasa(dp6809
g2
VILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer.
p6810
sg4
(lp6811
(dp6812
g7
I134
sg8
VEMT
p6813
sg10
I3
sg11
g12
sg13
I1
sa(dp6814
g7
I0
sg8
VILEI
p6815
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6816
(dp6817
g7
I139
sg8
Vmetastasis
p6818
sg10
I10
sg28
VC0027627
p6819
sg13
I1
sa(dp6820
g7
I125
sg8
Vinvasion
p6821
sg10
I8
sg28
VC2699153
p6822
sg13
I1
sa(dp6823
g7
I85
sg8
Vtumors
p6824
sg10
I6
sg28
VC0027651
p6825
sg13
I1
sa(dp6826
g7
I193
sg8
Vbreast cancer
p6827
sg10
I13
sg28
VC0678222
p6828
sg13
I2
sasa(dp6829
g135
(dp6830
(Vc-myc gene
p6831
VBL
p6832
tp6833
I00
ssg2
VKeeping in view the fact that molecular basis of Burkitt's lymphoma (BL) is poorly understood, we attempted to explore the small interfering RNA (siRNA) mediated c-myc gene regulation using BL-derived EB-3 cell line as archetype cellular model.
p6834
sg4
(lp6835
(dp6836
g7
I162
sg8
g6831
sg10
I10
sg11
VP12524
p6837
sg13
I2
sasg24
(lp6838
(dp6839
g7
I49
sg8
VBurkitt's lymphoma
p6840
sg10
I18
sg28
VC0006413
p6841
sg13
I2
sa(dp6842
g7
I69
sg8
VBL
p6843
sg10
I2
sg28
VC0006413
p6844
sg13
I1
sa(dp6845
g7
I69
sg8
g6832
sg10
I2
sg28
VC0006413
p6846
sg13
I1
sasa(dp6847
g135
(dp6848
(Vanti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen
p6849
VBurkitt lymphoma
p6850
tp6851
I00
ssg2
VWith other procedures, as anti-complement immunoperoxidase (ACIP) and anti-IgG immunoperoxidase (AIIP) the Epstein-Barr Nuclear Antigen (EBNA) was detected precisely in EB3, Jijoye and Raji lymphocytes using anti-EBNA antibodies from patients with nasopharyngeal carcinoma or Burkitt lymphoma, in dilution 1:10-1:5120.
p6852
sg4
(lp6853
(dp6854
g7
I169
sg8
VEB3
p6855
sg10
I3
sg11
g12
sg13
I1
sa(dp6856
g7
I60
sg8
VACIP
p6857
sg10
I4
sg11
g12
sg13
I1
sa(dp6858
g7
I26
sg8
Vanti-complement immunoperoxidase
p6859
sg10
I32
sg11
g12
sg13
I2
sa(dp6860
g7
I70
sg8
g6849
sg10
I65
sg11
VP14209
p6861
sg13
I7
sasg24
(lp6862
(dp6863
g7
I248
sg8
Vnasopharyngeal carcinoma
p6864
sg10
I24
sg28
VC2931822
p6865
sg13
I2
sa(dp6866
g7
I276
sg8
g6850
sg10
I16
sg28
VC0006413
p6867
sg13
I2
sasa(dp6868
g2
VThe virus in the EB-3 cell line derived from a Burkitt lymphoma was partially purified by digestion with proteolytic enzyme and by density-gradient centrifugation on potassium tartrate.
p6869
sg4
(lp6870
sg24
(lp6871
(dp6872
g7
I47
sg8
VBurkitt lymphoma
p6873
sg10
I16
sg28
VC0006413
p6874
sg13
I2
sasa(dp6875
g2
VThis conjugate proved to be a potent cytotoxin for surface Ig positive Burkitt lymphoma EB-3 cells, growing in vitro and produced 50% inhibition of protein synthesis at level of 1.4 x 10(-9) M. When tested for cytotoxic action on target cells, the composite conjugate molecule was at least 100 times more effective than antibodies alone, ricin A-chain alone or a conjugate ricin A-chain--normal rabbit IgG.
p6876
sg4
(lp6877
(dp6878
g7
I395
sg8
Vrabbit IgG
p6879
sg10
I10
sg11
g12
sg13
I2
sa(dp6880
g7
I338
sg8
Vricin A-chain
p6881
sg10
I13
sg11
g12
sg13
I2
sasg24
(lp6882
(dp6883
g7
I71
sg8
VBurkitt lymphoma
p6884
sg10
I16
sg28
VC0006413
p6885
sg13
I2
sasa(dp6886
g2
VThe interaction of poly- and monoclonal antibodies against the L-chain of human Ig with Burkitt lymphoma EB-3 cells was studied using a fluorescent lipid probe, anthrylvinyl-labelled sphingomyelin, incorporated into the cell plasma membrane.
p6887
sg4
(lp6888
sg24
(lp6889
(dp6890
g7
I88
sg8
VBurkitt lymphoma
p6891
sg10
I16
sg28
VC0006413
p6892
sg13
I2
sasa(dp6893
g2
VThe only gangliosides in Burkitt's lymphoma EB-3 cells is GM3.
p6894
sg4
(lp6895
sg24
(lp6896
(dp6897
g7
I25
sg8
VBurkitt's lymphoma
p6898
sg10
I18
sg28
VC0006413
p6899
sg13
I2
sasa(dp6900
g2
VTreatment of Burkitt's lymphoma EB-3 cells with gangliosides GM1 or GM3 results in their binding to and partial incorporation into the cell membrane.
p6901
sg4
(lp6902
sg24
(lp6903
(dp6904
g7
I13
sg8
VBurkitt's lymphoma
p6905
sg10
I18
sg28
VC0006413
p6906
sg13
I2
sasa(dp6907
g2
VWe sought to investigate the renoprotection of CIRP in a rat model of deep hypothermic circulatory arrest.
p6908
sg4
(lp6909
(dp6910
g7
I47
sg8
VCIRP
p6911
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6912
(dp6913
g7
I87
sg8
Vcirculatory arrest
p6914
sg10
I18
sg28
VC0444720
p6915
sg13
I2
sasa(dp6916
g2
VOverexpression and knockdown of CIRP were achieved in vivo by directly injecting lentivirus vectors containing packaging lentivirus (pL)/internal ribosome entry site (IRES)/green fluorescent protein (GFP)-CIRP or pL/short hairpin RNA (shRNA)/F-cold inducible RNA binding protein (F-CIRP)-A into the renal parenchyma of rats 7 days before deep hypothermic circulatory arrest under the ultrasound guidance.
p6917
sg4
(lp6918
(dp6919
g7
I173
sg8
Vgreen fluorescent protein
p6920
sg10
I25
sg11
g12
sg13
I3
sa(dp6921
g7
I241
sg8
V/F-cold inducible RNA binding protein
p6922
sg10
I37
sg11
g12
sg13
I5
sa(dp6923
g7
I280
sg8
VF-CIRP
p6924
sg10
I6
sg11
g12
sg13
I1
sa(dp6925
g7
I32
sg8
VCIRP
p6926
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6927
(dp6928
g7
I244
sg8
Vcold
p6929
sg10
I4
sg28
VC0024117
p6930
sg13
I1
sa(dp6931
g7
I355
sg8
Vcirculatory arrest
p6932
sg10
I18
sg28
VC0444720
p6933
sg13
I2
sasa(dp6934
g2
VOur findings suggest that the CIRP exerts a robust renoprotective effect by inhibiting apoptosis in the rat model of deep hypothermic circulatory arrest.
p6935
sg4
(lp6936
(dp6937
g7
I30
sg8
VCIRP
p6938
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6939
(dp6940
g7
I134
sg8
Vcirculatory arrest
p6941
sg10
I18
sg28
VC0444720
p6942
sg13
I2
sasa(dp6943
g135
(dp6944
(VCaspase 9
p6945
Vcardiac arrest
p6946
tp6947
I00
ssg2
VCompared with baseline, rats resuscitated from cardiac arrest showed increased expression of CIRP, Bax, Caspase 9, and Caspase 3 and decreased expression of Bcl-2 in hippocampus (P &lt; 0.05).
p6948
sg4
(lp6949
(dp6950
g7
I157
sg8
VBcl-2
p6951
sg10
I5
sg11
VP10415
p6952
sg13
I1
sa(dp6953
g7
I119
sg8
VCaspase 3
p6954
sg10
I9
sg11
VP42574
p6955
sg13
I2
sa(dp6956
g7
I93
sg8
VCIRP
p6957
sg10
I4
sg11
g12
sg13
I1
sa(dp6958
g7
I104
sg8
g6945
sg10
I9
sg11
VP55211
p6959
sg13
I2
sasg24
(lp6960
(dp6961
g7
I47
sg8
g6946
sg10
I14
sg28
VC0018790
p6962
sg13
I2
sasa(dp6963
g2
VOur findings suggest that 32 C therapeutic hypothermia exerts an important neuroprotective effects by up-regulating CIRP expression and inhibiting mitochondrial apoptosis factor production in the cardiac arrest rat model.
p6964
sg4
(lp6965
(dp6966
g7
I116
sg8
VCIRP
p6967
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp6968
(dp6969
g7
I196
sg8
Vcardiac arrest
p6970
sg10
I14
sg28
VC0018790
p6971
sg13
I2
sasa(dp6972
g135
(dp6973
(VIGFBP3
p6974
VAspiration
p6975
tp6976
I00
ssg2
VA previously reported expression signature of three genes (IGFBP3, F3 and VGLL3) was shown to have potential prognostic value in estimating overall and cancer-specific survivals at diagnosis of prostate cancer in a pilot cohort study using freshly frozen Fine Needle Aspiration (FNA) samples.
p6977
sg4
(lp6978
(dp6979
g7
I74
sg8
VVGLL3
p6980
sg10
I5
sg11
g12
sg13
I1
sa(dp6981
g7
I59
sg8
g6974
sg10
I6
sg11
VP17936
p6982
sg13
I1
sasg24
(lp6983
(dp6984
g7
I194
sg8
Vprostate cancer
p6985
sg10
I15
sg28
VC0600139
p6986
sg13
I2
sa(dp6987
g7
I267
sg8
g6975
sg10
I10
sg28
VC0700198
p6988
sg13
I1
sa(dp6989
g7
I152
sg8
Vcancer
p6990
sg10
I6
sg28
VC0006826
p6991
sg13
I1
sasa(dp6992
g135
(dp6993
(VIGFBP3
p6994
Vprostate cancer
p6995
tp6996
I00
ssg2
VMultiple biopsy samples from 43 patients were evaluated using a previously reported gene signature of IGFBP3, F3 and VGLL3 with potential prognostic value in estimating overall survival at diagnosis of prostate cancer.
p6997
sg4
(lp6998
(dp6999
g7
I117
sg8
VVGLL3
p7000
sg10
I5
sg11
g12
sg13
I1
sa(dp7001
g7
I102
sg8
g6994
sg10
I6
sg11
VP17936
p7002
sg13
I1
sasg24
(lp7003
(dp7004
g7
I202
sg8
g6995
sg10
I15
sg28
VC0600139
p7005
sg13
I2
sasa(dp7006
g135
(dp7007
(VIGFBP3
p7008
Vprostate cancer
p7009
tp7010
I00
ssg2
VThe gene expression levels of IGFBP3 and F3 in prostate cancer epithelial cell-containing tissue representing the primary and secondary Gleason patterns were high and consistent, while the low expressed VGLL3 showed more variation in its expression levels.
p7011
sg4
(lp7012
(dp7013
g7
I203
sg8
VVGLL3
p7014
sg10
I5
sg11
g12
sg13
I1
sa(dp7015
g7
I30
sg8
g7008
sg10
I6
sg11
VP17936
p7016
sg13
I1
sasg24
(lp7017
(dp7018
g7
I47
sg8
g7009
sg10
I15
sg28
VC0600139
p7019
sg13
I2
sasa(dp7020
g135
(dp7021
(Vtumor suppressor gene
p7022
Vovarian carcinomas
p7023
tp7024
I00
ssg2
VPrevious studies have implicated vestigial like 3 (VGLL3), a chromosome 3p12.3 gene that encodes a putative transcription co-factor, as a candidate tumor suppressor gene (TSG) in high-grade serous ovarian carcinomas (HGSC), the most common type of epithelial ovarian cancer.
p7025
sg4
(lp7026
(dp7027
g7
I171
sg8
VTSG
p7028
sg10
I3
sg11
g12
sg13
I1
sa(dp7029
g7
I33
sg8
Vvestigial like 3
p7030
sg10
I16
sg11
g12
sg13
I3
sa(dp7031
g7
I148
sg8
g7022
sg10
I21
sg11
VP25054
p7032
sg13
I3
sa(dp7033
g7
I51
sg8
VVGLL3
p7034
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7035
(dp7036
g7
I248
sg8
Vepithelial ovarian cancer
p7037
sg10
I25
sg28
VC0677886
p7038
sg13
I3
sa(dp7039
g7
I148
sg8
Vtumor
p7040
sg10
I5
sg28
VC0027651
p7041
sg13
I1
sa(dp7042
g7
I197
sg8
g7023
sg10
I18
sg28
VC0029925
p7043
sg13
I2
sasa(dp7044
g2
VA complementation analysis based on microcell-mediated chromosome transfer (MMCT) using a centric fragment of chromosome 3 (der3p12-q12.1) into the OV-90 ovarian cancer cell line haploinsufficient for 3p and lacking VGLL3 expression was performed to assess the effect on tumorigenic potential and growth characteristics.
p7045
sg4
(lp7046
(dp7047
g7
I216
sg8
VVGLL3
p7048
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7049
(dp7050
g7
I154
sg8
Vovarian cancer
p7051
sg10
I14
sg28
VC1140680
p7052
sg13
I2
sasa(dp7053
g2
VInterestingly, underexpression of VGLL3 and ZNF654 were observed in malignant ovarian tumor samples as compared with primary cultures of normal ovarian surface epithelial cells or benign ovarian tumors, and this occurred regardless of allelic content of 3p12.3-pcen.
p7054
sg4
(lp7055
(dp7056
g7
I44
sg8
VZNF654
p7057
sg10
I6
sg11
g12
sg13
I1
sa(dp7058
g7
I34
sg8
VVGLL3
p7059
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7060
(dp7061
g7
I68
sg8
Vmalignant ovarian tumor
p7062
sg10
I23
sg28
VC1140680
p7063
sg13
I3
sa(dp7064
g7
I180
sg8
Vbenign ovarian tumors
p7065
sg10
I21
sg28
VC0004997
p7066
sg13
I3
sasa(dp7067
g135
(dp7068
(VMEK
p7069
Vbreast carcinoma
p7070
tp7071
I00
ssg2
VWe tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers.
p7072
sg4
(lp7073
(dp7074
g7
I90
sg8
VHDAC
p7075
sg10
I4
sg11
VP56524
p7076
sg13
I1
sa(dp7077
g7
I29
sg8
g7069
sg10
I3
sg11
VP45985
p7078
sg13
I1
sa(dp7079
g7
I56
sg8
VAkt
p7080
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp7081
(dp7082
g7
I206
sg8
Vgastric carcinoma
p7083
sg10
I17
sg28
VC0699791
p7084
sg13
I2
sa(dp7085
g7
I187
sg8
Vhepatic carcinoma
p7086
sg10
I17
sg28
VC2239176
p7087
sg13
I2
sa(dp7088
g7
I146
sg8
Vcancer
p7089
sg10
I6
sg28
VC0006826
p7090
sg13
I1
sa(dp7091
g7
I225
sg8
Vcolon carcinoma
p7092
sg10
I15
sg28
VC0699790
p7093
sg13
I2
sa(dp7094
g7
I177
sg8
Vmelanoma
p7095
sg10
I8
sg28
VC0025202
p7096
sg13
I1
sa(dp7097
g7
I264
sg8
Vbrain cancers
p7098
sg10
I13
sg28
VC0153633
p7099
sg13
I2
sa(dp7100
g7
I242
sg8
g7070
sg10
I16
sg28
VC0678222
p7101
sg13
I2
sasa(dp7102
g2
VHere, we report that escape of human T-cell acute lymphoblastic leukemia (T-ALL) cells or colorectal cancer cells from dormancy is associated with Dll4 expression in the tumor microenvironment and increased Notch3 signaling in tumor cells.
p7103
sg4
(lp7104
(dp7105
g7
I207
sg8
VNotch3
p7106
sg10
I6
sg11
g12
sg13
I1
sa(dp7107
g7
I147
sg8
VDll4
p7108
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp7109
(dp7110
g7
I170
sg8
Vtumor
p7111
sg10
I5
sg28
VC0027651
p7112
sg13
I1
sa(dp7113
g7
I37
sg8
VT-cell acute lymphoblastic leukemia
p7114
sg10
I35
sg28
VC1961099
p7115
sg13
I4
sa(dp7116
g7
I170
sg8
Vtumor
p7117
sg10
I5
sg28
VC0027651
p7118
sg13
I1
sa(dp7119
g7
I90
sg8
Vcolorectal cancer
p7120
sg10
I17
sg28
VC1527249
p7121
sg13
I2
sa(dp7122
g7
I74
sg8
VT-ALL
p7123
sg10
I5
sg28
VC1961099
p7124
sg13
I1
sasa(dp7125
g135
(dp7126
(VAPOBEC1
p7127
VBarrett's esophagus
p7128
tp7129
I01
ssg2
VAPOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.
p7130
sg4
(lp7131
(dp7132
g7
I0
sg8
g7127
sg10
I7
sg11
VP41238
p7133
sg13
I1
sasg24
(lp7134
(dp7135
g7
I142
sg8
Vcondition
p7136
sg10
I9
sg28
VC0012634
p7137
sg13
I1
sa(dp7138
g7
I74
sg8
Vcarcinogenesis
p7139
sg10
I14
sg28
VC0596263
p7140
sg13
I1
sa(dp7141
g7
I29
sg8
Vcancer
p7142
sg10
I6
sg28
VC0006826
p7143
sg13
I1
sa(dp7144
g7
I174
sg8
Vesophageal adenocarcinoma
p7145
sg10
I25
sg28
VC0279628
p7146
sg13
I2
sa(dp7147
g7
I119
sg8
g7128
sg10
I19
sg28
VC0004763
p7148
sg13
I2
sasa(dp7149
g2
VThe differential diagnosis includes Klippel-Trenaunay-Weber syndrome, neurofibromatosis, Milroy disease, and Proteus syndrome.
p7150
sg4
(lp7151
sg24
(lp7152
(dp7153
g7
I109
sg8
VProteus syndrome
p7154
sg10
I16
sg28
VC0085261
p7155
sg13
I2
sa(dp7156
g7
I60
sg8
Vsyndrome, neurofibromatosis
p7157
sg10
I27
sg28
VC0162678
p7158
sg13
I2
sa(dp7159
g7
I89
sg8
VMilroy disease
p7160
sg10
I14
sg28
VC1704423
p7161
sg13
I2
sa(dp7162
g7
I36
sg8
VKlippel-Trenaunay-Weber syndrome
p7163
sg10
I32
sg28
VC0022739
p7164
sg13
I2
sasa(dp7165
g2
VNotably, new experimental data have shown protective immune responses of bee venom group III sPLA2 against a wide range of diseases including asthma, Parkinson's disease, and drug-induced organ inflammation.
p7166
sg4
(lp7167
sg24
(lp7168
(dp7169
g7
I194
sg8
Vinflammation
p7170
sg10
I12
sg28
VC0021368
p7171
sg13
I1
sa(dp7172
g7
I142
sg8
Vasthma
p7173
sg10
I6
sg28
VC0004096
p7174
sg13
I1
sa(dp7175
g7
I150
sg8
VParkinson's disease
p7176
sg10
I19
sg28
VC0030567
p7177
sg13
I2
sasa(dp7178
g135
(dp7179
(VPLA2s
p7180
Vhemorrhage
p7181
tp7182
I00
ssg2
VSnake venom are known containing PLA2s (svPLA2s) which exhibit a wide variety of pharmacological effects including neurotoxicity, cardiotoxicity, myotoxicity and hemorrhage.
p7183
sg4
(lp7184
(dp7185
g7
I33
sg8
g7180
sg10
I5
sg11
VP04054
p7186
sg13
I1
sasg24
(lp7187
(dp7188
g7
I162
sg8
g7181
sg10
I10
sg28
VC0019080
p7189
sg13
I1
sasa(dp7190
g135
(dp7191
(VsPLA2
p7192
Vrelapsing remitting multiple sclerosis
p7193
tp7194
I00
ssg2
VThis study was aimed to assess regulation of surface-membrane enzymes such as Delta-6-desaturase (FADS2), secretory Phospholipase A2(sPLA2) by hemp seed and evening primrose oils as well as Hot-natured dietary intervention in relapsing remitting multiple sclerosis (RRMS) patients.
p7195
sg4
(lp7196
(dp7197
g7
I78
sg8
VDelta-6-desaturase
p7198
sg10
I18
sg11
g12
sg13
I1
sa(dp7199
g7
I116
sg8
VPhospholipase A2
p7200
sg10
I16
sg11
VP04054
p7201
sg13
I2
sa(dp7202
g7
I133
sg8
g7192
sg10
I5
sg11
VP14555
p7203
sg13
I1
sa(dp7204
g7
I98
sg8
VFADS2
p7205
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7206
(dp7207
g7
I266
sg8
VRRMS
p7208
sg10
I4
sg28
VC0751967
p7209
sg13
I1
sa(dp7210
g7
I226
sg8
g7193
sg10
I38
sg28
VC0751967
p7211
sg13
I4
sasa(dp7212
g135
(dp7213
(VPLA2s
p7214
Vedema
p7215
tp7216
I00
ssg2
VPhospholipases A2 (PLA2s) are enzymes responsible for inflammatory effects, edema formation, myotoxicity, neurotoxicity and other manifestations from envenoming.
p7217
sg4
(lp7218
(dp7219
g7
I0
sg8
VPhospholipases A2
p7220
sg10
I17
sg11
VP04054
p7221
sg13
I2
sa(dp7222
g7
I19
sg8
g7214
sg10
I5
sg11
VP04054
p7223
sg13
I1
sasg24
(lp7224
(dp7225
g7
I76
sg8
g7215
sg10
I5
sg28
VC0013604
p7226
sg13
I1
sasa(dp7227
g2
VDefects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.
p7228
sg4
(lp7229
(dp7230
g7
I30
sg8
Vintegrin-binding protein 2
p7231
sg10
I26
sg11
g12
sg13
I3
sa(dp7232
g7
I11
sg8
VCIB2
p7233
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp7234
(dp7235
g7
I116
sg8
VUsher syndrome
p7236
sg10
I14
sg28
VC0271097
p7237
sg13
I2
sa(dp7238
g7
I207
sg8
Vblindness
p7239
sg10
I9
sg28
VC0456909
p7240
sg13
I1
sa(dp7241
g7
I95
sg8
Vdeafness
p7242
sg10
I8
sg28
VC0011053
p7243
sg13
I1
sa(dp7244
g7
I105
sg8
VDFNB48
p7245
sg10
I6
sg28
VC1836199
p7246
sg13
I1
sa(dp7247
g7
I95
sg8
Vdeafness
p7248
sg10
I8
sg28
VC0011053
p7249
sg13
I1
sasa(dp7250
g2
VHere, we report that mutations in CIB2, which encodes a calcium- and integrin-binding protein, are associated with nonsyndromic deafness (DFNB48) and Usher syndrome type 1J (USH1J).
p7251
sg4
(lp7252
(dp7253
g7
I34
sg8
VCIB2
p7254
sg10
I4
sg11
g12
sg13
I1
sa(dp7255
g7
I69
sg8
Vintegrin-binding protein
p7256
sg10
I24
sg11
g12
sg13
I2
sasg24
(lp7257
(dp7258
g7
I150
sg8
VUsher syndrome
p7259
sg10
I14
sg28
VC0271097
p7260
sg13
I2
sa(dp7261
g7
I138
sg8
VDFNB48
p7262
sg10
I6
sg28
VC1836199
p7263
sg13
I1
sa(dp7264
g7
I128
sg8
Vdeafness
p7265
sg10
I8
sg28
VC0011053
p7266
sg13
I1
sasa(dp7267
g2
VIn polymyositis and inclusion body myositis, KIF4 cells were mainly located around individual muscle fibers, whereas in dermatomyositis, they were also near blood vessels.
p7268
sg4
(lp7269
(dp7270
g7
I45
sg8
VKIF4
p7271
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp7272
(dp7273
g7
I3
sg8
Vpolymyositis
p7274
sg10
I12
sg28
VC0085655
p7275
sg13
I1
sa(dp7276
g7
I120
sg8
Vdermatomyositis
p7277
sg10
I15
sg28
VC0221056
p7278
sg13
I1
sa(dp7279
g7
I20
sg8
Vinclusion body myositis
p7280
sg10
I23
sg28
VC0238190
p7281
sg13
I3
sasa(dp7282
g135
(dp7283
(VCD9
p7284
Vadhesion
p7285
tp7286
I00
ssg2
VCD9 expression obviously increased bortezomib sensitivity through inducing apoptosis, significantly inhibiting U266 cells' adhesion to HS-5 and primary bone marrow stromal cells, but increasing U266 cells' adhesion to fibronectin.
p7287
sg4
(lp7288
(dp7289
g7
I0
sg8
g7284
sg10
I3
sg11
VP21926
p7290
sg13
I1
sasg24
(lp7291
(dp7292
g7
I123
sg8
Vadhesion
p7293
sg10
I8
sg28
VC0001511
p7294
sg13
I1
sa(dp7295
g7
I123
sg8
g7285
sg10
I8
sg28
VC0001511
p7296
sg13
I1
sasa(dp7297
g135
(dp7298
(VCD28
p7299
VPCA
p7300
tp7301
I00
ssg2
VThe immunoprofiles of MOLP-6 and MOLP-7 correspond to that seen typically in primary MM cells: positive for cytoplasmic immunoglobulin (Ig) chains, a heavy and kappa light chains, CD9, CD28, CD40, CD44, CD45, CD56, and PCA-1; the cells were negative for surface Igs and various other B-cell, T-cell and myelomonocyte associated markers.
p7302
sg4
(lp7303
(dp7304
g7
I203
sg8
VCD45
p7305
sg10
I4
sg11
VP08575
p7306
sg13
I1
sa(dp7307
g7
I219
sg8
VPCA-1
p7308
sg10
I5
sg11
g12
sg13
I1
sa(dp7309
g7
I180
sg8
VCD9
p7310
sg10
I3
sg11
VP21926
p7311
sg13
I1
sa(dp7312
g7
I191
sg8
VCD40
p7313
sg10
I4
sg11
VP25942
p7314
sg13
I1
sa(dp7315
g7
I150
sg8
Vheavy and kappa light chains
p7316
sg10
I28
sg11
g12
sg13
I5
sa(dp7317
g7
I185
sg8
g7299
sg10
I4
sg11
VP33681
p7318
sg13
I1
sa(dp7319
g7
I262
sg8
VIgs
p7320
sg10
I3
sg11
g12
sg13
I1
sa(dp7321
g7
I108
sg8
Vcytoplasmic immunoglobulin (Ig) chains
p7322
sg10
I38
sg11
g12
sg13
I4
sasg24
(lp7323
(dp7324
g7
I262
sg8
VIgs
p7325
sg10
I3
sg28
VC1306856
p7326
sg13
I1
sa(dp7327
g7
I219
sg8
g7300
sg10
I3
sg28
VC0268398
p7328
sg13
I1
sasa(dp7329
g135
(dp7330
(VCD14
p7331
Vanemia
p7332
tp7333
I00
ssg2
VThe univariate analysis showed that five parameters had an adverse effect on both complete remission (CR) and survival: advanced age (greater than 60 years), anemia (hemoglobin concentration (Hb) less than 10g/dl), the expression of the antigens detected by the anti-megakaryocytic antibodies (CDw41/CDw42), the monocytic antibodies (CD14), and the CD9 (FMC56, FMC8) antigen.
p7334
sg4
(lp7335
(dp7336
g7
I166
sg8
Vhemoglobin
p7337
sg10
I10
sg11
g12
sg13
I1
sa(dp7338
g7
I349
sg8
VCD9
p7339
sg10
I3
sg11
VP21926
p7340
sg13
I1
sa(dp7341
g7
I334
sg8
g7331
sg10
I4
sg11
VP08571
p7342
sg13
I1
sasg24
(lp7343
(dp7344
g7
I59
sg8
Vadverse effect
p7345
sg10
I14
sg28
VC0879626
p7346
sg13
I2
sa(dp7347
g7
I158
sg8
g7332
sg10
I6
sg28
VC0002871
p7348
sg13
I1
sa(dp7349
g7
I91
sg8
Vremission
p7350
sg10
I9
sg28
VC0687702
p7351
sg13
I1
sasa(dp7352
g135
(dp7353
(VVIP
p7354
Vgynaecomastia
p7355
tp7356
I00
ssg2
VIn this review, we consider the following paraneoplastic hormonal syndromes: malign hypercalcaemia, hyponatraemia (inappropiate secretion of the antidiuretic hormone), ectopic Cushing's syndrome, ectopic acromegaly, hypoglycaemia due to tumours different from those of the islet cells and paraneoplastic gynaecomastia; we make a brief final reference to other hormones (calcitonin, somatostatin, and VIP).
p7357
sg4
(lp7358
(dp7359
g7
I382
sg8
Vsomatostatin
p7360
sg10
I12
sg11
VP61278
p7361
sg13
I1
sa(dp7362
g7
I370
sg8
Vcalcitonin
p7363
sg10
I10
sg11
VP06881
p7364
sg13
I1
sa(dp7365
g7
I400
sg8
g7354
sg10
I3
sg11
VP01282
p7366
sg13
I1
sasg24
(lp7367
(dp7368
g7
I216
sg8
Vhypoglycaemia
p7369
sg10
I13
sg28
VC0020615
p7370
sg13
I1
sa(dp7371
g7
I176
sg8
VCushing's syndrome
p7372
sg10
I18
sg28
VC0010481
p7373
sg13
I2
sa(dp7374
g7
I204
sg8
Vacromegaly
p7375
sg10
I10
sg28
VC0001206
p7376
sg13
I1
sa(dp7377
g7
I84
sg8
Vhypercalcaemia
p7378
sg10
I14
sg28
VC0020437
p7379
sg13
I1
sa(dp7380
g7
I66
sg8
Vsyndromes
p7381
sg10
I9
sg28
VC0039082
p7382
sg13
I1
sa(dp7383
g7
I237
sg8
Vtumours
p7384
sg10
I7
sg28
VC0027651
p7385
sg13
I1
sa(dp7386
g7
I304
sg8
g7355
sg10
I13
sg28
VC0018418
p7387
sg13
I1
sasa(dp7388
g135
(dp7389
(VSPG2
p7390
VSPG12
p7391
tp7392
I00
ssg2
VProtrudin was found to interact with other HSP-related proteins including myelin proteolipid protein 1 (SPG2), atlastin-1 (SPG3A), REEP1 (SPG31), REEP5 (similar to REEP1), Kif5A (SPG10), Kif5B, Kif5C, and reticulon 1, 3, and 4 (similar to reticulon 2, SPG12).
p7393
sg4
(lp7394
(dp7395
g7
I138
sg8
VSPG31
p7396
sg10
I5
sg11
g12
sg13
I1
sa(dp7397
g7
I187
sg8
VKif5B
p7398
sg10
I5
sg11
VP33176
p7399
sg13
I1
sa(dp7400
g7
I146
sg8
VREEP5
p7401
sg10
I5
sg11
g12
sg13
I1
sa(dp7402
g7
I111
sg8
Vatlastin-1
p7403
sg10
I10
sg11
g12
sg13
I1
sa(dp7404
g7
I74
sg8
Vmyelin proteolipid protein 1
p7405
sg10
I28
sg11
VP60201
p7406
sg13
I4
sa(dp7407
g7
I43
sg8
VHSP-related proteins
p7408
sg10
I20
sg11
g12
sg13
I2
sa(dp7409
g7
I131
sg8
VREEP1
p7410
sg10
I5
sg11
g12
sg13
I1
sa(dp7411
g7
I179
sg8
VSPG10
p7412
sg10
I5
sg11
g12
sg13
I1
sa(dp7413
g7
I172
sg8
VKif5A
p7414
sg10
I5
sg11
g12
sg13
I1
sa(dp7415
g7
I123
sg8
VSPG3A
p7416
sg10
I5
sg11
g12
sg13
I1
sa(dp7417
g7
I131
sg8
VREEP1
p7418
sg10
I5
sg11
g12
sg13
I1
sa(dp7419
g7
I194
sg8
VKif5C
p7420
sg10
I5
sg11
g12
sg13
I1
sa(dp7421
g7
I104
sg8
g7390
sg10
I4
sg11
VP60201
p7422
sg13
I1
sasg24
(lp7423
(dp7424
g7
I138
sg8
VSPG31
p7425
sg10
I5
sg28
VC1853247
p7426
sg13
I1
sa(dp7427
g7
I179
sg8
VSPG10
p7428
sg10
I5
sg28
VC1858712
p7429
sg13
I1
sa(dp7430
g7
I123
sg8
VSPG3A
p7431
sg10
I5
sg28
VC2931355
p7432
sg13
I1
sa(dp7433
g7
I104
sg8
VSPG2
p7434
sg10
I4
sg28
VC1839264
p7435
sg13
I1
sa(dp7436
g7
I43
sg8
VHSP
p7437
sg10
I3
sg28
VC0034152
p7438
sg13
I1
sa(dp7439
g7
I252
sg8
g7391
sg10
I5
sg28
VC1858106
p7440
sg13
I1
sasa(dp7441
g2
VDownregulation of ACE2 is always associated with the ALI or ARDS induced by avian influenza virus, severe acute respiratory syndrome-coronavirus, respiratory syncytial virus and sepsis.
p7442
sg4
(lp7443
(dp7444
g7
I18
sg8
VACE2
p7445
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp7446
(dp7447
g7
I178
sg8
Vsepsis
p7448
sg10
I6
sg28
VC0243026
p7449
sg13
I1
sa(dp7450
g7
I60
sg8
VARDS
p7451
sg10
I4
sg28
VC0035222
p7452
sg13
I1
sa(dp7453
g7
I99
sg8
Vsevere acute respiratory syndrome
p7454
sg10
I33
sg28
VC1175175
p7455
sg13
I4
sa(dp7456
g7
I76
sg8
Vavian influenza
p7457
sg10
I15
sg28
VC0016627
p7458
sg13
I2
sasa(dp7459
g2
VA virus infection assay showed that rWIV1-DeltaX replicated as efficiently as rWIV1 in Vero E6, Calu-3, and HeLa-hACE2 cells.
p7460
sg4
(lp7461
(dp7462
g7
I96
sg8
VCalu-3
p7463
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp7464
(dp7465
g7
I2
sg8
Vvirus infection
p7466
sg10
I15
sg28
VC0042769
p7467
sg13
I2
sasa(dp7468
g2
VResults show that 106 cases of tetanus occurred in Aceh, with a case fatality ratio (CFR) of 18.9%; 71 cases occurred in Yogyakarta, with CFR of 36.6%.
p7469
sg4
(lp7470
sg24
(lp7471
(dp7472
g7
I31
sg8
Vtetanus
p7473
sg10
I7
sg28
VC0039614
p7474
sg13
I1
sasa(dp7475
g2
VTreatment of (DR-BB x WF)F1 x WF animals (all lyp+/+) using a standard induction protocol caused type 1 diabetes in 58% of progeny.
p7476
sg4
(lp7477
sg24
(lp7478
(dp7479
g7
I97
sg8
Vtype 1 diabetes
p7480
sg10
I15
sg28
VC0011854
p7481
sg13
I3
sasa(dp7482
g2
VAll genetic analyses of BB rat diabetes to date have backcrossed to the DP-BB strain or used (DP-BB x non-BB)F2 animals to ensure that a fraction of progeny are homozygous for lyp.
p7483
sg4
(lp7484
(dp7485
g7
I176
sg8
Vlyp
p7486
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp7487
(dp7488
g7
I31
sg8
Vdiabetes
p7489
sg10
I8
sg28
VC0011849
p7490
sg13
I1
sa(dp7491
g7
I176
sg8
Vlyp
p7492
sg10
I3
sg28
VC1868674
p7493
sg13
I1
sasa(dp7494
g135
(dp7495
(VIddm2
p7496
VIddm2
p7497
tp7498
I00
ssg2
VSince, type 1 diabetes is characterised by hyperglycaemia we analysed 22 diabetic and 43 non-diabetic [(BB x SHR)FI x BB] backcross hybrids (28M:37F) which were already homozygous for Iddml and Iddm2 to search for quantitative trait loci (QTLs) affecting blood glucose in BB/OK rats.
p7499
sg4
(lp7500
(dp7501
g7
I194
sg8
g7496
sg10
I5
sg11
VP01308
p7502
sg13
I1
sasg24
(lp7503
(dp7504
g7
I43
sg8
Vhyperglycaemia
p7505
sg10
I14
sg28
VC0020456
p7506
sg13
I1
sa(dp7507
g7
I7
sg8
Vtype 1 diabetes
p7508
sg10
I15
sg28
VC0011854
p7509
sg13
I3
sa(dp7510
g7
I194
sg8
g7497
sg10
I5
sg28
VC1852092
p7511
sg13
I1
sasa(dp7512
g2
VThis prompted us to investigate the inheritance of IDDM in two subpopulations of BB rats (BB/OK and BB/PhiK) by crossing studies with the production of (diabetic BB x LEW 1.A) F1, F2 generations and of first backcross hybrids onto BB (B1BB) and LEW.1A (B1A) rats respectively.
p7513
sg4
(lp7514
sg24
(lp7515
(dp7516
g7
I51
sg8
VIDDM
p7517
sg10
I4
sg28
VC0011854
p7518
sg13
I1
sasa(dp7519
g135
(dp7520
(VTUBB4
p7521
Vdystonia type 4
p7522
tp7523
I00
ssg2
VLRRK2 selectively interacts with three Beta-tubulin isoforms: TUBB, TUBB4, and TUBB6, one of which (TUBB4) is mutated in the movement disorder dystonia type 4 (DYT4).
p7524
sg4
(lp7525
(dp7526
g7
I79
sg8
VTUBB6
p7527
sg10
I5
sg11
g12
sg13
I1
sa(dp7528
g7
I0
sg8
VLRRK2
p7529
sg10
I5
sg11
g12
sg13
I1
sa(dp7530
g7
I39
sg8
VBeta-tubulin isoforms
p7531
sg10
I21
sg11
VP68371
p7532
sg13
I2
sa(dp7533
g7
I68
sg8
VTUBB4
p7534
sg10
I5
sg11
VP04350
p7535
sg13
I1
sa(dp7536
g7
I62
sg8
VTUBB
p7537
sg10
I4
sg11
VP04350
p7538
sg13
I1
sa(dp7539
g7
I68
sg8
g7521
sg10
I5
sg11
VP04350
p7540
sg13
I1
sasg24
(lp7541
(dp7542
g7
I125
sg8
Vmovement disorder
p7543
sg10
I17
sg28
VC0026650
p7544
sg13
I2
sa(dp7545
g7
I160
sg8
VDYT4
p7546
sg10
I4
sg28
VC1851943
p7547
sg13
I1
sa(dp7548
g7
I143
sg8
g7522
sg10
I15
sg28
VC1851943
p7549
sg13
I3
sasa(dp7550
g135
(dp7551
(VETV5
p7552
Vobesity
p7553
tp7554
I00
ssg2
VIn this study, we aimed to analyze pairwise interactions that are associated with Body Mass Index (BMI) between SNPs from twelve genes robustly associated with obesity (BDNF, ETV5, FAIM2, FTO, GNPDA2, KCTD15, MC4R, MTCH2, NEGR1, SEC16B, SH2B1, and TMEM18).
p7555
sg4
(lp7556
(dp7557
g7
I209
sg8
VMC4R
p7558
sg10
I4
sg11
VP32245
p7559
sg13
I1
sa(dp7560
g7
I188
sg8
VFTO
p7561
sg10
I3
sg11
g12
sg13
I1
sa(dp7562
g7
I222
sg8
VNEGR1
p7563
sg10
I5
sg11
g12
sg13
I1
sa(dp7564
g7
I175
sg8
g7552
sg10
I4
sg11
VP41161
p7565
sg13
I1
sa(dp7566
g7
I229
sg8
VSEC16B
p7567
sg10
I6
sg11
g12
sg13
I1
sa(dp7568
g7
I181
sg8
VFAIM2
p7569
sg10
I5
sg11
g12
sg13
I1
sa(dp7570
g7
I193
sg8
VGNPDA2
p7571
sg10
I6
sg11
g12
sg13
I1
sa(dp7572
g7
I237
sg8
VSH2B1
p7573
sg10
I5
sg11
g12
sg13
I1
sa(dp7574
g7
I248
sg8
VTMEM18
p7575
sg10
I6
sg11
g12
sg13
I1
sa(dp7576
g7
I201
sg8
VKCTD15
p7577
sg10
I6
sg11
g12
sg13
I1
sa(dp7578
g7
I215
sg8
VMTCH2
p7579
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7580
(dp7581
g7
I160
sg8
g7553
sg10
I7
sg28
VC0028754
p7582
sg13
I1
sasa(dp7583
g135
(dp7584
(VADCY3
p7585
Vchildhood obesity
p7586
tp7587
I00
ssg2
VIn total, 15 loci reached genome-wide significance (P-value &lt; 5 x 10(-8)) in the joint discovery and replication analysis, of which 12 are previously identified loci in or close to ADCY3, GNPDA2, TMEM18, SEC16B, FAIM2, FTO, TFAP2B, TNNI3K, MC4R, GPR61, LMX1B and OLFM4 associated with adult body mass index or childhood obesity.
p7588
sg4
(lp7589
(dp7590
g7
I256
sg8
VLMX1B
p7591
sg10
I5
sg11
g12
sg13
I1
sa(dp7592
g7
I222
sg8
VFTO
p7593
sg10
I3
sg11
g12
sg13
I1
sa(dp7594
g7
I199
sg8
VTMEM18
p7595
sg10
I6
sg11
g12
sg13
I1
sa(dp7596
g7
I215
sg8
VFAIM2
p7597
sg10
I5
sg11
g12
sg13
I1
sa(dp7598
g7
I266
sg8
VOLFM4
p7599
sg10
I5
sg11
g12
sg13
I1
sa(dp7600
g7
I227
sg8
VTFAP2B
p7601
sg10
I6
sg11
g12
sg13
I1
sa(dp7602
g7
I243
sg8
VMC4R
p7603
sg10
I4
sg11
VP32245
p7604
sg13
I1
sa(dp7605
g7
I191
sg8
VGNPDA2
p7606
sg10
I6
sg11
g12
sg13
I1
sa(dp7607
g7
I207
sg8
VSEC16B
p7608
sg10
I6
sg11
g12
sg13
I1
sa(dp7609
g7
I184
sg8
g7585
sg10
I5
sg11
VP40145
p7610
sg13
I1
sa(dp7611
g7
I249
sg8
VGPR61
p7612
sg10
I5
sg11
g12
sg13
I1
sa(dp7613
g7
I235
sg8
VTNNI3K
p7614
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp7615
(dp7616
g7
I313
sg8
g7586
sg10
I17
sg28
VC2362324
p7617
sg13
I2
sasa(dp7618
g2
VAn obesity-related gene, Fas apoptotic inhibitory molecule 2 (FAIM2), is regulated by nutritional state and the methylation levels of the FAIM2 promoter are significantly associated with obesity.
p7619
sg4
(lp7620
(dp7621
g7
I25
sg8
VFas apoptotic inhibitory molecule 2
p7622
sg10
I35
sg11
g12
sg13
I5
sa(dp7623
g7
I138
sg8
VFAIM2 promoter
p7624
sg10
I14
sg11
g12
sg13
I2
sa(dp7625
g7
I62
sg8
VFAIM2
p7626
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7627
(dp7628
g7
I3
sg8
Vobesity
p7629
sg10
I7
sg28
VC0028754
p7630
sg13
I1
sa(dp7631
g7
I3
sg8
Vobesity
p7632
sg10
I7
sg28
VC0028754
p7633
sg13
I1
sa(dp7634
g7
I25
sg8
VFas
p7635
sg10
I3
sg28
VC0015923
p7636
sg13
I1
sasa(dp7637
g2
VWhether the molecular mechanisms by which FAIM2 affects obesity are involved in lifestyle is unclear.
p7638
sg4
(lp7639
(dp7640
g7
I42
sg8
VFAIM2
p7641
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7642
(dp7643
g7
I56
sg8
Vobesity
p7644
sg10
I7
sg28
VC0028754
p7645
sg13
I1
sasa(dp7646
g2
VOur results suggest that lifestyle may possibly be mediating the process of the FAIM2 involved in obesity.
p7647
sg4
(lp7648
(dp7649
g7
I80
sg8
VFAIM2
p7650
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp7651
(dp7652
g7
I98
sg8
Vobesity
p7653
sg10
I7
sg28
VC0028754
p7654
sg13
I1
sasa(dp7655
g2
VFas apoptotic inhibitory molecule 2 (FAIM2) is an obesity-related gene, but the mechanisms by which FAIM2 is involved in obesity are not understood.
p7656
sg4
(lp7657
(dp7658
g7
I37
sg8
VFAIM2
p7659
sg10
I5
sg11
g12
sg13
I1
sa(dp7660
g7
I37
sg8
VFAIM2
p7661
sg10
I5
sg11
g12
sg13
I1
sa(dp7662
g7
I0
sg8
VFas apoptotic inhibitory molecule 2
p7663
sg10
I35
sg11
g12
sg13
I5
sasg24
(lp7664
(dp7665
g7
I0
sg8
VFas
p7666
sg10
I3
sg28
VC0015923
p7667
sg13
I1
sa(dp7668
g7
I50
sg8
Vobesity
p7669
sg10
I7
sg28
VC0028754
p7670
sg13
I1
sa(dp7671
g7
I50
sg8
Vobesity
p7672
sg10
I7
sg28
VC0028754
p7673
sg13
I1
sasa(dp7674
g2
VThe purpose of this study was to investigate the potential associations of FAIM2 promoter methylation with obesity and components of dyslipidaemia in Chinese children.
p7675
sg4
(lp7676
(dp7677
g7
I75
sg8
VFAIM2 promoter
p7678
sg10
I14
sg11
g12
sg13
I2
sasg24
(lp7679
(dp7680
g7
I107
sg8
Vobesity
p7681
sg10
I7
sg28
VC0028754
p7682
sg13
I1
sa(dp7683
g7
I133
sg8
Vdyslipidaemia
p7684
sg10
I13
sg28
VC0242339
p7685
sg13
I1
sasa(dp7686
g2
VThis study provides the first evidence that the methylation levels of the FAIM2 promoter are significantly associated with obesity and are independently associated with dyslipidaemia and its components in Chinese children.
p7687
sg4
(lp7688
(dp7689
g7
I74
sg8
VFAIM2 promoter
p7690
sg10
I14
sg11
g12
sg13
I2
sasg24
(lp7691
(dp7692
g7
I169
sg8
Vdyslipidaemia
p7693
sg10
I13
sg28
VC0242339
p7694
sg13
I1
sa(dp7695
g7
I123
sg8
Vobesity
p7696
sg10
I7
sg28
VC0028754
p7697
sg13
I1
sasa(dp7698
g135
(dp7699
(VMC4R rs17782313-C
p7700
Vobesity
p7701
tp7702
I00
ssg2
VThe association of FTO rs9939609-A, MC4R rs17782313-C, GNPDA2 rs10938397-G, and FAIM2 rs7138803-A with higher BMI, fat mass percentage, waist circumference, and waist-to height ratio and risk of obesity, and BDNF rs6265-G allele may increase BMI and obesity risk in Chinese children.
p7703
sg4
(lp7704
(dp7705
g7
I80
sg8
VFAIM2 rs7138803-A
p7706
sg10
I17
sg11
g12
sg13
I2
sa(dp7707
g7
I36
sg8
g7700
sg10
I17
sg11
VP32245
p7708
sg13
I2
sa(dp7709
g7
I55
sg8
VGNPDA2 rs10938397-G
p7710
sg10
I19
sg11
g12
sg13
I2
sa(dp7711
g7
I19
sg8
VFTO rs9939609-A
p7712
sg10
I15
sg11
g12
sg13
I2
sasg24
(lp7713
(dp7714
g7
I195
sg8
Vobesity
p7715
sg10
I7
sg28
VC0028754
p7716
sg13
I1
sa(dp7717
g7
I195
sg8
g7701
sg10
I7
sg28
VC0028754
p7718
sg13
I1
sasa(dp7719
g135
(dp7720
(VMC4R
p7721
Vobesity
p7722
tp7723
I00
ssg2
VHere we aim to see whether variants in obesity-associated genes--NEGR1, FTO, MTCH2, MC4R, LRRN6C, MAP2K5, FAIM2, SEC16B, ETV5, BDNF-AS, ATXN2L, ATP2A1, KCTD15, and TNN13K--are associated with white matter microstructural properties, assessed by high angular resolution diffusion imaging (HARDI) in young healthy adults between 20 and 30 years of age from the Queensland Twin Imaging study (QTIM).
p7724
sg4
(lp7725
(dp7726
g7
I65
sg8
VNEGR1
p7727
sg10
I5
sg11
g12
sg13
I1
sa(dp7728
g7
I144
sg8
VATP2A1
p7729
sg10
I6
sg11
g12
sg13
I1
sa(dp7730
g7
I72
sg8
VFTO
p7731
sg10
I3
sg11
g12
sg13
I1
sa(dp7732
g7
I98
sg8
VMAP2K5
p7733
sg10
I6
sg11
g12
sg13
I1
sa(dp7734
g7
I106
sg8
VFAIM2
p7735
sg10
I5
sg11
g12
sg13
I1
sa(dp7736
g7
I113
sg8
VSEC16B
p7737
sg10
I6
sg11
g12
sg13
I1
sa(dp7738
g7
I152
sg8
VKCTD15
p7739
sg10
I6
sg11
g12
sg13
I1
sa(dp7740
g7
I121
sg8
VETV5
p7741
sg10
I4
sg11
VP41161
p7742
sg13
I1
sa(dp7743
g7
I77
sg8
VMTCH2
p7744
sg10
I5
sg11
g12
sg13
I1
sa(dp7745
g7
I84
sg8
g7721
sg10
I4
sg11
VP32245
p7746
sg13
I1
sa(dp7747
g7
I90
sg8
VLRRN6C
p7748
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp7749
(dp7750
g7
I39
sg8
g7722
sg10
I7
sg28
VC0028754
p7751
sg13
I1
sasa(dp7752
g2
VOur results reflect an epigenetic regulation of Rbl2/p130 expression in breast cancer.
p7753
sg4
(lp7754
(dp7755
g7
I48
sg8
VRbl2
p7756
sg10
I4
sg11
g12
sg13
I1
sa(dp7757
g7
I53
sg8
Vp130
p7758
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp7759
(dp7760
g7
I72
sg8
Vbreast cancer
p7761
sg10
I13
sg28
VC0678222
p7762
sg13
I2
sasa(dp7763
g2
VThis highlights the importance of Rbl2/p130 promoter methylation in breast cancer pathogenesis.
p7764
sg4
(lp7765
(dp7766
g7
I39
sg8
Vp130
p7767
sg10
I4
sg11
g12
sg13
I1
sa(dp7768
g7
I34
sg8
VRbl2
p7769
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp7770
(dp7771
g7
I68
sg8
Vbreast cancer
p7772
sg10
I13
sg28
VC0678222
p7773
sg13
I2
sa(dp7774
g7
I82
sg8
Vpathogenesis
p7775
sg10
I12
sg28
VC0699748
p7776
sg13
I1
sasa(dp7777
g135
(dp7778
(VpRb2
p7779
Vbreast cancer
p7780
tp7781
I00
ssg2
VHere, we report that ER-beta and pRb2/p130 proteins co-immunoprecipitate in both nucleus and cytoplasm of MCF-7 breast cancer cells.
p7782
sg4
(lp7783
(dp7784
g7
I38
sg8
Vp130
p7785
sg10
I4
sg11
g12
sg13
I1
sa(dp7786
g7
I33
sg8
g7779
sg10
I4
sg11
VP02812
p7787
sg13
I1
sasg24
(lp7788
(dp7789
g7
I112
sg8
g7780
sg10
I13
sg28
VC0678222
p7790
sg13
I2
sasa(dp7791
g135
(dp7792
(VpRb2
p7793
Vbreast cancer
p7794
tp7795
I00
ssg2
VHere we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells.
p7796
sg4
(lp7797
(dp7798
g7
I81
sg8
g7793
sg10
I4
sg11
VP02812
p7799
sg13
I1
sa(dp7800
g7
I42
sg8
VER-alpha gene
p7801
sg10
I13
sg11
g12
sg13
I2
sa(dp7802
g7
I86
sg8
Vp130
p7803
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp7804
(dp7805
g7
I106
sg8
g7794
sg10
I13
sg28
VC0678222
p7806
sg13
I2
sa(dp7807
g7
I56
sg8
Vinactivation
p7808
sg10
I12
sg28
VC0544461
p7809
sg13
I1
sasa(dp7810
g135
(dp7811
(VpRb2
p7812
Vbreast cancer
p7813
tp7814
I00
ssg2
VThese findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.
p7815
sg4
(lp7816
(dp7817
g7
I33
sg8
Vp130
p7818
sg10
I4
sg11
g12
sg13
I1
sa(dp7819
g7
I104
sg8
VER-alpha gene
p7820
sg10
I13
sg11
g12
sg13
I2
sa(dp7821
g7
I28
sg8
g7812
sg10
I4
sg11
VP02812
p7822
sg13
I1
sasg24
(lp7823
(dp7824
g7
I240
sg8
g7813
sg10
I13
sg28
VC0678222
p7825
sg13
I2
sa(dp7826
g7
I276
sg8
Vtumors
p7827
sg10
I6
sg28
VC0027651
p7828
sg13
I1
sasa(dp7829
g135
(dp7830
(Vsteroid hormone receptor
p7831
Vbreast cancer
p7832
tp7833
I00
ssg2
VIn order to further analyze the role of CEACAM1 in the development of breast cancer, we performed Western-blot analysis and immunohistochemistry with highly specific monoclonal antibodies in a cohort of 68 mammary carcinomas which had also been analyzed for expression of cell-cycle regulatory proteins cyclin D1, cyclin E, p16, p21, p27, Rb, and Rb2, as well as for steroid hormone receptor status, Ki67, and HER2/neu immunoreactivity.
p7834
sg4
(lp7835
(dp7836
g7
I347
sg8
VRb2
p7837
sg10
I3
sg11
g12
sg13
I1
sa(dp7838
g7
I324
sg8
Vp16
p7839
sg10
I3
sg11
VP42771
p7840
sg13
I1
sa(dp7841
g7
I334
sg8
Vp27
p7842
sg10
I3
sg11
VP40305
p7843
sg13
I1
sa(dp7844
g7
I415
sg8
Vneu
p7845
sg10
I3
sg11
VP04626
p7846
sg13
I1
sa(dp7847
g7
I40
sg8
VCEACAM1
p7848
sg10
I7
sg11
VP13688
p7849
sg13
I1
sa(dp7850
g7
I329
sg8
Vp21
p7851
sg10
I3
sg11
VP42857
p7852
sg13
I1
sa(dp7853
g7
I314
sg8
Vcyclin E
p7854
sg10
I8
sg11
VP24864
p7855
sg13
I2
sa(dp7856
g7
I410
sg8
VHER2
p7857
sg10
I4
sg11
VP04626
p7858
sg13
I1
sa(dp7859
g7
I303
sg8
Vcyclin D1
p7860
sg10
I9
sg11
VP24385
p7861
sg13
I2
sa(dp7862
g7
I367
sg8
g7831
sg10
I24
sg11
VP22736
p7863
sg13
I3
sasg24
(lp7864
(dp7865
g7
I70
sg8
g7832
sg10
I13
sg28
VC0678222
p7866
sg13
I2
sa(dp7867
g7
I214
sg8
Vcarcinomas
p7868
sg10
I10
sg28
VC0007097
p7869
sg13
I1
sasa(dp7870
g2
VWeak or absent Rb2 expression was more often found in endometrial (59%) than in mammary carcinomas (24%).
p7871
sg4
(lp7872
(dp7873
g7
I15
sg8
VRb2
p7874
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp7875
(dp7876
g7
I88
sg8
Vcarcinomas
p7877
sg10
I10
sg28
VC0007097
p7878
sg13
I1
sasa(dp7879
g2
VWe found significant positive correlations of Rb2 expression with Rb, ER, and PR-B in breast cancer samples, and of Rb2 with Rb, PR-A, PR-B, and younger age in endometrial carcinomas.
p7880
sg4
(lp7881
(dp7882
g7
I46
sg8
VRb2
p7883
sg10
I3
sg11
g12
sg13
I1
sa(dp7884
g7
I46
sg8
VRb2
p7885
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp7886
(dp7887
g7
I86
sg8
Vbreast cancer
p7888
sg10
I13
sg28
VC0678222
p7889
sg13
I2
sa(dp7890
g7
I160
sg8
Vendometrial carcinomas
p7891
sg10
I22
sg28
VC0476089
p7892
sg13
I2
sasa(dp7893
g2
VOur results indicate that loss of Rb2 expression, mostly by transcriptional down-regulation, may be associated with the development and dedifferentiation of most endometrial and a subset of mammary carcinomas.
p7894
sg4
(lp7895
(dp7896
g7
I34
sg8
VRb2
p7897
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp7898
(dp7899
g7
I198
sg8
Vcarcinomas
p7900
sg10
I10
sg28
VC0007097
p7901
sg13
I1
sa(dp7902
g7
I136
sg8
Vdedifferentiation
p7903
sg10
I17
sg28
VC0002793
p7904
sg13
I1
sasa(dp7905
g135
(dp7906
(Vfucosylated haptoglobin
p7907
Vpancreatic cancer
p7908
tp7909
I00
ssg2
VWe have developed a novel glycocancer biomarker, fucosylated haptoglobin (Fuc-Hpt), and have investigated its usefulness for the diagnosis of pancreatic cancer over approximately 10 years.
p7910
sg4
(lp7911
(dp7912
g7
I74
sg8
VFuc-Hpt
p7913
sg10
I7
sg11
VP00738
p7914
sg13
I1
sa(dp7915
g7
I49
sg8
g7907
sg10
I23
sg11
VP00738
p7916
sg13
I2
sasg24
(lp7917
(dp7918
g7
I142
sg8
g7908
sg10
I17
sg28
VC0235974
p7919
sg13
I2
sasa(dp7920
g135
(dp7921
(VFuc-Hpt
p7922
Vpancreatic cancer
p7923
tp7924
I00
ssg2
VIn this review, we provide a historical summary of our research on Fuc-Hpt as a cancer biomarker, and discuss a potential early detection system for pancreatic cancer.
p7925
sg4
(lp7926
(dp7927
g7
I67
sg8
g7922
sg10
I7
sg11
VP00738
p7928
sg13
I1
sasg24
(lp7929
(dp7930
g7
I80
sg8
Vcancer
p7931
sg10
I6
sg28
VC0006826
p7932
sg13
I1
sa(dp7933
g7
I149
sg8
g7923
sg10
I17
sg28
VC0235974
p7934
sg13
I2
sasa(dp7935
g135
(dp7936
(Vcore-Fuc-Hpt
p7937
Vpancreatic cancer
p7938
tp7939
I00
ssg2
VWe developed a lectin-antibody ELISA kit using PhoSL to determine core-Fuc-Hpt levels in sera from colorectal or pancreatic cancer patients.
p7940
sg4
(lp7941
(dp7942
g7
I66
sg8
g7937
sg10
I12
sg11
VP00738
p7943
sg13
I1
sa(dp7944
g7
I15
sg8
Vlectin-antibody
p7945
sg10
I15
sg11
g12
sg13
I1
sasg24
(lp7946
(dp7947
g7
I113
sg8
g7938
sg10
I17
sg28
VC0235974
p7948
sg13
I2
sasa(dp7949
g135
(dp7950
(VAAL-reactive Hpt
p7951
Vcolorectal cancer
p7952
tp7953
I01
ssg2
VSerum levels of AAL-reactive Hpt are higher in pancreatic cancer patients, whereas those of PhoSL-reactive Hpt are higher in colorectal cancer patients.
p7954
sg4
(lp7955
(dp7956
g7
I92
sg8
VPhoSL-reactive Hpt
p7957
sg10
I18
sg11
VP00738
p7958
sg13
I2
sa(dp7959
g7
I16
sg8
g7951
sg10
I16
sg11
VP00738
p7960
sg13
I2
sasg24
(lp7961
(dp7962
g7
I47
sg8
Vpancreatic cancer
p7963
sg10
I17
sg28
VC0235974
p7964
sg13
I2
sa(dp7965
g7
I125
sg8
g7952
sg10
I17
sg28
VC1527249
p7966
sg13
I2
sasa(dp7967
g135
(dp7968
(VFucosylated haptoglobin
p7969
Vpancreatic cancer
p7970
tp7971
I00
ssg2
VFucosylated haptoglobin (Fuc-Hpt) has been identified as a novel biomarker for pancreatic cancer.
p7972
sg4
(lp7973
(dp7974
g7
I25
sg8
VFuc-Hpt
p7975
sg10
I7
sg11
VP00738
p7976
sg13
I1
sa(dp7977
g7
I0
sg8
g7969
sg10
I23
sg11
VP00738
p7978
sg13
I2
sasg24
(lp7979
(dp7980
g7
I79
sg8
g7970
sg10
I17
sg28
VC0235974
p7981
sg13
I2
sasa(dp7982
g135
(dp7983
(VFuc-Hpt
p7984
Vpancreatic cancer
p7985
tp7986
I00
ssg2
VWe previously found that the level of Fuc-Hpt is increased in the sera of patients with pancreatic cancer, and established a lectin antibody ELISA using Aleuria aurantia lectin, which specifically binds to fucosylated residues on oligosaccharides.
p7987
sg4
(lp7988
(dp7989
g7
I38
sg8
g7984
sg10
I7
sg11
VP00738
p7990
sg13
I1
sa(dp7991
g7
I153
sg8
VAleuria aurantia lectin
p7992
sg10
I23
sg11
g12
sg13
I3
sa(dp7993
g7
I125
sg8
Vlectin antibody
p7994
sg10
I15
sg11
g12
sg13
I2
sasg24
(lp7995
(dp7996
g7
I88
sg8
g7985
sg10
I17
sg28
VC0235974
p7997
sg13
I2
sasa(dp7998
g2
VUsing the model checking method, we verified several Alzheimer's disease and cancer-related properties, and also identified important proteins (NFKB, ATF4, ASK1 and TRAF2) in the ER-Golgi network, which might be responsible for the pathogenesis of cancer and AD.
p7999
sg4
(lp8000
(dp8001
g7
I156
sg8
VASK1
p8002
sg10
I4
sg11
g12
sg13
I1
sa(dp8003
g7
I144
sg8
VNFKB
p8004
sg10
I4
sg11
g12
sg13
I1
sa(dp8005
g7
I165
sg8
VTRAF2
p8006
sg10
I5
sg11
g12
sg13
I1
sa(dp8007
g7
I150
sg8
VATF4
p8008
sg10
I4
sg11
VP18848
p8009
sg13
I1
sasg24
(lp8010
(dp8011
g7
I77
sg8
Vcancer
p8012
sg10
I6
sg28
VC0006826
p8013
sg13
I1
sa(dp8014
g7
I53
sg8
VAlzheimer's disease
p8015
sg10
I19
sg28
VC1521724
p8016
sg13
I2
sa(dp8017
g7
I232
sg8
Vpathogenesis
p8018
sg10
I12
sg28
VC0699748
p8019
sg13
I1
sa(dp8020
g7
I77
sg8
Vcancer
p8021
sg10
I6
sg28
VC0006826
p8022
sg13
I1
sasa(dp8023
g2
VWe genotyped 107 AIH-1 children and up to 326 healthy subjects for TNFA G-308A, TNFA G-238A, LTA A+252G, LTA A+80C, NFKBIL1 T-63A, BAT1 C-348T, BAT1 G-22C, MICA, and HLA-B polymorphisms.
p8024
sg4
(lp8025
(dp8026
g7
I105
sg8
VLTA A+80C
p8027
sg10
I9
sg11
VP10515
p8028
sg13
I2
sa(dp8029
g7
I166
sg8
VHLA-B
p8030
sg10
I5
sg11
VP30461
p8031
sg13
I1
sa(dp8032
g7
I131
sg8
VBAT1 C-348T
p8033
sg10
I11
sg11
VP82251
p8034
sg13
I2
sa(dp8035
g7
I144
sg8
VBAT1 G-22C
p8036
sg10
I10
sg11
VP82251
p8037
sg13
I2
sa(dp8038
g7
I93
sg8
VLTA A+252G
p8039
sg10
I10
sg11
VP10515
p8040
sg13
I2
sa(dp8041
g7
I67
sg8
VTNFA G-308A
p8042
sg10
I11
sg11
VP01375
p8043
sg13
I2
sa(dp8044
g7
I116
sg8
VNFKBIL1 T-63A
p8045
sg10
I13
sg11
g12
sg13
I2
sa(dp8046
g7
I80
sg8
VTNFA G-238A
p8047
sg10
I11
sg11
VP01375
p8048
sg13
I2
sasg24
(lp8049
(dp8050
g7
I156
sg8
VMICA
p8051
sg10
I4
sg28
VC0700319
p8052
sg13
I1
sasa(dp8053
g135
(dp8054
(VFIM
p8055
VFIM
p8056
tp8057
I00
ssg2
VTandem repeats of a novel, putative, zinc-binding motif (MYM) have been described within the products of two, highly homologous genes: ZNF198/RAMP/FIM and ZNF261/DXS6673E.
p8058
sg4
(lp8059
(dp8060
g7
I155
sg8
VZNF261
p8061
sg10
I6
sg11
g12
sg13
I1
sa(dp8062
g7
I142
sg8
VRAMP
p8063
sg10
I4
sg11
g12
sg13
I1
sa(dp8064
g7
I147
sg8
g8055
sg10
I3
sg11
VP28329
p8065
sg13
I1
sa(dp8066
g7
I162
sg8
VDXS6673E
p8067
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp8068
(dp8069
g7
I147
sg8
g8056
sg10
I3
sg28
VC0393929
p8070
sg13
I1
sasa(dp8071
g135
(dp8072
(VLIG4
p8073
VSCID
p8074
tp8075
I00
ssg2
VFrom 2005 to 2010, our unit performed testing for IL2RG, JAK3, IL7R, RAG1, RAG2, DCLRE1C, LIG4, AK2, and ZAP70 mutations in 42 Chinese and Southeast Asian infants with SCID adopting a candidate gene approach, based on patient's gender, immune phenotype, and inheritance pattern.
p8076
sg4
(lp8077
(dp8078
g7
I50
sg8
VIL2RG
p8079
sg10
I5
sg11
VP31785
p8080
sg13
I1
sa(dp8081
g7
I96
sg8
VAK2
p8082
sg10
I3
sg11
g12
sg13
I1
sa(dp8083
g7
I105
sg8
VZAP70 mutations
p8084
sg10
I15
sg11
VP43403
p8085
sg13
I2
sa(dp8086
g7
I69
sg8
VRAG1
p8087
sg10
I4
sg11
VP15918
p8088
sg13
I1
sa(dp8089
g7
I75
sg8
VRAG2
p8090
sg10
I4
sg11
VP55895
p8091
sg13
I1
sa(dp8092
g7
I57
sg8
VJAK3
p8093
sg10
I4
sg11
VP52333
p8094
sg13
I1
sa(dp8095
g7
I90
sg8
g8073
sg10
I4
sg11
VP49917
p8096
sg13
I1
sasg24
(lp8097
(dp8098
g7
I168
sg8
g8074
sg10
I4
sg28
VC0085110
p8099
sg13
I1
sasa(dp8100
g2
VMutations were identified in 26 patients, including IL2RG (n = 19), IL7R (n = 2), JAK3 (n = 2), RAG1 (n = 1), RAG2 (n = 1), and DCLRE1C (n = 1).
p8101
sg4
(lp8102
(dp8103
g7
I82
sg8
VJAK3
p8104
sg10
I4
sg11
VP52333
p8105
sg13
I1
sa(dp8106
g7
I52
sg8
VIL2RG
p8107
sg10
I5
sg11
VP31785
p8108
sg13
I1
sa(dp8109
g7
I110
sg8
VRAG2
p8110
sg10
I4
sg11
VP55895
p8111
sg13
I1
sa(dp8112
g7
I96
sg8
VRAG1
p8113
sg10
I4
sg11
VP15918
p8114
sg13
I1
sasg24
(lp8115
sa(dp8116
g135
(dp8117
(VRAG2
p8118
VSCID
p8119
tp8120
I00
ssg2
VMutations in any of eight known genes: IL2RG, ARTEMIS, RAG1, RAG2, ADA, CD45, JAK3, and IL7R cause SCID.
p8121
sg4
(lp8122
(dp8123
g7
I39
sg8
VIL2RG
p8124
sg10
I5
sg11
VP31785
p8125
sg13
I1
sa(dp8126
g7
I78
sg8
VJAK3
p8127
sg10
I4
sg11
VP52333
p8128
sg13
I1
sa(dp8129
g7
I55
sg8
VRAG1
p8130
sg10
I4
sg11
VP15918
p8131
sg13
I1
sa(dp8132
g7
I72
sg8
VCD45
p8133
sg10
I4
sg11
VP08575
p8134
sg13
I1
sa(dp8135
g7
I67
sg8
VADA
p8136
sg10
I3
sg11
VP00813
p8137
sg13
I1
sa(dp8138
g7
I61
sg8
g8118
sg10
I4
sg11
VP55895
p8139
sg13
I1
sasg24
(lp8140
(dp8141
g7
I99
sg8
g8119
sg10
I4
sg28
VC0085110
p8142
sg13
I1
sasa(dp8143
g2
VPrevious studies have reported that Nit2, a member of the nitrilase superfamily, is a potential tumor suppressor, although its function remains elusive in colon cancer.
p8144
sg4
(lp8145
(dp8146
g7
I36
sg8
VNit2
p8147
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8148
(dp8149
g7
I155
sg8
Vcolon cancer
p8150
sg10
I12
sg28
VC0699790
p8151
sg13
I2
sa(dp8152
g7
I96
sg8
Vtumor
p8153
sg10
I5
sg28
VC0027651
p8154
sg13
I1
sasa(dp8155
g2
VIn the present study, we employed an RNA interference lentivirus system to silence endogenous NIT2 expression in the colon cancer cell line, HCT116.
p8156
sg4
(lp8157
(dp8158
g7
I94
sg8
VNIT2
p8159
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8160
(dp8161
g7
I75
sg8
Vsilence
p8162
sg10
I7
sg28
VC0858952
p8163
sg13
I1
sa(dp8164
g7
I117
sg8
Vcolon cancer
p8165
sg10
I12
sg28
VC0699790
p8166
sg13
I2
sasa(dp8167
g2
VThe depletion of NIT2 markedly inhibited colon cancer cell proliferation and colony formation and induced cell cycle arrest in the G0/G1 phase, as shown by MTT assay, colony formation assay and flow cytometric analysis, respectively.
p8168
sg4
(lp8169
(dp8170
g7
I17
sg8
VNIT2
p8171
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8172
(dp8173
g7
I59
sg8
Vproliferation
p8174
sg10
I13
sg28
VC0334094
p8175
sg13
I1
sa(dp8176
g7
I41
sg8
Vcolon cancer
p8177
sg10
I12
sg28
VC0699790
p8178
sg13
I2
sasa(dp8179
g135
(dp8180
(Vpoly(ADP-ribose) polymerase
p8181
Vcolon cancer
p8182
tp8183
I00
ssg2
VFurther investigation with an intracellular signaling array demonstrated that the depletion of NIT2 triggered the apoptosis of colon cancer cells through the caspase-3 and poly(ADP-ribose) polymerase (PARP) pathways.
p8184
sg4
(lp8185
(dp8186
g7
I95
sg8
VNIT2
p8187
sg10
I4
sg11
g12
sg13
I1
sa(dp8188
g7
I201
sg8
VPARP
p8189
sg10
I4
sg11
VP09874
p8190
sg13
I1
sa(dp8191
g7
I158
sg8
Vcaspase-3
p8192
sg10
I9
sg11
VP42574
p8193
sg13
I1
sa(dp8194
g7
I172
sg8
g8181
sg10
I27
sg11
VP09874
p8195
sg13
I2
sasg24
(lp8196
(dp8197
g7
I127
sg8
g8182
sg10
I12
sg28
VC0699790
p8198
sg13
I2
sasa(dp8199
g2
VOur findings suggest that NIT2 may be an oncogene in human colon cancer and may thus serve as a promising therapeutic target for the treatment of colon cancer.
p8200
sg4
(lp8201
(dp8202
g7
I26
sg8
VNIT2
p8203
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8204
(dp8205
g7
I59
sg8
Vcolon cancer
p8206
sg10
I12
sg28
VC0699790
p8207
sg13
I2
sa(dp8208
g7
I59
sg8
Vcolon cancer
p8209
sg10
I12
sg28
VC0699790
p8210
sg13
I2
sasa(dp8211
g2
VOur report may provide clues regarding the nature of the biological amidase substrate(s) of Nit1 (another member of the Nit family), which is a well-established tumor suppressor protein), and emphasizes a) the crucial role of Nit2 in nitrogen and sulfur metabolism, and b) the possible link of Nit2 to cancer biology.
p8212
sg4
(lp8213
(dp8214
g7
I226
sg8
VNit2
p8215
sg10
I4
sg11
g12
sg13
I1
sa(dp8216
g7
I92
sg8
VNit1
p8217
sg10
I4
sg11
g12
sg13
I1
sa(dp8218
g7
I226
sg8
VNit2
p8219
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8220
(dp8221
g7
I161
sg8
Vtumor
p8222
sg10
I5
sg28
VC0027651
p8223
sg13
I1
sa(dp8224
g7
I302
sg8
Vcancer
p8225
sg10
I6
sg28
VC0006826
p8226
sg13
I1
sasa(dp8227
g2
VThe purpose of this study was to retrospectively characterize benign and malignant prostate peripheral zone tissue by using endorectal MRI and 3D 1H MRS. Fifty-two men with untreated biopsy-proven prostate cancer underwent combined endorectal MRI and MRSI.
p8228
sg4
(lp8229
sg24
(lp8230
(dp8231
g7
I197
sg8
Vprostate cancer
p8232
sg10
I15
sg28
VC0600139
p8233
sg13
I2
sa(dp8234
g7
I149
sg8
VMRS
p8235
sg10
I3
sg28
VC0025235
p8236
sg13
I1
sasa(dp8237
g2
VThe addition of 3D1H MRSI to MRI can improve diagnosis of prostate cancer contributing indirectly to improve local staging.
p8238
sg4
(lp8239
sg24
(lp8240
(dp8241
g7
I58
sg8
Vprostate cancer
p8242
sg10
I15
sg28
VC0600139
p8243
sg13
I2
sasa(dp8244
g2
VIn addition, the correlation between metabolic 3D1H MRSI data with pathological Gleason grade may offer a non-invasive means to better predict prostate cancer aggressiveness.
p8245
sg4
(lp8246
sg24
(lp8247
(dp8248
g7
I143
sg8
Vprostate cancer aggressiveness
p8249
sg10
I30
sg28
VC1853195
p8250
sg13
I3
sasa(dp8251
g2
VThe objective of our study was to establish the sensitivity and specificity for prostate cancer detection using a combined 1H MR spectroscopy and diffusion-weighted MRI approach.
p8252
sg4
(lp8253
sg24
(lp8254
(dp8255
g7
I80
sg8
Vprostate cancer
p8256
sg10
I15
sg28
VC0600139
p8257
sg13
I2
sasa(dp8258
g2
VMRI, dynamic MRI, and 1H-MR spectroscopic imaging were performed in 10 patients with prostate cancer on 1.5T and 3T whole-body scanners.
p8259
sg4
(lp8260
sg24
(lp8261
(dp8262
g7
I85
sg8
Vprostate cancer
p8263
sg10
I15
sg28
VC0600139
p8264
sg13
I2
sasa(dp8265
g2
VInitial results of endorectal 3T 1H-MR spectroscopic imaging in prostate cancer patients showed potential advantages: the increase in spatial, temporal, and spectral resolution at higher field strength may result in an improved accuracy in delineating and staging prostate cancer.
p8266
sg4
(lp8267
sg24
(lp8268
(dp8269
g7
I64
sg8
Vprostate cancer
p8270
sg10
I15
sg28
VC0600139
p8271
sg13
I2
sa(dp8272
g7
I64
sg8
Vprostate cancer
p8273
sg10
I15
sg28
VC0600139
p8274
sg13
I2
sasa(dp8275
g2
VTo establish an experimental setting for monitoring perfusion and metabolism in orthotopic prostate cancer at 1.5 T using dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) and 1H-MR spectroscopy (MRS).
p8276
sg4
(lp8277
sg24
(lp8278
(dp8279
g7
I91
sg8
Vprostate cancer
p8280
sg10
I15
sg28
VC0600139
p8281
sg13
I2
sa(dp8282
g7
I209
sg8
VMRS
p8283
sg10
I3
sg28
VC0025235
p8284
sg13
I1
sa(dp8285
g7
I189
sg8
V1H-MR spectroscopy
p8286
sg10
I18
sg28
VC0025235
p8287
sg13
I2
sasa(dp8288
g2
VDCE MRI and 1H-MRS has potential to characterize orthotopic Dunning prostate cancer in rats, which is a promising model similar to human prostate carcinomas.
p8289
sg4
(lp8290
sg24
(lp8291
(dp8292
g7
I15
sg8
VMRS
p8293
sg10
I3
sg28
VC0025235
p8294
sg13
I1
sa(dp8295
g7
I68
sg8
Vprostate cancer
p8296
sg10
I15
sg28
VC0600139
p8297
sg13
I2
sa(dp8298
g7
I146
sg8
Vcarcinomas
p8299
sg10
I10
sg28
VC0007097
p8300
sg13
I1
sasa(dp8301
g135
(dp8302
(Vglucocorticoid-regulated gene
p8303
Vrenal cell carcinoma
p8304
tp8305
I00
ssg2
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p8306
sg4
(lp8307
(dp8308
g7
I117
sg8
VFam107A
p8309
sg10
I7
sg11
g12
sg13
I1
sa(dp8310
g7
I111
sg8
VDRR1
p8311
sg10
I4
sg11
g12
sg13
I1
sa(dp8312
g7
I39
sg8
g8303
sg10
I29
sg11
VP48506
p8313
sg13
I2
sasg24
(lp8314
(dp8315
g7
I88
sg8
g8304
sg10
I20
sg28
VC0007134
p8316
sg13
I3
sasa(dp8317
g2
VTU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).
p8318
sg4
(lp8319
(dp8320
g7
I0
sg8
VTU3A
p8321
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8322
(dp8323
g7
I91
sg8
Vrenal cell carcinoma
p8324
sg10
I20
sg28
VC0007134
p8325
sg13
I3
sa(dp8326
g7
I66
sg8
Vtumor
p8327
sg10
I5
sg28
VC0027651
p8328
sg13
I1
sa(dp8329
g7
I113
sg8
VRCC
p8330
sg10
I3
sg28
VC0007134
p8331
sg13
I1
sasa(dp8332
g2
VIn our search for tumor suppressor genes from this region, we have cloned a gene that we have called DRR 1 (downregulated in renal cell carcinoma).
p8333
sg4
(lp8334
(dp8335
g7
I101
sg8
VDRR 1
p8336
sg10
I5
sg11
g12
sg13
I2
sasg24
(lp8337
(dp8338
g7
I18
sg8
Vtumor
p8339
sg10
I5
sg28
VC0027651
p8340
sg13
I1
sa(dp8341
g7
I125
sg8
Vrenal cell carcinoma
p8342
sg10
I20
sg28
VC0007134
p8343
sg13
I3
sasa(dp8344
g2
VOur results suggest that loss of expression of the DRR 1 gene may play an important role in the development of renal cell carcinoma and possibly other tumors.
p8345
sg4
(lp8346
(dp8347
g7
I51
sg8
VDRR 1 gene
p8348
sg10
I10
sg11
g12
sg13
I3
sasg24
(lp8349
(dp8350
g7
I151
sg8
Vtumors
p8351
sg10
I6
sg28
VC0027651
p8352
sg13
I1
sa(dp8353
g7
I111
sg8
Vrenal cell carcinoma
p8354
sg10
I20
sg28
VC0007134
p8355
sg13
I3
sasa(dp8356
g2
VE2F5 was identified as one of the most deregulated genes in prostate cancer tissues, predominantly in samples with Gleason-score 6.
p8357
sg4
(lp8358
(dp8359
g7
I0
sg8
VE2F5
p8360
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8361
(dp8362
g7
I60
sg8
Vprostate cancer
p8363
sg10
I15
sg28
VC0600139
p8364
sg13
I2
sasa(dp8365
g135
(dp8366
(Vp38
p8367
Vprostate cancer
p8368
tp8369
I00
ssg2
VFunction of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
p8370
sg4
(lp8371
(dp8372
g7
I21
sg8
g8367
sg10
I3
sg11
VP46108
p8373
sg13
I1
sa(dp8374
g7
I12
sg8
VE2F5
p8375
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8376
(dp8377
g7
I28
sg8
g8368
sg10
I15
sg28
VC0600139
p8378
sg13
I2
sasa(dp8379
g135
(dp8380
(Vp38
p8381
Vprostate cancer
p8382
tp8383
I00
ssg2
VOur findings unearthed that E2F5/p38 axis played a cardinal role in uncontrolled cellular proliferation in prostate cancer through pSMAD3L activation.
p8384
sg4
(lp8385
(dp8386
g7
I33
sg8
g8381
sg10
I3
sg11
VP46108
p8387
sg13
I1
sa(dp8388
g7
I28
sg8
VE2F5
p8389
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8390
(dp8391
g7
I81
sg8
Vcellular proliferation
p8392
sg10
I22
sg28
VC0020507
p8393
sg13
I2
sa(dp8394
g7
I107
sg8
g8382
sg10
I15
sg28
VC0600139
p8395
sg13
I2
sasa(dp8396
g2
VIt also underscores a strong potential for E2F5 to be incorporated as a tool in early detection of prostate cancer.
p8397
sg4
(lp8398
(dp8399
g7
I43
sg8
VE2F5
p8400
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp8401
(dp8402
g7
I99
sg8
Vprostate cancer
p8403
sg10
I15
sg28
VC0600139
p8404
sg13
I2
sasa(dp8405
g2
VWe report the coexistence of otitis media and epididymo-orchitis owing to Hemophilus influenzae, type b in 2 children.
p8406
sg4
(lp8407
sg24
(lp8408
(dp8409
g7
I29
sg8
Votitis media
p8410
sg10
I12
sg28
VC0029882
p8411
sg13
I2
sa(dp8412
g7
I46
sg8
Vepididymo-orchitis
p8413
sg10
I18
sg28
VC0149881
p8414
sg13
I1
sasa(dp8415
g2
VOverexpression of tau rescued the Nogo-66-induced inhibition of neurite outgrowth in neuroblastoma 2a (N2a) cells and primary cortical neurons.
p8416
sg4
(lp8417
sg24
(lp8418
(dp8419
g7
I85
sg8
Vneuroblastoma
p8420
sg10
I13
sg28
VC0027819
p8421
sg13
I1
sasa(dp8422
g2
VTaken together, we suggest that Nogo-A is closely involved in the neuronal response to hypoxic and oxidative stress, an observation that may be of relevance not only in stroke-induced ischaemia, but also in neuroblastoma formation.
p8423
sg4
(lp8424
sg24
(lp8425
(dp8426
g7
I99
sg8
Voxidative stress
p8427
sg10
I16
sg28
VC0242606
p8428
sg13
I2
sa(dp8429
g7
I184
sg8
Vischaemia
p8430
sg10
I9
sg28
VC0022116
p8431
sg13
I1
sa(dp8432
g7
I87
sg8
Vhypoxic
p8433
sg10
I7
sg28
VC0242184
p8434
sg13
I1
sa(dp8435
g7
I169
sg8
Vstroke
p8436
sg10
I6
sg28
VC0038454
p8437
sg13
I1
sa(dp8438
g7
I207
sg8
Vneuroblastoma
p8439
sg10
I13
sg28
VC0027819
p8440
sg13
I1
sasa(dp8441
g2
VIn the present study, we report on the role of GSK-3Beta signaling on Nogo-66-treated mouse neuroblastoma N2a cells.
p8442
sg4
(lp8443
(dp8444
g7
I47
sg8
VGSK-3Beta
p8445
sg10
I9
sg11
VP49841
p8446
sg13
I1
sasg24
(lp8447
(dp8448
g7
I86
sg8
Vmouse neuroblastoma
p8449
sg10
I19
sg28
VC1524043
p8450
sg13
I2
sasa(dp8451
g2
VBrain-derived neurotrophic factor stimulates the phosphorylation, suppressing Nogo-dependent inhibition of neurite outgrowth from neuroblastoma-derived neural cells.
p8452
sg4
(lp8453
(dp8454
g7
I0
sg8
VBrain-derived neurotrophic factor
p8455
sg10
I33
sg11
g12
sg13
I3
sasg24
(lp8456
(dp8457
g7
I130
sg8
Vneuroblastoma
p8458
sg10
I13
sg28
VC0027819
p8459
sg13
I1
sasa(dp8460
g135
(dp8461
(VBMP4
p8462
Vmyopia
p8463
tp8464
I01
ssg2
VIn our per-SNP analysis, eight myopia gene associations were replicated successfully: GJD2, RASGRF1, BICC1, KCNQ5, CD55, CYP26A1, LRRC4C, and B4GALNT2.Seven additional gene associations were replicated in our gene-based analyses: GRIA4, BMP2, QKI, BMP4, SFRP1, SH3GL2, and EHBP1L1.
p8465
sg4
(lp8466
(dp8467
g7
I254
sg8
VSFRP1
p8468
sg10
I5
sg11
g12
sg13
I1
sa(dp8469
g7
I261
sg8
VSH3GL2
p8470
sg10
I6
sg11
g12
sg13
I1
sa(dp8471
g7
I130
sg8
VLRRC4C
p8472
sg10
I6
sg11
g12
sg13
I1
sa(dp8473
g7
I237
sg8
VBMP2
p8474
sg10
I4
sg11
VP12643
p8475
sg13
I1
sa(dp8476
g7
I86
sg8
VGJD2
p8477
sg10
I4
sg11
g12
sg13
I1
sa(dp8478
g7
I121
sg8
VCYP26A1
p8479
sg10
I7
sg11
g12
sg13
I1
sa(dp8480
g7
I273
sg8
VEHBP1L1
p8481
sg10
I7
sg11
g12
sg13
I1
sa(dp8482
g7
I108
sg8
VKCNQ5
p8483
sg10
I5
sg11
g12
sg13
I1
sa(dp8484
g7
I101
sg8
VBICC1
p8485
sg10
I5
sg11
g12
sg13
I1
sa(dp8486
g7
I115
sg8
VCD55
p8487
sg10
I4
sg11
VP08174
p8488
sg13
I1
sa(dp8489
g7
I230
sg8
VGRIA4
p8490
sg10
I5
sg11
VP48058
p8491
sg13
I1
sa(dp8492
g7
I248
sg8
g8462
sg10
I4
sg11
VP12644
p8493
sg13
I1
sa(dp8494
g7
I142
sg8
VB4GALNT2
p8495
sg10
I8
sg11
g12
sg13
I1
sa(dp8496
g7
I92
sg8
VRASGRF1
p8497
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp8498
(dp8499
g7
I31
sg8
g8463
sg10
I6
sg28
VC0027092
p8500
sg13
I1
sasa(dp8501
g135
(dp8502
(VS100A10
p8503
Vadenocarcinomas
p8504
tp8505
I00
ssg2
VThe aims of the present study were to immunohistochemically examine S100A10 expression in surgically resected lung adenocarcinomas, and evaluate any relationships with clinicopathological parameters and prognosis of patients.
p8506
sg4
(lp8507
(dp8508
g7
I68
sg8
g8503
sg10
I7
sg11
VP60903
p8509
sg13
I1
sasg24
(lp8510
(dp8511
g7
I115
sg8
g8504
sg10
I15
sg28
VC0001418
p8512
sg13
I1
sasa(dp8513
g135
(dp8514
(VS100A10
p8515
Vadenocarcinomas
p8516
tp8517
I00
ssg2
VS100A10 expression was immunohistochemically studied in 202 consecutive resected lung adenocarcinomas, and its associations with clinicopathological parameters were evaluated.
p8518
sg4
(lp8519
(dp8520
g7
I0
sg8
g8515
sg10
I7
sg11
VP60903
p8521
sg13
I1
sasg24
(lp8522
(dp8523
g7
I86
sg8
g8516
sg10
I15
sg28
VC0001418
p8524
sg13
I1
sasa(dp8525
g135
(dp8526
(VS100A10
p8527
Vadenocarcinomas
p8528
tp8529
I00
ssg2
VS100A10 expression was detected in 65 of the 202 (32.2%) lung adenocarcinomas, being significantly correlated with poorer differentiation (P =0.015), a higher pathological TNM stage (stages II and III) (P=0.004), more frequent and severe intratumoral vascular invasion (P=0.001), and a poorer prognosis (P=0.030).
p8530
sg4
(lp8531
(dp8532
g7
I0
sg8
g8527
sg10
I7
sg11
VP60903
p8533
sg13
I1
sasg24
(lp8534
(dp8535
g7
I62
sg8
g8528
sg10
I15
sg28
VC0001418
p8536
sg13
I1
sa(dp8537
g7
I260
sg8
Vinvasion
p8538
sg10
I8
sg28
VC2699153
p8539
sg13
I1
sasa(dp8540
g135
(dp8541
(VS100A10
p8542
Vlung adenocarcinoma
p8543
tp8544
I00
ssg2
VThe present study reveals that S100A10 is expressed in a subset of lung adenocarcinomas, and this is related to some clinicopathological parameters, although further studies are required to confirm the correlation between S100A10 expression and prognosis of lung adenocarcinoma patients.
p8545
sg4
(lp8546
(dp8547
g7
I31
sg8
VS100A10
p8548
sg10
I7
sg11
VP60903
p8549
sg13
I1
sa(dp8550
g7
I31
sg8
g8542
sg10
I7
sg11
VP60903
p8551
sg13
I1
sasg24
(lp8552
(dp8553
g7
I72
sg8
Vadenocarcinomas
p8554
sg10
I15
sg28
VC0001418
p8555
sg13
I1
sa(dp8556
g7
I67
sg8
g8543
sg10
I19
sg28
VC0152013
p8557
sg13
I2
sasa(dp8558
g135
(dp8559
(VS100
p8560
VBarrett's adenocarcinoma
p8561
tp8562
I00
ssg2
VUsing mass spectrometry for protein identification and validating the results by immunohistochemistry on an independent validation set, we could identify two of 60 differentially expressed m/z species between Barrett's adenocarcinoma and the precursor lesion: COX7A2 and S100-A10.
p8563
sg4
(lp8564
(dp8565
g7
I260
sg8
VCOX7A2
p8566
sg10
I6
sg11
VP14406
p8567
sg13
I1
sa(dp8568
g7
I271
sg8
g8560
sg10
I4
sg11
VP04271
p8569
sg13
I1
sasg24
(lp8570
(dp8571
g7
I209
sg8
g8561
sg10
I24
sg28
VC1332460
p8572
sg13
I2
sasa(dp8573
g135
(dp8574
(VTAGLN2
p8575
VBarrett's adenocarcinoma
p8576
tp8577
I00
ssg2
VIn the validation set, we found a correlation of the expression levels of COX7A2 and TAGLN2 with a poor prognosis while S100-A10 was confirmed by multivariate analysis as a novel independent prognostic factor in Barrett's adenocarcinoma.
p8578
sg4
(lp8579
(dp8580
g7
I74
sg8
VCOX7A2
p8581
sg10
I6
sg11
VP14406
p8582
sg13
I1
sa(dp8583
g7
I85
sg8
g8575
sg10
I6
sg11
VP37802
p8584
sg13
I1
sasg24
(lp8585
(dp8586
g7
I212
sg8
g8576
sg10
I24
sg28
VC1332460
p8587
sg13
I2
sasa(dp8588
g135
(dp8589
(Vplasminogen
p8590
Vmetastasis
p8591
tp8592
I00
ssg2
VS100A10, a member of the S100 family, forms a heterotetramer with annexin IIH and promotes carcinoma invasion and metastasis by plasminogen activation.
p8593
sg4
(lp8594
(dp8595
g7
I25
sg8
VS100 family
p8596
sg10
I11
sg11
VP04271
p8597
sg13
I2
sa(dp8598
g7
I0
sg8
VS100A10
p8599
sg10
I7
sg11
VP60903
p8600
sg13
I1
sa(dp8601
g7
I128
sg8
g8590
sg10
I11
sg11
VP00747
p8602
sg13
I1
sasg24
(lp8603
(dp8604
g7
I101
sg8
Vinvasion
p8605
sg10
I8
sg28
VC2699153
p8606
sg13
I1
sa(dp8607
g7
I114
sg8
g8591
sg10
I10
sg28
VC0027627
p8608
sg13
I1
sa(dp8609
g7
I91
sg8
Vcarcinoma
p8610
sg10
I9
sg28
VC0007097
p8611
sg13
I1
sasa(dp8612
g2
VCells stained positively in 14.6% and 20.8% of follicular carcinomas for S100A10 and annexin II, respectively, but their expression levels were always low.
p8613
sg4
(lp8614
(dp8615
g7
I85
sg8
Vannexin II
p8616
sg10
I10
sg11
VP07355
p8617
sg13
I2
sa(dp8618
g7
I73
sg8
VS100A10
p8619
sg10
I7
sg11
VP60903
p8620
sg13
I1
sasg24
(lp8621
(dp8622
g7
I58
sg8
Vcarcinomas
p8623
sg10
I10
sg28
VC0007097
p8624
sg13
I1
sasa(dp8625
g135
(dp8626
(VS100A10
p8627
Vpapillary carcinomas
p8628
tp8629
I01
ssg2
VS100A10 and annexin II were expressed in all papillary carcinomas, but 88.2% and 82.8% ofpapillary carcinomas were classified in the low group.
p8630
sg4
(lp8631
(dp8632
g7
I12
sg8
Vannexin II
p8633
sg10
I10
sg11
VP07355
p8634
sg13
I2
sa(dp8635
g7
I0
sg8
g8627
sg10
I7
sg11
VP60903
p8636
sg13
I1
sasg24
(lp8637
(dp8638
g7
I45
sg8
g8628
sg10
I20
sg28
VC0007133
p8639
sg13
I2
sa(dp8640
g7
I55
sg8
Vcarcinomas
p8641
sg10
I10
sg28
VC0007097
p8642
sg13
I1
sasa(dp8643
g135
(dp8644
(VS100A10
p8645
Vpapillary carcinoma
p8646
tp8647
I01
ssg2
VThese findings suggest that S100A10 and annexin II contribute to the aggressive characteristics of anaplastic carcinoma, while playing a constitutive role in papillary carcinoma.
p8648
sg4
(lp8649
(dp8650
g7
I40
sg8
Vannexin II
p8651
sg10
I10
sg11
VP07355
p8652
sg13
I2
sa(dp8653
g7
I28
sg8
g8645
sg10
I7
sg11
VP60903
p8654
sg13
I1
sasg24
(lp8655
(dp8656
g7
I69
sg8
Vaggressive
p8657
sg10
I10
sg28
VC0001807
p8658
sg13
I1
sa(dp8659
g7
I99
sg8
Vanaplastic carcinoma
p8660
sg10
I20
sg28
VC0205698
p8661
sg13
I2
sa(dp8662
g7
I158
sg8
g8646
sg10
I19
sg28
VC0007133
p8663
sg13
I2
sasa(dp8664
g2
VThe spin-labeled derivative of podophyllotoxin, N'-podophyllic acid-N-[3-(2,2,5,5-tetramethyl pyrrolinenyloxy)] semicarbazide (GP-11), was synthesized and tested for its antitumor activity against mouse transplantable tumors, Sarcoma-180, Hepatoma-A, P388 leukemia and Ehrlich ascites carcinoma.
p8665
sg4
(lp8666
sg24
(lp8667
(dp8668
g7
I239
sg8
VHepatoma
p8669
sg10
I8
sg28
VC0023903
p8670
sg13
I1
sa(dp8671
g7
I285
sg8
Vcarcinoma
p8672
sg10
I9
sg28
VC0007097
p8673
sg13
I1
sa(dp8674
g7
I226
sg8
VSarcoma
p8675
sg10
I7
sg28
VC1261473
p8676
sg13
I1
sa(dp8677
g7
I256
sg8
Vleukemia
p8678
sg10
I8
sg28
VC0023418
p8679
sg13
I1
sa(dp8680
g7
I218
sg8
Vtumors
p8681
sg10
I6
sg28
VC0027651
p8682
sg13
I1
sasa(dp8683
g135
(dp8684
(Vtissue-type plasminogen activator
p8685
Vcerebral amyloid angiopathy
p8686
tp8687
I00
ssg2
VRemote parenchymal hemorrhage (rPH) after intravenous thrombolysis with recombinant tissue-type plasminogen activator may be associated with cerebral amyloid angiopathy, although supportive data are limited.
p8688
sg4
(lp8689
(dp8690
g7
I84
sg8
g8685
sg10
I33
sg11
VP00747
p8691
sg13
I3
sasg24
(lp8692
(dp8693
g7
I141
sg8
g8686
sg10
I27
sg28
VC0085220
p8694
sg13
I3
sa(dp8695
g7
I7
sg8
Vparenchymal hemorrhage
p8696
sg10
I22
sg28
VC0747264
p8697
sg13
I2
sasa(dp8698
g135
(dp8699
(Vfibrin
p8700
Vamyloidosis
p8701
tp8702
I00
ssg2
VWe here review the data with respect to the activation of tPA by fibrin and its multiple other cofactors, in relation to tPA's role in pathophysiology, notably fibrinolysis and amyloidosis, with emphasis on Alzheimer's disease.
p8703
sg4
(lp8704
(dp8705
g7
I65
sg8
g8700
sg10
I6
sg11
VP22087
p8706
sg13
I1
sasg24
(lp8707
(dp8708
g7
I177
sg8
g8701
sg10
I11
sg28
VC0002726
p8709
sg13
I1
sa(dp8710
g7
I207
sg8
VAlzheimer's disease
p8711
sg10
I19
sg28
VC1521724
p8712
sg13
I2
sasa(dp8713
g135
(dp8714
(Vrecombinant tissue-type plasminogen activator
p8715
VCerebral amyloid angiopathy
p8716
tp8717
I00
ssg2
VCerebral amyloid angiopathy (CAA) may be an important predisposing factor for the hemorrhagic complications of recombinant tissue-type plasminogen activator (rt-PA) therapy.
p8718
sg4
(lp8719
(dp8720
g7
I158
sg8
Vrt-PA
p8721
sg10
I5
sg11
VP00747
p8722
sg13
I1
sa(dp8723
g7
I111
sg8
g8715
sg10
I45
sg11
VP00747
p8724
sg13
I4
sasg24
(lp8725
(dp8726
g7
I29
sg8
VCAA
p8727
sg10
I3
sg28
VC1842937
p8728
sg13
I1
sa(dp8729
g7
I0
sg8
g8716
sg10
I27
sg28
VC0085220
p8730
sg13
I3
sasa(dp8731
g135
(dp8732
(Vglycoprotein B
p8733
Vherpes simplex
p8734
tp8735
I00
ssg2
VThe purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice.
p8736
sg4
(lp8737
(dp8738
g7
I180
sg8
g8733
sg10
I14
sg11
VP36222
p8739
sg13
I2
sa(dp8740
g7
I196
sg8
VgBs
p8741
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp8742
(dp8743
g7
I196
sg8
VgBs
p8744
sg10
I3
sg28
VC1841700
p8745
sg13
I1
sa(dp8746
g7
I112
sg8
Vvesicles
p8747
sg10
I8
sg28
VC0333262
p8748
sg13
I1
sa(dp8749
g7
I330
sg8
Vherpes infection
p8750
sg10
I16
sg28
VC0019372
p8751
sg13
I2
sa(dp8752
g7
I204
sg8
g8734
sg10
I14
sg28
VC0019348
p8753
sg13
I2
sasa(dp8754
g135
(dp8755
(VCDK
p8756
Vrunt
p8757
tp8758
I00
ssg2
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p8759
sg4
(lp8760
(dp8761
g7
I57
sg8
VT-cell-specific transcription factor
p8762
sg10
I36
sg11
VP35398
p8763
sg13
I3
sa(dp8764
g7
I276
sg8
Vvitamin D receptor
p8765
sg10
I18
sg11
VP11473
p8766
sg13
I3
sa(dp8767
g7
I109
sg8
V"proto-oncogene tyrosine-protein kinase
p8768
sg10
I39
sg11
VP00519
p8769
sg13
I3
sa(dp8770
g7
I399
sg8
VPR domain zinc finger protein 1
p8771
sg10
I31
sg11
g12
sg13
I6
sa(dp8772
g7
I322
sg8
VERK
p8773
sg10
I3
sg11
VP29323
p8774
sg13
I1
sa(dp8775
g7
I362
sg8
Vrunt-related transcription factor 1
p8776
sg10
I35
sg11
VP20823
p8777
sg13
I4
sa(dp8778
g7
I477
sg8
Vinterleukin 1
p8779
sg10
I13
sg11
VP01584
p8780
sg13
I2
sa(dp8781
g7
I152
sg8
Vsarcoma"
p8782
sg10
I8
sg11
VP12931
p8783
sg13
I1
sa(dp8784
g7
I163
sg8
Vinterferon regulatory factor 1
p8785
sg10
I30
sg11
VP10914
p8786
sg13
I4
sa(dp8787
g7
I227
sg8
Vcyclin-dependent kinase (CDK) 4
p8788
sg10
I31
sg11
VP49336
p8789
sg13
I4
sa(dp8790
g7
I296
sg8
Vhistone deacetylase
p8791
sg10
I19
sg11
VP56524
p8792
sg13
I2
sa(dp8793
g7
I95
sg8
VSrc
p8794
sg10
I3
sg11
VP12931
p8795
sg13
I1
sa(dp8796
g7
I217
sg8
Vcyclin B
p8797
sg10
I8
sg11
VP14635
p8798
sg13
I2
sa(dp8799
g7
I334
sg8
Vbcl-2-associated X protein
p8800
sg10
I26
sg11
VP10415
p8801
sg13
I3
sa(dp8802
g7
I317
sg8
VMAPK
p8803
sg10
I4
sg11
VP53779
p8804
sg13
I1
sa(dp8805
g7
I432
sg8
Vplatelet-derived growth factor receptor
p8806
sg10
I39
sg11
VP09619
p8807
sg13
I4
sa(dp8808
g7
I265
sg8
Vcaspase-1
p8809
sg10
I9
sg11
VP29466
p8810
sg13
I1
sa(dp8811
g7
I195
sg8
Vthymidylate synthase
p8812
sg10
I20
sg11
VP04818
p8813
sg13
I2
sa(dp8814
g7
I252
sg8
g8756
sg10
I3
sg11
VP24941
p8815
sg13
I1
sasg24
(lp8816
(dp8817
g7
I152
sg8
Vsarcoma
p8818
sg10
I7
sg28
VC1261473
p8819
sg13
I1
sa(dp8820
g7
I362
sg8
g8757
sg10
I4
sg28
VC0013336
p8821
sg13
I1
sasa(dp8822
g2
VThe IRF-1 priming of TEXs enhances antitumour immune response.British Journal of Cancer advance online publication, 7 November 2017; doi:10.1038/bjc.2017.389 www.bjcancer.com.
p8823
sg4
(lp8824
(dp8825
g7
I4
sg8
VIRF-1
p8826
sg10
I5
sg11
VP10914
p8827
sg13
I1
sasg24
(lp8828
(dp8829
g7
I81
sg8
VCancer
p8830
sg10
I6
sg28
VC0006826
p8831
sg13
I1
sasa(dp8832
g2
VInterferon regulatory factor 1 (IRF1) has been suggested to act as a tumor suppressor in human cancers.
p8833
sg4
(lp8834
(dp8835
g7
I0
sg8
VInterferon regulatory factor 1
p8836
sg10
I30
sg11
VP10914
p8837
sg13
I4
sa(dp8838
g7
I32
sg8
VIRF1
p8839
sg10
I4
sg11
VP10914
p8840
sg13
I1
sasg24
(lp8841
(dp8842
g7
I69
sg8
Vtumor
p8843
sg10
I5
sg28
VC0027651
p8844
sg13
I1
sa(dp8845
g7
I95
sg8
Vcancers
p8846
sg10
I7
sg28
VC0006826
p8847
sg13
I1
sasa(dp8848
g135
(dp8849
(VIRF1
p8850
Vcholangiocarcinoma
p8851
tp8852
I00
ssg2
VHowever, the clinical significance and biological function of IRF1 in cholangiocarcinoma is poorly understood.
p8853
sg4
(lp8854
(dp8855
g7
I62
sg8
g8850
sg10
I4
sg11
VP10914
p8856
sg13
I1
sasg24
(lp8857
(dp8858
g7
I70
sg8
g8851
sg10
I18
sg28
VC0206698
p8859
sg13
I1
sasa(dp8860
g135
(dp8861
(VIRF1 mRNA
p8862
Vcholangiocarcinoma
p8863
tp8864
I00
ssg2
VIn our results, IRF1 mRNA and protein expressions were decreased in cholangiocarcinoma tissues and cell lines compared with paired normal hepatic tissues and intrahepatic bile duct epithelial cell line.
p8865
sg4
(lp8866
(dp8867
g7
I16
sg8
g8862
sg10
I9
sg11
VP10914
p8868
sg13
I2
sasg24
(lp8869
(dp8870
g7
I68
sg8
g8863
sg10
I18
sg28
VC0206698
p8871
sg13
I1
sasa(dp8872
g135
(dp8873
(VIRF1
p8874
Vcholangiocarcinoma
p8875
tp8876
I00
ssg2
VIRF1 protein low-expression was associated with tumor stage, tumor size, vascular invasion and metastasis and served as a poor independent prognostic parameter in cholangiocarcinoma patients.
p8877
sg4
(lp8878
(dp8879
g7
I0
sg8
g8874
sg10
I4
sg11
VP10914
p8880
sg13
I1
sasg24
(lp8881
(dp8882
g7
I95
sg8
Vmetastasis
p8883
sg10
I10
sg28
VC0027627
p8884
sg13
I1
sa(dp8885
g7
I163
sg8
g8875
sg10
I18
sg28
VC0206698
p8886
sg13
I1
sa(dp8887
g7
I48
sg8
Vtumor
p8888
sg10
I5
sg28
VC0027651
p8889
sg13
I1
sa(dp8890
g7
I82
sg8
Vinvasion
p8891
sg10
I8
sg28
VC2699153
p8892
sg13
I1
sa(dp8893
g7
I48
sg8
Vtumor
p8894
sg10
I5
sg28
VC0027651
p8895
sg13
I1
sasa(dp8896
g135
(dp8897
(VIRF1
p8898
Vcholangiocarcinoma
p8899
tp8900
I00
ssg2
VUp-regulation of IRF1 expression suppressed cholangiocarcinoma cells proliferation, migration and invasion, and blocked cell cycle progression, but has no effect on apoptosis.
p8901
sg4
(lp8902
(dp8903
g7
I17
sg8
g8898
sg10
I4
sg11
VP10914
p8904
sg13
I1
sasg24
(lp8905
(dp8906
g7
I44
sg8
g8899
sg10
I18
sg28
VC0206698
p8907
sg13
I1
sa(dp8908
g7
I69
sg8
Vproliferation
p8909
sg10
I13
sg28
VC0334094
p8910
sg13
I1
sa(dp8911
g7
I98
sg8
Vinvasion
p8912
sg10
I8
sg28
VC2699153
p8913
sg13
I1
sasa(dp8914
g135
(dp8915
(VIRF1
p8916
Vcholangiocarcinoma
p8917
tp8918
I00
ssg2
VIn conclusion, IRF1 is low-expressed in cholangiocarcinoma tissues and cell lines, and correlated with malignant status and prognosis in cholangiocarcinoma patients.
p8919
sg4
(lp8920
(dp8921
g7
I15
sg8
g8916
sg10
I4
sg11
VP10914
p8922
sg13
I1
sasg24
(lp8923
(dp8924
g7
I40
sg8
Vcholangiocarcinoma
p8925
sg10
I18
sg28
VC0206698
p8926
sg13
I1
sa(dp8927
g7
I40
sg8
g8917
sg10
I18
sg28
VC0206698
p8928
sg13
I1
sasa(dp8929
g135
(dp8930
(VIRF1
p8931
Vcholangiocarcinoma
p8932
tp8933
I00
ssg2
VIRF1 served as tumor suppressor in the regulation of cholangiocarcinoma cells proliferation, cell cycle, migration and invasion.
p8934
sg4
(lp8935
(dp8936
g7
I0
sg8
g8931
sg10
I4
sg11
VP10914
p8937
sg13
I1
sasg24
(lp8938
(dp8939
g7
I119
sg8
Vinvasion
p8940
sg10
I8
sg28
VC2699153
p8941
sg13
I1
sa(dp8942
g7
I15
sg8
Vtumor
p8943
sg10
I5
sg28
VC0027651
p8944
sg13
I1
sa(dp8945
g7
I53
sg8
g8932
sg10
I18
sg28
VC0206698
p8946
sg13
I1
sa(dp8947
g7
I78
sg8
Vproliferation
p8948
sg10
I13
sg28
VC0334094
p8949
sg13
I1
sasa(dp8950
g135
(dp8951
(VIRF1
p8952
VLuAd
p8953
tp8954
I00
ssg2
VTo examine genetic defects of the IFNGamma-IRF1 pathway in non-small cell lung cancer (NSCLC), we analyzed The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LuAd) and lung squamous cell carcinoma (LuSc) data.
p8955
sg4
(lp8956
(dp8957
g7
I43
sg8
g8952
sg10
I4
sg11
VP10914
p8958
sg13
I1
sasg24
(lp8959
(dp8960
g7
I111
sg8
VCancer
p8961
sg10
I6
sg28
VC0006826
p8962
sg13
I1
sa(dp8963
g7
I59
sg8
Vnon-small cell lung cancer
p8964
sg10
I26
sg28
VC0007131
p8965
sg13
I4
sa(dp8966
g7
I169
sg8
Vlung squamous cell carcinoma
p8967
sg10
I28
sg28
VC0149782
p8968
sg13
I4
sa(dp8969
g7
I199
sg8
VLuSc
p8970
sg10
I4
sg28
VC0149782
p8971
sg13
I1
sa(dp8972
g7
I138
sg8
Vlung adenocarcinoma
p8973
sg10
I19
sg28
VC0152013
p8974
sg13
I2
sa(dp8975
g7
I87
sg8
VNSCLC
p8976
sg10
I5
sg28
VC0007131
p8977
sg13
I1
sa(dp8978
g7
I159
sg8
g8953
sg10
I4
sg28
VC0152013
p8979
sg13
I1
sasa(dp8980
g135
(dp8981
(VIRF1
p8982
VNSCLC
p8983
tp8984
I00
ssg2
VIRF1 expression was correlated with immune cytolytic activity markers GZMA and PRF1 in NSCLC.
p8985
sg4
(lp8986
(dp8987
g7
I79
sg8
VPRF1
p8988
sg10
I4
sg11
VP14222
p8989
sg13
I1
sa(dp8990
g7
I70
sg8
VGZMA
p8991
sg10
I4
sg11
VP12544
p8992
sg13
I1
sa(dp8993
g7
I0
sg8
g8982
sg10
I4
sg11
VP10914
p8994
sg13
I1
sasg24
(lp8995
(dp8996
g7
I87
sg8
g8983
sg10
I5
sg28
VC0007131
p8997
sg13
I1
sasa(dp8998
g135
(dp8999
(VIRF1
p9000
VNSCLC
p9001
tp9002
I00
ssg2
VDeletion of JAK2 or inhibition of the JAK2 kinase activity resulted in loss of IFNGamma-induced IRF1 and cell surface HLA-ABC in JAK2 wildtype NSCLC cells, whereas expression of exogenous JAK2 in H1573 cells restored the IFNGamma responses.
p9003
sg4
(lp9004
(dp9005
g7
I12
sg8
VJAK2
p9006
sg10
I4
sg11
g12
sg13
I1
sa(dp9007
g7
I96
sg8
g9000
sg10
I4
sg11
VP10914
p9008
sg13
I1
sa(dp9009
g7
I12
sg8
VJAK2
p9010
sg10
I4
sg11
g12
sg13
I1
sa(dp9011
g7
I118
sg8
VHLA-ABC
p9012
sg10
I7
sg11
VP30486
p9013
sg13
I1
sa(dp9014
g7
I12
sg8
VJAK2
p9015
sg10
I4
sg11
g12
sg13
I1
sa(dp9016
g7
I38
sg8
VJAK2 kinase
p9017
sg10
I11
sg11
g12
sg13
I2
sasg24
(lp9018
(dp9019
g7
I143
sg8
g9001
sg10
I5
sg28
VC0007131
p9020
sg13
I1
sasa(dp9021
g135
(dp9022
(VIFNGamma-IRF1
p9023
VNSCLC
p9024
tp9025
I00
ssg2
VThese findings show that JAK2 deficiency is the major mechanism of genetic defects of the IFNGamma-IRF1 pathway in NSCLC and reveal a previously unrecognized significance of chromosome 9p deletion in NSCLC.
p9026
sg4
(lp9027
(dp9028
g7
I25
sg8
VJAK2
p9029
sg10
I4
sg11
g12
sg13
I1
sa(dp9030
g7
I90
sg8
g9023
sg10
I13
sg11
VP10914
p9031
sg13
I1
sasg24
(lp9032
(dp9033
g7
I115
sg8
VNSCLC
p9034
sg10
I5
sg28
VC0007131
p9035
sg13
I1
sa(dp9036
g7
I115
sg8
g9024
sg10
I5
sg28
VC0007131
p9037
sg13
I1
sasa(dp9038
g135
(dp9039
(VABL1
p9040
VBladder Cancer
p9041
tp9042
I00
ssg2
VPerformance of the investigational use only-labeled GeneXpert(R) (Cepheid, Sunnyvale, CA) Bladder Cancer Assay, an assay for detection of the five mRNAs (ABL1, CRH, IGF2, ANXA10, and UPK1B), was evaluated in an independent test cohort (n=450).
p9043
sg4
(lp9044
(dp9045
g7
I171
sg8
VANXA10
p9046
sg10
I6
sg11
g12
sg13
I1
sa(dp9047
g7
I160
sg8
VCRH
p9048
sg10
I3
sg11
VP06850
p9049
sg13
I1
sa(dp9050
g7
I165
sg8
VIGF2
p9051
sg10
I4
sg11
VP01344
p9052
sg13
I1
sa(dp9053
g7
I183
sg8
VUPK1B
p9054
sg10
I5
sg11
g12
sg13
I1
sa(dp9055
g7
I154
sg8
g9040
sg10
I4
sg11
VP00519
p9056
sg13
I1
sasg24
(lp9057
(dp9058
g7
I90
sg8
g9041
sg10
I14
sg28
VC0699885
p9059
sg13
I2
sasa(dp9060
g135
(dp9061
(VCD24
p9062
Vadenocarcinoma
p9063
tp9064
I00
ssg2
VOur previous mass spectrometry-based proteomics study revealed that annexin A10 (ANXA10) was uniquely overexpressed in pancreatic CD24+ adenocarcinoma cells that were dissected from clinical PDAC tissues but was absent in CD24- adjacent normal cells.
p9065
sg4
(lp9066
(dp9067
g7
I81
sg8
VANXA10
p9068
sg10
I6
sg11
g12
sg13
I1
sa(dp9069
g7
I68
sg8
Vannexin A10
p9070
sg10
I11
sg11
g12
sg13
I2
sa(dp9071
g7
I130
sg8
g9062
sg10
I4
sg11
VP25063
p9072
sg13
I1
sasg24
(lp9073
(dp9074
g7
I136
sg8
g9063
sg10
I14
sg28
VC0001418
p9075
sg13
I1
sasa(dp9076
g2
VThe correlation between ANXA10 expression and the progression of pancreatic cancer remains unknown.
p9077
sg4
(lp9078
(dp9079
g7
I24
sg8
VANXA10
p9080
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp9081
(dp9082
g7
I65
sg8
Vpancreatic cancer
p9083
sg10
I17
sg28
VC0235974
p9084
sg13
I2
sasa(dp9085
g2
VIn this study, we performed an immunostaining assay to evaluate ANXA10 expression in 155 primary human tissue specimens, including normal pancreas, chronic pancreatitis (CP), pancreatic adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN, the most important precursor of PDAC), and intraductal papillary mucinous neoplasm (IPMN).
p9086
sg4
(lp9087
(dp9088
g7
I64
sg8
VANXA10
p9089
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp9090
(dp9091
g7
I209
sg8
Vpancreatic intraepithelial neoplasia
p9092
sg10
I36
sg28
VC1301034
p9093
sg13
I3
sa(dp9094
g7
I297
sg8
Vintraductal papillary mucinous neoplasm
p9095
sg10
I39
sg28
VC3160815
p9096
sg13
I4
sa(dp9097
g7
I175
sg8
Vpancreatic adenocarcinoma
p9098
sg10
I25
sg28
VC0281361
p9099
sg13
I2
sa(dp9100
g7
I148
sg8
Vchronic pancreatitis
p9101
sg10
I20
sg28
VC0149521
p9102
sg13
I2
sa(dp9103
g7
I202
sg8
VPDAC
p9104
sg10
I4
sg28
VC0281361
p9105
sg13
I1
sa(dp9106
g7
I202
sg8
VPDAC
p9107
sg10
I4
sg28
VC0281361
p9108
sg13
I1
sa(dp9109
g7
I170
sg8
VCP
p9110
sg10
I2
sg28
VC0149521
p9111
sg13
I1
sa(dp9112
g7
I247
sg8
VPanIN
p9113
sg10
I5
sg28
VC1301034
p9114
sg13
I1
sa(dp9115
g7
I338
sg8
VIPMN
p9116
sg10
I4
sg28
VC3160815
p9117
sg13
I1
sasa(dp9118
g2
VSince PDAC develops through a series of PanINs which in turn arise from pancreatic ducts, the consistent overexpression of ANXA10 in ductal epithelial cells in PanINs and PDACs but negative in normal pancreatic ducts suggests that ANXA10 could serve as a potential marker indicating the presence of PDAC at its earliest precancerous stages.
p9119
sg4
(lp9120
(dp9121
g7
I123
sg8
VANXA10
p9122
sg10
I6
sg11
g12
sg13
I1
sa(dp9123
g7
I123
sg8
VANXA10
p9124
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp9125
sa(dp9126
g2
VIn this study, we evaluated the effects of simvastatin on ANXA10 signaling in androgen-independent prostate cancer cells.
p9127
sg4
(lp9128
(dp9129
g7
I58
sg8
VANXA10
p9130
sg10
I6
sg11
g12
sg13
I1
sa(dp9131
g7
I43
sg8
Vsimvastatin
p9132
sg10
I11
sg11
g12
sg13
I1
sasg24
(lp9133
(dp9134
g7
I99
sg8
Vprostate cancer
p9135
sg10
I15
sg28
VC0600139
p9136
sg13
I2
sasa(dp9137
g2
VIn human prostate biopsy samples, ANXA10 mRNA expression was significantly lower in the prostate cancer group than in the BPH group.
p9138
sg4
(lp9139
(dp9140
g7
I34
sg8
VANXA10 mRNA
p9141
sg10
I11
sg11
g12
sg13
I2
sasg24
(lp9142
(dp9143
g7
I122
sg8
VBPH
p9144
sg10
I3
sg28
VC0005001
p9145
sg13
I1
sa(dp9146
g7
I88
sg8
Vprostate cancer
p9147
sg10
I15
sg28
VC0600139
p9148
sg13
I2
sasa(dp9149
g135
(dp9150
(VS100 calcium binding protein A4
p9151
Vaggressiveness
p9152
tp9153
I00
ssg2
VNext, we found that up-regulation of ANXA10 in PC-3 resulted in down-regulation of S100 calcium binding protein A4 (S100A4), which is reportedly correlated with aggressiveness and a worse prognosis for patients with different types of carcinomas.
p9154
sg4
(lp9155
(dp9156
g7
I116
sg8
VS100A4
p9157
sg10
I6
sg11
VP26447
p9158
sg13
I1
sa(dp9159
g7
I83
sg8
g9151
sg10
I31
sg11
VP26447
p9160
sg13
I5
sa(dp9161
g7
I47
sg8
VPC-3
p9162
sg10
I4
sg11
g12
sg13
I1
sa(dp9163
g7
I37
sg8
VANXA10
p9164
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp9165
(dp9166
g7
I235
sg8
Vcarcinomas
p9167
sg10
I10
sg28
VC0007097
p9168
sg13
I1
sa(dp9169
g7
I161
sg8
g9152
sg10
I14
sg28
VC0001807
p9170
sg13
I1
sasa(dp9171
g2
VOur results suggest that statins inhibit the proliferation, migration, and invasion of androgen-independent prostate cancer cells by up-regulation of ANXA10.
p9172
sg4
(lp9173
(dp9174
g7
I150
sg8
VANXA10
p9175
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp9176
(dp9177
g7
I75
sg8
Vinvasion
p9178
sg10
I8
sg28
VC2699153
p9179
sg13
I1
sa(dp9180
g7
I108
sg8
Vprostate cancer
p9181
sg10
I15
sg28
VC0600139
p9182
sg13
I2
sa(dp9183
g7
I45
sg8
Vproliferation
p9184
sg10
I13
sg28
VC0334094
p9185
sg13
I1
sasa(dp9186
g135
(dp9187
(VCTSE
p9188
VMSI
p9189
tp9190
I00
ssg2
VImmunohistochemistry for 7 gastric-type markers (ANXA10, VSIG1, CLDN18, CTSE, TFF2, MUC5AC, and MUC6) and 2 intestinal-type markers (CDX2 and CK20) was performed in 36 normal gastric/colorectal mucosa tissues, 163 colorectal polyps, and 175 microsatellite-unstable colorectal carcinomas (MSI-H CRCs).
p9191
sg4
(lp9192
(dp9193
g7
I133
sg8
VCDX2
p9194
sg10
I4
sg11
g12
sg13
I1
sa(dp9195
g7
I57
sg8
VVSIG1
p9196
sg10
I5
sg11
g12
sg13
I1
sa(dp9197
g7
I64
sg8
VCLDN18
p9198
sg10
I6
sg11
VP56856
p9199
sg13
I1
sa(dp9200
g7
I142
sg8
VCK20
p9201
sg10
I4
sg11
VP35900
p9202
sg13
I1
sa(dp9203
g7
I78
sg8
VTFF2
p9204
sg10
I4
sg11
g12
sg13
I1
sa(dp9205
g7
I72
sg8
g9188
sg10
I4
sg11
VP14091
p9206
sg13
I1
sa(dp9207
g7
I96
sg8
VMUC6
p9208
sg10
I4
sg11
g12
sg13
I1
sa(dp9209
g7
I49
sg8
VANXA10
p9210
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp9211
(dp9212
g7
I265
sg8
Vcolorectal carcinomas
p9213
sg10
I21
sg28
VC0009402
p9214
sg13
I2
sa(dp9215
g7
I214
sg8
Vcolorectal polyps
p9216
sg10
I17
sg28
VC0949059
p9217
sg13
I2
sa(dp9218
g7
I288
sg8
g9189
sg10
I3
sg28
VC0920269
p9219
sg13
I1
sasa(dp9220
g135
(dp9221
(VGalectin-8
p9222
Vprostate carcinoma
p9223
tp9224
I00
ssg2
VTwo decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue.
p9225
sg4
(lp9226
(dp9227
g7
I17
sg8
g9222
sg10
I10
sg11
VP09382
p9228
sg13
I1
sasg24
(lp9229
(dp9230
g7
I47
sg8
g9223
sg10
I18
sg28
VC0600139
p9231
sg13
I2
sasa(dp9232
g135
(dp9233
(VPC3
p9234
Vprostate cancer
p9235
tp9236
I00
ssg2
VIn this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages.
p9237
sg4
(lp9238
(dp9239
g7
I26
sg8
VGalectin-8
p9240
sg10
I10
sg11
VP09382
p9241
sg13
I1
sa(dp9242
g7
I78
sg8
g9234
sg10
I3
sg11
VP42025
p9243
sg13
I1
sa(dp9244
g7
I86
sg8
VIGR-CaP1
p9245
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp9246
(dp9247
g7
I170
sg8
Vpathology
p9248
sg10
I9
sg28
VC0677042
p9249
sg13
I1
sa(dp9250
g7
I50
sg8
g9235
sg10
I15
sg28
VC0600139
p9251
sg13
I2
sasa(dp9252
g135
(dp9253
(VGal-8
p9254
Vprostate cancer
p9255
tp9256
I00
ssg2
VWe show for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer.
p9257
sg4
(lp9258
(dp9259
g7
I72
sg8
g9254
sg10
I5
sg11
VP16278
p9260
sg13
I1
sasg24
(lp9261
(dp9262
g7
I81
sg8
Vtumour
p9263
sg10
I6
sg28
VC0027651
p9264
sg13
I1
sa(dp9265
g7
I141
sg8
g9255
sg10
I15
sg28
VC0600139
p9266
sg13
I2
sasa(dp9267
g135
(dp9268
(VGalectin-8
p9269
Vprostate cancer
p9270
tp9271
I00
ssg2
VCollectively, our results highlight Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer.
p9272
sg4
(lp9273
(dp9274
g7
I36
sg8
g9269
sg10
I10
sg11
VP09382
p9275
sg13
I1
sasg24
(lp9276
(dp9277
g7
I105
sg8
g9270
sg10
I15
sg28
VC0600139
p9278
sg13
I2
sasa(dp9279
g135
(dp9280
(Vprostate carcinoma tumour antigen
p9281
Vprostate carcinoma
p9282
tp9283
I00
ssg2
VImmunocytochemistry for prostate carcinoma tumour antigen (PCTA-1) was performed for culture purity evaluation.
p9284
sg4
(lp9285
(dp9286
g7
I24
sg8
g9281
sg10
I33
sg11
VP49221
p9287
sg13
I4
sasg24
(lp9288
(dp9289
g7
I24
sg8
g9282
sg10
I18
sg28
VC0600139
p9290
sg13
I2
sa(dp9291
g7
I43
sg8
Vtumour
p9292
sg10
I6
sg28
VC0027651
p9293
sg13
I1
sasa(dp9294
g135
(dp9295
(VGalectin-8
p9296
Vneoplasms, prostate
p9297
tp9298
I01
ssg2
VGalectin-8 levels of expression positively correlate with certain human neoplasms, prostate cancer being the best example studied thus far.
p9299
sg4
(lp9300
(dp9301
g7
I0
sg8
g9296
sg10
I10
sg11
VP09382
p9302
sg13
I1
sasg24
(lp9303
(dp9304
g7
I72
sg8
g9297
sg10
I19
sg28
VC0033578
p9305
sg13
I2
sa(dp9306
g7
I92
sg8
Vcancer
p9307
sg10
I6
sg28
VC0006826
p9308
sg13
I1
sasa(dp9309
g135
(dp9310
(VCarcinoma Tumor Antigen-1
p9311
VPCaP
p9312
tp9313
I00
ssg2
VThe Prostate Carcinoma Tumor Antigen-1 (PCTA-1) is located at the prostate cancer susceptibility locus on chromosome 1q42.2-43 (PCaP).
p9314
sg4
(lp9315
(dp9316
g7
I13
sg8
g9311
sg10
I25
sg11
VP14209
p9317
sg13
I3
sa(dp9318
g7
I66
sg8
Vprostate cancer susceptibility
p9319
sg10
I30
sg11
g12
sg13
I3
sasg24
(lp9320
(dp9321
g7
I66
sg8
Vprostate cancer susceptibility locus on chromosome 1q42.2-43
p9322
sg10
I60
sg28
VC1864472
p9323
sg13
I7
sa(dp9324
g7
I23
sg8
VTumor
p9325
sg10
I5
sg28
VC0027651
p9326
sg13
I1
sa(dp9327
g7
I4
sg8
VProstate Carcinoma
p9328
sg10
I18
sg28
VC0600139
p9329
sg13
I2
sa(dp9330
g7
I128
sg8
g9312
sg10
I4
sg28
VC1864472
p9331
sg13
I1
sasa(dp9332
g2
VSeventy-seven familial prostate cancer cases from 36 German and French pedigrees were screened for germline mutations in the PCTA-1 gene using enzymatic mutation detection (EMD).
p9333
sg4
(lp9334
sg24
(lp9335
(dp9336
g7
I143
sg8
Venzymatic mutation detection
p9337
sg10
I28
sg28
VC0340861
p9338
sg13
I3
sa(dp9339
g7
I173
sg8
VEMD
p9340
sg10
I3
sg28
VC0340861
p9341
sg13
I1
sa(dp9342
g7
I23
sg8
Vprostate cancer
p9343
sg10
I15
sg28
VC0600139
p9344
sg13
I2
sasa(dp9345
g2
VPCTA-1 is not a classical high risk gene with deleterious mutations predisposing to hereditary prostate cancer.
p9346
sg4
(lp9347
sg24
(lp9348
(dp9349
g7
I84
sg8
Vhereditary prostate cancer
p9350
sg10
I26
sg28
VC2931456
p9351
sg13
I3
sasa(dp9352
g135
(dp9353
(VGalectin-8
p9354
VSEM
p9355
tp9356
I00
ssg2
VThe isolation of Prostate Carcinoma Tumor Antigen-1 (PCTA-1), a cDNA closely related to rat and human Galectin-8, as a surface marker associated with prostate cancer was achieved using a previously described immunological subtraction approach, Surface Epitope Masking (SEM) approach, in combination with expression screening.
p9357
sg4
(lp9358
(dp9359
g7
I26
sg8
VCarcinoma Tumor Antigen-1
p9360
sg10
I25
sg11
VP14209
p9361
sg13
I3
sa(dp9362
g7
I102
sg8
g9354
sg10
I10
sg11
VP09382
p9363
sg13
I1
sasg24
(lp9364
(dp9365
g7
I36
sg8
VTumor
p9366
sg10
I5
sg28
VC0027651
p9367
sg13
I1
sa(dp9368
g7
I150
sg8
Vprostate cancer
p9369
sg10
I15
sg28
VC0600139
p9370
sg13
I2
sa(dp9371
g7
I244
sg8
VSurface Epitope Masking
p9372
sg10
I23
sg28
VC0432222
p9373
sg13
I3
sa(dp9374
g7
I17
sg8
VProstate Carcinoma
p9375
sg10
I18
sg28
VC0600139
p9376
sg13
I2
sa(dp9377
g7
I269
sg8
g9355
sg10
I3
sg28
VC0432222
p9378
sg13
I1
sasa(dp9379
g2
VPCTA-1 maps to 1q42-43, a locus associated with predisposition to prostate cancer.
p9380
sg4
(lp9381
sg24
(lp9382
(dp9383
g7
I66
sg8
Vprostate cancer
p9384
sg10
I15
sg28
VC0600139
p9385
sg13
I2
sasa(dp9386
g135
(dp9387
(VPCTA-1
p9388
Vprostate carcinoma
p9389
tp9390
I00
ssg2
VScreening a human LNCaP prostate cancer cDNA expression library with the Pro 1.5 mAb identifies a gene, prostate carcinoma tumor antigen-1 (PCTA-1).
p9391
sg4
(lp9392
(dp9393
g7
I73
sg8
VPro 1.5 mAb
p9394
sg10
I11
sg11
VP63125
p9395
sg13
I3
sa(dp9396
g7
I104
sg8
Vprostate carcinoma tumor antigen-1
p9397
sg10
I34
sg11
VP49221
p9398
sg13
I4
sa(dp9399
g7
I140
sg8
g9388
sg10
I6
sg11
VP49221
p9400
sg13
I1
sasg24
(lp9401
(dp9402
g7
I24
sg8
Vprostate cancer
p9403
sg10
I15
sg28
VC0600139
p9404
sg13
I2
sa(dp9405
g7
I123
sg8
Vtumor
p9406
sg10
I5
sg28
VC0027651
p9407
sg13
I1
sa(dp9408
g7
I104
sg8
g9389
sg10
I18
sg28
VC0600139
p9409
sg13
I2
sasa(dp9410
g2
VPrimer pairs within the 3' untranslated region of PCTA-1 and reverse transcription-PCR demonstrate selective expression of PCTA-1 by prostate carcinomas versus normal prostate and benign prostatic hypertrophy.
p9411
sg4
(lp9412
sg24
(lp9413
(dp9414
g7
I142
sg8
Vcarcinomas
p9415
sg10
I10
sg28
VC0007097
p9416
sg13
I1
sa(dp9417
g7
I180
sg8
Vbenign prostatic hypertrophy
p9418
sg10
I28
sg28
VC0005001
p9419
sg13
I3
sasa(dp9420
g135
(dp9421
(VLMO2
p9422
VT-cell acute lymphoblastic leukemia
p9423
tp9424
I00
ssg2
VMoreover, Foxp3 could interact with LMO2 and affect the expression level of TAL1, which was in accordance with the findings in T-cell acute lymphoblastic leukemia.
p9425
sg4
(lp9426
(dp9427
g7
I76
sg8
VTAL1
p9428
sg10
I4
sg11
VP17542
p9429
sg13
I1
sa(dp9430
g7
I36
sg8
g9422
sg10
I4
sg11
VP25791
p9431
sg13
I1
sa(dp9432
g7
I10
sg8
VFoxp3
p9433
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp9434
(dp9435
g7
I127
sg8
g9423
sg10
I35
sg28
VC1961099
p9436
sg13
I4
sasa(dp9437
g135
(dp9438
(VLMO2
p9439
VT-cell acute lymphoblastic leukemia
p9440
tp9441
I00
ssg2
VOverexpression of LMO2 is known to be one of the causes of T-cell acute lymphoblastic leukemia (T-ALL) development; however, the mechanisms behind its oncogenic activity are incompletely understood.
p9442
sg4
(lp9443
(dp9444
g7
I18
sg8
g9439
sg10
I4
sg11
VP25791
p9445
sg13
I1
sasg24
(lp9446
(dp9447
g7
I96
sg8
VT-ALL
p9448
sg10
I5
sg28
VC1961099
p9449
sg13
I1
sa(dp9450
g7
I59
sg8
g9440
sg10
I35
sg28
VC1961099
p9451
sg13
I4
sasa(dp9452
g135
(dp9453
(Vleukemia viral oncogene homolog 1
p9454
VT-cell acute lymphoblastic leukemia
p9455
tp9456
I00
ssg2
VExpression of LMO2 has been evaluated in B-cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia; however, information concerning its role in breakpoint cluster region/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) negative B-cell acute lymphoblastic leukemia (B-ALL) remains limited.
p9457
sg4
(lp9458
(dp9459
g7
I14
sg8
VLMO2
p9460
sg10
I4
sg11
VP25791
p9461
sg13
I1
sa(dp9462
g7
I246
sg8
VABL
p9463
sg10
I3
sg11
VP55157
p9464
sg13
I1
sa(dp9465
g7
I242
sg8
VBCR
p9466
sg10
I3
sg11
VP11274
p9467
sg13
I1
sa(dp9468
g7
I207
sg8
g9454
sg10
I33
sg11
VP35125
p9469
sg13
I5
sasg24
(lp9470
(dp9471
g7
I98
sg8
Vacute myeloid leukemia
p9472
sg10
I22
sg28
VC0023467
p9473
sg13
I3
sa(dp9474
g7
I85
sg8
Vleukemia
p9475
sg10
I8
sg28
VC0023418
p9476
sg13
I1
sa(dp9477
g7
I246
sg8
VABL
p9478
sg10
I3
sg28
VC0000744
p9479
sg13
I1
sa(dp9480
g7
I297
sg8
VB-ALL
p9481
sg10
I5
sg28
VC0006413
p9482
sg13
I1
sa(dp9483
g7
I260
sg8
VB-cell acute lymphoblastic leukemia
p9484
sg10
I35
sg28
VC1292769
p9485
sg13
I4
sa(dp9486
g7
I58
sg8
g9455
sg10
I35
sg28
VC1961099
p9487
sg13
I4
sasa(dp9488
g135
(dp9489
(VLMO2
p9490
VT-cell acute lymphoblastic leukemia
p9491
tp9492
I00
ssg2
VOncogenic transcription factors are commonly activated in acute leukemias and subvert normal gene expression networks to reprogram hematopoietic progenitors into preleukemic stem cells, as exemplified by LIM-only 2 (LMO2) in T-cell acute lymphoblastic leukemia (T-ALL).
p9493
sg4
(lp9494
(dp9495
g7
I216
sg8
g9490
sg10
I4
sg11
VP25791
p9496
sg13
I1
sa(dp9497
g7
I204
sg8
VLIM-only 2
p9498
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp9499
(dp9500
g7
I58
sg8
Vacute leukemias
p9501
sg10
I15
sg28
VC0085669
p9502
sg13
I2
sa(dp9503
g7
I262
sg8
VT-ALL
p9504
sg10
I5
sg28
VC1961099
p9505
sg13
I1
sa(dp9506
g7
I225
sg8
g9491
sg10
I35
sg28
VC1961099
p9507
sg13
I4
sasa(dp9508
g135
(dp9509
(VTAL1 transcriptional complex
p9510
VT-cell acute lymphocytic leukemia
p9511
tp9512
I00
ssg2
VT-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex.
p9513
sg4
(lp9514
(dp9515
g7
I93
sg8
VT-cell acute lymphocytic leukemia 1
p9516
sg10
I35
sg11
VP17542
p9517
sg13
I5
sa(dp9518
g7
I134
sg8
VLMO2
p9519
sg10
I4
sg11
VP25791
p9520
sg13
I1
sa(dp9521
g7
I0
sg8
VT-cell acute
p9522
sg10
I12
sg11
g12
sg13
I2
sa(dp9523
g7
I87
sg8
VTAL1
p9524
sg10
I4
sg11
VP17542
p9525
sg13
I1
sa(dp9526
g7
I165
sg8
g9510
sg10
I28
sg11
VP17542
p9527
sg13
I3
sasg24
(lp9528
(dp9529
g7
I0
sg8
VT-cell acute lymphoblastic leukemia
p9530
sg10
I35
sg28
VC1961099
p9531
sg13
I4
sa(dp9532
g7
I37
sg8
VT-ALL
p9533
sg10
I5
sg28
VC1961099
p9534
sg13
I1
sa(dp9535
g7
I93
sg8
g9511
sg10
I33
sg28
VC1961099
p9536
sg13
I4
sasa(dp9537
g135
(dp9538
(VLmo2
p9539
Vacute lymphoblastic leukemia
p9540
tp9541
I00
ssg2
VLmo2 is an oncogenic transcription factor that is frequently overexpressed in T-cell acute leukemias, in particular poor prognosis early T-cell precursor-like (ETP-) acute lymphoblastic leukemia (ALL).
p9542
sg4
(lp9543
(dp9544
g7
I160
sg8
VETP
p9545
sg10
I3
sg11
g12
sg13
I1
sa(dp9546
g7
I137
sg8
VT-cell precursor-like
p9547
sg10
I21
sg11
VP01275
p9548
sg13
I2
sa(dp9549
g7
I0
sg8
g9539
sg10
I4
sg11
VP25791
p9550
sg13
I1
sasg24
(lp9551
(dp9552
g7
I85
sg8
Vacute leukemias
p9553
sg10
I15
sg28
VC0085669
p9554
sg13
I2
sa(dp9555
g7
I196
sg8
VALL
p9556
sg10
I3
sg28
VC1961102
p9557
sg13
I1
sa(dp9558
g7
I166
sg8
g9540
sg10
I28
sg28
VC1961102
p9559
sg13
I3
sasa(dp9560
g2
VParticipants (N = 4,901) were from Look AHEAD, a randomized controlled trial that compared ILI to diabetes support and education (DSE).
p9561
sg4
(lp9562
sg24
(lp9563
(dp9564
g7
I98
sg8
Vdiabetes
p9565
sg10
I8
sg28
VC0011849
p9566
sg13
I1
sasa(dp9567
g2
VA multidomain intensive lifestyle intervention (ILI) to induce weight loss and increase physical activity for 8 to 11 years or diabetes support and education (DSE), a control condition.
p9568
sg4
(lp9569
sg24
(lp9570
(dp9571
g7
I175
sg8
Vcondition
p9572
sg10
I9
sg28
VC0012634
p9573
sg13
I1
sa(dp9574
g7
I127
sg8
Vdiabetes
p9575
sg10
I8
sg28
VC0011849
p9576
sg13
I1
sasa(dp9577
g2
VOverweight and obese (BMI &gt;=25 kg/m 2) middle-aged and older adults (aged 45-76 years at enrollment) with type 2 diabetes enrolled in Look AHEAD, a trial evaluating an intensive lifestyle intervention (ILI) designed to achieve weight loss through caloric restriction and increased physical activity compared to diabetes support and education (DSE), underwent standardized assessments of performance-based physical function including a 4- and 400-m walk, lower extremity physical performance (expanded Short Physical Performance Battery, SPPBexp), and grip strength approximately 11 years post-randomization and 1.5 years after the intervention was stopped (n=3,783).
p9578
sg4
(lp9579
sg24
(lp9580
(dp9581
g7
I116
sg8
Vdiabetes
p9582
sg10
I8
sg28
VC0011849
p9583
sg13
I1
sa(dp9584
g7
I15
sg8
Vobese
p9585
sg10
I5
sg28
VC0028754
p9586
sg13
I1
sa(dp9587
g7
I0
sg8
VOverweight
p9588
sg10
I10
sg28
VC0497406
p9589
sg13
I1
sa(dp9590
g7
I109
sg8
Vtype 2 diabetes
p9591
sg10
I15
sg28
VC0011860
p9592
sg13
I3
sasa(dp9593
g2
VTo address the unique nature of prions, our group targets epitopes, termed disease specific epitopes (DSEs), whose exposure for antibody binding depends on disease-associated misfolding of PrPC into PrPSc.
p9594
sg4
(lp9595
(dp9596
g7
I189
sg8
VPrPC
p9597
sg10
I4
sg11
VP48637
p9598
sg13
I1
sasg24
(lp9599
sa(dp9600
g2
VDuring 5 years spanning the end of intervention and post-intervention follow-up, repeated cognitive assessments were obtained in 1,091 individuals who had been assigned to ILI or a control condition of diabetes support and education (DSE).
p9601
sg4
(lp9602
sg24
(lp9603
(dp9604
g7
I189
sg8
Vcondition
p9605
sg10
I9
sg28
VC0012634
p9606
sg13
I1
sa(dp9607
g7
I202
sg8
Vdiabetes
p9608
sg10
I8
sg28
VC0011849
p9609
sg13
I1
sasa(dp9610
g2
VA total of 5145 persons aged 45 to 76 years with DM were randomized to either an intensive lifestyle intervention (ILI) with reduced calorie consumption and increased physical activity designed to achieve and maintain &gt;=7% weight loss or to diabetes support and education intervention (DSE).
p9611
sg4
(lp9612
sg24
(lp9613
(dp9614
g7
I244
sg8
Vdiabetes
p9615
sg10
I8
sg28
VC0011849
p9616
sg13
I1
sasa(dp9617
g2
VThe purpose of this study was to assess range of motion (ROM), pain, and incidence of radiographic degenerative joint disease (DJD) after volar radioscapholunate (RSL) arthrodesis and distal scaphoidectomy (DSE) following malunited distal radius fractures (DRF).
p9618
sg4
(lp9619
sg24
(lp9620
(dp9621
g7
I127
sg8
VDJD
p9622
sg10
I3
sg28
VC0029408
p9623
sg13
I1
sa(dp9624
g7
I99
sg8
Vdegenerative joint disease
p9625
sg10
I26
sg28
VC0029408
p9626
sg13
I3
sasa(dp9627
g2
VFourteen patients with malunited DRF and DJD limited to the radiocarpal joint underwent RSL arthrodesis and DSE between 2006 and 2014.
p9628
sg4
(lp9629
sg24
(lp9630
sa(dp9631
g2
VThe impact of a static electric field (EF) on amyloid peptide aggregation has been much less studied, although EFs may have some applications to treat Parkinson's disease symptoms.
p9632
sg4
(lp9633
sg24
(lp9634
(dp9635
g7
I46
sg8
Vamyloid
p9636
sg10
I7
sg28
VC0011560
p9637
sg13
I1
sa(dp9638
g7
I151
sg8
VParkinson's disease
p9639
sg10
I19
sg28
VC0030567
p9640
sg13
I2
sasa(dp9641
g2
VCognitive impairments occur frequently and early in multiple sclerosis (MS) and contribute significantly to a reduced quality of life of patients with MS. Executive functions (EFs) play a pivotal role for the behavioral adaption to the environment and are also crucial for compensatory processes of cognitive impairments.
p9642
sg4
(lp9643
sg24
(lp9644
(dp9645
g7
I299
sg8
Vcognitive impairments
p9646
sg10
I21
sg28
VC0338656
p9647
sg13
I2
sa(dp9648
g7
I72
sg8
VMS
p9649
sg10
I2
sg28
VC0036429
p9650
sg13
I1
sa(dp9651
g7
I72
sg8
VMS
p9652
sg10
I2
sg28
VC0036429
p9653
sg13
I1
sa(dp9654
g7
I0
sg8
VCognitive impairments
p9655
sg10
I21
sg28
VC0338656
p9656
sg13
I2
sa(dp9657
g7
I52
sg8
Vmultiple sclerosis
p9658
sg10
I18
sg28
VC0026769
p9659
sg13
I2
sasa(dp9660
g2
VSeveral recent studies have pointed out that early impairment of executive functions (EFs) in Parkinson's Disease (PD) may be a crucial marker to detect patients at risk for developing dementia.
p9661
sg4
(lp9662
sg24
(lp9663
(dp9664
g7
I51
sg8
Vimpairment
p9665
sg10
I10
sg28
VC0684336
p9666
sg13
I1
sa(dp9667
g7
I94
sg8
VParkinson's Disease
p9668
sg10
I19
sg28
VC0030567
p9669
sg13
I2
sa(dp9670
g7
I115
sg8
VPD
p9671
sg10
I2
sg28
VC0030567
p9672
sg13
I1
sa(dp9673
g7
I185
sg8
Vdementia
p9674
sg10
I8
sg28
VC0497327
p9675
sg13
I1
sasa(dp9676
g2
VImportantly, analysis of circulating EVs from plasma of alcoholic hepatitis patients revealed increased numbers of EVs that contained high levels of miR-27a as compared with healthy controls.
p9677
sg4
(lp9678
(dp9679
g7
I149
sg8
VmiR-27a
p9680
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp9681
(dp9682
g7
I56
sg8
Valcoholic hepatitis
p9683
sg10
I19
sg28
VC0019187
p9684
sg13
I2
sasa(dp9685
g135
(dp9686
(Vinsulin
p9687
Vvitiligo
p9688
tp9689
I00
ssg2
VThe following associations were found: auto-immune thyroid disease (4.3% of DH patients and 6.0% of CD patients), insulin dependent diabetes (1.0% DH and 5.5% CD), lupus erythematosus (1.3% DH and 0.3% CD), Sjoegren's syndrome (1.0% DH and 2.9% CD), sarcoidosis (1.3% DH and 1.8% CD), and vitiligo or alopecia areata (1.6% DH and 0% CD).
p9690
sg4
(lp9691
(dp9692
g7
I114
sg8
g9687
sg10
I7
sg11
VP01308
p9693
sg13
I1
sasg24
(lp9694
(dp9695
g7
I51
sg8
Vthyroid disease
p9696
sg10
I15
sg28
VC0040128
p9697
sg13
I2
sa(dp9698
g7
I114
sg8
Vinsulin dependent diabetes
p9699
sg10
I26
sg28
VC0011854
p9700
sg13
I3
sa(dp9701
g7
I164
sg8
Vlupus erythematosus
p9702
sg10
I19
sg28
VC0409974
p9703
sg13
I2
sa(dp9704
g7
I250
sg8
Vsarcoidosis
p9705
sg10
I11
sg28
VC0036202
p9706
sg13
I1
sa(dp9707
g7
I301
sg8
Valopecia areata
p9708
sg10
I15
sg28
VC0002171
p9709
sg13
I2
sa(dp9710
g7
I207
sg8
VSjoegren's syndrome
p9711
sg10
I19
sg28
VC1527336
p9712
sg13
I2
sa(dp9713
g7
I289
sg8
g9688
sg10
I8
sg28
VC0042900
p9714
sg13
I1
sasa(dp9715
g135
(dp9716
(VBeta-glucocerebrosidase
p9717
VGaucher disease
p9718
tp9719
I00
ssg2
VRarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the Beta-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations.
p9720
sg4
(lp9721
(dp9722
g7
I331
sg8
VATXN3
p9723
sg10
I5
sg11
g12
sg13
I1
sa(dp9724
g7
I511
sg8
VGBA
p9725
sg10
I3
sg11
VP04062
p9726
sg13
I1
sa(dp9727
g7
I486
sg8
g9717
sg10
I23
sg11
VP02774
p9728
sg13
I1
sa(dp9729
g7
I557
sg8
VLYST gene
p9730
sg10
I9
sg11
g12
sg13
I2
sa(dp9731
g7
I388
sg8
VATP13A2 gene
p9732
sg10
I12
sg11
g12
sg13
I2
sa(dp9733
g7
I321
sg8
Vataxin-3
p9734
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp9735
(dp9736
g7
I344
sg8
VKufor-Rakeb syndrome
p9737
sg10
I20
sg28
VC1847640
p9738
sg13
I2
sa(dp9739
g7
I75
sg8
Vneurodegenerative diseases
p9740
sg10
I26
sg28
VC0524851
p9741
sg13
I2
sa(dp9742
g7
I525
sg8
VChediak-Higashi syndrome
p9743
sg10
I24
sg28
VC0007965
p9744
sg13
I2
sa(dp9745
g7
I149
sg8
Vsyndrome
p9746
sg10
I8
sg28
VC0039082
p9747
sg13
I1
sa(dp9748
g7
I219
sg8
Vmental retardation
p9749
sg10
I18
sg28
VC0025362
p9750
sg13
I2
sa(dp9751
g7
I142
sg8
Vataxia
p9752
sg10
I6
sg28
VC0004134
p9753
sg13
I1
sa(dp9754
g7
I26
sg8
Vparkinsonism
p9755
sg10
I12
sg28
VC0242422
p9756
sg13
I1
sa(dp9757
g7
I131
sg8
Vtremor
p9758
sg10
I6
sg28
VC0040822
p9759
sg13
I1
sa(dp9760
g7
I251
sg8
VMachado-Joseph disease
p9761
sg10
I22
sg28
VC0024408
p9762
sg13
I2
sa(dp9763
g7
I446
sg8
g9718
sg10
I15
sg28
VC0017205
p9764
sg13
I2
sasa(dp9765
g2
VWe also identified the mutation of the LYST gene, that is causative gene for Chediak-Higashi syndrome, for the autosomal recessive complicated spastic paraplegia with cerebellar ataxia and neuropathy.
p9766
sg4
(lp9767
(dp9768
g7
I39
sg8
VLYST gene
p9769
sg10
I9
sg11
g12
sg13
I2
sasg24
(lp9770
(dp9771
g7
I167
sg8
Vcerebellar ataxia
p9772
sg10
I17
sg28
VC0007758
p9773
sg13
I2
sa(dp9774
g7
I189
sg8
Vneuropathy
p9775
sg10
I10
sg28
VC0442874
p9776
sg13
I1
sa(dp9777
g7
I143
sg8
Vspastic paraplegia
p9778
sg10
I18
sg28
VC0037772
p9779
sg13
I2
sa(dp9780
g7
I77
sg8
VChediak-Higashi syndrome
p9781
sg10
I24
sg28
VC0007965
p9782
sg13
I2
sasa(dp9783
g2
VTo our knowledge, this is the first study on spina bifida to determine the nucleotide sequences of breakpoints for trisomy 2p24.3-pter and monosomy 5p14.3-pter.
p9784
sg4
(lp9785
sg24
(lp9786
(dp9787
g7
I45
sg8
Vspina bifida
p9788
sg10
I12
sg28
VC0080178
p9789
sg13
I2
sa(dp9790
g7
I139
sg8
Vmonosomy
p9791
sg10
I8
sg28
VC0026499
p9792
sg13
I1
sa(dp9793
g7
I115
sg8
Vtrisomy
p9794
sg10
I7
sg28
VC0041107
p9795
sg13
I1
sasa(dp9796
g2
VOur report serves to emphasize the consistency in the prenatal sonographic feature of spina bifida in consecutive pregnancies with fetuses associated with partial trisomy 3q (3q26.1-qter) and partial monosomy 5p (5p13.33-pter).
p9797
sg4
(lp9798
sg24
(lp9799
(dp9800
g7
I155
sg8
Vpartial trisomy
p9801
sg10
I15
sg28
VC1297882
p9802
sg13
I2
sa(dp9803
g7
I163
sg8
Vtrisomy 3q
p9804
sg10
I10
sg28
VC0795809
p9805
sg13
I2
sa(dp9806
g7
I192
sg8
Vpartial monosomy
p9807
sg10
I16
sg28
VC0008628
p9808
sg13
I2
sa(dp9809
g7
I86
sg8
Vspina bifida
p9810
sg10
I12
sg28
VC0080178
p9811
sg13
I2
sasa(dp9812
g135
(dp9813
(VPLCD1
p9814
Vnail disorders
p9815
tp9816
I00
ssg2
VThese are classified into ten different types (NDNC1-10), which are described in OMIM.1 The genes described for isolated nail disorders include PLCD1 (MIM 602142), RSPO4 (MIM 610573), FZD6 (MIM 603409), COL7A1 (MIM 120120), HPGD (MIM 601688) and SLCO2A1 (MIM 601460).
p9817
sg4
(lp9818
(dp9819
g7
I151
sg8
VMIM 602142
p9820
sg10
I10
sg11
g12
sg13
I2
sa(dp9821
g7
I255
sg8
VMIM 601460
p9822
sg10
I10
sg11
g12
sg13
I2
sa(dp9823
g7
I203
sg8
VCOL7A1
p9824
sg10
I6
sg11
g12
sg13
I1
sa(dp9825
g7
I190
sg8
VMIM 603409
p9826
sg10
I10
sg11
g12
sg13
I2
sa(dp9827
g7
I184
sg8
VFZD6
p9828
sg10
I4
sg11
g12
sg13
I1
sa(dp9829
g7
I211
sg8
VMIM 120120
p9830
sg10
I10
sg11
g12
sg13
I2
sa(dp9831
g7
I144
sg8
g9814
sg10
I5
sg11
VP51178
p9832
sg13
I1
sa(dp9833
g7
I171
sg8
VMIM 610573
p9834
sg10
I10
sg11
g12
sg13
I2
sa(dp9835
g7
I164
sg8
VRSPO4
p9836
sg10
I5
sg11
g12
sg13
I1
sa(dp9837
g7
I246
sg8
VSLCO2A1
p9838
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp9839
(dp9840
g7
I121
sg8
g9815
sg10
I14
sg28
VC0027339
p9841
sg13
I2
sa(dp9842
g7
I47
sg8
VNDNC1
p9843
sg10
I5
sg28
VC0406443
p9844
sg13
I1
sasa(dp9845
g2
VAnonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence (anonychia) or hypoplasia (hyponuchia) of finger- and/or toenails frequently caused by mutations in the R-spondin 4 (RSPO4) gene.
p9846
sg4
(lp9847
(dp9848
g7
I217
sg8
VR-spondin 4
p9849
sg10
I11
sg11
g12
sg13
I2
sa(dp9850
g7
I230
sg8
VRSPO4
p9851
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp9852
(dp9853
g7
I128
sg8
Vhypoplasia
p9854
sg10
I10
sg28
VC0243069
p9855
sg13
I1
sa(dp9856
g7
I0
sg8
VAnonychia/hyponychia congenita is a rare autosomal recessive developmental disorder characterized by the absence
p9857
sg10
I112
sg28
VC0265998
p9858
sg13
I13
sa(dp9859
g7
I114
sg8
Vanonychia
p9860
sg10
I9
sg28
VC0265998
p9861
sg13
I1
sasa(dp9862
g2
VBecause there were no other congenital abnormalities, this was considered to be anonychia congenita; probably caused by a recessive defect of the R-spondin 4-coding gene.
p9863
sg4
(lp9864
(dp9865
g7
I146
sg8
VR-spondin 4-coding gene
p9866
sg10
I23
sg11
g12
sg13
I3
sasg24
(lp9867
(dp9868
g7
I80
sg8
Vanonychia congenita
p9869
sg10
I19
sg28
VC0265998
p9870
sg13
I2
sa(dp9871
g7
I28
sg8
Vcongenital abnormalities
p9872
sg10
I24
sg28
VC0000768
p9873
sg13
I2
sasa(dp9874
g135
(dp9875
(Vantithrombin
p9876
Vrespiratory failure
p9877
tp9878
I00
ssg2
VTo investigate whether receipt of any antithrombin concentrate improves laboratory and clinical outcomes in children undergoing extracorporeal membrane oxygenation for respiratory failure during their hospitalization compared with those who did not receive antithrombin.
p9879
sg4
(lp9880
(dp9881
g7
I38
sg8
Vantithrombin
p9882
sg10
I12
sg11
VP05546
p9883
sg13
I1
sa(dp9884
g7
I38
sg8
g9876
sg10
I12
sg11
VP05546
p9885
sg13
I1
sasg24
(lp9886
(dp9887
g7
I168
sg8
g9877
sg10
I19
sg28
VC1145670
p9888
sg13
I2
sasa(dp9889
g135
(dp9890
(Vantithrombin
p9891
Vrespiratory failure
p9892
tp9893
I00
ssg2
VIntermittent, on-demand dosing of antithrombin concentrate in pediatric patients on extracorporeal membrane oxygenation for respiratory failure increased antithrombin levels, but not typically to the targeted level.
p9894
sg4
(lp9895
(dp9896
g7
I34
sg8
Vantithrombin
p9897
sg10
I12
sg11
VP05546
p9898
sg13
I1
sa(dp9899
g7
I34
sg8
g9891
sg10
I12
sg11
VP05546
p9900
sg13
I1
sasg24
(lp9901
(dp9902
g7
I124
sg8
g9892
sg10
I19
sg28
VC1145670
p9903
sg13
I2
sasa(dp9904
g135
(dp9905
(Vtissue plasminogen activator
p9906
VARDS
p9907
tp9908
I00
ssg2
VWe hypothesized that combining intravenous recombinant human antithrombin (rhAT), nebulized heparin, and nebulized tissue plasminogen activator (TPA) more effectively improves pulmonary gas exchange compared with a single rhAT infusion, while maintaining the anti-inflammatory properties of rhAT in ARDS.
p9909
sg4
(lp9910
(dp9911
g7
I75
sg8
VrhAT
p9912
sg10
I4
sg11
VP05546
p9913
sg13
I1
sa(dp9914
g7
I75
sg8
VrhAT
p9915
sg10
I4
sg11
VP05546
p9916
sg13
I1
sa(dp9917
g7
I43
sg8
Vrecombinant human antithrombin
p9918
sg10
I30
sg11
VP05546
p9919
sg13
I3
sa(dp9920
g7
I145
sg8
VTPA
p9921
sg10
I3
sg11
VP00747
p9922
sg13
I1
sa(dp9923
g7
I75
sg8
VrhAT
p9924
sg10
I4
sg11
VP05546
p9925
sg13
I1
sa(dp9926
g7
I115
sg8
g9906
sg10
I28
sg11
VP00747
p9927
sg13
I3
sasg24
(lp9928
(dp9929
g7
I299
sg8
g9907
sg10
I4
sg28
VC0035222
p9930
sg13
I1
sasa(dp9931
g135
(dp9932
(VXPB
p9933
VXPB
p9934
tp9935
I00
ssg2
VAfter 12 months, bonds fell from 43.9 +/- 9.5 MPa to 20.1 +/- 5.4 MPa and from 39.6 +/- 9.4 MPa to 14.2 +/- 5.0 MPa in control specimens for SB1 and XPB respectively, while bond fell only from 41.9 +/- 9.6MPa to 33.2 +/- 8.3 MPa and 38.3 +/- 8.9 MPa to 26.5 +/- 10.9 (for SB1 and XPB, respectively) when 0.2% CHX was previously used.
p9936
sg4
(lp9937
(dp9938
g7
I141
sg8
VSB1
p9939
sg10
I3
sg11
g12
sg13
I1
sa(dp9940
g7
I149
sg8
g9933
sg10
I3
sg11
VP19447
p9941
sg13
I1
sasg24
(lp9942
(dp9943
g7
I149
sg8
VXPB
p9944
sg10
I3
sg28
VC0268136
p9945
sg13
I1
sa(dp9946
g7
I149
sg8
g9934
sg10
I3
sg28
VC0268136
p9947
sg13
I1
sasa(dp9948
g135
(dp9949
(VTNF-Alfa
p9950
Vrheumatoid arthritis
p9951
tp9952
I00
ssg2
VPrimary SFs from patients with rheumatoid arthritis (RA) were treated with recombinant human bone morphogenetic protein-2 or transduced with a constitutively active mutant of the ALK3 gene (ALK3CA) with or without TNF-Alfa, and then cultured in pellets.
p9953
sg4
(lp9954
(dp9955
g7
I179
sg8
VALK3 gene
p9956
sg10
I9
sg11
VP36894
p9957
sg13
I2
sa(dp9958
g7
I214
sg8
g9950
sg10
I8
sg11
VP01375
p9959
sg13
I1
sasg24
(lp9960
(dp9961
g7
I53
sg8
VRA
p9962
sg10
I2
sg28
VC0003873
p9963
sg13
I1
sa(dp9964
g7
I165
sg8
Vmutant
p9965
sg10
I6
sg28
VC0596988
p9966
sg13
I1
sa(dp9967
g7
I31
sg8
g9951
sg10
I20
sg28
VC0003873
p9968
sg13
I2
sasa(dp9969
g2
VWe describe a patient with ALK-negative ALCL presenting with clinical and radiographic findings suggesting osteomyelitis 6 months after left rotator cuff repair surgery.
p9970
sg4
(lp9971
sg24
(lp9972
(dp9973
g7
I40
sg8
VALCL
p9974
sg10
I4
sg28
VC0206180
p9975
sg13
I1
sa(dp9976
g7
I107
sg8
Vosteomyelitis
p9977
sg10
I13
sg28
VC0029443
p9978
sg13
I1
sasa(dp9979
g2
VWe compared levels of GABA(B) receptor subunits GABA(B) receptor 1 (GABBR1) and GABA(B) receptor 2 (GABBR2) in cerebellum, Brodmann's area 9 (BA9), and BA40 of subjects with autism and matched controls.
p9980
sg4
(lp9981
(dp9982
g7
I80
sg8
VGABA(B) receptor 2
p9983
sg10
I18
sg11
g12
sg13
I3
sa(dp9984
g7
I100
sg8
VGABBR2
p9985
sg10
I6
sg11
g12
sg13
I1
sa(dp9986
g7
I48
sg8
VGABA(B) receptor 1
p9987
sg10
I18
sg11
g12
sg13
I3
sa(dp9988
g7
I22
sg8
VGABA(B) receptor
p9989
sg10
I16
sg11
g12
sg13
I2
sa(dp9990
g7
I68
sg8
VGABBR1
p9991
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp9992
(dp9993
g7
I174
sg8
Vautism
p9994
sg10
I6
sg28
VC0004352
p9995
sg13
I1
sasa(dp9996
g2
VSclerosteosis is caused by loss-of-function mutations in the SOST gene which encodes a secreted glycoprotein, sclerostin.
p9997
sg4
(lp9998
(dp9999
g7
I61
sg8
VSOST gene
p10000
sg10
I9
sg11
g12
sg13
I2
sasg24
(lp10001
(dp10002
g7
I0
sg8
VSclerosteosis
p10003
sg10
I13
sg28
VC0265301
p10004
sg13
I1
sa(dp10005
g7
I61
sg8
VSOST
p10006
sg10
I4
sg28
VC0265301
p10007
sg13
I1
sasa(dp10008
g2
VVBD is caused by a noncoding deletion that removes a SOST-specific regulatory element in bone.
p10009
sg4
(lp10010
sg24
(lp10011
(dp10012
g7
I53
sg8
VSOST
p10013
sg10
I4
sg28
VC0265301
p10014
sg13
I1
sasa(dp10015
g2
VHere we describe how human genetics studies in sclerosteosis and VBD patients, in combination with the generation of transgenic and knockout mice, has led to a better understanding of the role of sclerostin in bone metabolism.
p10016
sg4
(lp10017
(dp10018
g7
I196
sg8
Vsclerostin
p10019
sg10
I10
sg11
g12
sg13
I1
sasg24
(lp10020
(dp10021
g7
I47
sg8
Vsclerosteosis
p10022
sg10
I13
sg28
VC0265301
p10023
sg13
I1
sasa(dp10024
g2
VIn addition, expression of SOST is delayed or suppressed; resulting in active WNT signaling and enhanced periosteal bone formation, and the combined outcome is generalized hyperostosis.
p10025
sg4
(lp10026
(dp10027
g7
I27
sg8
VSOST
p10028
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10029
(dp10030
g7
I27
sg8
VSOST
p10031
sg10
I4
sg28
VC0265301
p10032
sg13
I1
sa(dp10033
g7
I172
sg8
Vhyperostosis
p10034
sg10
I12
sg28
VC0020492
p10035
sg13
I1
sasa(dp10036
g2
VInitially, we and others reported that sclerosteosis was caused by loss-of-function mutations in SOST, encoding sclerostin.
p10037
sg4
(lp10038
(dp10039
g7
I97
sg8
VSOST
p10040
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10041
(dp10042
g7
I97
sg8
VSOST
p10043
sg10
I4
sg28
VC0265301
p10044
sg13
I1
sa(dp10045
g7
I39
sg8
Vsclerosteosis
p10046
sg10
I13
sg28
VC0265301
p10047
sg13
I1
sasa(dp10048
g2
VMore recently, we identified disease-causing mutations in LRP4, a binding partner of sclerostin, in three sclerosteosis patients.
p10049
sg4
(lp10050
(dp10051
g7
I85
sg8
Vsclerostin
p10052
sg10
I10
sg11
g12
sg13
I1
sa(dp10053
g7
I58
sg8
VLRP4
p10054
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10055
(dp10056
g7
I106
sg8
Vsclerosteosis
p10057
sg10
I13
sg28
VC0265301
p10058
sg13
I1
sasa(dp10059
g2
VThe positive correlation we found between sclerostin and age in Paget disease of bone patients indicates that in comparative studies, sclerostin serum levels must be adjusted for age.
p10060
sg4
(lp10061
sg24
(lp10062
(dp10063
g7
I64
sg8
VPaget disease of bone
p10064
sg10
I21
sg28
VC0029401
p10065
sg13
I4
sasa(dp10066
g2
VSclerosteosis and van Buchem disease are two rare bone sclerosing dysplasias caused by genetic defects in the synthesis of sclerostin.
p10067
sg4
(lp10068
sg24
(lp10069
(dp10070
g7
I0
sg8
VSclerosteosis
p10071
sg10
I13
sg28
VC0265301
p10072
sg13
I1
sa(dp10073
g7
I18
sg8
Vvan Buchem disease
p10074
sg10
I18
sg28
VC0432272
p10075
sg13
I3
sa(dp10076
g7
I66
sg8
Vdysplasias
p10077
sg10
I10
sg28
VC0334044
p10078
sg13
I1
sasa(dp10079
g2
VIn this article we review the demographic, clinical, biochemical, radiological, and histological characteristics of patients with sclerosteosis and van Buchem disease that led to a better understanding of the role of sclerostin in bone metabolism in humans and we discuss the relevance of these findings for the development of new therapeutics for the treatment of patients with osteoporosis.
p10080
sg4
(lp10081
(dp10082
g7
I217
sg8
Vsclerostin
p10083
sg10
I10
sg11
g12
sg13
I1
sasg24
(lp10084
(dp10085
g7
I148
sg8
Vvan Buchem disease
p10086
sg10
I18
sg28
VC0432272
p10087
sg13
I3
sa(dp10088
g7
I379
sg8
Vosteoporosis
p10089
sg10
I12
sg28
VC0029456
p10090
sg13
I1
sa(dp10091
g7
I130
sg8
Vsclerosteosis
p10092
sg10
I13
sg28
VC0265301
p10093
sg13
I1
sasa(dp10094
g2
VAfter discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation.
p10095
sg4
(lp10096
(dp10097
g7
I36
sg8
Vsclerostin
p10098
sg10
I10
sg11
g12
sg13
I1
sa(dp10099
g7
I31
sg8
VSost
p10100
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10101
(dp10102
g7
I132
sg8
Vsclerosteosis
p10103
sg10
I13
sg28
VC0265301
p10104
sg13
I1
sa(dp10105
g7
I99
sg8
Vsyndromes
p10106
sg10
I9
sg28
VC0039082
p10107
sg13
I1
sa(dp10108
g7
I31
sg8
VSost
p10109
sg10
I4
sg28
VC0265301
p10110
sg13
I1
sa(dp10111
g7
I109
sg8
VVan Buchem disease
p10112
sg10
I18
sg28
VC0432272
p10113
sg13
I3
sasa(dp10114
g2
VLoss-of-function mutations of the sclerostin gene (SOST) cause sclerosteosis and Van Buchem disease characterized by bone overgrowth.
p10115
sg4
(lp10116
(dp10117
g7
I34
sg8
Vsclerostin gene
p10118
sg10
I15
sg11
g12
sg13
I2
sa(dp10119
g7
I51
sg8
VSOST
p10120
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10121
(dp10122
g7
I34
sg8
Vsclerostin gene
p10123
sg10
I15
sg28
VC0265301
p10124
sg13
I2
sa(dp10125
g7
I63
sg8
Vsclerosteosis
p10126
sg10
I13
sg28
VC0265301
p10127
sg13
I1
sa(dp10128
g7
I51
sg8
VSOST
p10129
sg10
I4
sg28
VC0265301
p10130
sg13
I1
sa(dp10131
g7
I81
sg8
VVan Buchem disease
p10132
sg10
I18
sg28
VC0432272
p10133
sg13
I3
sasa(dp10134
g2
VMutations in the human sclerostin gene (SOST) lead to sclerosteosis with progressive skeletal overgrowth, whereas sclerostin-deficient (Sost(-/-)) mice exhibit increased bone mass and strength.
p10135
sg4
(lp10136
(dp10137
g7
I17
sg8
Vhuman sclerostin gene
p10138
sg10
I21
sg11
g12
sg13
I3
sa(dp10139
g7
I40
sg8
VSOST
p10140
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10141
(dp10142
g7
I23
sg8
Vsclerostin gene
p10143
sg10
I15
sg28
VC0265301
p10144
sg13
I2
sa(dp10145
g7
I136
sg8
VSost
p10146
sg10
I4
sg28
VC0265301
p10147
sg13
I1
sa(dp10148
g7
I40
sg8
VSOST
p10149
sg10
I4
sg28
VC0265301
p10150
sg13
I1
sa(dp10151
g7
I54
sg8
Vsclerosteosis
p10152
sg10
I13
sg28
VC0265301
p10153
sg13
I1
sasa(dp10154
g2
VTherefore, this study provides additional support to develop OGA inhibitors as a treatment for Alzheimer's disease and other neurodegenerative tauopathies.
p10155
sg4
(lp10156
(dp10157
g7
I61
sg8
VOGA
p10158
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp10159
(dp10160
g7
I143
sg8
Vtauopathies
p10161
sg10
I11
sg28
VC0949664
p10162
sg13
I1
sa(dp10163
g7
I95
sg8
VAlzheimer's disease
p10164
sg10
I19
sg28
VC1521724
p10165
sg13
I2
sasa(dp10166
g2
VTo identify the association between gastrointestinal carcinomas (GIC) risk and UDP-glucuronosyltransferases (UGTs) 1A7 polymorphisms through a systematic review and network meta-analysis.
p10167
sg4
(lp10168
(dp10169
g7
I79
sg8
VUDP-glucuronosyltransferases
p10170
sg10
I28
sg11
g12
sg13
I1
sa(dp10171
g7
I109
sg8
VUGTs
p10172
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10173
(dp10174
g7
I53
sg8
Vcarcinomas
p10175
sg10
I10
sg28
VC0007097
p10176
sg13
I1
sasa(dp10177
g135
(dp10178
(VUDP-glucuronosyltransferases UGT2B15
p10179
Vbreast cancer
p10180
tp10181
I00
ssg2
VIn this study, the expression and regulation of two androgen-inactivating enzymes, the UDP-glucuronosyltransferases UGT2B15 and UGT2B17, was assessed in breast cancer.
p10182
sg4
(lp10183
(dp10184
g7
I128
sg8
VUGT2B17
p10185
sg10
I7
sg11
g12
sg13
I1
sa(dp10186
g7
I87
sg8
g10179
sg10
I36
sg11
VP54855
p10187
sg13
I2
sasg24
(lp10188
(dp10189
g7
I153
sg8
g10180
sg10
I13
sg28
VC0678222
p10190
sg13
I2
sasa(dp10191
g135
(dp10192
(VINSL3 hormone
p10193
Vcryptorchidism
p10194
tp10195
I00
ssg2
VGlobal ablation of INSL3 hormone or its receptor RXFP2 in male mice results in cryptorchidism and infertility.
p10196
sg4
(lp10197
(dp10198
g7
I49
sg8
VRXFP2
p10199
sg10
I5
sg11
g12
sg13
I1
sa(dp10200
g7
I19
sg8
g10193
sg10
I13
sg11
VP51460
p10201
sg13
I2
sasg24
(lp10202
(dp10203
g7
I98
sg8
Vinfertility
p10204
sg10
I11
sg28
VC0021359
p10205
sg13
I1
sa(dp10206
g7
I79
sg8
g10194
sg10
I14
sg28
VC0010417
p10207
sg13
I1
sasa(dp10208
g2
VWe have also produced shRNA transgenic mice with reduced RXFP2 expression Such males manifested various degree of uni- and bilateral cryptorchidism.
p10209
sg4
(lp10210
(dp10211
g7
I57
sg8
VRXFP2
p10212
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp10213
(dp10214
g7
I123
sg8
Vbilateral cryptorchidism
p10215
sg10
I24
sg28
VC0431663
p10216
sg13
I2
sasa(dp10217
g2
VTo study the consequences of an aberrant testicular environment in cryptorchidism we used a mouse model with a deletion of Rxfp2 gene resulting in a high intra-abdominal testicular position.
p10218
sg4
(lp10219
(dp10220
g7
I123
sg8
VRxfp2 gene
p10221
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp10222
(dp10223
g7
I67
sg8
Vcryptorchidism
p10224
sg10
I14
sg28
VC0010417
p10225
sg13
I1
sasa(dp10226
g135
(dp10227
(VInsl3
p10228
Vcryptorchidism
p10229
tp10230
I00
ssg2
VDeletion of Insl3 or Rxfp2 genes in mice caused cryptorchidism resulting from a failure of gubernaculum development.
p10231
sg4
(lp10232
(dp10233
g7
I12
sg8
g10228
sg10
I5
sg11
VP51460
p10234
sg13
I1
sa(dp10235
g7
I21
sg8
VRxfp2 genes
p10236
sg10
I11
sg11
g12
sg13
I2
sasg24
(lp10237
(dp10238
g7
I48
sg8
g10229
sg10
I14
sg28
VC0010417
p10239
sg13
I1
sasa(dp10240
g135
(dp10241
(Vretinoic acid receptor beta promoter
p10242
Vcryptorchidism
p10243
tp10244
I00
ssg2
VUsing Cre transgene driven by retinoic acid receptor beta promoter, conditional gene targeting in gubernacular mesenchymal cells at early embryonic stages caused high intraabdominal cryptorchidism as in males with a global deletion of Rxfp2.
p10245
sg4
(lp10246
(dp10247
g7
I30
sg8
g10242
sg10
I36
sg11
VP10826
p10248
sg13
I5
sa(dp10249
g7
I6
sg8
VCre transgene
p10250
sg10
I13
sg11
g12
sg13
I2
sa(dp10251
g7
I235
sg8
VRxfp2
p10252
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp10253
(dp10254
g7
I182
sg8
g10243
sg10
I14
sg28
VC0010417
p10255
sg13
I1
sasa(dp10256
g135
(dp10257
(VLGR8 mRNA
p10258
Vcryptorchidism
p10259
tp10260
I00
ssg2
VPrenatal exposure to diethylstilbestrol affected the expression of LGR8 mRNA in the mouse gubernaculum testis, which suggests that diethylstilbestrol may induce cryptorchidism by interfering with the INSL3-LGR8 signaling system and consequently the development of the gubernaculum testis.
p10261
sg4
(lp10262
(dp10263
g7
I67
sg8
VLGR8
p10264
sg10
I4
sg11
VP51460
p10265
sg13
I1
sa(dp10266
g7
I200
sg8
VINSL3
p10267
sg10
I5
sg11
VP51460
p10268
sg13
I1
sa(dp10269
g7
I67
sg8
g10258
sg10
I9
sg11
VP51460
p10270
sg13
I2
sasg24
(lp10271
(dp10272
g7
I161
sg8
g10259
sg10
I14
sg28
VC0010417
p10273
sg13
I1
sasa(dp10274
g135
(dp10275
(VMYH1
p10276
Vhydrocele
p10277
tp10278
I00
ssg2
VProspectively collected cremaster muscle and/or hernia sac tissues from boys with congenital (79) or acquired (66) nonsyndromic cryptorchidism and hernia/hydrocele (controls, 84) were analyzed for hormone receptor (RXFP2, AR, ESR1, ESR2) and myosin heavy chain specific (MYH1, MYH2, MYH7) mRNA expression using real-time reverse transcriptase polymerase chain reaction.
p10279
sg4
(lp10280
(dp10281
g7
I226
sg8
VESR1
p10282
sg10
I4
sg11
VP03372
p10283
sg13
I1
sa(dp10284
g7
I277
sg8
VMYH2
p10285
sg10
I4
sg11
g12
sg13
I1
sa(dp10286
g7
I242
sg8
Vmyosin heavy chain
p10287
sg10
I18
sg11
VP13535
p10288
sg13
I3
sa(dp10289
g7
I193
sg8
Vfor hormone receptor
p10290
sg10
I20
sg11
VP22736
p10291
sg13
I3
sa(dp10292
g7
I271
sg8
g10276
sg10
I4
sg11
VP12882
p10293
sg13
I1
sa(dp10294
g7
I215
sg8
VRXFP2
p10295
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp10296
(dp10297
g7
I48
sg8
Vhernia sac
p10298
sg10
I10
sg28
VC0333062
p10299
sg13
I2
sa(dp10300
g7
I128
sg8
Vcryptorchidism
p10301
sg10
I14
sg28
VC0010417
p10302
sg13
I1
sa(dp10303
g7
I48
sg8
Vhernia
p10304
sg10
I6
sg28
VC0019270
p10305
sg13
I1
sa(dp10306
g7
I154
sg8
g10277
sg10
I9
sg28
VC1720771
p10307
sg13
I1
sasa(dp10308
g2
VExon sequencing of candidate genes identified mutations in mice with cystic kidneys (Bicc1), cryptorchidism (Rxfp2), restricted germ cell deficiency (Plk4), and severe germ cell deficiency (Prdm9).
p10309
sg4
(lp10310
(dp10311
g7
I150
sg8
VPlk4
p10312
sg10
I4
sg11
g12
sg13
I1
sa(dp10313
g7
I109
sg8
VRxfp2
p10314
sg10
I5
sg11
g12
sg13
I1
sa(dp10315
g7
I190
sg8
VPrdm9
p10316
sg10
I5
sg11
g12
sg13
I1
sa(dp10317
g7
I85
sg8
VBicc1
p10318
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp10319
(dp10320
g7
I93
sg8
Vcryptorchidism
p10321
sg10
I14
sg28
VC0010417
p10322
sg13
I1
sa(dp10323
g7
I69
sg8
Vcystic kidneys
p10324
sg10
I14
sg28
VC0022679
p10325
sg13
I2
sasa(dp10326
g135
(dp10327
(Valbumin
p10328
Vleft-sided heart failure
p10329
tp10330
I00
ssg2
VPatients with definite pneumonia at the time of admission, those with left-sided heart failure, pulmonary embolism and an identifiable cause of acute lung injury, and those whose albumin or C-reactive protein levels were not measured were excluded.
p10331
sg4
(lp10332
(dp10333
g7
I190
sg8
VC-reactive protein
p10334
sg10
I18
sg11
VP02741
p10335
sg13
I2
sa(dp10336
g7
I179
sg8
g10328
sg10
I7
sg11
VP00441
p10337
sg13
I1
sasg24
(lp10338
(dp10339
g7
I96
sg8
Vpulmonary embolism
p10340
sg10
I18
sg28
VC0034065
p10341
sg13
I2
sa(dp10342
g7
I23
sg8
Vpneumonia
p10343
sg10
I9
sg28
VC0032285
p10344
sg13
I1
sa(dp10345
g7
I70
sg8
g10329
sg10
I24
sg28
VC0023212
p10346
sg13
I3
sasa(dp10347
g135
(dp10348
(VJAK1
p10349
Vadenocarcinomas
p10350
tp10351
I00
ssg2
VAnalyzing gene expression signatures in endometrial and stomach adenocarcinomas revealed that tumors with a JAK1 frameshift exhibited reduced expression of interferon response signatures and multiple anti-tumor immune signatures.
p10352
sg4
(lp10353
(dp10354
g7
I156
sg8
Vinterferon
p10355
sg10
I10
sg11
VP01563
p10356
sg13
I1
sa(dp10357
g7
I108
sg8
g10349
sg10
I4
sg11
VP23458
p10358
sg13
I1
sasg24
(lp10359
(dp10360
g7
I64
sg8
g10350
sg10
I15
sg28
VC0001418
p10361
sg13
I1
sa(dp10362
g7
I113
sg8
Vframeshift
p10363
sg10
I10
sg28
VC0079380
p10364
sg13
I1
sa(dp10365
g7
I94
sg8
Vtumors
p10366
sg10
I6
sg28
VC0027651
p10367
sg13
I1
sa(dp10368
g7
I94
sg8
Vtumor
p10369
sg10
I5
sg28
VC0027651
p10370
sg13
I1
sasa(dp10371
g135
(dp10372
(VJAK1
p10373
Vmicrosatellite instability
p10374
tp10375
I00
ssg2
VFrom these data, we derive two primary conclusions: 1) JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability; 2) The mechanism by which JAK1 loss of function contributes to tumor immune evasion is likely associated with loss of the JAK1-mediated interferon response.
p10376
sg4
(lp10377
(dp10378
g7
I358
sg8
Vinterferon
p10379
sg10
I10
sg11
VP01563
p10380
sg13
I1
sa(dp10381
g7
I55
sg8
VJAK1
p10382
sg10
I4
sg11
VP23458
p10383
sg13
I1
sa(dp10384
g7
I55
sg8
VJAK1
p10385
sg10
I4
sg11
VP23458
p10386
sg13
I1
sa(dp10387
g7
I55
sg8
g10373
sg10
I4
sg11
VP23458
p10388
sg13
I1
sasg24
(lp10389
(dp10390
g7
I136
sg8
Vcancer
p10391
sg10
I6
sg28
VC0006826
p10392
sg13
I1
sa(dp10393
g7
I182
sg8
Vtumors
p10394
sg10
I6
sg28
VC0027651
p10395
sg13
I1
sa(dp10396
g7
I285
sg8
Vtumor immune evasion
p10397
sg10
I20
sg28
VC0282683
p10398
sg13
I3
sa(dp10399
g7
I194
sg8
g10374
sg10
I26
sg28
VC0920269
p10400
sg13
I2
sasa(dp10401
g135
(dp10402
(VJAK1/2
p10403
Vpolycythemia vera
p10404
tp10405
I00
ssg2
VMAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC.
p10406
sg4
(lp10407
(dp10408
g7
I69
sg8
g10403
sg10
I6
sg11
VP23458
p10409
sg13
I1
sasg24
(lp10410
(dp10411
g7
I129
sg8
g10404
sg10
I17
sg28
VC0032463
p10412
sg13
I2
sasa(dp10413
g135
(dp10414
(VJAK1/2
p10415
Vpolycythemia vera
p10416
tp10417
I00
ssg2
VRuxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.
p10418
sg4
(lp10419
(dp10420
g7
I21
sg8
g10415
sg10
I6
sg11
VP23458
p10421
sg13
I1
sasg24
(lp10422
(dp10423
g7
I75
sg8
Vmyelofibrosis
p10424
sg10
I13
sg28
VC0001815
p10425
sg13
I1
sa(dp10426
g7
I96
sg8
g10416
sg10
I17
sg28
VC0032463
p10427
sg13
I2
sasa(dp10428
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder that is characterized by episodic yet cumulative heterotopic ossification (HO) in skeletal muscles, tendons, and ligaments over a patient's lifetime.
p10429
sg4
(lp10430
sg24
(lp10431
(dp10432
g7
I157
sg8
VHO
p10433
sg10
I2
sg28
VC0029396
p10434
sg13
I1
sa(dp10435
g7
I0
sg8
VFibrodysplasia ossificans progressiva
p10436
sg10
I37
sg28
VC0016037
p10437
sg13
I3
sa(dp10438
g7
I131
sg8
Vheterotopic ossification
p10439
sg10
I24
sg28
VC0029396
p10440
sg13
I2
sa(dp10441
g7
I39
sg8
VFOP
p10442
sg10
I3
sg28
VC0016037
p10443
sg13
I1
sasa(dp10444
g135
(dp10445
(VType I Bone Morphogenic Protein
p10446
VFibrodysplasia Ossificans Progressiva
p10447
tp10448
I00
ssg2
VGain-of-function mutations in the Type I Bone Morphogenic Protein (BMP) receptor ACVR1 have been identified in two diseases: Fibrodysplasia Ossificans Progressiva (FOP), a rare autosomal dominant disorder characterized by genetically driven heterotopic ossification, and in 20-25% of Diffuse Intrinsic Pontine Gliomas (DIPGs), a pediatric brain tumor with no effective therapies and dismal median survival.
p10449
sg4
(lp10450
(dp10451
g7
I34
sg8
g10446
sg10
I31
sg11
VP29475
p10452
sg13
I5
sasg24
(lp10453
(dp10454
g7
I329
sg8
Vpediatric brain tumor
p10455
sg10
I21
sg28
VC0220603
p10456
sg13
I3
sa(dp10457
g7
I310
sg8
VGliomas
p10458
sg10
I7
sg28
VC0017638
p10459
sg13
I1
sa(dp10460
g7
I241
sg8
Vheterotopic ossification
p10461
sg10
I24
sg28
VC0029396
p10462
sg13
I2
sa(dp10463
g7
I164
sg8
VFOP
p10464
sg10
I3
sg28
VC0016037
p10465
sg13
I1
sa(dp10466
g7
I125
sg8
g10447
sg10
I37
sg28
VC0016037
p10467
sg13
I3
sasa(dp10468
g2
VFibrodysplasia ossificans progressiva is an autosomal dominant disorder due to germline mutations of ACVR1/ALK2 causing progressive heterotopic endochondral ossifications.
p10469
sg4
(lp10470
(dp10471
g7
I107
sg8
VALK2
p10472
sg10
I4
sg11
g12
sg13
I1
sa(dp10473
g7
I101
sg8
VACVR1
p10474
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp10475
(dp10476
g7
I0
sg8
VFibrodysplasia ossificans progressiva
p10477
sg10
I37
sg28
VC0016037
p10478
sg13
I3
sasa(dp10479
g2
VIt is an autosomal dominant disease, usually caused by a new mutation in the ACVR1 receptor gene, which is in the signaling pathway for bone morphogenic protein.
p10480
sg4
(lp10481
(dp10482
g7
I77
sg8
VACVR1 receptor gene
p10483
sg10
I19
sg11
g12
sg13
I3
sasg24
(lp10484
(dp10485
g7
I57
sg8
Vnew mutation
p10486
sg10
I12
sg28
VC2985439
p10487
sg13
I2
sasa(dp10488
g2
VFibrodysplasia ossificans progressiva (FOP), characterized by congenital malformation of bones, is an autosomal dominant disorder.
p10489
sg4
(lp10490
sg24
(lp10491
(dp10492
g7
I0
sg8
VFibrodysplasia ossificans progressiva
p10493
sg10
I37
sg28
VC0016037
p10494
sg13
I3
sa(dp10495
g7
I62
sg8
Vcongenital malformation
p10496
sg10
I23
sg28
VC1705254
p10497
sg13
I2
sa(dp10498
g7
I39
sg8
VFOP
p10499
sg10
I3
sg28
VC0016037
p10500
sg13
I1
sasa(dp10501
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification in skeletal muscle tissue.
p10502
sg4
(lp10503
sg24
(lp10504
(dp10505
g7
I0
sg8
VFibrodysplasia ossificans progressiva
p10506
sg10
I37
sg28
VC0016037
p10507
sg13
I3
sa(dp10508
g7
I111
sg8
Vheterotopic ossification
p10509
sg10
I24
sg28
VC0029396
p10510
sg13
I2
sa(dp10511
g7
I39
sg8
VFOP
p10512
sg10
I3
sg28
VC0016037
p10513
sg13
I1
sasa(dp10514
g2
VFibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic ossification.
p10515
sg4
(lp10516
sg24
(lp10517
(dp10518
g7
I0
sg8
VFibrodysplasia ossificans progressiva
p10519
sg10
I37
sg28
VC0016037
p10520
sg13
I3
sa(dp10521
g7
I111
sg8
Vheterotopic ossification
p10522
sg10
I24
sg28
VC0029396
p10523
sg13
I2
sa(dp10524
g7
I39
sg8
VFOP
p10525
sg10
I3
sg28
VC0016037
p10526
sg13
I1
sasa(dp10527
g2
VLoss of ORAI1 function is linked with rheumatoid arthritis (RA) and hence pharmacological blockers of ORAI1 could be potential therapeutic agents for the treatment of RA.
p10528
sg4
(lp10529
(dp10530
g7
I8
sg8
VORAI1
p10531
sg10
I5
sg11
g12
sg13
I1
sa(dp10532
g7
I8
sg8
VORAI1
p10533
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp10534
(dp10535
g7
I9
sg8
VRA
p10536
sg10
I2
sg28
VC0003873
p10537
sg13
I1
sa(dp10538
g7
I9
sg8
VRA
p10539
sg10
I2
sg28
VC0003873
p10540
sg13
I1
sa(dp10541
g7
I38
sg8
Vrheumatoid arthritis
p10542
sg10
I20
sg28
VC0003873
p10543
sg13
I2
sasa(dp10544
g2
VTo determine whether Ca(2+) release-activated Ca(2+) (CRAC) channels contribute to the abnormal behaviour of T cells in patients with rheumatoid arthritis (RA), we performed a cross-sectional study to characterize the expression and functional status of CRACM1 channels in RA patients.
p10545
sg4
(lp10546
sg24
(lp10547
(dp10548
g7
I87
sg8
Vabnormal behaviour
p10549
sg10
I18
sg28
VC0233514
p10550
sg13
I2
sa(dp10551
g7
I134
sg8
Vrheumatoid arthritis
p10552
sg10
I20
sg28
VC0003873
p10553
sg13
I2
sa(dp10554
g7
I55
sg8
VRA
p10555
sg10
I2
sg28
VC0003873
p10556
sg13
I1
sa(dp10557
g7
I55
sg8
VRA
p10558
sg10
I2
sg28
VC0003873
p10559
sg13
I1
sasa(dp10560
g2
VSince autoreactive T cells play an important role in the development of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and organ transplantation, Orai1 becomes an attractive therapeutic target for ameliorating autoimmune disease.
p10561
sg4
(lp10562
(dp10563
g7
I169
sg8
VOrai1
p10564
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp10565
(dp10566
g7
I100
sg8
Vrheumatoid arthritis
p10567
sg10
I20
sg28
VC0003873
p10568
sg13
I2
sa(dp10569
g7
I72
sg8
Vautoimmune diseases
p10570
sg10
I19
sg28
VC0004364
p10571
sg13
I2
sa(dp10572
g7
I72
sg8
Vautoimmune disease
p10573
sg10
I18
sg28
VC0004364
p10574
sg13
I2
sa(dp10575
g7
I122
sg8
Vmultiple sclerosis
p10576
sg10
I18
sg28
VC0026769
p10577
sg13
I2
sasa(dp10578
g2
VOur results demonstrate that a few point mutations in the Lol p 5 sequence yield mutants with reduced allergenic activity that represent potential vaccine candidates for immunotherapy of grass pollen allergy.
p10579
sg4
(lp10580
(dp10581
g7
I58
sg8
VLol p 5 sequence yield mutants
p10582
sg10
I30
sg11
g12
sg13
I6
sasg24
(lp10583
(dp10584
g7
I187
sg8
Vgrass pollen allergy
p10585
sg10
I20
sg28
VC0740919
p10586
sg13
I3
sasa(dp10587
g2
VHerein we present data relative to the effect of knocking down BCKDK gene on the real time oxygen consumption rate of fibroblasts obtained from a Maple Syrup Urine Disease (MSUD) patient.
p10588
sg4
(lp10589
(dp10590
g7
I63
sg8
VBCKDK gene
p10591
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp10592
(dp10593
g7
I173
sg8
VMSUD
p10594
sg10
I4
sg28
VC0024776
p10595
sg13
I1
sa(dp10596
g7
I146
sg8
VMaple Syrup Urine Disease
p10597
sg10
I25
sg28
VC0024776
p10598
sg13
I4
sasa(dp10599
g135
(dp10600
(VAlfa-ketoacid dehydrogenase
p10601
VMSUD
p10602
tp10603
I00
ssg2
VData relative to the effectiveness of the knockdown together with the potentiality of the BCKDK-knockdown to increase the deficient branched-chain Alfa-ketoacid dehydrogenase activity detected in MSUD patients are also shown.
p10604
sg4
(lp10605
(dp10606
g7
I90
sg8
VBCKDK
p10607
sg10
I5
sg11
g12
sg13
I1
sa(dp10608
g7
I147
sg8
g10601
sg10
I27
sg11
VP49366
p10609
sg13
I2
sasg24
(lp10610
(dp10611
g7
I196
sg8
g10602
sg10
I4
sg28
VC0024776
p10612
sg13
I1
sasa(dp10613
g2
VIn the study, 800 patients with coronary artery disease, cerebrovascular disease, or peripheral artery disease (PAD) or multiple cardiovascular risk factors (MRF) were recruited.
p10614
sg4
(lp10615
sg24
(lp10616
(dp10617
g7
I112
sg8
VPAD
p10618
sg10
I3
sg28
VC1704436
p10619
sg13
I1
sa(dp10620
g7
I32
sg8
Vcoronary artery disease
p10621
sg10
I23
sg28
VC1956346
p10622
sg13
I3
sa(dp10623
g7
I57
sg8
Vcerebrovascular disease
p10624
sg10
I23
sg28
VC0007820
p10625
sg13
I2
sa(dp10626
g7
I85
sg8
Vperipheral artery disease
p10627
sg10
I25
sg28
VC1704436
p10628
sg13
I3
sasa(dp10629
g2
VTo obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease (CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined vascular-related hospitalisation rates and associated costs in France and Germany.
p10630
sg4
(lp10631
sg24
(lp10632
(dp10633
g7
I66
sg8
Vatherothrombosis
p10634
sg10
I16
sg28
VC1963943
p10635
sg13
I1
sa(dp10636
g7
I159
sg8
VCVD
p10637
sg10
I3
sg28
VC0007222
p10638
sg13
I1
sa(dp10639
g7
I275
sg8
VPAD
p10640
sg10
I3
sg28
VC1704436
p10641
sg13
I1
sa(dp10642
g7
I246
sg8
Vperipheral arterial disease
p10643
sg10
I27
sg28
VC1704436
p10644
sg13
I3
sa(dp10645
g7
I190
sg8
VCAD
p10646
sg10
I3
sg28
VC0010054
p10647
sg13
I1
sa(dp10648
g7
I134
sg8
Vcerebrovascular disease
p10649
sg10
I23
sg28
VC0007820
p10650
sg13
I2
sa(dp10651
g7
I165
sg8
Vcoronary artery disease
p10652
sg10
I23
sg28
VC0010054
p10653
sg13
I3
sasa(dp10654
g2
VThe stroke relationships of a Chinese character reflect its structure, which can be statistically represented by the neighborhood system and clique potentials within the MRF framework.
p10655
sg4
(lp10656
sg24
(lp10657
(dp10658
g7
I4
sg8
Vstroke
p10659
sg10
I6
sg28
VC0038454
p10660
sg13
I1
sasa(dp10661
g2
VWe penalize the structurally mismatched stroke relationships with MRFs using the prior clique potentials, and derive the likelihood clique potentials from Gaussian mixture models, which encode the large variations of stroke relationships statistically.
p10662
sg4
(lp10663
sg24
(lp10664
(dp10665
g7
I40
sg8
Vstroke
p10666
sg10
I6
sg28
VC0038454
p10667
sg13
I1
sa(dp10668
g7
I40
sg8
Vstroke
p10669
sg10
I6
sg28
VC0038454
p10670
sg13
I1
sasa(dp10671
g2
VIn the proposed HCCR system, we use the single-site likelihood clique potentials to extract many candidate strokes from character images, and use the pairsite clique potentials to determine the best structural match between the input candidate strokes and the MRF-based character models by relaxation labeling.
p10672
sg4
(lp10673
sg24
(lp10674
(dp10675
g7
I107
sg8
Vstrokes
p10676
sg10
I7
sg28
VC0038454
p10677
sg13
I1
sa(dp10678
g7
I107
sg8
Vstrokes
p10679
sg10
I7
sg28
VC0038454
p10680
sg13
I1
sasa(dp10681
g2
VTotal left ventricular stroke volume (TSV), antegrade stroke volume (ASV), and mitral regurgitation volume (MRV) and fraction (MRF) were determined and compared between the two modalities.
p10682
sg4
(lp10683
sg24
(lp10684
(dp10685
g7
I23
sg8
Vstroke
p10686
sg10
I6
sg28
VC0038454
p10687
sg13
I1
sa(dp10688
g7
I23
sg8
Vstroke
p10689
sg10
I6
sg28
VC0038454
p10690
sg13
I1
sa(dp10691
g7
I79
sg8
Vmitral regurgitation
p10692
sg10
I20
sg28
VC0026266
p10693
sg13
I2
sasa(dp10694
g2
VThe reliability of non-invasive quantification of mitral regurgitation (MR) was assessed in 76 patients with angiographically demonstrated MR by comparing the results of different echo-Doppler (ED) indices with angiographic grade and MR fraction (MRF).
p10695
sg4
(lp10696
sg24
(lp10697
(dp10698
g7
I72
sg8
VMR
p10699
sg10
I2
sg28
VC0026266
p10700
sg13
I1
sa(dp10701
g7
I50
sg8
Vmitral regurgitation
p10702
sg10
I20
sg28
VC0026266
p10703
sg13
I2
sa(dp10704
g7
I72
sg8
VMR
p10705
sg10
I2
sg28
VC0026266
p10706
sg13
I1
sa(dp10707
g7
I72
sg8
VMR
p10708
sg10
I2
sg28
VC0026266
p10709
sg13
I1
sasa(dp10710
g2
VAllergic asthma from mint is less well-recognized.
p10711
sg4
(lp10712
sg24
(lp10713
(dp10714
g7
I0
sg8
VAllergic asthma
p10715
sg10
I15
sg28
VC0155877
p10716
sg13
I2
sasa(dp10717
g2
VA case of a 54-year-old woman with dyspnea on exposure to the scent of peppermint is presented in whom mint exposure, as seemingly innocuous as the breath of others who had consumed Tic Tac candies, exacerbated her underlying asthma.
p10718
sg4
(lp10719
(dp10720
g7
I182
sg8
VTic Tac
p10721
sg10
I7
sg11
g12
sg13
I2
sasg24
(lp10722
(dp10723
g7
I35
sg8
Vdyspnea
p10724
sg10
I7
sg28
VC0013404
p10725
sg13
I1
sa(dp10726
g7
I182
sg8
VTic
p10727
sg10
I3
sg28
VC0278076
p10728
sg13
I1
sa(dp10729
g7
I226
sg8
Vasthma
p10730
sg10
I6
sg28
VC0004096
p10731
sg13
I1
sasa(dp10732
g2
VAdditionally, this cases suggests that asthma can result from inhaling the scent of mint and gives consideration to obtaining confirmatory pre- and postexposure pulmonary function data by both impulse oscillometry and spirometry.
p10733
sg4
(lp10734
sg24
(lp10735
(dp10736
g7
I39
sg8
Vasthma
p10737
sg10
I6
sg28
VC0004096
p10738
sg13
I1
sasa(dp10739
g135
(dp10740
(Valpha-fetoprotein
p10741
VHodgkin's lymphoma
p10742
tp10743
I00
ssg2
VWe review the significance of elevated alpha-fetoprotein levels and discuss the clinical relevance of this unusual presentation of a possible primary Hodgkin's lymphoma.
p10744
sg4
(lp10745
(dp10746
g7
I39
sg8
g10741
sg10
I17
sg11
VP02771
p10747
sg13
I1
sasg24
(lp10748
(dp10749
g7
I150
sg8
g10742
sg10
I18
sg28
VC0019829
p10750
sg13
I2
sasa(dp10751
g135
(dp10752
(Vnuclear factor-KB
p10753
Vcolitis
p10754
tp10755
I00
ssg2
VHowever, we have found that exogenous 8-OHdG can paradoxically reduce ROS production, attenuate the nuclear factor-KB signaling pathway, and ameliorate the expression of proinflammatory mediators such as interleukin (IL)-1, IL-6, cyclo-oxygenase-2, and inducible nitric oxide synthase in addition to expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-1, NOX organizer-1 and NOX activator-1 in various conditions of inflammation-based gastrointestinal (GI) diseases including gastritis, inflammatory bowel disease, pancreatitis, and even colitis-associated carcinogenesis.
p10756
sg4
(lp10757
(dp10758
g7
I230
sg8
Vcyclo-oxygenase-2
p10759
sg10
I17
sg11
VP00403
p10760
sg13
I1
sa(dp10761
g7
I395
sg8
VNOX activator-1
p10762
sg10
I15
sg11
VP05154
p10763
sg13
I2
sa(dp10764
g7
I263
sg8
Vnitric oxide synthase
p10765
sg10
I21
sg11
VP29475
p10766
sg13
I3
sa(dp10767
g7
I204
sg8
Vinterleukin (IL)-1
p10768
sg10
I18
sg11
VP60568
p10769
sg13
I2
sa(dp10770
g7
I224
sg8
VIL-6
p10771
sg10
I4
sg11
VP05231
p10772
sg13
I1
sa(dp10773
g7
I100
sg8
g10753
sg10
I17
sg11
VP01160
p10774
sg13
I2
sa(dp10775
g7
I314
sg8
Vnicotinamide adenine dinucleotide phosphate oxidase (NOX)-1
p10776
sg10
I59
sg11
g12
sg13
I6
sasg24
(lp10777
(dp10778
g7
I436
sg8
Vinflammation
p10779
sg10
I12
sg28
VC0021368
p10780
sg13
I1
sa(dp10781
g7
I535
sg8
Vpancreatitis
p10782
sg10
I12
sg28
VC0030305
p10783
sg13
I1
sa(dp10784
g7
I496
sg8
Vgastritis
p10785
sg10
I9
sg28
VC0017152
p10786
sg13
I1
sa(dp10787
g7
I577
sg8
Vcarcinogenesis
p10788
sg10
I14
sg28
VC0596263
p10789
sg13
I1
sa(dp10790
g7
I507
sg8
Vinflammatory bowel disease
p10791
sg10
I26
sg28
VC0021390
p10792
sg13
I3
sa(dp10793
g7
I558
sg8
g10754
sg10
I7
sg28
VC0009319
p10794
sg13
I1
sasa(dp10795
g2
VWe studied nine patients (56 +/- 7 years) with complete AV-block and permanent dual-chamber pacemaker (DDD) under different pacing modes: ventricle pacing (VVI) 70 bpm, DDD 106 +/- 4 bpm, rate adaptive pacing (VVI-FA) 108 +/- 3 bpm.
p10796
sg4
(lp10797
sg24
(lp10798
(dp10799
g7
I103
sg8
VDDD
p10800
sg10
I3
sg28
VC0406811
p10801
sg13
I1
sa(dp10802
g7
I103
sg8
VDDD
p10803
sg10
I3
sg28
VC0406811
p10804
sg13
I1
sasa(dp10805
g2
VRecently, several reports have demonstrated that dysregulation of miR-4262 is in numerous cancers.
p10806
sg4
(lp10807
(dp10808
g7
I66
sg8
VmiR-4262
p10809
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp10810
(dp10811
g7
I90
sg8
Vcancers
p10812
sg10
I7
sg28
VC0006826
p10813
sg13
I1
sasa(dp10814
g2
VOverexpression of miR-4262 was demonstrated to decrease GALNT4 mRNA and protein expression levels, and thereby suppressed cell viability, growth and cell-cycle progression in SW480 and SW620 colon cancer cells.
p10815
sg4
(lp10816
(dp10817
g7
I18
sg8
VmiR-4262
p10818
sg10
I8
sg11
g12
sg13
I1
sa(dp10819
g7
I56
sg8
VGALNT4 mRNA
p10820
sg10
I11
sg11
g12
sg13
I2
sasg24
(lp10821
(dp10822
g7
I191
sg8
Vcolon cancer
p10823
sg10
I12
sg28
VC0699790
p10824
sg13
I2
sasa(dp10825
g2
VThe expression level of miR-4262 was observed to be downregulated as the expression of GALNT4 was upregulated in colon cancer tissues and cell lines.
p10826
sg4
(lp10827
(dp10828
g7
I87
sg8
VGALNT4
p10829
sg10
I6
sg11
g12
sg13
I1
sa(dp10830
g7
I24
sg8
VmiR-4262
p10831
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp10832
(dp10833
g7
I113
sg8
Vcolon cancer
p10834
sg10
I12
sg28
VC0699790
p10835
sg13
I2
sasa(dp10836
g2
VIn conclusion, the results demonstrated that miR-4262 may be involved in the development of colon cancer via targeting of GALNT4.
p10837
sg4
(lp10838
(dp10839
g7
I122
sg8
VGALNT4
p10840
sg10
I6
sg11
g12
sg13
I1
sa(dp10841
g7
I45
sg8
VmiR-4262
p10842
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp10843
(dp10844
g7
I92
sg8
Vcolon cancer
p10845
sg10
I12
sg28
VC0699790
p10846
sg13
I2
sasa(dp10847
g2
VThe miR-4262/GALNT4 axis may be a novel target for diagnosing and understanding the underlying molecular mechanism of colon cancer.
p10848
sg4
(lp10849
(dp10850
g7
I13
sg8
VGALNT4
p10851
sg10
I6
sg11
g12
sg13
I1
sa(dp10852
g7
I4
sg8
VmiR-4262
p10853
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp10854
(dp10855
g7
I118
sg8
Vcolon cancer
p10856
sg10
I12
sg28
VC0699790
p10857
sg13
I2
sasa(dp10858
g2
VThe aim of this study was to investigate whether miR-4262 was associated with the prognosis of acute myeloid leukemia (AML) patients.
p10859
sg4
(lp10860
sg24
(lp10861
(dp10862
g7
I119
sg8
VAML
p10863
sg10
I3
sg28
VC0023467
p10864
sg13
I1
sa(dp10865
g7
I95
sg8
Vacute myeloid leukemia
p10866
sg10
I22
sg28
VC0023467
p10867
sg13
I3
sasa(dp10868
g2
VIn this study, we investigated the role and underlying mechanism of miR-4262 in the proliferation of human cutaneous malignant melanoma (CMM) cells.
p10869
sg4
(lp10870
sg24
(lp10871
(dp10872
g7
I84
sg8
Vproliferation
p10873
sg10
I13
sg28
VC0334094
p10874
sg13
I1
sa(dp10875
g7
I107
sg8
Vcutaneous malignant melanoma
p10876
sg10
I28
sg28
VC0151779
p10877
sg13
I3
sa(dp10878
g7
I137
sg8
VCMM
p10879
sg10
I3
sg28
VC0151779
p10880
sg13
I1
sasa(dp10881
g2
VThe expression levels of miR-4262 were significantly upregulated in cancerous tissues compared with those in matched adjacent normal tissues from 110 CMM patients.
p10882
sg4
(lp10883
sg24
(lp10884
sa(dp10885
g2
VmiR-4262 was also regulated in five types of CMM cell lines, displaying an opposite expression pattern to that of Kruppel-like 6 (KLF6), a proven tumor suppressor in several cancers other than CMM.
p10886
sg4
(lp10887
(dp10888
g7
I0
sg8
VmiR-4262
p10889
sg10
I8
sg11
g12
sg13
I1
sa(dp10890
g7
I114
sg8
VKruppel-like 6
p10891
sg10
I14
sg11
g12
sg13
I2
sa(dp10892
g7
I130
sg8
VKLF6
p10893
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10894
(dp10895
g7
I174
sg8
Vcancers
p10896
sg10
I7
sg28
VC0006826
p10897
sg13
I1
sa(dp10898
g7
I146
sg8
Vtumor
p10899
sg10
I5
sg28
VC0027651
p10900
sg13
I1
sasa(dp10901
g2
VmiR-4262 is a potential tumor promoter in human cancers.
p10902
sg4
(lp10903
(dp10904
g7
I0
sg8
VmiR-4262
p10905
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp10906
(dp10907
g7
I48
sg8
Vcancers
p10908
sg10
I7
sg28
VC0006826
p10909
sg13
I1
sa(dp10910
g7
I24
sg8
Vtumor
p10911
sg10
I5
sg28
VC0027651
p10912
sg13
I1
sasa(dp10913
g2
VIn this study, we first investigated the role of miR-4262 in the proliferation and invasion of human breast cancer cells.
p10914
sg4
(lp10915
sg24
(lp10916
(dp10917
g7
I65
sg8
Vproliferation
p10918
sg10
I13
sg28
VC0334094
p10919
sg13
I1
sa(dp10920
g7
I101
sg8
Vbreast cancer
p10921
sg10
I13
sg28
VC0678222
p10922
sg13
I2
sa(dp10923
g7
I83
sg8
Vinvasion
p10924
sg10
I8
sg28
VC2699153
p10925
sg13
I1
sasa(dp10926
g2
VOur results showed that, compared with the adjacent tissues and MCF-10A normal breast epithelial cells, miR-4262 was markedly increased in the breast cancer tissues and five cell lines, including MDA-MB-231, MDA-MB-468, MDA-MB-435, SKBR3, and MCF-7.
p10927
sg4
(lp10928
(dp10929
g7
I104
sg8
VmiR-4262
p10930
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp10931
(dp10932
g7
I143
sg8
Vbreast cancer
p10933
sg10
I13
sg28
VC0678222
p10934
sg13
I2
sasa(dp10935
g2
VThen the miR-4262 mimic or oligo anta-miR-4262 was transfected into MDA-MB-231 and MCF-7 breast cancer cell lines.
p10936
sg4
(lp10937
sg24
(lp10938
(dp10939
g7
I89
sg8
Vbreast cancer
p10940
sg10
I13
sg28
VC0678222
p10941
sg13
I2
sasa(dp10942
g2
VIn conclusion, miR-4262 positively regulates proliferation and invasion of human breast cancer cells via suppression of KLF6 and KLF15.
p10943
sg4
(lp10944
(dp10945
g7
I15
sg8
VmiR-4262
p10946
sg10
I8
sg11
g12
sg13
I1
sa(dp10947
g7
I129
sg8
VKLF15
p10948
sg10
I5
sg11
g12
sg13
I1
sa(dp10949
g7
I120
sg8
VKLF6
p10950
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp10951
(dp10952
g7
I63
sg8
Vinvasion
p10953
sg10
I8
sg28
VC2699153
p10954
sg13
I1
sa(dp10955
g7
I105
sg8
Vsuppression
p10956
sg10
I11
sg28
VC0221103
p10957
sg13
I1
sa(dp10958
g7
I81
sg8
Vbreast cancer
p10959
sg10
I13
sg28
VC0678222
p10960
sg13
I2
sa(dp10961
g7
I45
sg8
Vproliferation
p10962
sg10
I13
sg28
VC0334094
p10963
sg13
I1
sasa(dp10964
g135
(dp10965
(VOPN
p10966
Vmetastases
p10967
tp10968
I00
ssg2
VTogether, our data suggest that suppression of miR-4262 in OS cells may promote OPN-mediated cancer invasion, highlighting miR-4262 as an intriguing therapeutic target to prevent OS metastases.
p10969
sg4
(lp10970
(dp10971
g7
I80
sg8
g10966
sg10
I3
sg11
VP10451
p10972
sg13
I1
sasg24
(lp10973
(dp10974
g7
I100
sg8
Vinvasion
p10975
sg10
I8
sg28
VC2699153
p10976
sg13
I1
sa(dp10977
g7
I32
sg8
Vsuppression
p10978
sg10
I11
sg28
VC0221103
p10979
sg13
I1
sa(dp10980
g7
I182
sg8
g10967
sg10
I10
sg28
VC0027627
p10981
sg13
I1
sa(dp10982
g7
I93
sg8
Vcancer
p10983
sg10
I6
sg28
VC0006826
p10984
sg13
I1
sasa(dp10985
g135
(dp10986
(VCASR
p10987
VKearns-Sayre syndrome
p10988
tp10989
I00
ssg2
VThose can be classified into four groups: hypercalciuric hypomagnesemias (encompassing mutations in CLDN16, CLDN19, CASR, CLCNKB), Gitelman-like hypomagnesemias (CLCNKB, SLC12A3, BSND, KCNJ10, FYXD2, HNF1B, PCBD1), mitochondrial hypomagnesemias (SARS2, MT-TI, Kearns-Sayre syndrome) and other hypomagnesemias (TRPM6, CNMM2, EGF, EGFR, KCNA1, FAM111A).
p10990
sg4
(lp10991
(dp10992
g7
I246
sg8
VSARS2
p10993
sg10
I5
sg11
g12
sg13
I1
sa(dp10994
g7
I324
sg8
VEGF
p10995
sg10
I3
sg11
VP01133
p10996
sg13
I1
sa(dp10997
g7
I108
sg8
VCLDN19
p10998
sg10
I6
sg11
g12
sg13
I1
sa(dp10999
g7
I310
sg8
VTRPM6
p11000
sg10
I5
sg11
g12
sg13
I1
sa(dp11001
g7
I122
sg8
VCLCNKB
p11002
sg10
I6
sg11
VP51801
p11003
sg13
I1
sa(dp11004
g7
I342
sg8
VFAM111A
p11005
sg10
I7
sg11
g12
sg13
I1
sa(dp11006
g7
I335
sg8
VKCNA1
p11007
sg10
I5
sg11
g12
sg13
I1
sa(dp11008
g7
I170
sg8
VSLC12A3
p11009
sg10
I7
sg11
VP55017
p11010
sg13
I1
sa(dp11011
g7
I207
sg8
VPCBD1
p11012
sg10
I5
sg11
VP61457
p11013
sg13
I1
sa(dp11014
g7
I200
sg8
VHNF1B
p11015
sg10
I5
sg11
VP35680
p11016
sg13
I1
sa(dp11017
g7
I179
sg8
VBSND
p11018
sg10
I4
sg11
g12
sg13
I1
sa(dp11019
g7
I185
sg8
VKCNJ10
p11020
sg10
I6
sg11
VP78508
p11021
sg13
I1
sa(dp11022
g7
I100
sg8
VCLDN16
p11023
sg10
I6
sg11
g12
sg13
I1
sa(dp11024
g7
I122
sg8
VCLCNKB
p11025
sg10
I6
sg11
VP51801
p11026
sg13
I1
sa(dp11027
g7
I116
sg8
g10987
sg10
I4
sg11
VP41180
p11028
sg13
I1
sasg24
(lp11029
(dp11030
g7
I179
sg8
VBSND
p11031
sg10
I4
sg28
VC1865270
p11032
sg13
I1
sa(dp11033
g7
I260
sg8
g10988
sg10
I21
sg28
VC0022541
p11034
sg13
I2
sasa(dp11035
g2
VFor radiculopathy, epidural corticosteroids were associated with greater immediate-term reduction in pain (weighted mean difference on a scale of 0 to 100, -7.55 [95% CI, -11.4 to -3.74]; SOE, moderate), function (standardized mean difference after exclusion of an outlier trial, -0.33 [CI, -0.56 to -0.09]; SOE, low), and short-term surgery risk (relative risk, 0.62 [CI, 0.41 to 0.92]; SOE, low).
p11036
sg4
(lp11037
sg24
(lp11038
(dp11039
g7
I4
sg8
Vradiculopathy
p11040
sg10
I13
sg28
VC0700594
p11041
sg13
I1
sasa(dp11042
g2
VThe final multilevel growth model revealed improvements in RMDQ scores in patients with radiculopathy at the 6-week (-8.1, 95 % CI -12.6 to -2.6; P = 0.006) and 6-month (-4.1, 95 % CI -7.4 to -0.7; P = 0.020) follow-up occasions compared to patients without radiculopathy.
p11043
sg4
(lp11044
sg24
(lp11045
(dp11046
g7
I88
sg8
Vradiculopathy
p11047
sg10
I13
sg28
VC0700594
p11048
sg13
I1
sa(dp11049
g7
I88
sg8
Vradiculopathy
p11050
sg10
I13
sg28
VC0700594
p11051
sg13
I1
sasa(dp11052
g2
VAn interaction between electrodiagnostic status and time revealed faster weekly improvements in RMDQ scores in patients with radiculopathy at the 6-week (-0.72, 95 % CI -1.4 to -0.04; P = 0.040) through the 16-week (-0.30, 95 % CI, -0.57 to -0.04; P = 0.028) follow-up occasions compared to patients without radiculopathy.
p11053
sg4
(lp11054
sg24
(lp11055
(dp11056
g7
I125
sg8
Vradiculopathy
p11057
sg10
I13
sg28
VC0700594
p11058
sg13
I1
sa(dp11059
g7
I125
sg8
Vradiculopathy
p11060
sg10
I13
sg28
VC0700594
p11061
sg13
I1
sasa(dp11062
g2
VFor patients with radiculopathy, a repeated-measures analysis of variance showed a significant decrease in the H reflex amplitude (from 0.81 +/- 0.4 to 0.69 +/- 0.39 mV), an increase in radicular symptoms after reading (from 4.2 +/- 1.3 to 5.6 +/- 1.4 on the visual analog scale), an increase in the H reflex amplitude (from 0.69 +/- 0.39 to 1.01 +/- 0.49 mV), and a decrease in pain intensity (from 5.6 +/- 1.4 to 1.5 +/- 1.3) after repeated neck retractions.
p11063
sg4
(lp11064
sg24
(lp11065
(dp11066
g7
I18
sg8
Vradiculopathy
p11067
sg10
I13
sg28
VC0700594
p11068
sg13
I1
sasa(dp11069
g135
(dp11070
(VIL-1Beta
p11071
Vheart failure
p11072
tp11073
I00
ssg2
VAlthough some autoinflammatory diseases are due to gain-of-function mutations for caspase-1 activity, common diseases such as gout, type 2 diabetes, heart failure, recurrent pericarditis, rheumatoid arthritis, and smoldering myeloma also are responsive to IL-1Beta neutralization.
p11074
sg4
(lp11075
(dp11076
g7
I82
sg8
Vcaspase-1
p11077
sg10
I9
sg11
VP29466
p11078
sg13
I1
sa(dp11079
g7
I256
sg8
g11071
sg10
I8
sg11
VP01584
p11080
sg13
I1
sasg24
(lp11081
(dp11082
g7
I126
sg8
Vgout
p11083
sg10
I4
sg28
VC0018099
p11084
sg13
I1
sa(dp11085
g7
I214
sg8
Vsmoldering myeloma
p11086
sg10
I18
sg28
VC1531608
p11087
sg13
I2
sa(dp11088
g7
I188
sg8
Vrheumatoid arthritis
p11089
sg10
I20
sg28
VC0003873
p11090
sg13
I2
sa(dp11091
g7
I174
sg8
Vpericarditis
p11092
sg10
I12
sg28
VC0031046
p11093
sg13
I1
sa(dp11094
g7
I132
sg8
Vtype 2 diabetes
p11095
sg10
I15
sg28
VC0011860
p11096
sg13
I3
sa(dp11097
g7
I149
sg8
g11072
sg10
I13
sg28
VC0018802
p11098
sg13
I2
sasa(dp11099
g135
(dp11100
(VCcl2
p11101
Vendometrial cancer
p11102
tp11103
I01
ssg2
VInactivation of Ccl2 in an Lkb1-driven mouse model of endometrial cancer slowed tumor progression and increased survival.
p11104
sg4
(lp11105
(dp11106
g7
I16
sg8
g11101
sg10
I4
sg11
VP13500
p11107
sg13
I1
sa(dp11108
g7
I27
sg8
VLkb1
p11109
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp11110
(dp11111
g7
I80
sg8
Vtumor progression
p11112
sg10
I17
sg28
VC0178874
p11113
sg13
I2
sa(dp11114
g7
I54
sg8
g11102
sg10
I18
sg28
VC0476089
p11115
sg13
I2
sa(dp11116
g7
I0
sg8
VInactivation
p11117
sg10
I12
sg28
VC0544461
p11118
sg13
I1
sasa(dp11119
g135
(dp11120
(VCCL2
p11121
Vendometrial cancers
p11122
tp11123
I01
ssg2
VIn human primary endometrial cancers, loss of LKB1 protein was strongly associated with increased CCL2 expression by tumor cells as well as increased macrophage density in the tumor microenvironment.
p11124
sg4
(lp11125
(dp11126
g7
I46
sg8
VLKB1 protein
p11127
sg10
I12
sg11
g12
sg13
I2
sa(dp11128
g7
I98
sg8
g11121
sg10
I4
sg11
VP13500
p11129
sg13
I1
sasg24
(lp11130
(dp11131
g7
I117
sg8
Vtumor
p11132
sg10
I5
sg28
VC0027651
p11133
sg13
I1
sa(dp11134
g7
I17
sg8
g11122
sg10
I19
sg28
VC0476089
p11135
sg13
I2
sa(dp11136
g7
I117
sg8
Vtumor
p11137
sg10
I5
sg28
VC0027651
p11138
sg13
I1
sasa(dp11139
g135
(dp11140
(VCCL2
p11141
Vendometrial cancer
p11142
tp11143
I01
ssg2
VThese data demonstrate that CCL2 is a potent effector of LKB1 loss in endometrial cancer, creating potential avenues for therapeutic opportunities.
p11144
sg4
(lp11145
(dp11146
g7
I28
sg8
g11141
sg10
I4
sg11
VP13500
p11147
sg13
I1
sa(dp11148
g7
I57
sg8
VLKB1
p11149
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp11150
(dp11151
g7
I70
sg8
g11142
sg10
I18
sg28
VC0476089
p11152
sg13
I2
sasa(dp11153
g135
(dp11154
(VCCL2
p11155
Vendometrial cancer
p11156
tp11157
I01
ssg2
VOur results showed that in HEC-1-B (human endometrial cancer) cells, IL-17 stimulation induced mRNA level increases of CCL2, CCL5, CCL20, CXCL2, and IL-8.
p11158
sg4
(lp11159
(dp11160
g7
I131
sg8
VCCL20
p11161
sg10
I5
sg11
VP78556
p11162
sg13
I1
sa(dp11163
g7
I27
sg8
VHEC-1-B
p11164
sg10
I7
sg11
g12
sg13
I1
sa(dp11165
g7
I138
sg8
VCXCL2
p11166
sg10
I5
sg11
VP19875
p11167
sg13
I1
sa(dp11168
g7
I125
sg8
VCCL5
p11169
sg10
I4
sg11
VP13501
p11170
sg13
I1
sa(dp11171
g7
I119
sg8
g11155
sg10
I4
sg11
VP13500
p11172
sg13
I1
sasg24
(lp11173
(dp11174
g7
I42
sg8
g11156
sg10
I18
sg28
VC0476089
p11175
sg13
I2
sasa(dp11176
g135
(dp11177
(VCCL2 A2518G
p11178
Vendometrial cancer
p11179
tp11180
I01
ssg2
VIn this study of Turkish women, the association of CCL2 A2518G and CCR2 V64I polymorphisms with endometrial cancer was investigated using 50 endometrial cancer patients and 211 controls.
p11181
sg4
(lp11182
(dp11183
g7
I67
sg8
VCCR2
p11184
sg10
I4
sg11
VP41597
p11185
sg13
I1
sa(dp11186
g7
I51
sg8
g11178
sg10
I11
sg11
VP13500
p11187
sg13
I2
sasg24
(lp11188
(dp11189
g7
I96
sg8
Vendometrial cancer
p11190
sg10
I18
sg28
VC0476089
p11191
sg13
I2
sa(dp11192
g7
I96
sg8
g11179
sg10
I18
sg28
VC0476089
p11193
sg13
I2
sasa(dp11194
g135
(dp11195
(VCCL2 A2518G A allele
p11196
Vendometrium cancer
p11197
tp11198
I01
ssg2
VIn our study, individuals with CCL2 A2518G GG genotype showed a 6.7-fold increased risk for endometrial cancer (p&lt;0.0001) and individuals with CCL2 A2518G A allele had a 7.14-fold lower risk of endometrium cancer (p&lt;0.0001).
p11199
sg4
(lp11200
(dp11201
g7
I31
sg8
VCCL2 A2518G GG genotype
p11202
sg10
I23
sg11
VP13500
p11203
sg13
I4
sa(dp11204
g7
I146
sg8
g11196
sg10
I20
sg11
VP13500
p11205
sg13
I4
sasg24
(lp11206
(dp11207
g7
I92
sg8
Vendometrial cancer
p11208
sg10
I18
sg28
VC0476089
p11209
sg13
I2
sa(dp11210
g7
I197
sg8
g11197
sg10
I18
sg28
VC0476089
p11211
sg13
I2
sasa(dp11212
g135
(dp11213
(VCCL2
p11214
Vendometrial cancer
p11215
tp11216
I01
ssg2
VIn conclusion, we state that there appears to be an association between polymorphism of CCL2 and its receptor CCR2 and endometrial cancer.
p11217
sg4
(lp11218
(dp11219
g7
I110
sg8
VCCR2
p11220
sg10
I4
sg11
VP41597
p11221
sg13
I1
sa(dp11222
g7
I88
sg8
g11214
sg10
I4
sg11
VP13500
p11223
sg13
I1
sasg24
(lp11224
(dp11225
g7
I119
sg8
g11215
sg10
I18
sg28
VC0476089
p11226
sg13
I2
sasa(dp11227
g2
VA total of 146 cryptorchid and 140 infertile patients without a history of cryptorchidism were screened with a sequence tagged site plus/minus method and further confirmed and characterized by CDY1/DAZ gene dosage and copy analysis.
p11228
sg4
(lp11229
(dp11230
g7
I193
sg8
VCDY1
p11231
sg10
I4
sg11
g12
sg13
I1
sa(dp11232
g7
I198
sg8
VDAZ
p11233
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp11234
(dp11235
g7
I35
sg8
Vinfertile
p11236
sg10
I9
sg28
VC0021359
p11237
sg13
I1
sa(dp11238
g7
I75
sg8
Vcryptorchidism
p11239
sg10
I14
sg28
VC0010417
p11240
sg13
I1
sasa(dp11241
g2
VThe aim of this study is to explore the various modes of action miR-497 has on human cervical cancer (CC) cell behavior.
p11242
sg4
(lp11243
sg24
(lp11244
(dp11245
g7
I85
sg8
Vcervical cancer
p11246
sg10
I15
sg28
VC0302592
p11247
sg13
I2
sasa(dp11248
g2
VIn this study, the expression levels of PVT1 and miR-497 in NSCLC cells were determined by qRT-PCR.
p11249
sg4
(lp11250
(dp11251
g7
I49
sg8
VmiR-497
p11252
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp11253
(dp11254
g7
I60
sg8
VNSCLC
p11255
sg10
I5
sg28
VC0007131
p11256
sg13
I1
sasa(dp11257
g2
VOur findings indicated that PVT1 was significantly upregulated and miR-497 was markedly downregulated in NSCLC cell lines.
p11258
sg4
(lp11259
(dp11260
g7
I67
sg8
VmiR-497
p11261
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp11262
(dp11263
g7
I105
sg8
VNSCLC
p11264
sg10
I5
sg28
VC0007131
p11265
sg13
I1
sasa(dp11266
g2
VMoreover, PVT1 overexpression reversed the inhibitory effect of miR-497 on cell viability, invasion and promotion effect on apoptosis of NSCLC cells.
p11267
sg4
(lp11268
sg24
(lp11269
(dp11270
g7
I137
sg8
VNSCLC
p11271
sg10
I5
sg28
VC0007131
p11272
sg13
I1
sa(dp11273
g7
I91
sg8
Vinvasion
p11274
sg10
I8
sg28
VC2699153
p11275
sg13
I1
sasa(dp11276
g2
VIn conclusion, knockdown of PVT1 inhibited cell viability, invasion and induced apoptosis in NSCLC by regulating miR-497 expression, elucidating the molecular mechanism of the oncogenic role of PVT1 in NSCLC and providing an lncRNA-directed target for NSCLC.
p11277
sg4
(lp11278
sg24
(lp11279
(dp11280
g7
I93
sg8
VNSCLC
p11281
sg10
I5
sg28
VC0007131
p11282
sg13
I1
sa(dp11283
g7
I59
sg8
Vinvasion
p11284
sg10
I8
sg28
VC2699153
p11285
sg13
I1
sa(dp11286
g7
I93
sg8
VNSCLC
p11287
sg10
I5
sg28
VC0007131
p11288
sg13
I1
sa(dp11289
g7
I93
sg8
VNSCLC
p11290
sg10
I5
sg28
VC0007131
p11291
sg13
I1
sasa(dp11292
g2
VMany prominent cancer-associated molecules have been identified over the recent years which include EGFR, CD44, TGFbRII, HER2, miR-497, NMP22, BTA, Fibrin/FDP etc.
p11293
sg4
(lp11294
(dp11295
g7
I127
sg8
VmiR-497
p11296
sg10
I7
sg11
g12
sg13
I1
sa(dp11297
g7
I155
sg8
VFDP
p11298
sg10
I3
sg11
g12
sg13
I1
sa(dp11299
g7
I148
sg8
VFibrin
p11300
sg10
I6
sg11
VP22087
p11301
sg13
I1
sa(dp11302
g7
I121
sg8
VHER2
p11303
sg10
I4
sg11
VP04626
p11304
sg13
I1
sasg24
(lp11305
(dp11306
g7
I15
sg8
Vcancer
p11307
sg10
I6
sg28
VC0006826
p11308
sg13
I1
sasa(dp11309
g2
VThe expression levels of miR-497 in the cancerous and the adjacent noncancerous tissues were detected using reverse transcription-quantitative polymerase chain reaction.
p11310
sg4
(lp11311
sg24
(lp11312
sa(dp11313
g2
VAn miR-497-overexpressing vector was transfected into the T24 and BIU-87 bladder cancer cell lines in order to determine the effect of miR-497 expression on cell migration and invasion using Transwell assays.
p11314
sg4
(lp11315
sg24
(lp11316
(dp11317
g7
I176
sg8
Vinvasion
p11318
sg10
I8
sg28
VC2699153
p11319
sg13
I1
sa(dp11320
g7
I73
sg8
Vbladder cancer
p11321
sg10
I14
sg28
VC0699885
p11322
sg13
I2
sasa(dp11323
g2
VThe findings of the present study revealed that miR-497 was expressed at low levels in the cancer bladder tissue compared with the adjacent noncancerous tissue, and its expression was associated with the pathological classification, TNM stage and metastasis.
p11324
sg4
(lp11325
(dp11326
g7
I48
sg8
VmiR-497
p11327
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp11328
(dp11329
g7
I247
sg8
Vmetastasis
p11330
sg10
I10
sg28
VC0027627
p11331
sg13
I1
sa(dp11332
g7
I91
sg8
Vcancer
p11333
sg10
I6
sg28
VC0006826
p11334
sg13
I1
sasa(dp11335
g2
VThe present study revealed that miR-497 overexpression may be a suppressor of the metastasis of bladder cancer, and may have an important role in the diagnosis of bladder cancer.
p11336
sg4
(lp11337
sg24
(lp11338
(dp11339
g7
I82
sg8
Vmetastasis
p11340
sg10
I10
sg28
VC0027627
p11341
sg13
I1
sa(dp11342
g7
I96
sg8
Vbladder cancer
p11343
sg10
I14
sg28
VC0699885
p11344
sg13
I2
sa(dp11345
g7
I96
sg8
Vbladder cancer
p11346
sg10
I14
sg28
VC0699885
p11347
sg13
I2
sasa(dp11348
g2
VPHR patient portal users (34 percent of eligible persons) were older and more likely to be White, have private health insurance, and develop gestational diabetes than nonusers.
p11349
sg4
(lp11350
sg24
(lp11351
(dp11352
g7
I141
sg8
Vgestational diabetes
p11353
sg10
I20
sg28
VC0085207
p11354
sg13
I2
sasa(dp11355
g2
VWe searched the Internet to review patient-held medical records (PHRs) of patients with diabetes and examine current levels of integration of diabetes and depression care in Japan.
p11356
sg4
(lp11357
sg24
(lp11358
(dp11359
g7
I88
sg8
Vdiabetes
p11360
sg10
I8
sg28
VC0011849
p11361
sg13
I1
sa(dp11362
g7
I155
sg8
Vdepression
p11363
sg10
I10
sg28
VC0011581
p11364
sg13
I1
sa(dp11365
g7
I88
sg8
Vdiabetes
p11366
sg10
I8
sg28
VC0011849
p11367
sg13
I1
sasa(dp11368
g2
VEight sets of PHRs were found for people with diabetes.
p11369
sg4
(lp11370
sg24
(lp11371
(dp11372
g7
I46
sg8
Vdiabetes
p11373
sg10
I8
sg28
VC0011849
p11374
sg13
I1
sasa(dp11375
g2
VAll PHRs included clinical follow-up of diabetes and multidisciplinary clinical pathways for diabetes care.
p11376
sg4
(lp11377
sg24
(lp11378
(dp11379
g7
I40
sg8
Vdiabetes
p11380
sg10
I8
sg28
VC0011849
p11381
sg13
I1
sa(dp11382
g7
I40
sg8
Vdiabetes
p11383
sg10
I8
sg28
VC0011849
p11384
sg13
I1
sasa(dp11385
g2
VIn terms of an integrated PHR for a patient comorbid with diabetes and depression, necessary components include hopes/preferences, educational information on diabetes complications and treatment, medical history, stress and coping, resources, and monitoring diabetes and depression.
p11386
sg4
(lp11387
sg24
(lp11388
(dp11389
g7
I58
sg8
Vdiabetes
p11390
sg10
I8
sg28
VC0011849
p11391
sg13
I1
sa(dp11392
g7
I71
sg8
Vdepression
p11393
sg10
I10
sg28
VC0011581
p11394
sg13
I1
sa(dp11395
g7
I58
sg8
Vdiabetes
p11396
sg10
I8
sg28
VC0011849
p11397
sg13
I1
sa(dp11398
g7
I158
sg8
Vdiabetes complications
p11399
sg10
I22
sg28
VC0342257
p11400
sg13
I2
sa(dp11401
g7
I71
sg8
Vdepression
p11402
sg10
I10
sg28
VC0011581
p11403
sg13
I1
sasa(dp11404
g2
VA new PHR may be suitable for comorbid patients with diabetes and depression.
p11405
sg4
(lp11406
sg24
(lp11407
(dp11408
g7
I66
sg8
Vdepression
p11409
sg10
I10
sg28
VC0011581
p11410
sg13
I1
sa(dp11411
g7
I53
sg8
Vdiabetes
p11412
sg10
I8
sg28
VC0011849
p11413
sg13
I1
sasa(dp11414
g2
Vto evaluate the attitude of patients with Type II diabetes towards using a PHR to manage their condition.
p11415
sg4
(lp11416
sg24
(lp11417
(dp11418
g7
I42
sg8
VType II diabetes
p11419
sg10
I16
sg28
VC0011860
p11420
sg13
I3
sa(dp11421
g7
I95
sg8
Vcondition
p11422
sg10
I9
sg28
VC0012634
p11423
sg13
I1
sasa(dp11424
g2
VThe attitude of patients towards using PHR in management of their diabetes was positive.
p11425
sg4
(lp11426
sg24
(lp11427
(dp11428
g7
I66
sg8
Vdiabetes
p11429
sg10
I8
sg28
VC0011849
p11430
sg13
I1
sasa(dp11431
g2
VPersonal health records (PHRs) have the potential to improve patient self-management for chronic conditions such as diabetes.
p11432
sg4
(lp11433
sg24
(lp11434
(dp11435
g7
I116
sg8
Vdiabetes
p11436
sg10
I8
sg28
VC0011849
p11437
sg13
I1
sasa(dp11438
g2
VThe purpose of this qualitative study was to explore how patients with type 2 diabetes used a PHR to manage their diabetes-related health information for self-care.
p11439
sg4
(lp11440
sg24
(lp11441
(dp11442
g7
I71
sg8
Vtype 2 diabetes
p11443
sg10
I15
sg28
VC0011860
p11444
sg13
I3
sa(dp11445
g7
I78
sg8
Vdiabetes
p11446
sg10
I8
sg28
VC0011849
p11447
sg13
I1
sasa(dp11448
g2
VFifty-nine patients with type 2 diabetes were interviewed 3-6 months after receiving initial training on a free-of-charge, Web-based PHR.
p11449
sg4
(lp11450
sg24
(lp11451
(dp11452
g7
I123
sg8
VWeb
p11453
sg10
I3
sg28
VC0332875
p11454
sg13
I1
sa(dp11455
g7
I25
sg8
Vtype 2 diabetes
p11456
sg10
I15
sg28
VC0011860
p11457
sg13
I3
sasa(dp11458
g2
VThe objective of this paper is to describe the design and implementation of a Personal Health Record System (PHR-S) for supporting monitoring of blood glucose in diabetes mellitus type 2 patients.
p11459
sg4
(lp11460
sg24
(lp11461
(dp11462
g7
I162
sg8
Vdiabetes mellitus type 2
p11463
sg10
I24
sg28
VC0011860
p11464
sg13
I4
sasa(dp11465
g135
(dp11466
(VRPB2
p11467
VIGS
p11468
tp11469
I00
ssg2
VIn this study the different applications and functionalities of the program are demonstrated such as: exhaustive assembly (rDNA region and mitochondrial genome), extracting homologous regions or genes (IGS, RPB1, RPB2 and TEF1a), as well as extracting multiple regions within a single run.
p11470
sg4
(lp11471
(dp11472
g7
I207
sg8
VRPB1
p11473
sg10
I4
sg11
VP24928
p11474
sg13
I1
sa(dp11475
g7
I213
sg8
g11467
sg10
I4
sg11
VP30876
p11476
sg13
I1
sa(dp11477
g7
I202
sg8
VIGS
p11478
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp11479
(dp11480
g7
I202
sg8
g11468
sg10
I3
sg28
VC1306856
p11481
sg13
I1
sasa(dp11482
g135
(dp11483
(VRNA polymerase II subunit B2
p11484
VIGS
p11485
tp11486
I00
ssg2
VSequences of the translation elongation factor 1Alfa (tef1Alfa), RNA polymerase II subunit B2 (rpb2), ATP citrate lyase subunit A (acla), and internal transcribed spacer (ITS) regions were monomorphic, while the intergenic spacer (IGS) region showed length polymorphisms at two minisatellites of 23 and 39 nucleotides (nt).
p11487
sg4
(lp11488
(dp11489
g7
I102
sg8
VATP citrate lyase subunit A
p11490
sg10
I27
sg11
g12
sg13
I5
sa(dp11491
g7
I54
sg8
Vtef1Alfa
p11492
sg10
I8
sg11
g12
sg13
I1
sa(dp11493
g7
I95
sg8
Vrpb2
p11494
sg10
I4
sg11
VP30876
p11495
sg13
I1
sa(dp11496
g7
I131
sg8
Vacla
p11497
sg10
I4
sg11
g12
sg13
I1
sa(dp11498
g7
I65
sg8
g11484
sg10
I28
sg11
VP30876
p11499
sg13
I5
sa(dp11500
g7
I17
sg8
Vtranslation elongation factor 1Alfa
p11501
sg10
I35
sg11
g12
sg13
I4
sasg24
(lp11502
(dp11503
g7
I212
sg8
Vintergenic spacer
p11504
sg10
I17
sg28
VC1306856
p11505
sg13
I2
sa(dp11506
g7
I231
sg8
g11485
sg10
I3
sg28
VC1306856
p11507
sg13
I1
sasa(dp11508
g135
(dp11509
(VRNA polymerase II
p11510
VIGS
p11511
tp11512
I00
ssg2
VThe phylogenetic relationships of these species were determined using sequences from the ITS and IGS region of the nuclear rRNA gene complex, two nuclear genes ( Beta -tubulin (benA) and RNA polymerase II second largest subunit (rpb2)) and two mitochondrial genes (small rRNA subunit (rns) and cytochrome oxidase subunit I (cox1)) and, where available, related sequences from databases.
p11513
sg4
(lp11514
(dp11515
g7
I324
sg8
Vcox1
p11516
sg10
I4
sg11
VP00395
p11517
sg13
I1
sa(dp11518
g7
I294
sg8
Vcytochrome oxidase subunit I
p11519
sg10
I28
sg11
VP00395
p11520
sg13
I4
sa(dp11521
g7
I229
sg8
Vrpb2
p11522
sg10
I4
sg11
VP30876
p11523
sg13
I1
sa(dp11524
g7
I187
sg8
g11510
sg10
I17
sg11
VP19388
p11525
sg13
I3
sasg24
(lp11526
(dp11527
g7
I285
sg8
Vrns
p11528
sg10
I3
sg28
VC1850106
p11529
sg13
I1
sa(dp11530
g7
I97
sg8
g11511
sg10
I3
sg28
VC1306856
p11531
sg13
I1
sasa(dp11532
g135
(dp11533
(Vrpb2
p11534
Vrns
p11535
tp11536
I00
ssg2
VThe combined use of the three commonly employed nuclear genes (benA, rpb2, and ITS), the IGS region, and two less often used mitochondrial gene sequences (rns and cox1) as a single unit resolved several taxonomic ambiguities.
p11537
sg4
(lp11538
(dp11539
g7
I155
sg8
Vrns
p11540
sg10
I3
sg11
g12
sg13
I1
sa(dp11541
g7
I163
sg8
Vcox1
p11542
sg10
I4
sg11
VP00395
p11543
sg13
I1
sa(dp11544
g7
I69
sg8
g11534
sg10
I4
sg11
VP30876
p11545
sg13
I1
sa(dp11546
g7
I89
sg8
VIGS region
p11547
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp11548
(dp11549
g7
I89
sg8
VIGS
p11550
sg10
I3
sg28
VC1306856
p11551
sg13
I1
sa(dp11552
g7
I155
sg8
g11535
sg10
I3
sg28
VC1850106
p11553
sg13
I1
sasa(dp11554
g135
(dp11555
(Vcox1
p11556
VIGS
p11557
tp11558
I00
ssg2
VIn order to find other markers that, in combination with the ITS rDNA region can be used for species identification in Cladonia, we studied the loci IGS rDNA, ef1Alfa, rpb2 and cox1.
p11559
sg4
(lp11560
(dp11561
g7
I149
sg8
VIGS rDNA
p11562
sg10
I8
sg11
g12
sg13
I2
sa(dp11563
g7
I168
sg8
Vrpb2
p11564
sg10
I4
sg11
VP30876
p11565
sg13
I1
sa(dp11566
g7
I177
sg8
g11556
sg10
I4
sg11
VP00395
p11567
sg13
I1
sasg24
(lp11568
(dp11569
g7
I149
sg8
g11557
sg10
I3
sg28
VC1306856
p11570
sg13
I1
sasa(dp11571
g2
VThree-gene combined analyses (ITS+IGS+rpb2) were performed and the results indicated that the Chinese 'G.
p11572
sg4
(lp11573
sg24
(lp11574
sa(dp11575
g135
(dp11576
(VCAM
p11577
VCAM
p11578
tp11579
I00
ssg2
VSeven loci were analyzed: the translation elongation factor 1 alpha gene (EF-1Alfa); the nuclear rRNA internal transcribed spacer (ITS), large subunit (LSU), and intergenic spacer (IGS) regions; the second largest subunit of the RNA polymerase gene (RPB2); the calmodulin gene (CAM); and the mitochondrial small subunit (mtSSU) rRNA gene.
p11580
sg4
(lp11581
(dp11582
g7
I30
sg8
Vtranslation elongation factor 1 alpha gene
p11583
sg10
I42
sg11
g12
sg13
I6
sa(dp11584
g7
I250
sg8
VRPB2
p11585
sg10
I4
sg11
VP30876
p11586
sg13
I1
sa(dp11587
g7
I278
sg8
g11577
sg10
I3
sg11
VP01768
p11588
sg13
I1
sa(dp11589
g7
I261
sg8
Vcalmodulin gene
p11590
sg10
I15
sg11
g12
sg13
I2
sasg24
(lp11591
(dp11592
g7
I162
sg8
Vintergenic spacer
p11593
sg10
I17
sg28
VC1306856
p11594
sg13
I2
sa(dp11595
g7
I261
sg8
Vcalmodulin gene
p11596
sg10
I15
sg28
VC1861821
p11597
sg13
I2
sa(dp11598
g7
I181
sg8
VIGS
p11599
sg10
I3
sg28
VC1306856
p11600
sg13
I1
sa(dp11601
g7
I278
sg8
g11578
sg10
I3
sg28
VC1861821
p11602
sg13
I1
sasa(dp11603
g2
VTwenty-nine IGS, 27 EF-1Alfa, 26 RPB2, 24 CAM, 18 ITS, 19 LSU, and 18 mtSSU haplotypes were identified; 29 were unique, and haplotypes for 24 clinical strains were novel.
p11604
sg4
(lp11605
(dp11606
g7
I12
sg8
VIGS, 27 EF-1Alfa, 26 RPB2
p11607
sg10
I25
sg11
g12
sg13
I5
sasg24
(lp11608
(dp11609
g7
I12
sg8
VIGS
p11610
sg10
I3
sg28
VC1306856
p11611
sg13
I1
sa(dp11612
g7
I42
sg8
VCAM
p11613
sg10
I3
sg28
VC1861821
p11614
sg13
I1
sasa(dp11615
g135
(dp11616
(VSTAT6
p11617
Valveolar soft part sarcoma
p11618
tp11619
I00
ssg2
VComplete absence of STAT6 was most common in pleomorphic liposarcoma and alveolar soft part sarcoma (60% and 72% cases negative, respectively).
p11620
sg4
(lp11621
(dp11622
g7
I20
sg8
g11617
sg10
I5
sg11
VP42226
p11623
sg13
I1
sasg24
(lp11624
(dp11625
g7
I45
sg8
Vpleomorphic liposarcoma
p11626
sg10
I23
sg28
VC0205825
p11627
sg13
I2
sa(dp11628
g7
I73
sg8
g11618
sg10
I26
sg28
VC0206657
p11629
sg13
I4
sasa(dp11630
g135
(dp11631
(VmyL
p11632
Vcoagulopathy
p11633
tp11634
I00
ssg2
VPatients with ASC due to choledocholithiasis were allocated to two groups: Those who underwent EST immediately and those who underwent EBD followed by EST 1 wk later because they were under anticoagulant therapy, had a coagulopathy (international normalized ratio &gt; 1.3, partial thromboplastin time greater than twice that of control), or had a platelet count &lt; 50000 x 10(3)/myL.
p11635
sg4
(lp11636
(dp11637
g7
I282
sg8
Vthromboplastin
p11638
sg10
I14
sg11
VP13726
p11639
sg13
I1
sa(dp11640
g7
I382
sg8
g11632
sg10
I3
sg11
VP29590
p11641
sg13
I1
sasg24
(lp11642
(dp11643
g7
I25
sg8
Vcholedocholithiasis
p11644
sg10
I19
sg28
VC0701818
p11645
sg13
I1
sa(dp11646
g7
I219
sg8
g11633
sg10
I12
sg28
VC0005779
p11647
sg13
I1
sasa(dp11648
g135
(dp11649
(VAsd-4 mutant
p11650
VAsd
p11651
tp11652
I00
ssg2
VA cross of the Asd-4 mutant with wild-type resulted in fruiting bodies that appeared to be normal macroscopically but which were complete devoid of asci and ascospores.
p11653
sg4
(lp11654
(dp11655
g7
I15
sg8
g11650
sg10
I12
sg11
VP51689
p11656
sg13
I2
sasg24
(lp11657
(dp11658
g7
I15
sg8
g11651
sg10
I3
sg28
VC1510586
p11659
sg13
I1
sa(dp11660
g7
I21
sg8
Vmutant
p11661
sg10
I6
sg28
VC0596988
p11662
sg13
I1
sasa(dp11663
g135
(dp11664
(Vasd-1
p11665
Vasd
p11666
tp11667
I00
ssg2
VA mutant strain (asd-1) with a recessive crossing defect (apparently caused by the RIP process) was isolated; in this strain, early development is normal and may asci are formed, but ascospores are never delineated.
p11668
sg4
(lp11669
(dp11670
g7
I17
sg8
g11665
sg10
I5
sg11
VP51689
p11671
sg13
I1
sasg24
(lp11672
(dp11673
g7
I17
sg8
g11666
sg10
I3
sg28
VC1510586
p11674
sg13
I1
sa(dp11675
g7
I2
sg8
Vmutant
p11676
sg10
I6
sg28
VC0596988
p11677
sg13
I1
sasa(dp11678
g2
VcPGES and mPGES-2 have been found expressed in normal gastric mucosa, with no change in expression levels seen in gastritis or gastric ulcer tissue.
p11679
sg4
(lp11680
(dp11681
g7
I10
sg8
VmPGES-2
p11682
sg10
I7
sg11
g12
sg13
I1
sa(dp11683
g7
I0
sg8
VcPGES
p11684
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp11685
(dp11686
g7
I114
sg8
Vgastritis
p11687
sg10
I9
sg28
VC0017152
p11688
sg13
I1
sa(dp11689
g7
I127
sg8
Vgastric ulcer
p11690
sg10
I13
sg28
VC0038358
p11691
sg13
I2
sasa(dp11692
g2
VHerein we investigated the ATR-Chk1 and ATM-Chk2 signalings in male breast cancer (MBC).
p11693
sg4
(lp11694
(dp11695
g7
I31
sg8
VChk1
p11696
sg10
I4
sg11
g12
sg13
I1
sa(dp11697
g7
I40
sg8
VATM
p11698
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp11699
(dp11700
g7
I83
sg8
VMBC
p11701
sg10
I3
sg28
VC0242787
p11702
sg13
I1
sa(dp11703
g7
I63
sg8
Vmale breast cancer
p11704
sg10
I18
sg28
VC0242787
p11705
sg13
I3
sasa(dp11706
g2
VWe have previously shown that the1100delC variant of the cell-cycle-checkpoint kinase gene CHEK2, which is carried by approximately 1% of the population confers a two-fold increase in female breast cancer and a 10-fold increase in male breast cancer.
p11707
sg4
(lp11708
sg24
(lp11709
(dp11710
g7
I184
sg8
Vfemale breast cancer
p11711
sg10
I20
sg28
VC0235653
p11712
sg13
I3
sa(dp11713
g7
I186
sg8
Vmale breast cancer
p11714
sg10
I18
sg28
VC0242787
p11715
sg13
I3
sasa(dp11716
g2
VThe purpose of present study was to investigate the relation of serum interleukin-19 (IL-19) levels with diabetic nephropathy (DN).
p11717
sg4
(lp11718
(dp11719
g7
I70
sg8
Vinterleukin-19
p11720
sg10
I14
sg11
g12
sg13
I1
sa(dp11721
g7
I86
sg8
VIL-19
p11722
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp11723
(dp11724
g7
I105
sg8
Vdiabetic nephropathy
p11725
sg10
I20
sg28
VC0011881
p11726
sg13
I2
sa(dp11727
g7
I127
sg8
VDN
p11728
sg10
I2
sg28
VC0011881
p11729
sg13
I1
sasa(dp11730
g135
(dp11731
(VCystatin C
p11732
Vdiabetic nephropathy
p11733
tp11734
I01
ssg2
VIL-19 is significantly positive correlated with UAE and Cystatin C. IL-19 may play an important role that contributes to the progression of diabetic nephropathy.
p11735
sg4
(lp11736
(dp11737
g7
I0
sg8
VIL-19
p11738
sg10
I5
sg11
g12
sg13
I1
sa(dp11739
g7
I0
sg8
VIL-19
p11740
sg10
I5
sg11
g12
sg13
I1
sa(dp11741
g7
I56
sg8
g11732
sg10
I10
sg11
VP01034
p11742
sg13
I2
sasg24
(lp11743
(dp11744
g7
I140
sg8
g11733
sg10
I20
sg28
VC0011881
p11745
sg13
I2
sasa(dp11746
g2
VWe also demonstrate a large increase in levels of IL-19 in urine of patients with chronic kidney disease, which significantly correlated with estimated glomerular filtration rate levels.
p11747
sg4
(lp11748
(dp11749
g7
I50
sg8
VIL-19
p11750
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp11751
(dp11752
g7
I82
sg8
Vchronic kidney disease
p11753
sg10
I22
sg28
VC1561643
p11754
sg13
I3
sasa(dp11755
g2
VNon-clustered protocadherins (PCDHs) are calcium-dependent adhesion molecules which have attracted attention for their possible roles in the neuronal circuit formation during development and their implications in the neurological disorders such as autism and mental retardation.
p11756
sg4
(lp11757
sg24
(lp11758
(dp11759
g7
I217
sg8
Vneurological disorders
p11760
sg10
I22
sg28
VC0027765
p11761
sg13
I2
sa(dp11762
g7
I59
sg8
Vadhesion
p11763
sg10
I8
sg28
VC0001511
p11764
sg13
I1
sa(dp11765
g7
I248
sg8
Vautism
p11766
sg10
I6
sg28
VC0004352
p11767
sg13
I1
sa(dp11768
g7
I259
sg8
Vmental retardation
p11769
sg10
I18
sg28
VC0025362
p11770
sg13
I2
sasa(dp11771
g2
VMutation screening of 30 individuals with autism identified two PCDH11Y polymorphic amino acid changes, F885V and K980N.
p11772
sg4
(lp11773
sg24
(lp11774
(dp11775
g7
I42
sg8
Vautism
p11776
sg10
I6
sg28
VC0004352
p11777
sg13
I1
sasa(dp11778
g2
VIn the present study, we analyzed the expression levels of LETM1 in bladder cancer tissues and non-cancerous tissues as well as in four bladder cancer cell lines (T24, EJ, 5637 and J82) and a human bladder epithelial immortalized cell line SV-HUC-1.
p11779
sg4
(lp11780
(dp11781
g7
I59
sg8
VLETM1
p11782
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp11783
(dp11784
g7
I68
sg8
Vbladder cancer
p11785
sg10
I14
sg28
VC0699885
p11786
sg13
I2
sa(dp11787
g7
I68
sg8
Vbladder cancer
p11788
sg10
I14
sg28
VC0699885
p11789
sg13
I2
sasa(dp11790
g135
(dp11791
(Vinterleukin (IL)-2
p11792
Vbladder cancer
p11793
tp11794
I00
ssg2
VThe PD-L1 mRNA and protein expression levels were measured in the bladder cancer T24 cell line and the human uroepithelial SV-HUC-1 cell line, following treatment with interleukin (IL)-2, interferon (IFN)-Alfa and IFN-Gamma, by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively.
p11795
sg4
(lp11796
(dp11797
g7
I200
sg8
VIFN
p11798
sg10
I3
sg11
VP01562
p11799
sg13
I1
sa(dp11800
g7
I188
sg8
Vinterferon
p11801
sg10
I10
sg11
VP01563
p11802
sg13
I1
sa(dp11803
g7
I214
sg8
VIFN-Gamma
p11804
sg10
I9
sg11
VP01579
p11805
sg13
I1
sa(dp11806
g7
I168
sg8
g11792
sg10
I18
sg11
VP60568
p11807
sg13
I2
sasg24
(lp11808
(dp11809
g7
I66
sg8
g11793
sg10
I14
sg28
VC0699885
p11810
sg13
I2
sasa(dp11811
g135
(dp11812
(VIFN-Gamma
p11813
Vbladder cancer
p11814
tp11815
I00
ssg2
VRT-qPCR and western blotting demonstrated that cytokines IL-2, IFN-Alfa and IFN-Gamma markedly upregulated PD-L1 mRNA expression rates and protein levels in bladder cancer T24 cells (P&lt;0.05), but had no significant effect in non-tumor SV-HUC-1 cells.
p11816
sg4
(lp11817
(dp11818
g7
I63
sg8
VIFN-Alfa
p11819
sg10
I8
sg11
VP01562
p11820
sg13
I1
sa(dp11821
g7
I57
sg8
VIL-2
p11822
sg10
I4
sg11
VP60568
p11823
sg13
I1
sa(dp11824
g7
I76
sg8
g11813
sg10
I9
sg11
VP01579
p11825
sg13
I1
sasg24
(lp11826
(dp11827
g7
I157
sg8
g11814
sg10
I14
sg28
VC0699885
p11828
sg13
I2
sa(dp11829
g7
I232
sg8
Vtumor
p11830
sg10
I5
sg28
VC0027651
p11831
sg13
I1
sasa(dp11832
g2
VOur data showed that miR-6838 was sharply up-regulated in the bladder tissues from bladder cancer patients and 4 human bladder cancer cell lines, compared with the healthy volunteers and SU-HUC-1 human normal bladder epithelial cells.
p11833
sg4
(lp11834
(dp11835
g7
I187
sg8
VSU-HUC-1
p11836
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp11837
(dp11838
g7
I83
sg8
Vbladder cancer
p11839
sg10
I14
sg28
VC0699885
p11840
sg13
I2
sa(dp11841
g7
I83
sg8
Vbladder cancer
p11842
sg10
I14
sg28
VC0699885
p11843
sg13
I2
sasa(dp11844
g2
VTreatment with dioscin decreased viability of BC 5637 and T24 cells, but not non-cancer bladder epithelial cell, SV-HUC-1.
p11845
sg4
(lp11846
sg24
(lp11847
(dp11848
g7
I81
sg8
Vcancer
p11849
sg10
I6
sg28
VC0006826
p11850
sg13
I1
sasa(dp11851
g135
(dp11852
(Vthrombomodulin
p11853
Vthrombosis
p11854
tp11855
I00
ssg2
VA primary deficiency of protein C or S is proposed which would produce cerebral thrombosis with exposure of phospholipids; this thrombosis then, like antigens, would generate antibodies acting on the thrombin-thrombomodulin complex, exacerbating the thrombotic process.
p11856
sg4
(lp11857
(dp11858
g7
I24
sg8
Vprotein C
p11859
sg10
I9
sg11
VP02810
p11860
sg13
I2
sa(dp11861
g7
I200
sg8
Vthrombin
p11862
sg10
I8
sg11
VP00734
p11863
sg13
I1
sa(dp11864
g7
I209
sg8
g11853
sg10
I14
sg11
VP07204
p11865
sg13
I1
sasg24
(lp11866
(dp11867
g7
I71
sg8
Vcerebral thrombosis
p11868
sg10
I19
sg28
VC0795687
p11869
sg13
I2
sa(dp11870
g7
I80
sg8
g11854
sg10
I10
sg28
VC0040053
p11871
sg13
I1
sasa(dp11872
g2
VTo investigate whether defects in the SPATA17 gene are associated with azoospermia due to meiotic arrest, a mutational analysis was conducted, in which the SPATA17 coding regions of 18 Japanese patients with this condition were sequenced.
p11873
sg4
(lp11874
(dp11875
g7
I38
sg8
VSPATA17 gene
p11876
sg10
I12
sg11
g12
sg13
I2
sa(dp11877
g7
I38
sg8
VSPATA17
p11878
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp11879
(dp11880
g7
I213
sg8
Vcondition
p11881
sg10
I9
sg28
VC0012634
p11882
sg13
I1
sa(dp11883
g7
I71
sg8
Vazoospermia
p11884
sg10
I11
sg28
VC1321542
p11885
sg13
I1
sasa(dp11886
g135
(dp11887
(Vcertain histocompatibility leukocyte antigen
p11888
Vmeningitis
p11889
tp11890
I00
ssg2
VThe frequencies of erythrocyte MNSs antigens and certain histocompatibility leukocyte antigen (HLA) specificities (HLA-A, HLA-B, and HLA-DR) were determined in white patients with meningitis or epiglottitis due to Haemophilus influenzae type b and in controls.
p11891
sg4
(lp11892
(dp11893
g7
I19
sg8
Verythrocyte MNSs antigens
p11894
sg10
I25
sg11
VP21333
p11895
sg13
I3
sa(dp11896
g7
I49
sg8
g11888
sg10
I44
sg11
VP14209
p11897
sg13
I4
sa(dp11898
g7
I122
sg8
VHLA-B
p11899
sg10
I5
sg11
VP30461
p11900
sg13
I1
sa(dp11901
g7
I133
sg8
VHLA-DR
p11902
sg10
I6
sg11
VP30486
p11903
sg13
I1
sa(dp11904
g7
I115
sg8
VHLA-A
p11905
sg10
I5
sg11
VP30447
p11906
sg13
I1
sa(dp11907
g7
I95
sg8
VHLA
p11908
sg10
I3
sg11
VP30486
p11909
sg13
I1
sasg24
(lp11910
(dp11911
g7
I194
sg8
Vepiglottitis
p11912
sg10
I12
sg28
VC0014541
p11913
sg13
I1
sa(dp11914
g7
I180
sg8
g11889
sg10
I10
sg28
VC0025289
p11915
sg13
I1
sasa(dp11916
g135
(dp11917
(VT cell-associated antigen
p11918
Vthymoma
p11919
tp11920
I00
ssg2
VAnalysis of antigen expression pattern, the presence or absence of T cell-associated antigen deletion, and the expression of CD10 and CD34 by 4-color flow cytometry can help differentiate thymoma from T-cell ALL/LBL.
p11921
sg4
(lp11922
(dp11923
g7
I125
sg8
VCD10
p11924
sg10
I4
sg11
VP08473
p11925
sg13
I1
sa(dp11926
g7
I134
sg8
VCD34
p11927
sg10
I4
sg11
VP28906
p11928
sg13
I1
sa(dp11929
g7
I67
sg8
g11918
sg10
I25
sg11
VP14209
p11930
sg13
I3
sasg24
(lp11931
(dp11932
g7
I188
sg8
g11919
sg10
I7
sg28
VC0040100
p11933
sg13
I1
sasa(dp11934
g135
(dp11935
(VCYC1
p11936
Vlymph node metastasis
p11937
tp11938
I00
ssg2
VWe found that CYC1 was upregulated in breast tumor tissues, especially in tissues with lymph node metastasis.
p11939
sg4
(lp11940
(dp11941
g7
I14
sg8
g11936
sg10
I4
sg11
VP08574
p11942
sg13
I1
sasg24
(lp11943
(dp11944
g7
I38
sg8
Vbreast tumor
p11945
sg10
I12
sg28
VC1458155
p11946
sg13
I2
sa(dp11947
g7
I87
sg8
g11937
sg10
I21
sg28
VC0686619
p11948
sg13
I3
sasa(dp11949
g135
(dp11950
(VCYC1
p11951
Vbreast cancer
p11952
tp11953
I00
ssg2
VAnd higher expression of CYC1 correlates with poor prognosis in breast cancer patients using online databases and tools.
p11954
sg4
(lp11955
(dp11956
g7
I25
sg8
g11951
sg10
I4
sg11
VP08574
p11957
sg13
I1
sasg24
(lp11958
(dp11959
g7
I64
sg8
g11952
sg10
I13
sg28
VC0678222
p11960
sg13
I2
sasa(dp11961
g135
(dp11962
(VCYC1
p11963
Vbreast cancer
p11964
tp11965
I00
ssg2
VThen we confirmed that CYC1 contributed to metastasis and proliferation in two highly metastatic human breast cancer cell lines.
p11966
sg4
(lp11967
(dp11968
g7
I23
sg8
g11963
sg10
I4
sg11
VP08574
p11969
sg13
I1
sasg24
(lp11970
(dp11971
g7
I43
sg8
Vmetastasis
p11972
sg10
I10
sg28
VC0027627
p11973
sg13
I1
sa(dp11974
g7
I58
sg8
Vproliferation
p11975
sg10
I13
sg28
VC0334094
p11976
sg13
I1
sa(dp11977
g7
I103
sg8
g11964
sg10
I13
sg28
VC0678222
p11978
sg13
I2
sasa(dp11979
g135
(dp11980
(VCYC1
p11981
Vcancer progression
p11982
tp11983
I00
ssg2
VOur results indicated that CYC1 plays crucial roles in breast cancer progression and might be a predictive factor assisting future patient diagnosis.
p11984
sg4
(lp11985
(dp11986
g7
I27
sg8
g11981
sg10
I4
sg11
VP08574
p11987
sg13
I1
sasg24
(lp11988
(dp11989
g7
I62
sg8
g11982
sg10
I18
sg28
VC0178874
p11990
sg13
I2
sasa(dp11991
g135
(dp11992
(VUbiquinol-cytochrome c reductase hinge protein
p11993
Vclear cell renal cell carcinoma
p11994
tp11995
I00
ssg2
VUbiquinol-cytochrome c reductase hinge protein (UQCRH), as a connecter between cytochrome c1 with cytochrome c in complex III of respiratory chain, is top-ranked hypermethylated gene in clear cell renal cell carcinoma (ccRCC).
p11996
sg4
(lp11997
(dp11998
g7
I48
sg8
VUQCRH
p11999
sg10
I5
sg11
VP07919
p12000
sg13
I1
sa(dp12001
g7
I79
sg8
Vcytochrome c1
p12002
sg10
I13
sg11
VP08574
p12003
sg13
I2
sa(dp12004
g7
I10
sg8
Vcytochrome c
p12005
sg10
I12
sg11
VP99999
p12006
sg13
I2
sa(dp12007
g7
I0
sg8
g11993
sg10
I46
sg11
VP99999
p12008
sg13
I5
sasg24
(lp12009
(dp12010
g7
I219
sg8
VccRCC
p12011
sg10
I5
sg28
VC0279702
p12012
sg13
I1
sa(dp12013
g7
I186
sg8
g11994
sg10
I31
sg28
VC0279702
p12014
sg13
I5
sasa(dp12015
g135
(dp12016
(Vsuccinate dehydrogenase
p12017
Vglioma
p12018
tp12019
I00
ssg2
VThis study aimed at testing a panel of nine reference genes [beta-2-microglobulin, cytochrome c-1 (CYC1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase, hypoxanthine guanine phosphoribosyl transferase 1, ribosomal protein L13a (RPL13A), succinate dehydrogenase, TATA-box binding protein and 14-3-3 protein zeta] to identify and validate the most suitable reference genes for expression studies in human glioma of different grades (World Health Organization grades II-IV).
p12020
sg4
(lp12021
(dp12022
g7
I99
sg8
VCYC1
p12023
sg10
I4
sg11
VP08574
p12024
sg13
I1
sa(dp12025
g7
I61
sg8
Vbeta-2-microglobulin
p12026
sg10
I20
sg11
VP61769
p12027
sg13
I1
sa(dp12028
g7
I237
sg8
Vribosomal protein L13a
p12029
sg10
I22
sg11
VP40429
p12030
sg13
I3
sa(dp12031
g7
I295
sg8
VTATA-box binding protein
p12032
sg10
I24
sg11
VP20226
p12033
sg13
I3
sa(dp12034
g7
I83
sg8
Vcytochrome c-1
p12035
sg10
I14
sg11
VP99999
p12036
sg13
I2
sa(dp12037
g7
I261
sg8
VRPL13A
p12038
sg10
I6
sg11
VP40429
p12039
sg13
I1
sa(dp12040
g7
I106
sg8
Vglyceraldehyde-3-phosphate dehydrogenase
p12041
sg10
I40
sg11
VP04406
p12042
sg13
I2
sa(dp12043
g7
I186
sg8
Vhypoxanthine guanine phosphoribosyl transferase 1
p12044
sg10
I49
sg11
VP00492
p12045
sg13
I5
sa(dp12046
g7
I156
sg8
Vhydroxymethylbilane synthase
p12047
sg10
I28
sg11
VP08397
p12048
sg13
I2
sa(dp12049
g7
I148
sg8
VGAPDH
p12050
sg10
I5
sg11
VP04406
p12051
sg13
I1
sa(dp12052
g7
I270
sg8
g12017
sg10
I23
sg11
VP49366
p12053
sg13
I2
sasg24
(lp12054
(dp12055
g7
I436
sg8
g12018
sg10
I6
sg28
VC0017638
p12056
sg13
I1
sasa(dp12057
g135
(dp12058
(VGAPDH
p12059
Vglioma
p12060
tp12061
I00
ssg2
VAfter analysis of the stability values calculated using geNorm, NormFinder, and BestKeeper algorithms, GAPDH, RPL13A, and CYC1 can be indicated as reference genes applicable for accurate normalization of gene expression in glioma compared with normal brain and anaplastic astrocytoma or glioblastoma alone within this experimental setting.
p12062
sg4
(lp12063
(dp12064
g7
I110
sg8
VRPL13A
p12065
sg10
I6
sg11
VP40429
p12066
sg13
I1
sa(dp12067
g7
I122
sg8
VCYC1
p12068
sg10
I4
sg11
VP08574
p12069
sg13
I1
sa(dp12070
g7
I103
sg8
g12059
sg10
I5
sg11
VP04406
p12071
sg13
I1
sasg24
(lp12072
(dp12073
g7
I287
sg8
Vglioblastoma
p12074
sg10
I12
sg28
VC0017636
p12075
sg13
I1
sa(dp12076
g7
I261
sg8
Vanaplastic astrocytoma
p12077
sg10
I22
sg28
VC0334579
p12078
sg13
I2
sa(dp12079
g7
I223
sg8
g12060
sg10
I6
sg28
VC0017638
p12080
sg13
I1
sasa(dp12081
g135
(dp12082
(VTTK
p12083
Vbreast cancer
p12084
tp12085
I00
ssg2
VKaplan-Meier plots identified correlations between individual or combined overexpression of E2F1, E2F3a, Mps1/TTK, Nek2, BubR1, or Hec1 and poor overall and relapse-free survival of breast cancer patients.
p12086
sg4
(lp12087
(dp12088
g7
I131
sg8
VHec1
p12089
sg10
I4
sg11
g12
sg13
I1
sa(dp12090
g7
I105
sg8
VMps1
p12091
sg10
I4
sg11
VP33981
p12092
sg13
I1
sa(dp12093
g7
I115
sg8
VNek2
p12094
sg10
I4
sg11
VP51955
p12095
sg13
I1
sa(dp12096
g7
I92
sg8
VE2F1
p12097
sg10
I4
sg11
g12
sg13
I1
sa(dp12098
g7
I110
sg8
g12083
sg10
I3
sg11
VP49841
p12099
sg13
I1
sa(dp12100
g7
I98
sg8
VE2F3a
p12101
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp12102
(dp12103
g7
I157
sg8
Vrelapse
p12104
sg10
I7
sg28
VC0277556
p12105
sg13
I1
sa(dp12106
g7
I182
sg8
g12084
sg10
I13
sg28
VC0678222
p12107
sg13
I2
sasa(dp12108
g135
(dp12109
(VTTK
p12110
VAbl
p12111
tp12112
I00
ssg2
VBy interrogating the METABRIC database, we observed a significant correlation between p53 expression and that of c-Abl and TTK in basal-like breast cancers.
p12113
sg4
(lp12114
(dp12115
g7
I86
sg8
Vp53
p12116
sg10
I3
sg11
VP42771
p12117
sg13
I1
sa(dp12118
g7
I113
sg8
Vc-Abl
p12119
sg10
I5
sg11
VP00519
p12120
sg13
I1
sa(dp12121
g7
I123
sg8
g12110
sg10
I3
sg11
VP49841
p12122
sg13
I1
sasg24
(lp12123
(dp12124
g7
I141
sg8
Vbreast cancers
p12125
sg10
I14
sg28
VC0006142
p12126
sg13
I2
sa(dp12127
g7
I115
sg8
g12111
sg10
I3
sg28
VC0000744
p12128
sg13
I1
sasa(dp12129
g135
(dp12130
(VMps1
p12131
Vaggressive
p12132
tp12133
I00
ssg2
VThe protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a critical component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple negative breast cancer.
p12134
sg4
(lp12135
(dp12136
g7
I46
sg8
VTTK
p12137
sg10
I3
sg11
VP49841
p12138
sg13
I1
sa(dp12139
g7
I4
sg8
Vprotein kinase threonine tyrosine kinase
p12140
sg10
I40
sg11
VP29401
p12141
sg13
I5
sa(dp12142
g7
I65
sg8
g12131
sg10
I4
sg11
VP33981
p12143
sg13
I1
sasg24
(lp12144
(dp12145
g7
I190
sg8
Vcancers
p12146
sg10
I7
sg28
VC0006826
p12147
sg13
I1
sa(dp12148
g7
I223
sg8
Vbreast cancer
p12149
sg10
I13
sg28
VC0678222
p12150
sg13
I2
sa(dp12151
g7
I179
sg8
g12132
sg10
I10
sg28
VC0001807
p12152
sg13
I1
sasa(dp12153
g135
(dp12154
(VMps1
p12155
VBC
p12156
tp12157
I00
ssg2
VHigh levels of the mitotic checkpoint kinase Mps1/TTK have correlated with high histologic grade in breast cancer, suggesting a potential new therapeutic target for aggressive breast cancers (BC).
p12158
sg4
(lp12159
(dp12160
g7
I50
sg8
VTTK
p12161
sg10
I3
sg11
VP49841
p12162
sg13
I1
sa(dp12163
g7
I45
sg8
g12155
sg10
I4
sg11
VP33981
p12164
sg13
I1
sasg24
(lp12165
(dp12166
g7
I165
sg8
Vaggressive
p12167
sg10
I10
sg28
VC0001807
p12168
sg13
I1
sa(dp12169
g7
I176
sg8
Vbreast cancers
p12170
sg10
I14
sg28
VC0006142
p12171
sg13
I2
sa(dp12172
g7
I100
sg8
Vbreast cancer
p12173
sg10
I13
sg28
VC0006142
p12174
sg13
I2
sa(dp12175
g7
I192
sg8
g12156
sg10
I2
sg28
VC0006142
p12176
sg13
I1
sasa(dp12177
g135
(dp12178
(VMps1
p12179
Vbreast cancer
p12180
tp12181
I00
ssg2
VThese compounds were evaluated in anti-proliferative assays of a panel of 15 breast cancer cell lines and further examined for their ability to inhibit a variety of Mps1-dependent biological functions.
p12182
sg4
(lp12183
(dp12184
g7
I165
sg8
g12179
sg10
I4
sg11
VP33981
p12185
sg13
I1
sasg24
(lp12186
(dp12187
g7
I77
sg8
g12180
sg10
I13
sg28
VC0678222
p12188
sg13
I2
sa(dp12189
g7
I39
sg8
Vproliferative
p12190
sg10
I13
sg28
VC0334094
p12191
sg13
I1
sasa(dp12192
g135
(dp12193
(VMps1 kinase
p12194
Vbreast cancer
p12195
tp12196
I00
ssg2
VIn addition, the lead compounds 1 and 13 inhibit Mps1 kinase enzymatic activity with IC50 values from 0.356myM to 0.809myM, and inhibited Mps1-associated cellular functions such as centrosome duplication and the spindle checkpoint in triple negative breast cancer cells.
p12197
sg4
(lp12198
(dp12199
g7
I49
sg8
VMps1
p12200
sg10
I4
sg11
VP33981
p12201
sg13
I1
sa(dp12202
g7
I49
sg8
g12194
sg10
I11
sg11
VP33981
p12203
sg13
I2
sasg24
(lp12204
(dp12205
g7
I250
sg8
g12195
sg10
I13
sg28
VC0678222
p12206
sg13
I2
sa(dp12207
g7
I192
sg8
Vduplication
p12208
sg10
I11
sg28
VC1705960
p12209
sg13
I1
sasa(dp12210
g135
(dp12211
(VMps1
p12212
Vbreast cancers
p12213
tp12214
I00
ssg2
VUsing drug discovery technologies, computational modeling, medicinal chemistry, cell culture and in vivo assays, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers.
p12215
sg4
(lp12216
(dp12217
g7
I139
sg8
VTTK
p12218
sg10
I3
sg11
VP49841
p12219
sg13
I1
sa(dp12220
g7
I134
sg8
g12212
sg10
I4
sg11
VP33981
p12221
sg13
I1
sasg24
(lp12222
(dp12223
g7
I211
sg8
g12213
sg10
I14
sg28
VC0006142
p12224
sg13
I2
sasa(dp12225
g135
(dp12226
(VMps1
p12227
Vbreast cancer
p12228
tp12229
I00
ssg2
VHowever, high levels of Mps1 are found in many types of human malignancies, including glioblastoma, thyroid carcinoma, breast cancer, and other cancers.
p12230
sg4
(lp12231
(dp12232
g7
I24
sg8
g12227
sg10
I4
sg11
VP33981
p12233
sg13
I1
sasg24
(lp12234
(dp12235
g7
I100
sg8
Vthyroid carcinoma
p12236
sg10
I17
sg28
VC0549473
p12237
sg13
I2
sa(dp12238
g7
I86
sg8
Vglioblastoma
p12239
sg10
I12
sg28
VC0017636
p12240
sg13
I1
sa(dp12241
g7
I62
sg8
Vmalignancies
p12242
sg10
I12
sg28
VC0006826
p12243
sg13
I1
sa(dp12244
g7
I144
sg8
Vcancers
p12245
sg10
I7
sg28
VC0006826
p12246
sg13
I1
sa(dp12247
g7
I119
sg8
g12228
sg10
I13
sg28
VC0678222
p12248
sg13
I2
sasa(dp12249
g135
(dp12250
(VTTK
p12251
Vbreast cancer
p12252
tp12253
I00
ssg2
VHere, we employed amphiphilic polymers and silenced the expression of two cell cycle proteins, TTK and CDC20, and the anti-apoptosis protein survivin to determine the efficacy of polymer-mediated siRNA treatment in breast cancer cells as well as side effects in nonmalignant cells in vitro.
p12254
sg4
(lp12255
(dp12256
g7
I95
sg8
g12251
sg10
I3
sg11
VP49841
p12257
sg13
I1
sa(dp12258
g7
I103
sg8
VCDC20
p12259
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp12260
(dp12261
g7
I215
sg8
g12252
sg10
I13
sg28
VC0678222
p12262
sg13
I2
sasa(dp12263
g135
(dp12264
(Vmatrix metalloproteinase-1
p12265
VRHD
p12266
tp12267
I00
ssg2
VTo explore expressions of matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinases-1 (TIMP-1) and transforming growth factor-Beta1 (TGF-Beta1) in valve tissue of rheumatic heart disease (RHD), and to analyzed their roles in RHD.
p12268
sg4
(lp12269
(dp12270
g7
I62
sg8
Vtissue inhibitor of metalloproteinases-1
p12271
sg10
I40
sg11
VP01033
p12272
sg13
I4
sa(dp12273
g7
I150
sg8
VTGF-Beta1
p12274
sg10
I9
sg11
VP01137
p12275
sg13
I1
sa(dp12276
g7
I116
sg8
Vtransforming growth factor-Beta1
p12277
sg10
I32
sg11
VP01137
p12278
sg13
I3
sa(dp12279
g7
I104
sg8
VTIMP-1
p12280
sg10
I6
sg11
VP01033
p12281
sg13
I1
sa(dp12282
g7
I54
sg8
VMMP-1
p12283
sg10
I5
sg11
VP03956
p12284
sg13
I1
sa(dp12285
g7
I26
sg8
g12265
sg10
I26
sg11
VP03956
p12286
sg13
I2
sasg24
(lp12287
(dp12288
g7
I205
sg8
VRHD
p12289
sg10
I3
sg28
VC0035439
p12290
sg13
I1
sa(dp12291
g7
I180
sg8
Vrheumatic heart disease
p12292
sg10
I23
sg28
VC0035439
p12293
sg13
I3
sa(dp12294
g7
I205
sg8
g12266
sg10
I3
sg28
VC0035439
p12295
sg13
I1
sasa(dp12296
g2
VObjectives The aim of this study was to investigate plasma ADAMTS-13 activity in patients with proliferative lupus nephritis and to evaluate the role of clinical, laboratory and pathological features, especially the vascular lesions in lupus nephritis.
p12297
sg4
(lp12298
sg24
(lp12299
(dp12300
g7
I109
sg8
Vlupus nephritis
p12301
sg10
I15
sg28
VC0024143
p12302
sg13
I2
sa(dp12303
g7
I216
sg8
Vvascular lesions
p12304
sg10
I16
sg28
VC1402315
p12305
sg13
I2
sa(dp12306
g7
I95
sg8
Vproliferative
p12307
sg10
I13
sg28
VC0334094
p12308
sg13
I1
sa(dp12309
g7
I109
sg8
Vlupus nephritis
p12310
sg10
I15
sg28
VC0024143
p12311
sg13
I2
sasa(dp12312
g2
VResults Plasma ADAMTS-13 activity in lupus nephritis patients was significantly lower than that in normal controls (84 +/- 21% vs. 90 +/- 13%, p = 0.005).
p12313
sg4
(lp12314
sg24
(lp12315
(dp12316
g7
I37
sg8
Vlupus nephritis
p12317
sg10
I15
sg28
VC0024143
p12318
sg13
I2
sasa(dp12319
g2
VConclusions Decreased ADAMTS-13 activity was found in patients with proliferative lupus nephritis, and plasma ADAMTS-13 activity was closely associated with renal injury indices, especially pathological vascular scores.
p12320
sg4
(lp12321
sg24
(lp12322
(dp12323
g7
I82
sg8
Vlupus nephritis
p12324
sg10
I15
sg28
VC0024143
p12325
sg13
I2
sa(dp12326
g7
I68
sg8
Vproliferative
p12327
sg10
I13
sg28
VC0334094
p12328
sg13
I1
sasa(dp12329
g2
VThe serum ADAMTS-13 activity was significantly lower in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (40% versus 69%, P = 0.012; 40% versus 81%, P &lt; 0.001, respectively).
p12330
sg4
(lp12331
sg24
(lp12332
(dp12333
g7
I75
sg8
Vlupus nephritis
p12334
sg10
I15
sg28
VC0024143
p12335
sg13
I2
sa(dp12336
g7
I75
sg8
Vlupus nephritis
p12337
sg10
I15
sg28
VC0024143
p12338
sg13
I2
sa(dp12339
g7
I95
sg8
VTTP
p12340
sg10
I3
sg28
VC1268935
p12341
sg13
I1
sasa(dp12342
g2
VThe prevalence of ADAMTS-13 autoantibodies was significantly higher in patients with both lupus nephritis and TTP-HUS than in patients with lupus nephritis only and in normal control (6/7, 86% versus 10/55, 18%, P &lt; 0.001; 6/7, 86% versus 0, P &lt; 0.001, respectively).
p12343
sg4
(lp12344
sg24
(lp12345
(dp12346
g7
I90
sg8
Vlupus nephritis
p12347
sg10
I15
sg28
VC0024143
p12348
sg13
I2
sa(dp12349
g7
I110
sg8
VTTP
p12350
sg10
I3
sg28
VC1268935
p12351
sg13
I1
sa(dp12352
g7
I90
sg8
Vlupus nephritis
p12353
sg10
I15
sg28
VC0024143
p12354
sg13
I2
sasa(dp12355
g2
VADAMTS-13 autoantibodies might play an important role in the pathogenesis of TTP-HUS associated with lupus nephritis.
p12356
sg4
(lp12357
(dp12358
g7
I77
sg8
VTTP-HUS
p12359
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp12360
(dp12361
g7
I77
sg8
VTTP
p12362
sg10
I3
sg28
VC1268935
p12363
sg13
I1
sa(dp12364
g7
I101
sg8
Vlupus nephritis
p12365
sg10
I15
sg28
VC0024143
p12366
sg13
I2
sa(dp12367
g7
I61
sg8
Vpathogenesis
p12368
sg10
I12
sg28
VC0699748
p12369
sg13
I1
sasa(dp12370
g135
(dp12371
(VvWF
p12372
Vchronic glomerulonephritis
p12373
tp12374
I00
ssg2
VPlasma vWF and vWF-CP activities were measured using enzyme-linked immunosorbent assay (ELISA) and residual collagen binding assay respectively in patients with lupus nephritis (n = 31), primary nephritic syndrome (n = 25), diabetic nephropathy (n = 45), chronic glomerulonephritis (n = 38) and 40 normal controls.
p12375
sg4
(lp12376
(dp12377
g7
I15
sg8
VvWF-CP
p12378
sg10
I6
sg11
VP04275
p12379
sg13
I1
sa(dp12380
g7
I7
sg8
g12372
sg10
I3
sg11
VP04275
p12381
sg13
I1
sasg24
(lp12382
(dp12383
g7
I195
sg8
Vnephritic syndrome
p12384
sg10
I18
sg28
VC0268732
p12385
sg13
I2
sa(dp12386
g7
I161
sg8
Vlupus nephritis
p12387
sg10
I15
sg28
VC0024143
p12388
sg13
I2
sa(dp12389
g7
I224
sg8
Vdiabetic nephropathy
p12390
sg10
I20
sg28
VC0011881
p12391
sg13
I2
sa(dp12392
g7
I255
sg8
g12373
sg10
I26
sg28
VC0152451
p12393
sg13
I2
sasa(dp12394
g135
(dp12395
(VvWF-CP
p12396
Vlupus nephritis
p12397
tp12398
I00
ssg2
VRenal biopsy demonstrated that the vWF level in stage IV was higher than in stages II and III while vWF-CP activity was lower in patients with lupus nephritis.
p12399
sg4
(lp12400
(dp12401
g7
I35
sg8
VvWF
p12402
sg10
I3
sg11
VP04275
p12403
sg13
I1
sa(dp12404
g7
I100
sg8
g12396
sg10
I6
sg11
VP04275
p12405
sg13
I1
sasg24
(lp12406
(dp12407
g7
I143
sg8
g12397
sg10
I15
sg28
VC0024143
p12408
sg13
I2
sasa(dp12409
g135
(dp12410
(VvWF
p12411
VTTP
p12412
tp12413
I00
ssg2
VFurthermore the demonstration of a normal vWF-CP assay aided in the distinction between TTP and MAHA due to lupus nephritis.
p12414
sg4
(lp12415
(dp12416
g7
I42
sg8
g12411
sg10
I3
sg11
VP04275
p12417
sg13
I1
sasg24
(lp12418
(dp12419
g7
I108
sg8
Vlupus nephritis
p12420
sg10
I15
sg28
VC0024143
p12421
sg13
I2
sa(dp12422
g7
I88
sg8
g12412
sg10
I3
sg28
VC1268935
p12423
sg13
I1
sasa(dp12424
g2
VIn this study we have investigated the distribution and the level of expression of kinesin light chains (KLCs) (responsible for binding of cargos during anterograde transport) and of dynein intermediate chain (DIC) (a component of the dynein complex during retrograde transport) in frontal cortex and cerebellar cortex of control subjects and Alzheimer's disease patients.
p12425
sg4
(lp12426
(dp12427
g7
I83
sg8
Vkinesin light chains
p12428
sg10
I20
sg11
g12
sg13
I3
sa(dp12429
g7
I105
sg8
VKLCs
p12430
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp12431
(dp12432
g7
I210
sg8
VDIC
p12433
sg10
I3
sg28
VC0012739
p12434
sg13
I1
sa(dp12435
g7
I343
sg8
VAlzheimer's disease
p12436
sg10
I19
sg28
VC1521724
p12437
sg13
I2
sa(dp12438
g7
I183
sg8
Vdynein intermediate chain
p12439
sg10
I25
sg28
VC0012739
p12440
sg13
I3
sasa(dp12441
g2
VBy immunoblotting, we found a significant decrease in the levels of expression of KLC1 and 2 and DIC in the frontal cortex, but not in the cerebellar cortex, of Alzheimer's disease patients.
p12442
sg4
(lp12443
sg24
(lp12444
(dp12445
g7
I97
sg8
VDIC
p12446
sg10
I3
sg28
VC0012739
p12447
sg13
I1
sa(dp12448
g7
I161
sg8
VAlzheimer's disease
p12449
sg10
I19
sg28
VC1521724
p12450
sg13
I2
sasa(dp12451
g135
(dp12452
(VGSK-3Beta
p12453
VDIC
p12454
tp12455
I00
ssg2
VWe suggest that reduction of KLCs and DIC proteins in AD cortex results from both reduced expression and neuronal loss, and that these reductions and GSK-3Beta-mediated phosphorylation of KLC1 contribute to disturbances of axoplasmic flows and synaptic integrity in Alzheimer's disease.
p12456
sg4
(lp12457
(dp12458
g7
I150
sg8
g12453
sg10
I9
sg11
VP49841
p12459
sg13
I1
sasg24
(lp12460
(dp12461
g7
I266
sg8
VAlzheimer's disease
p12462
sg10
I19
sg28
VC1521724
p12463
sg13
I2
sa(dp12464
g7
I38
sg8
g12454
sg10
I3
sg28
VC0012739
p12465
sg13
I1
sasa(dp12466
g2
VChildren with cystic fibrosis (CF) often have suboptimal adherence rates to nebulized medication.
p12467
sg4
(lp12468
sg24
(lp12469
(dp12470
g7
I14
sg8
Vcystic fibrosis
p12471
sg10
I15
sg28
VC0010674
p12472
sg13
I2
sa(dp12473
g7
I31
sg8
VCF
p12474
sg10
I2
sg28
VC0010674
p12475
sg13
I1
sasa(dp12476
g2
VA cocktail of three phages active against Pseudomonas aeruginosa isolates from cystic fibrosis patients was developed for a potential nebulized formulation.
p12477
sg4
(lp12478
sg24
(lp12479
(dp12480
g7
I79
sg8
Vcystic fibrosis
p12481
sg10
I15
sg28
VC0010674
p12482
sg13
I2
sasa(dp12483
g2
VTreatment regimen for families of children with cystic fibrosis (CF) is considerable, particularly when nebulised therapies for chronic Pseudomonas aeruginosa airway infection are prescribed.
p12484
sg4
(lp12485
sg24
(lp12486
(dp12487
g7
I166
sg8
Vinfection
p12488
sg10
I9
sg28
VC0009450
p12489
sg13
I1
sa(dp12490
g7
I48
sg8
Vcystic fibrosis
p12491
sg10
I15
sg28
VC0010674
p12492
sg13
I2
sa(dp12493
g7
I65
sg8
VCF
p12494
sg10
I2
sg28
VC0010674
p12495
sg13
I1
sasa(dp12496
g2
VThe time requirements for multiple daily nebulizer treatments are important impediments to the quality of life for most patients with cystic fibrosis (CF).
p12497
sg4
(lp12498
sg24
(lp12499
(dp12500
g7
I134
sg8
Vcystic fibrosis
p12501
sg10
I15
sg28
VC0010674
p12502
sg13
I2
sa(dp12503
g7
I151
sg8
VCF
p12504
sg10
I2
sg28
VC0010674
p12505
sg13
I1
sasa(dp12506
g2
VTherefore, in this study, the author describes for the first time the common feature of oral clefts in patients carrying a microduplication of 15q13.3 encompassing the CHRNA7 gene, which sheds light on the correlation between CHRNA7 and cleft palate.
p12507
sg4
(lp12508
(dp12509
g7
I168
sg8
VCHRNA7 gene
p12510
sg10
I11
sg11
VP36544
p12511
sg13
I2
sasg24
(lp12512
(dp12513
g7
I237
sg8
Vcleft palate
p12514
sg10
I12
sg28
VC0008925
p12515
sg13
I2
sasa(dp12516
g135
(dp12517
(VACTC
p12518
Vcongenital heart defect
p12519
tp12520
I01
ssg2
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p12521
sg4
(lp12522
(dp12523
g7
I169
sg8
VMEIS2
p12524
sg10
I5
sg11
g12
sg13
I1
sa(dp12525
g7
I163
sg8
VCX36
p12526
sg10
I4
sg11
g12
sg13
I1
sa(dp12527
g7
I272
sg8
VCHRM5
p12528
sg10
I5
sg11
VP08912
p12529
sg13
I1
sa(dp12530
g7
I202
sg8
g12518
sg10
I4
sg11
VP68032
p12531
sg13
I1
sa(dp12532
g7
I264
sg8
VCHRNA7
p12533
sg10
I6
sg11
VP36544
p12534
sg13
I1
sa(dp12535
g7
I169
sg8
VMEIS2
p12536
sg10
I5
sg11
g12
sg13
I1
sa(dp12537
g7
I156
sg8
VGREM1
p12538
sg10
I5
sg11
g12
sg13
I1
sa(dp12539
g7
I156
sg8
VGREM1
p12540
sg10
I5
sg11
g12
sg13
I1
sa(dp12541
g7
I163
sg8
VCX36
p12542
sg10
I4
sg11
g12
sg13
I1
sa(dp12543
g7
I253
sg8
VARHGAP11A
p12544
sg10
I9
sg11
g12
sg13
I1
sasg24
(lp12545
(dp12546
g7
I233
sg8
Vmental retardation
p12547
sg10
I18
sg28
VC0025362
p12548
sg13
I2
sa(dp12549
g7
I142
sg8
Vcleft palate
p12550
sg10
I12
sg28
VC0008925
p12551
sg13
I2
sa(dp12552
g7
I34
sg8
VCGH
p12553
sg10
I3
sg28
VC1855900
p12554
sg13
I1
sa(dp12555
g7
I177
sg8
g12519
sg10
I23
sg28
VC0018798
p12556
sg13
I3
sasa(dp12557
g2
VComparative deletion mapping shows that this region can be dissected into five chromosomal segments containing at least six candidate genes (DAB1, HOOK1, NFIA, DOCK7, DNAJC6, and PDE4B) most likely responsible for syndromic intellectual disability, which was corroborated by their reduced transcript levels in RT-qPCR.
p12558
sg4
(lp12559
(dp12560
g7
I154
sg8
VNFIA
p12561
sg10
I4
sg11
g12
sg13
I1
sa(dp12562
g7
I147
sg8
VHOOK1
p12563
sg10
I5
sg11
g12
sg13
I1
sa(dp12564
g7
I167
sg8
VDNAJC6
p12565
sg10
I6
sg11
g12
sg13
I1
sa(dp12566
g7
I179
sg8
VPDE4B
p12567
sg10
I5
sg11
g12
sg13
I1
sa(dp12568
g7
I141
sg8
VDAB1
p12569
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp12570
(dp12571
g7
I224
sg8
Vintellectual disability
p12572
sg10
I23
sg28
VC0025362
p12573
sg13
I2
sasa(dp12574
g2
VImportantly, one patient with an intragenic microdeletion within NFIA and an additional patient with a balanced translocation disrupting NFIA display intellectual disability coupled with macrocephaly.
p12575
sg4
(lp12576
(dp12577
g7
I65
sg8
VNFIA
p12578
sg10
I4
sg11
g12
sg13
I1
sa(dp12579
g7
I65
sg8
VNFIA
p12580
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp12581
(dp12582
g7
I150
sg8
Vintellectual disability
p12583
sg10
I23
sg28
VC0025362
p12584
sg13
I2
sa(dp12585
g7
I112
sg8
Vtranslocation
p12586
sg10
I13
sg28
VC0040715
p12587
sg13
I1
sa(dp12588
g7
I187
sg8
Vmacrocephaly
p12589
sg10
I12
sg28
VC0221355
p12590
sg13
I1
sasa(dp12591
g2
VWe propose NFIA is responsible for intellectual disability coupled with macrocephaly, and microdeletions at 1p31.3p32.2 constitute a contiguous gene syndrome with several genes contributing to syndromic intellectual disability.
p12592
sg4
(lp12593
(dp12594
g7
I11
sg8
VNFIA
p12595
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp12596
(dp12597
g7
I72
sg8
Vmacrocephaly
p12598
sg10
I12
sg28
VC0221355
p12599
sg13
I1
sa(dp12600
g7
I149
sg8
Vsyndrome
p12601
sg10
I8
sg28
VC0039082
p12602
sg13
I1
sa(dp12603
g7
I35
sg8
Vintellectual disability
p12604
sg10
I23
sg28
VC0025362
p12605
sg13
I2
sa(dp12606
g7
I35
sg8
Vintellectual disability
p12607
sg10
I23
sg28
VC0025362
p12608
sg13
I2
sasa(dp12609
g135
(dp12610
(Vnuclear factor 1 A
p12611
Vmono
p12612
tp12613
I00
ssg2
VNon-progressive cerebellar ataxia with mental retardation (CANPMR, OMIM 614756) and chromosome 1p32-p31 deletion syndrome (OMIM 613735) are two very rare inherited disorders, which are caused by mono-allelic deficiency (haplo-insufficiency) of calmodulin-binding transcription activator 1 (CAMTA1) and, respectively, nuclear factor 1 A (NFIA) genes.
p12614
sg4
(lp12615
(dp12616
g7
I244
sg8
Vcalmodulin-binding transcription activator 1
p12617
sg10
I44
sg11
g12
sg13
I4
sa(dp12618
g7
I317
sg8
g12611
sg10
I18
sg11
VP01160
p12619
sg13
I4
sa(dp12620
g7
I290
sg8
VCAMTA1
p12621
sg10
I6
sg11
g12
sg13
I1
sa(dp12622
g7
I337
sg8
VNFIA
p12623
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp12624
(dp12625
g7
I4
sg8
Vprogressive cerebellar ataxia
p12626
sg10
I29
sg28
VC0393525
p12627
sg13
I3
sa(dp12628
g7
I84
sg8
Vchromosome 1p32-p31 deletion syndrome
p12629
sg10
I37
sg28
VC3151036
p12630
sg13
I4
sa(dp12631
g7
I39
sg8
Vmental retardation
p12632
sg10
I18
sg28
VC0025362
p12633
sg13
I2
sa(dp12634
g7
I195
sg8
g12612
sg10
I4
sg28
VC0021345
p12635
sg13
I1
sasa(dp12636
g135
(dp12637
(VNr4a2
p12638
Vautism
p12639
tp12640
I00
ssg2
VAmong these 24 genes, four transcription factors Auts2, Nfia, Nr4a2, and Sox5 were found, suggesting that TBR1 controls a transcriptional cascade relevant to autism pathogenesis.
p12641
sg4
(lp12642
(dp12643
g7
I49
sg8
VAuts2
p12644
sg10
I5
sg11
g12
sg13
I1
sa(dp12645
g7
I56
sg8
VNfia
p12646
sg10
I4
sg11
g12
sg13
I1
sa(dp12647
g7
I106
sg8
VTBR1
p12648
sg10
I4
sg11
g12
sg13
I1
sa(dp12649
g7
I62
sg8
g12638
sg10
I5
sg11
VP43354
p12650
sg13
I1
sasg24
(lp12651
(dp12652
g7
I165
sg8
Vpathogenesis
p12653
sg10
I12
sg28
VC0699748
p12654
sg13
I1
sa(dp12655
g7
I158
sg8
g12639
sg10
I6
sg28
VC0004352
p12656
sg13
I1
sasa(dp12657
g135
(dp12658
(VGABRB3
p12659
Vautism
p12660
tp12661
I00
ssg2
VSome of these maternal and maternal-child associations were in or adjacent to autism candidate genes including: PCDH9, FOXP1, GABRB3, NRXN1, RELN, MACROD2, FHIT, RORA, CNTN4, CNTNAP2, FAM135B, LAMA1, NFIA, NLGN4X, RAPGEF4, and SDK1.
p12662
sg4
(lp12663
(dp12664
g7
I200
sg8
VNFIA
p12665
sg10
I4
sg11
g12
sg13
I1
sa(dp12666
g7
I78
sg8
Vautism candidate genes
p12667
sg10
I22
sg11
VP27635
p12668
sg13
I3
sa(dp12669
g7
I162
sg8
VRORA
p12670
sg10
I4
sg11
VP35398
p12671
sg13
I1
sa(dp12672
g7
I227
sg8
VSDK1
p12673
sg10
I4
sg11
g12
sg13
I1
sa(dp12674
g7
I206
sg8
VNLGN4X
p12675
sg10
I6
sg11
g12
sg13
I1
sa(dp12676
g7
I112
sg8
VPCDH9
p12677
sg10
I5
sg11
g12
sg13
I1
sa(dp12678
g7
I156
sg8
VFHIT
p12679
sg10
I4
sg11
VP49789
p12680
sg13
I1
sa(dp12681
g7
I119
sg8
VFOXP1
p12682
sg10
I5
sg11
g12
sg13
I1
sa(dp12683
g7
I214
sg8
VRAPGEF4
p12684
sg10
I7
sg11
g12
sg13
I1
sa(dp12685
g7
I175
sg8
VCNTNAP2
p12686
sg10
I7
sg11
g12
sg13
I1
sa(dp12687
g7
I184
sg8
VFAM135B
p12688
sg10
I7
sg11
g12
sg13
I1
sa(dp12689
g7
I193
sg8
VLAMA1
p12690
sg10
I5
sg11
VP25391
p12691
sg13
I1
sa(dp12692
g7
I168
sg8
VCNTN4
p12693
sg10
I5
sg11
g12
sg13
I1
sa(dp12694
g7
I147
sg8
VMACROD2
p12695
sg10
I7
sg11
g12
sg13
I1
sa(dp12696
g7
I141
sg8
VRELN
p12697
sg10
I4
sg11
VP78509
p12698
sg13
I1
sa(dp12699
g7
I126
sg8
g12659
sg10
I6
sg11
VP28472
p12700
sg13
I1
sa(dp12701
g7
I134
sg8
VNRXN1
p12702
sg10
I5
sg11
VP58400
p12703
sg13
I1
sasg24
(lp12704
(dp12705
g7
I78
sg8
g12660
sg10
I6
sg28
VC0004352
p12706
sg13
I1
sasa(dp12707
g135
(dp12708
(Vp47
p12709
Voxidative stress
p12710
tp12711
I00
ssg2
VThese results provided a mechanistic linking between TRPM2-mediated Ca2+ influx and p47 phox signaling to induce excess ROS production and TXNIP-mediated NLRP3 inflammasome activation under HG, and suggested that TRPM2 represented a potential target for alleviating NLRP3 inflammasome activation related to hyperglycemia-induced oxidative stress in Type 2 diabetes Mellitus (T2DM).
p12712
sg4
(lp12713
(dp12714
g7
I53
sg8
VTRPM2
p12715
sg10
I5
sg11
VP10909
p12716
sg13
I1
sa(dp12717
g7
I139
sg8
VTXNIP
p12718
sg10
I5
sg11
g12
sg13
I1
sa(dp12719
g7
I88
sg8
Vphox
p12720
sg10
I4
sg11
VP19878
p12721
sg13
I1
sa(dp12722
g7
I53
sg8
VTRPM2
p12723
sg10
I5
sg11
VP10909
p12724
sg13
I1
sa(dp12725
g7
I84
sg8
g12709
sg10
I3
sg11
VP08567
p12726
sg13
I1
sasg24
(lp12727
(dp12728
g7
I349
sg8
VType 2 diabetes Mellitus
p12729
sg10
I24
sg28
VC0011860
p12730
sg13
I4
sa(dp12731
g7
I375
sg8
VT2DM
p12732
sg10
I4
sg28
VC0011860
p12733
sg13
I1
sa(dp12734
g7
I307
sg8
Vhyperglycemia
p12735
sg10
I13
sg28
VC0020456
p12736
sg13
I1
sa(dp12737
g7
I329
sg8
g12710
sg10
I16
sg28
VC0242606
p12738
sg13
I2
sasa(dp12739
g135
(dp12740
(VSOX3
p12741
Vmental retardation
p12742
tp12743
I00
ssg2
VSOX3 mutations have been associated with growth hormone deficiency, variable degrees of additional pituitary hormone deficiencies, and mental retardation.
p12744
sg4
(lp12745
(dp12746
g7
I41
sg8
Vgrowth hormone
p12747
sg10
I14
sg11
VP01242
p12748
sg13
I2
sa(dp12749
g7
I99
sg8
Vpituitary hormone
p12750
sg10
I17
sg11
VP18509
p12751
sg13
I2
sa(dp12752
g7
I0
sg8
g12741
sg10
I4
sg11
VP41225
p12753
sg13
I1
sasg24
(lp12754
(dp12755
g7
I41
sg8
Vgrowth hormone deficiency
p12756
sg10
I25
sg28
VC0271561
p12757
sg13
I3
sa(dp12758
g7
I135
sg8
g12742
sg10
I18
sg28
VC0025362
p12759
sg13
I2
sasa(dp12760
g135
(dp12761
(VSOX3
p12762
Vshort stature
p12763
tp12764
I00
ssg2
VSOX3 involvement should be considered in a male with short stature due to GH deficiency associated with intellectual disability.
p12765
sg4
(lp12766
(dp12767
g7
I0
sg8
g12762
sg10
I4
sg11
VP41225
p12768
sg13
I1
sasg24
(lp12769
(dp12770
g7
I104
sg8
Vintellectual disability
p12771
sg10
I23
sg28
VC0025362
p12772
sg13
I2
sa(dp12773
g7
I53
sg8
g12763
sg10
I13
sg28
VC0013336
p12774
sg13
I2
sasa(dp12775
g135
(dp12776
(VSOX3
p12777
VXX male
p12778
tp12779
I00
ssg2
VA further XX male, ascertained because of intellectual disability, carried a de novo cryptic duplication at Xq27.1, involving SOX3.
p12780
sg4
(lp12781
(dp12782
g7
I126
sg8
g12777
sg10
I4
sg11
VP41225
p12783
sg13
I1
sasg24
(lp12784
(dp12785
g7
I42
sg8
Vintellectual disability
p12786
sg10
I23
sg28
VC0025362
p12787
sg13
I2
sa(dp12788
g7
I93
sg8
Vduplication
p12789
sg10
I11
sg28
VC1705960
p12790
sg13
I1
sa(dp12791
g7
I10
sg8
g12778
sg10
I7
sg28
VC0432475
p12792
sg13
I2
sasa(dp12793
g135
(dp12794
(VSOX3
p12795
VGH deficiency
p12796
tp12797
I00
ssg2
VIn humans, over- and underdosage of SOX3 is associated with X-linked hypopituitarism with variable phenotypes ranging from isolated GH deficiency (GHD) to panhypopituitarism, with or without mental retardation and, in most cases, with reported pituitary imaging, an ectopic/undescended posterior pituitary.
p12798
sg4
(lp12799
(dp12800
g7
I36
sg8
g12795
sg10
I4
sg11
VP41225
p12801
sg13
I1
sasg24
(lp12802
(dp12803
g7
I191
sg8
Vmental retardation
p12804
sg10
I18
sg28
VC0025362
p12805
sg13
I2
sa(dp12806
g7
I147
sg8
VGHD
p12807
sg10
I3
sg28
VC0271561
p12808
sg13
I1
sa(dp12809
g7
I155
sg8
Vpanhypopituitarism
p12810
sg10
I18
sg28
VC0242343
p12811
sg13
I1
sa(dp12812
g7
I69
sg8
Vhypopituitarism
p12813
sg10
I15
sg28
VC0020635
p12814
sg13
I1
sa(dp12815
g7
I132
sg8
g12796
sg10
I13
sg28
VC0271561
p12816
sg13
I2
sasa(dp12817
g135
(dp12818
(VSOX3
p12819
Vmental retardation
p12820
tp12821
I00
ssg2
VScreening for SOX3 should be advised not only for hypopituitary patients with an ectopic posterior pituitary, but also for those with a structurally normal pituitary and additional findings, including clefts and a persistent craniopharyngeal canal, with or without mental retardation.
p12822
sg4
(lp12823
(dp12824
g7
I14
sg8
g12819
sg10
I4
sg11
VP41225
p12825
sg13
I1
sasg24
(lp12826
(dp12827
g7
I265
sg8
g12820
sg10
I18
sg28
VC0025362
p12828
sg13
I2
sasa(dp12829
g135
(dp12830
(VSOX3
p12831
VGHD
p12832
tp12833
I00
ssg2
VBoth duplications encompassing SOX3 and loss-of function mutations in SOX3 have been reported in a minor portion of X-linked isolated growth hormone deficiency (GHD) or combined pituitary hormone deficiency (CPHD) patients with or without mental retardation.
p12834
sg4
(lp12835
(dp12836
g7
I169
sg8
Vcombined pituitary hormone
p12837
sg10
I26
sg11
VP18509
p12838
sg13
I3
sa(dp12839
g7
I134
sg8
Vgrowth hormone
p12840
sg10
I14
sg11
VP01242
p12841
sg13
I2
sa(dp12842
g7
I31
sg8
g12831
sg10
I4
sg11
VP41225
p12843
sg13
I1
sasg24
(lp12844
(dp12845
g7
I239
sg8
Vmental retardation
p12846
sg10
I18
sg28
VC0025362
p12847
sg13
I2
sa(dp12848
g7
I161
sg8
g12832
sg10
I3
sg28
VC0271561
p12849
sg13
I1
sa(dp12850
g7
I141
sg8
Vhormone deficiency
p12851
sg10
I18
sg28
VC0599750
p12852
sg13
I2
sa(dp12853
g7
I125
sg8
Visolated growth hormone deficiency
p12854
sg10
I34
sg28
VC0271563
p12855
sg13
I4
sasa(dp12856
g135
(dp12857
(VSOX3
p12858
Vintellectual disability
p12859
tp12860
I00
ssg2
VIn humans, duplication of SOX3 and polyalanine expansions at its C-terminus may cause intellectual disability and hypopituitarism.
p12861
sg4
(lp12862
(dp12863
g7
I26
sg8
g12858
sg10
I4
sg11
VP41225
p12864
sg13
I1
sasg24
(lp12865
(dp12866
g7
I11
sg8
Vduplication
p12867
sg10
I11
sg28
VC1705960
p12868
sg13
I1
sa(dp12869
g7
I114
sg8
Vhypopituitarism
p12870
sg10
I15
sg28
VC0020635
p12871
sg13
I1
sa(dp12872
g7
I86
sg8
g12859
sg10
I23
sg28
VC0025362
p12873
sg13
I2
sasa(dp12874
g135
(dp12875
(VSRY-box containing gene 3
p12876
Vatrx
p12877
tp12878
I00
ssg2
VThe UNH159 marker as well as RNA-binding motif protein, X-linked (rbmx), SRY-box containing gene 3 (sox3) and alpha-thalassemia/mental retardation syndrome X-linked (atrx) genes were mapped to linkage group 2.
p12879
sg4
(lp12880
(dp12881
g7
I100
sg8
Vsox3
p12882
sg10
I4
sg11
VP41225
p12883
sg13
I1
sa(dp12884
g7
I73
sg8
g12876
sg10
I25
sg11
VP41225
p12885
sg13
I4
sasg24
(lp12886
(dp12887
g7
I110
sg8
Valpha-thalassemia/mental retardation syndrome X-linked
p12888
sg10
I54
sg28
VC1845055
p12889
sg13
I4
sa(dp12890
g7
I166
sg8
g12877
sg10
I4
sg28
VC1845055
p12891
sg13
I1
sasa(dp12892
g135
(dp12893
(VSOX3
p12894
Vhypopituitarism
p12895
tp12896
I00
ssg2
VBoth overdosage of SOX3, as a result of gene duplication, and loss of function resulting from expansion of the first polyalanine (PA) tract are associated with variable degrees of hypopituitarism, with or without mental retardation.
p12897
sg4
(lp12898
(dp12899
g7
I19
sg8
g12894
sg10
I4
sg11
VP41225
p12900
sg13
I1
sasg24
(lp12901
(dp12902
g7
I213
sg8
Vmental retardation
p12903
sg10
I18
sg28
VC0025362
p12904
sg13
I2
sa(dp12905
g7
I180
sg8
g12895
sg10
I15
sg28
VC0020635
p12906
sg13
I1
sa(dp12907
g7
I40
sg8
Vgene duplication
p12908
sg10
I16
sg28
VC1705960
p12909
sg13
I2
sasa(dp12910
g135
(dp12911
(VSOX3
p12912
Voesophageal atresia
p12913
tp12914
I00
ssg2
VDuplications and polyalanine expansions within the transcription factor SOX3 have recently been described in association with infundibular hypoplasia, hypopituitarism and variable mental retardation, whilst mutations in SOX2 are associated with variable hypopituitarism in association with learning difficulties, oesophageal atresia and anophthalmia.
p12915
sg4
(lp12916
(dp12917
g7
I220
sg8
VSOX2
p12918
sg10
I4
sg11
VP48431
p12919
sg13
I1
sa(dp12920
g7
I72
sg8
g12912
sg10
I4
sg11
VP41225
p12921
sg13
I1
sasg24
(lp12922
(dp12923
g7
I151
sg8
Vhypopituitarism
p12924
sg10
I15
sg28
VC0020635
p12925
sg13
I1
sa(dp12926
g7
I139
sg8
Vhypoplasia
p12927
sg10
I10
sg28
VC0243069
p12928
sg13
I1
sa(dp12929
g7
I337
sg8
Vanophthalmia
p12930
sg10
I12
sg28
VC0003119
p12931
sg13
I1
sa(dp12932
g7
I180
sg8
Vmental retardation
p12933
sg10
I18
sg28
VC0025362
p12934
sg13
I2
sa(dp12935
g7
I151
sg8
Vhypopituitarism
p12936
sg10
I15
sg28
VC0020635
p12937
sg13
I1
sa(dp12938
g7
I313
sg8
g12913
sg10
I19
sg28
VC0014850
p12939
sg13
I2
sasa(dp12940
g135
(dp12941
(VTCP-1
p12942
VTCP
p12943
tp12944
I00
ssg2
VUsing mouse P19 embryonal carcinoma cells, which divide rapidly, yet in retinoic acid adopt a neuronal phenotype, admixed with occasional (approximately 10%) fibroblast-like cells, together with a panel of peptide-specific antibodies raised to 7 of the 8 CCT subunits we show that; (1) adoption of a post mitotic phenotype is accompanied by reduced CCT protein expression, significantly more so for CCTbeta, CCTdelta, CCTepsilon, and CCTtheta than for CCTalpha (TCP-1), CCTgamma and CCTzeta; (2) CCTalpha is detected preferentially over other subunits in neurites of P19 neurons; (3) small amounts of CCTalpha and gamma are localised in nuclei (i.e.
p12945
sg4
(lp12946
(dp12947
g7
I462
sg8
g12942
sg10
I5
sg11
VP00995
p12948
sg13
I1
sa(dp12949
g7
I349
sg8
VCCT protein
p12950
sg10
I11
sg11
g12
sg13
I2
sasg24
(lp12951
(dp12952
g7
I16
sg8
Vembryonal carcinoma
p12953
sg10
I19
sg28
VC0206659
p12954
sg13
I2
sa(dp12955
g7
I255
sg8
VCCT
p12956
sg10
I3
sg28
VC2752078
p12957
sg13
I1
sa(dp12958
g7
I462
sg8
g12943
sg10
I3
sg28
VC1842402
p12959
sg13
I1
sa(dp12960
g7
I255
sg8
VCCT
p12961
sg10
I3
sg28
VC2752078
p12962
sg13
I1
sasa(dp12963
g135
(dp12964
(VTNF
p12965
Vstaphylococcal infection
p12966
tp12967
I01
ssg2
VIn line with these observations, in preclinical models, SIRT2 deficiency increases survival of mice with chronic staphylococcal infection, while having no effect on the course of toxic shock syndrome toxin-1, LPS or TNF-induced shock, fulminant Escherichia coli peritonitis, sub-lethal Klebsiella pneumoniae pneumonia, and chronic candidiasis.
p12968
sg4
(lp12969
(dp12970
g7
I216
sg8
g12965
sg10
I3
sg11
VP01375
p12971
sg13
I1
sa(dp12972
g7
I56
sg8
VSIRT2
p12973
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp12974
(dp12975
g7
I179
sg8
Vtoxic shock syndrome
p12976
sg10
I20
sg28
VC0600327
p12977
sg13
I3
sa(dp12978
g7
I262
sg8
Vperitonitis
p12979
sg10
I11
sg28
VC0031154
p12980
sg13
I1
sa(dp12981
g7
I209
sg8
VLPS
p12982
sg10
I3
sg28
VC0175697
p12983
sg13
I1
sa(dp12984
g7
I286
sg8
VKlebsiella pneumoniae pneumonia
p12985
sg10
I31
sg28
VC0519030
p12986
sg13
I3
sa(dp12987
g7
I323
sg8
Vchronic candidiasis
p12988
sg10
I19
sg28
VC0857069
p12989
sg13
I2
sa(dp12990
g7
I113
sg8
g12966
sg10
I24
sg28
VC0038160
p12991
sg13
I2
sasa(dp12992
g135
(dp12993
(Vnuclear factor-kappa B
p12994
Vpulmonary edema
p12995
tp12996
I00
ssg2
VLung injury was studied by measuring: vascular permeability-related pulmonary edema; histopathologic scores, neutrophil infiltration and concentrations of inflammatory cytokines in bronchoalveolar fluid; expression of inflammatory enzymes and sirtuin (SIRT) 1 as well as nuclear factor-kappa B (NF-KB) activity in pulmonary tissues.
p12997
sg4
(lp12998
(dp12999
g7
I295
sg8
VNF-KB
p13000
sg10
I5
sg11
VP01160
p13001
sg13
I1
sa(dp13002
g7
I271
sg8
g12994
sg10
I22
sg11
VP01160
p13003
sg13
I3
sasg24
(lp13004
(dp13005
g7
I120
sg8
Vinfiltration
p13006
sg10
I12
sg28
VC0332448
p13007
sg13
I1
sa(dp13008
g7
I68
sg8
g12995
sg10
I15
sg28
VC0034063
p13009
sg13
I2
sasa(dp13010
g2
VThe aim of our study was to compare the expression of sirtuin in large and small airways in nonsmokers, asymptomatic smokers, and smokers with chronic obstructive pulmonary disease.
p13011
sg4
(lp13012
(dp13013
g7
I54
sg8
Vsirtuin
p13014
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13015
(dp13016
g7
I143
sg8
Vchronic obstructive pulmonary disease
p13017
sg10
I37
sg28
VC0024117
p13018
sg13
I4
sasa(dp13019
g2
VSmokers both with and without chronic obstructive pulmonary disease had decreased sirtuin expression in large airways.
p13020
sg4
(lp13021
(dp13022
g7
I82
sg8
Vsirtuin
p13023
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13024
(dp13025
g7
I30
sg8
Vchronic obstructive pulmonary disease
p13026
sg10
I37
sg28
VC0024117
p13027
sg13
I4
sasa(dp13028
g2
VHowever, in small airways, sirtuin expression was decreased only in patients with chronic obstructive pulmonary disease.
p13029
sg4
(lp13030
sg24
(lp13031
(dp13032
g7
I82
sg8
Vchronic obstructive pulmonary disease
p13033
sg10
I37
sg28
VC0024117
p13034
sg13
I4
sasa(dp13035
g2
VSmoking is characterized by suppressed sirtuin expression in large airways, whereas chronic obstructive pulmonary disease is characterized by more severe suppression of sirtuin expression both in large and small airways.
p13036
sg4
(lp13037
(dp13038
g7
I39
sg8
Vsirtuin
p13039
sg10
I7
sg11
g12
sg13
I1
sa(dp13040
g7
I39
sg8
Vsirtuin
p13041
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13042
(dp13043
g7
I154
sg8
Vsuppression
p13044
sg10
I11
sg28
VC0221103
p13045
sg13
I1
sa(dp13046
g7
I84
sg8
Vchronic obstructive pulmonary disease
p13047
sg10
I37
sg28
VC0024117
p13048
sg13
I4
sasa(dp13049
g2
VHuman equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC).
p13050
sg4
(lp13051
(dp13052
g7
I83
sg8
VSLC29A2
p13053
sg10
I7
sg11
g12
sg13
I1
sa(dp13054
g7
I71
sg8
VSLC29A1
p13055
sg10
I7
sg11
g12
sg13
I1
sa(dp13056
g7
I0
sg8
VHuman equilibrative nucleoside transporters
p13057
sg10
I43
sg11
g12
sg13
I4
sa(dp13058
g7
I45
sg8
VhENT
p13059
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp13060
(dp13061
g7
I254
sg8
VCRC
p13062
sg10
I3
sg28
VC1527249
p13063
sg13
I1
sa(dp13064
g7
I235
sg8
Vcolorectal cancer
p13065
sg10
I17
sg28
VC1527249
p13066
sg13
I2
sasa(dp13067
g2
VThe purpose of this study was to evaluate the expression profiles of SLC29A1 and SLC29A2 in human cancer cell lines.
p13068
sg4
(lp13069
(dp13070
g7
I81
sg8
VSLC29A2
p13071
sg10
I7
sg11
g12
sg13
I1
sa(dp13072
g7
I69
sg8
VSLC29A1
p13073
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13074
(dp13075
g7
I98
sg8
Vcancer
p13076
sg10
I6
sg28
VC0006826
p13077
sg13
I1
sasa(dp13078
g2
VUsing quantitative real-time polymerase chain reaction, we comprehensively profiled the transcription levels of SLC29A1 and SLC29A2 in 16 colon cancer cell lines.
p13079
sg4
(lp13080
(dp13081
g7
I124
sg8
VSLC29A2
p13082
sg10
I7
sg11
g12
sg13
I1
sa(dp13083
g7
I112
sg8
VSLC29A1
p13084
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13085
(dp13086
g7
I138
sg8
Vcolon cancer
p13087
sg10
I12
sg28
VC0699790
p13088
sg13
I2
sasa(dp13089
g2
VWe validated the ubiquitous and heterogeneous distribution of SLC29A1 and SLC29A2 in human colon cancer cell lines and demonstrated that SLC29A1 was highly expressed in 25% of metastatic cell lines (Colo201 and Colo205) and 62.5% of primary cell lines (Caco2, Colo320, HCT116, RKO, and SW48).
p13090
sg4
(lp13091
(dp13092
g7
I62
sg8
VSLC29A1
p13093
sg10
I7
sg11
g12
sg13
I1
sa(dp13094
g7
I74
sg8
VSLC29A2
p13095
sg10
I7
sg11
g12
sg13
I1
sa(dp13096
g7
I62
sg8
VSLC29A1
p13097
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13098
(dp13099
g7
I91
sg8
Vcolon cancer
p13100
sg10
I12
sg28
VC0699790
p13101
sg13
I2
sasa(dp13102
g2
VFor the first time, we showed that both SLC29A1 and SLC29A2 were expressed at lower levels in colon cancer cell lines originating from metastatic sites than from primary sites.
p13103
sg4
(lp13104
(dp13105
g7
I40
sg8
VSLC29A1
p13106
sg10
I7
sg11
g12
sg13
I1
sa(dp13107
g7
I52
sg8
VSLC29A2
p13108
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13109
(dp13110
g7
I94
sg8
Vcolon cancer
p13111
sg10
I12
sg28
VC0699790
p13112
sg13
I2
sasa(dp13113
g2
VAs ENT inhibitors including dilazep have shown efficacy improving oHSV1 targeted oncolytic cancer therapy, a series of dilazep analogues was synthesized and biologically evaluated to examine both ENT1 and ENT2 inhibition.
p13114
sg4
(lp13115
(dp13116
g7
I196
sg8
VENT1
p13117
sg10
I4
sg11
g12
sg13
I1
sa(dp13118
g7
I205
sg8
VENT2
p13119
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp13120
(dp13121
g7
I91
sg8
Vcancer
p13122
sg10
I6
sg28
VC0006826
p13123
sg13
I1
sasa(dp13124
g135
(dp13125
(VBMP antagonist Inhibin alpha
p13126
VHLHS
p13127
tp13128
I00
ssg2
VThe most significant changes common to HLHS-RV versus control-RV and control-LV sample groups is observed for Anti mullerian hormone receptor 2 (AMHR2) (+18.79 control-RV, +3.38 control-LV), and the BMP antagonist Inhibin alpha (INHA) (+11.47 control-RV, +5.73 control-LV).
p13129
sg4
(lp13130
(dp13131
g7
I110
sg8
VAnti mullerian hormone receptor 2
p13132
sg10
I33
sg11
VP22736
p13133
sg13
I5
sa(dp13134
g7
I145
sg8
VAMHR2
p13135
sg10
I5
sg11
g12
sg13
I1
sa(dp13136
g7
I229
sg8
VINHA
p13137
sg10
I4
sg11
VP05111
p13138
sg13
I1
sa(dp13139
g7
I39
sg8
VHLHS-RV
p13140
sg10
I7
sg11
VP17302
p13141
sg13
I1
sa(dp13142
g7
I199
sg8
g13126
sg10
I28
sg11
VP18075
p13143
sg13
I4
sasg24
(lp13144
(dp13145
g7
I39
sg8
g13127
sg10
I4
sg28
VC0152101
p13146
sg13
I1
sasa(dp13147
g135
(dp13148
(VEts family member
p13149
Vendometrioid carcinoma
p13150
tp13151
I00
ssg2
VWe have described previously the Ets family member ERM/ETV5 specifically upregulated in endometrial endometrioid carcinoma (EEC) associated with myometrial infiltration.
p13152
sg4
(lp13153
(dp13154
g7
I55
sg8
VETV5
p13155
sg10
I4
sg11
VP41161
p13156
sg13
I1
sa(dp13157
g7
I51
sg8
VERM
p13158
sg10
I3
sg11
VP41161
p13159
sg13
I1
sa(dp13160
g7
I33
sg8
g13149
sg10
I17
sg11
VP20908
p13161
sg13
I3
sasg24
(lp13162
(dp13163
g7
I156
sg8
Vinfiltration
p13164
sg10
I12
sg28
VC0332448
p13165
sg13
I1
sa(dp13166
g7
I124
sg8
VEEC
p13167
sg10
I3
sg28
VC1851841
p13168
sg13
I1
sa(dp13169
g7
I100
sg8
g13150
sg10
I22
sg28
VC0206687
p13170
sg13
I2
sasa(dp13171
g135
(dp13172
(VEts family transcription factor
p13173
VEEC
p13174
tp13175
I00
ssg2
VWe have described recently the Ets family transcription factor, ERM/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration.
p13176
sg4
(lp13177
(dp13178
g7
I68
sg8
VETV5
p13179
sg10
I4
sg11
VP41161
p13180
sg13
I1
sa(dp13181
g7
I64
sg8
VERM
p13182
sg10
I3
sg11
VP41161
p13183
sg13
I1
sa(dp13184
g7
I31
sg8
g13173
sg10
I31
sg11
VP35398
p13185
sg13
I4
sasg24
(lp13186
(dp13187
g7
I175
sg8
Vinfiltration
p13188
sg10
I12
sg28
VC0332448
p13189
sg13
I1
sa(dp13190
g7
I116
sg8
Vendometrial carcinoma
p13191
sg10
I21
sg28
VC0476089
p13192
sg13
I2
sa(dp13193
g7
I139
sg8
g13174
sg10
I3
sg28
VC1851841
p13194
sg13
I1
sasa(dp13195
g135
(dp13196
(VETV5
p13197
Vendometrial carcinomas
p13198
tp13199
I00
ssg2
VFinally, the specific localization of ERM/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM/ETV5 in the early steps of endometrial dissemination.
p13200
sg4
(lp13201
(dp13202
g7
I42
sg8
VETV5
p13203
sg10
I4
sg11
VP41161
p13204
sg13
I1
sa(dp13205
g7
I38
sg8
VERM
p13206
sg10
I3
sg11
VP41161
p13207
sg13
I1
sa(dp13208
g7
I38
sg8
VERM
p13209
sg10
I3
sg11
VP41161
p13210
sg13
I1
sa(dp13211
g7
I51
sg8
VMMP-2
p13212
sg10
I5
sg11
VP08253
p13213
sg13
I1
sa(dp13214
g7
I42
sg8
g13197
sg10
I4
sg11
VP41161
p13215
sg13
I1
sasg24
(lp13216
(dp13217
g7
I93
sg8
Vinfiltrating
p13218
sg10
I12
sg28
VC0332448
p13219
sg13
I1
sa(dp13220
g7
I112
sg8
g13198
sg10
I22
sg28
VC0476089
p13221
sg13
I2
sasa(dp13222
g2
VMost importantly, the defects seen in Gfi1 deficient mice also point to roles of Gfi1 in diseases of the immune system that involve auto-immune responses and acute lymphoid leukemia and lymphoma.
p13223
sg4
(lp13224
(dp13225
g7
I38
sg8
VGfi1
p13226
sg10
I4
sg11
g12
sg13
I1
sa(dp13227
g7
I38
sg8
VGfi1
p13228
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp13229
(dp13230
g7
I186
sg8
Vlymphoma
p13231
sg10
I8
sg28
VC0024299
p13232
sg13
I1
sa(dp13233
g7
I158
sg8
Vacute lymphoid leukemia
p13234
sg10
I23
sg28
VC1961102
p13235
sg13
I3
sasa(dp13236
g2
VThe results showed that the gfi-1 expression level in all leukemia patients was significantly higher than that in normal group (p &lt; 0.05); the gfi-1 mRNA expression in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL) patients was significantly higher than that in normal group (p &lt; 0.05); but the difference of gfi-1 mRNA expression between AL and CML or ALL and AML was not significant.
p13237
sg4
(lp13238
(dp13239
g7
I28
sg8
Vgfi-1
p13240
sg10
I5
sg11
g12
sg13
I1
sa(dp13241
g7
I146
sg8
Vgfi-1 mRNA
p13242
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp13243
(dp13244
g7
I238
sg8
Vacute lymphoid leukemia
p13245
sg10
I23
sg28
VC1961102
p13246
sg13
I3
sa(dp13247
g7
I206
sg8
Vacute myeloid leukemia
p13248
sg10
I22
sg28
VC0023467
p13249
sg13
I3
sa(dp13250
g7
I171
sg8
Vchronic myeloid leukemia
p13251
sg10
I24
sg28
VC0023473
p13252
sg13
I3
sa(dp13253
g7
I263
sg8
VALL
p13254
sg10
I3
sg28
VC1961102
p13255
sg13
I1
sa(dp13256
g7
I230
sg8
VAML
p13257
sg10
I3
sg28
VC0023467
p13258
sg13
I1
sa(dp13259
g7
I197
sg8
VCML
p13260
sg10
I3
sg28
VC0023473
p13261
sg13
I1
sa(dp13262
g7
I197
sg8
VCML
p13263
sg10
I3
sg28
VC0023473
p13264
sg13
I1
sa(dp13265
g7
I58
sg8
Vleukemia
p13266
sg10
I8
sg28
VC0023418
p13267
sg13
I1
sa(dp13268
g7
I230
sg8
VAML
p13269
sg10
I3
sg28
VC0023467
p13270
sg13
I1
sa(dp13271
g7
I263
sg8
VALL
p13272
sg10
I3
sg28
VC1961102
p13273
sg13
I1
sasa(dp13274
g2
VThe MDM2 309GG genotype was linked to a higher risk of acute G3-4 dermatitis.
p13275
sg4
(lp13276
sg24
(lp13277
(dp13278
g7
I66
sg8
Vdermatitis
p13279
sg10
I10
sg28
VC0011603
p13280
sg13
I1
sasa(dp13281
g2
VIn an antibody microarray chip analysis, MDM2 expression was increased in atopic dermatitis patients.
p13282
sg4
(lp13283
sg24
(lp13284
(dp13285
g7
I74
sg8
Vatopic dermatitis
p13286
sg10
I17
sg28
VC0011615
p13287
sg13
I2
sasa(dp13288
g2
VAll doxorubicin (Dox)-resistant tumors expressed higher levels of cancer stem-like cell biomarkers, including CD44, Wnt and its receptor LRP5/6, relative to Dox-sensitive tumors.
p13289
sg4
(lp13290
(dp13291
g7
I137
sg8
VLRP5/6
p13292
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp13293
(dp13294
g7
I66
sg8
Vcancer
p13295
sg10
I6
sg28
VC0006826
p13296
sg13
I1
sa(dp13297
g7
I32
sg8
Vtumors
p13298
sg10
I6
sg28
VC0027651
p13299
sg13
I1
sa(dp13300
g7
I32
sg8
Vtumors
p13301
sg10
I6
sg28
VC0027651
p13302
sg13
I1
sasa(dp13303
g2
VOur results showed that simultaneous binding to LRP5/6 and uPAR by the dual receptor targeted IONPs was required to inhibit breast cancer cell invasion.
p13304
sg4
(lp13305
(dp13306
g7
I48
sg8
VLRP5/6
p13307
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp13308
(dp13309
g7
I138
sg8
Vcell invasion
p13310
sg10
I13
sg28
VC2699153
p13311
sg13
I2
sa(dp13312
g7
I124
sg8
Vbreast cancer
p13313
sg10
I13
sg28
VC0678222
p13314
sg13
I2
sasa(dp13315
g135
(dp13316
(VSTAT5
p13317
Vhyperglycemia
p13318
tp13319
I00
ssg2
VSTAT5 LKO caused hyperglycemia, hyperinsulinemia, hyperleptinemia and elevated free fatty acid and cholesterol concentrations under HFD feeding but induced only hyperglycemia on normal diet.
p13320
sg4
(lp13321
(dp13322
g7
I0
sg8
g13317
sg10
I5
sg11
VP42229
p13323
sg13
I1
sasg24
(lp13324
(dp13325
g7
I32
sg8
Vhyperinsulinemia
p13326
sg10
I16
sg28
VC0020459
p13327
sg13
I1
sa(dp13328
g7
I17
sg8
Vhyperglycemia
p13329
sg10
I13
sg28
VC0020456
p13330
sg13
I1
sa(dp13331
g7
I17
sg8
g13318
sg10
I13
sg28
VC0020456
p13332
sg13
I1
sasa(dp13333
g135
(dp13334
(VPrx2
p13335
VBeta-thalassemia
p13336
tp13337
I01
ssg2
VPrx2 is a key cytoprotector against IO that is induced either by iron supplementation or due to chronic hemolysis as in Beta-thalassemia.
p13338
sg4
(lp13339
(dp13340
g7
I0
sg8
g13335
sg10
I4
sg11
VP32119
p13341
sg13
I1
sasg24
(lp13342
(dp13343
g7
I104
sg8
Vhemolysis
p13344
sg10
I9
sg28
VC0019054
p13345
sg13
I1
sa(dp13346
g7
I120
sg8
g13336
sg10
I16
sg28
VC0005283
p13347
sg13
I1
sasa(dp13348
g135
(dp13349
(VPrx2
p13350
Vthalassemia
p13351
tp13352
I00
ssg2
VPeroxiredoxin-2 (Prx2), a typical 2-cysteine peroxiredoxin, is upregulated during Beta-thalassemic erythropoiesis, but its contribution to stress erythropoiesis, a common feature of thalassemia, is yet to be fully defined.
p13353
sg4
(lp13354
(dp13355
g7
I0
sg8
VPeroxiredoxin-2
p13356
sg10
I15
sg11
VP32119
p13357
sg13
I1
sa(dp13358
g7
I17
sg8
g13350
sg10
I4
sg11
VP32119
p13359
sg13
I1
sasg24
(lp13360
(dp13361
g7
I182
sg8
g13351
sg10
I11
sg28
VC0039730
p13362
sg13
I1
sasa(dp13363
g135
(dp13364
(VTrxR
p13365
Vthalassemia major
p13366
tp13367
I00
ssg2
VIn the present study, we aimed to investigate plasma levels of peroxiredoxin 2 (Prx2) and thioredoxin 1 (Trx1), and the activity of thioredoxin reductase (TrxR), in thalassemia major (TM) patients living in the Antalya region, Turkey.
p13368
sg4
(lp13369
(dp13370
g7
I80
sg8
VPrx2
p13371
sg10
I4
sg11
VP32119
p13372
sg13
I1
sa(dp13373
g7
I90
sg8
Vthioredoxin 1
p13374
sg10
I13
sg11
VP10599
p13375
sg13
I2
sa(dp13376
g7
I132
sg8
Vthioredoxin reductase
p13377
sg10
I21
sg11
VP10599
p13378
sg13
I2
sa(dp13379
g7
I105
sg8
VTrx1
p13380
sg10
I4
sg11
VP60606
p13381
sg13
I1
sa(dp13382
g7
I63
sg8
Vperoxiredoxin 2
p13383
sg10
I15
sg11
VP32119
p13384
sg13
I2
sa(dp13385
g7
I155
sg8
g13365
sg10
I4
sg11
VP30044
p13386
sg13
I1
sasg24
(lp13387
(dp13388
g7
I184
sg8
VTM
p13389
sg10
I2
sg28
VC0002875
p13390
sg13
I1
sa(dp13391
g7
I165
sg8
g13366
sg10
I17
sg28
VC0002875
p13392
sg13
I2
sasa(dp13393
g135
(dp13394
(Vcarbonic anhydrase
p13395
Vthalassemia intermedia
p13396
tp13397
I00
ssg2
VProteomic analysis of microparticles released from thalassemia intermedia erythrocytes indicated that, besides hemichromes and clustered band 3, the microparticles contain a characteristic set of proteins that includes catalase, heat shock protein 70, peroxiredoxin 2 and carbonic anhydrase.
p13398
sg4
(lp13399
(dp13400
g7
I219
sg8
Vcatalase
p13401
sg10
I8
sg11
VP04040
p13402
sg13
I1
sa(dp13403
g7
I229
sg8
Vheat shock protein 70
p13404
sg10
I21
sg11
VP34932
p13405
sg13
I4
sa(dp13406
g7
I252
sg8
Vperoxiredoxin 2
p13407
sg10
I15
sg11
VP32119
p13408
sg13
I2
sa(dp13409
g7
I272
sg8
g13395
sg10
I18
sg11
VP35218
p13410
sg13
I2
sasg24
(lp13411
(dp13412
g7
I51
sg8
g13396
sg10
I22
sg28
VC0271979
p13413
sg13
I2
sasa(dp13414
g135
(dp13415
(VPrx II
p13416
VTHAL
p13417
tp13418
I00
ssg2
VInterestingly, Prx II interacted with Hb in mouse RBCs, and their interaction, in particular, was severely impaired in RBCs of patients with thalassemia (THAL) and sickle cell anemia (SCA).
p13419
sg4
(lp13420
(dp13421
g7
I15
sg8
g13416
sg10
I6
sg11
VP30041
p13422
sg13
I2
sasg24
(lp13423
(dp13424
g7
I141
sg8
Vthalassemia
p13425
sg10
I11
sg28
VC0039730
p13426
sg13
I1
sa(dp13427
g7
I184
sg8
VSCA
p13428
sg10
I3
sg28
VC0002895
p13429
sg13
I1
sa(dp13430
g7
I164
sg8
Vsickle cell anemia
p13431
sg10
I18
sg28
VC0002895
p13432
sg13
I3
sa(dp13433
g7
I154
sg8
g13417
sg10
I4
sg28
VC0039730
p13434
sg13
I1
sa(dp13435
g7
I107
sg8
Vimpaired
p13436
sg10
I8
sg28
VC0684336
p13437
sg13
I1
sasa(dp13438
g2
VThe cover image, by Lihadh Al Gazali et al., is based on the Original Article A recessive syndrome of intellectual disability, moderate overgrowth, and renal dysplasia predisposing to Wilms tumor is caused by a mutation in FIBP gene, DOI:10.1002/ajmg.a.37741.
p13439
sg4
(lp13440
(dp13441
g7
I223
sg8
VFIBP gene
p13442
sg10
I9
sg11
g12
sg13
I2
sasg24
(lp13443
(dp13444
g7
I102
sg8
Vintellectual disability
p13445
sg10
I23
sg28
VC0025362
p13446
sg13
I2
sa(dp13447
g7
I152
sg8
Vrenal dysplasia
p13448
sg10
I15
sg28
VC0266313
p13449
sg13
I2
sa(dp13450
g7
I90
sg8
Vsyndrome
p13451
sg10
I8
sg28
VC0039082
p13452
sg13
I1
sa(dp13453
g7
I184
sg8
VWilms tumor
p13454
sg10
I11
sg28
VC0027708
p13455
sg13
I2
sasa(dp13456
g2
VDifferent observational clinical studies reported that circulating levels of ANGPTL2 increase significantly in various chronic inflammatory diseases and showed associations between ANGPTL2 levels and diagnosis and/or prognosis of cardiovascular diseases, diabetes, chronic kidney disease, and various types of cancers.
p13457
sg4
(lp13458
(dp13459
g7
I77
sg8
VANGPTL2
p13460
sg10
I7
sg11
g12
sg13
I1
sa(dp13461
g7
I77
sg8
VANGPTL2
p13462
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13463
(dp13464
g7
I255
sg8
Vdiabetes
p13465
sg10
I8
sg28
VC0011849
p13466
sg13
I1
sa(dp13467
g7
I310
sg8
Vcancers
p13468
sg10
I7
sg28
VC0006826
p13469
sg13
I1
sa(dp13470
g7
I230
sg8
Vcardiovascular diseases
p13471
sg10
I23
sg28
VC0007222
p13472
sg13
I2
sa(dp13473
g7
I265
sg8
Vchronic kidney disease
p13474
sg10
I22
sg28
VC1561643
p13475
sg13
I3
sasa(dp13476
g2
VCirculating ANGPTL2 is increased in chronic kidney disease (CKD), where the risk of CVD is amplified.
p13477
sg4
(lp13478
(dp13479
g7
I12
sg8
VANGPTL2
p13480
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13481
(dp13482
g7
I60
sg8
VCKD
p13483
sg10
I3
sg28
VC1561643
p13484
sg13
I1
sa(dp13485
g7
I36
sg8
Vchronic kidney disease
p13486
sg10
I22
sg28
VC1561643
p13487
sg13
I3
sa(dp13488
g7
I84
sg8
VCVD
p13489
sg10
I3
sg28
VC0007222
p13490
sg13
I1
sasa(dp13491
g2
VThe positive association between post-KTx ANGPTL2, aortic stiffness and mortality, suggests that ANGPTL2 may play a biological role in CKD-related CVD.
p13492
sg4
(lp13493
(dp13494
g7
I42
sg8
VANGPTL2
p13495
sg10
I7
sg11
g12
sg13
I1
sa(dp13496
g7
I42
sg8
VANGPTL2
p13497
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13498
(dp13499
g7
I147
sg8
VCVD
p13500
sg10
I3
sg28
VC0007222
p13501
sg13
I1
sa(dp13502
g7
I51
sg8
Vaortic stiffness
p13503
sg10
I16
sg28
VC3178782
p13504
sg13
I2
sasa(dp13505
g2
VHistological analysis of human kidneys indicated abundant expression of angiopoietin-like protein 2 (ANGPTL2) in renal tubule epithelial cells during progression of renal fibrosis.
p13506
sg4
(lp13507
(dp13508
g7
I72
sg8
Vangiopoietin-like protein 2
p13509
sg10
I27
sg11
g12
sg13
I3
sa(dp13510
g7
I101
sg8
VANGPTL2
p13511
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13512
(dp13513
g7
I165
sg8
Vrenal fibrosis
p13514
sg10
I14
sg28
VC0151650
p13515
sg13
I2
sasa(dp13516
g135
(dp13517
(VTGF-Beta1
p13518
Vureteral obstruction
p13519
tp13520
I00
ssg2
VFurthermore, ANGPTL2 deficiency in a mouse unilateral ureteral obstruction model significantly reduced renal fibrosis by decreasing TGF-Beta1 signal amplification in kidney.
p13521
sg4
(lp13522
(dp13523
g7
I132
sg8
g13518
sg10
I9
sg11
VP01137
p13524
sg13
I1
sa(dp13525
g7
I13
sg8
VANGPTL2
p13526
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13527
(dp13528
g7
I103
sg8
Vrenal fibrosis
p13529
sg10
I14
sg28
VC0151650
p13530
sg13
I2
sa(dp13531
g7
I54
sg8
g13519
sg10
I20
sg28
VC0041956
p13532
sg13
I2
sa(dp13533
g7
I149
sg8
Vamplification
p13534
sg10
I13
sg28
VC1705759
p13535
sg13
I1
sasa(dp13536
g135
(dp13537
(VTGF-Beta1
p13538
Vrenal fibrosis
p13539
tp13540
I00
ssg2
VThus, ANGPTL2 and TGF-Beta1 positively regulate each other as renal fibrosis progresses.
p13541
sg4
(lp13542
(dp13543
g7
I6
sg8
VANGPTL2
p13544
sg10
I7
sg11
g12
sg13
I1
sa(dp13545
g7
I18
sg8
g13538
sg10
I9
sg11
VP01137
p13546
sg13
I1
sasg24
(lp13547
(dp13548
g7
I62
sg8
g13539
sg10
I14
sg28
VC0151650
p13549
sg13
I2
sasa(dp13550
g135
(dp13551
(Vtransforming growth factor-Beta
p13552
Vureteral obstruction
p13553
tp13554
I00
ssg2
Vdemonstrated that genetic depletion of Angptl2 confers amelioration of the mouse kidney fibrosis induced by a unilateral ureteral obstruction, implicating that ANGPTL2, predominantly in the renal tubular compartments, activates the transforming growth factor-Beta signaling and vice versa through miR-221.
p13555
sg4
(lp13556
(dp13557
g7
I160
sg8
VANGPTL2
p13558
sg10
I7
sg11
g12
sg13
I1
sa(dp13559
g7
I39
sg8
VAngptl2
p13560
sg10
I7
sg11
g12
sg13
I1
sa(dp13561
g7
I232
sg8
g13552
sg10
I31
sg11
VP18075
p13562
sg13
I3
sasg24
(lp13563
(dp13564
g7
I81
sg8
Vkidney fibrosis
p13565
sg10
I15
sg28
VC0151650
p13566
sg13
I2
sa(dp13567
g7
I121
sg8
g13553
sg10
I20
sg28
VC0041956
p13568
sg13
I2
sasa(dp13569
g2
VIn the present study, we tested whether there is a correlation between increased ANGPTL2 expression and inflammation in response to Staphylococcus aureus in murine mastitis and the mechanisms involved.
p13570
sg4
(lp13571
(dp13572
g7
I81
sg8
VANGPTL2
p13573
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13574
(dp13575
g7
I104
sg8
Vinflammation
p13576
sg10
I12
sg28
VC0021368
p13577
sg13
I1
sa(dp13578
g7
I164
sg8
Vmastitis
p13579
sg10
I8
sg28
VC3251795
p13580
sg13
I1
sasa(dp13581
g135
(dp13582
(VTNF-Alfa
p13583
Vinflammation
p13584
tp13585
I00
ssg2
VThe present findings indicate ANGPTL2 may mediate the inflammation in murine mastitis through the activation of IL-6 and TNF-Alfa.
p13586
sg4
(lp13587
(dp13588
g7
I112
sg8
VIL-6
p13589
sg10
I4
sg11
VP05231
p13590
sg13
I1
sa(dp13591
g7
I121
sg8
g13583
sg10
I8
sg11
VP01375
p13592
sg13
I1
sa(dp13593
g7
I30
sg8
VANGPTL2
p13594
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13595
(dp13596
g7
I54
sg8
g13584
sg10
I12
sg28
VC0021368
p13597
sg13
I1
sa(dp13598
g7
I77
sg8
Vmastitis
p13599
sg10
I8
sg28
VC3251795
p13600
sg13
I1
sasa(dp13601
g2
VThe aim of this study was to investigate the relationship between serum Angptl2 level and chronic kidney disease (CKD).
p13602
sg4
(lp13603
(dp13604
g7
I72
sg8
VAngptl2
p13605
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13606
(dp13607
g7
I90
sg8
Vchronic kidney disease
p13608
sg10
I22
sg28
VC1561643
p13609
sg13
I3
sa(dp13610
g7
I114
sg8
VCKD
p13611
sg10
I3
sg28
VC1561643
p13612
sg13
I1
sasa(dp13613
g2
VThe age- and sex-adjusted ORs for the presence of CKD increased with higher serum Angptl2 level.
p13614
sg4
(lp13615
(dp13616
g7
I82
sg8
VAngptl2
p13617
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13618
sa(dp13619
g2
VElevated serum Angptl2 is associated with the likelihood of CKD in the general population.
p13620
sg4
(lp13621
(dp13622
g7
I9
sg8
Vserum Angptl2
p13623
sg10
I13
sg11
g12
sg13
I2
sasg24
(lp13624
sa(dp13625
g2
VWe investigated whether serum Angptl2 levels are associated with diabetic nephropathy in patients with type 2 diabetes.
p13626
sg4
(lp13627
(dp13628
g7
I30
sg8
VAngptl2
p13629
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13630
(dp13631
g7
I103
sg8
Vtype 2 diabetes
p13632
sg10
I15
sg28
VC0011860
p13633
sg13
I3
sa(dp13634
g7
I65
sg8
Vdiabetic nephropathy
p13635
sg10
I20
sg28
VC0011881
p13636
sg13
I2
sasa(dp13637
g2
VThis suggests a possible role of Angptl2 in progressive nephropathy in patients with type 2 diabetes.
p13638
sg4
(lp13639
(dp13640
g7
I33
sg8
VAngptl2
p13641
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp13642
(dp13643
g7
I85
sg8
Vtype 2 diabetes
p13644
sg10
I15
sg28
VC0011860
p13645
sg13
I3
sa(dp13646
g7
I56
sg8
Vnephropathy
p13647
sg10
I11
sg28
VC0022658
p13648
sg13
I1
sasa(dp13649
g135
(dp13650
(Vmyophosphorylase
p13651
Vhyperkalemic periodic paralysis
p13652
tp13653
I00
ssg2
VImprovements to restriction fragment length polymorphism (RFLP)-based genotyping assays currently used for detection of mutations responsible for bovine ferrochelatase and myophosphorylase deficiencies, and equine hyperkalemic periodic paralysis (HYPP) are described.
p13654
sg4
(lp13655
(dp13656
g7
I146
sg8
Vbovine ferrochelatase
p13657
sg10
I21
sg11
VP22830
p13658
sg13
I2
sa(dp13659
g7
I172
sg8
g13651
sg10
I16
sg11
VP11217
p13660
sg13
I1
sasg24
(lp13661
(dp13662
g7
I247
sg8
VHYPP
p13663
sg10
I4
sg28
VC0238357
p13664
sg13
I1
sa(dp13665
g7
I214
sg8
g13652
sg10
I31
sg28
VC0238357
p13666
sg13
I3
sasa(dp13667
g2
VThus, peripheral changes of TOAG-1 and RHAMM expression can be used to predict clinical response to Alefacept treatment in psoriasis patients.
p13668
sg4
(lp13669
(dp13670
g7
I39
sg8
VRHAMM
p13671
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp13672
(dp13673
g7
I123
sg8
Vpsoriasis
p13674
sg10
I9
sg28
VC0033860
p13675
sg13
I1
sasa(dp13676
g135
(dp13677
(VPARP
p13678
Vcerebral infarction
p13679
tp13680
I00
ssg2
VIn this study, we examined the pharmacological profile of KCL-440, a new PARP inhibitor, and its neuroprotective effects in the rat acute cerebral infarction model induced by photothrombotic middle cerebral artery (MCA) occlusion.
p13681
sg4
(lp13682
(dp13683
g7
I73
sg8
g13678
sg10
I4
sg11
VP09874
p13684
sg13
I1
sasg24
(lp13685
(dp13686
g7
I220
sg8
Vocclusion
p13687
sg10
I9
sg28
VC0028778
p13688
sg13
I1
sa(dp13689
g7
I138
sg8
g13679
sg10
I19
sg28
VC0038454
p13690
sg13
I2
sasa(dp13691
g135
(dp13692
(VPARP
p13693
Vstroke
p13694
tp13695
I00
ssg2
VOur data thus suggest that the tested PARP polymorphisms do not principally contribute to cerebral infarction, although extensive searches would be required to clarify whether the PARP gene plays an important role in the pathogenesis of human stroke.
p13696
sg4
(lp13697
(dp13698
g7
I180
sg8
VPARP gene
p13699
sg10
I9
sg11
VP09874
p13700
sg13
I2
sa(dp13701
g7
I38
sg8
g13693
sg10
I4
sg11
VP09874
p13702
sg13
I1
sasg24
(lp13703
(dp13704
g7
I221
sg8
Vpathogenesis
p13705
sg10
I12
sg28
VC0699748
p13706
sg13
I1
sa(dp13707
g7
I90
sg8
Vcerebral infarction
p13708
sg10
I19
sg28
VC0038454
p13709
sg13
I2
sa(dp13710
g7
I243
sg8
g13694
sg10
I6
sg28
VC0038454
p13711
sg13
I1
sasa(dp13712
g135
(dp13713
(VSUB1
p13714
Vbreast cancer
p13715
tp13716
I01
ssg2
VThe OR of breast cancer for the percentage BPE measure (BPE%) quantified from SUB1 was 3.5 (95% Confidence Interval: 1.3, 9.8; p = 0.015) for 20% increments.
p13717
sg4
(lp13718
(dp13719
g7
I78
sg8
g13714
sg10
I4
sg11
VP53999
p13720
sg13
I1
sasg24
(lp13721
(dp13722
g7
I10
sg8
g13715
sg10
I13
sg28
VC0678222
p13723
sg13
I2
sasa(dp13724
g135
(dp13725
(VSUB1
p13726
Vprostate cancer
p13727
tp13728
I01
ssg2
VIn this study, we show elevated expression of SUB1 in aggressive prostate cancer.
p13729
sg4
(lp13730
(dp13731
g7
I46
sg8
g13726
sg10
I4
sg11
VP53999
p13732
sg13
I1
sasg24
(lp13733
(dp13734
g7
I54
sg8
Vaggressive
p13735
sg10
I10
sg28
VC0001807
p13736
sg13
I1
sa(dp13737
g7
I65
sg8
g13727
sg10
I15
sg28
VC0600139
p13738
sg13
I2
sasa(dp13739
g135
(dp13740
(VSUB1
p13741
Vprostate cancer
p13742
tp13743
I01
ssg2
VKnockdown of SUB1 in prostate cancer cells resulted in reduced cell proliferation, invasion and migration in vitro, and tumor growth and metastasis in vivo.
p13744
sg4
(lp13745
(dp13746
g7
I13
sg8
g13741
sg10
I4
sg11
VP53999
p13747
sg13
I1
sasg24
(lp13748
(dp13749
g7
I120
sg8
Vtumor growth
p13750
sg10
I12
sg28
VC0598934
p13751
sg13
I2
sa(dp13752
g7
I137
sg8
Vmetastasis
p13753
sg10
I10
sg28
VC0027627
p13754
sg13
I1
sa(dp13755
g7
I68
sg8
Vproliferation
p13756
sg10
I13
sg28
VC0334094
p13757
sg13
I1
sa(dp13758
g7
I21
sg8
g13742
sg10
I15
sg28
VC0600139
p13759
sg13
I2
sa(dp13760
g7
I83
sg8
Vinvasion
p13761
sg10
I8
sg28
VC2699153
p13762
sg13
I1
sasa(dp13763
g135
(dp13764
(VPLK1
p13765
Vprostate cancer
p13766
tp13767
I00
ssg2
VPLK1 knockdown or use of PLK1 inhibitor can mitigate oncogenic function of SUB1 in benign prostate cancer cells.
p13768
sg4
(lp13769
(dp13770
g7
I75
sg8
VSUB1
p13771
sg10
I4
sg11
VP53999
p13772
sg13
I1
sa(dp13773
g7
I0
sg8
VPLK1
p13774
sg10
I4
sg11
VP53350
p13775
sg13
I1
sa(dp13776
g7
I0
sg8
g13765
sg10
I4
sg11
VP53350
p13777
sg13
I1
sasg24
(lp13778
(dp13779
g7
I90
sg8
g13766
sg10
I15
sg28
VC0600139
p13780
sg13
I2
sasa(dp13781
g135
(dp13782
(VSUB1
p13783
Vmetastasis
p13784
tp13785
I01
ssg2
VThus, our study suggests that miR-101 loss results in increased SUB1 expression and subsequent activation of known oncogenes driving prostate cancer progression and metastasis.
p13786
sg4
(lp13787
(dp13788
g7
I64
sg8
g13783
sg10
I4
sg11
VP53999
p13789
sg13
I1
sa(dp13790
g7
I30
sg8
VmiR-101 loss
p13791
sg10
I12
sg11
g12
sg13
I2
sasg24
(lp13792
(dp13793
g7
I142
sg8
Vcancer progression
p13794
sg10
I18
sg28
VC0178874
p13795
sg13
I2
sa(dp13796
g7
I165
sg8
g13784
sg10
I10
sg28
VC0027627
p13797
sg13
I1
sasa(dp13798
g135
(dp13799
(VSUB1
p13800
Vprostate cancer
p13801
tp13802
I01
ssg2
VThis study therefore demonstrates functional role of SUB1 in prostate cancer, and identifies its regulation and potential downstream therapeutic targets of SUB1 in prostate cancer.
p13803
sg4
(lp13804
(dp13805
g7
I53
sg8
VSUB1
p13806
sg10
I4
sg11
VP53999
p13807
sg13
I1
sa(dp13808
g7
I53
sg8
g13800
sg10
I4
sg11
VP53999
p13809
sg13
I1
sasg24
(lp13810
(dp13811
g7
I61
sg8
Vprostate cancer
p13812
sg10
I15
sg28
VC0600139
p13813
sg13
I2
sa(dp13814
g7
I61
sg8
g13801
sg10
I15
sg28
VC0600139
p13815
sg13
I2
sasa(dp13816
g135
(dp13817
(VVEGFR
p13818
Vlymph node metastasis
p13819
tp13820
I00
ssg2
VThe proposed study aims to explore whether PC4 correlates with VEGF-C/VEGF-D/VEGFR-3 axis of lymphangiogenesis in the lymph node metastasis during lung adenocarcinoma.
p13821
sg4
(lp13822
(dp13823
g7
I63
sg8
VVEGF-C
p13824
sg10
I6
sg11
VP49767
p13825
sg13
I1
sa(dp13826
g7
I77
sg8
g13818
sg10
I5
sg11
VP35968
p13827
sg13
I1
sasg24
(lp13828
(dp13829
g7
I147
sg8
Vlung adenocarcinoma
p13830
sg10
I19
sg28
VC0152013
p13831
sg13
I2
sa(dp13832
g7
I118
sg8
g13819
sg10
I21
sg28
VC0686619
p13833
sg13
I3
sasa(dp13834
g135
(dp13835
(VVEGFR-3
p13836
Vlung adenocarcinoma
p13837
tp13838
I00
ssg2
VHere, small interfering RNA technique was employed to investigate the relationship of PC4 and the VEGF-C/VEGF-D/VEGFR-3 axis in lung adenocarcinoma cell lines as well as tumor xenografts of mice model.
p13839
sg4
(lp13840
(dp13841
g7
I98
sg8
VVEGF-C
p13842
sg10
I6
sg11
VP49767
p13843
sg13
I1
sa(dp13844
g7
I86
sg8
VPC4
p13845
sg10
I3
sg11
VP53999
p13846
sg13
I1
sa(dp13847
g7
I112
sg8
g13836
sg10
I7
sg11
VP35916
p13848
sg13
I1
sasg24
(lp13849
(dp13850
g7
I128
sg8
g13837
sg10
I19
sg28
VC0152013
p13851
sg13
I2
sa(dp13852
g7
I170
sg8
Vtumor
p13853
sg10
I5
sg28
VC0027651
p13854
sg13
I1
sasa(dp13855
g135
(dp13856
(VVEGFR-3
p13857
Vlymphatic metastasis
p13858
tp13859
I00
ssg2
VPC4 expression correlated with the levels of VEGF-C, VEGF-D and VEGFR-3 during the development of lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma in vitro and in vivo, which may be a novel marker in the development of lymphangiogenesis and lymphatic metastasis of tumors.
p13860
sg4
(lp13861
(dp13862
g7
I45
sg8
VVEGF-C
p13863
sg10
I6
sg11
VP49767
p13864
sg13
I1
sa(dp13865
g7
I53
sg8
VVEGF-D
p13866
sg10
I6
sg11
g12
sg13
I1
sa(dp13867
g7
I0
sg8
VPC4
p13868
sg10
I3
sg11
VP53999
p13869
sg13
I1
sa(dp13870
g7
I64
sg8
g13857
sg10
I7
sg11
VP35916
p13871
sg13
I1
sasg24
(lp13872
(dp13873
g7
I144
sg8
Vlung adenocarcinoma
p13874
sg10
I19
sg28
VC0152013
p13875
sg13
I2
sa(dp13876
g7
I282
sg8
Vtumors
p13877
sg10
I6
sg28
VC0027651
p13878
sg13
I1
sa(dp13879
g7
I120
sg8
Vlymphatic metastasis
p13880
sg10
I20
sg28
VC0024232
p13881
sg13
I2
sa(dp13882
g7
I120
sg8
g13858
sg10
I20
sg28
VC0024232
p13883
sg13
I2
sasa(dp13884
g2
VTo test the hypothesis that elevated urinary levels of soluble E-cadherin (sE-cadherin) would aid in the detection of transitional cell carcinoma (TCC) of the urinary bladder.
p13885
sg4
(lp13886
(dp13887
g7
I75
sg8
VsE-cadherin
p13888
sg10
I11
sg11
g12
sg13
I1
sa(dp13889
g7
I55
sg8
Vsoluble E-cadherin
p13890
sg10
I18
sg11
g12
sg13
I2
sasg24
(lp13891
(dp13892
g7
I118
sg8
Vtransitional cell carcinoma
p13893
sg10
I27
sg28
VC0007138
p13894
sg13
I3
sa(dp13895
g7
I147
sg8
VTCC
p13896
sg10
I3
sg28
VC1861305
p13897
sg13
I1
sasa(dp13898
g2
VWe propose potential pathogenic pathways for transitional cell carcinoma of the bladder in diabetic patients based on altered integrin and cadherin distribution in urothelial cells in diabetic patients.
p13899
sg4
(lp13900
(dp13901
g7
I139
sg8
Vcadherin
p13902
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp13903
(dp13904
g7
I45
sg8
Vtransitional cell carcinoma of the bladder
p13905
sg10
I42
sg28
VC0279680
p13906
sg13
I6
sasa(dp13907
g135
(dp13908
(Vsoluble E-cadherin
p13909
Vtransitional cell carcinoma
p13910
tp13911
I00
ssg2
VTo evaluate soluble E-cadherin (sE-cadherin) as a potential tumour marker in patients with transitional cell carcinoma (TCC) of the bladder (previously shown to correlate with tumour grade, number of Ta/T1 tumours at presentation and a positive 3-month check cystoscopy) by assessing its serum concentration in relation to transurethral resection of bladder tumour (TURBT).
p13912
sg4
(lp13913
(dp13914
g7
I12
sg8
g13909
sg10
I18
sg11
VP35558
p13915
sg13
I2
sa(dp13916
g7
I32
sg8
VsE-cadherin
p13917
sg10
I11
sg11
g12
sg13
I1
sasg24
(lp13918
(dp13919
g7
I60
sg8
Vtumour
p13920
sg10
I6
sg28
VC0027651
p13921
sg13
I1
sa(dp13922
g7
I120
sg8
VTCC
p13923
sg10
I3
sg28
VC1861305
p13924
sg13
I1
sa(dp13925
g7
I60
sg8
Vtumour
p13926
sg10
I6
sg28
VC0027651
p13927
sg13
I1
sa(dp13928
g7
I91
sg8
g13910
sg10
I27
sg28
VC0007138
p13929
sg13
I3
sa(dp13930
g7
I60
sg8
Vtumour
p13931
sg10
I6
sg28
VC0027651
p13932
sg13
I1
sa(dp13933
g7
I206
sg8
Vtumours
p13934
sg10
I7
sg28
VC0027651
p13935
sg13
I1
sasa(dp13936
g135
(dp13937
(VTGF-Beta1
p13938
VSMA
p13939
tp13940
I00
ssg2
VElevated mRNA expression of liver IL-6, IL-17A, IL-17F, TGF-Beta1, Alfa-SMA, TGR5, NTCP, OATP1a1, and ileum ASBT and decreased liver IL-10, FXR, CAR, VDR, BSEP, MRP2, MRP3, MRP4 was also observed in ANIT-induced cholestasis but were attenuated or normalized by YCHT.
p13941
sg4
(lp13942
(dp13943
g7
I34
sg8
VIL-6
p13944
sg10
I4
sg11
VP05231
p13945
sg13
I1
sa(dp13946
g7
I67
sg8
VAlfa-SMA
p13947
sg10
I8
sg11
g12
sg13
I1
sa(dp13948
g7
I83
sg8
VNTCP
p13949
sg10
I4
sg11
g12
sg13
I1
sa(dp13950
g7
I140
sg8
VFXR
p13951
sg10
I3
sg11
VP23945
p13952
sg13
I1
sa(dp13953
g7
I155
sg8
VBSEP
p13954
sg10
I4
sg11
g12
sg13
I1
sa(dp13955
g7
I150
sg8
VVDR
p13956
sg10
I3
sg11
VP11473
p13957
sg13
I1
sa(dp13958
g7
I173
sg8
VMRP4
p13959
sg10
I4
sg11
g12
sg13
I1
sa(dp13960
g7
I56
sg8
g13938
sg10
I9
sg11
VP01137
p13961
sg13
I1
sa(dp13962
g7
I77
sg8
VTGR5
p13963
sg10
I4
sg11
g12
sg13
I1
sa(dp13964
g7
I161
sg8
VMRP2
p13965
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp13966
(dp13967
g7
I145
sg8
VCAR
p13968
sg10
I3
sg28
VC2607929
p13969
sg13
I1
sa(dp13970
g7
I212
sg8
Vcholestasis
p13971
sg10
I11
sg28
VC0008370
p13972
sg13
I1
sa(dp13973
g7
I72
sg8
g13939
sg10
I3
sg28
VC0026847
p13974
sg13
I1
sasa(dp13975
g135
(dp13976
(VTNF-Alfa
p13977
Vbiliary atresia
p13978
tp13979
I01
ssg2
VThe objective of the present study is to evaluate whether IL-6, TNF-Alfa, IL-10 are associated with nutritional status in patients with cirrhosis secondary to biliary atresia and compare to healthy controls.
p13980
sg4
(lp13981
(dp13982
g7
I58
sg8
VIL-6
p13983
sg10
I4
sg11
VP05231
p13984
sg13
I1
sa(dp13985
g7
I64
sg8
g13977
sg10
I8
sg11
VP01375
p13986
sg13
I1
sasg24
(lp13987
(dp13988
g7
I136
sg8
Vcirrhosis
p13989
sg10
I9
sg28
VC0023890
p13990
sg13
I1
sa(dp13991
g7
I159
sg8
g13978
sg10
I15
sg28
VC0005411
p13992
sg13
I2
sasa(dp13993
g135
(dp13994
(VIL-6
p13995
Vcirrhosis
p13996
tp13997
I00
ssg2
VThe authors suggest that, in patients with cirrhosis secondary to biliary atresia, IL-6 could be used as a possible supporting biomarker of deficient nutritional status and elevated IL-10 levels could be used as a possible early-stage supporting biomarker of deteriorating nutritional status.
p13998
sg4
(lp13999
(dp14000
g7
I83
sg8
g13995
sg10
I4
sg11
VP05231
p14001
sg13
I1
sasg24
(lp14002
(dp14003
g7
I66
sg8
Vbiliary atresia
p14004
sg10
I15
sg28
VC0005411
p14005
sg13
I2
sa(dp14006
g7
I43
sg8
g13996
sg10
I9
sg28
VC0023890
p14007
sg13
I1
sasa(dp14008
g135
(dp14009
(VCRP
p14010
Vtumor necrosis
p14011
tp14012
I01
ssg2
VIn a prospective study, 47 patients with obstructive jaundice secondary to malignant lesions were evaluated before, at the fifth hour after, and on the fifth day after PTBD for neopterin, nitrate, tumor necrosis factor (TNF)-Alfa, interleukin (IL)-6, IL-10, CRP levels, and liver function.
p14013
sg4
(lp14014
(dp14015
g7
I197
sg8
Vtumor necrosis factor (TNF)-Alfa
p14016
sg10
I32
sg11
VP01375
p14017
sg13
I4
sa(dp14018
g7
I231
sg8
Vinterleukin (IL)-6
p14019
sg10
I18
sg11
VP60568
p14020
sg13
I2
sa(dp14021
g7
I258
sg8
g14010
sg10
I3
sg11
VP02741
p14022
sg13
I1
sasg24
(lp14023
(dp14024
g7
I41
sg8
Vobstructive jaundice
p14025
sg10
I20
sg28
VC0022354
p14026
sg13
I2
sa(dp14027
g7
I197
sg8
g14011
sg10
I14
sg28
VC0333516
p14028
sg13
I2
sasa(dp14029
g135
(dp14030
(VDAPK-1
p14031
Vrenal cell carcinoma
p14032
tp14033
I00
ssg2
VIt has been reported that the hypermethylation of APAF-1, DAPK-1 and other tumor suppressive genes (TSGs) correlates with progression of renal cell carcinoma and exerts prognostic and diagnostic relevance in renal cell carcinoma.
p14034
sg4
(lp14035
(dp14036
g7
I58
sg8
g14031
sg10
I6
sg11
VP53355
p14037
sg13
I1
sasg24
(lp14038
(dp14039
g7
I137
sg8
Vrenal cell carcinoma
p14040
sg10
I20
sg28
VC0007134
p14041
sg13
I3
sa(dp14042
g7
I137
sg8
g14032
sg10
I20
sg28
VC0007134
p14043
sg13
I3
sa(dp14044
g7
I75
sg8
Vtumor
p14045
sg10
I5
sg28
VC0027651
p14046
sg13
I1
sasa(dp14047
g135
(dp14048
(VDAC
p14049
Vrenal carcinoma
p14050
tp14051
I01
ssg2
VThe present study confirmed that DAC demethylated the CpGs, particularly APAF-1 in renal carcinoma cells, and that the demethylation synergized the cytotoxity of CDDP in renal carcinoma cells via enhancing the CDDP-induced apoptosis.
p14052
sg4
(lp14053
(dp14054
g7
I33
sg8
g14049
sg10
I3
sg11
VP57775
p14055
sg13
I1
sasg24
(lp14056
(dp14057
g7
I83
sg8
Vrenal carcinoma
p14058
sg10
I15
sg28
VC0007134
p14059
sg13
I2
sa(dp14060
g7
I83
sg8
g14050
sg10
I15
sg28
VC0007134
p14061
sg13
I2
sasa(dp14062
g135
(dp14063
(VSPARC
p14064
VRCC
p14065
tp14066
I00
ssg2
VThe aim of this study was to investigate the occurrence and relevance of promoter methylation of the tumor suppressor DAPK-1, APAF-1 () and SPARC in relation to different pathological stages and histological grades of tumor progression that might act as possible independent prognostic factor in the susceptibility towards renal cell carcinoma (RCC) in North Indian population.
p14067
sg4
(lp14068
(dp14069
g7
I118
sg8
VDAPK-1
p14070
sg10
I6
sg11
VP53355
p14071
sg13
I1
sa(dp14072
g7
I140
sg8
g14064
sg10
I5
sg11
VP09486
p14073
sg13
I1
sasg24
(lp14074
(dp14075
g7
I101
sg8
Vtumor
p14076
sg10
I5
sg28
VC0027651
p14077
sg13
I1
sa(dp14078
g7
I323
sg8
Vrenal cell carcinoma
p14079
sg10
I20
sg28
VC0007134
p14080
sg13
I3
sa(dp14081
g7
I218
sg8
Vtumor progression
p14082
sg10
I17
sg28
VC0178874
p14083
sg13
I2
sa(dp14084
g7
I345
sg8
g14065
sg10
I3
sg28
VC0007134
p14085
sg13
I1
sasa(dp14086
g135
(dp14087
(Vdeath-associated protein kinase-1
p14088
Vrenal cell carcinoma
p14089
tp14090
I00
ssg2
VTo examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue.
p14091
sg4
(lp14092
(dp14093
g7
I186
sg8
VDAPK-1
p14094
sg10
I6
sg11
VP53355
p14095
sg13
I1
sa(dp14096
g7
I60
sg8
Vp53 target and tumour suppressor genes apoptotic protease activating factor-1
p14097
sg10
I77
sg11
g12
sg13
I10
sa(dp14098
g7
I151
sg8
g14088
sg10
I33
sg11
VP53355
p14099
sg13
I3
sasg24
(lp14100
(dp14101
g7
I75
sg8
Vtumour
p14102
sg10
I6
sg28
VC0027651
p14103
sg13
I1
sa(dp14104
g7
I75
sg8
Vtumour
p14105
sg10
I6
sg28
VC0027651
p14106
sg13
I1
sa(dp14107
g7
I344
sg8
VRCC
p14108
sg10
I3
sg28
VC0007134
p14109
sg13
I1
sa(dp14110
g7
I264
sg8
VTCC
p14111
sg10
I3
sg28
VC1861305
p14112
sg13
I1
sa(dp14113
g7
I235
sg8
Vtransitional cell carcinoma
p14114
sg10
I27
sg28
VC0007138
p14115
sg13
I3
sa(dp14116
g7
I75
sg8
Vtumour
p14117
sg10
I6
sg28
VC0027651
p14118
sg13
I1
sa(dp14119
g7
I322
sg8
g14089
sg10
I20
sg28
VC0007134
p14120
sg13
I3
sasa(dp14121
g135
(dp14122
(VPKD1
p14123
VPKD1
p14124
tp14125
I00
ssg2
VQuantification of mRNA expression of HNF1B, six of its potential target genes (PKHD1, PKD1, PKD2, IFT88, TMEM27 and UMOD) and three genes involved in the Mg(2+) renal homeostasis (ATP1A1, FXYD2 and CLDN16) in the urinary sediment of 11 individuals with mutation of HNF1B and in 9 controls (non-invasive assessment of the renal transcriptome).
p14126
sg4
(lp14127
(dp14128
g7
I105
sg8
VTMEM27
p14129
sg10
I6
sg11
g12
sg13
I1
sa(dp14130
g7
I188
sg8
VFXYD2
p14131
sg10
I5
sg11
VP54710
p14132
sg13
I1
sa(dp14133
g7
I37
sg8
VHNF1B
p14134
sg10
I5
sg11
VP35680
p14135
sg13
I1
sa(dp14136
g7
I92
sg8
VPKD2
p14137
sg10
I4
sg11
g12
sg13
I1
sa(dp14138
g7
I180
sg8
VATP1A1
p14139
sg10
I6
sg11
VP05023
p14140
sg13
I1
sa(dp14141
g7
I37
sg8
VHNF1B
p14142
sg10
I5
sg11
VP35680
p14143
sg13
I1
sa(dp14144
g7
I98
sg8
VIFT88
p14145
sg10
I5
sg11
g12
sg13
I1
sa(dp14146
g7
I116
sg8
VUMOD
p14147
sg10
I4
sg11
VP07911
p14148
sg13
I1
sa(dp14149
g7
I79
sg8
VPKHD1
p14150
sg10
I5
sg11
VP08F94
p14151
sg13
I1
sa(dp14152
g7
I198
sg8
VCLDN16
p14153
sg10
I6
sg11
g12
sg13
I1
sa(dp14154
g7
I86
sg8
g14123
sg10
I4
sg11
VP98161
p14155
sg13
I1
sasg24
(lp14156
(dp14157
g7
I79
sg8
VPKHD1
p14158
sg10
I5
sg28
VC0085548
p14159
sg13
I1
sa(dp14160
g7
I92
sg8
VPKD2
p14161
sg10
I4
sg28
VC2751306
p14162
sg13
I1
sa(dp14163
g7
I86
sg8
g14124
sg10
I4
sg28
VC3149841
p14164
sg13
I1
sasa(dp14165
g135
(dp14166
(Vmaturity-onset diabetes of the young subtype 3
p14167
Vmaturity-onset diabetes of the young subtype 3
p14168
tp14169
I00
ssg2
VCollectrin is a downstream target of the transcription factor hepatocyte nuclear factor-1alpha (HNF-1alpha), which is mutated in maturity-onset diabetes of the young subtype 3 (MODY3).
p14170
sg4
(lp14171
(dp14172
g7
I62
sg8
Vhepatocyte nuclear factor-1alpha
p14173
sg10
I32
sg11
VP20823
p14174
sg13
I3
sa(dp14175
g7
I177
sg8
VMODY3
p14176
sg10
I5
sg11
VP20823
p14177
sg13
I1
sa(dp14178
g7
I0
sg8
VCollectrin
p14179
sg10
I10
sg11
g12
sg13
I1
sa(dp14180
g7
I96
sg8
VHNF-1alpha
p14181
sg10
I10
sg11
VP20823
p14182
sg13
I1
sa(dp14183
g7
I129
sg8
g14167
sg10
I46
sg11
VP20823
p14184
sg13
I7
sasg24
(lp14185
(dp14186
g7
I177
sg8
VMODY3
p14187
sg10
I5
sg28
VC1838100
p14188
sg13
I1
sa(dp14189
g7
I129
sg8
g14168
sg10
I46
sg28
VC1838100
p14190
sg13
I7
sasa(dp14191
g2
VSeveral forms of ichthyosis are associated with neurologic manifestations, including Sjoegren-Larsson syndrome, Refsum disease, and mental retardation-enteropathy-deafness-neuropathy-ichthyosis-keratoderma (MEDNIK) syndrome.
p14192
sg4
(lp14193
sg24
(lp14194
(dp14195
g7
I194
sg8
Vkeratoderma
p14196
sg10
I11
sg28
VC0022579
p14197
sg13
I1
sa(dp14198
g7
I85
sg8
VSjoegren-Larsson syndrome
p14199
sg10
I25
sg28
VC0037231
p14200
sg13
I2
sa(dp14201
g7
I163
sg8
Vdeafness
p14202
sg10
I8
sg28
VC0011053
p14203
sg13
I1
sa(dp14204
g7
I17
sg8
Vichthyosis
p14205
sg10
I10
sg28
VC0020758
p14206
sg13
I1
sa(dp14207
g7
I112
sg8
VRefsum disease
p14208
sg10
I14
sg28
VC0034960
p14209
sg13
I2
sa(dp14210
g7
I17
sg8
Vichthyosis
p14211
sg10
I10
sg28
VC0020758
p14212
sg13
I1
sa(dp14213
g7
I102
sg8
Vsyndrome
p14214
sg10
I8
sg28
VC0039082
p14215
sg13
I1
sa(dp14216
g7
I132
sg8
Vmental retardation
p14217
sg10
I18
sg28
VC0025362
p14218
sg13
I2
sa(dp14219
g7
I151
sg8
Venteropathy
p14220
sg10
I11
sg28
VC0021831
p14221
sg13
I1
sa(dp14222
g7
I172
sg8
Vneuropathy
p14223
sg10
I10
sg28
VC0442874
p14224
sg13
I1
sasa(dp14225
g135
(dp14226
(Vthrombomodulin
p14227
Vmyoma
p14228
tp14229
I00
ssg2
VTo determine the difference in thrombomodulin expression in the myometrium and in myoma; and to understand the correlation of anticoagulation/fibrinolytic function and the mechanism of uterine artery occlusion in the treatment of leiomyoma.
p14230
sg4
(lp14231
(dp14232
g7
I31
sg8
g14227
sg10
I14
sg11
VP07204
p14233
sg13
I1
sasg24
(lp14234
(dp14235
g7
I230
sg8
Vleiomyoma
p14236
sg10
I9
sg28
VC0023267
p14237
sg13
I1
sa(dp14238
g7
I82
sg8
g14228
sg10
I5
sg28
VC0027086
p14239
sg13
I1
sa(dp14240
g7
I193
sg8
Vartery occlusion
p14241
sg10
I16
sg28
VC0264995
p14242
sg13
I2
sasa(dp14243
g2
VThe relative transcription of thrombomodulin mRNA was 1.28 times higher in myometrial tissue than in myomal tissue (P &lt; 0.05).
p14244
sg4
(lp14245
(dp14246
g7
I30
sg8
Vthrombomodulin mRNA
p14247
sg10
I19
sg11
VP07204
p14248
sg13
I2
sasg24
(lp14249
sa(dp14250
g135
(dp14251
(Vthrombomodulin
p14252
Vleiomyoma
p14253
tp14254
I00
ssg2
VSimilarly, leiomyoma-associated endometrium expressed less PAI-1 and thrombomodulin in vivo.
p14255
sg4
(lp14256
(dp14257
g7
I59
sg8
VPAI-1
p14258
sg10
I5
sg11
VP05121
p14259
sg13
I1
sa(dp14260
g7
I69
sg8
g14252
sg10
I14
sg11
VP07204
p14261
sg13
I1
sasg24
(lp14262
(dp14263
g7
I11
sg8
g14253
sg10
I9
sg28
VC0023267
p14264
sg13
I1
sasa(dp14265
g135
(dp14266
(Vinsulin-like growth factor-II mRNA-binding protein 3
p14267
VBarrett esophagus
p14268
tp14269
I00
ssg2
VAlfa-methylacyl coenzyme A racemase (AMACR) and insulin-like growth factor-II mRNA-binding protein 3 (IMP3) are 2 markers helpful in detecting difficult cases of dysplasia in Barrett esophagus (BE).
p14270
sg4
(lp14271
(dp14272
g7
I48
sg8
g14267
sg10
I52
sg11
VP01308
p14273
sg13
I6
sa(dp14274
g7
I102
sg8
VIMP3
p14275
sg10
I4
sg11
g12
sg13
I1
sa(dp14276
g7
I37
sg8
VAMACR
p14277
sg10
I5
sg11
g12
sg13
I1
sa(dp14278
g7
I0
sg8
VAlfa-methylacyl coenzyme A racemase
p14279
sg10
I35
sg11
g12
sg13
I4
sasg24
(lp14280
(dp14281
g7
I194
sg8
VBE
p14282
sg10
I2
sg28
VC0004763
p14283
sg13
I1
sa(dp14284
g7
I162
sg8
Vdysplasia
p14285
sg10
I9
sg28
VC0334044
p14286
sg13
I1
sa(dp14287
g7
I175
sg8
g14268
sg10
I17
sg28
VC0004763
p14288
sg13
I2
sasa(dp14289
g2
VTo investigate the value of Alfa-methylacyl-CoA racemase (AMACR) immunohistochemistry for predicting neoplastic progression in Barrett's oesophagus (BO).
p14290
sg4
(lp14291
(dp14292
g7
I28
sg8
VAlfa-methylacyl-CoA racemase
p14293
sg10
I28
sg11
g12
sg13
I2
sa(dp14294
g7
I58
sg8
VAMACR
p14295
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp14296
(dp14297
g7
I44
sg8
VCoA
p14298
sg10
I3
sg28
VC2678439
p14299
sg13
I1
sa(dp14300
g7
I127
sg8
VBarrett's oesophagus
p14301
sg10
I20
sg28
VC0004763
p14302
sg13
I2
sa(dp14303
g7
I101
sg8
Vneoplastic progression
p14304
sg10
I22
sg28
VC0178874
p14305
sg13
I2
sa(dp14306
g7
I149
sg8
VBO
p14307
sg10
I2
sg28
VC0004763
p14308
sg13
I1
sasa(dp14309
g2
VThe aim of this study was to evaluate AMACR expression in the metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus (BE), ulcerative colitis (UC), and Crohn's disease (CD) and to determine whether its expression can be used to detect dysplastic epithelium in these conditions.
p14310
sg4
(lp14311
sg24
(lp14312
(dp14313
g7
I160
sg8
VCrohn's disease
p14314
sg10
I15
sg28
VC0010346
p14315
sg13
I2
sa(dp14316
g7
I243
sg8
Vdysplastic
p14317
sg10
I10
sg28
VC0334044
p14318
sg13
I1
sa(dp14319
g7
I62
sg8
Vmetaplasia
p14320
sg10
I10
sg28
VC0025568
p14321
sg13
I1
sa(dp14322
g7
I73
sg8
Vdysplasia
p14323
sg10
I9
sg28
VC0334044
p14324
sg13
I1
sa(dp14325
g7
I83
sg8
Vcarcinoma
p14326
sg10
I9
sg28
VC0007097
p14327
sg13
I1
sa(dp14328
g7
I105
sg8
VBarrett's esophagus
p14329
sg10
I19
sg28
VC0004763
p14330
sg13
I2
sa(dp14331
g7
I126
sg8
VBE
p14332
sg10
I2
sg28
VC0004763
p14333
sg13
I1
sa(dp14334
g7
I177
sg8
VCD
p14335
sg10
I2
sg28
VC0010346
p14336
sg13
I1
sa(dp14337
g7
I131
sg8
Vulcerative colitis
p14338
sg10
I18
sg28
VC0009324
p14339
sg13
I2
sa(dp14340
g7
I151
sg8
VUC
p14341
sg10
I2
sg28
VC0009324
p14342
sg13
I1
sasa(dp14343
g135
(dp14344
(VDPP4
p14345
Vcognitive decline
p14346
tp14347
I01
ssg2
VThese associations implicate genes related to apoptosis (HRK), development (WIF1), oxidative stress (MSR3B), ubiquitination (FBXW8) and neuronal migration (ASTN2), as well as enzymes targeted by new diabetes medications (DPP4), indicating new genetic influences on hippocampal size and possibly the risk of cognitive decline and dementia.
p14348
sg4
(lp14349
(dp14350
g7
I221
sg8
g14345
sg10
I4
sg11
VP27487
p14351
sg13
I1
sa(dp14352
g7
I125
sg8
VFBXW8
p14353
sg10
I5
sg11
g12
sg13
I1
sa(dp14354
g7
I76
sg8
VWIF1
p14355
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp14356
(dp14357
g7
I199
sg8
Vdiabetes
p14358
sg10
I8
sg28
VC0011849
p14359
sg13
I1
sa(dp14360
g7
I329
sg8
Vdementia
p14361
sg10
I8
sg28
VC0497327
p14362
sg13
I1
sa(dp14363
g7
I83
sg8
Voxidative stress
p14364
sg10
I16
sg28
VC0242606
p14365
sg13
I2
sa(dp14366
g7
I307
sg8
g14346
sg10
I17
sg28
VC0338656
p14367
sg13
I2
sasa(dp14368
g2
VHistomorphometrical analysis of experimental implants inserted in the femurs of CKD mice revealed a trend of decreased BIC ratio at 2-week healing.
p14369
sg4
(lp14370
sg24
(lp14371
sa(dp14372
g2
VA Cochrane Collaboration review (Roderick, Cochrane Data base of systemic reviews 2007, DOI 10.1002/14651858.CD0018.90.pub3) reported that there was no evidence for correction of acidosis by sodium bicarbonate in pre-end-stage renal disease (ESRD) patients, and concluded that randomized controlled trials (RCTs) are necessary to evaluate the benefits and harms of correcting metabolic acidosis in pre-ESRD patients.
p14373
sg4
(lp14374
sg24
(lp14375
(dp14376
g7
I376
sg8
Vmetabolic acidosis
p14377
sg10
I18
sg28
VC0220981
p14378
sg13
I2
sa(dp14379
g7
I179
sg8
Vacidosis
p14380
sg10
I8
sg28
VC0001122
p14381
sg13
I1
sa(dp14382
g7
I213
sg8
Vpre-end-stage renal disease
p14383
sg10
I27
sg28
VC0022661
p14384
sg13
I3
sa(dp14385
g7
I242
sg8
VESRD
p14386
sg10
I4
sg28
VC0022661
p14387
sg13
I1
sa(dp14388
g7
I242
sg8
VESRD
p14389
sg10
I4
sg28
VC0022661
p14390
sg13
I1
sasa(dp14391
g2
VWe will randomize 600 patients with chronic kidney disease (CKD) stages 3b and 4; 300 of these patients will be included in the bicarbonate study group (Bic), in which levels of bicarbonate should be kept &gt;24 mEq/L; the other 300 patients will be included in the usual-treatment group (no-Bic).
p14392
sg4
(lp14393
sg24
(lp14394
(dp14395
g7
I60
sg8
VCKD
p14396
sg10
I3
sg28
VC1561643
p14397
sg13
I1
sa(dp14398
g7
I36
sg8
Vchronic kidney disease
p14399
sg10
I22
sg28
VC1561643
p14400
sg13
I3
sasa(dp14401
g2
VAcid-Base Disorders in CKD: Moderate metabolic acidosis (Bic 16-20) mEq/L is common with glomerular filtration rates below 20 ml/min, and favors bone demineralization due to the release of calcium and phosphate from the bone, chronic hyperventilation, and muscular weakness and atrophy.
p14402
sg4
(lp14403
(dp14404
g7
I0
sg8
VAcid-Base
p14405
sg10
I9
sg11
g12
sg13
I1
sasg24
(lp14406
(dp14407
g7
I0
sg8
VAcid-Base Disorders
p14408
sg10
I19
sg28
VC0740265
p14409
sg13
I2
sa(dp14410
g7
I256
sg8
Vmuscular weakness
p14411
sg10
I17
sg28
VC0151786
p14412
sg13
I2
sa(dp14413
g7
I145
sg8
Vbone demineralization
p14414
sg10
I21
sg28
VC0242699
p14415
sg13
I2
sa(dp14416
g7
I226
sg8
Vchronic hyperventilation
p14417
sg10
I24
sg28
VC0268054
p14418
sg13
I2
sa(dp14419
g7
I37
sg8
Vmetabolic acidosis
p14420
sg10
I18
sg28
VC0220981
p14421
sg13
I2
sa(dp14422
g7
I278
sg8
Vatrophy
p14423
sg10
I7
sg28
VC0333641
p14424
sg13
I1
sasa(dp14425
g135
(dp14426
(VLac
p14427
Vacute renal failure
p14428
tp14429
I00
ssg2
VIn a prospective randomized crossover trial, patients with acute renal failure received CRRT with either sodium bicarbonate (Bic) or sodium lactate (Lac) as a buffering agent over 2 consecutive 24-h periods.
p14430
sg4
(lp14431
(dp14432
g7
I140
sg8
Vlactate
p14433
sg10
I7
sg11
VP09848
p14434
sg13
I1
sa(dp14435
g7
I149
sg8
g14427
sg10
I3
sg11
VP09848
p14436
sg13
I1
sasg24
(lp14437
(dp14438
g7
I59
sg8
g14428
sg10
I19
sg28
VC0022660
p14439
sg13
I3
sasa(dp14440
g2
VThe combination of bicarbonate and mannitol (BIC/MAN) is commonly used to prevent renal failure (RF) in patients with rhabdomyolysis despite the absence of sufficient evidence validating its use.
p14441
sg4
(lp14442
sg24
(lp14443
(dp14444
g7
I118
sg8
Vrhabdomyolysis
p14445
sg10
I14
sg28
VC0035410
p14446
sg13
I1
sa(dp14447
g7
I82
sg8
Vrenal failure
p14448
sg10
I13
sg28
VC0035078
p14449
sg13
I2
sa(dp14450
g7
I97
sg8
VRF
p14451
sg10
I2
sg28
VC0035078
p14452
sg13
I1
sasa(dp14453
g135
(dp14454
(Vconventional RF
p14455
Vconventional RF
p14456
tp14457
I00
ssg2
VTo unmask weak inputs from outside the conventional RF (CRF), cell excitability was raised by iontophoretic application of glutamate (GLU) and/or bicuculline methiodide (BIC) or by light stimulation of the CRF.
p14458
sg4
(lp14459
(dp14460
g7
I56
sg8
VCRF
p14461
sg10
I3
sg11
VP06850
p14462
sg13
I1
sa(dp14463
g7
I39
sg8
g14455
sg10
I15
sg11
VP06850
p14464
sg13
I2
sasg24
(lp14465
(dp14466
g7
I56
sg8
VCRF
p14467
sg10
I3
sg28
VC0022661
p14468
sg13
I1
sa(dp14469
g7
I67
sg8
Vexcitability
p14470
sg10
I12
sg28
VC0235169
p14471
sg13
I1
sa(dp14472
g7
I56
sg8
VCRF
p14473
sg10
I3
sg28
VC0022661
p14474
sg13
I1
sa(dp14475
g7
I39
sg8
g14456
sg10
I15
sg28
VC0022661
p14476
sg13
I2
sasa(dp14477
g2
VBicarbonate-buffered replacement fluid (RF-bic) in continuous venovenous hemofiltration (CVVH) may be superior to lactate-buffered replacement fluid (RF-lac) in acute renal failure.
p14478
sg4
(lp14479
sg24
(lp14480
(dp14481
g7
I161
sg8
Vacute renal failure
p14482
sg10
I19
sg28
VC0022660
p14483
sg13
I3
sasa(dp14484
g135
(dp14485
(VRF-lac
p14486
Vacute renal failure
p14487
tp14488
I00
ssg2
VIn an open, randomized, multicenter study, we investigated the effects of RF-bic and RF-lac on cardiovascular outcome in patients requiring CVVH following acute renal failure.
p14489
sg4
(lp14490
(dp14491
g7
I85
sg8
g14486
sg10
I6
sg11
VP09848
p14492
sg13
I1
sasg24
(lp14493
(dp14494
g7
I155
sg8
g14487
sg10
I19
sg28
VC0022660
p14495
sg13
I3
sasa(dp14496
g2
VThe data also suggest that the use of RF-bic during CVVH reduces cardiovascular events in critically ill patients with acute renal failure, particularly those with previous cardiovascular disease or heart failure.
p14497
sg4
(lp14498
sg24
(lp14499
(dp14500
g7
I119
sg8
Vacute renal failure
p14501
sg10
I19
sg28
VC0022660
p14502
sg13
I3
sa(dp14503
g7
I199
sg8
Vheart failure
p14504
sg10
I13
sg28
VC0018802
p14505
sg13
I2
sa(dp14506
g7
I173
sg8
Vcardiovascular disease
p14507
sg10
I22
sg28
VC0007222
p14508
sg13
I2
sa(dp14509
g7
I90
sg8
Vcritically ill
p14510
sg10
I14
sg28
VC0010340
p14511
sg13
I2
sasa(dp14512
g2
VThe effect of BIC on whisker-evoked responses was a preferential enhancement in the responses elicited by the whisker giving rise to the highest probability response (center receptive field whisker or CRF).
p14513
sg4
(lp14514
sg24
(lp14515
(dp14516
g7
I201
sg8
VCRF
p14517
sg10
I3
sg28
VC0022661
p14518
sg13
I1
sasa(dp14519
g135
(dp14520
(VCRF
p14521
VCRF
p14522
tp14523
I00
ssg2
VThe primary influence of BIC and, to a lesser degree, 2-OH-S was to prolong the response duration of VPM neurons to CRF whisker stimulation.
p14524
sg4
(lp14525
(dp14526
g7
I116
sg8
g14521
sg10
I3
sg11
VP06850
p14527
sg13
I1
sasg24
(lp14528
(dp14529
g7
I116
sg8
g14522
sg10
I3
sg28
VC0022661
p14530
sg13
I1
sasa(dp14531
g2
VSelective PDE5 inhibitors have shown potential in treating kidney fibrosis in patients with chronic kidney disease (CKD), via their downstream signaling, and these inhibitors also have known activity as antithrombotic and anticancer agents.
p14532
sg4
(lp14533
(dp14534
g7
I10
sg8
VPDE5
p14535
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp14536
(dp14537
g7
I92
sg8
Vchronic kidney disease
p14538
sg10
I22
sg28
VC1561643
p14539
sg13
I3
sa(dp14540
g7
I116
sg8
VCKD
p14541
sg10
I3
sg28
VC1561643
p14542
sg13
I1
sa(dp14543
g7
I59
sg8
Vkidney fibrosis
p14544
sg10
I15
sg28
VC0151650
p14545
sg13
I2
sasa(dp14546
g135
(dp14547
(VFGF9
p14548
VHCC
p14549
tp14550
I00
ssg2
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p14551
sg4
(lp14552
(dp14553
g7
I4
sg8
VFGF9 subfamily
p14554
sg10
I14
sg11
VP31371
p14555
sg13
I2
sa(dp14556
g7
I4
sg8
g14548
sg10
I4
sg11
VP31371
p14557
sg13
I1
sa(dp14558
g7
I36
sg8
VFGF16
p14559
sg10
I5
sg11
g12
sg13
I1
sa(dp14560
g7
I47
sg8
VFGF20
p14561
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp14562
(dp14563
g7
I169
sg8
Vhepatocellular carcinoma
p14564
sg10
I24
sg28
VC2239176
p14565
sg13
I2
sa(dp14566
g7
I195
sg8
g14549
sg10
I3
sg28
VC2239176
p14567
sg13
I1
sa(dp14568
g7
I127
sg8
Vproliferation
p14569
sg10
I13
sg28
VC0334094
p14570
sg13
I1
sasa(dp14571
g135
(dp14572
(VERK
p14573
Vliver cancer
p14574
tp14575
I00
ssg2
VFurthermore, the results indicate that exogenous rhFGF9- and rhFGF20-activated ERK/NF-KB signal transduction pathways play important roles in the regulation of HCC cell proliferation and migration, and this discovery helps to find the potential for new solutions of the treatment of liver cancer.
p14576
sg4
(lp14577
(dp14578
g7
I79
sg8
g14573
sg10
I3
sg11
VP29323
p14579
sg13
I1
sasg24
(lp14580
(dp14581
g7
I169
sg8
Vproliferation
p14582
sg10
I13
sg28
VC0334094
p14583
sg13
I1
sa(dp14584
g7
I160
sg8
VHCC
p14585
sg10
I3
sg28
VC2239176
p14586
sg13
I1
sa(dp14587
g7
I283
sg8
g14574
sg10
I12
sg28
VC0345904
p14588
sg13
I2
sasa(dp14589
g135
(dp14590
(VFGF3
p14591
Vspinocerebellar ataxia
p14592
tp14593
I00
ssg2
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p14594
sg4
(lp14595
(dp14596
g7
I120
sg8
VFGF10
p14597
sg10
I5
sg11
g12
sg13
I1
sa(dp14598
g7
I277
sg8
VFGF23
p14599
sg10
I5
sg11
g12
sg13
I1
sa(dp14600
g7
I38
sg8
VFGF8
p14601
sg10
I4
sg11
VP55075
p14602
sg13
I1
sa(dp14603
g7
I212
sg8
VFGF14
p14604
sg10
I5
sg11
g12
sg13
I1
sa(dp14605
g7
I101
sg8
VFGF9
p14606
sg10
I4
sg11
VP31371
p14607
sg13
I1
sa(dp14608
g7
I14
sg8
g14591
sg10
I4
sg11
VP11487
p14609
sg13
I1
sasg24
(lp14610
(dp14611
g7
I254
sg8
VParkinson disease
p14612
sg10
I17
sg28
VC0030567
p14613
sg13
I2
sa(dp14614
g7
I29
sg8
Vaplasia
p14615
sg10
I7
sg28
VC0243065
p14616
sg13
I1
sa(dp14617
g7
I171
sg8
Vlacrimo-auriculo-dento-digital syndrome
p14618
sg10
I39
sg28
VC0265269
p14619
sg13
I2
sa(dp14620
g7
I46
sg8
Vcleft lip/palate
p14621
sg10
I16
sg28
VC0158646
p14622
sg13
I2
sa(dp14623
g7
I309
sg8
Vhypophosphatemic rickets
p14624
sg10
I24
sg28
VC1704375
p14625
sg13
I2
sa(dp14626
g7
I286
sg8
Vtumoral calcinosis
p14627
sg10
I18
sg28
VC0263628
p14628
sg13
I2
sa(dp14629
g7
I109
sg8
Vcarcinoma
p14630
sg10
I9
sg28
VC0007097
p14631
sg13
I1
sa(dp14632
g7
I29
sg8
Vaplasia
p14633
sg10
I7
sg28
VC0243065
p14634
sg13
I1
sa(dp14635
g7
I70
sg8
Vhypogonadotropic hypogonadism
p14636
sg10
I29
sg28
VC0022735
p14637
sg13
I2
sa(dp14638
g7
I221
sg8
g14592
sg10
I22
sg28
VC0087012
p14639
sg13
I2
sasa(dp14640
g135
(dp14641
(VFGFR1
p14642
Vdepression
p14643
tp14644
I00
ssg2
VMolecular genetics and developmental studies have identified 21 genes in this region (ADRA1A, ARHGEF10, CHRNA2, CHRNA6, CHRNB3, DKK4, DPYSL2, EGR3, FGF17, FGF20, FGFR1, FZD3, LDL, NAT2, NEF3, NRG1, PCM1, PLAT, PPP3CC, SFRP1 and VMAT1/SLC18A1) that are most likely to contribute to neuropsychiatric disorders (schizophrenia, autism, bipolar disorder and depression), neurodegenerative disorders (Parkinson's and Alzheimer's disease) and cancer.
p14645
sg4
(lp14646
(dp14647
g7
I94
sg8
VARHGEF10
p14648
sg10
I8
sg11
g12
sg13
I1
sa(dp14649
g7
I186
sg8
VNEF3
p14650
sg10
I4
sg11
VP07197
p14651
sg13
I1
sa(dp14652
g7
I210
sg8
VPPP3CC
p14653
sg10
I6
sg11
VP48454
p14654
sg13
I1
sa(dp14655
g7
I142
sg8
VEGR3
p14656
sg10
I4
sg11
g12
sg13
I1
sa(dp14657
g7
I120
sg8
VCHRNB3
p14658
sg10
I6
sg11
g12
sg13
I1
sa(dp14659
g7
I86
sg8
VADRA1A
p14660
sg10
I6
sg11
VP25100
p14661
sg13
I1
sa(dp14662
g7
I234
sg8
VSLC18A1
p14663
sg10
I7
sg11
VP54219
p14664
sg13
I1
sa(dp14665
g7
I228
sg8
VVMAT1
p14666
sg10
I5
sg11
VP54219
p14667
sg13
I1
sa(dp14668
g7
I180
sg8
VNAT2
p14669
sg10
I4
sg11
VP18440
p14670
sg13
I1
sa(dp14671
g7
I128
sg8
VDKK4
p14672
sg10
I4
sg11
g12
sg13
I1
sa(dp14673
g7
I162
sg8
g14642
sg10
I5
sg11
VP20930
p14674
sg13
I1
sa(dp14675
g7
I104
sg8
VCHRNA2
p14676
sg10
I6
sg11
g12
sg13
I1
sa(dp14677
g7
I134
sg8
VDPYSL2
p14678
sg10
I6
sg11
g12
sg13
I1
sa(dp14679
g7
I169
sg8
VFZD3
p14680
sg10
I4
sg11
g12
sg13
I1
sa(dp14681
g7
I148
sg8
VFGF17
p14682
sg10
I5
sg11
g12
sg13
I1
sa(dp14683
g7
I155
sg8
VFGF20
p14684
sg10
I5
sg11
g12
sg13
I1
sa(dp14685
g7
I218
sg8
VSFRP1
p14686
sg10
I5
sg11
g12
sg13
I1
sa(dp14687
g7
I198
sg8
VPCM1
p14688
sg10
I4
sg11
g12
sg13
I1
sa(dp14689
g7
I112
sg8
VCHRNA6
p14690
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp14691
(dp14692
g7
I436
sg8
Vcancer
p14693
sg10
I6
sg28
VC0006826
p14694
sg13
I1
sa(dp14695
g7
I309
sg8
Vschizophrenia
p14696
sg10
I13
sg28
VC0036341
p14697
sg13
I1
sa(dp14698
g7
I332
sg8
Vbipolar disorder
p14699
sg10
I16
sg28
VC0005586
p14700
sg13
I2
sa(dp14701
g7
I324
sg8
Vautism
p14702
sg10
I6
sg28
VC0004352
p14703
sg13
I1
sa(dp14704
g7
I366
sg8
Vneurodegenerative disorders
p14705
sg10
I27
sg28
VC0524851
p14706
sg13
I2
sa(dp14707
g7
I353
sg8
g14643
sg10
I10
sg28
VC0011581
p14708
sg13
I1
sa(dp14709
g7
I411
sg8
VAlzheimer's disease
p14710
sg10
I19
sg28
VC1521724
p14711
sg13
I2
sasa(dp14712
g135
(dp14713
(VEphrinB2
p14714
Vhepatoma
p14715
tp14716
I00
ssg2
VEphrinB2 (erythropoietin-producing hepatoma interactor B2), a pivotal bidirectional signaling molecule ubiquitously expressed in mammals, is crucial in angiogenesis during development and disease progression.
p14717
sg4
(lp14718
(dp14719
g7
I10
sg8
Verythropoietin
p14720
sg10
I14
sg11
VP01588
p14721
sg13
I1
sa(dp14722
g7
I0
sg8
g14714
sg10
I8
sg11
VP52799
p14723
sg13
I1
sasg24
(lp14724
(dp14725
g7
I35
sg8
g14715
sg10
I8
sg28
VC0023903
p14726
sg13
I1
sa(dp14727
g7
I188
sg8
Vdisease progression
p14728
sg10
I19
sg28
VC0242656
p14729
sg13
I2
sasa(dp14730
g135
(dp14731
(Vendocrine gland-derived vascular endothelial growth factor
p14732
Vhepatocellular carcinoma
p14733
tp14734
I00
ssg2
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p14735
sg4
(lp14736
(dp14737
g7
I128
sg8
Vangiopoietin 2
p14738
sg10
I14
sg11
g12
sg13
I2
sa(dp14739
g7
I85
sg8
Vvascular endothelial growth factor
p14740
sg10
I34
sg11
g12
sg13
I4
sa(dp14741
g7
I151
sg8
VephrinB2
p14742
sg10
I8
sg11
VP52799
p14743
sg13
I1
sa(dp14744
g7
I224
sg8
VEG-VEGF
p14745
sg10
I7
sg11
VP58294
p14746
sg13
I1
sa(dp14747
g7
I164
sg8
g14732
sg10
I58
sg11
VP58294
p14748
sg13
I6
sa(dp14749
g7
I144
sg8
VAng2
p14750
sg10
I4
sg11
g12
sg13
I1
sa(dp14751
g7
I121
sg8
VVEGF
p14752
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp14753
(dp14754
g7
I334
sg8
VHCC
p14755
sg10
I3
sg28
VC2239176
p14756
sg13
I1
sa(dp14757
g7
I237
sg8
Vcarcinogenesis
p14758
sg10
I14
sg28
VC0596263
p14759
sg13
I1
sa(dp14760
g7
I267
sg8
Vtumor thrombus
p14761
sg10
I14
sg28
VC3163918
p14762
sg13
I2
sa(dp14763
g7
I308
sg8
g14733
sg10
I24
sg28
VC2239176
p14764
sg13
I2
sasa(dp14765
g2
VWe investigated whether the human MBX gene was associated with susceptibility to microphthalmia by analyzing four Korean families demonstrating microphthalmia with congenital cataract.
p14766
sg4
(lp14767
(dp14768
g7
I28
sg8
Vhuman MBX gene
p14769
sg10
I14
sg11
g12
sg13
I3
sasg24
(lp14770
(dp14771
g7
I81
sg8
Vmicrophthalmia
p14772
sg10
I14
sg28
VC0026010
p14773
sg13
I1
sa(dp14774
g7
I81
sg8
Vmicrophthalmia
p14775
sg10
I14
sg28
VC0026010
p14776
sg13
I1
sa(dp14777
g7
I164
sg8
Vcongenital cataract
p14778
sg10
I19
sg28
VC0009691
p14779
sg13
I2
sasa(dp14780
g2
VTherefore, no indications were found for an association between the MBX gene and microphthalmia with congenital cataract in humans.
p14781
sg4
(lp14782
(dp14783
g7
I68
sg8
VMBX gene
p14784
sg10
I8
sg11
g12
sg13
I2
sasg24
(lp14785
(dp14786
g7
I81
sg8
Vmicrophthalmia
p14787
sg10
I14
sg28
VC0026010
p14788
sg13
I1
sa(dp14789
g7
I101
sg8
Vcongenital cataract
p14790
sg10
I19
sg28
VC0009691
p14791
sg13
I2
sasa(dp14792
g2
VSequence changes have been observed for both NCKX1 and NCKX2 in patients with retinal diseases, but a definitive association with retinal disease has not been shown.
p14793
sg4
(lp14794
(dp14795
g7
I55
sg8
VNCKX2
p14796
sg10
I5
sg11
g12
sg13
I1
sa(dp14797
g7
I45
sg8
VNCKX1
p14798
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp14799
(dp14800
g7
I78
sg8
Vretinal disease
p14801
sg10
I15
sg28
VC0035309
p14802
sg13
I2
sa(dp14803
g7
I78
sg8
Vretinal diseases
p14804
sg10
I16
sg28
VC0035309
p14805
sg13
I2
sasa(dp14806
g135
(dp14807
(Vrod
p14808
Vretinal diseases
p14809
tp14810
I00
ssg2
VTo study the possible involvement of the rod (SLC24A1) and cone (SLC24A2) Na-Ca+K exchanger (NCKX) genes in retinal diseases.
p14811
sg4
(lp14812
(dp14813
g7
I74
sg8
VNa-Ca+K exchanger (NCKX) genes
p14814
sg10
I30
sg11
g12
sg13
I4
sa(dp14815
g7
I65
sg8
VSLC24A2
p14816
sg10
I7
sg11
g12
sg13
I1
sa(dp14817
g7
I41
sg8
g14808
sg10
I3
sg11
VP50748
p14818
sg13
I1
sa(dp14819
g7
I46
sg8
VSLC24A1
p14820
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp14821
(dp14822
g7
I108
sg8
g14809
sg10
I16
sg28
VC0035309
p14823
sg13
I2
sasa(dp14824
g135
(dp14825
(VBRCA1
p14826
Vprostate cancer
p14827
tp14828
I00
ssg2
VApproximately 23% of patients with metastatic castration-resistant prostate cancer exhibit somatic or germline aberrations in genes implicated in DNA repair, such as BRCA2, BRCA1, ATM, CHEK2, and PALB2, as well as mismatch repair genes.
p14829
sg4
(lp14830
(dp14831
g7
I166
sg8
VBRCA2
p14832
sg10
I5
sg11
VP51587
p14833
sg13
I1
sa(dp14834
g7
I196
sg8
VPALB2
p14835
sg10
I5
sg11
g12
sg13
I1
sa(dp14836
g7
I180
sg8
VATM
p14837
sg10
I3
sg11
g12
sg13
I1
sa(dp14838
g7
I173
sg8
g14826
sg10
I5
sg11
VP38398
p14839
sg13
I1
sasg24
(lp14840
(dp14841
g7
I67
sg8
g14827
sg10
I15
sg28
VC0600139
p14842
sg13
I2
sasa(dp14843
g135
(dp14844
(VMSH6
p14845
Vprostate cancer
p14846
tp14847
I00
ssg2
VMen who inherit pathogenic germline mutations in BRCA2 and BRCA1 are at increased risk of developing aggressive prostate cancer, and those with germline mutations in other DNA repair genes such as ATM, CHEK2, and MSH2/MSH6 may also have increased risks.
p14848
sg4
(lp14849
(dp14850
g7
I213
sg8
VMSH2
p14851
sg10
I4
sg11
VP43246
p14852
sg13
I1
sa(dp14853
g7
I197
sg8
VATM
p14854
sg10
I3
sg11
g12
sg13
I1
sa(dp14855
g7
I49
sg8
VBRCA2
p14856
sg10
I5
sg11
VP51587
p14857
sg13
I1
sa(dp14858
g7
I59
sg8
VBRCA1
p14859
sg10
I5
sg11
VP38398
p14860
sg13
I1
sa(dp14861
g7
I218
sg8
g14845
sg10
I4
sg11
VP52701
p14862
sg13
I1
sasg24
(lp14863
(dp14864
g7
I101
sg8
Vaggressive
p14865
sg10
I10
sg28
VC0001807
p14866
sg13
I1
sa(dp14867
g7
I112
sg8
g14846
sg10
I15
sg28
VC0600139
p14868
sg13
I2
sasa(dp14869
g2
VThe CHEK2 gene del5395 is a founder mutation in the Latvian population, which, however, does not have a direct impact on genetic predisposition toward colorectal, breast, ovarian and prostate cancer.
p14870
sg4
(lp14871
sg24
(lp14872
(dp14873
g7
I183
sg8
Vprostate cancer
p14874
sg10
I15
sg28
VC0600139
p14875
sg13
I2
sa(dp14876
g7
I28
sg8
Vfounder mutation
p14877
sg10
I16
sg28
VC2985435
p14878
sg13
I2
sasa(dp14879
g135
(dp14880
(VN-cadherin
p14881
Vmicrophthalmia
p14882
tp14883
I00
ssg2
VHuman limbal neurospheres expressed the neural lineage markers, Nestin, sex determining region box-2 and N-cadherin, and the retinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2 and orthodentical homeobox-2.
p14884
sg4
(lp14885
(dp14886
g7
I250
sg8
Vhomeobox-2
p14887
sg10
I10
sg11
VP52954
p14888
sg13
I1
sa(dp14889
g7
I64
sg8
VNestin, sex determining region box-2
p14890
sg10
I36
sg11
VP48681
p14891
sg13
I5
sa(dp14892
g7
I105
sg8
g14881
sg10
I10
sg11
VP19022
p14893
sg13
I1
sa(dp14894
g7
I125
sg8
Vretinal transcription factors microphthalmia-associated transcription factor, sex determining region box-2
p14895
sg10
I106
sg11
g12
sg13
I10
sasg24
(lp14896
(dp14897
g7
I155
sg8
g14882
sg10
I14
sg28
VC0026010
p14898
sg13
I1
sasa(dp14899
g135
(dp14900
(VOTX2
p14901
Vnyctalopia
p14902
tp14903
I00
ssg2
VMutations of orthodentricle homeobox 2 (OTX2) in human and mice often cause retinal dystrophy and nyctalopia, suggesting a role of OTX2 in mature retina, in addition to its functions in the development of the eye and retina.
p14904
sg4
(lp14905
(dp14906
g7
I40
sg8
VOTX2
p14907
sg10
I4
sg11
VP32243
p14908
sg13
I1
sa(dp14909
g7
I13
sg8
Vorthodentricle homeobox 2
p14910
sg10
I25
sg11
VP32243
p14911
sg13
I3
sa(dp14912
g7
I40
sg8
g14901
sg10
I4
sg11
VP32243
p14913
sg13
I1
sasg24
(lp14914
(dp14915
g7
I76
sg8
Vretinal dystrophy
p14916
sg10
I17
sg28
VC0854723
p14917
sg13
I2
sa(dp14918
g7
I98
sg8
g14902
sg10
I10
sg28
VC0028077
p14919
sg13
I1
sasa(dp14920
g135
(dp14921
(Vbradykinin
p14922
Vglomerulosclerosis
p14923
tp14924
I00
ssg2
VTHE ROLE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: Angiotensin-converting enzyme inhibitors (ACE) affect the different mechanisms that lead to glomerulosclerosis: antihypertensive effect, with the normalisation of blood pressure having demonstrated its determining role in the production of nephrosis in various epidemiological studies; hemodynamic effect with a decrease in glomerular capillary pressure, in the filtration fraction, and inhibition of the bradykinin deterioration; antiproteinuric effect superior to that of other anti-hypertensive drugs (excepting angiotensin II-receptor antagonists).
p14925
sg4
(lp14926
(dp14927
g7
I96
sg8
VACE
p14928
sg10
I3
sg11
VP12821
p14929
sg13
I1
sa(dp14930
g7
I569
sg8
Vangiotensin II-receptor
p14931
sg10
I23
sg11
VP01019
p14932
sg13
I2
sa(dp14933
g7
I54
sg8
VAngiotensin-converting enzyme inhibitors
p14934
sg10
I40
sg11
VP12821
p14935
sg13
I3
sa(dp14936
g7
I459
sg8
g14922
sg10
I10
sg11
VP01042
p14937
sg13
I1
sasg24
(lp14938
(dp14939
g7
I294
sg8
Vnephrosis
p14940
sg10
I9
sg28
VC0027720
p14941
sg13
I1
sa(dp14942
g7
I146
sg8
g14923
sg10
I18
sg28
VC0178664
p14943
sg13
I1
sasa(dp14944
g135
(dp14945
(Vangiotensin II
p14946
Vnephrosis
p14947
tp14948
I01
ssg2
VTo investigate whether the reduction in proteinuria is due to decreased generation of angiotensin II (AngII) or to decreased degradation of bradykinin, four series of experiments in established adriamycin nephrosis were performed.
p14949
sg4
(lp14950
(dp14951
g7
I140
sg8
Vbradykinin
p14952
sg10
I10
sg11
VP01042
p14953
sg13
I1
sa(dp14954
g7
I102
sg8
VAngII
p14955
sg10
I5
sg11
VP01019
p14956
sg13
I1
sa(dp14957
g7
I86
sg8
g14946
sg10
I14
sg11
VP01019
p14958
sg13
I2
sasg24
(lp14959
(dp14960
g7
I205
sg8
g14947
sg10
I9
sg28
VC0027720
p14961
sg13
I1
sasa(dp14962
g135
(dp14963
(Vkinin and kininogen
p14964
Vnephrotic syndrome
p14965
tp14966
I00
ssg2
VThere were few reports demonstrating behavior of kinin and kininogen in the nephrotic syndrome.
p14967
sg4
(lp14968
(dp14969
g7
I49
sg8
g14964
sg10
I19
sg11
VP01042
p14970
sg13
I3
sasg24
(lp14971
(dp14972
g7
I76
sg8
g14965
sg10
I18
sg28
VC0027726
p14973
sg13
I2
sasa(dp14974
g135
(dp14975
(Vprekallikrein (PK), high molecular weight kininogen
p14976
Vnephrotic syndrome
p14977
tp14978
I00
ssg2
VIn this paper, coagulation factors related to contact activation, such as factor XII (FXII), factor XI (FXI), prekallikrein (PK), high molecular weight kininogen (HMWKG), and kinins were measured in 15 cases of nephrotic syndrome, and clinical significance of these results were discussed.
p14979
sg4
(lp14980
(dp14981
g7
I74
sg8
Vfactor XII (FXII), factor XI
p14982
sg10
I28
sg11
VP00748
p14983
sg13
I5
sa(dp14984
g7
I86
sg8
VFXI
p14985
sg10
I3
sg11
g12
sg13
I1
sa(dp14986
g7
I110
sg8
g14976
sg10
I51
sg11
VP03952
p14987
sg13
I6
sasg24
(lp14988
(dp14989
g7
I211
sg8
g14977
sg10
I18
sg28
VC0027726
p14990
sg13
I2
sasa(dp14991
g2
VIt was concluded that kinin formation in the nephrotic syndrome was not due to the activation of intrinsic coagulation system but due to release of kinin from low molecular weight kininogen.
p14992
sg4
(lp14993
sg24
(lp14994
(dp14995
g7
I45
sg8
Vnephrotic syndrome
p14996
sg10
I18
sg28
VC0027726
p14997
sg13
I2
sasa(dp14998
g135
(dp14999
(VMMP-1
p15000
VCCh
p15001
tp15002
I00
ssg2
VTo investigate the role of anti-inflammatory TSG-6 in controlling MMP-1 and MMP-3, which have been shown to be upregulated in conjunctivochalasis (CCh).
p15003
sg4
(lp15004
(dp15005
g7
I45
sg8
VTSG-6
p15006
sg10
I5
sg11
VP98066
p15007
sg13
I1
sa(dp15008
g7
I76
sg8
VMMP-3
p15009
sg10
I5
sg11
VP08254
p15010
sg13
I1
sa(dp15011
g7
I66
sg8
g15000
sg10
I5
sg11
VP03956
p15012
sg13
I1
sasg24
(lp15013
(dp15014
g7
I126
sg8
Vconjunctivochalasis
p15015
sg10
I19
sg28
VC0878693
p15016
sg13
I1
sa(dp15017
g7
I147
sg8
g15001
sg10
I3
sg28
VC0878693
p15018
sg13
I1
sasa(dp15019
g135
(dp15020
(VANG
p15021
VALS/frontotemporal lobar degeneration
p15022
tp15023
I00
ssg2
VDirect sequencing analyses were performed in 19 genes, including ALS/frontotemporal lobar degeneration (FTLD)-related genes (SOD2, SOD3, ALS2/alsin, SMN1, PGRN, ANG, VEGF, VCP, VAPB, DCTN1, CHMP2B, and TARDBP or TDP-43), tauopathy-related gene (GSK3beta), and parkinsonism-related genes (alpha-synuclein, LRRK2, parkin, DJ-1, PINK1, and ATP13A2).
p15024
sg4
(lp15025
(dp15026
g7
I305
sg8
VLRRK2
p15027
sg10
I5
sg11
g12
sg13
I1
sa(dp15028
g7
I260
sg8
Vparkinsonism-related genes
p15029
sg10
I26
sg11
VP01893
p15030
sg13
I2
sa(dp15031
g7
I202
sg8
VTARDBP
p15032
sg10
I6
sg11
g12
sg13
I1
sa(dp15033
g7
I183
sg8
VDCTN1
p15034
sg10
I5
sg11
g12
sg13
I1
sa(dp15035
g7
I125
sg8
VSOD2
p15036
sg10
I4
sg11
VP04179
p15037
sg13
I1
sa(dp15038
g7
I288
sg8
Valpha-synuclein
p15039
sg10
I15
sg11
VP37840
p15040
sg13
I1
sa(dp15041
g7
I190
sg8
VCHMP2B
p15042
sg10
I6
sg11
g12
sg13
I1
sa(dp15043
g7
I177
sg8
VVAPB
p15044
sg10
I4
sg11
g12
sg13
I1
sa(dp15045
g7
I149
sg8
VSMN1
p15046
sg10
I4
sg11
g12
sg13
I1
sa(dp15047
g7
I320
sg8
VDJ-1
p15048
sg10
I4
sg11
g12
sg13
I1
sa(dp15049
g7
I172
sg8
VVCP
p15050
sg10
I3
sg11
VP55072
p15051
sg13
I1
sa(dp15052
g7
I137
sg8
VALS2
p15053
sg10
I4
sg11
g12
sg13
I1
sa(dp15054
g7
I142
sg8
Valsin
p15055
sg10
I5
sg11
g12
sg13
I1
sa(dp15056
g7
I212
sg8
VTDP-43
p15057
sg10
I6
sg11
g12
sg13
I1
sa(dp15058
g7
I326
sg8
VPINK1
p15059
sg10
I5
sg11
g12
sg13
I1
sa(dp15060
g7
I337
sg8
VATP13A2
p15061
sg10
I7
sg11
g12
sg13
I1
sa(dp15062
g7
I131
sg8
VSOD3
p15063
sg10
I4
sg11
VP08294
p15064
sg13
I1
sa(dp15065
g7
I161
sg8
g15021
sg10
I3
sg11
VP03950
p15066
sg13
I1
sasg24
(lp15067
(dp15068
g7
I137
sg8
VALS2
p15069
sg10
I4
sg28
VC1859807
p15070
sg13
I1
sa(dp15071
g7
I104
sg8
VFTLD
p15072
sg10
I4
sg28
VC0751072
p15073
sg13
I1
sa(dp15074
g7
I260
sg8
Vparkinsonism
p15075
sg10
I12
sg28
VC0242422
p15076
sg13
I1
sa(dp15077
g7
I221
sg8
Vtauopathy
p15078
sg10
I9
sg28
VC0949664
p15079
sg13
I1
sa(dp15080
g7
I65
sg8
g15022
sg10
I37
sg28
VC0751072
p15081
sg13
I3
sasa(dp15082
g2
VThis patient broadens the phenotypic spectrum of the 22q11.2 microduplication syndrome and raises the possibility that TUBA8 and USP18 may play an important role in the pathogenesis of amyoplasia.
p15083
sg4
(lp15084
(dp15085
g7
I119
sg8
VTUBA8
p15086
sg10
I5
sg11
g12
sg13
I1
sa(dp15087
g7
I129
sg8
VUSP18
p15088
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp15089
(dp15090
g7
I169
sg8
Vpathogenesis
p15091
sg10
I12
sg28
VC0699748
p15092
sg13
I1
sa(dp15093
g7
I78
sg8
Vsyndrome
p15094
sg10
I8
sg28
VC0039082
p15095
sg13
I1
sasa(dp15096
g2
VDespite the support for including patient-reported outcomes (PROs) and health-related quality of life in clinical trials, there have been deficiencies in how these have been assessed and reported in epithelial ovarian cancer (EOC) clinical trials.
p15097
sg4
(lp15098
sg24
(lp15099
(dp15100
g7
I199
sg8
Vepithelial ovarian cancer
p15101
sg10
I25
sg28
VC0677886
p15102
sg13
I3
sa(dp15103
g7
I226
sg8
VEOC
p15104
sg10
I3
sg28
VC0677886
p15105
sg13
I1
sasa(dp15106
g2
VTo redress this, the 5th Ovarian Cancer Consensus Conference, included a plenary session entitled 'How to include PROs in clinical trials'.
p15107
sg4
(lp15108
sg24
(lp15109
(dp15110
g7
I25
sg8
VOvarian Cancer
p15111
sg10
I14
sg28
VC1140680
p15112
sg13
I2
sasa(dp15113
g2
VTo test the hypothesis that ovarian cancer patients with worse PROs would drop out earlier, we examined how patients differed by time of dropout on health-related quality of life (HRQOL), anxiety, depression, optimism and insomnia.
p15114
sg4
(lp15115
sg24
(lp15116
(dp15117
g7
I28
sg8
Vovarian cancer
p15118
sg10
I14
sg28
VC1140680
p15119
sg13
I2
sa(dp15120
g7
I222
sg8
Vinsomnia
p15121
sg10
I8
sg28
VC0917801
p15122
sg13
I1
sa(dp15123
g7
I197
sg8
Vdepression
p15124
sg10
I10
sg28
VC0011581
p15125
sg13
I1
sasa(dp15126
g2
VProgression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial.
p15127
sg4
(lp15128
sg24
(lp15129
(dp15130
g7
I190
sg8
Vovarian cancer
p15131
sg10
I14
sg28
VC1140680
p15132
sg13
I2
sasa(dp15133
g2
VDespite increased recognition of the value of including patient-reported outcomes (PROs) as important end points in phase III clinical trials, there has been a lack of pre-specified PRO hypotheses and shortcomings with the analyses and interpretation of PROs in many ovarian cancer trials.
p15134
sg4
(lp15135
sg24
(lp15136
(dp15137
g7
I267
sg8
Vovarian cancer
p15138
sg10
I14
sg28
VC1140680
p15139
sg13
I2
sasa(dp15140
g2
VPromoting the importance of hypothesis-driven PROs in ovarian cancer clinical trials will lead to improvements in the design of these trials and the interpretation of their results.
p15141
sg4
(lp15142
sg24
(lp15143
(dp15144
g7
I54
sg8
Vovarian cancer
p15145
sg10
I14
sg28
VC1140680
p15146
sg13
I2
sasa(dp15147
g2
VWe conducted the Surgery in Ovarian Cancer Quality of life Evaluation Research study (SOCQER 1), a prospective study investigating the feasibility of collection of serial PROs in patients who had extensive surgery and standard surgery for ovarian cancer.
p15148
sg4
(lp15149
sg24
(lp15150
(dp15151
g7
I28
sg8
VOvarian Cancer
p15152
sg10
I14
sg28
VC1140680
p15153
sg13
I2
sa(dp15154
g7
I239
sg8
Vovarian cancer
p15155
sg10
I14
sg28
VC1140680
p15156
sg13
I2
sasa(dp15157
g2
VThere is no consensus as to what symptoms or quality-of-life (QOL) domains should be measured as patient-reported outcomes (PROs) in ovarian cancer clinical trials.
p15158
sg4
(lp15159
sg24
(lp15160
(dp15161
g7
I133
sg8
Vovarian cancer
p15162
sg10
I14
sg28
VC1140680
p15163
sg13
I2
sasa(dp15164
g2
VThe results were included in and combined with an expert consensus-building process to identify the most salient PROs for ovarian cancer clinical trials.
p15165
sg4
(lp15166
sg24
(lp15167
(dp15168
g7
I122
sg8
Vovarian cancer
p15169
sg10
I14
sg28
VC1140680
p15170
sg13
I2
sasa(dp15171
g135
(dp15172
(VPROs
p15173
Vcramping
p15174
tp15175
I00
ssg2
VWe identified a set of PROs specific to ovarian cancer: abdominal pain, bloating, cramping, fear of recurrence/disease progression, indigestion, sexual dysfunction, vomiting, weight gain, and weight loss.
p15176
sg4
(lp15177
(dp15178
g7
I23
sg8
g15173
sg10
I4
sg11
VP07225
p15179
sg13
I1
sasg24
(lp15180
(dp15181
g7
I132
sg8
Vindigestion
p15182
sg10
I11
sg28
VC0013395
p15183
sg13
I1
sa(dp15184
g7
I165
sg8
Vvomiting
p15185
sg10
I8
sg28
VC0042963
p15186
sg13
I1
sa(dp15187
g7
I72
sg8
Vbloating
p15188
sg10
I8
sg28
VC1291077
p15189
sg13
I1
sa(dp15190
g7
I56
sg8
Vabdominal pain
p15191
sg10
I14
sg28
VC0000737
p15192
sg13
I2
sa(dp15193
g7
I100
sg8
Vrecurrence
p15194
sg10
I10
sg28
VC1458156
p15195
sg13
I1
sa(dp15196
g7
I111
sg8
Vdisease progression
p15197
sg10
I19
sg28
VC0242656
p15198
sg13
I2
sa(dp15199
g7
I40
sg8
Vovarian cancer
p15200
sg10
I14
sg28
VC1140680
p15201
sg13
I2
sa(dp15202
g7
I145
sg8
Vsexual dysfunction
p15203
sg10
I18
sg28
VC0036877
p15204
sg13
I2
sa(dp15205
g7
I82
sg8
g15174
sg10
I8
sg28
VC1446787
p15206
sg13
I1
sasa(dp15207
g2
VFindings of the review and consensus process provide good support for use of these ovarian cancer-specific PROs in ovarian cancer clinical trials.
p15208
sg4
(lp15209
sg24
(lp15210
(dp15211
g7
I83
sg8
Vovarian cancer
p15212
sg10
I14
sg28
VC1140680
p15213
sg13
I2
sa(dp15214
g7
I83
sg8
Vovarian cancer
p15215
sg10
I14
sg28
VC1140680
p15216
sg13
I2
sasa(dp15217
g2
VMutations within this gene are responsible for kinesigenic paroxysmal dyskinesias (PKD) as well as for benign familial infantile epilepsy (BFIE), a disease associating infantile convulsions and choreoathetosis (ICCA), a form of familial hemiplegic migraine (FHM type 4), paroxysmal benign torticollis of childhood, and episodic ataxia.
p15218
sg4
(lp15219
sg24
(lp15220
(dp15221
g7
I319
sg8
Vepisodic ataxia
p15222
sg10
I15
sg28
VC1720189
p15223
sg13
I2
sa(dp15224
g7
I83
sg8
VPKD
p15225
sg10
I3
sg28
VC1868682
p15226
sg13
I1
sa(dp15227
g7
I258
sg8
VFHM
p15228
sg10
I3
sg28
VC1832894
p15229
sg13
I1
sa(dp15230
g7
I59
sg8
Vparoxysmal dyskinesias
p15231
sg10
I22
sg28
VC0752210
p15232
sg13
I2
sa(dp15233
g7
I211
sg8
VICCA
p15234
sg10
I4
sg28
VC1865926
p15235
sg13
I1
sa(dp15236
g7
I289
sg8
Vtorticollis
p15237
sg10
I11
sg28
VC0040485
p15238
sg13
I1
sa(dp15239
g7
I228
sg8
Vfamilial hemiplegic migraine
p15240
sg10
I28
sg28
VC0338484
p15241
sg13
I3
sa(dp15242
g7
I129
sg8
Vepilepsy
p15243
sg10
I8
sg28
VC0014544
p15244
sg13
I1
sa(dp15245
g7
I168
sg8
Vinfantile convulsions and choreoathetosis
p15246
sg10
I41
sg28
VC1865926
p15247
sg13
I4
sasa(dp15248
g2
VFHM type 4 is attributed to mutations in the PRRT2 gene, which encodes a proline-rich transmembrane protein of as yet unknown function.
p15249
sg4
(lp15250
(dp15251
g7
I45
sg8
VPRRT2 gene
p15252
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp15253
(dp15254
g7
I0
sg8
VFHM
p15255
sg10
I3
sg28
VC1832894
p15256
sg13
I1
sasa(dp15257
g135
(dp15258
(VSLC2A1
p15259
Vepisodic ataxia
p15260
tp15261
I01
ssg2
VTwo PRRT2 mutations were in familial hemiplegic migraine or episodic ataxia, one SLC2A1 family had episodic ataxia and one PNKD family had familial hemiplegic migraine alone.
p15262
sg4
(lp15263
(dp15264
g7
I123
sg8
VPNKD family
p15265
sg10
I11
sg11
g12
sg13
I2
sa(dp15266
g7
I4
sg8
VPRRT2 mutations
p15267
sg10
I15
sg11
g12
sg13
I2
sa(dp15268
g7
I81
sg8
g15259
sg10
I6
sg11
VP11166
p15269
sg13
I1
sasg24
(lp15270
(dp15271
g7
I60
sg8
Vepisodic ataxia
p15272
sg10
I15
sg28
VC1720189
p15273
sg13
I2
sa(dp15274
g7
I28
sg8
Vfamilial hemiplegic migraine
p15275
sg10
I28
sg28
VC0338484
p15276
sg13
I3
sa(dp15277
g7
I28
sg8
Vfamilial hemiplegic migraine
p15278
sg10
I28
sg28
VC0338484
p15279
sg13
I3
sa(dp15280
g7
I60
sg8
g15260
sg10
I15
sg28
VC1720189
p15281
sg13
I2
sasa(dp15282
g135
(dp15283
(VSLC2A1
p15284
Vfamilial hemiplegic migraine
p15285
tp15286
I01
ssg2
VSLC2A1 mutations were associated with variable phenotypes including paroxysmal kinesigenic dyskinesia, paroxysmal non-kinesigenic dyskinesia, episodic ataxia and myotonia and we identified a novel PNKD gene deletion in familial hemiplegic migraine.
p15287
sg4
(lp15288
(dp15289
g7
I197
sg8
VPNKD gene
p15290
sg10
I9
sg11
g12
sg13
I2
sa(dp15291
g7
I0
sg8
g15284
sg10
I6
sg11
VP11166
p15292
sg13
I1
sasg24
(lp15293
(dp15294
g7
I142
sg8
Vepisodic ataxia
p15295
sg10
I15
sg28
VC1720189
p15296
sg13
I2
sa(dp15297
g7
I68
sg8
Vparoxysmal kinesigenic dyskinesia
p15298
sg10
I33
sg28
VC1868682
p15299
sg13
I3
sa(dp15300
g7
I202
sg8
Vgene deletion
p15301
sg10
I13
sg28
VC1442161
p15302
sg13
I2
sa(dp15303
g7
I91
sg8
Vdyskinesia
p15304
sg10
I10
sg28
VC0013384
p15305
sg13
I1
sa(dp15306
g7
I219
sg8
g15285
sg10
I28
sg28
VC0338484
p15307
sg13
I3
sasa(dp15308
g2
VWe assessed the clinical features of both FHM families and performed direct sequencing of all coding exons (and adjacent sequences) of the CACNA1A, ATP1A2, PRRT2 and SCN1A genes.
p15309
sg4
(lp15310
(dp15311
g7
I148
sg8
VATP1A2
p15312
sg10
I6
sg11
VP50993
p15313
sg13
I1
sa(dp15314
g7
I166
sg8
VSCN1A genes
p15315
sg10
I11
sg11
VP35498
p15316
sg13
I2
sa(dp15317
g7
I42
sg8
VFHM families
p15318
sg10
I12
sg11
VP19883
p15319
sg13
I2
sa(dp15320
g7
I156
sg8
VPRRT2
p15321
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp15322
(dp15323
g7
I42
sg8
VFHM
p15324
sg10
I3
sg28
VC1832894
p15325
sg13
I1
sasa(dp15326
g2
VIn 2012, PRRT2 has been identified as the fourth FHM gene, and encodes an axonal protein associated to the exocytosis complex.
p15327
sg4
(lp15328
(dp15329
g7
I9
sg8
VPRRT2
p15330
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp15331
(dp15332
g7
I49
sg8
VFHM
p15333
sg10
I3
sg28
VC1832894
p15334
sg13
I1
sasa(dp15335
g2
VTo characterise the phenotype of a family with paroxysmal exercise induced dystonia (PED) and migraine and establish whether it is linked to the paroxysmal non-kinesigenic dyskinesia (PNKD) locus on chromosome 2q33-35, the familial hemiplegic migraine (FHM) locus on chromosome 19p, or the familial infantile convulsions and paroxysmal choreoathetosis (ICCA syndrome) locus on chromosome 16.
p15336
sg4
(lp15337
sg24
(lp15338
(dp15339
g7
I172
sg8
Vdyskinesia
p15340
sg10
I10
sg28
VC0013384
p15341
sg13
I1
sa(dp15342
g7
I253
sg8
VFHM
p15343
sg10
I3
sg28
VC1832894
p15344
sg13
I1
sa(dp15345
g7
I309
sg8
Vconvulsions
p15346
sg10
I11
sg28
VC0009951
p15347
sg13
I1
sa(dp15348
g7
I358
sg8
Vsyndrome
p15349
sg10
I8
sg28
VC0039082
p15350
sg13
I1
sa(dp15351
g7
I75
sg8
Vdystonia
p15352
sg10
I8
sg28
VC0393593
p15353
sg13
I1
sa(dp15354
g7
I223
sg8
Vfamilial hemiplegic migraine
p15355
sg10
I28
sg28
VC0338484
p15356
sg13
I3
sa(dp15357
g7
I58
sg8
Vexercise induced
p15358
sg10
I16
sg28
VC0239313
p15359
sg13
I2
sa(dp15360
g7
I94
sg8
Vmigraine
p15361
sg10
I8
sg28
VC0149931
p15362
sg13
I1
sa(dp15363
g7
I353
sg8
VICCA
p15364
sg10
I4
sg28
VC1865926
p15365
sg13
I1
sa(dp15366
g7
I325
sg8
Vparoxysmal choreoathetosis
p15367
sg10
I26
sg28
VC1868682
p15368
sg13
I2
sasa(dp15369
g2
VHaplotypes were reconstructed for all the available family members by typing several microsatellite markers spanning the PNKD, FHM, and ICCA loci.
p15370
sg4
(lp15371
(dp15372
g7
I121
sg8
VPNKD
p15373
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp15374
(dp15375
g7
I127
sg8
VFHM
p15376
sg10
I3
sg28
VC1832894
p15377
sg13
I1
sa(dp15378
g7
I136
sg8
VICCA
p15379
sg10
I4
sg28
VC1865926
p15380
sg13
I1
sasa(dp15381
g2
VLinkage of the disease to the PNKD, FHM, or ICCA loci was excluded as no common haplotype was shared by all the affected members for each locus.
p15382
sg4
(lp15383
(dp15384
g7
I30
sg8
VPNKD
p15385
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp15386
(dp15387
g7
I44
sg8
VICCA
p15388
sg10
I4
sg28
VC1865926
p15389
sg13
I1
sa(dp15390
g7
I36
sg8
VFHM
p15391
sg10
I3
sg28
VC1832894
p15392
sg13
I1
sasa(dp15393
g2
VThis family presented with the classic phenotype of PED and is not linked to the PNKD, FHM, or ICCA loci.
p15394
sg4
(lp15395
(dp15396
g7
I81
sg8
VPNKD
p15397
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp15398
(dp15399
g7
I87
sg8
VFHM
p15400
sg10
I3
sg28
VC1832894
p15401
sg13
I1
sa(dp15402
g7
I95
sg8
VICCA
p15403
sg10
I4
sg28
VC1865926
p15404
sg13
I1
sasa(dp15405
g2
VThe (FZr-EUl/FZl-EUr) and (FZr-EUr)/(FZl-EUl) were used for the patients with unicoronal craniosynostosis.
p15406
sg4
(lp15407
sg24
(lp15408
(dp15409
g7
I78
sg8
Vunicoronal craniosynostosis
p15410
sg10
I27
sg28
VC0432124
p15411
sg13
I2
sasa(dp15412
g2
VOur findings indicated that all evaluated parameters (epididymal sperm profile, Johnsen score, Plzf, GfrAlfa-1, Scp-1, Tekt-1 expressions, and histopathological profile) were significantly decreased following testicular torsion (group 3) when compared to the control group (p &lt;= 0.05).
p15413
sg4
(lp15414
(dp15415
g7
I112
sg8
VScp-1
p15416
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp15417
(dp15418
g7
I209
sg8
Vtesticular torsion
p15419
sg10
I18
sg28
VC0037856
p15420
sg13
I2
sasa(dp15421
g2
VDyschromatosis symmetrica hereditaria (DSH) is a rare type of pigmentary genodermatosis, which is autosomal dominantly inherited with high penetrance.
p15422
sg4
(lp15423
sg24
(lp15424
(dp15425
g7
I39
sg8
VDSH
p15426
sg10
I3
sg28
VC0406775
p15427
sg13
I1
sa(dp15428
g7
I73
sg8
Vgenodermatosis
p15429
sg10
I14
sg28
VC0037277
p15430
sg13
I1
sa(dp15431
g7
I0
sg8
VDyschromatosis symmetrica hereditaria
p15432
sg10
I37
sg28
VC0406775
p15433
sg13
I3
sasa(dp15434
g135
(dp15435
(VDSH
p15436
VDSH
p15437
tp15438
I00
ssg2
VThe onset of DSH is typically during infancy or childhood.
p15439
sg4
(lp15440
(dp15441
g7
I13
sg8
g15436
sg10
I3
sg11
VP55265
p15442
sg13
I1
sasg24
(lp15443
(dp15444
g7
I13
sg8
g15437
sg10
I3
sg28
VC0406775
p15445
sg13
I1
sasa(dp15446
g135
(dp15447
(VDSH
p15448
VDSH
p15449
tp15450
I00
ssg2
VAdditionally, there have been few significant non-cutaneous complications reported with DSH.
p15451
sg4
(lp15452
(dp15453
g7
I88
sg8
g15448
sg10
I3
sg11
VP55265
p15454
sg13
I1
sasg24
(lp15455
(dp15456
g7
I88
sg8
g15449
sg10
I3
sg28
VC0406775
p15457
sg13
I1
sasa(dp15458
g135
(dp15459
(VADAR1
p15460
VDSH
p15461
tp15462
I00
ssg2
VThe present study reported two sporadic cases of patients born with DSH, confirmed by the identification of ADAR1 mutations.
p15463
sg4
(lp15464
(dp15465
g7
I68
sg8
VDSH
p15466
sg10
I3
sg11
VP55265
p15467
sg13
I1
sa(dp15468
g7
I108
sg8
g15460
sg10
I5
sg11
VP55265
p15469
sg13
I1
sasg24
(lp15470
(dp15471
g7
I68
sg8
g15461
sg10
I3
sg28
VC0406775
p15472
sg13
I1
sasa(dp15473
g135
(dp15474
(VDSH
p15475
VDSH
p15476
tp15477
I00
ssg2
VAdditionally, comorbidity of DSH, congenital heart disease (CHD) and hemangioma disease were first reported.
p15478
sg4
(lp15479
(dp15480
g7
I29
sg8
g15475
sg10
I3
sg11
VP55265
p15481
sg13
I1
sasg24
(lp15482
(dp15483
g7
I69
sg8
Vhemangioma
p15484
sg10
I10
sg28
VC0018916
p15485
sg13
I1
sa(dp15486
g7
I60
sg8
VCHD
p15487
sg10
I3
sg28
VC0152021
p15488
sg13
I1
sa(dp15489
g7
I34
sg8
Vcongenital heart disease
p15490
sg10
I24
sg28
VC0152021
p15491
sg13
I3
sa(dp15492
g7
I29
sg8
g15476
sg10
I3
sg28
VC0406775
p15493
sg13
I1
sasa(dp15494
g135
(dp15495
(VDSH
p15496
VDSH
p15497
tp15498
I00
ssg2
VIn the patient with isolated DSH from birth, a nonsense mutation (p.Y1192X) was identified, whereas in the second patient with DSH, CHD and hemangioma from birth, a frameshift mutation (p.Glu673ValfsX652) in ADAR1 was identified.
p15499
sg4
(lp15500
(dp15501
g7
I208
sg8
VADAR1
p15502
sg10
I5
sg11
VP55265
p15503
sg13
I1
sa(dp15504
g7
I29
sg8
g15496
sg10
I3
sg11
VP55265
p15505
sg13
I1
sasg24
(lp15506
(dp15507
g7
I47
sg8
Vnonsense mutation
p15508
sg10
I17
sg28
VC0544885
p15509
sg13
I2
sa(dp15510
g7
I140
sg8
Vhemangioma
p15511
sg10
I10
sg28
VC0018916
p15512
sg13
I1
sa(dp15513
g7
I29
sg8
VDSH
p15514
sg10
I3
sg28
VC0406775
p15515
sg13
I1
sa(dp15516
g7
I29
sg8
g15497
sg10
I3
sg28
VC0406775
p15517
sg13
I1
sa(dp15518
g7
I165
sg8
Vframeshift mutation
p15519
sg10
I19
sg28
VC0079380
p15520
sg13
I2
sasa(dp15521
g135
(dp15522
(VADAR1
p15523
VDSH
p15524
tp15525
I00
ssg2
VTo the best of the authors' knowledge, &gt;120 mutations in ADAR1 have been reported to cause DSH; however, no previous studies have reported mutations in ADAR1 in DSH at birth, with CHD and hemangioma.
p15526
sg4
(lp15527
(dp15528
g7
I60
sg8
VADAR1
p15529
sg10
I5
sg11
VP55265
p15530
sg13
I1
sa(dp15531
g7
I94
sg8
VDSH
p15532
sg10
I3
sg11
VP55265
p15533
sg13
I1
sa(dp15534
g7
I60
sg8
g15523
sg10
I5
sg11
VP55265
p15535
sg13
I1
sasg24
(lp15536
(dp15537
g7
I191
sg8
Vhemangioma
p15538
sg10
I10
sg28
VC0018916
p15539
sg13
I1
sa(dp15540
g7
I94
sg8
VDSH
p15541
sg10
I3
sg28
VC0406775
p15542
sg13
I1
sa(dp15543
g7
I94
sg8
g15524
sg10
I3
sg28
VC0406775
p15544
sg13
I1
sasa(dp15545
g135
(dp15546
(VADAR1
p15547
VDSH
p15548
tp15549
I00
ssg2
VThe novel variants described in the current study add to the current knowledge of ADAR1 mutations in DSH.
p15550
sg4
(lp15551
(dp15552
g7
I101
sg8
VDSH
p15553
sg10
I3
sg11
VP55265
p15554
sg13
I1
sa(dp15555
g7
I82
sg8
g15547
sg10
I5
sg11
VP55265
p15556
sg13
I1
sasg24
(lp15557
(dp15558
g7
I101
sg8
g15548
sg10
I3
sg28
VC0406775
p15559
sg13
I1
sa(dp15560
g7
I50
sg8
Vadd
p15561
sg10
I3
sg28
VC0004269
p15562
sg13
I1
sasa(dp15563
g135
(dp15564
(VADAR gene
p15565
Vencephalopathy
p15566
tp15567
I00
ssg2
VPathogenic molecular variants in the ADAR gene are a known cause of rare diseases, autosomal recessive Aicardi- Goutieres syndrome type 6, severe infantile encephalopathy with intracranial calcifications and dominant dyschromatosis symmetrica hereditaria, demonstrated mainly in Asian adults.
p15568
sg4
(lp15569
(dp15570
g7
I37
sg8
g15565
sg10
I9
sg11
VP55265
p15571
sg13
I2
sasg24
(lp15572
(dp15573
g7
I122
sg8
Vsyndrome
p15574
sg10
I8
sg28
VC0039082
p15575
sg13
I1
sa(dp15576
g7
I217
sg8
Vdyschromatosis symmetrica hereditaria
p15577
sg10
I37
sg28
VC0406775
p15578
sg13
I3
sa(dp15579
g7
I68
sg8
Vrare diseases
p15580
sg10
I13
sg28
VC0678236
p15581
sg13
I2
sa(dp15582
g7
I156
sg8
g15566
sg10
I14
sg28
VC0085584
p15583
sg13
I1
sasa(dp15584
g135
(dp15585
(VADAR1 gene
p15586
Vdyschromatosis symmetrica hereditaria
p15587
tp15588
I00
ssg2
VTo identify potential mutation of the ADAR1 gene in a Chinese family and a sporadic case affected with dyschromatosis symmetrica hereditaria(DSH).
p15589
sg4
(lp15590
(dp15591
g7
I38
sg8
g15586
sg10
I10
sg11
VP55265
p15592
sg13
I2
sasg24
(lp15593
(dp15594
g7
I141
sg8
VDSH
p15595
sg10
I3
sg28
VC0406775
p15596
sg13
I1
sa(dp15597
g7
I103
sg8
g15587
sg10
I37
sg28
VC0406775
p15598
sg13
I3
sasa(dp15599
g135
(dp15600
(VADAR1 gene
p15601
VDSH
p15602
tp15603
I00
ssg2
VThe frame-shift mutation c.2638delG (p.Asp880ThrfsX15) and the nonsense mutation c.2867C&gt;A (p.Ser956X) in the ADAR1 gene probably underlie the DSH in our patients.
p15604
sg4
(lp15605
(dp15606
g7
I146
sg8
VDSH
p15607
sg10
I3
sg11
VP55265
p15608
sg13
I1
sa(dp15609
g7
I113
sg8
g15601
sg10
I10
sg11
VP55265
p15610
sg13
I2
sasg24
(lp15611
(dp15612
g7
I146
sg8
g15602
sg10
I3
sg28
VC0406775
p15613
sg13
I1
sa(dp15614
g7
I63
sg8
Vnonsense mutation
p15615
sg10
I17
sg28
VC0544885
p15616
sg13
I2
sasa(dp15617
g135
(dp15618
(Vadenosine deaminase acting on RNA1
p15619
VDyschromatosis symmetrica hereditaria
p15620
tp15621
I00
ssg2
VDyschromatosis symmetrica hereditaria (DSH) is a rare autosomal dominant cutaneous disorder caused by the mutations of adenosine deaminase acting on RNA1 (ADAR1) gene.
p15622
sg4
(lp15623
(dp15624
g7
I155
sg8
VADAR1
p15625
sg10
I5
sg11
VP55265
p15626
sg13
I1
sa(dp15627
g7
I119
sg8
g15619
sg10
I34
sg11
VP55265
p15628
sg13
I5
sasg24
(lp15629
(dp15630
g7
I39
sg8
VDSH
p15631
sg10
I3
sg28
VC0406775
p15632
sg13
I1
sa(dp15633
g7
I73
sg8
Vcutaneous disorder
p15634
sg10
I18
sg28
VC0037274
p15635
sg13
I2
sa(dp15636
g7
I0
sg8
g15620
sg10
I37
sg28
VC0406775
p15637
sg13
I3
sasa(dp15638
g135
(dp15639
(VADAR1 gene
p15640
VDSH
p15641
tp15642
I00
ssg2
VWe present a clinical and genetic study of seven unrelated families and two sporadic cases with DSH for mutations in the full coding sequence of ADAR1 gene.
p15643
sg4
(lp15644
(dp15645
g7
I96
sg8
VDSH
p15646
sg10
I3
sg11
VP55265
p15647
sg13
I1
sa(dp15648
g7
I145
sg8
g15640
sg10
I10
sg11
VP55265
p15649
sg13
I2
sasg24
(lp15650
(dp15651
g7
I96
sg8
g15641
sg10
I3
sg28
VC0406775
p15652
sg13
I1
sasa(dp15653
g135
(dp15654
(VADAR1 gene
p15655
VDSH
p15656
tp15657
I00
ssg2
VADAR1 gene was sequenced in seven unrelated families and two sporadic cases with DSH and 120 controls.
p15658
sg4
(lp15659
(dp15660
g7
I0
sg8
g15655
sg10
I10
sg11
VP55265
p15661
sg13
I2
sasg24
(lp15662
(dp15663
g7
I81
sg8
g15656
sg10
I3
sg28
VC0406775
p15664
sg13
I1
sasa(dp15665
g135
(dp15666
(VADAR1 gene
p15667
VDSH
p15668
tp15669
I00
ssg2
VWe describe six novel mutations of the ADAR1 gene in Chinese patients with DSH including a nonstop mutation p.Stop1227R, which was firstly reported in ADAR1 gene.
p15670
sg4
(lp15671
(dp15672
g7
I39
sg8
VADAR1 gene
p15673
sg10
I10
sg11
VP55265
p15674
sg13
I2
sa(dp15675
g7
I39
sg8
g15667
sg10
I10
sg11
VP55265
p15676
sg13
I2
sasg24
(lp15677
(dp15678
g7
I75
sg8
g15668
sg10
I3
sg28
VC0406775
p15679
sg13
I1
sasa(dp15680
g135
(dp15681
(VADAR1
p15682
Vchilblain
p15683
tp15684
I00
ssg2
VA three-generation family exhibiting phenotypic variability with a single germline ADAR1 mutation suggests that chilblain might aggravate the clinical phenotypes of DSH.
p15685
sg4
(lp15686
(dp15687
g7
I165
sg8
VDSH
p15688
sg10
I3
sg11
VP55265
p15689
sg13
I1
sa(dp15690
g7
I83
sg8
g15682
sg10
I5
sg11
VP55265
p15691
sg13
I1
sasg24
(lp15692
(dp15693
g7
I165
sg8
VDSH
p15694
sg10
I3
sg28
VC0406775
p15695
sg13
I1
sa(dp15696
g7
I112
sg8
g15683
sg10
I9
sg28
VC0008058
p15697
sg13
I1
sasa(dp15698
g2
VAll patients underwent upper endoscopy and subsequently liver CT. Three radiologists independently evaluated the presence of high-risk esophageal varices with transverse images alone and with three orthogonal multiplanar reformation (MPR) images, respectively.
p15699
sg4
(lp15700
sg24
(lp15701
(dp15702
g7
I135
sg8
Vesophageal varices
p15703
sg10
I18
sg28
VC0014867
p15704
sg13
I2
sasa(dp15705
g2
VTo study the correlation between changes in portosystemic collaterals, evaluated by multidetector-row computed tomography imaging using multiplanar reconstruction (MDCT-MPR), and prognosis in patients with hemorrhagic esophageal varices (EV) after endoscopic treatment.
p15706
sg4
(lp15707
(dp15708
g7
I164
sg8
VMDCT-MPR
p15709
sg10
I8
sg11
g12
sg13
I1
sa(dp15710
g7
I84
sg8
Vmultidetector-row computed tomography imaging using multiplanar reconstruction
p15711
sg10
I78
sg11
g12
sg13
I7
sasg24
(lp15712
(dp15713
g7
I238
sg8
VEV
p15714
sg10
I2
sg28
VC0014867
p15715
sg13
I1
sa(dp15716
g7
I218
sg8
Vesophageal varices
p15717
sg10
I18
sg28
VC0014867
p15718
sg13
I2
sasa(dp15719
g2
VThe purpose of our study was to assess the relationship between hemodynamic changes in portosystemic collaterals and the prognosis of patients with esophageal varices after endoscopic injection sclerotherapy using multiplanar reconstruction (MPR) MDCT images.
p15720
sg4
(lp15721
sg24
(lp15722
(dp15723
g7
I148
sg8
Vesophageal varices
p15724
sg10
I18
sg28
VC0014867
p15725
sg13
I2
sasa(dp15726
g2
VMPR MDCT images on portosystemic collaterals can accurately predict relapse of esophageal varices after endoscopic injection sclerotherapy.
p15727
sg4
(lp15728
sg24
(lp15729
(dp15730
g7
I68
sg8
Vrelapse
p15731
sg10
I7
sg28
VC0277556
p15732
sg13
I1
sa(dp15733
g7
I79
sg8
Vesophageal varices
p15734
sg10
I18
sg28
VC0014867
p15735
sg13
I2
sasa(dp15736
g135
(dp15737
(VXPD
p15738
VXPD
p15739
tp15740
I00
ssg2
VTTD is caused by mutations in DNA repair/transcription genes XPD, XPB or TTDA, and in TTDN1, a gene of unknown function.
p15741
sg4
(lp15742
(dp15743
g7
I66
sg8
VXPB
p15744
sg10
I3
sg11
VP19447
p15745
sg13
I1
sa(dp15746
g7
I61
sg8
g15738
sg10
I3
sg11
VP18074
p15747
sg13
I1
sa(dp15748
g7
I73
sg8
VTTDA
p15749
sg10
I4
sg11
g12
sg13
I1
sa(dp15750
g7
I86
sg8
VTTDN1
p15751
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp15752
(dp15753
g7
I66
sg8
VXPB
p15754
sg10
I3
sg28
VC0268136
p15755
sg13
I1
sa(dp15756
g7
I61
sg8
g15739
sg10
I3
sg28
VC0268138
p15757
sg13
I1
sa(dp15758
g7
I86
sg8
VTTDN1
p15759
sg10
I5
sg28
VC1961117
p15760
sg13
I1
sasa(dp15761
g135
(dp15762
(VXPB
p15763
VXPB
p15764
tp15765
I00
ssg2
VTo date, four genes have been identified as responsible for TTD: XPD, XPB, p8/TTDA, and TTDN1.
p15766
sg4
(lp15767
(dp15768
g7
I65
sg8
VXPD
p15769
sg10
I3
sg11
VP18074
p15770
sg13
I1
sa(dp15771
g7
I70
sg8
g15763
sg10
I3
sg11
VP19447
p15772
sg13
I1
sa(dp15773
g7
I88
sg8
VTTDN1
p15774
sg10
I5
sg11
g12
sg13
I1
sa(dp15775
g7
I78
sg8
VTTDA
p15776
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp15777
(dp15778
g7
I65
sg8
VXPD
p15779
sg10
I3
sg28
VC0268138
p15780
sg13
I1
sa(dp15781
g7
I70
sg8
g15764
sg10
I3
sg28
VC0268136
p15782
sg13
I1
sa(dp15783
g7
I88
sg8
VTTDN1
p15784
sg10
I5
sg28
VC1961117
p15785
sg13
I1
sasa(dp15786
g135
(dp15787
(VHsp90 families
p15788
Vscrapie
p15789
tp15790
I00
ssg2
VWe analysed the gene expression and protein distribution of different members of the Hsp27, Hsp70, and Hsp90 families in the central nervous system of sheep naturally infected with scrapie.
p15791
sg4
(lp15792
(dp15793
g7
I92
sg8
VHsp70
p15794
sg10
I5
sg11
VP34932
p15795
sg13
I1
sa(dp15796
g7
I103
sg8
g15788
sg10
I14
sg11
VP19883
p15797
sg13
I2
sa(dp15798
g7
I85
sg8
VHsp27
p15799
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp15800
(dp15801
g7
I181
sg8
g15789
sg10
I7
sg28
VC0036457
p15802
sg13
I1
sa(dp15803
g7
I133
sg8
Vnervous
p15804
sg10
I7
sg28
VC0027769
p15805
sg13
I1
sasa(dp15806
g2
VWe have previously shown that scrapie-infected mouse neuroblastoma (ScN2a) cells fail to induce the expression of Hsp72 and Hsp28 after various stress conditions.
p15807
sg4
(lp15808
(dp15809
g7
I114
sg8
VHsp72
p15810
sg10
I5
sg11
VP08107
p15811
sg13
I1
sasg24
(lp15812
(dp15813
g7
I30
sg8
Vscrapie
p15814
sg10
I7
sg28
VC0036457
p15815
sg13
I1
sa(dp15816
g7
I47
sg8
Vmouse neuroblastoma
p15817
sg10
I19
sg28
VC1524043
p15818
sg13
I2
sasa(dp15819
g2
VIn scrapie-infected N2a (ScN2a) cells, Hsp72 and Hsp28 were not induced by heat shock, sodium arsenite, or an amino acid analog, in contrast to uninfected control N2a cells, while other inducible Hsps were increased by these treatments.
p15820
sg4
(lp15821
(dp15822
g7
I39
sg8
VHsp72
p15823
sg10
I5
sg11
VP08107
p15824
sg13
I1
sa(dp15825
g7
I196
sg8
VHsps
p15826
sg10
I4
sg11
VP08107
p15827
sg13
I1
sa(dp15828
g7
I25
sg8
VScN2a
p15829
sg10
I5
sg11
g12
sg13
I1
sa(dp15830
g7
I3
sg8
Vscrapie-infected N2a
p15831
sg10
I20
sg11
g12
sg13
I2
sasg24
(lp15832
(dp15833
g7
I3
sg8
Vscrapie
p15834
sg10
I7
sg28
VC0036457
p15835
sg13
I1
sasa(dp15836
g135
(dp15837
(VRIP4
p15838
Vlung adenocarcinoma
p15839
tp15840
I00
ssg2
VWe have identified Receptor-interacting serine/threonine protein kinase 4 (RIP4) as a regulator of tumor differentiation in lung adenocarcinoma (AC).
p15841
sg4
(lp15842
(dp15843
g7
I75
sg8
g15838
sg10
I4
sg11
VP57078
p15844
sg13
I1
sa(dp15845
g7
I19
sg8
VReceptor-interacting serine/threonine protein kinase 4
p15846
sg10
I54
sg11
g12
sg13
I5
sasg24
(lp15847
(dp15848
g7
I99
sg8
Vtumor
p15849
sg10
I5
sg28
VC0027651
p15850
sg13
I1
sa(dp15851
g7
I124
sg8
g15839
sg10
I19
sg28
VC0152013
p15852
sg13
I2
sasa(dp15853
g135
(dp15854
(VRIP4
p15855
Vdedifferentiation
p15856
tp15857
I00
ssg2
VAltogether, our work has identified that loss of RIP4 enhances STAT3 signaling in lung cancer cells, promoting the expression of ECM remodeling genes and cancer dedifferentiation.
p15858
sg4
(lp15859
(dp15860
g7
I129
sg8
VECM remodeling genes
p15861
sg10
I20
sg11
g12
sg13
I3
sa(dp15862
g7
I63
sg8
VSTAT3
p15863
sg10
I5
sg11
VP40763
p15864
sg13
I1
sa(dp15865
g7
I49
sg8
g15855
sg10
I4
sg11
VP57078
p15866
sg13
I1
sasg24
(lp15867
(dp15868
g7
I82
sg8
Vlung cancer
p15869
sg10
I11
sg28
VC0684249
p15870
sg13
I2
sa(dp15871
g7
I87
sg8
Vcancer
p15872
sg10
I6
sg28
VC0006826
p15873
sg13
I1
sa(dp15874
g7
I161
sg8
g15856
sg10
I17
sg28
VC0002793
p15875
sg13
I1
sasa(dp15876
g135
(dp15877
(VRIPK4
p15878
Vcervical cancer
p15879
tp15880
I01
ssg2
VIn conclusion, our data suggest that RIPK4/EZH2 markers might be used as potential predictors of prognosis in cervical cancer.
p15881
sg4
(lp15882
(dp15883
g7
I43
sg8
VEZH2
p15884
sg10
I4
sg11
g12
sg13
I1
sa(dp15885
g7
I37
sg8
g15878
sg10
I5
sg11
VP57078
p15886
sg13
I1
sasg24
(lp15887
(dp15888
g7
I110
sg8
g15879
sg10
I15
sg28
VC0302592
p15889
sg13
I2
sasa(dp15890
g135
(dp15891
(VRIPK4
p15892
VCRC
p15893
tp15894
I00
ssg2
VTo investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.
p15895
sg4
(lp15896
(dp15897
g7
I78
sg8
g15892
sg10
I5
sg11
VP57078
p15898
sg13
I1
sa(dp15899
g7
I39
sg8
Vreceptor-interacting kinase protein 4
p15900
sg10
I37
sg11
g12
sg13
I4
sasg24
(lp15901
(dp15902
g7
I140
sg8
Vcolorectal cancer
p15903
sg10
I17
sg28
VC1527249
p15904
sg13
I2
sa(dp15905
g7
I159
sg8
g15893
sg10
I3
sg28
VC1527249
p15906
sg13
I1
sasa(dp15907
g135
(dp15908
(VRIPK4 RCN
p15909
VRFS
p15910
tp15911
I00
ssg2
VIn colon cancer subgroup, high RIPK4 RCN was significantly associated with poor OS (median OS, 31.5 months vs. 56.6 months, P=0.015) but not with RFS (P=0.135).
p15912
sg4
(lp15913
(dp15914
g7
I31
sg8
g15909
sg10
I9
sg11
VP57078
p15915
sg13
I2
sasg24
(lp15916
(dp15917
g7
I3
sg8
Vcolon cancer
p15918
sg10
I12
sg28
VC0699790
p15919
sg13
I2
sa(dp15920
g7
I146
sg8
g15910
sg10
I3
sg28
VC0015624
p15921
sg13
I1
sasa(dp15922
g135
(dp15923
(VRIPK4 RCN
p15924
VRFS
p15925
tp15926
I00
ssg2
VIn rectal cancer subgroup, RIPK4 RCN was not associated with both OS and RFS (P=0.981, P=0.738).
p15927
sg4
(lp15928
(dp15929
g7
I27
sg8
g15924
sg10
I9
sg11
VP57078
p15930
sg13
I2
sasg24
(lp15931
(dp15932
g7
I3
sg8
Vrectal cancer
p15933
sg10
I13
sg28
VC0007113
p15934
sg13
I2
sa(dp15935
g7
I73
sg8
g15925
sg10
I3
sg28
VC0015624
p15936
sg13
I1
sasa(dp15937
g135
(dp15938
(VRIPK4 RCN
p15939
Vcolon cancer
p15940
tp15941
I00
ssg2
VRIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.
p15942
sg4
(lp15943
(dp15944
g7
I0
sg8
g15939
sg10
I9
sg11
VP57078
p15945
sg13
I2
sasg24
(lp15946
(dp15947
g7
I60
sg8
Vcolon cancer
p15948
sg10
I12
sg28
VC0699790
p15949
sg13
I2
sa(dp15950
g7
I60
sg8
g15940
sg10
I12
sg28
VC0699790
p15951
sg13
I2
sasa(dp15952
g2
VAberrant expression of receptor interacting protein kinase 4 (RIPK4), a crucial regulatory protein of Wnt/Beta-catenin signaling, has recently been reported to be involved in several cancers.
p15953
sg4
(lp15954
(dp15955
g7
I62
sg8
VRIPK4
p15956
sg10
I5
sg11
VP57078
p15957
sg13
I1
sa(dp15958
g7
I23
sg8
Vreceptor interacting protein kinase 4
p15959
sg10
I37
sg11
g12
sg13
I5
sasg24
(lp15960
(dp15961
g7
I183
sg8
Vcancers
p15962
sg10
I7
sg28
VC0006826
p15963
sg13
I1
sasa(dp15964
g135
(dp15965
(VRIPK4
p15966
Vcervical squamous cell carcinoma
p15967
tp15968
I01
ssg2
VHere, we report the potential clinical implication and biological functions of RIPK4 in cervical squamous cell carcinoma (CSCC).
p15969
sg4
(lp15970
(dp15971
g7
I79
sg8
g15966
sg10
I5
sg11
VP57078
p15972
sg13
I1
sasg24
(lp15973
(dp15974
g7
I122
sg8
VCSCC
p15975
sg10
I4
sg28
VC0279671
p15976
sg13
I1
sa(dp15977
g7
I88
sg8
g15967
sg10
I32
sg28
VC0279671
p15978
sg13
I4
sasa(dp15979
g135
(dp15980
(VRIPK4
p15981
Vchronic cervicitis
p15982
tp15983
I01
ssg2
VRIPK4 expression increased significantly with disease progression from 3.2% in chronic cervicitis, 19.3% in LSILs and 85.1% in HSILs to 94.4% in CSCCs (P &lt; 0.001).
p15984
sg4
(lp15985
(dp15986
g7
I0
sg8
g15981
sg10
I5
sg11
VP57078
p15987
sg13
I1
sasg24
(lp15988
(dp15989
g7
I79
sg8
g15982
sg10
I18
sg28
VC0269062
p15990
sg13
I2
sa(dp15991
g7
I46
sg8
Vdisease progression
p15992
sg10
I19
sg28
VC0242656
p15993
sg13
I2
sasa(dp15994
g135
(dp15995
(VRIPK4
p15996
Vcervical cancer
p15997
tp15998
I01
ssg2
VKnockdown of RIPK4 reduced cell migration and invasion via inhibition of Vimentin, MMP2 and Fibronectin expression in cervical cancer cells.
p15999
sg4
(lp16000
(dp16001
g7
I83
sg8
VMMP2
p16002
sg10
I4
sg11
VP08253
p16003
sg13
I1
sa(dp16004
g7
I13
sg8
g15996
sg10
I5
sg11
VP57078
p16005
sg13
I1
sasg24
(lp16006
(dp16007
g7
I118
sg8
g15997
sg10
I15
sg28
VC0302592
p16008
sg13
I2
sa(dp16009
g7
I46
sg8
Vinvasion
p16010
sg10
I8
sg28
VC2699153
p16011
sg13
I1
sasa(dp16012
g2
VRIPK4 might act as a potential diagnostic and independent prognostic biomarker for CSCC patients.
p16013
sg4
(lp16014
(dp16015
g7
I0
sg8
VRIPK4
p16016
sg10
I5
sg11
VP57078
p16017
sg13
I1
sasg24
(lp16018
sa(dp16019
g135
(dp16020
(VRIP4
p16021
Vdiffuse large B cell lymphoma
p16022
tp16023
I01
ssg2
VWe previously showed that protein kinase C-associated kinase (PKK, also known as DIK/RIP4), which belongs to the receptor-interacting protein (RIP) kinase family, mediates the B cell activating factor of the TNF family (BAFF)-induced NF-KB activation in diffuse large B cell lymphoma (DLBCL) cell lines.
p16024
sg4
(lp16025
(dp16026
g7
I113
sg8
Vreceptor-interacting protein
p16027
sg10
I28
sg11
g12
sg13
I2
sa(dp16028
g7
I26
sg8
Vprotein kinase C-associated kinase
p16029
sg10
I34
sg11
VP17252
p16030
sg13
I4
sa(dp16031
g7
I176
sg8
VB cell activating factor of the TNF family
p16032
sg10
I42
sg11
g12
sg13
I8
sa(dp16033
g7
I85
sg8
VRIP
p16034
sg10
I3
sg11
VP52594
p16035
sg13
I1
sa(dp16036
g7
I81
sg8
VDIK
p16037
sg10
I3
sg11
VP57078
p16038
sg13
I1
sa(dp16039
g7
I62
sg8
VPKK
p16040
sg10
I3
sg11
VP57078
p16041
sg13
I1
sa(dp16042
g7
I85
sg8
g16021
sg10
I4
sg11
VP57078
p16043
sg13
I1
sa(dp16044
g7
I220
sg8
VBAFF
p16045
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp16046
(dp16047
g7
I285
sg8
VDLBCL
p16048
sg10
I5
sg28
VC0079744
p16049
sg13
I1
sa(dp16050
g7
I254
sg8
g16022
sg10
I29
sg28
VC0079744
p16051
sg13
I5
sasa(dp16052
g2
VSuppression of PKK expression by RNA interference inhibits phosphorylation of IKKAlfa and IKKBeta as well as activation of NF-KB in human cancer cell lines.
p16053
sg4
(lp16054
(dp16055
g7
I90
sg8
VIKKBeta
p16056
sg10
I7
sg11
g12
sg13
I1
sa(dp16057
g7
I15
sg8
VPKK
p16058
sg10
I3
sg11
VP57078
p16059
sg13
I1
sasg24
(lp16060
(dp16061
g7
I0
sg8
VSuppression
p16062
sg10
I11
sg28
VC0221103
p16063
sg13
I1
sa(dp16064
g7
I138
sg8
Vcancer
p16065
sg10
I6
sg28
VC0006826
p16066
sg13
I1
sasa(dp16067
g2
VWe propose that PKK may provide a critical link between IKK activation and various upstream signaling cascades, and may represent a potential target for inhibiting abnormal NF-KB activation in human cancers.
p16068
sg4
(lp16069
(dp16070
g7
I16
sg8
VPKK
p16071
sg10
I3
sg11
VP57078
p16072
sg13
I1
sa(dp16073
g7
I56
sg8
VIKK
p16074
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp16075
(dp16076
g7
I199
sg8
Vcancers
p16077
sg10
I7
sg28
VC0006826
p16078
sg13
I1
sasa(dp16079
g2
VTo assess RIPK4 expression in various differentiated TSCC and to determine its basic biological function.
p16080
sg4
(lp16081
(dp16082
g7
I10
sg8
VRIPK4
p16083
sg10
I5
sg11
VP57078
p16084
sg13
I1
sasg24
(lp16085
sa(dp16086
g2
VA significantly higher level of RIPK4 was found in well-differentiated TSCC samples than in the poorly differentiated ones (p&lt;0.01).
p16087
sg4
(lp16088
(dp16089
g7
I32
sg8
VRIPK4
p16090
sg10
I5
sg11
VP57078
p16091
sg13
I1
sasg24
(lp16092
sa(dp16093
g2
VIn the present work we found a correlation between RIPK4 expression and TSCC degree of differentiation, age, and gender.
p16094
sg4
(lp16095
(dp16096
g7
I51
sg8
VRIPK4
p16097
sg10
I5
sg11
VP57078
p16098
sg13
I1
sasg24
(lp16099
sa(dp16100
g135
(dp16101
(VRIPK4
p16102
Vtongue cancer
p16103
tp16104
I00
ssg2
VThe better understanding of the molecular mechanism of RIPK4 in TSCC may provide a promising biomarker for tongue cancer prognosis and treatment.
p16105
sg4
(lp16106
(dp16107
g7
I55
sg8
g16102
sg10
I5
sg11
VP57078
p16108
sg13
I1
sasg24
(lp16109
(dp16110
g7
I107
sg8
g16103
sg10
I13
sg28
VC0558353
p16111
sg13
I2
sasa(dp16112
g135
(dp16113
(VMMP-2
p16114
VAVM
p16115
tp16116
I00
ssg2
VInterestingly, maladaptive ECM remodeling was observed in early AVM without AVD and worsened with late AVD, as evidenced by increased MMP-2 and MMP-9 expression and activity, as well as abnormalities in ADAMTS-mediated versican processing.
p16117
sg4
(lp16118
(dp16119
g7
I144
sg8
VMMP-9
p16120
sg10
I5
sg11
VP14780
p16121
sg13
I1
sa(dp16122
g7
I134
sg8
g16114
sg10
I5
sg11
VP08253
p16123
sg13
I1
sasg24
(lp16124
(dp16125
g7
I64
sg8
g16115
sg10
I3
sg28
VC0003857
p16126
sg13
I1
sasa(dp16127
g135
(dp16128
(VvWF
p16129
Vaortic stenosis
p16130
tp16131
I01
ssg2
VIn patients with aortic stenosis or the hemolytic-uremic syndrome, abnormally high levels of shear stress across the stenotic valve or in the microcirculation inflicted with thrombosis may promote cleavage of vWF by ADAMTS13, contributing to the loss of large multimers commonly observed among these patients.
p16132
sg4
(lp16133
(dp16134
g7
I209
sg8
g16129
sg10
I3
sg11
VP04275
p16135
sg13
I1
sa(dp16136
g7
I216
sg8
VADAMTS13
p16137
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp16138
(dp16139
g7
I174
sg8
Vthrombosis
p16140
sg10
I10
sg28
VC0040053
p16141
sg13
I1
sa(dp16142
g7
I40
sg8
Vhemolytic-uremic syndrome
p16143
sg10
I25
sg28
VC0019061
p16144
sg13
I2
sa(dp16145
g7
I17
sg8
g16130
sg10
I15
sg28
VC0003507
p16146
sg13
I2
sasa(dp16147
g135
(dp16148
(VMTNR1B
p16149
Vscrapie
p16150
tp16151
I00
ssg2
VThe gene and protein expression profiles and protein distribution of six potential genetic biomarkers (i.e., CAPN6, COL1A2, COL3A1, GALA1, MT2A and MTNR1B) are presented here for both the early and terminal stages of scrapie in five different brain regions.
p16152
sg4
(lp16153
(dp16154
g7
I109
sg8
VCAPN6
p16155
sg10
I5
sg11
g12
sg13
I1
sa(dp16156
g7
I139
sg8
VMT2A
p16157
sg10
I4
sg11
VP02795
p16158
sg13
I1
sa(dp16159
g7
I148
sg8
g16149
sg10
I6
sg11
VP49286
p16160
sg13
I1
sasg24
(lp16161
(dp16162
g7
I217
sg8
g16150
sg10
I7
sg28
VC0036457
p16163
sg13
I1
sasa(dp16164
g135
(dp16165
(VMT2A
p16166
Vscrapie
p16167
tp16168
I00
ssg2
VThe distribution of the GALA1 was identified in glial cells from the cerebellum of scrapie-infected animals, GALA1 protein expression was increased in clinical animals in the majority of regions, and the increase of MT2A was in agreement with previous reports.
p16169
sg4
(lp16170
(dp16171
g7
I216
sg8
g16166
sg10
I4
sg11
VP02795
p16172
sg13
I1
sasg24
(lp16173
(dp16174
g7
I83
sg8
g16167
sg10
I7
sg28
VC0036457
p16175
sg13
I1
sasa(dp16176
g135
(dp16177
(VMT2A
p16178
Vprion disease
p16179
tp16180
I00
ssg2
VIn conclusion, this study of gene transcription and protein expression and distribution confirm CAPN6, GALA1, MTNR1B and MT2A as potential targets for further prion disease research.
p16181
sg4
(lp16182
(dp16183
g7
I110
sg8
VMTNR1B
p16184
sg10
I6
sg11
VP49286
p16185
sg13
I1
sa(dp16186
g7
I96
sg8
VCAPN6
p16187
sg10
I5
sg11
g12
sg13
I1
sa(dp16188
g7
I121
sg8
g16178
sg10
I4
sg11
VP02795
p16189
sg13
I1
sasg24
(lp16190
(dp16191
g7
I159
sg8
g16179
sg10
I13
sg28
VC0162534
p16192
sg13
I2
sasa(dp16193
g135
(dp16194
(Vp21
p16195
VARDS
p16196
tp16197
I00
ssg2
VLincRNA-p21 could lead to pulmonary fibrosis in ARDS by inhibition of the expression of Thy-1.
p16198
sg4
(lp16199
(dp16200
g7
I88
sg8
VThy-1
p16201
sg10
I5
sg11
VP04216
p16202
sg13
I1
sa(dp16203
g7
I8
sg8
g16195
sg10
I3
sg11
VP42857
p16204
sg13
I1
sasg24
(lp16205
(dp16206
g7
I26
sg8
Vpulmonary fibrosis
p16207
sg10
I18
sg28
VC0034069
p16208
sg13
I2
sa(dp16209
g7
I48
sg8
g16196
sg10
I4
sg28
VC0035222
p16210
sg13
I1
sasa(dp16211
g135
(dp16212
(VHDAC
p16213
VLPS
p16214
tp16215
I00
ssg2
VLPS-induced pulmonary fibrosis was related with activation of HDAC, deacetylation of histone H3 and H4 and Thy-1 gene silencing.
p16216
sg4
(lp16217
(dp16218
g7
I107
sg8
VThy-1 gene
p16219
sg10
I10
sg11
VP04216
p16220
sg13
I2
sa(dp16221
g7
I85
sg8
Vhistone H3
p16222
sg10
I10
sg11
g12
sg13
I2
sa(dp16223
g7
I62
sg8
g16213
sg10
I4
sg11
VP56524
p16224
sg13
I1
sasg24
(lp16225
(dp16226
g7
I12
sg8
Vpulmonary fibrosis
p16227
sg10
I18
sg28
VC0034069
p16228
sg13
I2
sa(dp16229
g7
I0
sg8
g16214
sg10
I3
sg28
VC0175697
p16230
sg13
I1
sasa(dp16231
g135
(dp16232
(VHDAC
p16233
VLPS
p16234
tp16235
I00
ssg2
VHDAC inhibitor BA could inhibit LPS-induced pulmonary fibrosis and Thy-1 gene silencing through inhibiting activation of HDAC and deacetylation of histone H4.
p16236
sg4
(lp16237
(dp16238
g7
I0
sg8
VHDAC
p16239
sg10
I4
sg11
VP56524
p16240
sg13
I1
sa(dp16241
g7
I147
sg8
Vhistone H4
p16242
sg10
I10
sg11
VP62805
p16243
sg13
I2
sa(dp16244
g7
I0
sg8
g16233
sg10
I4
sg11
VP56524
p16245
sg13
I1
sasg24
(lp16246
(dp16247
g7
I44
sg8
Vpulmonary fibrosis
p16248
sg10
I18
sg28
VC0034069
p16249
sg13
I2
sa(dp16250
g7
I32
sg8
g16234
sg10
I3
sg28
VC0175697
p16251
sg13
I1
sasa(dp16252
g2
VSSc patients with pulmonary fibrosis (P = 0.006) and patients with PAH (P &lt; 0.001) had increased sCD90 serum concentrations compared to patients without the respective pulmonary manifestation of SSc.
p16253
sg4
(lp16254
sg24
(lp16255
(dp16256
g7
I18
sg8
Vpulmonary fibrosis
p16257
sg10
I18
sg28
VC0034069
p16258
sg13
I2
sa(dp16259
g7
I67
sg8
VPAH
p16260
sg10
I3
sg28
VC0152171
p16261
sg13
I1
sasa(dp16262
g2
VOsteoporosis pseudoglioma syndrome (OPPGS) is a rare autosomal recessive genetic disorder characterised by congenital blindness and osteoporosis, caused by biallelic mutations in the LRP5 gene.
p16263
sg4
(lp16264
(dp16265
g7
I183
sg8
VLRP5 gene
p16266
sg10
I9
sg11
g12
sg13
I2
sasg24
(lp16267
(dp16268
g7
I73
sg8
Vgenetic disorder
p16269
sg10
I16
sg28
VC0019247
p16270
sg13
I2
sa(dp16271
g7
I107
sg8
Vcongenital blindness
p16272
sg10
I20
sg28
VC0005754
p16273
sg13
I2
sa(dp16274
g7
I26
sg8
Vsyndrome
p16275
sg10
I8
sg28
VC0039082
p16276
sg13
I1
sa(dp16277
g7
I132
sg8
Vosteoporosis
p16278
sg10
I12
sg28
VC0029456
p16279
sg13
I1
sa(dp16280
g7
I0
sg8
VOsteoporosis pseudoglioma
p16281
sg10
I25
sg28
VC0432252
p16282
sg13
I2
sasa(dp16283
g2
VMolecular genetic examination detected the LRP5 gene for FEVR.
p16284
sg4
(lp16285
(dp16286
g7
I43
sg8
VLRP5 gene
p16287
sg10
I9
sg11
g12
sg13
I2
sasg24
(lp16288
sa(dp16289
g2
VThe majority of mutations identified in FEVR are found within four genes that encode the receptor complex (FZD4, LRP5, and TSPAN12) and ligand (NDP) of a molecular pathway that controls angiogenesis, the Norrin-Beta-catenin signaling pathway.
p16290
sg4
(lp16291
(dp16292
g7
I211
sg8
VBeta-catenin
p16293
sg10
I12
sg11
VP35222
p16294
sg13
I1
sa(dp16295
g7
I107
sg8
VFZD4
p16296
sg10
I4
sg11
g12
sg13
I1
sa(dp16297
g7
I113
sg8
VLRP5
p16298
sg10
I4
sg11
g12
sg13
I1
sa(dp16299
g7
I123
sg8
VTSPAN12
p16300
sg10
I7
sg11
g12
sg13
I1
sa(dp16301
g7
I204
sg8
VNorrin
p16302
sg10
I6
sg11
g12
sg13
I1
sa(dp16303
g7
I40
sg8
VFEVR
p16304
sg10
I4
sg11
g12
sg13
I1
sasg24
(lp16305
sa(dp16306
g2
VPrimers were designed to amplify the coding exons and adjacent intronic regions of the FEVR-causing genes FZD4, LRP5, NDP and TSPAN12.
p16307
sg4
(lp16308
(dp16309
g7
I112
sg8
VLRP5
p16310
sg10
I4
sg11
g12
sg13
I1
sa(dp16311
g7
I126
sg8
VTSPAN12
p16312
sg10
I7
sg11
g12
sg13
I1
sa(dp16313
g7
I106
sg8
VFZD4
p16314
sg10
I4
sg11
g12
sg13
I1
sa(dp16315
g7
I118
sg8
VNDP
p16316
sg10
I3
sg11
g12
sg13
I1
sasg24
(lp16317
sa(dp16318
g2
VWe identified five LRP5 mutations: three novel heterozygous mutations-p.M181R, p.R399S and p.G503R and two known mutations that were never reported in FEVR patients: p.R494Q and p.G876S.
p16319
sg4
(lp16320
(dp16321
g7
I19
sg8
VLRP5 mutations
p16322
sg10
I14
sg11
g12
sg13
I2
sasg24
(lp16323
sa(dp16324
g2
VSurprisingly, we then found mutations in familial exudative vitreoretinopathy (FEVR) genes; low-density lipoprotein receptor-related protein 5 mutations (six families), tetraspanin 12 mutations (two families), and NDP mutations (two families).
p16325
sg4
(lp16326
(dp16327
g7
I214
sg8
VNDP mutations
p16328
sg10
I13
sg11
g12
sg13
I2
sa(dp16329
g7
I92
sg8
Vlow-density lipoprotein receptor-related protein 5 mutations
p16330
sg10
I60
sg11
g12
sg13
I6
sa(dp16331
g7
I169
sg8
Vtetraspanin 12
p16332
sg10
I14
sg11
g12
sg13
I2
sasg24
(lp16333
(dp16334
g7
I79
sg8
VFEVR
p16335
sg10
I4
sg28
VC0339539
p16336
sg13
I1
sa(dp16337
g7
I41
sg8
Vfamilial exudative vitreoretinopathy
p16338
sg10
I36
sg28
VC0339539
p16339
sg13
I3
sasa(dp16340
g2
VTherefore, this study aimed to determine the role of the Mdm2 SNIP 309 polymorphism in the gastric mucosal morphological patterns in patients with Helicobacter pylori associated gastritis.
p16341
sg4
(lp16342
(dp16343
g7
I57
sg8
VMdm2 SNIP
p16344
sg10
I9
sg11
g12
sg13
I2
sasg24
(lp16345
(dp16346
g7
I178
sg8
Vgastritis
p16347
sg10
I9
sg28
VC0017152
p16348
sg13
I1
sasa(dp16349
g2
VTherefore, this study aimed to determine the correlation between the patterns of Mdm2 SNIP 309 and the inflammation grading of Helicobacter pylori associated gastritis in a Thai population.
p16350
sg4
(lp16351
(dp16352
g7
I81
sg8
VMdm2 SNIP 309
p16353
sg10
I13
sg11
g12
sg13
I3
sasg24
(lp16354
(dp16355
g7
I158
sg8
Vgastritis
p16356
sg10
I9
sg28
VC0017152
p16357
sg13
I1
sa(dp16358
g7
I103
sg8
Vinflammation
p16359
sg10
I12
sg28
VC0021368
p16360
sg13
I1
sasa(dp16361
g2
VGastric mucosa from 100 patients with Helicobacter pylori associated gastritis was analyzed for MDM2 SNP309 using real-time PCR hybridization (light-cycler) probes.
p16362
sg4
(lp16363
sg24
(lp16364
(dp16365
g7
I69
sg8
Vgastritis
p16366
sg10
I9
sg28
VC0017152
p16367
sg13
I1
sasa(dp16368
g135
(dp16369
(VKCNQ1
p16370
Vtype 2 diabetes
p16371
tp16372
I00
ssg2
VWhile planning genomics, we describe that 11 well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, KCNJ11, FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) showed similar associations compared to literature.
p16373
sg4
(lp16374
(dp16375
g7
I168
sg8
VCDKAL1
p16376
sg10
I6
sg11
g12
sg13
I1
sa(dp16377
g7
I131
sg8
VIGF2BP2
p16378
sg10
I7
sg11
g12
sg13
I1
sa(dp16379
g7
I118
sg8
VKCNJ11
p16380
sg10
I6
sg11
g12
sg13
I1
sa(dp16381
g7
I176
sg8
g16370
sg10
I5
sg11
VP51787
p16382
sg13
I1
sa(dp16383
g7
I162
sg8
VHHEX
p16384
sg10
I4
sg11
g12
sg13
I1
sa(dp16385
g7
I112
sg8
VP12A
p16386
sg10
I4
sg11
g12
sg13
I1
sa(dp16387
g7
I106
sg8
VPPARG
p16388
sg10
I5
sg11
g12
sg13
I1
sa(dp16389
g7
I126
sg8
VFTO
p16390
sg10
I3
sg11
g12
sg13
I1
sa(dp16391
g7
I140
sg8
VDUSP9
p16392
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp16393
(dp16394
g7
I56
sg8
g16371
sg10
I15
sg28
VC0011860
p16395
sg13
I3
sasa(dp16396
g135
(dp16397
(Vinsulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene
p16398
VT2D
p16399
tp16400
I00
ssg2
VAssociations between insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs11705701, insulin receptor substrate 1 rs7578326, gastric inhibitory polypeptide receptor rs10423928 and transcription factor 7-like 2 rs12255372 gene polymorphisms with prediabetes and type 2 diabetes (T2D) have not been evaluated in the Han Chinese population.
p16401
sg4
(lp16402
(dp16403
g7
I74
sg8
VIGF2BP2
p16404
sg10
I7
sg11
g12
sg13
I1
sa(dp16405
g7
I21
sg8
Vinsulin-like growth factor 2 mRNA-binding protein 2
p16406
sg10
I51
sg11
VP01308
p16407
sg13
I7
sa(dp16408
g7
I95
sg8
g16398
sg10
I140
sg11
VP35568
p16409
sg13
I17
sasg24
(lp16410
(dp16411
g7
I271
sg8
Vtype 2 diabetes
p16412
sg10
I15
sg28
VC0011860
p16413
sg13
I3
sa(dp16414
g7
I255
sg8
Vprediabetes
p16415
sg10
I11
sg28
VC0362046
p16416
sg13
I1
sa(dp16417
g7
I288
sg8
g16399
sg10
I3
sg28
VC0011860
p16418
sg13
I1
sasa(dp16419
g2
VA breakdown analysis by gender revealed a significant association of IGF2BP2 rs11705701 with prediabetes under the dominant genetic model in females following application of the Bonferroni correction (odds ratio = 0.26; 95% confidence interval = 0.10-0.67; P=0.005).
p16420
sg4
(lp16421
(dp16422
g7
I69
sg8
VIGF2BP2 rs11705701
p16423
sg10
I18
sg11
g12
sg13
I2
sasg24
(lp16424
(dp16425
g7
I2
sg8
Vbreakdown
p16426
sg10
I9
sg28
VC1265875
p16427
sg13
I1
sa(dp16428
g7
I93
sg8
Vprediabetes
p16429
sg10
I11
sg28
VC0362046
p16430
sg13
I1
sasa(dp16431
g2
VThe present case-control study reveals a significant association between IGF2BP2 rs11705701 and prediabetes in female patients.
p16432
sg4
(lp16433
(dp16434
g7
I73
sg8
VIGF2BP2 rs11705701
p16435
sg10
I18
sg11
g12
sg13
I2
sasg24
(lp16436
(dp16437
g7
I96
sg8
Vprediabetes
p16438
sg10
I11
sg28
VC0362046
p16439
sg13
I1
sasa(dp16440
g2
VGenome-wide association studies (GWAS) found that IGF2BP2 rs4402960 and rs1470579 polymorphisms were associated with type 2 diabetes mellitus (T2DM) risk.
p16441
sg4
(lp16442
(dp16443
g7
I50
sg8
VIGF2BP2
p16444
sg10
I7
sg11
g12
sg13
I1
sasg24
(lp16445
(dp16446
g7
I117
sg8
Vtype 2 diabetes mellitus
p16447
sg10
I24
sg28
VC0011860
p16448
sg13
I4
sa(dp16449
g7
I143
sg8
VT2DM
p16450
sg10
I4
sg28
VC0011860
p16451
sg13
I1
sasa(dp16452
g2
VDecreased expression of CHC1L is linked to pathogenesis and progression of both prostate cancer and multiple myeloma.
p16453
sg4
(lp16454
(dp16455
g7
I24
sg8
VCHC1L
p16456
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp16457
(dp16458
g7
I43
sg8
Vpathogenesis
p16459
sg10
I12
sg28
VC0699748
p16460
sg13
I1
sa(dp16461
g7
I80
sg8
Vprostate cancer
p16462
sg10
I15
sg28
VC0600139
p16463
sg13
I2
sa(dp16464
g7
I100
sg8
Vmultiple myeloma
p16465
sg10
I16
sg28
VC0026764
p16466
sg13
I2
sasa(dp16467
g2
VRecent studies of the RAN (6p21), ZHX-2 (8q24.3), CHC1L (13q14.3) loci highlight the importance of these genes in multiple myeloma (MM) prognosis and therapeutic applications.
p16468
sg4
(lp16469
(dp16470
g7
I34
sg8
VZHX-2 (8q24.3), CHC1L (13q14.3) loci
p16471
sg10
I36
sg11
g12
sg13
I5
sasg24
(lp16472
(dp16473
g7
I114
sg8
Vmultiple myeloma
p16474
sg10
I16
sg28
VC0026764
p16475
sg13
I2
sasa(dp16476
g2
VLow expression levels of RAN, ZHX-2, and CHC1L were observed in myeloma patients, compared with peripheral blood lymphocytes and MOLP-8 cells.
p16477
sg4
(lp16478
(dp16479
g7
I41
sg8
VCHC1L
p16480
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp16481
(dp16482
g7
I64
sg8
Vmyeloma
p16483
sg10
I7
sg28
VC0026764
p16484
sg13
I1
sasa(dp16485
g2
VRAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines.
p16486
sg4
(lp16487
(dp16488
g7
I22
sg8
VCHC1L
p16489
sg10
I5
sg11
g12
sg13
I1
sa(dp16490
g7
I5
sg8
VZHX2
p16491
sg10
I4
sg11
g12
sg13
I1
sa(dp16492
g7
I14
sg8
VRCBTB2
p16493
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp16494
(dp16495
g7
I271
sg8
Vmonoclonal gammopathy of undetermined significance
p16496
sg10
I50
sg28
VC0026470
p16497
sg13
I5
sa(dp16498
g7
I340
sg8
Vleukaemias
p16499
sg10
I10
sg28
VC0023418
p16500
sg13
I1
sa(dp16501
g7
I192
sg8
Vmultiple myeloma
p16502
sg10
I16
sg28
VC0026764
p16503
sg13
I2
sa(dp16504
g7
I152
sg8
Vmonoclonal gammopathies
p16505
sg10
I23
sg28
VC1136085
p16506
sg13
I2
sasa(dp16507
g2
VBCCIP deficiency impaired embryonic and postnatal neural development, causing severe ataxia, cerebral and cerebellar defects, and microcephaly.
p16508
sg4
(lp16509
sg24
(lp16510
(dp16511
g7
I17
sg8
Vimpaired
p16512
sg10
I8
sg28
VC0684336
p16513
sg13
I1
sa(dp16514
g7
I130
sg8
Vmicrocephaly
p16515
sg10
I12
sg28
VC0025958
p16516
sg13
I1
sa(dp16517
g7
I85
sg8
Vataxia
p16518
sg10
I6
sg28
VC0004134
p16519
sg13
I1
sasa(dp16520
g135
(dp16521
(VVav1
p16522
VHS1
p16523
tp16524
I00
ssg2
VPhosphorylation also links HS1 to multiple signaling proteins, including Lck, PLCgamma1, and Vav1, and is essential for the stable recruitment of Vav1 to the IS.
p16525
sg4
(lp16526
(dp16527
g7
I93
sg8
VVav1
p16528
sg10
I4
sg11
VP15498
p16529
sg13
I1
sa(dp16530
g7
I27
sg8
VHS1
p16531
sg10
I3
sg11
VP27348
p16532
sg13
I1
sa(dp16533
g7
I78
sg8
VPLCgamma1
p16534
sg10
I9
sg11
VP19174
p16535
sg13
I1
sa(dp16536
g7
I93
sg8
g16522
sg10
I4
sg11
VP15498
p16537
sg13
I1
sasg24
(lp16538
(dp16539
g7
I27
sg8
g16523
sg10
I3
sg28
VC2674218
p16540
sg13
I1
sa(dp16541
g7
I131
sg8
Vrecruitment
p16542
sg10
I11
sg28
VC0271510
p16543
sg13
I1
sasa(dp16544
g135
(dp16545
(VSH3 binding sites
p16546
VHS1
p16547
tp16548
I00
ssg2
VOn the other hand, we confirmed previously mapped Lck SH3 binding sites in ADAM15, HS1, SLP76, and NS5A, and identified putative Lck SH3 binding sites of Sam68, FasL, c-Cbl, and Cbl-b.
p16549
sg4
(lp16550
(dp16551
g7
I83
sg8
VHS1
p16552
sg10
I3
sg11
VP27348
p16553
sg13
I1
sa(dp16554
g7
I161
sg8
VFasL
p16555
sg10
I4
sg11
VP48023
p16556
sg13
I1
sa(dp16557
g7
I154
sg8
VSam68
p16558
sg10
I5
sg11
g12
sg13
I1
sa(dp16559
g7
I167
sg8
Vc-Cbl
p16560
sg10
I5
sg11
VP22681
p16561
sg13
I1
sa(dp16562
g7
I75
sg8
VADAM15
p16563
sg10
I6
sg11
g12
sg13
I1
sa(dp16564
g7
I54
sg8
VSH3 binding sites
p16565
sg10
I17
sg11
VP63244
p16566
sg13
I3
sa(dp16567
g7
I54
sg8
g16546
sg10
I17
sg11
VP63244
p16568
sg13
I3
sa(dp16569
g7
I88
sg8
VSLP76
p16570
sg10
I5
sg11
g12
sg13
I1
sa(dp16571
g7
I178
sg8
VCbl-b
p16572
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp16573
(dp16574
g7
I83
sg8
g16547
sg10
I3
sg28
VC2674218
p16575
sg13
I1
sasa(dp16576
g135
(dp16577
(VSHP-1
p16578
VHS1
p16579
tp16580
I00
ssg2
VThe SH2 domains of ZAP70, SHP-1 and PLC gamma 1 and the SH3 domains of lck, vav and HS1 did not bind to pp85--90.
p16581
sg4
(lp16582
(dp16583
g7
I84
sg8
VHS1
p16584
sg10
I3
sg11
VP27348
p16585
sg13
I1
sa(dp16586
g7
I76
sg8
Vvav
p16587
sg10
I3
sg11
VP15498
p16588
sg13
I1
sa(dp16589
g7
I36
sg8
VPLC gamma 1
p16590
sg10
I11
sg11
VP98160
p16591
sg13
I3
sa(dp16592
g7
I19
sg8
VZAP70
p16593
sg10
I5
sg11
VP43403
p16594
sg13
I1
sa(dp16595
g7
I26
sg8
g16578
sg10
I5
sg11
VP29350
p16596
sg13
I1
sasg24
(lp16597
(dp16598
g7
I84
sg8
g16579
sg10
I3
sg28
VC2674218
p16599
sg13
I1
sasa(dp16600
g135
(dp16601
(Vglyceraldehyde-3-phosphate dehydrogenase
p16602
VHIV
p16603
tp16604
I00
ssg2
VThese analyses identified several cellular proteins inside HIV-1: elongation factor 1alpha, glyceraldehyde-3-phosphate dehydrogenase, HS-1, phosphatidylethanolamine-binding protein, Pin1, Lck, Nm23-H1, and the C-terminal tail of CD43.
p16605
sg4
(lp16606
(dp16607
g7
I59
sg8
VHIV-1: elongation factor 1alpha
p16608
sg10
I31
sg11
g12
sg13
I4
sa(dp16609
g7
I140
sg8
Vphosphatidylethanolamine-binding protein
p16610
sg10
I40
sg11
VP30086
p16611
sg13
I2
sa(dp16612
g7
I182
sg8
VPin1
p16613
sg10
I4
sg11
g12
sg13
I1
sa(dp16614
g7
I193
sg8
VNm23-H1
p16615
sg10
I7
sg11
VP22392
p16616
sg13
I1
sa(dp16617
g7
I229
sg8
VCD43
p16618
sg10
I4
sg11
VP16150
p16619
sg13
I1
sa(dp16620
g7
I92
sg8
g16602
sg10
I40
sg11
VP04406
p16621
sg13
I2
sasg24
(lp16622
(dp16623
g7
I59
sg8
g16603
sg10
I3
sg28
VC0019693
p16624
sg13
I1
sasa(dp16625
g135
(dp16626
(VHS1
p16627
VHS1
p16628
tp16629
I00
ssg2
VWe find that the Src homology 3 domains of Grb2 directly associate, in vitro and in vivo, with murine hemopoietic specific protein 1 (HS1), a protein identical to Lck-binding protein 1.
p16630
sg4
(lp16631
(dp16632
g7
I43
sg8
VGrb2
p16633
sg10
I4
sg11
VP62993
p16634
sg13
I1
sa(dp16635
g7
I163
sg8
VLck-binding protein 1
p16636
sg10
I21
sg11
VP14222
p16637
sg13
I3
sa(dp16638
g7
I95
sg8
Vmurine hemopoietic specific protein 1
p16639
sg10
I37
sg11
VP14222
p16640
sg13
I5
sa(dp16641
g7
I17
sg8
VSrc homology 3
p16642
sg10
I14
sg11
VP12931
p16643
sg13
I3
sa(dp16644
g7
I134
sg8
g16627
sg10
I3
sg11
VP27348
p16645
sg13
I1
sasg24
(lp16646
(dp16647
g7
I102
sg8
Vhemopoietic specific protein 1
p16648
sg10
I30
sg28
VC2674218
p16649
sg13
I4
sa(dp16650
g7
I134
sg8
g16628
sg10
I3
sg28
VC2674218
p16651
sg13
I1
sasa(dp16652
g135
(dp16653
(Vtyrosine kinases
p16654
VHS1
p16655
tp16656
I00
ssg2
VBecause HS1 associates with the p56(lck) and p59(lyn) tyrosine kinases in vitro and in vivo, and becomes tyrosine phosphorylated upon various receptor stimulations, our present data suggest that HS1 mediates linkage between Lck or Lyn and Grb2 in lymphoid lineage cells.
p16657
sg4
(lp16658
(dp16659
g7
I8
sg8
VHS1
p16660
sg10
I3
sg11
VP27348
p16661
sg13
I1
sa(dp16662
g7
I49
sg8
Vlyn
p16663
sg10
I3
sg11
VP07948
p16664
sg13
I1
sa(dp16665
g7
I231
sg8
VLyn
p16666
sg10
I3
sg11
VP07948
p16667
sg13
I1
sa(dp16668
g7
I32
sg8
Vp56
p16669
sg10
I3
sg11
VP62191
p16670
sg13
I1
sa(dp16671
g7
I239
sg8
VGrb2
p16672
sg10
I4
sg11
VP62993
p16673
sg13
I1
sa(dp16674
g7
I45
sg8
Vp59
p16675
sg10
I3
sg11
g12
sg13
I1
sa(dp16676
g7
I54
sg8
g16654
sg10
I16
sg11
VP29401
p16677
sg13
I2
sasg24
(lp16678
(dp16679
g7
I8
sg8
VHS1
p16680
sg10
I3
sg28
VC2674218
p16681
sg13
I1
sa(dp16682
g7
I8
sg8
g16655
sg10
I3
sg28
VC2674218
p16683
sg13
I1
sasa(dp16684
g135
(dp16685
(Vtyrosine kinase-associated protein
p16686
VHS1
p16687
tp16688
I00
ssg2
VWith this method, we previously isolated an Lck tyrosine kinase-associated protein, LckBP1, which is identical to HS1 (Kitamura et al., 1989, 1995; Takemoto et al., 1995).
p16689
sg4
(lp16690
(dp16691
g7
I84
sg8
VLckBP1
p16692
sg10
I6
sg11
VP14317
p16693
sg13
I1
sa(dp16694
g7
I48
sg8
g16686
sg10
I34
sg11
VP29401
p16695
sg13
I3
sasg24
(lp16696
(dp16697
g7
I114
sg8
g16687
sg10
I3
sg28
VC2674218
p16698
sg13
I1
sasa(dp16699
g2
VWe have previously found that purine-rich element binding protein, PURalpha, was significantly repressed in androgen-independent prostate cancer cell lines in comparison to an androgen-dependent line.
p16700
sg4
(lp16701
(dp16702
g7
I30
sg8
Vpurine-rich element binding protein
p16703
sg10
I35
sg11
g12
sg13
I4
sa(dp16704
g7
I67
sg8
VPURalpha
p16705
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp16706
(dp16707
g7
I129
sg8
Vprostate cancer
p16708
sg10
I15
sg28
VC0600139
p16709
sg13
I2
sasa(dp16710
g2
VMoreover, over-expressing PURalpha in androgen-independent prostate cancer cells attenuated their cell proliferation.
p16711
sg4
(lp16712
(dp16713
g7
I26
sg8
VPURalpha
p16714
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp16715
(dp16716
g7
I103
sg8
Vproliferation
p16717
sg10
I13
sg28
VC0334094
p16718
sg13
I1
sa(dp16719
g7
I59
sg8
Vprostate cancer
p16720
sg10
I15
sg28
VC0600139
p16721
sg13
I2
sasa(dp16722
g2
VThese findings suggest that regulation of PURalpha expression in prostate cancer cells may serve as a therapeutic target for hormone refractory prostate cancer.
p16723
sg4
(lp16724
(dp16725
g7
I42
sg8
VPURalpha
p16726
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp16727
(dp16728
g7
I125
sg8
Vhormone refractory prostate cancer
p16729
sg10
I34
sg28
VC1328504
p16730
sg13
I4
sa(dp16731
g7
I65
sg8
Vprostate cancer
p16732
sg10
I15
sg28
VC0600139
p16733
sg13
I2
sasa(dp16734
g2
VWe investigated the effects of the DNA damage-inducing cancer chemotherapeutic agent cisplatin on mouse embryo fibroblasts (MEFs) from PURA(-/-) knockout mice that lack Puralpha.
p16735
sg4
(lp16736
(dp16737
g7
I169
sg8
VPuralpha
p16738
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp16739
(dp16740
g7
I55
sg8
Vcancer
p16741
sg10
I6
sg28
VC0006826
p16742
sg13
I1
sa(dp16743
g7
I35
sg8
VDNA damage
p16744
sg10
I10
sg28
VC0012860
p16745
sg13
I2
sasa(dp16746
g2
VMoreover, PURalpha was decreased in its expression both at the protein and mRNA levels in the androgen-independent prostate cancer cell lines, PC3 and DU145 in comparison to LNCaP cells.
p16747
sg4
(lp16748
(dp16749
g7
I10
sg8
VPURalpha
p16750
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp16751
(dp16752
g7
I115
sg8
Vprostate cancer
p16753
sg10
I15
sg28
VC0600139
p16754
sg13
I2
sasa(dp16755
g2
VFrequent SIs were pneumonia (15.9%), cellulitis (9.9%), and sepsis (5.0%).
p16756
sg4
(lp16757
sg24
(lp16758
(dp16759
g7
I18
sg8
Vpneumonia
p16760
sg10
I9
sg28
VC0032285
p16761
sg13
I1
sa(dp16762
g7
I60
sg8
Vsepsis
p16763
sg10
I6
sg28
VC0243026
p16764
sg13
I1
sa(dp16765
g7
I37
sg8
Vcellulitis
p16766
sg10
I10
sg28
VC0007642
p16767
sg13
I1
sasa(dp16768
g135
(dp16769
(VPDGF-B
p16770
Vpulmonary fibrosis
p16771
tp16772
I01
ssg2
VWe additionally show that pulmonary fibrosis in MyD88-KO mice was associated with the accumulation of pro-fibrotic regulatory T lymphocytes (T regs) and pro-fibrotic cytokine expression (TGF-Beta, IL-10 and PDGF-B), not with T helper (Th) 17 cell influx.
p16773
sg4
(lp16774
(dp16775
g7
I187
sg8
VTGF-Beta
p16776
sg10
I8
sg11
VP18075
p16777
sg13
I1
sa(dp16778
g7
I207
sg8
g16770
sg10
I6
sg11
VP01127
p16779
sg13
I1
sa(dp16780
g7
I48
sg8
VMyD88-KO
p16781
sg10
I8
sg11
g12
sg13
I1
sasg24
(lp16782
(dp16783
g7
I26
sg8
g16771
sg10
I18
sg28
VC0034069
p16784
sg13
I2
sasa(dp16785
g135
(dp16786
(VIL-1 beta
p16787
Vmultiple sclerosis
p16788
tp16789
I00
ssg2
VThe aim of our investigation was to analyze the pattern of interleukin-1 (IL-1) family compounds: IL-1 beta, IL-1 receptor accessory protein (Acp), IL-1 receptor antagonist (IL-1Ra) and IL-1 receptor type II (IL-1RII) in the serum and cerebrospinal fluid (CSF) from 67 multiple sclerosis (MS) patients and 31 controls.
p16790
sg4
(lp16791
(dp16792
g7
I209
sg8
VIL-1RII
p16793
sg10
I7
sg11
g12
sg13
I1
sa(dp16794
g7
I109
sg8
VIL-1 receptor accessory protein
p16795
sg10
I31
sg11
g12
sg13
I4
sa(dp16796
g7
I59
sg8
Vinterleukin-1
p16797
sg10
I13
sg11
VP60568
p16798
sg13
I1
sa(dp16799
g7
I148
sg8
VIL-1 receptor antagonist
p16800
sg10
I24
sg11
g12
sg13
I3
sa(dp16801
g7
I174
sg8
VIL-1Ra
p16802
sg10
I6
sg11
VP18510
p16803
sg13
I1
sa(dp16804
g7
I235
sg8
Vcerebrospinal fluid (CSF)
p16805
sg10
I25
sg11
VP04141
p16806
sg13
I3
sa(dp16807
g7
I142
sg8
VAcp
p16808
sg10
I3
sg11
VP13686
p16809
sg13
I1
sa(dp16810
g7
I74
sg8
VIL-1
p16811
sg10
I4
sg11
VP01584
p16812
sg13
I1
sa(dp16813
g7
I98
sg8
g16787
sg10
I9
sg11
VP01584
p16814
sg13
I2
sa(dp16815
g7
I186
sg8
VIL-1 receptor type II
p16816
sg10
I21
sg11
g12
sg13
I4
sasg24
(lp16817
(dp16818
g7
I123
sg8
Vaccessory protein
p16819
sg10
I17
sg28
VC0394005
p16820
sg13
I2
sa(dp16821
g7
I142
sg8
VAcp
p16822
sg10
I3
sg28
VC0394005
p16823
sg13
I1
sa(dp16824
g7
I289
sg8
VMS
p16825
sg10
I2
sg28
VC0026769
p16826
sg13
I1
sa(dp16827
g7
I269
sg8
g16788
sg10
I18
sg28
VC0026769
p16828
sg13
I2
sasa(dp16829
g2
VPartial loss of IFT80 function leads Jeune asphyxiating thoracic dystrophy (JATD) or short-rib polydactyly (SRP) syndrome type III, displaying narrow thoracic cavity and multiple cartilage anomalies.
p16830
sg4
(lp16831
(dp16832
g7
I16
sg8
VIFT80
p16833
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp16834
(dp16835
g7
I56
sg8
Vthoracic
p16836
sg10
I8
sg28
VC0729233
p16837
sg13
I1
sa(dp16838
g7
I95
sg8
Vpolydactyly
p16839
sg10
I11
sg28
VC0152427
p16840
sg13
I1
sa(dp16841
g7
I43
sg8
Vasphyxiating thoracic dystrophy
p16842
sg10
I31
sg28
VC0265275
p16843
sg13
I3
sa(dp16844
g7
I113
sg8
Vsyndrome
p16845
sg10
I8
sg28
VC0039082
p16846
sg13
I1
sa(dp16847
g7
I159
sg8
Vcavity
p16848
sg10
I6
sg28
VC0011334
p16849
sg13
I1
sasa(dp16850
g2
VPartial mutation of intraflagellar transport 80 (IFT80) in humans causes Jeune asphyxiating thoracic dystrophy (JATD) and short-rib polydactyly (SRP) syndrome type III.
p16851
sg4
(lp16852
(dp16853
g7
I49
sg8
VIFT80
p16854
sg10
I5
sg11
g12
sg13
I1
sa(dp16855
g7
I20
sg8
Vintraflagellar transport 80
p16856
sg10
I27
sg11
g12
sg13
I3
sasg24
(lp16857
(dp16858
g7
I150
sg8
Vsyndrome
p16859
sg10
I8
sg28
VC0039082
p16860
sg13
I1
sa(dp16861
g7
I132
sg8
Vpolydactyly
p16862
sg10
I11
sg28
VC0152427
p16863
sg13
I1
sa(dp16864
g7
I79
sg8
Vasphyxiating thoracic dystrophy
p16865
sg10
I31
sg28
VC0265275
p16866
sg13
I3
sasa(dp16867
g2
VPartial mutation of IFT80 in humans causes diseases such as Jeune asphyxiating thoracic dystrophy (JATD) and short rib polydactyly (SRP) type III with abnormal skeletal development.
p16868
sg4
(lp16869
(dp16870
g7
I20
sg8
VIFT80
p16871
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp16872
(dp16873
g7
I66
sg8
Vasphyxiating thoracic dystrophy
p16874
sg10
I31
sg28
VC0265275
p16875
sg13
I3
sa(dp16876
g7
I119
sg8
Vpolydactyly
p16877
sg10
I11
sg28
VC0152427
p16878
sg13
I1
sasa(dp16879
g2
VJeune's asphyxiating thoracic dystrophy (JATD) is an autosomal recessive disorder with symptoms of retinal degeneration, kidney cysts, and chondrodysplasia and results from mutations in the ift80 gene.
p16880
sg4
(lp16881
(dp16882
g7
I190
sg8
Vift80 gene
p16883
sg10
I10
sg11
g12
sg13
I2
sasg24
(lp16884
(dp16885
g7
I99
sg8
Vretinal degeneration
p16886
sg10
I20
sg28
VC0035304
p16887
sg13
I2
sa(dp16888
g7
I121
sg8
Vkidney cysts
p16889
sg10
I12
sg28
VC0268800
p16890
sg13
I2
sa(dp16891
g7
I8
sg8
Vasphyxiating thoracic dystrophy
p16892
sg10
I31
sg28
VC0265275
p16893
sg13
I3
sa(dp16894
g7
I139
sg8
Vchondrodysplasia
p16895
sg10
I16
sg28
VC0343284
p16896
sg13
I1
sasa(dp16897
g2
VIL-33 is associated with a variety of autoimmune diseases, such as sclerosis, inflammatory bowel disease, and rheumatoid arthritis.
p16898
sg4
(lp16899
sg24
(lp16900
(dp16901
g7
I38
sg8
Vautoimmune diseases
p16902
sg10
I19
sg28
VC0004364
p16903
sg13
I2
sa(dp16904
g7
I78
sg8
Vinflammatory bowel disease
p16905
sg10
I26
sg28
VC0021390
p16906
sg13
I3
sa(dp16907
g7
I67
sg8
Vsclerosis
p16908
sg10
I9
sg28
VC0036429
p16909
sg13
I1
sa(dp16910
g7
I110
sg8
Vrheumatoid arthritis
p16911
sg10
I20
sg28
VC0003873
p16912
sg13
I2
sasa(dp16913
g2
VIL-33 was significantly higher in BD patients (101.2+/-20.1pg/ml) as compared to healthy controls (31.5+/-10.5 pg/ml) but lower than rheumatoid arthritis patients (132.5+/-19.1 pg/ml).
p16914
sg4
(lp16915
sg24
(lp16916
(dp16917
g7
I133
sg8
Vrheumatoid arthritis
p16918
sg10
I20
sg28
VC0003873
p16919
sg13
I2
sasa(dp16920
g2
VIt has been shown that the administration of interleukin-33 exacerbates collagen-induced arthritis in experimental models, and a positive correlation between cytokine concentrations in serum and synovial fluid of patients with rheumatoid arthritis and disease activity was found.
p16921
sg4
(lp16922
(dp16923
g7
I45
sg8
Vinterleukin-33
p16924
sg10
I14
sg11
g12
sg13
I1
sasg24
(lp16925
(dp16926
g7
I227
sg8
Vrheumatoid arthritis
p16927
sg10
I20
sg28
VC0003873
p16928
sg13
I2
sa(dp16929
g7
I89
sg8
Varthritis
p16930
sg10
I9
sg28
VC0003864
p16931
sg13
I1
sasa(dp16932
g2
VThis review discusses evidence for the role of interleukin-33 with a focus on rheumatoid arthritis.
p16933
sg4
(lp16934
(dp16935
g7
I47
sg8
Vinterleukin-33
p16936
sg10
I14
sg11
g12
sg13
I1
sasg24
(lp16937
(dp16938
g7
I78
sg8
Vrheumatoid arthritis
p16939
sg10
I20
sg28
VC0003873
p16940
sg13
I2
sasa(dp16941
g135
(dp16942
(Vprohibitin
p16943
Vpropionyl-CoA carboxylase
p16944
tp16945
I00
ssg2
VThe antigenic protein spots reacted against sera from clonorchiasis patients and were identified as cysteine proteases, glutathione transferases, gelsolin, propionyl-CoA carboxylase (PCC), prohibitin and 14-3-3 protein (14-3-3) using LC-coupled ESI-MS/MS and an EST database for C. sinensis.
p16946
sg4
(lp16947
(dp16948
g7
I183
sg8
VPCC
p16949
sg10
I3
sg11
VP07320
p16950
sg13
I1
sa(dp16951
g7
I120
sg8
Vglutathione transferases
p16952
sg10
I24
sg11
VP48637
p16953
sg13
I2
sa(dp16954
g7
I100
sg8
Vcysteine proteases
p16955
sg10
I18
sg11
VP49662
p16956
sg13
I2
sa(dp16957
g7
I146
sg8
Vgelsolin, propionyl-CoA carboxylase
p16958
sg10
I35
sg11
VP06396
p16959
sg13
I3
sa(dp16960
g7
I189
sg8
g16943
sg10
I10
sg11
VP35232
p16961
sg13
I1
sasg24
(lp16962
(dp16963
g7
I54
sg8
Vclonorchiasis
p16964
sg10
I13
sg28
VC0009021
p16965
sg13
I1
sa(dp16966
g7
I183
sg8
VPCC
p16967
sg10
I3
sg28
VC1832526
p16968
sg13
I1
sa(dp16969
g7
I22
sg8
Vspots
p16970
sg10
I5
sg28
VC0015230
p16971
sg13
I1
sa(dp16972
g7
I156
sg8
g16944
sg10
I25
sg28
VC1832526
p16973
sg13
I2
sasa(dp16974
g2
VTo report the effect of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia (type 2 IMT).
p16975
sg4
(lp16976
sg24
(lp16977
(dp16978
g7
I78
sg8
Vtelangiectasia
p16979
sg10
I14
sg28
VC0039446
p16980
sg13
I1
sasa(dp16981
g135
(dp16982
(Vtransforming growth factor-Beta
p16983
Vcyclosporine-A
p16984
tp16985
I00
ssg2
VTo identify the possible biological roles of keratinocyte growth factor (KGF), connective tissue growth factor (CTGF) and transforming growth factor-Beta (TGF-Beta) in cyclosporine-A (CsA) and phenytoin (PNT)-induced gingival overgrowth (GO) and to correlate them with each other.
p16986
sg4
(lp16987
(dp16988
g7
I45
sg8
Vkeratinocyte growth factor
p16989
sg10
I26
sg11
VP21781
p16990
sg13
I3
sa(dp16991
g7
I112
sg8
VCTGF
p16992
sg10
I4
sg11
VP29279
p16993
sg13
I1
sa(dp16994
g7
I155
sg8
VTGF-Beta
p16995
sg10
I8
sg11
VP18075
p16996
sg13
I1
sa(dp16997
g7
I73
sg8
VKGF
p16998
sg10
I3
sg11
VP21781
p16999
sg13
I1
sa(dp17000
g7
I79
sg8
Vconnective tissue growth factor
p17001
sg10
I31
sg11
VP29279
p17002
sg13
I4
sa(dp17003
g7
I122
sg8
g16983
sg10
I31
sg11
VP18075
p17004
sg13
I3
sasg24
(lp17005
(dp17006
g7
I184
sg8
VCsA
p17007
sg10
I3
sg28
VC0751039
p17008
sg13
I1
sa(dp17009
g7
I168
sg8
g16984
sg10
I14
sg28
VC0751039
p17010
sg13
I1
sasa(dp17011
g2
VKeratinocyte growth factor (KGF) and scatter factor (SF) are fibroblast-derived growth factors with potent mitogenic and motogenic effects on epithelial cells, and, therefore, could be involved in the pathogenesis of gingival overgrowth.
p17012
sg4
(lp17013
(dp17014
g7
I0
sg8
VKeratinocyte growth factor
p17015
sg10
I26
sg11
VP21781
p17016
sg13
I3
sa(dp17017
g7
I28
sg8
VKGF
p17018
sg10
I3
sg11
VP21781
p17019
sg13
I1
sasg24
(lp17020
(dp17021
g7
I201
sg8
Vpathogenesis
p17022
sg10
I12
sg28
VC0699748
p17023
sg13
I1
sasa(dp17024
g2
VThese results suggest that KGF and SF may have an important role in cyclosporin-induced gingival overgrowth.
p17025
sg4
(lp17026
(dp17027
g7
I27
sg8
VKGF
p17028
sg10
I3
sg11
VP21781
p17029
sg13
I1
sasg24
(lp17030
sa(dp17031
g2
VOn return to the district to calve, 54% of calves from herd 1 and 30% of calves from herd 2 were affected with congenital arthrogryposis or hydranencephaly caused by Akabane virus infection.
p17032
sg4
(lp17033
sg24
(lp17034
(dp17035
g7
I122
sg8
Varthrogryposis
p17036
sg10
I14
sg28
VC0003886
p17037
sg13
I1
sa(dp17038
g7
I140
sg8
Vhydranencephaly
p17039
sg10
I15
sg28
VC0020225
p17040
sg13
I1
sa(dp17041
g7
I174
sg8
Vvirus infection
p17042
sg10
I15
sg28
VC0042769
p17043
sg13
I2
sasa(dp17044
g135
(dp17045
(VUSP6 locus
p17046
Vbrown tumors
p17047
tp17048
I00
ssg2
VTwelve patients with classic radiologic and histologic features of MO, 6 with brown tumors, and 5 with cherubism diagnosed at our institution were studied for the presence of USP6 rearrangements using fluorescence in situ hybridization with probes flanking the USP6 locus on chromosome 17p13.
p17049
sg4
(lp17050
(dp17051
g7
I175
sg8
VUSP6 rearrangements
p17052
sg10
I19
sg11
VP35125
p17053
sg13
I2
sa(dp17054
g7
I261
sg8
g17046
sg10
I10
sg11
VP35125
p17055
sg13
I2
sasg24
(lp17056
(dp17057
g7
I103
sg8
Vcherubism
p17058
sg10
I9
sg28
VC0008029
p17059
sg13
I1
sa(dp17060
g7
I78
sg8
g17047
sg10
I12
sg28
VC0029405
p17061
sg13
I2
sasa(dp17062
g135
(dp17063
(VUSP6 rearrangements
p17064
Vcherubism
p17065
tp17066
I00
ssg2
VNone of the patients with brown tumor or cherubism demonstrated USP6 rearrangements.
p17067
sg4
(lp17068
(dp17069
g7
I64
sg8
g17064
sg10
I19
sg11
VP35125
p17070
sg13
I2
sasg24
(lp17071
(dp17072
g7
I26
sg8
Vbrown tumor
p17073
sg10
I11
sg28
VC0029405
p17074
sg13
I2
sa(dp17075
g7
I41
sg8
g17065
sg10
I9
sg28
VC0008029
p17076
sg13
I1
sasa(dp17077
g135
(dp17078
(VUSP6 rearrangements
p17079
Vbrown tumor
p17080
tp17081
I00
ssg2
VIn contrast, no USP6 rearrangements were found in patients with cherubism or brown tumor, supporting the prevailing view that these lesions are distinct biologic entities.
p17082
sg4
(lp17083
(dp17084
g7
I16
sg8
g17079
sg10
I19
sg11
VP35125
p17085
sg13
I2
sasg24
(lp17086
(dp17087
g7
I64
sg8
Vcherubism
p17088
sg10
I9
sg28
VC0008029
p17089
sg13
I1
sa(dp17090
g7
I77
sg8
g17080
sg10
I11
sg28
VC0029405
p17091
sg13
I2
sasa(dp17092
g135
(dp17093
(VRanGAP1
p17094
VHuntington's disease
p17095
tp17096
I00
ssg2
VConsistent with findings in mice, marked alterations in nuclear envelope morphology, abnormal localization of RanGAP1, and nuclear accumulation of mRNA were found in cortex of Huntington's disease patients.
p17097
sg4
(lp17098
(dp17099
g7
I110
sg8
g17094
sg10
I7
sg11
VP46060
p17100
sg13
I1
sasg24
(lp17101
(dp17102
g7
I176
sg8
g17095
sg10
I20
sg28
VC0020179
p17103
sg13
I2
sasa(dp17104
g135
(dp17105
(VNup107
p17106
Vamyotrophic lateral sclerosis
p17107
tp17108
I00
ssg2
VDouble immunofluorescent analyses revealed nuclear retention and apparent colocalization of RanGap1 with Nup205, Gp210 with Nup205, and partial colocalization of Nup205 with Nup107; most of the ischemic changes above were similar to those observed in patients with C9orf72-genetic amyotrophic lateral sclerosis.
p17109
sg4
(lp17110
(dp17111
g7
I105
sg8
VNup205
p17112
sg10
I6
sg11
g12
sg13
I1
sa(dp17113
g7
I92
sg8
VRanGap1
p17114
sg10
I7
sg11
VP46060
p17115
sg13
I1
sa(dp17116
g7
I174
sg8
g17106
sg10
I6
sg11
VP57740
p17117
sg13
I1
sa(dp17118
g7
I105
sg8
VNup205
p17119
sg10
I6
sg11
g12
sg13
I1
sa(dp17120
g7
I105
sg8
VNup205
p17121
sg10
I6
sg11
g12
sg13
I1
sa(dp17122
g7
I113
sg8
VGp210
p17123
sg10
I5
sg11
g12
sg13
I1
sasg24
(lp17124
(dp17125
g7
I281
sg8
g17107
sg10
I29
sg28
VC0002736
p17126
sg13
I3
sasa(dp17127
g135
(dp17128
(VCaM genes
p17129
VCaM
p17130
tp17131
I00
ssg2
VDetection of the expression of these proteins and genes encoding these proteins in human gastric cancer tissues by real-time PCR (RT-qPCR) and western blot revealed that the expression of Beta-ACTIN, LDH, DLD, PRPF19 and CaM genes were up-regulated and RanGAP was down-regulated in gastric cancer tissues and/or metastatic lymph nodes compared to peri-cancerous tissues.
p17132
sg4
(lp17133
(dp17134
g7
I205
sg8
VDLD
p17135
sg10
I3
sg11
VP98173
p17136
sg13
I1
sa(dp17137
g7
I200
sg8
VLDH
p17138
sg10
I3
sg11
g12
sg13
I1
sa(dp17139
g7
I188
sg8
VBeta-ACTIN
p17140
sg10
I10
sg11
VP63261
p17141
sg13
I1
sa(dp17142
g7
I221
sg8
g17129
sg10
I9
sg11
VP01768
p17143
sg13
I2
sa(dp17144
g7
I210
sg8
VPRPF19
p17145
sg10
I6
sg11
g12
sg13
I1
sasg24
(lp17146
(dp17147
g7
I89
sg8
Vgastric cancer
p17148
sg10
I14
sg28
VC0024623
p17149
sg13
I2
sa(dp17150
g7
I89
sg8
Vgastric cancer
p17151
sg10
I14
sg28
VC0024623
p17152
sg13
I2
sa(dp17153
g7
I221
sg8
g17130
sg10
I3
sg28
VC1861821
p17154
sg13
I1
sasa(dp17155
g135
(dp17156
(VCYP2C19 allele
p17157
VSCAD
p17158
tp17159
I00
ssg2
VStable coronary artery disease (SCAD) patients scheduled for PCI were randomized to one of the three study arms: 1) genotyping, 2) PFT, and 3) control and evaluated by the CYP2C19 allele genotyping and PFT with P2Y12 assay.
p17160
sg4
(lp17161
(dp17162
g7
I172
sg8
g17157
sg10
I14
sg11
VP33261
p17163
sg13
I2
sasg24
(lp17164
(dp17165
g7
I0
sg8
VStable coronary artery disease
p17166
sg10
I30
sg28
VC0342783
p17167
sg13
I4
sa(dp17168
g7
I107
sg8
Varms
p17169
sg10
I4
sg28
VC0206655
p17170
sg13
I1
sa(dp17171
g7
I32
sg8
g17158
sg10
I4
sg28
VC0342783
p17172
sg13
I1
sasa(dp17173
g135
(dp17174
(VITGB3 T1565C
p17175
Vcoronary heart disease
p17176
tp17177
I00
ssg2
VTo assess the association of CYP2C19 G681A, P2RY12 H1/H2, and ITGB3 T1565C polymorphisms with the extent of platelet aggregation in patients with coronary heart disease (CHD) during antiplatelet therapy.
p17178
sg4
(lp17179
(dp17180
g7
I44
sg8
VP2RY12 H1/H2
p17181
sg10
I12
sg11
g12
sg13
I2
sa(dp17182
g7
I29
sg8
VCYP2C19 G681A
p17183
sg10
I13
sg11
VP33261
p17184
sg13
I2
sa(dp17185
g7
I62
sg8
g17175
sg10
I12
sg11
VP05106
p17186
sg13
I2
sasg24
(lp17187
(dp17188
g7
I170
sg8
VCHD
p17189
sg10
I3
sg28
VC0010054
p17190
sg13
I1
sa(dp17191
g7
I146
sg8
g17176
sg10
I22
sg28
VC0010054
p17192
sg13
I3
sasa(dp17193
g135
(dp17194
(VCstF-64
p17195
Vbreast cancer
p17196
tp17197
I00
ssg2
VThis shortening of the HuR mRNA 3'-UTR via alternative polyadenylation (APA) was observed to be dependent on cleavage stimulation factor subunit 2 (CSTF2/CstF-64), which is up-regulated in the TAMR breast cancer cells.
p17198
sg4
(lp17199
(dp17200
g7
I148
sg8
VCSTF2
p17201
sg10
I5
sg11
VP33240
p17202
sg13
I1
sa(dp17203
g7
I23
sg8
VHuR mRNA 3'-UTR
p17204
sg10
I15
sg11
g12
sg13
I3
sa(dp17205
g7
I154
sg8
g17195
sg10
I7
sg11
VP33240
p17206
sg13
I1
sa(dp17207
g7
I130
sg8
Vfactor subunit 2
p17208
sg10
I16
sg11
g12
sg13
I3
sasg24
(lp17209
(dp17210
g7
I198
sg8
g17196
sg10
I13
sg28
VC0678222
p17211
sg13
I2
sasa(dp17212
g135
(dp17213
(VCSTF2
p17214
Vbladder cancer
p17215
tp17216
I00
ssg2
VMoreover, CSTF2, POLA1, HMOX2, and EFNB2 may be associated with the prognosis of bladder cancer patient.
p17217
sg4
(lp17218
(dp17219
g7
I24
sg8
VHMOX2
p17220
sg10
I5
sg11
VP30519
p17221
sg13
I1
sa(dp17222
g7
I17
sg8
VPOLA1
p17223
sg10
I5
sg11
VP09884
p17224
sg13
I1
sa(dp17225
g7
I35
sg8
VEFNB2
p17226
sg10
I5
sg11
VP52799
p17227
sg13
I1
sa(dp17228
g7
I10
sg8
g17214
sg10
I5
sg11
VP33240
p17229
sg13
I1
sasg24
(lp17230
(dp17231
g7
I81
sg8
g17215
sg10
I14
sg28
VC0699885
p17232
sg13
I2
sasa(dp17233
g2
VAccordingly, RNAi-induced silencing of CSTF2 decreased the proliferative rate of cancer cells.
p17234
sg4
(lp17235
(dp17236
g7
I39
sg8
VCSTF2
p17237
sg10
I5
sg11
VP33240
p17238
sg13
I1
sasg24
(lp17239
(dp17240
g7
I81
sg8
Vcancer
p17241
sg10
I6
sg28
VC0006826
p17242
sg13
I1
sa(dp17243
g7
I59
sg8
Vproliferative
p17244
sg10
I13
sg28
VC0334094
p17245
sg13
I1
sasa(dp17246
g135
(dp17247
(VCSTF2 protein
p17248
Vlung cancers
p17249
tp17250
I01
ssg2
VImmunohistochemical staining using tissue microarray consisting of 327 lung cancers was applied to examine the expression of CSTF2 protein and its prognostic value.
p17251
sg4
(lp17252
(dp17253
g7
I125
sg8
g17248
sg10
I13
sg11
VP33240
p17254
sg13
I2
sasg24
(lp17255
(dp17256
g7
I71
sg8
g17249
sg10
I12
sg28
VC0242379
p17257
sg13
I2
sasa(dp17258
g2
VA role of CSTF2 in cancer cell growth was examined by siRNA experiments.
p17259
sg4
(lp17260
(dp17261
g7
I10
sg8
VCSTF2
p17262
sg10
I5
sg11
VP33240
p17263
sg13
I1
sasg24
(lp17264
(dp17265
g7
I19
sg8
Vcancer cell growth
p17266
sg10
I18
sg28
VC1516170
p17267
sg13
I3
sasa(dp17268
g135
(dp17269
(VCSTF2
p17270
Vnon-small cell lung cancer
p17271
tp17272
I01
ssg2
VImmunohistochemical analysis using tissue microarray showed an association of strong CSTF2 expression with poor prognosis of patients with non-small cell lung cancer (P = 0.0079), and multivariate analysis showed that CSTF2 positivity is an independent prognostic factor.
p17273
sg4
(lp17274
(dp17275
g7
I85
sg8
VCSTF2
p17276
sg10
I5
sg11
VP33240
p17277
sg13
I1
sa(dp17278
g7
I85
sg8
g17270
sg10
I5
sg11
VP33240
p17279
sg13
I1
sasg24
(lp17280
(dp17281
g7
I139
sg8
g17271
sg10
I26
sg28
VC0007131
p17282
sg13
I4
sasa(dp17283
g2
VIn addition, suppression of CSTF2 expression by siRNAs suppressed lung cancer cell growth, whereas exogenous expression of CSTF2 promoted growth and invasion of mammalian cells.
p17284
sg4
(lp17285
(dp17286
g7
I28
sg8
VCSTF2
p17287
sg10
I5
sg11
VP33240
p17288
sg13
I1
sa(dp17289
g7
I28
sg8
VCSTF2
p17290
sg10
I5
sg11
VP33240
p17291
sg13
I1
sasg24
(lp17292
(dp17293
g7
I71
sg8
Vcancer cell growth
p17294
sg10
I18
sg28
VC1516170
p17295
sg13
I3
sa(dp17296
g7
I13
sg8
Vsuppression
p17297
sg10
I11
sg28
VC0221103
p17298
sg13
I1
sa(dp17299
g7
I149
sg8
Vinvasion
p17300
sg10
I8
sg28
VC2699153
p17301
sg13
I1
sasa(dp17302
g135
(dp17303
(VCD68
p17304
Vmammary tumor
p17305
tp17306
I01
ssg2
VImmunohistochemistry analysis of cellular immune parameters (CD4+ or CD8+ T cells, CIITA, MHC-II and CD68) was performed on NMU-induced rat mammary tumor nodules, followed by evaluation of the serum level of 34 cytokines using the cytokine antibody array.
p17307
sg4
(lp17308
(dp17309
g7
I90
sg8
VMHC-II
p17310
sg10
I6
sg11
VP13747
p17311
sg13
I1
sa(dp17312
g7
I69
sg8
VCD8+
p17313
sg10
I4
sg11
VP01732
p17314
sg13
I1
sa(dp17315
g7
I83
sg8
VCIITA
p17316
sg10
I5
sg11
VP33076
p17317
sg13
I1
sa(dp17318
g7
I61
sg8
VCD4+
p17319
sg10
I4
sg11
VP01730
p17320
sg13
I1
sa(dp17321
g7
I101
sg8
g17304
sg10
I4
sg11
VP34810
p17322
sg13
I1
sasg24
(lp17323
(dp17324
g7
I154
sg8
Vnodules
p17325
sg10
I7
sg28
VC0028259
p17326
sg13
I1
sa(dp17327
g7
I140
sg8
g17305
sg10
I13
sg28
VC1458155
p17328
sg13
I2
sasa(dp17329
g135
(dp17330
(VCD4
p17331
Vbreast cancers
p17332
tp17333
I01
ssg2
VImmunohistochemistry was performed to determine PD-L1 tumor cell expression and to enumerate CD8, CD4 and CD68 tumor-infiltrating leucocytes (TIL) in a cohort of 443 breast cancers categorized by molecular subtype.
p17334
sg4
(lp17335
(dp17336
g7
I106
sg8
VCD68
p17337
sg10
I4
sg11
VP34810
p17338
sg13
I1
sa(dp17339
g7
I142
sg8
VTIL
p17340
sg10
I3
sg11
VP01765
p17341
sg13
I1
sa(dp17342
g7
I93
sg8
VCD8
p17343
sg10
I3
sg11
VP01732
p17344
sg13
I1
sa(dp17345
g7
I98
sg8
g17331
sg10
I3
sg11
VP01730
p17346
sg13
I1
sa(dp17347
g7
I111
sg8
Vtumor-infiltrating leucocytes
p17348
sg10
I29
sg11
VP01765
p17349
sg13
I2
sasg24
(lp17350
(dp17351
g7
I54
sg8
Vtumor
p17352
sg10
I5
sg28
VC0027651
p17353
sg13
I1
sa(dp17354
g7
I54
sg8
Vtumor
p17355
sg10
I5
sg28
VC0027651
p17356
sg13
I1
sa(dp17357
g7
I117
sg8
Vinfiltrating
p17358
sg10
I12
sg28
VC0332448
p17359
sg13
I1
sa(dp17360
g7
I166
sg8
g17332
sg10
I14
sg28
VC0006142
p17361
sg13
I2
sasa(dp17362
g135
(dp17363
(VCD11b+CD68+ TAMs
p17364
Vbreast tumors
p17365
tp17366
I00
ssg2
VThese findings demonstrate, for the first time, a novel capacity of a P-Alexa647-FA conjugate to colocalize to CD11b+CD68+ TAMs in both primary and metastatic breast tumors.
p17367
sg4
(lp17368
(dp17369
g7
I111
sg8
g17364
sg10
I16
sg11
VP11215
p17370
sg13
I2
sasg24
(lp17371
(dp17372
g7
I159
sg8
g17365
sg10
I13
sg28
VC1458155
p17373
sg13
I2
sasa(dp17374
g135
(dp17375
(VCD4
p17376
Vbreast tumor
p17377
tp17378
I01
ssg2
VWe used breast tumor tissues from each patient to make tissue microarrays that were then stained for leukocyte and myeloid markers including CD4, CD8, CD20, CD25, CD68, and CD163 using immunohistochemical techniques.
p17379
sg4
(lp17380
(dp17381
g7
I151
sg8
VCD20
p17382
sg10
I4
sg11
VP35900
p17383
sg13
I1
sa(dp17384
g7
I173
sg8
VCD163
p17385
sg10
I5
sg11
g12
sg13
I1
sa(dp17386
g7
I146
sg8
VCD8
p17387
sg10
I3
sg11
VP01732
p17388
sg13
I1
sa(dp17389
g7
I157
sg8
VCD25
p17390
sg10
I4
sg11
VP01589
p17391
sg13
I1
sa(dp17392
g7
I163
sg8
VCD68
p17393
sg10
I4
sg11
VP34810
p17394
sg13
I1
sa(dp17395
g7
I141
sg8
g17376
sg10
I3
sg11
VP01730
p17396
sg13
I1
sasg24
(lp17397
(dp17398
g7
I8
sg8
g17377
sg10
I12
sg28
VC1458155
p17399
sg13
I2
sasa(dp17400
g135
(dp17401
(VCD68+
p17402
Vovarian cancer
p17403
tp17404
I00
ssg2
VFurthermore, high density of CD163+ and CD68+ TAMs was observed in ovarian cancer with advanced TNM stage.
p17405
sg4
(lp17406
(dp17407
g7
I29
sg8
VCD163+
p17408
sg10
I6
sg11
g12
sg13
I1
sa(dp17409
g7
I40
sg8
g17402
sg10
I5
sg11
VP34810
p17410
sg13
I1
sasg24
(lp17411
(dp17412
g7
I67
sg8
g17403
sg10
I14
sg28
VC1140680
p17413
sg13
I2
sasa(dp17414
g135
(dp17415
(VCD68+CD163+ M2-like
p17416
Vbreast cancer
p17417
tp17418
I00
ssg2
VThe number of CD68+CD163+ M2-like macrophages was significantly higher in breast cancer tissues than in benign tissues.
p17419
sg4
(lp17420
(dp17421
g7
I14
sg8
g17416
sg10
I19
sg11
VP34810
p17422
sg13
I2
sasg24
(lp17423
(dp17424
g7
I74
sg8
g17417
sg10
I13
sg28
VC0678222
p17425
sg13
I2
sasa(dp17426
g135
(dp17427
(Vchloride channel ClC-2
p17428
Vleukodystrophy
p17429
tp17430
I00
ssS'line'
p17431
VCharacterisation of most mutations found in CLCN2 in patients with CC2L leukodystrophy show that they cause a reduction in function of the chloride channel ClC-2.
p17432
sS'genes'
p17433
(lp17434
(dp17435
S'index'
p17436
I139
sS'name'
p17437
g17428
sS'lengthInChars'
p17438
I22
sS'uniprot'
p17439
VP51800
p17440
sS'lengthInWords'
p17441
I3
sasS'diseases'
p17442
(lp17443
(dp17444
g17436
I72
sg17437
g17429
sg17438
I14
sS'cui'
p17445
VC0023520
p17446
sg17441
I1
sasa(dp17447
g135
(dp17448
(VClC-2
p17449
VMLC
p17450
tp17451
I00
ssg17431
VGlialCAM, a regulatory subunit of ClC-2 in glial cells and involved in the leukodystrophy megalencephalic leukoencephalopathy with subcortical cysts (MLC), increases the activity of a ClC-2 mutant by affecting ClC-2 gating and by stabilising the mutant at the plasma membrane.
p17452
sg17433
(lp17453
(dp17454
g17436
I0
sg17437
VGlialCAM
p17455
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp17456
g17436
I184
sg17437
VClC-2 mutant
p17457
sg17438
I12
sg17439
VP51788
p17458
sg17441
I2
sa(dp17459
g17436
I34
sg17437
g17449
sg17438
I5
sg17439
VP51788
p17460
sg17441
I1
sasg17442
(lp17461
(dp17462
g17436
I90
sg17437
Vmegalencephalic leukoencephalopathy with subcortical cysts
p17463
sg17438
I58
sg17445
VC1858854
p17464
sg17441
I5
sa(dp17465
g17436
I190
sg17437
Vmutant
p17466
sg17438
I6
sg17445
VC0596988
p17467
sg17441
I1
sa(dp17468
g17436
I75
sg17437
Vleukodystrophy
p17469
sg17438
I14
sg17445
VC0023520
p17470
sg17441
I1
sa(dp17471
g17436
I190
sg17437
Vmutant
p17472
sg17438
I6
sg17445
VC0596988
p17473
sg17441
I1
sa(dp17474
g17436
I150
sg17437
g17450
sg17438
I3
sg17445
VC1858854
p17475
sg17441
I1
sasa(dp17476
g135
(dp17477
(VCLCN2 mutations
p17478
Vleukodystrophy
p17479
tp17480
I00
ssg17431
VWe suggest that leukodystrophy-causing CLCN2 mutations reduce the functional expression of ClC-2, which is partly counteracted by GlialCAM/MLC1-mediated increase in the gating and stability of the channel.
p17481
sg17433
(lp17482
(dp17483
g17436
I139
sg17437
VMLC1
p17484
sg17438
I4
sg17439
VP12829
p17485
sg17441
I1
sa(dp17486
g17436
I130
sg17437
VGlialCAM
p17487
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp17488
g17436
I91
sg17437
VClC-2
p17489
sg17438
I5
sg17439
VP51788
p17490
sg17441
I1
sa(dp17491
g17436
I39
sg17437
g17478
sg17438
I15
sg17439
VP51788
p17492
sg17441
I2
sasg17442
(lp17493
(dp17494
g17436
I139
sg17437
VMLC1
p17495
sg17438
I4
sg17445
VC1858854
p17496
sg17441
I1
sa(dp17497
g17436
I16
sg17437
g17479
sg17438
I14
sg17445
VC0023520
p17498
sg17441
I1
sasa(dp17499
g135
(dp17500
(VClC-2
p17501
Vdiabetes mellitus
p17502
tp17503
I00
ssg17431
VThe review then discusses the diseases associated with ClC-2, including degeneration of the retina, Sjoegren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus.
p17504
sg17433
(lp17505
(dp17506
g17436
I55
sg17437
g17501
sg17438
I5
sg17439
VP51788
p17507
sg17441
I1
sasg17442
(lp17508
(dp17509
g17436
I268
sg17437
Vcystic fibrosis
p17510
sg17438
I15
sg17445
VC0010674
p17511
sg17441
I2
sa(dp17512
g17436
I306
sg17437
Vepilepsy
p17513
sg17438
I8
sg17445
VC0014544
p17514
sg17441
I1
sa(dp17515
g17436
I285
sg17437
Vleukoencephalopathy
p17516
sg17438
I19
sg17445
VC0270612
p17517
sg17441
I1
sa(dp17518
g17436
I133
sg17437
Vcataracts
p17519
sg17438
I9
sg17445
VC0521707
p17520
sg17441
I1
sa(dp17521
g17436
I72
sg17437
Vdegeneration
p17522
sg17438
I12
sg17445
VC0011164
p17523
sg17441
I1
sa(dp17524
g17436
I185
sg17437
Vlung cancer
p17525
sg17438
I11
sg17445
VC0684249
p17526
sg17441
I2
sa(dp17527
g17436
I258
sg17437
Vleukemia
p17528
sg17438
I8
sg17445
VC0023418
p17529
sg17441
I1
sa(dp17530
g17436
I100
sg17437
VSjoegren's syndrome
p17531
sg17438
I19
sg17445
VC1527336
p17532
sg17441
I2
sa(dp17533
g17436
I222
sg17437
Vimpaired
p17534
sg17438
I8
sg17445
VC0684336
p17535
sg17441
I1
sa(dp17536
g17436
I72
sg17437
Vdegeneration
p17537
sg17438
I12
sg17445
VC0011164
p17538
sg17441
I1
sa(dp17539
g17436
I198
sg17437
Vconstipation
p17540
sg17438
I12
sg17445
VC0009806
p17541
sg17441
I1
sa(dp17542
g17436
I172
sg17437
Vazoospermia
p17543
sg17438
I11
sg17445
VC1321542
p17544
sg17441
I1
sa(dp17545
g17436
I319
sg17437
g17502
sg17438
I17
sg17445
VC0011849
p17546
sg17441
I2
sasa(dp17547
g135
(dp17548
(VCLCN2
p17549
VTourette syndrome
p17550
tp17551
I00
ssg17431
VA subset of these genes has been implicated in other neurobehavioral disorders including depression (SLIT3), epilepsy (CLCN2, PRICKLE1), intellectual disability (AP4M1), schizophrenia (WDR60), and Tourette syndrome (OFCC1).
p17552
sg17433
(lp17553
(dp17554
g17436
I126
sg17437
VPRICKLE1
p17555
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp17556
g17436
I162
sg17437
VAP4M1
p17557
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17558
g17436
I101
sg17437
VSLIT3
p17559
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17560
g17436
I185
sg17437
VWDR60
p17561
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17562
g17436
I109
sg17437
Vepilepsy
p17563
sg17438
I8
sg17439
VP10646
p17564
sg17441
I1
sa(dp17565
g17436
I119
sg17437
g17549
sg17438
I5
sg17439
VP51788
p17566
sg17441
I1
sasg17442
(lp17567
(dp17568
g17436
I137
sg17437
Vintellectual disability
p17569
sg17438
I23
sg17445
VC0025362
p17570
sg17441
I2
sa(dp17571
g17436
I170
sg17437
Vschizophrenia
p17572
sg17438
I13
sg17445
VC0036341
p17573
sg17441
I1
sa(dp17574
g17436
I109
sg17437
Vepilepsy
p17575
sg17438
I8
sg17445
VC0014544
p17576
sg17441
I1
sa(dp17577
g17436
I89
sg17437
Vdepression
p17578
sg17438
I10
sg17445
VC0011581
p17579
sg17441
I1
sa(dp17580
g17436
I197
sg17437
g17550
sg17438
I17
sg17445
VC0040517
p17581
sg17441
I2
sasa(dp17582
g17431
VEpilepsy with grand mal on awakening (EGMA) is a well-defined subtype of idiopathic generalized epilepsy.
p17583
sg17433
(lp17584
sg17442
(lp17585
(dp17586
g17436
I73
sg17437
Vidiopathic generalized epilepsy
p17587
sg17438
I31
sg17445
VC0270850
p17588
sg17441
I3
sa(dp17589
g17436
I0
sg17437
VEpilepsy
p17590
sg17438
I8
sg17445
VC0014544
p17591
sg17441
I1
sa(dp17592
g17436
I14
sg17437
Vgrand mal
p17593
sg17438
I9
sg17445
VC0494475
p17594
sg17441
I2
sasa(dp17595
g17431
VAdditionally, using global gene expression analysis of partially reprogrammed cells, we identified SNAI3 as a novel invasion-related marker in human melanoma.
p17596
sg17433
(lp17597
(dp17598
g17436
I99
sg17437
VSNAI3
p17599
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp17600
(dp17601
g17436
I149
sg17437
Vmelanoma
p17602
sg17438
I8
sg17445
VC0025202
p17603
sg17441
I1
sa(dp17604
g17436
I116
sg17437
Vinvasion
p17605
sg17438
I8
sg17445
VC2699153
p17606
sg17441
I1
sasa(dp17607
g17431
VSNAI3 expression correlates with tumor thickness in primary melanomas and thus, may be of prognostic value.
p17608
sg17433
(lp17609
(dp17610
g17436
I0
sg17437
VSNAI3
p17611
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp17612
(dp17613
g17436
I60
sg17437
Vmelanomas
p17614
sg17438
I9
sg17445
VC0025202
p17615
sg17441
I1
sa(dp17616
g17436
I33
sg17437
Vtumor
p17617
sg17438
I5
sg17445
VC0027651
p17618
sg17441
I1
sasa(dp17619
g135
(dp17620
(Vvasculogenic factors
p17621
Vthyroid carcinoma
p17622
tp17623
I00
ssg17431
VEffective silencing of Runx2 by short interfering RNA (siRNA) demonstrated downregulation of EMT-related molecules (SNAI2, SNAI3 and TWIST1), MMP2 and vasculogenic factors (VEGFA and VEGFC) in thyroid carcinoma cells.
p17624
sg17433
(lp17625
(dp17626
g17436
I123
sg17437
VSNAI3
p17627
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17628
g17436
I142
sg17437
VMMP2
p17629
sg17438
I4
sg17439
VP08253
p17630
sg17441
I1
sa(dp17631
g17436
I133
sg17437
VTWIST1
p17632
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp17633
g17436
I93
sg17437
VEMT-related molecules
p17634
sg17438
I21
sg17439
g12
sg17441
I2
sa(dp17635
g17436
I23
sg17437
VRunx2
p17636
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17637
g17436
I183
sg17437
VVEGFC
p17638
sg17438
I5
sg17439
VP49767
p17639
sg17441
I1
sa(dp17640
g17436
I116
sg17437
VSNAI2
p17641
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17642
g17436
I151
sg17437
g17621
sg17438
I20
sg17439
VP19883
p17643
sg17441
I2
sasg17442
(lp17644
(dp17645
g17436
I193
sg17437
g17622
sg17438
I17
sg17445
VC0549473
p17646
sg17441
I2
sasa(dp17647
g135
(dp17648
(VThyroid-stimulating hormone
p17649
Vautoimmunity
p17650
tp17651
I00
ssg17431
VThyroid-stimulating hormone levels, goiter and thyroid dysfunction were higher in children who were anti-TPO1 than in diabetic children without thyroid autoimmunity.
p17652
sg17433
(lp17653
(dp17654
g17436
I0
sg17437
g17649
sg17438
I27
sg17439
VP01222
p17655
sg17441
I2
sa(dp17656
g17436
I100
sg17437
Vanti-TPO1
p17657
sg17438
I9
sg17439
g12
sg17441
I1
sasg17442
(lp17658
(dp17659
g17436
I36
sg17437
Vgoiter
p17660
sg17438
I6
sg17445
VC0018021
p17661
sg17441
I1
sa(dp17662
g17436
I152
sg17437
g17650
sg17438
I12
sg17445
VC0004368
p17663
sg17441
I1
sa(dp17664
g17436
I47
sg17437
Vthyroid dysfunction
p17665
sg17438
I19
sg17445
VC0348024
p17666
sg17441
I2
sasa(dp17667
g17431
VMultiplex ligation-dependent probe amplification (MLPA) can be used to detect rearrangements that cause Alfa-thalassemia, particularly large deletions involving the whole Alfa cluster and/or deletions in the HS-40 region.
p17668
sg17433
(lp17669
(dp17670
g17436
I208
sg17437
VHS-40 region
p17671
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp17672
(dp17673
g17436
I109
sg17437
Vthalassemia
p17674
sg17438
I11
sg17445
VC0039730
p17675
sg17441
I1
sa(dp17676
g17436
I35
sg17437
Vamplification
p17677
sg17438
I13
sg17445
VC1705759
p17678
sg17441
I1
sasa(dp17679
g17431
VIn addition to the -Alfa3.7 deletion identified in the patients with Hb H disease, four different Alfa0 deletions removing 15 to 225 kb DNA segments were found: two of them remove both the Alfa genes, one affects only the regulatory element (HS-40) region, and another one extends over the entire Alfa cluster and the HS-40 region.
p17680
sg17433
(lp17681
(dp17682
g17436
I318
sg17437
VHS-40 region
p17683
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp17684
(dp17685
g17436
I72
sg17437
VH disease
p17686
sg17438
I9
sg17445
VC0018609
p17687
sg17441
I2
sasa(dp17688
g135
(dp17689
(VVDBP
p17690
Vdiabetes
p17691
tp17692
I01
ssg17431
VThe impact of urinary VDBP and KIM-1 on MARE was independent of known CIN risk factors such as anemia, preexisting renal failure, preexisting heart failure, and diabetes.
p17693
sg17433
(lp17694
(dp17695
g17436
I40
sg17437
VMARE
p17696
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp17697
g17436
I31
sg17437
VKIM-1
p17698
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17699
g17436
I22
sg17437
g17690
sg17438
I4
sg17439
VP02774
p17700
sg17441
I1
sasg17442
(lp17701
(dp17702
g17436
I95
sg17437
Vanemia
p17703
sg17438
I6
sg17445
VC0002871
p17704
sg17441
I1
sa(dp17705
g17436
I70
sg17437
VCIN
p17706
sg17438
I3
sg17445
VC0206708
p17707
sg17441
I1
sa(dp17708
g17436
I142
sg17437
Vheart failure
p17709
sg17438
I13
sg17445
VC0018802
p17710
sg17441
I2
sa(dp17711
g17436
I115
sg17437
Vrenal failure
p17712
sg17438
I13
sg17445
VC0035078
p17713
sg17441
I2
sa(dp17714
g17436
I161
sg17437
g17691
sg17438
I8
sg17445
VC0011849
p17715
sg17441
I1
sasa(dp17716
g17431
VThe data show that a tandem Maf recognition element (MARE) in locus control region (LCR) hypersensitive site 2 (HS2) reveals a remarkably high degree of occupancy during differentiation of mouse erythroleukemia cells.
p17717
sg17433
(lp17718
(dp17719
g17436
I53
sg17437
VMARE
p17720
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp17721
g17436
I28
sg17437
VMaf recognition element
p17722
sg17438
I23
sg17439
g12
sg17441
I3
sasg17442
(lp17723
(dp17724
g17436
I195
sg17437
Verythroleukemia
p17725
sg17438
I15
sg17445
VC0023440
p17726
sg17441
I1
sasa(dp17727
g17431
VTargeting of an artificial zinc finger DNA-binding domain (ZF-DBD) to the HS2 tandem MARE caused a reduction in the association of MARE-binding proteins and transcription complexes at LCR HS2 and the adult Betamajor-globin gene promoter but did not affect expression of the Betaminor-globin gene.
p17728
sg17433
(lp17729
(dp17730
g17436
I27
sg17437
Vzinc finger DNA-binding domain
p17731
sg17438
I30
sg17439
g12
sg17441
I4
sa(dp17732
g17436
I59
sg17437
VZF-DBD
p17733
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp17734
g17436
I131
sg17437
VMARE-binding proteins
p17735
sg17438
I21
sg17439
g12
sg17441
I2
sasg17442
(lp17736
sa(dp17737
g17431
VThe data demonstrate that a stable MARE-associated footprint in LCR HS2 is important for the recruitment of transcription complexes to the adult Betamajor-globin gene promoter during erythroid cell differentiation.
p17738
sg17433
(lp17739
sg17442
(lp17740
(dp17741
g17436
I93
sg17437
Vrecruitment
p17742
sg17438
I11
sg17445
VC0271510
p17743
sg17441
I1
sasa(dp17744
g135
(dp17745
(VIL-1Beta
p17746
VDCs
p17747
tp17748
I00
ssg17431
VNext, we demonstrate that CD172a(+)Slan DCs that produced IL-1Beta and TNF-Alfa accumulated in mLNs and colons of CD patients.
p17749
sg17433
(lp17750
(dp17751
g17436
I71
sg17437
VTNF-Alfa
p17752
sg17438
I8
sg17439
VP01375
p17753
sg17441
I1
sa(dp17754
g17436
I58
sg17437
g17746
sg17438
I8
sg17439
VP01584
p17755
sg17441
I1
sasg17442
(lp17756
(dp17757
g17436
I95
sg17437
VmLNs
p17758
sg17438
I4
sg17445
VC0026691
p17759
sg17441
I1
sa(dp17760
g17436
I40
sg17437
g17747
sg17438
I3
sg17445
VC0268238
p17761
sg17441
I1
sasa(dp17762
g135
(dp17763
(VCD14(bright)CD172a(+)Slan DCs
p17764
VmLNs
p17765
tp17766
I00
ssg17431
VIn conclusion, we propose that proinflammatory CD14(bright)CD172a(+)Slan DCs are a distinguishing feature between CD and UC, as these cells accumulate uniquely in mLNs and colonic mucosa of CD patients.
p17767
sg17433
(lp17768
(dp17769
g17436
I47
sg17437
g17764
sg17438
I29
sg17439
VP08571
p17770
sg17441
I2
sasg17442
(lp17771
(dp17772
g17436
I73
sg17437
VDCs
p17773
sg17438
I3
sg17445
VC0268238
p17774
sg17441
I1
sa(dp17775
g17436
I163
sg17437
g17765
sg17438
I4
sg17445
VC0026691
p17776
sg17441
I1
sasa(dp17777
g135
(dp17778
(VCD172a(+)CD11c
p17779
VCD
p17780
tp17781
I00
ssg17431
VHere, we show that CD172a(+)CD11c(+) cells accumulate in the mesenteric lymph nodes (mLNs) and inflamed intestinal mucosa in patients with Crohn's disease (CD).
p17782
sg17433
(lp17783
(dp17784
g17436
I19
sg17437
g17779
sg17438
I14
sg17439
VP20702
p17785
sg17441
I1
sasg17442
(lp17786
(dp17787
g17436
I85
sg17437
VmLNs
p17788
sg17438
I4
sg17445
VC0026691
p17789
sg17441
I1
sa(dp17790
g17436
I139
sg17437
VCrohn's disease
p17791
sg17438
I15
sg17445
VC0010346
p17792
sg17441
I2
sa(dp17793
g17436
I61
sg17437
Vmesenteric lymph nodes
p17794
sg17438
I22
sg17445
VC0026691
p17795
sg17441
I3
sa(dp17796
g17436
I19
sg17437
g17780
sg17438
I2
sg17445
VC0010346
p17797
sg17441
I1
sasa(dp17798
g17431
VAn avidity-improved CD47 fusion protein (CD47-Var1) suppresses the release of a wide array of inflammatory cytokines by CD172a(+) cells, which may include HLA-DR(-)CD172a(+) neutrophils, in inflamed colonic explant cultures and impairs the ability of HLA-DR(+)CD172a(+) cells to activate memory Th17 but not Th1 responses in mLNs.
p17799
sg17433
(lp17800
(dp17801
g17436
I41
sg17437
VCD47-Var1
p17802
sg17438
I9
sg17439
g12
sg17441
I1
sa(dp17803
g17436
I251
sg17437
VHLA-DR(+)CD172a
p17804
sg17438
I15
sg17439
VP30486
p17805
sg17441
I1
sa(dp17806
g17436
I155
sg17437
VHLA-DR(-)CD172a
p17807
sg17438
I15
sg17439
VP30486
p17808
sg17441
I1
sa(dp17809
g17436
I20
sg17437
VCD47 fusion protein
p17810
sg17438
I19
sg17439
g12
sg17441
I3
sasg17442
(lp17811
(dp17812
g17436
I325
sg17437
VmLNs
p17813
sg17438
I4
sg17445
VC0026691
p17814
sg17441
I1
sasa(dp17815
g135
(dp17816
(VCD103(-) DCs
p17817
Vcolitis
p17818
tp17819
I00
ssg17431
VWe first show that mucosal CD103(-) DCs selectively express SIRPalpha and that their frequency was augmented in the lamina propria and mLNs of mice that developed Th17-biased colitis in response to trinitrobenzene sulfonic acid.
p17820
sg17433
(lp17821
(dp17822
g17436
I27
sg17437
g17817
sg17438
I12
sg17439
VP38570
p17823
sg17441
I2
sasg17442
(lp17824
(dp17825
g17436
I135
sg17437
VmLNs
p17826
sg17438
I4
sg17445
VC0026691
p17827
sg17441
I1
sa(dp17828
g17436
I36
sg17437
VDCs
p17829
sg17438
I3
sg17445
VC0268238
p17830
sg17441
I1
sa(dp17831
g17436
I175
sg17437
g17818
sg17438
I7
sg17445
VC0009319
p17832
sg17441
I1
sasa(dp17833
g135
(dp17834
(VSIRPalpha(+)CD103(-)
p17835
VmLNs
p17836
tp17837
I00
ssg17431
VCD47 expression was required on the SIRPalpha(+)CD103(-) DCs for efficient trafficking to mLNs in vivo, whereas it was dispensable on both DCs and T cells for Th17 polarization in vitro.
p17838
sg17433
(lp17839
(dp17840
g17436
I36
sg17437
g17835
sg17438
I20
sg17439
VP38570
p17841
sg17441
I1
sa(dp17842
g17436
I0
sg17437
VCD47
p17843
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp17844
(dp17845
g17436
I57
sg17437
VDCs
p17846
sg17438
I3
sg17445
VC0268238
p17847
sg17441
I1
sa(dp17848
g17436
I57
sg17437
VDCs
p17849
sg17438
I3
sg17445
VC0268238
p17850
sg17441
I1
sa(dp17851
g17436
I90
sg17437
g17836
sg17438
I4
sg17445
VC0026691
p17852
sg17441
I1
sasa(dp17853
g135
(dp17854
(Vprolactin
p17855
Vgrowth hormone-producing pituitary tumor
p17856
tp17857
I00
ssg17431
VEffects of Ca2+ and calmodulin on the adenylate cyclase activity of a prolactin and growth hormone-producing pituitary tumor cell strain (GH3) were examined.
p17858
sg17433
(lp17859
(dp17860
g17436
I38
sg17437
Vadenylate cyclase
p17861
sg17438
I17
sg17439
g12
sg17441
I2
sa(dp17862
g17436
I84
sg17437
Vgrowth hormone
p17863
sg17438
I14
sg17439
VP01242
p17864
sg17441
I2
sa(dp17865
g17436
I20
sg17437
Vcalmodulin
p17866
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp17867
g17436
I70
sg17437
g17855
sg17438
I9
sg17439
VP01236
p17868
sg17441
I1
sasg17442
(lp17869
(dp17870
g17436
I84
sg17437
g17856
sg17438
I40
sg17445
VC0278864
p17871
sg17441
I4
sasa(dp17872
g17431
VThe control of PTG hyperplasia is most important in the management of secondary hyperparathyroidism (SHPT), because the advanced stage of hyperplasia is considered irreversible.
p17873
sg17433
(lp17874
sg17442
(lp17875
(dp17876
g17436
I19
sg17437
Vhyperplasia
p17877
sg17438
I11
sg17445
VC0020507
p17878
sg17441
I1
sa(dp17879
g17436
I101
sg17437
VSHPT
p17880
sg17438
I4
sg17445
VC0020503
p17881
sg17441
I1
sa(dp17882
g17436
I19
sg17437
Vhyperplasia
p17883
sg17438
I11
sg17445
VC0020507
p17884
sg17441
I1
sa(dp17885
g17436
I70
sg17437
Vsecondary hyperparathyroidism
p17886
sg17438
I29
sg17445
VC0020503
p17887
sg17441
I2
sasa(dp17888
g17431
VControl of secondary hyperparathyroidism (SHPT) using active vitamin D analogues becomes difficult in advanced SHPT, because the enlarged parathyroid glands (PTGs) are resistant to medical therapy.
p17889
sg17433
(lp17890
sg17442
(lp17891
(dp17892
g17436
I11
sg17437
Vsecondary hyperparathyroidism
p17893
sg17438
I29
sg17445
VC0020503
p17894
sg17441
I2
sa(dp17895
g17436
I42
sg17437
VSHPT
p17896
sg17438
I4
sg17445
VC0020503
p17897
sg17441
I1
sa(dp17898
g17436
I42
sg17437
VSHPT
p17899
sg17438
I4
sg17445
VC0020503
p17900
sg17441
I1
sasa(dp17901
g17431
VThe long-term effect of cinacalcet hydrochloride treatment on parathyroid gland (PTG) volume has been scarcely investigated in patients with moderate to advanced secondary hyperparathyroidism (SHPT).
p17902
sg17433
(lp17903
sg17442
(lp17904
(dp17905
g17436
I193
sg17437
VSHPT
p17906
sg17438
I4
sg17445
VC0020503
p17907
sg17441
I1
sa(dp17908
g17436
I162
sg17437
Vsecondary hyperparathyroidism
p17909
sg17438
I29
sg17445
VC0020503
p17910
sg17441
I2
sasa(dp17911
g17431
VIt has been suggested that microRNA-9 (miR-9) is associated with the development of knee osteoarthritis (OA).
p17912
sg17433
(lp17913
(dp17914
g17436
I27
sg17437
VmicroRNA-9
p17915
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp17916
g17436
I39
sg17437
VmiR-9
p17917
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp17918
(dp17919
g17436
I84
sg17437
Vknee osteoarthritis
p17920
sg17438
I19
sg17445
VC0409959
p17921
sg17441
I2
sasa(dp17922
g135
(dp17923
(Vecto-nucleotide pyro phosphatase/phosphodiesterase 1
p17924
Vautosomal recessive HR
p17925
tp17926
I01
ssg17431
VX-linked hypophosphatemia (XLH), autosomal dominant HR (ADHR), and autosomal recessive HR (ARHR) are examples of hereditary forms of HR, which are mainly caused by mutations in the phosphate regulating endopeptidase homolog, X-linked (PHEX), FGF23, and, dentin matrix protein-1 (DMP1) and ecto-nucleotide pyro phosphatase/phosphodiesterase 1 (ENPP1) genes, respectively.
p17927
sg17433
(lp17928
(dp17929
g17436
I242
sg17437
VFGF23
p17930
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17931
g17436
I202
sg17437
Vendopeptidase homolog, X-linked
p17932
sg17438
I31
sg17439
g12
sg17441
I3
sa(dp17933
g17436
I33
sg17437
Vautosomal dominant HR
p17934
sg17438
I21
sg17439
VP56715
p17935
sg17441
I3
sa(dp17936
g17436
I254
sg17437
Vdentin matrix protein-1
p17937
sg17438
I23
sg17439
g12
sg17441
I3
sa(dp17938
g17436
I56
sg17437
VADHR
p17939
sg17438
I4
sg17439
VP30518
p17940
sg17441
I1
sa(dp17941
g17436
I279
sg17437
VDMP1
p17942
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp17943
g17436
I343
sg17437
VENPP1
p17944
sg17438
I5
sg17439
VP22413
p17945
sg17441
I1
sa(dp17946
g17436
I235
sg17437
VPHEX
p17947
sg17438
I4
sg17439
VP78562
p17948
sg17441
I1
sa(dp17949
g17436
I289
sg17437
g17924
sg17438
I52
sg17439
VP22413
p17950
sg17441
I4
sasg17442
(lp17951
(dp17952
g17436
I0
sg17437
VX-linked hypophosphatemia
p17953
sg17438
I25
sg17445
VC0733682
p17954
sg17441
I2
sa(dp17955
g17436
I91
sg17437
VARHR
p17956
sg17438
I4
sg17445
VC0342643
p17957
sg17441
I1
sa(dp17958
g17436
I33
sg17437
Vautosomal dominant HR
p17959
sg17438
I21
sg17445
VC0342642
p17960
sg17441
I3
sa(dp17961
g17436
I56
sg17437
VADHR
p17962
sg17438
I4
sg17445
VC0342642
p17963
sg17441
I1
sa(dp17964
g17436
I27
sg17437
VXLH
p17965
sg17438
I3
sg17445
VC0733682
p17966
sg17441
I1
sa(dp17967
g17436
I67
sg17437
g17925
sg17438
I22
sg17445
VC0342643
p17968
sg17441
I3
sasa(dp17969
g17431
VHomozygous inactivating mutations in DMP1 (dentin matrix protein 1), the gene encoding a noncollagenous bone matrix protein expressed in osteoblasts and osteocytes, cause autosomal recessive hypophosphatemia (ARHP).
p17970
sg17433
(lp17971
sg17442
(lp17972
(dp17973
g17436
I171
sg17437
Vautosomal recessive hypophosphatemia
p17974
sg17438
I36
sg17445
VC0342643
p17975
sg17441
I3
sa(dp17976
g17436
I209
sg17437
VARHP
p17977
sg17438
I4
sg17445
VC0342643
p17978
sg17441
I1
sasa(dp17979
g17431
VAn autosomal recessive form of hypophosphatemia (ARHP) was recently shown to be caused by homozygous mutations in DMP1, the gene encoding dentin matrix protein-1 (DMP-1), a non-collagenous bone matrix protein with an important role in the development and mineralization of bone and teeth.
p17980
sg17433
(lp17981
(dp17982
g17436
I163
sg17437
VDMP-1
p17983
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp17984
g17436
I173
sg17437
Vnon-collagenous bone matrix protein
p17985
sg17438
I35
sg17439
VP63145
p17986
sg17441
I4
sa(dp17987
g17436
I124
sg17437
Vgene encoding dentin matrix protein-1
p17988
sg17438
I37
sg17439
g12
sg17441
I5
sa(dp17989
g17436
I114
sg17437
VDMP1
p17990
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp17991
(dp17992
g17436
I49
sg17437
VARHP
p17993
sg17438
I4
sg17445
VC0342643
p17994
sg17441
I1
sa(dp17995
g17436
I3
sg17437
Vautosomal recessive form of hypophosphatemia
p17996
sg17438
I44
sg17445
VC0342643
p17997
sg17441
I5
sasa(dp17998
g135
(dp17999
(Vautosomal dominant hypophosphatemic rickets
p18000
VX-linked hypophosphatemia
p18001
tp18002
I00
ssg17431
VAmong various causes of low serum phosphorous are inherited disorders associated with increased urinary excretion of phosphate, including autosomal dominant hypophosphatemic rickets (ADHR), X-linked hypophosphatemia (XLH), autosomal recessive hypophosphatemia (ARHP), and hereditary hypophosphatemic rickets with hypercalciuria (HHRH).
p18003
sg17433
(lp18004
(dp18005
g17436
I183
sg17437
VADHR
p18006
sg17438
I4
sg17439
VP30518
p18007
sg17441
I1
sa(dp18008
g17436
I138
sg17437
g18000
sg17438
I43
sg17439
VP30518
p18009
sg17441
I4
sasg17442
(lp18010
(dp18011
g17436
I261
sg17437
VARHP
p18012
sg17438
I4
sg17445
VC0342643
p18013
sg17441
I1
sa(dp18014
g17436
I138
sg17437
Vautosomal dominant hypophosphatemic rickets
p18015
sg17438
I43
sg17445
VC0342642
p18016
sg17441
I4
sa(dp18017
g17436
I283
sg17437
Vhypophosphatemic rickets with hypercalciuria
p18018
sg17438
I44
sg17445
VC0342645
p18019
sg17441
I4
sa(dp18020
g17436
I329
sg17437
VHHRH
p18021
sg17438
I4
sg17445
VC0342645
p18022
sg17441
I1
sa(dp18023
g17436
I217
sg17437
VXLH
p18024
sg17438
I3
sg17445
VC0733682
p18025
sg17441
I1
sa(dp18026
g17436
I223
sg17437
Vautosomal recessive hypophosphatemia
p18027
sg17438
I36
sg17445
VC0342643
p18028
sg17441
I3
sa(dp18029
g17436
I183
sg17437
VADHR
p18030
sg17438
I4
sg17445
VC0342642
p18031
sg17441
I1
sa(dp18032
g17436
I190
sg17437
g18001
sg17438
I25
sg17445
VC0733682
p18033
sg17441
I2
sasa(dp18034
g135
(dp18035
(Vdentin matrix protein 1
p18036
Vhypophosphatemia
p18037
tp18038
I00
ssg17431
VRecently, positional cloning approaches furthermore led to the identification of homozygous inactivating mutations in dentin matrix protein 1 (DMP1) as the cause of an autosomal recessive form of hypophosphatemia.
p18039
sg17433
(lp18040
(dp18041
g17436
I118
sg17437
g18036
sg17438
I23
sg17439
VP14222
p18042
sg17441
I4
sa(dp18043
g17436
I143
sg17437
VDMP1
p18044
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp18045
(dp18046
g17436
I196
sg17437
g18037
sg17438
I16
sg17445
VC0085682
p18047
sg17441
I1
sasa(dp18048
g17431
VPharmacological treatment of SOD1(G37R) mice with minocycline, a compound that attenuates microgliosis and slows down disease, lessened the dysregulation of Cdk5/Cdk4 and the phosphorylation of Rb.
p18049
sg17433
(lp18050
(dp18051
g17436
I29
sg17437
VSOD1
p18052
sg17438
I4
sg17439
VP00441
p18053
sg17441
I1
sa(dp18054
g17436
I157
sg17437
VCdk5
p18055
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp18056
g17436
I162
sg17437
VCdk4
p18057
sg17438
I4
sg17439
VP11802
p18058
sg17441
I1
sasg17442
(lp18059
sa(dp18060
g135
(dp18061
(VCDK
p18062
Vrunt
p18063
tp18064
I00
ssg17431
VSeventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma"), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules.
p18065
sg17433
(lp18066
(dp18067
g17436
I57
sg17437
VT-cell-specific transcription factor
p18068
sg17438
I36
sg17439
VP35398
p18069
sg17441
I3
sa(dp18070
g17436
I276
sg17437
Vvitamin D receptor
p18071
sg17438
I18
sg17439
VP11473
p18072
sg17441
I3
sa(dp18073
g17436
I109
sg17437
V"proto-oncogene tyrosine-protein kinase
p18074
sg17438
I39
sg17439
VP00519
p18075
sg17441
I3
sa(dp18076
g17436
I399
sg17437
VPR domain zinc finger protein 1
p18077
sg17438
I31
sg17439
g12
sg17441
I6
sa(dp18078
g17436
I322
sg17437
VERK
p18079
sg17438
I3
sg17439
VP29323
p18080
sg17441
I1
sa(dp18081
g17436
I362
sg17437
Vrunt-related transcription factor 1
p18082
sg17438
I35
sg17439
VP20823
p18083
sg17441
I4
sa(dp18084
g17436
I477
sg17437
Vinterleukin 1
p18085
sg17438
I13
sg17439
VP01584
p18086
sg17441
I2
sa(dp18087
g17436
I152
sg17437
Vsarcoma"
p18088
sg17438
I8
sg17439
VP12931
p18089
sg17441
I1
sa(dp18090
g17436
I163
sg17437
Vinterferon regulatory factor 1
p18091
sg17438
I30
sg17439
VP10914
p18092
sg17441
I4
sa(dp18093
g17436
I227
sg17437
Vcyclin-dependent kinase (CDK) 4
p18094
sg17438
I31
sg17439
VP49336
p18095
sg17441
I4
sa(dp18096
g17436
I296
sg17437
Vhistone deacetylase
p18097
sg17438
I19
sg17439
VP56524
p18098
sg17441
I2
sa(dp18099
g17436
I95
sg17437
VSrc
p18100
sg17438
I3
sg17439
VP12931
p18101
sg17441
I1
sa(dp18102
g17436
I217
sg17437
Vcyclin B
p18103
sg17438
I8
sg17439
VP14635
p18104
sg17441
I2
sa(dp18105
g17436
I334
sg17437
Vbcl-2-associated X protein
p18106
sg17438
I26
sg17439
VP10415
p18107
sg17441
I3
sa(dp18108
g17436
I317
sg17437
VMAPK
p18109
sg17438
I4
sg17439
VP53779
p18110
sg17441
I1
sa(dp18111
g17436
I432
sg17437
Vplatelet-derived growth factor receptor
p18112
sg17438
I39
sg17439
VP09619
p18113
sg17441
I4
sa(dp18114
g17436
I265
sg17437
Vcaspase-1
p18115
sg17438
I9
sg17439
VP29466
p18116
sg17441
I1
sa(dp18117
g17436
I195
sg17437
Vthymidylate synthase
p18118
sg17438
I20
sg17439
VP04818
p18119
sg17441
I2
sa(dp18120
g17436
I252
sg17437
g18062
sg17438
I3
sg17439
VP24941
p18121
sg17441
I1
sasg17442
(lp18122
(dp18123
g17436
I152
sg17437
Vsarcoma
p18124
sg17438
I7
sg17445
VC1261473
p18125
sg17441
I1
sa(dp18126
g17436
I362
sg17437
g18063
sg17438
I4
sg17445
VC0013336
p18127
sg17441
I1
sasa(dp18128
g135
(dp18129
(Vcaspase-1
p18130
Vtumor progression
p18131
tp18132
I00
ssg17431
VTherefore, targeting the caspase-1/PPARGamma/MCAD pathway might be a promising therapeutic approach to prevent tumor progression.Tumor associated macrophages (TAMs) promote cancer progression.
p18133
sg17433
(lp18134
(dp18135
g17436
I45
sg17437
VMCAD
p18136
sg17438
I4
sg17439
VP11310
p18137
sg17441
I1
sa(dp18138
g17436
I25
sg17437
g18130
sg17438
I9
sg17439
VP29466
p18139
sg17441
I1
sasg17442
(lp18140
(dp18141
g17436
I173
sg17437
Vcancer progression
p18142
sg17438
I18
sg17445
VC0178874
p18143
sg17441
I2
sa(dp18144
g17436
I45
sg17437
VMCAD
p18145
sg17438
I4
sg17445
VC0220710
p18146
sg17441
I1
sa(dp18147
g17436
I129
sg17437
VTumor
p18148
sg17438
I5
sg17445
VC0027651
p18149
sg17441
I1
sa(dp18150
g17436
I111
sg17437
g18131
sg17438
I17
sg17445
VC0178874
p18151
sg17441
I2
sasa(dp18152
g135
(dp18153
(Vcaspase-1
p18154
Vbreast cancer
p18155
tp18156
I01
ssg17431
VHere, the author show that caspase-1 promotes TAMs differentiation by attenuating medium-chain acyl-CoA dehydrogenase activity and that inhibition of this axis results in suppression of tumour growth in a transgenic mouse model of breast cancer.
p18157
sg17433
(lp18158
(dp18159
g17436
I95
sg17437
Vacyl-CoA dehydrogenase
p18160
sg17438
I22
sg17439
VP49366
p18161
sg17441
I2
sa(dp18162
g17436
I27
sg17437
g18154
sg17438
I9
sg17439
VP29466
p18163
sg17441
I1
sasg17442
(lp18164
(dp18165
g17436
I100
sg17437
VCoA
p18166
sg17438
I3
sg17445
VC2678439
p18167
sg17441
I1
sa(dp18168
g17436
I231
sg17437
g18155
sg17438
I13
sg17445
VC0678222
p18169
sg17441
I2
sa(dp18170
g17436
I171
sg17437
Vsuppression
p18171
sg17438
I11
sg17445
VC0221103
p18172
sg17441
I1
sa(dp18173
g17436
I186
sg17437
Vtumour
p18174
sg17438
I6
sg17445
VC0027651
p18175
sg17441
I1
sasa(dp18176
g17431
VEnsuing western blotting or immunostaining results showed that Rictor/mTORC2 signaling was activated in kidney interstitial myofibroblasts from mice with unilateral ureteral obstruction.
p18177
sg17433
(lp18178
(dp18179
g17436
I63
sg17437
VRictor
p18180
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp18181
(dp18182
g17436
I165
sg17437
Vureteral obstruction
p18183
sg17438
I20
sg17445
VC0041956
p18184
sg17441
I2
sasa(dp18185
g17431
VCompared with control littermates, the kidneys of Rictor knockout mice developed less interstitial extracellular matrix deposition and inflammatory cell infiltration at 1 or 2 weeks after ureteral obstruction.
p18186
sg17433
(lp18187
sg17442
(lp18188
(dp18189
g17436
I188
sg17437
Vureteral obstruction
p18190
sg17438
I20
sg17445
VC0041956
p18191
sg17441
I2
sa(dp18192
g17436
I135
sg17437
Vinflammatory cell infiltration
p18193
sg17438
I30
sg17445
VC0302158
p18194
sg17441
I3
sasa(dp18195
g17431
VLess progression of Hoffa-synovitis and effusion-synovitis was observed in the TG-C group compared to placebo (9.6% vs. 21.1%, adjusted RR 0.5, 95%CI [0.2,1.2], p = 0.115).
p18196
sg17433
(lp18197
sg17442
(lp18198
(dp18199
g17436
I40
sg17437
Veffusion
p18200
sg17438
I8
sg17445
VC0013687
p18201
sg17441
I1
sa(dp18202
g17436
I26
sg17437
Vsynovitis
p18203
sg17438
I9
sg17445
VC0039103
p18204
sg17441
I1
sa(dp18205
g17436
I26
sg17437
Vsynovitis
p18206
sg17438
I9
sg17445
VC0039103
p18207
sg17441
I1
sasa(dp18208
g17431
VIntraarticular treatment with TG-C showed fewer patients in the treated group with progression in structural OA features and other MRI-defined inflammatory markers such as Hoffa-synovitis and effusion-synovitis.
p18209
sg17433
(lp18210
sg17442
(lp18211
(dp18212
g17436
I192
sg17437
Veffusion
p18213
sg17438
I8
sg17445
VC0013687
p18214
sg17441
I1
sa(dp18215
g17436
I178
sg17437
Vsynovitis
p18216
sg17438
I9
sg17445
VC0039103
p18217
sg17441
I1
sa(dp18218
g17436
I178
sg17437
Vsynovitis
p18219
sg17438
I9
sg17445
VC0039103
p18220
sg17441
I1
sasa(dp18221
g135
(dp18222
(VtTG-2
p18223
VIBS
p18224
tp18225
I00
ssg17431
VA total of 104 patients (89.4% females) fulfilling the 1990 ACR criteria for FMS and the Rome III criteria for IBS classification and 125 unrelated age- and sex-matched IBS patients without FMS underwent the following studies: haematological, coagulation and biochemistry tests, serological and genetic markers for CD (i.e., tissue transglutaminase 2 (tTG-2) and major histocompatibility complex HLA-DQ2/HLA-DQ8), multiple gastric and duodenal biopsies, FMS tender points (TPs), Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), 36-Item Short Form Health Survey (SF-36) and Visual Analogue Scales (VASs) for tiredness and gastrointestinal complaints.
p18226
sg17433
(lp18227
(dp18228
g17436
I325
sg17437
Vtissue transglutaminase 2
p18229
sg17438
I25
sg17439
VP21980
p18230
sg17441
I3
sa(dp18231
g17436
I400
sg17437
VDQ2
p18232
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp18233
g17436
I363
sg17437
Vmajor histocompatibility complex HLA
p18234
sg17438
I36
sg17439
VP18464
p18235
sg17441
I4
sa(dp18236
g17436
I352
sg17437
g18223
sg17438
I5
sg17439
VP21980
p18237
sg17441
I1
sa(dp18238
g17436
I404
sg17437
VHLA-DQ8
p18239
sg17438
I7
sg17439
VP30486
p18240
sg17441
I1
sasg17442
(lp18241
(dp18242
g17436
I111
sg17437
VIBS
p18243
sg17438
I3
sg17445
VC0022104
p18244
sg17441
I1
sa(dp18245
g17436
I77
sg17437
VFMS
p18246
sg17438
I3
sg17445
VC0016053
p18247
sg17441
I1
sa(dp18248
g17436
I638
sg17437
Vtiredness
p18249
sg17438
I9
sg17445
VC0015672
p18250
sg17441
I1
sa(dp18251
g17436
I479
sg17437
VFibromyalgia
p18252
sg17438
I12
sg17445
VC0016053
p18253
sg17441
I1
sa(dp18254
g17436
I77
sg17437
VFMS
p18255
sg17438
I3
sg17445
VC0016053
p18256
sg17441
I1
sa(dp18257
g17436
I77
sg17437
VFMS
p18258
sg17438
I3
sg17445
VC0016053
p18259
sg17441
I1
sa(dp18260
g17436
I111
sg17437
g18224
sg17438
I3
sg17445
VC0022104
p18261
sg17441
I1
sasa(dp18262
g135
(dp18263
(VtTG
p18264
VFibromyalgia
p18265
tp18266
I00
ssg17431
VGFD effectiveness was assessed at baseline and after 1 year, examining the score changes in the Tender Points (TPs) test, Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal complaints, pain and tiredness, drug prescriptions and tissue-Trans-Glutaminase (tTG) serum levels.
p18267
sg17433
(lp18268
(dp18269
g17436
I367
sg17437
g18264
sg17438
I3
sg17439
VP21980
p18270
sg17441
I1
sa(dp18271
g17436
I341
sg17437
Vtissue-Trans-Glutaminase
p18272
sg17438
I24
sg17439
g12
sg17441
I1
sasg17442
(lp18273
(dp18274
g17436
I307
sg17437
Vtiredness
p18275
sg17438
I9
sg17445
VC0015672
p18276
sg17441
I1
sa(dp18277
g17436
I0
sg17437
VGFD
p18278
sg17438
I3
sg17445
VC1851112
p18279
sg17441
I1
sa(dp18280
g17436
I122
sg17437
g18265
sg17438
I12
sg17445
VC0016053
p18281
sg17441
I1
sasa(dp18282
g135
(dp18283
(Vanti-tissue transglutaminase
p18284
Vpsoriasis
p18285
tp18286
I01
ssg17431
VNon-organ specific AAb (ANA, anti-Ro52, anti-Ro60, anti-La, anti-RNP) but not anti-thyroid peroxidase, anti-tissue transglutaminase or myositis-specific antibodies, were more frequent in s-IBM patients, and 14/51 (27%) had another autoimmune disease (Sjoegren's syndrome, thyroiditis, psoriasis, vitiligo).
p18287
sg17433
(lp18288
(dp18289
g17436
I40
sg17437
Vanti-Ro60
p18290
sg17438
I9
sg17439
VP10155
p18291
sg17441
I1
sa(dp18292
g17436
I78
sg17437
Vanti-thyroid peroxidase
p18293
sg17438
I23
sg17439
VP40225
p18294
sg17441
I2
sa(dp18295
g17436
I60
sg17437
Vanti-RNP
p18296
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp18297
g17436
I135
sg17437
Vmyositis-specific antibodies
p18298
sg17438
I28
sg17439
VP04280
p18299
sg17441
I2
sa(dp18300
g17436
I24
sg17437
VANA
p18301
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp18302
g17436
I29
sg17437
Vanti-Ro52
p18303
sg17438
I9
sg17439
VP19474
p18304
sg17441
I1
sa(dp18305
g17436
I103
sg17437
g18284
sg17438
I28
sg17439
VP21980
p18306
sg17441
I2
sasg17442
(lp18307
(dp18308
g17436
I189
sg17437
VIBM
p18309
sg17438
I3
sg17445
VC0238190
p18310
sg17441
I1
sa(dp18311
g17436
I251
sg17437
VSjoegren's syndrome
p18312
sg17438
I19
sg17445
VC1527336
p18313
sg17441
I2
sa(dp18314
g17436
I231
sg17437
Vautoimmune disease
p18315
sg17438
I18
sg17445
VC0004364
p18316
sg17441
I2
sa(dp18317
g17436
I296
sg17437
Vvitiligo
p18318
sg17438
I8
sg17445
VC0042900
p18319
sg17441
I1
sa(dp18320
g17436
I135
sg17437
Vmyositis
p18321
sg17438
I8
sg17445
VC0027121
p18322
sg17441
I1
sa(dp18323
g17436
I272
sg17437
Vthyroiditis
p18324
sg17438
I11
sg17445
VC0040147
p18325
sg17441
I1
sa(dp18326
g17436
I285
sg17437
g18285
sg17438
I9
sg17445
VC0033860
p18327
sg17441
I1
sasa(dp18328
g135
(dp18329
(VCD105
p18330
Vganglion
p18331
tp18332
I00
ssg17431
VBy applying CD146 and CD105 antibodies on human retinas from glaucomatous eyes, CD146-positive retinal ganglion cells (RGCs) were found, some being placed in perivascular positions; ongoing processes of neurites extension were related to these neurons.
p18333
sg17433
(lp18334
(dp18335
g17436
I12
sg17437
VCD146
p18336
sg17438
I5
sg17439
VP43121
p18337
sg17441
I1
sa(dp18338
g17436
I12
sg17437
VCD146
p18339
sg17438
I5
sg17439
VP43121
p18340
sg17441
I1
sa(dp18341
g17436
I22
sg17437
g18330
sg17438
I5
sg17439
VP17813
p18342
sg17441
I1
sasg17442
(lp18343
(dp18344
g17436
I103
sg17437
g18331
sg17438
I8
sg17445
VC1258666
p18345
sg17441
I1
sasa(dp18346
g135
(dp18347
(VCD146-positive RGCs
p18348
Vglaucoma
p18349
tp18350
I00
ssg17431
VThese results support the hypothesis that in glaucoma eyes the CD146-positive RGCs result from regenerative processes driven by stem cells in the retinal perivascular niches.
p18351
sg17433
(lp18352
(dp18353
g17436
I63
sg17437
g18348
sg17438
I19
sg17439
VP43121
p18354
sg17441
I2
sasg17442
(lp18355
(dp18356
g17436
I45
sg17437
g18349
sg17438
I8
sg17445
VC0017601
p18357
sg17441
I1
sasa(dp18358
g17431
VCD146/MCAM and CD166/ALCAM, previously unreported in cells from fvERMs, were also expressed.
p18359
sg17433
(lp18360
(dp18361
g17436
I15
sg17437
VCD166
p18362
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp18363
g17436
I21
sg17437
VALCAM
p18364
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp18365
g17436
I6
sg17437
VMCAM
p18366
sg17438
I4
sg17439
VP43121
p18367
sg17441
I1
sa(dp18368
g17436
I0
sg17437
VCD146
p18369
sg17438
I5
sg17439
VP43121
p18370
sg17441
I1
sasg17442
(lp18371
sa(dp18372
g135
(dp18373
(Vmelanoma cell adhesion molecule
p18374
Vadhesion
p18375
tp18376
I00
ssg17431
VTwo new and potentially promising melanocytic markers, microphthalmia transcription factor (MiTF) and melanoma cell adhesion molecule (Mel-CAM), have been shown to be sensitive markers of epithelioid melanoma, but have not been tested in desmoplastic/spindle cell melanoma or in other rare melanocytic neuroectodermal tumors such as clear cell sarcoma.
p18377
sg17433
(lp18378
(dp18379
g17436
I55
sg17437
Vmicrophthalmia transcription factor
p18380
sg17438
I35
sg17439
VP35398
p18381
sg17441
I3
sa(dp18382
g17436
I135
sg17437
VMel-CAM
p18383
sg17438
I7
sg17439
VP61006
p18384
sg17441
I1
sa(dp18385
g17436
I92
sg17437
VMiTF
p18386
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp18387
g17436
I102
sg17437
g18374
sg17438
I31
sg17439
VP43121
p18388
sg17441
I4
sasg17442
(lp18389
(dp18390
g17436
I238
sg17437
Vdesmoplastic
p18391
sg17438
I12
sg17445
VC1511789
p18392
sg17441
I1
sa(dp18393
g17436
I55
sg17437
Vmicrophthalmia
p18394
sg17438
I14
sg17445
VC0026010
p18395
sg17441
I1
sa(dp18396
g17436
I333
sg17437
Vclear cell sarcoma
p18397
sg17438
I18
sg17445
VC0206651
p18398
sg17441
I3
sa(dp18399
g17436
I139
sg17437
VCAM
p18400
sg17438
I3
sg17445
VC1861821
p18401
sg17441
I1
sa(dp18402
g17436
I135
sg17437
VMel
p18403
sg17438
I3
sg17445
VC3149631
p18404
sg17441
I1
sa(dp18405
g17436
I188
sg17437
Vepithelioid melanoma
p18406
sg17438
I20
sg17445
VC0334443
p18407
sg17441
I2
sa(dp18408
g17436
I302
sg17437
Vneuroectodermal tumors
p18409
sg17438
I22
sg17445
VC0206093
p18410
sg17441
I2
sa(dp18411
g17436
I102
sg17437
Vmelanoma
p18412
sg17438
I8
sg17445
VC0025202
p18413
sg17441
I1
sa(dp18414
g17436
I251
sg17437
Vspindle cell melanoma
p18415
sg17438
I21
sg17445
VC0334444
p18416
sg17441
I3
sa(dp18417
g17436
I116
sg17437
g18375
sg17438
I8
sg17445
VC0001511
p18418
sg17441
I1
sasa(dp18419
g135
(dp18420
(VA1M
p18421
Vnephropathy
p18422
tp18423
I00
ssg17431
VWe investigated the effect of carnosine as an adjuvant therapy on urinary albumin excretion (UAE), the tubular damage marker alpha 1-microglobulin (A1M), and oxidative stress in pediatric patients with type 1 diabetes and nephropathy.
p18424
sg17433
(lp18425
(dp18426
g17436
I74
sg17437
Valbumin
p18427
sg17438
I7
sg17439
VP00441
p18428
sg17441
I1
sa(dp18429
g17436
I125
sg17437
Valpha 1-microglobulin
p18430
sg17438
I21
sg17439
VP25100
p18431
sg17441
I2
sa(dp18432
g17436
I148
sg17437
g18421
sg17438
I3
sg17439
VP02760
p18433
sg17441
I1
sasg17442
(lp18434
(dp18435
g17436
I158
sg17437
Voxidative stress
p18436
sg17438
I16
sg17445
VC0242606
p18437
sg17441
I2
sa(dp18438
g17436
I202
sg17437
Vtype 1 diabetes
p18439
sg17438
I15
sg17445
VC0011854
p18440
sg17441
I3
sa(dp18441
g17436
I222
sg17437
g18422
sg17438
I11
sg17445
VC0022658
p18442
sg17441
I1
sasa(dp18443
g135
(dp18444
(VA1M
p18445
Vtype 2 diabetes
p18446
tp18447
I00
ssg17431
VThe following parameters were measured in 377 patients with type 2 diabetes: HbA1c, serum concentrations of 1,5-AG, GA and creatinine, hemoglobin, urinary albumin/creatinine ratio, and urinary excretion of Alfa1 -microglobulin (A1M).
p18448
sg17433
(lp18449
(dp18450
g17436
I206
sg17437
VAlfa1 -microglobulin
p18451
sg17438
I20
sg17439
VP02760
p18452
sg17441
I2
sa(dp18453
g17436
I135
sg17437
Vhemoglobin
p18454
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp18455
g17436
I155
sg17437
Valbumin
p18456
sg17438
I7
sg17439
VP00441
p18457
sg17441
I1
sa(dp18458
g17436
I228
sg17437
g18445
sg17438
I3
sg17439
VP02760
p18459
sg17441
I1
sasg17442
(lp18460
(dp18461
g17436
I60
sg17437
g18446
sg17438
I15
sg17445
VC0011860
p18462
sg17441
I3
sasa(dp18463
g135
(dp18464
(VTAK-438F
p18465
VARDs
p18466
tp18467
I00
ssg17431
VVonoprazan Fumarate (TAK-438F) is a new and effective drug approved in Japan in 2014 for treatment and prevention of acid-related diseases (ARDs), which exhibits many advantages compared with traditional proton-pump inhibitors (PPIs).
p18468
sg17433
(lp18469
(dp18470
g17436
I21
sg17437
g18465
sg17438
I8
sg17439
VP50750
p18471
sg17441
I1
sasg17442
(lp18472
(dp18473
g17436
I117
sg17437
Vacid-related diseases
p18474
sg17438
I21
sg17445
VC0035222
p18475
sg17441
I2
sa(dp18476
g17436
I140
sg17437
g18466
sg17438
I4
sg17445
VC0035222
p18477
sg17441
I1
sasa(dp18478
g17431
VIn many countries, the introduction of generic proton pump inhibitors (PPIs) onto the pharmaceutical market increased the phenomenon of therapeutic substitution in acid-related disorders (ARDs).
p18479
sg17433
(lp18480
sg17442
(lp18481
(dp18482
g17436
I164
sg17437
Vacid-related disorders
p18483
sg17438
I22
sg17445
VC0035222
p18484
sg17441
I2
sa(dp18485
g17436
I188
sg17437
VARDs
p18486
sg17438
I4
sg17445
VC0035222
p18487
sg17441
I1
sasa(dp18488
g17431
VWe present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.
p18489
sg17433
(lp18490
(dp18491
g17436
I120
sg17437
VPRKRA
p18492
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp18493
g17436
I135
sg17437
VANO3
p18494
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp18495
(dp18496
g17436
I47
sg17437
Vdystonia
p18497
sg17438
I8
sg17445
VC0393593
p18498
sg17441
I1
sasa(dp18499
g135
(dp18500
(VCa+2-dependent phospholipid scramblase
p18501
VDystonia
p18502
tp18503
I01
ssg17431
VANO3 encodes anoctamin-3, a Ca+2-dependent phospholipid scramblase expressed in striatal-neurons, that has been implicated in autosomal dominant craniocervical dystonia (Dystonia-24, DYT24, MIM# 615034).
p18504
sg17433
(lp18505
(dp18506
g17436
I13
sg17437
Vanoctamin-3
p18507
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp18508
g17436
I0
sg17437
VANO3
p18509
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp18510
g17436
I28
sg17437
g18501
sg17438
I38
sg17439
VP19525
p18511
sg17441
I3
sasg17442
(lp18512
(dp18513
g17436
I160
sg17437
Vdystonia
p18514
sg17438
I8
sg17445
VC0393593
p18515
sg17441
I1
sa(dp18516
g17436
I170
sg17437
g18502
sg17438
I8
sg17445
VC0393593
p18517
sg17441
I1
sasa(dp18518
g135
(dp18519
(VGCH1
p18520
Vmyoclonus
p18521
tp18522
I01
ssg17431
VThree genes (GCH1, THAP1, TOR1A) were associated with isolated generalized dystonia, whereas 2 (ANO3, ADCY5) gave rise to combined dystonia-myoclonus phenotypes.
p18523
sg17433
(lp18524
(dp18525
g17436
I102
sg17437
VADCY5
p18526
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp18527
g17436
I13
sg17437
g18520
sg17438
I4
sg17439
VP30793
p18528
sg17441
I1
sa(dp18529
g17436
I26
sg17437
VTOR1A
p18530
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp18531
g17436
I19
sg17437
VTHAP1
p18532
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp18533
g17436
I96
sg17437
VANO3
p18534
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp18535
(dp18536
g17436
I75
sg17437
Vdystonia
p18537
sg17438
I8
sg17445
VC0393593
p18538
sg17441
I1
sa(dp18539
g17436
I63
sg17437
Vgeneralized dystonia
p18540
sg17438
I20
sg17445
VC1848954
p18541
sg17441
I2
sa(dp18542
g17436
I140
sg17437
g18521
sg17438
I9
sg17445
VC0027066
p18543
sg17441
I1
sasa(dp18544
g17431
VFurthermore, it provides confirmatory evidence for a dystonia-relevant role of ANO3 and ADCY5, both of which likely associate with a broader spectrum of dystonic expressions than previously thought.
p18545
sg17433
(lp18546
(dp18547
g17436
I88
sg17437
VADCY5
p18548
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp18549
g17436
I79
sg17437
VANO3
p18550
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp18551
(dp18552
g17436
I53
sg17437
Vdystonia
p18553
sg17438
I8
sg17445
VC0393593
p18554
sg17441
I1
sasa(dp18555
g17431
VIn the past 4 years, the definition and classification of dystonia have been revised, and new genes have been identified in patients with isolated hereditary dystonia (DYT23, DYT24, and DYT25).
p18556
sg17433
(lp18557
sg17442
(lp18558
(dp18559
g17436
I58
sg17437
Vdystonia
p18560
sg17438
I8
sg17445
VC0393593
p18561
sg17441
I1
sa(dp18562
g17436
I147
sg17437
Vhereditary dystonia
p18563
sg17438
I19
sg17445
VC0752207
p18564
sg17441
I2
sasa(dp18565
g17431
VCompromised anoctamin function is causing a wide range of diseases, such as hearing loss (ANO2), bleeding disorder (ANO6), ataxia and dystonia (ANO3, 10), persistent borrelia and mycobacteria infection (ANO10), skeletal syndromes like gnathodiaphyseal dysplasia and limb girdle muscle dystrophy (ANO5), and cancer (ANO1, 6, 7).
p18566
sg17433
(lp18567
(dp18568
g17436
I266
sg17437
Vlimb girdle muscle dystrophy (ANO5)
p18569
sg17438
I35
sg17439
g12
sg17441
I5
sa(dp18570
g17436
I203
sg17437
VANO10
p18571
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp18572
(dp18573
g17436
I166
sg17437
Vborrelia
p18574
sg17438
I8
sg17445
VC0024198
p18575
sg17441
I1
sa(dp18576
g17436
I97
sg17437
Vbleeding disorder
p18577
sg17438
I17
sg17445
VC0005779
p18578
sg17441
I2
sa(dp18579
g17436
I192
sg17437
Vinfection
p18580
sg17438
I9
sg17445
VC0009450
p18581
sg17441
I1
sa(dp18582
g17436
I134
sg17437
Vdystonia
p18583
sg17438
I8
sg17445
VC0393593
p18584
sg17441
I1
sa(dp18585
g17436
I123
sg17437
Vataxia
p18586
sg17438
I6
sg17445
VC0004134
p18587
sg17441
I1
sa(dp18588
g17436
I307
sg17437
Vcancer
p18589
sg17438
I6
sg17445
VC0006826
p18590
sg17441
I1
sa(dp18591
g17436
I220
sg17437
Vsyndromes
p18592
sg17438
I9
sg17445
VC0039082
p18593
sg17441
I1
sa(dp18594
g17436
I235
sg17437
Vgnathodiaphyseal dysplasia
p18595
sg17438
I26
sg17445
VC1833736
p18596
sg17441
I2
sa(dp18597
g17436
I76
sg17437
Vhearing loss
p18598
sg17438
I12
sg17445
VC0011053
p18599
sg17441
I2
sa(dp18600
g17436
I285
sg17437
Vdystrophy
p18601
sg17438
I9
sg17445
VC0333606
p18602
sg17441
I1
sasa(dp18603
g135
(dp18604
(VGNAL
p18605
Vcervical dystonia
p18606
tp18607
I00
ssg17431
VSome genes, such as ANO3, GNAL and CIZ1, have been discovered for isolated dystonia, but they are probably not a common cause of classic cervical dystonia.
p18608
sg17433
(lp18609
(dp18610
g17436
I20
sg17437
VANO3
p18611
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp18612
g17436
I35
sg17437
VCIZ1
p18613
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp18614
g17436
I26
sg17437
g18605
sg17438
I4
sg17439
VP38405
p18615
sg17441
I1
sasg17442
(lp18616
(dp18617
g17436
I75
sg17437
Vdystonia
p18618
sg17438
I8
sg17445
VC0393593
p18619
sg17441
I1
sa(dp18620
g17436
I137
sg17437
g18606
sg17438
I17
sg17445
VC0949445
p18621
sg17441
I2
sasa(dp18622
g135
(dp18623
(VGCH1
p18624
Vbenign hereditary chorea
p18625
tp18626
I01
ssg17431
VClinical and genetic heterogeneity also characterizes myoclonus-dystonia, which includes not only the classical phenotype associated with epsilon-sarcoglycan mutations but rarely also presentation of ANO3 gene mutations, TITF1 gene mutations typically underlying benign hereditary chorea, and some dopamine synthesis pathway conditions due to GCH1 and TH mutations.
p18627
sg17433
(lp18628
(dp18629
g17436
I221
sg17437
VTITF1 gene
p18630
sg17438
I10
sg17439
VP43699
p18631
sg17441
I2
sa(dp18632
g17436
I200
sg17437
VANO3 gene
p18633
sg17438
I9
sg17439
g12
sg17441
I2
sa(dp18634
g17436
I343
sg17437
g18624
sg17438
I4
sg17439
VP30793
p18635
sg17441
I1
sasg17442
(lp18636
(dp18637
g17436
I54
sg17437
Vmyoclonus
p18638
sg17438
I9
sg17445
VC0027066
p18639
sg17441
I1
sa(dp18640
g17436
I64
sg17437
Vdystonia
p18641
sg17438
I8
sg17445
VC0393593
p18642
sg17441
I1
sa(dp18643
g17436
I263
sg17437
g18625
sg17438
I24
sg17445
VC0393584
p18644
sg17441
I3
sasa(dp18645
g17431
VWhen 10 cases of M5 were subdivided by the differential level into undifferentiated (M5a) and differentiated monocytic leukemia (M5b), expression of CD45RA and CD45RO was strictly restricted to cases with M5a and M5b, respectively.
p18646
sg17433
(lp18647
sg17442
(lp18648
(dp18649
g17436
I129
sg17437
VM5b
p18650
sg17438
I3
sg17445
VC0598894
p18651
sg17441
I1
sa(dp18652
g17436
I109
sg17437
Vmonocytic leukemia
p18653
sg17438
I18
sg17445
VC0598894
p18654
sg17441
I2
sa(dp18655
g17436
I129
sg17437
VM5b
p18656
sg17438
I3
sg17445
VC0598894
p18657
sg17441
I1
sasa(dp18658
g17431
VIn this review, we describe the fusion genes recently reported in bone and soft-tissue tumors such as solitary fibrous tumor, aneurysmal bone cyst, nodular fasciitis, CIC-DUX4 fusion gene-positive small round cell tumors, or BCOR-CCNB3-positive sarcoma as well as other genetic aberrations in dedifferentiated liposarcoma, malignant rhabdoid tumor, cartilaginous tumor, Langerhans cell histiocytosis chondroblastoma, or giant cell tumor of the bone.
p18659
sg17433
(lp18660
(dp18661
g17436
I171
sg17437
VDUX4
p18662
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp18663
g17436
I225
sg17437
VBCOR-CCNB3
p18664
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp18665
g17436
I167
sg17437
VCIC
p18666
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp18667
(dp18668
g17436
I245
sg17437
Vsarcoma
p18669
sg17438
I7
sg17445
VC1261473
p18670
sg17441
I1
sa(dp18671
g17436
I87
sg17437
Vtumors
p18672
sg17438
I6
sg17445
VC0027651
p18673
sg17441
I1
sa(dp18674
g17436
I420
sg17437
Vgiant
p18675
sg17438
I5
sg17445
VC0017547
p18676
sg17441
I1
sa(dp18677
g17436
I349
sg17437
Vcartilaginous tumor
p18678
sg17438
I19
sg17445
VC0476147
p18679
sg17441
I2
sa(dp18680
g17436
I148
sg17437
Vnodular fasciitis
p18681
sg17438
I17
sg17445
VC0410005
p18682
sg17441
I2
sa(dp18683
g17436
I370
sg17437
VLangerhans cell histiocytosis
p18684
sg17438
I29
sg17445
VC0019621
p18685
sg17441
I3
sa(dp18686
g17436
I87
sg17437
Vtumors
p18687
sg17438
I6
sg17445
VC0027651
p18688
sg17441
I1
sa(dp18689
g17436
I293
sg17437
Vdedifferentiated liposarcoma
p18690
sg17438
I28
sg17445
VC0205824
p18691
sg17441
I2
sa(dp18692
g17436
I400
sg17437
Vchondroblastoma
p18693
sg17438
I15
sg17445
VC0008441
p18694
sg17441
I1
sa(dp18695
g17436
I323
sg17437
Vmalignant rhabdoid tumor
p18696
sg17438
I24
sg17445
VC0206743
p18697
sg17441
I3
sa(dp18698
g17436
I102
sg17437
Vsolitary fibrous tumor
p18699
sg17438
I22
sg17445
VC1266119
p18700
sg17441
I3
sa(dp18701
g17436
I431
sg17437
Vtumor of the bone
p18702
sg17438
I17
sg17445
VC0005967
p18703
sg17441
I4
sa(dp18704
g17436
I126
sg17437
Vaneurysmal bone cyst
p18705
sg17438
I20
sg17445
VC0152244
p18706
sg17441
I3
sasa(dp18707
g135
(dp18708
(VWilms tumor protein 1
p18709
VWilms tumor
p18710
tp18711
I00
ssg17431
VThe individual diagnostic marker positivity was 98% for GATA-binding protein 3, 95% for androgen receptor, 90% for progesterone receptor, 88% for deleted in pancreatic cancer 4, 75% for gross cystic disease fluid protein 15, 72% for cytokeratin 7, 55% for mammaglobin, and 15% for vimentin and Wilms tumor protein 1.
p18712
sg17433
(lp18713
(dp18714
g17436
I56
sg17437
VGATA-binding protein 3
p18715
sg17438
I22
sg17439
VP23771
p18716
sg17441
I3
sa(dp18717
g17436
I256
sg17437
Vmammaglobin
p18718
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp18719
g17436
I115
sg17437
Vprogesterone receptor
p18720
sg17438
I21
sg17439
VP06401
p18721
sg17441
I2
sa(dp18722
g17436
I88
sg17437
Vandrogen receptor
p18723
sg17438
I17
sg17439
VP10275
p18724
sg17441
I2
sa(dp18725
g17436
I294
sg17437
g18709
sg17438
I21
sg17439
VP14222
p18726
sg17441
I4
sasg17442
(lp18727
(dp18728
g17436
I192
sg17437
Vcystic disease
p18729
sg17438
I14
sg17445
VC0334054
p18730
sg17441
I2
sa(dp18731
g17436
I157
sg17437
Vpancreatic cancer
p18732
sg17438
I17
sg17445
VC0235974
p18733
sg17441
I2
sa(dp18734
g17436
I294
sg17437
g18710
sg17438
I11
sg17445
VC0027708
p18735
sg17441
I2
sasa(dp18736
g135
(dp18737
(Vaquaporin-4 antibodies
p18738
Vmajor depressive disorder
p18739
tp18740
I00
ssg17431
VAstrocyte loss may be caused by cytotoxic T cells as seen in Rasmussen encephalitis, auto-antibodies such as in neuromyelitis optica (aquaporin-4 antibodies), or cytokines such as TNF-Alfa in major depressive disorder.
p18741
sg17433
(lp18742
(dp18743
g17436
I180
sg17437
VTNF-Alfa
p18744
sg17438
I8
sg17439
VP01375
p18745
sg17441
I1
sa(dp18746
g17436
I134
sg17437
g18738
sg17438
I22
sg17439
VP55087
p18747
sg17441
I2
sasg17442
(lp18748
(dp18749
g17436
I112
sg17437
Vneuromyelitis optica
p18750
sg17438
I20
sg17445
VC0027873
p18751
sg17441
I2
sa(dp18752
g17436
I61
sg17437
VRasmussen encephalitis
p18753
sg17438
I22
sg17445
VC0393484
p18754
sg17441
I2
sa(dp18755
g17436
I192
sg17437
g18739
sg17438
I25
sg17445
VC1269683
p18756
sg17441
I3
sasa(dp18757
g135
(dp18758
(VATP1A1
p18759
Vhyperaldosteronism
p18760
tp18761
I01
ssg17431
VMutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D are found in aldosterone producing adenoma (APA) and familial hyperaldosteronism (FH).
p18762
sg17433
(lp18763
(dp18764
g17436
I13
sg17437
VKCNJ5
p18765
sg17438
I5
sg17439
VP48544
p18766
sg17441
I1
sa(dp18767
g17436
I39
sg17437
VCACNA1D
p18768
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp18769
g17436
I20
sg17437
g18759
sg17438
I6
sg17439
VP05023
p18770
sg17441
I1
sa(dp18771
g17436
I28
sg17437
VATP2B3
p18772
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp18773
(dp18774
g17436
I82
sg17437
Vadenoma
p18775
sg17438
I7
sg17445
VC0001430
p18776
sg17441
I1
sa(dp18777
g17436
I109
sg17437
g18760
sg17438
I18
sg17445
VC0020428
p18778
sg17441
I1
sasa(dp18779
g135
(dp18780
(VATP1A1
p18781
VCushing's syndrome
p18782
tp18783
I00
ssg17431
VOur results suggest that these mutations, in addition to mutations in the KCNJ5 gene and other genes such as ATP1A1, ATP2B3 and CACNA1D, may be responsible for the tumorigenesis of APAs and CPAs with subclinical Cushing's syndrome.
p18784
sg17433
(lp18785
(dp18786
g17436
I74
sg17437
VKCNJ5 gene
p18787
sg17438
I10
sg17439
VP48544
p18788
sg17441
I2
sa(dp18789
g17436
I117
sg17437
VATP2B3
p18790
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp18791
g17436
I128
sg17437
VCACNA1D
p18792
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp18793
g17436
I109
sg17437
g18781
sg17438
I6
sg17439
VP05023
p18794
sg17441
I1
sasg17442
(lp18795
(dp18796
g17436
I164
sg17437
Vtumorigenesis
p18797
sg17438
I13
sg17445
VC0007621
p18798
sg17441
I1
sa(dp18799
g17436
I212
sg17437
g18782
sg17438
I18
sg17445
VC0010481
p18800
sg17441
I2
sasa(dp18801
g135
(dp18802
(VSOX2
p18803
Vcataract
p18804
tp18805
I00
ssg17431
VScreening of SOX2 was completed in 89 patients with a variety of ocular anomalies, including 28 with A/M and 61 with normal eye size and anterior segment dysgenesis (28), cataract (14), isolated coloboma (5), or other eye disorders (14).
p18806
sg17433
(lp18807
(dp18808
g17436
I13
sg17437
g18803
sg17438
I4
sg17439
VP48431
p18809
sg17441
I1
sasg17442
(lp18810
(dp18811
g17436
I218
sg17437
Veye disorders
p18812
sg17438
I13
sg17445
VC0015397
p18813
sg17441
I2
sa(dp18814
g17436
I195
sg17437
Vcoloboma
p18815
sg17438
I8
sg17445
VC0009363
p18816
sg17441
I1
sa(dp18817
g17436
I137
sg17437
Vanterior segment dysgenesis
p18818
sg17438
I27
sg17445
VC0266525
p18819
sg17441
I3
sa(dp18820
g17436
I171
sg17437
g18804
sg17438
I8
sg17445
VC0086543
p18821
sg17441
I1
sasa(dp18822
g135
(dp18823
(VKir3.2
p18824
VDS
p18825
tp18826
I00
ssg17431
VThe overexpression of Kir3.2, a subunit of the G protein-gated inwardly rectifying K(+) channel, is implicated in some of the neurological phenotypes of Down syndrome (DS).
p18827
sg17433
(lp18828
(dp18829
g17436
I47
sg17437
VG protein
p18830
sg17438
I9
sg17439
g12
sg17441
I2
sa(dp18831
g17436
I22
sg17437
g18824
sg17438
I6
sg17439
VP48051
p18832
sg17441
I1
sasg17442
(lp18833
(dp18834
g17436
I153
sg17437
VDown syndrome
p18835
sg17438
I13
sg17445
VC0013080
p18836
sg17441
I2
sa(dp18837
g17436
I168
sg17437
g18825
sg17438
I2
sg17445
VC0013080
p18838
sg17441
I1
sasa(dp18839
g17431
VKeppen-Lubinsky syndrome (KPLBS) is a rare disease mainly characterized by severe developmental delay and intellectual disability, microcephaly, large prominent eyes, a narrow nasal bridge, a tented upper lip, a high palate, an open mouth, tightly adherent skin, an aged appearance, and severe generalized lipodystrophy.
p18840
sg17433
(lp18841
sg17442
(lp18842
(dp18843
g17436
I131
sg17437
Vmicrocephaly
p18844
sg17438
I12
sg17445
VC0025958
p18845
sg17441
I1
sa(dp18846
g17436
I82
sg17437
Vdevelopmental delay
p18847
sg17438
I19
sg17445
VC0424605
p18848
sg17441
I2
sa(dp18849
g17436
I0
sg17437
VKeppen-Lubinsky syndrome
p18850
sg17438
I24
sg17445
VC3279800
p18851
sg17441
I2
sa(dp18852
g17436
I294
sg17437
Vgeneralized lipodystrophy
p18853
sg17438
I25
sg17445
VC0221032
p18854
sg17441
I2
sa(dp18855
g17436
I212
sg17437
Vhigh palate
p18856
sg17438
I11
sg17445
VC1398297
p18857
sg17441
I2
sa(dp18858
g17436
I38
sg17437
Vrare disease
p18859
sg17438
I12
sg17445
VC0678236
p18860
sg17441
I2
sa(dp18861
g17436
I106
sg17437
Vintellectual disability
p18862
sg17438
I23
sg17445
VC0025362
p18863
sg17441
I2
sa(dp18864
g17436
I26
sg17437
VKPLBS
p18865
sg17438
I5
sg17445
VC3279800
p18866
sg17441
I1
sa(dp18867
g17436
I205
sg17437
Vlip
p18868
sg17438
I3
sg17445
VC0264511
p18869
sg17441
I1
sasa(dp18870
g135
(dp18871
(VGIRK2
p18872
VDown syndrome critical region
p18873
tp18874
I01
ssg17431
VWe sequenced the exomes of three unrelated individuals affected by KPLBS and found de novo heterozygous mutations in KCNJ6 (GIRK2), which encodes an inwardly rectifying potassium channel and maps to the Down syndrome critical region between DIRK1A and DSCR4.
p18875
sg17433
(lp18876
(dp18877
g17436
I104
sg17437
Vmutations in KCNJ6
p18878
sg17438
I18
sg17439
VP48051
p18879
sg17441
I3
sa(dp18880
g17436
I252
sg17437
VDSCR4
p18881
sg17438
I5
sg17439
VP56555
p18882
sg17441
I1
sa(dp18883
g17436
I124
sg17437
g18872
sg17438
I5
sg17439
VP48051
p18884
sg17441
I1
sasg17442
(lp18885
(dp18886
g17436
I67
sg17437
VKPLBS
p18887
sg17438
I5
sg17445
VC3279800
p18888
sg17441
I1
sa(dp18889
g17436
I203
sg17437
g18873
sg17438
I29
sg17445
VC1860787
p18890
sg17441
I4
sasa(dp18891
g17431
VWe evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water.
p18892
sg17433
(lp18893
(dp18894
g17436
I27
sg17437
Vglucose-lysine Maillard reaction products
p18895
sg17438
I41
sg17439
g12
sg17441
I4
sa(dp18896
g17436
I70
sg17437
VGlc-Lys MRPs
p18897
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp18898
(dp18899
g17436
I139
sg17437
Vdextran sulfate sodium
p18900
sg17438
I22
sg17445
VC0011195
p18901
sg17441
I3
sa(dp18902
g17436
I163
sg17437
VDSS
p18903
sg17438
I3
sg17445
VC0011195
p18904
sg17441
I1
sa(dp18905
g17436
I87
sg17437
Vcolitis
p18906
sg17438
I7
sg17445
VC0009319
p18907
sg17441
I1
sasa(dp18908
g135
(dp18909
(Vcolon length and serum lysozyme
p18910
Vcolitis
p18911
tp18912
I01
ssg17431
VGlc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels.
p18913
sg17433
(lp18914
(dp18915
g17436
I0
sg17437
VGlc-Lys MRPs
p18916
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp18917
g17436
I187
sg17437
g18910
sg17438
I31
sg17439
VP61626
p18918
sg17441
I5
sasg17442
(lp18919
(dp18920
g17436
I24
sg17437
VDSS
p18921
sg17438
I3
sg17445
VC0011195
p18922
sg17441
I1
sa(dp18923
g17436
I36
sg17437
g18911
sg17438
I7
sg17445
VC0009319
p18924
sg17441
I1
sasa(dp18925
g17431
VThis study was aimed at determining whether repeated low-level exposure to MRPs, generated via two different heat treatments, can contribute to the modulation of experimental colitis in mice.
p18926
sg17433
(lp18927
sg17442
(lp18928
(dp18929
g17436
I175
sg17437
Vcolitis
p18930
sg17438
I7
sg17445
VC0009319
p18931
sg17441
I1
sasa(dp18932
g17431
VFurthermore, we used a sandwich immunoassay to measure serum concentrations of MRPs in 62 patients were simultaneously assessed by the Crohn's disease activity index (CDAI) and the severity activity index of Goebell (SAI).
p18933
sg17433
(lp18934
(dp18935
g17436
I135
sg17437
VCrohn's disease activity index
p18936
sg17438
I30
sg17439
g12
sg17441
I4
sa(dp18937
g17436
I167
sg17437
VCDAI
p18938
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp18939
(dp18940
g17436
I135
sg17437
VCrohn's disease
p18941
sg17438
I15
sg17445
VC0010346
p18942
sg17441
I2
sasa(dp18943
g17431
VIn the present study monospecific antibodies against MRPs were used to investigate immunohistochemically the distribution of these proteins in routinely processed bowel tissues from 23 patients with ulcerative colitis (UC).
p18944
sg17433
(lp18945
sg17442
(lp18946
(dp18947
g17436
I219
sg17437
VUC
p18948
sg17438
I2
sg17445
VC0009324
p18949
sg17441
I1
sa(dp18950
g17436
I199
sg17437
Vulcerative colitis
p18951
sg17438
I18
sg17445
VC0009324
p18952
sg17441
I2
sasa(dp18953
g135
(dp18954
(VIgA
p18955
VBurkitt's lymphoma
p18956
tp18957
I01
ssg17431
VThe dimeric hybrid-IgG/IgA inhibited the binding of digoxigenin-conjugated Stx1B to natural ligands (CD77) displayed on Burkitt's lymphoma cell line Ramos.
p18958
sg17433
(lp18959
(dp18960
g17436
I75
sg17437
VStx1B
p18961
sg17438
I5
sg17439
VP61266
p18962
sg17441
I1
sa(dp18963
g17436
I23
sg17437
g18955
sg17438
I3
sg17439
VP11912
p18964
sg17441
I1
sasg17442
(lp18965
(dp18966
g17436
I120
sg17437
g18956
sg17438
I18
sg17445
VC0006413
p18967
sg17441
I2
sasa(dp18968
g17431
VFurthermore, the purified Stx1 B subunit was able to bind specifically to Gb3Cer expressed on Burkitt's lymphoma cells.
p18969
sg17433
(lp18970
(dp18971
g17436
I26
sg17437
VStx1 B subunit
p18972
sg17438
I14
sg17439
g12
sg17441
I3
sasg17442
(lp18973
(dp18974
g17436
I94
sg17437
VBurkitt's lymphoma
p18975
sg17438
I18
sg17445
VC0006413
p18976
sg17441
I2
sasa(dp18977
g135
(dp18978
(VMcl-1
p18979
VMcl
p18980
tp18981
I00
ssg17431
VFurthermore, we found that Mcl-1 could be a potential therapeutic target of MECK-induced apoptosis and its stability is regulated by extracellular signal-regulated kinases 1/2 (ERK1/2) signaling MECK can be used as a safe and efficient therapeutic alternative for the treatment of salivary gland cancer.
p18982
sg17433
(lp18983
(dp18984
g17436
I177
sg17437
VERK1/2
p18985
sg17438
I6
sg17439
VP27361
p18986
sg17441
I1
sa(dp18987
g17436
I133
sg17437
Vextracellular signal-regulated kinases 1/2
p18988
sg17438
I42
sg17439
g12
sg17441
I4
sa(dp18989
g17436
I27
sg17437
g18979
sg17438
I5
sg17439
VP07954
p18990
sg17441
I1
sasg17442
(lp18991
(dp18992
g17436
I281
sg17437
Vsalivary gland cancer
p18993
sg17438
I21
sg17445
VC0220636
p18994
sg17441
I3
sa(dp18995
g17436
I27
sg17437
g18980
sg17438
I3
sg17445
VC1708350
p18996
sg17441
I1
sasa(dp18997
g135
(dp18998
(Vp65
p18999
Vpneumonia
p19000
tp19001
I00
ssg17431
VAlthough NF-KB RelA (p65) is essential for the expression of many cytokines during pneumonia, its targeted mutation in the lung epithelium was inconsequential for pneumonia-driven LIF induction.
p19002
sg17433
(lp19003
(dp19004
g17436
I9
sg17437
VNF-KB RelA
p19005
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp19006
g17436
I21
sg17437
g18999
sg17438
I3
sg17439
VP21579
p19007
sg17441
I1
sasg17442
(lp19008
(dp19009
g17436
I83
sg17437
Vpneumonia
p19010
sg17438
I9
sg17445
VC0032285
p19011
sg17441
I1
sa(dp19012
g17436
I83
sg17437
g19000
sg17438
I9
sg17445
VC0032285
p19013
sg17441
I1
sasa(dp19014
g135
(dp19015
(Vepithelial LIF
p19016
Vpneumonia
p19017
tp19018
I00
ssg17431
VOverall, our data suggest a signaling axis whereby activation of NF-KB RelA in myeloid cells promotes epithelial LIF induction during lung infections, representing a means through which these two cell types collaborate to improve tissue resilience during pneumonia.
p19019
sg17433
(lp19020
(dp19021
g17436
I102
sg17437
g19016
sg17438
I14
sg17439
VP15018
p19022
sg17441
I2
sa(dp19023
g17436
I65
sg17437
VNF-KB RelA
p19024
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp19025
(dp19026
g17436
I139
sg17437
Vinfections
p19027
sg17438
I10
sg17445
VC0021311
p19028
sg17441
I1
sa(dp19029
g17436
I255
sg17437
g19017
sg17438
I9
sg17445
VC0032285
p19030
sg17441
I1
sasa(dp19031
g17431
VSectm1 was induced during the early stages of pneumococcal pneumonia, and mutation of NF-KB RelA in epithelial cells did not diminish its expression.
p19032
sg17433
(lp19033
(dp19034
g17436
I86
sg17437
VNF-KB RelA
p19035
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp19036
g17436
I0
sg17437
VSectm1
p19037
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp19038
(dp19039
g17436
I46
sg17437
Vpneumococcal pneumonia
p19040
sg17438
I22
sg17445
VC0155862
p19041
sg17441
I2
sasa(dp19042
g135
(dp19043
(VSTAT3
p19044
Vpneumonia
p19045
tp19046
I00
ssg17431
VTo determine the functional significance of the hepatic APR during pneumonia, we challenged APR-null mice lacking hepatocyte signal transducer and activator of transcription 3 (STAT3) and v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) with Escherichia coli in the airspaces.
p19047
sg17433
(lp19048
(dp19049
g17436
I114
sg17437
Vhepatocyte signal transducer and activator of transcription 3
p19050
sg17438
I61
sg17439
VP40763
p19051
sg17441
I8
sa(dp19052
g17436
I188
sg17437
Vv-rel avian reticuloendotheliosis viral oncogene homolog A
p19053
sg17438
I58
sg17439
g12
sg17441
I7
sa(dp19054
g17436
I248
sg17437
VRelA
p19055
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19056
g17436
I177
sg17437
g19044
sg17438
I5
sg17439
VP40763
p19057
sg17441
I1
sasg17442
(lp19058
(dp19059
g17436
I67
sg17437
g19045
sg17438
I9
sg17445
VC0032285
p19060
sg17441
I1
sa(dp19061
g17436
I194
sg17437
Vavian reticuloendotheliosis
p19062
sg17438
I27
sg17445
VC0276487
p19063
sg17441
I2
sasa(dp19064
g17431
VEpithelial cells expressed multiple neutrophil-stimulating cytokines during pneumonia, all of which depended on RelA.
p19065
sg17433
(lp19066
(dp19067
g17436
I112
sg17437
VRelA
p19068
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19069
(dp19070
g17436
I76
sg17437
Vpneumonia
p19071
sg17438
I9
sg17445
VC0032285
p19072
sg17441
I1
sasa(dp19073
g135
(dp19074
(VCXCL5
p19075
Vpneumococcal pneumonia
p19076
tp19077
I00
ssg17431
VEpithelial RelA mutation decreased whole lung levels of CXCL5 and GM-CSF during pneumococcal pneumonia, whereas lung levels of other neutrophil-recruiting factors were unaffected.
p19078
sg17433
(lp19079
(dp19080
g17436
I66
sg17437
VGM-CSF
p19081
sg17438
I6
sg17439
VP04141
p19082
sg17441
I1
sa(dp19083
g17436
I56
sg17437
g19075
sg17438
I5
sg17439
VP42830
p19084
sg17441
I1
sa(dp19085
g17436
I11
sg17437
VRelA
p19086
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19087
(dp19088
g17436
I80
sg17437
g19076
sg17438
I22
sg17445
VC0155862
p19089
sg17441
I2
sasa(dp19090
g17431
VWe demonstrate that RelA-P-Ser536 is a feature of human lung and skin fibroblasts, but not lung epithelial cells, in vitro and is present in sclerotic skin and diseased lungs of patients suffering from idiopathic pulmonary fibrosis.
p19091
sg17433
(lp19092
(dp19093
g17436
I20
sg17437
VRelA-P
p19094
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp19095
(dp19096
g17436
I202
sg17437
Vidiopathic pulmonary fibrosis
p19097
sg17438
I29
sg17445
VC3161101
p19098
sg17441
I3
sa(dp19099
g17436
I187
sg17437
Vsuffering
p19100
sg17438
I9
sg17445
VC0683278
p19101
sg17441
I1
sa(dp19102
g17436
I141
sg17437
Vsclerotic
p19103
sg17438
I9
sg17445
VC0036429
p19104
sg17441
I1
sasa(dp19105
g135
(dp19106
(Vp65
p19107
Vpneumonia
p19108
tp19109
I00
ssg17431
VBecause innate immunity gene induction depends on NF-KB RelA (also known as p65) during pneumonia, we generated a murine model of RelA mutated throughout the alveolar epithelium.
p19110
sg17433
(lp19111
(dp19112
g17436
I76
sg17437
g19107
sg17438
I3
sg17439
VP21579
p19113
sg17441
I1
sa(dp19114
g17436
I56
sg17437
VRelA
p19115
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19116
g17436
I50
sg17437
VNF-KB RelA
p19117
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp19118
(dp19119
g17436
I88
sg17437
g19108
sg17438
I9
sg17445
VC0032285
p19120
sg17441
I1
sasa(dp19121
g135
(dp19122
(VCXCL5
p19123
Vpneumonia
p19124
tp19125
I00
ssg17431
VSorted cell populations from mouse lungs revealed that CXCL5 was induced during pneumonia in type I cells, which did not require RelA.
p19126
sg17433
(lp19127
(dp19128
g17436
I129
sg17437
VRelA
p19129
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19130
g17436
I55
sg17437
g19123
sg17438
I5
sg17439
VP42830
p19131
sg17441
I1
sasg17442
(lp19132
(dp19133
g17436
I80
sg17437
g19124
sg17438
I9
sg17445
VC0032285
p19134
sg17441
I1
sasa(dp19135
g17431
VThese are also, to our knowledge, the first evidence for entirely RelA-independent pathways of innate immunity gene induction in any cell during pneumonia.
p19136
sg17433
(lp19137
(dp19138
g17436
I66
sg17437
VRelA
p19139
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19140
(dp19141
g17436
I145
sg17437
Vpneumonia
p19142
sg17438
I9
sg17445
VC0032285
p19143
sg17441
I1
sasa(dp19144
g135
(dp19145
(VGCH1
p19146
VSCA2
p19147
tp19148
I00
ssg17431
VWe review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).
p19149
sg17433
(lp19150
(dp19151
g17436
I421
sg17437
VRAB39B
p19152
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19153
g17436
I204
sg17437
VPINK1
p19154
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19155
g17436
I440
sg17437
VSCA2
p19156
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19157
g17436
I267
sg17437
VLRRK2
p19158
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19159
g17436
I349
sg17437
g19146
sg17438
I4
sg17439
VP30793
p19160
sg17441
I1
sa(dp19161
g17436
I414
sg17437
VFBXO7
p19162
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19163
g17436
I355
sg17437
VATP13A2
p19164
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp19165
g17436
I364
sg17437
VPLA2G6
p19166
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19167
g17436
I433
sg17437
VATXN2
p19168
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp19169
(dp19170
g17436
I295
sg17437
VGaucher disease
p19171
sg17438
I15
sg17445
VC0017205
p19172
sg17441
I2
sa(dp19173
g17436
I93
sg17437
Vparkinsonism
p19174
sg17438
I12
sg17445
VC0242422
p19175
sg17441
I1
sa(dp19176
g17436
I461
sg17437
V22q deletion syndrome
p19177
sg17438
I21
sg17445
VC0795880
p19178
sg17441
I3
sa(dp19179
g17436
I93
sg17437
Vparkinsonism
p19180
sg17438
I12
sg17445
VC0242422
p19181
sg17441
I1
sa(dp19182
g17436
I440
sg17437
g19147
sg17438
I4
sg17445
VC0752121
p19183
sg17441
I1
sasa(dp19184
g17431
VWe performed genetic testing consisting of C9orf72 hexanucleotide expansion, ATXN2 polyglutamine (polyQ) expansion, and targeted next generation sequencing using the ONDRISeq, a gene panel consisting of 80 genes known to be associated with neurodegenerative diseases such as ALS, FTD, Alzheimer's disease, Parkinson's disease, and vascular cognitive impairment.
p19185
sg17433
(lp19186
(dp19187
g17436
I77
sg17437
VATXN2
p19188
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp19189
(dp19190
g17436
I340
sg17437
Vcognitive impairment
p19191
sg17438
I20
sg17445
VC0338656
p19192
sg17441
I2
sa(dp19193
g17436
I306
sg17437
VParkinson's disease
p19194
sg17438
I19
sg17445
VC0030567
p19195
sg17441
I2
sa(dp19196
g17436
I240
sg17437
Vneurodegenerative diseases
p19197
sg17438
I26
sg17445
VC0524851
p19198
sg17441
I2
sa(dp19199
g17436
I285
sg17437
VAlzheimer's disease
p19200
sg17438
I19
sg17445
VC1521724
p19201
sg17441
I2
sa(dp19202
g17436
I280
sg17437
VFTD
p19203
sg17438
I3
sg17445
VC0338451
p19204
sg17441
I1
sa(dp19205
g17436
I275
sg17437
VALS
p19206
sg17438
I3
sg17445
VC0002736
p19207
sg17441
I1
sasa(dp19208
g135
(dp19209
(VHNRNPA1
p19210
Vamyotrophic lateral sclerosis
p19211
tp19212
I00
ssg17431
VPathological developments leading to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are associated with misbehavior of several key proteins, such as SOD1 (superoxide dismutase 1), TARDBP/TDP-43, FUS, C9orf72, and dipeptide repeat proteins generated as a result of the translation of the intronic hexanucleotide expansions in the C9orf72 gene, PFN1 (profilin 1), GLE1 (GLE1, RNA export mediator), PURA (purine rich element binding protein A), FLCN (folliculin), RBM45 (RNA binding motif protein 45), SS18L1/CREST, HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1), HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1), ATXN2 (ataxin 2), MAPT (microtubule associated protein tau), and TIA1 (TIA1 cytotoxic granule associated RNA binding protein).
p19213
sg17433
(lp19214
(dp19215
g17436
I556
sg17437
Vheterogeneous nuclear ribonucleoprotein A1
p19216
sg17438
I42
sg17439
VP09651
p19217
sg17441
I4
sa(dp19218
g17436
I684
sg17437
Vmicrotubule associated protein tau
p19219
sg17438
I34
sg17439
g12
sg17441
I4
sa(dp19220
g17436
I396
sg17437
VGLE1
p19221
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19222
g17436
I430
sg17437
VPURA
p19223
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19224
g17436
I383
sg17437
Vprofilin 1
p19225
sg17438
I10
sg17439
VP07737
p19226
sg17441
I2
sa(dp19227
g17436
I482
sg17437
Vfolliculin
p19228
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp19229
g17436
I436
sg17437
Vpurine rich element binding protein A
p19230
sg17438
I37
sg17439
g12
sg17441
I6
sa(dp19231
g17436
I725
sg17437
VTIA1
p19232
sg17438
I4
sg17439
VP31483
p19233
sg17441
I1
sa(dp19234
g17436
I183
sg17437
VSOD1
p19235
sg17438
I4
sg17439
VP00441
p19236
sg17441
I1
sa(dp19237
g17436
I229
sg17437
VFUS
p19238
sg17438
I3
sg17439
VP35637
p19239
sg17441
I1
sa(dp19240
g17436
I189
sg17437
Vsuperoxide dismutase 1
p19241
sg17438
I22
sg17439
VP00441
p19242
sg17441
I3
sa(dp19243
g17436
I678
sg17437
VMAPT
p19244
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19245
g17436
I396
sg17437
VGLE1
p19246
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19247
g17436
I667
sg17437
Vataxin 2
p19248
sg17438
I8
sg17439
g12
sg17441
I2
sa(dp19249
g17436
I612
sg17437
Vheterogeneous nuclear ribonucleoprotein A2/B1
p19250
sg17438
I45
sg17439
VP22626
p19251
sg17441
I4
sa(dp19252
g17436
I234
sg17437
VC9orf72
p19253
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp19254
g17436
I214
sg17437
VTARDBP/TDP-43
p19255
sg17438
I13
sg17439
g12
sg17441
I1
sa(dp19256
g17436
I731
sg17437
VTIA1 cytotoxic granule associated RNA binding protein
p19257
sg17438
I53
sg17439
VP00390
p19258
sg17441
I7
sa(dp19259
g17436
I601
sg17437
VHNRNPA2B1
p19260
sg17438
I9
sg17439
VP22626
p19261
sg17441
I1
sa(dp19262
g17436
I377
sg17437
VPFN1
p19263
sg17438
I4
sg17439
VP07737
p19264
sg17441
I1
sa(dp19265
g17436
I363
sg17437
VC9orf72 gene
p19266
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp19267
g17436
I476
sg17437
VFLCN
p19268
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19269
g17436
I660
sg17437
VATXN2
p19270
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19271
g17436
I547
sg17437
g19210
sg17438
I7
sg17439
VP09651
p19272
sg17441
I1
sasg17442
(lp19273
(dp19274
g17436
I68
sg17437
VALS
p19275
sg17438
I3
sg17445
VC0002736
p19276
sg17441
I1
sa(dp19277
g17436
I77
sg17437
Vfrontotemporal lobar degeneration
p19278
sg17438
I33
sg17445
VC0751072
p19279
sg17441
I3
sa(dp19280
g17436
I540
sg17437
VCREST
p19281
sg17438
I5
sg17445
VC0206138
p19282
sg17441
I1
sa(dp19283
g17436
I112
sg17437
VFTLD
p19284
sg17438
I4
sg17445
VC0751072
p19285
sg17441
I1
sa(dp19286
g17436
I37
sg17437
g19211
sg17438
I29
sg17445
VC0002736
p19287
sg17441
I3
sasa(dp19288
g17431
VSpinocerebellar ataxia type 2 (SCA2) is an autosomal dominant cerebellar ataxia that occurs as a consequence of abnormal CAG expansions in the ATXN2 gene.
p19289
sg17433
(lp19290
(dp19291
g17436
I143
sg17437
VATXN2 gene
p19292
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp19293
g17436
I0
sg17437
VSpinocerebellar ataxia type 2
p19294
sg17438
I29
sg17439
g12
sg17441
I4
sa(dp19295
g17436
I31
sg17437
VSCA2
p19296
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19297
(dp19298
g17436
I5
sg17437
Vcerebellar ataxia
p19299
sg17438
I17
sg17445
VC0007758
p19300
sg17441
I2
sa(dp19301
g17436
I0
sg17437
VSpinocerebellar ataxia type 2
p19302
sg17438
I29
sg17445
VC0752121
p19303
sg17441
I4
sa(dp19304
g17436
I31
sg17437
VSCA2
p19305
sg17438
I4
sg17445
VC0752121
p19306
sg17441
I1
sasa(dp19307
g17431
VRecent findings linking ataxin-2 intermediate expansions to other neurodegenerative diseases such as amyotrophic lateral sclerosis have provided insights into the ataxin-2-related toxicity mechanism in neurodegenerative diseases and have raised new ethical challenges to molecular predictive diagnosis of SCA2.
p19308
sg17433
(lp19309
(dp19310
g17436
I305
sg17437
VSCA2
p19311
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19312
(dp19313
g17436
I101
sg17437
Vamyotrophic lateral sclerosis
p19314
sg17438
I29
sg17445
VC0002736
p19315
sg17441
I3
sa(dp19316
g17436
I66
sg17437
Vneurodegenerative diseases
p19317
sg17438
I26
sg17445
VC0524851
p19318
sg17441
I2
sa(dp19319
g17436
I66
sg17437
Vneurodegenerative diseases
p19320
sg17438
I26
sg17445
VC0524851
p19321
sg17441
I2
sa(dp19322
g17436
I305
sg17437
VSCA2
p19323
sg17438
I4
sg17445
VC0752121
p19324
sg17441
I1
sasa(dp19325
g17431
VSpinocerebellar ataxia type 2 (SCA2) is among the most common forms of autosomal dominant ataxias, accounting for 15% of the total families.
p19326
sg17433
(lp19327
(dp19328
g17436
I0
sg17437
VSpinocerebellar ataxia type 2
p19329
sg17438
I29
sg17439
g12
sg17441
I4
sa(dp19330
g17436
I31
sg17437
VSCA2
p19331
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19332
(dp19333
g17436
I90
sg17437
Vataxias
p19334
sg17438
I7
sg17445
VC0004134
p19335
sg17441
I1
sa(dp19336
g17436
I0
sg17437
VSpinocerebellar ataxia type 2
p19337
sg17438
I29
sg17445
VC0752121
p19338
sg17441
I4
sa(dp19339
g17436
I31
sg17437
VSCA2
p19340
sg17438
I4
sg17445
VC0752121
p19341
sg17441
I1
sasa(dp19342
g17431
VSpinocerebellar ataxia type 2 (SCA2) is due to a CAG expansion (CAGexp) at ATXN2.
p19343
sg17433
(lp19344
(dp19345
g17436
I75
sg17437
VATXN2
p19346
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19347
g17436
I0
sg17437
VSpinocerebellar ataxia type 2
p19348
sg17438
I29
sg17439
g12
sg17441
I4
sa(dp19349
g17436
I31
sg17437
VSCA2
p19350
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19351
(dp19352
g17436
I0
sg17437
VSpinocerebellar ataxia type 2
p19353
sg17438
I29
sg17445
VC0752121
p19354
sg17441
I4
sa(dp19355
g17436
I31
sg17437
VSCA2
p19356
sg17438
I4
sg17445
VC0752121
p19357
sg17441
I1
sasa(dp19358
g17431
VExpansion of polyglutamine trinucleotide (CAG) within ATXN2 gene with 35 or more repeats, results in spinocerebellar ataxia type-2.
p19359
sg17433
(lp19360
(dp19361
g17436
I54
sg17437
VATXN2 gene
p19362
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp19363
(dp19364
g17436
I101
sg17437
Vspinocerebellar ataxia
p19365
sg17438
I22
sg17445
VC0087012
p19366
sg17441
I2
sasa(dp19367
g135
(dp19368
(Vataxia type II
p19369
Vspinocerebellar ataxia
p19370
tp19371
I00
ssg17431
VRecent studies have identified the RNA-binding protein Ataxin-2 as a genetic determinant or risk factor for various diseases including spinocerebellar ataxia type II (SCA2) and amyotrophic lateral sclerosis (ALS), amongst others.
p19372
sg17433
(lp19373
(dp19374
g17436
I167
sg17437
VSCA2
p19375
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19376
g17436
I55
sg17437
VAtaxin-2
p19377
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp19378
g17436
I151
sg17437
g19369
sg17438
I14
sg17439
VP27037
p19379
sg17441
I3
sasg17442
(lp19380
(dp19381
g17436
I167
sg17437
VSCA2
p19382
sg17438
I4
sg17445
VC0752121
p19383
sg17441
I1
sa(dp19384
g17436
I177
sg17437
Vamyotrophic lateral sclerosis
p19385
sg17438
I29
sg17445
VC0002736
p19386
sg17441
I3
sa(dp19387
g17436
I208
sg17437
VALS
p19388
sg17438
I3
sg17445
VC0002736
p19389
sg17441
I1
sa(dp19390
g17436
I135
sg17437
g19370
sg17438
I22
sg17445
VC0087012
p19391
sg17441
I2
sasa(dp19392
g135
(dp19393
(Vsynaptobrevin 2
p19394
Vmyeloid leukemia
p19395
tp19396
I00
ssg17431
VHere we show that synaptobrevin 2 sorting involves determinants within its SNARE motif that are recognized by the ANTH domains of the endocytic adaptors AP180 and clathrin assembly lymphoid myeloid leukemia (CALM).
p19397
sg17433
(lp19398
(dp19399
g17436
I18
sg17437
g19394
sg17438
I15
sg17439
VP63027
p19400
sg17441
I2
sa(dp19401
g17436
I153
sg17437
VAP180
p19402
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp19403
(dp19404
g17436
I190
sg17437
g19395
sg17438
I16
sg17445
VC0023470
p19405
sg17441
I2
sasa(dp19406
g135
(dp19407
(VE3 ubiquitin
p19408
VB-cell lymphoma
p19409
tp19410
I00
ssg17431
VSpecifically, fibroblast growth factor receptor 3 (FGFR3), desmoglein 2 (DSG2), E3 ubiquitin ligase c-CBL (casitas B-cell lymphoma), cancer/testis antigen NY-ESO-1 (CTAG1A/B), undifferentiated embryonic cell transcription factor 1 (UTF1) and synaptosomal-associated protein, 91 kDa homolog (SNAP91) were shown to represent specific biomarkers of human spermatogonia.
p19411
sg17433
(lp19412
(dp19413
g17436
I51
sg17437
VFGFR3
p19414
sg17438
I5
sg17439
VP22607
p19415
sg17441
I1
sa(dp19416
g17436
I100
sg17437
Vc-CBL
p19417
sg17438
I5
sg17439
VP22681
p19418
sg17441
I1
sa(dp19419
g17436
I59
sg17437
Vdesmoglein 2
p19420
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp19421
g17436
I155
sg17437
VNY-ESO-1
p19422
sg17438
I8
sg17439
VP78358
p19423
sg17441
I1
sa(dp19424
g17436
I80
sg17437
g19408
sg17438
I12
sg17439
VP62979
p19425
sg17441
I2
sa(dp19426
g17436
I14
sg17437
Vfibroblast growth factor receptor 3
p19427
sg17438
I35
sg17439
g12
sg17441
I5
sa(dp19428
g17436
I176
sg17437
Vundifferentiated embryonic cell transcription factor 1
p19429
sg17438
I54
sg17439
g12
sg17441
I6
sa(dp19430
g17436
I291
sg17437
VSNAP91
p19431
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19432
g17436
I73
sg17437
VDSG2
p19433
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19434
g17436
I275
sg17437
V91 kDa homolog
p19435
sg17438
I14
sg17439
g12
sg17441
I3
sa(dp19436
g17436
I165
sg17437
VCTAG1A/B
p19437
sg17438
I8
sg17439
VP78358
p19438
sg17441
I1
sa(dp19439
g17436
I232
sg17437
VUTF1
p19440
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19441
(dp19442
g17436
I115
sg17437
g19409
sg17438
I15
sg17445
VC0079731
p19443
sg17441
I2
sa(dp19444
g17436
I133
sg17437
Vcancer
p19445
sg17438
I6
sg17445
VC0006826
p19446
sg17441
I1
sasa(dp19447
g17431
VRecently, the gene encoding clathrin assembly protein of lymphoid myeloid leukemia (CALM), which is homologous to the AP180, was cloned from rat brain, and its expression differential to AP180 was reported (Kim and Lee, 1999).
p19448
sg17433
(lp19449
(dp19450
g17436
I118
sg17437
VAP180
p19451
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp19452
(dp19453
g17436
I66
sg17437
Vmyeloid leukemia
p19454
sg17438
I16
sg17445
VC0023470
p19455
sg17441
I2
sasa(dp19456
g17431
VThe clathrin assembly protein lymphoid myeloid leukemia (CALM) gene, encodes a homologoue of the neuronal clathrin assembly protein AP180.
p19457
sg17433
(lp19458
sg17442
(lp19459
(dp19460
g17436
I39
sg17437
Vmyeloid leukemia
p19461
sg17438
I16
sg17445
VC0023470
p19462
sg17441
I2
sasa(dp19463
g17431
VThe clathrin assembly lymphoid myeloid leukemia (CALM) gene encodes a putative homologue of the clathrin assembly synaptic protein AP180.
p19464
sg17433
(lp19465
sg17442
(lp19466
(dp19467
g17436
I31
sg17437
Vmyeloid leukemia
p19468
sg17438
I16
sg17445
VC0023470
p19469
sg17441
I2
sasa(dp19470
g135
(dp19471
(VERp57
p19472
Vinsulinoma
p19473
tp19474
I00
ssg17431
VThe expression level of ERp57 was also elevated in rat insulinoma INS-1 cells by inducible knock-down of the atg7-gene.
p19475
sg17433
(lp19476
(dp19477
g17436
I51
sg17437
Vrat insulinoma INS-1
p19478
sg17438
I20
sg17439
VP01308
p19479
sg17441
I3
sa(dp19480
g17436
I109
sg17437
Vatg7-gene
p19481
sg17438
I9
sg17439
g12
sg17441
I1
sa(dp19482
g17436
I24
sg17437
g19472
sg17438
I5
sg17439
VP30101
p19483
sg17441
I1
sasg17442
(lp19484
(dp19485
g17436
I66
sg17437
VINS
p19486
sg17438
I3
sg17445
VC1533172
p19487
sg17441
I1
sa(dp19488
g17436
I55
sg17437
g19473
sg17438
I10
sg17445
VC0021670
p19489
sg17441
I1
sasa(dp19490
g135
(dp19491
(Vp62
p19492
Vameloblastomas
p19493
tp19494
I00
ssg17431
VTissue specimens of nine dental follicles and 69 ameloblastomas were immunohistochemically examined with antibodies against ATG7, LC3, and p62.
p19495
sg17433
(lp19496
(dp19497
g17436
I130
sg17437
VLC3
p19498
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp19499
g17436
I139
sg17437
g19492
sg17438
I3
sg17439
VP37198
p19500
sg17441
I1
sa(dp19501
g17436
I124
sg17437
VATG7
p19502
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19503
(dp19504
g17436
I49
sg17437
g19493
sg17438
I14
sg17445
VC0002448
p19505
sg17441
I1
sasa(dp19506
g135
(dp19507
(Vp62
p19508
Vameloblastomas
p19509
tp19510
I00
ssg17431
VImmunohistochemical reactivity for ATG7, LC3, and p62 was detected in many odontogenic epithelial cells and several endothelial cells and fibroblasts in dental follicles and ameloblastomas.
p19511
sg17433
(lp19512
(dp19513
g17436
I35
sg17437
VATG7
p19514
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19515
g17436
I41
sg17437
VLC3
p19516
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp19517
g17436
I50
sg17437
g19508
sg17438
I3
sg17439
VP37198
p19518
sg17441
I1
sasg17442
(lp19519
(dp19520
g17436
I174
sg17437
g19509
sg17438
I14
sg17445
VC0002448
p19521
sg17441
I1
sasa(dp19522
g135
(dp19523
(Vp62
p19524
Vameloblastomas
p19525
tp19526
I00
ssg17431
VExpression of ATG7, LC3, and p62 was found markedly in neoplastic cells near the basement membrane rather than central polyhedral cells in ameloblastomas.
p19527
sg17433
(lp19528
(dp19529
g17436
I29
sg17437
g19524
sg17438
I3
sg17439
VP37198
p19530
sg17441
I1
sa(dp19531
g17436
I20
sg17437
VLC3
p19532
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp19533
g17436
I14
sg17437
VATG7
p19534
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19535
(dp19536
g17436
I139
sg17437
g19525
sg17438
I14
sg17445
VC0002448
p19537
sg17441
I1
sasa(dp19538
g135
(dp19539
(Vp62
p19540
Vameloblastomas
p19541
tp19542
I00
ssg17431
VExpression of ATG7, LC3, and p62 in dental follicles and ameloblastomas suggests that autophagy regulation might be affected by microenvironment alterations during tumorigenesis.
p19543
sg17433
(lp19544
(dp19545
g17436
I29
sg17437
g19540
sg17438
I3
sg17439
VP37198
p19546
sg17441
I1
sa(dp19547
g17436
I20
sg17437
VLC3
p19548
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp19549
g17436
I14
sg17437
VATG7
p19550
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19551
(dp19552
g17436
I164
sg17437
Vtumorigenesis
p19553
sg17438
I13
sg17445
VC0007621
p19554
sg17441
I1
sa(dp19555
g17436
I57
sg17437
g19541
sg17438
I14
sg17445
VC0002448
p19556
sg17441
I1
sasa(dp19557
g17431
VAtg7 deficiency alters progression of Braf(V600E)-driven tumors from adenomas (Braf(V600E); atg7(-/-)) and adenocarcinomas (trp53(-/-); Braf(V600E); atg7(-/-)) to benign oncocytomas that accumulated morphologically and functionally defective mitochondria, suggesting that defects in mitochondrial metabolism may compromise continued tumor growth.
p19558
sg17433
(lp19559
(dp19560
g17436
I124
sg17437
Vtrp53
p19561
sg17438
I5
sg17439
VP42771
p19562
sg17441
I1
sa(dp19563
g17436
I0
sg17437
VAtg7
p19564
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19565
(dp19566
g17436
I170
sg17437
Voncocytomas
p19567
sg17438
I11
sg17445
VC0949541
p19568
sg17441
I1
sa(dp19569
g17436
I57
sg17437
Vtumors
p19570
sg17438
I6
sg17445
VC0027651
p19571
sg17441
I1
sa(dp19572
g17436
I107
sg17437
Vadenocarcinomas
p19573
sg17438
I15
sg17445
VC0001418
p19574
sg17441
I1
sa(dp19575
g17436
I69
sg17437
Vadenomas
p19576
sg17438
I8
sg17445
VC0001430
p19577
sg17441
I1
sa(dp19578
g17436
I333
sg17437
Vtumor growth
p19579
sg17438
I12
sg17445
VC0598934
p19580
sg17441
I2
sasa(dp19581
g17431
VAt later stages of tumorigenesis, Atg7 deficiency resulted in an accumulation of defective mitochondria, proliferative defects, reduced tumor burden, conversion of adenomas and adenocarcinomas to oncocytomas, and increased mouse life span.
p19582
sg17433
(lp19583
(dp19584
g17436
I34
sg17437
VAtg7
p19585
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19586
(dp19587
g17436
I19
sg17437
Vtumor
p19588
sg17438
I5
sg17445
VC0027651
p19589
sg17441
I1
sa(dp19590
g17436
I196
sg17437
Voncocytomas
p19591
sg17438
I11
sg17445
VC0949541
p19592
sg17441
I1
sa(dp19593
g17436
I177
sg17437
Vadenocarcinomas
p19594
sg17438
I15
sg17445
VC0001418
p19595
sg17441
I1
sa(dp19596
g17436
I19
sg17437
Vtumorigenesis
p19597
sg17438
I13
sg17445
VC0007621
p19598
sg17441
I1
sa(dp19599
g17436
I164
sg17437
Vadenomas
p19600
sg17438
I8
sg17445
VC0001430
p19601
sg17441
I1
sa(dp19602
g17436
I105
sg17437
Vproliferative
p19603
sg17438
I13
sg17445
VC0334094
p19604
sg17441
I1
sasa(dp19605
g135
(dp19606
(VKRAS
p19607
Vadenocarcinomas
p19608
tp19609
I00
ssg17431
VUsing genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.
p19610
sg17433
(lp19611
(dp19612
g17436
I152
sg17437
VAtg7
p19613
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19614
g17436
I161
sg17437
g19607
sg17438
I4
sg17439
VP01116
p19615
sg17441
I1
sasg17442
(lp19616
(dp19617
g17436
I194
sg17437
Vtumor growth
p19618
sg17438
I12
sg17445
VC0598934
p19619
sg17441
I2
sa(dp19620
g17436
I88
sg17437
VNSCLC
p19621
sg17438
I5
sg17445
VC0007131
p19622
sg17441
I1
sa(dp19623
g17436
I220
sg17437
Vadenomas
p19624
sg17438
I8
sg17445
VC0001430
p19625
sg17441
I1
sa(dp19626
g17436
I259
sg17437
Voncocytomas
p19627
sg17438
I11
sg17445
VC0949541
p19628
sg17441
I1
sa(dp19629
g17436
I88
sg17437
VNSCLC
p19630
sg17438
I5
sg17445
VC0007131
p19631
sg17441
I1
sa(dp19632
g17436
I60
sg17437
Vnon-small-cell lung cancer
p19633
sg17438
I26
sg17445
VC0007131
p19634
sg17441
I3
sa(dp19635
g17436
I233
sg17437
g19608
sg17438
I15
sg17445
VC0001418
p19636
sg17441
I1
sasa(dp19637
g17431
Vatg7 loss altered tumor fate from adenomas and carcinomas to oncocytomas-rare, predominantly benign tumors characterized by the accumulation of defective mitochondria.
p19638
sg17433
(lp19639
(dp19640
g17436
I0
sg17437
Vatg7
p19641
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19642
(dp19643
g17436
I18
sg17437
Vtumor
p19644
sg17438
I5
sg17445
VC0027651
p19645
sg17441
I1
sa(dp19646
g17436
I61
sg17437
Voncocytomas
p19647
sg17438
I11
sg17445
VC0949541
p19648
sg17441
I1
sa(dp19649
g17436
I34
sg17437
Vadenomas
p19650
sg17438
I8
sg17445
VC0001430
p19651
sg17441
I1
sa(dp19652
g17436
I47
sg17437
Vcarcinomas
p19653
sg17438
I10
sg17445
VC0007097
p19654
sg17441
I1
sa(dp19655
g17436
I93
sg17437
Vbenign tumors
p19656
sg17438
I13
sg17445
VC0086692
p19657
sg17441
I2
sasa(dp19658
g17431
VSubsequent studies demonstrated that Atg5(-/-) and Atg7(-/-) livers give rise to adenomas, Atg4C(-/-) mice are susceptible to chemical carcinogenesis, and Bif1(-/-) mice are prone to spontaneous tumors, indicating that autophagy defects promote tumorigenesis.
p19659
sg17433
(lp19660
(dp19661
g17436
I91
sg17437
VAtg4C
p19662
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19663
g17436
I155
sg17437
VBif1
p19664
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19665
g17436
I37
sg17437
VAtg5
p19666
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19667
g17436
I51
sg17437
VAtg7
p19668
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19669
(dp19670
g17436
I126
sg17437
Vchemical carcinogenesis
p19671
sg17438
I23
sg17445
VC0596321
p19672
sg17441
I2
sa(dp19673
g17436
I245
sg17437
Vtumorigenesis
p19674
sg17438
I13
sg17445
VC0007621
p19675
sg17441
I1
sa(dp19676
g17436
I81
sg17437
Vadenomas
p19677
sg17438
I8
sg17445
VC0001430
p19678
sg17441
I1
sa(dp19679
g17436
I195
sg17437
Vtumors
p19680
sg17438
I6
sg17445
VC0027651
p19681
sg17441
I1
sasa(dp19682
g17431
VScavenger receptor class A, member 3 (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with breast carcinoma effusions by global gene expression analysis.
p19683
sg17433
(lp19684
(dp19685
g17436
I38
sg17437
VSCARA3
p19686
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19687
g17436
I0
sg17437
VScavenger receptor class A, member 3
p19688
sg17438
I36
sg17439
g12
sg17441
I6
sasg17442
(lp19689
(dp19690
g17436
I150
sg17437
Vbreast carcinoma
p19691
sg17438
I16
sg17445
VC0678222
p19692
sg17441
I2
sa(dp19693
g17436
I167
sg17437
Veffusions
p19694
sg17438
I9
sg17445
VC0013687
p19695
sg17441
I1
sa(dp19696
g17436
I98
sg17437
Vprimary peritoneal carcinoma
p19697
sg17438
I28
sg17445
VC1514428
p19698
sg17441
I3
sasa(dp19699
g135
(dp19700
(Vcyclin D
p19701
Vmetastatic melanoma
p19702
tp19703
I01
ssg17431
Vp15RS is a ubiquitously expressed nuclear protein that is positively regulated by p15 and, in turn, inhibits the expression of cyclin D and cyclin E. To determine whether p15RS has malignancy inhibitory functions in addition to its inhibitory effects on cell cycle entry, we ectopically expressed p15RS in metastatic melanoma A375 cells, in which p15 gene is deleted and p15RS expression is dramatically downregulated, and examined the effect on various malignant phenotypes.
p19704
sg17433
(lp19705
(dp19706
g17436
I0
sg17437
Vp15RS
p19707
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19708
g17436
I0
sg17437
Vp15RS
p19709
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19710
g17436
I0
sg17437
Vp15RS
p19711
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19712
g17436
I0
sg17437
Vp15RS
p19713
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19714
g17436
I347
sg17437
Vp15 gene
p19715
sg17438
I8
sg17439
VP53999
p19716
sg17441
I2
sa(dp19717
g17436
I0
sg17437
Vp15
p19718
sg17438
I3
sg17439
VP53999
p19719
sg17441
I1
sa(dp19720
g17436
I140
sg17437
Vcyclin E
p19721
sg17438
I8
sg17439
VP24864
p19722
sg17441
I2
sa(dp19723
g17436
I127
sg17437
g19701
sg17438
I8
sg17439
VP24385
p19724
sg17441
I2
sasg17442
(lp19725
(dp19726
g17436
I181
sg17437
Vmalignancy
p19727
sg17438
I10
sg17445
VC0006826
p19728
sg17441
I1
sa(dp19729
g17436
I306
sg17437
g19702
sg17438
I19
sg17445
VC0278883
p19730
sg17441
I2
sasa(dp19731
g17431
VWilms' tumor 1-associating protein (WTAP) has been reported to be a ubiquitously expressed nuclear protein.
p19732
sg17433
(lp19733
(dp19734
g17436
I0
sg17437
VWilms' tumor 1-associating protein
p19735
sg17438
I34
sg17439
g12
sg17441
I4
sa(dp19736
g17436
I36
sg17437
VWTAP
p19737
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp19738
(dp19739
g17436
I0
sg17437
VWilms' tumor
p19740
sg17438
I12
sg17445
VC0027708
p19741
sg17441
I2
sasa(dp19742
g17431
VThe results showed that TCF7L2 polymorphism was associated with breast cancer (Homogeneous model: OR=1.17, 95%CI=1.02-1.35, I (2) =21.8%, p for heterogeneity=0.276; Heterogeneous model: OR=1.11, 95%CI=1.03-1.20, I (2) =0.0%, p for heterogeneity=0.543), prostate cancer (Homogeneous model: OR=0.89, 95%CI=0.84-0.96, I (2) =0.0%, p for heterogeneity=0.640; Heterogeneous model: OR=0.89, 95%CI=0.84-0.95, I (2) =0.0%, p for heterogeneity=0.871), and colon cancer (Heterogeneous model: OR=1.15, 95%CI=1.01-1.31, I (2) =0.0%, p for heterogeneity=0.658), but not with colorectal cancer, lung cancer, and ovarian cancer.
p19743
sg17433
(lp19744
sg17442
(lp19745
(dp19746
g17436
I598
sg17437
Vovarian cancer
p19747
sg17438
I14
sg17445
VC1140680
p19748
sg17441
I2
sa(dp19749
g17436
I253
sg17437
Vprostate cancer
p19750
sg17438
I15
sg17445
VC0600139
p19751
sg17441
I2
sa(dp19752
g17436
I64
sg17437
Vbreast cancer
p19753
sg17438
I13
sg17445
VC0678222
p19754
sg17441
I2
sa(dp19755
g17436
I447
sg17437
Vcolon cancer
p19756
sg17438
I12
sg17445
VC0699790
p19757
sg17441
I2
sa(dp19758
g17436
I562
sg17437
Vcolorectal cancer
p19759
sg17438
I17
sg17445
VC1527249
p19760
sg17441
I2
sa(dp19761
g17436
I581
sg17437
Vlung cancer
p19762
sg17438
I11
sg17445
VC0684249
p19763
sg17441
I2
sasa(dp19764
g17431
VThe present meta-analysis indicated that there were significantly associations between the TCF7L2 rs7903146 polymorphism and risk of breast, prostate and colon cancers, rather than colorectal cancer, lung cancer, and ovarian cancer.
p19765
sg17433
(lp19766
sg17442
(lp19767
(dp19768
g17436
I200
sg17437
Vlung cancer
p19769
sg17438
I11
sg17445
VC0684249
p19770
sg17441
I2
sa(dp19771
g17436
I154
sg17437
Vcolon cancers
p19772
sg17438
I13
sg17445
VC0007102
p19773
sg17441
I2
sa(dp19774
g17436
I217
sg17437
Vovarian cancer
p19775
sg17438
I14
sg17445
VC1140680
p19776
sg17441
I2
sa(dp19777
g17436
I181
sg17437
Vcolorectal cancer
p19778
sg17438
I17
sg17445
VC1527249
p19779
sg17441
I2
sasa(dp19780
g17431
VMutations in the gene encoding comparative gene identification 58 (CGI-58), also known as Alfa Beta hydrolase domain-containing 5 (ABHD5), cause neutral lipid storage disorder with ichthyosis (NLSDI).
p19781
sg17433
(lp19782
(dp19783
g17436
I90
sg17437
VAlfa Beta hydrolase domain-containing 5
p19784
sg17438
I39
sg17439
g12
sg17441
I5
sa(dp19785
g17436
I131
sg17437
VABHD5
p19786
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp19787
(dp19788
g17436
I193
sg17437
VNLSDI
p19789
sg17438
I5
sg17445
VC0268238
p19790
sg17441
I1
sa(dp19791
g17436
I145
sg17437
Vneutral lipid storage disorder with ichthyosis
p19792
sg17438
I46
sg17445
VC0268238
p19793
sg17441
I6
sasa(dp19794
g17431
VIt has been elucidated that, of the ichthyosis-causative genes, ABCA12, ALOXE3, ALOX12B, CYP4F22, CERS3, ABHD5, PNPLA1 and ELOVL4 work in the formation of the corneocyte lipid envelope (CLE), a structure that is essential to sound skin barrier function.
p19795
sg17433
(lp19796
(dp19797
g17436
I72
sg17437
VALOXE3
p19798
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19799
g17436
I89
sg17437
VCYP4F22
p19800
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp19801
g17436
I186
sg17437
VCLE
p19802
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp19803
g17436
I80
sg17437
VALOX12B
p19804
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp19805
g17436
I64
sg17437
VABCA12
p19806
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19807
g17436
I105
sg17437
VABHD5
p19808
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19809
g17436
I98
sg17437
VCERS3
p19810
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19811
g17436
I123
sg17437
VELOVL4
p19812
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19813
g17436
I159
sg17437
Vcorneocyte lipid envelope
p19814
sg17438
I25
sg17439
g12
sg17441
I3
sa(dp19815
g17436
I112
sg17437
VPNPLA1
p19816
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp19817
(dp19818
g17436
I159
sg17437
Vcorneocyte lipid envelope
p19819
sg17438
I25
sg17445
VC2931489
p19820
sg17441
I3
sa(dp19821
g17436
I186
sg17437
VCLE
p19822
sg17438
I3
sg17445
VC2931489
p19823
sg17441
I1
sa(dp19824
g17436
I36
sg17437
Vichthyosis
p19825
sg17438
I10
sg17445
VC0020758
p19826
sg17441
I1
sasa(dp19827
g135
(dp19828
(Vadipose triglyceride lipase
p19829
Vinsulin resistance
p19830
tp19831
I00
ssg17431
VWe discuss known inborn errors of CTGM, including deficiencies of: AGPAT2 (a form of generalized lipodystrophy), LPIN1 (childhood rhabdomyolysis), LPIN2 (an inflammatory condition, Majeed syndrome, described elsewhere in this issue), DGAT1 (protein loosing enteropathy), perilipin 1 (partial lipodystrophy), CGI-58 (gene ABHD5, neutral lipid storage disease (NLSD) with ichthyosis and "Jordan's anomaly" of vacuolated polymorphonuclear leukocytes), adipose triglyceride lipase (ATGL, gene PNPLA2, NLSD with myopathy, cardiomyopathy and Jordan's anomaly), hormone-sensitive lipase (HSL, gene LIPE, hypertriglyceridemia, and insulin resistance).
p19832
sg17433
(lp19833
(dp19834
g17436
I623
sg17437
Vinsulin
p19835
sg17438
I7
sg17439
VP01308
p19836
sg17441
I1
sa(dp19837
g17436
I586
sg17437
Vgene LIPE
p19838
sg17438
I9
sg17439
g12
sg17441
I2
sa(dp19839
g17436
I478
sg17437
VATGL
p19840
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp19841
g17436
I581
sg17437
VHSL
p19842
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp19843
g17436
I484
sg17437
Vgene PNPLA2
p19844
sg17438
I11
sg17439
g12
sg17441
I2
sa(dp19845
g17436
I555
sg17437
Vhormone-sensitive lipase
p19846
sg17438
I24
sg17439
g12
sg17441
I2
sa(dp19847
g17436
I321
sg17437
VABHD5
p19848
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19849
g17436
I271
sg17437
Vperilipin 1
p19850
sg17438
I11
sg17439
g12
sg17441
I2
sa(dp19851
g17436
I234
sg17437
VDGAT1
p19852
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp19853
g17436
I67
sg17437
VAGPAT2
p19854
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19855
g17436
I449
sg17437
g19829
sg17438
I27
sg17439
VP04118
p19856
sg17441
I3
sa(dp19857
g17436
I113
sg17437
VLPIN1
p19858
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp19859
(dp19860
g17436
I507
sg17437
Vmyopathy
p19861
sg17438
I8
sg17445
VC0026848
p19862
sg17441
I1
sa(dp19863
g17436
I359
sg17437
VNLSD
p19864
sg17438
I4
sg17445
VC0268238
p19865
sg17441
I1
sa(dp19866
g17436
I181
sg17437
VMajeed syndrome
p19867
sg17438
I15
sg17445
VC1864997
p19868
sg17441
I2
sa(dp19869
g17436
I359
sg17437
VNLSD
p19870
sg17438
I4
sg17445
VC0268238
p19871
sg17441
I1
sa(dp19872
g17436
I370
sg17437
Vichthyosis
p19873
sg17438
I10
sg17445
VC0020758
p19874
sg17441
I1
sa(dp19875
g17436
I328
sg17437
Vneutral lipid storage disease
p19876
sg17438
I29
sg17445
VC0268238
p19877
sg17441
I4
sa(dp19878
g17436
I517
sg17437
Vcardiomyopathy
p19879
sg17438
I14
sg17445
VC0878544
p19880
sg17441
I1
sa(dp19881
g17436
I130
sg17437
Vrhabdomyolysis
p19882
sg17438
I14
sg17445
VC0035410
p19883
sg17441
I1
sa(dp19884
g17436
I85
sg17437
Vgeneralized lipodystrophy
p19885
sg17438
I25
sg17445
VC0221032
p19886
sg17441
I2
sa(dp19887
g17436
I257
sg17437
Venteropathy
p19888
sg17438
I11
sg17445
VC0021831
p19889
sg17441
I1
sa(dp19890
g17436
I170
sg17437
Vcondition
p19891
sg17438
I9
sg17445
VC0012634
p19892
sg17441
I1
sa(dp19893
g17436
I284
sg17437
Vpartial lipodystrophy
p19894
sg17438
I21
sg17445
VC0220989
p19895
sg17441
I2
sa(dp19896
g17436
I623
sg17437
g19830
sg17438
I18
sg17445
VC0021655
p19897
sg17441
I2
sasa(dp19898
g17431
VIn current study, we have discovered, using a comprehensive investigative regimen, a novel and tissue-specific role of claudin-3, a tight junction integral protein, in inhibiting colon cancer progression by serving as the common rheostat of Stat-3 and Wnt-signaling activation.
p19899
sg17433
(lp19900
(dp19901
g17436
I119
sg17437
Vclaudin-3
p19902
sg17438
I9
sg17439
g12
sg17441
I1
sa(dp19903
g17436
I241
sg17437
VStat-3
p19904
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp19905
(dp19906
g17436
I185
sg17437
Vcancer progression
p19907
sg17438
I18
sg17445
VC0178874
p19908
sg17441
I2
sasa(dp19909
g17431
VClaudin-3-/- mice revealed dedifferentiated and leaky colonic epithelium, and developed invasive adenocarcinoma when subjected to colon cancer.
p19910
sg17433
(lp19911
sg17442
(lp19912
(dp19913
g17436
I97
sg17437
Vadenocarcinoma
p19914
sg17438
I14
sg17445
VC0001418
p19915
sg17441
I1
sa(dp19916
g17436
I130
sg17437
Vcolon cancer
p19917
sg17438
I12
sg17445
VC0699790
p19918
sg17441
I2
sasa(dp19919
g135
(dp19920
(VGSK-3Beta
p19921
Vcolon cancer
p19922
tp19923
I00
ssg17431
VWnt-signaling hyperactivation, albeit in GSK-3Beta independent manner, differentiated colon cancer in claudin-3-/- mice versus WT-mice.
p19924
sg17433
(lp19925
(dp19926
g17436
I41
sg17437
g19921
sg17438
I9
sg17439
VP49841
p19927
sg17441
I1
sasg17442
(lp19928
(dp19929
g17436
I86
sg17437
g19922
sg17438
I12
sg17445
VC0699790
p19930
sg17441
I2
sasa(dp19931
g135
(dp19932
(VBeta-catenin
p19933
Vcolon cancer
p19934
tp19935
I00
ssg17431
VGenetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/Beta-catenin activation, which is further exacerbated by Stat-3-activation and help promote colon cancer.
p19936
sg17433
(lp19937
(dp19938
g17436
I51
sg17437
Vclaudin-3 loss
p19939
sg17438
I14
sg17439
g12
sg17441
I2
sa(dp19940
g17436
I135
sg17437
VStat-3
p19941
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp19942
g17436
I78
sg17437
g19933
sg17438
I12
sg17439
VP35222
p19943
sg17441
I1
sasg17442
(lp19944
(dp19945
g17436
I170
sg17437
g19934
sg17438
I12
sg17445
VC0699790
p19946
sg17441
I2
sasa(dp19947
g17431
VAmong the paradoxical claudin reaction nuclear localization of marker was observed relatively rarely: claudin-3 in 2.5% cases of colon cancer; claudin-4 in 8.5% of colon polyps.
p19948
sg17433
(lp19949
sg17442
(lp19950
(dp19951
g17436
I129
sg17437
Vcolon cancer
p19952
sg17438
I12
sg17445
VC0699790
p19953
sg17441
I2
sa(dp19954
g17436
I164
sg17437
Vcolon polyps
p19955
sg17438
I12
sg17445
VC0009376
p19956
sg17441
I2
sasa(dp19957
g17431
VMislocalization claudin-3 to nucleus in colon cancer and mislocalization claudin-4 to nucleus in adenomas of the colon were detected for the first time.
p19958
sg17433
(lp19959
(dp19960
g17436
I0
sg17437
VMislocalization claudin-3
p19961
sg17438
I25
sg17439
g12
sg17441
I2
sa(dp19962
g17436
I73
sg17437
Vclaudin-4
p19963
sg17438
I9
sg17439
g12
sg17441
I1
sasg17442
(lp19964
(dp19965
g17436
I97
sg17437
Vadenomas
p19966
sg17438
I8
sg17445
VC0001430
p19967
sg17441
I1
sa(dp19968
g17436
I40
sg17437
Vcolon cancer
p19969
sg17438
I12
sg17445
VC0699790
p19970
sg17441
I2
sasa(dp19971
g17431
VOur approach aimed at evaluation of a selective and targeted cancer gene therapy of claudin-3- and/or claudin-4- expressing colon carcinoma in vitro and in vivo by using translation optimized CPE expressing vector.
p19972
sg17433
(lp19973
sg17442
(lp19974
(dp19975
g17436
I124
sg17437
Vcolon carcinoma
p19976
sg17438
I15
sg17445
VC0699790
p19977
sg17441
I2
sa(dp19978
g17436
I61
sg17437
Vcancer
p19979
sg17438
I6
sg17445
VC0006826
p19980
sg17441
I1
sasa(dp19981
g17431
VIn this study the recombinant CPE and a translation optimized CPE expressing vector (optCPE) was used for targeted gene therapy of claudin-3 and/or -4 overexpressing colon cancer cell lines.
p19982
sg17433
(lp19983
sg17442
(lp19984
(dp19985
g17436
I166
sg17437
Vcolon cancer
p19986
sg17438
I12
sg17445
VC0699790
p19987
sg17441
I2
sasa(dp19988
g17431
VAll experiments were performed in the human SW480, SW620, HCT116, CaCo-2 and HT-29 colon cancer and the isogenic Sk-Mel5 and Sk-Mel5 Cldn-3-YFP melanoma cell lines.
p19989
sg17433
(lp19990
sg17442
(lp19991
(dp19992
g17436
I83
sg17437
Vcolon cancer
p19993
sg17438
I12
sg17445
VC0699790
p19994
sg17441
I2
sa(dp19995
g17436
I144
sg17437
Vmelanoma
p19996
sg17438
I8
sg17445
VC0025202
p19997
sg17441
I1
sasa(dp19998
g17431
VClaudin-3 and -4 overexpressing colon carcinoma lines showed high sensitivity towards both recCPE application and optCPE gene transfer.
p19999
sg17433
(lp20000
(dp20001
g17436
I0
sg17437
VClaudin-3 and -4
p20002
sg17438
I16
sg17439
g12
sg17441
I3
sasg17442
(lp20003
(dp20004
g17436
I32
sg17437
Vcolon carcinoma
p20005
sg17438
I15
sg17445
VC0699790
p20006
sg17441
I2
sasa(dp20007
g17431
VThis novel approach demonstrates that optCPE gene transfer represents a promising and efficient therapeutic option for a targeted suicide gene therapy of claudin-3 and/or claudin-4 overexpressing colon carcinomas, leading to rapid and effective tumor cell killing in vitro and in vivo.
p20008
sg17433
(lp20009
(dp20010
g17436
I171
sg17437
Vclaudin-4
p20011
sg17438
I9
sg17439
g12
sg17441
I1
sasg17442
(lp20012
(dp20013
g17436
I245
sg17437
Vtumor
p20014
sg17438
I5
sg17445
VC0027651
p20015
sg17441
I1
sa(dp20016
g17436
I202
sg17437
Vcarcinomas
p20017
sg17438
I10
sg17445
VC0007097
p20018
sg17441
I1
sasa(dp20019
g17431
VTo investigate the expression of claudin-3 in colorectal carcinoma and its association with the occurrence, progression and prognosis of colorectal cancer.
p20020
sg17433
(lp20021
(dp20022
g17436
I33
sg17437
Vclaudin-3
p20023
sg17438
I9
sg17439
g12
sg17441
I1
sasg17442
(lp20024
(dp20025
g17436
I46
sg17437
Vcolorectal carcinoma
p20026
sg17438
I20
sg17445
VC0009402
p20027
sg17441
I2
sa(dp20028
g17436
I137
sg17437
Vcolorectal cancer
p20029
sg17438
I17
sg17445
VC0009402
p20030
sg17441
I2
sasa(dp20031
g17431
VClaudin-3 is over-expressed in colorectal cancer tissues, and its high expression may promote the occurrence and progression of colorectal cancer.
p20032
sg17433
(lp20033
(dp20034
g17436
I0
sg17437
VClaudin-3
p20035
sg17438
I9
sg17439
g12
sg17441
I1
sasg17442
(lp20036
(dp20037
g17436
I31
sg17437
Vcolorectal cancer
p20038
sg17438
I17
sg17445
VC1527249
p20039
sg17441
I2
sa(dp20040
g17436
I31
sg17437
Vcolorectal cancer
p20041
sg17438
I17
sg17445
VC1527249
p20042
sg17441
I2
sasa(dp20043
g135
(dp20044
(Vepidermal growth factor
p20045
Vcolorectal adenocarcinoma
p20046
tp20047
I00
ssg17431
VHere, we report that epidermal growth factor (EGF) increases the expression of claudin-3 in human colorectal adenocarcinoma HT-29 cells.
p20048
sg17433
(lp20049
(dp20050
g17436
I79
sg17437
Vclaudin-3
p20051
sg17438
I9
sg17439
g12
sg17441
I1
sa(dp20052
g17436
I46
sg17437
VEGF
p20053
sg17438
I3
sg17439
VP01133
p20054
sg17441
I1
sa(dp20055
g17436
I21
sg17437
g20045
sg17438
I23
sg17439
VP01133
p20056
sg17441
I3
sasg17442
(lp20057
(dp20058
g17436
I98
sg17437
g20046
sg17438
I25
sg17445
VC1319315
p20059
sg17441
I2
sasa(dp20060
g135
(dp20061
(VERK1/2
p20062
Vcolorectal cancer
p20063
tp20064
I00
ssg17431
VIn conclusion, our results show a novel role for claudin-3 overexpression in promoting the malignant potential of colorectal cancer cells, which is potentially regulated by the EGF-activated ERK1/2 and PI3K-Akt pathways.
p20065
sg17433
(lp20066
(dp20067
g17436
I49
sg17437
Vclaudin-3
p20068
sg17438
I9
sg17439
g12
sg17441
I1
sa(dp20069
g17436
I177
sg17437
VEGF
p20070
sg17438
I3
sg17439
VP01133
p20071
sg17441
I1
sa(dp20072
g17436
I202
sg17437
VPI3K
p20073
sg17438
I4
sg17439
VP42336
p20074
sg17441
I1
sa(dp20075
g17436
I207
sg17437
VAkt
p20076
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp20077
g17436
I191
sg17437
g20062
sg17438
I6
sg17439
VP27361
p20078
sg17441
I1
sasg17442
(lp20079
(dp20080
g17436
I114
sg17437
g20063
sg17438
I17
sg17445
VC1527249
p20081
sg17441
I2
sasa(dp20082
g135
(dp20083
(Vthrombomodulin
p20084
Vpolycythemia vera
p20085
tp20086
I00
ssg17431
VPatients with essential thrombocythemia (ET) and polycythemia vera (PV), complicated by microvascular ischemic or thrombotic events, have shortened platelet survival, increased beta-thromboglobulin, platelet factor 4, and thrombomodulin levels, and increased urinary thromboxane B2 excretion.
p20087
sg17433
(lp20088
(dp20089
g17436
I177
sg17437
Vbeta-thromboglobulin
p20090
sg17438
I20
sg17439
VP02775
p20091
sg17441
I1
sa(dp20092
g17436
I199
sg17437
Vplatelet factor 4
p20093
sg17438
I17
sg17439
VP02776
p20094
sg17441
I3
sa(dp20095
g17436
I222
sg17437
g20084
sg17438
I14
sg17439
VP07204
p20096
sg17441
I1
sasg17442
(lp20097
(dp20098
g17436
I68
sg17437
VPV
p20099
sg17438
I2
sg17445
VC0032463
p20100
sg17441
I1
sa(dp20101
g17436
I14
sg17437
Vessential thrombocythemia
p20102
sg17438
I25
sg17445
VC0040028
p20103
sg17441
I2
sa(dp20104
g17436
I41
sg17437
VET
p20105
sg17438
I2
sg17445
VC0040028
p20106
sg17441
I1
sa(dp20107
g17436
I49
sg17437
g20085
sg17438
I17
sg17445
VC0032463
p20108
sg17441
I2
sasa(dp20109
g17431
VOur results suggest that CEP68 gene variants may play an important role in MNSAID-UA susceptibility and, despite the different regulatory mechanisms involved depending on the specific affected organ, in the development of hypersensitivity reactions to NSAIDs.
p20110
sg17433
(lp20111
(dp20112
g17436
I25
sg17437
VCEP68 gene variants
p20113
sg17438
I19
sg17439
g12
sg17441
I3
sasg17442
(lp20114
(dp20115
g17436
I222
sg17437
Vhypersensitivity reactions
p20116
sg17438
I26
sg17445
VC0020517
p20117
sg17441
I2
sasa(dp20118
g17431
VBaboon anti-pig antibody (Ab) was measured before CPB, before circulatory arrest, during AbA, at the end of CPB, and daily after HTx.
p20119
sg17433
(lp20120
sg17442
(lp20121
(dp20122
g17436
I62
sg17437
Vcirculatory arrest
p20123
sg17438
I18
sg17445
VC0444720
p20124
sg17441
I2
sasa(dp20125
g17431
VAt 4 dpi a severe fibrinosuppurative bronchopneumonia had developed.
p20126
sg17433
(lp20127
sg17442
(lp20128
(dp20129
g17436
I37
sg17437
Vbronchopneumonia
p20130
sg17438
I16
sg17445
VC0006285
p20131
sg17441
I1
sasa(dp20132
g17431
VHowever, the SrGAP3-deficient mice showed little to no interest in burying marbles; a behavior that is seen in some animal models related to autism, supporting the view that SrGAP3 plays a role in neurodevelopmental disorders.
p20133
sg17433
(lp20134
(dp20135
g17436
I13
sg17437
VSrGAP3
p20136
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp20137
g17436
I13
sg17437
VSrGAP3
p20138
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp20139
(dp20140
g17436
I141
sg17437
Vautism
p20141
sg17438
I6
sg17445
VC0004352
p20142
sg17441
I1
sasa(dp20143
g17431
VBA synthesis was directly quantified by measuring serum concentrations of 7alpha-hydroxycholest-4-en-3-one (C4), along with serum FGF19 and other parameters, in 44 patients with primary biliary cirrhosis (PBC) and 10 healthy subjects.
p20144
sg17433
(lp20145
(dp20146
g17436
I130
sg17437
VFGF19
p20147
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20148
(dp20149
g17436
I178
sg17437
Vprimary biliary cirrhosis
p20150
sg17438
I25
sg17445
VC0008312
p20151
sg17441
I3
sa(dp20152
g17436
I205
sg17437
VPBC
p20153
sg17438
I3
sg17445
VC0008312
p20154
sg17441
I1
sasa(dp20155
g135
(dp20156
(VFXR
p20157
Vprimary biliary cirrhosis
p20158
tp20159
I00
ssg17431
VWhether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are involved in the regulation of BA homeostasis in primary biliary cirrhosis (PBC) remains unknown.
p20160
sg17433
(lp20161
(dp20162
g17436
I8
sg17437
Vfibroblast growth factor 19
p20163
sg17438
I27
sg17439
g12
sg17441
I4
sa(dp20164
g17436
I69
sg17437
g20157
sg17438
I3
sg17439
VP23945
p20165
sg17441
I1
sa(dp20166
g17436
I47
sg17437
Vfarnesoid X receptor
p20167
sg17438
I20
sg17439
g12
sg17441
I3
sa(dp20168
g17436
I37
sg17437
VFGF19
p20169
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20170
(dp20171
g17436
I173
sg17437
VPBC
p20172
sg17438
I3
sg17445
VC0008312
p20173
sg17441
I1
sa(dp20174
g17436
I146
sg17437
g20158
sg17438
I25
sg17445
VC0008312
p20175
sg17441
I3
sasa(dp20176
g17431
VOur results provide further insight into the specific relationship between histone H4 modification and gene expression during spermatogenesis, which could help to elucidate the epigenetic disorders underlying male infertility.
p20177
sg17433
(lp20178
(dp20179
g17436
I75
sg17437
Vhistone H4
p20180
sg17438
I10
sg17439
VP62805
p20181
sg17441
I2
sasg17442
(lp20182
(dp20183
g17436
I209
sg17437
Vmale infertility
p20184
sg17438
I16
sg17445
VC0021364
p20185
sg17441
I2
sasa(dp20186
g135
(dp20187
(Vhuman HSST gene
p20188
VTreacher Collins syndrome
p20189
tp20190
I00
ssg17431
VPrevious studies have resulted in the isolation of the human HSST gene from within the Treacher Collins syndrome locus (TCOF1) critical region on 5q.
p20191
sg17433
(lp20192
(dp20193
g17436
I120
sg17437
VTCOF1
p20194
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20195
g17436
I55
sg17437
g20188
sg17438
I15
sg17439
VP52848
p20196
sg17441
I3
sasg17442
(lp20197
(dp20198
g17436
I87
sg17437
g20189
sg17438
I25
sg17445
VC0242387
p20199
sg17441
I3
sasa(dp20200
g17431
VAs a result of these studies, mutations within the coding sequence and adjacent splice junctions of HSST can be excluded from a causative role in the pathogenesis of Treacher Collins syndrome.
p20201
sg17433
(lp20202
sg17442
(lp20203
(dp20204
g17436
I150
sg17437
Vpathogenesis
p20205
sg17438
I12
sg17445
VC0699748
p20206
sg17441
I1
sa(dp20207
g17436
I166
sg17437
VTreacher Collins syndrome
p20208
sg17438
I25
sg17445
VC0242387
p20209
sg17441
I3
sasa(dp20210
g17431
VIn univariate analyses, diabetes mellitus, chronic kidney disease, ischemic etiology of LBBB, dilated left atrium, reduced LVEF, dilated left ventricle, and impaired LV global strain (GLS &gt; -12.2%, global circumferential strain &gt; -11.8%, and twist &lt; 6.5) showed associations with the composite end point.
p20211
sg17433
(lp20212
sg17442
(lp20213
(dp20214
g17436
I157
sg17437
Vimpaired
p20215
sg17438
I8
sg17445
VC0684336
p20216
sg17441
I1
sa(dp20217
g17436
I24
sg17437
Vdiabetes mellitus
p20218
sg17438
I17
sg17445
VC0011849
p20219
sg17441
I2
sa(dp20220
g17436
I129
sg17437
Vdilated left ventricle
p20221
sg17438
I22
sg17445
VC0745674
p20222
sg17441
I3
sa(dp20223
g17436
I88
sg17437
VLBBB
p20224
sg17438
I4
sg17445
VC0023211
p20225
sg17441
I1
sa(dp20226
g17436
I43
sg17437
Vchronic kidney disease
p20227
sg17438
I22
sg17445
VC1561643
p20228
sg17441
I3
sasa(dp20229
g17431
VIndividuals with T1D had increased systolic torsion (P = 0.035), systolic torsion rate (P = 0.032), peak Ecl (P = 0.001), and rates of change of systolic (P = 0.007) and diastolic (P = 0.007) Ecl Individuals with T1D, with normal structure, LVEF, and strain, have increased extracellular volume and increased native T1 values with associated augmented torsion and Ecl These measures may be useful in detecting the early stages of diabetic cardiomyopathy and warrant larger prospective studies.NEW &amp; NOTEWORTHY Individuals with type 1 diabetes, with normal left ventricular structure and function (ejection fraction and strain), have signs of interstitial fibrosis, measured with MRI as increased extracellular volume fraction and increased native myocardial T1, which significantly correlated with a number of measures of augmented left ventricular twist function.
p20230
sg17433
(lp20231
sg17442
(lp20232
(dp20233
g17436
I531
sg17437
Vtype 1 diabetes
p20234
sg17438
I15
sg17445
VC0011854
p20235
sg17441
I3
sa(dp20236
g17436
I44
sg17437
Vtorsion
p20237
sg17438
I7
sg17445
VC1265748
p20238
sg17441
I1
sa(dp20239
g17436
I646
sg17437
Vinterstitial fibrosis
p20240
sg17438
I21
sg17445
VC0240035
p20241
sg17441
I2
sa(dp20242
g17436
I44
sg17437
Vtorsion
p20243
sg17438
I7
sg17445
VC1265748
p20244
sg17441
I1
sa(dp20245
g17436
I430
sg17437
Vdiabetic cardiomyopathy
p20246
sg17438
I23
sg17445
VC0853897
p20247
sg17441
I2
sa(dp20248
g17436
I44
sg17437
Vtorsion
p20249
sg17438
I7
sg17445
VC1265748
p20250
sg17441
I1
sasa(dp20251
g135
(dp20252
(VMKR
p20253
Vhyperinsulinemia
p20254
tp20255
I00
ssg17431
VIn this study, we show that hyperinsulinemia in the Rag/MKR mice increases the expression of mesenchymal transcription factors, TWIST1 and ZEB1, and increases the expression of the angiogenesis marker, vascular endothelial growth factor A (VEGFA).
p20256
sg17433
(lp20257
(dp20258
g17436
I240
sg17437
VVEGFA
p20259
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20260
g17436
I52
sg17437
VRag
p20261
sg17438
I3
sg17439
VP52803
p20262
sg17441
I1
sa(dp20263
g17436
I139
sg17437
VZEB1
p20264
sg17438
I4
sg17439
VP37275
p20265
sg17441
I1
sa(dp20266
g17436
I56
sg17437
g20253
sg17438
I3
sg17439
VP33032
p20267
sg17441
I1
sa(dp20268
g17436
I128
sg17437
VTWIST1
p20269
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp20270
g17436
I202
sg17437
Vvascular endothelial growth factor A
p20271
sg17438
I36
sg17439
g12
sg17441
I5
sasg17442
(lp20272
(dp20273
g17436
I28
sg17437
g20254
sg17438
I16
sg17445
VC0020459
p20274
sg17441
I1
sasa(dp20275
g17431
VAortic PWV correlated crudely with age (p &lt; 0.001), the presence of diabetes (p &lt; 0.001), hypertension (p &lt; 0.001), eGFR (p &lt; 0.001), LVMI (p = 0.01), e/e' (p &lt; 0.001) and LV twist (p = 0.003).
p20276
sg17433
(lp20277
sg17442
(lp20278
(dp20279
g17436
I96
sg17437
Vhypertension
p20280
sg17438
I12
sg17445
VC0020538
p20281
sg17441
I1
sa(dp20282
g17436
I71
sg17437
Vdiabetes
p20283
sg17438
I8
sg17445
VC0011849
p20284
sg17441
I1
sasa(dp20285
g17431
VThere is limited information regarding the role of left ventricular (LV) twist and the effect of exercise in type 2 diabetes (T2D).
p20286
sg17433
(lp20287
sg17442
(lp20288
(dp20289
g17436
I126
sg17437
VT2D
p20290
sg17438
I3
sg17445
VC0011860
p20291
sg17441
I1
sa(dp20292
g17436
I109
sg17437
Vtype 2 diabetes
p20293
sg17438
I15
sg17445
VC0011860
p20294
sg17441
I3
sasa(dp20295
g17431
VThese results demonstrated that quercetin ameliorates the EMT of HK-2 and NRK-52E cells induced by high glucose and renal fibrosis induced by diabetes, and these effects have been associated with the inhibition of the two transcriptional factors (snail and twist) and the activation of mTORC1/p70S6K.
p20296
sg17433
(lp20297
(dp20298
g17436
I74
sg17437
VNRK-52E
p20299
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp20300
(dp20301
g17436
I142
sg17437
Vdiabetes
p20302
sg17438
I8
sg17445
VC0011849
p20303
sg17441
I1
sa(dp20304
g17436
I116
sg17437
Vrenal fibrosis
p20305
sg17438
I14
sg17445
VC0151650
p20306
sg17441
I2
sasa(dp20307
g17431
VActivin Receptor-Like Kinase 5 (ALK-5) is related to some types of cancer, such as breast, lung and pancreas.
p20308
sg17433
(lp20309
(dp20310
g17436
I0
sg17437
VActivin Receptor-Like Kinase 5
p20311
sg17438
I30
sg17439
VP36897
p20312
sg17441
I4
sa(dp20313
g17436
I32
sg17437
VALK-5
p20314
sg17438
I5
sg17439
VP36897
p20315
sg17441
I1
sasg17442
(lp20316
(dp20317
g17436
I67
sg17437
Vcancer
p20318
sg17438
I6
sg17445
VC0006826
p20319
sg17441
I1
sasa(dp20320
g17431
VOverall, we discussed about the main interactions between ALK-5 and six inhibitors that may be used as starting point for designing of new molecules to the cancer treatment.
p20321
sg17433
(lp20322
(dp20323
g17436
I58
sg17437
VALK-5
p20324
sg17438
I5
sg17439
VP36897
p20325
sg17441
I1
sasg17442
(lp20326
(dp20327
g17436
I156
sg17437
Vcancer
p20328
sg17438
I6
sg17445
VC0006826
p20329
sg17441
I1
sasa(dp20330
g135
(dp20331
(VALK5
p20332
Vbreast cancer
p20333
tp20334
I00
ssg17431
VIn summary, the results suggest that eupatolide suppresses the migration and invasion of breast cancer cells by blocking the canonical ALK5-SMAD3 signaling pathway and the non-canonical ERK and AKT signaling pathways.
p20335
sg17433
(lp20336
(dp20337
g17436
I186
sg17437
VERK
p20338
sg17438
I3
sg17439
VP29323
p20339
sg17441
I1
sa(dp20340
g17436
I135
sg17437
g20332
sg17438
I4
sg17439
VP36897
p20341
sg17441
I1
sa(dp20342
g17436
I194
sg17437
VAKT
p20343
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp20344
(dp20345
g17436
I77
sg17437
Vinvasion
p20346
sg17438
I8
sg17445
VC2699153
p20347
sg17441
I1
sa(dp20348
g17436
I112
sg17437
Vblocking
p20349
sg17438
I8
sg17445
VC0233660
p20350
sg17441
I1
sa(dp20351
g17436
I89
sg17437
g20333
sg17438
I13
sg17445
VC0678222
p20352
sg17441
I2
sasa(dp20353
g17431
VExpression of a mutant TBetaRI that signals but does not interact with Smad7 prevented the CerS4-mediated inhibition of migration in various cancer cells.
p20354
sg17433
(lp20355
(dp20356
g17436
I71
sg17437
VSmad7
p20357
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20358
g17436
I91
sg17437
VCerS4
p20359
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20360
(dp20361
g17436
I141
sg17437
Vcancer
p20362
sg17438
I6
sg17445
VC0006826
p20363
sg17441
I1
sa(dp20364
g17436
I16
sg17437
Vmutant
p20365
sg17438
I6
sg17445
VC0596988
p20366
sg17441
I1
sasa(dp20367
g17431
VTBetaRI-Smo cross-talk at the cilia in CerS4-deficient 4T1 mammary cancer cells induced liver metastasis from orthotopic allografts in both wild-type and CerS4-deficient mice, which was prevented by overexpression of Smad7 or knockdown of intraflagellar transport protein 88 (IFT88).
p20368
sg17433
(lp20369
(dp20370
g17436
I239
sg17437
Vintraflagellar transport protein 88
p20371
sg17438
I35
sg17439
g12
sg17441
I4
sa(dp20372
g17436
I39
sg17437
VCerS4
p20373
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20374
g17436
I8
sg17437
VSmo
p20375
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp20376
g17436
I276
sg17437
VIFT88
p20377
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20378
g17436
I39
sg17437
VCerS4
p20379
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20380
g17436
I217
sg17437
VSmad7
p20381
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20382
(dp20383
g17436
I67
sg17437
Vcancer
p20384
sg17438
I6
sg17445
VC0006826
p20385
sg17441
I1
sa(dp20386
g17436
I88
sg17437
Vliver metastasis
p20387
sg17438
I16
sg17445
VC0494165
p20388
sg17441
I2
sasa(dp20389
g17431
VTransforming growth factor type 1 receptor (ALK5) is kinase associated with a wide variety of pathological processes, and inhibition of ALK5 is a good strategy to treat many kinds of cancer and fibrotic diseases.
p20390
sg17433
(lp20391
(dp20392
g17436
I0
sg17437
VTransforming growth factor type 1 receptor
p20393
sg17438
I42
sg17439
g12
sg17441
I6
sa(dp20394
g17436
I44
sg17437
VALK5
p20395
sg17438
I4
sg17439
VP36897
p20396
sg17441
I1
sa(dp20397
g17436
I44
sg17437
VALK5
p20398
sg17438
I4
sg17439
VP36897
p20399
sg17441
I1
sasg17442
(lp20400
(dp20401
g17436
I94
sg17437
Vpathological processes
p20402
sg17438
I22
sg17445
VC0030660
p20403
sg17441
I2
sa(dp20404
g17436
I183
sg17437
Vcancer
p20405
sg17438
I6
sg17445
VC0006826
p20406
sg17441
I1
sasa(dp20407
g17431
VThe high mortality rates observed in patients with invasive aspergillosis caused by azole-resistant A. fumigatus (ARAF) isolates pose serious challenges to the clinical microbiologist for timely identification of resistance and appropriate therapeutic interventions.
p20408
sg17433
(lp20409
sg17442
(lp20410
(dp20411
g17436
I51
sg17437
Vinvasive aspergillosis
p20412
sg17438
I22
sg17445
VC0238013
p20413
sg17441
I2
sasa(dp20414
g17431
VMKL/myocardin-like 2 (MKL2) encodes myocardin-related transcription factor B in a megakaryoblastic leukemia gene family, and C11orf95 (chromosome 11 open reading frame 95) is a hypothetical protein.
p20415
sg17433
(lp20416
(dp20417
g17436
I0
sg17437
VMKL/myocardin-like 2
p20418
sg17438
I20
sg17439
g12
sg17441
I2
sa(dp20419
g17436
I36
sg17437
Vmyocardin-related transcription factor B
p20420
sg17438
I40
sg17439
g12
sg17441
I4
sa(dp20421
g17436
I22
sg17437
VMKL2
p20422
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp20423
(dp20424
g17436
I82
sg17437
Vmegakaryoblastic leukemia
p20425
sg17438
I25
sg17445
VC0023462
p20426
sg17441
I2
sasa(dp20427
g17431
VSerum levels of IL-16, IL-33 and the decoy receptor of IL-33, soluble ST2, are elevated in allergic rhinitis.
p20428
sg17433
(lp20429
(dp20430
g17436
I16
sg17437
VIL-16
p20431
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20432
(dp20433
g17436
I91
sg17437
Vallergic rhinitis
p20434
sg17438
I17
sg17445
VC2607914
p20435
sg17441
I2
sasa(dp20436
g135
(dp20437
(VIL-5
p20438
Veosinophilia
p20439
tp20440
I00
ssg17431
VRecent studies show that IL-16, soluble ST2 or anti-IL-33 reduce type 2 cytokines (such as IL-5) and eosinophilia in murine models of allergic asthma or allergic rhinitis respectively.
p20441
sg17433
(lp20442
(dp20443
g17436
I65
sg17437
Vtype 2 cytokines
p20444
sg17438
I16
sg17439
VP01374
p20445
sg17441
I3
sa(dp20446
g17436
I91
sg17437
g20438
sg17438
I4
sg17439
VP05113
p20447
sg17441
I1
sa(dp20448
g17436
I25
sg17437
VIL-16, soluble ST2
p20449
sg17438
I18
sg17439
g12
sg17441
I3
sasg17442
(lp20450
(dp20451
g17436
I134
sg17437
Vallergic asthma
p20452
sg17438
I15
sg17445
VC0155877
p20453
sg17441
I2
sa(dp20454
g17436
I153
sg17437
Vallergic rhinitis
p20455
sg17438
I17
sg17445
VC2607914
p20456
sg17441
I2
sa(dp20457
g17436
I101
sg17437
g20439
sg17438
I12
sg17445
VC0014457
p20458
sg17441
I1
sasa(dp20459
g135
(dp20460
(VIL-5
p20461
Vallergic rhinitis
p20462
tp20463
I00
ssg17431
VIn this study, we studied the release of IL-5, IL-16, IL-33 and soluble ST2 in allergic rhinitis patients after nasal allergen challenge and natural pollen exposure.
p20464
sg17433
(lp20465
(dp20466
g17436
I47
sg17437
VIL-16
p20467
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20468
g17436
I41
sg17437
g20461
sg17438
I4
sg17439
VP05113
p20469
sg17441
I1
sasg17442
(lp20470
(dp20471
g17436
I79
sg17437
g20462
sg17438
I17
sg17445
VC2607914
p20472
sg17441
I2
sasa(dp20473
g135
(dp20474
(VST2
p20475
Vinflammatory reaction
p20476
tp20477
I00
ssg17431
VThe observed upregulation of soluble ST2 and IL-16 after nasal allergen challenge and during peak pollination season suggests potential regulatory roles of these cytokines in the inflammatory reaction in allergic rhinitis.
p20478
sg17433
(lp20479
(dp20480
g17436
I45
sg17437
VIL-16
p20481
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20482
g17436
I37
sg17437
g20475
sg17438
I3
sg17439
VP10767
p20483
sg17441
I1
sasg17442
(lp20484
(dp20485
g17436
I204
sg17437
Vallergic rhinitis
p20486
sg17438
I17
sg17445
VC2607914
p20487
sg17441
I2
sa(dp20488
g17436
I179
sg17437
g20476
sg17438
I21
sg17445
VC0021368
p20489
sg17441
I2
sasa(dp20490
g135
(dp20491
(Vsurfactant protein D
p20492
Vallergic rhinitis
p20493
tp20494
I00
ssg17431
VTo detect the expression and distribution of the lung surfactant protein D (surfactant protein D,SP-D ) and IL-16 in nasal mucosa of allergic rhinitis and nasal polyps, and then probe into their significance in the pathology of allergic rhinitis and nasal polyps.
p20495
sg17433
(lp20496
(dp20497
g17436
I97
sg17437
VSP-D
p20498
sg17438
I4
sg17439
VP35247
p20499
sg17441
I1
sa(dp20500
g17436
I54
sg17437
Vsurfactant protein D
p20501
sg17438
I20
sg17439
VP35247
p20502
sg17441
I3
sa(dp20503
g17436
I54
sg17437
g20492
sg17438
I20
sg17439
VP35247
p20504
sg17441
I3
sa(dp20505
g17436
I108
sg17437
VIL-16
p20506
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20507
(dp20508
g17436
I215
sg17437
Vpathology
p20509
sg17438
I9
sg17445
VC0677042
p20510
sg17441
I1
sa(dp20511
g17436
I155
sg17437
Vnasal polyps
p20512
sg17438
I12
sg17445
VC0027430
p20513
sg17441
I2
sa(dp20514
g17436
I133
sg17437
Vallergic rhinitis
p20515
sg17438
I17
sg17445
VC2607914
p20516
sg17441
I2
sa(dp20517
g17436
I155
sg17437
Vnasal polyps
p20518
sg17438
I12
sg17445
VC0027430
p20519
sg17441
I2
sa(dp20520
g17436
I133
sg17437
g20493
sg17438
I17
sg17445
VC2607914
p20521
sg17441
I2
sasa(dp20522
g135
(dp20523
(VSP-D
p20524
Vnasal polyps
p20525
tp20526
I00
ssg17431
VFifteen cases of allergic rhinitis, fifteen cases of nasal polyps and fifteen cases of inferior turbinate mucosa were studied to detect the expression of SP-D and IL-16 by immunohistochemistry method.
p20527
sg17433
(lp20528
(dp20529
g17436
I154
sg17437
g20524
sg17438
I4
sg17439
VP35247
p20530
sg17441
I1
sa(dp20531
g17436
I163
sg17437
VIL-16
p20532
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20533
(dp20534
g17436
I17
sg17437
Vallergic rhinitis
p20535
sg17438
I17
sg17445
VC2607914
p20536
sg17441
I2
sa(dp20537
g17436
I53
sg17437
g20525
sg17438
I12
sg17445
VC0027430
p20538
sg17441
I2
sasa(dp20539
g135
(dp20540
(VSP-D
p20541
Vnasal polyps
p20542
tp20543
I00
ssg17431
VThe expression of SP-D and IL-16 in allergic rhinitis and nasal polyps were dramatically higher in controls (P &lt; 0.01).
p20544
sg17433
(lp20545
(dp20546
g17436
I27
sg17437
VIL-16
p20547
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20548
g17436
I18
sg17437
g20541
sg17438
I4
sg17439
VP35247
p20549
sg17441
I1
sasg17442
(lp20550
(dp20551
g17436
I36
sg17437
Vallergic rhinitis
p20552
sg17438
I17
sg17445
VC2607914
p20553
sg17441
I2
sa(dp20554
g17436
I58
sg17437
g20542
sg17438
I12
sg17445
VC0027430
p20555
sg17441
I2
sasa(dp20556
g135
(dp20557
(VSP-D
p20558
Vallergic rhinitis
p20559
tp20560
I00
ssg17431
VThere was no remarkable difference in the expression of SP-D and IL-16 between allergic rhinitis and nasal polyps (P &gt; 0.05).
p20561
sg17433
(lp20562
(dp20563
g17436
I65
sg17437
VIL-16
p20564
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20565
g17436
I56
sg17437
g20558
sg17438
I4
sg17439
VP35247
p20566
sg17441
I1
sasg17442
(lp20567
(dp20568
g17436
I101
sg17437
Vnasal polyps
p20569
sg17438
I12
sg17445
VC0027430
p20570
sg17441
I2
sa(dp20571
g17436
I79
sg17437
g20559
sg17438
I17
sg17445
VC2607914
p20572
sg17441
I2
sasa(dp20573
g17431
VIL-16 is an important eosinophil chemokine in the process of allergic rhinitis and nasal polyps,and it can also enhance the local role of eosinophils,thus it can involve in the process of allergic rhinitis and nasal polyps disease.
p20574
sg17433
(lp20575
(dp20576
g17436
I0
sg17437
VIL-16
p20577
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20578
(dp20579
g17436
I61
sg17437
Vallergic rhinitis
p20580
sg17438
I17
sg17445
VC2607914
p20581
sg17441
I2
sa(dp20582
g17436
I61
sg17437
Vallergic rhinitis
p20583
sg17438
I17
sg17445
VC2607914
p20584
sg17441
I2
sa(dp20585
g17436
I83
sg17437
Vnasal polyps
p20586
sg17438
I12
sg17445
VC0027430
p20587
sg17441
I2
sa(dp20588
g17436
I83
sg17437
Vnasal polyps
p20589
sg17438
I12
sg17445
VC0027430
p20590
sg17441
I2
sasa(dp20591
g135
(dp20592
(VCD4
p20593
Vallergic rhinitis
p20594
tp20595
I00
ssg17431
VThough a chemotactin for CD4(+) cells and eosinophils, IL-16 also modulates their production of factors that influence inflammatory lung diseases, e.g., asthma and allergic rhinitis.
p20596
sg17433
(lp20597
(dp20598
g17436
I55
sg17437
VIL-16
p20599
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20600
g17436
I25
sg17437
g20593
sg17438
I3
sg17439
VP01730
p20601
sg17441
I1
sasg17442
(lp20602
(dp20603
g17436
I153
sg17437
Vasthma
p20604
sg17438
I6
sg17445
VC0004096
p20605
sg17441
I1
sa(dp20606
g17436
I132
sg17437
Vlung diseases
p20607
sg17438
I13
sg17445
VC0024115
p20608
sg17441
I2
sa(dp20609
g17436
I164
sg17437
g20594
sg17438
I17
sg17445
VC2607914
p20610
sg17441
I2
sasa(dp20611
g135
(dp20612
(VCD4+
p20613
Vallergic rhinitis
p20614
tp20615
I00
ssg17431
VInterleukin-16 (IL-16) is a cytokine that induces selective migration of CD4+ cells and participates in inflammatory diseases including allergic rhinitis.
p20616
sg17433
(lp20617
(dp20618
g17436
I16
sg17437
VIL-16
p20619
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20620
g17436
I0
sg17437
VInterleukin-16
p20621
sg17438
I14
sg17439
g12
sg17441
I1
sa(dp20622
g17436
I73
sg17437
g20613
sg17438
I4
sg17439
VP01730
p20623
sg17441
I1
sasg17442
(lp20624
(dp20625
g17436
I136
sg17437
g20614
sg17438
I17
sg17445
VC2607914
p20626
sg17441
I2
sasa(dp20627
g17431
VWe evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model.
p20628
sg17433
(lp20629
(dp20630
g17436
I32
sg17437
VIL-16
p20631
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20632
g17436
I32
sg17437
VIL-16
p20633
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20634
(dp20635
g17436
I195
sg17437
Vallergic rhinitis
p20636
sg17438
I17
sg17445
VC2607914
p20637
sg17441
I2
sasa(dp20638
g17431
VThese results suggest that IL-16 was both systemically and locally upregulated in the murine allergic rhinitis model and that IL-16 changed in parallel to allergic state by treatment with the drugs.
p20639
sg17433
(lp20640
(dp20641
g17436
I27
sg17437
VIL-16
p20642
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20643
g17436
I27
sg17437
VIL-16
p20644
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20645
(dp20646
g17436
I155
sg17437
Vallergic state
p20647
sg17438
I14
sg17445
VC0020517
p20648
sg17441
I2
sa(dp20649
g17436
I93
sg17437
Vallergic rhinitis
p20650
sg17438
I17
sg17445
VC2607914
p20651
sg17441
I2
sasa(dp20652
g135
(dp20653
(Vserum IgE
p20654
Vasthma
p20655
tp20656
I00
ssg17431
VThe results showed abnormally increased levels of IL-16 (294.4 +/- 15.24 pg/ml), serum eosinophils with absolute count (510.0 +/- 93.57, P&gt;0.05), and total serum IgE (287.9 +/- 61.22 IU/ml) using ELFA in patients of combined asthma and rhinitis, than in each of them alone.
p20657
sg17433
(lp20658
(dp20659
g17436
I159
sg17437
g20654
sg17438
I9
sg17439
VP01854
p20660
sg17441
I2
sa(dp20661
g17436
I50
sg17437
VIL-16
p20662
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20663
(dp20664
g17436
I239
sg17437
Vrhinitis
p20665
sg17438
I8
sg17445
VC0035455
p20666
sg17441
I1
sa(dp20667
g17436
I165
sg17437
VIgE
p20668
sg17438
I3
sg17445
VC0270850
p20669
sg17441
I1
sa(dp20670
g17436
I228
sg17437
g20655
sg17438
I6
sg17445
VC0004096
p20671
sg17441
I1
sasa(dp20672
g17431
VWe first examined the IL-16 expression of serum and mucosal tissue in patients with allergic rhinitis.
p20673
sg17433
(lp20674
(dp20675
g17436
I22
sg17437
VIL-16
p20676
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20677
(dp20678
g17436
I84
sg17437
Vallergic rhinitis
p20679
sg17438
I17
sg17445
VC2607914
p20680
sg17441
I2
sasa(dp20681
g17431
VIL-16 levels were elevated in the serum of patients with allergic rhinitis compared with normal controls.
p20682
sg17433
(lp20683
(dp20684
g17436
I0
sg17437
VIL-16
p20685
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20686
(dp20687
g17436
I57
sg17437
Vallergic rhinitis
p20688
sg17438
I17
sg17445
VC2607914
p20689
sg17441
I2
sasa(dp20690
g17431
VIL-16 was significantly correlated with eosinophils in the peripheral blood of allergic rhinitis patients.
p20691
sg17433
(lp20692
(dp20693
g17436
I0
sg17437
VIL-16
p20694
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20695
(dp20696
g17436
I79
sg17437
Vallergic rhinitis
p20697
sg17438
I17
sg17445
VC2607914
p20698
sg17441
I2
sasa(dp20699
g17431
VThis IL-16 cytokine may be strongly associated with the developmental mechanism of allergic rhinitis.
p20700
sg17433
(lp20701
(dp20702
g17436
I5
sg17437
VIL-16 cytokine
p20703
sg17438
I14
sg17439
g12
sg17441
I2
sasg17442
(lp20704
(dp20705
g17436
I83
sg17437
Vallergic rhinitis
p20706
sg17438
I17
sg17445
VC2607914
p20707
sg17441
I2
sasa(dp20708
g17431
VSpeech fluency was assessed in 35 patients with frontotemporal lobar degeneration (FTLD) who presented with progressive non-fluent aphasia (PNFA, n=11), semantic dementia (SemD, n=12), or a social and executive disorder without aphasia (SOC/EXEC, n=12).
p20709
sg17433
(lp20710
(dp20711
g17436
I172
sg17437
VSemD
p20712
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp20713
g17436
I153
sg17437
Vsemantic dementia
p20714
sg17438
I17
sg17439
g12
sg17441
I2
sasg17442
(lp20715
(dp20716
g17436
I48
sg17437
Vfrontotemporal lobar degeneration
p20717
sg17438
I33
sg17445
VC0751072
p20718
sg17441
I3
sa(dp20719
g17436
I153
sg17437
Vsemantic dementia
p20720
sg17438
I17
sg17445
VC0338462
p20721
sg17441
I2
sa(dp20722
g17436
I172
sg17437
VSemD
p20723
sg17438
I4
sg17445
VC0338462
p20724
sg17441
I1
sa(dp20725
g17436
I83
sg17437
VFTLD
p20726
sg17438
I4
sg17445
VC0751072
p20727
sg17441
I1
sa(dp20728
g17436
I131
sg17437
Vaphasia
p20729
sg17438
I7
sg17445
VC0003537
p20730
sg17441
I1
sa(dp20731
g17436
I120
sg17437
Vnon-fluent aphasia
p20732
sg17438
I18
sg17445
VC0349390
p20733
sg17441
I2
sasa(dp20734
g17431
VTwo subtypes commonly present with a language disorder: semantic dementia (SemD) and progressive nonfluent aphasia (PNFA).
p20735
sg17433
(lp20736
(dp20737
g17436
I56
sg17437
Vsemantic dementia
p20738
sg17438
I17
sg17439
g12
sg17441
I2
sa(dp20739
g17436
I75
sg17437
VSemD
p20740
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp20741
(dp20742
g17436
I37
sg17437
Vlanguage disorder
p20743
sg17438
I17
sg17445
VC0023015
p20744
sg17441
I2
sa(dp20745
g17436
I56
sg17437
Vsemantic dementia
p20746
sg17438
I17
sg17445
VC0338462
p20747
sg17441
I2
sa(dp20748
g17436
I85
sg17437
Vprogressive nonfluent aphasia
p20749
sg17438
I29
sg17445
VC0751706
p20750
sg17441
I3
sa(dp20751
g17436
I116
sg17437
VPNFA
p20752
sg17438
I4
sg17445
VC0751706
p20753
sg17441
I1
sa(dp20754
g17436
I75
sg17437
VSemD
p20755
sg17438
I4
sg17445
VC0338462
p20756
sg17441
I1
sasa(dp20757
g135
(dp20758
(VVldlr
p20759
Vautism
p20760
tp20761
I00
ssg17431
VExpression of several genes associated with schizophrenia or autism including Sema3a, Trfr2 and Vldlr were found to be altered as were protein levels of Foxp2.
p20762
sg17433
(lp20763
(dp20764
g17436
I96
sg17437
g20759
sg17438
I5
sg17439
VP98155
p20765
sg17441
I1
sa(dp20766
g17436
I78
sg17437
VSema3a
p20767
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp20768
(dp20769
g17436
I44
sg17437
Vschizophrenia
p20770
sg17438
I13
sg17445
VC0036341
p20771
sg17441
I1
sa(dp20772
g17436
I61
sg17437
g20760
sg17438
I6
sg17445
VC0004352
p20773
sg17441
I1
sasa(dp20774
g17431
VWe classified 67 patients with PPA into three clinical variants: semantic dementia (SEMD), progressive nonfluent aphasia (PNFA), and logopenic progressive aphasia (LPA), and we compared the severity of behavioral dysfunction, as measured by the Neuropsychiatric Inventory, in these groups and patients with frontotemporal dementia (FTD) and Alzheimer disease (AD).
p20775
sg17433
(lp20776
sg17442
(lp20777
(dp20778
g17436
I65
sg17437
Vsemantic dementia
p20779
sg17438
I17
sg17445
VC0338462
p20780
sg17441
I2
sa(dp20781
g17436
I332
sg17437
VFTD
p20782
sg17438
I3
sg17445
VC0338451
p20783
sg17441
I1
sa(dp20784
g17436
I91
sg17437
Vprogressive nonfluent aphasia
p20785
sg17438
I29
sg17445
VC0751706
p20786
sg17441
I3
sa(dp20787
g17436
I341
sg17437
VAlzheimer disease
p20788
sg17438
I17
sg17445
VC0002395
p20789
sg17441
I2
sa(dp20790
g17436
I84
sg17437
VSEMD
p20791
sg17438
I4
sg17445
VC0338462
p20792
sg17441
I1
sa(dp20793
g17436
I122
sg17437
VPNFA
p20794
sg17438
I4
sg17445
VC0751706
p20795
sg17441
I1
sa(dp20796
g17436
I307
sg17437
Vfrontotemporal dementia
p20797
sg17438
I23
sg17445
VC0338451
p20798
sg17441
I2
sa(dp20799
g17436
I143
sg17437
Vprogressive aphasia
p20800
sg17438
I19
sg17445
VC0338457
p20801
sg17441
I2
sa(dp20802
g17436
I360
sg17437
VAD
p20803
sg17438
I2
sg17445
VC0002395
p20804
sg17441
I1
sa(dp20805
g17436
I31
sg17437
VPPA
p20806
sg17438
I3
sg17445
VC0282513
p20807
sg17441
I1
sasa(dp20808
g17431
VThe authors asked patients with progressive nonfluent aphasia (PNFA), patients with semantic dementia (SemD), and nonaphasic patients with a disorder of social comportment and executive functioning (SOC/EXEC) to narrate the story of a wordless children's picture book.
p20809
sg17433
(lp20810
(dp20811
g17436
I84
sg17437
Vsemantic dementia
p20812
sg17438
I17
sg17439
g12
sg17441
I2
sa(dp20813
g17436
I199
sg17437
VSOC
p20814
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp20815
g17436
I103
sg17437
VSemD
p20816
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp20817
(dp20818
g17436
I32
sg17437
Vprogressive nonfluent aphasia
p20819
sg17438
I29
sg17445
VC0751706
p20820
sg17441
I3
sa(dp20821
g17436
I63
sg17437
VPNFA
p20822
sg17438
I4
sg17445
VC0751706
p20823
sg17441
I1
sa(dp20824
g17436
I103
sg17437
VSemD
p20825
sg17438
I4
sg17445
VC0338462
p20826
sg17441
I1
sa(dp20827
g17436
I84
sg17437
Vsemantic dementia
p20828
sg17438
I17
sg17445
VC0338462
p20829
sg17441
I2
sasa(dp20830
g17431
VEach sequence is manually annotated with primary function, subfunction and subcellular location, and extensively annotated in an automated process with data extracted from external databases, including gene information from LocusLink and Ensembl; disease information from OMIM; protein-protein interaction data from MINT and DIP; functional domain information from Pfam; protein fingerprints from PRINTS; protein family and family-specific signatures from InterPro; structure data from PDB; mutation data from PMD; BLAST homology data from NCBI NR; and proteins found to be related based on LocusLink and SWISS-PROT references and sequence and taxonomy data.
p20831
sg17433
(lp20832
sg17442
(lp20833
(dp20834
g17436
I510
sg17437
VPMD
p20835
sg17438
I3
sg17445
VC1832661
p20836
sg17441
I1
sa(dp20837
g17436
I325
sg17437
VDIP
p20838
sg17438
I3
sg17445
VC0238378
p20839
sg17441
I1
sa(dp20840
g17436
I486
sg17437
VPDB
p20841
sg17438
I3
sg17445
VC0029401
p20842
sg17441
I1
sasa(dp20843
g135
(dp20844
(VMUT
p20845
Vfamilial Alzheimer's disease
p20846
tp20847
I01
ssg17431
VAn increase in the ratio of Abeta(WT)/Abeta(MUT(Arctic)), therefore, may result in the accumulation of potential neurotoxic protofibrils and acceleration of disease progression in familial Alzheimer's disease mutation carriers.
p20848
sg17433
(lp20849
(dp20850
g17436
I44
sg17437
g20845
sg17438
I3
sg17439
VP22033
p20851
sg17441
I1
sa(dp20852
g17436
I28
sg17437
VAbeta
p20853
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp20854
g17436
I28
sg17437
VAbeta
p20855
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp20856
(dp20857
g17436
I157
sg17437
Vdisease progression
p20858
sg17438
I19
sg17445
VC0242656
p20859
sg17441
I2
sa(dp20860
g17436
I180
sg17437
g20846
sg17438
I28
sg17445
VC0276496
p20861
sg17441
I3
sasa(dp20862
g135
(dp20863
(VKRAS
p20864
Vendometrial carcinomas
p20865
tp20866
I00
ssg17431
VTo gain insight into the pathogenesis of these tumors we have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, b-catenin, SMARCB1, synaptophysin, chromogranin A, and CD56) and mutational status (PTEN, KRAS, PIK3CA, TP53 and POLE) of 4 dedifferentiated endometrial carcinomas with strong and diffuse neuroendocrine expression.
p20867
sg17433
(lp20868
(dp20869
g17436
I140
sg17437
VSMARCB1
p20870
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp20871
g17436
I112
sg17437
VMSH2
p20872
sg17438
I4
sg17439
VP43246
p20873
sg17441
I1
sa(dp20874
g17436
I164
sg17437
Vchromogranin A
p20875
sg17438
I14
sg17439
VP10645
p20876
sg17441
I2
sa(dp20877
g17436
I149
sg17437
Vsynaptophysin
p20878
sg17438
I13
sg17439
VP08247
p20879
sg17441
I1
sa(dp20880
g17436
I100
sg17437
VMLH1
p20881
sg17438
I4
sg17439
VP40692
p20882
sg17441
I1
sa(dp20883
g17436
I124
sg17437
Vp53
p20884
sg17438
I3
sg17439
VP42771
p20885
sg17441
I1
sa(dp20886
g17436
I225
sg17437
VPIK3CA
p20887
sg17438
I6
sg17439
VP42336
p20888
sg17441
I1
sa(dp20889
g17436
I118
sg17437
VMSH6
p20890
sg17438
I4
sg17439
VP52701
p20891
sg17441
I1
sa(dp20892
g17436
I106
sg17437
VPMS2
p20893
sg17438
I4
sg17439
VP25054
p20894
sg17441
I1
sa(dp20895
g17436
I213
sg17437
VPTEN
p20896
sg17438
I4
sg17439
VP60484
p20897
sg17441
I1
sa(dp20898
g17436
I219
sg17437
g20864
sg17438
I4
sg17439
VP01116
p20899
sg17441
I1
sa(dp20900
g17436
I242
sg17437
VPOLE
p20901
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp20902
(dp20903
g17436
I270
sg17437
g20865
sg17438
I22
sg17445
VC0476089
p20904
sg17441
I2
sa(dp20905
g17436
I47
sg17437
Vtumors
p20906
sg17438
I6
sg17445
VC0027651
p20907
sg17441
I1
sa(dp20908
g17436
I25
sg17437
Vpathogenesis
p20909
sg17438
I12
sg17445
VC0699748
p20910
sg17441
I1
sasa(dp20911
g17431
VIn gynecological cancer, ARID1A mutations have been identified in 46-57% of clear cell carcinoma and 30% of endometrioid carcinoma.
p20912
sg17433
(lp20913
sg17442
(lp20914
(dp20915
g17436
I76
sg17437
Vclear cell carcinoma
p20916
sg17438
I20
sg17445
VC0206681
p20917
sg17441
I3
sa(dp20918
g17436
I17
sg17437
Vcancer
p20919
sg17438
I6
sg17445
VC0006826
p20920
sg17441
I1
sa(dp20921
g17436
I108
sg17437
Vendometrioid carcinoma
p20922
sg17438
I22
sg17445
VC0206687
p20923
sg17441
I2
sasa(dp20924
g135
(dp20925
(VBRG1
p20926
Vdedifferentiation
p20927
tp20928
I01
ssg17431
VWe recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma.
p20929
sg17433
(lp20930
(dp20931
g17436
I89
sg17437
VSWI
p20932
sg17438
I3
sg17439
VP28370
p20933
sg17441
I1
sa(dp20934
g17436
I120
sg17437
g20926
sg17438
I4
sg17439
VP51532
p20935
sg17441
I1
sa(dp20936
g17436
I139
sg17437
VINI1
p20937
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp20938
g17436
I167
sg17437
VARID1B
p20939
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp20940
g17436
I93
sg17437
VSNF
p20941
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp20942
(dp20943
g17436
I106
sg17437
Vinactivation
p20944
sg17438
I12
sg17445
VC0544461
p20945
sg17441
I1
sa(dp20946
g17436
I281
sg17437
Vendometrial carcinoma
p20947
sg17438
I21
sg17445
VC0476089
p20948
sg17441
I2
sa(dp20949
g17436
I106
sg17437
Vinactivation
p20950
sg17438
I12
sg17445
VC0544461
p20951
sg17441
I1
sa(dp20952
g17436
I227
sg17437
g20927
sg17438
I17
sg17445
VC0002793
p20953
sg17441
I1
sa(dp20954
g17436
I106
sg17437
Vinactivation
p20955
sg17438
I12
sg17445
VC0544461
p20956
sg17441
I1
sa(dp20957
g17436
I106
sg17437
Vinactivation
p20958
sg17438
I12
sg17445
VC0544461
p20959
sg17441
I1
sasa(dp20960
g17431
VThe tumor suppressor gene, AT Rich Interactive Domain 1A (ARID1A) mutation has been reported in a variety of cancers, especially the endometrium-related gynecological cancers, including the ovarian clear cell carcinoma, ovarian endometrioid carcinoma, and uterine endometrioid carcinoma.
p20961
sg17433
(lp20962
(dp20963
g17436
I27
sg17437
VAT Rich Interactive Domain 1A
p20964
sg17438
I29
sg17439
g12
sg17441
I5
sa(dp20965
g17436
I58
sg17437
VARID1A
p20966
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp20967
(dp20968
g17436
I109
sg17437
Vcancers
p20969
sg17438
I7
sg17445
VC0006826
p20970
sg17441
I1
sa(dp20971
g17436
I198
sg17437
Vclear cell carcinoma
p20972
sg17438
I20
sg17445
VC0206681
p20973
sg17441
I3
sa(dp20974
g17436
I220
sg17437
Vovarian endometrioid carcinoma
p20975
sg17438
I30
sg17445
VC0346163
p20976
sg17441
I3
sa(dp20977
g17436
I228
sg17437
Vendometrioid carcinoma
p20978
sg17438
I22
sg17445
VC0206687
p20979
sg17441
I2
sa(dp20980
g17436
I109
sg17437
Vcancers
p20981
sg17438
I7
sg17445
VC0006826
p20982
sg17441
I1
sa(dp20983
g17436
I4
sg17437
Vtumor
p20984
sg17438
I5
sg17445
VC0027651
p20985
sg17441
I1
sasa(dp20986
g135
(dp20987
(VMFAP4
p20988
Vpulmonary fibrosis
p20989
tp20990
I00
ssg17431
VThe current study aimed to evaluate serum levels of MFAP4 in patients with pulmonary fibrosis in order to test its potential as biomarker in clinical practice.
p20991
sg17433
(lp20992
(dp20993
g17436
I52
sg17437
g20988
sg17438
I5
sg17439
VP55083
p20994
sg17441
I1
sasg17442
(lp20995
(dp20996
g17436
I75
sg17437
g20989
sg17438
I18
sg17445
VC0034069
p20997
sg17441
I2
sasa(dp20998
g135
(dp20999
(VMFAP4
p21000
Vlung fibrosis
p21001
tp21002
I00
ssg17431
VA further aim was to determine whether MFAP4 deficiency in mice affects the formation of pulmonary fibrosis in the bleomycin model of lung fibrosis.
p21003
sg17433
(lp21004
(dp21005
g17436
I39
sg17437
g21000
sg17438
I5
sg17439
VP55083
p21006
sg17441
I1
sasg17442
(lp21007
(dp21008
g17436
I89
sg17437
Vpulmonary fibrosis
p21009
sg17438
I18
sg17445
VC0034069
p21010
sg17441
I2
sa(dp21011
g17436
I134
sg17437
g21001
sg17438
I13
sg17445
VC0034069
p21012
sg17441
I2
sasa(dp21013
g135
(dp21014
(VMFAP4
p21015
Vpulmonary fibrosis
p21016
tp21017
I00
ssg17431
VMFAP4 levels were increased in BAL of bleomycin treated mice with pulmonary fibrosis.
p21018
sg17433
(lp21019
(dp21020
g17436
I0
sg17437
g21015
sg17438
I5
sg17439
VP55083
p21021
sg17441
I1
sasg17442
(lp21022
(dp21023
g17436
I66
sg17437
g21016
sg17438
I18
sg17445
VC0034069
p21024
sg17441
I2
sasa(dp21025
g135
(dp21026
(VMFAP4
p21027
Vpulmonary fibrosis
p21028
tp21029
I00
ssg17431
VMFAP4 is not elevated in sera of patients with pulmonary fibrosis or bleomycin treated mice with pulmonary fibrosis.
p21030
sg17433
(lp21031
(dp21032
g17436
I0
sg17437
g21027
sg17438
I5
sg17439
VP55083
p21033
sg17441
I1
sasg17442
(lp21034
(dp21035
g17436
I47
sg17437
Vpulmonary fibrosis
p21036
sg17438
I18
sg17445
VC0034069
p21037
sg17441
I2
sa(dp21038
g17436
I47
sg17437
g21028
sg17438
I18
sg17445
VC0034069
p21039
sg17441
I2
sasa(dp21040
g135
(dp21041
(VMFAP4
p21042
Vchronic obstructive pulmonary disease
p21043
tp21044
I01
ssg17431
VThe aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD).
p21045
sg17433
(lp21046
(dp21047
g17436
I61
sg17437
g21042
sg17438
I5
sg17439
VP55083
p21048
sg17441
I1
sasg17442
(lp21049
(dp21050
g17436
I145
sg17437
VCOPD
p21051
sg17438
I4
sg17445
VC0024117
p21052
sg17441
I1
sa(dp21053
g17436
I106
sg17437
g21043
sg17438
I37
sg17445
VC0024117
p21054
sg17441
I4
sasa(dp21055
g17431
VMultiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p &lt; 0.0001) and BODE index (p = 0.04).
p21056
sg17433
(lp21057
sg17442
(lp21058
(dp21059
g17436
I16
sg17437
Vregressions
p21060
sg17438
I11
sg17445
VC0684320
p21061
sg17441
I1
sa(dp21062
g17436
I102
sg17437
VObstructive Lung Disease
p21063
sg17438
I24
sg17445
VC0600260
p21064
sg17441
I3
sasa(dp21065
g135
(dp21066
(VIDH2
p21067
Vthrombocytosis
p21068
tp21069
I00
ssg17431
VFor essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3.
p21070
sg17433
(lp21071
(dp21072
g17436
I598
sg17437
VCEBPA
p21073
sg17438
I5
sg17439
VP49715
p21074
sg17441
I1
sa(dp21075
g17436
I200
sg17437
VEZH2
p21076
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21077
g17436
I362
sg17437
g21067
sg17438
I4
sg17439
VP48735
p21078
sg17441
I1
sa(dp21079
g17436
I609
sg17437
VSH2B3
p21080
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21081
(dp21082
g17436
I265
sg17437
Vpolycythemia vera
p21083
sg17438
I17
sg17445
VC0032463
p21084
sg17441
I2
sa(dp21085
g17436
I4
sg17437
Vessential thrombocythemia
p21086
sg17438
I25
sg17445
VC0040028
p21087
sg17441
I2
sa(dp21088
g17436
I66
sg17437
Vtransformation
p21089
sg17438
I14
sg17445
VC1510411
p21090
sg17441
I1
sa(dp21091
g17436
I135
sg17437
Vleukocytosis
p21092
sg17438
I12
sg17445
VC0023518
p21093
sg17441
I1
sa(dp21094
g17436
I127
sg17437
Vanemia
p21095
sg17438
I6
sg17445
VC0002871
p21096
sg17441
I1
sa(dp21097
g17436
I135
sg17437
Vleukocytosis
p21098
sg17438
I12
sg17445
VC0023518
p21099
sg17441
I1
sa(dp21100
g17436
I111
sg17437
g21068
sg17438
I14
sg17445
VC0836924
p21101
sg17441
I1
sasa(dp21102
g17431
VIn the present case, i(17q)/-17, der(12p), del(5q26), del(7q36), and del(20q11) indicate possible alterations in TP53, ETV6, IDH2, EZH2, and SRSF2 genes, which are responsible for pathomechanism, genetic instability, clonal evolution, and advancement of disease condition.
p21103
sg17433
(lp21104
(dp21105
g17436
I119
sg17437
VETV6
p21106
sg17438
I4
sg17439
VP41212
p21107
sg17441
I1
sa(dp21108
g17436
I125
sg17437
VIDH2
p21109
sg17438
I4
sg17439
VP48735
p21110
sg17441
I1
sa(dp21111
g17436
I141
sg17437
VSRSF2 genes
p21112
sg17438
I11
sg17439
VP01893
p21113
sg17441
I2
sa(dp21114
g17436
I131
sg17437
VEZH2
p21115
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp21116
(dp21117
g17436
I262
sg17437
Vcondition
p21118
sg17438
I9
sg17445
VC0012634
p21119
sg17441
I1
sa(dp21120
g17436
I217
sg17437
Vclonal evolution
p21121
sg17438
I16
sg17445
VC1516669
p21122
sg17441
I2
sasa(dp21123
g17431
VAccumulating evidence indicates that enhancer of zeste homolog 2 (EZH2) promotes the metastatic ability of solid tumors, but the role of EZH2 in extramedullary infiltration (EMI) in acute myeloid leukemia (AML) has not been thoroughly explored.
p21124
sg17433
(lp21125
(dp21126
g17436
I66
sg17437
VEZH2
p21127
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21128
g17436
I37
sg17437
Venhancer of zeste homolog 2
p21129
sg17438
I27
sg17439
g12
sg17441
I5
sa(dp21130
g17436
I66
sg17437
VEZH2
p21131
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp21132
(dp21133
g17436
I182
sg17437
Vacute myeloid leukemia
p21134
sg17438
I22
sg17445
VC0023467
p21135
sg17441
I3
sa(dp21136
g17436
I160
sg17437
Vinfiltration
p21137
sg17438
I12
sg17445
VC0332448
p21138
sg17441
I1
sa(dp21139
g17436
I107
sg17437
Vsolid tumors
p21140
sg17438
I12
sg17445
VC0280100
p21141
sg17441
I2
sa(dp21142
g17436
I206
sg17437
VAML
p21143
sg17438
I3
sg17445
VC0023467
p21144
sg17441
I1
sasa(dp21145
g17431
VWe found that the messenger RNA (mRNA) and protein expression levels of EZH2 in AML patients were both significantly higher than in idiopathic thrombocytopenic purpura (ITP) patients.
p21146
sg17433
(lp21147
(dp21148
g17436
I72
sg17437
VEZH2
p21149
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp21150
(dp21151
g17436
I80
sg17437
VAML
p21152
sg17438
I3
sg17445
VC0023467
p21153
sg17441
I1
sa(dp21154
g17436
I169
sg17437
VITP
p21155
sg17438
I3
sg17445
VC0043117
p21156
sg17441
I1
sa(dp21157
g17436
I132
sg17437
Vidiopathic thrombocytopenic purpura
p21158
sg17438
I35
sg17445
VC0043117
p21159
sg17441
I3
sasa(dp21160
g135
(dp21161
(VPSA
p21162
Vadenomas
p21163
tp21164
I00
ssg17431
VHistopathological examination (HPE) of excised gland showed multiple Hurthle cell adenomas in both lobes of thyroid along with foci of papillary thyroid carcinoma which on immunohistochemistry were thyroglobulin positive and PSA negative.
p21165
sg17433
(lp21166
(dp21167
g17436
I225
sg17437
g21162
sg17438
I3
sg17439
VP55786
p21168
sg17441
I1
sa(dp21169
g17436
I198
sg17437
Vthyroglobulin
p21170
sg17438
I13
sg17439
g12
sg17441
I1
sasg17442
(lp21171
(dp21172
g17436
I225
sg17437
VPSA
p21173
sg17438
I3
sg17445
VC1519176
p21174
sg17441
I1
sa(dp21175
g17436
I135
sg17437
Vpapillary thyroid carcinoma
p21176
sg17438
I27
sg17445
VC0238463
p21177
sg17441
I3
sa(dp21178
g17436
I82
sg17437
g21163
sg17438
I8
sg17445
VC0001430
p21179
sg17441
I1
sasa(dp21180
g17431
VUnivariate analysis showed that male gender, thyroglobulin concentrations &gt;=300 ng/ml and tumor diameter &gt;30 mm were significantly more frequent in patients with oxyphile carcinoma compared to patients with oxyphile adenoma, while coexisting Hashimoto thyreoiditis and positive AntiTPO antibodies appeared significantly less frequent in the carcinoma group.
p21181
sg17433
(lp21182
(dp21183
g17436
I45
sg17437
Vthyroglobulin
p21184
sg17438
I13
sg17439
g12
sg17441
I1
sasg17442
(lp21185
(dp21186
g17436
I93
sg17437
Vtumor
p21187
sg17438
I5
sg17445
VC0027651
p21188
sg17441
I1
sa(dp21189
g17436
I177
sg17437
Vcarcinoma
p21190
sg17438
I9
sg17445
VC0007097
p21191
sg17441
I1
sa(dp21192
g17436
I177
sg17437
Vcarcinoma
p21193
sg17438
I9
sg17445
VC0007097
p21194
sg17441
I1
sa(dp21195
g17436
I222
sg17437
Vadenoma
p21196
sg17438
I7
sg17445
VC0001430
p21197
sg17441
I1
sasa(dp21198
g17431
VThe histologic appearance together with the immune profile was diagnostic of WCCA, with diffuse positivity for GATA3, focal weak positivity for parathyroid hormone, and negativity for PAX8, thyroglobulin, TTF1, synaptophysin, chromogranin, and S100p.
p21199
sg17433
(lp21200
(dp21201
g17436
I205
sg17437
VTTF1
p21202
sg17438
I4
sg17439
VP43699
p21203
sg17441
I1
sa(dp21204
g17436
I226
sg17437
Vchromogranin
p21205
sg17438
I12
sg17439
VP08311
p21206
sg17441
I1
sa(dp21207
g17436
I190
sg17437
Vthyroglobulin
p21208
sg17438
I13
sg17439
g12
sg17441
I1
sa(dp21209
g17436
I211
sg17437
Vsynaptophysin
p21210
sg17438
I13
sg17439
VP08247
p21211
sg17441
I1
sa(dp21212
g17436
I184
sg17437
VPAX8
p21213
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21214
g17436
I144
sg17437
Vparathyroid hormone
p21215
sg17438
I19
sg17439
VP01270
p21216
sg17441
I2
sa(dp21217
g17436
I244
sg17437
VS100p
p21218
sg17438
I5
sg17439
VP25815
p21219
sg17441
I1
sa(dp21220
g17436
I111
sg17437
VGATA3
p21221
sg17438
I5
sg17439
VP23771
p21222
sg17441
I1
sasg17442
(lp21223
sa(dp21224
g135
(dp21225
(Vchromogranin A
p21226
Vadenomas
p21227
tp21228
I00
ssg17431
VAfter immunohistochemical characterization using a panel of chromogranin A, thyroglobulin, and calcitonin, 7 of the former thyroid neoplasms were diagnosed as thyroid adenomas, 1 was diagnosed as a thyroid carcinoma, and 4 were diagnosed as parathyroid adenomas.
p21229
sg17433
(lp21230
(dp21231
g17436
I95
sg17437
Vcalcitonin
p21232
sg17438
I10
sg17439
VP06881
p21233
sg17441
I1
sa(dp21234
g17436
I60
sg17437
g21226
sg17438
I14
sg17439
VP10645
p21235
sg17441
I2
sa(dp21236
g17436
I76
sg17437
Vthyroglobulin
p21237
sg17438
I13
sg17439
g12
sg17441
I1
sasg17442
(lp21238
(dp21239
g17436
I123
sg17437
Vthyroid neoplasms
p21240
sg17438
I17
sg17445
VC0040136
p21241
sg17441
I2
sa(dp21242
g17436
I198
sg17437
Vthyroid carcinoma
p21243
sg17438
I17
sg17445
VC0549473
p21244
sg17441
I2
sa(dp21245
g17436
I241
sg17437
Vparathyroid adenomas
p21246
sg17438
I20
sg17445
VC0262587
p21247
sg17441
I2
sa(dp21248
g17436
I167
sg17437
g21227
sg17438
I8
sg17445
VC0001430
p21249
sg17441
I1
sasa(dp21250
g17431
VThe findings obtained using these cell lines derived from ovarian clear cell adenocarcinoma indicate that integrin alpha3 may associated with the acquisition of malignant potential by clear cell adenocarcinoma.
p21251
sg17433
(lp21252
sg17442
(lp21253
(dp21254
g17436
I66
sg17437
Vclear cell adenocarcinoma
p21255
sg17438
I25
sg17445
VC0206681
p21256
sg17441
I3
sa(dp21257
g17436
I58
sg17437
Vovarian clear cell adenocarcinoma
p21258
sg17438
I33
sg17445
VC1518693
p21259
sg17441
I4
sasa(dp21260
g17431
VNo entanto, a existencia de uma patologia cronica pode determinar um elevado nivel de cuidados preventivos gerais, inclusivamente resultando numa melhoria global do seu nivel de saude oral, o que podera justificar os resultados obtidos.Conclusao: A presenca de diabetes mellitus tipo 1 em doentes tratados com bomba de insulina nao esta associada a um aumento da prevalencia de lesoes de carie dentaria.
p21261
sg17433
(lp21262
sg17442
(lp21263
(dp21264
g17436
I261
sg17437
Vdiabetes mellitus
p21265
sg17438
I17
sg17445
VC0011849
p21266
sg17441
I2
sasa(dp21267
g135
(dp21268
(VTRF1
p21269
Vdiabetes
p21270
tp21271
I00
ssg17431
VFew of the substrates of Tankyrases are Telomeric Repeat binding Factor protein (TRF1), Axis Inhibitory protein (AXIN 1&amp;amp;2), Insulin Responsive Amino Peptidase (IRAP), Nuclear Mitotic Apparatus protein (NuMa), that become aberrantly active due to the apparent overexpression of the enzyme during hyper proliferative disease conditions like cancer, fibrosis and metabolic disorders like diabetes.
p21272
sg17433
(lp21273
(dp21274
g17436
I168
sg17437
VIRAP
p21275
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21276
g17436
I25
sg17437
VTankyrases
p21277
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp21278
g17436
I132
sg17437
VInsulin Responsive Amino Peptidase
p21279
sg17438
I34
sg17439
g12
sg17441
I4
sa(dp21280
g17436
I40
sg17437
VTelomeric Repeat binding Factor protein
p21281
sg17438
I39
sg17439
VP54274
p21282
sg17441
I5
sa(dp21283
g17436
I-1
sg17437
VAXIN 1&2
p21284
sg17438
I8
sg17439
g12
sg17441
I2
sa(dp21285
g17436
I81
sg17437
g21269
sg17438
I4
sg17439
VP54274
p21286
sg17441
I1
sasg17442
(lp21287
(dp21288
g17436
I309
sg17437
Vproliferative
p21289
sg17438
I13
sg17445
VC0334094
p21290
sg17441
I1
sa(dp21291
g17436
I368
sg17437
Vmetabolic disorders
p21292
sg17438
I19
sg17445
VC0025517
p21293
sg17441
I2
sa(dp21294
g17436
I355
sg17437
Vfibrosis
p21295
sg17438
I8
sg17445
VC0016059
p21296
sg17441
I1
sa(dp21297
g17436
I393
sg17437
g21270
sg17438
I8
sg17445
VC0011849
p21298
sg17441
I1
sa(dp21299
g17436
I347
sg17437
Vcancer
p21300
sg17438
I6
sg17445
VC0006826
p21301
sg17441
I1
sasa(dp21302
g17431
VO objetivo deste estudo foi avaliar a utilidade deste exame numa populacao de criancas e adolescentes obesos, maioritariamente de etnia caucasiana.Material e Metodos: Foram recrutados 226 doentes [indice de massa corporal z-score 3,35 A+/- 0,59, 90% caucasianos, 55% do sexo feminino, idade mediana de 12,3 (ambito: 8,9 a 17,6) anos] referenciados a consulta de obesidade pediatrica de um hospital terciario, com criterios para rastreio de diabetes mellitus tipo 2.
p21303
sg17433
(lp21304
sg17442
(lp21305
(dp21306
g17436
I440
sg17437
Vdiabetes mellitus
p21307
sg17438
I17
sg17445
VC0011849
p21308
sg17441
I2
sasa(dp21309
g17431
VFinally, we speculate on the potential benefits of the inhibition of Sin3B-containing complexes for the treatment of cancer.
p21310
sg17433
(lp21311
(dp21312
g17436
I69
sg17437
VSin3B
p21313
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21314
(dp21315
g17436
I117
sg17437
Vcancer
p21316
sg17438
I6
sg17445
VC0006826
p21317
sg17441
I1
sasa(dp21318
g17431
VExpert opinion: Further identification and characterization of specific Sin3B-containing complexes provide a unique opportunity to prevent the pro-tumorigenic effects of the senescence-associated secretory phenotype, and to abrogate cancer stem cell quiescence and the associated resistance to therapy.
p21319
sg17433
(lp21320
(dp21321
g17436
I72
sg17437
VSin3B
p21322
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21323
(dp21324
g17436
I233
sg17437
Vcancer
p21325
sg17438
I6
sg17445
VC0006826
p21326
sg17441
I1
sasa(dp21327
g17431
VSIN3B has been implicated in the initiation of senescence in vitro Here we show that in a mouse model of prostate cancer, SIN3B provides a barrier to malignant progression.
p21328
sg17433
(lp21329
(dp21330
g17436
I0
sg17437
VSIN3B
p21331
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21332
g17436
I0
sg17437
VSIN3B
p21333
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21334
(dp21335
g17436
I105
sg17437
Vprostate cancer
p21336
sg17438
I15
sg17445
VC0600139
p21337
sg17441
I2
sasa(dp21338
g135
(dp21339
(VPTEN
p21340
Vprostate adenocarcinoma
p21341
tp21342
I00
ssg17431
VSIN3B was required for PTEN-induced cellular senescence and prevented progression to invasive prostate adenocarcinoma.
p21343
sg17433
(lp21344
(dp21345
g17436
I0
sg17437
VSIN3B
p21346
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21347
g17436
I23
sg17437
g21340
sg17438
I4
sg17439
VP60484
p21348
sg17441
I1
sasg17442
(lp21349
(dp21350
g17436
I94
sg17437
g21341
sg17438
I23
sg17445
VC0007112
p21351
sg17441
I2
sasa(dp21352
g17431
VFurthermore, SIN3B was downregulated in human prostate adenocarcinoma correlating with upregulation of its target genes.
p21353
sg17433
(lp21354
(dp21355
g17436
I13
sg17437
VSIN3B
p21356
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21357
(dp21358
g17436
I46
sg17437
Vprostate adenocarcinoma
p21359
sg17438
I23
sg17445
VC0007112
p21360
sg17441
I2
sasa(dp21361
g17431
VOur results suggest a tumor suppressor function for SIN3B that limits prostate adenocarcinoma progression, with potential implications for the use of SIN3B and its target genes as candidate diagnostic markers to distinguish indolent from aggressive disease.
p21362
sg17433
(lp21363
(dp21364
g17436
I52
sg17437
VSIN3B
p21365
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21366
g17436
I52
sg17437
VSIN3B
p21367
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21368
(dp21369
g17436
I22
sg17437
Vtumor
p21370
sg17438
I5
sg17445
VC0027651
p21371
sg17441
I1
sa(dp21372
g17436
I70
sg17437
Vprostate adenocarcinoma
p21373
sg17438
I23
sg17445
VC0007112
p21374
sg17441
I2
sa(dp21375
g17436
I238
sg17437
Vaggressive
p21376
sg17438
I10
sg17445
VC0001807
p21377
sg17441
I1
sasa(dp21378
g17431
VHowever, specific roles for SIN3A and SIN3B in breast cancer progression have not been characterized.
p21379
sg17433
(lp21380
(dp21381
g17436
I38
sg17437
VSIN3B
p21382
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21383
g17436
I28
sg17437
VSIN3A
p21384
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21385
(dp21386
g17436
I54
sg17437
Vcancer progression
p21387
sg17438
I18
sg17445
VC0178874
p21388
sg17441
I2
sasa(dp21389
g17431
VAdditionally, we analyzed microarray data sets to identify correlations of SIN3A and SIN3B expression with survival in patients with breast cancer.
p21390
sg17433
(lp21391
(dp21392
g17436
I85
sg17437
VSIN3B
p21393
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21394
g17436
I75
sg17437
VSIN3A
p21395
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21396
(dp21397
g17436
I133
sg17437
Vbreast cancer
p21398
sg17438
I13
sg17445
VC0678222
p21399
sg17441
I2
sasa(dp21400
g17431
VThese data sets indicated that high mRNA expression of SIN3A as well as low mRNA expression of SIN3B correlates with longer relapse free survival specifically in patients with triple negative breast cancer which corresponds with our in vitro and in vivo data.
p21401
sg17433
(lp21402
(dp21403
g17436
I95
sg17437
VSIN3B
p21404
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21405
g17436
I55
sg17437
VSIN3A
p21406
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21407
(dp21408
g17436
I124
sg17437
Vrelapse
p21409
sg17438
I7
sg17445
VC0277556
p21410
sg17441
I1
sa(dp21411
g17436
I192
sg17437
Vbreast cancer
p21412
sg17438
I13
sg17445
VC0678222
p21413
sg17441
I2
sasa(dp21414
g17431
VThese results demonstrate key functional differences between SIN3 paralogs in regulating the process of breast cancer metastasis and suggest metastasis suppressive roles of SIN3A and metastasis promoting roles of SIN3B.
p21415
sg17433
(lp21416
(dp21417
g17436
I173
sg17437
VSIN3A
p21418
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21419
g17436
I213
sg17437
VSIN3B
p21420
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21421
g17436
I61
sg17437
VSIN3
p21422
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp21423
(dp21424
g17436
I118
sg17437
Vmetastasis
p21425
sg17438
I10
sg17445
VC0027627
p21426
sg17441
I1
sa(dp21427
g17436
I104
sg17437
Vbreast cancer
p21428
sg17438
I13
sg17445
VC0678222
p21429
sg17441
I2
sa(dp21430
g17436
I118
sg17437
Vmetastasis
p21431
sg17438
I10
sg17445
VC0027627
p21432
sg17441
I1
sa(dp21433
g17436
I118
sg17437
Vmetastasis
p21434
sg17438
I10
sg17445
VC0027627
p21435
sg17441
I1
sasa(dp21436
g135
(dp21437
(VKDM5A
p21438
Vbreast cancer
p21439
tp21440
I01
ssg17431
VFinally, by immunohistochemical staining of primary breast tissue microarrays we find that EMSY/KDM5A/SIN3B complex subunits are frequently overexpressed in primary breast cancer cases in a correlative manner.
p21441
sg17433
(lp21442
(dp21443
g17436
I96
sg17437
g21438
sg17438
I5
sg17439
VP29375
p21444
sg17441
I1
sa(dp21445
g17436
I102
sg17437
VSIN3B
p21446
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21447
g17436
I91
sg17437
VEMSY
p21448
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp21449
(dp21450
g17436
I165
sg17437
g21439
sg17438
I13
sg17445
VC0678222
p21451
sg17441
I2
sasa(dp21452
g135
(dp21453
(VKRAS
p21454
Vpancreatic cancer
p21455
tp21456
I00
ssg17431
VHere, using a mouse model of pancreatic cancer, we have demonstrated that SIN3B is required for activated KRAS-induced senescence in vivo.
p21457
sg17433
(lp21458
(dp21459
g17436
I106
sg17437
g21454
sg17438
I4
sg17439
VP01116
p21460
sg17441
I1
sa(dp21461
g17436
I74
sg17437
VSIN3B
p21462
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21463
(dp21464
g17436
I29
sg17437
g21455
sg17438
I17
sg17445
VC0235974
p21465
sg17441
I2
sasa(dp21466
g17431
VFurthermore, evaluation of human pancreatic tissue and cancer cells revealed that Sin3B was decreased in control and PDAC samples, compared with samples from patients with pancreatic inflammation.
p21467
sg17433
(lp21468
(dp21469
g17436
I82
sg17437
VSin3B
p21470
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21471
(dp21472
g17436
I183
sg17437
Vinflammation
p21473
sg17438
I12
sg17445
VC0021368
p21474
sg17441
I1
sa(dp21475
g17436
I55
sg17437
Vcancer
p21476
sg17438
I6
sg17445
VC0006826
p21477
sg17441
I1
sasa(dp21478
g135
(dp21479
(VMad
p21480
Vglioblastoma multiforme
p21481
tp21482
I00
ssg17431
VAmong proteins in the c-Myc/Max/Mad/Sin3 regulatory complex, Mad4 and Sin3B are routinely detected in human glioblastoma multiforme (GBM) cell lines.
p21483
sg17433
(lp21484
(dp21485
g17436
I36
sg17437
VSin3
p21486
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21487
g17436
I61
sg17437
VMad4
p21488
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21489
g17436
I22
sg17437
Vc-Myc
p21490
sg17438
I5
sg17439
VP12524
p21491
sg17441
I1
sa(dp21492
g17436
I70
sg17437
VSin3B
p21493
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21494
g17436
I32
sg17437
g21480
sg17438
I3
sg17439
VP23109
p21495
sg17441
I1
sasg17442
(lp21496
(dp21497
g17436
I133
sg17437
VGBM
p21498
sg17438
I3
sg17445
VC1621958
p21499
sg17441
I1
sa(dp21500
g17436
I108
sg17437
g21481
sg17438
I23
sg17445
VC1621958
p21501
sg17441
I2
sasa(dp21502
g17431
VIn response to gamma radiation, the expression of Sin3B and Mad4 in GBM cells was upregulated in parallel over time, suggesting that Sin3B may play a role in the regulation of Mad4 stability.
p21503
sg17433
(lp21504
(dp21505
g17436
I50
sg17437
VSin3B
p21506
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21507
g17436
I60
sg17437
VMad4
p21508
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21509
g17436
I60
sg17437
VMad4
p21510
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp21511
g17436
I50
sg17437
VSin3B
p21512
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21513
(dp21514
g17436
I68
sg17437
VGBM
p21515
sg17438
I3
sg17445
VC0017636
p21516
sg17441
I1
sasa(dp21517
g135
(dp21518
(Vcardiac transcription factor
p21519
Vheart disease
p21520
tp21521
I00
ssg17431
VUsing the Drosophila heart as a platform for identifying novel gene interactions leading to heart disease, we found that the Rho-GTPase Cdc42 cooperates with the cardiac transcription factor Tinman/Nkx2-5.
p21522
sg17433
(lp21523
(dp21524
g17436
I198
sg17437
VNkx2-5
p21525
sg17438
I6
sg17439
VP52952
p21526
sg17441
I1
sa(dp21527
g17436
I125
sg17437
VRho-GTPase
p21528
sg17438
I10
sg17439
VP08100
p21529
sg17441
I1
sa(dp21530
g17436
I136
sg17437
VCdc42
p21531
sg17438
I5
sg17439
VP60953
p21532
sg17441
I1
sa(dp21533
g17436
I162
sg17437
g21519
sg17438
I28
sg17439
VP35398
p21534
sg17441
I3
sasg17442
(lp21535
(dp21536
g17436
I92
sg17437
g21520
sg17438
I13
sg17445
VC0018799
p21537
sg17441
I2
sasa(dp21538
g17431
VWhat is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.
p21539
sg17433
(lp21540
(dp21541
g17436
I105
sg17437
VSnapin
p21542
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp21543
g17436
I59
sg17437
VCav1.3
p21544
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp21545
(dp21546
g17436
I171
sg17437
VAF
p21547
sg17438
I2
sg17445
VC0004238
p21548
sg17441
I1
sa(dp21549
g17436
I150
sg17437
Vatrial fibrillation
p21550
sg17438
I19
sg17445
VC0004238
p21551
sg17441
I2
sasa(dp21552
g17431
VFurthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.
p21553
sg17433
(lp21554
(dp21555
g17436
I29
sg17437
VCav1.3 channels
p21556
sg17438
I15
sg17439
g12
sg17441
I2
sasg17442
(lp21557
(dp21558
g17436
I59
sg17437
Vatrial fibrillation and flutter
p21559
sg17438
I31
sg17445
VC0155709
p21560
sg17441
I4
sa(dp21561
g17436
I13
sg17437
Vinactivation
p21562
sg17438
I12
sg17445
VC0544461
p21563
sg17441
I1
sasa(dp21564
g17431
VThe significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.
p21565
sg17433
(lp21566
(dp21567
g17436
I139
sg17437
VCav1.3
p21568
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp21569
(dp21570
g17436
I151
sg17437
Vmutant
p21571
sg17438
I6
sg17445
VC0596988
p21572
sg17441
I1
sa(dp21573
g17436
I114
sg17437
Vatrial fibrillation
p21574
sg17438
I19
sg17445
VC0004238
p21575
sg17441
I2
sasa(dp21576
g17431
VThe novel Cav1.3 (Alfa1D) L-type Ca^2+ channel plays a significant role in sinoatrial (SA) and atrioventricular (AV) nodes function and in atrial fibrillation.
p21577
sg17433
(lp21578
(dp21579
g17436
I10
sg17437
VCav1.3
p21580
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp21581
(dp21582
g17436
I139
sg17437
Vatrial fibrillation
p21583
sg17438
I19
sg17445
VC0004238
p21584
sg17441
I2
sasa(dp21585
g17431
VInterestingly, oncogenic CARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(Ub)n-Bcl10 production to extents that correlate with their abilities to activate NF-KB and with their enhanced abilities to bind HOIP and Bcl10.
p21586
sg17433
(lp21587
(dp21588
g17436
I15
sg17437
Voncogenic CARD11 variants
p21589
sg17438
I25
sg17439
g12
sg17441
I3
sa(dp21590
g17436
I117
sg17437
VBcl10
p21591
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21592
(dp21593
g17436
I57
sg17437
Vdiffuse large B cell lymphoma
p21594
sg17438
I29
sg17445
VC0079744
p21595
sg17441
I5
sasa(dp21596
g17431
VOur previous studies showed important regulatory functions of RNF31 in controlling important oncogenic pathways in breast cancer, such as ERAlfa and p53.
p21597
sg17433
(lp21598
(dp21599
g17436
I62
sg17437
VRNF31
p21600
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21601
g17436
I149
sg17437
Vp53
p21602
sg17438
I3
sg17439
VP42771
p21603
sg17441
I1
sasg17442
(lp21604
(dp21605
g17436
I115
sg17437
Vbreast cancer
p21606
sg17438
I13
sg17445
VC0678222
p21607
sg17441
I2
sasa(dp21608
g17431
VThis review highlights recent discoveries on RNF31 functions in nuclear factor modifications, breast cancer progression and possible therapeutic inhibitors targeting RNF31.
p21609
sg17433
(lp21610
(dp21611
g17436
I45
sg17437
VRNF31
p21612
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21613
g17436
I45
sg17437
VRNF31
p21614
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21615
(dp21616
g17436
I101
sg17437
Vcancer progression
p21617
sg17438
I18
sg17445
VC0178874
p21618
sg17441
I2
sasa(dp21619
g135
(dp21620
(VE3 ubiquitin
p21621
Vbreast cancer
p21622
tp21623
I01
ssg17431
VThe atypical E3 ubiquitin ligase RNF31 is highly expressed in human breast cancer, the most frequent neoplastic lethality among women.
p21624
sg17433
(lp21625
(dp21626
g17436
I13
sg17437
g21621
sg17438
I12
sg17439
VP62979
p21627
sg17441
I2
sa(dp21628
g17436
I33
sg17437
VRNF31
p21629
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21630
(dp21631
g17436
I68
sg17437
g21622
sg17438
I13
sg17445
VC0678222
p21632
sg17441
I2
sasa(dp21633
g17431
VHere, RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 (TP53) signaling as a potential RNF31 target.
p21634
sg17433
(lp21635
(dp21636
g17436
I107
sg17437
Vp53
p21637
sg17438
I3
sg17439
VP42771
p21638
sg17441
I1
sa(dp21639
g17436
I6
sg17437
VRNF31
p21640
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21641
g17436
I6
sg17437
VRNF31
p21642
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21643
(dp21644
g17436
I25
sg17437
Vbreast cancer
p21645
sg17438
I13
sg17445
VC0678222
p21646
sg17441
I2
sasa(dp21647
g17431
VInterestingly, RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner.
p21648
sg17433
(lp21649
(dp21650
g17436
I15
sg17437
VRNF31
p21651
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21652
g17436
I31
sg17437
Vp53
p21653
sg17438
I3
sg17439
VP42771
p21654
sg17441
I1
sa(dp21655
g17436
I31
sg17437
Vp53
p21656
sg17438
I3
sg17439
VP42771
p21657
sg17441
I1
sa(dp21658
g17436
I15
sg17437
VRNF31
p21659
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21660
(dp21661
g17436
I76
sg17437
Vbreast cancer
p21662
sg17438
I13
sg17445
VC0678222
p21663
sg17441
I2
sasa(dp21664
g17431
VTogether, our findings suggest RNF31 as a potential therapeutic target to restore p53 function in breast cancer.
p21665
sg17433
(lp21666
(dp21667
g17436
I82
sg17437
Vp53
p21668
sg17438
I3
sg17439
VP42771
p21669
sg17441
I1
sa(dp21670
g17436
I31
sg17437
VRNF31
p21671
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21672
(dp21673
g17436
I98
sg17437
Vbreast cancer
p21674
sg17438
I13
sg17445
VC0678222
p21675
sg17441
I2
sasa(dp21676
g135
(dp21677
(VTRAIL
p21678
Vlymphoma
p21679
tp21680
I00
ssg17431
VBy examining the kinetics of pathway activation in TRAIL-sensitive lymphoma cells wild-type or deficient for RIP1, TRAF2, cIAP1/2 or HOIP, we report here that TRAIL induces two phases of JNK and NF-KB activation.
p21681
sg17433
(lp21682
(dp21683
g17436
I115
sg17437
VTRAF2
p21684
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21685
g17436
I109
sg17437
VRIP1
p21686
sg17438
I4
sg17439
VP47985
p21687
sg17441
I1
sa(dp21688
g17436
I122
sg17437
VcIAP1/2
p21689
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp21690
g17436
I187
sg17437
VJNK
p21691
sg17438
I3
sg17439
VP53779
p21692
sg17441
I1
sa(dp21693
g17436
I51
sg17437
g21678
sg17438
I5
sg17439
VP50591
p21694
sg17441
I1
sasg17442
(lp21695
(dp21696
g17436
I67
sg17437
g21679
sg17438
I8
sg17445
VC0024299
p21697
sg17441
I1
sasa(dp21698
g135
(dp21699
(Vnorepinephrine transporter
p21700
Vanalgesia
p21701
tp21702
I00
ssg17431
VLiterature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. 2012).
p21703
sg17433
(lp21704
(dp21705
g17436
I102
sg17437
g21700
sg17438
I26
sg17439
VP23975
p21706
sg17441
I2
sasg17442
(lp21707
(dp21708
g17436
I170
sg17437
VWeb
p21709
sg17438
I3
sg17445
VC0332875
p21710
sg17441
I1
sa(dp21711
g17436
I86
sg17437
g21701
sg17438
I9
sg17445
VC0344307
p21712
sg17441
I1
sasa(dp21713
g17431
VNorepinephrine transporter blockade seems to be essential for analgesia, but optimal concentrations are unknown.
p21714
sg17433
(lp21715
sg17442
(lp21716
(dp21717
g17436
I62
sg17437
Vanalgesia
p21718
sg17438
I9
sg17445
VC0344307
p21719
sg17441
I1
sasa(dp21720
g17431
VThe third type is the secondary PHA1, which is strongly associated with urinary tract infections and/or urinary tract malformations.
p21721
sg17433
(lp21722
sg17442
(lp21723
(dp21724
g17436
I118
sg17437
Vmalformations
p21725
sg17438
I13
sg17445
VC0000768
p21726
sg17441
I1
sa(dp21727
g17436
I72
sg17437
Vurinary tract infections
p21728
sg17438
I24
sg17445
VC0042029
p21729
sg17441
I3
sasa(dp21730
g135
(dp21731
(VSCNN1G genes
p21732
VLiddle syndrome
p21733
tp21734
I00
ssg17431
VTo identify mutation in SCNN1B and SCNN1G genes in an adolescent with suspicious Liddle syndrome and his family members and to explore the screening target subjects of Liddle syndrome.
p21735
sg17433
(lp21736
(dp21737
g17436
I24
sg17437
VSCNN1B
p21738
sg17438
I6
sg17439
VP51168
p21739
sg17441
I1
sa(dp21740
g17436
I35
sg17437
g21732
sg17438
I12
sg17439
VP51168
p21741
sg17441
I2
sasg17442
(lp21742
(dp21743
g17436
I81
sg17437
VLiddle syndrome
p21744
sg17438
I15
sg17445
VC0221043
p21745
sg17441
I2
sa(dp21746
g17436
I81
sg17437
g21733
sg17438
I15
sg17445
VC0221043
p21747
sg17441
I2
sasa(dp21748
g135
(dp21749
(VSCNN1G genes
p21750
VLiddle syndrome
p21751
tp21752
I00
ssg17431
VGenetic analysis of the C-terminus of SCNN1B and SCNN1G genes was conducted in an adolescent, with treatment-resistant hypertension and hypokalemia, who was suspected of having Liddle syndrome, and his family members.
p21753
sg17433
(lp21754
(dp21755
g17436
I38
sg17437
VSCNN1B
p21756
sg17438
I6
sg17439
VP51168
p21757
sg17441
I1
sa(dp21758
g17436
I49
sg17437
g21750
sg17438
I12
sg17439
VP51168
p21759
sg17441
I2
sasg17442
(lp21760
(dp21761
g17436
I119
sg17437
Vhypertension
p21762
sg17438
I12
sg17445
VC0020538
p21763
sg17441
I1
sa(dp21764
g17436
I177
sg17437
g21751
sg17438
I15
sg17445
VC0221043
p21765
sg17441
I2
sasa(dp21766
g135
(dp21767
(VScnn1a
p21768
Vmetabolic acidosis
p21769
tp21770
I01
ssg17431
VIn adulthood, an induced nephron-specific deficiency of AlfaENaC (Scnn1a) resulted in pseudohypoaldosteronism type 1 (PHA-1) with sodium loss, hyperkalemia, and metabolic acidosis that is rescued through high-sodium/low-potassium (HNa+/LK+) diet.
p21771
sg17433
(lp21772
(dp21773
g17436
I86
sg17437
Vpseudohypoaldosteronism type 1
p21774
sg17438
I30
sg17439
VP37088
p21775
sg17441
I3
sa(dp21776
g17436
I66
sg17437
g21768
sg17438
I6
sg17439
VP37088
p21777
sg17441
I1
sa(dp21778
g17436
I118
sg17437
VPHA-1
p21779
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp21780
(dp21781
g17436
I86
sg17437
Vpseudohypoaldosteronism type 1
p21782
sg17438
I30
sg17445
VC0268436
p21783
sg17441
I3
sa(dp21784
g17436
I118
sg17437
VPHA-1
p21785
sg17438
I5
sg17445
VC0268436
p21786
sg17441
I1
sa(dp21787
g17436
I161
sg17437
g21769
sg17438
I18
sg17445
VC0220981
p21788
sg17441
I2
sasa(dp21789
g135
(dp21790
(VSCNN1G genes
p21791
Vhypertension
p21792
tp21793
I00
ssg17431
VLiddle syndrome is an autosomal dominant genetic condition that causes hypertension and hypokalemia due to a gain-of-function mutation in the SCNN1B or SCNN1G genes which code for the epithelial sodium channel in the kidney.
p21794
sg17433
(lp21795
(dp21796
g17436
I142
sg17437
VSCNN1B
p21797
sg17438
I6
sg17439
VP51168
p21798
sg17441
I1
sa(dp21799
g17436
I152
sg17437
g21791
sg17438
I12
sg17439
VP51168
p21800
sg17441
I2
sasg17442
(lp21801
(dp21802
g17436
I41
sg17437
Vgenetic condition
p21803
sg17438
I17
sg17445
VC0019247
p21804
sg17441
I2
sa(dp21805
g17436
I0
sg17437
VLiddle syndrome
p21806
sg17438
I15
sg17445
VC0221043
p21807
sg17441
I2
sa(dp21808
g17436
I71
sg17437
g21792
sg17438
I12
sg17445
VC0020538
p21809
sg17441
I1
sasa(dp21810
g135
(dp21811
(VPHA1
p21812
Vdehydration
p21813
tp21814
I01
ssg17431
VLoss-of-function mutations of the MR are responsible for renal pseudohypoaldosteronism type 1 (PHA1), a rare disease of mineralocorticoid resistance presenting in the newborn with weight loss, failure to thrive, vomiting and dehydration, associated with hyperkalemia and metabolic acidosis, despite extremely elevated levels of plasma renin and aldosterone.
p21815
sg17433
(lp21816
(dp21817
g17436
I57
sg17437
Vrenal pseudohypoaldosteronism type 1
p21818
sg17438
I36
sg17439
VP37088
p21819
sg17441
I4
sa(dp21820
g17436
I328
sg17437
Vplasma renin
p21821
sg17438
I12
sg17439
VP00797
p21822
sg17441
I2
sa(dp21823
g17436
I95
sg17437
g21812
sg17438
I4
sg17439
VP37088
p21824
sg17441
I1
sasg17442
(lp21825
(dp21826
g17436
I212
sg17437
Vvomiting
p21827
sg17438
I8
sg17445
VC0042963
p21828
sg17441
I1
sa(dp21829
g17436
I104
sg17437
Vrare disease
p21830
sg17438
I12
sg17445
VC0678236
p21831
sg17441
I2
sa(dp21832
g17436
I271
sg17437
Vmetabolic acidosis
p21833
sg17438
I18
sg17445
VC0220981
p21834
sg17441
I2
sa(dp21835
g17436
I193
sg17437
Vfailure to thrive
p21836
sg17438
I17
sg17445
VC0015544
p21837
sg17441
I3
sa(dp21838
g17436
I95
sg17437
VPHA1
p21839
sg17438
I4
sg17445
VC0268436
p21840
sg17441
I1
sa(dp21841
g17436
I63
sg17437
Vpseudohypoaldosteronism type 1
p21842
sg17438
I30
sg17445
VC0268436
p21843
sg17441
I3
sa(dp21844
g17436
I225
sg17437
g21813
sg17438
I11
sg17445
VC0011175
p21845
sg17441
I1
sasa(dp21846
g17431
VIn the presence of pyelonephritis, the same biochemical picture can occur with transient type 1 pseudohypoaldosteronism (PHA-1) also termed type 4 renal tubular acidosis.
p21847
sg17433
(lp21848
(dp21849
g17436
I121
sg17437
VPHA-1
p21850
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp21851
g17436
I56
sg17437
Vpicture can occur with transient type 1 pseudohypoaldosteronism
p21852
sg17438
I63
sg17439
g12
sg17441
I8
sasg17442
(lp21853
(dp21854
g17436
I147
sg17437
Vrenal tubular acidosis
p21855
sg17438
I22
sg17445
VC0001126
p21856
sg17441
I3
sa(dp21857
g17436
I96
sg17437
Vpseudohypoaldosteronism
p21858
sg17438
I23
sg17445
VC0033805
p21859
sg17441
I1
sa(dp21860
g17436
I121
sg17437
VPHA
p21861
sg17438
I3
sg17445
VC0030779
p21862
sg17441
I1
sa(dp21863
g17436
I19
sg17437
Vpyelonephritis
p21864
sg17438
I14
sg17445
VC0034186
p21865
sg17441
I1
sasa(dp21866
g135
(dp21867
(VPseudohypoaldosteronism type 1
p21868
VPseudohypoaldosteronism type 1
p21869
tp21870
I00
ssg17431
VPseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease characterized by resistance to aldosterone, and the renal form of PHA1 is associated with heterozygous inactivating mutations in NR3C2, which encodes mineralocorticoid receptor (MR).
p21871
sg17433
(lp21872
(dp21873
g17436
I32
sg17437
VPHA1
p21874
sg17438
I4
sg17439
VP37088
p21875
sg17441
I1
sa(dp21876
g17436
I32
sg17437
VPHA1
p21877
sg17438
I4
sg17439
VP37088
p21878
sg17441
I1
sa(dp21879
g17436
I193
sg17437
VNR3C2
p21880
sg17438
I5
sg17439
VP08235
p21881
sg17441
I1
sa(dp21882
g17436
I0
sg17437
g21868
sg17438
I30
sg17439
VP37088
p21883
sg17441
I3
sasg17442
(lp21884
(dp21885
g17436
I32
sg17437
VPHA1
p21886
sg17438
I4
sg17445
VC0268436
p21887
sg17441
I1
sa(dp21888
g17436
I32
sg17437
VPHA1
p21889
sg17438
I4
sg17445
VC0268436
p21890
sg17441
I1
sa(dp21891
g17436
I0
sg17437
g21869
sg17438
I30
sg17445
VC0268436
p21892
sg17441
I3
sa(dp21893
g17436
I48
sg17437
Vgenetic disease
p21894
sg17438
I15
sg17445
VC0019247
p21895
sg17441
I2
sasa(dp21896
g17431
VRecent work has identified cancer-associated U2AF35 missense mutations in two zinc-finger (ZnF) domains, but little is known about Q157R/P substitutions within the second ZnF.
p21897
sg17433
(lp21898
(dp21899
g17436
I45
sg17437
VU2AF35
p21900
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp21901
(dp21902
g17436
I27
sg17437
Vcancer
p21903
sg17438
I6
sg17445
VC0006826
p21904
sg17441
I1
sasa(dp21905
g17431
VZinc finger (ZNF) proteins, a diverse family of proteins, have multiple biological functions in cancer.
p21906
sg17433
(lp21907
(dp21908
g17436
I0
sg17437
VZinc finger (ZNF) proteins
p21909
sg17438
I26
sg17439
g12
sg17441
I4
sasg17442
(lp21910
(dp21911
g17436
I96
sg17437
Vcancer
p21912
sg17438
I6
sg17445
VC0006826
p21913
sg17441
I1
sasa(dp21914
g17431
VHowever, the function and underlying mechanisms of ZNF185 in the tumorigenesis of lung adenocarcinoma (LAC) remain unclear.
p21915
sg17433
(lp21916
(dp21917
g17436
I51
sg17437
VZNF185
p21918
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp21919
(dp21920
g17436
I103
sg17437
VLAC
p21921
sg17438
I3
sg17445
VC0152013
p21922
sg17441
I1
sa(dp21923
g17436
I82
sg17437
Vlung adenocarcinoma
p21924
sg17438
I19
sg17445
VC0152013
p21925
sg17441
I2
sa(dp21926
g17436
I65
sg17437
Vtumorigenesis
p21927
sg17438
I13
sg17445
VC0007621
p21928
sg17441
I1
sasa(dp21929
g17431
VWe found that the protein expression of ZNF185 was significantly downregulated in LAC tissues compared with the adjacent non-cancerous tissues (ANCT) (37.10% vs 58.06%, P=0.015), and was negatively correlated with the lymph node metastasis of the LAC patients (P=0.005).
p21930
sg17433
(lp21931
(dp21932
g17436
I40
sg17437
VZNF185
p21933
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp21934
(dp21935
g17436
I218
sg17437
Vlymph node metastasis
p21936
sg17438
I21
sg17445
VC0686619
p21937
sg17441
I3
sasa(dp21938
g17431
VIn view of the exploitation of tetraspanins by organisms for survival, these proteins could be targeted using specific antibodies, recombinant large extracellular loop (LEL) domains, small-molecule mimetics and siRNAs as potential novel and efficacious putative targets to combat African trypanosomiasis by killing the tsetse fly vector.
p21939
sg17433
(lp21940
sg17442
(lp21941
(dp21942
g17436
I280
sg17437
VAfrican trypanosomiasis
p21943
sg17438
I23
sg17445
VC0041228
p21944
sg17441
I2
sa(dp21945
g17436
I143
sg17437
Vlarge extracellular loop
p21946
sg17438
I24
sg17445
VC1846721
p21947
sg17441
I3
sa(dp21948
g17436
I169
sg17437
VLEL
p21949
sg17438
I3
sg17445
VC1846721
p21950
sg17441
I1
sasa(dp21951
g17431
VInfection of hepatocytic cells by two major pathogens, the hepatitis C virus and the malaria parasite, also requires the tetraspanin CD81.
p21952
sg17433
(lp21953
(dp21954
g17436
I121
sg17437
Vtetraspanin CD81
p21955
sg17438
I16
sg17439
g12
sg17441
I2
sasg17442
(lp21956
(dp21957
g17436
I0
sg17437
VInfection
p21958
sg17438
I9
sg17445
VC0009450
p21959
sg17441
I1
sa(dp21960
g17436
I59
sg17437
Vhepatitis C
p21961
sg17438
I11
sg17445
VC0019196
p21962
sg17441
I2
sa(dp21963
g17436
I85
sg17437
Vmalaria
p21964
sg17438
I7
sg17445
VC0024530
p21965
sg17441
I1
sasa(dp21966
g135
(dp21967
(VCD81
p21968
Vmalaria
p21969
tp21970
I00
ssg17431
VOur results unravel a functional link between CD81 and cholesterol during infection by malaria parasites, and illustrate that tetraspanin microdomains constitute a novel type of membrane microdomains that could be used by pathogens for infection.
p21971
sg17433
(lp21972
(dp21973
g17436
I46
sg17437
g21968
sg17438
I4
sg17439
VP60033
p21974
sg17441
I1
sa(dp21975
g17436
I126
sg17437
Vtetraspanin microdomains
p21976
sg17438
I24
sg17439
g12
sg17441
I2
sasg17442
(lp21977
(dp21978
g17436
I87
sg17437
g21969
sg17438
I7
sg17445
VC0024530
p21979
sg17441
I1
sa(dp21980
g17436
I74
sg17437
Vinfection
p21981
sg17438
I9
sg17445
VC0009450
p21982
sg17441
I1
sa(dp21983
g17436
I74
sg17437
Vinfection
p21984
sg17438
I9
sg17445
VC0009450
p21985
sg17441
I1
sasa(dp21986
g17431
VThe CXCL11 gene may also play a role in BK polyomavirus-associated nephropathy.
p21987
sg17433
(lp21988
(dp21989
g17436
I4
sg17437
VCXCL11 gene
p21990
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp21991
(dp21992
g17436
I43
sg17437
Vpolyomavirus-associated nephropathy
p21993
sg17438
I35
sg17445
VC1696946
p21994
sg17441
I2
sasa(dp21995
g17431
VOur aim was to compare expression levels of CXCL11 in BK polyomavirus-infected versus noninfected kidney transplant patients with nephropathy and healthy controls.
p21996
sg17433
(lp21997
(dp21998
g17436
I44
sg17437
VCXCL11
p21999
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp22000
(dp22001
g17436
I130
sg17437
Vnephropathy
p22002
sg17438
I11
sg17445
VC0022658
p22003
sg17441
I1
sasa(dp22004
g135
(dp22005
(VCXCR3
p22006
Vrenal fibrosis
p22007
tp22008
I01
ssg17431
VTaken together, the results indicated that sorafenib had protective effects against renal fibrosis; its mechanism of action was associated with inhibition of macrophage infiltration via the CXCR3/CXCL11 pathway.
p22009
sg17433
(lp22010
(dp22011
g17436
I190
sg17437
g22006
sg17438
I5
sg17439
VP49682
p22012
sg17441
I1
sa(dp22013
g17436
I196
sg17437
VCXCL11
p22014
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp22015
(dp22016
g17436
I169
sg17437
Vinfiltration
p22017
sg17438
I12
sg17445
VC0332448
p22018
sg17441
I1
sa(dp22019
g17436
I84
sg17437
g22007
sg17438
I14
sg17445
VC0151650
p22020
sg17441
I2
sasa(dp22021
g135
(dp22022
(VCXCL10
p22023
Vdiabetic nephropathy
p22024
tp22025
I01
ssg17431
VUrinary mRNA levels of CXCL10 and CXCL11 are decreased, and those of collagen I A1 chain and fibronectin are increased in diabetic nephropathy.
p22026
sg17433
(lp22027
(dp22028
g17436
I23
sg17437
g22023
sg17438
I6
sg17439
VP02778
p22029
sg17441
I1
sa(dp22030
g17436
I34
sg17437
VCXCL11
p22031
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp22032
(dp22033
g17436
I122
sg17437
g22024
sg17438
I20
sg17445
VC0011881
p22034
sg17441
I2
sasa(dp22035
g135
(dp22036
(Vinterleukin 10
p22037
VMycoplasma
p22038
tp22039
I00
ssg17431
VFor this purpose, serum concentration of interleukin 2 (IL2), interleukin 10 (IL10), interferon-gamma (IFNG), Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9) were measured in blood samples obtained from F(2) piglets (n = 334) of a Duroc x Pietrain resource population (DUPI) after Mycoplasma hypopneumoniae (Mh), tetanus toxoid (TT) and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccination at 6, 9 and 15 weeks of age.
p22040
sg17433
(lp22041
(dp22042
g17436
I78
sg17437
VIL10
p22043
sg17438
I4
sg17439
VP22301
p22044
sg17441
I1
sa(dp22045
g17436
I164
sg17437
VTLR9
p22046
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp22047
g17436
I56
sg17437
VIL2
p22048
sg17438
I3
sg17439
VP60568
p22049
sg17441
I1
sa(dp22050
g17436
I142
sg17437
VToll-like receptor 9
p22051
sg17438
I20
sg17439
g12
sg17441
I3
sa(dp22052
g17436
I41
sg17437
Vinterleukin 2
p22053
sg17438
I13
sg17439
VP60568
p22054
sg17441
I2
sa(dp22055
g17436
I110
sg17437
VToll-like receptor 2
p22056
sg17438
I20
sg17439
g12
sg17441
I3
sa(dp22057
g17436
I132
sg17437
VTLR2
p22058
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp22059
g17436
I85
sg17437
Vinterferon-gamma
p22060
sg17438
I16
sg17439
VP01579
p22061
sg17441
I1
sa(dp22062
g17436
I103
sg17437
VIFNG
p22063
sg17438
I4
sg17439
VP01579
p22064
sg17441
I1
sa(dp22065
g17436
I62
sg17437
g22037
sg17438
I14
sg17439
VP22301
p22066
sg17441
I2
sasg17442
(lp22067
(dp22068
g17436
I325
sg17437
Vtetanus
p22069
sg17438
I7
sg17445
VC0039614
p22070
sg17441
I1
sa(dp22071
g17436
I349
sg17437
VPorcine Reproductive and Respiratory Syndrome
p22072
sg17438
I45
sg17445
VC0376538
p22073
sg17441
I5
sa(dp22074
g17436
I293
sg17437
g22038
sg17438
I10
sg17445
VC0026936
p22075
sg17441
I1
sasa(dp22076
g135
(dp22077
(VIgA
p22078
Vimmunodeficiencies
p22079
tp22080
I01
ssg17431
VNot only TLR-2 gene polymorphisms but also immunoglobulins (IgG, IgM, IgA), IgG subsets (G1, G2, G3), and specific antibody levels (anti-tetanus and anti-hemophilus influenza) were determined to exclude humoral immunodeficiencies.
p22081
sg17433
(lp22082
(dp22083
g17436
I65
sg17437
VIgM
p22084
sg17438
I3
sg17439
VP29965
p22085
sg17441
I1
sa(dp22086
g17436
I9
sg17437
VTLR-2 gene
p22087
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp22088
g17436
I70
sg17437
g22078
sg17438
I3
sg17439
VP11912
p22089
sg17441
I1
sa(dp22090
g17436
I43
sg17437
Vimmunoglobulins
p22091
sg17438
I15
sg17439
g12
sg17441
I1
sasg17442
(lp22092
(dp22093
g17436
I165
sg17437
Vinfluenza
p22094
sg17438
I9
sg17445
VC0021400
p22095
sg17441
I1
sa(dp22096
g17436
I211
sg17437
g22079
sg17438
I18
sg17445
VC0021051
p22097
sg17441
I1
sa(dp22098
g17436
I137
sg17437
Vtetanus
p22099
sg17438
I7
sg17445
VC0039614
p22100
sg17441
I1
sasa(dp22101
g17431
VWhile glutamate is not a known OAT4 or OATP2B1 substrate, we propose that its high intracellular concentration has the potential to drive accumulation of substrates from the fetal circulation.
p22102
sg17433
(lp22103
(dp22104
g17436
I39
sg17437
VOATP2B1
p22105
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp22106
g17436
I31
sg17437
VOAT4
p22107
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp22108
sa(dp22109
g17431
VCycling of glutamate across the placenta involving efflux via OAT4 and OATP2B1 and subsequent reuptake will drive placental uptake of organic anions from the fetal circulation.
p22110
sg17433
(lp22111
(dp22112
g17436
I71
sg17437
VOATP2B1
p22113
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp22114
g17436
I62
sg17437
VOAT4
p22115
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp22116
sa(dp22117
g17431
VEfflux transport of olmesartan via OAT4 from syncytiotrophoblasts to the fetal circulation might be facilitated in the presence of an inwardly directed physiological chloride gradient and extracellular DHEAS.
p22118
sg17433
(lp22119
(dp22120
g17436
I35
sg17437
VOAT4
p22121
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp22122
sa(dp22123
g17431
VThis is probably the first case report of cobalamin intracellular metabolism defect (CblC/CblD/CblF/CblJ or ABCD4) presenting as diabetic ketoacidosis.
p22124
sg17433
(lp22125
(dp22126
g17436
I85
sg17437
VCblC
p22127
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp22128
g17436
I108
sg17437
VABCD4
p22129
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22130
g17436
I90
sg17437
VCblD
p22131
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp22132
g17436
I95
sg17437
VCblF
p22133
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp22134
(dp22135
g17436
I129
sg17437
Vdiabetic ketoacidosis
p22136
sg17438
I21
sg17445
VC0011880
p22137
sg17441
I2
sa(dp22138
g17436
I95
sg17437
VCblF
p22139
sg17438
I4
sg17445
VC1848578
p22140
sg17441
I1
sasa(dp22141
g17431
VModerate to severe sensorineural hearing loss and progressive RP characterizes Usher syndrome type IIa (USH2A), which maps to the long arm of chromosome 1q41.
p22142
sg17433
(lp22143
(dp22144
g17436
I104
sg17437
VUSH2A
p22145
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22146
(dp22147
g17436
I104
sg17437
VUSH2A
p22148
sg17438
I5
sg17445
VC1848634
p22149
sg17441
I1
sa(dp22150
g17436
I79
sg17437
VUsher syndrome
p22151
sg17438
I14
sg17445
VC0271097
p22152
sg17441
I2
sa(dp22153
g17436
I19
sg17437
Vsensorineural hearing loss
p22154
sg17438
I26
sg17445
VC0018784
p22155
sg17441
I3
sasa(dp22156
g17431
VUsher syndrome type IIa (OMIM 276901), an autosomal recessive disorder characterized by moderate to severe sensorineural hearing loss and progressive retinitis pigmentosa, maps to the long arm of human chromosome 1q41 between markers AFM268ZD1 and AFM144XF2.
p22157
sg17433
(lp22158
sg17442
(lp22159
(dp22160
g17436
I150
sg17437
Vretinitis pigmentosa
p22161
sg17438
I20
sg17445
VC0035334
p22162
sg17441
I2
sa(dp22163
g17436
I0
sg17437
VUsher syndrome
p22164
sg17438
I14
sg17445
VC0271097
p22165
sg17441
I2
sa(dp22166
g17436
I107
sg17437
Vsensorineural hearing loss
p22167
sg17438
I26
sg17445
VC0018784
p22168
sg17441
I3
sasa(dp22169
g17431
VModerate to severe non-progressive high frequency hearing loss with RP and normal vestibular function describes Usher syndrome type IIa, which has been localized to 1q41.
p22170
sg17433
(lp22171
sg17442
(lp22172
(dp22173
g17436
I35
sg17437
Vhigh frequency hearing loss
p22174
sg17438
I27
sg17445
VC0018780
p22175
sg17441
I4
sa(dp22176
g17436
I112
sg17437
VUsher syndrome
p22177
sg17438
I14
sg17445
VC0271097
p22178
sg17441
I2
sasa(dp22179
g17431
VAs one subtype of the class IIa HDACs, HDAC9 is capable to repress/de-repress their target genes in tumor, inflammation, atherosclerosis and metabolic diseases.
p22180
sg17433
(lp22181
(dp22182
g17436
I22
sg17437
Vclass IIa HDACs
p22183
sg17438
I15
sg17439
g12
sg17441
I3
sa(dp22184
g17436
I39
sg17437
VHDAC9
p22185
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22186
(dp22187
g17436
I100
sg17437
Vtumor
p22188
sg17438
I5
sg17445
VC0027651
p22189
sg17441
I1
sa(dp22190
g17436
I107
sg17437
Vinflammation
p22191
sg17438
I12
sg17445
VC0021368
p22192
sg17441
I1
sa(dp22193
g17436
I141
sg17437
Vmetabolic diseases
p22194
sg17438
I18
sg17445
VC0025517
p22195
sg17441
I2
sa(dp22196
g17436
I121
sg17437
Vatherosclerosis
p22197
sg17438
I15
sg17445
VC0004153
p22198
sg17441
I1
sasa(dp22199
g17431
VTaken together, our data suggest that SNP rs2107595 may contribute to coronary atherosclerosis and CAD risk through a possible mechanism of regulating HDAC9 expression and gene-environment interactions.
p22200
sg17433
(lp22201
(dp22202
g17436
I151
sg17437
VHDAC9
p22203
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22204
(dp22205
g17436
I99
sg17437
VCAD
p22206
sg17438
I3
sg17445
VC0010054
p22207
sg17441
I1
sa(dp22208
g17436
I70
sg17437
Vcoronary atherosclerosis
p22209
sg17438
I24
sg17445
VC0010054
p22210
sg17441
I2
sasa(dp22211
g17431
VThese results suggest that HDAC9 may participate in ox-LDL-induced endothelial damage and inflammation during atherosclerosis development.
p22212
sg17433
(lp22213
(dp22214
g17436
I27
sg17437
VHDAC9
p22215
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22216
(dp22217
g17436
I90
sg17437
Vinflammation
p22218
sg17438
I12
sg17445
VC0021368
p22219
sg17441
I1
sa(dp22220
g17436
I110
sg17437
Vatherosclerosis
p22221
sg17438
I15
sg17445
VC0004153
p22222
sg17441
I1
sasa(dp22223
g17431
VOur results also supported robust associations with ischaemic stroke for four other loci that have been reported in previous studies, including PITX2 (first stage OR 1*39, 1*29-1*49, p=3*26 x 10-19; joint OR 1*37, 1*30-1*45, p=2*79 x 10-32) and ZFHX3 (first stage OR 1*19, 1*11-1*27, p=2*93 x 10-7; joint OR 1*17, 1*11-1*23, p=2*29 x 10-10) for cardioembolic stroke, and HDAC9 (first stage OR 1*29, 1*18-1*42, p=3*50 x 10-8; joint OR 1*24, 1*15-1*33, p=4*52 x 10-9) for large artery atherosclerosis stroke.
p22224
sg17433
(lp22225
(dp22226
g17436
I144
sg17437
VPITX2
p22227
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22228
g17436
I371
sg17437
VHDAC9
p22229
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22230
g17436
I245
sg17437
VZFHX3
p22231
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22232
(dp22233
g17436
I62
sg17437
Vstroke
p22234
sg17438
I6
sg17445
VC0038454
p22235
sg17441
I1
sa(dp22236
g17436
I52
sg17437
Vischaemic stroke
p22237
sg17438
I16
sg17445
VC0948008
p22238
sg17441
I2
sa(dp22239
g17436
I483
sg17437
Vatherosclerosis
p22240
sg17438
I15
sg17445
VC0004153
p22241
sg17441
I1
sa(dp22242
g17436
I345
sg17437
Vcardioembolic stroke
p22243
sg17438
I20
sg17445
VC1531624
p22244
sg17441
I2
sasa(dp22245
g17431
VIn this study, we investigated the candidacy and directionality of HDAC9 in atherosclerosis and analyzed associations between risk alleles at 7p21.1 and plaque characteristics.
p22246
sg17433
(lp22247
(dp22248
g17436
I67
sg17437
VHDAC9
p22249
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22250
(dp22251
g17436
I76
sg17437
Vatherosclerosis
p22252
sg17438
I15
sg17445
VC0004153
p22253
sg17441
I1
sa(dp22254
g17436
I153
sg17437
Vplaque
p22255
sg17438
I6
sg17445
VC0011389
p22256
sg17441
I1
sasa(dp22257
g17431
VTargeted inhibition of HDAC9 might be a viable strategy to prevent atherosclerosis.
p22258
sg17433
(lp22259
(dp22260
g17436
I23
sg17437
VHDAC9
p22261
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22262
(dp22263
g17436
I67
sg17437
Vatherosclerosis
p22264
sg17438
I15
sg17445
VC0004153
p22265
sg17441
I1
sasa(dp22266
g17431
VThe ability of a pulsed oxygen delivery system (Puritan-Bennett Companion Oxygen Saver (COS-5) to track respiratory rate during exercise and the oxygenation achieved during the exercise while oxygen was being delivered by this system was compared to that attained while oxygen was delivered continuously in six patients with chronic obstructive pulmonary disease (COPD) and six patients with idiopathic pulmonary fibrosis (IPF).
p22267
sg17433
(lp22268
sg17442
(lp22269
(dp22270
g17436
I325
sg17437
Vchronic obstructive pulmonary disease
p22271
sg17438
I37
sg17445
VC0024117
p22272
sg17441
I4
sa(dp22273
g17436
I392
sg17437
Vidiopathic pulmonary fibrosis
p22274
sg17438
I29
sg17445
VC3161101
p22275
sg17441
I3
sa(dp22276
g17436
I423
sg17437
VIPF
p22277
sg17438
I3
sg17445
VC3161101
p22278
sg17441
I1
sa(dp22279
g17436
I364
sg17437
VCOPD
p22280
sg17438
I4
sg17445
VC0024117
p22281
sg17441
I1
sasa(dp22282
g135
(dp22283
(VCD14
p22284
Vnon-alcoholic fatty liver disease
p22285
tp22286
I01
ssg17431
VPeripheral blood monocyte surface marker (CD14, CD16, CD163, CSF1R, CCR2, CCR4, CCR5, CXCR3, CXCR4, CX3CR1, HLA-DR, CD62L, SIGLEC-1) expression and capacity for phagocytosis, oxidative burst and LPS-stimulated TNF production were assessed in patients with hepatitis C (HCV) (n = 39) or non-alcoholic fatty liver disease (NAFLD) (n = 34) (classified as non-advanced disease, compensated cirrhosis and decompensated cirrhosis) and healthy controls (n = 11) by flow cytometry.
p22287
sg17433
(lp22288
(dp22289
g17436
I48
sg17437
VCD16
p22290
sg17438
I4
sg17439
VP08637
p22291
sg17441
I1
sa(dp22292
g17436
I100
sg17437
VCX3CR1
p22293
sg17438
I6
sg17439
VP78423
p22294
sg17441
I1
sa(dp22295
g17436
I80
sg17437
VCCR5
p22296
sg17438
I4
sg17439
VP32302
p22297
sg17441
I1
sa(dp22298
g17436
I74
sg17437
VCCR4
p22299
sg17438
I4
sg17439
VP51679
p22300
sg17441
I1
sa(dp22301
g17436
I86
sg17437
VCXCR3
p22302
sg17438
I5
sg17439
VP49682
p22303
sg17441
I1
sa(dp22304
g17436
I54
sg17437
VCD163
p22305
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22306
g17436
I210
sg17437
VTNF
p22307
sg17438
I3
sg17439
VP01375
p22308
sg17441
I1
sa(dp22309
g17436
I61
sg17437
VCSF1R
p22310
sg17438
I5
sg17439
VP09619
p22311
sg17441
I1
sa(dp22312
g17436
I108
sg17437
VHLA-DR
p22313
sg17438
I6
sg17439
VP30486
p22314
sg17441
I1
sa(dp22315
g17436
I93
sg17437
VCXCR4
p22316
sg17438
I5
sg17439
VP61073
p22317
sg17441
I1
sa(dp22318
g17436
I123
sg17437
VSIGLEC-1
p22319
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp22320
g17436
I116
sg17437
VCD62L
p22321
sg17438
I5
sg17439
VP14151
p22322
sg17441
I1
sa(dp22323
g17436
I68
sg17437
VCCR2
p22324
sg17438
I4
sg17439
VP41597
p22325
sg17441
I1
sa(dp22326
g17436
I42
sg17437
g22284
sg17438
I4
sg17439
VP08571
p22327
sg17441
I1
sasg17442
(lp22328
(dp22329
g17436
I374
sg17437
Vcompensated cirrhosis
p22330
sg17438
I21
sg17445
VC1608426
p22331
sg17441
I2
sa(dp22332
g17436
I400
sg17437
Vdecompensated cirrhosis
p22333
sg17438
I23
sg17445
VC1619727
p22334
sg17441
I2
sa(dp22335
g17436
I321
sg17437
VNAFLD
p22336
sg17438
I5
sg17445
VC0400966
p22337
sg17441
I1
sa(dp22338
g17436
I195
sg17437
VLPS
p22339
sg17438
I3
sg17445
VC0175697
p22340
sg17441
I1
sa(dp22341
g17436
I256
sg17437
Vhepatitis C
p22342
sg17438
I11
sg17445
VC0019196
p22343
sg17441
I2
sa(dp22344
g17436
I286
sg17437
g22285
sg17438
I33
sg17445
VC0400966
p22345
sg17441
I4
sasa(dp22346
g17431
VSoluble CD163 (sCD163), a marker of Kupffer cell activation detectable in serum, correlates with inflammation and fibrosis in chronic viral hepatitis, but its role in nonalcoholic fatty liver disease is unknown.
p22347
sg17433
(lp22348
(dp22349
g17436
I15
sg17437
VsCD163
p22350
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp22351
g17436
I0
sg17437
VSoluble CD163
p22352
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp22353
(dp22354
g17436
I126
sg17437
Vchronic viral hepatitis
p22355
sg17438
I23
sg17445
VC0276623
p22356
sg17441
I3
sa(dp22357
g17436
I114
sg17437
Vfibrosis
p22358
sg17438
I8
sg17445
VC0016059
p22359
sg17441
I1
sa(dp22360
g17436
I97
sg17437
Vinflammation
p22361
sg17438
I12
sg17445
VC0021368
p22362
sg17441
I1
sa(dp22363
g17436
I167
sg17437
Vnonalcoholic fatty liver disease
p22364
sg17438
I32
sg17445
VC0400966
p22365
sg17441
I4
sasa(dp22366
g17431
VWe hypothesized that sCD163 would correlate with nonalcoholic fatty liver disease activity and fibrosis.
p22367
sg17433
(lp22368
(dp22369
g17436
I21
sg17437
VsCD163
p22370
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp22371
(dp22372
g17436
I49
sg17437
Vnonalcoholic fatty liver disease
p22373
sg17438
I32
sg17445
VC0400966
p22374
sg17441
I4
sa(dp22375
g17436
I95
sg17437
Vfibrosis
p22376
sg17438
I8
sg17445
VC0016059
p22377
sg17441
I1
sasa(dp22378
g17431
Vdermatoses presenting with erythematous-desquamative patches/plaques (plaque psoriasis, eczematous dermatitis, pityriasis rosea, mycosis fungoides and subacute cutaneous lupus erythematosus), papulosquamous/papulokeratotic dermatoses (lichen planus, pityriasis rosea, papulosquamous sarcoidosis, guttate psoriasis, pityriasis lichenoides chronica, classical pityriasis rubra pilaris, porokeratosis, lymphomatoid papulosis, papulosquamous chronic GVHD, parakeratosis variegata, Grover disease, Darier disease and BRAF-inhibitor-induced acantholytic dyskeratosis), facial inflammatory skin diseases (rosacea, seborrheic dermatitis, discoid lupus erythematosus, sarcoidosis, cutaneous leishmaniasis, lupus vulgaris, granuloma faciale and demodicidosis), acquired keratodermas (chronic hand eczema, palmar psoriasis, keratoderma due to mycosis fungoides, keratoderma resulting from pityriasis rubra pilaris, tinea manuum, palmar lichen planus and aquagenic palmar keratoderma), sclero-atrophic dermatoses (necrobiosis lipoidica, morphea and cutaneous lichen sclerosus), hypopigmented macular diseases (extragenital guttate lichen sclerosus, achromic pityriasis versicolor, guttate vitiligo, idiopathic guttate hypomelanosis, progressive macular hypomelanosis and postinflammatory hypopigmentations), hyperpigmented maculopapular diseases (pityriasis versicolor, lichen planus pigmentosus, Gougerot-Carteaud syndrome, Dowling-Degos disease, erythema ab igne, macular amyloidosis, lichen amyloidosus, friction melanosis, terra firma-forme dermatosis, urticaria pigmentosa and telangiectasia macularis eruptiva perstans), itchy papulonodular dermatoses (hypertrophic lichen planus, prurigo nodularis, nodular scabies and acquired perforating dermatosis), erythrodermas (due to psoriasis, atopic dermatitis, mycosis fungoides, pityriasis rubra pilaris and scabies), noninfectious balanitis (Zoon's plasma cell balanitis, psoriatic balanitis, seborrheic dermatitis and non-specific balanitis) and erythroplasia of Queyrat, inflammatory cicatricial alopecias (scalp discoid lupus erythematosus, lichen planopilaris, frontal fibrosing alopecia and folliculitis decalvans), nonscarring alopecias (alopecia areata, trichotillomania, androgenetic alopecia and telogen effluvium) and scaling disorders of the scalp (tinea capitis, scalp psoriasis, seborrheic dermatitis and pityriasis amiantacea).
p22379
sg17433
(lp22380
sg17442
(lp22381
(dp22382
g17436
I77
sg17437
Vpsoriasis
p22383
sg17438
I9
sg17445
VC0033860
p22384
sg17441
I1
sa(dp22385
g17436
I88
sg17437
Veczematous dermatitis
p22386
sg17438
I21
sg17445
VC0013595
p22387
sg17441
I2
sa(dp22388
g17436
I607
sg17437
Vseborrheic dermatitis
p22389
sg17438
I21
sg17445
VC0036508
p22390
sg17441
I2
sa(dp22391
g17436
I2316
sg17437
Vscalp psoriasis
p22392
sg17438
I15
sg17445
VC0406326
p22393
sg17441
I2
sa(dp22394
g17436
I129
sg17437
Vmycosis fungoides
p22395
sg17438
I17
sg17445
VC0026948
p22396
sg17441
I2
sa(dp22397
g17436
I358
sg17437
Vpityriasis rubra pilaris
p22398
sg17438
I24
sg17445
VC0032027
p22399
sg17441
I3
sa(dp22400
g17436
I1413
sg17437
VDowling-Degos disease
p22401
sg17438
I21
sg17445
VC0406811
p22402
sg17441
I2
sa(dp22403
g17436
I235
sg17437
Vlichen planus
p22404
sg17438
I13
sg17445
VC0023646
p22405
sg17441
I2
sa(dp22406
g17436
I1111
sg17437
Vguttate lichen sclerosus
p22407
sg17438
I24
sg17445
VC0406644
p22408
sg17441
I3
sa(dp22409
g17436
I1694
sg17437
Vnodular scabies
p22410
sg17438
I15
sg17445
VC0344064
p22411
sg17441
I2
sa(dp22412
g17436
I1177
sg17437
Vvitiligo
p22413
sg17438
I8
sg17445
VC0042900
p22414
sg17441
I1
sa(dp22415
g17436
I1723
sg17437
Vperforating dermatosis
p22416
sg17438
I22
sg17445
VC1304435
p22417
sg17441
I2
sa(dp22418
g17436
I283
sg17437
Vsarcoidosis
p22419
sg17438
I11
sg17445
VC0036202
p22420
sg17441
I1
sa(dp22421
g17436
I1025
sg17437
Vmorphea
p22422
sg17438
I7
sg17445
VC0036420
p22423
sg17441
I1
sa(dp22424
g17436
I0
sg17437
Vdermatoses
p22425
sg17438
I10
sg17445
VC0037274
p22426
sg17441
I1
sa(dp22427
g17436
I2301
sg17437
Vtinea capitis
p22428
sg17438
I13
sg17445
VC0040250
p22429
sg17441
I2
sa(dp22430
g17436
I1146
sg17437
Vpityriasis versicolor
p22431
sg17438
I21
sg17445
VC0040262
p22432
sg17441
I2
sa(dp22433
g17436
I981
sg17437
Vatrophic
p22434
sg17438
I8
sg17445
VC0333641
p22435
sg17441
I1
sa(dp22436
g17436
I2185
sg17437
Valopecia areata
p22437
sg17438
I15
sg17445
VC0002171
p22438
sg17441
I2
sa(dp22439
g17436
I1475
sg17437
Vlichen amyloidosus
p22440
sg17438
I18
sg17445
VC0268397
p22441
sg17441
I2
sa(dp22442
g17436
I630
sg17437
Vdiscoid lupus erythematosus
p22443
sg17438
I27
sg17445
VC0024138
p22444
sg17441
I3
sa(dp22445
g17436
I774
sg17437
Vchronic hand eczema
p22446
sg17438
I19
sg17445
VC1276092
p22447
sg17441
I3
sa(dp22448
g17436
I2106
sg17437
Vfrontal fibrosing alopecia
p22449
sg17438
I26
sg17445
VC1274700
p22450
sg17441
I3
sa(dp22451
g17436
I1462
sg17437
Vamyloidosis
p22452
sg17438
I11
sg17445
VC0002726
p22453
sg17441
I1
sa(dp22454
g17436
I1146
sg17437
Vpityriasis versicolor
p22455
sg17438
I21
sg17445
VC0040262
p22456
sg17441
I2
sa(dp22457
g17436
I713
sg17437
Vgranuloma faciale
p22458
sg17438
I17
sg17445
VC0239495
p22459
sg17441
I2
sa(dp22460
g17436
I1988
sg17437
Verythroplasia of Queyrat
p22461
sg17438
I24
sg17445
VC0154089
p22462
sg17441
I3
sa(dp22463
g17436
I672
sg17437
Vcutaneous leishmaniasis
p22464
sg17438
I23
sg17445
VC0023283
p22465
sg17441
I2
sa(dp22466
g17436
I0
sg17437
Vdermatoses
p22467
sg17438
I10
sg17445
VC0037274
p22468
sg17441
I1
sa(dp22469
g17436
I151
sg17437
Vsubacute cutaneous lupus erythematosus
p22470
sg17438
I38
sg17445
VC0024140
p22471
sg17441
I4
sa(dp22472
g17436
I1570
sg17437
Vtelangiectasia macularis eruptiva perstans
p22473
sg17438
I42
sg17445
VC0263402
p22474
sg17441
I4
sa(dp22475
g17436
I0
sg17437
Vdermatoses
p22476
sg17438
I10
sg17445
VC0037274
p22477
sg17441
I1
sa(dp22478
g17436
I607
sg17437
Vseborrheic dermatitis
p22479
sg17438
I21
sg17445
VC0036508
p22480
sg17441
I2
sa(dp22481
g17436
I1436
sg17437
Verythema ab igne
p22482
sg17438
I16
sg17445
VC0494853
p22483
sg17441
I3
sa(dp22484
g17436
I77
sg17437
Vpsoriasis
p22485
sg17438
I9
sg17445
VC0033860
p22486
sg17441
I1
sa(dp22487
g17436
I1702
sg17437
Vscabies
p22488
sg17438
I7
sg17445
VC0036262
p22489
sg17441
I1
sa(dp22490
g17436
I358
sg17437
Vpityriasis rubra pilaris
p22491
sg17438
I24
sg17445
VC0032027
p22492
sg17441
I3
sa(dp22493
g17436
I399
sg17437
Vlymphomatoid papulosis
p22494
sg17438
I22
sg17445
VC0206182
p22495
sg17441
I2
sa(dp22496
g17436
I0
sg17437
Vdermatoses
p22497
sg17438
I10
sg17445
VC0037274
p22498
sg17441
I1
sa(dp22499
g17436
I1206
sg17437
Vhypomelanosis
p22500
sg17438
I13
sg17445
VC0162835
p22501
sg17441
I1
sa(dp22502
g17436
I607
sg17437
Vseborrheic dermatitis
p22503
sg17438
I21
sg17445
VC0036508
p22504
sg17441
I2
sa(dp22505
g17436
I760
sg17437
Vkeratoderma
p22506
sg17438
I11
sg17445
VC0022579
p22507
sg17441
I1
sa(dp22508
g17436
I1187
sg17437
Vidiopathic guttate hypomelanosis
p22509
sg17438
I32
sg17445
VC0263583
p22510
sg17441
I3
sa(dp22511
g17436
I1647
sg17437
Vhypertrophic lichen planus
p22512
sg17438
I26
sg17445
VC0023649
p22513
sg17441
I3
sa(dp22514
g17436
I1358
sg17437
Vlichen planus pigmentosus
p22515
sg17438
I25
sg17445
VC0406366
p22516
sg17441
I3
sa(dp22517
g17436
I598
sg17437
Vrosacea
p22518
sg17438
I7
sg17445
VC0035854
p22519
sg17441
I1
sa(dp22520
g17436
I1002
sg17437
Vnecrobiosis lipoidica
p22521
sg17438
I21
sg17445
VC0027538
p22522
sg17441
I2
sa(dp22523
g17436
I1047
sg17437
Vlichen sclerosus
p22524
sg17438
I16
sg17445
VC0023652
p22525
sg17441
I2
sa(dp22526
g17436
I2202
sg17437
Vtrichotillomania
p22527
sg17438
I16
sg17445
VC0040953
p22528
sg17441
I1
sa(dp22529
g17436
I2246
sg17437
Vtelogen effluvium
p22530
sg17438
I17
sg17445
VC0263518
p22531
sg17441
I2
sa(dp22532
g17436
I111
sg17437
Vpityriasis rosea
p22533
sg17438
I16
sg17445
VC0032026
p22534
sg17441
I2
sa(dp22535
g17436
I1872
sg17437
Vbalanitis
p22536
sg17438
I9
sg17445
VC0004690
p22537
sg17441
I1
sa(dp22538
g17436
I760
sg17437
Vkeratoderma
p22539
sg17438
I11
sg17445
VC0022579
p22540
sg17441
I1
sa(dp22541
g17436
I2085
sg17437
Vlichen planopilaris
p22542
sg17438
I19
sg17445
VC0023645
p22543
sg17441
I2
sa(dp22544
g17436
I315
sg17437
Vpityriasis lichenoides chronica
p22545
sg17438
I31
sg17445
VC0162851
p22546
sg17441
I3
sa(dp22547
g17436
I452
sg17437
Vparakeratosis variegata
p22548
sg17438
I23
sg17445
VC0030437
p22549
sg17441
I2
sa(dp22550
g17436
I2137
sg17437
Vfolliculitis decalvans
p22551
sg17438
I22
sg17445
VC0263503
p22552
sg17441
I2
sa(dp22553
g17436
I1615
sg17437
Vitchy
p22554
sg17438
I5
sg17445
VC0033774
p22555
sg17441
I1
sa(dp22556
g17436
I235
sg17437
Vlichen planus
p22557
sg17438
I13
sg17445
VC0023646
p22558
sg17441
I2
sa(dp22559
g17436
I129
sg17437
Vmycosis fungoides
p22560
sg17438
I17
sg17445
VC0026948
p22561
sg17441
I2
sa(dp22562
g17436
I548
sg17437
Vdyskeratosis
p22563
sg17438
I12
sg17445
VC0334061
p22564
sg17441
I1
sa(dp22565
g17436
I358
sg17437
Vpityriasis rubra pilaris
p22566
sg17438
I24
sg17445
VC0032027
p22567
sg17441
I3
sa(dp22568
g17436
I1385
sg17437
VGougerot-Carteaud syndrome
p22569
sg17438
I26
sg17445
VC0263385
p22570
sg17441
I2
sa(dp22571
g17436
I2220
sg17437
Vandrogenetic alopecia
p22572
sg17438
I21
sg17445
VC0162311
p22573
sg17441
I2
sa(dp22574
g17436
I484
sg17437
Vdisease, Darier
p22575
sg17438
I15
sg17445
VC0022595
p22576
sg17441
I2
sa(dp22577
g17436
I1545
sg17437
Vurticaria pigmentosa
p22578
sg17438
I20
sg17445
VC0042111
p22579
sg17441
I2
sa(dp22580
g17436
I1872
sg17437
Vbalanitis
p22581
sg17438
I9
sg17445
VC0004690
p22582
sg17441
I1
sa(dp22583
g17436
I438
sg17437
Vchronic GVHD
p22584
sg17438
I12
sg17445
VC0867389
p22585
sg17441
I2
sa(dp22586
g17436
I697
sg17437
Vlupus vulgaris
p22587
sg17438
I14
sg17445
VC0024131
p22588
sg17441
I2
sa(dp22589
g17436
I384
sg17437
Vporokeratosis
p22590
sg17438
I13
sg17445
VC0162839
p22591
sg17441
I1
sa(dp22592
g17436
I904
sg17437
Vtinea manuum
p22593
sg17438
I12
sg17445
VC0153246
p22594
sg17441
I2
sa(dp22595
g17436
I70
sg17437
Vplaque psoriasis
p22596
sg17438
I16
sg17445
VC0406317
p22597
sg17441
I2
sa(dp22598
g17436
I1675
sg17437
Vprurigo nodularis
p22599
sg17438
I17
sg17445
VC0263353
p22600
sg17441
I2
sa(dp22601
g17436
I1781
sg17437
Vatopic dermatitis
p22602
sg17438
I17
sg17445
VC0011615
p22603
sg17441
I2
sa(dp22604
g17436
I1748
sg17437
Verythrodermas
p22605
sg17438
I13
sg17445
VC0011606
p22606
sg17441
I1
sa(dp22607
g17436
I583
sg17437
Vskin diseases
p22608
sg17438
I13
sg17445
VC0037274
p22609
sg17441
I2
sa(dp22610
g17436
I2359
sg17437
Vpityriasis amiantacea
p22611
sg17438
I21
sg17445
VC0343100
p22612
sg17441
I2
sa(dp22613
g17436
I283
sg17437
Vsarcoidosis
p22614
sg17438
I11
sg17445
VC0036202
p22615
sg17441
I1
sa(dp22616
g17436
I1515
sg17437
Vterra firma-forme dermatosis
p22617
sg17438
I28
sg17445
VC2721650
p22618
sg17441
I3
sa(dp22619
g17436
I111
sg17437
Vpityriasis rosea
p22620
sg17438
I16
sg17445
VC0032026
p22621
sg17441
I2
sa(dp22622
g17436
I630
sg17437
Vdiscoid lupus erythematosus
p22623
sg17438
I27
sg17445
VC0024138
p22624
sg17441
I3
sa(dp22625
g17436
I1210
sg17437
Vmelanosis
p22626
sg17438
I9
sg17445
VC0221391
p22627
sg17441
I1
sa(dp22628
g17436
I61
sg17437
Vplaques
p22629
sg17438
I7
sg17445
VC0333463
p22630
sg17441
I1
sa(dp22631
g17436
I129
sg17437
Vmycosis fungoides
p22632
sg17438
I17
sg17445
VC0026948
p22633
sg17441
I2
sa(dp22634
g17436
I1890
sg17437
Vplasma cell balanitis
p22635
sg17438
I21
sg17445
VC0403761
p22636
sg17441
I3
sa(dp22637
g17436
I296
sg17437
Vguttate psoriasis
p22638
sg17438
I17
sg17445
VC0343052
p22639
sg17441
I2
sa(dp22640
g17436
I760
sg17437
Vkeratoderma
p22641
sg17438
I11
sg17445
VC0022579
p22642
sg17441
I1
sa(dp22643
g17436
I1872
sg17437
Vbalanitis
p22644
sg17438
I9
sg17445
VC0004690
p22645
sg17441
I1
sa(dp22646
g17436
I760
sg17437
Vkeratodermas
p22647
sg17438
I12
sg17445
VC0022579
p22648
sg17441
I1
sasa(dp22649
g17431
VKaposi varicelliform eruption or eczema herpeticum is well known to be associated with several chronic dermatoses, including atopic dermatitis, foliaceus pemphigus, seborrheic dermatitis, Darier disease, and congenital ichthyosiform erythroderma.
p22650
sg17433
(lp22651
sg17442
(lp22652
(dp22653
g17436
I208
sg17437
Vcongenital ichthyosiform erythroderma
p22654
sg17438
I37
sg17445
VC0079583
p22655
sg17441
I3
sa(dp22656
g17436
I0
sg17437
VKaposi varicelliform eruption
p22657
sg17438
I29
sg17445
VC0022504
p22658
sg17441
I3
sa(dp22659
g17436
I165
sg17437
Vseborrheic dermatitis
p22660
sg17438
I21
sg17445
VC0036508
p22661
sg17441
I2
sa(dp22662
g17436
I188
sg17437
VDarier disease
p22663
sg17438
I14
sg17445
VC0022595
p22664
sg17441
I2
sa(dp22665
g17436
I154
sg17437
Vpemphigus
p22666
sg17438
I9
sg17445
VC0030807
p22667
sg17441
I1
sa(dp22668
g17436
I103
sg17437
Vdermatoses
p22669
sg17438
I10
sg17445
VC0037274
p22670
sg17441
I1
sa(dp22671
g17436
I33
sg17437
Veczema herpeticum
p22672
sg17438
I17
sg17445
VC0936250
p22673
sg17441
I2
sa(dp22674
g17436
I125
sg17437
Vatopic dermatitis
p22675
sg17438
I17
sg17445
VC0011615
p22676
sg17441
I2
sasa(dp22677
g17431
VMCI-186, a dose that prevents ischemic brain edema, had no significant effect on brain concentrations of dopamine, norepinephrine, 5-hydroxytryptamine, or their metabolites.
p22678
sg17433
(lp22679
sg17442
(lp22680
(dp22681
g17436
I39
sg17437
Vbrain edema
p22682
sg17438
I11
sg17445
VC1527311
p22683
sg17441
I2
sa(dp22684
g17436
I0
sg17437
VMCI
p22685
sg17438
I3
sg17445
VC1270972
p22686
sg17441
I1
sasa(dp22687
g17431
VPretreatments with dexamethasone, parachlorophenylalanine (an inhibitor of 5-hydroxytryptamine synthesis), mepyramine and metiamide (H1 and H2 histamine receptor antagonists) or aminophylline did not influence significantly the development of brain edema evaluated 24 h after embolization.
p22688
sg17433
(lp22689
(dp22690
g17436
I140
sg17437
VH2 histamine receptor
p22691
sg17438
I21
sg17439
g12
sg17441
I3
sasg17442
(lp22692
(dp22693
g17436
I243
sg17437
Vbrain edema
p22694
sg17438
I11
sg17445
VC1527311
p22695
sg17441
I2
sasa(dp22696
g135
(dp22697
(Vmature protein-1
p22698
Vmultiple myeloma
p22699
tp22700
I00
ssg17431
VTo study the effect of B lymphocyte-induced mature protein-1(Blimp1) expression in bone marrow mononuclear cells on the prognosis of patients with multiple myeloma.
p22701
sg17433
(lp22702
(dp22703
g17436
I61
sg17437
VBlimp1
p22704
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp22705
g17436
I44
sg17437
g22698
sg17438
I16
sg17439
VP17980
p22706
sg17441
I2
sasg17442
(lp22707
(dp22708
g17436
I147
sg17437
g22699
sg17438
I16
sg17445
VC0026764
p22709
sg17441
I2
sasa(dp22710
g135
(dp22711
(Vc-MYC
p22712
Vmyeloma
p22713
tp22714
I00
ssg17431
VHere we further dissect the anti-myeloma mechanisms mediated by EZH2 inhibition and show that pharmacological inhibition of EZH2 reduces the expression of MM-associated oncogenes; IRF-4, XBP-1, PRDM1/BLIMP-1 and c-MYC.
p22715
sg17433
(lp22716
(dp22717
g17436
I64
sg17437
VEZH2
p22718
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp22719
g17436
I187
sg17437
VXBP-1
p22720
sg17438
I5
sg17439
VP17861
p22721
sg17441
I1
sa(dp22722
g17436
I64
sg17437
VEZH2
p22723
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp22724
g17436
I194
sg17437
VPRDM1
p22725
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22726
g17436
I212
sg17437
g22712
sg17438
I5
sg17439
VP12524
p22727
sg17441
I1
sa(dp22728
g17436
I200
sg17437
VBLIMP-1
p22729
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp22730
g17436
I180
sg17437
VIRF-4
p22731
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22732
(dp22733
g17436
I33
sg17437
g22713
sg17438
I7
sg17445
VC0026764
p22734
sg17441
I1
sasa(dp22735
g135
(dp22736
(Vmaturation protein-1
p22737
Vmultiple myeloma
p22738
tp22739
I00
ssg17431
VTo investigate the expression level of B lymphocyte-induced maturation protein-1(Blimp-1) mRNA in bone marrow mononuclear cells(BMMNC) of multiple myeloma(MM) patients and its clinical significance.
p22740
sg17433
(lp22741
(dp22742
g17436
I60
sg17437
g22737
sg17438
I20
sg17439
VP17980
p22743
sg17441
I2
sasg17442
(lp22744
(dp22745
g17436
I138
sg17437
g22738
sg17438
I16
sg17445
VC0026764
p22746
sg17441
I2
sasa(dp22747
g135
(dp22748
(VXBP-1
p22749
Vmyeloma
p22750
tp22751
I00
ssg17431
VMeanwhile, plasma could promote myeloma differentiation by up-regulating Blimp-1 and XBP-1 expression.
p22752
sg17433
(lp22753
(dp22754
g17436
I85
sg17437
g22749
sg17438
I5
sg17439
VP17861
p22755
sg17441
I1
sa(dp22756
g17436
I73
sg17437
VBlimp-1
p22757
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp22758
(dp22759
g17436
I32
sg17437
g22750
sg17438
I7
sg17445
VC0026764
p22760
sg17441
I1
sasa(dp22761
g17431
VHowever, how Blimp-1 ensures the survival of plasma cell malignancy, multiple myeloma (MM), has remained elusive.
p22762
sg17433
(lp22763
sg17442
(lp22764
(dp22765
g17436
I57
sg17437
Vmalignancy
p22766
sg17438
I10
sg17445
VC0006826
p22767
sg17441
I1
sa(dp22768
g17436
I69
sg17437
Vmultiple myeloma
p22769
sg17438
I16
sg17445
VC0026764
p22770
sg17441
I2
sasa(dp22771
g17431
VThe finding that Blimp-1/PRDM1 enhances transcription of CS1 gene in multiple myeloma cells may help in developing novel strategies for therapeutic intervention in multiple myeloma.
p22772
sg17433
(lp22773
(dp22774
g17436
I57
sg17437
VCS1 gene
p22775
sg17438
I8
sg17439
g12
sg17441
I2
sa(dp22776
g17436
I17
sg17437
VBlimp-1
p22777
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp22778
g17436
I25
sg17437
VPRDM1
p22779
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22780
(dp22781
g17436
I69
sg17437
Vmultiple myeloma
p22782
sg17438
I16
sg17445
VC0026764
p22783
sg17441
I2
sa(dp22784
g17436
I69
sg17437
Vmultiple myeloma
p22785
sg17438
I16
sg17445
VC0026764
p22786
sg17441
I2
sasa(dp22787
g17431
VLhx9 is an LIM (named for the first three proteins in which the domain was found, Lin-11, Isl1 and Mec-3) homeodomain protein involved in development and differentiation of the gonad.
p22788
sg17433
(lp22789
(dp22790
g17436
I106
sg17437
Vhomeodomain
p22791
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp22792
g17436
I99
sg17437
VMec-3
p22793
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22794
g17436
I11
sg17437
VLIM
p22795
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp22796
g17436
I90
sg17437
VIsl1
p22797
sg17438
I4
sg17439
VP61371
p22798
sg17441
I1
sa(dp22799
g17436
I0
sg17437
VLhx9
p22800
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp22801
sa(dp22802
g17431
VWe report that CCRL2-deficient mice have a defect in neutrophil recruitment and are protected in 2 models of inflammatory arthritis.
p22803
sg17433
(lp22804
(dp22805
g17436
I15
sg17437
VCCRL2
p22806
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp22807
(dp22808
g17436
I64
sg17437
Vrecruitment
p22809
sg17438
I11
sg17445
VC0271510
p22810
sg17441
I1
sa(dp22811
g17436
I109
sg17437
Vinflammatory arthritis
p22812
sg17438
I22
sg17445
VC0003864
p22813
sg17441
I2
sasa(dp22814
g17431
VThe concurrence of PJS and feminizing SCTs of the testes is an increasingly recognized cause of prepubertal gynecomastia.
p22815
sg17433
(lp22816
(dp22817
g17436
I19
sg17437
VPJS and feminizing SCTs
p22818
sg17438
I23
sg17439
g12
sg17441
I4
sasg17442
(lp22819
(dp22820
g17436
I38
sg17437
VSCTs
p22821
sg17438
I4
sg17445
VC0796149
p22822
sg17441
I1
sa(dp22823
g17436
I108
sg17437
Vgynecomastia
p22824
sg17438
I12
sg17445
VC0018418
p22825
sg17441
I1
sa(dp22826
g17436
I19
sg17437
VPJS
p22827
sg17438
I3
sg17445
VC0031269
p22828
sg17441
I1
sasa(dp22829
g135
(dp22830
(VG11-4.5
p22831
VCVID
p22832
tp22833
I00
ssg17431
VMost IgAD and CVID patients in our clinic population in the Southeastern United States have inherited part or all of two extended MHC haplotypes, referred to as haplotype 1 (HLA-DQB1 0201, HLA-DR3, C4B-Sf, C4A-0, G1-15, Bf-0.4, C2-a, HSP-7.5, TNF alpha-5, HLA-B8, HLA-A1) and haplotype 2 (HLA-DQB1 0201, HLA-DR-7, C4B-S, C4A-L, G11-4.5, Bf-0.6, C2-b, HSP-9, TNF alpha-9, HLA-B44, HLA-A29).
p22834
sg17433
(lp22835
(dp22836
g17436
I371
sg17437
VHLA-B44
p22837
sg17438
I7
sg17439
VP30486
p22838
sg17441
I1
sa(dp22839
g17436
I243
sg17437
VTNF alpha-5
p22840
sg17438
I11
sg17439
VP01375
p22841
sg17441
I2
sa(dp22842
g17436
I351
sg17437
VHSP-9
p22843
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22844
g17436
I358
sg17437
VTNF alpha-9
p22845
sg17438
I11
sg17439
VP01375
p22846
sg17441
I2
sa(dp22847
g17436
I174
sg17437
VHLA-DQB1 0201
p22848
sg17438
I13
sg17439
VP09471
p22849
sg17441
I2
sa(dp22850
g17436
I380
sg17437
VHLA-A29
p22851
sg17438
I7
sg17439
VP30486
p22852
sg17441
I1
sa(dp22853
g17436
I130
sg17437
VMHC haplotypes
p22854
sg17438
I14
sg17439
VP13747
p22855
sg17441
I2
sa(dp22856
g17436
I198
sg17437
VC4B
p22857
sg17438
I3
sg17439
VP04003
p22858
sg17441
I1
sa(dp22859
g17436
I189
sg17437
VHLA-DR3
p22860
sg17438
I7
sg17439
VP30486
p22861
sg17441
I1
sa(dp22862
g17436
I198
sg17437
VC4B-S
p22863
sg17438
I5
sg17439
VP04003
p22864
sg17441
I1
sa(dp22865
g17436
I234
sg17437
VHSP-7.5
p22866
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp22867
g17436
I304
sg17437
VHLA-DR-7
p22868
sg17438
I8
sg17439
VP30486
p22869
sg17441
I1
sa(dp22870
g17436
I256
sg17437
VHLA-B8
p22871
sg17438
I6
sg17439
VP30486
p22872
sg17441
I1
sa(dp22873
g17436
I174
sg17437
VHLA-DQB1 0201
p22874
sg17438
I13
sg17439
VP09471
p22875
sg17441
I2
sa(dp22876
g17436
I328
sg17437
g22831
sg17438
I7
sg17439
VP56715
p22877
sg17441
I1
sasg17442
(lp22878
(dp22879
g17436
I234
sg17437
VHSP
p22880
sg17438
I3
sg17445
VC0034152
p22881
sg17441
I1
sa(dp22882
g17436
I234
sg17437
VHSP
p22883
sg17438
I3
sg17445
VC0034152
p22884
sg17441
I1
sa(dp22885
g17436
I14
sg17437
g22832
sg17438
I4
sg17445
VC0009447
p22886
sg17441
I1
sasa(dp22887
g135
(dp22888
(Vsteroid 21-hydroxylase
p22889
VIgA deficiency
p22890
tp22891
I01
ssg17431
VIn search of a genetic linkage between the two immunodeficiencies, we examined the major histocompatibility complex (MHC) class III genes encoding complement components C2, C4A, and C4B and steroid 21-hydroxylase in addition to the HLA serotypes in individuals with either common variable immunodeficiency or IgA deficiency.
p22892
sg17433
(lp22893
(dp22894
g17436
I232
sg17437
VHLA
p22895
sg17438
I3
sg17439
VP30486
p22896
sg17441
I1
sa(dp22897
g17436
I309
sg17437
VIgA
p22898
sg17438
I3
sg17439
VP11912
p22899
sg17441
I1
sa(dp22900
g17436
I182
sg17437
VC4B
p22901
sg17438
I3
sg17439
VP04003
p22902
sg17441
I1
sa(dp22903
g17436
I190
sg17437
g22889
sg17438
I22
sg17439
VP08686
p22904
sg17441
I2
sa(dp22905
g17436
I83
sg17437
Vmajor histocompatibility complex (MHC) class III genes encoding complement
p22906
sg17438
I74
sg17439
g12
sg17441
I9
sasg17442
(lp22907
(dp22908
g17436
I47
sg17437
Vimmunodeficiencies
p22909
sg17438
I18
sg17445
VC0021051
p22910
sg17441
I1
sa(dp22911
g17436
I273
sg17437
Vcommon variable immunodeficiency
p22912
sg17438
I32
sg17445
VC0009447
p22913
sg17441
I3
sa(dp22914
g17436
I309
sg17437
g22890
sg17438
I14
sg17445
VC0162538
p22915
sg17441
I2
sasa(dp22916
g135
(dp22917
(VIgA
p22918
VIgA deficiency
p22919
tp22920
I00
ssg17431
VTwelve of 19 patients with common variable immunodeficiency (63%, P less than 0.001) and 9 of 16 patients with IgA deficiency (56%, P less than 0.01) had rare C2 alleles and/or C4A and 21-hydroxylase A deletions, whereas these gene features were seen in only 5 of 34 healthy individuals (15%) in the control group.
p22921
sg17433
(lp22922
(dp22923
g17436
I185
sg17437
V21-hydroxylase A
p22924
sg17438
I16
sg17439
VP08686
p22925
sg17441
I2
sa(dp22926
g17436
I111
sg17437
g22918
sg17438
I3
sg17439
VP11912
p22927
sg17441
I1
sasg17442
(lp22928
(dp22929
g17436
I27
sg17437
Vcommon variable immunodeficiency
p22930
sg17438
I32
sg17445
VC0009447
p22931
sg17441
I3
sa(dp22932
g17436
I111
sg17437
g22919
sg17438
I14
sg17445
VC0162538
p22933
sg17441
I2
sasa(dp22934
g17431
VTotally implantable venous access port (TIVAP)-related infections (RIs) remain a serious health problem in cancer patients receiving an intravenous (i.v.)
p22935
sg17433
(lp22936
sg17442
(lp22937
(dp22938
g17436
I107
sg17437
Vcancer
p22939
sg17438
I6
sg17445
VC0006826
p22940
sg17441
I1
sa(dp22941
g17436
I55
sg17437
Vinfections
p22942
sg17438
I10
sg17445
VC0021311
p22943
sg17441
I1
sasa(dp22944
g17431
VFurthermore, we provided a RIs-based algorithm for biomarker discovery and validation to screen for diseases such as cancer.
p22945
sg17433
(lp22946
sg17442
(lp22947
(dp22948
g17436
I117
sg17437
Vcancer
p22949
sg17438
I6
sg17445
VC0006826
p22950
sg17441
I1
sasa(dp22951
g17431
VThe first survey, sent to 94 cancer control and supportive care responsible individuals (CCL RIs) at 94 COG institutions, asked if the institution had a standardized approach to practice and focused on antiemetic agent choice.
p22952
sg17433
(lp22953
sg17442
(lp22954
(dp22955
g17436
I29
sg17437
Vcancer
p22956
sg17438
I6
sg17445
VC0006826
p22957
sg17441
I1
sa(dp22958
g17436
I89
sg17437
VCCL
p22959
sg17438
I3
sg17445
VC1852438
p22960
sg17441
I1
sasa(dp22961
g135
(dp22962
(VS100A4
p22963
VSMA
p22964
tp22965
I00
ssg17431
VLiver sections from patients with biliary atresia were evaluated to detect antigen for the BECs marker 4 and cytokeratin-7 (CK-7), proteins (fibroblast-specific protein 1, also known S100A4; the collagen chaperone heat shock protein 47, HSP47) characteristically expressed by cells undergoing EMT, as well as myofibroblasts marker a-smooth muscle actin (a-SMA).
p22966
sg17433
(lp22967
(dp22968
g17436
I124
sg17437
VCK-7), proteins (fibroblast-specific protein 1
p22969
sg17438
I46
sg17439
VP14222
p22970
sg17441
I5
sa(dp22971
g17436
I109
sg17437
Vcytokeratin-7
p22972
sg17438
I13
sg17439
VP08729
p22973
sg17441
I1
sa(dp22974
g17436
I237
sg17437
VHSP47
p22975
sg17438
I5
sg17439
VP50454
p22976
sg17441
I1
sa(dp22977
g17436
I195
sg17437
Vcollagen chaperone heat shock protein 47
p22978
sg17438
I40
sg17439
VP34931
p22979
sg17441
I6
sa(dp22980
g17436
I183
sg17437
g22963
sg17438
I6
sg17439
VP26447
p22981
sg17441
I1
sa(dp22982
g17436
I354
sg17437
Va-SMA
p22983
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp22984
g17436
I331
sg17437
Va-smooth muscle actin
p22985
sg17438
I21
sg17439
g12
sg17441
I3
sasg17442
(lp22986
(dp22987
g17436
I34
sg17437
Vbiliary atresia
p22988
sg17438
I15
sg17445
VC0005411
p22989
sg17441
I2
sa(dp22990
g17436
I356
sg17437
g22964
sg17438
I3
sg17445
VC0026847
p22991
sg17441
I1
sasa(dp22992
g135
(dp22993
(VS100A4
p22994
VSMA
p22995
tp22996
I00
ssg17431
VHowever, BECs from biliary atresia resulted in increased expression of a-SMA, S100A4, with concurrent transition to a fibroblast-like morphology and decreased expression of AK-7.
p22997
sg17433
(lp22998
(dp22999
g17436
I173
sg17437
VAK-7
p23000
sg17438
I4
sg17439
VP55263
p23001
sg17441
I1
sa(dp23002
g17436
I78
sg17437
g22994
sg17438
I6
sg17439
VP26447
p23003
sg17441
I1
sa(dp23004
g17436
I73
sg17437
VSMA
p23005
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp23006
(dp23007
g17436
I102
sg17437
Vtransition
p23008
sg17438
I10
sg17445
VC0599156
p23009
sg17441
I1
sa(dp23010
g17436
I19
sg17437
Vbiliary atresia
p23011
sg17438
I15
sg17445
VC0005411
p23012
sg17441
I2
sa(dp23013
g17436
I73
sg17437
g22995
sg17438
I3
sg17445
VC0026847
p23014
sg17441
I1
sasa(dp23015
g135
(dp23016
(VTPL-2
p23017
Vrheumatoid arthritis
p23018
tp23019
I00
ssg17431
VConsequently, there has been considerable interest in the pharmaceutical industry to develop selective TPL-2 inhibitors as drugs for the treatment of TNF-dependent inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
p23020
sg17433
(lp23021
(dp23022
g17436
I150
sg17437
VTNF
p23023
sg17438
I3
sg17439
VP01375
p23024
sg17441
I1
sa(dp23025
g17436
I103
sg17437
g23017
sg17438
I5
sg17439
VP41279
p23026
sg17441
I1
sasg17442
(lp23027
(dp23028
g17436
I220
sg17437
Vinflammatory bowel disease
p23029
sg17438
I26
sg17445
VC0021390
p23030
sg17441
I3
sa(dp23031
g17436
I195
sg17437
g23018
sg17438
I20
sg17445
VC0003873
p23032
sg17441
I2
sasa(dp23033
g135
(dp23034
(VTpl2
p23035
Vrheumatoid arthritis
p23036
tp23037
I00
ssg17431
VThus, pharmacologic inhibition of Tpl2 should be a valid approach to therapeutic intervention in the pathogenesis of rheumatoid arthritis and other inflammatory diseases in humans.
p23038
sg17433
(lp23039
(dp23040
g17436
I34
sg17437
g23035
sg17438
I4
sg17439
VP41279
p23041
sg17441
I1
sasg17442
(lp23042
(dp23043
g17436
I117
sg17437
g23036
sg17438
I20
sg17445
VC0003873
p23044
sg17441
I2
sa(dp23045
g17436
I101
sg17437
Vpathogenesis
p23046
sg17438
I12
sg17445
VC0699748
p23047
sg17441
I1
sasa(dp23048
g135
(dp23049
(VTpl2
p23050
Vrheumatoid arthritis
p23051
tp23052
I00
ssg17431
VTaken together, our results show that inhibition of Tpl2 in primary human cell types can decrease the production of TNFalpha and other pro-inflammatory mediators during inflammatory events, and they further support the notion that Tpl2 is an appropriate therapeutic target for rheumatoid arthritis and other human inflammatory diseases.
p23053
sg17433
(lp23054
(dp23055
g17436
I116
sg17437
VTNFalpha
p23056
sg17438
I8
sg17439
VP01375
p23057
sg17441
I1
sa(dp23058
g17436
I52
sg17437
VTpl2
p23059
sg17438
I4
sg17439
VP41279
p23060
sg17441
I1
sa(dp23061
g17436
I52
sg17437
g23050
sg17438
I4
sg17439
VP41279
p23062
sg17441
I1
sasg17442
(lp23063
(dp23064
g17436
I277
sg17437
g23051
sg17438
I20
sg17445
VC0003873
p23065
sg17441
I2
sasa(dp23066
g135
(dp23067
(VTNF-alpha
p23068
Vrheumatoid arthritis
p23069
tp23070
I00
ssg17431
VRecent studies using Tpl2 knockout mice have indicated an important role for Tpl2 in the lipopolysaccharide (LPS) induced production of tumor necrosis factor alpha (TNF-alpha) and other proinflammatory cytokines involved in diseases such as rheumatoid arthritis.
p23071
sg17433
(lp23072
(dp23073
g17436
I136
sg17437
Vtumor necrosis factor alpha
p23074
sg17438
I27
sg17439
VP01375
p23075
sg17441
I4
sa(dp23076
g17436
I21
sg17437
VTpl2
p23077
sg17438
I4
sg17439
VP41279
p23078
sg17441
I1
sa(dp23079
g17436
I21
sg17437
VTpl2
p23080
sg17438
I4
sg17439
VP41279
p23081
sg17441
I1
sa(dp23082
g17436
I165
sg17437
g23068
sg17438
I9
sg17439
VP01375
p23083
sg17441
I1
sasg17442
(lp23084
(dp23085
g17436
I136
sg17437
Vtumor necrosis
p23086
sg17438
I14
sg17445
VC0333516
p23087
sg17441
I2
sa(dp23088
g17436
I89
sg17437
Vlipopolysaccharide
p23089
sg17438
I18
sg17445
VC0175697
p23090
sg17441
I1
sa(dp23091
g17436
I109
sg17437
VLPS
p23092
sg17438
I3
sg17445
VC0175697
p23093
sg17441
I1
sa(dp23094
g17436
I241
sg17437
g23069
sg17438
I20
sg17445
VC0003873
p23095
sg17441
I2
sasa(dp23096
g17431
VIn all, 78.08% had stage 1 HTN while 22% had stage 2 HTN.
p23097
sg17433
(lp23098
sg17442
(lp23099
(dp23100
g17436
I27
sg17437
VHTN
p23101
sg17438
I3
sg17445
VC0020538
p23102
sg17441
I1
sa(dp23103
g17436
I27
sg17437
VHTN
p23104
sg17438
I3
sg17445
VC0020538
p23105
sg17441
I1
sasa(dp23106
g17431
VMoreover, ba-PWV showed a significant increase with increasing plasma tHcy level in subjects with both high normal BP and grade 1 HTN (p &lt; 0.05).
p23107
sg17433
(lp23108
sg17442
(lp23109
(dp23110
g17436
I130
sg17437
VHTN
p23111
sg17438
I3
sg17445
VC0020538
p23112
sg17441
I1
sasa(dp23113
g17431
VCompared with optimal BP stage, ba-PWV was significantly associated with high normal BP stage (Beta = 193, p &lt; 0.001) and grade 1 HTN (Beta = 413, p &lt; 0.001).There was a statistical interaction effect between high normal BP stage and optimal BP stage (p = 0.045).
p23114
sg17433
(lp23115
sg17442
(lp23116
(dp23117
g17436
I133
sg17437
VHTN
p23118
sg17438
I3
sg17445
VC0020538
p23119
sg17441
I1
sasa(dp23120
g17431
VThe similar result was found between subjects with optimal BP and those with grade 1 HTN (p = 0.037).
p23121
sg17433
(lp23122
sg17442
(lp23123
(dp23124
g17436
I85
sg17437
VHTN
p23125
sg17438
I3
sg17445
VC0020538
p23126
sg17441
I1
sasa(dp23127
g17431
VIn conclusion, tHcy was independently correlated with ba-PWV in subjects with high normal BP and grade 1 HTN.
p23128
sg17433
(lp23129
sg17442
(lp23130
(dp23131
g17436
I105
sg17437
VHTN
p23132
sg17438
I3
sg17445
VC0020538
p23133
sg17441
I1
sasa(dp23134
g17431
VHigh normal BP and grade 1 HTN may worsen the impact of tHcy on arterial stiffness in a Chinese rural community population.
p23135
sg17433
(lp23136
sg17442
(lp23137
(dp23138
g17436
I73
sg17437
Vstiffness
p23139
sg17438
I9
sg17445
VC0427008
p23140
sg17441
I1
sa(dp23141
g17436
I27
sg17437
VHTN
p23142
sg17438
I3
sg17445
VC0020538
p23143
sg17441
I1
sasa(dp23144
g17431
VNpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA, ocTpoN oKKnh3NeN BHyTpeHHeN coHHoN apTepNN.
p23145
sg17433
(lp23146
(dp23147
g17436
I0
sg17437
VNpeAMeToM npoAonXahweNcR ANcKyccNN RBnReTcR npoBeAeHNe EKcTpeHHblx EHAapTepEKToMNN N TpoMbNHTNMEKToMNN y namyNeHToB c NHcynbToM B xoAy, crescendo TNA
p23148
sg17438
I149
sg17439
VP05452
p23149
sg17441
I17
sasg17442
(lp23150
sa(dp23151
g17431
VThe upper bound of a 95% confidence interval for the difference in prevalence of Stage 1 and 2 HTN between study arms indicates that discontinuation of study medication is unlikely to be associated with an increase in Stage 1 HTN of &gt;4.8 percentage points and in Stage 2 HTN of no &gt;5.8 percentage points.
p23152
sg17433
(lp23153
sg17442
(lp23154
(dp23155
g17436
I95
sg17437
VHTN
p23156
sg17438
I3
sg17445
VC0020538
p23157
sg17441
I1
sa(dp23158
g17436
I113
sg17437
Varms
p23159
sg17438
I4
sg17445
VC0206655
p23160
sg17441
I1
sa(dp23161
g17436
I95
sg17437
VHTN
p23162
sg17438
I3
sg17445
VC0020538
p23163
sg17441
I1
sa(dp23164
g17436
I95
sg17437
VHTN
p23165
sg17438
I3
sg17445
VC0020538
p23166
sg17441
I1
sasa(dp23167
g135
(dp23168
(VCRK-Like Proto-Oncogene, Adaptor Protein
p23169
Vhsa
p23170
tp23171
I00
ssg17431
VTarget genes (e.g., cyclin-dependent kinase 6) of hsa-miR-942-5p were mainly enriched in cancer-related pathways, whereas target genes (e.g., CRK-Like Proto-Oncogene, Adaptor Protein) of hsa-miR-940 were enriched in the ErbB signaling pathway.
p23172
sg17433
(lp23173
(dp23174
g17436
I142
sg17437
g23169
sg17438
I40
sg17439
VP46108
p23175
sg17441
I4
sa(dp23176
g17436
I187
sg17437
Vhsa-miR-940
p23177
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp23178
g17436
I50
sg17437
Vhsa-miR-942-5p
p23179
sg17438
I14
sg17439
g12
sg17441
I1
sa(dp23180
g17436
I220
sg17437
VErbB
p23181
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp23182
g17436
I20
sg17437
Vcyclin-dependent kinase 6
p23183
sg17438
I25
sg17439
g12
sg17441
I3
sasg17442
(lp23184
(dp23185
g17436
I89
sg17437
Vcancer
p23186
sg17438
I6
sg17445
VC0006826
p23187
sg17441
I1
sa(dp23188
g17436
I50
sg17437
Vhsa
p23189
sg17438
I3
sg17445
VC0393754
p23190
sg17441
I1
sa(dp23191
g17436
I50
sg17437
g23170
sg17438
I3
sg17445
VC0393754
p23192
sg17441
I1
sasa(dp23193
g17431
VHerein, we demonstrated that hypoxia induces the high expression of microRNA-940 (miR-940) in exosomes derived from epithelial ovarian cancer (EOC).
p23194
sg17433
(lp23195
sg17442
(lp23196
(dp23197
g17436
I143
sg17437
VEOC
p23198
sg17438
I3
sg17445
VC0677886
p23199
sg17441
I1
sa(dp23200
g17436
I29
sg17437
Vhypoxia
p23201
sg17438
I7
sg17445
VC0242184
p23202
sg17441
I1
sa(dp23203
g17436
I116
sg17437
Vepithelial ovarian cancer
p23204
sg17438
I25
sg17445
VC0677886
p23205
sg17441
I3
sasa(dp23206
g17431
VResults: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).
p23207
sg17433
(lp23208
(dp23209
g17436
I24
sg17437
Vhsa
p23210
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23211
g17436
I38
sg17437
Vhsa-mir-149
p23212
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp23213
g17436
I51
sg17437
Vhsa-mir-744
p23214
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp23215
g17436
I24
sg17437
Vhsa-mir-1180
p23216
sg17438
I12
sg17439
g12
sg17441
I1
sasg17442
(lp23217
(dp23218
g17436
I24
sg17437
Vhsa
p23219
sg17438
I3
sg17445
VC0393754
p23220
sg17441
I1
sa(dp23221
g17436
I24
sg17437
Vhsa
p23222
sg17438
I3
sg17445
VC0393754
p23223
sg17441
I1
sa(dp23224
g17436
I24
sg17437
Vhsa
p23225
sg17438
I3
sg17445
VC0393754
p23226
sg17441
I1
sa(dp23227
g17436
I24
sg17437
Vhsa
p23228
sg17438
I3
sg17445
VC0393754
p23229
sg17441
I1
sa(dp23230
g17436
I109
sg17437
Vinvasion
p23231
sg17438
I8
sg17445
VC2699153
p23232
sg17441
I1
sa(dp23233
g17436
I190
sg17437
Vhepatocellular carcinoma
p23234
sg17438
I24
sg17445
VC1512411
p23235
sg17441
I2
sa(dp23236
g17436
I109
sg17437
Vinvasion
p23237
sg17438
I8
sg17445
VC2699153
p23238
sg17441
I1
sasa(dp23239
g17431
VResults from the Survival analysis showed that hsa-mir-1180 (HR=1.623, 95% CI: 1.114-2.365, P=0.012), hsa-mir-149 (HR=2.400, 95% CI: 1.639-3.514) and hsa-mir-940 (HR=1.704, 95%CI: 1.188-2.443, P=0.004) were independent risk factors on the prognosis of patients with hepatocellular carcinoma (P&lt;0.05).
p23240
sg17433
(lp23241
(dp23242
g17436
I47
sg17437
Vhsa
p23243
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23244
g17436
I47
sg17437
Vhsa
p23245
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23246
g17436
I47
sg17437
Vhsa
p23247
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp23248
(dp23249
g17436
I47
sg17437
Vhsa
p23250
sg17438
I3
sg17445
VC0393754
p23251
sg17441
I1
sa(dp23252
g17436
I47
sg17437
Vhsa
p23253
sg17438
I3
sg17445
VC0393754
p23254
sg17441
I1
sa(dp23255
g17436
I266
sg17437
Vhepatocellular carcinoma
p23256
sg17438
I24
sg17445
VC1512411
p23257
sg17441
I2
sa(dp23258
g17436
I47
sg17437
Vhsa
p23259
sg17438
I3
sg17445
VC0393754
p23260
sg17441
I1
sasa(dp23261
g17431
VConclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.
p23262
sg17433
(lp23263
(dp23264
g17436
I57
sg17437
Vhsa-mir-1180
p23265
sg17438
I12
sg17439
g12
sg17441
I1
sa(dp23266
g17436
I71
sg17437
Vhsa-mir-149
p23267
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp23268
g17436
I84
sg17437
Vhsa-mir-744
p23269
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp23270
g17436
I57
sg17437
Vhsa
p23271
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp23272
(dp23273
g17436
I57
sg17437
Vhsa
p23274
sg17438
I3
sg17445
VC0393754
p23275
sg17441
I1
sa(dp23276
g17436
I156
sg17437
Vhepatocellular carcinoma
p23277
sg17438
I24
sg17445
VC1512411
p23278
sg17441
I2
sa(dp23279
g17436
I156
sg17437
Vhepatocellular carcinoma
p23280
sg17438
I24
sg17445
VC1512411
p23281
sg17441
I2
sa(dp23282
g17436
I57
sg17437
Vhsa
p23283
sg17438
I3
sg17445
VC0393754
p23284
sg17441
I1
sa(dp23285
g17436
I57
sg17437
Vhsa
p23286
sg17438
I3
sg17445
VC0393754
p23287
sg17441
I1
sa(dp23288
g17436
I57
sg17437
Vhsa
p23289
sg17438
I3
sg17445
VC0393754
p23290
sg17441
I1
sasa(dp23291
g17431
V#\u76ee#\u7684#\uff1a #\u901a#\u8fc7#\u5bf9GEO (Gene Expression Omnibus) #\u4e0eTCGA (The Cancer Genome Atlas) #\u6570#\u636e#\u5e93#\u5206#\u6790, #\u6316#\u6398#\u809d#\u764c#\u8840#\u7ba1#\u4fb5#\u88ad#\u76f8#\u5173#\u7684microRNA, #\u5e76#\u5206#\u6790#\u5176#\u9884#\u540e#\u548c#\u53ef#\u80fd#\u673a#\u5236#\u3002 #\u65b9#\u6cd5#\uff1a #\u5229#\u7528GEO#\u6570#\u636e#\u5e93#\u83b7#\u5f97#\u809d#\u764c#\u8840#\u7ba1#\u4fb5#\u88admicroRNA#\u82af#\u7247#\u6570#\u636e (GSE67140) , #\u5bf95#\u79cd#\u4fb5#\u88ad#\u80fd#\u529b#\u4e0d#\u540c#\u7684#\u7ec6#\u80de#\u7cfb (SNU423#\u3001SNU449#\u3001HepG2#\u3001Hep3B#\u3001SNU398) #\u8868#\u8fbe#\u8c31#\u8fdb#\u884c#\u5dee#\u5f02#\u5206#\u6790, #\u5e76#\u572881#\u4efd#\u8840#\u7ba1#\u4fb5#\u88ad#\u9633#\u6027#\u7ec4#\u7ec7#\u6837#\u672c#\u4e0e91#\u4efd#\u8840#\u7ba1#\u4fb5#\u88ad#\u9634#\u6027#\u7ec4#\u7ec7#\u6837#\u672c#\u4e2d#\u9a8c#\u8bc1#\u5dee#\u5f02#\u5206#\u6790#\u7ed3#\u679c#\u3002#\u7ed3#\u5408TCGA#\u6570#\u636e#\u5e93#\u4e2d362#\u4f8b#\u809d#\u764c#\u75c5#\u4f8b#\u6570#\u636e#\u5206#\u6790#\u5176#\u9884#\u540e, #\u5e76#\u5bf9microRNA#\u6240#\u8c03#\u63a7#\u7684#\u57fa#\u56e0#\u8fdb#\u884cGO#\u4e0eKEGG#\u5206#\u6790#\u3002 #\u7ed3#\u679c#\uff1a hsa-mir-1180#\u3001hsa-mir-149#\u3001hsa-mir-744#\u3001hsa-mir-940#\u5728#\u4fb5#\u88ad#\u80fd#\u529b#\u5f3a#\u7684#\u809d#\u764c#\u7ec6#\u80de#\u548c#\u6709#\u8840#\u7ba1#\u4fb5#\u88ad#\u7684#\u809d#\u764c#\u7ec4#\u7ec7#\u4e2d#\u8868#\u8fbe#\u4e0a#\u8c03 (logFC&gt;1, P&lt;0.05) #\u3002#\u751f#\u5b58#\u5206#\u6790#\u663e#\u793a, hsa-mir-1180 (HR=1.623, 95%CI#\uff1a1.114~2.365, P=0.012) #\u3001hsa-mir-149 (HR=2.400, 95% CI#\uff1a1.639~3.514, P&lt;0.001) #\u3001hsa-mir-744 (HR=1.679, 95%CI#\uff1a1.161~2.427, P=0.006) #\u3001hsa-mir-940 (HR=1.704, 95%CI#\uff1a1.188~2.443, P=0.004) #\u662f#\u809d#\u764c#\u75c5#\u4f8b#\u9884#\u540e#\u72ec#\u7acb#\u5371#\u9669#\u56e0#\u7d20, #\u9ad8#\u8868#\u8fbe#\u4e0e#\u60a3#\u8005#\u751f#\u5b58#\u671f#\u7f29#\u77ed#\u663e#\u8457#\u76f8#\u5173 (P&lt;0.05) #\u3002GO#\u4e0eKEGG#\u5206#\u6790#\u5176#\u673a#\u5236#\u53ef#\u80fd#\u4e0e#\u514d#\u75ab#\u53cd#\u5e94#\u3001#\u7ec6#\u80de#\u9ecf#\u9644#\u3001#\u7d27#\u5bc6#\u8fde#\u63a5#\u7b49#\u4fe1#\u53f7#\u901a#\u8def#\u6709#\u5173#\u3002 #\u7ed3#\u8bba#\uff1a #\u901a#\u8fc7#\u5bf9TCGA#\u4e0eGEO#\u6570#\u636e#\u5e93#\u7684#\u6316#\u6398, #\u521d#\u6b65#\u53d1#\u73b0hsa-mir-1180#\u3001hsa-mir-149#\u3001hsa-mir-744#\u3001hsa-mir-940#\u5bf9#\u809d#\u764c#\u7684#\u9884#\u540e#\u6709#\u5f71#\u54cd, #\u53ef#\u4f5c#\u4e3a#\u809d#\u764c#\u9884#\u540e#\u7684#\u751f#\u7269#\u6807#\u5fd7#\u7269#\u3002.
p23292
sg17433
(lp23293
sg17442
(lp23294
(dp23295
g17436
I465
sg17437
Vhsa
p23296
sg17438
I3
sg17445
VC0393754
p23297
sg17441
I1
sa(dp23298
g17436
I478
sg17437
V\u3001hsa
p23299
sg17438
I4
sg17445
VC0393754
p23300
sg17441
I1
sa(dp23301
g17436
I478
sg17437
V\u3001hsa
p23302
sg17438
I4
sg17445
VC0393754
p23303
sg17441
I1
sa(dp23304
g17436
I478
sg17437
V\u3001hsa
p23305
sg17438
I4
sg17445
VC0393754
p23306
sg17441
I1
sa(dp23307
g17436
I478
sg17437
V\u3001hsa
p23308
sg17438
I4
sg17445
VC0393754
p23309
sg17441
I1
sa(dp23310
g17436
I465
sg17437
Vhsa
p23311
sg17438
I3
sg17445
VC0393754
p23312
sg17441
I1
sa(dp23313
g17436
I478
sg17437
V\u3001hsa
p23314
sg17438
I4
sg17445
VC0393754
p23315
sg17441
I1
sa(dp23316
g17436
I478
sg17437
V\u3001hsa
p23317
sg17438
I4
sg17445
VC0393754
p23318
sg17441
I1
sa(dp23319
g17436
I478
sg17437
V\u3001hsa
p23320
sg17438
I4
sg17445
VC0393754
p23321
sg17441
I1
sa(dp23322
g17436
I478
sg17437
V\u3001hsa
p23323
sg17438
I4
sg17445
VC0393754
p23324
sg17441
I1
sa(dp23325
g17436
I478
sg17437
V\u3001hsa
p23326
sg17438
I4
sg17445
VC0393754
p23327
sg17441
I1
sa(dp23328
g17436
I55
sg17437
VCancer
p23329
sg17438
I6
sg17445
VC0006826
p23330
sg17441
I1
sasa(dp23331
g17431
VThe high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma.
p23332
sg17433
(lp23333
(dp23334
g17436
I23
sg17437
VmiR-940
p23335
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp23336
(dp23337
g17436
I83
sg17437
Vovarian serous cystadenocarcinoma
p23338
sg17438
I33
sg17445
VC0279663
p23339
sg17441
I3
sasa(dp23340
g17431
VIn our study, real-time (RT) quantitative PCR indicated that miR-940 levels were upregulated in human cervical cancer tissue samples and cell lines.
p23341
sg17433
(lp23342
sg17442
(lp23343
(dp23344
g17436
I102
sg17437
Vcervical cancer
p23345
sg17438
I15
sg17445
VC0302592
p23346
sg17441
I2
sasa(dp23347
g17431
VEctopic miR-940 accelerated cervical cancer cell growth, proliferation and cell cycle arrest in vitro as well as tumor formation in vivo.
p23348
sg17433
(lp23349
sg17442
(lp23350
(dp23351
g17436
I37
sg17437
Vcancer cell growth
p23352
sg17438
I18
sg17445
VC1516170
p23353
sg17441
I3
sa(dp23354
g17436
I113
sg17437
Vtumor
p23355
sg17438
I5
sg17445
VC0027651
p23356
sg17441
I1
sa(dp23357
g17436
I57
sg17437
Vproliferation
p23358
sg17438
I13
sg17445
VC0334094
p23359
sg17441
I1
sasa(dp23360
g135
(dp23361
(VPTEN
p23362
Vcervical cancer
p23363
tp23364
I00
ssg17431
Vp27 and PTEN were evidenced as direct targets for miR-940 and inhibition of p27 and PTEN recovered the suppressive function of miR-940-silenced cell towards to proliferation and tumorigenicity in cervical cancer cells.
p23365
sg17433
(lp23366
(dp23367
g17436
I0
sg17437
Vp27
p23368
sg17438
I3
sg17439
VP40305
p23369
sg17441
I1
sa(dp23370
g17436
I8
sg17437
VPTEN
p23371
sg17438
I4
sg17439
VP60484
p23372
sg17441
I1
sa(dp23373
g17436
I0
sg17437
Vp27
p23374
sg17438
I3
sg17439
VP40305
p23375
sg17441
I1
sa(dp23376
g17436
I8
sg17437
g23362
sg17438
I4
sg17439
VP60484
p23377
sg17441
I1
sasg17442
(lp23378
(dp23379
g17436
I196
sg17437
g23363
sg17438
I15
sg17445
VC0302592
p23380
sg17441
I2
sa(dp23381
g17436
I160
sg17437
Vproliferation
p23382
sg17438
I13
sg17445
VC0334094
p23383
sg17441
I1
sa(dp23384
g17436
I178
sg17437
Vtumorigenicity
p23385
sg17438
I14
sg17445
VC1519697
p23386
sg17441
I1
sasa(dp23387
g135
(dp23388
(VPTEN
p23389
Vcervical cancer
p23390
tp23391
I00
ssg17431
VIn addition, miR-940 expression was inversely associated with p27 and PTEN expression levels and actively with cyclin D1 in cervical cancer specimens.
p23392
sg17433
(lp23393
(dp23394
g17436
I111
sg17437
Vcyclin D1
p23395
sg17438
I9
sg17439
VP24385
p23396
sg17441
I2
sa(dp23397
g17436
I62
sg17437
Vp27
p23398
sg17438
I3
sg17439
VP40305
p23399
sg17441
I1
sa(dp23400
g17436
I70
sg17437
g23389
sg17438
I4
sg17439
VP60484
p23401
sg17441
I1
sasg17442
(lp23402
(dp23403
g17436
I124
sg17437
g23390
sg17438
I15
sg17445
VC0302592
p23404
sg17441
I2
sasa(dp23405
g135
(dp23406
(Vp27
p23407
Vcervical cancer
p23408
tp23409
I01
ssg17431
VThe results from our study demonstrated that miR-940 regulated p27 and PTEN post-transcriptionally and might play a significant role in cervical cancer development and progression.
p23410
sg17433
(lp23411
(dp23412
g17436
I45
sg17437
VmiR-940
p23413
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp23414
g17436
I71
sg17437
VPTEN
p23415
sg17438
I4
sg17439
VP60484
p23416
sg17441
I1
sa(dp23417
g17436
I63
sg17437
g23407
sg17438
I3
sg17439
VP40305
p23418
sg17441
I1
sasg17442
(lp23419
(dp23420
g17436
I136
sg17437
g23408
sg17438
I15
sg17445
VC0302592
p23421
sg17441
I2
sasa(dp23422
g17431
VThus, miR-940 might provide a potential value as therapeutic target for cervical cancer treatment in future.
p23423
sg17433
(lp23424
(dp23425
g17436
I6
sg17437
VmiR-940
p23426
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp23427
(dp23428
g17436
I72
sg17437
Vcervical cancer
p23429
sg17438
I15
sg17445
VC0302592
p23430
sg17441
I2
sasa(dp23431
g17431
VWe aimed to explore the roles and regulatory mechanism of microRNA-940 (miR-940) in bladder cancer development.
p23432
sg17433
(lp23433
sg17442
(lp23434
(dp23435
g17436
I84
sg17437
Vbladder cancer
p23436
sg17438
I14
sg17445
VC0699885
p23437
sg17441
I2
sasa(dp23438
g17431
VThe expressions of miR-940 in bladder cancer tissues and cells were measured.
p23439
sg17433
(lp23440
sg17442
(lp23441
(dp23442
g17436
I30
sg17437
Vbladder cancer
p23443
sg17438
I14
sg17445
VC0699885
p23444
sg17441
I2
sasa(dp23445
g17431
VmiR-940 was up-regulated in bladder cancer tissues and cells.
p23446
sg17433
(lp23447
sg17442
(lp23448
(dp23449
g17436
I28
sg17437
Vbladder cancer
p23450
sg17438
I14
sg17445
VC0699885
p23451
sg17441
I2
sasa(dp23452
g17431
VOverexpression of miR-940 significantly increased bladder cancer cell proliferation, promoted migration and invasion, and inhibited cell apoptosis.
p23453
sg17433
(lp23454
sg17442
(lp23455
(dp23456
g17436
I108
sg17437
Vinvasion
p23457
sg17438
I8
sg17445
VC2699153
p23458
sg17441
I1
sa(dp23459
g17436
I50
sg17437
Vbladder cancer
p23460
sg17438
I14
sg17445
VC0699885
p23461
sg17441
I2
sa(dp23462
g17436
I70
sg17437
Vproliferation
p23463
sg17438
I13
sg17445
VC0334094
p23464
sg17441
I1
sasa(dp23465
g17431
VINPP4A and GSK3Beta were the direct targets of miR-940, and knockdown of INPP4A or GSK3Beta significantly increased cancer cell proliferation, migration and invasion, and inhibited cell apoptosis.
p23466
sg17433
(lp23467
(dp23468
g17436
I0
sg17437
VINPP4A
p23469
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp23470
g17436
I0
sg17437
VINPP4A
p23471
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp23472
(dp23473
g17436
I128
sg17437
Vproliferation
p23474
sg17438
I13
sg17445
VC0334094
p23475
sg17441
I1
sa(dp23476
g17436
I157
sg17437
Vinvasion
p23477
sg17438
I8
sg17445
VC2699153
p23478
sg17441
I1
sa(dp23479
g17436
I116
sg17437
Vcancer
p23480
sg17438
I6
sg17445
VC0006826
p23481
sg17441
I1
sasa(dp23482
g17431
VOur results indicate that overexpression of miR-940 may promote bladder cancer cell proliferation, migration and invasion, and inhibited cell apoptosis via targeting INPP4A or GSK3Beta and activating Wnt/Beta-catenin pathway.
p23483
sg17433
(lp23484
(dp23485
g17436
I44
sg17437
VmiR-940
p23486
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp23487
g17436
I166
sg17437
VINPP4A
p23488
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp23489
(dp23490
g17436
I113
sg17437
Vinvasion
p23491
sg17438
I8
sg17445
VC2699153
p23492
sg17441
I1
sa(dp23493
g17436
I64
sg17437
Vbladder cancer
p23494
sg17438
I14
sg17445
VC0699885
p23495
sg17441
I2
sa(dp23496
g17436
I84
sg17437
Vproliferation
p23497
sg17438
I13
sg17445
VC0334094
p23498
sg17441
I1
sasa(dp23499
g17431
VExpressions of miR-940, miR-15a, miR-16 and IL-23 in PTC tissues might be useful biomarkers and promising targets in the diagnosis of papillary thyroid carcinoma.
p23500
sg17433
(lp23501
(dp23502
g17436
I24
sg17437
VmiR-15a
p23503
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp23504
g17436
I44
sg17437
VIL-23
p23505
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp23506
g17436
I15
sg17437
VmiR-940
p23507
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp23508
g17436
I33
sg17437
VmiR-16
p23509
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp23510
g17436
I53
sg17437
VPTC
p23511
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp23512
(dp23513
g17436
I134
sg17437
Vpapillary thyroid carcinoma
p23514
sg17438
I27
sg17445
VC0238463
p23515
sg17441
I3
sa(dp23516
g17436
I53
sg17437
VPTC
p23517
sg17438
I3
sg17445
VC0238463
p23518
sg17441
I1
sasa(dp23519
g17431
VThis study investigated the pivotal role of miR-940 in the progression of ovarian cancer and to reveal the possible molecular mechanism of its action.
p23520
sg17433
(lp23521
sg17442
(lp23522
(dp23523
g17436
I74
sg17437
Vovarian cancer
p23524
sg17438
I14
sg17445
VC1140680
p23525
sg17441
I2
sasa(dp23526
g135
(dp23527
(VPKC-Delta
p23528
VPKC
p23529
tp23530
I00
ssg17431
VOvarian cancer OVCAR3 cells were transfected with the miR-940 vector, miR-940 inhibitor, and/or small interfering RNA (siRNA) targeting PKC-Delta (si-PKC-Delta), respectively.
p23531
sg17433
(lp23532
(dp23533
g17436
I147
sg17437
Vsi-PKC-Delta
p23534
sg17438
I12
sg17439
VP17252
p23535
sg17441
I1
sa(dp23536
g17436
I136
sg17437
g23528
sg17438
I9
sg17439
VP17252
p23537
sg17441
I1
sasg17442
(lp23538
(dp23539
g17436
I0
sg17437
VOvarian cancer
p23540
sg17438
I14
sg17445
VC1140680
p23541
sg17441
I2
sa(dp23542
g17436
I136
sg17437
VPKC
p23543
sg17438
I3
sg17445
VC1868682
p23544
sg17441
I1
sa(dp23545
g17436
I136
sg17437
g23529
sg17438
I3
sg17445
VC1868682
p23546
sg17441
I1
sasa(dp23547
g135
(dp23548
(VPKC-Delta
p23549
VPKC
p23550
tp23551
I00
ssg17431
VTaken together, the results of our study suggest that upregulation of miR-940 may function as a suppressor in the progression of ovarian cancer by inhibiting cell proliferation and inducing apoptosis by targeting PKC-Delta.
p23552
sg17433
(lp23553
(dp23554
g17436
I213
sg17437
g23549
sg17438
I9
sg17439
VP17252
p23555
sg17441
I1
sa(dp23556
g17436
I70
sg17437
VmiR-940
p23557
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp23558
(dp23559
g17436
I129
sg17437
Vovarian cancer
p23560
sg17438
I14
sg17445
VC1140680
p23561
sg17441
I2
sa(dp23562
g17436
I213
sg17437
g23550
sg17438
I3
sg17445
VC1868682
p23563
sg17441
I1
sa(dp23564
g17436
I163
sg17437
Vproliferation
p23565
sg17438
I13
sg17445
VC0334094
p23566
sg17441
I1
sasa(dp23567
g17431
VThis study may provide a basis for the possible application of miR-940 in illustrating the molecular pathogenic mechanism of ovarian cancer.
p23568
sg17433
(lp23569
sg17442
(lp23570
(dp23571
g17436
I125
sg17437
Vovarian cancer
p23572
sg17438
I14
sg17445
VC1140680
p23573
sg17441
I2
sasa(dp23574
g17431
VTo investigate the expression of miR-940 in the hepatocellular carcinoma (HCC) and its impact on function and biological mechanism in the HCC cells.
p23575
sg17433
(lp23576
sg17442
(lp23577
(dp23578
g17436
I74
sg17437
VHCC
p23579
sg17438
I3
sg17445
VC2239176
p23580
sg17441
I1
sa(dp23581
g17436
I74
sg17437
VHCC
p23582
sg17438
I3
sg17445
VC2239176
p23583
sg17441
I1
sa(dp23584
g17436
I48
sg17437
Vhepatocellular carcinoma
p23585
sg17438
I24
sg17445
VC2239176
p23586
sg17441
I2
sasa(dp23587
g135
(dp23588
(VCIITA
p23589
VAutoimmune Addison's disease
p23590
tp23591
I01
ssg17431
VGene variants known to contribute to Autoimmune Addison's disease (AAD) susceptibility include those at the MHC, MICA, CIITA, CTLA4, PTPN22, CYP27B1, NLRP-1 and CD274 loci.
p23592
sg17433
(lp23593
(dp23594
g17436
I108
sg17437
VMHC
p23595
sg17438
I3
sg17439
VP13747
p23596
sg17441
I1
sa(dp23597
g17436
I161
sg17437
VCD274 loci
p23598
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp23599
g17436
I126
sg17437
VCTLA4
p23600
sg17438
I5
sg17439
VP16410
p23601
sg17441
I1
sa(dp23602
g17436
I141
sg17437
VCYP27B1
p23603
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp23604
g17436
I150
sg17437
VNLRP-1
p23605
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp23606
g17436
I119
sg17437
g23589
sg17438
I5
sg17439
VP33076
p23607
sg17441
I1
sa(dp23608
g17436
I133
sg17437
VPTPN22
p23609
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp23610
(dp23611
g17436
I67
sg17437
VAAD
p23612
sg17438
I3
sg17445
VC0271737
p23613
sg17441
I1
sa(dp23614
g17436
I37
sg17437
g23590
sg17438
I28
sg17445
VC0271737
p23615
sg17441
I3
sa(dp23616
g17436
I113
sg17437
VMICA
p23617
sg17438
I4
sg17445
VC0700319
p23618
sg17441
I1
sasa(dp23619
g17431
VNLRP1 is genetically associated with risk of several autoimmune diseases including generalized vitiligo, Addison disease, type 1 diabetes, rheumatoid arthritis, and others.
p23620
sg17433
(lp23621
(dp23622
g17436
I0
sg17437
VNLRP1
p23623
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp23624
(dp23625
g17436
I83
sg17437
Vgeneralized vitiligo
p23626
sg17438
I20
sg17445
VC1304470
p23627
sg17441
I2
sa(dp23628
g17436
I122
sg17437
Vtype 1 diabetes
p23629
sg17438
I15
sg17445
VC0011854
p23630
sg17441
I3
sa(dp23631
g17436
I53
sg17437
Vautoimmune diseases
p23632
sg17438
I19
sg17445
VC0004364
p23633
sg17441
I2
sa(dp23634
g17436
I105
sg17437
VAddison disease
p23635
sg17438
I15
sg17445
VC0266273
p23636
sg17441
I2
sa(dp23637
g17436
I139
sg17437
Vrheumatoid arthritis
p23638
sg17438
I20
sg17445
VC0003873
p23639
sg17441
I2
sasa(dp23640
g17431
VInvestigating large patient cohorts from six different autoimmune diseases, that is autoimmune Addison's disease (n=333), type 1 diabetes (n=1086), multiple sclerosis (n=502), rheumatoid arthritis (n=945), systemic lupus erythematosus (n=156) and juvenile idiopathic arthritis (n=505), against 3273 healthy controls, we analyzed four single nucleotide polymorphisms (SNPs) in NALP1.
p23641
sg17433
(lp23642
(dp23643
g17436
I376
sg17437
VNALP1
p23644
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp23645
(dp23646
g17436
I122
sg17437
Vtype 1 diabetes
p23647
sg17438
I15
sg17445
VC0011854
p23648
sg17441
I3
sa(dp23649
g17436
I148
sg17437
Vmultiple sclerosis
p23650
sg17438
I18
sg17445
VC0026769
p23651
sg17441
I2
sa(dp23652
g17436
I176
sg17437
Vrheumatoid arthritis
p23653
sg17438
I20
sg17445
VC0003873
p23654
sg17441
I2
sa(dp23655
g17436
I206
sg17437
Vsystemic lupus erythematosus
p23656
sg17438
I28
sg17445
VC0024141
p23657
sg17441
I3
sa(dp23658
g17436
I55
sg17437
Vautoimmune diseases
p23659
sg17438
I19
sg17445
VC0004364
p23660
sg17441
I2
sa(dp23661
g17436
I247
sg17437
Vjuvenile idiopathic arthritis
p23662
sg17438
I29
sg17445
VC0553662
p23663
sg17441
I3
sa(dp23664
g17436
I84
sg17437
Vautoimmune Addison's disease
p23665
sg17438
I28
sg17445
VC0271737
p23666
sg17441
I3
sasa(dp23667
g17431
VForty-four formalin-fixed, paraffin-embedded MRCL samples and 60 control cases (atypical/well-differentiated liposarcoma, pleomorphic liposarcoma, low-grade myofibrosarcoma, etc.)
p23668
sg17433
(lp23669
sg17442
(lp23670
(dp23671
g17436
I109
sg17437
Vliposarcoma, pleomorphic
p23672
sg17438
I24
sg17445
VC0205825
p23673
sg17441
I2
sa(dp23674
g17436
I109
sg17437
Vliposarcoma
p23675
sg17438
I11
sg17445
VC0023827
p23676
sg17441
I1
sa(dp23677
g17436
I157
sg17437
Vmyofibrosarcoma
p23678
sg17438
I15
sg17445
VC1708751
p23679
sg17441
I1
sasa(dp23680
g135
(dp23681
(VEX-CA 1
p23682
VPCOS
p23683
tp23684
I00
ssg17431
VThe most frequent acupoints of acupuncture for PCOS were Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongji (CV 3) and Qihai (CV 6).
p23685
sg17433
(lp23686
(dp23687
g17436
I101
sg17437
g23682
sg17438
I7
sg17439
VP00915
p23688
sg17441
I2
sasg17442
(lp23689
(dp23690
g17436
I47
sg17437
g23683
sg17438
I4
sg17445
VC0032460
p23691
sg17441
I1
sasa(dp23692
g135
(dp23693
(VEX-CA 1
p23694
VPCOS
p23695
tp23696
I00
ssg17431
VIn the modern treatment of acupuncture for PCOS, Sanyinjiao (SP 6), Guanyuan (CV 4), Zigong (EX-CA 1), Zhongii (CV 3) and Qihai (CV 6) are most used.
p23697
sg17433
(lp23698
(dp23699
g17436
I93
sg17437
g23694
sg17438
I7
sg17439
VP00915
p23700
sg17441
I2
sasg17442
(lp23701
(dp23702
g17436
I43
sg17437
g23695
sg17438
I4
sg17445
VC0032460
p23703
sg17441
I1
sasa(dp23704
g135
(dp23705
(VCA II
p23706
Vprimary biliary cirrhosis
p23707
tp23708
I00
ssg17431
VCarbonic anhydrase II (CA II) has an important role in thyroid hormone synthesis via regulating iodide (I-) transport across thyroidal cell membranes and the existence of autoantibodies against CA I and/or CA II have been shown in sera from patient with various autoimmune diseases such as Sjoegren's Syndrome, Systemic Lupus Erythmatosus, type 1 diabetes, primary biliary cirrhosis and ulcerative colitis.
p23709
sg17433
(lp23710
(dp23711
g17436
I23
sg17437
VCA I
p23712
sg17438
I4
sg17439
VP00915
p23713
sg17441
I2
sa(dp23714
g17436
I0
sg17437
VCarbonic anhydrase II
p23715
sg17438
I21
sg17439
VP00918
p23716
sg17441
I3
sa(dp23717
g17436
I23
sg17437
VCA II
p23718
sg17438
I5
sg17439
VP00918
p23719
sg17441
I2
sa(dp23720
g17436
I23
sg17437
g23706
sg17438
I5
sg17439
VP00918
p23721
sg17441
I2
sasg17442
(lp23722
(dp23723
g17436
I340
sg17437
Vtype 1 diabetes
p23724
sg17438
I15
sg17445
VC0011854
p23725
sg17441
I3
sa(dp23726
g17436
I387
sg17437
Vulcerative colitis
p23727
sg17438
I18
sg17445
VC0009324
p23728
sg17441
I2
sa(dp23729
g17436
I320
sg17437
VLupus
p23730
sg17438
I5
sg17445
VC0024131
p23731
sg17441
I1
sa(dp23732
g17436
I290
sg17437
VSjoegren's Syndrome
p23733
sg17438
I19
sg17445
VC1527336
p23734
sg17441
I2
sa(dp23735
g17436
I262
sg17437
Vautoimmune diseases
p23736
sg17438
I19
sg17445
VC0004364
p23737
sg17441
I2
sa(dp23738
g17436
I357
sg17437
g23707
sg17438
I25
sg17445
VC0008312
p23739
sg17441
I3
sasa(dp23740
g135
(dp23741
(Vchemokine receptor CCR9
p23742
VCrohn's disease
p23743
tp23744
I01
ssg17431
VEfforts to inhibit the chemokine receptor CCR9 using the agent CCX282-B in Crohn's disease were not successful.
p23745
sg17433
(lp23746
(dp23747
g17436
I23
sg17437
g23742
sg17438
I23
sg17439
VP51686
p23748
sg17441
I3
sasg17442
(lp23749
(dp23750
g17436
I75
sg17437
g23743
sg17438
I15
sg17445
VC0010346
p23751
sg17441
I2
sasa(dp23752
g135
(dp23753
(VCCR9
p23754
VCrohn's disease
p23755
tp23756
I01
ssg17431
VOther therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients.
p23757
sg17433
(lp23758
(dp23759
g17436
I112
sg17437
Vaddressin cell adhesion molecule
p23760
sg17438
I32
sg17439
g12
sg17441
I4
sa(dp23761
g17436
I213
sg17437
g23754
sg17438
I4
sg17439
VP51686
p23762
sg17441
I1
sa(dp23763
g17436
I269
sg17437
VSMAD7 antisense oligonucleotide
p23764
sg17438
I31
sg17439
g12
sg17441
I3
sasg17442
(lp23765
(dp23766
g17436
I127
sg17437
Vadhesion
p23767
sg17438
I8
sg17445
VC0001511
p23768
sg17441
I1
sa(dp23769
g17436
I333
sg17437
g23755
sg17438
I15
sg17445
VC0010346
p23770
sg17441
I2
sasa(dp23771
g135
(dp23772
(VCCR9
p23773
VCrohn's disease
p23774
tp23775
I01
ssg17431
VThe chemokine CCL25, and its receptor CCR9, constitute a unique chemokine/receptor pair, which regulates trafficking of T lymphocytes to the small intestine under physiological conditions and is an attractive target for small bowel Crohn's disease drug development.
p23776
sg17433
(lp23777
(dp23778
g17436
I14
sg17437
VCCL25
p23779
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp23780
g17436
I38
sg17437
g23773
sg17438
I4
sg17439
VP51686
p23781
sg17441
I1
sasg17442
(lp23782
(dp23783
g17436
I232
sg17437
g23774
sg17438
I15
sg17445
VC0010346
p23784
sg17441
I2
sasa(dp23785
g135
(dp23786
(VCCR9 chemokine receptor
p23787
VCrohn's disease
p23788
tp23789
I01
ssg17431
VVercirnon is a CCR9 chemokine receptor antagonist being developed for the treatment of Crohn's disease.
p23790
sg17433
(lp23791
(dp23792
g17436
I15
sg17437
g23787
sg17438
I23
sg17439
VP51686
p23793
sg17441
I3
sasg17442
(lp23794
(dp23795
g17436
I87
sg17437
g23788
sg17438
I15
sg17445
VC0010346
p23796
sg17441
I2
sasa(dp23797
g135
(dp23798
(Vanti-Ro/SSA antibodies
p23799
Vcongenital heart block
p23800
tp23801
I00
ssg17431
VIt is well established that the passive trans-placental passage of anti-Ro/SSA antibodies from mother to foetus is associated with the risk to develop an uncommon syndrome named neonatal lupus (NLE), where the congenital heart block represents the most severe clinical feature.
p23802
sg17433
(lp23803
(dp23804
g17436
I67
sg17437
g23799
sg17438
I22
sg17439
VP19474
p23805
sg17441
I2
sasg17442
(lp23806
(dp23807
g17436
I178
sg17437
Vneonatal lupus
p23808
sg17438
I14
sg17445
VC0409979
p23809
sg17441
I2
sa(dp23810
g17436
I210
sg17437
g23800
sg17438
I22
sg17445
VC0149530
p23811
sg17441
I3
sa(dp23812
g17436
I163
sg17437
Vsyndrome
p23813
sg17438
I8
sg17445
VC0039082
p23814
sg17441
I1
sasa(dp23815
g17431
VThe characteristics of NLE that were studied included congenital complete heart block (CCHB), second degree heart block, and hepatic fibrosis.
p23816
sg17433
(lp23817
sg17442
(lp23818
(dp23819
g17436
I54
sg17437
Vcongenital complete heart block
p23820
sg17438
I31
sg17445
VC0340496
p23821
sg17441
I4
sa(dp23822
g17436
I94
sg17437
Vsecond degree heart block
p23823
sg17438
I25
sg17445
VC0264906
p23824
sg17441
I4
sa(dp23825
g17436
I87
sg17437
VCCHB
p23826
sg17438
I4
sg17445
VC0340496
p23827
sg17441
I1
sa(dp23828
g17436
I125
sg17437
Vhepatic fibrosis
p23829
sg17438
I16
sg17445
VC0239946
p23830
sg17441
I2
sasa(dp23831
g135
(dp23832
(Vanti-SS-A/Ro antibody
p23833
Vsubacute cutaneous lupus erythematosus
p23834
tp23835
I00
ssg17431
VSera from patients known to frequently produce precipitating anti-SS-A/Ro antibody (subacute cutaneous lupus erythematosus [SCLE], 56 patients; Sjoegren's syndrome [SS], 41 patients; mothers of infants with neonatal LE [NLE], 10 individuals; infants with congenital heart block [CHB], 5 patients) were tested for reactivity to RoSP7-24 in ELISA.
p23836
sg17433
(lp23837
(dp23838
g17436
I61
sg17437
g23833
sg17438
I21
sg17439
VP37268
p23839
sg17441
I2
sasg17442
(lp23840
(dp23841
g17436
I279
sg17437
VCHB
p23842
sg17438
I3
sg17445
VC0151517
p23843
sg17441
I1
sa(dp23844
g17436
I144
sg17437
VSjoegren's syndrome
p23845
sg17438
I19
sg17445
VC1527336
p23846
sg17441
I2
sa(dp23847
g17436
I255
sg17437
Vcongenital heart block
p23848
sg17438
I22
sg17445
VC0149530
p23849
sg17441
I3
sa(dp23850
g17436
I84
sg17437
g23834
sg17438
I38
sg17445
VC0024140
p23851
sg17441
I4
sasa(dp23852
g17431
VNLE is manifested most typically as transient subacute cutaneous lupus lesions or isolated complete congenital heart block.
p23853
sg17433
(lp23854
(dp23855
g17436
I0
sg17437
VNLE
p23856
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp23857
(dp23858
g17436
I46
sg17437
Vsubacute cutaneous lupus
p23859
sg17438
I24
sg17445
VC2362320
p23860
sg17441
I3
sa(dp23861
g17436
I100
sg17437
Vcongenital heart block
p23862
sg17438
I22
sg17445
VC0149530
p23863
sg17441
I3
sasa(dp23864
g135
(dp23865
(VMEK
p23866
Vcancer progression
p23867
tp23868
I00
ssg17431
VOur findings also suggested that the inhibitory effects of AC-93253 iodide on lung cancer progression may be attributable to its ability to modulate multiple proteins, including Src, PI3K, JNK, Paxillin, p130cas, MEK, ERK, and EGFR.
p23869
sg17433
(lp23870
(dp23871
g17436
I178
sg17437
VSrc
p23872
sg17438
I3
sg17439
VP12931
p23873
sg17441
I1
sa(dp23874
g17436
I204
sg17437
Vp130cas
p23875
sg17438
I7
sg17439
VP56945
p23876
sg17441
I1
sa(dp23877
g17436
I183
sg17437
VPI3K
p23878
sg17438
I4
sg17439
VP42336
p23879
sg17441
I1
sa(dp23880
g17436
I189
sg17437
VJNK
p23881
sg17438
I3
sg17439
VP53779
p23882
sg17441
I1
sa(dp23883
g17436
I218
sg17437
VERK
p23884
sg17438
I3
sg17439
VP29323
p23885
sg17441
I1
sa(dp23886
g17436
I194
sg17437
VPaxillin
p23887
sg17438
I8
sg17439
VP49023
p23888
sg17441
I1
sa(dp23889
g17436
I213
sg17437
g23866
sg17438
I3
sg17439
VP45985
p23890
sg17441
I1
sasg17442
(lp23891
(dp23892
g17436
I83
sg17437
g23867
sg17438
I18
sg17445
VC0178874
p23893
sg17441
I2
sasa(dp23894
g135
(dp23895
(VPaxillin
p23896
Vlung cancer
p23897
tp23898
I00
ssg17431
VPaxillin and FAK activity are reduced in lung cancer cell lines following wiskostatin and nWASP knockdown as shown by immunofluorescence and western blot.
p23899
sg17433
(lp23900
(dp23901
g17436
I13
sg17437
VFAK
p23902
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23903
g17436
I90
sg17437
VnWASP
p23904
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp23905
g17436
I0
sg17437
g23896
sg17438
I8
sg17439
VP49023
p23906
sg17441
I1
sasg17442
(lp23907
(dp23908
g17436
I41
sg17437
g23897
sg17438
I11
sg17445
VC0684249
p23909
sg17441
I2
sasa(dp23910
g135
(dp23911
(Vpaxillin
p23912
Vmetastasis
p23913
tp23914
I00
ssg17431
VTaken together, these results suggested that treatment with DBL may act as a potential candidate to inhibit lung cancer metastasis by inhibiting MMP-2 and -9 via affecting PI3K/AKT, MAPKs, FAK/paxillin, EMT/Snail and Slug, Nrf2/antioxidant enzymes, and NFKB signaling pathways.
p23915
sg17433
(lp23916
(dp23917
g17436
I189
sg17437
VFAK
p23918
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23919
g17436
I145
sg17437
VMMP-2
p23920
sg17438
I5
sg17439
VP08253
p23921
sg17441
I1
sa(dp23922
g17436
I217
sg17437
VSlug
p23923
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp23924
g17436
I177
sg17437
VAKT
p23925
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23926
g17436
I203
sg17437
VEMT
p23927
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23928
g17436
I172
sg17437
VPI3K
p23929
sg17438
I4
sg17439
VP42336
p23930
sg17441
I1
sa(dp23931
g17436
I223
sg17437
VNrf2
p23932
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp23933
g17436
I253
sg17437
VNFKB
p23934
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp23935
g17436
I182
sg17437
VMAPKs
p23936
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp23937
g17436
I207
sg17437
VSnail
p23938
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp23939
g17436
I193
sg17437
g23912
sg17438
I8
sg17439
VP49023
p23940
sg17441
I1
sasg17442
(lp23941
(dp23942
g17436
I108
sg17437
Vlung cancer
p23943
sg17438
I11
sg17445
VC0684249
p23944
sg17441
I2
sa(dp23945
g17436
I120
sg17437
g23913
sg17438
I10
sg17445
VC0027627
p23946
sg17441
I1
sasa(dp23947
g135
(dp23948
(Vpaxillin
p23949
Vlung cancer
p23950
tp23951
I00
ssg17431
VEL decreased phosphorylation of FAK and its downstream targets, Src, paxillin, and decreased mRNA expression of cell motility-related genes, RhoA, Rac1, and Cdc42 in lung cancer cells.
p23952
sg17433
(lp23953
(dp23954
g17436
I147
sg17437
VRac1
p23955
sg17438
I4
sg17439
VP63000
p23956
sg17441
I1
sa(dp23957
g17436
I141
sg17437
VRhoA
p23958
sg17438
I4
sg17439
VP61586
p23959
sg17441
I1
sa(dp23960
g17436
I32
sg17437
VFAK
p23961
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23962
g17436
I64
sg17437
VSrc
p23963
sg17438
I3
sg17439
VP12931
p23964
sg17441
I1
sa(dp23965
g17436
I157
sg17437
VCdc42
p23966
sg17438
I5
sg17439
VP60953
p23967
sg17441
I1
sa(dp23968
g17436
I69
sg17437
g23949
sg17438
I8
sg17439
VP49023
p23969
sg17441
I1
sasg17442
(lp23970
(dp23971
g17436
I166
sg17437
g23950
sg17438
I11
sg17445
VC0684249
p23972
sg17441
I2
sasa(dp23973
g135
(dp23974
(VPI3K
p23975
Vvascularization
p23976
tp23977
I00
ssg17431
VIt efficiently inhibits metastasis on NSCLC by reducing vascularization, and eliciting depression of the PI3K-AKT and FAK-Paxillin signaling pathways.
p23978
sg17433
(lp23979
(dp23980
g17436
I122
sg17437
VPaxillin
p23981
sg17438
I8
sg17439
VP49023
p23982
sg17441
I1
sa(dp23983
g17436
I110
sg17437
VAKT
p23984
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp23985
g17436
I105
sg17437
g23975
sg17438
I4
sg17439
VP42336
p23986
sg17441
I1
sa(dp23987
g17436
I118
sg17437
VFAK
p23988
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp23989
(dp23990
g17436
I38
sg17437
VNSCLC
p23991
sg17438
I5
sg17445
VC0007131
p23992
sg17441
I1
sa(dp23993
g17436
I24
sg17437
Vmetastasis
p23994
sg17438
I10
sg17445
VC0027627
p23995
sg17441
I1
sa(dp23996
g17436
I87
sg17437
Vdepression
p23997
sg17438
I10
sg17445
VC0011581
p23998
sg17441
I1
sa(dp23999
g17436
I56
sg17437
g23976
sg17438
I15
sg17445
VC0027686
p24000
sg17441
I1
sasa(dp24001
g17431
VHere, we assessed the impact of CD101 on the course of inflammatory bowel disease (IBD).
p24002
sg17433
(lp24003
(dp24004
g17436
I32
sg17437
VCD101
p24005
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24006
(dp24007
g17436
I83
sg17437
VIBD
p24008
sg17438
I3
sg17445
VC0021390
p24009
sg17441
I1
sa(dp24010
g17436
I55
sg17437
Vinflammatory bowel disease
p24011
sg17438
I26
sg17445
VC0021390
p24012
sg17441
I3
sasa(dp24013
g135
(dp24014
(Vinterleukin (IL)-2
p24015
Vchronic colitis
p24016
tp24017
I00
ssg17431
VUsing a T-cell transfer model of chronic colitis, we found that in recipients of naive T cells from CD101(+/+) donors up to 30% of the recovered lymphocytes expressed CD101, correlating with an increased interleukin (IL)-2-mediated FoxP3 expression.
p24018
sg17433
(lp24019
(dp24020
g17436
I204
sg17437
g24015
sg17438
I18
sg17439
VP60568
p24021
sg17441
I2
sa(dp24022
g17436
I232
sg17437
VFoxP3
p24023
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24024
g17436
I100
sg17437
VCD101
p24025
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24026
(dp24027
g17436
I33
sg17437
g24016
sg17438
I15
sg17445
VC0267375
p24028
sg17441
I2
sasa(dp24029
g17431
VTransfer of CD101(-/-) T cells caused more severe colitis and was associated with an expansion of IL-17-producing T cells and an enhanced expression of IL-2RAlfa/Beta independently of FoxP3.
p24030
sg17433
(lp24031
(dp24032
g17436
I184
sg17437
VFoxP3
p24033
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24034
(dp24035
g17436
I50
sg17437
Vcolitis
p24036
sg17438
I7
sg17445
VC0009319
p24037
sg17441
I1
sasa(dp24038
g17431
VThe co-transfer of naive and regulatory T cells (Treg) protected most effectively from colitis, when both donor and recipient mice expressed CD101.
p24039
sg17433
(lp24040
(dp24041
g17436
I141
sg17437
VCD101
p24042
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24043
(dp24044
g17436
I87
sg17437
Vcolitis
p24045
sg17438
I7
sg17445
VC0009319
p24046
sg17441
I1
sasa(dp24047
g17431
VThus, CD101 deficiency is a novel marker for progressive colitis and potential target for therapeutic intervention.
p24048
sg17433
(lp24049
(dp24050
g17436
I6
sg17437
VCD101
p24051
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24052
(dp24053
g17436
I57
sg17437
Vcolitis
p24054
sg17438
I7
sg17445
VC0009319
p24055
sg17441
I1
sasa(dp24056
g135
(dp24057
(VCD4(+) CD25(+) FOXP3(+) CD127
p24058
Vcoeliac disease
p24059
tp24060
I00
ssg17431
VSubgroups of T cells (Th : CD4(+) or Tc : CD8(+) ); naive (CD27(+) CD28(+) CD45RA(+) CCR7(+) ), central memory (CD27(+) CD28(+) CD45RA(-) CCR7(+) ), effector memory (early differentiated; CD27(+) CD28(+) CD45RA(-) CCR7(-) and late differentiated; CD27(-) CD28(-) CD45RA(-) CCR7(-) ), terminally differentiated effector cells (TEMRA; CD27(-) CD28(-) CD45RA(+) CCR7(-) ) and Treg (CD4(+) CD25(+) FOXP3(+) CD127(-) ) cells, and their expression of CD39, CD45RA, CD101 and CD129, were studied by flow cytometry in T1D and/or coeliac disease children or without any of these diseases (reference group).
p24061
sg17433
(lp24062
(dp24063
g17436
I247
sg17437
VCD27(-)
p24064
sg17438
I7
sg17439
VP26842
p24065
sg17441
I1
sa(dp24066
g17436
I445
sg17437
VCD39
p24067
sg17438
I4
sg17439
VP49961
p24068
sg17441
I1
sa(dp24069
g17436
I255
sg17437
VCD28(-) CD45RA(-) CCR7
p24070
sg17438
I22
sg17439
VP33681
p24071
sg17441
I3
sa(dp24072
g17436
I27
sg17437
VCD4
p24073
sg17438
I3
sg17439
VP01730
p24074
sg17441
I1
sa(dp24075
g17436
I341
sg17437
VCD28(-) CD45RA(+) CCR7
p24076
sg17438
I22
sg17439
VP33681
p24077
sg17441
I3
sa(dp24078
g17436
I247
sg17437
VCD27(-)
p24079
sg17438
I7
sg17439
VP26842
p24080
sg17441
I1
sa(dp24081
g17436
I112
sg17437
VCD27(+) CD28(+) CD45RA(-) CCR7
p24082
sg17438
I30
sg17439
VP26842
p24083
sg17441
I4
sa(dp24084
g17436
I42
sg17437
VCD8
p24085
sg17438
I3
sg17439
VP01732
p24086
sg17441
I1
sa(dp24087
g17436
I59
sg17437
VCD27(+) CD28(+) CD45RA(+) CCR7
p24088
sg17438
I30
sg17439
VP26842
p24089
sg17441
I4
sa(dp24090
g17436
I188
sg17437
VCD27(+) CD28(+) CD45RA(-) CCR7(-)
p24091
sg17438
I33
sg17439
VP26842
p24092
sg17441
I4
sa(dp24093
g17436
I459
sg17437
VCD101
p24094
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24095
g17436
I469
sg17437
VCD129
p24096
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24097
g17436
I379
sg17437
g24058
sg17438
I29
sg17439
VP01730
p24098
sg17441
I4
sasg17442
(lp24099
(dp24100
g17436
I521
sg17437
g24059
sg17438
I15
sg17445
VC0007570
p24101
sg17441
I2
sasa(dp24102
g135
(dp24103
(VCD4(+) CD25
p24104
Vcoeliac disease
p24105
tp24106
I00
ssg17431
VChildren with exclusively coeliac disease had a higher MFI of CD101 (P &lt; 0*01), as well as a higher percentage of CD129(+) (P &lt; 0*05), in the CD4(+) CD25(hi) lymphocyte population, compared to references.
p24107
sg17433
(lp24108
(dp24109
g17436
I62
sg17437
VCD101
p24110
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24111
g17436
I148
sg17437
g24104
sg17438
I11
sg17439
VP01730
p24112
sg17441
I2
sasg17442
(lp24113
(dp24114
g17436
I26
sg17437
g24105
sg17438
I15
sg17445
VC0007570
p24115
sg17441
I2
sasa(dp24116
g17431
VConversely, children with coeliac disease show signs of CD101(+) /CD129(+) Treg cells that may indicate suppressor activity.
p24117
sg17433
(lp24118
(dp24119
g17436
I66
sg17437
VCD129
p24120
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24121
(dp24122
g17436
I26
sg17437
Vcoeliac disease
p24123
sg17438
I15
sg17445
VC0007570
p24124
sg17441
I2
sasa(dp24125
g135
(dp24126
(VGARP
p24127
Vcholangitis
p24128
tp24129
I00
ssg17431
VFurther, to define the mechanism of action that explains the differential ability of C57BL/6 Treg versus dnTGF-BetaRII Treg on the ability to down-regulate autoimmune cholangitis, we noted significant differential expression of glycoprotein A repetitions predominant (GARP), CD73, CD101 and CD103 and a functionally significant increase in interleukin (IL)-10 in Treg from C57BL/6 compared to dnTGF-BetaRII mice.
p24130
sg17433
(lp24131
(dp24132
g17436
I340
sg17437
Vinterleukin (IL)-10
p24133
sg17438
I19
sg17439
VP60568
p24134
sg17441
I2
sa(dp24135
g17436
I275
sg17437
VCD73
p24136
sg17438
I4
sg17439
VP21589
p24137
sg17441
I1
sa(dp24138
g17436
I291
sg17437
VCD103
p24139
sg17438
I5
sg17439
VP38570
p24140
sg17441
I1
sa(dp24141
g17436
I281
sg17437
VCD101
p24142
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24143
g17436
I228
sg17437
Vglycoprotein A repetitions predominant
p24144
sg17438
I38
sg17439
VP55822
p24145
sg17441
I4
sa(dp24146
g17436
I268
sg17437
g24127
sg17438
I4
sg17439
VP55822
p24147
sg17441
I1
sasg17442
(lp24148
(dp24149
g17436
I167
sg17437
g24128
sg17438
I11
sg17445
VC0008311
p24150
sg17441
I1
sa(dp24151
g17436
I156
sg17437
Vautoimmune
p24152
sg17438
I10
sg17445
VC0443146
p24153
sg17441
I1
sasa(dp24154
g135
(dp24155
(VIFN-Gamma
p24156
Vliver disease
p24157
tp24158
I00
ssg17431
VCD101-knockout mice generated on the B6 background also exhibit substantially more severe N. aromaticivorans-induced liver disease correlating with increased IFN-Gamma and IL-17 responses compared with wild-type mice.
p24159
sg17433
(lp24160
(dp24161
g17436
I0
sg17437
VCD101
p24162
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24163
g17436
I158
sg17437
g24156
sg17438
I9
sg17439
VP01579
p24164
sg17441
I1
sasg17442
(lp24165
(dp24166
g17436
I117
sg17437
g24157
sg17438
I13
sg17445
VC0023895
p24167
sg17441
I2
sasa(dp24168
g135
(dp24169
(Vplasmin
p24170
Vgastroduodenitis
p24171
tp24172
I00
ssg17431
VGastric juice from 15 normals, 20 patients with gastric ulcer and 14 patients with erosive haemorrhagic gastroduodenitis was investigated in respect of its activity on unheated and heated fibrin plates and its content of FDP and plasminogen or plasmin with immunochemical methods.
p24173
sg17433
(lp24174
(dp24175
g17436
I188
sg17437
Vfibrin
p24176
sg17438
I6
sg17439
VP22087
p24177
sg17441
I1
sa(dp24178
g17436
I221
sg17437
VFDP
p24179
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp24180
g17436
I229
sg17437
Vplasminogen
p24181
sg17438
I11
sg17439
VP00747
p24182
sg17441
I1
sa(dp24183
g17436
I229
sg17437
g24170
sg17438
I7
sg17439
VP00747
p24184
sg17441
I1
sasg17442
(lp24185
(dp24186
g17436
I48
sg17437
Vgastric ulcer
p24187
sg17438
I13
sg17445
VC0038358
p24188
sg17441
I2
sa(dp24189
g17436
I104
sg17437
g24171
sg17438
I16
sg17445
VC0267166
p24190
sg17441
I1
sasa(dp24191
g135
(dp24192
(Vplasminogen
p24193
Vgastroduodenitis
p24194
tp24195
I00
ssg17431
VThe patients with erosive haemorrhagic gastroduodenitis showed no increase in fibrinolysis in the blood, but low values for plasminogen and alpha2-M, and the serum contained FDP.
p24196
sg17433
(lp24197
(dp24198
g17436
I174
sg17437
VFDP
p24199
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp24200
g17436
I124
sg17437
g24193
sg17438
I11
sg17439
VP00747
p24201
sg17441
I1
sasg17442
(lp24202
(dp24203
g17436
I39
sg17437
g24194
sg17438
I16
sg17445
VC0267166
p24204
sg17441
I1
sasa(dp24205
g17431
VIn the patient's lymphocytes, mRNA expression of TGFBeta2 was lower than control, and might cause DORV as it does in TGFBeta2-deficient mice.
p24206
sg17433
(lp24207
sg17442
(lp24208
(dp24209
g17436
I98
sg17437
VDORV
p24210
sg17438
I4
sg17445
VC0013069
p24211
sg17441
I1
sasa(dp24212
g135
(dp24213
(Vactivin receptor type IIA proteins
p24214
Vcleft palate
p24215
tp24216
I00
ssg17431
VActivin BA, follistatin, and activin receptor type IIA proteins were observed in normal and cleft palate tissues throughout pregnancy (gestational weeks 11 to 40).
p24217
sg17433
(lp24218
(dp24219
g17436
I0
sg17437
VActivin
p24220
sg17438
I7
sg17439
VP58166
p24221
sg17441
I1
sa(dp24222
g17436
I29
sg17437
g24214
sg17438
I34
sg17439
VP27037
p24223
sg17441
I5
sasg17442
(lp24224
(dp24225
g17436
I92
sg17437
g24215
sg17438
I12
sg17445
VC0008925
p24226
sg17441
I2
sasa(dp24227
g135
(dp24228
(Vfollistatin
p24229
Vcleft palate
p24230
tp24231
I00
ssg17431
VWe have previously shown that follistatin-deficient mice have numerous embryonic defects including shiny, taut skin, growth retardation, and cleft palate leading to death within hours of birth.
p24232
sg17433
(lp24233
(dp24234
g17436
I30
sg17437
g24229
sg17438
I11
sg17439
VP19883
p24235
sg17441
I1
sasg17442
(lp24236
(dp24237
g17436
I117
sg17437
Vgrowth retardation
p24238
sg17438
I18
sg17445
VC0151686
p24239
sg17441
I2
sa(dp24240
g17436
I141
sg17437
g24230
sg17438
I12
sg17445
VC0008925
p24241
sg17441
I2
sasa(dp24242
g135
(dp24243
(VIgG(2)anti-p80-coilin antibodies
p24244
Vrheumatic disease
p24245
tp24246
I00
ssg17431
VTwo rheumatic disease patients had a relatively high titer of IgG(2)anti-p80-coilin antibodies.
p24247
sg17433
(lp24248
(dp24249
g17436
I62
sg17437
g24244
sg17438
I32
sg17439
VP38432
p24250
sg17441
I2
sasg17442
(lp24251
(dp24252
g17436
I4
sg17437
g24245
sg17438
I17
sg17445
VC0035435
p24253
sg17441
I2
sasa(dp24254
g17431
VThe IgG(2)subclass of anti-p80-coilin antibodies may be a specific marker for systemic autoimmune disease.
p24255
sg17433
(lp24256
(dp24257
g17436
I22
sg17437
Vanti-p80-coilin antibodies
p24258
sg17438
I26
sg17439
VP38432
p24259
sg17441
I2
sasg17442
(lp24260
(dp24261
g17436
I78
sg17437
Vsystemic autoimmune disease
p24262
sg17438
I27
sg17445
VC2895206
p24263
sg17441
I3
sasa(dp24264
g135
(dp24265
(Vanti-p80-coilin antibody
p24266
Vlinear scleroderma
p24267
tp24268
I00
ssg17431
VThe patients with localized scleroderma who were positive for anti-p80-coilin antibody had all been classified as having linear scleroderma.
p24269
sg17433
(lp24270
(dp24271
g17436
I62
sg17437
g24266
sg17438
I24
sg17439
VP38432
p24272
sg17441
I2
sasg17442
(lp24273
(dp24274
g17436
I18
sg17437
Vlocalized scleroderma
p24275
sg17438
I21
sg17445
VC0036420
p24276
sg17441
I2
sa(dp24277
g17436
I121
sg17437
g24267
sg17438
I18
sg17445
VC0263409
p24278
sg17441
I2
sasa(dp24279
g135
(dp24280
(Vanti-p80-coilin antibody
p24281
Vlinear scleroderma
p24282
tp24283
I00
ssg17431
VOur data indicate that anti-p80-coilin antibody is uncommon in skin diseases: however, this antibody is present in patients with a milder form of linear scleroderma, although the incidence of positivity may not be high.
p24284
sg17433
(lp24285
(dp24286
g17436
I23
sg17437
g24281
sg17438
I24
sg17439
VP38432
p24287
sg17441
I2
sasg17442
(lp24288
(dp24289
g17436
I63
sg17437
Vskin diseases
p24290
sg17438
I13
sg17445
VC0037274
p24291
sg17441
I2
sa(dp24292
g17436
I146
sg17437
g24282
sg17438
I18
sg17445
VC0263409
p24293
sg17441
I2
sasa(dp24294
g135
(dp24295
(VSS-B
p24296
Vdermatomyositis
p24297
tp24298
I00
ssg17431
VWe also discuss several of the antigen-autoantibody systems found in systemic lupus erythematosus (Smith antigen, U1-nuclear ribonucleoprotein, SS-A/Ro, SS-B/La, proliferating cell nuclear antigen ribosomal ribonucleoprotein, double-strand DNA, histones, antiphospholipids, Ku, Ki/SL), systemic sclerosis (centromere, topo I, RNA polymerases, fibrillarin, polymyositis-Scl, Th/To), polymyositis/dermatomyositis (transferRNA synthetases, signal recognition particle, and others), and SS (SS-A/Ro, SS-B/La, nucleolar organizing region-90, p80-coilin), addressing their clinical significance, common detection methods, immunogenetic associations, and the molecular and cellular biology of the cognate antigens.
p24299
sg17433
(lp24300
(dp24301
g17436
I162
sg17437
Vproliferating cell nuclear antigen ribosomal ribonucleoprotein
p24302
sg17438
I62
sg17439
VP12004
p24303
sg17441
I6
sa(dp24304
g17436
I144
sg17437
VSS-A
p24305
sg17438
I4
sg17439
VP37268
p24306
sg17441
I1
sa(dp24307
g17436
I326
sg17437
VRNA polymerases
p24308
sg17438
I15
sg17439
g12
sg17441
I2
sa(dp24309
g17436
I343
sg17437
Vfibrillarin
p24310
sg17438
I11
sg17439
VP22087
p24311
sg17441
I1
sa(dp24312
g17436
I537
sg17437
Vp80
p24313
sg17438
I3
sg17439
VP20333
p24314
sg17441
I1
sa(dp24315
g17436
I153
sg17437
VSS-B
p24316
sg17438
I4
sg17439
VP37268
p24317
sg17441
I1
sa(dp24318
g17436
I114
sg17437
VU1-nuclear ribonucleoprotein
p24319
sg17438
I28
sg17439
VP26599
p24320
sg17441
I2
sa(dp24321
g17436
I541
sg17437
Vcoilin
p24322
sg17438
I6
sg17439
VP38432
p24323
sg17441
I1
sa(dp24324
g17436
I99
sg17437
VSmith antigen
p24325
sg17438
I13
sg17439
VP14209
p24326
sg17441
I2
sa(dp24327
g17436
I153
sg17437
g24296
sg17438
I4
sg17439
VP37268
p24328
sg17441
I1
sasg17442
(lp24329
(dp24330
g17436
I286
sg17437
Vsystemic sclerosis
p24331
sg17438
I18
sg17445
VC0036421
p24332
sg17441
I2
sa(dp24333
g17436
I356
sg17437
Vpolymyositis
p24334
sg17438
I12
sg17445
VC0085655
p24335
sg17441
I1
sa(dp24336
g17436
I69
sg17437
Vsystemic lupus erythematosus
p24337
sg17438
I28
sg17445
VC0024141
p24338
sg17441
I3
sa(dp24339
g17436
I356
sg17437
Vpolymyositis
p24340
sg17438
I12
sg17445
VC0085655
p24341
sg17441
I1
sa(dp24342
g17436
I395
sg17437
g24297
sg17438
I15
sg17445
VC0221056
p24343
sg17441
I1
sasa(dp24344
g17431
VHowever, IL-17 deficiency did not affect the development of dermatitis at all, in clear contrast to that of arthritis and aortitis.
p24345
sg17433
(lp24346
sg17442
(lp24347
(dp24348
g17436
I108
sg17437
Varthritis
p24349
sg17438
I9
sg17445
VC0003864
p24350
sg17441
I1
sa(dp24351
g17436
I122
sg17437
Vaortitis
p24352
sg17438
I8
sg17445
VC0003509
p24353
sg17441
I1
sa(dp24354
g17436
I60
sg17437
Vdermatitis
p24355
sg17438
I10
sg17445
VC0011603
p24356
sg17441
I1
sasa(dp24357
g135
(dp24358
(VTNFalpha
p24359
Varthritis
p24360
tp24361
I00
ssg17431
VThe development of arthritis and aortitis was significantly suppressed by the deficiency of TNFalpha or IL-17.
p24362
sg17433
(lp24363
(dp24364
g17436
I92
sg17437
g24359
sg17438
I8
sg17439
VP01375
p24365
sg17441
I1
sasg17442
(lp24366
(dp24367
g17436
I19
sg17437
g24360
sg17438
I9
sg17445
VC0003864
p24368
sg17441
I1
sa(dp24369
g17436
I33
sg17437
Vaortitis
p24370
sg17438
I8
sg17445
VC0003509
p24371
sg17441
I1
sasa(dp24372
g17431
VApolipoprotein E (ApoE) has been extensively studied in Alzheimer's disease (AD), but little is known of apolipoprotein A-I (ApoA-I) in cerebrospinal fluid (CSF).
p24373
sg17433
(lp24374
(dp24375
g17436
I105
sg17437
Vapolipoprotein A-I
p24376
sg17438
I18
sg17439
VP02647
p24377
sg17441
I2
sa(dp24378
g17436
I18
sg17437
VApoE
p24379
sg17438
I4
sg17439
VP02649
p24380
sg17441
I1
sa(dp24381
g17436
I0
sg17437
VApolipoprotein E
p24382
sg17438
I16
sg17439
VP02649
p24383
sg17441
I2
sa(dp24384
g17436
I125
sg17437
VApoA-I
p24385
sg17438
I6
sg17439
VP02647
p24386
sg17441
I1
sasg17442
(lp24387
(dp24388
g17436
I56
sg17437
VAlzheimer's disease
p24389
sg17438
I19
sg17445
VC1521724
p24390
sg17441
I2
sa(dp24391
g17436
I77
sg17437
VAD
p24392
sg17438
I2
sg17445
VC1521724
p24393
sg17441
I1
sasa(dp24394
g135
(dp24395
(VSyt1
p24396
Vbehavior disorders
p24397
tp24398
I00
ssg17431
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p24399
sg17433
(lp24400
(dp24401
g17436
I2137
sg17437
VSyt1
p24402
sg17438
I4
sg17439
VP21579
p24403
sg17441
I1
sa(dp24404
g17436
I1886
sg17437
VApoA1
p24405
sg17438
I5
sg17439
VP02647
p24406
sg17441
I1
sa(dp24407
g17436
I1065
sg17437
VLZ-H group
p24408
sg17438
I10
sg17439
VP00390
p24409
sg17441
I2
sa(dp24410
g17436
I2142
sg17437
VApoE
p24411
sg17438
I4
sg17439
VP02649
p24412
sg17441
I1
sa(dp24413
g17436
I145
sg17437
VAPP/PS-1
p24414
sg17438
I8
sg17439
VP48651
p24415
sg17441
I1
sa(dp24416
g17436
I2142
sg17437
VApoE
p24417
sg17438
I4
sg17439
VP02649
p24418
sg17441
I1
sa(dp24419
g17436
I2603
sg17437
VABeta-40 protein
p24420
sg17438
I16
sg17439
g12
sg17441
I2
sa(dp24421
g17436
I1886
sg17437
VApoA1
p24422
sg17438
I5
sg17439
VP02647
p24423
sg17441
I1
sa(dp24424
g17436
I2021
sg17437
VABeta-40
p24425
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp24426
g17436
I1065
sg17437
VLZ-H group
p24427
sg17438
I10
sg17439
VP00390
p24428
sg17441
I2
sa(dp24429
g17436
I145
sg17437
VAPP
p24430
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp24431
g17436
I1065
sg17437
VLZ-H group
p24432
sg17438
I10
sg17439
VP00390
p24433
sg17441
I2
sa(dp24434
g17436
I149
sg17437
VPS-1
p24435
sg17438
I4
sg17439
VP48651
p24436
sg17441
I1
sa(dp24437
g17436
I2137
sg17437
g24396
sg17438
I4
sg17439
VP21579
p24438
sg17441
I1
sasg17442
(lp24439
(dp24440
g17436
I102
sg17437
Vautoimmunity
p24441
sg17438
I12
sg17445
VC0004368
p24442
sg17441
I1
sa(dp24443
g17436
I172
sg17437
VAlzheimer's disease
p24444
sg17438
I19
sg17445
VC1521724
p24445
sg17441
I2
sa(dp24446
g17436
I2494
sg17437
g24397
sg17438
I18
sg17445
VC0004930
p24447
sg17441
I2
sa(dp24448
g17436
I653
sg17437
Vautoimmune
p24449
sg17438
I10
sg17445
VC0443146
p24450
sg17441
I1
sa(dp24451
g17436
I653
sg17437
Vautoimmune
p24452
sg17438
I10
sg17445
VC0443146
p24453
sg17441
I1
sasa(dp24454
g17431
VWe aimed to explore the correlations between eukaryotic translation initiation factor 3, subunit A (eIF3a) polymorphisms and susceptibility to and chemoradiotherapy efficacy in cervical carcinoma.
p24455
sg17433
(lp24456
(dp24457
g17436
I100
sg17437
VeIF3a
p24458
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24459
(dp24460
g17436
I177
sg17437
Vcervical carcinoma
p24461
sg17438
I18
sg17445
VC0302592
p24462
sg17441
I2
sasa(dp24463
g17431
VCompared with carriers of the CC genotype, carriers of the T genotype of the eIF3a Arg803Lys C&gt;T polymorphism had a higher risk of cervical carcinoma.
p24464
sg17433
(lp24465
(dp24466
g17436
I77
sg17437
VeIF3a Arg803Lys C
p24467
sg17438
I17
sg17439
g12
sg17441
I3
sasg17442
(lp24468
(dp24469
g17436
I134
sg17437
Vcervical carcinoma
p24470
sg17438
I18
sg17445
VC0302592
p24471
sg17441
I2
sasa(dp24472
g17431
VUnivariate analysis revealed that age, eIF3a Arg803Lys C&gt;T polymorphism, differentiation degree, FIGO stage, and LNM were prognostic factors of cervical carcinoma, and multivariate analysis showed that age &gt;= 60 years, higher FIGO stage, and LNM, as well as the CT and TT genotypes of the eIF3a Arg803Lys C&gt;T polymorphism, were risk factors related to the prognosis of cervical carcinoma.
p24473
sg17433
(lp24474
(dp24475
g17436
I39
sg17437
VeIF3a Arg803Lys C
p24476
sg17438
I17
sg17439
g12
sg17441
I3
sa(dp24477
g17436
I39
sg17437
VeIF3a Arg803Lys C
p24478
sg17438
I17
sg17439
g12
sg17441
I3
sasg17442
(lp24479
(dp24480
g17436
I147
sg17437
Vcervical carcinoma
p24481
sg17438
I18
sg17445
VC0302592
p24482
sg17441
I2
sa(dp24483
g17436
I147
sg17437
Vcervical carcinoma
p24484
sg17438
I18
sg17445
VC0302592
p24485
sg17441
I2
sasa(dp24486
g17431
VThe eIF3a Arg803Lys C&gt;T polymorphism is connected with a higher susceptibility to cervical carcinoma and may affect chemoradiotherapy efficacy in and prognosis of cervical carcinoma.
p24487
sg17433
(lp24488
(dp24489
g17436
I4
sg17437
VeIF3a Arg803Lys C
p24490
sg17438
I17
sg17439
g12
sg17441
I3
sasg17442
(lp24491
(dp24492
g17436
I85
sg17437
Vcervical carcinoma
p24493
sg17438
I18
sg17445
VC0302592
p24494
sg17441
I2
sa(dp24495
g17436
I85
sg17437
Vcervical carcinoma
p24496
sg17438
I18
sg17445
VC0302592
p24497
sg17441
I2
sasa(dp24498
g135
(dp24499
(Vneu
p24500
Vlymphoproliferative disorders
p24501
tp24502
I01
ssg17431
VThese findings suggest that the p185 neu may be a prognostic indicator not only for breast adenocarcinomas but also for lymphoproliferative disorders, and that the transforming p185 protein may be involved in the mechanisms of aggressive expansion of lymphoid neoplasias.
p24503
sg17433
(lp24504
(dp24505
g17436
I37
sg17437
g24500
sg17438
I3
sg17439
VP04626
p24506
sg17441
I1
sa(dp24507
g17436
I32
sg17437
Vp185
p24508
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp24509
g17436
I177
sg17437
Vp185 protein
p24510
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp24511
(dp24512
g17436
I227
sg17437
Vaggressive
p24513
sg17438
I10
sg17445
VC0001807
p24514
sg17441
I1
sa(dp24515
g17436
I91
sg17437
Vadenocarcinomas
p24516
sg17438
I15
sg17445
VC0001418
p24517
sg17441
I1
sa(dp24518
g17436
I120
sg17437
g24501
sg17438
I29
sg17445
VC0024314
p24519
sg17441
I2
sa(dp24520
g17436
I260
sg17437
Vneoplasias
p24521
sg17438
I10
sg17445
VC0027651
p24522
sg17441
I1
sasa(dp24523
g135
(dp24524
(VHER2
p24525
Vgastric adenocarcinoma
p24526
tp24527
I00
ssg17431
VThe authors investigated the correlation between clinicopathologic factors and the overexpression of the p185(HER2) in Korean gastric adenocarcinoma patients, and determined whether the antiproliferative effects of anti- p185(HER2) antibody can also be observed on gastric cancer cell lines that overexpress this growth factor receptor.
p24528
sg17433
(lp24529
(dp24530
g17436
I215
sg17437
Vanti- p185
p24531
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp24532
g17436
I110
sg17437
VHER2
p24533
sg17438
I4
sg17439
VP04626
p24534
sg17441
I1
sa(dp24535
g17436
I105
sg17437
Vp185
p24536
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp24537
g17436
I313
sg17437
Vgrowth factor receptor
p24538
sg17438
I22
sg17439
g12
sg17441
I3
sa(dp24539
g17436
I110
sg17437
g24525
sg17438
I4
sg17439
VP04626
p24540
sg17441
I1
sasg17442
(lp24541
(dp24542
g17436
I265
sg17437
Vgastric cancer
p24543
sg17438
I14
sg17445
VC0024623
p24544
sg17441
I2
sa(dp24545
g17436
I126
sg17437
g24526
sg17438
I22
sg17445
VC0278701
p24546
sg17441
I2
sasa(dp24547
g135
(dp24548
(VHER2
p24549
Vgastric adenocarcinoma
p24550
tp24551
I00
ssg17431
VWe evaluated the relationship between p185(HER2) overexpression and clinicopathological features in 94 (M: F=52: 42) gastric adenocarcinoma patients (median age 59 years).
p24552
sg17433
(lp24553
(dp24554
g17436
I43
sg17437
g24549
sg17438
I4
sg17439
VP04626
p24555
sg17441
I1
sa(dp24556
g17436
I38
sg17437
Vp185
p24557
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp24558
(dp24559
g17436
I117
sg17437
g24550
sg17438
I22
sg17445
VC0278701
p24560
sg17441
I2
sasa(dp24561
g135
(dp24562
(VHER2
p24563
Vgastric cancer
p24564
tp24565
I00
ssg17431
VTo explore the role of humanized anti-p185(HER2) monoclonal antibody trastuzumab (Herceptin ) in vitro, the growth curve of Korean gastric cancer cells that overexpress the p185(HER2) protein was studied and a cell cycle analysis was performed.
p24566
sg17433
(lp24567
(dp24568
g17436
I43
sg17437
VHER2
p24569
sg17438
I4
sg17439
VP04626
p24570
sg17441
I1
sa(dp24571
g17436
I23
sg17437
Vhumanized anti-p185
p24572
sg17438
I19
sg17439
g12
sg17441
I2
sa(dp24573
g17436
I43
sg17437
g24563
sg17438
I4
sg17439
VP04626
p24574
sg17441
I1
sa(dp24575
g17436
I38
sg17437
Vp185
p24576
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp24577
(dp24578
g17436
I131
sg17437
g24564
sg17438
I14
sg17445
VC0024623
p24579
sg17441
I2
sasa(dp24580
g135
(dp24581
(VHER2
p24582
Vgastric cancer
p24583
tp24584
I00
ssg17431
Vp185(HER2) overexpression was found to be more frequent in advanced gastric cancer than early gastric cancer (54.1% vs 24.2%, p=0.008).
p24585
sg17433
(lp24586
(dp24587
g17436
I5
sg17437
g24582
sg17438
I4
sg17439
VP04626
p24588
sg17441
I1
sa(dp24589
g17436
I0
sg17437
Vp185
p24590
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp24591
(dp24592
g17436
I88
sg17437
Vearly gastric cancer
p24593
sg17438
I20
sg17445
VC0349530
p24594
sg17441
I3
sa(dp24595
g17436
I68
sg17437
g24583
sg17438
I14
sg17445
VC0024623
p24596
sg17441
I2
sasa(dp24597
g135
(dp24598
(VHER2
p24599
Vgastric cancer
p24600
tp24601
I00
ssg17431
VAmong several Korean gastric cancer cell lines, SNU-1, SNU-5, and SNU-620 overexpress p185(HER2).
p24602
sg17433
(lp24603
(dp24604
g17436
I86
sg17437
Vp185
p24605
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp24606
g17436
I91
sg17437
g24599
sg17438
I4
sg17439
VP04626
p24607
sg17441
I1
sasg17442
(lp24608
(dp24609
g17436
I21
sg17437
g24600
sg17438
I14
sg17445
VC0024623
p24610
sg17441
I2
sasa(dp24611
g135
(dp24612
(VHER2
p24613
Vgastric cancer
p24614
tp24615
I00
ssg17431
VTrastuzumab inhibited the proliferation of p185(HER2) overexpressed Korean gastric cancer cell line by 21% with down-regulation of p185(HER2) protein expression.
p24616
sg17433
(lp24617
(dp24618
g17436
I43
sg17437
Vp185
p24619
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp24620
g17436
I48
sg17437
VHER2
p24621
sg17438
I4
sg17439
VP04626
p24622
sg17441
I1
sa(dp24623
g17436
I48
sg17437
g24613
sg17438
I4
sg17439
VP04626
p24624
sg17441
I1
sa(dp24625
g17436
I43
sg17437
Vp185
p24626
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp24627
(dp24628
g17436
I75
sg17437
g24614
sg17438
I14
sg17445
VC0024623
p24629
sg17441
I2
sa(dp24630
g17436
I26
sg17437
Vproliferation
p24631
sg17438
I13
sg17445
VC0334094
p24632
sg17441
I1
sasa(dp24633
g135
(dp24634
(VHER2
p24635
Vgastric adenocarcinoma
p24636
tp24637
I00
ssg17431
VS: Taken together, our observations suggest the potential prognostic significance of p185(HER2) overexpression in Korean gastric adenocarcinoma patients and point to the need for further research on this mechanism.
p24638
sg17433
(lp24639
(dp24640
g17436
I85
sg17437
Vp185
p24641
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp24642
g17436
I90
sg17437
g24635
sg17438
I4
sg17439
VP04626
p24643
sg17441
I1
sasg17442
(lp24644
(dp24645
g17436
I121
sg17437
g24636
sg17438
I22
sg17445
VC0278701
p24646
sg17441
I2
sasa(dp24647
g135
(dp24648
(VHER2
p24649
Vgastric cancer
p24650
tp24651
I00
ssg17431
VThis suggests the possible use of p185(HER2) as a therapeutic target in gastric cancer.
p24652
sg17433
(lp24653
(dp24654
g17436
I39
sg17437
g24649
sg17438
I4
sg17439
VP04626
p24655
sg17441
I1
sa(dp24656
g17436
I34
sg17437
Vp185
p24657
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp24658
(dp24659
g17436
I72
sg17437
g24650
sg17438
I14
sg17445
VC0024623
p24660
sg17441
I2
sasa(dp24661
g135
(dp24662
(VHER2
p24663
VGC
p24664
tp24665
I00
ssg17431
VAdministration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER2, p185), has improved outcomes for patients with HER2-positive gastric cancer (GC), but some relevant issues remain to be investigated and will emerge with new anti-GC drugs.
p24666
sg17433
(lp24667
(dp24668
g17436
I85
sg17437
Vhuman epidermal growth factor receptor 2
p24669
sg17438
I40
sg17439
VP01133
p24670
sg17441
I6
sa(dp24671
g17436
I127
sg17437
VHER2
p24672
sg17438
I4
sg17439
VP04626
p24673
sg17441
I1
sa(dp24674
g17436
I133
sg17437
Vp185
p24675
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp24676
g17436
I127
sg17437
g24663
sg17438
I4
sg17439
VP04626
p24677
sg17441
I1
sasg17442
(lp24678
(dp24679
g17436
I194
sg17437
Vgastric cancer
p24680
sg17438
I14
sg17445
VC0024623
p24681
sg17441
I2
sa(dp24682
g17436
I210
sg17437
VGC
p24683
sg17438
I2
sg17445
VC0024623
p24684
sg17441
I1
sa(dp24685
g17436
I210
sg17437
g24664
sg17438
I2
sg17445
VC0024623
p24686
sg17441
I1
sasa(dp24687
g17431
VEukaryotic translation initiation factor 3 subunit A (eIF3a) plays critical roles in regulating the initiation of protein translation, and eIF3a is highly expressed in lung cancer.
p24688
sg17433
(lp24689
(dp24690
g17436
I54
sg17437
VeIF3a
p24691
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24692
g17436
I54
sg17437
VeIF3a
p24693
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24694
g17436
I0
sg17437
VEukaryotic translation initiation factor 3 subunit A
p24695
sg17438
I52
sg17439
g12
sg17441
I7
sasg17442
(lp24696
(dp24697
g17436
I168
sg17437
Vlung cancer
p24698
sg17438
I11
sg17445
VC0684249
p24699
sg17441
I2
sasa(dp24700
g17431
VIn this study, we investigated the association of the positively selected SNPs of eIF3a with the response to and toxicity of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC).
p24701
sg17433
(lp24702
(dp24703
g17436
I82
sg17437
VeIF3a
p24704
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24705
(dp24706
g17436
I206
sg17437
VNSCLC
p24707
sg17438
I5
sg17445
VC0007131
p24708
sg17441
I1
sa(dp24709
g17436
I178
sg17437
Vnon-small cell lung cancer
p24710
sg17438
I26
sg17445
VC0007131
p24711
sg17441
I4
sasa(dp24712
g17431
VThe positively selected SNPs of eIF3a are significantly correlated with platinum-based chemotherapy toxicities in Chinese NSCLC patients.
p24713
sg17433
(lp24714
(dp24715
g17436
I32
sg17437
VeIF3a
p24716
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24717
(dp24718
g17436
I122
sg17437
VNSCLC
p24719
sg17438
I5
sg17445
VC0007131
p24720
sg17441
I1
sasa(dp24721
g135
(dp24722
(Vhuman epididymis protein 4
p24723
Vovarian cancer
p24724
tp24725
I00
ssg17431
VTo investigate the correlation between eukaryotic translation initiation factor 3, subunit A (eIF3a) and human epididymis protein 4 (HE4) expression and ovarian cancer.
p24726
sg17433
(lp24727
(dp24728
g17436
I133
sg17437
VHE4
p24729
sg17438
I3
sg17439
VP01031
p24730
sg17441
I1
sa(dp24731
g17436
I105
sg17437
g24723
sg17438
I26
sg17439
VP01031
p24732
sg17441
I4
sa(dp24733
g17436
I94
sg17437
VeIF3a
p24734
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24735
(dp24736
g17436
I153
sg17437
g24724
sg17438
I14
sg17445
VC1140680
p24737
sg17441
I2
sasa(dp24738
g17431
VRT-PCR or immunohistochemistry was used to examine eIF3a and HE4 mRNA or protein expression in ovarian tissues from patients with ovarian cancer (n=181) or benign ovarian tumors, or from the healthy women.
p24739
sg17433
(lp24740
(dp24741
g17436
I51
sg17437
VeIF3a
p24742
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24743
(dp24744
g17436
I130
sg17437
Vovarian cancer
p24745
sg17438
I14
sg17445
VC1140680
p24746
sg17441
I2
sa(dp24747
g17436
I156
sg17437
Vbenign ovarian tumors
p24748
sg17438
I21
sg17445
VC0004997
p24749
sg17441
I3
sasa(dp24750
g17431
VThere were significant differences in mRNA and protein expression of eIF3a and HE4 among normal ovarian tissues, benign ovarian tumor tissues, and ovarian cancer tissues (P&lt; 0.05).
p24751
sg17433
(lp24752
(dp24753
g17436
I69
sg17437
VeIF3a
p24754
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24755
(dp24756
g17436
I147
sg17437
Vovarian cancer
p24757
sg17438
I14
sg17445
VC1140680
p24758
sg17441
I2
sa(dp24759
g17436
I113
sg17437
Vbenign ovarian tumor
p24760
sg17438
I20
sg17445
VC0004997
p24761
sg17441
I3
sasa(dp24762
g17431
VThere were significant differences in mRNA expression of eIF3a and HE4 between the normal tissues and the ovarian cancer tissues, or between the benign ovarian tumor tissues and the normal tissues (P&lt; 0.001).
p24763
sg17433
(lp24764
(dp24765
g17436
I57
sg17437
VeIF3a
p24766
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24767
(dp24768
g17436
I145
sg17437
Vbenign ovarian tumor
p24769
sg17438
I20
sg17445
VC0004997
p24770
sg17441
I3
sa(dp24771
g17436
I106
sg17437
Vovarian cancer
p24772
sg17438
I14
sg17445
VC1140680
p24773
sg17441
I2
sasa(dp24774
g17431
VThe mRNA expression of eIF3a in the normal ovarian tissues was significantly higher than that in the benign ovarian tumor tissues or that in the ovarian cancer tissues.
p24775
sg17433
(lp24776
(dp24777
g17436
I23
sg17437
VeIF3a
p24778
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24779
(dp24780
g17436
I101
sg17437
Vbenign ovarian tumor
p24781
sg17438
I20
sg17445
VC0004997
p24782
sg17441
I3
sa(dp24783
g17436
I145
sg17437
Vovarian cancer
p24784
sg17438
I14
sg17445
VC1140680
p24785
sg17441
I2
sasa(dp24786
g17431
VPositive expression rates for eIF3a or HE4 protein in normal, benign tumor, and cancer tissues were 0, 66.7%, and 81.0% or 0, 27.8%, and 56.2%, respectively.
p24787
sg17433
(lp24788
(dp24789
g17436
I30
sg17437
VeIF3a
p24790
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24791
(dp24792
g17436
I62
sg17437
Vbenign tumor
p24793
sg17438
I12
sg17445
VC0086692
p24794
sg17441
I2
sa(dp24795
g17436
I80
sg17437
Vcancer
p24796
sg17438
I6
sg17445
VC0006826
p24797
sg17441
I1
sasa(dp24798
g17431
VThere were significant differences in positive expression rates of eIF3a protein and HE4 protein between the ovarian tumor tissues and benign ovarian tumor tissues, between the ovarian cancer tissues and the normal ovarian tissues, or between the benign ovarian tumor tissues and the normal ovarian tissues (P&lt; 0.001).
p24799
sg17433
(lp24800
(dp24801
g17436
I67
sg17437
VeIF3a protein
p24802
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp24803
(dp24804
g17436
I135
sg17437
Vbenign ovarian tumor
p24805
sg17438
I20
sg17445
VC0004997
p24806
sg17441
I3
sa(dp24807
g17436
I109
sg17437
Vovarian tumor
p24808
sg17438
I13
sg17445
VC0919267
p24809
sg17441
I2
sa(dp24810
g17436
I135
sg17437
Vbenign ovarian tumor
p24811
sg17438
I20
sg17445
VC0004997
p24812
sg17441
I3
sa(dp24813
g17436
I177
sg17437
Vovarian cancer
p24814
sg17438
I14
sg17445
VC1140680
p24815
sg17441
I2
sasa(dp24816
g135
(dp24817
(Vextracellular regulated protein kinases
p24818
Vovarian cancer
p24819
tp24820
I00
ssg17431
VThe expressions of eIF3a and HE4 are associated with ovarian cancer, and extracellular regulated protein kinases may play a role in the interaction between eIF3a and HE4.
p24821
sg17433
(lp24822
(dp24823
g17436
I19
sg17437
VeIF3a
p24824
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp24825
g17436
I73
sg17437
g24818
sg17438
I39
sg17439
VP10398
p24826
sg17441
I4
sa(dp24827
g17436
I19
sg17437
VeIF3a
p24828
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp24829
(dp24830
g17436
I53
sg17437
g24819
sg17438
I14
sg17445
VC1140680
p24831
sg17441
I2
sasa(dp24832
g135
(dp24833
(VBCR
p24834
VALL
p24835
tp24836
I00
ssg17431
VWe describe an ultrasensitive electrochemical nucleic acid assay amplified by carbon nanotubes (CNTs)-based labels for the detection of human acute lymphocytic leukemia (ALL)-related p185 BCR-ABL fusion transcript.
p24837
sg17433
(lp24838
(dp24839
g17436
I192
sg17437
VABL
p24840
sg17438
I3
sg17439
VP55157
p24841
sg17441
I1
sa(dp24842
g17436
I183
sg17437
Vp185
p24843
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp24844
g17436
I188
sg17437
g24834
sg17438
I3
sg17439
VP11274
p24845
sg17441
I1
sasg17442
(lp24846
(dp24847
g17436
I192
sg17437
VABL
p24848
sg17438
I3
sg17445
VC0000744
p24849
sg17441
I1
sa(dp24850
g17436
I142
sg17437
Vacute lymphocytic leukemia
p24851
sg17438
I26
sg17445
VC1961102
p24852
sg17441
I3
sa(dp24853
g17436
I170
sg17437
g24835
sg17438
I3
sg17445
VC1961102
p24854
sg17441
I1
sasa(dp24855
g135
(dp24856
(VCD61+
p24857
Vobesity
p24858
tp24859
I00
ssg17431
VPlasma levels of annexin V-MP, endothelial-derived MP, platelet-derived MP (CD61+ and P-Selectin+), leukocyte-derived MP, tissue factor-bearing (TF+) and CD36+MP were prospectively measured in 20 patients with III degree obesity (BMI &gt;= 40 kg/m(2)) before (T0) and 3 (T3) and 12 (T12) months after sleeve gastrectomy (SLG).
p24860
sg17433
(lp24861
(dp24862
g17436
I100
sg17437
Vleukocyte-derived MP, tissue factor-bearing (TF+)
p24863
sg17438
I49
sg17439
VP13726
p24864
sg17441
I5
sa(dp24865
g17436
I17
sg17437
Vannexin V-MP, endothelial-derived MP, platelet-derived MP
p24866
sg17438
I57
sg17439
VP08758
p24867
sg17441
I6
sa(dp24868
g17436
I76
sg17437
g24857
sg17438
I5
sg17439
VP05106
p24869
sg17441
I1
sasg17442
(lp24870
(dp24871
g17436
I221
sg17437
g24858
sg17438
I7
sg17445
VC0028754
p24872
sg17441
I1
sasa(dp24873
g135
(dp24874
(Vheme oxygenase-1
p24875
Vacute myocardial infarction
p24876
tp24877
I00
ssg17431
VKey messages Bilirubin levels are inversely related to cardiovascular disease, and overexpression of heme oxygenase-1 (the enzyme that determines bilirubin production) has prevented post-infarction ventricular remodeling in experimental animals, but the association between bilirubin levels and the progression of ventricular volumes and function in patients with acute myocardial infarction remained unexplored.
p24878
sg17433
(lp24879
(dp24880
g17436
I101
sg17437
g24875
sg17438
I16
sg17439
VP09601
p24881
sg17441
I2
sasg17442
(lp24882
(dp24883
g17436
I187
sg17437
Vinfarction
p24884
sg17438
I10
sg17445
VC0021308
p24885
sg17441
I1
sa(dp24886
g17436
I55
sg17437
Vcardiovascular disease
p24887
sg17438
I22
sg17445
VC0007222
p24888
sg17441
I2
sa(dp24889
g17436
I364
sg17437
g24876
sg17438
I27
sg17445
VC0155626
p24890
sg17441
I3
sasa(dp24891
g135
(dp24892
(VHO-1
p24893
Vacute myocardial infarction
p24894
tp24895
I00
ssg17431
VHO-1 is known to be protective in the setting of acute myocardial infarction.
p24896
sg17433
(lp24897
(dp24898
g17436
I0
sg17437
g24893
sg17438
I4
sg17439
VP09601
p24899
sg17441
I1
sasg17442
(lp24900
(dp24901
g17436
I49
sg17437
g24894
sg17438
I27
sg17445
VC0155626
p24902
sg17441
I3
sasa(dp24903
g135
(dp24904
(Venteropeptidase
p24905
Vacute pancreatitis
p24906
tp24907
I00
ssg17431
VIn vitro experiments revealed enteropeptidase as a putative substrate for Bace1 suggesting a role in acute pancreatitis.
p24908
sg17433
(lp24909
(dp24910
g17436
I74
sg17437
VBace1
p24911
sg17438
I5
sg17439
VP56817
p24912
sg17441
I1
sa(dp24913
g17436
I30
sg17437
g24905
sg17438
I15
sg17439
VP98073
p24914
sg17441
I1
sasg17442
(lp24915
(dp24916
g17436
I101
sg17437
g24906
sg17438
I18
sg17445
VC0001339
p24917
sg17441
I2
sasa(dp24918
g135
(dp24919
(VU/kg enterokinase
p24920
Vacute necrotizing pancreatitis
p24921
tp24922
I00
ssg17431
Vacute necrotizing pancreatitis was induced in anesthetized pigs by the retrograde infusion of 1 ml/kg of 5% sodium taurocholate and 8 U/kg enterokinase in the pancreatic duct.
p24923
sg17433
(lp24924
(dp24925
g17436
I134
sg17437
g24920
sg17438
I17
sg17439
VP98073
p24926
sg17441
I2
sasg17442
(lp24927
(dp24928
g17436
I0
sg17437
g24921
sg17438
I30
sg17445
VC0267941
p24929
sg17441
I3
sasa(dp24930
g135
(dp24931
(Venteropeptidase
p24932
Vreflux
p24933
tp24934
I00
ssg17431
VConversely, duodenopancreatic reflux of proteolytically active enteropeptidase may cause acute and chronic pancreatitis.
p24935
sg17433
(lp24936
(dp24937
g17436
I63
sg17437
g24932
sg17438
I15
sg17439
VP98073
p24938
sg17441
I1
sasg17442
(lp24939
(dp24940
g17436
I99
sg17437
Vchronic pancreatitis
p24941
sg17438
I20
sg17445
VC0149521
p24942
sg17441
I2
sa(dp24943
g17436
I30
sg17437
g24933
sg17438
I6
sg17445
VC0017168
p24944
sg17441
I1
sasa(dp24945
g135
(dp24946
(Vcerulein/enterokinase
p24947
Vpancreatitis
p24948
tp24949
I00
ssg17431
VA noninvasive model of necrohemorrhagic pancreatitis induced by simultaneous intravenous cerulein/enterokinase (EK) infusion has recently been established in rats.
p24950
sg17433
(lp24951
(dp24952
g17436
I112
sg17437
VEK
p24953
sg17438
I2
sg17439
VP98073
p24954
sg17441
I1
sa(dp24955
g17436
I89
sg17437
g24947
sg17438
I21
sg17439
VP98073
p24956
sg17441
I1
sasg17442
(lp24957
(dp24958
g17436
I40
sg17437
g24948
sg17438
I12
sg17445
VC0030305
p24959
sg17441
I1
sasa(dp24960
g135
(dp24961
(Vtaurocholate - enterokinase
p24962
VAP
p24963
tp24964
I00
ssg17431
VStudy hemodynamic pattern and lipoperoxidation during methylene blue (MB) treatment on taurocholate - enterokinase induced acute pancreatitis (AP).
p24965
sg17433
(lp24966
(dp24967
g17436
I87
sg17437
g24962
sg17438
I27
sg17439
VP98073
p24968
sg17441
I3
sasg17442
(lp24969
(dp24970
g17436
I123
sg17437
Vacute pancreatitis
p24971
sg17438
I18
sg17445
VC0001339
p24972
sg17441
I2
sa(dp24973
g17436
I143
sg17437
g24963
sg17438
I2
sg17445
VC0001339
p24974
sg17441
I1
sasa(dp24975
g135
(dp24976
(V21-hydroxylase
p24977
V21-hydroxylase deficiency
p24978
tp24979
I00
ssg17431
VThe HLA-B47,DR7 haplotype in congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency contains a deletion of most of the active CYP21 gene and the entire adjacent C4B gene.
p24980
sg17433
(lp24981
(dp24982
g17436
I141
sg17437
VCYP21 gene
p24983
sg17438
I10
sg17439
VP08686
p24984
sg17441
I2
sa(dp24985
g17436
I176
sg17437
VC4B gene
p24986
sg17438
I8
sg17439
VP04003
p24987
sg17441
I2
sa(dp24988
g17436
I12
sg17437
VDR7 haplotype
p24989
sg17438
I13
sg17439
VP13761
p24990
sg17441
I2
sa(dp24991
g17436
I4
sg17437
VHLA-B47
p24992
sg17438
I7
sg17439
VP30486
p24993
sg17441
I1
sa(dp24994
g17436
I73
sg17437
g24977
sg17438
I14
sg17439
VP08686
p24995
sg17441
I1
sasg17442
(lp24996
(dp24997
g17436
I61
sg17437
VCAH
p24998
sg17438
I3
sg17445
VC0520463
p24999
sg17441
I1
sa(dp25000
g17436
I29
sg17437
Vcongenital adrenal hyperplasia
p25001
sg17438
I30
sg17445
VC0001627
p25002
sg17441
I3
sa(dp25003
g17436
I73
sg17437
g24978
sg17438
I25
sg17445
VC0852654
p25004
sg17441
I2
sasa(dp25005
g135
(dp25006
(Vsteroid 21-hydroxylase A pseudogene
p25007
VCAH
p25008
tp25009
I00
ssg17431
VThe HLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7 is associated with congenital adrenal hyperplasia (CAH), since it only carries the dysfunctional steroid 21-hydroxylase A pseudogene as well as the 5' adjacent complement C4A gene.
p25010
sg17433
(lp25011
(dp25012
g17436
I4
sg17437
VHLA haplotype A3-Cw6-B47-C4A91-BQ0-DR7
p25013
sg17438
I38
sg17439
VP30486
p25014
sg17441
I3
sa(dp25015
g17436
I140
sg17437
g25007
sg17438
I35
sg17439
VP08686
p25016
sg17441
I4
sa(dp25017
g17436
I191
sg17437
V5' adjacent complement C4A gene
p25018
sg17438
I31
sg17439
g12
sg17441
I5
sasg17442
(lp25019
(dp25020
g17436
I62
sg17437
Vcongenital adrenal hyperplasia
p25021
sg17438
I30
sg17445
VC0001627
p25022
sg17441
I3
sa(dp25023
g17436
I94
sg17437
g25008
sg17438
I3
sg17445
VC0520463
p25024
sg17441
I1
sasa(dp25025
g17431
VThe mutation of vesicle-associated membrane protein-associated protein B (VAPB) was proved to cause family amyotrophic lateral sclerosis (FALS).
p25026
sg17433
(lp25027
(dp25028
g17436
I16
sg17437
Vvesicle-associated membrane protein-associated protein B
p25029
sg17438
I56
sg17439
g12
sg17441
I5
sa(dp25030
g17436
I74
sg17437
VVAPB
p25031
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp25032
(dp25033
g17436
I138
sg17437
VFALS
p25034
sg17438
I4
sg17445
VC1862939
p25035
sg17441
I1
sa(dp25036
g17436
I100
sg17437
Vfamily amyotrophic lateral sclerosis
p25037
sg17438
I36
sg17445
VC1862939
p25038
sg17441
I4
sa(dp25039
g17436
I16
sg17437
Vvesicle
p25040
sg17438
I7
sg17445
VC0333262
p25041
sg17441
I1
sasa(dp25042
g17431
VALS8 is a late-onset familial autosomal dominant form of Amyotrophic Lateral Sclerosis (ALS) caused by a point mutation (P56S) in the VAPB gene (VAMP associated protein isoform B).
p25043
sg17433
(lp25044
(dp25045
g17436
I0
sg17437
VALS8
p25046
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25047
g17436
I134
sg17437
VVAPB gene
p25048
sg17438
I9
sg17439
g12
sg17441
I2
sa(dp25049
g17436
I145
sg17437
VVAMP associated protein isoform B
p25050
sg17438
I33
sg17439
g12
sg17441
I5
sasg17442
(lp25051
(dp25052
g17436
I0
sg17437
VALS8
p25053
sg17438
I4
sg17445
VC1837728
p25054
sg17441
I1
sa(dp25055
g17436
I0
sg17437
VALS
p25056
sg17438
I3
sg17445
VC0002736
p25057
sg17441
I1
sa(dp25058
g17436
I57
sg17437
VAmyotrophic Lateral Sclerosis
p25059
sg17438
I29
sg17445
VC0002736
p25060
sg17441
I3
sasa(dp25061
g17431
VThis supports the loss of VAPB function in ALS8 pathogenesis and suggests that reducing intracellular PtdIns4P might be an effective therapeutic strategy in delaying progressive loss of motor neurons.
p25062
sg17433
(lp25063
(dp25064
g17436
I43
sg17437
VALS8
p25065
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25066
g17436
I26
sg17437
VVAPB
p25067
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25068
g17436
I79
sg17437
Vreducing intracellular PtdIns4P
p25069
sg17438
I31
sg17439
g12
sg17441
I3
sasg17442
(lp25070
(dp25071
g17436
I48
sg17437
Vpathogenesis
p25072
sg17438
I12
sg17445
VC0699748
p25073
sg17441
I1
sa(dp25074
g17436
I43
sg17437
VALS8
p25075
sg17438
I4
sg17445
VC1837728
p25076
sg17441
I1
sasa(dp25077
g17431
VMutations in VAP-B that have been identified in familial forms of amyotrophic lateral sclerosis (ALS or Lou-Gehrig's disease) cause aggregation of the VAP-B protein, which then impairs its binding to several proteins, including Nir2.
p25078
sg17433
(lp25079
(dp25080
g17436
I228
sg17437
VNir2
p25081
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25082
g17436
I13
sg17437
VVAP-B
p25083
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25084
g17436
I151
sg17437
VVAP-B protein
p25085
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp25086
(dp25087
g17436
I97
sg17437
VALS
p25088
sg17438
I3
sg17445
VC0002736
p25089
sg17441
I1
sa(dp25090
g17436
I66
sg17437
Vamyotrophic lateral sclerosis
p25091
sg17438
I29
sg17445
VC0002736
p25092
sg17441
I3
sa(dp25093
g17436
I108
sg17437
VGehrig's disease
p25094
sg17438
I16
sg17445
VC0002736
p25095
sg17441
I2
sasa(dp25096
g17431
VA mutation in VAPB causes a familial form of Amyotrophic Lateral Sclerosis.
p25097
sg17433
(lp25098
(dp25099
g17436
I14
sg17437
VVAPB
p25100
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp25101
(dp25102
g17436
I45
sg17437
VAmyotrophic Lateral Sclerosis
p25103
sg17438
I29
sg17445
VC0002736
p25104
sg17441
I3
sasa(dp25105
g17431
VWe present two cases of Peters anomaly (Peters plus syndrome and a maximum manifestation variant) with abnormally thickened cornea and corneal staphyloma.
p25106
sg17433
(lp25107
sg17442
(lp25108
(dp25109
g17436
I24
sg17437
VPeters anomaly
p25110
sg17438
I14
sg17445
VC0344559
p25111
sg17441
I2
sa(dp25112
g17436
I135
sg17437
Vcorneal staphyloma
p25113
sg17438
I18
sg17445
VC0152440
p25114
sg17441
I2
sa(dp25115
g17436
I40
sg17437
VPeters plus syndrome
p25116
sg17438
I20
sg17445
VC0796012
p25117
sg17441
I3
sasa(dp25118
g135
(dp25119
(VWnt3a
p25120
Vhepatocellular carcinoma
p25121
tp25122
I00
ssg17431
VWnt3a and Wnt5a are ligands orchestrating the canonical and non-canonical pathways, respectively, with involvement in hepatocellular carcinoma (HCC).
p25123
sg17433
(lp25124
(dp25125
g17436
I10
sg17437
VWnt5a
p25126
sg17438
I5
sg17439
VP41221
p25127
sg17441
I1
sa(dp25128
g17436
I0
sg17437
g25120
sg17438
I5
sg17439
VP56704
p25129
sg17441
I1
sasg17442
(lp25130
(dp25131
g17436
I144
sg17437
VHCC
p25132
sg17438
I3
sg17445
VC2239176
p25133
sg17441
I1
sa(dp25134
g17436
I118
sg17437
g25121
sg17438
I24
sg17445
VC2239176
p25135
sg17441
I2
sasa(dp25136
g135
(dp25137
(VWnt3a
p25138
Vhepatocellular carcinoma
p25139
tp25140
I00
ssg17431
VTo investigate member 3a of Wingless-type MMTV integration site family (Wnt3a) expression in cancerous and surrounding tissues and the relationship between clinicopathologic features of hepatocellular carcinoma (HCC) and Wnt3a expression.
p25141
sg17433
(lp25142
(dp25143
g17436
I15
sg17437
Vmember 3a
p25144
sg17438
I9
sg17439
VP61587
p25145
sg17441
I2
sa(dp25146
g17436
I72
sg17437
VWnt3a
p25147
sg17438
I5
sg17439
VP56704
p25148
sg17441
I1
sa(dp25149
g17436
I28
sg17437
VWingless-type MMTV integration site family
p25150
sg17438
I42
sg17439
g12
sg17441
I5
sa(dp25151
g17436
I72
sg17437
g25138
sg17438
I5
sg17439
VP56704
p25152
sg17441
I1
sasg17442
(lp25153
(dp25154
g17436
I212
sg17437
VHCC
p25155
sg17438
I3
sg17445
VC2239176
p25156
sg17441
I1
sa(dp25157
g17436
I186
sg17437
g25139
sg17438
I24
sg17445
VC2239176
p25158
sg17441
I2
sasa(dp25159
g135
(dp25160
(VGAD67
p25161
VSchizophrenia
p25162
tp25163
I01
ssg17431
VWe then use a realistic GENESIS model to test two hypothesis about interneuron hypofunction and conclude that a reduction in GAD67 is the most likely candidate as the cause for hypofrontality as observed in Schizophrenia.
p25164
sg17433
(lp25165
(dp25166
g17436
I125
sg17437
g25161
sg17438
I5
sg17439
VP49419
p25167
sg17441
I1
sasg17442
(lp25168
(dp25169
g17436
I79
sg17437
Vhypofunction
p25170
sg17438
I12
sg17445
VC0679221
p25171
sg17441
I1
sa(dp25172
g17436
I207
sg17437
g25162
sg17438
I13
sg17445
VC0036341
p25173
sg17441
I1
sasa(dp25174
g135
(dp25175
(VCYP3A5
p25176
Vmetastatic renal cell carcinoma
p25177
tp25178
I01
ssg17431
VThe objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients.
p25179
sg17433
(lp25180
(dp25181
g17436
I74
sg17437
VATP binding cassette subfamily B member 1
p25182
sg17438
I41
sg17439
g12
sg17441
I7
sa(dp25183
g17436
I117
sg17437
VABCB1
p25184
sg17438
I5
sg17439
VP08183
p25185
sg17441
I1
sa(dp25186
g17436
I63
sg17437
g25176
sg17438
I6
sg17439
VP20815
p25187
sg17441
I1
sasg17442
(lp25188
(dp25189
g17436
I271
sg17437
g25177
sg17438
I31
sg17445
VC0278678
p25190
sg17441
I4
sasa(dp25191
g17431
VPolymorphisms in VEGFR3 and CYP3A5*1 might be able to define a subset of patients with renal-cell carcinoma with decreased sunitinib response and tolerability.
p25192
sg17433
(lp25193
(dp25194
g17436
I28
sg17437
VCYP3A5*1
p25195
sg17438
I8
sg17439
VP20815
p25196
sg17441
I1
sa(dp25197
g17436
I17
sg17437
VVEGFR3
p25198
sg17438
I6
sg17439
VP35916
p25199
sg17441
I1
sasg17442
(lp25200
(dp25201
g17436
I98
sg17437
Vcarcinoma
p25202
sg17438
I9
sg17445
VC0007097
p25203
sg17441
I1
sasa(dp25204
g135
(dp25205
(VSRs
p25206
VSRs
p25207
tp25208
I00
ssg17431
VTo examine whether common genetic variation at the SLC10A1 locus is associated with risk of persistent HBV infection, haplotype-tagging and imputed single nucleotide polymorphisms (SNPs) were assessed in two case-control sample sets, totally including 2,550 cases (persistently HBV infected subjects, PIs) and 2,124 controls (spontaneously recovered subjects, SRs) of Southern Chinese ancestry.
p25209
sg17433
(lp25210
(dp25211
g17436
I360
sg17437
g25206
sg17438
I3
sg17439
VP35270
p25212
sg17441
I1
sa(dp25213
g17436
I51
sg17437
VSLC10A1 locus
p25214
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp25215
(dp25216
g17436
I107
sg17437
Vinfection
p25217
sg17438
I9
sg17445
VC0009450
p25218
sg17441
I1
sa(dp25219
g17436
I103
sg17437
VHBV
p25220
sg17438
I3
sg17445
VC0019163
p25221
sg17441
I1
sa(dp25222
g17436
I103
sg17437
VHBV
p25223
sg17438
I3
sg17445
VC0019163
p25224
sg17441
I1
sa(dp25225
g17436
I360
sg17437
g25207
sg17438
I3
sg17445
VC0175693
p25226
sg17441
I1
sasa(dp25227
g17431
VThe effectiveness of topical terbinafine (TBF) to tinea pedis was evaluated an animal model in which guinea pigs were experimentally infected through their planta pedis with Trichophyton mentagrophytes, then a 1% TBF or butenafine (BTF) cream was administered topically once daily for 4 consecutive weeks.
p25228
sg17433
(lp25229
sg17442
(lp25230
(dp25231
g17436
I50
sg17437
Vtinea pedis
p25232
sg17438
I11
sg17445
VC0040259
p25233
sg17441
I2
sasa(dp25234
g17431
VHowever, mutations in RecQL4 result in three human disorders: (I) Rothmund-Thomson syndrome (RTS), (II) RAPADILINO and (III) Baller-Gerold syndrome (BGS).
p25235
sg17433
(lp25236
(dp25237
g17436
I22
sg17437
VRecQL4
p25238
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp25239
(dp25240
g17436
I66
sg17437
VRothmund-Thomson syndrome
p25241
sg17438
I25
sg17445
VC0032339
p25242
sg17441
I2
sa(dp25243
g17436
I149
sg17437
VBGS
p25244
sg17438
I3
sg17445
VC0265308
p25245
sg17441
I1
sa(dp25246
g17436
I93
sg17437
VRTS
p25247
sg17438
I3
sg17445
VC0032339
p25248
sg17441
I1
sa(dp25249
g17436
I125
sg17437
VBaller-Gerold syndrome
p25250
sg17438
I22
sg17445
VC0265308
p25251
sg17441
I2
sasa(dp25252
g135
(dp25253
(VBLM
p25254
VBLM
p25255
tp25256
I00
ssg17431
VThis is in accordance with clinical and epidemiological findings demonstrating that defects in three RecQL helicases, i.e., WRN, BLM, RECQL4, are related to human progeroid and cancer predisposition syndromes, i.e., Werner, Bloom, and Rothmund Thomson syndrome, respectively.
p25257
sg17433
(lp25258
(dp25259
g17436
I101
sg17437
VRecQL helicases
p25260
sg17438
I15
sg17439
VP46063
p25261
sg17441
I2
sa(dp25262
g17436
I129
sg17437
g25254
sg17438
I3
sg17439
VP54132
p25263
sg17441
I1
sa(dp25264
g17436
I134
sg17437
VRECQL4
p25265
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp25266
(dp25267
g17436
I235
sg17437
VRothmund Thomson syndrome
p25268
sg17438
I25
sg17445
VC0032339
p25269
sg17441
I3
sa(dp25270
g17436
I199
sg17437
Vsyndromes
p25271
sg17438
I9
sg17445
VC0039082
p25272
sg17441
I1
sa(dp25273
g17436
I124
sg17437
VWRN
p25274
sg17438
I3
sg17445
VC0043119
p25275
sg17441
I1
sa(dp25276
g17436
I177
sg17437
Vcancer
p25277
sg17438
I6
sg17445
VC0006826
p25278
sg17441
I1
sa(dp25279
g17436
I129
sg17437
g25255
sg17438
I3
sg17445
VC0005859
p25280
sg17441
I1
sasa(dp25281
g135
(dp25282
(VBLM
p25283
VWRN
p25284
tp25285
I00
ssg17431
VHuman RecQ homologs include RECQ1, BLM, WRN, RECQ4, and RECQ5Beta, three of which have been linked to diseases with elevated risk of cancer and growth defects (Bloom Syndrome and Rothmund-Thomson Syndrome) or premature aging (Werner Syndrome).
p25286
sg17433
(lp25287
(dp25288
g17436
I45
sg17437
VRECQ4
p25289
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25290
g17436
I40
sg17437
VWRN
p25291
sg17438
I3
sg17439
VP02545
p25292
sg17441
I1
sa(dp25293
g17436
I0
sg17437
VHuman RecQ homologs
p25294
sg17438
I19
sg17439
g12
sg17441
I3
sa(dp25295
g17436
I28
sg17437
VRECQ1
p25296
sg17438
I5
sg17439
VP46063
p25297
sg17441
I1
sa(dp25298
g17436
I35
sg17437
g25283
sg17438
I3
sg17439
VP54132
p25299
sg17441
I1
sasg17442
(lp25300
(dp25301
g17436
I226
sg17437
VWerner Syndrome
p25302
sg17438
I15
sg17445
VC0043119
p25303
sg17441
I2
sa(dp25304
g17436
I209
sg17437
Vpremature aging
p25305
sg17438
I15
sg17445
VC0231341
p25306
sg17441
I2
sa(dp25307
g17436
I35
sg17437
VBLM
p25308
sg17438
I3
sg17445
VC0005859
p25309
sg17441
I1
sa(dp25310
g17436
I133
sg17437
Vcancer
p25311
sg17438
I6
sg17445
VC0006826
p25312
sg17441
I1
sa(dp25313
g17436
I160
sg17437
VBloom Syndrome
p25314
sg17438
I14
sg17445
VC0005859
p25315
sg17441
I2
sa(dp25316
g17436
I179
sg17437
VRothmund-Thomson Syndrome
p25317
sg17438
I25
sg17445
VC0032339
p25318
sg17441
I2
sa(dp25319
g17436
I40
sg17437
g25284
sg17438
I3
sg17445
VC0043119
p25320
sg17441
I1
sasa(dp25321
g17431
VDepletion of PAICS largely cancelled breast cancer expansion, exemplifying a prognostic gene with breast cancer activity.
p25322
sg17433
(lp25323
sg17442
(lp25324
(dp25325
g17436
I37
sg17437
Vbreast cancer
p25326
sg17438
I13
sg17445
VC0678222
p25327
sg17441
I2
sa(dp25328
g17436
I37
sg17437
Vbreast cancer
p25329
sg17438
I13
sg17445
VC0678222
p25330
sg17441
I2
sasa(dp25331
g135
(dp25332
(VPAICS
p25333
VFra
p25334
tp25335
I00
ssg17431
VWe propose that pharmacological inhibition of components within this network, such as PAICS, may be used in conjunction with the Fra-1 prognostic classifier towards personalized management of poor prognosis breast cancer.
p25336
sg17433
(lp25337
(dp25338
g17436
I129
sg17437
VFra-1
p25339
sg17438
I5
sg17439
VP15407
p25340
sg17441
I1
sa(dp25341
g17436
I86
sg17437
g25333
sg17438
I5
sg17439
VP22234
p25342
sg17441
I1
sasg17442
(lp25343
(dp25344
g17436
I207
sg17437
Vbreast cancer
p25345
sg17438
I13
sg17445
VC0678222
p25346
sg17441
I2
sa(dp25347
g17436
I129
sg17437
g25334
sg17438
I3
sg17445
VC1858361
p25348
sg17441
I1
sasa(dp25349
g17431
VOur goal was to investigate de novo purine biosynthetic gene PAICS expression and evaluate its role in prostate cancer progression.
p25350
sg17433
(lp25351
sg17442
(lp25352
(dp25353
g17436
I112
sg17437
Vcancer progression
p25354
sg17438
I18
sg17445
VC0178874
p25355
sg17441
I2
sasa(dp25356
g135
(dp25357
(VPhosphoribosylaminoimidazole Succinocarboxamide Synthetase
p25358
Vprostate cancer
p25359
tp25360
I00
ssg17431
VNext-generation sequencing, qRTPCR and immunoblot analysis revealed an elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a progressive manner in prostate cancer.
p25361
sg17433
(lp25362
(dp25363
g17436
I130
sg17437
VPhosphoribosylaminoimidazole Carboxylase
p25364
sg17438
I40
sg17439
VP22234
p25365
sg17441
I2
sa(dp25366
g17436
I232
sg17437
VPAICS
p25367
sg17438
I5
sg17439
VP22234
p25368
sg17441
I1
sa(dp25369
g17436
I172
sg17437
g25358
sg17438
I58
sg17439
VP22234
p25370
sg17441
I3
sasg17442
(lp25371
(dp25372
g17436
I266
sg17437
g25359
sg17438
I15
sg17445
VC0600139
p25373
sg17441
I2
sasa(dp25374
g135
(dp25375
(VPAICS
p25376
Vprostate cancer
p25377
tp25378
I00
ssg17431
VThrough several in vitro and in vivo functional studies, we show that PAICS is necessary for proliferation and invasion in prostate cancer cells.
p25379
sg17433
(lp25380
(dp25381
g17436
I70
sg17437
g25376
sg17438
I5
sg17439
VP22234
p25382
sg17441
I1
sasg17442
(lp25383
(dp25384
g17436
I93
sg17437
Vproliferation
p25385
sg17438
I13
sg17445
VC0334094
p25386
sg17441
I1
sa(dp25387
g17436
I123
sg17437
g25377
sg17438
I15
sg17445
VC0600139
p25388
sg17441
I2
sa(dp25389
g17436
I111
sg17437
Vinvasion
p25390
sg17438
I8
sg17445
VC2699153
p25391
sg17441
I1
sasa(dp25392
g135
(dp25393
(VPAICS
p25394
Vprostate cancer
p25395
tp25396
I00
ssg17431
VWe identified JQ1, a BET bromodomain inhibitor previously implicated in regulating MYC expression and demonstrated role in prostate cancer, abrogates PAICS expression in several prostate cancer cells.
p25397
sg17433
(lp25398
(dp25399
g17436
I83
sg17437
VMYC
p25400
sg17438
I3
sg17439
VP12524
p25401
sg17441
I1
sa(dp25402
g17436
I150
sg17437
g25394
sg17438
I5
sg17439
VP22234
p25403
sg17441
I1
sasg17442
(lp25404
(dp25405
g17436
I123
sg17437
Vprostate cancer
p25406
sg17438
I15
sg17445
VC0600139
p25407
sg17441
I2
sa(dp25408
g17436
I123
sg17437
g25395
sg17438
I15
sg17445
VC0600139
p25409
sg17441
I2
sasa(dp25410
g17431
VHere, we report that evaluation of PAICS in prostate cancer progression and its role in prostate cancer cell proliferation and invasion and suggest it as a valid therapeutic target.
p25411
sg17433
(lp25412
sg17442
(lp25413
(dp25414
g17436
I127
sg17437
Vinvasion
p25415
sg17438
I8
sg17445
VC2699153
p25416
sg17441
I1
sa(dp25417
g17436
I53
sg17437
Vcancer progression
p25418
sg17438
I18
sg17445
VC0178874
p25419
sg17441
I2
sa(dp25420
g17436
I109
sg17437
Vproliferation
p25421
sg17438
I13
sg17445
VC0334094
p25422
sg17441
I1
sa(dp25423
g17436
I44
sg17437
Vprostate cancer
p25424
sg17438
I15
sg17445
VC0600139
p25425
sg17441
I2
sasa(dp25426
g17431
VWe suggest JQ1, a BET-domain inhibitor, as possible therapeutic option in targeting PAICS in prostate cancer.
p25427
sg17433
(lp25428
sg17442
(lp25429
(dp25430
g17436
I93
sg17437
Vprostate cancer
p25431
sg17438
I15
sg17445
VC0600139
p25432
sg17441
I2
sasa(dp25433
g135
(dp25434
(Vphosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase
p25435
Vadenocarcinomas
p25436
tp25437
I00
ssg17431
VWe discovered increased expression of phosphoribosyl amidotransferase (PPAT) and phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase (PAICS) enzymes of de novo purine biosynthetic pathway in lung adenocarcinomas.
p25438
sg17433
(lp25439
(dp25440
g17436
I71
sg17437
VPPAT
p25441
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25442
g17436
I183
sg17437
VPAICS
p25443
sg17438
I5
sg17439
VP22234
p25444
sg17441
I1
sa(dp25445
g17436
I38
sg17437
Vphosphoribosyl amidotransferase
p25446
sg17438
I31
sg17439
g12
sg17441
I2
sa(dp25447
g17436
I81
sg17437
g25435
sg17438
I100
sg17439
VP22234
p25448
sg17441
I5
sasg17442
(lp25449
(dp25450
g17436
I245
sg17437
g25436
sg17438
I15
sg17445
VC0001418
p25451
sg17441
I1
sasa(dp25452
g135
(dp25453
(VPAICS
p25454
Vaggressive
p25455
tp25456
I00
ssg17431
VTranscript analyses from next-generation RNA sequencing and gene expression profiling studies suggested that PPAT and PAICS can serve as prognostic biomarkers for aggressive lung adenocarcinoma.
p25457
sg17433
(lp25458
(dp25459
g17436
I109
sg17437
VPPAT
p25460
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25461
g17436
I118
sg17437
g25454
sg17438
I5
sg17439
VP22234
p25462
sg17441
I1
sasg17442
(lp25463
(dp25464
g17436
I174
sg17437
Vlung adenocarcinoma
p25465
sg17438
I19
sg17445
VC0152013
p25466
sg17441
I2
sa(dp25467
g17436
I163
sg17437
g25455
sg17438
I10
sg17445
VC0001807
p25468
sg17441
I1
sasa(dp25469
g135
(dp25470
(VPAICS
p25471
Vaneuploidy
p25472
tp25473
I00
ssg17431
VFurthermore we identified genomic amplification and aneuploidy of the divergently transcribed PPAT-PAICS genomic region in a subset of lung cancers.
p25474
sg17433
(lp25475
(dp25476
g17436
I99
sg17437
g25471
sg17438
I5
sg17439
VP22234
p25477
sg17441
I1
sa(dp25478
g17436
I94
sg17437
VPPAT
p25479
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp25480
(dp25481
g17436
I135
sg17437
Vlung cancers
p25482
sg17438
I12
sg17445
VC0242379
p25483
sg17441
I2
sa(dp25484
g17436
I52
sg17437
g25472
sg17438
I10
sg17445
VC0002938
p25485
sg17441
I1
sa(dp25486
g17436
I34
sg17437
Vamplification
p25487
sg17438
I13
sg17445
VC1705759
p25488
sg17441
I1
sasa(dp25489
g135
(dp25490
(VPAICS
p25491
Vlung cancer
p25492
tp25493
I00
ssg17431
VIn summary, this study reveals the regulatory mechanisms by which purine biosynthetic pathway enzymes PPAT and PAICS, and pyruvate kinase activity is increased and exposes an existing metabolic vulnerability in lung cancer cells that can be explored for pharmacological intervention.
p25494
sg17433
(lp25495
(dp25496
g17436
I102
sg17437
VPPAT
p25497
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25498
g17436
I122
sg17437
Vpyruvate kinase
p25499
sg17438
I15
sg17439
VP30613
p25500
sg17441
I2
sa(dp25501
g17436
I111
sg17437
g25491
sg17438
I5
sg17439
VP22234
p25502
sg17441
I1
sasg17442
(lp25503
(dp25504
g17436
I211
sg17437
g25492
sg17438
I11
sg17445
VC0684249
p25505
sg17441
I2
sasa(dp25506
g135
(dp25507
(VPAICS
p25508
Vmelanoma
p25509
tp25510
I00
ssg17431
VWe also identified mutations in four genes (MUC19, PAICS, RBMXL1, KIF23) never reported in melanoma, which might deserve further investigations.
p25511
sg17433
(lp25512
(dp25513
g17436
I58
sg17437
VRBMXL1
p25514
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp25515
g17436
I44
sg17437
VMUC19
p25516
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25517
g17436
I51
sg17437
g25508
sg17438
I5
sg17439
VP22234
p25518
sg17441
I1
sa(dp25519
g17436
I66
sg17437
VKIF23
p25520
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp25521
(dp25522
g17436
I91
sg17437
g25509
sg17438
I8
sg17445
VC0025202
p25523
sg17441
I1
sasa(dp25524
g17431
VAlterations in PAICS expression in humans have been associated with various types of cancer.
p25525
sg17433
(lp25526
(dp25527
g17436
I15
sg17437
VPAICS
p25528
sg17438
I5
sg17439
VP22234
p25529
sg17441
I1
sasg17442
(lp25530
(dp25531
g17436
I85
sg17437
Vcancer
p25532
sg17438
I6
sg17445
VC0006826
p25533
sg17441
I1
sasa(dp25534
g135
(dp25535
(VIST1
p25536
Vshigellosis
p25537
tp25538
I00
ssg17431
VAn IST1 clone, detected for the first time in 2000, was the most prevalent and responsible for the shigellosis epidemic in 2001 to 2003.
p25539
sg17433
(lp25540
(dp25541
g17436
I3
sg17437
g25536
sg17438
I4
sg17439
VP53990
p25542
sg17441
I1
sasg17442
(lp25543
(dp25544
g17436
I99
sg17437
g25537
sg17438
I11
sg17445
VC0013371
p25545
sg17441
I1
sasa(dp25546
g135
(dp25547
(VBALP
p25548
Vbone disease
p25549
tp25550
I00
ssg17431
VIn this observational, cross-sectional study, circulating levels of sclerostin and other laboratory parameters of mineral and bone disease, including intact parathyroid hormone (PTH), calcium, phosphate, magnesium, 25(OH) D-vitamin, 1,25 (OH)2 D-vitamin, and bone specific alkaline phosphatase (BALP) were assessed in 100 patients with end-stage renal disease recruited from an ongoing longitudinal cohort study in Stockholm, Sweden.
p25551
sg17433
(lp25552
(dp25553
g17436
I259
sg17437
Vbone specific alkaline phosphatase
p25554
sg17438
I34
sg17439
VP10696
p25555
sg17441
I4
sa(dp25556
g17436
I178
sg17437
VPTH
p25557
sg17438
I3
sg17439
VP01270
p25558
sg17441
I1
sa(dp25559
g17436
I150
sg17437
Vintact parathyroid hormone
p25560
sg17438
I26
sg17439
VP01270
p25561
sg17441
I3
sa(dp25562
g17436
I295
sg17437
g25548
sg17438
I4
sg17439
VP10696
p25563
sg17441
I1
sasg17442
(lp25564
(dp25565
g17436
I336
sg17437
Vend-stage renal disease
p25566
sg17438
I23
sg17445
VC0022661
p25567
sg17441
I3
sa(dp25568
g17436
I126
sg17437
g25549
sg17438
I12
sg17445
VC0005940
p25569
sg17441
I2
sasa(dp25570
g135
(dp25571
(Vparathyroid hormone
p25572
Vbone disorder
p25573
tp25574
I00
ssg17431
VFindings from research into mineral bone disorder associated with CKD (CKD-MBD) could help the medical community to better understand the vascular actions of certain molecules, such as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their relevance to the management of different pathologies in the general population.
p25575
sg17433
(lp25576
(dp25577
g17436
I197
sg17437
Vfibroblast growth factor 23
p25578
sg17438
I27
sg17439
g12
sg17441
I4
sa(dp25579
g17436
I226
sg17437
g25572
sg17438
I19
sg17439
VP01270
p25580
sg17441
I2
sasg17442
(lp25581
(dp25582
g17436
I36
sg17437
g25573
sg17438
I13
sg17445
VC0005940
p25583
sg17441
I2
sasa(dp25584
g17431
VIn chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis.
p25585
sg17433
(lp25586
(dp25587
g17436
I33
sg17437
Vsclerostin
p25588
sg17438
I10
sg17439
g12
sg17441
I1
sasg17442
(lp25589
(dp25590
g17436
I3
sg17437
Vchronic kidney disease
p25591
sg17438
I22
sg17445
VC1561643
p25592
sg17441
I3
sa(dp25593
g17436
I27
sg17437
VCKD
p25594
sg17438
I3
sg17445
VC1561643
p25595
sg17441
I1
sasa(dp25596
g17431
VClinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.
p25597
sg17433
(lp25598
sg17442
(lp25599
sa(dp25600
g135
(dp25601
(VCD63
p25602
Vshock lung
p25603
tp25604
I00
ssg17431
V(3) Compared with the control group, the expression of CD63 in basophils increased in anaphylactic shock lung tissue.
p25605
sg17433
(lp25606
(dp25607
g17436
I55
sg17437
g25602
sg17438
I4
sg17439
VP08962
p25608
sg17441
I1
sasg17442
(lp25609
(dp25610
g17436
I86
sg17437
Vanaphylactic shock
p25611
sg17438
I18
sg17445
VC0002792
p25612
sg17441
I2
sa(dp25613
g17436
I99
sg17437
g25603
sg17438
I10
sg17445
VC0035222
p25614
sg17441
I2
sasa(dp25615
g17431
VTo elucidate a potential mechanism involving BM88/Cend1, RanBPM and Dyrk1B in cell cycle progression/exit, we transiently co-expressed these proteins in mouse neuroblastoma Neuro 2a cells.
p25616
sg17433
(lp25617
(dp25618
g17436
I68
sg17437
VDyrk1B
p25619
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp25620
g17436
I50
sg17437
VCend1
p25621
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25622
g17436
I45
sg17437
VBM88
p25623
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25624
g17436
I57
sg17437
VRanBPM
p25625
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp25626
(dp25627
g17436
I153
sg17437
Vmouse neuroblastoma
p25628
sg17438
I19
sg17445
VC1524043
p25629
sg17441
I2
sasa(dp25630
g17431
VCalcium imaging experiments revealed that P2Y-induced calcium mobilization is diminished in mouse neuroblastoma Neuro 2a cells stably transfected with BM88 (N2A-BM88 cells) as compared with N2A cells or N2A cells differentiated with retinoic acid.
p25631
sg17433
(lp25632
sg17442
(lp25633
(dp25634
g17436
I92
sg17437
Vmouse neuroblastoma
p25635
sg17438
I19
sg17445
VC1524043
p25636
sg17441
I2
sasa(dp25637
g135
(dp25638
(Vtrichostatin-A
p25639
Vneuroblastoma
p25640
tp25641
I00
ssg17431
VWe report here that trichostatin-A (TSA) specifically induces the transcription of Cend1, a neuronal-lineage specific regulator of cell cycle exit and differentiation, in neuroblastoma Neuro2A cells, but not in non-neuronal cells.
p25642
sg17433
(lp25643
(dp25644
g17436
I36
sg17437
VTSA
p25645
sg17438
I3
sg17439
VP32119
p25646
sg17441
I1
sa(dp25647
g17436
I83
sg17437
VCend1
p25648
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25649
g17436
I20
sg17437
g25639
sg17438
I14
sg17439
VP32119
p25650
sg17441
I1
sasg17442
(lp25651
(dp25652
g17436
I171
sg17437
g25640
sg17438
I13
sg17445
VC0027819
p25653
sg17441
I1
sasa(dp25654
g17431
VHere we have used mouse neuroblastoma Neuro 2a cells as an in vitro model of neuronal differentiation to dissect the functional properties of BM88 by implementing gain- and loss-of-function approaches.
p25655
sg17433
(lp25656
sg17442
(lp25657
(dp25658
g17436
I18
sg17437
Vmouse neuroblastoma
p25659
sg17438
I19
sg17445
VC1524043
p25660
sg17441
I2
sasa(dp25661
g135
(dp25662
(Vcyclin D1
p25663
Vretinoblastoma
p25664
tp25665
I00
ssg17431
VBM88 overexpression also results in increased levels of the cell cycle regulatory protein p53, and accumulation of the hypophosphorylated form of the retinoblastoma protein leading to cell cycle arrest, with concomitant decreased levels and, in many cells, cytoplasmic localization of cyclin D1.
p25666
sg17433
(lp25667
(dp25668
g17436
I0
sg17437
VBM88
p25669
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp25670
g17436
I285
sg17437
g25663
sg17438
I9
sg17439
VP24385
p25671
sg17441
I2
sa(dp25672
g17436
I150
sg17437
Vretinoblastoma protein
p25673
sg17438
I22
sg17439
g12
sg17441
I2
sa(dp25674
g17436
I82
sg17437
Vprotein p53
p25675
sg17438
I11
sg17439
VP42771
p25676
sg17441
I2
sasg17442
(lp25677
(dp25678
g17436
I150
sg17437
g25664
sg17438
I14
sg17445
VC0035335
p25679
sg17441
I1
sasa(dp25680
g17431
VPrevious studies have shown that the BM88 antigen, a neuron-specific molecule, promotes the differentiation of mouse neuroblastoma cells [23] (Mamalaki A., Boutou E., Hurel C., Patsavoudi E., Tzartos S. and Matsas R. (1995) The BM88 antigen, a novel neuron-specific molecule, enhances the differentiation of mouse neuroblastoma cells.
p25681
sg17433
(lp25682
(dp25683
g17436
I37
sg17437
VBM88 antigen
p25684
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp25685
g17436
I37
sg17437
VBM88 antigen
p25686
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp25687
(dp25688
g17436
I111
sg17437
Vmouse neuroblastoma
p25689
sg17438
I19
sg17445
VC1524043
p25690
sg17441
I2
sa(dp25691
g17436
I111
sg17437
Vmouse neuroblastoma
p25692
sg17438
I19
sg17445
VC1524043
p25693
sg17441
I2
sasa(dp25694
g17431
VMoreover, they respond differentially to growth factors [10] (Gomez J., Boutou E., Hurel C., Mamalaki A., Kentroti S. , Vernadakis A. and Matsas R. (1998) Overexpression of the neuron-specific molecule BM88 in mouse neuroblastoma cells: Altered responsiveness to growth factors.
p25695
sg17433
(lp25696
sg17442
(lp25697
(dp25698
g17436
I210
sg17437
Vmouse neuroblastoma
p25699
sg17438
I19
sg17445
VC1524043
p25700
sg17441
I2
sasa(dp25701
g17431
VPrevious studies have shown that the BM88 antigen, a novel neuron-specific molecule, promotes the differentiation of mouse neuroblastoma (Neuro 2a) cells.
p25702
sg17433
(lp25703
(dp25704
g17436
I37
sg17437
VBM88 antigen
p25705
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp25706
(dp25707
g17436
I117
sg17437
Vmouse neuroblastoma
p25708
sg17438
I19
sg17445
VC1524043
p25709
sg17441
I2
sasa(dp25710
g135
(dp25711
(Vneuron-specific antigen BM88
p25712
Vneuroblastoma
p25713
tp25714
I00
ssg17431
VIn conclusion, our findings show that overexpression of the neuron-specific antigen BM88 in neuroblastoma cells modifies their properties with respect to growth factor sensitivity, and, hence, the Neuro 2a and Neuro 2a-BM88 are suitable cell models to examine the role of growth factors in neuronal differentiation.
p25715
sg17433
(lp25716
(dp25717
g17436
I60
sg17437
g25712
sg17438
I28
sg17439
VP14209
p25718
sg17441
I3
sa(dp25719
g17436
I210
sg17437
VNeuro 2a-BM88
p25720
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp25721
(dp25722
g17436
I92
sg17437
g25713
sg17438
I13
sg17445
VC0027819
p25723
sg17441
I1
sasa(dp25724
g135
(dp25725
(VEF1A
p25726
Vpowdery mildew
p25727
tp25728
I00
ssg17431
VHere, we investigated the expression stabilities of ten previously recommended reference genes (ABCT, CYP, EF1A, FBOX, GPDH, RPL30, TUA4, TUB4, TUA5, and UNK2) in soybean under biotic stress from Bean pod mottle virus (BPMV), powdery mildew (PMD), soybean aphid (SBA), and two-spotted spider mite (TSSM).
p25729
sg17433
(lp25730
(dp25731
g17436
I102
sg17437
VCYP
p25732
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp25733
g17436
I125
sg17437
VRPL30
p25734
sg17438
I5
sg17439
VP62888
p25735
sg17441
I1
sa(dp25736
g17436
I107
sg17437
g25726
sg17438
I4
sg17439
VP68104
p25737
sg17441
I1
sasg17442
(lp25738
(dp25739
g17436
I242
sg17437
VPMD
p25740
sg17438
I3
sg17445
VC1832661
p25741
sg17441
I1
sa(dp25742
g17436
I226
sg17437
g25727
sg17438
I14
sg17445
VC1832661
p25743
sg17441
I2
sasa(dp25744
g17431
VIn conclusion, the anti-B7-1 antibody approach may provide a novel therapy for allergic asthma.
p25745
sg17433
(lp25746
sg17442
(lp25747
(dp25748
g17436
I79
sg17437
Vallergic asthma
p25749
sg17438
I15
sg17445
VC0155877
p25750
sg17441
I2
sasa(dp25751
g17431
VTo investigate whether there is altered expression and the clinical significance of soluble co-stimulatory molecules in asthmatic patients, plasma concentrations of sCTLA-4, sCD28, sCD80 and sCD86 in 51 adult allergic asthmatic adults with or without steroid treatment, and 35 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay (ELISA).
p25752
sg17433
(lp25753
sg17442
(lp25754
(dp25755
g17436
I120
sg17437
Vasthmatic
p25756
sg17438
I9
sg17445
VC0004096
p25757
sg17441
I1
sa(dp25758
g17436
I120
sg17437
Vasthmatic
p25759
sg17438
I9
sg17445
VC0004096
p25760
sg17441
I1
sasa(dp25761
g135
(dp25762
(VCD80
p25763
Vallergic asthma
p25764
tp25765
I00
ssg17431
VThe surface expression of T cell costimulatory molecules CTLA-4 and CD28 and their counter-ligands, B7 molecules (CD80, CD86), is differentially induced for T cell activation and expansion in allergic asthma.
p25766
sg17433
(lp25767
(dp25768
g17436
I68
sg17437
VCD28
p25769
sg17438
I4
sg17439
VP33681
p25770
sg17441
I1
sa(dp25771
g17436
I120
sg17437
VCD86
p25772
sg17438
I4
sg17439
VP42081
p25773
sg17441
I1
sa(dp25774
g17436
I26
sg17437
VT cell costimulatory molecules CTLA-4
p25775
sg17438
I37
sg17439
VP16410
p25776
sg17441
I5
sa(dp25777
g17436
I114
sg17437
g25763
sg17438
I4
sg17439
VP33681
p25778
sg17441
I1
sasg17442
(lp25779
(dp25780
g17436
I192
sg17437
g25764
sg17438
I15
sg17445
VC0155877
p25781
sg17441
I2
sasa(dp25782
g135
(dp25783
(VCTLA-4
p25784
Vallergic asthma
p25785
tp25786
I00
ssg17431
VPlasma concentrations of soluble CTLA-4 (sCTLA-4), CD28, CD80 and CD86 in 51 children with chronic allergic asthma with or without inhaled corticosteroid treatment, and 22 sex- and age-matched control subjects were measured by enzyme-linked immunosorbent assay.
p25787
sg17433
(lp25788
(dp25789
g17436
I57
sg17437
VCD80
p25790
sg17438
I4
sg17439
VP33681
p25791
sg17441
I1
sa(dp25792
g17436
I66
sg17437
VCD86
p25793
sg17438
I4
sg17439
VP42081
p25794
sg17441
I1
sa(dp25795
g17436
I51
sg17437
VCD28
p25796
sg17438
I4
sg17439
VP33681
p25797
sg17441
I1
sa(dp25798
g17436
I33
sg17437
g25784
sg17438
I6
sg17439
VP16410
p25799
sg17441
I1
sasg17442
(lp25800
(dp25801
g17436
I99
sg17437
g25785
sg17438
I15
sg17445
VC0155877
p25802
sg17441
I2
sasa(dp25803
g17431
VPlasma sCTLA-4, sCD28 and sCD80 concentrations are elevated in allergic asthma.
p25804
sg17433
(lp25805
sg17442
(lp25806
(dp25807
g17436
I63
sg17437
Vallergic asthma
p25808
sg17438
I15
sg17445
VC0155877
p25809
sg17441
I2
sasa(dp25810
g135
(dp25811
(Vmyoglobin
p25812
Vpercentage of myoglobin denaturation
p25813
tp25814
I00
ssg17431
VThe percentage of myoglobin denaturation (PMD) of the CA groups was also increased according to the level of CA during storage.
p25815
sg17433
(lp25816
(dp25817
g17436
I18
sg17437
g25812
sg17438
I9
sg17439
VP02144
p25818
sg17441
I1
sasg17442
(lp25819
(dp25820
g17436
I42
sg17437
VPMD
p25821
sg17438
I3
sg17445
VC1832661
p25822
sg17441
I1
sa(dp25823
g17436
I4
sg17437
g25813
sg17438
I36
sg17445
VC1832661
p25824
sg17441
I4
sasa(dp25825
g135
(dp25826
(VERCC1
p25827
Vesophageal cancer
p25828
tp25829
I00
ssg17431
VLow expression of (or IHC-negative) COX2, miR-200c, ERCC1 and TS, or high expression of (or IHC-positive) CDC25B and p16 are potential biomarkers for predicting the response of esophageal cancer patients treated with chemo(radio)therapy.
p25830
sg17433
(lp25831
(dp25832
g17436
I36
sg17437
VCOX2
p25833
sg17438
I4
sg17439
VP35354
p25834
sg17441
I1
sa(dp25835
g17436
I117
sg17437
Vp16
p25836
sg17438
I3
sg17439
VP42771
p25837
sg17441
I1
sa(dp25838
g17436
I42
sg17437
VmiR-200c
p25839
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp25840
g17436
I106
sg17437
VCDC25B
p25841
sg17438
I6
sg17439
VP30305
p25842
sg17441
I1
sa(dp25843
g17436
I52
sg17437
g25827
sg17438
I5
sg17439
VP07992
p25844
sg17441
I1
sasg17442
(lp25845
(dp25846
g17436
I177
sg17437
g25828
sg17438
I17
sg17445
VC0014859
p25847
sg17441
I2
sasa(dp25848
g135
(dp25849
(VERCC1
p25850
Vesophageal cancer
p25851
tp25852
I00
ssg17431
VERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.
p25853
sg17433
(lp25854
(dp25855
g17436
I6
sg17437
VSNP
p25856
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp25857
g17436
I0
sg17437
VERCC1
p25858
sg17438
I5
sg17439
VP07992
p25859
sg17441
I1
sa(dp25860
g17436
I52
sg17437
VERBB2
p25861
sg17438
I5
sg17439
VP04626
p25862
sg17441
I1
sa(dp25863
g17436
I0
sg17437
g25850
sg17438
I5
sg17439
VP07992
p25864
sg17441
I1
sasg17442
(lp25865
(dp25866
g17436
I194
sg17437
g25851
sg17438
I17
sg17445
VC0014859
p25867
sg17441
I2
sasa(dp25868
g135
(dp25869
(VERCC1
p25870
Vesophageal cancer
p25871
tp25872
I00
ssg17431
VERCC1 C118T could be a predictive factor for the response to radiotherapy and chemotherapy, but not a prognostic factor for OS in esophageal cancer patients after surgery.
p25873
sg17433
(lp25874
(dp25875
g17436
I0
sg17437
g25870
sg17438
I5
sg17439
VP07992
p25876
sg17441
I1
sasg17442
(lp25877
(dp25878
g17436
I130
sg17437
g25871
sg17438
I17
sg17445
VC0014859
p25879
sg17441
I2
sasa(dp25880
g135
(dp25881
(VERCC1 rs3212986
p25882
Vesophageal cancer
p25883
tp25884
I00
ssg17431
VIn the present meta-analysis, we demonstrated that the ERCC1 rs3212986 polymorphism was significantly correlated with the response rate of esophageal cancer patients to neoadjuvant therapy (OR =  .49, 95% CI = 0.31-0.76, heterogeneity P = 0.480).
p25885
sg17433
(lp25886
(dp25887
g17436
I55
sg17437
g25882
sg17438
I15
sg17439
VP07992
p25888
sg17441
I2
sasg17442
(lp25889
(dp25890
g17436
I139
sg17437
g25883
sg17438
I17
sg17445
VC0014859
p25891
sg17441
I2
sasa(dp25892
g135
(dp25893
(VERCC1
p25894
Vesophageal cancer
p25895
tp25896
I00
ssg17431
VFurthermore, a considerable correlation was observed between ERCC1 rs11615 and the response rate of esophageal cancer patients to neoadjuvant therapy (OR = 0.228, 95% CI = 0.125-0.418, heterogeneity P = 0.291).
p25897
sg17433
(lp25898
(dp25899
g17436
I61
sg17437
g25894
sg17438
I5
sg17439
VP07992
p25900
sg17441
I1
sasg17442
(lp25901
(dp25902
g17436
I100
sg17437
g25895
sg17438
I17
sg17445
VC0014859
p25903
sg17441
I2
sasa(dp25904
g135
(dp25905
(VERCC1
p25906
Vesophageal cancer
p25907
tp25908
I00
ssg17431
VThese findings indicate that the ERCC1 rs11615 and ERCC1 rs312986 polymorphisms may be candidate pharmacogenomic factors capable of predicting the response rate of esophageal cancer patients who accept neoadjuvant therapy.
p25909
sg17433
(lp25910
(dp25911
g17436
I33
sg17437
VERCC1 rs11615
p25912
sg17438
I13
sg17439
VP07992
p25913
sg17441
I2
sa(dp25914
g17436
I33
sg17437
g25906
sg17438
I5
sg17439
VP07992
p25915
sg17441
I1
sasg17442
(lp25916
(dp25917
g17436
I164
sg17437
g25907
sg17438
I17
sg17445
VC0014859
p25918
sg17441
I2
sasa(dp25919
g135
(dp25920
(VMAGE
p25921
Vcolon cancer
p25922
tp25923
I00
ssg17431
VIn patients with colon cancer, the expression of TSP50, MAGE-A(1-6), and SSX1,2,4 genes was associated with a poor prognosis, that of MAGE-C1 and XAGE1 was related to a favorable prognosis.
p25924
sg17433
(lp25925
(dp25926
g17436
I73
sg17437
VSSX1,2,4 genes
p25927
sg17438
I14
sg17439
g12
sg17441
I2
sa(dp25928
g17436
I49
sg17437
VTSP50
p25929
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25930
g17436
I146
sg17437
VXAGE1
p25931
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25932
g17436
I56
sg17437
g25921
sg17438
I4
sg17439
VP43355
p25933
sg17441
I1
sasg17442
(lp25934
(dp25935
g17436
I17
sg17437
g25922
sg17438
I12
sg17445
VC0699790
p25936
sg17441
I2
sasa(dp25937
g135
(dp25938
(VMAGE-A4
p25939
Vmelanomas
p25940
tp25941
I00
ssg17431
VConsequently, the expression of CT antigens MAGE-A1, MAGE-A4, CT7/MAGE-C1, NY-ESO-1, and GAGE was analyzed in a series of pediatric melanomas.
p25942
sg17433
(lp25943
(dp25944
g17436
I32
sg17437
VCT antigens MAGE-A1
p25945
sg17438
I19
sg17439
VP43355
p25946
sg17441
I3
sa(dp25947
g17436
I44
sg17437
VMAGE
p25948
sg17438
I4
sg17439
VP43355
p25949
sg17441
I1
sa(dp25950
g17436
I62
sg17437
VCT7
p25951
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp25952
g17436
I75
sg17437
VNY-ESO-1
p25953
sg17438
I8
sg17439
VP78358
p25954
sg17441
I1
sa(dp25955
g17436
I53
sg17437
g25939
sg17438
I7
sg17439
VP43355
p25956
sg17441
I1
sasg17442
(lp25957
(dp25958
g17436
I132
sg17437
g25940
sg17438
I9
sg17445
VC0025202
p25959
sg17441
I1
sasa(dp25960
g135
(dp25961
(VMAGE-A3
p25962
Vheat shock protein
p25963
tp25964
I00
ssg17431
VIn this study, we show that the dying myeloma cells treated with chaetocin resulted in the induction of heat shock protein (HSP) 90, which was inhibited by antioxidant N-acetyl cysteine, and showed an increase in the expression of MAGE-A3 and MAGE-C1/CT7.
p25965
sg17433
(lp25966
(dp25967
g17436
I104
sg17437
Vheat shock protein (HSP) 90
p25968
sg17438
I27
sg17439
VP34931
p25969
sg17441
I5
sa(dp25970
g17436
I251
sg17437
VCT7
p25971
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp25972
g17436
I231
sg17437
VMAGE
p25973
sg17438
I4
sg17439
VP43355
p25974
sg17441
I1
sa(dp25975
g17436
I231
sg17437
g25962
sg17438
I7
sg17439
VP43355
p25976
sg17441
I1
sasg17442
(lp25977
(dp25978
g17436
I124
sg17437
VHSP
p25979
sg17438
I3
sg17445
VC0034152
p25980
sg17441
I1
sa(dp25981
g17436
I38
sg17437
Vmyeloma
p25982
sg17438
I7
sg17445
VC0026764
p25983
sg17441
I1
sa(dp25984
g17436
I104
sg17437
g25963
sg17438
I18
sg17445
VC0034152
p25985
sg17441
I3
sasa(dp25986
g135
(dp25987
(VMAGE-A
p25988
Vsalivary gland carcinoma
p25989
tp25990
I00
ssg17431
VWe used immunohistochemistry to examine the expression of four CTAs (MAGE-A, NY-ESO-1, CT7, and GAGE7) in various types of salivary gland carcinoma (n = 95).
p25991
sg17433
(lp25992
(dp25993
g17436
I77
sg17437
VNY-ESO-1
p25994
sg17438
I8
sg17439
VP78358
p25995
sg17441
I1
sa(dp25996
g17436
I96
sg17437
VGAGE7
p25997
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp25998
g17436
I87
sg17437
VCT7
p25999
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp26000
g17436
I69
sg17437
g25988
sg17438
I6
sg17439
VP43355
p26001
sg17441
I1
sasg17442
(lp26002
(dp26003
g17436
I123
sg17437
g25989
sg17438
I24
sg17445
VC0948750
p26004
sg17441
I3
sasa(dp26005
g17431
VWhen carcinoma cases were divided into low-grade and intermediate/high-grade types, NY-ESO-1 and CT7 were expressed more frequently in intermediate/high-grade carcinomas.
p26006
sg17433
(lp26007
(dp26008
g17436
I84
sg17437
VNY-ESO-1
p26009
sg17438
I8
sg17439
VP78358
p26010
sg17441
I1
sa(dp26011
g17436
I97
sg17437
VCT7
p26012
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp26013
(dp26014
g17436
I159
sg17437
Vcarcinomas
p26015
sg17438
I10
sg17445
VC0007097
p26016
sg17441
I1
sa(dp26017
g17436
I5
sg17437
Vcarcinoma
p26018
sg17438
I9
sg17445
VC0007097
p26019
sg17441
I1
sasa(dp26020
g135
(dp26021
(Vtestis antigen MAGE C1
p26022
Vcancer testis
p26023
tp26024
I00
ssg17431
VThe expression of cancer testis antigen MAGE C1 has been linked to the malignant stem cell in this disease, and thus, we investigated the use of both flow cytometric and qRTPCR approaches to monitor its expression as an alternative monitoring methodology in this pilot study.
p26025
sg17433
(lp26026
(dp26027
g17436
I25
sg17437
g26022
sg17438
I22
sg17439
VP15735
p26028
sg17441
I4
sasg17442
(lp26029
(dp26030
g17436
I18
sg17437
g26023
sg17438
I13
sg17445
VC0153594
p26031
sg17441
I2
sasa(dp26032
g17431
VThese variants were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related signaling pathways (THSD1, MORN2, PTCRA).
p26033
sg17433
(lp26034
(dp26035
g17436
I152
sg17437
VMORN2
p26036
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26037
g17436
I84
sg17437
VTOX3
p26038
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26039
g17436
I69
sg17437
VDNAH9
p26040
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26041
g17436
I145
sg17437
VTHSD1
p26042
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26043
g17436
I76
sg17437
VMAGEC1
p26044
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp26045
g17436
I159
sg17437
VPTCRA
p26046
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26047
g17436
I60
sg17437
VANKRD35
p26048
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp26049
(dp26050
g17436
I51
sg17437
Vcancer
p26051
sg17438
I6
sg17445
VC0006826
p26052
sg17441
I1
sa(dp26053
g17436
I51
sg17437
Vcancers
p26054
sg17438
I7
sg17445
VC0006826
p26055
sg17441
I1
sasa(dp26056
g135
(dp26057
(VMAGE
p26058
Vbreast cancer
p26059
tp26060
I01
ssg17431
VOur study aims to analyze the expression pattern, mechanism, and prognostic significance of melanoma-associated antigen MAGE-C1 and MAGE-C2 in breast cancer.
p26061
sg17433
(lp26062
(dp26063
g17436
I132
sg17437
VMAGE-C2
p26064
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp26065
g17436
I120
sg17437
g26058
sg17438
I4
sg17439
VP43355
p26066
sg17441
I1
sasg17442
(lp26067
(dp26068
g17436
I92
sg17437
Vmelanoma
p26069
sg17438
I8
sg17445
VC0025202
p26070
sg17441
I1
sa(dp26071
g17436
I143
sg17437
g26059
sg17438
I13
sg17445
VC0678222
p26072
sg17441
I2
sasa(dp26073
g135
(dp26074
(VMAGE
p26075
Vbreast cancer
p26076
tp26077
I01
ssg17431
VReverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to investigate the expressions of MAGE-C1 and MAGE-C2 in breast benign disease specimens, tumor-free breast specimens, and breast cancer specimens; their correlation with clinicopathologic parameters and recurrence-free survival was elucidated.
p26078
sg17433
(lp26079
(dp26080
g17436
I126
sg17437
VMAGE
p26081
sg17438
I4
sg17439
VP43355
p26082
sg17441
I1
sa(dp26083
g17436
I126
sg17437
g26075
sg17438
I4
sg17439
VP43355
p26084
sg17441
I1
sasg17442
(lp26085
(dp26086
g17436
I215
sg17437
g26076
sg17438
I13
sg17445
VC0678222
p26087
sg17441
I2
sa(dp26088
g17436
I182
sg17437
Vtumor
p26089
sg17438
I5
sg17445
VC0027651
p26090
sg17441
I1
sa(dp26091
g17436
I296
sg17437
Vrecurrence
p26092
sg17438
I10
sg17445
VC1458156
p26093
sg17441
I1
sasa(dp26094
g135
(dp26095
(Vhistone deacetylase
p26096
Vbreast cancer
p26097
tp26098
I00
ssg17431
VWe examined the influence of DNA methylase inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR) together with histone deacetylase inhibitor trichostatin A on the expression of MAGE-C1 and MAGE-C2 in breast cancer cell lines.
p26099
sg17433
(lp26100
(dp26101
g17436
I122
sg17437
Vinhibitor trichostatin A
p26102
sg17438
I24
sg17439
VP32119
p26103
sg17441
I3
sa(dp26104
g17436
I168
sg17437
VMAGE
p26105
sg17438
I4
sg17439
VP43355
p26106
sg17441
I1
sa(dp26107
g17436
I102
sg17437
g26096
sg17438
I19
sg17439
VP56524
p26108
sg17441
I2
sa(dp26109
g17436
I180
sg17437
VMAGE-C2
p26110
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp26111
(dp26112
g17436
I191
sg17437
g26097
sg17438
I13
sg17445
VC0678222
p26113
sg17441
I2
sasa(dp26114
g135
(dp26115
(VMAGE
p26116
Vbreast cancer
p26117
tp26118
I01
ssg17431
VProteins for MAGE-C1 and MAGE-C2 expressions were 38.3% and 58.3% in breast cancer specimens, messenger RNA for MAGE-C1 and MAGE-C2 expressions were 43.3% and 61.7%, respectively.
p26119
sg17433
(lp26120
(dp26121
g17436
I13
sg17437
VMAGE
p26122
sg17438
I4
sg17439
VP43355
p26123
sg17441
I1
sa(dp26124
g17436
I13
sg17437
VMAGE
p26125
sg17438
I4
sg17439
VP43355
p26126
sg17441
I1
sa(dp26127
g17436
I13
sg17437
VMAGE
p26128
sg17438
I4
sg17439
VP43355
p26129
sg17441
I1
sa(dp26130
g17436
I13
sg17437
g26116
sg17438
I4
sg17439
VP43355
p26131
sg17441
I1
sasg17442
(lp26132
(dp26133
g17436
I69
sg17437
g26117
sg17438
I13
sg17445
VC0678222
p26134
sg17441
I2
sasa(dp26135
g135
(dp26136
(VMAGE
p26137
Vbreast cancer
p26138
tp26139
I01
ssg17431
VMAGE-C1 and MAGE-C2 maybe potential targets for tumor immunotherapy, and their expressions are associated with advanced breast cancer and poor outcome.
p26140
sg17433
(lp26141
(dp26142
g17436
I0
sg17437
VMAGE
p26143
sg17438
I4
sg17439
VP43355
p26144
sg17441
I1
sa(dp26145
g17436
I0
sg17437
g26137
sg17438
I4
sg17439
VP43355
p26146
sg17441
I1
sasg17442
(lp26147
(dp26148
g17436
I120
sg17437
g26138
sg17438
I13
sg17445
VC0678222
p26149
sg17441
I2
sa(dp26150
g17436
I48
sg17437
Vtumor
p26151
sg17438
I5
sg17445
VC0027651
p26152
sg17441
I1
sasa(dp26153
g17431
VAs CT7 and CT10 are highly expressed in cutaneous melanoma and are immunogenic in this disease, we analysed their expression throughout the different subtypes of mucosal melanoma and tumor development.
p26154
sg17433
(lp26155
(dp26156
g17436
I3
sg17437
VCT7
p26157
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp26158
g17436
I11
sg17437
VCT10
p26159
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp26160
(dp26161
g17436
I50
sg17437
Vmelanoma
p26162
sg17438
I8
sg17445
VC0025202
p26163
sg17441
I1
sa(dp26164
g17436
I183
sg17437
Vtumor
p26165
sg17438
I5
sg17445
VC0027651
p26166
sg17441
I1
sa(dp26167
g17436
I40
sg17437
Vcutaneous melanoma
p26168
sg17438
I18
sg17445
VC0025202
p26169
sg17441
I2
sasa(dp26170
g17431
VIn the present study, we investigated expression patterns of nanog in the rat heart after acute myocardial infarction by semi-quantitative RT-PCR, immunohistochemistry and Western blot analyses.
p26171
sg17433
(lp26172
sg17442
(lp26173
(dp26174
g17436
I90
sg17437
Vacute myocardial infarction
p26175
sg17438
I27
sg17445
VC0155626
p26176
sg17441
I3
sasa(dp26177
g135
(dp26178
(VCD34
p26179
Vparaganglioma
p26180
tp26181
I00
ssg17431
VMRI represents the gold standard tool for differential diagnosis (with schwannoma, paraganglioma and haemangioma) and correct staging, while immunohistochemical and cytomorphologic analysis (bcl-2 and CD34 positivity in 90% of cases) is needed for definitive diagnosis.
p26182
sg17433
(lp26183
(dp26184
g17436
I191
sg17437
Vbcl-2
p26185
sg17438
I5
sg17439
VP10415
p26186
sg17441
I1
sa(dp26187
g17436
I201
sg17437
g26179
sg17438
I4
sg17439
VP28906
p26188
sg17441
I1
sasg17442
(lp26189
(dp26190
g17436
I101
sg17437
Vhaemangioma
p26191
sg17438
I11
sg17445
VC0018916
p26192
sg17441
I1
sa(dp26193
g17436
I71
sg17437
Vschwannoma
p26194
sg17438
I10
sg17445
VC0027809
p26195
sg17441
I1
sa(dp26196
g17436
I83
sg17437
g26180
sg17438
I13
sg17445
VC0030421
p26197
sg17441
I1
sasa(dp26198
g135
(dp26199
(Vbcl-2
p26200
Vschwannoma
p26201
tp26202
I00
ssg17431
VL'RMN rappresenta l'esame principale per escludere altre diagnosi (schwannoma, paragangliome ed emangioma) e per una corretta stadiazione mentre l'immunoistochimica e l'analisi citomorfologica (bcl-2 e CD34 positiva nel 90% dei casi) e la base per una diagnosi definitiva.
p26203
sg17433
(lp26204
(dp26205
g17436
I202
sg17437
VCD34
p26206
sg17438
I4
sg17439
VP28906
p26207
sg17441
I1
sa(dp26208
g17436
I194
sg17437
g26200
sg17438
I5
sg17439
VP10415
p26209
sg17441
I1
sasg17442
(lp26210
(dp26211
g17436
I67
sg17437
g26201
sg17438
I10
sg17445
VC0027809
p26212
sg17441
I1
sasa(dp26213
g135
(dp26214
(VSOX2
p26215
VPMD
p26216
tp26217
I00
ssg17431
VDisease-specific iPS cells were generated from skin fibroblasts obtained from the indicated PMD patient and two other PMD patients having a 637-kb chromosomal duplication including entire PLP1 and a novel missense mutation (W212C) of PLP1, by transfections of OCT3/4, C-MYC, KLF4 and SOX2 using retro-virus vectors.
p26218
sg17433
(lp26219
(dp26220
g17436
I188
sg17437
VPLP1
p26221
sg17438
I4
sg17439
VP60201
p26222
sg17441
I1
sa(dp26223
g17436
I188
sg17437
VPLP1
p26224
sg17438
I4
sg17439
VP60201
p26225
sg17441
I1
sa(dp26226
g17436
I275
sg17437
VKLF4
p26227
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26228
g17436
I268
sg17437
VC-MYC
p26229
sg17438
I5
sg17439
VP12524
p26230
sg17441
I1
sa(dp26231
g17436
I284
sg17437
g26215
sg17438
I4
sg17439
VP48431
p26232
sg17441
I1
sa(dp26233
g17436
I260
sg17437
VOCT3/4
p26234
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp26235
(dp26236
g17436
I147
sg17437
Vchromosomal duplication
p26237
sg17438
I23
sg17445
VC1516516
p26238
sg17441
I2
sa(dp26239
g17436
I17
sg17437
ViPS
p26240
sg17438
I3
sg17445
VC1837610
p26241
sg17441
I1
sa(dp26242
g17436
I92
sg17437
VPMD
p26243
sg17438
I3
sg17445
VC1832661
p26244
sg17441
I1
sa(dp26245
g17436
I92
sg17437
g26216
sg17438
I3
sg17445
VC1832661
p26246
sg17441
I1
sasa(dp26247
g17431
VMice with increased KLF4 in NSCs and NSCs-derived ependymal cells developed hydrocephalus-like characteristics, including enlarged ventricles, thinned cortex, agenesis of the corpus callosum, and significantly reduced subcommissural organ.
p26248
sg17433
(lp26249
(dp26250
g17436
I20
sg17437
VKLF4
p26251
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp26252
(dp26253
g17436
I76
sg17437
Vhydrocephalus
p26254
sg17438
I13
sg17445
VC0020255
p26255
sg17441
I1
sa(dp26256
g17436
I159
sg17437
Vagenesis of the corpus callosum
p26257
sg17438
I31
sg17445
VC0175754
p26258
sg17441
I5
sasa(dp26259
g17431
VThese results indicate that down-regulation of KLF4 is critical for neural development and its dysregulation may lead to hydrocephalus.
p26260
sg17433
(lp26261
(dp26262
g17436
I47
sg17437
VKLF4
p26263
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp26264
(dp26265
g17436
I121
sg17437
Vhydrocephalus
p26266
sg17438
I13
sg17445
VC0020255
p26267
sg17441
I1
sasa(dp26268
g135
(dp26269
(VSTAT3
p26270
Vmyeloma
p26271
tp26272
I00
ssg17431
VOur findings further reveal that activated Akt and STAT3 pathways induce the upregulation of HIF1Alfa and its downstream targets (LDHA and PDK1), leading to increased glycolysis in myeloma cells.
p26273
sg17433
(lp26274
(dp26275
g17436
I43
sg17437
VAkt
p26276
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp26277
g17436
I139
sg17437
VPDK1
p26278
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26279
g17436
I130
sg17437
VLDHA
p26280
sg17438
I4
sg17439
VP00338
p26281
sg17441
I1
sa(dp26282
g17436
I51
sg17437
g26270
sg17438
I5
sg17439
VP40763
p26283
sg17441
I1
sasg17442
(lp26284
(dp26285
g17436
I181
sg17437
g26271
sg17438
I7
sg17445
VC0026764
p26286
sg17441
I1
sasa(dp26287
g135
(dp26288
(VLDHA
p26289
Vmultiple myeloma
p26290
tp26291
I01
ssg17431
VWe show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism.
p26292
sg17433
(lp26293
(dp26294
g17436
I94
sg17437
VLDHA
p26295
sg17438
I4
sg17439
VP00338
p26296
sg17441
I1
sa(dp26297
g17436
I103
sg17437
VHIF1A
p26298
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26299
g17436
I103
sg17437
VHIF1A
p26300
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26301
g17436
I94
sg17437
g26289
sg17438
I4
sg17439
VP00338
p26302
sg17441
I1
sasg17442
(lp26303
(dp26304
g17436
I263
sg17437
Vtumor growth
p26305
sg17438
I12
sg17445
VC0598934
p26306
sg17441
I2
sa(dp26307
g17436
I112
sg17437
g26290
sg17438
I16
sg17445
VC0026764
p26308
sg17441
I2
sasa(dp26309
g135
(dp26310
(VLDHA
p26311
Vmultiple myeloma
p26312
tp26313
I01
ssg17431
VNovel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance.
p26314
sg17433
(lp26315
(dp26316
g17436
I89
sg17437
g26311
sg17438
I4
sg17439
VP00338
p26317
sg17441
I1
sasg17442
(lp26318
(dp26319
g17436
I48
sg17437
g26312
sg17438
I16
sg17445
VC0026764
p26320
sg17441
I2
sa(dp26321
g17436
I124
sg17437
Vtumor growth
p26322
sg17438
I12
sg17445
VC0598934
p26323
sg17441
I2
sasa(dp26324
g135
(dp26325
(Vlactate dehydrogenase A
p26326
Vmyeloma
p26327
tp26328
I00
ssg17431
VA 36,000-Mr protein purified from mouse myeloma on the basis of selective binding to a single-stranded DNA (ssDNA)-cellulose column has been identified as the lactate dehydrogenase A (LDH-A) subunit.
p26329
sg17433
(lp26330
(dp26331
g17436
I184
sg17437
VLDH-A
p26332
sg17438
I5
sg17439
VP00338
p26333
sg17441
I1
sa(dp26334
g17436
I159
sg17437
g26326
sg17438
I23
sg17439
VP49366
p26335
sg17441
I3
sasg17442
(lp26336
(dp26337
g17436
I40
sg17437
g26327
sg17438
I7
sg17445
VC0026764
p26338
sg17441
I1
sasa(dp26339
g135
(dp26340
(VLDH-A subunits
p26341
Vmyeloma
p26342
tp26343
I01
ssg17431
VA homogeneous preparation of this mouse myeloma ssDNA-binding protein, termed the 'low-salt-eluting protein', was found to possess LDH activity, and rabbit antiserum prepared against this protein was shown to cross-react with purified 36,000-Mr LDH-A subunits from mouse and bovine sources.
p26344
sg17433
(lp26345
(dp26346
g17436
I131
sg17437
VLDH
p26347
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp26348
g17436
I245
sg17437
g26341
sg17438
I14
sg17439
VP00338
p26349
sg17441
I2
sa(dp26350
g17436
I34
sg17437
Vmouse myeloma ssDNA-binding protein
p26351
sg17438
I35
sg17439
g12
sg17441
I4
sasg17442
(lp26352
(dp26353
g17436
I40
sg17437
g26342
sg17438
I7
sg17445
VC0026764
p26354
sg17441
I1
sa(dp26355
g17436
I123
sg17437
Vpossess
p26356
sg17438
I7
sg17445
VC0850310
p26357
sg17441
I1
sasa(dp26358
g135
(dp26359
(VLDH-A
p26360
Vmyeloma
p26361
tp26362
I01
ssg17431
VThese enzymic and immunological identities with LDH-A were not observed with purified helix-destabilizing protein 1 from mouse myeloma.
p26363
sg17433
(lp26364
(dp26365
g17436
I48
sg17437
g26360
sg17438
I5
sg17439
VP00338
p26366
sg17441
I1
sasg17442
(lp26367
(dp26368
g17436
I127
sg17437
g26361
sg17438
I7
sg17445
VC0026764
p26369
sg17441
I1
sasa(dp26370
g135
(dp26371
(Vlactate dehydrogenase
p26372
Vmultiple myeloma
p26373
tp26374
I00
ssg17431
VConcentrations of total lactate dehydrogenase (LDH; EC 1.1.1.27) and LDH isoenzyme patterns were studied in serum of 19 patients with multiple myeloma and in 19 healthy controls.
p26375
sg17433
(lp26376
(dp26377
g17436
I24
sg17437
g26372
sg17438
I21
sg17439
VP49366
p26378
sg17441
I2
sa(dp26379
g17436
I47
sg17437
VLDH
p26380
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp26381
g17436
I69
sg17437
VLDH isoenzyme
p26382
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp26383
(dp26384
g17436
I134
sg17437
g26373
sg17438
I16
sg17445
VC0026764
p26385
sg17441
I2
sasa(dp26386
g135
(dp26387
(VAPE1
p26388
Vstroke
p26389
tp26390
I00
ssg17431
VDefective DNA repair is tightly correlated with worse neurological outcomes after stroke, whereas upregulation of DNA repair enzymes, such as APE1, OGG1, and XRCC1, improves long-term functional recovery following stroke.
p26391
sg17433
(lp26392
(dp26393
g17436
I158
sg17437
VXRCC1
p26394
sg17438
I5
sg17439
VP18887
p26395
sg17441
I1
sa(dp26396
g17436
I142
sg17437
g26388
sg17438
I4
sg17439
VP27695
p26397
sg17441
I1
sasg17442
(lp26398
(dp26399
g17436
I184
sg17437
Vfunctional recovery
p26400
sg17438
I19
sg17445
VC0599766
p26401
sg17441
I2
sa(dp26402
g17436
I82
sg17437
Vstroke
p26403
sg17438
I6
sg17445
VC0038454
p26404
sg17441
I1
sa(dp26405
g17436
I82
sg17437
g26389
sg17438
I6
sg17445
VC0038454
p26406
sg17441
I1
sasa(dp26407
g135
(dp26408
(VXRCC1 Arg399Gln gene
p26409
Vstroke
p26410
tp26411
I00
ssg17431
VOur data showed that OGG1 Ser326Cys and XRCC1 Arg399Gln gene polymorphisms had impacts on the development of stroke.
p26412
sg17433
(lp26413
(dp26414
g17436
I40
sg17437
g26409
sg17438
I20
sg17439
VP18887
p26415
sg17441
I3
sasg17442
(lp26416
(dp26417
g17436
I109
sg17437
g26410
sg17438
I6
sg17445
VC0038454
p26418
sg17441
I1
sasa(dp26419
g17431
VPreviously, our laboratory showed that mice lacking the BER glycosylases 8-oxoguanine glycosylase 1 (Ogg1) or nei endonuclease VIII-like 1 (Neil1) recover more poorly from focal ischemic stroke than wild-type mice.
p26420
sg17433
(lp26421
(dp26422
g17436
I140
sg17437
VNeil1
p26423
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26424
g17436
I110
sg17437
Vnei endonuclease VIII-like 1
p26425
sg17438
I28
sg17439
g12
sg17441
I4
sasg17442
(lp26426
(dp26427
g17436
I178
sg17437
Vischemic stroke
p26428
sg17438
I15
sg17445
VC3272363
p26429
sg17441
I2
sasa(dp26430
g135
(dp26431
(VXRCC1
p26432
Vstroke
p26433
tp26434
I00
ssg17431
VGenotyping of polymorphisms of the OGG1 (Ser326Cys), XRCC1 (Arg399Gln), ERCC2 (Lys751Gln), and ERCC5 (Asp1104His) genes was performed and used to evaluate LAA stroke susceptibility.
p26435
sg17433
(lp26436
(dp26437
g17436
I95
sg17437
VERCC5 (Asp1104His) genes
p26438
sg17438
I24
sg17439
VP28715
p26439
sg17441
I3
sa(dp26440
g17436
I72
sg17437
VERCC2
p26441
sg17438
I5
sg17439
VP18074
p26442
sg17441
I1
sa(dp26443
g17436
I53
sg17437
g26432
sg17438
I5
sg17439
VP18887
p26444
sg17441
I1
sasg17442
(lp26445
(dp26446
g17436
I159
sg17437
g26433
sg17438
I6
sg17445
VC0038454
p26447
sg17441
I1
sasa(dp26448
g135
(dp26449
(VERCC2
p26450
Vstroke
p26451
tp26452
I00
ssg17431
VA joint effect on risk elevation of LAA stroke was seen in those patients with OGG1 and ERCC2 polymorphisms (OR: 2.75, 95%CI: 1.26-6.00).
p26453
sg17433
(lp26454
(dp26455
g17436
I88
sg17437
g26450
sg17438
I5
sg17439
VP18074
p26456
sg17441
I1
sasg17442
(lp26457
(dp26458
g17436
I40
sg17437
g26451
sg17438
I6
sg17445
VC0038454
p26459
sg17441
I1
sasa(dp26460
g135
(dp26461
(VXRCC1
p26462
Vstroke
p26463
tp26464
I00
ssg17431
VMoreover, among smokers carrying the OGG1 Ser326Cys polymorphism, there was a tendency toward an increased risk of LAA stroke in those patients who had a greater number of high-risk genotypes of XRCC1, ERCC2, and ERCC5 polymorphisms (p(trend)=0.010).
p26465
sg17433
(lp26466
(dp26467
g17436
I202
sg17437
VERCC2
p26468
sg17438
I5
sg17439
VP18074
p26469
sg17441
I1
sa(dp26470
g17436
I213
sg17437
VERCC5
p26471
sg17438
I5
sg17439
VP28715
p26472
sg17441
I1
sa(dp26473
g17436
I195
sg17437
g26462
sg17438
I5
sg17439
VP18887
p26474
sg17441
I1
sasg17442
(lp26475
(dp26476
g17436
I119
sg17437
g26463
sg17438
I6
sg17445
VC0038454
p26477
sg17441
I1
sasa(dp26478
g17431
VAmong 22 patients who underwent LP shunt placement for IIH, 16 (72.8%) patients had severe and fulminant opening CSF pressures with values of more than 400 mmH(2)O.
p26479
sg17433
(lp26480
sg17442
(lp26481
sa(dp26482
g17431
VThis study implicates increased I(NaL) in excessive atrial APD prolongation and arrhythmic EAD occurrence in a congenital LQTS3 mouse model.
p26483
sg17433
(lp26484
sg17442
(lp26485
(dp26486
g17436
I91
sg17437
VEAD
p26487
sg17438
I3
sg17445
VC1864233
p26488
sg17441
I1
sasa(dp26489
g17431
V(1) To report the different patterns of NAL and discuss the mechanisms encountered; (2) to determine the relationship between a given type of lymphoma and a specific type of neuropathy; and (3) to assess the prognosis of NAL.
p26490
sg17433
(lp26491
sg17442
(lp26492
(dp26493
g17436
I142
sg17437
Vlymphoma
p26494
sg17438
I8
sg17445
VC0024299
p26495
sg17441
I1
sa(dp26496
g17436
I174
sg17437
Vneuropathy
p26497
sg17438
I10
sg17445
VC0442874
p26498
sg17441
I1
sasa(dp26499
g135
(dp26500
(VDisperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1
p26501
Vdermatitis
p26502
tp26503
I00
ssg17431
VTwo thousand four hundred ninety-three consecutive dermatitis patients in 9 dermatology clinics were patch tested with a TDM 6.6%, consisting of Disperse (D) Blue 35, D Yellow 3, D Orange 1 and 3, D Red 1 and 17, all 1.0% each, and D Blue 106 and D Blue 124, each 0.3%.
p26504
sg17433
(lp26505
(dp26506
g17436
I145
sg17437
g26501
sg17438
I59
sg17439
VP16435
p26507
sg17441
I15
sasg17442
(lp26508
(dp26509
g17436
I51
sg17437
g26502
sg17438
I10
sg17445
VC0011603
p26510
sg17441
I1
sasa(dp26511
g17431
VThe name hydrolethalus refers to the main findings, namely polyhydramnios, hydrocephalus and lethality.
p26512
sg17433
(lp26513
sg17442
(lp26514
(dp26515
g17436
I75
sg17437
Vhydrocephalus
p26516
sg17438
I13
sg17445
VC0020255
p26517
sg17441
I1
sa(dp26518
g17436
I59
sg17437
Vpolyhydramnios
p26519
sg17438
I14
sg17445
VC0020224
p26520
sg17441
I1
sasa(dp26521
g17431
VVACTERL with hydrocephalus appears distinct from hydrolethalus and similar conditions but is itself heterogeneous.
p26522
sg17433
(lp26523
sg17442
(lp26524
(dp26525
g17436
I13
sg17437
Vhydrocephalus
p26526
sg17438
I13
sg17445
VC0020255
p26527
sg17441
I1
sasa(dp26528
g135
(dp26529
(VrAd
p26530
Vprostate cancer
p26531
tp26532
I01
ssg17431
VIn this study, we evaluated the feasibility of combining p53-DC vaccine and rAd-p53 gene therapy, using the p53-overexpressing and non-expressing prostate cancer cells in vitro.
p26533
sg17433
(lp26534
(dp26535
g17436
I57
sg17437
Vp53-DC
p26536
sg17438
I6
sg17439
VP42771
p26537
sg17441
I1
sa(dp26538
g17436
I57
sg17437
Vp53-
p26539
sg17438
I4
sg17439
VP42771
p26540
sg17441
I1
sa(dp26541
g17436
I57
sg17437
Vp53
p26542
sg17438
I3
sg17439
VP42771
p26543
sg17441
I1
sa(dp26544
g17436
I76
sg17437
g26530
sg17438
I3
sg17439
VP55042
p26545
sg17441
I1
sasg17442
(lp26546
(dp26547
g17436
I146
sg17437
g26531
sg17438
I15
sg17445
VC0600139
p26548
sg17441
I2
sasa(dp26549
g135
(dp26550
(VrAd-p53
p26551
Vprostate cancer
p26552
tp26553
I01
ssg17431
VIn addition, rAd-p53 infection can induce overexpression of p53 and thus the cytotoxicity of CTLs differentiated by the p53-DC vaccine in p53 non-expressing prostate cancer cells.
p26554
sg17433
(lp26555
(dp26556
g17436
I17
sg17437
Vp53
p26557
sg17438
I3
sg17439
VP42771
p26558
sg17441
I1
sa(dp26559
g17436
I120
sg17437
Vp53-DC
p26560
sg17438
I6
sg17439
VP42771
p26561
sg17441
I1
sa(dp26562
g17436
I13
sg17437
g26551
sg17438
I7
sg17439
VP55042
p26563
sg17441
I1
sa(dp26564
g17436
I17
sg17437
Vp53
p26565
sg17438
I3
sg17439
VP42771
p26566
sg17441
I1
sasg17442
(lp26567
(dp26568
g17436
I77
sg17437
Vcytotoxicity
p26569
sg17438
I12
sg17445
VC0596402
p26570
sg17441
I1
sa(dp26571
g17436
I21
sg17437
Vinfection
p26572
sg17438
I9
sg17445
VC0009450
p26573
sg17441
I1
sa(dp26574
g17436
I157
sg17437
g26552
sg17438
I15
sg17445
VC0600139
p26575
sg17441
I2
sasa(dp26576
g135
(dp26577
(VNK4
p26578
Vmetastasis
p26579
tp26580
I00
ssg17431
VThis study detected the migration of MSCs to high metastasis liver carcinoma cells MHCC-97H in vitro, investigated the inhibitory effect of rAd-NK4-MSCs on the growth and metastasis of MHCC-97H cells, further explored the inhibitory mechanism of rAd-NK4-MSCs to MHCC-97H cell metastasis, and examined the inhibitory effect of rAd-NK4-MSCs on the migration of human umbilical vein endothelial cells (HUVECs) in vitro.
p26581
sg17433
(lp26582
(dp26583
g17436
I140
sg17437
VrAd-NK4-MSCs
p26584
sg17438
I12
sg17439
VP55042
p26585
sg17441
I1
sa(dp26586
g17436
I140
sg17437
VrAd
p26587
sg17438
I3
sg17439
VP55042
p26588
sg17441
I1
sa(dp26589
g17436
I140
sg17437
VrAd-NK4-MSCs
p26590
sg17438
I12
sg17439
VP55042
p26591
sg17441
I1
sa(dp26592
g17436
I144
sg17437
g26578
sg17438
I3
sg17439
VP24001
p26593
sg17441
I1
sasg17442
(lp26594
(dp26595
g17436
I50
sg17437
Vmetastasis
p26596
sg17438
I10
sg17445
VC0027627
p26597
sg17441
I1
sa(dp26598
g17436
I50
sg17437
Vmetastasis
p26599
sg17438
I10
sg17445
VC0027627
p26600
sg17441
I1
sa(dp26601
g17436
I61
sg17437
Vliver carcinoma
p26602
sg17438
I15
sg17445
VC2239176
p26603
sg17441
I2
sa(dp26604
g17436
I50
sg17437
g26579
sg17438
I10
sg17445
VC0027627
p26605
sg17441
I1
sasa(dp26606
g135
(dp26607
(VrAd
p26608
VcSCC
p26609
tp26610
I00
ssg17431
VThe present study was conducted to identify the anti-tumor effects of rAd/p53, which is a recombinant human serotype 5 adenovirus, in cutaneous squamous cell carcinoma (cSCC).
p26611
sg17433
(lp26612
(dp26613
g17436
I70
sg17437
g26608
sg17438
I3
sg17439
VP55042
p26614
sg17441
I1
sa(dp26615
g17436
I74
sg17437
Vp53
p26616
sg17438
I3
sg17439
VP42771
p26617
sg17441
I1
sasg17442
(lp26618
(dp26619
g17436
I134
sg17437
Vcutaneous squamous cell carcinoma
p26620
sg17438
I33
sg17445
VC0553723
p26621
sg17441
I4
sa(dp26622
g17436
I119
sg17437
Vadenovirus
p26623
sg17438
I10
sg17445
VC0001486
p26624
sg17441
I1
sa(dp26625
g17436
I169
sg17437
g26609
sg17438
I4
sg17445
VC0553723
p26626
sg17441
I1
sa(dp26627
g17436
I53
sg17437
Vtumor
p26628
sg17438
I5
sg17445
VC0027651
p26629
sg17441
I1
sasa(dp26630
g135
(dp26631
(VRas
p26632
VNSCLC
p26633
tp26634
I00
ssg17431
VFinally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells.
p26635
sg17433
(lp26636
(dp26637
g17436
I79
sg17437
VHistone demethylase Lysine specific demethylase1
p26638
sg17438
I48
sg17439
g12
sg17441
I5
sa(dp26639
g17436
I165
sg17437
VLarge tumor suppressor 2
p26640
sg17438
I24
sg17439
g12
sg17441
I4
sa(dp26641
g17436
I191
sg17437
VLATS2
p26642
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26643
g17436
I202
sg17437
g26632
sg17438
I3
sg17439
VP01116
p26644
sg17441
I1
sasg17442
(lp26645
(dp26646
g17436
I147
sg17437
Vtumor
p26647
sg17438
I5
sg17445
VC0027651
p26648
sg17441
I1
sa(dp26649
g17436
I230
sg17437
Vdiabetes
p26650
sg17438
I8
sg17445
VC0011849
p26651
sg17441
I1
sa(dp26652
g17436
I147
sg17437
Vtumor
p26653
sg17438
I5
sg17445
VC0027651
p26654
sg17441
I1
sa(dp26655
g17436
I263
sg17437
g26633
sg17438
I5
sg17445
VC0007131
p26656
sg17441
I1
sasa(dp26657
g135
(dp26658
(Vchemoradiotherapy
p26659
VNPC
p26660
tp26661
I00
ssg17431
VTo compare clinical curative effects and toxicity of recombinant human adenovirus-p53 injection (rAd-p53, Gendicine) combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal carcinoma (NPC).
p26662
sg17433
(lp26663
(dp26664
g17436
I97
sg17437
VrAd-p53
p26665
sg17438
I7
sg17439
VP55042
p26666
sg17441
I1
sa(dp26667
g17436
I146
sg17437
VCRT
p26668
sg17438
I3
sg17439
VP27797
p26669
sg17441
I1
sa(dp26670
g17436
I53
sg17437
Vrecombinant human adenovirus-p53 injection
p26671
sg17438
I42
sg17439
VP55042
p26672
sg17441
I4
sa(dp26673
g17436
I127
sg17437
g26659
sg17438
I17
sg17439
VP27797
p26674
sg17441
I1
sasg17442
(lp26675
(dp26676
g17436
I71
sg17437
Vadenovirus
p26677
sg17438
I10
sg17445
VC0001486
p26678
sg17441
I1
sa(dp26679
g17436
I210
sg17437
Vnasopharyngeal carcinoma
p26680
sg17438
I24
sg17445
VC2931822
p26681
sg17441
I2
sa(dp26682
g17436
I236
sg17437
g26660
sg17438
I3
sg17445
VC2931822
p26683
sg17441
I1
sasa(dp26684
g17431
VWe used data generated from a haploid hydatidiform mole genome (CHM1) and a diploid human genome (NA12878) to test our approach.
p26685
sg17433
(lp26686
(dp26687
g17436
I64
sg17437
VCHM1
p26688
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp26689
(dp26690
g17436
I38
sg17437
Vhydatidiform mole
p26691
sg17438
I17
sg17445
VC0020217
p26692
sg17441
I2
sasa(dp26693
g17431
VOur results show the recovery of an allele of the non-coding minisatellite MS1 (located on chromosome 1 at 1p33-35) at greater than 97% identity to reference (GRCh38) from the unprocessed sequence data of a haploid complete hydatidiform mole (CHM1) cell line.
p26694
sg17433
(lp26695
sg17442
(lp26696
(dp26697
g17436
I215
sg17437
Vcomplete hydatidiform mole
p26698
sg17438
I26
sg17445
VC0678213
p26699
sg17441
I3
sasa(dp26700
g17431
VWe demonstrate the utility of Alpha-CENTAURI in characterizing repeat structure for alpha satellite containing reads in the hydatidiform mole (CHM1, haploid-like) genome.
p26701
sg17433
(lp26702
(dp26703
g17436
I143
sg17437
VCHM1
p26704
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp26705
(dp26706
g17436
I124
sg17437
Vhydatidiform mole
p26707
sg17438
I17
sg17445
VC0020217
p26708
sg17441
I2
sasa(dp26709
g17431
VIn order to overcome the issue of allelic diversity, we used genomic DNA from an essentially haploid hydatidiform mole, CHM1.
p26710
sg17433
(lp26711
(dp26712
g17436
I120
sg17437
VCHM1
p26713
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp26714
(dp26715
g17436
I101
sg17437
Vhydatidiform mole
p26716
sg17438
I17
sg17445
VC0020217
p26717
sg17441
I2
sasa(dp26718
g135
(dp26719
(VIL-13
p26720
Vasthmatic
p26721
tp26722
I00
ssg17431
VConsistent with these findings, we observed that in an IL-33-administered asthmatic airway inflammation model, IL-13 levels were markedly increased in bronchoalveolar lavage fluid, but its levels were markedly suppressed by treatment with inhibitors of 5-LO, 12-LO or BLT2, further suggesting roles of 5-/12-LO in IL-33-induced IL-13 production.
p26723
sg17433
(lp26724
(dp26725
g17436
I268
sg17437
VBLT2
p26726
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26727
g17436
I111
sg17437
VIL-13
p26728
sg17438
I5
sg17439
VP35225
p26729
sg17441
I1
sa(dp26730
g17436
I111
sg17437
g26720
sg17438
I5
sg17439
VP35225
p26731
sg17441
I1
sasg17442
(lp26732
(dp26733
g17436
I91
sg17437
Vinflammation
p26734
sg17438
I12
sg17445
VC0021368
p26735
sg17441
I1
sa(dp26736
g17436
I74
sg17437
g26721
sg17438
I9
sg17445
VC0004096
p26737
sg17441
I1
sasa(dp26738
g135
(dp26739
(VIL-13
p26740
Vasthmatic
p26741
tp26742
I00
ssg17431
VOur results suggest that "MyD88-5-/12-LO-BLT2-NF-KB" cascade significantly contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus potentially contributing to asthmatic development and exacerbation.
p26743
sg17433
(lp26744
(dp26745
g17436
I41
sg17437
VBLT2
p26746
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26747
g17436
I26
sg17437
VMyD88
p26748
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp26749
g17436
I121
sg17437
g26740
sg17438
I5
sg17439
VP35225
p26750
sg17441
I1
sasg17442
(lp26751
(dp26752
g17436
I175
sg17437
g26741
sg17438
I9
sg17445
VC0004096
p26753
sg17441
I1
sasa(dp26754
g135
(dp26755
(Vgastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia
p26756
VWilms tumor
p26757
tp26758
I00
ssg17431
VDNA methylation changes at a number of these genes have been linked to various forms of human disease, including cancers, such as asthma and acute myeloid leukemia (ALOX12), gastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia (KCNK15), Wilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L), suggesting a potential etiologic role for MEs in tumorigenesis and underscoring the possible developmental origins of these malignancies.
p26759
sg17433
(lp26760
(dp26761
g17436
I174
sg17437
g26756
sg17438
I85
sg17439
VP12830
p26762
sg17441
I12
sa(dp26763
g17436
I270
sg17437
VWilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L)
p26764
sg17438
I80
sg17439
g12
sg17441
I10
sa(dp26765
g17436
I261
sg17437
VKCNK15
p26766
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp26767
(dp26768
g17436
I197
sg17437
Vbreast cancer
p26769
sg17438
I13
sg17445
VC0678222
p26770
sg17441
I2
sa(dp26771
g17436
I401
sg17437
Vtumorigenesis
p26772
sg17438
I13
sg17445
VC0007621
p26773
sg17441
I1
sa(dp26774
g17436
I174
sg17437
Vgastric cancer
p26775
sg17438
I14
sg17445
VC0024623
p26776
sg17441
I2
sa(dp26777
g17436
I141
sg17437
Vacute myeloid leukemia
p26778
sg17438
I22
sg17445
VC0023467
p26779
sg17441
I3
sa(dp26780
g17436
I236
sg17437
Vacute lymphoid leukemia
p26781
sg17438
I23
sg17445
VC1961102
p26782
sg17441
I3
sa(dp26783
g17436
I219
sg17437
Vcolon cancer
p26784
sg17438
I12
sg17445
VC0699790
p26785
sg17441
I2
sa(dp26786
g17436
I130
sg17437
Vasthma
p26787
sg17438
I6
sg17445
VC0004096
p26788
sg17441
I1
sa(dp26789
g17436
I476
sg17437
Vmalignancies
p26790
sg17438
I12
sg17445
VC0006826
p26791
sg17441
I1
sa(dp26792
g17436
I323
sg17437
Vcolorectal cancer
p26793
sg17438
I17
sg17445
VC1527249
p26794
sg17441
I2
sa(dp26795
g17436
I394
sg17437
VMEs
p26796
sg17438
I3
sg17445
VC0265215
p26797
sg17441
I1
sa(dp26798
g17436
I113
sg17437
Vcancers
p26799
sg17438
I7
sg17445
VC0006826
p26800
sg17441
I1
sa(dp26801
g17436
I270
sg17437
g26757
sg17438
I11
sg17445
VC0027708
p26802
sg17441
I2
sasa(dp26803
g135
(dp26804
(VALOX12
p26805
Vasthma
p26806
tp26807
I01
ssg17431
VDNA methylation of ALOX12 may be an epigenetic biomarker for the risk of asthma-related phenotypes.
p26808
sg17433
(lp26809
(dp26810
g17436
I19
sg17437
g26805
sg17438
I6
sg17439
VP18054
p26811
sg17441
I1
sasg17442
(lp26812
(dp26813
g17436
I73
sg17437
g26806
sg17438
I6
sg17445
VC0004096
p26814
sg17441
I1
sasa(dp26815
g135
(dp26816
(VAACT
p26817
VMJD
p26818
tp26819
I00
ssg17431
VWe provide evidence that MJD in five pedigrees of Azorean descent is also linked to chromosome 14q in an 18-cM region between the markers D14S67 and AACT (multipoint lod score +7.00 near D14S81).
p26820
sg17433
(lp26821
(dp26822
g17436
I149
sg17437
g26817
sg17438
I4
sg17439
VP05154
p26823
sg17441
I1
sasg17442
(lp26824
(dp26825
g17436
I25
sg17437
g26818
sg17438
I3
sg17445
VC0024408
p26826
sg17441
I1
sasa(dp26827
g17431
VHere we report linkage disequilibrium of rs2288904 with rs3087969 and the association of these SLC44A2 SNPs with Meniere's disease severity.
p26828
sg17433
(lp26829
(dp26830
g17436
I95
sg17437
VSLC44A2 SNPs
p26831
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp26832
(dp26833
g17436
I23
sg17437
Vdisequilibrium
p26834
sg17438
I14
sg17445
VC0394006
p26835
sg17441
I1
sa(dp26836
g17436
I113
sg17437
VMeniere's disease
p26837
sg17438
I17
sg17445
VC0025281
p26838
sg17441
I2
sasa(dp26839
g17431
VThe association of SLC44A2 SNPs with VTE suggests that thrombi affecting cochlear vessels could be a factor in Meniere's disease.
p26840
sg17433
(lp26841
(dp26842
g17436
I19
sg17437
VSLC44A2 SNPs
p26843
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp26844
(dp26845
g17436
I55
sg17437
Vthrombi
p26846
sg17438
I7
sg17445
VC0087086
p26847
sg17441
I1
sa(dp26848
g17436
I111
sg17437
VMeniere's disease
p26849
sg17438
I17
sg17445
VC0025281
p26850
sg17441
I2
sasa(dp26851
g135
(dp26852
(VCTLA-4 gene
p26853
Vbreast cancer
p26854
tp26855
I00
ssg17431
VThe present study deals with CTLA-4 gene selected polymorphisms (rs11571317 C/T and rs3087243G/A) to explore their relation with breast cancer susceptibility and progression in BC patients.
p26856
sg17433
(lp26857
(dp26858
g17436
I29
sg17437
g26853
sg17438
I11
sg17439
VP16410
p26859
sg17441
I2
sasg17442
(lp26860
(dp26861
g17436
I129
sg17437
g26854
sg17438
I13
sg17445
VC0678222
p26862
sg17441
I2
sasa(dp26863
g135
(dp26864
(Vanti-CTLA-4
p26865
Vhepatocellular carcinoma
p26866
tp26867
I00
ssg17431
VClinical experience with checkpoint inhibitors in hepatocellular carcinoma includes early trials with the anti-CTLA-4 agent tremelimumab, and a large phase 2 trial with the anti-PD-1 agent nivolumab.
p26868
sg17433
(lp26869
(dp26870
g17436
I106
sg17437
g26865
sg17438
I11
sg17439
VP16410
p26871
sg17441
I1
sasg17442
(lp26872
(dp26873
g17436
I50
sg17437
g26866
sg17438
I24
sg17445
VC1512411
p26874
sg17441
I2
sasa(dp26875
g135
(dp26876
(Vprogrammed cell death protein 1
p26877
Vbladder cancer
p26878
tp26879
I00
ssg17431
VSeveral immune checkpoint inhibitors that target programmed cell death protein 1 (PD1), its ligand PDL1, and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have already been approved for use in bladder cancer, representing the most important change to the urological oncologist's tool-kit in over a decade.
p26880
sg17433
(lp26881
(dp26882
g17436
I154
sg17437
VCTLA4
p26883
sg17438
I5
sg17439
VP16410
p26884
sg17441
I1
sa(dp26885
g17436
I99
sg17437
VPDL1
p26886
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26887
g17436
I82
sg17437
VPD1
p26888
sg17438
I3
sg17439
VP37840
p26889
sg17441
I1
sa(dp26890
g17436
I109
sg17437
Vcytotoxic T lymphocyte-associated protein 4
p26891
sg17438
I43
sg17439
VP16410
p26892
sg17441
I5
sa(dp26893
g17436
I49
sg17437
g26877
sg17438
I31
sg17439
VP37840
p26894
sg17441
I5
sasg17442
(lp26895
(dp26896
g17436
I199
sg17437
g26878
sg17438
I14
sg17445
VC0699885
p26897
sg17441
I2
sasa(dp26898
g135
(dp26899
(Vanti-PD-1
p26900
Vlung cancer
p26901
tp26902
I00
ssg17431
VOur model predicts survival in anti-CTLA-4-treated patients with melanoma and anti-PD-1-treated patients with lung cancer.
p26903
sg17433
(lp26904
(dp26905
g17436
I31
sg17437
Vanti-CTLA-4
p26906
sg17438
I11
sg17439
VP16410
p26907
sg17441
I1
sa(dp26908
g17436
I78
sg17437
g26900
sg17438
I9
sg17439
VP18621
p26909
sg17441
I1
sasg17442
(lp26910
(dp26911
g17436
I65
sg17437
Vmelanoma
p26912
sg17438
I8
sg17445
VC0025202
p26913
sg17441
I1
sa(dp26914
g17436
I110
sg17437
g26901
sg17438
I11
sg17445
VC0684249
p26915
sg17441
I2
sasa(dp26916
g135
(dp26917
(Vanti-CTLA4
p26918
VNSCLC
p26919
tp26920
I00
ssg17431
VSmall animal PET/CT studies showed that 89Zr-C4 detected antigen levels on a patient derived xenograft (PDX) established from a non-small-cell lung cancer (NSCLC) patient before an 8-month response to anti-PD-1 and anti-CTLA4 therapy.
p26921
sg17433
(lp26922
(dp26923
g17436
I201
sg17437
Vanti-PD-1
p26924
sg17438
I9
sg17439
VP18621
p26925
sg17441
I1
sa(dp26926
g17436
I215
sg17437
g26918
sg17438
I10
sg17439
VP16410
p26927
sg17441
I1
sasg17442
(lp26928
(dp26929
g17436
I128
sg17437
Vnon-small-cell lung cancer
p26930
sg17438
I26
sg17445
VC0007131
p26931
sg17441
I3
sa(dp26932
g17436
I156
sg17437
g26919
sg17438
I5
sg17445
VC0007131
p26933
sg17441
I1
sasa(dp26934
g135
(dp26935
(VFSH receptor
p26936
VPOF
p26937
tp26938
I00
ssg17431
VAutosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identified in patients with POF.
p26939
sg17433
(lp26940
(dp26941
g17436
I124
sg17437
VGALT
p26942
sg17438
I4
sg17439
VP15291
p26943
sg17441
I1
sa(dp26944
g17436
I154
sg17437
VFSHR
p26945
sg17438
I4
sg17439
VP23945
p26946
sg17441
I1
sa(dp26947
g17436
I140
sg17437
g26936
sg17438
I12
sg17439
VP23945
p26948
sg17441
I2
sa(dp26949
g17436
I67
sg17437
VPMM2
p26950
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26951
g17436
I83
sg17437
Vgalactose-1-phosphate uridyltransferase
p26952
sg17438
I39
sg17439
g12
sg17441
I2
sa(dp26953
g17436
I45
sg17437
Vphosphomannomutase 2
p26954
sg17438
I20
sg17439
g12
sg17441
I2
sasg17442
(lp26955
(dp26956
g17436
I294
sg17437
Vcandidiasis
p26957
sg17438
I11
sg17445
VC0006840
p26958
sg17441
I1
sa(dp26959
g17436
I317
sg17437
Vdystrophy
p26960
sg17438
I9
sg17445
VC0333606
p26961
sg17441
I1
sa(dp26962
g17436
I195
sg17437
VBlepharophimosis
p26963
sg17438
I16
sg17445
VC0005744
p26964
sg17441
I1
sa(dp26965
g17436
I225
sg17437
Vautoimmune
p26966
sg17438
I10
sg17445
VC0443146
p26967
sg17441
I1
sa(dp26968
g17436
I366
sg17437
g26937
sg17438
I3
sg17445
VC0085215
p26969
sg17441
I1
sasa(dp26970
g135
(dp26971
(VCtsk
p26972
Vmicrophthalmia
p26973
tp26974
I00
ssg17431
VOsteoclast-specific genes such as Trap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7 (Clcn7), cathepsin K (Ctsk) as well as osteoclast-specific transcription factor and microphthalmia transcription factor (MITF) were up-regulated in the treated cells, whilst the messenger RNA (mRNA) levels of Dspp, Dmp1 and Opg were reduced in the induced cells.
p26975
sg17433
(lp26976
(dp26977
g17436
I332
sg17437
VDmp1
p26978
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26979
g17436
I126
sg17437
Vcathepsin K
p26980
sg17438
I11
sg17439
VP43235
p26981
sg17441
I2
sa(dp26982
g17436
I118
sg17437
VClcn7
p26983
sg17438
I5
sg17439
VP51798
p26984
sg17441
I1
sa(dp26985
g17436
I201
sg17437
Vmicrophthalmia transcription factor
p26986
sg17438
I35
sg17439
VP35398
p26987
sg17441
I3
sa(dp26988
g17436
I326
sg17437
VDspp
p26989
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26990
g17436
I139
sg17437
g26972
sg17438
I4
sg17439
VP43235
p26991
sg17441
I1
sa(dp26992
g17436
I238
sg17437
VMITF
p26993
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp26994
g17436
I34
sg17437
VTrap, osteopetrosis-associated transmembrane protein 1 (Ostm1), chloride channel 7
p26995
sg17438
I82
sg17439
g12
sg17441
I9
sa(dp26996
g17436
I341
sg17437
VOpg
p26997
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp26998
(dp26999
g17436
I40
sg17437
Vosteopetrosis
p27000
sg17438
I13
sg17445
VC0029454
p27001
sg17441
I1
sa(dp27002
g17436
I201
sg17437
g26973
sg17438
I14
sg17445
VC0026010
p27003
sg17441
I1
sasa(dp27004
g135
(dp27005
(Vmicrophthalmia transcription factor
p27006
Vmicrophthalmia
p27007
tp27008
I00
ssg17431
VCathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts.
p27009
sg17433
(lp27010
(dp27011
g17436
I0
sg17437
VCathepsin K
p27012
sg17438
I11
sg17439
VP43235
p27013
sg17441
I2
sa(dp27014
g17436
I56
sg17437
g27006
sg17438
I35
sg17439
VP35398
p27015
sg17441
I3
sa(dp27016
g17436
I93
sg17437
VMITF
p27017
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp27018
(dp27019
g17436
I56
sg17437
g27007
sg17438
I14
sg17445
VC0026010
p27020
sg17441
I1
sasa(dp27021
g135
(dp27022
(VCD68
p27023
VLCA
p27024
tp27025
I00
ssg17431
VAmong cell species that infiltrated in perichondral granulation, LCA, CD68 (monocytes/macrophages), and CD4 cells were dominant in number; MMP-8, MMP-9, and elastase were expressed only in the perichondral granulation; whereas MMP-3 and cathepsin K and L were detected in both chondrocytes and granulations.
p27026
sg17433
(lp27027
(dp27028
g17436
I146
sg17437
VMMP-9
p27029
sg17438
I5
sg17439
VP14780
p27030
sg17441
I1
sa(dp27031
g17436
I139
sg17437
VMMP-8
p27032
sg17438
I5
sg17439
VP22894
p27033
sg17441
I1
sa(dp27034
g17436
I237
sg17437
Vcathepsin K and L
p27035
sg17438
I17
sg17439
VP43235
p27036
sg17441
I4
sa(dp27037
g17436
I104
sg17437
VCD4
p27038
sg17438
I3
sg17439
VP01730
p27039
sg17441
I1
sa(dp27040
g17436
I157
sg17437
Velastase
p27041
sg17438
I8
sg17439
VP30740
p27042
sg17441
I1
sa(dp27043
g17436
I227
sg17437
VMMP-3
p27044
sg17438
I5
sg17439
VP08254
p27045
sg17441
I1
sa(dp27046
g17436
I65
sg17437
VLCA
p27047
sg17438
I3
sg17439
VP09496
p27048
sg17441
I1
sa(dp27049
g17436
I70
sg17437
g27023
sg17438
I4
sg17439
VP34810
p27050
sg17441
I1
sasg17442
(lp27051
(dp27052
g17436
I24
sg17437
Vinfiltrated
p27053
sg17438
I11
sg17445
VC0332448
p27054
sg17441
I1
sa(dp27055
g17436
I65
sg17437
g27024
sg17438
I3
sg17445
VC0339527
p27056
sg17441
I1
sasa(dp27057
g135
(dp27058
(Vcathepsin-K
p27059
Vmicrophthalmia
p27060
tp27061
I00
ssg17431
VOverexpression of microphthalmia transcription factor has been shown to mediate the expression of cathepsin-K in osteoclasts.
p27062
sg17433
(lp27063
(dp27064
g17436
I18
sg17437
Vmicrophthalmia transcription factor
p27065
sg17438
I35
sg17439
VP35398
p27066
sg17441
I3
sa(dp27067
g17436
I98
sg17437
g27059
sg17438
I11
sg17439
VP43235
p27068
sg17441
I1
sasg17442
(lp27069
(dp27070
g17436
I18
sg17437
g27060
sg17438
I14
sg17445
VC0026010
p27071
sg17441
I1
sasa(dp27072
g135
(dp27073
(Vmicrophthalmia transcription factor
p27074
Vtranslocation
p27075
tp27076
I00
ssg17431
VWe studied cathepsin-K in 17 cytogenetically confirmed microphthalmia transcription factor/TFE-family translocation renal cell carcinomas.
p27077
sg17433
(lp27078
(dp27079
g17436
I55
sg17437
g27074
sg17438
I35
sg17439
VP35398
p27080
sg17441
I3
sasg17442
(lp27081
(dp27082
g17436
I116
sg17437
Vrenal cell carcinomas
p27083
sg17438
I21
sg17445
VC0007134
p27084
sg17441
I3
sa(dp27085
g17436
I55
sg17437
Vmicrophthalmia
p27086
sg17438
I14
sg17445
VC0026010
p27087
sg17441
I1
sa(dp27088
g17436
I102
sg17437
g27075
sg17438
I13
sg17445
VC0040715
p27089
sg17441
I1
sasa(dp27090
g135
(dp27091
(VTRP II
p27092
Vtrichorhinophalangeal syndrome I
p27093
tp27094
I00
ssg17431
VRadiographs of the hands of 60 patients with cartilage hair hypoplasia (CHH), 69 with trichorhinophalangeal syndrome I (TRP I) and 11 with TRP II were examined, including 26 longitudinal observations.
p27095
sg17433
(lp27096
(dp27097
g17436
I139
sg17437
g27092
sg17438
I6
sg17439
VP13686
p27098
sg17441
I2
sasg17442
(lp27099
(dp27100
g17436
I120
sg17437
VTRP I
p27101
sg17438
I5
sg17445
VC0432233
p27102
sg17441
I2
sa(dp27103
g17436
I45
sg17437
Vcartilage hair hypoplasia
p27104
sg17438
I25
sg17445
VC0220748
p27105
sg17441
I3
sa(dp27106
g17436
I72
sg17437
VCHH
p27107
sg17438
I3
sg17445
VC0220748
p27108
sg17441
I1
sa(dp27109
g17436
I86
sg17437
g27093
sg17438
I32
sg17445
VC0432233
p27110
sg17441
I3
sasa(dp27111
g17431
VWe report here the new approach of fusing putidaredoxin reductase (PdR) to the carboxy-terminus of CYP101A1 (P450cam) via a linker peptide and reconstituting camphor hydroxylase activity with free putidaredoxin (Pdx).
p27112
sg17433
(lp27113
(dp27114
g17436
I42
sg17437
Vputidaredoxin reductase
p27115
sg17438
I23
sg17439
g12
sg17441
I2
sa(dp27116
g17436
I67
sg17437
VPdR
p27117
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp27118
(dp27119
g17436
I42
sg17437
Vputidaredoxin reductase
p27120
sg17438
I23
sg17445
VC1845050
p27121
sg17441
I2
sa(dp27122
g17436
I67
sg17437
VPdR
p27123
sg17438
I3
sg17445
VC1845050
p27124
sg17441
I1
sasa(dp27125
g17431
VFor other diseases, a well-established example relates to CYP1B1 where homozygosity for rare mutations occurs in primary congenital glaucoma.
p27126
sg17433
(lp27127
(dp27128
g17436
I58
sg17437
VCYP1B1
p27129
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27130
(dp27131
g17436
I113
sg17437
Vprimary congenital glaucoma
p27132
sg17438
I27
sg17445
VC1533041
p27133
sg17441
I3
sasa(dp27134
g17431
VRare CYP1B1 mutations and possibly polymorphisms may also contribute to risk for more common forms of glaucoma.
p27135
sg17433
(lp27136
(dp27137
g17436
I0
sg17437
VRare CYP1B1
p27138
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp27139
(dp27140
g17436
I102
sg17437
Vglaucoma
p27141
sg17438
I8
sg17445
VC0017601
p27142
sg17441
I1
sasa(dp27143
g135
(dp27144
(Vhuman cytochrome P450
p27145
VLCA
p27146
tp27147
I00
ssg17431
VHowever, the effects of the potential herb-drug interactions (HDIs) between LCA and therapeutic drugs on the inhibition of human cytochrome P450 (CYP) enzymes remain unclear.
p27148
sg17433
(lp27149
(dp27150
g17436
I146
sg17437
VCYP
p27151
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp27152
g17436
I123
sg17437
g27145
sg17438
I21
sg17439
VP20853
p27153
sg17441
I3
sasg17442
(lp27154
(dp27155
g17436
I76
sg17437
g27146
sg17438
I3
sg17445
VC0339527
p27156
sg17441
I1
sasa(dp27157
g135
(dp27158
(VCYP1A2
p27159
VLCA
p27160
tp27161
I00
ssg17431
VIn the present study, the inhibitory effects of LCA on seven major human CYP isoforms, including CYP1A2, 2D6, 2E1, 2C19, 2C8, 2C9 and 3A4, were investigated in human liver microsomes (HLMs).
p27162
sg17433
(lp27163
(dp27164
g17436
I61
sg17437
Vmajor human CYP isoforms
p27165
sg17438
I24
sg17439
g12
sg17441
I4
sa(dp27166
g17436
I97
sg17437
g27159
sg17438
I6
sg17439
VP05177
p27167
sg17441
I1
sasg17442
(lp27168
(dp27169
g17436
I48
sg17437
g27160
sg17438
I3
sg17445
VC0339527
p27170
sg17441
I1
sasa(dp27171
g135
(dp27172
(VCYP2D6
p27173
VLCA
p27174
tp27175
I00
ssg17431
VThe results demonstrated that LCA significantly inhibited the activities of CYP1A2, 2C19, 2C8, 2C9 and 3A4 and exhibited weak inhibitory effects on CYP2E1 and CYP2D6.
p27176
sg17433
(lp27177
(dp27178
g17436
I76
sg17437
VCYP1A2
p27179
sg17438
I6
sg17439
VP05177
p27180
sg17441
I1
sa(dp27181
g17436
I148
sg17437
VCYP2E1
p27182
sg17438
I6
sg17439
VP05181
p27183
sg17441
I1
sa(dp27184
g17436
I159
sg17437
g27173
sg17438
I6
sg17439
VP10635
p27185
sg17441
I1
sasg17442
(lp27186
(dp27187
g17436
I30
sg17437
g27174
sg17438
I3
sg17445
VC0339527
p27188
sg17441
I1
sasa(dp27189
g135
(dp27190
(VCYP1A2
p27191
Vfit
p27192
tp27193
I00
ssg17431
VDixon and Lineweaver-Burk plots revealed that the inhibition types of LCA against CYP1A2, 2C9, 2C19 and 2C8 were best fit as mixed-type inhibitions, while LCA was a competitive inhibitor towards CYP3A4.
p27194
sg17433
(lp27195
(dp27196
g17436
I195
sg17437
VCYP3A4
p27197
sg17438
I6
sg17439
VP08684
p27198
sg17441
I1
sa(dp27199
g17436
I82
sg17437
g27191
sg17438
I6
sg17439
VP05177
p27200
sg17441
I1
sasg17442
(lp27201
(dp27202
g17436
I70
sg17437
VLCA
p27203
sg17438
I3
sg17445
VC0339527
p27204
sg17441
I1
sa(dp27205
g17436
I70
sg17437
VLCA
p27206
sg17438
I3
sg17445
VC0339527
p27207
sg17441
I1
sa(dp27208
g17436
I118
sg17437
g27192
sg17438
I3
sg17445
VC0036572
p27209
sg17441
I1
sasa(dp27210
g17431
VFurthermore, the areas under the plasma concentration-time curves (AUCs) of several drugs that are primarily metabolized by CYPs were estimated to increase by 2-398% in the presence of LCA, which suggested that LCA exhibited high HDI potentials via CYP inhibition.
p27211
sg17433
(lp27212
sg17442
(lp27213
(dp27214
g17436
I185
sg17437
VLCA
p27215
sg17438
I3
sg17445
VC0339527
p27216
sg17441
I1
sa(dp27217
g17436
I185
sg17437
VLCA
p27218
sg17438
I3
sg17445
VC0339527
p27219
sg17441
I1
sasa(dp27220
g17431
VTo evaluate safety and efficacy of intravenous pulse cyclophosphamide (CyP) in acute macular serpiginous choroiditis (SC).
p27221
sg17433
(lp27222
sg17442
(lp27223
(dp27224
g17436
I118
sg17437
VSC
p27225
sg17438
I2
sg17445
VC0729842
p27226
sg17441
I1
sa(dp27227
g17436
I93
sg17437
Vserpiginous choroiditis
p27228
sg17438
I23
sg17445
VC0729842
p27229
sg17441
I2
sasa(dp27230
g135
(dp27231
(VCtgf
p27232
VDiabetes
p27233
tp27234
I00
ssg17431
VDiabetes significantly changed the kidney expression of Rage, Sod2, Tgfb1 and Ctgf, Pdp2, nephrin, and Lias.
p27235
sg17433
(lp27236
(dp27237
g17436
I68
sg17437
VTgfb1
p27238
sg17438
I5
sg17439
VP01137
p27239
sg17441
I1
sa(dp27240
g17436
I103
sg17437
VLias
p27241
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27242
g17436
I56
sg17437
VRage
p27243
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27244
g17436
I62
sg17437
VSod2
p27245
sg17438
I4
sg17439
VP04179
p27246
sg17441
I1
sa(dp27247
g17436
I84
sg17437
VPdp2
p27248
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27249
g17436
I78
sg17437
g27232
sg17438
I4
sg17439
VP29279
p27250
sg17441
I1
sa(dp27251
g17436
I90
sg17437
Vnephrin
p27252
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp27253
(dp27254
g17436
I0
sg17437
g27233
sg17438
I8
sg17445
VC0011849
p27255
sg17441
I1
sasa(dp27256
g17431
VThe main findings were 1) obesity resulted in a 46% decrease in PDP activity expressed per milligram extracted mitochondrial protein only in RG, while PDP isoform content was unchanged; 2) 8 wk of endurance training led to a significant 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; 3) 8 wk of endurance training led to a trending 1.4-2.2-fold increase in PDP activity of all muscle examined from obese rats, and the concomitant increase in PDP1 protein was only seen in soleus and RG; and 4) PDP2 protein content was not affected by obesity or training.
p27257
sg17433
(lp27258
(dp27259
g17436
I64
sg17437
VPDP
p27260
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp27261
g17436
I347
sg17437
VPDP1 protein
p27262
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp27263
g17436
I347
sg17437
VPDP1 protein
p27264
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp27265
g17436
I602
sg17437
VPDP2
p27266
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp27267
(dp27268
g17436
I303
sg17437
Vobese
p27269
sg17438
I5
sg17445
VC0028754
p27270
sg17441
I1
sa(dp27271
g17436
I303
sg17437
Vobese
p27272
sg17438
I5
sg17445
VC0028754
p27273
sg17441
I1
sa(dp27274
g17436
I26
sg17437
Vobesity
p27275
sg17438
I7
sg17445
VC0028754
p27276
sg17441
I1
sa(dp27277
g17436
I26
sg17437
Vobesity
p27278
sg17438
I7
sg17445
VC0028754
p27279
sg17441
I1
sasa(dp27280
g17431
VStarvation and streptozotocin-induced diabetes cause decreases in PDP2 mRNA abundance, PDP2 protein amount, and PDP activity in rat heart and kidney.
p27281
sg17433
(lp27282
(dp27283
g17436
I66
sg17437
VPDP2 mRNA
p27284
sg17438
I9
sg17439
g12
sg17441
I2
sa(dp27285
g17436
I87
sg17437
VPDP2 protein
p27286
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp27287
g17436
I66
sg17437
VPDP
p27288
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp27289
(dp27290
g17436
I38
sg17437
Vdiabetes
p27291
sg17438
I8
sg17445
VC0011849
p27292
sg17441
I1
sasa(dp27293
g135
(dp27294
(VTP53 genes
p27295
Vpancreatic adenocarcinoma
p27296
tp27297
I00
ssg17431
VThis study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013).
p27298
sg17433
(lp27299
(dp27300
g17436
I73
sg17437
VCDKN2A
p27301
sg17438
I6
sg17439
VP42771
p27302
sg17441
I1
sa(dp27303
g17436
I81
sg17437
VSMAD4
p27304
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27305
g17436
I67
sg17437
VKRAS
p27306
sg17438
I4
sg17439
VP01116
p27307
sg17441
I1
sa(dp27308
g17436
I92
sg17437
g27295
sg17438
I10
sg17439
VP01893
p27309
sg17441
I2
sasg17442
(lp27310
(dp27311
g17436
I195
sg17437
Vtumors
p27312
sg17438
I6
sg17445
VC0027651
p27313
sg17441
I1
sa(dp27314
g17436
I232
sg17437
g27296
sg17438
I25
sg17445
VC0281361
p27315
sg17441
I2
sa(dp27316
g17436
I314
sg17437
VCancer
p27317
sg17438
I6
sg17445
VC0006826
p27318
sg17441
I1
sa(dp27319
g17436
I314
sg17437
VCancer
p27320
sg17438
I6
sg17445
VC0006826
p27321
sg17441
I1
sasa(dp27322
g17431
VWe established a genetic diagnosis in six families with autosomal recessive HSP (SPG11 in three families and TFG/SPG57, SACS and ALS2 in one family each).
p27323
sg17433
(lp27324
(dp27325
g17436
I109
sg17437
VTFG
p27326
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp27327
g17436
I129
sg17437
VALS2
p27328
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27329
g17436
I120
sg17437
VSACS
p27330
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27331
g17436
I76
sg17437
VHSP
p27332
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp27333
(dp27334
g17436
I129
sg17437
VALS2
p27335
sg17438
I4
sg17445
VC1859807
p27336
sg17441
I1
sa(dp27337
g17436
I120
sg17437
VSACS
p27338
sg17438
I4
sg17445
VC1849140
p27339
sg17441
I1
sa(dp27340
g17436
I76
sg17437
VHSP
p27341
sg17438
I3
sg17445
VC0034152
p27342
sg17441
I1
sa(dp27343
g17436
I81
sg17437
VSPG11
p27344
sg17438
I5
sg17445
VC1858479
p27345
sg17441
I1
sasa(dp27346
g135
(dp27347
(VABCD1
p27348
VHSP
p27349
tp27350
I00
ssg17431
VWe are now performing molecular testing of the HSP patients using Sanger sequencing (SPG4, SPG11, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 15, 17, 20, 21, 31, 33, 39, 42, ABCD1, alsin, and ARSACS), and resequencing microarray (SPG1, 2, 3A, 4, 5, 6, 7, 8, 10, 11, 13, 17, 20, 21, 31, 33, and ABCD1).
p27351
sg17433
(lp27352
(dp27353
g17436
I237
sg17437
VABCD1
p27354
sg17438
I5
sg17439
VP33897
p27355
sg17441
I1
sa(dp27356
g17436
I244
sg17437
Valsin
p27357
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27358
g17436
I98
sg17437
VSPG31
p27359
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27360
g17436
I85
sg17437
VSPG4
p27361
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27362
g17436
I237
sg17437
g27348
sg17438
I5
sg17439
VP33897
p27363
sg17441
I1
sasg17442
(lp27364
(dp27365
g17436
I118
sg17437
Vcomparative genomic hybridization
p27366
sg17438
I33
sg17445
VC1855900
p27367
sg17441
I3
sa(dp27368
g17436
I98
sg17437
VSPG31
p27369
sg17438
I5
sg17445
VC1853247
p27370
sg17441
I1
sa(dp27371
g17436
I153
sg17437
VCGH
p27372
sg17438
I3
sg17445
VC1855900
p27373
sg17441
I1
sa(dp27374
g17436
I109
sg17437
VARSACS
p27375
sg17438
I6
sg17445
VC1849140
p27376
sg17441
I1
sa(dp27377
g17436
I91
sg17437
VSPG1
p27378
sg17438
I4
sg17445
VC0795953
p27379
sg17441
I1
sa(dp27380
g17436
I85
sg17437
VSPG4
p27381
sg17438
I4
sg17445
VC1866855
p27382
sg17441
I1
sa(dp27383
g17436
I91
sg17437
VSPG1
p27384
sg17438
I4
sg17445
VC0795953
p27385
sg17441
I1
sa(dp27386
g17436
I91
sg17437
VSPG11
p27387
sg17438
I5
sg17445
VC1858479
p27388
sg17441
I1
sa(dp27389
g17436
I109
sg17437
VARSACS
p27390
sg17438
I6
sg17445
VC1849140
p27391
sg17441
I1
sa(dp27392
g17436
I47
sg17437
g27349
sg17438
I3
sg17445
VC0034152
p27393
sg17441
I1
sasa(dp27394
g17431
VMeanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.
p27395
sg17433
(lp27396
sg17442
(lp27397
(dp27398
g17436
I40
sg17437
VSPG11
p27399
sg17438
I5
sg17445
VC1858479
p27400
sg17441
I1
sa(dp27401
g17436
I50
sg17437
VARSACS
p27402
sg17438
I6
sg17445
VC1849140
p27403
sg17441
I1
sasa(dp27404
g135
(dp27405
(VABCD1
p27406
VSPG4
p27407
tp27408
I00
ssg17431
VWe are now performing molecular testing for the HSP patients using direct sequencing (SPG4, SPG31, and ARSACS), comparative genomic hybridization (CGH) array (SPG1/2/3A/4/5/6/7/8/10/11/13/15/17/20/21/31/33/39/42/ABCD1/alsin/SACS), and resequencing microarray (SPG1/2/3A/4/5/6/7/8/10/11/13/17/20/21/31/33/ABCD1).
p27409
sg17433
(lp27410
(dp27411
g17436
I92
sg17437
VSPG31
p27412
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27413
g17436
I212
sg17437
VABCD1
p27414
sg17438
I5
sg17439
VP33897
p27415
sg17441
I1
sa(dp27416
g17436
I212
sg17437
g27406
sg17438
I5
sg17439
VP33897
p27417
sg17441
I1
sa(dp27418
g17436
I86
sg17437
VSPG4
p27419
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27420
g17436
I105
sg17437
VSACS
p27421
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27422
g17436
I218
sg17437
Valsin
p27423
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp27424
(dp27425
g17436
I92
sg17437
VSPG31
p27426
sg17438
I5
sg17445
VC1853247
p27427
sg17441
I1
sa(dp27428
g17436
I103
sg17437
VARSACS
p27429
sg17438
I6
sg17445
VC1849140
p27430
sg17441
I1
sa(dp27431
g17436
I112
sg17437
Vcomparative genomic hybridization
p27432
sg17438
I33
sg17445
VC1855900
p27433
sg17441
I3
sa(dp27434
g17436
I147
sg17437
VCGH
p27435
sg17438
I3
sg17445
VC1855900
p27436
sg17441
I1
sa(dp27437
g17436
I48
sg17437
VHSP
p27438
sg17438
I3
sg17445
VC0034152
p27439
sg17441
I1
sa(dp27440
g17436
I159
sg17437
VSPG1
p27441
sg17438
I4
sg17445
VC0795953
p27442
sg17441
I1
sa(dp27443
g17436
I159
sg17437
VSPG1
p27444
sg17438
I4
sg17445
VC0795953
p27445
sg17441
I1
sa(dp27446
g17436
I105
sg17437
VSACS
p27447
sg17438
I4
sg17445
VC1849140
p27448
sg17441
I1
sa(dp27449
g17436
I86
sg17437
g27407
sg17438
I4
sg17445
VC1866855
p27450
sg17441
I1
sasa(dp27451
g17431
VMeanwhile, preliminary data showed that SPG11 and ARSACS were common in Japanese ARHSP families.
p27452
sg17433
(lp27453
sg17442
(lp27454
(dp27455
g17436
I40
sg17437
VSPG11
p27456
sg17438
I5
sg17445
VC1858479
p27457
sg17441
I1
sa(dp27458
g17436
I50
sg17437
VARSACS
p27459
sg17438
I6
sg17445
VC1849140
p27460
sg17441
I1
sasa(dp27461
g17431
VAutosomal recessive spastic ataxia of Charlevoix-Saguenay is an early onset form of hereditary spastic paraplegia with a peculiar clinical presentation.
p27462
sg17433
(lp27463
sg17442
(lp27464
(dp27465
g17436
I0
sg17437
VAutosomal recessive spastic ataxia of Charlevoix-Saguenay
p27466
sg17438
I57
sg17445
VC1849140
p27467
sg17441
I6
sa(dp27468
g17436
I84
sg17437
Vhereditary spastic paraplegia
p27469
sg17438
I29
sg17445
VC0037773
p27470
sg17441
I3
sasa(dp27471
g17431
VOn the basis of our data, we therefore suggest that social avoidance (expressed as social phobia or avoidant personality disorder) has been underestimated in previous studies of carriers with the FMR-1 full mutation or premutation.
p27472
sg17433
(lp27473
(dp27474
g17436
I196
sg17437
VFMR-1
p27475
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp27476
(dp27477
g17436
I83
sg17437
Vsocial phobia
p27478
sg17438
I13
sg17445
VC0031572
p27479
sg17441
I2
sa(dp27480
g17436
I100
sg17437
Vavoidant personality disorder
p27481
sg17438
I29
sg17445
VC0004444
p27482
sg17441
I3
sasa(dp27483
g17431
VAnalysis of GenBank-derived clones on the Y chromosome revealed the presence of two full-length copies in azoospermia factor region b (AZFb) (PRY1 and PRY2) and two shorter versions of the PRY gene containing exons 3, 4 and 5 in AZFc (PRY3 and PRY4).
p27484
sg17433
(lp27485
(dp27486
g17436
I151
sg17437
VPRY2
p27487
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27488
g17436
I106
sg17437
Vazoospermia factor region b
p27489
sg17438
I27
sg17439
g12
sg17441
I4
sa(dp27490
g17436
I135
sg17437
VAZFb
p27491
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27492
g17436
I189
sg17437
VPRY gene
p27493
sg17438
I8
sg17439
g12
sg17441
I2
sa(dp27494
g17436
I142
sg17437
VPRY1
p27495
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp27496
(dp27497
g17436
I106
sg17437
Vazoospermia factor
p27498
sg17438
I18
sg17445
VC1384583
p27499
sg17441
I2
sasa(dp27500
g17431
VPRY1 and PRY2, two gene copies that are located in AZFb, a region often deleted in patients with severe male infertility, were shown to be expressed in the testis.
p27501
sg17433
(lp27502
(dp27503
g17436
I9
sg17437
VPRY2
p27504
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp27505
g17436
I0
sg17437
VPRY1
p27506
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp27507
(dp27508
g17436
I104
sg17437
Vmale infertility
p27509
sg17438
I16
sg17445
VC0021364
p27510
sg17441
I2
sasa(dp27511
g135
(dp27512
(VKIR3DL2
p27513
Varthritis
p27514
tp27515
I01
ssg17431
VExpression of KIR3DL2 on NK and T cells was quantified in peripheral blood (PB) from 35 patients with SpA and 5 patients with juvenile enthesitis-related arthritis (juvenile ERA); samples were compared with samples from healthy and rheumatoid arthritis (RA) controls.
p27516
sg17433
(lp27517
(dp27518
g17436
I14
sg17437
g27513
sg17438
I7
sg17439
VP43630
p27519
sg17441
I1
sasg17442
(lp27520
(dp27521
g17436
I175
sg17437
VRA
p27522
sg17438
I2
sg17445
VC0003873
p27523
sg17441
I1
sa(dp27524
g17436
I135
sg17437
Venthesitis
p27525
sg17438
I10
sg17445
VC1282952
p27526
sg17441
I1
sa(dp27527
g17436
I232
sg17437
Vrheumatoid arthritis
p27528
sg17438
I20
sg17445
VC0003873
p27529
sg17441
I2
sa(dp27530
g17436
I154
sg17437
g27514
sg17438
I9
sg17445
VC0003864
p27531
sg17441
I1
sasa(dp27532
g135
(dp27533
(VNKB1
p27534
VRA
p27535
tp27536
I01
ssg17431
VNKB1 inhibits cytoxic activity of T lymphocytes mediated by superantigens, which is one of the contributing factors in the pathogenesis of rheumatoid arthritis (RA).
p27537
sg17433
(lp27538
(dp27539
g17436
I0
sg17437
g27534
sg17438
I4
sg17439
VP43629
p27540
sg17441
I1
sasg17442
(lp27541
(dp27542
g17436
I139
sg17437
Vrheumatoid arthritis
p27543
sg17438
I20
sg17445
VC0003873
p27544
sg17441
I2
sa(dp27545
g17436
I123
sg17437
Vpathogenesis
p27546
sg17438
I12
sg17445
VC0699748
p27547
sg17441
I1
sa(dp27548
g17436
I161
sg17437
g27535
sg17438
I2
sg17445
VC0003873
p27549
sg17441
I1
sasa(dp27550
g135
(dp27551
(VCD4
p27552
Vrheumatoid arthritis
p27553
tp27554
I00
ssg17431
VKiller Ig-like receptors (KIRs) are expressed on CD4(+)CD28(null) T cells, a highly oligoclonal subset of T cells that is expanded in patients with rheumatoid arthritis.
p27555
sg17433
(lp27556
(dp27557
g17436
I0
sg17437
VKiller Ig-like receptors
p27558
sg17438
I24
sg17439
g12
sg17441
I3
sa(dp27559
g17436
I26
sg17437
VKIRs
p27560
sg17438
I4
sg17439
VP55040
p27561
sg17441
I1
sa(dp27562
g17436
I55
sg17437
VCD28
p27563
sg17438
I4
sg17439
VP33681
p27564
sg17441
I1
sa(dp27565
g17436
I49
sg17437
g27552
sg17438
I3
sg17439
VP01730
p27566
sg17441
I1
sasg17442
(lp27567
(dp27568
g17436
I148
sg17437
g27553
sg17438
I20
sg17445
VC0003873
p27569
sg17441
I2
sasa(dp27570
g17431
VFunctional involvement of NKAIN2 in miR-181d-regulated pancreatic cancer development was tested by small interfering RNA-mediated NKAIN2 knockdown in miR-181d-downregulated PANC-1 and AsPC-1 cells.
p27571
sg17433
(lp27572
(dp27573
g17436
I26
sg17437
VNKAIN2
p27574
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp27575
g17436
I36
sg17437
VmiR-181d
p27576
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp27577
g17436
I36
sg17437
VmiR-181d
p27578
sg17438
I8
sg17439
g12
sg17441
I1
sasg17442
(lp27579
(dp27580
g17436
I55
sg17437
Vpancreatic cancer
p27581
sg17438
I17
sg17445
VC0235974
p27582
sg17441
I2
sasa(dp27583
g17431
VNKAIN2 was directly targeted by miR-181d in pancreatic cancer.
p27584
sg17433
(lp27585
(dp27586
g17436
I32
sg17437
VmiR-181d
p27587
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp27588
g17436
I0
sg17437
VNKAIN2
p27589
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27590
(dp27591
g17436
I44
sg17437
Vpancreatic cancer
p27592
sg17438
I17
sg17445
VC0235974
p27593
sg17441
I2
sasa(dp27594
g17431
VSmall interfering RNA-mediated NKAIN2 knockdown reversed the inhibition of miR-181d downregulation on pancreatic cancer development.
p27595
sg17433
(lp27596
(dp27597
g17436
I75
sg17437
VmiR-181d
p27598
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp27599
g17436
I31
sg17437
VNKAIN2
p27600
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27601
(dp27602
g17436
I102
sg17437
Vpancreatic cancer
p27603
sg17438
I17
sg17445
VC0235974
p27604
sg17441
I2
sasa(dp27605
g17431
VInhibiting miR-181d may suppress pancreatic cancer development, possibly through the inverse regulation on NKAIN2.
p27606
sg17433
(lp27607
(dp27608
g17436
I107
sg17437
VNKAIN2
p27609
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp27610
g17436
I11
sg17437
VmiR-181d
p27611
sg17438
I8
sg17439
g12
sg17441
I1
sasg17442
(lp27612
(dp27613
g17436
I33
sg17437
Vpancreatic cancer
p27614
sg17438
I17
sg17445
VC0235974
p27615
sg17441
I2
sasa(dp27616
g17431
VRecurrent chromosome breakpoints at 6q22.31, leading to truncation and potential loss-of-function of the NKAIN2 gene, in Chinese prostate cancer patients were previously identified.
p27617
sg17433
(lp27618
(dp27619
g17436
I105
sg17437
VNKAIN2 gene
p27620
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp27621
(dp27622
g17436
I129
sg17437
Vprostate cancer
p27623
sg17438
I15
sg17445
VC0600139
p27624
sg17441
I2
sa(dp27625
g17436
I56
sg17437
Vtruncation
p27626
sg17438
I10
sg17445
VC1706395
p27627
sg17441
I1
sasa(dp27628
g17431
VIn this study we investigated genomic, methylation and expression changes of NKAIN2 in a large number of prostate cancer samples and determined its functional role in prostate cancer cells.
p27629
sg17433
(lp27630
(dp27631
g17436
I77
sg17437
VNKAIN2
p27632
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27633
(dp27634
g17436
I105
sg17437
Vprostate cancer
p27635
sg17438
I15
sg17445
VC0600139
p27636
sg17441
I2
sa(dp27637
g17436
I105
sg17437
Vprostate cancer
p27638
sg17438
I15
sg17445
VC0600139
p27639
sg17441
I2
sasa(dp27640
g17431
VFluorescence in situ hybridization analysis confirmed that NKAIN2 truncation is specific to Chinese while deletion of the gene is frequent in both Chinese and UK prostate cancers.
p27641
sg17433
(lp27642
(dp27643
g17436
I59
sg17437
VNKAIN2
p27644
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27645
(dp27646
g17436
I162
sg17437
Vprostate cancers
p27647
sg17438
I16
sg17445
VC0376358
p27648
sg17441
I2
sa(dp27649
g17436
I66
sg17437
Vtruncation
p27650
sg17438
I10
sg17445
VC1706395
p27651
sg17441
I1
sasa(dp27652
g17431
VSomatic mutations of NKAIN2 in prostate cancer samples exist but at very low frequency, suggesting that it is a putative tumor suppressor gene (TSG) with haploid insufficiency.
p27653
sg17433
(lp27654
(dp27655
g17436
I21
sg17437
VNKAIN2
p27656
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27657
(dp27658
g17436
I31
sg17437
Vprostate cancer
p27659
sg17438
I15
sg17445
VC0600139
p27660
sg17441
I2
sa(dp27661
g17436
I0
sg17437
VSomatic mutations
p27662
sg17438
I17
sg17445
VC0544886
p27663
sg17441
I2
sa(dp27664
g17436
I121
sg17437
Vtumor
p27665
sg17438
I5
sg17445
VC0027651
p27666
sg17441
I1
sasa(dp27667
g17431
VOur functional studies showed that overexpression of NKAIN2 in prostate cancer cells inhibits cellular growth by promoting cell apoptosis, and decreasing cell migration and invasion.
p27668
sg17433
(lp27669
(dp27670
g17436
I53
sg17437
VNKAIN2
p27671
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27672
(dp27673
g17436
I63
sg17437
Vprostate cancer
p27674
sg17438
I15
sg17445
VC0600139
p27675
sg17441
I2
sa(dp27676
g17436
I173
sg17437
Vinvasion
p27677
sg17438
I8
sg17445
VC2699153
p27678
sg17441
I1
sasa(dp27679
g17431
VConversely, knockdown of NKAIN2 promotes prostate cancer cell growth by inhibiting cell apoptosis, and increasing cell migration and invasion.
p27680
sg17433
(lp27681
(dp27682
g17436
I25
sg17437
VNKAIN2
p27683
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27684
(dp27685
g17436
I133
sg17437
Vinvasion
p27686
sg17438
I8
sg17445
VC2699153
p27687
sg17441
I1
sa(dp27688
g17436
I50
sg17437
Vcancer cell growth
p27689
sg17438
I18
sg17445
VC1516170
p27690
sg17441
I3
sasa(dp27691
g17431
VThese data imply that NKAIN2 is a novel TSG whose activity is commonly reduced in prostate cancer.
p27692
sg17433
(lp27693
(dp27694
g17436
I40
sg17437
VTSG
p27695
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp27696
g17436
I22
sg17437
VNKAIN2
p27697
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27698
(dp27699
g17436
I82
sg17437
Vprostate cancer
p27700
sg17438
I15
sg17445
VC0600139
p27701
sg17441
I2
sasa(dp27702
g17431
VOur recent work detected recurrent chromosomal truncation at the Na(+)/K(+) transporting ATPase interacting 2 (NKAIN2) gene in prostate cancer, which was also found to be truncated in leukemia and lymphoma, suggesting that NKAIN2 is potentially one of the TSGs located in the 6q commonly deleted region in human cancers.
p27703
sg17433
(lp27704
(dp27705
g17436
I65
sg17437
VNa(+)/K(+) transporting ATPase interacting 2
p27706
sg17438
I44
sg17439
g12
sg17441
I5
sa(dp27707
g17436
I111
sg17437
VNKAIN2
p27708
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp27709
g17436
I108
sg17437
V2 (NKAIN2) gene
p27710
sg17438
I15
sg17439
g12
sg17441
I3
sasg17442
(lp27711
(dp27712
g17436
I184
sg17437
Vleukemia
p27713
sg17438
I8
sg17445
VC0023418
p27714
sg17441
I1
sa(dp27715
g17436
I197
sg17437
Vlymphoma
p27716
sg17438
I8
sg17445
VC0024299
p27717
sg17441
I1
sa(dp27718
g17436
I47
sg17437
Vtruncation
p27719
sg17438
I10
sg17445
VC1706395
p27720
sg17441
I1
sa(dp27721
g17436
I312
sg17437
Vcancers
p27722
sg17438
I7
sg17445
VC0006826
p27723
sg17441
I1
sa(dp27724
g17436
I127
sg17437
Vprostate cancer
p27725
sg17438
I15
sg17445
VC0600139
p27726
sg17441
I2
sasa(dp27727
g17431
VFluorescent in situ hybridisation with BAC/PAC clones and long range polymerase chain reaction products assessed in the human genome sequence localised the chromosome 1 breakpoint to a 9.8 kb segment within a hypothetical gene, LOC388735, and the chromosome 6 breakpoint to a 12.8 kb segment in intron 4 of the T-cell lymphoma breakpoint-associated target 1 (TCBA1) gene.
p27728
sg17433
(lp27729
(dp27730
g17436
I359
sg17437
VTCBA1
p27731
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27732
g17436
I311
sg17437
VT-cell lymphoma breakpoint-associated target 1
p27733
sg17438
I46
sg17439
g12
sg17441
I5
sasg17442
(lp27734
(dp27735
g17436
I311
sg17437
VT-cell lymphoma
p27736
sg17438
I15
sg17445
VC0079772
p27737
sg17441
I2
sa(dp27738
g17436
I43
sg17437
VPAC
p27739
sg17438
I3
sg17445
VC0033036
p27740
sg17441
I1
sasa(dp27741
g17431
VDisruption and/or formation of TCBA1 fusion genes in T cell lymphoma and leukaemia cell lines suggests a role for this gene in tumorigenesis.
p27742
sg17433
(lp27743
(dp27744
g17436
I31
sg17437
VTCBA1 fusion genes
p27745
sg17438
I18
sg17439
g12
sg17441
I3
sasg17442
(lp27746
(dp27747
g17436
I73
sg17437
Vleukaemia
p27748
sg17438
I9
sg17445
VC0023418
p27749
sg17441
I1
sa(dp27750
g17436
I127
sg17437
Vtumorigenesis
p27751
sg17438
I13
sg17445
VC0007621
p27752
sg17441
I1
sa(dp27753
g17436
I53
sg17437
VT cell lymphoma
p27754
sg17438
I15
sg17445
VC0079772
p27755
sg17441
I3
sasa(dp27756
g17431
VWe identified two T-cell lymphoma/leukemia cell lines with different differentiation stages that had breakpoints within the same novel gene, TCBA1 (T-cell lymphoma breakpoint associated target 1).
p27757
sg17433
(lp27758
(dp27759
g17436
I18
sg17437
VT-cell lymphoma
p27760
sg17438
I15
sg17439
g12
sg17441
I2
sa(dp27761
g17436
I148
sg17437
VT-cell lymphoma breakpoint associated target 1
p27762
sg17438
I46
sg17439
g12
sg17441
I6
sa(dp27763
g17436
I141
sg17437
VTCBA1
p27764
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp27765
(dp27766
g17436
I18
sg17437
VT-cell lymphoma
p27767
sg17438
I15
sg17445
VC0079772
p27768
sg17441
I2
sa(dp27769
g17436
I18
sg17437
VT-cell lymphoma
p27770
sg17438
I15
sg17445
VC0079772
p27771
sg17441
I2
sa(dp27772
g17436
I34
sg17437
Vleukemia
p27773
sg17438
I8
sg17445
VC0023418
p27774
sg17441
I1
sasa(dp27775
g17431
VIn a T-cell lymphoblastic lymphoma cell line, HT-1, the TCBA1 fused to SUSP1 (SUMO-1-specific protease), creating a SUSP1-TCBA1 chimeric gene.
p27776
sg17433
(lp27777
(dp27778
g17436
I56
sg17437
VTCBA1
p27779
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27780
g17436
I56
sg17437
VTCBA1
p27781
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27782
g17436
I71
sg17437
VSUSP1
p27783
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27784
g17436
I71
sg17437
VSUSP1
p27785
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp27786
(dp27787
g17436
I12
sg17437
Vlymphoblastic lymphoma
p27788
sg17438
I22
sg17445
VC0079748
p27789
sg17441
I2
sasa(dp27790
g17431
VHowever, in an adult T-cell leukemia cell line, ATN-1, no chimeric gene was detected, although aberrant TCBA1 transcripts were produced.
p27791
sg17433
(lp27792
(dp27793
g17436
I104
sg17437
VTCBA1 transcripts
p27794
sg17438
I17
sg17439
g12
sg17441
I2
sasg17442
(lp27795
(dp27796
g17436
I15
sg17437
Vadult T-cell leukemia
p27797
sg17438
I21
sg17445
VC0023492
p27798
sg17441
I3
sa(dp27799
g17436
I48
sg17437
VATN
p27800
sg17438
I3
sg17445
VC0268494
p27801
sg17441
I1
sasa(dp27802
g17431
VThe expression levels of TUG1 were determined using Real-Time qPCR in a total of 44 patients with bladder urothelial carcinomas.
p27803
sg17433
(lp27804
sg17442
(lp27805
(dp27806
g17436
I117
sg17437
Vcarcinomas
p27807
sg17438
I10
sg17445
VC0007097
p27808
sg17441
I1
sasa(dp27809
g17431
VBladder urothelial carcinoma T24 and 5637 cells were transfected with TUG1 siRNA or negative control siRNA.
p27810
sg17433
(lp27811
sg17442
(lp27812
(dp27813
g17436
I0
sg17437
VBladder urothelial carcinoma
p27814
sg17438
I28
sg17445
VC0279680
p27815
sg17441
I3
sasa(dp27816
g17431
VTUG1 was up-regulated in bladder urothelial carcinoma compared to paired normal urothelium.
p27817
sg17433
(lp27818
sg17442
(lp27819
(dp27820
g17436
I25
sg17437
Vbladder urothelial carcinoma
p27821
sg17438
I28
sg17445
VC0279680
p27822
sg17441
I3
sasa(dp27823
g17431
VCell proliferation inhibition and apoptosis induction were observed in TUG1 siRNA-transfected bladder urothelial carcinoma T24 and 5637 cells.
p27824
sg17433
(lp27825
sg17442
(lp27826
(dp27827
g17436
I5
sg17437
Vproliferation
p27828
sg17438
I13
sg17445
VC0334094
p27829
sg17441
I1
sa(dp27830
g17436
I94
sg17437
Vbladder urothelial carcinoma
p27831
sg17438
I28
sg17445
VC0279680
p27832
sg17441
I3
sasa(dp27833
g17431
VOur data suggest that lincRNA TUG1 is emerging as a novel player in the disease state of bladder urothelial carcinoma.
p27834
sg17433
(lp27835
sg17442
(lp27836
(dp27837
g17436
I89
sg17437
Vbladder urothelial carcinoma
p27838
sg17438
I28
sg17445
VC0279680
p27839
sg17441
I3
sasa(dp27840
g17431
VTUG1 may have potential roles as a biomarker and/or a therapeutic target in bladder urothelial carcinoma.
p27841
sg17433
(lp27842
sg17442
(lp27843
(dp27844
g17436
I76
sg17437
Vbladder urothelial carcinoma
p27845
sg17438
I28
sg17445
VC0279680
p27846
sg17441
I3
sasa(dp27847
g135
(dp27848
(VCystatin C
p27849
Vcongenital heart defects
p27850
tp27851
I01
ssg17431
VSerial samples of serum Cystatin C and urine NGAL were collected from 139 consecutive patients with congenital heart defects aged 3 days to 30 years after admission to the intensive care unit, 2 and 6 hours after the end of cardiopulmonary bypass.
p27852
sg17433
(lp27853
(dp27854
g17436
I39
sg17437
Vurine NGAL
p27855
sg17438
I10
sg17439
VP80188
p27856
sg17441
I2
sa(dp27857
g17436
I24
sg17437
g27849
sg17438
I10
sg17439
VP01034
p27858
sg17441
I2
sasg17442
(lp27859
(dp27860
g17436
I100
sg17437
g27850
sg17438
I24
sg17445
VC0018798
p27861
sg17441
I3
sasa(dp27862
g135
(dp27863
(Vserum IgE
p27864
Vrecurrent bacterial infections
p27865
tp27866
I00
ssg17431
VHyper-IgE syndrome (HIES) is a very rare primary immune deficiency characterized by elevated serum IgE levels, recurrent bacterial infections, chronic dermatitis, and connective tissue abnormalities.
p27867
sg17433
(lp27868
(dp27869
g17436
I0
sg17437
VHyper-IgE
p27870
sg17438
I9
sg17439
VP01854
p27871
sg17441
I1
sa(dp27872
g17436
I93
sg17437
g27864
sg17438
I9
sg17439
VP01854
p27873
sg17441
I2
sasg17442
(lp27874
(dp27875
g17436
I6
sg17437
VIgE
p27876
sg17438
I3
sg17445
VC0270850
p27877
sg17441
I1
sa(dp27878
g17436
I0
sg17437
VHyper-IgE syndrome
p27879
sg17438
I18
sg17445
VC0022398
p27880
sg17441
I2
sa(dp27881
g17436
I20
sg17437
VHIES
p27882
sg17438
I4
sg17445
VC0022398
p27883
sg17441
I1
sa(dp27884
g17436
I143
sg17437
Vchronic dermatitis
p27885
sg17438
I18
sg17445
VC0262975
p27886
sg17441
I2
sa(dp27887
g17436
I49
sg17437
Vimmune deficiency
p27888
sg17438
I17
sg17445
VC0850497
p27889
sg17441
I2
sa(dp27890
g17436
I111
sg17437
g27865
sg17438
I30
sg17445
VC1844383
p27891
sg17441
I3
sasa(dp27892
g135
(dp27893
(Vdominant Hyper IgE
p27894
Vperiorbital cellulitis
p27895
tp27896
I00
ssg17431
VWe describe the clinical course of a 2-month-old infant who was evaluated for autosomal dominant Hyper IgE Syndrome based on eczema, periorbital cellulitis, skin abscesses, increased total IgE levels and blood eosinophilia.
p27897
sg17433
(lp27898
(dp27899
g17436
I103
sg17437
VIgE
p27900
sg17438
I3
sg17439
VP01854
p27901
sg17441
I1
sa(dp27902
g17436
I88
sg17437
g27894
sg17438
I18
sg17439
VP01854
p27903
sg17441
I3
sasg17442
(lp27904
(dp27905
g17436
I97
sg17437
VHyper IgE Syndrome
p27906
sg17438
I18
sg17445
VC0022398
p27907
sg17441
I3
sa(dp27908
g17436
I125
sg17437
Veczema
p27909
sg17438
I6
sg17445
VC0013595
p27910
sg17441
I1
sa(dp27911
g17436
I210
sg17437
Veosinophilia
p27912
sg17438
I12
sg17445
VC0014457
p27913
sg17441
I1
sa(dp27914
g17436
I157
sg17437
Vskin abscesses
p27915
sg17438
I14
sg17445
VC0149777
p27916
sg17441
I2
sa(dp27917
g17436
I103
sg17437
VIgE
p27918
sg17438
I3
sg17445
VC0270850
p27919
sg17441
I1
sa(dp27920
g17436
I133
sg17437
g27895
sg17438
I22
sg17445
VC0149754
p27921
sg17441
I2
sasa(dp27922
g135
(dp27923
(VSTAT3
p27924
Vpsoriasis
p27925
tp27926
I00
ssg17431
VIL-22 induces STAT3 phosphorylation and mediates psoriasis-related gene expression.
p27927
sg17433
(lp27928
(dp27929
g17436
I14
sg17437
g27924
sg17438
I5
sg17439
VP40763
p27930
sg17441
I1
sa(dp27931
g17436
I0
sg17437
VIL-22
p27932
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp27933
(dp27934
g17436
I49
sg17437
g27925
sg17438
I9
sg17445
VC0033860
p27935
sg17441
I1
sasa(dp27936
g17431
VThe IL-22-STAT3-Bcl-3 pathway may be important in the pathogenesis of psoriasis.
p27937
sg17433
(lp27938
(dp27939
g17436
I4
sg17437
VIL-22-STAT3-Bcl-3
p27940
sg17438
I17
sg17439
g12
sg17441
I1
sasg17442
(lp27941
(dp27942
g17436
I54
sg17437
Vpathogenesis
p27943
sg17438
I12
sg17445
VC0699748
p27944
sg17441
I1
sa(dp27945
g17436
I70
sg17437
Vpsoriasis
p27946
sg17438
I9
sg17445
VC0033860
p27947
sg17441
I1
sasa(dp27948
g17431
VBy using quantitative real-time polymerase chain reaction, we identified significant upregulation of PMEPA1 gene expression in malignant tissues of patients with gastric adenocarcinoma.
p27949
sg17433
(lp27950
(dp27951
g17436
I101
sg17437
VPMEPA1 gene
p27952
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp27953
(dp27954
g17436
I162
sg17437
Vgastric adenocarcinoma
p27955
sg17438
I22
sg17445
VC0278701
p27956
sg17441
I2
sasa(dp27957
g17431
VBy using developed antibodies, we observed pronounced expression of TMEPAI in normal gastric epithelial cells while tumor cells from gastric adenomas, and adenocarcinoma samples were mostly negative for target protein expression.
p27958
sg17433
(lp27959
sg17442
(lp27960
(dp27961
g17436
I141
sg17437
Vadenomas
p27962
sg17438
I8
sg17445
VC0001430
p27963
sg17441
I1
sa(dp27964
g17436
I116
sg17437
Vtumor
p27965
sg17438
I5
sg17445
VC0027651
p27966
sg17441
I1
sa(dp27967
g17436
I155
sg17437
Vadenocarcinoma
p27968
sg17438
I14
sg17445
VC0001418
p27969
sg17441
I1
sasa(dp27970
g17431
VAnalysis of expressed sequence tag databases showed that STAG1/PMEPA1 also was expressed in pancreatic, endometrial, and prostatic adenocarcinomas.
p27971
sg17433
(lp27972
(dp27973
g17436
I57
sg17437
VSTAG1
p27974
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp27975
g17436
I63
sg17437
VPMEPA1
p27976
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp27977
(dp27978
g17436
I31
sg17437
Vtag
p27979
sg17438
I3
sg17445
VC0037293
p27980
sg17441
I1
sa(dp27981
g17436
I131
sg17437
Vadenocarcinomas
p27982
sg17438
I15
sg17445
VC0001418
p27983
sg17441
I1
sasa(dp27984
g17431
VIt is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.
p27985
sg17433
(lp27986
(dp27987
g17436
I115
sg17437
VTRPV1
p27988
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp27989
(dp27990
g17436
I85
sg17437
Voxidative stress
p27991
sg17438
I16
sg17445
VC0242606
p27992
sg17441
I2
sa(dp27993
g17436
I61
sg17437
Vallergic asthma
p27994
sg17438
I15
sg17445
VC0155877
p27995
sg17441
I2
sasa(dp27996
g17431
VOur data suggests the involvement of TRPV1 in allergic asthma and thus we feel this target merits further investigation.
p27997
sg17433
(lp27998
(dp27999
g17436
I37
sg17437
VTRPV1
p28000
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp28001
(dp28002
g17436
I46
sg17437
Vallergic asthma
p28003
sg17438
I15
sg17445
VC0155877
p28004
sg17441
I2
sasa(dp28005
g17431
VTNFAlfa, a proinflammatory cytokine known to be involved in the pathogenesis of allergic asthma, has been shown to induce hyperalgesia in somatic tissue via a sensitizing effect on dorsal root ganglion neurons expressing transient receptor potential vanilloid type 1 receptor (TRPV1).
p28006
sg17433
(lp28007
(dp28008
g17436
I277
sg17437
VTRPV1
p28009
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp28010
g17436
I221
sg17437
Vtransient receptor potential vanilloid type 1 receptor
p28011
sg17438
I54
sg17439
g12
sg17441
I7
sasg17442
(lp28012
(dp28013
g17436
I193
sg17437
Vganglion
p28014
sg17438
I8
sg17445
VC1258666
p28015
sg17441
I1
sa(dp28016
g17436
I64
sg17437
Vpathogenesis
p28017
sg17438
I12
sg17445
VC0699748
p28018
sg17441
I1
sa(dp28019
g17436
I122
sg17437
Vhyperalgesia
p28020
sg17438
I12
sg17445
VC0020429
p28021
sg17441
I1
sa(dp28022
g17436
I80
sg17437
Vallergic asthma
p28023
sg17438
I15
sg17445
VC0155877
p28024
sg17441
I2
sasa(dp28025
g135
(dp28026
(VPax3
p28027
Vdepigmentation
p28028
tp28029
I00
ssg17431
VSequencing of genes known to be causative for WS [microphthalmia transcription factor (MITF), Pax3, Sox10, SNAI2 ] failed to show any candidate mutations to explain this complex cutaneous depigmentation phenotype.
p28030
sg17433
(lp28031
(dp28032
g17436
I87
sg17437
VMITF
p28033
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp28034
g17436
I100
sg17437
VSox10
p28035
sg17438
I5
sg17439
VP56693
p28036
sg17441
I1
sa(dp28037
g17436
I49
sg17437
V[microphthalmia transcription factor
p28038
sg17438
I36
sg17439
g12
sg17441
I3
sa(dp28039
g17436
I107
sg17437
VSNAI2
p28040
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp28041
g17436
I94
sg17437
g28027
sg17438
I4
sg17439
VP23760
p28042
sg17441
I1
sasg17442
(lp28043
(dp28044
g17436
I50
sg17437
Vmicrophthalmia
p28045
sg17438
I14
sg17445
VC0026010
p28046
sg17441
I1
sa(dp28047
g17436
I188
sg17437
g28028
sg17438
I14
sg17445
VC0162835
p28048
sg17441
I1
sasa(dp28049
g135
(dp28050
(VWS4
p28051
Vmicrophthalmia
p28052
tp28053
I00
ssg17431
VThe mice include splotch (Sp), microphthalmia (mi), Slugh-/-, WS4, JF1, lethal-spotting (ls), and Dominant megacolon (Dom).
p28054
sg17433
(lp28055
(dp28056
g17436
I62
sg17437
g28051
sg17438
I3
sg17439
VP56693
p28057
sg17441
I1
sasg17442
(lp28058
(dp28059
g17436
I4
sg17437
Vmi
p28060
sg17438
I2
sg17445
VC0026010
p28061
sg17441
I1
sa(dp28062
g17436
I62
sg17437
VWS4
p28063
sg17438
I3
sg17445
VC1848519
p28064
sg17441
I1
sa(dp28065
g17436
I79
sg17437
Vspotting
p28066
sg17438
I8
sg17445
VC0025874
p28067
sg17441
I1
sa(dp28068
g17436
I107
sg17437
Vmegacolon
p28069
sg17438
I9
sg17445
VC0235904
p28070
sg17441
I1
sa(dp28071
g17436
I31
sg17437
g28052
sg17438
I14
sg17445
VC0026010
p28072
sg17441
I1
sasa(dp28073
g17431
VThe effect of ELL3 depletion on cell morphology, latent Epstein Barr Virus (EBV) lytic replication and differentiation markers in a Burkitt's lymphoma (BL) cell line cells are presented.
p28074
sg17433
(lp28075
(dp28076
g17436
I14
sg17437
VELL3
p28077
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp28078
(dp28079
g17436
I132
sg17437
VBurkitt's lymphoma
p28080
sg17438
I18
sg17445
VC0006413
p28081
sg17441
I2
sa(dp28082
g17436
I152
sg17437
VBL
p28083
sg17438
I2
sg17445
VC0006413
p28084
sg17441
I1
sa(dp28085
g17436
I81
sg17437
Vlytic
p28086
sg17438
I5
sg17445
VC0024348
p28087
sg17441
I1
sasa(dp28088
g17431
VBurkitt's lymphoma and a sub-set of Diffuse Large B cell lymphoma cell lines abundantly express ELL3.
p28089
sg17433
(lp28090
(dp28091
g17436
I96
sg17437
VELL3
p28092
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp28093
(dp28094
g17436
I0
sg17437
VBurkitt's lymphoma
p28095
sg17438
I18
sg17445
VC0006413
p28096
sg17441
I2
sa(dp28097
g17436
I36
sg17437
VDiffuse Large B cell lymphoma
p28098
sg17438
I29
sg17445
VC0079744
p28099
sg17441
I5
sasa(dp28100
g17431
VThis article provides a comprehensive review of the syndromes and disorders associated with NTDs, including Pallister-Hall syndrome, Walker-Warburg syndrome and Fukuyama congenital muscular dystrophy, MURCS association, Roberts syndrome, cerebro-costo-mandibular syndrome, laterality sequences, hydrolethalus syndrome, Knobloch syndrome, oculoauriculovertebral spectrum (hemifacial microsomia), cervico-oculo-acoustic syndrome, Fanconi anemia, Miller-Dieker lissencephaly syndrome, Fraser syndrome, frontonasal dysplasia, Adams-Oliver syndrome, CHILD syndrome, dyssegmental dysplasia, and monozygotic twinning.
p28101
sg17433
(lp28102
sg17442
(lp28103
(dp28104
g17436
I328
sg17437
Vsyndrome, oculoauriculovertebral
p28105
sg17438
I32
sg17445
VC0220681
p28106
sg17441
I2
sa(dp28107
g17436
I52
sg17437
Vsyndromes
p28108
sg17438
I9
sg17445
VC0039082
p28109
sg17441
I1
sa(dp28110
g17436
I238
sg17437
Vcerebro-costo-mandibular syndrome
p28111
sg17438
I33
sg17445
VC0265342
p28112
sg17441
I2
sa(dp28113
g17436
I511
sg17437
Vdysplasia
p28114
sg17438
I9
sg17445
VC0334044
p28115
sg17441
I1
sa(dp28116
g17436
I499
sg17437
Vfrontonasal dysplasia
p28117
sg17438
I21
sg17445
VC1876203
p28118
sg17441
I2
sa(dp28119
g17436
I201
sg17437
VMURCS association
p28120
sg17438
I17
sg17445
VC1832817
p28121
sg17441
I2
sa(dp28122
g17436
I52
sg17437
Vsyndrome
p28123
sg17438
I8
sg17445
VC0039082
p28124
sg17441
I1
sa(dp28125
g17436
I522
sg17437
VAdams-Oliver syndrome
p28126
sg17438
I21
sg17445
VC0265268
p28127
sg17441
I2
sa(dp28128
g17436
I395
sg17437
Vcervico-oculo-acoustic syndrome
p28129
sg17438
I31
sg17445
VC0265239
p28130
sg17441
I2
sa(dp28131
g17436
I108
sg17437
VPallister-Hall syndrome
p28132
sg17438
I23
sg17445
VC0265220
p28133
sg17441
I2
sa(dp28134
g17436
I371
sg17437
Vhemifacial microsomia
p28135
sg17438
I21
sg17445
VC1306710
p28136
sg17441
I2
sa(dp28137
g17436
I295
sg17437
Vhydrolethalus syndrome
p28138
sg17438
I22
sg17445
VC2931104
p28139
sg17441
I2
sa(dp28140
g17436
I123
sg17437
Vsyndrome, Walker-Warburg
p28141
sg17438
I24
sg17445
VC0265221
p28142
sg17441
I2
sa(dp28143
g17436
I161
sg17437
VFukuyama congenital muscular dystrophy
p28144
sg17438
I38
sg17445
VC0410174
p28145
sg17441
I4
sa(dp28146
g17436
I482
sg17437
VFraser syndrome
p28147
sg17438
I15
sg17445
VC0265233
p28148
sg17441
I2
sa(dp28149
g17436
I220
sg17437
VRoberts syndrome
p28150
sg17438
I16
sg17445
VC0392475
p28151
sg17441
I2
sa(dp28152
g17436
I545
sg17437
VCHILD syndrome
p28153
sg17438
I14
sg17445
VC0265267
p28154
sg17441
I2
sa(dp28155
g17436
I472
sg17437
Vsyndrome, Fraser
p28156
sg17438
I16
sg17445
VC0265233
p28157
sg17441
I2
sa(dp28158
g17436
I428
sg17437
VFanconi anemia
p28159
sg17438
I14
sg17445
VC3469521
p28160
sg17441
I2
sa(dp28161
g17436
I444
sg17437
VMiller-Dieker lissencephaly syndrome
p28162
sg17438
I36
sg17445
VC0265219
p28163
sg17441
I3
sasa(dp28164
g135
(dp28165
(VEtv5 mutation
p28166
Vpolydactyly
p28167
tp28168
I00
ssg17431
VMoreover, the Etv5 mutation resulted in several developmental abnormalities including an increased incidence of embryonic and perinatal lethality, postnatal growth restriction, polydactyly and renal asymmetry.
p28169
sg17433
(lp28170
(dp28171
g17436
I14
sg17437
g28166
sg17438
I13
sg17439
VP41161
p28172
sg17441
I2
sasg17442
(lp28173
(dp28174
g17436
I177
sg17437
g28167
sg17438
I11
sg17445
VC0152427
p28175
sg17441
I1
sasa(dp28176
g135
(dp28177
(VEtv5
p28178
VPPD
p28179
tp28180
I01
ssg17431
VHere, we show that conditional knockout of the FGF-activated transcription factor genes Etv4 and Etv5 in mouse led to ectopic Shh expression in the anterior limb bud and a preaxial polydactyly (PPD) skeletal phenotype.
p28181
sg17433
(lp28182
(dp28183
g17436
I126
sg17437
VShh
p28184
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp28185
g17436
I172
sg17437
Vpreaxial polydactyly
p28186
sg17438
I20
sg17439
VP32754
p28187
sg17441
I2
sa(dp28188
g17436
I194
sg17437
VPPD
p28189
sg17438
I3
sg17439
VP32754
p28190
sg17441
I1
sa(dp28191
g17436
I47
sg17437
VFGF-activated transcription factor genes Etv4
p28192
sg17438
I45
sg17439
VP35398
p28193
sg17441
I5
sa(dp28194
g17436
I97
sg17437
g28178
sg17438
I4
sg17439
VP41161
p28195
sg17441
I1
sasg17442
(lp28196
(dp28197
g17436
I172
sg17437
Vpreaxial polydactyly
p28198
sg17438
I20
sg17445
VC0345354
p28199
sg17441
I2
sa(dp28200
g17436
I194
sg17437
g28179
sg17438
I3
sg17445
VC0432215
p28201
sg17441
I1
sasa(dp28202
g135
(dp28203
(VCD82
p28204
Vmetastatic melanoma
p28205
tp28206
I00
ssg17431
VMechanistic studies showed that inducible expression of CD82 in highly metastatic melanoma cells significantly increased p21 expression upon binding of Duffy antigen receptor group (DARC), inducing tumor cell senescence and interrupting IL-8-mediated vascular endothelial (VE)-cadherin disassembly.
p28207
sg17433
(lp28208
(dp28209
g17436
I182
sg17437
VDARC
p28210
sg17438
I4
sg17439
VP00390
p28211
sg17441
I1
sa(dp28212
g17436
I152
sg17437
VDuffy antigen receptor group
p28213
sg17438
I28
sg17439
VP00390
p28214
sg17441
I4
sa(dp28215
g17436
I121
sg17437
Vp21
p28216
sg17438
I3
sg17439
VP42857
p28217
sg17441
I1
sa(dp28218
g17436
I56
sg17437
g28204
sg17438
I4
sg17439
VP27701
p28219
sg17441
I1
sa(dp28220
g17436
I237
sg17437
VIL-8-mediated vascular endothelial (VE)-cadherin
p28221
sg17438
I48
sg17439
g12
sg17441
I4
sasg17442
(lp28222
(dp28223
g17436
I198
sg17437
Vtumor
p28224
sg17438
I5
sg17445
VC0027651
p28225
sg17441
I1
sa(dp28226
g17436
I71
sg17437
g28205
sg17438
I19
sg17445
VC0278883
p28227
sg17441
I2
sasa(dp28228
g135
(dp28229
(VCXCL12
p28230
Vinvasive carcinoma
p28231
tp28232
I00
ssg17431
VOur oneway ANOVA analysis results showed that in all cases from benign diseases to invasive carcinoma, the concentration of CXCL8, CXCR4 and CXCL12 was significantly different; in benign subgroups (benign change, benign change with proliferation, atypia), the concentration of CCL2 and CCR5 was significantly different; in invasive carcinoma cases, DARC concentration was significantly correlated with the relapse risk of patients.
p28233
sg17433
(lp28234
(dp28235
g17436
I286
sg17437
VCCR5
p28236
sg17438
I4
sg17439
VP32302
p28237
sg17441
I1
sa(dp28238
g17436
I131
sg17437
VCXCR4
p28239
sg17438
I5
sg17439
VP61073
p28240
sg17441
I1
sa(dp28241
g17436
I277
sg17437
VCCL2
p28242
sg17438
I4
sg17439
VP13500
p28243
sg17441
I1
sa(dp28244
g17436
I141
sg17437
g28230
sg17438
I6
sg17439
VP48061
p28245
sg17441
I1
sasg17442
(lp28246
(dp28247
g17436
I83
sg17437
Vinvasive carcinoma
p28248
sg17438
I18
sg17445
VC1334274
p28249
sg17441
I2
sa(dp28250
g17436
I83
sg17437
g28231
sg17438
I18
sg17445
VC1334274
p28251
sg17441
I2
sa(dp28252
g17436
I232
sg17437
Vproliferation
p28253
sg17438
I13
sg17445
VC0334094
p28254
sg17441
I1
sa(dp28255
g17436
I406
sg17437
Vrelapse
p28256
sg17438
I7
sg17445
VC0277556
p28257
sg17441
I1
sasa(dp28258
g135
(dp28259
(VMAX = myc-associated factor X
p28260
Vhypoxia
p28261
tp28262
I00
ssg17431
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p28263
sg17433
(lp28264
(dp28265
g17436
I1876
sg17437
Vsuccinate dehydrogenase complex assembly factor 2
p28266
sg17438
I49
sg17439
VP49366
p28267
sg17441
I6
sa(dp28268
g17436
I1927
sg17437
VSDHB
p28269
sg17438
I4
sg17439
VP21912
p28270
sg17441
I1
sa(dp28271
g17436
I1771
sg17437
VSDH
p28272
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp28273
g17436
I2023
sg17437
VSSTRs = somatostatin receptors
p28274
sg17438
I30
sg17439
VP61278
p28275
sg17441
I4
sa(dp28276
g17436
I438
sg17437
VEGLN2
p28277
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp28278
g17436
I2266
sg17437
VVHL
p28279
sg17438
I3
sg17439
VP40337
p28280
sg17441
I1
sa(dp28281
g17436
I1802
sg17437
VSDHA
p28282
sg17438
I4
sg17439
VP31040
p28283
sg17441
I1
sa(dp28284
g17436
I1760
sg17437
VS6 kinase
p28285
sg17438
I9
sg17439
VP33981
p28286
sg17441
I2
sa(dp28287
g17436
I578
sg17437
VEPAS1
p28288
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp28289
g17436
I1434
sg17437
Vprolyl hydroxylase domain protein
p28290
sg17438
I33
sg17439
VP13674
p28291
sg17441
I4
sa(dp28292
g17436
I2303
sg17437
Valpha-ketoglutarate dehydrogenase
p28293
sg17438
I33
sg17439
VP49366
p28294
sg17441
I2
sa(dp28295
g17436
I464
sg17437
Vhypoxia inducible factor 2
p28296
sg17438
I26
sg17439
g12
sg17441
I4
sa(dp28297
g17436
I1140
sg17437
VmTOR
p28298
sg17438
I4
sg17439
VP42345
p28299
sg17441
I1
sa(dp28300
g17436
I1754
sg17437
VS6K
p28301
sg17438
I3
sg17439
VP62753
p28302
sg17441
I1
sa(dp28303
g17436
I592
sg17437
Vendothelial PAS domain protein 2
p28304
sg17438
I32
sg17439
g12
sg17441
I5
sa(dp28305
g17436
I492
sg17437
VelF
p28306
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp28307
g17436
I584
sg17437
VHIF2A
p28308
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp28309
g17436
I2063
sg17437
Vsuccinyl-CoA synthase
p28310
sg17438
I21
sg17439
g12
sg17441
I2
sa(dp28311
g17436
I231
sg17437
VO-methyl transferase
p28312
sg17438
I20
sg17439
VP31947
p28313
sg17441
I2
sa(dp28314
g17436
I958
sg17437
VIGF-1R = growth factor 1 receptor
p28315
sg17438
I33
sg17439
g12
sg17441
I6
sa(dp28316
g17436
I1777
sg17437
Vsuccinate dehydrogenase
p28317
sg17438
I23
sg17439
VP49366
p28318
sg17441
I2
sa(dp28319
g17436
I926
sg17437
VIDH = isocitrate dehydrogenase
p28320
sg17438
I30
sg17439
VP48735
p28321
sg17441
I4
sa(dp28322
g17436
I748
sg17437
VH3F3A
p28323
sg17438
I5
sg17439
VP84243
p28324
sg17441
I1
sa(dp28325
g17436
I900
sg17437
VRAS
p28326
sg17438
I3
sg17439
VP01116
p28327
sg17441
I1
sa(dp28328
g17436
I1058
sg17437
VMDH2 = malate dehydrogenase
p28329
sg17438
I27
sg17439
VP49366
p28330
sg17441
I4
sa(dp28331
g17436
I385
sg17437
VEGLN1/2
p28332
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp28333
g17436
I253
sg17437
VCPE = carboxypeptidase E
p28334
sg17438
I24
sg17439
VP16870
p28335
sg17441
I4
sa(dp28336
g17436
I1001
sg17437
Vkinesin
p28337
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp28338
g17436
I756
sg17437
Vhistone 3.3 encoding gene
p28339
sg17438
I25
sg17439
VP62805
p28340
sg17441
I4
sa(dp28341
g17436
I625
sg17437
Vhypoxia-inducible factor 2Alfa
p28342
sg17438
I30
sg17439
g12
sg17441
I3
sa(dp28343
g17436
I1648
sg17437
Vrat sarcoma oncogene
p28344
sg17438
I20
sg17439
VP35125
p28345
sg17441
I3
sa(dp28346
g17436
I1670
sg17437
VRET
p28347
sg17438
I3
sg17439
VP07949
p28348
sg17441
I1
sa(dp28349
g17436
I657
sg17437
VERK
p28350
sg17438
I3
sg17439
VP29323
p28351
sg17441
I1
sa(dp28352
g17436
I1027
sg17437
g28260
sg17438
I29
sg17439
VP61244
p28353
sg17441
I5
sa(dp28354
g17436
I408
sg17437
Vhypoxia inducible factor 1/2
p28355
sg17438
I28
sg17439
g12
sg17441
I4
sa(dp28356
g17436
I2230
sg17437
Vvascular endothelial growth factor
p28357
sg17438
I34
sg17439
g12
sg17441
I4
sa(dp28358
g17436
I444
sg17437
VPHD1
p28359
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp28360
(dp28361
g17436
I1771
sg17437
VSDH
p28362
sg17438
I3
sg17445
VC0018946
p28363
sg17441
I1
sa(dp28364
g17436
I1261
sg17437
Vneuroendocrine tumors
p28365
sg17438
I21
sg17445
VC0206754
p28366
sg17441
I2
sa(dp28367
g17436
I1477
sg17437
VPheochromocytoma
p28368
sg17438
I16
sg17445
VC0031511
p28369
sg17441
I1
sa(dp28370
g17436
I1648
sg17437
Vrat sarcoma
p28371
sg17438
I11
sg17445
VC1882848
p28372
sg17441
I2
sa(dp28373
g17436
I408
sg17437
Vhypoxia
p28374
sg17438
I7
sg17445
VC0242184
p28375
sg17441
I1
sa(dp28376
g17436
I790
sg17437
VHypoxia
p28377
sg17438
I7
sg17445
VC0242184
p28378
sg17441
I1
sa(dp28379
g17436
I1213
sg17437
VNAd
p28380
sg17438
I3
sg17445
VC1850380
p28381
sg17441
I1
sa(dp28382
g17436
I94
sg17437
VATRX
p28383
sg17438
I4
sg17445
VC1845055
p28384
sg17441
I1
sa(dp28385
g17436
I197
sg17437
VCoA
p28386
sg17438
I3
sg17445
VC2678439
p28387
sg17441
I1
sa(dp28388
g17436
I1498
sg17437
VParagangliomas
p28389
sg17438
I14
sg17445
VC0030421
p28390
sg17441
I1
sa(dp28391
g17436
I883
sg17437
Vparagangliomas
p28392
sg17438
I14
sg17445
VC0030421
p28393
sg17441
I1
sa(dp28394
g17436
I408
sg17437
Vhypoxia
p28395
sg17438
I7
sg17445
VC0242184
p28396
sg17441
I1
sa(dp28397
g17436
I1284
sg17437
VNF1
p28398
sg17438
I3
sg17445
VC0027831
p28399
sg17441
I1
sa(dp28400
g17436
I408
sg17437
Vhypoxia
p28401
sg17438
I7
sg17445
VC0242184
p28402
sg17441
I1
sa(dp28403
g17436
I2266
sg17437
VVHL
p28404
sg17438
I3
sg17445
VC0019562
p28405
sg17441
I1
sa(dp28406
g17436
I729
sg17437
VGSH
p28407
sg17438
I3
sg17445
VC1260386
p28408
sg17441
I1
sa(dp28409
g17436
I135
sg17437
Vclear cell renal cell carcinoma
p28410
sg17438
I31
sg17445
VC0279702
p28411
sg17441
I5
sa(dp28412
g17436
I566
sg17437
Vtransition
p28413
sg17438
I10
sg17445
VC0599156
p28414
sg17441
I1
sa(dp28415
g17436
I94
sg17437
VATRX
p28416
sg17438
I4
sg17445
VC1845055
p28417
sg17441
I1
sa(dp28418
g17436
I2144
sg17437
Vtranslocation
p28419
sg17438
I13
sg17445
VC0040715
p28420
sg17441
I1
sa(dp28421
g17436
I197
sg17437
VCoA
p28422
sg17438
I3
sg17445
VC2678439
p28423
sg17441
I1
sa(dp28424
g17436
I408
sg17437
g28261
sg17438
I7
sg17445
VC0242184
p28425
sg17441
I1
sasa(dp28426
g135
(dp28427
(VmTOR
p28428
Vkidney cancer
p28429
tp28430
I00
ssg17431
VImmunohistochemistry for phosphorylated-S6, phosphorylated-mTOR, mTOR, phosphorylated-AKT, hypoxia inducible factor-1Alfa, Raptor, phosphatase and tensin homolog (PTEN), phosphoinositide 3-kinase (PI3K), and phosphorylated 4E-binding protein-1 was performed on tissue microarray constructs of patients treated for nonmetastatic kidney cancer from 1997 to 2010.
p28431
sg17433
(lp28432
(dp28433
g17436
I86
sg17437
VAKT
p28434
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp28435
g17436
I163
sg17437
VPTEN
p28436
sg17438
I4
sg17439
VP60484
p28437
sg17441
I1
sa(dp28438
g17436
I59
sg17437
VmTOR
p28439
sg17438
I4
sg17439
VP42345
p28440
sg17441
I1
sa(dp28441
g17436
I197
sg17437
VPI3K
p28442
sg17438
I4
sg17439
VP42336
p28443
sg17441
I1
sa(dp28444
g17436
I123
sg17437
VRaptor, phosphatase
p28445
sg17438
I19
sg17439
g12
sg17441
I2
sa(dp28446
g17436
I131
sg17437
Vphosphatase and tensin homolog
p28447
sg17438
I30
sg17439
VP60484
p28448
sg17441
I4
sa(dp28449
g17436
I59
sg17437
g28428
sg17438
I4
sg17439
VP42345
p28450
sg17441
I1
sa(dp28451
g17436
I91
sg17437
Vhypoxia inducible factor-1Alfa
p28452
sg17438
I30
sg17439
g12
sg17441
I3
sa(dp28453
g17436
I208
sg17437
Vphosphorylated 4E-binding protein-1
p28454
sg17438
I35
sg17439
g12
sg17441
I3
sa(dp28455
g17436
I170
sg17437
Vphosphoinositide 3-kinase
p28456
sg17438
I25
sg17439
g12
sg17441
I2
sasg17442
(lp28457
(dp28458
g17436
I91
sg17437
Vhypoxia
p28459
sg17438
I7
sg17445
VC0242184
p28460
sg17441
I1
sa(dp28461
g17436
I328
sg17437
g28429
sg17438
I13
sg17445
VC0740457
p28462
sg17441
I2
sasa(dp28463
g17431
VCholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA).
p28464
sg17433
(lp28465
sg17442
(lp28466
(dp28467
g17436
I211
sg17437
ViCCA
p28468
sg17438
I4
sg17445
VC1865926
p28469
sg17441
I1
sa(dp28470
g17436
I0
sg17437
VCholangiocarcinoma
p28471
sg17438
I18
sg17445
VC0206698
p28472
sg17441
I1
sa(dp28473
g17436
I229
sg17437
VpCCA
p28474
sg17438
I4
sg17445
VC3151140
p28475
sg17441
I1
sa(dp28476
g17436
I69
sg17437
Vtumours
p28477
sg17438
I7
sg17445
VC0027651
p28478
sg17441
I1
sa(dp28479
g17436
I125
sg17437
Vcholangiocarcinomas
p28480
sg17438
I19
sg17445
VC0206698
p28481
sg17441
I1
sasa(dp28482
g17431
VCholangiocarcinoma (CCA) represents a diverse group of epithelial cancers associated with the biliary tract, and can best be stratified anatomically into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) subsets.
p28483
sg17433
(lp28484
sg17442
(lp28485
(dp28486
g17436
I0
sg17437
VCholangiocarcinoma
p28487
sg17438
I18
sg17445
VC0206698
p28488
sg17441
I1
sa(dp28489
g17436
I168
sg17437
ViCCA
p28490
sg17438
I4
sg17445
VC1865926
p28491
sg17441
I1
sa(dp28492
g17436
I186
sg17437
VpCCA
p28493
sg17438
I4
sg17445
VC3151140
p28494
sg17441
I1
sa(dp28495
g17436
I20
sg17437
VCCA
p28496
sg17438
I3
sg17445
VC0220668
p28497
sg17441
I1
sa(dp28498
g17436
I66
sg17437
Vcancers
p28499
sg17438
I7
sg17445
VC0006826
p28500
sg17441
I1
sasa(dp28501
g17431
VPreoperative evaluation of vasculobiliary anatomy in the umbilical fissure (U-point) is pivotal for perihilar cholangiocarcinoma (PCCA) applied to right-sided hepatectomy.
p28502
sg17433
(lp28503
sg17442
(lp28504
(dp28505
g17436
I100
sg17437
Vperihilar cholangiocarcinoma
p28506
sg17438
I28
sg17445
VC3151140
p28507
sg17441
I2
sa(dp28508
g17436
I130
sg17437
VPCCA
p28509
sg17438
I4
sg17445
VC3151140
p28510
sg17441
I1
sasa(dp28511
g17431
VThis study sought to define the role of adjuvant radiation therapy (RT) for patients with curative intent resection of perihilar cholangiocarcinoma (pCCA).
p28512
sg17433
(lp28513
sg17442
(lp28514
(dp28515
g17436
I119
sg17437
Vperihilar cholangiocarcinoma
p28516
sg17438
I28
sg17445
VC3151140
p28517
sg17441
I2
sa(dp28518
g17436
I149
sg17437
VpCCA
p28519
sg17438
I4
sg17445
VC3151140
p28520
sg17441
I1
sasa(dp28521
g135
(dp28522
(VPD-1
p28523
ViCCA
p28524
tp28525
I00
ssg17431
VOur goal was to characterize PD-L1 expression in intra-hepatic (iCCA) and perihilar (pCCA) cholangiocarcinomas, and to correlate our results with clinicopathological features, density of tumor-infiltrating lymphocytes (TILs) and PD-1 expression.A series of 58 iCCAs and 41 pCCAs was included in the study.
p28526
sg17433
(lp28527
(dp28528
g17436
I229
sg17437
g28523
sg17438
I4
sg17439
VP18621
p28529
sg17441
I1
sasg17442
(lp28530
(dp28531
g17436
I91
sg17437
Vcholangiocarcinomas
p28532
sg17438
I19
sg17445
VC0206698
p28533
sg17441
I1
sa(dp28534
g17436
I193
sg17437
Vinfiltrating
p28535
sg17438
I12
sg17445
VC0332448
p28536
sg17441
I1
sa(dp28537
g17436
I85
sg17437
VpCCA
p28538
sg17438
I4
sg17445
VC3151140
p28539
sg17441
I1
sa(dp28540
g17436
I64
sg17437
g28524
sg17438
I4
sg17445
VC1865926
p28541
sg17441
I1
sa(dp28542
g17436
I187
sg17437
Vtumor
p28543
sg17438
I5
sg17445
VC0027651
p28544
sg17441
I1
sasa(dp28545
g17431
VLiver transplantation (LT) provides a good chance of cure for selected patients with hepatocellular carcinoma (HCC) and perihilar cholangiocarcinoma (pCCA).
p28546
sg17433
(lp28547
sg17442
(lp28548
(dp28549
g17436
I150
sg17437
VpCCA
p28550
sg17438
I4
sg17445
VC3151140
p28551
sg17441
I1
sa(dp28552
g17436
I111
sg17437
VHCC
p28553
sg17438
I3
sg17445
VC2239176
p28554
sg17441
I1
sa(dp28555
g17436
I120
sg17437
Vperihilar cholangiocarcinoma
p28556
sg17438
I28
sg17445
VC3151140
p28557
sg17441
I2
sa(dp28558
g17436
I85
sg17437
Vhepatocellular carcinoma
p28559
sg17438
I24
sg17445
VC2239176
p28560
sg17441
I2
sasa(dp28561
g135
(dp28562
(VBTC
p28563
ViCCA
p28564
tp28565
I00
ssg17431
VBTC are sub-classified as intrahepatic cholangiocarcinoma (iCCA), perhilar/hilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA), and gallbladder carcinoma.
p28566
sg17433
(lp28567
(dp28568
g17436
I0
sg17437
g28563
sg17438
I3
sg17439
VP35070
p28569
sg17441
I1
sasg17442
(lp28570
(dp28571
g17436
I39
sg17437
Vcholangiocarcinoma
p28572
sg17438
I18
sg17445
VC0206698
p28573
sg17441
I1
sa(dp28574
g17436
I66
sg17437
Vperhilar/hilar cholangiocarcinoma
p28575
sg17438
I33
sg17445
VC3151140
p28576
sg17441
I2
sa(dp28577
g17436
I146
sg17437
Vgallbladder carcinoma
p28578
sg17438
I21
sg17445
VC0235782
p28579
sg17441
I2
sa(dp28580
g17436
I26
sg17437
Vintrahepatic cholangiocarcinoma
p28581
sg17438
I31
sg17445
VC0345905
p28582
sg17441
I2
sa(dp28583
g17436
I101
sg17437
VpCCA
p28584
sg17438
I4
sg17445
VC3151140
p28585
sg17441
I1
sa(dp28586
g17436
I59
sg17437
g28564
sg17438
I4
sg17445
VC1865926
p28587
sg17441
I1
sasa(dp28588
g17431
VTo evaluate prognostic factors for stent patency and survival in patients with perihilar cholangiocarcinoma (pCCA) who underwent percutaneous biliary stent placement.
p28589
sg17433
(lp28590
sg17442
(lp28591
(dp28592
g17436
I109
sg17437
VpCCA
p28593
sg17438
I4
sg17445
VC3151140
p28594
sg17441
I1
sa(dp28595
g17436
I79
sg17437
Vperihilar cholangiocarcinoma
p28596
sg17438
I28
sg17445
VC3151140
p28597
sg17441
I2
sasa(dp28598
g135
(dp28599
(VJun
p28600
Vocular hypertension
p28601
tp28602
I01
ssg17431
VClinical data were collected and analyzed from 71 cases of primary nephrotic syndrome with glucocorticoid-induced ocular hypertension, glaucoma or cataract from Jun.
p28603
sg17433
(lp28604
(dp28605
g17436
I161
sg17437
g28600
sg17438
I3
sg17439
VP05412
p28606
sg17441
I1
sasg17442
(lp28607
(dp28608
g17436
I147
sg17437
Vcataract
p28609
sg17438
I8
sg17445
VC0086543
p28610
sg17441
I1
sa(dp28611
g17436
I135
sg17437
Vglaucoma
p28612
sg17438
I8
sg17445
VC0017601
p28613
sg17441
I1
sa(dp28614
g17436
I67
sg17437
Vnephrotic syndrome
p28615
sg17438
I18
sg17445
VC0027726
p28616
sg17441
I2
sa(dp28617
g17436
I114
sg17437
g28601
sg17438
I19
sg17445
VC0028840
p28618
sg17441
I2
sasa(dp28619
g135
(dp28620
(Vc-Jun N-terminal kinase
p28621
Vglaucoma
p28622
tp28623
I00
ssg17431
Vc-Jun, c-Jun N-terminal kinase(JNK) and endothelin B (ETB) receptor have been shown to contribute to the pathogenesis of glaucoma.
p28624
sg17433
(lp28625
(dp28626
g17436
I0
sg17437
Vc-Jun
p28627
sg17438
I5
sg17439
VP05412
p28628
sg17441
I1
sa(dp28629
g17436
I31
sg17437
VJNK
p28630
sg17438
I3
sg17439
VP53779
p28631
sg17441
I1
sa(dp28632
g17436
I40
sg17437
Vendothelin B (ETB) receptor
p28633
sg17438
I27
sg17439
g12
sg17441
I4
sa(dp28634
g17436
I7
sg17437
g28621
sg17438
I23
sg17439
VP53779
p28635
sg17441
I3
sasg17442
(lp28636
(dp28637
g17436
I105
sg17437
Vpathogenesis
p28638
sg17438
I12
sg17445
VC0699748
p28639
sg17441
I1
sa(dp28640
g17436
I121
sg17437
g28622
sg17438
I8
sg17445
VC0017601
p28641
sg17441
I1
sasa(dp28642
g135
(dp28643
(VcFos
p28644
VOcular hypertension
p28645
tp28646
I00
ssg17431
VOcular hypertension also caused upregulations in the iron-regulating protein ceruloplasmin, the anaerobic glycolytic enzyme lactate dehydrogenase, and the transcription factors cFos and p-cJun.
p28647
sg17433
(lp28648
(dp28649
g17436
I53
sg17437
Viron-regulating protein ceruloplasmin
p28650
sg17438
I37
sg17439
VP00450
p28651
sg17441
I3
sa(dp28652
g17436
I124
sg17437
Vlactate dehydrogenase
p28653
sg17438
I21
sg17439
VP49366
p28654
sg17441
I2
sa(dp28655
g17436
I177
sg17437
g28644
sg17438
I4
sg17439
VP01100
p28656
sg17441
I1
sasg17442
(lp28657
(dp28658
g17436
I0
sg17437
g28645
sg17438
I19
sg17445
VC0028840
p28659
sg17441
I2
sasa(dp28660
g135
(dp28661
(VJUN
p28662
Vglaucoma
p28663
tp28664
I00
ssg17431
VJUN is expressed after glaucoma-relevant injuries and Jun deficiency protects RGCs after mechanical injury to the optic nerve.
p28665
sg17433
(lp28666
(dp28667
g17436
I54
sg17437
VJun
p28668
sg17438
I3
sg17439
VP05412
p28669
sg17441
I1
sa(dp28670
g17436
I0
sg17437
g28662
sg17438
I3
sg17439
VP05412
p28671
sg17441
I1
sasg17442
(lp28672
(dp28673
g17436
I23
sg17437
g28663
sg17438
I8
sg17445
VC0017601
p28674
sg17441
I1
sasa(dp28675
g135
(dp28676
(VJNK
p28677
Vocular hypertension
p28678
tp28679
I00
ssg17431
VHere, we tested the importance of JNK-JUN signaling for RGC death after ocular hypertensive axonal injury in an age-related, mouse model of ocular hypertension.
p28680
sg17433
(lp28681
(dp28682
g17436
I38
sg17437
VJUN
p28683
sg17438
I3
sg17439
VP05412
p28684
sg17441
I1
sa(dp28685
g17436
I34
sg17437
g28677
sg17438
I3
sg17439
VP53779
p28686
sg17441
I1
sasg17442
(lp28687
(dp28688
g17436
I140
sg17437
g28678
sg17438
I19
sg17445
VC0028840
p28689
sg17441
I2
sasa(dp28690
g17431
VJUN was expressed in a temporal and spatial pattern consistent with a role in glaucomatous injury.
p28691
sg17433
(lp28692
(dp28693
g17436
I0
sg17437
VJUN
p28694
sg17438
I3
sg17439
VP05412
p28695
sg17441
I1
sasg17442
(lp28696
sa(dp28697
g135
(dp28698
(VJun
p28699
Vocular hypertension
p28700
tp28701
I01
ssg17431
VTo determine the importance of JUN in ocular hypertension-induced RGC death, a floxed allele of Jun and a retinal expressed cre recombinase (Six3-cre) were backcrossed onto the DBA/2J background.
p28702
sg17433
(lp28703
(dp28704
g17436
I124
sg17437
Vcre recombinase
p28705
sg17438
I15
sg17439
g12
sg17441
I2
sa(dp28706
g17436
I141
sg17437
VSix3-cre
p28707
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp28708
g17436
I96
sg17437
g28699
sg17438
I3
sg17439
VP05412
p28709
sg17441
I1
sasg17442
(lp28710
(dp28711
g17436
I177
sg17437
VDBA
p28712
sg17438
I3
sg17445
VC0398550
p28713
sg17441
I1
sa(dp28714
g17436
I38
sg17437
g28700
sg17438
I19
sg17445
VC0028840
p28715
sg17441
I2
sasa(dp28716
g135
(dp28717
(VJun
p28718
Vneurodegeneration
p28719
tp28720
I00
ssg17431
VJun deficiency protected RGC somas from ocular hypertensive injury, but did not protect RGC axons from glaucomatous neurodegeneration.
p28721
sg17433
(lp28722
(dp28723
g17436
I0
sg17437
g28718
sg17438
I3
sg17439
VP05412
p28724
sg17441
I1
sasg17442
(lp28725
(dp28726
g17436
I116
sg17437
g28719
sg17438
I17
sg17445
VC0027746
p28727
sg17441
I1
sasa(dp28728
g17431
VJun is a major regulator of RGC somal degeneration after glaucomatous ocular hypertensive injury.
p28729
sg17433
(lp28730
(dp28731
g17436
I0
sg17437
VJun
p28732
sg17438
I3
sg17439
VP05412
p28733
sg17441
I1
sasg17442
(lp28734
(dp28735
g17436
I38
sg17437
Vdegeneration
p28736
sg17438
I12
sg17445
VC0011164
p28737
sg17441
I1
sasa(dp28738
g135
(dp28739
(VJNK
p28740
Vneurodegeneration
p28741
tp28742
I00
ssg17431
VThese results suggest in glaucomatous neurodegeneration, JNK-JUN signaling has a major role as a pro-death signaling pathway between axonal injury and somal degeneration.
p28743
sg17433
(lp28744
(dp28745
g17436
I61
sg17437
VJUN
p28746
sg17438
I3
sg17439
VP05412
p28747
sg17441
I1
sa(dp28748
g17436
I57
sg17437
g28740
sg17438
I3
sg17439
VP53779
p28749
sg17441
I1
sasg17442
(lp28750
(dp28751
g17436
I43
sg17437
Vdegeneration
p28752
sg17438
I12
sg17445
VC0011164
p28753
sg17441
I1
sa(dp28754
g17436
I38
sg17437
g28741
sg17438
I17
sg17445
VC0027746
p28755
sg17441
I1
sasa(dp28756
g17431
VTo our knowledge the co-existence of Pompe disease and thymic neuroendocrine tumor in the same patient has not been previously reported.
p28757
sg17433
(lp28758
sg17442
(lp28759
(dp28760
g17436
I62
sg17437
Vneuroendocrine tumor
p28761
sg17438
I20
sg17445
VC0206754
p28762
sg17441
I2
sa(dp28763
g17436
I37
sg17437
VPompe disease
p28764
sg17438
I13
sg17445
VC0017921
p28765
sg17441
I2
sasa(dp28766
g17431
VSignificantly more A-C (block 2: rs230528-rs230521) haplotypes (P = 0.0003 after Bonferroni's corrections) and G-A-A (block 4: rs4648068-rs3774964-rs3774968) haplotypes (P = 0.021) were found in the patients with ovarian cancer.
p28767
sg17433
(lp28768
sg17442
(lp28769
(dp28770
g17436
I213
sg17437
Vovarian cancer
p28771
sg17438
I14
sg17445
VC1140680
p28772
sg17441
I2
sasa(dp28773
g17431
VThe thyroid conditions for which surgery was indicated were: diffuse toxic goiter in 8 patients; multinodular toxic and nontoxic goiter in 30 patients; autonomous nodule in 2 patients; 2 patients with benign nodules at fine needle aspiration biopsy (FNAB); 4 patients with nodules positive for carcinoma at FNAB, among them 2 with unilateral cervical lymph nodes enlargement; 4 patients with highly suspect nodule on FNAB.
p28774
sg17433
(lp28775
sg17442
(lp28776
(dp28777
g17436
I61
sg17437
Vdiffuse toxic goiter
p28778
sg17438
I20
sg17445
VC0342122
p28779
sg17441
I3
sa(dp28780
g17436
I163
sg17437
Vnodule
p28781
sg17438
I6
sg17445
VC0028259
p28782
sg17441
I1
sa(dp28783
g17436
I120
sg17437
Vnontoxic goiter
p28784
sg17438
I15
sg17445
VC0221777
p28785
sg17441
I2
sa(dp28786
g17436
I163
sg17437
Vnodule
p28787
sg17438
I6
sg17445
VC0028259
p28788
sg17441
I1
sa(dp28789
g17436
I208
sg17437
Vnodules
p28790
sg17438
I7
sg17445
VC0028259
p28791
sg17441
I1
sa(dp28792
g17436
I208
sg17437
Vnodules
p28793
sg17438
I7
sg17445
VC0028259
p28794
sg17441
I1
sa(dp28795
g17436
I363
sg17437
Venlargement
p28796
sg17438
I11
sg17445
VC2711450
p28797
sg17441
I1
sa(dp28798
g17436
I294
sg17437
Vcarcinoma
p28799
sg17438
I9
sg17445
VC0007097
p28800
sg17441
I1
sa(dp28801
g17436
I231
sg17437
Vaspiration
p28802
sg17438
I10
sg17445
VC0700198
p28803
sg17441
I1
sasa(dp28804
g17431
VThe aim of the present study was to comparatively investigate the effects of piroxicam, a selective COX-I inhibitor, and celecoxib, a selective COX-II inhibitor, on cognitive functions in an AlCl3-induced neurotoxicity mouse model to understand the specific role of each COX enzyme in the hippocampus and cortex.
p28805
sg17433
(lp28806
(dp28807
g17436
I100
sg17437
VCOX-I
p28808
sg17438
I5
sg17439
VP00395
p28809
sg17441
I1
sa(dp28810
g17436
I144
sg17437
VCOX-II
p28811
sg17438
I6
sg17439
VP00403
p28812
sg17441
I1
sasg17442
(lp28813
sa(dp28814
g17431
VOf these differentially expressed genes, we elected to further examine the increase in COX1 expression, because of data implicating energy utilization in METH neurotoxicity and the known role of COX1 in energy metabolism.
p28815
sg17433
(lp28816
(dp28817
g17436
I87
sg17437
VCOX1
p28818
sg17438
I4
sg17439
VP00395
p28819
sg17441
I1
sa(dp28820
g17436
I87
sg17437
VCOX1
p28821
sg17438
I4
sg17439
VP00395
p28822
sg17441
I1
sasg17442
(lp28823
sa(dp28824
g17431
VThe precise role of COX1 and other genes in METH neurotoxicity remains to be elucidated.
p28825
sg17433
(lp28826
(dp28827
g17436
I20
sg17437
VCOX1
p28828
sg17438
I4
sg17439
VP00395
p28829
sg17441
I1
sasg17442
(lp28830
sa(dp28831
g135
(dp28832
(VE-cadherin
p28833
Vthyroid cancer
p28834
tp28835
I00
ssg17431
VVarious genes involved in the control of cell proliferation and invasion (p16INK4A, RASSF1A, PTEN, Rap1GAP, TIMP3, DAPK, RARBeta2, E-cadherin, and CITED1) as well as genes specific of thyroid differentiation (Na+/I- symport, TSH receptor, pendrin, SL5A8, and TTF-1) present aberrant methylation in thyroid cancer.
p28836
sg17433
(lp28837
(dp28838
g17436
I93
sg17437
VPTEN
p28839
sg17438
I4
sg17439
VP60484
p28840
sg17441
I1
sa(dp28841
g17436
I115
sg17437
VDAPK
p28842
sg17438
I4
sg17439
VP53355
p28843
sg17441
I1
sa(dp28844
g17436
I225
sg17437
VTSH receptor
p28845
sg17438
I12
sg17439
VP16473
p28846
sg17441
I2
sa(dp28847
g17436
I74
sg17437
Vp16INK4A
p28848
sg17438
I8
sg17439
VP42771
p28849
sg17441
I1
sa(dp28850
g17436
I108
sg17437
VTIMP3
p28851
sg17438
I5
sg17439
VP35625
p28852
sg17441
I1
sa(dp28853
g17436
I147
sg17437
VCITED1
p28854
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp28855
g17436
I99
sg17437
VRap1GAP
p28856
sg17438
I7
sg17439
VP47736
p28857
sg17441
I1
sa(dp28858
g17436
I259
sg17437
VTTF-1
p28859
sg17438
I5
sg17439
VP43699
p28860
sg17441
I1
sa(dp28861
g17436
I131
sg17437
g28833
sg17438
I10
sg17439
VP12830
p28862
sg17441
I1
sa(dp28863
g17436
I239
sg17437
Vpendrin
p28864
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp28865
(dp28866
g17436
I298
sg17437
g28834
sg17438
I14
sg17445
VC0007115
p28867
sg17441
I2
sa(dp28868
g17436
I46
sg17437
Vproliferation
p28869
sg17438
I13
sg17445
VC0334094
p28870
sg17441
I1
sa(dp28871
g17436
I64
sg17437
Vinvasion
p28872
sg17438
I8
sg17445
VC2699153
p28873
sg17441
I1
sasa(dp28874
g17431
VImmunohistochemistry was performed using primary antibodies to cytokeratin 19, HBME1, and CITED1 that have been found to be useful in the diagnosis of thyroid carcinoma.
p28875
sg17433
(lp28876
(dp28877
g17436
I90
sg17437
VCITED1
p28878
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp28879
g17436
I63
sg17437
Vcytokeratin 19
p28880
sg17438
I14
sg17439
g12
sg17441
I2
sasg17442
(lp28881
(dp28882
g17436
I151
sg17437
Vthyroid carcinoma
p28883
sg17438
I17
sg17445
VC0549473
p28884
sg17441
I2
sasa(dp28885
g17431
VMarkers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary thyroid carcinomas from follicular adenomas.
p28886
sg17433
(lp28887
(dp28888
g17436
I27
sg17437
VCITED1
p28889
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp28890
(dp28891
g17436
I124
sg17437
Vcarcinomas
p28892
sg17438
I10
sg17445
VC0007097
p28893
sg17441
I1
sa(dp28894
g17436
I140
sg17437
Vfollicular adenomas
p28895
sg17438
I19
sg17445
VC0205647
p28896
sg17441
I2
sasa(dp28897
g135
(dp28898
(VS100A4
p28899
Vfollicular adenomas
p28900
tp28901
I01
ssg17431
VThese analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p &lt; 0.0001).
p28902
sg17433
(lp28903
(dp28904
g17436
I178
sg17437
Vgalectin-3, cytokeratin 19
p28905
sg17438
I26
sg17439
VP17931
p28906
sg17441
I3
sa(dp28907
g17436
I210
sg17437
g28899
sg17438
I6
sg17439
VP26447
p28908
sg17441
I1
sa(dp28909
g17436
I170
sg17437
VCITED1
p28910
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp28911
(dp28912
g17436
I76
sg17437
g28900
sg17438
I19
sg17445
VC0205647
p28913
sg17441
I2
sa(dp28914
g17436
I141
sg17437
Vcarcinomas
p28915
sg17438
I10
sg17445
VC0007097
p28916
sg17441
I1
sasa(dp28917
g135
(dp28918
(Vgalectin-3
p28919
Vfollicular adenoma
p28920
tp28921
I00
ssg17431
VA combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma.
p28922
sg17433
(lp28923
(dp28924
g17436
I58
sg17437
Vgalectin-3
p28925
sg17438
I10
sg17439
VP17931
p28926
sg17441
I1
sa(dp28927
g17436
I101
sg17437
VCITED1
p28928
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp28929
g17436
I58
sg17437
g28919
sg17438
I10
sg17439
VP17931
p28930
sg17441
I1
sasg17442
(lp28931
(dp28932
g17436
I215
sg17437
Vpapillary thyroid carcinoma
p28933
sg17438
I27
sg17445
VC0238463
p28934
sg17441
I3
sa(dp28935
g17436
I169
sg17437
g28920
sg17438
I18
sg17445
VC0205647
p28936
sg17441
I2
sasa(dp28937
g135
(dp28938
(Vplasma neuronal proteins, secreted beta-amyloid precursor protein
p28939
Vautism
p28940
tp28941
I00
ssg17431
VWe examined acetylcholinesterase, plasma neuronal proteins, secreted beta-amyloid precursor protein (APP), and amyloid-beta 40 and amyloid-beta 42 peptides in children with and without autism.
p28942
sg17433
(lp28943
(dp28944
g17436
I101
sg17437
VAPP
p28945
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp28946
g17436
I12
sg17437
Vacetylcholinesterase
p28947
sg17438
I20
sg17439
VP12821
p28948
sg17441
I1
sa(dp28949
g17436
I34
sg17437
g28939
sg17438
I65
sg17439
VP29475
p28950
sg17441
I7
sa(dp28951
g17436
I111
sg17437
Vamyloid-beta 40 and amyloid-beta 42 peptides
p28952
sg17438
I44
sg17439
g12
sg17441
I6
sasg17442
(lp28953
(dp28954
g17436
I185
sg17437
g28940
sg17438
I6
sg17445
VC0004352
p28955
sg17441
I1
sa(dp28956
g17436
I74
sg17437
Vamyloid
p28957
sg17438
I7
sg17445
VC0011560
p28958
sg17441
I1
sa(dp28959
g17436
I74
sg17437
Vamyloid
p28960
sg17438
I7
sg17445
VC0011560
p28961
sg17441
I1
sa(dp28962
g17436
I74
sg17437
Vamyloid
p28963
sg17438
I7
sg17445
VC0011560
p28964
sg17441
I1
sasa(dp28965
g17431
VThe growth associated protein 43-positive fibres also seemed to be less in six samples of club foot.
p28966
sg17433
(lp28967
sg17442
(lp28968
(dp28969
g17436
I90
sg17437
Vclub foot
p28970
sg17438
I9
sg17445
VC0009081
p28971
sg17441
I2
sasa(dp28972
g135
(dp28973
(VNAA10 mRNA
p28974
Vtumorigenesis
p28975
tp28976
I00
ssg17431
VHere we showed that miR-342-5p and miR-608 suppressed the tumorigenesis of colon cancer cells in vitro and in vivo by targeting NAA10 mRNA for degradation.
p28977
sg17433
(lp28978
(dp28979
g17436
I20
sg17437
VmiR-342-5p
p28980
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp28981
g17436
I128
sg17437
g28974
sg17438
I10
sg17439
VP41227
p28982
sg17441
I2
sasg17442
(lp28983
(dp28984
g17436
I75
sg17437
Vcolon cancer
p28985
sg17438
I12
sg17445
VC0699790
p28986
sg17441
I2
sa(dp28987
g17436
I58
sg17437
g28975
sg17438
I13
sg17445
VC0007621
p28988
sg17441
I1
sasa(dp28989
g135
(dp28990
(VNAA10
p28991
Vcolon cancer
p28992
tp28993
I00
ssg17431
VOur results implicate miR-342-5p and miR-608 in colon cancer development and unveil the underlying mechanism of this phenomenon, which involves NAA10.
p28994
sg17433
(lp28995
(dp28996
g17436
I22
sg17437
VmiR-342-5p
p28997
sg17438
I10
sg17439
g12
sg17441
I1
sa(dp28998
g17436
I144
sg17437
g28991
sg17438
I5
sg17439
VP41227
p28999
sg17441
I1
sa(dp29000
g17436
I37
sg17437
VmiR-608
p29001
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp29002
(dp29003
g17436
I48
sg17437
g28992
sg17438
I12
sg17445
VC0699790
p29004
sg17441
I2
sasa(dp29005
g135
(dp29006
(VHER2
p29007
Vbreast tumors
p29008
tp29009
I00
ssg17431
VWe demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases).
p29010
sg17433
(lp29011
(dp29012
g17436
I127
sg17437
VHER2
p29013
sg17438
I4
sg17439
VP04626
p29014
sg17441
I1
sa(dp29015
g17436
I83
sg17437
VmiR-744*
p29016
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp29017
g17436
I127
sg17437
g29007
sg17438
I4
sg17439
VP04626
p29018
sg17441
I1
sa(dp29019
g17436
I68
sg17437
VmiR-342-5p
p29020
sg17438
I10
sg17439
g12
sg17441
I1
sasg17442
(lp29021
(dp29022
g17436
I211
sg17437
Vbreast cancer
p29023
sg17438
I13
sg17445
VC0678222
p29024
sg17441
I2
sa(dp29025
g17436
I141
sg17437
g29008
sg17438
I13
sg17445
VC1458155
p29026
sg17441
I2
sa(dp29027
g17436
I148
sg17437
Vtumors
p29028
sg17438
I6
sg17445
VC0027651
p29029
sg17441
I1
sasa(dp29030
g17431
VFurthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts.
p29031
sg17433
(lp29032
(dp29033
g17436
I34
sg17437
VmiR-342-5p
p29034
sg17438
I10
sg17439
g12
sg17441
I1
sasg17442
(lp29035
(dp29036
g17436
I89
sg17437
Vbreast cancer
p29037
sg17438
I13
sg17445
VC0678222
p29038
sg17441
I2
sasa(dp29039
g135
(dp29040
(VGDF-5
p29041
Verectile dysfunction
p29042
tp29043
I00
ssg17431
VCompromised CN function is a significant cause of erectile dysfunction development following prostatectomy and serves as the primary target for potential neuroprotective or regenerative strategies utilizing NGFs such as BDNF, GDF-5, and NTN, and/or targeted novel therapeutics modulating signaling pathways.
p29044
sg17433
(lp29045
(dp29046
g17436
I226
sg17437
g29041
sg17438
I5
sg17439
VP43026
p29047
sg17441
I1
sasg17442
(lp29048
(dp29049
g17436
I50
sg17437
g29042
sg17438
I20
sg17445
VC0242350
p29050
sg17441
I2
sasa(dp29051
g17431
VThe manifestation of LHON was associated with increased mortality and increased incidence of several disorders including stroke, demyelinating disorder, dementia, and epilepsy.
p29052
sg17433
(lp29053
sg17442
(lp29054
(dp29055
g17436
I121
sg17437
Vstroke
p29056
sg17438
I6
sg17445
VC0038454
p29057
sg17441
I1
sa(dp29058
g17436
I153
sg17437
Vdementia
p29059
sg17438
I8
sg17445
VC0497327
p29060
sg17441
I1
sa(dp29061
g17436
I21
sg17437
VLHON
p29062
sg17438
I4
sg17445
VC0917796
p29063
sg17441
I1
sa(dp29064
g17436
I129
sg17437
Vdemyelinating disorder
p29065
sg17438
I22
sg17445
VC0011303
p29066
sg17441
I2
sa(dp29067
g17436
I167
sg17437
Vepilepsy
p29068
sg17438
I8
sg17445
VC0014544
p29069
sg17441
I1
sasa(dp29070
g17431
VLeber's Hereditary Optic Neuropathy (LHON) shares features with Multiple Sclerosis (MS).
p29071
sg17433
(lp29072
sg17442
(lp29073
(dp29074
g17436
I0
sg17437
VLeber's Hereditary Optic Neuropathy
p29075
sg17438
I35
sg17445
VC0917796
p29076
sg17441
I4
sa(dp29077
g17436
I37
sg17437
VLHON
p29078
sg17438
I4
sg17445
VC0917796
p29079
sg17441
I1
sa(dp29080
g17436
I64
sg17437
VMultiple Sclerosis
p29081
sg17438
I18
sg17445
VC0026769
p29082
sg17441
I2
sa(dp29083
g17436
I84
sg17437
VMS
p29084
sg17438
I2
sg17445
VC0026769
p29085
sg17441
I1
sasa(dp29086
g17431
VLeber's hereditary optic neuropathy (LHON) is a mitochondrial DNA (mtDNA) associated neurodegenerative disorder of retinal ganglion cells.
p29087
sg17433
(lp29088
sg17442
(lp29089
(dp29090
g17436
I0
sg17437
VLeber's hereditary optic neuropathy
p29091
sg17438
I35
sg17445
VC0917796
p29092
sg17441
I4
sa(dp29093
g17436
I37
sg17437
VLHON
p29094
sg17438
I4
sg17445
VC0917796
p29095
sg17441
I1
sa(dp29096
g17436
I85
sg17437
Vneurodegenerative disorder
p29097
sg17438
I26
sg17445
VC0524851
p29098
sg17441
I2
sa(dp29099
g17436
I123
sg17437
Vganglion
p29100
sg17438
I8
sg17445
VC1258666
p29101
sg17441
I1
sasa(dp29102
g135
(dp29103
(VMT-ND4
p29104
VMELAS
p29105
tp29106
I00
ssg17431
VMT-ND4: mitochondrially encoded NADH dehydrogenase 4; MT-TL1: mitochondrially encoded tRNA leucine 1 (UUA/G); PCR: polymerase chain reaction; OXPHOS: mitochondrial oxidative phosphorylation; ATP: adenosine triphosphate; mtDNA: mitochondrial DNA; SNPs: single nucleotide substitutions; AD: alzheimer's disease; PD: parkinson's disease; MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; ROS: reactive oxygen species.
p29107
sg17433
(lp29108
(dp29109
g17436
I54
sg17437
VMT-TL1
p29110
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp29111
g17436
I62
sg17437
Vmitochondrially encoded tRNA leucine 1
p29112
sg17438
I38
sg17439
VP30740
p29113
sg17441
I5
sa(dp29114
g17436
I8
sg17437
Vmitochondrially encoded NADH dehydrogenase 4
p29115
sg17438
I44
sg17439
VP49366
p29116
sg17441
I5
sa(dp29117
g17436
I0
sg17437
g29104
sg17438
I6
sg17439
VP03905
p29118
sg17441
I1
sasg17442
(lp29119
(dp29120
g17436
I314
sg17437
Vparkinson's disease
p29121
sg17438
I19
sg17445
VC0030567
p29122
sg17441
I2
sa(dp29123
g17436
I342
sg17437
Vmitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
p29124
sg17438
I77
sg17445
VC1964017
p29125
sg17441
I8
sa(dp29126
g17436
I335
sg17437
g29105
sg17438
I5
sg17445
VC0162671
p29127
sg17441
I1
sa(dp29128
g17436
I289
sg17437
Valzheimer's disease
p29129
sg17438
I19
sg17445
VC1521724
p29130
sg17441
I2
sasa(dp29131
g17431
VLeber's hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding's disease.
p29132
sg17433
(lp29133
sg17442
(lp29134
(dp29135
g17436
I0
sg17437
VLeber's hereditary optic neuropathy
p29136
sg17438
I35
sg17445
VC0917796
p29137
sg17441
I4
sa(dp29138
g17436
I37
sg17437
VLHON
p29139
sg17438
I4
sg17445
VC0917796
p29140
sg17441
I1
sa(dp29141
g17436
I37
sg17437
VLHON
p29142
sg17438
I4
sg17445
VC0917796
p29143
sg17441
I1
sa(dp29144
g17436
I60
sg17437
Vmultiple sclerosis
p29145
sg17438
I18
sg17445
VC0026769
p29146
sg17441
I2
sasa(dp29147
g135
(dp29148
(VMERRF
p29149
VMERRF
p29150
tp29151
I01
ssg17431
VThe role of oxidative stress in the five most common inherited mitochondrial diseases, Friedreich ataxia, LHON, MELAS, MERRF, and Leigh syndrome (LS), is discussed.
p29152
sg17433
(lp29153
(dp29154
g17436
I112
sg17437
VMELAS
p29155
sg17438
I5
sg17439
VP03886
p29156
sg17441
I1
sa(dp29157
g17436
I119
sg17437
g29149
sg17438
I5
sg17439
VP03915
p29158
sg17441
I1
sasg17442
(lp29159
(dp29160
g17436
I63
sg17437
Vmitochondrial diseases
p29161
sg17438
I22
sg17445
VC0751651
p29162
sg17441
I2
sa(dp29163
g17436
I112
sg17437
VMELAS
p29164
sg17438
I5
sg17445
VC0162671
p29165
sg17441
I1
sa(dp29166
g17436
I130
sg17437
VLeigh syndrome
p29167
sg17438
I14
sg17445
VC0023264
p29168
sg17441
I2
sa(dp29169
g17436
I12
sg17437
Voxidative stress
p29170
sg17438
I16
sg17445
VC0242606
p29171
sg17441
I2
sa(dp29172
g17436
I146
sg17437
VLS
p29173
sg17438
I2
sg17445
VC0023264
p29174
sg17441
I1
sa(dp29175
g17436
I87
sg17437
VFriedreich ataxia
p29176
sg17438
I17
sg17445
VC0016719
p29177
sg17441
I2
sa(dp29178
g17436
I106
sg17437
VLHON
p29179
sg17438
I4
sg17445
VC0917796
p29180
sg17441
I1
sa(dp29181
g17436
I119
sg17437
g29150
sg17438
I5
sg17445
VC0162672
p29182
sg17441
I1
sasa(dp29183
g17431
VOf the five most common mitochondrial diseases, the strongest support for oxidative stress is for Friedreich ataxia (6.42%), followed by LHON (2.45%), MELAS (2.18%), MERRF (1.71%), and LS (1.03%).
p29184
sg17433
(lp29185
sg17442
(lp29186
(dp29187
g17436
I137
sg17437
VLHON
p29188
sg17438
I4
sg17445
VC0917796
p29189
sg17441
I1
sa(dp29190
g17436
I166
sg17437
VMERRF
p29191
sg17438
I5
sg17445
VC0162672
p29192
sg17441
I1
sa(dp29193
g17436
I24
sg17437
Vmitochondrial diseases
p29194
sg17438
I22
sg17445
VC0751651
p29195
sg17441
I2
sa(dp29196
g17436
I151
sg17437
VMELAS
p29197
sg17438
I5
sg17445
VC0162671
p29198
sg17441
I1
sa(dp29199
g17436
I98
sg17437
VFriedreich ataxia
p29200
sg17438
I17
sg17445
VC0016719
p29201
sg17441
I2
sa(dp29202
g17436
I74
sg17437
Voxidative stress
p29203
sg17438
I16
sg17445
VC0242606
p29204
sg17441
I2
sasa(dp29205
g17431
VLeber's hereditary optic neuropathy (LHON) and a multiple sclerosis (MS)-like illness appear to coexist 50 times more frequently than would be expected by chance.
p29206
sg17433
(lp29207
sg17442
(lp29208
(dp29209
g17436
I0
sg17437
VLeber's hereditary optic neuropathy
p29210
sg17438
I35
sg17445
VC0917796
p29211
sg17441
I4
sa(dp29212
g17436
I37
sg17437
VLHON
p29213
sg17438
I4
sg17445
VC0917796
p29214
sg17441
I1
sa(dp29215
g17436
I69
sg17437
VMS
p29216
sg17438
I2
sg17445
VC0026769
p29217
sg17441
I1
sa(dp29218
g17436
I49
sg17437
Vmultiple sclerosis
p29219
sg17438
I18
sg17445
VC0026769
p29220
sg17441
I2
sasa(dp29221
g135
(dp29222
(VRP1
p29223
VRP1
p29224
tp29225
I00
ssg17431
VMutations in the retinitis pigmentosa 1 (RP1) gene are a common cause of retinitis pigmentosa (RP).
p29226
sg17433
(lp29227
(dp29228
g17436
I17
sg17437
Vretinitis pigmentosa 1
p29229
sg17438
I22
sg17439
VP56715
p29230
sg17441
I3
sa(dp29231
g17436
I41
sg17437
g29223
sg17438
I3
sg17439
VP56715
p29232
sg17441
I1
sasg17442
(lp29233
(dp29234
g17436
I17
sg17437
Vretinitis pigmentosa 1
p29235
sg17438
I22
sg17445
VC0220701
p29236
sg17441
I3
sa(dp29237
g17436
I41
sg17437
VRP
p29238
sg17438
I2
sg17445
VC0035334
p29239
sg17441
I1
sa(dp29240
g17436
I17
sg17437
Vretinitis pigmentosa
p29241
sg17438
I20
sg17445
VC0035334
p29242
sg17441
I2
sa(dp29243
g17436
I41
sg17437
g29224
sg17438
I3
sg17445
VC0220701
p29244
sg17441
I1
sasa(dp29245
g135
(dp29246
(VRP1
p29247
Vretinal degeneration
p29248
tp29249
I00
ssg17431
VFurthermore, these findings indicate that the RP1 form of inherited retinal degeneration is part of the larger class of neurodegenerative diseases caused by MAP dysfunction.
p29250
sg17433
(lp29251
(dp29252
g17436
I46
sg17437
g29247
sg17438
I3
sg17439
VP56715
p29253
sg17441
I1
sasg17442
(lp29254
(dp29255
g17436
I46
sg17437
VRP1
p29256
sg17438
I3
sg17445
VC0220701
p29257
sg17441
I1
sa(dp29258
g17436
I120
sg17437
Vneurodegenerative diseases
p29259
sg17438
I26
sg17445
VC0524851
p29260
sg17441
I2
sa(dp29261
g17436
I68
sg17437
g29248
sg17438
I20
sg17445
VC0035304
p29262
sg17441
I2
sasa(dp29263
g17431
VOur objective was to determine the ethical options of Paediatric Intensive Care Unit (PICU) paediatricians as regards a child with SMA-1 and respiratory failure.
p29264
sg17433
(lp29265
(dp29266
g17436
I131
sg17437
VSMA-1
p29267
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29268
(dp29269
g17436
I141
sg17437
Vrespiratory failure
p29270
sg17438
I19
sg17445
VC1145670
p29271
sg17441
I2
sa(dp29272
g17436
I131
sg17437
VSMA
p29273
sg17438
I3
sg17445
VC0026847
p29274
sg17441
I1
sasa(dp29275
g17431
VFaced with child with SMA-1 and respiratory failure, most paediatricians are in favour of initiating NIV and LET when such support is insufficient, but they would accept the family's decision, even in case of disagreement.
p29276
sg17433
(lp29277
(dp29278
g17436
I22
sg17437
VSMA-1
p29279
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29280
(dp29281
g17436
I22
sg17437
VSMA
p29282
sg17438
I3
sg17445
VC0026847
p29283
sg17441
I1
sa(dp29284
g17436
I32
sg17437
Vrespiratory failure
p29285
sg17438
I19
sg17445
VC1145670
p29286
sg17441
I2
sasa(dp29287
g17431
VA scenario of acute respiratory failure in an infant with SMA-1 has been included in a training program using advanced simulation for Primary Care pediatricians (PCP).
p29288
sg17433
(lp29289
(dp29290
g17436
I58
sg17437
VSMA-1
p29291
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29292
(dp29293
g17436
I58
sg17437
VSMA
p29294
sg17438
I3
sg17445
VC0026847
p29295
sg17441
I1
sa(dp29296
g17436
I134
sg17437
VPrimary Care pediatricians
p29297
sg17438
I26
sg17445
VC2919094
p29298
sg17441
I3
sa(dp29299
g17436
I162
sg17437
VPCP
p29300
sg17438
I3
sg17445
VC2919094
p29301
sg17441
I1
sa(dp29302
g17436
I14
sg17437
Vacute respiratory failure
p29303
sg17438
I25
sg17445
VC0264490
p29304
sg17441
I3
sasa(dp29305
g17431
VWhen faced with a simulated SMA-1 infant with respiratory failure, PCP have difficulties in interacting with the family, and to involve it in the decision making process.
p29306
sg17433
(lp29307
sg17442
(lp29308
(dp29309
g17436
I67
sg17437
VPCP
p29310
sg17438
I3
sg17445
VC2919094
p29311
sg17441
I1
sa(dp29312
g17436
I46
sg17437
Vrespiratory failure
p29313
sg17438
I19
sg17445
VC1145670
p29314
sg17441
I2
sa(dp29315
g17436
I28
sg17437
VSMA
p29316
sg17438
I3
sg17445
VC0026847
p29317
sg17441
I1
sasa(dp29318
g17431
VTREX1 acts in concert with the SET complex in granzyme A-mediated apoptosis, and mutations in TREX1 cause Aicardi-Goutieres syndrome and familial chilblain lupus.
p29319
sg17433
(lp29320
(dp29321
g17436
I0
sg17437
VTREX1
p29322
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp29323
g17436
I0
sg17437
VTREX1
p29324
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29325
(dp29326
g17436
I146
sg17437
Vchilblain lupus
p29327
sg17438
I15
sg17445
VC0024145
p29328
sg17441
I2
sa(dp29329
g17436
I106
sg17437
VAicardi-Goutieres syndrome
p29330
sg17438
I26
sg17445
VC0796126
p29331
sg17441
I2
sasa(dp29332
g17431
VLymphoblastoid cells carrying the D18N mutation are significantly less sensitive to granzyme A-mediated cell death, suggesting a novel role for this caspase-independent form of apoptosis in the pathogenesis of familial chilblain lupus.
p29333
sg17433
(lp29334
(dp29335
g17436
I149
sg17437
Vcaspase
p29336
sg17438
I7
sg17439
VP39880
p29337
sg17441
I1
sasg17442
(lp29338
(dp29339
g17436
I194
sg17437
Vpathogenesis
p29340
sg17438
I12
sg17445
VC0699748
p29341
sg17441
I1
sa(dp29342
g17436
I219
sg17437
Vchilblain lupus
p29343
sg17438
I15
sg17445
VC0024145
p29344
sg17441
I2
sasa(dp29345
g135
(dp29346
(VPLS3
p29347
VSMA
p29348
tp29349
I00
ssg17431
VA recent article explored protective modifiers, including plastin 3 (PLS3) and coronin 1C (CORO1C), in spinal muscular atrophy (SMA).
p29350
sg17433
(lp29351
(dp29352
g17436
I58
sg17437
Vplastin 3
p29353
sg17438
I9
sg17439
VP13797
p29354
sg17441
I2
sa(dp29355
g17436
I69
sg17437
g29347
sg17438
I4
sg17439
VP13797
p29356
sg17441
I1
sa(dp29357
g17436
I79
sg17437
Vcoronin 1C
p29358
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp29359
g17436
I91
sg17437
VCORO1C
p29360
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp29361
(dp29362
g17436
I103
sg17437
Vspinal muscular atrophy
p29363
sg17438
I23
sg17445
VC0026847
p29364
sg17441
I3
sa(dp29365
g17436
I128
sg17437
g29348
sg17438
I3
sg17445
VC0026847
p29366
sg17441
I1
sasa(dp29367
g17431
VHowever, the expression of CYP26C1, another CYP26 family member, in primary breast carcinoma remains to be clarified.
p29368
sg17433
(lp29369
(dp29370
g17436
I44
sg17437
VCYP26 family member
p29371
sg17438
I19
sg17439
g12
sg17441
I3
sa(dp29372
g17436
I27
sg17437
VCYP26C1
p29373
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp29374
(dp29375
g17436
I76
sg17437
Vbreast carcinoma
p29376
sg17438
I16
sg17445
VC0678222
p29377
sg17441
I2
sasa(dp29378
g17431
VIn the present study, we examined the expression of CYP26C1 by immunohistochemistry, using three different types of microarray, and observed strong cytoplasmic staining of CYP26C1 in 73 of the 219 (33.3 %) breast carcinomas.
p29379
sg17433
(lp29380
(dp29381
g17436
I52
sg17437
VCYP26C1
p29382
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp29383
g17436
I52
sg17437
VCYP26C1
p29384
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp29385
(dp29386
g17436
I206
sg17437
Vbreast carcinomas
p29387
sg17438
I17
sg17445
VC0678222
p29388
sg17441
I2
sasa(dp29389
g17431
VIn addition, CYP26C1 positivity was independent of the expression status of the hormone receptors and immunohistochemical surrogates for the intrinsic subtypes of breast cancer.
p29390
sg17433
(lp29391
(dp29392
g17436
I13
sg17437
VCYP26C1
p29393
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp29394
(dp29395
g17436
I163
sg17437
Vbreast cancer
p29396
sg17438
I13
sg17445
VC0678222
p29397
sg17441
I2
sasa(dp29398
g17431
VThis report is the first to demonstrate elevated expression of CYP26C1 in primary breast carcinomas.
p29399
sg17433
(lp29400
(dp29401
g17436
I63
sg17437
VCYP26C1
p29402
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp29403
(dp29404
g17436
I82
sg17437
Vbreast carcinomas
p29405
sg17438
I17
sg17445
VC0678222
p29406
sg17441
I2
sasa(dp29407
g135
(dp29408
(VALDH1A1
p29409
Vschizophrenia
p29410
tp29411
I00
ssg17431
VIn the present study we chose to investigate 7 genes involved in the synthesis, degradation and transportation of RA, ALDH1A1, ALDH1A2, ALDH1A3, CYP26A1, CYP26B1, CYP26C1 and Transthyretin (TTR), for their roles in the development of schizophrenia.
p29412
sg17433
(lp29413
(dp29414
g17436
I136
sg17437
VALDH1A3
p29415
sg17438
I7
sg17439
VP47895
p29416
sg17441
I1
sa(dp29417
g17436
I190
sg17437
VTTR
p29418
sg17438
I3
sg17439
VP02766
p29419
sg17441
I1
sa(dp29420
g17436
I175
sg17437
VTransthyretin
p29421
sg17438
I13
sg17439
VP02766
p29422
sg17441
I1
sa(dp29423
g17436
I163
sg17437
VCYP26C1
p29424
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp29425
g17436
I154
sg17437
VCYP26B1
p29426
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp29427
g17436
I145
sg17437
VCYP26A1
p29428
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp29429
g17436
I127
sg17437
VALDH1A2
p29430
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp29431
g17436
I118
sg17437
g29409
sg17438
I7
sg17439
VP00352
p29432
sg17441
I1
sasg17442
(lp29433
(dp29434
g17436
I234
sg17437
g29410
sg17438
I13
sg17445
VC0036341
p29435
sg17441
I1
sasa(dp29436
g17431
VThe index of low SIRT1 and high MMP2 respectively correlated with patients history of MI (p=0.3, p=0.01) and marginally with presence or history of atrial fibrillation (AF) (p=0.213, p=0.076).
p29437
sg17433
(lp29438
(dp29439
g17436
I17
sg17437
VSIRT1
p29440
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29441
(dp29442
g17436
I148
sg17437
Vatrial fibrillation
p29443
sg17438
I19
sg17445
VC0004238
p29444
sg17441
I2
sa(dp29445
g17436
I169
sg17437
VAF
p29446
sg17438
I2
sg17445
VC0004238
p29447
sg17441
I1
sasa(dp29448
g135
(dp29449
(VBcl-2
p29450
VAF
p29451
tp29452
I00
ssg17431
VBACKGROUND To examine changes of mRNA and protein expressions of MMP-2, Bcl-2, and BAX in atrial fibrillation (AF) patients, and investigate the correlations among these 3 biomarkers.
p29453
sg17433
(lp29454
(dp29455
g17436
I65
sg17437
VMMP-2
p29456
sg17438
I5
sg17439
VP08253
p29457
sg17441
I1
sa(dp29458
g17436
I72
sg17437
g29450
sg17438
I5
sg17439
VP10415
p29459
sg17441
I1
sasg17442
(lp29460
(dp29461
g17436
I90
sg17437
Vatrial fibrillation
p29462
sg17438
I19
sg17445
VC0004238
p29463
sg17441
I2
sa(dp29464
g17436
I111
sg17437
g29451
sg17438
I2
sg17445
VC0004238
p29465
sg17441
I1
sasa(dp29466
g17431
VIn conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.
p29467
sg17433
(lp29468
(dp29469
g17436
I29
sg17437
VKcnj16
p29470
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp29471
(dp29472
g17436
I147
sg17437
VEAST syndrome
p29473
sg17438
I13
sg17445
VC2748572
p29474
sg17441
I2
sasa(dp29475
g135
(dp29476
(VKCNJ10 mutations
p29477
VEAST syndrome
p29478
tp29479
I00
ssg17431
VWe investigated the localization of KCNJ10 and the homologous KCNJ16 in kidney and the functional consequences of KCNJ10 mutations found in our patients with EAST syndrome.
p29480
sg17433
(lp29481
(dp29482
g17436
I62
sg17437
VKCNJ16
p29483
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp29484
g17436
I36
sg17437
VKCNJ10
p29485
sg17438
I6
sg17439
VP78508
p29486
sg17441
I1
sa(dp29487
g17436
I114
sg17437
g29477
sg17438
I16
sg17439
VP78508
p29488
sg17441
I2
sasg17442
(lp29489
(dp29490
g17436
I158
sg17437
g29478
sg17438
I13
sg17445
VC2748572
p29491
sg17441
I2
sasa(dp29492
g17431
VToxin C13S1C1 was also cytotoxic against breast adenocarcinoma MDA-MB-231 cells (LC50 = 62+/-2myg/ml) and colorectal adenocarcinoma HT-29 cells (LC50 = 110+/-4myg/ml).
p29493
sg17433
(lp29494
(dp29495
g17436
I0
sg17437
VToxin
p29496
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29497
(dp29498
g17436
I106
sg17437
Vcolorectal adenocarcinoma
p29499
sg17438
I25
sg17445
VC1319315
p29500
sg17441
I2
sa(dp29501
g17436
I41
sg17437
Vbreast adenocarcinoma
p29502
sg17438
I21
sg17445
VC0858252
p29503
sg17441
I2
sasa(dp29504
g17431
VWe report an unusual case of invasive papillary carcinoma of the breast with high nuclear grade, brisk mitosis, necrosis, extensive apocrine differentiation, and intense lymphoplasmacytic infiltrate; additionally triple-negativity for estrogen and progesterone receptors and Her2 neu.
p29505
sg17433
(lp29506
(dp29507
g17436
I248
sg17437
Vprogesterone receptors
p29508
sg17438
I22
sg17439
VP06401
p29509
sg17441
I2
sa(dp29510
g17436
I280
sg17437
Vneu
p29511
sg17438
I3
sg17439
VP04626
p29512
sg17441
I1
sa(dp29513
g17436
I275
sg17437
VHer2
p29514
sg17438
I4
sg17439
VP04626
p29515
sg17441
I1
sasg17442
(lp29516
(dp29517
g17436
I38
sg17437
Vpapillary carcinoma of the breast
p29518
sg17438
I33
sg17445
VC1335320
p29519
sg17441
I5
sa(dp29520
g17436
I188
sg17437
Vinfiltrate
p29521
sg17438
I10
sg17445
VC0332448
p29522
sg17441
I1
sasa(dp29523
g17431
VMoreover, Sec24bY613 genetically interacts with a loss-of-function Vangl2 allele (Vangl2LP), causing a marked increase in the prevalence of spina bifida.
p29524
sg17433
(lp29525
(dp29526
g17436
I67
sg17437
VVangl2 allele
p29527
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp29528
(dp29529
g17436
I140
sg17437
Vspina bifida
p29530
sg17438
I12
sg17445
VC0080178
p29531
sg17441
I2
sasa(dp29532
g17431
VThe overall goal of TASK2 of the AES/ILAE Translational Task Force is to organize and coordinate systematic reviews on selected topics regarding animal research in epilepsy.
p29533
sg17433
(lp29534
(dp29535
g17436
I20
sg17437
VTASK2
p29536
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29537
(dp29538
g17436
I164
sg17437
Vepilepsy
p29539
sg17438
I8
sg17445
VC0014544
p29540
sg17441
I1
sasa(dp29541
g17431
VK2P 5.1 channels (also called TASK-2 or Kcnk5) have already been shown to be relevant in the pathophysiology of autoimmune disease because they are known to be upregulated on peripheral and central T lymphocytes of multiple sclerosis (MS) patients.
p29542
sg17433
(lp29543
(dp29544
g17436
I0
sg17437
VK2P 5.1 channels
p29545
sg17438
I16
sg17439
g12
sg17441
I3
sa(dp29546
g17436
I40
sg17437
VKcnk5
p29547
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp29548
g17436
I30
sg17437
VTASK-2
p29549
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp29550
(dp29551
g17436
I235
sg17437
VMS
p29552
sg17438
I2
sg17445
VC0026769
p29553
sg17441
I1
sa(dp29554
g17436
I112
sg17437
Vautoimmune disease
p29555
sg17438
I18
sg17445
VC0004364
p29556
sg17441
I2
sa(dp29557
g17436
I215
sg17437
Vmultiple sclerosis
p29558
sg17438
I18
sg17445
VC0026769
p29559
sg17441
I2
sasa(dp29560
g17431
VRecent studies have indicated the impact of K2P5.1 upregulation in T lymphocytes on the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
p29561
sg17433
(lp29562
(dp29563
g17436
I44
sg17437
VK2P5.1
p29564
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp29565
(dp29566
g17436
I157
sg17437
Vmultiple sclerosis
p29567
sg17438
I18
sg17445
VC0026769
p29568
sg17441
I2
sa(dp29569
g17436
I132
sg17437
Vrheumatoid arthritis
p29570
sg17438
I20
sg17445
VC0003873
p29571
sg17441
I2
sa(dp29572
g17436
I88
sg17437
Vpathogenesis
p29573
sg17438
I12
sg17445
VC0699748
p29574
sg17441
I1
sa(dp29575
g17436
I104
sg17437
Vautoimmune diseases
p29576
sg17438
I19
sg17445
VC0004364
p29577
sg17441
I2
sasa(dp29578
g17431
VSo far KCNK5 has been described to be up-regulated in T cells in multiple sclerosis patients and to be implicated in the volume regulatory mechanism regulatory volume decrease (RVD) in T cells.
p29579
sg17433
(lp29580
(dp29581
g17436
I7
sg17437
VKCNK5
p29582
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29583
(dp29584
g17436
I65
sg17437
Vmultiple sclerosis
p29585
sg17438
I18
sg17445
VC0026769
p29586
sg17441
I2
sasa(dp29587
g17431
VRecent studies highlighted the potential role of the K2P5.1 K(+) channel in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.
p29588
sg17433
(lp29589
(dp29590
g17436
I53
sg17437
VK2P5.1 K
p29591
sg17438
I8
sg17439
g12
sg17441
I2
sasg17442
(lp29592
(dp29593
g17436
I96
sg17437
Vautoimmune diseases
p29594
sg17438
I19
sg17445
VC0004364
p29595
sg17441
I2
sa(dp29596
g17436
I149
sg17437
Vmultiple sclerosis
p29597
sg17438
I18
sg17445
VC0026769
p29598
sg17441
I2
sa(dp29599
g17436
I80
sg17437
Vpathogenesis
p29600
sg17438
I12
sg17445
VC0699748
p29601
sg17441
I1
sa(dp29602
g17436
I124
sg17437
Vrheumatoid arthritis
p29603
sg17438
I20
sg17445
VC0003873
p29604
sg17441
I2
sasa(dp29605
g17431
VExpression levels of K2P5.1 (TASK2; KCNK5) channels belonging to the family of two-pore domain potassium channels have previously been correlated to the activity of autoreactive T lymphocytes in patients with multiple sclerosis and rheumatoid arthritis.
p29606
sg17433
(lp29607
(dp29608
g17436
I21
sg17437
VK2P5.1
p29609
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp29610
g17436
I29
sg17437
VTASK2
p29611
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp29612
g17436
I36
sg17437
VKCNK5
p29613
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29614
(dp29615
g17436
I209
sg17437
Vmultiple sclerosis
p29616
sg17438
I18
sg17445
VC0026769
p29617
sg17441
I2
sa(dp29618
g17436
I232
sg17437
Vrheumatoid arthritis
p29619
sg17438
I20
sg17445
VC0003873
p29620
sg17441
I2
sasa(dp29621
g135
(dp29622
(VSDHA
p29623
Vcolon adenocarcinoma
p29624
tp29625
I00
ssg17431
VThus, we evaluated the effect of serum availability on the expression of commonly used HKG (ACTB, B2M, GAPDH, GUSB, HPRT1, IPO8, MRPL19, PGK1, PPIA, RPLP0, RPS23, SDHA, TBP, UBC, and YWHAZ) in seven colon adenocarcinoma cell lines (Caco-2, DLD-1, HCT116, HT29, Lovo, SW480, and SW620).
p29626
sg17433
(lp29627
(dp29628
g17436
I110
sg17437
VGUSB
p29629
sg17438
I4
sg17439
VP08236
p29630
sg17441
I1
sa(dp29631
g17436
I98
sg17437
VB2M
p29632
sg17438
I3
sg17439
VP61769
p29633
sg17441
I1
sa(dp29634
g17436
I123
sg17437
VIPO8
p29635
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp29636
g17436
I169
sg17437
VTBP
p29637
sg17438
I3
sg17439
VP20226
p29638
sg17441
I1
sa(dp29639
g17436
I240
sg17437
VDLD-1
p29640
sg17438
I5
sg17439
VP98173
p29641
sg17441
I1
sa(dp29642
g17436
I137
sg17437
VPGK1
p29643
sg17438
I4
sg17439
VP00558
p29644
sg17441
I1
sa(dp29645
g17436
I103
sg17437
VGAPDH
p29646
sg17438
I5
sg17439
VP04406
p29647
sg17441
I1
sa(dp29648
g17436
I156
sg17437
VRPS23
p29649
sg17438
I5
sg17439
VP62266
p29650
sg17441
I1
sa(dp29651
g17436
I92
sg17437
VACTB
p29652
sg17438
I4
sg17439
VP63261
p29653
sg17441
I1
sa(dp29654
g17436
I149
sg17437
VRPLP0
p29655
sg17438
I5
sg17439
VP05388
p29656
sg17441
I1
sa(dp29657
g17436
I143
sg17437
VPPIA
p29658
sg17438
I4
sg17439
VP62937
p29659
sg17441
I1
sa(dp29660
g17436
I116
sg17437
VHPRT1
p29661
sg17438
I5
sg17439
VP55884
p29662
sg17441
I1
sa(dp29663
g17436
I129
sg17437
VMRPL19
p29664
sg17438
I6
sg17439
VP49406
p29665
sg17441
I1
sa(dp29666
g17436
I163
sg17437
g29623
sg17438
I4
sg17439
VP31040
p29667
sg17441
I1
sa(dp29668
g17436
I174
sg17437
VUBC
p29669
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp29670
(dp29671
g17436
I199
sg17437
g29624
sg17438
I20
sg17445
VC0338106
p29672
sg17441
I2
sasa(dp29673
g135
(dp29674
(VPGK1
p29675
Vmetastatic colon cancer
p29676
tp29677
I01
ssg17431
VWe investigated whether the expression of PGK1 varies between metastatic and non-metastatic colon cancer.
p29678
sg17433
(lp29679
(dp29680
g17436
I42
sg17437
g29675
sg17438
I4
sg17439
VP00558
p29681
sg17441
I1
sasg17442
(lp29682
(dp29683
g17436
I81
sg17437
g29676
sg17438
I23
sg17445
VC0278484
p29684
sg17441
I3
sasa(dp29685
g135
(dp29686
(VPGK1
p29687
Vmetastasis
p29688
tp29689
I00
ssg17431
VWe compared PGK1 expression in colon cancer patients either with or without metastasis via polymerase chain reaction (PCR) and immunohistochemistry.
p29690
sg17433
(lp29691
(dp29692
g17436
I12
sg17437
g29687
sg17438
I4
sg17439
VP00558
p29693
sg17441
I1
sasg17442
(lp29694
(dp29695
g17436
I31
sg17437
Vcolon cancer
p29696
sg17438
I12
sg17445
VC0699790
p29697
sg17441
I2
sa(dp29698
g17436
I76
sg17437
g29688
sg17438
I10
sg17445
VC0027627
p29699
sg17441
I1
sasa(dp29700
g135
(dp29701
(VPGK1
p29702
Vcolon cancer
p29703
tp29704
I00
ssg17431
VPCR results showed an increased expression of PGK1 in colon cancer tissue from metastatic patients in comparison to patients with no metastasis (fold change 2.6, p&lt;0.001).
p29705
sg17433
(lp29706
(dp29707
g17436
I46
sg17437
g29702
sg17438
I4
sg17439
VP00558
p29708
sg17441
I1
sasg17442
(lp29709
(dp29710
g17436
I133
sg17437
Vmetastasis
p29711
sg17438
I10
sg17445
VC0027627
p29712
sg17441
I1
sa(dp29713
g17436
I54
sg17437
g29703
sg17438
I12
sg17445
VC0699790
p29714
sg17441
I2
sasa(dp29715
g135
(dp29716
(VPGK1
p29717
Vmetastasis
p29718
tp29719
I00
ssg17431
VThe results indicate that increased expression of PGK1 in colon cancer tissue is associated with metastasis.
p29720
sg17433
(lp29721
(dp29722
g17436
I50
sg17437
g29717
sg17438
I4
sg17439
VP00558
p29723
sg17441
I1
sasg17442
(lp29724
(dp29725
g17436
I58
sg17437
Vcolon cancer
p29726
sg17438
I12
sg17445
VC0699790
p29727
sg17441
I2
sa(dp29728
g17436
I97
sg17437
g29718
sg17438
I10
sg17445
VC0027627
p29729
sg17441
I1
sasa(dp29730
g135
(dp29731
(VTYMS
p29732
Vcolon cancer
p29733
tp29734
I00
ssg17431
VTYMS and PGK1, as well as their epitope peptides, might be appropriate target molecules for specific immunotherapy of HLA-A2(+) colon cancer patients because of the positive role of TYMS and PGK1 in chemoresistance (5-fluorouracil) and angiogenesis of tumor cells, respectively.
p29735
sg17433
(lp29736
(dp29737
g17436
I9
sg17437
VPGK1
p29738
sg17438
I4
sg17439
VP00558
p29739
sg17441
I1
sa(dp29740
g17436
I9
sg17437
VPGK1
p29741
sg17438
I4
sg17439
VP00558
p29742
sg17441
I1
sa(dp29743
g17436
I0
sg17437
VTYMS
p29744
sg17438
I4
sg17439
VP04818
p29745
sg17441
I1
sa(dp29746
g17436
I118
sg17437
VHLA-A2(+)
p29747
sg17438
I9
sg17439
VP30486
p29748
sg17441
I1
sa(dp29749
g17436
I0
sg17437
g29732
sg17438
I4
sg17439
VP04818
p29750
sg17441
I1
sasg17442
(lp29751
(dp29752
g17436
I128
sg17437
g29733
sg17438
I12
sg17445
VC0699790
p29753
sg17441
I2
sa(dp29754
g17436
I252
sg17437
Vtumor
p29755
sg17438
I5
sg17445
VC0027651
p29756
sg17441
I1
sasa(dp29757
g135
(dp29758
(Vhypoxanthine-guanine phosphoribosyltransferase
p29759
Vrrs
p29760
tp29761
I00
ssg17431
VIn one sample we sequenced 7231 contiguous base pairs that covered completely the region from the 5'end of the 16S rRNA gene to the 5'end of the 23S rRNA gene comprising the whole 16S rRNA (rrs), and the following genes: Ala tRNA (alaT), Ile tRNA (ileT), adenylosuccinate lyase (purB), adenylosuccinate synthetase (purA), methylpurine-DNA glycosylase (mag), hypoxanthine-guanine phosphoribosyltransferase (hpt), an hydrolase (HAD superfamily) and a 135 bp 5' fragment of the 23S rRNA (rrlA) genes.
p29762
sg17433
(lp29763
(dp29764
g17436
I315
sg17437
VpurA
p29765
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp29766
g17436
I352
sg17437
Vmag
p29767
sg17438
I3
sg17439
VP20916
p29768
sg17441
I1
sa(dp29769
g17436
I279
sg17437
VpurB
p29770
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp29771
g17436
I322
sg17437
Vmethylpurine-DNA glycosylase
p29772
sg17438
I28
sg17439
g12
sg17441
I2
sa(dp29773
g17436
I255
sg17437
Vadenylosuccinate lyase
p29774
sg17438
I22
sg17439
VP30566
p29775
sg17441
I2
sa(dp29776
g17436
I406
sg17437
Vhpt
p29777
sg17438
I3
sg17439
VP00738
p29778
sg17441
I1
sa(dp29779
g17436
I221
sg17437
VAla tRNA (alaT), Ile tRNA
p29780
sg17438
I25
sg17439
VP00709
p29781
sg17441
I5
sa(dp29782
g17436
I190
sg17437
Vrrs
p29783
sg17438
I3
sg17439
VP49788
p29784
sg17441
I1
sa(dp29785
g17436
I475
sg17437
V23S rRNA (rrlA) genes
p29786
sg17438
I21
sg17439
VP01893
p29787
sg17441
I4
sa(dp29788
g17436
I286
sg17437
Vadenylosuccinate synthetase
p29789
sg17438
I27
sg17439
VP30520
p29790
sg17441
I2
sa(dp29791
g17436
I358
sg17437
g29759
sg17438
I46
sg17439
VP00492
p29792
sg17441
I2
sasg17442
(lp29793
(dp29794
g17436
I190
sg17437
g29760
sg17438
I3
sg17445
VC1849334
p29795
sg17441
I1
sasa(dp29796
g17431
VAdditionally, NOLC1 expression was decreased in human hepatocellular carcinoma (HCC) tissue, and the ectopic expression of NOLC1 repressed the proliferation of HCC cells and tumor growth in a HCC xenograft model.
p29797
sg17433
(lp29798
(dp29799
g17436
I14
sg17437
VNOLC1
p29800
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp29801
g17436
I14
sg17437
VNOLC1
p29802
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29803
(dp29804
g17436
I174
sg17437
Vtumor growth
p29805
sg17438
I12
sg17445
VC0598934
p29806
sg17441
I2
sa(dp29807
g17436
I80
sg17437
VHCC
p29808
sg17438
I3
sg17445
VC2239176
p29809
sg17441
I1
sa(dp29810
g17436
I143
sg17437
Vproliferation
p29811
sg17438
I13
sg17445
VC0334094
p29812
sg17441
I1
sa(dp29813
g17436
I80
sg17437
VHCC
p29814
sg17438
I3
sg17445
VC2239176
p29815
sg17441
I1
sa(dp29816
g17436
I80
sg17437
VHCC
p29817
sg17438
I3
sg17445
VC2239176
p29818
sg17441
I1
sa(dp29819
g17436
I54
sg17437
Vhepatocellular carcinoma
p29820
sg17438
I24
sg17445
VC2239176
p29821
sg17441
I2
sasa(dp29822
g17431
VCUL3(KBTBD8) monoubiquitylates NOLC1 and its paralogue TCOF1, the mutation of which underlies the neurocristopathy Treacher Collins syndrome.
p29823
sg17433
(lp29824
(dp29825
g17436
I5
sg17437
VKBTBD8
p29826
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp29827
g17436
I0
sg17437
VCUL3
p29828
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp29829
g17436
I55
sg17437
VTCOF1
p29830
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp29831
g17436
I31
sg17437
VNOLC1
p29832
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29833
(dp29834
g17436
I115
sg17437
VTreacher Collins syndrome
p29835
sg17438
I25
sg17445
VC0242387
p29836
sg17441
I3
sasa(dp29837
g17431
VTreacher Collins syndrome (TCS), a representative human ribosomopathy with craniofacial abnormalities, is attributed to mutations in the tcof1 gene that has a homologous gene called nopp140.
p29838
sg17433
(lp29839
(dp29840
g17436
I137
sg17437
Vtcof1 gene
p29841
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp29842
g17436
I182
sg17437
Vnopp140
p29843
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp29844
(dp29845
g17436
I27
sg17437
VTCS
p29846
sg17438
I3
sg17445
VC0242387
p29847
sg17441
I1
sa(dp29848
g17436
I0
sg17437
VTreacher Collins syndrome
p29849
sg17438
I25
sg17445
VC0242387
p29850
sg17441
I3
sa(dp29851
g17436
I75
sg17437
Vcraniofacial abnormalities
p29852
sg17438
I26
sg17445
VC0376634
p29853
sg17441
I2
sasa(dp29854
g17431
VPrevious studies suggest that NOLC1 is crucial for normal cell growth, and plays a role in the regulation of tumorigenesis of nasopharyngeal carcinoma (NPC) and demonstrate that both NOLC1 and tumor protein 53 work synergistically to activate the MDM2 promoter in NPC cells.
p29855
sg17433
(lp29856
(dp29857
g17436
I30
sg17437
VNOLC1
p29858
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp29859
g17436
I30
sg17437
VNOLC1
p29860
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29861
(dp29862
g17436
I109
sg17437
Vtumorigenesis
p29863
sg17438
I13
sg17445
VC0007621
p29864
sg17441
I1
sa(dp29865
g17436
I126
sg17437
Vnasopharyngeal carcinoma
p29866
sg17438
I24
sg17445
VC2931822
p29867
sg17441
I2
sa(dp29868
g17436
I152
sg17437
VNPC
p29869
sg17438
I3
sg17445
VC2931822
p29870
sg17441
I1
sa(dp29871
g17436
I152
sg17437
VNPC
p29872
sg17438
I3
sg17445
VC2931822
p29873
sg17441
I1
sa(dp29874
g17436
I109
sg17437
Vtumor
p29875
sg17438
I5
sg17445
VC0027651
p29876
sg17441
I1
sasa(dp29877
g17431
VYet, the functioning of NOLC1 in liver cancer remains unknown.
p29878
sg17433
(lp29879
(dp29880
g17436
I24
sg17437
VNOLC1
p29881
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29882
(dp29883
g17436
I33
sg17437
Vliver cancer
p29884
sg17438
I12
sg17445
VC0345904
p29885
sg17441
I2
sasa(dp29886
g17431
VIn this study, we showed that NOLC1 was silenced or downregulated in liver tumor tissues when compared with that in the matched non-cancer tissues.
p29887
sg17433
(lp29888
(dp29889
g17436
I30
sg17437
VNOLC1
p29890
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29891
(dp29892
g17436
I69
sg17437
Vliver tumor
p29893
sg17438
I11
sg17445
VC0023903
p29894
sg17441
I2
sa(dp29895
g17436
I132
sg17437
Vcancer
p29896
sg17438
I6
sg17445
VC0006826
p29897
sg17441
I1
sasa(dp29898
g135
(dp29899
(Vcyclin D3
p29900
Vliver cancer
p29901
tp29902
I00
ssg17431
VLow expression of NOLC1 in hepatoma cell lines and liver cancer tissues was associated with cyclin D3.
p29903
sg17433
(lp29904
(dp29905
g17436
I92
sg17437
g29900
sg17438
I9
sg17439
VP30281
p29906
sg17441
I2
sa(dp29907
g17436
I18
sg17437
VNOLC1
p29908
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29909
(dp29910
g17436
I27
sg17437
Vhepatoma
p29911
sg17438
I8
sg17445
VC0023903
p29912
sg17441
I1
sa(dp29913
g17436
I51
sg17437
g29901
sg17438
I12
sg17445
VC0345904
p29914
sg17441
I2
sasa(dp29915
g17431
VIn conclusion, our study demonstrated that DNA methylation is a key mechanism of silenced NOLC1 expression in human hepatocellular carcinoma cells, and NOLC1 gene hypermethylation of the four CpG dinucleotides is a potential biomarker for hepatocellular carcinoma.
p29916
sg17433
(lp29917
(dp29918
g17436
I152
sg17437
VNOLC1 gene
p29919
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp29920
g17436
I90
sg17437
VNOLC1
p29921
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29922
(dp29923
g17436
I116
sg17437
Vhepatocellular carcinoma
p29924
sg17438
I24
sg17445
VC1512411
p29925
sg17441
I2
sa(dp29926
g17436
I116
sg17437
Vhepatocellular carcinoma
p29927
sg17438
I24
sg17445
VC1512411
p29928
sg17441
I2
sasa(dp29929
g17431
VSevere combined immunodeficiency mice bearing NPC xenografts derived from NOLC1-short hairpin-RNA-transfected animals were found to have 82% lower levels of tumor growth than control mice as well as marked tumor cell apoptosis.
p29930
sg17433
(lp29931
(dp29932
g17436
I74
sg17437
VNOLC1
p29933
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp29934
(dp29935
g17436
I157
sg17437
Vtumor growth
p29936
sg17438
I12
sg17445
VC0598934
p29937
sg17441
I2
sa(dp29938
g17436
I0
sg17437
VSevere combined immunodeficiency
p29939
sg17438
I32
sg17445
VC0085110
p29940
sg17441
I3
sa(dp29941
g17436
I157
sg17437
Vtumor
p29942
sg17438
I5
sg17445
VC0027651
p29943
sg17441
I1
sa(dp29944
g17436
I46
sg17437
VNPC
p29945
sg17438
I3
sg17445
VC2931822
p29946
sg17441
I1
sasa(dp29947
g135
(dp29948
(Vvascular cell adhesion molecule-1
p29949
Valpha-thalassemia
p29950
tp29951
I01
ssg17431
VThe aim of the study was to examine the effects of endurance exercise on circulating vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p29952
sg17433
(lp29953
(dp29954
g17436
I133
sg17437
Vintercellular adhesion molecule-1
p29955
sg17438
I33
sg17439
VP05362
p29956
sg17441
I3
sa(dp29957
g17436
I85
sg17437
g29949
sg17438
I33
sg17439
VP19320
p29958
sg17441
I4
sasg17442
(lp29959
(dp29960
g17436
I180
sg17437
Vsickle cell trait
p29961
sg17438
I17
sg17445
VC0037054
p29962
sg17441
I3
sa(dp29963
g17436
I199
sg17437
VSCT
p29964
sg17438
I3
sg17445
VC1848934
p29965
sg17441
I1
sa(dp29966
g17436
I99
sg17437
Vadhesion
p29967
sg17438
I8
sg17445
VC0001511
p29968
sg17441
I1
sa(dp29969
g17436
I99
sg17437
Vadhesion
p29970
sg17438
I8
sg17445
VC0001511
p29971
sg17441
I1
sa(dp29972
g17436
I229
sg17437
g29950
sg17438
I17
sg17445
VC0002312
p29973
sg17441
I1
sasa(dp29974
g135
(dp29975
(Vvascular cell adhesion molecule-1
p29976
VSCT
p29977
tp29978
I01
ssg17431
VThe aim of the study was to examine the effects of exercise on soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) in sickle cell trait (SCT) athletes with or without alpha-thalassemia.
p29979
sg17433
(lp29980
(dp29981
g17436
I119
sg17437
Vintercellular adhesion molecule-1
p29982
sg17438
I33
sg17439
VP05362
p29983
sg17441
I3
sa(dp29984
g17436
I71
sg17437
g29976
sg17438
I33
sg17439
VP19320
p29985
sg17441
I4
sasg17442
(lp29986
(dp29987
g17436
I85
sg17437
Vadhesion
p29988
sg17438
I8
sg17445
VC0001511
p29989
sg17441
I1
sa(dp29990
g17436
I85
sg17437
Vadhesion
p29991
sg17438
I8
sg17445
VC0001511
p29992
sg17441
I1
sa(dp29993
g17436
I215
sg17437
Valpha-thalassemia
p29994
sg17438
I17
sg17445
VC0002312
p29995
sg17441
I1
sa(dp29996
g17436
I166
sg17437
Vsickle cell trait
p29997
sg17438
I17
sg17445
VC0037054
p29998
sg17441
I3
sa(dp29999
g17436
I185
sg17437
g29977
sg17438
I3
sg17445
VC1848934
p30000
sg17441
I1
sasa(dp30001
g135
(dp30002
(VELAM-1
p30003
VHbH
p30004
tp30005
I00
ssg17431
VAs compared to normal, increased sICAM-1 was found in beta-thal/HbE patients with non-splenectomy; BE-NS (p = 0.002), increased ELAM-1 in beta-thal/HbE patients with splenectomy; BE-S (p = 0.01) and HbH with Hb Constant Spring; HbH/CS (p = 0.001), and increased sVCAM-1 in BE-NS; (p = &lt; 0.0001) and BE-S (p = 0.002).
p30006
sg17433
(lp30007
(dp30008
g17436
I64
sg17437
VHbE
p30009
sg17438
I3
sg17439
VP02100
p30010
sg17441
I1
sa(dp30011
g17436
I128
sg17437
g30003
sg17438
I6
sg17439
VP16581
p30012
sg17441
I1
sa(dp30013
g17436
I208
sg17437
VHb Constant Spring
p30014
sg17438
I18
sg17439
g12
sg17441
I3
sasg17442
(lp30015
(dp30016
g17436
I199
sg17437
VHbH
p30017
sg17438
I3
sg17445
VC3161174
p30018
sg17441
I1
sa(dp30019
g17436
I199
sg17437
g30004
sg17438
I3
sg17445
VC3161174
p30020
sg17441
I1
sasa(dp30021
g135
(dp30022
(Vretinoic acid receptor
p30023
Vallergic rhinitis
p30024
tp30025
I00
ssg17431
VFurthermore, treatment with AST or DEX significantly suppressed the mRNA and protein expression levels of the transcription factor GATA-3 and retinoic acid receptor-related orphan nuclear receptor (ROR)Gammat in tissue samples isolated from the spleen and nasal mucosa of mice with allergic rhinitis.
p30026
sg17433
(lp30027
(dp30028
g17436
I173
sg17437
Vorphan nuclear receptor
p30029
sg17438
I23
sg17439
VP51843
p30030
sg17441
I3
sa(dp30031
g17436
I110
sg17437
Vtranscription factor GATA-3
p30032
sg17438
I27
sg17439
VP23771
p30033
sg17441
I3
sa(dp30034
g17436
I142
sg17437
g30023
sg17438
I22
sg17439
VP10826
p30035
sg17441
I3
sasg17442
(lp30036
(dp30037
g17436
I282
sg17437
g30024
sg17438
I17
sg17445
VC2607914
p30038
sg17441
I2
sasa(dp30039
g135
(dp30040
(Vtranscription factors GATA-3
p30041
Vallergic rhinitis
p30042
tp30043
I00
ssg17431
VThe present results suggested that treatment with AST may attenuate OVA-induced allergic rhinitis via regulating the expression of the transcription factors GATA-3, RORGammat, T-bet and Foxp3, which commit T helper cells to the Th1 phenotype.
p30044
sg17433
(lp30045
(dp30046
g17436
I50
sg17437
VAST
p30047
sg17438
I3
sg17439
VP51689
p30048
sg17441
I1
sa(dp30049
g17436
I135
sg17437
g30041
sg17438
I28
sg17439
VP19883
p30050
sg17441
I3
sa(dp30051
g17436
I176
sg17437
VT-bet
p30052
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp30053
g17436
I186
sg17437
VFoxp3
p30054
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp30055
(dp30056
g17436
I80
sg17437
g30042
sg17438
I17
sg17445
VC2607914
p30057
sg17441
I2
sasa(dp30058
g17431
VCanagliflozin was associated with a low incidence of hypoglycemia when used with background AHAs that are not associated with hypoglycemia; the incidence was higher among patients on background AHAs associated with hypoglycemia (i.e.
p30059
sg17433
(lp30060
sg17442
(lp30061
(dp30062
g17436
I53
sg17437
Vhypoglycemia
p30063
sg17438
I12
sg17445
VC0020615
p30064
sg17441
I1
sa(dp30065
g17436
I53
sg17437
Vhypoglycemia
p30066
sg17438
I12
sg17445
VC0020615
p30067
sg17441
I1
sa(dp30068
g17436
I53
sg17437
Vhypoglycemia
p30069
sg17438
I12
sg17445
VC0020615
p30070
sg17441
I1
sasa(dp30071
g135
(dp30072
(Vinsulin
p30073
Vhypoglycemia
p30074
tp30075
I00
ssg17431
VCanagliflozin was associated with a low incidence of hypoglycemia when not used in conjunction with AHAs associated with hypoglycemia (i.e., insulin or sulfonylurea).
p30076
sg17433
(lp30077
(dp30078
g17436
I141
sg17437
g30073
sg17438
I7
sg17439
VP01308
p30079
sg17441
I1
sasg17442
(lp30080
(dp30081
g17436
I53
sg17437
Vhypoglycemia
p30082
sg17438
I12
sg17445
VC0020615
p30083
sg17441
I1
sa(dp30084
g17436
I53
sg17437
g30074
sg17438
I12
sg17445
VC0020615
p30085
sg17441
I1
sasa(dp30086
g17431
VAdding different AHAs to metformin was associated with varying effects on HbA1c, BW, SBP, hypoglycemia, UTI and GTI which should impact clinician choice when selecting adjunctive therapy.
p30087
sg17433
(lp30088
sg17442
(lp30089
(dp30090
g17436
I90
sg17437
Vhypoglycemia
p30091
sg17438
I12
sg17445
VC0020615
p30092
sg17441
I1
sa(dp30093
g17436
I104
sg17437
VUTI
p30094
sg17438
I3
sg17445
VC0042029
p30095
sg17441
I1
sasa(dp30096
g135
(dp30097
(VMT-TL2 gene
p30098
Vatherosclerosis
p30099
tp30100
I00
ssg17431
VIt has been shown at least four mutations of mitochondrial genome, namely, A1555G in MT-RNR1 gene, C3256T in MT-TL1 gene, G12315A in MT-TL2 gene, and G15059A in MT-CYB gene have significantly higher prevalence and mean value in lipofibrous plaques as compared to non-atherosclerotic intima, and therefore are associated with atherosclerosis.
p30101
sg17433
(lp30102
(dp30103
g17436
I85
sg17437
VMT-RNR1 gene
p30104
sg17438
I12
sg17439
VP43354
p30105
sg17441
I2
sa(dp30106
g17436
I133
sg17437
g30098
sg17438
I11
sg17439
VP50591
p30107
sg17441
I2
sa(dp30108
g17436
I109
sg17437
VMT-TL1 gene
p30109
sg17438
I11
sg17439
g12
sg17441
I2
sa(dp30110
g17436
I161
sg17437
VMT-CYB gene
p30111
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp30112
(dp30113
g17436
I240
sg17437
Vplaques
p30114
sg17438
I7
sg17445
VC0333463
p30115
sg17441
I1
sa(dp30116
g17436
I325
sg17437
g30099
sg17438
I15
sg17445
VC0004153
p30117
sg17441
I1
sasa(dp30118
g135
(dp30119
(VMT-ND1
p30120
Vatherosclerosis
p30121
tp30122
I00
ssg17431
VTen mitochondrial mutations belonging to mitochondrial genes MT-RNR1 (rRNA 12S); MT-TL1 (tRNA-Leu, recognizes UUR); MT-TL2 (tRNA-Leu, recognizes CUN); MT-ND1, MT-ND2, MT-ND5, and MT-ND6 (subunits 1, 2, 5, and 6, respectively, of NADH dehydrogenase); and MT-CYB (cytochrome b) were potentially associated with atherosclerosis.
p30123
sg17433
(lp30124
(dp30125
g17436
I81
sg17437
VMT-TL1
p30126
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30127
g17436
I116
sg17437
VMT-TL2
p30128
sg17438
I6
sg17439
VP50591
p30129
sg17441
I1
sa(dp30130
g17436
I254
sg17437
VMT-CYB
p30131
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30132
g17436
I167
sg17437
VMT-ND5
p30133
sg17438
I6
sg17439
VP03915
p30134
sg17441
I1
sa(dp30135
g17436
I159
sg17437
VMT-ND2
p30136
sg17438
I6
sg17439
VP03891
p30137
sg17441
I1
sa(dp30138
g17436
I229
sg17437
VNADH dehydrogenase
p30139
sg17438
I18
sg17439
VP49366
p30140
sg17441
I2
sa(dp30141
g17436
I61
sg17437
VMT-RNR1
p30142
sg17438
I7
sg17439
VP43354
p30143
sg17441
I1
sa(dp30144
g17436
I124
sg17437
VtRNA-Leu, recognizes CUN
p30145
sg17438
I24
sg17439
VP30740
p30146
sg17441
I3
sa(dp30147
g17436
I89
sg17437
VtRNA-Leu, recognizes UUR
p30148
sg17438
I24
sg17439
VP30740
p30149
sg17441
I3
sa(dp30150
g17436
I151
sg17437
g30120
sg17438
I6
sg17439
VP03886
p30151
sg17441
I1
sasg17442
(lp30152
(dp30153
g17436
I309
sg17437
g30121
sg17438
I15
sg17445
VC0004153
p30154
sg17441
I1
sasa(dp30155
g17431
VThe vectors of chikungunya and dengue virus, Aedes aegypti and Aedes albopictus, the vector of lymphatic filariasis, Culex quinquefasciatus, and that of Japanese encephalitis, Culex tritaeniorhynchus, were found from 70 to 2,000 m asl in eastern Nepal.
p30156
sg17433
(lp30157
sg17442
(lp30158
(dp30159
g17436
I153
sg17437
VJapanese encephalitis
p30160
sg17438
I21
sg17445
VC0014057
p30161
sg17441
I2
sa(dp30162
g17436
I95
sg17437
Vlymphatic filariasis
p30163
sg17438
I20
sg17445
VC0013884
p30164
sg17441
I2
sa(dp30165
g17436
I15
sg17437
Vchikungunya
p30166
sg17438
I11
sg17445
VC0008055
p30167
sg17441
I1
sa(dp30168
g17436
I31
sg17437
Vdengue
p30169
sg17438
I6
sg17445
VC0011311
p30170
sg17441
I1
sasa(dp30171
g135
(dp30172
(VB-cell lymphoma 2
p30173
Vtrisomy 18
p30174
tp30175
I00
ssg17431
VThe results of an examination of a paraffin block histopathology specimen by fluorescence in-situ hybridization (FISH) showed no mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) (18q21.1), B-cell lymphoma 2 (BCL2) (18q21.3), or BCL6 (3q27) split signals in either the uterus or the greater omentum, however, trisomy 18 was detected in approximately 50%-70% of the tumor cells in both the uterus and the greater omentum.
p30176
sg17433
(lp30177
(dp30178
g17436
I251
sg17437
VBCL6
p30179
sg17438
I4
sg17439
VP41182
p30180
sg17441
I1
sa(dp30181
g17436
I231
sg17437
VBCL2
p30182
sg17438
I4
sg17439
VP10415
p30183
sg17441
I1
sa(dp30184
g17436
I212
sg17437
g30173
sg17438
I17
sg17439
VP10415
p30185
sg17441
I3
sasg17442
(lp30186
(dp30187
g17436
I172
sg17437
Vtranslocation
p30188
sg17438
I13
sg17445
VC0040715
p30189
sg17441
I1
sa(dp30190
g17436
I387
sg17437
Vtumor
p30191
sg17438
I5
sg17445
VC0027651
p30192
sg17441
I1
sa(dp30193
g17436
I129
sg17437
Vmucosa associated lymphoid tissue lymphoma
p30194
sg17438
I42
sg17445
VC0242647
p30195
sg17441
I5
sa(dp30196
g17436
I212
sg17437
VB-cell lymphoma
p30197
sg17438
I15
sg17445
VC0079731
p30198
sg17441
I2
sa(dp30199
g17436
I331
sg17437
g30174
sg17438
I10
sg17445
VC0152096
p30200
sg17441
I2
sasa(dp30201
g17431
VThe following abnormalities were most frequently observed: rearrangements involving 14q32, 19q13, 19p13, 1p, 3q27, and 8q24; del(6q); dup(1q); and trisomy 18.
p30202
sg17433
(lp30203
sg17442
(lp30204
(dp30205
g17436
I147
sg17437
Vtrisomy 18
p30206
sg17438
I10
sg17445
VC0152096
p30207
sg17441
I2
sasa(dp30208
g135
(dp30209
(VGB1
p30210
VArc
p30211
tp30212
I00
ssg17431
VPassive avoidance test showed four Group rats shuttle times were 6.8+/-0.6, 1.2+/-0.2, 5.4+/-0.5, 3.6+/-0.3, incubation period were 26.1+/-3.9, 152.2+/-12.9, 65.8+/-7.0, 91.2+/-9.1, and water maze test had the same trend, with values in epilepsy groups significantly lower than the normal group of rats, which meant cognitive dysfunction.The above results also showed Baclofen further inhibited the learning and memory ability of the rats and CGP35348 promoted the learning and memory ability.The results of the Arc/Arg3.1 and GB1, GB2 level detection showed that epilepsy groups had significantly higher expression levels of Arc/Arg3.1 and GB1, GB2 than the normal group.Comparison among epilepsy groups showed that Baclofen group expressed lower levels of Arc/Arg3.1 and expressed higher levels of GB1, GB2, however CGP35348 group expressed higher levels of Arc/Arg3.1 and expressed lower levels of GB1, GB2.
p30213
sg17433
(lp30214
(dp30215
g17436
I516
sg17437
VArg3.1
p30216
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30217
g17436
I532
sg17437
VGB2
p30218
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30219
g17436
I527
sg17437
VGB1
p30220
sg17438
I3
sg17439
VP62873
p30221
sg17441
I1
sa(dp30222
g17436
I516
sg17437
VArg3.1
p30223
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30224
g17436
I532
sg17437
VGB2
p30225
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30226
g17436
I532
sg17437
VGB2
p30227
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30228
g17436
I512
sg17437
VArc
p30229
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30230
g17436
I516
sg17437
VArg3.1
p30231
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30232
g17436
I512
sg17437
VArc
p30233
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30234
g17436
I512
sg17437
VArc
p30235
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30236
g17436
I527
sg17437
VGB1
p30237
sg17438
I3
sg17439
VP62873
p30238
sg17441
I1
sa(dp30239
g17436
I527
sg17437
VGB1
p30240
sg17438
I3
sg17439
VP62873
p30241
sg17441
I1
sa(dp30242
g17436
I532
sg17437
VGB2
p30243
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30244
g17436
I818
sg17437
VCGP35348 group
p30245
sg17438
I14
sg17439
VP00390
p30246
sg17441
I2
sa(dp30247
g17436
I512
sg17437
VArc
p30248
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30249
g17436
I516
sg17437
VArg3.1
p30250
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30251
g17436
I527
sg17437
g30210
sg17438
I3
sg17439
VP62873
p30252
sg17441
I1
sasg17442
(lp30253
(dp30254
g17436
I237
sg17437
Vepilepsy
p30255
sg17438
I8
sg17445
VC0014544
p30256
sg17441
I1
sa(dp30257
g17436
I512
sg17437
VArc
p30258
sg17438
I3
sg17445
VC0001857
p30259
sg17441
I1
sa(dp30260
g17436
I237
sg17437
Vepilepsy
p30261
sg17438
I8
sg17445
VC0014544
p30262
sg17441
I1
sa(dp30263
g17436
I512
sg17437
VArc
p30264
sg17438
I3
sg17445
VC0001857
p30265
sg17441
I1
sa(dp30266
g17436
I512
sg17437
VArc
p30267
sg17438
I3
sg17445
VC0001857
p30268
sg17441
I1
sa(dp30269
g17436
I316
sg17437
Vcognitive dysfunction
p30270
sg17438
I21
sg17445
VC0338656
p30271
sg17441
I2
sa(dp30272
g17436
I237
sg17437
Vepilepsy
p30273
sg17438
I8
sg17445
VC0014544
p30274
sg17441
I1
sa(dp30275
g17436
I512
sg17437
g30211
sg17438
I3
sg17445
VC0001857
p30276
sg17441
I1
sasa(dp30277
g135
(dp30278
(Vprohormone convertase 1/3
p30279
VPC1
p30280
tp30281
I00
ssg17431
VTo search for the mechanism causing clinically silent corticotroph adenoma, we immunohistochemically examined the expression of prohormone convertase 1/3 (PC1/3) in this type of adenoma and compared our results with those obtained for Cushing's disease.
p30282
sg17433
(lp30283
(dp30284
g17436
I155
sg17437
VPC1/3
p30285
sg17438
I5
sg17439
VP29120
p30286
sg17441
I1
sa(dp30287
g17436
I128
sg17437
g30279
sg17438
I25
sg17439
VP29120
p30288
sg17441
I3
sasg17442
(lp30289
(dp30290
g17436
I67
sg17437
Vadenoma
p30291
sg17438
I7
sg17445
VC0001430
p30292
sg17441
I1
sa(dp30293
g17436
I54
sg17437
Vcorticotroph adenoma
p30294
sg17438
I20
sg17445
VC1306214
p30295
sg17441
I2
sa(dp30296
g17436
I235
sg17437
VCushing's disease
p30297
sg17438
I17
sg17445
VC0221406
p30298
sg17441
I2
sa(dp30299
g17436
I155
sg17437
g30280
sg17438
I3
sg17445
VC1706595
p30300
sg17441
I1
sasa(dp30301
g17431
VIn the present study, we tested the therapeutic and immunomodulatory effects of FTS and its derivative 5-fluoro-FTS (F-FTS) in the rat adjuvant-induced arthritis model (AIA).
p30302
sg17433
(lp30303
(dp30304
g17436
I117
sg17437
VF-FTS
p30305
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp30306
g17436
I103
sg17437
V5-fluoro-FTS
p30307
sg17438
I12
sg17439
g12
sg17441
I1
sasg17442
(lp30308
(dp30309
g17436
I152
sg17437
Varthritis
p30310
sg17438
I9
sg17445
VC0003864
p30311
sg17441
I1
sasa(dp30312
g17431
VMR features were scored (0-3) following the Oslo hand OA score: BMLs, synovitis, cysts, flexor tenosynovitis (FTS).
p30313
sg17433
(lp30314
sg17442
(lp30315
(dp30316
g17436
I110
sg17437
VFTS
p30317
sg17438
I3
sg17445
VC0744058
p30318
sg17441
I1
sa(dp30319
g17436
I81
sg17437
Vcysts
p30320
sg17438
I5
sg17445
VC0010709
p30321
sg17441
I1
sa(dp30322
g17436
I70
sg17437
Vsynovitis
p30323
sg17438
I9
sg17445
VC0039103
p30324
sg17441
I1
sa(dp30325
g17436
I88
sg17437
Vflexor tenosynovitis
p30326
sg17438
I20
sg17445
VC0744058
p30327
sg17441
I2
sasa(dp30328
g17431
VBMLs, synovitis, cysts, FTS and ETI were demonstrated in 56%, 90%, 22%, 16% and 30% of patients, respectively.
p30329
sg17433
(lp30330
sg17442
(lp30331
(dp30332
g17436
I17
sg17437
Vcysts
p30333
sg17438
I5
sg17445
VC0010709
p30334
sg17441
I1
sa(dp30335
g17436
I6
sg17437
Vsynovitis
p30336
sg17438
I9
sg17445
VC0039103
p30337
sg17441
I1
sasa(dp30338
g17431
VBMLs (grade 2/3 vs 0: 3.5 (1.6-7.7)) and synovitis (3 vs 0: OR 3.6 (95% CI 1.9-6.6)) were severity-dependent associated with joint pain, but FTS and ETI were not.
p30339
sg17433
(lp30340
sg17442
(lp30341
(dp30342
g17436
I125
sg17437
Vjoint pain
p30343
sg17438
I10
sg17445
VC0003862
p30344
sg17441
I2
sa(dp30345
g17436
I41
sg17437
Vsynovitis
p30346
sg17438
I9
sg17445
VC0039103
p30347
sg17441
I1
sasa(dp30348
g17431
VInfectious flexor tenosynovitis (FTS) is a serious infection of the hand and wrist that can lead to necrosis and amputation without prompt diagnosis and surgical debridement.
p30349
sg17433
(lp30350
sg17442
(lp30351
(dp30352
g17436
I33
sg17437
VFTS
p30353
sg17438
I3
sg17445
VC0744058
p30354
sg17441
I1
sa(dp30355
g17436
I11
sg17437
Vflexor tenosynovitis
p30356
sg17438
I20
sg17445
VC0744058
p30357
sg17441
I2
sa(dp30358
g17436
I51
sg17437
Vinfection
p30359
sg17438
I9
sg17445
VC0009450
p30360
sg17441
I1
sa(dp30361
g17436
I0
sg17437
VInfectious
p30362
sg17438
I10
sg17445
VC0009450
p30363
sg17441
I1
sasa(dp30364
g135
(dp30365
(VRas
p30366
Varthritis
p30367
tp30368
I00
ssg17431
VOur objective in this work was to investigate the anti-inflammatory effects of the Ras inhibitor farnesylthiosalicylic acid (FTS) on adjuvant-induced arthritis (AIA) in rats, an experimental model for RA.
p30369
sg17433
(lp30370
(dp30371
g17436
I83
sg17437
g30366
sg17438
I3
sg17439
VP01116
p30372
sg17441
I1
sasg17442
(lp30373
(dp30374
g17436
I150
sg17437
g30367
sg17438
I9
sg17445
VC0003864
p30375
sg17441
I1
sasa(dp30376
g17431
VDiabetic patients are susceptible to stenosing flexor tenosynovitis (FTS) and may have a diminished response to treatment.
p30377
sg17433
(lp30378
sg17442
(lp30379
(dp30380
g17436
I47
sg17437
Vflexor tenosynovitis
p30381
sg17438
I20
sg17445
VC0744058
p30382
sg17441
I2
sa(dp30383
g17436
I69
sg17437
VFTS
p30384
sg17438
I3
sg17445
VC0744058
p30385
sg17441
I1
sasa(dp30386
g17431
VWith the rising participation of women in sports events, the prevalence of eating disorders and the female athlete triad (FTS), a syndrome of disordered eating, amenorrhea, and osteoporosis, have also increased in recent years.
p30387
sg17433
(lp30388
sg17442
(lp30389
(dp30390
g17436
I161
sg17437
Vamenorrhea
p30391
sg17438
I10
sg17445
VC0002453
p30392
sg17441
I1
sa(dp30393
g17436
I100
sg17437
Vfemale athlete triad
p30394
sg17438
I20
sg17445
VC1721053
p30395
sg17441
I3
sa(dp30396
g17436
I75
sg17437
Veating disorders
p30397
sg17438
I16
sg17445
VC0013473
p30398
sg17441
I2
sa(dp30399
g17436
I130
sg17437
Vsyndrome
p30400
sg17438
I8
sg17445
VC0039082
p30401
sg17441
I1
sa(dp30402
g17436
I177
sg17437
Vosteoporosis
p30403
sg17438
I12
sg17445
VC0029456
p30404
sg17441
I1
sasa(dp30405
g17431
VDupuytren's contracture (DC) (42 vs. 29.3%, respectively; P=0.01), limited joint mobility (LJM) (39 vs. 28.5%, respectively; P=0.01) and carpal tunnel syndrome (CTS) (5.3 vs. 1%, respectively; P=0.01) were significantly higher in T2DM patients than in the controls, but not stenosing flexor tenosynovitis (FTS, 'trigger finger').
p30406
sg17433
(lp30407
sg17442
(lp30408
(dp30409
g17436
I161
sg17437
VCTS
p30410
sg17438
I3
sg17445
VC0007286
p30411
sg17441
I1
sa(dp30412
g17436
I137
sg17437
Vcarpal tunnel syndrome
p30413
sg17438
I22
sg17445
VC0007286
p30414
sg17441
I3
sa(dp30415
g17436
I311
sg17437
V'trigger finger
p30416
sg17438
I15
sg17445
VC0158328
p30417
sg17441
I2
sa(dp30418
g17436
I25
sg17437
VDC
p30419
sg17438
I2
sg17445
VC0013312
p30420
sg17441
I1
sa(dp30421
g17436
I0
sg17437
VDupuytren's contracture
p30422
sg17438
I23
sg17445
VC0013312
p30423
sg17441
I2
sa(dp30424
g17436
I284
sg17437
Vflexor tenosynovitis
p30425
sg17438
I20
sg17445
VC0744058
p30426
sg17441
I2
sa(dp30427
g17436
I306
sg17437
VFTS
p30428
sg17438
I3
sg17445
VC0744058
p30429
sg17441
I1
sasa(dp30430
g135
(dp30431
(Vgrowth factors
p30432
Vcolorectal cancer
p30433
tp30434
I00
ssg17431
VData from several studies suggest that the gastrin family of growth factors potentiates colorectal cancer tumourigenesis.
p30435
sg17433
(lp30436
(dp30437
g17436
I43
sg17437
Vgastrin family
p30438
sg17438
I14
sg17439
VP01350
p30439
sg17441
I2
sa(dp30440
g17436
I61
sg17437
g30432
sg17438
I14
sg17439
VP19883
p30441
sg17441
I2
sasg17442
(lp30442
(dp30443
g17436
I88
sg17437
g30433
sg17438
I17
sg17445
VC1527249
p30444
sg17441
I2
sasa(dp30445
g17431
VThe aim of this study was to investigate whether progastrin expression may predict clinical outcome in colorectal cancer.
p30446
sg17433
(lp30447
sg17442
(lp30448
(dp30449
g17436
I103
sg17437
Vcolorectal cancer
p30450
sg17438
I17
sg17445
VC1527249
p30451
sg17441
I2
sasa(dp30452
g17431
VThis is the first study to show that progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer and supports its clinical relevance and potential use as a biomarker.
p30453
sg17433
(lp30454
sg17442
(lp30455
(dp30456
g17436
I80
sg17437
Vaggressive
p30457
sg17438
I10
sg17445
VC0001807
p30458
sg17441
I1
sa(dp30459
g17436
I91
sg17437
Vtumour
p30460
sg17438
I6
sg17445
VC0027651
p30461
sg17441
I1
sa(dp30462
g17436
I125
sg17437
Vcolorectal cancer
p30463
sg17438
I17
sg17445
VC1527249
p30464
sg17441
I2
sasa(dp30465
g135
(dp30466
(Vmotilin
p30467
Vcolorectal cancer
p30468
tp30469
I00
ssg17431
VThe aim of this study was to analyze plasma concentrations of enterohormones (motilin, ghrelin, gastrin and pancreatic polypeptide) and to verify if their abnormal levels may contribute to the severity of dyspeptic symptoms in colorectal cancer patients.
p30470
sg17433
(lp30471
(dp30472
g17436
I87
sg17437
Vghrelin
p30473
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp30474
g17436
I96
sg17437
Vgastrin
p30475
sg17438
I7
sg17439
VP01350
p30476
sg17441
I1
sa(dp30477
g17436
I78
sg17437
g30467
sg17438
I7
sg17439
VP12872
p30478
sg17441
I1
sasg17442
(lp30479
(dp30480
g17436
I227
sg17437
g30468
sg17438
I17
sg17445
VC1527249
p30481
sg17441
I2
sasa(dp30482
g135
(dp30483
(Vgastrin
p30484
Vcolon cancer
p30485
tp30486
I00
ssg17431
VThis study examined the expression level, subcellular localization, and binding activity of CacyBP/SIP in human colon cancer cells in the presence and absence of the hormone gastrin.
p30487
sg17433
(lp30488
(dp30489
g17436
I99
sg17437
VSIP
p30490
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp30491
g17436
I92
sg17437
VCacyBP
p30492
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30493
g17436
I174
sg17437
g30484
sg17438
I7
sg17439
VP01350
p30494
sg17441
I1
sasg17442
(lp30495
(dp30496
g17436
I112
sg17437
g30485
sg17438
I12
sg17445
VC0699790
p30497
sg17441
I2
sasa(dp30498
g135
(dp30499
(Vgastrin
p30500
Vcolon cancer
p30501
tp30502
I00
ssg17431
VCacyBP/SIP promoted the cell proliferation of colon cancer cells under both basal and gastrin stimulated conditions as shown by knockdown studies.
p30503
sg17433
(lp30504
(dp30505
g17436
I86
sg17437
g30500
sg17438
I7
sg17439
VP01350
p30506
sg17441
I1
sa(dp30507
g17436
I0
sg17437
VCacyBP
p30508
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp30509
g17436
I7
sg17437
VSIP
p30510
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp30511
(dp30512
g17436
I46
sg17437
g30501
sg17438
I12
sg17445
VC0699790
p30513
sg17441
I2
sa(dp30514
g17436
I29
sg17437
Vproliferation
p30515
sg17438
I13
sg17445
VC0334094
p30516
sg17441
I1
sasa(dp30517
g135
(dp30518
(Vgastrin
p30519
VCRC
p30520
tp30521
I00
ssg17431
VAs treatment with proton pump inhibitors (PPIs) increases the biosynthesis and secretion of gastrin, it has been postulated that treatment with PPIs could increase the risk of cancer, especially in Barrett's esophagus, gastric carcinoids, and colorectal cancer (CRC).
p30522
sg17433
(lp30523
(dp30524
g17436
I92
sg17437
g30519
sg17438
I7
sg17439
VP01350
p30525
sg17441
I1
sasg17442
(lp30526
(dp30527
g17436
I198
sg17437
VBarrett's esophagus
p30528
sg17438
I19
sg17445
VC0004763
p30529
sg17441
I2
sa(dp30530
g17436
I243
sg17437
Vcolorectal cancer
p30531
sg17438
I17
sg17445
VC1527249
p30532
sg17441
I2
sa(dp30533
g17436
I227
sg17437
Vcarcinoids
p30534
sg17438
I10
sg17445
VC0007095
p30535
sg17441
I1
sa(dp30536
g17436
I262
sg17437
g30520
sg17438
I3
sg17445
VC1527249
p30537
sg17441
I1
sa(dp30538
g17436
I176
sg17437
Vcancer
p30539
sg17438
I6
sg17445
VC0006826
p30540
sg17441
I1
sasa(dp30541
g17431
VPathological studies showed lymph nodes metastasis in 2 patients with pancreatic gastrinomas, and in one patient with duodenal gastrinoma.
p30542
sg17433
(lp30543
sg17442
(lp30544
(dp30545
g17436
I81
sg17437
Vgastrinomas
p30546
sg17438
I11
sg17445
VC0017150
p30547
sg17441
I1
sa(dp30548
g17436
I118
sg17437
Vduodenal gastrinoma
p30549
sg17438
I19
sg17445
VC1333321
p30550
sg17441
I2
sa(dp30551
g17436
I40
sg17437
Vmetastasis
p30552
sg17438
I10
sg17445
VC0027627
p30553
sg17441
I1
sasa(dp30554
g135
(dp30555
(VPD-1
p30556
Vnon-obese diabetic
p30557
tp30558
I00
ssg17431
VA progressive increase in the expression of PD-1 and B7-H1/B7-DC on T cells and APC, respectively, was observed in the pancreatic lymph nodes of female non-obese diabetic (NOD) mice as they developed diabetes.
p30559
sg17433
(lp30560
(dp30561
g17436
I53
sg17437
VB7-H1
p30562
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp30563
g17436
I80
sg17437
VAPC
p30564
sg17438
I3
sg17439
VP25054
p30565
sg17441
I1
sa(dp30566
g17436
I44
sg17437
g30556
sg17438
I4
sg17439
VP18621
p30567
sg17441
I1
sa(dp30568
g17436
I59
sg17437
VB7-DC
p30569
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp30570
(dp30571
g17436
I172
sg17437
VNOD
p30572
sg17438
I3
sg17445
VC0751781
p30573
sg17441
I1
sa(dp30574
g17436
I80
sg17437
VAPC
p30575
sg17438
I3
sg17445
VC0033036
p30576
sg17441
I1
sa(dp30577
g17436
I200
sg17437
Vdiabetes
p30578
sg17438
I8
sg17445
VC0011849
p30579
sg17441
I1
sa(dp30580
g17436
I152
sg17437
g30557
sg17438
I18
sg17445
VC0751781
p30581
sg17441
I2
sasa(dp30582
g135
(dp30583
(VPD-1
p30584
Vdiabetes
p30585
tp30586
I00
ssg17431
VB7-H1 and B7-DC have negative regulatory effects upon binding PD-1 on activated T cells and B7-H1 deficiency increases severity of both diabetes and EAE.
p30587
sg17433
(lp30588
(dp30589
g17436
I10
sg17437
VB7-DC
p30590
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp30591
g17436
I0
sg17437
VB7-H1
p30592
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp30593
g17436
I62
sg17437
g30584
sg17438
I4
sg17439
VP18621
p30594
sg17441
I1
sa(dp30595
g17436
I0
sg17437
VB7-H1
p30596
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp30597
(dp30598
g17436
I136
sg17437
g30585
sg17438
I8
sg17445
VC0011849
p30599
sg17441
I1
sasa(dp30600
g135
(dp30601
(VKIR3DL2
p30602
Vmycosis fungoides
p30603
tp30604
I00
ssg17431
VThese characteristics have implicated KIR3DL2 in several pathologies: ankylosing spondylitis and cutaneous T-cell lymphomas such as Sezary syndrome, CD30+ cutaneous lymphoma, and transformed mycosis fungoides.
p30605
sg17433
(lp30606
(dp30607
g17436
I38
sg17437
g30602
sg17438
I7
sg17439
VP43630
p30608
sg17441
I1
sasg17442
(lp30609
(dp30610
g17436
I132
sg17437
VSezary syndrome
p30611
sg17438
I15
sg17445
VC0036920
p30612
sg17441
I2
sa(dp30613
g17436
I97
sg17437
Vcutaneous T-cell lymphomas
p30614
sg17438
I26
sg17445
VC0079773
p30615
sg17441
I3
sa(dp30616
g17436
I70
sg17437
Vankylosing spondylitis
p30617
sg17438
I22
sg17445
VC0038013
p30618
sg17441
I2
sa(dp30619
g17436
I155
sg17437
Vcutaneous lymphoma
p30620
sg17438
I18
sg17445
VC1276146
p30621
sg17441
I2
sa(dp30622
g17436
I191
sg17437
g30603
sg17438
I17
sg17445
VC0026948
p30623
sg17441
I2
sasa(dp30624
g135
(dp30625
(VCD8
p30626
Vmycosis fungoides and Sezary syndrome
p30627
tp30628
I00
ssg17431
VKIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sezary syndrome.
p30629
sg17433
(lp30630
(dp30631
g17436
I0
sg17437
VKIR3DL2
p30632
sg17438
I7
sg17439
VP43630
p30633
sg17441
I1
sa(dp30634
g17436
I89
sg17437
g30626
sg17438
I3
sg17439
VP01732
p30635
sg17441
I1
sasg17442
(lp30636
(dp30637
g17436
I164
sg17437
g30627
sg17438
I37
sg17445
VC0862196
p30638
sg17441
I5
sasa(dp30639
g135
(dp30640
(VCD158k
p30641
Vmycosis fungoides
p30642
tp30643
I00
ssg17431
VNot only we confirmed the expression of this marker in the blood and/or skin of mycosis fungoides patients but we also show for the first time CD158k expression (often associated with CD160) on cutaneous CD4+ T cells from healthy individuals (25.3 +/- 15%).
p30644
sg17433
(lp30645
(dp30646
g17436
I184
sg17437
VCD160
p30647
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp30648
g17436
I143
sg17437
g30641
sg17438
I6
sg17439
VP43627
p30649
sg17441
I1
sasg17442
(lp30650
(dp30651
g17436
I80
sg17437
g30642
sg17438
I17
sg17445
VC0026948
p30652
sg17441
I2
sasa(dp30653
g135
(dp30654
(VCD158k
p30655
Vmycosis fungoides
p30656
tp30657
I00
ssg17431
VTherefore, CD4+ CD160+ T cells expressing CD158k might represent specialized cutaneous lymphocytes devoted to immune surveillance, from which could originate cutaneous T-cell lymphomas such as mycosis fungoides.
p30658
sg17433
(lp30659
(dp30660
g17436
I11
sg17437
VCD4+
p30661
sg17438
I4
sg17439
VP01730
p30662
sg17441
I1
sa(dp30663
g17436
I42
sg17437
g30655
sg17438
I6
sg17439
VP43627
p30664
sg17441
I1
sasg17442
(lp30665
(dp30666
g17436
I158
sg17437
Vcutaneous T-cell lymphomas
p30667
sg17438
I26
sg17445
VC0079773
p30668
sg17441
I3
sa(dp30669
g17436
I193
sg17437
g30656
sg17438
I17
sg17445
VC0026948
p30670
sg17441
I2
sasa(dp30671
g135
(dp30672
(Vp140
p30673
Vmycosis fungoides
p30674
tp30675
I00
ssg17431
Vp140/KIR3DL2 has been identified in malignant cell lines isolated from the skin and blood of patients with transformed mycosis fungoides (MF) and Sezary's syndrome (SS).
p30676
sg17433
(lp30677
(dp30678
g17436
I5
sg17437
VKIR3DL2
p30679
sg17438
I7
sg17439
VP43630
p30680
sg17441
I1
sa(dp30681
g17436
I0
sg17437
g30673
sg17438
I4
sg17439
VP43630
p30682
sg17441
I1
sasg17442
(lp30683
(dp30684
g17436
I146
sg17437
VSezary's syndrome
p30685
sg17438
I17
sg17445
VC0036920
p30686
sg17441
I2
sa(dp30687
g17436
I119
sg17437
g30674
sg17438
I17
sg17445
VC0026948
p30688
sg17441
I2
sasa(dp30689
g17431
VChromosomal aberration (DS especially) are among the most frequent prenatally diagnosed birth defects, further being heart defects, neural tube defects (anencephaly, encephalocele, spina bifida), hydrocephalus, congenital skeletal system defects, abdominal wall defects (omphalocele, gastroschisis) and renal defects.
p30690
sg17433
(lp30691
sg17442
(lp30692
(dp30693
g17436
I153
sg17437
Vanencephaly
p30694
sg17438
I11
sg17445
VC0002902
p30695
sg17441
I1
sa(dp30696
g17436
I196
sg17437
Vhydrocephalus, congenital
p30697
sg17438
I25
sg17445
VC0020256
p30698
sg17441
I2
sa(dp30699
g17436
I166
sg17437
Vencephalocele
p30700
sg17438
I13
sg17445
VC0014065
p30701
sg17441
I1
sa(dp30702
g17436
I181
sg17437
Vspina bifida
p30703
sg17438
I12
sg17445
VC0080178
p30704
sg17441
I2
sa(dp30705
g17436
I0
sg17437
VChromosomal aberration
p30706
sg17438
I22
sg17445
VC0008625
p30707
sg17441
I2
sa(dp30708
g17436
I271
sg17437
Vomphalocele
p30709
sg17438
I11
sg17445
VC0795690
p30710
sg17441
I1
sa(dp30711
g17436
I284
sg17437
Vgastroschisis
p30712
sg17438
I13
sg17445
VC0265706
p30713
sg17441
I1
sa(dp30714
g17436
I117
sg17437
Vheart defects
p30715
sg17438
I13
sg17445
VC0018798
p30716
sg17441
I2
sa(dp30717
g17436
I88
sg17437
Vbirth defects
p30718
sg17438
I13
sg17445
VC0000768
p30719
sg17441
I2
sasa(dp30720
g17431
VIn some defects, prenatal diagnostics has also significantly influenced their incidence in births (anencephaly, gastroschisis and DS e.g.
p30721
sg17433
(lp30722
sg17442
(lp30723
(dp30724
g17436
I99
sg17437
Vanencephaly
p30725
sg17438
I11
sg17445
VC0002902
p30726
sg17441
I1
sa(dp30727
g17436
I112
sg17437
Vgastroschisis
p30728
sg17438
I13
sg17445
VC0265706
p30729
sg17441
I1
sasa(dp30730
g135
(dp30731
(VFxn KO
p30732
VFriedreich ataxia
p30733
tp30734
I00
ssg17431
VThe Fxn KO/Mck model reproduces some key features of patients with Friedreich ataxia and provides an opportunity of ameliorating their symptoms with experimental therapies.
p30735
sg17433
(lp30736
(dp30737
g17436
I4
sg17437
g30732
sg17438
I6
sg17439
VP51587
p30738
sg17441
I2
sasg17442
(lp30739
(dp30740
g17436
I67
sg17437
g30733
sg17438
I17
sg17445
VC0016719
p30741
sg17441
I2
sasa(dp30742
g135
(dp30743
(VMPS VI
p30744
VMPS VI
p30745
tp30746
I00
ssg17431
VFurther confirmation is obtained with identification of two mutations in the ARSB gene for MPS VI or mutations in the GALNS gene for MPS IVA.We report slowly progressing patients, one with MPS VI and two with MPS IVA, who presented with skeletal changes and hip findings resembling Legg-Calve-Perthes disease or spondyloepiphyseal dysplasia and normal/near normal urine GAG levels.
p30747
sg17433
(lp30748
(dp30749
g17436
I118
sg17437
VGALNS gene
p30750
sg17438
I10
sg17439
VP34059
p30751
sg17441
I2
sa(dp30752
g17436
I133
sg17437
VMPS IVA
p30753
sg17438
I7
sg17439
VP05164
p30754
sg17441
I2
sa(dp30755
g17436
I91
sg17437
g30744
sg17438
I6
sg17439
VP05164
p30756
sg17441
I2
sasg17442
(lp30757
(dp30758
g17436
I133
sg17437
VMPS IVA
p30759
sg17438
I7
sg17445
VC0086651
p30760
sg17441
I2
sa(dp30761
g17436
I91
sg17437
VMPS VI
p30762
sg17438
I6
sg17445
VC0026709
p30763
sg17441
I2
sa(dp30764
g17436
I312
sg17437
Vspondyloepiphyseal dysplasia
p30765
sg17438
I28
sg17445
VC2745959
p30766
sg17441
I2
sa(dp30767
g17436
I282
sg17437
VLegg-Calve-Perthes disease
p30768
sg17438
I26
sg17445
VC0023234
p30769
sg17441
I2
sa(dp30770
g17436
I133
sg17437
VMPS IVA
p30771
sg17438
I7
sg17445
VC0086651
p30772
sg17441
I2
sa(dp30773
g17436
I91
sg17437
g30745
sg17438
I6
sg17445
VC0026709
p30774
sg17441
I2
sasa(dp30775
g17431
VWe identified genes that might be truly causative, but GWAS might have failed to identify for 148 out of the GWAS-identified SNPs; for example, TUFM (P = 3.3E-48) was identified for inflammatory bowel disease (early onset); ZFP90 (P = 4.4E-34) for ulcerative colitis; and IDUA (P = 2.2E-11) for Parkinson's disease.
p30776
sg17433
(lp30777
(dp30778
g17436
I224
sg17437
VZFP90
p30779
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp30780
(dp30781
g17436
I248
sg17437
Vulcerative colitis
p30782
sg17438
I18
sg17445
VC0009324
p30783
sg17441
I2
sa(dp30784
g17436
I295
sg17437
VParkinson's disease
p30785
sg17438
I19
sg17445
VC0030567
p30786
sg17441
I2
sa(dp30787
g17436
I182
sg17437
Vinflammatory bowel disease
p30788
sg17438
I26
sg17445
VC0021390
p30789
sg17441
I3
sasa(dp30790
g17431
VApart from allergic bronchopulmonary aspergillosis (ABPA) and mould-caused mycoses, only sufficient evidence for an association between moisture/mould damage and the following health effects has been established: allergic respiratory disease, asthma (manifestation, progression and exacerbation), allergic rhinitis, hypersensitivity pneumonitis (extrinsic allergic alveolitis), and increased likelihood of respiratory infections/bronchitis.
p30791
sg17433
(lp30792
sg17442
(lp30793
(dp30794
g17436
I346
sg17437
Vextrinsic allergic alveolitis
p30795
sg17438
I29
sg17445
VC0002390
p30796
sg17441
I3
sa(dp30797
g17436
I429
sg17437
Vbronchitis
p30798
sg17438
I10
sg17445
VC0006277
p30799
sg17441
I1
sa(dp30800
g17436
I11
sg17437
Vallergic bronchopulmonary aspergillosis
p30801
sg17438
I39
sg17445
VC0004031
p30802
sg17441
I3
sa(dp30803
g17436
I316
sg17437
Vhypersensitivity pneumonitis
p30804
sg17438
I28
sg17445
VC0002390
p30805
sg17441
I2
sa(dp30806
g17436
I52
sg17437
VABPA
p30807
sg17438
I4
sg17445
VC0004031
p30808
sg17441
I1
sa(dp30809
g17436
I75
sg17437
Vmycoses
p30810
sg17438
I7
sg17445
VC0026946
p30811
sg17441
I1
sa(dp30812
g17436
I213
sg17437
Vallergic respiratory disease
p30813
sg17438
I28
sg17445
VC1504369
p30814
sg17441
I3
sa(dp30815
g17436
I243
sg17437
Vasthma
p30816
sg17438
I6
sg17445
VC0004096
p30817
sg17441
I1
sa(dp30818
g17436
I406
sg17437
Vrespiratory infections
p30819
sg17438
I22
sg17445
VC0035243
p30820
sg17441
I2
sa(dp30821
g17436
I297
sg17437
Vallergic rhinitis
p30822
sg17438
I17
sg17445
VC2607914
p30823
sg17441
I2
sasa(dp30824
g17431
VWe studied the relationship between GORD and allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), or Aspergillus bronchitis.
p30825
sg17433
(lp30826
sg17442
(lp30827
(dp30828
g17436
I61
sg17437
Vpulmonary aspergillosis
p30829
sg17438
I23
sg17445
VC2350529
p30830
sg17441
I2
sa(dp30831
g17436
I45
sg17437
Vallergic bronchopulmonary aspergillosis
p30832
sg17438
I39
sg17445
VC0004031
p30833
sg17441
I3
sa(dp30834
g17436
I135
sg17437
VAspergillus bronchitis
p30835
sg17438
I22
sg17445
VC2919277
p30836
sg17441
I2
sa(dp30837
g17436
I86
sg17437
VABPA
p30838
sg17438
I4
sg17445
VC0004031
p30839
sg17441
I1
sasa(dp30840
g17431
VWe reviewed four patients referred with elevated Aspergillus serology markers and marked pulmonary symptoms for ABPA, CPA, and Aspergillus bronchitis, and discussed the underlying pathophysiological relationship with GORD.
p30841
sg17433
(lp30842
sg17442
(lp30843
(dp30844
g17436
I112
sg17437
VABPA
p30845
sg17438
I4
sg17445
VC0004031
p30846
sg17441
I1
sa(dp30847
g17436
I127
sg17437
VAspergillus bronchitis
p30848
sg17438
I22
sg17445
VC2919277
p30849
sg17441
I2
sasa(dp30850
g135
(dp30851
(Vanti-Aspergillus IgE
p30852
VABPA
p30853
tp30854
I00
ssg17431
VData were collected retrospectively from medical records included age, gender, predisposing factors for ABPA, chronic pulmonary aspergillosis, or Aspergillus bronchitis; presence of nocturnal reflux, nausea, epigastric pain, Medical Research Council dyspnea scale score, pH manometry data, endoscopic results (ulcers, Barrett's esophagus), treatment of GORD [proton-pump inhibitors (PPIs), surgical operation]; history of smoking, alcohol consumption; concomitant COPD; serological markers (anti-Aspergillus IgG, anti-Aspergillus IgE), and antifungal treatment.
p30855
sg17433
(lp30856
(dp30857
g17436
I513
sg17437
g30852
sg17438
I20
sg17439
VP01854
p30858
sg17441
I2
sasg17442
(lp30859
(dp30860
g17436
I310
sg17437
Vulcers
p30861
sg17438
I6
sg17445
VC0041582
p30862
sg17441
I1
sa(dp30863
g17436
I200
sg17437
Vnausea
p30864
sg17438
I6
sg17445
VC0027497
p30865
sg17441
I1
sa(dp30866
g17436
I208
sg17437
Vepigastric pain
p30867
sg17438
I15
sg17445
VC0232493
p30868
sg17441
I2
sa(dp30869
g17436
I192
sg17437
Vreflux
p30870
sg17438
I6
sg17445
VC0017168
p30871
sg17441
I1
sa(dp30872
g17436
I530
sg17437
VIgE
p30873
sg17438
I3
sg17445
VC0270850
p30874
sg17441
I1
sa(dp30875
g17436
I250
sg17437
Vdyspnea
p30876
sg17438
I7
sg17445
VC0013404
p30877
sg17441
I1
sa(dp30878
g17436
I118
sg17437
Vpulmonary aspergillosis
p30879
sg17438
I23
sg17445
VC2350529
p30880
sg17441
I2
sa(dp30881
g17436
I464
sg17437
VCOPD
p30882
sg17438
I4
sg17445
VC0024117
p30883
sg17441
I1
sa(dp30884
g17436
I146
sg17437
VAspergillus bronchitis
p30885
sg17438
I22
sg17445
VC2919277
p30886
sg17441
I2
sa(dp30887
g17436
I318
sg17437
VBarrett's esophagus
p30888
sg17438
I19
sg17445
VC0004763
p30889
sg17441
I2
sa(dp30890
g17436
I104
sg17437
g30853
sg17438
I4
sg17445
VC0004031
p30891
sg17441
I1
sasa(dp30892
g17431
VOne had ABPA, one CPA, and two had Aspergillus bronchitis; median age was 57 years [range 39-71]; males-to-females ratio was 1:3.
p30893
sg17433
(lp30894
sg17442
(lp30895
(dp30896
g17436
I8
sg17437
VABPA
p30897
sg17438
I4
sg17445
VC0004031
p30898
sg17441
I1
sa(dp30899
g17436
I35
sg17437
VAspergillus bronchitis
p30900
sg17438
I22
sg17445
VC2919277
p30901
sg17441
I2
sasa(dp30902
g17431
VApart from the allergic bronchopulmonary aspergillosis (ABPA) and the mycoses caused by mold, there is only sufficient evidence for the following associations between moisture/mold damages and different health effects: Allergic respiratory diseases, asthma (manifestation, progression, exacerbation), allergic rhinitis, exogenous allergic alveolitis and respiratory tract infections/bronchitis.
p30903
sg17433
(lp30904
sg17442
(lp30905
(dp30906
g17436
I383
sg17437
Vbronchitis
p30907
sg17438
I10
sg17445
VC0006277
p30908
sg17441
I1
sa(dp30909
g17436
I228
sg17437
Vrespiratory diseases
p30910
sg17438
I20
sg17445
VC0035204
p30911
sg17441
I2
sa(dp30912
g17436
I56
sg17437
VABPA
p30913
sg17438
I4
sg17445
VC0004031
p30914
sg17441
I1
sa(dp30915
g17436
I301
sg17437
Vallergic rhinitis
p30916
sg17438
I17
sg17445
VC2607914
p30917
sg17441
I2
sa(dp30918
g17436
I354
sg17437
Vrespiratory tract infections
p30919
sg17438
I28
sg17445
VC0035243
p30920
sg17441
I3
sa(dp30921
g17436
I15
sg17437
Vallergic bronchopulmonary aspergillosis
p30922
sg17438
I39
sg17445
VC0004031
p30923
sg17441
I3
sa(dp30924
g17436
I250
sg17437
Vasthma
p30925
sg17438
I6
sg17445
VC0004096
p30926
sg17441
I1
sa(dp30927
g17436
I70
sg17437
Vmycoses
p30928
sg17438
I7
sg17445
VC0026946
p30929
sg17441
I1
sa(dp30930
g17436
I330
sg17437
Vallergic alveolitis
p30931
sg17438
I19
sg17445
VC0002390
p30932
sg17441
I2
sasa(dp30933
g17431
Vcan lead to allergic bronchopulmonary aspergillosis (ABPA), Aspergillus sensitisation and Aspergillus bronchitis in CF.
p30934
sg17433
(lp30935
sg17442
(lp30936
(dp30937
g17436
I12
sg17437
Vallergic bronchopulmonary aspergillosis
p30938
sg17438
I39
sg17445
VC0004031
p30939
sg17441
I3
sa(dp30940
g17436
I90
sg17437
VAspergillus bronchitis
p30941
sg17438
I22
sg17445
VC2919277
p30942
sg17441
I2
sa(dp30943
g17436
I53
sg17437
VABPA
p30944
sg17438
I4
sg17445
VC0004031
p30945
sg17441
I1
sasa(dp30946
g17431
VPublished proportions of ABPA (17.7%), Aspergillus sensitisation (14.6%) and Aspergillus bronchitis (30%) in CF were applied to those &gt;18 years and compared with notified ABPA cases.
p30947
sg17433
(lp30948
sg17442
(lp30949
(dp30950
g17436
I25
sg17437
VABPA
p30951
sg17438
I4
sg17445
VC0004031
p30952
sg17441
I1
sa(dp30953
g17436
I25
sg17437
VABPA
p30954
sg17438
I4
sg17445
VC0004031
p30955
sg17441
I1
sa(dp30956
g17436
I77
sg17437
VAspergillus bronchitis
p30957
sg17438
I22
sg17445
VC2919277
p30958
sg17441
I2
sasa(dp30959
g17431
VAspergillus sensitisation, associated with increased bronchiectasis and reduced FEV1, affects an anticipated 5,506 patients without ABPA or Aspergillus bronchitis.
p30960
sg17433
(lp30961
sg17442
(lp30962
(dp30963
g17436
I140
sg17437
VAspergillus bronchitis
p30964
sg17438
I22
sg17445
VC2919277
p30965
sg17441
I2
sa(dp30966
g17436
I132
sg17437
VABPA
p30967
sg17438
I4
sg17445
VC0004031
p30968
sg17441
I1
sa(dp30969
g17436
I53
sg17437
Vbronchiectasis
p30970
sg17438
I14
sg17445
VC0006267
p30971
sg17441
I1
sasa(dp30972
g17431
VTogether ABPA and Aspergillus bronchitis are estimated to affect 17,989 adults, 47.7% of the adult CF population.
p30973
sg17433
(lp30974
sg17442
(lp30975
(dp30976
g17436
I9
sg17437
VABPA
p30977
sg17438
I4
sg17445
VC0004031
p30978
sg17441
I1
sa(dp30979
g17436
I18
sg17437
VAspergillus bronchitis
p30980
sg17438
I22
sg17445
VC2919277
p30981
sg17441
I2
sasa(dp30982
g17431
VItraconazole is prescribed for allergic bronchopulmonary aspergillosis (ABPA) or Aspergillus bronchitis in CF subjects.
p30983
sg17433
(lp30984
sg17442
(lp30985
(dp30986
g17436
I31
sg17437
Vallergic bronchopulmonary aspergillosis
p30987
sg17438
I39
sg17445
VC0004031
p30988
sg17441
I3
sa(dp30989
g17436
I81
sg17437
VAspergillus bronchitis
p30990
sg17438
I22
sg17445
VC2919277
p30991
sg17441
I2
sa(dp30992
g17436
I72
sg17437
VABPA
p30993
sg17438
I4
sg17445
VC0004031
p30994
sg17441
I1
sasa(dp30995
g17431
VWe selected an average of five serum samples from each of the 17 patients with ABPA (13 proven and 4 probable ABPA) and from 3 patients with Aspergillus bronchitis and rhinosinusitis.
p30996
sg17433
(lp30997
sg17442
(lp30998
(dp30999
g17436
I141
sg17437
VAspergillus bronchitis
p31000
sg17438
I22
sg17445
VC2919277
p31001
sg17441
I2
sa(dp31002
g17436
I79
sg17437
VABPA
p31003
sg17438
I4
sg17445
VC0004031
p31004
sg17441
I1
sa(dp31005
g17436
I168
sg17437
Vrhinosinusitis
p31006
sg17438
I14
sg17445
VC0948780
p31007
sg17441
I1
sa(dp31008
g17436
I79
sg17437
VABPA
p31009
sg17438
I4
sg17445
VC0004031
p31010
sg17441
I1
sasa(dp31011
g17431
VPatients were diagnosed with ABPA and Aspergillus bronchitis related to innate immune defects.
p31012
sg17433
(lp31013
sg17442
(lp31014
(dp31015
g17436
I29
sg17437
VABPA
p31016
sg17438
I4
sg17445
VC0004031
p31017
sg17441
I1
sa(dp31018
g17436
I38
sg17437
VAspergillus bronchitis
p31019
sg17438
I22
sg17445
VC2919277
p31020
sg17441
I2
sasa(dp31021
g17431
VYeasts and filamentous fungi are beginning to emerge as significant microbial pathogens in patients with cystic fibrosis (CF), particularly in relation to allergic-type responses, as seen in patients with allergic bronchopulmonary aspergillosis (ABPA), Aspergillus bronchitis and in invasive fungal disease in lung transplant patients.
p31022
sg17433
(lp31023
sg17442
(lp31024
(dp31025
g17436
I246
sg17437
VABPA
p31026
sg17438
I4
sg17445
VC0004031
p31027
sg17441
I1
sa(dp31028
g17436
I122
sg17437
VCF
p31029
sg17438
I2
sg17445
VC0010674
p31030
sg17441
I1
sa(dp31031
g17436
I105
sg17437
Vcystic fibrosis
p31032
sg17438
I15
sg17445
VC0010674
p31033
sg17441
I2
sa(dp31034
g17436
I253
sg17437
VAspergillus bronchitis
p31035
sg17438
I22
sg17445
VC2919277
p31036
sg17441
I2
sa(dp31037
g17436
I292
sg17437
Vfungal disease
p31038
sg17438
I14
sg17445
VC0026946
p31039
sg17441
I2
sa(dp31040
g17436
I205
sg17437
Vallergic bronchopulmonary aspergillosis
p31041
sg17438
I39
sg17445
VC0004031
p31042
sg17441
I3
sasa(dp31043
g135
(dp31044
(VCK 10
p31045
VPaget's disease
p31046
tp31047
I00
ssg17431
VOn the other hand, a widespread positive reaction for CK 5/8, CK 7, CK 19, and negative reaction for CK 10, was a helpful feature in the differentiation of Paget's disease from Bowen's disease and BAK.
p31048
sg17433
(lp31049
(dp31050
g17436
I54
sg17437
VCK 5/8
p31051
sg17438
I6
sg17439
VP02533
p31052
sg17441
I2
sa(dp31053
g17436
I62
sg17437
VCK 7
p31054
sg17438
I4
sg17439
VP08729
p31055
sg17441
I2
sa(dp31056
g17436
I101
sg17437
g31045
sg17438
I5
sg17439
VP13645
p31057
sg17441
I2
sasg17442
(lp31058
(dp31059
g17436
I177
sg17437
VBowen's disease
p31060
sg17438
I15
sg17445
VC0006079
p31061
sg17441
I2
sa(dp31062
g17436
I156
sg17437
g31046
sg17438
I15
sg17445
VC0029401
p31063
sg17441
I2
sasa(dp31064
g135
(dp31065
(Vleptin
p31066
Vrenal osteodystrophy
p31067
tp31068
I00
ssg17431
VTo date, the relation between serum leptin levels of dialysis patients and renal osteodystrophy, defined by histomorphometric and histodynamic parameters of bone, has not been studied.
p31069
sg17433
(lp31070
(dp31071
g17436
I36
sg17437
g31066
sg17438
I6
sg17439
VP41159
p31072
sg17441
I1
sasg17442
(lp31073
(dp31074
g17436
I75
sg17437
g31067
sg17438
I20
sg17445
VC0035086
p31075
sg17441
I2
sasa(dp31076
g17431
VFor 100 years, it has been obvious that Salmonella enterica strains sharing the serotype with the formula 1,4,[5],12:b:1,2-now known as Paratyphi B-can cause diseases ranging from serious systemic infections to self-limiting gastroenteritis.
p31077
sg17433
(lp31078
sg17442
(lp31079
(dp31080
g17436
I225
sg17437
Vgastroenteritis
p31081
sg17438
I15
sg17445
VC0017160
p31082
sg17441
I1
sa(dp31083
g17436
I40
sg17437
VSalmonella
p31084
sg17438
I10
sg17445
VC0036117
p31085
sg17441
I1
sa(dp31086
g17436
I188
sg17437
Vsystemic infections
p31087
sg17438
I19
sg17445
VC0243026
p31088
sg17441
I2
sasa(dp31089
g17431
VInterestingly, in the case of breast cancer patients, this phenomenon correlated with high expression level of several molecular chaperones belonging to the HSPA, DNAJB and HSPC families.
p31090
sg17433
(lp31091
sg17442
(lp31092
(dp31093
g17436
I30
sg17437
Vbreast cancer
p31094
sg17438
I13
sg17445
VC0678222
p31095
sg17441
I2
sasa(dp31096
g17431
VUnexpectedly, conditioning before HSPC infusion was required to protect the mice from lymphoma developing when transplanting small numbers of progenitors.
p31097
sg17433
(lp31098
sg17442
(lp31099
(dp31100
g17436
I86
sg17437
Vlymphoma
p31101
sg17438
I8
sg17445
VC0024299
p31102
sg17441
I1
sasa(dp31103
g135
(dp31104
(Vhuman CD34+
p31105
Vovarian cancer
p31106
tp31107
I00
ssg17431
VHere, we evaluated the potency of highly active NK cells derived from human CD34+ haematopoietic stem and progenitor cells (HSPC) to infiltrate and mediate killing of human ovarian cancer spheroids using an in vivo-like model system and mouse xenograft model.
p31108
sg17433
(lp31109
(dp31110
g17436
I70
sg17437
g31105
sg17438
I11
sg17439
VP28906
p31111
sg17441
I2
sasg17442
(lp31112
(dp31113
g17436
I173
sg17437
g31106
sg17438
I14
sg17445
VC1140680
p31114
sg17441
I2
sa(dp31115
g17436
I133
sg17437
Vinfiltrate
p31116
sg17438
I10
sg17445
VC0332448
p31117
sg17441
I1
sasa(dp31118
g135
(dp31119
(VIL-15
p31120
Vovarian cancer
p31121
tp31122
I00
ssg17431
VThese CD56+Perforin+ HSPC-NK cells were generated under stroma-free conditions in the presence of StemRegenin-1, IL-15, and IL-12, and exerted efficient cytolytic activity and IFNGamma production toward ovarian cancer monolayer cultures.
p31123
sg17433
(lp31124
(dp31125
g17436
I6
sg17437
VCD56+Perforin+ HSPC-NK
p31126
sg17438
I22
sg17439
VP14222
p31127
sg17441
I2
sa(dp31128
g17436
I113
sg17437
g31120
sg17438
I5
sg17439
VP40933
p31129
sg17441
I1
sasg17442
(lp31130
(dp31131
g17436
I203
sg17437
g31121
sg17438
I14
sg17445
VC1140680
p31132
sg17441
I2
sasa(dp31133
g17431
VLive-imaging confocal microscopy demonstrated that these HSPC-NK cells actively migrate, infiltrate, and mediate tumor cell killing in a three-dimensional multicellular ovarian cancer spheroid.
p31134
sg17433
(lp31135
sg17442
(lp31136
(dp31137
g17436
I113
sg17437
Vtumor
p31138
sg17438
I5
sg17445
VC0027651
p31139
sg17441
I1
sa(dp31140
g17436
I89
sg17437
Vinfiltrate
p31141
sg17438
I10
sg17445
VC0332448
p31142
sg17441
I1
sa(dp31143
g17436
I169
sg17437
Vovarian cancer
p31144
sg17438
I14
sg17445
VC1140680
p31145
sg17441
I2
sasa(dp31146
g135
(dp31147
(VNOD
p31148
Vtumor progression
p31149
tp31150
I00
ssg17431
VFurthermore, intraperitoneal HSPC-NK cell infusions in NOD/SCID-IL2RGammanull (NSG) mice bearing ovarian carcinoma significantly reduced tumor progression.
p31151
sg17433
(lp31152
(dp31153
g17436
I59
sg17437
VSCID-IL2RGammanull
p31154
sg17438
I18
sg17439
VP31785
p31155
sg17441
I1
sa(dp31156
g17436
I55
sg17437
g31148
sg17438
I3
sg17439
VP54259
p31157
sg17441
I1
sasg17442
(lp31158
(dp31159
g17436
I97
sg17437
Vovarian carcinoma
p31160
sg17438
I17
sg17445
VC0029925
p31161
sg17441
I2
sa(dp31162
g17436
I55
sg17437
VNOD
p31163
sg17438
I3
sg17445
VC0751781
p31164
sg17441
I1
sa(dp31165
g17436
I59
sg17437
VSCID
p31166
sg17438
I4
sg17445
VC0085110
p31167
sg17441
I1
sa(dp31168
g17436
I137
sg17437
g31149
sg17438
I17
sg17445
VC0178874
p31169
sg17441
I2
sasa(dp31170
g17431
VThese findings demonstrate that highly functional HSPC-NK cells efficiently destruct ovarian carcinoma spheroids in vitro and kill intraperitoneal ovarian tumors in vivo, providing great promise for effective immunotherapy through intraperitoneal HSPC-NK cell adoptive transfer in ovarian carcinoma patients.
p31171
sg17433
(lp31172
sg17442
(lp31173
(dp31174
g17436
I85
sg17437
Vovarian carcinoma
p31175
sg17438
I17
sg17445
VC0029925
p31176
sg17441
I2
sa(dp31177
g17436
I147
sg17437
Vovarian tumors
p31178
sg17438
I14
sg17445
VC0919267
p31179
sg17441
I2
sa(dp31180
g17436
I85
sg17437
Vovarian carcinoma
p31181
sg17438
I17
sg17445
VC0029925
p31182
sg17441
I2
sasa(dp31183
g17431
VTreatment with vitamin C, a co-factor of Fe2+ and Alfa-KG-dependent dioxygenases, mimics TET2 restoration by enhancing 5-hydroxymethylcytosine formation in Tet2-deficient mouse HSPCs and suppresses human leukemic colony formation and leukemia progression of primary human leukemia PDXs.
p31184
sg17433
(lp31185
(dp31186
g17436
I156
sg17437
VTet2-deficient mouse HSPCs
p31187
sg17438
I26
sg17439
g12
sg17441
I3
sa(dp31188
g17436
I89
sg17437
VTET2
p31189
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp31190
(dp31191
g17436
I234
sg17437
Vleukemia
p31192
sg17438
I8
sg17445
VC0023418
p31193
sg17441
I1
sa(dp31194
g17436
I234
sg17437
Vleukemia
p31195
sg17438
I8
sg17445
VC0023418
p31196
sg17441
I1
sasa(dp31197
g17431
VWe quantified extracellular IL-16 protein (ELISA) and intracellular IL-16 in NK cells, T-cells, B-cells, and monocytes (flow cytometry) in blood samples from long-term tobacco smokers with and without chronic obstructive pulmonary disease (COPD) and in never-smokers.
p31198
sg17433
(lp31199
(dp31200
g17436
I14
sg17437
Vextracellular IL-16 protein
p31201
sg17438
I27
sg17439
g12
sg17441
I3
sa(dp31202
g17436
I28
sg17437
VIL-16
p31203
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp31204
(dp31205
g17436
I240
sg17437
VCOPD
p31206
sg17438
I4
sg17445
VC0024117
p31207
sg17441
I1
sa(dp31208
g17436
I201
sg17437
Vchronic obstructive pulmonary disease
p31209
sg17438
I37
sg17445
VC0024117
p31210
sg17441
I4
sasa(dp31211
g135
(dp31212
(VETC, monocyte hemotactic protein-1
p31213
Vasthmatic
p31214
tp31215
I00
ssg17431
VIn asthmatic children with positive ETC, monocyte hemotactic protein-1 (MCP-1) and IL-16 adjusted to pre-EBC forced expiratory volume in 1 s (FEV1) were significantly higher compared to children with negative ETC (p = 0.022 and p = 0.017 respectively).
p31216
sg17433
(lp31217
(dp31218
g17436
I83
sg17437
VIL-16
p31219
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31220
g17436
I72
sg17437
VMCP-1
p31221
sg17438
I5
sg17439
VP41597
p31222
sg17441
I1
sa(dp31223
g17436
I36
sg17437
g31213
sg17438
I34
sg17439
VP17980
p31224
sg17441
I4
sasg17442
(lp31225
(dp31226
g17436
I3
sg17437
g31214
sg17438
I9
sg17445
VC0004096
p31227
sg17441
I1
sasa(dp31228
g17431
VCompared with the control group, silica dust exposed group, the observation group of objects, the pneumosilicosis patients of IL-16 in induced sputum IL-16 (21.40 +/- 9.24) decreased, the content of PDGF [(5.96 +/- 0.51) ng/L], MMP-2 [(447.86 +/- 27.10) ng/L], MMP-9 [(223.91 +/- 12.28) ng/L], MCP-1 [(122.87 +/- 6.08) ng/L] increased, the differences are statistically significant (P &lt; 0.05).
p31229
sg17433
(lp31230
(dp31231
g17436
I294
sg17437
VMCP-1
p31232
sg17438
I5
sg17439
VP41597
p31233
sg17441
I1
sa(dp31234
g17436
I126
sg17437
VIL-16
p31235
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31236
g17436
I228
sg17437
VMMP-2
p31237
sg17438
I5
sg17439
VP08253
p31238
sg17441
I1
sa(dp31239
g17436
I261
sg17437
VMMP-9
p31240
sg17438
I5
sg17439
VP14780
p31241
sg17441
I1
sa(dp31242
g17436
I199
sg17437
VPDGF
p31243
sg17438
I4
sg17439
VP04085
p31244
sg17441
I1
sa(dp31245
g17436
I143
sg17437
Vsputum IL-16
p31246
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp31247
sa(dp31248
g135
(dp31249
(VTGF-beta
p31250
Vsilicosis
p31251
tp31252
I01
ssg17431
VAs silicosis biomarkers, TNF-alpha, TGF-beta, IL-16, PDGF, MMP-2, MMP-9 and MCP-1 have certain significance, further suggesting that early detection rate of patients with silicosis can be improved by employing the multiple indexes discriminate equation.
p31253
sg17433
(lp31254
(dp31255
g17436
I66
sg17437
VMMP-9
p31256
sg17438
I5
sg17439
VP14780
p31257
sg17441
I1
sa(dp31258
g17436
I53
sg17437
VPDGF
p31259
sg17438
I4
sg17439
VP04085
p31260
sg17441
I1
sa(dp31261
g17436
I46
sg17437
VIL-16
p31262
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31263
g17436
I25
sg17437
VTNF-alpha
p31264
sg17438
I9
sg17439
VP01375
p31265
sg17441
I1
sa(dp31266
g17436
I59
sg17437
VMMP-2
p31267
sg17438
I5
sg17439
VP08253
p31268
sg17441
I1
sa(dp31269
g17436
I76
sg17437
VMCP-1
p31270
sg17438
I5
sg17439
VP41597
p31271
sg17441
I1
sa(dp31272
g17436
I36
sg17437
g31250
sg17438
I8
sg17439
VP18075
p31273
sg17441
I1
sasg17442
(lp31274
(dp31275
g17436
I3
sg17437
Vsilicosis
p31276
sg17438
I9
sg17445
VC0037116
p31277
sg17441
I1
sa(dp31278
g17436
I3
sg17437
g31251
sg17438
I9
sg17445
VC0037116
p31279
sg17441
I1
sasa(dp31280
g135
(dp31281
(VIL-5
p31282
Vasthma
p31283
tp31284
I00
ssg17431
VBy contrast, compared to eosinophil-normal asthma (eosinophils&lt;=0.3%), eosinophil-high asthma (eosinophils&gt;0.3%) had higher levels of IL-5, IL-13, IL-16, and PDGF-bb, but same neutrophil percentage, IL-8, and FEV1.
p31285
sg17433
(lp31286
(dp31287
g17436
I146
sg17437
VIL-13
p31288
sg17438
I5
sg17439
VP35225
p31289
sg17441
I1
sa(dp31290
g17436
I164
sg17437
VPDGF-bb
p31291
sg17438
I7
sg17439
VP04085
p31292
sg17441
I1
sa(dp31293
g17436
I153
sg17437
VIL-16
p31294
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31295
g17436
I140
sg17437
g31282
sg17438
I4
sg17439
VP05113
p31296
sg17441
I1
sasg17442
(lp31297
(dp31298
g17436
I43
sg17437
Vasthma
p31299
sg17438
I6
sg17445
VC0004096
p31300
sg17441
I1
sa(dp31301
g17436
I43
sg17437
g31283
sg17438
I6
sg17445
VC0004096
p31302
sg17441
I1
sasa(dp31303
g17431
VHere, we demonstrate that DRG1 is elevated in lung adenocarcinomas while weakly expressed in adjacent lung tissues.
p31304
sg17433
(lp31305
(dp31306
g17436
I26
sg17437
VDRG1
p31307
sg17438
I4
sg17439
VP55039
p31308
sg17441
I1
sasg17442
(lp31309
(dp31310
g17436
I51
sg17437
Vadenocarcinomas
p31311
sg17438
I15
sg17445
VC0001418
p31312
sg17441
I1
sasa(dp31313
g135
(dp31314
(VCD4
p31315
Vmelanoma
p31316
tp31317
I00
ssg17431
VTo this end, we describe the identification of developmentally regulated GTP-binding protein 1 (DRG-1) as a melanoma-associated antigen recognized by HLA-DR11-restricted CD4(+) Th1 cells.
p31318
sg17433
(lp31319
(dp31320
g17436
I96
sg17437
VDRG-1
p31321
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31322
g17436
I150
sg17437
VHLA-DR11
p31323
sg17438
I8
sg17439
VP30486
p31324
sg17441
I1
sa(dp31325
g17436
I108
sg17437
Vmelanoma-associated antigen
p31326
sg17438
I27
sg17439
VP08962
p31327
sg17441
I2
sa(dp31328
g17436
I47
sg17437
Vdevelopmentally regulated GTP-binding protein 1
p31329
sg17438
I47
sg17439
g12
sg17441
I5
sa(dp31330
g17436
I170
sg17437
g31315
sg17438
I3
sg17439
VP01730
p31331
sg17441
I1
sasg17442
(lp31332
(dp31333
g17436
I108
sg17437
g31316
sg17438
I8
sg17445
VC0025202
p31334
sg17441
I1
sasa(dp31335
g17431
VReverse transcription-polymerase chain reaction revealed that DRG-1 was highly expressed in melanoma cell lines but not in normal tissues.
p31336
sg17433
(lp31337
(dp31338
g17436
I62
sg17437
VDRG-1
p31339
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp31340
(dp31341
g17436
I92
sg17437
Vmelanoma
p31342
sg17438
I8
sg17445
VC0025202
p31343
sg17441
I1
sasa(dp31344
g17431
VDRG-1 knockdown by lentiviral-based shRNA suppressed melanoma cell proliferation and soft agar colony formation.
p31345
sg17433
(lp31346
sg17442
(lp31347
(dp31348
g17436
I67
sg17437
Vproliferation
p31349
sg17438
I13
sg17445
VC0334094
p31350
sg17441
I1
sa(dp31351
g17436
I53
sg17437
Vmelanoma
p31352
sg17438
I8
sg17445
VC0025202
p31353
sg17441
I1
sasa(dp31354
g135
(dp31355
(VCD4
p31356
Vmelanoma
p31357
tp31358
I00
ssg17431
VTaken together, these data suggest that DRG-1 plays an important role in melanoma cell growth and transformation, indicating that DRG1 may represent a novel target for CD4(+) T cell-mediated immunotherapy in melanoma.
p31359
sg17433
(lp31360
(dp31361
g17436
I168
sg17437
g31356
sg17438
I3
sg17439
VP01730
p31362
sg17441
I1
sa(dp31363
g17436
I40
sg17437
VDRG-1
p31364
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31365
g17436
I130
sg17437
VDRG1
p31366
sg17438
I4
sg17439
VP55039
p31367
sg17441
I1
sasg17442
(lp31368
(dp31369
g17436
I98
sg17437
Vtransformation
p31370
sg17438
I14
sg17445
VC1510411
p31371
sg17441
I1
sa(dp31372
g17436
I73
sg17437
Vmelanoma
p31373
sg17438
I8
sg17445
VC0025202
p31374
sg17441
I1
sa(dp31375
g17436
I73
sg17437
g31357
sg17438
I8
sg17445
VC0025202
p31376
sg17441
I1
sasa(dp31377
g17431
VFBXW7 mRNA was identified as a direct target of miR-155 in glioma.
p31378
sg17433
(lp31379
(dp31380
g17436
I0
sg17437
VFBXW7 mRNA
p31381
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp31382
(dp31383
g17436
I59
sg17437
Vglioma
p31384
sg17438
I6
sg17445
VC0017638
p31385
sg17441
I1
sasa(dp31386
g17431
VFinally, we found that MALAT1 positively regulated FBXW7 expression, which was responsible for glioma progression mediated by MALAT1-miR-155 pathway.
p31387
sg17433
(lp31388
(dp31389
g17436
I51
sg17437
VFBXW7
p31390
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31391
g17436
I23
sg17437
VMALAT1
p31392
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp31393
g17436
I126
sg17437
VMALAT1-miR
p31394
sg17438
I10
sg17439
g12
sg17441
I1
sasg17442
(lp31395
(dp31396
g17436
I95
sg17437
Vglioma
p31397
sg17438
I6
sg17445
VC0017638
p31398
sg17441
I1
sasa(dp31399
g17431
VBesides those, Fbxw7 activity is controlled at different levels, resulting in specific and tunable regulation of the abundance and activity of its substrates in a variety of human solid tumor types, including glioma malignancy, nasopharyngeal carcinoma, osteosarcoma, melanoma as well as colorectal, lung, breast, gastric, liver, pancreatic, renal, prostate, endometrial, and esophageal cancers.
p31400
sg17433
(lp31401
(dp31402
g17436
I15
sg17437
VFbxw7
p31403
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp31404
(dp31405
g17436
I376
sg17437
Vesophageal cancers
p31406
sg17438
I18
sg17445
VC0546837
p31407
sg17441
I2
sa(dp31408
g17436
I216
sg17437
Vmalignancy
p31409
sg17438
I10
sg17445
VC0006826
p31410
sg17441
I1
sa(dp31411
g17436
I228
sg17437
Vnasopharyngeal carcinoma
p31412
sg17438
I24
sg17445
VC2931822
p31413
sg17441
I2
sa(dp31414
g17436
I209
sg17437
Vglioma
p31415
sg17438
I6
sg17445
VC0017638
p31416
sg17441
I1
sa(dp31417
g17436
I268
sg17437
Vmelanoma
p31418
sg17438
I8
sg17445
VC0025202
p31419
sg17441
I1
sa(dp31420
g17436
I254
sg17437
Vosteosarcoma
p31421
sg17438
I12
sg17445
VC0029463
p31422
sg17441
I1
sa(dp31423
g17436
I180
sg17437
Vsolid tumor
p31424
sg17438
I11
sg17445
VC0280100
p31425
sg17441
I2
sasa(dp31426
g135
(dp31427
(VCyclin E
p31428
VGBM
p31429
tp31430
I01
ssg17431
VSubsequently, miR-15/16 activities are reduced and many of their direct targets are de-repressed, including ubiquitin ligase FBXW7 that destabilizes Cyclin E. Conversely, GBM cells expressing low p21 level, or after p21 knock-down, exhibit weaker or no E2F1 response to miR-10b inhibition.
p31431
sg17433
(lp31432
(dp31433
g17436
I270
sg17437
VmiR-10b
p31434
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp31435
g17436
I14
sg17437
VmiR-15/16
p31436
sg17438
I9
sg17439
g12
sg17441
I1
sa(dp31437
g17436
I108
sg17437
Vubiquitin ligase FBXW7
p31438
sg17438
I22
sg17439
g12
sg17441
I3
sa(dp31439
g17436
I196
sg17437
Vp21
p31440
sg17438
I3
sg17439
VP42857
p31441
sg17441
I1
sa(dp31442
g17436
I253
sg17437
VE2F1
p31443
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp31444
g17436
I216
sg17437
Vp21 knock
p31445
sg17438
I9
sg17439
VP42857
p31446
sg17441
I2
sa(dp31447
g17436
I149
sg17437
g31428
sg17438
I8
sg17439
VP24864
p31448
sg17441
I2
sasg17442
(lp31449
(dp31450
g17436
I171
sg17437
g31429
sg17438
I3
sg17445
VC0017636
p31451
sg17441
I1
sasa(dp31452
g135
(dp31453
(VNotch pathway genes
p31454
Vgliomas
p31455
tp31456
I00
ssg17431
VNotch pathway genes are overexpressed in ependymomas and gliomas along with FBXW7 downregulation.
p31457
sg17433
(lp31458
(dp31459
g17436
I0
sg17437
g31454
sg17438
I19
sg17439
VP01893
p31460
sg17441
I3
sa(dp31461
g17436
I76
sg17437
VFBXW7
p31462
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp31463
(dp31464
g17436
I41
sg17437
Vependymomas
p31465
sg17438
I11
sg17445
VC0014474
p31466
sg17441
I1
sa(dp31467
g17436
I57
sg17437
g31455
sg17438
I7
sg17445
VC0017638
p31468
sg17441
I1
sasa(dp31469
g17431
VWe propose that p53 mutations contribute to gliomagenesis by both allowing the overexpression of c-Myc through downregulation of Fbxw7 and by protecting against c-Myc-induced apoptosis.
p31470
sg17433
(lp31471
(dp31472
g17436
I16
sg17437
Vp53 mutations
p31473
sg17438
I13
sg17439
VP42771
p31474
sg17441
I2
sa(dp31475
g17436
I97
sg17437
Vc-Myc
p31476
sg17438
I5
sg17439
VP12524
p31477
sg17441
I1
sa(dp31478
g17436
I129
sg17437
VFbxw7
p31479
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp31480
g17436
I97
sg17437
Vc-Myc
p31481
sg17438
I5
sg17439
VP12524
p31482
sg17441
I1
sasg17442
(lp31483
sa(dp31484
g135
(dp31485
(VnNOS
p31486
VPMD
p31487
tp31488
I00
ssg17431
VPMD is located adjacent and medial to the nucleus prepositus hypoglossi (PH) in the dorsal medulla and is distinguished by the pattern of immunoreactivity of cells and fibers to several markers including calcium-binding proteins, a synthetic enzyme for nitric oxide (neuronal nitric oxide synthase, nNOS) and a nonphosphorylated neurofilament protein (antibody SMI-32).
p31489
sg17433
(lp31490
(dp31491
g17436
I42
sg17437
Vnucleus prepositus hypoglossi
p31492
sg17438
I29
sg17439
VP61457
p31493
sg17441
I3
sa(dp31494
g17436
I299
sg17437
g31486
sg17438
I4
sg17439
VP29475
p31495
sg17441
I1
sasg17442
(lp31496
(dp31497
g17436
I0
sg17437
g31487
sg17438
I3
sg17445
VC1832661
p31498
sg17441
I1
sasa(dp31499
g135
(dp31500
(VnNOS
p31501
VPMD
p31502
tp31503
I00
ssg17431
VCells in PMD are also immunoreactive to nNOS, and immunoreactivity to a neurofilament protein shows many labeled cells and fibers.
p31504
sg17433
(lp31505
(dp31506
g17436
I40
sg17437
g31501
sg17438
I4
sg17439
VP29475
p31507
sg17441
I1
sasg17442
(lp31508
(dp31509
g17436
I9
sg17437
g31502
sg17438
I3
sg17445
VC1832661
p31510
sg17441
I1
sasa(dp31511
g135
(dp31512
(VPOS-OP2
p31513
Vperiodontitis
p31514
tp31515
I00
ssg17431
VRegardless of the type of surgery (PRE-OP, POS-OP1, POS-OP2), the prevalence of periodontitis proved to be high (81.45%).
p31516
sg17433
(lp31517
(dp31518
g17436
I43
sg17437
VPOS-OP1
p31519
sg17438
I7
sg17439
VP18075
p31520
sg17441
I1
sa(dp31521
g17436
I52
sg17437
g31513
sg17438
I7
sg17439
VP34820
p31522
sg17441
I1
sasg17442
(lp31523
(dp31524
g17436
I80
sg17437
g31514
sg17438
I13
sg17445
VC0031099
p31525
sg17441
I1
sasa(dp31526
g135
(dp31527
(VPOS-OP1
p31528
Vperiodontitis
p31529
tp31530
I00
ssg17431
VThere was a statistically significant difference in the prevalence of periodontitis among the PRE-OP, POS-OP1, and POS-OP2 groups (P = 0.040).
p31531
sg17433
(lp31532
(dp31533
g17436
I94
sg17437
VPRE-OP
p31534
sg17438
I6
sg17439
VP58743
p31535
sg17441
I1
sa(dp31536
g17436
I102
sg17437
g31528
sg17438
I7
sg17439
VP18075
p31537
sg17441
I1
sasg17442
(lp31538
(dp31539
g17436
I70
sg17437
g31529
sg17438
I13
sg17445
VC0031099
p31540
sg17441
I1
sasa(dp31541
g17431
VLong-term studies with gamma-irradiated 0.5 and 2.5mg hOP-1 per gram of xenogeneic bovine collagenous matrix induce the restitutio ad integrum of the periodontal tissues in furcation defects exposed by chronic periodontitis in P. ursinus.
p31542
sg17433
(lp31543
sg17442
(lp31544
(dp31545
g17436
I173
sg17437
Vfurcation defects
p31546
sg17438
I17
sg17445
VC0206306
p31547
sg17441
I2
sa(dp31548
g17436
I202
sg17437
Vchronic periodontitis
p31549
sg17438
I21
sg17445
VC0266929
p31550
sg17441
I2
sasa(dp31551
g135
(dp31552
(VBMP 7
p31553
Vperiodontitis
p31554
tp31555
I00
ssg17431
VBone morphogenetic protein-7 (BMP 7) induces cementogenesis in periodontitis-associated periodontal ligament (PDL) defects.
p31556
sg17433
(lp31557
(dp31558
g17436
I0
sg17437
VBone morphogenetic protein-7
p31559
sg17438
I28
sg17439
VP18075
p31560
sg17441
I3
sa(dp31561
g17436
I30
sg17437
g31553
sg17438
I5
sg17439
VP18075
p31562
sg17441
I2
sasg17442
(lp31563
(dp31564
g17436
I63
sg17437
g31554
sg17438
I13
sg17445
VC0031099
p31565
sg17441
I1
sasa(dp31566
g17431
VBoth KRT19 and ANXA8 mRNA may be useful markers for detecting lymph node metastases in OSCC patients.
p31567
sg17433
(lp31568
(dp31569
g17436
I15
sg17437
VANXA8 mRNA
p31570
sg17438
I10
sg17439
VP13928
p31571
sg17441
I2
sasg17442
(lp31572
(dp31573
g17436
I62
sg17437
Vlymph node metastases
p31574
sg17438
I21
sg17445
VC0686619
p31575
sg17441
I3
sasa(dp31576
g135
(dp31577
(Vv-RAF murine sarcoma viral oncogene homolog B1
p31578
Vglioblastomas
p31579
tp31580
I00
ssg17431
VNone of the NF1 glioblastomas harbored isocitrate dehydrogenase 1 (IDH1) gene mutation, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation, and telomerase reverse transcriptase (TERT) gene promoter mutation.
p31581
sg17433
(lp31582
(dp31583
g17436
I161
sg17437
Vtelomerase reverse transcriptase
p31584
sg17438
I32
sg17439
g12
sg17441
I3
sa(dp31585
g17436
I39
sg17437
Visocitrate dehydrogenase 1
p31586
sg17438
I26
sg17439
VP48735
p31587
sg17441
I3
sa(dp31588
g17436
I136
sg17437
VBRAF
p31589
sg17438
I4
sg17439
VP15056
p31590
sg17441
I1
sa(dp31591
g17436
I67
sg17437
VIDH1
p31592
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp31593
g17436
I195
sg17437
VTERT
p31594
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp31595
g17436
I12
sg17437
VNF1 glioblastomas
p31596
sg17438
I17
sg17439
VP21359
p31597
sg17441
I2
sa(dp31598
g17436
I88
sg17437
g31578
sg17438
I46
sg17439
VP15056
p31599
sg17441
I7
sasg17442
(lp31600
(dp31601
g17436
I101
sg17437
Vsarcoma
p31602
sg17438
I7
sg17445
VC1261473
p31603
sg17441
I1
sa(dp31604
g17436
I12
sg17437
VNF1
p31605
sg17438
I3
sg17445
VC0027831
p31606
sg17441
I1
sa(dp31607
g17436
I16
sg17437
g31579
sg17438
I13
sg17445
VC0017636
p31608
sg17441
I1
sasa(dp31609
g135
(dp31610
(VSomatic v-Raf murine sarcoma viral oncogene homolog B
p31611
Vmetastatic colorectal cancer
p31612
tp31613
I00
ssg17431
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p31614
sg17433
(lp31615
(dp31616
g17436
I55
sg17437
VBRAF
p31617
sg17438
I4
sg17439
VP15056
p31618
sg17441
I1
sa(dp31619
g17436
I0
sg17437
g31611
sg17438
I53
sg17439
VP04049
p31620
sg17441
I8
sasg17442
(lp31621
(dp31622
g17436
I21
sg17437
Vsarcoma
p31623
sg17438
I7
sg17445
VC1261473
p31624
sg17441
I1
sa(dp31625
g17436
I133
sg17437
VmCRC
p31626
sg17438
I4
sg17445
VC0948380
p31627
sg17441
I1
sa(dp31628
g17436
I103
sg17437
g31612
sg17438
I28
sg17445
VC0948380
p31629
sg17441
I3
sasa(dp31630
g135
(dp31631
(VBRAF
p31632
Vcolorectal cancer
p31633
tp31634
I00
ssg17431
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p31635
sg17433
(lp31636
(dp31637
g17436
I42
sg17437
g31632
sg17438
I4
sg17439
VP15056
p31638
sg17441
I1
sasg17442
(lp31639
(dp31640
g17436
I4
sg17437
g31633
sg17438
I17
sg17445
VC1527249
p31641
sg17441
I2
sasa(dp31642
g135
(dp31643
(Vserine/threonine-protein kinase b-raf
p31644
VNSCLC
p31645
tp31646
I00
ssg17431
VWe highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins.
p31647
sg17433
(lp31648
(dp31649
g17436
I333
sg17437
VBRAF
p31650
sg17438
I4
sg17439
VP15056
p31651
sg17441
I1
sa(dp31652
g17436
I241
sg17437
VROS1 proto-oncogene receptor tyrosine kinase
p31653
sg17438
I44
sg17439
VP29401
p31654
sg17441
I5
sa(dp31655
g17436
I200
sg17437
VEGFR
p31656
sg17438
I4
sg17439
VP01133
p31657
sg17441
I1
sa(dp31658
g17436
I241
sg17437
VROS1
p31659
sg17438
I4
sg17439
VP08922
p31660
sg17441
I1
sa(dp31661
g17436
I166
sg17437
Vepidermal growth factor receptor
p31662
sg17438
I32
sg17439
VP01133
p31663
sg17441
I4
sa(dp31664
g17436
I294
sg17437
g31644
sg17438
I37
sg17439
VP15056
p31665
sg17441
I3
sa(dp31666
g17436
I235
sg17437
VALK
p31667
sg17438
I3
sg17439
g12
sg17441
I1
sa(dp31668
g17436
I207
sg17437
Vanaplastic lymphoma kinase
p31669
sg17438
I26
sg17439
g12
sg17441
I3
sasg17442
(lp31670
(dp31671
g17436
I207
sg17437
Vanaplastic lymphoma
p31672
sg17438
I19
sg17445
VC1321546
p31673
sg17441
I2
sa(dp31674
g17436
I104
sg17437
g31645
sg17438
I5
sg17445
VC0007131
p31675
sg17441
I1
sasa(dp31676
g135
(dp31677
(VMEK
p31678
Vsarcoma
p31679
tp31680
I00
ssg17431
VHere, we investigated the response of normal human keratinocytes to the MEK inhibitors trametinib and cobimetinib, alone and in combination with the v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors dabrafenib and vemurafenib, in terms of signal transduction and de novo gene expression.
p31681
sg17433
(lp31682
(dp31683
g17436
I196
sg17437
VBRAF
p31684
sg17438
I4
sg17439
VP15056
p31685
sg17441
I1
sa(dp31686
g17436
I149
sg17437
Vv-Raf murine sarcoma viral oncogene homolog B
p31687
sg17438
I45
sg17439
VP04049
p31688
sg17441
I7
sa(dp31689
g17436
I72
sg17437
g31678
sg17438
I3
sg17439
VP45985
p31690
sg17441
I1
sasg17442
(lp31691
(dp31692
g17436
I162
sg17437
g31679
sg17438
I7
sg17445
VC1261473
p31693
sg17441
I1
sasa(dp31694
g135
(dp31695
(Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p31696
Vsarcoma
p31697
tp31698
I00
ssg17431
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p31699
sg17433
(lp31700
(dp31701
g17436
I45
sg17437
g31696
sg17438
I92
sg17439
VP15056
p31702
sg17441
I13
sasg17442
(lp31703
(dp31704
g17436
I132
sg17437
VmCRC
p31705
sg17438
I4
sg17445
VC0948380
p31706
sg17441
I1
sa(dp31707
g17436
I102
sg17437
Vmetastatic colorectal cancer
p31708
sg17438
I28
sg17445
VC0948380
p31709
sg17441
I3
sa(dp31710
g17436
I58
sg17437
g31697
sg17438
I7
sg17445
VC1261473
p31711
sg17441
I1
sasa(dp31712
g135
(dp31713
(VKRAS
p31714
Vneuroblastoma
p31715
tp31716
I00
ssg17431
VKirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and BRAF mutational status was assayed using direct sequencing.
p31717
sg17433
(lp31718
(dp31719
g17436
I104
sg17437
VBRAF
p31720
sg17438
I4
sg17439
VP15056
p31721
sg17441
I1
sa(dp31722
g17436
I51
sg17437
Vneuroblastoma RAS viral oncogene homolog
p31723
sg17438
I40
sg17439
VP01116
p31724
sg17441
I5
sa(dp31725
g17436
I0
sg17437
VKirsten rat sarcoma viral oncogene homolog
p31726
sg17438
I42
sg17439
VP35125
p31727
sg17441
I6
sa(dp31728
g17436
I93
sg17437
VNRAS
p31729
sg17438
I4
sg17439
VP01111
p31730
sg17441
I1
sa(dp31731
g17436
I44
sg17437
g31714
sg17438
I4
sg17439
VP01116
p31732
sg17441
I1
sasg17442
(lp31733
(dp31734
g17436
I51
sg17437
g31715
sg17438
I13
sg17445
VC0027819
p31735
sg17441
I1
sa(dp31736
g17436
I8
sg17437
Vrat sarcoma
p31737
sg17438
I11
sg17445
VC1882848
p31738
sg17441
I2
sasa(dp31739
g135
(dp31740
(VBRAF
p31741
V'addiction
p31742
tp31743
I00
ssg17431
VWe performed an unbiased CRISPR-Cas9 knockout screen on melanoma cells that were both resistant and addicted to inhibition of the serine/threonine-protein kinase BRAF, in order to functionally mine their genome for 'addiction genes'.
p31744
sg17433
(lp31745
(dp31746
g17436
I130
sg17437
Vserine/threonine-protein kinase
p31747
sg17438
I31
sg17439
g12
sg17441
I2
sa(dp31748
g17436
I162
sg17437
g31741
sg17438
I4
sg17439
VP15056
p31749
sg17441
I1
sasg17442
(lp31750
(dp31751
g17436
I56
sg17437
Vmelanoma
p31752
sg17438
I8
sg17445
VC0025202
p31753
sg17441
I1
sa(dp31754
g17436
I215
sg17437
g31742
sg17438
I10
sg17445
VC0085281
p31755
sg17441
I1
sasa(dp31756
g135
(dp31757
(VAXL
p31758
Vmelanoma
p31759
tp31760
I00
ssg17431
VIn patients with melanoma that had progressed during treatment with a BRAF inhibitor, treatment cessation was followed by increased expression of the receptor tyrosine kinase AXL, which is associated with the phenotype switch.
p31761
sg17433
(lp31762
(dp31763
g17436
I150
sg17437
Vreceptor tyrosine kinase
p31764
sg17438
I24
sg17439
VP29401
p31765
sg17441
I3
sa(dp31766
g17436
I70
sg17437
VBRAF
p31767
sg17438
I4
sg17439
VP15056
p31768
sg17441
I1
sa(dp31769
g17436
I175
sg17437
g31758
sg17438
I3
sg17439
VP30530
p31770
sg17441
I1
sasg17442
(lp31771
(dp31772
g17436
I17
sg17437
g31759
sg17438
I8
sg17445
VC0025202
p31773
sg17441
I1
sasa(dp31774
g135
(dp31775
(Vmitogen-activated protein kinase
p31776
Vgangliogliomas
p31777
tp31778
I00
ssg17431
Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant anaplastic xanthoastrocytomas and gangliogliomas may benefit from BRAF and mitogen-activated protein kinase inhibitors.
p31779
sg17433
(lp31780
(dp31781
g17436
I0
sg17437
Vv-raf murine sarcoma viral oncogene homolog B1
p31782
sg17438
I46
sg17439
VP15056
p31783
sg17441
I7
sa(dp31784
g17436
I48
sg17437
VBRAF
p31785
sg17438
I4
sg17439
VP15056
p31786
sg17441
I1
sa(dp31787
g17436
I48
sg17437
VBRAF
p31788
sg17438
I4
sg17439
VP15056
p31789
sg17441
I1
sa(dp31790
g17436
I136
sg17437
g31776
sg17438
I32
sg17439
VP53779
p31791
sg17441
I3
sasg17442
(lp31792
(dp31793
g17436
I13
sg17437
Vsarcoma
p31794
sg17438
I7
sg17445
VC1261473
p31795
sg17441
I1
sa(dp31796
g17436
I54
sg17437
Vmutant
p31797
sg17438
I6
sg17445
VC0596988
p31798
sg17441
I1
sa(dp31799
g17436
I95
sg17437
g31777
sg17438
I14
sg17445
VC0206716
p31800
sg17441
I1
sasa(dp31801
g135
(dp31802
(Vproto-oncogene B-raf
p31803
VNSCLC
p31804
tp31805
I00
ssg17431
VMutations in the proto-oncogene B-raf (BRAF) occur in approximately 3% of NSCLC cases.
p31806
sg17433
(lp31807
(dp31808
g17436
I39
sg17437
VBRAF
p31809
sg17438
I4
sg17439
VP15056
p31810
sg17441
I1
sa(dp31811
g17436
I17
sg17437
g31803
sg17438
I20
sg17439
VP15056
p31812
sg17441
I2
sasg17442
(lp31813
(dp31814
g17436
I74
sg17437
g31804
sg17438
I5
sg17445
VC0007131
p31815
sg17441
I1
sasa(dp31816
g17431
VTo our knowledge, this is only the second well-documented case of gastrointestinal metastasis from BRAF-mutated lung cancer.
p31817
sg17433
(lp31818
sg17442
(lp31819
(dp31820
g17436
I83
sg17437
Vmetastasis
p31821
sg17438
I10
sg17445
VC0027627
p31822
sg17441
I1
sa(dp31823
g17436
I112
sg17437
Vlung cancer
p31824
sg17438
I11
sg17445
VC0684249
p31825
sg17441
I2
sasa(dp31826
g135
(dp31827
(Vepidermal growth factor receptor
p31828
Vanaplastic lymphoma
p31829
tp31830
I00
ssg17431
VChanges in the epidermal growth factor receptor (EGFR) gene, Kirsten rat sarcoma viral oncogene (KRAS), v-Raf murine sarcoma viral oncogene homolog B (BRAF), gene encoding neurofibromin (NF1), anaplastic lymphoma kinase (ALK) and ROS1 are the main genes that suffer alterations in the tumors of patients with ADC.
p31831
sg17433
(lp31832
(dp31833
g17436
I187
sg17437
VNF1
p31834
sg17438
I3
sg17439
VP21359
p31835
sg17441
I1
sa(dp31836
g17436
I104
sg17437
Vv-Raf murine sarcoma viral oncogene homolog B
p31837
sg17438
I45
sg17439
VP04049
p31838
sg17441
I7
sa(dp31839
g17436
I230
sg17437
VROS1
p31840
sg17438
I4
sg17439
VP08922
p31841
sg17441
I1
sa(dp31842
g17436
I97
sg17437
VKRAS
p31843
sg17438
I4
sg17439
VP01116
p31844
sg17441
I1
sa(dp31845
g17436
I61
sg17437
VKirsten rat sarcoma viral oncogene
p31846
sg17438
I34
sg17439
VP35125
p31847
sg17441
I5
sa(dp31848
g17436
I172
sg17437
Vneurofibromin
p31849
sg17438
I13
sg17439
VP21359
p31850
sg17441
I1
sa(dp31851
g17436
I49
sg17437
VEGFR
p31852
sg17438
I4
sg17439
VP01133
p31853
sg17441
I1
sa(dp31854
g17436
I151
sg17437
VBRAF
p31855
sg17438
I4
sg17439
VP15056
p31856
sg17441
I1
sa(dp31857
g17436
I15
sg17437
g31828
sg17438
I32
sg17439
VP01133
p31858
sg17441
I4
sasg17442
(lp31859
(dp31860
g17436
I187
sg17437
VNF1
p31861
sg17438
I3
sg17445
VC0027831
p31862
sg17441
I1
sa(dp31863
g17436
I69
sg17437
Vrat sarcoma
p31864
sg17438
I11
sg17445
VC1882848
p31865
sg17441
I2
sa(dp31866
g17436
I73
sg17437
Vsarcoma
p31867
sg17438
I7
sg17445
VC1261473
p31868
sg17441
I1
sa(dp31869
g17436
I259
sg17437
Vsuffer
p31870
sg17438
I6
sg17445
VC0683278
p31871
sg17441
I1
sa(dp31872
g17436
I285
sg17437
Vtumors
p31873
sg17438
I6
sg17445
VC0027651
p31874
sg17441
I1
sa(dp31875
g17436
I193
sg17437
g31829
sg17438
I19
sg17445
VC1321546
p31876
sg17441
I2
sasa(dp31877
g17431
VFor example, "Mongolism" was changed to Down's syndrome; "Australia" antigen to HBsAg; "Mexican" Swine flu to H1N1; "GRID" (Gay Related Immune Deficiency) and 4H-Disease (Haitians, Homosexuals, Haemophiliacs and Heroin Users Disease) to AIDS.
p31878
sg17433
(lp31879
sg17442
(lp31880
(dp31881
g17436
I40
sg17437
VDown's syndrome
p31882
sg17438
I15
sg17445
VC0013080
p31883
sg17441
I2
sa(dp31884
g17436
I14
sg17437
VMongolism
p31885
sg17438
I9
sg17445
VC0013080
p31886
sg17441
I1
sa(dp31887
g17436
I97
sg17437
VSwine flu
p31888
sg17438
I9
sg17445
VC2076600
p31889
sg17441
I2
sa(dp31890
g17436
I136
sg17437
VImmune Deficiency
p31891
sg17438
I17
sg17445
VC0850497
p31892
sg17441
I2
sasa(dp31893
g17431
VWHEN IT WAS CALLED 'GRID': One year ago today, I told my colleagues that I was dying of AIDS.
p31894
sg17433
(lp31895
sg17442
(lp31896
sa(dp31897
g135
(dp31898
(VAPL
p31899
VAPL
p31900
tp31901
I00
ssg17431
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and comedication with proton-pump inhibitors.
p31902
sg17433
(lp31903
(dp31904
g17436
I0
sg17437
g31899
sg17438
I3
sg17439
VP10276
p31905
sg17441
I1
sasg17442
(lp31906
(dp31907
g17436
I53
sg17437
Vcystic fibrosis
p31908
sg17438
I15
sg17445
VC0010674
p31909
sg17441
I2
sa(dp31910
g17436
I0
sg17437
g31900
sg17438
I3
sg17445
VC0023487
p31911
sg17441
I1
sasa(dp31912
g17431
VDMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.
p31913
sg17433
(lp31914
(dp31915
g17436
I12
sg17437
VMEN1
p31916
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp31917
(dp31918
g17436
I47
sg17437
Vneuroendocrine tumor
p31919
sg17438
I20
sg17445
VC0206754
p31920
sg17441
I2
sa(dp31921
g17436
I85
sg17437
Vpancreatic neuroendocrine tumor
p31922
sg17438
I31
sg17445
VC1337011
p31923
sg17441
I3
sa(dp31924
g17436
I12
sg17437
VMEN1
p31925
sg17438
I4
sg17445
VC0025267
p31926
sg17441
I1
sa(dp31927
g17436
I180
sg17437
Vmultiple endocrine neoplasia type 1
p31928
sg17438
I35
sg17445
VC0025267
p31929
sg17441
I5
sa(dp31930
g17436
I47
sg17437
Vneuroendocrine tumor
p31931
sg17438
I20
sg17445
VC0206754
p31932
sg17441
I2
sa(dp31933
g17436
I47
sg17437
Vneuroendocrine tumor
p31934
sg17438
I20
sg17445
VC0206754
p31935
sg17441
I2
sasa(dp31936
g135
(dp31937
(VAPL
p31938
VAPL
p31939
tp31940
I00
ssg17431
VAPL are significantly influenced by azole dose, age, cystic fibrosis, type of LTx, and co-medication with proton-pump inhibitors.
p31941
sg17433
(lp31942
(dp31943
g17436
I0
sg17437
g31938
sg17438
I3
sg17439
VP10276
p31944
sg17441
I1
sasg17442
(lp31945
(dp31946
g17436
I53
sg17437
Vcystic fibrosis
p31947
sg17438
I15
sg17445
VC0010674
p31948
sg17441
I2
sa(dp31949
g17436
I0
sg17437
g31939
sg17438
I3
sg17445
VC0023487
p31950
sg17441
I1
sasa(dp31951
g17431
VIn both cases, the diagnosis of multiple endocrine neoplasia type 1 was made after proton pump therapy was discontinued.
p31952
sg17433
(lp31953
sg17442
(lp31954
(dp31955
g17436
I32
sg17437
Vmultiple endocrine neoplasia type 1
p31956
sg17438
I35
sg17445
VC0025267
p31957
sg17441
I5
sasa(dp31958
g17431
VClinical assessment for features of multiple endocrine neoplasia type 1 (eg, serum calcium levels, personal and family history of hypercalcemia, pituitary or pancreatic tumors) could identify patients with higher risk for a tumoral source of hypergastrinemia where imaging studies can help support the diagnosis without the potential side effects of abrupt discontinuation of proton pump inhibitor therapy.
p31959
sg17433
(lp31960
sg17442
(lp31961
(dp31962
g17436
I36
sg17437
Vmultiple endocrine neoplasia type 1
p31963
sg17438
I35
sg17445
VC0025267
p31964
sg17441
I5
sa(dp31965
g17436
I130
sg17437
Vhypercalcemia
p31966
sg17438
I13
sg17445
VC0020437
p31967
sg17441
I1
sa(dp31968
g17436
I158
sg17437
Vpancreatic tumors
p31969
sg17438
I17
sg17445
VC0030297
p31970
sg17441
I2
sasa(dp31971
g17431
VNo correlation was detected between Ki-67 values of HGPs in CLD patients and the presence of portal hypertension, infection with Helicobacter pylori, or proton pump inhibitor use.
p31972
sg17433
(lp31973
sg17442
(lp31974
(dp31975
g17436
I93
sg17437
Vportal hypertension
p31976
sg17438
I19
sg17445
VC0020541
p31977
sg17441
I2
sa(dp31978
g17436
I52
sg17437
VHGPs
p31979
sg17438
I4
sg17445
VC0033300
p31980
sg17441
I1
sa(dp31981
g17436
I114
sg17437
Vinfection
p31982
sg17438
I9
sg17445
VC0009450
p31983
sg17441
I1
sa(dp31984
g17436
I60
sg17437
VCLD
p31985
sg17438
I3
sg17445
VC0746102
p31986
sg17441
I1
sasa(dp31987
g135
(dp31988
(VTUBA4A
p31989
VFTD
p31990
tp31991
I00
ssg17431
VMutation screening and phenotypic profiling of 2 amyotrophic lateral sclerosis-(ALS) and frontotemporal dementia-(FTD) associated genes, CHCHD10 and TUBA4A, were performed in a Belgian cohort of 459 FTD, 28 FTD-ALS, and 429 ALS patients.
p31992
sg17433
(lp31993
(dp31994
g17436
I137
sg17437
VCHCHD10
p31995
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp31996
g17436
I149
sg17437
g31989
sg17438
I6
sg17439
VP68366
p31997
sg17441
I1
sasg17442
(lp31998
(dp31999
g17436
I207
sg17437
VFTD-ALS
p32000
sg17438
I7
sg17445
VC1862937
p32001
sg17441
I1
sa(dp32002
g17436
I114
sg17437
VFTD
p32003
sg17438
I3
sg17445
VC0338451
p32004
sg17441
I1
sa(dp32005
g17436
I49
sg17437
Vamyotrophic lateral sclerosis
p32006
sg17438
I29
sg17445
VC0002736
p32007
sg17441
I3
sa(dp32008
g17436
I80
sg17437
VALS
p32009
sg17438
I3
sg17445
VC0002736
p32010
sg17441
I1
sa(dp32011
g17436
I80
sg17437
VALS
p32012
sg17438
I3
sg17445
VC0002736
p32013
sg17441
I1
sa(dp32014
g17436
I89
sg17437
Vfrontotemporal dementia
p32015
sg17438
I23
sg17445
VC0338451
p32016
sg17441
I2
sa(dp32017
g17436
I114
sg17437
g31990
sg17438
I3
sg17445
VC0338451
p32018
sg17441
I1
sasa(dp32019
g135
(dp32020
(VTUBA4A
p32021
VParkinson's disease
p32022
tp32023
I00
ssg17431
VIn TUBA4A, we detected a novel frameshift mutation (p.Arg64Glyfs*90) leading to a truncated protein in 1 FTD patient (1/459 of 0.22%) with family history of Parkinson's disease and cognitive impairment, and a novel missense mutation (p.Thr381Met) in 2 sibs with familial ALS and memory problems (1 index patient/429, 0.23%) in whom we previously identified a pathogenic Chromosome 9 open reading frame 72 repeat expansion mutation.
p32024
sg17433
(lp32025
(dp32026
g17436
I3
sg17437
g32021
sg17438
I6
sg17439
VP68366
p32027
sg17441
I1
sasg17442
(lp32028
(dp32029
g17436
I105
sg17437
VFTD
p32030
sg17438
I3
sg17445
VC0338451
p32031
sg17441
I1
sa(dp32032
g17436
I31
sg17437
Vframeshift mutation
p32033
sg17438
I19
sg17445
VC0079380
p32034
sg17441
I2
sa(dp32035
g17436
I181
sg17437
Vcognitive impairment
p32036
sg17438
I20
sg17445
VC0338656
p32037
sg17441
I2
sa(dp32038
g17436
I279
sg17437
Vmemory problems
p32039
sg17438
I15
sg17445
VC0233794
p32040
sg17441
I2
sa(dp32041
g17436
I271
sg17437
VALS
p32042
sg17438
I3
sg17445
VC0002736
p32043
sg17441
I1
sa(dp32044
g17436
I157
sg17437
g32022
sg17438
I19
sg17445
VC0030567
p32045
sg17441
I2
sasa(dp32046
g135
(dp32047
(VTUBA4A
p32048
VParkinson's disease
p32049
tp32050
I00
ssg17431
VThe present study confirms the role of CHCHD10 and TUBA4A in the FTD-ALS spectrum, although genetic variations in these 2 genes are extremely rare in the Belgian population and often associated with symptomatology of related neurodegenerative diseases including Parkinson's disease and Alzheimer's disease.
p32051
sg17433
(lp32052
(dp32053
g17436
I51
sg17437
g32048
sg17438
I6
sg17439
VP68366
p32054
sg17441
I1
sa(dp32055
g17436
I39
sg17437
VCHCHD10
p32056
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp32057
(dp32058
g17436
I225
sg17437
Vneurodegenerative diseases
p32059
sg17438
I26
sg17445
VC0524851
p32060
sg17441
I2
sa(dp32061
g17436
I262
sg17437
g32049
sg17438
I19
sg17445
VC0030567
p32062
sg17441
I2
sa(dp32063
g17436
I65
sg17437
VFTD-ALS
p32064
sg17438
I7
sg17445
VC1862937
p32065
sg17441
I1
sa(dp32066
g17436
I286
sg17437
VAlzheimer's disease
p32067
sg17438
I19
sg17445
VC1521724
p32068
sg17441
I2
sasa(dp32069
g135
(dp32070
(Vtubulin alpha 4a
p32071
Vamyotrophic lateral sclerosis
p32072
tp32073
I00
ssg17431
VThe tubulin alpha 4a (TUBA4A) gene has been recently associated with amyotrophic lateral sclerosis.
p32074
sg17433
(lp32075
(dp32076
g17436
I22
sg17437
VTUBA4A
p32077
sg17438
I6
sg17439
VP68366
p32078
sg17441
I1
sa(dp32079
g17436
I4
sg17437
g32071
sg17438
I16
sg17439
VP68366
p32080
sg17441
I3
sasg17442
(lp32081
(dp32082
g17436
I69
sg17437
g32072
sg17438
I29
sg17445
VC0002736
p32083
sg17441
I3
sasa(dp32084
g135
(dp32085
(VTUBA4A gene
p32086
VALS
p32087
tp32088
I00
ssg17431
VTUBA4A gene has recently been identified as a potential candidate amyotrophic lateral sclerosis(ALS)-associated gene using exome-wide rare variant burden analysis.
p32089
sg17433
(lp32090
(dp32091
g17436
I0
sg17437
g32086
sg17438
I11
sg17439
VP68366
p32092
sg17441
I2
sasg17442
(lp32093
(dp32094
g17436
I66
sg17437
Vamyotrophic lateral sclerosis
p32095
sg17438
I29
sg17445
VC0002736
p32096
sg17441
I3
sa(dp32097
g17436
I96
sg17437
g32087
sg17438
I3
sg17445
VC0002736
p32098
sg17441
I1
sasa(dp32099
g17431
VHere we studied the physiological function of CLAC-P/collagen XXV, a transmembrane-type collagen originally identified as a component of senile plaque amyloid of Alzheimer's disease brains, by means of generating Col25a1-deficient (KO) mice.
p32100
sg17433
(lp32101
(dp32102
g17436
I46
sg17437
VCLAC-P
p32103
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp32104
g17436
I213
sg17437
VCol25a1
p32105
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp32106
(dp32107
g17436
I151
sg17437
Vamyloid
p32108
sg17438
I7
sg17445
VC0011560
p32109
sg17441
I1
sa(dp32110
g17436
I137
sg17437
Vsenile plaque
p32111
sg17438
I13
sg17445
VC0333463
p32112
sg17441
I2
sa(dp32113
g17436
I162
sg17437
VAlzheimer's disease
p32114
sg17438
I19
sg17445
VC1521724
p32115
sg17441
I2
sasa(dp32116
g135
(dp32117
(Vcollagenous type II transmembrane protein
p32118
Vsenile plaques
p32119
tp32120
I00
ssg17431
VCollagen XXV alpha 1 (COL25A1) is a collagenous type II transmembrane protein purified from senile plaques of Alzheimer's disease (AD) brains.
p32121
sg17433
(lp32122
(dp32123
g17436
I0
sg17437
VCollagen XXV alpha 1
p32124
sg17438
I20
sg17439
VP25100
p32125
sg17441
I4
sa(dp32126
g17436
I36
sg17437
g32118
sg17438
I41
sg17439
VP27037
p32127
sg17441
I5
sa(dp32128
g17436
I22
sg17437
VCOL25A1
p32129
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp32130
(dp32131
g17436
I131
sg17437
VAD
p32132
sg17438
I2
sg17445
VC1521724
p32133
sg17441
I1
sa(dp32134
g17436
I92
sg17437
g32119
sg17438
I14
sg17445
VC0333463
p32135
sg17441
I2
sa(dp32136
g17436
I110
sg17437
VAlzheimer's disease
p32137
sg17438
I19
sg17445
VC1521724
p32138
sg17441
I2
sasa(dp32139
g17431
VThe COL25A1 gene, located in 4q25, encodes the CLAC protein, which has been implicated in Alzheimer's disease (AD) pathogenesis.
p32140
sg17433
(lp32141
(dp32142
g17436
I47
sg17437
VCLAC protein
p32143
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp32144
g17436
I4
sg17437
VCOL25A1 gene
p32145
sg17438
I12
sg17439
g12
sg17441
I2
sasg17442
(lp32146
(dp32147
g17436
I115
sg17437
Vpathogenesis
p32148
sg17438
I12
sg17445
VC0699748
p32149
sg17441
I1
sa(dp32150
g17436
I111
sg17437
VAD
p32151
sg17438
I2
sg17445
VC1521724
p32152
sg17441
I1
sa(dp32153
g17436
I90
sg17437
VAlzheimer's disease
p32154
sg17438
I19
sg17445
VC1521724
p32155
sg17441
I2
sasa(dp32156
g17431
VThus, in addition to the biochemical data, there is now genetic evidence of association between COL25A1 and risk for Alzheimer's disease.
p32157
sg17433
(lp32158
(dp32159
g17436
I96
sg17437
VCOL25A1
p32160
sg17438
I7
sg17439
g12
sg17441
I1
sasg17442
(lp32161
(dp32162
g17436
I117
sg17437
VAlzheimer's disease
p32163
sg17438
I19
sg17445
VC1521724
p32164
sg17441
I2
sasa(dp32165
g17431
VRecently, a novel plaque-associated protein, collagenous Alzheimer amyloid plaque component (CLAC), was identified in brains from patients with Alzheimer's disease.
p32166
sg17433
(lp32167
sg17442
(lp32168
(dp32169
g17436
I67
sg17437
Vamyloid plaque
p32170
sg17438
I14
sg17445
VC0333463
p32171
sg17441
I2
sa(dp32172
g17436
I18
sg17437
Vplaque
p32173
sg17438
I6
sg17445
VC0011389
p32174
sg17441
I1
sa(dp32175
g17436
I144
sg17437
VAlzheimer's disease
p32176
sg17438
I19
sg17445
VC1521724
p32177
sg17441
I2
sasa(dp32178
g17431
VThe biological function and the contribution of CLAC to the pathogenesis of Alzheimer's disease and plaque formation are unknown.
p32179
sg17433
(lp32180
sg17442
(lp32181
(dp32182
g17436
I76
sg17437
VAlzheimer's disease
p32183
sg17438
I19
sg17445
VC1521724
p32184
sg17441
I2
sa(dp32185
g17436
I100
sg17437
Vplaque
p32186
sg17438
I6
sg17445
VC0011389
p32187
sg17441
I1
sa(dp32188
g17436
I60
sg17437
Vpathogenesis
p32189
sg17438
I12
sg17445
VC0699748
p32190
sg17441
I1
sasa(dp32191
g17431
VCLAC (collagenous Alzheimer amyloid plaque component) is a proteolytic fragment derived from a novel membrane-bound collagen, CLAC-P/collagen type XXV, that deposits in senile plaques associated with amyloid beta peptides (Abeta) in the brains of patients with Alzheimer's disease.
p32192
sg17433
(lp32193
(dp32194
g17436
I200
sg17437
Vamyloid beta peptides
p32195
sg17438
I21
sg17439
g12
sg17441
I3
sa(dp32196
g17436
I126
sg17437
VCLAC-P
p32197
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp32198
g17436
I223
sg17437
VAbeta
p32199
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp32200
(dp32201
g17436
I28
sg17437
Vamyloid plaque
p32202
sg17438
I14
sg17445
VC0333463
p32203
sg17441
I2
sa(dp32204
g17436
I169
sg17437
Vsenile plaques
p32205
sg17438
I14
sg17445
VC0333463
p32206
sg17441
I2
sa(dp32207
g17436
I28
sg17437
Vamyloid
p32208
sg17438
I7
sg17445
VC0011560
p32209
sg17441
I1
sa(dp32210
g17436
I261
sg17437
VAlzheimer's disease
p32211
sg17438
I19
sg17445
VC1521724
p32212
sg17441
I2
sasa(dp32213
g17431
VThese results suggest the anti-amyloidogenic roles of CLAC in the pathophysiology of Alzheimer's disease.
p32214
sg17433
(lp32215
(dp32216
g17436
I54
sg17437
VCLAC
p32217
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp32218
(dp32219
g17436
I85
sg17437
VAlzheimer's disease
p32220
sg17438
I19
sg17445
VC1521724
p32221
sg17441
I2
sasa(dp32222
g17431
VThe analysis of breast cancer and pancreatic cancer data further shows iSPCA's satisfactory performance.
p32223
sg17433
(lp32224
sg17442
(lp32225
(dp32226
g17436
I16
sg17437
Vbreast cancer
p32227
sg17438
I13
sg17445
VC0678222
p32228
sg17441
I2
sa(dp32229
g17436
I34
sg17437
Vpancreatic cancer
p32230
sg17438
I17
sg17445
VC0235974
p32231
sg17441
I2
sasa(dp32232
g17431
VTissue factor (TF) is a transmembrane receptor for coagulation factor VII/VIIa and is frequently overexpressed by cancer cells.
p32233
sg17433
(lp32234
(dp32235
g17436
I51
sg17437
Vcoagulation factor VII
p32236
sg17438
I22
sg17439
VP08709
p32237
sg17441
I3
sasg17442
(lp32238
(dp32239
g17436
I114
sg17437
Vcancer
p32240
sg17438
I6
sg17445
VC0006826
p32241
sg17441
I1
sasa(dp32242
g17431
VTo identify the location of missed significant prostate cancer (sPCa) lesions by transrectal ultrasound-guided biopsy (TRUSbx) and multiparametric magnetic resonance imaging-guided biopsy (mpMRIbx) in men undergoing repeat biopsies.
p32243
sg17433
(lp32244
sg17442
(lp32245
(dp32246
g17436
I47
sg17437
Vprostate cancer
p32247
sg17438
I15
sg17445
VC0600139
p32248
sg17441
I2
sasa(dp32249
g135
(dp32250
(VsPCa
p32251
Vprostate cancer
p32252
tp32253
I00
ssg17431
VOf the 289 patients, prostate cancer was detected in 128 (44%) with 88 (30%) having sPCa.
p32254
sg17433
(lp32255
(dp32256
g17436
I84
sg17437
g32251
sg17438
I4
sg17439
VP08709
p32257
sg17441
I1
sasg17442
(lp32258
(dp32259
g17436
I21
sg17437
g32252
sg17438
I15
sg17445
VC0600139
p32260
sg17441
I2
sasa(dp32261
g17431
VOverall, 165 separate prostate cancer lesions were detected with 100 being sPCa.
p32262
sg17433
(lp32263
sg17442
(lp32264
(dp32265
g17436
I22
sg17437
Vprostate cancer
p32266
sg17438
I15
sg17445
VC0600139
p32267
sg17441
I2
sasa(dp32268
g135
(dp32269
(Vserine protease
p32270
Vthrombosis
p32271
tp32272
I00
ssg17431
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p32273
sg17433
(lp32274
(dp32275
g17436
I0
sg17437
VFactor VII (FVII) activating protease
p32276
sg17438
I37
sg17439
VP08709
p32277
sg17441
I5
sa(dp32278
g17436
I39
sg17437
VFSAP
p32279
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp32280
g17436
I62
sg17437
g32270
sg17438
I15
sg17439
VP57727
p32281
sg17441
I2
sasg17442
(lp32282
(dp32283
g17436
I150
sg17437
Vstroke
p32284
sg17438
I6
sg17445
VC0038454
p32285
sg17441
I1
sa(dp32286
g17436
I158
sg17437
Vatherosclerosis
p32287
sg17438
I15
sg17445
VC0004153
p32288
sg17441
I1
sa(dp32289
g17436
I175
sg17437
Vliver fibrosis
p32290
sg17438
I14
sg17445
VC0239946
p32291
sg17441
I2
sa(dp32292
g17436
I206
sg17437
Vcancer
p32293
sg17438
I6
sg17445
VC0006826
p32294
sg17441
I1
sa(dp32295
g17436
I191
sg17437
g32271
sg17438
I10
sg17445
VC0040053
p32296
sg17441
I1
sasa(dp32297
g135
(dp32298
(Vthrombin
p32299
Vpancreatic cancer
p32300
tp32301
I00
ssg17431
VIn the absence of factor VII in platelet-free plasma, thrombin generation in solid pancreatic cancer cell lines was significantly reduced unlike in haematological cell lines.
p32302
sg17433
(lp32303
(dp32304
g17436
I54
sg17437
g32299
sg17438
I8
sg17439
VP00734
p32305
sg17441
I1
sasg17442
(lp32306
(dp32307
g17436
I83
sg17437
g32300
sg17438
I17
sg17445
VC0235974
p32308
sg17441
I2
sasa(dp32309
g135
(dp32310
(VSPCA gene
p32311
Vbreast cancer
p32312
tp32313
I00
ssg17431
VSPCA gene expression is significantly elevated in breast cancer subtypes that are associated with microcalcifications.
p32314
sg17433
(lp32315
(dp32316
g17436
I0
sg17437
g32311
sg17438
I9
sg17439
VP08709
p32317
sg17441
I2
sasg17442
(lp32318
(dp32319
g17436
I50
sg17437
g32312
sg17438
I13
sg17445
VC0678222
p32320
sg17441
I2
sa(dp32321
g17436
I98
sg17437
Vmicrocalcifications
p32322
sg17438
I19
sg17445
VC0521174
p32323
sg17441
I1
sasa(dp32324
g17431
VClinically significant cancer (SPCa) was defined as Gleason score &gt;=3 + 4.
p32325
sg17433
(lp32326
sg17442
(lp32327
(dp32328
g17436
I23
sg17437
Vcancer
p32329
sg17438
I6
sg17445
VC0006826
p32330
sg17441
I1
sasa(dp32331
g17431
VHeritable disorders of connective tissue (marfan syndrome, Ehlers-Danlos syndrome, adult polycystic kidney disease, floppy mitral valve/mitral valve prolapse); congenital heart disease (bicuspid aortic valve); inflammatory/immunologic disorders (rheumatic fever, AIDS, Kawasaki disease, syphilis, seronegative spondyloarthropathies, systemic lupus erythematosus, antiphospholipid syndrome); endocardial disorders (nonbacteremic thrombotic endocarditis, infective endocarditis, endomyocardial fibroelastosis); myocardial dysfunction (ischemic heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy); diseases and disorders of other organs (chronic renal failure, carcinoid heart disease); aging (calcific aortic stenosis, mitral annular calcification); postinterventional valvular disease; drugs and physical agents are all clinical entities associated with VHD.
p32332
sg17433
(lp32333
sg17442
(lp32334
(dp32335
g17436
I136
sg17437
Vmitral valve prolapse
p32336
sg17438
I21
sg17445
VC0026267
p32337
sg17441
I3
sa(dp32338
g17436
I533
sg17437
Vischemic heart disease
p32339
sg17438
I22
sg17445
VC0151744
p32340
sg17441
I3
sa(dp32341
g17436
I116
sg17437
Vfloppy mitral valve
p32342
sg17438
I19
sg17445
VC0026267
p32343
sg17441
I3
sa(dp32344
g17436
I160
sg17437
Vcongenital heart disease
p32345
sg17438
I24
sg17445
VC0152021
p32346
sg17441
I3
sa(dp32347
g17436
I565
sg17437
Vcardiomyopathy
p32348
sg17438
I14
sg17445
VC0878544
p32349
sg17441
I1
sa(dp32350
g17436
I186
sg17437
Vbicuspid aortic valve
p32351
sg17438
I21
sg17445
VC0149630
p32352
sg17441
I3
sa(dp32353
g17436
I223
sg17437
Vimmunologic disorders
p32354
sg17438
I21
sg17445
VC0021053
p32355
sg17441
I2
sa(dp32356
g17436
I611
sg17437
Vdiseases and disorders
p32357
sg17438
I22
sg17445
VC0012634
p32358
sg17441
I3
sa(dp32359
g17436
I477
sg17437
Vendomyocardial fibroelastosis
p32360
sg17438
I29
sg17445
VC0014117
p32361
sg17441
I2
sa(dp32362
g17436
I333
sg17437
Vsystemic lupus erythematosus
p32363
sg17438
I28
sg17445
VC0024141
p32364
sg17441
I3
sa(dp32365
g17436
I674
sg17437
Vcarcinoid heart disease
p32366
sg17438
I23
sg17445
VC0007093
p32367
sg17441
I3
sa(dp32368
g17436
I565
sg17437
Vcardiomyopathy, hypertrophic
p32369
sg17438
I28
sg17445
VC0007194
p32370
sg17441
I2
sa(dp32371
g17436
I723
sg17437
Vstenosis, mitral
p32372
sg17438
I16
sg17445
VC0026269
p32373
sg17441
I2
sa(dp32374
g17436
I439
sg17437
Vendocarditis, infective
p32375
sg17438
I23
sg17445
VC1541923
p32376
sg17441
I2
sa(dp32377
g17436
I310
sg17437
Vspondyloarthropathies
p32378
sg17438
I21
sg17445
VC0949691
p32379
sg17441
I1
sa(dp32380
g17436
I246
sg17437
Vrheumatic fever
p32381
sg17438
I15
sg17445
VC0035436
p32382
sg17441
I2
sa(dp32383
g17436
I439
sg17437
Vendocarditis
p32384
sg17438
I12
sg17445
VC0014118
p32385
sg17441
I1
sa(dp32386
g17436
I49
sg17437
Vsyndrome, Ehlers-Danlos
p32387
sg17438
I23
sg17445
VC0013720
p32388
sg17441
I2
sa(dp32389
g17436
I509
sg17437
Vmyocardial dysfunction
p32390
sg17438
I22
sg17445
VC0340515
p32391
sg17441
I2
sa(dp32392
g17436
I269
sg17437
VKawasaki disease
p32393
sg17438
I16
sg17445
VC0026691
p32394
sg17441
I2
sa(dp32395
g17436
I83
sg17437
Vadult polycystic kidney disease
p32396
sg17438
I31
sg17445
VC0085413
p32397
sg17441
I4
sa(dp32398
g17436
I651
sg17437
Vchronic renal failure
p32399
sg17438
I21
sg17445
VC0022661
p32400
sg17441
I3
sa(dp32401
g17436
I49
sg17437
Vsyndrome
p32402
sg17438
I8
sg17445
VC0039082
p32403
sg17441
I1
sa(dp32404
g17436
I363
sg17437
Vantiphospholipid syndrome
p32405
sg17438
I25
sg17445
VC0085278
p32406
sg17441
I2
sa(dp32407
g17436
I287
sg17437
Vsyphilis
p32408
sg17438
I8
sg17445
VC0039128
p32409
sg17441
I1
sasa(dp32410
g17431
VDescribed here is an autopsy case of a 61-year-old man with polycystic kidney disease who had P. multocida bacteremia and acute infective endocarditis with multiple bacterial clumps involving bicuspid aortic valve.
p32411
sg17433
(lp32412
sg17442
(lp32413
(dp32414
g17436
I192
sg17437
Vbicuspid aortic valve
p32415
sg17438
I21
sg17445
VC0149630
p32416
sg17441
I3
sa(dp32417
g17436
I107
sg17437
Vbacteremia
p32418
sg17438
I10
sg17445
VC0004610
p32419
sg17441
I1
sa(dp32420
g17436
I122
sg17437
Vacute infective endocarditis
p32421
sg17438
I28
sg17445
VC0155685
p32422
sg17441
I3
sa(dp32423
g17436
I60
sg17437
Vpolycystic kidney disease
p32424
sg17438
I25
sg17445
VC0022680
p32425
sg17441
I3
sasa(dp32426
g17431
VTwenty-five people with COPD + PC (mean (standard deviation (SD)) age 73 (11) years, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II-IV), 25 people with COPD (70 (8) years, GOLD stage II-IV) and 25 controls (70 (7) years) wore the SenseWear Pro3 Armband for 7 days.
p32427
sg17433
(lp32428
sg17442
(lp32429
(dp32430
g17436
I24
sg17437
VCOPD
p32431
sg17438
I4
sg17445
VC0024117
p32432
sg17441
I1
sa(dp32433
g17436
I141
sg17437
VGOLD
p32434
sg17438
I4
sg17445
VC0024117
p32435
sg17441
I1
sa(dp32436
g17436
I141
sg17437
VGOLD
p32437
sg17438
I4
sg17445
VC0024117
p32438
sg17441
I1
sa(dp32439
g17436
I85
sg17437
VGlobal Initiative for Chronic Obstructive Lung Disease
p32440
sg17438
I54
sg17445
VC0024117
p32441
sg17441
I7
sa(dp32442
g17436
I24
sg17437
VCOPD
p32443
sg17438
I4
sg17445
VC0024117
p32444
sg17441
I1
sasa(dp32445
g135
(dp32446
(VCD4+CD29+
p32447
Vatopic dermatitis
p32448
tp32449
I00
ssg17431
VPatients with severe atopic dermatitis had a decreased CD4+CD29+: CD4+CD45RA+ ratio (p &lt; 0.01).
p32450
sg17433
(lp32451
(dp32452
g17436
I66
sg17437
VCD4+CD45RA+
p32453
sg17438
I11
sg17439
VP01730
p32454
sg17441
I1
sa(dp32455
g17436
I55
sg17437
g32447
sg17438
I9
sg17439
VP01730
p32456
sg17441
I1
sasg17442
(lp32457
(dp32458
g17436
I21
sg17437
g32448
sg17438
I17
sg17445
VC0011615
p32459
sg17441
I2
sasa(dp32460
g135
(dp32461
(VCD4+CD45RA+
p32462
Vatopic dermatitis
p32463
tp32464
I00
ssg17431
VNo significant changes in the CD4+CD29+: CD4+CD45RA+ ratio were found in the peripheral blood of patients with clinically mild or moderate atopic dermatitis.
p32465
sg17433
(lp32466
(dp32467
g17436
I30
sg17437
VCD4+CD29+
p32468
sg17438
I9
sg17439
VP01730
p32469
sg17441
I1
sa(dp32470
g17436
I41
sg17437
g32462
sg17438
I11
sg17439
VP01730
p32471
sg17441
I1
sasg17442
(lp32472
(dp32473
g17436
I139
sg17437
g32463
sg17438
I17
sg17445
VC0011615
p32474
sg17441
I2
sasa(dp32475
g135
(dp32476
(Vperoxidase
p32477
Vatopic dermatitis
p32478
tp32479
I00
ssg17431
VTissue sections from the skin of patients with atopic dermatitis were investigated by means of hematoxylin-eosin staining, the avidin-biotin-peroxidase complex method, and double-labeling immunofluorescence using monoclonal antibodies to cell-surface antigens, including CD45R and CD29.
p32480
sg17433
(lp32481
(dp32482
g17436
I271
sg17437
VCD45R
p32483
sg17438
I5
sg17439
VP08575
p32484
sg17441
I1
sa(dp32485
g17436
I141
sg17437
g32477
sg17438
I10
sg17439
VP05164
p32486
sg17441
I1
sasg17442
(lp32487
(dp32488
g17436
I47
sg17437
g32478
sg17438
I17
sg17445
VC0011615
p32489
sg17441
I2
sasa(dp32490
g17431
VThese novel data demonstrate the role of HDAC2-mediated epigenetic mechanisms in anxiety and alcoholism.
p32491
sg17433
(lp32492
(dp32493
g17436
I41
sg17437
VHDAC2
p32494
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp32495
(dp32496
g17436
I93
sg17437
Valcoholism
p32497
sg17438
I10
sg17445
VC0001973
p32498
sg17441
I1
sasa(dp32499
g135
(dp32500
(Vcholesterol sulfate transporter ABCC1
p32501
Vlamellar ichthyosis
p32502
tp32503
I00
ssg17431
VThe mRNA levels of cholesterol transport regulators ABCA1 and ABCG1 were markedly downregulated by UVB, parallel to the lamellar ichthyosis related glucosylceramide transporter ABCA12 and the suspected sphingosine-1-phosphate and cholesterol sulfate transporter ABCC1.
p32504
sg17433
(lp32505
(dp32506
g17436
I230
sg17437
g32501
sg17438
I37
sg17439
VP50443
p32507
sg17441
I4
sasg17442
(lp32508
(dp32509
g17436
I120
sg17437
g32502
sg17438
I19
sg17445
VC0020758
p32510
sg17441
I2
sasa(dp32511
g17431
VTo investigate the potential tumour suppressor functions of glutathione peroxidase 7 (GPX7) and examine the interplay between epigenetic and genetic events in regulating its expression in oesophageal adenocarcinomas (OAC).
p32512
sg17433
(lp32513
(dp32514
g17436
I86
sg17437
VGPX7
p32515
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp32516
g17436
I60
sg17437
Vglutathione peroxidase 7
p32517
sg17438
I24
sg17439
g12
sg17441
I3
sasg17442
(lp32518
(dp32519
g17436
I200
sg17437
Vadenocarcinomas
p32520
sg17438
I15
sg17445
VC0001418
p32521
sg17441
I1
sa(dp32522
g17436
I29
sg17437
Vtumour
p32523
sg17438
I6
sg17445
VC0027651
p32524
sg17441
I1
sasa(dp32525
g17431
VThe goal of this study was to investigate the expression and secretion levels in vitro and in vivo of kallikrein 10 in uterine serous papillary carcinoma, a highly aggressive variant of endometrial tumor.
p32526
sg17433
(lp32527
(dp32528
g17436
I102
sg17437
Vkallikrein 10
p32529
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp32530
(dp32531
g17436
I134
sg17437
Vpapillary carcinoma
p32532
sg17438
I19
sg17445
VC0007133
p32533
sg17441
I2
sa(dp32534
g17436
I164
sg17437
Vaggressive
p32535
sg17438
I10
sg17445
VC0001807
p32536
sg17441
I1
sa(dp32537
g17436
I186
sg17437
Vendometrial tumor
p32538
sg17438
I17
sg17445
VC0014170
p32539
sg17441
I2
sasa(dp32540
g17431
VHuman kallikrein 10 gene expression levels were evaluated in 11 snap-frozen uterine serous papillary carcinoma biopsies and 6 normal endometrial cell biopsies by real-time polymerase chain reaction.
p32541
sg17433
(lp32542
(dp32543
g17436
I0
sg17437
VHuman kallikrein 10 gene
p32544
sg17438
I24
sg17439
g12
sg17441
I4
sasg17442
(lp32545
(dp32546
g17436
I91
sg17437
Vpapillary carcinoma
p32547
sg17438
I19
sg17445
VC0007133
p32548
sg17441
I2
sasa(dp32549
g17431
VSecretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA.
p32550
sg17433
(lp32551
(dp32552
g17436
I13
sg17437
Vkallikrein 10 protein
p32553
sg17438
I21
sg17439
g12
sg17441
I3
sasg17442
(lp32554
(dp32555
g17436
I171
sg17437
Vtumors
p32556
sg17438
I6
sg17445
VC0027651
p32557
sg17441
I1
sa(dp32558
g17436
I91
sg17437
Vpapillary carcinomas
p32559
sg17438
I20
sg17445
VC0007133
p32560
sg17441
I2
sa(dp32561
g17436
I41
sg17437
Vprimary tumor
p32562
sg17438
I13
sg17445
VC0677930
p32563
sg17441
I2
sa(dp32564
g17436
I115
sg17437
Vendometrioid carcinomas
p32565
sg17438
I23
sg17445
VC0206687
p32566
sg17441
I2
sasa(dp32567
g17431
VFinally, kallikrein 10 concentration in 75 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 21 women with endometrioid carcinomas, and 12 uterine serous papillary carcinoma patients was studied.
p32568
sg17433
(lp32569
(dp32570
g17436
I9
sg17437
Vkallikrein 10
p32571
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp32572
(dp32573
g17436
I183
sg17437
Vpapillary carcinoma
p32574
sg17438
I19
sg17445
VC0007133
p32575
sg17441
I2
sa(dp32576
g17436
I136
sg17437
Vendometrioid carcinomas
p32577
sg17438
I23
sg17445
VC0206687
p32578
sg17441
I2
sasa(dp32579
g17431
VKallikrein 10 gene expression levels were significantly higher in uterine serous papillary carcinoma when compared with normal endometrial cell biopsies (mean copy number by real time polymerase chain reaction = 743 versus 1.4; uterine serous papillary carcinoma versus endometrioid carcinoma: P &lt; .02).
p32580
sg17433
(lp32581
(dp32582
g17436
I0
sg17437
VKallikrein 10 gene
p32583
sg17438
I18
sg17439
g12
sg17441
I3
sasg17442
(lp32584
(dp32585
g17436
I81
sg17437
Vpapillary carcinoma
p32586
sg17438
I19
sg17445
VC0007133
p32587
sg17441
I2
sa(dp32588
g17436
I81
sg17437
Vpapillary carcinoma
p32589
sg17438
I19
sg17445
VC0007133
p32590
sg17441
I2
sa(dp32591
g17436
I270
sg17437
Vendometrioid carcinoma
p32592
sg17438
I22
sg17445
VC0206687
p32593
sg17441
I2
sasa(dp32594
g17431
VIn vitro kallikrein 10 secretion was detected in all primary uterine serous papillary carcinoma cell lines tested (mean = 2.7 microg/L), and the secretion levels were not significantly different to those found in primary ovarian serous papillary tumor cultures (mean 4.2 microg/L).
p32595
sg17433
(lp32596
(dp32597
g17436
I9
sg17437
Vkallikrein 10
p32598
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp32599
(dp32600
g17436
I76
sg17437
Vpapillary carcinoma
p32601
sg17438
I19
sg17445
VC0007133
p32602
sg17441
I2
sa(dp32603
g17436
I236
sg17437
Vpapillary tumor
p32604
sg17438
I15
sg17445
VC0476073
p32605
sg17441
I2
sasa(dp32606
g135
(dp32607
(Vplasma kallikrein
p32608
Vendometrioid carcinoma
p32609
tp32610
I00
ssg17431
VIn contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005).
p32611
sg17433
(lp32612
(dp32613
g17436
I23
sg17437
g32608
sg17438
I17
sg17439
VP03952
p32614
sg17441
I2
sasg17442
(lp32615
(dp32616
g17436
I160
sg17437
Vcancer
p32617
sg17438
I6
sg17445
VC0006826
p32618
sg17441
I1
sa(dp32619
g17436
I69
sg17437
Vpapillary carcinoma
p32620
sg17438
I19
sg17445
VC0007133
p32621
sg17441
I2
sa(dp32622
g17436
I214
sg17437
g32609
sg17438
I22
sg17445
VC0206687
p32623
sg17441
I2
sasa(dp32624
g135
(dp32625
(VKallikrein
p32626
Vpapillary carcinoma
p32627
tp32628
I00
ssg17431
VKallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients.
p32629
sg17433
(lp32630
(dp32631
g17436
I0
sg17437
g32626
sg17438
I10
sg17439
VP06870
p32632
sg17441
I1
sasg17442
(lp32633
(dp32634
g17436
I52
sg17437
Vpapillary carcinoma
p32635
sg17438
I19
sg17445
VC0007133
p32636
sg17441
I2
sa(dp32637
g17436
I52
sg17437
g32627
sg17438
I19
sg17445
VC0007133
p32638
sg17441
I2
sasa(dp32639
g135
(dp32640
(VKallikrein
p32641
Vpapillary carcinoma
p32642
tp32643
I00
ssg17431
VKallikrein 10 may represent a novel biomarker for uterine serous papillary carcinoma.
p32644
sg17433
(lp32645
(dp32646
g17436
I0
sg17437
g32641
sg17438
I10
sg17439
VP06870
p32647
sg17441
I1
sasg17442
(lp32648
(dp32649
g17436
I65
sg17437
g32642
sg17438
I19
sg17445
VC0007133
p32650
sg17441
I2
sasa(dp32651
g17431
VThe present investigation was designed to clarify the role of the subcommissural organ (SCO) in the pathogenesis of hydrocephalus occurring in the HTx rat.
p32652
sg17433
(lp32653
sg17442
(lp32654
(dp32655
g17436
I116
sg17437
Vhydrocephalus
p32656
sg17438
I13
sg17445
VC0020255
p32657
sg17441
I1
sa(dp32658
g17436
I100
sg17437
Vpathogenesis
p32659
sg17438
I12
sg17445
VC0699748
p32660
sg17441
I1
sasa(dp32661
g135
(dp32662
(VHMGB-1
p32663
Vhydrocephalus
p32664
tp32665
I00
ssg17431
VAt the same time, it functions as a transcriptional regulator of particular genes and as a cytokine: HMGB-1 released from a defective cell has been reported to induce damage to the adjacent cells.With a view to examine the relationship between neuronal damage caused by hydrocephalus and HMGB-1, we analyzed the expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus of 1-day-old congenitally hydrocephalic H-Tx rats.As opposed to nonhydrocephalic H-Tx rats, the hydrocephalic H-Tx rats were observed to show stronger expression of HMGB-1 in the cerebellum, cerebrum, and hippocampus.
p32666
sg17433
(lp32667
(dp32668
g17436
I101
sg17437
VHMGB-1
p32669
sg17438
I6
sg17439
VP09429
p32670
sg17441
I1
sa(dp32671
g17436
I101
sg17437
VHMGB-1
p32672
sg17438
I6
sg17439
VP09429
p32673
sg17441
I1
sa(dp32674
g17436
I101
sg17437
VHMGB-1
p32675
sg17438
I6
sg17439
VP09429
p32676
sg17441
I1
sa(dp32677
g17436
I101
sg17437
g32663
sg17438
I6
sg17439
VP09429
p32678
sg17441
I1
sasg17442
(lp32679
(dp32680
g17436
I270
sg17437
g32664
sg17438
I13
sg17445
VC0020255
p32681
sg17441
I1
sasa(dp32682
g135
(dp32683
(VAQP4
p32684
Vhydrocephalus
p32685
tp32686
I01
ssg17431
VAll studies utilized an animal model such as AQP4-knockout mice, H-Tx rats, and kaolin and L-Alfa-lysophosphatidylcholine (LPC) stearoyl injection models of hydrocephalus.
p32687
sg17433
(lp32688
(dp32689
g17436
I45
sg17437
g32684
sg17438
I4
sg17439
VP55087
p32690
sg17441
I1
sasg17442
(lp32691
(dp32692
g17436
I157
sg17437
g32685
sg17438
I13
sg17445
VC0020255
p32693
sg17441
I1
sasa(dp32694
g17431
VThe purpose of this study was to determine the efficacy of minocycline, an antibiotic known for its anti-inflammatory properties, to reduce gliosis in the H-Tx rat model of congenital hydrocephalus.
p32695
sg17433
(lp32696
sg17442
(lp32697
(dp32698
g17436
I173
sg17437
Vcongenital hydrocephalus
p32699
sg17438
I24
sg17445
VC0020256
p32700
sg17441
I2
sa(dp32701
g17436
I140
sg17437
Vgliosis
p32702
sg17438
I7
sg17445
VC0017639
p32703
sg17441
I1
sasa(dp32704
g17431
VIt has been well documented that up to 70% of H-Tx rats' offspring suffer from severe hydrocephalus, which can be fatal if it remains untreated.
p32705
sg17433
(lp32706
sg17442
(lp32707
(dp32708
g17436
I86
sg17437
Vhydrocephalus
p32709
sg17438
I13
sg17445
VC0020255
p32710
sg17441
I1
sa(dp32711
g17436
I67
sg17437
Vsuffer
p32712
sg17438
I6
sg17445
VC0683278
p32713
sg17441
I1
sasa(dp32714
g17431
VAside from the well-documented hydrocephalus, H-Tx rats may develop other intracranial malformations that have not yet been documented in the literature.
p32715
sg17433
(lp32716
sg17442
(lp32717
(dp32718
g17436
I31
sg17437
Vhydrocephalus
p32719
sg17438
I13
sg17445
VC0020255
p32720
sg17441
I1
sa(dp32721
g17436
I87
sg17437
Vmalformations
p32722
sg17438
I13
sg17445
VC0000768
p32723
sg17441
I1
sasa(dp32724
g17431
VWe investigated the effect of vascular endothelial growth factor (VEGF)-C on lymphangiogenesis, inflammation, and fibrosis in the mouse kidney using the unilateral ureteral obstruction (UUO) model.
p32725
sg17433
(lp32726
(dp32727
g17436
I30
sg17437
Vvascular endothelial growth factor
p32728
sg17438
I34
sg17439
g12
sg17441
I4
sa(dp32729
g17436
I66
sg17437
VVEGF
p32730
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp32731
(dp32732
g17436
I164
sg17437
Vureteral obstruction
p32733
sg17438
I20
sg17445
VC0041956
p32734
sg17441
I2
sa(dp32735
g17436
I114
sg17437
Vfibrosis
p32736
sg17438
I8
sg17445
VC0016059
p32737
sg17441
I1
sa(dp32738
g17436
I96
sg17437
Vinflammation
p32739
sg17438
I12
sg17445
VC0021368
p32740
sg17441
I1
sa(dp32741
g17436
I186
sg17437
VUUO
p32742
sg17438
I3
sg17445
VC0041956
p32743
sg17441
I1
sasa(dp32744
g135
(dp32745
(VUUO+VEGF-C
p32746
VRenal fibrosis
p32747
tp32748
I00
ssg17431
VRenal fibrosis was consequently attenuated in the UUO+VEGF-C group.
p32749
sg17433
(lp32750
(dp32751
g17436
I50
sg17437
g32746
sg17438
I10
sg17439
VP49767
p32752
sg17441
I1
sasg17442
(lp32753
(dp32754
g17436
I0
sg17437
g32747
sg17438
I14
sg17445
VC0151650
p32755
sg17441
I2
sasa(dp32756
g135
(dp32757
(VVEGF-C
p32758
Vrenal fibrosis
p32759
tp32760
I00
ssg17431
VEnhancement of the VEGF-C signaling pathway in LECs may be a therapeutic strategy for renal fibrosis.Laboratory Investigation advance online publication, 30 October 2017; doi:10.1038/labinvest.2017.77.
p32761
sg17433
(lp32762
(dp32763
g17436
I19
sg17437
g32758
sg17438
I6
sg17439
VP49767
p32764
sg17441
I1
sasg17442
(lp32765
(dp32766
g17436
I86
sg17437
g32759
sg17438
I14
sg17445
VC0151650
p32767
sg17441
I2
sasa(dp32768
g17431
VHowever, the relevance of urinary and circulating VEGF-A165b levels in chronic kidney disease patients remains unclear.
p32769
sg17433
(lp32770
sg17442
(lp32771
(dp32772
g17436
I71
sg17437
Vchronic kidney disease
p32773
sg17438
I22
sg17445
VC1561643
p32774
sg17441
I3
sasa(dp32775
g17431
VTherefore, the present study aimed to investigate the urinary and circulating VEGF-A165b levels in patients with chronic kidney disease.
p32776
sg17433
(lp32777
sg17442
(lp32778
(dp32779
g17436
I113
sg17437
Vchronic kidney disease
p32780
sg17438
I22
sg17445
VC1561643
p32781
sg17441
I3
sasa(dp32782
g17431
VA low urinary VEGF-A165b level reflects renal dysfunction in the chronic kidney disease stage, while a high circulating VEGF-A165b level cannot be attributed to decreased renal clearance.
p32783
sg17433
(lp32784
sg17442
(lp32785
(dp32786
g17436
I65
sg17437
Vchronic kidney disease
p32787
sg17438
I22
sg17445
VC1561643
p32788
sg17441
I3
sasa(dp32789
g135
(dp32790
(VPTEN
p32791
Vaggressive
p32792
tp32793
I00
ssg17431
VBy using a novel, advanced, multicolor fluorescence in situ hybridization approach, we enumerated copy numbers of six genes previously identified by array comparative genomic hybridization to be involved in aggressive prostate cancer [TBL1XR1, CTTNBP2, MYC (alias c-myc), PTEN, MEN1, and PDGFB] in six nonrecurrent and seven recurrent radical prostatectomy cases.
p32794
sg17433
(lp32795
(dp32796
g17436
I264
sg17437
Vc-myc
p32797
sg17438
I5
sg17439
VP12524
p32798
sg17441
I1
sa(dp32799
g17436
I253
sg17437
VMYC
p32800
sg17438
I3
sg17439
VP12524
p32801
sg17441
I1
sa(dp32802
g17436
I244
sg17437
VCTTNBP2
p32803
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp32804
g17436
I235
sg17437
VTBL1XR1
p32805
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp32806
g17436
I272
sg17437
g32791
sg17438
I4
sg17439
VP60484
p32807
sg17441
I1
sa(dp32808
g17436
I278
sg17437
VMEN1
p32809
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp32810
(dp32811
g17436
I278
sg17437
VMEN1
p32812
sg17438
I4
sg17445
VC0025267
p32813
sg17441
I1
sa(dp32814
g17436
I218
sg17437
Vprostate cancer
p32815
sg17438
I15
sg17445
VC0600139
p32816
sg17441
I2
sa(dp32817
g17436
I207
sg17437
g32792
sg17438
I10
sg17445
VC0001807
p32818
sg17441
I1
sasa(dp32819
g135
(dp32820
(Vnerve growth factor
p32821
Vstroke
p32822
tp32823
I00
ssg17431
VThe identification of higher NIHSS scores, higher HAMD scores, lower dopamine level, lower 5-hydroxytryptamine level, higher tumor necrosis factor-Alfa level, and lower nerve growth factor level might be useful for clinicians in recognizing and treating depression in patients after a stroke.
p32824
sg17433
(lp32825
(dp32826
g17436
I125
sg17437
Vtumor necrosis factor-Alfa
p32827
sg17438
I26
sg17439
VP01375
p32828
sg17441
I3
sa(dp32829
g17436
I169
sg17437
g32821
sg17438
I19
sg17439
VP01138
p32830
sg17441
I3
sasg17442
(lp32831
(dp32832
g17436
I254
sg17437
Vdepression
p32833
sg17438
I10
sg17445
VC0011581
p32834
sg17441
I1
sa(dp32835
g17436
I125
sg17437
Vtumor necrosis
p32836
sg17438
I14
sg17445
VC0333516
p32837
sg17441
I2
sa(dp32838
g17436
I285
sg17437
g32822
sg17438
I6
sg17445
VC0038454
p32839
sg17441
I1
sasa(dp32840
g135
(dp32841
(VBeta-thromboglobulin
p32842
Vocclusive vascular disease
p32843
tp32844
I00
ssg17431
VOther effects include a reduction in the platelet levels of adenosine triphosphate (ATP), serotonin (5-hydroxytryptamine), platelet factor 3 (PF3), PF4 and Beta-thromboglobulin (BTG), decreased platelet adhesiveness in platelets from healthy volunteers and from atherosclerotic patients and an improvement in red blood cell deformability in patients with occlusive vascular disease.
p32845
sg17433
(lp32846
(dp32847
g17436
I148
sg17437
VPF4
p32848
sg17438
I3
sg17439
VP02776
p32849
sg17441
I1
sa(dp32850
g17436
I178
sg17437
VBTG
p32851
sg17438
I3
sg17439
VP02775
p32852
sg17441
I1
sa(dp32853
g17436
I123
sg17437
Vplatelet factor 3
p32854
sg17438
I17
sg17439
VP14770
p32855
sg17441
I3
sa(dp32856
g17436
I142
sg17437
VPF3
p32857
sg17438
I3
sg17439
VP14770
p32858
sg17441
I1
sa(dp32859
g17436
I156
sg17437
g32842
sg17438
I20
sg17439
VP02775
p32860
sg17441
I1
sasg17442
(lp32861
(dp32862
g17436
I355
sg17437
g32843
sg17438
I26
sg17445
VC0750145
p32863
sg17441
I3
sasa(dp32864
g135
(dp32865
(VSERT
p32866
Vmyocardial infarction
p32867
tp32868
I00
ssg17431
VObjective: To explore the effect of trimetazidine pre-treatments on serum 5-hydroxytryptamine (5-HT) and serotonin transporter (SERT), platelet 5-HT and SERT in the Sprague Dawley rats with myocardial infarction(MI), depression, and myocardial infarction co-exist with depression (MI+ depression) and in sham operated rats.
p32869
sg17433
(lp32870
(dp32871
g17436
I128
sg17437
VSERT
p32872
sg17438
I4
sg17439
VP31645
p32873
sg17441
I1
sa(dp32874
g17436
I105
sg17437
Vserotonin transporter
p32875
sg17438
I21
sg17439
VP31645
p32876
sg17441
I2
sa(dp32877
g17436
I128
sg17437
g32866
sg17438
I4
sg17439
VP31645
p32878
sg17441
I1
sasg17442
(lp32879
(dp32880
g17436
I217
sg17437
Vdepression
p32881
sg17438
I10
sg17445
VC0011581
p32882
sg17441
I1
sa(dp32883
g17436
I217
sg17437
Vdepression
p32884
sg17438
I10
sg17445
VC0011581
p32885
sg17441
I1
sa(dp32886
g17436
I217
sg17437
Vdepression
p32887
sg17438
I10
sg17445
VC0011581
p32888
sg17441
I1
sa(dp32889
g17436
I190
sg17437
Vmyocardial infarction
p32890
sg17438
I21
sg17445
VC0027051
p32891
sg17441
I2
sa(dp32892
g17436
I190
sg17437
g32867
sg17438
I21
sg17445
VC0027051
p32893
sg17441
I2
sasa(dp32894
g135
(dp32895
(Vhistone deacetylase-3
p32896
Vskin inflammation
p32897
tp32898
I00
ssg17431
VThe role of histone deacetylase-3 (HDAC3) in allergic skin inflammation was reported.
p32899
sg17433
(lp32900
(dp32901
g17436
I35
sg17437
VHDAC3
p32902
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp32903
g17436
I12
sg17437
g32896
sg17438
I21
sg17439
VP56524
p32904
sg17441
I2
sasg17442
(lp32905
(dp32906
g17436
I54
sg17437
g32897
sg17438
I17
sg17445
VC0011603
p32907
sg17441
I2
sasa(dp32908
g17431
VIn this study, we investigated SERPINA3 expression in glioma tissue samples and its significance in predicting the prognosis of glioma patients.
p32909
sg17433
(lp32910
sg17442
(lp32911
(dp32912
g17436
I54
sg17437
Vglioma
p32913
sg17438
I6
sg17445
VC0017638
p32914
sg17441
I1
sa(dp32915
g17436
I54
sg17437
Vglioma
p32916
sg17438
I6
sg17445
VC0017638
p32917
sg17441
I1
sasa(dp32918
g17431
VWe found that SERPINA3 was upregulated in glioma tissue at both mRNA and protein levels, compared with noncancerous brain tissues.
p32919
sg17433
(lp32920
sg17442
(lp32921
(dp32922
g17436
I42
sg17437
Vglioma
p32923
sg17438
I6
sg17445
VC0017638
p32924
sg17441
I1
sasa(dp32925
g17431
VWe also found that high SERPINA3 expression in glioma tissues correlated significantly with advanced World Health Organization grade.
p32926
sg17433
(lp32927
sg17442
(lp32928
(dp32929
g17436
I47
sg17437
Vglioma
p32930
sg17438
I6
sg17445
VC0017638
p32931
sg17441
I1
sasa(dp32932
g17431
VUnivariate and multivariate analyses revealed that high SERPINA3 expression was an independent prognostic factor for poor overall survival of glioma patients.
p32933
sg17433
(lp32934
sg17442
(lp32935
(dp32936
g17436
I142
sg17437
Vglioma
p32937
sg17438
I6
sg17445
VC0017638
p32938
sg17441
I1
sasa(dp32939
g17431
VTaken together, our results suggest that SERPINA3 plays an oncogenic role in glioma progression and provide an insight into the application of SERPINA3 as a novel predictor of clinical outcomes and a potential biomarker of glioma.
p32940
sg17433
(lp32941
sg17442
(lp32942
(dp32943
g17436
I77
sg17437
Vglioma
p32944
sg17438
I6
sg17445
VC0017638
p32945
sg17441
I1
sa(dp32946
g17436
I77
sg17437
Vglioma
p32947
sg17438
I6
sg17445
VC0017638
p32948
sg17441
I1
sasa(dp32949
g135
(dp32950
(Vantichymotrypsin
p32951
VHCC
p32952
tp32953
I00
ssg17431
VTo investigate the expression and prognostic value of Alfa1-ACT (Alpha1-antichymotrypsin) in patients with HCC (hepatocellular carcinoma) and identify the mechanism by which Alfa1-ACT inhibits proliferation and promotes apoptosis of HCC.
p32954
sg17433
(lp32955
(dp32956
g17436
I54
sg17437
VAlfa1-ACT
p32957
sg17438
I9
sg17439
VP63267
p32958
sg17441
I1
sa(dp32959
g17436
I54
sg17437
VAlfa1-ACT
p32960
sg17438
I9
sg17439
VP63267
p32961
sg17441
I1
sa(dp32962
g17436
I72
sg17437
g32951
sg17438
I16
sg17439
VP05154
p32963
sg17441
I1
sasg17442
(lp32964
(dp32965
g17436
I112
sg17437
Vhepatocellular carcinoma
p32966
sg17438
I24
sg17445
VC2239176
p32967
sg17441
I2
sa(dp32968
g17436
I107
sg17437
VHCC
p32969
sg17438
I3
sg17445
VC2239176
p32970
sg17441
I1
sa(dp32971
g17436
I193
sg17437
Vproliferation
p32972
sg17438
I13
sg17445
VC0334094
p32973
sg17441
I1
sa(dp32974
g17436
I107
sg17437
g32952
sg17438
I3
sg17445
VC2239176
p32975
sg17441
I1
sasa(dp32976
g135
(dp32977
(VcagA
p32978
Vgastritis
p32979
tp32980
I00
ssg17431
VDeletions were found in LEC1 (9.5% versus 14.3%), LEC2 (4.8% versus 14.3%), cagT (33.3% versus 28.6%), cagE (28.6% versus 28.6%) and the promoter region of the cagA (19.0% versus 42.9%) of gastritis and PUD strains, respectively.
p32981
sg17433
(lp32982
(dp32983
g17436
I103
sg17437
VcagE
p32984
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp32985
g17436
I50
sg17437
VLEC2
p32986
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp32987
g17436
I24
sg17437
VLEC1
p32988
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp32989
g17436
I160
sg17437
g32978
sg17438
I4
sg17439
VP05109
p32990
sg17441
I1
sasg17442
(lp32991
(dp32992
g17436
I203
sg17437
VPUD
p32993
sg17438
I3
sg17445
VC0030920
p32994
sg17441
I1
sa(dp32995
g17436
I189
sg17437
g32979
sg17438
I9
sg17445
VC0017152
p32996
sg17441
I1
sasa(dp32997
g17431
VIn the seven women, increased FDG uptake was due to physiological endometrial uptake (n=2), leiomyoma (n=1), corpus luteum cyst (n=1), physiological ovarian uptake (n=1), urinary leak (n=1), and nonspecific colitis (n=1).
p32998
sg17433
(lp32999
sg17442
(lp33000
(dp33001
g17436
I207
sg17437
Vcolitis
p33002
sg17438
I7
sg17445
VC0009319
p33003
sg17441
I1
sa(dp33004
g17436
I92
sg17437
Vleiomyoma
p33005
sg17438
I9
sg17445
VC0023267
p33006
sg17441
I1
sa(dp33007
g17436
I109
sg17437
Vcorpus luteum cyst
p33008
sg17438
I18
sg17445
VC0010093
p33009
sg17441
I3
sasa(dp33010
g17431
VThe most significant quantitative trait locus, Hsm1 (hereditary spherocytosis modifier 1), localizes to mouse Chromosome 12 and is dominant.
p33011
sg17433
(lp33012
(dp33013
g17436
I53
sg17437
Vhereditary spherocytosis modifier 1
p33014
sg17438
I35
sg17439
g12
sg17441
I4
sa(dp33015
g17436
I47
sg17437
VHsm1
p33016
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp33017
(dp33018
g17436
I53
sg17437
Vhereditary spherocytosis
p33019
sg17438
I24
sg17445
VC0037889
p33020
sg17441
I2
sasa(dp33021
g17431
VRates of noninfective synovitis and effusion ranged from 0.2% in the LARS ACL group to 27.6% in the Gore-Tex ACL group.
p33022
sg17433
(lp33023
sg17442
(lp33024
(dp33025
g17436
I22
sg17437
Vsynovitis
p33026
sg17438
I9
sg17445
VC0039103
p33027
sg17441
I1
sa(dp33028
g17436
I36
sg17437
Veffusion
p33029
sg17438
I8
sg17445
VC0013687
p33030
sg17441
I1
sasa(dp33031
g17431
VPreliminary results for newer-generation devices, specifically the LARS, show lower reported rates of failure, revision, and sterile effusion/synovitis when compared with older devices.
p33032
sg17433
(lp33033
sg17442
(lp33034
(dp33035
g17436
I142
sg17437
Vsynovitis
p33036
sg17438
I9
sg17445
VC0039103
p33037
sg17441
I1
sa(dp33038
g17436
I133
sg17437
Veffusion
p33039
sg17438
I8
sg17445
VC0013687
p33040
sg17441
I1
sa(dp33041
g17436
I125
sg17437
Vsterile
p33042
sg17438
I7
sg17445
VC0678108
p33043
sg17441
I1
sasa(dp33044
g17431
VThe Ligament Augmentation and Reconstruction System (LARS) is a third generation of synthetic ligament, designed to overcome the issues of graft failure and synovitis which led previous generations of synthetic ligaments to fall out of favour.
p33045
sg17433
(lp33046
sg17442
(lp33047
(dp33048
g17436
I139
sg17437
Vgraft failure
p33049
sg17438
I13
sg17445
VC1262018
p33050
sg17441
I2
sa(dp33051
g17436
I157
sg17437
Vsynovitis
p33052
sg17438
I9
sg17445
VC0039103
p33053
sg17441
I1
sasa(dp33054
g135
(dp33055
(Vclarin-1
p33056
Vbalance disorder
p33057
tp33058
I00
ssg17431
VUsher syndrome type III (USH3), characterized by progressive deafness, variable balance disorder and blindness, is caused by destabilizing mutations in the gene encoding the clarin-1 (CLRN1) protein.
p33059
sg17433
(lp33060
(dp33061
g17436
I25
sg17437
VUSH3
p33062
sg17438
I4
sg17439
VP58418
p33063
sg17441
I1
sa(dp33064
g17436
I184
sg17437
VCLRN1
p33065
sg17438
I5
sg17439
VP58418
p33066
sg17441
I1
sa(dp33067
g17436
I174
sg17437
g33056
sg17438
I8
sg17439
VP58418
p33068
sg17441
I1
sasg17442
(lp33069
(dp33070
g17436
I25
sg17437
VUSH3
p33071
sg17438
I4
sg17445
VC1568248
p33072
sg17441
I1
sa(dp33073
g17436
I61
sg17437
Vdeafness
p33074
sg17438
I8
sg17445
VC0011053
p33075
sg17441
I1
sa(dp33076
g17436
I101
sg17437
Vblindness
p33077
sg17438
I9
sg17445
VC0456909
p33078
sg17441
I1
sa(dp33079
g17436
I0
sg17437
VUsher syndrome
p33080
sg17438
I14
sg17445
VC0271097
p33081
sg17441
I2
sa(dp33082
g17436
I80
sg17437
g33057
sg17438
I16
sg17445
VC0575090
p33083
sg17441
I2
sasa(dp33084
g135
(dp33085
(VUsher syndrome type 3
p33086
Vdeafness
p33087
tp33088
I00
ssg17431
VMutations in the CLRN1 gene cause Usher syndrome type 3 (USH3), a human disease characterized by progressive blindness and deafness.
p33089
sg17433
(lp33090
(dp33091
g17436
I57
sg17437
VUSH3
p33092
sg17438
I4
sg17439
VP58418
p33093
sg17441
I1
sa(dp33094
g17436
I17
sg17437
VCLRN1 gene
p33095
sg17438
I10
sg17439
VP58418
p33096
sg17441
I2
sa(dp33097
g17436
I34
sg17437
g33086
sg17438
I21
sg17439
VP58418
p33098
sg17441
I4
sasg17442
(lp33099
(dp33100
g17436
I109
sg17437
Vblindness
p33101
sg17438
I9
sg17445
VC0456909
p33102
sg17441
I1
sa(dp33103
g17436
I34
sg17437
VUsher syndrome type 3
p33104
sg17438
I21
sg17445
VC1568248
p33105
sg17441
I4
sa(dp33106
g17436
I57
sg17437
VUSH3
p33107
sg17438
I4
sg17445
VC1568248
p33108
sg17441
I1
sa(dp33109
g17436
I123
sg17437
g33087
sg17438
I8
sg17445
VC0011053
p33110
sg17441
I1
sasa(dp33111
g135
(dp33112
(Vanti-PD-1
p33113
Vsquamous cell cancer
p33114
tp33115
I00
ssg17431
VTaken together, CD47 might be a novel target to enhance anti-PD-1 and CLTA-4 efficacy in esophageal squamous cell cancer.
p33116
sg17433
(lp33117
(dp33118
g17436
I16
sg17437
VCD47
p33119
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp33120
g17436
I70
sg17437
VCLTA-4
p33121
sg17438
I6
sg17439
VP09496
p33122
sg17441
I1
sa(dp33123
g17436
I56
sg17437
g33113
sg17438
I9
sg17439
VP18621
p33124
sg17441
I1
sasg17442
(lp33125
(dp33126
g17436
I100
sg17437
g33114
sg17438
I20
sg17445
VC0007137
p33127
sg17441
I3
sasa(dp33128
g135
(dp33129
(VCLTA-4 antibody
p33130
Vmelanoma
p33131
tp33132
I00
ssg17431
VIpilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma.
p33133
sg17433
(lp33134
(dp33135
g17436
I24
sg17437
g33130
sg17438
I15
sg17439
VP09496
p33136
sg17441
I2
sasg17442
(lp33137
(dp33138
g17436
I91
sg17437
g33131
sg17438
I8
sg17445
VC0025202
p33139
sg17441
I1
sasa(dp33140
g135
(dp33141
(VMEK
p33142
Vmetastatic melanoma
p33143
tp33144
I00
ssg17431
VThe most prominent example of this shift is the management of metastatic melanoma, where BRAF and MEK inhibition and CLTA-4 blockade have established an entirely new standard of care in the last 3 years.
p33145
sg17433
(lp33146
(dp33147
g17436
I89
sg17437
VBRAF
p33148
sg17438
I4
sg17439
VP15056
p33149
sg17441
I1
sa(dp33150
g17436
I117
sg17437
VCLTA-4
p33151
sg17438
I6
sg17439
VP09496
p33152
sg17441
I1
sa(dp33153
g17436
I98
sg17437
g33142
sg17438
I3
sg17439
VP45985
p33154
sg17441
I1
sasg17442
(lp33155
(dp33156
g17436
I62
sg17437
g33143
sg17438
I19
sg17445
VC0278883
p33157
sg17441
I2
sasa(dp33158
g135
(dp33159
(VNotch1
p33160
Vcolon cancer
p33161
tp33162
I00
ssg17431
VThis was associated with the decreased protein expression of Notch1, Notch2, Notch3 and Hey1, and the increased expression of the tumor suppressor microRNA (miR or miRNA)-200 family members (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) that are typically downregulated in colon cancer.
p33163
sg17433
(lp33164
(dp33165
g17436
I211
sg17437
VmiR-200c
p33166
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp33167
g17436
I88
sg17437
VHey1
p33168
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp33169
g17436
I233
sg17437
VmiR-429
p33170
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp33171
g17436
I221
sg17437
VmiR-141
p33172
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp33173
g17436
I201
sg17437
VmiR-200b
p33174
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp33175
g17436
I77
sg17437
VNotch3
p33176
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp33177
g17436
I61
sg17437
g33160
sg17438
I6
sg17439
VP46531
p33178
sg17441
I1
sa(dp33179
g17436
I191
sg17437
VmiR-200a
p33180
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp33181
g17436
I69
sg17437
VNotch2
p33182
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp33183
(dp33184
g17436
I130
sg17437
Vtumor
p33185
sg17438
I5
sg17445
VC0027651
p33186
sg17441
I1
sa(dp33187
g17436
I278
sg17437
g33161
sg17438
I12
sg17445
VC0699790
p33188
sg17441
I2
sasa(dp33189
g135
(dp33190
(VIR
p33191
Vinvasive breast cancer
p33192
tp33193
I00
ssg17431
VPhosphorylated IGF-IR/IR (P-IGF-IR/IR) and its downstream signaling partner phospho-S6 (P-S6) were evaluated immunohistochemically in tumor tissue microarrays representing 438 cases of invasive breast cancer.
p33194
sg17433
(lp33195
(dp33196
g17436
I15
sg17437
VIGF-IR
p33197
sg17438
I6
sg17439
VP06213
p33198
sg17441
I1
sa(dp33199
g17436
I19
sg17437
VIR
p33200
sg17438
I2
sg17439
VP06213
p33201
sg17441
I1
sa(dp33202
g17436
I26
sg17437
VP-IGF-IR
p33203
sg17438
I8
sg17439
VP06213
p33204
sg17441
I1
sa(dp33205
g17436
I19
sg17437
g33191
sg17438
I2
sg17439
VP06213
p33206
sg17441
I1
sasg17442
(lp33207
(dp33208
g17436
I185
sg17437
g33192
sg17438
I22
sg17445
VC0853879
p33209
sg17441
I3
sa(dp33210
g17436
I134
sg17437
Vtumor
p33211
sg17438
I5
sg17445
VC0027651
p33212
sg17441
I1
sasa(dp33213
g135
(dp33214
(VIR
p33215
Vbreast cancer
p33216
tp33217
I00
ssg17431
VImportantly, P-IGF-IR/IR was detected in all breast cancer subtypes (luminal, 48.1%; triple negative, 41.9%; and HER2, 64.3%).
p33218
sg17433
(lp33219
(dp33220
g17436
I13
sg17437
VP-IGF-IR
p33221
sg17438
I8
sg17439
VP06213
p33222
sg17441
I1
sa(dp33223
g17436
I19
sg17437
g33215
sg17438
I2
sg17439
VP06213
p33224
sg17441
I1
sasg17442
(lp33225
(dp33226
g17436
I45
sg17437
g33216
sg17438
I13
sg17445
VC0678222
p33227
sg17441
I2
sasa(dp33228
g135
(dp33229
(VIR
p33230
Vbreast cancer
p33231
tp33232
I00
ssg17431
VThus, we can determine which patients have the activated receptor and provide evidence that P-IGF-IR/IR is a prognostic factor for breast cancer.
p33233
sg17433
(lp33234
(dp33235
g17436
I92
sg17437
VP-IGF-IR
p33236
sg17438
I8
sg17439
VP06213
p33237
sg17441
I1
sa(dp33238
g17436
I98
sg17437
g33230
sg17438
I2
sg17439
VP06213
p33239
sg17441
I1
sasg17442
(lp33240
(dp33241
g17436
I131
sg17437
g33231
sg17438
I13
sg17445
VC0678222
p33242
sg17441
I2
sasa(dp33243
g135
(dp33244
(VIR
p33245
Vbreast cancer
p33246
tp33247
I00
ssg17431
VBeyond this, P-IGF-IR/IR could be a predictive marker for response to IGF-IR and/or IR-targeted therapies, as these inhibitors may be of benefit in all breast cancer subtypes including those with acquired resistance to tamoxifen.
p33248
sg17433
(lp33249
(dp33250
g17436
I13
sg17437
VP-IGF-IR
p33251
sg17438
I8
sg17439
VP06213
p33252
sg17441
I1
sa(dp33253
g17436
I15
sg17437
VIGF-IR
p33254
sg17438
I6
sg17439
VP06213
p33255
sg17441
I1
sa(dp33256
g17436
I19
sg17437
g33245
sg17438
I2
sg17439
VP06213
p33257
sg17441
I1
sasg17442
(lp33258
(dp33259
g17436
I152
sg17437
g33246
sg17438
I13
sg17445
VC0678222
p33260
sg17441
I2
sasa(dp33261
g17431
VThe genes plo, fimA, fimC, fimE, fimG, nanH, nanP, and cbpA were investigated in 71 T. pyogenes strains recovered from cattle, sheep, goats, dogs, equines, and a pig, recovered from mastitis (n = 35), and non-mastitis (n = 36) cases (abscesses, reproductive tract diseases, pneumonia, lymphadenitis, encephalitis).
p33262
sg17433
(lp33263
(dp33264
g17436
I39
sg17437
VnanH
p33265
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp33266
g17436
I45
sg17437
VnanP
p33267
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp33268
(dp33269
g17436
I182
sg17437
Vmastitis
p33270
sg17438
I8
sg17445
VC3251795
p33271
sg17441
I1
sa(dp33272
g17436
I285
sg17437
Vlymphadenitis
p33273
sg17438
I13
sg17445
VC0024205
p33274
sg17441
I1
sa(dp33275
g17436
I27
sg17437
VfimE
p33276
sg17438
I4
sg17445
VC0917800
p33277
sg17441
I1
sa(dp33278
g17436
I274
sg17437
Vpneumonia
p33279
sg17438
I9
sg17445
VC0032285
p33280
sg17441
I1
sa(dp33281
g17436
I234
sg17437
Vabscesses
p33282
sg17438
I9
sg17445
VC0000833
p33283
sg17441
I1
sa(dp33284
g17436
I182
sg17437
Vmastitis
p33285
sg17438
I8
sg17445
VC3251795
p33286
sg17441
I1
sa(dp33287
g17436
I300
sg17437
Vencephalitis
p33288
sg17438
I12
sg17445
VC0014038
p33289
sg17441
I1
sasa(dp33290
g17431
VThe aim was to assess the prevalence of anaemia among quranic schoolchildren in khalawi Wad EL Magboul village, rural Rufaa, Gezira State, central Sudan.
p33291
sg17433
(lp33292
sg17442
(lp33293
(dp33294
g17436
I40
sg17437
Vanaemia
p33295
sg17438
I7
sg17445
VC0002871
p33296
sg17441
I1
sasa(dp33297
g17431
VThrombophilia was present in 294/482 (60.9%) patients: 189/350 LC (54.0%), 31/47 (66.0%) HCC, 29/39 (74.4%) MPN, 35/38 AD (92.1%), and 10/10 (100%) WAD, and 54/150 (36.0%) in HC.
p33298
sg17433
(lp33299
sg17442
(lp33300
(dp33301
g17436
I0
sg17437
VThrombophilia
p33302
sg17438
I13
sg17445
VC2827470
p33303
sg17441
I1
sa(dp33304
g17436
I89
sg17437
VHCC
p33305
sg17438
I3
sg17445
VC2239176
p33306
sg17441
I1
sasa(dp33307
g17431
VA cross-sectional study was conducted to investigate the prevalence of anaemia, iron, zinc and copper deficiencies among pregnant women in Wad Medani hospital, central Sudan and to examine the relationship of these micronutrients with haemoglobin (Hb) levels.
p33308
sg17433
(lp33309
(dp33310
g17436
I235
sg17437
Vhaemoglobin
p33311
sg17438
I11
sg17439
g12
sg17441
I1
sa(dp33312
g17436
I248
sg17437
VHb
p33313
sg17438
I2
sg17439
g12
sg17441
I1
sasg17442
(lp33314
(dp33315
g17436
I71
sg17437
Vanaemia
p33316
sg17438
I7
sg17445
VC0002871
p33317
sg17441
I1
sasa(dp33318
g17431
VIn the orbivirinae this would result in 2 genera of cyanovirus (bluetongue, epizootic hemorrhagic disease, Eubenangee and Palyam sub-genera) and Kemerovovirus (Chenunda, Great Island, Kemerovo and Wad Medani sub-genera) and a number of ungrouped sub-genera (African horsesickness, Changuinola, Corriparta, equine encephalosis, Wallal and Warrego sub-genera and the remaining ungrouped viruses).
p33319
sg17433
(lp33320
sg17442
(lp33321
(dp33322
g17436
I86
sg17437
Vhemorrhagic disease
p33323
sg17438
I19
sg17445
VC0019087
p33324
sg17441
I2
sa(dp33325
g17436
I258
sg17437
VAfrican horsesickness
p33326
sg17438
I21
sg17445
VC0001748
p33327
sg17441
I2
sa(dp33328
g17436
I64
sg17437
Vbluetongue
p33329
sg17438
I10
sg17445
VC0005866
p33330
sg17441
I1
sasa(dp33331
g135
(dp33332
(Vgp130
p33333
VCHF
p33334
tp33335
I00
ssg17431
VWe examined the expression of CT-1, leukemia inhibitory factor (LIF), and gp130 by competitive RT-PCR and Western blotting in Dahl salt-sensitive (DS) rats with a high-salt diet, which showed a distinct transition from left ventricular hypertrophy (LVH) to congestive heart failure (CHF).
p33336
sg17433
(lp33337
(dp33338
g17436
I36
sg17437
Vleukemia inhibitory factor
p33339
sg17438
I26
sg17439
VP15018
p33340
sg17441
I3
sa(dp33341
g17436
I64
sg17437
VLIF
p33342
sg17438
I3
sg17439
VP15018
p33343
sg17441
I1
sa(dp33344
g17436
I74
sg17437
g33333
sg17438
I5
sg17439
VP40189
p33345
sg17441
I1
sa(dp33346
g17436
I30
sg17437
VCT-1
p33347
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp33348
(dp33349
g17436
I249
sg17437
VLVH
p33350
sg17438
I3
sg17445
VC0149721
p33351
sg17441
I1
sa(dp33352
g17436
I36
sg17437
Vleukemia
p33353
sg17438
I8
sg17445
VC0023418
p33354
sg17441
I1
sa(dp33355
g17436
I257
sg17437
Vcongestive heart failure
p33356
sg17438
I24
sg17445
VC0018802
p33357
sg17441
I3
sa(dp33358
g17436
I203
sg17437
Vtransition
p33359
sg17438
I10
sg17445
VC0599156
p33360
sg17441
I1
sa(dp33361
g17436
I219
sg17437
Vleft ventricular hypertrophy
p33362
sg17438
I28
sg17445
VC0149721
p33363
sg17441
I3
sa(dp33364
g17436
I283
sg17437
g33334
sg17438
I3
sg17445
VC0018802
p33365
sg17441
I1
sasa(dp33366
g17431
VNew factors signaling independently of the leukemia inhibitory-factor receptor pathway may sustain cardiomyocyte cell proliferation and thus be a future target for gene therapy of cardiomyopathies and cell therapy of the myocardium.
p33367
sg17433
(lp33368
(dp33369
g17436
I43
sg17437
Vleukemia inhibitory-factor receptor
p33370
sg17438
I35
sg17439
g12
sg17441
I3
sasg17442
(lp33371
(dp33372
g17436
I118
sg17437
Vproliferation
p33373
sg17438
I13
sg17445
VC0334094
p33374
sg17441
I1
sa(dp33375
g17436
I180
sg17437
Vcardiomyopathies
p33376
sg17438
I16
sg17445
VC0878544
p33377
sg17441
I1
sa(dp33378
g17436
I43
sg17437
Vleukemia
p33379
sg17438
I8
sg17445
VC0023418
p33380
sg17441
I1
sasa(dp33381
g135
(dp33382
(VCXCR4
p33383
Vbreast cancer
p33384
tp33385
I00
ssg17431
VWe propose a model in which P-Rex1 acts as a crucial node for the integration of upstream inputs from HER/ErbB receptors and CXCR4 in luminal breast cancer cells.
p33386
sg17433
(lp33387
(dp33388
g17436
I125
sg17437
g33383
sg17438
I5
sg17439
VP61073
p33389
sg17441
I1
sa(dp33390
g17436
I28
sg17437
VP-Rex1
p33391
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp33392
g17436
I106
sg17437
VErbB receptors
p33393
sg17438
I14
sg17439
g12
sg17441
I2
sasg17442
(lp33394
(dp33395
g17436
I142
sg17437
g33384
sg17438
I13
sg17445
VC0678222
p33396
sg17441
I2
sasa(dp33397
g135
(dp33398
(VMMP10
p33399
Vbreast cancer
p33400
tp33401
I01
ssg17431
VNotably, there is a significant association in the expression of P-Rex1 and MMP10 in human luminal breast cancer, and their co-expression is indicative of poor prognosis.
p33402
sg17433
(lp33403
(dp33404
g17436
I76
sg17437
g33399
sg17438
I5
sg17439
VP09238
p33405
sg17441
I1
sa(dp33406
g17436
I65
sg17437
VP-Rex1
p33407
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp33408
(dp33409
g17436
I99
sg17437
g33400
sg17438
I13
sg17445
VC0678222
p33410
sg17441
I2
sasa(dp33411
g135
(dp33412
(Vhistone deacetylase
p33413
Vbreast cancer
p33414
tp33415
I00
ssg17431
VTreatment of normal MCF-10A or basal-like cancer cells, MDA-MB-231 with the demethylating agent 5-aza-2'-deoxycitidine in combination with the histone deacetylase inhibitor trichostatin A restores P-REX1 levels to those observed in luminal breast cancer cell lines, suggesting that aberrant expression of P-REX1 in luminal breast cancer is a consequence of PREX1 promoter demethylation.
p33416
sg17433
(lp33417
(dp33418
g17436
I197
sg17437
VP-REX1
p33419
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp33420
g17436
I197
sg17437
VP-REX1
p33421
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp33422
g17436
I163
sg17437
Vinhibitor trichostatin A
p33423
sg17438
I24
sg17439
VP32119
p33424
sg17441
I3
sa(dp33425
g17436
I143
sg17437
g33413
sg17438
I19
sg17439
VP56524
p33426
sg17441
I2
sasg17442
(lp33427
(dp33428
g17436
I240
sg17437
Vbreast cancer
p33429
sg17438
I13
sg17445
VC0678222
p33430
sg17441
I2
sa(dp33431
g17436
I42
sg17437
Vcancer
p33432
sg17438
I6
sg17445
VC0006826
p33433
sg17441
I1
sa(dp33434
g17436
I240
sg17437
g33414
sg17438
I13
sg17445
VC0678222
p33435
sg17441
I2
sasa(dp33436
g135
(dp33437
(Vubiquitin
p33438
Vautosomal dominant retinitis pigmentosa
p33439
tp33440
I00
ssg17431
VWe identify 112 candidate ciliogenesis and ciliopathy genes, including 44 components of the ubiquitin-proteasome system, 12 G-protein-coupled receptors, and 3 pre-mRNA processing factors (PRPF6, PRPF8 and PRPF31) mutated in autosomal dominant retinitis pigmentosa.
p33441
sg17433
(lp33442
(dp33443
g17436
I195
sg17437
VPRPF8
p33444
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp33445
g17436
I121
sg17437
V12 G-protein-coupled receptors
p33446
sg17438
I30
sg17439
g12
sg17441
I3
sa(dp33447
g17436
I205
sg17437
VPRPF31
p33448
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp33449
g17436
I188
sg17437
VPRPF6
p33450
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp33451
g17436
I92
sg17437
g33438
sg17438
I9
sg17439
VP62979
p33452
sg17441
I1
sasg17442
(lp33453
(dp33454
g17436
I224
sg17437
g33439
sg17438
I39
sg17445
VC0339525
p33455
sg17441
I4
sasa(dp33456
g17431
VMutations in six spliceosomal proteins, PRPF3, PRPF4, PRPF6, PRPF8, PRPF31 and SNRNP200, cause retinitis pigmentosa (RP), a disease characterized by progressive photoreceptor degeneration.
p33457
sg17433
(lp33458
(dp33459
g17436
I47
sg17437
VPRPF4
p33460
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp33461
g17436
I68
sg17437
VPRPF31
p33462
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp33463
g17436
I79
sg17437
VSNRNP200
p33464
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp33465
g17436
I54
sg17437
VPRPF6
p33466
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp33467
g17436
I61
sg17437
VPRPF8
p33468
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp33469
g17436
I40
sg17437
VPRPF3
p33470
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp33471
(dp33472
g17436
I41
sg17437
VRP
p33473
sg17438
I2
sg17445
VC0035334
p33474
sg17441
I1
sa(dp33475
g17436
I95
sg17437
Vretinitis pigmentosa
p33476
sg17438
I20
sg17445
VC0035334
p33477
sg17441
I2
sa(dp33478
g17436
I161
sg17437
Vphotoreceptor degeneration
p33479
sg17438
I26
sg17445
VC1998028
p33480
sg17441
I2
sasa(dp33481
g17431
VIn addition, a pAsn477Ser change in the neighboring gene PRPF6, a gene previously found to be associated with retinitis pigmentosa, segregated with the ADKD phenotype.
p33482
sg17433
(lp33483
(dp33484
g17436
I52
sg17437
Vgene PRPF6
p33485
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp33486
(dp33487
g17436
I110
sg17437
Vretinitis pigmentosa
p33488
sg17438
I20
sg17445
VC0035334
p33489
sg17441
I2
sasa(dp33490
g17431
VYeast two-hybrid analyses suggest a link between retinitis pigmentosa and an aberrant hPrp31-hPrp6 interaction that blocks U4/U6-U5 tri-snRNP formation.
p33491
sg17433
(lp33492
(dp33493
g17436
I93
sg17437
VhPrp6
p33494
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp33495
g17436
I86
sg17437
VhPrp31
p33496
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp33497
(dp33498
g17436
I49
sg17437
Vretinitis pigmentosa
p33499
sg17438
I20
sg17445
VC0035334
p33500
sg17441
I2
sasa(dp33501
g17431
VIn humans and in mice, mutations in the Ostm1 gene cause the most severe form of osteopetrosis, a major bone disease, and neuronal degeneration, both of which are associated with early death.
p33502
sg17433
(lp33503
(dp33504
g17436
I40
sg17437
VOstm1 gene
p33505
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp33506
(dp33507
g17436
I81
sg17437
Vosteopetrosis
p33508
sg17438
I13
sg17445
VC0029454
p33509
sg17441
I1
sa(dp33510
g17436
I131
sg17437
Vdegeneration
p33511
sg17438
I12
sg17445
VC0011164
p33512
sg17441
I1
sa(dp33513
g17436
I104
sg17437
Vbone disease
p33514
sg17438
I12
sg17445
VC0005940
p33515
sg17441
I2
sasa(dp33516
g17431
VGenetic defects in OSTM1 (osteopetrosis-associated transmembrane protein 1) cause autosomal recessive osteopetrosis in humans.
p33517
sg17433
(lp33518
sg17442
(lp33519
(dp33520
g17436
I26
sg17437
Vosteopetrosis
p33521
sg17438
I13
sg17445
VC0029454
p33522
sg17441
I1
sa(dp33523
g17436
I26
sg17437
Vosteopetrosis
p33524
sg17438
I13
sg17445
VC0029454
p33525
sg17441
I1
sasa(dp33526
g17431
VThus, these findings suggest that autosomal recessive osteopetrosis patients with an OSTM1 gene mutation lacking the transmembrane domain produce a secreted form of truncated OSTM1 that inhibits osteoclastogenesis.
p33527
sg17433
(lp33528
(dp33529
g17436
I85
sg17437
VOSTM1 gene
p33530
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp33531
(dp33532
g17436
I54
sg17437
Vosteopetrosis
p33533
sg17438
I13
sg17445
VC0029454
p33534
sg17441
I1
sasa(dp33535
g135
(dp33536
(Vlysosomal ClC-7
p33537
Vosteopetrosis
p33538
tp33539
I00
ssg17431
VLoss of the lysosomal ClC-7/Ostm1 2Cl(-)/H(+) exchanger causes lysosomal storage disease and osteopetrosis in humans and additionally changes fur colour in mice.
p33540
sg17433
(lp33541
(dp33542
g17436
I12
sg17437
g33537
sg17438
I15
sg17439
VP51798
p33543
sg17441
I2
sa(dp33544
g17436
I28
sg17437
VOstm1
p33545
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp33546
(dp33547
g17436
I63
sg17437
Vlysosomal storage disease
p33548
sg17438
I25
sg17445
VC0085078
p33549
sg17441
I3
sa(dp33550
g17436
I93
sg17437
g33538
sg17438
I13
sg17445
VC0029454
p33551
sg17441
I1
sasa(dp33552
g17431
VLoss of Ostm1 leads to the most severe form of osteopetrosis in mice and humans.
p33553
sg17433
(lp33554
(dp33555
g17436
I8
sg17437
VOstm1
p33556
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp33557
(dp33558
g17436
I47
sg17437
Vosteopetrosis
p33559
sg17438
I13
sg17445
VC0029454
p33560
sg17441
I1
sasa(dp33561
g135
(dp33562
(VClC-7
p33563
Vosteopetrosis
p33564
tp33565
I00
ssg17431
VMice lacking either ClC-7 or Ostm1 develop a lysosomal storage disease and mutations in either protein have been found to underlie osteopetrosis in mice and humans.
p33566
sg17433
(lp33567
(dp33568
g17436
I20
sg17437
g33563
sg17438
I5
sg17439
VP51798
p33569
sg17441
I1
sa(dp33570
g17436
I29
sg17437
VOstm1
p33571
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp33572
(dp33573
g17436
I45
sg17437
Vlysosomal storage disease
p33574
sg17438
I25
sg17445
VC0085078
p33575
sg17441
I3
sa(dp33576
g17436
I131
sg17437
g33564
sg17438
I13
sg17445
VC0029454
p33577
sg17441
I1
sasa(dp33578
g135
(dp33579
(VClC-7
p33580
Vosteopetrosis
p33581
tp33582
I00
ssg17431
VMice or humans lacking ClC-7 or Ostm1 display osteopetrosis and lysosomal storage disease.
p33583
sg17433
(lp33584
(dp33585
g17436
I32
sg17437
VOstm1
p33586
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp33587
g17436
I23
sg17437
g33580
sg17438
I5
sg17439
VP51798
p33588
sg17441
I1
sasg17442
(lp33589
(dp33590
g17436
I64
sg17437
Vlysosomal storage disease
p33591
sg17438
I25
sg17445
VC0085078
p33592
sg17441
I3
sa(dp33593
g17436
I46
sg17437
g33581
sg17438
I13
sg17445
VC0029454
p33594
sg17441
I1
sasa(dp33595
g17431
VHere we describe for the first time homozygous microdeletions of different sizes affecting the OSTM1 gene in two unrelated consanguineous families with children suffering from neuronopathic infantile malignant osteopetrosis.
p33596
sg17433
(lp33597
(dp33598
g17436
I95
sg17437
VOSTM1 gene
p33599
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp33600
(dp33601
g17436
I161
sg17437
Vsuffering
p33602
sg17438
I9
sg17445
VC0683278
p33603
sg17441
I1
sa(dp33604
g17436
I190
sg17437
Vinfantile malignant osteopetrosis
p33605
sg17438
I33
sg17445
VC1318518
p33606
sg17441
I3
sasa(dp33607
g135
(dp33608
(Vtestis basic protein
p33609
VEwing's sarcoma
p33610
tp33611
I00
ssg17431
VOur findings are summarized as follows: i) BPY2 (testis basic protein on Y, 2), DAZ1 (deleted in azoospermia 1), TTY4 (testis transcript Y 4) mRNAs and 23 ESTs were found; ii) Eighteen of 23 ESTs were transcripts of the DAZ gene(s), one EST was a transcript of TTY4 gene, and the remaining 4 probably corresponded to 4 different pseudogenes; iii) DAZ gene(s) were expressed not only in testis, but also in lung carcinoma cells, stomach and Ewing's sarcoma cells; iv) beta-satellite clusters were present around and within the BPY2 and TTY4 gene region; v) In this study, TTY4, BPY2 and DAZ1 genes were mapped precisely to the AC010088 region.
p33612
sg17433
(lp33613
(dp33614
g17436
I80
sg17437
VDAZ1
p33615
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp33616
g17436
I49
sg17437
g33609
sg17438
I20
sg17439
VP15735
p33617
sg17441
I3
sa(dp33618
g17436
I43
sg17437
VBPY2
p33619
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp33620
g17436
I220
sg17437
VDAZ gene
p33621
sg17438
I8
sg17439
g12
sg17441
I2
sa(dp33622
g17436
I220
sg17437
VDAZ gene(s)
p33623
sg17438
I11
sg17439
g12
sg17441
I2
sa(dp33624
g17436
I43
sg17437
VBPY2
p33625
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp33626
g17436
I586
sg17437
VDAZ1 genes
p33627
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp33628
g17436
I43
sg17437
VBPY2
p33629
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp33630
g17436
I86
sg17437
Vdeleted in azoospermia 1
p33631
sg17438
I24
sg17439
g12
sg17441
I4
sasg17442
(lp33632
(dp33633
g17436
I406
sg17437
Vlung carcinoma
p33634
sg17438
I14
sg17445
VC0684249
p33635
sg17441
I2
sa(dp33636
g17436
I440
sg17437
g33610
sg17438
I15
sg17445
VC0553580
p33637
sg17441
I2
sa(dp33638
g17436
I97
sg17437
Vazoospermia
p33639
sg17438
I11
sg17445
VC1321542
p33640
sg17441
I1
sasa(dp33641
g135
(dp33642
(VPOMC
p33643
Vhyperphagia
p33644
tp33645
I01
ssg17431
VLowered POMC and heightened TRPV3 expressions in the HN and mNTS are involved in development of hyperphagia and obesity in OP rats.
p33646
sg17433
(lp33647
(dp33648
g17436
I8
sg17437
g33643
sg17438
I4
sg17439
VP01189
p33649
sg17441
I1
sa(dp33650
g17436
I28
sg17437
VTRPV3
p33651
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp33652
(dp33653
g17436
I112
sg17437
Vobesity
p33654
sg17438
I7
sg17445
VC0028754
p33655
sg17441
I1
sa(dp33656
g17436
I96
sg17437
g33644
sg17438
I11
sg17445
VC0020505
p33657
sg17441
I1
sasa(dp33658
g17431
VHere, we have shown that it is applicable to 10 human colorectal carcinoma cell lines with a direct correlation between viral toxicity and CPG2 production.
p33659
sg17433
(lp33660
sg17442
(lp33661
(dp33662
g17436
I54
sg17437
Vcolorectal carcinoma
p33663
sg17438
I20
sg17445
VC0009402
p33664
sg17441
I2
sasa(dp33665
g135
(dp33666
(VCPG2
p33667
Vcolorectal carcinoma
p33668
tp33669
I00
ssg17431
VTen patients with colorectal carcinoma expressing carcinoembryonic antigen received antibody-directed enzyme prodrug therapy with A5B7 F(ab')2 antibody to carcinoembryonic antigen conjugated to carboxypeptidase G2 (CPG2).
p33670
sg17433
(lp33671
(dp33672
g17436
I194
sg17437
Vcarboxypeptidase G2
p33673
sg17438
I19
sg17439
VP10619
p33674
sg17441
I2
sa(dp33675
g17436
I50
sg17437
Vcarcinoembryonic antigen
p33676
sg17438
I24
sg17439
VP40198
p33677
sg17441
I2
sa(dp33678
g17436
I215
sg17437
g33667
sg17438
I4
sg17439
VP10619
p33679
sg17441
I1
sasg17442
(lp33680
(dp33681
g17436
I18
sg17437
g33668
sg17438
I20
sg17445
VC0009402
p33682
sg17441
I2
sasa(dp33683
g135
(dp33684
(Vbacterial beta-galactosidase
p33685
Vadenocarcinomas
p33686
tp33687
I01
ssg17431
VHuman tumor cell lines A2780, SK-OV-3 (ovarian adenocarcinomas), LS174T, and WiDr (colon carcinomas) were engineered to express constitutively either CPG2 or bacterial beta-galactosidase.
p33688
sg17433
(lp33689
(dp33690
g17436
I158
sg17437
g33685
sg17438
I28
sg17439
VP16278
p33691
sg17441
I2
sasg17442
(lp33692
(dp33693
g17436
I6
sg17437
Vtumor
p33694
sg17438
I5
sg17445
VC0027651
p33695
sg17441
I1
sa(dp33696
g17436
I47
sg17437
g33686
sg17438
I15
sg17445
VC0001418
p33697
sg17441
I1
sa(dp33698
g17436
I52
sg17437
Vcarcinomas
p33699
sg17438
I10
sg17445
VC0007097
p33700
sg17441
I1
sasa(dp33701
g135
(dp33702
(Vlumican-null
p33703
Vmucopolysaccharidosis
p33704
tp33705
I00
ssg17431
VThey have been used to treat mouse models of connective tissue disease such as lumican-null (Lum) and mucopolysaccharidosis (Gusb) mice.
p33706
sg17433
(lp33707
(dp33708
g17436
I93
sg17437
VLum
p33709
sg17438
I3
sg17439
VP51884
p33710
sg17441
I1
sa(dp33711
g17436
I79
sg17437
g33703
sg17438
I12
sg17439
VP51884
p33712
sg17441
I1
sasg17442
(lp33713
(dp33714
g17436
I45
sg17437
Vconnective tissue disease
p33715
sg17438
I25
sg17445
VC0009782
p33716
sg17441
I3
sa(dp33717
g17436
I102
sg17437
g33704
sg17438
I21
sg17445
VC0026703
p33718
sg17441
I1
sasa(dp33719
g135
(dp33720
(Vlumican
p33721
Vdiabetes
p33722
tp33723
I00
ssg17431
VExpression of fibromodulin was significantly higher in plaques obtained from patients with diabetes and a high fibromodulin expression was associated with a higher incidence of post-operative cerebrovascular events, whereas no such associations were seen for lumican.
p33724
sg17433
(lp33725
(dp33726
g17436
I14
sg17437
Vfibromodulin
p33727
sg17438
I12
sg17439
g12
sg17441
I1
sa(dp33728
g17436
I259
sg17437
g33721
sg17438
I7
sg17439
VP51884
p33729
sg17441
I1
sa(dp33730
g17436
I14
sg17437
Vfibromodulin
p33731
sg17438
I12
sg17439
g12
sg17441
I1
sasg17442
(lp33732
(dp33733
g17436
I55
sg17437
Vplaques
p33734
sg17438
I7
sg17445
VC0333463
p33735
sg17441
I1
sa(dp33736
g17436
I91
sg17437
g33722
sg17438
I8
sg17445
VC0011849
p33737
sg17441
I1
sasa(dp33738
g135
(dp33739
(Vdecorin
p33740
Vdiabetes
p33741
tp33742
I00
ssg17431
VThis study aimed to identify which myometrial ECM components are affected by diabetes, including fibril-forming collagen types I, III and V, as well as proteoglycans, decorin, lumican, fibromodulin and biglycan.
p33743
sg17433
(lp33744
(dp33745
g17436
I185
sg17437
Vfibromodulin
p33746
sg17438
I12
sg17439
g12
sg17441
I1
sa(dp33747
g17436
I176
sg17437
Vlumican
p33748
sg17438
I7
sg17439
VP51884
p33749
sg17441
I1
sa(dp33750
g17436
I35
sg17437
Vmyometrial ECM components
p33751
sg17438
I25
sg17439
g12
sg17441
I3
sa(dp33752
g17436
I167
sg17437
g33740
sg17438
I7
sg17439
VP07585
p33753
sg17441
I1
sasg17442
(lp33754
(dp33755
g17436
I77
sg17437
g33741
sg17438
I8
sg17445
VC0011849
p33756
sg17441
I1
sasa(dp33757
g135
(dp33758
(VC5a receptors
p33759
Vlymphopenia
p33760
tp33761
I00
ssg17431
VUsing the polymicrobial model of murine sepsis, we investigated the role of C5a receptors in septic lymphopenia.
p33762
sg17433
(lp33763
(dp33764
g17436
I76
sg17437
g33759
sg17438
I13
sg17439
VP21730
p33765
sg17441
I2
sasg17442
(lp33766
(dp33767
g17436
I40
sg17437
Vsepsis
p33768
sg17438
I6
sg17445
VC0243026
p33769
sg17441
I1
sa(dp33770
g17436
I100
sg17437
g33760
sg17438
I11
sg17445
VC0024312
p33771
sg17441
I1
sasa(dp33772
g135
(dp33773
(VC5aR1
p33774
Vlymphopenia
p33775
tp33776
I00
ssg17431
VIn wild-type mice, cecal ligation and puncture resulted in splenocyte apoptosis and significant lymphopenia after 3 d, which was not observed in C5aR1(-/-) or C5aR2(-/-) mice.
p33777
sg17433
(lp33778
(dp33779
g17436
I145
sg17437
g33774
sg17438
I5
sg17439
VP21730
p33780
sg17441
I1
sasg17442
(lp33781
(dp33782
g17436
I96
sg17437
g33775
sg17438
I11
sg17445
VC0024312
p33783
sg17441
I1
sasa(dp33784
g17431
VNDT 9513727 effectively inhibited C5a-induced neutropenia in gerbil and cynomolgus macaque in vivo.
p33785
sg17433
(lp33786
(dp33787
g17436
I34
sg17437
VC5a
p33788
sg17438
I3
sg17439
VP21730
p33789
sg17441
I1
sasg17442
(lp33790
sa(dp33791
g135
(dp33792
(VC5aR
p33793
VLPS
p33794
tp33795
I00
ssg17431
VNonetheless, topical application of C5aR antagonists produced circulating levels of the drugs that antagonized the LPS-induced systemic responses of neutropenia and hypotension.
p33796
sg17433
(lp33797
(dp33798
g17436
I36
sg17437
g33793
sg17438
I4
sg17439
VP21730
p33799
sg17441
I1
sasg17442
(lp33800
(dp33801
g17436
I115
sg17437
g33794
sg17438
I3
sg17445
VC0175697
p33802
sg17441
I1
sasa(dp33803
g135
(dp33804
(VCD35
p33805
Vsystemic mastocytosis
p33806
tp33807
I00
ssg17431
VSeveral of these antigens (CD2, CD25, CD35, CD88, CD203c) appear to be upregulated on MCs in patients with systemic mastocytosis and therefore are used as diagnostic markers.
p33808
sg17433
(lp33809
(dp33810
g17436
I27
sg17437
VCD2
p33811
sg17438
I3
sg17439
VP06729
p33812
sg17441
I1
sa(dp33813
g17436
I50
sg17437
VCD203c
p33814
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp33815
g17436
I32
sg17437
VCD25
p33816
sg17438
I4
sg17439
VP01589
p33817
sg17441
I1
sa(dp33818
g17436
I44
sg17437
VCD88
p33819
sg17438
I4
sg17439
VP21730
p33820
sg17441
I1
sa(dp33821
g17436
I38
sg17437
g33805
sg17438
I4
sg17439
VP11274
p33822
sg17441
I1
sasg17442
(lp33823
(dp33824
g17436
I86
sg17437
VMCs
p33825
sg17438
I3
sg17445
VC0036221
p33826
sg17441
I1
sa(dp33827
g17436
I107
sg17437
g33806
sg17438
I21
sg17445
VC0221013
p33828
sg17441
I2
sasa(dp33829
g135
(dp33830
(VCD88
p33831
Vsystemic mastocytosis
p33832
tp33833
I00
ssg17431
VThis study analysed the expression of various complement-related cell surface antigens (CD11b/CR3, CD11c/CR4, CD35/CR1, CD55/DAF, CD59/MIRL, CD88/C5aR) on bone marrow mast cells (BMMC) in patients suffering from systemic mastocytosis (SM), other haematological diseases and non-haematological disorders (control groups).
p33834
sg17433
(lp33835
(dp33836
g17436
I125
sg17437
VDAF
p33837
sg17438
I3
sg17439
VP08174
p33838
sg17441
I1
sa(dp33839
g17436
I146
sg17437
VC5aR
p33840
sg17438
I4
sg17439
VP21730
p33841
sg17441
I1
sa(dp33842
g17436
I46
sg17437
Vcomplement-related cell surface antigens
p33843
sg17438
I40
sg17439
g12
sg17441
I4
sa(dp33844
g17436
I130
sg17437
VCD59
p33845
sg17438
I4
sg17439
VP13987
p33846
sg17441
I1
sa(dp33847
g17436
I115
sg17437
VCR1
p33848
sg17438
I3
sg17439
VP17927
p33849
sg17441
I1
sa(dp33850
g17436
I105
sg17437
VCR4
p33851
sg17438
I3
sg17439
VP20702
p33852
sg17441
I1
sa(dp33853
g17436
I88
sg17437
VCD11b
p33854
sg17438
I5
sg17439
VP11215
p33855
sg17441
I1
sa(dp33856
g17436
I110
sg17437
VCD35
p33857
sg17438
I4
sg17439
VP11274
p33858
sg17441
I1
sa(dp33859
g17436
I120
sg17437
VCD55
p33860
sg17438
I4
sg17439
VP08174
p33861
sg17441
I1
sa(dp33862
g17436
I94
sg17437
VCR3
p33863
sg17438
I3
sg17439
VP51864
p33864
sg17441
I1
sa(dp33865
g17436
I135
sg17437
VMIRL
p33866
sg17438
I4
sg17439
VP13987
p33867
sg17441
I1
sa(dp33868
g17436
I99
sg17437
VCD11c
p33869
sg17438
I5
sg17439
VP20702
p33870
sg17441
I1
sa(dp33871
g17436
I141
sg17437
g33831
sg17438
I4
sg17439
VP21730
p33872
sg17441
I1
sasg17442
(lp33873
(dp33874
g17436
I278
sg17437
Vhaematological disorders
p33875
sg17438
I24
sg17445
VC0018939
p33876
sg17441
I2
sa(dp33877
g17436
I197
sg17437
Vsuffering
p33878
sg17438
I9
sg17445
VC0683278
p33879
sg17441
I1
sa(dp33880
g17436
I235
sg17437
VSM
p33881
sg17438
I2
sg17445
VC0221013
p33882
sg17441
I1
sa(dp33883
g17436
I212
sg17437
g33832
sg17438
I21
sg17445
VC0221013
p33884
sg17441
I2
sasa(dp33885
g135
(dp33886
(VC5a
p33887
Vlipopolysaccharide
p33888
tp33889
I00
ssg17431
VA cyclic peptide, Phe-[Orn-Pro-D-Cyclohexylalanine-Trp-Arg] (F-[OPdChaWR]), was recently shown in vitro to antagonise the binding of C5a to its receptor (CD88) on human polymorphonuclear leukocytes (PMNs) and in vivo to inhibit the neutropenia associated with septic shock induced by lipopolysaccharide (LPS) in rats.
p33890
sg17433
(lp33891
(dp33892
g17436
I154
sg17437
VCD88
p33893
sg17438
I4
sg17439
VP21730
p33894
sg17441
I1
sa(dp33895
g17436
I133
sg17437
g33887
sg17438
I3
sg17439
VP21730
p33896
sg17441
I1
sasg17442
(lp33897
(dp33898
g17436
I260
sg17437
Vseptic shock
p33899
sg17438
I12
sg17445
VC0036983
p33900
sg17441
I2
sa(dp33901
g17436
I304
sg17437
VLPS
p33902
sg17438
I3
sg17445
VC0175697
p33903
sg17441
I1
sa(dp33904
g17436
I284
sg17437
g33888
sg17438
I18
sg17445
VC0175697
p33905
sg17441
I1
sasa(dp33906
g17431
VSome in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs).
p33907
sg17433
(lp33908
(dp33909
g17436
I31
sg17437
Vcomplement C5a
p33910
sg17438
I14
sg17439
g12
sg17441
I2
sasg17442
(lp33911
sa(dp33912
g135
(dp33913
(VC5aR
p33914
Veosinophilia
p33915
tp33916
I00
ssg17431
VThe abnormal C5aR expression on eosinophils and neutrophils became normal after spontaneous resolution of symptoms and blood eosinophilia.
p33917
sg17433
(lp33918
(dp33919
g17436
I13
sg17437
g33914
sg17438
I4
sg17439
VP21730
p33920
sg17441
I1
sasg17442
(lp33921
(dp33922
g17436
I125
sg17437
g33915
sg17438
I12
sg17445
VC0014457
p33923
sg17441
I1
sasa(dp33924
g135
(dp33925
(VSgcb-null Rag2-null Gammac-null
p33926
VScid
p33927
tp33928
I00
ssg17431
VThe therapeutic potential of DPPSC was tested in a wound healing mouse model and in two genetic mouse models of muscular dystrophy (Scid/mdx and Sgcb-null Rag2-null Gammac-null).
p33929
sg17433
(lp33930
(dp33931
g17436
I145
sg17437
g33926
sg17438
I31
sg17439
VP55895
p33932
sg17441
I3
sasg17442
(lp33933
(dp33934
g17436
I112
sg17437
Vmuscular dystrophy
p33935
sg17438
I18
sg17445
VC0026850
p33936
sg17441
I2
sa(dp33937
g17436
I137
sg17437
Vmdx
p33938
sg17438
I3
sg17445
VC1839839
p33939
sg17441
I1
sa(dp33940
g17436
I132
sg17437
g33927
sg17438
I4
sg17445
VC0085110
p33941
sg17441
I1
sasa(dp33942
g135
(dp33943
(VRAG1
p33944
Vautoimmune diseases
p33945
tp33946
I00
ssg17431
VMutations in the RAG1/RAG2 genes are associated with a broad spectrum of clinical phenotypes, ranging from severe combined immunodeficiency to various autoimmune diseases.
p33947
sg17433
(lp33948
(dp33949
g17436
I22
sg17437
VRAG2
p33950
sg17438
I4
sg17439
VP55895
p33951
sg17441
I1
sa(dp33952
g17436
I17
sg17437
g33944
sg17438
I4
sg17439
VP15918
p33953
sg17441
I1
sasg17442
(lp33954
(dp33955
g17436
I107
sg17437
Vsevere combined immunodeficiency
p33956
sg17438
I32
sg17445
VC0085110
p33957
sg17441
I3
sa(dp33958
g17436
I151
sg17437
g33945
sg17438
I19
sg17445
VC0004364
p33959
sg17441
I2
sasa(dp33960
g135
(dp33961
(VRAG2
p33962
VOmenn syndrome
p33963
tp33964
I00
ssg17431
VIn this review, the molecular pathology of diseases caused by RAG1/RAG2 mutations, in particular Omenn syndrome, will be discussed.
p33965
sg17433
(lp33966
(dp33967
g17436
I62
sg17437
VRAG1
p33968
sg17438
I4
sg17439
VP15918
p33969
sg17441
I1
sa(dp33970
g17436
I67
sg17437
g33962
sg17438
I4
sg17439
VP55895
p33971
sg17441
I1
sasg17442
(lp33972
(dp33973
g17436
I30
sg17437
Vpathology
p33974
sg17438
I9
sg17445
VC0677042
p33975
sg17441
I1
sa(dp33976
g17436
I97
sg17437
g33963
sg17438
I14
sg17445
VC1801959
p33977
sg17441
I2
sasa(dp33978
g135
(dp33979
(VJAK3
p33980
VPID
p33981
tp33982
I00
ssg17431
VSevere combined immunodeficiency (SCID) is a potentially fatal primary immunodeficiency (PID) that is caused by mutations in genes such as IL2RG, JAK3, IL7RA, RAG1, RAG2, and ADA.
p33983
sg17433
(lp33984
(dp33985
g17436
I159
sg17437
VRAG1
p33986
sg17438
I4
sg17439
VP15918
p33987
sg17441
I1
sa(dp33988
g17436
I139
sg17437
VIL2RG
p33989
sg17438
I5
sg17439
VP31785
p33990
sg17441
I1
sa(dp33991
g17436
I175
sg17437
VADA
p33992
sg17438
I3
sg17439
VP00813
p33993
sg17441
I1
sa(dp33994
g17436
I165
sg17437
VRAG2
p33995
sg17438
I4
sg17439
VP55895
p33996
sg17441
I1
sa(dp33997
g17436
I146
sg17437
g33980
sg17438
I4
sg17439
VP52333
p33998
sg17441
I1
sasg17442
(lp33999
(dp34000
g17436
I34
sg17437
VSCID
p34001
sg17438
I4
sg17445
VC0085110
p34002
sg17441
I1
sa(dp34003
g17436
I63
sg17437
Vprimary immunodeficiency
p34004
sg17438
I24
sg17445
VC0398686
p34005
sg17441
I2
sa(dp34006
g17436
I0
sg17437
VSevere combined immunodeficiency
p34007
sg17438
I32
sg17445
VC0085110
p34008
sg17441
I3
sa(dp34009
g17436
I89
sg17437
g33981
sg17438
I3
sg17445
VC0242172
p34010
sg17441
I1
sasa(dp34011
g135
(dp34012
(VRAG1
p34013
VSevere combined immunodeficiency
p34014
tp34015
I00
ssg17431
VSevere combined immunodeficiency can be caused by loss-of-function mutations in genes involved in the DNA recombination machinery, such as recombination-activating gene 1 (RAG1), RAG2, or DNA cross-link repair 1C (DCLRE1C).
p34016
sg17433
(lp34017
(dp34018
g17436
I139
sg17437
Vrecombination-activating gene 1
p34019
sg17438
I31
sg17439
VP15918
p34020
sg17441
I3
sa(dp34021
g17436
I179
sg17437
VRAG2
p34022
sg17438
I4
sg17439
VP55895
p34023
sg17441
I1
sa(dp34024
g17436
I172
sg17437
g34013
sg17438
I4
sg17439
VP15918
p34025
sg17441
I1
sasg17442
(lp34026
(dp34027
g17436
I0
sg17437
g34014
sg17438
I32
sg17445
VC0085110
p34028
sg17441
I3
sasa(dp34029
g17431
VSeven of the 98 cases (7%) of carcinomas showed TLE-1 expression, including 1 each of prostate adenocarcinoma (ADCA), esophageal ADCA, basal cell carcinoma, adrenocortical carcinoma, endometrial ADCA, ovarian serous carcinoma, and small cell carcinoma.
p34030
sg17433
(lp34031
sg17442
(lp34032
(dp34033
g17436
I86
sg17437
Vprostate adenocarcinoma
p34034
sg17438
I23
sg17445
VC0007112
p34035
sg17441
I2
sa(dp34036
g17436
I231
sg17437
Vsmall cell carcinoma
p34037
sg17438
I20
sg17445
VC0262584
p34038
sg17441
I3
sa(dp34039
g17436
I111
sg17437
VADCA
p34040
sg17438
I4
sg17445
VC0007112
p34041
sg17441
I1
sa(dp34042
g17436
I111
sg17437
VADCA
p34043
sg17438
I4
sg17445
VC0007112
p34044
sg17441
I1
sa(dp34045
g17436
I48
sg17437
VTLE
p34046
sg17438
I3
sg17445
VC0014556
p34047
sg17441
I1
sa(dp34048
g17436
I146
sg17437
Vcarcinoma, adrenocortical
p34049
sg17438
I25
sg17445
VC0206686
p34050
sg17441
I2
sa(dp34051
g17436
I30
sg17437
Vcarcinomas
p34052
sg17438
I10
sg17445
VC0007097
p34053
sg17441
I1
sa(dp34054
g17436
I111
sg17437
VADCA
p34055
sg17438
I4
sg17445
VC0007112
p34056
sg17441
I1
sa(dp34057
g17436
I172
sg17437
Vcarcinoma, endometrial
p34058
sg17438
I22
sg17445
VC0476089
p34059
sg17441
I2
sa(dp34060
g17436
I201
sg17437
Vovarian serous carcinoma
p34061
sg17438
I24
sg17445
VC1335177
p34062
sg17441
I3
sasa(dp34063
g135
(dp34064
(VTKI
p34065
VMES
p34066
tp34067
I00
ssg17431
VHere, we evaluated the effects of 15d-PGJ2 alone and in combination with the tyrosine kinas inhibitor (TKI) dasatinib in uterine sarcoma cell lines (MES-SA, MES-SA/DX5 and SKN).
p34068
sg17433
(lp34069
(dp34070
g17436
I149
sg17437
VMES-SA
p34071
sg17438
I6
sg17439
VP31947
p34072
sg17441
I1
sa(dp34073
g17436
I77
sg17437
Vtyrosine kinas inhibitor
p34074
sg17438
I24
sg17439
VP14679
p34075
sg17441
I3
sa(dp34076
g17436
I103
sg17437
g34065
sg17438
I3
sg17439
VP14679
p34077
sg17441
I1
sa(dp34078
g17436
I172
sg17437
VSKN
p34079
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp34080
(dp34081
g17436
I149
sg17437
VMES
p34082
sg17438
I3
sg17445
VC0265215
p34083
sg17441
I1
sa(dp34084
g17436
I121
sg17437
Vuterine sarcoma
p34085
sg17438
I15
sg17445
VC0338113
p34086
sg17441
I2
sa(dp34087
g17436
I149
sg17437
g34066
sg17438
I3
sg17445
VC0265215
p34088
sg17441
I1
sasa(dp34089
g135
(dp34090
(VRNase P
p34091
Vprostate cancer
p34092
tp34093
I00
ssg17431
VPrevious studies have shown that N(1),N(12)-bis(all-trans-retinoyl)spermine (RASP), a retinoid analog, inhibits RNase P activity and angiogenesis in the chicken embryo chorioallantoic membrane, demonstrates anti-tumor activity on prostate cancer cells, and acts as anti-inflammatory agent, being more effective and less toxic than all-trans retinoic acid.
p34094
sg17433
(lp34095
(dp34096
g17436
I112
sg17437
g34091
sg17438
I7
sg17439
VP07998
p34097
sg17441
I2
sasg17442
(lp34098
(dp34099
g17436
I212
sg17437
Vtumor
p34100
sg17438
I5
sg17445
VC0027651
p34101
sg17441
I1
sa(dp34102
g17436
I230
sg17437
g34092
sg17438
I15
sg17445
VC0600139
p34103
sg17441
I2
sasa(dp34104
g17431
VThese results suggest RASP, as a promising lead compound for the treatment of several dermatological disorders and certain cancer types, has apparently minimal toxic side-effects as revealed in this two-generation reproduction study in rats.
p34105
sg17433
(lp34106
(dp34107
g17436
I22
sg17437
VRASP
p34108
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp34109
(dp34110
g17436
I86
sg17437
Vdermatological disorders
p34111
sg17438
I24
sg17445
VC0037274
p34112
sg17441
I2
sa(dp34113
g17436
I123
sg17437
Vcancer
p34114
sg17438
I6
sg17445
VC0006826
p34115
sg17441
I1
sasa(dp34116
g135
(dp34117
(Vestrogen receptor
p34118
Vbreast cancer
p34119
tp34120
I00
ssg17431
VTo determine the functional significance of Hhat expression in breast cancer, we used a panel of breast cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen resistant cells.
p34121
sg17433
(lp34122
(dp34123
g17436
I155
sg17437
VER
p34124
sg17438
I2
sg17439
VP03372
p34125
sg17441
I1
sa(dp34126
g17436
I169
sg17437
VHER2
p34127
sg17438
I4
sg17439
VP04626
p34128
sg17441
I1
sa(dp34129
g17436
I136
sg17437
g34118
sg17438
I17
sg17439
VP03372
p34130
sg17441
I2
sasg17442
(lp34131
(dp34132
g17436
I63
sg17437
Vbreast cancer
p34133
sg17438
I13
sg17445
VC0678222
p34134
sg17441
I2
sa(dp34135
g17436
I63
sg17437
g34119
sg17438
I13
sg17445
VC0678222
p34136
sg17441
I2
sasa(dp34137
g17431
VDepletion of Hhat decreased anchorage-dependent and anchorage-independent proliferation of ER positive, but not triple negative, breast cancer cells.
p34138
sg17433
(lp34139
sg17442
(lp34140
(dp34141
g17436
I129
sg17437
Vbreast cancer
p34142
sg17438
I13
sg17445
VC0678222
p34143
sg17441
I2
sa(dp34144
g17436
I74
sg17437
Vproliferation
p34145
sg17438
I13
sg17445
VC0334094
p34146
sg17441
I1
sasa(dp34147
g135
(dp34148
(VHER2
p34149
Vbreast cancer
p34150
tp34151
I00
ssg17431
VThese data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic benefit in breast cancer.
p34152
sg17433
(lp34153
(dp34154
g17436
I67
sg17437
g34149
sg17438
I4
sg17439
VP04626
p34155
sg17441
I1
sasg17442
(lp34156
(dp34157
g17436
I105
sg17437
Vbreast cancer
p34158
sg17438
I13
sg17445
VC0678222
p34159
sg17441
I2
sa(dp34160
g17436
I119
sg17437
Vproliferation
p34161
sg17438
I13
sg17445
VC0334094
p34162
sg17441
I1
sa(dp34163
g17436
I105
sg17437
g34150
sg17438
I13
sg17445
VC0678222
p34164
sg17441
I2
sasa(dp34165
g17431
VHedgehog acyltransferase (HHAT) is the enzyme in the endoplasmic reticulum that palmitoylates Hedgehog proteins, is a member of a small subfamily of membrane-bound O-acyltransferase proteins that acylate secreted proteins, and is an important drug target in cancer.
p34166
sg17433
(lp34167
(dp34168
g17436
I26
sg17437
VHHAT
p34169
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34170
g17436
I164
sg17437
VO-acyltransferase proteins
p34171
sg17438
I26
sg17439
VP02649
p34172
sg17441
I2
sa(dp34173
g17436
I0
sg17437
VHedgehog acyltransferase
p34174
sg17438
I24
sg17439
g12
sg17441
I2
sasg17442
(lp34175
(dp34176
g17436
I258
sg17437
Vcancer
p34177
sg17438
I6
sg17445
VC0006826
p34178
sg17441
I1
sasa(dp34179
g135
(dp34180
(Vcholesterol-binding membrane protein
p34181
Vbreast cancers
p34182
tp34183
I00
ssg17431
VThe STARD3 gene belongs to the minimal amplicon in HER2-positive breast cancers and encodes a cholesterol-binding membrane protein.
p34184
sg17433
(lp34185
(dp34186
g17436
I51
sg17437
VHER2
p34187
sg17438
I4
sg17439
VP04626
p34188
sg17441
I1
sa(dp34189
g17436
I4
sg17437
VSTARD3 gene
p34190
sg17438
I11
sg17439
g12
sg17441
I2
sa(dp34191
g17436
I94
sg17437
g34181
sg17438
I36
sg17439
VP63244
p34192
sg17441
I3
sasg17442
(lp34193
(dp34194
g17436
I65
sg17437
g34182
sg17438
I14
sg17445
VC0006142
p34195
sg17441
I2
sasa(dp34196
g17431
VTo study how elevated StAR-related lipid transfer protein 3 (StARD3) expression affects breast cancer cells, we generated MCF-7 cells stably overexpressing StARD3-green fluorescent protein.
p34197
sg17433
(lp34198
(dp34199
g17436
I156
sg17437
VStARD3-green fluorescent protein
p34200
sg17438
I32
sg17439
g12
sg17441
I3
sa(dp34201
g17436
I22
sg17437
VStAR-related lipid transfer protein 3
p34202
sg17438
I37
sg17439
g12
sg17441
I5
sa(dp34203
g17436
I61
sg17437
VStARD3
p34204
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp34205
(dp34206
g17436
I88
sg17437
Vbreast cancer
p34207
sg17438
I13
sg17445
VC0678222
p34208
sg17441
I2
sa(dp34209
g17436
I22
sg17437
VStAR
p34210
sg17438
I4
sg17445
VC2678045
p34211
sg17441
I1
sasa(dp34212
g135
(dp34213
(VHER2
p34214
Vbreast cancer
p34215
tp34216
I00
ssg17431
VIn two Finnish nationwide patient cohorts, approximately 10% (212/2220) breast cancers exhibited high StARD3 protein levels, which was strongly associated with HER2 amplification; several factors related to poor disease outcome and poor breast cancer-specific survival.
p34217
sg17433
(lp34218
(dp34219
g17436
I160
sg17437
g34214
sg17438
I4
sg17439
VP04626
p34220
sg17441
I1
sa(dp34221
g17436
I102
sg17437
VStARD3 protein
p34222
sg17438
I14
sg17439
g12
sg17441
I2
sasg17442
(lp34223
(dp34224
g17436
I165
sg17437
Vamplification
p34225
sg17438
I13
sg17445
VC1705759
p34226
sg17441
I1
sa(dp34227
g17436
I72
sg17437
Vbreast cancers
p34228
sg17438
I14
sg17445
VC0006142
p34229
sg17441
I2
sa(dp34230
g17436
I72
sg17437
g34215
sg17438
I13
sg17445
VC0006142
p34231
sg17441
I2
sasa(dp34232
g135
(dp34233
(Vanti-Src
p34234
Vbreast cancers
p34235
tp34236
I00
ssg17431
VIn addition, high StARD3 levels in breast cancers were associated with elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and anti-Src-Tyr416 immunoreactivity.
p34237
sg17433
(lp34238
(dp34239
g17436
I80
sg17437
V3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA
p34240
sg17438
I52
sg17439
VP04035
p34241
sg17441
I4
sa(dp34242
g17436
I144
sg17437
g34234
sg17438
I8
sg17439
VP12931
p34243
sg17441
I1
sa(dp34244
g17436
I18
sg17437
VStARD3
p34245
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp34246
(dp34247
g17436
I35
sg17437
g34235
sg17438
I14
sg17445
VC0006142
p34248
sg17441
I2
sasa(dp34249
g135
(dp34250
(VSrc kinase
p34251
Vbreast cancer
p34252
tp34253
I00
ssg17431
VThese results provide evidence that StARD3 overexpression results in increased cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and enhancing oncogenic signaling.
p34254
sg17433
(lp34255
(dp34256
g17436
I36
sg17437
VStARD3
p34257
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34258
g17436
I108
sg17437
g34251
sg17438
I10
sg17439
VP12931
p34259
sg17441
I2
sa(dp34260
g17436
I36
sg17437
VStARD3
p34261
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp34262
(dp34263
g17436
I227
sg17437
Vaggressiveness
p34264
sg17438
I14
sg17445
VC0001807
p34265
sg17441
I1
sa(dp34266
g17436
I131
sg17437
Vbreast cancer
p34267
sg17438
I13
sg17445
VC0678222
p34268
sg17441
I2
sa(dp34269
g17436
I131
sg17437
g34252
sg17438
I13
sg17445
VC0678222
p34270
sg17441
I2
sasa(dp34271
g135
(dp34272
(VKRT20
p34273
Vbreast cancer
p34274
tp34275
I00
ssg17431
VIn addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer.
p34276
sg17433
(lp34277
(dp34278
g17436
I124
sg17437
VMED1
p34279
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34280
g17436
I138
sg17437
VGRB7
p34281
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34282
g17436
I144
sg17437
VTHRA
p34283
sg17438
I4
sg17439
VP10827
p34284
sg17441
I1
sa(dp34285
g17436
I187
sg17437
VGAST
p34286
sg17438
I4
sg17439
VP01350
p34287
sg17441
I1
sa(dp34288
g17436
I130
sg17437
VSTARD3
p34289
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34290
g17436
I164
sg17437
VCCR7
p34291
sg17438
I4
sg17439
VP32248
p34292
sg17441
I1
sa(dp34293
g17436
I150
sg17437
VRARA
p34294
sg17438
I4
sg17439
VP10276
p34295
sg17441
I1
sa(dp34296
g17436
I170
sg17437
g34273
sg17438
I5
sg17439
VP35900
p34297
sg17441
I1
sasg17442
(lp34298
(dp34299
g17436
I196
sg17437
g34274
sg17438
I13
sg17445
VC0678222
p34300
sg17441
I2
sa(dp34301
g17436
I76
sg17437
Vamplification
p34302
sg17438
I13
sg17445
VC1705759
p34303
sg17441
I1
sasa(dp34304
g135
(dp34305
(VRARA
p34306
Vbreast cancer
p34307
tp34308
I00
ssg17431
VUsing a quantitative polymerase chain reaction method and DNA extracted from frozen tumor specimens, 11 genes (MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20, KRT19 and GAS), which are localized within Chr17q12-q21 and have a putative role in breast cancer development, were quantified.
p34309
sg17433
(lp34310
(dp34311
g17436
I156
sg17437
VIGFBP4
p34312
sg17438
I6
sg17439
VP22692
p34313
sg17441
I1
sa(dp34314
g17436
I131
sg17437
VGRB7
p34315
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34316
g17436
I111
sg17437
VMED1
p34317
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34318
g17436
I117
sg17437
VSTARD3
p34319
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34320
g17436
I170
sg17437
VKRT20
p34321
sg17438
I5
sg17439
VP35900
p34322
sg17441
I1
sa(dp34323
g17436
I149
sg17437
VTOP2A
p34324
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34325
g17436
I164
sg17437
VCCR7
p34326
sg17438
I4
sg17439
VP32248
p34327
sg17441
I1
sa(dp34328
g17436
I125
sg17437
VHER2
p34329
sg17438
I4
sg17439
VP04626
p34330
sg17441
I1
sa(dp34331
g17436
I137
sg17437
VTHRA
p34332
sg17438
I4
sg17439
VP10827
p34333
sg17441
I1
sa(dp34334
g17436
I187
sg17437
VGAS
p34335
sg17438
I3
sg17439
VP01350
p34336
sg17441
I1
sa(dp34337
g17436
I143
sg17437
g34306
sg17438
I4
sg17439
VP10276
p34338
sg17441
I1
sasg17442
(lp34339
(dp34340
g17436
I261
sg17437
g34307
sg17438
I13
sg17445
VC0678222
p34341
sg17441
I2
sa(dp34342
g17436
I84
sg17437
Vtumor
p34343
sg17438
I5
sg17445
VC0027651
p34344
sg17441
I1
sasa(dp34345
g17431
VThe metastatic lymph node 64 (MLN64) gene was initially identified as highly expressed in the metastatic lymph node from breast cancer.
p34346
sg17433
(lp34347
(dp34348
g17436
I30
sg17437
VMLN64
p34349
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34350
g17436
I4
sg17437
Vmetastatic lymph node 64
p34351
sg17438
I24
sg17439
g12
sg17441
I4
sasg17442
(lp34352
(dp34353
g17436
I121
sg17437
Vbreast cancer
p34354
sg17438
I13
sg17445
VC0678222
p34355
sg17441
I2
sasa(dp34356
g17431
VHowever, the role played by MLN64 in breast cancer remains unclear.
p34357
sg17433
(lp34358
(dp34359
g17436
I28
sg17437
VMLN64
p34360
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34361
(dp34362
g17436
I37
sg17437
Vbreast cancer
p34363
sg17438
I13
sg17445
VC0678222
p34364
sg17441
I2
sasa(dp34365
g17431
VIn the present study, the expression of MLN64 was examined in a breast cancer cohort using quantitative real-time PCR and immunohistochemical staining.
p34366
sg17433
(lp34367
(dp34368
g17436
I40
sg17437
VMLN64
p34369
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34370
(dp34371
g17436
I64
sg17437
Vbreast cancer
p34372
sg17438
I13
sg17445
VC0678222
p34373
sg17441
I2
sasa(dp34374
g17431
VA panel of breast cancer cell sublines was subsequently developed by knockdown of MLN64 expression.
p34375
sg17433
(lp34376
(dp34377
g17436
I82
sg17437
VMLN64
p34378
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34379
(dp34380
g17436
I11
sg17437
Vbreast cancer
p34381
sg17438
I13
sg17445
VC0678222
p34382
sg17441
I2
sasa(dp34383
g17431
VIn conclusion, MLN64 is overexpressed in breast cancer, and its level correlates with poor prognosis and patient survival.
p34384
sg17433
(lp34385
(dp34386
g17436
I15
sg17437
VMLN64
p34387
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34388
(dp34389
g17436
I41
sg17437
Vbreast cancer
p34390
sg17438
I13
sg17445
VC0678222
p34391
sg17441
I2
sasa(dp34392
g17431
VMLN64 contributes to the development and progression of breast cancer through the regulation of cell proliferation and adhesive capacity.
p34393
sg17433
(lp34394
(dp34395
g17436
I0
sg17437
VMLN64
p34396
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34397
(dp34398
g17436
I101
sg17437
Vproliferation
p34399
sg17438
I13
sg17445
VC0334094
p34400
sg17441
I1
sa(dp34401
g17436
I56
sg17437
Vbreast cancer
p34402
sg17438
I13
sg17445
VC0678222
p34403
sg17441
I2
sasa(dp34404
g135
(dp34405
(VRARA
p34406
Vbreast cancer
p34407
tp34408
I00
ssg17431
VSTARD3 and RARA also hold clinical relevance, the former having been shown to function in steroidogenesis and therefore implicated in hormone-receptor-positive breast cancer.
p34409
sg17433
(lp34410
(dp34411
g17436
I0
sg17437
VSTARD3
p34412
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34413
g17436
I11
sg17437
g34406
sg17438
I4
sg17439
VP10276
p34414
sg17441
I1
sasg17442
(lp34415
(dp34416
g17436
I160
sg17437
g34407
sg17438
I13
sg17445
VC0678222
p34417
sg17441
I2
sasa(dp34418
g135
(dp34419
(VERBB2
p34420
Vbreast cancer
p34421
tp34422
I00
ssg17431
VWe used a genetic association study design to determine if common genetic variation (frequency&gt;or=5%) in a 400-kb region surrounding ERBB2 and containing the PPARBP, CRK7, NEUROD2, PPP1R1B, STARD3, TCAP, PNMT, CAB2, ERBB2, C17ORF37, GRB7 and ZNFN1A3 genes, was associated with breast cancer risk.
p34423
sg17433
(lp34424
(dp34425
g17436
I169
sg17437
VCRK7
p34426
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34427
g17436
I175
sg17437
VNEUROD2
p34428
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp34429
g17436
I207
sg17437
VPNMT
p34430
sg17438
I4
sg17439
VP11086
p34431
sg17441
I1
sa(dp34432
g17436
I226
sg17437
VC17ORF37
p34433
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp34434
g17436
I184
sg17437
VPPP1R1B
p34435
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp34436
g17436
I236
sg17437
VGRB7
p34437
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34438
g17436
I161
sg17437
VPPARBP
p34439
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34440
g17436
I213
sg17437
VCAB2
p34441
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34442
g17436
I245
sg17437
VZNFN1A3 genes
p34443
sg17438
I13
sg17439
g12
sg17441
I2
sa(dp34444
g17436
I193
sg17437
VSTARD3
p34445
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34446
g17436
I136
sg17437
VERBB2
p34447
sg17438
I5
sg17439
VP04626
p34448
sg17441
I1
sa(dp34449
g17436
I136
sg17437
g34420
sg17438
I5
sg17439
VP04626
p34450
sg17441
I1
sa(dp34451
g17436
I201
sg17437
VTCAP
p34452
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp34453
(dp34454
g17436
I280
sg17437
g34421
sg17438
I13
sg17445
VC0678222
p34455
sg17441
I2
sasa(dp34456
g17431
VThe applicability of salivary Beta -hexosaminidase (Beta-HEX A%, percentage of Beta-HEX A isoenzyme to total Beta-HEX) and Beta-HEX B% (Beta-HEX B/Beta-HEX) indexes was investigated as a possible marker of periodontitis.
p34457
sg17433
(lp34458
(dp34459
g17436
I21
sg17437
Vsalivary Beta -hexosaminidase
p34460
sg17438
I29
sg17439
VP04745
p34461
sg17441
I3
sa(dp34462
g17436
I52
sg17437
VBeta-HEX
p34463
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp34464
g17436
I52
sg17437
VBeta-HEX
p34465
sg17438
I8
sg17439
g12
sg17441
I1
sa(dp34466
g17436
I123
sg17437
VBeta-HEX B%
p34467
sg17438
I11
sg17439
g12
sg17441
I2
sa(dp34468
g17436
I123
sg17437
VBeta-HEX B
p34469
sg17438
I10
sg17439
g12
sg17441
I2
sa(dp34470
g17436
I52
sg17437
VBeta-HEX A
p34471
sg17438
I10
sg17439
g12
sg17441
I2
sasg17442
(lp34472
(dp34473
g17436
I206
sg17437
Vperiodontitis
p34474
sg17438
I13
sg17445
VC0031099
p34475
sg17441
I1
sasa(dp34476
g17431
VSalivary Beta-HEX A% is a promising excellent marker for the diagnosis of periodontitis.
p34477
sg17433
(lp34478
sg17442
(lp34479
(dp34480
g17436
I74
sg17437
Vperiodontitis
p34481
sg17438
I13
sg17445
VC0031099
p34482
sg17441
I1
sasa(dp34483
g17431
VTo evaluate the prognostic impact of gene expression levels (ELs) of two tumor suppressor genes, sprouty 4 (SPRY4, located on 5q) and lysine methyltransferase 2C (KMT2C, located on 7q) in correlation with clinical characteristics and genetic abnormalities assessed at initial diagnosis in acute myeloid leukemia (AML).
p34484
sg17433
(lp34485
(dp34486
g17436
I163
sg17437
VKMT2C
p34487
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34488
g17436
I134
sg17437
Vlysine methyltransferase 2C
p34489
sg17438
I27
sg17439
g12
sg17441
I3
sa(dp34490
g17436
I97
sg17437
Vsprouty 4
p34491
sg17438
I9
sg17439
g12
sg17441
I2
sa(dp34492
g17436
I108
sg17437
VSPRY4
p34493
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34494
(dp34495
g17436
I73
sg17437
Vtumor
p34496
sg17438
I5
sg17445
VC0027651
p34497
sg17441
I1
sa(dp34498
g17436
I313
sg17437
VAML
p34499
sg17438
I3
sg17445
VC0023467
p34500
sg17441
I1
sa(dp34501
g17436
I289
sg17437
Vacute myeloid leukemia
p34502
sg17438
I22
sg17445
VC0023467
p34503
sg17441
I3
sasa(dp34504
g135
(dp34505
(VRAS
p34506
Vgastric cancer
p34507
tp34508
I00
ssg17431
VAs a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
p34509
sg17433
(lp34510
(dp34511
g17436
I50
sg17437
VERK
p34512
sg17438
I3
sg17439
VP29323
p34513
sg17441
I1
sa(dp34514
g17436
I46
sg17437
g34506
sg17438
I3
sg17439
VP01116
p34515
sg17441
I1
sasg17442
(lp34516
(dp34517
g17436
I143
sg17437
Vcancers
p34518
sg17438
I7
sg17445
VC0006826
p34519
sg17441
I1
sa(dp34520
g17436
I158
sg17437
g34507
sg17438
I14
sg17445
VC0024623
p34521
sg17441
I2
sasa(dp34522
g17431
VSprouty proteins are modulators of mitogeninduced signal transduction processes and therefore can influence the process of cancerogenesis.
p34523
sg17433
(lp34524
sg17442
(lp34525
sa(dp34526
g17431
VThe encoded protein of Sprouty homolog 4 (SPRY4) is associated with various human cancers.
p34527
sg17433
(lp34528
(dp34529
g17436
I23
sg17437
VSprouty homolog 4
p34530
sg17438
I17
sg17439
g12
sg17441
I3
sa(dp34531
g17436
I42
sg17437
VSPRY4
p34532
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34533
(dp34534
g17436
I82
sg17437
Vcancers
p34535
sg17438
I7
sg17445
VC0006826
p34536
sg17441
I1
sasa(dp34537
g135
(dp34538
(VSOX2
p34539
Vrhabdoid tumor
p34540
tp34541
I00
ssg17431
VWe show that these retained super-enhancers are essential for rhabdoid tumor survival, including some that are shared by all subtypes, such as SPRY1, and other lineage-specific super-enhancers, such as SOX2 in brain-derived rhabdoid tumors.
p34542
sg17433
(lp34543
(dp34544
g17436
I202
sg17437
g34539
sg17438
I4
sg17439
VP48431
p34545
sg17441
I1
sa(dp34546
g17436
I143
sg17437
VSPRY1
p34547
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34548
(dp34549
g17436
I224
sg17437
Vrhabdoid tumors
p34550
sg17438
I15
sg17445
VC0206743
p34551
sg17441
I2
sa(dp34552
g17436
I62
sg17437
g34540
sg17438
I14
sg17445
VC0206743
p34553
sg17441
I2
sasa(dp34554
g17431
VAs a member of the Sprouty family, Sprouty4 has been previously shown to function as a tumour suppressor in lung and breast cancer.
p34555
sg17433
(lp34556
sg17442
(lp34557
(dp34558
g17436
I117
sg17437
Vbreast cancer
p34559
sg17438
I13
sg17445
VC0678222
p34560
sg17441
I2
sa(dp34561
g17436
I87
sg17437
Vtumour
p34562
sg17438
I6
sg17445
VC0027651
p34563
sg17441
I1
sasa(dp34564
g135
(dp34565
(VCDKN1B mutation
p34566
VHCL
p34567
tp34568
I00
ssg17431
VIn this issue of Blood, Dietrich et al make the first observation of the presence of deleterious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).
p34569
sg17433
(lp34570
(dp34571
g17436
I97
sg17437
g34566
sg17438
I15
sg17439
VP46527
p34572
sg17441
I2
sasg17442
(lp34573
(dp34574
g17436
I137
sg17437
Vhairy cell leukemia
p34575
sg17438
I19
sg17445
VC0023443
p34576
sg17441
I3
sa(dp34577
g17436
I158
sg17437
g34567
sg17438
I3
sg17445
VC0023443
p34578
sg17441
I1
sasa(dp34579
g17431
VWe previously found that global CypD knockout mice (KO) are protected from diet-induced glucose intolerance; however, the tissue-specific function of CypD and mPTP, particularly in the control of glucose homeostasis, has not been ascertained.
p34580
sg17433
(lp34581
(dp34582
g17436
I32
sg17437
VCypD
p34583
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp34584
(dp34585
g17436
I88
sg17437
Vglucose intolerance
p34586
sg17438
I19
sg17445
VC0271650
p34587
sg17441
I2
sasa(dp34588
g17431
VMice lacking CypD were protected from high fat diet-induced glucose intolerance due to increased glucose uptake in skeletal muscle.
p34589
sg17433
(lp34590
(dp34591
g17436
I13
sg17437
VCypD
p34592
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp34593
(dp34594
g17436
I60
sg17437
Vglucose intolerance
p34595
sg17438
I19
sg17445
VC0271650
p34596
sg17441
I2
sasa(dp34597
g135
(dp34598
(Vinsulin
p34599
Vinsulin resistance
p34600
tp34601
I00
ssg17431
VAdult CypD(-/-) developed hyperglycemia, insulin resistance and glucose intolerance albeit resistant to DIO.
p34602
sg17433
(lp34603
(dp34604
g17436
I6
sg17437
VCypD
p34605
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34606
g17436
I41
sg17437
g34599
sg17438
I7
sg17439
VP01308
p34607
sg17441
I1
sasg17442
(lp34608
(dp34609
g17436
I64
sg17437
Vglucose intolerance
p34610
sg17438
I19
sg17445
VC0271650
p34611
sg17441
I2
sa(dp34612
g17436
I26
sg17437
Vhyperglycemia
p34613
sg17438
I13
sg17445
VC0020456
p34614
sg17441
I1
sa(dp34615
g17436
I41
sg17437
g34600
sg17438
I18
sg17445
VC0021655
p34616
sg17441
I2
sasa(dp34617
g135
(dp34618
(Vvon Willebrand factor
p34619
Vatrial fibrillation
p34620
tp34621
I00
ssg17431
Vvon Willebrand factor (VWF) is an independent risk factor for adverse events in patients with non-valvular atrial fibrillation (NVAF).
p34622
sg17433
(lp34623
(dp34624
g17436
I23
sg17437
VVWF
p34625
sg17438
I3
sg17439
VP04275
p34626
sg17441
I1
sa(dp34627
g17436
I0
sg17437
g34619
sg17438
I21
sg17439
VP04275
p34628
sg17441
I3
sasg17442
(lp34629
(dp34630
g17436
I107
sg17437
g34620
sg17438
I19
sg17445
VC0004238
p34631
sg17441
I2
sasa(dp34632
g17431
VHigher VWF level correlated with higher CHADS2 scores and with progressing intensity of blood stasis in the left atrium and thrombus formation in all three time periods of atrial fibrillation duration.
p34633
sg17433
(lp34634
sg17442
(lp34635
(dp34636
g17436
I172
sg17437
Vatrial fibrillation
p34637
sg17438
I19
sg17445
VC0004238
p34638
sg17441
I2
sa(dp34639
g17436
I94
sg17437
Vstasis
p34640
sg17438
I6
sg17445
VC0333138
p34641
sg17441
I1
sa(dp34642
g17436
I124
sg17437
Vthrombus
p34643
sg17438
I8
sg17445
VC0302148
p34644
sg17441
I1
sasa(dp34645
g135
(dp34646
(VvWF
p34647
Vatrial fibrillation
p34648
tp34649
I00
ssg17431
VPatients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 levels.
p34650
sg17433
(lp34651
(dp34652
g17436
I61
sg17437
g34647
sg17438
I3
sg17439
VP04275
p34653
sg17441
I1
sasg17442
(lp34654
(dp34655
g17436
I35
sg17437
VAF
p34656
sg17438
I2
sg17445
VC0004238
p34657
sg17441
I1
sa(dp34658
g17436
I14
sg17437
g34648
sg17438
I19
sg17445
VC0004238
p34659
sg17441
I2
sasa(dp34660
g135
(dp34661
(Vphosphatidylinositol binding clatrin
p34662
Vcognitive impairment
p34663
tp34664
I00
ssg17431
VIn a multicenter case-control association study, we studied the SNPs rs11136000 (clusterin, CLU), rs541458 (phosphatidylinositol binding clatrin assembly protein, PICALM), and rs1554948 (transcription factor A, and tyrosine kinase, non-receptor, 1, TNK1) according to the three age groups 50-65 years (group 1), 66-80 years (group 2), and 80+ years (group 3) in 569 older subjects without cognitive impairment (NoCI) and 520 Alzheimer's disease (AD) patients.
p34665
sg17433
(lp34666
(dp34667
g17436
I215
sg17437
Vtyrosine kinase
p34668
sg17438
I15
sg17439
VP29401
p34669
sg17441
I2
sa(dp34670
g17436
I108
sg17437
g34662
sg17438
I36
sg17439
VP63244
p34671
sg17441
I3
sa(dp34672
g17436
I232
sg17437
Vnon-receptor, 1
p34673
sg17438
I15
sg17439
g12
sg17441
I2
sa(dp34674
g17436
I249
sg17437
VTNK1
p34675
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp34676
(dp34677
g17436
I446
sg17437
VAD
p34678
sg17438
I2
sg17445
VC1521724
p34679
sg17441
I1
sa(dp34680
g17436
I389
sg17437
g34663
sg17438
I20
sg17445
VC0338656
p34681
sg17441
I2
sa(dp34682
g17436
I425
sg17437
VAlzheimer's disease
p34683
sg17438
I19
sg17445
VC1521724
p34684
sg17441
I2
sasa(dp34685
g17431
VTo study the association of apolipoprotein E (APOE), Clusterin (CLU) and phosphatidylinositol binding clathrin assembly protein (PICALM) polymorphisms in Alzheimer's disease (AD) subjects compared to cognitively normal control subjects in an Indian population.
p34686
sg17433
(lp34687
(dp34688
g17436
I64
sg17437
VCLU
p34689
sg17438
I3
sg17439
VP10909
p34690
sg17441
I1
sa(dp34691
g17436
I46
sg17437
VAPOE
p34692
sg17438
I4
sg17439
VP02649
p34693
sg17441
I1
sa(dp34694
g17436
I28
sg17437
Vapolipoprotein E
p34695
sg17438
I16
sg17439
VP02649
p34696
sg17441
I2
sa(dp34697
g17436
I73
sg17437
Vphosphatidylinositol binding clathrin
p34698
sg17438
I37
sg17439
VP63244
p34699
sg17441
I3
sa(dp34700
g17436
I53
sg17437
VClusterin
p34701
sg17438
I9
sg17439
VP10909
p34702
sg17441
I1
sasg17442
(lp34703
(dp34704
g17436
I175
sg17437
VAD
p34705
sg17438
I2
sg17445
VC1521724
p34706
sg17441
I1
sa(dp34707
g17436
I154
sg17437
VAlzheimer's disease
p34708
sg17438
I19
sg17445
VC1521724
p34709
sg17441
I2
sasa(dp34710
g135
(dp34711
(VCR1
p34712
VAD
p34713
tp34714
I00
ssg17431
VGenome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.
p34715
sg17433
(lp34716
(dp34717
g17436
I292
sg17437
VPICALM
p34718
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34719
g17436
I176
sg17437
VCD2AP
p34720
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34721
g17436
I270
sg17437
VMS4A4E
p34722
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34723
g17436
I255
sg17437
VMEF2C
p34724
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34725
g17436
I227
sg17437
VHLA
p34726
sg17438
I3
sg17439
VP30486
p34727
sg17441
I1
sa(dp34728
g17436
I206
sg17437
VDSG2
p34729
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34730
g17436
I189
sg17437
VCELF1
p34731
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34732
g17436
I157
sg17437
VAPOE
p34733
sg17438
I4
sg17439
VP02649
p34734
sg17441
I1
sa(dp34735
g17436
I150
sg17437
VABCA7
p34736
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34737
g17436
I313
sg17437
VRIN3
p34738
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34739
g17436
I328
sg17437
VSORL1
p34740
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34741
g17436
I319
sg17437
VSLC24A4
p34742
sg17438
I7
sg17439
g12
sg17441
I1
sa(dp34743
g17436
I247
sg17437
VINPP5D
p34744
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34745
g17436
I262
sg17437
VMS4A4A
p34746
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34747
g17436
I183
sg17437
VCD33
p34748
sg17438
I4
sg17439
VP20138
p34749
sg17441
I1
sa(dp34750
g17436
I300
sg17437
VPLD3
p34751
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34752
g17436
I219
sg17437
VFERMT2
p34753
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34754
g17436
I169
sg17437
VCASS4
p34755
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34756
g17436
I196
sg17437
VCLU
p34757
sg17438
I3
sg17439
VP10909
p34758
sg17441
I1
sa(dp34759
g17436
I306
sg17437
VPTK2B
p34760
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34761
g17436
I212
sg17437
VEPHA1
p34762
sg17438
I5
sg17439
VP21709
p34763
sg17441
I1
sa(dp34764
g17436
I278
sg17437
VMS4A6E
p34765
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34766
g17436
I227
sg17437
VHLA
p34767
sg17438
I3
sg17439
VP30486
p34768
sg17441
I1
sa(dp34769
g17436
I201
sg17437
g34712
sg17438
I3
sg17439
VP17927
p34770
sg17441
I1
sa(dp34771
g17436
I339
sg17437
VZCWPW1 genes
p34772
sg17438
I12
sg17439
g12
sg17441
I2
sa(dp34773
g17436
I286
sg17437
VNME8
p34774
sg17438
I4
sg17439
g12
sg17441
I1
sa(dp34775
g17436
I231
sg17437
VDRB1
p34776
sg17438
I4
sg17439
g12
sg17441
I1
sasg17442
(lp34777
(dp34778
g17436
I95
sg17437
VAlzheimer's diseases
p34779
sg17438
I20
sg17445
VC0002395
p34780
sg17441
I2
sa(dp34781
g17436
I117
sg17437
g34713
sg17438
I2
sg17445
VC0002395
p34782
sg17441
I1
sasa(dp34783
g17431
VThe PICALM rs541458 T allele has been recognized as a risk factor for late-onset Alzheimer's disease, and age might modulate the effects that genetic factors have on cognitive functions and brain.
p34784
sg17433
(lp34785
(dp34786
g17436
I4
sg17437
VPICALM rs541458 T allele
p34787
sg17438
I24
sg17439
g12
sg17441
I4
sasg17442
(lp34788
(dp34789
g17436
I81
sg17437
VAlzheimer's disease
p34790
sg17438
I19
sg17445
VC1521724
p34791
sg17441
I2
sasa(dp34792
g17431
VThe association of variants in CLU, CR1, PICALM, BIN1, ABCA7, and CD33 genes with late-onset Alzheimer's disease (LOAD) was evaluated and confirmed through genome-wide association study.
p34793
sg17433
(lp34794
(dp34795
g17436
I31
sg17437
VCLU
p34796
sg17438
I3
sg17439
VP10909
p34797
sg17441
I1
sa(dp34798
g17436
I41
sg17437
VPICALM
p34799
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34800
g17436
I55
sg17437
VABCA7
p34801
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34802
g17436
I66
sg17437
VCD33 genes
p34803
sg17438
I10
sg17439
VP20138
p34804
sg17441
I2
sa(dp34805
g17436
I36
sg17437
VCR1
p34806
sg17438
I3
sg17439
VP17927
p34807
sg17441
I1
sasg17442
(lp34808
(dp34809
g17436
I93
sg17437
VAlzheimer's disease
p34810
sg17438
I19
sg17445
VC1521724
p34811
sg17441
I2
sasa(dp34812
g135
(dp34813
(VRas
p34814
Vpancreatic cancer
p34815
tp34816
I00
ssg17431
VIn vivo, depletion of GDF-15 in Ras-driven tumor xenografts and in an orthotopic model of pancreatic cancer delayed tumor development.
p34817
sg17433
(lp34818
(dp34819
g17436
I22
sg17437
VGDF-15
p34820
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34821
g17436
I32
sg17437
g34814
sg17438
I3
sg17439
VP01116
p34822
sg17441
I1
sasg17442
(lp34823
(dp34824
g17436
I43
sg17437
Vtumor
p34825
sg17438
I5
sg17445
VC0027651
p34826
sg17441
I1
sa(dp34827
g17436
I90
sg17437
g34815
sg17438
I17
sg17445
VC0235974
p34828
sg17441
I2
sa(dp34829
g17436
I43
sg17437
Vtumor
p34830
sg17438
I5
sg17445
VC0027651
p34831
sg17441
I1
sasa(dp34832
g17431
VFurther, production of GDF-15 is directly regulated by NF-KB, and the colocalization of activated NF-KB and GDF-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of this observation.
p34833
sg17433
(lp34834
(dp34835
g17436
I23
sg17437
VGDF-15
p34836
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34837
g17436
I23
sg17437
VGDF-15
p34838
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp34839
(dp34840
g17436
I144
sg17437
Vpancreatic adenocarcinoma
p34841
sg17438
I25
sg17445
VC0281361
p34842
sg17441
I2
sasa(dp34843
g17431
VThe present study investigated the association between cancer-associated weight loss and plasma GDF-15 concentration, as well as other biomarkers, in patients with metastatic lung or exocrine pancreatic cancer.
p34844
sg17433
(lp34845
(dp34846
g17436
I89
sg17437
Vplasma GDF-15
p34847
sg17438
I13
sg17439
g12
sg17441
I2
sasg17442
(lp34848
(dp34849
g17436
I183
sg17437
Vexocrine pancreatic cancer
p34850
sg17438
I26
sg17445
VC0346648
p34851
sg17441
I3
sa(dp34852
g17436
I55
sg17437
Vcancer
p34853
sg17438
I6
sg17445
VC0006826
p34854
sg17441
I1
sasa(dp34855
g17431
VIn pancreatic cancer patients, no association between GDF-15 levels and weight loss was identified.
p34856
sg17433
(lp34857
(dp34858
g17436
I54
sg17437
VGDF-15
p34859
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp34860
(dp34861
g17436
I3
sg17437
Vpancreatic cancer
p34862
sg17438
I17
sg17445
VC0235974
p34863
sg17441
I2
sasa(dp34864
g135
(dp34865
(Vcarbohydrate antigen 19-9
p34866
Vchronic pancreatitis
p34867
tp34868
I00
ssg17431
VThe aim of the present case-control study was to compare the diagnostic value of ULBP2, MIC-1 and carbohydrate antigen 19-9 (CA19-9) in 359 serum samples, consisting of 152 cases of PC, 20 cases of pre-pancreatic cancer, 91 cases of chronic pancreatitis (CP) and 96 normal controls (NC).
p34869
sg17433
(lp34870
(dp34871
g17436
I125
sg17437
VCA19-9
p34872
sg17438
I6
sg17439
VP14209
p34873
sg17441
I1
sa(dp34874
g17436
I88
sg17437
VMIC-1
p34875
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34876
g17436
I81
sg17437
VULBP2
p34877
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34878
g17436
I98
sg17437
g34866
sg17438
I25
sg17439
VP14209
p34879
sg17441
I3
sasg17442
(lp34880
(dp34881
g17436
I202
sg17437
Vpancreatic cancer
p34882
sg17438
I17
sg17445
VC0235974
p34883
sg17441
I2
sa(dp34884
g17436
I255
sg17437
VCP
p34885
sg17438
I2
sg17445
VC0149521
p34886
sg17441
I1
sa(dp34887
g17436
I233
sg17437
g34867
sg17438
I20
sg17445
VC0149521
p34888
sg17441
I2
sasa(dp34889
g17431
VMacrophage inhibitory cytokine 1 (MIC-1/GDF15) has been identified as a potential novel biomarker for detection of pancreatic cancer (PCa).
p34890
sg17433
(lp34891
(dp34892
g17436
I34
sg17437
VMIC-1
p34893
sg17438
I5
sg17439
g12
sg17441
I1
sa(dp34894
g17436
I0
sg17437
VMacrophage inhibitory cytokine 1
p34895
sg17438
I32
sg17439
g12
sg17441
I4
sa(dp34896
g17436
I40
sg17437
VGDF15
p34897
sg17438
I5
sg17439
g12
sg17441
I1
sasg17442
(lp34898
(dp34899
g17436
I115
sg17437
Vpancreatic cancer
p34900
sg17438
I17
sg17445
VC0235974
p34901
sg17441
I2
sa(dp34902
g17436
I134
sg17437
VPCa
p34903
sg17438
I3
sg17445
VC0268398
p34904
sg17441
I1
sasa(dp34905
g17431
VHowever, the diagnostic value of serum MIC-1 for pancreatic ductal adenocarcinoma (PDAC), particularly for those at the early stage, and the value for treatment response monitoring have not yet been investigated.
p34906
sg17433
(lp34907
(dp34908
g17436
I33
sg17437
Vserum MIC-1
p34909
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp34910
(dp34911
g17436
I83
sg17437
VPDAC
p34912
sg17438
I4
sg17445
VC1335302
p34913
sg17441
I1
sa(dp34914
g17436
I49
sg17437
Vpancreatic ductal adenocarcinoma
p34915
sg17438
I32
sg17445
VC1335302
p34916
sg17441
I3
sasa(dp34917
g135
(dp34918
(VTNFSF8
p34919
Vpancreatic cancer
p34920
tp34921
I00
ssg17431
VCD30 ligand/TNFSF8, chordin-like 2, FGF-10/KGF-2, growth/differentiation factor 15, I-TAC/CXCL11, OSM, and SCF might represent as predictive biomarkers for gemcitabine and erlotinib response of patients with pancreatic cancer.
p34922
sg17433
(lp34923
(dp34924
g17436
I43
sg17437
VKGF-2
p34925
sg17438
I5
sg17439
VP21781
p34926
sg17441
I1
sa(dp34927
g17436
I107
sg17437
VSCF
p34928
sg17438
I3
sg17439
VP21583
p34929
sg17441
I1
sa(dp34930
g17436
I98
sg17437
VOSM
p34931
sg17438
I3
sg17439
VP13725
p34932
sg17441
I1
sa(dp34933
g17436
I20
sg17437
Vchordin-like 2
p34934
sg17438
I14
sg17439
g12
sg17441
I2
sa(dp34935
g17436
I50
sg17437
Vgrowth/differentiation factor
p34936
sg17438
I29
sg17439
g12
sg17441
I2
sa(dp34937
g17436
I0
sg17437
VCD30 ligand
p34938
sg17438
I11
sg17439
VP32971
p34939
sg17441
I2
sa(dp34940
g17436
I90
sg17437
VCXCL11
p34941
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp34942
g17436
I12
sg17437
g34919
sg17438
I6
sg17439
VP32971
p34943
sg17441
I1
sasg17442
(lp34944
(dp34945
g17436
I208
sg17437
g34920
sg17438
I17
sg17445
VC0235974
p34946
sg17441
I2
sasa(dp34947
g17431
VRadiologists evaluated following CT findings: maximum tumor diameter, percentage of solid component (%solid), air bronchogram, spiculation, adjacency of bullae or interstitial pneumonia (IP) around the tumor, notch, and pleural indent.
p34948
sg17433
(lp34949
sg17442
(lp34950
(dp34951
g17436
I54
sg17437
Vtumor
p34952
sg17438
I5
sg17445
VC0027651
p34953
sg17441
I1
sa(dp34954
g17436
I54
sg17437
Vtumor
p34955
sg17438
I5
sg17445
VC0027651
p34956
sg17441
I1
sa(dp34957
g17436
I163
sg17437
Vinterstitial pneumonia
p34958
sg17438
I22
sg17445
VC0206061
p34959
sg17441
I2
sa(dp34960
g17436
I153
sg17437
Vbullae
p34961
sg17438
I6
sg17445
VC0005758
p34962
sg17441
I1
sa(dp34963
g17436
I187
sg17437
VIP
p34964
sg17438
I2
sg17445
VC0206061
p34965
sg17441
I1
sasa(dp34966
g17431
VThe results strongly suggest that electronic self-auscultation at a single location (suprasternal notch) can support diagnosis of pneumonia in patients with COPD.
p34967
sg17433
(lp34968
sg17442
(lp34969
(dp34970
g17436
I130
sg17437
Vpneumonia
p34971
sg17438
I9
sg17445
VC0032285
p34972
sg17441
I1
sa(dp34973
g17436
I157
sg17437
VCOPD
p34974
sg17438
I4
sg17445
VC0024117
p34975
sg17441
I1
sasa(dp34976
g17431
VWe compared patients who underwent PAO for the treatment of Charcot-Marie-Tooth disease hip dysplasia (CMTHD group) with patients who underwent PAO for treatment of hip dysplasia secondary to DDH in terms of (1) modified Harris Hip scores; (2) radiographic correction of acetabular dysplasia; and (3) the rate of complications.
p34977
sg17433
(lp34978
(dp34979
g17436
I192
sg17437
VDDH
p34980
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp34981
(dp34982
g17436
I271
sg17437
Vacetabular dysplasia
p34983
sg17438
I20
sg17445
VC1306065
p34984
sg17441
I2
sa(dp34985
g17436
I88
sg17437
Vhip dysplasia
p34986
sg17438
I13
sg17445
VC1328407
p34987
sg17441
I2
sa(dp34988
g17436
I60
sg17437
VCharcot-Marie-Tooth disease
p34989
sg17438
I27
sg17445
VC0007959
p34990
sg17441
I2
sa(dp34991
g17436
I88
sg17437
Vhip dysplasia
p34992
sg17438
I13
sg17445
VC1328407
p34993
sg17441
I2
sasa(dp34994
g17431
VTwenty-seven subjects with Charcot-Marie-Tooth disease who underwent a PAO between January 1991 and December 2010 were matched to 54 subjects with DDH on the basis of sex, age, date of surgery, and body mass index.
p34995
sg17433
(lp34996
(dp34997
g17436
I147
sg17437
VDDH
p34998
sg17438
I3
sg17439
g12
sg17441
I1
sasg17442
(lp34999
(dp35000
g17436
I27
sg17437
VCharcot-Marie-Tooth disease
p35001
sg17438
I27
sg17445
VC0007959
p35002
sg17441
I2
sasa(dp35003
g17431
VThe purpose of this study is to evaluate the use of the Dega osteotomy in the treatment of hip pathology resulting from both developmental dysplasia (DDH) and neuromuscular disease (NM).
p35004
sg17433
(lp35005
sg17442
(lp35006
(dp35007
g17436
I95
sg17437
Vpathology
p35008
sg17438
I9
sg17445
VC0677042
p35009
sg17441
I1
sa(dp35010
g17436
I182
sg17437
VNM
p35011
sg17438
I2
sg17445
VC0027868
p35012
sg17441
I1
sa(dp35013
g17436
I139
sg17437
Vdysplasia
p35014
sg17438
I9
sg17445
VC0334044
p35015
sg17441
I1
sa(dp35016
g17436
I159
sg17437
Vneuromuscular disease
p35017
sg17438
I21
sg17445
VC0027868
p35018
sg17441
I2
sasa(dp35019
g17431
VNeuromuscular dysplasia of the hip (NDH) is a sequel of neuromuscular disease, and generally presents later in childhood than DDH.
p35020
sg17433
(lp35021
sg17442
(lp35022
(dp35023
g17436
I56
sg17437
Vneuromuscular disease
p35024
sg17438
I21
sg17445
VC0027868
p35025
sg17441
I2
sa(dp35026
g17436
I14
sg17437
Vdysplasia
p35027
sg17438
I9
sg17445
VC0334044
p35028
sg17441
I1
sasa(dp35029
g17431
VTo explore this suggestion we ascertained the presence of neuromuscular disease within a cohort of DDH patients, and asked whether the neuromuscular condition is the initial etiology of the dysplasia or a coincidental finding.
p35030
sg17433
(lp35031
sg17442
(lp35032
(dp35033
g17436
I190
sg17437
Vdysplasia
p35034
sg17438
I9
sg17445
VC0334044
p35035
sg17441
I1
sa(dp35036
g17436
I149
sg17437
Vcondition
p35037
sg17438
I9
sg17445
VC0012634
p35038
sg17441
I1
sa(dp35039
g17436
I58
sg17437
Vneuromuscular disease
p35040
sg17438
I21
sg17445
VC0027868
p35041
sg17441
I2
sasa(dp35042
g17431
VWe examined 45 infants with nondevelopmental dysplasia of the hip (non-DDH), including congenital deficiency of the femur (CDF) (20 infants), neuromuscular syndrome (five infants), skeletal dysplasia (15 infants), and infection (five infants), and present the sonographic findings.
p35043
sg17433
(lp35044
sg17442
(lp35045
(dp35046
g17436
I87
sg17437
Vcongenital deficiency
p35047
sg17438
I21
sg17445
VC0333006
p35048
sg17441
I2
sa(dp35049
g17436
I218
sg17437
Vinfection
p35050
sg17438
I9
sg17445
VC0009450
p35051
sg17441
I1
sa(dp35052
g17436
I156
sg17437
Vsyndrome
p35053
sg17438
I8
sg17445
VC0039082
p35054
sg17441
I1
sa(dp35055
g17436
I181
sg17437
Vskeletal dysplasia
p35056
sg17438
I18
sg17445
VC0410528
p35057
sg17441
I2
sa(dp35058
g17436
I45
sg17437
Vdysplasia
p35059
sg17438
I9
sg17445
VC0334044
p35060
sg17441
I1
sasa(dp35061
g17431
VIn previous studies, we demonstrated that human RHBDD2 is over-expressed in the advanced stages of breast and colorectal cancers, suggesting a favorable role in cell proliferation.
p35062
sg17433
(lp35063
sg17442
(lp35064
(dp35065
g17436
I166
sg17437
Vproliferation
p35066
sg17438
I13
sg17445
VC0334094
p35067
sg17441
I1
sa(dp35068
g17436
I110
sg17437
Vcolorectal cancers
p35069
sg17438
I18
sg17445
VC1527249
p35070
sg17441
I2
sasa(dp35071
g17431
VSo far little is known about the expression of RHBDD2 in other tissues and other species, and because of similarities between cancer and embryonic cells, this study focused on the evaluation of Rhbdd2 expression in embryonic and adult rat tissues.
p35072
sg17433
(lp35073
(dp35074
g17436
I47
sg17437
VRHBDD2
p35075
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp35076
g17436
I194
sg17437
VRhbdd2
p35077
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp35078
(dp35079
g17436
I126
sg17437
Vcancer
p35080
sg17438
I6
sg17445
VC0006826
p35081
sg17441
I1
sasa(dp35082
g17431
VQuantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis showed a significant RHBDD2 mRNA overexpression in advanced breast cancer compared with normal tissue samples (p = 0.012).
p35083
sg17433
(lp35084
(dp35085
g17436
I100
sg17437
VRHBDD2 mRNA
p35086
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp35087
(dp35088
g17436
I139
sg17437
Vbreast cancer
p35089
sg17438
I13
sg17445
VC0678222
p35090
sg17441
I2
sasa(dp35091
g135
(dp35092
(Vprogesterone receptor
p35093
Vbreast cancer
p35094
tp35095
I00
ssg17431
VImmunohistochemistry analysis showed a significant increase of RHBDD2 protein expression in association with breast cancer samples negative for progesterone receptor (p = 0.015).
p35096
sg17433
(lp35097
(dp35098
g17436
I63
sg17437
VRHBDD2 protein
p35099
sg17438
I14
sg17439
g12
sg17441
I2
sa(dp35100
g17436
I144
sg17437
g35093
sg17438
I21
sg17439
VP06401
p35101
sg17441
I2
sasg17442
(lp35102
(dp35103
g17436
I109
sg17437
g35094
sg17438
I13
sg17445
VC0678222
p35104
sg17441
I2
sasa(dp35105
g17431
VRhomboid domain containing 2 (RHBDD2) was previously observed overexpressed and amplified in breast cancer samples.
p35106
sg17433
(lp35107
(dp35108
g17436
I0
sg17437
VRhomboid domain containing 2
p35109
sg17438
I28
sg17439
g12
sg17441
I4
sa(dp35110
g17436
I30
sg17437
VRHBDD2
p35111
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp35112
(dp35113
g17436
I93
sg17437
Vbreast cancer
p35114
sg17438
I13
sg17445
VC0678222
p35115
sg17441
I2
sasa(dp35116
g17431
VIn order to identify biological pathways modulated by RHBDD2, gene expression profiles of RHBDD2 silenced breast cancer cells were analyzed using whole genome human microarray.
p35117
sg17433
(lp35118
(dp35119
g17436
I54
sg17437
VRHBDD2
p35120
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp35121
g17436
I54
sg17437
VRHBDD2
p35122
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp35123
(dp35124
g17436
I106
sg17437
Vbreast cancer
p35125
sg17438
I13
sg17445
VC0678222
p35126
sg17441
I2
sasa(dp35127
g17431
VWe used a lentivirus-based approach for stable silencing of RHBDD2 mRNA in the T47D breast cancer cell line, and we examined the transcriptional consequences on UPR genes as well as the phenotypic effects on migration and proliferation processes.
p35128
sg17433
(lp35129
(dp35130
g17436
I60
sg17437
VRHBDD2 mRNA
p35131
sg17438
I11
sg17439
g12
sg17441
I2
sasg17442
(lp35132
(dp35133
g17436
I84
sg17437
Vbreast cancer
p35134
sg17438
I13
sg17445
VC0678222
p35135
sg17441
I2
sa(dp35136
g17436
I222
sg17437
Vproliferation
p35137
sg17438
I13
sg17445
VC0334094
p35138
sg17441
I1
sasa(dp35139
g17431
VBased on these studies, we hypothesize that RHBDD2 overexpression in breast cancer could represent an adaptive phenotype to the stressful tumor microenvironment by modulating the ER stress response.
p35140
sg17433
(lp35141
(dp35142
g17436
I44
sg17437
VRHBDD2
p35143
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp35144
(dp35145
g17436
I69
sg17437
Vbreast cancer
p35146
sg17438
I13
sg17445
VC0678222
p35147
sg17441
I2
sa(dp35148
g17436
I138
sg17437
Vtumor
p35149
sg17438
I5
sg17445
VC0027651
p35150
sg17441
I1
sasa(dp35151
g17431
VIn previous studies, we identified rhomboid domain containing 2 (RHBDD2) gene to be markedly overexpressed in breast cancer patients that developed recurrence of the disease.
p35152
sg17433
(lp35153
(dp35154
g17436
I65
sg17437
VRHBDD2
p35155
sg17438
I6
sg17439
g12
sg17441
I1
sa(dp35156
g17436
I35
sg17437
Vrhomboid domain containing 2
p35157
sg17438
I28
sg17439
g12
sg17441
I4
sasg17442
(lp35158
(dp35159
g17436
I148
sg17437
Vrecurrence
p35160
sg17438
I10
sg17445
VC1458156
p35161
sg17441
I1
sa(dp35162
g17436
I110
sg17437
Vbreast cancer
p35163
sg17438
I13
sg17445
VC0678222
p35164
sg17441
I2
sasa(dp35165
g17431
VIn this study, we evaluated for the first time RHBDD2 gene expression in colorectal cancer (CRC).
p35166
sg17433
(lp35167
(dp35168
g17436
I42
sg17437
Vtime RHBDD2 gene
p35169
sg17438
I16
sg17439
g12
sg17441
I3
sasg17442
(lp35170
(dp35171
g17436
I92
sg17437
VCRC
p35172
sg17438
I3
sg17445
VC1527249
p35173
sg17441
I1
sa(dp35174
g17436
I73
sg17437
Vcolorectal cancer
p35175
sg17438
I17
sg17445
VC1527249
p35176
sg17441
I2
sasa(dp35177
g17431
VOverall, these results showed that RHBDD2 overexpression might play a role in colorectal cancer progression.
p35178
sg17433
(lp35179
(dp35180
g17436
I35
sg17437
VRHBDD2
p35181
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp35182
(dp35183
g17436
I89
sg17437
Vcancer progression
p35184
sg17438
I18
sg17445
VC0178874
p35185
sg17441
I2
sasa(dp35186
g17431
VIn the course of breast cancer global gene expression studies, we identified an uncharacterized gene known as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients with recurrent disease.
p35187
sg17433
(lp35188
(dp35189
g17436
I118
sg17437
VRhomboid domain containing 2
p35190
sg17438
I28
sg17439
g12
sg17441
I4
sa(dp35191
g17436
I110
sg17437
VRHBDD2
p35192
sg17438
I6
sg17439
g12
sg17441
I1
sasg17442
(lp35193
(dp35194
g17436
I181
sg17437
Vprimary tumors
p35195
sg17438
I14
sg17445
VC0677930
p35196
sg17441
I2
sa(dp35197
g17436
I17
sg17437
Vbreast cancer
p35198
sg17438
I13
sg17445
VC0678222
p35199
sg17441
I2
sa(dp35200
g17436
I215
sg17437
Vrecurrent disease
p35201
sg17438
I17
sg17445
VC0277556
p35202
sg17441
I2
sasa(dp35203
S'line'
p35204
VWestern-blot, RT-PCR and cDNA sequencing analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer cell lines.
p35205
sS'genes'
p35206
(lp35207
sS'diseases'
p35208
(lp35209
(dp35210
S'index'
p35211
I133
sS'name'
p35212
Vbreast cancer
p35213
sS'lengthInChars'
p35214
I13
sS'cui'
p35215
VC0678222
p35216
sS'lengthInWords'
p35217
I2
sasa(dp35218
g35204
VInterestingly, siRNA-mediated silencing of RHBDD2 expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding controls (p=0.001).
p35219
sg35206
(lp35220
(dp35221
g35211
I43
sg35212
VRHBDD2
p35222
sg35214
I6
sS'uniprot'
p35223
g12
sg35217
I1
sasg35208
(lp35224
(dp35225
g35211
I111
sg35212
Vproliferation
p35226
sg35214
I13
sg35215
VC0334094
p35227
sg35217
I1
sa(dp35228
g35211
I91
sg35212
Vbreast cancer
p35229
sg35214
I13
sg35215
VC0678222
p35230
sg35217
I2
sasa(dp35231
g35204
VIn conclusion, our findings suggest that RHBDD2 over-expression behaves as an indicator of poor prognosis and may play a role facilitating breast cancer progression.
p35232
sg35206
(lp35233
(dp35234
g35211
I41
sg35212
VRHBDD2
p35235
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp35236
(dp35237
g35211
I146
sg35212
Vcancer progression
p35238
sg35214
I18
sg35215
VC0178874
p35239
sg35217
I2
sasa(dp35240
g135
(dp35241
(VPI3 K
p35242
VPKC
p35243
tp35244
I00
ssg35204
VThese effects could also be exerted via the upregulation of eight specific target genes, the subsequent over-activation of the PKC and PI3 K-Akt pathways, and the eventual abnormal cardiac development and VSD.
p35245
sg35206
(lp35246
(dp35247
g35211
I141
sg35212
VAkt
p35248
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp35249
g35211
I127
sg35212
VPKC
p35250
sg35214
I3
sg35223
VP17252
p35251
sg35217
I1
sa(dp35252
g35211
I135
sg35212
g35242
sg35214
I5
sg35223
VP19957
p35253
sg35217
I2
sasg35208
(lp35254
(dp35255
g35211
I205
sg35212
VVSD
p35256
sg35214
I3
sg35215
VC0018818
p35257
sg35217
I1
sa(dp35258
g35211
I127
sg35212
g35243
sg35214
I3
sg35215
VC1868682
p35259
sg35217
I1
sasa(dp35260
g135
(dp35261
(VCEBPA mRNA
p35262
Vasthma
p35263
tp35264
I01
ssg35204
VReduced translation of CEBPA mRNA has been associated with increased proliferation of bronchial smooth muscle (BSM) cells of asthma patients.
p35265
sg35206
(lp35266
(dp35267
g35211
I23
sg35212
g35262
sg35214
I10
sg35223
VP49715
p35268
sg35217
I2
sasg35208
(lp35269
(dp35270
g35211
I125
sg35212
g35263
sg35214
I6
sg35215
VC0004096
p35271
sg35217
I1
sa(dp35272
g35211
I69
sg35212
Vproliferation
p35273
sg35214
I13
sg35215
VC0334094
p35274
sg35217
I1
sasa(dp35275
g135
(dp35276
(VCRT
p35277
Vasthma
p35278
tp35279
I00
ssg35204
VHDM extract reduced the C/EBPAlfa expression in BSM cells of asthma patients, which coincided with significantly increased levels of calreticulin (CRT) protein, an inhibitor of CEBPA mRNA translation.
p35280
sg35206
(lp35281
(dp35282
g35211
I133
sg35212
Vcalreticulin
p35283
sg35214
I12
sg35223
VP27797
p35284
sg35217
I1
sa(dp35285
g35211
I177
sg35212
VCEBPA mRNA
p35286
sg35214
I10
sg35223
VP49715
p35287
sg35217
I2
sa(dp35288
g35211
I147
sg35212
g35277
sg35214
I3
sg35223
VP27797
p35289
sg35217
I1
sasg35208
(lp35290
(dp35291
g35211
I61
sg35212
g35278
sg35214
I6
sg35215
VC0004096
p35292
sg35217
I1
sasa(dp35293
g135
(dp35294
(VPAR2
p35295
Vasthmatic
p35296
tp35297
I00
ssg35204
VIn conclusion, HDM extract reduced CEBPA mRNA translation, specifically in asthmatic BSM cells, and 1) upregulated CRT, 2) activated PAR2, and increased 3) IL-6 expression and 4) the proliferation of asthmatic BSM cells.
p35298
sg35206
(lp35299
(dp35300
g35211
I35
sg35212
VCEBPA mRNA
p35301
sg35214
I10
sg35223
VP49715
p35302
sg35217
I2
sa(dp35303
g35211
I156
sg35212
VIL-6
p35304
sg35214
I4
sg35223
VP05231
p35305
sg35217
I1
sa(dp35306
g35211
I133
sg35212
g35295
sg35214
I4
sg35223
VP55085
p35307
sg35217
I1
sasg35208
(lp35308
(dp35309
g35211
I183
sg35212
Vproliferation
p35310
sg35214
I13
sg35215
VC0334094
p35311
sg35217
I1
sa(dp35312
g35211
I75
sg35212
Vasthmatic
p35313
sg35214
I9
sg35215
VC0004096
p35314
sg35217
I1
sa(dp35315
g35211
I75
sg35212
g35296
sg35214
I9
sg35215
VC0004096
p35316
sg35217
I1
sasa(dp35317
g35204
VAirway smooth muscle cells from persons with asthma are deficient in C/EBP-alpha, which may explain the finding that CSs do not inhibit the proliferation of these cells in vitro.
p35318
sg35206
(lp35319
(dp35320
g35211
I69
sg35212
VC/EBP-alpha
p35321
sg35214
I11
sg35223
g12
sg35217
I1
sasg35208
(lp35322
(dp35323
g35211
I45
sg35212
Vasthma
p35324
sg35214
I6
sg35215
VC0004096
p35325
sg35217
I1
sa(dp35326
g35211
I117
sg35212
VCSs
p35327
sg35214
I3
sg35215
VC0265338
p35328
sg35217
I1
sa(dp35329
g35211
I140
sg35212
Vproliferation
p35330
sg35214
I13
sg35215
VC0334094
p35331
sg35217
I1
sasa(dp35332
g135
(dp35333
(VCCAAT/enhancer-binding proteins
p35334
Vasthmatic
p35335
tp35336
I01
ssg35204
VCCAAT/enhancer-binding proteins (C/EBPs) control cell proliferation; lack of C/EBPalpha correlates with increased proliferation of bronchial smooth muscle cells (BSMCs) of asthmatic patients.
p35337
sg35206
(lp35338
(dp35339
g35211
I33
sg35212
VC/EBPs
p35340
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp35341
g35211
I0
sg35212
g35334
sg35214
I31
sg35223
VP63244
p35342
sg35217
I2
sasg35208
(lp35343
(dp35344
g35211
I54
sg35212
Vproliferation
p35345
sg35214
I13
sg35215
VC0334094
p35346
sg35217
I1
sa(dp35347
g35211
I54
sg35212
Vproliferation
p35348
sg35214
I13
sg35215
VC0334094
p35349
sg35217
I1
sa(dp35350
g35211
I172
sg35212
g35335
sg35214
I9
sg35215
VC0004096
p35351
sg35217
I1
sasa(dp35352
g35204
VExpression and function of C/EBPalpha, beta, delta, and epsilon BSMCs of control subjects (n = 9), asthmatic patients (n = 12), and patients with chronic obstructive pulmonary disease (COPD; n = 10) were determined.
p35353
sg35206
(lp35354
sg35208
(lp35355
(dp35356
g35211
I185
sg35212
VCOPD
p35357
sg35214
I4
sg35215
VC0024117
p35358
sg35217
I1
sa(dp35359
g35211
I146
sg35212
Vchronic obstructive pulmonary disease
p35360
sg35214
I37
sg35215
VC0024117
p35361
sg35217
I4
sa(dp35362
g35211
I99
sg35212
Vasthmatic
p35363
sg35214
I9
sg35215
VC0004096
p35364
sg35217
I1
sasa(dp35365
g35204
VThe asthmatic group did not appropriately express C/EBPalpha.
p35366
sg35206
(lp35367
sg35208
(lp35368
(dp35369
g35211
I4
sg35212
Vasthmatic
p35370
sg35214
I9
sg35215
VC0004096
p35371
sg35217
I1
sasa(dp35372
g35204
VProtein analysis and electrophoretic mobility shift assay confirmed the disease-specific expression pattern of C/EBPalpha in asthmatic patients and C/EBPdelta in patients with COPD.
p35373
sg35206
(lp35374
sg35208
(lp35375
(dp35376
g35211
I176
sg35212
VCOPD
p35377
sg35214
I4
sg35215
VC0024117
p35378
sg35217
I1
sa(dp35379
g35211
I125
sg35212
Vasthmatic
p35380
sg35214
I9
sg35215
VC0004096
p35381
sg35217
I1
sasa(dp35382
g35204
VThe reason for the differences which have been observed in the in vitro properties of airway smooth muscle derived from asthmatic individuals may result from an inherent "supercontractility", an increased tendency to proliferate due to the absence of an inhibitory transcription factor C/EBP-alpha, the influence of an altered extracellular matrix and/or a decrease in release of factors such as PGE(2) which would under normal circumstances inhibit both proliferation and contraction.
p35383
sg35206
(lp35384
(dp35385
g35211
I265
sg35212
Vtranscription factor C/EBP-alpha
p35386
sg35214
I32
sg35223
g12
sg35217
I3
sasg35208
(lp35387
(dp35388
g35211
I455
sg35212
Vproliferation
p35389
sg35214
I13
sg35215
VC0334094
p35390
sg35217
I1
sa(dp35391
g35211
I120
sg35212
Vasthmatic
p35392
sg35214
I9
sg35215
VC0004096
p35393
sg35217
I1
sa(dp35394
g35211
I473
sg35212
Vcontraction
p35395
sg35214
I11
sg35215
VC1140999
p35396
sg35217
I1
sasa(dp35397
g35204
VHepatocellular carcinoma etiology had no detectable influence on miR-122 expression, whereas miR-152 was increased in HCV+ tissue samples.
p35398
sg35206
(lp35399
(dp35400
g35211
I93
sg35212
VmiR-152
p35401
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp35402
g35211
I65
sg35212
VmiR-122
p35403
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp35404
(dp35405
g35211
I0
sg35212
VHepatocellular carcinoma
p35406
sg35214
I24
sg35215
VC1512411
p35407
sg35217
I2
sasa(dp35408
g35204
VAberrant expressions of the miR-148/152 family (miR-148a, miR-148b, and miR-152) have been documented in many tumor tissues, including hepatocellular carcinoma (HCC).
p35409
sg35206
(lp35410
(dp35411
g35211
I28
sg35212
VmiR-148/152 family
p35412
sg35214
I18
sg35223
g12
sg35217
I2
sa(dp35413
g35211
I58
sg35212
VmiR-148b
p35414
sg35214
I8
sg35223
g12
sg35217
I1
sa(dp35415
g35211
I48
sg35212
VmiR-148a
p35416
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp35417
(dp35418
g35211
I135
sg35212
Vhepatocellular carcinoma
p35419
sg35214
I24
sg35215
VC2239176
p35420
sg35217
I2
sa(dp35421
g35211
I110
sg35212
Vtumor
p35422
sg35214
I5
sg35215
VC0027651
p35423
sg35217
I1
sa(dp35424
g35211
I161
sg35212
VHCC
p35425
sg35214
I3
sg35215
VC2239176
p35426
sg35217
I1
sasa(dp35427
g35204
VAnd high expression of HLA-G further suppressed NK against cancer cells, providing a new concept that miR-152 was involved in HBV-induced hepatocellular carcinoma.
p35428
sg35206
(lp35429
(dp35430
g35211
I23
sg35212
VHLA
p35431
sg35214
I3
sg35223
VP30486
p35432
sg35217
I1
sasg35208
(lp35433
(dp35434
g35211
I59
sg35212
Vcancer
p35435
sg35214
I6
sg35215
VC0006826
p35436
sg35217
I1
sa(dp35437
g35211
I138
sg35212
Vhepatocellular carcinoma
p35438
sg35214
I24
sg35215
VC1512411
p35439
sg35217
I2
sa(dp35440
g35211
I126
sg35212
VHBV
p35441
sg35214
I3
sg35215
VC0019163
p35442
sg35217
I1
sasa(dp35443
g135
(dp35444
(VND2-SmoA1
p35445
VMedulloblastoma
p35446
tp35447
I00
ssg35204
VFurther, FDA-approved arsenic trioxide (ATO) and the ND2-SmoA1 mouse model of Medulloblastoma (MB) were used to extend our analyses of combined MRI and Reverse Phase Protein Microarray (RPMA) data to assess tumor responses to ATO and to uncover the complexity of therapeutic molecular biology.
p35448
sg35206
(lp35449
(dp35450
g35211
I53
sg35212
g35445
sg35214
I9
sg35223
VP03891
p35451
sg35217
I1
sasg35208
(lp35452
(dp35453
g35211
I95
sg35212
VMB
p35454
sg35214
I2
sg35215
VC0025149
p35455
sg35217
I1
sa(dp35456
g35211
I78
sg35212
g35446
sg35214
I15
sg35215
VC0025149
p35457
sg35217
I1
sa(dp35458
g35211
I207
sg35212
Vtumor
p35459
sg35214
I5
sg35215
VC0027651
p35460
sg35217
I1
sasa(dp35461
g135
(dp35462
(VASC
p35463
Vmedulloblastoma
p35464
tp35465
I00
ssg35204
VImportantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2:SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset.
p35466
sg35206
(lp35467
(dp35468
g35211
I117
sg35212
VND2
p35469
sg35214
I3
sg35223
VP03891
p35470
sg35217
I1
sa(dp35471
g35211
I19
sg35212
g35463
sg35214
I3
sg35223
VP08842
p35472
sg35217
I1
sasg35208
(lp35473
(dp35474
g35211
I148
sg35212
Vmedulloblastoma
p35475
sg35214
I15
sg35215
VC0025149
p35476
sg35217
I1
sa(dp35477
g35211
I148
sg35212
g35464
sg35214
I15
sg35215
VC0025149
p35478
sg35217
I1
sa(dp35479
g35211
I238
sg35212
Vtumor
p35480
sg35214
I5
sg35215
VC0027651
p35481
sg35217
I1
sasa(dp35482
g135
(dp35483
(VND2
p35484
Vbrain tumors
p35485
tp35486
I00
ssg35204
VWe report the use of IRDye 800CW chlorotoxin (CLTX) as a targeted imaging agent for brain tumors in a spontaneous mouse model of medulloblastoma, ND2:SmoA1.
p35487
sg35206
(lp35488
(dp35489
g35211
I146
sg35212
g35484
sg35214
I3
sg35223
VP03891
p35490
sg35217
I1
sasg35208
(lp35491
(dp35492
g35211
I129
sg35212
Vmedulloblastoma
p35493
sg35214
I15
sg35215
VC0025149
p35494
sg35217
I1
sa(dp35495
g35211
I84
sg35212
g35485
sg35214
I12
sg35215
VC0006118
p35496
sg35217
I2
sasa(dp35497
g135
(dp35498
(VND2
p35499
Vmedulloblastoma
p35500
tp35501
I00
ssg35204
VImportantly, genetic deletion of Bax in medulloblastoma-prone ND2:SmoA1 transgenic mice greatly accelerated tumorigenesis.
p35502
sg35206
(lp35503
(dp35504
g35211
I62
sg35212
g35499
sg35214
I3
sg35223
VP03891
p35505
sg35217
I1
sasg35208
(lp35506
(dp35507
g35211
I108
sg35212
Vtumorigenesis
p35508
sg35214
I13
sg35215
VC0007621
p35509
sg35217
I1
sa(dp35510
g35211
I40
sg35212
g35500
sg35214
I15
sg35215
VC0025149
p35511
sg35217
I1
sasa(dp35512
g135
(dp35513
(VND2 gene
p35514
Vpancreatic cancer
p35515
tp35516
I01
ssg35204
VFive common variants were associated with pancreatic cancer at nominal statistical significance (P &lt; 0.05) with the strongest finding for mt5460g in the ND2 gene [OR = 3.9; 95% confidence interval (CI), 1.5-10; P = 0.004] which encodes an A331T substitution.
p35517
sg35206
(lp35518
(dp35519
g35211
I156
sg35212
g35514
sg35214
I8
sg35223
VP03891
p35520
sg35217
I2
sasg35208
(lp35521
(dp35522
g35211
I42
sg35212
g35515
sg35214
I17
sg35215
VC0235974
p35523
sg35217
I2
sasa(dp35524
g135
(dp35525
(VHsp70
p35526
Vneurodegenerative diseases
p35527
tp35528
I00
ssg35204
VOur findings indicate a critical role of HspBP1 in differential CHIP/Hsp70 activities in neuronal and glial cells and the greater neuronal vulnerability to misfolded proteins in neurodegenerative diseases.
p35529
sg35206
(lp35530
(dp35531
g35211
I41
sg35212
VHspBP1
p35532
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp35533
g35211
I69
sg35212
g35526
sg35214
I5
sg35223
VP34932
p35534
sg35217
I1
sa(dp35535
g35211
I64
sg35212
VCHIP
p35536
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp35537
(dp35538
g35211
I178
sg35212
g35527
sg35214
I26
sg35215
VC0524851
p35539
sg35217
I2
sasa(dp35540
g135
(dp35541
(VHIP
p35542
VMuscular Atrophy
p35543
tp35544
I00
ssg35204
VIn this study the adenoviral mediated over-expression of HSP70 interacting protein (HIP) alone was shown to significantly reduce inclusion formation in both an in vitro model of Spinal Bulbar Muscular Atrophy and a primary neuronal model of polyglutamine disease.
p35545
sg35206
(lp35546
(dp35547
g35211
I57
sg35212
VHSP70 interacting protein
p35548
sg35214
I25
sg35223
VP50502
p35549
sg35217
I3
sa(dp35550
g35211
I84
sg35212
g35542
sg35214
I3
sg35223
VP47914
p35551
sg35217
I1
sasg35208
(lp35552
(dp35553
g35211
I192
sg35212
g35543
sg35214
I16
sg35215
VC0026846
p35554
sg35217
I2
sasa(dp35555
g135
(dp35556
(VMYC
p35557
VPV
p35558
tp35559
I00
ssg35204
VTo explore the relationship of telomerase, MYC and JAK2 in chronic myeloproliferative diseases, we investigated hTERT and MYC expression in bone marrow cells of essential thrombocythemia (ET) and polycythemia vera (PV).
p35560
sg35206
(lp35561
(dp35562
g35211
I112
sg35212
VhTERT
p35563
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp35564
g35211
I51
sg35212
VJAK2
p35565
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp35566
g35211
I43
sg35212
VMYC
p35567
sg35214
I3
sg35223
VP12524
p35568
sg35217
I1
sa(dp35569
g35211
I43
sg35212
g35557
sg35214
I3
sg35223
VP12524
p35570
sg35217
I1
sasg35208
(lp35571
(dp35572
g35211
I161
sg35212
Vessential thrombocythemia
p35573
sg35214
I25
sg35215
VC0040028
p35574
sg35217
I2
sa(dp35575
g35211
I188
sg35212
VET
p35576
sg35214
I2
sg35215
VC0040028
p35577
sg35217
I1
sa(dp35578
g35211
I196
sg35212
Vpolycythemia vera
p35579
sg35214
I17
sg35215
VC0032463
p35580
sg35217
I2
sa(dp35581
g35211
I215
sg35212
g35558
sg35214
I2
sg35215
VC0032463
p35582
sg35217
I1
sasa(dp35583
g35204
VDCAF17 mutations are associated with Woodhouse-Sakati syndrome, a rare disorder characterized by alopecia, hypogonadotropic hypogonadism, sensorineural hearing loss, diabetes mellitus, and extrapyramidal movements.
p35584
sg35206
(lp35585
(dp35586
g35211
I0
sg35212
VDCAF17
p35587
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp35588
(dp35589
g35211
I166
sg35212
Vdiabetes mellitus
p35590
sg35214
I17
sg35215
VC0011849
p35591
sg35217
I2
sa(dp35592
g35211
I107
sg35212
Vhypogonadotropic hypogonadism
p35593
sg35214
I29
sg35215
VC0022735
p35594
sg35217
I2
sa(dp35595
g35211
I66
sg35212
Vrare disorder
p35596
sg35214
I13
sg35215
VC0678236
p35597
sg35217
I2
sa(dp35598
g35211
I138
sg35212
Vsensorineural hearing loss
p35599
sg35214
I26
sg35215
VC0018784
p35600
sg35217
I3
sa(dp35601
g35211
I37
sg35212
VWoodhouse-Sakati syndrome
p35602
sg35214
I25
sg35215
VC0342286
p35603
sg35217
I2
sasa(dp35604
g135
(dp35605
(Vlow insulinlike growth factor 1
p35606
Vdiabetes mellitus
p35607
tp35608
I00
ssg35204
VWoodhouse-Sakati syndrome (WSS) is a rare autosomal recessive disorder characterized by alopecia, hypogonadism, diabetes mellitus, intellectual disability, sensorineural deafness, extrapyramidal signs, and low insulinlike growth factor 1 levels.
p35609
sg35206
(lp35610
(dp35611
g35211
I206
sg35212
g35606
sg35214
I31
sg35223
VP05019
p35612
sg35217
I5
sasg35208
(lp35613
(dp35614
g35211
I180
sg35212
Vextrapyramidal signs
p35615
sg35214
I20
sg35215
VC0234133
p35616
sg35217
I2
sa(dp35617
g35211
I98
sg35212
Vhypogonadism
p35618
sg35214
I12
sg35215
VC0020619
p35619
sg35217
I1
sa(dp35620
g35211
I0
sg35212
VWoodhouse-Sakati syndrome
p35621
sg35214
I25
sg35215
VC0342286
p35622
sg35217
I2
sa(dp35623
g35211
I27
sg35212
VWSS
p35624
sg35214
I3
sg35215
VC0406587
p35625
sg35217
I1
sa(dp35626
g35211
I156
sg35212
Vsensorineural deafness
p35627
sg35214
I22
sg35215
VC0018784
p35628
sg35217
I2
sa(dp35629
g35211
I131
sg35212
Vintellectual disability
p35630
sg35214
I23
sg35215
VC0025362
p35631
sg35217
I2
sa(dp35632
g35211
I112
sg35212
g35607
sg35214
I17
sg35215
VC0011849
p35633
sg35217
I2
sasa(dp35634
g35204
VWoodhouse-Sakati syndrome consists of alopecia, hypogonadism, diabetes mellitus, mild mental retardation, sensorineural deafness and ECG abnormalities.
p35635
sg35206
(lp35636
sg35208
(lp35637
(dp35638
g35211
I62
sg35212
Vdiabetes mellitus
p35639
sg35214
I17
sg35215
VC0011849
p35640
sg35217
I2
sa(dp35641
g35211
I81
sg35212
Vmild mental retardation
p35642
sg35214
I23
sg35215
VC0026106
p35643
sg35217
I3
sa(dp35644
g35211
I48
sg35212
Vhypogonadism
p35645
sg35214
I12
sg35215
VC0020619
p35646
sg35217
I1
sa(dp35647
g35211
I106
sg35212
Vsensorineural deafness
p35648
sg35214
I22
sg35215
VC0018784
p35649
sg35217
I2
sa(dp35650
g35211
I0
sg35212
VWoodhouse-Sakati syndrome
p35651
sg35214
I25
sg35215
VC0342286
p35652
sg35217
I2
sasa(dp35653
g135
(dp35654
(VIFN-gamma
p35655
Vdisseminated candidiasis
p35656
tp35657
I00
ssg35204
VA population of CD80+Gr-1+ myeloid cells was found to be expanded in conventional as well as in bone marrow-transplanted mice with disseminated candidiasis, but its depletion increased the IFN-gamma-mediated antifungal resistance.
p35658
sg35206
(lp35659
(dp35660
g35211
I16
sg35212
VCD80+Gr-1+
p35661
sg35214
I10
sg35223
VP00390
p35662
sg35217
I1
sa(dp35663
g35211
I189
sg35212
g35655
sg35214
I9
sg35223
VP01579
p35664
sg35217
I1
sasg35208
(lp35665
(dp35666
g35211
I131
sg35212
g35656
sg35214
I24
sg35215
VC0153252
p35667
sg35217
I2
sasa(dp35668
g135
(dp35669
(VCD4
p35670
Voropharyngeal candidiasis
p35671
tp35672
I00
ssg35204
VThe patients with esophageal candidiasis had lower CD4+ cell counts (129/microliter) and CD4:CD8 ratios (0.23) than those with oropharyngeal candidiasis (CD4 179/microliter; CD4:CD8 0.35).
p35673
sg35206
(lp35674
(dp35675
g35211
I178
sg35212
VCD8 0.35
p35676
sg35214
I8
sg35223
VP01732
p35677
sg35217
I2
sa(dp35678
g35211
I51
sg35212
VCD4
p35679
sg35214
I3
sg35223
VP01730
p35680
sg35217
I1
sa(dp35681
g35211
I51
sg35212
VCD4+
p35682
sg35214
I4
sg35223
VP01730
p35683
sg35217
I1
sa(dp35684
g35211
I51
sg35212
VCD4
p35685
sg35214
I3
sg35223
VP01730
p35686
sg35217
I1
sa(dp35687
g35211
I93
sg35212
VCD8
p35688
sg35214
I3
sg35223
VP01732
p35689
sg35217
I1
sa(dp35690
g35211
I51
sg35212
g35670
sg35214
I3
sg35223
VP01730
p35691
sg35217
I1
sasg35208
(lp35692
(dp35693
g35211
I18
sg35212
Vesophageal candidiasis
p35694
sg35214
I22
sg35215
VC0239295
p35695
sg35217
I2
sa(dp35696
g35211
I127
sg35212
g35671
sg35214
I25
sg35215
VC0919659
p35697
sg35217
I2
sasa(dp35698
g35204
VWe served patients with cystic fibrosis (CF, n=29), cystic fibrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized breakfast (23 g protein, 25 g fat and 76 g carbohydrates) after an overnight fasting.
p35699
sg35206
(lp35700
sg35208
(lp35701
(dp35702
g35211
I41
sg35212
VCF
p35703
sg35214
I2
sg35215
VC0010674
p35704
sg35217
I1
sa(dp35705
g35211
I24
sg35212
Vcystic fibrosis
p35706
sg35214
I15
sg35215
VC0010674
p35707
sg35217
I2
sa(dp35708
g35211
I52
sg35212
Vcystic fibrosis related diabetes
p35709
sg35214
I32
sg35215
VC2242728
p35710
sg35217
I4
sa(dp35711
g35211
I86
sg35212
VCFRD
p35712
sg35214
I4
sg35215
VC2242728
p35713
sg35217
I1
sasa(dp35714
g35204
VCNS anomalies included 12 Chiari malformations, 2 Dandy-Walker malformations (DWM), 1 variant of Dandy-Walker syndrome (DWS), 3 iniencephalies, 15 anencephalies, 1 alobar holoprosencephaly, 2 isolated hydrocephalies, 3 hydrocephalies with cerebellar hypoplasia, 1 occipital encephalocele, 1 lumbosacral myelomeningocele accompanied with microcephaly.
p35715
sg35206
(lp35716
sg35208
(lp35717
(dp35718
g35211
I50
sg35212
VDandy-Walker malformations
p35719
sg35214
I26
sg35215
VC0010964
p35720
sg35217
I2
sa(dp35721
g35211
I303
sg35212
Vmyelomeningocele
p35722
sg35214
I16
sg35215
VC0025312
p35723
sg35217
I1
sa(dp35724
g35211
I239
sg35212
Vcerebellar hypoplasia
p35725
sg35214
I21
sg35215
VC0266470
p35726
sg35217
I2
sa(dp35727
g35211
I26
sg35212
VChiari malformations
p35728
sg35214
I20
sg35215
VC0003803
p35729
sg35217
I2
sa(dp35730
g35211
I78
sg35212
VDWM
p35731
sg35214
I3
sg35215
VC0010964
p35732
sg35217
I1
sa(dp35733
g35211
I264
sg35212
Voccipital encephalocele
p35734
sg35214
I23
sg35215
VC0014067
p35735
sg35217
I2
sa(dp35736
g35211
I97
sg35212
VDandy-Walker syndrome
p35737
sg35214
I21
sg35215
VC0010964
p35738
sg35217
I2
sa(dp35739
g35211
I337
sg35212
Vmicrocephaly
p35740
sg35214
I12
sg35215
VC0025958
p35741
sg35217
I1
sa(dp35742
g35211
I120
sg35212
VDWS
p35743
sg35214
I3
sg35215
VC0010964
p35744
sg35217
I1
sa(dp35745
g35211
I128
sg35212
Viniencephalies
p35746
sg35214
I14
sg35215
VC0152234
p35747
sg35217
I1
sa(dp35748
g35211
I164
sg35212
Valobar holoprosencephaly
p35749
sg35214
I24
sg35215
VC0431363
p35750
sg35217
I2
sasa(dp35751
g35204
VAcrania, alobar holoprosencephaly, cephaloceles, and spina bifida can confidently be diagnosed at that stage and should actively be looked for in every fetus undergoing first-trimester ultrasound.
p35752
sg35206
(lp35753
sg35208
(lp35754
(dp35755
g35211
I9
sg35212
Valobar holoprosencephaly
p35756
sg35214
I24
sg35215
VC0431363
p35757
sg35217
I2
sa(dp35758
g35211
I53
sg35212
Vspina bifida
p35759
sg35214
I12
sg35215
VC0080178
p35760
sg35217
I2
sa(dp35761
g35211
I0
sg35212
VAcrania
p35762
sg35214
I7
sg35215
VC0702169
p35763
sg35217
I1
sa(dp35764
g35211
I35
sg35212
Vcephaloceles
p35765
sg35214
I12
sg35215
VC0014065
p35766
sg35217
I1
sasa(dp35767
g35204
VWe present a new case with 13q deletion syndrome phenotypically characterized by severe major malformations, some of them still undescribed, consisting of left diaphragmatic hernia, right pulmonary sequestration, hypoplastic left heart syndrome, pancreatic agenesis, polysplenia, and catastrophic central nervous system malformations: semilobar holoprosencephaly, occipital myelomeningocele, partial agenesis of the corpus callosum and agenesis of olfactory bulbs.
p35768
sg35206
(lp35769
sg35208
(lp35770
(dp35771
g35211
I257
sg35212
Vagenesis
p35772
sg35214
I8
sg35215
VC0332907
p35773
sg35217
I1
sa(dp35774
g35211
I213
sg35212
Vhypoplastic left heart syndrome
p35775
sg35214
I31
sg35215
VC0152101
p35776
sg35217
I4
sa(dp35777
g35211
I188
sg35212
Vpulmonary sequestration
p35778
sg35214
I23
sg35215
VC0006288
p35779
sg35217
I2
sa(dp35780
g35211
I335
sg35212
Vsemilobar holoprosencephaly
p35781
sg35214
I27
sg35215
VC0751617
p35782
sg35217
I2
sa(dp35783
g35211
I305
sg35212
Vnervous system malformations
p35784
sg35214
I28
sg35215
VC0497552
p35785
sg35217
I3
sa(dp35786
g35211
I374
sg35212
Vmyelomeningocele
p35787
sg35214
I16
sg35215
VC0025312
p35788
sg35217
I1
sa(dp35789
g35211
I392
sg35212
Vpartial agenesis of the corpus callosum
p35790
sg35214
I39
sg35215
VC0431368
p35791
sg35217
I6
sa(dp35792
g35211
I160
sg35212
Vdiaphragmatic hernia
p35793
sg35214
I20
sg35215
VC0019284
p35794
sg35217
I2
sa(dp35795
g35211
I94
sg35212
Vmalformations
p35796
sg35214
I13
sg35215
VC0000768
p35797
sg35217
I1
sa(dp35798
g35211
I267
sg35212
Vpolysplenia
p35799
sg35214
I11
sg35215
VC0266631
p35800
sg35217
I1
sa(dp35801
g35211
I27
sg35212
V13q deletion syndrome
p35802
sg35214
I21
sg35215
VC0265451
p35803
sg35217
I3
sa(dp35804
g35211
I257
sg35212
Vagenesis
p35805
sg35214
I8
sg35215
VC0332907
p35806
sg35217
I1
sasa(dp35807
g35204
VThe early scan detected all cases of acrania, alobar holoprosencephaly, exomphalos, gastroschisis, megacystis and body stalk anomaly, 77% of absent hand or foot, 50% of diaphragmatic hernia, 50% of lethal skeletal dysplasias, 60% of polydactyly, 34% of major cardiac defects, 5% of facial clefts and 14% of open spina bifida, but none of agenesis of the corpus callosum, cerebellar or vermian hypoplasia, echogenic lung lesions, bowel obstruction, most renal defects or talipes.
p35808
sg35206
(lp35809
sg35208
(lp35810
(dp35811
g35211
I393
sg35212
Vhypoplasia
p35812
sg35214
I10
sg35215
VC0243069
p35813
sg35217
I1
sa(dp35814
g35211
I214
sg35212
Vdysplasias
p35815
sg35214
I10
sg35215
VC0334044
p35816
sg35217
I1
sa(dp35817
g35211
I307
sg35212
Vopen spina bifida
p35818
sg35214
I17
sg35215
VC0917813
p35819
sg35217
I3
sa(dp35820
g35211
I338
sg35212
Vagenesis of the corpus callosum
p35821
sg35214
I31
sg35215
VC0175754
p35822
sg35217
I5
sa(dp35823
g35211
I84
sg35212
Vgastroschisis
p35824
sg35214
I13
sg35215
VC0265706
p35825
sg35217
I1
sa(dp35826
g35211
I37
sg35212
Vacrania
p35827
sg35214
I7
sg35215
VC0702169
p35828
sg35217
I1
sa(dp35829
g35211
I429
sg35212
Vbowel obstruction
p35830
sg35214
I17
sg35215
VC0021843
p35831
sg35217
I2
sa(dp35832
g35211
I470
sg35212
Vtalipes
p35833
sg35214
I7
sg35215
VC0009081
p35834
sg35217
I1
sa(dp35835
g35211
I259
sg35212
Vcardiac defects
p35836
sg35214
I15
sg35215
VC0741916
p35837
sg35217
I2
sa(dp35838
g35211
I46
sg35212
Valobar holoprosencephaly
p35839
sg35214
I24
sg35215
VC0431363
p35840
sg35217
I2
sa(dp35841
g35211
I282
sg35212
Vfacial clefts
p35842
sg35214
I13
sg35215
VC0685787
p35843
sg35217
I2
sa(dp35844
g35211
I169
sg35212
Vdiaphragmatic hernia
p35845
sg35214
I20
sg35215
VC0019284
p35846
sg35217
I2
sa(dp35847
g35211
I72
sg35212
Vexomphalos
p35848
sg35214
I10
sg35215
VC1306503
p35849
sg35217
I1
sa(dp35850
g35211
I233
sg35212
Vpolydactyly
p35851
sg35214
I11
sg35215
VC0152427
p35852
sg35217
I1
sa(dp35853
g35211
I119
sg35212
Vstalk
p35854
sg35214
I5
sg35215
VC0935572
p35855
sg35217
I1
sasa(dp35856
g35204
VThe case presented is, to our knowledge, the first published report comprising a combination of a semilobar holoprosencephaly associated with a Chiari II malformation and a myelomeningocele diagnosed prenatally and confirmed by postmortem neuropathologic evaluation.
p35857
sg35206
(lp35858
sg35208
(lp35859
(dp35860
g35211
I154
sg35212
Vmalformation
p35861
sg35214
I12
sg35215
VC0000768
p35862
sg35217
I1
sa(dp35863
g35211
I98
sg35212
Vsemilobar holoprosencephaly
p35864
sg35214
I27
sg35215
VC0751617
p35865
sg35217
I2
sa(dp35866
g35211
I173
sg35212
Vmyelomeningocele
p35867
sg35214
I16
sg35215
VC0025312
p35868
sg35217
I1
sasa(dp35869
g35204
VThese findings indicate that in the case of pre- and postnatal detection of a myelomeningocele and/or Chiari II malformation, possible additional intracranial malformation, such as a semilobar holoprosencephaly, should also be taken into account and vice versa.
p35870
sg35206
(lp35871
sg35208
(lp35872
(dp35873
g35211
I78
sg35212
Vmyelomeningocele
p35874
sg35214
I16
sg35215
VC0025312
p35875
sg35217
I1
sa(dp35876
g35211
I183
sg35212
Vsemilobar holoprosencephaly
p35877
sg35214
I27
sg35215
VC0751617
p35878
sg35217
I2
sa(dp35879
g35211
I112
sg35212
Vmalformation
p35880
sg35214
I12
sg35215
VC0000768
p35881
sg35217
I1
sa(dp35882
g35211
I112
sg35212
Vmalformation
p35883
sg35214
I12
sg35215
VC0000768
p35884
sg35217
I1
sasa(dp35885
g35204
VWe report on a female still-birth with cebocephaly, alobar holoprosencephaly, cleft palate, lumbar spina bifida, sirenomelia, a single umbilical artery, and a 46,XX karyotype, but without maternal diabetes mellitus.
p35886
sg35206
(lp35887
sg35208
(lp35888
(dp35889
g35211
I188
sg35212
Vmaternal diabetes mellitus
p35890
sg35214
I26
sg35215
VC1283034
p35891
sg35217
I3
sa(dp35892
g35211
I99
sg35212
Vspina bifida
p35893
sg35214
I12
sg35215
VC0080178
p35894
sg35217
I2
sa(dp35895
g35211
I113
sg35212
Vsirenomelia
p35896
sg35214
I11
sg35215
VC0037205
p35897
sg35217
I1
sa(dp35898
g35211
I78
sg35212
Vcleft palate
p35899
sg35214
I12
sg35215
VC0008925
p35900
sg35217
I2
sa(dp35901
g35211
I39
sg35212
Vcebocephaly
p35902
sg35214
I11
sg35215
VC0266679
p35903
sg35217
I1
sa(dp35904
g35211
I52
sg35212
Valobar holoprosencephaly
p35905
sg35214
I24
sg35215
VC0431363
p35906
sg35217
I2
sa(dp35907
g35211
I128
sg35212
Vsingle umbilical artery
p35908
sg35214
I23
sg35215
VC0266795
p35909
sg35217
I3
sasa(dp35910
g135
(dp35911
(VIGF1R
p35912
Vhepatocellular carcinoma
p35913
tp35914
I00
ssg35204
VThe current study provides novel evidence that TGFBeta upregulates the expression of multiple receptor tyrosine kinases (RTKs), including IGF1R, EGFR, PDGFBetaR, and FGFR1 in human hepatocellular carcinoma (HCC) cells.
p35915
sg35206
(lp35916
(dp35917
g35211
I47
sg35212
VTGFBeta
p35918
sg35214
I7
sg35223
VP01137
p35919
sg35217
I1
sa(dp35920
g35211
I166
sg35212
VFGFR1
p35921
sg35214
I5
sg35223
VP20930
p35922
sg35217
I1
sa(dp35923
g35211
I94
sg35212
Vreceptor tyrosine kinases
p35924
sg35214
I25
sg35223
VP29401
p35925
sg35217
I3
sa(dp35926
g35211
I121
sg35212
VRTKs
p35927
sg35214
I4
sg35223
VP35968
p35928
sg35217
I1
sa(dp35929
g35211
I138
sg35212
g35912
sg35214
I5
sg35223
VP08069
p35930
sg35217
I1
sasg35208
(lp35931
(dp35932
g35211
I207
sg35212
VHCC
p35933
sg35214
I3
sg35215
VC2239176
p35934
sg35217
I1
sa(dp35935
g35211
I181
sg35212
g35913
sg35214
I24
sg35215
VC2239176
p35936
sg35217
I2
sasa(dp35937
g135
(dp35938
(VCD1d
p35939
Vrheumatoid arthritis
p35940
tp35941
I01
ssg35204
VWhile numerical and functional defects of invariant NKT cells have been demonstrated in rheumatoid arthritis (RA), the detailed characterization of proliferative and secretory responses following CD1d-mediated presentation is lacking; the presence of non-invariant populations has never been assessed in human autoimmunity.
p35942
sg35206
(lp35943
(dp35944
g35211
I196
sg35212
g35939
sg35214
I4
sg35223
VP15813
p35945
sg35217
I1
sasg35208
(lp35946
(dp35947
g35211
I310
sg35212
Vautoimmunity
p35948
sg35214
I12
sg35215
VC0004368
p35949
sg35217
I1
sa(dp35950
g35211
I110
sg35212
VRA
p35951
sg35214
I2
sg35215
VC0003873
p35952
sg35217
I1
sa(dp35953
g35211
I148
sg35212
Vproliferative
p35954
sg35214
I13
sg35215
VC0334094
p35955
sg35217
I1
sa(dp35956
g35211
I88
sg35212
g35940
sg35214
I20
sg35215
VC0003873
p35957
sg35217
I2
sasa(dp35958
g135
(dp35959
(VAng-2
p35960
VOSA
p35961
tp35962
I00
ssg35204
VIn adults, angiopoietin-2 (Ang-2) and its soluble receptor (sTie-2) are associated with diabetes, hypertension, and obesity and could be increased in children with OSA and obesity, particularly those with evidence of cardiometabolic alterations.
p35963
sg35206
(lp35964
(dp35965
g35211
I27
sg35212
g35960
sg35214
I5
sg35223
VP03950
p35966
sg35217
I1
sa(dp35967
g35211
I11
sg35212
Vangiopoietin-2
p35968
sg35214
I14
sg35223
g12
sg35217
I1
sasg35208
(lp35969
(dp35970
g35211
I98
sg35212
Vhypertension
p35971
sg35214
I12
sg35215
VC0020538
p35972
sg35217
I1
sa(dp35973
g35211
I88
sg35212
Vdiabetes
p35974
sg35214
I8
sg35215
VC0011849
p35975
sg35217
I1
sa(dp35976
g35211
I116
sg35212
Vobesity
p35977
sg35214
I7
sg35215
VC0028754
p35978
sg35217
I1
sa(dp35979
g35211
I116
sg35212
Vobesity
p35980
sg35214
I7
sg35215
VC0028754
p35981
sg35217
I1
sa(dp35982
g35211
I164
sg35212
g35961
sg35214
I3
sg35215
VC0520679
p35983
sg35217
I1
sasa(dp35984
g135
(dp35985
(Vplasma Ang-2
p35986
VOSA
p35987
tp35988
I00
ssg35204
VChildren with obesity and OSA had significantly elevated plasma Ang-2 and sTie-2 levels compared to corresponding controls with and without obesity.
p35989
sg35206
(lp35990
(dp35991
g35211
I57
sg35212
g35986
sg35214
I12
sg35223
VP03950
p35992
sg35217
I2
sasg35208
(lp35993
(dp35994
g35211
I14
sg35212
Vobesity
p35995
sg35214
I7
sg35215
VC0028754
p35996
sg35217
I1
sa(dp35997
g35211
I14
sg35212
Vobesity
p35998
sg35214
I7
sg35215
VC0028754
p35999
sg35217
I1
sa(dp36000
g35211
I26
sg35212
g35987
sg35214
I3
sg35215
VC0520679
p36001
sg35217
I1
sasa(dp36002
g135
(dp36003
(VAng-2
p36004
Vendothelial dysfunction
p36005
tp36006
I00
ssg35204
VAng-2 and sTie-2 plasma levels are increased in pediatric OSA and obesity, particularly when endothelial dysfunction or insulin resistance is detectable, and appear to decrease upon OSA treatment.
p36007
sg35206
(lp36008
(dp36009
g35211
I120
sg35212
Vinsulin
p36010
sg35214
I7
sg35223
VP01308
p36011
sg35217
I1
sa(dp36012
g35211
I0
sg35212
g36004
sg35214
I5
sg35223
VP03950
p36013
sg35217
I1
sasg35208
(lp36014
(dp36015
g35211
I58
sg35212
VOSA
p36016
sg35214
I3
sg35215
VC0520679
p36017
sg35217
I1
sa(dp36018
g35211
I66
sg35212
Vobesity
p36019
sg35214
I7
sg35215
VC0028754
p36020
sg35217
I1
sa(dp36021
g35211
I58
sg35212
VOSA
p36022
sg35214
I3
sg35215
VC0520679
p36023
sg35217
I1
sa(dp36024
g35211
I120
sg35212
Vinsulin resistance
p36025
sg35214
I18
sg35215
VC0021655
p36026
sg35217
I2
sa(dp36027
g35211
I93
sg35212
g36005
sg35214
I23
sg35215
VC0856169
p36028
sg35217
I2
sasa(dp36029
g135
(dp36030
(VANG-2
p36031
Vvascularization
p36032
tp36033
I00
ssg35204
VANG-2 overexpressing mice show increased sWAT vascularization and are resistant to HFD-induced obesity.
p36034
sg35206
(lp36035
(dp36036
g35211
I0
sg35212
g36031
sg35214
I5
sg35223
VP03950
p36037
sg35217
I1
sasg35208
(lp36038
(dp36039
g35211
I95
sg35212
Vobesity
p36040
sg35214
I7
sg35215
VC0028754
p36041
sg35217
I1
sa(dp36042
g35211
I46
sg35212
g36032
sg35214
I15
sg35215
VC0027686
p36043
sg35217
I1
sasa(dp36044
g35204
VWe studied the effect of sleeve gastrectomy and the influence of FTO rs9930506 polymorphism on Tie-2, angiopoietin-1 and angiopoietin-2 expression in morbid obesity.
p36045
sg35206
(lp36046
(dp36047
g35211
I102
sg35212
Vangiopoietin-1
p36048
sg35214
I14
sg35223
g12
sg35217
I1
sa(dp36049
g35211
I121
sg35212
Vangiopoietin-2
p36050
sg35214
I14
sg35223
g12
sg35217
I1
sa(dp36051
g35211
I65
sg35212
VFTO rs9930506
p36052
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp36053
g35211
I95
sg35212
VTie-2
p36054
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp36055
(dp36056
g35211
I150
sg35212
Vmorbid obesity
p36057
sg35214
I14
sg35215
VC0028756
p36058
sg35217
I2
sasa(dp36059
g35204
VThose most at risk report a family history of at least one parent with a pre-existing G-alpha protein defect, including night blindness, pseudohypoparathyroidism or adenoma of the thyroid or pituitary gland.
p36060
sg35206
(lp36061
sg35208
(lp36062
(dp36063
g35211
I165
sg35212
Vadenoma of the thyroid
p36064
sg35214
I22
sg35215
VC0151468
p36065
sg35217
I4
sa(dp36066
g35211
I137
sg35212
Vpseudohypoparathyroidism
p36067
sg35214
I24
sg35215
VC3494506
p36068
sg35217
I1
sa(dp36069
g35211
I120
sg35212
Vnight blindness
p36070
sg35214
I15
sg35215
VC0028077
p36071
sg35217
I2
sasa(dp36072
g135
(dp36073
(VAR
p36074
Vprostate cancer
p36075
tp36076
I00
ssg35204
VWe have previously shown that the ethanol extract of dried Angelica gigas Nakai (AGN) root exerts anticancer activity against androgen receptor (AR)-negative human DU145 and PC-3 prostate cancer xenografts and primary carcinogenesis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
p36077
sg35206
(lp36078
(dp36079
g35211
I126
sg35212
Vandrogen receptor
p36080
sg35214
I17
sg35223
VP10275
p36081
sg35217
I2
sa(dp36082
g35211
I145
sg35212
g36074
sg35214
I2
sg35223
VP10275
p36083
sg35217
I1
sasg35208
(lp36084
(dp36085
g35211
I251
sg35212
Vadenocarcinoma
p36086
sg35214
I14
sg35215
VC0001418
p36087
sg35217
I1
sa(dp36088
g35211
I218
sg35212
Vcarcinogenesis
p36089
sg35214
I14
sg35215
VC0596263
p36090
sg35217
I1
sa(dp36091
g35211
I179
sg35212
g36075
sg35214
I15
sg35215
VC0600139
p36092
sg35217
I2
sasa(dp36093
g135
(dp36094
(Vandrogen receptor
p36095
VEAC
p36096
tp36097
I00
ssg35204
VWe showed previously that nuclear localization of the androgen receptor (AR) and expression of the androgen-responsive gene FK506-binding protein 5 (FKBP5) in esophageal adenocarcinoma (EAC) tissues were associated with decreased patient survival, suggesting a role for androgens in this cancer.
p36098
sg35206
(lp36099
(dp36100
g35211
I73
sg35212
VAR
p36101
sg35214
I2
sg35223
VP10275
p36102
sg35217
I1
sa(dp36103
g35211
I99
sg35212
Vandrogen-responsive gene FK506-binding protein 5
p36104
sg35214
I48
sg35223
g12
sg35217
I5
sa(dp36105
g35211
I149
sg35212
VFKBP5
p36106
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp36107
g35211
I54
sg35212
g36095
sg35214
I17
sg35223
VP10275
p36108
sg35217
I2
sasg35208
(lp36109
(dp36110
g35211
I159
sg35212
Vesophageal adenocarcinoma
p36111
sg35214
I25
sg35215
VC0279628
p36112
sg35217
I2
sa(dp36113
g35211
I288
sg35212
Vcancer
p36114
sg35214
I6
sg35215
VC0006826
p36115
sg35217
I1
sa(dp36116
g35211
I186
sg35212
g36096
sg35214
I3
sg35215
VC1275122
p36117
sg35217
I1
sasa(dp36118
g135
(dp36119
(Vadenocarcinoma GS
p36120
Vadenocarcinoma
p36121
tp36122
I00
ssg35204
VOnly 5 samples were ERG-/AR- corresponding to adenocarcinoma GS of 6.
p36123
sg35206
(lp36124
(dp36125
g35211
I46
sg35212
g36120
sg35214
I17
sg35223
VP15104
p36126
sg35217
I2
sasg35208
(lp36127
(dp36128
g35211
I46
sg35212
g36121
sg35214
I14
sg35215
VC0001418
p36129
sg35217
I1
sasa(dp36130
g35204
VAR was expressed by 54% (27/50) of ECA including 60% of low grade endometrioid carcinomas, 70% high grade endometrioid carcinomas, 70% serous carcinomas, 50% carcinosarcomas, and 20% clear cell carcinomas.
p36131
sg35206
(lp36132
sg35208
(lp36133
(dp36134
g35211
I79
sg35212
Vcarcinomas
p36135
sg35214
I10
sg35215
VC0007097
p36136
sg35217
I1
sa(dp36137
g35211
I66
sg35212
Vendometrioid carcinomas
p36138
sg35214
I23
sg35215
VC0206687
p36139
sg35217
I2
sa(dp36140
g35211
I79
sg35212
Vcarcinomas
p36141
sg35214
I10
sg35215
VC0007097
p36142
sg35217
I1
sa(dp36143
g35211
I158
sg35212
Vcarcinosarcomas
p36144
sg35214
I15
sg35215
VC0007140
p36145
sg35217
I1
sa(dp36146
g35211
I66
sg35212
Vendometrioid carcinomas
p36147
sg35214
I23
sg35215
VC0206687
p36148
sg35217
I2
sasa(dp36149
g35204
VHigh AR expression was chiefly restricted to a subset of serous carcinomas (50%).
p36150
sg35206
(lp36151
sg35208
(lp36152
(dp36153
g35211
I64
sg35212
Vcarcinomas
p36154
sg35214
I10
sg35215
VC0007097
p36155
sg35217
I1
sasa(dp36156
g35204
VAR expression occurred most often in concert with ER staining, although 5 high grade cancers (1 serous carcinoma, 4 carcinosarcomas) showed AR expression in the absence of ER.
p36157
sg35206
(lp36158
sg35208
(lp36159
(dp36160
g35211
I85
sg35212
Vcancers
p36161
sg35214
I7
sg35215
VC0006826
p36162
sg35217
I1
sa(dp36163
g35211
I116
sg35212
Vcarcinosarcomas
p36164
sg35214
I15
sg35215
VC0007140
p36165
sg35217
I1
sa(dp36166
g35211
I96
sg35212
Vserous carcinoma
p36167
sg35214
I16
sg35215
VC0206701
p36168
sg35217
I2
sasa(dp36169
g35204
VIn summary, AR positivity is seen in over half of ECA in our study, including the majority of low grade endometrioid carcinomas, high grade endometrioid carcinomas, and serous carcinomas.
p36170
sg35206
(lp36171
sg35208
(lp36172
(dp36173
g35211
I104
sg35212
Vendometrioid carcinomas
p36174
sg35214
I23
sg35215
VC0206687
p36175
sg35217
I2
sa(dp36176
g35211
I117
sg35212
Vcarcinomas
p36177
sg35214
I10
sg35215
VC0007097
p36178
sg35217
I1
sa(dp36179
g35211
I104
sg35212
Vendometrioid carcinomas
p36180
sg35214
I23
sg35215
VC0206687
p36181
sg35217
I2
sasa(dp36182
g35204
VHigh level expression is seen in half of serous carcinomas and a subset of serous carcinomas and carcinosarcomas show some degree of AR staining in the absence of ER, suggesting a possible role for androgen inhibition in treatment of these cases.
p36183
sg35206
(lp36184
sg35208
(lp36185
(dp36186
g35211
I48
sg35212
Vcarcinomas
p36187
sg35214
I10
sg35215
VC0007097
p36188
sg35217
I1
sa(dp36189
g35211
I97
sg35212
Vcarcinosarcomas
p36190
sg35214
I15
sg35215
VC0007140
p36191
sg35217
I1
sa(dp36192
g35211
I48
sg35212
Vcarcinomas
p36193
sg35214
I10
sg35215
VC0007097
p36194
sg35217
I1
sasa(dp36195
g135
(dp36196
(VIL-6
p36197
Vosteoarthritis
p36198
tp36199
I00
ssg35204
VIL-6 and the MSC markers CD166 and nestin were colocalized in macroscopically normal human cartilage taken from the lateral femoral compartment of knees with medial tibiofemoral osteoarthritis.
p36200
sg35206
(lp36201
(dp36202
g35211
I35
sg35212
Vnestin
p36203
sg35214
I6
sg35223
VP48681
p36204
sg35217
I1
sa(dp36205
g35211
I25
sg35212
VCD166
p36206
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp36207
g35211
I13
sg35212
VMSC
p36208
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp36209
g35211
I0
sg35212
g36197
sg35214
I4
sg35223
VP05231
p36210
sg35217
I1
sasg35208
(lp36211
(dp36212
g35211
I178
sg35212
g36198
sg35214
I14
sg35215
VC0029408
p36213
sg35217
I1
sasa(dp36214
g35204
VIn conclusion, our findings support a model where Sirt3 plays a protective role against oxidative stress in oocytes exposed to maternal diabetes through deacetylating SOD2K68.
p36215
sg35206
(lp36216
(dp36217
g35211
I50
sg35212
VSirt3
p36218
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp36219
(dp36220
g35211
I127
sg35212
Vmaternal diabetes
p36221
sg35214
I17
sg35215
VC0085207
p36222
sg35217
I2
sa(dp36223
g35211
I88
sg35212
Voxidative stress
p36224
sg35214
I16
sg35215
VC0242606
p36225
sg35217
I2
sasa(dp36226
g35204
VThe aim of our study was to investigate the effects of LPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), PON1 (rs662), and MNSOD (rs4880) gene polymorphisms on lipid metabolism and diabetic dyslipidemia.
p36227
sg35206
(lp36228
(dp36229
g35211
I55
sg35212
VLPL
p36230
sg35214
I3
sg35223
VP06858
p36231
sg35217
I1
sa(dp36232
g35211
I194
sg35212
VMNSOD
p36233
sg35214
I5
sg35223
VP04179
p36234
sg35217
I1
sa(dp36235
g35211
I121
sg35212
VCETP
p36236
sg35214
I4
sg35223
VP11597
p36237
sg35217
I1
sa(dp36238
g35211
I86
sg35212
VSCARB1
p36239
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp36240
g35211
I158
sg35212
VRETN
p36241
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36242
g35211
I68
sg35212
VLIPC (rs2070895)
p36243
sg35214
I16
sg35223
VP11150
p36244
sg35217
I2
sa(dp36245
g35211
I176
sg35212
VPON1
p36246
sg35214
I4
sg35223
VP27169
p36247
sg35217
I1
sasg35208
(lp36248
(dp36249
g35211
I252
sg35212
Vdiabetic dyslipidemia
p36250
sg35214
I21
sg35215
VC3160761
p36251
sg35217
I2
sasa(dp36252
g35204
VSignificant associations were observed between LPL (rs320) (p&lt;0.001), LIPC (rs2070895) (p&lt;0.001), SCARB1 (rs5888) (p&lt;0.001), LCAT (rs2292318) (p&lt;0.001), CETP (rs708272) (p&lt;0.001), ADIPOQ (rs1501299) (p=0.01), RETN (rs3745367) (p&lt;0.001), and MNSOD (rs4880) (p&lt;0.001) polymorphisms and diabetic dyslipidemia.
p36253
sg35206
(lp36254
(dp36255
g35211
I73
sg35212
VLIPC
p36256
sg35214
I4
sg35223
VP11150
p36257
sg35217
I1
sa(dp36258
g35211
I47
sg35212
VLPL
p36259
sg35214
I3
sg35223
VP06858
p36260
sg35217
I1
sa(dp36261
g35211
I104
sg35212
VSCARB1
p36262
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp36263
g35211
I259
sg35212
VMNSOD
p36264
sg35214
I5
sg35223
VP04179
p36265
sg35217
I1
sa(dp36266
g35211
I165
sg35212
VCETP
p36267
sg35214
I4
sg35223
VP11597
p36268
sg35217
I1
sa(dp36269
g35211
I224
sg35212
VRETN
p36270
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36271
(dp36272
g35211
I305
sg35212
Vdiabetic dyslipidemia
p36273
sg35214
I21
sg35215
VC3160761
p36274
sg35217
I2
sasa(dp36275
g35204
VLPL (rs320), LIPC (rs2070895), SCARB1 (rs5888), LCAT (rs2292318), CETP (rs708272), ADIPOQ (rs1501299), RETN (rs3745367), and MNSOD (rs4880) polymorphisms play an important role in basic molecular metabolism in diabetic dyslipidemia.
p36276
sg35206
(lp36277
(dp36278
g35211
I31
sg35212
VSCARB1
p36279
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp36280
g35211
I13
sg35212
VLIPC (rs2070895)
p36281
sg35214
I16
sg35223
VP11150
p36282
sg35217
I2
sa(dp36283
g35211
I103
sg35212
VRETN
p36284
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36285
g35211
I0
sg35212
VLPL
p36286
sg35214
I3
sg35223
VP06858
p36287
sg35217
I1
sa(dp36288
g35211
I66
sg35212
VCETP
p36289
sg35214
I4
sg35223
VP11597
p36290
sg35217
I1
sa(dp36291
g35211
I125
sg35212
VMNSOD
p36292
sg35214
I5
sg35223
VP04179
p36293
sg35217
I1
sasg35208
(lp36294
(dp36295
g35211
I210
sg35212
Vdiabetic dyslipidemia
p36296
sg35214
I21
sg35215
VC3160761
p36297
sg35217
I2
sasa(dp36298
g35204
VWe studied if YKL-40 is related to inflammation, fibrosis, and/or lung function in subjects exposed to asbestosis.
p36299
sg35206
(lp36300
sg35208
(lp36301
(dp36302
g35211
I35
sg35212
Vinflammation
p36303
sg35214
I12
sg35215
VC0021368
p36304
sg35217
I1
sa(dp36305
g35211
I103
sg35212
Vasbestosis
p36306
sg35214
I10
sg35215
VC0003949
p36307
sg35217
I1
sa(dp36308
g35211
I49
sg35212
Vfibrosis
p36309
sg35214
I8
sg35215
VC0016059
p36310
sg35217
I1
sasa(dp36311
g135
(dp36312
(VPlasma YKL-40
p36313
Vasbestosis
p36314
tp36315
I00
ssg35204
VPlasma YKL-40 levels were significantly higher in subjects with asbestosis (n = 19) than in those with no fibrotic findings in HRCT following asbestos exposure (n = 66) or in unexposed healthy controls.
p36316
sg35206
(lp36317
(dp36318
g35211
I0
sg35212
g36313
sg35214
I13
sg35223
VP36222
p36319
sg35217
I2
sasg35208
(lp36320
(dp36321
g35211
I64
sg35212
g36314
sg35214
I10
sg35215
VC0003949
p36322
sg35217
I1
sasa(dp36323
g135
(dp36324
(VYKL-40
p36325
Vcardiovascular disease
p36326
tp36327
I00
ssg35204
VYKL-40 is a promising marker of cardiovascular disease and liver siderosis in Beta-TM patients.
p36328
sg35206
(lp36329
(dp36330
g35211
I0
sg35212
g36325
sg35214
I6
sg35223
VP36222
p36331
sg35217
I1
sasg35208
(lp36332
(dp36333
g35211
I65
sg35212
Vsiderosis
p36334
sg35214
I9
sg35215
VC0037061
p36335
sg35217
I1
sa(dp36336
g35211
I32
sg35212
g36326
sg35214
I22
sg35215
VC0007222
p36337
sg35217
I2
sasa(dp36338
g135
(dp36339
(Vserum YKL-40
p36340
Vliver disease
p36341
tp36342
I00
ssg35204
VThe aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis.
p36343
sg35206
(lp36344
(dp36345
g35211
I49
sg35212
g36340
sg35214
I12
sg35223
VP36222
p36346
sg35217
I2
sa(dp36347
g35211
I66
sg35212
Vplasma chitotriosidase
p36348
sg35214
I22
sg35223
g12
sg35217
I2
sasg35208
(lp36349
(dp36350
g35211
I115
sg35212
Vbeta-thalassemia
p36351
sg35214
I16
sg35215
VC0005283
p36352
sg35217
I1
sa(dp36353
g35211
I217
sg35212
Vsiderosis
p36354
sg35214
I9
sg35215
VC0037061
p36355
sg35217
I1
sa(dp36356
g35211
I183
sg35212
g36341
sg35214
I13
sg35215
VC0023895
p36357
sg35217
I2
sasa(dp36358
g35204
VOur results demonstrated that (1) Invasive ductal carcinoma patients with low expression of Slit2 or Robo1 exhibited worse prognosis and brain-specific metastasis, but not liver, bone or lung.
p36359
sg35206
(lp36360
(dp36361
g35211
I101
sg35212
VRobo1
p36362
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp36363
g35211
I92
sg35212
VSlit2
p36364
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp36365
(dp36366
g35211
I152
sg35212
Vmetastasis
p36367
sg35214
I10
sg35215
VC0027627
p36368
sg35217
I1
sa(dp36369
g35211
I34
sg35212
VInvasive ductal carcinoma
p36370
sg35214
I25
sg35215
VC1134719
p36371
sg35217
I3
sasa(dp36372
g135
(dp36373
(VPLAU
p36374
Vinvasive ductal carcinoma of the breast
p36375
tp36376
I01
ssg35204
VTen prognostic and diagnostic epigenetic breast cancer biomarkers (PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast.
p36377
sg35206
(lp36378
(dp36379
g35211
I102
sg35212
VLIMK1
p36380
sg35214
I5
sg35223
VP53667
p36381
sg35217
I1
sa(dp36382
g35211
I137
sg35212
VTFF1
p36383
sg35214
I4
sg35223
VP04155
p36384
sg35217
I1
sa(dp36385
g35211
I125
sg35212
VHS3ST2
p36386
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp36387
g35211
I83
sg35212
g36374
sg35214
I4
sg35223
VP00749
p36388
sg35217
I1
sa(dp36389
g35211
I109
sg35212
VSLITRK1
p36390
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp36391
g35211
I89
sg35212
VLHX3
p36392
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36393
g35211
I67
sg35212
VPITX2
p36394
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp36395
g35211
I118
sg35212
VSLIT2
p36396
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp36397
g35211
I95
sg35212
VPITX3
p36398
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp36399
(dp36400
g35211
I41
sg35212
Vbreast cancer
p36401
sg35214
I13
sg35215
VC0678222
p36402
sg35217
I2
sa(dp36403
g35211
I207
sg35212
g36375
sg35214
I39
sg35215
VC1134719
p36404
sg35217
I6
sasa(dp36405
g135
(dp36406
(VCyclin D2
p36407
Vmultiple cancer
p36408
tp36409
I01
ssg35204
VThe aim of this study is to determine the correlation between methylation status of multiple cancer genes, p16(INK4A), p14(ARF), Cyclin D2 and Slit2 in invasive ductal carcinoma of the breast and paired serum DNA and clinicopathological parameters.
p36410
sg35206
(lp36411
(dp36412
g35211
I119
sg35212
Vp14
p36413
sg35214
I3
sg35223
VP03971
p36414
sg35217
I1
sa(dp36415
g35211
I129
sg35212
g36407
sg35214
I9
sg35223
VP30279
p36416
sg35217
I2
sa(dp36417
g35211
I107
sg35212
Vp16
p36418
sg35214
I3
sg35223
VP42771
p36419
sg35217
I1
sa(dp36420
g35211
I123
sg35212
VARF
p36421
sg35214
I3
sg35223
VP42771
p36422
sg35217
I1
sa(dp36423
g35211
I143
sg35212
VSlit2
p36424
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp36425
g35211
I111
sg35212
VINK4A
p36426
sg35214
I5
sg35223
VP42771
p36427
sg35217
I1
sasg35208
(lp36428
(dp36429
g35211
I123
sg35212
VARF
p36430
sg35214
I3
sg35215
VC0264490
p36431
sg35217
I1
sa(dp36432
g35211
I152
sg35212
Vinvasive ductal carcinoma of the breast
p36433
sg35214
I39
sg35215
VC1134719
p36434
sg35217
I6
sa(dp36435
g35211
I84
sg35212
g36408
sg35214
I15
sg35215
VC0346429
p36436
sg35217
I2
sasa(dp36437
g35204
VTo examine the role of IRS2 in allergic disease, we evaluated the responses of IRS2-deficient (IRS2(-/-)) mice.
p36438
sg35206
(lp36439
(dp36440
g35211
I23
sg35212
VIRS2
p36441
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36442
g35211
I23
sg35212
VIRS2
p36443
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36444
g35211
I23
sg35212
VIRS2
p36445
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36446
sa(dp36447
g35204
VAdditional work further confirmed CDK6, RICTOR, and CTSB (cathepsin B) as targets of miR-218 and examined the functional role of one of these targets, CDK6, in medulloblastoma.
p36448
sg35206
(lp36449
(dp36450
g35211
I34
sg35212
VCDK6
p36451
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36452
g35211
I34
sg35212
VCDK6
p36453
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36454
g35211
I40
sg35212
VRICTOR
p36455
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp36456
(dp36457
g35211
I160
sg35212
Vmedulloblastoma
p36458
sg35214
I15
sg35215
VC0025149
p36459
sg35217
I1
sasa(dp36460
g35204
VOverexpression of CDK6 is present in approximately one-third of medulloblastomas and is an independent poor prognostic marker for this disease.
p36461
sg35206
(lp36462
(dp36463
g35211
I18
sg35212
VCDK6
p36464
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36465
(dp36466
g35211
I64
sg35212
Vmedulloblastomas
p36467
sg35214
I16
sg35215
VC0025149
p36468
sg35217
I1
sasa(dp36469
g35204
VMicroRNA (miR)-124 inhibits expression of CDK6 and prevents proliferation of glioblastoma and medulloblastoma cells in vitro.
p36470
sg35206
(lp36471
(dp36472
g35211
I42
sg35212
VCDK6
p36473
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36474
(dp36475
g35211
I94
sg35212
Vmedulloblastoma
p36476
sg35214
I15
sg35215
VC0025149
p36477
sg35217
I1
sa(dp36478
g35211
I77
sg35212
Vglioblastoma
p36479
sg35214
I12
sg35215
VC0017636
p36480
sg35217
I1
sa(dp36481
g35211
I60
sg35212
Vproliferation
p36482
sg35214
I13
sg35215
VC0334094
p36483
sg35217
I1
sasa(dp36484
g35204
VWe examined the effects of miR-124 overexpression on medulloblastoma cells both in vitro and in vivo and compared cell lines that have low and high CDK6 expression.
p36485
sg35206
(lp36486
(dp36487
g35211
I148
sg35212
VCDK6
p36488
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36489
(dp36490
g35211
I53
sg35212
Vmedulloblastoma
p36491
sg35214
I15
sg35215
VC0025149
p36492
sg35217
I1
sasa(dp36493
g35204
VMiR-124 overexpression inhibits the proliferation of medulloblastoma cells, and this effect is mediated mostly through the action of miR-124 upon CDK6.
p36494
sg35206
(lp36495
(dp36496
g35211
I133
sg35212
VmiR-124
p36497
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp36498
g35211
I0
sg35212
VMiR
p36499
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp36500
g35211
I146
sg35212
VCDK6
p36501
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36502
(dp36503
g35211
I53
sg35212
Vmedulloblastoma
p36504
sg35214
I15
sg35215
VC0025149
p36505
sg35217
I1
sa(dp36506
g35211
I36
sg35212
Vproliferation
p36507
sg35214
I13
sg35215
VC0334094
p36508
sg35217
I1
sasa(dp36509
g35204
VCDK6 is overexpressed in medulloblastoma patients and is associated with an adverse prognosis.
p36510
sg35206
(lp36511
(dp36512
g35211
I0
sg35212
VCDK6
p36513
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36514
(dp36515
g35211
I25
sg35212
Vmedulloblastoma
p36516
sg35214
I15
sg35215
VC0025149
p36517
sg35217
I1
sasa(dp36518
g35204
VTo investigate the role of CDK6 in medulloblastoma, we assayed the effect of CDK6 inhibition on proliferation by depleting expression with RNA interference (RNAi) or by inhibiting kinase function with a small molecule inhibitor, PD0332991.
p36519
sg35206
(lp36520
(dp36521
g35211
I27
sg35212
VCDK6
p36522
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp36523
g35211
I27
sg35212
VCDK6
p36524
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36525
(dp36526
g35211
I35
sg35212
Vmedulloblastoma
p36527
sg35214
I15
sg35215
VC0025149
p36528
sg35217
I1
sa(dp36529
g35211
I96
sg35212
Vproliferation
p36530
sg35214
I13
sg35215
VC0334094
p36531
sg35217
I1
sasa(dp36532
g35204
VGene expression analysis revealed that CDK6 mRNA expression is higher than normal cerebellum in fifteen out of sixteen medulloblastoma patient samples.
p36533
sg35206
(lp36534
(dp36535
g35211
I39
sg35212
VCDK6 mRNA
p36536
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp36537
(dp36538
g35211
I119
sg35212
Vmedulloblastoma
p36539
sg35214
I15
sg35215
VC0025149
p36540
sg35217
I1
sasa(dp36541
g35204
VInhibition of CDK6 by RNAi significantly decreased medulloblastoma cell proliferation and colony forming potential.
p36542
sg35206
(lp36543
(dp36544
g35211
I14
sg35212
VCDK6
p36545
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36546
(dp36547
g35211
I51
sg35212
Vmedulloblastoma
p36548
sg35214
I15
sg35215
VC0025149
p36549
sg35217
I1
sa(dp36550
g35211
I72
sg35212
Vproliferation
p36551
sg35214
I13
sg35215
VC0334094
p36552
sg35217
I1
sasa(dp36553
g35204
VOur findings suggest that targeting CDK6 with small molecule inhibitors may prove beneficial in the treatment of medulloblastoma, especially when combined with radiation.
p36554
sg35206
(lp36555
(dp36556
g35211
I36
sg35212
VCDK6
p36557
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp36558
(dp36559
g35211
I113
sg35212
Vmedulloblastoma
p36560
sg35214
I15
sg35215
VC0025149
p36561
sg35217
I1
sasa(dp36562
g135
(dp36563
(VCK1/5/10/14
p36564
Vcysts
p36565
tp36566
I00
ssg35204
VIn trichoblastic fibroma (three cases), CK1/5/10/14, CK7, CK8/18, CK10/11, CK14, CK17 and CK19 were expressed in the basaloid nests, and CK6 and involucrin were detected in the inner layers of keratinous cysts.
p36567
sg35206
(lp36568
(dp36569
g35211
I75
sg35212
VCK14
p36570
sg35214
I4
sg35223
VP02533
p36571
sg35217
I1
sa(dp36572
g35211
I145
sg35212
Vinvolucrin
p36573
sg35214
I10
sg35223
VP07476
p36574
sg35217
I1
sa(dp36575
g35211
I66
sg35212
VCK10/11
p36576
sg35214
I7
sg35223
VP13645
p36577
sg35217
I1
sa(dp36578
g35211
I53
sg35212
VCK7
p36579
sg35214
I3
sg35223
VP08729
p36580
sg35217
I1
sa(dp36581
g35211
I40
sg35212
g36564
sg35214
I11
sg35223
VP48729
p36582
sg35217
I1
sasg35208
(lp36583
(dp36584
g35211
I3
sg35212
Vtrichoblastic fibroma
p36585
sg35214
I21
sg35215
VC1704236
p36586
sg35217
I2
sa(dp36587
g35211
I204
sg35212
g36565
sg35214
I5
sg35215
VC0010709
p36588
sg35217
I1
sasa(dp36589
g35204
VSince type 1 diabetes mellitus often begins in childhood, we used juvenile (4- to 5-wk-old) rats to demonstrate that a single bout of IIH (5 U/kg sc) reduced plasma glucose by 24% and peak epinephrine by 59% 1 day later.
p36590
sg35206
(lp36591
sg35208
(lp36592
(dp36593
g35211
I6
sg35212
Vtype 1 diabetes mellitus
p36594
sg35214
I24
sg35215
VC0011854
p36595
sg35217
I4
sasa(dp36596
g135
(dp36597
(VPlasma membrane NADH oxidoreductase
p36598
VIDDM
p36599
tp36600
I00
ssg35204
VPlasma membrane NADH oxidoreductase activity, studied using cytosolic NADH as substrate and assayed with DCIP as acceptor, was significantly increased in IDDM patients, suggesting a response to a deficient mitochondrial energetic activity.
p36601
sg35206
(lp36602
(dp36603
g35211
I60
sg35212
Vcytosolic NADH
p36604
sg35214
I14
sg35223
VP0C870
p36605
sg35217
I2
sa(dp36606
g35211
I0
sg35212
g36598
sg35214
I35
sg35223
VP28331
p36607
sg35217
I4
sasg35208
(lp36608
(dp36609
g35211
I154
sg35212
g36599
sg35214
I4
sg35215
VC0011854
p36610
sg35217
I1
sasa(dp36611
g135
(dp36612
(Vinsulin
p36613
VNIDDM
p36614
tp36615
I00
ssg35204
VNon insulin-dependent diabetic (NIDDM) mortality is 1.4 to 3.7 times that of non-diabetics.
p36616
sg35206
(lp36617
(dp36618
g35211
I4
sg35212
g36613
sg35214
I7
sg35223
VP01308
p36619
sg35217
I1
sasg35208
(lp36620
(dp36621
g35211
I32
sg35212
g36614
sg35214
I5
sg35215
VC0011860
p36622
sg35217
I1
sasa(dp36623
g35204
VIn the COPD and asthma patients, the median urinary cotinine concentration was 167 ng/mL (range, 2-5,348 ng/mL) and 47 ng/mL (range, 5-2,735 ng/mL), respectively (p &lt; 0.0001), whereas the median eCO level was 8 ppm (range, 0-31 ppm) and 5 ppm (range, 2-45 ppm), respectively (p &lt; 0.05).
p36624
sg35206
(lp36625
(dp36626
g35211
I198
sg35212
VeCO
p36627
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36628
(dp36629
g35211
I16
sg35212
Vasthma
p36630
sg35214
I6
sg35215
VC0004096
p36631
sg35217
I1
sa(dp36632
g35211
I198
sg35212
VeCO
p36633
sg35214
I3
sg35215
VC2675227
p36634
sg35217
I1
sa(dp36635
g35211
I7
sg35212
VCOPD
p36636
sg35214
I4
sg35215
VC0024117
p36637
sg35217
I1
sasa(dp36638
g35204
VIn 30 (29%) of the patients with asthma or COPD, the urinary cotinine concentration and the eCO level both belied the patient claims of not being current smokers.
p36639
sg35206
(lp36640
(dp36641
g35211
I92
sg35212
VeCO
p36642
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36643
(dp36644
g35211
I43
sg35212
VCOPD
p36645
sg35214
I4
sg35215
VC0024117
p36646
sg35217
I1
sa(dp36647
g35211
I33
sg35212
Vasthma
p36648
sg35214
I6
sg35215
VC0004096
p36649
sg35217
I1
sa(dp36650
g35211
I92
sg35212
VeCO
p36651
sg35214
I3
sg35215
VC2675227
p36652
sg35217
I1
sasa(dp36653
g35204
VWe aimed to study eCO levels in asthmatics and detect the possible factors influencing them.
p36654
sg35206
(lp36655
sg35208
(lp36656
(dp36657
g35211
I18
sg35212
VeCO
p36658
sg35214
I3
sg35215
VC2675227
p36659
sg35217
I1
sa(dp36660
g35211
I32
sg35212
Vasthmatics
p36661
sg35214
I10
sg35215
VC0004096
p36662
sg35217
I1
sasa(dp36663
g135
(dp36664
(VIgE
p36665
VIgE
p36666
tp36667
I01
ssg35204
VThe differences in eCO levels among various asthmatic phenotypes and the correlations between eCO and other measured parameters (spirometric indices, Asthma Control Test score, exhaled nitric oxide, total IgE, blood eosinophils and marker of oxidative damage of proteins) were analysed.
p36668
sg35206
(lp36669
(dp36670
g35211
I19
sg35212
VeCO
p36671
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp36672
g35211
I19
sg35212
VeCO
p36673
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp36674
g35211
I205
sg35212
g36665
sg35214
I3
sg35223
VP01854
p36675
sg35217
I1
sasg35208
(lp36676
(dp36677
g35211
I19
sg35212
VeCO
p36678
sg35214
I3
sg35215
VC2675227
p36679
sg35217
I1
sa(dp36680
g35211
I44
sg35212
Vasthmatic
p36681
sg35214
I9
sg35215
VC0004096
p36682
sg35217
I1
sa(dp36683
g35211
I19
sg35212
VeCO
p36684
sg35214
I3
sg35215
VC2675227
p36685
sg35217
I1
sa(dp36686
g35211
I150
sg35212
VAsthma
p36687
sg35214
I6
sg35215
VC0004096
p36688
sg35217
I1
sa(dp36689
g35211
I205
sg35212
g36666
sg35214
I3
sg35215
VC0270850
p36690
sg35217
I1
sasa(dp36691
g35204
VLevels of eCO widely differed according to the selected characteristics of asthma.
p36692
sg35206
(lp36693
sg35208
(lp36694
(dp36695
g35211
I10
sg35212
VeCO
p36696
sg35214
I3
sg35215
VC2675227
p36697
sg35217
I1
sa(dp36698
g35211
I75
sg35212
Vasthma
p36699
sg35214
I6
sg35215
VC0004096
p36700
sg35217
I1
sasa(dp36701
g35204
VAsthmatics showed higher eCO concentrations than controls (1.44 +/- 0.12 ppm vs. 0.91 +/- 0.11 ppm, p &lt; 0.001).
p36702
sg35206
(lp36703
(dp36704
g35211
I25
sg35212
VeCO
p36705
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36706
(dp36707
g35211
I0
sg35212
VAsthmatics
p36708
sg35214
I10
sg35215
VC0004096
p36709
sg35217
I1
sa(dp36710
g35211
I25
sg35212
VeCO
p36711
sg35214
I3
sg35215
VC2675227
p36712
sg35217
I1
sasa(dp36713
g35204
VAcute exacerbation of asthma was accompanied by a significant increase in eCO compared to the clinically controlled stage (2.17 +/- 0.36 ppm vs. 1.33 +/- 0.13 ppm, p &lt; 0.001).
p36714
sg35206
(lp36715
sg35208
(lp36716
(dp36717
g35211
I74
sg35212
VeCO
p36718
sg35214
I3
sg35215
VC2675227
p36719
sg35217
I1
sa(dp36720
g35211
I22
sg35212
Vasthma
p36721
sg35214
I6
sg35215
VC0004096
p36722
sg35217
I1
sasa(dp36723
g35204
VAtopic, non-atopic asthma and asthma associated with allergic rhinitis (AR) showed elevated levels of eCO.
p36724
sg35206
(lp36725
(dp36726
g35211
I53
sg35212
Vallergic rhinitis (AR)
p36727
sg35214
I22
sg35223
g12
sg35217
I3
sa(dp36728
g35211
I102
sg35212
VeCO
p36729
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36730
(dp36731
g35211
I12
sg35212
Vatopic asthma
p36732
sg35214
I13
sg35215
VC0155877
p36733
sg35217
I2
sa(dp36734
g35211
I53
sg35212
Vallergic rhinitis
p36735
sg35214
I17
sg35215
VC2607914
p36736
sg35217
I2
sa(dp36737
g35211
I19
sg35212
Vasthma
p36738
sg35214
I6
sg35215
VC0004096
p36739
sg35217
I1
sa(dp36740
g35211
I102
sg35212
VeCO
p36741
sg35214
I3
sg35215
VC2675227
p36742
sg35217
I1
sa(dp36743
g35211
I72
sg35212
VAR
p36744
sg35214
I2
sg35215
VC2607914
p36745
sg35217
I1
sa(dp36746
g35211
I0
sg35212
VAtopic
p36747
sg35214
I6
sg35215
VC0392707
p36748
sg35217
I1
sasa(dp36749
g35204
VThe levels of eCO negatively correlated with the marker of protein oxidation in asthmatics, especially in atopic form and during acute exacerbation.
p36750
sg35206
(lp36751
(dp36752
g35211
I14
sg35212
VeCO
p36753
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36754
(dp36755
g35211
I14
sg35212
VeCO
p36756
sg35214
I3
sg35215
VC2675227
p36757
sg35217
I1
sa(dp36758
g35211
I80
sg35212
Vasthmatics
p36759
sg35214
I10
sg35215
VC0004096
p36760
sg35217
I1
sa(dp36761
g35211
I106
sg35212
Vatopic
p36762
sg35214
I6
sg35215
VC0392707
p36763
sg35217
I1
sasa(dp36764
g35204
VIn a population of asthmatic children, eCO levels could be considered as a marker of both allergic inflammation and oxidative stress in the airways.
p36765
sg35206
(lp36766
(dp36767
g35211
I39
sg35212
VeCO
p36768
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36769
(dp36770
g35211
I90
sg35212
Vallergic inflammation
p36771
sg35214
I21
sg35215
VC0021375
p36772
sg35217
I2
sa(dp36773
g35211
I116
sg35212
Voxidative stress
p36774
sg35214
I16
sg35215
VC0242606
p36775
sg35217
I2
sa(dp36776
g35211
I39
sg35212
VeCO
p36777
sg35214
I3
sg35215
VC2675227
p36778
sg35217
I1
sa(dp36779
g35211
I19
sg35212
Vasthmatic
p36780
sg35214
I9
sg35215
VC0004096
p36781
sg35217
I1
sasa(dp36782
g35204
VConcomitant AR and asthma control were the most important factors affecting the levels of eCO in asthmatic children.
p36783
sg35206
(lp36784
(dp36785
g35211
I90
sg35212
VeCO
p36786
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36787
(dp36788
g35211
I97
sg35212
Vasthmatic
p36789
sg35214
I9
sg35215
VC0004096
p36790
sg35217
I1
sa(dp36791
g35211
I90
sg35212
VeCO
p36792
sg35214
I3
sg35215
VC2675227
p36793
sg35217
I1
sa(dp36794
g35211
I19
sg35212
Vasthma
p36795
sg35214
I6
sg35215
VC0004096
p36796
sg35217
I1
sasa(dp36797
g35204
VeCO values have been evaluated as potential indicators of inflammation in asthma, stable COPD and exacerbations, cystic fibrosis, lung cancer, or during surgery or critical care.
p36798
sg35206
(lp36799
(dp36800
g35211
I0
sg35212
VeCO
p36801
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36802
(dp36803
g35211
I0
sg35212
VeCO
p36804
sg35214
I3
sg35215
VC2675227
p36805
sg35217
I1
sa(dp36806
g35211
I58
sg35212
Vinflammation
p36807
sg35214
I12
sg35215
VC0021368
p36808
sg35217
I1
sa(dp36809
g35211
I113
sg35212
Vcystic fibrosis
p36810
sg35214
I15
sg35215
VC0010674
p36811
sg35217
I2
sa(dp36812
g35211
I74
sg35212
Vasthma
p36813
sg35214
I6
sg35215
VC0004096
p36814
sg35217
I1
sa(dp36815
g35211
I130
sg35212
Vlung cancer
p36816
sg35214
I11
sg35215
VC0684249
p36817
sg35217
I2
sa(dp36818
g35211
I89
sg35212
VCOPD
p36819
sg35214
I4
sg35215
VC0024117
p36820
sg35217
I1
sasa(dp36821
g35204
VTwenty-four non-smokers (10 male, 14 female, mean age 17.6 years) and 24 smokers (mean of 3.5 pack-years; 15 male, 9 female, mean age 17.8 years) were compared in terms of lung function, bronchial hyperreactivity (BHR), levels of exhaled carbon monoxide (eCO), exhaled nitric oxide (eNO), and blood counts.
p36822
sg35206
(lp36823
sg35208
(lp36824
(dp36825
g35211
I214
sg35212
VBHR
p36826
sg35214
I3
sg35215
VC0085129
p36827
sg35217
I1
sa(dp36828
g35211
I255
sg35212
VeCO
p36829
sg35214
I3
sg35215
VC2675227
p36830
sg35217
I1
sa(dp36831
g35211
I187
sg35212
Vbronchial hyperreactivity
p36832
sg35214
I25
sg35215
VC0085129
p36833
sg35217
I2
sa(dp36834
g35211
I230
sg35212
Vexhaled carbon monoxide
p36835
sg35214
I23
sg35215
VC2675227
p36836
sg35217
I3
sasa(dp36837
g35204
VThe concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known.
p36838
sg35206
(lp36839
sg35208
(lp36840
(dp36841
g35211
I46
sg35212
VeCO
p36842
sg35214
I3
sg35215
VC2675227
p36843
sg35217
I1
sa(dp36844
g35211
I21
sg35212
Vexhaled carbon monoxide
p36845
sg35214
I23
sg35215
VC2675227
p36846
sg35217
I3
sa(dp36847
g35211
I105
sg35212
Vasthma attack
p36848
sg35214
I13
sg35215
VC0347950
p36849
sg35217
I2
sa(dp36850
g35211
I81
sg35212
Vasthma
p36851
sg35214
I6
sg35215
VC0004096
p36852
sg35217
I1
sasa(dp36853
g35204
VIn preschool-age children, eCO levels of those with asthma attacks (mean +/- SE, 2.7 +/- 0.3 p.p.m., n= 43) were significantly higher than those of subjects with asymptomatic asthma (0.5 +/- 0.1 p.p.m., P &lt; 0.05), URI (0.8 +/- 0.1 p.p.m., P &lt; 0.05) and healthy children (0.4 +/- 0.1 p.p.m., P &lt; 0.05).
p36854
sg35206
(lp36855
(dp36856
g35211
I27
sg35212
VeCO
p36857
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36858
(dp36859
g35211
I52
sg35212
Vasthma
p36860
sg35214
I6
sg35215
VC0004096
p36861
sg35217
I1
sa(dp36862
g35211
I27
sg35212
VeCO
p36863
sg35214
I3
sg35215
VC2675227
p36864
sg35217
I1
sa(dp36865
g35211
I52
sg35212
Vasthma attacks
p36866
sg35214
I14
sg35215
VC0347950
p36867
sg35217
I2
sasa(dp36868
g35204
VA multivariate linear regression model showed that eCO was higher in children with asthma attacks independent of age and gender.
p36869
sg35206
(lp36870
(dp36871
g35211
I51
sg35212
VeCO
p36872
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36873
(dp36874
g35211
I51
sg35212
VeCO
p36875
sg35214
I3
sg35215
VC2675227
p36876
sg35217
I1
sa(dp36877
g35211
I83
sg35212
Vasthma attacks
p36878
sg35214
I14
sg35215
VC0347950
p36879
sg35217
I2
sasa(dp36880
g35204
VIn 33 asthmatic children followed before and after treatment, eCO levels during asthma attacks significantly decreased after inhalation therapy with a combination of salbutamol and sodium cromoglycate (before therapy, 2.9 +/- 0.4 p.p.m.
p36881
sg35206
(lp36882
(dp36883
g35211
I62
sg35212
VeCO
p36884
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36885
(dp36886
g35211
I80
sg35212
Vasthma attacks
p36887
sg35214
I14
sg35215
VC0347950
p36888
sg35217
I2
sa(dp36889
g35211
I62
sg35212
VeCO
p36890
sg35214
I3
sg35215
VC2675227
p36891
sg35217
I1
sa(dp36892
g35211
I6
sg35212
Vasthmatic
p36893
sg35214
I9
sg35215
VC0004096
p36894
sg35217
I1
sasa(dp36895
g35204
VThe measurement of eCO using a novel collecting system is useful in the recognition of asthma in preschool children.
p36896
sg35206
(lp36897
(dp36898
g35211
I19
sg35212
VeCO
p36899
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36900
(dp36901
g35211
I87
sg35212
Vasthma
p36902
sg35214
I6
sg35215
VC0004096
p36903
sg35217
I1
sa(dp36904
g35211
I19
sg35212
VeCO
p36905
sg35214
I3
sg35215
VC2675227
p36906
sg35217
I1
sasa(dp36907
g35204
VElevations in E-CO have been observed in critically ill or post-surgical patients and those with various pulmonary diseases associated with inflammation, including chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis and infections.
p36908
sg35206
(lp36909
sg35208
(lp36910
(dp36911
g35211
I238
sg35212
Vinfections
p36912
sg35214
I10
sg35215
VC0021311
p36913
sg35217
I1
sa(dp36914
g35211
I164
sg35212
Vchronic obstructive pulmonary disease
p36915
sg35214
I37
sg35215
VC0024117
p36916
sg35217
I4
sa(dp36917
g35211
I210
sg35212
Vasthma
p36918
sg35214
I6
sg35215
VC0004096
p36919
sg35217
I1
sa(dp36920
g35211
I203
sg35212
VCOPD
p36921
sg35214
I4
sg35215
VC0024117
p36922
sg35217
I1
sa(dp36923
g35211
I140
sg35212
Vinflammation
p36924
sg35214
I12
sg35215
VC0021368
p36925
sg35217
I1
sa(dp36926
g35211
I105
sg35212
Vpulmonary diseases
p36927
sg35214
I18
sg35215
VC0024115
p36928
sg35217
I2
sa(dp36929
g35211
I218
sg35212
Vcystic fibrosis
p36930
sg35214
I15
sg35215
VC0010674
p36931
sg35217
I2
sa(dp36932
g35211
I41
sg35212
Vcritically ill
p36933
sg35214
I14
sg35215
VC0010340
p36934
sg35217
I2
sasa(dp36935
g35204
VThe purpose of this meta-analysis is to determine whether eCO is elevated in asthmatics, is regulated by steroid treatment and reflects disease severity and control.
p36936
sg35206
(lp36937
(dp36938
g35211
I58
sg35212
VeCO
p36939
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36940
(dp36941
g35211
I58
sg35212
VeCO
p36942
sg35214
I3
sg35215
VC2675227
p36943
sg35217
I1
sa(dp36944
g35211
I77
sg35212
Vasthmatics
p36945
sg35214
I10
sg35215
VC0004096
p36946
sg35217
I1
sasa(dp36947
g35204
VObservational studies comparing eCO in non-smoking asthmatics and healthy subjects or asthmatics before and after steroid treatment were included.
p36948
sg35206
(lp36949
sg35208
(lp36950
(dp36951
g35211
I32
sg35212
VeCO
p36952
sg35214
I3
sg35215
VC2675227
p36953
sg35217
I1
sa(dp36954
g35211
I51
sg35212
Vasthmatics
p36955
sg35214
I10
sg35215
VC0004096
p36956
sg35217
I1
sa(dp36957
g35211
I51
sg35212
Vasthmatics
p36958
sg35214
I10
sg35215
VC0004096
p36959
sg35217
I1
sasa(dp36960
g35204
VThe eCO level was significantly higher in asthmatics as compared to healthy subjects and in intermittent asthma as compared to persistent asthma.
p36961
sg35206
(lp36962
(dp36963
g35211
I4
sg35212
VeCO
p36964
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36965
(dp36966
g35211
I42
sg35212
Vasthmatics
p36967
sg35214
I10
sg35215
VC0004096
p36968
sg35217
I1
sa(dp36969
g35211
I92
sg35212
Vintermittent asthma
p36970
sg35214
I19
sg35215
VC1740754
p36971
sg35217
I2
sa(dp36972
g35211
I4
sg35212
VeCO
p36973
sg35214
I3
sg35215
VC2675227
p36974
sg35217
I1
sa(dp36975
g35211
I127
sg35212
Vpersistent asthma
p36976
sg35214
I17
sg35215
VC3266628
p36977
sg35217
I2
sasa(dp36978
g35204
VHowever, eCO could not distinguish between steroid-treated asthmatics and steroid-free patients nor separate controlled and partly-controlled asthma from uncontrolled asthma in cross-sectional studies.
p36979
sg35206
(lp36980
(dp36981
g35211
I9
sg35212
VeCO
p36982
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp36983
(dp36984
g35211
I59
sg35212
Vasthma
p36985
sg35214
I6
sg35215
VC0004096
p36986
sg35217
I1
sa(dp36987
g35211
I9
sg35212
VeCO
p36988
sg35214
I3
sg35215
VC2675227
p36989
sg35217
I1
sa(dp36990
g35211
I59
sg35212
Vasthmatics
p36991
sg35214
I10
sg35215
VC0004096
p36992
sg35217
I1
sa(dp36993
g35211
I59
sg35212
Vasthma
p36994
sg35214
I6
sg35215
VC0004096
p36995
sg35217
I1
sasa(dp36996
g35204
VeCO is elevated in asthmatics but levels only partially reflect disease severity and control.
p36997
sg35206
(lp36998
(dp36999
g35211
I0
sg35212
VeCO
p37000
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp37001
(dp37002
g35211
I19
sg35212
Vasthmatics
p37003
sg35214
I10
sg35215
VC0004096
p37004
sg35217
I1
sa(dp37005
g35211
I0
sg35212
VeCO
p37006
sg35214
I3
sg35215
VC2675227
p37007
sg35217
I1
sasa(dp37008
g35204
VeCO might be a potentially useful non-invasive biomarker of airway inflammation and oxidative stress in nonsmoking asthmatics.
p37009
sg35206
(lp37010
(dp37011
g35211
I0
sg35212
VeCO
p37012
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp37013
(dp37014
g35211
I67
sg35212
Vinflammation
p37015
sg35214
I12
sg35215
VC0021368
p37016
sg35217
I1
sa(dp37017
g35211
I0
sg35212
VeCO
p37018
sg35214
I3
sg35215
VC2675227
p37019
sg35217
I1
sa(dp37020
g35211
I115
sg35212
Vasthmatics
p37021
sg35214
I10
sg35215
VC0004096
p37022
sg35217
I1
sa(dp37023
g35211
I84
sg35212
Voxidative stress
p37024
sg35214
I16
sg35215
VC0242606
p37025
sg35217
I2
sasa(dp37026
g35204
VHowever, recent studies revealed that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.
p37027
sg35206
(lp37028
(dp37029
g35211
I60
sg35212
VSphK2
p37030
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37031
g35211
I60
sg35212
VSphK2
p37032
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp37033
(dp37034
g35211
I139
sg35212
Varthritis
p37035
sg35214
I9
sg35215
VC0003864
p37036
sg35217
I1
sa(dp37037
g35211
I126
sg35212
Vinflammatory arthritis
p37038
sg35214
I22
sg35215
VC0003864
p37039
sg35217
I2
sasa(dp37040
g35204
VTherefore, SphK2 plays a controversial role in arthritis.
p37041
sg35206
(lp37042
(dp37043
g35211
I11
sg35212
VSphK2
p37044
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp37045
(dp37046
g35211
I47
sg35212
Varthritis
p37047
sg35214
I9
sg35215
VC0003864
p37048
sg35217
I1
sasa(dp37049
g35204
VA specific SphK2 inhibitor inhibited inflammatory arthritis in one model, while siRNA knockdown of SphK2 worsened arthritis in another.
p37050
sg35206
(lp37051
(dp37052
g35211
I11
sg35212
VSphK2
p37053
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37054
g35211
I11
sg35212
VSphK2
p37055
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp37056
(dp37057
g35211
I37
sg35212
Vinflammatory arthritis
p37058
sg35214
I22
sg35215
VC0003864
p37059
sg35217
I2
sa(dp37060
g35211
I50
sg35212
Varthritis
p37061
sg35214
I9
sg35215
VC0003864
p37062
sg35217
I1
sasa(dp37063
g135
(dp37064
(VTNF
p37065
Varthritis
p37066
tp37067
I00
ssg35204
VTo investigate the role of SphK2 in TNF-Alfa-induced arthritis, we developed SphK2 deficient hTNF-Alfa overexpressing mice and separately treated hTNF-Alfa mice with ABC294640, a SphK2-specific inhibitor.
p37068
sg35206
(lp37069
(dp37070
g35211
I27
sg35212
VSphK2
p37071
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37072
g35211
I27
sg35212
VSphK2
p37073
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37074
g35211
I27
sg35212
VSphK2
p37075
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37076
g35211
I36
sg35212
g37065
sg35214
I3
sg35223
VP01375
p37077
sg35217
I1
sasg35208
(lp37078
(dp37079
g35211
I53
sg35212
g37066
sg35214
I9
sg35215
VC0003864
p37080
sg35217
I1
sasa(dp37081
g35204
VOur data show that genetic inhibition of SphK2 did not significantly impact the severity or progression of inflammatory arthritis, while pharmacologic inhibition of SphK2 led to significantly more severe arthritis.
p37082
sg35206
(lp37083
(dp37084
g35211
I41
sg35212
VSphK2
p37085
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37086
g35211
I41
sg35212
VSphK2
p37087
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp37088
(dp37089
g35211
I107
sg35212
Vinflammatory arthritis
p37090
sg35214
I22
sg35215
VC0003864
p37091
sg35217
I2
sa(dp37092
g35211
I120
sg35212
Varthritis
p37093
sg35214
I9
sg35215
VC0003864
p37094
sg35217
I1
sasa(dp37095
g35204
VIn this study, we examined the role of SphK1 and SphK2 in a murine collagen-induced arthritis model by down-regulating each isoenzyme via specific small interfering RNA (siRNA).
p37096
sg35206
(lp37097
(dp37098
g35211
I39
sg35212
VSphK1
p37099
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37100
g35211
I49
sg35212
VSphK2
p37101
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp37102
(dp37103
g35211
I84
sg35212
Varthritis
p37104
sg35214
I9
sg35215
VC0003864
p37105
sg35217
I1
sasa(dp37106
g35204
VTogether, these results demonstrate the distinct immunomodulatory roles of SphK1 and SphK2 in the development of inflammatory arthritis by regulating the release of proinflammatory cytokines and T cell responses.
p37107
sg35206
(lp37108
(dp37109
g35211
I75
sg35212
VSphK1
p37110
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37111
g35211
I85
sg35212
VSphK2
p37112
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp37113
(dp37114
g35211
I113
sg35212
Vinflammatory arthritis
p37115
sg35214
I22
sg35215
VC0003864
p37116
sg35217
I2
sasa(dp37117
g35204
VPrefrontal Brodmann Areas (BA) BA46, BA47, and BA9 in autism and age-matched controls were analyzed by blinded researchers.
p37118
sg35206
(lp37119
sg35208
(lp37120
(dp37121
g35211
I54
sg35212
Vautism
p37122
sg35214
I6
sg35215
VC0004352
p37123
sg35217
I1
sasa(dp37124
g135
(dp37125
(Vparvalbumin+
p37126
Vautism
p37127
tp37128
I01
ssg35204
VWe show that the number of parvalbumin+ interneurons in these 3 cortical areas-BA46, BA47, and BA9-is significantly reduced in autism compared with controls.
p37129
sg35206
(lp37130
(dp37131
g35211
I27
sg35212
g37126
sg35214
I12
sg35223
VP20472
p37132
sg35217
I1
sasg35208
(lp37133
(dp37134
g35211
I127
sg35212
g37127
sg35214
I6
sg35215
VC0004352
p37135
sg35217
I1
sasa(dp37136
g35204
VThese fetal structures generate regions with abnormal activity in autism, including the dorsolateral prefrontal cortex (BA46), the pars opercularis of the inferior frontal cortex and the fusiform gyrus.
p37137
sg35206
(lp37138
sg35208
(lp37139
(dp37140
g35211
I66
sg35212
Vautism
p37141
sg35214
I6
sg35215
VC0004352
p37142
sg35217
I1
sasa(dp37143
g135
(dp37144
(VS100A12
p37145
VL-lep
p37146
tp37147
I00
ssg35204
VAt the site of disease in leprosy, we found that S100A12 was more strongly expressed in skin lesions from tuberculoid leprosy (T-lep), the self-limiting form of the disease, compared to lepromatous leprosy (L-lep), the progressive form of the disease.
p37148
sg35206
(lp37149
(dp37150
g35211
I49
sg35212
g37145
sg35214
I7
sg35223
VP80511
p37151
sg35217
I1
sasg35208
(lp37152
(dp37153
g35211
I26
sg35212
Vleprosy
p37154
sg35214
I7
sg35215
VC0023343
p37155
sg35217
I1
sa(dp37156
g35211
I127
sg35212
VT-lep
p37157
sg35214
I5
sg35215
VC0023351
p37158
sg35217
I1
sa(dp37159
g35211
I186
sg35212
Vlepromatous leprosy
p37160
sg35214
I19
sg35215
VC0023348
p37161
sg35217
I2
sa(dp37162
g35211
I106
sg35212
Vtuberculoid leprosy
p37163
sg35214
I19
sg35215
VC0023351
p37164
sg35217
I2
sa(dp37165
g35211
I207
sg35212
g37146
sg35214
I5
sg35215
VC0023348
p37166
sg35217
I1
sasa(dp37167
g135
(dp37168
(Vcardiac troponin I
p37169
Vpulmonary embolism
p37170
tp37171
I00
ssg35204
VThe aim of this study was to predict right ventricular dysfunction (RVD) using plasma concentration of D-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide (BNP), endothelin-1 (ET-1) and cardiac troponin I (TNI) in patients with pulmonary embolism (PE).
p37172
sg35206
(lp37173
(dp37174
g35211
I201
sg35212
VET-1
p37175
sg35214
I4
sg35223
VP05305
p37176
sg35217
I1
sa(dp37177
g35211
I187
sg35212
Vendothelin-1
p37178
sg35214
I12
sg35223
VP20800
p37179
sg35217
I1
sa(dp37180
g35211
I231
sg35212
VTNI
p37181
sg35214
I3
sg35223
VP48788
p37182
sg35217
I1
sa(dp37183
g35211
I103
sg35212
VD-dimer, pro-atrial natriuretic peptide (pro-ANP), brain natriuretic peptide
p37184
sg35214
I76
sg35223
VP16066
p37185
sg35217
I8
sa(dp37186
g35211
I181
sg35212
VBNP
p37187
sg35214
I3
sg35223
VP16860
p37188
sg35217
I1
sa(dp37189
g35211
I211
sg35212
g37169
sg35214
I18
sg35223
VP24821
p37190
sg35217
I3
sasg35208
(lp37191
(dp37192
g35211
I37
sg35212
Vright ventricular dysfunction
p37193
sg35214
I29
sg35215
VC0242707
p37194
sg35217
I3
sa(dp37195
g35211
I273
sg35212
VPE
p37196
sg35214
I2
sg35215
VC0034065
p37197
sg35217
I1
sa(dp37198
g35211
I68
sg35212
VRVD
p37199
sg35214
I3
sg35215
VC0242707
p37200
sg35217
I1
sa(dp37201
g35211
I253
sg35212
g37170
sg35214
I18
sg35215
VC0034065
p37202
sg35217
I2
sasa(dp37203
g135
(dp37204
(VAtrial natriuretic petide
p37205
Vpulmonary embolism
p37206
tp37207
I00
ssg35204
VAtrial natriuretic petide (ANP), brain natriuretic peptide (BNP) and endothelin-1 (ET-1) may reflect the severity of right ventricular dysfunction (RVD) in patients with pulmonary embolism (PE).
p37208
sg35206
(lp37209
(dp37210
g35211
I27
sg35212
VANP
p37211
sg35214
I3
sg35223
VP16066
p37212
sg35217
I1
sa(dp37213
g35211
I83
sg35212
VET-1
p37214
sg35214
I4
sg35223
VP05305
p37215
sg35217
I1
sa(dp37216
g35211
I69
sg35212
Vendothelin-1
p37217
sg35214
I12
sg35223
VP20800
p37218
sg35217
I1
sa(dp37219
g35211
I0
sg35212
g37205
sg35214
I25
sg35223
VP16066
p37220
sg35217
I3
sasg35208
(lp37221
(dp37222
g35211
I190
sg35212
VPE
p37223
sg35214
I2
sg35215
VC0034065
p37224
sg35217
I1
sa(dp37225
g35211
I148
sg35212
VRVD
p37226
sg35214
I3
sg35215
VC0242707
p37227
sg35217
I1
sa(dp37228
g35211
I117
sg35212
Vright ventricular dysfunction
p37229
sg35214
I29
sg35215
VC0242707
p37230
sg35217
I3
sa(dp37231
g35211
I170
sg35212
g37206
sg35214
I18
sg35215
VC0034065
p37232
sg35217
I2
sasa(dp37233
g135
(dp37234
(VET-1
p37235
Vvasoconstriction
p37236
tp37237
I01
ssg35204
VAcute pulmonary embolism (PE) is a life-threatening disease, and several vasoconstrictors, including endothelin-1 (ET-1), play a key role in vasoconstriction and hypoxemia during the development of PE.
p37238
sg35206
(lp37239
(dp37240
g35211
I101
sg35212
Vendothelin-1
p37241
sg35214
I12
sg35223
VP20800
p37242
sg35217
I1
sa(dp37243
g35211
I115
sg35212
g37235
sg35214
I4
sg35223
VP05305
p37244
sg35217
I1
sasg35208
(lp37245
(dp37246
g35211
I6
sg35212
Vpulmonary embolism
p37247
sg35214
I18
sg35215
VC0034065
p37248
sg35217
I2
sa(dp37249
g35211
I26
sg35212
VPE
p37250
sg35214
I2
sg35215
VC0034065
p37251
sg35217
I1
sa(dp37252
g35211
I26
sg35212
VPE
p37253
sg35214
I2
sg35215
VC0034065
p37254
sg35217
I1
sa(dp37255
g35211
I141
sg35212
g37236
sg35214
I16
sg35215
VC1456863
p37256
sg35217
I1
sasa(dp37257
g35204
VImpaired repression of cone-specific genes by the corepressors atrophin-1 (dentatorubral-pallidoluysian atrophy [DRPLA] gene product) and atrophin-2 (arginine-glutamic acid dipeptide repeat [RERE] protein) appeared to be a molecular mechanism mediating the beneficial effect of the p.R311Q mutation.
p37258
sg35206
(lp37259
sg35208
(lp37260
(dp37261
g35211
I113
sg35212
VDRPLA
p37262
sg35214
I5
sg35215
VC0751781
p37263
sg35217
I1
sa(dp37264
g35211
I75
sg35212
Vdentatorubral-pallidoluysian atrophy
p37265
sg35214
I36
sg35215
VC0751781
p37266
sg35217
I2
sa(dp37267
g35211
I0
sg35212
VImpaired
p37268
sg35214
I8
sg35215
VC0684336
p37269
sg35217
I1
sasa(dp37270
g135
(dp37271
(Vatrophin-1 protein
p37272
Vhereditary neurodegenerative disorder
p37273
tp37274
I00
ssg35204
VRE repeats encoded (RERE) was identified recently as a protein with high homology to the atrophin-1 protein, which appears to be causal in the hereditary neurodegenerative disorder termed dentatorubral-pallidoluysian atrophy (DRPLA) caused by an abnormal glutamine expansion.
p37275
sg35206
(lp37276
(dp37277
g35211
I89
sg35212
g37272
sg35214
I18
sg35223
VP54259
p37278
sg35217
I2
sasg35208
(lp37279
(dp37280
g35211
I188
sg35212
Vdentatorubral-pallidoluysian atrophy
p37281
sg35214
I36
sg35215
VC0751781
p37282
sg35217
I2
sa(dp37283
g35211
I226
sg35212
VDRPLA
p37284
sg35214
I5
sg35215
VC0751781
p37285
sg35217
I1
sa(dp37286
g35211
I143
sg35212
g37273
sg35214
I37
sg35215
VC3273225
p37287
sg35217
I3
sasa(dp37288
g135
(dp37289
(VDRPLA
p37290
VDRPLA
p37291
tp37292
I00
ssg35204
VThe gene isolated, designated RERE, has an open reading frame of 1566 amino acids, of which the C-terminal portion has 67% homology to DRPLA, whereas the N-terminal portion is distinctive.
p37293
sg35206
(lp37294
(dp37295
g35211
I135
sg35212
g37290
sg35214
I5
sg35223
VP54259
p37296
sg35217
I1
sa(dp37297
g35211
I30
sg35212
VRERE
p37298
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp37299
(dp37300
g35211
I135
sg35212
g37291
sg35214
I5
sg35215
VC0751781
p37301
sg35217
I1
sasa(dp37302
g135
(dp37303
(VDRPLA
p37304
VDRPLA
p37305
tp37306
I00
ssg35204
VImmunoprecipitation and in vitro binding assays demonstrate that the DRPLA and RERE proteins bind each other, for which one of the RE repeats has a primary role, and extended polyglutamine enhances the binding.
p37307
sg35206
(lp37308
(dp37309
g35211
I79
sg35212
VRERE proteins
p37310
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp37311
g35211
I69
sg35212
g37304
sg35214
I5
sg35223
VP54259
p37312
sg35217
I1
sasg35208
(lp37313
(dp37314
g35211
I69
sg35212
g37305
sg35214
I5
sg35215
VC0751781
p37315
sg35217
I1
sasa(dp37316
g135
(dp37317
(Vendogenous DRPLA protein
p37318
VDRPLA
p37319
tp37320
I00
ssg35204
VMoreover, when RERE is overexpressed, the distribution of endogenous DRPLA protein alters from the diffused to the speckled pattern in the nucleus so as to co-localize with RERE.
p37321
sg35206
(lp37322
(dp37323
g35211
I15
sg35212
VRERE
p37324
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp37325
g35211
I58
sg35212
g37318
sg35214
I24
sg35223
VP54259
p37326
sg35217
I3
sasg35208
(lp37327
(dp37328
g35211
I69
sg35212
g37319
sg35214
I5
sg35215
VC0751781
p37329
sg35217
I1
sasa(dp37330
g135
(dp37331
(VDRPLA protein
p37332
VDRPLA
p37333
tp37334
I00
ssg35204
VMore RERE protein is recruited into nuclear aggregates of the DRPLA protein with extended polyglutamine than into those of pure polyglutamine.
p37335
sg35206
(lp37336
(dp37337
g35211
I62
sg35212
g37332
sg35214
I13
sg35223
VP54259
p37338
sg35217
I2
sasg35208
(lp37339
(dp37340
g35211
I62
sg35212
g37333
sg35214
I5
sg35215
VC0751781
p37341
sg35217
I1
sasa(dp37342
g135
(dp37343
(VDNB1
p37344
Vatrophy
p37345
tp37346
I00
ssg35204
VThe DNB1/ARPh gene, which was found to be ubiquitously expressed in human adult and fetal tissues, is highly related to the DRPLA gene, in which expansion of a CAG triplet appears to be causal in the dentatorubral and pallidolysian atrophy disease phenotype.
p37347
sg35206
(lp37348
(dp37349
g35211
I124
sg35212
VDRPLA gene
p37350
sg35214
I10
sg35223
VP54259
p37351
sg35217
I2
sa(dp37352
g35211
I4
sg35212
g37344
sg35214
I4
sg35223
VP55145
p37353
sg35217
I1
sasg35208
(lp37354
(dp37355
g35211
I124
sg35212
VDRPLA
p37356
sg35214
I5
sg35215
VC0751781
p37357
sg35217
I1
sa(dp37358
g35211
I232
sg35212
g37345
sg35214
I7
sg35215
VC0333641
p37359
sg35217
I1
sasa(dp37360
g135
(dp37361
(VCSNK2A1
p37362
Vbreast carcinoma
p37363
tp37364
I01
ssg35204
VTherefore, we evaluated the roles of CSNK2A1, SIRT6, and phosphorylated SIRT6 and their relationships in breast carcinoma.
p37365
sg35206
(lp37366
(dp37367
g35211
I37
sg35212
g37362
sg35214
I7
sg35223
VP19784
p37368
sg35217
I1
sasg35208
(lp37369
(dp37370
g35211
I105
sg35212
g37363
sg35214
I16
sg35215
VC0678222
p37371
sg35217
I2
sasa(dp37372
g135
(dp37373
(VCSNK2A1
p37374
Vbreast carcinomas
p37375
tp37376
I01
ssg35204
VThis study demonstrates that CSNK2A1 and SIRT6 are indicators of poor prognosis for breast carcinomas and that CSNK2A1-mediated phosphorylation of SIRT6 might be involved in the progression of breast carcinoma.
p37377
sg35206
(lp37378
(dp37379
g35211
I29
sg35212
VCSNK2A1
p37380
sg35214
I7
sg35223
VP19784
p37381
sg35217
I1
sa(dp37382
g35211
I29
sg35212
g37374
sg35214
I7
sg35223
VP19784
p37383
sg35217
I1
sasg35208
(lp37384
(dp37385
g35211
I84
sg35212
Vbreast carcinoma
p37386
sg35214
I16
sg35215
VC0678222
p37387
sg35217
I2
sa(dp37388
g35211
I84
sg35212
g37375
sg35214
I17
sg35215
VC0678222
p37389
sg35217
I2
sasa(dp37390
g135
(dp37391
(VCSNK2A1
p37392
Vbreast cancer
p37393
tp37394
I01
ssg35204
VRNA expression levels of CDC2L1, CDC2L2, CCNL1, CCNL2, CSNK2A1, CSNK2A2, and CSNK2B genes in breast cancer subtypes were analyzed.
p37395
sg35206
(lp37396
(dp37397
g35211
I77
sg35212
VCSNK2B genes
p37398
sg35214
I12
sg35223
VP67870
p37399
sg35217
I2
sa(dp37400
g35211
I64
sg35212
VCSNK2A2
p37401
sg35214
I7
sg35223
VP19784
p37402
sg35217
I1
sa(dp37403
g35211
I41
sg35212
VCCNL1
p37404
sg35214
I5
sg35223
VP49736
p37405
sg35217
I1
sa(dp37406
g35211
I55
sg35212
g37392
sg35214
I7
sg35223
VP19784
p37407
sg35217
I1
sasg35208
(lp37408
(dp37409
g35211
I93
sg35212
g37393
sg35214
I13
sg35215
VC0678222
p37410
sg35217
I2
sasa(dp37411
g135
(dp37412
(VDVL-1
p37413
Vbreast cancer
p37414
tp37415
I01
ssg35204
VRecent evidence suggests the role of Wnt signaling in human breast cancer involves elevated levels of nuclear and/or cytoplasmic beta-catenin using immunohistochemistry, overexpression or downregulation of specific Wnt proteins, overexpression of CKII and sFRP4, downregulation of WIF-1 and sFRP1, as well as amplification of DVL-1.
p37416
sg35206
(lp37417
(dp37418
g35211
I117
sg35212
Vcytoplasmic beta-catenin
p37419
sg35214
I24
sg35223
g12
sg35217
I2
sa(dp37420
g35211
I247
sg35212
VCKII
p37421
sg35214
I4
sg35223
VP68400
p37422
sg35217
I1
sa(dp37423
g35211
I326
sg35212
g37413
sg35214
I5
sg35223
VP54792
p37424
sg35217
I1
sa(dp37425
g35211
I291
sg35212
VsFRP1
p37426
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp37427
g35211
I256
sg35212
VsFRP4
p37428
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp37429
(dp37430
g35211
I60
sg35212
g37414
sg35214
I13
sg35215
VC0678222
p37431
sg35217
I2
sa(dp37432
g35211
I309
sg35212
Vamplification
p37433
sg35214
I13
sg35215
VC1705759
p37434
sg35217
I1
sasa(dp37435
g135
(dp37436
(VCHRM2
p37437
VPDB
p37438
tp37439
I00
ssg35204
VBy combining the mutational data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and the spatial information in the Protein Data Bank (PDB), SpacePAC is able to identify novel mutation clusters in many proteins such as FGFR3 and CHRM2.
p37440
sg35206
(lp37441
(dp37442
g35211
I228
sg35212
VFGFR3
p37443
sg35214
I5
sg35223
VP22607
p37444
sg35217
I1
sa(dp37445
g35211
I238
sg35212
g37437
sg35214
I5
sg35223
VP08172
p37446
sg35217
I1
sasg35208
(lp37447
(dp37448
g35211
I53
sg35212
VSomatic Mutations
p37449
sg35214
I17
sg35215
VC0544886
p37450
sg35217
I2
sa(dp37451
g35211
I125
sg35212
VProtein Data Bank
p37452
sg35214
I17
sg35215
VC0029401
p37453
sg35217
I3
sa(dp37454
g35211
I179
sg35212
Vnovel mutation
p37455
sg35214
I14
sg35215
VC2985438
p37456
sg35217
I2
sa(dp37457
g35211
I74
sg35212
VCancer
p37458
sg35214
I6
sg35215
VC0006826
p37459
sg35217
I1
sa(dp37460
g35211
I144
sg35212
g37438
sg35214
I3
sg35215
VC0029401
p37461
sg35217
I1
sasa(dp37462
g135
(dp37463
(VIGI
p37464
VCCD
p37465
tp37466
I00
ssg35204
VColorectal cancer (HCT 116, LoVo, C 170 HM 2, CaCO-2), fibroblast (46-BR.IGI, CCD-18 Co) and fibrosarcoma (HT1080) cell lines were irradiated at 4 gray (4 Gy) and matrix metalloproteinase gene and protein expression examined over a 96 h period by real time polymerase chain reaction and gelatin zymography.
p37467
sg35206
(lp37468
(dp37469
g35211
I78
sg35212
VCCD-18 Co
p37470
sg35214
I9
sg35223
VP21817
p37471
sg35217
I2
sa(dp37472
g35211
I163
sg35212
Vmatrix metalloproteinase gene
p37473
sg35214
I29
sg35223
g12
sg35217
I3
sa(dp37474
g35211
I73
sg35212
g37464
sg35214
I3
sg35223
VP12018
p37475
sg35217
I1
sasg35208
(lp37476
(dp37477
g35211
I0
sg35212
VColorectal cancer
p37478
sg35214
I17
sg35215
VC1527249
p37479
sg35217
I2
sa(dp37480
g35211
I93
sg35212
Vfibrosarcoma
p37481
sg35214
I12
sg35215
VC0016057
p37482
sg35217
I1
sa(dp37483
g35211
I78
sg35212
g37465
sg35214
I3
sg35215
VC0008928
p37484
sg35217
I1
sasa(dp37485
g135
(dp37486
(VHm2
p37487
Vhemolysis
p37488
tp37489
I00
ssg35204
VIn addition, because HBL is a major enterotoxin, we also designed HBL gene-specific polymerase chain reaction (PCR) primers, i.e., Hm1 and Hm2, that generated the same results as those of the hemolysis and BCET-RPLA assays.
p37490
sg35206
(lp37491
(dp37492
g35211
I66
sg35212
VHBL gene
p37493
sg35214
I8
sg35223
VP09382
p37494
sg35217
I2
sa(dp37495
g35211
I131
sg35212
VHm1
p37496
sg35214
I3
sg35223
VP11229
p37497
sg35217
I1
sa(dp37498
g35211
I21
sg35212
VHBL
p37499
sg35214
I3
sg35223
VP09382
p37500
sg35217
I1
sa(dp37501
g35211
I139
sg35212
g37487
sg35214
I3
sg35223
VP08172
p37502
sg35217
I1
sasg35208
(lp37503
(dp37504
g35211
I192
sg35212
g37488
sg35214
I9
sg35215
VC0019054
p37505
sg35217
I1
sasa(dp37506
g35204
VPrimers B16S1/B16S2 and Hm1/Hm2 could be combined into a multiplex PCR system for the simultaneous detection of B. cereus group cells and the possible presence of their HBL enterotoxins.
p37507
sg35206
(lp37508
(dp37509
g35211
I24
sg35212
VHm1
p37510
sg35214
I3
sg35223
VP11229
p37511
sg35217
I1
sa(dp37512
g35211
I169
sg35212
VHBL enterotoxins
p37513
sg35214
I16
sg35223
VP09382
p37514
sg35217
I2
sa(dp37515
g35211
I28
sg35212
VHm2
p37516
sg35214
I3
sg35223
VP08172
p37517
sg35217
I1
sasg35208
(lp37518
sa(dp37519
g135
(dp37520
(Vhm2
p37521
Vdm2
p37522
tp37523
I00
ssg35204
VPositive cancer invasion in the cut end was classified as hm2 or dm2 in 8 patients and em2 in 13.
p37524
sg35206
(lp37525
(dp37526
g35211
I58
sg35212
g37521
sg35214
I3
sg35223
VP08172
p37527
sg35217
I1
sasg35208
(lp37528
(dp37529
g35211
I16
sg35212
Vinvasion
p37530
sg35214
I8
sg35215
VC2699153
p37531
sg35217
I1
sa(dp37532
g35211
I65
sg35212
g37522
sg35214
I3
sg35215
VC2931689
p37533
sg35217
I1
sa(dp37534
g35211
I9
sg35212
Vcancer
p37535
sg35214
I6
sg35215
VC0006826
p37536
sg35217
I1
sasa(dp37537
g135
(dp37538
(VFGF5
p37539
VAIDS
p37540
tp37541
I01
ssg35204
VBiopsy samples from five acquired immune deficiency syndrome (AIDS)-Kaposi's sarcomas and one non-AIDS-associated Kaposi's sarcoma were assayed by in situ RNA hybridization onto paraformaldehyde-fixed, paraffin-embedded skin sections for the presence of two fibroblast growth factor gene transcripts, FGFB and FGF5.
p37542
sg35206
(lp37543
(dp37544
g35211
I258
sg35212
Vfibroblast growth factor gene transcripts
p37545
sg35214
I41
sg35223
g12
sg35217
I5
sa(dp37546
g35211
I310
sg35212
g37539
sg35214
I4
sg35223
VP12034
p37547
sg35217
I1
sasg35208
(lp37548
(dp37549
g35211
I25
sg35212
Vacquired immune deficiency syndrome
p37550
sg35214
I35
sg35215
VC0001175
p37551
sg35217
I4
sa(dp37552
g35211
I62
sg35212
VAIDS
p37553
sg35214
I4
sg35215
VC0001175
p37554
sg35217
I1
sa(dp37555
g35211
I77
sg35212
Vsarcomas
p37556
sg35214
I8
sg35215
VC1261473
p37557
sg35217
I1
sa(dp37558
g35211
I68
sg35212
VKaposi's sarcoma
p37559
sg35214
I16
sg35215
VC0036220
p37560
sg35217
I2
sa(dp37561
g35211
I62
sg35212
g37540
sg35214
I4
sg35215
VC0001175
p37562
sg35217
I1
sasa(dp37563
g135
(dp37564
(VFGF5 gene
p37565
VKaposi's sarcoma
p37566
tp37567
I01
ssg35204
VFGF5 gene expression was detected in the characteristic Kaposi's sarcoma spindle-shaped cells in the five samples from human immunodeficiency-positive (HIV+) patients.
p37568
sg35206
(lp37569
(dp37570
g35211
I0
sg35212
g37565
sg35214
I9
sg35223
VP12034
p37571
sg35217
I2
sasg35208
(lp37572
(dp37573
g35211
I125
sg35212
Vimmunodeficiency
p37574
sg35214
I16
sg35215
VC0021051
p37575
sg35217
I1
sa(dp37576
g35211
I56
sg35212
g37566
sg35214
I16
sg35215
VC0036220
p37577
sg35217
I2
sasa(dp37578
g135
(dp37579
(VFGF5
p37580
VKaposi's sarcoma
p37581
tp37582
I01
ssg35204
VFurthermore, they demonstrate a contrasting expression pattern of FGF5 and FGFB genes, both involved in the growth factor pathogenic cascade leading to Kaposi's sarcoma.
p37583
sg35206
(lp37584
(dp37585
g35211
I75
sg35212
VFGFB genes
p37586
sg35214
I10
sg35223
VP01893
p37587
sg35217
I2
sa(dp37588
g35211
I66
sg35212
g37580
sg35214
I4
sg35223
VP12034
p37589
sg35217
I1
sasg35208
(lp37590
(dp37591
g35211
I152
sg35212
g37581
sg35214
I16
sg35215
VC0036220
p37592
sg35217
I2
sasa(dp37593
g35204
VObjective To explore the efficacy of ganoderma lucidum preparation(Ling Zhi) in treating APP/PS-1 transgenic mouse models of Alzheimer's disease(AD).Methods APP/PS-1 transgenic mice of 4 months were randomly divided into model group,ganoderma lucidum treatment groups,including high [2250 mg/(kg*d)] and middle [750 mg/(kg*d)] dose groups,i.e.LZ-H and LZ-M groups,and the positive control group(treated with donepezil hydrochloride [2 mg/(kg*d)]).In addition,C57BL/6J wild mice were selected as normal group.The animals were administered for 4 months.Histopathological examinations including hematoxylin-eosin(HE) staining,immunohistochemistry,special staining,and electron microscopy were applied,and then the pathological morphology and structures in different groups were compared.
p37594
sg35206
(lp37595
(dp37596
g35211
I89
sg35212
VAPP
p37597
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp37598
g35211
I93
sg35212
VPS-1
p37599
sg35214
I4
sg35223
VP48651
p37600
sg35217
I1
sasg35208
(lp37601
(dp37602
g35211
I125
sg35212
VAlzheimer's disease
p37603
sg35214
I19
sg35215
VC1521724
p37604
sg35217
I2
sasa(dp37605
g35204
VFor the hydrogel prepared using the comonomer mixture with 5.0 wt % SBMA, the amount of adsorbed Lyz is 0.91 myg/cm2, which corresponds to only 56.8% of the amount adsorbed on EASY DAY(R) SCLs.
p37606
sg35206
(lp37607
sg35208
(lp37608
(dp37609
g35211
I68
sg35212
VSBMA
p37610
sg35214
I4
sg35215
VC1839259
p37611
sg35217
I1
sa(dp37612
g35211
I113
sg35212
Vcm2
p37613
sg35214
I3
sg35215
VC0555206
p37614
sg35217
I1
sasa(dp37615
g135
(dp37616
(VSyt1
p37617
Vbehavior disorders
p37618
tp37619
I00
ssg35204
VObjective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In addition,10 4-month-old C57BL/6 mice were used as the control group.Water maze test was conducted to observe the behavior changes,and the protein expressions in brain tissues were detected by Western blot analysis.The autoimmune indicators were detected by indirect immunofluorescence method.Results In the navigation experiment,the time of finding the platform was gradually shortened since the 2nd day in the control,LZ-H,and LZ-M groups,and the time of searching the platform in the AD model group gradually increased.On the 5th day,the time of finding platform was significantly shorter in control group (t=5.607,P=0.000) and LZ-H group(t=2.750,P=0.010)than AD model group.In the space exploration experiment,the number of crossing the target platform(t=2.452,P=0.025)and the residence time in the target quadrant(t=2.530,P=0.020)in AD model group mice was significantly smaller/shorter than those in control group;in addition,the number of crossing the target platform in the AD model group was significantly smaller than that in LZ-H group(t=2.317,P=0.030)and LZ-M group(t=2.443,P=0.030),while the residence time in target quadrant decreased significantly(t=2.770,P=0.020)compared with LZ-H group;the number of crossing through the target platform quadrant(t=2.493,P=0.022)and residence time in the target quadrant(t=2.683,P=0.015)in LZ-H group were significantly higher than in Aricept group.Western blot analysis showed that the expression of ApoA1 in the brain tissues of mice in LZ-H and LZ-M groups were significantly higher than those in AD model group(P&lt;0.01,P&lt;0.05);ABeta-40 expression in LZ-H group was significantly lower than that in AD model group(P&lt;0.05);the expressions of Syt1,ApoE,and ABCA1 in brain tissues of mice in LZ-H group were significantly higher than those in model group(P&lt;0.01,P&lt;0.05).The plasma IgG level in Aricept group(t=30.945,P=0.000),LZ-M group(t=25.639,P=0.000)and LZ-H group(t=4.689,P=0.001)were significantly higher than that in the control group.Conclusion Ganoderma lucidum preparation can improve behavior disorders of AD model mice,promote the expressions of ApoA1,ApoE and Syt1,inhibit the expression of ABeta-40 protein,and improve the autoimmune function.
p37620
sg35206
(lp37621
(dp37622
g35211
I2137
sg35212
VSyt1
p37623
sg35214
I4
sg35223
VP21579
p37624
sg35217
I1
sa(dp37625
g35211
I1886
sg35212
VApoA1
p37626
sg35214
I5
sg35223
VP02647
p37627
sg35217
I1
sa(dp37628
g35211
I1065
sg35212
VLZ-H group
p37629
sg35214
I10
sg35223
VP00390
p37630
sg35217
I2
sa(dp37631
g35211
I2142
sg35212
VApoE
p37632
sg35214
I4
sg35223
VP02649
p37633
sg35217
I1
sa(dp37634
g35211
I145
sg35212
VAPP/PS-1
p37635
sg35214
I8
sg35223
VP48651
p37636
sg35217
I1
sa(dp37637
g35211
I2142
sg35212
VApoE
p37638
sg35214
I4
sg35223
VP02649
p37639
sg35217
I1
sa(dp37640
g35211
I2603
sg35212
VABeta-40 protein
p37641
sg35214
I16
sg35223
g12
sg35217
I2
sa(dp37642
g35211
I1886
sg35212
VApoA1
p37643
sg35214
I5
sg35223
VP02647
p37644
sg35217
I1
sa(dp37645
g35211
I2021
sg35212
VABeta-40
p37646
sg35214
I8
sg35223
g12
sg35217
I1
sa(dp37647
g35211
I1065
sg35212
VLZ-H group
p37648
sg35214
I10
sg35223
VP00390
p37649
sg35217
I2
sa(dp37650
g35211
I145
sg35212
VAPP
p37651
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp37652
g35211
I1065
sg35212
VLZ-H group
p37653
sg35214
I10
sg35223
VP00390
p37654
sg35217
I2
sa(dp37655
g35211
I149
sg35212
VPS-1
p37656
sg35214
I4
sg35223
VP48651
p37657
sg35217
I1
sa(dp37658
g35211
I2137
sg35212
g37617
sg35214
I4
sg35223
VP21579
p37659
sg35217
I1
sasg35208
(lp37660
(dp37661
g35211
I102
sg35212
Vautoimmunity
p37662
sg35214
I12
sg35215
VC0004368
p37663
sg35217
I1
sa(dp37664
g35211
I172
sg35212
VAlzheimer's disease
p37665
sg35214
I19
sg35215
VC1521724
p37666
sg35217
I2
sa(dp37667
g35211
I2494
sg35212
g37618
sg35214
I18
sg35215
VC0004930
p37668
sg35217
I2
sa(dp37669
g35211
I653
sg35212
Vautoimmune
p37670
sg35214
I10
sg35215
VC0443146
p37671
sg35217
I1
sa(dp37672
g35211
I653
sg35212
Vautoimmune
p37673
sg35214
I10
sg35215
VC0443146
p37674
sg35217
I1
sasa(dp37675
g135
(dp37676
(VSomatic v-Raf murine sarcoma viral oncogene homolog B
p37677
Vmetastatic colorectal cancer
p37678
tp37679
I00
ssg35204
VSomatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis.
p37680
sg35206
(lp37681
(dp37682
g35211
I55
sg35212
VBRAF
p37683
sg35214
I4
sg35223
VP15056
p37684
sg35217
I1
sa(dp37685
g35211
I0
sg35212
g37677
sg35214
I53
sg35223
VP04049
p37686
sg35217
I8
sasg35208
(lp37687
(dp37688
g35211
I21
sg35212
Vsarcoma
p37689
sg35214
I7
sg35215
VC1261473
p37690
sg35217
I1
sa(dp37691
g35211
I133
sg35212
VmCRC
p37692
sg35214
I4
sg35215
VC0948380
p37693
sg35217
I1
sa(dp37694
g35211
I103
sg35212
g37678
sg35214
I28
sg35215
VC0948380
p37695
sg35217
I3
sasa(dp37696
g135
(dp37697
(VBRAF
p37698
Vcolorectal cancer
p37699
tp37700
I00
ssg35204
VAll colorectal cancer patients tested for BRAF mutation, from October 2010 to November 2014 were identified.
p37701
sg35206
(lp37702
(dp37703
g35211
I42
sg35212
g37698
sg35214
I4
sg35223
VP15056
p37704
sg35217
I1
sasg35208
(lp37705
(dp37706
g35211
I4
sg35212
g37699
sg35214
I17
sg35215
VC1527249
p37707
sg35217
I2
sasa(dp37708
g135
(dp37709
(Vv-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC)
p37710
Vsarcoma
p37711
tp37712
I00
ssg35204
VThe prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking.
p37713
sg35206
(lp37714
(dp37715
g35211
I45
sg35212
g37710
sg35214
I92
sg35223
VP15056
p37716
sg35217
I13
sasg35208
(lp37717
(dp37718
g35211
I132
sg35212
VmCRC
p37719
sg35214
I4
sg35215
VC0948380
p37720
sg35217
I1
sa(dp37721
g35211
I102
sg35212
Vmetastatic colorectal cancer
p37722
sg35214
I28
sg35215
VC0948380
p37723
sg35217
I3
sa(dp37724
g35211
I58
sg35212
g37711
sg35214
I7
sg35215
VC1261473
p37725
sg35217
I1
sasa(dp37726
g135
(dp37727
(VKRAS
p37728
Vmetastatic colorectal cancer
p37729
tp37730
I00
ssg35204
VThe aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving first line oxaliplatin based chemotherapy with or without bevacizumab and to evaluate their prognostic and predictive significance.
p37731
sg35206
(lp37732
(dp37733
g35211
I66
sg35212
VBRAF
p37734
sg35214
I4
sg35223
VP15056
p37735
sg35217
I1
sa(dp37736
g35211
I60
sg35212
VNRAS
p37737
sg35214
I4
sg35223
VP01111
p37738
sg35217
I1
sa(dp37739
g35211
I75
sg35212
VPIK3CA
p37740
sg35214
I6
sg35223
VP42336
p37741
sg35217
I1
sa(dp37742
g35211
I54
sg35212
g37728
sg35214
I4
sg35223
VP01116
p37743
sg35217
I1
sasg35208
(lp37744
(dp37745
g35211
I95
sg35212
g37729
sg35214
I28
sg35215
VC0948380
p37746
sg35217
I3
sasa(dp37747
g135
(dp37748
(VV-raf murine sarcoma viral oncogene homolog B
p37749
Vmetastatic colorectal cancer
p37750
tp37751
I00
ssg35204
VActivating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features.
p37752
sg35206
(lp37753
(dp37754
g35211
I11
sg35212
VBRAF
p37755
sg35214
I4
sg35223
VP15056
p37756
sg35217
I1
sa(dp37757
g35211
I17
sg35212
g37749
sg35214
I45
sg35223
VP04049
p37758
sg35217
I7
sasg35208
(lp37759
(dp37760
g35211
I30
sg35212
Vsarcoma
p37761
sg35214
I7
sg35215
VC1261473
p37762
sg35217
I1
sa(dp37763
g35211
I124
sg35212
g37750
sg35214
I28
sg35215
VC0948380
p37764
sg35217
I3
sasa(dp37765
g135
(dp37766
(VBRAF gene
p37767
Vmetastatic colorectal cancer
p37768
tp37769
I00
ssg35204
VThis review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.
p37770
sg35206
(lp37771
(dp37772
g35211
I67
sg35212
g37767
sg35214
I9
sg35223
VP15056
p37773
sg35217
I2
sasg35208
(lp37774
(dp37775
g35211
I89
sg35212
g37768
sg35214
I28
sg35215
VC0948380
p37776
sg35217
I3
sa(dp37777
g35211
I67
sg35212
VBRAF gene mutation
p37778
sg35214
I18
sg35215
VC1511021
p37779
sg35217
I3
sasa(dp37780
g135
(dp37781
(Vprothrombin
p37782
VHepatic Encephalopathy
p37783
tp37784
I01
ssg35204
VThe variables of age, incidence of autoimmune hepatitis, model of end-stage liver disease (MELD) score, values for total bilirubin and prothrombin time-international ratio (PT-INR), and Japan Hepatic Encephalopathy Prediction Model (JHEPM) probability at registration were significantly higher in ALF patients than in ALI patients.
p37785
sg35206
(lp37786
(dp37787
g35211
I135
sg35212
g37782
sg35214
I11
sg35223
VP00734
p37788
sg35217
I1
sasg35208
(lp37789
(dp37790
g35211
I35
sg35212
Vautoimmune hepatitis
p37791
sg35214
I20
sg35215
VC0241910
p37792
sg35217
I2
sa(dp37793
g35211
I76
sg35212
Vliver disease
p37794
sg35214
I13
sg35215
VC0023895
p37795
sg35217
I2
sa(dp37796
g35211
I192
sg35212
g37783
sg35214
I22
sg35215
VC0019151
p37797
sg35217
I2
sasa(dp37798
g135
(dp37799
(Vprothrombin
p37800
VAutoimmune Hepatitis
p37801
tp37802
I00
ssg35204
VOn the other hand, the multivariate Cox proportional hazard model showed that positivity for serum anti-PD-1 antibody, probable diagnosis based on the revised scoring system proposed by the International Autoimmune Hepatitis Group, and prothrombin activity of less than 60% were associated with the later normalization of serum transaminase levels.
p37803
sg35206
(lp37804
(dp37805
g35211
I93
sg35212
Vserum anti-PD-1 antibody
p37806
sg35214
I24
sg35223
VP18621
p37807
sg35217
I3
sa(dp37808
g35211
I322
sg35212
Vserum transaminase
p37809
sg35214
I18
sg35223
g12
sg35217
I2
sa(dp37810
g35211
I236
sg35212
g37800
sg35214
I11
sg35223
VP00734
p37811
sg35217
I1
sasg35208
(lp37812
(dp37813
g35211
I204
sg35212
g37801
sg35214
I20
sg35215
VC0241910
p37814
sg35217
I2
sasa(dp37815
g135
(dp37816
(VCD49e
p37817
VMyeloma
p37818
tp37819
I00
ssg35204
VMyeloma cell maturity was classified via immunophenotyping: myeloma cells showing mature plasma cell 1 (MPC-1)-positive and CD49e-positive cells were considered mature type; MPC-1-positive and CD49e-negative cells were considered intermediate type; and MPC-1-negative cells were considered immature type.
p37820
sg35206
(lp37821
(dp37822
g35211
I124
sg35212
VCD49e
p37823
sg35214
I5
sg35223
VP08648
p37824
sg35217
I1
sa(dp37825
g35211
I124
sg35212
g37817
sg35214
I5
sg35223
VP08648
p37826
sg35217
I1
sasg35208
(lp37827
(dp37828
g35211
I60
sg35212
Vmyeloma
p37829
sg35214
I7
sg35215
VC0026764
p37830
sg35217
I1
sa(dp37831
g35211
I0
sg35212
g37818
sg35214
I7
sg35215
VC0026764
p37832
sg35217
I1
sasa(dp37833
g135
(dp37834
(VCD49e antibodies
p37835
Vmyeloma
p37836
tp37837
I00
ssg35204
VThe findings of this study demonstrate the clinical importance of myeloma cell classification according to immunophenotyping using MPC-1 and CD49e antibodies to determine patient prognosis in this era of novel therapeutic agents.
p37838
sg35206
(lp37839
(dp37840
g35211
I131
sg35212
VMPC-1
p37841
sg35214
I5
sg35223
VP28062
p37842
sg35217
I1
sa(dp37843
g35211
I141
sg35212
g37835
sg35214
I16
sg35223
VP08648
p37844
sg35217
I2
sasg35208
(lp37845
(dp37846
g35211
I66
sg35212
g37836
sg35214
I7
sg35215
VC0026764
p37847
sg35217
I1
sasa(dp37848
g135
(dp37849
(VMPC-1
p37850
Vplasmacytoma
p37851
tp37852
I00
ssg35204
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p37853
sg35206
(lp37854
(dp37855
g35211
I177
sg35212
VCD49e
p37856
sg35214
I5
sg35223
VP08648
p37857
sg35217
I1
sa(dp37858
g35211
I154
sg35212
VCD45(+)
p37859
sg35214
I7
sg35223
VP08575
p37860
sg35217
I1
sa(dp37861
g35211
I163
sg35212
g37850
sg35214
I5
sg35223
VP28062
p37862
sg35217
I1
sasg35208
(lp37863
(dp37864
g35211
I117
sg35212
g37851
sg35214
I12
sg35215
VC0032131
p37865
sg35217
I1
sasa(dp37866
g135
(dp37867
(VCD45 negativity
p37868
Vplasmacytoma
p37869
tp37870
I00
ssg35204
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p37871
sg35206
(lp37872
(dp37873
g35211
I31
sg35212
VMPC-1
p37874
sg35214
I5
sg35223
VP28062
p37875
sg35217
I1
sa(dp37876
g35211
I73
sg35212
VCD49e
p37877
sg35214
I5
sg35223
VP08648
p37878
sg35217
I1
sa(dp37879
g35211
I11
sg35212
g37868
sg35214
I15
sg35223
VP08575
p37880
sg35217
I2
sasg35208
(lp37881
(dp37882
g35211
I135
sg35212
g37869
sg35214
I12
sg35215
VC0032131
p37883
sg35217
I1
sasa(dp37884
g135
(dp37885
(VCD49e
p37886
Vplasmacytomas
p37887
tp37888
I00
ssg35204
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p37889
sg35206
(lp37890
(dp37891
g35211
I212
sg35212
VMPC1
p37892
sg35214
I4
sg35223
VP28062
p37893
sg35217
I1
sa(dp37894
g35211
I223
sg35212
VCD45+
p37895
sg35214
I5
sg35223
VP08575
p37896
sg35217
I1
sa(dp37897
g35211
I217
sg35212
g37886
sg35214
I5
sg35223
VP08648
p37898
sg35217
I1
sasg35208
(lp37899
(dp37900
g35211
I99
sg35212
Vmyeloma
p37901
sg35214
I7
sg35215
VC0026764
p37902
sg35217
I1
sa(dp37903
g35211
I111
sg35212
Veffusion
p37904
sg35214
I8
sg35215
VC0013687
p37905
sg35217
I1
sa(dp37906
g35211
I99
sg35212
Vmyeloma
p37907
sg35214
I7
sg35215
VC0026764
p37908
sg35217
I1
sa(dp37909
g35211
I73
sg35212
g37887
sg35214
I13
sg35215
VC0032131
p37910
sg35217
I1
sasa(dp37911
g135
(dp37912
(VCD32
p37913
Vmyeloma
p37914
tp37915
I00
ssg35204
VCD32 was significantly expressed on primary myeloma cells, but immature, MPC-1- myeloma cells expressed CD32 more weakly than mature, MPC-1+ cells.
p37916
sg35206
(lp37917
(dp37918
g35211
I0
sg35212
VCD32
p37919
sg35214
I4
sg35223
VP12318
p37920
sg35217
I1
sa(dp37921
g35211
I73
sg35212
VMPC-1
p37922
sg35214
I5
sg35223
VP28062
p37923
sg35217
I1
sa(dp37924
g35211
I0
sg35212
g37913
sg35214
I4
sg35223
VP12318
p37925
sg35217
I1
sasg35208
(lp37926
(dp37927
g35211
I44
sg35212
Vmyeloma
p37928
sg35214
I7
sg35215
VC0026764
p37929
sg35217
I1
sa(dp37930
g35211
I44
sg35212
g37914
sg35214
I7
sg35215
VC0026764
p37931
sg35217
I1
sasa(dp37932
g135
(dp37933
(VCD32
p37934
Vmyeloma
p37935
tp37936
I00
ssg35204
VTreatment with anti-CD32 antibody decreased the viability of normal plasma cells (CD38++ CD19+) more than that of myeloma cells (CD38++ CD19-); CD32-mediated growth suppression was greater in mature MPC-1+ cells than in immature MPC-1- cells.
p37937
sg35206
(lp37938
(dp37939
g35211
I15
sg35212
Vanti-CD32 antibody
p37940
sg35214
I18
sg35223
VP12318
p37941
sg35217
I2
sa(dp37942
g35211
I82
sg35212
VCD38++ CD19+
p37943
sg35214
I12
sg35223
VP28907
p37944
sg35217
I2
sa(dp37945
g35211
I20
sg35212
g37934
sg35214
I4
sg35223
VP12318
p37946
sg35217
I1
sasg35208
(lp37947
(dp37948
g35211
I158
sg35212
Vgrowth suppression
p37949
sg35214
I18
sg35215
VC0151686
p37950
sg35217
I2
sa(dp37951
g35211
I114
sg35212
g37935
sg35214
I7
sg35215
VC0026764
p37952
sg35217
I1
sasa(dp37953
g135
(dp37954
(VMPC-1(+)CD49e(-)CD45(+)
p37955
Vmyeloma
p37956
tp37957
I00
ssg35204
VTo date, at least 5 subpopulations of plasma cells have been identified in the bone marrow of multiple myeloma (MM) patients with regard to the expression of MPC-1, CD49e (VLA-5), and CD45: MPC-1(-)CD49e(-)CD45(+) proliferative immature cells, MPC-1(-)CD49e(-)CD45(-) immature myeloma cells, MPC-1(+)CD49e(-)CD45(-) and MPC-1(+)CD49e(-)CD45(+) intermediate myeloma cells, and MPC-1(+)CD49e(+)CD45(+) mature myeloma cells.
p37958
sg35206
(lp37959
(dp37960
g35211
I376
sg35212
VMPC-1(+)CD49e(+)CD45(+)
p37961
sg35214
I23
sg35223
VP28062
p37962
sg35217
I1
sa(dp37963
g35211
I184
sg35212
VCD45: MPC-1(-)CD49e(-)CD45
p37964
sg35214
I26
sg35223
VP08575
p37965
sg35217
I2
sa(dp37966
g35211
I158
sg35212
VMPC-1
p37967
sg35214
I5
sg35223
VP28062
p37968
sg35217
I1
sa(dp37969
g35211
I260
sg35212
VCD45(-)
p37970
sg35214
I7
sg35223
VP08575
p37971
sg35217
I1
sa(dp37972
g35211
I190
sg35212
VMPC-1(-)CD49e(-)
p37973
sg35214
I16
sg35223
VP28062
p37974
sg35217
I1
sa(dp37975
g35211
I292
sg35212
VMPC-1(+)CD49e(-)CD45(-)
p37976
sg35214
I23
sg35223
VP28062
p37977
sg35217
I1
sa(dp37978
g35211
I172
sg35212
VVLA-5
p37979
sg35214
I5
sg35223
VP08648
p37980
sg35217
I1
sa(dp37981
g35211
I165
sg35212
VCD49e
p37982
sg35214
I5
sg35223
VP08648
p37983
sg35217
I1
sa(dp37984
g35211
I320
sg35212
g37955
sg35214
I23
sg35223
VP28062
p37985
sg35217
I1
sasg35208
(lp37986
(dp37987
g35211
I103
sg35212
Vmyeloma
p37988
sg35214
I7
sg35215
VC0026764
p37989
sg35217
I1
sa(dp37990
g35211
I94
sg35212
Vmultiple myeloma
p37991
sg35214
I16
sg35215
VC0026764
p37992
sg35217
I2
sa(dp37993
g35211
I214
sg35212
Vproliferative
p37994
sg35214
I13
sg35215
VC0334094
p37995
sg35217
I1
sa(dp37996
g35211
I112
sg35212
VMM
p37997
sg35214
I2
sg35215
VC0026764
p37998
sg35217
I1
sa(dp37999
g35211
I103
sg35212
Vmyeloma
p38000
sg35214
I7
sg35215
VC0026764
p38001
sg35217
I1
sa(dp38002
g35211
I103
sg35212
g37956
sg35214
I7
sg35215
VC0026764
p38003
sg35217
I1
sasa(dp38004
g135
(dp38005
(VMPC-1(-)
p38006
Vmyeloma
p38007
tp38008
I00
ssg35204
VIn 31 cases of progressive MM disease, MPC-1(-) immature and MPC-1(-)CD45(+) proliferative immature myeloma cells were significantly increased up to &gt;25% and &gt;10%, respectively, of the plasma cell fractions (CD38(++) cells), whereas there were no increases in MPC-1(-) or MPC-1(-)CD45(+) proliferative immature myeloma cells in 15 cases of stable disease.
p38009
sg35206
(lp38010
(dp38011
g35211
I61
sg35212
VMPC-1(-)CD45(+)
p38012
sg35214
I15
sg35223
VP28062
p38013
sg35217
I1
sa(dp38014
g35211
I214
sg35212
VCD38
p38015
sg35214
I4
sg35223
VP28907
p38016
sg35217
I1
sa(dp38017
g35211
I61
sg35212
VMPC-1(-)CD45(+)
p38018
sg35214
I15
sg35223
VP28062
p38019
sg35217
I1
sa(dp38020
g35211
I39
sg35212
g38006
sg35214
I8
sg35223
VP28062
p38021
sg35217
I1
sasg35208
(lp38022
(dp38023
g35211
I77
sg35212
Vproliferative
p38024
sg35214
I13
sg35215
VC0334094
p38025
sg35217
I1
sa(dp38026
g35211
I77
sg35212
Vproliferative
p38027
sg35214
I13
sg35215
VC0334094
p38028
sg35217
I1
sa(dp38029
g35211
I100
sg35212
Vmyeloma
p38030
sg35214
I7
sg35215
VC0026764
p38031
sg35217
I1
sa(dp38032
g35211
I100
sg35212
g38007
sg35214
I7
sg35215
VC0026764
p38033
sg35217
I1
sasa(dp38034
g135
(dp38035
(VMPC-1
p38036
VMGUS
p38037
tp38038
I00
ssg35204
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p38039
sg35206
(lp38040
(dp38041
g35211
I47
sg35212
VMPC-1(-)CD45(+)
p38042
sg35214
I15
sg35223
VP28062
p38043
sg35217
I1
sa(dp38044
g35211
I34
sg35212
g38036
sg35214
I5
sg35223
VP28062
p38045
sg35217
I1
sasg35208
(lp38046
(dp38047
g35211
I141
sg35212
g38037
sg35214
I4
sg35215
VC0026470
p38048
sg35217
I1
sasa(dp38049
g135
(dp38050
(VCD45
p38051
Vmyeloma
p38052
tp38053
I00
ssg35204
VResults with flow cytometry using a combination of MPC1, CD49e, and CD45 supported the morphologic findings for the myeloma cells.
p38054
sg35206
(lp38055
(dp38056
g35211
I51
sg35212
VMPC1
p38057
sg35214
I4
sg35223
VP28062
p38058
sg35217
I1
sa(dp38059
g35211
I57
sg35212
VCD49e
p38060
sg35214
I5
sg35223
VP08648
p38061
sg35217
I1
sa(dp38062
g35211
I68
sg35212
g38051
sg35214
I4
sg35223
VP08575
p38063
sg35217
I1
sasg35208
(lp38064
(dp38065
g35211
I116
sg35212
g38052
sg35214
I7
sg35215
VC0026764
p38066
sg35217
I1
sasa(dp38067
g35204
VInterestingly, the region encompassing the SNF1LK locus has been implicated in congenital heart defects often observed in patients with Down syndrome.
p38068
sg35206
(lp38069
(dp38070
g35211
I43
sg35212
VSNF1LK locus
p38071
sg35214
I12
sg35223
VP57059
p38072
sg35217
I2
sasg35208
(lp38073
(dp38074
g35211
I136
sg35212
VDown syndrome
p38075
sg35214
I13
sg35215
VC0013080
p38076
sg35217
I2
sa(dp38077
g35211
I79
sg35212
Vcongenital heart defects
p38078
sg35214
I24
sg35215
VC0018798
p38079
sg35217
I3
sasa(dp38080
g135
(dp38081
(VCD14
p38082
Varthritis
p38083
tp38084
I01
ssg35204
VOn the other hand, a significant increase was demonstrated in CD14-positive cells at 3 weeks after immunization in only arthritis-developed monkeys regardless of sex.
p38085
sg35206
(lp38086
(dp38087
g35211
I62
sg35212
g38082
sg35214
I4
sg35223
VP08571
p38088
sg35217
I1
sasg35208
(lp38089
(dp38090
g35211
I120
sg35212
g38083
sg35214
I9
sg35215
VC0003864
p38091
sg35217
I1
sasa(dp38092
g135
(dp38093
(VCD14
p38094
Vrheumatoid arthritis
p38095
tp38096
I00
ssg35204
VWe previously reported the accumulation of abnormal myeloid cell populations reacting with CD14 (MY4) monoclonal antibody in the iliac and epiphyseal bone marrow of patients with severe rheumatoid arthritis (RA).
p38097
sg35206
(lp38098
(dp38099
g35211
I91
sg35212
g38094
sg35214
I4
sg35223
VP08571
p38100
sg35217
I1
sasg35208
(lp38101
(dp38102
g35211
I208
sg35212
VRA
p38103
sg35214
I2
sg35215
VC0003873
p38104
sg35217
I1
sa(dp38105
g35211
I186
sg35212
g38095
sg35214
I20
sg35215
VC0003873
p38106
sg35217
I2
sasa(dp38107
g135
(dp38108
(Vinterleukin-1
p38109
Vrheumatoid arthritis
p38110
tp38111
I00
ssg35204
VPrior to treatment, monocyte-macrophage activation in rheumatoid arthritis was signified by an increased expression of HLA-class II antigens and the CD14 antigen, and by an increased production of neopterin and interleukin-1.
p38112
sg35206
(lp38113
(dp38114
g35211
I149
sg35212
VCD14 antigen
p38115
sg35214
I12
sg35223
VP08571
p38116
sg35217
I2
sa(dp38117
g35211
I211
sg35212
g38109
sg35214
I13
sg35223
VP60568
p38118
sg35217
I1
sa(dp38119
g35211
I119
sg35212
VHLA-class II antigens
p38120
sg35214
I21
sg35223
VP30486
p38121
sg35217
I3
sasg35208
(lp38122
(dp38123
g35211
I54
sg35212
g38110
sg35214
I20
sg35215
VC0003873
p38124
sg35217
I2
sasa(dp38125
g135
(dp38126
(VCD14 antigen
p38127
Vrheumatoid arthritis
p38128
tp38129
I00
ssg35204
VMonocytes, defined by staining with the Mo-2 and Leu-M3 monoclonal antibodies which both detect the CD14 antigen, were studied in peripheral blood of control subjects and patients with rheumatoid arthritis as well as in rheumatoid synovial fluid of the latter for expression of activation/differentiation markers.
p38130
sg35206
(lp38131
(dp38132
g35211
I49
sg35212
VLeu-M3 monoclonal antibodies
p38133
sg35214
I28
sg35223
VP30740
p38134
sg35217
I3
sa(dp38135
g35211
I100
sg35212
g38127
sg35214
I12
sg35223
VP08571
p38136
sg35217
I2
sasg35208
(lp38137
(dp38138
g35211
I185
sg35212
g38128
sg35214
I20
sg35215
VC0003873
p38139
sg35217
I2
sasa(dp38140
g135
(dp38141
(VIL2
p38142
Vtype 1 diabetes mellitus
p38143
tp38144
I00
ssg35204
VWe review recent findings implicating variants of FCRL3 (gene for FC receptor-like-3 protein), SCGB3A2 (gene for secretory uteroglobin-related protein 1- UGRP1) as well as other unverified possible candidate genes for GD selected through their documented association with type 1 diabetes mellitus: Tenr-IL2-IL21, CAPSL (encoding calcyphosine-like protein), IFIH1(gene for interferon-induced helicase C domain 1), AFF3, CD226 and PTPN2.
p38145
sg35206
(lp38146
(dp38147
g35211
I413
sg35212
VAFF3
p38148
sg35214
I4
sg35223
VP51826
p38149
sg35217
I1
sa(dp38150
g35211
I307
sg35212
VIL21
p38151
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp38152
g35211
I113
sg35212
Vsecretory uteroglobin-related protein 1- UGRP1
p38153
sg35214
I46
sg35223
VP11684
p38154
sg35217
I5
sa(dp38155
g35211
I50
sg35212
VFCRL3
p38156
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38157
g35211
I329
sg35212
Vcalcyphosine-like protein
p38158
sg35214
I25
sg35223
g12
sg35217
I2
sa(dp38159
g35211
I429
sg35212
VPTPN2
p38160
sg35214
I5
sg35223
VP17706
p38161
sg35217
I1
sa(dp38162
g35211
I66
sg35212
VFC receptor-like-3 protein
p38163
sg35214
I26
sg35223
g12
sg35217
I3
sa(dp38164
g35211
I372
sg35212
Vinterferon-induced helicase C domain 1
p38165
sg35214
I38
sg35223
VP01563
p38166
sg35217
I5
sa(dp38167
g35211
I357
sg35212
VIFIH1
p38168
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38169
g35211
I95
sg35212
VSCGB3A2
p38170
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp38171
g35211
I303
sg35212
g38142
sg35214
I3
sg35223
VP60568
p38172
sg35217
I1
sa(dp38173
g35211
I419
sg35212
VCD226
p38174
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38175
g35211
I313
sg35212
VCAPSL
p38176
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp38177
(dp38178
g35211
I272
sg35212
g38143
sg35214
I24
sg35215
VC0011854
p38179
sg35217
I4
sasa(dp38180
g35204
VAutoantibody-positive diabetic subjects (n = 1,384) and population-based control subjects (n = 2,235) were genotyped at 20 childhood-onset type 1 diabetes loci and FCRL3, GAD2, TCF7L2, and FTO.
p38181
sg35206
(lp38182
(dp38183
g35211
I171
sg35212
VGAD2
p38184
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp38185
(dp38186
g35211
I139
sg35212
Vtype 1 diabetes
p38187
sg35214
I15
sg35215
VC0011854
p38188
sg35217
I3
sasa(dp38189
g35204
VWe analyzed the same four 5' FCRL3 single nucleotide polymorphism markers, together with three additional exonic single nucleotide polymorphisms in the FCRL3 gene, in cohorts of white Caucasians with Graves' disease (n = 625), type 1 diabetes (n = 279), autoimmune Addison's disease (AAD; n = 200), and RA (n = 769).
p38190
sg35206
(lp38191
sg35208
(lp38192
(dp38193
g35211
I227
sg35212
Vtype 1 diabetes
p38194
sg35214
I15
sg35215
VC0011854
p38195
sg35217
I3
sa(dp38196
g35211
I254
sg35212
Vautoimmune Addison's disease
p38197
sg35214
I28
sg35215
VC0271737
p38198
sg35217
I3
sa(dp38199
g35211
I200
sg35212
VGraves' disease
p38200
sg35214
I15
sg35215
VC0018213
p38201
sg35217
I2
sa(dp38202
g35211
I284
sg35212
VAAD
p38203
sg35214
I3
sg35215
VC0271737
p38204
sg35217
I1
sasa(dp38205
g135
(dp38206
(VCD4+Foxp3+
p38207
Vencephalomyelitis
p38208
tp38209
I00
ssg35204
VIn vivo, in a model of experimental autoimmune encephalomyelitis, we show that an agonist of DR3 suppressed disease, correlating with expansion of CD4+Foxp3+ Tregs, and this protective effect was lost in Galectin-9-/- mice.
p38210
sg35206
(lp38211
(dp38212
g35211
I147
sg35212
g38207
sg35214
I10
sg35223
VP01730
p38213
sg35217
I1
sa(dp38214
g35211
I204
sg35212
VGalectin-9
p38215
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp38216
(dp38217
g35211
I36
sg35212
Vautoimmune
p38218
sg35214
I10
sg35215
VC0443146
p38219
sg35217
I1
sa(dp38220
g35211
I47
sg35212
g38208
sg35214
I17
sg35215
VC0014070
p38221
sg35217
I1
sasa(dp38222
g35204
VGalectin-9 concentrations in CSF were higher in SPMS patients than healthy controls and RRMS patients in both cohorts.
p38223
sg35206
(lp38224
(dp38225
g35211
I0
sg35212
VGalectin-9
p38226
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp38227
sa(dp38228
g135
(dp38229
(VCD43
p38230
VSLE
p38231
tp38232
I00
ssg35204
VOur objective is to identify phenotypically the position of CD43(+) B cells among peripheral B-lineage cell compartments in healthy donors, with reference to B-cell subsets from patients with systemic lupus erythematosus (SLE).
p38233
sg35206
(lp38234
(dp38235
g35211
I60
sg35212
g38230
sg35214
I4
sg35223
VP16150
p38236
sg35217
I1
sasg35208
(lp38237
(dp38238
g35211
I192
sg35212
Vsystemic lupus erythematosus
p38239
sg35214
I28
sg35215
VC0024141
p38240
sg35217
I3
sa(dp38241
g35211
I222
sg35212
g38231
sg35214
I3
sg35215
VC0024141
p38242
sg35217
I1
sasa(dp38243
g135
(dp38244
(VCD43
p38245
Vsystemic lupus erythematosus
p38246
tp38247
I00
ssg35204
VPrevious studies indicate that CD43 plays a role in regulating the adhesion of lymphocytes, cell mutation and activation, however, little is known about its effect on systemic lupus erythematosus (SLE).
p38248
sg35206
(lp38249
(dp38250
g35211
I31
sg35212
g38245
sg35214
I4
sg35223
VP16150
p38251
sg35217
I1
sasg35208
(lp38252
(dp38253
g35211
I197
sg35212
VSLE
p38254
sg35214
I3
sg35215
VC0024141
p38255
sg35217
I1
sa(dp38256
g35211
I67
sg35212
Vadhesion
p38257
sg35214
I8
sg35215
VC0001511
p38258
sg35217
I1
sa(dp38259
g35211
I167
sg35212
g38246
sg35214
I28
sg35215
VC0024141
p38260
sg35217
I3
sasa(dp38261
g35204
VTwo new cases of primary Ficolin-3 deficiency are reported here: a 50-year old male, suffering from membranous nephropathy and an 11-month old male infant who was operated on to repair congenital heart disease.
p38262
sg35206
(lp38263
(dp38264
g35211
I25
sg35212
VFicolin-3
p38265
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38266
(dp38267
g35211
I185
sg35212
Vcongenital heart disease
p38268
sg35214
I24
sg35215
VC0152021
p38269
sg35217
I3
sa(dp38270
g35211
I85
sg35212
Vsuffering
p38271
sg35214
I9
sg35215
VC0683278
p38272
sg35217
I1
sa(dp38273
g35211
I100
sg35212
Vmembranous nephropathy
p38274
sg35214
I22
sg35215
VC0017665
p38275
sg35217
I2
sasa(dp38276
g35204
VIn order to investigate its potential pathogenicity for turkeys a UK isolate of Mim from a partridge with sinusitis was first passaged through turkey poults and then assessed for pathogenicity in turkey embryo tracheal organ cultures (TOCs) and in one-day-old turkey poults with or without turkey rhinotracheitis virus (TRTV).
p38277
sg35206
(lp38278
(dp38279
g35211
I80
sg35212
VMim
p38280
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp38281
(dp38282
g35211
I290
sg35212
Vturkey rhinotracheitis
p38283
sg35214
I22
sg35215
VC0275744
p38284
sg35217
I2
sa(dp38285
g35211
I106
sg35212
Vsinusitis
p38286
sg35214
I9
sg35215
VC0037199
p38287
sg35217
I1
sasa(dp38288
g35204
VBoth up- and down-regulation of the Toll-like receptors (TLRs) and antimicrobial peptides (AMPs) of the sinonasal mucosa have already been associated with the pathogenesis of chronic rhinosinusitis with (CRSwNP) or without (CRSsNP) nasal polyps.
p38289
sg35206
(lp38290
(dp38291
g35211
I36
sg35212
VToll-like receptors
p38292
sg35214
I19
sg35223
g12
sg35217
I2
sa(dp38293
g35211
I57
sg35212
VTLRs
p38294
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp38295
(dp38296
g35211
I159
sg35212
Vpathogenesis
p38297
sg35214
I12
sg35215
VC0699748
p38298
sg35217
I1
sa(dp38299
g35211
I175
sg35212
Vchronic rhinosinusitis
p38300
sg35214
I22
sg35215
VC0149516
p38301
sg35217
I2
sa(dp38302
g35211
I232
sg35212
Vnasal polyps
p38303
sg35214
I12
sg35215
VC0027430
p38304
sg35217
I2
sasa(dp38305
g135
(dp38306
(Vaminopeptidase N
p38307
VWilson disease
p38308
tp38309
I00
ssg35204
VIt is suggested that elevated plasma nociceptin level found in Wilson disease patients is due to inhibition of nociceptin-inactivating Zn-metallopeptidases (aminopeptidase N (APN) and endopeptidase 24.15) by the toxic copper deposits in liver and/or brain.
p38310
sg35206
(lp38311
(dp38312
g35211
I175
sg35212
VAPN
p38313
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp38314
g35211
I111
sg35212
Vnociceptin-inactivating Zn-metallopeptidases
p38315
sg35214
I44
sg35223
g12
sg35217
I2
sa(dp38316
g35211
I184
sg35212
Vendopeptidase 24.15
p38317
sg35214
I19
sg35223
VP52888
p38318
sg35217
I2
sa(dp38319
g35211
I157
sg35212
g38307
sg35214
I16
sg35223
VP15144
p38320
sg35217
I2
sa(dp38321
g35211
I30
sg35212
Vplasma nociceptin
p38322
sg35214
I17
sg35223
g12
sg35217
I2
sasg35208
(lp38323
(dp38324
g35211
I63
sg35212
g38308
sg35214
I14
sg35215
VC0019202
p38325
sg35217
I2
sasa(dp38326
g135
(dp38327
(Vtransferrin
p38328
Vacute myocardial infarction
p38329
tp38330
I00
ssg35204
VIt is evident from the study that body iron (serum iron, TIBC &amp; transferrin saturation) level significantly increases among acute myocardial infarction patients in Bangladesh.
p38331
sg35206
(lp38332
(dp38333
g35211
I68
sg35212
g38328
sg35214
I11
sg35223
VP02787
p38334
sg35217
I1
sasg35208
(lp38335
(dp38336
g35211
I128
sg35212
g38329
sg35214
I27
sg35215
VC0155626
p38337
sg35217
I3
sasa(dp38338
g135
(dp38339
(Vtransferrin
p38340
VAMI
p38341
tp38342
I00
ssg35204
VWe investigated the relation of NTBI, serum iron, transferrin saturation, and serum ferritin with risk of CHD and acute myocardial infarction (AMI).
p38343
sg35206
(lp38344
(dp38345
g35211
I78
sg35212
Vserum ferritin
p38346
sg35214
I14
sg35223
VP02794
p38347
sg35217
I2
sa(dp38348
g35211
I50
sg35212
g38340
sg35214
I11
sg35223
VP02787
p38349
sg35217
I1
sasg35208
(lp38350
(dp38351
g35211
I114
sg35212
Vacute myocardial infarction
p38352
sg35214
I27
sg35215
VC0155626
p38353
sg35217
I3
sa(dp38354
g35211
I143
sg35212
g38341
sg35214
I3
sg35215
VC0155626
p38355
sg35217
I1
sasa(dp38356
g135
(dp38357
(VCYP3A
p38358
Vhepatoma
p38359
tp38360
I00
ssg35204
VIn this study, the effects of chiral pesticide metalaxyl on CYP1A1, CYP1A2, CYP2B1, CYP2B2, CYP2E1 and CYP3A were investigated in human hepatoma HepG2, rat hepatic H4IIE, chicken hepatic LMH and grass carp hepatic L8824 cells.
p38361
sg35206
(lp38362
(dp38363
g35211
I171
sg35212
Vchicken hepatic LMH
p38364
sg35214
I19
sg35223
g12
sg35217
I3
sa(dp38365
g35211
I68
sg35212
VCYP1A2
p38366
sg35214
I6
sg35223
VP05177
p38367
sg35217
I1
sa(dp38368
g35211
I92
sg35212
VCYP2E1
p38369
sg35214
I6
sg35223
VP05181
p38370
sg35217
I1
sa(dp38371
g35211
I60
sg35212
VCYP1A1
p38372
sg35214
I6
sg35223
VP04798
p38373
sg35217
I1
sa(dp38374
g35211
I103
sg35212
g38358
sg35214
I5
sg35223
VP08684
p38375
sg35217
I1
sasg35208
(lp38376
(dp38377
g35211
I201
sg35212
Vcarp
p38378
sg35214
I4
sg35215
VC0263385
p38379
sg35217
I1
sa(dp38380
g35211
I136
sg35212
g38359
sg35214
I8
sg35215
VC0023903
p38381
sg35217
I1
sasa(dp38382
g35204
VER+ cancers exhibited lower ADORA1, ADORA2B, and RYR1 and elevated PDE4A, CYP2A6, and CYP2E expressions.
p38383
sg35206
(lp38384
(dp38385
g35211
I28
sg35212
VADORA1
p38386
sg35214
I6
sg35223
VP30542
p38387
sg35217
I1
sa(dp38388
g35211
I36
sg35212
VADORA2B
p38389
sg35214
I7
sg35223
VP29275
p38390
sg35217
I1
sa(dp38391
g35211
I86
sg35212
VCYP2E
p38392
sg35214
I5
sg35223
VP05181
p38393
sg35217
I1
sa(dp38394
g35211
I49
sg35212
VRYR1
p38395
sg35214
I4
sg35223
VP21817
p38396
sg35217
I1
sasg35208
(lp38397
(dp38398
g35211
I4
sg35212
Vcancers
p38399
sg35214
I7
sg35215
VC0006826
p38400
sg35217
I1
sasa(dp38401
g135
(dp38402
(VBcl-2
p38403
VB-cell lymphoma
p38404
tp38405
I00
ssg35204
VThe mechanisms were investigated by detecting levels of NADPH Oxidase 4 (NOX4),p22phox, cytochrome P4502E1 (CYP2E1),Bax,B-cell lymphoma 2 (Bcl-2),cleaved-caspase 3 and 9 and phosphorylated extracellular regulated protein kinases(ERK),phosphorylated c-Jun N-terminal kinase (JNK), and phosphorylated p38 mitogen-activated protein kinase (MAPK) using real-time polymerase chain reaction (PCR) and Western blotting.
p38406
sg35206
(lp38407
(dp38408
g35211
I337
sg35212
VMAPK
p38409
sg35214
I4
sg35223
VP53779
p38410
sg35217
I1
sa(dp38411
g35211
I249
sg35212
Vc-Jun N-terminal kinase
p38412
sg35214
I23
sg35223
VP53779
p38413
sg35217
I3
sa(dp38414
g35211
I79
sg35212
Vp22phox
p38415
sg35214
I7
sg35223
VP13498
p38416
sg35217
I1
sa(dp38417
g35211
I299
sg35212
Vp38 mitogen-activated protein kinase
p38418
sg35214
I36
sg35223
g12
sg35217
I4
sa(dp38419
g35211
I108
sg35212
VCYP2E1
p38420
sg35214
I6
sg35223
VP05181
p38421
sg35217
I1
sa(dp38422
g35211
I274
sg35212
VJNK
p38423
sg35214
I3
sg35223
VP53779
p38424
sg35217
I1
sa(dp38425
g35211
I88
sg35212
Vcytochrome P4502E1
p38426
sg35214
I18
sg35223
VP05181
p38427
sg35217
I2
sa(dp38428
g35211
I154
sg35212
Vcaspase
p38429
sg35214
I7
sg35223
VP39880
p38430
sg35217
I1
sa(dp38431
g35211
I115
sg35212
V,Bax,B-cell lymphoma 2
p38432
sg35214
I22
sg35223
VP10415
p38433
sg35217
I3
sa(dp38434
g35211
I56
sg35212
VNADPH Oxidase 4
p38435
sg35214
I15
sg35223
g12
sg35217
I3
sa(dp38436
g35211
I189
sg35212
Vextracellular regulated protein kinases
p38437
sg35214
I39
sg35223
VP10398
p38438
sg35217
I4
sa(dp38439
g35211
I73
sg35212
VNOX4
p38440
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp38441
g35211
I229
sg35212
VERK
p38442
sg35214
I3
sg35223
VP29323
p38443
sg35217
I1
sa(dp38444
g35211
I139
sg35212
g38403
sg35214
I5
sg35223
VP10415
p38445
sg35217
I1
sasg35208
(lp38446
(dp38447
g35211
I120
sg35212
g38404
sg35214
I15
sg35215
VC0079731
p38448
sg35217
I2
sasa(dp38449
g135
(dp38450
(VCXCR2 rs1126579
p38451
Vlung cancer
p38452
tp38453
I00
ssg35204
VTwenty-two variants from 21 genes (APEX1 rs1130409 and rs1760944, ATM rs664677, AXIN2 rs2240308, CHRNA3 rs6495309, CHRNA5 rs16969968, CLPTM1L rs402710, CXCR2 rs1126579, CYP1A1 rs4646903, CYP2E1 rs6413432, ERCC1 rs11615, ERCC2 rs13181, FGFR4 rs351855, HYKK rs931794, MIR146A rs2910164, MIR196A2 rs11614913, OGG1 rs1052133, PON1 rs662, REV3L rs462779, SOD2 rs4880, TERT rs2736098, and TP53 rs1042522) showed significant associations with lung cancer susceptibility with strong cumulative epidemiological evidence.
p38454
sg35206
(lp38455
(dp38456
g35211
I322
sg35212
VPON1 rs662
p38457
sg35214
I10
sg35223
VP27169
p38458
sg35217
I2
sa(dp38459
g35211
I35
sg35212
VAPEX1 rs1130409
p38460
sg35214
I15
sg35223
VP27695
p38461
sg35217
I2
sa(dp38462
g35211
I205
sg35212
VERCC1 rs11615
p38463
sg35214
I13
sg35223
VP07992
p38464
sg35217
I2
sa(dp38465
g35211
I334
sg35212
VREV3L rs462779
p38466
sg35214
I14
sg35223
g12
sg35217
I2
sa(dp38467
g35211
I436
sg35212
Vlung cancer susceptibility
p38468
sg35214
I26
sg35223
g12
sg35217
I3
sa(dp38469
g35211
I363
sg35212
VTERT rs2736098
p38470
sg35214
I14
sg35223
g12
sg35217
I2
sa(dp38471
g35211
I80
sg35212
VAXIN2 rs2240308
p38472
sg35214
I15
sg35223
g12
sg35217
I2
sa(dp38473
g35211
I350
sg35212
VSOD2 rs4880
p38474
sg35214
I11
sg35223
VP04179
p38475
sg35217
I2
sa(dp38476
g35211
I169
sg35212
VCYP1A1 rs4646903
p38477
sg35214
I16
sg35223
VP04798
p38478
sg35217
I2
sa(dp38479
g35211
I235
sg35212
VFGFR4 rs351855
p38480
sg35214
I14
sg35223
VP22455
p38481
sg35217
I2
sa(dp38482
g35211
I97
sg35212
VCHRNA3 rs6495309
p38483
sg35214
I16
sg35223
VP32297
p38484
sg35217
I2
sa(dp38485
g35211
I66
sg35212
VATM rs664677
p38486
sg35214
I12
sg35223
g12
sg35217
I2
sa(dp38487
g35211
I187
sg35212
VCYP2E1 rs6413432
p38488
sg35214
I16
sg35223
VP05181
p38489
sg35217
I2
sa(dp38490
g35211
I115
sg35212
VCHRNA5 rs16969968
p38491
sg35214
I17
sg35223
VP30532
p38492
sg35217
I2
sa(dp38493
g35211
I134
sg35212
VCLPTM1L rs402710
p38494
sg35214
I16
sg35223
g12
sg35217
I2
sa(dp38495
g35211
I220
sg35212
VERCC2 rs13181
p38496
sg35214
I13
sg35223
VP18074
p38497
sg35217
I2
sa(dp38498
g35211
I152
sg35212
g38451
sg35214
I15
sg35223
VP25025
p38499
sg35217
I2
sasg35208
(lp38500
(dp38501
g35211
I436
sg35212
g38452
sg35214
I11
sg35215
VC0684249
p38502
sg35217
I2
sasa(dp38503
g35204
VThis study aimed to determine the serum levels of angiopoietin-like 4 (ANGPTL4) in patients with renal cell carcinoma (RCC) and explore its potential as a biomarker.
p38504
sg35206
(lp38505
(dp38506
g35211
I50
sg35212
Vangiopoietin-like 4
p38507
sg35214
I19
sg35223
g12
sg35217
I2
sa(dp38508
g35211
I71
sg35212
VANGPTL4
p38509
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp38510
(dp38511
g35211
I119
sg35212
VRCC
p38512
sg35214
I3
sg35215
VC0007134
p38513
sg35217
I1
sa(dp38514
g35211
I97
sg35212
Vrenal cell carcinoma
p38515
sg35214
I20
sg35215
VC0007134
p38516
sg35217
I3
sasa(dp38517
g35204
VWe have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available.
p38518
sg35206
(lp38519
(dp38520
g35211
I51
sg35212
Vangptl4
p38521
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp38522
g35211
I30
sg35212
Vangiopoietin-like 4
p38523
sg35214
I19
sg35223
g12
sg35217
I2
sasg35208
(lp38524
(dp38525
g35211
I68
sg35212
Vhypoxia
p38526
sg35214
I7
sg35215
VC0242184
p38527
sg35217
I1
sa(dp38528
g35211
I137
sg35212
Vcarcinoma
p38529
sg35214
I9
sg35215
VC0007097
p38530
sg35217
I1
sa(dp38531
g35211
I150
sg35212
VRCC
p38532
sg35214
I3
sg35215
VC0007134
p38533
sg35217
I1
sasa(dp38534
g35204
VWe observed particularly high levels of ANGPTL4 mRNA in tumor cells of conventional renal cell carcinoma.
p38535
sg35206
(lp38536
(dp38537
g35211
I40
sg35212
VANGPTL4 mRNA
p38538
sg35214
I12
sg35223
g12
sg35217
I2
sasg35208
(lp38539
(dp38540
g35211
I56
sg35212
Vtumor
p38541
sg35214
I5
sg35215
VC0027651
p38542
sg35217
I1
sa(dp38543
g35211
I71
sg35212
Vconventional renal cell carcinoma
p38544
sg35214
I33
sg35215
VC0279702
p38545
sg35217
I4
sasa(dp38546
g35204
VResults The smoking subgroup (n=15) of NSIP patients had a significantly lower % diffusing capacity for carbon monoxide/ alveolar ventilation (DLCO/VA) and tended to have higher SP-D values than the nonsmoking subgroup (n=16).
p38547
sg35206
(lp38548
sg35208
(lp38549
sa(dp38550
g135
(dp38551
(VSP-D
p38552
Vnonspecific interstitial pneumonia
p38553
tp38554
I00
ssg35204
VAs compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6.
p38555
sg35206
(lp38556
(dp38557
g35211
I258
sg35212
g38552
sg35214
I4
sg35223
VP35247
p38558
sg35217
I1
sasg35208
(lp38559
(dp38560
g35211
I36
sg35212
Vidiopathic pulmonary fibrosis
p38561
sg35214
I29
sg35215
VC3161101
p38562
sg35217
I3
sa(dp38563
g35211
I79
sg35212
g38553
sg35214
I34
sg35215
VC1290344
p38564
sg35217
I3
sasa(dp38565
g135
(dp38566
(VSP-D
p38567
Vnonspecific interstitial pneumonia
p38568
tp38569
I00
ssg35204
VHowever, associations of serum KL-6 and SP-D with radiologic findings in nonspecific interstitial pneumonia (NSIP) remain unclear.
p38570
sg35206
(lp38571
(dp38572
g35211
I25
sg35212
Vserum KL-6
p38573
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp38574
g35211
I40
sg35212
g38567
sg35214
I4
sg35223
VP35247
p38575
sg35217
I1
sasg35208
(lp38576
(dp38577
g35211
I109
sg35212
VNSIP
p38578
sg35214
I4
sg35215
VC1290344
p38579
sg35217
I1
sa(dp38580
g35211
I73
sg35212
g38568
sg35214
I34
sg35215
VC1290344
p38581
sg35217
I3
sasa(dp38582
g35204
VTo determine whether serum levels of KL-6 and SP-D reflect fibrotic and/or inflammatory processes in NSIP, we investigated the correlation between high-resolution computed tomography (HRCT) findings and serum KL-6 and SP-D levels.
p38583
sg35206
(lp38584
(dp38585
g35211
I46
sg35212
VSP-D
p38586
sg35214
I4
sg35223
VP35247
p38587
sg35217
I1
sa(dp38588
g35211
I46
sg35212
VSP-D
p38589
sg35214
I4
sg35223
VP35247
p38590
sg35217
I1
sasg35208
(lp38591
sa(dp38592
g35204
VSerum levels of KL-6 and SP-D were measured in 21 patients with biopsy-confirmed NSIP.
p38593
sg35206
(lp38594
(dp38595
g35211
I25
sg35212
VSP-D
p38596
sg35214
I4
sg35223
VP35247
p38597
sg35217
I1
sasg35208
(lp38598
sa(dp38599
g35204
VSerum levels of SP-D in NSIP showed a positive correlation with the area of ground-glass attenuation without traction bronchiectasis and the inflammatory CT pattern, but the levels were inversely correlated with the area of ground-glass attenuation with traction bronchiectasis and the fibrotic CT pattern.
p38600
sg35206
(lp38601
(dp38602
g35211
I16
sg35212
VSP-D
p38603
sg35214
I4
sg35223
VP35247
p38604
sg35217
I1
sasg35208
(lp38605
(dp38606
g35211
I109
sg35212
Vtraction bronchiectasis
p38607
sg35214
I23
sg35215
VC0264361
p38608
sg35217
I2
sa(dp38609
g35211
I109
sg35212
Vtraction bronchiectasis
p38610
sg35214
I23
sg35215
VC0264361
p38611
sg35217
I2
sasa(dp38612
g35204
VThe results indicate that serum levels of KL-6 in NSIP reflect the overall extent of interstitial lesions, which include both inflammatory and fibrotic lesions, while the levels of SP-D mainly reflect the extent of inflammatory lesions.
p38613
sg35206
(lp38614
(dp38615
g35211
I181
sg35212
VSP-D
p38616
sg35214
I4
sg35223
VP35247
p38617
sg35217
I1
sasg35208
(lp38618
sa(dp38619
g35204
VRecently, we identified high expression of 2 RHOGAPs, ARHGAP11A and RACGAP1, in the basal-like breast cancer subtype.
p38620
sg35206
(lp38621
(dp38622
g35211
I68
sg35212
VRACGAP1
p38623
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp38624
g35211
I54
sg35212
VARHGAP11A
p38625
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38626
(dp38627
g35211
I95
sg35212
Vbreast cancer
p38628
sg35214
I13
sg35215
VC0678222
p38629
sg35217
I2
sasa(dp38630
g35204
VWe have established that, via the suppression of RhoA, ArhGAP11A and RacGAP1 are both critical drivers of BLBC growth, and propose that RhoGAPs can act as oncogenes in cancer.
p38631
sg35206
(lp38632
(dp38633
g35211
I69
sg35212
VRacGAP1
p38634
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp38635
g35211
I49
sg35212
VRhoA
p38636
sg35214
I4
sg35223
VP61586
p38637
sg35217
I1
sa(dp38638
g35211
I55
sg35212
VArhGAP11A
p38639
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38640
(dp38641
g35211
I168
sg35212
Vcancer
p38642
sg35214
I6
sg35215
VC0006826
p38643
sg35217
I1
sa(dp38644
g35211
I34
sg35212
Vsuppression
p38645
sg35214
I11
sg35215
VC0221103
p38646
sg35217
I1
sasa(dp38647
g35204
VWe found significant methylation differences at a number of experimentally implicated breast cancer-related genes, including attenuated 5' untranslated region (UTR)/first exon methylation at the proinvasive ARHGAP11A gene in variant mimic-transfected cells.
p38648
sg35206
(lp38649
(dp38650
g35211
I207
sg35212
VARHGAP11A gene
p38651
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp38652
(dp38653
g35211
I86
sg35212
Vbreast cancer
p38654
sg35214
I13
sg35215
VC0678222
p38655
sg35217
I2
sasa(dp38656
g35204
VFollow-up functional analyses revealed both concurrent increased ARHGAP11A mRNA expression and enhanced invasiveness in variant versus WT piR-021285 mimic-transfected breast cancer cell lines.
p38657
sg35206
(lp38658
(dp38659
g35211
I65
sg35212
VARHGAP11A mRNA
p38660
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp38661
(dp38662
g35211
I167
sg35212
Vbreast cancer
p38663
sg35214
I13
sg35215
VC0678222
p38664
sg35217
I2
sasa(dp38665
g135
(dp38666
(VRhoA
p38667
Vadhesion
p38668
tp38669
I00
ssg35204
VExpression of ARHGAP11A in cancer cells suppressed RhoA-dependent mechanisms, such as stress fiber formation and focal adhesion, which made the cells more prone to migrate.
p38670
sg35206
(lp38671
(dp38672
g35211
I14
sg35212
VARHGAP11A
p38673
sg35214
I9
sg35223
g12
sg35217
I1
sa(dp38674
g35211
I51
sg35212
g38667
sg35214
I4
sg35223
VP61586
p38675
sg35217
I1
sasg35208
(lp38676
(dp38677
g35211
I119
sg35212
g38668
sg35214
I8
sg35215
VC0001511
p38678
sg35217
I1
sa(dp38679
g35211
I27
sg35212
Vcancer
p38680
sg35214
I6
sg35215
VC0006826
p38681
sg35217
I1
sasa(dp38682
g35204
VRNAi-based inhibition of Arhgap11a reduced the invasion and in vivo expansion of cancers.
p38683
sg35206
(lp38684
(dp38685
g35211
I25
sg35212
VArhgap11a
p38686
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38687
(dp38688
g35211
I81
sg35212
Vcancers
p38689
sg35214
I7
sg35215
VC0006826
p38690
sg35217
I1
sa(dp38691
g35211
I47
sg35212
Vinvasion
p38692
sg35214
I8
sg35215
VC2699153
p38693
sg35217
I1
sasa(dp38694
g35204
VAdditionally, analysis of human specimens showed the significant up-regulation of Arhgap11a in colon cancers, which was correlated with clinical invasion status.
p38695
sg35206
(lp38696
(dp38697
g35211
I82
sg35212
VArhgap11a
p38698
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38699
(dp38700
g35211
I95
sg35212
Vcolon cancers
p38701
sg35214
I13
sg35215
VC0007102
p38702
sg35217
I2
sa(dp38703
g35211
I145
sg35212
Vinvasion
p38704
sg35214
I8
sg35215
VC2699153
p38705
sg35217
I1
sasa(dp38706
g35204
VThe present study suggests that ARHGAP11A, a cell cycle-dependent RhoGAP, is a critical regulator of cancer cell mobility and is thus a promising therapeutic target in invasive cancers.
p38707
sg35206
(lp38708
(dp38709
g35211
I66
sg35212
VRhoGAP
p38710
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp38711
g35211
I32
sg35212
VARHGAP11A
p38712
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38713
(dp38714
g35211
I177
sg35212
Vcancers
p38715
sg35214
I7
sg35215
VC0006826
p38716
sg35217
I1
sa(dp38717
g35211
I101
sg35212
Vcancer
p38718
sg35214
I6
sg35215
VC0006826
p38719
sg35217
I1
sasa(dp38720
g135
(dp38721
(VCHRNA3
p38722
Vobesity
p38723
tp38724
I00
ssg35204
VIdentified genome-wide significant loci: 1) corroborated genes implicated in other studies (MTNR1B, ZNF259/APOA5, XPA/FOXE1 (TTF-2), DARC, CCR3, ABO); 2) localized novel genes in plausible biological pathways (PCSK2, ARHGAP11A, CHRNA3); and 3) revealed novel genes with unknown function in obesity pathogenesis (MATK, COL4A1).
p38725
sg35206
(lp38726
(dp38727
g35211
I312
sg35212
VMATK
p38728
sg35214
I4
sg35223
VP42679
p38729
sg35217
I1
sa(dp38730
g35211
I114
sg35212
VXPA
p38731
sg35214
I3
sg35223
VP23025
p38732
sg35217
I1
sa(dp38733
g35211
I139
sg35212
VCCR3
p38734
sg35214
I4
sg35223
VP51677
p38735
sg35217
I1
sa(dp38736
g35211
I118
sg35212
VFOXE1
p38737
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38738
g35211
I125
sg35212
VTTF-2
p38739
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38740
g35211
I318
sg35212
VCOL4A1
p38741
sg35214
I6
sg35223
VP02462
p38742
sg35217
I1
sa(dp38743
g35211
I210
sg35212
VPCSK2
p38744
sg35214
I5
sg35223
VP16519
p38745
sg35217
I1
sa(dp38746
g35211
I217
sg35212
VARHGAP11A
p38747
sg35214
I9
sg35223
g12
sg35217
I1
sa(dp38748
g35211
I100
sg35212
VZNF259
p38749
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp38750
g35211
I92
sg35212
VMTNR1B
p38751
sg35214
I6
sg35223
VP49286
p38752
sg35217
I1
sa(dp38753
g35211
I228
sg35212
g38722
sg35214
I6
sg35223
VP32297
p38754
sg35217
I1
sa(dp38755
g35211
I107
sg35212
VAPOA5
p38756
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp38757
(dp38758
g35211
I290
sg35212
g38723
sg35214
I7
sg35215
VC0028754
p38759
sg35217
I1
sa(dp38760
g35211
I298
sg35212
Vpathogenesis
p38761
sg35214
I12
sg35215
VC0699748
p38762
sg35217
I1
sasa(dp38763
g135
(dp38764
(VACTC
p38765
Vcongenital heart defect
p38766
tp38767
I01
ssg35204
VIn contrast to GTG banding, array CGH determined the exact number of deleted genes and thus allowed the identification of candidate genes for cleft palate (GREM1, CX36, MEIS2), congenital heart defect (ACTC, GREM1, CX36, MEIS2), and mental retardation (ARHGAP11A, CHRNA7, CHRM5).
p38768
sg35206
(lp38769
(dp38770
g35211
I169
sg35212
VMEIS2
p38771
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38772
g35211
I163
sg35212
VCX36
p38773
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp38774
g35211
I272
sg35212
VCHRM5
p38775
sg35214
I5
sg35223
VP08912
p38776
sg35217
I1
sa(dp38777
g35211
I202
sg35212
g38765
sg35214
I4
sg35223
VP68032
p38778
sg35217
I1
sa(dp38779
g35211
I264
sg35212
VCHRNA7
p38780
sg35214
I6
sg35223
VP36544
p38781
sg35217
I1
sa(dp38782
g35211
I169
sg35212
VMEIS2
p38783
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38784
g35211
I156
sg35212
VGREM1
p38785
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38786
g35211
I156
sg35212
VGREM1
p38787
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38788
g35211
I163
sg35212
VCX36
p38789
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp38790
g35211
I253
sg35212
VARHGAP11A
p38791
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38792
(dp38793
g35211
I233
sg35212
Vmental retardation
p38794
sg35214
I18
sg35215
VC0025362
p38795
sg35217
I2
sa(dp38796
g35211
I142
sg35212
Vcleft palate
p38797
sg35214
I12
sg35215
VC0008925
p38798
sg35217
I2
sa(dp38799
g35211
I34
sg35212
VCGH
p38800
sg35214
I3
sg35215
VC1855900
p38801
sg35217
I1
sa(dp38802
g35211
I177
sg35212
g38766
sg35214
I23
sg35215
VC0018798
p38803
sg35217
I3
sasa(dp38804
g135
(dp38805
(VCTSS
p38806
VCrohn's disease
p38807
tp38808
I01
ssg35204
VThe expression levels of four genes identified by microarray screening (PLCB2, HVCN1, CTSS, and DEF8) and one purine/thiopurine related gene (NME6) correlated significantly with the clinical activity of Crohn's disease.
p38809
sg35206
(lp38810
(dp38811
g35211
I86
sg35212
g38806
sg35214
I4
sg35223
VP25774
p38812
sg35217
I1
sa(dp38813
g35211
I110
sg35212
Vpurine/thiopurine related gene
p38814
sg35214
I30
sg35223
g12
sg35217
I3
sa(dp38815
g35211
I79
sg35212
VHVCN1
p38816
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp38817
g35211
I96
sg35212
VDEF8
p38818
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp38819
g35211
I142
sg35212
VNME6
p38820
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp38821
g35211
I72
sg35212
VPLCB2
p38822
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp38823
(dp38824
g35211
I203
sg35212
g38807
sg35214
I15
sg35215
VC0010346
p38825
sg35217
I2
sasa(dp38826
g35204
VZNF366, involved in estrogen metabolism and progression of breast cancer, is a new biologically plausible candidate for endometriosis.
p38827
sg35206
(lp38828
(dp38829
g35211
I0
sg35212
VZNF366
p38830
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp38831
(dp38832
g35211
I59
sg35212
Vbreast cancer
p38833
sg35214
I13
sg35215
VC0678222
p38834
sg35217
I2
sa(dp38835
g35211
I120
sg35212
Vendometriosis
p38836
sg35214
I13
sg35215
VC0014175
p38837
sg35217
I1
sasa(dp38838
g135
(dp38839
(VESR1
p38840
Vbreast cancer
p38841
tp38842
I00
ssg35204
VRecently, we have identified DC-SCRIPT (ZNF366) as a co-suppressor of ERAlfa and as a strong and independent prognostic marker in ESR1 (ERAlfa gene)-positive breast cancer patients.
p38843
sg35206
(lp38844
(dp38845
g35211
I29
sg35212
VDC-SCRIPT
p38846
sg35214
I9
sg35223
g12
sg35217
I1
sa(dp38847
g35211
I40
sg35212
VZNF366
p38848
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp38849
g35211
I130
sg35212
g38840
sg35214
I4
sg35223
VP03372
p38850
sg35217
I1
sasg35208
(lp38851
(dp38852
g35211
I158
sg35212
g38841
sg35214
I13
sg35215
VC0678222
p38853
sg35217
I2
sasa(dp38854
g35204
VIn this study, we further investigated the molecular mechanism on how DC-SCRIPT inhibits breast cancer cell growth.
p38855
sg35206
(lp38856
sg35208
(lp38857
(dp38858
g35211
I96
sg35212
Vcancer cell growth
p38859
sg35214
I18
sg35215
VC1516170
p38860
sg35217
I3
sasa(dp38861
g35204
VDC-SCRIPT mRNA levels from 190 primary ESR1-positive breast tumors were related to global gene expression, followed by gene ontology and pathway analysis.
p38862
sg35206
(lp38863
(dp38864
g35211
I0
sg35212
VDC-SCRIPT mRNA
p38865
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp38866
(dp38867
g35211
I53
sg35212
Vbreast tumors
p38868
sg35214
I13
sg35215
VC1458155
p38869
sg35217
I2
sasa(dp38870
g35204
VThe effect of DC-SCRIPT on breast cancer cell growth and cell cycle arrest was investigated using novel DC-SCRIPT-inducible MCF7 breast cancer cell lines.
p38871
sg35206
(lp38872
sg35208
(lp38873
(dp38874
g35211
I27
sg35212
Vbreast cancer
p38875
sg35214
I13
sg35215
VC0678222
p38876
sg35217
I2
sa(dp38877
g35211
I34
sg35212
Vcancer cell growth
p38878
sg35214
I18
sg35215
VC1516170
p38879
sg35217
I3
sasa(dp38880
g135
(dp38881
(VESR1
p38882
Vbreast tumors
p38883
tp38884
I00
ssg35204
VIn the primary ESR1-positive breast tumors, DC-SCRIPT expression negatively correlated with several cell cycle gene ontologies and pathways.
p38885
sg35206
(lp38886
(dp38887
g35211
I15
sg35212
g38882
sg35214
I4
sg35223
VP03372
p38888
sg35217
I1
sasg35208
(lp38889
(dp38890
g35211
I29
sg35212
g38883
sg35214
I13
sg35215
VC1458155
p38891
sg35217
I2
sasa(dp38892
g35204
VDC-SCRIPT expression strongly reduced breast cancer cell growth in vitro, breast tumor growth in vivo, and induced cell cycle arrest.
p38893
sg35206
(lp38894
(dp38895
g35211
I0
sg35212
VDC-SCRIPT
p38896
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38897
(dp38898
g35211
I45
sg35212
Vcancer cell growth
p38899
sg35214
I18
sg35215
VC1516170
p38900
sg35217
I3
sa(dp38901
g35211
I81
sg35212
Vtumor growth
p38902
sg35214
I12
sg35215
VC0598934
p38903
sg35217
I2
sasa(dp38904
g135
(dp38905
(VESR1
p38906
Vbreast tumors
p38907
tp38908
I00
ssg35204
VMoreover, in 1,132 primary ESR1-positive breast tumors, DC-SCRIPT expression also correlated with CDKN2B expression.
p38909
sg35206
(lp38910
(dp38911
g35211
I98
sg35212
VCDKN2B
p38912
sg35214
I6
sg35223
VP42772
p38913
sg35217
I1
sa(dp38914
g35211
I27
sg35212
g38906
sg35214
I4
sg35223
VP03372
p38915
sg35217
I1
sasg35208
(lp38916
(dp38917
g35211
I41
sg35212
g38907
sg35214
I13
sg35215
VC1458155
p38918
sg35217
I2
sasa(dp38919
g135
(dp38920
(VESR1
p38921
Vbreast cancer
p38922
tp38923
I00
ssg35204
VCollectively, these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells.
p38924
sg35206
(lp38925
(dp38926
g35211
I74
sg35212
VCDKN2B
p38927
sg35214
I6
sg35223
VP42772
p38928
sg35217
I1
sa(dp38929
g35211
I114
sg35212
g38921
sg35214
I4
sg35223
VP03372
p38930
sg35217
I1
sasg35208
(lp38931
(dp38932
g35211
I128
sg35212
g38922
sg35214
I13
sg35215
VC0678222
p38933
sg35217
I2
sasa(dp38934
g35204
VWe recently found that DC-SCRIPT is a prognostic marker in breast cancer and a unique NR coregulator differentially regulating different classes of NRs.
p38935
sg35206
(lp38936
sg35208
(lp38937
(dp38938
g35211
I59
sg35212
Vbreast cancer
p38939
sg35214
I13
sg35215
VC0678222
p38940
sg35217
I2
sasa(dp38941
g35204
VIn this study we aimed to validate the prognostic value of DC-SCRIPT mRNA expression in a large independent breast cancer cohort.
p38942
sg35206
(lp38943
(dp38944
g35211
I59
sg35212
VDC-SCRIPT mRNA
p38945
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp38946
(dp38947
g35211
I108
sg35212
Vbreast cancer
p38948
sg35214
I13
sg35215
VC0678222
p38949
sg35217
I2
sasa(dp38950
g35204
VDC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS)) using univariate and multivariable Cox regression analysis.
p38951
sg35206
(lp38952
(dp38953
g35211
I0
sg35212
VDC-SCRIPT mRNA
p38954
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp38955
(dp38956
g35211
I152
sg35212
Vmetastasis
p38957
sg35214
I10
sg35215
VC0027627
p38958
sg35217
I1
sa(dp38959
g35211
I79
sg35212
Vbreast cancers
p38960
sg35214
I14
sg35215
VC0006142
p38961
sg35217
I2
sa(dp38962
g35211
I178
sg35212
VMFS
p38963
sg35214
I3
sg35215
VC0024796
p38964
sg35217
I1
sasa(dp38965
g35204
VThis study provides a higher level of evidence that DC-SCRIPT is indeed an independent, pure prognostic, factor for primary breast cancer and shows that DC-SCRIPT mRNA expression is most informative for either ESR1-positive and/or ESR2-low pT1 tumors.
p38966
sg35206
(lp38967
(dp38968
g35211
I153
sg35212
VDC-SCRIPT mRNA
p38969
sg35214
I14
sg35223
g12
sg35217
I2
sa(dp38970
g35211
I52
sg35212
VDC-SCRIPT
p38971
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp38972
(dp38973
g35211
I244
sg35212
Vtumors
p38974
sg35214
I6
sg35215
VC0027651
p38975
sg35217
I1
sa(dp38976
g35211
I124
sg35212
Vbreast cancer
p38977
sg35214
I13
sg35215
VC0678222
p38978
sg35217
I2
sasa(dp38979
g35204
VWe investigated the role of dendritic cell-specific transcript (DC-SCRIPT) as coregulator of these nuclear receptors and as a prognostic factor in breast cancer.
p38980
sg35206
(lp38981
sg35208
(lp38982
(dp38983
g35211
I147
sg35212
Vbreast cancer
p38984
sg35214
I13
sg35215
VC0678222
p38985
sg35217
I2
sasa(dp38986
g35204
VDC-SCRIPT expression in normal and tumor tissue from breast cancer patients was analyzed by polymerase chain reaction and immunohistochemistry.
p38987
sg35206
(lp38988
sg35208
(lp38989
(dp38990
g35211
I35
sg35212
Vtumor
p38991
sg35214
I5
sg35215
VC0027651
p38992
sg35217
I1
sa(dp38993
g35211
I53
sg35212
Vbreast cancer
p38994
sg35214
I13
sg35215
VC0678222
p38995
sg35217
I2
sasa(dp38996
g135
(dp38997
(Vporphobilinogen deaminase transcript
p38998
Vbreast cancer
p38999
tp39000
I01
ssg35204
VThe prognostic value of tumor DC-SCRIPT mRNA expression was assessed in three independent cohorts of breast cancer patients: a discovery group (n = 47) and a validation group (n = 97) (neither of which had received systemic adjuvant therapy) and in a tamoxifen-treated validation group (n = 68) by using a DC-SCRIPT to porphobilinogen deaminase transcript ratio cutoff of 0.15 determined in the discovery group.
p39001
sg35206
(lp39002
(dp39003
g35211
I319
sg35212
g38998
sg35214
I36
sg35223
VP08397
p39004
sg35217
I3
sa(dp39005
g35211
I30
sg35212
VDC-SCRIPT
p39006
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp39007
(dp39008
g35211
I101
sg35212
g38999
sg35214
I13
sg35215
VC0678222
p39009
sg35217
I2
sa(dp39010
g35211
I24
sg35212
Vtumor
p39011
sg35214
I5
sg35215
VC0027651
p39012
sg35217
I1
sasa(dp39013
g35204
VDC-SCRIPT is a key regulator of nuclear receptor activity that has prognostic value in breast cancer.
p39014
sg35206
(lp39015
sg35208
(lp39016
(dp39017
g35211
I87
sg35212
Vbreast cancer
p39018
sg35214
I13
sg35215
VC0678222
p39019
sg35217
I2
sasa(dp39020
g135
(dp39021
(VKLK2
p39022
Vbreast cancer
p39023
tp39024
I00
ssg35204
VBoth SNP and gene-based analyses showed promising associations with breast cancer risk for 17 genes: OR10J3, FCER1A, NCF4, CNTNAP1, CTNNB1, KLKB1, ITGB2, ALOX12B, KLK2, IRAK3, KLK4, STAT6, NCF2, CCL1, C1QR1, MBP and NOS1.
p39025
sg35206
(lp39026
(dp39027
g35211
I140
sg35212
VKLKB1
p39028
sg35214
I5
sg35223
VP03952
p39029
sg35217
I1
sa(dp39030
g35211
I176
sg35212
VKLK4
p39031
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39032
g35211
I189
sg35212
VNCF2
p39033
sg35214
I4
sg35223
VP19878
p39034
sg35217
I1
sa(dp39035
g35211
I195
sg35212
VCCL1
p39036
sg35214
I4
sg35223
VP22362
p39037
sg35217
I1
sa(dp39038
g35211
I201
sg35212
VC1QR1
p39039
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39040
g35211
I182
sg35212
VSTAT6
p39041
sg35214
I5
sg35223
VP42226
p39042
sg35217
I1
sa(dp39043
g35211
I169
sg35212
VIRAK3
p39044
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39045
g35211
I123
sg35212
VCNTNAP1
p39046
sg35214
I7
sg35223
VP78357
p39047
sg35217
I1
sa(dp39048
g35211
I132
sg35212
VCTNNB1
p39049
sg35214
I6
sg35223
VP35222
p39050
sg35217
I1
sa(dp39051
g35211
I147
sg35212
VITGB2
p39052
sg35214
I5
sg35223
VP05107
p39053
sg35217
I1
sa(dp39054
g35211
I109
sg35212
VFCER1A
p39055
sg35214
I6
sg35223
VP12319
p39056
sg35217
I1
sa(dp39057
g35211
I117
sg35212
VNCF4
p39058
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39059
g35211
I208
sg35212
VMBP
p39060
sg35214
I3
sg35223
VP13727
p39061
sg35217
I1
sa(dp39062
g35211
I101
sg35212
VOR10J3
p39063
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp39064
g35211
I216
sg35212
VNOS1
p39065
sg35214
I4
sg35223
VP29475
p39066
sg35217
I1
sa(dp39067
g35211
I154
sg35212
VALOX12B
p39068
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp39069
g35211
I163
sg35212
g39022
sg35214
I4
sg35223
VP20151
p39070
sg35217
I1
sasg35208
(lp39071
(dp39072
g35211
I68
sg35212
g39023
sg35214
I13
sg35215
VC0678222
p39073
sg35217
I2
sasa(dp39074
g135
(dp39075
(VNAF hK2
p39076
Vbreast cancer
p39077
tp39078
I00
ssg35204
VWhen the data were divided by menopausal status, the optimal models to predict breast cancer, which included NAF hK2 or PSA and age, were 100% sensitive and 41% specific in pre- vs. 93% sensitive and 12% specific in postmenopausal women.
p39079
sg35206
(lp39080
(dp39081
g35211
I120
sg35212
VPSA
p39082
sg35214
I3
sg35223
VP55786
p39083
sg35217
I1
sa(dp39084
g35211
I109
sg35212
g39076
sg35214
I7
sg35223
VP20151
p39085
sg35217
I2
sasg35208
(lp39086
(dp39087
g35211
I120
sg35212
VPSA
p39088
sg35214
I3
sg35215
VC1519176
p39089
sg35217
I1
sa(dp39090
g35211
I79
sg35212
g39077
sg35214
I13
sg35215
VC0678222
p39091
sg35217
I2
sasa(dp39092
g135
(dp39093
(VPSA
p39094
Vprostate
p39095
tp39096
I00
ssg35204
VSeveral lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14).
p39097
sg35206
(lp39098
(dp39099
g35211
I173
sg35212
VKLK8
p39100
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39101
g35211
I155
sg35212
VKLK4
p39102
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39103
g35211
I179
sg35212
VKLK10
p39104
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39105
g35211
I213
sg35212
VKLK13
p39106
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39107
g35211
I132
sg35212
VKLK2
p39108
sg35214
I4
sg35223
VP20151
p39109
sg35217
I1
sa(dp39110
g35211
I54
sg35212
Vkallikrein family
p39111
sg35214
I17
sg35223
VP06870
p39112
sg35217
I2
sa(dp39113
g35211
I167
sg35212
VKLK6
p39114
sg35214
I4
sg35223
VP06870
p39115
sg35217
I1
sa(dp39116
g35211
I138
sg35212
VKLK15
p39117
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39118
g35211
I220
sg35212
VKLK14
p39119
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39120
g35211
I179
sg35212
VKLK10
p39121
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39122
g35211
I161
sg35212
VKLK5
p39123
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39124
g35211
I117
sg35212
Vprostate
p39125
sg35214
I8
sg35223
VP55786
p39126
sg35217
I1
sa(dp39127
g35211
I127
sg35212
g39094
sg35214
I3
sg35223
VP55786
p39128
sg35217
I1
sasg35208
(lp39129
(dp39130
g35211
I127
sg35212
VPSA
p39131
sg35214
I3
sg35215
VC1519176
p39132
sg35217
I1
sa(dp39133
g35211
I191
sg35212
Vbreast cancer
p39134
sg35214
I13
sg35215
VC0678222
p39135
sg35217
I2
sa(dp39136
g35211
I96
sg35212
Vmalignancies
p39137
sg35214
I12
sg35215
VC0006826
p39138
sg35217
I1
sa(dp39139
g35211
I117
sg35212
g39095
sg35214
I8
sg35215
VC1519176
p39140
sg35217
I1
sasa(dp39141
g135
(dp39142
(Vhuman kallikrein 2
p39143
VPSA
p39144
tp39145
I00
ssg35204
VWe examined previously the steroid hormone regulation of 2 known androgen-regulated kallikreins, KLK3 (encoding PSA) and KLK2 (encoding human kallikrein 2 or hK2) in BT-474, T-47D, ZR75-1, MCF-7, MFM-223 and BT-20 human breast cancer cells and found that they were differentially regulated, with the cells showing variable responses to androgen.
p39146
sg35206
(lp39147
(dp39148
g35211
I121
sg35212
VKLK2
p39149
sg35214
I4
sg35223
VP20151
p39150
sg35217
I1
sa(dp39151
g35211
I142
sg35212
Vkallikrein 2 or hK2
p39152
sg35214
I19
sg35223
VP20151
p39153
sg35217
I4
sa(dp39154
g35211
I65
sg35212
Vandrogen-regulated kallikreins
p39155
sg35214
I30
sg35223
VP10398
p39156
sg35217
I2
sa(dp39157
g35211
I136
sg35212
g39143
sg35214
I18
sg35223
VP20151
p39158
sg35217
I3
sasg35208
(lp39159
(dp39160
g35211
I220
sg35212
Vbreast cancer
p39161
sg35214
I13
sg35215
VC0678222
p39162
sg35217
I2
sa(dp39163
g35211
I112
sg35212
g39144
sg35214
I3
sg35215
VC1519176
p39164
sg35217
I1
sasa(dp39165
g135
(dp39166
(VKLK2
p39167
Vbreast cancer
p39168
tp39169
I00
ssg35204
VEvery breast cancer cell line exhibited a distinct expression pattern of the nuclear receptor co-regulators examined raising the possibility that the relative levels of these co-activators/-repressors might differentially modulate androgen receptor transcriptional activity within the promoter/enhancer region of KLK2 and KLK3 of these cells.
p39170
sg35206
(lp39171
(dp39172
g35211
I231
sg35212
Vandrogen receptor
p39173
sg35214
I17
sg35223
VP10275
p39174
sg35217
I2
sa(dp39175
g35211
I322
sg35212
VKLK3
p39176
sg35214
I4
sg35223
VP03952
p39177
sg35217
I1
sa(dp39178
g35211
I313
sg35212
g39167
sg35214
I4
sg35223
VP20151
p39179
sg35217
I1
sasg35208
(lp39180
(dp39181
g35211
I6
sg35212
g39168
sg35214
I13
sg35215
VC0678222
p39182
sg35217
I2
sasa(dp39183
g135
(dp39184
(VKLK3
p39185
Vbreast cancer
p39186
tp39187
I00
ssg35204
VLike KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line.
p39188
sg35206
(lp39189
(dp39190
g35211
I5
sg35212
VKLK2
p39191
sg35214
I4
sg35223
VP20151
p39192
sg35217
I1
sa(dp39193
g35211
I14
sg35212
g39185
sg35214
I4
sg35223
VP03952
p39194
sg35217
I1
sa(dp39195
g35211
I24
sg35212
VKLK5 gene
p39196
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp39197
(dp39198
g35211
I81
sg35212
g39186
sg35214
I13
sg35215
VC0678222
p39199
sg35217
I2
sasa(dp39200
g135
(dp39201
(VKLK2
p39202
Vprostate cancer
p39203
tp39204
I00
ssg35204
VKLK2 and KLK3 have important applications in prostate cancer diagnostics and, more recently, in breast cancer diagnostics.
p39205
sg35206
(lp39206
(dp39207
g35211
I9
sg35212
VKLK3
p39208
sg35214
I4
sg35223
VP03952
p39209
sg35217
I1
sa(dp39210
g35211
I0
sg35212
g39202
sg35214
I4
sg35223
VP20151
p39211
sg35217
I1
sasg35208
(lp39212
(dp39213
g35211
I96
sg35212
Vbreast cancer
p39214
sg35214
I13
sg35215
VC0678222
p39215
sg35217
I2
sa(dp39216
g35211
I45
sg35212
g39203
sg35214
I15
sg35215
VC0600139
p39217
sg35217
I2
sasa(dp39218
g35204
VOligonucleotide 5'-SH-(A)(12)-AGACAAGAGAGG-3' (Oligo 1) modified AuNPs and oligonucleotide 5'-CAACAGAGAACG-(A)(12)-HS-3' (Oligo 2) modified AuNPs could hybridize with oligonulceotide 5'-CGTTCTCTGTTGCCTCTCTTGTCT-3' (Oligo 3), which resulted in the aggregation of Oligo-AuNPs probes, and triggered the increase of their average diameter.
p39219
sg35206
(lp39220
sg35208
(lp39221
sa(dp39222
g135
(dp39223
(VBMP-2
p39224
VCRF
p39225
tp39226
I01
ssg35204
VTo observe the effect of Bushen Huoxue Recipe (BHR) on inhibiting vascular calcification (VC) in chronic renal failure (CRF) rats by regulating BMP-2/Runx2/Osterix signal pathway, and to explore its possible mechanism.
p39227
sg35206
(lp39228
(dp39229
g35211
I144
sg35212
g39224
sg35214
I5
sg35223
VP12643
p39230
sg35217
I1
sa(dp39231
g35211
I150
sg35212
VRunx2
p39232
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39233
g35211
I156
sg35212
VOsterix
p39234
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp39235
(dp39236
g35211
I90
sg35212
VVC
p39237
sg35214
I2
sg35215
VC0342649
p39238
sg35217
I1
sa(dp39239
g35211
I66
sg35212
Vvascular calcification
p39240
sg35214
I22
sg35215
VC0342649
p39241
sg35217
I2
sa(dp39242
g35211
I97
sg35212
Vchronic renal failure
p39243
sg35214
I21
sg35215
VC0022661
p39244
sg35217
I3
sa(dp39245
g35211
I120
sg35212
g39225
sg35214
I3
sg35215
VC0022661
p39246
sg35217
I1
sasa(dp39247
g135
(dp39248
(VSrc
p39249
Vtuberculosis
p39250
tp39251
I00
ssg35204
VHere, we report that inhibition of Src significantly reduced survival of H37Rv as well as multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of M. tuberculosis in THP-1 macrophages.
p39252
sg35206
(lp39253
(dp39254
g35211
I35
sg35212
g39249
sg35214
I3
sg35223
VP12931
p39255
sg35217
I1
sasg35208
(lp39256
(dp39257
g35211
I165
sg35212
g39250
sg35214
I12
sg35215
VC0041296
p39258
sg35217
I1
sasa(dp39259
g135
(dp39260
(VSrc
p39261
Vtuberculosis infection
p39262
tp39263
I00
ssg35204
VSrc inhibition was also effective in controlling M. tuberculosis infection in guinea pigs.
p39264
sg35206
(lp39265
(dp39266
g35211
I0
sg35212
g39261
sg35214
I3
sg35223
VP12931
p39267
sg35217
I1
sasg35208
(lp39268
(dp39269
g35211
I52
sg35212
g39262
sg35214
I22
sg35215
VC0041296
p39270
sg35217
I2
sasa(dp39271
g135
(dp39272
(VSrc
p39273
Vtuberculosis
p39274
tp39275
I00
ssg35204
VIn guinea pigs, reduced M. tuberculosis burden due to Src inhibition also led to a marked decline in the disease pathology.
p39276
sg35206
(lp39277
(dp39278
g35211
I54
sg35212
g39273
sg35214
I3
sg35223
VP12931
p39279
sg35217
I1
sasg35208
(lp39280
(dp39281
g35211
I27
sg35212
g39274
sg35214
I12
sg35215
VC0041296
p39282
sg35217
I1
sa(dp39283
g35211
I113
sg35212
Vpathology
p39284
sg35214
I9
sg35215
VC0677042
p39285
sg35217
I1
sasa(dp39286
g135
(dp39287
(VSrc
p39288
Vtuberculosis
p39289
tp39290
I00
ssg35204
VWe propose that Src inhibitors could be developed into effective host-directed anti-TB drugs, which could be indiscriminately used against both drug-sensitive and drug-resistant strains of M. tuberculosis.
p39291
sg35206
(lp39292
(dp39293
g35211
I16
sg35212
g39288
sg35214
I3
sg35223
VP12931
p39294
sg35217
I1
sasg35208
(lp39295
(dp39296
g35211
I192
sg35212
g39289
sg35214
I12
sg35215
VC0041296
p39297
sg35217
I1
sasa(dp39298
g135
(dp39299
(Vtyrosine kinase Src
p39300
Vtuberculosis
p39301
tp39302
I00
ssg35204
VWe explored tyrosine kinase Src as a host factor exploited by virulent M. tuberculosis for intracellular survival.
p39303
sg35206
(lp39304
(dp39305
g35211
I12
sg35212
g39300
sg35214
I19
sg35223
VP29401
p39306
sg35217
I3
sasg35208
(lp39307
(dp39308
g35211
I74
sg35212
g39301
sg35214
I12
sg35215
VC0041296
p39309
sg35217
I1
sasa(dp39310
g135
(dp39311
(VSrc
p39312
Vtuberculosis
p39313
tp39314
I00
ssg35204
VWe show that Src inhibition can effectively control tuberculosis in infected guinea pigs.
p39315
sg35206
(lp39316
(dp39317
g35211
I13
sg35212
g39312
sg35214
I3
sg35223
VP12931
p39318
sg35217
I1
sasg35208
(lp39319
(dp39320
g35211
I52
sg35212
g39313
sg35214
I12
sg35215
VC0041296
p39321
sg35217
I1
sasa(dp39322
g35204
VIn the current study we aimed to find out the impact of cytokine-inducible Src homology 2 domain protein (CISH) gene polymorphisms on the risk of pulmonary tuberculosis (PTB) in a sample of Iranian population.
p39323
sg35206
(lp39324
(dp39325
g35211
I56
sg35212
Vcytokine-inducible Src homology 2 domain protein
p39326
sg35214
I48
sg35223
g12
sg35217
I6
sa(dp39327
g35211
I106
sg35212
VCISH
p39328
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp39329
(dp39330
g35211
I170
sg35212
VPTB
p39331
sg35214
I3
sg35215
VC0041327
p39332
sg35217
I1
sa(dp39333
g35211
I146
sg35212
Vpulmonary tuberculosis
p39334
sg35214
I22
sg35215
VC0041327
p39335
sg35217
I2
sasa(dp39336
g35204
VA recent multi-center case-control study identified several single nucleotide polymorphisms (SNPs) within the cytokine-inducible SRC homology 2 domain (CISH) gene that are associated with susceptibility to tuberculosis (TB) in both African and Asian populations.
p39337
sg35206
(lp39338
(dp39339
g35211
I152
sg35212
VCISH
p39340
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39341
g35211
I110
sg35212
Vcytokine-inducible SRC homology 2 domain
p39342
sg35214
I40
sg35223
g12
sg35217
I5
sasg35208
(lp39343
(dp39344
g35211
I220
sg35212
VTB
p39345
sg35214
I2
sg35215
VC0041296
p39346
sg35217
I1
sa(dp39347
g35211
I206
sg35212
Vtuberculosis
p39348
sg35214
I12
sg35215
VC0041296
p39349
sg35217
I1
sasa(dp39350
g135
(dp39351
(VSrc homology 2
p39352
Vtuberculosis infection
p39353
tp39354
I00
ssg35204
VAmong them, the human Cytokine-inducible Src homology 2(SH2) domain protein (CISH) gene has been very recently reported to be involved in T cell activation and differentiation in response to Mycobacterium tuberculosis infection.
p39355
sg35206
(lp39356
(dp39357
g35211
I41
sg35212
g39352
sg35214
I14
sg35223
VP12931
p39358
sg35217
I3
sasg35208
(lp39359
(dp39360
g35211
I205
sg35212
g39353
sg35214
I22
sg35215
VC0041296
p39361
sg35217
I2
sasa(dp39362
g35204
VFor the first time, we report different genetic anomalies between adult and paediatric BLs, suggesting age-related heterogeneity in Burkitt lymphomagenesis.
p39363
sg35206
(lp39364
sg35208
(lp39365
(dp39366
g35211
I87
sg35212
VBLs
p39367
sg35214
I3
sg35215
VC0005859
p39368
sg35217
I1
sa(dp39369
g35211
I140
sg35212
Vlymphomagenesis
p39370
sg35214
I15
sg35215
VC0598766
p39371
sg35217
I1
sasa(dp39372
g135
(dp39373
(VB-cell chronic lymphocytic leukemia/lymphoma 2
p39374
Vlymphoma
p39375
tp39376
I00
ssg35204
VAlthough there are conflicting data regarding prognostic implications of isolated MYC aberrancy in these non-BLs, the co-occurrence of MYC rearrangements and either the antiapoptotic gene B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL2) or the transcriptional repressor BCL6 leads to an entity termed double-hit B-cell lymphoma (DHL) (or triple-hit if all 3 abnormalities are observed) with a particularly poor prognosis and no established treatment paradigms.
p39377
sg35206
(lp39378
(dp39379
g35211
I275
sg35212
VBCL6
p39380
sg35214
I4
sg35223
VP41182
p39381
sg35217
I1
sa(dp39382
g35211
I236
sg35212
VBCL2
p39383
sg35214
I4
sg35223
VP10415
p39384
sg35217
I1
sa(dp39385
g35211
I82
sg35212
VMYC
p39386
sg35214
I3
sg35223
VP12524
p39387
sg35217
I1
sa(dp39388
g35211
I188
sg35212
g39374
sg35214
I46
sg35223
VP10415
p39389
sg35217
I5
sasg35208
(lp39390
(dp39391
g35211
I317
sg35212
VB-cell lymphoma
p39392
sg35214
I15
sg35215
VC0079731
p39393
sg35217
I2
sa(dp39394
g35211
I188
sg35212
VB-cell chronic lymphocytic leukemia
p39395
sg35214
I35
sg35215
VC1868683
p39396
sg35217
I4
sa(dp39397
g35211
I109
sg35212
VBLs
p39398
sg35214
I3
sg35215
VC0005859
p39399
sg35217
I1
sa(dp39400
g35211
I224
sg35212
g39375
sg35214
I8
sg35215
VC0024299
p39401
sg35217
I1
sasa(dp39402
g135
(dp39403
(VMYC
p39404
VBLs
p39405
tp39406
I00
ssg35204
VThe clinicopathologic findings in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) may show significant overlap, and MYC abnormalities, found in all BLs, also occur in a subset of DLBCL.
p39407
sg35206
(lp39408
(dp39409
g35211
I132
sg35212
g39404
sg35214
I3
sg35223
VP12524
p39410
sg35217
I1
sasg35208
(lp39411
(dp39412
g35211
I34
sg35212
VBurkitt lymphoma
p39413
sg35214
I16
sg35215
VC0006413
p39414
sg35217
I2
sa(dp39415
g35211
I91
sg35212
VDLBCL
p39416
sg35214
I5
sg35215
VC0079744
p39417
sg35217
I1
sa(dp39418
g35211
I91
sg35212
VDLBCL
p39419
sg35214
I5
sg35215
VC0079744
p39420
sg35217
I1
sa(dp39421
g35211
I60
sg35212
Vdiffuse large B-cell lymphoma
p39422
sg35214
I29
sg35215
VC0079744
p39423
sg35217
I4
sa(dp39424
g35211
I52
sg35212
VBL
p39425
sg35214
I2
sg35215
VC0006413
p39426
sg35217
I1
sa(dp39427
g35211
I164
sg35212
g39405
sg35214
I3
sg35215
VC0005859
p39428
sg35217
I1
sasa(dp39429
g35204
VDouble negative cases were absent in the group of BLs but could be found in approximately one third of the remaining cases of mature aggressive B-cell lymphomas.
p39430
sg35206
(lp39431
sg35208
(lp39432
(dp39433
g35211
I133
sg35212
Vaggressive
p39434
sg35214
I10
sg35215
VC0001807
p39435
sg35217
I1
sa(dp39436
g35211
I50
sg35212
VBLs
p39437
sg35214
I3
sg35215
VC0005859
p39438
sg35217
I1
sa(dp39439
g35211
I144
sg35212
VB-cell lymphomas
p39440
sg35214
I16
sg35215
VC0079731
p39441
sg35217
I2
sasa(dp39442
g135
(dp39443
(VLeptin
p39444
Vmeningioma
p39445
tp39446
I00
ssg35204
VIn particular, we determined the expression and production of several angiogenic factors including tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), Leptin, connective tissue growth factor (CTGF), meningioma-associated complimentary DNA (Mac25), basic fibroblast growth factor (bFGF), and Midkine.
p39447
sg35206
(lp39448
(dp39449
g35211
I70
sg35212
Vangiogenic factors including tissue inhibitor of matrix metalloproteinases-1
p39450
sg35214
I76
sg35223
VP19883
p39451
sg35217
I8
sa(dp39452
g35211
I254
sg35212
Vbasic fibroblast growth factor
p39453
sg35214
I30
sg35223
VP53370
p39454
sg35217
I4
sa(dp39455
g35211
I148
sg35212
VTIMP-1
p39456
sg35214
I6
sg35223
VP01033
p39457
sg35217
I1
sa(dp39458
g35211
I286
sg35212
VbFGF
p39459
sg35214
I4
sg35223
VP53370
p39460
sg35217
I1
sa(dp39461
g35211
I198
sg35212
VCTGF
p39462
sg35214
I4
sg35223
VP29279
p39463
sg35217
I1
sa(dp39464
g35211
I165
sg35212
Vconnective tissue growth factor
p39465
sg35214
I31
sg35223
VP29279
p39466
sg35217
I4
sa(dp39467
g35211
I157
sg35212
g39444
sg35214
I6
sg35223
VP41159
p39468
sg35217
I1
sasg35208
(lp39469
(dp39470
g35211
I205
sg35212
g39445
sg35214
I10
sg35215
VC0025286
p39471
sg35217
I1
sasa(dp39472
g135
(dp39473
(Vgrowth hormone receptor
p39474
Vmeningiomas
p39475
tp39476
I00
ssg35204
VAltered expression levels of several genes identified in this study have been previously noted in meningiomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2).
p39477
sg35206
(lp39478
(dp39479
g35211
I149
sg35212
Vendothelin receptor A
p39480
sg35214
I21
sg35223
g12
sg35217
I3
sa(dp39481
g35211
I172
sg35212
VIGF2
p39482
sg35214
I4
sg35223
VP01344
p39483
sg35217
I1
sa(dp39484
g35211
I115
sg35212
g39474
sg35214
I23
sg35223
VP10912
p39485
sg35217
I3
sasg35208
(lp39486
(dp39487
g35211
I98
sg35212
g39475
sg35214
I11
sg35215
VC0025286
p39488
sg35217
I1
sasa(dp39489
g35204
Vmac25, a retinoic acid-inducible gene that is expressed at high levels in senescent epithelial cells, was initially cloned as a gene that is differentially expressed in meningioma.
p39490
sg35206
(lp39491
(dp39492
g35211
I0
sg35212
Vmac25
p39493
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp39494
(dp39495
g35211
I169
sg35212
Vmeningioma
p39496
sg35214
I10
sg35215
VC0025286
p39497
sg35217
I1
sasa(dp39498
g35204
Vmac25 had previously been cloned as a discrete gene, preferentially expressed in normal, leptomeningial cells compared with meningioma tumors.
p39499
sg35206
(lp39500
(dp39501
g35211
I0
sg35212
Vmac25
p39502
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp39503
(dp39504
g35211
I135
sg35212
Vtumors
p39505
sg35214
I6
sg35215
VC0027651
p39506
sg35217
I1
sa(dp39507
g35211
I124
sg35212
Vmeningioma
p39508
sg35214
I10
sg35215
VC0025286
p39509
sg35217
I1
sasa(dp39510
g35204
VOutcome assessments included the Sheehan Panic Disorder Scale (SPS), Panic Disorder Severity Scale (PDSS), Bandelow Panic and Agoraphobia Scale (PAS), Hamilton Rating Scale for Anxiety (HAM-A), 21-point Clinician Global Improvement Scale (CGI-21), 21-point Patient Global Improvement (PGI-21) and the Sheehan Disability Scale (SDS).
p39511
sg35206
(lp39512
sg35208
(lp39513
(dp39514
g35211
I327
sg35212
VSDS
p39515
sg35214
I3
sg35215
VC0272170
p39516
sg35217
I1
sa(dp39517
g35211
I186
sg35212
VHAM
p39518
sg35214
I3
sg35215
VC0030481
p39519
sg35217
I1
sa(dp39520
g35211
I33
sg35212
VSheehan Panic Disorder Scale
p39521
sg35214
I28
sg35215
VC0085292
p39522
sg35217
I4
sa(dp39523
g35211
I126
sg35212
VAgoraphobia
p39524
sg35214
I11
sg35215
VC0001818
p39525
sg35217
I1
sa(dp39526
g35211
I63
sg35212
VSPS
p39527
sg35214
I3
sg35215
VC0085292
p39528
sg35217
I1
sa(dp39529
g35211
I301
sg35212
VSheehan Disability Scale
p39530
sg35214
I24
sg35215
VC0272170
p39531
sg35217
I3
sa(dp39532
g35211
I41
sg35212
VPanic Disorder
p39533
sg35214
I14
sg35215
VC1868649
p39534
sg35217
I2
sasa(dp39535
g135
(dp39536
(VPCP
p39537
Vspinal meningioma
p39538
tp39539
I00
ssg35204
VTaken together, the results of the present study concluded that human FAT2 may function as a key molecule that governs not only PCP, but also NF2-Hpo signaling in arachnoid cells; thus, a mutation in this gene may result in spinal meningioma.
p39540
sg35206
(lp39541
(dp39542
g35211
I146
sg35212
VHpo
p39543
sg35214
I3
sg35223
VP55789
p39544
sg35217
I1
sa(dp39545
g35211
I70
sg35212
VFAT2
p39546
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39547
g35211
I128
sg35212
g39537
sg35214
I3
sg35223
VP42785
p39548
sg35217
I1
sasg35208
(lp39549
(dp39550
g35211
I142
sg35212
VNF2
p39551
sg35214
I3
sg35215
VC0027832
p39552
sg35217
I1
sa(dp39553
g35211
I128
sg35212
VPCP
p39554
sg35214
I3
sg35215
VC2919094
p39555
sg35217
I1
sa(dp39556
g35211
I224
sg35212
g39538
sg35214
I17
sg35215
VC0347515
p39557
sg35217
I2
sasa(dp39558
g35204
VEight human STS cell lines were used: fibrosarcoma (HT1080), liposarcoma (SW872, T778, MLS-402), synovial sarcoma (SW982, SYO1, 1273), and malignant fibrous histiocytoma (U2197).
p39559
sg35206
(lp39560
sg35208
(lp39561
(dp39562
g35211
I139
sg35212
Vmalignant fibrous histiocytoma
p39563
sg35214
I30
sg35215
VC0334463
p39564
sg35217
I3
sa(dp39565
g35211
I87
sg35212
VMLS
p39566
sg35214
I3
sg35215
VC0796070
p39567
sg35217
I1
sa(dp39568
g35211
I12
sg35212
VSTS
p39569
sg35214
I3
sg35215
VC0079588
p39570
sg35217
I1
sa(dp39571
g35211
I38
sg35212
Vfibrosarcoma
p39572
sg35214
I12
sg35215
VC0016057
p39573
sg35217
I1
sa(dp39574
g35211
I61
sg35212
Vliposarcoma
p39575
sg35214
I11
sg35215
VC0023827
p39576
sg35217
I1
sa(dp39577
g35211
I97
sg35212
Vsynovial sarcoma
p39578
sg35214
I16
sg35215
VC0039101
p39579
sg35217
I2
sasa(dp39580
g35204
VVAE diminished the CI in most of the synovial sarcoma (SW982, SYO1) and liposarcoma (SW872, T778) cell lines as well as HT1080.
p39581
sg35206
(lp39582
sg35208
(lp39583
(dp39584
g35211
I72
sg35212
Vliposarcoma
p39585
sg35214
I11
sg35215
VC0023827
p39586
sg35217
I1
sa(dp39587
g35211
I37
sg35212
Vsynovial sarcoma
p39588
sg35214
I16
sg35215
VC0039101
p39589
sg35217
I2
sasa(dp39590
g35204
VA total of eight different human STS cell lines were used in the study: Fibrosarcoma (HT1080), liposarcoma (SW872, T778 and MLS-402), synovial sarcoma (SW982, SYO1 and 1273) and pleomorphic sarcoma (U2197).
p39591
sg35206
(lp39592
sg35208
(lp39593
(dp39594
g35211
I33
sg35212
VSTS
p39595
sg35214
I3
sg35215
VC0079588
p39596
sg35217
I1
sa(dp39597
g35211
I77
sg35212
Vsarcoma
p39598
sg35214
I7
sg35215
VC1261473
p39599
sg35217
I1
sa(dp39600
g35211
I72
sg35212
VFibrosarcoma
p39601
sg35214
I12
sg35215
VC0016057
p39602
sg35217
I1
sa(dp39603
g35211
I124
sg35212
VMLS
p39604
sg35214
I3
sg35215
VC0796070
p39605
sg35217
I1
sa(dp39606
g35211
I95
sg35212
Vliposarcoma
p39607
sg35214
I11
sg35215
VC0023827
p39608
sg35217
I1
sa(dp39609
g35211
I134
sg35212
Vsynovial sarcoma
p39610
sg35214
I16
sg35215
VC0039101
p39611
sg35217
I2
sasa(dp39612
g35204
VIn SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/Beta-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels.
p39613
sg35206
(lp39614
(dp39615
g35211
I170
sg35212
VAXIN2 protein
p39616
sg35214
I13
sg35223
g12
sg35217
I2
sasg35208
(lp39617
(dp39618
g35211
I9
sg35212
Vsynovial sarcoma
p39619
sg35214
I16
sg35215
VC0039101
p39620
sg35217
I2
sa(dp39621
g35211
I129
sg35212
Vtumor growth
p39622
sg35214
I12
sg35215
VC0598934
p39623
sg35217
I2
sasa(dp39624
g35204
VThese plasmids were transfected in synovial sarcoma SYO-1 cells and we observed the expression of these proteins using a fluorescence microscope.
p39625
sg35206
(lp39626
sg35208
(lp39627
(dp39628
g35211
I35
sg35212
Vsynovial sarcoma
p39629
sg35214
I16
sg35215
VC0039101
p39630
sg35217
I2
sasa(dp39631
g35204
VFurthermore, cell proliferation and colony formation of synovial sarcoma SYO-1 and YaFuSS cells were suppressed by exogenous tSSX expression.
p39632
sg35206
(lp39633
sg35208
(lp39634
(dp39635
g35211
I18
sg35212
Vproliferation
p39636
sg35214
I13
sg35215
VC0334094
p39637
sg35217
I1
sa(dp39638
g35211
I56
sg35212
Vsynovial sarcoma
p39639
sg35214
I16
sg35215
VC0039101
p39640
sg35217
I2
sasa(dp39641
g135
(dp39642
(Vinterleukin (IL)-6
p39643
VPsoriasis
p39644
tp39645
I00
ssg35204
VPsoriasis area and severity index (PASI), serum P-selectin and interleukin (IL)-6 were monitored throughout the treatment.
p39646
sg35206
(lp39647
(dp39648
g35211
I42
sg35212
Vserum P-selectin
p39649
sg35214
I16
sg35223
VP16109
p39650
sg35217
I2
sa(dp39651
g35211
I63
sg35212
g39643
sg35214
I18
sg35223
VP60568
p39652
sg35217
I2
sasg35208
(lp39653
(dp39654
g35211
I0
sg35212
g39644
sg35214
I9
sg35215
VC0033860
p39655
sg35217
I1
sasa(dp39656
g135
(dp39657
(VP-selectin
p39658
Vpsoriasis
p39659
tp39660
I00
ssg35204
VWe aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-Alfa therapy.
p39661
sg35206
(lp39662
(dp39663
g35211
I41
sg35212
Vendothelial activation biomarkers monocyte chemoattractant protein 1
p39664
sg35214
I68
sg35223
VP14222
p39665
sg35217
I7
sa(dp39666
g35211
I227
sg35212
Vanti-TNF-Alfa
p39667
sg35214
I13
sg35223
VP01375
p39668
sg35217
I1
sa(dp39669
g35211
I146
sg35212
g39658
sg35214
I10
sg35223
VP16109
p39670
sg35217
I1
sasg35208
(lp39671
(dp39672
g35211
I195
sg35212
g39659
sg35214
I9
sg35215
VC0033860
p39673
sg35217
I1
sasa(dp39674
g135
(dp39675
(VPlasma soluble P-selectin
p39676
Vpsoriasis
p39677
tp39678
I00
ssg35204
VPlasma soluble P-selectin concentrations, PDMP and platelet aggregation were significantly elevated in patients with psoriasis, as compared to controls.
p39679
sg35206
(lp39680
(dp39681
g35211
I0
sg35212
g39676
sg35214
I25
sg35223
VP16109
p39682
sg35217
I3
sasg35208
(lp39683
(dp39684
g35211
I117
sg35212
g39677
sg35214
I9
sg35215
VC0033860
p39685
sg35217
I1
sasa(dp39686
g35204
VMost efficient among them is the newly identified SOXN (neuroblastoma-derived sulfhydryl oxidase), which comprises 12 exons and maps to 9q34.3.
p39687
sg35206
(lp39688
sg35208
(lp39689
(dp39690
g35211
I56
sg35212
Vneuroblastoma
p39691
sg35214
I13
sg35215
VC0027819
p39692
sg35217
I1
sasa(dp39693
g135
(dp39694
(VIFN-gamma
p39695
Vneuroblastoma
p39696
tp39697
I00
ssg35204
VThese results identify SOXN as a major player in regulating the sensitization of neuroblastoma cells for IFN-gamma-induced apoptosis.
p39698
sg35206
(lp39699
(dp39700
g35211
I105
sg35212
g39695
sg35214
I9
sg35223
VP01579
p39701
sg35217
I1
sa(dp39702
g35211
I23
sg35212
VSOXN
p39703
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp39704
(dp39705
g35211
I81
sg35212
g39696
sg35214
I13
sg35215
VC0027819
p39706
sg35217
I1
sasa(dp39707
g35204
VThe cartilage proteins melanoma inhibitory activity (MIA) and human cartilage gp-39 (HC gp-39) are candidate autoantigens in rheumatoid arthritis (RA).
p39708
sg35206
(lp39709
sg35208
(lp39710
(dp39711
g35211
I125
sg35212
Vrheumatoid arthritis
p39712
sg35214
I20
sg35215
VC0003873
p39713
sg35217
I2
sa(dp39714
g35211
I23
sg35212
Vmelanoma
p39715
sg35214
I8
sg35215
VC0025202
p39716
sg35217
I1
sa(dp39717
g35211
I147
sg35212
VRA
p39718
sg35214
I2
sg35215
VC0003873
p39719
sg35217
I1
sasa(dp39720
g35204
VThe presented results confirm expression of CDRAP by normal and osteoarthritic articular chondrocytes, but indicate that increased expression levels by chondrocytes are not the cause of the increased levels of CDRAP in the synovial fluid of patients with osteoarthritis.
p39721
sg35206
(lp39722
(dp39723
g35211
I44
sg35212
VCDRAP
p39724
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp39725
g35211
I44
sg35212
VCDRAP
p39726
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp39727
(dp39728
g35211
I255
sg35212
Vosteoarthritis
p39729
sg35214
I14
sg35215
VC0029408
p39730
sg35217
I1
sasa(dp39731
g35204
VWe have measured the concentration of cartilage-derived retinoic-acid-sensitive protein (CD-RAP) in synovial fluid (SF) from the knees of 49 patients with osteoarthritis (OA) and 79 with rheumatoid arthritis (RA) in order to investigate the correlation between the type of joint disease and level of CD-RAP.
p39732
sg35206
(lp39733
sg35208
(lp39734
(dp39735
g35211
I92
sg35212
VRA
p39736
sg35214
I2
sg35215
VC0003873
p39737
sg35217
I1
sa(dp39738
g35211
I171
sg35212
VOA
p39739
sg35214
I2
sg35215
VC0029408
p39740
sg35217
I1
sa(dp39741
g35211
I155
sg35212
Vosteoarthritis
p39742
sg35214
I14
sg35215
VC0029408
p39743
sg35217
I1
sa(dp39744
g35211
I187
sg35212
Vrheumatoid arthritis
p39745
sg35214
I20
sg35215
VC0003873
p39746
sg35217
I2
sa(dp39747
g35211
I273
sg35212
Vjoint disease
p39748
sg35214
I13
sg35215
VC0022408
p39749
sg35217
I2
sasa(dp39750
g135
(dp39751
(VTSC2
p39752
VTSC2
p39753
tp39754
I00
ssg35204
VIn this study, we demonstrated that osteopontin (OPN) was dramatically reduced by loss of TSC1/TSC2 complex in Tsc2-null mouse embryonic fibroblasts (MEFs), rat uterine leiomyoma-derived Tsc2-deficient cells, genetically modified mouse TSC models, and clinical samples.
p39755
sg35206
(lp39756
(dp39757
g35211
I111
sg35212
VTsc2
p39758
sg35214
I4
sg35223
VP49815
p39759
sg35217
I1
sa(dp39760
g35211
I49
sg35212
VOPN
p39761
sg35214
I3
sg35223
VP10451
p39762
sg35217
I1
sa(dp39763
g35211
I90
sg35212
VTSC1
p39764
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp39765
g35211
I36
sg35212
Vosteopontin
p39766
sg35214
I11
sg35223
VP10451
p39767
sg35217
I1
sa(dp39768
g35211
I111
sg35212
VTsc2
p39769
sg35214
I4
sg35223
VP49815
p39770
sg35217
I1
sa(dp39771
g35211
I95
sg35212
g39752
sg35214
I4
sg35223
VP49815
p39772
sg35217
I1
sasg35208
(lp39773
(dp39774
g35211
I111
sg35212
VTsc2
p39775
sg35214
I4
sg35215
VC1860707
p39776
sg35217
I1
sa(dp39777
g35211
I161
sg35212
Vuterine leiomyoma
p39778
sg35214
I17
sg35215
VC0042133
p39779
sg35217
I2
sa(dp39780
g35211
I90
sg35212
VTSC1
p39781
sg35214
I4
sg35215
VC1854465
p39782
sg35217
I1
sa(dp39783
g35211
I90
sg35212
VTSC
p39784
sg35214
I3
sg35215
VC0041341
p39785
sg35217
I1
sa(dp39786
g35211
I111
sg35212
VTsc2
p39787
sg35214
I4
sg35215
VC1860707
p39788
sg35217
I1
sa(dp39789
g35211
I95
sg35212
g39753
sg35214
I4
sg35215
VC1860707
p39790
sg35217
I1
sasa(dp39791
g135
(dp39792
(VTSC2
p39793
VTSC2
p39794
tp39795
I00
ssg35204
VTSC2-deficient Eker rat uterine leiomyoma ELT3 cells were stably transfected with empty vector or plasmid for the expression of TSC2.
p39796
sg35206
(lp39797
(dp39798
g35211
I0
sg35212
VTSC2
p39799
sg35214
I4
sg35223
VP49815
p39800
sg35217
I1
sa(dp39801
g35211
I0
sg35212
g39793
sg35214
I4
sg35223
VP49815
p39802
sg35217
I1
sasg35208
(lp39803
(dp39804
g35211
I0
sg35212
VTSC2
p39805
sg35214
I4
sg35215
VC1860707
p39806
sg35217
I1
sa(dp39807
g35211
I24
sg35212
Vuterine leiomyoma
p39808
sg35214
I17
sg35215
VC0042133
p39809
sg35217
I2
sa(dp39810
g35211
I0
sg35212
g39794
sg35214
I4
sg35215
VC1860707
p39811
sg35217
I1
sasa(dp39812
g135
(dp39813
(Vcyclooxygenase 2
p39814
VTsc2
p39815
tp39816
I00
ssg35204
VBy analyzing Tsc2-null mouse embryonic fibroblasts (MEFs) and rat uterine leiomyoma-derived Tsc2-null ELT3 cells, we detected evidence for the involvement of cyclooxygenase 2 (COX2) as a downstream target of mTORC1 in the development of TSC tumors.
p39817
sg35206
(lp39818
(dp39819
g35211
I13
sg35212
VTsc2
p39820
sg35214
I4
sg35223
VP49815
p39821
sg35217
I1
sa(dp39822
g35211
I13
sg35212
VTsc2
p39823
sg35214
I4
sg35223
VP49815
p39824
sg35217
I1
sa(dp39825
g35211
I176
sg35212
VCOX2
p39826
sg35214
I4
sg35223
VP35354
p39827
sg35217
I1
sa(dp39828
g35211
I158
sg35212
g39814
sg35214
I16
sg35223
VP35354
p39829
sg35217
I2
sasg35208
(lp39830
(dp39831
g35211
I66
sg35212
Vuterine leiomyoma
p39832
sg35214
I17
sg35215
VC0042133
p39833
sg35217
I2
sa(dp39834
g35211
I237
sg35212
VTSC
p39835
sg35214
I3
sg35215
VC0041341
p39836
sg35217
I1
sa(dp39837
g35211
I13
sg35212
VTsc2
p39838
sg35214
I4
sg35215
VC1860707
p39839
sg35217
I1
sa(dp39840
g35211
I13
sg35212
g39815
sg35214
I4
sg35215
VC1860707
p39841
sg35217
I1
sa(dp39842
g35211
I241
sg35212
Vtumors
p39843
sg35214
I6
sg35215
VC0027651
p39844
sg35217
I1
sasa(dp39845
g135
(dp39846
(VTSC2
p39847
VTSC2
p39848
tp39849
I00
ssg35204
VTSC2-positive and TSC2-negative mouse embryonic fibroblasts (MEF), 323-TSC2-positive and 323-TSC2-null MEF and Eker rat uterine leiomyoma (ELT3) cells were treated with doxycycline or rapamycin alone, or in combination.
p39850
sg35206
(lp39851
(dp39852
g35211
I0
sg35212
VTSC2
p39853
sg35214
I4
sg35223
VP49815
p39854
sg35217
I1
sa(dp39855
g35211
I0
sg35212
VTSC2
p39856
sg35214
I4
sg35223
VP49815
p39857
sg35217
I1
sa(dp39858
g35211
I0
sg35212
VTSC2
p39859
sg35214
I4
sg35223
VP49815
p39860
sg35217
I1
sa(dp39861
g35211
I0
sg35212
g39847
sg35214
I4
sg35223
VP49815
p39862
sg35217
I1
sasg35208
(lp39863
(dp39864
g35211
I0
sg35212
VTSC2
p39865
sg35214
I4
sg35215
VC1860707
p39866
sg35217
I1
sa(dp39867
g35211
I0
sg35212
VTSC2
p39868
sg35214
I4
sg35215
VC1860707
p39869
sg35217
I1
sa(dp39870
g35211
I0
sg35212
VTSC2
p39871
sg35214
I4
sg35215
VC1860707
p39872
sg35217
I1
sa(dp39873
g35211
I120
sg35212
Vuterine leiomyoma
p39874
sg35214
I17
sg35215
VC0042133
p39875
sg35217
I2
sa(dp39876
g35211
I0
sg35212
g39848
sg35214
I4
sg35215
VC1860707
p39877
sg35217
I1
sasa(dp39878
g135
(dp39879
(VTSC2-deficient mouse embryonic fibroblast
p39880
VTsc2
p39881
tp39882
I00
ssg35204
VImportantly, rapamycin treatment did not affect the expression of AdPLA2 and the production of PGE2 by TSC2-deficient mouse embryonic fibroblast (Tsc2-/-MEFs), rat uterine leiomyoma-derived ELT3 cells, and LAM patient-associated renal angiomyolipoma-derived "mesenchymal" cells.
p39883
sg35206
(lp39884
(dp39885
g35211
I146
sg35212
VTsc2-/-MEFs
p39886
sg35214
I11
sg35223
VP49815
p39887
sg35217
I1
sa(dp39888
g35211
I103
sg35212
g39880
sg35214
I41
sg35223
VP49815
p39889
sg35217
I4
sasg35208
(lp39890
(dp39891
g35211
I229
sg35212
Vrenal angiomyolipoma
p39892
sg35214
I20
sg35215
VC0241961
p39893
sg35217
I2
sa(dp39894
g35211
I206
sg35212
VLAM
p39895
sg35214
I3
sg35215
VC0751674
p39896
sg35217
I1
sa(dp39897
g35211
I164
sg35212
Vuterine leiomyoma
p39898
sg35214
I17
sg35215
VC0042133
p39899
sg35217
I2
sa(dp39900
g35211
I103
sg35212
VTSC2
p39901
sg35214
I4
sg35215
VC1860707
p39902
sg35217
I1
sa(dp39903
g35211
I146
sg35212
g39881
sg35214
I4
sg35215
VC1860707
p39904
sg35217
I1
sasa(dp39905
g135
(dp39906
(VTuberous Sclerosis 2
p39907
VTuberous Sclerosis 2
p39908
tp39909
I00
ssg35204
VLoss of the Tuberous Sclerosis 2 (TSC2) tumor suppressor has been proposed as a mechanism important for the etiology of uterine leiomyomata based on the Eker rat model.
p39910
sg35206
(lp39911
(dp39912
g35211
I34
sg35212
VTSC2
p39913
sg35214
I4
sg35223
VP49815
p39914
sg35217
I1
sa(dp39915
g35211
I12
sg35212
g39907
sg35214
I20
sg35223
VP49815
p39916
sg35217
I3
sasg35208
(lp39917
(dp39918
g35211
I120
sg35212
Vuterine leiomyomata
p39919
sg35214
I19
sg35215
VC0042133
p39920
sg35217
I2
sa(dp39921
g35211
I34
sg35212
VTSC2
p39922
sg35214
I4
sg35215
VC1860707
p39923
sg35217
I1
sa(dp39924
g35211
I12
sg35212
g39908
sg35214
I20
sg35215
VC1860707
p39925
sg35217
I3
sa(dp39926
g35211
I40
sg35212
Vtumor
p39927
sg35214
I5
sg35215
VC0027651
p39928
sg35217
I1
sasa(dp39929
g135
(dp39930
(VTSC2
p39931
VTSC2
p39932
tp39933
I00
ssg35204
VHowever, conflicting evidence showing increased TSC2 expression has been reported in human uterine leiomyomata, suggesting that TSC2 might not be involved in the pathogenesis of this disorder.
p39934
sg35206
(lp39935
(dp39936
g35211
I48
sg35212
VTSC2
p39937
sg35214
I4
sg35223
VP49815
p39938
sg35217
I1
sa(dp39939
g35211
I48
sg35212
g39931
sg35214
I4
sg35223
VP49815
p39940
sg35217
I1
sasg35208
(lp39941
(dp39942
g35211
I162
sg35212
Vpathogenesis
p39943
sg35214
I12
sg35215
VC0699748
p39944
sg35217
I1
sa(dp39945
g35211
I91
sg35212
Vuterine leiomyomata
p39946
sg35214
I19
sg35215
VC0042133
p39947
sg35217
I2
sa(dp39948
g35211
I48
sg35212
VTSC2
p39949
sg35214
I4
sg35215
VC1860707
p39950
sg35217
I1
sa(dp39951
g35211
I48
sg35212
g39932
sg35214
I4
sg35215
VC1860707
p39952
sg35217
I1
sasa(dp39953
g135
(dp39954
(VERK1/2
p39955
Vuterine leiomyoma
p39956
tp39957
I00
ssg35204
VIn cell culture models of TSC2-deficient LAM patient-derived and rat uterine leiomyoma-derived cells, we found that progesterone treatment or progesterone plus estradiol resulted in increased phosphorylation of Protein Kinase B (Akt) and Extracellular signal-regulated kinases1/2 (ERK1/2), induced the proliferation, and enhanced the migration and invasiveness.
p39958
sg35206
(lp39959
(dp39960
g35211
I211
sg35212
VProtein Kinase B
p39961
sg35214
I16
sg35223
VP31749
p39962
sg35217
I3
sa(dp39963
g35211
I26
sg35212
VTSC2
p39964
sg35214
I4
sg35223
VP49815
p39965
sg35217
I1
sa(dp39966
g35211
I238
sg35212
VExtracellular signal-regulated kinases1/2
p39967
sg35214
I41
sg35223
VP35555
p39968
sg35217
I3
sa(dp39969
g35211
I229
sg35212
VAkt
p39970
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp39971
g35211
I281
sg35212
g39955
sg35214
I6
sg35223
VP27361
p39972
sg35217
I1
sasg35208
(lp39973
(dp39974
g35211
I41
sg35212
VLAM
p39975
sg35214
I3
sg35215
VC0751674
p39976
sg35217
I1
sa(dp39977
g35211
I302
sg35212
Vproliferation
p39978
sg35214
I13
sg35215
VC0334094
p39979
sg35217
I1
sa(dp39980
g35211
I26
sg35212
VTSC2
p39981
sg35214
I4
sg35215
VC1860707
p39982
sg35217
I1
sa(dp39983
g35211
I69
sg35212
g39956
sg35214
I17
sg35215
VC0042133
p39984
sg35217
I2
sasa(dp39985
g135
(dp39986
(VTsc2
p39987
Vlung lymphangioleiomyomatosis
p39988
tp39989
I00
ssg35204
VWe report here that expression of AlfaB-crystallin was upregulated in Tsc1-/- or Tsc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules.
p39990
sg35206
(lp39991
(dp39992
g35211
I81
sg35212
VTsc2
p39993
sg35214
I4
sg35223
VP49815
p39994
sg35217
I1
sa(dp39995
g35211
I34
sg35212
VAlfaB-crystallin
p39996
sg35214
I16
sg35223
VP22914
p39997
sg35217
I1
sa(dp39998
g35211
I81
sg35212
VTsc2
p39999
sg35214
I4
sg35223
VP49815
p40000
sg35217
I1
sa(dp40001
g35211
I81
sg35212
g39987
sg35214
I4
sg35223
VP49815
p40002
sg35217
I1
sa(dp40003
g35211
I70
sg35212
VTsc1
p40004
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40005
(dp40006
g35211
I81
sg35212
VTsc2
p40007
sg35214
I4
sg35215
VC1860707
p40008
sg35217
I1
sa(dp40009
g35211
I70
sg35212
VTsc1
p40010
sg35214
I4
sg35215
VC1854465
p40011
sg35217
I1
sa(dp40012
g35211
I209
sg35212
Vkidney tumors
p40013
sg35214
I13
sg35215
VC0022665
p40014
sg35217
I2
sa(dp40015
g35211
I81
sg35212
VTsc2
p40016
sg35214
I4
sg35215
VC1860707
p40017
sg35217
I1
sa(dp40018
g35211
I264
sg35212
Vnodules
p40019
sg35214
I7
sg35215
VC0028259
p40020
sg35217
I1
sa(dp40021
g35211
I127
sg35212
Vuterine leiomyoma
p40022
sg35214
I17
sg35215
VC0042133
p40023
sg35217
I2
sa(dp40024
g35211
I81
sg35212
VTsc2
p40025
sg35214
I4
sg35215
VC1860707
p40026
sg35217
I1
sa(dp40027
g35211
I180
sg35212
Vmutant
p40028
sg35214
I6
sg35215
VC0596988
p40029
sg35217
I1
sa(dp40030
g35211
I234
sg35212
g39988
sg35214
I29
sg35215
VC0349649
p40031
sg35217
I2
sasa(dp40032
g135
(dp40033
(Vtuberous sclerosis complex 2
p40034
Vuterine leiomyoma
p40035
tp40036
I00
ssg35204
VFemale Eker rats harboring an insertional deletion in one copy of the tuberous sclerosis complex 2 (Tsc2) gene develop uterine leiomyoma, but the underlying mechanism of human uterine leiomyoma is not completely understood.
p40037
sg35206
(lp40038
(dp40039
g35211
I100
sg35212
VTsc2
p40040
sg35214
I4
sg35223
VP49815
p40041
sg35217
I1
sa(dp40042
g35211
I70
sg35212
g40034
sg35214
I28
sg35223
VP49815
p40043
sg35217
I4
sasg35208
(lp40044
(dp40045
g35211
I119
sg35212
Vuterine leiomyoma
p40046
sg35214
I17
sg35215
VC0042133
p40047
sg35217
I2
sa(dp40048
g35211
I100
sg35212
VTsc2
p40049
sg35214
I4
sg35215
VC1860707
p40050
sg35217
I1
sa(dp40051
g35211
I70
sg35212
Vtuberous sclerosis complex 2
p40052
sg35214
I28
sg35215
VC1860707
p40053
sg35217
I4
sa(dp40054
g35211
I119
sg35212
g40035
sg35214
I17
sg35215
VC0042133
p40055
sg35217
I2
sasa(dp40056
g135
(dp40057
(Vmitogen-activated protein kinase
p40058
VTSC2
p40059
tp40060
I00
ssg35204
VTo examine whether down-regulation of tuberin, a TSC2 gene product, is present in human uterine leiomyoma, we analyzed leiomyoma and matched myometrium tissues from 22 Chinese patients with Western blotting and real-time polymerase chain reaction analyses, and found that the expression of tuberin was significantly increased in leiomyoma tissues compared with matched myometrium tissues with inhibition of both the mammalian target of rapacmycin pathway and mitogen-activated protein kinase pathways.
p40061
sg35206
(lp40062
(dp40063
g35211
I38
sg35212
Vtuberin
p40064
sg35214
I7
sg35223
VP49815
p40065
sg35217
I1
sa(dp40066
g35211
I49
sg35212
VTSC2 gene product
p40067
sg35214
I17
sg35223
VP49815
p40068
sg35217
I3
sa(dp40069
g35211
I38
sg35212
Vtuberin
p40070
sg35214
I7
sg35223
VP49815
p40071
sg35217
I1
sa(dp40072
g35211
I459
sg35212
g40058
sg35214
I32
sg35223
VP53779
p40073
sg35217
I3
sasg35208
(lp40074
(dp40075
g35211
I96
sg35212
Vleiomyoma
p40076
sg35214
I9
sg35215
VC0042133
p40077
sg35217
I1
sa(dp40078
g35211
I88
sg35212
Vuterine leiomyoma
p40079
sg35214
I17
sg35215
VC0042133
p40080
sg35217
I2
sa(dp40081
g35211
I96
sg35212
Vleiomyoma
p40082
sg35214
I9
sg35215
VC0042133
p40083
sg35217
I1
sa(dp40084
g35211
I49
sg35212
g40059
sg35214
I4
sg35215
VC1860707
p40085
sg35217
I1
sasa(dp40086
g135
(dp40087
(VTsc2-null
p40088
VTsc2
p40089
tp40090
I00
ssg35204
VCells derived from an Eker rat uterine leiomyoma (ELT3 cells) are Tsc2-null and these have been used in a rodent cell models for LAM.
p40091
sg35206
(lp40092
(dp40093
g35211
I66
sg35212
g40088
sg35214
I9
sg35223
VP49815
p40094
sg35217
I1
sasg35208
(lp40095
(dp40096
g35211
I129
sg35212
VLAM
p40097
sg35214
I3
sg35215
VC0751674
p40098
sg35217
I1
sa(dp40099
g35211
I31
sg35212
Vuterine leiomyoma
p40100
sg35214
I17
sg35215
VC0042133
p40101
sg35217
I2
sa(dp40102
g35211
I66
sg35212
g40089
sg35214
I4
sg35215
VC1860707
p40103
sg35217
I1
sasa(dp40104
g135
(dp40105
(Vfurin
p40106
Vrheumatoid arthritis
p40107
tp40108
I00
ssg35204
VIn patients with rheumatoid arthritis, furin is reported to be highly expressed in the synovial pannus compared with healthy persons.
p40109
sg35206
(lp40110
(dp40111
g35211
I39
sg35212
g40106
sg35214
I5
sg35223
VP09958
p40112
sg35217
I1
sasg35208
(lp40113
(dp40114
g35211
I96
sg35212
Vpannus
p40115
sg35214
I6
sg35215
VC0155094
p40116
sg35217
I1
sa(dp40117
g35211
I17
sg35212
g40107
sg35214
I20
sg35215
VC0003873
p40118
sg35217
I2
sasa(dp40119
g135
(dp40120
(Vfurin
p40121
Vrheumatoid arthritis
p40122
tp40123
I00
ssg35204
VInhibition of furin enhances invasive phenotype of synoviocytes from patients with rheumatoid arthritis, implying a protective role of furin.
p40124
sg35206
(lp40125
(dp40126
g35211
I14
sg35212
Vfurin
p40127
sg35214
I5
sg35223
VP09958
p40128
sg35217
I1
sa(dp40129
g35211
I14
sg35212
g40121
sg35214
I5
sg35223
VP09958
p40130
sg35217
I1
sasg35208
(lp40131
(dp40132
g35211
I83
sg35212
g40122
sg35214
I20
sg35215
VC0003873
p40133
sg35217
I2
sasa(dp40134
g135
(dp40135
(Vfurin
p40136
Vrheumatoid arthritis
p40137
tp40138
I00
ssg35204
VAgents targeting upregulation of furin may have therapeutic potential for rheumatoid arthritis.
p40139
sg35206
(lp40140
(dp40141
g35211
I33
sg35212
g40136
sg35214
I5
sg35223
VP09958
p40142
sg35217
I1
sasg35208
(lp40143
(dp40144
g35211
I74
sg35212
g40137
sg35214
I20
sg35215
VC0003873
p40145
sg35217
I2
sasa(dp40146
g135
(dp40147
(Vfurin
p40148
Varthritis
p40149
tp40150
I00
ssg35204
VThe effect of furin and its inhibitor Alfa1-PDX was tested in mice with collagen-induced arthritis (CIA).
p40151
sg35206
(lp40152
(dp40153
g35211
I14
sg35212
g40148
sg35214
I5
sg35223
VP09958
p40154
sg35217
I1
sasg35208
(lp40155
(dp40156
g35211
I89
sg35212
g40149
sg35214
I9
sg35215
VC0003864
p40157
sg35217
I1
sasa(dp40158
g135
(dp40159
(Vfurin
p40160
Vbone loss
p40161
tp40162
I00
ssg35204
VSystemic administration of furin prevented increases in the arthritis score, joint destruction, and bone loss, in contrast to systemic administration of the furin inhibitor Alfa1-PDX, which enhanced these parameters.
p40163
sg35206
(lp40164
(dp40165
g35211
I27
sg35212
Vfurin
p40166
sg35214
I5
sg35223
VP09958
p40167
sg35217
I1
sa(dp40168
g35211
I27
sg35212
g40160
sg35214
I5
sg35223
VP09958
p40169
sg35217
I1
sasg35208
(lp40170
(dp40171
g35211
I60
sg35212
Varthritis
p40172
sg35214
I9
sg35215
VC0003864
p40173
sg35217
I1
sa(dp40174
g35211
I100
sg35212
g40161
sg35214
I9
sg35215
VC0029453
p40175
sg35217
I2
sasa(dp40176
g135
(dp40177
(Vfurin
p40178
Varthritis
p40179
tp40180
I00
ssg35204
VThey also suggest that Adamts5 induction in joint components other than cartilage, and its post-translational activation by PACE4 and/or furin may be important in the pathophysiology of arthritis.
p40181
sg35206
(lp40182
(dp40183
g35211
I23
sg35212
VAdamts5
p40184
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp40185
g35211
I137
sg35212
g40178
sg35214
I5
sg35223
VP09958
p40186
sg35217
I1
sasg35208
(lp40187
(dp40188
g35211
I186
sg35212
g40179
sg35214
I9
sg35215
VC0003864
p40189
sg35217
I1
sasa(dp40190
g135
(dp40191
(Vp10
p40192
Vpreterm labor
p40193
tp40194
I00
ssg35204
VWhen comparing the chorioamniotic membranes from women in spontaneous preterm labor with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the mRNA of NLR family pyrin domain-containing protein ( NLRP) 1, NLRP3, NLR family CARD domain-containing protein 4 ( NLRC4), and NOD2 were higher; (2) the NLRP3 protein was increased; (3) the mRNA and active form (p10) of CASP-1 were greater; (4) the mRNA and active form of CASP-4 were increased; (5) the mRNA and mature form of IL-1Beta were higher; (6) the mature form of IL-18 was elevated; and (7) ASC/CASP-1 complex formation was increased.
p40195
sg35206
(lp40196
(dp40197
g35211
I193
sg35212
VNLR family pyrin domain-containing protein ( NLRP) 1
p40198
sg35214
I52
sg35223
g12
sg35217
I8
sa(dp40199
g35211
I513
sg35212
VIL-1Beta
p40200
sg35214
I8
sg35223
VP01584
p40201
sg35217
I1
sa(dp40202
g35211
I300
sg35212
VNLRC4
p40203
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40204
g35211
I254
sg35212
VNLR family CARD domain-containing protein 4
p40205
sg35214
I43
sg35223
g12
sg35217
I6
sa(dp40206
g35211
I458
sg35212
VCASP-4
p40207
sg35214
I6
sg35223
VP39880
p40208
sg35217
I1
sa(dp40209
g35211
I405
sg35212
VCASP-1
p40210
sg35214
I6
sg35223
VP39880
p40211
sg35217
I1
sa(dp40212
g35211
I312
sg35212
VNOD2
p40213
sg35214
I4
sg35223
VP22301
p40214
sg35217
I1
sa(dp40215
g35211
I397
sg35212
g40192
sg35214
I3
sg35223
VP60903
p40216
sg35217
I1
sasg35208
(lp40217
(dp40218
g35211
I106
sg35212
Vchorioamnionitis
p40219
sg35214
I16
sg35215
VC0008495
p40220
sg35217
I1
sa(dp40221
g35211
I70
sg35212
g40193
sg35214
I13
sg35215
VC0022876
p40222
sg35217
I2
sasa(dp40223
g135
(dp40224
(VNOD2
p40225
Vmelanoma
p40226
tp40227
I00
ssg35204
VWhen comparing the chorioamniotic membranes from women in spontaneous labor at term with acute histologic chorioamnionitis to those without this placental lesion, we found that (1) the messenger RNA (mRNA) abundance of NLR family pyrin domain containing 3 ( NLRP3), NLR family CARD domain containing 4 ( NLRC4), absent in melanoma 2 ( AIM2), and nucleotide binding oligomerization domain 2 ( NOD2) was higher; (2) the NLRP3 and NLRC4 protein quantities were increased; (3) the mRNA and protein expressions of CASP-1 and its active forms were greater; (4) CASP-4 was increased at the mRNA level only; (5) the mRNA and protein expressions of IL-1Beta and its mature form were higher; and (6) a modest increase in the total protein concentration and abundance of the mature form of IL-18 was observed.
p40228
sg35206
(lp40229
(dp40230
g35211
I335
sg35212
VAIM2
p40231
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40232
g35211
I266
sg35212
VNLR family CARD domain containing 4
p40233
sg35214
I35
sg35223
g12
sg35217
I6
sa(dp40234
g35211
I640
sg35212
VIL-1Beta
p40235
sg35214
I8
sg35223
VP01584
p40236
sg35217
I1
sa(dp40237
g35211
I304
sg35212
VNLRC4
p40238
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40239
g35211
I509
sg35212
VCASP-1
p40240
sg35214
I6
sg35223
VP39880
p40241
sg35217
I1
sa(dp40242
g35211
I219
sg35212
VNLR family pyrin domain containing 3
p40243
sg35214
I36
sg35223
g12
sg35217
I6
sa(dp40244
g35211
I346
sg35212
Vnucleotide binding oligomerization domain 2
p40245
sg35214
I43
sg35223
VP63244
p40246
sg35217
I5
sa(dp40247
g35211
I428
sg35212
VNLRC4 protein
p40248
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp40249
g35211
I392
sg35212
g40225
sg35214
I4
sg35223
VP22301
p40250
sg35217
I1
sasg35208
(lp40251
(dp40252
g35211
I106
sg35212
Vchorioamnionitis
p40253
sg35214
I16
sg35215
VC0008495
p40254
sg35217
I1
sa(dp40255
g35211
I322
sg35212
g40226
sg35214
I8
sg35215
VC0025202
p40256
sg35217
I1
sasa(dp40257
g135
(dp40258
(VNOD-like-receptor family
p40259
VHYDM1
p40260
tp40261
I01
ssg35204
VMutations in NLRP7 (NOD-like-receptor family, pyrin domain containing 7) are responsible for a type of recurrent pregnancy loss known as recurrent hydatidiform mole (HYDM1).
p40262
sg35206
(lp40263
(dp40264
g35211
I20
sg35212
g40259
sg35214
I24
sg35223
VP54259
p40265
sg35217
I2
sa(dp40266
g35211
I13
sg35212
VNLRP7
p40267
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40268
g35211
I46
sg35212
Vpyrin domain containing 7
p40269
sg35214
I25
sg35223
g12
sg35217
I4
sasg35208
(lp40270
(dp40271
g35211
I20
sg35212
VNOD
p40272
sg35214
I3
sg35215
VC0751781
p40273
sg35217
I1
sa(dp40274
g35211
I103
sg35212
Vrecurrent pregnancy loss
p40275
sg35214
I24
sg35215
VC2921106
p40276
sg35217
I3
sa(dp40277
g35211
I147
sg35212
Vhydatidiform mole
p40278
sg35214
I17
sg35215
VC0020217
p40279
sg35217
I2
sa(dp40280
g35211
I166
sg35212
g40260
sg35214
I5
sg35215
VC3463897
p40281
sg35217
I1
sasa(dp40282
g35204
VNRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown.
p40283
sg35206
(lp40284
sg35208
(lp40285
(dp40286
g35211
I26
sg35212
Vcancers
p40287
sg35214
I7
sg35215
VC0006826
p40288
sg35217
I1
sa(dp40289
g35211
I21
sg35212
Vlung cancers
p40290
sg35214
I12
sg35215
VC0242379
p40291
sg35217
I2
sa(dp40292
g35211
I21
sg35212
Vlung cancer
p40293
sg35214
I11
sg35215
VC0242379
p40294
sg35217
I2
sasa(dp40295
g135
(dp40296
(VSDC4
p40297
Vlung cancers
p40298
tp40299
I00
ssg35204
VIn patient 1 an SDC4-NRG1 gene fusion was detected, similar gene fusions having been described in lung cancers previously.
p40300
sg35206
(lp40301
(dp40302
g35211
I60
sg35212
Vgene fusions
p40303
sg35214
I12
sg35223
VP35637
p40304
sg35217
I2
sa(dp40305
g35211
I16
sg35212
g40297
sg35214
I4
sg35223
VP31431
p40306
sg35217
I1
sasg35208
(lp40307
(dp40308
g35211
I26
sg35212
Vgene fusion
p40309
sg35214
I11
sg35215
VC1705736
p40310
sg35217
I2
sa(dp40311
g35211
I98
sg35212
g40298
sg35214
I12
sg35215
VC0242379
p40312
sg35217
I2
sasa(dp40313
g35204
VUnexpected molecular lesions of the NRG1 gene followed by an aberrant ErbB signaling were recently described as a new molecular features of non-small cell lung cancer, but it has been also sporadically reported in other tumors.
p40314
sg35206
(lp40315
(dp40316
g35211
I70
sg35212
VErbB
p40317
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40318
(dp40319
g35211
I220
sg35212
Vtumors
p40320
sg35214
I6
sg35215
VC0027651
p40321
sg35217
I1
sa(dp40322
g35211
I140
sg35212
Vnon-small cell lung cancer
p40323
sg35214
I26
sg35215
VC0007131
p40324
sg35217
I4
sasa(dp40325
g135
(dp40326
(VPI3K
p40327
Vlung cancer
p40328
tp40329
I00
ssg35204
VWe highlight the current knowledge about the ErbB network and NRG1 deregulation in lung cancer and their merger into the ErbB/PI3K-AKT axis modulation and current therapeutic strategies.
p40330
sg35206
(lp40331
(dp40332
g35211
I45
sg35212
VErbB
p40333
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40334
g35211
I131
sg35212
VAKT
p40335
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp40336
g35211
I126
sg35212
g40327
sg35214
I4
sg35223
VP42336
p40337
sg35217
I1
sa(dp40338
g35211
I45
sg35212
VErbB network
p40339
sg35214
I12
sg35223
g12
sg35217
I2
sasg35208
(lp40340
(dp40341
g35211
I83
sg35212
g40328
sg35214
I11
sg35215
VC0684249
p40342
sg35217
I2
sasa(dp40343
g135
(dp40344
(VErbB3
p40345
Vlung cancer
p40346
tp40347
I00
ssg35204
VMore advances in knowledge of crosstalk between NRG1, ErbB3 and PI3K-AKT pathways may increase and strongly support the therapeutic choice for lung cancer patients.
p40348
sg35206
(lp40349
(dp40350
g35211
I64
sg35212
VPI3K
p40351
sg35214
I4
sg35223
VP42336
p40352
sg35217
I1
sa(dp40353
g35211
I54
sg35212
g40345
sg35214
I5
sg35223
VP21860
p40354
sg35217
I1
sa(dp40355
g35211
I69
sg35212
VAKT
p40356
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp40357
(dp40358
g35211
I143
sg35212
g40346
sg35214
I11
sg35215
VC0684249
p40359
sg35217
I2
sasa(dp40360
g135
(dp40361
(VGABRG2
p40362
VSMEI
p40363
tp40364
I00
ssg35204
VAll coding exons of SCN1B, GABRG2, and CACNB4 genes were screened for mutations in 38 SCN1A-mutation-positive SMEI probands.
p40365
sg35206
(lp40366
(dp40367
g35211
I86
sg35212
VSCN1A
p40368
sg35214
I5
sg35223
VP35498
p40369
sg35217
I1
sa(dp40370
g35211
I20
sg35212
VSCN1B
p40371
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40372
g35211
I39
sg35212
VCACNB4 genes
p40373
sg35214
I12
sg35223
g12
sg35217
I2
sa(dp40374
g35211
I27
sg35212
g40362
sg35214
I6
sg35223
VP18507
p40375
sg35217
I1
sasg35208
(lp40376
(dp40377
g35211
I110
sg35212
g40363
sg35214
I4
sg35215
VC0751122
p40378
sg35217
I1
sasa(dp40379
g35204
VFollowing the univariate analysis, high expressions of nuclear Beta-arrestin1 and p300 were classed as poor prognostic factors for both OS (P = .016) and DFS (P = .025).The expression of Beta-arrestin1 in the nucleus is associated with increased malignant tendency of lung adenocarcinoma, and the predictive value of Beta-arrestin1 may be optimized by combining information about the expression of p300 acetyltransferase.
p40380
sg35206
(lp40381
(dp40382
g35211
I82
sg35212
Vp300
p40383
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40384
g35211
I398
sg35212
Vp300 acetyltransferase
p40385
sg35214
I22
sg35223
g12
sg35217
I2
sasg35208
(lp40386
(dp40387
g35211
I268
sg35212
Vlung adenocarcinoma
p40388
sg35214
I19
sg35215
VC0152013
p40389
sg35217
I2
sasa(dp40390
g135
(dp40391
(VCOX-2
p40392
VNSCLC
p40393
tp40394
I00
ssg35204
VFurthermore, we demonstrated that the activation of COX-2 expression by hnRNPA2/B1 was mediated through the cooperation with p300, a transcriptional co-activator, in NSCLC cells.
p40395
sg35206
(lp40396
(dp40397
g35211
I72
sg35212
VhnRNPA2
p40398
sg35214
I7
sg35223
VP22626
p40399
sg35217
I1
sa(dp40400
g35211
I52
sg35212
g40392
sg35214
I5
sg35223
VP35354
p40401
sg35217
I1
sa(dp40402
g35211
I125
sg35212
Vp300
p40403
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40404
(dp40405
g35211
I166
sg35212
g40393
sg35214
I5
sg35215
VC0007131
p40406
sg35217
I1
sasa(dp40407
g35204
VPPARGC1A and PPARGC1B) are key agents in the development and pathophysiology of type 2 diabetes mellitus (T2DM).
p40408
sg35206
(lp40409
(dp40410
g35211
I0
sg35212
VPPARGC1A
p40411
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp40412
(dp40413
g35211
I106
sg35212
VT2DM
p40414
sg35214
I4
sg35215
VC0011860
p40415
sg35217
I1
sa(dp40416
g35211
I80
sg35212
Vtype 2 diabetes mellitus
p40417
sg35214
I24
sg35215
VC0011860
p40418
sg35217
I4
sasa(dp40419
g135
(dp40420
(VNXPH1
p40421
Vobesity
p40422
tp40423
I00
ssg35204
VFurthermore, eight of the 17 CpG sites reside in genes (FSTL1, SORCS2, NRF1, DLC1, PPARGC1B, CHN2, NXPH1) that have prior known associations with obesity, diabetes, and the insulin pathway.
p40424
sg35206
(lp40425
(dp40426
g35211
I63
sg35212
VSORCS2
p40427
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp40428
g35211
I93
sg35212
VCHN2
p40429
sg35214
I4
sg35223
VP52757
p40430
sg35217
I1
sa(dp40431
g35211
I71
sg35212
VNRF1
p40432
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40433
g35211
I56
sg35212
VFSTL1
p40434
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40435
g35211
I77
sg35212
VDLC1
p40436
sg35214
I4
sg35223
VP63167
p40437
sg35217
I1
sa(dp40438
g35211
I173
sg35212
Vinsulin
p40439
sg35214
I7
sg35223
VP01308
p40440
sg35217
I1
sa(dp40441
g35211
I99
sg35212
g40421
sg35214
I5
sg35223
VP58417
p40442
sg35217
I1
sasg35208
(lp40443
(dp40444
g35211
I155
sg35212
Vdiabetes
p40445
sg35214
I8
sg35215
VC0011849
p40446
sg35217
I1
sa(dp40447
g35211
I146
sg35212
g40422
sg35214
I7
sg35215
VC0028754
p40448
sg35217
I1
sasa(dp40449
g135
(dp40450
(VLRPAP1
p40451
Vobesity
p40452
tp40453
I00
ssg35204
VNo significant associations were found, although the top significant CpGs in boys were located in the LRPAP1, HAGH, PPARGC1B, KCNQ1 and KCNQ1DN genes, previously associated to birth weight, Type 2 diabetes, obesity or steroid hormone signaling.
p40454
sg35206
(lp40455
(dp40456
g35211
I136
sg35212
VKCNQ1DN genes
p40457
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp40458
g35211
I126
sg35212
VKCNQ1
p40459
sg35214
I5
sg35223
VP51787
p40460
sg35217
I1
sa(dp40461
g35211
I102
sg35212
g40451
sg35214
I6
sg35223
VP30533
p40462
sg35217
I1
sa(dp40463
g35211
I110
sg35212
VHAGH
p40464
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40465
(dp40466
g35211
I190
sg35212
VType 2 diabetes
p40467
sg35214
I15
sg35215
VC0011860
p40468
sg35217
I3
sa(dp40469
g35211
I207
sg35212
g40452
sg35214
I7
sg35215
VC0028754
p40470
sg35217
I1
sasa(dp40471
g135
(dp40472
(Vgene families
p40473
Vtype 2 diabetes
p40474
tp40475
I00
ssg35204
VWe used a two-stage study design to evaluate whether variations in the peroxisome proliferator-activated receptors (PPAR) and the PPAR gamma co-activator 1 (PGC1) gene families (PPARA, PPARG, PPARD, PPARGC1A, and PPARGC1B) are associated with type 2 diabetes (T2D) risk.
p40476
sg35206
(lp40477
(dp40478
g35211
I163
sg35212
g40473
sg35214
I13
sg35223
VP19883
p40479
sg35217
I2
sa(dp40480
g35211
I157
sg35212
VPGC1
p40481
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40482
g35211
I199
sg35212
VPPARGC1A
p40483
sg35214
I8
sg35223
g12
sg35217
I1
sa(dp40484
g35211
I116
sg35212
VPPAR
p40485
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40486
g35211
I71
sg35212
Vperoxisome proliferator-activated receptors
p40487
sg35214
I43
sg35223
g12
sg35217
I3
sa(dp40488
g35211
I130
sg35212
VPPAR gamma co-activator 1
p40489
sg35214
I25
sg35223
g12
sg35217
I4
sa(dp40490
g35211
I185
sg35212
VPPARG
p40491
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40492
g35211
I192
sg35212
VPPARD
p40493
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40494
g35211
I178
sg35212
VPPARA
p40495
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp40496
(dp40497
g35211
I260
sg35212
VT2D
p40498
sg35214
I3
sg35215
VC0011860
p40499
sg35217
I1
sa(dp40500
g35211
I243
sg35212
g40474
sg35214
I15
sg35215
VC0011860
p40501
sg35217
I3
sasa(dp40502
g135
(dp40503
(Vmuscular dystrophy gene TOR1AIP1
p40504
Vdysferlinopathy
p40505
tp40506
I00
ssg35204
VA recently identified muscular dystrophy gene TOR1AIP1 was detected as a hub gene in dysferlinopathy.
p40507
sg35206
(lp40508
(dp40509
g35211
I73
sg35212
Vhub gene
p40510
sg35214
I8
sg35223
g12
sg35217
I2
sa(dp40511
g35211
I22
sg35212
g40504
sg35214
I32
sg35223
VP43034
p40512
sg35217
I4
sasg35208
(lp40513
(dp40514
g35211
I22
sg35212
Vmuscular dystrophy
p40515
sg35214
I18
sg35215
VC0026850
p40516
sg35217
I2
sa(dp40517
g35211
I85
sg35212
g40505
sg35214
I15
sg35215
VC2931687
p40518
sg35217
I1
sasa(dp40519
g135
(dp40520
(VTorsinA-interacting protein 1
p40521
VLGMD
p40522
tp40523
I00
ssg35204
VTorsinA-interacting protein 1 (TOR1AIP1) gene is a novel gene that has recently been described to cause limb-girdle muscular dystrophy (LGMD) with mild dilated cardiomyopathy.
p40524
sg35206
(lp40525
(dp40526
g35211
I0
sg35212
g40521
sg35214
I29
sg35223
VP14222
p40527
sg35217
I3
sasg35208
(lp40528
(dp40529
g35211
I152
sg35212
Vdilated cardiomyopathy
p40530
sg35214
I22
sg35215
VC0007193
p40531
sg35217
I2
sa(dp40532
g35211
I104
sg35212
Vlimb-girdle muscular dystrophy
p40533
sg35214
I30
sg35215
VC0686353
p40534
sg35217
I3
sa(dp40535
g35211
I136
sg35212
g40522
sg35214
I4
sg35215
VC0686353
p40536
sg35217
I1
sasa(dp40537
g35204
VWe report a family with mutations in TOR1AIP1 where the striking clinical feature is severe cardiac failure requiring cardiac transplant in two siblings, in addition to musculoskeletal weakness and muscular dystrophy.
p40538
sg35206
(lp40539
sg35208
(lp40540
(dp40541
g35211
I92
sg35212
Vcardiac failure
p40542
sg35214
I15
sg35215
VC0018801
p40543
sg35217
I2
sa(dp40544
g35211
I198
sg35212
Vmuscular dystrophy
p40545
sg35214
I18
sg35215
VC0026850
p40546
sg35217
I2
sa(dp40547
g35211
I185
sg35212
Vweakness
p40548
sg35214
I8
sg35215
VC1883552
p40549
sg35217
I1
sasa(dp40550
g135
(dp40551
(VLAP1
p40552
Vmuscular dystrophy
p40553
tp40554
I00
ssg35204
VThese scientific contributions strengthen the role of LAP1 in DYT1 dystonia and muscular dystrophy.
p40555
sg35206
(lp40556
(dp40557
g35211
I62
sg35212
VDYT1 dystonia
p40558
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp40559
g35211
I54
sg35212
g40552
sg35214
I4
sg35223
VP15144
p40560
sg35217
I1
sasg35208
(lp40561
(dp40562
g35211
I62
sg35212
VDYT1
p40563
sg35214
I4
sg35215
VC1851945
p40564
sg35217
I1
sa(dp40565
g35211
I67
sg35212
Vdystonia
p40566
sg35214
I8
sg35215
VC0393593
p40567
sg35217
I1
sa(dp40568
g35211
I80
sg35212
g40553
sg35214
I18
sg35215
VC0026850
p40569
sg35217
I2
sasa(dp40570
g135
(dp40571
(VLAP1
p40572
Vdystonia
p40573
tp40574
I00
ssg35204
VMoreover, LAP1 also interacts with torsinA and emerin, proteins involved in DYT1 dystonia and X-linked Emery-Dreifuss muscular dystrophy disorder, respectively.
p40575
sg35206
(lp40576
(dp40577
g35211
I76
sg35212
VDYT1
p40578
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40579
g35211
I47
sg35212
Vemerin
p40580
sg35214
I6
sg35223
VP50402
p40581
sg35217
I1
sa(dp40582
g35211
I35
sg35212
VtorsinA
p40583
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp40584
g35211
I10
sg35212
g40572
sg35214
I4
sg35223
VP15144
p40585
sg35217
I1
sasg35208
(lp40586
(dp40587
g35211
I76
sg35212
VDYT1
p40588
sg35214
I4
sg35215
VC1851945
p40589
sg35217
I1
sa(dp40590
g35211
I94
sg35212
VX-linked Emery-Dreifuss muscular dystrophy
p40591
sg35214
I42
sg35215
VC0751337
p40592
sg35217
I4
sa(dp40593
g35211
I81
sg35212
g40573
sg35214
I8
sg35215
VC0393593
p40594
sg35217
I1
sasa(dp40595
g35204
VDeletions encompassing TAK1-binding protein 2 (TAB2) associated with isolated and syndromic congenital heart defects.
p40596
sg35206
(lp40597
(dp40598
g35211
I23
sg35212
VTAK1-binding protein 2
p40599
sg35214
I22
sg35223
g12
sg35217
I3
sa(dp40600
g35211
I47
sg35212
VTAB2
p40601
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40602
(dp40603
g35211
I92
sg35212
Vcongenital heart defects
p40604
sg35214
I24
sg35215
VC0018798
p40605
sg35217
I3
sasa(dp40606
g35204
VHaploinsufficiency of TAB2 was recently implicated as a cause for a variety of congenital heart defects.
p40607
sg35206
(lp40608
(dp40609
g35211
I22
sg35212
VTAB2
p40610
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40611
(dp40612
g35211
I79
sg35212
Vcongenital heart defects
p40613
sg35214
I24
sg35215
VC0018798
p40614
sg35217
I3
sasa(dp40615
g35204
VThis is the smallest reported deletion involving TAB2 that segregates with congenital heart defects.
p40616
sg35206
(lp40617
(dp40618
g35211
I49
sg35212
VTAB2
p40619
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40620
(dp40621
g35211
I75
sg35212
Vcongenital heart defects
p40622
sg35214
I24
sg35215
VC0018798
p40623
sg35217
I3
sasa(dp40624
g35204
VFindings from this family support a key role of TAB2 haploinsufficiency in congenital heart defects and expand the phenotypic spectrum of TAB2-microdeletion syndrome.
p40625
sg35206
(lp40626
(dp40627
g35211
I48
sg35212
VTAB2
p40628
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40629
g35211
I48
sg35212
VTAB2
p40630
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40631
(dp40632
g35211
I157
sg35212
Vsyndrome
p40633
sg35214
I8
sg35215
VC0039082
p40634
sg35217
I1
sa(dp40635
g35211
I75
sg35212
Vcongenital heart defects
p40636
sg35214
I24
sg35215
VC0018798
p40637
sg35217
I3
sasa(dp40638
g35204
VIn addition, the present deletion is the smallest so far recorded in the 6q25 region encompassing eight known genes [vs. 41 of Bisgaard et al., and 23 of Caselli et al.,], including the TAB2 (likely responsible for the girl's congenital heart defect), LATS1 gene, and the UST gene (a regulator of the homeostasis of proteoglycans, which could have played a role in the abnormal dermal and cartilage elasticity).
p40639
sg35206
(lp40640
(dp40641
g35211
I272
sg35212
VUST gene
p40642
sg35214
I8
sg35223
g12
sg35217
I2
sa(dp40643
g35211
I252
sg35212
VLATS1 gene
p40644
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp40645
g35211
I186
sg35212
VTAB2
p40646
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40647
(dp40648
g35211
I226
sg35212
Vcongenital heart defect
p40649
sg35214
I23
sg35215
VC0018798
p40650
sg35217
I3
sasa(dp40651
g35204
VThe isozymes hPAD2 and hPAD4 have been implicated in the development and progression of several autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
p40652
sg35206
(lp40653
sg35208
(lp40654
(dp40655
g35211
I96
sg35212
Vautoimmune diseases
p40656
sg35214
I19
sg35215
VC0004364
p40657
sg35217
I2
sa(dp40658
g35211
I127
sg35212
Vrheumatoid arthritis
p40659
sg35214
I20
sg35215
VC0003873
p40660
sg35217
I2
sa(dp40661
g35211
I152
sg35212
Vmultiple sclerosis
p40662
sg35214
I18
sg35215
VC0026769
p40663
sg35217
I2
sasa(dp40664
g35204
VProtein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.
p40665
sg35206
(lp40666
(dp40667
g35211
I0
sg35212
VProtein arginine deiminase 2
p40668
sg35214
I28
sg35223
g12
sg35217
I4
sa(dp40669
g35211
I30
sg35212
VPAD2
p40670
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40671
(dp40672
g35211
I105
sg35212
Vrheumatoid arthritis
p40673
sg35214
I20
sg35215
VC0003873
p40674
sg35217
I2
sa(dp40675
g35211
I131
sg35212
Vbreast cancer
p40676
sg35214
I13
sg35215
VC0678222
p40677
sg35217
I2
sa(dp40678
g35211
I85
sg35212
Vmultiple sclerosis
p40679
sg35214
I18
sg35215
VC0026769
p40680
sg35217
I2
sasa(dp40681
g35204
VThe enzyme peptidylarginine deiminase 2 (PAD2) has been associated with inflammatory diseases, such as rheumatoid arthritis and neurodegenerative diseases including multiple sclerosis.
p40682
sg35206
(lp40683
(dp40684
g35211
I11
sg35212
Vpeptidylarginine deiminase 2
p40685
sg35214
I28
sg35223
g12
sg35217
I3
sa(dp40686
g35211
I41
sg35212
VPAD2
p40687
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40688
(dp40689
g35211
I103
sg35212
Vrheumatoid arthritis
p40690
sg35214
I20
sg35215
VC0003873
p40691
sg35217
I2
sa(dp40692
g35211
I128
sg35212
Vneurodegenerative diseases
p40693
sg35214
I26
sg35215
VC0524851
p40694
sg35217
I2
sa(dp40695
g35211
I165
sg35212
Vmultiple sclerosis
p40696
sg35214
I18
sg35215
VC0026769
p40697
sg35217
I2
sasa(dp40698
g35204
VPeptidylarginine deiminase 2 (PAD2) and peptidylarginine deiminase 4 (PAD4) are two members of PAD family which are over-expressed in the multiple sclerosis (MS) brain.
p40699
sg35206
(lp40700
(dp40701
g35211
I95
sg35212
VPAD family
p40702
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp40703
g35211
I70
sg35212
VPAD4
p40704
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp40705
g35211
I40
sg35212
Vpeptidylarginine deiminase 4
p40706
sg35214
I28
sg35223
g12
sg35217
I3
sa(dp40707
g35211
I0
sg35212
VPeptidylarginine deiminase 2
p40708
sg35214
I28
sg35223
g12
sg35217
I3
sa(dp40709
g35211
I30
sg35212
VPAD2
p40710
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp40711
(dp40712
g35211
I138
sg35212
Vmultiple sclerosis
p40713
sg35214
I18
sg35215
VC0026769
p40714
sg35217
I2
sa(dp40715
g35211
I158
sg35212
VMS
p40716
sg35214
I2
sg35215
VC0026769
p40717
sg35217
I1
sa(dp40718
g35211
I30
sg35212
VPAD
p40719
sg35214
I3
sg35215
VC1704436
p40720
sg35217
I1
sasa(dp40721
g35204
VRecent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis.
p40722
sg35206
(lp40723
(dp40724
g35211
I57
sg35212
VPADI2
p40725
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp40726
(dp40727
g35211
I158
sg35212
Vpathogenesis
p40728
sg35214
I12
sg35215
VC0699748
p40729
sg35217
I1
sa(dp40730
g35211
I266
sg35212
Vmultiple sclerosis
p40731
sg35214
I18
sg35215
VC0026769
p40732
sg35217
I2
sa(dp40733
g35211
I111
sg35212
Vnervous
p40734
sg35214
I7
sg35215
VC0027769
p40735
sg35217
I1
sa(dp40736
g35211
I242
sg35212
VAlzheimer's disease
p40737
sg35214
I19
sg35215
VC1521724
p40738
sg35217
I2
sasa(dp40739
g35204
VVEGF-Flt-1 signaling induces osteoclastogenesis in OSCC through two possible ways: 1) VEGF produced from OSCC cells can directly stimulate the Flt-1 pathway in preosteoclasts to induce migration to future bone resorbing area and differentiation into osteoclasts, and 2) VEGF-Flt-1 signaling upregulates RANKL expression in OSCC cells, which indirectly leads to osteoclast differentiation.
p40740
sg35206
(lp40741
(dp40742
g35211
I0
sg35212
VVEGF-Flt-1
p40743
sg35214
I10
sg35223
VP17948
p40744
sg35217
I1
sa(dp40745
g35211
I5
sg35212
VFlt-1
p40746
sg35214
I5
sg35223
VP17948
p40747
sg35217
I1
sa(dp40748
g35211
I303
sg35212
VRANKL
p40749
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40750
g35211
I5
sg35212
VFlt-1
p40751
sg35214
I5
sg35223
VP17948
p40752
sg35217
I1
sasg35208
(lp40753
sa(dp40754
g135
(dp40755
(VNF-kappaB
p40756
Vbreast cancers
p40757
tp40758
I00
ssg35204
VThus, the transcriptional targets normally activated by RANKL that promote a proliferative response in luminal progenitors can contribute to the susceptibility of mammary epithelial cells to BRCA1-mutated breast cancers as a consequence of DDR-induced NF-kappaB.
p40759
sg35206
(lp40760
(dp40761
g35211
I191
sg35212
VBRCA1
p40762
sg35214
I5
sg35223
VP38398
p40763
sg35217
I1
sa(dp40764
g35211
I252
sg35212
g40756
sg35214
I9
sg35223
VP19838
p40765
sg35217
I1
sa(dp40766
g35211
I56
sg35212
VRANKL
p40767
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp40768
(dp40769
g35211
I77
sg35212
Vproliferative
p40770
sg35214
I13
sg35215
VC0334094
p40771
sg35217
I1
sa(dp40772
g35211
I205
sg35212
g40757
sg35214
I14
sg35215
VC0006142
p40773
sg35217
I2
sasa(dp40774
g35204
VOur finding provides mechanistic support for a breast cancer chemoprevention trial with a RANKL inhibitor among high-risk premenopausal women with dense breasts.
p40775
sg35206
(lp40776
(dp40777
g35211
I90
sg35212
VRANKL
p40778
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp40779
(dp40780
g35211
I47
sg35212
Vbreast cancer
p40781
sg35214
I13
sg35215
VC0678222
p40782
sg35217
I2
sasa(dp40783
g35204
VThe present study examined the effects of brucine on the OPG/RANKL/RANK signaling pathway for exploring the mechanism of brucine suppression of bone metastasis in breast cancer.
p40784
sg35206
(lp40785
(dp40786
g35211
I61
sg35212
VRANKL
p40787
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40788
g35211
I57
sg35212
VOPG
p40789
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp40790
(dp40791
g35211
I129
sg35212
Vsuppression
p40792
sg35214
I11
sg35215
VC0221103
p40793
sg35217
I1
sa(dp40794
g35211
I163
sg35212
Vbreast cancer
p40795
sg35214
I13
sg35215
VC0678222
p40796
sg35217
I2
sa(dp40797
g35211
I144
sg35212
Vbone metastasis
p40798
sg35214
I15
sg35215
VC0153690
p40799
sg35217
I2
sasa(dp40800
g35204
VIn the present study, we evaluated the clinical usefulness of OPG and sRANKL assessment in bronchoalveolar lavage fluid (BALF) of patients with advanced non-small cell lung cancer (NSCLC).
p40801
sg35206
(lp40802
(dp40803
g35211
I62
sg35212
VOPG
p40804
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp40805
(dp40806
g35211
I181
sg35212
VNSCLC
p40807
sg35214
I5
sg35215
VC0007131
p40808
sg35217
I1
sa(dp40809
g35211
I153
sg35212
Vnon-small cell lung cancer
p40810
sg35214
I26
sg35215
VC0007131
p40811
sg35217
I4
sasa(dp40812
g35204
VWe measured the concentration of OPG and sRANKL in BALF of 44 NSCLC patients and 15 healthy volunteers taken as control subjects.
p40813
sg35206
(lp40814
(dp40815
g35211
I33
sg35212
VOPG
p40816
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp40817
(dp40818
g35211
I62
sg35212
VNSCLC
p40819
sg35214
I5
sg35215
VC0007131
p40820
sg35217
I1
sasa(dp40821
g35204
VThere were no significant differences in sRANKL content between the NSCLC and control groups [1.22 (0.74-23.00) vs. 1.12 (0.79-4.39) pmol/l; p = 0.67].
p40822
sg35206
(lp40823
sg35208
(lp40824
(dp40825
g35211
I68
sg35212
VNSCLC
p40826
sg35214
I5
sg35215
VC0007131
p40827
sg35217
I1
sasa(dp40828
g35204
VHowever, we found that the greater the level of sRANKL in NSCLC patients, the shorter the overall survival.
p40829
sg35206
(lp40830
sg35208
(lp40831
(dp40832
g35211
I58
sg35212
VNSCLC
p40833
sg35214
I5
sg35215
VC0007131
p40834
sg35217
I1
sasa(dp40835
g35204
VWe found a correlation between the content of sRANKL and the percentage of lymphocytes in BALF of NSCLC patients (r = 0.52; p = 0.041).
p40836
sg35206
(lp40837
sg35208
(lp40838
(dp40839
g35211
I98
sg35212
VNSCLC
p40840
sg35214
I5
sg35215
VC0007131
p40841
sg35217
I1
sasa(dp40842
g35204
VA high level of sRANKL in BALF of NSCLC patients may predict worse survival.
p40843
sg35206
(lp40844
sg35208
(lp40845
(dp40846
g35211
I34
sg35212
VNSCLC
p40847
sg35214
I5
sg35215
VC0007131
p40848
sg35217
I1
sasa(dp40849
g35204
VThe goal of our study was to assess the prognostic impact of the necroptosis relative protein RIPK1 genetic polymorphism in ischemia-reperfusion injury and survival after hepatectomy in hepatocellular carcinoma (HCC) patients.
p40850
sg35206
(lp40851
(dp40852
g35211
I94
sg35212
VRIPK1
p40853
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp40854
(dp40855
g35211
I212
sg35212
VHCC
p40856
sg35214
I3
sg35215
VC2239176
p40857
sg35217
I1
sa(dp40858
g35211
I186
sg35212
Vhepatocellular carcinoma
p40859
sg35214
I24
sg35215
VC2239176
p40860
sg35217
I2
sa(dp40861
g35211
I124
sg35212
Vischemia
p40862
sg35214
I8
sg35215
VC0022116
p40863
sg35217
I1
sa(dp40864
g35211
I65
sg35212
Vnecroptosis
p40865
sg35214
I11
sg35215
VC2610958
p40866
sg35217
I1
sasa(dp40867
g35204
VHere, we discuss our recent data on RIPK1 in liver injury and hepatocellular carcinoma development and put these into relation to previous experimental findings to underpin that it exerts opposing kinase-dependent and kinase independent functions in liver cells.
p40868
sg35206
(lp40869
(dp40870
g35211
I36
sg35212
VRIPK1
p40871
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp40872
(dp40873
g35211
I62
sg35212
Vhepatocellular carcinoma
p40874
sg35214
I24
sg35215
VC1512411
p40875
sg35217
I2
sasa(dp40876
g35204
VMoreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8 hyperactivation but also impaired NF-KB activation, promoting the spontaneous development of hepatocellular carcinoma.
p40877
sg35206
(lp40878
(dp40879
g35211
I23
sg35212
VRipk1
p40880
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40881
g35211
I33
sg35212
VTraf2
p40882
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp40883
g35211
I67
sg35212
Vcaspase-8
p40884
sg35214
I9
sg35223
VP39880
p40885
sg35217
I1
sasg35208
(lp40886
(dp40887
g35211
I170
sg35212
Vhepatocellular carcinoma
p40888
sg35214
I24
sg35215
VC1512411
p40889
sg35217
I2
sa(dp40890
g35211
I102
sg35212
Vimpaired
p40891
sg35214
I8
sg35215
VC0684336
p40892
sg35217
I1
sasa(dp40893
g35204
VThe single-stranded DNA cytidine deaminases APOBEC3B, APOBEC3H haplotype I, and APOBEC3A can contribute to cancer through deamination of cytosine to form promutagenic uracil in genomic DNA.
p40894
sg35206
(lp40895
(dp40896
g35211
I54
sg35212
VAPOBEC3H haplotype I
p40897
sg35214
I20
sg35223
g12
sg35217
I3
sa(dp40898
g35211
I44
sg35212
VAPOBEC3B
p40899
sg35214
I8
sg35223
g12
sg35217
I1
sa(dp40900
g35211
I80
sg35212
VAPOBEC3A
p40901
sg35214
I8
sg35223
VP31941
p40902
sg35217
I1
sa(dp40903
g35211
I4
sg35212
Vsingle-stranded DNA cytidine deaminases
p40904
sg35214
I39
sg35223
VP32320
p40905
sg35217
I4
sasg35208
(lp40906
(dp40907
g35211
I107
sg35212
Vcancer
p40908
sg35214
I6
sg35215
VC0006826
p40909
sg35217
I1
sasa(dp40910
g35204
VTo study this, we developed a method to purify full length APOBEC3B and characterized it in comparison to APOBEC3A and APOBEC3H on substrates relevant to cancer mutagenesis.
p40911
sg35206
(lp40912
(dp40913
g35211
I106
sg35212
VAPOBEC3A
p40914
sg35214
I8
sg35223
VP31941
p40915
sg35217
I1
sa(dp40916
g35211
I119
sg35212
VAPOBEC3H
p40917
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp40918
(dp40919
g35211
I154
sg35212
Vcancer
p40920
sg35214
I6
sg35215
VC0006826
p40921
sg35217
I1
sasa(dp40922
g35204
VA3H-I also associates with clonal TCA/T-biased mutations in lung adenocarcinoma suggesting this enzyme makes broader contributions to cancer mutagenesis.
p40923
sg35206
(lp40924
sg35208
(lp40925
(dp40926
g35211
I134
sg35212
Vcancer
p40927
sg35214
I6
sg35215
VC0006826
p40928
sg35217
I1
sa(dp40929
g35211
I60
sg35212
Vlung adenocarcinoma
p40930
sg35214
I19
sg35215
VC0152013
p40931
sg35217
I2
sasa(dp40932
g35204
VThese studies combine to suggest that A3B and A3H-I, together, explain the bulk of 'APOBEC signature' mutations in cancer.
p40933
sg35206
(lp40934
(dp40935
g35211
I38
sg35212
VA3B
p40936
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp40937
(dp40938
g35211
I115
sg35212
Vcancer
p40939
sg35214
I6
sg35215
VC0006826
p40940
sg35217
I1
sasa(dp40941
g135
(dp40942
(VCD3D
p40943
Vmultiple cancer
p40944
tp40945
I00
ssg35204
VTCGA data analyses revealed that expression of APOBEC3D and APOBEC3H also correlates with CD3D across multiple cancer types.
p40946
sg35206
(lp40947
(dp40948
g35211
I90
sg35212
g40943
sg35214
I4
sg35223
VP04234
p40949
sg35217
I1
sa(dp40950
g35211
I60
sg35212
VAPOBEC3H
p40951
sg35214
I8
sg35223
g12
sg35217
I1
sa(dp40952
g35211
I47
sg35212
VAPOBEC3D
p40953
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp40954
(dp40955
g35211
I102
sg35212
g40944
sg35214
I15
sg35215
VC0346429
p40956
sg35217
I2
sasa(dp40957
g35204
VWe found that the T allele of rs139293 in exon 2 of APOBEC3H was significantly associated with decreased risk of lung cancer (odds ratio = 0.76, 95% confidence interval: 0.63-0.91).
p40958
sg35206
(lp40959
(dp40960
g35211
I52
sg35212
VAPOBEC3H
p40961
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp40962
(dp40963
g35211
I113
sg35212
Vlung cancer
p40964
sg35214
I11
sg35215
VC0684249
p40965
sg35217
I2
sasa(dp40966
g35204
VThese results indicate that genetic variants in APOBEC3H may contribute to lung cancer susceptibility in Chinese population.
p40967
sg35206
(lp40968
(dp40969
g35211
I48
sg35212
VAPOBEC3H
p40970
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp40971
(dp40972
g35211
I75
sg35212
Vlung cancer
p40973
sg35214
I11
sg35215
VC0684249
p40974
sg35217
I2
sasa(dp40975
g35204
VA 56-year-old male with cirrhosis presented with acute bleeding from cardiofundal gastroesophageal varices (GOV) and was treated with endoscopic cyanoacrylate glue.
p40976
sg35206
(lp40977
sg35208
(lp40978
(dp40979
g35211
I24
sg35212
Vcirrhosis
p40980
sg35214
I9
sg35215
VC0023890
p40981
sg35217
I1
sa(dp40982
g35211
I82
sg35212
Vgastroesophageal varices
p40983
sg35214
I24
sg35215
VC2609266
p40984
sg35217
I2
sa(dp40985
g35211
I108
sg35212
VGOV
p40986
sg35214
I3
sg35215
VC2609266
p40987
sg35217
I1
sa(dp40988
g35211
I49
sg35212
Vacute bleeding
p40989
sg35214
I14
sg35215
VC0333276
p40990
sg35217
I2
sasa(dp40991
g35204
VAt that time, he underwent retreatment with balloon-occluded retrograde obliteration (BRTO), with no recurrence at a follow-up of 14 months.Available treatments for bleeding GOV include methods to (a) directly obstruct the varices (endoscopic variceal ligation , sclerotherapy and cyanoacrylate glue, BRTO) or to (b) decrease portal pressure (surgical portacaval shunts; transportal intrahepatic portosystemic shunt).
p40992
sg35206
(lp40993
sg35208
(lp40994
(dp40995
g35211
I101
sg35212
Vrecurrence
p40996
sg35214
I10
sg35215
VC1458156
p40997
sg35217
I1
sa(dp40998
g35211
I165
sg35212
Vbleeding
p40999
sg35214
I8
sg35215
VC0019080
p41000
sg35217
I1
sa(dp41001
g35211
I52
sg35212
Voccluded
p41002
sg35214
I8
sg35215
VC0028778
p41003
sg35217
I1
sa(dp41004
g35211
I223
sg35212
Vvarices
p41005
sg35214
I7
sg35215
VC0042345
p41006
sg35217
I1
sasa(dp41007
g35204
VGastroesophageal varices (GOV) is a common complication in patients with portal hypertension.
p41008
sg35206
(lp41009
sg35208
(lp41010
(dp41011
g35211
I73
sg35212
Vportal hypertension
p41012
sg35214
I19
sg35215
VC0020541
p41013
sg35217
I2
sa(dp41014
g35211
I0
sg35212
VGastroesophageal varices
p41015
sg35214
I24
sg35215
VC2609266
p41016
sg35217
I2
sa(dp41017
g35211
I26
sg35212
VGOV
p41018
sg35214
I3
sg35215
VC2609266
p41019
sg35217
I1
sa(dp41020
g35211
I43
sg35212
Vcomplication
p41021
sg35214
I12
sg35215
VC0009566
p41022
sg35217
I1
sasa(dp41023
g35204
VGastric varices were categorized as GOV-1 (3%), GOV-2 (61%), and isolated gastric varices type 1 (36%) per Sarin classification.
p41024
sg35206
(lp41025
sg35208
(lp41026
(dp41027
g35211
I74
sg35212
Vgastric varices
p41028
sg35214
I15
sg35215
VC0017145
p41029
sg35217
I2
sa(dp41030
g35211
I0
sg35212
VGastric varices
p41031
sg35214
I15
sg35215
VC0017145
p41032
sg35217
I2
sasa(dp41033
g35204
VOf the 9 children with associated gastroeosophageal varices (GOV), the severity of lesions was reduced in 8 of them.
p41034
sg35206
(lp41035
sg35208
(lp41036
(dp41037
g35211
I52
sg35212
Vvarices
p41038
sg35214
I7
sg35215
VC0042345
p41039
sg35217
I1
sasa(dp41040
g135
(dp41041
(VEP3 receptor
p41042
Vtransient cerebral ischemia
p41043
tp41044
I00
ssg35204
VHere, we address the contribution of the EP3 receptor in dictating early outcomes after transient cerebral ischemia.
p41045
sg35206
(lp41046
(dp41047
g35211
I41
sg35212
g41042
sg35214
I12
sg35223
VP43115
p41048
sg35217
I2
sasg35208
(lp41049
(dp41050
g35211
I88
sg35212
g41043
sg35214
I27
sg35215
VC0917805
p41051
sg35217
I3
sasa(dp41052
g35204
VFollowing S1, separate scalp recordings in 4 patients in the epilepsy group displayed EP 3 times in the 'over 300 ms' time window.
p41053
sg35206
(lp41054
sg35208
(lp41055
(dp41056
g35211
I61
sg35212
Vepilepsy
p41057
sg35214
I8
sg35215
VC0014544
p41058
sg35217
I1
sasa(dp41059
g135
(dp41060
(Vthromboplastin
p41061
Vendometriosis
p41062
tp41063
I01
ssg35204
VConversely, patients with endometriosis had significantly shortened activated partial thromboplastin time (APTT) when compared to controls (1.08 +/- 0.06 and 1.12 +/- 0.19, respectively; P &lt; .01).
p41064
sg35206
(lp41065
(dp41066
g35211
I86
sg35212
g41061
sg35214
I14
sg35223
VP13726
p41067
sg35217
I1
sasg35208
(lp41068
(dp41069
g35211
I26
sg35212
g41062
sg35214
I13
sg35215
VC0014175
p41070
sg35217
I1
sasa(dp41071
g135
(dp41072
(Vthromboplastin
p41073
Vendometriosis
p41074
tp41075
I01
ssg35204
VActivated partial thromboplastin time is shorter in women with endometriosis but still in the normal range.
p41076
sg35206
(lp41077
(dp41078
g35211
I18
sg35212
g41073
sg35214
I14
sg35223
VP13726
p41079
sg35217
I1
sasg35208
(lp41080
(dp41081
g35211
I63
sg35212
g41074
sg35214
I13
sg35215
VC0014175
p41082
sg35217
I1
sasa(dp41083
g135
(dp41084
(VcMP-TF
p41085
Vendometriosis
p41086
tp41087
I00
ssg35204
VAre the levels of total circulating cell-derived microparticles (cMPs) and circulating tissue factor-containing microparticles (cMP-TF) increased in patients with endometriosis?
p41088
sg35206
(lp41089
(dp41090
g35211
I128
sg35212
g41085
sg35214
I6
sg35223
VP21941
p41091
sg35217
I1
sasg35208
(lp41092
(dp41093
g35211
I163
sg35212
g41086
sg35214
I13
sg35215
VC0014175
p41094
sg35217
I1
sasa(dp41095
g135
(dp41096
(VFactor VII/VIIa
p41097
Vendometriosis
p41098
tp41099
I00
ssg35204
VIncreased expression of tissue factor (a transmembrane receptor for Factor VII/VIIa) in eutopic and ectopic endometrium from patients with endometriosis has been described.
p41100
sg35206
(lp41101
(dp41102
g35211
I68
sg35212
g41097
sg35214
I15
sg35223
VP08709
p41103
sg35217
I2
sasg35208
(lp41104
(dp41105
g35211
I139
sg35212
g41098
sg35214
I13
sg35215
VC0014175
p41106
sg35217
I1
sasa(dp41107
g35204
VTissue factor (TF) expression was elevated in endometriosis and TF concentrations were significantly elevated both in the supernatant of cultured primary endometriotic stromal cells and in peritoneal fluid from women with endometriosis.
p41108
sg35206
(lp41109
sg35208
(lp41110
(dp41111
g35211
I46
sg35212
Vendometriosis
p41112
sg35214
I13
sg35215
VC0014175
p41113
sg35217
I1
sa(dp41114
g35211
I46
sg35212
Vendometriosis
p41115
sg35214
I13
sg35215
VC0014175
p41116
sg35217
I1
sasa(dp41117
g35204
VHere, we first determined the value of ALCAM as a marker of recurrence in endometrioid endometrial cancer by conducting a retrospective multicentre study of 174 primary tumours.
p41118
sg35206
(lp41119
(dp41120
g35211
I39
sg35212
VALCAM
p41121
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41122
(dp41123
g35211
I169
sg35212
Vtumours
p41124
sg35214
I7
sg35215
VC0027651
p41125
sg35217
I1
sa(dp41126
g35211
I60
sg35212
Vrecurrence
p41127
sg35214
I10
sg35215
VC1458156
p41128
sg35217
I1
sa(dp41129
g35211
I87
sg35212
Vendometrial cancer
p41130
sg35214
I18
sg35215
VC0476089
p41131
sg35217
I2
sasa(dp41132
g35204
VThen we demonstrated in vitro a role for ALCAM in cell migration and invasion by using a loss-of-function model in two endometrial cancer cell lines.
p41133
sg35206
(lp41134
(dp41135
g35211
I41
sg35212
VALCAM
p41136
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41137
(dp41138
g35211
I69
sg35212
Vinvasion
p41139
sg35214
I8
sg35215
VC2699153
p41140
sg35217
I1
sa(dp41141
g35211
I119
sg35212
Vendometrial cancer
p41142
sg35214
I18
sg35215
VC0476089
p41143
sg35217
I2
sasa(dp41144
g35204
VIn conclusion, our results highlight the potential of ALCAM as a recurrent biomarker in early-stage endometrioid endometrial cancer and point to ALCAM as an important molecule in endometrial cancer dissemination by regulating cell migration, invasion, and metastasis.
p41145
sg35206
(lp41146
(dp41147
g35211
I54
sg35212
VALCAM
p41148
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41149
(dp41150
g35211
I113
sg35212
Vendometrial cancer
p41151
sg35214
I18
sg35215
VC0476089
p41152
sg35217
I2
sa(dp41153
g35211
I242
sg35212
Vinvasion
p41154
sg35214
I8
sg35215
VC2699153
p41155
sg35217
I1
sa(dp41156
g35211
I256
sg35212
Vmetastasis
p41157
sg35214
I10
sg35215
VC0027627
p41158
sg35217
I1
sa(dp41159
g35211
I113
sg35212
Vendometrial cancer
p41160
sg35214
I18
sg35215
VC0476089
p41161
sg35217
I2
sasa(dp41162
g135
(dp41163
(VELK3
p41164
Vovarian cancer
p41165
tp41166
I00
ssg35204
VOverexpressing miR-378 in ovarian cancer cells altered expression of genes associated with angiogenesis (ALCAM, EHD1, ELK3, TLN1), apoptosis (RPN2, HIPK3), and cell cycle regulation (SWAP-70, LSM14A, RDX).
p41167
sg35206
(lp41168
(dp41169
g35211
I148
sg35212
VHIPK3
p41170
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41171
g35211
I15
sg35212
VmiR-378
p41172
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp41173
g35211
I105
sg35212
VALCAM
p41174
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41175
g35211
I192
sg35212
VLSM14A
p41176
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp41177
g35211
I142
sg35212
VRPN2
p41178
sg35214
I4
sg35223
VP04844
p41179
sg35217
I1
sa(dp41180
g35211
I200
sg35212
VRDX
p41181
sg35214
I3
sg35223
VP35241
p41182
sg35217
I1
sa(dp41183
g35211
I183
sg35212
VSWAP-70
p41184
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp41185
g35211
I118
sg35212
g41164
sg35214
I4
sg35223
VP41970
p41186
sg35217
I1
sa(dp41187
g35211
I124
sg35212
VTLN1
p41188
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp41189
g35211
I112
sg35212
VEHD1
p41190
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp41191
(dp41192
g35211
I26
sg35212
g41165
sg35214
I14
sg35215
VC1140680
p41193
sg35217
I2
sasa(dp41194
g135
(dp41195
(VADAM-17
p41196
Vepithelial ovarian cancer
p41197
tp41198
I01
ssg35204
VActivated leukocyte cell adhesion molecule (ALCAM) is expressed at the surface of epithelial ovarian cancer (EOC) cells and is released in a soluble form (sALCAM) by ADAM-17-mediated shedding.
p41199
sg35206
(lp41200
(dp41201
g35211
I44
sg35212
VALCAM
p41202
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41203
g35211
I166
sg35212
g41196
sg35214
I7
sg35223
VP78536
p41204
sg35217
I1
sa(dp41205
g35211
I0
sg35212
VActivated leukocyte cell adhesion molecule
p41206
sg35214
I42
sg35223
g12
sg35217
I5
sasg35208
(lp41207
(dp41208
g35211
I109
sg35212
VEOC
p41209
sg35214
I3
sg35215
VC0677886
p41210
sg35217
I1
sa(dp41211
g35211
I25
sg35212
Vadhesion
p41212
sg35214
I8
sg35215
VC0001511
p41213
sg35217
I1
sa(dp41214
g35211
I82
sg35212
g41197
sg35214
I25
sg35215
VC0677886
p41215
sg35217
I3
sasa(dp41216
g35204
VHere, we show that serum sALCAM levels were significantly higher in epithelial ovarian cancer (EOC) (p &lt; 0.005) than in controls.
p41217
sg35206
(lp41218
(dp41219
g35211
I19
sg35212
Vserum sALCAM
p41220
sg35214
I12
sg35223
g12
sg35217
I2
sasg35208
(lp41221
(dp41222
g35211
I95
sg35212
VEOC
p41223
sg35214
I3
sg35215
VC0677886
p41224
sg35217
I1
sa(dp41225
g35211
I68
sg35212
Vepithelial ovarian cancer
p41226
sg35214
I25
sg35215
VC0677886
p41227
sg35217
I3
sasa(dp41228
g35204
VTo date there are no data on the role of ALCAM in cervical cancer available.
p41229
sg35206
(lp41230
(dp41231
g35211
I41
sg35212
VALCAM
p41232
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41233
(dp41234
g35211
I50
sg35212
Vcervical cancer
p41235
sg35214
I15
sg35215
VC0302592
p41236
sg35217
I2
sasa(dp41237
g35204
VIn this study, ALCAM expression was analysed by immunohistochemistry (IHC) in tissue samples of 233 patients with cervical cancer, among them 178 with complete follow-up information.
p41238
sg35206
(lp41239
sg35208
(lp41240
(dp41241
g35211
I114
sg35212
Vcervical cancer
p41242
sg35214
I15
sg35215
VC0302592
p41243
sg35217
I2
sasa(dp41244
g35204
VALCAM overexpression was detected (immunoreactive score (IRS) 2-12) in 58.4% of the cervical cancer samples.
p41245
sg35206
(lp41246
(dp41247
g35211
I0
sg35212
VALCAM
p41248
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41249
(dp41250
g35211
I84
sg35212
Vcervical cancer
p41251
sg35214
I15
sg35215
VC0302592
p41252
sg35217
I2
sasa(dp41253
g35204
VESs and USTSs were further separated by CD166 staining, wherein increased expression was associated with ES (P &lt; 0.0001).
p41254
sg35206
(lp41255
(dp41256
g35211
I40
sg35212
VCD166
p41257
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41258
sa(dp41259
g35204
VUSP22 is one of the important targets for inhibiting tumor growth, but clear illustration regarding its effects of telomerase, tumor cell immortality and retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway remains to be elusive.
p41260
sg35206
(lp41261
(dp41262
g35211
I209
sg35212
VTERT
p41263
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp41264
g35211
I0
sg35212
VUSP22
p41265
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41266
g35211
I214
sg35212
VP53
p41267
sg35214
I3
sg35223
VP42771
p41268
sg35217
I1
sasg35208
(lp41269
(dp41270
g35211
I53
sg35212
Vtumor
p41271
sg35214
I5
sg35215
VC0027651
p41272
sg35217
I1
sa(dp41273
g35211
I154
sg35212
Vretinoblastoma
p41274
sg35214
I14
sg35215
VC0035335
p41275
sg35217
I1
sa(dp41276
g35211
I53
sg35212
Vtumor growth
p41277
sg35214
I12
sg35215
VC0598934
p41278
sg35217
I2
sasa(dp41279
g35204
VUSP22 played an important role in retinoblastoma cell proliferation/aging and apoptosis.
p41280
sg35206
(lp41281
(dp41282
g35211
I0
sg35212
VUSP22
p41283
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41284
(dp41285
g35211
I34
sg35212
Vretinoblastoma
p41286
sg35214
I14
sg35215
VC0035335
p41287
sg35217
I1
sa(dp41288
g35211
I54
sg35212
Vproliferation
p41289
sg35214
I13
sg35215
VC0334094
p41290
sg35217
I1
sasa(dp41291
g35204
VThe reduction of USP22 expression facilitated human retinoblastoma cell aging or apoptosis via suppressing TERT/P53 signal pathway.
p41292
sg35206
(lp41293
(dp41294
g35211
I17
sg35212
VUSP22
p41295
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41296
g35211
I112
sg35212
VP53
p41297
sg35214
I3
sg35223
VP42771
p41298
sg35217
I1
sa(dp41299
g35211
I107
sg35212
VTERT
p41300
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp41301
(dp41302
g35211
I52
sg35212
Vretinoblastoma
p41303
sg35214
I14
sg35215
VC0035335
p41304
sg35217
I1
sasa(dp41305
g35204
VUSP22, thus, may work as a target for treating retinoblastoma.
p41306
sg35206
(lp41307
(dp41308
g35211
I0
sg35212
VUSP22
p41309
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41310
(dp41311
g35211
I47
sg35212
Vretinoblastoma
p41312
sg35214
I14
sg35215
VC0035335
p41313
sg35217
I1
sasa(dp41314
g135
(dp41315
(Vubiquitin-specific peptidase 22
p41316
Vlung adenocarcinoma
p41317
tp41318
I00
ssg35204
VThe present study aimed to investigate the correlation of ubiquitin-specific peptidase 22 (USP22) with acquired resistance to cisplatin in lung adenocarcinoma.
p41319
sg35206
(lp41320
(dp41321
g35211
I58
sg35212
g41316
sg35214
I31
sg35223
VP62979
p41322
sg35217
I3
sa(dp41323
g35211
I91
sg35212
VUSP22
p41324
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41325
(dp41326
g35211
I139
sg35212
g41317
sg35214
I19
sg35215
VC0152013
p41327
sg35217
I2
sasa(dp41328
g35204
VUSP22 is a potential target in cisplatin-resistant lung adenocarcinoma and should be considered in future therapeutic practice.
p41329
sg35206
(lp41330
(dp41331
g35211
I0
sg35212
VUSP22
p41332
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41333
(dp41334
g35211
I51
sg35212
Vlung adenocarcinoma
p41335
sg35214
I19
sg35215
VC0152013
p41336
sg35217
I2
sasa(dp41337
g35204
VUbiquitin specific peptidase 22 (USP22), a putative cancer stem cell marker, is overexpressed in liver metastases of colorectal cancer (CRC).
p41338
sg35206
(lp41339
(dp41340
g35211
I0
sg35212
VUbiquitin specific peptidase 22
p41341
sg35214
I31
sg35223
g12
sg35217
I4
sa(dp41342
g35211
I33
sg35212
VUSP22
p41343
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41344
(dp41345
g35211
I52
sg35212
Vcancer
p41346
sg35214
I6
sg35215
VC0006826
p41347
sg35217
I1
sa(dp41348
g35211
I97
sg35212
Vliver metastases
p41349
sg35214
I16
sg35215
VC0494165
p41350
sg35217
I2
sa(dp41351
g35211
I136
sg35212
VCRC
p41352
sg35214
I3
sg35215
VC1527249
p41353
sg35217
I1
sa(dp41354
g35211
I117
sg35212
Vcolorectal cancer
p41355
sg35214
I17
sg35215
VC1527249
p41356
sg35217
I2
sasa(dp41357
g135
(dp41358
(Vc-Myc
p41359
Vcancer progression
p41360
tp41361
I00
ssg35204
VIn this study, we explored the functional role of USP22 in modulating c-Myc stability and its physiological relevance in breast cancer progression.
p41362
sg35206
(lp41363
(dp41364
g35211
I70
sg35212
g41359
sg35214
I5
sg35223
VP12524
p41365
sg35217
I1
sa(dp41366
g35211
I50
sg35212
VUSP22
p41367
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41368
(dp41369
g35211
I128
sg35212
g41360
sg35214
I18
sg35215
VC0178874
p41370
sg35217
I2
sasa(dp41371
g135
(dp41372
(Vc-Myc
p41373
Vbreast cancer
p41374
tp41375
I00
ssg35204
VWe found that USP22 promotes deubiquitination of c-Myc in several breast cancer cell lines, resulting in increased levels of c-Myc.
p41376
sg35206
(lp41377
(dp41378
g35211
I49
sg35212
Vc-Myc
p41379
sg35214
I5
sg35223
VP12524
p41380
sg35217
I1
sa(dp41381
g35211
I14
sg35212
VUSP22
p41382
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41383
g35211
I49
sg35212
g41373
sg35214
I5
sg35223
VP12524
p41384
sg35217
I1
sasg35208
(lp41385
(dp41386
g35211
I66
sg35212
g41374
sg35214
I13
sg35215
VC0678222
p41387
sg35217
I2
sasa(dp41388
g35204
VFurthermore, overexpression of USP22 stimulates breast cancer cell growth and colony formation, and increases c-Myc tumorigenic activity.
p41389
sg35206
(lp41390
(dp41391
g35211
I110
sg35212
Vc-Myc
p41392
sg35214
I5
sg35223
VP12524
p41393
sg35217
I1
sa(dp41394
g35211
I31
sg35212
VUSP22
p41395
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41396
(dp41397
g35211
I55
sg35212
Vcancer cell growth
p41398
sg35214
I18
sg35215
VC1516170
p41399
sg35217
I3
sasa(dp41400
g135
(dp41401
(Vc-Myc
p41402
Vbreast cancer
p41403
tp41404
I00
ssg35204
VIn conclusion, the present study reveals that USP22 in breast cancer cell lines increases c-Myc stability through c-Myc deubiquitination, which is closely correlated with breast cancer progression.
p41405
sg35206
(lp41406
(dp41407
g35211
I90
sg35212
Vc-Myc
p41408
sg35214
I5
sg35223
VP12524
p41409
sg35217
I1
sa(dp41410
g35211
I90
sg35212
g41402
sg35214
I5
sg35223
VP12524
p41411
sg35217
I1
sa(dp41412
g35211
I46
sg35212
VUSP22
p41413
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41414
(dp41415
g35211
I178
sg35212
Vcancer progression
p41416
sg35214
I18
sg35215
VC0178874
p41417
sg35217
I2
sa(dp41418
g35211
I55
sg35212
g41403
sg35214
I13
sg35215
VC0678222
p41419
sg35217
I2
sasa(dp41420
g35204
VIn this study, we investigated the effects of the deubiquitinating enzyme USP22 on the expression of the drug-resistance genes BMI1 and EZH2 in hepatocellular carcinoma (HCC) and on prognosis.
p41421
sg35206
(lp41422
(dp41423
g35211
I136
sg35212
VEZH2
p41424
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp41425
g35211
I74
sg35212
VUSP22
p41426
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41427
g35211
I127
sg35212
VBMI1
p41428
sg35214
I4
sg35223
VP35226
p41429
sg35217
I1
sasg35208
(lp41430
(dp41431
g35211
I170
sg35212
VHCC
p41432
sg35214
I3
sg35215
VC2239176
p41433
sg35217
I1
sa(dp41434
g35211
I144
sg35212
Vhepatocellular carcinoma
p41435
sg35214
I24
sg35215
VC2239176
p41436
sg35217
I2
sasa(dp41437
g35204
VUbiquitin-specific protease 22 (USP22) aberrance has been implicated in several malignancies; however, whether USP22 plays a role in anaplastic thyroid carcinoma (ATC) remains unclear.
p41438
sg35206
(lp41439
(dp41440
g35211
I0
sg35212
VUbiquitin-specific protease 22
p41441
sg35214
I30
sg35223
g12
sg35217
I3
sa(dp41442
g35211
I32
sg35212
VUSP22
p41443
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41444
g35211
I32
sg35212
VUSP22
p41445
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41446
(dp41447
g35211
I80
sg35212
Vmalignancies
p41448
sg35214
I12
sg35215
VC0006826
p41449
sg35217
I1
sa(dp41450
g35211
I163
sg35212
VATC
p41451
sg35214
I3
sg35215
VC0238461
p41452
sg35217
I1
sa(dp41453
g35211
I133
sg35212
Vanaplastic thyroid carcinoma
p41454
sg35214
I28
sg35215
VC0238461
p41455
sg35217
I3
sasa(dp41456
g135
(dp41457
(VSERPINE1
p41458
Vbreast cancer
p41459
tp41460
I00
ssg35204
VCurcumin might have therapeutic potential in breast cancer through regulating breast cancer-related genes, including SERPINE1, PGAP3, MAP3K1, MAPK1, GSTO2, VIM, SPARC, and FGF2.
p41461
sg35206
(lp41462
(dp41463
g35211
I161
sg35212
VSPARC
p41464
sg35214
I5
sg35223
VP09486
p41465
sg35217
I1
sa(dp41466
g35211
I142
sg35212
VMAPK1
p41467
sg35214
I5
sg35223
VP28482
p41468
sg35217
I1
sa(dp41469
g35211
I134
sg35212
VMAP3K1
p41470
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp41471
g35211
I78
sg35212
Vbreast cancer-related genes
p41472
sg35214
I27
sg35223
VP01893
p41473
sg35217
I3
sa(dp41474
g35211
I117
sg35212
g41458
sg35214
I8
sg35223
VP05121
p41475
sg35217
I1
sa(dp41476
g35211
I149
sg35212
VGSTO2
p41477
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41478
g35211
I127
sg35212
VPGAP3
p41479
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41480
g35211
I172
sg35212
VFGF2
p41481
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp41482
(dp41483
g35211
I45
sg35212
Vbreast cancer
p41484
sg35214
I13
sg35215
VC0678222
p41485
sg35217
I2
sa(dp41486
g35211
I45
sg35212
g41459
sg35214
I13
sg35215
VC0678222
p41487
sg35217
I2
sasa(dp41488
g135
(dp41489
(VP4HB
p41490
Vovarian cancer
p41491
tp41492
I01
ssg35204
VOur data showed that the level of CENPE, BAG2, SOD2, GDI2, CORO1C, CFL1, DSTN, CALD1, PHGDH, PDHA1, AKR1B1, TST and TBCA proteins were significantly up-regulated in the fibroblasts co-cultured with ovarian cancer cells, whereas HSPB1, P4HB and VIM were significantly down-regulated.
p41493
sg35206
(lp41494
(dp41495
g35211
I93
sg35212
VPDHA1
p41496
sg35214
I5
sg35223
VP08559
p41497
sg35217
I1
sa(dp41498
g35211
I100
sg35212
VAKR1B1
p41499
sg35214
I6
sg35223
VP15121
p41500
sg35217
I1
sa(dp41501
g35211
I79
sg35212
VCALD1
p41502
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41503
g35211
I67
sg35212
VCFL1
p41504
sg35214
I4
sg35223
VP23528
p41505
sg35217
I1
sa(dp41506
g35211
I59
sg35212
VCORO1C
p41507
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp41508
g35211
I116
sg35212
VTBCA proteins
p41509
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp41510
g35211
I73
sg35212
VDSTN
p41511
sg35214
I4
sg35223
VP60981
p41512
sg35217
I1
sa(dp41513
g35211
I47
sg35212
VSOD2
p41514
sg35214
I4
sg35223
VP04179
p41515
sg35217
I1
sa(dp41516
g35211
I53
sg35212
VGDI2
p41517
sg35214
I4
sg35223
VP50395
p41518
sg35217
I1
sa(dp41519
g35211
I235
sg35212
g41490
sg35214
I4
sg35223
VP07237
p41520
sg35217
I1
sa(dp41521
g35211
I108
sg35212
VTST
p41522
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp41523
g35211
I41
sg35212
VBAG2
p41524
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp41525
g35211
I86
sg35212
VPHGDH
p41526
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41527
g35211
I34
sg35212
VCENPE
p41528
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41529
(dp41530
g35211
I198
sg35212
g41491
sg35214
I14
sg35215
VC1140680
p41531
sg35217
I2
sasa(dp41532
g135
(dp41533
(VCSNK2B
p41534
Vbreast cancer
p41535
tp41536
I01
ssg35204
VPreviously, using systems biology approach and cancer signaling networks, we identified top-5 highly expressed and connected proteins (HSP90AB1, CSNK2B, TK1, YWHAB and VIM) in the invasive MDA-MB-231 breast cancer cell line.
p41537
sg35206
(lp41538
(dp41539
g35211
I158
sg35212
VYWHAB
p41540
sg35214
I5
sg35223
VP31946
p41541
sg35217
I1
sa(dp41542
g35211
I135
sg35212
VHSP90AB1
p41543
sg35214
I8
sg35223
VP08238
p41544
sg35217
I1
sa(dp41545
g35211
I153
sg35212
VTK1
p41546
sg35214
I3
sg35223
VP04183
p41547
sg35217
I1
sa(dp41548
g35211
I145
sg35212
g41534
sg35214
I6
sg35223
VP67870
p41549
sg35217
I1
sasg35208
(lp41550
(dp41551
g35211
I200
sg35212
g41535
sg35214
I13
sg35215
VC0678222
p41552
sg35217
I2
sa(dp41553
g35211
I47
sg35212
Vcancer
p41554
sg35214
I6
sg35215
VC0006826
p41555
sg35217
I1
sasa(dp41556
g35204
VMiR-208b was also upregulated in DCM patients, but not in heart failure patients due to ischemic heart disease or myocarditis.
p41557
sg35206
(lp41558
(dp41559
g35211
I0
sg35212
VMiR-208b
p41560
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp41561
(dp41562
g35211
I58
sg35212
Vheart failure
p41563
sg35214
I13
sg35215
VC0018802
p41564
sg35217
I2
sa(dp41565
g35211
I114
sg35212
Vmyocarditis
p41566
sg35214
I11
sg35215
VC0027059
p41567
sg35217
I1
sa(dp41568
g35211
I88
sg35212
Vischemic heart disease
p41569
sg35214
I22
sg35215
VC0151744
p41570
sg35217
I3
sasa(dp41571
g135
(dp41572
(VBnp
p41573
VHCM
p41574
tp41575
I00
ssg35204
VElevated cAMP levels increased cell size and altered expression levels of cardiac genes and micro-RNAs associated with hypertrophic cardiomyopathy (HCM), including Myh6, Myh7, Myh7b, Tnni3, Anp, Bnp, Gata4, Mef2c, Mef2d, Nfatc1, miR208a, and miR208b.
p41576
sg35206
(lp41577
(dp41578
g35211
I221
sg35212
VNfatc1
p41579
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp41580
g35211
I214
sg35212
VMef2d
p41581
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41582
g35211
I176
sg35212
VMyh7b
p41583
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41584
g35211
I183
sg35212
VTnni3
p41585
sg35214
I5
sg35223
VP19429
p41586
sg35217
I1
sa(dp41587
g35211
I200
sg35212
VGata4
p41588
sg35214
I5
sg35223
VP43694
p41589
sg35217
I1
sa(dp41590
g35211
I190
sg35212
VAnp
p41591
sg35214
I3
sg35223
VP16066
p41592
sg35217
I1
sa(dp41593
g35211
I164
sg35212
VMyh6
p41594
sg35214
I4
sg35223
VP13533
p41595
sg35217
I1
sa(dp41596
g35211
I195
sg35212
g41573
sg35214
I3
sg35223
VP16860
p41597
sg35217
I1
sa(dp41598
g35211
I207
sg35212
VMef2c
p41599
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41600
(dp41601
g35211
I119
sg35212
Vhypertrophic cardiomyopathy
p41602
sg35214
I27
sg35215
VC0007194
p41603
sg35217
I2
sa(dp41604
g35211
I148
sg35212
g41574
sg35214
I3
sg35215
VC0007194
p41605
sg35217
I1
sasa(dp41606
g135
(dp41607
(VMHC mRNA
p41608
Vdilated cardiomyopathy
p41609
tp41610
I00
ssg35204
VThe aim of this study was to determine whether miR-208, miR-208b, and miR-499 are expressed with MHC mRNA in human dilated cardiomyopathy (DCM), and whether these levels are related to left ventricular (LV) function and to clinical outcomes.
p41611
sg35206
(lp41612
(dp41613
g35211
I56
sg35212
VmiR-208b
p41614
sg35214
I8
sg35223
g12
sg35217
I1
sa(dp41615
g35211
I47
sg35212
VmiR-208
p41616
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp41617
g35211
I70
sg35212
VmiR-499
p41618
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp41619
g35211
I97
sg35212
g41608
sg35214
I8
sg35223
VP13747
p41620
sg35217
I2
sasg35208
(lp41621
(dp41622
g35211
I139
sg35212
VDCM
p41623
sg35214
I3
sg35215
VC0007193
p41624
sg35217
I1
sa(dp41625
g35211
I115
sg35212
g41609
sg35214
I22
sg35215
VC0007193
p41626
sg35217
I2
sasa(dp41627
g35204
VThe goal of this study was to examine the long-term effects of maternal postpartum corticosterone (CORT, a model of postpartum depression) and concurrent FLX on hippocampal neurogenesis in male and female offspring.
p41628
sg35206
(lp41629
sg35208
(lp41630
(dp41631
g35211
I116
sg35212
Vpostpartum depression
p41632
sg35214
I21
sg35215
VC0221074
p41633
sg35217
I2
sasa(dp41634
g35204
VUsing high-resolution magnetic resonance imaging (MRI), the present pilot study examined the relationship between morning serum cortisol, DHEA(S), and HCV in nineteen normal controls and eighteen unmedicated subjects with Major Depressive Disorder (MDD).
p41635
sg35206
(lp41636
sg35208
(lp41637
(dp41638
g35211
I222
sg35212
VMajor Depressive Disorder
p41639
sg35214
I25
sg35215
VC1269683
p41640
sg35217
I3
sa(dp41641
g35211
I249
sg35212
VMDD
p41642
sg35214
I3
sg35215
VC1269683
p41643
sg35217
I1
sasa(dp41644
g35204
VTo assess the association of neural development-related genes LIS1and TSNAX with bipolar disorder in a Chinese Han population.
p41645
sg35206
(lp41646
(dp41647
g35211
I56
sg35212
Vgenes LIS1and TSNAX
p41648
sg35214
I19
sg35223
g12
sg35217
I3
sasg35208
(lp41649
(dp41650
g35211
I81
sg35212
Vbipolar disorder
p41651
sg35214
I16
sg35215
VC0005586
p41652
sg35217
I2
sasa(dp41653
g135
(dp41654
(VLIS1
p41655
Vbipolar I disorder
p41656
tp41657
I00
ssg35204
VOur results indicated that LIS1 and TSNAX genes are not associated with susceptibility to bipolar I disorder in Chinese Han population.
p41658
sg35206
(lp41659
(dp41660
g35211
I27
sg35212
g41655
sg35214
I4
sg35223
VP43034
p41661
sg35217
I1
sa(dp41662
g35211
I36
sg35212
VTSNAX genes
p41663
sg35214
I11
sg35223
g12
sg35217
I2
sasg35208
(lp41664
(dp41665
g35211
I27
sg35212
VLIS1
p41666
sg35214
I4
sg35215
VC1843916
p41667
sg35217
I1
sa(dp41668
g35211
I90
sg35212
g41656
sg35214
I18
sg35215
VC0853193
p41669
sg35217
I3
sasa(dp41670
g35204
VThe translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) has been associated with psychiatric disorders, including schizophrenia, MDD and bipolar disorder.
p41671
sg35206
(lp41672
(dp41673
g35211
I4
sg35212
Vtranslin-associated factor X gene
p41674
sg35214
I33
sg35223
g12
sg35217
I4
sa(dp41675
g35211
I81
sg35212
VDISC1
p41676
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41677
g35211
I39
sg35212
VTSNAX
p41678
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41679
g35211
I45
sg35212
V/disrupted-in-schizophrenia-1 gene
p41680
sg35214
I34
sg35223
g12
sg35217
I2
sasg35208
(lp41681
(dp41682
g35211
I59
sg35212
Vschizophrenia
p41683
sg35214
I13
sg35215
VC0036341
p41684
sg35217
I1
sa(dp41685
g35211
I59
sg35212
Vschizophrenia
p41686
sg35214
I13
sg35215
VC0036341
p41687
sg35217
I1
sa(dp41688
g35211
I161
sg35212
VMDD
p41689
sg35214
I3
sg35215
VC1269683
p41690
sg35217
I1
sa(dp41691
g35211
I113
sg35212
Vpsychiatric disorders
p41692
sg35214
I21
sg35215
VC0004936
p41693
sg35217
I2
sa(dp41694
g35211
I169
sg35212
Vbipolar disorder
p41695
sg35214
I16
sg35215
VC0005586
p41696
sg35217
I2
sasa(dp41697
g35204
VSeveral investigations have reported that the translin-associated factor X gene (TSNAX)/disrupted-in-schizophrenia-1 gene (DISC1) was associated with major psychiatric disorders including schizophrenia, bipolar disorder (BP), and major depressive disorder (MDD).
p41698
sg35206
(lp41699
(dp41700
g35211
I123
sg35212
VDISC1
p41701
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41702
g35211
I87
sg35212
V/disrupted-in-schizophrenia-1 gene
p41703
sg35214
I34
sg35223
g12
sg35217
I2
sa(dp41704
g35211
I46
sg35212
Vtranslin-associated factor X gene
p41705
sg35214
I33
sg35223
g12
sg35217
I4
sa(dp41706
g35211
I81
sg35212
VTSNAX
p41707
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41708
(dp41709
g35211
I230
sg35212
Vmajor depressive disorder
p41710
sg35214
I25
sg35215
VC1269683
p41711
sg35217
I3
sa(dp41712
g35211
I101
sg35212
Vschizophrenia
p41713
sg35214
I13
sg35215
VC0036341
p41714
sg35217
I1
sa(dp41715
g35211
I257
sg35212
VMDD
p41716
sg35214
I3
sg35215
VC1269683
p41717
sg35217
I1
sa(dp41718
g35211
I156
sg35212
Vpsychiatric disorders
p41719
sg35214
I21
sg35215
VC0004936
p41720
sg35217
I2
sa(dp41721
g35211
I221
sg35212
VBP
p41722
sg35214
I2
sg35215
VC0005586
p41723
sg35217
I1
sa(dp41724
g35211
I203
sg35212
Vbipolar disorder
p41725
sg35214
I16
sg35215
VC0005586
p41726
sg35217
I2
sa(dp41727
g35211
I101
sg35212
Vschizophrenia
p41728
sg35214
I13
sg35215
VC0036341
p41729
sg35217
I1
sasa(dp41730
g135
(dp41731
(VSchizophrenia 1
p41732
VSchizophrenia 1
p41733
tp41734
I00
ssg35204
VThe Translin-associated factor X/Disrupted in Schizophrenia 1 (TRAX/DISC) region was first implicated as a susceptibility locus for schizophrenia by analysis of a large Scottish family in which a t(1;11) translocation cosegregates with schizophrenia, bipolar disorder and recurrent major depression.
p41735
sg35206
(lp41736
(dp41737
g35211
I4
sg35212
VTranslin-associated factor X
p41738
sg35214
I28
sg35223
g12
sg35217
I3
sa(dp41739
g35211
I46
sg35212
g41732
sg35214
I15
sg35223
VP35462
p41740
sg35217
I2
sa(dp41741
g35211
I63
sg35212
VTRAX
p41742
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp41743
(dp41744
g35211
I272
sg35212
Vrecurrent major depression
p41745
sg35214
I26
sg35215
VC0154409
p41746
sg35217
I3
sa(dp41747
g35211
I132
sg35212
Vschizophrenia
p41748
sg35214
I13
sg35215
VC0036341
p41749
sg35217
I1
sa(dp41750
g35211
I132
sg35212
Vschizophrenia
p41751
sg35214
I13
sg35215
VC0036341
p41752
sg35217
I1
sa(dp41753
g35211
I204
sg35212
Vtranslocation
p41754
sg35214
I13
sg35215
VC0040715
p41755
sg35217
I1
sa(dp41756
g35211
I251
sg35212
Vbipolar disorder
p41757
sg35214
I16
sg35215
VC0005586
p41758
sg35217
I2
sa(dp41759
g35211
I46
sg35212
g41733
sg35214
I15
sg35215
VC0220702
p41760
sg35217
I2
sasa(dp41761
g35204
VTwo further regions, one in TRAX and the second in DISC1, showed weaker evidence for sex-specific associations of individual haplotypes with bipolar disorder in men and women respectively, P&lt;0.01.
p41762
sg35206
(lp41763
(dp41764
g35211
I51
sg35212
VDISC1
p41765
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41766
(dp41767
g35211
I141
sg35212
Vbipolar disorder
p41768
sg35214
I16
sg35215
VC0005586
p41769
sg35217
I2
sasa(dp41770
g35204
VCompared with non-CKD controls, mice with CKD had downregulated expression of GSTA4 at the mRNA and protein levels, with concomitant increase in 4-HNE in arteries and veins.
p41771
sg35206
(lp41772
(dp41773
g35211
I78
sg35212
VGSTA4
p41774
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp41775
sa(dp41776
g135
(dp41777
(Vmitogen activated protein kinases (MAPKs), activator protein-1
p41778
Vnephropathy
p41779
tp41780
I00
ssg35204
VThe data showed age-related upregulation of downstream signaling molecules such as mitogen activated protein kinases (MAPKs), activator protein-1 (AP-1), NF-KB, and COX-2 in a cell culture cell system.Taken together, the results of this study show that the formation of adducts between 4-HNE and Src activates inflammatory signaling pathways in the aged kidney, contributing to age-related nephropathy.
p41781
sg35206
(lp41782
(dp41783
g35211
I165
sg35212
VCOX-2
p41784
sg35214
I5
sg35223
VP35354
p41785
sg35217
I1
sa(dp41786
g35211
I296
sg35212
VSrc
p41787
sg35214
I3
sg35223
VP12931
p41788
sg35217
I1
sa(dp41789
g35211
I147
sg35212
VAP-1
p41790
sg35214
I4
sg35223
VP01100
p41791
sg35217
I1
sa(dp41792
g35211
I288
sg35212
VHNE
p41793
sg35214
I3
sg35223
VP08246
p41794
sg35217
I1
sa(dp41795
g35211
I83
sg35212
g41778
sg35214
I62
sg35223
VP17980
p41796
sg35217
I7
sasg35208
(lp41797
(dp41798
g35211
I390
sg35212
g41779
sg35214
I11
sg35215
VC0022658
p41799
sg35217
I1
sasa(dp41800
g135
(dp41801
(Vplasma 4-HNE
p41802
Vrenal failure
p41803
tp41804
I00
ssg35204
VElevated plasma 4-HNE has been associated with renal failure, septic shock and cardiopulmonary bypass surgery.
p41805
sg35206
(lp41806
(dp41807
g35211
I9
sg35212
g41802
sg35214
I12
sg35223
VP08246
p41808
sg35217
I2
sasg35208
(lp41809
(dp41810
g35211
I62
sg35212
Vseptic shock
p41811
sg35214
I12
sg35215
VC0036983
p41812
sg35217
I2
sa(dp41813
g35211
I47
sg35212
g41803
sg35214
I13
sg35215
VC0035078
p41814
sg35217
I2
sasa(dp41815
g135
(dp41816
(VPlGF
p41817
Vglaucoma
p41818
tp41819
I00
ssg35204
VAdditionally, the effect of PlGF (inhibition) on IOP was investigated, since aqueous PlGF is known to be upregulated in glaucoma patients.
p41820
sg35206
(lp41821
(dp41822
g35211
I28
sg35212
VPlGF
p41823
sg35214
I4
sg35223
VP49763
p41824
sg35217
I1
sa(dp41825
g35211
I28
sg35212
g41817
sg35214
I4
sg35223
VP49763
p41826
sg35217
I1
sasg35208
(lp41827
(dp41828
g35211
I120
sg35212
g41818
sg35214
I8
sg35215
VC0017601
p41829
sg35217
I1
sasa(dp41830
g135
(dp41831
(VPlGF
p41832
Vglaucoma
p41833
tp41834
I00
ssg35204
VInhibition of PlGF also might open alternative perspectives as IOP-lowering strategy for glaucoma patients with increased aqueous PlGF levels.
p41835
sg35206
(lp41836
(dp41837
g35211
I14
sg35212
VPlGF
p41838
sg35214
I4
sg35223
VP49763
p41839
sg35217
I1
sa(dp41840
g35211
I14
sg35212
g41832
sg35214
I4
sg35223
VP49763
p41841
sg35217
I1
sasg35208
(lp41842
(dp41843
g35211
I89
sg35212
g41833
sg35214
I8
sg35215
VC0017601
p41844
sg35217
I1
sasa(dp41845
g135
(dp41846
(Vplacental growth factor
p41847
VNVG
p41848
tp41849
I00
ssg35204
VTo evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and after an intravitreal injection of ranibizumab (IVR) and to determine the underlying correlation between the levels.
p41850
sg35206
(lp41851
(dp41852
g35211
I80
sg35212
Vvascular endothelial growth factor-A
p41853
sg35214
I36
sg35223
g12
sg35217
I4
sa(dp41854
g35211
I118
sg35212
VVEGF-A
p41855
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp41856
g35211
I70
sg35212
VPlGF
p41857
sg35214
I4
sg35223
VP49763
p41858
sg35217
I1
sa(dp41859
g35211
I45
sg35212
g41847
sg35214
I23
sg35223
VP49763
p41860
sg35217
I3
sasg35208
(lp41861
(dp41862
g35211
I160
sg35212
Vneovascular glaucoma
p41863
sg35214
I20
sg35215
VC0017609
p41864
sg35217
I2
sa(dp41865
g35211
I129
sg35212
Vaqueous humor
p41866
sg35214
I13
sg35215
VC0595936
p41867
sg35217
I2
sa(dp41868
g35211
I182
sg35212
g41848
sg35214
I3
sg35215
VC0017609
p41869
sg35217
I1
sasa(dp41870
g135
(dp41871
(VPlGF
p41872
Vglaucoma
p41873
tp41874
I00
ssg35204
VELISA experiments showed that PlGF levels were significantly increased in aqueous humour of glaucoma patients and after VEGF treatment, which may indicate an important contribution of this growth factor to wound healing after trabeculectomy.
p41875
sg35206
(lp41876
(dp41877
g35211
I30
sg35212
g41872
sg35214
I4
sg35223
VP49763
p41878
sg35217
I1
sasg35208
(lp41879
(dp41880
g35211
I92
sg35212
g41873
sg35214
I8
sg35215
VC0017601
p41881
sg35217
I1
sasa(dp41882
g135
(dp41883
(Vanti-PlGF antibody
p41884
Vglaucoma
p41885
tp41886
I00
ssg35204
VUsing a mouse model of glaucoma filtration surgery, we were able to show that intracameral injection of a previously characterized anti-PlGF antibody (ThromboGenics NV) significantly improved surgical outcome by increasing bleb survival and bleb area.
p41887
sg35206
(lp41888
(dp41889
g35211
I131
sg35212
g41884
sg35214
I18
sg35223
VP49763
p41890
sg35217
I2
sasg35208
(lp41891
(dp41892
g35211
I223
sg35212
Vbleb
p41893
sg35214
I4
sg35215
VC0005758
p41894
sg35217
I1
sa(dp41895
g35211
I223
sg35212
Vbleb
p41896
sg35214
I4
sg35215
VC0005758
p41897
sg35217
I1
sa(dp41898
g35211
I23
sg35212
g41885
sg35214
I8
sg35215
VC0017601
p41899
sg35217
I1
sasa(dp41900
g35204
VThe 17-phenyl PGF(2Alfa) analogue bimatoprost (10a) is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma or ocular hypertension.
p41901
sg35206
(lp41902
sg35208
(lp41903
(dp41904
g35211
I154
sg35212
Vocular hypertension
p41905
sg35214
I19
sg35215
VC0028840
p41906
sg35217
I2
sa(dp41907
g35211
I142
sg35212
Vglaucoma
p41908
sg35214
I8
sg35215
VC0017601
p41909
sg35217
I1
sa(dp41910
g35211
I83
sg35212
Vhypotensive
p41911
sg35214
I11
sg35215
VC0857353
p41912
sg35217
I1
sasa(dp41913
g35204
VLatanoprost, a synthetic derivative of the natural prostaglandin F(2a) (PGF(2a)), is a powerful antiglaucoma agent with ocular hypotensive and neuroprotective effects.
p41914
sg35206
(lp41915
sg35208
(lp41916
(dp41917
g35211
I127
sg35212
Vhypotensive
p41918
sg35214
I11
sg35215
VC0857353
p41919
sg35217
I1
sasa(dp41920
g35204
VEndotoxaemia enhanced early VT occurs in a TLR-4 and ICAM-1 dependent fashion, and is potentiated by neutropenia.
p41921
sg35206
(lp41922
(dp41923
g35211
I43
sg35212
VTLR-4
p41924
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41925
g35211
I53
sg35212
VICAM-1
p41926
sg35214
I6
sg35223
VP05362
p41927
sg35217
I1
sasg35208
(lp41928
sa(dp41929
g135
(dp41930
(VACE
p41931
Vfebrile neutropenia
p41932
tp41933
I00
ssg35204
VThe aim of this study was to investigate the mannose-binding lectin 2 (MBL-2), interleukin (IL)-4, Toll-like receptor 4 (TLR-4), angiotensin converting enzyme (ACE), chemokine receptor 5 (CCR-5), and IL-1 receptor antagonist (RA) gene polymorphisms (GPs) in acute leukemias (ALs) and to evaluate their roles in febrile neutropenia (FN) resulting from chemotherapy.
p41934
sg35206
(lp41935
(dp41936
g35211
I45
sg35212
Vmannose-binding lectin 2
p41937
sg35214
I24
sg35223
VP11226
p41938
sg35217
I3
sa(dp41939
g35211
I71
sg35212
VMBL-2
p41940
sg35214
I5
sg35223
VP11226
p41941
sg35217
I1
sa(dp41942
g35211
I200
sg35212
VIL-1 receptor
p41943
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp41944
g35211
I79
sg35212
Vinterleukin (IL)-4
p41945
sg35214
I18
sg35223
VP60568
p41946
sg35217
I2
sa(dp41947
g35211
I129
sg35212
Vangiotensin converting enzyme
p41948
sg35214
I29
sg35223
VP12821
p41949
sg35217
I3
sa(dp41950
g35211
I188
sg35212
VCCR-5
p41951
sg35214
I5
sg35223
VP61073
p41952
sg35217
I1
sa(dp41953
g35211
I121
sg35212
VTLR-4
p41954
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp41955
g35211
I166
sg35212
Vchemokine receptor 5
p41956
sg35214
I20
sg35223
VP61073
p41957
sg35217
I3
sa(dp41958
g35211
I99
sg35212
VToll-like receptor 4
p41959
sg35214
I20
sg35223
g12
sg35217
I3
sa(dp41960
g35211
I160
sg35212
g41931
sg35214
I3
sg35223
VP12821
p41961
sg35217
I1
sasg35208
(lp41962
(dp41963
g35211
I332
sg35212
VFN
p41964
sg35214
I2
sg35215
VC0746883
p41965
sg35217
I1
sa(dp41966
g35211
I250
sg35212
VGPs
p41967
sg35214
I3
sg35215
VC0272302
p41968
sg35217
I1
sa(dp41969
g35211
I230
sg35212
Vgene polymorphisms
p41970
sg35214
I18
sg35215
VC0272302
p41971
sg35217
I2
sa(dp41972
g35211
I258
sg35212
Vacute leukemias
p41973
sg35214
I15
sg35215
VC0085669
p41974
sg35217
I2
sa(dp41975
g35211
I275
sg35212
VALs
p41976
sg35214
I3
sg35215
VC0002736
p41977
sg35217
I1
sa(dp41978
g35211
I311
sg35212
g41932
sg35214
I19
sg35215
VC0746883
p41979
sg35217
I2
sasa(dp41980
g135
(dp41981
(VIFNG 874T
p41982
Vinvasive aspergillosis
p41983
tp41984
I00
ssg35204
VIn a multivariate analysis, adjusted for occurrence of graft-versus-host-disease, Cytomegalovirus serostatus and duration of neutropenia, paired presence of the TLR4 1063A&gt;G and IFNG 874T&gt;A single nucleotide polymorphisms showed a trend towards increased susceptibility to invasive aspergillosis (p = 0.04).
p41985
sg35206
(lp41986
(dp41987
g35211
I181
sg35212
g41982
sg35214
I9
sg35223
VP01579
p41988
sg35217
I2
sasg35208
(lp41989
(dp41990
g35211
I55
sg35212
Vgraft-versus-host-disease
p41991
sg35214
I25
sg35215
VC0018133
p41992
sg35217
I1
sa(dp41993
g35211
I279
sg35212
g41983
sg35214
I22
sg35215
VC0238013
p41994
sg35217
I2
sasa(dp41995
g35204
VFour SNPs in the TLR4 gene (rs10759931, rs11536889, rs1927911 and rs6478317) were associated with an increased risk of developing chemotherapy-induced neutropenia, each sustaining correction for multiple testing.
p41996
sg35206
(lp41997
sg35208
(lp41998
(dp41999
g35211
I130
sg35212
Vchemotherapy-induced neutropenia
p42000
sg35214
I32
sg35215
VC1827687
p42001
sg35217
I2
sasa(dp42002
g35204
VThe rs1064395 single nucleotide polymorphism, within the gene encoding neurocan (NCAN), is reported to be associated with schizophrenia in European populations and may influence brain structure in patients with schizophrenia.
p42003
sg35206
(lp42004
(dp42005
g35211
I81
sg35212
VNCAN
p42006
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp42007
g35211
I57
sg35212
Vgene encoding neurocan
p42008
sg35214
I22
sg35223
g12
sg35217
I3
sasg35208
(lp42009
(dp42010
g35211
I122
sg35212
Vschizophrenia
p42011
sg35214
I13
sg35215
VC0036341
p42012
sg35217
I1
sa(dp42013
g35211
I122
sg35212
Vschizophrenia
p42014
sg35214
I13
sg35215
VC0036341
p42015
sg35217
I1
sasa(dp42016
g35204
VIn this study, we aimed to explore whether NCAN rs1064395 confers some risk for schizophrenia and cognitive dysfunction in Han Chinese.
p42017
sg35206
(lp42018
(dp42019
g35211
I43
sg35212
VNCAN rs1064395
p42020
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp42021
(dp42022
g35211
I80
sg35212
Vschizophrenia
p42023
sg35214
I13
sg35215
VC0036341
p42024
sg35217
I1
sa(dp42025
g35211
I98
sg35212
Vcognitive dysfunction
p42026
sg35214
I21
sg35215
VC0338656
p42027
sg35217
I2
sasa(dp42028
g35204
VThe A allele of the single nucleotide polymorphism (SNP) rs1064395 in the NCAN gene has recently been identified as a susceptibility factor for bipolar disorder and schizophrenia.
p42029
sg35206
(lp42030
(dp42031
g35211
I74
sg35212
VNCAN gene
p42032
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp42033
(dp42034
g35211
I144
sg35212
Vbipolar disorder
p42035
sg35214
I16
sg35215
VC0005586
p42036
sg35217
I2
sa(dp42037
g35211
I165
sg35212
Vschizophrenia
p42038
sg35214
I13
sg35215
VC0036341
p42039
sg35217
I1
sasa(dp42040
g135
(dp42041
(Vaggrecan
p42042
Vschizophrenia
p42043
tp42044
I01
ssg35204
VRecently, it was shown that some CSPGs members like aggrecan, versican, and neurocan were strongly involved in brain disorders like bipolar disorder (BD), schizophrenia, and ADHD.
p42045
sg35206
(lp42046
(dp42047
g35211
I52
sg35212
g42042
sg35214
I8
sg35223
VP16112
p42048
sg35217
I1
sa(dp42049
g35211
I174
sg35212
VADHD
p42050
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp42051
(dp42052
g35211
I174
sg35212
VADHD
p42053
sg35214
I4
sg35215
VC1263846
p42054
sg35217
I1
sa(dp42055
g35211
I111
sg35212
Vbrain disorders
p42056
sg35214
I15
sg35215
VC0006111
p42057
sg35217
I2
sa(dp42058
g35211
I132
sg35212
Vbipolar disorder
p42059
sg35214
I16
sg35215
VC0005586
p42060
sg35217
I2
sa(dp42061
g35211
I150
sg35212
VBD
p42062
sg35214
I2
sg35215
VC0005586
p42063
sg35217
I1
sa(dp42064
g35211
I155
sg35212
g42043
sg35214
I13
sg35215
VC0036341
p42065
sg35217
I1
sasa(dp42066
g35204
VRecent studies have provided strong evidence that variation in the gene neurocan (NCAN, rs1064395) is a common risk factor for bipolar disorder (BD) and schizophrenia.
p42067
sg35206
(lp42068
(dp42069
g35211
I82
sg35212
VNCAN
p42070
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp42071
g35211
I72
sg35212
Vneurocan
p42072
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp42073
(dp42074
g35211
I145
sg35212
VBD
p42075
sg35214
I2
sg35215
VC0005586
p42076
sg35217
I1
sa(dp42077
g35211
I153
sg35212
Vschizophrenia
p42078
sg35214
I13
sg35215
VC0036341
p42079
sg35217
I1
sa(dp42080
g35211
I127
sg35212
Vbipolar disorder
p42081
sg35214
I16
sg35215
VC0005586
p42082
sg35217
I2
sasa(dp42083
g35204
VIn this work, authors investigated the association between previously confirmed bipolar disorder genetic risk factor- neurocan with schizophrenia in a population sample of Bosnia and Herzegovina.
p42084
sg35206
(lp42085
sg35208
(lp42086
(dp42087
g35211
I132
sg35212
Vschizophrenia
p42088
sg35214
I13
sg35215
VC0036341
p42089
sg35217
I1
sa(dp42090
g35211
I80
sg35212
Vbipolar disorder
p42091
sg35214
I16
sg35215
VC0005586
p42092
sg35217
I2
sasa(dp42093
g35204
VA case-control analysis of common genetic polymorphism within neurocan gene and schizophrenia status in a consecutively sampled patient cohort have been done using Fisher-exact test with odds-ratio calculation.
p42094
sg35206
(lp42095
sg35208
(lp42096
(dp42097
g35211
I80
sg35212
Vschizophrenia
p42098
sg35214
I13
sg35215
VC0036341
p42099
sg35217
I1
sasa(dp42100
g35204
VOur data suggest that genetic variation in NCAN is a common risk factor for BD and schizophrenia.
p42101
sg35206
(lp42102
(dp42103
g35211
I43
sg35212
VNCAN
p42104
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp42105
(dp42106
g35211
I83
sg35212
Vschizophrenia
p42107
sg35214
I13
sg35215
VC0036341
p42108
sg35217
I1
sasa(dp42109
g135
(dp42110
(VCD28
p42111
Vprimary sclerosing cholangitis
p42112
tp42113
I01
ssg35204
VIn contrast, studies have associated primary biliary cirrhosis and primary sclerosing cholangitis with genes encoding major histocompatibility complex proteins and identified loci associated with microbial sensing and immune regulatory pathways outside this region, such as genes encoding IL12, STAT4, IRF5, IL2 and its receptor (IL2R), CD28, and CD80.
p42114
sg35206
(lp42115
(dp42116
g35211
I308
sg35212
VIL2 and its receptor
p42117
sg35214
I20
sg35223
VP01589
p42118
sg35217
I4
sa(dp42119
g35211
I330
sg35212
VIL2R
p42120
sg35214
I4
sg35223
VP01589
p42121
sg35217
I1
sa(dp42122
g35211
I302
sg35212
VIRF5
p42123
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp42124
g35211
I118
sg35212
Vmajor histocompatibility complex proteins
p42125
sg35214
I41
sg35223
VP18464
p42126
sg35217
I4
sa(dp42127
g35211
I347
sg35212
VCD80
p42128
sg35214
I4
sg35223
VP33681
p42129
sg35217
I1
sa(dp42130
g35211
I295
sg35212
VSTAT4
p42131
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp42132
g35211
I337
sg35212
g42111
sg35214
I4
sg35223
VP33681
p42133
sg35217
I1
sasg35208
(lp42134
(dp42135
g35211
I37
sg35212
Vprimary biliary cirrhosis
p42136
sg35214
I25
sg35215
VC0008312
p42137
sg35217
I3
sa(dp42138
g35211
I67
sg35212
g42112
sg35214
I30
sg35215
VC0566602
p42139
sg35217
I3
sasa(dp42140
g135
(dp42141
(VsPLA2
p42142
Vtumor necrosis
p42143
tp42144
I00
ssg35204
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p42145
sg35206
(lp42146
(dp42147
g35211
I216
sg35212
VTNF-Alfa
p42148
sg35214
I8
sg35223
VP01375
p42149
sg35217
I1
sa(dp42150
g35211
I177
sg35212
VIL-1Beta
p42151
sg35214
I8
sg35223
VP01584
p42152
sg35217
I1
sa(dp42153
g35211
I158
sg35212
Vinterleukin-1Beta
p42154
sg35214
I17
sg35223
VP01584
p42155
sg35217
I1
sa(dp42156
g35211
I188
sg35212
Vtumor necrosis factor Alfa
p42157
sg35214
I26
sg35223
VP01375
p42158
sg35217
I4
sa(dp42159
g35211
I70
sg35212
g42142
sg35214
I5
sg35223
VP14555
p42160
sg35217
I1
sasg35208
(lp42161
(dp42162
g35211
I8
sg35212
Vcondition
p42163
sg35214
I9
sg35215
VC0012634
p42164
sg35217
I1
sa(dp42165
g35211
I43
sg35212
Vmyonecrosis
p42166
sg35214
I11
sg35215
VC0235957
p42167
sg35217
I1
sa(dp42168
g35211
I33
sg35212
Vedema
p42169
sg35214
I5
sg35215
VC0013604
p42170
sg35217
I1
sa(dp42171
g35211
I188
sg35212
g42143
sg35214
I14
sg35215
VC0333516
p42172
sg35217
I2
sasa(dp42173
g135
(dp42174
(VsPLA2
p42175
Voxidative stress
p42176
tp42177
I00
ssg35204
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p42178
sg35206
(lp42179
(dp42180
g35211
I60
sg35212
g42175
sg35214
I5
sg35223
VP14555
p42181
sg35217
I1
sasg35208
(lp42182
(dp42183
g35211
I115
sg35212
Vmyonecrosis
p42184
sg35214
I11
sg35215
VC0235957
p42185
sg35217
I1
sa(dp42186
g35211
I105
sg35212
Vedema
p42187
sg35214
I5
sg35215
VC0013604
p42188
sg35217
I1
sa(dp42189
g35211
I81
sg35212
g42176
sg35214
I16
sg35215
VC0242606
p42190
sg35217
I2
sasa(dp42191
g35204
VTherefore, it's necessary to express CssPLA2 in water-soluble form and determine whether the enzymatic activity of CssPLA2 or cell signalling pathways is involved in liver fibrosis caused by clonorchiasis.
p42192
sg35206
(lp42193
sg35208
(lp42194
(dp42195
g35211
I191
sg35212
Vclonorchiasis
p42196
sg35214
I13
sg35215
VC0009021
p42197
sg35217
I1
sa(dp42198
g35211
I166
sg35212
Vliver fibrosis
p42199
sg35214
I14
sg35215
VC0239946
p42200
sg35217
I2
sasa(dp42201
g35204
VWe sought to investigate if mast cell activation and increases in secretory sPLA2s are associated with an increase in PAF and occurrence of dengue haemorrhagic fever (DHF).
p42202
sg35206
(lp42203
(dp42204
g35211
I66
sg35212
Vsecretory sPLA2s
p42205
sg35214
I16
sg35223
g12
sg35217
I2
sasg35208
(lp42206
(dp42207
g35211
I167
sg35212
VDHF
p42208
sg35214
I3
sg35215
VC0019100
p42209
sg35217
I1
sa(dp42210
g35211
I140
sg35212
Vdengue haemorrhagic fever
p42211
sg35214
I25
sg35215
VC0019100
p42212
sg35217
I3
sa(dp42213
g35211
I118
sg35212
VPAF
p42214
sg35214
I3
sg35215
VC0235480
p42215
sg35217
I1
sasa(dp42216
g135
(dp42217
(VsPLA2
p42218
VDF
p42219
tp42220
I00
ssg35204
VThe changes in the levels of mast cell tryptase, PAF and the activity of sPLA2 were determined throughout the course of illness in 13 adult patients with DHF, and 30 patients with dengue fever (DF).
p42221
sg35206
(lp42222
(dp42223
g35211
I49
sg35212
VPAF
p42224
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp42225
g35211
I73
sg35212
g42218
sg35214
I5
sg35223
VP14555
p42226
sg35217
I1
sa(dp42227
g35211
I29
sg35212
Vmast cell tryptase
p42228
sg35214
I18
sg35223
VP15157
p42229
sg35217
I3
sasg35208
(lp42230
(dp42231
g35211
I49
sg35212
VPAF
p42232
sg35214
I3
sg35215
VC0235480
p42233
sg35217
I1
sa(dp42234
g35211
I180
sg35212
Vdengue fever
p42235
sg35214
I12
sg35215
VC0011311
p42236
sg35217
I2
sa(dp42237
g35211
I110
sg35212
Vcourse of illness
p42238
sg35214
I17
sg35215
VC0242656
p42239
sg35217
I3
sa(dp42240
g35211
I194
sg35212
g42219
sg35214
I2
sg35215
VC0011311
p42241
sg35217
I1
sasa(dp42242
g135
(dp42243
(VPLA2G2A
p42244
VHCC
p42245
tp42246
I00
ssg35204
VThe difference in serum levels of PLA2G2A was analyzed among chronic hepatitis B (CHB), LC, and HCC patients.
p42247
sg35206
(lp42248
(dp42249
g35211
I34
sg35212
g42244
sg35214
I7
sg35223
VP14555
p42250
sg35217
I1
sasg35208
(lp42251
(dp42252
g35211
I82
sg35212
VCHB
p42253
sg35214
I3
sg35215
VC0151517
p42254
sg35217
I1
sa(dp42255
g35211
I61
sg35212
Vchronic hepatitis B
p42256
sg35214
I19
sg35215
VC0524909
p42257
sg35217
I3
sa(dp42258
g35211
I96
sg35212
g42245
sg35214
I3
sg35215
VC2239176
p42259
sg35217
I1
sasa(dp42260
g135
(dp42261
(Vphospholipases A2
p42262
Vmalaria
p42263
tp42264
I00
ssg35204
VWe have previously shown that secreted phospholipases A2 (sPLA2s) from animal venoms inhibit the in vitro development of Plasmodium falciparum, the agent of malaria.
p42265
sg35206
(lp42266
(dp42267
g35211
I58
sg35212
VsPLA2s
p42268
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp42269
g35211
I39
sg35212
g42262
sg35214
I17
sg35223
VP04054
p42270
sg35217
I2
sasg35208
(lp42271
(dp42272
g35211
I157
sg35212
g42263
sg35214
I7
sg35215
VC0024530
p42273
sg35217
I1
sasa(dp42274
g135
(dp42275
(VsPLA2
p42276
Vmalaria
p42277
tp42278
I00
ssg35204
VIn addition, the inflammatory-type human group IIA (hGIIA) sPLA2 circulates at high levels in the serum of malaria patients.
p42279
sg35206
(lp42280
(dp42281
g35211
I59
sg35212
g42276
sg35214
I5
sg35223
VP14555
p42282
sg35217
I1
sasg35208
(lp42283
(dp42284
g35211
I107
sg35212
g42277
sg35214
I7
sg35215
VC0024530
p42285
sg35217
I1
sasa(dp42286
g35204
VTogether, our findings indicate that 4 human sPLA2s are active against P. falciparum in vitro and pave the way to future investigations on their in vivo contribution in malaria pathophysiology.
p42287
sg35206
(lp42288
sg35208
(lp42289
(dp42290
g35211
I169
sg35212
Vmalaria
p42291
sg35214
I7
sg35215
VC0024530
p42292
sg35217
I1
sasa(dp42293
g35204
VTwo subtypes of phospholipases A2 (PLA2s) with the ability to induce myonecrosis, 'Asp49' and 'Lys49' myotoxins, often coexist in viperid snake venoms.
p42294
sg35206
(lp42295
(dp42296
g35211
I16
sg35212
Vphospholipases A2
p42297
sg35214
I17
sg35223
VP04054
p42298
sg35217
I2
sa(dp42299
g35211
I35
sg35212
VPLA2s
p42300
sg35214
I5
sg35223
VP04054
p42301
sg35217
I1
sasg35208
(lp42302
(dp42303
g35211
I69
sg35212
Vmyonecrosis
p42304
sg35214
I11
sg35215
VC0235957
p42305
sg35217
I1
sasa(dp42306
g35204
VIn order to assess the contribution of the IL-18 to susceptibility to Chronic Chagas Disease, we investigated the association between a single nucleotide polymorphism (SNP) located in the IL-18 gene with the risk of developing Chagas cardiomyopathy.
p42307
sg35206
(lp42308
sg35208
(lp42309
(dp42310
g35211
I227
sg35212
VChagas cardiomyopathy
p42311
sg35214
I21
sg35215
VC0007930
p42312
sg35217
I2
sa(dp42313
g35211
I78
sg35212
VChagas Disease
p42314
sg35214
I14
sg35215
VC0041234
p42315
sg35217
I2
sasa(dp42316
g35204
VWe analyzed the rs2043055 marker in the IL18 gene in a cohort of Chagas disease cardiomyopathy patients (n=849) and asymptomatic subjects (n=202).
p42317
sg35206
(lp42318
(dp42319
g35211
I40
sg35212
VIL18 gene
p42320
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp42321
(dp42322
g35211
I80
sg35212
Vcardiomyopathy
p42323
sg35214
I14
sg35215
VC0878544
p42324
sg35217
I1
sa(dp42325
g35211
I65
sg35212
VChagas disease
p42326
sg35214
I14
sg35215
VC0041234
p42327
sg35217
I2
sasa(dp42328
g35204
VTo describe a peculiar flecked-retina phenotype in a young female affected by early-onset retinal dystrophy due to a heterozygous mutation in the cone-rod transcription factor CRX gene.
p42329
sg35206
(lp42330
(dp42331
g35211
I176
sg35212
VCRX gene
p42332
sg35214
I8
sg35223
g12
sg35217
I2
sasg35208
(lp42333
(dp42334
g35211
I90
sg35212
Vretinal dystrophy
p42335
sg35214
I17
sg35215
VC0854723
p42336
sg35217
I2
sasa(dp42337
g35204
VWe identified a novel early-onset retinal dystrophy-related heterozygous CRX mutation associated with early and severe rod and cone dysfunction and regressive flecked-retina appearance on ophthalmoscopy.
p42338
sg35206
(lp42339
(dp42340
g35211
I73
sg35212
VCRX mutation
p42341
sg35214
I12
sg35223
g12
sg35217
I2
sasg35208
(lp42342
(dp42343
g35211
I34
sg35212
Vretinal dystrophy
p42344
sg35214
I17
sg35215
VC0854723
p42345
sg35217
I2
sasa(dp42346
g35204
VWe found that retinal disease-related genes were efficiently detected in CRX-transduced cells, most of which are crucial to photoreceptor functions.
p42347
sg35206
(lp42348
sg35208
(lp42349
(dp42350
g35211
I14
sg35212
Vretinal disease
p42351
sg35214
I15
sg35215
VC0035309
p42352
sg35217
I2
sasa(dp42353
g35204
VMoreover, by modification of the culture conditions including additional transduction of RAX1 and NEUROD1, we found a greater variety of retinal disease-related genes than that observed in CRX-transduced PBMCs.
p42354
sg35206
(lp42355
(dp42356
g35211
I98
sg35212
VNEUROD1
p42357
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp42358
(dp42359
g35211
I137
sg35212
Vretinal disease
p42360
sg35214
I15
sg35215
VC0035309
p42361
sg35217
I2
sasa(dp42362
g35204
VThese data suggest that CRX acts as a master control gene for reprogramming PBMCs into photoreceptor-like cells and that our induced photoreceptor-like cells might contribute to individualized drug screening and disease modeling of inherited retinal degeneration.
p42363
sg35206
(lp42364
(dp42365
g35211
I24
sg35212
VCRX
p42366
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp42367
(dp42368
g35211
I242
sg35212
Vretinal degeneration
p42369
sg35214
I20
sg35215
VC0035304
p42370
sg35217
I2
sasa(dp42371
g135
(dp42372
(VRgs7
p42373
Vhypertension
p42374
tp42375
I00
ssg35204
VFinally, anisomycin was the highest correlation with DEGs.MiR-124a might be involved in the pathogenesis of hypertension via targeting Ebf3 and Rgs7 bp, which possibly represent a novel and effective strategy for treatment of hypertension.
p42376
sg35206
(lp42377
(dp42378
g35211
I135
sg35212
VEbf3
p42379
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp42380
g35211
I53
sg35212
VDEGs.MiR-124a
p42381
sg35214
I13
sg35223
g12
sg35217
I1
sa(dp42382
g35211
I144
sg35212
g42373
sg35214
I4
sg35223
VP49802
p42383
sg35217
I1
sasg35208
(lp42384
(dp42385
g35211
I92
sg35212
Vpathogenesis
p42386
sg35214
I12
sg35215
VC0699748
p42387
sg35217
I1
sa(dp42388
g35211
I108
sg35212
Vhypertension
p42389
sg35214
I12
sg35215
VC0020538
p42390
sg35217
I1
sa(dp42391
g35211
I108
sg35212
g42374
sg35214
I12
sg35215
VC0020538
p42392
sg35217
I1
sasa(dp42393
g35204
VThe serum miR-124 expression levels in 114 osteosarcoma patients, 40 periostitis patients and 50 normal controls were detected using real-time quantitative polymerase chain reaction (RT-qPCR).
p42394
sg35206
(lp42395
(dp42396
g35211
I10
sg35212
VmiR-124
p42397
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp42398
(dp42399
g35211
I43
sg35212
Vosteosarcoma
p42400
sg35214
I12
sg35215
VC0029463
p42401
sg35217
I1
sa(dp42402
g35211
I69
sg35212
Vperiostitis
p42403
sg35214
I11
sg35215
VC0031111
p42404
sg35217
I1
sasa(dp42405
g35204
VThe level of serum miR-124 was remarkably decreased in osteosarcoma patients when compared to periostitis patients and healthy controls (both p&lt; 0.05).
p42406
sg35206
(lp42407
(dp42408
g35211
I13
sg35212
Vserum miR-124
p42409
sg35214
I13
sg35223
g12
sg35217
I2
sasg35208
(lp42410
(dp42411
g35211
I94
sg35212
Vperiostitis
p42412
sg35214
I11
sg35215
VC0031111
p42413
sg35217
I1
sa(dp42414
g35211
I55
sg35212
Vosteosarcoma
p42415
sg35214
I12
sg35215
VC0029463
p42416
sg35217
I1
sasa(dp42417
g35204
VMoreover, the Kaplan-Meier method with log-rank test showed that osteosarcoma patients with lower serum miR-124 levels had unfavorable 5 year overall survival and disease free survival rates.
p42418
sg35206
(lp42419
sg35208
(lp42420
(dp42421
g35211
I65
sg35212
Vosteosarcoma
p42422
sg35214
I12
sg35215
VC0029463
p42423
sg35217
I1
sasa(dp42424
g135
(dp42425
(VmTOR
p42426
Vtuberous sclerosis
p42427
tp42428
I00
ssg35204
VIt was also demonstrated that miR-124-3p expression was positively associated with mTOR signaling and this relationship was dependent on the tuberous sclerosis proteins 1/2 complex.
p42429
sg35206
(lp42430
(dp42431
g35211
I30
sg35212
VmiR-124-3p
p42432
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp42433
g35211
I83
sg35212
g42426
sg35214
I4
sg35223
VP42345
p42434
sg35217
I1
sasg35208
(lp42435
(dp42436
g35211
I141
sg35212
g42427
sg35214
I18
sg35215
VC0041341
p42437
sg35217
I2
sasa(dp42438
g35204
VAmong these microRNAs, miR-142-3p/5p and miR-146a expression was found to be significantly increased in MPA-treated lupus CD4(+)T cells compared to untreated controls.
p42439
sg35206
(lp42440
(dp42441
g35211
I23
sg35212
VmiR-142-3p/5p
p42442
sg35214
I13
sg35223
g12
sg35217
I1
sa(dp42443
g35211
I41
sg35212
VmiR-146a
p42444
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp42445
(dp42446
g35211
I116
sg35212
Vlupus
p42447
sg35214
I5
sg35215
VC0024131
p42448
sg35217
I1
sasa(dp42449
g35204
VTo examine the role of microRNA-142-3p/5p (miR-142-3p/5p) in the development of autoimmunity in patients with systemic lupus erythematosus (SLE).
p42450
sg35206
(lp42451
(dp42452
g35211
I43
sg35212
VmiR-142-3p/5p
p42453
sg35214
I13
sg35223
g12
sg35217
I1
sa(dp42454
g35211
I23
sg35212
VmicroRNA-142-3p/5p
p42455
sg35214
I18
sg35223
g12
sg35217
I1
sasg35208
(lp42456
(dp42457
g35211
I110
sg35212
Vsystemic lupus erythematosus
p42458
sg35214
I28
sg35215
VC0024141
p42459
sg35217
I3
sa(dp42460
g35211
I140
sg35212
VSLE
p42461
sg35214
I3
sg35215
VC0024141
p42462
sg35217
I1
sa(dp42463
g35211
I80
sg35212
Vautoimmunity
p42464
sg35214
I12
sg35215
VC0004368
p42465
sg35217
I1
sasa(dp42466
g35204
VTo establish the cytologic and immunocytochemical features of lymphangioleiomyomatosis (LAM) cell clusters (LCCs) and to clarify its diagnostic significance for LAM.
p42467
sg35206
(lp42468
sg35208
(lp42469
(dp42470
g35211
I108
sg35212
VLCCs
p42471
sg35214
I4
sg35215
VC1854664
p42472
sg35217
I1
sa(dp42473
g35211
I62
sg35212
Vlymphangioleiomyomatosis
p42474
sg35214
I24
sg35215
VC0751674
p42475
sg35217
I1
sa(dp42476
g35211
I88
sg35212
VLAM
p42477
sg35214
I3
sg35215
VC0751674
p42478
sg35217
I1
sa(dp42479
g35211
I88
sg35212
VLAM
p42480
sg35214
I3
sg35215
VC0751674
p42481
sg35217
I1
sasa(dp42482
g135
(dp42483
(Velastin
p42484
Vfibrosis
p42485
tp42486
I00
ssg35204
VThis study aimed to evaluate fibrosis and elastin destruction in childhood interstitial lung disease (chILD) patients.
p42487
sg35206
(lp42488
(dp42489
g35211
I42
sg35212
g42484
sg35214
I7
sg35223
VP49918
p42490
sg35217
I1
sasg35208
(lp42491
(dp42492
g35211
I75
sg35212
Vinterstitial lung disease
p42493
sg35214
I25
sg35215
VC0206062
p42494
sg35217
I3
sa(dp42495
g35211
I29
sg35212
g42485
sg35214
I8
sg35215
VC0016059
p42496
sg35217
I1
sasa(dp42497
g135
(dp42498
(VcGMP-degrading phosphodiesterase
p42499
Verectile dysfunction
p42500
tp42501
I00
ssg35204
VInhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster status in the treatment of penile erectile dysfunction (PED).
p42502
sg35206
(lp42503
(dp42504
g35211
I52
sg35212
VPDE
p42505
sg35214
I3
sg35223
VP49419
p42506
sg35217
I1
sa(dp42507
g35211
I18
sg35212
g42499
sg35214
I32
sg35223
VP22413
p42508
sg35217
I2
sasg35208
(lp42509
(dp42510
g35211
I52
sg35212
VPDE
p42511
sg35214
I3
sg35215
VC1849508
p42512
sg35217
I1
sa(dp42513
g35211
I33
sg35212
Vphosphodiesterase
p42514
sg35214
I17
sg35215
VC1849508
p42515
sg35217
I1
sa(dp42516
g35211
I119
sg35212
g42500
sg35214
I20
sg35215
VC0242350
p42517
sg35217
I2
sasa(dp42518
g135
(dp42519
(VPDE-5i
p42520
Verectile dysfunction
p42521
tp42522
I01
ssg35204
VTo compare the effectiveness of the phosphodiesterase type 5 inhibitor (PDE-5i) tadalafil alone and in combination with a biologically active dietary supplement (BADS) NeyroDoz, containing the precursors of serotonin in patients with erectile dysfunction (ED) associated with secondary premature ejaculation (SPE).
p42523
sg35206
(lp42524
(dp42525
g35211
I36
sg35212
Vphosphodiesterase type 5 inhibitor
p42526
sg35214
I34
sg35223
VP22413
p42527
sg35217
I4
sa(dp42528
g35211
I72
sg35212
g42520
sg35214
I6
sg35223
VP49419
p42529
sg35217
I1
sasg35208
(lp42530
(dp42531
g35211
I72
sg35212
VPDE
p42532
sg35214
I3
sg35215
VC1849508
p42533
sg35217
I1
sa(dp42534
g35211
I286
sg35212
Vpremature ejaculation
p42535
sg35214
I21
sg35215
VC0033038
p42536
sg35217
I2
sa(dp42537
g35211
I256
sg35212
VED
p42538
sg35214
I2
sg35215
VC0242350
p42539
sg35217
I1
sa(dp42540
g35211
I234
sg35212
g42521
sg35214
I20
sg35215
VC0242350
p42541
sg35217
I2
sasa(dp42542
g35204
VOf these enzymes, PDE5 has attracted a special attention over the years after its recognition as being the target enzyme in treating erectile dysfunction.
p42543
sg35206
(lp42544
(dp42545
g35211
I18
sg35212
VPDE5
p42546
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp42547
(dp42548
g35211
I133
sg35212
Verectile dysfunction
p42549
sg35214
I20
sg35215
VC0242350
p42550
sg35217
I2
sasa(dp42551
g135
(dp42552
(VPhosphodiesterase (PDE) 5
p42553
Verectile dysfunction
p42554
tp42555
I00
ssg35204
VPhosphodiesterase (PDE) 5 inhibitor induced muscle relaxation in corporal smooth muscle cells and was used to treat erectile dysfunction by inhibiting cGMP degradation.
p42556
sg35206
(lp42557
(dp42558
g35211
I0
sg35212
g42553
sg35214
I25
sg35223
VP22413
p42559
sg35217
I3
sasg35208
(lp42560
(dp42561
g35211
I0
sg35212
VPhosphodiesterase
p42562
sg35214
I17
sg35215
VC1849508
p42563
sg35217
I1
sa(dp42564
g35211
I19
sg35212
VPDE
p42565
sg35214
I3
sg35215
VC1849508
p42566
sg35217
I1
sa(dp42567
g35211
I44
sg35212
Vmuscle relaxation
p42568
sg35214
I17
sg35215
VC0700323
p42569
sg35217
I2
sa(dp42570
g35211
I116
sg35212
g42554
sg35214
I20
sg35215
VC0242350
p42571
sg35217
I2
sasa(dp42572
g135
(dp42573
(VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase
p42574
VPDE
p42575
tp42576
I00
ssg35204
VCyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitors are hypothesized to improve cognition in schizophrenia and Alzheimer disease by increasing cGMP levels in certain brain regions.
p42577
sg35206
(lp42578
(dp42579
g35211
I66
sg35212
VPDE
p42580
sg35214
I3
sg35223
VP49419
p42581
sg35217
I1
sa(dp42582
g35211
I0
sg35212
g42574
sg35214
I64
sg35223
VP22413
p42583
sg35217
I5
sasg35208
(lp42584
(dp42585
g35211
I47
sg35212
Vphosphodiesterase
p42586
sg35214
I17
sg35215
VC1849508
p42587
sg35217
I1
sa(dp42588
g35211
I141
sg35212
VAlzheimer disease
p42589
sg35214
I17
sg35215
VC0002395
p42590
sg35217
I2
sa(dp42591
g35211
I123
sg35212
Vschizophrenia
p42592
sg35214
I13
sg35215
VC0036341
p42593
sg35217
I1
sa(dp42594
g35211
I66
sg35212
g42575
sg35214
I3
sg35215
VC1849508
p42595
sg35217
I1
sasa(dp42596
g35204
VTo find out whether increased spinal nociception represents a premotor feature, experimental pain sensitivity was assessed in idiopathic REM-sleep behavior disorder (IRBD) patients with or without signs of a neurodegenerative disorder compared to early Parkinson's disease (ePD) patients and healthy controls (HC).
p42597
sg35206
(lp42598
sg35208
(lp42599
(dp42600
g35211
I247
sg35212
Vearly Parkinson's disease
p42601
sg35214
I25
sg35215
VC1849508
p42602
sg35217
I3
sa(dp42603
g35211
I208
sg35212
Vneurodegenerative disorder
p42604
sg35214
I26
sg35215
VC0524851
p42605
sg35217
I2
sa(dp42606
g35211
I147
sg35212
Vbehavior disorder
p42607
sg35214
I17
sg35215
VC0004930
p42608
sg35217
I2
sa(dp42609
g35211
I274
sg35212
VePD
p42610
sg35214
I3
sg35215
VC1849508
p42611
sg35217
I1
sasa(dp42612
g135
(dp42613
(VPhosphodiesterase (PDE)
p42614
Vcognitive impairment
p42615
tp42616
I00
ssg35204
VPhosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease.
p42617
sg35206
(lp42618
(dp42619
g35211
I0
sg35212
g42614
sg35214
I23
sg35223
VP22413
p42620
sg35217
I2
sasg35208
(lp42621
(dp42622
g35211
I0
sg35212
VPhosphodiesterase
p42623
sg35214
I17
sg35215
VC1849508
p42624
sg35217
I1
sa(dp42625
g35211
I152
sg35212
VAlzheimer's disease
p42626
sg35214
I19
sg35215
VC1521724
p42627
sg35217
I2
sa(dp42628
g35211
I19
sg35212
VPDE
p42629
sg35214
I3
sg35215
VC1849508
p42630
sg35217
I1
sa(dp42631
g35211
I115
sg35212
g42615
sg35214
I20
sg35215
VC0338656
p42632
sg35217
I2
sasa(dp42633
g35204
VNotably, much experimental and clinical evidence show that PXR senses xenobiotics and triggers the detoxification response to prevent diseases such as diabetes, obesity, intestinal inflammatory diseases and liver fibrosis.
p42634
sg35206
(lp42635
sg35208
(lp42636
(dp42637
g35211
I161
sg35212
Vobesity
p42638
sg35214
I7
sg35215
VC0028754
p42639
sg35217
I1
sa(dp42640
g35211
I151
sg35212
Vdiabetes
p42641
sg35214
I8
sg35215
VC0011849
p42642
sg35217
I1
sa(dp42643
g35211
I99
sg35212
Vdetoxification response
p42644
sg35214
I23
sg35215
VC1622680
p42645
sg35217
I2
sa(dp42646
g35211
I207
sg35212
Vliver fibrosis
p42647
sg35214
I14
sg35215
VC0239946
p42648
sg35217
I2
sasa(dp42649
g35204
VRescued Tg(INV-Cst6)Cst6ichq/ichq mice survive the neonatal phase, but display severe eye pathology and alopecia after 4 mo.
p42650
sg35206
(lp42651
(dp42652
g35211
I11
sg35212
VINV-Cst6
p42653
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp42654
(dp42655
g35211
I90
sg35212
Vpathology
p42656
sg35214
I9
sg35215
VC0677042
p42657
sg35217
I1
sasa(dp42658
g135
(dp42659
(VCst6
p42660
Vscarring alopecia
p42661
tp42662
I00
ssg35204
VIntriguingly, both Cst6(-/-)Ctsl(-/-) and Cst6(-/-)Ctsl(+/-) mice were viable, but the absence of cystatin M/E caused scarring alopecia in adult animals.
p42663
sg35206
(lp42664
(dp42665
g35211
I19
sg35212
VCst6
p42666
sg35214
I4
sg35223
VP04080
p42667
sg35217
I1
sa(dp42668
g35211
I19
sg35212
g42660
sg35214
I4
sg35223
VP04080
p42669
sg35217
I1
sa(dp42670
g35211
I98
sg35212
Vcystatin M/E
p42671
sg35214
I12
sg35223
g12
sg35217
I2
sasg35208
(lp42672
(dp42673
g35211
I118
sg35212
g42661
sg35214
I17
sg35215
VC2936846
p42674
sg35217
I2
sasa(dp42675
g135
(dp42676
(VTCF-4
p42677
Vtype 2 diabetes
p42678
tp42679
I00
ssg35204
VTranscription factor 4 (TCF-4) was recently identified as a candidate gene for the cause of type 2 diabetes, although the mechanisms have not been fully elucidated.
p42680
sg35206
(lp42681
(dp42682
g35211
I0
sg35212
VTranscription factor 4
p42683
sg35214
I22
sg35223
VP15884
p42684
sg35217
I3
sa(dp42685
g35211
I24
sg35212
g42677
sg35214
I5
sg35223
VP15884
p42686
sg35217
I1
sasg35208
(lp42687
(dp42688
g35211
I92
sg35212
g42678
sg35214
I15
sg35215
VC0011860
p42689
sg35217
I3
sasa(dp42690
g135
(dp42691
(VE2-2
p42692
Vautoimmune diabetes
p42693
tp42694
I00
ssg35204
VCollectively, these observations demonstrate a disease-promoting role of E2-2 dependent pDCs in the pancreas during autoimmune diabetes in the NOD mouse.
p42695
sg35206
(lp42696
(dp42697
g35211
I73
sg35212
g42692
sg35214
I4
sg35223
VP15884
p42698
sg35217
I1
sasg35208
(lp42699
(dp42700
g35211
I143
sg35212
VNOD
p42701
sg35214
I3
sg35215
VC0751781
p42702
sg35217
I1
sa(dp42703
g35211
I116
sg35212
g42693
sg35214
I19
sg35215
VC0205734
p42704
sg35217
I2
sasa(dp42705
g35204
VFecal incontinence and constipation still remain the major complications after procedures for anorectal malformations (ARMs).
p42706
sg35206
(lp42707
sg35208
(lp42708
(dp42709
g35211
I23
sg35212
Vconstipation
p42710
sg35214
I12
sg35215
VC0009806
p42711
sg35217
I1
sa(dp42712
g35211
I94
sg35212
Vanorectal malformations
p42713
sg35214
I23
sg35215
VC2974527
p42714
sg35217
I2
sa(dp42715
g35211
I119
sg35212
VARMs
p42716
sg35214
I4
sg35215
VC0206655
p42717
sg35217
I1
sa(dp42718
g35211
I0
sg35212
VFecal incontinence
p42719
sg35214
I18
sg35215
VC0015732
p42720
sg35217
I2
sasa(dp42721
g35204
VNumerous patients with anorectal malformations (ARMs) continue to experience fecal incontinence and constipation following surgical procedures.
p42722
sg35206
(lp42723
sg35208
(lp42724
(dp42725
g35211
I100
sg35212
Vconstipation
p42726
sg35214
I12
sg35215
VC0009806
p42727
sg35217
I1
sa(dp42728
g35211
I48
sg35212
VARMs
p42729
sg35214
I4
sg35215
VC0206655
p42730
sg35217
I1
sa(dp42731
g35211
I77
sg35212
Vfecal incontinence
p42732
sg35214
I18
sg35215
VC0015732
p42733
sg35217
I2
sa(dp42734
g35211
I23
sg35212
Vanorectal malformations
p42735
sg35214
I23
sg35215
VC2974527
p42736
sg35217
I2
sasa(dp42737
g35204
VOver the last two decades, advances in laparoscopic surgery and minimally invasive techniques have transformed the operative management of neonatal colorectal surgery for conditions such as anorectal malformations (ARMs) and Hirschsprung's disease.
p42738
sg35206
(lp42739
sg35208
(lp42740
(dp42741
g35211
I215
sg35212
VARMs
p42742
sg35214
I4
sg35215
VC0206655
p42743
sg35217
I1
sa(dp42744
g35211
I190
sg35212
Vanorectal malformations
p42745
sg35214
I23
sg35215
VC2974527
p42746
sg35217
I2
sa(dp42747
g35211
I225
sg35212
VHirschsprung's disease
p42748
sg35214
I22
sg35215
VC0019569
p42749
sg35217
I2
sasa(dp42750
g35204
VThis review describes these advances and outlines the main minimally invasive techniques currently used for management of ARMs and Hirschsprung's disease.
p42751
sg35206
(lp42752
sg35208
(lp42753
(dp42754
g35211
I122
sg35212
VARMs
p42755
sg35214
I4
sg35215
VC0206655
p42756
sg35217
I1
sa(dp42757
g35211
I131
sg35212
VHirschsprung's disease
p42758
sg35214
I22
sg35215
VC0019569
p42759
sg35217
I2
sasa(dp42760
g35204
VFurther analysis of the PRKAG3 signaling pathway may provide insights into muscle physiology as well as the pathogenesis of noninsulin-dependent diabetes mellitus in humans, a metabolic disorder associated with impaired glycogen synthesis.
p42761
sg35206
(lp42762
(dp42763
g35211
I24
sg35212
VPRKAG3
p42764
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp42765
(dp42766
g35211
I211
sg35212
Vimpaired
p42767
sg35214
I8
sg35215
VC0684336
p42768
sg35217
I1
sa(dp42769
g35211
I124
sg35212
Vnoninsulin-dependent diabetes mellitus
p42770
sg35214
I38
sg35215
VC0011860
p42771
sg35217
I3
sa(dp42772
g35211
I176
sg35212
Vmetabolic disorder
p42773
sg35214
I18
sg35215
VC0025517
p42774
sg35217
I2
sa(dp42775
g35211
I108
sg35212
Vpathogenesis
p42776
sg35214
I12
sg35215
VC0699748
p42777
sg35217
I1
sasa(dp42778
g135
(dp42779
(VCSB
p42780
VCSB
p42781
tp42782
I00
ssg35204
VIn primates, a PGBD3 element inserted into the Cockayne syndrome group B (CSB) gene over 43 Mya serves as an alternative 3' terminal exon, enabling the CSB gene to generate both full length CSB and a conserved CSB-PGBD3 fusion protein that joins an N-terminal CSB domain to the C-terminal transposase domain.
p42783
sg35206
(lp42784
(dp42785
g35211
I152
sg35212
VCSB gene
p42786
sg35214
I8
sg35223
VP35548
p42787
sg35217
I2
sa(dp42788
g35211
I278
sg35212
VC-terminal transposase domain
p42789
sg35214
I29
sg35223
g12
sg35217
I3
sa(dp42790
g35211
I74
sg35212
VCSB
p42791
sg35214
I3
sg35223
VP35548
p42792
sg35217
I1
sa(dp42793
g35211
I15
sg35212
VPGBD3 element
p42794
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp42795
g35211
I15
sg35212
VPGBD3
p42796
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp42797
g35211
I47
sg35212
VCockayne syndrome group B
p42798
sg35214
I25
sg35223
VP35548
p42799
sg35217
I4
sa(dp42800
g35211
I74
sg35212
g42780
sg35214
I3
sg35223
VP35548
p42801
sg35217
I1
sasg35208
(lp42802
(dp42803
g35211
I74
sg35212
VCSB
p42804
sg35214
I3
sg35215
VC1858160
p42805
sg35217
I1
sa(dp42806
g35211
I74
sg35212
VCSB
p42807
sg35214
I3
sg35215
VC1858160
p42808
sg35217
I1
sa(dp42809
g35211
I74
sg35212
VCSB
p42810
sg35214
I3
sg35215
VC1858160
p42811
sg35217
I1
sa(dp42812
g35211
I47
sg35212
VCockayne syndrome group B
p42813
sg35214
I25
sg35215
VC1858160
p42814
sg35217
I4
sa(dp42815
g35211
I74
sg35212
VCSB
p42816
sg35214
I3
sg35215
VC1858160
p42817
sg35217
I1
sa(dp42818
g35211
I74
sg35212
g42781
sg35214
I3
sg35215
VC1858160
p42819
sg35217
I1
sasa(dp42820
g135
(dp42821
(VCockayne syndrome Group B
p42822
VCSB
p42823
tp42824
I00
ssg35204
VThe CSB-PGBD3 fusion protein arose more than 43 million years ago when a 2.5-kb piggyBac 3 (PGBD3) transposon inserted into intron 5 of the Cockayne syndrome Group B (CSB) gene in the common ancestor of all higher primates.
p42825
sg35206
(lp42826
(dp42827
g35211
I4
sg35212
VCSB
p42828
sg35214
I3
sg35223
VP35548
p42829
sg35217
I1
sa(dp42830
g35211
I8
sg35212
VPGBD3
p42831
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp42832
g35211
I8
sg35212
VPGBD3
p42833
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp42834
g35211
I4
sg35212
VCSB
p42835
sg35214
I3
sg35223
VP35548
p42836
sg35217
I1
sa(dp42837
g35211
I140
sg35212
g42822
sg35214
I25
sg35223
VP35548
p42838
sg35217
I4
sasg35208
(lp42839
(dp42840
g35211
I4
sg35212
VCSB
p42841
sg35214
I3
sg35215
VC1858160
p42842
sg35217
I1
sa(dp42843
g35211
I140
sg35212
VCockayne syndrome Group B
p42844
sg35214
I25
sg35215
VC1858160
p42845
sg35217
I4
sa(dp42846
g35211
I4
sg35212
g42823
sg35214
I3
sg35215
VC1858160
p42847
sg35217
I1
sasa(dp42848
g135
(dp42849
(VCSB
p42850
VCSB
p42851
tp42852
I00
ssg35204
VOur data suggest that the CSB-PGBD3 fusion protein is important in both health and disease, and could play a role in Cockayne syndrome.
p42853
sg35206
(lp42854
(dp42855
g35211
I30
sg35212
VPGBD3
p42856
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp42857
g35211
I26
sg35212
g42850
sg35214
I3
sg35223
VP35548
p42858
sg35217
I1
sasg35208
(lp42859
(dp42860
g35211
I117
sg35212
VCockayne syndrome
p42861
sg35214
I17
sg35215
VC0009207
p42862
sg35217
I2
sa(dp42863
g35211
I26
sg35212
g42851
sg35214
I3
sg35215
VC1858160
p42864
sg35217
I1
sasa(dp42865
g35204
VIn this study, we searched for cerebral MBs in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a unique type of small-vessel disease caused by mutations in the Notch3 gene.
p42866
sg35206
(lp42867
(dp42868
g35211
I214
sg35212
VNotch3 gene
p42869
sg35214
I11
sg35223
g12
sg35217
I2
sasg35208
(lp42870
(dp42871
g35211
I47
sg35212
Vcerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
p42872
sg35214
I90
sg35215
VC0751587
p42873
sg35217
I9
sa(dp42874
g35211
I139
sg35212
VCADASIL
p42875
sg35214
I7
sg35215
VC0751587
p42876
sg35217
I1
sa(dp42877
g35211
I40
sg35212
VMBs
p42878
sg35214
I3
sg35215
VC0221060
p42879
sg35217
I1
sasa(dp42880
g35204
VOur purposes were (1) to determine the frequency, extent, and pattern of MBs in CADASIL; (2) to analyze the relationship between MBs and T2-hyperintense lesions; and (3) to evaluate the histopathology of brain tissue affected by MBs.
p42881
sg35206
(lp42882
(dp42883
g35211
I73
sg35212
VMBs
p42884
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp42885
(dp42886
g35211
I73
sg35212
VMBs
p42887
sg35214
I3
sg35215
VC0221060
p42888
sg35217
I1
sa(dp42889
g35211
I73
sg35212
VMBs
p42890
sg35214
I3
sg35215
VC0221060
p42891
sg35217
I1
sa(dp42892
g35211
I73
sg35212
VMBs
p42893
sg35214
I3
sg35215
VC0221060
p42894
sg35217
I1
sa(dp42895
g35211
I80
sg35212
VCADASIL
p42896
sg35214
I7
sg35215
VC0751587
p42897
sg35217
I1
sasa(dp42898
g35204
VFocal areas of signal loss on gradient-echo images suggesting past MBs were found in 11 CADASIL individuals (69%) and no control subjects (P&lt;0.001).
p42899
sg35206
(lp42900
(dp42901
g35211
I67
sg35212
VMBs
p42902
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp42903
(dp42904
g35211
I67
sg35212
VMBs
p42905
sg35214
I3
sg35215
VC0221060
p42906
sg35217
I1
sa(dp42907
g35211
I88
sg35212
VCADASIL
p42908
sg35214
I7
sg35215
VC0751587
p42909
sg35217
I1
sasa(dp42910
g35204
VThe average number of MBs was 5.9+/-7.3 (range, 0 to 22) in individual CADASIL patients.
p42911
sg35206
(lp42912
sg35208
(lp42913
(dp42914
g35211
I22
sg35212
VMBs
p42915
sg35214
I3
sg35215
VC0221060
p42916
sg35217
I1
sa(dp42917
g35211
I71
sg35212
VCADASIL
p42918
sg35214
I7
sg35215
VC0751587
p42919
sg35217
I1
sasa(dp42920
g35204
VThis study shows a high frequency and multiplicity of MBs in individuals with CADASIL.
p42921
sg35206
(lp42922
sg35208
(lp42923
(dp42924
g35211
I78
sg35212
VCADASIL
p42925
sg35214
I7
sg35215
VC0751587
p42926
sg35217
I1
sa(dp42927
g35211
I54
sg35212
VMBs
p42928
sg35214
I3
sg35215
VC0221060
p42929
sg35217
I1
sasa(dp42930
g135
(dp42931
(VHK-ATPase
p42932
Vgastritis
p42933
tp42934
I00
ssg35204
VAt stimulation, the tubulovesicles fuse with the apical canaliculi and the HK-ATPase is incorporated into the apical membrane where it actively pumps H ions in exchange for K. Acute infection with Helicobacter pylori results in hypochlorhydria, whereas chronic infection can cause either hypo- or hyperchlorhydria, depending on the distribution of the infection and the degree of corpus gastritis.
p42935
sg35206
(lp42936
(dp42937
g35211
I75
sg35212
g42932
sg35214
I9
sg35223
VP38606
p42938
sg35217
I1
sasg35208
(lp42939
(dp42940
g35211
I176
sg35212
VAcute infection
p42941
sg35214
I15
sg35215
VC0275518
p42942
sg35217
I2
sa(dp42943
g35211
I297
sg35212
Vhyperchlorhydria
p42944
sg35214
I16
sg35215
VC0151713
p42945
sg35217
I1
sa(dp42946
g35211
I253
sg35212
Vchronic infection
p42947
sg35214
I17
sg35215
VC0151317
p42948
sg35217
I2
sa(dp42949
g35211
I182
sg35212
Vinfection
p42950
sg35214
I9
sg35215
VC0009450
p42951
sg35217
I1
sa(dp42952
g35211
I387
sg35212
g42933
sg35214
I9
sg35215
VC0017152
p42953
sg35217
I1
sa(dp42954
g35211
I228
sg35212
Vhypochlorhydria
p42955
sg35214
I15
sg35215
VC0079581
p42956
sg35217
I1
sasa(dp42957
g135
(dp42958
(Vgastric H+/K(+)-ATPase
p42959
Vautoimmune gastritis
p42960
tp42961
I00
ssg35204
VThe results directly confirm that the gastric H+/K(+)-ATPase is the causative autoantigen in the genesis of autoimmune gastritis.
p42962
sg35206
(lp42963
(dp42964
g35211
I38
sg35212
g42959
sg35214
I22
sg35223
VP38606
p42965
sg35217
I2
sasg35208
(lp42966
(dp42967
g35211
I108
sg35212
g42960
sg35214
I20
sg35215
VC0017154
p42968
sg35217
I2
sasa(dp42969
g135
(dp42970
(Vgastric H/K ATPase
p42971
Vautoimmune gastritis
p42972
tp42973
I00
ssg35204
VWe conclude that the beta subunit of the gastric H/K ATPase is a major T cell target in autoimmune gastritis and that thymic expression of a single autoantigen can abrogate an autoimmune response to multiple autoantigens.
p42974
sg35206
(lp42975
(dp42976
g35211
I41
sg35212
g42971
sg35214
I18
sg35223
VP38606
p42977
sg35217
I3
sasg35208
(lp42978
(dp42979
g35211
I176
sg35212
Vautoimmune response
p42980
sg35214
I19
sg35215
VC0004366
p42981
sg35217
I2
sa(dp42982
g35211
I88
sg35212
g42972
sg35214
I20
sg35215
VC0017154
p42983
sg35217
I2
sasa(dp42984
g135
(dp42985
(Vppo
p42986
Vdeformities
p42987
tp42988
I00
ssg35204
V8 cases of pneumophathia osteoplastica (ppo) of branching type observed at patients having no vascular deformities and one case of a focal ppo at a patient with mitral stenosis are reported.
p42989
sg35206
(lp42990
(dp42991
g35211
I40
sg35212
g42986
sg35214
I3
sg35223
VP50336
p42992
sg35217
I1
sasg35208
(lp42993
(dp42994
g35211
I161
sg35212
Vmitral stenosis
p42995
sg35214
I15
sg35215
VC0026269
p42996
sg35217
I2
sa(dp42997
g35211
I103
sg35212
g42987
sg35214
I11
sg35215
VC0000768
p42998
sg35217
I1
sasa(dp42999
g35204
VCDKN3 is often overexpressed in human cancer, and this overexpression correlates with reduced survival in several types of cancer.
p43000
sg35206
(lp43001
sg35208
(lp43002
(dp43003
g35211
I38
sg35212
Vcancer
p43004
sg35214
I6
sg35215
VC0006826
p43005
sg35217
I1
sa(dp43006
g35211
I38
sg35212
Vcancer
p43007
sg35214
I6
sg35215
VC0006826
p43008
sg35217
I1
sasa(dp43009
g35204
VThe mechanism of CDKN3 overexpression and the role of CDKN3 transcript variants in human cancer are not entirely clear.
p43010
sg35206
(lp43011
(dp43012
g35211
I54
sg35212
VCDKN3 transcript variants
p43013
sg35214
I25
sg35223
VP26640
p43014
sg35217
I3
sasg35208
(lp43015
(dp43016
g35211
I89
sg35212
Vcancer
p43017
sg35214
I6
sg35215
VC0006826
p43018
sg35217
I1
sasa(dp43019
g35204
VBesides the full-length CDKN3 encoding transcript and a major transcript that skips exon 2 express in normal and cancer cells, minor aberrant transcript variants have been reported.
p43020
sg35206
(lp43021
sg35208
(lp43022
(dp43023
g35211
I113
sg35212
Vcancer
p43024
sg35214
I6
sg35215
VC0006826
p43025
sg35217
I1
sasa(dp43026
g35204
VAberrant CDKN3 transcripts were postulated to encode dominant-negative inhibitors of CDKN3 as an explanation for overexpression of the perceived tumor suppressor gene in human cancer.
p43027
sg35206
(lp43028
sg35208
(lp43029
(dp43030
g35211
I145
sg35212
Vtumor
p43031
sg35214
I5
sg35215
VC0027651
p43032
sg35217
I1
sa(dp43033
g35211
I176
sg35212
Vcancer
p43034
sg35214
I6
sg35215
VC0006826
p43035
sg35217
I1
sasa(dp43036
g35204
VHowever, while CDKN3 is often overexpressed in human cancer, aberrant CDKN3 transcripts occur infrequently and at lower levels.
p43037
sg35206
(lp43038
sg35208
(lp43039
(dp43040
g35211
I53
sg35212
Vcancer
p43041
sg35214
I6
sg35215
VC0006826
p43042
sg35217
I1
sasa(dp43043
g35204
VCDKN3 mutations and copy number alternation are rare in human cancer, implying that neither loss of CDKN3 activity nor constitutive gain of CDKN3 expression offer an advantage to tumorigenesis.
p43044
sg35206
(lp43045
sg35208
(lp43046
(dp43047
g35211
I179
sg35212
Vtumorigenesis
p43048
sg35214
I13
sg35215
VC0007621
p43049
sg35217
I1
sa(dp43050
g35211
I62
sg35212
Vcancer
p43051
sg35214
I6
sg35215
VC0006826
p43052
sg35217
I1
sa(dp43053
g35211
I32
sg35212
Valternation
p43054
sg35214
I11
sg35215
VC0919661
p43055
sg35217
I1
sasa(dp43056
g35204
VGiven that rapidly growing tumors have more mitotic cells, the high level of mitotic CDKN3 expression is the most plausible mechanism of frequent CDKN3 overexpression in human cancer.
p43057
sg35206
(lp43058
sg35208
(lp43059
(dp43060
g35211
I27
sg35212
Vtumors
p43061
sg35214
I6
sg35215
VC0027651
p43062
sg35217
I1
sa(dp43063
g35211
I176
sg35212
Vcancer
p43064
sg35214
I6
sg35215
VC0006826
p43065
sg35217
I1
sasa(dp43066
g35204
VThis finding clarifies the mechanism of CDKN3 overexpression in human cancer and questions the view of CDKN3 as a tumor suppressor.
p43067
sg35206
(lp43068
sg35208
(lp43069
(dp43070
g35211
I70
sg35212
Vcancer
p43071
sg35214
I6
sg35215
VC0006826
p43072
sg35217
I1
sa(dp43073
g35211
I114
sg35212
Vtumor
p43074
sg35214
I5
sg35215
VC0027651
p43075
sg35217
I1
sasa(dp43076
g35204
VAbnormal expression of CDKN3 has been found in numerous types of cancer.
p43077
sg35206
(lp43078
sg35208
(lp43079
(dp43080
g35211
I65
sg35212
Vcancer
p43081
sg35214
I6
sg35215
VC0006826
p43082
sg35217
I1
sasa(dp43083
g35204
VSince it is unclear whether CDKN3 participates in the development of human gastric cancer, this study assessed the association between CDKN3 expression and cell biological function and demonstrated the clinical significance and prognosis of CDKN3 in human gastric cancer.
p43084
sg35206
(lp43085
sg35208
(lp43086
(dp43087
g35211
I75
sg35212
Vgastric cancer
p43088
sg35214
I14
sg35215
VC0024623
p43089
sg35217
I2
sa(dp43090
g35211
I75
sg35212
Vgastric cancer
p43091
sg35214
I14
sg35215
VC0024623
p43092
sg35217
I2
sasa(dp43093
g35204
VIn this study, we found that CDKN3 showed a high expression in 35 paired human gastric cancer tissues and was correlated with poor patient survival, AJCC clinical staging, and recurrence.
p43094
sg35206
(lp43095
sg35208
(lp43096
(dp43097
g35211
I79
sg35212
Vgastric cancer
p43098
sg35214
I14
sg35215
VC0024623
p43099
sg35217
I2
sa(dp43100
g35211
I176
sg35212
Vrecurrence
p43101
sg35214
I10
sg35215
VC1458156
p43102
sg35217
I1
sasa(dp43103
g35204
VSilencing of CDKN3 in human gastric cancer cells can significantly reduce proliferation, migration, invasion, and adhesion abilities.
p43104
sg35206
(lp43105
sg35208
(lp43106
(dp43107
g35211
I100
sg35212
Vinvasion
p43108
sg35214
I8
sg35215
VC2699153
p43109
sg35217
I1
sa(dp43110
g35211
I28
sg35212
Vgastric cancer
p43111
sg35214
I14
sg35215
VC0024623
p43112
sg35217
I2
sa(dp43113
g35211
I74
sg35212
Vproliferation
p43114
sg35214
I13
sg35215
VC0334094
p43115
sg35217
I1
sa(dp43116
g35211
I114
sg35212
Vadhesion
p43117
sg35214
I8
sg35215
VC0001511
p43118
sg35217
I1
sasa(dp43119
g35204
VAlso, silencing of CDKN3 in human gastric cancer cells can induce G0-G1 cell cycle arrest and apoptosis.
p43120
sg35206
(lp43121
sg35208
(lp43122
(dp43123
g35211
I34
sg35212
Vgastric cancer
p43124
sg35214
I14
sg35215
VC0024623
p43125
sg35217
I2
sasa(dp43126
g135
(dp43127
(VCDC25A
p43128
Vgastric cancer
p43129
tp43130
I01
ssg35204
VDetection of cell cycle marker expression showed that CDKN3 knockdown promotes cell cycle arrest by decreasing the expression of CDK2, CDC25A, CCNB1, and CCNB2 in human gastric cancer cells.
p43131
sg35206
(lp43132
(dp43133
g35211
I129
sg35212
VCDK2
p43134
sg35214
I4
sg35223
VP24941
p43135
sg35217
I1
sa(dp43136
g35211
I154
sg35212
VCCNB2
p43137
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp43138
g35211
I143
sg35212
VCCNB1
p43139
sg35214
I5
sg35223
VP14635
p43140
sg35217
I1
sa(dp43141
g35211
I135
sg35212
g43128
sg35214
I6
sg35223
VP30304
p43142
sg35217
I1
sasg35208
(lp43143
(dp43144
g35211
I169
sg35212
g43129
sg35214
I14
sg35215
VC0024623
p43145
sg35217
I2
sasa(dp43146
g35204
VThe results of this study will help elucidate the oncogene function of CDKN3 in human gastric cancer.
p43147
sg35206
(lp43148
sg35208
(lp43149
(dp43150
g35211
I86
sg35212
Vgastric cancer
p43151
sg35214
I14
sg35215
VC0024623
p43152
sg35217
I2
sasa(dp43153
g35204
VHowever, whether CDKN3 is a potential therapeutic target for breast cancer remains to be elucidated.
p43154
sg35206
(lp43155
sg35208
(lp43156
(dp43157
g35211
I61
sg35212
Vbreast cancer
p43158
sg35214
I13
sg35215
VC0678222
p43159
sg35217
I2
sasa(dp43160
g35204
VThe present in vitro study aimed to investigate the potential roles of CDKN3 in breast cancer.
p43161
sg35206
(lp43162
sg35208
(lp43163
(dp43164
g35211
I80
sg35212
Vbreast cancer
p43165
sg35214
I13
sg35215
VC0678222
p43166
sg35217
I2
sasa(dp43167
g35204
VBreast cancer cell lines were used to detect CDKN3 expression, and CDKN3 expression was silenced to investigate its role in cell apoptosis, cell cycle arrest and migration.
p43168
sg35206
(lp43169
sg35208
(lp43170
(dp43171
g35211
I0
sg35212
VBreast cancer
p43172
sg35214
I13
sg35215
VC0678222
p43173
sg35217
I2
sasa(dp43174
g35204
VThese results suggest that CDKN3 acts as an oncogene during breast cancer progression.
p43175
sg35206
(lp43176
sg35208
(lp43177
(dp43178
g35211
I67
sg35212
Vcancer progression
p43179
sg35214
I18
sg35215
VC0178874
p43180
sg35217
I2
sasa(dp43181
g35204
VCDKN3 may therefore be considered a potential target for the treatment of breast cancer.
p43182
sg35206
(lp43183
sg35208
(lp43184
(dp43185
g35211
I74
sg35212
Vbreast cancer
p43186
sg35214
I13
sg35215
VC0678222
p43187
sg35217
I2
sasa(dp43188
g35204
VParadoxically, CDKN3 is often overexpressed in human cancer.
p43189
sg35206
(lp43190
sg35208
(lp43191
(dp43192
g35211
I53
sg35212
Vcancer
p43193
sg35214
I6
sg35215
VC0006826
p43194
sg35217
I1
sasa(dp43195
g35204
VWe analysed CDKN3 expression and its association with patient survival in three cohorts of lung adenocarcinoma.
p43196
sg35206
(lp43197
sg35208
(lp43198
(dp43199
g35211
I91
sg35212
Vlung adenocarcinoma
p43200
sg35214
I19
sg35215
VC0152013
p43201
sg35217
I2
sasa(dp43202
g35204
VWe also examined CDKN3 mutations in the Cancer Genome Atlas (TCGA) and the Moffitt Cancer Center's Total Cancer Care (TCC) projects.
p43203
sg35206
(lp43204
sg35208
(lp43205
(dp43206
g35211
I40
sg35212
VCancer
p43207
sg35214
I6
sg35215
VC0006826
p43208
sg35217
I1
sa(dp43209
g35211
I118
sg35212
VTCC
p43210
sg35214
I3
sg35215
VC1861305
p43211
sg35217
I1
sa(dp43212
g35211
I40
sg35212
VCancer
p43213
sg35214
I6
sg35215
VC0006826
p43214
sg35217
I1
sa(dp43215
g35211
I99
sg35212
VTotal Cancer Care
p43216
sg35214
I17
sg35215
VC1861305
p43217
sg35217
I3
sasa(dp43218
g35204
VCDKN3 transcripts were further analysed in a panel of cell lines and lung adenocarcinoma tissues.
p43219
sg35206
(lp43220
sg35208
(lp43221
(dp43222
g35211
I69
sg35212
Vlung adenocarcinoma
p43223
sg35214
I19
sg35215
VC0152013
p43224
sg35217
I2
sasa(dp43225
g35204
VCDKN3 is overexpressed in non small cell lung cancer.
p43226
sg35206
(lp43227
sg35208
(lp43228
(dp43229
g35211
I26
sg35212
Vnon small cell lung cancer
p43230
sg35214
I26
sg35215
VC0007131
p43231
sg35217
I5
sasa(dp43232
g35204
VHigh CDKN3 expression is associated with poor overall survival in lung adenocarcinoma.
p43233
sg35206
(lp43234
sg35208
(lp43235
(dp43236
g35211
I66
sg35212
Vlung adenocarcinoma
p43237
sg35214
I19
sg35215
VC0152013
p43238
sg35217
I2
sasa(dp43239
g35204
VCDKN3 overexpression is prognostic of poor overall survival in lung adenocarcinoma.
p43240
sg35206
(lp43241
sg35208
(lp43242
(dp43243
g35211
I63
sg35212
Vlung adenocarcinoma
p43244
sg35214
I19
sg35215
VC0152013
p43245
sg35217
I2
sasa(dp43246
g35204
VCDKN3 overexpression in lung adenocarcinoma is not attributed to alternative splicing or mutation but is likely due to increased mitotic activity, arguing against CDKN3 as a tumour suppressor.
p43247
sg35206
(lp43248
sg35208
(lp43249
(dp43250
g35211
I174
sg35212
Vtumour
p43251
sg35214
I6
sg35215
VC0027651
p43252
sg35217
I1
sa(dp43253
g35211
I24
sg35212
Vlung adenocarcinoma
p43254
sg35214
I19
sg35215
VC0152013
p43255
sg35217
I2
sasa(dp43256
g135
(dp43257
(VCDKN3
p43258
Vcervical cancer
p43259
tp43260
I00
ssg35204
VThe cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC).
p43261
sg35206
(lp43262
(dp43263
g35211
I4
sg35212
Vcyclin-dependent kinase inhibitor 3
p43264
sg35214
I35
sg35223
VP38936
p43265
sg35217
I4
sa(dp43266
g35211
I41
sg35212
g43258
sg35214
I5
sg35223
VP38936
p43267
sg35217
I1
sasg35208
(lp43268
(dp43269
g35211
I93
sg35212
g43259
sg35214
I15
sg35215
VC0302592
p43270
sg35217
I2
sasa(dp43271
g35204
VThe aim of this study is to investigate the possible mechanisms of silence of CDKN3 exerting the suppressive role on epithelial ovarian cancer (EOC).
p43272
sg35206
(lp43273
sg35208
(lp43274
(dp43275
g35211
I144
sg35212
VEOC
p43276
sg35214
I3
sg35215
VC0677886
p43277
sg35217
I1
sa(dp43278
g35211
I67
sg35212
Vsilence
p43279
sg35214
I7
sg35215
VC0858952
p43280
sg35217
I1
sa(dp43281
g35211
I117
sg35212
Vepithelial ovarian cancer
p43282
sg35214
I25
sg35215
VC0677886
p43283
sg35217
I3
sasa(dp43284
g35204
VFunctional studies showed that silence of CDKN3 inhibited cancer cell proliferation by promoting cell cycle progression in G1 phase, decreased cell invasion and promoted EOC cells apoptosis.
p43285
sg35206
(lp43286
sg35208
(lp43287
(dp43288
g35211
I31
sg35212
Vsilence
p43289
sg35214
I7
sg35215
VC0858952
p43290
sg35217
I1
sa(dp43291
g35211
I58
sg35212
Vcancer
p43292
sg35214
I6
sg35215
VC0006826
p43293
sg35217
I1
sa(dp43294
g35211
I143
sg35212
Vcell invasion
p43295
sg35214
I13
sg35215
VC2699153
p43296
sg35217
I2
sa(dp43297
g35211
I70
sg35212
Vproliferation
p43298
sg35214
I13
sg35215
VC0334094
p43299
sg35217
I1
sasa(dp43300
g35204
VThese findings indicated that CDKN3 might serve as a useful potential target for treatment of ovarian cancer.
p43301
sg35206
(lp43302
sg35208
(lp43303
(dp43304
g35211
I94
sg35212
Vovarian cancer
p43305
sg35214
I14
sg35215
VC1140680
p43306
sg35217
I2
sasa(dp43307
g135
(dp43308
(VCDKN3
p43309
Vcolorectal cancer
p43310
tp43311
I00
ssg35204
VWe first discovered the pro-tumor effect of a controversial cell cycle regulator, cylin-dependent kinase inhibitor 3 (CDKN3), which is highly expressed in colorectal cancer, and the possible related signaling pathways, by bioinformatics tools.
p43312
sg35206
(lp43313
(dp43314
g35211
I82
sg35212
Vcylin-dependent kinase inhibitor 3
p43315
sg35214
I34
sg35223
VP19525
p43316
sg35217
I4
sa(dp43317
g35211
I118
sg35212
g43309
sg35214
I5
sg35223
VP19525
p43318
sg35217
I1
sasg35208
(lp43319
(dp43320
g35211
I28
sg35212
Vtumor
p43321
sg35214
I5
sg35215
VC0027651
p43322
sg35217
I1
sa(dp43323
g35211
I155
sg35212
g43310
sg35214
I17
sg35215
VC1527249
p43324
sg35217
I2
sasa(dp43325
g35204
VWe found that CDKN3 had remarkable effects in suppressing colorectal cancer cell proliferation and migration, inducing cell cycle arrest and apoptosis in a colorectal cancer cell line, SW480 cells.
p43326
sg35206
(lp43327
sg35208
(lp43328
(dp43329
g35211
I58
sg35212
Vcolorectal cancer
p43330
sg35214
I17
sg35215
VC1527249
p43331
sg35217
I2
sa(dp43332
g35211
I58
sg35212
Vcolorectal cancer
p43333
sg35214
I17
sg35215
VC1527249
p43334
sg35217
I2
sa(dp43335
g35211
I81
sg35212
Vproliferation
p43336
sg35214
I13
sg35215
VC0334094
p43337
sg35217
I1
sasa(dp43338
g35204
VOur study, for the first time, provided consistent evidence showing overexpression of cell cycle regulator CDKN3, in colorectal cancer.
p43339
sg35206
(lp43340
sg35208
(lp43341
(dp43342
g35211
I117
sg35212
Vcolorectal cancer
p43343
sg35214
I17
sg35215
VC1527249
p43344
sg35217
I2
sasa(dp43345
g35204
VThe in vitro studies in SW480 cells revealed a unique role of CDKN3 in regulating cellular behavior of colorectal cancer cells, and implied the possibility of targeting CDKN3 as a novel treatment for colorectal cancer.
p43346
sg35206
(lp43347
sg35208
(lp43348
(dp43349
g35211
I103
sg35212
Vcolorectal cancer
p43350
sg35214
I17
sg35215
VC1527249
p43351
sg35217
I2
sa(dp43352
g35211
I103
sg35212
Vcolorectal cancer
p43353
sg35214
I17
sg35215
VC1527249
p43354
sg35217
I2
sasa(dp43355
g135
(dp43356
(VAbl
p43357
VAbl
p43358
tp43359
I00
ssg35204
VHowever, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown.
p43360
sg35206
(lp43361
(dp43362
g35211
I30
sg35212
VBcr
p43363
sg35214
I3
sg35223
VP11274
p43364
sg35217
I1
sa(dp43365
g35211
I34
sg35212
g43357
sg35214
I3
sg35223
VP55157
p43366
sg35217
I1
sasg35208
(lp43367
(dp43368
g35211
I47
sg35212
Vchronic myelogenous leukemia
p43369
sg35214
I28
sg35215
VC0023473
p43370
sg35217
I3
sa(dp43371
g35211
I77
sg35212
VCML
p43372
sg35214
I3
sg35215
VC0023473
p43373
sg35217
I1
sa(dp43374
g35211
I34
sg35212
g43358
sg35214
I3
sg35215
VC0000744
p43375
sg35217
I1
sasa(dp43376
g35204
VIn contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice.
p43377
sg35206
(lp43378
sg35208
(lp43379
(dp43380
g35211
I156
sg35212
Vleukemia
p43381
sg35214
I8
sg35215
VC0023418
p43382
sg35217
I1
sasa(dp43383
g135
(dp43384
(VAbl
p43385
VAbl
p43386
tp43387
I00
ssg35204
VOur results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.
p43388
sg35206
(lp43389
(dp43390
g35211
I49
sg35212
VBcr
p43391
sg35214
I3
sg35223
VP11274
p43392
sg35217
I1
sa(dp43393
g35211
I53
sg35212
g43385
sg35214
I3
sg35223
VP55157
p43394
sg35217
I1
sasg35208
(lp43395
(dp43396
g35211
I148
sg35212
Vleukemia
p43397
sg35214
I8
sg35215
VC0023418
p43398
sg35217
I1
sa(dp43399
g35211
I66
sg35212
Vleukemogenesis
p43400
sg35214
I14
sg35215
VC0598766
p43401
sg35217
I1
sa(dp43402
g35211
I53
sg35212
g43386
sg35214
I3
sg35215
VC0000744
p43403
sg35217
I1
sasa(dp43404
g135
(dp43405
(Vcasein kinase 1Epsilon
p43406
Vcolorectal carcinoma
p43407
tp43408
I01
ssg35204
VUsing in situ hybridization, the expression of key clock genes, including period circadian protein homolog (Per) 1 and 2, cryptochrome 1 (Cry1), circadian locomoter output cycles protein kaput (Clock), brain and muscle ARNT-like protein 1 (Bmal1) and casein kinase 1Epsilon (CK1Epsilon) were retrospectively examined in 51 cases of colorectal carcinoma and 10 cases of adenoma.
p43409
sg35206
(lp43410
(dp43411
g35211
I219
sg35212
VARNT-like protein 1
p43412
sg35214
I19
sg35223
VP14222
p43413
sg35217
I3
sa(dp43414
g35211
I275
sg35212
VCK1Epsilon
p43415
sg35214
I10
sg35223
VP48729
p43416
sg35217
I1
sa(dp43417
g35211
I138
sg35212
VCry1
p43418
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp43419
g35211
I122
sg35212
Vcryptochrome 1
p43420
sg35214
I14
sg35223
g12
sg35217
I2
sa(dp43421
g35211
I81
sg35212
Vcircadian protein homolog (Per) 1 and 2
p43422
sg35214
I39
sg35223
g12
sg35217
I7
sa(dp43423
g35211
I251
sg35212
g43406
sg35214
I22
sg35223
VP48729
p43424
sg35217
I3
sasg35208
(lp43425
(dp43426
g35211
I369
sg35212
Vadenoma
p43427
sg35214
I7
sg35215
VC0001430
p43428
sg35217
I1
sa(dp43429
g35211
I332
sg35212
g43407
sg35214
I20
sg35215
VC0009402
p43430
sg35217
I2
sasa(dp43431
g35204
VThe present study demonstrated that the protein expression levels of human circadian locomoter output cycles protein kaput (hCLOCK) is significantly increased, while miR-124 is attenuated in high-grade human CRC tissues and in the more invasive colorectal cancer cell lines SW620 and LOVO.
p43432
sg35206
(lp43433
(dp43434
g35211
I166
sg35212
VmiR-124
p43435
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp43436
g35211
I124
sg35212
VhCLOCK
p43437
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp43438
g35211
I69
sg35212
Vhuman circadian locomoter output cycles protein kaput
p43439
sg35214
I53
sg35223
g12
sg35217
I7
sasg35208
(lp43440
(dp43441
g35211
I208
sg35212
VCRC
p43442
sg35214
I3
sg35215
VC1527249
p43443
sg35217
I1
sa(dp43444
g35211
I245
sg35212
Vcolorectal cancer
p43445
sg35214
I17
sg35215
VC1527249
p43446
sg35217
I2
sasa(dp43447
g35204
VThe CLOCK gene may be designated as a novel candidate for targeted gene therapy in drug-resistant ovarian cancer.
p43448
sg35206
(lp43449
(dp43450
g35211
I4
sg35212
VCLOCK gene
p43451
sg35214
I10
sg35223
g12
sg35217
I2
sasg35208
(lp43452
(dp43453
g35211
I98
sg35212
Vovarian cancer
p43454
sg35214
I14
sg35215
VC1140680
p43455
sg35217
I2
sasa(dp43456
g135
(dp43457
(VPER3
p43458
Vcolorectal cancer
p43459
tp43460
I00
ssg35204
VStudy distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
p43461
sg35206
(lp43462
(dp43463
g35211
I495
sg35212
VCLOCK rs3749474
p43464
sg35214
I15
sg35223
g12
sg35217
I2
sa(dp43465
g35211
I376
sg35212
VNPAS2 rs10165970
p43466
sg35214
I16
sg35223
g12
sg35217
I2
sa(dp43467
g35211
I671
sg35212
g43458
sg35214
I4
sg35223
VP56645
p43468
sg35217
I1
sa(dp43469
g35211
I624
sg35212
VRORB rs7867494
p43470
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp43471
(dp43472
g35211
I219
sg35212
Vnon-small cell lung cancer
p43473
sg35214
I26
sg35215
VC0007131
p43474
sg35217
I4
sa(dp43475
g35211
I144
sg35212
Vglioma
p43476
sg35214
I6
sg35215
VC0017638
p43477
sg35217
I1
sa(dp43478
g35211
I22
sg35212
Vtumor
p43479
sg35214
I5
sg35215
VC0027651
p43480
sg35217
I1
sa(dp43481
g35211
I44
sg35212
Vbreast cancer
p43482
sg35214
I13
sg35215
VC0678222
p43483
sg35217
I2
sa(dp43484
g35211
I44
sg35212
Vbreast cancer
p43485
sg35214
I13
sg35215
VC0678222
p43486
sg35217
I2
sa(dp43487
g35211
I44
sg35212
Vbreast cancer
p43488
sg35214
I13
sg35215
VC0678222
p43489
sg35217
I2
sa(dp43490
g35211
I51
sg35212
Vcancer
p43491
sg35214
I6
sg35215
VC0006826
p43492
sg35217
I1
sa(dp43493
g35211
I89
sg35212
Vpancreatic cancer
p43494
sg35214
I17
sg35215
VC0235974
p43495
sg35217
I2
sa(dp43496
g35211
I256
sg35212
Vovarian cancer
p43497
sg35214
I14
sg35215
VC1140680
p43498
sg35217
I2
sa(dp43499
g35211
I44
sg35212
Vbreast cancer
p43500
sg35214
I13
sg35215
VC0678222
p43501
sg35217
I2
sa(dp43502
g35211
I44
sg35212
Vbreast cancer
p43503
sg35214
I13
sg35215
VC0678222
p43504
sg35217
I2
sa(dp43505
g35211
I158
sg35212
Vchronic lymphocytic leukemia
p43506
sg35214
I28
sg35215
VC0023434
p43507
sg35217
I3
sa(dp43508
g35211
I114
sg35212
Vnon-Hodgkin's lymphoma
p43509
sg35214
I22
sg35215
VC0024305
p43510
sg35217
I2
sa(dp43511
g35211
I66
sg35212
Vprostate cancer
p43512
sg35214
I15
sg35215
VC0600139
p43513
sg35217
I2
sa(dp43514
g35211
I194
sg35212
g43459
sg35214
I17
sg35215
VC1527249
p43515
sg35217
I2
sasa(dp43516
g135
(dp43517
(VTIMELESS
p43518
Vbreast cancer
p43519
tp43520
I01
ssg35204
VWe summarize fifteen epidemiological studies, including five studies on shift work that have indicated BMAL1, BMAL2, CLOCK, NPAS2, CRY1, CRY2, PER1, PER3 and TIMELESS as a candidate breast cancer risk variants.
p43521
sg35206
(lp43522
(dp43523
g35211
I149
sg35212
VPER3
p43524
sg35214
I4
sg35223
VP56645
p43525
sg35217
I1
sa(dp43526
g35211
I131
sg35212
VCRY1
p43527
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp43528
g35211
I124
sg35212
VNPAS2
p43529
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp43530
g35211
I158
sg35212
g43518
sg35214
I8
sg35223
VP60174
p43531
sg35217
I1
sa(dp43532
g35211
I143
sg35212
VPER1
p43533
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp43534
g35211
I117
sg35212
VCLOCK
p43535
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp43536
g35211
I137
sg35212
VCRY2
p43537
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp43538
(dp43539
g35211
I182
sg35212
g43519
sg35214
I13
sg35215
VC0678222
p43540
sg35217
I2
sasa(dp43541
g35204
VThis study sought to determine TANK (rs1921310, rs3820998) gene polymorphism in patients suffering from chronic periodontitis and peri-implantitis among an Iranian population.
p43542
sg35206
(lp43543
(dp43544
g35211
I31
sg35212
VTANK
p43545
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp43546
(dp43547
g35211
I89
sg35212
Vsuffering
p43548
sg35214
I9
sg35215
VC0683278
p43549
sg35217
I1
sa(dp43550
g35211
I104
sg35212
Vchronic periodontitis
p43551
sg35214
I21
sg35215
VC0266929
p43552
sg35217
I2
sa(dp43553
g35211
I130
sg35212
Vperi-implantitis
p43554
sg35214
I16
sg35215
VC2936258
p43555
sg35217
I1
sasa(dp43556
g135
(dp43557
(VTNF-Alfa
p43558
VHBV
p43559
tp43560
I00
ssg35204
VThe tumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB (NF-KB) activator (TANK) takes part in the tumor necrosis factor-Alfa (TNF-Alfa)-mediated NF-KB signaling pathway and the interferon (IFN)-induction pathways that have relevance to HBV-related liver disease.
p43561
sg35206
(lp43562
(dp43563
g35211
I4
sg35212
Vtumor necrosis factor receptor-associated factor family member-associated nuclear factor-KB
p43564
sg35214
I91
sg35223
VP01375
p43565
sg35217
I9
sa(dp43566
g35211
I218
sg35212
Vinterferon
p43567
sg35214
I10
sg35223
VP01563
p43568
sg35217
I1
sa(dp43569
g35211
I115
sg35212
VTANK
p43570
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp43571
g35211
I139
sg35212
Vtumor necrosis factor-Alfa
p43572
sg35214
I26
sg35223
VP01375
p43573
sg35217
I3
sa(dp43574
g35211
I167
sg35212
g43558
sg35214
I8
sg35223
VP01375
p43575
sg35217
I1
sa(dp43576
g35211
I230
sg35212
VIFN
p43577
sg35214
I3
sg35223
VP01562
p43578
sg35217
I1
sasg35208
(lp43579
(dp43580
g35211
I4
sg35212
Vtumor necrosis
p43581
sg35214
I14
sg35215
VC0333516
p43582
sg35217
I2
sa(dp43583
g35211
I289
sg35212
Vliver disease
p43584
sg35214
I13
sg35215
VC0023895
p43585
sg35217
I2
sa(dp43586
g35211
I4
sg35212
Vtumor necrosis
p43587
sg35214
I14
sg35215
VC0333516
p43588
sg35217
I2
sa(dp43589
g35211
I277
sg35212
g43559
sg35214
I3
sg35215
VC0019163
p43590
sg35217
I1
sasa(dp43591
g135
(dp43592
(VIDE
p43593
Vhyperinsulinemia
p43594
tp43595
I00
ssg35204
VThese results indicate that treatment with TUDCA may be helpful to counteract obesity-induced hyperinsulinemia through increasing insulin clearance, likely through enhanced liver IDE expression in a mechanism dependent on S1PR2-Insulin pathway activation.
p43596
sg35206
(lp43597
(dp43598
g35211
I228
sg35212
VInsulin
p43599
sg35214
I7
sg35223
VP01308
p43600
sg35217
I1
sa(dp43601
g35211
I99
sg35212
Vinsulin
p43602
sg35214
I7
sg35223
VP01308
p43603
sg35217
I1
sa(dp43604
g35211
I179
sg35212
g43593
sg35214
I3
sg35223
VP14735
p43605
sg35217
I1
sa(dp43606
g35211
I222
sg35212
VS1PR2
p43607
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp43608
(dp43609
g35211
I78
sg35212
Vobesity
p43610
sg35214
I7
sg35215
VC0028754
p43611
sg35217
I1
sa(dp43612
g35211
I119
sg35212
Vincreasing insulin
p43613
sg35214
I18
sg35215
VC0020459
p43614
sg35217
I2
sa(dp43615
g35211
I94
sg35212
g43594
sg35214
I16
sg35215
VC0020459
p43616
sg35217
I1
sasa(dp43617
g135
(dp43618
(Vinsulin
p43619
Vdiabetes
p43620
tp43621
I00
ssg35204
VInsulin-degrading enzyme (IDE) is a ubiquitous zinc peptidase of the inverzincin family, which has been initially discovered as the enzyme responsible for insulin catabolism; therefore, its involvement in the onset of diabetes has been largely investigated.
p43622
sg35206
(lp43623
(dp43624
g35211
I0
sg35212
VInsulin-degrading enzyme
p43625
sg35214
I24
sg35223
VP14735
p43626
sg35217
I2
sa(dp43627
g35211
I47
sg35212
Vzinc peptidase
p43628
sg35214
I14
sg35223
g12
sg35217
I2
sa(dp43629
g35211
I26
sg35212
VIDE
p43630
sg35214
I3
sg35223
VP14735
p43631
sg35217
I1
sa(dp43632
g35211
I155
sg35212
g43619
sg35214
I7
sg35223
VP01308
p43633
sg35217
I1
sasg35208
(lp43634
(dp43635
g35211
I218
sg35212
g43620
sg35214
I8
sg35215
VC0011849
p43636
sg35217
I1
sasa(dp43637
g135
(dp43638
(VIDE
p43639
Vobesity
p43640
tp43641
I00
ssg35204
VImpairment of the insulin-degrading enzyme (IDE) is associated with obesity and type 2 diabetes mellitus (T2DM).
p43642
sg35206
(lp43643
(dp43644
g35211
I18
sg35212
Vinsulin-degrading enzyme
p43645
sg35214
I24
sg35223
VP14735
p43646
sg35217
I2
sa(dp43647
g35211
I44
sg35212
g43639
sg35214
I3
sg35223
VP14735
p43648
sg35217
I1
sasg35208
(lp43649
(dp43650
g35211
I106
sg35212
VT2DM
p43651
sg35214
I4
sg35215
VC0011860
p43652
sg35217
I1
sa(dp43653
g35211
I80
sg35212
Vtype 2 diabetes mellitus
p43654
sg35214
I24
sg35215
VC0011860
p43655
sg35217
I4
sa(dp43656
g35211
I0
sg35212
VImpairment
p43657
sg35214
I10
sg35215
VC0684336
p43658
sg35217
I1
sa(dp43659
g35211
I68
sg35212
g43640
sg35214
I7
sg35215
VC0028754
p43660
sg35217
I1
sasa(dp43661
g135
(dp43662
(Vinsulin
p43663
Vdiabetes
p43664
tp43665
I00
ssg35204
VSeveral mechanisms have been reported underlying the association of the two disorders, diabetes and dementia, one among which is the insulin-degrading enzyme (IDE) which is known to degrade insulin as well beta-amyloid peptides.
p43666
sg35206
(lp43667
(dp43668
g35211
I159
sg35212
VIDE
p43669
sg35214
I3
sg35223
VP14735
p43670
sg35217
I1
sa(dp43671
g35211
I133
sg35212
Vinsulin-degrading enzyme
p43672
sg35214
I24
sg35223
VP14735
p43673
sg35217
I2
sa(dp43674
g35211
I133
sg35212
g43663
sg35214
I7
sg35223
VP01308
p43675
sg35217
I1
sasg35208
(lp43676
(dp43677
g35211
I100
sg35212
Vdementia
p43678
sg35214
I8
sg35215
VC0497327
p43679
sg35217
I1
sa(dp43680
g35211
I211
sg35212
Vamyloid
p43681
sg35214
I7
sg35215
VC0011560
p43682
sg35217
I1
sa(dp43683
g35211
I87
sg35212
g43664
sg35214
I8
sg35215
VC0011849
p43684
sg35217
I1
sasa(dp43685
g135
(dp43686
(Vinsulin receptor
p43687
Vinsulin resistance
p43688
tp43689
I00
ssg35204
VWe concluded that vitamin D3 ameliorated insulin resistance and hyperinsulinemia in diabetic rat model received HFW through reduction of IDE and activation of insulin receptor phosphorylation.
p43690
sg35206
(lp43691
(dp43692
g35211
I41
sg35212
Vinsulin
p43693
sg35214
I7
sg35223
VP01308
p43694
sg35217
I1
sa(dp43695
g35211
I159
sg35212
g43687
sg35214
I16
sg35223
VP01308
p43696
sg35217
I2
sasg35208
(lp43697
(dp43698
g35211
I64
sg35212
Vhyperinsulinemia
p43699
sg35214
I16
sg35215
VC0020459
p43700
sg35217
I1
sa(dp43701
g35211
I41
sg35212
g43688
sg35214
I18
sg35215
VC0021655
p43702
sg35217
I2
sasa(dp43703
g35204
VIndependently, the same approach identified a second homozygous truncating GZF1 variant in another multiplex consanguineous family affected by severe myopia, retinal detachment, and milder skeletal involvement.
p43704
sg35206
(lp43705
(dp43706
g35211
I64
sg35212
Vtruncating GZF1 variant
p43707
sg35214
I23
sg35223
g12
sg35217
I3
sasg35208
(lp43708
(dp43709
g35211
I158
sg35212
Vretinal detachment
p43710
sg35214
I18
sg35215
VC0035305
p43711
sg35217
I2
sa(dp43712
g35211
I143
sg35212
Vsevere myopia
p43713
sg35214
I13
sg35215
VC0271183
p43714
sg35217
I2
sasa(dp43715
g35204
VSubgroup analyses found that the IL4RA I50V polymorphism was significantly associated with asthma risk in Asians (OR = 1.72, 95% CI 1.31-2.25, P&lt;0.0001), pediatric asthma risk (OR = 1.50, 95% CI 1.13-1.99, P = 0.005), and atopic asthma risk (OR = 1.88, 95% CI 1.27-2.79, P = 0.002).
p43716
sg35206
(lp43717
sg35208
(lp43718
(dp43719
g35211
I225
sg35212
Vatopic asthma
p43720
sg35214
I13
sg35215
VC0155877
p43721
sg35217
I2
sa(dp43722
g35211
I91
sg35212
Vasthma
p43723
sg35214
I6
sg35215
VC0004096
p43724
sg35217
I1
sa(dp43725
g35211
I91
sg35212
Vasthma
p43726
sg35214
I6
sg35215
VC0004096
p43727
sg35217
I1
sasa(dp43728
g135
(dp43729
(VCD14
p43730
Vasthma
p43731
tp43732
I00
ssg35204
VTo verify the association of transforming growth factor-beta1(TGF-beta1) (C-509T and T869C), CD14 (C-159T), IL-4 (C-590T), IL-4R (ILe50Val) and ADAM33 (S_2) gene polymorphisms with asthma severity in a sample of patients with mild, moderate and severe persistent atopic asthma.
p43733
sg35206
(lp43734
(dp43735
g35211
I108
sg35212
VIL-4
p43736
sg35214
I4
sg35223
VP05112
p43737
sg35217
I1
sa(dp43738
g35211
I29
sg35212
Vtransforming growth factor-beta1
p43739
sg35214
I32
sg35223
VP01137
p43740
sg35217
I3
sa(dp43741
g35211
I144
sg35212
VADAM33
p43742
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp43743
g35211
I62
sg35212
VTGF-beta1
p43744
sg35214
I9
sg35223
VP01137
p43745
sg35217
I1
sa(dp43746
g35211
I93
sg35212
g43730
sg35214
I4
sg35223
VP08571
p43747
sg35217
I1
sasg35208
(lp43748
(dp43749
g35211
I263
sg35212
Vatopic asthma
p43750
sg35214
I13
sg35215
VC0155877
p43751
sg35217
I2
sa(dp43752
g35211
I181
sg35212
g43731
sg35214
I6
sg35215
VC0004096
p43753
sg35217
I1
sasa(dp43754
g35204
VTo investigate the correlation between Chlamydia pneumonia (Cpn) infection and chronic obstructive pulmonary disease (COPD).
p43755
sg35206
(lp43756
sg35208
(lp43757
(dp43758
g35211
I79
sg35212
Vchronic obstructive pulmonary disease
p43759
sg35214
I37
sg35215
VC0024117
p43760
sg35217
I4
sa(dp43761
g35211
I118
sg35212
VCOPD
p43762
sg35214
I4
sg35215
VC0024117
p43763
sg35217
I1
sa(dp43764
g35211
I49
sg35212
Vpneumonia
p43765
sg35214
I9
sg35215
VC0032285
p43766
sg35217
I1
sa(dp43767
g35211
I65
sg35212
Vinfection
p43768
sg35214
I9
sg35215
VC0009450
p43769
sg35217
I1
sasa(dp43770
g135
(dp43771
(VCpn
p43772
Vchronic obstructive pulmonary disease
p43773
tp43774
I00
ssg35204
VChlamydia pneumoniae (Cpn) infection may play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD).
p43775
sg35206
(lp43776
(dp43777
g35211
I0
sg35212
VChlamydia pneumoniae
p43778
sg35214
I20
sg35223
VP15169
p43779
sg35217
I2
sa(dp43780
g35211
I22
sg35212
g43772
sg35214
I3
sg35223
VP15169
p43781
sg35217
I1
sasg35208
(lp43782
(dp43783
g35211
I27
sg35212
Vinfection
p43784
sg35214
I9
sg35215
VC0009450
p43785
sg35217
I1
sa(dp43786
g35211
I115
sg35212
VCOPD
p43787
sg35214
I4
sg35215
VC0024117
p43788
sg35217
I1
sa(dp43789
g35211
I76
sg35212
g43773
sg35214
I37
sg35215
VC0024117
p43790
sg35217
I4
sa(dp43791
g35211
I60
sg35212
Vpathogenesis
p43792
sg35214
I12
sg35215
VC0699748
p43793
sg35217
I1
sasa(dp43794
g135
(dp43795
(VCpn
p43796
Vchronic obstructive pulmonary disease
p43797
tp43798
I00
ssg35204
VTo determine the possible association between Chlamydiae pneumoniae (Cpn) infection and chronic obstructive pulmonary disease (COPD).
p43799
sg35206
(lp43800
(dp43801
g35211
I46
sg35212
VChlamydiae pneumoniae
p43802
sg35214
I21
sg35223
VP15169
p43803
sg35217
I2
sa(dp43804
g35211
I69
sg35212
g43796
sg35214
I3
sg35223
VP15169
p43805
sg35217
I1
sasg35208
(lp43806
(dp43807
g35211
I127
sg35212
VCOPD
p43808
sg35214
I4
sg35215
VC0024117
p43809
sg35217
I1
sa(dp43810
g35211
I88
sg35212
g43797
sg35214
I37
sg35215
VC0024117
p43811
sg35217
I4
sa(dp43812
g35211
I74
sg35212
Vinfection
p43813
sg35214
I9
sg35215
VC0009450
p43814
sg35217
I1
sasa(dp43815
g135
(dp43816
(VChlamydia pneumoniae
p43817
VCOPD
p43818
tp43819
I00
ssg35204
VThe objective of the study was to investigate the possible association of Chlamydia pneumoniae (Cpn) in acute exacerbations of chronic obstructive pulmonary disease (COPD) patients.
p43820
sg35206
(lp43821
(dp43822
g35211
I96
sg35212
VCpn
p43823
sg35214
I3
sg35223
VP15169
p43824
sg35217
I1
sa(dp43825
g35211
I74
sg35212
g43817
sg35214
I20
sg35223
VP15169
p43826
sg35217
I2
sasg35208
(lp43827
(dp43828
g35211
I127
sg35212
Vchronic obstructive pulmonary disease
p43829
sg35214
I37
sg35215
VC0024117
p43830
sg35217
I4
sa(dp43831
g35211
I166
sg35212
g43818
sg35214
I4
sg35215
VC0024117
p43832
sg35217
I1
sasa(dp43833
g135
(dp43834
(VChlamydia pneumoniae
p43835
Vasthma
p43836
tp43837
I00
ssg35204
VReading this article will familiarize the reader with (1) the unique chlamydial intracellular life cycle and the propensity for human chlamydial infections to become persistent and to result in immunopathologic (inflammatory) damage in target organs and (2) current evidence linking Chlamydia pneumoniae (Cpn) infection to obstructive lung diseases (asthma and chronic obstructive pulmonary disease, COPD).
p43838
sg35206
(lp43839
(dp43840
g35211
I305
sg35212
VCpn
p43841
sg35214
I3
sg35223
VP15169
p43842
sg35217
I1
sa(dp43843
g35211
I283
sg35212
g43835
sg35214
I20
sg35223
VP15169
p43844
sg35217
I2
sasg35208
(lp43845
(dp43846
g35211
I400
sg35212
VCOPD
p43847
sg35214
I4
sg35215
VC0024117
p43848
sg35217
I1
sa(dp43849
g35211
I145
sg35212
Vinfection
p43850
sg35214
I9
sg35215
VC0009450
p43851
sg35217
I1
sa(dp43852
g35211
I323
sg35212
Vobstructive lung diseases
p43853
sg35214
I25
sg35215
VC0600260
p43854
sg35217
I3
sa(dp43855
g35211
I134
sg35212
Vchlamydial infections
p43856
sg35214
I21
sg35215
VC0008149
p43857
sg35217
I2
sa(dp43858
g35211
I361
sg35212
Vchronic obstructive pulmonary disease
p43859
sg35214
I37
sg35215
VC0024117
p43860
sg35217
I4
sa(dp43861
g35211
I350
sg35212
g43836
sg35214
I6
sg35215
VC0004096
p43862
sg35217
I1
sasa(dp43863
g35204
VAlthough the full clinical significance of these Cpn-obstructive lung disease associations remains to be established, reports of asthma improvement after treatment of Cpn infection deserve further investigation.
p43864
sg35206
(lp43865
sg35208
(lp43866
(dp43867
g35211
I53
sg35212
Vobstructive lung disease
p43868
sg35214
I24
sg35215
VC0600260
p43869
sg35217
I3
sa(dp43870
g35211
I129
sg35212
Vasthma
p43871
sg35214
I6
sg35215
VC0004096
p43872
sg35217
I1
sa(dp43873
g35211
I171
sg35212
Vinfection
p43874
sg35214
I9
sg35215
VC0009450
p43875
sg35217
I1
sasa(dp43876
g35204
VTaken together, we conclude that EGFR TKIs enhance the sensitivity of NSCLC cells to vATPase inhibitors by decreasing Hif-1Alfa/Bnip3 expression.
p43877
sg35206
(lp43878
(dp43879
g35211
I128
sg35212
VBnip3
p43880
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp43881
(dp43882
g35211
I70
sg35212
VNSCLC
p43883
sg35214
I5
sg35215
VC0007131
p43884
sg35217
I1
sasa(dp43885
g35204
VWe found a significant upregulation of BNIP3 in human lung cancer datasets, and we identified a direct association between BNIP3 expression and survival rate of lung cancer patients.
p43886
sg35206
(lp43887
(dp43888
g35211
I39
sg35212
VBNIP3
p43889
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp43890
g35211
I39
sg35212
VBNIP3
p43891
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp43892
(dp43893
g35211
I54
sg35212
Vlung cancer
p43894
sg35214
I11
sg35215
VC0684249
p43895
sg35217
I2
sa(dp43896
g35211
I54
sg35212
Vlung cancer
p43897
sg35214
I11
sg35215
VC0684249
p43898
sg35217
I2
sasa(dp43899
g135
(dp43900
(Vanti-autophagic protein Bcl-2
p43901
VNSCLC
p43902
tp43903
I00
ssg35204
VIn this study we used 115 NSCLC tissues to examine the immunohistochemical expression of four distinct molecules - the major regulator of autophagy Beclin 1, the anti-apoptotic and anti-autophagic protein Bcl-2, the pro-apoptotic and pro-autophagic protein BNIP3, and a marker of hypoxia and glucolysis, the glucose transporter Glut 1.
p43904
sg35206
(lp43905
(dp43906
g35211
I138
sg35212
Vautophagy Beclin 1
p43907
sg35214
I18
sg35223
g12
sg35217
I3
sa(dp43908
g35211
I181
sg35212
g43901
sg35214
I29
sg35223
VP10415
p43909
sg35217
I3
sa(dp43910
g35211
I234
sg35212
Vpro-autophagic protein BNIP3
p43911
sg35214
I28
sg35223
g12
sg35217
I3
sasg35208
(lp43912
(dp43913
g35211
I280
sg35212
Vhypoxia
p43914
sg35214
I7
sg35215
VC0242184
p43915
sg35217
I1
sa(dp43916
g35211
I26
sg35212
g43902
sg35214
I5
sg35215
VC0007131
p43917
sg35217
I1
sasa(dp43918
g135
(dp43919
(VBcl-2
p43920
VNSCLC
p43921
tp43922
I00
ssg35204
VIn conclusion, the accelerated autophagic status in NSCLC is unrelated to Beclin 1 and BNIP3 expression, but does show significant association with Bcl-2 reactivity.
p43923
sg35206
(lp43924
(dp43925
g35211
I74
sg35212
VBeclin 1
p43926
sg35214
I8
sg35223
g12
sg35217
I2
sa(dp43927
g35211
I87
sg35212
VBNIP3
p43928
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp43929
g35211
I148
sg35212
g43920
sg35214
I5
sg35223
VP10415
p43930
sg35217
I1
sasg35208
(lp43931
(dp43932
g35211
I52
sg35212
g43921
sg35214
I5
sg35215
VC0007131
p43933
sg35217
I1
sasa(dp43934
g135
(dp43935
(VTGM2
p43936
Vlaryngeal cancer
p43937
tp43938
I00
ssg35204
VThis study was designed to determine the pattern and correlation between expression of the HIF-1Alfa transcriptional targets TGM2 and BNIP3 in laryngeal cancer, and investigate the association of BNIP3 and TGM2 with clinical outcome in laryngeal squamous cell carcinoma (SCC) patients receiving postoperative radiotherapy.
p43939
sg35206
(lp43940
(dp43941
g35211
I134
sg35212
VBNIP3
p43942
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp43943
g35211
I125
sg35212
VTGM2
p43944
sg35214
I4
sg35223
VP21980
p43945
sg35217
I1
sa(dp43946
g35211
I125
sg35212
g43936
sg35214
I4
sg35223
VP21980
p43947
sg35217
I1
sa(dp43948
g35211
I134
sg35212
VBNIP3
p43949
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp43950
(dp43951
g35211
I236
sg35212
Vlaryngeal squamous cell carcinoma
p43952
sg35214
I33
sg35215
VC0280324
p43953
sg35217
I4
sa(dp43954
g35211
I143
sg35212
g43937
sg35214
I16
sg35215
VC0595989
p43955
sg35217
I2
sasa(dp43956
g135
(dp43957
(VCRC
p43958
VNSCLC
p43959
tp43960
I00
ssg35204
VConsidering tumors with telomere shortening, expression for BNIP3, DAPK1, NDRG1, EGFR, and CDKN2A was significantly higher in NSCLC than in CRC, whereas TP53 was overexpressed in CRC with respect to NSCLC.
p43961
sg35206
(lp43962
(dp43963
g35211
I140
sg35212
VCRC, whereas TP53
p43964
sg35214
I17
sg35223
VP31749
p43965
sg35217
I3
sa(dp43966
g35211
I91
sg35212
VCDKN2A
p43967
sg35214
I6
sg35223
VP42771
p43968
sg35217
I1
sa(dp43969
g35211
I67
sg35212
VDAPK1
p43970
sg35214
I5
sg35223
VP53355
p43971
sg35217
I1
sa(dp43972
g35211
I140
sg35212
g43958
sg35214
I3
sg35223
VP31749
p43973
sg35217
I1
sa(dp43974
g35211
I74
sg35212
VNDRG1
p43975
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp43976
g35211
I60
sg35212
VBNIP3
p43977
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp43978
(dp43979
g35211
I24
sg35212
Vtelomere shortening
p43980
sg35214
I19
sg35215
VC1515263
p43981
sg35217
I2
sa(dp43982
g35211
I140
sg35212
VCRC
p43983
sg35214
I3
sg35215
VC1527249
p43984
sg35217
I1
sa(dp43985
g35211
I12
sg35212
Vtumors
p43986
sg35214
I6
sg35215
VC0027651
p43987
sg35217
I1
sa(dp43988
g35211
I126
sg35212
VNSCLC
p43989
sg35214
I5
sg35215
VC0007131
p43990
sg35217
I1
sa(dp43991
g35211
I140
sg35212
VCRC
p43992
sg35214
I3
sg35215
VC1527249
p43993
sg35217
I1
sa(dp43994
g35211
I126
sg35212
g43959
sg35214
I5
sg35215
VC0007131
p43995
sg35217
I1
sasa(dp43996
g35204
VKIAA0513 was previously identified as upregulated in the dorsolateral prefrontal cortex of subjects with schizophrenia by microarray analysis.
p43997
sg35206
(lp43998
sg35208
(lp43999
(dp44000
g35211
I105
sg35212
Vschizophrenia
p44001
sg35214
I13
sg35215
VC0036341
p44002
sg35217
I1
sasa(dp44003
g35204
VHigher fasting glucose levels may amplify obesity-risk in FTO carriers and lead to an exaggerated weight gain over time.
p44004
sg35206
(lp44005
sg35208
(lp44006
(dp44007
g35211
I42
sg35212
Vobesity
p44008
sg35214
I7
sg35215
VC0028754
p44009
sg35217
I1
sasa(dp44010
g35204
VType 2 diabetes-associated genes TCF7L2 and FTO; and a miRNA, miR21 were further investigated in another B12-supplementation cohort.
p44011
sg35206
(lp44012
(dp44013
g35211
I44
sg35212
VFTO
p44014
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp44015
(dp44016
g35211
I0
sg35212
VType 2 diabetes
p44017
sg35214
I15
sg35215
VC0011860
p44018
sg35217
I3
sasa(dp44019
g35204
VRecent studies show that FTO single nucleotide polymorphisms (SNPs) are associated with obesity and type 2 diabetes mellitus (T2DM).
p44020
sg35206
(lp44021
sg35208
(lp44022
(dp44023
g35211
I88
sg35212
Vobesity
p44024
sg35214
I7
sg35215
VC0028754
p44025
sg35217
I1
sa(dp44026
g35211
I126
sg35212
VT2DM
p44027
sg35214
I4
sg35215
VC0011860
p44028
sg35217
I1
sa(dp44029
g35211
I100
sg35212
Vtype 2 diabetes mellitus
p44030
sg35214
I24
sg35215
VC0011860
p44031
sg35217
I4
sasa(dp44032
g35204
VThe FTO gene is associated with type-2 diabetes (T2D) and increased fat mass.
p44033
sg35206
(lp44034
(dp44035
g35211
I4
sg35212
VFTO gene
p44036
sg35214
I8
sg35223
g12
sg35217
I2
sasg35208
(lp44037
(dp44038
g35211
I32
sg35212
Vtype-2 diabetes
p44039
sg35214
I15
sg35215
VC0011860
p44040
sg35217
I2
sa(dp44041
g35211
I49
sg35212
VT2D
p44042
sg35214
I3
sg35215
VC0011860
p44043
sg35217
I1
sasa(dp44044
g35204
VA significant association was found between the perilipin rs1052700 polymorphism and T2D, and between the FTO rs3751812 polymorphism and obesity (P = 0.03 and 0.003, respectively); however, no significant relationship was found between rs3751812 and T2D.
p44045
sg35206
(lp44046
(dp44047
g35211
I48
sg35212
Vperilipin rs1052700
p44048
sg35214
I19
sg35223
g12
sg35217
I2
sasg35208
(lp44049
(dp44050
g35211
I85
sg35212
VT2D
p44051
sg35214
I3
sg35215
VC0011860
p44052
sg35217
I1
sa(dp44053
g35211
I85
sg35212
VT2D
p44054
sg35214
I3
sg35215
VC0011860
p44055
sg35217
I1
sa(dp44056
g35211
I137
sg35212
Vobesity
p44057
sg35214
I7
sg35215
VC0028754
p44058
sg35217
I1
sasa(dp44059
g35204
VThe FTO rs3751812 polymorphism is a major genetic determinant of obesity, but not T2D.
p44060
sg35206
(lp44061
sg35208
(lp44062
(dp44063
g35211
I65
sg35212
Vobesity
p44064
sg35214
I7
sg35215
VC0028754
p44065
sg35217
I1
sa(dp44066
g35211
I82
sg35212
VT2D
p44067
sg35214
I3
sg35215
VC0011860
p44068
sg35217
I1
sasa(dp44069
g35204
VRecent studies have implicated the FTO gene in child and adult obesity.
p44070
sg35206
(lp44071
(dp44072
g35211
I35
sg35212
VFTO gene
p44073
sg35214
I8
sg35223
g12
sg35217
I2
sasg35208
(lp44074
(dp44075
g35211
I63
sg35212
Vobesity
p44076
sg35214
I7
sg35215
VC0028754
p44077
sg35217
I1
sasa(dp44078
g35204
VVariants (rs1558902, rs1121980, rs9939609, and rs9941349) in the fat mass and obesity-associated (FTO) gene exhibited strong but ethnicity-independent association with obesity.
p44079
sg35206
(lp44080
sg35208
(lp44081
(dp44082
g35211
I78
sg35212
Vobesity
p44083
sg35214
I7
sg35215
VC0028754
p44084
sg35217
I1
sa(dp44085
g35211
I78
sg35212
Vobesity
p44086
sg35214
I7
sg35215
VC0028754
p44087
sg35217
I1
sasa(dp44088
g35204
VThere is increasing interest of which dietary patterns can modify the association of fat mass and obesity associated (FTO) variants with obesity.
p44089
sg35206
(lp44090
sg35208
(lp44091
(dp44092
g35211
I98
sg35212
Vobesity
p44093
sg35214
I7
sg35215
VC0028754
p44094
sg35217
I1
sa(dp44095
g35211
I98
sg35212
Vobesity
p44096
sg35214
I7
sg35215
VC0028754
p44097
sg35217
I1
sasa(dp44098
g35204
VThis study was aimed at investigating the interaction of the Mediterranean dietary pattern (Med Diet) with FTO polymorphisms in relation to obesity phenotypes.
p44099
sg35206
(lp44100
sg35208
(lp44101
(dp44102
g35211
I140
sg35212
Vobesity
p44103
sg35214
I7
sg35215
VC0028754
p44104
sg35217
I1
sasa(dp44105
g135
(dp44106
(Vleptin
p44107
Vobesity
p44108
tp44109
I00
ssg35204
VObesity is a heritable disorder, and some of the many obesity susceptible genes are fat mass and obesity (FTO), leptin, and Melanocortin-4 receptor (MC4R).
p44110
sg35206
(lp44111
(dp44112
g35211
I124
sg35212
VMelanocortin-4 receptor
p44113
sg35214
I23
sg35223
VP32245
p44114
sg35217
I2
sa(dp44115
g35211
I149
sg35212
VMC4R
p44116
sg35214
I4
sg35223
VP32245
p44117
sg35217
I1
sa(dp44118
g35211
I112
sg35212
g44107
sg35214
I6
sg35223
VP41159
p44119
sg35217
I1
sasg35208
(lp44120
(dp44121
g35211
I0
sg35212
VObesity
p44122
sg35214
I7
sg35215
VC0028754
p44123
sg35217
I1
sa(dp44124
g35211
I54
sg35212
Vobesity
p44125
sg35214
I7
sg35215
VC0028754
p44126
sg35217
I1
sa(dp44127
g35211
I54
sg35212
g44108
sg35214
I7
sg35215
VC0028754
p44128
sg35217
I1
sasa(dp44129
g135
(dp44130
(VCD79B
p44131
VMALT lymphoma
p44132
tp44133
I01
ssg35204
VWe showed that: (1) there was a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-KB (NF-KB) pathway] in ocular adnexal MALT lymphoma; (2) IGHV1-69 was significantly overrepresented (54%) in MALT lymphoma of the salivary gland, but was not associated with mutation in any of the 17 genes investigated; and (3) MALT lymphoma lacked mutations that are frequently seen in other B-cell lymphomas characterized by constitutive NF-KB activities, including mutations in CD79B, CARD11, MYD88, TNFRSF11A, and TRAF3.
p44134
sg35206
(lp44135
(dp44136
g35211
I637
sg35212
VMYD88
p44137
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp44138
g35211
I644
sg35212
VTNFRSF11A
p44139
sg35214
I9
sg35223
g12
sg35217
I1
sa(dp44140
g35211
I226
sg35212
Vnuclear factor-KB
p44141
sg35214
I17
sg35223
VP01160
p44142
sg35217
I2
sa(dp44143
g35211
I629
sg35212
VCARD11
p44144
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp44145
g35211
I245
sg35212
VNF-KB
p44146
sg35214
I5
sg35223
VP01160
p44147
sg35217
I1
sa(dp44148
g35211
I659
sg35212
VTRAF3
p44149
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp44150
g35211
I245
sg35212
VNF-KB
p44151
sg35214
I5
sg35223
VP01160
p44152
sg35217
I1
sa(dp44153
g35211
I107
sg35212
Vcarbohydrate I/i antigens
p44154
sg35214
I25
sg35223
g12
sg35217
I3
sa(dp44155
g35211
I163
sg35212
VTNFAIP3
p44156
sg35214
I7
sg35223
VP21580
p44157
sg35217
I1
sa(dp44158
g35211
I622
sg35212
g44131
sg35214
I5
sg35223
VP40259
p44159
sg35217
I1
sasg35208
(lp44160
(dp44161
g35211
I279
sg35212
VMALT lymphoma
p44162
sg35214
I13
sg35215
VC0242647
p44163
sg35217
I2
sa(dp44164
g35211
I534
sg35212
VB-cell lymphomas
p44165
sg35214
I16
sg35215
VC0079731
p44166
sg35217
I2
sa(dp44167
g35211
I264
sg35212
Vocular adnexal MALT lymphoma
p44168
sg35214
I28
sg35215
VC1335103
p44169
sg35217
I4
sa(dp44170
g35211
I279
sg35212
g44132
sg35214
I13
sg35215
VC0242647
p44171
sg35217
I2
sasa(dp44172
g135
(dp44173
(Vendothelin-1
p44174
Vknee osteoarthritis
p44175
tp44176
I00
ssg35204
VTherefore, we aim to assess the correlation of endothelin-1 concentrations with the development and severity of knee osteoarthritis (OA).
p44177
sg35206
(lp44178
(dp44179
g35211
I47
sg35212
g44174
sg35214
I12
sg35223
VP20800
p44180
sg35217
I1
sasg35208
(lp44181
(dp44182
g35211
I112
sg35212
g44175
sg35214
I19
sg35215
VC0409959
p44183
sg35217
I2
sasa(dp44184
g135
(dp44185
(Vcytokines TNF-Alfa
p44186
VCRF
p44187
tp44188
I00
ssg35204
VTogether, the results here demonstrate that the febrile response in zymosan-induced arthritis in rats depends on the centrally acting pyrogenic cytokines TNF-Alfa, IL-1Beta, and IL-6, but does not depend on either CRF or ET-1.
p44189
sg35206
(lp44190
(dp44191
g35211
I221
sg35212
VET-1
p44192
sg35214
I4
sg35223
VP05305
p44193
sg35217
I1
sa(dp44194
g35211
I178
sg35212
VIL-6
p44195
sg35214
I4
sg35223
VP05231
p44196
sg35217
I1
sa(dp44197
g35211
I164
sg35212
VIL-1Beta
p44198
sg35214
I8
sg35223
VP01584
p44199
sg35217
I1
sa(dp44200
g35211
I214
sg35212
VCRF
p44201
sg35214
I3
sg35223
VP06850
p44202
sg35217
I1
sa(dp44203
g35211
I144
sg35212
g44186
sg35214
I18
sg35223
VP01375
p44204
sg35217
I2
sasg35208
(lp44205
(dp44206
g35211
I84
sg35212
Varthritis
p44207
sg35214
I9
sg35215
VC0003864
p44208
sg35217
I1
sa(dp44209
g35211
I214
sg35212
g44187
sg35214
I3
sg35215
VC0022661
p44210
sg35217
I1
sasa(dp44211
g135
(dp44212
(VAQP1
p44213
Vneuromyelitis optica
p44214
tp44215
I01
ssg35204
VAntibodies to AQP4 and AQP1 are detected in neuromyelitis optica and are believed to play a pathogenic role.
p44216
sg35206
(lp44217
(dp44218
g35211
I14
sg35212
VAQP4
p44219
sg35214
I4
sg35223
VP55087
p44220
sg35217
I1
sa(dp44221
g35211
I23
sg35212
g44213
sg35214
I4
sg35223
VP29972
p44222
sg35217
I1
sasg35208
(lp44223
(dp44224
g35211
I44
sg35212
g44214
sg35214
I20
sg35215
VC0027873
p44225
sg35217
I2
sasa(dp44226
g135
(dp44227
(VAQP1
p44228
Vedema
p44229
tp44230
I00
ssg35204
VAmong thirteen different mammalian AQPs, AQP1 and AQP4 have been mainly studied in the CNS and evidence has been presented that they play important roles in the pathogenesis of CNS injury, edema and multiple diseases such as multiple sclerosis, neuromyelitis optica spectrum disorders, amyotrophic lateral sclerosis, glioblastoma multiforme, Alzheimer's disease and Parkinson's disease.
p44231
sg35206
(lp44232
(dp44233
g35211
I50
sg35212
VAQP4
p44234
sg35214
I4
sg35223
VP55087
p44235
sg35217
I1
sa(dp44236
g35211
I41
sg35212
g44228
sg35214
I4
sg35223
VP29972
p44237
sg35217
I1
sasg35208
(lp44238
(dp44239
g35211
I161
sg35212
Vpathogenesis
p44240
sg35214
I12
sg35215
VC0699748
p44241
sg35217
I1
sa(dp44242
g35211
I366
sg35212
VParkinson's disease
p44243
sg35214
I19
sg35215
VC0030567
p44244
sg35217
I2
sa(dp44245
g35211
I317
sg35212
Vglioblastoma multiforme
p44246
sg35214
I23
sg35215
VC1621958
p44247
sg35217
I2
sa(dp44248
g35211
I286
sg35212
Vamyotrophic lateral sclerosis
p44249
sg35214
I29
sg35215
VC0002736
p44250
sg35217
I3
sa(dp44251
g35211
I245
sg35212
Vneuromyelitis optica
p44252
sg35214
I20
sg35215
VC0027873
p44253
sg35217
I2
sa(dp44254
g35211
I342
sg35212
VAlzheimer's disease
p44255
sg35214
I19
sg35215
VC1521724
p44256
sg35217
I2
sa(dp44257
g35211
I225
sg35212
Vmultiple sclerosis
p44258
sg35214
I18
sg35215
VC0026769
p44259
sg35217
I2
sa(dp44260
g35211
I189
sg35212
g44229
sg35214
I5
sg35215
VC0013604
p44261
sg35217
I1
sasa(dp44262
g35204
VICOSL knockout (ICOSL-KO) mice and wild-type C57BL/6J mice were used as experimental Schistosomiasis model infected with Schistosoma japonicum.
p44263
sg35206
(lp44264
sg35208
(lp44265
(dp44266
g35211
I85
sg35212
VSchistosomiasis
p44267
sg35214
I15
sg35215
VC0036323
p44268
sg35217
I1
sasa(dp44269
g135
(dp44270
(VICOS-ICOSL
p44271
VSchistosomiasis
p44272
tp44273
I00
ssg35204
VThe ICOS-ICOSL signaling has a regulatory effect on CD154-CD40 signaling pathway, and may play an important role in the hepatic egg granuloma formation of Schistosomiasis.
p44274
sg35206
(lp44275
(dp44276
g35211
I52
sg35212
VCD154
p44277
sg35214
I5
sg35223
VP29965
p44278
sg35217
I1
sa(dp44279
g35211
I58
sg35212
VCD40
p44280
sg35214
I4
sg35223
VP25942
p44281
sg35217
I1
sa(dp44282
g35211
I4
sg35212
g44271
sg35214
I10
sg35223
VP16410
p44283
sg35217
I1
sasg35208
(lp44284
(dp44285
g35211
I132
sg35212
Vgranuloma
p44286
sg35214
I9
sg35215
VC0018188
p44287
sg35217
I1
sa(dp44288
g35211
I155
sg35212
g44272
sg35214
I15
sg35215
VC0036323
p44289
sg35217
I1
sasa(dp44290
g135
(dp44291
(VICOS
p44292
Vliver fibrosis
p44293
tp44294
I00
ssg35204
VUsing models of schistosomiasis in ICOSL KO and the C57BL/6 WT mice, we studied the role of the ICOSL/ICOS interaction in the mediation of the Th17 response in host granulomatous inflammation, particularly in liver fibrosis during S. japonicum infection, and investigated the immune responses and pathology of ICOSL KO mice in these models.
p44295
sg35206
(lp44296
(dp44297
g35211
I35
sg35212
VICOSL KO
p44298
sg35214
I8
sg35223
g12
sg35217
I2
sa(dp44299
g35211
I35
sg35212
g44292
sg35214
I4
sg35223
VP16410
p44300
sg35217
I1
sa(dp44301
g35211
I35
sg35212
VICOSL KO
p44302
sg35214
I8
sg35223
g12
sg35217
I2
sa(dp44303
g35211
I35
sg35212
VICOSL
p44304
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp44305
(dp44306
g35211
I16
sg35212
Vschistosomiasis
p44307
sg35214
I15
sg35215
VC0036323
p44308
sg35217
I1
sa(dp44309
g35211
I209
sg35212
g44293
sg35214
I14
sg35215
VC0239946
p44310
sg35217
I2
sa(dp44311
g35211
I244
sg35212
Vinfection
p44312
sg35214
I9
sg35215
VC0009450
p44313
sg35217
I1
sa(dp44314
g35211
I165
sg35212
Vgranulomatous inflammation
p44315
sg35214
I26
sg35215
VC0553697
p44316
sg35217
I2
sa(dp44317
g35211
I297
sg35212
Vpathology
p44318
sg35214
I9
sg35215
VC0677042
p44319
sg35217
I1
sasa(dp44320
g35204
VImportantly, there was a clearly positive correlation between the presence of IL-17-producing cells and ICOS expression in ICOSL KO mice, and additional results indicated that Th17 was involved in the pathological tissue remodeling in liver fibrosis induced by schistosomiasis.
p44321
sg35206
(lp44322
(dp44323
g35211
I123
sg35212
VICOSL KO
p44324
sg35214
I8
sg35223
g12
sg35217
I2
sasg35208
(lp44325
(dp44326
g35211
I235
sg35212
Vliver fibrosis
p44327
sg35214
I14
sg35215
VC0239946
p44328
sg35217
I2
sa(dp44329
g35211
I261
sg35212
Vschistosomiasis
p44330
sg35214
I15
sg35215
VC0036323
p44331
sg35217
I1
sasa(dp44332
g135
(dp44333
(VLncRNA ZEB1 Antisense 1
p44334
Vglioma
p44335
tp44336
I00
ssg35204
VLncRNA ZEB1 Antisense 1 (ZEB1-AS1) has been suggested to be an oncogenic role in human hepatocellular carcinoma, osteosarcoma, glioma and esophageal carcinoma progression.
p44337
sg35206
(lp44338
(dp44339
g35211
I7
sg35212
VZEB1
p44340
sg35214
I4
sg35223
VP37275
p44341
sg35217
I1
sa(dp44342
g35211
I30
sg35212
VAS1
p44343
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp44344
g35211
I0
sg35212
g44334
sg35214
I23
sg35223
VP37275
p44345
sg35217
I4
sasg35208
(lp44346
(dp44347
g35211
I87
sg35212
Vhepatocellular carcinoma
p44348
sg35214
I24
sg35215
VC1512411
p44349
sg35217
I2
sa(dp44350
g35211
I138
sg35212
Vesophageal carcinoma
p44351
sg35214
I20
sg35215
VC0152018
p44352
sg35217
I2
sa(dp44353
g35211
I30
sg35212
VAS1
p44354
sg35214
I3
sg35215
VC1846534
p44355
sg35217
I1
sa(dp44356
g35211
I113
sg35212
Vosteosarcoma
p44357
sg35214
I12
sg35215
VC0029463
p44358
sg35217
I1
sa(dp44359
g35211
I127
sg35212
g44335
sg35214
I6
sg35215
VC0017638
p44360
sg35217
I1
sasa(dp44361
g135
(dp44362
(VZEB1
p44363
VAS1
p44364
tp44365
I00
ssg35204
VZEB1-AS1 acts as an oncogene in hepatocellular carcinoma, accelerating tumor growth and promoting metastasis.
p44366
sg35206
(lp44367
(dp44368
g35211
I0
sg35212
g44363
sg35214
I4
sg35223
VP37275
p44369
sg35217
I1
sa(dp44370
g35211
I5
sg35212
VAS1
p44371
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp44372
(dp44373
g35211
I32
sg35212
Vhepatocellular carcinoma
p44374
sg35214
I24
sg35215
VC1512411
p44375
sg35217
I2
sa(dp44376
g35211
I98
sg35212
Vmetastasis
p44377
sg35214
I10
sg35215
VC0027627
p44378
sg35217
I1
sa(dp44379
g35211
I5
sg35212
g44364
sg35214
I3
sg35215
VC1846534
p44380
sg35217
I1
sa(dp44381
g35211
I71
sg35212
Vtumor growth
p44382
sg35214
I12
sg35215
VC0598934
p44383
sg35217
I2
sasa(dp44384
g135
(dp44385
(VZEB1
p44386
Vhepatocellular carcinoma
p44387
tp44388
I00
ssg35204
VLncRNA ZEB1-AS1 has been identified as a tumor oncogene in hepatocellular carcinoma.
p44389
sg35206
(lp44390
(dp44391
g35211
I12
sg35212
VAS1
p44392
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp44393
g35211
I7
sg35212
g44386
sg35214
I4
sg35223
VP37275
p44394
sg35217
I1
sasg35208
(lp44395
(dp44396
g35211
I12
sg35212
VAS1
p44397
sg35214
I3
sg35215
VC1846534
p44398
sg35217
I1
sa(dp44399
g35211
I59
sg35212
g44387
sg35214
I24
sg35215
VC1512411
p44400
sg35217
I2
sa(dp44401
g35211
I41
sg35212
Vtumor
p44402
sg35214
I5
sg35215
VC0027651
p44403
sg35217
I1
sasa(dp44404
g135
(dp44405
(VFLT3
p44406
VAML
p44407
tp44408
I00
ssg35204
VWe analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms' tumor (WT1) gene.
p44409
sg35206
(lp44410
(dp44411
g35211
I55
sg35212
g44406
sg35214
I4
sg35223
VP36888
p44412
sg35217
I1
sasg35208
(lp44413
(dp44414
g35211
I220
sg35212
VWilms' tumor
p44415
sg35214
I12
sg35215
VC0027708
p44416
sg35217
I2
sa(dp44417
g35211
I32
sg35212
VSCT
p44418
sg35214
I3
sg35215
VC1848934
p44419
sg35217
I1
sa(dp44420
g35211
I105
sg35212
VMRD
p44421
sg35214
I3
sg35215
VC1840451
p44422
sg35217
I1
sa(dp44423
g35211
I234
sg35212
VWT1
p44424
sg35214
I3
sg35215
VC0027708
p44425
sg35217
I1
sa(dp44426
g35211
I69
sg35212
g44407
sg35214
I3
sg35215
VC0023467
p44427
sg35217
I1
sasa(dp44428
g135
(dp44429
(VCXCR7
p44430
VHelicobacter pylori-associated gastritis
p44431
tp44432
I00
ssg35204
VTo determine the chemokine receptor expression profile in gastric mucosa-associated lymphoid tissue (MALT) lymphoma, we performed an expression analysis of 19 chemokine receptors at mRNA levels by using real-time RT-PCR, as well as of five chemokine receptors--CCR8, CCR9, CXCR4, CXCR6 and CXCR7--by immunohistochemistry on human tissue samples of Helicobacter pylori-associated gastritis, gastric MALT lymphoma and gastric extranodal diffuse large B-cell lymphoma originating from MALT lymphoma (transformed MALT lymphoma).
p44433
sg35206
(lp44434
(dp44435
g35211
I261
sg35212
VCCR8
p44436
sg35214
I4
sg35223
VP51685
p44437
sg35217
I1
sa(dp44438
g35211
I267
sg35212
VCCR9
p44439
sg35214
I4
sg35223
VP51686
p44440
sg35217
I1
sa(dp44441
g35211
I273
sg35212
VCXCR4
p44442
sg35214
I5
sg35223
VP61073
p44443
sg35217
I1
sa(dp44444
g35211
I290
sg35212
g44430
sg35214
I5
sg35223
VP25106
p44445
sg35217
I1
sa(dp44446
g35211
I280
sg35212
VCXCR6
p44447
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp44448
(dp44449
g35211
I398
sg35212
VMALT lymphoma
p44450
sg35214
I13
sg35215
VC0242647
p44451
sg35217
I2
sa(dp44452
g35211
I107
sg35212
Vlymphoma
p44453
sg35214
I8
sg35215
VC0024299
p44454
sg35217
I1
sa(dp44455
g35211
I435
sg35212
Vdiffuse large B-cell lymphoma
p44456
sg35214
I29
sg35215
VC0079744
p44457
sg35217
I4
sa(dp44458
g35211
I398
sg35212
VMALT lymphoma
p44459
sg35214
I13
sg35215
VC0242647
p44460
sg35217
I2
sa(dp44461
g35211
I390
sg35212
Vgastric MALT lymphoma
p44462
sg35214
I21
sg35215
VC1333782
p44463
sg35217
I3
sa(dp44464
g35211
I348
sg35212
g44431
sg35214
I40
sg35215
VC0343378
p44465
sg35217
I3
sasa(dp44466
g135
(dp44467
(VCCR7
p44468
VMALT lymphomas
p44469
tp44470
I00
ssg35204
VThe transformation of gastric MALT lymphomas to gastric extranodal diffuse large B-cell lymphoma was accompanied by upregulation of CCR1, CCR5, CCR7, CCR8, CCR9, CXCR3, CXCR6, CXCR7 and XCR1.
p44471
sg35206
(lp44472
(dp44473
g35211
I162
sg35212
VCXCR3
p44474
sg35214
I5
sg35223
VP49682
p44475
sg35217
I1
sa(dp44476
g35211
I169
sg35212
VCXCR6
p44477
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp44478
g35211
I138
sg35212
VCCR5
p44479
sg35214
I4
sg35223
VP32302
p44480
sg35217
I1
sa(dp44481
g35211
I132
sg35212
VCCR1
p44482
sg35214
I4
sg35223
VP32246
p44483
sg35217
I1
sa(dp44484
g35211
I176
sg35212
VCXCR7
p44485
sg35214
I5
sg35223
VP25106
p44486
sg35217
I1
sa(dp44487
g35211
I156
sg35212
VCCR9
p44488
sg35214
I4
sg35223
VP51686
p44489
sg35217
I1
sa(dp44490
g35211
I150
sg35212
VCCR8
p44491
sg35214
I4
sg35223
VP51685
p44492
sg35217
I1
sa(dp44493
g35211
I186
sg35212
VXCR1
p44494
sg35214
I4
sg35223
VP46094
p44495
sg35217
I1
sa(dp44496
g35211
I144
sg35212
g44468
sg35214
I4
sg35223
VP32248
p44497
sg35217
I1
sasg35208
(lp44498
(dp44499
g35211
I67
sg35212
Vdiffuse large B-cell lymphoma
p44500
sg35214
I29
sg35215
VC0079744
p44501
sg35217
I4
sa(dp44502
g35211
I4
sg35212
Vtransformation
p44503
sg35214
I14
sg35215
VC1510411
p44504
sg35217
I1
sa(dp44505
g35211
I30
sg35212
g44469
sg35214
I14
sg35215
VC0242647
p44506
sg35217
I2
sasa(dp44507
g135
(dp44508
(Vp27
p44509
VFeline leukemia
p44510
tp44511
I00
ssg35204
VFeline leukemia virus (FeLV) p27 or gp70 antigen was detected in 21 lymphomas (54%).
p44512
sg35206
(lp44513
(dp44514
g35211
I29
sg35212
g44509
sg35214
I3
sg35223
VP40305
p44515
sg35217
I1
sa(dp44516
g35211
I36
sg35212
Vgp70 antigen
p44517
sg35214
I12
sg35223
g12
sg35217
I2
sasg35208
(lp44518
(dp44519
g35211
I68
sg35212
Vlymphomas
p44520
sg35214
I9
sg35215
VC0024299
p44521
sg35217
I1
sa(dp44522
g35211
I0
sg35212
g44510
sg35214
I15
sg35215
VC0085164
p44523
sg35217
I2
sasa(dp44524
g135
(dp44525
(VMeL
p44526
VMeL
p44527
tp44528
I00
ssg35204
VVaccines to large B cell lymphoma were made by the covalent attachment of an epitope from the gp70 glycoprotein (SSWDFITV) to the N-termini of the conformationally biased, response-selective C5a agonists EP54 (YSFKPMPLaR) and EP67 (YSFKDMP(MeL)aR).
p44529
sg35206
(lp44530
(dp44531
g35211
I94
sg35212
Vgp70 glycoprotein
p44532
sg35214
I17
sg35223
g12
sg35217
I2
sa(dp44533
g35211
I191
sg35212
VC5a
p44534
sg35214
I3
sg35223
VP21730
p44535
sg35217
I1
sa(dp44536
g35211
I240
sg35212
g44526
sg35214
I3
sg35223
VP61006
p44537
sg35217
I1
sasg35208
(lp44538
(dp44539
g35211
I18
sg35212
VB cell lymphoma
p44540
sg35214
I15
sg35215
VC0079731
p44541
sg35217
I3
sa(dp44542
g35211
I240
sg35212
g44527
sg35214
I3
sg35215
VC3149631
p44543
sg35217
I1
sasa(dp44544
g35204
VSyngeneic Balb/c mice were immunized with these EP54/EP67-containing vaccines and challenged with a lethal dose of the highly liver metastatic and gp70-expressing lymphoma cell line RAW117-H10 to evaluate the ability of these vaccines to induce protective immune outcomes.
p44545
sg35206
(lp44546
(dp44547
g35211
I147
sg35212
Vgp70
p44548
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp44549
(dp44550
g35211
I163
sg35212
Vlymphoma
p44551
sg35214
I8
sg35215
VC0024299
p44552
sg35217
I1
sasa(dp44553
g135
(dp44554
(VCD8
p44555
Vbreast cancer
p44556
tp44557
I00
ssg35204
VCD8(+) T lymphocytes activated in response to Vaccines 2 and 3 express cytotoxic specificity for gp70-expressing RAW117-H10 lymphoma cells, but not antigen-irrelevant MDA-MB231A human breast cancer cells.
p44558
sg35206
(lp44559
(dp44560
g35211
I0
sg35212
g44555
sg35214
I3
sg35223
VP01732
p44561
sg35217
I1
sa(dp44562
g35211
I97
sg35212
Vgp70
p44563
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp44564
(dp44565
g35211
I124
sg35212
Vlymphoma
p44566
sg35214
I8
sg35215
VC0024299
p44567
sg35217
I1
sa(dp44568
g35211
I184
sg35212
g44556
sg35214
I13
sg35215
VC0678222
p44569
sg35217
I2
sasa(dp44570
g135
(dp44571
(VNa(+)-dependent phosphate symporters
p44572
Vleukemia
p44573
tp44574
I00
ssg35204
VOur strategy relies on the fact that feline leukemia virus subgroup B (FeLV-B) and amphotropic murine leukemia virus (A-MLV) have closely related gp70 surface envelope glycoproteins and use related Na(+)-dependent phosphate symporters, Pit1 and Pit2, respectively, as their receptors.
p44575
sg35206
(lp44576
(dp44577
g35211
I245
sg35212
VPit2
p44578
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp44579
g35211
I236
sg35212
VPit1
p44580
sg35214
I4
sg35223
VP28069
p44581
sg35217
I1
sa(dp44582
g35211
I146
sg35212
Vgp70 surface envelope glycoproteins
p44583
sg35214
I35
sg35223
g12
sg35217
I4
sa(dp44584
g35211
I198
sg35212
g44572
sg35214
I36
sg35223
VP19525
p44585
sg35217
I3
sasg35208
(lp44586
(dp44587
g35211
I37
sg35212
Vfeline leukemia
p44588
sg35214
I15
sg35215
VC0085164
p44589
sg35217
I2
sa(dp44590
g35211
I44
sg35212
g44573
sg35214
I8
sg35215
VC0023418
p44591
sg35217
I1
sasa(dp44592
g135
(dp44593
(VI-FABP
p44594
Vacute abdomen
p44595
tp44596
I00
ssg35204
VNumerous studies have investigated the utility of serum intestinal fatty-acid binding protein (I-FABP) in differentiating acute intestinal ischemia from acute abdomen.
p44597
sg35206
(lp44598
(dp44599
g35211
I56
sg35212
Vintestinal fatty-acid binding protein
p44600
sg35214
I37
sg35223
VP12104
p44601
sg35217
I4
sa(dp44602
g35211
I95
sg35212
g44594
sg35214
I6
sg35223
VP12104
p44603
sg35217
I1
sasg35208
(lp44604
(dp44605
g35211
I122
sg35212
Vacute intestinal ischemia
p44606
sg35214
I25
sg35215
VC0001363
p44607
sg35217
I3
sa(dp44608
g35211
I153
sg35212
g44595
sg35214
I13
sg35215
VC0000727
p44609
sg35217
I2
sasa(dp44610
g35204
VThe aim of this meta-analysis is to determine the overall accuracy of serum I-FABP in the diagnosis of acute intestinal ischemia.
p44611
sg35206
(lp44612
(dp44613
g35211
I70
sg35212
Vserum I-FABP
p44614
sg35214
I12
sg35223
VP12104
p44615
sg35217
I2
sasg35208
(lp44616
(dp44617
g35211
I103
sg35212
Vacute intestinal ischemia
p44618
sg35214
I25
sg35215
VC0001363
p44619
sg35217
I3
sasa(dp44620
g135
(dp44621
(VI-FABP
p44622
Vacute abdomen
p44623
tp44624
I00
ssg35204
VThe meta-analysis carried out in this report suggests that the I-FABP may be a useful diagnostic tool to confirm acute intestinal ischemia in acute abdomen, but better-designed trials are still required to confirm our findings.
p44625
sg35206
(lp44626
(dp44627
g35211
I63
sg35212
g44622
sg35214
I6
sg35223
VP12104
p44628
sg35217
I1
sasg35208
(lp44629
(dp44630
g35211
I142
sg35212
g44623
sg35214
I13
sg35215
VC0000727
p44631
sg35217
I2
sa(dp44632
g35211
I113
sg35212
Vacute intestinal ischemia
p44633
sg35214
I25
sg35215
VC0001363
p44634
sg35217
I3
sasa(dp44635
g35204
VThe aim of the present study was to evaluate whether I-FABP can predict active disease or remission in Crohn's disease (CD) and ulcerative colitis (UC) in a real-life IBD cohort.
p44636
sg35206
(lp44637
sg35208
(lp44638
(dp44639
g35211
I120
sg35212
VCD
p44640
sg35214
I2
sg35215
VC0010346
p44641
sg35217
I1
sa(dp44642
g35211
I167
sg35212
VIBD
p44643
sg35214
I3
sg35215
VC0021390
p44644
sg35217
I1
sa(dp44645
g35211
I90
sg35212
Vremission
p44646
sg35214
I9
sg35215
VC0687702
p44647
sg35217
I1
sa(dp44648
g35211
I148
sg35212
VUC
p44649
sg35214
I2
sg35215
VC0009324
p44650
sg35217
I1
sa(dp44651
g35211
I103
sg35212
VCrohn's disease
p44652
sg35214
I15
sg35215
VC0010346
p44653
sg35217
I2
sa(dp44654
g35211
I128
sg35212
Vulcerative colitis
p44655
sg35214
I18
sg35215
VC0009324
p44656
sg35217
I2
sasa(dp44657
g35204
VIn our study, we found the expression of EWSAT1 was upregulated in ovarian cancer cell lines and samples.
p44658
sg35206
(lp44659
sg35208
(lp44660
(dp44661
g35211
I67
sg35212
Vovarian cancer
p44662
sg35214
I14
sg35215
VC1140680
p44663
sg35217
I2
sasa(dp44664
g35204
VEcoptic expression of EWSAT1 suppressed miR-330-5p expression in ovarian cancer cell.
p44665
sg35206
(lp44666
(dp44667
g35211
I40
sg35212
VmiR-330-5p
p44668
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp44669
(dp44670
g35211
I65
sg35212
Vovarian cancer
p44671
sg35214
I14
sg35215
VC1140680
p44672
sg35217
I2
sasa(dp44673
g35204
VMoreover, the expression of miR-330-5p was negatively related with the expression of EWSAT1 in ovarian cancer samples.
p44674
sg35206
(lp44675
(dp44676
g35211
I28
sg35212
VmiR-330-5p
p44677
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp44678
(dp44679
g35211
I95
sg35212
Vovarian cancer
p44680
sg35214
I14
sg35215
VC1140680
p44681
sg35217
I2
sasa(dp44682
g135
(dp44683
(VPdia3
p44684
Vovarian cancer
p44685
tp44686
I01
ssg35204
VEcoptic expression of miR-330-5p suppressed Pdia3 expression and overexpression of EWSAT1 promoted Pdia3 expression in ovarian cancer cell.
p44687
sg35206
(lp44688
(dp44689
g35211
I22
sg35212
VmiR-330-5p
p44690
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp44691
g35211
I44
sg35212
VPdia3
p44692
sg35214
I5
sg35223
VP30101
p44693
sg35217
I1
sa(dp44694
g35211
I44
sg35212
g44684
sg35214
I5
sg35223
VP30101
p44695
sg35217
I1
sasg35208
(lp44696
(dp44697
g35211
I119
sg35212
g44685
sg35214
I14
sg35215
VC1140680
p44698
sg35217
I2
sasa(dp44699
g35204
VOverexpression of EWSAT1 increased ovarian cancer cell proliferation, colony formation and invasion through targeting miR-330-5p.
p44700
sg35206
(lp44701
(dp44702
g35211
I118
sg35212
VmiR-330-5p
p44703
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp44704
(dp44705
g35211
I55
sg35212
Vproliferation
p44706
sg35214
I13
sg35215
VC0334094
p44707
sg35217
I1
sa(dp44708
g35211
I91
sg35212
Vinvasion
p44709
sg35214
I8
sg35215
VC2699153
p44710
sg35217
I1
sa(dp44711
g35211
I35
sg35212
Vovarian cancer
p44712
sg35214
I14
sg35215
VC1140680
p44713
sg35217
I2
sasa(dp44714
g35204
VThese data suggested that EWSAT1 might act as an oncogene in the development of ovarian cancer partly through inhibiting miR-330-5p expression.
p44715
sg35206
(lp44716
(dp44717
g35211
I121
sg35212
VmiR-330-5p
p44718
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp44719
(dp44720
g35211
I80
sg35212
Vovarian cancer
p44721
sg35214
I14
sg35215
VC1140680
p44722
sg35217
I2
sasa(dp44723
g135
(dp44724
(VlncRNA Ewing sarcoma-associated transcript 1
p44725
VEwing sarcoma
p44726
tp44727
I00
ssg35204
VRecently, lncRNA Ewing sarcoma-associated transcript 1 (EWSAT1) was functionally identified in Ewing sarcoma, a highly aggressive primary pediatric bone tumor.
p44728
sg35206
(lp44729
(dp44730
g35211
I10
sg35212
g44725
sg35214
I44
sg35223
VP11308
p44731
sg35217
I5
sasg35208
(lp44732
(dp44733
g35211
I148
sg35212
Vbone tumor
p44734
sg35214
I10
sg35215
VC0005967
p44735
sg35217
I2
sa(dp44736
g35211
I17
sg35212
VEwing sarcoma
p44737
sg35214
I13
sg35215
VC0553580
p44738
sg35217
I2
sa(dp44739
g35211
I119
sg35212
Vaggressive
p44740
sg35214
I10
sg35215
VC0001807
p44741
sg35217
I1
sa(dp44742
g35211
I17
sg35212
g44726
sg35214
I13
sg35215
VC0553580
p44743
sg35217
I2
sasa(dp44744
g35204
VLong non-coding RNA (lncRNA) Ewing sarcoma associated transcript 1 (EWSAT1) has been identified as an oncogene, and its dysregulation is closed corrected with tumor progression in Ewing sarcoma.
p44745
sg35206
(lp44746
sg35208
(lp44747
(dp44748
g35211
I29
sg35212
VEwing sarcoma
p44749
sg35214
I13
sg35215
VC0553580
p44750
sg35217
I2
sa(dp44751
g35211
I159
sg35212
Vtumor progression
p44752
sg35214
I17
sg35215
VC0178874
p44753
sg35217
I2
sa(dp44754
g35211
I29
sg35212
VEwing sarcoma
p44755
sg35214
I13
sg35215
VC0553580
p44756
sg35217
I2
sasa(dp44757
g35204
VRecently, high-through put analysis reveals that EWSAT1 is also highly expressed in human nasopharyngeal carcinoma (NPC).
p44758
sg35206
(lp44759
sg35208
(lp44760
(dp44761
g35211
I90
sg35212
Vnasopharyngeal carcinoma
p44762
sg35214
I24
sg35215
VC2931822
p44763
sg35217
I2
sa(dp44764
g35211
I116
sg35212
VNPC
p44765
sg35214
I3
sg35215
VC2931822
p44766
sg35217
I1
sasa(dp44767
g35204
VWe determined that long noncoding RNA-277 (Ewing sarcoma-associated transcript 1 [EWSAT1]) is upregulated by EWS-FLI1 in pMPCs.
p44768
sg35206
(lp44769
(dp44770
g35211
I82
sg35212
VEWS
p44771
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp44772
g35211
I113
sg35212
VFLI1
p44773
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp44774
(dp44775
g35211
I43
sg35212
VEwing sarcoma
p44776
sg35214
I13
sg35215
VC0553580
p44777
sg35217
I2
sasa(dp44778
g35204
VInhibition of EWSAT1 expression diminished the ability of Ewing sarcoma cell lines to proliferate and form colonies in soft agar, whereas EWSAT1 inhibition had no effect on other cell types tested.
p44779
sg35206
(lp44780
sg35208
(lp44781
(dp44782
g35211
I58
sg35212
VEwing sarcoma
p44783
sg35214
I13
sg35215
VC0553580
p44784
sg35217
I2
sasa(dp44785
g35204
VAnalysis of RNAseq data from primary human Ewing sarcoma further supported a role for EWSAT1 in mediating gene repression.
p44786
sg35206
(lp44787
sg35208
(lp44788
(dp44789
g35211
I43
sg35212
VEwing sarcoma
p44790
sg35214
I13
sg35215
VC0553580
p44791
sg35217
I2
sasa(dp44792
g35204
VTogether, our data reveal that EWSAT1 is a downstream target of EWS-FLI1 that facilitates the development of Ewing sarcoma via the repression of target genes.
p44793
sg35206
(lp44794
(dp44795
g35211
I31
sg35212
VEWS
p44796
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp44797
g35211
I68
sg35212
VFLI1
p44798
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp44799
(dp44800
g35211
I109
sg35212
VEwing sarcoma
p44801
sg35214
I13
sg35215
VC0553580
p44802
sg35217
I2
sasa(dp44803
g135
(dp44804
(VMZF-1
p44805
Vhepatocellular carcinoma
p44806
tp44807
I00
ssg35204
VResults: The data show that the expression of MZF-1/Elk-1 is correlated with that of PKCAlfa in hepatocellular carcinoma (HCC), but not in bladder and lung cancers.
p44808
sg35206
(lp44809
(dp44810
g35211
I52
sg35212
VElk-1
p44811
sg35214
I5
sg35223
VP54762
p44812
sg35217
I1
sa(dp44813
g35211
I46
sg35212
g44805
sg35214
I5
sg35223
VP28698
p44814
sg35217
I1
sasg35208
(lp44815
(dp44816
g35211
I122
sg35212
VHCC
p44817
sg35214
I3
sg35215
VC2239176
p44818
sg35217
I1
sa(dp44819
g35211
I151
sg35212
Vlung cancers
p44820
sg35214
I12
sg35215
VC0242379
p44821
sg35217
I2
sa(dp44822
g35211
I96
sg35212
g44806
sg35214
I24
sg35215
VC2239176
p44823
sg35217
I2
sasa(dp44824
g135
(dp44825
(VPEI-MZF-NPs
p44826
VNPs
p44827
tp44828
I00
ssg35204
VHere, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/(131)I-antiAFPMcAb-GCV/MFH, for hepatoma is developed.
p44829
sg35206
(lp44830
(dp44831
g35211
I179
sg35212
VpHRE-Egr1-HSV-TK
p44832
sg35214
I16
sg35223
VP29401
p44833
sg35217
I1
sa(dp44834
g35211
I12
sg35212
VPEI-Mn0.5Zn0.5Fe2O4 nanoparticles
p44835
sg35214
I33
sg35223
g12
sg35217
I2
sa(dp44836
g35211
I47
sg35212
g44826
sg35214
I11
sg35223
VP28698
p44837
sg35217
I1
sasg35208
(lp44838
(dp44839
g35211
I228
sg35212
Vhepatoma
p44840
sg35214
I8
sg35215
VC0023903
p44841
sg35217
I1
sa(dp44842
g35211
I55
sg35212
g44827
sg35214
I3
sg35215
VC0027341
p44843
sg35217
I1
sasa(dp44844
g135
(dp44845
(VMZF-NPs
p44846
VNPs
p44847
tp44848
I00
ssg35204
VTo explore a new combination of thermal treatment and gene therapy for hepatoma, a heat-inducible herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapy system was developed in which thermal energy generated by Mn0.5Zn0.5Fe2O4 nanoparticles (MZF-NPs) under an alternating magnetic field was used to activate gene expression.
p44849
sg35206
(lp44850
(dp44851
g35211
I232
sg35212
VMn0.5Zn0.5Fe2O4 nanoparticles
p44852
sg35214
I29
sg35223
g12
sg35217
I2
sa(dp44853
g35211
I156
sg35212
VGCV
p44854
sg35214
I3
sg35223
VP23434
p44855
sg35217
I1
sa(dp44856
g35211
I153
sg35212
VTK
p44857
sg35214
I2
sg35223
VP29401
p44858
sg35217
I1
sa(dp44859
g35211
I263
sg35212
g44846
sg35214
I7
sg35223
VP28698
p44860
sg35217
I1
sasg35208
(lp44861
(dp44862
g35211
I71
sg35212
Vhepatoma
p44863
sg35214
I8
sg35215
VC0023903
p44864
sg35217
I1
sa(dp44865
g35211
I98
sg35212
Vherpes simplex
p44866
sg35214
I14
sg35215
VC0019348
p44867
sg35217
I2
sa(dp44868
g35211
I267
sg35212
g44847
sg35214
I3
sg35215
VC0027341
p44869
sg35217
I1
sasa(dp44870
g135
(dp44871
(VTK
p44872
VNPs
p44873
tp44874
I00
ssg35204
VMagnet-induced heating was then applied to cells to assess the antihepatoma effects of the polyethylenimine (PEI)-MZF-NPs/pHsp 70-HSV-TK/GCV complex, in vitro and in vivo.
p44875
sg35206
(lp44876
(dp44877
g35211
I137
sg35212
VGCV
p44878
sg35214
I3
sg35223
VP23434
p44879
sg35217
I1
sa(dp44880
g35211
I118
sg35212
VNPs
p44881
sg35214
I3
sg35223
VP0C0P6
p44882
sg35217
I1
sa(dp44883
g35211
I114
sg35212
VMZF
p44884
sg35214
I3
sg35223
VP28698
p44885
sg35217
I1
sa(dp44886
g35211
I134
sg35212
g44872
sg35214
I2
sg35223
VP29401
p44887
sg35217
I1
sasg35208
(lp44888
(dp44889
g35211
I118
sg35212
g44873
sg35214
I3
sg35215
VC0027341
p44890
sg35217
I1
sasa(dp44891
g135
(dp44892
(VMZF-1
p44893
Vhepatocellular carcinoma
p44894
tp44895
I00
ssg35204
VIn this study, the molecular mechanism of protein kinase C alpha (PKCAlfa) gene regulation in hepatocellular carcinoma (HCC) involving Ets-like protein-1 (Elk-1) and myeloid zinc finger-1 (MZF-1) was investigated.
p44896
sg35206
(lp44897
(dp44898
g35211
I166
sg35212
Vmyeloid zinc finger-1
p44899
sg35214
I21
sg35223
VP28698
p44900
sg35217
I3
sa(dp44901
g35211
I155
sg35212
VElk-1
p44902
sg35214
I5
sg35223
VP54762
p44903
sg35217
I1
sa(dp44904
g35211
I135
sg35212
VEts-like protein-1
p44905
sg35214
I18
sg35223
VP17980
p44906
sg35217
I2
sa(dp44907
g35211
I42
sg35212
Vprotein kinase C alpha
p44908
sg35214
I22
sg35223
VP17252
p44909
sg35217
I4
sa(dp44910
g35211
I189
sg35212
g44893
sg35214
I5
sg35223
VP28698
p44911
sg35217
I1
sasg35208
(lp44912
(dp44913
g35211
I120
sg35212
VHCC
p44914
sg35214
I3
sg35215
VC2239176
p44915
sg35217
I1
sa(dp44916
g35211
I94
sg35212
g44894
sg35214
I24
sg35215
VC2239176
p44917
sg35217
I2
sasa(dp44918
g135
(dp44919
(VPEI-MZF-NPs
p44920
Vhepatoma
p44921
tp44922
I00
ssg35204
VBesides, PEI-MZF-NPs were used as magnetic media for thermotherapy to treat hepatoma by magnet-induced heating, combined with radiation-gene therapy.
p44923
sg35206
(lp44924
(dp44925
g35211
I9
sg35212
g44920
sg35214
I11
sg35223
VP28698
p44926
sg35217
I1
sasg35208
(lp44927
(dp44928
g35211
I17
sg35212
VNPs
p44929
sg35214
I3
sg35215
VC0027341
p44930
sg35217
I1
sa(dp44931
g35211
I76
sg35212
g44921
sg35214
I8
sg35215
VC0023903
p44932
sg35217
I1
sasa(dp44933
g135
(dp44934
(VElk-1
p44935
VHCC
p44936
tp44937
I00
ssg35204
VIn a recent study on hepatocellular carcinoma (HCC), we have shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 (Elk-1) are significantly related to protein kinase C alpha (PKCAlfa) expression.
p44938
sg35206
(lp44939
(dp44940
g35211
I121
sg35212
VMZF-1
p44941
sg35214
I5
sg35223
VP28698
p44942
sg35217
I1
sa(dp44943
g35211
I132
sg35212
VEts-like-protein 1
p44944
sg35214
I18
sg35223
VP14222
p44945
sg35217
I2
sa(dp44946
g35211
I188
sg35212
Vprotein kinase C alpha
p44947
sg35214
I22
sg35223
VP17252
p44948
sg35217
I4
sa(dp44949
g35211
I98
sg35212
VMyeloid Zinc Finger-1
p44950
sg35214
I21
sg35223
VP28698
p44951
sg35217
I3
sa(dp44952
g35211
I152
sg35212
g44935
sg35214
I5
sg35223
VP54762
p44953
sg35217
I1
sasg35208
(lp44954
(dp44955
g35211
I21
sg35212
Vhepatocellular carcinoma
p44956
sg35214
I24
sg35215
VC2239176
p44957
sg35217
I2
sa(dp44958
g35211
I47
sg35212
g44936
sg35214
I3
sg35215
VC2239176
p44959
sg35217
I1
sasa(dp44960
g135
(dp44961
(VEts-like-protein 1
p44962
Vhepatocellular carcinoma
p44963
tp44964
I01
ssg35204
VRecently, our research into hepatocellular carcinoma (HCC) has shown that the transcription factors Myeloid Zinc Finger-1 (MZF-1) and Ets-like-protein 1 are related to protein kinase C alpha (PKCAlfa) expression.
p44965
sg35206
(lp44966
(dp44967
g35211
I100
sg35212
VMyeloid Zinc Finger-1
p44968
sg35214
I21
sg35223
VP28698
p44969
sg35217
I3
sa(dp44970
g35211
I123
sg35212
VMZF-1
p44971
sg35214
I5
sg35223
VP28698
p44972
sg35217
I1
sa(dp44973
g35211
I168
sg35212
Vprotein kinase C alpha
p44974
sg35214
I22
sg35223
VP17252
p44975
sg35217
I4
sa(dp44976
g35211
I134
sg35212
g44962
sg35214
I18
sg35223
VP14222
p44977
sg35217
I2
sasg35208
(lp44978
(dp44979
g35211
I54
sg35212
VHCC
p44980
sg35214
I3
sg35215
VC2239176
p44981
sg35217
I1
sa(dp44982
g35211
I28
sg35212
g44963
sg35214
I24
sg35215
VC2239176
p44983
sg35217
I2
sasa(dp44984
g135
(dp44985
(Vchromogranin A
p44986
Vtemporal lobe epilepsy
p44987
tp44988
I00
ssg35204
VUsing immunocytochemistry, we investigated the distribution of chromogranin A, chromogranin B, secretoneurin, and, for comparison, dynorphin in hippocampal specimens removed at routine surgery from patients with drug-resistant mesial temporal lobe epilepsy and in autopsy tissues from nonneurologically deceased subjects.
p44989
sg35206
(lp44990
(dp44991
g35211
I79
sg35212
Vchromogranin B
p44992
sg35214
I14
sg35223
VP08311
p44993
sg35217
I2
sa(dp44994
g35211
I131
sg35212
Vdynorphin
p44995
sg35214
I9
sg35223
VP01213
p44996
sg35217
I1
sa(dp44997
g35211
I95
sg35212
Vsecretoneurin
p44998
sg35214
I13
sg35223
VP13521
p44999
sg35217
I1
sa(dp45000
g35211
I63
sg35212
g44986
sg35214
I14
sg35223
VP10645
p45001
sg35217
I2
sasg35208
(lp45002
(dp45003
g35211
I234
sg35212
g44987
sg35214
I22
sg35215
VC0014556
p45004
sg35217
I3
sasa(dp45005
g135
(dp45006
(Vchromogranins A and B and secretoneurin
p45007
Vtemporal lobe epilepsy
p45008
tp45009
I00
ssg35204
VThe most intriguing change seen in human temporal lobe epilepsy specimens and in the kainic acid model of the rat was the prominent staining of the inner molecular layer, indicating storage of chromogranins A and B and secretoneurin in terminals of reorganized mossy fibers, from which they may be released upon nerve stimulation.
p45010
sg35206
(lp45011
(dp45012
g35211
I193
sg35212
g45007
sg35214
I39
sg35223
VP08311
p45013
sg35217
I6
sasg35208
(lp45014
(dp45015
g35211
I41
sg35212
g45008
sg35214
I22
sg35215
VC0014556
p45016
sg35217
I3
sasa(dp45017
g135
(dp45018
(Vplasma insulin
p45019
VSCD
p45020
tp45021
I00
ssg35204
VTransition of control prediabetic ZDF rats to diabetes was associated with reduced plasma insulin levels, reduced islet insulin content and GSIS, reduced stearoyl-CoA desaturase 2 (SCD 2) expression, and increased islet TAG, diacylglyceride (DAG) and ceramides species containing saturated FA.
p45022
sg35206
(lp45023
(dp45024
g35211
I114
sg35212
Vislet insulin
p45025
sg35214
I13
sg35223
VP01308
p45026
sg35217
I2
sa(dp45027
g35211
I154
sg35212
Vstearoyl-CoA desaturase 2
p45028
sg35214
I25
sg35223
g12
sg35217
I3
sa(dp45029
g35211
I83
sg35212
g45019
sg35214
I14
sg35223
VP01308
p45030
sg35217
I2
sa(dp45031
g35211
I181
sg35212
VSCD 2
p45032
sg35214
I5
sg35223
g12
sg35217
I2
sasg35208
(lp45033
(dp45034
g35211
I46
sg35212
Vdiabetes
p45035
sg35214
I8
sg35215
VC0011849
p45036
sg35217
I1
sa(dp45037
g35211
I0
sg35212
VTransition
p45038
sg35214
I10
sg35215
VC0599156
p45039
sg35217
I1
sa(dp45040
g35211
I163
sg35212
VCoA
p45041
sg35214
I3
sg35215
VC2678439
p45042
sg35217
I1
sa(dp45043
g35211
I220
sg35212
VTAG
p45044
sg35214
I3
sg35215
VC0037293
p45045
sg35217
I1
sa(dp45046
g35211
I181
sg35212
g45020
sg35214
I3
sg35215
VC0002895
p45047
sg35217
I1
sasa(dp45048
g35204
VIn this research, we have found that lycorine significantly induces the apoptotic and autophagic capacities of hepatocellular carcinoma (HCC) cells in vitro and in vivo Treatment with specific autophagy inhibitor (3-methyladenine/Bafilomycin A1) or knockdown of LC-3B/Atg5 by siRNA drastically enhances the apoptotic cell death effect by facilitating the switch from autophagy to apoptosis.
p45049
sg35206
(lp45050
(dp45051
g35211
I268
sg35212
VAtg5
p45052
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp45053
(dp45054
g35211
I137
sg35212
VHCC
p45055
sg35214
I3
sg35215
VC2239176
p45056
sg35217
I1
sa(dp45057
g35211
I111
sg35212
Vhepatocellular carcinoma
p45058
sg35214
I24
sg35215
VC2239176
p45059
sg35217
I2
sasa(dp45060
g35204
VThe differential expression of 10 miRNAs were validated by RT-qPCR (let-7a, let-7d, let-7f and miR-16 were downregulated while miR-29b, miR-142-3p, miR-144, miR-203, and miR-223 were upregulated in OSCC; the expression of miR-1275 was variable in tumours, with high levels associated to regional lymph node invasion; additionally, miR-223 exhibited an association with advanced tumour stage/size).
p45061
sg35206
(lp45062
(dp45063
g35211
I136
sg35212
VmiR-142-3p
p45064
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp45065
g35211
I157
sg35212
VmiR-203
p45066
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp45067
g35211
I127
sg35212
VmiR-29b
p45068
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp45069
g35211
I148
sg35212
VmiR-144
p45070
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp45071
g35211
I95
sg35212
VmiR-16
p45072
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp45073
(dp45074
g35211
I247
sg35212
Vtumour
p45075
sg35214
I6
sg35215
VC0027651
p45076
sg35217
I1
sa(dp45077
g35211
I247
sg35212
Vtumours
p45078
sg35214
I7
sg35215
VC0027651
p45079
sg35217
I1
sa(dp45080
g35211
I307
sg35212
Vinvasion
p45081
sg35214
I8
sg35215
VC2699153
p45082
sg35217
I1
sasa(dp45083
g35204
VTo the best of our knowledge, this is the first report to show the association of miR-1275 with nodal invasion and the upregulation of miR-144 in OSCC.
p45084
sg35206
(lp45085
(dp45086
g35211
I82
sg35212
VmiR-1275
p45087
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp45088
(dp45089
g35211
I102
sg35212
Vinvasion
p45090
sg35214
I8
sg35215
VC2699153
p45091
sg35217
I1
sasa(dp45092
g135
(dp45093
(VETK
p45094
VWE
p45095
tp45096
I00
ssg35204
VIn the subgroup of non-vomiting drinkers with Wernicke's encephalopathy (WE), the slope of the linear regression of AETK on ETK was 1.21, so that apoTK decreased as ETK decreased.
p45097
sg35206
(lp45098
(dp45099
g35211
I117
sg35212
VETK
p45100
sg35214
I3
sg35223
VP51813
p45101
sg35217
I1
sa(dp45102
g35211
I117
sg35212
g45094
sg35214
I3
sg35223
VP51813
p45103
sg35217
I1
sasg35208
(lp45104
(dp45105
g35211
I46
sg35212
VWernicke's encephalopathy
p45106
sg35214
I25
sg35215
VC0043121
p45107
sg35217
I2
sa(dp45108
g35211
I23
sg35212
Vvomiting
p45109
sg35214
I8
sg35215
VC0042963
p45110
sg35217
I1
sa(dp45111
g35211
I73
sg35212
g45095
sg35214
I2
sg35215
VC0043121
p45112
sg35217
I1
sasa(dp45113
g135
(dp45114
(VCCR2
p45115
Vpancreatic ductal adenocarcinoma
p45116
tp45117
I00
ssg35204
VIn pancreatic ductal adenocarcinoma, the CCL2-CCR2 chemokine axis is used to recruit tumour-associated macrophages for construction of an immunosuppressive tumour microenvironment.
p45118
sg35206
(lp45119
(dp45120
g35211
I41
sg35212
VCCL2
p45121
sg35214
I4
sg35223
VP13500
p45122
sg35217
I1
sa(dp45123
g35211
I46
sg35212
g45115
sg35214
I4
sg35223
VP41597
p45124
sg35217
I1
sasg35208
(lp45125
(dp45126
g35211
I3
sg35212
g45116
sg35214
I32
sg35215
VC1335302
p45127
sg35217
I3
sa(dp45128
g35211
I85
sg35212
Vtumour
p45129
sg35214
I6
sg35215
VC0027651
p45130
sg35217
I1
sa(dp45131
g35211
I85
sg35212
Vtumour
p45132
sg35214
I6
sg35215
VC0027651
p45133
sg35217
I1
sasa(dp45134
g135
(dp45135
(VCCR2
p45136
Vpancreatic cancer
p45137
tp45138
I01
ssg35204
VThis pathway has prognostic implications in pancreatic cancer, and blockade of CCR2 restores anti-tumour immunity in preclinical models.
p45139
sg35206
(lp45140
(dp45141
g35211
I79
sg35212
g45136
sg35214
I4
sg35223
VP41597
p45142
sg35217
I1
sasg35208
(lp45143
(dp45144
g35211
I44
sg35212
g45137
sg35214
I17
sg35215
VC0235974
p45145
sg35217
I2
sa(dp45146
g35211
I98
sg35212
Vtumour
p45147
sg35214
I6
sg35215
VC0027651
p45148
sg35217
I1
sasa(dp45149
g135
(dp45150
(VCD14
p45151
Vpancreatic cancer
p45152
tp45153
I01
ssg35204
VTo determine the role of the CCL2/CCR2 axis and inflammatory monocytes (CCR2(+)/CD14(+)) as immunotherapeutic targets in the treatment of pancreatic cancer.
p45154
sg35206
(lp45155
(dp45156
g35211
I29
sg35212
VCCL2
p45157
sg35214
I4
sg35223
VP13500
p45158
sg35217
I1
sa(dp45159
g35211
I34
sg35212
VCCR2
p45160
sg35214
I4
sg35223
VP41597
p45161
sg35217
I1
sa(dp45162
g35211
I34
sg35212
VCCR2
p45163
sg35214
I4
sg35223
VP41597
p45164
sg35217
I1
sa(dp45165
g35211
I80
sg35212
g45151
sg35214
I4
sg35223
VP08571
p45166
sg35217
I1
sasg35208
(lp45167
(dp45168
g35211
I138
sg35212
g45152
sg35214
I17
sg35215
VC0235974
p45169
sg35217
I2
sasa(dp45170
g135
(dp45171
(VCCR2
p45172
Vpancreatic cancer
p45173
tp45174
I01
ssg35204
VA novel CCR2 inhibitor (PF-04136309) was tested in an orthotopic model of murine pancreatic cancer.
p45175
sg35206
(lp45176
(dp45177
g35211
I8
sg35212
g45172
sg35214
I4
sg35223
VP41597
p45178
sg35217
I1
sasg35208
(lp45179
(dp45180
g35211
I81
sg35212
g45173
sg35214
I17
sg35215
VC0235974
p45181
sg35217
I2
sasa(dp45182
g135
(dp45183
(VCCL2
p45184
Vpancreatic cancer
p45185
tp45186
I00
ssg35204
VHuman pancreatic cancer produces CCL2, and immunosuppressive CCR2(+) macrophages infiltrate these tumors.
p45187
sg35206
(lp45188
(dp45189
g35211
I33
sg35212
g45184
sg35214
I4
sg35223
VP13500
p45190
sg35217
I1
sasg35208
(lp45191
(dp45192
g35211
I6
sg35212
g45185
sg35214
I17
sg35215
VC0235974
p45193
sg35217
I2
sa(dp45194
g35211
I98
sg35212
Vtumors
p45195
sg35214
I6
sg35215
VC0027651
p45196
sg35217
I1
sa(dp45197
g35211
I81
sg35212
Vinfiltrate
p45198
sg35214
I10
sg35215
VC0332448
p45199
sg35217
I1
sasa(dp45200
g135
(dp45201
(VCCR2
p45202
Vcancer progression
p45203
tp45204
I00
ssg35204
VInflammatory monocyte recruitment is critical to pancreatic cancer progression, and targeting CCR2 may be an effective immunotherapeutic strategy in this disease.
p45205
sg35206
(lp45206
(dp45207
g35211
I94
sg35212
g45202
sg35214
I4
sg35223
VP41597
p45208
sg35217
I1
sasg35208
(lp45209
(dp45210
g35211
I22
sg35212
Vrecruitment
p45211
sg35214
I11
sg35215
VC0271510
p45212
sg35217
I1
sa(dp45213
g35211
I60
sg35212
g45203
sg35214
I18
sg35215
VC0178874
p45214
sg35217
I2
sasa(dp45215
g35204
VWeaver syndrome (WS) is a rare congenital overgrowth disorder caused by heterozygous mutations in EZH2 (enhancer of zeste homolog 2) or EED (embryonic ectoderm development).
p45216
sg35206
(lp45217
sg35208
(lp45218
(dp45219
g35211
I17
sg35212
VWS
p45220
sg35214
I2
sg35215
VC0265210
p45221
sg35217
I1
sa(dp45222
g35211
I0
sg35212
VWeaver syndrome
p45223
sg35214
I15
sg35215
VC0265210
p45224
sg35217
I2
sa(dp45225
g35211
I31
sg35212
Vcongenital overgrowth
p45226
sg35214
I21
sg35215
VC0332887
p45227
sg35217
I2
sasa(dp45228
g135
(dp45229
(VMMP8
p45230
Vbasal cell carcinoma
p45231
tp45232
I01
ssg35204
VWe evaluated the associations of six nonsynonymous SNPs in the MMP3, MMP8, and MMP9 genes with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 normal controls.
p45233
sg35206
(lp45234
(dp45235
g35211
I79
sg35212
VMMP9 genes
p45236
sg35214
I10
sg35223
VP14780
p45237
sg35217
I2
sa(dp45238
g35211
I63
sg35212
VMMP3
p45239
sg35214
I4
sg35223
VP08254
p45240
sg35217
I1
sa(dp45241
g35211
I69
sg35212
g45230
sg35214
I4
sg35223
VP22894
p45242
sg35217
I1
sasg35208
(lp45243
(dp45244
g35211
I199
sg35212
Vmelanoma
p45245
sg35214
I8
sg35215
VC0025202
p45246
sg35217
I1
sa(dp45247
g35211
I244
sg35212
VSCC
p45248
sg35214
I3
sg35215
VC0007137
p45249
sg35217
I1
sa(dp45250
g35211
I95
sg35212
Vskin cancer
p45251
sg35214
I11
sg35215
VC0007114
p45252
sg35217
I2
sa(dp45253
g35211
I219
sg35212
Vsquamous cell carcinoma
p45254
sg35214
I23
sg35215
VC0007137
p45255
sg35217
I3
sa(dp45256
g35211
I282
sg35212
VBCC
p45257
sg35214
I3
sg35215
VC0007117
p45258
sg35217
I1
sa(dp45259
g35211
I260
sg35212
g45231
sg35214
I20
sg35215
VC0007117
p45260
sg35217
I3
sasa(dp45261
g135
(dp45262
(VKi-67
p45263
Vbasal cell carcinoma
p45264
tp45265
I00
ssg35204
VNinety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
p45266
sg35206
(lp45267
(dp45268
g35211
I199
sg35212
VMMP-3
p45269
sg35214
I5
sg35223
VP08254
p45270
sg35217
I1
sa(dp45271
g35211
I189
sg35212
VMMP-1
p45272
sg35214
I5
sg35223
VP03956
p45273
sg35217
I1
sa(dp45274
g35211
I170
sg35212
Vp53
p45275
sg35214
I3
sg35223
VP42771
p45276
sg35217
I1
sa(dp45277
g35211
I163
sg35212
g45263
sg35214
I5
sg35223
VP46013
p45278
sg35217
I1
sasg35208
(lp45279
(dp45280
g35211
I21
sg35212
Vsquamous cell carcinoma
p45281
sg35214
I23
sg35215
VC0007137
p45282
sg35217
I3
sa(dp45283
g35211
I62
sg35212
g45264
sg35214
I20
sg35215
VC0007117
p45284
sg35217
I3
sasa(dp45285
g135
(dp45286
(Vzinc oxide-binding peptide
p45287
Vscrub typhus
p45288
tp45289
I00
ssg35204
VA novel zinc oxide-binding peptide (ZBP), FPYPGGDA, with high affinity to ZNP (K a  = 2.26 x 106 M-1) was isolated from a random peptide library and fused with a bacterial antigen, ScaA of Orientia tsutsugamushi, the causative agent of scrub typhus.
p45290
sg35206
(lp45291
(dp45292
g35211
I36
sg35212
VZBP
p45293
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp45294
g35211
I8
sg35212
g45287
sg35214
I26
sg35223
VP10070
p45295
sg35217
I3
sa(dp45296
g35211
I162
sg35212
Vbacterial antigen
p45297
sg35214
I17
sg35223
g12
sg35217
I2
sasg35208
(lp45298
(dp45299
g35211
I198
sg35212
Vtsutsugamushi
p45300
sg35214
I13
sg35215
VC0036472
p45301
sg35217
I1
sa(dp45302
g35211
I236
sg35212
g45288
sg35214
I12
sg35215
VC0036472
p45303
sg35217
I2
sasa(dp45304
g35204
VThe results show that the main latex allergen, a glycine-rich protein molecule, can cause cutaneous, inhalant and systemic hypersensitivity reactions.
p45305
sg35206
(lp45306
(dp45307
g35211
I49
sg35212
Vglycine-rich protein molecule
p45308
sg35214
I29
sg35223
g12
sg35217
I3
sasg35208
(lp45309
(dp45310
g35211
I123
sg35212
Vhypersensitivity reactions
p45311
sg35214
I26
sg35215
VC0020517
p45312
sg35217
I2
sasa(dp45313
g135
(dp45314
(VCYP2C9
p45315
Vrheumatic heart disease
p45316
tp45317
I00
ssg35204
VOne hundred and one consecutive patients of Han nationality with rheumatic heart disease undergoing valve surgery were enrolled and randomly assigned to an experimental group (n=50, based on CYP2C9 and VKORC1 genotypes, pharmacogenetic-based "predicted warfarin dose" for 3 days and then was adjusted to INR until stable warfarin maintenance dose) or a control group (n=51, 2.5mg/d for 3 days and then was adjusted to INR until stable warfarin maintenance dose).
p45318
sg35206
(lp45319
(dp45320
g35211
I191
sg35212
g45315
sg35214
I6
sg35223
VP11712
p45321
sg35217
I1
sa(dp45322
g35211
I202
sg35212
VVKORC1
p45323
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp45324
(dp45325
g35211
I65
sg35212
g45316
sg35214
I23
sg35215
VC0035439
p45326
sg35217
I3
sasa(dp45327
g35204
VRNF216) have recently been identified in patients suffering from Gordon Holmes syndrome (GHS), characterized by cognitive decline, dementia, and movement disorders.
p45328
sg35206
(lp45329
(dp45330
g35211
I0
sg35212
VRNF216
p45331
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp45332
(dp45333
g35211
I131
sg35212
Vdementia
p45334
sg35214
I8
sg35215
VC0497327
p45335
sg35217
I1
sa(dp45336
g35211
I89
sg35212
VGHS
p45337
sg35214
I3
sg35215
VC1859305
p45338
sg35217
I1
sa(dp45339
g35211
I50
sg35212
Vsuffering
p45340
sg35214
I9
sg35215
VC0683278
p45341
sg35217
I1
sa(dp45342
g35211
I145
sg35212
Vmovement disorders
p45343
sg35214
I18
sg35215
VC0026650
p45344
sg35217
I2
sa(dp45345
g35211
I65
sg35212
VGordon Holmes syndrome
p45346
sg35214
I22
sg35215
VC1859305
p45347
sg35217
I3
sa(dp45348
g35211
I112
sg35212
Vcognitive decline
p45349
sg35214
I17
sg35215
VC0338656
p45350
sg35217
I2
sasa(dp45351
g35204
VOur current findings of Arc misregulation by TRIAD3A variants suggest that loss-of-function mutations in TRIAD3A may contribute to dementia observed in patients with GHS driven by dysfunctional UPS components, leading to cognitive impairments through the synaptic protein Arc.
p45352
sg35206
(lp45353
(dp45354
g35211
I24
sg35212
VArc
p45355
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp45356
g35211
I255
sg35212
Vsynaptic protein Arc
p45357
sg35214
I20
sg35223
g12
sg35217
I3
sa(dp45358
g35211
I45
sg35212
VTRIAD3A variants
p45359
sg35214
I16
sg35223
g12
sg35217
I2
sa(dp45360
g35211
I45
sg35212
VTRIAD3A
p45361
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp45362
(dp45363
g35211
I24
sg35212
VArc
p45364
sg35214
I3
sg35215
VC0001857
p45365
sg35217
I1
sa(dp45366
g35211
I221
sg35212
Vcognitive impairments
p45367
sg35214
I21
sg35215
VC0338656
p45368
sg35217
I2
sa(dp45369
g35211
I24
sg35212
VArc
p45370
sg35214
I3
sg35215
VC0001857
p45371
sg35217
I1
sa(dp45372
g35211
I131
sg35212
Vdementia
p45373
sg35214
I8
sg35215
VC0497327
p45374
sg35217
I1
sasa(dp45375
g35204
VGordon Holmes syndrome (GHS) is a distinct phenotype of autosomal recessive cerebellar ataxia, characterized by ataxia, dementia, reproductive defects and hypogonadism; it has been recently found to be associated with RNF216 mutation.
p45376
sg35206
(lp45377
(dp45378
g35211
I218
sg35212
VRNF216 mutation
p45379
sg35214
I15
sg35223
g12
sg35217
I2
sasg35208
(lp45380
(dp45381
g35211
I87
sg35212
Vataxia
p45382
sg35214
I6
sg35215
VC0004134
p45383
sg35217
I1
sa(dp45384
g35211
I120
sg35212
Vdementia
p45385
sg35214
I8
sg35215
VC0497327
p45386
sg35217
I1
sa(dp45387
g35211
I155
sg35212
Vhypogonadism
p45388
sg35214
I12
sg35215
VC0020619
p45389
sg35217
I1
sa(dp45390
g35211
I0
sg35212
VGordon Holmes syndrome
p45391
sg35214
I22
sg35215
VC1859305
p45392
sg35217
I3
sa(dp45393
g35211
I76
sg35212
Vcerebellar ataxia
p45394
sg35214
I17
sg35215
VC0007758
p45395
sg35217
I2
sa(dp45396
g35211
I24
sg35212
VGHS
p45397
sg35214
I3
sg35215
VC1859305
p45398
sg35217
I1
sasa(dp45399
g35204
VThe syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4.
p45400
sg35206
(lp45401
(dp45402
g35211
I111
sg35212
VRNF216
p45403
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp45404
g35211
I167
sg35212
VOTUD4
p45405
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp45406
g35211
I111
sg35212
VRNF216
p45407
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp45408
(dp45409
g35211
I16
sg35212
Vhypogonadotropic hypogonadism
p45410
sg35214
I29
sg35215
VC0022735
p45411
sg35217
I2
sa(dp45412
g35211
I59
sg35212
Vdementia
p45413
sg35214
I8
sg35215
VC0497327
p45414
sg35217
I1
sa(dp45415
g35211
I47
sg35212
Vataxia
p45416
sg35214
I6
sg35215
VC0004134
p45417
sg35217
I1
sa(dp45418
g35211
I4
sg35212
Vsyndrome
p45419
sg35214
I8
sg35215
VC0039082
p45420
sg35217
I1
sasa(dp45421
g135
(dp45422
(Vprogesterone receptor
p45423
Vuterine leiomyoma
p45424
tp45425
I00
ssg35204
Vto investigate the molecular mechanisms and morphological substrate of reduced uterine leiomyoma in patients receiving the selective progesterone receptor modulator (SPRM) ulipristal acetate for 3 months, by estimating the immunohistochemical expression of the markers steroid receptor coactivator 1 (SRC-1), nuclear receptor corepressor 1 (NCoR-1), ER, PgR, Ki-67, p16, TGF-Beta, and VEGF in tumor tissue.
p45426
sg35206
(lp45427
(dp45428
g35211
I371
sg35212
VTGF-Beta
p45429
sg35214
I8
sg35223
VP18075
p45430
sg35217
I1
sa(dp45431
g35211
I354
sg35212
VPgR
p45432
sg35214
I3
sg35223
VP06401
p45433
sg35217
I1
sa(dp45434
g35211
I301
sg35212
VSRC-1
p45435
sg35214
I5
sg35223
VP12931
p45436
sg35217
I1
sa(dp45437
g35211
I341
sg35212
VNCoR-1
p45438
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp45439
g35211
I366
sg35212
Vp16
p45440
sg35214
I3
sg35223
VP42771
p45441
sg35217
I1
sa(dp45442
g35211
I309
sg35212
Vnuclear receptor corepressor 1
p45443
sg35214
I30
sg35223
g12
sg35217
I4
sa(dp45444
g35211
I359
sg35212
VKi-67
p45445
sg35214
I5
sg35223
VP46013
p45446
sg35217
I1
sa(dp45447
g35211
I269
sg35212
Vsteroid receptor coactivator 1
p45448
sg35214
I30
sg35223
g12
sg35217
I4
sa(dp45449
g35211
I133
sg35212
g45423
sg35214
I21
sg35223
VP06401
p45450
sg35217
I2
sasg35208
(lp45451
(dp45452
g35211
I79
sg35212
g45424
sg35214
I17
sg35215
VC0042133
p45453
sg35217
I2
sa(dp45454
g35211
I393
sg35212
Vtumor
p45455
sg35214
I5
sg35215
VC0027651
p45456
sg35217
I1
sasa(dp45457
g135
(dp45458
(VSRC-1
p45459
Vsclerosis
p45460
tp45461
I00
ssg35204
VThe morphological substrate of partial leiomyoma reduction was leiomyocyte apoptosis and dystrophy, tumor stroma sclerosis and hyalinosis with diminished Ki-67 expression and elevated p16 in the smooth muscle cells, trophic nodular tissue disorders exhibited by vascular wall sclerosis and lower VEGF and TGF-Beta expression, and leiomyocyte hormonal reception dysregulation that made itself evident through the reduced expression of SRC-1 with the unchanged expression of PR and ER and the maintained level of NCoR-1.
p45462
sg35206
(lp45463
(dp45464
g35211
I305
sg35212
VTGF-Beta
p45465
sg35214
I8
sg35223
VP18075
p45466
sg35217
I1
sa(dp45467
g35211
I511
sg35212
VNCoR-1
p45468
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp45469
g35211
I184
sg35212
Vp16
p45470
sg35214
I3
sg35223
VP42771
p45471
sg35217
I1
sa(dp45472
g35211
I434
sg35212
g45459
sg35214
I5
sg35223
VP12931
p45473
sg35217
I1
sasg35208
(lp45474
(dp45475
g35211
I113
sg35212
Vsclerosis
p45476
sg35214
I9
sg35215
VC0036429
p45477
sg35217
I1
sa(dp45478
g35211
I89
sg35212
Vdystrophy
p45479
sg35214
I9
sg35215
VC0333606
p45480
sg35217
I1
sa(dp45481
g35211
I100
sg35212
Vtumor
p45482
sg35214
I5
sg35215
VC0027651
p45483
sg35217
I1
sa(dp45484
g35211
I39
sg35212
Vleiomyoma
p45485
sg35214
I9
sg35215
VC0023267
p45486
sg35217
I1
sa(dp45487
g35211
I127
sg35212
Vhyalinosis
p45488
sg35214
I10
sg35215
VC0333438
p45489
sg35217
I1
sa(dp45490
g35211
I113
sg35212
g45460
sg35214
I9
sg35215
VC0036429
p45491
sg35217
I1
sasa(dp45492
g35204
VUenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec, Ha ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1, NCoR-1, ER, PGR, Ki-67, p16, TGF-Beta, VEGF B TKaHN onyxonN.
p45493
sg35206
(lp45494
(dp45495
g35211
I208
sg35212
VHa ocHoBaHNN omyeHKN NMMyHorNcToxNMN4ecKoN EKcnpeccNN SRC-1
p45496
sg35214
I59
sg35223
VP12931
p45497
sg35217
I6
sa(dp45498
g35211
I269
sg35212
VNCoR-1
p45499
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp45500
g35211
I293
sg35212
Vp16
p45501
sg35214
I3
sg35223
VP42771
p45502
sg35217
I1
sa(dp45503
g35211
I281
sg35212
VPGR
p45504
sg35214
I3
sg35223
VP06401
p45505
sg35217
I1
sa(dp45506
g35211
I0
sg35212
VUenb - N3y4NTb MoneKynRpHble MexaHN3Mbl N MopoonorN4ecKNN cybcTpaT peAyKmyNN neNoMNoMbl MaTKN y namyNeHToK, nony4aBwNx ceneKTNBHblN MoAynRTop nporecTepoHoBblx pemyenTopoB ynNnpNcTana amyeTaT B Te4eHNe 3 Mec
p45507
sg35214
I206
sg35223
g12
sg35217
I24
sa(dp45508
g35211
I308
sg35212
VVEGF B TKaHN onyxonN
p45509
sg35214
I20
sg35223
VP49765
p45510
sg35217
I4
sa(dp45511
g35211
I286
sg35212
VKi-67
p45512
sg35214
I5
sg35223
VP46013
p45513
sg35217
I1
sa(dp45514
g35211
I298
sg35212
VTGF-Beta
p45515
sg35214
I8
sg35223
VP18075
p45516
sg35217
I1
sasg35208
(lp45517
sa(dp45518
g35204
VWe find that AML1-ETO and corepressor NCoR co-occupy the miR-29a/b-1 locus and downregulate its expression in leukemia cells.
p45519
sg35206
(lp45520
(dp45521
g35211
I57
sg35212
VmiR-29a/b-1 locus
p45522
sg35214
I17
sg35223
g12
sg35217
I2
sa(dp45523
g35211
I38
sg35212
VNCoR
p45524
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp45525
(dp45526
g35211
I110
sg35212
Vleukemia
p45527
sg35214
I8
sg35215
VC0023418
p45528
sg35217
I1
sasa(dp45529
g35204
VAuthors present the history of a patient with extra-adrenal pheochromocytoma who represents in Hungary the first genetically confirmed case of hereditary paraganglioma/pheochromocytoma syndrome due to disease-causing mutation of the SDHD gene.
p45530
sg35206
(lp45531
(dp45532
g35211
I233
sg35212
VSDHD gene
p45533
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp45534
(dp45535
g35211
I46
sg35212
Vextra-adrenal pheochromocytoma
p45536
sg35214
I30
sg35215
VC1257877
p45537
sg35217
I2
sa(dp45538
g35211
I168
sg35212
Vpheochromocytoma syndrome
p45539
sg35214
I25
sg35215
VC0031511
p45540
sg35217
I2
sa(dp45541
g35211
I143
sg35212
Vhereditary paraganglioma
p45542
sg35214
I24
sg35215
VC1333993
p45543
sg35217
I2
sa(dp45544
g35211
I201
sg35212
Vdisease-causing mutation
p45545
sg35214
I24
sg35215
VC2985434
p45546
sg35217
I2
sasa(dp45547
g135
(dp45548
(VSDHB mutations
p45549
Vparagangliomas
p45550
tp45551
I00
ssg35204
VWhile SDHD has been more frequently associated with the pathogenesis of head and neck paragangliomas, SDHB mutations were mainly associated with malignant and/or extra-adrenal pheochromocytoma/paraganglioma.
p45552
sg35206
(lp45553
(dp45554
g35211
I102
sg35212
g45549
sg35214
I14
sg35223
VP21912
p45555
sg35217
I2
sa(dp45556
g35211
I6
sg35212
VSDHD
p45557
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp45558
(dp45559
g35211
I56
sg35212
Vpathogenesis
p45560
sg35214
I12
sg35215
VC0699748
p45561
sg35217
I1
sa(dp45562
g35211
I162
sg35212
Vextra-adrenal pheochromocytoma
p45563
sg35214
I30
sg35215
VC1257877
p45564
sg35217
I2
sa(dp45565
g35211
I86
sg35212
Vparaganglioma
p45566
sg35214
I13
sg35215
VC0030421
p45567
sg35217
I1
sa(dp45568
g35211
I86
sg35212
g45550
sg35214
I14
sg35215
VC0030421
p45569
sg35217
I1
sasa(dp45570
g135
(dp45571
(VSDHB
p45572
Vparagangliomas
p45573
tp45574
I00
ssg35204
VSDHB mutation carriers were more likely than SDHD mutation carriers to develop extraadrenal pheochromocytomas and malignant disease, whereas SDHD mutation carriers had a greater propensity to develop head and neck paragangliomas and multiple tumors.
p45575
sg35206
(lp45576
(dp45577
g35211
I45
sg35212
VSDHD
p45578
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp45579
g35211
I45
sg35212
VSDHD mutation
p45580
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp45581
g35211
I0
sg35212
g45572
sg35214
I4
sg35223
VP21912
p45582
sg35217
I1
sasg35208
(lp45583
(dp45584
g35211
I92
sg35212
Vpheochromocytomas
p45585
sg35214
I17
sg35215
VC0031511
p45586
sg35217
I1
sa(dp45587
g35211
I233
sg35212
Vmultiple tumors
p45588
sg35214
I15
sg35215
VC0260037
p45589
sg35217
I2
sa(dp45590
g35211
I114
sg35212
Vmalignant disease
p45591
sg35214
I17
sg35215
VC0442867
p45592
sg35217
I2
sa(dp45593
g35211
I214
sg35212
g45573
sg35214
I14
sg35215
VC0030421
p45594
sg35217
I1
sasa(dp45595
g35204
VIn contrast, SDHD mutation carriers, in addition to head and neck paragangliomas, should be observed for multifocal tumors, infrequent malignancy, and the possibility of extraadrenal pheochromocytoma.
p45596
sg35206
(lp45597
(dp45598
g35211
I13
sg35212
VSDHD
p45599
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp45600
(dp45601
g35211
I170
sg35212
Vextraadrenal pheochromocytoma
p45602
sg35214
I29
sg35215
VC1257877
p45603
sg35217
I2
sa(dp45604
g35211
I116
sg35212
Vtumors
p45605
sg35214
I6
sg35215
VC0027651
p45606
sg35217
I1
sa(dp45607
g35211
I135
sg35212
Vmalignancy
p45608
sg35214
I10
sg35215
VC0006826
p45609
sg35217
I1
sa(dp45610
g35211
I66
sg35212
Vparagangliomas
p45611
sg35214
I14
sg35215
VC0030421
p45612
sg35217
I1
sasa(dp45613
g135
(dp45614
(VVHL
p45615
VVHL
p45616
tp45617
I00
ssg35204
VHowever, in the presence of extra-adrenal pheochromocytoma, it may be more useful to screen for VHL, SDHD and SDHB mutations.
p45618
sg35206
(lp45619
(dp45620
g35211
I110
sg35212
VSDHB
p45621
sg35214
I4
sg35223
VP21912
p45622
sg35217
I1
sa(dp45623
g35211
I96
sg35212
g45615
sg35214
I3
sg35223
VP40337
p45624
sg35217
I1
sa(dp45625
g35211
I101
sg35212
VSDHD
p45626
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp45627
(dp45628
g35211
I28
sg35212
Vextra-adrenal pheochromocytoma
p45629
sg35214
I30
sg35215
VC1257877
p45630
sg35217
I2
sa(dp45631
g35211
I96
sg35212
g45616
sg35214
I3
sg35215
VC0019562
p45632
sg35217
I1
sasa(dp45633
g135
(dp45634
(VSHFM3
p45635
VSHFM3
p45636
tp45637
I00
ssg35204
VHere we show, using two different techniques, FISH and quantitative PCR that SHFM3 is caused by a minimal 325 kb duplication containing only two genes (BTRC and POLL).
p45638
sg35206
(lp45639
(dp45640
g35211
I161
sg35212
VPOLL
p45641
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp45642
g35211
I152
sg35212
VBTRC
p45643
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp45644
g35211
I77
sg35212
g45635
sg35214
I5
sg35223
VP57775
p45645
sg35217
I1
sasg35208
(lp45646
(dp45647
g35211
I77
sg35212
g45636
sg35214
I5
sg35215
VC1838652
p45648
sg35217
I1
sa(dp45649
g35211
I113
sg35212
Vduplication
p45650
sg35214
I11
sg35215
VC1705960
p45651
sg35217
I1
sasa(dp45652
g135
(dp45653
(VLBX1
p45654
VSHFM3
p45655
tp45656
I00
ssg35204
VThe smaller duplication in the second patient contained the LBX1, BTRC, POLL, and DPCD genes and a disrupted extra copy of the dactylin gene, and was nearly identical to the smallest known duplicated region of SHFM3.
p45657
sg35206
(lp45658
(dp45659
g35211
I82
sg35212
VDPCD genes
p45660
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp45661
g35211
I127
sg35212
Vdactylin gene
p45662
sg35214
I13
sg35223
VP57775
p45663
sg35217
I2
sa(dp45664
g35211
I72
sg35212
VPOLL
p45665
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp45666
g35211
I210
sg35212
VSHFM3
p45667
sg35214
I5
sg35223
VP57775
p45668
sg35217
I1
sa(dp45669
g35211
I60
sg35212
g45654
sg35214
I4
sg35223
VP52954
p45670
sg35217
I1
sa(dp45671
g35211
I66
sg35212
VBTRC
p45672
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp45673
(dp45674
g35211
I210
sg35212
g45655
sg35214
I5
sg35215
VC1838652
p45675
sg35217
I1
sa(dp45676
g35211
I12
sg35212
Vduplication
p45677
sg35214
I11
sg35215
VC1705960
p45678
sg35217
I1
sasa(dp45679
g35204
VIn the diagnostic work-up of alcoholic cardiomyopathy, the confirmation of alcohol abuse by carbohydrate deficient transferrin (CDT) and increased liver enzymes, and the involvement of the heart by markers of heart failure (e.g., NT-proBNP) and of necrosis (e.g., troponins or CKMb) is mandatory.
p45680
sg35206
(lp45681
(dp45682
g35211
I92
sg35212
Vcarbohydrate deficient transferrin
p45683
sg35214
I34
sg35223
g12
sg35217
I3
sa(dp45684
g35211
I128
sg35212
VCDT
p45685
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp45686
(dp45687
g35211
I209
sg35212
Vheart failure
p45688
sg35214
I13
sg35215
VC0018802
p45689
sg35217
I2
sa(dp45690
g35211
I92
sg35212
Vcarbohydrate deficient transferrin
p45691
sg35214
I34
sg35215
VC1846385
p45692
sg35217
I3
sa(dp45693
g35211
I75
sg35212
Valcohol abuse
p45694
sg35214
I13
sg35215
VC0085762
p45695
sg35217
I2
sa(dp45696
g35211
I128
sg35212
VCDT
p45697
sg35214
I3
sg35215
VC1846385
p45698
sg35217
I1
sa(dp45699
g35211
I29
sg35212
Valcoholic cardiomyopathy
p45700
sg35214
I24
sg35215
VC0007192
p45701
sg35217
I2
sasa(dp45702
g35204
VEach 10 myg/m(3) increment in daily mean concentration at lag 2 day was associated with a 0.61% (95% CI: 0.19%, 1.03%) increase in overall respiratory mortality and a 0.67% (95% CI: 0.14%, 1.21%) increase in pneumonia mortality.
p45703
sg35206
(lp45704
sg35208
(lp45705
(dp45706
g35211
I208
sg35212
Vpneumonia
p45707
sg35214
I9
sg35215
VC0032285
p45708
sg35217
I1
sasa(dp45709
g135
(dp45710
(Vlag 4
p45711
Vasthma
p45712
tp45713
I00
ssg35204
VThe values of the relative risks for hospitalization for pneumonia and asthma were significant for lag 0 (RR=1.051, 95%CI; 1.016 to 1.088); lag 2 (RR=1.066, 95%CI: 1.023 to 1.113); lag 3 (RR=1.053, 95%CI: 1.015 to 1.092); lag 4 (RR=1.043, 95%CI: 1.004 to 1.088) and lag 5 (RR=1.061, 95%CI: 1.018 to 1.106).
p45714
sg35206
(lp45715
(dp45716
g35211
I140
sg35212
Vlag 2
p45717
sg35214
I5
sg35223
VP16949
p45718
sg35217
I2
sa(dp45719
g35211
I266
sg35212
Vlag 5
p45720
sg35214
I5
sg35223
VP16949
p45721
sg35217
I2
sa(dp45722
g35211
I181
sg35212
Vlag 3
p45723
sg35214
I5
sg35223
VP16949
p45724
sg35217
I2
sa(dp45725
g35211
I99
sg35212
Vlag 0
p45726
sg35214
I5
sg35223
VP16949
p45727
sg35217
I2
sa(dp45728
g35211
I222
sg35212
g45711
sg35214
I5
sg35223
VP16949
p45729
sg35217
I2
sasg35208
(lp45730
(dp45731
g35211
I57
sg35212
Vpneumonia
p45732
sg35214
I9
sg35215
VC0032285
p45733
sg35217
I1
sa(dp45734
g35211
I71
sg35212
g45712
sg35214
I6
sg35215
VC0004096
p45735
sg35217
I1
sasa(dp45736
g135
(dp45737
(Vlag 2
p45738
Vchronic obstructive pulmonary disease
p45739
tp45740
I00
ssg35204
VA 10 microg/m increase in bushfire PM10 was associated with a 1.24% (95% confidence interval = 0.22% to 2.27%) increase in all respiratory disease admissions (at lag 0), a 3.80% (1.40% to 6.26%) increase in chronic obstructive pulmonary disease admissions (at lag 2), and a 5.02% (1.77% to 8.37%) increase in adult asthma admissions (at lag 0).
p45741
sg35206
(lp45742
(dp45743
g35211
I260
sg35212
g45738
sg35214
I5
sg35223
VP16949
p45744
sg35217
I2
sasg35208
(lp45745
(dp45746
g35211
I315
sg35212
Vasthma
p45747
sg35214
I6
sg35215
VC0004096
p45748
sg35217
I1
sa(dp45749
g35211
I127
sg35212
Vrespiratory disease
p45750
sg35214
I19
sg35215
VC0035242
p45751
sg35217
I2
sa(dp45752
g35211
I207
sg35212
g45739
sg35214
I37
sg35215
VC0024117
p45753
sg35217
I4
sasa(dp45754
g35204
VWe confirmed that inhibition of TREM-1 attenuates the severity of colitis at clinically, endoscopically and histologically levels.
p45755
sg35206
(lp45756
(dp45757
g35211
I32
sg35212
VTREM-1
p45758
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp45759
(dp45760
g35211
I66
sg35212
Vcolitis
p45761
sg35214
I7
sg35215
VC0009319
p45762
sg35217
I1
sasa(dp45763
g35204
VIndeed, TREM-1 receptor and its signaling pathways contribute to the pathology of several non-infectious acute and chronic inflammatory diseases, including atherosclerosis, ischemia reperfusion-induced tissue injury, colitis, fibrosis and cancer.
p45764
sg35206
(lp45765
(dp45766
g35211
I8
sg35212
VTREM-1 receptor
p45767
sg35214
I15
sg35223
g12
sg35217
I2
sasg35208
(lp45768
(dp45769
g35211
I217
sg35212
Vcolitis
p45770
sg35214
I7
sg35215
VC0009319
p45771
sg35217
I1
sa(dp45772
g35211
I173
sg35212
Vischemia
p45773
sg35214
I8
sg35215
VC0022116
p45774
sg35217
I1
sa(dp45775
g35211
I156
sg35212
Vatherosclerosis
p45776
sg35214
I15
sg35215
VC0004153
p45777
sg35217
I1
sa(dp45778
g35211
I239
sg35212
Vcancer
p45779
sg35214
I6
sg35215
VC0006826
p45780
sg35217
I1
sa(dp45781
g35211
I226
sg35212
Vfibrosis
p45782
sg35214
I8
sg35215
VC0016059
p45783
sg35217
I1
sa(dp45784
g35211
I69
sg35212
Vpathology
p45785
sg35214
I9
sg35215
VC0677042
p45786
sg35217
I1
sa(dp45787
g35211
I94
sg35212
Vinfectious
p45788
sg35214
I10
sg35215
VC0009450
p45789
sg35217
I1
sasa(dp45790
g135
(dp45791
(VCD4
p45792
Vcolitis
p45793
tp45794
I00
ssg35204
VIn CD4(+) T cell- and dextran sodium sulfate-induced models of colitis, Trem1(-/-) mice displayed significantly attenuated disease that was associated with reduced inflammatory infiltrates and diminished expression of pro-inflammatory cytokines.
p45795
sg35206
(lp45796
(dp45797
g35211
I3
sg35212
g45792
sg35214
I3
sg35223
VP01730
p45798
sg35217
I1
sa(dp45799
g35211
I72
sg35212
VTrem1
p45800
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp45801
(dp45802
g35211
I63
sg35212
g45793
sg35214
I7
sg35215
VC0009319
p45803
sg35217
I1
sa(dp45804
g35211
I177
sg35212
Vinfiltrates
p45805
sg35214
I11
sg35215
VC0332448
p45806
sg35217
I1
sasa(dp45807
g35204
VIn vivo, the treatment with the TREM-1 antagonist LP17 or control peptide was initiated at the beginning of or after induction of experimental colitis or colitis-associated tumorigenesis.
p45808
sg35206
(lp45809
(dp45810
g35211
I32
sg35212
VTREM-1
p45811
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp45812
(dp45813
g35211
I143
sg35212
Vcolitis
p45814
sg35214
I7
sg35215
VC0009319
p45815
sg35217
I1
sa(dp45816
g35211
I143
sg35212
Vcolitis
p45817
sg35214
I7
sg35215
VC0009319
p45818
sg35217
I1
sa(dp45819
g35211
I173
sg35212
Vtumorigenesis
p45820
sg35214
I13
sg35215
VC0007621
p45821
sg35217
I1
sasa(dp45822
g135
(dp45823
(VC-reactive protein
p45824
Vulcerative colitis
p45825
tp45826
I00
ssg35204
VIn ulcerative colitis, sTREM-1 level was correlated more strongly with the endoscopic activity (r=0.498) than the C-reactive protein level (r=0.386) or erythrocyte sedimentation rate (r=0.272), although not superior to the partial Mayo score (r=0.611).
p45827
sg35206
(lp45828
(dp45829
g35211
I114
sg35212
g45824
sg35214
I18
sg35223
VP02741
p45830
sg35217
I2
sasg35208
(lp45831
(dp45832
g35211
I3
sg35212
g45825
sg35214
I18
sg35215
VC0009324
p45833
sg35217
I2
sasa(dp45834
g35204
VIn ulcerative colitis, sTREM-1 level was correlated most closely with the endoscopic disease activity among serum biomarkers, but was not superior to the clinical activity index.
p45835
sg35206
(lp45836
sg35208
(lp45837
(dp45838
g35211
I3
sg35212
Vulcerative colitis
p45839
sg35214
I18
sg35215
VC0009324
p45840
sg35217
I2
sasa(dp45841
g35204
VOur results suggest that sTREM-1 level may represent a complementary marker for the assessment of endoscopic activity in ulcerative colitis, but not in Crohn's disease.
p45842
sg35206
(lp45843
sg35208
(lp45844
(dp45845
g35211
I152
sg35212
VCrohn's disease
p45846
sg35214
I15
sg35215
VC0010346
p45847
sg35217
I2
sa(dp45848
g35211
I121
sg35212
Vulcerative colitis
p45849
sg35214
I18
sg35215
VC0009324
p45850
sg35217
I2
sasa(dp45851
g35204
VIntestinal biopsies and concurrently collected sera from patients with Crohn's disease (CD) and Ulcerative colitis (UC) enrolled in the Swiss IBD cohort study were analyzed for intestinal TREM-1 mRNA and serum sTREM-1 expression.
p45852
sg35206
(lp45853
(dp45854
g35211
I204
sg35212
Vserum sTREM-1
p45855
sg35214
I13
sg35223
g12
sg35217
I2
sa(dp45856
g35211
I188
sg35212
VTREM-1 mRNA
p45857
sg35214
I11
sg35223
g12
sg35217
I2
sasg35208
(lp45858
(dp45859
g35211
I96
sg35212
VUlcerative colitis
p45860
sg35214
I18
sg35215
VC0009324
p45861
sg35217
I2
sa(dp45862
g35211
I71
sg35212
VCrohn's disease
p45863
sg35214
I15
sg35215
VC0010346
p45864
sg35217
I2
sa(dp45865
g35211
I142
sg35212
VIBD
p45866
sg35214
I3
sg35215
VC0021390
p45867
sg35217
I1
sa(dp45868
g35211
I116
sg35212
VUC
p45869
sg35214
I2
sg35215
VC0009324
p45870
sg35217
I1
sa(dp45871
g35211
I88
sg35212
VCD
p45872
sg35214
I2
sg35215
VC0010346
p45873
sg35217
I1
sasa(dp45874
g35204
VSerum sTREM-1 and TREM-1 mRNA expression levels were further determined in sera and colonic tissues collected at various time-points post disease induction in an experimental mouse model of colitis and correlated with disease activity.
p45875
sg35206
(lp45876
(dp45877
g35211
I18
sg35212
VTREM-1 mRNA
p45878
sg35214
I11
sg35223
g12
sg35217
I2
sasg35208
(lp45879
(dp45880
g35211
I190
sg35212
Vcolitis
p45881
sg35214
I7
sg35215
VC0009319
p45882
sg35217
I1
sasa(dp45883
g35204
VThree TREM-1 single nucleotide polymorphisms (SNPs, rs2234237, rs3789205, and rs9471535) were genotyped by Taqman technology on 202 Crohn's disease (CD), 265 ulcerative colitis (UC), 138 with intestinal Behcet's disease (BD), and 234 healthy controls and the relationships between these SNPs and IBD development and phenotypes were evaluated.
p45884
sg35206
(lp45885
sg35208
(lp45886
(dp45887
g35211
I203
sg35212
VBehcet's disease
p45888
sg35214
I16
sg35215
VC0004943
p45889
sg35217
I2
sa(dp45890
g35211
I149
sg35212
VCD
p45891
sg35214
I2
sg35215
VC0010346
p45892
sg35217
I1
sa(dp45893
g35211
I221
sg35212
VBD
p45894
sg35214
I2
sg35215
VC0004943
p45895
sg35217
I1
sa(dp45896
g35211
I132
sg35212
VCrohn's disease
p45897
sg35214
I15
sg35215
VC0010346
p45898
sg35217
I2
sa(dp45899
g35211
I158
sg35212
Vulcerative colitis
p45900
sg35214
I18
sg35215
VC0009324
p45901
sg35217
I2
sa(dp45902
g35211
I178
sg35212
VUC
p45903
sg35214
I2
sg35215
VC0009324
p45904
sg35217
I1
sa(dp45905
g35211
I296
sg35212
VIBD
p45906
sg35214
I3
sg35215
VC0021390
p45907
sg35217
I1
sasa(dp45908
g35204
VHowever, TREM-1 SNPs were not significantly associated with the development of Crohn's disease or ulcerative colitis.
p45909
sg35206
(lp45910
(dp45911
g35211
I9
sg35212
VTREM-1 SNPs
p45912
sg35214
I11
sg35223
g12
sg35217
I2
sasg35208
(lp45913
(dp45914
g35211
I79
sg35212
VCrohn's disease
p45915
sg35214
I15
sg35215
VC0010346
p45916
sg35217
I2
sa(dp45917
g35211
I98
sg35212
Vulcerative colitis
p45918
sg35214
I18
sg35215
VC0009324
p45919
sg35217
I2
sasa(dp45920
g35204
VStable expression of miR-124 in diffuse large B cell lymphoma (DLBCL) cell lines diminished PDE4B expression.
p45921
sg35206
(lp45922
(dp45923
g35211
I92
sg35212
VPDE4B
p45924
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp45925
g35211
I21
sg35212
VmiR-124
p45926
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp45927
(dp45928
g35211
I63
sg35212
VDLBCL
p45929
sg35214
I5
sg35215
VC0079744
p45930
sg35217
I1
sa(dp45931
g35211
I32
sg35212
Vdiffuse large B cell lymphoma
p45932
sg35214
I29
sg35215
VC0079744
p45933
sg35217
I5
sasa(dp45934
g35204
VStarting from the GSEA, we found that overexpression of the PDE4B in diffuse large B-cell lymphoma (DLBCL) impinge on the same genes/pathways that are abnormally active in GC-resistant tumors.
p45935
sg35206
(lp45936
(dp45937
g35211
I60
sg35212
VPDE4B
p45938
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp45939
(dp45940
g35211
I69
sg35212
Vdiffuse large B-cell lymphoma
p45941
sg35214
I29
sg35215
VC0079744
p45942
sg35217
I4
sa(dp45943
g35211
I185
sg35212
Vtumors
p45944
sg35214
I6
sg35215
VC0027651
p45945
sg35217
I1
sa(dp45946
g35211
I100
sg35212
VDLBCL
p45947
sg35214
I5
sg35215
VC0079744
p45948
sg35217
I1
sasa(dp45949
g135
(dp45950
(VMPC-1
p45951
Vplasmacytoma
p45952
tp45953
I00
ssg35204
VOn the basis of biopsies of the masses in the pharynx and finger, he was diagnosed with extramedullary plasmablastic plasmacytoma, with somewhat immature CD45(+), MPC-1(-), and CD49e(-).
p45954
sg35206
(lp45955
(dp45956
g35211
I177
sg35212
VCD49e
p45957
sg35214
I5
sg35223
VP08648
p45958
sg35217
I1
sa(dp45959
g35211
I154
sg35212
VCD45(+)
p45960
sg35214
I7
sg35223
VP08575
p45961
sg35217
I1
sa(dp45962
g35211
I163
sg35212
g45951
sg35214
I5
sg35223
VP28062
p45963
sg35217
I1
sasg35208
(lp45964
(dp45965
g35211
I117
sg35212
g45952
sg35214
I12
sg35215
VC0032131
p45966
sg35217
I1
sasa(dp45967
g135
(dp45968
(VCD45 negativity
p45969
Vplasmacytoma
p45970
tp45971
I00
ssg35204
VChanges to CD45 negativity and MPC-1 partial positivity were seen, while CD49e negativity persisted, suggesting that the plasmablastic plasmacytoma had reverted to a more immature state.
p45972
sg35206
(lp45973
(dp45974
g35211
I31
sg35212
VMPC-1
p45975
sg35214
I5
sg35223
VP28062
p45976
sg35217
I1
sa(dp45977
g35211
I73
sg35212
VCD49e
p45978
sg35214
I5
sg35223
VP08648
p45979
sg35217
I1
sa(dp45980
g35211
I11
sg35212
g45969
sg35214
I15
sg35223
VP08575
p45981
sg35217
I2
sasg35208
(lp45982
(dp45983
g35211
I135
sg35212
g45970
sg35214
I12
sg35215
VC0032131
p45984
sg35217
I1
sasa(dp45985
g135
(dp45986
(VCD49e
p45987
Vplasmacytomas
p45988
tp45989
I00
ssg35204
VHe had the following poor prognostic factors: 1) multiple extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature myeloma cells with plasmablastic morphology, and 4) predominance of MPC1-CD49e-CD45+ phenotype immature myeloma cells.
p45990
sg35206
(lp45991
(dp45992
g35211
I212
sg35212
VMPC1
p45993
sg35214
I4
sg35223
VP28062
p45994
sg35217
I1
sa(dp45995
g35211
I223
sg35212
VCD45+
p45996
sg35214
I5
sg35223
VP08575
p45997
sg35217
I1
sa(dp45998
g35211
I217
sg35212
g45987
sg35214
I5
sg35223
VP08648
p45999
sg35217
I1
sasg35208
(lp46000
(dp46001
g35211
I99
sg35212
Vmyeloma
p46002
sg35214
I7
sg35215
VC0026764
p46003
sg35217
I1
sa(dp46004
g35211
I111
sg35212
Veffusion
p46005
sg35214
I8
sg35215
VC0013687
p46006
sg35217
I1
sa(dp46007
g35211
I99
sg35212
Vmyeloma
p46008
sg35214
I7
sg35215
VC0026764
p46009
sg35217
I1
sa(dp46010
g35211
I73
sg35212
g45988
sg35214
I13
sg35215
VC0032131
p46011
sg35217
I1
sasa(dp46012
g135
(dp46013
(VMPC-1
p46014
VMGUS
p46015
tp46016
I00
ssg35204
VInterestingly, the proportions of MPC-1(-) and MPC-1(-)CD45(+) immature monoclonal plasma cells also increased in the 7 progressive cases of MGUS.
p46017
sg35206
(lp46018
(dp46019
g35211
I47
sg35212
VMPC-1(-)CD45(+)
p46020
sg35214
I15
sg35223
VP28062
p46021
sg35217
I1
sa(dp46022
g35211
I34
sg35212
g46014
sg35214
I5
sg35223
VP28062
p46023
sg35217
I1
sasg35208
(lp46024
(dp46025
g35211
I141
sg35212
g46015
sg35214
I4
sg35215
VC0026470
p46026
sg35217
I1
sasa(dp46027
g35204
VThe main hereditary LMNSs in adulthood are Kennedy's disease, late-onset spinal muscular atrophy and distal hereditary motor neuropathies.
p46028
sg35206
(lp46029
sg35208
(lp46030
(dp46031
g35211
I125
sg35212
Vneuropathies
p46032
sg35214
I12
sg35215
VC0442874
p46033
sg35217
I1
sa(dp46034
g35211
I73
sg35212
Vspinal muscular atrophy
p46035
sg35214
I23
sg35215
VC0026847
p46036
sg35217
I3
sa(dp46037
g35211
I43
sg35212
VKennedy's disease
p46038
sg35214
I17
sg35215
VC1839259
p46039
sg35217
I2
sasa(dp46040
g35204
VIn contrast, spinal muscular atrophy (SMA) involves the specific degeneration of LMNs, with symmetrical muscle weakness and atrophy.
p46041
sg35206
(lp46042
sg35208
(lp46043
(dp46044
g35211
I38
sg35212
VSMA
p46045
sg35214
I3
sg35215
VC0026847
p46046
sg35217
I1
sa(dp46047
g35211
I65
sg35212
Vdegeneration
p46048
sg35214
I12
sg35215
VC0011164
p46049
sg35217
I1
sa(dp46050
g35211
I13
sg35212
Vspinal muscular atrophy
p46051
sg35214
I23
sg35215
VC0026847
p46052
sg35217
I3
sa(dp46053
g35211
I104
sg35212
Vmuscle weakness
p46054
sg35214
I15
sg35215
VC0030552
p46055
sg35217
I2
sa(dp46056
g35211
I29
sg35212
Vatrophy
p46057
sg35214
I7
sg35215
VC0333641
p46058
sg35217
I1
sasa(dp46059
g35204
VTargeting lower motor neurons (LMNs) for gene delivery could be useful for disorders such as spinal muscular atrophy and amyotrophic lateral sclerosis.
p46060
sg35206
(lp46061
sg35208
(lp46062
(dp46063
g35211
I93
sg35212
Vspinal muscular atrophy
p46064
sg35214
I23
sg35215
VC0026847
p46065
sg35217
I3
sa(dp46066
g35211
I121
sg35212
Vamyotrophic lateral sclerosis
p46067
sg35214
I29
sg35215
VC0002736
p46068
sg35217
I3
sasa(dp46069
g35204
VOur previous study showed that reduction of KCa3.1 channel expression by lyso-globotriaosylceramide (lyso-Gb3) inhibits differentiation into myofibroblasts and collagen synthesis, which might lead to development of ascending thoracic aortic aneurysm secondary to Fabry disease.
p46070
sg35206
(lp46071
sg35208
(lp46072
(dp46073
g35211
I225
sg35212
Vthoracic aortic aneurysm
p46074
sg35214
I24
sg35215
VC0162872
p46075
sg35217
I3
sa(dp46076
g35211
I263
sg35212
VFabry disease
p46077
sg35214
I13
sg35215
VC0002986
p46078
sg35217
I2
sasa(dp46079
g135
(dp46080
(VPKA
p46081
Vthoracic aortic aneurysms
p46082
tp46083
I00
ssg35204
VMoreover, lyso-Gb3 suppressed expression of class II phosphatidylinositol 3-kinase C2Beta (PI3KC2Beta) by PKA activation, which reduces the production of phosphatidylinositol 3-phosphate [PI(3)P], and the reduced membrane surface expression of KCa3.1 channel was recovered by increasing the intracellular levels of PI(3)P. Consequently, our findings that lyso-Gb3 inhibited both KCa3.1 channel synthesis and surface expression by increasing intracellular cAMP, and controlled surface expression through changes in PI3KC2Beta-mediated PI(3)P production, suggest that modulation of PKA and PI3KC2Beta activity to control of KCa3.1 channel expression can be an alternative important target to attenuate ascending thoracic aortic aneurysms in Fabry disease.
p46084
sg35206
(lp46085
(dp46086
g35211
I244
sg35212
VKCa3.1
p46087
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46088
g35211
I44
sg35212
Vclass II phosphatidylinositol 3-kinase C2Beta
p46089
sg35214
I45
sg35223
g12
sg35217
I5
sa(dp46090
g35211
I244
sg35212
VKCa3.1
p46091
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46092
g35211
I244
sg35212
VKCa3.1
p46093
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46094
g35211
I106
sg35212
VPKA
p46095
sg35214
I3
sg35223
VP17612
p46096
sg35217
I1
sa(dp46097
g35211
I154
sg35212
Vphosphatidylinositol 3-phosphate [PI(3)P]
p46098
sg35214
I41
sg35223
VP48426
p46099
sg35217
I3
sa(dp46100
g35211
I106
sg35212
g46081
sg35214
I3
sg35223
VP17612
p46101
sg35217
I1
sasg35208
(lp46102
(dp46103
g35211
I739
sg35212
VFabry disease
p46104
sg35214
I13
sg35215
VC0002986
p46105
sg35217
I2
sa(dp46106
g35211
I710
sg35212
g46082
sg35214
I25
sg35215
VC0162872
p46107
sg35217
I3
sasa(dp46108
g35204
VThese findings suggest that the KCa3.1 channel can serve as a new target to attenuate and prevent development of ascending thoracic aortic aneurysm in Fabry disease.
p46109
sg35206
(lp46110
(dp46111
g35211
I32
sg35212
VKCa3.1 channel
p46112
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp46113
(dp46114
g35211
I151
sg35212
VFabry disease
p46115
sg35214
I13
sg35215
VC0002986
p46116
sg35217
I2
sa(dp46117
g35211
I123
sg35212
Vthoracic aortic aneurysm
p46118
sg35214
I24
sg35215
VC0162872
p46119
sg35217
I3
sasa(dp46120
g135
(dp46121
(VTCF4
p46122
Vpsychiatric disorders
p46123
tp46124
I00
ssg35204
VWe sequenced BCAs in patients with autism or related NDDs, revealing disruption of 33 loci in four general categories: (1) genes previously associated with abnormal neurodevelopment (e.g., AUTS2, FOXP1, and CDKL5), (2) single-gene contributors to microdeletion syndromes (MBD5, SATB2, EHMT1, and SNURF-SNRPN), (3) novel risk loci (e.g., CHD8, KIRREL3, and ZNF507), and (4) genes associated with later-onset psychiatric disorders (e.g., TCF4, ZNF804A, PDE10A, GRIN2B, and ANK3).
p46125
sg35206
(lp46126
(dp46127
g35211
I436
sg35212
g46122
sg35214
I4
sg35223
VP15884
p46128
sg35217
I1
sa(dp46129
g35211
I459
sg35212
VGRIN2B
p46130
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46131
g35211
I189
sg35212
VAUTS2
p46132
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46133
g35211
I296
sg35212
VSNURF-SNRPN
p46134
sg35214
I11
sg35223
VP63162
p46135
sg35217
I1
sa(dp46136
g35211
I196
sg35212
VFOXP1
p46137
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46138
g35211
I471
sg35212
VANK3
p46139
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46140
g35211
I278
sg35212
VSATB2
p46141
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46142
g35211
I356
sg35212
VZNF507
p46143
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46144
g35211
I207
sg35212
VCDKL5
p46145
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46146
g35211
I285
sg35212
VEHMT1
p46147
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46148
g35211
I272
sg35212
VMBD5
p46149
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46150
g35211
I343
sg35212
VKIRREL3
p46151
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp46152
g35211
I442
sg35212
VZNF804A
p46153
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp46154
g35211
I451
sg35212
VPDE10A
p46155
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp46156
(dp46157
g35211
I35
sg35212
Vautism
p46158
sg35214
I6
sg35215
VC0004352
p46159
sg35217
I1
sa(dp46160
g35211
I407
sg35212
g46123
sg35214
I21
sg35215
VC0004936
p46161
sg35217
I2
sa(dp46162
g35211
I261
sg35212
Vsyndromes
p46163
sg35214
I9
sg35215
VC0039082
p46164
sg35217
I1
sasa(dp46165
g135
(dp46166
(Vphosphoinositide-3-kinase
p46167
Vtranslocation
p46168
tp46169
I00
ssg35204
VTheir protein products listed below immediately suggest cell signalling pathways/processes worthy of further investigation in elucidating the mechanism of CpG 5mer activity: caspase 2, the transcription factors Atf4, Hic, HoxB3 and Rqcd1, the splicing factors Rbmx, Sfrs5 and Sfrs7, the DNA replication factors Mcm5 and Brd4, phosphoinositide-3-kinase, annexin A1, mucosa-associated lymphoid tissue lymphoma translocation 1 and three enzymes involved in protein ubiquitylation, Siah1, Gsa7 and Nin283.
p46170
sg35206
(lp46171
(dp46172
g35211
I266
sg35212
VSfrs5
p46173
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46174
g35211
I211
sg35212
VAtf4
p46175
sg35214
I4
sg35223
VP18848
p46176
sg35217
I1
sa(dp46177
g35211
I276
sg35212
VSfrs7
p46178
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46179
g35211
I232
sg35212
VRqcd1
p46180
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46181
g35211
I485
sg35212
VGsa7
p46182
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46183
g35211
I217
sg35212
VHic
p46184
sg35214
I3
sg35223
VP18136
p46185
sg35217
I1
sa(dp46186
g35211
I311
sg35212
VMcm5
p46187
sg35214
I4
sg35223
VP33992
p46188
sg35217
I1
sa(dp46189
g35211
I222
sg35212
VHoxB3
p46190
sg35214
I5
sg35223
VP14651
p46191
sg35217
I1
sa(dp46192
g35211
I320
sg35212
VBrd4
p46193
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46194
g35211
I494
sg35212
VNin283
p46195
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46196
g35211
I353
sg35212
Vannexin A1
p46197
sg35214
I10
sg35223
VP04083
p46198
sg35217
I2
sa(dp46199
g35211
I260
sg35212
VRbmx
p46200
sg35214
I4
sg35223
VP38159
p46201
sg35217
I1
sa(dp46202
g35211
I478
sg35212
VSiah1
p46203
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46204
g35211
I174
sg35212
Vcaspase 2
p46205
sg35214
I9
sg35223
VP42575
p46206
sg35217
I2
sa(dp46207
g35211
I326
sg35212
g46167
sg35214
I25
sg35223
VP33981
p46208
sg35217
I1
sasg35208
(lp46209
(dp46210
g35211
I365
sg35212
Vmucosa-associated lymphoid tissue lymphoma
p46211
sg35214
I42
sg35215
VC0242647
p46212
sg35217
I4
sa(dp46213
g35211
I408
sg35212
g46168
sg35214
I13
sg35215
VC0040715
p46214
sg35217
I1
sasa(dp46215
g35204
VMultiple cylindromas can have a syndromic association as seen in Brooke-Spiegler syndrome and familial cylindromatosis.
p46216
sg35206
(lp46217
sg35208
(lp46218
(dp46219
g35211
I9
sg35212
Vcylindromas
p46220
sg35214
I11
sg35215
VC0010606
p46221
sg35217
I1
sa(dp46222
g35211
I94
sg35212
Vfamilial cylindromatosis
p46223
sg35214
I24
sg35215
VC1851526
p46224
sg35217
I2
sa(dp46225
g35211
I65
sg35212
VBrooke-Spiegler syndrome
p46226
sg35214
I24
sg35215
VC1857941
p46227
sg35217
I2
sasa(dp46228
g35204
VA predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD.
p46229
sg35206
(lp46230
(dp46231
g35211
I146
sg35212
Vgene CYLD
p46232
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp46233
(dp46234
g35211
I29
sg35212
Vcylindromas
p46235
sg35214
I11
sg35215
VC0010606
p46236
sg35217
I1
sa(dp46237
g35211
I66
sg35212
VBrooke-Spiegler syndrome
p46238
sg35214
I24
sg35215
VC1857941
p46239
sg35217
I2
sa(dp46240
g35211
I128
sg35212
Vtumour
p46241
sg35214
I6
sg35215
VC0027651
p46242
sg35217
I1
sasa(dp46243
g35204
VPrevious studies of inherited cylindromas have highlighted the frequent presence of bi-allelic truncating CYLD mutations as a recurrent driver mutation.
p46244
sg35206
(lp46245
(dp46246
g35211
I106
sg35212
VCYLD mutations
p46247
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp46248
(dp46249
g35211
I30
sg35212
Vcylindromas
p46250
sg35214
I11
sg35215
VC0010606
p46251
sg35217
I1
sasa(dp46252
g135
(dp46253
(VMYB
p46254
Vcylindromas
p46255
tp46256
I00
ssg35204
VHere, we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of MYB activation.
p46257
sg35206
(lp46258
(dp46259
g35211
I115
sg35212
g46254
sg35214
I3
sg35223
VP10243
p46260
sg35217
I1
sa(dp46261
g35211
I80
sg35212
VCYLD
p46262
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp46263
(dp46264
g35211
I32
sg35212
g46255
sg35214
I11
sg35215
VC0010606
p46265
sg35217
I1
sasa(dp46266
g35204
VCylindroma is a rare skin tumour that is inherited in several skin-tumour syndromes caused by germline mutations in the tumour suppressor gene, CYLD.
p46267
sg35206
(lp46268
(dp46269
g35211
I144
sg35212
VCYLD
p46270
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp46271
(dp46272
g35211
I0
sg35212
VCylindroma
p46273
sg35214
I10
sg35215
VC0010606
p46274
sg35217
I1
sa(dp46275
g35211
I26
sg35212
Vtumour
p46276
sg35214
I6
sg35215
VC0027651
p46277
sg35217
I1
sa(dp46278
g35211
I26
sg35212
Vtumour
p46279
sg35214
I6
sg35215
VC0027651
p46280
sg35217
I1
sa(dp46281
g35211
I74
sg35212
Vsyndromes
p46282
sg35214
I9
sg35215
VC0039082
p46283
sg35217
I1
sa(dp46284
g35211
I21
sg35212
Vskin tumour
p46285
sg35214
I11
sg35215
VC0037286
p46286
sg35217
I2
sasa(dp46287
g135
(dp46288
(VMYB
p46289
Vcylindroma
p46290
tp46291
I00
ssg35204
VThe aims of this study were to perform a whole-exome sequencing analysis of a breast cylindroma and to investigate the role of molecular analyses in the differentiation between breast cylindroma, a benign tumour that displays MYB expression, and CYLD gene mutations, and its main differential diagnosis, the breast solid-basaloid adenoid cystic carcinoma, a malignant tumour that is characterized by the presence of the MYB-NFIB fusion gene and MYB overexpression.
p46292
sg35206
(lp46293
(dp46294
g35211
I424
sg35212
VNFIB fusion gene
p46295
sg35214
I16
sg35223
g12
sg35217
I3
sa(dp46296
g35211
I226
sg35212
VMYB
p46297
sg35214
I3
sg35223
VP10243
p46298
sg35217
I1
sa(dp46299
g35211
I226
sg35212
VMYB
p46300
sg35214
I3
sg35223
VP10243
p46301
sg35217
I1
sa(dp46302
g35211
I246
sg35212
VCYLD gene
p46303
sg35214
I9
sg35223
g12
sg35217
I2
sa(dp46304
g35211
I226
sg35212
g46289
sg35214
I3
sg35223
VP10243
p46305
sg35217
I1
sasg35208
(lp46306
(dp46307
g35211
I330
sg35212
Vadenoid cystic carcinoma
p46308
sg35214
I24
sg35215
VC0010606
p46309
sg35217
I3
sa(dp46310
g35211
I358
sg35212
Vmalignant tumour
p46311
sg35214
I16
sg35215
VC0006826
p46312
sg35217
I2
sa(dp46313
g35211
I85
sg35212
Vcylindroma
p46314
sg35214
I10
sg35215
VC0010606
p46315
sg35217
I1
sa(dp46316
g35211
I198
sg35212
Vbenign tumour
p46317
sg35214
I13
sg35215
VC0086692
p46318
sg35217
I2
sa(dp46319
g35211
I85
sg35212
g46290
sg35214
I10
sg35215
VC0010606
p46320
sg35217
I1
sasa(dp46321
g35204
VThe clinical presentation of multiple, rare, skin appendage tumours called cylindromas has been attributed to germline mutations in the tumour suppressor gene CYLD (OMIM 605018).
p46322
sg35206
(lp46323
(dp46324
g35211
I159
sg35212
VCYLD
p46325
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp46326
(dp46327
g35211
I75
sg35212
Vcylindromas
p46328
sg35214
I11
sg35215
VC0010606
p46329
sg35217
I1
sa(dp46330
g35211
I60
sg35212
Vtumour
p46331
sg35214
I6
sg35215
VC0027651
p46332
sg35217
I1
sa(dp46333
g35211
I60
sg35212
Vtumours
p46334
sg35214
I7
sg35215
VC0027651
p46335
sg35217
I1
sasa(dp46336
g35204
VBrooke-Spiegler Syndrome (BSS), familial cylindromatosis (FC) and multiple familial trichoepitheliomas (MFT) (OMIM #605041, #132700, #601606 respectively) differ due to the types of other skin appendage tumour seen together with cylindroma, such as spiradenoma and trichoepithelioma.
p46337
sg35206
(lp46338
sg35208
(lp46339
(dp46340
g35211
I84
sg35212
Vtrichoepithelioma
p46341
sg35214
I17
sg35215
VC0349658
p46342
sg35217
I1
sa(dp46343
g35211
I84
sg35212
Vtrichoepitheliomas
p46344
sg35214
I18
sg35215
VC0349658
p46345
sg35217
I1
sa(dp46346
g35211
I41
sg35212
Vcylindroma
p46347
sg35214
I10
sg35215
VC0010606
p46348
sg35217
I1
sa(dp46349
g35211
I188
sg35212
Vskin appendage tumour
p46350
sg35214
I21
sg35215
VC0345988
p46351
sg35217
I3
sa(dp46352
g35211
I32
sg35212
Vfamilial cylindromatosis
p46353
sg35214
I24
sg35215
VC1851526
p46354
sg35217
I2
sa(dp46355
g35211
I58
sg35212
VFC
p46356
sg35214
I2
sg35215
VC1851526
p46357
sg35217
I1
sa(dp46358
g35211
I249
sg35212
Vspiradenoma
p46359
sg35214
I11
sg35215
VC0334347
p46360
sg35217
I1
sa(dp46361
g35211
I0
sg35212
VBrooke-Spiegler Syndrome
p46362
sg35214
I24
sg35215
VC1857941
p46363
sg35217
I2
sa(dp46364
g35211
I26
sg35212
VBSS
p46365
sg35214
I3
sg35215
VC1857941
p46366
sg35217
I1
sasa(dp46367
g35204
VUnique tumors included a cutaneous cylindroma invasive of skull convexity occurring in familial cylindromatosis and a ganglioneuroma of the middle ear with massive bilateral skull base extension.
p46368
sg35206
(lp46369
sg35208
(lp46370
(dp46371
g35211
I118
sg35212
Vganglioneuroma
p46372
sg35214
I14
sg35215
VC0017075
p46373
sg35217
I1
sa(dp46374
g35211
I87
sg35212
Vfamilial cylindromatosis
p46375
sg35214
I24
sg35215
VC1851526
p46376
sg35217
I2
sa(dp46377
g35211
I35
sg35212
Vcylindroma
p46378
sg35214
I10
sg35215
VC0010606
p46379
sg35217
I1
sa(dp46380
g35211
I7
sg35212
Vtumors
p46381
sg35214
I6
sg35215
VC0027651
p46382
sg35217
I1
sasa(dp46383
g35204
VThis review will examine and extrapolate from the recent literature to build support for the use of AXT in mitigating neuropathy in normal aging and neurodegenerative disease.
p46384
sg35206
(lp46385
(dp46386
g35211
I100
sg35212
VAXT
p46387
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp46388
(dp46389
g35211
I149
sg35212
Vneurodegenerative disease
p46390
sg35214
I25
sg35215
VC0524851
p46391
sg35217
I2
sa(dp46392
g35211
I118
sg35212
Vneuropathy
p46393
sg35214
I10
sg35215
VC0442874
p46394
sg35217
I1
sasa(dp46395
g135
(dp46396
(VBlk
p46397
Vautoimmune diseases
p46398
tp46399
I00
ssg35204
VWe investigated frequencies of single nucleotide polymorphisms (SNPs) in the candidate genes protein tyrosine phosphatase, non-receptor type 22 (PTPN22), B-cell scaffold protein with ankyrin repeats (BANK1), B lymphocyte kinase (Blk), and Fc gamma receptor class IIB (FCGR2B), which have been found to be associated with other autoimmune diseases, CD1A and CD1E, important for antigen presentation of glycolipids, and transient axonal glycoprotein 1 (TAG-1), which is associated with responsiveness to intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
p46400
sg35206
(lp46401
(dp46402
g35211
I348
sg35212
VCD1A
p46403
sg35214
I4
sg35223
VP15813
p46404
sg35217
I1
sa(dp46405
g35211
I200
sg35212
VBANK1
p46406
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46407
g35211
I514
sg35212
Vimmunoglobulin
p46408
sg35214
I14
sg35223
g12
sg35217
I1
sa(dp46409
g35211
I208
sg35212
VB lymphocyte kinase
p46410
sg35214
I19
sg35223
VP51451
p46411
sg35217
I3
sa(dp46412
g35211
I87
sg35212
Vgenes protein tyrosine phosphatase
p46413
sg35214
I34
sg35223
VP60484
p46414
sg35217
I4
sa(dp46415
g35211
I418
sg35212
Vtransient axonal glycoprotein 1
p46416
sg35214
I31
sg35223
g12
sg35217
I4
sa(dp46417
g35211
I268
sg35212
VFCGR2B
p46418
sg35214
I6
sg35223
VP31995
p46419
sg35217
I1
sa(dp46420
g35211
I239
sg35212
VFc gamma receptor class IIB
p46421
sg35214
I27
sg35223
VP12314
p46422
sg35217
I5
sa(dp46423
g35211
I145
sg35212
VPTPN22
p46424
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46425
g35211
I183
sg35212
Vankyrin
p46426
sg35214
I7
sg35223
VP16157
p46427
sg35217
I1
sa(dp46428
g35211
I451
sg35212
VTAG-1
p46429
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46430
g35211
I229
sg35212
g46397
sg35214
I3
sg35223
VP51451
p46431
sg35217
I1
sa(dp46432
g35211
I123
sg35212
Vnon-receptor type 22
p46433
sg35214
I20
sg35223
g12
sg35217
I3
sasg35208
(lp46434
(dp46435
g35211
I546
sg35212
Vchronic inflammatory demyelinating polyneuropathy
p46436
sg35214
I49
sg35215
VC0393819
p46437
sg35217
I4
sa(dp46438
g35211
I451
sg35212
VTAG
p46439
sg35214
I3
sg35215
VC0037293
p46440
sg35217
I1
sa(dp46441
g35211
I327
sg35212
g46398
sg35214
I19
sg35215
VC0004364
p46442
sg35217
I2
sasa(dp46443
g35204
VTo investigate the clinical features of A-pattern exotropia and to evaluate the efficacy of surgical treatment for the correction of A-pattern exotropia (A-XT).
p46444
sg35206
(lp46445
sg35208
(lp46446
(dp46447
g35211
I50
sg35212
Vexotropia
p46448
sg35214
I9
sg35215
VC0015310
p46449
sg35217
I1
sa(dp46450
g35211
I50
sg35212
Vexotropia
p46451
sg35214
I9
sg35215
VC0015310
p46452
sg35217
I1
sasa(dp46453
g35204
VWe identified 10 patients from three CA and from two GMS families with WDR73 mutations including the original family described with CA, mental retardation, optic atrophy, and skin abnormalities (CAMOS).
p46454
sg35206
(lp46455
(dp46456
g35211
I71
sg35212
VWDR73
p46457
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp46458
(dp46459
g35211
I136
sg35212
Vmental retardation
p46460
sg35214
I18
sg35215
VC0025362
p46461
sg35217
I2
sa(dp46462
g35211
I156
sg35212
Voptic atrophy
p46463
sg35214
I13
sg35215
VC0029124
p46464
sg35217
I2
sa(dp46465
g35211
I175
sg35212
Vskin abnormalities
p46466
sg35214
I18
sg35215
VC0037268
p46467
sg35217
I2
sa(dp46468
g35211
I195
sg35212
VCAMOS
p46469
sg35214
I5
sg35215
VC1847114
p46470
sg35217
I1
sasa(dp46471
g35204
VCAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities) is a rare autosomal recessive syndrome characterized by a nonprogressive congenital cerebellar ataxia associated with mental retardation, optic atrophy, and skin abnormalities.
p46472
sg35206
(lp46473
sg35208
(lp46474
(dp46475
g35211
I161
sg35212
Vcongenital cerebellar ataxia
p46476
sg35214
I28
sg35215
VC0852975
p46477
sg35217
I3
sa(dp46478
g35211
I206
sg35212
Vmental retardation
p46479
sg35214
I18
sg35215
VC0025362
p46480
sg35217
I2
sa(dp46481
g35211
I118
sg35212
Vsyndrome
p46482
sg35214
I8
sg35215
VC0039082
p46483
sg35217
I1
sa(dp46484
g35211
I0
sg35212
VCAMOS
p46485
sg35214
I5
sg35215
VC1847114
p46486
sg35217
I1
sa(dp46487
g35211
I30
sg35212
VMental retardation
p46488
sg35214
I18
sg35215
VC0025362
p46489
sg35217
I2
sa(dp46490
g35211
I226
sg35212
Voptic atrophy
p46491
sg35214
I13
sg35215
VC0029124
p46492
sg35217
I2
sa(dp46493
g35211
I7
sg35212
VCerebellar Ataxia
p46494
sg35214
I17
sg35215
VC0007758
p46495
sg35217
I2
sa(dp46496
g35211
I68
sg35212
VSkin abnormalities
p46497
sg35214
I18
sg35215
VC0037268
p46498
sg35217
I2
sa(dp46499
g35211
I50
sg35212
VOptic atrophy
p46500
sg35214
I13
sg35215
VC0029124
p46501
sg35217
I2
sa(dp46502
g35211
I245
sg35212
Vskin abnormalities
p46503
sg35214
I18
sg35215
VC0037268
p46504
sg35217
I2
sasa(dp46505
g35204
VEyes with laser-treated threshold ROP had significant myopia at both ages (mean spherical equivalent [MSE] in right eye at both refractions -0.72, -1.21 diopters [D]), astigmatism (MSE -1.62, -1.80 D), and anisometropia (MSE 0.82, 1.02 D; ANOVA p &lt; 0.05), and increased refractive errors across ages (paired t test p &lt; 0.05).
p46506
sg35206
(lp46507
sg35208
(lp46508
(dp46509
g35211
I54
sg35212
Vmyopia
p46510
sg35214
I6
sg35215
VC0027092
p46511
sg35217
I1
sa(dp46512
g35211
I206
sg35212
Vanisometropia
p46513
sg35214
I13
sg35215
VC0003081
p46514
sg35217
I1
sa(dp46515
g35211
I168
sg35212
Vastigmatism
p46516
sg35214
I11
sg35215
VC0004106
p46517
sg35217
I1
sa(dp46518
g35211
I273
sg35212
Vrefractive errors
p46519
sg35214
I17
sg35215
VC0034951
p46520
sg35217
I2
sa(dp46521
g35211
I34
sg35212
VROP
p46522
sg35214
I3
sg35215
VC0035344
p46523
sg35217
I1
sasa(dp46524
g35204
VMonocular deprivation does affect the binding parameters (KD and Bmax) of GluRs, which may be a molecular mechanism of the development of amblyopia.
p46525
sg35206
(lp46526
sg35208
(lp46527
sa(dp46528
g135
(dp46529
(Vcalbindin D-28k
p46530
VGCL
p46531
tp46532
I00
ssg35204
VExpressions of GluRs and CaBPs (i.e., parvalbumin and calbindin D-28k) were observed to be increased in the retinal ganglion cell layer (GCL) and inner nuclear layer (INL) at 3 days and 1 week after the onset of glaucoma.
p46533
sg35206
(lp46534
(dp46535
g35211
I38
sg35212
Vparvalbumin
p46536
sg35214
I11
sg35223
VP20472
p46537
sg35217
I1
sa(dp46538
g35211
I54
sg35212
g46530
sg35214
I15
sg35223
VP05937
p46539
sg35217
I2
sasg35208
(lp46540
(dp46541
g35211
I116
sg35212
Vganglion cell layer
p46542
sg35214
I19
sg35215
VC0023521
p46543
sg35217
I3
sa(dp46544
g35211
I212
sg35212
Vglaucoma
p46545
sg35214
I8
sg35215
VC0017601
p46546
sg35217
I1
sa(dp46547
g35211
I137
sg35212
g46531
sg35214
I3
sg35215
VC0023521
p46548
sg35217
I1
sasa(dp46549
g35204
VThe finding that both NMDA and non-NMDA GluRs were involved in glutamate-induced excitotoxicity suggests that isolated pig RGCs provide a good model for glaucoma.
p46550
sg35206
(lp46551
sg35208
(lp46552
(dp46553
g35211
I153
sg35212
Vglaucoma
p46554
sg35214
I8
sg35215
VC0017601
p46555
sg35217
I1
sasa(dp46556
g135
(dp46557
(VERCC1
p46558
VXPF
p46559
tp46560
I00
ssg35204
VUSP45 associates with ERCC1, a subunit of the DNA repair endonuclease XPF-ERCC1, via a short acidic motif outside of the USP45 catalytic domain.
p46561
sg35206
(lp46562
(dp46563
g35211
I22
sg35212
VERCC1
p46564
sg35214
I5
sg35223
VP07992
p46565
sg35217
I1
sa(dp46566
g35211
I46
sg35212
VDNA repair endonuclease XPF
p46567
sg35214
I27
sg35223
g12
sg35217
I4
sa(dp46568
g35211
I22
sg35212
g46558
sg35214
I5
sg35223
VP07992
p46569
sg35217
I1
sa(dp46570
g35211
I0
sg35212
VUSP45
p46571
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46572
g35211
I121
sg35212
VUSP45 catalytic domain
p46573
sg35214
I22
sg35223
g12
sg35217
I3
sasg35208
(lp46574
(dp46575
g35211
I70
sg35212
g46559
sg35214
I3
sg35215
VC0268140
p46576
sg35217
I1
sasa(dp46577
g135
(dp46578
(VERCC1
p46579
VXPF
p46580
tp46581
I00
ssg35204
VFinally, USP45 localises to sites of DNA damage in a manner dependent on its deubiquitylase activity, but independent of its ability to bind ERCC1-XPF.
p46582
sg35206
(lp46583
(dp46584
g35211
I147
sg35212
VXPF
p46585
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp46586
g35211
I141
sg35212
g46579
sg35214
I5
sg35223
VP07992
p46587
sg35217
I1
sa(dp46588
g35211
I9
sg35212
VUSP45
p46589
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp46590
(dp46591
g35211
I37
sg35212
VDNA damage
p46592
sg35214
I10
sg35215
VC0012860
p46593
sg35217
I2
sa(dp46594
g35211
I147
sg35212
g46580
sg35214
I3
sg35215
VC0268140
p46595
sg35217
I1
sasa(dp46596
g35204
VTogether, these results establish USP45 as a new regulator of XPF-ERCC1 crucial for efficient DNA repair.
p46597
sg35206
(lp46598
(dp46599
g35211
I34
sg35212
VUSP45
p46600
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp46601
g35211
I62
sg35212
VXPF-ERCC1
p46602
sg35214
I9
sg35223
g12
sg35217
I1
sasg35208
(lp46603
(dp46604
g35211
I62
sg35212
VXPF
p46605
sg35214
I3
sg35215
VC0268140
p46606
sg35217
I1
sasa(dp46607
g135
(dp46608
(VSOX2
p46609
VBeta-Thal
p46610
tp46611
I00
ssg35204
VWe used a polycistronic lentiviral vector (hSTEMCCA-loxP) encoding OCT4, SOX2, KLF4, and cMYC genes and containing loxP sites, excisible by Cre recombinase, to reprogram patient-specific fetal cells derived from prenatal diagnosis for several genetic disorders, such as myotonic dystrophy type 1 (DM1), Beta-thalassemia (Beta-Thal), lymphedema-distichiasis syndrome (LDS), spinal muscular atrophy (SMA), cystic fibrosis (CF), as well as from wild-type (WT) fetal cells.
p46612
sg35206
(lp46613
(dp46614
g35211
I297
sg35212
VDM1
p46615
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp46616
g35211
I140
sg35212
VCre recombinase
p46617
sg35214
I15
sg35223
g12
sg35217
I2
sa(dp46618
g35211
I79
sg35212
VKLF4
p46619
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46620
g35211
I270
sg35212
Vmyotonic dystrophy type 1
p46621
sg35214
I25
sg35223
g12
sg35217
I4
sa(dp46622
g35211
I89
sg35212
VcMYC genes
p46623
sg35214
I10
sg35223
VP01893
p46624
sg35217
I2
sa(dp46625
g35211
I73
sg35212
g46609
sg35214
I4
sg35223
VP48431
p46626
sg35217
I1
sasg35208
(lp46627
(dp46628
g35211
I333
sg35212
Vlymphedema-distichiasis syndrome
p46629
sg35214
I32
sg35215
VC0265345
p46630
sg35217
I2
sa(dp46631
g35211
I421
sg35212
VCF
p46632
sg35214
I2
sg35215
VC0010674
p46633
sg35217
I1
sa(dp46634
g35211
I270
sg35212
Vmyotonic dystrophy
p46635
sg35214
I18
sg35215
VC0027126
p46636
sg35217
I2
sa(dp46637
g35211
I404
sg35212
Vcystic fibrosis
p46638
sg35214
I15
sg35215
VC0010674
p46639
sg35217
I2
sa(dp46640
g35211
I243
sg35212
Vgenetic disorders
p46641
sg35214
I17
sg35215
VC0019247
p46642
sg35217
I2
sa(dp46643
g35211
I297
sg35212
VDM1
p46644
sg35214
I3
sg35215
VC2931688
p46645
sg35217
I1
sa(dp46646
g35211
I303
sg35212
VBeta-thalassemia
p46647
sg35214
I16
sg35215
VC0005283
p46648
sg35217
I1
sa(dp46649
g35211
I398
sg35212
VSMA
p46650
sg35214
I3
sg35215
VC0026847
p46651
sg35217
I1
sa(dp46652
g35211
I373
sg35212
Vspinal muscular atrophy
p46653
sg35214
I23
sg35215
VC0026847
p46654
sg35217
I3
sa(dp46655
g35211
I367
sg35212
VLDS
p46656
sg35214
I3
sg35215
VC0265345
p46657
sg35217
I1
sa(dp46658
g35211
I321
sg35212
g46610
sg35214
I9
sg35215
VC0005283
p46659
sg35217
I1
sasa(dp46660
g35204
VTwelve CpG loci (11 genes) showed greater than 10% comparative difference in DNA methylation, including hyper-methylated loci of FAM181A, MRI1, PIWIL1, CHFR, DEFA1, MRPL28, AURKA, and hypo-methylated loci of NALP1L5, MAP8KIP3, ACAT2, and PM20D1 in maternal asthma.
p46661
sg35206
(lp46662
(dp46663
g35211
I173
sg35212
VAURKA
p46664
sg35214
I5
sg35223
VP17038
p46665
sg35217
I1
sa(dp46666
g35211
I138
sg35212
VMRI1
p46667
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46668
g35211
I129
sg35212
VFAM181A
p46669
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp46670
g35211
I144
sg35212
VPIWIL1
p46671
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46672
g35211
I165
sg35212
VMRPL28
p46673
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46674
g35211
I152
sg35212
VCHFR
p46675
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46676
g35211
I238
sg35212
VPM20D1
p46677
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp46678
g35211
I158
sg35212
VDEFA1
p46679
sg35214
I5
sg35223
VP59665
p46680
sg35217
I1
sa(dp46681
g35211
I227
sg35212
VACAT2
p46682
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp46683
(dp46684
g35211
I257
sg35212
Vasthma
p46685
sg35214
I6
sg35215
VC0004096
p46686
sg35217
I1
sasa(dp46687
g35204
VSystemic expression of DEFA1,1B,3,4,CTSG and ELA2 was significantly higher in the neutrophilic asthma (NA) phenotype.
p46688
sg35206
(lp46689
(dp46690
g35211
I45
sg35212
VELA2
p46691
sg35214
I4
sg35223
VP08246
p46692
sg35217
I1
sa(dp46693
g35211
I23
sg35212
VDEFA1
p46694
sg35214
I5
sg35223
VP59665
p46695
sg35217
I1
sa(dp46696
g35211
I36
sg35212
VCTSG
p46697
sg35214
I4
sg35223
VP08311
p46698
sg35217
I1
sasg35208
(lp46699
(dp46700
g35211
I103
sg35212
VNA
p46701
sg35214
I2
sg35215
VC2363774
p46702
sg35217
I1
sa(dp46703
g35211
I82
sg35212
Vneutrophilic asthma
p46704
sg35214
I19
sg35215
VC2363774
p46705
sg35217
I2
sasa(dp46706
g135
(dp46707
(VUGT1A1
p46708
Valpha thalassemia
p46709
tp46710
I00
ssg35204
VThe objective of this study was to determine the combined influence of alpha thalassemia, fetal hemoglobin, and the UGT1A1 polymorphism on serum bilirubin levels and cholelithiasis in patients with sickle cell disease.
p46711
sg35206
(lp46712
(dp46713
g35211
I90
sg35212
Vfetal hemoglobin
p46714
sg35214
I16
sg35223
VP14207
p46715
sg35217
I2
sa(dp46716
g35211
I116
sg35212
g46708
sg35214
I6
sg35223
VP35504
p46717
sg35217
I1
sasg35208
(lp46718
(dp46719
g35211
I198
sg35212
Vsickle cell disease
p46720
sg35214
I19
sg35215
VC0002895
p46721
sg35217
I3
sa(dp46722
g35211
I166
sg35212
Vcholelithiasis
p46723
sg35214
I14
sg35215
VC0008350
p46724
sg35217
I1
sa(dp46725
g35211
I71
sg35212
g46709
sg35214
I17
sg35215
VC0002312
p46726
sg35217
I2
sasa(dp46727
g35204
VThe present study investigated the role of several genetic factors (UGT1A1 promoter (TA)n repeat polymorphism, alpha-globin status), hematological parameters, clinical severity, and hydroxyurea (HU) therapy on the occurrence of cholelithiasis in SCD.
p46728
sg35206
(lp46729
(dp46730
g35211
I111
sg35212
Valpha-globin
p46731
sg35214
I12
sg35223
VP69905
p46732
sg35217
I1
sasg35208
(lp46733
(dp46734
g35211
I246
sg35212
VSCD
p46735
sg35214
I3
sg35215
VC0002895
p46736
sg35217
I1
sa(dp46737
g35211
I228
sg35212
Vcholelithiasis
p46738
sg35214
I14
sg35215
VC0008350
p46739
sg35217
I1
sasa(dp46740
g35204
VWe confirmed that alpha-thalassemia and low basal reticulocyte (RET) count were independent protective factors for cholelithiasis while 7/7, 8/8 and 7/8 UGT1A1 (TA)n genotypes were independent predisposing factors for this complication.
p46741
sg35206
(lp46742
sg35208
(lp46743
(dp46744
g35211
I18
sg35212
Valpha-thalassemia
p46745
sg35214
I17
sg35215
VC0002312
p46746
sg35217
I1
sa(dp46747
g35211
I115
sg35212
Vcholelithiasis
p46748
sg35214
I14
sg35215
VC0008350
p46749
sg35217
I1
sa(dp46750
g35211
I223
sg35212
Vcomplication
p46751
sg35214
I12
sg35215
VC0009566
p46752
sg35217
I1
sasa(dp46753
g135
(dp46754
(VUGT1A1 gene A
p46755
Vcholelithiasis
p46756
tp46757
I00
ssg35204
VWe explored the potential relationship between steady state serum bilirubin levels and the incidence of cholelithiasis in the context of UGT1A1 gene A(TA)nTAA promoter polymorphism in Omani sickle cell anemia (SCA) patients, homozygotes for African (Benin and Bantu) and Arab-Indian Beta(S) haplotypes, but sharing the same microgeographical environment and comparable life style factors.
p46758
sg35206
(lp46759
(dp46760
g35211
I137
sg35212
g46755
sg35214
I13
sg35223
VP35504
p46761
sg35217
I3
sasg35208
(lp46762
(dp46763
g35211
I210
sg35212
VSCA
p46764
sg35214
I3
sg35215
VC0002895
p46765
sg35217
I1
sa(dp46766
g35211
I190
sg35212
Vsickle cell anemia
p46767
sg35214
I18
sg35215
VC0002895
p46768
sg35217
I3
sa(dp46769
g35211
I104
sg35212
g46756
sg35214
I14
sg35215
VC0008350
p46770
sg35217
I1
sasa(dp46771
g135
(dp46772
(VUGT1A1
p46773
Vcholelithiasis
p46774
tp46775
I00
ssg35204
VThus, not cholelithiasis but total serum bilirubin was influenced by UGT1A1 polymorphism in this SCA cohort.
p46776
sg35206
(lp46777
(dp46778
g35211
I69
sg35212
g46773
sg35214
I6
sg35223
VP35504
p46779
sg35217
I1
sasg35208
(lp46780
(dp46781
g35211
I10
sg35212
g46774
sg35214
I14
sg35215
VC0008350
p46782
sg35217
I1
sasa(dp46783
g135
(dp46784
(VUGT1A1
p46785
Vcholelithiasis
p46786
tp46787
I00
ssg35204
VAltogether our data provide the implication of UGT1A1 and SLCO1A2 in sickle cell anemia-related cholelithiasis.
p46788
sg35206
(lp46789
(dp46790
g35211
I58
sg35212
VSLCO1A2
p46791
sg35214
I7
sg35223
VP46721
p46792
sg35217
I1
sa(dp46793
g35211
I47
sg35212
g46785
sg35214
I6
sg35223
VP35504
p46794
sg35217
I1
sasg35208
(lp46795
(dp46796
g35211
I69
sg35212
Vsickle cell anemia
p46797
sg35214
I18
sg35215
VC0002895
p46798
sg35217
I3
sa(dp46799
g35211
I96
sg35212
g46786
sg35214
I14
sg35215
VC0008350
p46800
sg35217
I1
sasa(dp46801
g135
(dp46802
(VUGT1A1 gene promoter
p46803
VSCA
p46804
tp46805
I00
ssg35204
VPresent study was aimed to explore the effect of (TA)n UGT1A1 gene promoter polymorphism on bilirubin metabolism, bilirubinaemia, predisposition to cholelithiasis and subsequent cholecystectomy, in Sickle-Cell Anemia (SCA) and beta-Thalasemia major (bTH) in Kuwaiti subjects compared to other population.
p46806
sg35206
(lp46807
(dp46808
g35211
I55
sg35212
g46803
sg35214
I20
sg35223
VP35504
p46809
sg35217
I3
sasg35208
(lp46810
(dp46811
g35211
I198
sg35212
VSickle-Cell Anemia
p46812
sg35214
I18
sg35215
VC0002895
p46813
sg35217
I2
sa(dp46814
g35211
I114
sg35212
Vbilirubinaemia
p46815
sg35214
I14
sg35215
VC0020433
p46816
sg35217
I1
sa(dp46817
g35211
I148
sg35212
Vcholelithiasis
p46818
sg35214
I14
sg35215
VC0008350
p46819
sg35217
I1
sa(dp46820
g35211
I218
sg35212
g46804
sg35214
I3
sg35215
VC0002895
p46821
sg35217
I1
sasa(dp46822
g135
(dp46823
(VUGT1A1
p46824
Vcholelithiasis
p46825
tp46826
I00
ssg35204
VOur results confirm UGT1A1 (TA)7 allele as one of the factors accounting for the hyperbilirubinemia and cholelithiasis observed in SCA and bTH.
p46827
sg35206
(lp46828
(dp46829
g35211
I20
sg35212
g46824
sg35214
I6
sg35223
VP35504
p46830
sg35217
I1
sasg35208
(lp46831
(dp46832
g35211
I81
sg35212
Vhyperbilirubinemia
p46833
sg35214
I18
sg35215
VC0020433
p46834
sg35217
I1
sa(dp46835
g35211
I104
sg35212
g46825
sg35214
I14
sg35215
VC0008350
p46836
sg35217
I1
sasa(dp46837
g135
(dp46838
(VUGT1A1 promoter
p46839
Vcholelithiasis
p46840
tp46841
I00
ssg35204
VWe analyzed the polymorphism A(TA)nTAA at the UGT1A1 promoter and the relationships between the various A(TA)nTAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p46842
sg35206
(lp46843
(dp46844
g35211
I46
sg35212
g46839
sg35214
I15
sg35223
VP35504
p46845
sg35217
I2
sasg35208
(lp46846
(dp46847
g35211
I175
sg35212
g46840
sg35214
I14
sg35215
VC0008350
p46848
sg35217
I1
sasa(dp46849
g135
(dp46850
(VUGT1A1 promoter
p46851
VTAA
p46852
tp46853
I00
ssg35204
VWe analyzed the polymorphism A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA at the UGT1A1 promoter and the relationships between the various A(TA)&lt;formula&gt;_{n}&lt;/formula&gt; TAA genotypes and alleles and bilirubin levels and occurrence of cholelithiasis.
p46854
sg35206
(lp46855
(dp46856
g35211
I81
sg35212
g46851
sg35214
I15
sg35223
VP35504
p46857
sg35217
I2
sasg35208
(lp46858
(dp46859
g35211
I245
sg35212
Vcholelithiasis
p46860
sg35214
I14
sg35215
VC0008350
p46861
sg35217
I1
sa(dp46862
g35211
I70
sg35212
VTAA
p46863
sg35214
I3
sg35215
VC0162872
p46864
sg35217
I1
sa(dp46865
g35211
I70
sg35212
g46852
sg35214
I3
sg35215
VC0162872
p46866
sg35217
I1
sasa(dp46867
g35204
VThe ADP-ribosyltransferase 3 gene (ART3) has been reported to be associated with non-obstructive azoospermia (NOA) in the Japanese population.
p46868
sg35206
(lp46869
(dp46870
g35211
I35
sg35212
VART3
p46871
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46872
g35211
I4
sg35212
VADP-ribosyltransferase 3 gene
p46873
sg35214
I29
sg35223
g12
sg35217
I3
sasg35208
(lp46874
(dp46875
g35211
I97
sg35212
Vazoospermia
p46876
sg35214
I11
sg35215
VC1321542
p46877
sg35217
I1
sasa(dp46878
g35204
VA recent Japanese study provided evidence that the rs6836703: G&gt;A single-nucleotide polymorphism (SNP) from the ADP-ribosyltransferase 3 (ART3) gene is significantly associated with non-obstructive azoospermia.
p46879
sg35206
(lp46880
(dp46881
g35211
I115
sg35212
VADP-ribosyltransferase 3
p46882
sg35214
I24
sg35223
g12
sg35217
I2
sa(dp46883
g35211
I141
sg35212
VART3
p46884
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp46885
(dp46886
g35211
I201
sg35212
Vazoospermia
p46887
sg35214
I11
sg35215
VC1321542
p46888
sg35217
I1
sasa(dp46889
g35204
VThe analysis of genes involved in hereditary spherocytosis, by next-generation sequencing in two patients with clinical diagnosis of the disease, showed the presence of the c.1795+1G&gt;A mutation in the SPTB gene.
p46890
sg35206
(lp46891
(dp46892
g35211
I204
sg35212
VSPTB gene
p46893
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp46894
(dp46895
g35211
I34
sg35212
Vhereditary spherocytosis
p46896
sg35214
I24
sg35215
VC0037889
p46897
sg35217
I2
sasa(dp46898
g135
(dp46899
(Vanion exchanger 1
p46900
VHereditary spherocytosis
p46901
tp46902
I00
ssg35204
VHereditary spherocytosis stems from mutations in one of the genes encoding ankyrin-1 (ANKI), alpha spectrin (SPTA1) and beta spectrin (SPTB), the anion exchanger 1 (SLC4A 1), and protein 4.2 (EPB42).
p46903
sg35206
(lp46904
(dp46905
g35211
I120
sg35212
Vbeta spectrin
p46906
sg35214
I13
sg35223
VP11277
p46907
sg35217
I2
sa(dp46908
g35211
I93
sg35212
Valpha spectrin
p46909
sg35214
I14
sg35223
VP02549
p46910
sg35217
I2
sa(dp46911
g35211
I192
sg35212
VEPB42
p46912
sg35214
I5
sg35223
VP16452
p46913
sg35217
I1
sa(dp46914
g35211
I86
sg35212
VANKI
p46915
sg35214
I4
sg35223
VP16157
p46916
sg35217
I1
sa(dp46917
g35211
I135
sg35212
VSPTB
p46918
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46919
g35211
I109
sg35212
VSPTA1
p46920
sg35214
I5
sg35223
VP02549
p46921
sg35217
I1
sa(dp46922
g35211
I75
sg35212
Vankyrin-1
p46923
sg35214
I9
sg35223
VP16157
p46924
sg35217
I1
sa(dp46925
g35211
I179
sg35212
Vprotein 4.2
p46926
sg35214
I11
sg35223
VP01031
p46927
sg35217
I2
sa(dp46928
g35211
I146
sg35212
g46900
sg35214
I17
sg35223
VP02730
p46929
sg35217
I3
sasg35208
(lp46930
(dp46931
g35211
I0
sg35212
g46901
sg35214
I24
sg35215
VC0037889
p46932
sg35217
I2
sasa(dp46933
g135
(dp46934
(Vprotein 4.2
p46935
Vhereditary spherocytosis
p46936
tp46937
I00
ssg35204
VWe also investigated methylation profiles in peripheral blood mononuclear cells from patients with red cell membrane diseases, such as complete protein 4.2 deficiency due to ELB42 mutations, hereditary spherocytosis with EPB3 mutations, and hereditary elliptocytosis with SPTB mutations.
p46938
sg35206
(lp46939
(dp46940
g35211
I221
sg35212
VEPB3 mutations
p46941
sg35214
I14
sg35223
VP02730
p46942
sg35217
I2
sa(dp46943
g35211
I272
sg35212
VSPTB
p46944
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp46945
g35211
I144
sg35212
g46935
sg35214
I11
sg35223
VP01031
p46946
sg35217
I2
sasg35208
(lp46947
(dp46948
g35211
I241
sg35212
Vhereditary elliptocytosis
p46949
sg35214
I25
sg35215
VC0013902
p46950
sg35217
I2
sa(dp46951
g35211
I191
sg35212
g46936
sg35214
I24
sg35215
VC0037889
p46952
sg35217
I2
sasa(dp46953
g135
(dp46954
(Vankyrin
p46955
VHS
p46956
tp46957
I00
ssg35204
VThe mutations of most cases of hereditary spherocytosis (HS) are located in the following genes: ANK1, SPTB, SLC4A1, EPB42 and SPTA1, which encode ankyrin, spectrin beta-chain, the anion exchanger 1 (band 3), protein 4.2 and spectrin alpha-chain, respectively.
p46958
sg35206
(lp46959
(dp46960
g35211
I97
sg35212
VANK1
p46961
sg35214
I4
sg35223
VP16157
p46962
sg35217
I1
sa(dp46963
g35211
I156
sg35212
Vspectrin beta-chain
p46964
sg35214
I19
sg35223
g12
sg35217
I2
sa(dp46965
g35211
I109
sg35212
VSLC4A1
p46966
sg35214
I6
sg35223
VP02730
p46967
sg35217
I1
sa(dp46968
g35211
I209
sg35212
Vprotein 4.2
p46969
sg35214
I11
sg35223
VP01031
p46970
sg35217
I2
sa(dp46971
g35211
I117
sg35212
VEPB42
p46972
sg35214
I5
sg35223
VP16452
p46973
sg35217
I1
sa(dp46974
g35211
I225
sg35212
Vspectrin alpha-chain
p46975
sg35214
I20
sg35223
VP55899
p46976
sg35217
I2
sa(dp46977
g35211
I127
sg35212
VSPTA1
p46978
sg35214
I5
sg35223
VP02549
p46979
sg35217
I1
sa(dp46980
g35211
I147
sg35212
g46955
sg35214
I7
sg35223
VP16157
p46981
sg35217
I1
sa(dp46982
g35211
I103
sg35212
VSPTB
p46983
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp46984
(dp46985
g35211
I31
sg35212
Vhereditary spherocytosis
p46986
sg35214
I24
sg35215
VC0037889
p46987
sg35217
I2
sa(dp46988
g35211
I57
sg35212
g46956
sg35214
I2
sg35215
VC0037889
p46989
sg35217
I1
sasa(dp46990
g135
(dp46991
(Vbone morphogenetic protein 1
p46992
Vosteogenesis imperfecta
p46993
tp46994
I00
ssg35204
VMutations in bone morphogenetic protein 1 (BMP1) in humans or deletion of BMP1 and related protease tolloid like 1 (TLL1) in mice lead to osteogenesis imperfecta (OI).
p46995
sg35206
(lp46996
(dp46997
g35211
I43
sg35212
VBMP1
p46998
sg35214
I4
sg35223
VP14222
p46999
sg35217
I1
sa(dp47000
g35211
I100
sg35212
Vtolloid like 1
p47001
sg35214
I14
sg35223
g12
sg35217
I3
sa(dp47002
g35211
I116
sg35212
VTLL1
p47003
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47004
g35211
I74
sg35212
VBMP1 and related protease
p47005
sg35214
I25
sg35223
VP63123
p47006
sg35217
I4
sa(dp47007
g35211
I13
sg35212
g46992
sg35214
I28
sg35223
VP14222
p47008
sg35217
I4
sasg35208
(lp47009
(dp47010
g35211
I163
sg35212
VOI
p47011
sg35214
I2
sg35215
VC0029434
p47012
sg35217
I1
sa(dp47013
g35211
I138
sg35212
g46993
sg35214
I23
sg35215
VC0029434
p47014
sg35217
I2
sasa(dp47015
g35204
VMutations in the proteinase bone morphogenetic protein-1 (BMP1) were recently identified in patients with osteogenesis imperfecta, which can be associated with type 1 dentinogenesis imperfecta.
p47016
sg35206
(lp47017
(dp47018
g35211
I17
sg35212
Vproteinase bone morphogenetic protein-1
p47019
sg35214
I39
sg35223
VP63123
p47020
sg35217
I4
sasg35208
(lp47021
(dp47022
g35211
I167
sg35212
Vdentinogenesis imperfecta
p47023
sg35214
I25
sg35215
VC0011436
p47024
sg35217
I2
sa(dp47025
g35211
I106
sg35212
Vosteogenesis imperfecta
p47026
sg35214
I23
sg35215
VC0029434
p47027
sg35217
I2
sasa(dp47028
g35204
VWe previously showed these mice to have a skeletal phenotype that includes elements of osteogenesis imperfecta (OI), osteomalacia, and deficient osteocyte maturation, observations validated by the finding of BMP1 mutations in a subset of human patients with OI-like phenotypes.
p47029
sg35206
(lp47030
sg35208
(lp47031
(dp47032
g35211
I112
sg35212
VOI
p47033
sg35214
I2
sg35215
VC0029434
p47034
sg35217
I1
sa(dp47035
g35211
I87
sg35212
Vosteogenesis imperfecta
p47036
sg35214
I23
sg35215
VC0029434
p47037
sg35217
I2
sa(dp47038
g35211
I112
sg35212
VOI
p47039
sg35214
I2
sg35215
VC0029434
p47040
sg35217
I1
sa(dp47041
g35211
I117
sg35212
Vosteomalacia
p47042
sg35214
I12
sg35215
VC0029442
p47043
sg35217
I1
sasa(dp47044
g135
(dp47045
(VWNT1
p47046
VOI
p47047
tp47048
I00
ssg35204
VAutosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.
p47049
sg35206
(lp47050
(dp47051
g35211
I171
sg35212
VSP7
p47052
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp47053
g35211
I182
sg35212
VTMEM38B
p47054
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp47055
g35211
I122
sg35212
VCRTAP
p47056
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47057
g35211
I137
sg35212
VPPIB
p47058
sg35214
I4
sg35223
VP23284
p47059
sg35217
I1
sa(dp47060
g35211
I143
sg35212
VSERPINH1
p47061
sg35214
I8
sg35223
VP50454
p47062
sg35217
I1
sa(dp47063
g35211
I153
sg35212
VFKBP10
p47064
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp47065
g35211
I161
sg35212
VSERPINF1
p47066
sg35214
I8
sg35223
VP36955
p47067
sg35217
I1
sa(dp47068
g35211
I195
sg35212
g47046
sg35214
I4
sg35223
VP04628
p47069
sg35217
I1
sasg35208
(lp47070
(dp47071
g35211
I20
sg35212
Vosteogenesis imperfecta
p47072
sg35214
I23
sg35215
VC0029434
p47073
sg35217
I2
sa(dp47074
g35211
I45
sg35212
VOI
p47075
sg35214
I2
sg35215
VC0029434
p47076
sg35217
I1
sa(dp47077
g35211
I45
sg35212
g47047
sg35214
I2
sg35215
VC0029434
p47078
sg35217
I1
sasa(dp47079
g35204
VIsolated 3-methylcrotonyl-CoA carboxylase deficiency (3MCCD) is an autosomal recessive disorder of leucine metabolism biochemically characterized by accumulation of 3-methylcrotonylglycine (3MCG), 3-methylcrotonic acid (3MCA) and 3-hydroxyisovaleric acid.
p47080
sg35206
(lp47081
(dp47082
g35211
I0
sg35212
VIsolated 3-methylcrotonyl-CoA carboxylase
p47083
sg35214
I41
sg35223
g12
sg35217
I3
sasg35208
(lp47084
(dp47085
g35211
I54
sg35212
V3MCCD
p47086
sg35214
I5
sg35215
VC0268600
p47087
sg35217
I1
sa(dp47088
g35211
I9
sg35212
V3-methylcrotonyl-CoA carboxylase deficiency
p47089
sg35214
I43
sg35215
VC0268600
p47090
sg35217
I3
sasa(dp47091
g135
(dp47092
(VMCC
p47093
V3-methylcrotonyl-CoA carboxylase
p47094
tp47095
I00
ssg35204
VIsolated 3-methylcrotonyl-CoA carboxylase (MCC) deficiency is an autosomal recessive disorder of leucine metabolism caused by mutations in MCCC1 or MCCC2 encoding the Alfa and Beta subunit of MCC, respectively.
p47096
sg35206
(lp47097
(dp47098
g35211
I0
sg35212
VIsolated 3-methylcrotonyl-CoA carboxylase
p47099
sg35214
I41
sg35223
g12
sg35217
I3
sa(dp47100
g35211
I43
sg35212
VMCC
p47101
sg35214
I3
sg35223
VP23508
p47102
sg35217
I1
sa(dp47103
g35211
I139
sg35212
VMCCC1
p47104
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47105
g35211
I148
sg35212
VMCCC2
p47106
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47107
g35211
I43
sg35212
g47093
sg35214
I3
sg35223
VP23508
p47108
sg35217
I1
sasg35208
(lp47109
(dp47110
g35211
I43
sg35212
VMCC
p47111
sg35214
I3
sg35215
VC0007129
p47112
sg35217
I1
sa(dp47113
g35211
I43
sg35212
VMCC
p47114
sg35214
I3
sg35215
VC0007129
p47115
sg35217
I1
sa(dp47116
g35211
I9
sg35212
g47094
sg35214
I32
sg35215
VC0007129
p47117
sg35217
I2
sasa(dp47118
g135
(dp47119
(VTGIF
p47120
Vpolydactyly
p47121
tp47122
I00
ssg35204
VWe performed mutational analysis in the four main HPE causing genes (SHH, SIX3, TGIF, and ZIC2) and GLI3, a gene associated with polydactyly as well as fluorescent in situ hybridization (FISH) to search for microdeletions in these genes and two candidate HPE genes (DISP1 and FOXA2).
p47123
sg35206
(lp47124
(dp47125
g35211
I90
sg35212
VZIC2
p47126
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47127
g35211
I69
sg35212
VSHH
p47128
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp47129
g35211
I276
sg35212
VFOXA2
p47130
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47131
g35211
I255
sg35212
VHPE genes
p47132
sg35214
I9
sg35223
VP01893
p47133
sg35217
I2
sa(dp47134
g35211
I100
sg35212
VGLI3
p47135
sg35214
I4
sg35223
VP10071
p47136
sg35217
I1
sa(dp47137
g35211
I266
sg35212
VDISP1
p47138
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47139
g35211
I74
sg35212
VSIX3
p47140
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47141
g35211
I80
sg35212
g47120
sg35214
I4
sg35223
VP22301
p47142
sg35217
I1
sasg35208
(lp47143
(dp47144
g35211
I129
sg35212
g47121
sg35214
I11
sg35215
VC0152427
p47145
sg35217
I1
sasa(dp47146
g135
(dp47147
(VCCK-1 receptor
p47148
Vpancreatic cancer
p47149
tp47150
I00
ssg35204
VAlthough the CCK-1 receptor has been shown to be highly expressed in resected human pancreatic cancer samples, its role is less clear.
p47151
sg35206
(lp47152
(dp47153
g35211
I13
sg35212
g47148
sg35214
I14
sg35223
VP06307
p47154
sg35217
I2
sasg35208
(lp47155
(dp47156
g35211
I84
sg35212
g47149
sg35214
I17
sg35215
VC0235974
p47157
sg35217
I2
sasa(dp47158
g135
(dp47159
(VCCK-CCK-1 receptor
p47160
Vpancreatic adenocarcinoma
p47161
tp47162
I01
ssg35204
VThe aim of this in vitro study was to investigate the CCK-1 receptor expression and the function of the CCK-CCK-1 receptor pathway in the human pancreatic adenocarcinoma cell line, Mia PaCa-2.
p47163
sg35206
(lp47164
(dp47165
g35211
I54
sg35212
VCCK-1 receptor
p47166
sg35214
I14
sg35223
VP06307
p47167
sg35217
I2
sa(dp47168
g35211
I104
sg35212
g47160
sg35214
I18
sg35223
VP06307
p47169
sg35217
I2
sa(dp47170
g35211
I181
sg35212
VMia PaCa-2
p47171
sg35214
I10
sg35223
g12
sg35217
I2
sasg35208
(lp47172
(dp47173
g35211
I185
sg35212
VPaCa
p47174
sg35214
I4
sg35215
VC1836780
p47175
sg35217
I1
sa(dp47176
g35211
I144
sg35212
g47161
sg35214
I25
sg35215
VC0281361
p47177
sg35217
I2
sasa(dp47178
g135
(dp47179
(VCCK receptors
p47180
Vpancreatic tumor
p47181
tp47182
I01
ssg35204
VHowever, the main source of CCK receptors in the pancreatic tumor samples consisted of CCK2-expressing islets and/or CCK1-expressing nerves rather than neoplastic tissue.
p47183
sg35206
(lp47184
(dp47185
g35211
I28
sg35212
g47180
sg35214
I13
sg35223
VP06307
p47186
sg35217
I2
sa(dp47187
g35211
I117
sg35212
VCCK1
p47188
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47189
(dp47190
g35211
I49
sg35212
g47181
sg35214
I16
sg35215
VC0030297
p47191
sg35217
I2
sasa(dp47192
g135
(dp47193
(VCCK receptors
p47194
Vpancreatic tumor
p47195
tp47196
I01
ssg35204
VThese data indicate that the presence of CCK receptors in human ductal pancreatic tumor samples is mainly due to CCK2 expression in residual pancreatic islets and CCK1 in pancreatic nerves.
p47197
sg35206
(lp47198
(dp47199
g35211
I41
sg35212
g47194
sg35214
I13
sg35223
VP06307
p47200
sg35217
I2
sa(dp47201
g35211
I163
sg35212
VCCK1
p47202
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47203
(dp47204
g35211
I71
sg35212
g47195
sg35214
I16
sg35215
VC0030297
p47205
sg35217
I2
sasa(dp47206
g135
(dp47207
(VTCN2 (rs1801198) gene
p47208
Vcleft lip
p47209
tp47210
I00
ssg35204
VThe aim of this study was to evaluate the association of the polymorphisms in TCN2 (rs1801198) gene and in MTRR (rs1801394) gene with nonsyndromic cleft lip and/or palate (NSCL/P) in a Brazilian population.
p47211
sg35206
(lp47212
(dp47213
g35211
I78
sg35212
g47208
sg35214
I21
sg35223
VP20062
p47214
sg35217
I3
sasg35208
(lp47215
(dp47216
g35211
I147
sg35212
g47209
sg35214
I9
sg35215
VC0008924
p47217
sg35217
I2
sasa(dp47218
g35204
VWhile the roles of the GluN2A and GluN2B subunit in ischemic stroke have been well developed, the role of the GluN2C subunit in ischemia is not well understood.
p47219
sg35206
(lp47220
sg35208
(lp47221
(dp47222
g35211
I128
sg35212
Vischemia
p47223
sg35214
I8
sg35215
VC0022116
p47224
sg35217
I1
sa(dp47225
g35211
I52
sg35212
Vischemic stroke
p47226
sg35214
I15
sg35215
VC3272363
p47227
sg35217
I2
sasa(dp47228
g35204
VIn the Western blotting assay, clonidine treatment led to significant up-regulation of the expression level of NR2B and Phospho-NR2B in the hippocampus of the rats when compared with the cerebral ischemia group.
p47229
sg35206
(lp47230
(dp47231
g35211
I120
sg35212
VPhospho-NR2B
p47232
sg35214
I12
sg35223
g12
sg35217
I1
sa(dp47233
g35211
I111
sg35212
VNR2B
p47234
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47235
(dp47236
g35211
I187
sg35212
Vcerebral ischemia
p47237
sg35214
I17
sg35215
VC0917798
p47238
sg35217
I2
sasa(dp47239
g135
(dp47240
(VERK1/2
p47241
Vcerebral ischemia
p47242
tp47243
I00
ssg35204
VIn conclusion, clonidine could improve the learning and memory ability of rats with cerebral ischemia, and NR2B, ERK1/2, CREB, NF-KB were involved in this effect.
p47244
sg35206
(lp47245
(dp47246
g35211
I121
sg35212
VCREB
p47247
sg35214
I4
sg35223
VP16220
p47248
sg35217
I1
sa(dp47249
g35211
I113
sg35212
g47241
sg35214
I6
sg35223
VP27361
p47250
sg35217
I1
sa(dp47251
g35211
I107
sg35212
VNR2B
p47252
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47253
(dp47254
g35211
I84
sg35212
g47242
sg35214
I17
sg35215
VC0917798
p47255
sg35217
I2
sasa(dp47256
g35204
VDWEYS-IgG cross-reactive with DNA and the N-methyl-D-aspartate receptor subunits GluN2A/GluN2B has been associated with neuropsychiatric systemic lupus erythematosus (NPSLE).
p47257
sg35206
(lp47258
(dp47259
g35211
I42
sg35212
VN-methyl-D-aspartate receptor subunits GluN2A/GluN2B
p47260
sg35214
I52
sg35223
g12
sg35217
I4
sasg35208
(lp47261
(dp47262
g35211
I167
sg35212
VNPSLE
p47263
sg35214
I5
sg35215
VC0752335
p47264
sg35217
I1
sa(dp47265
g35211
I120
sg35212
Vneuropsychiatric systemic lupus erythematosus
p47266
sg35214
I45
sg35215
VC0752335
p47267
sg35217
I4
sasa(dp47268
g35204
VTherefore, NMDAR antagonists, especially NR2B-selective ones, combined with IGF-1 may serve as an alternative therapeutic agent for oxidative stress related neurodegenerative disease.
p47269
sg35206
(lp47270
(dp47271
g35211
I41
sg35212
VNR2B
p47272
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47273
g35211
I76
sg35212
VIGF-1
p47274
sg35214
I5
sg35223
VP01343
p47275
sg35217
I1
sasg35208
(lp47276
(dp47277
g35211
I157
sg35212
Vneurodegenerative disease
p47278
sg35214
I25
sg35215
VC0524851
p47279
sg35217
I2
sa(dp47280
g35211
I132
sg35212
Voxidative stress
p47281
sg35214
I16
sg35215
VC0242606
p47282
sg35217
I2
sasa(dp47283
g135
(dp47284
(VLBP
p47285
VLBP
p47286
tp47287
I00
ssg35204
VTaken together, our results demonstrated that LBP is neuroprotective against ischemic injury by its dual roles in activation of NR2A and inhibition of NR2B signaling pathways, which suggests that LBP may be a superior therapeutic candidate for targeting glutamate excitotoxicity for the treatment of ischemic stroke.
p47288
sg35206
(lp47289
(dp47290
g35211
I151
sg35212
VNR2B
p47291
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47292
g35211
I128
sg35212
VNR2A
p47293
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47294
g35211
I46
sg35212
VLBP
p47295
sg35214
I3
sg35223
VP18428
p47296
sg35217
I1
sa(dp47297
g35211
I46
sg35212
g47285
sg35214
I3
sg35223
VP18428
p47298
sg35217
I1
sasg35208
(lp47299
(dp47300
g35211
I300
sg35212
Vischemic stroke
p47301
sg35214
I15
sg35215
VC3272363
p47302
sg35217
I2
sa(dp47303
g35211
I46
sg35212
VLBP
p47304
sg35214
I3
sg35215
VC0024031
p47305
sg35217
I1
sa(dp47306
g35211
I46
sg35212
g47286
sg35214
I3
sg35215
VC0024031
p47307
sg35217
I1
sasa(dp47308
g135
(dp47309
(VCD11b+ F4/80+ CD11c+
p47310
Vobesity
p47311
tp47312
I00
ssg35204
VThe obesity-induced changes in adipose tissue macrophage numbers are mainly due to increases in the triple-positive CD11b+ F4/80+ CD11c+ adipose tissue macrophage subpopulation.
p47313
sg35206
(lp47314
(dp47315
g35211
I116
sg35212
g47310
sg35214
I20
sg35223
VP11215
p47316
sg35217
I3
sasg35208
(lp47317
(dp47318
g35211
I4
sg35212
g47311
sg35214
I7
sg35215
VC0028754
p47319
sg35217
I1
sasa(dp47320
g135
(dp47321
(VCd11c
p47322
Vinflammation
p47323
tp47324
I00
ssg35204
VContrary to our hypothesis that obesity-mediated white AT inflammation is Nlrp3-dependent, we found that Western diet-induced expression of AT inflammatory markers (i.e., Cd68, Cd11c, Emr1, Itgam, Lgals, Il18, Mcp1, Tnf, Ccr2, Ccl5 mRNAs, and Mac-2 protein) were not accompanied by increased caspase-1 cleavage, a hallmark feature of NLRP3 inflammasome activation.
p47325
sg35206
(lp47326
(dp47327
g35211
I227
sg35212
VCcl5 mRNAs
p47328
sg35214
I10
sg35223
VP13501
p47329
sg35217
I2
sa(dp47330
g35211
I292
sg35212
Vcaspase-1
p47331
sg35214
I9
sg35223
VP29466
p47332
sg35217
I1
sa(dp47333
g35211
I221
sg35212
VCcr2
p47334
sg35214
I4
sg35223
VP41597
p47335
sg35217
I1
sa(dp47336
g35211
I210
sg35212
VMcp1
p47337
sg35214
I4
sg35223
VP13500
p47338
sg35217
I1
sa(dp47339
g35211
I190
sg35212
VItgam
p47340
sg35214
I5
sg35223
VP11215
p47341
sg35217
I1
sa(dp47342
g35211
I243
sg35212
VMac-2 protein
p47343
sg35214
I13
sg35223
VP17931
p47344
sg35217
I2
sa(dp47345
g35211
I216
sg35212
VTnf
p47346
sg35214
I3
sg35223
VP01375
p47347
sg35217
I1
sa(dp47348
g35211
I184
sg35212
VEmr1
p47349
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47350
g35211
I171
sg35212
VCd68
p47351
sg35214
I4
sg35223
VP34810
p47352
sg35217
I1
sa(dp47353
g35211
I177
sg35212
g47322
sg35214
I5
sg35223
VP20702
p47354
sg35217
I1
sa(dp47355
g35211
I204
sg35212
VIl18
p47356
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47357
(dp47358
g35211
I32
sg35212
Vobesity
p47359
sg35214
I7
sg35215
VC0028754
p47360
sg35217
I1
sa(dp47361
g35211
I58
sg35212
g47323
sg35214
I12
sg35215
VC0021368
p47362
sg35217
I1
sasa(dp47363
g35204
VIn current practice, an antibody cocktail comprising p63, CK903, and AMACR (PIN-4 cocktail) is frequently utilized to evaluate foci suspicious for prostatic adenocarcinoma.
p47364
sg35206
(lp47365
(dp47366
g35211
I53
sg35212
Vp63
p47367
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp47368
(dp47369
g35211
I76
sg35212
VPIN
p47370
sg35214
I3
sg35215
VC0282612
p47371
sg35217
I1
sa(dp47372
g35211
I147
sg35212
Vprostatic adenocarcinoma
p47373
sg35214
I24
sg35215
VC0007112
p47374
sg35217
I2
sasa(dp47375
g35204
VOnly 2 NA cases displayed an overall PIN-4 staining pattern compatible with prostate cancer.
p47376
sg35206
(lp47377
sg35208
(lp47378
(dp47379
g35211
I76
sg35212
Vprostate cancer
p47380
sg35214
I15
sg35215
VC0600139
p47381
sg35217
I2
sa(dp47382
g35211
I37
sg35212
VPIN
p47383
sg35214
I3
sg35215
VC0282612
p47384
sg35217
I1
sasa(dp47385
g135
(dp47386
(VPIN-4
p47387
Vprostate cancer
p47388
tp47389
I00
ssg35204
VAlthough heterogenous staining patterns were seen within individual cases, use of the PIN-4 cocktail effectively discriminates NA from prostate cancer because of the high frequency of coexpression of AMACR and CK903 within NA.
p47390
sg35206
(lp47391
(dp47392
g35211
I86
sg35212
g47387
sg35214
I5
sg35223
VP63167
p47393
sg35217
I1
sasg35208
(lp47394
(dp47395
g35211
I86
sg35212
VPIN
p47396
sg35214
I3
sg35215
VC0282612
p47397
sg35217
I1
sa(dp47398
g35211
I135
sg35212
g47388
sg35214
I15
sg35215
VC0600139
p47399
sg35217
I2
sasa(dp47400
g135
(dp47401
(VPIN-4
p47402
VPIN
p47403
tp47404
I00
ssg35204
VKidney and prostate cancer tumor and benign biopsies were stained with hemotoxylin and eosin and prostate biopsies were subjected to PIN-4 immunohistochemistry.
p47405
sg35206
(lp47406
(dp47407
g35211
I133
sg35212
g47402
sg35214
I5
sg35223
VP63167
p47408
sg35217
I1
sasg35208
(lp47409
(dp47410
g35211
I11
sg35212
Vprostate cancer
p47411
sg35214
I15
sg35215
VC0600139
p47412
sg35217
I2
sa(dp47413
g35211
I133
sg35212
g47403
sg35214
I3
sg35215
VC0282612
p47414
sg35217
I1
sa(dp47415
g35211
I27
sg35212
Vtumor
p47416
sg35214
I5
sg35215
VC0027651
p47417
sg35217
I1
sasa(dp47418
g35204
VA subset of biopsy sections was analyzed by IHC, and cancerous and non-cancerous regions could be readily visualized by PIN4 staining.
p47419
sg35206
(lp47420
(dp47421
g35211
I120
sg35212
VPIN4
p47422
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47423
sa(dp47424
g135
(dp47425
(VAng-1
p47426
Vvivax malaria
p47427
tp47428
I00
ssg35204
VElevated serum levels of Ang-2 and high values for the Ang-2/Ang-1 ratio may potentially be used as predictors of worst-case prognoses for P. vivax malaria, especially in patients with thrombocytopenia.
p47429
sg35206
(lp47430
(dp47431
g35211
I25
sg35212
VAng-2
p47432
sg35214
I5
sg35223
VP03950
p47433
sg35217
I1
sa(dp47434
g35211
I25
sg35212
VAng-2
p47435
sg35214
I5
sg35223
VP03950
p47436
sg35217
I1
sa(dp47437
g35211
I61
sg35212
g47426
sg35214
I5
sg35223
VP03950
p47438
sg35217
I1
sasg35208
(lp47439
(dp47440
g35211
I142
sg35212
g47427
sg35214
I13
sg35215
VC0024537
p47441
sg35217
I2
sasa(dp47442
g35204
VDengue-associated thrombocytopenia and endothelial activation are associated with an imbalance in angiopoietin-2: angiopoietin-1 plasma levels.
p47443
sg35206
(lp47444
(dp47445
g35211
I114
sg35212
Vangiopoietin-1
p47446
sg35214
I14
sg35223
g12
sg35217
I1
sa(dp47447
g35211
I98
sg35212
Vangiopoietin-2
p47448
sg35214
I14
sg35223
g12
sg35217
I1
sasg35208
(lp47449
(dp47450
g35211
I85
sg35212
Vimbalance
p47451
sg35214
I9
sg35215
VC1397014
p47452
sg35217
I1
sa(dp47453
g35211
I0
sg35212
VDengue
p47454
sg35214
I6
sg35215
VC0011311
p47455
sg35217
I1
sasa(dp47456
g135
(dp47457
(Vretinal G protein coupled receptor
p47458
Vretinitis pigmentosa
p47459
tp47460
I00
ssg35204
VIt has been previously reported that mutations in retinal G protein coupled receptor (RGR) are associated with retinitis pigmentosa.
p47461
sg35206
(lp47462
(dp47463
g35211
I86
sg35212
VRGR
p47464
sg35214
I3
sg35223
VP47804
p47465
sg35217
I1
sa(dp47466
g35211
I50
sg35212
g47458
sg35214
I34
sg35223
VP47804
p47467
sg35217
I5
sasg35208
(lp47468
(dp47469
g35211
I111
sg35212
g47459
sg35214
I20
sg35215
VC0035334
p47470
sg35217
I2
sasa(dp47471
g135
(dp47472
(VRGR
p47473
Vretinal diseases
p47474
tp47475
I01
ssg35204
VThe present study aims to systemically analyze the potential role of variants of RGR in retinal diseases.
p47476
sg35206
(lp47477
(dp47478
g35211
I81
sg35212
g47473
sg35214
I3
sg35223
VP47804
p47479
sg35217
I1
sasg35208
(lp47480
(dp47481
g35211
I88
sg35212
g47474
sg35214
I16
sg35215
VC0035309
p47482
sg35217
I2
sasa(dp47483
g135
(dp47484
(VRGR knock-out
p47485
Vretinal disorder
p47486
tp47487
I01
ssg35204
VThese data suggest that the recessive retinal disorder previously reported to be due to homozygous mutation in RGR is, at least in part, due to variants in CDHR1 and that the true consequences of RGR knock-out on human retinal structure and function are yet to be determined.
p47488
sg35206
(lp47489
(dp47490
g35211
I111
sg35212
VRGR
p47491
sg35214
I3
sg35223
VP47804
p47492
sg35217
I1
sa(dp47493
g35211
I196
sg35212
g47485
sg35214
I13
sg35223
VP47804
p47494
sg35217
I2
sa(dp47495
g35211
I156
sg35212
VCDHR1
p47496
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp47497
(dp47498
g35211
I38
sg35212
g47486
sg35214
I16
sg35215
VC0035309
p47499
sg35217
I2
sasa(dp47500
g135
(dp47501
(Vhuman RGR gene
p47502
Vautosomal recessive retinitis pigmentosa
p47503
tp47504
I00
ssg35204
VRare mutations in the human RGR gene lead to autosomal recessive retinitis pigmentosa or dominantly inherited peripapillary choroidal atrophy.
p47505
sg35206
(lp47506
(dp47507
g35211
I22
sg35212
g47502
sg35214
I14
sg35223
VP47804
p47508
sg35217
I3
sasg35208
(lp47509
(dp47510
g35211
I134
sg35212
Vatrophy
p47511
sg35214
I7
sg35215
VC0333641
p47512
sg35217
I1
sa(dp47513
g35211
I45
sg35212
g47503
sg35214
I40
sg35215
VC0339526
p47514
sg35217
I4
sasa(dp47515
g135
(dp47516
(VRGR-d protein
p47517
VAMD
p47518
tp47519
I01
ssg35204
VIn Western blot assays, the RGR-d protein was detected in retinas of a large proportion ( approximately 53%) of individual donors, including patients with age-related macular degeneration (AMD).
p47520
sg35206
(lp47521
(dp47522
g35211
I28
sg35212
g47517
sg35214
I13
sg35223
VP47804
p47523
sg35217
I2
sasg35208
(lp47524
(dp47525
g35211
I155
sg35212
Vage-related macular degeneration
p47526
sg35214
I32
sg35215
VC0242383
p47527
sg35217
I3
sa(dp47528
g35211
I189
sg35212
g47518
sg35214
I3
sg35215
VC0242383
p47529
sg35217
I1
sasa(dp47530
g135
(dp47531
(Vhuman gene encoding RGR
p47532
Vretinitis pigmentosa
p47533
tp47534
I00
ssg35204
VMutations in the human gene encoding RGR are associated with retinitis pigmentosa.
p47535
sg35206
(lp47536
(dp47537
g35211
I17
sg35212
g47532
sg35214
I23
sg35223
VP47804
p47538
sg35217
I4
sasg35208
(lp47539
(dp47540
g35211
I61
sg35212
g47533
sg35214
I20
sg35215
VC0035334
p47541
sg35217
I2
sasa(dp47542
g35204
VIn recognition of the clinical significance of AML MRD, the European LeukemiaNet (ELN) recently recommended the establishment of CR-MRDNegative as a separate category of treatment response.
p47543
sg35206
(lp47544
sg35208
(lp47545
(dp47546
g35211
I51
sg35212
VMRD
p47547
sg35214
I3
sg35215
VC1840451
p47548
sg35217
I1
sa(dp47549
g35211
I47
sg35212
VAML
p47550
sg35214
I3
sg35215
VC0023467
p47551
sg35217
I1
sasa(dp47552
g35204
VThe distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse.
p47553
sg35206
(lp47554
sg35208
(lp47555
sa(dp47556
g35204
VPatients were stratified using the ELN European Leukemia Net classification.
p47557
sg35206
(lp47558
sg35208
(lp47559
(dp47560
g35211
I48
sg35212
VLeukemia
p47561
sg35214
I8
sg35215
VC0023418
p47562
sg35217
I1
sasa(dp47563
g135
(dp47564
(Velastin
p47565
Vpancreatic tumors
p47566
tp47567
I00
ssg35204
VoH(E)mT-DCN treatment also attenuated the expression of major ECM components, such as collagen I/III, elastin and fibronectin and induced tumor cell apoptosis, leading to extensive viral dispersion within orthotopic pancreatic tumors and pancreatic cancer patient-derived tumor spheroids.
p47568
sg35206
(lp47569
(dp47570
g35211
I102
sg35212
g47565
sg35214
I7
sg35223
VP49918
p47571
sg35217
I1
sasg35208
(lp47572
(dp47573
g35211
I138
sg35212
Vtumor
p47574
sg35214
I5
sg35215
VC0027651
p47575
sg35217
I1
sa(dp47576
g35211
I138
sg35212
Vtumor
p47577
sg35214
I5
sg35215
VC0027651
p47578
sg35217
I1
sa(dp47579
g35211
I238
sg35212
Vpancreatic cancer
p47580
sg35214
I17
sg35215
VC0235974
p47581
sg35217
I2
sa(dp47582
g35211
I216
sg35212
g47566
sg35214
I17
sg35215
VC0030297
p47583
sg35217
I2
sasa(dp47584
g35204
VIn this study, we firstly examined neuroprotective effects of pre- or post-treatment with 15 and 30 mg/kg ATX against ischemic damage in the gerbil hippocampal cornus ammonis 1 (CA1) region subjected to 5 min of transient cerebral ischemia using cresyl violet staining, neuronal nuclei immunohistochemistry and Fluoro-J B histofluorescence staining.
p47585
sg35206
(lp47586
sg35208
(lp47587
(dp47588
g35211
I212
sg35212
Vtransient cerebral ischemia
p47589
sg35214
I27
sg35215
VC0917805
p47590
sg35217
I3
sasa(dp47591
g135
(dp47592
(Vcysteinyl cathepsins
p47593
Vinverted papilloma
p47594
tp47595
I00
ssg35204
VDysregulation of cysteinyl cathepsins and their inhibitors, cystatins (stefins), were implied in progression of tumorgenesis; nevertheless, their role in sinonasal inverted papilloma (IP) is still unrecognized.
p47596
sg35206
(lp47597
(dp47598
g35211
I17
sg35212
g47593
sg35214
I20
sg35223
VP25774
p47599
sg35217
I2
sasg35208
(lp47600
(dp47601
g35211
I184
sg35212
VIP
p47602
sg35214
I2
sg35215
VC1881254
p47603
sg35217
I1
sa(dp47604
g35211
I164
sg35212
g47594
sg35214
I18
sg35215
VC1881254
p47605
sg35217
I2
sasa(dp47606
g135
(dp47607
(VPrkcsh
p47608
VPkd1
p47609
tp47610
I00
ssg35204
VDespite fundamental limitations applying to these models, such as the distinct immune system and the different metabolism regulating liver homeostasis in rodents when compared to humans, multiple approaches, such as surgery (bile duct ligation), chemical-induced (3,5-diethoxycarbonyl-1,4-dihydrocollidine, DDC, Alfa-naphthylisothiocyanate, ANIT), viral infections (Rhesus rotavirustype A, RRV-A), and genetic manipulation (Mdr2, Cftr, Pkd1, Pkd2, Prkcsh, Sec63, Pkhd1) have been developed.
p47611
sg35206
(lp47612
(dp47613
g35211
I424
sg35212
VMdr2
p47614
sg35214
I4
sg35223
VP21439
p47615
sg35217
I1
sa(dp47616
g35211
I442
sg35212
VPkd2
p47617
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47618
g35211
I463
sg35212
VPkhd1
p47619
sg35214
I5
sg35223
VP08F94
p47620
sg35217
I1
sa(dp47621
g35211
I436
sg35212
VPkd1
p47622
sg35214
I4
sg35223
VP98161
p47623
sg35217
I1
sa(dp47624
g35211
I456
sg35212
VSec63
p47625
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47626
g35211
I430
sg35212
VCftr
p47627
sg35214
I4
sg35223
VP13569
p47628
sg35217
I1
sa(dp47629
g35211
I448
sg35212
g47608
sg35214
I6
sg35223
VP14314
p47630
sg35217
I1
sasg35208
(lp47631
(dp47632
g35211
I442
sg35212
VPkd2
p47633
sg35214
I4
sg35215
VC2751306
p47634
sg35217
I1
sa(dp47635
g35211
I463
sg35212
VPkhd1
p47636
sg35214
I5
sg35215
VC0085548
p47637
sg35217
I1
sa(dp47638
g35211
I348
sg35212
Vviral infections
p47639
sg35214
I16
sg35215
VC0042769
p47640
sg35217
I2
sa(dp47641
g35211
I436
sg35212
g47609
sg35214
I4
sg35215
VC3149841
p47642
sg35217
I1
sasa(dp47643
g135
(dp47644
(VABCB4
p47645
VProgressive familial intrahepatic cholestasis type 3
p47646
tp47647
I00
ssg35204
VProgressive familial intrahepatic cholestasis type 3 (PFIC3) is an autosomal recessive disorder of cholestasis of hepatocellular origin, typically seen in infancy or childhood caused by a defect in the ABCB4 located on chromosome 7.
p47648
sg35206
(lp47649
(dp47650
g35211
I54
sg35212
VPFIC3
p47651
sg35214
I5
sg35223
VP21439
p47652
sg35217
I1
sa(dp47653
g35211
I0
sg35212
VProgressive familial intrahepatic cholestasis type 3
p47654
sg35214
I52
sg35223
VP21439
p47655
sg35217
I6
sa(dp47656
g35211
I202
sg35212
g47645
sg35214
I5
sg35223
VP21439
p47657
sg35217
I1
sasg35208
(lp47658
(dp47659
g35211
I54
sg35212
VPFIC3
p47660
sg35214
I5
sg35215
VC1865643
p47661
sg35217
I1
sa(dp47662
g35211
I34
sg35212
Vcholestasis
p47663
sg35214
I11
sg35215
VC0008370
p47664
sg35217
I1
sa(dp47665
g35211
I0
sg35212
g47646
sg35214
I52
sg35215
VC1865643
p47666
sg35217
I6
sasa(dp47667
g135
(dp47668
(VABCB4
p47669
Vsitosterolaemia
p47670
tp47671
I00
ssg35204
VFor example, mutations in ABCA1 cause Tangier disease associated with defective efflux of cholesterol and phosphatidylcholine from the plasma membrane to the lipid acceptor protein apoA1 (apolipoprotein AI), mutations in ABCA3 cause neonatal surfactant deficiency associated with a loss in secretion of the lipid pulmonary surfactants from lungs of newborns, mutations in ABCA4 cause Stargardt macular degeneration, a retinal degenerative disease linked to the reduced clearance of retinoid compounds from photoreceptor cells, mutations in ABCA12 cause harlequin and lamellar ichthyosis, skin diseases associated with defective lipid trafficking in keratinocytes, and mutations in ABCB4 and ABCG5/ABCG8 are responsible for progressive intrafamilial hepatic disease and sitosterolaemia associated with defective phospholipid and sterol transport respectively.
p47672
sg35206
(lp47673
(dp47674
g35211
I188
sg35212
Vapolipoprotein AI
p47675
sg35214
I17
sg35223
VP02656
p47676
sg35217
I2
sa(dp47677
g35211
I181
sg35212
VapoA1
p47678
sg35214
I5
sg35223
VP02647
p47679
sg35217
I1
sa(dp47680
g35211
I372
sg35212
VABCA4
p47681
sg35214
I5
sg35223
VP78363
p47682
sg35217
I1
sa(dp47683
g35211
I221
sg35212
VABCA3
p47684
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47685
g35211
I540
sg35212
VABCA12
p47686
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp47687
g35211
I681
sg35212
g47669
sg35214
I5
sg35223
VP21439
p47688
sg35217
I1
sa(dp47689
g35211
I697
sg35212
VABCG8
p47690
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47691
g35211
I691
sg35212
VABCG5
p47692
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp47693
(dp47694
g35211
I38
sg35212
VTangier disease
p47695
sg35214
I15
sg35215
VC0039292
p47696
sg35217
I2
sa(dp47697
g35211
I588
sg35212
Vskin diseases
p47698
sg35214
I13
sg35215
VC0037274
p47699
sg35217
I2
sa(dp47700
g35211
I426
sg35212
Vdegenerative disease
p47701
sg35214
I20
sg35215
VC1285162
p47702
sg35217
I2
sa(dp47703
g35211
I394
sg35212
Vmacular degeneration
p47704
sg35214
I20
sg35215
VC0242383
p47705
sg35217
I2
sa(dp47706
g35211
I749
sg35212
Vhepatic disease
p47707
sg35214
I15
sg35215
VC0023895
p47708
sg35217
I2
sa(dp47709
g35211
I567
sg35212
Vlamellar ichthyosis
p47710
sg35214
I19
sg35215
VC0020758
p47711
sg35217
I2
sa(dp47712
g35211
I769
sg35212
g47670
sg35214
I15
sg35215
VC0342907
p47713
sg35217
I1
sasa(dp47714
g135
(dp47715
(VITGB6
p47716
Vbreast cancer
p47717
tp47718
I01
ssg35204
VWe further analyze two independent breast cancer datasets and find that specific isoforms of IGF2BP2, NECTIN4, ITGB6, and KLHDC9 are significantly associated with AZD6244, lapatinib, erlotinib, and paclitaxel, respectively.
p47719
sg35206
(lp47720
(dp47721
g35211
I122
sg35212
VKLHDC9
p47722
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp47723
g35211
I93
sg35212
VIGF2BP2
p47724
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp47725
g35211
I111
sg35212
g47716
sg35214
I5
sg35223
VP18564
p47726
sg35217
I1
sa(dp47727
g35211
I102
sg35212
VNECTIN4
p47728
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp47729
(dp47730
g35211
I35
sg35212
g47717
sg35214
I13
sg35215
VC0678222
p47731
sg35217
I2
sasa(dp47732
g35204
VRT-qPCR and Spearman's correlation analysis were then performed to measure IGF2BP2 mRNA expression in clinical glioma tissues and its correlation with miR-188 expression.
p47733
sg35206
(lp47734
(dp47735
g35211
I75
sg35212
VIGF2BP2 mRNA
p47736
sg35214
I12
sg35223
g12
sg35217
I2
sasg35208
(lp47737
(dp47738
g35211
I111
sg35212
Vglioma
p47739
sg35214
I6
sg35215
VC0017638
p47740
sg35217
I1
sasa(dp47741
g35204
VFinally, the biological roles of IGF2BP2 in glioma cells were assessed.
p47742
sg35206
(lp47743
(dp47744
g35211
I33
sg35212
VIGF2BP2
p47745
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp47746
(dp47747
g35211
I44
sg35212
Vglioma
p47748
sg35214
I6
sg35215
VC0017638
p47749
sg35217
I1
sasa(dp47750
g35204
VThe present study identified IGF2BP2 as a direct target of miR-188 in glioma, and IGF2BP2 under-expression served tumour-suppressive roles in glioma growth and metastasis.
p47751
sg35206
(lp47752
(dp47753
g35211
I29
sg35212
VIGF2BP2
p47754
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp47755
g35211
I29
sg35212
VIGF2BP2
p47756
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp47757
g35211
I59
sg35212
VmiR-188
p47758
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp47759
(dp47760
g35211
I114
sg35212
Vtumour
p47761
sg35214
I6
sg35215
VC0027651
p47762
sg35217
I1
sa(dp47763
g35211
I70
sg35212
Vglioma
p47764
sg35214
I6
sg35215
VC0017638
p47765
sg35217
I1
sa(dp47766
g35211
I70
sg35212
Vglioma
p47767
sg35214
I6
sg35215
VC0017638
p47768
sg35217
I1
sa(dp47769
g35211
I160
sg35212
Vmetastasis
p47770
sg35214
I10
sg35215
VC0027627
p47771
sg35217
I1
sasa(dp47772
g35204
VThus, miR-188 had a similar role in glioma by inhibiting the action of its downstream target, IGF2BP2.
p47773
sg35206
(lp47774
(dp47775
g35211
I6
sg35212
VmiR-188
p47776
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp47777
g35211
I94
sg35212
VIGF2BP2
p47778
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp47779
(dp47780
g35211
I36
sg35212
Vglioma
p47781
sg35214
I6
sg35215
VC0017638
p47782
sg35217
I1
sasa(dp47783
g135
(dp47784
(VTAAs
p47785
Vchronic atrophic gastritis
p47786
tp47787
I00
ssg35204
VBackground: Serum autoantibodies against tumor-associated antigens (TAAs) are detectable in early-stage gastric cancer patients; however, the time point during cancerogenesis when they appear in circulation is still obscure.Methods: In this study, we developed a recombinant antigen microarray and analyzed the prevalence of autoantibodies against 102 TAAs in 829 gastric cancer patients and 929 healthy controls from Caucasian and Asian populations, as well as 100 patients with chronic atrophic gastritis and 775 individuals staged according to different grades of intestinal metaplasia.Results: Six antigens, including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53, and MAGEA3, were predominantly reacting with sera from gastric cancer patients when compared with healthy controls, and the seroreactivity was associated with intestinal-type gastric cancer, but not with patients' Helicobacter pylori status, grade, age, gender, or stage of gastric cancer.
p47788
sg35206
(lp47789
(dp47790
g35211
I643
sg35212
VIGF2BP2
p47791
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp47792
g35211
I636
sg35212
VDDX53
p47793
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47794
g35211
I41
sg35212
Vtumor-associated antigens
p47795
sg35214
I25
sg35223
VP51572
p47796
sg35217
I2
sa(dp47797
g35211
I68
sg35212
VTAAs
p47798
sg35214
I4
sg35223
VP51572
p47799
sg35217
I1
sa(dp47800
g35211
I629
sg35212
VCTAG2
p47801
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47802
g35211
I68
sg35212
g47785
sg35214
I4
sg35223
VP51572
p47803
sg35217
I1
sa(dp47804
g35211
I622
sg35212
VCTAG1B
p47805
sg35214
I6
sg35223
VP78358
p47806
sg35217
I1
sasg35208
(lp47807
(dp47808
g35211
I104
sg35212
Vgastric cancer
p47809
sg35214
I14
sg35215
VC0024623
p47810
sg35217
I2
sa(dp47811
g35211
I104
sg35212
Vgastric cancer
p47812
sg35214
I14
sg35215
VC0024623
p47813
sg35217
I2
sa(dp47814
g35211
I567
sg35212
Vintestinal metaplasia
p47815
sg35214
I21
sg35215
VC0334037
p47816
sg35217
I2
sa(dp47817
g35211
I41
sg35212
Vtumor
p47818
sg35214
I5
sg35215
VC0027651
p47819
sg35217
I1
sa(dp47820
g35211
I104
sg35212
Vgastric cancer
p47821
sg35214
I14
sg35215
VC0024623
p47822
sg35217
I2
sa(dp47823
g35211
I104
sg35212
Vgastric cancer
p47824
sg35214
I14
sg35215
VC0024623
p47825
sg35217
I2
sa(dp47826
g35211
I104
sg35212
Vgastric cancer
p47827
sg35214
I14
sg35215
VC0024623
p47828
sg35217
I2
sa(dp47829
g35211
I480
sg35212
g47786
sg35214
I26
sg35215
VC0017154
p47830
sg35217
I3
sasa(dp47831
g35204
VThe gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2 is amplified and overexpressed in many human cancers, accompanied by a poorer prognosis.
p47832
sg35206
(lp47833
(dp47834
g35211
I74
sg35212
VIMP2
p47835
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47836
g35211
I22
sg35212
VInsulin-like Growth Factor 2 mRNA binding protein 2
p47837
sg35214
I51
sg35223
VP01308
p47838
sg35217
I8
sasg35208
(lp47839
(dp47840
g35211
I124
sg35212
Vcancers
p47841
sg35214
I7
sg35215
VC0006826
p47842
sg35217
I1
sasa(dp47843
g35204
VHerein we show in a diverse array of human cancer cells that IMP2 overexpression stimulates and IMP2 elimination diminishes proliferation by 50-80%.
p47844
sg35206
(lp47845
(dp47846
g35211
I61
sg35212
VIMP2
p47847
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47848
g35211
I61
sg35212
VIMP2
p47849
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47850
(dp47851
g35211
I43
sg35212
Vcancer
p47852
sg35214
I6
sg35215
VC0006826
p47853
sg35217
I1
sa(dp47854
g35211
I124
sg35212
Vproliferation
p47855
sg35214
I13
sg35215
VC0334094
p47856
sg35217
I1
sasa(dp47857
g35204
VIMP2 stabilization of HMGA1 mRNA plus IMP2 stimulated IGF2 production synergistically drive cancer cell proliferation and account for IMP2's tumor promoting action.
p47858
sg35206
(lp47859
(dp47860
g35211
I0
sg35212
VIMP2
p47861
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47862
g35211
I0
sg35212
VIMP2
p47863
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp47864
g35211
I54
sg35212
VIGF2
p47865
sg35214
I4
sg35223
VP01344
p47866
sg35217
I1
sa(dp47867
g35211
I22
sg35212
VHMGA1 mRNA
p47868
sg35214
I10
sg35223
VP17096
p47869
sg35217
I2
sa(dp47870
g35211
I0
sg35212
VIMP2
p47871
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp47872
(dp47873
g35211
I141
sg35212
Vtumor
p47874
sg35214
I5
sg35215
VC0027651
p47875
sg35217
I1
sa(dp47876
g35211
I92
sg35212
Vcancer
p47877
sg35214
I6
sg35215
VC0006826
p47878
sg35217
I1
sa(dp47879
g35211
I104
sg35212
Vproliferation
p47880
sg35214
I13
sg35215
VC0334094
p47881
sg35217
I1
sasa(dp47882
g35204
VIn conclusion, miR-1193 suppressed proliferation and invasion of human breast cancer cells via translational suppression of IGF2BP2.
p47883
sg35206
(lp47884
(dp47885
g35211
I124
sg35212
VIGF2BP2
p47886
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp47887
(dp47888
g35211
I53
sg35212
Vinvasion
p47889
sg35214
I8
sg35215
VC2699153
p47890
sg35217
I1
sa(dp47891
g35211
I109
sg35212
Vsuppression
p47892
sg35214
I11
sg35215
VC0221103
p47893
sg35217
I1
sa(dp47894
g35211
I35
sg35212
Vproliferation
p47895
sg35214
I13
sg35215
VC0334094
p47896
sg35217
I1
sa(dp47897
g35211
I71
sg35212
Vbreast cancer
p47898
sg35214
I13
sg35215
VC0678222
p47899
sg35217
I2
sasa(dp47900
g135
(dp47901
(VCOL4A5
p47902
Vmegalocornea
p47903
tp47904
I00
ssg35204
VNew genes HTRP5, CAPN6, STPK, 14-3-3PKR, and CALM1 and previously known genes including BTK, DDP, GLA, PLP, COL4A5, COL4A6, PAK3, and DCX are localized; candidate loci for other disorders for which genes have not yet been identified, including DFN-2, POF, megalocornea, and syndromic and nonsyndromic mental retardation, are also mapped in the region.
p47905
sg35206
(lp47906
(dp47907
g35211
I134
sg35212
VDCX
p47908
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp47909
g35211
I98
sg35212
VGLA
p47910
sg35214
I3
sg35223
VP06280
p47911
sg35217
I1
sa(dp47912
g35211
I251
sg35212
VPOF
p47913
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp47914
g35211
I0
sg35212
VNew genes HTRP5
p47915
sg35214
I15
sg35223
VP01701
p47916
sg35217
I3
sa(dp47917
g35211
I17
sg35212
VCAPN6
p47918
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp47919
g35211
I103
sg35212
VPLP
p47920
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp47921
g35211
I24
sg35212
VSTPK
p47922
sg35214
I4
sg35223
VP53350
p47923
sg35217
I1
sa(dp47924
g35211
I88
sg35212
VBTK
p47925
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp47926
g35211
I108
sg35212
g47902
sg35214
I6
sg35223
VP29400
p47927
sg35217
I1
sa(dp47928
g35211
I93
sg35212
VDDP
p47929
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp47930
(dp47931
g35211
I251
sg35212
VPOF
p47932
sg35214
I3
sg35215
VC0085215
p47933
sg35217
I1
sa(dp47934
g35211
I93
sg35212
VDDP
p47935
sg35214
I3
sg35215
VC0796074
p47936
sg35217
I1
sa(dp47937
g35211
I301
sg35212
Vmental retardation
p47938
sg35214
I18
sg35215
VC0025362
p47939
sg35217
I2
sa(dp47940
g35211
I256
sg35212
g47903
sg35214
I12
sg35215
VC0344530
p47941
sg35217
I1
sasa(dp47942
g135
(dp47943
(VRas-association domain family 7
p47944
Vmedullary thyroid carcinoma
p47945
tp47946
I00
ssg35204
VTo study the expression status of Ras-association domain family 7 (RASSF7) and Ras-association domain family 8 (RASSF8) in nodular thyroid goiter (NTG), medullary thyroid carcinoma (MTC), and papillary thyroid carcinoma (PTC) and establish whether a correlation exists between the presence of RASSF7 and RASSF8 proteins and clinicopathological parameters of the disease.
p47947
sg35206
(lp47948
(dp47949
g35211
I67
sg35212
VRASSF7
p47950
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp47951
g35211
I67
sg35212
VRASSF7
p47952
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp47953
g35211
I304
sg35212
VRASSF8 proteins
p47954
sg35214
I15
sg35223
g12
sg35217
I2
sa(dp47955
g35211
I79
sg35212
VRas-association domain family 8
p47956
sg35214
I31
sg35223
VP01116
p47957
sg35217
I4
sa(dp47958
g35211
I112
sg35212
VRASSF8
p47959
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp47960
g35211
I34
sg35212
g47944
sg35214
I31
sg35223
VP01116
p47961
sg35217
I4
sasg35208
(lp47962
(dp47963
g35211
I131
sg35212
Vthyroid goiter
p47964
sg35214
I14
sg35215
VC0018021
p47965
sg35217
I2
sa(dp47966
g35211
I192
sg35212
Vpapillary thyroid carcinoma
p47967
sg35214
I27
sg35215
VC0238463
p47968
sg35217
I3
sa(dp47969
g35211
I221
sg35212
VPTC
p47970
sg35214
I3
sg35215
VC0238463
p47971
sg35217
I1
sa(dp47972
g35211
I182
sg35212
VMTC
p47973
sg35214
I3
sg35215
VC1833921
p47974
sg35217
I1
sa(dp47975
g35211
I153
sg35212
g47945
sg35214
I27
sg35215
VC0238462
p47976
sg35217
I3
sasa(dp47977
g135
(dp47978
(VMyoD
p47979
Vischemia
p47980
tp47981
I00
ssg35204
VMoreover, HO-1 diminished ischemia-induced expression of MyoD involved in satellite cell differentiation in HO-1 KO mice.
p47982
sg35206
(lp47983
(dp47984
g35211
I57
sg35212
g47979
sg35214
I4
sg35223
VP15172
p47985
sg35217
I1
sasg35208
(lp47986
(dp47987
g35211
I26
sg35212
g47980
sg35214
I8
sg35215
VC0022116
p47988
sg35217
I1
sasa(dp47989
g135
(dp47990
(VCD9
p47991
VGlanzmann thrombasthenia
p47992
tp47993
I00
ssg35204
VCoprecipitation of CD36, CD9, and alpha6beta1 was also observed on platelets from a patient with Glanzmann thrombasthenia, indicating that alphaII(b)beta3 is not required for the other proteins to associate.
p47994
sg35206
(lp47995
(dp47996
g35211
I25
sg35212
g47991
sg35214
I3
sg35223
VP21926
p47997
sg35217
I1
sasg35208
(lp47998
(dp47999
g35211
I97
sg35212
g47992
sg35214
I24
sg35215
VC0040015
p48000
sg35217
I2
sasa(dp48001
g135
(dp48002
(VCD9
p48003
VGlanzmann's thrombasthenia
p48004
tp48005
I00
ssg35204
VTo rule out a cross-reactivity of the two polyclonal antibodies with GPIIb/IIIa, we studied PECAM1 and CD9 expression on the platelets from a patient with type I Glanzmann's thrombasthenia whose platelets are devoid of GPIIb/IIIa.
p48006
sg35206
(lp48007
(dp48008
g35211
I69
sg35212
VGPIIb/IIIa
p48009
sg35214
I10
sg35223
VP08514
p48010
sg35217
I1
sa(dp48011
g35211
I69
sg35212
VGPIIb/IIIa
p48012
sg35214
I10
sg35223
VP08514
p48013
sg35217
I1
sa(dp48014
g35211
I103
sg35212
g48003
sg35214
I3
sg35223
VP21926
p48015
sg35217
I1
sasg35208
(lp48016
(dp48017
g35211
I162
sg35212
g48004
sg35214
I26
sg35215
VC0040015
p48018
sg35217
I2
sasa(dp48019
g135
(dp48020
(VSLC5A3
p48021
Vadenocarcinomas
p48022
tp48023
I00
ssg35204
VIn contrast to TASK-1, which was not differentially expressed in lung cancer vs. normal lung tissue, we found the Na+-coupled nutrient transporters, SLC5A3, SLC5A6, and SLC38A1, transporters for myo-inositol, biotin and glutamine, respectively, to be significantly overexpressed in lung adenocarcinomas.
p48024
sg35206
(lp48025
(dp48026
g35211
I15
sg35212
VTASK-1
p48027
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp48028
g35211
I114
sg35212
VNa+-coupled nutrient transporters
p48029
sg35214
I33
sg35223
g12
sg35217
I3
sa(dp48030
g35211
I157
sg35212
VSLC5A6
p48031
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp48032
g35211
I169
sg35212
VSLC38A1
p48033
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp48034
g35211
I149
sg35212
g48021
sg35214
I6
sg35223
VP53794
p48035
sg35217
I1
sasg35208
(lp48036
(dp48037
g35211
I65
sg35212
Vlung cancer
p48038
sg35214
I11
sg35215
VC0684249
p48039
sg35217
I2
sa(dp48040
g35211
I287
sg35212
g48022
sg35214
I15
sg35215
VC0001418
p48041
sg35217
I1
sasa(dp48042
g135
(dp48043
(VP-glycoprotein
p48044
Vbreast cancer
p48045
tp48046
I00
ssg35204
VqPCR analysis showed elevated expression of efflux transporters (P-glycoprotein, multidrug resistant protein 2, breast cancer resistant protein) and influx transporters (folate receptor-Alfa, cationic and neutral amino acid transporter, sodium dependent multivitamin transporter) in a time dependent manner.
p48047
sg35206
(lp48048
(dp48049
g35211
I237
sg35212
Vsodium dependent multivitamin transporter
p48050
sg35214
I41
sg35223
VP19525
p48051
sg35217
I4
sa(dp48052
g35211
I44
sg35212
Vefflux transporters
p48053
sg35214
I19
sg35223
g12
sg35217
I2
sa(dp48054
g35211
I213
sg35212
Vamino acid transporter
p48055
sg35214
I22
sg35223
g12
sg35217
I3
sa(dp48056
g35211
I65
sg35212
g48044
sg35214
I14
sg35223
VP08183
p48057
sg35217
I1
sasg35208
(lp48058
(dp48059
g35211
I112
sg35212
g48045
sg35214
I13
sg35215
VC0678222
p48060
sg35217
I2
sasa(dp48061
g135
(dp48062
(Vsodium dependent multivitamin transporter
p48063
Vbreast cancer
p48064
tp48065
I00
ssg35204
VImmunoblot analysis further confirmed elevated expression of breast cancer resistant protein and sodium dependent multivitamin transporter.
p48066
sg35206
(lp48067
(dp48068
g35211
I97
sg35212
g48063
sg35214
I41
sg35223
VP19525
p48069
sg35217
I4
sasg35208
(lp48070
(dp48071
g35211
I61
sg35212
g48064
sg35214
I13
sg35215
VC0678222
p48072
sg35217
I2
sasa(dp48073
g135
(dp48074
(Vsodium dependent multivitamin transporter
p48075
Vbreast cancer
p48076
tp48077
I00
ssg35204
VAll these studies demonstrated for the first time the functional and molecular expression of sodium dependent multivitamin transporter (SMVT), a specific carrier-mediated system for biotin uptake, in human derived breast cancer (T47D) cells.
p48078
sg35206
(lp48079
(dp48080
g35211
I93
sg35212
g48075
sg35214
I41
sg35223
VP19525
p48081
sg35217
I4
sa(dp48082
g35211
I136
sg35212
VSMVT
p48083
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp48084
(dp48085
g35211
I214
sg35212
g48076
sg35214
I13
sg35215
VC0678222
p48086
sg35217
I2
sasa(dp48087
g135
(dp48088
(Vfolate receptor-alpha
p48089
Vretinoblastoma
p48090
tp48091
I00
ssg35204
VThe overall objective of this study was to investigate the differential expression of folate receptor-alpha (FR-Alfa), sodium-dependent multivitamin transporter (SMVT), and amino acid transporter [B ((0, +))] in retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cells.
p48092
sg35206
(lp48093
(dp48094
g35211
I86
sg35212
g48089
sg35214
I21
sg35223
VP15328
p48095
sg35217
I2
sa(dp48096
g35211
I162
sg35212
VSMVT
p48097
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp48098
g35211
I119
sg35212
Vsodium-dependent multivitamin transporter
p48099
sg35214
I41
sg35223
g12
sg35217
I3
sasg35208
(lp48100
(dp48101
g35211
I212
sg35212
g48090
sg35214
I14
sg35215
VC0035335
p48102
sg35217
I1
sasa(dp48103
g35204
VThis work demonstrated for the first time the higher expression and affinity of FR-Alfa, SMVT, and B ((0, +)) mRNA levels in retinoblastoma (Y-79) cells compared with retinal pigment epithelial (ARPE-19) cells.
p48104
sg35206
(lp48105
(dp48106
g35211
I89
sg35212
VSMVT
p48107
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp48108
(dp48109
g35211
I125
sg35212
Vretinoblastoma
p48110
sg35214
I14
sg35215
VC0035335
p48111
sg35217
I1
sasa(dp48112
g35204
VTo synthesize a novel camptothecin-poly(ethylene glycol) conjugate (CPT-PEG) which includes biotin as a moiety to enhance nonspecific and/or targeted uptake via the sodium-dependent multivitamin transporter (SMVT) and to evaluate its anticancer activity and apoptosis induction.
p48113
sg35206
(lp48114
(dp48115
g35211
I165
sg35212
Vsodium-dependent multivitamin transporter
p48116
sg35214
I41
sg35223
g12
sg35217
I3
sa(dp48117
g35211
I208
sg35212
VSMVT
p48118
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp48119
sa(dp48120
g35204
VThis suggests that the targeting approach utilizing transporters such as SMVT may substantially improve the delivery of CPT and its anticancer activity by enhancing cellular permeability and possibly retention of CPT.
p48121
sg35206
(lp48122
sg35208
(lp48123
sa(dp48124
g35204
VWe have cloned the human Na+-dependent multivitamin transporter (SMVT), which transports the water-soluble vitamins pantothenate, biotin, and lipoate, from a placental choriocarcinoma cell line (JAR).
p48125
sg35206
(lp48126
(dp48127
g35211
I19
sg35212
Vhuman Na+-dependent multivitamin transporter
p48128
sg35214
I44
sg35223
g12
sg35217
I4
sa(dp48129
g35211
I65
sg35212
VSMVT
p48130
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp48131
(dp48132
g35211
I158
sg35212
Vplacental choriocarcinoma
p48133
sg35214
I25
sg35215
VC0855173
p48134
sg35217
I2
sasa(dp48135
g35204
VWhile the association between IL-16 plasma levels and tumor progression has been reported for many types of cancer, the mechanism for IL-16 involvement has been partially elucidated for three of the cancer types, cutaneous T cell lymphoma (CTCL), multiple myeloma (MM), and breast cancer.
p48136
sg35206
(lp48137
(dp48138
g35211
I30
sg35212
VIL-16
p48139
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp48140
g35211
I30
sg35212
VIL-16
p48141
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp48142
(dp48143
g35211
I213
sg35212
Vcutaneous T cell lymphoma
p48144
sg35214
I25
sg35215
VC0079773
p48145
sg35217
I4
sa(dp48146
g35211
I108
sg35212
Vcancer
p48147
sg35214
I6
sg35215
VC0006826
p48148
sg35217
I1
sa(dp48149
g35211
I108
sg35212
Vcancer
p48150
sg35214
I6
sg35215
VC0006826
p48151
sg35217
I1
sa(dp48152
g35211
I54
sg35212
Vtumor progression
p48153
sg35214
I17
sg35215
VC0178874
p48154
sg35217
I2
sa(dp48155
g35211
I240
sg35212
VCTCL
p48156
sg35214
I4
sg35215
VC0079773
p48157
sg35217
I1
sa(dp48158
g35211
I274
sg35212
Vbreast cancer
p48159
sg35214
I13
sg35215
VC0678222
p48160
sg35217
I2
sa(dp48161
g35211
I247
sg35212
Vmultiple myeloma
p48162
sg35214
I16
sg35215
VC0026764
p48163
sg35217
I2
sasa(dp48164
g35204
VNuclear translocation of pro-interleukin-16 was not observed in late stages of Sezary syndrome, indicating this loss is not reversible.
p48165
sg35206
(lp48166
(dp48167
g35211
I25
sg35212
Vpro-interleukin-16
p48168
sg35214
I18
sg35223
g12
sg35217
I1
sasg35208
(lp48169
(dp48170
g35211
I8
sg35212
Vtranslocation
p48171
sg35214
I13
sg35215
VC0040715
p48172
sg35217
I1
sa(dp48173
g35211
I79
sg35212
VSezary syndrome
p48174
sg35214
I15
sg35215
VC0036920
p48175
sg35217
I2
sasa(dp48176
g35204
VWe propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sezary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.
p48177
sg35206
(lp48178
(dp48179
g35211
I55
sg35212
VIL-16
p48180
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp48181
g35211
I55
sg35212
VIL-16
p48182
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp48183
(dp48184
g35211
I97
sg35212
VSezary syndrome
p48185
sg35214
I15
sg35215
VC0036920
p48186
sg35217
I2
sasa(dp48187
g35204
VBy reverse transcription-polymerase chain reaction, interleukin-16 mRNA was detected in 18 of 18 mycosis fungoides lesions investigated.
p48188
sg35206
(lp48189
(dp48190
g35211
I52
sg35212
Vinterleukin-16 mRNA
p48191
sg35214
I19
sg35223
g12
sg35217
I2
sasg35208
(lp48192
(dp48193
g35211
I97
sg35212
Vmycosis fungoides
p48194
sg35214
I17
sg35215
VC0026948
p48195
sg35217
I2
sasa(dp48196
g135
(dp48197
(VCD25
p48198
Vinflammation
p48199
tp48200
I00
ssg35204
VGiven the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4+ lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.
p48201
sg35206
(lp48202
(dp48203
g35211
I182
sg35212
VCD4+
p48204
sg35214
I4
sg35223
VP01730
p48205
sg35217
I1
sa(dp48206
g35211
I83
sg35212
Vinterleukin-2
p48207
sg35214
I13
sg35223
VP60568
p48208
sg35217
I1
sa(dp48209
g35211
I33
sg35212
Vinterleukin-16
p48210
sg35214
I14
sg35223
g12
sg35217
I1
sa(dp48211
g35211
I33
sg35212
Vinterleukin-16
p48212
sg35214
I14
sg35223
g12
sg35217
I1
sa(dp48213
g35211
I97
sg35212
g48198
sg35214
I4
sg35223
VP01589
p48214
sg35217
I1
sasg35208
(lp48215
(dp48216
g35211
I202
sg35212
Vmycosis fungoides
p48217
sg35214
I17
sg35215
VC0026948
p48218
sg35217
I2
sa(dp48219
g35211
I151
sg35212
Vrecruitment
p48220
sg35214
I11
sg35215
VC0271510
p48221
sg35217
I1
sa(dp48222
g35211
I301
sg35212
g48199
sg35214
I12
sg35215
VC0021368
p48223
sg35217
I1
sasa(dp48224
g135
(dp48225
(Vparathyroid hormone
p48226
Vparathyroid adenomas
p48227
tp48228
I00
ssg35204
VThree additional patients with possible parathyroid adenomas at 11C-choline PET/CT were ultimately found to have thyroid lesions on the basis of tissue diagnosis; however, none of these patients had abnormal calcium or parathyroid hormone levels.
p48229
sg35206
(lp48230
(dp48231
g35211
I219
sg35212
g48226
sg35214
I19
sg35223
VP01270
p48232
sg35217
I2
sasg35208
(lp48233
(dp48234
g35211
I40
sg35212
g48227
sg35214
I20
sg35215
VC0262587
p48235
sg35217
I2
sasa(dp48236
g135
(dp48237
(Vparathyroid hormone
p48238
Vprimary hyperparathyroidism
p48239
tp48240
I00
ssg35204
VPatients with primary hyperparathyroidism generally have a single parathyroid adenoma that causes excessive excretion of parathyroid hormone.
p48241
sg35206
(lp48242
(dp48243
g35211
I121
sg35212
g48238
sg35214
I19
sg35223
VP01270
p48244
sg35217
I2
sasg35208
(lp48245
(dp48246
g35211
I66
sg35212
Vparathyroid adenoma
p48247
sg35214
I19
sg35215
VC0262587
p48248
sg35217
I2
sa(dp48249
g35211
I14
sg35212
g48239
sg35214
I27
sg35215
VC0221002
p48250
sg35217
I2
sasa(dp48251
g135
(dp48252
(Vparathyroid hormone
p48253
Vadenomas
p48254
tp48255
I00
ssg35204
VAlthough double adenomas are not yet widely acknowledged, presurgical imaging and nuclear scans can help to localize multiple lesions, and intraoperative parathyroid hormone assays can confirm the diagnosis and cure.
p48256
sg35206
(lp48257
(dp48258
g35211
I154
sg35212
g48253
sg35214
I19
sg35223
VP01270
p48259
sg35217
I2
sasg35208
(lp48260
(dp48261
g35211
I16
sg35212
g48254
sg35214
I8
sg35215
VC0001430
p48262
sg35217
I1
sasa(dp48263
g135
(dp48264
(Vproliferation-related genes
p48265
Vmultiple myeloma
p48266
tp48267
I00
ssg35204
VFinally, MMGP analysis revealed a positive correlation between the transcript levels of B7-H4 and proliferation-related genes including MKI67, CCNA1, and Myc in several patients with multiple myeloma.
p48268
sg35206
(lp48269
(dp48270
g35211
I154
sg35212
VMyc
p48271
sg35214
I3
sg35223
VP12524
p48272
sg35217
I1
sa(dp48273
g35211
I143
sg35212
VCCNA1
p48274
sg35214
I5
sg35223
VP78396
p48275
sg35217
I1
sa(dp48276
g35211
I88
sg35212
VB7-H4
p48277
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp48278
g35211
I136
sg35212
VMKI67
p48279
sg35214
I5
sg35223
VP46013
p48280
sg35217
I1
sa(dp48281
g35211
I98
sg35212
g48265
sg35214
I27
sg35223
VP01893
p48282
sg35217
I2
sasg35208
(lp48283
(dp48284
g35211
I98
sg35212
Vproliferation
p48285
sg35214
I13
sg35215
VC0334094
p48286
sg35217
I1
sa(dp48287
g35211
I183
sg35212
g48266
sg35214
I16
sg35215
VC0026764
p48288
sg35217
I2
sasa(dp48289
g135
(dp48290
(Vcyclin A1 mRNA
p48291
VMDS
p48292
tp48293
I00
ssg35204
VThe purpose of this study was to evaluate the expression of cyclin A1 mRNA in patients with myelodysplastic syndrome (MDS) and its clinical significance.
p48294
sg35206
(lp48295
(dp48296
g35211
I60
sg35212
g48291
sg35214
I14
sg35223
VP78396
p48297
sg35217
I3
sasg35208
(lp48298
(dp48299
g35211
I92
sg35212
Vmyelodysplastic syndrome
p48300
sg35214
I24
sg35215
VC3463824
p48301
sg35217
I2
sa(dp48302
g35211
I118
sg35212
g48292
sg35214
I3
sg35215
VC0265219
p48303
sg35217
I1
sasa(dp48304
g135
(dp48305
(Vcyclin A1 RT
p48306
Vleukemias
p48307
tp48308
I00
ssg35204
VCyclin A1 mRNA was detectable in 11 of 11 patients with acute myeloid leukemia, three of three patients with acute biphenotypic leukemia, eight of eight patients with myelodysplastic syndrome, 59 of 69 patients with chronic myelogenous leukemia (CML) at diagnosis, 13 of 15 patients with CML in blastic transformation, 10 of 18 patients with chronic lymphocytic leukemia, two of nine patients with essential thrombocythemia, and only two of 10 patients with acute lymphoblastic leukemia (ALL) with both cyclin A1 RT-PCR positive ALL leukemias being undifferentiated relapses.
p48309
sg35206
(lp48310
(dp48311
g35211
I0
sg35212
VCyclin A1 mRNA
p48312
sg35214
I14
sg35223
VP78396
p48313
sg35217
I3
sa(dp48314
g35211
I503
sg35212
g48306
sg35214
I12
sg35223
VP78396
p48315
sg35217
I3
sasg35208
(lp48316
(dp48317
g35211
I488
sg35212
VALL
p48318
sg35214
I3
sg35215
VC1961102
p48319
sg35217
I1
sa(dp48320
g35211
I246
sg35212
VCML
p48321
sg35214
I3
sg35215
VC0023473
p48322
sg35217
I1
sa(dp48323
g35211
I109
sg35212
Vacute biphenotypic leukemia
p48324
sg35214
I27
sg35215
VC0023464
p48325
sg35217
I3
sa(dp48326
g35211
I246
sg35212
VCML
p48327
sg35214
I3
sg35215
VC0023473
p48328
sg35217
I1
sa(dp48329
g35211
I342
sg35212
Vchronic lymphocytic leukemia
p48330
sg35214
I28
sg35215
VC0023434
p48331
sg35217
I3
sa(dp48332
g35211
I56
sg35212
Vacute myeloid leukemia
p48333
sg35214
I22
sg35215
VC0023467
p48334
sg35217
I3
sa(dp48335
g35211
I167
sg35212
Vmyelodysplastic syndrome
p48336
sg35214
I24
sg35215
VC0033027
p48337
sg35217
I2
sa(dp48338
g35211
I398
sg35212
Vessential thrombocythemia
p48339
sg35214
I25
sg35215
VC0040028
p48340
sg35217
I2
sa(dp48341
g35211
I303
sg35212
Vtransformation
p48342
sg35214
I14
sg35215
VC1510411
p48343
sg35217
I1
sa(dp48344
g35211
I216
sg35212
Vchronic myelogenous leukemia
p48345
sg35214
I28
sg35215
VC0023473
p48346
sg35217
I3
sa(dp48347
g35211
I458
sg35212
Vacute lymphoblastic leukemia
p48348
sg35214
I28
sg35215
VC1961102
p48349
sg35217
I3
sa(dp48350
g35211
I488
sg35212
VALL
p48351
sg35214
I3
sg35215
VC1961102
p48352
sg35217
I1
sa(dp48353
g35211
I533
sg35212
g48307
sg35214
I9
sg35215
VC0023418
p48354
sg35217
I1
sasa(dp48355
g135
(dp48356
(VIL-6
p48357
Vtumor necrosis
p48358
tp48359
I01
ssg35204
VMice with ANP showed increased apoptosis of pancreatic acinar cells, pancreatic myeloperoxidase activity, serum lactate dehydrogenase activity, amylase, tumor necrosis factor-Alfa (TNF-Alfa), interleukin-6 (IL-6) levels as well as decreased serum IL-10 level, pancreatic expression of heat shock factor 1 (HSF1), sirtuin 1 (SIRT1) and p53, but the ratio of acetylated HSF1 and p53 was markedly increased.
p48360
sg35206
(lp48361
(dp48362
g35211
I80
sg35212
Vmyeloperoxidase
p48363
sg35214
I15
sg35223
VP05164
p48364
sg35217
I1
sa(dp48365
g35211
I324
sg35212
VSIRT1
p48366
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp48367
g35211
I335
sg35212
Vp53
p48368
sg35214
I3
sg35223
VP42771
p48369
sg35217
I1
sa(dp48370
g35211
I144
sg35212
Vamylase
p48371
sg35214
I7
sg35223
VP04746
p48372
sg35217
I1
sa(dp48373
g35211
I313
sg35212
Vsirtuin 1
p48374
sg35214
I9
sg35223
g12
sg35217
I2
sa(dp48375
g35211
I306
sg35212
VHSF1
p48376
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp48377
g35211
I153
sg35212
Vtumor necrosis factor-Alfa
p48378
sg35214
I26
sg35223
VP01375
p48379
sg35217
I3
sa(dp48380
g35211
I285
sg35212
Vheat shock factor 1
p48381
sg35214
I19
sg35223
g12
sg35217
I4
sa(dp48382
g35211
I192
sg35212
Vinterleukin-6
p48383
sg35214
I13
sg35223
VP05231
p48384
sg35217
I1
sa(dp48385
g35211
I335
sg35212
Vp53
p48386
sg35214
I3
sg35223
VP42771
p48387
sg35217
I1
sa(dp48388
g35211
I306
sg35212
VHSF1
p48389
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp48390
g35211
I106
sg35212
Vserum lactate dehydrogenase
p48391
sg35214
I27
sg35223
VP49366
p48392
sg35217
I3
sa(dp48393
g35211
I241
sg35212
Vserum IL-10
p48394
sg35214
I11
sg35223
g12
sg35217
I2
sa(dp48395
g35211
I10
sg35212
VANP
p48396
sg35214
I3
sg35223
VP16066
p48397
sg35217
I1
sa(dp48398
g35211
I181
sg35212
VTNF-Alfa
p48399
sg35214
I8
sg35223
VP01375
p48400
sg35217
I1
sa(dp48401
g35211
I207
sg35212
g48357
sg35214
I4
sg35223
VP05231
p48402
sg35217
I1
sasg35208
(lp48403
(dp48404
g35211
I153
sg35212
g48358
sg35214
I14
sg35215
VC0333516
p48405
sg35217
I2
sasa(dp48406
g35204
VThese data suggest that resveratrol protects against L-arginine-induced ANP, which may be related to the enhancement of SIRT1-mediated deacetylation of p53 and HSF1.
p48407
sg35206
(lp48408
(dp48409
g35211
I72
sg35212
VANP
p48410
sg35214
I3
sg35223
VP16066
p48411
sg35217
I1
sa(dp48412
g35211
I160
sg35212
VHSF1
p48413
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp48414
g35211
I120
sg35212
VSIRT1
p48415
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp48416
g35211
I152
sg35212
Vp53
p48417
sg35214
I3
sg35223
VP42771
p48418
sg35217
I1
sasg35208
(lp48419
sa(dp48420
g35204
VThe aim of this study was to explore the role of the p38 mitogen-activated protein kinase (p38MAPK)/p53 signaling pathway in injury to the intestinal mucosal barrier during severe acute pancreatitis (SAP).
p48421
sg35206
(lp48422
(dp48423
g35211
I91
sg35212
Vp38MAPK
p48424
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp48425
g35211
I53
sg35212
Vp38 mitogen-activated protein kinase
p48426
sg35214
I36
sg35223
g12
sg35217
I4
sa(dp48427
g35211
I100
sg35212
Vp53
p48428
sg35214
I3
sg35223
VP42771
p48429
sg35217
I1
sasg35208
(lp48430
(dp48431
g35211
I180
sg35212
Vacute pancreatitis
p48432
sg35214
I18
sg35215
VC0001339
p48433
sg35217
I2
sasa(dp48434
g35204
VFurthermore, compared with homozygous missense mutations, compound heterozygous mutations appeared to have a more severe effect on phenotype, causing more severe growth retardation in ORC4 and more frequently pulmonary emphysema in CDT1.
p48435
sg35206
(lp48436
(dp48437
g35211
I232
sg35212
VCDT1
p48438
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp48439
(dp48440
g35211
I162
sg35212
Vgrowth retardation
p48441
sg35214
I18
sg35215
VC0151686
p48442
sg35217
I2
sa(dp48443
g35211
I209
sg35212
Vpulmonary emphysema
p48444
sg35214
I19
sg35215
VC0034067
p48445
sg35217
I2
sasa(dp48446
g35204
VWe recently identified an RBP HNRNPL as a novel prostate cancer dependency via regulation of RNA splicing, suggesting the potential to target RBP or RBP-RNA interaction to treat cancer.
p48447
sg35206
(lp48448
(dp48449
g35211
I26
sg35212
VRBP
p48450
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp48451
g35211
I26
sg35212
VRBP HNRNPL
p48452
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp48453
g35211
I149
sg35212
VRBP-RNA
p48454
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp48455
(dp48456
g35211
I57
sg35212
Vcancer
p48457
sg35214
I6
sg35215
VC0006826
p48458
sg35217
I1
sa(dp48459
g35211
I48
sg35212
Vprostate cancer
p48460
sg35214
I15
sg35215
VC0600139
p48461
sg35217
I2
sasa(dp48462
g135
(dp48463
(Vandrogen receptor
p48464
Vprostate cancer
p48465
tp48466
I00
ssg35204
VHNRNPL directly regulates the alternative splicing of a set of RNAs, including those encoding the androgen receptor, the key lineage-specific prostate cancer oncogene.
p48467
sg35206
(lp48468
(dp48469
g35211
I0
sg35212
VHNRNPL
p48470
sg35214
I6
sg35223
VP14866
p48471
sg35217
I1
sa(dp48472
g35211
I98
sg35212
g48464
sg35214
I17
sg35223
VP10275
p48473
sg35217
I2
sasg35208
(lp48474
(dp48475
g35211
I142
sg35212
g48465
sg35214
I15
sg35215
VC0600139
p48476
sg35217
I2
sasa(dp48477
g35204
VCollectively, our data reveal HNRNPL and its RNA clients as players in prostate cancer growth and potential therapeutic targets.
p48478
sg35206
(lp48479
sg35208
(lp48480
(dp48481
g35211
I71
sg35212
Vprostate cancer
p48482
sg35214
I15
sg35215
VC0600139
p48483
sg35217
I2
sasa(dp48484
g135
(dp48485
(VhnRNP-L
p48486
VBC
p48487
tp48488
I00
ssg35204
VHeterogeneous nuclear ribonucleoprotein L (hnRNP-L) is a promoter of various kinds of cancers, but its actions in bladder cancer (BC) are unclear.
p48489
sg35206
(lp48490
(dp48491
g35211
I0
sg35212
VHeterogeneous nuclear ribonucleoprotein L
p48492
sg35214
I41
sg35223
VP14866
p48493
sg35217
I4
sa(dp48494
g35211
I43
sg35212
g48486
sg35214
I7
sg35223
VP14866
p48495
sg35217
I1
sasg35208
(lp48496
(dp48497
g35211
I86
sg35212
Vcancers
p48498
sg35214
I7
sg35215
VC0006826
p48499
sg35217
I1
sa(dp48500
g35211
I114
sg35212
Vbladder cancer
p48501
sg35214
I14
sg35215
VC0699885
p48502
sg35217
I2
sa(dp48503
g35211
I130
sg35212
g48487
sg35214
I2
sg35215
VC0699885
p48504
sg35217
I1
sasa(dp48505
g135
(dp48506
(VHnRNP-L in prostate cancer
p48507
VPca
p48508
tp48509
I00
ssg35204
VIn this study, we examined the role of HnRNP-L in prostate cancer (Pca).
p48510
sg35206
(lp48511
(dp48512
g35211
I39
sg35212
g48507
sg35214
I26
sg35223
VP14866
p48513
sg35217
I4
sa(dp48514
g35211
I67
sg35212
VPca
p48515
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp48516
(dp48517
g35211
I50
sg35212
Vprostate cancer
p48518
sg35214
I15
sg35215
VC0600139
p48519
sg35217
I2
sa(dp48520
g35211
I67
sg35212
g48508
sg35214
I3
sg35215
VC0268398
p48521
sg35217
I1
sasa(dp48522
g35204
VThese results suggest a rationale for dose reduction of doxorubicin and docetaxel in prostate cancer therapy, since the doses needed to achieve 50% cell death may be decreased by approximately 4- to 15-fold or 3- to 8-fold, respectively, after a pre-treatment with ciprofloxacin.
p48523
sg35206
(lp48524
sg35208
(lp48525
(dp48526
g35211
I85
sg35212
Vprostate cancer
p48527
sg35214
I15
sg35215
VC0600139
p48528
sg35217
I2
sasa(dp48529
g135
(dp48530
(VCA I and II autoantibodies
p48531
Viron deficiency anemia
p48532
tp48533
I00
ssg35204
VThis study investigated the presence of CA I and II autoantibodies in patients with iron deficiency anemia (IDA).
p48534
sg35206
(lp48535
(dp48536
g35211
I40
sg35212
g48531
sg35214
I26
sg35223
VP00915
p48537
sg35217
I5
sasg35208
(lp48538
(dp48539
g35211
I108
sg35212
VIDA
p48540
sg35214
I3
sg35215
VC0162316
p48541
sg35217
I1
sa(dp48542
g35211
I84
sg35212
g48532
sg35214
I22
sg35215
VC0162316
p48543
sg35217
I3
sasa(dp48544
g135
(dp48545
(VCAIII
p48546
Viron deficiency anemia
p48547
tp48548
I00
ssg35204
VCompared with controls, CAIII concentration was lower in iron deficiency anemia (P&lt;0.01), but higher in beta-thalassemia anemia (P&lt;0.001).
p48549
sg35206
(lp48550
(dp48551
g35211
I24
sg35212
g48546
sg35214
I5
sg35223
VP07451
p48552
sg35217
I1
sasg35208
(lp48553
(dp48554
g35211
I73
sg35212
Vanemia
p48555
sg35214
I6
sg35215
VC0002871
p48556
sg35217
I1
sa(dp48557
g35211
I107
sg35212
Vbeta-thalassemia
p48558
sg35214
I16
sg35215
VC0005283
p48559
sg35217
I1
sa(dp48560
g35211
I57
sg35212
g48547
sg35214
I22
sg35215
VC0162316
p48561
sg35217
I3
sasa(dp48562
g135
(dp48563
(Verythrocyte carbonic anhydrase isozymes
p48564
Viron deficiency anemia
p48565
tp48566
I00
ssg35204
VThe levels of erythrocyte carbonic anhydrase isozymes (CA-B and CA-C) were determined by a quantitative immunochemical technique in order to elucidate their clinical significances in patients with iron deficiency anemia.
p48567
sg35206
(lp48568
(dp48569
g35211
I14
sg35212
g48564
sg35214
I39
sg35223
VP35218
p48570
sg35217
I4
sasg35208
(lp48571
(dp48572
g35211
I197
sg35212
g48565
sg35214
I22
sg35215
VC0162316
p48573
sg35217
I3
sasa(dp48574
g35204
V1 The levels of erythrocyte CA-B per gram hemoglobin, CA-B per ml erythrocyte and CA-C per gram hemoglobin all increased but CA-C per ml erythrocyte did not increased in iron deficiency anemia.
p48575
sg35206
(lp48576
(dp48577
g35211
I42
sg35212
Vhemoglobin
p48578
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp48579
g35211
I37
sg35212
Vgram hemoglobin
p48580
sg35214
I15
sg35223
g12
sg35217
I2
sasg35208
(lp48581
(dp48582
g35211
I170
sg35212
Viron deficiency anemia
p48583
sg35214
I22
sg35215
VC0162316
p48584
sg35217
I3
sasa(dp48585
g35204
VThe content of CA-B synthesized in lysates was much higher than that of CA-C. 6 In iron deficiency anemia, the increase of erythrocyte CA is speculated to be compensatory mechanism, which brought about the transportation of CO2 and right shifts of O2 dissociation curve.
p48586
sg35206
(lp48587
sg35208
(lp48588
(dp48589
g35211
I83
sg35212
Viron deficiency anemia
p48590
sg35214
I22
sg35215
VC0162316
p48591
sg35217
I3
sa(dp48592
g35211
I251
sg35212
Vdissociation
p48593
sg35214
I12
sg35215
VC0086168
p48594
sg35217
I1
sasa(dp48595
g135
(dp48596
(Vinducible T-cell kinase
p48597
Vallergic asthma
p48598
tp48599
I00
ssg35204
VInhibition of inducible T-cell kinase (ITK), a nonreceptor tyrosine kinase, may represent a novel treatment for allergic asthma.
p48600
sg35206
(lp48601
(dp48602
g35211
I39
sg35212
VITK
p48603
sg35214
I3
sg35223
VP19823
p48604
sg35217
I1
sa(dp48605
g35211
I14
sg35212
g48597
sg35214
I23
sg35223
VP19823
p48606
sg35217
I3
sasg35208
(lp48607
(dp48608
g35211
I112
sg35212
g48598
sg35214
I15
sg35215
VC0155877
p48609
sg35217
I2
sasa(dp48610
g135
(dp48611
(VItk
p48612
Vasthma
p48613
tp48614
I00
ssg35204
VHere we show that Itk, a mediator of T cell receptor signalling required for Th2 immune responses and the development of asthma, is a positive regulator of Th9 differentiation.
p48615
sg35206
(lp48616
(dp48617
g35211
I37
sg35212
VT cell receptor
p48618
sg35214
I15
sg35223
g12
sg35217
I3
sa(dp48619
g35211
I18
sg35212
g48612
sg35214
I3
sg35223
VP19823
p48620
sg35217
I1
sasg35208
(lp48621
(dp48622
g35211
I121
sg35212
g48613
sg35214
I6
sg35215
VC0004096
p48623
sg35217
I1
sasa(dp48624
g35204
VCompared to wild-type mice, ITK knockout mice are resistant to asthma and exhibit reduced lung inflammation and decreased amounts of TH2-type cytokines in the bronchoalveolar lavage fluid.
p48625
sg35206
(lp48626
sg35208
(lp48627
(dp48628
g35211
I90
sg35212
Vlung inflammation
p48629
sg35214
I17
sg35215
VC0032285
p48630
sg35217
I2
sa(dp48631
g35211
I63
sg35212
Vasthma
p48632
sg35214
I6
sg35215
VC0004096
p48633
sg35217
I1
sasa(dp48634
g135
(dp48635
(VITK
p48636
Vinflammation
p48637
tp48638
I01
ssg35204
VUnexpectedly, inhibition of the kinase activity of ITK during or after antigen rechallenge in an ovalbumin-induced mouse model of asthma failed to reduce airway hyperresponsiveness and inflammation.
p48639
sg35206
(lp48640
(dp48641
g35211
I51
sg35212
g48636
sg35214
I3
sg35223
VP19823
p48642
sg35217
I1
sasg35208
(lp48643
(dp48644
g35211
I130
sg35212
Vasthma
p48645
sg35214
I6
sg35215
VC0004096
p48646
sg35217
I1
sa(dp48647
g35211
I185
sg35212
g48637
sg35214
I12
sg35215
VC0021368
p48648
sg35217
I1
sasa(dp48649
g135
(dp48650
(VITK
p48651
Vasthma
p48652
tp48653
I00
ssg35204
VThus, our studies predict that inhibition of the kinase activity of ITK may not be therapeutic in patients with asthma.
p48654
sg35206
(lp48655
(dp48656
g35211
I68
sg35212
g48651
sg35214
I3
sg35223
VP19823
p48657
sg35217
I1
sasg35208
(lp48658
(dp48659
g35211
I112
sg35212
g48652
sg35214
I6
sg35215
VC0004096
p48660
sg35217
I1
sasa(dp48661
g35204
VFeNO levels were significantly elevated in the asthma compared to the control group (26 +/- 18 versus 11 +/- 4 ppb; p &lt; 0.05), and trended higher than levels in the tetraplegia group (15 +/- 6; p = 0.08).
p48662
sg35206
(lp48663
sg35208
(lp48664
(dp48665
g35211
I47
sg35212
Vasthma
p48666
sg35214
I6
sg35215
VC0004096
p48667
sg35217
I1
sa(dp48668
g35211
I111
sg35212
Vppb
p48669
sg35214
I3
sg35215
VC1266144
p48670
sg35217
I1
sa(dp48671
g35211
I168
sg35212
Vtetraplegia
p48672
sg35214
I11
sg35215
VC0034372
p48673
sg35217
I1
sasa(dp48674
g135
(dp48675
(VITK
p48676
Vasthma
p48677
tp48678
I00
ssg35204
VThe medicinal chemistry community has directed considerable efforts toward the discovery of selective inhibitors of interleukin-2 inducible T-cell kinase (ITK), given its role in T-cell signaling downstream of the T-cell receptor (TCR) and the implications of this target for inflammatory disorders such as asthma.
p48679
sg35206
(lp48680
(dp48681
g35211
I130
sg35212
Vinducible T-cell kinase
p48682
sg35214
I23
sg35223
VP19823
p48683
sg35217
I3
sa(dp48684
g35211
I214
sg35212
VT-cell receptor
p48685
sg35214
I15
sg35223
g12
sg35217
I2
sa(dp48686
g35211
I116
sg35212
Vinterleukin-2
p48687
sg35214
I13
sg35223
VP60568
p48688
sg35217
I1
sa(dp48689
g35211
I231
sg35212
VTCR
p48690
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp48691
g35211
I155
sg35212
g48676
sg35214
I3
sg35223
VP19823
p48692
sg35217
I1
sasg35208
(lp48693
(dp48694
g35211
I307
sg35212
g48677
sg35214
I6
sg35215
VC0004096
p48695
sg35217
I1
sasa(dp48696
g135
(dp48697
(Vcaspase-3
p48698
Vgestational trophoblastic neoplasia
p48699
tp48700
I00
ssg35204
VThe caspase-3 apoptotic index was a strong risk factor for subsequent gestational trophoblastic neoplasia development.
p48701
sg35206
(lp48702
(dp48703
g35211
I4
sg35212
g48698
sg35214
I9
sg35223
VP42574
p48704
sg35217
I1
sasg35208
(lp48705
(dp48706
g35211
I70
sg35212
g48699
sg35214
I35
sg35215
VC1135868
p48707
sg35217
I3
sasa(dp48708
g135
(dp48709
(V(C-X-C motif) ligand 6
p48710
VBardet-Biedl syndrome
p48711
tp48712
I00
ssg35204
VThe two genes were CXCL6 (chemokine (C-X-C motif) ligand 6) and BBS5 (Bardet-Biedl syndrome 5).
p48713
sg35206
(lp48714
(dp48715
g35211
I19
sg35212
VCXCL6
p48716
sg35214
I5
sg35223
VP80162
p48717
sg35217
I1
sa(dp48718
g35211
I64
sg35212
VBBS5
p48719
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp48720
g35211
I70
sg35212
VBardet-Biedl syndrome 5
p48721
sg35214
I23
sg35223
g12
sg35217
I3
sa(dp48722
g35211
I36
sg35212
g48710
sg35214
I22
sg35223
VP80162
p48723
sg35217
I4
sasg35208
(lp48724
(dp48725
g35211
I70
sg35212
g48711
sg35214
I21
sg35215
VC0752166
p48726
sg35217
I2
sasa(dp48727
g35204
VCompared with patients with a false-positive penicillin allergy result (confirmed by negative penicillin skin testing result), patients reporting a true penicillin allergy confirmed by positive penicillin skin test results tended to be more frequently men (61.5% versus 44.5%; Delta 17.0%; 95% CI -13.5% to 42%), black (69.2% versus 44.5%; Delta 24.7%; 95% CI -6.9% to 46.8%), and have no family history of drug allergy (7.7% versus 17.5%; Delta9.8%; 95% CI -20.9% to 20.4%), but self-reported other drug allergies more frequently (61.5% versus 38.7%; Delta 22.9%; 95% CI -7.7% to 47.5%).
p48728
sg35206
(lp48729
sg35208
(lp48730
(dp48731
g35211
I407
sg35212
Vdrug allergy
p48732
sg35214
I12
sg35215
VC0013182
p48733
sg35217
I2
sa(dp48734
g35211
I45
sg35212
Vpenicillin allergy
p48735
sg35214
I18
sg35215
VC0030824
p48736
sg35217
I2
sa(dp48737
g35211
I45
sg35212
Vpenicillin allergy
p48738
sg35214
I18
sg35215
VC0030824
p48739
sg35217
I2
sa(dp48740
g35211
I500
sg35212
Vdrug allergies
p48741
sg35214
I14
sg35215
VC0013182
p48742
sg35217
I2
sasa(dp48743
g35204
VWe identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.
p48744
sg35206
(lp48745
(dp48746
g35211
I147
sg35212
VCD14
p48747
sg35214
I4
sg35223
VP08571
p48748
sg35217
I1
sa(dp48749
g35211
I173
sg35212
VRAB24
p48750
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp48751
g35211
I153
sg35212
VFCGR1A
p48752
sg35214
I6
sg35223
VP12314
p48753
sg35217
I1
sa(dp48754
g35211
I268
sg35212
VCD3E
p48755
sg35214
I4
sg35223
VP07766
p48756
sg35217
I1
sa(dp48757
g35211
I274
sg35212
VCD8A
p48758
sg35214
I4
sg35223
VP01732
p48759
sg35217
I1
sa(dp48760
g35211
I262
sg35212
VBLR1
p48761
sg35214
I4
sg35223
VP32302
p48762
sg35217
I1
sa(dp48763
g35211
I180
sg35212
VSEC14L1
p48764
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp48765
g35211
I167
sg35212
VMMP9
p48766
sg35214
I4
sg35223
VP14780
p48767
sg35217
I1
sa(dp48768
g35211
I193
sg35212
VTIMP2
p48769
sg35214
I5
sg35223
VP16035
p48770
sg35217
I1
sa(dp48771
g35211
I161
sg35212
VFPR1
p48772
sg35214
I4
sg35223
VP21462
p48773
sg35217
I1
sa(dp48774
g35211
I290
sg35212
VTGFBR2
p48775
sg35214
I6
sg35223
VP37173
p48776
sg35217
I1
sasg35208
(lp48777
(dp48778
g35211
I341
sg35212
Vpathology
p48779
sg35214
I9
sg35215
VC0677042
p48780
sg35217
I1
sasa(dp48781
g135
(dp48782
(VBeta-tubulin
p48783
Vepiretinal membranes
p48784
tp48785
I00
ssg35204
VHowever, aberrant expression of class III Beta-tubulin has been observed in passaged RPE cells and RPE cells with dedifferentiated morphology in pathologic epiretinal membranes from idiopathic macular pucker, proliferative vitreoretinopathy (PVR) and proliferative diabetic retinopathy (PDR).
p48786
sg35206
(lp48787
(dp48788
g35211
I42
sg35212
g48783
sg35214
I12
sg35223
VP68371
p48789
sg35217
I1
sasg35208
(lp48790
(dp48791
g35211
I251
sg35212
Vproliferative diabetic retinopathy
p48792
sg35214
I34
sg35215
VC0154830
p48793
sg35217
I3
sa(dp48794
g35211
I209
sg35212
Vproliferative vitreoretinopathy
p48795
sg35214
I31
sg35215
VC1860404
p48796
sg35217
I2
sa(dp48797
g35211
I242
sg35212
VPVR
p48798
sg35214
I3
sg35215
VC1860404
p48799
sg35217
I1
sa(dp48800
g35211
I287
sg35212
VPDR
p48801
sg35214
I3
sg35215
VC0154830
p48802
sg35217
I1
sa(dp48803
g35211
I156
sg35212
g48784
sg35214
I20
sg35215
VC0339543
p48804
sg35217
I2
sa(dp48805
g35211
I193
sg35212
Vmacular pucker
p48806
sg35214
I14
sg35215
VC0154853
p48807
sg35217
I2
sasa(dp48808
g135
(dp48809
(VIFN-gamma
p48810
Vbronchial asthma
p48811
tp48812
I00
ssg35204
VDisorders in the ability ofleukocytes to produce IFN-alpha and IFN-gamma were detected in patients with bronchial asthma and allergic rhinitis.
p48813
sg35206
(lp48814
(dp48815
g35211
I63
sg35212
g48810
sg35214
I9
sg35223
VP01579
p48816
sg35217
I1
sa(dp48817
g35211
I49
sg35212
VIFN-alpha
p48818
sg35214
I9
sg35223
VP01562
p48819
sg35217
I1
sasg35208
(lp48820
(dp48821
g35211
I125
sg35212
Vallergic rhinitis
p48822
sg35214
I17
sg35215
VC2607914
p48823
sg35217
I2
sa(dp48824
g35211
I104
sg35212
g48811
sg35214
I16
sg35215
VC0004096
p48825
sg35217
I2
sasa(dp48826
g135
(dp48827
(VIFN-beta
p48828
Vrhinosinusitis
p48829
tp48830
I00
ssg35204
VFactors underlying the 'exacerbation-prone' phenotype are incompletely understood but include extrinsic factors: cigarette smoking, medication non-compliance, psychosocial factors, and co-morbidities such as gastroesophageal reflux disease, rhinosinusitis, obesity, and intolerance to non-steroidal anti-inflammatory medications; as well as intrinsic factors such as deficient epithelial cell production of the anti-viral type I interferons (IFN-alpha and IFN-beta).
p48831
sg35206
(lp48832
(dp48833
g35211
I411
sg35212
Vanti-viral type I interferons
p48834
sg35214
I29
sg35223
VP29475
p48835
sg35217
I4
sa(dp48836
g35211
I442
sg35212
VIFN-alpha
p48837
sg35214
I9
sg35223
VP01562
p48838
sg35217
I1
sa(dp48839
g35211
I456
sg35212
g48828
sg35214
I8
sg35223
VP01574
p48840
sg35217
I1
sasg35208
(lp48841
(dp48842
g35211
I257
sg35212
Vobesity
p48843
sg35214
I7
sg35215
VC0028754
p48844
sg35217
I1
sa(dp48845
g35211
I208
sg35212
Vgastroesophageal reflux disease
p48846
sg35214
I31
sg35215
VC0017168
p48847
sg35217
I3
sa(dp48848
g35211
I241
sg35212
g48829
sg35214
I14
sg35215
VC0948780
p48849
sg35217
I1
sasa(dp48850
g135
(dp48851
(Vapolipoprotein A-I
p48852
Vpulmonary edema
p48853
tp48854
I00
ssg35204
VThese data indicate that therapeutic strategies using SAHPs targeting CD36, but not necessarily mimicking all apolipoprotein A-I functions, may be considered a possible new treatment approach for inflammation-induced ALI and pulmonary edema.
p48855
sg35206
(lp48856
(dp48857
g35211
I110
sg35212
g48852
sg35214
I18
sg35223
VP02647
p48858
sg35217
I2
sasg35208
(lp48859
(dp48860
g35211
I196
sg35212
Vinflammation
p48861
sg35214
I12
sg35215
VC0021368
p48862
sg35217
I1
sa(dp48863
g35211
I225
sg35212
g48853
sg35214
I15
sg35215
VC0034063
p48864
sg35217
I2
sasa(dp48865
g135
(dp48866
(Vtranscription factor NFKBIZ and proinflammatory chemokine CXCL1
p48867
VCrohn's disease
p48868
tp48869
I00
ssg35204
VThe enhanced expression of IL-17 that is observed in patients with Crohn's disease could act on intestinal fibroblasts to induce expression of transcription factor NFKBIZ and proinflammatory chemokine CXCL1.
p48870
sg35206
(lp48871
(dp48872
g35211
I143
sg35212
g48867
sg35214
I63
sg35223
VP35398
p48873
sg35217
I7
sasg35208
(lp48874
(dp48875
g35211
I67
sg35212
g48868
sg35214
I15
sg35215
VC0010346
p48876
sg35217
I2
sasa(dp48877
g35204
VIn the majority of cases, autosomal dominant nonsyndromic hearing loss is postlingual and progressive, with the exception of hearing impairment in families in which the impairment is linked to DFNA3, DFNA8/12, and DFNA24, the novel locus described in this report.
p48878
sg35206
(lp48879
(dp48880
g35211
I193
sg35212
VDFNA3
p48881
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp48882
g35211
I200
sg35212
VDFNA8/12
p48883
sg35214
I8
sg35223
g12
sg35217
I1
sasg35208
(lp48884
(dp48885
g35211
I214
sg35212
VDFNA24
p48886
sg35214
I6
sg35215
VC1853451
p48887
sg35217
I1
sa(dp48888
g35211
I133
sg35212
Vimpairment
p48889
sg35214
I10
sg35215
VC0684336
p48890
sg35217
I1
sa(dp48891
g35211
I58
sg35212
Vhearing loss
p48892
sg35214
I12
sg35215
VC0011053
p48893
sg35217
I2
sa(dp48894
g35211
I200
sg35212
VDFNA8
p48895
sg35214
I5
sg35215
VC1832187
p48896
sg35217
I1
sa(dp48897
g35211
I133
sg35212
Vimpairment
p48898
sg35214
I10
sg35215
VC0684336
p48899
sg35217
I1
sasa(dp48900
g135
(dp48901
(VBeta-catenin
p48902
Vcysts
p48903
tp48904
I00
ssg35204
VThe morphological similarity and resemblance of keratin 1, 10, and 14 profiles, and p63 and Beta-catenin expression between mixed epidermal and inner root sheath hybrid cysts and keratoacanthomas suggests that hybrid cysts progressed to keratoacanthomas, and the cells from infundibular cells to inner root sheath cells of the pilar segment seem to be the origin of rat keratoacanthomas.
p48905
sg35206
(lp48906
(dp48907
g35211
I48
sg35212
Vkeratin 1
p48908
sg35214
I9
sg35223
VP04264
p48909
sg35217
I2
sa(dp48910
g35211
I84
sg35212
Vp63
p48911
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp48912
g35211
I92
sg35212
g48902
sg35214
I12
sg35223
VP35222
p48913
sg35217
I1
sasg35208
(lp48914
(dp48915
g35211
I179
sg35212
Vkeratoacanthomas
p48916
sg35214
I16
sg35215
VC0022572
p48917
sg35217
I1
sa(dp48918
g35211
I179
sg35212
Vkeratoacanthomas
p48919
sg35214
I16
sg35215
VC0022572
p48920
sg35217
I1
sa(dp48921
g35211
I169
sg35212
Vcysts
p48922
sg35214
I5
sg35215
VC0010709
p48923
sg35217
I1
sa(dp48924
g35211
I179
sg35212
Vkeratoacanthomas
p48925
sg35214
I16
sg35215
VC0022572
p48926
sg35217
I1
sa(dp48927
g35211
I169
sg35212
g48903
sg35214
I5
sg35215
VC0010709
p48928
sg35217
I1
sasa(dp48929
g135
(dp48930
(Vargininosuccinate lyase
p48931
VOTC
p48932
tp48933
I00
ssg35204
VUCDs include a spectrum of enzyme deficiencies, namely n-acetylglutamate synthase deficiency (NAGS), carbamoyl phosphate synthetase I deficiency (CPS1), ornithine transcarbamylase deficiency (OTC), argininosuccinate lyase deficiency (ASL), citrullinemia type I (ASS1), and argininemia (ARG).
p48934
sg35206
(lp48935
(dp48936
g35211
I55
sg35212
Vn-acetylglutamate synthase
p48937
sg35214
I26
sg35223
g12
sg35217
I2
sa(dp48938
g35211
I153
sg35212
Vornithine transcarbamylase
p48939
sg35214
I26
sg35223
VP00480
p48940
sg35217
I2
sa(dp48941
g35211
I146
sg35212
VCPS1
p48942
sg35214
I4
sg35223
VP31327
p48943
sg35217
I1
sa(dp48944
g35211
I101
sg35212
Vcarbamoyl phosphate synthetase I
p48945
sg35214
I32
sg35223
VP31327
p48946
sg35217
I4
sa(dp48947
g35211
I262
sg35212
VASS1
p48948
sg35214
I4
sg35223
VP00966
p48949
sg35217
I1
sa(dp48950
g35211
I240
sg35212
Vcitrullinemia type I
p48951
sg35214
I20
sg35223
VP00966
p48952
sg35217
I3
sa(dp48953
g35211
I198
sg35212
g48931
sg35214
I23
sg35223
VP04424
p48954
sg35217
I2
sasg35208
(lp48955
(dp48956
g35211
I153
sg35212
Vornithine transcarbamylase deficiency
p48957
sg35214
I37
sg35215
VC0268542
p48958
sg35217
I3
sa(dp48959
g35211
I286
sg35212
VARG
p48960
sg35214
I3
sg35215
VC0268548
p48961
sg35217
I1
sa(dp48962
g35211
I101
sg35212
Vcarbamoyl phosphate synthetase I deficiency
p48963
sg35214
I43
sg35215
VC0751753
p48964
sg35217
I5
sa(dp48965
g35211
I240
sg35212
Vcitrullinemia
p48966
sg35214
I13
sg35215
VC0175683
p48967
sg35217
I1
sa(dp48968
g35211
I55
sg35212
Vn-acetylglutamate synthase deficiency
p48969
sg35214
I37
sg35215
VC0268543
p48970
sg35217
I3
sa(dp48971
g35211
I234
sg35212
VASL
p48972
sg35214
I3
sg35215
VC0268547
p48973
sg35217
I1
sa(dp48974
g35211
I273
sg35212
Vargininemia
p48975
sg35214
I11
sg35215
VC0268548
p48976
sg35217
I1
sa(dp48977
g35211
I94
sg35212
VNAGS
p48978
sg35214
I4
sg35215
VC0268543
p48979
sg35217
I1
sa(dp48980
g35211
I198
sg35212
Vargininosuccinate lyase deficiency
p48981
sg35214
I34
sg35215
VC0268547
p48982
sg35217
I3
sa(dp48983
g35211
I192
sg35212
g48932
sg35214
I3
sg35215
VC0268542
p48984
sg35217
I1
sasa(dp48985
g35204
VRecovery was also associated with maternal obesity, and there was some ethnic variation - in the adjusted analysis indigenous (Orang Asal) Malaysians had lower odds of recovery.
p48986
sg35206
(lp48987
sg35208
(lp48988
(dp48989
g35211
I43
sg35212
Vobesity
p48990
sg35214
I7
sg35215
VC0028754
p48991
sg35217
I1
sasa(dp48992
g135
(dp48993
(VASL
p48994
Vurea cycle disorder
p48995
tp48996
I00
ssg35204
VArgininosuccinic acid lyase (ASL) deficiency, caused by mutations in the ASL gene (OMIM: 608310) is a urea cycle disorder that has pleiotropic presentations.
p48997
sg35206
(lp48998
(dp48999
g35211
I73
sg35212
VASL gene
p49000
sg35214
I8
sg35223
VP30566
p49001
sg35217
I2
sa(dp49002
g35211
I29
sg35212
g48994
sg35214
I3
sg35223
VP30566
p49003
sg35217
I1
sa(dp49004
g35211
I0
sg35212
VArgininosuccinic acid lyase
p49005
sg35214
I27
sg35223
g12
sg35217
I3
sasg35208
(lp49006
(dp49007
g35211
I102
sg35212
g48995
sg35214
I19
sg35215
VC0154246
p49008
sg35217
I3
sasa(dp49009
g135
(dp49010
(VArgininosuccinate synthetase
p49011
VArginase deficiency
p49012
tp49013
I00
ssg35204
VThese include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]).
p49014
sg35206
(lp49015
(dp49016
g35211
I407
sg35212
Vmitochondrial ornithine transporter 1
p49017
sg35214
I37
sg35223
g12
sg35217
I4
sa(dp49018
g35211
I61
sg35212
VCarbamyl phosphate synthetase 1
p49019
sg35214
I31
sg35223
g12
sg35217
I4
sa(dp49020
g35211
I223
sg35212
VArgininosuccinate lyase
p49021
sg35214
I23
sg35223
VP04424
p49022
sg35217
I2
sa(dp49023
g35211
I294
sg35212
VArginase
p49024
sg35214
I8
sg35223
VP05089
p49025
sg35217
I1
sa(dp49026
g35211
I113
sg35212
VOrnithine transcarbamylase
p49027
sg35214
I26
sg35223
VP00480
p49028
sg35217
I2
sa(dp49029
g35211
I159
sg35212
g49011
sg35214
I28
sg35223
VP00966
p49030
sg35217
I2
sa(dp49031
g35211
I14
sg35212
VN-acetylglutamate synthase
p49032
sg35214
I26
sg35223
g12
sg35217
I2
sa(dp49033
g35211
I494
sg35212
Vmitochondrial aspartate/glutamate carrier deficiency [CITRIN]
p49034
sg35214
I61
sg35223
g12
sg35217
I5
sasg35208
(lp49035
(dp49036
g35211
I389
sg35212
VHHH
p49037
sg35214
I3
sg35215
VC0268540
p49038
sg35217
I1
sa(dp49039
g35211
I335
sg35212
VHyperornithinemia
p49040
sg35214
I17
sg35215
VC0599035
p49041
sg35217
I1
sa(dp49042
g35211
I394
sg35212
Vsyndrome
p49043
sg35214
I8
sg35215
VC0039082
p49044
sg35217
I1
sa(dp49045
g35211
I159
sg35212
VArgininosuccinate synthetase deficiency
p49046
sg35214
I39
sg35215
VC0175683
p49047
sg35217
I3
sa(dp49048
g35211
I14
sg35212
VN-acetylglutamate synthase deficiency
p49049
sg35214
I37
sg35215
VC0268543
p49050
sg35217
I3
sa(dp49051
g35211
I315
sg35212
VARGD
p49052
sg35214
I4
sg35215
VC0268548
p49053
sg35217
I1
sa(dp49054
g35211
I223
sg35212
VArgininosuccinate lyase deficiency
p49055
sg35214
I34
sg35215
VC0268547
p49056
sg35217
I3
sa(dp49057
g35211
I207
sg35212
VCitrullinemia
p49058
sg35214
I13
sg35215
VC0175683
p49059
sg35217
I1
sa(dp49060
g35211
I152
sg35212
VOTCD
p49061
sg35214
I4
sg35215
VC0268542
p49062
sg35217
I1
sa(dp49063
g35211
I53
sg35212
VNAGSD
p49064
sg35214
I5
sg35215
VC0268543
p49065
sg35217
I1
sa(dp49066
g35211
I200
sg35212
VASSD
p49067
sg35214
I4
sg35215
VC0175683
p49068
sg35217
I1
sa(dp49069
g35211
I259
sg35212
VASLD
p49070
sg35214
I4
sg35215
VC0268547
p49071
sg35217
I1
sa(dp49072
g35211
I207
sg35212
VCitrullinemia
p49073
sg35214
I13
sg35215
VC0175683
p49074
sg35217
I1
sa(dp49075
g35211
I321
sg35212
VArgininemia
p49076
sg35214
I11
sg35215
VC0268548
p49077
sg35217
I1
sa(dp49078
g35211
I266
sg35212
VArgininosuccinic aciduria
p49079
sg35214
I25
sg35215
VC0268547
p49080
sg35217
I2
sa(dp49081
g35211
I354
sg35212
Vhyperammonemia
p49082
sg35214
I14
sg35215
VC0220994
p49083
sg35217
I1
sa(dp49084
g35211
I113
sg35212
VOrnithine transcarbamylase deficiency
p49085
sg35214
I37
sg35215
VC0268542
p49086
sg35217
I3
sa(dp49087
g35211
I294
sg35212
g49012
sg35214
I19
sg35215
VC0268548
p49088
sg35217
I2
sasa(dp49089
g135
(dp49090
(Vargininosuccinate lyase
p49091
VIVA
p49092
tp49093
I00
ssg35204
VCardiomyopathy [methylmalonic (MMA) and propionic aciduria (PA)], prolonged QTc interval (PA), optic nerve atrophy [MMA, isovaleric aciduria (IVA)], pancytopenia (PA), and macrocephaly [glutaric aciduria type 1 (GA1)] were exclusively found in OAD patients, whereas hepatic involvement was more frequent in UCD patients, in particular in argininosuccinate lyase (ASL) deficiency.
p49094
sg35206
(lp49095
(dp49096
g35211
I363
sg35212
VASL
p49097
sg35214
I3
sg35223
VP30566
p49098
sg35217
I1
sa(dp49099
g35211
I338
sg35212
g49091
sg35214
I23
sg35223
VP04424
p49100
sg35217
I2
sasg35208
(lp49101
(dp49102
g35211
I186
sg35212
Vglutaric aciduria type 1
p49103
sg35214
I24
sg35215
VC0268595
p49104
sg35217
I4
sa(dp49105
g35211
I60
sg35212
VPA
p49106
sg35214
I2
sg35215
VC2717876
p49107
sg35217
I1
sa(dp49108
g35211
I149
sg35212
Vpancytopenia
p49109
sg35214
I12
sg35215
VC0030312
p49110
sg35217
I1
sa(dp49111
g35211
I121
sg35212
Visovaleric aciduria
p49112
sg35214
I19
sg35215
VC0268575
p49113
sg35217
I2
sa(dp49114
g35211
I31
sg35212
VMMA
p49115
sg35214
I3
sg35215
VC0276096
p49116
sg35217
I1
sa(dp49117
g35211
I60
sg35212
VPA
p49118
sg35214
I2
sg35215
VC2717876
p49119
sg35217
I1
sa(dp49120
g35211
I0
sg35212
VCardiomyopathy
p49121
sg35214
I14
sg35215
VC0878544
p49122
sg35217
I1
sa(dp49123
g35211
I95
sg35212
Voptic nerve atrophy
p49124
sg35214
I19
sg35215
VC0029124
p49125
sg35217
I3
sa(dp49126
g35211
I40
sg35212
Vpropionic aciduria
p49127
sg35214
I18
sg35215
VC2717876
p49128
sg35217
I2
sa(dp49129
g35211
I60
sg35212
VPA
p49130
sg35214
I2
sg35215
VC2717876
p49131
sg35217
I1
sa(dp49132
g35211
I172
sg35212
Vmacrocephaly
p49133
sg35214
I12
sg35215
VC0221355
p49134
sg35217
I1
sa(dp49135
g35211
I15
sg35212
V[methylmalonic
p49136
sg35214
I14
sg35215
VC0276096
p49137
sg35217
I1
sa(dp49138
g35211
I31
sg35212
VMMA
p49139
sg35214
I3
sg35215
VC0276096
p49140
sg35217
I1
sa(dp49141
g35211
I66
sg35212
Vprolonged QTc interval
p49142
sg35214
I22
sg35215
VC1560305
p49143
sg35217
I3
sa(dp49144
g35211
I142
sg35212
g49092
sg35214
I3
sg35215
VC0268575
p49145
sg35217
I1
sasa(dp49146
g135
(dp49147
(V3 ornithine transcarbamylase deficiency, 1 arginase
p49148
Vargininosuccinate lyase deficiency
p49149
tp49150
I00
ssg35204
VFifteen patients (8 argininosuccinate lyase deficiency, 3 argininosuccinic acid synthetase deficiency, 3 ornithine transcarbamylase deficiency, 1 arginase deficiency) ages 2 months through 5 years enrolled in and completed the study.
p49151
sg35206
(lp49152
(dp49153
g35211
I58
sg35212
Vargininosuccinic acid synthetase
p49154
sg35214
I32
sg35223
g12
sg35217
I3
sa(dp49155
g35211
I20
sg35212
Vargininosuccinate lyase
p49156
sg35214
I23
sg35223
VP04424
p49157
sg35217
I2
sa(dp49158
g35211
I103
sg35212
g49148
sg35214
I51
sg35223
VP00480
p49159
sg35217
I6
sasg35208
(lp49160
(dp49161
g35211
I105
sg35212
Vornithine transcarbamylase deficiency
p49162
sg35214
I37
sg35215
VC0268542
p49163
sg35217
I3
sa(dp49164
g35211
I146
sg35212
Varginase deficiency
p49165
sg35214
I19
sg35215
VC0268548
p49166
sg35217
I2
sa(dp49167
g35211
I58
sg35212
Vargininosuccinic acid synthetase deficiency
p49168
sg35214
I43
sg35215
VC0175683
p49169
sg35217
I4
sa(dp49170
g35211
I20
sg35212
g49149
sg35214
I34
sg35215
VC0268547
p49171
sg35217
I3
sasa(dp49172
g135
(dp49173
(Vaspartoacylase
p49174
VBBB syndrome
p49175
tp49176
I00
ssg35204
VThe 20 genes with at least a 3-fold change, annotated with known phenotypic associations in the current gene databank (phenotype association, fold change) were aspartoacylase (Canavan disease, 9.96), growth hormone receptor (Laron dwarfism, idiopathic short stature, 8.25), lipoprotein lipase (familial chylomicronemia syndrome, lipoprotein lipase deficiency, 8.00), vitamin D (1,25- dihydroxyvitamin D3) receptor (involutional osteoporosis, vitamin D resistant rickets, 7.94), intercellular adhesion molecule 1 human rhinovirus receptor (cerebral malaria susceptibility, 7.16), peroxisomal membrane protein 3 35-kDa (Refsum disease, infantile form, Zellweger syndrome-3, 6.00), Bardet-Biedl syndrome 2 (Bardet-Biedl syndrome, 5.87), ribosomal protein S19 (Diamond Blackfan anemia, 5.85), apolipoprotein C-III (hypertriglyceridemia, 5.44), argininosuccinate lyase (argininosuccinicaciduria, 5.22), myosin VA (Griscelli syndrome-type pigmentary dilution with mental retardation, 4.92), lysozyme (renal amyloidosis, 4.17), SAM domain, SH3 domain and nuclear localisation signals 1 (Cherubism, 4.12 ), von Hippel-Lindau syndrome (hemangioblastoma, cerebellar, somatic, von Hippel-Lindau syndrome, 3.94), early-onset breast cancer 1 (BRCA1, papillary serous carcinoma of the peritoneum, 3.73), UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (inclusion body myopathy, autosomal recessive, sialuria, 3.53), apolipoprotein A-I (amyloidosis, 3 or more types, hypoalphalipoproteinemia, 3.29), midline 1 Opitz/BBB syndrome (Opitz G syndrome, type I, 3.28), ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide (familial hemiplegic migraine, 3.05).
p49177
sg35206
(lp49178
(dp49179
g35211
I789
sg35212
Vapolipoprotein C-III
p49180
sg35214
I20
sg35223
VP02656
p49181
sg35217
I2
sa(dp49182
g35211
I274
sg35212
Vlipoprotein lipase
p49183
sg35214
I18
sg35223
VP06858
p49184
sg35217
I2
sa(dp49185
g35211
I898
sg35212
Vmyosin VA
p49186
sg35214
I9
sg35223
g12
sg35217
I2
sa(dp49187
g35211
I274
sg35212
Vlipoprotein lipase
p49188
sg35214
I18
sg35223
VP06858
p49189
sg35217
I2
sa(dp49190
g35211
I1201
sg35212
Vearly-onset breast cancer 1
p49191
sg35214
I27
sg35223
VP38398
p49192
sg35217
I4
sa(dp49193
g35211
I865
sg35212
Vargininosuccinicaciduria, 5.22
p49194
sg35214
I30
sg35223
VP04424
p49195
sg35217
I2
sa(dp49196
g35211
I985
sg35212
Vlysozyme
p49197
sg35214
I8
sg35223
VP61626
p49198
sg35217
I1
sa(dp49199
g35211
I1417
sg35212
Vapolipoprotein A-I
p49200
sg35214
I18
sg35223
VP02647
p49201
sg35217
I2
sa(dp49202
g35211
I840
sg35212
Vargininosuccinate lyase
p49203
sg35214
I23
sg35223
VP04424
p49204
sg35217
I2
sa(dp49205
g35211
I200
sg35212
Vgrowth hormone receptor
p49206
sg35214
I23
sg35223
VP10912
p49207
sg35217
I3
sa(dp49208
g35211
I478
sg35212
Vintercellular adhesion molecule 1 human rhinovirus receptor
p49209
sg35214
I59
sg35223
VP05362
p49210
sg35217
I7
sa(dp49211
g35211
I734
sg35212
Vribosomal protein S19
p49212
sg35214
I21
sg35223
VP39019
p49213
sg35217
I3
sa(dp49214
g35211
I1021
sg35212
VSAM domain
p49215
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp49216
g35211
I1230
sg35212
VBRCA1
p49217
sg35214
I5
sg35223
VP38398
p49218
sg35217
I1
sa(dp49219
g35211
I1563
sg35212
VATPase
p49220
sg35214
I6
sg35223
VP38606
p49221
sg35217
I1
sa(dp49222
g35211
I160
sg35212
g49174
sg35214
I14
sg35223
VP45381
p49223
sg35217
I1
sasg35208
(lp49224
(dp49225
g35211
I492
sg35212
Vadhesion
p49226
sg35214
I8
sg35215
VC0001511
p49227
sg35217
I1
sa(dp49228
g35211
I225
sg35212
VLaron dwarfism
p49229
sg35214
I14
sg35215
VC0271568
p49230
sg35217
I2
sa(dp49231
g35211
I1237
sg35212
Vpapillary serous carcinoma
p49232
sg35214
I26
sg35215
VC0334359
p49233
sg35217
I3
sa(dp49234
g35211
I995
sg35212
Vrenal amyloidosis
p49235
sg35214
I17
sg35215
VC0268382
p49236
sg35217
I2
sa(dp49237
g35211
I865
sg35212
Vargininosuccinicaciduria
p49238
sg35214
I24
sg35215
VC0268547
p49239
sg35217
I1
sa(dp49240
g35211
I303
sg35212
Vchylomicronemia syndrome
p49241
sg35214
I24
sg35215
VC1274228
p49242
sg35217
I2
sa(dp49243
g35211
I757
sg35212
VDiamond Blackfan anemia
p49244
sg35214
I23
sg35215
VC1260899
p49245
sg35217
I3
sa(dp49246
g35211
I176
sg35212
VCanavan disease
p49247
sg35214
I15
sg35215
VC0206307
p49248
sg35217
I2
sa(dp49249
g35211
I442
sg35212
Vvitamin D resistant rickets
p49250
sg35214
I27
sg35215
VC2363065
p49251
sg35217
I4
sa(dp49252
g35211
I958
sg35212
Vmental retardation
p49253
sg35214
I18
sg35215
VC0025362
p49254
sg35217
I2
sa(dp49255
g35211
I329
sg35212
Vlipoprotein lipase deficiency
p49256
sg35214
I29
sg35215
VC0023817
p49257
sg35217
I3
sa(dp49258
g35211
I539
sg35212
Vcerebral malaria
p49259
sg35214
I16
sg35215
VC0024534
p49260
sg35217
I2
sa(dp49261
g35211
I679
sg35212
VBardet-Biedl syndrome 2
p49262
sg35214
I23
sg35215
VC2936863
p49263
sg35217
I3
sa(dp49264
g35211
I1099
sg35212
Vvon Hippel-Lindau syndrome
p49265
sg35214
I26
sg35215
VC0019562
p49266
sg35217
I3
sa(dp49267
g35211
I1080
sg35212
VCherubism
p49268
sg35214
I9
sg35215
VC0008029
p49269
sg35217
I1
sa(dp49270
g35211
I1400
sg35212
Vsialuria
p49271
sg35214
I8
sg35215
VC0342853
p49272
sg35217
I1
sa(dp49273
g35211
I241
sg35212
Vidiopathic short stature
p49274
sg35214
I24
sg35215
VC1740819
p49275
sg35217
I3
sa(dp49276
g35211
I1099
sg35212
Vvon Hippel-Lindau syndrome
p49277
sg35214
I26
sg35215
VC0019562
p49278
sg35217
I3
sa(dp49279
g35211
I1213
sg35212
Vbreast cancer
p49280
sg35214
I13
sg35215
VC0678222
p49281
sg35217
I2
sa(dp49282
g35211
I319
sg35212
Vsyndrome
p49283
sg35214
I8
sg35215
VC0039082
p49284
sg35217
I1
sa(dp49285
g35211
I618
sg35212
VRefsum disease, infantile form
p49286
sg35214
I30
sg35215
VC0282527
p49287
sg35217
I4
sa(dp49288
g35211
I1127
sg35212
Vhemangioblastoma
p49289
sg35214
I16
sg35215
VC0206734
p49290
sg35217
I1
sa(dp49291
g35211
I1536
sg35212
VG syndrome
p49292
sg35214
I10
sg35215
VC2936904
p49293
sg35217
I2
sa(dp49294
g35211
I650
sg35212
VZellweger syndrome
p49295
sg35214
I18
sg35215
VC0043459
p49296
sg35217
I2
sa(dp49297
g35211
I1021
sg35212
VSAM
p49298
sg35214
I3
sg35215
VC1563296
p49299
sg35217
I1
sa(dp49300
g35211
I415
sg35212
Vinvolutional osteoporosis
p49301
sg35214
I25
sg35215
VC0029459
p49302
sg35217
I2
sa(dp49303
g35211
I1354
sg35212
Vinclusion body myopathy, autosomal recessive
p49304
sg35214
I44
sg35215
VC1833373
p49305
sg35217
I5
sa(dp49306
g35211
I679
sg35212
VBardet-Biedl syndrome
p49307
sg35214
I21
sg35215
VC0752166
p49308
sg35217
I2
sa(dp49309
g35211
I1617
sg35212
Vfamilial hemiplegic migraine
p49310
sg35214
I28
sg35215
VC0338484
p49311
sg35217
I3
sa(dp49312
g35211
I1001
sg35212
Vamyloidosis
p49313
sg35214
I11
sg35215
VC0002726
p49314
sg35217
I1
sa(dp49315
g35211
I1516
sg35212
g49175
sg35214
I12
sg35215
VC2936904
p49316
sg35217
I2
sasa(dp49317
g135
(dp49318
(Vornithine transcarbamylase
p49319
Vargininosuccinate lyase deficiency
p49320
tp49321
I00
ssg35204
VThirteen families were investigated, of which two were affected by N-acetylglutamate synthase deficiency, four by carbamoylphosphate synthetase 1 deficiency, one by ornithine transcarbamylase deficiency, three by argininosuccinate synthetase deficiency, two by argininosuccinate lyase deficiency, and one by arginase deficiency.
p49322
sg35206
(lp49323
(dp49324
g35211
I67
sg35212
VN-acetylglutamate synthase
p49325
sg35214
I26
sg35223
g12
sg35217
I2
sa(dp49326
g35211
I261
sg35212
Vargininosuccinate lyase
p49327
sg35214
I23
sg35223
VP04424
p49328
sg35217
I2
sa(dp49329
g35211
I213
sg35212
Vargininosuccinate synthetase
p49330
sg35214
I28
sg35223
VP00966
p49331
sg35217
I2
sa(dp49332
g35211
I308
sg35212
Varginase
p49333
sg35214
I8
sg35223
VP05089
p49334
sg35217
I1
sa(dp49335
g35211
I114
sg35212
Vcarbamoylphosphate synthetase 1
p49336
sg35214
I31
sg35223
VP31327
p49337
sg35217
I3
sa(dp49338
g35211
I165
sg35212
g49319
sg35214
I26
sg35223
VP00480
p49339
sg35217
I2
sasg35208
(lp49340
(dp49341
g35211
I213
sg35212
Vargininosuccinate synthetase deficiency
p49342
sg35214
I39
sg35215
VC0175683
p49343
sg35217
I3
sa(dp49344
g35211
I308
sg35212
Varginase deficiency
p49345
sg35214
I19
sg35215
VC0268548
p49346
sg35217
I2
sa(dp49347
g35211
I165
sg35212
Vornithine transcarbamylase deficiency
p49348
sg35214
I37
sg35215
VC0268542
p49349
sg35217
I3
sa(dp49350
g35211
I67
sg35212
VN-acetylglutamate synthase deficiency
p49351
sg35214
I37
sg35215
VC0268543
p49352
sg35217
I3
sa(dp49353
g35211
I261
sg35212
g49320
sg35214
I34
sg35215
VC0268547
p49354
sg35217
I3
sasa(dp49355
g135
(dp49356
(VGLUT1
p49357
Vhead and neck squamous cell carcinoma
p49358
tp49359
I00
ssg35204
VIn this study, we examined the relationship between the lactic acid concentration and expression of LDHA and GLUT1, which are related to the Warburg effect, in human head and neck squamous cell carcinoma (HNSCC).
p49360
sg35206
(lp49361
(dp49362
g35211
I100
sg35212
VLDHA
p49363
sg35214
I4
sg35223
VP00338
p49364
sg35217
I1
sa(dp49365
g35211
I109
sg35212
g49357
sg35214
I5
sg35223
VP11166
p49366
sg35217
I1
sasg35208
(lp49367
(dp49368
g35211
I141
sg35212
VWarburg effect
p49369
sg35214
I14
sg35215
VC1520120
p49370
sg35217
I2
sa(dp49371
g35211
I205
sg35212
VHNSCC
p49372
sg35214
I5
sg35215
VC1168401
p49373
sg35217
I1
sa(dp49374
g35211
I166
sg35212
g49358
sg35214
I37
sg35215
VC1168401
p49375
sg35217
I6
sasa(dp49376
g135
(dp49377
(VLDH-A
p49378
Vhead and neck squamous cell carcinoma
p49379
tp49380
I01
ssg35204
VWe found that cetuximab downregulated lactate dehydrogenase A (LDH-A) and inhibited glycolysis in cetuximab-sensitive head and neck squamous cell carcinoma (HNSCC) cells in an HIF-1Alfa downregulation-dependent manner.
p49381
sg35206
(lp49382
(dp49383
g35211
I38
sg35212
Vlactate dehydrogenase A
p49384
sg35214
I23
sg35223
VP49366
p49385
sg35217
I3
sa(dp49386
g35211
I63
sg35212
g49378
sg35214
I5
sg35223
VP00338
p49387
sg35217
I1
sasg35208
(lp49388
(dp49389
g35211
I157
sg35212
VHNSCC
p49390
sg35214
I5
sg35215
VC1168401
p49391
sg35217
I1
sa(dp49392
g35211
I118
sg35212
g49379
sg35214
I37
sg35215
VC1168401
p49393
sg35217
I6
sasa(dp49394
g135
(dp49395
(VCa(2+) regulatory genes
p49396
Vfamilial hypertrophic cardiomyopathy
p49397
tp49398
I00
ssg35204
VAn Australian cohort of 252 unrelated familial hypertrophic cardiomyopathy patients were screened for mutations in the Ca(2+) regulatory genes, sorcin (SRI), calstabin (FKBP1B), calsequestrin (CASQ2), phospholamban (PLN), sarcolipin (SLN), calreticulin (CALR3) and calmodulin (CALM).
p49399
sg35206
(lp49400
(dp49401
g35211
I277
sg35212
VCALM
p49402
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp49403
g35211
I169
sg35212
VFKBP1B
p49404
sg35214
I6
sg35223
VP68106
p49405
sg35217
I1
sa(dp49406
g35211
I265
sg35212
Vcalmodulin
p49407
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp49408
g35211
I240
sg35212
Vcalreticulin (CALR3)
p49409
sg35214
I20
sg35223
VP27797
p49410
sg35217
I2
sa(dp49411
g35211
I178
sg35212
Vcalsequestrin
p49412
sg35214
I13
sg35223
VP31415
p49413
sg35217
I1
sa(dp49414
g35211
I222
sg35212
Vsarcolipin
p49415
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp49416
g35211
I193
sg35212
VCASQ2
p49417
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49418
g35211
I234
sg35212
VSLN
p49419
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp49420
g35211
I144
sg35212
Vsorcin (SRI)
p49421
sg35214
I12
sg35223
VP30626
p49422
sg35217
I2
sa(dp49423
g35211
I119
sg35212
g49396
sg35214
I23
sg35223
VP01893
p49424
sg35217
I3
sasg35208
(lp49425
(dp49426
g35211
I38
sg35212
g49397
sg35214
I36
sg35215
VC0949658
p49427
sg35217
I3
sasa(dp49428
g135
(dp49429
(VHSP90
p49430
VHSP
p49431
tp49432
I00
ssg35204
VThe validated proteins contain the clinically used hepatocellular carcinoma (HCC) biomarker alpha-fetoprotein (AFP) and the reported biomarker candidates Heat shock protein HSP 90-beta (HSP90), fatty acid-binding protein, epidermal (FABP5) and alcohol dehydrogenase 4 (ADH4), which demonstrated the robustness of the strategy.
p49433
sg35206
(lp49434
(dp49435
g35211
I269
sg35212
VADH4
p49436
sg35214
I4
sg35223
VP40394
p49437
sg35217
I1
sa(dp49438
g35211
I111
sg35212
VAFP
p49439
sg35214
I3
sg35223
VP02771
p49440
sg35217
I1
sa(dp49441
g35211
I194
sg35212
Vfatty acid-binding protein
p49442
sg35214
I26
sg35223
VP00505
p49443
sg35217
I3
sa(dp49444
g35211
I173
sg35212
VHSP 90-beta
p49445
sg35214
I11
sg35223
g12
sg35217
I2
sa(dp49446
g35211
I222
sg35212
Vepidermal (FABP5) and alcohol dehydrogenase 4
p49447
sg35214
I45
sg35223
VP08319
p49448
sg35217
I6
sa(dp49449
g35211
I92
sg35212
Valpha-fetoprotein
p49450
sg35214
I17
sg35223
VP02771
p49451
sg35217
I1
sa(dp49452
g35211
I186
sg35212
g49430
sg35214
I5
sg35223
VP07900
p49453
sg35217
I1
sasg35208
(lp49454
(dp49455
g35211
I77
sg35212
VHCC
p49456
sg35214
I3
sg35215
VC2239176
p49457
sg35217
I1
sa(dp49458
g35211
I51
sg35212
Vhepatocellular carcinoma
p49459
sg35214
I24
sg35215
VC2239176
p49460
sg35217
I2
sa(dp49461
g35211
I173
sg35212
g49431
sg35214
I3
sg35215
VC0034152
p49462
sg35217
I1
sasa(dp49463
g135
(dp49464
(VHsp90Beta
p49465
Vhepatocellular carcinoma
p49466
tp49467
I00
ssg35204
VIn vivo, Hsp90Beta promoted VEGFRs and CD31 expression in human hepatocellular carcinoma tumor xenografts and was associated with increased tumor microvessel density.
p49468
sg35206
(lp49469
(dp49470
g35211
I28
sg35212
VVEGFRs
p49471
sg35214
I6
sg35223
VP35968
p49472
sg35217
I1
sa(dp49473
g35211
I39
sg35212
VCD31
p49474
sg35214
I4
sg35223
VP69905
p49475
sg35217
I1
sa(dp49476
g35211
I9
sg35212
g49465
sg35214
I9
sg35223
VP08238
p49477
sg35217
I1
sasg35208
(lp49478
(dp49479
g35211
I89
sg35212
Vtumor
p49480
sg35214
I5
sg35215
VC0027651
p49481
sg35217
I1
sa(dp49482
g35211
I64
sg35212
g49466
sg35214
I24
sg35215
VC1512411
p49483
sg35217
I2
sa(dp49484
g35211
I89
sg35212
Vtumor
p49485
sg35214
I5
sg35215
VC0027651
p49486
sg35217
I1
sasa(dp49487
g135
(dp49488
(VTGF-Beta1 and Hsp90Beta
p49489
Vcolon cancer
p49490
tp49491
I00
ssg35204
VIn this study we report an apparent synergy between TGF-Beta1 and Hsp90Beta in stimulating migratory behaviour of colon cancer cells when signalling occurs via AlfavBeta6 integrin as opposed to the canonical TGF-Beta1 pathway.
p49492
sg35206
(lp49493
(dp49494
g35211
I52
sg35212
VTGF-Beta1
p49495
sg35214
I9
sg35223
VP01137
p49496
sg35217
I1
sa(dp49497
g35211
I52
sg35212
g49489
sg35214
I23
sg35223
VP01137
p49498
sg35217
I3
sasg35208
(lp49499
(dp49500
g35211
I114
sg35212
g49490
sg35214
I12
sg35215
VC0699790
p49501
sg35217
I2
sasa(dp49502
g135
(dp49503
(Vcolorectal cancer-associated variant rs2282151
p49504
Vcolorectal tumor
p49505
tp49506
I00
ssg35204
VOur findings indicate that the C allele of the novel colorectal cancer-associated variant rs2282151 is associated with increased expression levels of HSP90AB1, which is expressed higher in colorectal tumor tissues than in normal tissues.
p49507
sg35206
(lp49508
(dp49509
g35211
I150
sg35212
VHSP90AB1
p49510
sg35214
I8
sg35223
VP08238
p49511
sg35217
I1
sa(dp49512
g35211
I53
sg35212
g49504
sg35214
I46
sg35223
VP31749
p49513
sg35217
I4
sasg35208
(lp49514
(dp49515
g35211
I53
sg35212
Vcolorectal cancer
p49516
sg35214
I17
sg35215
VC1527249
p49517
sg35217
I2
sa(dp49518
g35211
I189
sg35212
g49505
sg35214
I16
sg35215
VC0009404
p49519
sg35217
I2
sasa(dp49520
g135
(dp49521
(Vc-KIT
p49522
VGIST
p49523
tp49524
I00
ssg35204
VBortezomib induced internalization and degradation of c-KIT by binding c-KIT to Cbl, an E3 ubiquitin-protein ligase, and the subsequent release of Apaf-1, which was originally bound to the c-KIT-Hsp90Beta-Apaf-1 complex, induced primary apoptosis in GIST-T1 cells.
p49525
sg35206
(lp49526
(dp49527
g35211
I54
sg35212
Vc-KIT
p49528
sg35214
I5
sg35223
VP10721
p49529
sg35217
I1
sa(dp49530
g35211
I189
sg35212
Vc-KIT-Hsp90Beta
p49531
sg35214
I15
sg35223
VP10721
p49532
sg35217
I1
sa(dp49533
g35211
I91
sg35212
Vubiquitin-protein ligase
p49534
sg35214
I24
sg35223
VP49427
p49535
sg35217
I2
sa(dp49536
g35211
I80
sg35212
VCbl
p49537
sg35214
I3
sg35223
VP22681
p49538
sg35217
I1
sa(dp49539
g35211
I54
sg35212
g49522
sg35214
I5
sg35223
VP10721
p49540
sg35217
I1
sasg35208
(lp49541
(dp49542
g35211
I250
sg35212
g49523
sg35214
I4
sg35215
VC1847319
p49543
sg35217
I1
sasa(dp49544
g135
(dp49545
(VHSP90Beta
p49546
Vcolon cancer
p49547
tp49548
I00
ssg35204
VBoth Annexin A1 and HSP90Beta were GlcNAcylated, and their protein expressions were elevated in colon cancer, compared to normal tissues.
p49549
sg35206
(lp49550
(dp49551
g35211
I5
sg35212
VAnnexin A1
p49552
sg35214
I10
sg35223
VP04083
p49553
sg35217
I2
sa(dp49554
g35211
I20
sg35212
g49546
sg35214
I9
sg35223
VP08238
p49555
sg35217
I1
sasg35208
(lp49556
(dp49557
g35211
I96
sg35212
g49547
sg35214
I12
sg35215
VC0699790
p49558
sg35217
I2
sasa(dp49559
g135
(dp49560
(VAnnexin A1
p49561
Vcolon cancer
p49562
tp49563
I00
ssg35204
VMoreover, specific changes of GlcNAc abundances in Annexin A1 and HSP90Beta suggested that tumor-specific glycan patterns could serve as candidate biomarkers of colon cancer for distinguishing cancer patients from healthy individuals.
p49564
sg35206
(lp49565
(dp49566
g35211
I66
sg35212
VHSP90Beta
p49567
sg35214
I9
sg35223
VP08238
p49568
sg35217
I1
sa(dp49569
g35211
I51
sg35212
g49561
sg35214
I10
sg35223
VP04083
p49570
sg35217
I2
sasg35208
(lp49571
(dp49572
g35211
I91
sg35212
Vtumor
p49573
sg35214
I5
sg35215
VC0027651
p49574
sg35217
I1
sa(dp49575
g35211
I167
sg35212
Vcancer
p49576
sg35214
I6
sg35215
VC0006826
p49577
sg35217
I1
sa(dp49578
g35211
I161
sg35212
g49562
sg35214
I12
sg35215
VC0699790
p49579
sg35217
I2
sasa(dp49580
g135
(dp49581
(VPEPCK
p49582
Vhepatoma
p49583
tp49584
I00
ssg35204
VIn addition, the knockdown of PEPCK, which is the rate-limiting enzyme for gluconeogenesis, led to a reduction in glucose production in rat hepatoma H4IIEC3 cells.
p49585
sg35206
(lp49586
(dp49587
g35211
I30
sg35212
g49582
sg35214
I5
sg35223
VP35558
p49588
sg35217
I1
sasg35208
(lp49589
(dp49590
g35211
I140
sg35212
g49583
sg35214
I8
sg35215
VC0023903
p49591
sg35217
I1
sasa(dp49592
g135
(dp49593
(VCCR4
p49594
Vadult T-cell leukemia/lymphoma
p49595
tp49596
I00
ssg35204
VWe recently reported expression of the chemokine receptors CXC chemokine receptor 3 (CXCR3) and CC chemokine receptor 4 (CCR4) in adult T-cell leukemia/lymphoma and showed a preferential expression of CCR4 and its association with an unfavorable outcome.
p49597
sg35206
(lp49598
(dp49599
g35211
I39
sg35212
Vchemokine receptors CXC chemokine receptor 3
p49600
sg35214
I44
sg35223
VP55773
p49601
sg35217
I6
sa(dp49602
g35211
I96
sg35212
VCC chemokine receptor 4
p49603
sg35214
I23
sg35223
g12
sg35217
I4
sa(dp49604
g35211
I121
sg35212
VCCR4
p49605
sg35214
I4
sg35223
VP51679
p49606
sg35217
I1
sa(dp49607
g35211
I85
sg35212
VCXCR3
p49608
sg35214
I5
sg35223
VP49682
p49609
sg35217
I1
sa(dp49610
g35211
I121
sg35212
g49594
sg35214
I4
sg35223
VP51679
p49611
sg35217
I1
sasg35208
(lp49612
(dp49613
g35211
I130
sg35212
g49595
sg35214
I30
sg35215
VC0023493
p49614
sg35217
I3
sasa(dp49615
g35204
VWe present a review of the current knowledge on cellular metabolism in non-cancerous and cancerous thyroid tissues, focusing on the monocarboxylate transporters MCT1 and MCT4, and on a transporter of the outer mitochondrial membrane TOMM20.
p49616
sg35206
(lp49617
(dp49618
g35211
I132
sg35212
Vmonocarboxylate transporters MCT1
p49619
sg35214
I33
sg35223
VP23946
p49620
sg35217
I3
sa(dp49621
g35211
I204
sg35212
Vouter mitochondrial membrane TOMM20
p49622
sg35214
I35
sg35223
g12
sg35217
I4
sa(dp49623
g35211
I170
sg35212
VMCT4
p49624
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp49625
sa(dp49626
g35204
VPapillary thyroid cancer and FA thyrocytes had high staining for TOMM20 compared to NCT and nodular goiter (NG) (P &lt; 0.01).
p49627
sg35206
(lp49628
(dp49629
g35211
I65
sg35212
VTOMM20
p49630
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp49631
(dp49632
g35211
I0
sg35212
VPapillary thyroid cancer
p49633
sg35214
I24
sg35215
VC0238463
p49634
sg35217
I3
sa(dp49635
g35211
I108
sg35212
VNG
p49636
sg35214
I2
sg35215
VC1318500
p49637
sg35217
I1
sa(dp49638
g35211
I92
sg35212
Vnodular goiter
p49639
sg35214
I14
sg35215
VC1318500
p49640
sg35217
I2
sasa(dp49641
g135
(dp49642
(VMCT1 and TOMM20
p49643
VPTC
p49644
tp49645
I00
ssg35204
VStaining patterns of MCT1 and TOMM20 in 35 human thyroid samples (15 ATC, 12 papillary thyroid cancer [PTC], and eight non-cancerous thyroid) and nine ATC mouse orthotopic xenografts were assessed by visual and Aperio digital scoring.
p49646
sg35206
(lp49647
(dp49648
g35211
I21
sg35212
g49643
sg35214
I15
sg35223
VP23946
p49649
sg35217
I3
sasg35208
(lp49650
(dp49651
g35211
I77
sg35212
Vpapillary thyroid cancer
p49652
sg35214
I24
sg35215
VC0238463
p49653
sg35217
I3
sa(dp49654
g35211
I103
sg35212
g49644
sg35214
I3
sg35215
VC0238463
p49655
sg35217
I1
sasa(dp49656
g35204
VTOMM20 is also highly expressed in both ATC and PTC compared to non-cancerous thyroid tissue (P&lt;.01 for both).
p49657
sg35206
(lp49658
(dp49659
g35211
I0
sg35212
VTOMM20
p49660
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp49661
(dp49662
g35211
I48
sg35212
VPTC
p49663
sg35214
I3
sg35215
VC0238463
p49664
sg35217
I1
sasa(dp49665
g35204
VHigh MCT1 and TOMM20 expression is also found in ATC mouse xenograft tumors compared to non-cancerous thyroid tissue (P&lt;.001).
p49666
sg35206
(lp49667
(dp49668
g35211
I5
sg35212
VMCT1
p49669
sg35214
I4
sg35223
VP23946
p49670
sg35217
I1
sa(dp49671
g35211
I14
sg35212
VTOMM20
p49672
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp49673
(dp49674
g35211
I69
sg35212
Vtumors
p49675
sg35214
I6
sg35215
VC0027651
p49676
sg35217
I1
sasa(dp49677
g135
(dp49678
(VMCT1
p49679
VPTC
p49680
tp49681
I00
ssg35204
VATC has metabolic features that distinguish it from PTC and non-cancerous thyroid tissue, including high expression of MCT1 and TOMM20.
p49682
sg35206
(lp49683
(dp49684
g35211
I128
sg35212
VTOMM20
p49685
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp49686
g35211
I119
sg35212
g49679
sg35214
I4
sg35223
VP23946
p49687
sg35217
I1
sasg35208
(lp49688
(dp49689
g35211
I52
sg35212
g49680
sg35214
I3
sg35215
VC0238463
p49690
sg35217
I1
sasa(dp49691
g135
(dp49692
(VMCT1
p49693
VPTC
p49694
tp49695
I00
ssg35204
VPTC has low expression of MCT1 and non-cancerous thyroid tissue has low expression of both MCT1 and TOMM20.
p49696
sg35206
(lp49697
(dp49698
g35211
I100
sg35212
VTOMM20
p49699
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp49700
g35211
I26
sg35212
VMCT1
p49701
sg35214
I4
sg35223
VP23946
p49702
sg35217
I1
sa(dp49703
g35211
I26
sg35212
g49693
sg35214
I4
sg35223
VP23946
p49704
sg35217
I1
sa(dp49705
g35211
I0
sg35212
VPTC
p49706
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp49707
(dp49708
g35211
I0
sg35212
g49694
sg35214
I3
sg35215
VC0238463
p49709
sg35217
I1
sasa(dp49710
g35204
VAM can induce a metastatic phenotype in prostate cancer cells through its action on TRPV2 calcium channels and is also capable of influencing localised levels of RANKL in the bone to favour tumourigenesis.
p49711
sg35206
(lp49712
(dp49713
g35211
I84
sg35212
VTRPV2 calcium channels
p49714
sg35214
I22
sg35223
g12
sg35217
I3
sa(dp49715
g35211
I162
sg35212
VRANKL
p49716
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49717
(dp49718
g35211
I40
sg35212
Vprostate cancer
p49719
sg35214
I15
sg35215
VC0600139
p49720
sg35217
I2
sasa(dp49721
g35204
VTo determine the profiles of soluble cytokine receptors and cytokines, including mostly their ligands, in the vitreous humor of patients with B-cell vitreoretinal lymphoma (VRL) and uveitis.
p49722
sg35206
(lp49723
sg35208
(lp49724
(dp49725
g35211
I163
sg35212
Vlymphoma
p49726
sg35214
I8
sg35215
VC0024299
p49727
sg35217
I1
sa(dp49728
g35211
I182
sg35212
Vuveitis
p49729
sg35214
I7
sg35215
VC0042164
p49730
sg35217
I1
sasa(dp49731
g35204
VIn analyses in patients with VRL, elevation of sVEGFR1 and sVEGFR2 levels was more prominent in patients with systemic metastatic retinal lymphoma (SMRL) than in those with primary VRL/primary central nervous system lymphoma (PVRL/PCNSL).
p49732
sg35206
(lp49733
sg35208
(lp49734
(dp49735
g35211
I231
sg35212
VPCNSL
p49736
sg35214
I5
sg35215
VC0280803
p49737
sg35217
I1
sa(dp49738
g35211
I185
sg35212
Vprimary central nervous system lymphoma
p49739
sg35214
I39
sg35215
VC0280803
p49740
sg35217
I5
sa(dp49741
g35211
I130
sg35212
Vretinal lymphoma
p49742
sg35214
I16
sg35215
VC0339556
p49743
sg35217
I2
sasa(dp49744
g135
(dp49745
(Vadrenomedullin
p49746
Vprostate cancer
p49747
tp49748
I00
ssg35204
VFor example in prostate cancer cells, the TRPV2 activation following lysophospholipid or adrenomedullin stimulation enhances the invasiveness of cancer cells; furthermore, the increased malignancy of castration-resistant prostate cancer cells was associated with enhanced TRPV2 expression, mainly in metastatic prostate cancer cells.
p49749
sg35206
(lp49750
(dp49751
g35211
I42
sg35212
VTRPV2
p49752
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49753
g35211
I42
sg35212
VTRPV2
p49754
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49755
g35211
I89
sg35212
g49746
sg35214
I14
sg35223
VP35318
p49756
sg35217
I1
sasg35208
(lp49757
(dp49758
g35211
I300
sg35212
Vmetastatic prostate cancer
p49759
sg35214
I26
sg35215
VC0936223
p49760
sg35217
I3
sa(dp49761
g35211
I186
sg35212
Vmalignancy
p49762
sg35214
I10
sg35215
VC0006826
p49763
sg35217
I1
sa(dp49764
g35211
I15
sg35212
Vprostate cancer
p49765
sg35214
I15
sg35215
VC0600139
p49766
sg35217
I2
sa(dp49767
g35211
I15
sg35212
g49747
sg35214
I15
sg35215
VC0600139
p49768
sg35217
I2
sa(dp49769
g35211
I24
sg35212
Vcancer
p49770
sg35214
I6
sg35215
VC0006826
p49771
sg35217
I1
sasa(dp49772
g35204
VIn this regard, bladder cancer tumors show loss or reduction of a short TRPV2 variant during cancer progression, with increased malignancy and invasiveness.
p49773
sg35206
(lp49774
(dp49775
g35211
I72
sg35212
VTRPV2
p49776
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49777
(dp49778
g35211
I31
sg35212
Vtumors
p49779
sg35214
I6
sg35215
VC0027651
p49780
sg35217
I1
sa(dp49781
g35211
I128
sg35212
Vmalignancy
p49782
sg35214
I10
sg35215
VC0006826
p49783
sg35217
I1
sa(dp49784
g35211
I93
sg35212
Vcancer progression
p49785
sg35214
I18
sg35215
VC0178874
p49786
sg35217
I2
sa(dp49787
g35211
I16
sg35212
Vbladder cancer
p49788
sg35214
I14
sg35215
VC0699885
p49789
sg35217
I2
sasa(dp49790
g35204
VTRPV2 and TRPM7 expression levels and TRPV2 activator-induced intracellular Ca(2+) increases were significantly higher, whereas TRPV4 expression and TRPV4 activator-induced intracellular Ca(2+) increases were significantly lower in mouse bladder cancer (MBT-2) cells compared to normal mouse urothelial cells.
p49791
sg35206
(lp49792
(dp49793
g35211
I0
sg35212
VTRPV2
p49794
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49795
g35211
I0
sg35212
VTRPV2
p49796
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49797
g35211
I10
sg35212
VTRPM7
p49798
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49799
(dp49800
g35211
I238
sg35212
Vbladder cancer
p49801
sg35214
I14
sg35215
VC0699885
p49802
sg35217
I2
sasa(dp49803
g35204
VIncreases in the expression of TRPV2 mRNA, immunoreactivity, and TRPV2 activator-induced intracellular Ca(2+) were also observed in T24 human bladder cancer cells.
p49804
sg35206
(lp49805
(dp49806
g35211
I31
sg35212
VTRPV2 mRNA
p49807
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp49808
g35211
I31
sg35212
VTRPV2
p49809
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49810
(dp49811
g35211
I142
sg35212
Vbladder cancer
p49812
sg35214
I14
sg35215
VC0699885
p49813
sg35217
I2
sasa(dp49814
g35204
VThese results suggested that TRPV2 and TRPM7 were functionally expressed in bladder cancer cells and served as negative regulators of bladder cancer cell proliferation, most likely to prevent excess mechanical stresses.
p49815
sg35206
(lp49816
(dp49817
g35211
I39
sg35212
VTRPM7
p49818
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49819
g35211
I29
sg35212
VTRPV2
p49820
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49821
(dp49822
g35211
I76
sg35212
Vbladder cancer
p49823
sg35214
I14
sg35215
VC0699885
p49824
sg35217
I2
sa(dp49825
g35211
I76
sg35212
Vbladder cancer
p49826
sg35214
I14
sg35215
VC0699885
p49827
sg35217
I2
sa(dp49828
g35211
I154
sg35212
Vproliferation
p49829
sg35214
I13
sg35215
VC0334094
p49830
sg35217
I1
sasa(dp49831
g35204
VOn the other hand, in prostate cancer cells, Ca2+-dependent activation of TRPV2 induced by lysophospholipids increases the invasion of tumor cells.
p49832
sg35206
(lp49833
(dp49834
g35211
I74
sg35212
VTRPV2
p49835
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49836
(dp49837
g35211
I123
sg35212
Vinvasion
p49838
sg35214
I8
sg35215
VC2699153
p49839
sg35217
I1
sa(dp49840
g35211
I22
sg35212
Vprostate cancer
p49841
sg35214
I15
sg35215
VC0600139
p49842
sg35217
I2
sa(dp49843
g35211
I135
sg35212
Vtumor
p49844
sg35214
I5
sg35215
VC0027651
p49845
sg35217
I1
sasa(dp49846
g35204
VIn addition, the progression of prostate cancer to the castration-resistant phenotype is characterized by de novo TRPV2 expression, with higher TRPV2 transcript levels in patients with metastatic cancer.
p49847
sg35206
(lp49848
(dp49849
g35211
I114
sg35212
VTRPV2
p49850
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49851
g35211
I144
sg35212
VTRPV2 transcript
p49852
sg35214
I16
sg35223
g12
sg35217
I2
sasg35208
(lp49853
(dp49854
g35211
I17
sg35212
Vprogression of prostate cancer
p49855
sg35214
I30
sg35215
VC1739135
p49856
sg35217
I4
sa(dp49857
g35211
I185
sg35212
Vmetastatic cancer
p49858
sg35214
I17
sg35215
VC0027627
p49859
sg35217
I2
sasa(dp49860
g35204
VThe aim of the present study was to investigate the effects of TRPV2 on the proliferation, migration and invasion of 5637 bladder cancer cells in vitro.
p49861
sg35206
(lp49862
(dp49863
g35211
I63
sg35212
VTRPV2
p49864
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49865
(dp49866
g35211
I76
sg35212
Vproliferation
p49867
sg35214
I13
sg35215
VC0334094
p49868
sg35217
I1
sa(dp49869
g35211
I105
sg35212
Vinvasion
p49870
sg35214
I8
sg35215
VC2699153
p49871
sg35217
I1
sa(dp49872
g35211
I122
sg35212
Vbladder cancer
p49873
sg35214
I14
sg35215
VC0699885
p49874
sg35217
I2
sasa(dp49875
g35204
VRat TRPV2 cDNA was transfected into 5637 bladder cancer cells and changes in the behavior of the cells were detected.
p49876
sg35206
(lp49877
(dp49878
g35211
I0
sg35212
VRat TRPV2 cDNA
p49879
sg35214
I14
sg35223
g12
sg35217
I3
sasg35208
(lp49880
(dp49881
g35211
I41
sg35212
Vbladder cancer
p49882
sg35214
I14
sg35215
VC0699885
p49883
sg35217
I2
sasa(dp49884
g35204
VIt was observed that TRPV2 enhanced bladder cancer cell migration and invasion; however, it did not affect cell proliferation in vitro.
p49885
sg35206
(lp49886
(dp49887
g35211
I21
sg35212
VTRPV2
p49888
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49889
(dp49890
g35211
I112
sg35212
Vproliferation
p49891
sg35214
I13
sg35215
VC0334094
p49892
sg35217
I1
sa(dp49893
g35211
I36
sg35212
Vbladder cancer
p49894
sg35214
I14
sg35215
VC0699885
p49895
sg35217
I2
sa(dp49896
g35211
I70
sg35212
Vinvasion
p49897
sg35214
I8
sg35215
VC2699153
p49898
sg35217
I1
sasa(dp49899
g35204
VThe results of this study suggest that TRPV2 channels are a potential therapeutic target for bladder carcinoma.
p49900
sg35206
(lp49901
(dp49902
g35211
I39
sg35212
VTRPV2 channels
p49903
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp49904
(dp49905
g35211
I93
sg35212
Vbladder carcinoma
p49906
sg35214
I17
sg35215
VC0699885
p49907
sg35217
I2
sasa(dp49908
g35204
VThe Transient Receptor Potential channel TRPV2 is known to promote in prostate cancer cell migration and invasive phenotype and is correlated with the stage and grade of bladder cancer.
p49909
sg35206
(lp49910
(dp49911
g35211
I41
sg35212
VTRPV2
p49912
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp49913
(dp49914
g35211
I170
sg35212
Vbladder cancer
p49915
sg35214
I14
sg35215
VC0699885
p49916
sg35217
I2
sa(dp49917
g35211
I70
sg35212
Vprostate cancer
p49918
sg35214
I15
sg35215
VC0600139
p49919
sg35217
I2
sasa(dp49920
g35204
VInitial studies showed that expression profile of some TRP channels, notably TRP melastatin 8 (TRPM8), TRP vanilloid 6 (TRPV6),TRP canonical (TRPC6) and TRPV2, is changing during the development and the progression of prostate cancer towards the hormone-refractory stages.
p49921
sg35206
(lp49922
(dp49923
g35211
I95
sg35212
VTRPM8
p49924
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49925
g35211
I142
sg35212
VTRPC6
p49926
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49927
g35211
I55
sg35212
VTRP
p49928
sg35214
I3
sg35223
VP13686
p49929
sg35217
I1
sa(dp49930
g35211
I120
sg35212
VTRPV6
p49931
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49932
g35211
I103
sg35212
VTRP vanilloid 6
p49933
sg35214
I15
sg35223
VP13686
p49934
sg35217
I3
sa(dp49935
g35211
I153
sg35212
VTRPV2
p49936
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp49937
g35211
I55
sg35212
VTRP channels
p49938
sg35214
I12
sg35223
VP13686
p49939
sg35217
I2
sa(dp49940
g35211
I77
sg35212
VTRP melastatin 8
p49941
sg35214
I16
sg35223
VP13686
p49942
sg35217
I3
sasg35208
(lp49943
(dp49944
g35211
I203
sg35212
Vprogression of prostate cancer
p49945
sg35214
I30
sg35215
VC1739135
p49946
sg35217
I4
sasa(dp49947
g35204
VThe expression of TRPV2 mRNA in bladder cancer cell lines (T24, a poorly differentiated UC cell line and RT4, a well-differentiated UC cell line) was analyzed using reverse transcriptase-polymerase chain reaction.
p49948
sg35206
(lp49949
(dp49950
g35211
I18
sg35212
VTRPV2 mRNA
p49951
sg35214
I10
sg35223
g12
sg35217
I2
sa(dp49952
g35211
I165
sg35212
Vreverse transcriptase
p49953
sg35214
I21
sg35223
VP63136
p49954
sg35217
I2
sasg35208
(lp49955
(dp49956
g35211
I32
sg35212
Vbladder cancer
p49957
sg35214
I14
sg35215
VC0699885
p49958
sg35217
I2
sasa(dp49959
g35204
VFurthermore, the effects of resveratrol and Shh on human colorectal cancer HCT116 cells were in a dose- and time-dependent manner.
p49960
sg35206
(lp49961
(dp49962
g35211
I44
sg35212
VShh
p49963
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp49964
(dp49965
g35211
I57
sg35212
Vcolorectal cancer
p49966
sg35214
I17
sg35215
VC1527249
p49967
sg35217
I2
sasa(dp49968
g135
(dp49969
(VGli-1
p49970
VPtc
p49971
tp49972
I00
ssg35204
VFurthermore, knockdown of PFTK1 suppressed the expression of Shh as well as Smo, Ptc, and Gli-1 in colon cancer cells.
p49973
sg35206
(lp49974
(dp49975
g35211
I76
sg35212
VSmo
p49976
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp49977
g35211
I61
sg35212
VShh
p49978
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp49979
g35211
I81
sg35212
VPtc
p49980
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp49981
g35211
I90
sg35212
g49970
sg35214
I5
sg35223
VP08151
p49982
sg35217
I1
sasg35208
(lp49983
(dp49984
g35211
I99
sg35212
Vcolon cancer
p49985
sg35214
I12
sg35215
VC0699790
p49986
sg35217
I2
sa(dp49987
g35211
I81
sg35212
g49971
sg35214
I3
sg35215
VC0238463
p49988
sg35217
I1
sasa(dp49989
g35204
VTaken together, these results suggest that knockdown of PFTK1 inhibited the proliferation and invasion of colon cancer cells as well as the EMT progress by suppressing the Sonic hedgehog signaling pathway.
p49990
sg35206
(lp49991
(dp49992
g35211
I140
sg35212
VEMT
p49993
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp49994
g35211
I172
sg35212
VSonic hedgehog
p49995
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp49996
(dp49997
g35211
I106
sg35212
Vcolon cancer
p49998
sg35214
I12
sg35215
VC0699790
p49999
sg35217
I2
sa(dp50000
g35211
I76
sg35212
Vproliferation
p50001
sg35214
I13
sg35215
VC0334094
p50002
sg35217
I1
sa(dp50003
g35211
I94
sg35212
Vinvasion
p50004
sg35214
I8
sg35215
VC2699153
p50005
sg35217
I1
sasa(dp50006
g35204
VThis case illustrates the potential severity of the renal anomalies in the BOR syndrome and the inadequacy of oligohydramnios and maternal serum alpha-fetoprotein as screening methods for renal agenesis.
p50007
sg35206
(lp50008
sg35208
(lp50009
(dp50010
g35211
I75
sg35212
VBOR syndrome
p50011
sg35214
I12
sg35215
VC0265234
p50012
sg35217
I2
sa(dp50013
g35211
I52
sg35212
Vrenal anomalies
p50014
sg35214
I15
sg35215
VC0266292
p50015
sg35217
I2
sa(dp50016
g35211
I188
sg35212
Vrenal agenesis
p50017
sg35214
I14
sg35215
VC0542519
p50018
sg35217
I2
sa(dp50019
g35211
I110
sg35212
Voligohydramnios
p50020
sg35214
I15
sg35215
VC0079924
p50021
sg35217
I1
sasa(dp50022
g35204
VSevere sepsis and antibiotic use were both associated with moderate thrombocytopenia, and proton pump inhibitor use was statistically significant in both univariate and multivariate analysis.
p50023
sg35206
(lp50024
sg35208
(lp50025
(dp50026
g35211
I0
sg35212
VSevere sepsis
p50027
sg35214
I13
sg35215
VC1719672
p50028
sg35217
I2
sasa(dp50029
g35204
VThrombocytopenia is associated with poor prognosis, and the association between moderate thrombocytopenia and proton pump inhibitor use is relatively novel and should be validated in prospective studies.
p50030
sg35206
(lp50031
sg35208
(lp50032
sa(dp50033
g35204
VWe identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.
p50034
sg35206
(lp50035
(dp50036
g35211
I147
sg35212
VCD14
p50037
sg35214
I4
sg35223
VP08571
p50038
sg35217
I1
sa(dp50039
g35211
I173
sg35212
VRAB24
p50040
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp50041
g35211
I153
sg35212
VFCGR1A
p50042
sg35214
I6
sg35223
VP12314
p50043
sg35217
I1
sa(dp50044
g35211
I268
sg35212
VCD3E
p50045
sg35214
I4
sg35223
VP07766
p50046
sg35217
I1
sa(dp50047
g35211
I274
sg35212
VCD8A
p50048
sg35214
I4
sg35223
VP01732
p50049
sg35217
I1
sa(dp50050
g35211
I262
sg35212
VBLR1
p50051
sg35214
I4
sg35223
VP32302
p50052
sg35217
I1
sa(dp50053
g35211
I180
sg35212
VSEC14L1
p50054
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp50055
g35211
I167
sg35212
VMMP9
p50056
sg35214
I4
sg35223
VP14780
p50057
sg35217
I1
sa(dp50058
g35211
I193
sg35212
VTIMP2
p50059
sg35214
I5
sg35223
VP16035
p50060
sg35217
I1
sa(dp50061
g35211
I161
sg35212
VFPR1
p50062
sg35214
I4
sg35223
VP21462
p50063
sg35217
I1
sa(dp50064
g35211
I290
sg35212
VTGFBR2
p50065
sg35214
I6
sg35223
VP37173
p50066
sg35217
I1
sasg35208
(lp50067
(dp50068
g35211
I341
sg35212
Vpathology
p50069
sg35214
I9
sg35215
VC0677042
p50070
sg35217
I1
sasa(dp50071
g35204
VWestern blot assay further confirmed that anti-ICAM-T0901317 liposomes inhibited retinoblastoma (Rb) phosphorylation and MCM6 expression.
p50072
sg35206
(lp50073
(dp50074
g35211
I81
sg35212
Vretinoblastoma (Rb)
p50075
sg35214
I19
sg35223
g12
sg35217
I2
sa(dp50076
g35211
I121
sg35212
VMCM6
p50077
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp50078
(dp50079
g35211
I97
sg35212
VRb
p50080
sg35214
I2
sg35215
VC0035335
p50081
sg35217
I1
sa(dp50082
g35211
I81
sg35212
Vretinoblastoma
p50083
sg35214
I14
sg35215
VC0035335
p50084
sg35217
I1
sasa(dp50085
g135
(dp50086
(VMCM7
p50087
Vretinoblastoma
p50088
tp50089
I00
ssg35204
VInhibition of MCM6 and MCM7 expression by nTZDpa and rosiglitazone paralleled their effect to inhibit phosphorylation of the retinoblastoma protein and cell proliferation.
p50090
sg35206
(lp50091
(dp50092
g35211
I125
sg35212
Vretinoblastoma protein
p50093
sg35214
I22
sg35223
g12
sg35217
I2
sa(dp50094
g35211
I23
sg35212
g50087
sg35214
I4
sg35223
VP33993
p50095
sg35217
I1
sa(dp50096
g35211
I14
sg35212
VMCM6
p50097
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp50098
(dp50099
g35211
I125
sg35212
g50088
sg35214
I14
sg35215
VC0035335
p50100
sg35217
I1
sa(dp50101
g35211
I157
sg35212
Vproliferation
p50102
sg35214
I13
sg35215
VC0334094
p50103
sg35217
I1
sasa(dp50104
g35204
VSnord3A expression was also elevated in scrapie infected mice, but not in PrP(0/0) mice, indicating that while the expression levels of this transcript may reflect diverse prion etiologies, they are not related to the loss of PrP(C)'s function.
p50105
sg35206
(lp50106
(dp50107
g35211
I74
sg35212
VPrP
p50108
sg35214
I3
sg35223
g12
sg35217
I1
sasg35208
(lp50109
(dp50110
g35211
I40
sg35212
Vscrapie
p50111
sg35214
I7
sg35215
VC0036457
p50112
sg35217
I1
sasa(dp50113
g35204
VWe hypothesize that in addition to its function as a disease marker, Snord3A may play an important role in the mechanism of prion disease manifestation and progression.
p50114
sg35206
(lp50115
sg35208
(lp50116
(dp50117
g35211
I124
sg35212
Vprion disease
p50118
sg35214
I13
sg35215
VC0162534
p50119
sg35217
I2
sasa(dp50120
g135
(dp50121
(VIgA
p50122
VIgA deficiency
p50123
tp50124
I00
ssg35204
VHer son has type 1 diabetes, arthritis, reduced IgG levels and IgA deficiency, but has not inherited the TNFRSF13B/TACI mutation.
p50125
sg35206
(lp50126
(dp50127
g35211
I63
sg35212
g50122
sg35214
I3
sg35223
VP11912
p50128
sg35217
I1
sa(dp50129
g35211
I105
sg35212
VTNFRSF13B
p50130
sg35214
I9
sg35223
g12
sg35217
I1
sa(dp50131
g35211
I115
sg35212
VTACI
p50132
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp50133
(dp50134
g35211
I29
sg35212
Varthritis
p50135
sg35214
I9
sg35215
VC0003864
p50136
sg35217
I1
sa(dp50137
g35211
I12
sg35212
Vtype 1 diabetes
p50138
sg35214
I15
sg35215
VC0011854
p50139
sg35217
I3
sa(dp50140
g35211
I63
sg35212
g50123
sg35214
I14
sg35215
VC0162538
p50141
sg35217
I2
sasa(dp50142
g135
(dp50143
(VNOD B
p50144
VNOD
p50145
tp50146
I00
ssg35204
VOur results support the hypothesis that increased TACI expression on NOD B cells contributes to the pathogenesis of type 1 diabetes in the NOD mouse.
p50147
sg35206
(lp50148
(dp50149
g35211
I69
sg35212
g50144
sg35214
I5
sg35223
VP54259
p50150
sg35217
I2
sa(dp50151
g35211
I50
sg35212
VTACI
p50152
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp50153
(dp50154
g35211
I116
sg35212
Vtype 1 diabetes
p50155
sg35214
I15
sg35215
VC0011854
p50156
sg35217
I3
sa(dp50157
g35211
I69
sg35212
VNOD
p50158
sg35214
I3
sg35215
VC0751781
p50159
sg35217
I1
sa(dp50160
g35211
I69
sg35212
g50145
sg35214
I3
sg35215
VC0751781
p50161
sg35217
I1
sa(dp50162
g35211
I100
sg35212
Vpathogenesis
p50163
sg35214
I12
sg35215
VC0699748
p50164
sg35217
I1
sasa(dp50165
g135
(dp50166
(VIgA
p50167
VIgA deficiency
p50168
tp50169
I00
ssg35204
VA family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes.
p50170
sg35206
(lp50171
(dp50172
g35211
I50
sg35212
VCVID-related phenotype
p50173
sg35214
I22
sg35223
g12
sg35217
I2
sa(dp50174
g35211
I23
sg35212
Vwild type TACI variant
p50175
sg35214
I22
sg35223
g12
sg35217
I4
sa(dp50176
g35211
I83
sg35212
g50167
sg35214
I3
sg35223
VP11912
p50177
sg35217
I1
sasg35208
(lp50178
(dp50179
g35211
I102
sg35212
Vtype 1 diabetes
p50180
sg35214
I15
sg35215
VC0011854
p50181
sg35217
I3
sa(dp50182
g35211
I50
sg35212
VCVID
p50183
sg35214
I4
sg35215
VC0009447
p50184
sg35217
I1
sa(dp50185
g35211
I83
sg35212
g50168
sg35214
I14
sg35215
VC0162538
p50186
sg35217
I2
sasa(dp50187
g135
(dp50188
(Vinsulin
p50189
VIdd
p50190
tp50191
I00
ssg35204
VWe mapped the loci contributing to the increased proportion of TACI(high) expressing splenic B cells and found that the control of TACI expression was strongly linked to chromosome 1, in a region which includes the insulin-dependent diabetes (Idd) 5 loci.
p50192
sg35206
(lp50193
(dp50194
g35211
I63
sg35212
VTACI
p50195
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp50196
g35211
I215
sg35212
g50189
sg35214
I7
sg35223
VP01308
p50197
sg35217
I1
sasg35208
(lp50198
(dp50199
g35211
I215
sg35212
Vinsulin-dependent diabetes
p50200
sg35214
I26
sg35215
VC0011854
p50201
sg35217
I2
sa(dp50202
g35211
I243
sg35212
g50190
sg35214
I3
sg35215
VC0011854
p50203
sg35217
I1
sasa(dp50204
g35204
VOur findings corroborate the notion that B cell deviations contribute to type 1 diabetes development, and suggest a temporal regulation of TACI(high) expression, possibly influenced by the ongoing autoimmune process.
p50205
sg35206
(lp50206
sg35208
(lp50207
(dp50208
g35211
I73
sg35212
Vtype 1 diabetes
p50209
sg35214
I15
sg35215
VC0011854
p50210
sg35217
I3
sa(dp50211
g35211
I197
sg35212
Vautoimmune process
p50212
sg35214
I18
sg35215
VC0443146
p50213
sg35217
I2
sasa(dp50214
g135
(dp50215
(VOCT4
p50216
Vcancer progression
p50217
tp50218
I01
ssg35204
VOctamer-binding transcription factor 4 (OCT4) was closely related to pancreatic cancer progression, but its regulation in pancreatic cancer by microRNA (miRNA) is not fully clear.
p50219
sg35206
(lp50220
(dp50221
g35211
I0
sg35212
VOctamer-binding transcription factor 4
p50222
sg35214
I38
sg35223
VP15884
p50223
sg35217
I4
sa(dp50224
g35211
I40
sg35212
g50216
sg35214
I4
sg35223
VP15884
p50225
sg35217
I1
sasg35208
(lp50226
(dp50227
g35211
I69
sg35212
Vpancreatic cancer
p50228
sg35214
I17
sg35215
VC0235974
p50229
sg35217
I2
sa(dp50230
g35211
I80
sg35212
g50217
sg35214
I18
sg35215
VC0178874
p50231
sg35217
I2
sasa(dp50232
g135
(dp50233
(VT-box transcription factor 4
p50234
Vpancreatic ductal adenocarcinoma
p50235
tp50236
I00
ssg35204
VThis study was designed to investigate the expression of the T-box transcription factor 4 (TBX4), a tumor biomarker that was previously identified by proteomics, in pancreatic ductal adenocarcinoma (PDAC) and evaluate its clinical utility as a potential prognostic biomarkers for PDAC.
p50237
sg35206
(lp50238
(dp50239
g35211
I91
sg35212
VTBX4
p50240
sg35214
I4
sg35223
VP57082
p50241
sg35217
I1
sa(dp50242
g35211
I61
sg35212
g50234
sg35214
I28
sg35223
VP15884
p50243
sg35217
I4
sasg35208
(lp50244
(dp50245
g35211
I100
sg35212
Vtumor
p50246
sg35214
I5
sg35215
VC0027651
p50247
sg35217
I1
sa(dp50248
g35211
I199
sg35212
VPDAC
p50249
sg35214
I4
sg35215
VC1335302
p50250
sg35217
I1
sa(dp50251
g35211
I199
sg35212
VPDAC
p50252
sg35214
I4
sg35215
VC1335302
p50253
sg35217
I1
sa(dp50254
g35211
I165
sg35212
g50235
sg35214
I32
sg35215
VC1335302
p50255
sg35217
I3
sasa(dp50256
g35204
VWhereas the pathological functions of LTB4/BLT1 axis in allergy, autoimmunity and cardiovascular disorders are well established; its role in cancer is only beginning to emerge.
p50257
sg35206
(lp50258
(dp50259
g35211
I43
sg35212
VBLT1
p50260
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp50261
(dp50262
g35211
I141
sg35212
Vcancer
p50263
sg35214
I6
sg35215
VC0006826
p50264
sg35217
I1
sa(dp50265
g35211
I56
sg35212
Vallergy
p50266
sg35214
I7
sg35215
VC0020517
p50267
sg35217
I1
sa(dp50268
g35211
I65
sg35212
Vautoimmunity
p50269
sg35214
I12
sg35215
VC0004368
p50270
sg35217
I1
sa(dp50271
g35211
I82
sg35212
Vcardiovascular disorders
p50272
sg35214
I24
sg35215
VC0007222
p50273
sg35217
I2
sasa(dp50274
g35204
VBioluminescence tomography (BLT) is a powerful non-invasive molecular imaging tool for in vivo studies of glioma in mice.
p50275
sg35206
(lp50276
sg35208
(lp50277
(dp50278
g35211
I106
sg35212
Vglioma
p50279
sg35214
I6
sg35215
VC0017638
p50280
sg35217
I1
sasa(dp50281
g35204
VTo the best of our knowledge, this is the first study that achieved such accurate BLT morphological reconstruction of orthotopic glioma without using any segmented tumor structure from any other structural imaging modalities as the prior for reconstruction guidance.
p50282
sg35206
(lp50283
sg35208
(lp50284
(dp50285
g35211
I129
sg35212
Vglioma
p50286
sg35214
I6
sg35215
VC0017638
p50287
sg35217
I1
sa(dp50288
g35211
I164
sg35212
Vtumor
p50289
sg35214
I5
sg35215
VC0027651
p50290
sg35217
I1
sasa(dp50291
g35204
VThis enabled BLT more suitable and practical for in vivo imaging of orthotopic glioma mouse models.
p50292
sg35206
(lp50293
sg35208
(lp50294
(dp50295
g35211
I79
sg35212
Vglioma
p50296
sg35214
I6
sg35215
VC0017638
p50297
sg35217
I1
sasa(dp50298
g135
(dp50299
(VIDO1
p50300
VGBM
p50301
tp50302
I00
ssg35204
VThe major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patient outcome.Experimental Design: Patient-resected GBM, The Cancer Genome Atlas, human T-cell:GBM cocultures, as well as nu/nu, NOD-scid, and humanized (NSG-SGM3-BLT) mice-engrafted human GBM form the basis of our investigation.Results:In situ hybridization for IDO1 revealed transcript expression throughout patient-resected GBM, whereas immunohistochemical IDO1 positivity was highly variable.
p50303
sg35206
(lp50304
(dp50305
g35211
I85
sg35212
VIDO1
p50306
sg35214
I4
sg35223
VP14902
p50307
sg35217
I1
sa(dp50308
g35211
I85
sg35212
g50300
sg35214
I4
sg35223
VP14902
p50309
sg35217
I1
sasg35208
(lp50310
(dp50311
g35211
I331
sg35212
Vscid
p50312
sg35214
I4
sg35215
VC0085110
p50313
sg35217
I1
sa(dp50314
g35211
I131
sg35212
VGBM
p50315
sg35214
I3
sg35215
VC0017636
p50316
sg35217
I1
sa(dp50317
g35211
I259
sg35212
VCancer
p50318
sg35214
I6
sg35215
VC0006826
p50319
sg35217
I1
sa(dp50320
g35211
I327
sg35212
VNOD
p50321
sg35214
I3
sg35215
VC0751781
p50322
sg35217
I1
sa(dp50323
g35211
I131
sg35212
VGBM
p50324
sg35214
I3
sg35215
VC0017636
p50325
sg35217
I1
sa(dp50326
g35211
I131
sg35212
VGBM
p50327
sg35214
I3
sg35215
VC0017636
p50328
sg35217
I1
sa(dp50329
g35211
I131
sg35212
VGBM
p50330
sg35214
I3
sg35215
VC0017636
p50331
sg35217
I1
sa(dp50332
g35211
I131
sg35212
VGBM
p50333
sg35214
I3
sg35215
VC0017636
p50334
sg35217
I1
sa(dp50335
g35211
I131
sg35212
g50301
sg35214
I3
sg35215
VC0017636
p50336
sg35217
I1
sasa(dp50337
g35204
VTogether with CT, BLT can provide precision radiation guidance and robust tumor volume assessment in small animal cancer research.
p50338
sg35206
(lp50339
sg35208
(lp50340
(dp50341
g35211
I114
sg35212
Vcancer
p50342
sg35214
I6
sg35215
VC0006826
p50343
sg35217
I1
sa(dp50344
g35211
I74
sg35212
Vtumor
p50345
sg35214
I5
sg35215
VC0027651
p50346
sg35217
I1
sasa(dp50347
g35204
VVariation of detected bioluminescence signals emitted from molecular cancer cells was depicted on BLT images.
p50348
sg35206
(lp50349
sg35208
(lp50350
(dp50351
g35211
I69
sg35212
Vcancer
p50352
sg35214
I6
sg35215
VC0006826
p50353
sg35217
I1
sasa(dp50354
g35204
VMultispectral BLT images elaborated on early detection of cancer cells, characteristics of tumor growth, and metastasis for more accurate determination of internal bioluminescent sources.
p50355
sg35206
(lp50356
sg35208
(lp50357
(dp50358
g35211
I58
sg35212
Vcancer
p50359
sg35214
I6
sg35215
VC0006826
p50360
sg35217
I1
sa(dp50361
g35211
I91
sg35212
Vtumor growth
p50362
sg35214
I12
sg35215
VC0598934
p50363
sg35217
I2
sa(dp50364
g35211
I109
sg35212
Vmetastasis
p50365
sg35214
I10
sg35215
VC0027627
p50366
sg35217
I1
sasa(dp50367
g35204
VRegistration of BLT with CT images guided molecular cancer cells on anatomical coordinates.
p50368
sg35206
(lp50369
sg35208
(lp50370
(dp50371
g35211
I52
sg35212
Vcancer
p50372
sg35214
I6
sg35215
VC0006826
p50373
sg35217
I1
sasa(dp50374
g35204
VThe BLT imaging was a useful tool to localize cancer cells and to quantify radiation response.
p50375
sg35206
(lp50376
sg35208
(lp50377
(dp50378
g35211
I46
sg35212
Vcancer
p50379
sg35214
I6
sg35215
VC0006826
p50380
sg35217
I1
sasa(dp50381
g35204
VApplication of BLT led to more accurate definition of tumor volumes including molecular probe-based microscopic cancer cells.
p50382
sg35206
(lp50383
sg35208
(lp50384
(dp50385
g35211
I54
sg35212
Vtumor
p50386
sg35214
I5
sg35215
VC0027651
p50387
sg35217
I1
sa(dp50388
g35211
I112
sg35212
Vcancer
p50389
sg35214
I6
sg35215
VC0006826
p50390
sg35217
I1
sasa(dp50391
g35204
VThus, in this report, we not only provide a novel strategy to expand super-charged NK cells, but also demonstrate that rapid and sustained expansion of residual T cells within the purified NK cells during expansion with DCs or OCs could be a potential mechanism by which the numbers and function of NK cells decline in cancer patients and in BLT-humanized mice.
p50392
sg35206
(lp50393
sg35208
(lp50394
(dp50395
g35211
I220
sg35212
VDCs
p50396
sg35214
I3
sg35215
VC0268238
p50397
sg35217
I1
sa(dp50398
g35211
I319
sg35212
Vcancer
p50399
sg35214
I6
sg35215
VC0006826
p50400
sg35217
I1
sasa(dp50401
g35204
VVerrucous carcinoma (VC) is a variant of well-differentiated squamous cell carcinoma and in the anal region is regarded as synonymous with giant condyloma (Buschke-Loewenstein tumour) (BLT).
p50402
sg35206
(lp50403
sg35208
(lp50404
(dp50405
g35211
I176
sg35212
Vtumour
p50406
sg35214
I6
sg35215
VC0027651
p50407
sg35217
I1
sa(dp50408
g35211
I145
sg35212
Vcondyloma
p50409
sg35214
I9
sg35215
VC0009663
p50410
sg35217
I1
sa(dp50411
g35211
I0
sg35212
VVerrucous carcinoma
p50412
sg35214
I19
sg35215
VC0206706
p50413
sg35217
I2
sa(dp50414
g35211
I139
sg35212
Vgiant
p50415
sg35214
I5
sg35215
VC0017547
p50416
sg35217
I1
sa(dp50417
g35211
I21
sg35212
VVC
p50418
sg35214
I2
sg35215
VC0206706
p50419
sg35217
I1
sa(dp50420
g35211
I61
sg35212
Vsquamous cell carcinoma
p50421
sg35214
I23
sg35215
VC0007137
p50422
sg35217
I3
sasa(dp50423
g135
(dp50424
(VFgf8
p50425
VCrouzon syndrome
p50426
tp50427
I00
ssg35204
VTo test this idea, we infected migrating neural crest cells of chicken embryos with  replication-competent avian sarcoma virus expressing either FgfR2(C278F), a receptor mutation found in Crouzon syndrome or the ligand Fgf8.
p50428
sg35206
(lp50429
(dp50430
g35211
I219
sg35212
g50425
sg35214
I4
sg35223
VP55075
p50431
sg35217
I1
sasg35208
(lp50432
(dp50433
g35211
I48
sg35212
Vcrest
p50434
sg35214
I5
sg35215
VC0206138
p50435
sg35217
I1
sa(dp50436
g35211
I188
sg35212
g50426
sg35214
I16
sg35215
VC0010273
p50437
sg35217
I2
sa(dp50438
g35211
I107
sg35212
Vavian sarcoma
p50439
sg35214
I13
sg35215
VC0004426
p50440
sg35217
I2
sasa(dp50441
g135
(dp50442
(Vfgf8
p50443
Vhemifacial microsomia
p50444
tp50445
I00
ssg35204
VThese defects are similar in presentation to several human craniofacial disorders (e.g., craniosynostosis, hemifacial microsomia), and may be related to increased levels of bone metabolism observed in ace(ti282a)/fgf8 heterozygotes.
p50446
sg35206
(lp50447
(dp50448
g35211
I213
sg35212
g50443
sg35214
I4
sg35223
VP55075
p50449
sg35217
I1
sasg35208
(lp50450
(dp50451
g35211
I89
sg35212
Vcraniosynostosis
p50452
sg35214
I16
sg35215
VC0010278
p50453
sg35217
I1
sa(dp50454
g35211
I107
sg35212
g50444
sg35214
I21
sg35215
VC1306710
p50455
sg35217
I2
sasa(dp50456
g135
(dp50457
(VFGF8
p50458
Vcraniosynostosis
p50459
tp50460
I01
ssg35204
VSince FGF8 maps to the same chromosomal region as FGFR2, has indeed been shown to be a ligand for FGFR2, and has an expression pattern consistent with limb and craniofacial anomalies, we have screened two kindreds with Pfeiffer syndrome that were previously linked to markers from 10q24-25 and a large number of individuals with craniosynostosis and limb anomalies for mutations in the coding sequence of FGF8.
p50461
sg35206
(lp50462
(dp50463
g35211
I6
sg35212
VFGF8
p50464
sg35214
I4
sg35223
VP55075
p50465
sg35217
I1
sa(dp50466
g35211
I6
sg35212
g50458
sg35214
I4
sg35223
VP55075
p50467
sg35217
I1
sasg35208
(lp50468
(dp50469
g35211
I329
sg35212
g50459
sg35214
I16
sg35215
VC0010278
p50470
sg35217
I1
sa(dp50471
g35211
I219
sg35212
VPfeiffer syndrome
p50472
sg35214
I17
sg35215
VC0265303
p50473
sg35217
I2
sasa(dp50474
g35204
VThe results demonstrated that rhTrx-1 significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death at 24h after MCAO.
p50475
sg35206
(lp50476
sg35208
(lp50477
(dp50478
g35211
I96
sg35212
Vcerebral infarction
p50479
sg35214
I19
sg35215
VC0038454
p50480
sg35217
I2
sasa(dp50481
g35204
VTreatment with Trx1 siRNA significantly increased mortality, behavioral deficits, and cerebral infarction volume and exacerbated neuronal cell apoptotic death after MCAO injury.
p50482
sg35206
(lp50483
(dp50484
g35211
I15
sg35212
VTrx1 siRNA
p50485
sg35214
I10
sg35223
VP60606
p50486
sg35217
I2
sasg35208
(lp50487
(dp50488
g35211
I86
sg35212
Vcerebral infarction
p50489
sg35214
I19
sg35215
VC0038454
p50490
sg35217
I2
sasa(dp50491
g35204
VThe results showed that intravenously administered rhTrx-1 (10 mg/kg) significantly improved neurological functions and reduced cerebral infarction and apoptotic cell death following cerebral ischemia.
p50492
sg35206
(lp50493
sg35208
(lp50494
(dp50495
g35211
I128
sg35212
Vcerebral infarction
p50496
sg35214
I19
sg35215
VC0038454
p50497
sg35217
I2
sa(dp50498
g35211
I183
sg35212
Vcerebral ischemia
p50499
sg35214
I17
sg35215
VC0917798
p50500
sg35217
I2
sasa(dp50501
g35204
VFurthermore, the suppression on ONOO- formation by either rhTrx-1 or an ONOO- scavenger uric acid reduced cerebral infarct size in mice subjected to cerebral ischemia.
p50502
sg35206
(lp50503
sg35208
(lp50504
(dp50505
g35211
I149
sg35212
Vcerebral ischemia
p50506
sg35214
I17
sg35215
VC0007785
p50507
sg35217
I2
sa(dp50508
g35211
I17
sg35212
Vsuppression
p50509
sg35214
I11
sg35215
VC0221103
p50510
sg35217
I1
sa(dp50511
g35211
I106
sg35212
Vcerebral infarct
p50512
sg35214
I16
sg35215
VC0007785
p50513
sg35217
I2
sasa(dp50514
g135
(dp50515
(Vpro-ENK
p50516
Vchronic renal failure
p50517
tp50518
I00
ssg35204
VProenkephalin (pro-ENK), a stable and reliable surrogate marker for unstable enkephalins, was found to be associated with acute kidney injury and chronic renal failure in previous studies.
p50519
sg35206
(lp50520
(dp50521
g35211
I0
sg35212
VProenkephalin
p50522
sg35214
I13
sg35223
VP01210
p50523
sg35217
I1
sa(dp50524
g35211
I15
sg35212
g50516
sg35214
I7
sg35223
VP01210
p50525
sg35217
I1
sasg35208
(lp50526
(dp50527
g35211
I146
sg35212
g50517
sg35214
I21
sg35215
VC0022661
p50528
sg35217
I3
sasa(dp50529
g135
(dp50530
(VCKD-EPI
p50531
VEPI
p50532
tp50533
I00
ssg35204
VPENK and NGAL concentrations were measured and GFR was estimated by using the isotope dilution mass spectrometry traceable-Modification of Diet in Renal Disease (MDRD) Study and three Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations: CKD-EPI(Cr), CDK-EPI(CysC), and CKD-EPI(Cr-CysC).
p50534
sg35206
(lp50535
(dp50536
g35211
I268
sg35212
VCDK-EPI
p50537
sg35214
I7
sg35223
VP10646
p50538
sg35217
I1
sa(dp50539
g35211
I0
sg35212
VPENK
p50540
sg35214
I4
sg35223
VP01210
p50541
sg35217
I1
sa(dp50542
g35211
I184
sg35212
VChronic Kidney Disease Epidemiology Collaboration
p50543
sg35214
I49
sg35223
VP10646
p50544
sg35217
I5
sa(dp50545
g35211
I9
sg35212
VNGAL
p50546
sg35214
I4
sg35223
VP80188
p50547
sg35217
I1
sa(dp50548
g35211
I295
sg35212
VCr-CysC
p50549
sg35214
I7
sg35223
VP22676
p50550
sg35217
I1
sa(dp50551
g35211
I235
sg35212
g50531
sg35214
I7
sg35223
VP10646
p50552
sg35217
I1
sasg35208
(lp50553
(dp50554
g35211
I184
sg35212
VChronic Kidney Disease
p50555
sg35214
I22
sg35215
VC1561643
p50556
sg35217
I3
sa(dp50557
g35211
I239
sg35212
VEPI
p50558
sg35214
I3
sg35215
VC0267963
p50559
sg35217
I1
sa(dp50560
g35211
I147
sg35212
VRenal Disease
p50561
sg35214
I13
sg35215
VC0022658
p50562
sg35217
I2
sa(dp50563
g35211
I239
sg35212
VEPI
p50564
sg35214
I3
sg35215
VC0267963
p50565
sg35217
I1
sa(dp50566
g35211
I239
sg35212
VEPI
p50567
sg35214
I3
sg35215
VC0267963
p50568
sg35217
I1
sa(dp50569
g35211
I239
sg35212
g50532
sg35214
I3
sg35215
VC0267963
p50570
sg35217
I1
sasa(dp50571
g135
(dp50572
(VProenkephalin
p50573
VCRF
p50574
tp50575
I00
ssg35204
VProenkephalin cleavage products stored within cells, which included the 5.3-kDa peptide, could be released upon stimulation of cells with BaCl2 (2-fold above basal levels), 8-bromo-cAMP or CRF (7- and 8-fold above basal levels, respectively), and a mixture of BaCl2 and 8-bromo-cAMP (20-fold above basal levels).
p50576
sg35206
(lp50577
(dp50578
g35211
I0
sg35212
g50573
sg35214
I13
sg35223
VP01210
p50579
sg35217
I1
sasg35208
(lp50580
(dp50581
g35211
I189
sg35212
g50574
sg35214
I3
sg35215
VC0022661
p50582
sg35217
I1
sasa(dp50583
g135
(dp50584
(Vepidermal growth factor-related receptor
p50585
Vcerebellar degeneration
p50586
tp50587
I00
ssg35204
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p50588
sg35206
(lp50589
(dp50590
g35211
I59
sg35212
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p50591
sg35214
I126
sg35223
g12
sg35217
I12
sa(dp50592
g35211
I527
sg35212
VAP3B2
p50593
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp50594
g35211
I247
sg35212
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p50595
sg35214
I61
sg35223
VP05129
p50596
sg35217
I7
sa(dp50597
g35211
I18
sg35212
Vanti-metabotropic glutamate receptor 1
p50598
sg35214
I38
sg35223
VP42261
p50599
sg35217
I4
sa(dp50600
g35211
I356
sg35212
Vanti-voltage-gated calcium channel-associated ACA
p50601
sg35214
I49
sg35223
g12
sg35217
I4
sa(dp50602
g35211
I476
sg35212
g50585
sg35214
I40
sg35223
VP01133
p50603
sg35217
I4
sasg35208
(lp50604
(dp50605
g35211
I227
sg35212
VACA
p50606
sg35214
I3
sg35215
VC0007758
p50607
sg35217
I1
sa(dp50608
g35211
I227
sg35212
VACA
p50609
sg35214
I3
sg35215
VC0007758
p50610
sg35217
I1
sa(dp50611
g35211
I227
sg35212
VACA
p50612
sg35214
I3
sg35215
VC0007758
p50613
sg35217
I1
sa(dp50614
g35211
I197
sg35212
Vautoimmune cerebellar ataxia
p50615
sg35214
I28
sg35215
VC0007758
p50616
sg35217
I3
sa(dp50617
g35211
I543
sg35212
g50586
sg35214
I23
sg35215
VC0262404
p50618
sg35217
I2
sasa(dp50619
g135
(dp50620
(Vepidermal growth factor-related receptor
p50621
Vcerebellar degeneration
p50622
tp50623
I00
ssg35204
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects, and provides a summary and outlook.
p50624
sg35206
(lp50625
(dp50626
g35211
I59
sg35212
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p50627
sg35214
I126
sg35223
g12
sg35217
I12
sa(dp50628
g35211
I527
sg35212
VAP3B2
p50629
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp50630
g35211
I247
sg35212
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p50631
sg35214
I61
sg35223
VP05129
p50632
sg35217
I7
sa(dp50633
g35211
I18
sg35212
Vanti-metabotropic glutamate receptor 1
p50634
sg35214
I38
sg35223
VP42261
p50635
sg35217
I4
sa(dp50636
g35211
I356
sg35212
Vanti-voltage-gated calcium channel-associated ACA
p50637
sg35214
I49
sg35223
g12
sg35217
I4
sa(dp50638
g35211
I476
sg35212
g50621
sg35214
I40
sg35223
VP01133
p50639
sg35217
I4
sasg35208
(lp50640
(dp50641
g35211
I227
sg35212
VACA
p50642
sg35214
I3
sg35215
VC0007758
p50643
sg35217
I1
sa(dp50644
g35211
I227
sg35212
VACA
p50645
sg35214
I3
sg35215
VC0007758
p50646
sg35217
I1
sa(dp50647
g35211
I227
sg35212
VACA
p50648
sg35214
I3
sg35215
VC0007758
p50649
sg35217
I1
sa(dp50650
g35211
I197
sg35212
Vautoimmune cerebellar ataxia
p50651
sg35214
I28
sg35215
VC0007758
p50652
sg35217
I3
sa(dp50653
g35211
I543
sg35212
g50622
sg35214
I23
sg35215
VC0262404
p50654
sg35217
I2
sasa(dp50655
g135
(dp50656
(Vepidermal growth factor-related receptor
p50657
Vcerebellar degeneration
p50658
tp50659
I00
ssg35204
VPart 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.
p50660
sg35206
(lp50661
(dp50662
g35211
I59
sg35212
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p50663
sg35214
I126
sg35223
g12
sg35217
I12
sa(dp50664
g35211
I527
sg35212
VAP3B2
p50665
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp50666
g35211
I247
sg35212
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p50667
sg35214
I61
sg35223
VP05129
p50668
sg35217
I7
sa(dp50669
g35211
I18
sg35212
Vanti-metabotropic glutamate receptor 1
p50670
sg35214
I38
sg35223
VP42261
p50671
sg35217
I4
sa(dp50672
g35211
I356
sg35212
Vanti-voltage-gated calcium channel-associated ACA
p50673
sg35214
I49
sg35223
g12
sg35217
I4
sa(dp50674
g35211
I476
sg35212
g50657
sg35214
I40
sg35223
VP01133
p50675
sg35217
I4
sasg35208
(lp50676
(dp50677
g35211
I227
sg35212
VACA
p50678
sg35214
I3
sg35215
VC0007758
p50679
sg35217
I1
sa(dp50680
g35211
I227
sg35212
VACA
p50681
sg35214
I3
sg35215
VC0007758
p50682
sg35217
I1
sa(dp50683
g35211
I227
sg35212
VACA
p50684
sg35214
I3
sg35215
VC0007758
p50685
sg35217
I1
sa(dp50686
g35211
I197
sg35212
Vautoimmune cerebellar ataxia
p50687
sg35214
I28
sg35215
VC0007758
p50688
sg35217
I3
sa(dp50689
g35211
I543
sg35212
g50658
sg35214
I23
sg35215
VC0262404
p50690
sg35217
I2
sasa(dp50691
g135
(dp50692
(Vepidermal growth factor-related receptor
p50693
Vcerebellar ataxia
p50694
tp50695
I00
ssg35204
VLastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma.
p50696
sg35206
(lp50697
(dp50698
g35211
I51
sg35212
g50693
sg35214
I40
sg35223
VP01133
p50699
sg35217
I4
sasg35208
(lp50700
(dp50701
g35211
I173
sg35212
VHodgkin's lymphoma
p50702
sg35214
I18
sg35215
VC0019829
p50703
sg35217
I2
sa(dp50704
g35211
I151
sg35212
g50694
sg35214
I17
sg35215
VC0007758
p50705
sg35217
I2
sasa(dp50706
g35204
VReal-time quantitative PCR confirmed significantly increased expression of HAS2, CHSY1, and C4ST1 in the combined groups of CLE lesions (n = 8) compared to healthy controls (n = 4).
p50707
sg35206
(lp50708
(dp50709
g35211
I75
sg35212
VHAS2
p50710
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp50711
g35211
I81
sg35212
VCHSY1
p50712
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp50713
g35211
I92
sg35212
VC4ST1
p50714
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp50715
(dp50716
g35211
I124
sg35212
VCLE
p50717
sg35214
I3
sg35215
VC2931489
p50718
sg35217
I1
sasa(dp50719
g35204
VThus, the increase in HA in CLE presumably results from upregulation of HAS2, whereas CHSY1 and C4ST1 appear to contribute to increased CS.
p50720
sg35206
(lp50721
(dp50722
g35211
I96
sg35212
VC4ST1
p50723
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp50724
g35211
I86
sg35212
VCHSY1
p50725
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp50726
g35211
I72
sg35212
VHAS2
p50727
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp50728
(dp50729
g35211
I28
sg35212
VCLE
p50730
sg35214
I3
sg35215
VC2931489
p50731
sg35217
I1
sasa(dp50732
g35204
VThrough Part 4 of Maintenance of Certification for Family Physicians (MC-FP), American Board of Family Medicine (ABFM) diplomates participate in quality improvement (QI) modules for diabetes.
p50733
sg35206
(lp50734
sg35208
(lp50735
(dp50736
g35211
I182
sg35212
Vdiabetes
p50737
sg35214
I8
sg35215
VC0011849
p50738
sg35217
I1
sasa(dp50739
g35204
VFamily physicians participating in MC-FP implemented improvement projects and showed quality improvements in caring for patients with diabetes.
p50740
sg35206
(lp50741
sg35208
(lp50742
(dp50743
g35211
I134
sg35212
Vdiabetes
p50744
sg35214
I8
sg35215
VC0011849
p50745
sg35217
I1
sasa(dp50746
g135
(dp50747
(VInsulin
p50748
VIDDM
p50749
tp50750
I00
ssg35204
VInsulin-dependent diabetes mellitus (IDDM) and Graves' disease (GD) are autoimmune endocrinopathies and associated with distinct HLA-DR and -DQ alleles as well as several tumor necrosis factor alpha (TNF-alpha) and beta (TNF-beta) alleles.
p50751
sg35206
(lp50752
(dp50753
g35211
I129
sg35212
VHLA-DR
p50754
sg35214
I6
sg35223
VP30486
p50755
sg35217
I1
sa(dp50756
g35211
I171
sg35212
Vtumor necrosis factor alpha
p50757
sg35214
I27
sg35223
VP01375
p50758
sg35217
I4
sa(dp50759
g35211
I200
sg35212
VTNF-alpha
p50760
sg35214
I9
sg35223
VP01375
p50761
sg35217
I1
sa(dp50762
g35211
I221
sg35212
VTNF-beta
p50763
sg35214
I8
sg35223
VP01375
p50764
sg35217
I1
sa(dp50765
g35211
I0
sg35212
g50748
sg35214
I7
sg35223
VP01308
p50766
sg35217
I1
sasg35208
(lp50767
(dp50768
g35211
I64
sg35212
VGD
p50769
sg35214
I2
sg35215
VC0018213
p50770
sg35217
I1
sa(dp50771
g35211
I72
sg35212
Vautoimmune
p50772
sg35214
I10
sg35215
VC0443146
p50773
sg35217
I1
sa(dp50774
g35211
I171
sg35212
Vtumor necrosis
p50775
sg35214
I14
sg35215
VC0333516
p50776
sg35217
I2
sa(dp50777
g35211
I0
sg35212
VInsulin-dependent diabetes mellitus
p50778
sg35214
I35
sg35215
VC0011854
p50779
sg35217
I3
sa(dp50780
g35211
I47
sg35212
VGraves' disease
p50781
sg35214
I15
sg35215
VC0018213
p50782
sg35217
I2
sa(dp50783
g35211
I83
sg35212
Vendocrinopathies
p50784
sg35214
I16
sg35215
VC0014130
p50785
sg35217
I1
sa(dp50786
g35211
I37
sg35212
g50749
sg35214
I4
sg35215
VC0011854
p50787
sg35217
I1
sasa(dp50788
g135
(dp50789
(VTNFB gene
p50790
VGraves' disease
p50791
tp50792
I00
ssg35204
VStudies in Caucasians have suggested that the TNFB gene might be a susceptibility gene for Graves' disease.
p50793
sg35206
(lp50794
(dp50795
g35211
I46
sg35212
g50790
sg35214
I9
sg35223
VP10515
p50796
sg35217
I2
sasg35208
(lp50797
(dp50798
g35211
I91
sg35212
g50791
sg35214
I15
sg35215
VC0018213
p50799
sg35217
I2
sasa(dp50800
g135
(dp50801
(VTNFB
p50802
VGraves' disease
p50803
tp50804
I00
ssg35204
VTo investigate further the role of TNFB in predisposition to Graves' disease, we determined whether the TNFB disease associations in the Chinese were similar to those in Caucasians.
p50805
sg35206
(lp50806
(dp50807
g35211
I35
sg35212
g50802
sg35214
I4
sg35223
VP10515
p50808
sg35217
I1
sasg35208
(lp50809
(dp50810
g35211
I61
sg35212
g50803
sg35214
I15
sg35215
VC0018213
p50811
sg35217
I2
sasa(dp50812
g35204
VWe conclude that the TNFB associations with Graves' disease in the Hong Kong Chinese differ between the genders and from those described in Caucasians.
p50813
sg35206
(lp50814
sg35208
(lp50815
(dp50816
g35211
I44
sg35212
VGraves' disease
p50817
sg35214
I15
sg35215
VC0018213
p50818
sg35217
I2
sasa(dp50819
g135
(dp50820
(VTNFB gene
p50821
VGraves' disease
p50822
tp50823
I00
ssg35204
VThe TNFB gene is not a susceptibility gene for Graves' disease.
p50824
sg35206
(lp50825
(dp50826
g35211
I4
sg35212
g50821
sg35214
I9
sg35223
VP10515
p50827
sg35217
I2
sasg35208
(lp50828
(dp50829
g35211
I47
sg35212
g50822
sg35214
I15
sg35215
VC0018213
p50830
sg35217
I2
sasa(dp50831
g135
(dp50832
(VTNF beta
p50833
VGraves' disease
p50834
tp50835
I00
ssg35204
VWe show here a significant association of TNF beta polymorphisms with Graves' disease.
p50836
sg35206
(lp50837
(dp50838
g35211
I42
sg35212
g50833
sg35214
I8
sg35223
VP01375
p50839
sg35217
I2
sasg35208
(lp50840
(dp50841
g35211
I70
sg35212
g50834
sg35214
I15
sg35215
VC0018213
p50842
sg35217
I2
sasa(dp50843
g135
(dp50844
(VTNF beta
p50845
VGraves' disease
p50846
tp50847
I00
ssg35204
VAlthough TNF beta polymorphisms are linked to A1B8DR3, these results suggest that they represent an additional susceptibility marker in Graves' disease.
p50848
sg35206
(lp50849
(dp50850
g35211
I9
sg35212
g50845
sg35214
I8
sg35223
VP01375
p50851
sg35217
I2
sasg35208
(lp50852
(dp50853
g35211
I136
sg35212
g50846
sg35214
I15
sg35215
VC0018213
p50854
sg35217
I2
sasa(dp50855
g135
(dp50856
(VSkp1
p50857
Vmedulloblastoma
p50858
tp50859
I00
ssg35204
VHere, we summarize our findings of targeted SOX9 destruction by SCFFBW7 (Skp1/Cul1/F-box) in medulloblastoma and its potential for therapeutic intervention.
p50860
sg35206
(lp50861
(dp50862
g35211
I78
sg35212
VCul1
p50863
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp50864
g35211
I44
sg35212
VSOX9 destruction
p50865
sg35214
I16
sg35223
VP48436
p50866
sg35217
I2
sa(dp50867
g35211
I73
sg35212
g50857
sg35214
I4
sg35223
VP63208
p50868
sg35217
I1
sasg35208
(lp50869
(dp50870
g35211
I93
sg35212
g50858
sg35214
I15
sg35215
VC0025149
p50871
sg35217
I1
sasa(dp50872
g35204
VA point mutation in mouse Vps33a (Buff mouse) causes albinism and bleeding (Hermansky-Pudlak syndrome) because of abnormalities in the trafficking of melanosomes and platelets.
p50873
sg35206
(lp50874
(dp50875
g35211
I26
sg35212
VVps33a
p50876
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp50877
(dp50878
g35211
I53
sg35212
Valbinism
p50879
sg35214
I8
sg35215
VC0001916
p50880
sg35217
I1
sa(dp50881
g35211
I66
sg35212
Vbleeding
p50882
sg35214
I8
sg35215
VC0019080
p50883
sg35217
I1
sa(dp50884
g35211
I76
sg35212
VHermansky-Pudlak syndrome
p50885
sg35214
I25
sg35215
VC0079504
p50886
sg35217
I2
sasa(dp50887
g35204
VA mutation in the Vps33a gene causes Hermansky-Pudlak Syndrome (HPS)-like-symptoms in the buff (bf) mouse mutant.
p50888
sg35206
(lp50889
(dp50890
g35211
I18
sg35212
VVps33a gene
p50891
sg35214
I11
sg35223
g12
sg35217
I2
sasg35208
(lp50892
(dp50893
g35211
I64
sg35212
VHPS
p50894
sg35214
I3
sg35215
VC0242994
p50895
sg35217
I1
sa(dp50896
g35211
I37
sg35212
VHermansky-Pudlak Syndrome
p50897
sg35214
I25
sg35215
VC0079504
p50898
sg35217
I2
sa(dp50899
g35211
I106
sg35212
Vmutant
p50900
sg35214
I6
sg35215
VC0596988
p50901
sg35217
I1
sasa(dp50902
g35204
VEpicardial LGEs were identified in 10/13 and pericarditis in 6/13 RAH.
p50903
sg35206
(lp50904
sg35208
(lp50905
(dp50906
g35211
I45
sg35212
Vpericarditis
p50907
sg35214
I12
sg35215
VC0031046
p50908
sg35217
I1
sasa(dp50909
g35204
VAn RA relapse was observed after 7-40 days in 10/13 RAH with myopericarditis.
p50910
sg35206
(lp50911
sg35208
(lp50912
(dp50913
g35211
I6
sg35212
Vrelapse
p50914
sg35214
I7
sg35215
VC0277556
p50915
sg35217
I1
sa(dp50916
g35211
I61
sg35212
Vmyopericarditis
p50917
sg35214
I15
sg35215
VC0854532
p50918
sg35217
I1
sasa(dp50919
g35204
VWe found that LGI3 and its receptors, ADAM22 and ADAM23, were significantly downregulated in glioma tissues.
p50920
sg35206
(lp50921
(dp50922
g35211
I49
sg35212
VADAM23
p50923
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp50924
g35211
I14
sg35212
VLGI3
p50925
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp50926
g35211
I38
sg35212
VADAM22
p50927
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp50928
(dp50929
g35211
I93
sg35212
Vglioma
p50930
sg35214
I6
sg35215
VC0017638
p50931
sg35217
I1
sasa(dp50932
g35204
VAnalysis of expression microarray data of glioma cohorts demonstrated that low expression levels of LGI3, ADAM22 and ADAM23 were significantly associated with poor prognosis of glioma.
p50933
sg35206
(lp50934
(dp50935
g35211
I106
sg35212
VADAM22
p50936
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp50937
g35211
I100
sg35212
VLGI3
p50938
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp50939
g35211
I117
sg35212
VADAM23
p50940
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp50941
(dp50942
g35211
I42
sg35212
Vglioma
p50943
sg35214
I6
sg35215
VC0017638
p50944
sg35217
I1
sa(dp50945
g35211
I42
sg35212
Vglioma
p50946
sg35214
I6
sg35215
VC0017638
p50947
sg35217
I1
sasa(dp50948
g135
(dp50949
(VLeucine-rich Glioma Inactivated 4
p50950
Vmetastasis
p50951
tp50952
I00
ssg35204
VRather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO).
p50953
sg35206
(lp50954
(dp50955
g35211
I227
sg35212
g50950
sg35214
I33
sg35223
VP30740
p50956
sg35217
I4
sa(dp50957
g35211
I221
sg35212
VLGI4
p50958
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp50959
(dp50960
g35211
I92
sg35212
Vtumor growth
p50961
sg35214
I12
sg35215
VC0598934
p50962
sg35217
I2
sa(dp50963
g35211
I137
sg35212
Vproliferation
p50964
sg35214
I13
sg35215
VC0334094
p50965
sg35217
I1
sa(dp50966
g35211
I155
sg35212
Vinvasion
p50967
sg35214
I8
sg35215
VC2699153
p50968
sg35217
I1
sa(dp50969
g35211
I240
sg35212
VGlioma
p50970
sg35214
I6
sg35215
VC0017638
p50971
sg35217
I1
sa(dp50972
g35211
I109
sg35212
g50951
sg35214
I10
sg35215
VC0027627
p50973
sg35217
I1
sasa(dp50974
g135
(dp50975
(VInsulin Like Growth Factor Binding Protein-3
p50976
Voverweight
p50977
tp50978
I00
ssg35204
VThe aim of the present study was to evaluate ADAM28 and Insulin Like Growth Factor Binding Protein-3 (IGFBP-3)) gene expression in colorectal carcinoma tissues with regard to the overweight or obese status of the patients using an oligonucleotide microarray technique.
p50979
sg35206
(lp50980
(dp50981
g35211
I102
sg35212
VIGFBP-3
p50982
sg35214
I7
sg35223
VP17936
p50983
sg35217
I1
sa(dp50984
g35211
I45
sg35212
VADAM28
p50985
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp50986
g35211
I56
sg35212
g50976
sg35214
I44
sg35223
VP01308
p50987
sg35217
I6
sasg35208
(lp50988
(dp50989
g35211
I193
sg35212
Vobese
p50990
sg35214
I5
sg35215
VC0028754
p50991
sg35217
I1
sa(dp50992
g35211
I131
sg35212
Vcolorectal carcinoma
p50993
sg35214
I20
sg35215
VC0009402
p50994
sg35217
I2
sa(dp50995
g35211
I179
sg35212
g50977
sg35214
I10
sg35215
VC0497406
p50996
sg35217
I1
sasa(dp50997
g35204
VThe expression of cancer stem cell marker cluster of differentiation 271 (CD271) was determined in traditional two-dimensional (2D) and 3D cultures of C918 uveal melanoma cells by fluorescent immunocytochemistry.
p50998
sg35206
(lp50999
sg35208
(lp51000
(dp51001
g35211
I156
sg35212
Vuveal melanoma
p51002
sg35214
I14
sg35215
VC0220633
p51003
sg35217
I2
sa(dp51004
g35211
I18
sg35212
Vcancer
p51005
sg35214
I6
sg35215
VC0006826
p51006
sg35217
I1
sasa(dp51007
g35204
VThe missense mutation (c.370G &gt; A) in the TGFBI gene and insert mutation (c.1456-1457ins GAT) in the KRT12 gene were identified in a 23-year-old male patient with concurrent KC and GCD.
p51008
sg35206
(lp51009
(dp51010
g35211
I77
sg35212
Vc.1456-1457ins GAT
p51011
sg35214
I18
sg35223
g12
sg35217
I2
sa(dp51012
g35211
I104
sg35212
VKRT12 gene
p51013
sg35214
I10
sg35223
g12
sg35217
I2
sasg35208
(lp51014
sa(dp51015
g35204
VThis study investigated the TGFBI gene mutation types in outpatients clinically diagnosed with granular corneal dystrophy (GCD) prior to phototherapeutic keratectomy (PTK), also calculated the mutation rate of subjects with normal corneas, but positive family history.
p51016
sg35206
(lp51017
(dp51018
g35211
I167
sg35212
VPTK
p51019
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp51020
g35211
I137
sg35212
Vphototherapeutic keratectomy
p51021
sg35214
I28
sg35223
g12
sg35217
I2
sasg35208
(lp51022
(dp51023
g35211
I95
sg35212
Vgranular corneal dystrophy
p51024
sg35214
I26
sg35215
VC0018179
p51025
sg35217
I3
sa(dp51026
g35211
I123
sg35212
VGCD
p51027
sg35214
I3
sg35215
VC0018179
p51028
sg35217
I1
sasa(dp51029
g135
(dp51030
(Vtransforming growth factor Beta
p51031
Vgranular corneal dystrophy type 1
p51032
tp51033
I00
ssg35204
VTo describe 2 unrelated families with multiple members demonstrating a less commonly recognized vortex pattern of corneal deposits confirmed to be granular corneal dystrophy type 1 (GCD1) after identification of the p.(Arg555Trp) mutation in the transforming growth factor Beta-induced gene (TGFBI).
p51034
sg35206
(lp51035
(dp51036
g35211
I246
sg35212
g51031
sg35214
I31
sg35223
VP18075
p51037
sg35217
I4
sasg35208
(lp51038
(dp51039
g35211
I182
sg35212
VGCD1
p51040
sg35214
I4
sg35215
VC1641846
p51041
sg35217
I1
sa(dp51042
g35211
I114
sg35212
Vcorneal deposits
p51043
sg35214
I16
sg35215
VC0162281
p51044
sg35217
I2
sa(dp51045
g35211
I147
sg35212
g51032
sg35214
I33
sg35215
VC1641846
p51046
sg35217
I5
sasa(dp51047
g35204
VScreening of TGFBI in both families revealed a heterozygous missense mutation [p.(Arg555Trp)] in exon 12, confirming the diagnosis of GCD1.
p51048
sg35206
(lp51049
sg35208
(lp51050
(dp51051
g35211
I134
sg35212
VGCD1
p51052
sg35214
I4
sg35215
VC1641846
p51053
sg35217
I1
sasa(dp51054
g35204
VAlthough this pattern of dystrophic deposits is not recognized by clinicians as a typical phenotype of GCD1, it is consistent with the production of the majority of the TGFBI protein by the corneal epithelium.
p51055
sg35206
(lp51056
sg35208
(lp51057
(dp51058
g35211
I103
sg35212
VGCD1
p51059
sg35214
I4
sg35215
VC1641846
p51060
sg35217
I1
sasa(dp51061
g35204
VIn this study, patients with macular corneal dystrophy (MCD; n = 18), granular corneal dystrophy type 1 (GCD1; n = 12), and lattice corneal dystrophy type 1 (LCD1; n = 4), as well as 50 healthy controls, were subjected to clinical and genetic examinations.
p51062
sg35206
(lp51063
sg35208
(lp51064
(dp51065
g35211
I158
sg35212
VLCD1
p51066
sg35214
I4
sg35215
VC1690006
p51067
sg35217
I1
sa(dp51068
g35211
I70
sg35212
Vgranular corneal dystrophy type 1
p51069
sg35214
I33
sg35215
VC1641846
p51070
sg35217
I5
sa(dp51071
g35211
I105
sg35212
VGCD1
p51072
sg35214
I4
sg35215
VC1641846
p51073
sg35217
I1
sa(dp51074
g35211
I29
sg35212
Vmacular corneal dystrophy
p51075
sg35214
I25
sg35215
VC0024439
p51076
sg35217
I3
sa(dp51077
g35211
I56
sg35212
VMCD
p51078
sg35214
I3
sg35215
VC1636149
p51079
sg35217
I1
sa(dp51080
g35211
I124
sg35212
Vlattice corneal dystrophy type 1
p51081
sg35214
I32
sg35215
VC2931650
p51082
sg35217
I5
sasa(dp51083
g35204
VVariations were analyzed with DNA sequencing in the coding region of CHST6 in patients with MCD and exons 4 and 12 in TGFBI in patients with LCD1 and GCD1.
p51084
sg35206
(lp51085
(dp51086
g35211
I69
sg35212
VCHST6
p51087
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp51088
(dp51089
g35211
I141
sg35212
VLCD1
p51090
sg35214
I4
sg35215
VC1690006
p51091
sg35217
I1
sa(dp51092
g35211
I92
sg35212
VMCD
p51093
sg35214
I3
sg35215
VC1636149
p51094
sg35217
I1
sa(dp51095
g35211
I150
sg35212
VGCD1
p51096
sg35214
I4
sg35215
VC1641846
p51097
sg35217
I1
sasa(dp51098
g35204
VThe previously reported R555W mutation in TGFBI was detected in 12 patients with GCD1, and the R124C mutation in TGFBI was detected in four patients with LCD1.
p51099
sg35206
(lp51100
sg35208
(lp51101
(dp51102
g35211
I81
sg35212
VGCD1
p51103
sg35214
I4
sg35215
VC1641846
p51104
sg35217
I1
sa(dp51105
g35211
I154
sg35212
VLCD1
p51106
sg35214
I4
sg35215
VC1690006
p51107
sg35217
I1
sasa(dp51108
g35204
VWe detected previously reported, well-known hot spot mutations in TGFBI in the patients with GCD1 and LCD1.
p51109
sg35206
(lp51110
sg35208
(lp51111
(dp51112
g35211
I93
sg35212
VGCD1
p51113
sg35214
I4
sg35215
VC1641846
p51114
sg35217
I1
sa(dp51115
g35211
I44
sg35212
Vhot spot
p51116
sg35214
I8
sg35215
VC0263214
p51117
sg35217
I2
sa(dp51118
g35211
I102
sg35212
VLCD1
p51119
sg35214
I4
sg35215
VC1690006
p51120
sg35217
I1
sasa(dp51121
g135
(dp51122
(Vtransforming growth factor Beta
p51123
Vgranular corneal dystrophy type 2
p51124
tp51125
I00
ssg35204
VTGFBeta1-induced expression of transforming growth factor Beta-induced protein (TGFBIp) and extracellular matrix (ECM) genes plays a major role in the development of granular corneal dystrophy type 2 (GCD2: also called Avellino corneal dystrophy).
p51126
sg35206
(lp51127
(dp51128
g35211
I0
sg35212
VTGFBeta1
p51129
sg35214
I8
sg35223
VP01137
p51130
sg35217
I1
sa(dp51131
g35211
I31
sg35212
g51123
sg35214
I31
sg35223
VP18075
p51132
sg35217
I4
sa(dp51133
g35211
I92
sg35212
Vextracellular matrix (ECM) genes
p51134
sg35214
I32
sg35223
g12
sg35217
I4
sasg35208
(lp51135
(dp51136
g35211
I219
sg35212
VAvellino corneal dystrophy
p51137
sg35214
I26
sg35215
VC1275685
p51138
sg35217
I3
sa(dp51139
g35211
I166
sg35212
g51124
sg35214
I33
sg35215
VC1275685
p51140
sg35217
I5
sasa(dp51141
g35204
VWe examined the role of chromatin markers such as histone H3 lysine methylation (H3Kme) in TGFBeta1-induced TGFBIp and ECM gene expression in normal and GCD2-derived human corneal fibroblasts.
p51142
sg35206
(lp51143
(dp51144
g35211
I91
sg35212
VTGFBeta1
p51145
sg35214
I8
sg35223
VP01137
p51146
sg35217
I1
sa(dp51147
g35211
I119
sg35212
VECM gene
p51148
sg35214
I8
sg35223
g12
sg35217
I2
sa(dp51149
g35211
I50
sg35212
Vhistone H3
p51150
sg35214
I10
sg35223
g12
sg35217
I2
sasg35208
(lp51151
sa(dp51152
g35204
VTranscription and extracellular-secretion levels of TGFBIp were high in normal cells compared with those in GCD2-derived cells and were related to H3K4me3 levels but not to DNA methylation over the TGFBI locus.
p51153
sg35206
(lp51154
sg35208
(lp51155
sa(dp51156
g35204
VThis study expands on our previous research investigating dystrophic stromal aggregates, with the aim of better elucidating the pathomechanism of two conditions arising from the most common TGFBI mutations: granular corneal dystrophy type 1 (GCD1; R555W) and lattice corneal dystrophy type 1 (LCD1; R124C).
p51157
sg35206
(lp51158
sg35208
(lp51159
(dp51160
g35211
I259
sg35212
Vlattice corneal dystrophy type 1
p51161
sg35214
I32
sg35215
VC2931650
p51162
sg35217
I5
sa(dp51163
g35211
I207
sg35212
Vgranular corneal dystrophy type 1
p51164
sg35214
I33
sg35215
VC1641846
p51165
sg35217
I5
sa(dp51166
g35211
I293
sg35212
VLCD1
p51167
sg35214
I4
sg35215
VC1690006
p51168
sg35217
I1
sa(dp51169
g35211
I242
sg35212
VGCD1
p51170
sg35214
I4
sg35215
VC1641846
p51171
sg35217
I1
sasa(dp51172
g35204
VPatient corneas with GCD1 and LCD1 were stained with hematoxylin and eosin and Congo red to visualize stromal nonamyloid and amyloid deposits, respectively.
p51173
sg35206
(lp51174
sg35208
(lp51175
(dp51176
g35211
I30
sg35212
VLCD1
p51177
sg35214
I4
sg35215
VC1690006
p51178
sg35217
I1
sa(dp51179
g35211
I21
sg35212
VGCD1
p51180
sg35214
I4
sg35215
VC1641846
p51181
sg35217
I1
sa(dp51182
g35211
I125
sg35212
Vamyloid deposits
p51183
sg35214
I16
sg35215
VC2936349
p51184
sg35217
I2
sasa(dp51185
g35204
VAn increase in the number of residues experiencing cleavage was observed in both GCD1 aggregates and LCD1 deposits.
p51186
sg35206
(lp51187
sg35208
(lp51188
(dp51189
g35211
I81
sg35212
VGCD1
p51190
sg35214
I4
sg35215
VC1641846
p51191
sg35217
I1
sa(dp51192
g35211
I101
sg35212
VLCD1
p51193
sg35214
I4
sg35215
VC1690006
p51194
sg35217
I1
sasa(dp51195
g35204
VThe study reveals previously unknown differences between the protein composition of GCD1 and LCD1 aggregates, and confirms the presence of the HtrA1 protease in LCD1-amyloid aggregates.
p51196
sg35206
(lp51197
(dp51198
g35211
I143
sg35212
VHtrA1 protease
p51199
sg35214
I14
sg35223
g12
sg35217
I2
sasg35208
(lp51200
(dp51201
g35211
I93
sg35212
VLCD1
p51202
sg35214
I4
sg35215
VC1690006
p51203
sg35217
I1
sa(dp51204
g35211
I93
sg35212
VLCD1
p51205
sg35214
I4
sg35215
VC1690006
p51206
sg35217
I1
sa(dp51207
g35211
I166
sg35212
Vamyloid
p51208
sg35214
I7
sg35215
VC0011560
p51209
sg35217
I1
sa(dp51210
g35211
I84
sg35212
VGCD1
p51211
sg35214
I4
sg35215
VC1641846
p51212
sg35217
I1
sasa(dp51213
g35204
VGCD is a Category 1, Stromal, TGFBI-associated corneal dystrophy.
p51214
sg35206
(lp51215
sg35208
(lp51216
(dp51217
g35211
I47
sg35212
Vcorneal dystrophy
p51218
sg35214
I17
sg35215
VC0010036
p51219
sg35217
I2
sasa(dp51220
g135
(dp51221
(Vtrypsin
p51222
Vgranular corneal dystrophy
p51223
tp51224
I00
ssg35204
VWe show here that the Arg555Trp mutant of the fourth fasciclin 1 (FAS1-4) domain of the protein (TGFBIp/keratoepithelin/Betaig-h3), associated with granular corneal dystrophy type 1, is significantly less susceptible to proteolysis by thermolysin and trypsin than the WT domain.
p51225
sg35206
(lp51226
(dp51227
g35211
I66
sg35212
VFAS1-4
p51228
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51229
g35211
I251
sg35212
g51222
sg35214
I7
sg35223
VP35030
p51230
sg35217
I1
sa(dp51231
g35211
I22
sg35212
VArg555Trp mutant
p51232
sg35214
I16
sg35223
g12
sg35217
I2
sasg35208
(lp51233
(dp51234
g35211
I32
sg35212
Vmutant
p51235
sg35214
I6
sg35215
VC0596988
p51236
sg35217
I1
sa(dp51237
g35211
I148
sg35212
g51223
sg35214
I26
sg35215
VC0018179
p51238
sg35217
I3
sasa(dp51239
g35204
VMiR-139-5p has been reported to be overexpressed in many types of cancers, but its role in bladder cancer has not been elucidated yet.
p51240
sg35206
(lp51241
(dp51242
g35211
I0
sg35212
VMiR-139-5p
p51243
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp51244
(dp51245
g35211
I91
sg35212
Vbladder cancer
p51246
sg35214
I14
sg35215
VC0699885
p51247
sg35217
I2
sa(dp51248
g35211
I66
sg35212
Vcancers
p51249
sg35214
I7
sg35215
VC0006826
p51250
sg35217
I1
sasa(dp51251
g35204
VHere, we report that miR-139-5p functions as a tumor suppressor in bladder cancer and inhibits the cancer stem cell self-renewal by targeting Bmi1 directly.
p51252
sg35206
(lp51253
(dp51254
g35211
I21
sg35212
VmiR-139-5p
p51255
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp51256
g35211
I142
sg35212
VBmi1
p51257
sg35214
I4
sg35223
VP35226
p51258
sg35217
I1
sasg35208
(lp51259
(dp51260
g35211
I47
sg35212
Vtumor
p51261
sg35214
I5
sg35215
VC0027651
p51262
sg35217
I1
sa(dp51263
g35211
I67
sg35212
Vbladder cancer
p51264
sg35214
I14
sg35215
VC0699885
p51265
sg35217
I2
sa(dp51266
g35211
I75
sg35212
Vcancer
p51267
sg35214
I6
sg35215
VC0006826
p51268
sg35217
I1
sasa(dp51269
g35204
VWe found that miR-139-5p expression was significantly downregulated in the bladder cancer specimens compared with that in adjacent normal tissues.
p51270
sg35206
(lp51271
(dp51272
g35211
I14
sg35212
VmiR-139-5p
p51273
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp51274
(dp51275
g35211
I75
sg35212
Vbladder cancer
p51276
sg35214
I14
sg35215
VC0699885
p51277
sg35217
I2
sasa(dp51278
g35204
VIn vitro, restoration of miR-139-5p expression significantly inhibited the proliferation of bladder cancer cells.
p51279
sg35206
(lp51280
(dp51281
g35211
I25
sg35212
VmiR-139-5p
p51282
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp51283
(dp51284
g35211
I75
sg35212
Vproliferation
p51285
sg35214
I13
sg35215
VC0334094
p51286
sg35217
I1
sa(dp51287
g35211
I92
sg35212
Vbladder cancer
p51288
sg35214
I14
sg35215
VC0699885
p51289
sg35217
I2
sasa(dp51290
g135
(dp51291
(VStem cell-related proteins
p51292
Vbladder cancer
p51293
tp51294
I00
ssg35204
VStem cell-related proteins such as c-MYC, NANOG, OCT4, and KLF4 and signaling pathways such as Wnt signaling were suppressed by restoration of miR-139-5p in bladder cancer cells.
p51295
sg35206
(lp51296
(dp51297
g35211
I143
sg35212
VmiR-139-5p
p51298
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp51299
g35211
I42
sg35212
VNANOG
p51300
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp51301
g35211
I35
sg35212
Vc-MYC
p51302
sg35214
I5
sg35223
VP12524
p51303
sg35217
I1
sa(dp51304
g35211
I59
sg35212
VKLF4
p51305
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp51306
g35211
I0
sg35212
g51292
sg35214
I26
sg35223
VP02649
p51307
sg35217
I3
sasg35208
(lp51308
(dp51309
g35211
I157
sg35212
g51293
sg35214
I14
sg35215
VC0699885
p51310
sg35217
I2
sasa(dp51311
g35204
VIn addition, miR-139-5p expression also blocked self-renewal of bladder cancer stem cells by inhibiting Bmi1.
p51312
sg35206
(lp51313
(dp51314
g35211
I104
sg35212
VBmi1
p51315
sg35214
I4
sg35223
VP35226
p51316
sg35217
I1
sa(dp51317
g35211
I13
sg35212
VmiR-139-5p
p51318
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp51319
(dp51320
g35211
I64
sg35212
Vbladder cancer
p51321
sg35214
I14
sg35215
VC0699885
p51322
sg35217
I2
sasa(dp51323
g35204
VIn summary, our study supports that miR-139-5p acts as a tumor suppressor in bladder cancer development and suppresses cancer stem cell property of bladder cancer.
p51324
sg35206
(lp51325
(dp51326
g35211
I36
sg35212
VmiR-139-5p
p51327
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp51328
(dp51329
g35211
I77
sg35212
Vbladder cancer
p51330
sg35214
I14
sg35215
VC0699885
p51331
sg35217
I2
sa(dp51332
g35211
I57
sg35212
Vtumor
p51333
sg35214
I5
sg35215
VC0027651
p51334
sg35217
I1
sa(dp51335
g35211
I77
sg35212
Vbladder cancer
p51336
sg35214
I14
sg35215
VC0699885
p51337
sg35217
I2
sa(dp51338
g35211
I85
sg35212
Vcancer
p51339
sg35214
I6
sg35215
VC0006826
p51340
sg35217
I1
sasa(dp51341
g35204
VOur study also suggests that miR-139-5p has the potential to be used as a therapeutic molecule for bladder cancer treatment.
p51342
sg35206
(lp51343
(dp51344
g35211
I29
sg35212
VmiR-139-5p
p51345
sg35214
I10
sg35223
g12
sg35217
I1
sasg35208
(lp51346
(dp51347
g35211
I99
sg35212
Vbladder cancer
p51348
sg35214
I14
sg35215
VC0699885
p51349
sg35217
I2
sasa(dp51350
g35204
VWe present a case with CblC disease and pulmonary arterial hypertension (PAH) as the main symptom.
p51351
sg35206
(lp51352
(dp51353
g35211
I23
sg35212
VCblC
p51354
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp51355
(dp51356
g35211
I40
sg35212
Vpulmonary arterial hypertension
p51357
sg35214
I31
sg35215
VC0152171
p51358
sg35217
I3
sa(dp51359
g35211
I73
sg35212
VPAH
p51360
sg35214
I3
sg35215
VC0152171
p51361
sg35217
I1
sa(dp51362
g35211
I90
sg35212
Vsymptom
p51363
sg35214
I7
sg35215
VC1457887
p51364
sg35217
I1
sasa(dp51365
g35204
VCblC disease should be considered in the differential diagnosis of pulmonary hypertension.
p51366
sg35206
(lp51367
(dp51368
g35211
I0
sg35212
VCblC
p51369
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp51370
(dp51371
g35211
I67
sg35212
Vpulmonary hypertension
p51372
sg35214
I22
sg35215
VC0020542
p51373
sg35217
I2
sasa(dp51374
g135
(dp51375
(VOPRD1
p51376
Vdrug abuse
p51377
tp51378
I00
ssg35204
VGenetic association of rs678849 along with neuroimaging and biomarker phenotypes, parallel with the known involvements of the OPRD1 in drug abuse, provided additional support for targeting these receptors as potential therapeutic targets in both neurodegenerative diseases and neuropsychiactric disorders such as Alzheimer's disease.
p51379
sg35206
(lp51380
(dp51381
g35211
I126
sg35212
g51376
sg35214
I5
sg35223
VP41143
p51382
sg35217
I1
sasg35208
(lp51383
(dp51384
g35211
I313
sg35212
VAlzheimer's disease
p51385
sg35214
I19
sg35215
VC1521724
p51386
sg35217
I2
sa(dp51387
g35211
I246
sg35212
Vneurodegenerative diseases
p51388
sg35214
I26
sg35215
VC0524851
p51389
sg35217
I2
sa(dp51390
g35211
I135
sg35212
g51377
sg35214
I10
sg35215
VC0013146
p51391
sg35217
I2
sasa(dp51392
g35204
VRecently, a robust up-regulation of human natural killer-1 sulfotransferase (HNK-1ST) was found in several subsets of melanoma cells during RA-mediated differentiation.
p51393
sg35206
(lp51394
(dp51395
g35211
I36
sg35212
Vhuman natural killer-1 sulfotransferase
p51396
sg35214
I39
sg35223
g12
sg35217
I4
sa(dp51397
g35211
I77
sg35212
VHNK-1ST
p51398
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp51399
(dp51400
g35211
I118
sg35212
Vmelanoma
p51401
sg35214
I8
sg35215
VC0025202
p51402
sg35217
I1
sasa(dp51403
g35204
VHere, we show that HNK-1ST changed the glycosylation state and reduced the ligand binding activity of Alfa-dystroglycan (Alfa-DG) in RA-treated S91 melanoma cells, which contributed to an attenuation of cell migration.
p51404
sg35206
(lp51405
(dp51406
g35211
I121
sg35212
VAlfa-DG
p51407
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp51408
g35211
I102
sg35212
VAlfa-dystroglycan
p51409
sg35214
I17
sg35223
g12
sg35217
I1
sa(dp51410
g35211
I19
sg35212
VHNK-1ST
p51411
sg35214
I7
sg35223
g12
sg35217
I1
sasg35208
(lp51412
(dp51413
g35211
I148
sg35212
Vmelanoma
p51414
sg35214
I8
sg35215
VC0025202
p51415
sg35217
I1
sasa(dp51416
g135
(dp51417
(VHAPLN1
p51418
Vschizophrenia
p51419
tp51420
I00
ssg35204
VTen genes of importance for HNK-1 biosynthesis (B3GAT1, B3GAT2, and CHST10) or for the formation of perineuronal nets (TNR, BCAN, NCAN, HAPLN1, HAPLN2, HAPLN3, and HAPLN4) were investigated for potential involvement in schizophrenia (SCZ) susceptibility, by genotyping 104 tagSNPs in the Scandinavian Collaboration on Psychiatric Etiology sample (849 cases; 1602 control subjects).
p51421
sg35206
(lp51422
(dp51423
g35211
I144
sg35212
VHAPLN2
p51424
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51425
g35211
I28
sg35212
VHNK-1
p51426
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp51427
g35211
I119
sg35212
VTNR
p51428
sg35214
I3
sg35223
g12
sg35217
I1
sa(dp51429
g35211
I83
sg35212
Vthe formation of perineuronal nets
p51430
sg35214
I34
sg35223
g12
sg35217
I5
sa(dp51431
g35211
I130
sg35212
VNCAN
p51432
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp51433
g35211
I136
sg35212
g51418
sg35214
I6
sg35223
VP10915
p51434
sg35217
I1
sa(dp51435
g35211
I124
sg35212
VBCAN
p51436
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp51437
g35211
I152
sg35212
VHAPLN3
p51438
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51439
g35211
I48
sg35212
VB3GAT1
p51440
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51441
g35211
I68
sg35212
VCHST10
p51442
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51443
g35211
I56
sg35212
VB3GAT2
p51444
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51445
g35211
I164
sg35212
VHAPLN4
p51446
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp51447
(dp51448
g35211
I234
sg35212
VSCZ
p51449
sg35214
I3
sg35215
VC0036341
p51450
sg35217
I1
sa(dp51451
g35211
I219
sg35212
g51419
sg35214
I13
sg35215
VC0036341
p51452
sg35217
I1
sasa(dp51453
g135
(dp51454
(VRARgamma
p51455
Vmelanoma
p51456
tp51457
I00
ssg35204
VWe show that CHST10 is also regulated by RARgamma in a significant subset of human melanoma cells, and three-dimensional cell culture migration assays suggest that CHST10 functions as a suppressor of invasiveness, but not proliferation, in these cells.
p51458
sg35206
(lp51459
(dp51460
g35211
I41
sg35212
g51455
sg35214
I8
sg35223
VP13631
p51461
sg35217
I1
sa(dp51462
g35211
I13
sg35212
VCHST10
p51463
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51464
g35211
I13
sg35212
VCHST10
p51465
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp51466
(dp51467
g35211
I83
sg35212
g51456
sg35214
I8
sg35215
VC0025202
p51468
sg35217
I1
sa(dp51469
g35211
I222
sg35212
Vproliferation
p51470
sg35214
I13
sg35215
VC0334094
p51471
sg35217
I1
sasa(dp51472
g135
(dp51473
(VRARgamma
p51474
Vmelanoma
p51475
tp51476
I00
ssg35204
VInduction of CHST10 by RARgamma-activating retinoids may present a novel therapeutic strategy to inhibit invasiveness in a subset of melanoma patients.
p51477
sg35206
(lp51478
(dp51479
g35211
I23
sg35212
g51474
sg35214
I8
sg35223
VP13631
p51480
sg35217
I1
sa(dp51481
g35211
I13
sg35212
VCHST10
p51482
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp51483
(dp51484
g35211
I133
sg35212
g51475
sg35214
I8
sg35215
VC0025202
p51485
sg35217
I1
sasa(dp51486
g35204
VNo disease-associated mutations were detected in the candidate genes SEMA4C, CNGA3 or HNK1ST from within the region.
p51487
sg35206
(lp51488
(dp51489
g35211
I77
sg35212
VCNGA3
p51490
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp51491
g35211
I86
sg35212
VHNK1ST
p51492
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp51493
g35211
I69
sg35212
VSEMA4C
p51494
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp51495
sa(dp51496
g35204
VMost XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age.
p51497
sg35206
(lp51498
sg35208
(lp51499
(dp51500
g35211
I35
sg35212
Vmuscle weakness
p51501
sg35214
I15
sg35215
VC0030552
p51502
sg35217
I2
sa(dp51503
g35211
I62
sg35212
Vrespiratory failure
p51504
sg35214
I19
sg35215
VC1145670
p51505
sg35217
I2
sa(dp51506
g35211
I5
sg35212
VXLMTM
p51507
sg35214
I5
sg35215
VC0410203
p51508
sg35217
I1
sasa(dp51509
g35204
VMutations in the MTM1 gene cause X-linked myotubular myopathy (XLMTM), characterized by neonatal hypotonia and respiratory failure, and are responsible for a premature mortality in affected males.
p51510
sg35206
(lp51511
(dp51512
g35211
I17
sg35212
VMTM1 gene
p51513
sg35214
I9
sg35223
g12
sg35217
I2
sasg35208
(lp51514
(dp51515
g35211
I17
sg35212
VMTM1
p51516
sg35214
I4
sg35215
VC0410203
p51517
sg35217
I1
sa(dp51518
g35211
I33
sg35212
VX-linked myotubular myopathy
p51519
sg35214
I28
sg35215
VC0410203
p51520
sg35217
I3
sa(dp51521
g35211
I88
sg35212
Vneonatal hypotonia
p51522
sg35214
I18
sg35215
VC0270971
p51523
sg35217
I2
sa(dp51524
g35211
I63
sg35212
VXLMTM
p51525
sg35214
I5
sg35215
VC0410203
p51526
sg35217
I1
sa(dp51527
g35211
I111
sg35212
Vrespiratory failure
p51528
sg35214
I19
sg35215
VC1145670
p51529
sg35217
I2
sasa(dp51530
g35204
VX-linked myotubular myopathy (XLMTM) is a congenital neuromuscular disorder defined by severe hypotonia, respiratory failure and histopathologic changes in muscle biopsy.
p51531
sg35206
(lp51532
sg35208
(lp51533
(dp51534
g35211
I0
sg35212
VX-linked myotubular myopathy
p51535
sg35214
I28
sg35215
VC0410203
p51536
sg35217
I3
sa(dp51537
g35211
I105
sg35212
Vrespiratory failure
p51538
sg35214
I19
sg35215
VC1145670
p51539
sg35217
I2
sa(dp51540
g35211
I30
sg35212
VXLMTM
p51541
sg35214
I5
sg35215
VC0410203
p51542
sg35217
I1
sa(dp51543
g35211
I94
sg35212
Vhypotonia
p51544
sg35214
I9
sg35215
VC0026827
p51545
sg35217
I1
sa(dp51546
g35211
I42
sg35212
Vcongenital neuromuscular disorder
p51547
sg35214
I33
sg35215
VC0596371
p51548
sg35217
I3
sasa(dp51549
g35204
VCentronuclear (myotubular) myopathy (CNM) is congenital and produces various degrees of muscular weakness and associated complications such as respiratory failure.
p51550
sg35206
(lp51551
sg35208
(lp51552
(dp51553
g35211
I27
sg35212
Vmyopathy
p51554
sg35214
I8
sg35215
VC0026848
p51555
sg35217
I1
sa(dp51556
g35211
I143
sg35212
Vrespiratory failure
p51557
sg35214
I19
sg35215
VC1145670
p51558
sg35217
I2
sa(dp51559
g35211
I88
sg35212
Vmuscular weakness
p51560
sg35214
I17
sg35215
VC0151786
p51561
sg35217
I2
sasa(dp51562
g35204
VPatients with XLMTM often have severe perinatal weakness that requires mechanical ventilation to prevent death from respiratory failure.
p51563
sg35206
(lp51564
sg35208
(lp51565
(dp51566
g35211
I48
sg35212
Vweakness
p51567
sg35214
I8
sg35215
VC1883552
p51568
sg35217
I1
sa(dp51569
g35211
I116
sg35212
Vrespiratory failure
p51570
sg35214
I19
sg35215
VC1145670
p51571
sg35217
I2
sa(dp51572
g35211
I14
sg35212
VXLMTM
p51573
sg35214
I5
sg35215
VC0410203
p51574
sg35217
I1
sasa(dp51575
g35204
VThis review addresses hearing loss as it occurs and has been reported in Muenke syndrome as well as six additional FGFR related craniosynostosis syndromes (Apert syndrome, Pfeiffer syndrome, Crouzon syndrome, Beare-Stevenson syndrome, Crouzon syndrome with acanthosis nigricans, and Jackson-Weiss syndrome.
p51576
sg35206
(lp51577
sg35208
(lp51578
(dp51579
g35211
I235
sg35212
VCrouzon syndrome with acanthosis nigricans
p51580
sg35214
I42
sg35215
VC2677099
p51581
sg35217
I5
sa(dp51582
g35211
I22
sg35212
Vhearing loss
p51583
sg35214
I12
sg35215
VC0011053
p51584
sg35217
I2
sa(dp51585
g35211
I162
sg35212
Vsyndrome, Pfeiffer
p51586
sg35214
I18
sg35215
VC0220658
p51587
sg35217
I2
sa(dp51588
g35211
I128
sg35212
Vcraniosynostosis syndromes
p51589
sg35214
I26
sg35215
VC0010278
p51590
sg35217
I2
sa(dp51591
g35211
I181
sg35212
Vsyndrome, Crouzon
p51592
sg35214
I17
sg35215
VC2931196
p51593
sg35217
I2
sa(dp51594
g35211
I283
sg35212
VJackson-Weiss syndrome
p51595
sg35214
I22
sg35215
VC0795998
p51596
sg35217
I2
sa(dp51597
g35211
I209
sg35212
VBeare-Stevenson syndrome
p51598
sg35214
I24
sg35215
VC1852406
p51599
sg35217
I2
sa(dp51600
g35211
I73
sg35212
VMuenke syndrome
p51601
sg35214
I15
sg35215
VC1864436
p51602
sg35217
I2
sa(dp51603
g35211
I80
sg35212
Vsyndrome
p51604
sg35214
I8
sg35215
VC0039082
p51605
sg35217
I1
sa(dp51606
g35211
I181
sg35212
Vsyndrome, Crouzon
p51607
sg35214
I17
sg35215
VC2931196
p51608
sg35217
I2
sasa(dp51609
g35204
VOur literature review revealed the following incidences of hearing loss in FGFR craniosynostoses: 61% in Muenke syndrome, 80% in Apert Syndrome, 92% in Pfeiffer syndrome, 74% in Crouzon syndrome, 68% in Jackson Weiss syndrome, 4% in Beare Stevenson syndrome and 14% in Crouzon syndrome with Acanthosis Nigricans.
p51610
sg35206
(lp51611
sg35208
(lp51612
(dp51613
g35211
I112
sg35212
Vsyndrome
p51614
sg35214
I8
sg35215
VC0039082
p51615
sg35217
I1
sa(dp51616
g35211
I59
sg35212
Vhearing loss
p51617
sg35214
I12
sg35215
VC0011053
p51618
sg35217
I2
sa(dp51619
g35211
I80
sg35212
Vcraniosynostoses
p51620
sg35214
I16
sg35215
VC0010278
p51621
sg35217
I1
sa(dp51622
g35211
I203
sg35212
VJackson Weiss syndrome
p51623
sg35214
I22
sg35215
VC0795998
p51624
sg35217
I3
sa(dp51625
g35211
I269
sg35212
VCrouzon syndrome with Acanthosis Nigricans
p51626
sg35214
I42
sg35215
VC2677099
p51627
sg35217
I5
sa(dp51628
g35211
I105
sg35212
VMuenke syndrome
p51629
sg35214
I15
sg35215
VC1864436
p51630
sg35217
I2
sa(dp51631
g35211
I178
sg35212
VCrouzon syndrome
p51632
sg35214
I16
sg35215
VC0010273
p51633
sg35217
I2
sa(dp51634
g35211
I152
sg35212
VPfeiffer syndrome
p51635
sg35214
I17
sg35215
VC0265303
p51636
sg35217
I2
sa(dp51637
g35211
I129
sg35212
VApert Syndrome
p51638
sg35214
I14
sg35215
VC0001193
p51639
sg35217
I2
sasa(dp51640
g35204
VThis study reveals the pleiotropic effects of the FGFR2 Y394C mutation evidenced by cutis gyrata, acanthosis nigricans, and craniosynostosis and provides a useful model for investigating the molecular mechanisms of skin and skull development.
p51641
sg35206
(lp51642
sg35208
(lp51643
(dp51644
g35211
I98
sg35212
Vacanthosis nigricans
p51645
sg35214
I20
sg35215
VC0000889
p51646
sg35217
I2
sa(dp51647
g35211
I124
sg35212
Vcraniosynostosis
p51648
sg35214
I16
sg35215
VC0010278
p51649
sg35217
I1
sasa(dp51650
g35204
VSome cases of congenital skeletal disorders with an FGFR2 mutation show skin phenotypes, including acne, cutis gyrata, and acanthosis nigricans.
p51651
sg35206
(lp51652
sg35208
(lp51653
(dp51654
g35211
I99
sg35212
Vacne
p51655
sg35214
I4
sg35215
VC0001144
p51656
sg35217
I1
sa(dp51657
g35211
I123
sg35212
Vacanthosis nigricans
p51658
sg35214
I20
sg35215
VC0000889
p51659
sg35217
I2
sasa(dp51660
g35204
VPeripheral nerve and spinal cord injuries, along with other painful syndromes such as fibromyalgia, diabetic neuropathy, chemotherapeutic neuropathy, trigeminal neuralgia, complex regional pain syndrome, and/or irritable bowel syndrome, cause several neuroplasticity changes in the nervous system along its entire axis affecting the different neuronal nuclei.
p51661
sg35206
(lp51662
sg35208
(lp51663
(dp51664
g35211
I282
sg35212
Vnervous
p51665
sg35214
I7
sg35215
VC0027769
p51666
sg35217
I1
sa(dp51667
g35211
I100
sg35212
Vdiabetic neuropathy
p51668
sg35214
I19
sg35215
VC0011882
p51669
sg35217
I2
sa(dp51670
g35211
I60
sg35212
Vpainful
p51671
sg35214
I7
sg35215
VC0030193
p51672
sg35217
I1
sa(dp51673
g35211
I86
sg35212
Vfibromyalgia
p51674
sg35214
I12
sg35215
VC0016053
p51675
sg35217
I1
sa(dp51676
g35211
I172
sg35212
Vcomplex regional pain syndrome
p51677
sg35214
I30
sg35215
VC0458219
p51678
sg35217
I4
sa(dp51679
g35211
I161
sg35212
Vneuralgia
p51680
sg35214
I9
sg35215
VC0027796
p51681
sg35217
I1
sa(dp51682
g35211
I211
sg35212
Virritable bowel syndrome
p51683
sg35214
I24
sg35215
VC0022104
p51684
sg35217
I3
sa(dp51685
g35211
I138
sg35212
Vneuropathy, trigeminal
p51686
sg35214
I22
sg35215
VC0152177
p51687
sg35217
I2
sa(dp51688
g35211
I68
sg35212
Vsyndromes
p51689
sg35214
I9
sg35215
VC0039082
p51690
sg35217
I1
sa(dp51691
g35211
I28
sg35212
Vcord
p51692
sg35214
I4
sg35215
VC0035334
p51693
sg35217
I1
sasa(dp51694
g35204
VSortilin-related receptor with LDLR class A repeats (SORLA, SORL1, or LR11) is a genetic risk factor associated with Alzheimer's disease (AD).
p51695
sg35206
(lp51696
(dp51697
g35211
I0
sg35212
VSortilin-related receptor with LDLR class A repeats
p51698
sg35214
I51
sg35223
g12
sg35217
I7
sa(dp51699
g35211
I60
sg35212
VSORL1
p51700
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp51701
g35211
I53
sg35212
VSORLA
p51702
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp51703
(dp51704
g35211
I138
sg35212
VAD
p51705
sg35214
I2
sg35215
VC1521724
p51706
sg35217
I1
sa(dp51707
g35211
I117
sg35212
VAlzheimer's disease
p51708
sg35214
I19
sg35215
VC1521724
p51709
sg35217
I2
sasa(dp51710
g35204
VA meta-analysis was performed to identify empirical data assessing the effects of a single nucleotide polymorphisms of sortilin-related receptor on Alzheimer's disease based on 14 studies involving 37941 cases and 49727 control studies.
p51711
sg35206
(lp51712
(dp51713
g35211
I119
sg35212
Vsortilin-related receptor
p51714
sg35214
I25
sg35223
g12
sg35217
I2
sasg35208
(lp51715
(dp51716
g35211
I148
sg35212
VAlzheimer's disease
p51717
sg35214
I19
sg35215
VC1521724
p51718
sg35217
I2
sasa(dp51719
g35204
VGiven these data, we provide crucial evidence to manifest that a significant relationship exists between SORL1 polymorphisms and the susceptibility of Alzheimer's disease.
p51720
sg35206
(lp51721
(dp51722
g35211
I105
sg35212
VSORL1
p51723
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp51724
(dp51725
g35211
I151
sg35212
VAlzheimer's disease
p51726
sg35214
I19
sg35215
VC1521724
p51727
sg35217
I2
sasa(dp51728
g35204
VFurthermore, a third SORL1 variant, c.5195G &gt; C, recently identified in a Swedish case control cohort included in the European Early-Onset Dementia (EU EOD) consortium study, was detected in two affected siblings in a third family with familial EOAD.
p51729
sg35206
(lp51730
(dp51731
g35211
I21
sg35212
VSORL1 variant
p51732
sg35214
I13
sg35223
g12
sg35217
I2
sasg35208
(lp51733
(dp51734
g35211
I142
sg35212
VDementia
p51735
sg35214
I8
sg35215
VC0497327
p51736
sg35217
I1
sasa(dp51737
g135
(dp51738
(VThrombospondin-1
p51739
Vpulmonary hypertension
p51740
tp51741
I00
ssg35204
VThrombospondin-1 (TSP1) is a ligand for CD47 and TSP1-/- mice are protected from pulmonary hypertension (PH).
p51742
sg35206
(lp51743
(dp51744
g35211
I18
sg35212
VTSP1
p51745
sg35214
I4
sg35223
VP07996
p51746
sg35217
I1
sa(dp51747
g35211
I18
sg35212
VTSP1
p51748
sg35214
I4
sg35223
VP07996
p51749
sg35217
I1
sa(dp51750
g35211
I0
sg35212
g51739
sg35214
I16
sg35223
VP07996
p51751
sg35217
I1
sa(dp51752
g35211
I40
sg35212
VCD47
p51753
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp51754
(dp51755
g35211
I105
sg35212
VPH
p51756
sg35214
I2
sg35215
VC0020542
p51757
sg35217
I1
sa(dp51758
g35211
I81
sg35212
g51740
sg35214
I22
sg35215
VC0020542
p51759
sg35217
I2
sasa(dp51760
g35204
VWe further discuss therapeutic strategies for enhancing or inhibiting CD47 signaling and applications of such agents in preclinical models of ischemia and ischemia/reperfusion injuries, organ transplantation, pulmonary hypertension, radioprotection, and cancer.
p51761
sg35206
(lp51762
(dp51763
g35211
I70
sg35212
VCD47
p51764
sg35214
I4
sg35223
g12
sg35217
I1
sasg35208
(lp51765
(dp51766
g35211
I142
sg35212
Vischemia
p51767
sg35214
I8
sg35215
VC0022116
p51768
sg35217
I1
sa(dp51769
g35211
I254
sg35212
Vcancer
p51770
sg35214
I6
sg35215
VC0006826
p51771
sg35217
I1
sa(dp51772
g35211
I209
sg35212
Vpulmonary hypertension
p51773
sg35214
I22
sg35215
VC0020542
p51774
sg35217
I2
sa(dp51775
g35211
I142
sg35212
Vischemia
p51776
sg35214
I8
sg35215
VC0022116
p51777
sg35217
I1
sasa(dp51778
g35204
VIn present study, anticancer activity of ethanol extract of Chinese propolis (EECP) at 25, 50, 100, and 200  my g/mL was explored by testing the cytotoxicity in MCF-7 (human breast cancer ER(+)) and MDA-MB-231 (human breast cancer ER(-)) cells.
p51779
sg35206
(lp51780
sg35208
(lp51781
(dp51782
g35211
I145
sg35212
Vcytotoxicity
p51783
sg35214
I12
sg35215
VC0596402
p51784
sg35217
I1
sa(dp51785
g35211
I174
sg35212
Vbreast cancer
p51786
sg35214
I13
sg35215
VC0678222
p51787
sg35217
I2
sa(dp51788
g35211
I174
sg35212
Vbreast cancer
p51789
sg35214
I13
sg35215
VC0678222
p51790
sg35217
I2
sasa(dp51791
g35204
VWe exposed human pancreatic cancer cell line MiaPaCa-2 (CRL-1420) to 34  my g/mL of LE for 24, 48, and 72 hours.
p51792
sg35206
(lp51793
sg35208
(lp51794
(dp51795
g35211
I17
sg35212
Vpancreatic cancer
p51796
sg35214
I17
sg35215
VC0235974
p51797
sg35217
I2
sasa(dp51798
g135
(dp51799
(VJAG1
p51800
Vadrenocortical carcinoma
p51801
tp51802
I01
ssg35204
VIn addition, variations in JAG1 have been found to be associated with multiple types of cancer including breast cancer and adrenocortical carcinoma.
p51803
sg35206
(lp51804
(dp51805
g35211
I27
sg35212
g51800
sg35214
I4
sg35223
VP78504
p51806
sg35217
I1
sasg35208
(lp51807
(dp51808
g35211
I105
sg35212
Vbreast cancer
p51809
sg35214
I13
sg35215
VC0678222
p51810
sg35217
I2
sa(dp51811
g35211
I88
sg35212
Vcancer
p51812
sg35214
I6
sg35215
VC0006826
p51813
sg35217
I1
sa(dp51814
g35211
I123
sg35212
g51801
sg35214
I24
sg35215
VC0206686
p51815
sg35217
I2
sasa(dp51816
g35204
VThe role of the extract in pancreatic cancer treatment was associated with down-regulation of Notch-4 and Jagged-1 in Notch signaling pathway.
p51817
sg35206
(lp51818
sg35208
(lp51819
(dp51820
g35211
I27
sg35212
Vpancreatic cancer
p51821
sg35214
I17
sg35215
VC0235974
p51822
sg35217
I2
sasa(dp51823
g35204
VThe patient was a 64-year-old man with situs inversus totalis who had previously undergone sigmoidectomy with regional lymphadenectomy for sigmoid colon cancer at age 62.
p51824
sg35206
(lp51825
sg35208
(lp51826
(dp51827
g35211
I39
sg35212
Vsitus inversus
p51828
sg35214
I14
sg35215
VC0037221
p51829
sg35217
I2
sa(dp51830
g35211
I139
sg35212
Vsigmoid colon cancer
p51831
sg35214
I20
sg35215
VC0751498
p51832
sg35217
I3
sasa(dp51833
g35204
VFor the treatment of hepatic metastases from sigmoid colon cancer in a patient with situs inversus totalis, "left" hepatic lobectomy, partial hepatectomy, and radiofrequency ablation therapy were performed.
p51834
sg35206
(lp51835
sg35208
(lp51836
(dp51837
g35211
I21
sg35212
Vhepatic metastases
p51838
sg35214
I18
sg35215
VC0494165
p51839
sg35217
I2
sa(dp51840
g35211
I45
sg35212
Vsigmoid colon cancer
p51841
sg35214
I20
sg35215
VC0751498
p51842
sg35217
I3
sa(dp51843
g35211
I84
sg35212
Vsitus inversus
p51844
sg35214
I14
sg35215
VC0037221
p51845
sg35217
I2
sasa(dp51846
g135
(dp51847
(VYKL-40
p51848
Vpulmonary eosinophilia
p51849
tp51850
I00
ssg35204
VOn day 25, pulmonary eosinophilia, airway hyperresponsiveness, mucus hypersecretion, inflammatory cytokines such as IL-4, -5 and -13 in BAL fluid, gene expression of inflammatory mediators such as 5-LOX, E-selectin, VCAM-1, CCL5, TNF-Alfa, AMCase, Ym2, YKL-40, Muc5ac, CCL2 and iNOS in animal lung tissues, and serum IgE were determined.
p51851
sg35206
(lp51852
(dp51853
g35211
I278
sg35212
ViNOS
p51854
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp51855
g35211
I269
sg35212
VCCL2
p51856
sg35214
I4
sg35223
VP13500
p51857
sg35217
I1
sa(dp51858
g35211
I224
sg35212
VCCL5
p51859
sg35214
I4
sg35223
VP13501
p51860
sg35217
I1
sa(dp51861
g35211
I311
sg35212
Vserum IgE
p51862
sg35214
I9
sg35223
VP01854
p51863
sg35217
I2
sa(dp51864
g35211
I204
sg35212
VE-selectin
p51865
sg35214
I10
sg35223
VP16581
p51866
sg35217
I1
sa(dp51867
g35211
I230
sg35212
VTNF-Alfa
p51868
sg35214
I8
sg35223
VP01375
p51869
sg35217
I1
sa(dp51870
g35211
I197
sg35212
V5-LOX
p51871
sg35214
I5
sg35223
VP09917
p51872
sg35217
I1
sa(dp51873
g35211
I116
sg35212
VIL-4
p51874
sg35214
I4
sg35223
VP05112
p51875
sg35217
I1
sa(dp51876
g35211
I216
sg35212
VVCAM-1
p51877
sg35214
I6
sg35223
VP19320
p51878
sg35217
I1
sa(dp51879
g35211
I253
sg35212
g51848
sg35214
I6
sg35223
VP36222
p51880
sg35217
I1
sasg35208
(lp51881
(dp51882
g35211
I317
sg35212
VIgE
p51883
sg35214
I3
sg35215
VC0270850
p51884
sg35217
I1
sa(dp51885
g35211
I11
sg35212
g51849
sg35214
I22
sg35215
VC0034068
p51886
sg35217
I2
sasa(dp51887
g135
(dp51888
(VCCL5
p51889
Vtropical pulmonary eosinophilia
p51890
tp51891
I00
ssg35204
VOur results show that tropical pulmonary eosinophilia mice exhibited increased levels of IL-4, IL-5, CCL5, and CCL11 in the bronchoalveolar lavage fluid and lung parenchyma along with elevated titers of IgE and IgG subtypes in the serum.
p51892
sg35206
(lp51893
(dp51894
g35211
I95
sg35212
VIL-5
p51895
sg35214
I4
sg35223
VP05113
p51896
sg35217
I1
sa(dp51897
g35211
I203
sg35212
VIgE
p51898
sg35214
I3
sg35223
VP01854
p51899
sg35217
I1
sa(dp51900
g35211
I111
sg35212
VCCL11
p51901
sg35214
I5
sg35223
VP51671
p51902
sg35217
I1
sa(dp51903
g35211
I89
sg35212
VIL-4
p51904
sg35214
I4
sg35223
VP05112
p51905
sg35217
I1
sa(dp51906
g35211
I101
sg35212
g51889
sg35214
I4
sg35223
VP13501
p51907
sg35217
I1
sasg35208
(lp51908
(dp51909
g35211
I203
sg35212
VIgE
p51910
sg35214
I3
sg35215
VC0270850
p51911
sg35217
I1
sa(dp51912
g35211
I22
sg35212
g51890
sg35214
I31
sg35215
VC0014458
p51913
sg35217
I3
sasa(dp51914
g135
(dp51915
(VIL-5
p51916
Vpulmonary eosinophilia
p51917
tp51918
I00
ssg35204
VA(2B) R deficiency resulted in a dramatic reduction on Th2-type airways responses with decreased pulmonary eosinophilia without augmenting neutrophilia, and decreased lung IL-4, IL-5, and IL-13 production.
p51919
sg35206
(lp51920
(dp51921
g35211
I188
sg35212
VIL-13
p51922
sg35214
I5
sg35223
VP35225
p51923
sg35217
I1
sa(dp51924
g35211
I167
sg35212
Vlung IL-4
p51925
sg35214
I9
sg35223
VP05112
p51926
sg35217
I2
sa(dp51927
g35211
I178
sg35212
g51916
sg35214
I4
sg35223
VP05113
p51928
sg35217
I1
sasg35208
(lp51929
(dp51930
g35211
I97
sg35212
g51917
sg35214
I22
sg35215
VC0034068
p51931
sg35217
I2
sasa(dp51932
g135
(dp51933
(VIL-13
p51934
Vpulmonary eosinophilia
p51935
tp51936
I00
ssg35204
VBoth isoforms caused pulmonary infiltration of lymphocytes and neutrophils, whereas mm IL-33 also caused pulmonary eosinophilia and goblet cell hyperplasia and increased expression of IL-4, IL-5, IL-13, IL-17, MCP-1, and KC.
p51937
sg35206
(lp51938
(dp51939
g35211
I190
sg35212
VIL-5
p51940
sg35214
I4
sg35223
VP05113
p51941
sg35217
I1
sa(dp51942
g35211
I184
sg35212
VIL-4
p51943
sg35214
I4
sg35223
VP05112
p51944
sg35217
I1
sa(dp51945
g35211
I210
sg35212
VMCP-1
p51946
sg35214
I5
sg35223
VP41597
p51947
sg35217
I1
sa(dp51948
g35211
I196
sg35212
g51934
sg35214
I5
sg35223
VP35225
p51949
sg35217
I1
sasg35208
(lp51950
(dp51951
g35211
I21
sg35212
Vpulmonary infiltration
p51952
sg35214
I22
sg35215
VC0235896
p51953
sg35217
I2
sa(dp51954
g35211
I144
sg35212
Vhyperplasia
p51955
sg35214
I11
sg35215
VC0020507
p51956
sg35217
I1
sa(dp51957
g35211
I105
sg35212
g51935
sg35214
I22
sg35215
VC0034068
p51958
sg35217
I2
sasa(dp51959
g135
(dp51960
(VIL-5
p51961
Vhyperplasia
p51962
tp51963
I00
ssg35204
VGermline deficiency of the cell surface receptor chain ST2 abrogated the mm IL-33-induced Th2-associated effects (pulmonary eosinophilia, goblet cell hyperplasia, and increased IL-4 and IL-5), yet the lymphocytic infiltration induced by full-length mouse IL-33 or mm IL-33 was not fully abrogated by the absence of ST2.
p51964
sg35206
(lp51965
(dp51966
g35211
I177
sg35212
VIL-4
p51967
sg35214
I4
sg35223
VP05112
p51968
sg35217
I1
sa(dp51969
g35211
I237
sg35212
Vfull-length mouse IL-33
p51970
sg35214
I23
sg35223
g12
sg35217
I3
sa(dp51971
g35211
I186
sg35212
g51961
sg35214
I4
sg35223
VP05113
p51972
sg35217
I1
sasg35208
(lp51973
(dp51974
g35211
I114
sg35212
Vpulmonary eosinophilia
p51975
sg35214
I22
sg35215
VC0034068
p51976
sg35217
I2
sa(dp51977
g35211
I201
sg35212
Vlymphocytic infiltration
p51978
sg35214
I24
sg35215
VC1262091
p51979
sg35217
I2
sa(dp51980
g35211
I150
sg35212
g51962
sg35214
I11
sg35215
VC0020507
p51981
sg35217
I1
sasa(dp51982
g135
(dp51983
(VSTAT6
p51984
Vpulmonary eosinophilia
p51985
tp51986
I00
ssg35204
VOVA-challenged STAT6-/- mice had neither AHR nor pulmonary eosinophilia, but had increased expression of mRNA for TNF-Alfa, IFN-Gamma and IL-4.
p51987
sg35206
(lp51988
(dp51989
g35211
I138
sg35212
VIL-4
p51990
sg35214
I4
sg35223
VP05112
p51991
sg35217
I1
sa(dp51992
g35211
I114
sg35212
VTNF
p51993
sg35214
I3
sg35223
VP01375
p51994
sg35217
I1
sa(dp51995
g35211
I124
sg35212
VIFN-Gamma
p51996
sg35214
I9
sg35223
VP01579
p51997
sg35217
I1
sa(dp51998
g35211
I41
sg35212
VAHR
p51999
sg35214
I3
sg35223
VP35869
p52000
sg35217
I1
sa(dp52001
g35211
I15
sg35212
g51984
sg35214
I5
sg35223
VP42226
p52002
sg35217
I1
sasg35208
(lp52003
(dp52004
g35211
I49
sg35212
g51985
sg35214
I22
sg35215
VC0034068
p52005
sg35217
I2
sasa(dp52006
g35204
VGLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome.
p52007
sg35206
(lp52008
(dp52009
g35211
I0
sg35212
VGLP-1R
p52010
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp52011
g35211
I62
sg35212
VGLP-2R
p52012
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp52013
(dp52014
g35211
I47
sg35212
Vobesity
p52015
sg35214
I7
sg35215
VC0028754
p52016
sg35217
I1
sa(dp52017
g35211
I98
sg35212
Vshort bowel syndrome
p52018
sg35214
I20
sg35215
VC0036992
p52019
sg35217
I3
sa(dp52020
g35211
I34
sg35212
Vdiabetes
p52021
sg35214
I8
sg35215
VC0011849
p52022
sg35217
I1
sasa(dp52023
g35204
VRNA-seq analysis and quantitative real-time polymerase chain reaction (qRT-PCR) were performed to evaluate the presence of GLP-1R and GLP-2R in EAT and subcutaneous fat (SAT) obtained from 8 subjects with coronary artery disease and type 2 diabetes mellitus undergoing elective cardiac surgery.
p52024
sg35206
(lp52025
(dp52026
g35211
I134
sg35212
VGLP-2R
p52027
sg35214
I6
sg35223
g12
sg35217
I1
sa(dp52028
g35211
I123
sg35212
VGLP-1R
p52029
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp52030
(dp52031
g35211
I205
sg35212
Vcoronary artery disease
p52032
sg35214
I23
sg35215
VC1956346
p52033
sg35217
I3
sa(dp52034
g35211
I233
sg35212
Vtype 2 diabetes mellitus
p52035
sg35214
I24
sg35215
VC0011860
p52036
sg35217
I4
sasa(dp52037
g35204
VGastric tissue samples of non-obese patients (NOB, n=10) and obese patients without diabetes (OB, n=31) and with diabetes (OWD, n=12) were used to evaluate GLP2R expression and distribution.
p52038
sg35206
(lp52039
(dp52040
g35211
I156
sg35212
VGLP2R
p52041
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp52042
(dp52043
g35211
I30
sg35212
Vobese
p52044
sg35214
I5
sg35215
VC0028754
p52045
sg35217
I1
sa(dp52046
g35211
I84
sg35212
Vdiabetes
p52047
sg35214
I8
sg35215
VC0011849
p52048
sg35217
I1
sa(dp52049
g35211
I30
sg35212
Vobese
p52050
sg35214
I5
sg35215
VC0028754
p52051
sg35217
I1
sa(dp52052
g35211
I84
sg35212
Vdiabetes
p52053
sg35214
I8
sg35215
VC0011849
p52054
sg35217
I1
sasa(dp52055
g35204
VThis is the first evidence of increased GLP2R expression in chief cells of patients with severe obesity regardless of diabetes status.
p52056
sg35206
(lp52057
(dp52058
g35211
I40
sg35212
VGLP2R
p52059
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp52060
(dp52061
g35211
I118
sg35212
Vdiabetes
p52062
sg35214
I8
sg35215
VC0011849
p52063
sg35217
I1
sa(dp52064
g35211
I89
sg35212
Vsevere obesity
p52065
sg35214
I14
sg35215
VC0028756
p52066
sg35217
I2
sasa(dp52067
g35204
VWe examined the importance of GLP-2 receptor (GLP-2R) signaling for glucose homeostasis in multiple models of metabolic stress, diabetes, and obesity.
p52068
sg35206
(lp52069
(dp52070
g35211
I30
sg35212
VGLP-2 receptor
p52071
sg35214
I14
sg35223
g12
sg35217
I2
sa(dp52072
g35211
I46
sg35212
VGLP-2R
p52073
sg35214
I6
sg35223
g12
sg35217
I1
sasg35208
(lp52074
(dp52075
g35211
I128
sg35212
Vdiabetes
p52076
sg35214
I8
sg35215
VC0011849
p52077
sg35217
I1
sa(dp52078
g35211
I142
sg35212
Vobesity
p52079
sg35214
I7
sg35215
VC0028754
p52080
sg35217
I1
sasa(dp52081
g35204
VMoreover, glucose homeostasis was comparable in Glp2r(-/-) and Glp2r(+/+) mice fed a high-fat diet for 5 months or after induction of streptozotocin-induced diabetes.
p52082
sg35206
(lp52083
(dp52084
g35211
I48
sg35212
VGlp2r
p52085
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp52086
g35211
I48
sg35212
VGlp2r
p52087
sg35214
I5
sg35223
g12
sg35217
I1
sasg35208
(lp52088
(dp52089
g35211
I157
sg35212
Vdiabetes
p52090
sg35214
I8
sg35215
VC0011849
p52091
sg35217
I1
sasa(dp52092
g135
(dp52093
(Vcollagen I protein
p52094
Vureteral obstruction
p52095
tp52096
I00
ssg35204
VIn a model of tubulointerstitial fibrosis induced by unilateral ureteral obstruction in mice, increased collagen I protein content and an almost complete disappearance of erythropoietin mRNA expression were observed in the ureteral ligated kidney with respect to the contralateral control.
p52097
sg35206
(lp52098
(dp52099
g35211
I171
sg35212
Verythropoietin mRNA
p52100
sg35214
I19
sg35223
VP01588
p52101
sg35217
I2
sa(dp52102
g35211
I104
sg35212
g52094
sg35214
I18
sg35223
VP42768
p52103
sg35217
I3
sasg35208
(lp52104
(dp52105
g35211
I33
sg35212
Vfibrosis
p52106
sg35214
I8
sg35215
VC0016059
p52107
sg35217
I1
sa(dp52108
g35211
I64
sg35212
g52095
sg35214
I20
sg35215
VC0041956
p52109
sg35217
I2
sasa(dp52110
g135
(dp52111
(VMMP9
p52112
Vureteral obstruction
p52113
tp52114
I00
ssg35204
VIn the present study, employing a mouse model of renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction (UUO), we demonstrated that EPO markedly reduced the disruption of the tubular basement membrane (TBM) through attenuating the activation of tissue plasminogen activator (tPA) and matrix metalloproteinase 9 (MMP9), the major matrix proteolytic network in the obstructed kidney.
p52115
sg35206
(lp52116
(dp52117
g35211
I297
sg35212
VtPA
p52118
sg35214
I3
sg35223
VP00747
p52119
sg35217
I1
sa(dp52120
g35211
I306
sg35212
Vmatrix metalloproteinase 9
p52121
sg35214
I26
sg35223
VP14780
p52122
sg35217
I3
sa(dp52123
g35211
I154
sg35212
VEPO
p52124
sg35214
I3
sg35223
VP01588
p52125
sg35217
I1
sa(dp52126
g35211
I267
sg35212
Vtissue plasminogen activator
p52127
sg35214
I28
sg35223
VP00747
p52128
sg35217
I3
sa(dp52129
g35211
I334
sg35212
g52112
sg35214
I4
sg35223
VP14780
p52130
sg35217
I1
sasg35208
(lp52131
(dp52132
g35211
I127
sg35212
VUUO
p52133
sg35214
I3
sg35215
VC0041956
p52134
sg35217
I1
sa(dp52135
g35211
I74
sg35212
Vfibrosis
p52136
sg35214
I8
sg35215
VC0016059
p52137
sg35217
I1
sa(dp52138
g35211
I105
sg35212
g52113
sg35214
I20
sg35215
VC0041956
p52139
sg35217
I2
sasa(dp52140
g135
(dp52141
(VTGF-Beta1
p52142
Vfibrosis
p52143
tp52144
I00
ssg35204
VThe MVs derived from untreated MSCs (MSC-MVs) or from MSCs incubated in different concentrations of EPO (1, 10, 100, and 500 IU/ml EPO-MVs) were used to treat renal injury of unilateral ureteral obstruction (UUO) in vivo, and transforming growth factor-Beta1 (TGF-Beta1)-induced fibrosis in a human renal proximal tubular epithelial (HK2) cell line in vitro.
p52145
sg35206
(lp52146
(dp52147
g35211
I100
sg35212
VEPO
p52148
sg35214
I3
sg35223
VP01588
p52149
sg35217
I1
sa(dp52150
g35211
I226
sg35212
Vtransforming growth factor-Beta1
p52151
sg35214
I32
sg35223
VP01137
p52152
sg35217
I3
sa(dp52153
g35211
I260
sg35212
g52142
sg35214
I9
sg35223
VP01137
p52154
sg35217
I1
sasg35208
(lp52155
(dp52156
g35211
I208
sg35212
VUUO
p52157
sg35214
I3
sg35215
VC0041956
p52158
sg35217
I1
sa(dp52159
g35211
I186
sg35212
Vureteral obstruction
p52160
sg35214
I20
sg35215
VC0041956
p52161
sg35217
I2
sa(dp52162
g35211
I279
sg35212
g52143
sg35214
I8
sg35215
VC0016059
p52163
sg35217
I1
sasa(dp52164
g135
(dp52165
(VEPO
p52166
VUUO
p52167
tp52168
I00
ssg35204
VTwenty-four male C57BL6 mice were randomly divided into four groups, each comprising six mice: (i) control group (Sh); (ii) unilateral ureteral obstruction (UUO) plus vehicle group (U+V); (#\u2172) UUO plus 300 U/kg body weight recombinant human (rh)EPO (U+E1) and (#\u2173) UUO plus 1,000 U/kg body weight rhEPO (U+E2).
p52169
sg35206
(lp52170
(dp52171
g35211
I245
sg35212
g52166
sg35214
I3
sg35223
VP01588
p52172
sg35217
I1
sasg35208
(lp52173
(dp52174
g35211
I157
sg35212
VUUO
p52175
sg35214
I3
sg35215
VC0041956
p52176
sg35217
I1
sa(dp52177
g35211
I157
sg35212
VUUO
p52178
sg35214
I3
sg35215
VC0041956
p52179
sg35217
I1
sa(dp52180
g35211
I135
sg35212
Vureteral obstruction
p52181
sg35214
I20
sg35215
VC0041956
p52182
sg35217
I2
sa(dp52183
g35211
I157
sg35212
g52167
sg35214
I3
sg35215
VC0041956
p52184
sg35217
I1
sasa(dp52185
g135
(dp52186
(Vbasic fibroblast growth factor
p52187
Vureteral obstruction
p52188
tp52189
I00
ssg35204
VThe aim of this study is to show and compare the actions of Simvastatin (Simv) and Erythropoietin (Epo) in renal expression of nuclear factor kappa B (NFKB), transforming growth factor-Beta (TGF-Beta), basic fibroblast growth factor (bFGF), platelet-derived growth factor B (PDGF-B), fibronectin and development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO).
p52190
sg35206
(lp52191
(dp52192
g35211
I151
sg35212
VNFKB
p52193
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp52194
g35211
I99
sg35212
VEpo
p52195
sg35214
I3
sg35223
VP01588
p52196
sg35217
I1
sa(dp52197
g35211
I158
sg35212
Vtransforming growth factor-Beta
p52198
sg35214
I31
sg35223
VP18075
p52199
sg35217
I3
sa(dp52200
g35211
I191
sg35212
VTGF-Beta
p52201
sg35214
I8
sg35223
VP18075
p52202
sg35217
I1
sa(dp52203
g35211
I275
sg35212
VPDGF-B
p52204
sg35214
I6
sg35223
VP01127
p52205
sg35217
I1
sa(dp52206
g35211
I83
sg35212
VErythropoietin
p52207
sg35214
I14
sg35223
VP01588
p52208
sg35217
I1
sa(dp52209
g35211
I234
sg35212
VbFGF
p52210
sg35214
I4
sg35223
VP53370
p52211
sg35217
I1
sa(dp52212
g35211
I127
sg35212
Vnuclear factor kappa B
p52213
sg35214
I22
sg35223
VP01160
p52214
sg35217
I4
sa(dp52215
g35211
I241
sg35212
Vplatelet-derived growth factor B
p52216
sg35214
I32
sg35223
VP01127
p52217
sg35217
I4
sa(dp52218
g35211
I202
sg35212
g52187
sg35214
I30
sg35223
VP53370
p52219
sg35217
I4
sasg35208
(lp52220
(dp52221
g35211
I383
sg35212
VUUO
p52222
sg35214
I3
sg35215
VC0041956
p52223
sg35217
I1
sa(dp52224
g35211
I315
sg35212
Vinterstitial fibrosis
p52225
sg35214
I21
sg35215
VC0240035
p52226
sg35217
I2
sa(dp52227
g35211
I361
sg35212
g52188
sg35214
I20
sg35215
VC0041956
p52228
sg35217
I2
sasa(dp52229
g135
(dp52230
(VEpo
p52231
Vureteral obstruction
p52232
tp52233
I00
ssg35204
VIn a novel mouse model, unilateral ureteral obstruction-induced inflammatory milieu activated NFKB and Smad signaling pathways in REPs, rapidly repressed the Epo-producing potential of REPs, and led to myofibroblast transformation of these cells.
p52234
sg35206
(lp52235
(dp52236
g35211
I94
sg35212
VNFKB
p52237
sg35214
I4
sg35223
g12
sg35217
I1
sa(dp52238
g35211
I158
sg35212
g52231
sg35214
I3
sg35223
VP01588
p52239
sg35217
I1
sasg35208
(lp52240
(dp52241
g35211
I35
sg35212
g52232
sg35214
I20
sg35215
VC0041956
p52242
sg35217
I2
sa(dp52243
g35211
I216
sg35212
Vtransformation
p52244
sg35214
I14
sg35215
VC1510411
p52245
sg35217
I1
sasa(dp52246
g135
(dp52247
(VEpo
p52248
Vureteral obstruction
p52249
tp52250
I00
ssg35204
VReversing the unilateral ureteral obstruction-induced inflammatory microenvironment restored the Epo-producing potential and the physiologic phenotype of REPs.
p52251
sg35206
(lp52252
(dp52253
g35211
I97
sg35212
g52248
sg35214
I3
sg35223
VP01588
p52254
sg35217
I1
sasg35208
(lp52255
(dp52256
g35211
I25
sg35212
g52249
sg35214
I20
sg35215
VC0041956
p52257
sg35217
I2
sasa(dp52258
g135
(dp52259
(VEPO
p52260
Vkidney diseases
p52261
tp52262
I00
ssg35204
VSecondary polycythemia with increased production of erythropoietin (EPO) is known to occur in kidney diseases such as hydronephrosis and cystic disease, but the mechanism remains unclear.
p52263
sg35206
(lp52264
(dp52265
g35211
I52
sg35212
Verythropoietin
p52266
sg35214
I14
sg35223
VP01588
p52267
sg35217
I1
sa(dp52268
g35211
I68
sg35212
g52260
sg35214
I3
sg35223
VP01588
p52269
sg35217
I1
sasg35208
(lp52270
(dp52271
g35211
I118
sg35212
Vhydronephrosis
p52272
sg35214
I14
sg35215
VC0020295
p52273
sg35217
I1
sa(dp52274
g35211
I0
sg35212
VSecondary polycythemia
p52275
sg35214
I22
sg35215
VC1318533
p52276
sg35217
I2
sa(dp52277
g35211
I137
sg35212
Vcystic disease
p52278
sg35214
I14
sg35215
VC0334054
p52279
sg35217
I2
sa(dp52280
g35211
I94
sg35212
g52261
sg35214
I15
sg35215
VC0022658
p52281
sg35217
I2
sasa(dp52282
g135
(dp52283
(Varginase 1
p52284
Vpriapism
p52285
tp52286
I00
ssg35204
VDecompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke.
p52287
sg35206
(lp52288
(dp52289
g35211
I20
sg35212
Vhemoglobin
p52290
sg35214
I10
sg35223
g12
sg35217
I1
sa(dp52291
g35211
I32
sg35212
g52284
sg35214
I10
sg35223
VP05089
p52292
sg35217
I2
sasg35208
(lp52293
(dp52294
g35211
I307
sg35212
Vleg ulcers
p52295
sg35214
I10
sg35215
VC0023223
p52296
sg35217
I2
sa(dp52297
g35211
I329
sg35212
Vchronic kidney disease
p52298
sg35214
I22
sg35215
VC1561643
p52299
sg35217
I3
sa(dp52300
g35211
I163
sg35212
Vproliferative
p52301
sg35214
I13
sg35215
VC0334094
p52302
sg35217
I1
sa(dp52303
g35211
I283
sg35212
Vpulmonary hypertension
p52304
sg35214
I22
sg35215
VC0020542
p52305
sg35217
I2
sa(dp52306
g35211
I370
sg35212
Vischemic stroke
p52307
sg35214
I15
sg35215
VC3272363
p52308
sg35217
I2
sa(dp52309
g35211
I117
sg35212
Vhemolysis
p52310
sg35214
I9
sg35215
VC0019054
p52311
sg35217
I1
sa(dp52312
g35211
I319
sg35212
g52285
sg35214
I8
sg35215
VC0033117
p52313
sg35217
I1
sasa(dp52314
g35204
VWe report a patient with bilateral incyclotorsion, asymmetric facial palsy, monocular depression deficiency, and unilateral Type 3 Duane syndrome, along with contralateral anotia and a midline cleft palate.
p52315
sg35206
(lp52316
sg35208
(lp52317
(dp52318
g35211
I172
sg35212
Vanotia
p52319
sg35214
I6
sg35215
VC0702139
p52320
sg35217
I1
sa(dp52321
g35211
I86
sg35212
Vdepression
p52322
sg35214
I10
sg35215
VC0011581
p52323
sg35217
I1
sa(dp52324
g35211
I193
sg35212
Vcleft palate
p52325
sg35214
I12
sg35215
VC0008925
p52326
sg35217
I2
sa(dp52327
g35211
I131
sg35212
VDuane syndrome
p52328
sg35214
I14
sg35215
VC0013261
p52329
sg35217
I2
sa(dp52330
g35211
I62
sg35212
Vfacial palsy
p52331
sg35214
I12
sg35215
VC0015469
p52332
sg35217
I2
sasa(dp52333
g35204
VThe authors report a child with features of Cardiofacial syndrome with anotia and facial paralysis.
p52334
sg35206
(lp52335
sg35208
(lp52336
(dp52337
g35211
I82
sg35212
Vfacial paralysis
p52338
sg35214
I16
sg35215
VC0015469
p52339
sg35217
I2
sa(dp52340
g35211
I44
sg35212
VCardiofacial syndrome
p52341
sg35214
I21
sg35215
VC0431406
p52342
sg35217
I2
sa(dp52343
g35211
I71
sg35212
Vanotia
p52344
sg35214
I6
sg35215
VC0702139
p52345
sg35217
I1
sasa(dp52346
g35204
VThirty-three cases had microtia or anotia, and all instances of facial palsy were associated with auricular malformation.
p52347
sg35206
(lp52348
sg35208
(lp52349
(dp52350
g35211
I64
sg35212
Vfacial palsy
p52351
sg35214
I12
sg35215
VC0015469
p52352
sg35217
I2
sa(dp52353
g35211
I23
sg35212
Vmicrotia
p52354
sg35214
I8
sg35215
VC0152423
p52355
sg35217
I1
sa(dp52356
g35211
I108
sg35212
Vmalformation
p52357
sg35214
I12
sg35215
VC0000768
p52358
sg35217
I1
sa(dp52359
g35211
I35
sg35212
Vanotia
p52360
sg35214
I6
sg35215
VC0702139
p52361
sg35217
I1
sasa(dp52362
g35204
VA girl was born with anotia, facial palsy and cardiac malformations.
p52363
sg35206
(lp52364
sg35208
(lp52365
(dp52366
g35211
I21
sg35212
Vanotia
p52367
sg35214
I6
sg35215
VC0702139
p52368
sg35217
I1
sa(dp52369
g35211
I29
sg35212
Vfacial palsy
p52370
sg35214
I12
sg35215
VC0015469
p52371
sg35217
I2
sa(dp52372
g35211
I54
sg35212
Vmalformations
p52373
sg35214
I13
sg35215
VC0000768
p52374
sg35217
I1
sasa(dp52375
g35204
VFreshly isolated LSECs, Kupffer cells (KCs), and stabilin-1- and stabilin-2-transfected human embryonic kidney cells were incubated with fluorescently labeled or radiolabeled oxLDLs [oxidized for 3 h (oxLDL(3)), 6 h, or 24 h (oxLDL(24))] to measure endocytosis.
p52376
sg35206
(lp52377
(dp52378
g35211
I49
sg35212
Vstabilin-1- and stabilin-2
p52379
sg35214
I26
sg35223
g12
sg35217
I3
sasg35208
(lp52380
(dp52381
g35211
I39
sg35212
VKCs
p52382
sg35214
I3
sg35215
VC0022575
p52383
sg35217
I1
sa(dp52384
g35211
I24
sg35212
VKupffer cells
p52385
sg35214
I13
sg35215
VC0022575
p52386
sg35217
I2
sasa(dp52387
g135
(dp52388
(Vpleiotrophin
p52389
Vgastritis
p52390
tp52391
I00
ssg35204
VFurthermore, pleiotrophin (PTN), an endogenous ligand of Ptprz, also induced gastritis specifically in Ptprz+/+ mice when administered orally.
p52392
sg35206
(lp52393
(dp52394
g35211
I27
sg35212
VPTN
p52395
sg35214
I3
sg35223
VP21246
p52396
sg35217
I1
sa(dp52397
g35211
I13
sg35212
g52389
sg35214
I12
sg35223
VP21246
p52398
sg35217
I1
sasg35208
(lp52399
(dp52400
g35211
I77
sg35212
g52390
sg35214
I9
sg35215
VC0017152
p52401
sg35217
I1
sasa(dp52402
g135
(dp52403
(Vsurfactant protein-D
p52404
VMCTD
p52405
tp52406
I00
ssg35204
VWe aimed to determine whether serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) correlate with SSc/MCTD-associated ILD activity.
p52407
sg35206
(lp52408
(dp52409
g35211
I102
sg35212
VSP-D
p52410
sg35214
I4
sg35223
VP35247
p52411
sg35217
I1
sa(dp52412
g35211
I80
sg35212
g52404
sg35214
I20
sg35223
VP35453
p52413
sg35217
I2
sasg35208
(lp52414
(dp52415
g35211
I127
sg35212
g52405
sg35214
I4
sg35215
VC0026272
p52416
sg35217
I1
sasa(dp52417
g35204
VSerum KL-6 correlated positively with diffusing capacity of the lung for carbon monoxide (DLCO) (% predicted) and disease extent on HRCT, and the changes in serum levels of KL-6 were significantly related to the changes in forced vital capacity (FVC) in SSc/MCTD-associated ILD.
p52418
sg35206
(lp52419
(dp52420
g35211
I0
sg35212
VSerum KL-6
p52421
sg35214
I10
sg35223
g12
sg35217
I2
sasg35208
(lp52422
(dp52423
g35211
I258
sg35212
VMCTD
p52424
sg35214
I4
sg35215
VC0026272
p52425
sg35217
I1
sasa(dp52426
g35204
VOur study suggests that serum KL-6 can be a useful monitoring tool of SSc/MCTD-associated ILD activity.
p52427
sg35206
(lp52428
(dp52429
g35211
I24
sg35212
Vserum KL-6
p52430
sg35214
I10
sg35223
g12
sg35217
I2
sasg35208
(lp52431
(dp52432
g35211
I74
sg35212
VMCTD
p52433
sg35214
I4
sg35215
VC0026272
p52434
sg35217
I1
sasa(dp52435
g35204
VThe KL-6 levels did not differ significantly according to the connective tissue diseases in the diagnostic groups (systemic lupus erythematosus, Sjoegren's syndrome, rheumatoid arthritis, mixed connective tissue disease, scleroderma, polymyositis/ dermatomyositis).
p52436
sg35206
(lp52437
sg35208
(lp52438
(dp52439
g35211
I221
sg35212
Vscleroderma
p52440
sg35214
I11
sg35215
VC0011644
p52441
sg35217
I1
sa(dp52442
g35211
I234
sg35212
Vpolymyositis
p52443
sg35214
I12
sg35215
VC0085655
p52444
sg35217
I1
sa(dp52445
g35211
I166
sg35212
Vrheumatoid arthritis
p52446
sg35214
I20
sg35215
VC0003873
p52447
sg35217
I2
sa(dp52448
g35211
I145
sg35212
VSjoegren's syndrome
p52449
sg35214
I19
sg35215
VC1527336
p52450
sg35217
I2
sa(dp52451
g35211
I115
sg35212
Vsystemic lupus erythematosus
p52452
sg35214
I28
sg35215
VC0024141
p52453
sg35217
I3
sa(dp52454
g35211
I62
sg35212
Vconnective tissue diseases
p52455
sg35214
I26
sg35215
VC0009782
p52456
sg35217
I3
sa(dp52457
g35211
I188
sg35212
Vmixed connective tissue disease
p52458
sg35214
I31
sg35215
VC0026272
p52459
sg35217
I4
sa(dp52460
g35211
I248
sg35212
Vdermatomyositis
p52461
sg35214
I15
sg35215
VC0221056
p52462
sg35217
I1
sasa(dp52463
g35204
VTo quantify and compare human mucin 1 (MUC1) protein and mRNA expression in tears and conjunctival epithelial cells collected from Sjogren's syndrome (SS), non-Sjogren's keratoconjunctivitus sicca (KCS) and non-dry eyed (NDE) control subjects.
p52464
sg35206
(lp52465
(dp52466
g35211
I24
sg35212
Vhuman mucin 1
p52467
sg35214
I13
sg35223
g12
sg35217
I3
sasg35208
(lp52468
(dp52469
g35211
I131
sg35212
VSjogren's syndrome
p52470
sg35214
I18
sg35215
VC1527336
p52471
sg35217
I2
sa(dp52472
g35211
I131
sg35212
VSjogren's
p52473
sg35214
I9
sg35215
VC1527336
p52474
sg35217
I1
sa(dp52475
g35211
I198
sg35212
VKCS
p52476
sg35214
I3
sg35215
VC0022575
p52477
sg35217
I1
sa(dp52478
g35211
I170
sg35212
Vkeratoconjunctivitus sicca
p52479
sg35214
I26
sg35215
VC0022575
p52480
sg35217
I2
sa(dp52481
g35211
I151
sg35212
VSS
p52482
sg35214
I2
sg35215
VC1527336
p52483
sg35217
I1
sasa(dp52484
g35204
VWe studied 21 patients referred for idiopathic short stature, 5 with clinically suspected hypochondroplasia and 4 with achondroplasia.
p52485
sg35206
(lp52486
sg35208
(lp52487
(dp52488
g35211
I90
sg35212
Vhypochondroplasia
p52489
sg35214
I17
sg35215
VC0410529
p52490
sg35217
I1
sa(dp52491
g35211
I119
sg35212
Vachondroplasia
p52492
sg35214
I14
sg35215
VC0001080
p52493
sg35217
I1
sa(dp52494
g35211
I36
sg35212
Vidiopathic short stature
p52495
sg35214
I24
sg35215
VC1740819
p52496
sg35217
I3
sasa(dp52497
g35204
VA series of 140 patients with short stature operated on for limb lengthening (80 had achondroplasia, 20 had hypochondroplasia, 20 had Turner syndrome, 10 had idiopathic short stature due to an undemonstrated cause, 5 regarded their stature as too short, and 5 had a psychopathic personality due to dysmorphophobia that had developed because of their short stature) was reviewed.
p52498
sg35206
(lp52499
sg35208
(lp52500
(dp52501
g35211
I30
sg35212
Vshort stature
p52502
sg35214
I13
sg35215
VC0013336
p52503
sg35217
I2
sa(dp52504
g35211
I108
sg35212
Vhypochondroplasia
p52505
sg35214
I17
sg35215
VC0410529
p52506
sg35217
I1
sa(dp52507
g35211
I30
sg35212
Vshort stature
p52508
sg35214
I13
sg35215
VC0013336
p52509
sg35217
I2
sa(dp52510
g35211
I298
sg35212
Vdysmorphophobia
p52511
sg35214
I15
sg35215
VC0005887
p52512
sg35217
I1
sa(dp52513
g35211
I85
sg35212
Vachondroplasia
p52514
sg35214
I14
sg35215
VC0001080
p52515
sg35217
I1
sa(dp52516
g35211
I266
sg35212
Vpsychopathic personality
p52517
sg35214
I24
sg35215
VC0003431
p52518
sg35217
I2
sa(dp52519
g35211
I134
sg35212
VTurner syndrome
p52520
sg35214
I15
sg35215
VC0041408
p52521
sg35217
I2
sa(dp52522
g35211
I158
sg35212
Vidiopathic short stature
p52523
sg35214
I24
sg35215
VC1740819
p52524
sg35217
I3
sasa(dp52525
g35204
VIn the present study, we investigated whether the impairment of IRS-1-mediated insulin signaling contributes to neurite outgrowth and neuronal loss, both in mice fed a high-fat diet and in mouse neuroblastoma (Neuro2A) cells.
p52526
sg35206
(lp52527
(dp52528
g35211
I64
sg35212
VIRS-1
p52529
sg35214
I5
sg35223
VP35568
p52530
sg35217
I1
sa(dp52531
g35211
I79
sg35212
Vinsulin
p52532
sg35214
I7
sg35223
VP01308
p52533
sg35217
I1
sasg35208
(lp52534
(dp52535
g35211
I50
sg35212
Vimpairment
p52536
sg35214
I10
sg35215
VC0684336
p52537
sg35217
I1
sa(dp52538
g35211
I189
sg35212
Vmouse neuroblastoma
p52539
sg35214
I19
sg35215
VC1524043
p52540
sg35217
I2
sasa(dp52541
g135
(dp52542
(Vinsulin
p52543
Vneuroblastoma
p52544
tp52545
I00
ssg35204
VTo investigate the changes caused by the inhibition of IRS-1-mediated insulin signaling in neuroblastoma cells, we performed Western blot analysis, reverse transcription-PCR, and immunochemical analysis.
p52546
sg35206
(lp52547
(dp52548
g35211
I55
sg35212
VIRS-1
p52549
sg35214
I5
sg35223
VP35568
p52550
sg35217
I1
sa(dp52551
g35211
I70
sg35212
g52543
sg35214
I7
sg35223
VP01308
p52552
sg35217
I1
sasg35208
(lp52553
(dp52554
g35211
I91
sg35212
g52544
sg35214
I13
sg35215
VC0027819
p52555
sg35217
I1
sasa(dp52556
g135
(dp52557
(Vtarget IRS-1
p52558
Vuveal melanoma
p52559
tp52560
I00
ssg35204
VmiR-145 might act as a tumor suppressor in uveal melanoma, and downregulation of the target IRS-1 might be a potential mechanism.
p52561
sg35206
(lp52562
(dp52563
g35211
I0
sg35212
VmiR-145
p52564
sg35214
I7
sg35223
g12
sg35217
I1
sa(dp52565
g35211
I85
sg35212
g52558
sg35214
I12
sg35223
VP35568
p52566
sg35217
I2
sasg35208
(lp52567
(dp52568
g35211
I23
sg35212
Vtumor
p52569
sg35214
I5
sg35215
VC0027651
p52570
sg35217
I1
sa(dp52571
g35211
I43
sg35212
g52559
sg35214
I14
sg35215
VC0220633
p52572
sg35217
I2
sasa(dp52573
g135
(dp52574
(VJCV T-antigen
p52575
Vmedulloblastoma
p52576
tp52577
I00
ssg35204
VAlmost a decade ago, we reported the presence of nuclear IRS-1 in medulloblastoma clinical samples, which express viral oncoprotein, large T-antigen of human polyomavirus JC (JCV T-antigen).
p52578
sg35206
(lp52579
(dp52580
g35211
I133
sg35212
Vlarge T-antigen
p52581
sg35214
I15
sg35223
VP14209
p52582
sg35217
I2
sa(dp52583
g35211
I175
sg35212
g52575
sg35214
I13
sg35223
VP14209
p52584
sg35217
I2
sasg35208
(lp52585
(dp52586
g35211
I66
sg35212
g52576
sg35214
I15
sg35215
VC0025149
p52587
sg35217
I1
sasa(dp52588
g135
(dp52589
(VERBeta
p52590
Vmedulloblastoma
p52591
tp52592
I00
ssg35204
VMore recently, nuclear IRS-1 was detected in breast cancer cells in association with estrogen receptor alpha (ERAlfa), and in JC virus negative medulloblastoma cells expressing estrogen receptor beta (ERBeta), further implicating nuclear IRS-1 in cellular transformation.
p52593
sg35206
(lp52594
(dp52595
g35211
I85
sg35212
Vestrogen receptor alpha
p52596
sg35214
I23
sg35223
VP03372
p52597
sg35217
I3
sa(dp52598
g35211
I177
sg35212
Vestrogen receptor beta
p52599
sg35214
I22
sg35223
VP03372
p52600
sg35217
I3
sa(dp52601
g35211
I15
sg35212
Vnuclear IRS-1
p52602
sg35214
I13
sg35223
VP35568
p52603
sg35217
I2
sa(dp52604
g35211
I201
sg35212
g52590
sg35214
I6
sg35223
VP03372
p52605
sg35217
I1
sasg35208
(lp52606
(dp52607
g35211
I247
sg35212
Vcellular transformation
p52608
sg35214
I23
sg35215
VC1510411
p52609
sg35217
I2
sa(dp52610
g35211
I45
sg35212
Vbreast cancer
p52611
sg35214
I13
sg35215
VC0678222
p52612
sg35217
I2
sa(dp52613
g35211
I144
sg35212
g52591
sg35214
I15
sg35215
VC0025149
p52614
sg35217
I1
sasa(dp52615
g135
(dp52616
(VIRS-1
p52617
Vmedulloblastomas
p52618
tp52619
I00
ssg35204
VWe have previously reported that ERBeta, which is highly expressed in medulloblastomas, translocates insulin receptor substrate 1 (IRS-1) to the nucleus, and that nuclear IRS-1 binds to Rad51 and attenuates homologous recombination directed DNA repair (HRR).
p52620
sg35206
(lp52621
(dp52622
g35211
I186
sg35212
VRad51
p52623
sg35214
I5
sg35223
g12
sg35217
I1
sa(dp52624
g35211
I101
sg35212
Vinsulin receptor substrate 1
p52625
sg35214
I28
sg35223
VP35568
p52626
sg35217
I4
sa(dp52627
g35211
I163
sg35212
Vnuclear IRS-1
p52628
sg35214
I13
sg35223
VP35568
p52629
sg35217
I2
sa(dp52630
g35211
I131
sg35212
g52617
sg35214
I5
sg35223
VP35568
p52631
sg35217
I1
sasg35208
(lp52632
(dp52633
g35211
I70
sg35212
g52618
sg35214
I16
sg35215
VC0025149
p52634
sg35217
I1
sasa(dp52635
S'line'
p52636
VJacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving terminal chromosome 11q.
p52637
sS'genes'
p52638
(lp52639
sS'diseases'
p52640
(lp52641
(dp52642
S'index'
p52643
I0
sS'name'
p52644
VJacobsen syndrome
p52645
sS'lengthInChars'
p52646
I17
sS'cui'
p52647
VC0795841
p52648
sS'lengthInWords'
p52649
I2
sa(dp52650
g52643
I40
sg52644
Vgene deletion
p52651
sg52646
I13
sg52647
VC1442161
p52652
sg52649
I2
sa(dp52653
g52643
I9
sg52644
Vsyndrome
p52654
sg52646
I8
sg52647
VC0039082
p52655
sg52649
I1
sa(dp52656
g52643
I19
sg52644
VJBS
p52657
sg52646
I3
sg52647
VC0795841
p52658
sg52649
I1
sasa(dp52659
g52636
VWe investigated a boy with features of JBS using classic cytogenetic methods, FISH and high-resolution array CGH.
p52660
sg52638
(lp52661
sg52640
(lp52662
(dp52663
g52643
I109
sg52644
VCGH
p52664
sg52646
I3
sg52647
VC1855900
p52665
sg52649
I1
sa(dp52666
g52643
I39
sg52644
VJBS
p52667
sg52646
I3
sg52647
VC0795841
p52668
sg52649
I1
sasa(dp52669
g52636
VThe patient had a hemizygous deletion in the FLI1 gene region without apparent thrombocytopenia, and he developed diabetes mellitus type I, which has not previously been described in the spectrum of disorders associated with JBS.
p52670
sg52638
(lp52671
(dp52672
g52643
I45
sg52644
VFLI1 gene
p52673
sg52646
I9
sS'uniprot'
p52674
g12
sg52649
I2
sasg52640
(lp52675
(dp52676
g52643
I225
sg52644
VJBS
p52677
sg52646
I3
sg52647
VC0795841
p52678
sg52649
I1
sa(dp52679
g52643
I114
sg52644
Vdiabetes mellitus type I
p52680
sg52646
I24
sg52647
VC0011854
p52681
sg52649
I4
sasa(dp52682
g52636
VThe relationship of some of the genes within the context of the phenotype caused by a partial deletion of 11q has provided insights concerning the developmental anomalies presented in this patient with atypical features of JBS.
p52683
sg52638
(lp52684
sg52640
(lp52685
(dp52686
g52643
I223
sg52644
VJBS
p52687
sg52646
I3
sg52647
VC0795841
p52688
sg52649
I1
sasa(dp52689
g52636
VAll local patients were clustered "high-risk" for future CV events based on the Framingham score (mean 21.8%, 95% CI 20.0-23.6), JBS-2 (16.3%, 14.7-17.9) and ASSIGN (25.2%, 22.7-27.7).
p52690
sg52638
(lp52691
(dp52692
g52643
I129
sg52644
VJBS-2
p52693
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp52694
(dp52695
g52643
I129
sg52644
VJBS
p52696
sg52646
I3
sg52647
VC0795841
p52697
sg52649
I1
sasa(dp52698
g52636
VLoss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.
p52699
sg52638
(lp52700
(dp52701
g52643
I34
sg52644
VUBR1 gene
p52702
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp52703
(dp52704
g52643
I50
sg52644
VJohanson-Blizzard syndrome
p52705
sg52646
I26
sg52647
VC0175692
p52706
sg52649
I2
sasa(dp52707
g52636
VNo previous studies have examined an association of UBR1 variants with pancreatitis, in part due to the large size of the gene.
p52708
sg52638
(lp52709
(dp52710
g52643
I52
sg52644
VUBR1 variants
p52711
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp52712
(dp52713
g52643
I71
sg52644
Vpancreatitis
p52714
sg52646
I12
sg52647
VC0030305
p52715
sg52649
I1
sasa(dp52716
g52636
VThis study aimed to clarify whether UBR1 variants are associated with chronic pancreatitis (CP) by the application of targeted next generation sequencing.
p52717
sg52638
(lp52718
(dp52719
g52643
I36
sg52644
VUBR1 variants
p52720
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp52721
(dp52722
g52643
I70
sg52644
Vchronic pancreatitis
p52723
sg52646
I20
sg52647
VC0149521
p52724
sg52649
I2
sa(dp52725
g52643
I92
sg52644
VCP
p52726
sg52646
I2
sg52647
VC0149521
p52727
sg52649
I1
sasa(dp52728
g52636
VJacobsen syndrome (JBS) is a contiguous gene deletion syndrome involving 11q terminal deletion.
p52729
sg52638
(lp52730
sg52640
(lp52731
(dp52732
g52643
I0
sg52644
VJacobsen syndrome
p52733
sg52646
I17
sg52647
VC0795841
p52734
sg52649
I2
sa(dp52735
g52643
I40
sg52644
Vgene deletion
p52736
sg52646
I13
sg52647
VC1442161
p52737
sg52649
I2
sa(dp52738
g52643
I9
sg52644
Vsyndrome
p52739
sg52646
I8
sg52647
VC0039082
p52740
sg52649
I1
sa(dp52741
g52643
I19
sg52644
VJBS
p52742
sg52646
I3
sg52647
VC0795841
p52743
sg52649
I1
sasa(dp52744
g52636
VInterstitial deletions at distal 11q are rare and their contributions to the clinical phenotype of JBS are unknown.
p52745
sg52638
(lp52746
sg52640
(lp52747
(dp52748
g52643
I99
sg52644
VJBS
p52749
sg52646
I3
sg52647
VC0795841
p52750
sg52649
I1
sasa(dp52751
g52636
VOur finds support the notion that more than one critical region at 11q23.3-qter are responsible for the variable clinical presentation of JBS, thus JBS is a true contiguous gene deletion syndrome where multiple loci contributed to the clinical characteristics of JBS.
p52752
sg52638
(lp52753
(dp52754
g52643
I138
sg52644
VJBS
p52755
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp52756
(dp52757
g52643
I138
sg52644
VJBS
p52758
sg52646
I3
sg52647
VC0795841
p52759
sg52649
I1
sa(dp52760
g52643
I138
sg52644
VJBS
p52761
sg52646
I3
sg52647
VC0795841
p52762
sg52649
I1
sa(dp52763
g52643
I138
sg52644
VJBS
p52764
sg52646
I3
sg52647
VC0795841
p52765
sg52649
I1
sa(dp52766
g52643
I187
sg52644
Vsyndrome
p52767
sg52646
I8
sg52647
VC0039082
p52768
sg52649
I1
sa(dp52769
g52643
I173
sg52644
Vgene deletion
p52770
sg52646
I13
sg52647
VC1442161
p52771
sg52649
I2
sasa(dp52772
g52636
VJacobsen syndrome (JBS) is an uncommon contiguous gene syndrome.
p52773
sg52638
(lp52774
sg52640
(lp52775
(dp52776
g52643
I0
sg52644
VJacobsen syndrome
p52777
sg52646
I17
sg52647
VC0795841
p52778
sg52649
I2
sa(dp52779
g52643
I9
sg52644
Vsyndrome
p52780
sg52646
I8
sg52647
VC0039082
p52781
sg52649
I1
sa(dp52782
g52643
I19
sg52644
VJBS
p52783
sg52646
I3
sg52647
VC0795841
p52784
sg52649
I1
sasa(dp52785
g52636
VThe typical clinical features in JBS include intellectual disability, growth retardation, craniofacial dysmorphism as well as craniosynostosis, congenital heart disease, and platelet abnormalities.
p52786
sg52638
(lp52787
sg52640
(lp52788
(dp52789
g52643
I126
sg52644
Vcraniosynostosis
p52790
sg52646
I16
sg52647
VC0010278
p52791
sg52649
I1
sa(dp52792
g52643
I144
sg52644
Vcongenital heart disease
p52793
sg52646
I24
sg52647
VC0152021
p52794
sg52649
I3
sa(dp52795
g52643
I45
sg52644
Vintellectual disability
p52796
sg52646
I23
sg52647
VC0025362
p52797
sg52649
I2
sa(dp52798
g52643
I33
sg52644
VJBS
p52799
sg52646
I3
sg52647
VC0795841
p52800
sg52649
I1
sa(dp52801
g52643
I70
sg52644
Vgrowth retardation
p52802
sg52646
I18
sg52647
VC0151686
p52803
sg52649
I2
sa(dp52804
g52643
I103
sg52644
Vdysmorphism
p52805
sg52646
I11
sg52647
VC1737329
p52806
sg52649
I1
sasa(dp52807
g52636
VWe report a novel deletion in JBS that increases the knowledge of the variability in the mutation sites in this region and expands the spectrum of molecular and clinical defects in this syndrome.
p52808
sg52638
(lp52809
sg52640
(lp52810
(dp52811
g52643
I186
sg52644
Vsyndrome
p52812
sg52646
I8
sg52647
VC0039082
p52813
sg52649
I1
sa(dp52814
g52643
I30
sg52644
VJBS
p52815
sg52646
I3
sg52647
VC0795841
p52816
sg52649
I1
sasa(dp52817
g52636
VJohanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.
p52818
sg52638
(lp52819
sg52640
(lp52820
(dp52821
g52643
I336
sg52644
Vmalformations
p52822
sg52646
I13
sg52647
VC0000768
p52823
sg52649
I1
sa(dp52824
g52643
I0
sg52644
VJohanson-Blizzard syndrome
p52825
sg52646
I26
sg52647
VC0175692
p52826
sg52649
I2
sa(dp52827
g52643
I300
sg52644
Vhypothyroidism
p52828
sg52646
I14
sg52647
VC0020676
p52829
sg52649
I1
sa(dp52830
g52643
I28
sg52644
VJBS
p52831
sg52646
I3
sg52647
VC0175692
p52832
sg52649
I1
sa(dp52833
g52643
I174
sg52644
Vexocrine pancreatic insufficiency
p52834
sg52646
I33
sg52647
VC0267963
p52835
sg52649
I3
sasa(dp52836
g52636
VThere are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).
p52837
sg52638
(lp52838
sg52640
(lp52839
(dp52840
g52643
I199
sg52644
VOFCs
p52841
sg52646
I4
sg52647
VC1838348
p52842
sg52649
I1
sa(dp52843
g52643
I176
sg52644
Voblique facial clefts
p52844
sg52646
I21
sg52647
VC1838348
p52845
sg52649
I3
sa(dp52846
g52643
I39
sg52644
VJBS
p52847
sg52646
I3
sg52647
VC0795841
p52848
sg52649
I1
sasa(dp52849
g52636
VWe describe the clinical aspects in four patients with JBS and extensive OFCs.
p52850
sg52638
(lp52851
sg52640
(lp52852
(dp52853
g52643
I55
sg52644
VJBS
p52854
sg52646
I3
sg52647
VC0795841
p52855
sg52649
I1
sasa(dp52856
g52636
VIn all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.
p52857
sg52638
(lp52858
(dp52859
g52643
I128
sg52644
VUBR1 gene
p52860
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp52861
(dp52862
g52643
I33
sg52644
VJBS
p52863
sg52646
I3
sg52647
VC0795841
p52864
sg52649
I1
sasa(dp52865
g52636
VAdditionally, we review three previously reported cases of JBS with OFCs.
p52866
sg52638
(lp52867
sg52640
(lp52868
(dp52869
g52643
I59
sg52644
VJBS
p52870
sg52646
I3
sg52647
VC0795841
p52871
sg52649
I1
sasa(dp52872
g52636
VTaking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.
p52873
sg52638
(lp52874
sg52640
(lp52875
(dp52876
g52643
I74
sg52644
VJBS
p52877
sg52646
I3
sg52647
VC0795841
p52878
sg52649
I1
sa(dp52879
g52643
I74
sg52644
VJBS
p52880
sg52646
I3
sg52647
VC0795841
p52881
sg52649
I1
sasa(dp52882
g52636
VThis report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.
p52883
sg52638
(lp52884
sg52640
(lp52885
(dp52886
g52643
I84
sg52644
Vfacial malformations
p52887
sg52646
I20
sg52647
VC0266617
p52888
sg52649
I2
sa(dp52889
g52643
I118
sg52644
VJBS
p52890
sg52646
I3
sg52647
VC0795841
p52891
sg52649
I1
sasa(dp52892
g52636
VJacobsen syndrome (JBS) is a rare congenital disorder caused by a terminal deletion of the long arm of chromosome 11.
p52893
sg52638
(lp52894
sg52640
(lp52895
(dp52896
g52643
I0
sg52644
VJacobsen syndrome
p52897
sg52646
I17
sg52647
VC0795841
p52898
sg52649
I2
sa(dp52899
g52643
I34
sg52644
Vcongenital disorder
p52900
sg52646
I19
sg52647
VC0242354
p52901
sg52649
I2
sa(dp52902
g52643
I19
sg52644
VJBS
p52903
sg52646
I3
sg52647
VC0795841
p52904
sg52649
I1
sasa(dp52905
g52636
VPX-RICS is located in the chromosomal region commonly deleted in JBS patients with autistic-like behaviour.
p52906
sg52638
(lp52907
(dp52908
g52643
I0
sg52644
VPX-RICS
p52909
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp52910
(dp52911
g52643
I65
sg52644
VJBS
p52912
sg52646
I3
sg52647
VC0795841
p52913
sg52649
I1
sa(dp52914
g52643
I83
sg52644
Vautistic
p52915
sg52646
I8
sg52647
VC0004352
p52916
sg52649
I1
sasa(dp52917
g52636
VOur findings demonstrate a critical role of PX-RICS in cognition and suggest a causal link between PX-RICS deletion and ASD-like behaviour in JBS patients.
p52918
sg52638
(lp52919
(dp52920
g52643
I44
sg52644
VPX-RICS
p52921
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp52922
(dp52923
g52643
I142
sg52644
VJBS
p52924
sg52646
I3
sg52647
VC0795841
p52925
sg52649
I1
sa(dp52926
g52643
I120
sg52644
VASD
p52927
sg52646
I3
sg52647
VC1510586
p52928
sg52649
I1
sasa(dp52929
g52636
VJohanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.
p52930
sg52638
(lp52931
sg52640
(lp52932
(dp52933
g52643
I0
sg52644
VJohanson-Blizzard Syndrome
p52934
sg52646
I26
sg52647
VC0175692
p52935
sg52649
I2
sa(dp52936
g52643
I77
sg52644
Vgenetic disorder
p52937
sg52646
I16
sg52647
VC0019247
p52938
sg52649
I2
sa(dp52939
g52643
I28
sg52644
VJBS
p52940
sg52646
I3
sg52647
VC0175692
p52941
sg52649
I1
sa(dp52942
g52643
I196
sg52644
Vmental retardation
p52943
sg52646
I18
sg52647
VC0025362
p52944
sg52649
I2
sa(dp52945
g52643
I111
sg52644
Vexocrine pancreatic insufficiency
p52946
sg52646
I33
sg52647
VC0267963
p52947
sg52649
I3
sasa(dp52948
g52636
VHere, we report a 3 year-old mentally normal JBS girl.
p52949
sg52638
(lp52950
sg52640
(lp52951
(dp52952
g52643
I45
sg52644
VJBS
p52953
sg52646
I3
sg52647
VC0795841
p52954
sg52649
I1
sasa(dp52955
g52636
VWith these findings, JBS diagnosis was established clinically.
p52956
sg52638
(lp52957
sg52640
(lp52958
(dp52959
g52643
I21
sg52644
VJBS
p52960
sg52646
I3
sg52647
VC0795841
p52961
sg52649
I1
sasa(dp52962
g52636
VJoubert syndrome (JBS) is a rare neurodevelopmental disorder belonging to the group of ciliary diseases.
p52963
sg52638
(lp52964
sg52640
(lp52965
(dp52966
g52643
I18
sg52644
VJBS
p52967
sg52646
I3
sg52647
VC0795841
p52968
sg52649
I1
sa(dp52969
g52643
I0
sg52644
VJoubert syndrome
p52970
sg52646
I16
sg52647
VC0431399
p52971
sg52649
I2
sa(dp52972
g52643
I33
sg52644
Vneurodevelopmental disorder
p52973
sg52646
I27
sg52647
VC1535926
p52974
sg52649
I2
sasa(dp52975
g52636
VJBS is genetically heterogeneous, with &gt;20 causative genes identified to date.
p52976
sg52638
(lp52977
sg52640
(lp52978
(dp52979
g52643
I0
sg52644
VJBS
p52980
sg52646
I3
sg52647
VC0795841
p52981
sg52649
I1
sasa(dp52982
g52636
VA molecular diagnosis of JBS is essential for prediction of disease progression and genetic counseling.
p52983
sg52638
(lp52984
sg52640
(lp52985
(dp52986
g52643
I25
sg52644
VJBS
p52987
sg52646
I3
sg52647
VC0795841
p52988
sg52649
I1
sa(dp52989
g52643
I60
sg52644
Vdisease progression
p52990
sg52646
I19
sg52647
VC0242656
p52991
sg52649
I2
sasa(dp52992
g52636
VWe developed a targeted next-generation sequencing (NGS) approach for parallel sequencing of 22 known JBS genes plus 599 additional ciliary genes.
p52993
sg52638
(lp52994
sg52640
(lp52995
(dp52996
g52643
I102
sg52644
VJBS
p52997
sg52646
I3
sg52647
VC0795841
p52998
sg52649
I1
sasa(dp52999
g52636
VThis method was used to genotype a cohort of 51 well-phenotyped Northern European JBS cases (in some of the cases, Sanger sequencing of individual JBS genes had been performed previously).
p53000
sg52638
(lp53001
sg52640
(lp53002
(dp53003
g52643
I82
sg52644
VJBS
p53004
sg52646
I3
sg52647
VC0795841
p53005
sg52649
I1
sa(dp53006
g52643
I82
sg52644
VJBS
p53007
sg52646
I3
sg52647
VC0795841
p53008
sg52649
I1
sasa(dp53009
g52636
VAltogether, 21 of the 51 cases (41%) harbored biallelic pathogenic mutations in known JBS genes, including 14 mutations not previously described.
p53010
sg52638
(lp53011
sg52640
(lp53012
(dp53013
g52643
I86
sg52644
VJBS
p53014
sg52646
I3
sg52647
VC0795841
p53015
sg52649
I1
sasa(dp53016
g52636
VOur study represents a population-based cohort of JBS patients not enriched for consanguinity, providing insight into the relative importance of the different JBS genes in a Northern European population.
p53017
sg52638
(lp53018
(dp53019
g52643
I159
sg52644
VJBS genes
p53020
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp53021
(dp53022
g52643
I50
sg52644
VJBS
p53023
sg52646
I3
sg52647
VC0795841
p53024
sg52649
I1
sa(dp53025
g52643
I50
sg52644
VJBS
p53026
sg52646
I3
sg52647
VC0795841
p53027
sg52649
I1
sasa(dp53028
g52636
VFurthermore, we report a case with heterozygous mutations in CC2D2A and B9D1, a gene associated with the more severe Meckel-Gruber syndrome that was recently published as a potential new JBS gene, and discuss the significance of this finding.
p53029
sg52638
(lp53030
(dp53031
g52643
I187
sg52644
VJBS gene
p53032
sg52646
I8
sg52674
g12
sg52649
I2
sa(dp53033
g52643
I72
sg52644
VB9D1
p53034
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp53035
g52643
I61
sg52644
VCC2D2A
p53036
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp53037
(dp53038
g52643
I187
sg52644
VJBS
p53039
sg52646
I3
sg52647
VC0795841
p53040
sg52649
I1
sa(dp53041
g52643
I117
sg52644
VMeckel-Gruber syndrome
p53042
sg52646
I22
sg52647
VC0265215
p53043
sg52649
I2
sasa(dp53044
g135
(dp53045
(VCXCL10
p53046
Vnasopharyngeal carcinoma
p53047
tp53048
I00
ssg52636
VZIC2 and OVOL1 may function in nasopharyngeal carcinoma through targeting significantly up-regulated genes (such as PTGS2, FN1, CXCL9 and CXCL10) in the Transcription factor-differentially expressed gene regulatory network (e.g., ZIC2-&gt;PTGS2 and OVOL1-&gt;CXCL10).
p53049
sg52638
(lp53050
(dp53051
g52643
I116
sg52644
VPTGS2
p53052
sg52646
I5
sg52674
VP35354
p53053
sg52649
I1
sa(dp53054
g52643
I128
sg52644
VCXCL9
p53055
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp53056
g52643
I116
sg52644
VPTGS2
p53057
sg52646
I5
sg52674
VP35354
p53058
sg52649
I1
sa(dp53059
g52643
I0
sg52644
VZIC2
p53060
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp53061
g52643
I9
sg52644
VOVOL1
p53062
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp53063
g52643
I0
sg52644
VZIC2
p53064
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp53065
g52643
I-1
sg52644
VOVOL1->CXCL10
p53066
sg52646
I13
sg52674
g12
sg52649
I1
sa(dp53067
g52643
I138
sg52644
g53046
sg52646
I6
sg52674
VP02778
p53068
sg52649
I1
sasg52640
(lp53069
(dp53070
g52643
I31
sg52644
g53047
sg52646
I24
sg52647
VC2931822
p53071
sg52649
I2
sasa(dp53072
g135
(dp53073
(VPTGS2
p53074
Vnasopharyngeal carcinoma
p53075
tp53076
I00
ssg52636
VPTGS2, FN1, CXCL9, CXCL10, ZIC2 and OVOL1 might play roles in nasopharyngeal carcinoma.
p53077
sg52638
(lp53078
(dp53079
g52643
I12
sg52644
VCXCL9
p53080
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp53081
g52643
I36
sg52644
VOVOL1
p53082
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp53083
g52643
I27
sg52644
VZIC2
p53084
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp53085
g52643
I19
sg52644
VCXCL10
p53086
sg52646
I6
sg52674
VP02778
p53087
sg52649
I1
sa(dp53088
g52643
I0
sg52644
g53074
sg52646
I5
sg52674
VP35354
p53089
sg52649
I1
sasg52640
(lp53090
(dp53091
g52643
I48
sg52644
Vplay roles
p53092
sg52646
I10
sg52647
VC0699820
p53093
sg52649
I2
sa(dp53094
g52643
I62
sg52644
g53075
sg52646
I24
sg52647
VC2931822
p53095
sg52649
I2
sasa(dp53096
g135
(dp53097
(Vhyperprolactinemia
p53098
Vsystemic lupus erythematosus
p53099
tp53100
I00
ssg52636
VLiterature data indicate that hyperprolactinemia (HPRL) is one of the important factors in the pathogenesis and course of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjogren's syndrome.
p53101
sg52638
(lp53102
(dp53103
g52643
I50
sg52644
VHPRL
p53104
sg52646
I4
sg52674
VP01236
p53105
sg52649
I1
sa(dp53106
g52643
I30
sg52644
g53098
sg52646
I18
sg52674
VP01236
p53107
sg52649
I1
sasg52640
(lp53108
(dp53109
g52643
I225
sg52644
VSjogren's syndrome
p53110
sg52646
I18
sg52647
VC1527336
p53111
sg52649
I2
sa(dp53112
g52643
I180
sg52644
Vrheumatoid arthritis
p53113
sg52646
I20
sg52647
VC0003873
p53114
sg52649
I2
sa(dp53115
g52643
I202
sg52644
Vsystemic sclerosis
p53116
sg52646
I18
sg52647
VC0036421
p53117
sg52649
I2
sa(dp53118
g52643
I30
sg52644
Vhyperprolactinemia
p53119
sg52646
I18
sg52647
VC0020514
p53120
sg52649
I1
sa(dp53121
g52643
I122
sg52644
Vautoimmune diseases
p53122
sg52646
I19
sg52647
VC0004364
p53123
sg52649
I2
sa(dp53124
g52643
I50
sg52644
VHPRL
p53125
sg52646
I4
sg52647
VC0020514
p53126
sg52649
I1
sa(dp53127
g52643
I95
sg52644
Vpathogenesis
p53128
sg52646
I12
sg52647
VC0699748
p53129
sg52649
I1
sa(dp53130
g52643
I150
sg52644
g53099
sg52646
I28
sg52647
VC0024141
p53131
sg52649
I3
sasa(dp53132
g135
(dp53133
(VHPRL
p53134
VHashimoto's thyroiditis
p53135
tp53136
I00
ssg52636
VFurthermore in the last 2 decades multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT), multiple sclerosis (MS), psoriasis, hepatitis C patients, Behcet's disease, peripartum cardiomyopathy (PPCM) and active celiac disease were discussed to be associated with HPRL.
p53137
sg52638
(lp53138
(dp53139
g52643
I380
sg52644
g53134
sg52646
I4
sg52674
VP01236
p53140
sg52649
I1
sasg52640
(lp53141
(dp53142
g52643
I148
sg52644
VRA
p53143
sg52646
I2
sg52647
VC0003873
p53144
sg52649
I1
sa(dp53145
g52643
I120
sg52644
VSLE
p53146
sg52646
I3
sg52647
VC0024141
p53147
sg52649
I1
sa(dp53148
g52643
I173
sg52644
VSS
p53149
sg52646
I2
sg52647
VC1527336
p53150
sg52649
I1
sa(dp53151
g52643
I244
sg52644
Vhepatitis C
p53152
sg52646
I11
sg52647
VC0019196
p53153
sg52649
I2
sa(dp53154
g52643
I90
sg52644
Vsystemic lupus erythematosus
p53155
sg52646
I28
sg52647
VC0024141
p53156
sg52649
I3
sa(dp53157
g52643
I233
sg52644
Vpsoriasis
p53158
sg52646
I9
sg52647
VC0033860
p53159
sg52649
I1
sa(dp53160
g52643
I208
sg52644
Vmultiple sclerosis
p53161
sg52646
I18
sg52647
VC0026769
p53162
sg52649
I2
sa(dp53163
g52643
I153
sg52644
VSjogren's syndrome
p53164
sg52646
I18
sg52647
VC1527336
p53165
sg52649
I2
sa(dp53166
g52643
I284
sg52644
Vperipartum cardiomyopathy
p53167
sg52646
I25
sg52647
VC0877208
p53168
sg52649
I2
sa(dp53169
g52643
I203
sg52644
VHT
p53170
sg52646
I2
sg52647
VC0920350
p53171
sg52649
I1
sa(dp53172
g52643
I65
sg52644
Vautoimmune diseases
p53173
sg52646
I19
sg52647
VC0004364
p53174
sg52649
I2
sa(dp53175
g52643
I266
sg52644
VBehcet's disease
p53176
sg52646
I16
sg52647
VC0004943
p53177
sg52649
I2
sa(dp53178
g52643
I228
sg52644
VMS
p53179
sg52646
I2
sg52647
VC0026769
p53180
sg52649
I1
sa(dp53181
g52643
I126
sg52644
Vrheumatoid arthritis
p53182
sg52646
I20
sg52647
VC0003873
p53183
sg52649
I2
sa(dp53184
g52643
I328
sg52644
Vceliac disease
p53185
sg52646
I14
sg52647
VC0007570
p53186
sg52649
I2
sa(dp53187
g52643
I311
sg52644
VPPCM
p53188
sg52646
I4
sg52647
VC0877208
p53189
sg52649
I1
sa(dp53190
g52643
I178
sg52644
g53135
sg52646
I23
sg52647
VC0920350
p53191
sg52649
I2
sasa(dp53192
g135
(dp53193
(VHyperprolactinemia
p53194
VHT
p53195
tp53196
I00
ssg52636
VHyperprolactinemia (HPRL) is observed in multi-organ and organ specific autoimmune diseases like systemic lupus erythematosus (SLE) rheumatoid arthritis (RA), Sjogren's syndrome (SS), Hashimoto's thyroiditis (HT) and multiple sclerosis (MS).
p53197
sg52638
(lp53198
(dp53199
g52643
I20
sg52644
VHPRL
p53200
sg52646
I4
sg52674
VP01236
p53201
sg52649
I1
sa(dp53202
g52643
I0
sg52644
g53194
sg52646
I18
sg52674
VP01236
p53203
sg52649
I1
sasg52640
(lp53204
(dp53205
g52643
I97
sg52644
Vsystemic lupus erythematosus
p53206
sg52646
I28
sg52647
VC0024141
p53207
sg52649
I3
sa(dp53208
g52643
I154
sg52644
VRA
p53209
sg52646
I2
sg52647
VC0003873
p53210
sg52649
I1
sa(dp53211
g52643
I127
sg52644
VSLE
p53212
sg52646
I3
sg52647
VC0024141
p53213
sg52649
I1
sa(dp53214
g52643
I159
sg52644
VSjogren's syndrome
p53215
sg52646
I18
sg52647
VC1527336
p53216
sg52649
I2
sa(dp53217
g52643
I179
sg52644
VSS
p53218
sg52646
I2
sg52647
VC1527336
p53219
sg52649
I1
sa(dp53220
g52643
I217
sg52644
Vmultiple sclerosis
p53221
sg52646
I18
sg52647
VC0026769
p53222
sg52649
I2
sa(dp53223
g52643
I132
sg52644
Vrheumatoid arthritis
p53224
sg52646
I20
sg52647
VC0003873
p53225
sg52649
I2
sa(dp53226
g52643
I20
sg52644
VHPRL
p53227
sg52646
I4
sg52647
VC0020514
p53228
sg52649
I1
sa(dp53229
g52643
I72
sg52644
Vautoimmune diseases
p53230
sg52646
I19
sg52647
VC0004364
p53231
sg52649
I2
sa(dp53232
g52643
I237
sg52644
VMS
p53233
sg52646
I2
sg52647
VC0026769
p53234
sg52649
I1
sa(dp53235
g52643
I0
sg52644
VHyperprolactinemia
p53236
sg52646
I18
sg52647
VC0020514
p53237
sg52649
I1
sa(dp53238
g52643
I184
sg52644
VHashimoto's thyroiditis
p53239
sg52646
I23
sg52647
VC0920350
p53240
sg52649
I2
sa(dp53241
g52643
I209
sg52644
g53195
sg52646
I2
sg52647
VC0920350
p53242
sg52649
I1
sasa(dp53243
g135
(dp53244
(VPRL
p53245
Vrheumatic diseases
p53246
tp53247
I01
ssg52636
VWe describe the role of PRL in the pathogenesis of rheumatic diseases, particularly connective tissue diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), primary Sjoegren's syndrome, systemic sclerosis, polymyalgia rheumatica, and seronegative arthritis.
p53248
sg52638
(lp53249
(dp53250
g52643
I24
sg52644
g53245
sg52646
I3
sg52674
VP01236
p53251
sg52649
I1
sasg52640
(lp53252
(dp53253
g52643
I214
sg52644
Vsystemic sclerosis
p53254
sg52646
I18
sg52647
VC0036421
p53255
sg52649
I2
sa(dp53256
g52643
I158
sg52644
Vrheumatoid arthritis
p53257
sg52646
I20
sg52647
VC0003873
p53258
sg52649
I2
sa(dp53259
g52643
I35
sg52644
Vpathogenesis
p53260
sg52646
I12
sg52647
VC0699748
p53261
sg52649
I1
sa(dp53262
g52643
I193
sg52644
VSjoegren's syndrome
p53263
sg52646
I19
sg52647
VC1527336
p53264
sg52649
I2
sa(dp53265
g52643
I122
sg52644
Vsystemic lupus erythematosus
p53266
sg52646
I28
sg52647
VC0024141
p53267
sg52649
I3
sa(dp53268
g52643
I152
sg52644
VSLE
p53269
sg52646
I3
sg52647
VC0024141
p53270
sg52649
I1
sa(dp53271
g52643
I262
sg52644
Vseronegative arthritis
p53272
sg52646
I22
sg52647
VC0409679
p53273
sg52649
I2
sa(dp53274
g52643
I180
sg52644
VRA
p53275
sg52646
I2
sg52647
VC0003873
p53276
sg52649
I1
sa(dp53277
g52643
I84
sg52644
Vconnective tissue diseases
p53278
sg52646
I26
sg52647
VC0009782
p53279
sg52649
I3
sa(dp53280
g52643
I234
sg52644
Vpolymyalgia rheumatica
p53281
sg52646
I22
sg52647
VC0032533
p53282
sg52649
I2
sa(dp53283
g52643
I51
sg52644
g53246
sg52646
I18
sg52647
VC0035435
p53284
sg52649
I2
sasa(dp53285
g135
(dp53286
(VCCR2
p53287
Veosinophilia
p53288
tp53289
I00
ssg52636
VMoreover, we show that the reduction of eosinophilia and the recruitment of inflammatory monocytes to the lungs required early triggering of TLR9, IFN-Gamma and CCR2 by immunotherapy components.
p53290
sg52638
(lp53291
(dp53292
g52643
I147
sg52644
VIFN-Gamma
p53293
sg52646
I9
sg52674
VP01579
p53294
sg52649
I1
sa(dp53295
g52643
I161
sg52644
g53287
sg52646
I4
sg52674
VP41597
p53296
sg52649
I1
sa(dp53297
g52643
I141
sg52644
VTLR9
p53298
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp53299
(dp53300
g52643
I61
sg52644
Vrecruitment
p53301
sg52646
I11
sg52647
VC0271510
p53302
sg52649
I1
sa(dp53303
g52643
I40
sg52644
g53288
sg52646
I12
sg52647
VC0014457
p53304
sg52649
I1
sasa(dp53305
g52636
VSubjects treated with TLR9 agonists were at a higher risk of anemia (risk ratio [RR] 1.04, 95% confidence interval [CI]: 1.02-1.06), neutropenia (RR 1.16, 95% CI: 1.11-1.21), leukopenia (RR 1.16, 95% CI: 1.11-1.22), lymphopenia (RR 1.17, 95% CI: 1.10-1.25), thrombocytopenia (RR 1.20, 95% CI: 1.14-1.27), flu-like symptoms (RR 10.59, 95% CI: 3.66-30.66), diarrhea (RR 1.40, 95% CI: 1.18-1.67) and headache (RR 1.61, 95% CI: 1.26-2.06).
p53306
sg52638
(lp53307
(dp53308
g52643
I305
sg52644
Vflu
p53309
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp53310
g52643
I22
sg52644
VTLR9
p53311
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp53312
(dp53313
g52643
I61
sg52644
Vanemia
p53314
sg52646
I6
sg52647
VC0002871
p53315
sg52649
I1
sa(dp53316
g52643
I305
sg52644
Vflu-like symptoms
p53317
sg52646
I17
sg52647
VC0392171
p53318
sg52649
I2
sa(dp53319
g52643
I355
sg52644
Vdiarrhea
p53320
sg52646
I8
sg52647
VC0011991
p53321
sg52649
I1
sa(dp53322
g52643
I397
sg52644
Vheadache
p53323
sg52646
I8
sg52647
VC0018681
p53324
sg52649
I1
sa(dp53325
g52643
I216
sg52644
Vlymphopenia
p53326
sg52646
I11
sg52647
VC0024312
p53327
sg52649
I1
sa(dp53328
g52643
I175
sg52644
Vleukopenia
p53329
sg52646
I10
sg52647
VC0023530
p53330
sg52649
I1
sasa(dp53331
g52636
VBoth the TLR7 and TLR9 agonists dose dependently reduced airway eosinophilia, while the TLR3 agonist only reduced airway eosinophilia at a dose of 1.0 mg/kg.
p53332
sg52638
(lp53333
(dp53334
g52643
I18
sg52644
VTLR9
p53335
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp53336
g52643
I9
sg52644
VTLR7
p53337
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp53338
g52643
I88
sg52644
VTLR3
p53339
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp53340
(dp53341
g52643
I64
sg52644
Veosinophilia
p53342
sg52646
I12
sg52647
VC0014457
p53343
sg52649
I1
sa(dp53344
g52643
I64
sg52644
Veosinophilia
p53345
sg52646
I12
sg52647
VC0014457
p53346
sg52649
I1
sasa(dp53347
g52636
V&lt;p&gt;Lichen planopilaris (LPP) is a variant of lichen planus that affects the scalp causing scarring hair loss.
p53348
sg52638
(lp53349
sg52640
(lp53350
(dp53351
g52643
I51
sg52644
Vlichen planus
p53352
sg52646
I13
sg52647
VC0023646
p53353
sg52649
I2
sa(dp53354
g52643
I96
sg52644
Vscarring
p53355
sg52646
I8
sg52647
VC0008767
p53356
sg52649
I1
sa(dp53357
g52643
I9
sg52644
VLichen planopilaris
p53358
sg52646
I19
sg52647
VC0023645
p53359
sg52649
I2
sasa(dp53360
g52636
VThis family of diseases contains 2 subgroups, largely based on clinical features: keratosis pilaris atrophicans (KPA; including keratosis pilaris atrophicans faciei/ulerythema ophryogenes, atrophoderma vermiculata, and keratosis follicularis spinulosa decalvans); and the lichen planopilaris (LPP) subgroup (including LPP, frontal fibrosing alopecia, Graham-Little-Piccardi-Lassueur Syndrome and fibrosing alopecia in a pattern distribution).
p53361
sg52638
(lp53362
sg52640
(lp53363
(dp53364
g52643
I113
sg52644
VKPA
p53365
sg52646
I3
sg52647
VC0263428
p53366
sg52649
I1
sa(dp53367
g52643
I82
sg52644
Vkeratosis pilaris atrophicans
p53368
sg52646
I29
sg52647
VC0263428
p53369
sg52649
I3
sa(dp53370
g52643
I323
sg52644
Vfrontal fibrosing alopecia
p53371
sg52646
I26
sg52647
VC1274700
p53372
sg52649
I3
sa(dp53373
g52643
I189
sg52644
Vatrophoderma
p53374
sg52646
I12
sg52647
VC0151514
p53375
sg52649
I1
sa(dp53376
g52643
I383
sg52644
VSyndrome
p53377
sg52646
I8
sg52647
VC0039082
p53378
sg52649
I1
sa(dp53379
g52643
I293
sg52644
VLPP
p53380
sg52646
I3
sg52647
VC0023645
p53381
sg52649
I1
sa(dp53382
g52643
I219
sg52644
Vkeratosis follicularis spinulosa decalvans
p53383
sg52646
I42
sg52647
VC0343057
p53384
sg52649
I4
sa(dp53385
g52643
I165
sg52644
Vulerythema ophryogenes
p53386
sg52646
I22
sg52647
VC0263428
p53387
sg52649
I2
sa(dp53388
g52643
I82
sg52644
Vkeratosis pilaris atrophicans
p53389
sg52646
I29
sg52647
VC0263428
p53390
sg52649
I3
sa(dp53391
g52643
I293
sg52644
VLPP
p53392
sg52646
I3
sg52647
VC0023645
p53393
sg52649
I1
sa(dp53394
g52643
I272
sg52644
Vlichen planopilaris
p53395
sg52646
I19
sg52647
VC0023645
p53396
sg52649
I2
sasa(dp53397
g52636
VAn interface dermatitis with lichenoid inflammation is characteristic of the LPP group of disorders, but the literature provides scant information about the histopathology of the KPA group.
p53398
sg52638
(lp53399
sg52640
(lp53400
(dp53401
g52643
I39
sg52644
Vinflammation
p53402
sg52646
I12
sg52647
VC0021368
p53403
sg52649
I1
sa(dp53404
g52643
I3
sg52644
Vinterface dermatitis
p53405
sg52646
I20
sg52647
VC0262981
p53406
sg52649
I2
sasa(dp53407
g52636
VRecently, there have been25 cases reported in the literature of lichen planuspigmentosus (LPPi) that preceded the developmentof frontal fibrosing alopecia (FFA), which is a variantof lichen planopilaris (LPP).
p53408
sg52638
(lp53409
sg52640
(lp53410
(dp53411
g52643
I64
sg52644
Vlichen
p53412
sg52646
I6
sg52647
VC0023643
p53413
sg52649
I1
sa(dp53414
g52643
I90
sg52644
VLPP
p53415
sg52646
I3
sg52647
VC0023645
p53416
sg52649
I1
sa(dp53417
g52643
I128
sg52644
Vfrontal fibrosing alopecia
p53418
sg52646
I26
sg52647
VC1274700
p53419
sg52649
I3
sa(dp53420
g52643
I183
sg52644
Vlichen planopilaris
p53421
sg52646
I19
sg52647
VC0023645
p53422
sg52649
I2
sa(dp53423
g52643
I156
sg52644
VFFA
p53424
sg52646
I3
sg52647
VC1274700
p53425
sg52649
I1
sasa(dp53426
g52636
VLower levels of acylCer and LPP accompany skin diseases, such as atopic dermatitis, lamellar ichthyosis, and psoriasis.
p53427
sg52638
(lp53428
sg52640
(lp53429
(dp53430
g52643
I109
sg52644
Vpsoriasis
p53431
sg52646
I9
sg52647
VC0033860
p53432
sg52649
I1
sa(dp53433
g52643
I84
sg52644
Vlamellar ichthyosis
p53434
sg52646
I19
sg52647
VC0020758
p53435
sg52649
I2
sa(dp53436
g52643
I42
sg52644
Vskin diseases
p53437
sg52646
I13
sg52647
VC0037274
p53438
sg52649
I2
sa(dp53439
g52643
I65
sg52644
Vatopic dermatitis
p53440
sg52646
I17
sg52647
VC0011615
p53441
sg52649
I2
sasa(dp53442
g52636
VA number of associations such as hepatitis C virus infection, frontal fibrosing alopecia, acrokeratosis of Bazex and nephrotic syndrome have been reported with LPP.
p53443
sg52638
(lp53444
sg52640
(lp53445
(dp53446
g52643
I62
sg52644
Vfrontal fibrosing alopecia
p53447
sg52646
I26
sg52647
VC1274700
p53448
sg52649
I3
sa(dp53449
g52643
I117
sg52644
Vnephrotic syndrome
p53450
sg52646
I18
sg52647
VC0027726
p53451
sg52649
I2
sa(dp53452
g52643
I90
sg52644
Vacrokeratosis
p53453
sg52646
I13
sg52647
VC0001202
p53454
sg52649
I1
sa(dp53455
g52643
I33
sg52644
Vhepatitis C
p53456
sg52646
I11
sg52647
VC0019196
p53457
sg52649
I2
sa(dp53458
g52643
I45
sg52644
Vvirus infection
p53459
sg52646
I15
sg52647
VC0042769
p53460
sg52649
I2
sasa(dp53461
g52636
VLichen planopilaris (LPP) is a follicular variant of lichen planus.
p53462
sg52638
(lp53463
sg52640
(lp53464
(dp53465
g52643
I21
sg52644
VLPP
p53466
sg52646
I3
sg52647
VC0023645
p53467
sg52649
I1
sa(dp53468
g52643
I0
sg52644
VLichen planopilaris
p53469
sg52646
I19
sg52647
VC0023645
p53470
sg52649
I2
sa(dp53471
g52643
I53
sg52644
Vlichen planus
p53472
sg52646
I13
sg52647
VC0023646
p53473
sg52649
I2
sasa(dp53474
g135
(dp53475
(VCD247
p53476
Vpreeclampsia
p53477
tp53478
I00
ssg52636
VHowever, genes like HSP90, PAK2, CD247 and others included in the first 1% of the prioritized list need to be further explored in preeclampsia pathogenesis through experimental approaches.
p53479
sg52638
(lp53480
(dp53481
g52643
I20
sg52644
VHSP90
p53482
sg52646
I5
sg52674
VP07900
p53483
sg52649
I1
sa(dp53484
g52643
I33
sg52644
g53476
sg52646
I5
sg52674
VP20963
p53485
sg52649
I1
sa(dp53486
g52643
I27
sg52644
VPAK2
p53487
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp53488
(dp53489
g52643
I143
sg52644
Vpathogenesis
p53490
sg52646
I12
sg52647
VC0699748
p53491
sg52649
I1
sa(dp53492
g52643
I130
sg52644
g53477
sg52646
I12
sg52647
VC0032914
p53493
sg52649
I1
sasa(dp53494
g135
(dp53495
(Vserum myoglobin
p53496
Vacute renal failure
p53497
tp53498
I01
ssg52636
VWe report a case of acute pancreatitis with diabetic ketoacidosis associated with increased serum myoglobin concentration, acute renal failure, and disseminated intravascular coagulation.
p53499
sg52638
(lp53500
(dp53501
g52643
I92
sg52644
g53496
sg52646
I15
sg52674
VP02144
p53502
sg52649
I2
sasg52640
(lp53503
(dp53504
g52643
I148
sg52644
Vdisseminated intravascular coagulation
p53505
sg52646
I38
sg52647
VC0012739
p53506
sg52649
I3
sa(dp53507
g52643
I44
sg52644
Vdiabetic ketoacidosis
p53508
sg52646
I21
sg52647
VC0011880
p53509
sg52649
I2
sa(dp53510
g52643
I20
sg52644
Vacute pancreatitis
p53511
sg52646
I18
sg52647
VC0001339
p53512
sg52649
I2
sa(dp53513
g52643
I123
sg52644
g53497
sg52646
I19
sg52647
VC0022660
p53514
sg52649
I3
sasa(dp53515
g52636
VWe examined the relationship among acute pancreatitis, diabetic ketoacidosis, and hypermyoglobinemia in the literature.
p53516
sg52638
(lp53517
sg52640
(lp53518
(dp53519
g52643
I35
sg52644
Vacute pancreatitis
p53520
sg52646
I18
sg52647
VC0001339
p53521
sg52649
I2
sa(dp53522
g52643
I55
sg52644
Vdiabetic ketoacidosis
p53523
sg52646
I21
sg52647
VC0011880
p53524
sg52649
I2
sasa(dp53525
g135
(dp53526
(Vmyoglobin
p53527
Vdiabetic ketoacidosis
p53528
tp53529
I00
ssg52636
VThe frequency of nontraumatic rhabdomyolysis in diabetic ketoacidosis was investigated by serial measurements of the serum levels of myoglobin and the serum activity of creatine kinase isoenzyme MM in 12 consecutively admitted ketoacidotic patients.
p53530
sg52638
(lp53531
(dp53532
g52643
I133
sg52644
g53527
sg52646
I9
sg52674
VP02144
p53533
sg52649
I1
sa(dp53534
g52643
I169
sg52644
Vcreatine kinase
p53535
sg52646
I15
sg52674
VP12532
p53536
sg52649
I2
sasg52640
(lp53537
(dp53538
g52643
I30
sg52644
Vrhabdomyolysis
p53539
sg52646
I14
sg52647
VC0035410
p53540
sg52649
I1
sa(dp53541
g52643
I48
sg52644
g53528
sg52646
I21
sg52647
VC0011880
p53542
sg52649
I2
sasa(dp53543
g52636
VIn conclusion, our findings suggest that nontraumatic rhabdomyolysis with hypermyoglobinaemia and elevated serum activity of creatine kinase isoenzyme MM may be a hitherto unrecognized common feature of diabetic ketoacidosis.
p53544
sg52638
(lp53545
(dp53546
g52643
I125
sg52644
Vcreatine kinase isoenzyme MM
p53547
sg52646
I28
sg52674
VP12532
p53548
sg52649
I4
sasg52640
(lp53549
(dp53550
g52643
I54
sg52644
Vrhabdomyolysis
p53551
sg52646
I14
sg52647
VC0035410
p53552
sg52649
I1
sa(dp53553
g52643
I203
sg52644
Vdiabetic ketoacidosis
p53554
sg52646
I21
sg52647
VC0011880
p53555
sg52649
I2
sasa(dp53556
g52636
VBioinformatics and luciferase reporter assays demonstrated that miR-495 targets the 3'-untranslated region of high-mobility group nucleosome-binding domain 5 (HMGN5), a potential oncogene in various types of cancers.
p53557
sg52638
(lp53558
(dp53559
g52643
I110
sg52644
Vhigh-mobility group nucleosome-binding domain 5
p53560
sg52646
I47
sg52674
VP00390
p53561
sg52649
I5
sa(dp53562
g52643
I159
sg52644
VHMGN5
p53563
sg52646
I5
sg52674
VP82970
p53564
sg52649
I1
sasg52640
(lp53565
(dp53566
g52643
I208
sg52644
Vcancers
p53567
sg52646
I7
sg52647
VC0006826
p53568
sg52649
I1
sasa(dp53569
g135
(dp53570
(VHigh-mobility group nucleosome-binding domain 5
p53571
Vgliomas
p53572
tp53573
I00
ssg52636
VHigh-mobility group nucleosome-binding domain 5 (HMGN5), a well-known oncogene in gliomas, was identified as a functional target of miR-409-3p using bioinformatics, dual-luciferase reporter assay, real-time quantitative polymerase chain reaction, and Western blot analysis.
p53574
sg52638
(lp53575
(dp53576
g52643
I132
sg52644
VmiR-409-3p
p53577
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp53578
g52643
I49
sg52644
VHMGN5
p53579
sg52646
I5
sg52674
VP82970
p53580
sg52649
I1
sa(dp53581
g52643
I0
sg52644
g53571
sg52646
I47
sg52674
VP00390
p53582
sg52649
I5
sasg52640
(lp53583
(dp53584
g52643
I82
sg52644
g53572
sg52646
I7
sg52647
VC0017638
p53585
sg52649
I1
sasa(dp53586
g135
(dp53587
(VHMGN5
p53588
Vglioma
p53589
tp53590
I01
ssg52636
VRestoration of HMGN5 expression significantly reversed the inhibitory effects of miR-409-3p overexpression on glioma cell invasion and proliferation.
p53591
sg52638
(lp53592
(dp53593
g52643
I81
sg52644
VmiR-409-3p
p53594
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp53595
g52643
I15
sg52644
g53588
sg52646
I5
sg52674
VP82970
p53596
sg52649
I1
sasg52640
(lp53597
(dp53598
g52643
I135
sg52644
Vproliferation
p53599
sg52646
I13
sg52647
VC0334094
p53600
sg52649
I1
sa(dp53601
g52643
I110
sg52644
g53589
sg52646
I6
sg52647
VC0017638
p53602
sg52649
I1
sa(dp53603
g52643
I117
sg52644
Vcell invasion
p53604
sg52646
I13
sg52647
VC2699153
p53605
sg52649
I2
sasa(dp53606
g135
(dp53607
(VHMGN5
p53608
Vglioma
p53609
tp53610
I01
ssg52636
VTaken together, our results suggest that miR-409-3p inhibits glioma cell invasion and proliferation by targeting HMGN5, representing a potential therapeutic target for glioma.
p53611
sg52638
(lp53612
(dp53613
g52643
I41
sg52644
VmiR-409-3p
p53614
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp53615
g52643
I113
sg52644
g53608
sg52646
I5
sg52674
VP82970
p53616
sg52649
I1
sasg52640
(lp53617
(dp53618
g52643
I86
sg52644
Vproliferation
p53619
sg52646
I13
sg52647
VC0334094
p53620
sg52649
I1
sa(dp53621
g52643
I61
sg52644
Vglioma
p53622
sg52646
I6
sg52647
VC0017638
p53623
sg52649
I1
sa(dp53624
g52643
I68
sg52644
Vcell invasion
p53625
sg52646
I13
sg52647
VC2699153
p53626
sg52649
I2
sa(dp53627
g52643
I61
sg52644
g53609
sg52646
I6
sg52647
VC0017638
p53628
sg52649
I1
sasa(dp53629
g135
(dp53630
(VHMGN5
p53631
Vclear cell renal cell carcinoma
p53632
tp53633
I01
ssg52636
VIt was first discovered in mouse, and recent studies found that the expressions of HMGN5 in many human cancers were also highly regulated, such as prostate, bladder, breast, and lung and clear cell renal cell carcinoma.
p53634
sg52638
(lp53635
(dp53636
g52643
I83
sg52644
g53631
sg52646
I5
sg52674
VP82970
p53637
sg52649
I1
sasg52640
(lp53638
(dp53639
g52643
I103
sg52644
Vcancers
p53640
sg52646
I7
sg52647
VC0006826
p53641
sg52649
I1
sa(dp53642
g52643
I187
sg52644
g53632
sg52646
I31
sg52647
VC0279702
p53643
sg52649
I5
sasa(dp53644
g52636
VImportantly, deficiency of HMGN5 has been shown to be linked to cancer cell growth, cell cycle regulation, migration, invasion, and clinical outcomes, and it represents a promising therapeutic target for many malignant tumors.
p53645
sg52638
(lp53646
(dp53647
g52643
I27
sg52644
VHMGN5
p53648
sg52646
I5
sg52674
VP82970
p53649
sg52649
I1
sasg52640
(lp53650
(dp53651
g52643
I64
sg52644
Vcancer cell growth
p53652
sg52646
I18
sg52647
VC1516170
p53653
sg52649
I3
sa(dp53654
g52643
I209
sg52644
Vmalignant tumors
p53655
sg52646
I16
sg52647
VC0006826
p53656
sg52649
I2
sa(dp53657
g52643
I118
sg52644
Vinvasion
p53658
sg52646
I8
sg52647
VC2699153
p53659
sg52649
I1
sasa(dp53660
g52636
VIn the present review, we provide an overview of the current knowledge concerning the role of HMGN5 in cancer development and progression.
p53661
sg52638
(lp53662
(dp53663
g52643
I94
sg52644
VHMGN5
p53664
sg52646
I5
sg52674
VP82970
p53665
sg52649
I1
sasg52640
(lp53666
(dp53667
g52643
I103
sg52644
Vcancer
p53668
sg52646
I6
sg52647
VC0006826
p53669
sg52649
I1
sasa(dp53670
g52636
VNucleosome-binding protein 1 (NSBP1) has been suggested as an oncogene in various types of human cancers.
p53671
sg52638
(lp53672
(dp53673
g52643
I0
sg52644
VNucleosome-binding protein 1
p53674
sg52646
I28
sg52674
VP14222
p53675
sg52649
I3
sa(dp53676
g52643
I30
sg52644
VNSBP1
p53677
sg52646
I5
sg52674
VP82970
p53678
sg52649
I1
sasg52640
(lp53679
(dp53680
g52643
I97
sg52644
Vcancers
p53681
sg52646
I7
sg52647
VC0006826
p53682
sg52649
I1
sasa(dp53683
g135
(dp53684
(VNSBP1
p53685
VNSCLC
p53686
tp53687
I00
ssg52636
VWe found that NSBP1 was highly expressed in non-small cell lung cancer (NSCLC) cells, and knockdown of NSBP1 by NSBP1 small interfering RNA (siRNA) significantly suppressed NSCLC cell proliferation and invasion.
p53688
sg52638
(lp53689
(dp53690
g52643
I112
sg52644
VNSBP1 small interfering RNA
p53691
sg52646
I27
sg52674
VP82970
p53692
sg52649
I4
sa(dp53693
g52643
I14
sg52644
VNSBP1
p53694
sg52646
I5
sg52674
VP82970
p53695
sg52649
I1
sa(dp53696
g52643
I14
sg52644
g53685
sg52646
I5
sg52674
VP82970
p53697
sg52649
I1
sasg52640
(lp53698
(dp53699
g52643
I72
sg52644
VNSCLC
p53700
sg52646
I5
sg52647
VC0007131
p53701
sg52649
I1
sa(dp53702
g52643
I44
sg52644
Vnon-small cell lung cancer
p53703
sg52646
I26
sg52647
VC0007131
p53704
sg52649
I4
sa(dp53705
g52643
I184
sg52644
Vproliferation
p53706
sg52646
I13
sg52647
VC0334094
p53707
sg52649
I1
sa(dp53708
g52643
I72
sg52644
g53686
sg52646
I5
sg52647
VC0007131
p53709
sg52649
I1
sa(dp53710
g52643
I202
sg52644
Vinvasion
p53711
sg52646
I8
sg52647
VC2699153
p53712
sg52649
I1
sasa(dp53713
g135
(dp53714
(VNSBP1 siRNA
p53715
VNSCLC
p53716
tp53717
I00
ssg52636
VOverexpression of miR-326 significantly inhibited NSCLC cell proliferation and invasion, which mimicked the effect of NSBP1 siRNA.
p53718
sg52638
(lp53719
(dp53720
g52643
I118
sg52644
g53715
sg52646
I11
sg52674
VP82970
p53721
sg52649
I2
sa(dp53722
g52643
I18
sg52644
VmiR-326
p53723
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp53724
(dp53725
g52643
I50
sg52644
g53716
sg52646
I5
sg52647
VC0007131
p53726
sg52649
I1
sa(dp53727
g52643
I79
sg52644
Vinvasion
p53728
sg52646
I8
sg52647
VC2699153
p53729
sg52649
I1
sa(dp53730
g52643
I61
sg52644
Vproliferation
p53731
sg52646
I13
sg52647
VC0334094
p53732
sg52649
I1
sasa(dp53733
g52636
VFurthermore, suppression of NSBP1 by NSBP1 siRNA or miR-326 overexpression remarkably repressed the expression of cyclin B1 and matrix metalloproteinase 9 (MMP9), which are associated with cancer cell proliferation and invasion.
p53734
sg52638
(lp53735
(dp53736
g52643
I114
sg52644
Vcyclin B1
p53737
sg52646
I9
sg52674
VP14635
p53738
sg52649
I2
sa(dp53739
g52643
I37
sg52644
VNSBP1 siRNA
p53740
sg52646
I11
sg52674
VP82970
p53741
sg52649
I2
sa(dp53742
g52643
I28
sg52644
VNSBP1
p53743
sg52646
I5
sg52674
VP82970
p53744
sg52649
I1
sa(dp53745
g52643
I156
sg52644
VMMP9
p53746
sg52646
I4
sg52674
VP14780
p53747
sg52649
I1
sa(dp53748
g52643
I52
sg52644
VmiR-326
p53749
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp53750
g52643
I128
sg52644
Vmatrix metalloproteinase 9
p53751
sg52646
I26
sg52674
VP14780
p53752
sg52649
I3
sasg52640
(lp53753
(dp53754
g52643
I201
sg52644
Vproliferation
p53755
sg52646
I13
sg52647
VC0334094
p53756
sg52649
I1
sa(dp53757
g52643
I219
sg52644
Vinvasion
p53758
sg52646
I8
sg52647
VC2699153
p53759
sg52649
I1
sa(dp53760
g52643
I13
sg52644
Vsuppression
p53761
sg52646
I11
sg52647
VC0221103
p53762
sg52649
I1
sa(dp53763
g52643
I189
sg52644
Vcancer
p53764
sg52646
I6
sg52647
VC0006826
p53765
sg52649
I1
sasa(dp53766
g135
(dp53767
(VNSBP1
p53768
VNSCLC
p53769
tp53770
I00
ssg52636
VIn addition, an inverse correlation between miR-326 and NSBP1 expression levels was found in NSCLC clinical specimens.
p53771
sg52638
(lp53772
(dp53773
g52643
I56
sg52644
g53768
sg52646
I5
sg52674
VP82970
p53774
sg52649
I1
sasg52640
(lp53775
(dp53776
g52643
I93
sg52644
g53769
sg52646
I5
sg52647
VC0007131
p53777
sg52649
I1
sasa(dp53778
g135
(dp53779
(VNSBP1
p53780
VNSCLC
p53781
tp53782
I00
ssg52636
VOur study demonstrated a direct target relationship between NSBP1 and miR-326 through which miR-326 inhibited cell proliferation and invasion of NSCLC cells.
p53783
sg52638
(lp53784
(dp53785
g52643
I60
sg52644
g53780
sg52646
I5
sg52674
VP82970
p53786
sg52649
I1
sa(dp53787
g52643
I70
sg52644
VmiR-326
p53788
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp53789
(dp53790
g52643
I133
sg52644
Vinvasion
p53791
sg52646
I8
sg52647
VC2699153
p53792
sg52649
I1
sa(dp53793
g52643
I115
sg52644
Vproliferation
p53794
sg52646
I13
sg52647
VC0334094
p53795
sg52649
I1
sa(dp53796
g52643
I145
sg52644
g53781
sg52646
I5
sg52647
VC0007131
p53797
sg52649
I1
sasa(dp53798
g52636
VThus, miR-326-NSBP1 is a promising candidate target for developing novel anticancer therapeutics for NSCLC.
p53799
sg52638
(lp53800
(dp53801
g52643
I6
sg52644
VmiR-326-NSBP1
p53802
sg52646
I13
sg52674
g12
sg52649
I1
sasg52640
(lp53803
(dp53804
g52643
I101
sg52644
VNSCLC
p53805
sg52646
I5
sg52647
VC0007131
p53806
sg52649
I1
sasa(dp53807
g135
(dp53808
(VHMGN5
p53809
Vprostate cancer
p53810
tp53811
I00
ssg52636
VCorrelation analysis also showed that HMGN5 expression levels were significantly inversely correlated with the miR-340 expression in prostate cancer tissues.
p53812
sg52638
(lp53813
(dp53814
g52643
I38
sg52644
g53809
sg52646
I5
sg52674
VP82970
p53815
sg52649
I1
sa(dp53816
g52643
I111
sg52644
VmiR-340
p53817
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp53818
(dp53819
g52643
I133
sg52644
g53810
sg52646
I15
sg52647
VC0600139
p53820
sg52649
I2
sasa(dp53821
g135
(dp53822
(VHMGN5
p53823
Vprostate cancer
p53824
tp53825
I00
ssg52636
VIn addition, overexpression of HMGN5 significantly reversed the inhibitory effect of miR-340 on prostate cancer cell proliferation and invasion.
p53826
sg52638
(lp53827
(dp53828
g52643
I31
sg52644
g53823
sg52646
I5
sg52674
VP82970
p53829
sg52649
I1
sa(dp53830
g52643
I85
sg52644
VmiR-340
p53831
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp53832
(dp53833
g52643
I135
sg52644
Vinvasion
p53834
sg52646
I8
sg52647
VC2699153
p53835
sg52649
I1
sa(dp53836
g52643
I117
sg52644
Vproliferation
p53837
sg52646
I13
sg52647
VC0334094
p53838
sg52649
I1
sa(dp53839
g52643
I96
sg52644
g53824
sg52646
I15
sg52647
VC0600139
p53840
sg52649
I2
sasa(dp53841
g52636
VMoreover, the decreased miR-340 expression may contribute to the development and progression of prostate cancer through a mechanism that involves HMGN5.
p53842
sg52638
(lp53843
(dp53844
g52643
I146
sg52644
VHMGN5
p53845
sg52646
I5
sg52674
VP82970
p53846
sg52649
I1
sasg52640
(lp53847
(dp53848
g52643
I81
sg52644
Vprogression of prostate cancer
p53849
sg52646
I30
sg52647
VC1739135
p53850
sg52649
I4
sasa(dp53851
g135
(dp53852
(VHMGN5
p53853
Vprostate cancer
p53854
tp53855
I00
ssg52636
VThus, miR340 and its target gene HMGN5 can serve as potentially useful therapeutic candidates for prostate cancer treatment.
p53856
sg52638
(lp53857
(dp53858
g52643
I33
sg52644
g53853
sg52646
I5
sg52674
VP82970
p53859
sg52649
I1
sasg52640
(lp53860
(dp53861
g52643
I98
sg52644
g53854
sg52646
I15
sg52647
VC0600139
p53862
sg52649
I2
sasa(dp53863
g52636
VThe high-mobility group nucleosome-binding protein-5 (HMGN5) is frequently overexpressed in various malignant cancers.
p53864
sg52638
(lp53865
(dp53866
g52643
I54
sg52644
VHMGN5
p53867
sg52646
I5
sg52674
VP82970
p53868
sg52649
I1
sa(dp53869
g52643
I4
sg52644
Vhigh-mobility group nucleosome-binding protein-5
p53870
sg52646
I48
sg52674
VP00390
p53871
sg52649
I4
sasg52640
(lp53872
(dp53873
g52643
I110
sg52644
Vcancers
p53874
sg52646
I7
sg52647
VC0006826
p53875
sg52649
I1
sasa(dp53876
g135
(dp53877
(VHMGN5
p53878
Vmeningiomas
p53879
tp53880
I01
ssg52636
VHowever, the potential correlation between HMGN5 and prognosis in patients with meningiomas remains unknown.
p53881
sg52638
(lp53882
(dp53883
g52643
I43
sg52644
g53878
sg52646
I5
sg52674
VP82970
p53884
sg52649
I1
sasg52640
(lp53885
(dp53886
g52643
I80
sg52644
g53879
sg52646
I11
sg52647
VC0025286
p53887
sg52649
I1
sasa(dp53888
g135
(dp53889
(VHMGN5
p53890
Vmeningiomas
p53891
tp53892
I01
ssg52636
VIn the present study, we explored the expression of HMGN5 in meningiomas with immunohistochemistry and correlated the results to the patient outcome.
p53893
sg52638
(lp53894
(dp53895
g52643
I52
sg52644
g53890
sg52646
I5
sg52674
VP82970
p53896
sg52649
I1
sasg52640
(lp53897
(dp53898
g52643
I61
sg52644
g53891
sg52646
I11
sg52647
VC0025286
p53899
sg52649
I1
sasa(dp53900
g135
(dp53901
(VHMGN5
p53902
Vmeningioma
p53903
tp53904
I01
ssg52636
VWe demonstrate that there is a positive association between HMGN5 expression and meningioma histological grade.
p53905
sg52638
(lp53906
(dp53907
g52643
I60
sg52644
g53902
sg52646
I5
sg52674
VP82970
p53908
sg52649
I1
sasg52640
(lp53909
(dp53910
g52643
I81
sg52644
g53903
sg52646
I10
sg52647
VC0025286
p53911
sg52649
I1
sasa(dp53912
g135
(dp53913
(VHMGN5
p53914
Vmeningioma
p53915
tp53916
I01
ssg52636
VStatistical analysis reveals that lower HMGN5 expression predict lower meningioma recurrence.
p53917
sg52638
(lp53918
(dp53919
g52643
I40
sg52644
g53914
sg52646
I5
sg52674
VP82970
p53920
sg52649
I1
sasg52640
(lp53921
(dp53922
g52643
I82
sg52644
Vrecurrence
p53923
sg52646
I10
sg52647
VC1458156
p53924
sg52649
I1
sa(dp53925
g52643
I71
sg52644
g53915
sg52646
I10
sg52647
VC0025286
p53926
sg52649
I1
sasa(dp53927
g135
(dp53928
(VMRP-1
p53929
Vmeningioma
p53930
tp53931
I00
ssg52636
VOur results further revealed that HMGN5 inhibition decreased P-glycoprotein (MDR-1) expression without affecting multidrug resistance associated proteins 1 (MRP-1) expression to increase chemosensitivity to temozolomide (TMZ) of meningioma cells.
p53932
sg52638
(lp53933
(dp53934
g52643
I113
sg52644
Vmultidrug resistance associated proteins 1
p53935
sg52646
I42
sg52674
g12
sg52649
I5
sa(dp53936
g52643
I61
sg52644
VP-glycoprotein
p53937
sg52646
I14
sg52674
VP08183
p53938
sg52649
I1
sa(dp53939
g52643
I34
sg52644
VHMGN5
p53940
sg52646
I5
sg52674
VP82970
p53941
sg52649
I1
sa(dp53942
g52643
I77
sg52644
VMDR-1
p53943
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp53944
g52643
I157
sg52644
g53929
sg52646
I5
sg52674
VP08183
p53945
sg52649
I1
sasg52640
(lp53946
(dp53947
g52643
I229
sg52644
g53930
sg52646
I10
sg52647
VC0025286
p53948
sg52649
I1
sasa(dp53949
g135
(dp53950
(VHMGN5
p53951
Vmalignant meningiomas
p53952
tp53953
I01
ssg52636
VCollectively, this study indicates that HMGN5 is a novel target for developing effective therapeutic strategies for malignant meningiomas.
p53954
sg52638
(lp53955
(dp53956
g52643
I40
sg52644
g53951
sg52646
I5
sg52674
VP82970
p53957
sg52649
I1
sasg52640
(lp53958
(dp53959
g52643
I116
sg52644
g53952
sg52646
I21
sg52647
VC0259785
p53960
sg52649
I2
sasa(dp53961
g135
(dp53962
(VHMGN5
p53963
Vbladder cancer
p53964
tp53965
I01
ssg52636
VLuciferase reporter assay showed that miR-186 targets NSBP1 3'-untranslated region (UTR) directly and suppresses NSBP1 (HMGN5) expression in human bladder cancer cells.
p53966
sg52638
(lp53967
(dp53968
g52643
I54
sg52644
VNSBP1 3
p53969
sg52646
I7
sg52674
VP82970
p53970
sg52649
I2
sa(dp53971
g52643
I54
sg52644
VNSBP1
p53972
sg52646
I5
sg52674
VP82970
p53973
sg52649
I1
sa(dp53974
g52643
I38
sg52644
VmiR-186 targets
p53975
sg52646
I15
sg52674
g12
sg52649
I2
sa(dp53976
g52643
I120
sg52644
g53963
sg52646
I5
sg52674
VP82970
p53977
sg52649
I1
sasg52640
(lp53978
(dp53979
g52643
I147
sg52644
g53964
sg52646
I14
sg52647
VC0699885
p53980
sg52649
I2
sasa(dp53981
g135
(dp53982
(VNSBP1
p53983
Vbladder cancer
p53984
tp53985
I01
ssg52636
VOur data first time identified miR-186 as the upstream regulator of NSBP1 and also suggest miR-186-suppressed NSBP1 as a novel therapeutic approach for bladder cancer.
p53986
sg52638
(lp53987
(dp53988
g52643
I91
sg52644
VmiR-186-suppressed NSBP1
p53989
sg52646
I24
sg52674
g12
sg52649
I2
sa(dp53990
g52643
I68
sg52644
g53983
sg52646
I5
sg52674
VP82970
p53991
sg52649
I1
sa(dp53992
g52643
I31
sg52644
VmiR-186
p53993
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp53994
(dp53995
g52643
I152
sg52644
g53984
sg52646
I14
sg52647
VC0699885
p53996
sg52649
I2
sasa(dp53997
g135
(dp53998
(VTK1
p53999
VT cell leukemia
p54000
tp54001
I00
ssg52636
VIn this study, we show that TK1 is upregulated and localizes on the plasma membrane of Burkitt's lymphoma, acute promyelocytic leukemia, T cell leukemia, and acute lymphoblastic leukemia (ALL).
p54002
sg52638
(lp54003
(dp54004
g52643
I28
sg52644
g53999
sg52646
I3
sg52674
VP04183
p54005
sg52649
I1
sasg52640
(lp54006
(dp54007
g52643
I107
sg52644
Vacute promyelocytic leukemia
p54008
sg52646
I28
sg52647
VC0023487
p54009
sg52649
I3
sa(dp54010
g52643
I87
sg52644
VBurkitt's lymphoma
p54011
sg52646
I18
sg52647
VC0006413
p54012
sg52649
I2
sa(dp54013
g52643
I188
sg52644
VALL
p54014
sg52646
I3
sg52647
VC1961102
p54015
sg52649
I1
sa(dp54016
g52643
I158
sg52644
Vacute lymphoblastic leukemia
p54017
sg52646
I28
sg52647
VC1961102
p54018
sg52649
I3
sa(dp54019
g52643
I137
sg52644
g54000
sg52646
I15
sg52647
VC0023492
p54020
sg52649
I3
sasa(dp54021
g135
(dp54022
(VTK1
p54023
Vchronic lymphocytic leukemia
p54024
tp54025
I00
ssg52636
VTK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma.
p54026
sg52638
(lp54027
(dp54028
g52643
I0
sg52644
g54023
sg52646
I3
sg52674
VP04183
p54029
sg52649
I1
sasg52640
(lp54030
(dp54031
g52643
I57
sg52644
Vsolid tumors
p54032
sg52646
I12
sg52647
VC0280100
p54033
sg52649
I2
sa(dp54034
g52643
I170
sg52644
Vnon-Hodgkin lymphoma
p54035
sg52646
I20
sg52647
VC0024305
p54036
sg52649
I2
sa(dp54037
g52643
I74
sg52644
g54024
sg52646
I28
sg52647
VC0023434
p54038
sg52649
I3
sasa(dp54039
g135
(dp54040
(VTK1
p54041
VFL
p54042
tp54043
I00
ssg52636
VIn this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL).
p54044
sg52638
(lp54045
(dp54046
g52643
I46
sg52644
g54041
sg52646
I3
sg52674
VP04183
p54047
sg52649
I1
sasg52640
(lp54048
(dp54049
g52643
I135
sg52644
Vfollicular lymphoma
p54050
sg52646
I19
sg52647
VC0024301
p54051
sg52649
I2
sa(dp54052
g52643
I156
sg52644
g54042
sg52646
I2
sg52647
VC0024301
p54053
sg52649
I1
sasa(dp54054
g135
(dp54055
(Vlactate dehydrogenase
p54056
VFollicular Lymphoma
p54057
tp54058
I00
ssg52636
VThe TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, Beta(2)-microglobulin level, lactate dehydrogenase level and B symptoms.
p54059
sg52638
(lp54060
(dp54061
g52643
I164
sg52644
VBeta(2)-microglobulin
p54062
sg52646
I21
sg52674
VP61769
p54063
sg52649
I1
sa(dp54064
g52643
I4
sg52644
VTK1
p54065
sg52646
I3
sg52674
VP04183
p54066
sg52649
I1
sa(dp54067
g52643
I193
sg52644
g54056
sg52646
I21
sg52674
VP49366
p54068
sg52649
I2
sasg52640
(lp54069
(dp54070
g52643
I98
sg52644
g54057
sg52646
I19
sg52647
VC0024301
p54071
sg52649
I2
sasa(dp54072
g135
(dp54073
(VZAP-70
p54074
VB-cell lymphoma
p54075
tp54076
I00
ssg52636
VWe show that high serum TK1 levels predict poorer overall survival and correlate with unmutated immunoglobulin variable region genes, CD38 and ZAP-70 expression, and subsequent risk of developing large B-cell lymphoma (Richter syndrome).
p54077
sg52638
(lp54078
(dp54079
g52643
I134
sg52644
VCD38
p54080
sg52646
I4
sg52674
VP28907
p54081
sg52649
I1
sa(dp54082
g52643
I96
sg52644
Vimmunoglobulin variable region genes
p54083
sg52646
I36
sg52674
g12
sg52649
I4
sa(dp54084
g52643
I24
sg52644
VTK1
p54085
sg52646
I3
sg52674
VP04183
p54086
sg52649
I1
sa(dp54087
g52643
I143
sg52644
g54074
sg52646
I6
sg52674
VP43403
p54088
sg52649
I1
sasg52640
(lp54089
(dp54090
g52643
I219
sg52644
VRichter syndrome
p54091
sg52646
I16
sg52647
VC0349631
p54092
sg52649
I2
sa(dp54093
g52643
I202
sg52644
g54075
sg52646
I15
sg52647
VC0079731
p54094
sg52649
I2
sasa(dp54095
g52636
VIn the present study, we revealed that the Hippo transducer, the transcriptional coactivator with PDZ-binding motif (TAZ), acts as a downstream mediator of PODXL in colon cancer.
p54096
sg52638
(lp54097
(dp54098
g52643
I156
sg52644
VPODXL
p54099
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54100
g52643
I65
sg52644
Vtranscriptional coactivator with PDZ-binding motif
p54101
sg52646
I50
sg52674
g12
sg52649
I5
sa(dp54102
g52643
I117
sg52644
VTAZ
p54103
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp54104
(dp54105
g52643
I165
sg52644
Vcolon cancer
p54106
sg52646
I12
sg52647
VC0699790
p54107
sg52649
I2
sasa(dp54108
g52636
VMoreover, PODXL plays a critical role in cancer stemness, invasiveness, and sensitivity to chemotherapies in colon cancer HCT15 cells.
p54109
sg52638
(lp54110
(dp54111
g52643
I10
sg52644
VPODXL
p54112
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54113
(dp54114
g52643
I41
sg52644
Vcancer
p54115
sg52646
I6
sg52647
VC0006826
p54116
sg52649
I1
sa(dp54117
g52643
I109
sg52644
Vcolon cancer
p54118
sg52646
I12
sg52647
VC0699790
p54119
sg52649
I2
sasa(dp54120
g52636
VNotably, expression of PODXL showed a positive correlation with stem-like and epithelial-mesenchymal transition (EMT) core signatures, and was associated with poor survival outcomes in patients with colon cancer.
p54121
sg52638
(lp54122
(dp54123
g52643
I23
sg52644
VPODXL
p54124
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54125
(dp54126
g52643
I199
sg52644
Vcolon cancer
p54127
sg52646
I12
sg52647
VC0699790
p54128
sg52649
I2
sa(dp54129
g52643
I101
sg52644
Vtransition
p54130
sg52646
I10
sg52647
VC0599156
p54131
sg52649
I1
sasa(dp54132
g52636
VThese findings provide novel insights into the molecular mechanism of PODXL-mediated tumorigenesis in colon cancer.
p54133
sg52638
(lp54134
(dp54135
g52643
I70
sg52644
VPODXL
p54136
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54137
(dp54138
g52643
I102
sg52644
Vcolon cancer
p54139
sg52646
I12
sg52647
VC0699790
p54140
sg52649
I2
sa(dp54141
g52643
I85
sg52644
Vtumorigenesis
p54142
sg52646
I13
sg52647
VC0007621
p54143
sg52649
I1
sasa(dp54144
g135
(dp54145
(VCD34 family
p54146
Vlung cancer
p54147
tp54148
I01
ssg52636
VPodocalyxin (PODXL), which belongs to the CD34 family and regulates cell morphology, has been linked to EMT in lung cancer, and PODXL overexpression is associated with poor prognosis in several different classes of cancers.
p54149
sg52638
(lp54150
(dp54151
g52643
I104
sg52644
VEMT
p54152
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp54153
g52643
I13
sg52644
VPODXL
p54154
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54155
g52643
I42
sg52644
g54146
sg52646
I11
sg52674
VP28906
p54156
sg52649
I2
sa(dp54157
g52643
I13
sg52644
VPODXL
p54158
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54159
g52643
I0
sg52644
VPodocalyxin
p54160
sg52646
I11
sg52674
g12
sg52649
I1
sasg52640
(lp54161
(dp54162
g52643
I215
sg52644
Vcancers
p54163
sg52646
I7
sg52647
VC0006826
p54164
sg52649
I1
sa(dp54165
g52643
I111
sg52644
g54147
sg52646
I11
sg52647
VC0684249
p54166
sg52649
I2
sasa(dp54167
g52636
VThe aim of this study was to clarify the role of PODXL overexpression in EMT in lung cancer, and to determine the prognostic value of PODXL overexpression in tumors from lung cancer patients.
p54168
sg52638
(lp54169
(dp54170
g52643
I49
sg52644
VPODXL
p54171
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54172
g52643
I73
sg52644
VEMT
p54173
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp54174
g52643
I49
sg52644
VPODXL
p54175
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54176
(dp54177
g52643
I158
sg52644
Vtumors
p54178
sg52646
I6
sg52647
VC0027651
p54179
sg52649
I1
sa(dp54180
g52643
I80
sg52644
Vlung cancer
p54181
sg52646
I11
sg52647
VC0684249
p54182
sg52649
I2
sa(dp54183
g52643
I80
sg52644
Vlung cancer
p54184
sg52646
I11
sg52647
VC0684249
p54185
sg52649
I2
sasa(dp54186
g52636
VThe morphology, EMT marker expression, and migration and invasion abilities of engineered A549 PODXL-knockdown (KD) or PODXL-overexpression (OE) lung adenocarcinoma cells were examined.
p54187
sg52638
(lp54188
sg52640
(lp54189
(dp54190
g52643
I145
sg52644
Vlung adenocarcinoma
p54191
sg52646
I19
sg52647
VC0152013
p54192
sg52649
I2
sa(dp54193
g52643
I57
sg52644
Vinvasion
p54194
sg52646
I8
sg52647
VC2699153
p54195
sg52649
I1
sasa(dp54196
g52636
VPODXL expression levels were assessed by immunohistochemistry in 114 human clinical lung adenocarcinoma specimens and correlated with clinical outcomes.
p54197
sg52638
(lp54198
(dp54199
g52643
I0
sg52644
VPODXL
p54200
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54201
(dp54202
g52643
I84
sg52644
Vlung adenocarcinoma
p54203
sg52646
I19
sg52647
VC0152013
p54204
sg52649
I2
sasa(dp54205
g135
(dp54206
(Vphosphatidylinositol 3-kinase
p54207
Vlung adenocarcinoma
p54208
tp54209
I00
ssg52636
VA highly selective inhibitor of phosphatidylinositol 3-kinase-Akt signaling attenuated EMT of PODXL-OE cells, while a transforming growth factor inhibitor did not, suggesting that PODXL induces EMT of lung adenocarcinoma cells via the phosphatidylinositol 3-kinase pathway.
p54210
sg52638
(lp54211
(dp54212
g52643
I87
sg52644
VEMT
p54213
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp54214
g52643
I118
sg52644
Vtransforming growth factor
p54215
sg52646
I26
sg52674
g12
sg52649
I3
sa(dp54216
g52643
I94
sg52644
VPODXL
p54217
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54218
g52643
I32
sg52644
Vphosphatidylinositol 3-kinase
p54219
sg52646
I29
sg52674
VP42336
p54220
sg52649
I2
sa(dp54221
g52643
I32
sg52644
g54207
sg52646
I29
sg52674
VP42336
p54222
sg52649
I2
sa(dp54223
g52643
I94
sg52644
VPODXL-OE
p54224
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp54225
g52643
I62
sg52644
VAkt
p54226
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp54227
(dp54228
g52643
I201
sg52644
g54208
sg52646
I19
sg52647
VC0152013
p54229
sg52649
I2
sasa(dp54230
g52636
VIn lung adenocarcinoma clinical specimens, PODXL expression was detected in minimally invasive and invasive adenocarcinoma, but not in non-invasive adenocarcinoma.
p54231
sg52638
(lp54232
(dp54233
g52643
I43
sg52644
VPODXL
p54234
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54235
(dp54236
g52643
I3
sg52644
Vlung adenocarcinoma
p54237
sg52646
I19
sg52647
VC0152013
p54238
sg52649
I2
sa(dp54239
g52643
I8
sg52644
Vadenocarcinoma
p54240
sg52646
I14
sg52647
VC0001418
p54241
sg52649
I1
sa(dp54242
g52643
I8
sg52644
Vadenocarcinoma
p54243
sg52646
I14
sg52647
VC0001418
p54244
sg52649
I1
sasa(dp54245
g52636
VPODXL overexpression induces EMT in lung adenocarcinoma and contributes to tumor progression.
p54246
sg52638
(lp54247
(dp54248
g52643
I29
sg52644
VEMT
p54249
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp54250
g52643
I0
sg52644
VPODXL
p54251
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54252
(dp54253
g52643
I75
sg52644
Vtumor progression
p54254
sg52646
I17
sg52647
VC0178874
p54255
sg52649
I2
sa(dp54256
g52643
I36
sg52644
Vlung adenocarcinoma
p54257
sg52646
I19
sg52647
VC0152013
p54258
sg52649
I2
sasa(dp54259
g52636
VThe aim of this study was to investigate the impact of PODXL expression on survival in esophageal and gastric adenocarcinoma.
p54260
sg52638
(lp54261
(dp54262
g52643
I55
sg52644
VPODXL
p54263
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54264
(dp54265
g52643
I102
sg52644
Vgastric adenocarcinoma
p54266
sg52646
I22
sg52647
VC0278701
p54267
sg52649
I2
sasa(dp54268
g52636
VIn gastric adenocarcinoma, patients with PODXL negative tumors had a superior TTR and a trend towards an improved OS.
p54269
sg52638
(lp54270
sg52640
(lp54271
(dp54272
g52643
I56
sg52644
Vtumors
p54273
sg52646
I6
sg52647
VC0027651
p54274
sg52649
I1
sa(dp54275
g52643
I3
sg52644
Vgastric adenocarcinoma
p54276
sg52646
I22
sg52647
VC0278701
p54277
sg52649
I2
sasa(dp54278
g135
(dp54279
(VTTR
p54280
Vgastric adenocarcinoma
p54281
tp54282
I00
ssg52636
VIn esophageal and gastric adenocarcinoma combined, the prognostic significance of PODXL expression on TTR was confirmed in unadjusted Cox regression analysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and remained significant in the adjusted model (HR = 3.39, 95 % CI 1.01-11.35, p = 0.048).
p54283
sg52638
(lp54284
(dp54285
g52643
I82
sg52644
VPODXL
p54286
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54287
g52643
I102
sg52644
g54280
sg52646
I3
sg52674
VP02766
p54288
sg52649
I1
sasg52640
(lp54289
(dp54290
g52643
I18
sg52644
g54281
sg52646
I22
sg52647
VC0278701
p54291
sg52649
I2
sasa(dp54292
g52636
VIn esophageal and gastric adenocarcinoma, PODXL expression is an independent prognostic biomarker for reduced time to recurrence and poor overall survival.
p54293
sg52638
(lp54294
(dp54295
g52643
I42
sg52644
VPODXL
p54296
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54297
(dp54298
g52643
I118
sg52644
Vrecurrence
p54299
sg52646
I10
sg52647
VC1458156
p54300
sg52649
I1
sa(dp54301
g52643
I18
sg52644
Vgastric adenocarcinoma
p54302
sg52646
I22
sg52647
VC0278701
p54303
sg52649
I2
sasa(dp54304
g52636
VHere, we report that high PODXL expression was an independent predictor of worse overall survival of pancreatic cancer patients, and that PODXL promoted pancreatic cancer cell motility and invasion by physically binding to the cytoskeletal protein gelsolin.
p54305
sg52638
(lp54306
(dp54307
g52643
I26
sg52644
VPODXL
p54308
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54309
g52643
I26
sg52644
VPODXL
p54310
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54311
(dp54312
g52643
I101
sg52644
Vpancreatic cancer
p54313
sg52646
I17
sg52647
VC0235974
p54314
sg52649
I2
sa(dp54315
g52643
I101
sg52644
Vpancreatic cancer
p54316
sg52646
I17
sg52647
VC0235974
p54317
sg52649
I2
sa(dp54318
g52643
I189
sg52644
Vinvasion
p54319
sg52646
I8
sg52647
VC2699153
p54320
sg52649
I1
sasa(dp54321
g135
(dp54322
(Vgelsolin
p54323
Vpancreatic cancer
p54324
tp54325
I00
ssg52636
VFurthermore, transfection of a PODXL-rescue construct into pancreatic cancer cells in which both PODXL and gelsolin were suppressed failed to increase the formation of the protrusions.
p54326
sg52638
(lp54327
(dp54328
g52643
I31
sg52644
VPODXL
p54329
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54330
g52643
I107
sg52644
g54323
sg52646
I8
sg52674
VP06396
p54331
sg52649
I1
sa(dp54332
g52643
I31
sg52644
VPODXL-rescue construct
p54333
sg52646
I22
sg52674
g12
sg52649
I2
sasg52640
(lp54334
(dp54335
g52643
I172
sg52644
Vprotrusions
p54336
sg52646
I11
sg52647
VC0333056
p54337
sg52649
I1
sa(dp54338
g52643
I59
sg52644
g54324
sg52646
I17
sg52647
VC0235974
p54339
sg52649
I2
sasa(dp54340
g52636
VPodocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane protein that has been demonstrated to be an independent factor of poor prognosis in colorectal cancer (CRC).
p54341
sg52638
(lp54342
(dp54343
g52643
I20
sg52644
VPODXL
p54344
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54345
g52643
I0
sg52644
VPodocalyxin-like 1
p54346
sg52646
I18
sg52674
g12
sg52649
I2
sasg52640
(lp54347
(dp54348
g52643
I164
sg52644
VCRC
p54349
sg52646
I3
sg52647
VC1527249
p54350
sg52649
I1
sa(dp54351
g52643
I145
sg52644
Vcolorectal cancer
p54352
sg52646
I17
sg52647
VC1527249
p54353
sg52649
I2
sasa(dp54354
g52636
VIn addition, we identified a possible target of miR-5100, podocalyxin-like 1 (PODXL), and demonstrated miR-5100 directly binds to the 3' untranslated region of PODXL and post-transcriptionally regulates its expression in pancreatic cancer cells.
p54355
sg52638
(lp54356
(dp54357
g52643
I78
sg52644
VPODXL
p54358
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54359
g52643
I78
sg52644
VPODXL
p54360
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54361
g52643
I58
sg52644
Vpodocalyxin-like 1
p54362
sg52646
I18
sg52674
g12
sg52649
I2
sa(dp54363
g52643
I48
sg52644
VmiR-5100
p54364
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp54365
(dp54366
g52643
I221
sg52644
Vpancreatic cancer
p54367
sg52646
I17
sg52647
VC0235974
p54368
sg52649
I2
sasa(dp54369
g52636
VWe also clarified the close relationship between expression of PODXL in human pancreatic cancer specimens and liver metastasis (P=0.0003), and determined that post-operative survival was longer in the low-PODXL expression group than in the high-PODXL expression group (P&lt;0.05).
p54370
sg52638
(lp54371
(dp54372
g52643
I63
sg52644
VPODXL
p54373
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54374
g52643
I63
sg52644
VPODXL
p54375
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54376
(dp54377
g52643
I110
sg52644
Vliver metastasis
p54378
sg52646
I16
sg52647
VC0494165
p54379
sg52649
I2
sa(dp54380
g52643
I78
sg52644
Vpancreatic cancer
p54381
sg52646
I17
sg52647
VC0235974
p54382
sg52649
I2
sasa(dp54383
g52636
VThese results indicate that miR-5100 and PODXL have considerable therapeutic potential for anti-metastatic therapy and could be potential indicators for cancer metastases in patients with pancreatic cancer.
p54384
sg52638
(lp54385
(dp54386
g52643
I28
sg52644
VmiR-5100
p54387
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp54388
g52643
I41
sg52644
VPODXL
p54389
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54390
(dp54391
g52643
I188
sg52644
Vpancreatic cancer
p54392
sg52646
I17
sg52647
VC0235974
p54393
sg52649
I2
sa(dp54394
g52643
I160
sg52644
Vmetastases
p54395
sg52646
I10
sg52647
VC0027627
p54396
sg52649
I1
sa(dp54397
g52643
I153
sg52644
Vcancer
p54398
sg52646
I6
sg52647
VC0006826
p54399
sg52649
I1
sasa(dp54400
g52636
VPreviously we demonstrated that miR-199b was significantly downregulated in acute myeloid leukemia (AML) and targets podocalyxin and discoidin domain receptor 1.
p54401
sg52638
(lp54402
(dp54403
g52643
I117
sg52644
Vpodocalyxin
p54404
sg52646
I11
sg52674
g12
sg52649
I1
sa(dp54405
g52643
I133
sg52644
Vdiscoidin domain receptor 1
p54406
sg52646
I27
sg52674
g12
sg52649
I4
sa(dp54407
g52643
I32
sg52644
VmiR-199b
p54408
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp54409
(dp54410
g52643
I76
sg52644
Vacute myeloid leukemia
p54411
sg52646
I22
sg52647
VC0023467
p54412
sg52649
I3
sa(dp54413
g52643
I100
sg52644
VAML
p54414
sg52646
I3
sg52647
VC0023467
p54415
sg52649
I1
sasa(dp54416
g52636
VTherefore, we set out to determine if podocalyxin plays a functional role in breast tumor progression.
p54417
sg52638
(lp54418
sg52640
(lp54419
(dp54420
g52643
I84
sg52644
Vtumor progression
p54421
sg52646
I17
sg52647
VC0178874
p54422
sg52649
I2
sasa(dp54423
g52636
VForced overexpression of podocalyxin caused cohesive clusters of epithelial MCF-7 breast tumor cells to bud off from the primary tumor and collectively invade the stroma of the mouse mammary gland in vivo.
p54424
sg52638
(lp54425
sg52640
(lp54426
(dp54427
g52643
I121
sg52644
Vprimary tumor
p54428
sg52646
I13
sg52647
VC0677930
p54429
sg52649
I2
sa(dp54430
g52643
I82
sg52644
Vbreast tumor
p54431
sg52646
I12
sg52647
VC1458155
p54432
sg52649
I2
sasa(dp54433
g135
(dp54434
(VDSTN
p54435
Vchildhood obesity
p54436
tp54437
I00
ssg52636
VThe DEGs MAPT, DSTN, SPTBN1, ARHGEF2 and SKA1 are suggested to be candidate biomarkers for childhood obesity.
p54438
sg52638
(lp54439
(dp54440
g52643
I4
sg52644
VDEGs MAPT
p54441
sg52646
I9
sg52674
g12
sg52649
I2
sa(dp54442
g52643
I15
sg52644
g54435
sg52646
I4
sg52674
VP60981
p54443
sg52649
I1
sa(dp54444
g52643
I29
sg52644
VARHGEF2
p54445
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp54446
g52643
I21
sg52644
VSPTBN1
p54447
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp54448
g52643
I41
sg52644
VSKA1
p54449
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp54450
(dp54451
g52643
I91
sg52644
g54436
sg52646
I17
sg52647
VC2362324
p54452
sg52649
I2
sasa(dp54453
g52636
VAll received support and advice by community Diabetes Specialist Nurses (DSNs) and Dieticians covering Central and Eastern Cheshire, UK.
p54454
sg52638
(lp54455
sg52640
(lp54456
(dp54457
g52643
I45
sg52644
VDiabetes
p54458
sg52646
I8
sg52647
VC0011849
p54459
sg52649
I1
sasa(dp54460
g52636
VIn 2009, the PCT confirmed 3 years funding for a Paediatric Diabetes specialist nurse (PDSN) for schools.
p54461
sg52638
(lp54462
sg52640
(lp54463
(dp54464
g52643
I60
sg52644
VDiabetes
p54465
sg52646
I8
sg52647
VC0011849
p54466
sg52649
I1
sa(dp54467
g52643
I13
sg52644
VPCT
p54468
sg52646
I3
sg52647
VC0162566
p54469
sg52649
I1
sasa(dp54470
g52636
VThe aim of this study was to explore the interaction between diabetes specialist nurses (DSNs) and patients with type 2 diabetes (T2D) during group sessions about self-management.
p54471
sg52638
(lp54472
sg52640
(lp54473
(dp54474
g52643
I130
sg52644
VT2D
p54475
sg52646
I3
sg52647
VC0011860
p54476
sg52649
I1
sa(dp54477
g52643
I113
sg52644
Vtype 2 diabetes
p54478
sg52646
I15
sg52647
VC0011860
p54479
sg52649
I3
sa(dp54480
g52643
I61
sg52644
Vdiabetes
p54481
sg52646
I8
sg52647
VC0011849
p54482
sg52649
I1
sasa(dp54483
g52636
VIn 8 Italian municipalities, 2,512 men and women without both diabetes and CI-DSN at baseline are examined.
p54484
sg52638
(lp54485
sg52640
(lp54486
(dp54487
g52643
I78
sg52644
VDSN
p54488
sg52646
I3
sg52647
VC0011195
p54489
sg52649
I1
sa(dp54490
g52643
I62
sg52644
Vdiabetes
p54491
sg52646
I8
sg52647
VC0011849
p54492
sg52649
I1
sasa(dp54493
g52636
VThe majority (72%) of PHCCs had diabetes-responsible general practitioners (GPs) and almost all (97%) had diabetes specialist nurses (DSNs) with some degree of postgraduate education in diabetes.
p54494
sg52638
(lp54495
sg52640
(lp54496
(dp54497
g52643
I32
sg52644
Vdiabetes
p54498
sg52646
I8
sg52647
VC0011849
p54499
sg52649
I1
sa(dp54500
g52643
I32
sg52644
Vdiabetes
p54501
sg52646
I8
sg52647
VC0011849
p54502
sg52649
I1
sa(dp54503
g52643
I53
sg52644
Vgeneral practitioners
p54504
sg52646
I21
sg52647
VC0272302
p54505
sg52649
I2
sa(dp54506
g52643
I32
sg52644
Vdiabetes
p54507
sg52646
I8
sg52647
VC0011849
p54508
sg52649
I1
sa(dp54509
g52643
I76
sg52644
VGPs
p54510
sg52646
I3
sg52647
VC0272302
p54511
sg52649
I1
sasa(dp54512
g52636
VThe PHCCs reported that they used regional/local diabetes guidelines (93%), were engaged in call-recall diabetic reviews by GP(s) (66%) and DSN(s) (89%), checked that patients had participated in the reviews by GP(s) (69%) and DSN(s) (78%), arranged group education programmes (23%) and reported data to a National Diabetes Register (82%).
p54513
sg52638
(lp54514
sg52640
(lp54515
(dp54516
g52643
I315
sg52644
VDiabetes
p54517
sg52646
I8
sg52647
VC0011849
p54518
sg52649
I1
sa(dp54519
g52643
I140
sg52644
VDSN
p54520
sg52646
I3
sg52647
VC0011195
p54521
sg52649
I1
sa(dp54522
g52643
I140
sg52644
VDSN
p54523
sg52646
I3
sg52647
VC0011195
p54524
sg52649
I1
sa(dp54525
g52643
I49
sg52644
Vdiabetes
p54526
sg52646
I8
sg52647
VC0011849
p54527
sg52649
I1
sasa(dp54528
g52636
VThe presence of diabetes-responsible GP(s) and DSN(s) who use guidelines may contribute to good and equal quality of care.
p54529
sg52638
(lp54530
sg52640
(lp54531
(dp54532
g52643
I47
sg52644
VDSN
p54533
sg52646
I3
sg52647
VC0011195
p54534
sg52649
I1
sa(dp54535
g52643
I16
sg52644
Vdiabetes
p54536
sg52646
I8
sg52647
VC0011849
p54537
sg52649
I1
sasa(dp54538
g52636
VTo review the working practices of UK diabetes specialist nurses (DSNs), specific clinical roles, and to examine changes since 2000.
p54539
sg52638
(lp54540
sg52640
(lp54541
(dp54542
g52643
I38
sg52644
Vdiabetes
p54543
sg52646
I8
sg52647
VC0011849
p54544
sg52649
I1
sasa(dp54545
g52636
VPostal questionnaires were sent to lead DSNs from all identifiable UK diabetes centres (n = 361).
p54546
sg52638
(lp54547
sg52640
(lp54548
(dp54549
g52643
I70
sg52644
Vdiabetes
p54550
sg52646
I8
sg52647
VC0011849
p54551
sg52649
I1
sasa(dp54552
g52636
VQuantitative and qualitative data were collected on the specific clinical roles, employment, and continual professional development of hospital and community DSNs, Nurse Consultants and Diabetes Healthcare Assistants.
p54553
sg52638
(lp54554
sg52640
(lp54555
(dp54556
g52643
I186
sg52644
VDiabetes
p54557
sg52646
I8
sg52647
VC0011849
p54558
sg52649
I1
sasa(dp54559
g52636
V22% of DSNs have a formal role in diabetes research compared with 48% in 2000.
p54560
sg52638
(lp54561
sg52640
(lp54562
(dp54563
g52643
I34
sg52644
Vdiabetes
p54564
sg52646
I8
sg52647
VC0011849
p54565
sg52649
I1
sasa(dp54566
g52636
VPatients were recruited from 40 general practices and randomised (40:40:20 ratio) to receive routine care alone or, in addition, motivational telephone support from a peer supporter or a diabetes specialist nurse (9 peers and 12 DSNs) for a period of up to 6 months.
p54567
sg52638
(lp54568
sg52640
(lp54569
(dp54570
g52643
I187
sg52644
Vdiabetes
p54571
sg52646
I8
sg52647
VC0011849
p54572
sg52649
I1
sasa(dp54573
g52636
VWe exposed the human NSCLC cell lines Calu-1, CL3, H1299, CH27, H23, and H1355 to B[a]P and assessed cell cycle progression using flow cytometry.
p54574
sg52638
(lp54575
sg52640
(lp54576
(dp54577
g52643
I21
sg52644
VNSCLC
p54578
sg52646
I5
sg52647
VC0007131
p54579
sg52649
I1
sasa(dp54580
g52636
VMoreover, DOX-loaded micelles could slowly and efficiency decrease cell viability of non-small-cell lung carcinoma CL3 cells.
p54581
sg52638
(lp54582
sg52640
(lp54583
(dp54584
g52643
I85
sg52644
Vnon-small-cell lung carcinoma
p54585
sg52646
I29
sg52647
VC0007131
p54586
sg52649
I3
sasa(dp54587
g52636
VComet assay was used to evaluate the DNA damage induced by a relatively low dose of COF (100 g/ml) in human lung adenocarcinoma CL-3 cells.
p54588
sg52638
(lp54589
sg52640
(lp54590
(dp54591
g52643
I108
sg52644
Vlung adenocarcinoma
p54592
sg52646
I19
sg52647
VC0152013
p54593
sg52649
I2
sa(dp54594
g52643
I37
sg52644
VDNA damage
p54595
sg52646
I10
sg52647
VC0012860
p54596
sg52649
I2
sasa(dp54597
g135
(dp54598
(VJNK
p54599
Vlung adenocarcinoma
p54600
tp54601
I00
ssg52636
VPb(II) increased the phosphorylated ERK1/2 and phosphorylated AKT but not the phosphorylated ERK5, phosphorylated p38 and JNK activity in human non-small cell lung adenocarcinoma CL3 cells.
p54602
sg52638
(lp54603
(dp54604
g52643
I36
sg52644
VERK1/2
p54605
sg52646
I6
sg52674
VP27361
p54606
sg52649
I1
sa(dp54607
g52643
I93
sg52644
VERK5
p54608
sg52646
I4
sg52674
VP53778
p54609
sg52649
I1
sa(dp54610
g52643
I114
sg52644
Vp38
p54611
sg52646
I3
sg52674
VP46108
p54612
sg52649
I1
sa(dp54613
g52643
I122
sg52644
g54599
sg52646
I3
sg52674
VP53779
p54614
sg52649
I1
sa(dp54615
g52643
I62
sg52644
VAKT
p54616
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp54617
(dp54618
g52643
I159
sg52644
g54600
sg52646
I19
sg52647
VC0152013
p54619
sg52649
I2
sasa(dp54620
g52636
VThe results from reverse-transcription polymerase chain reaction showed that the hOGG1 mRNA expression was induced by hydrogen peroxide (H2O2) and COF in human lung adenocarcinoma CL-3 cells.
p54621
sg52638
(lp54622
sg52640
(lp54623
(dp54624
g52643
I160
sg52644
Vlung adenocarcinoma
p54625
sg52646
I19
sg52647
VC0152013
p54626
sg52649
I2
sasa(dp54627
g52636
VTo reveal the relationship between the high mortality rate of lung cancer in Chinese women and exposure to cooking oil fumes (COF), DNA adduct formation, induced by COF collected from frying fish under domestic conditions, was assessed in human lung adenocarcinoma CL-3 cell lines using the (32)P-postlabeling assay.
p54628
sg52638
(lp54629
sg52640
(lp54630
(dp54631
g52643
I245
sg52644
Vlung adenocarcinoma
p54632
sg52646
I19
sg52647
VC0152013
p54633
sg52649
I2
sa(dp54634
g52643
I62
sg52644
Vlung cancer
p54635
sg52646
I11
sg52647
VC0684249
p54636
sg52649
I2
sa(dp54637
g52643
I132
sg52644
VDNA adduct formation
p54638
sg52646
I20
sg52647
VC1511660
p54639
sg52649
I3
sasa(dp54640
g135
(dp54641
(VJNK
p54642
Voxidative stress
p54643
tp54644
I00
ssg52636
VIn this study we have explored the involvement of oxidative stress in Cr(VI)-induced JNK, p38 and ERK signaling pathways and their effects on Cr(VI) cytotoxicity in human non-small cell lung carcinoma CL3 cells.
p54645
sg52638
(lp54646
(dp54647
g52643
I90
sg52644
Vp38
p54648
sg52646
I3
sg52674
VP46108
p54649
sg52649
I1
sa(dp54650
g52643
I98
sg52644
VERK
p54651
sg52646
I3
sg52674
VP29323
p54652
sg52649
I1
sa(dp54653
g52643
I85
sg52644
g54642
sg52646
I3
sg52674
VP53779
p54654
sg52649
I1
sasg52640
(lp54655
(dp54656
g52643
I171
sg52644
Vnon-small cell lung carcinoma
p54657
sg52646
I29
sg52647
VC0007131
p54658
sg52649
I4
sa(dp54659
g52643
I149
sg52644
Vcytotoxicity
p54660
sg52646
I12
sg52647
VC0596402
p54661
sg52649
I1
sa(dp54662
g52643
I50
sg52644
g54643
sg52646
I16
sg52647
VC0242606
p54663
sg52649
I2
sasa(dp54664
g52636
VThe expression pattern of mucin genes was studied in 7 lung adenocarcinoma cell lines (CL1, CL2, CL3, NCL2, PC9, PC13, PC14) and 12 lung adenocarcinoma tissues.
p54665
sg52638
(lp54666
(dp54667
g52643
I102
sg52644
VNCL2
p54668
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp54669
g52643
I92
sg52644
VCL2
p54670
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp54671
g52643
I108
sg52644
VPC9
p54672
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp54673
g52643
I26
sg52644
Vmucin genes
p54674
sg52646
I11
sg52674
g12
sg52649
I2
sa(dp54675
g52643
I87
sg52644
VCL1
p54676
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp54677
(dp54678
g52643
I55
sg52644
Vlung adenocarcinoma
p54679
sg52646
I19
sg52647
VC0152013
p54680
sg52649
I2
sa(dp54681
g52643
I55
sg52644
Vlung adenocarcinoma
p54682
sg52646
I19
sg52647
VC0152013
p54683
sg52649
I2
sasa(dp54684
g52636
VOsteogenesis imperfecta model, oim(-/-) , mice have a defect in the collagen, which leads to brittle bone; PHOSPHO1 mutants, Phospho1(-/-) , have ductile bone resulting from altered mineralization.
p54685
sg52638
(lp54686
(dp54687
g52643
I107
sg52644
VPHOSPHO1 mutants
p54688
sg52646
I16
sg52674
g12
sg52649
I2
sasg52640
(lp54689
(dp54690
g52643
I0
sg52644
VOsteogenesis imperfecta
p54691
sg52646
I23
sg52647
VC0029434
p54692
sg52649
I2
sasa(dp54693
g52636
VBecause two mammalian isoforms of iPLA2 (iPLA2beta and iPLA2gamma) have been cloned and characterized, the aim of this study was to identify the specific isoform(s) in macrophages that regulates the expression of iNOS in response to virus infection.
p54694
sg52638
(lp54695
(dp54696
g52643
I34
sg52644
ViPLA2
p54697
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54698
g52643
I55
sg52644
ViPLA2gamma
p54699
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp54700
g52643
I41
sg52644
ViPLA2beta
p54701
sg52646
I9
sg52674
g12
sg52649
I1
sasg52640
(lp54702
(dp54703
g52643
I233
sg52644
Vvirus infection
p54704
sg52646
I15
sg52647
VC0042769
p54705
sg52649
I2
sasa(dp54706
g135
(dp54707
(VCREB
p54708
Vvirus infection
p54709
tp54710
I01
ssg52636
VcAMP response element-binding protein (CREB) is one downstream target of iPLA2 that is required for the transcriptional activation of iNOS in response to virus infection, and consistent with the effects of BEL enantiomers on iNOS expression, (S)-BEL more effectively inhibits EMCV-induced CREB phosphorylation than (R)-BEL in macrophages.
p54711
sg52638
(lp54712
(dp54713
g52643
I73
sg52644
ViPLA2
p54714
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54715
g52643
I0
sg52644
VcAMP response element-binding protein
p54716
sg52646
I37
sg52674
g12
sg52649
I4
sa(dp54717
g52643
I39
sg52644
VCREB
p54718
sg52646
I4
sg52674
VP16220
p54719
sg52649
I1
sa(dp54720
g52643
I39
sg52644
g54708
sg52646
I4
sg52674
VP16220
p54721
sg52649
I1
sa(dp54722
g52643
I134
sg52644
ViNOS
p54723
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp54724
(dp54725
g52643
I154
sg52644
g54709
sg52646
I15
sg52647
VC0042769
p54726
sg52649
I2
sasa(dp54727
g52636
VUsing macrophages isolated from iPLA2beta-null mice, virus infection fails to stimulate iNOS mRNA accumulation and protein expression, thus providing genetic evidence that iPLA2beta is required for EMCV-induced iNOS expression.
p54728
sg52638
(lp54729
(dp54730
g52643
I88
sg52644
ViNOS mRNA
p54731
sg52646
I9
sg52674
g12
sg52649
I2
sa(dp54732
g52643
I88
sg52644
ViNOS
p54733
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp54734
g52643
I32
sg52644
ViPLA2beta
p54735
sg52646
I9
sg52674
g12
sg52649
I1
sa(dp54736
g52643
I32
sg52644
ViPLA2beta
p54737
sg52646
I9
sg52674
g12
sg52649
I1
sasg52640
(lp54738
(dp54739
g52643
I53
sg52644
Vvirus infection
p54740
sg52646
I15
sg52647
VC0042769
p54741
sg52649
I2
sasa(dp54742
g135
(dp54743
(VMAPK
p54744
Vvirus infection
p54745
tp54746
I00
ssg52636
VSpecific attention will be placed on the ability of virus infection to activate multiple signaling cascades (such as PKR, MAPK, iPLA2, NF-kappaB) and how these pathways are integrated in the regulation of individual target gene expression.
p54747
sg52638
(lp54748
(dp54749
g52643
I135
sg52644
VNF-kappaB
p54750
sg52646
I9
sg52674
VP19838
p54751
sg52649
I1
sa(dp54752
g52643
I117
sg52644
VPKR
p54753
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp54754
g52643
I122
sg52644
g54744
sg52646
I4
sg52674
VP53779
p54755
sg52649
I1
sa(dp54756
g52643
I128
sg52644
ViPLA2
p54757
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54758
(dp54759
g52643
I52
sg52644
g54745
sg52646
I15
sg52647
VC0042769
p54760
sg52649
I2
sasa(dp54761
g52636
VIn comparison with PRCC1, PRCC2 cases showed upregulated expression of Alfa5-integrin (ITGA5) whereas the expression of Alfa6- (ITGA6) and Beta8-integrins (ITGB8) was downregulated.
p54762
sg52638
(lp54763
(dp54764
g52643
I87
sg52644
VITGA5
p54765
sg52646
I5
sg52674
VP08648
p54766
sg52649
I1
sa(dp54767
g52643
I156
sg52644
VITGB8
p54768
sg52646
I5
sg52674
VP26012
p54769
sg52649
I1
sasg52640
(lp54770
sa(dp54771
g135
(dp54772
(VUcp1 mRNA
p54773
Vobesity
p54774
tp54775
I00
ssg52636
VHFD-fed mice lacking Cnot7 and Tob express elevated levels of Ucp1 mRNA in iWAT and are resistant to diet-induced obesity.
p54776
sg52638
(lp54777
(dp54778
g52643
I31
sg52644
VTob
p54779
sg52646
I3
sg52674
VP50616
p54780
sg52649
I1
sa(dp54781
g52643
I21
sg52644
VCnot7
p54782
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp54783
g52643
I62
sg52644
g54773
sg52646
I9
sg52674
VP25874
p54784
sg52649
I2
sasg52640
(lp54785
(dp54786
g52643
I114
sg52644
g54774
sg52646
I7
sg52647
VC0028754
p54787
sg52649
I1
sasa(dp54788
g135
(dp54789
(VTob
p54790
Vobesity
p54791
tp54792
I00
ssg52636
VThus, the Cnot7-Tob-BRF1 axis inhibits Ucp1 expression and contributes to obesity.
p54793
sg52638
(lp54794
(dp54795
g52643
I39
sg52644
VUcp1
p54796
sg52646
I4
sg52674
VP25874
p54797
sg52649
I1
sa(dp54798
g52643
I20
sg52644
VBRF1
p54799
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp54800
g52643
I16
sg52644
g54790
sg52646
I3
sg52674
VP50616
p54801
sg52649
I1
sa(dp54802
g52643
I10
sg52644
VCnot7
p54803
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54804
(dp54805
g52643
I74
sg52644
g54791
sg52646
I7
sg52647
VC0028754
p54806
sg52649
I1
sasa(dp54807
g52636
VSince abnormal and unbalanced JAK/STAT activation is associated with immune disorders and cancer, hCAF1 could play a major role in innate immunity and oncogenesis, contributing to tumour escape.
p54808
sg52638
(lp54809
(dp54810
g52643
I34
sg52644
VSTAT
p54811
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp54812
g52643
I98
sg52644
VhCAF1
p54813
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp54814
(dp54815
g52643
I180
sg52644
Vtumour
p54816
sg52646
I6
sg52647
VC0027651
p54817
sg52649
I1
sa(dp54818
g52643
I69
sg52644
Vimmune disorders
p54819
sg52646
I16
sg52647
VC0021053
p54820
sg52649
I2
sa(dp54821
g52643
I151
sg52644
Voncogenesis
p54822
sg52646
I11
sg52647
VC0007621
p54823
sg52649
I1
sa(dp54824
g52643
I90
sg52644
Vcancer
p54825
sg52646
I6
sg52647
VC0006826
p54826
sg52649
I1
sasa(dp54827
g52636
VOur previous study (Nakamura et al., 2004) showed that deletion of the Cnot7 gene in mice caused almost no abnormal phenotypes except for male infertility, due to oligo-astheno-teratozoospermia.
p54828
sg52638
(lp54829
(dp54830
g52643
I71
sg52644
VCnot7 gene
p54831
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp54832
(dp54833
g52643
I138
sg52644
Vmale infertility
p54834
sg52646
I16
sg52647
VC0021364
p54835
sg52649
I2
sasa(dp54836
g52636
VMutations in the gene encoding the neural cell adhesion molecule L1CAM cause several neurological disorders collectively referred to as L1 syndrome.
p54837
sg52638
(lp54838
(dp54839
g52643
I35
sg52644
Vneural cell adhesion molecule L1CAM
p54840
sg52646
I35
sg52674
g12
sg52649
I5
sasg52640
(lp54841
(dp54842
g52643
I85
sg52644
Vneurological disorders
p54843
sg52646
I22
sg52647
VC0027765
p54844
sg52649
I2
sa(dp54845
g52643
I139
sg52644
Vsyndrome
p54846
sg52646
I8
sg52647
VC0039082
p54847
sg52649
I1
sa(dp54848
g52643
I47
sg52644
Vadhesion
p54849
sg52646
I8
sg52647
VC0001511
p54850
sg52649
I1
sasa(dp54851
g52636
VA 59-year-old woman receiving methotrexate and tacrolimus for rheumatoid arthritis (RA) was referred to our hospital following bilateral ground-glass opacity observed in her chest X-ray and elevated serum KL-6.
p54852
sg52638
(lp54853
(dp54854
g52643
I199
sg52644
Vserum KL-6
p54855
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp54856
(dp54857
g52643
I84
sg52644
VRA
p54858
sg52646
I2
sg52647
VC0003873
p54859
sg52649
I1
sa(dp54860
g52643
I150
sg52644
Vopacity
p54861
sg52646
I7
sg52647
VC1265876
p54862
sg52649
I1
sa(dp54863
g52643
I62
sg52644
Vrheumatoid arthritis
p54864
sg52646
I20
sg52647
VC0003873
p54865
sg52649
I2
sasa(dp54866
g52636
VDuring treatment of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) with prednisolone, chest image findings improved in association with decreased KL-6 levels.
p54867
sg52638
(lp54868
sg52640
(lp54869
(dp54870
g52643
I57
sg52644
Vinterstitial lung disease
p54871
sg52646
I25
sg52647
VC0206062
p54872
sg52649
I3
sa(dp54873
g52643
I20
sg52644
Vrheumatoid arthritis
p54874
sg52646
I20
sg52647
VC0003873
p54875
sg52649
I2
sa(dp54876
g52643
I42
sg52644
VRA
p54877
sg52646
I2
sg52647
VC0003873
p54878
sg52649
I1
sa(dp54879
g52643
I84
sg52644
VILD
p54880
sg52646
I3
sg52647
VC0206062
p54881
sg52649
I1
sasa(dp54882
g135
(dp54883
(VMBP
p54884
Vnodules
p54885
tp54886
I00
ssg52636
VThe results showed that treatment with the MUC1-MBP/BCG anti-tumor vaccine did not cause any organ toxicity, except for arthritis or local nodules induced by BCG in several rats.
p54887
sg52638
(lp54888
(dp54889
g52643
I48
sg52644
g54884
sg52646
I3
sg52674
VP13727
p54890
sg52649
I1
sasg52640
(lp54891
(dp54892
g52643
I120
sg52644
Varthritis
p54893
sg52646
I9
sg52647
VC0003864
p54894
sg52649
I1
sa(dp54895
g52643
I139
sg52644
g54885
sg52646
I7
sg52647
VC0028259
p54896
sg52649
I1
sa(dp54897
g52643
I61
sg52644
Vtumor
p54898
sg52646
I5
sg52647
VC0027651
p54899
sg52649
I1
sasa(dp54900
g135
(dp54901
(Vleptin
p54902
Vpolycystic ovary syndrome
p54903
tp54904
I00
ssg52636
VTo investigate leptin, adiponectin, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) levels and their relationship with each other and metabolic parameters in women with polycystic ovary syndrome (PCOS).
p54905
sg52638
(lp54906
(dp54907
g52643
I23
sg52644
Vadiponectin
p54908
sg52646
I11
sg52674
g12
sg52649
I1
sa(dp54909
g52643
I97
sg52644
Vvascular cell adhesion molecule-1
p54910
sg52646
I33
sg52674
VP19320
p54911
sg52649
I4
sa(dp54912
g52643
I79
sg52644
VsICAM-1
p54913
sg52646
I7
sg52674
VP05362
p54914
sg52649
I1
sa(dp54915
g52643
I36
sg52644
Vsoluble intercellular adhesion molecule-1
p54916
sg52646
I41
sg52674
VP05362
p54917
sg52649
I4
sa(dp54918
g52643
I15
sg52644
g54902
sg52646
I6
sg52674
VP41159
p54919
sg52649
I1
sasg52640
(lp54920
(dp54921
g52643
I253
sg52644
VPCOS
p54922
sg52646
I4
sg52647
VC0032460
p54923
sg52649
I1
sa(dp54924
g52643
I58
sg52644
Vadhesion
p54925
sg52646
I8
sg52647
VC0001511
p54926
sg52649
I1
sa(dp54927
g52643
I58
sg52644
Vadhesion
p54928
sg52646
I8
sg52647
VC0001511
p54929
sg52649
I1
sa(dp54930
g52643
I226
sg52644
g54903
sg52646
I25
sg52647
VC0032460
p54931
sg52649
I3
sasa(dp54932
g135
(dp54933
(Vinsulin
p54934
VPCOS
p54935
tp54936
I00
ssg52636
VNon-insulin resistant PCOS had significantly higher adiponectin and sVCAM-1 levels.
p54937
sg52638
(lp54938
(dp54939
g52643
I4
sg52644
g54934
sg52646
I7
sg52674
VP01308
p54940
sg52649
I1
sa(dp54941
g52643
I52
sg52644
Vadiponectin
p54942
sg52646
I11
sg52674
g12
sg52649
I1
sasg52640
(lp54943
(dp54944
g52643
I22
sg52644
g54935
sg52646
I4
sg52647
VC0032460
p54945
sg52649
I1
sasa(dp54946
g135
(dp54947
(VE-selectin
p54948
VPCOS
p54949
tp54950
I00
ssg52636
VIncreases in IL-6 and TNF-Alfa and adhesion molecules (E-selectin, ICAM-1 and VCAM-1) were also observed, particularly in the PCOS IR group, providing evidence that inflammation and oxidative stress are related in PCOS patients.
p54951
sg52638
(lp54952
(dp54953
g52643
I22
sg52644
VTNF-Alfa and adhesion molecules
p54954
sg52646
I31
sg52674
VP01375
p54955
sg52649
I4
sa(dp54956
g52643
I78
sg52644
VVCAM-1
p54957
sg52646
I6
sg52674
VP19320
p54958
sg52649
I1
sa(dp54959
g52643
I67
sg52644
VICAM-1
p54960
sg52646
I6
sg52674
VP05362
p54961
sg52649
I1
sa(dp54962
g52643
I13
sg52644
VIL-6
p54963
sg52646
I4
sg52674
VP05231
p54964
sg52649
I1
sa(dp54965
g52643
I55
sg52644
g54948
sg52646
I10
sg52674
VP16581
p54966
sg52649
I1
sasg52640
(lp54967
(dp54968
g52643
I182
sg52644
Voxidative stress
p54969
sg52646
I16
sg52647
VC0242606
p54970
sg52649
I2
sa(dp54971
g52643
I126
sg52644
VPCOS
p54972
sg52646
I4
sg52647
VC0032460
p54973
sg52649
I1
sa(dp54974
g52643
I165
sg52644
Vinflammation
p54975
sg52646
I12
sg52647
VC0021368
p54976
sg52649
I1
sa(dp54977
g52643
I35
sg52644
Vadhesion
p54978
sg52646
I8
sg52647
VC0001511
p54979
sg52649
I1
sa(dp54980
g52643
I126
sg52644
g54949
sg52646
I4
sg52647
VC0032460
p54981
sg52649
I1
sasa(dp54982
g135
(dp54983
(VVCAM-1
p54984
VPCOS
p54985
tp54986
I01
ssg52636
VInflammation in PCOS induces leukocyte-endothelium interactions and a simultaneous increase in IL-6, TNF-Alfa, E-selectin, ICAM-1 and VCAM-1.
p54987
sg52638
(lp54988
(dp54989
g52643
I123
sg52644
VICAM-1
p54990
sg52646
I6
sg52674
VP05362
p54991
sg52649
I1
sa(dp54992
g52643
I95
sg52644
VIL-6
p54993
sg52646
I4
sg52674
VP05231
p54994
sg52649
I1
sa(dp54995
g52643
I101
sg52644
VTNF-Alfa
p54996
sg52646
I8
sg52674
VP01375
p54997
sg52649
I1
sa(dp54998
g52643
I111
sg52644
VE-selectin
p54999
sg52646
I10
sg52674
VP16581
p55000
sg52649
I1
sa(dp55001
g52643
I134
sg52644
g54984
sg52646
I6
sg52674
VP19320
p55002
sg52649
I1
sasg52640
(lp55003
(dp55004
g52643
I0
sg52644
VInflammation
p55005
sg52646
I12
sg52647
VC0021368
p55006
sg52649
I1
sa(dp55007
g52643
I16
sg52644
g54985
sg52646
I4
sg52647
VC0032460
p55008
sg52649
I1
sasa(dp55009
g135
(dp55010
(Vc-Myc
p55011
Vchondrosarcoma
p55012
tp55013
I00
ssg52636
VIn conclusion, we disclosed a novel mechanism that JQ1 inhibits cell proliferation, induces cell senescence and apoptosis of chondrosarcoma cells through the regulation of the YAP/p21/c-Myc/Bcl-xL signaling axis.
p55014
sg52638
(lp55015
(dp55016
g52643
I190
sg52644
VBcl-xL
p55017
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55018
g52643
I176
sg52644
VYAP
p55019
sg52646
I3
sg52674
VP46937
p55020
sg52649
I1
sa(dp55021
g52643
I180
sg52644
Vp21
p55022
sg52646
I3
sg52674
VP42857
p55023
sg52649
I1
sa(dp55024
g52643
I184
sg52644
g55011
sg52646
I5
sg52674
VP12524
p55025
sg52649
I1
sasg52640
(lp55026
(dp55027
g52643
I125
sg52644
g55012
sg52646
I14
sg52647
VC0008479
p55028
sg52649
I1
sa(dp55029
g52643
I69
sg52644
Vproliferation
p55030
sg52646
I13
sg52647
VC0334094
p55031
sg52649
I1
sasa(dp55032
g135
(dp55033
(VBcl2
p55034
VB-cell lymphoma
p55035
tp55036
I00
ssg52636
VBH-3 mimetics ABT-737 and ABT-263 are synthetic small-molecule inhibitors of anti-apoptotic proteins B-cell lymphoma-2 (Bcl2) and Bcl-xL, which play a critical role in survival of chondrosarcoma cells.
p55037
sg52638
(lp55038
(dp55039
g52643
I120
sg52644
g55034
sg52646
I4
sg52674
VP10415
p55040
sg52649
I1
sa(dp55041
g52643
I77
sg52644
Vanti-apoptotic proteins B-cell lymphoma-2
p55042
sg52646
I41
sg52674
g12
sg52649
I4
sa(dp55043
g52643
I130
sg52644
VBcl-xL
p55044
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp55045
(dp55046
g52643
I180
sg52644
Vchondrosarcoma
p55047
sg52646
I14
sg52647
VC0008479
p55048
sg52649
I1
sa(dp55049
g52643
I101
sg52644
g55035
sg52646
I15
sg52647
VC0079731
p55050
sg52649
I2
sasa(dp55051
g135
(dp55052
(VGli1
p55053
VIHh
p55054
tp55055
I00
ssg52636
VHere we show that the IHh signal pathway was activated in chondrosarcoma, and knocking down the expression of Gli1 attenuated the disturbed IHh signal pathway, which not only suppressed cell proliferation and promoted G2/M cell cycle arrest but also enhanced cell apoptosis by downregulating Bcl-2 and Bcl-xl expression.
p55056
sg52638
(lp55057
(dp55058
g52643
I292
sg52644
VBcl-2
p55059
sg52646
I5
sg52674
VP10415
p55060
sg52649
I1
sa(dp55061
g52643
I22
sg52644
VIHh
p55062
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp55063
g52643
I110
sg52644
g55053
sg52646
I4
sg52674
VP08151
p55064
sg52649
I1
sa(dp55065
g52643
I302
sg52644
VBcl-xl
p55066
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp55067
(dp55068
g52643
I191
sg52644
Vproliferation
p55069
sg52646
I13
sg52647
VC0334094
p55070
sg52649
I1
sa(dp55071
g52643
I22
sg52644
VIHh
p55072
sg52646
I3
sg52647
VC0342384
p55073
sg52649
I1
sa(dp55074
g52643
I58
sg52644
Vchondrosarcoma
p55075
sg52646
I14
sg52647
VC0008479
p55076
sg52649
I1
sa(dp55077
g52643
I22
sg52644
g55054
sg52646
I3
sg52647
VC0342384
p55078
sg52649
I1
sasa(dp55079
g135
(dp55080
(VBcl-2
p55081
Vconventional chondrosarcoma
p55082
tp55083
I00
ssg52636
VAs in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and/or Bcl-xl) were highly expressed in all subtypes.
p55084
sg52638
(lp55085
(dp55086
g52643
I73
sg52644
VBcl-xl
p55087
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55088
g52643
I59
sg52644
g55081
sg52646
I5
sg52674
VP10415
p55089
sg52649
I1
sasg52640
(lp55090
(dp55091
g52643
I6
sg52644
g55082
sg52646
I27
sg52647
VC1335473
p55092
sg52649
I2
sasa(dp55093
g135
(dp55094
(VBid
p55095
Vchondrosarcoma
p55096
tp55097
I00
ssg52636
VBPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p55098
sg52638
(lp55099
(dp55100
g52643
I64
sg52644
VBcl-2
p55101
sg52646
I5
sg52674
VP10415
p55102
sg52649
I1
sa(dp55103
g52643
I71
sg52644
g55095
sg52646
I3
sg52674
VP55957
p55104
sg52649
I1
sa(dp55105
g52643
I79
sg52644
VBcl-XL
p55106
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55107
g52643
I41
sg52644
VBak
p55108
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp55109
g52643
I33
sg52644
VBad
p55110
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp55111
(dp55112
g52643
I121
sg52644
g55096
sg52646
I14
sg52647
VC0008479
p55113
sg52649
I1
sasa(dp55114
g135
(dp55115
(VBcl-2
p55116
Vchondrosarcoma
p55117
tp55118
I00
ssg52636
VEGCG induced upregulation of Bax and Bak, downregulation of Bcl-2 and Bcl-XL, and dysfunction of mitochondria in chondrosarcoma.
p55119
sg52638
(lp55120
(dp55121
g52643
I70
sg52644
VBcl-XL
p55122
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55123
g52643
I37
sg52644
VBak
p55124
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp55125
g52643
I60
sg52644
g55116
sg52646
I5
sg52674
VP10415
p55126
sg52649
I1
sasg52640
(lp55127
(dp55128
g52643
I113
sg52644
g55117
sg52646
I14
sg52647
VC0008479
p55129
sg52649
I1
sasa(dp55130
g135
(dp55131
(VFPTB
p55132
Vchondrosarcoma
p55133
tp55134
I00
ssg52636
VFPTB induced up-regulation of Bax and Bak, down-regulation of Bcl-2 and Bcl-XL and dysfunction of mitochondria in chondrosarcoma.
p55135
sg52638
(lp55136
(dp55137
g52643
I72
sg52644
VBcl-XL
p55138
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55139
g52643
I62
sg52644
VBcl-2
p55140
sg52646
I5
sg52674
VP10415
p55141
sg52649
I1
sa(dp55142
g52643
I38
sg52644
VBak
p55143
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp55144
g52643
I0
sg52644
g55132
sg52646
I4
sg52674
VP49356
p55145
sg52649
I1
sasg52640
(lp55146
(dp55147
g52643
I114
sg52644
g55133
sg52646
I14
sg52647
VC0008479
p55148
sg52649
I1
sasa(dp55149
g52636
VThis study aims to investigate the expression patterns of HIF-1Alfa in chondrosarcoma, and its association with clinicopathologic features, Bcl-xL expression, apoptosis index (AI), and overall survival of patients with chondrosarcoma.
p55150
sg52638
(lp55151
(dp55152
g52643
I140
sg52644
VBcl-xL
p55153
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp55154
(dp55155
g52643
I71
sg52644
Vchondrosarcoma
p55156
sg52646
I14
sg52647
VC0008479
p55157
sg52649
I1
sa(dp55158
g52643
I71
sg52644
Vchondrosarcoma
p55159
sg52646
I14
sg52647
VC0008479
p55160
sg52649
I1
sasa(dp55161
g52636
VIn eight patients with chondrosarcoma, increased expression of HIF-1Alfa and Bcl-xL was detected in chondrosarcoma tissues compared with the paired adjacent normal tissues.
p55162
sg52638
(lp55163
(dp55164
g52643
I77
sg52644
VBcl-xL
p55165
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp55166
(dp55167
g52643
I23
sg52644
Vchondrosarcoma
p55168
sg52646
I14
sg52647
VC0008479
p55169
sg52649
I1
sa(dp55170
g52643
I23
sg52644
Vchondrosarcoma
p55171
sg52646
I14
sg52647
VC0008479
p55172
sg52649
I1
sasa(dp55173
g52636
VThese findings suggest that increased HIF-1Alfa levels mediated up-regulation of Bcl-xL play a prominent role in evasion of apoptosis and tumor progression, and can be predictive for the prognosis in human chondrosarcoma.
p55174
sg52638
(lp55175
(dp55176
g52643
I81
sg52644
VBcl-xL
p55177
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp55178
(dp55179
g52643
I138
sg52644
Vtumor progression
p55180
sg52646
I17
sg52647
VC0178874
p55181
sg52649
I2
sa(dp55182
g52643
I206
sg52644
Vchondrosarcoma
p55183
sg52646
I14
sg52647
VC0008479
p55184
sg52649
I1
sasa(dp55185
g135
(dp55186
(Vinsulin
p55187
Vtype 2 diabetes
p55188
tp55189
I00
ssg52636
VThree-dimensional speckle tracking echocardiography (3D-STE) was used to evaluate the improvement of continuous subcutaneous insulin infusion on the left ventricular (LV) systolic function of patients with type 2 diabetes mellitu (T2DM).
p55190
sg52638
(lp55191
(dp55192
g52643
I125
sg52644
g55187
sg52646
I7
sg52674
VP01308
p55193
sg52649
I1
sasg52640
(lp55194
(dp55195
g52643
I206
sg52644
g55188
sg52646
I15
sg52647
VC0011860
p55196
sg52649
I3
sasa(dp55197
g52636
VTo elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (MI) and concomitant diabetes mellitus (DM).
p55198
sg52638
(lp55199
sg52640
(lp55200
(dp55201
g52643
I230
sg52644
VDM
p55202
sg52646
I2
sg52647
VC0011849
p55203
sg52649
I1
sa(dp55204
g52643
I211
sg52644
Vdiabetes mellitus
p55205
sg52646
I17
sg52647
VC0011849
p55206
sg52649
I2
sa(dp55207
g52643
I168
sg52644
Vmyocardial infarction
p55208
sg52646
I21
sg52647
VC0027051
p55209
sg52649
I2
sa(dp55210
g52643
I191
sg52644
VMI
p55211
sg52646
I2
sg52647
VC0027051
p55212
sg52649
I1
sasa(dp55213
g52636
VMultivariate regression analysis showed that GPLS and diabetes mellitus were independent predictors for complex NSTE-ACS.
p55214
sg52638
(lp55215
(dp55216
g52643
I112
sg52644
VNSTE-ACS
p55217
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp55218
(dp55219
g52643
I54
sg52644
Vdiabetes mellitus
p55220
sg52646
I17
sg52647
VC0011849
p55221
sg52649
I2
sasa(dp55222
g52636
VNo differences were observed between the two groups in baseline characteristics; except AS-STEMI group had more patients with diabetes and EA-STEMI group had more patients with family history of coronary artery disease.
p55223
sg52638
(lp55224
sg52640
(lp55225
(dp55226
g52643
I195
sg52644
Vcoronary artery disease
p55227
sg52646
I23
sg52647
VC1956346
p55228
sg52649
I3
sa(dp55229
g52643
I91
sg52644
VSTEMI
p55230
sg52646
I5
sg52647
VC1536220
p55231
sg52649
I1
sa(dp55232
g52643
I126
sg52644
Vdiabetes
p55233
sg52646
I8
sg52647
VC0011849
p55234
sg52649
I1
sa(dp55235
g52643
I91
sg52644
VSTEMI
p55236
sg52646
I5
sg52647
VC1536220
p55237
sg52649
I1
sasa(dp55238
g52636
VTo elucidate association of renal dysfunction (RD) with unfavorable outcomes of in-hospital and long-term (1 year) treatment stages of patients with ST-elevation (STE) myocardial infarction (M) and concomitant diabetes mellitus (DM).
p55239
sg52638
(lp55240
sg52640
(lp55241
(dp55242
g52643
I229
sg52644
VDM
p55243
sg52646
I2
sg52647
VC0011849
p55244
sg52649
I1
sa(dp55245
g52643
I210
sg52644
Vdiabetes mellitus
p55246
sg52646
I17
sg52647
VC0011849
p55247
sg52649
I2
sa(dp55248
g52643
I168
sg52644
Vmyocardial infarction
p55249
sg52646
I21
sg52647
VC0027051
p55250
sg52649
I2
sasa(dp55251
g52636
VIncidence of complicated diabetes (P &lt; 0.05), pre-PCI Killip &gt;= II (55.9% (19/34) vs. 26.8% (15/56), P &lt; 0.05) and multivessel disease (70.6% (24/34) vs. 35.7% (20/56), P &lt; 0.05) were significantly higher in group D than in group C. TIMI 3 and the opening time of IRA was similar between group A and group B and between group C and group D. The incidence of in-hospital MACE was significantly higher in group B than in group A (14.4% (13/90) vs. 3.0% (4/135), P &lt; 0.05) which was similar between group C and group D. Early (1 hour) but not late (24 hours) ST resolution post PCI is related to a favorable clinical outcome in STEMI patients.
p55252
sg52638
(lp55253
sg52640
(lp55254
(dp55255
g52643
I640
sg52644
VSTEMI
p55256
sg52646
I5
sg52647
VC1536220
p55257
sg52649
I1
sa(dp55258
g52643
I312
sg52644
Vgroup B
p55259
sg52646
I7
sg52647
VC0348801
p55260
sg52649
I2
sa(dp55261
g52643
I25
sg52644
Vdiabetes
p55262
sg52646
I8
sg52647
VC0011849
p55263
sg52649
I1
sa(dp55264
g52643
I312
sg52644
Vgroup B
p55265
sg52646
I7
sg52647
VC0348801
p55266
sg52649
I2
sasa(dp55267
g52636
VImmunohistochemistry (IHC) and Western blotting were performed to evaluate SOX4 expression between OLP and OLP-OSCC tissues and among oral cancer cell lines and normal human oral keratinocytes (NHOKs).
p55268
sg52638
(lp55269
(dp55270
g52643
I75
sg52644
VSOX4
p55271
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55272
(dp55273
g52643
I134
sg52644
Voral cancer
p55274
sg52646
I11
sg52647
VC0153381
p55275
sg52649
I2
sasa(dp55276
g52636
VLC-MS/MS analysis showed that 88 proteins including SOX4 were only identified in OLP-OSCC FFPE tissues when compared to OLP FFPE tissues.
p55277
sg52638
(lp55278
(dp55279
g52643
I52
sg52644
VSOX4
p55280
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55281
sa(dp55282
g52636
VIHC confirmed that SOX4 expression was significantly higher in OLP-OSCC than OLP and Western blot analysis indicated that SOX4 was over-expressed in UM1/UM2 cells when compared to NHOKs.
p55283
sg52638
(lp55284
(dp55285
g52643
I19
sg52644
VSOX4
p55286
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp55287
g52643
I19
sg52644
VSOX4
p55288
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55289
sa(dp55290
g52636
VOur study indicated that SOX4 is significantly upregulated in OLP-OSCC versus OLP tissues.
p55291
sg52638
(lp55292
(dp55293
g52643
I25
sg52644
VSOX4
p55294
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55295
sa(dp55296
g52636
VThese findings suggest that SOX4 might be actively involved in the progression of OLP to OSCC.
p55297
sg52638
(lp55298
(dp55299
g52643
I28
sg52644
VSOX4
p55300
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55301
sa(dp55302
g52636
VThis study evaluated whether SOX4 affects oncogenic behavior and chemoradiotherapy response in head and neck squamous cell carcinoma (HNSCC) cells, and documented the relationship between its expression and prognosis in oral squamous cell carcinoma (OSCC).
p55303
sg52638
(lp55304
(dp55305
g52643
I29
sg52644
VSOX4
p55306
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55307
(dp55308
g52643
I95
sg52644
Vhead and neck squamous cell carcinoma
p55309
sg52646
I37
sg52647
VC1168401
p55310
sg52649
I6
sa(dp55311
g52643
I109
sg52644
Vsquamous cell carcinoma
p55312
sg52646
I23
sg52647
VC0007137
p55313
sg52649
I3
sa(dp55314
g52643
I134
sg52644
VHNSCC
p55315
sg52646
I5
sg52647
VC1168401
p55316
sg52649
I1
sasa(dp55317
g52636
VSOX4 expression in OSCC tissues was investigated by immunohistochemistry.
p55318
sg52638
(lp55319
(dp55320
g52643
I0
sg52644
VSOX4
p55321
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55322
sa(dp55323
g52636
VImmunostaining showed SOX4 protein was significantly increased in OSCC tissues compared with adjacent normal mucosa.
p55324
sg52638
(lp55325
(dp55326
g52643
I22
sg52644
VSOX4 protein
p55327
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp55328
sa(dp55329
g52636
VSOX4 expression was observed in 51.8 % of 85 OSCC tissues, and was significantly correlated with treatment failure (P = 0.032) and shorter overall survival (P = 0.036) in patients with OSCC.
p55330
sg52638
(lp55331
(dp55332
g52643
I0
sg52644
VSOX4
p55333
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55334
sa(dp55335
g52636
VThis study was the first to investigate correlations between SOX4 expression levels and the clinicopathologic factors of oral squamous cell carcinoma (OSCC).
p55336
sg52638
(lp55337
(dp55338
g52643
I61
sg52644
VSOX4
p55339
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55340
(dp55341
g52643
I126
sg52644
Vsquamous cell carcinoma
p55342
sg52646
I23
sg52647
VC0007137
p55343
sg52649
I3
sasa(dp55344
g52636
VWe analyzed SOX4 expression levels in 50 patients with OSCC using immunohistochemistry.
p55345
sg52638
(lp55346
(dp55347
g52643
I12
sg52644
VSOX4
p55348
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55349
sa(dp55350
g52636
VThe expression level of SOX4 in primary foci of poorly differentiated OSCC was higher than that of well differentiated OSCC, which indicated that SOX4 expression is associated with the differentiation of OSCC.
p55351
sg52638
(lp55352
(dp55353
g52643
I24
sg52644
VSOX4
p55354
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp55355
g52643
I24
sg52644
VSOX4
p55356
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55357
sa(dp55358
g52636
VThese results indicate that undifferentiated OSCC cells expressing SOX4 are more likely to metastasize and neoadjuvant therapy including chemoradiation therapy may have some effect in metastatic prevention.
p55359
sg52638
(lp55360
(dp55361
g52643
I67
sg52644
VSOX4
p55362
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55363
(dp55364
g52643
I91
sg52644
Vmetastasize
p55365
sg52646
I11
sg52647
VC0027627
p55366
sg52649
I1
sasa(dp55367
g52636
VCryptorchidism was significantly associated with development of MGCSCTs, SCTs, and SEMs, but not ICTs (p&lt;0.01).
p55368
sg52638
(lp55369
sg52640
(lp55370
(dp55371
g52643
I0
sg52644
VCryptorchidism
p55372
sg52646
I14
sg52647
VC0010417
p55373
sg52649
I1
sa(dp55374
g52643
I67
sg52644
VSCTs
p55375
sg52646
I4
sg52647
VC0796149
p55376
sg52649
I1
sasa(dp55377
g135
(dp55378
(VNGF
p55379
Vleprosy
p55380
tp55381
I00
ssg52636
VSince nerve functions are affected by inflammatory response during the course of leprosy, changes in the production of NGF and its receptor (NGF R) may be directly associated with disability and sensory loss.
p55382
sg52638
(lp55383
(dp55384
g52643
I119
sg52644
VNGF
p55385
sg52646
I3
sg52674
VP01138
p55386
sg52649
I1
sa(dp55387
g52643
I119
sg52644
g55379
sg52646
I3
sg52674
VP01138
p55388
sg52649
I1
sasg52640
(lp55389
(dp55390
g52643
I38
sg52644
Vinflammatory response
p55391
sg52646
I21
sg52647
VC1155266
p55392
sg52649
I2
sa(dp55393
g52643
I195
sg52644
Vsensory loss
p55394
sg52646
I12
sg52647
VC0278134
p55395
sg52649
I2
sa(dp55396
g52643
I81
sg52644
g55380
sg52646
I7
sg52647
VC0023343
p55397
sg52649
I1
sasa(dp55398
g135
(dp55399
(VNGFR
p55400
Vtuberculoid leprosy
p55401
tp55402
I00
ssg52636
VSkin biopsies were collected and submitted to immunohistochemistry using specific antibodies to IL-17, NGF and NGF R. Quantitative analysis of NGF, NGFR and IL-17 immunostaining showed a significant difference between the clinical forms, with higher expression of NGF and NGFR in lepromatous leprosy and IL-17 in tuberculoid leprosy.
p55403
sg52638
(lp55404
(dp55405
g52643
I111
sg52644
VNGF R
p55406
sg52646
I5
sg52674
VP01138
p55407
sg52649
I2
sa(dp55408
g52643
I103
sg52644
VNGF
p55409
sg52646
I3
sg52674
VP01138
p55410
sg52649
I1
sa(dp55411
g52643
I103
sg52644
VNGF
p55412
sg52646
I3
sg52674
VP01138
p55413
sg52649
I1
sa(dp55414
g52643
I103
sg52644
VNGF
p55415
sg52646
I3
sg52674
VP01138
p55416
sg52649
I1
sa(dp55417
g52643
I148
sg52644
VNGFR
p55418
sg52646
I4
sg52674
VP08138
p55419
sg52649
I1
sa(dp55420
g52643
I148
sg52644
g55400
sg52646
I4
sg52674
VP08138
p55421
sg52649
I1
sasg52640
(lp55422
(dp55423
g52643
I280
sg52644
Vlepromatous leprosy
p55424
sg52646
I19
sg52647
VC0023348
p55425
sg52649
I2
sa(dp55426
g52643
I313
sg52644
g55401
sg52646
I19
sg52647
VC0023351
p55427
sg52649
I2
sasa(dp55428
g52636
VThe recovered CD271(+) BM-MSCs from post-therapy mice, when injected into healthy mice, caused active tuberculosis infection in the animal's lung.
p55429
sg52638
(lp55430
sg52640
(lp55431
(dp55432
g52643
I102
sg52644
Vtuberculosis infection
p55433
sg52646
I22
sg52647
VC0041296
p55434
sg52649
I2
sasa(dp55435
g135
(dp55436
(VCD146
p55437
Vhypoxia
p55438
tp55439
I00
ssg52636
VNext, in human subjects, previously treated for pulmonary tuberculosis, the MTB-containing CD271(+) BM-MSCs exhibited high expression of hypoxia-inducible factor 1Alfa and low expression of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.
p55440
sg52638
(lp55441
(dp55442
g52643
I137
sg52644
Vhypoxia-inducible factor 1Alfa
p55443
sg52646
I30
sg52674
g12
sg52649
I3
sa(dp55444
g52643
I190
sg52644
g55437
sg52646
I5
sg52674
VP43121
p55445
sg52649
I1
sasg52640
(lp55446
(dp55447
g52643
I48
sg52644
Vpulmonary tuberculosis
p55448
sg52646
I22
sg52647
VC0041327
p55449
sg52649
I2
sa(dp55450
g52643
I137
sg52644
Vhypoxia
p55451
sg52646
I7
sg52647
VC0242184
p55452
sg52649
I1
sa(dp55453
g52643
I137
sg52644
g55438
sg52646
I7
sg52647
VC0242184
p55454
sg52649
I1
sasa(dp55455
g52636
VThe bone marrow niche of Mycobacterium tuberculosis within CD271(+) BM-MSCs stem cells is the proposed explanation for the localized cortical resorption that is observed in bone stress markers.
p55456
sg52638
(lp55457
sg52640
(lp55458
(dp55459
g52643
I39
sg52644
Vtuberculosis
p55460
sg52646
I12
sg52647
VC0041296
p55461
sg52649
I1
sasa(dp55462
g135
(dp55463
(VTGF-Beta
p55464
Vleprosy
p55465
tp55466
I00
ssg52636
VTherefore, the objective of this study was to correlate the immunoexpression patterns of NGF and NGF-R in the different clinical forms of leprosy, and to associate the findings with the in situ expression of TGF-Beta and clinical classification of the disease.
p55467
sg52638
(lp55468
(dp55469
g52643
I89
sg52644
VNGF
p55470
sg52646
I3
sg52674
VP01138
p55471
sg52649
I1
sa(dp55472
g52643
I97
sg52644
VNGF-R
p55473
sg52646
I5
sg52674
VP01138
p55474
sg52649
I1
sa(dp55475
g52643
I208
sg52644
g55464
sg52646
I8
sg52674
VP18075
p55476
sg52649
I1
sasg52640
(lp55477
(dp55478
g52643
I138
sg52644
g55465
sg52646
I7
sg52647
VC0023343
p55479
sg52649
I1
sasa(dp55480
g135
(dp55481
(VNGF-R
p55482
Vleprosy
p55483
tp55484
I00
ssg52636
VThere was a significant positive correlation between NGF and NGF-R in the different clinical forms of leprosy.
p55485
sg52638
(lp55486
(dp55487
g52643
I53
sg52644
VNGF
p55488
sg52646
I3
sg52674
VP01138
p55489
sg52649
I1
sa(dp55490
g52643
I61
sg52644
g55482
sg52646
I5
sg52674
VP01138
p55491
sg52649
I1
sasg52640
(lp55492
(dp55493
g52643
I102
sg52644
g55483
sg52646
I7
sg52647
VC0023343
p55494
sg52649
I1
sasa(dp55495
g135
(dp55496
(VCD271(-)CD45
p55497
Vtuberculosis
p55498
tp55499
I00
ssg52636
VMoreover, most viable M. tuberculosis was recovered from the bone marrow CD271(+)CD45(-)-enriched cell fraction, and only few viable bacteria could be isolated from the CD271(-)CD45(+) cell fraction.
p55500
sg52638
(lp55501
(dp55502
g52643
I81
sg52644
VCD45
p55503
sg52646
I4
sg52674
VP08575
p55504
sg52649
I1
sa(dp55505
g52643
I169
sg52644
g55497
sg52646
I12
sg52674
VP08138
p55506
sg52649
I1
sasg52640
(lp55507
(dp55508
g52643
I25
sg52644
g55498
sg52646
I12
sg52647
VC0041296
p55509
sg52649
I1
sasa(dp55510
g135
(dp55511
(VCsf1
p55512
VNpc1
p55513
tp55514
I00
ssg52636
VWe recently developed a systems biological approach to vaccine safety evaluation where identification of specific biomarkers in a rat pre-clinical study evaluated the safety of vaccines for pandemic H5N1 influenza including Irf7, Lgals9, Lgalsbp3, Cxcl11, Timp1, Tap2, Psmb9, Psme1, Tapbp, C2, Csf1, Mx2, Zbp1, Ifrd1, Trafd1, Cxcl9, Beta2m, Npc1, Ngfr and Ifi47.
p55515
sg52638
(lp55516
(dp55517
g52643
I318
sg52644
VTrafd1
p55518
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55519
g52643
I326
sg52644
VCxcl9
p55520
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp55521
g52643
I311
sg52644
VIfrd1
p55522
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp55523
g52643
I300
sg52644
VMx2
p55524
sg52646
I3
sg52674
VP20592
p55525
sg52649
I1
sa(dp55526
g52643
I256
sg52644
VTimp1
p55527
sg52646
I5
sg52674
VP01033
p55528
sg52649
I1
sa(dp55529
g52643
I248
sg52644
VCxcl11
p55530
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55531
g52643
I347
sg52644
VNgfr
p55532
sg52646
I4
sg52674
VP08138
p55533
sg52649
I1
sa(dp55534
g52643
I224
sg52644
VIrf7
p55535
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp55536
g52643
I341
sg52644
VNpc1
p55537
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp55538
g52643
I230
sg52644
VLgals9
p55539
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp55540
g52643
I333
sg52644
VBeta2m
p55541
sg52646
I6
sg52674
VP61769
p55542
sg52649
I1
sa(dp55543
g52643
I269
sg52644
VPsmb9
p55544
sg52646
I5
sg52674
VP28065
p55545
sg52649
I1
sa(dp55546
g52643
I294
sg52644
g55512
sg52646
I4
sg52674
VP09919
p55547
sg52649
I1
sa(dp55548
g52643
I263
sg52644
VTap2
p55549
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp55550
g52643
I276
sg52644
VPsme1
p55551
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp55552
g52643
I305
sg52644
VZbp1
p55553
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55554
(dp55555
g52643
I341
sg52644
g55513
sg52646
I4
sg52647
VC3179455
p55556
sg52649
I1
sa(dp55557
g52643
I199
sg52644
VH5N1 influenza
p55558
sg52646
I14
sg52647
VC2748361
p55559
sg52649
I2
sasa(dp55560
g52636
VMdmX overexpression contributes to the development of cancer by inhibiting tumor suppressor p53.
p55561
sg52638
(lp55562
(dp55563
g52643
I75
sg52644
Vtumor suppressor p53
p55564
sg52646
I20
sg52674
VP42771
p55565
sg52649
I3
sa(dp55566
g52643
I0
sg52644
VMdmX
p55567
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55568
(dp55569
g52643
I54
sg52644
Vcancer
p55570
sg52646
I6
sg52647
VC0006826
p55571
sg52649
I1
sa(dp55572
g52643
I75
sg52644
Vtumor
p55573
sg52646
I5
sg52647
VC0027651
p55574
sg52649
I1
sasa(dp55575
g52636
VA switch in the alternative splicing of MdmX transcript, leading to the inclusion of exon 6, has been identified as the primary mechanism responsible for increased MdmX protein levels in human cancers, including melanoma.
p55576
sg52638
(lp55577
(dp55578
g52643
I164
sg52644
VMdmX protein
p55579
sg52646
I12
sg52674
g12
sg52649
I2
sa(dp55580
g52643
I40
sg52644
VMdmX transcript
p55581
sg52646
I15
sg52674
g12
sg52649
I2
sasg52640
(lp55582
(dp55583
g52643
I193
sg52644
Vcancers
p55584
sg52646
I7
sg52647
VC0006826
p55585
sg52649
I1
sa(dp55586
g52643
I212
sg52644
Vmelanoma
p55587
sg52646
I8
sg52647
VC0025202
p55588
sg52649
I1
sasa(dp55589
g52636
VRecent studies showed that interfering with cellular splicing machinery can result in MdmX downregulation in cancer cells.
p55590
sg52638
(lp55591
(dp55592
g52643
I86
sg52644
VMdmX
p55593
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55594
(dp55595
g52643
I109
sg52644
Vcancer
p55596
sg52646
I6
sg52647
VC0006826
p55597
sg52649
I1
sasa(dp55598
g52636
VWe, therefore, hypothesized that enoxacin could, by modulating miRNAs targeting splicing machinery, activate p53 in melanoma cells overexpressing MdmX.
p55599
sg52638
(lp55600
(dp55601
g52643
I146
sg52644
VMdmX
p55602
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp55603
g52643
I109
sg52644
Vp53
p55604
sg52646
I3
sg52674
VP42771
p55605
sg52649
I1
sasg52640
(lp55606
(dp55607
g52643
I116
sg52644
Vmelanoma
p55608
sg52646
I8
sg52647
VC0025202
p55609
sg52649
I1
sasa(dp55610
g52636
VNot only in melanoma, but also in MCF7 breast carcinoma and A2780 ovarian carcinoma cells overexpressing MdmX.
p55611
sg52638
(lp55612
(dp55613
g52643
I105
sg52644
VMdmX
p55614
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55615
(dp55616
g52643
I39
sg52644
Vbreast carcinoma
p55617
sg52646
I16
sg52647
VC0678222
p55618
sg52649
I2
sa(dp55619
g52643
I12
sg52644
Vmelanoma
p55620
sg52646
I8
sg52647
VC0025202
p55621
sg52649
I1
sa(dp55622
g52643
I66
sg52644
Vovarian carcinoma
p55623
sg52646
I17
sg52647
VC0029925
p55624
sg52649
I2
sasa(dp55625
g52636
VTogether, our results suggest that some clinically approved fluoroquinolones could potentially be repurposed as activators of p53 tumor suppressor in cancers overexpressing MdmX oncoprotein and that p53 activation might contribute to the previously reported activity of enoxacin towards human cancer cells.
p55626
sg52638
(lp55627
(dp55628
g52643
I126
sg52644
Vp53 tumor suppressor
p55629
sg52646
I20
sg52674
VP42771
p55630
sg52649
I3
sa(dp55631
g52643
I126
sg52644
Vp53
p55632
sg52646
I3
sg52674
VP42771
p55633
sg52649
I1
sa(dp55634
g52643
I173
sg52644
VMdmX oncoprotein
p55635
sg52646
I16
sg52674
g12
sg52649
I2
sasg52640
(lp55636
(dp55637
g52643
I130
sg52644
Vtumor
p55638
sg52646
I5
sg52647
VC0027651
p55639
sg52649
I1
sa(dp55640
g52643
I150
sg52644
Vcancer
p55641
sg52646
I6
sg52647
VC0006826
p55642
sg52649
I1
sa(dp55643
g52643
I150
sg52644
Vcancers
p55644
sg52646
I7
sg52647
VC0006826
p55645
sg52649
I1
sasa(dp55646
g52636
VThese will be discussed as will recent findings of MDMX inhibitors: these are of special importance as it has been shown that cancers that become resistant to MDM2 inhibitors often amplify MDM4.
p55647
sg52638
(lp55648
(dp55649
g52643
I51
sg52644
VMDMX
p55650
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp55651
g52643
I189
sg52644
VMDM4
p55652
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55653
(dp55654
g52643
I126
sg52644
Vcancers
p55655
sg52646
I7
sg52647
VC0006826
p55656
sg52649
I1
sasa(dp55657
g135
(dp55658
(VE3 ubiquitin
p55659
Vmalignant melanoma
p55660
tp55661
I00
ssg52636
VWe speculate that E3 ubiquitin ligases MDM2 and MDM4 can be attractive therapeutic target for p53 and Notch signaling pathways in malignant melanoma by using small molecule inhibitors.
p55662
sg52638
(lp55663
(dp55664
g52643
I94
sg52644
Vp53
p55665
sg52646
I3
sg52674
VP42771
p55666
sg52649
I1
sa(dp55667
g52643
I18
sg52644
g55659
sg52646
I12
sg52674
VP62979
p55668
sg52649
I2
sa(dp55669
g52643
I48
sg52644
VMDM4
p55670
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp55671
(dp55672
g52643
I130
sg52644
g55660
sg52646
I18
sg52647
VC0025202
p55673
sg52649
I2
sasa(dp55674
g52636
VOur recent studies conducted in South America have shown that mycotoxin contamination of red chili peppers (RCPs) may be associated with an increased risk of gallbladder cancer (GBC).
p55675
sg52638
(lp55676
sg52640
(lp55677
(dp55678
g52643
I178
sg52644
VGBC
p55679
sg52646
I3
sg52647
VC0153452
p55680
sg52649
I1
sa(dp55681
g52643
I158
sg52644
Vgallbladder cancer
p55682
sg52646
I18
sg52647
VC0153452
p55683
sg52649
I2
sasa(dp55684
g135
(dp55685
(Vhuman ribonuclease inhibitor
p55686
Vvaginal carcinoma
p55687
tp55688
I01
ssg52636
VThree proteins were uniquely altered in vaginal carcinoma (DDX48, erbB3-binding protein and biliverdin reductase) and five in cervical carcinoma (peroxiredoxin 2, annexin A2, sarcomeric tropomyosin kappa, human ribonuclease inhibitor and prolyl-4-hydrolase beta).
p55689
sg52638
(lp55690
(dp55691
g52643
I92
sg52644
Vbiliverdin reductase
p55692
sg52646
I20
sg52674
VP53004
p55693
sg52649
I2
sa(dp55694
g52643
I59
sg52644
VDDX48
p55695
sg52646
I5
sg52674
VP38919
p55696
sg52649
I1
sa(dp55697
g52643
I66
sg52644
VerbB3-binding protein
p55698
sg52646
I21
sg52674
VP21860
p55699
sg52649
I2
sa(dp55700
g52643
I163
sg52644
Vannexin A2, sarcomeric tropomyosin kappa
p55701
sg52646
I40
sg52674
VP07355
p55702
sg52649
I5
sa(dp55703
g52643
I146
sg52644
Vperoxiredoxin 2
p55704
sg52646
I15
sg52674
VP32119
p55705
sg52649
I2
sa(dp55706
g52643
I205
sg52644
g55686
sg52646
I28
sg52674
VP13489
p55707
sg52649
I3
sasg52640
(lp55708
(dp55709
g52643
I126
sg52644
Vcervical carcinoma
p55710
sg52646
I18
sg52647
VC0302592
p55711
sg52649
I2
sa(dp55712
g52643
I40
sg52644
g55687
sg52646
I17
sg52647
VC0262659
p55713
sg52649
I2
sasa(dp55714
g135
(dp55715
(VMT-ATP6 gene
p55716
Vataxia
p55717
tp55718
I00
ssg52636
VMitochondrial (mt) DNA-associated NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) syndrome is due to mutation in the MT-ATP6 gene.
p55719
sg52638
(lp55720
(dp55721
g52643
I34
sg52644
VNARP
p55722
sg52646
I4
sg52674
VP47972
p55723
sg52649
I1
sa(dp55724
g52643
I137
sg52644
g55716
sg52646
I12
sg52674
VP36543
p55725
sg52649
I2
sasg52640
(lp55726
(dp55727
g52643
I80
sg52644
Vretinitis pigmentosa
p55728
sg52646
I20
sg52647
VC0035334
p55729
sg52649
I2
sa(dp55730
g52643
I51
sg52644
Vmuscle weakness
p55731
sg52646
I15
sg52647
VC0030552
p55732
sg52649
I2
sa(dp55733
g52643
I68
sg52644
g55717
sg52646
I6
sg52647
VC0004134
p55734
sg52649
I1
sa(dp55735
g52643
I102
sg52644
Vsyndrome
p55736
sg52646
I8
sg52647
VC0039082
p55737
sg52649
I1
sasa(dp55738
g135
(dp55739
(VMT-ATP6
p55740
VLeigh syndrome
p55741
tp55742
I00
ssg52636
VPathogenic mutations in MT-ATP6 are associated with the Leigh syndrome, the syndrome of neuropathy, ataxia, and retinitis pigmentosa (NARP), as well as with non-classical phenotypes, while MT-ATP8 is less frequently mutated in patients with mitochondrial disease.
p55743
sg52638
(lp55744
(dp55745
g52643
I189
sg52644
VMT-ATP8
p55746
sg52646
I7
sg52674
VP03928
p55747
sg52649
I1
sa(dp55748
g52643
I24
sg52644
g55740
sg52646
I7
sg52674
VP36543
p55749
sg52649
I1
sasg52640
(lp55750
(dp55751
g52643
I241
sg52644
Vmitochondrial disease
p55752
sg52646
I21
sg52647
VC0751651
p55753
sg52649
I2
sa(dp55754
g52643
I88
sg52644
Vneuropathy, ataxia, and retinitis pigmentosa
p55755
sg52646
I44
sg52647
VC1328349
p55756
sg52649
I5
sa(dp55757
g52643
I56
sg52644
g55741
sg52646
I14
sg52647
VC0023264
p55758
sg52649
I2
sa(dp55759
g52643
I62
sg52644
Vsyndrome
p55760
sg52646
I8
sg52647
VC0039082
p55761
sg52649
I1
sasa(dp55762
g52636
VAnalysis of these populations demonstrated an altered metabolic signature in cells harbouring decreased levels of mutant m.8993T&gt;G mtDNA, associated with neuropathy, ataxia, and retinitis pigmentosa (NARP).
p55763
sg52638
(lp55764
sg52640
(lp55765
(dp55766
g52643
I157
sg52644
Vneuropathy, ataxia, and retinitis pigmentosa
p55767
sg52646
I44
sg52647
VC1328349
p55768
sg52649
I5
sa(dp55769
g52643
I114
sg52644
Vmutant
p55770
sg52646
I6
sg52647
VC0596988
p55771
sg52649
I1
sasa(dp55772
g135
(dp55773
(VMT-ATP6
p55774
Vmuscle weakness
p55775
tp55776
I00
ssg52636
VNeurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) is caused by m.8993T&gt;G/C mutations in the mitochondrial adenosine triphosphate synthase subunit 6 gene (MT-ATP6).
p55777
sg52638
(lp55778
(dp55779
g52643
I113
sg52644
Vmitochondrial adenosine triphosphate synthase subunit 6 gene
p55780
sg52646
I60
sg52674
VP56381
p55781
sg52649
I7
sa(dp55782
g52643
I175
sg52644
g55774
sg52646
I7
sg52674
VP36543
p55783
sg52649
I1
sasg52640
(lp55784
(dp55785
g52643
I28
sg52644
Vataxia
p55786
sg52646
I6
sg52647
VC0004134
p55787
sg52649
I1
sa(dp55788
g52643
I40
sg52644
Vretinitis pigmentosa
p55789
sg52646
I20
sg52647
VC0035334
p55790
sg52649
I2
sa(dp55791
g52643
I11
sg52644
g55775
sg52646
I15
sg52647
VC0030552
p55792
sg52649
I2
sasa(dp55793
g52636
VIn addition, we successfully reduced human mutated mtDNA levels responsible for Leber's hereditary optic neuropathy (LHOND), and neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), in mammalian oocytes using mitochondria-targeted TALEN (mito-TALENs).
p55794
sg52638
(lp55795
sg52640
(lp55796
(dp55797
g52643
I140
sg52644
Vmuscle weakness
p55798
sg52646
I15
sg52647
VC0030552
p55799
sg52649
I2
sa(dp55800
g52643
I80
sg52644
VLeber's hereditary optic neuropathy
p55801
sg52646
I35
sg52647
VC0917796
p55802
sg52649
I4
sa(dp55803
g52643
I169
sg52644
Vretinitis pigmentosa
p55804
sg52646
I20
sg52647
VC0035334
p55805
sg52649
I2
sa(dp55806
g52643
I157
sg52644
Vataxia
p55807
sg52646
I6
sg52647
VC0004134
p55808
sg52649
I1
sasa(dp55809
g52636
VBased on our previous findings that ROS level was higher in human osteosarcoma cybrids--Neuropathy, Ataxia and Retinitis Pigmentosa (NARP) and was reduced by selenite treatment, this study was designed to elucidate the effects of selenite administration on oxidative and nitrosative damage to lipids, proteins and DNA.
p55810
sg52638
(lp55811
sg52640
(lp55812
(dp55813
g52643
I100
sg52644
VAtaxia
p55814
sg52646
I6
sg52647
VC0004134
p55815
sg52649
I1
sa(dp55816
g52643
I66
sg52644
Vosteosarcoma
p55817
sg52646
I12
sg52647
VC0029463
p55818
sg52649
I1
sa(dp55819
g52643
I88
sg52644
VNeuropathy
p55820
sg52646
I10
sg52647
VC0442874
p55821
sg52649
I1
sa(dp55822
g52643
I111
sg52644
VRetinitis Pigmentosa
p55823
sg52646
I20
sg52647
VC0035334
p55824
sg52649
I2
sasa(dp55825
g52636
VWe report a patient having classical clinical feature of neurologic muscle weakness, ataxia, and retinitis pigmentosa (NARP) and a novel mutation, m.8729 G&gt;A in mitochondria DNA.
p55826
sg52638
(lp55827
sg52640
(lp55828
(dp55829
g52643
I97
sg52644
Vretinitis pigmentosa
p55830
sg52646
I20
sg52647
VC0035334
p55831
sg52649
I2
sa(dp55832
g52643
I68
sg52644
Vmuscle weakness
p55833
sg52646
I15
sg52647
VC0030552
p55834
sg52649
I2
sa(dp55835
g52643
I131
sg52644
Vnovel mutation
p55836
sg52646
I14
sg52647
VC2985438
p55837
sg52649
I2
sa(dp55838
g52643
I85
sg52644
Vataxia
p55839
sg52646
I6
sg52647
VC0004134
p55840
sg52649
I1
sasa(dp55841
g52636
VHis mother, who had previously been diagnosed with cerebral palsy, was concurrently diagnosed with neuropathy, ataxia, and retinitis pigmentosa (NARP) due to heteroplasmy of the same mutation.
p55842
sg52638
(lp55843
sg52640
(lp55844
(dp55845
g52643
I99
sg52644
Vneuropathy, ataxia, and retinitis pigmentosa
p55846
sg52646
I44
sg52647
VC1328349
p55847
sg52649
I5
sa(dp55848
g52643
I51
sg52644
Vcerebral palsy
p55849
sg52646
I14
sg52647
VC0007789
p55850
sg52649
I2
sasa(dp55851
g52636
VIn this issue, Gammage and colleagues successfully apply this improved technology on patients' cells with two types of genetic alterations responsible for neuropathy ataxia and retinitis pigmentosa (NARP) syndrome and Kearns Sayre syndrome and progressive external ophthalmoplegia (PEO).
p55852
sg52638
(lp55853
sg52640
(lp55854
(dp55855
g52643
I166
sg52644
Vataxia
p55856
sg52646
I6
sg52647
VC0004134
p55857
sg52649
I1
sa(dp55858
g52643
I155
sg52644
Vneuropathy
p55859
sg52646
I10
sg52647
VC0442874
p55860
sg52649
I1
sa(dp55861
g52643
I244
sg52644
Vprogressive external ophthalmoplegia
p55862
sg52646
I36
sg52647
VC0162674
p55863
sg52649
I3
sa(dp55864
g52643
I218
sg52644
VKearns Sayre syndrome
p55865
sg52646
I21
sg52647
VC0022541
p55866
sg52649
I3
sa(dp55867
g52643
I205
sg52644
Vsyndrome
p55868
sg52646
I8
sg52647
VC0039082
p55869
sg52649
I1
sa(dp55870
g52643
I177
sg52644
Vretinitis pigmentosa
p55871
sg52646
I20
sg52647
VC0035334
p55872
sg52649
I2
sa(dp55873
g52643
I282
sg52644
VPEO
p55874
sg52646
I3
sg52647
VC0162674
p55875
sg52649
I1
sasa(dp55876
g52636
VThere are several diseases that have a mitochondrial origin such as chronic progressive external ophthalmoplegia (CPEO) and the Kearns- Sayre syndrome (KSS), myoclonic epilepsy with ragged-red fibers (MERRF), mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS), Leber's hereditary optic neuropathy (LHON), the syndrome of neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP), and Leigh's syndrome.
p55877
sg52638
(lp55878
sg52640
(lp55879
(dp55880
g52643
I158
sg52644
Vmyoclonic epilepsy with ragged-red fibers
p55881
sg52646
I41
sg52647
VC0162672
p55882
sg52649
I5
sa(dp55883
g52643
I201
sg52644
VMERRF
p55884
sg52646
I5
sg52647
VC0162672
p55885
sg52649
I1
sa(dp55886
g52643
I128
sg52644
VKearns- Sayre syndrome
p55887
sg52646
I22
sg52647
VC0022541
p55888
sg52649
I3
sa(dp55889
g52643
I291
sg52644
VLeber's hereditary optic neuropathy
p55890
sg52646
I35
sg52647
VC0917796
p55891
sg52649
I4
sa(dp55892
g52643
I114
sg52644
VCPEO
p55893
sg52646
I4
sg52647
VC0162674
p55894
sg52649
I1
sa(dp55895
g52643
I142
sg52644
Vsyndrome
p55896
sg52646
I8
sg52647
VC0039082
p55897
sg52649
I1
sa(dp55898
g52643
I142
sg52644
Vsyndrome
p55899
sg52646
I8
sg52647
VC0039082
p55900
sg52649
I1
sa(dp55901
g52643
I242
sg52644
Vlactic acidosis
p55902
sg52646
I15
sg52647
VC0001125
p55903
sg52649
I2
sa(dp55904
g52643
I209
sg52644
Vmitochondrial encephalomyopathy
p55905
sg52646
I31
sg52647
VC0162666
p55906
sg52649
I2
sa(dp55907
g52643
I152
sg52644
VKSS
p55908
sg52646
I3
sg52647
VC0022541
p55909
sg52649
I1
sa(dp55910
g52643
I283
sg52644
VMELAS
p55911
sg52646
I5
sg52647
VC0162671
p55912
sg52649
I1
sa(dp55913
g52643
I328
sg52644
VLHON
p55914
sg52646
I4
sg52647
VC0917796
p55915
sg52649
I1
sa(dp55916
g52643
I351
sg52644
Vneurogenic muscle weakness, ataxia and retinitis pigmentosa
p55917
sg52646
I59
sg52647
VC0342772
p55918
sg52649
I7
sa(dp55919
g52643
I68
sg52644
Vchronic progressive external ophthalmoplegia
p55920
sg52646
I44
sg52647
VC0162674
p55921
sg52649
I4
sasa(dp55922
g135
(dp55923
(VCCL
p55924
VCCL
p55925
tp55926
I01
ssg52636
VNeuroblastoma cells treated with free myb-as or nontargeted CCL-myb-as showed the same level of c-myb protein expression as control cells.
p55927
sg52638
(lp55928
(dp55929
g52643
I96
sg52644
Vc-myb protein
p55930
sg52646
I13
sg52674
VP10243
p55931
sg52649
I2
sa(dp55932
g52643
I38
sg52644
Vmyb
p55933
sg52646
I3
sg52674
VP10243
p55934
sg52649
I1
sa(dp55935
g52643
I38
sg52644
Vmyb
p55936
sg52646
I3
sg52674
VP10243
p55937
sg52649
I1
sa(dp55938
g52643
I60
sg52644
g55924
sg52646
I3
sg52674
VP43320
p55939
sg52649
I1
sasg52640
(lp55940
(dp55941
g52643
I0
sg52644
VNeuroblastoma
p55942
sg52646
I13
sg52647
VC0027819
p55943
sg52649
I1
sa(dp55944
g52643
I60
sg52644
g55925
sg52646
I3
sg52647
VC1852438
p55945
sg52649
I1
sasa(dp55946
g52636
VImmune cell activation, involving the time-dependent activation of macrophages and NK cells, contributes to the antitumor activity of targeted liposome-CpG-myb-as against neuroblastoma and could improve the effectiveness of antitumor targeted liposomes.
p55947
sg52638
(lp55948
sg52640
(lp55949
(dp55950
g52643
I171
sg52644
Vneuroblastoma
p55951
sg52646
I13
sg52647
VC0027819
p55952
sg52649
I1
sasa(dp55953
g135
(dp55954
(Vnuclear-encoded mitochondrial proteins
p55955
Vneurodegeneration
p55956
tp55957
I00
ssg52636
VWhile YY1 is known to exert both positive and negative regulatory influences on nuclear-encoded mitochondrial proteins, as well as on neurodegeneration-related genes, in all cell lines we studied (including neuroblastoma) the effect of YY1 on GDAP1 expression is activatory.
p55958
sg52638
(lp55959
(dp55960
g52643
I6
sg52644
VYY1
p55961
sg52646
I3
sg52674
VP25490
p55962
sg52649
I1
sa(dp55963
g52643
I6
sg52644
VYY1
p55964
sg52646
I3
sg52674
VP25490
p55965
sg52649
I1
sa(dp55966
g52643
I243
sg52644
VGDAP1
p55967
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp55968
g52643
I80
sg52644
g55955
sg52646
I38
sg52674
VP02649
p55969
sg52649
I3
sasg52640
(lp55970
(dp55971
g52643
I207
sg52644
Vneuroblastoma
p55972
sg52646
I13
sg52647
VC0027819
p55973
sg52649
I1
sa(dp55974
g52643
I134
sg52644
g55956
sg52646
I17
sg52647
VC0027746
p55975
sg52649
I1
sasa(dp55976
g135
(dp55977
(VAP1
p55978
Vneuroblastoma
p55979
tp55980
I00
ssg52636
VUsing the DBH-expressing human neuroblastoma SK-N-BE(2)C and DBH-negative HeLa cell lines as model systems, we report here that this CRE/YY1/AP1 area interacts with multiple nuclear proteins, including CRE-binding protein (CREB) and transcription factor YY1 in a cell-specific manner.
p55981
sg52638
(lp55982
(dp55983
g52643
I202
sg52644
VCRE-binding protein
p55984
sg52646
I19
sg52674
g12
sg52649
I2
sa(dp55985
g52643
I233
sg52644
Vtranscription factor YY1
p55986
sg52646
I24
sg52674
VP25490
p55987
sg52649
I3
sa(dp55988
g52643
I10
sg52644
VDBH
p55989
sg52646
I3
sg52674
VP09172
p55990
sg52649
I1
sa(dp55991
g52643
I223
sg52644
VCREB
p55992
sg52646
I4
sg52674
VP16220
p55993
sg52649
I1
sa(dp55994
g52643
I137
sg52644
VYY1
p55995
sg52646
I3
sg52674
VP25490
p55996
sg52649
I1
sa(dp55997
g52643
I141
sg52644
g55978
sg52646
I3
sg52674
VP27695
p55998
sg52649
I1
sasg52640
(lp55999
(dp56000
g52643
I31
sg52644
g55979
sg52646
I13
sg52647
VC0027819
p56001
sg52649
I1
sasa(dp56002
g52636
VHowever, little is known about the expression of CD44v6 in Gastric Carcinoma (GC).
p56003
sg52638
(lp56004
sg52640
(lp56005
(dp56006
g52643
I59
sg52644
VGastric Carcinoma
p56007
sg52646
I17
sg52647
VC0699791
p56008
sg52649
I2
sa(dp56009
g52643
I78
sg52644
VGC
p56010
sg52646
I2
sg52647
VC0699791
p56011
sg52649
I1
sasa(dp56012
g52636
VMultiple carcinomas including breast, ovarian, colon, lung and stomach cancer, overexpress the hyaluronic acid (HA) receptor, CD44.
p56013
sg52638
(lp56014
sg52640
(lp56015
(dp56016
g52643
I63
sg52644
Vstomach cancer
p56017
sg52646
I14
sg52647
VC0024623
p56018
sg52649
I2
sa(dp56019
g52643
I9
sg52644
Vcarcinomas
p56020
sg52646
I10
sg52647
VC0007097
p56021
sg52649
I1
sasa(dp56022
g52636
VHere, we show that the transcription of a long non-coding RNA (lncRNA), Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA (GAPLINC), is directly activated by HIF-1Alfa in gastric cancer (GC).
p56023
sg52638
(lp56024
sg52640
(lp56025
(dp56026
g52643
I228
sg52644
VGC
p56027
sg52646
I2
sg52647
VC0024623
p56028
sg52649
I1
sa(dp56029
g52643
I72
sg52644
VGastric Adenocarcinoma
p56030
sg52646
I22
sg52647
VC0278701
p56031
sg52649
I2
sa(dp56032
g52643
I212
sg52644
Vgastric cancer
p56033
sg52646
I14
sg52647
VC0024623
p56034
sg52649
I2
sasa(dp56035
g135
(dp56036
(Valdehyde dehydrogenase
p56037
Vgastric carcinoma
p56038
tp56039
I01
ssg52636
VThe expressions of 10 putative cell surface markers of CSCs, as well as aldehyde dehydrogenase (ALDH) activity, were studied, and the tumorigenic properties of cells were evaluated by in vitro tumorsphere assays and in vivo xenografts by limiting dilution assays.Results: We found that a subpopulation of gastric carcinoma cells expressing EPCAM, CD133, CD166, CD44, and a high ALDH activity presented the properties to generate new heterogeneous tumorspheres in vitro and tumors in vivo CD44 and CD166 were coexpressed, representing 6.1% to 37.5% of the cells; ALDH activity was detected in 1.6% to 15.4% of the cells; and the ALDH+ cells represented a core within the CD44+/CD166+ subpopulation that contained the highest frequency of tumorigenic CSCs in vivo The ALDH+ cells possessed drug efflux properties and were more resistant to standard chemotherapy than the ALDH- cells, a process that was partially reversed by verapamil treatment.Conclusions: CD44 and ALDH are the most specific biomarkers to detect and isolate tumorigenic and chemoresistant gastric CSCs in noncardia gastric carcinomas independently of the histologic classification of the tumor.
p56040
sg52638
(lp56041
(dp56042
g52643
I96
sg52644
VALDH
p56043
sg52646
I4
sg52674
VP00352
p56044
sg52649
I1
sa(dp56045
g52643
I676
sg52644
VCD166+
p56046
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp56047
g52643
I354
sg52644
VCD166
p56048
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp56049
g52643
I340
sg52644
VEPCAM
p56050
sg52646
I5
sg52674
VP16422
p56051
sg52649
I1
sa(dp56052
g52643
I96
sg52644
VALDH
p56053
sg52646
I4
sg52674
VP49366
p56054
sg52649
I1
sa(dp56055
g52643
I96
sg52644
VALDH
p56056
sg52646
I4
sg52674
VP00352
p56057
sg52649
I1
sa(dp56058
g52643
I96
sg52644
VALDH
p56059
sg52646
I4
sg52674
VP00352
p56060
sg52649
I1
sa(dp56061
g52643
I354
sg52644
VCD166
p56062
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp56063
g52643
I96
sg52644
VALDH
p56064
sg52646
I4
sg52674
VP00352
p56065
sg52649
I1
sa(dp56066
g52643
I347
sg52644
VCD133
p56067
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp56068
g52643
I72
sg52644
g56037
sg52646
I22
sg52674
VP49366
p56069
sg52649
I2
sasg52640
(lp56070
(dp56071
g52643
I193
sg52644
Vtumors
p56072
sg52646
I6
sg52647
VC0027651
p56073
sg52649
I1
sa(dp56074
g52643
I778
sg52644
Vpossessed
p56075
sg52646
I9
sg52647
VC0850310
p56076
sg52649
I1
sa(dp56077
g52643
I305
sg52644
g56038
sg52646
I17
sg52647
VC0699791
p56078
sg52649
I2
sa(dp56079
g52643
I134
sg52644
Vtumor
p56080
sg52646
I5
sg52647
VC0027651
p56081
sg52649
I1
sa(dp56082
g52643
I1090
sg52644
Vcarcinomas
p56083
sg52646
I10
sg52647
VC0007097
p56084
sg52649
I1
sasa(dp56085
g135
(dp56086
(VCD10
p56087
Vovarian cancer
p56088
tp56089
I00
ssg52636
VClinically, low CD10 expression was consistent with a specific set of ovarian cancer patient samples.
p56090
sg52638
(lp56091
(dp56092
g52643
I16
sg52644
g56087
sg52646
I4
sg52674
VP08473
p56093
sg52649
I1
sasg52640
(lp56094
(dp56095
g52643
I70
sg52644
g56088
sg52646
I14
sg52647
VC1140680
p56096
sg52649
I2
sasa(dp56097
g135
(dp56098
(VCD10-/ALDH- CSCs
p56099
Vovarian cancer
p56100
tp56101
I00
ssg52636
VFurthermore, our data indicate that primary stage targeting of CD10-/ALDH- CSCs in specific ovarian cancer patients in future may facilitate targeting of recurrent disease, before it ever develops.
p56102
sg52638
(lp56103
(dp56104
g52643
I63
sg52644
g56099
sg52646
I16
sg52674
VP08473
p56105
sg52649
I2
sasg52640
(lp56106
(dp56107
g52643
I92
sg52644
g56100
sg52646
I14
sg52647
VC1140680
p56108
sg52649
I2
sa(dp56109
g52643
I154
sg52644
Vrecurrent disease
p56110
sg52646
I17
sg52647
VC0277556
p56111
sg52649
I2
sasa(dp56112
g135
(dp56113
(VCD10
p56114
Vendometrial stromal tumor
p56115
tp56116
I00
ssg52636
VAll cases were negative for CD10 and WT-1 ruling out endometrial stromal tumor and were negative for HMB-45 and melan-A ruling out perivascular epithelioid cell tumor (both endometrial stromal tumor and perivascular epithelioid cell tumor have prominent vessels but have different histomorphology).
p56117
sg52638
(lp56118
(dp56119
g52643
I112
sg52644
Vmelan-A
p56120
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp56121
g52643
I28
sg52644
g56114
sg52646
I4
sg52674
VP08473
p56122
sg52649
I1
sa(dp56123
g52643
I101
sg52644
VHMB-45
p56124
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp56125
(dp56126
g52643
I53
sg52644
Vendometrial stromal tumor
p56127
sg52646
I25
sg52647
VC0334695
p56128
sg52649
I3
sa(dp56129
g52643
I73
sg52644
Vtumor
p56130
sg52646
I5
sg52647
VC0027651
p56131
sg52649
I1
sa(dp56132
g52643
I73
sg52644
Vtumor
p56133
sg52646
I5
sg52647
VC0027651
p56134
sg52649
I1
sa(dp56135
g52643
I53
sg52644
g56115
sg52646
I25
sg52647
VC0334695
p56136
sg52649
I3
sasa(dp56137
g135
(dp56138
(VCD10
p56139
Vuterine tumor
p56140
tp56141
I00
ssg52636
VImmunohistochemistry indicated a phenotypic transition from a uterine leiomyosarcoma to a vaginal epithelioid lesion; marker expression changed from the uterine tumor actin+/desmin+/caldesmon+/CD10- phenotype, through the tumor emboli, to an actin-/desmin-/caldesmon-/CD10+ phenotype in the vaginal lesion.
p56142
sg52638
(lp56143
(dp56144
g52643
I182
sg52644
Vcaldesmon+
p56145
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp56146
g52643
I257
sg52644
Vcaldesmon-/CD10+ phenotype
p56147
sg52646
I26
sg52674
g12
sg52649
I2
sa(dp56148
g52643
I174
sg52644
Vdesmin+
p56149
sg52646
I7
sg52674
VP98155
p56150
sg52649
I1
sa(dp56151
g52643
I242
sg52644
Vactin-/desmin
p56152
sg52646
I13
sg52674
VP98155
p56153
sg52649
I1
sa(dp56154
g52643
I193
sg52644
g56139
sg52646
I4
sg52674
VP08473
p56155
sg52649
I1
sasg52640
(lp56156
(dp56157
g52643
I161
sg52644
Vtumor
p56158
sg52646
I5
sg52647
VC0027651
p56159
sg52649
I1
sa(dp56160
g52643
I44
sg52644
Vtransition
p56161
sg52646
I10
sg52647
VC0599156
p56162
sg52649
I1
sa(dp56163
g52643
I291
sg52644
Vvaginal lesion
p56164
sg52646
I14
sg52647
VC0566943
p56165
sg52649
I2
sa(dp56166
g52643
I62
sg52644
Vuterine leiomyosarcoma
p56167
sg52646
I22
sg52647
VC0280631
p56168
sg52649
I2
sa(dp56169
g52643
I153
sg52644
g56140
sg52646
I13
sg52647
VC0042138
p56170
sg52649
I2
sasa(dp56171
g135
(dp56172
(VCD10
p56173
Vendometrial stromal sarcoma
p56174
tp56175
I00
ssg52636
VImmunohistochemistry for IFITM1 and CD10 was performed in 20 cases of smooth muscle neoplasms (10 cases leiomyoma, 10 cases leiomyosarcoma), 14 cases of endometrial stromal sarcoma (ESS) (12 cases of low grade and 2 cases of high grade) and 12 cases of carcinosarcoma.
p56176
sg52638
(lp56177
(dp56178
g52643
I25
sg52644
VIFITM1
p56179
sg52646
I6
sg52674
VP13164
p56180
sg52649
I1
sa(dp56181
g52643
I36
sg52644
g56173
sg52646
I4
sg52674
VP08473
p56182
sg52649
I1
sasg52640
(lp56183
(dp56184
g52643
I124
sg52644
Vleiomyosarcoma
p56185
sg52646
I14
sg52647
VC0023269
p56186
sg52649
I1
sa(dp56187
g52643
I182
sg52644
VESS
p56188
sg52646
I3
sg52647
VC0206630
p56189
sg52649
I1
sa(dp56190
g52643
I253
sg52644
Vcarcinosarcoma
p56191
sg52646
I14
sg52647
VC0007140
p56192
sg52649
I1
sa(dp56193
g52643
I77
sg52644
Vmuscle neoplasms
p56194
sg52646
I16
sg52647
VC0282606
p56195
sg52649
I2
sa(dp56196
g52643
I104
sg52644
Vleiomyoma
p56197
sg52646
I9
sg52647
VC0023267
p56198
sg52649
I1
sa(dp56199
g52643
I153
sg52644
g56174
sg52646
I27
sg52647
VC0206630
p56200
sg52649
I3
sasa(dp56201
g135
(dp56202
(VIFITM1
p56203
Vmuscle neoplasms
p56204
tp56205
I00
ssg52636
VWhile both IFITM1 (83%) and CD10 (91%) had high sensitivity in differentiating low-grade ESSs from smooth muscle neoplasms, IFITM1 (70%) had higher specificity compared with CD10 (45%).
p56206
sg52638
(lp56207
(dp56208
g52643
I28
sg52644
VCD10
p56209
sg52646
I4
sg52674
VP08473
p56210
sg52649
I1
sa(dp56211
g52643
I28
sg52644
VCD10
p56212
sg52646
I4
sg52674
VP08473
p56213
sg52649
I1
sa(dp56214
g52643
I11
sg52644
VIFITM1
p56215
sg52646
I6
sg52674
VP13164
p56216
sg52649
I1
sa(dp56217
g52643
I11
sg52644
g56203
sg52646
I6
sg52674
VP13164
p56218
sg52649
I1
sasg52640
(lp56219
(dp56220
g52643
I106
sg52644
g56204
sg52646
I16
sg52647
VC0282606
p56221
sg52649
I2
sasa(dp56222
g135
(dp56223
(VCD10
p56224
Vmuscle neoplasms
p56225
tp56226
I00
ssg52636
VIn this study IFITM1 appears to be a more specific marker of endometrial stromal differentiation compared with CD10 in differentiating low-grade ESSs from smooth muscle neoplasms.
p56227
sg52638
(lp56228
(dp56229
g52643
I111
sg52644
g56224
sg52646
I4
sg52674
VP08473
p56230
sg52649
I1
sasg52640
(lp56231
(dp56232
g52643
I162
sg52644
g56225
sg52646
I16
sg52647
VC0282606
p56233
sg52649
I2
sasa(dp56234
g52636
VTo further evaluate the nature of the HLA association with alopecia areata (AA), we investigated the HLA-DRB1 locus in 161 AA patients and 165 matched controls from Belgium and Germany.
p56235
sg52638
(lp56236
(dp56237
g52643
I38
sg52644
VHLA
p56238
sg52646
I3
sg52674
VP30486
p56239
sg52649
I1
sa(dp56240
g52643
I101
sg52644
VHLA-DRB1 locus
p56241
sg52646
I14
sg52674
VP20039
p56242
sg52649
I2
sasg52640
(lp56243
(dp56244
g52643
I76
sg52644
VAA
p56245
sg52646
I2
sg52647
VC0002171
p56246
sg52649
I1
sa(dp56247
g52643
I76
sg52644
VAA
p56248
sg52646
I2
sg52647
VC0002171
p56249
sg52649
I1
sa(dp56250
g52643
I59
sg52644
Valopecia areata
p56251
sg52646
I15
sg52647
VC0002171
p56252
sg52649
I2
sasa(dp56253
g52636
VIn the present study, we found that miR-19a expression was significantly upregulated in metastatic clear cell renal carcinoma than that in adjacent and primary carcinoma tissues using qPCR and in situ hybridization experiments.
p56254
sg52638
(lp56255
(dp56256
g52643
I36
sg52644
VmiR-19a
p56257
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56258
(dp56259
g52643
I152
sg52644
Vprimary carcinoma
p56260
sg52646
I17
sg52647
VC1335475
p56261
sg52649
I2
sa(dp56262
g52643
I99
sg52644
Vclear cell renal carcinoma
p56263
sg52646
I26
sg52647
VC0279702
p56264
sg52649
I4
sasa(dp56265
g52636
VThus, we provide evidence demonstrating that downregulation of miR-19a may be therapeutically beneficial for metastatic renal carcinoma.
p56266
sg52638
(lp56267
(dp56268
g52643
I63
sg52644
VmiR-19a
p56269
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56270
(dp56271
g52643
I109
sg52644
Vmetastatic renal carcinoma
p56272
sg52646
I26
sg52647
VC0919989
p56273
sg52649
I3
sasa(dp56274
g52636
VTaqman probe stem-loop real-time PCR was used to accurately measure the levels of miR-19a in bladder cancer cell lines, 100 pairs of bladder cancer tissues and the adjacent non-neoplastic tissues and also the plasma collected from bladder cancer patients and normal controls.
p56275
sg52638
(lp56276
(dp56277
g52643
I82
sg52644
VmiR-19a
p56278
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56279
(dp56280
g52643
I93
sg52644
Vbladder cancer
p56281
sg52646
I14
sg52647
VC0699885
p56282
sg52649
I2
sa(dp56283
g52643
I93
sg52644
Vbladder cancer
p56284
sg52646
I14
sg52647
VC0699885
p56285
sg52649
I2
sa(dp56286
g52643
I93
sg52644
Vbladder cancer
p56287
sg52646
I14
sg52647
VC0699885
p56288
sg52649
I2
sasa(dp56289
g52636
VmiR-19a mimics and inhibitors were transfected into bladder cancer cells to investigate its role on regulating cell proliferation which was measured by CCK-8 and colony formation assay.
p56290
sg52638
(lp56291
(dp56292
g52643
I0
sg52644
VmiR-19a
p56293
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56294
(dp56295
g52643
I52
sg52644
Vbladder cancer
p56296
sg52646
I14
sg52647
VC0699885
p56297
sg52649
I2
sa(dp56298
g52643
I116
sg52644
Vproliferation
p56299
sg52646
I13
sg52647
VC0334094
p56300
sg52649
I1
sasa(dp56301
g52636
VmiR-19a was significantly up-regulated in bladder cancer tissues and high-level of miR-19a was correlative with more aggressive phenotypes of bladder cancer.
p56302
sg52638
(lp56303
(dp56304
g52643
I0
sg52644
VmiR-19a
p56305
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp56306
g52643
I0
sg52644
VmiR-19a
p56307
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56308
(dp56309
g52643
I42
sg52644
Vbladder cancer
p56310
sg52646
I14
sg52647
VC0699885
p56311
sg52649
I2
sa(dp56312
g52643
I117
sg52644
Vaggressive
p56313
sg52646
I10
sg52647
VC0001807
p56314
sg52649
I1
sa(dp56315
g52643
I42
sg52644
Vbladder cancer
p56316
sg52646
I14
sg52647
VC0699885
p56317
sg52649
I2
sasa(dp56318
g135
(dp56319
(VPTEN
p56320
Vbladder cancer
p56321
tp56322
I00
ssg52636
VMeanwhile, gain or loss of function of miR-19a demonstrated that miR-19a can promote cell growth of bladder cancer cells and the further mechanism studies indicated that its oncogenic role was dependent on targeting PTEN.
p56323
sg52638
(lp56324
(dp56325
g52643
I39
sg52644
VmiR-19a
p56326
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp56327
g52643
I216
sg52644
g56320
sg52646
I4
sg52674
VP60484
p56328
sg52649
I1
sa(dp56329
g52643
I39
sg52644
VmiR-19a
p56330
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56331
(dp56332
g52643
I100
sg52644
g56321
sg52646
I14
sg52647
VC0699885
p56333
sg52649
I2
sasa(dp56334
g52636
VFurthermore, investigation of miR-19a expression in the plasma of bladder cancer patients showed that miR-19a was also increased in plasma of bladder cancer patients which strongly supported miR-19a could be developed as potential diagnostic marker of bladder cancer.
p56335
sg52638
(lp56336
(dp56337
g52643
I30
sg52644
VmiR-19a
p56338
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp56339
g52643
I30
sg52644
VmiR-19a
p56340
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp56341
g52643
I30
sg52644
VmiR-19a
p56342
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56343
(dp56344
g52643
I66
sg52644
Vbladder cancer
p56345
sg52646
I14
sg52647
VC0699885
p56346
sg52649
I2
sa(dp56347
g52643
I66
sg52644
Vbladder cancer
p56348
sg52646
I14
sg52647
VC0699885
p56349
sg52649
I2
sa(dp56350
g52643
I66
sg52644
Vbladder cancer
p56351
sg52646
I14
sg52647
VC0699885
p56352
sg52649
I2
sasa(dp56353
g52636
VOur data indicated that miR-19a might act as an oncogenic microRNA in bladder cancer and was significantly up-regulated in bladder cancer carcinogenesis.
p56354
sg52638
(lp56355
(dp56356
g52643
I24
sg52644
VmiR-19a
p56357
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56358
(dp56359
g52643
I70
sg52644
Vbladder cancer
p56360
sg52646
I14
sg52647
VC0699885
p56361
sg52649
I2
sa(dp56362
g52643
I138
sg52644
Vcarcinogenesis
p56363
sg52646
I14
sg52647
VC0596263
p56364
sg52649
I1
sa(dp56365
g52643
I70
sg52644
Vbladder cancer
p56366
sg52646
I14
sg52647
VC0699885
p56367
sg52649
I2
sasa(dp56368
g135
(dp56369
(VPTEN
p56370
Vbladder cancer
p56371
tp56372
I00
ssg52636
VThe oncogenic role of miR19a in bladder cancer was dependent on targeting PTEN.
p56373
sg52638
(lp56374
(dp56375
g52643
I74
sg52644
g56370
sg52646
I4
sg52674
VP60484
p56376
sg52649
I1
sasg52640
(lp56377
(dp56378
g52643
I32
sg52644
g56371
sg52646
I14
sg52647
VC0699885
p56379
sg52649
I2
sasa(dp56380
g52636
VThe synergy effect between miRNA-19a and arsenic trioxide that advocates targeting the mir-19a may represent a potential approach to enhance the efficacy and safety of ATO to treat bladder cancer by a decrease in dose.
p56381
sg52638
(lp56382
(dp56383
g52643
I87
sg52644
Vmir-19a
p56384
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp56385
(dp56386
g52643
I181
sg52644
Vbladder cancer
p56387
sg52646
I14
sg52647
VC0699885
p56388
sg52649
I2
sasa(dp56389
g135
(dp56390
(Vhaptoglobin
p56391
Vhepatic dysfunction
p56392
tp56393
I00
ssg52636
VThere was significant decreases in serum albumin and haptoglobin and increases in alpha-1 globulin, ceruloplasmin and alpha-1 globulin, there were no significant differences between schistosomiasis patients and the controls in terms of changes in any laboratory test as a result of the treatment, thus suggesting that patients with active schistosomiasis do not incur a higher risk of hepatic dysfunction while using oral contraception.
p56394
sg52638
(lp56395
(dp56396
g52643
I100
sg52644
Vceruloplasmin
p56397
sg52646
I13
sg52674
VP00450
p56398
sg52649
I1
sa(dp56399
g52643
I82
sg52644
Valpha-1 globulin
p56400
sg52646
I16
sg52674
VP25100
p56401
sg52649
I2
sa(dp56402
g52643
I82
sg52644
Valpha-1 globulin
p56403
sg52646
I16
sg52674
VP25100
p56404
sg52649
I2
sa(dp56405
g52643
I35
sg52644
Vserum albumin
p56406
sg52646
I13
sg52674
g12
sg52649
I2
sa(dp56407
g52643
I53
sg52644
g56391
sg52646
I11
sg52674
VP00738
p56408
sg52649
I1
sasg52640
(lp56409
(dp56410
g52643
I182
sg52644
Vschistosomiasis
p56411
sg52646
I15
sg52647
VC0036323
p56412
sg52649
I1
sa(dp56413
g52643
I182
sg52644
Vschistosomiasis
p56414
sg52646
I15
sg52647
VC0036323
p56415
sg52649
I1
sa(dp56416
g52643
I385
sg52644
g56392
sg52646
I19
sg52647
VC0086565
p56417
sg52649
I2
sasa(dp56418
g135
(dp56419
(VIL-6
p56420
VMH
p56421
tp56422
I00
ssg52636
VAqueous flare values and the vitreous levels of VEGF, IL-6, MCP-1, sICAM-1, and sVEGFR-2 were compared between previously untreated patients with BRVO and patients with macular hole (MH).
p56423
sg52638
(lp56424
(dp56425
g52643
I60
sg52644
VMCP-1
p56426
sg52646
I5
sg52674
VP41597
p56427
sg52649
I1
sa(dp56428
g52643
I54
sg52644
g56420
sg52646
I4
sg52674
VP05231
p56429
sg52649
I1
sasg52640
(lp56430
(dp56431
g52643
I169
sg52644
Vmacular hole
p56432
sg52646
I12
sg52647
VC0024441
p56433
sg52649
I2
sa(dp56434
g52643
I183
sg52644
g56421
sg52646
I2
sg52647
VC0024441
p56435
sg52649
I1
sa(dp56436
g52643
I8
sg52644
Vflare
p56437
sg52646
I5
sg52647
VC1517205
p56438
sg52649
I1
sasa(dp56439
g135
(dp56440
(Vintercellular adhesion molecule-1
p56441
VMH
p56442
tp56443
I00
ssg52636
VWe investigated the relations between the aqueous flare value and vitreous levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule-1 (sICAM-1), and interleukin-6 (IL-6) in patients with CRVO and macular edema or patients with idiopathic macular hole (MH).
p56444
sg52638
(lp56445
(dp56446
g52643
I200
sg52644
VIL-6
p56447
sg52646
I4
sg52674
VP05231
p56448
sg52649
I1
sa(dp56449
g52643
I185
sg52644
Vinterleukin-6
p56450
sg52646
I13
sg52674
VP05231
p56451
sg52649
I1
sa(dp56452
g52643
I85
sg52644
Vvascular endothelial growth factor
p56453
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp56454
g52643
I136
sg52644
g56441
sg52646
I33
sg52674
VP05362
p56455
sg52649
I3
sa(dp56456
g52643
I121
sg52644
VVEGF
p56457
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp56458
(dp56459
g52643
I274
sg52644
Vmacular hole
p56460
sg52646
I12
sg52647
VC0024441
p56461
sg52649
I2
sa(dp56462
g52643
I232
sg52644
Vmacular edema
p56463
sg52646
I13
sg52647
VC0271051
p56464
sg52649
I2
sa(dp56465
g52643
I150
sg52644
Vadhesion
p56466
sg52646
I8
sg52647
VC0001511
p56467
sg52649
I1
sa(dp56468
g52643
I288
sg52644
g56442
sg52646
I2
sg52647
VC0024441
p56469
sg52649
I1
sa(dp56470
g52643
I50
sg52644
Vflare
p56471
sg52646
I5
sg52647
VC1517205
p56472
sg52649
I1
sasa(dp56473
g135
(dp56474
(Vmonocyte chemotactic protein 1
p56475
Vmacular hole
p56476
tp56477
I00
ssg52636
VVitreous fluid levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), and pentraxin 3 (PTX3) were significantly higher in CRVO patients than in macular hole patients.
p56478
sg52638
(lp56479
(dp56480
g52643
I61
sg52644
VVEGF
p56481
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp56482
g52643
I223
sg52644
Vpentraxin 3
p56483
sg52646
I11
sg52674
VP26022
p56484
sg52649
I2
sa(dp56485
g52643
I112
sg52644
Vintercellular adhesion molecule 1
p56486
sg52646
I33
sg52674
VP05362
p56487
sg52649
I4
sa(dp56488
g52643
I76
sg52644
VVEGF receptor 2
p56489
sg52646
I15
sg52674
g12
sg52649
I3
sa(dp56490
g52643
I236
sg52644
VPTX3
p56491
sg52646
I4
sg52674
VP26022
p56492
sg52649
I1
sa(dp56493
g52643
I211
sg52644
VMCP-1
p56494
sg52646
I5
sg52674
VP41597
p56495
sg52649
I1
sa(dp56496
g52643
I172
sg52644
VIL-6
p56497
sg52646
I4
sg52674
VP05231
p56498
sg52649
I1
sa(dp56499
g52643
I25
sg52644
Vvascular endothelial growth factor
p56500
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp56501
g52643
I157
sg52644
Vinterleukin 6
p56502
sg52646
I13
sg52674
VP05231
p56503
sg52649
I2
sa(dp56504
g52643
I179
sg52644
g56475
sg52646
I30
sg52674
VP14222
p56505
sg52649
I4
sasg52640
(lp56506
(dp56507
g52643
I126
sg52644
Vadhesion
p56508
sg52646
I8
sg52647
VC0001511
p56509
sg52649
I1
sa(dp56510
g52643
I293
sg52644
g56476
sg52646
I12
sg52647
VC0024441
p56511
sg52649
I2
sasa(dp56512
g135
(dp56513
(Vmonocyte chemotactic protein 1
p56514
Vadhesion
p56515
tp56516
I00
ssg52636
VIn 39 patients with BRVO and macular edema and 21 individuals with idiopathic macular hole (MH) serving as controls, vitreous fluid samples were obtained during vitreoretinal surgery, and the levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), soluble intercellular adhesion molecule 1 (sICAM-1), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), pentraxin 3 (PTX3), and pigment epithelium-derived factor (PEDF) were measured by enzyme-linked immunosorbent assay.
p56517
sg52638
(lp56518
(dp56519
g52643
I202
sg52644
Vvascular endothelial growth factor
p56520
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp56521
g52643
I238
sg52644
VVEGF
p56522
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp56523
g52643
I349
sg52644
VIL-6
p56524
sg52646
I4
sg52674
VP05231
p56525
sg52649
I1
sa(dp56526
g52643
I334
sg52644
Vinterleukin 6
p56527
sg52646
I13
sg52674
VP05231
p56528
sg52649
I2
sa(dp56529
g52643
I388
sg52644
VMCP-1
p56530
sg52646
I5
sg52674
VP41597
p56531
sg52649
I1
sa(dp56532
g52643
I409
sg52644
VPTX3
p56533
sg52646
I4
sg52674
VP26022
p56534
sg52649
I1
sa(dp56535
g52643
I396
sg52644
Vpentraxin 3
p56536
sg52646
I11
sg52674
VP26022
p56537
sg52649
I2
sa(dp56538
g52643
I289
sg52644
Vintercellular adhesion molecule 1
p56539
sg52646
I33
sg52674
VP05362
p56540
sg52649
I4
sa(dp56541
g52643
I356
sg52644
g56514
sg52646
I30
sg52674
VP14222
p56542
sg52649
I4
sa(dp56543
g52643
I253
sg52644
VVEGF receptor 2
p56544
sg52646
I15
sg52674
g12
sg52649
I3
sasg52640
(lp56545
(dp56546
g52643
I92
sg52644
VMH
p56547
sg52646
I2
sg52647
VC0024441
p56548
sg52649
I1
sa(dp56549
g52643
I78
sg52644
Vmacular hole
p56550
sg52646
I12
sg52647
VC0024441
p56551
sg52649
I2
sa(dp56552
g52643
I29
sg52644
Vmacular edema
p56553
sg52646
I13
sg52647
VC0271051
p56554
sg52649
I2
sa(dp56555
g52643
I303
sg52644
g56515
sg52646
I8
sg52647
VC0001511
p56556
sg52649
I1
sasa(dp56557
g135
(dp56558
(Vintercellular adhesion molecule 1
p56559
VBRVO
p56560
tp56561
I00
ssg52636
VTo investigate relationships among vitreous fluid levels of soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), vascular endothelial growth factor (VEGF), and soluble intercellular adhesion molecule 1 (sICAM-1) in patients with branch retinal vein occlusion (BRVO) and macular edema or patients with idiopathic macular hole.
p56562
sg52638
(lp56563
(dp56564
g52643
I116
sg52644
VVEGF
p56565
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp56566
g52643
I68
sg52644
Vvascular endothelial growth factor receptor-2
p56567
sg52646
I45
sg52674
VP35968
p56568
sg52649
I5
sa(dp56569
g52643
I181
sg52644
g56559
sg52646
I33
sg52674
VP05362
p56570
sg52649
I4
sa(dp56571
g52643
I68
sg52644
Vvascular endothelial growth factor
p56572
sg52646
I34
sg52674
g12
sg52649
I4
sasg52640
(lp56573
(dp56574
g52643
I283
sg52644
Vmacular edema
p56575
sg52646
I13
sg52647
VC0271051
p56576
sg52649
I2
sa(dp56577
g52643
I325
sg52644
Vmacular hole
p56578
sg52646
I12
sg52647
VC0024441
p56579
sg52649
I2
sa(dp56580
g52643
I242
sg52644
Vbranch retinal vein occlusion
p56581
sg52646
I29
sg52647
VC0339505
p56582
sg52649
I4
sa(dp56583
g52643
I195
sg52644
Vadhesion
p56584
sg52646
I8
sg52647
VC0001511
p56585
sg52649
I1
sa(dp56586
g52643
I273
sg52644
g56560
sg52646
I4
sg52647
VC0339505
p56587
sg52649
I1
sasa(dp56588
g52636
VBRVO patients had a significantly higher vitreous fluid level of sVEGFR-2 (median, 1670 pg/mL; interquartile range [IQL], 1205 to 2225 pg/mL) than macular hole patients (median, 1265 pg/mL; IQR, 731 to 1800 pg/mL; P = .017), as was the case for VEGF (median, 237 pg/mL; IQR, 42.2 to 1305 pg/mL; vs median, 15.6 pg/mL; IQR, 15.6 to 15.6 pg/mL; P &lt; .001) and sICAM-1 (median, 10.1 ng/mL; IQR, 6.3 to 22.5 ng/mL; vs median, 4.1 ng/mL; IQR, 3.3 to 6.0 ng/mL; P &lt; .001).
p56589
sg52638
(lp56590
sg52640
(lp56591
(dp56592
g52643
I147
sg52644
Vmacular hole
p56593
sg52646
I12
sg52647
VC0024441
p56594
sg52649
I2
sasa(dp56595
g52636
VVitreous levels of sICAM-1 were significantly increased in vitreous specimens from both PVR (median +/- SD; 12.0 +/- 76.3 ng/ml; P &lt; 0.01) and PDR (8.4 +/- 24.0 ng/ml; P &lt; 0.01) when compared to vitreous from eyes with macular holes (0.
p56596
sg52638
(lp56597
sg52640
(lp56598
(dp56599
g52643
I88
sg52644
VPVR
p56600
sg52646
I3
sg52647
VC1860404
p56601
sg52649
I1
sa(dp56602
g52643
I146
sg52644
VPDR
p56603
sg52646
I3
sg52647
VC1845050
p56604
sg52649
I1
sa(dp56605
g52643
I225
sg52644
Vmacular holes
p56606
sg52646
I13
sg52647
VC0024441
p56607
sg52649
I2
sasa(dp56608
g135
(dp56609
(VPVR
p56610
Vmacular holes
p56611
tp56612
I01
ssg52636
VLevels of sICAM-1 in this group were compared with those in vitreous from 31 eyes with RRD without clinical risk factors for PVR, 32 eyes with established PVR and 10 eyes with macular holes.
p56613
sg52638
(lp56614
(dp56615
g52643
I125
sg52644
g56610
sg52646
I3
sg52674
VP15151
p56616
sg52649
I1
sasg52640
(lp56617
(dp56618
g52643
I125
sg52644
VPVR
p56619
sg52646
I3
sg52647
VC1860404
p56620
sg52649
I1
sa(dp56621
g52643
I125
sg52644
VPVR
p56622
sg52646
I3
sg52647
VC1860404
p56623
sg52649
I1
sa(dp56624
g52643
I176
sg52644
g56611
sg52646
I13
sg52647
VC0024441
p56625
sg52649
I2
sasa(dp56626
g135
(dp56627
(VPVR
p56628
Vmacular holes
p56629
tp56630
I01
ssg52636
VVitreous sICAM-1 levels in eyes with RRD at high risk of developing PVR were significantly lower than in eyes with established PVR (p=0.037), but higher than in eyes with macular holes (p &lt;0.0001).
p56631
sg52638
(lp56632
(dp56633
g52643
I68
sg52644
g56628
sg52646
I3
sg52674
VP15151
p56634
sg52649
I1
sasg52640
(lp56635
(dp56636
g52643
I68
sg52644
VPVR
p56637
sg52646
I3
sg52647
VC1860404
p56638
sg52649
I1
sa(dp56639
g52643
I171
sg52644
g56629
sg52646
I13
sg52647
VC0024441
p56640
sg52649
I2
sa(dp56641
g52643
I68
sg52644
VPVR
p56642
sg52646
I3
sg52647
VC1860404
p56643
sg52649
I1
sasa(dp56644
g135
(dp56645
(VLPL
p56646
VPKU
p56647
tp56648
I00
ssg52636
VRare pathogenic alleles with high penetrance and associated haplotypes at 10 loci (CFTR, FAH, HBB, HEXA, LDLR, LPL, PAH, PABP2, PDDR, and SACS) are expressed in probands with cystic fibrosis, tyrosinemia, beta-thalassemia, Tay-Sachs, familial hypercholesterolemia, hyperchylomicronemia, PKU, oculopharyngeal muscular dystrophy, pseudo vitamin D deficiency rickets, and spastic ataxia of Charlevoix-Saguenay, respectively) reveal the interpopulation and intrapopulation genetic diversity of Quebec.
p56649
sg52638
(lp56650
(dp56651
g52643
I89
sg52644
VFAH
p56652
sg52646
I3
sg52674
VP16930
p56653
sg52649
I1
sa(dp56654
g52643
I94
sg52644
VHBB
p56655
sg52646
I3
sg52674
VP02042
p56656
sg52649
I1
sa(dp56657
g52643
I83
sg52644
VCFTR
p56658
sg52646
I4
sg52674
VP13569
p56659
sg52649
I1
sa(dp56660
g52643
I128
sg52644
VPDDR
p56661
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp56662
g52643
I116
sg52644
VPAH
p56663
sg52646
I3
sg52674
VP00439
p56664
sg52649
I1
sa(dp56665
g52643
I99
sg52644
VHEXA
p56666
sg52646
I4
sg52674
VP06865
p56667
sg52649
I1
sa(dp56668
g52643
I105
sg52644
VLDLR
p56669
sg52646
I4
sg52674
VP01130
p56670
sg52649
I1
sa(dp56671
g52643
I121
sg52644
VPABP2
p56672
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp56673
g52643
I111
sg52644
g56646
sg52646
I3
sg52674
VP06858
p56674
sg52649
I1
sasg52640
(lp56675
(dp56676
g52643
I175
sg52644
Vcystic fibrosis
p56677
sg52646
I15
sg52647
VC0010674
p56678
sg52649
I2
sa(dp56679
g52643
I192
sg52644
Vtyrosinemia
p56680
sg52646
I11
sg52647
VC0268483
p56681
sg52649
I1
sa(dp56682
g52643
I292
sg52644
Voculopharyngeal muscular dystrophy
p56683
sg52646
I34
sg52647
VC0270952
p56684
sg52649
I3
sa(dp56685
g52643
I116
sg52644
VPAH
p56686
sg52646
I3
sg52647
VC0152171
p56687
sg52649
I1
sa(dp56688
g52643
I138
sg52644
VSACS
p56689
sg52646
I4
sg52647
VC1849140
p56690
sg52649
I1
sa(dp56691
g52643
I356
sg52644
Vrickets
p56692
sg52646
I7
sg52647
VC0035579
p56693
sg52649
I1
sa(dp56694
g52643
I369
sg52644
Vspastic ataxia of Charlevoix-Saguenay
p56695
sg52646
I37
sg52647
VC1849140
p56696
sg52649
I4
sa(dp56697
g52643
I205
sg52644
Vbeta-thalassemia
p56698
sg52646
I16
sg52647
VC0005283
p56699
sg52649
I1
sa(dp56700
g52643
I265
sg52644
Vhyperchylomicronemia
p56701
sg52646
I20
sg52647
VC0023817
p56702
sg52649
I1
sa(dp56703
g52643
I234
sg52644
Vfamilial hypercholesterolemia
p56704
sg52646
I29
sg52647
VC0020445
p56705
sg52649
I2
sa(dp56706
g52643
I335
sg52644
Vvitamin D deficiency
p56707
sg52646
I20
sg52647
VC0042870
p56708
sg52649
I3
sa(dp56709
g52643
I287
sg52644
g56647
sg52646
I3
sg52647
VC0031485
p56710
sg52649
I1
sasa(dp56711
g52636
VBiochemical, neuropathological, and genetic evidence suggests an important role for TCERG1 in Huntington's disease (HD) pathogenesis.
p56712
sg52638
(lp56713
(dp56714
g52643
I84
sg52644
VTCERG1
p56715
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp56716
(dp56717
g52643
I94
sg52644
VHuntington's disease
p56718
sg52646
I20
sg52647
VC0020179
p56719
sg52649
I2
sa(dp56720
g52643
I120
sg52644
Vpathogenesis
p56721
sg52646
I12
sg52647
VC0699748
p56722
sg52649
I1
sa(dp56723
g52643
I116
sg52644
VHD
p56724
sg52646
I2
sg52647
VC0020179
p56725
sg52649
I1
sasa(dp56726
g52636
VFurther investigations on the underlying mechanisms showed that the depletion of dG9a repressed starvation-induced autophagy by controlling the expression level of Atg8a, a critical gene for the progression of autophagy, in a different manner to that in cancer cells.
p56727
sg52638
(lp56728
sg52640
(lp56729
(dp56730
g52643
I254
sg52644
Vcancer
p56731
sg52646
I6
sg52647
VC0006826
p56732
sg52649
I1
sasa(dp56733
g135
(dp56734
(VRas
p56735
Vpancreatic cancer
p56736
tp56737
I00
ssg52636
VBioinformatic analysis of human tumours revealed that several core autophagy genes, including GABARAP, correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a potential tumour-suppressive effect of the pathway in Ras-driven human cancers.
p56738
sg52638
(lp56739
(dp56740
g52643
I128
sg52644
VKRAS
p56741
sg52646
I4
sg52674
VP01116
p56742
sg52649
I1
sa(dp56743
g52643
I94
sg52644
VGABARAP
p56744
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp56745
g52643
I257
sg52644
g56735
sg52646
I3
sg52674
VP01116
p56746
sg52649
I1
sasg52640
(lp56747
(dp56748
g52643
I32
sg52644
Vtumours
p56749
sg52646
I7
sg52647
VC0027651
p56750
sg52649
I1
sa(dp56751
g52643
I32
sg52644
Vtumour
p56752
sg52646
I6
sg52647
VC0027651
p56753
sg52649
I1
sa(dp56754
g52643
I171
sg52644
g56736
sg52646
I17
sg52647
VC0235974
p56755
sg52649
I2
sa(dp56756
g52643
I274
sg52644
Vcancers
p56757
sg52646
I7
sg52647
VC0006826
p56758
sg52649
I1
sasa(dp56759
g135
(dp56760
(VCDH6
p56761
Vthyroid cancer
p56762
tp56763
I00
ssg52636
VUsing a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism.
p56764
sg52638
(lp56765
(dp56766
g52643
I152
sg52644
VBNIP3L
p56767
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp56768
g52643
I104
sg52644
VCDH6
p56769
sg52646
I4
sg52674
VP55285
p56770
sg52649
I1
sa(dp56771
g52643
I285
sg52644
VDRP1
p56772
sg52646
I4
sg52674
VP46939
p56773
sg52649
I1
sa(dp56774
g52643
I104
sg52644
g56761
sg52646
I4
sg52674
VP55285
p56775
sg52649
I1
sa(dp56776
g52643
I133
sg52644
VGABARAP
p56777
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp56778
g52643
I142
sg52644
VBNIP3
p56779
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp56780
(dp56781
g52643
I56
sg52644
g56762
sg52646
I14
sg52647
VC0007115
p56782
sg52649
I2
sasa(dp56783
g52636
VWe previously reported that GABARAPL1 expression was frequently downregulated in cancer cells while a high GABARAPL1 expression is a good prognosis marker for patients with lymph node-positive breast cancer.
p56784
sg52638
(lp56785
(dp56786
g52643
I28
sg52644
VGABARAPL1
p56787
sg52646
I9
sg52674
g12
sg52649
I1
sa(dp56788
g52643
I28
sg52644
VGABARAPL1
p56789
sg52646
I9
sg52674
g12
sg52649
I1
sasg52640
(lp56790
(dp56791
g52643
I179
sg52644
Vnode-positive breast cancer
p56792
sg52646
I27
sg52647
VC3160887
p56793
sg52649
I3
sa(dp56794
g52643
I81
sg52644
Vcancer
p56795
sg52646
I6
sg52647
VC0006826
p56796
sg52649
I1
sasa(dp56797
g52636
VIn this study, we asked using qRT-PCR, western blotting and epigenetic quantification whether the expression of the GABARAP family was regulated in breast cancer by epigenetic modifications.
p56798
sg52638
(lp56799
(dp56800
g52643
I116
sg52644
VGABARAP family
p56801
sg52646
I14
sg52674
g12
sg52649
I2
sasg52640
(lp56802
(dp56803
g52643
I148
sg52644
Vbreast cancer
p56804
sg52646
I13
sg52647
VC0678222
p56805
sg52649
I2
sasa(dp56806
g135
(dp56807
(VCREB-1
p56808
Vbreast cancers
p56809
tp56810
I00
ssg52636
VOur data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was required for GABARAPL1 expression.
p56811
sg52638
(lp56812
(dp56813
g52643
I50
sg52644
VGABARAPL1
p56814
sg52646
I9
sg52674
g12
sg52649
I1
sa(dp56815
g52643
I165
sg52644
g56808
sg52646
I6
sg52674
VP16220
p56816
sg52649
I1
sa(dp56817
g52643
I134
sg52644
Vhistone
p56818
sg52646
I7
sg52674
VP62805
p56819
sg52649
I1
sa(dp56820
g52643
I187
sg52644
VGABARAPL1 promoter
p56821
sg52646
I18
sg52674
g12
sg52649
I2
sa(dp56822
g52643
I50
sg52644
VGABARAPL1
p56823
sg52646
I9
sg52674
g12
sg52649
I1
sasg52640
(lp56824
(dp56825
g52643
I172
sg52644
Vrecruitment
p56826
sg52646
I11
sg52647
VC0271510
p56827
sg52649
I1
sa(dp56828
g52643
I74
sg52644
g56809
sg52646
I14
sg52647
VC0006142
p56829
sg52649
I2
sasa(dp56830
g135
(dp56831
(VMYH10
p56832
Vacute myeloid leukemia
p56833
tp56834
I01
ssg52636
VHere we demonstrate that runx1 deletion in mice induces the persistence of MYH10 in platelets, and a similar persistence was observed in platelets of patients with constitutional (familial platelet disorder/acute myeloid leukemia) or acquired (chronic myelomonocytic leukemia) RUNX1 mutations.
p56835
sg52638
(lp56836
(dp56837
g52643
I25
sg52644
Vrunx1 deletion
p56838
sg52646
I14
sg52674
VP01719
p56839
sg52649
I2
sa(dp56840
g52643
I75
sg52644
g56832
sg52646
I5
sg52674
VP35580
p56841
sg52649
I1
sasg52640
(lp56842
(dp56843
g52643
I244
sg52644
Vchronic myelomonocytic leukemia
p56844
sg52646
I31
sg52647
VC0023480
p56845
sg52649
I3
sa(dp56846
g52643
I189
sg52644
Vplatelet disorder
p56847
sg52646
I17
sg52647
VC0005818
p56848
sg52649
I2
sa(dp56849
g52643
I207
sg52644
g56833
sg52646
I22
sg52647
VC0023467
p56850
sg52649
I3
sasa(dp56851
g135
(dp56852
(VMYH10
p56853
VParis-Trousseau syndrome
p56854
tp56855
I01
ssg52636
VMYH10 was also detected in platelets of patients with the Paris-Trousseau syndrome, a thrombocytopenia related to the deletion of the transcription factor FLI1 that forms a complex with RUNX1 to regulate megakaryopoiesis, whereas MYH10 persistence was not observed in other inherited forms of thrombocytopenia.
p56856
sg52638
(lp56857
(dp56858
g52643
I155
sg52644
VFLI1
p56859
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp56860
g52643
I0
sg52644
VMYH10
p56861
sg52646
I5
sg52674
VP35580
p56862
sg52649
I1
sa(dp56863
g52643
I0
sg52644
g56853
sg52646
I5
sg52674
VP35580
p56864
sg52649
I1
sasg52640
(lp56865
(dp56866
g52643
I58
sg52644
g56854
sg52646
I24
sg52647
VC0795841
p56867
sg52649
I2
sasa(dp56868
g135
(dp56869
(VMYH10
p56870
Vplatelet disorders
p56871
tp56872
I01
ssg52636
VWe propose MYH10 detection as a new and simple tool to identify inherited platelet disorders and myeloid neoplasms with abnormalities in RUNX1 and its associated proteins.
p56873
sg52638
(lp56874
(dp56875
g52643
I11
sg52644
g56870
sg52646
I5
sg52674
VP35580
p56876
sg52649
I1
sasg52640
(lp56877
(dp56878
g52643
I74
sg52644
g56871
sg52646
I18
sg52647
VC0005818
p56879
sg52649
I2
sa(dp56880
g52643
I105
sg52644
Vneoplasms
p56881
sg52646
I9
sg52647
VC0027651
p56882
sg52649
I1
sasa(dp56883
g135
(dp56884
(Valpha-fetoprotein and beta HCG
p56885
Vgynecomastia
p56886
tp56887
I00
ssg52636
VThe existence of gynecomastia, age, detection of heterogeneous nodules on ultrasound, and preoperative alpha-fetoprotein and beta HCG are relevant data in relation to histological type of tumor.
p56888
sg52638
(lp56889
(dp56890
g52643
I103
sg52644
g56885
sg52646
I30
sg52674
VP02771
p56891
sg52649
I4
sasg52640
(lp56892
(dp56893
g52643
I130
sg52644
VHCG
p56894
sg52646
I3
sg52647
VC1855900
p56895
sg52649
I1
sa(dp56896
g52643
I63
sg52644
Vnodules
p56897
sg52646
I7
sg52647
VC0028259
p56898
sg52649
I1
sa(dp56899
g52643
I17
sg52644
g56886
sg52646
I12
sg52647
VC0018418
p56900
sg52649
I1
sa(dp56901
g52643
I188
sg52644
Vtumor
p56902
sg52646
I5
sg52647
VC0027651
p56903
sg52649
I1
sasa(dp56904
g135
(dp56905
(VPlasmodium lactate dehydrogenase
p56906
VTumour necrosis
p56907
tp56908
I00
ssg52636
VList of Abbreviations: AO: Acridine orange, AIDS: Acquired immunodeficiency syndrome, ACT: Artemisinin-based combination therapy, CM:Cerebral malaria, BCP:Benzothiocarboxypurine, DDT:Dichloro-diphenyl-trichloroethane, DNA:DeoxyriboNucleic Acid, ELAM-1: Endothelial leukocyte adhesion molecule, G6PD: Glucose-6-Phosphate Dehydrogenase, HIV: Human immuno deficiency virus, HRP 2: Histidine Rich Protein 2, ICAM -1: Inter cellular adhesion molecule1, ICER: Incremental cost effectiveness ratio, IL-1: Interleukin -1, IFN-g: Interferon-gamma, IgG: Immunoglobulin G, MP: Malaria parasite, NADP: Oxidised Nicotinamide Adenine Dinucleotide Phosphate, NADPH: Reduced Nicotinamide Adenine Dinucleotide Phosphate, PCV: Packed Cell Volume (haematocrit), P. falciparum: Plasmodium falciparum, PLDH: Plasmodium lactate dehydrogenase, PCR: Polymerase Chain Reaction, PPV: Positive predictive value, QBC: Quantitative Buffy Coat examination, TNF: Tumour necrosis factor, NPV: Negative predictive value, RDT: Rapid diagnostic test, SP: Sulphadoxine -Pyrimethamine, SMA: Severe malarial anaemia, UM: Uncomplicated malaria, USA:United States of America, VCAM-1: Vascular cell adhesion molecule, WBC: White Blood Cell, WHO: World Health Organization.
p56909
sg52638
(lp56910
(dp56911
g52643
I1144
sg52644
VVascular cell adhesion molecule
p56912
sg52646
I31
sg52674
g12
sg52649
I4
sa(dp56913
g52643
I521
sg52644
VInterferon-gamma
p56914
sg52646
I16
sg52674
VP01579
p56915
sg52649
I1
sa(dp56916
g52643
I413
sg52644
VInter cellular adhesion molecule1
p56917
sg52646
I33
sg52674
VP01185
p56918
sg52649
I4
sa(dp56919
g52643
I927
sg52644
VTNF
p56920
sg52646
I3
sg52674
VP01375
p56921
sg52649
I1
sa(dp56922
g52643
I514
sg52644
VIFN-g
p56923
sg52646
I5
sg52674
VP01579
p56924
sg52649
I1
sa(dp56925
g52643
I300
sg52644
VGlucose-6-Phosphate Dehydrogenase
p56926
sg52646
I33
sg52674
VP49366
p56927
sg52649
I2
sa(dp56928
g52643
I294
sg52644
VG6PD
p56929
sg52646
I4
sg52674
VP11441
p56930
sg52649
I1
sa(dp56931
g52643
I498
sg52644
VInterleukin -1
p56932
sg52646
I14
sg52674
VP60568
p56933
sg52649
I2
sa(dp56934
g52643
I245
sg52644
VELAM-1
p56935
sg52646
I6
sg52674
VP16581
p56936
sg52649
I1
sa(dp56937
g52643
I539
sg52644
VIgG: Immunoglobulin G
p56938
sg52646
I21
sg52674
g12
sg52649
I3
sa(dp56939
g52643
I492
sg52644
VIL-1
p56940
sg52646
I4
sg52674
VP01584
p56941
sg52649
I1
sa(dp56942
g52643
I1136
sg52644
VVCAM-1
p56943
sg52646
I6
sg52674
VP19320
p56944
sg52649
I1
sa(dp56945
g52643
I932
sg52644
VTumour necrosis factor
p56946
sg52646
I22
sg52674
VP01375
p56947
sg52649
I3
sa(dp56948
g52643
I340
sg52644
VHuman immuno deficiency virus, HRP 2: Histidine Rich Protein 2
p56949
sg52646
I62
sg52674
g12
sg52649
I10
sa(dp56950
g52643
I253
sg52644
VEndothelial leukocyte adhesion molecule
p56951
sg52646
I39
sg52674
g12
sg52649
I4
sa(dp56952
g52643
I787
sg52644
g56906
sg52646
I32
sg52674
VP49366
p56953
sg52649
I3
sasg52640
(lp56954
(dp56955
g52643
I133
sg52644
VCerebral malaria
p56956
sg52646
I16
sg52647
VC0024534
p56957
sg52649
I2
sa(dp56958
g52643
I275
sg52644
Vadhesion
p56959
sg52646
I8
sg52647
VC0001511
p56960
sg52649
I1
sa(dp56961
g52643
I988
sg52644
VRDT
p56962
sg52646
I3
sg52647
VC0206743
p56963
sg52649
I1
sa(dp56964
g52643
I275
sg52644
Vadhesion
p56965
sg52646
I8
sg52647
VC0001511
p56966
sg52649
I1
sa(dp56967
g52643
I1049
sg52644
VSMA
p56968
sg52646
I3
sg52647
VC0026847
p56969
sg52649
I1
sa(dp56970
g52643
I275
sg52644
Vadhesion
p56971
sg52646
I8
sg52647
VC0001511
p56972
sg52649
I1
sa(dp56973
g52643
I50
sg52644
VAcquired immunodeficiency syndrome
p56974
sg52646
I34
sg52647
VC0001175
p56975
sg52649
I3
sa(dp56976
g52643
I142
sg52644
Vmalaria
p56977
sg52646
I7
sg52647
VC0024530
p56978
sg52649
I1
sa(dp56979
g52643
I335
sg52644
VHIV
p56980
sg52646
I3
sg52647
VC0019693
p56981
sg52649
I1
sa(dp56982
g52643
I566
sg52644
VMalaria
p56983
sg52646
I7
sg52647
VC0024530
p56984
sg52649
I1
sa(dp56985
g52643
I1070
sg52644
Vanaemia
p56986
sg52646
I7
sg52647
VC0002871
p56987
sg52649
I1
sa(dp56988
g52643
I932
sg52644
g56907
sg52646
I15
sg52647
VC0333516
p56989
sg52649
I2
sasa(dp56990
g52636
VHS intake increased natriuresis, diuresis, and urinary DA while it decreased cortical NOS I expression (P &lt; 0.05 vs. NS), Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) activity in MD (P &lt; 0.001 vs. NS) and cortical nitrates+nitrites (NOx) production (NS 2.04 +/- 0.22 vs. HS 1.28 +/- 0.10 nmol mg protein-1, P &lt; 0.01).
p56991
sg52638
(lp56992
(dp56993
g52643
I125
sg52644
VNicotinamide adenine dinucleotide phosphate diaphorase
p56994
sg52646
I54
sg52674
VP28331
p56995
sg52649
I5
sa(dp56996
g52643
I181
sg52644
VNADPH-d
p56997
sg52646
I7
sg52674
VP30043
p56998
sg52649
I1
sasg52640
(lp56999
sa(dp57000
g135
(dp57001
(VG6PD
p57002
Vanemia
p57003
tp57004
I00
ssg52636
VDecreased G6PD activity and, as a result, decreased NADPH level have been associated with diabetic kidney disease, altered nitric oxide production, aldosterone-mediated endothelial dysfunction, and dialysis-associated anemia.
p57005
sg52638
(lp57006
(dp57007
g52643
I10
sg52644
g57002
sg52646
I4
sg52674
VP11441
p57008
sg52649
I1
sasg52640
(lp57009
(dp57010
g52643
I169
sg52644
Vendothelial dysfunction
p57011
sg52646
I23
sg52647
VC0856169
p57012
sg52649
I2
sa(dp57013
g52643
I90
sg52644
Vdiabetic kidney disease
p57014
sg52646
I23
sg52647
VC0011881
p57015
sg52649
I3
sa(dp57016
g52643
I218
sg52644
g57003
sg52646
I6
sg52647
VC0002871
p57017
sg52649
I1
sasa(dp57018
g135
(dp57019
(VG6PD
p57020
Vhemolytic anemia
p57021
tp57022
I01
ssg52636
VGlucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymatic disorder of red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine dinucleotide phosphate (NADPH) production and imbalanced redox homeostasis in erythrocytes.
p57023
sg52638
(lp57024
(dp57025
g52643
I0
sg52644
VGlucose-6-phosphate dehydrogenase
p57026
sg52646
I33
sg52674
VP49366
p57027
sg52649
I2
sa(dp57028
g52643
I35
sg52644
g57020
sg52646
I4
sg52674
VP11441
p57029
sg52649
I1
sasg52640
(lp57030
(dp57031
g52643
I163
sg52644
Vimpaired
p57032
sg52646
I8
sg52647
VC0684336
p57033
sg52649
I1
sa(dp57034
g52643
I136
sg52644
g57021
sg52646
I16
sg52647
VC0002878
p57035
sg52649
I2
sasa(dp57036
g52636
VInterestingly, D2 recovery was accompanied by improvements in photosynthetic parameters (Asat and Fv/Fm) and the NADPH/NADP(+) ratio.
p57037
sg52638
(lp57038
sg52640
(lp57039
(dp57040
g52643
I89
sg52644
VAsat
p57041
sg52646
I4
sg52647
VC1845028
p57042
sg52649
I1
sasa(dp57043
g135
(dp57044
(VNlrp3
p57045
VNod
p57046
tp57047
I00
ssg52636
VHFD significantly enhanced the Asm activity, ceramide production, colocalization of Nlrp3 (Nod-like receptor protein 3) with ASC (apoptosis-associated speck-like protein) or Caspase-1, NADPH-dependent superoxide (O2(*-)) production in glomeruli of Asm(+/+) mice than in control diet-fed mice.
p57048
sg52638
(lp57049
(dp57050
g52643
I31
sg52644
VAsm
p57051
sg52646
I3
sg52674
VP17405
p57052
sg52649
I1
sa(dp57053
g52643
I91
sg52644
VNod-like receptor protein 3
p57054
sg52646
I27
sg52674
VP54259
p57055
sg52649
I4
sa(dp57056
g52643
I185
sg52644
VNADPH-dependent superoxide
p57057
sg52646
I26
sg52674
VP30043
p57058
sg52649
I2
sa(dp57059
g52643
I174
sg52644
VCaspase-1
p57060
sg52646
I9
sg52674
VP29466
p57061
sg52649
I1
sa(dp57062
g52643
I84
sg52644
g57045
sg52646
I5
sg52674
VP54259
p57063
sg52649
I1
sasg52640
(lp57064
(dp57065
g52643
I91
sg52644
g57046
sg52646
I3
sg52647
VC0751781
p57066
sg52649
I1
sasa(dp57067
g52636
VWe have studied the effects of growth factors and cytokines on the tumorigenicity and invasion capacity of tumor cells by using regressor and progressor tumor cell lines (ER-1 and ERpP, respectively) derived from an SHR rat mammary adenocarcinoma.
p57068
sg52638
(lp57069
sg52640
(lp57070
(dp57071
g52643
I224
sg52644
Vmammary adenocarcinoma
p57072
sg52646
I22
sg52647
VC0858252
p57073
sg52649
I2
sa(dp57074
g52643
I86
sg52644
Vinvasion
p57075
sg52646
I8
sg52647
VC2699153
p57076
sg52649
I1
sa(dp57077
g52643
I67
sg52644
Vtumorigenicity
p57078
sg52646
I14
sg52647
VC1519697
p57079
sg52649
I1
sa(dp57080
g52643
I67
sg52644
Vtumor
p57081
sg52646
I5
sg52647
VC0027651
p57082
sg52649
I1
sa(dp57083
g52643
I67
sg52644
Vtumor
p57084
sg52646
I5
sg52647
VC0027651
p57085
sg52649
I1
sasa(dp57086
g52636
VWe have studied the effect of growth factors and cytokine on tumorigenesis and invasive capacity of tumor cells by examining a regressor tumor cell line (ER-1) derived from SHR rat mammary adenocarcinoma.
p57087
sg52638
(lp57088
sg52640
(lp57089
(dp57090
g52643
I61
sg52644
Vtumor
p57091
sg52646
I5
sg52647
VC0027651
p57092
sg52649
I1
sa(dp57093
g52643
I181
sg52644
Vmammary adenocarcinoma
p57094
sg52646
I22
sg52647
VC0858252
p57095
sg52649
I2
sa(dp57096
g52643
I61
sg52644
Vtumorigenesis
p57097
sg52646
I13
sg52647
VC0007621
p57098
sg52649
I1
sa(dp57099
g52643
I61
sg52644
Vtumor
p57100
sg52646
I5
sg52647
VC0027651
p57101
sg52649
I1
sasa(dp57102
g135
(dp57103
(Vvitronectin
p57104
Vgliomas
p57105
tp57106
I00
ssg52636
VLevel of several proteins including haptoglobin, transthyretin, osteopontin, vitronectin, complement factor H and different classes of immunoglobulins are found to be considerably increased in CSF of higher grades of gliomas.
p57107
sg52638
(lp57108
(dp57109
g52643
I36
sg52644
Vhaptoglobin
p57110
sg52646
I11
sg52674
VP00738
p57111
sg52649
I1
sa(dp57112
g52643
I49
sg52644
Vtransthyretin
p57113
sg52646
I13
sg52674
VP02766
p57114
sg52649
I1
sa(dp57115
g52643
I64
sg52644
Vosteopontin
p57116
sg52646
I11
sg52674
VP10451
p57117
sg52649
I1
sa(dp57118
g52643
I77
sg52644
g57104
sg52646
I11
sg52674
VP04004
p57119
sg52649
I1
sa(dp57120
g52643
I135
sg52644
Vimmunoglobulins
p57121
sg52646
I15
sg52674
g12
sg52649
I1
sa(dp57122
g52643
I90
sg52644
Vcomplement factor H
p57123
sg52646
I19
sg52674
g12
sg52649
I3
sasg52640
(lp57124
(dp57125
g52643
I217
sg52644
g57105
sg52646
I7
sg52647
VC0017638
p57126
sg52649
I1
sasa(dp57127
g135
(dp57128
(VVitronectin
p57129
Vglioma
p57130
tp57131
I00
ssg52636
VVitronectin is an extracellular matrix protein, the synthesis of which by glioma cells correlates with tumor grade.
p57132
sg52638
(lp57133
(dp57134
g52643
I18
sg52644
Vextracellular matrix protein
p57135
sg52646
I28
sg52674
VP55082
p57136
sg52649
I3
sa(dp57137
g52643
I0
sg52644
g57129
sg52646
I11
sg52674
VP04004
p57138
sg52649
I1
sasg52640
(lp57139
(dp57140
g52643
I103
sg52644
Vtumor
p57141
sg52646
I5
sg52647
VC0027651
p57142
sg52649
I1
sa(dp57143
g52643
I74
sg52644
g57130
sg52646
I6
sg52647
VC0017638
p57144
sg52649
I1
sasa(dp57145
g135
(dp57146
(Vserum vitronectin
p57147
Vglioma
p57148
tp57149
I00
ssg52636
VThe current study was designed to investigate the relationship between serum vitronectin levels and clinicopathological characteristics, diagnosis and prognosis in glioma patients.
p57150
sg52638
(lp57151
(dp57152
g52643
I71
sg52644
g57147
sg52646
I17
sg52674
VP04004
p57153
sg52649
I2
sasg52640
(lp57154
(dp57155
g52643
I164
sg52644
g57148
sg52646
I6
sg52647
VC0017638
p57156
sg52649
I1
sasa(dp57157
g135
(dp57158
(VSerum vitronectin
p57159
Vglioma
p57160
tp57161
I00
ssg52636
VSerum vitronectin levels were significantly elevated in glioma patients as compared with other groups.
p57162
sg52638
(lp57163
(dp57164
g52643
I0
sg52644
g57159
sg52646
I17
sg52674
VP04004
p57165
sg52649
I2
sasg52640
(lp57166
(dp57167
g52643
I56
sg52644
g57160
sg52646
I6
sg52647
VC0017638
p57168
sg52649
I1
sasa(dp57169
g135
(dp57170
(VSerum vitronectin
p57171
Vlow-grade glioma
p57172
tp57173
I00
ssg52636
VSerum vitronectin levels could significantly distinguish glioma patients from other groups and discriminate high-grade glioma from low-grade glioma.
p57174
sg52638
(lp57175
(dp57176
g52643
I0
sg52644
g57171
sg52646
I17
sg52674
VP04004
p57177
sg52649
I2
sasg52640
(lp57178
(dp57179
g52643
I57
sg52644
Vglioma
p57180
sg52646
I6
sg52647
VC0017638
p57181
sg52649
I1
sa(dp57182
g52643
I57
sg52644
Vglioma
p57183
sg52646
I6
sg52647
VC0017638
p57184
sg52649
I1
sa(dp57185
g52643
I131
sg52644
g57172
sg52646
I16
sg52647
VC1997217
p57186
sg52649
I2
sasa(dp57187
g135
(dp57188
(Vvitronectin
p57189
Vglioma
p57190
tp57191
I00
ssg52636
VSerum vitronectin may be a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
p57192
sg52638
(lp57193
(dp57194
g52643
I6
sg52644
g57189
sg52646
I11
sg52674
VP04004
p57195
sg52649
I1
sasg52640
(lp57196
(dp57197
g52643
I135
sg52644
g57190
sg52646
I6
sg52647
VC0017638
p57198
sg52649
I1
sasa(dp57199
g135
(dp57200
(Vhypoxia and vitronectin
p57201
Vmalignant glioma
p57202
tp57203
I01
ssg52636
VBioinformatics analysis emphasized key roles of integrin Beta3, hypoxia and vitronectin and their strong correlations with EGFRvIII expression in malignant glioma patient samples in vivo.
p57204
sg52638
(lp57205
(dp57206
g52643
I64
sg52644
g57201
sg52646
I23
sg52674
VP04004
p57207
sg52649
I3
sasg52640
(lp57208
(dp57209
g52643
I64
sg52644
Vhypoxia
p57210
sg52646
I7
sg52647
VC0242184
p57211
sg52649
I1
sa(dp57212
g52643
I146
sg52644
g57202
sg52646
I16
sg52647
VC0555198
p57213
sg52649
I2
sasa(dp57214
g52636
VIn conclusion, we demonstrate that EGFRvIII/integrin Beta3 complexes promote GBM progression and metastasis in the environment of hypoxia and vitronectin-enrichment, and cilengitide may serve as a promising therapeutics for EGFRvIII-positive GBMs.
p57215
sg52638
(lp57216
sg52640
(lp57217
(dp57218
g52643
I77
sg52644
VGBM
p57219
sg52646
I3
sg52647
VC0017636
p57220
sg52649
I1
sa(dp57221
g52643
I130
sg52644
Vhypoxia
p57222
sg52646
I7
sg52647
VC0242184
p57223
sg52649
I1
sa(dp57224
g52643
I97
sg52644
Vmetastasis
p57225
sg52646
I10
sg52647
VC0027627
p57226
sg52649
I1
sasa(dp57227
g135
(dp57228
(VRas
p57229
VGlioma
p57230
tp57231
I01
ssg52636
VGlioma cells derived from the brain of the (12) V-Ha-Ras transgenic mice were used to study the effect of PI-3 kinase inhibitor SF1126 on activation of AKT and ERK signaling, proliferation, vitronectin mediated migration and changes in the distribution of cortical actin on vitronectin in the glioma cells in vitro.
p57232
sg52638
(lp57233
(dp57234
g52643
I106
sg52644
VPI-3 kinase
p57235
sg52646
I11
sg52674
g12
sg52649
I2
sa(dp57236
g52643
I190
sg52644
Vvitronectin
p57237
sg52646
I11
sg52674
VP04004
p57238
sg52649
I1
sa(dp57239
g52643
I190
sg52644
Vvitronectin
p57240
sg52646
I11
sg52674
VP04004
p57241
sg52649
I1
sa(dp57242
g52643
I152
sg52644
VAKT
p57243
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp57244
g52643
I160
sg52644
VERK
p57245
sg52646
I3
sg52674
VP29323
p57246
sg52649
I1
sa(dp57247
g52643
I53
sg52644
g57229
sg52646
I3
sg52674
VP01116
p57248
sg52649
I1
sasg52640
(lp57249
(dp57250
g52643
I293
sg52644
Vglioma
p57251
sg52646
I6
sg52647
VC0017638
p57252
sg52649
I1
sa(dp57253
g52643
I175
sg52644
Vproliferation
p57254
sg52646
I13
sg52647
VC0334094
p57255
sg52649
I1
sa(dp57256
g52643
I0
sg52644
g57230
sg52646
I6
sg52647
VC0017638
p57257
sg52649
I1
sasa(dp57258
g135
(dp57259
(Vvitronectin
p57260
Vglioma
p57261
tp57262
I00
ssg52636
VMost notably, treatment of SF1126 blocked integrin-dependent migration in transwell and scratch assays and caused a significant change in the organization and distribution of cortical actin on vitronectin in the glioma cells.
p57263
sg52638
(lp57264
(dp57265
g52643
I193
sg52644
g57260
sg52646
I11
sg52674
VP04004
p57266
sg52649
I1
sasg52640
(lp57267
(dp57268
g52643
I212
sg52644
g57261
sg52646
I6
sg52647
VC0017638
p57269
sg52649
I1
sasa(dp57270
g135
(dp57271
(Vvitronectin
p57272
VGBM
p57273
tp57274
I00
ssg52636
VThe hit compound 5.3d inhibited invasion and migration of both GBM stem cells (Gli7 and Gli4) and GBM cancer cell lines (C6, SNB75) on fibronectin, vitronectin, and laminin.
p57275
sg52638
(lp57276
(dp57277
g52643
I148
sg52644
g57272
sg52646
I11
sg52674
VP04004
p57278
sg52649
I1
sa(dp57279
g52643
I165
sg52644
Vlaminin
p57280
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp57281
g52643
I88
sg52644
VGli4
p57282
sg52646
I4
sg52674
VP10075
p57283
sg52649
I1
sasg52640
(lp57284
(dp57285
g52643
I63
sg52644
VGBM
p57286
sg52646
I3
sg52647
VC0017636
p57287
sg52649
I1
sa(dp57288
g52643
I32
sg52644
Vinvasion
p57289
sg52646
I8
sg52647
VC2699153
p57290
sg52649
I1
sa(dp57291
g52643
I102
sg52644
Vcancer
p57292
sg52646
I6
sg52647
VC0006826
p57293
sg52649
I1
sa(dp57294
g52643
I63
sg52644
g57273
sg52646
I3
sg52647
VC0017636
p57295
sg52649
I1
sasa(dp57296
g135
(dp57297
(Vvitronectin
p57298
Vadhesion
p57299
tp57300
I00
ssg52636
VIn this study, efficient downregulation of cathepsin B and uPAR by siRNA treatments significantly reduced glioma cell adhesion to laminin as compared to vitronectin, fibronectin, or collagen I in U251 and 4910 glioma cell lines.
p57301
sg52638
(lp57302
(dp57303
g52643
I130
sg52644
Vlaminin
p57304
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp57305
g52643
I43
sg52644
Vcathepsin B
p57306
sg52646
I11
sg52674
VP07858
p57307
sg52649
I2
sa(dp57308
g52643
I153
sg52644
g57298
sg52646
I11
sg52674
VP04004
p57309
sg52649
I1
sasg52640
(lp57310
(dp57311
g52643
I106
sg52644
Vglioma
p57312
sg52646
I6
sg52647
VC0017638
p57313
sg52649
I1
sa(dp57314
g52643
I106
sg52644
Vglioma
p57315
sg52646
I6
sg52647
VC0017638
p57316
sg52649
I1
sa(dp57317
g52643
I118
sg52644
g57299
sg52646
I8
sg52647
VC0001511
p57318
sg52649
I1
sasa(dp57319
g135
(dp57320
(VNecl-5
p57321
VGBM
p57322
tp57323
I00
ssg52636
VNecl-5, a cell surface receptor for vitronectin, is expressed in GBM but not normal brain.
p57324
sg52638
(lp57325
(dp57326
g52643
I36
sg52644
Vvitronectin
p57327
sg52646
I11
sg52674
VP04004
p57328
sg52649
I1
sa(dp57329
g52643
I0
sg52644
g57321
sg52646
I6
sg52674
VP15151
p57330
sg52649
I1
sasg52640
(lp57331
(dp57332
g52643
I65
sg52644
g57322
sg52646
I3
sg52647
VC0017636
p57333
sg52649
I1
sasa(dp57334
g52636
VThese included sudden appearance of tender, erythematous nodular eruptions mimicking ENL, severe constitutional symptoms like high grade fever, malaise, vomiting, epistaxis, joint pain and tenosynovitis simulating Type 2 Lepra Reaction.
p57335
sg52638
(lp57336
sg52640
(lp57337
(dp57338
g52643
I65
sg52644
Veruptions
p57339
sg52646
I9
sg52647
VC0302295
p57340
sg52649
I1
sa(dp57341
g52643
I174
sg52644
Vjoint pain
p57342
sg52646
I10
sg52647
VC0003862
p57343
sg52649
I2
sa(dp57344
g52643
I144
sg52644
Vmalaise
p57345
sg52646
I7
sg52647
VC0231218
p57346
sg52649
I1
sa(dp57347
g52643
I189
sg52644
Vtenosynovitis
p57348
sg52646
I13
sg52647
VC0039520
p57349
sg52649
I1
sa(dp57350
g52643
I214
sg52644
VType 2 Lepra Reaction
p57351
sg52646
I21
sg52647
VC0343466
p57352
sg52649
I4
sa(dp57353
g52643
I153
sg52644
Vvomiting
p57354
sg52646
I8
sg52647
VC0042963
p57355
sg52649
I1
sa(dp57356
g52643
I163
sg52644
Vepistaxis
p57357
sg52646
I9
sg52647
VC0014591
p57358
sg52649
I1
sasa(dp57359
g52636
VOGR1 and TRPC4 are prominently expressed in healthy cerebellar tissue throughout postnatal development and in primary cerebellar medulloblastoma tissues.
p57360
sg52638
(lp57361
(dp57362
g52643
I9
sg52644
VTRPC4
p57363
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57364
g52643
I0
sg52644
VOGR1
p57365
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp57366
(dp57367
g52643
I118
sg52644
Vcerebellar medulloblastoma
p57368
sg52646
I26
sg52647
VC1862179
p57369
sg52649
I2
sasa(dp57370
g52636
VOur results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
p57371
sg52638
(lp57372
(dp57373
g52643
I25
sg52644
VOGR1
p57374
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp57375
g52643
I53
sg52644
VTRPC4
p57376
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp57377
(dp57378
g52643
I166
sg52644
Vmedulloblastoma
p57379
sg52646
I15
sg52647
VC0025149
p57380
sg52649
I1
sa(dp57381
g52643
I120
sg52644
Vmetastasis
p57382
sg52646
I10
sg52647
VC0027627
p57383
sg52649
I1
sa(dp57384
g52643
I107
sg52644
Vinvasion
p57385
sg52646
I8
sg52647
VC2699153
p57386
sg52649
I1
sasa(dp57387
g52636
VHere, we report that OGR1 and G2A are expressed in human medulloblastoma tissue and its corresponding neuronal cell line.
p57388
sg52638
(lp57389
(dp57390
g52643
I30
sg52644
VG2A
p57391
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp57392
g52643
I21
sg52644
VOGR1
p57393
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp57394
(dp57395
g52643
I57
sg52644
Vmedulloblastoma
p57396
sg52646
I15
sg52647
VC0025149
p57397
sg52649
I1
sasa(dp57398
g52636
VTwo daughters of an affected mother demonstrated symptoms of stage III ADNIV, with posterior uveitis, cystoid macular edema, intraocular fibrosis, retinal neovascularization, retinal degeneration, and cataract.
p57399
sg52638
(lp57400
sg52640
(lp57401
(dp57402
g52643
I175
sg52644
Vretinal degeneration
p57403
sg52646
I20
sg52647
VC0035304
p57404
sg52649
I2
sa(dp57405
g52643
I137
sg52644
Vfibrosis
p57406
sg52646
I8
sg52647
VC0016059
p57407
sg52649
I1
sa(dp57408
g52643
I201
sg52644
Vcataract
p57409
sg52646
I8
sg52647
VC0086543
p57410
sg52649
I1
sa(dp57411
g52643
I102
sg52644
Vcystoid macular edema
p57412
sg52646
I21
sg52647
VC0024440
p57413
sg52649
I3
sa(dp57414
g52643
I83
sg52644
Vposterior uveitis
p57415
sg52646
I17
sg52647
VC0042167
p57416
sg52649
I2
sa(dp57417
g52643
I155
sg52644
Vneovascularization, retinal
p57418
sg52646
I27
sg52647
VC0035320
p57419
sg52649
I2
sasa(dp57420
g52636
VVisual acuity and features of ADNIV, including inflammatory cells, neovascularization, fibrosis, and cystoid macular edema, were reviewed.
p57421
sg52638
(lp57422
sg52640
(lp57423
(dp57424
g52643
I67
sg52644
Vneovascularization
p57425
sg52646
I18
sg52647
VC0027686
p57426
sg52649
I1
sa(dp57427
g52643
I101
sg52644
Vcystoid macular edema
p57428
sg52646
I21
sg52647
VC0024440
p57429
sg52649
I3
sa(dp57430
g52643
I87
sg52644
Vfibrosis
p57431
sg52646
I8
sg52647
VC0016059
p57432
sg52649
I1
sasa(dp57433
g52636
VAutosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is an inherited eye disease characterized by retinal and iris neovascularization, abnormal retinal pigmentation, anterior chamber and vitreous inflammation, cystoid macular edema, vitreous hemorrhage, and traction retinal detachment.
p57434
sg52638
(lp57435
sg52640
(lp57436
(dp57437
g52643
I127
sg52644
Viris neovascularization
p57438
sg52646
I23
sg52647
VC0154916
p57439
sg52649
I2
sa(dp57440
g52643
I227
sg52644
Vcystoid macular edema
p57441
sg52646
I21
sg52647
VC0024440
p57442
sg52649
I3
sa(dp57443
g52643
I250
sg52644
Vvitreous hemorrhage
p57444
sg52646
I19
sg52647
VC0042909
p57445
sg52649
I2
sa(dp57446
g52643
I275
sg52644
Vtraction retinal detachment
p57447
sg52646
I27
sg52647
VC0154828
p57448
sg52649
I3
sa(dp57449
g52643
I86
sg52644
Veye disease
p57450
sg52646
I11
sg52647
VC0015397
p57451
sg52649
I2
sa(dp57452
g52643
I213
sg52644
Vinflammation
p57453
sg52646
I12
sg52647
VC0021368
p57454
sg52649
I1
sasa(dp57455
g52636
VCommon metabolic problems in northeastern Thailand include renal stone disease, distal renal tubular acidosis, hypokalemic periodic paralysis, sudden unexplained nocturnal death and malnutrition-related diabetes mellitus.
p57456
sg52638
(lp57457
sg52640
(lp57458
(dp57459
g52643
I111
sg52644
Vhypokalemic periodic paralysis
p57460
sg52646
I30
sg52647
VC0238358
p57461
sg52649
I3
sa(dp57462
g52643
I203
sg52644
Vdiabetes mellitus
p57463
sg52646
I17
sg52647
VC0011849
p57464
sg52649
I2
sa(dp57465
g52643
I80
sg52644
Vdistal renal tubular acidosis
p57466
sg52646
I29
sg52647
VC1704380
p57467
sg52649
I4
sa(dp57468
g52643
I59
sg52644
Vrenal stone
p57469
sg52646
I11
sg52647
VC0022650
p57470
sg52649
I2
sa(dp57471
g52643
I182
sg52644
Vmalnutrition
p57472
sg52646
I12
sg52647
VC0162429
p57473
sg52649
I1
sasa(dp57474
g52636
VHigh prevalence of CD in presence of anemia and short stature in seropositive FDR in index study indicates need of targeted screening of this subgroup for the presence of CD.CD is unlikely in the absence of HLADQ2/DQ8.
p57475
sg52638
(lp57476
sg52640
(lp57477
(dp57478
g52643
I48
sg52644
Vshort stature
p57479
sg52646
I13
sg52647
VC0013336
p57480
sg52649
I2
sa(dp57481
g52643
I37
sg52644
Vanemia
p57482
sg52646
I6
sg52647
VC0002871
p57483
sg52649
I1
sasa(dp57484
g52636
VThe concurrence of the intracranial multiple primary tumors (MPTs) consisting of acoustic neuroma (AN) and pituitary adenoma is very rare.
p57485
sg52638
(lp57486
sg52640
(lp57487
(dp57488
g52643
I99
sg52644
VAN
p57489
sg52646
I2
sg52647
VC0027859
p57490
sg52649
I1
sa(dp57491
g52643
I81
sg52644
Vacoustic neuroma
p57492
sg52646
I16
sg52647
VC0027859
p57493
sg52649
I2
sa(dp57494
g52643
I45
sg52644
Vprimary tumors
p57495
sg52646
I14
sg52647
VC0677930
p57496
sg52649
I2
sa(dp57497
g52643
I107
sg52644
Vpituitary adenoma
p57498
sg52646
I17
sg52647
VC0032000
p57499
sg52649
I2
sasa(dp57500
g52636
VThirty five cases of MPTs were subdivided into three subtypes, i.e., 1) main duct type, 2) branch duct type and 3) peripheral type (mucinous cystadenoma/cystadenocarcinoma).
p57501
sg52638
(lp57502
(dp57503
g52643
I21
sg52644
VMPTs
p57504
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp57505
(dp57506
g52643
I153
sg52644
Vcystadenocarcinoma
p57507
sg52646
I18
sg52647
VC0010631
p57508
sg52649
I1
sa(dp57509
g52643
I132
sg52644
Vmucinous cystadenoma
p57510
sg52646
I20
sg52647
VC0010635
p57511
sg52649
I2
sasa(dp57512
g135
(dp57513
(VIL11
p57514
Vpreeclampsia
p57515
tp57516
I00
ssg52636
VTogether, these data suggest that IL11 could trigger an ER stress response in the placenta, which may contribute to obstetric complications such as preeclampsia.
p57517
sg52638
(lp57518
(dp57519
g52643
I34
sg52644
g57514
sg52646
I4
sg52674
VP20809
p57520
sg52649
I1
sasg52640
(lp57521
(dp57522
g52643
I148
sg52644
g57515
sg52646
I12
sg52647
VC0032914
p57523
sg52649
I1
sasa(dp57524
g135
(dp57525
(VCLS
p57526
Vcolorectal cancer
p57527
tp57528
I01
ssg52636
VThe relationship between IL-11 and CLS has rarely been reported, especially in patients with colorectal cancer.
p57529
sg52638
(lp57530
(dp57531
g52643
I25
sg52644
VIL-11
p57532
sg52646
I5
sg52674
VP20809
p57533
sg52649
I1
sa(dp57534
g52643
I35
sg52644
g57526
sg52646
I3
sg52674
VP51812
p57535
sg52649
I1
sasg52640
(lp57536
(dp57537
g52643
I35
sg52644
VCLS
p57538
sg52646
I3
sg52647
VC0265252
p57539
sg52649
I1
sa(dp57540
g52643
I93
sg52644
g57527
sg52646
I17
sg52647
VC1527249
p57541
sg52649
I2
sasa(dp57542
g135
(dp57543
(VIL-11
p57544
VCLS
p57545
tp57546
I00
ssg52636
VAlthough rare, CLS could be a severe side effect after the administration of IL-11.
p57547
sg52638
(lp57548
(dp57549
g52643
I77
sg52644
g57544
sg52646
I5
sg52674
VP20809
p57550
sg52649
I1
sasg52640
(lp57551
(dp57552
g52643
I15
sg52644
g57545
sg52646
I3
sg52647
VC0265252
p57553
sg52649
I1
sa(dp57554
g52643
I37
sg52644
Vside effect
p57555
sg52646
I11
sg52647
VC0879626
p57556
sg52649
I2
sasa(dp57557
g135
(dp57558
(VIL-11
p57559
VST-elevation myocardial infarction
p57560
tp57561
I00
ssg52636
VWe describe four cases of the patients with ST-elevation myocardial infarction (STEMI) that were treated with interleukin-11 (IL-11), a cardioprotective cytokine.
p57562
sg52638
(lp57563
(dp57564
g52643
I110
sg52644
Vinterleukin-11
p57565
sg52646
I14
sg52674
VP20809
p57566
sg52649
I1
sa(dp57567
g52643
I126
sg52644
g57559
sg52646
I5
sg52674
VP20809
p57568
sg52649
I1
sasg52640
(lp57569
(dp57570
g52643
I80
sg52644
VSTEMI
p57571
sg52646
I5
sg52647
VC1536220
p57572
sg52649
I1
sa(dp57573
g52643
I44
sg52644
g57560
sg52646
I34
sg52647
VC1536220
p57574
sg52649
I3
sasa(dp57575
g135
(dp57576
(VIL-11
p57577
Vischemia
p57578
tp57579
I00
ssg52636
VThe protective role of IL-11, an IL-6 family cytokine, has been implicated in ischemia/reperfusion injury (IRI) in the heart and kidney, but its role has not been elucidated in liver IRI.
p57580
sg52638
(lp57581
(dp57582
g52643
I33
sg52644
VIL-6 family cytokine
p57583
sg52646
I20
sg52674
VP05231
p57584
sg52649
I3
sa(dp57585
g52643
I23
sg52644
g57577
sg52646
I5
sg52674
VP20809
p57586
sg52649
I1
sasg52640
(lp57587
(dp57588
g52643
I78
sg52644
g57578
sg52646
I8
sg52647
VC0022116
p57589
sg52649
I1
sasa(dp57590
g135
(dp57591
(VIL-11
p57592
Vischemia
p57593
tp57594
I00
ssg52636
VNext, IL-11 was injected intraperitoneally (ip) 1 hour before ischemia.
p57595
sg52638
(lp57596
(dp57597
g52643
I6
sg52644
g57592
sg52646
I5
sg52674
VP20809
p57598
sg52649
I1
sasg52640
(lp57599
(dp57600
g52643
I62
sg52644
g57593
sg52646
I8
sg52647
VC0022116
p57601
sg52649
I1
sasa(dp57602
g52636
VPertussis toxin gene (ptxA-Pr), insertion sequence genes (IS481 and IS1001), adenylate cyclase genes and structural porin and flagellin genes were chosen as targets for PCR, in different studies.
p57603
sg52638
(lp57604
(dp57605
g52643
I77
sg52644
Vadenylate cyclase
p57606
sg52646
I17
sg52674
g12
sg52649
I2
sa(dp57607
g52643
I0
sg52644
VPertussis toxin gene
p57608
sg52646
I20
sg52674
g12
sg52649
I3
sasg52640
(lp57609
(dp57610
g52643
I0
sg52644
VPertussis
p57611
sg52646
I9
sg52647
VC0043167
p57612
sg52649
I1
sasa(dp57613
g135
(dp57614
(Vpertussis toxin ptxA promoter region (PT), and outer membrane porin
p57615
Vpertussis
p57616
tp57617
I00
ssg52636
VPCR assays targeting insertion sequence IS481 (IS), pertussis toxin ptxA promoter region (PT), and outer membrane porin (PO), or recA (RA) were evaluated in respiratory specimens collected from 4,442 patients with suspected pertussis.
p57618
sg52638
(lp57619
(dp57620
g52643
I52
sg52644
g57615
sg52646
I67
sg52674
VP0CE72
p57621
sg52649
I10
sa(dp57622
g52643
I135
sg52644
VRA
p57623
sg52646
I2
sg52674
g12
sg52649
I1
sa(dp57624
g52643
I129
sg52644
VrecA
p57625
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp57626
(dp57627
g52643
I52
sg52644
Vpertussis
p57628
sg52646
I9
sg52647
VC0043167
p57629
sg52649
I1
sa(dp57630
g52643
I52
sg52644
g57616
sg52646
I9
sg52647
VC0043167
p57631
sg52649
I1
sasa(dp57632
g52636
VIn this study, we evaluated the role of miR-135b in colorectal cancer (CRC) and its regulatory role for metastasis suppressor-1 (MTSS1) and its mechanisms.
p57633
sg52638
(lp57634
(dp57635
g52643
I40
sg52644
VmiR-135b in colorectal cancer (CRC)
p57636
sg52646
I35
sg52674
g12
sg52649
I5
sa(dp57637
g52643
I129
sg52644
VMTSS1
p57638
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57639
g52643
I104
sg52644
Vmetastasis suppressor-1
p57640
sg52646
I23
sg52674
g12
sg52649
I2
sasg52640
(lp57641
(dp57642
g52643
I52
sg52644
Vcolorectal cancer
p57643
sg52646
I17
sg52647
VC1527249
p57644
sg52649
I2
sa(dp57645
g52643
I71
sg52644
VCRC
p57646
sg52646
I3
sg52647
VC1527249
p57647
sg52649
I1
sa(dp57648
g52643
I104
sg52644
Vmetastasis
p57649
sg52646
I10
sg52647
VC0027627
p57650
sg52649
I1
sasa(dp57651
g52636
VThe levels of miR-135b and MTSS1 gene expression in 35 CRC and corresponding cancer-adjacent tissues, 27 colorectal adenoma, and 16 normal tissue samples were quantified using qRT-PCR and western blot analysis.
p57652
sg52638
(lp57653
(dp57654
g52643
I14
sg52644
VmiR-135b
p57655
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp57656
g52643
I27
sg52644
VMTSS1 gene expression in 35 CRC
p57657
sg52646
I31
sg52674
g12
sg52649
I6
sasg52640
(lp57658
(dp57659
g52643
I55
sg52644
VCRC
p57660
sg52646
I3
sg52647
VC1527249
p57661
sg52649
I1
sa(dp57662
g52643
I105
sg52644
Vcolorectal adenoma
p57663
sg52646
I18
sg52647
VC1302401
p57664
sg52649
I2
sa(dp57665
g52643
I77
sg52644
Vcancer
p57666
sg52646
I6
sg52647
VC0006826
p57667
sg52649
I1
sasa(dp57668
g52636
VJahid and colleagues have shown that miR-23a promotes the transition from indolent to invasive colorectal cancer through inhibition of the MTSS1 tumor suppressor.
p57669
sg52638
(lp57670
(dp57671
g52643
I139
sg52644
VMTSS1 tumor suppressor
p57672
sg52646
I22
sg52674
g12
sg52649
I3
sa(dp57673
g52643
I37
sg52644
VmiR-23a
p57674
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp57675
(dp57676
g52643
I145
sg52644
Vtumor
p57677
sg52646
I5
sg52647
VC0027651
p57678
sg52649
I1
sa(dp57679
g52643
I95
sg52644
Vcolorectal cancer
p57680
sg52646
I17
sg52647
VC1527249
p57681
sg52649
I2
sa(dp57682
g52643
I58
sg52644
Vtransition
p57683
sg52646
I10
sg52647
VC0599156
p57684
sg52649
I1
sasa(dp57685
g52636
VTo investigate the expression of miR-23a and metastasis suppressor 1 (MTSS1) and their clinical significance in colon carcinoma.
p57686
sg52638
(lp57687
(dp57688
g52643
I33
sg52644
VmiR-23a and metastasis suppressor 1
p57689
sg52646
I35
sg52674
g12
sg52649
I5
sa(dp57690
g52643
I70
sg52644
VMTSS1
p57691
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp57692
(dp57693
g52643
I45
sg52644
Vmetastasis
p57694
sg52646
I10
sg52647
VC0027627
p57695
sg52649
I1
sa(dp57696
g52643
I112
sg52644
Vcolon carcinoma
p57697
sg52646
I15
sg52647
VC0699790
p57698
sg52649
I2
sasa(dp57699
g52636
VThe expression rates of miR-23a and MTSS1 were 87.0% (80/92) and 17.4% (16/92) in colon carcinoma cases, respectively (P &lt; 0.01).
p57700
sg52638
(lp57701
(dp57702
g52643
I24
sg52644
VmiR-23a and MTSS1
p57703
sg52646
I17
sg52674
g12
sg52649
I3
sasg52640
(lp57704
(dp57705
g52643
I82
sg52644
Vcolon carcinoma
p57706
sg52646
I15
sg52647
VC0699790
p57707
sg52649
I2
sasa(dp57708
g52636
VBoth the low expression of MTSS1 and high expression of miR-23a may serve as important biological markers for the malignant phenotypes of colon cancer, such as invasion and metastasis.
p57709
sg52638
(lp57710
(dp57711
g52643
I56
sg52644
VmiR-23a
p57712
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp57713
g52643
I27
sg52644
VMTSS1
p57714
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp57715
(dp57716
g52643
I160
sg52644
Vinvasion
p57717
sg52646
I8
sg52647
VC2699153
p57718
sg52649
I1
sa(dp57719
g52643
I138
sg52644
Vcolon cancer
p57720
sg52646
I12
sg52647
VC0699790
p57721
sg52649
I2
sa(dp57722
g52643
I173
sg52644
Vmetastasis
p57723
sg52646
I10
sg52647
VC0027627
p57724
sg52649
I1
sasa(dp57725
g52636
VThe aims of this study were to investigate metastasis suppressor 1 (MTSS1) expression in benign and malignant colorectal tissues and to explore its significance in the prognosis of colorectal cancer (CRC) patients.
p57726
sg52638
(lp57727
sg52640
(lp57728
(dp57729
g52643
I200
sg52644
VCRC
p57730
sg52646
I3
sg52647
VC1527249
p57731
sg52649
I1
sa(dp57732
g52643
I43
sg52644
Vmetastasis
p57733
sg52646
I10
sg52647
VC0027627
p57734
sg52649
I1
sa(dp57735
g52643
I181
sg52644
Vcolorectal cancer
p57736
sg52646
I17
sg52647
VC1527249
p57737
sg52649
I2
sasa(dp57738
g52636
VMTSS1 expression was detected by immunohistochemistry in CRC, colorectal adenomatous polyp (precancerous lesion) and normal colorectal tissues.
p57739
sg52638
(lp57740
(dp57741
g52643
I0
sg52644
VMTSS1
p57742
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp57743
(dp57744
g52643
I57
sg52644
VCRC
p57745
sg52646
I3
sg52647
VC1527249
p57746
sg52649
I1
sa(dp57747
g52643
I62
sg52644
Vcolorectal adenomatous polyp
p57748
sg52646
I28
sg52647
VC3272805
p57749
sg52649
I3
sasa(dp57750
g52636
VThese genes (CACNA1C, COL2A1, CPNE8, C3F, C12ORF4, DDX11, GDF11, HOXC8, KCNA1, MDS028, TMEM106C, NR4A1, PHB2, PRICKLE1, Q6ZUQ4, SCN8A, TUBA8 and USP18) are located on porcine chromosome 5 (SSC5) and represent positional and functional candidates for arthrogryposis multiplex congenita (AMC), which maps to SSC5.
p57751
sg52638
(lp57752
(dp57753
g52643
I128
sg52644
VSCN8A
p57754
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57755
g52643
I58
sg52644
VGDF11
p57756
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57757
g52643
I87
sg52644
VTMEM106C
p57758
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp57759
g52643
I51
sg52644
VDDX11
p57760
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57761
g52643
I110
sg52644
VPRICKLE1
p57762
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp57763
g52643
I37
sg52644
VC3F
p57764
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp57765
g52643
I104
sg52644
VPHB2
p57766
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp57767
g52643
I97
sg52644
VNR4A1
p57768
sg52646
I5
sg52674
VP22736
p57769
sg52649
I1
sa(dp57770
g52643
I65
sg52644
VHOXC8
p57771
sg52646
I5
sg52674
VP31273
p57772
sg52649
I1
sa(dp57773
g52643
I42
sg52644
VC12ORF4
p57774
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp57775
g52643
I30
sg52644
VCPNE8
p57776
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57777
g52643
I79
sg52644
VMDS028
p57778
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp57779
g52643
I72
sg52644
VKCNA1
p57780
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57781
g52643
I135
sg52644
VTUBA8
p57782
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57783
g52643
I145
sg52644
VUSP18
p57784
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp57785
(dp57786
g52643
I250
sg52644
Varthrogryposis multiplex congenita
p57787
sg52646
I34
sg52647
VC2931264
p57788
sg52649
I3
sa(dp57789
g52643
I286
sg52644
VAMC
p57790
sg52646
I3
sg52647
VC2931264
p57791
sg52649
I1
sasa(dp57792
g52636
VIn this study, we tested whether this tolerance is intact in systemic lupus erythematosus-prone (New Zealand Black x SWR)F1 mice (SNF1).
p57793
sg52638
(lp57794
sg52640
(lp57795
(dp57796
g52643
I38
sg52644
Vtolerance
p57797
sg52646
I9
sg52647
VC0020963
p57798
sg52649
I1
sa(dp57799
g52643
I61
sg52644
Vsystemic lupus erythematosus
p57800
sg52646
I28
sg52647
VC0024141
p57801
sg52649
I3
sasa(dp57802
g52636
VThe F1 cross between SWR and NZB mice, SNF1, develops severe immune complex glomerulonephritis, in a similar manner to humans with systemic lupus erythematosus (SLE).
p57803
sg52638
(lp57804
sg52640
(lp57805
(dp57806
g52643
I131
sg52644
Vsystemic lupus erythematosus
p57807
sg52646
I28
sg52647
VC0024141
p57808
sg52649
I3
sa(dp57809
g52643
I61
sg52644
Vimmune complex glomerulonephritis
p57810
sg52646
I33
sg52647
VC0744421
p57811
sg52649
I3
sa(dp57812
g52643
I161
sg52644
VSLE
p57813
sg52646
I3
sg52647
VC0024141
p57814
sg52649
I1
sasa(dp57815
g135
(dp57816
(VCD184
p57817
Vneuroblastoma
p57818
tp57819
I00
ssg52636
VExposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.
p57820
sg52638
(lp57821
(dp57822
g52643
I79
sg52644
VCD15
p57823
sg52646
I4
sg52674
VP22083
p57824
sg52649
I1
sa(dp57825
g52643
I194
sg52644
VNMYC protein
p57826
sg52646
I12
sg52674
VP04198
p57827
sg52649
I2
sa(dp57828
g52643
I17
sg52644
Vmorphogenetic protein (BMP)-4
p57829
sg52646
I29
sg52674
VP18075
p57830
sg52649
I3
sa(dp57831
g52643
I85
sg52644
g57817
sg52646
I5
sg52674
VP61073
p57832
sg52649
I1
sasg52640
(lp57833
(dp57834
g52643
I92
sg52644
g57818
sg52646
I13
sg52647
VC0027819
p57835
sg52649
I1
sasa(dp57836
g52636
VIn cell-based assays, it is demonstrated that PST3.1a alters the Beta1,6-GlcNAc N-glycans of GBM-initiating cells (GIC) by inhibiting MGAT5 enzymatic activity, resulting in the inhibition of TGFBetaR and FAK signaling associated with doublecortin (DCX) upregulation and increase oligodendrocyte lineage transcription factor 2 (OLIG2) expression.
p57837
sg52638
(lp57838
(dp57839
g52643
I279
sg52644
Voligodendrocyte lineage transcription factor 2
p57840
sg52646
I46
sg52674
g12
sg52649
I5
sa(dp57841
g52643
I234
sg52644
Vdoublecortin
p57842
sg52646
I12
sg52674
g12
sg52649
I1
sa(dp57843
g52643
I327
sg52644
VOLIG2
p57844
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57845
g52643
I204
sg52644
VFAK
p57846
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp57847
g52643
I248
sg52644
VDCX
p57848
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp57849
g52643
I134
sg52644
VMGAT5
p57850
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp57851
(dp57852
g52643
I93
sg52644
VGBM
p57853
sg52646
I3
sg52647
VC0017636
p57854
sg52649
I1
sasa(dp57855
g52636
VTo assess the expression of Toll-like receptor 3 (TLR-3) and TLR-7 in muscle tissue from patients with polymyositis (PM) and dermatomyositis (DM) and to investigate the function and regulation of TLR-3 in cultured muscle cells.
p57856
sg52638
(lp57857
(dp57858
g52643
I28
sg52644
VToll-like receptor 3
p57859
sg52646
I20
sg52674
g12
sg52649
I3
sa(dp57860
g52643
I50
sg52644
VTLR-3
p57861
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57862
g52643
I61
sg52644
VTLR-7
p57863
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp57864
g52643
I50
sg52644
VTLR-3
p57865
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp57866
(dp57867
g52643
I117
sg52644
VPM
p57868
sg52646
I2
sg52647
VC0085655
p57869
sg52649
I1
sa(dp57870
g52643
I142
sg52644
VDM
p57871
sg52646
I2
sg52647
VC0221056
p57872
sg52649
I1
sa(dp57873
g52643
I125
sg52644
Vdermatomyositis
p57874
sg52646
I15
sg52647
VC0221056
p57875
sg52649
I1
sa(dp57876
g52643
I103
sg52644
Vpolymyositis
p57877
sg52646
I12
sg52647
VC0085655
p57878
sg52649
I1
sasa(dp57879
g135
(dp57880
(VIgG-like cell adhesion protein
p57881
VAutism Spectrum Disorders
p57882
tp57883
I00
ssg52636
VWe analyzed the coding sequences and exon-intron boundaries of GLIALCAM, encoding an IgG-like cell adhesion protein, in 81 individuals with Autism Spectrum Disorders, either with or without comorbid epilepsy, paroxysmal EEG and/or macrocephaly, and the PTEN gene in the subsample with macrocephaly.
p57884
sg52638
(lp57885
(dp57886
g52643
I253
sg52644
VPTEN gene
p57887
sg52646
I9
sg52674
VP60484
p57888
sg52649
I2
sa(dp57889
g52643
I63
sg52644
VGLIALCAM
p57890
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp57891
g52643
I85
sg52644
g57881
sg52646
I30
sg52674
VP01185
p57892
sg52649
I4
sasg52640
(lp57893
(dp57894
g52643
I231
sg52644
Vmacrocephaly
p57895
sg52646
I12
sg52647
VC0221355
p57896
sg52649
I1
sa(dp57897
g52643
I199
sg52644
Vepilepsy
p57898
sg52646
I8
sg52647
VC0014544
p57899
sg52649
I1
sa(dp57900
g52643
I231
sg52644
Vmacrocephaly
p57901
sg52646
I12
sg52647
VC0221355
p57902
sg52649
I1
sa(dp57903
g52643
I99
sg52644
Vadhesion
p57904
sg52646
I8
sg52647
VC0001511
p57905
sg52649
I1
sa(dp57906
g52643
I140
sg52644
g57882
sg52646
I25
sg52647
VC1510586
p57907
sg52649
I3
sasa(dp57908
g135
(dp57909
(VPTEN
p57910
Vintellectual disability
p57911
tp57912
I00
ssg52636
VWhilst we detected in GLIALCAM several single nucleotide variants without clear pathogenic effects, we found a novel PTEN heterozygous frameshift mutation in one case with "extreme" macrocephaly, autism, intellectual disability and seizures.
p57913
sg52638
(lp57914
(dp57915
g52643
I117
sg52644
g57910
sg52646
I4
sg52674
VP60484
p57916
sg52649
I1
sasg52640
(lp57917
(dp57918
g52643
I232
sg52644
Vseizures
p57919
sg52646
I8
sg52647
VC0036572
p57920
sg52649
I1
sa(dp57921
g52643
I182
sg52644
Vmacrocephaly
p57922
sg52646
I12
sg52647
VC0221355
p57923
sg52649
I1
sa(dp57924
g52643
I135
sg52644
Vframeshift mutation
p57925
sg52646
I19
sg52647
VC0079380
p57926
sg52649
I2
sa(dp57927
g52643
I196
sg52644
Vautism
p57928
sg52646
I6
sg52647
VC0004352
p57929
sg52649
I1
sa(dp57930
g52643
I204
sg52644
g57911
sg52646
I23
sg52647
VC0025362
p57931
sg52649
I2
sasa(dp57932
g52636
VIn other families with dominant HEPACAM mutations, patients had macrocephaly and mental retardation with or without autism.
p57933
sg52638
(lp57934
sg52640
(lp57935
(dp57936
g52643
I64
sg52644
Vmacrocephaly
p57937
sg52646
I12
sg52647
VC0221355
p57938
sg52649
I1
sa(dp57939
g52643
I81
sg52644
Vmental retardation
p57940
sg52646
I18
sg52647
VC0025362
p57941
sg52649
I2
sa(dp57942
g52643
I116
sg52644
Vautism
p57943
sg52646
I6
sg52647
VC0004352
p57944
sg52649
I1
sasa(dp57945
g52636
VDominant HEPACAM mutations can cause either macrocephaly and mental retardation with or without autism or benign familial macrocephaly.
p57946
sg52638
(lp57947
sg52640
(lp57948
(dp57949
g52643
I106
sg52644
Vbenign familial macrocephaly
p57950
sg52646
I28
sg52647
VC0220690
p57951
sg52649
I3
sa(dp57952
g52643
I96
sg52644
Vautism
p57953
sg52646
I6
sg52647
VC0004352
p57954
sg52649
I1
sa(dp57955
g52643
I61
sg52644
Vmental retardation
p57956
sg52646
I18
sg52647
VC0025362
p57957
sg52649
I2
sa(dp57958
g52643
I44
sg52644
Vmacrocephaly
p57959
sg52646
I12
sg52647
VC0221355
p57960
sg52649
I1
sasa(dp57961
g52636
VB AaHHoe NccneAoBaHNe BownN 59 AeTeN c ANcoyHKmyNeN wyHTNpyhweN cNcTeMbl B Bo3pacTe oT 1 roAa Ao 14 neT, npoxoANBwNx ne4eHNe B OeAepanbHoM myeHTpe HeNpoxNpyprNN (HoBocNbNpcK) c 2014 no 2016 r. KpNTepNN BKnh4eHNR B NccneAoBaHNe: 1) Bo3pacT Ha MoMeHT obcneAoBaHNR cTapwe 1 roAa; 2) NMnnaHTamyNR wyHTNpyhweN cNcTeMbl B nepBble 12 Mec XN3HN.
p57962
sg52638
(lp57963
sg52640
(lp57964
sa(dp57965
g135
(dp57966
(VPKCalpha
p57967
Vinfarction
p57968
tp57969
I00
ssg52636
VThus, myocyte autonomous inhibition of PKCalpha protects the adult heart from decompensation and dilated cardiomyopathy after infarction injury in association with a primary enhancement in contractility.
p57970
sg52638
(lp57971
(dp57972
g52643
I39
sg52644
g57967
sg52646
I8
sg52674
VP17252
p57973
sg52649
I1
sasg52640
(lp57974
(dp57975
g52643
I97
sg52644
Vdilated cardiomyopathy
p57976
sg52646
I22
sg52647
VC0007193
p57977
sg52649
I2
sa(dp57978
g52643
I126
sg52644
g57968
sg52646
I10
sg52647
VC0021308
p57979
sg52649
I1
sasa(dp57980
g135
(dp57981
(Vgene encoding muscle LIM protein
p57982
Vdilated cardiomyopathy
p57983
tp57984
I00
ssg52636
VHypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3).
p57985
sg52638
(lp57986
(dp57987
g52643
I198
sg52644
VCsrp3
p57988
sg52646
I5
sg52674
VP50461
p57989
sg52649
I1
sa(dp57990
g52643
I164
sg52644
g57982
sg52646
I32
sg52674
VP50461
p57991
sg52649
I5
sasg52640
(lp57992
(dp57993
g52643
I61
sg52644
Vheart failure
p57994
sg52646
I13
sg52647
VC0018802
p57995
sg52649
I2
sa(dp57996
g52643
I117
sg52644
g57983
sg52646
I22
sg52647
VC0007193
p57997
sg52649
I2
sasa(dp57998
g52636
VDeletion of Prkca also rescues cardiomyopathy associated with overexpression of PP-1.
p57999
sg52638
(lp58000
(dp58001
g52643
I80
sg52644
VPP-1
p58002
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp58003
(dp58004
g52643
I31
sg52644
Vcardiomyopathy
p58005
sg52646
I14
sg52647
VC0878544
p58006
sg52649
I1
sasa(dp58007
g52636
VPD-L1 staining was detected in 80% of anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma and follicular dendritic cell sarcoma, 75% of nodular lymphocyte predominant Hodgkin lymphoma, 53% of primary mediastinal large B-cell lymphoma, 39% of extranodal NK/T cell lymphoma, 26% of peripheral T-cell lymphoma, 10% of diffuse large B-cell lymphoma and very rare examples of mantle, marginal zone and small lymphocytic lymphomas.
p58008
sg52638
(lp58009
sg52640
(lp58010
(dp58011
g52643
I109
sg52644
Vfollicular dendritic cell sarcoma
p58012
sg52646
I33
sg52647
VC1260325
p58013
sg52649
I4
sa(dp58014
g52643
I330
sg52644
Vdiffuse large B-cell lymphoma
p58015
sg52646
I29
sg52647
VC0079744
p58016
sg52649
I4
sa(dp58017
g52643
I271
sg52644
VT cell lymphoma
p58018
sg52646
I15
sg52647
VC0079772
p58019
sg52649
I3
sa(dp58020
g52643
I295
sg52644
Vperipheral T-cell lymphoma
p58021
sg52646
I26
sg52647
VC0079774
p58022
sg52649
I3
sa(dp58023
g52643
I207
sg52644
Vprimary mediastinal large B-cell lymphoma
p58024
sg52646
I41
sg52647
VC0855152
p58025
sg52649
I5
sa(dp58026
g52643
I412
sg52644
Vsmall lymphocytic lymphomas
p58027
sg52646
I27
sg52647
VC0023434
p58028
sg52649
I3
sa(dp58029
g52643
I151
sg52644
Vnodular lymphocyte predominant Hodgkin lymphoma
p58030
sg52646
I47
sg52647
VC1334968
p58031
sg52649
I5
sa(dp58032
g52643
I70
sg52644
Vangioimmunoblastic T-cell lymphoma
p58033
sg52646
I34
sg52647
VC0020981
p58034
sg52649
I3
sa(dp58035
g52643
I38
sg52644
Vanaplastic large cell lymphoma
p58036
sg52646
I30
sg52647
VC0206180
p58037
sg52649
I4
sasa(dp58038
g52636
VPD-L1 also showed stronger expression in ALK+ ALCL compared with ALK- ALCL, suggesting an additional role of C/EBPBeta in ALK+ ALCL in generating an immunosuppressive environment.
p58039
sg52638
(lp58040
(dp58041
g52643
I41
sg52644
VALK+ ALCL
p58042
sg52646
I9
sg52674
g12
sg52649
I2
sa(dp58043
g52643
I65
sg52644
VALK- ALCL
p58044
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp58045
(dp58046
g52643
I46
sg52644
VALCL
p58047
sg52646
I4
sg52647
VC0206180
p58048
sg52649
I1
sa(dp58049
g52643
I46
sg52644
VALCL
p58050
sg52646
I4
sg52647
VC0206180
p58051
sg52649
I1
sa(dp58052
g52643
I46
sg52644
VALCL
p58053
sg52646
I4
sg52647
VC0206180
p58054
sg52649
I1
sasa(dp58055
g135
(dp58056
(VCD147
p58057
VALCL
p58058
tp58059
I01
ssg52636
VIn conclusion, surface antigen expression profiling demonstrates that C/EBPBeta plays a critical role in the activation state of ALK+ ALCL cells and reveals CD147 and PD-L1 as important downstream targets.
p58060
sg52638
(lp58061
(dp58062
g52643
I157
sg52644
g58057
sg52646
I5
sg52674
VP35613
p58063
sg52649
I1
sasg52640
(lp58064
(dp58065
g52643
I134
sg52644
g58058
sg52646
I4
sg52647
VC0206180
p58066
sg52649
I1
sasa(dp58067
g52636
VAlso, the neoplastic cells of classical Hodgkin lymphoma, anaplastic large cell lymphoma, schwannoma, thymoma, and squamous cell carcinoma of various sites frequently expressed PD-L1.
p58068
sg52638
(lp58069
sg52640
(lp58070
(dp58071
g52643
I58
sg52644
Vanaplastic large cell lymphoma
p58072
sg52646
I30
sg52647
VC0206180
p58073
sg52649
I4
sa(dp58074
g52643
I102
sg52644
Vthymoma
p58075
sg52646
I7
sg52647
VC0040100
p58076
sg52649
I1
sa(dp58077
g52643
I30
sg52644
Vclassical Hodgkin lymphoma
p58078
sg52646
I26
sg52647
VC1333064
p58079
sg52649
I3
sa(dp58080
g52643
I115
sg52644
Vsquamous cell carcinoma
p58081
sg52646
I23
sg52647
VC0007137
p58082
sg52649
I3
sa(dp58083
g52643
I90
sg52644
Vschwannoma
p58084
sg52646
I10
sg52647
VC0027809
p58085
sg52649
I1
sasa(dp58086
g135
(dp58087
(VSTAT3
p58088
Vanaplastic large-cell lymphoma
p58089
tp58090
I00
ssg52636
VThese unique features, which are strictly dependent on NPM-ALK activity and expression, include perpetual cell growth, proliferation, and survival; activation of the key signal transduction pathways STAT3 and mTORC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine IL-10 and cell-surface protein PD-L1/CD274.
p58091
sg52638
(lp58092
(dp58093
g52643
I59
sg52644
VALK
p58094
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp58095
g52643
I360
sg52644
VCD274
p58096
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58097
g52643
I55
sg52644
VNPM
p58098
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp58099
g52643
I235
sg52644
VCD30
p58100
sg52646
I4
sg52674
VP28908
p58101
sg52649
I1
sa(dp58102
g52643
I199
sg52644
g58088
sg52646
I5
sg52674
VP40763
p58103
sg52649
I1
sasg52640
(lp58104
(dp58105
g52643
I119
sg52644
Vproliferation
p58106
sg52646
I13
sg52647
VC0334094
p58107
sg52649
I1
sa(dp58108
g52643
I257
sg52644
g58089
sg52646
I30
sg52647
VC0206180
p58109
sg52649
I3
sasa(dp58110
g52636
VPD-L1 was expressed uniformly by anaplastic large cell lymphoma (ALCL) cell lines, but rarely in B-cell NHL, confined to a subset of diffuse large B-cell lymphomas (DLBCL) with activated B-cell features (3 of 28 cell lines and 24% of primary DLBCL).
p58111
sg52638
(lp58112
sg52640
(lp58113
(dp58114
g52643
I147
sg52644
VB-cell lymphomas
p58115
sg52646
I16
sg52647
VC0079731
p58116
sg52649
I2
sa(dp58117
g52643
I104
sg52644
VNHL
p58118
sg52646
I3
sg52647
VC0024305
p58119
sg52649
I1
sa(dp58120
g52643
I65
sg52644
VALCL
p58121
sg52646
I4
sg52647
VC0206180
p58122
sg52649
I1
sa(dp58123
g52643
I33
sg52644
Vanaplastic large cell lymphoma
p58124
sg52646
I30
sg52647
VC0206180
p58125
sg52649
I4
sasa(dp58126
g135
(dp58127
(VIFN-Gamma
p58128
VALCL
p58129
tp58130
I01
ssg52636
VAnti-PD-L1 blocking antibody boosted proliferation and IFN-Gamma secretion by allogeneic T cells responding to ALCL and DLBCL cells.
p58131
sg52638
(lp58132
(dp58133
g52643
I55
sg52644
g58128
sg52646
I9
sg52674
VP01579
p58134
sg52649
I1
sasg52640
(lp58135
(dp58136
g52643
I111
sg52644
g58129
sg52646
I4
sg52647
VC0206180
p58137
sg52649
I1
sa(dp58138
g52643
I11
sg52644
Vblocking
p58139
sg52646
I8
sg52647
VC0233660
p58140
sg52649
I1
sa(dp58141
g52643
I37
sg52644
Vproliferation
p58142
sg52646
I13
sg52647
VC0334094
p58143
sg52649
I1
sasa(dp58144
g135
(dp58145
(VIL-6
p58146
VALCL
p58147
tp58148
I00
ssg52636
VIn autologous cultures of primary ALCL and DLBCL, PD-L1 blockade enhanced secretion of inflammatory cytokines IFN-Gamma, granulocyte macrophage colony-stimulating factor, interleukin (IL)-1, IL-6, IL-8, IL-13, TNF-Alfa, and macrophage inflammatory protein-1Alfa.
p58149
sg52638
(lp58150
(dp58151
g52643
I100
sg52644
Vcytokines IFN-Gamma
p58152
sg52646
I19
sg52674
VP01579
p58153
sg52649
I2
sa(dp58154
g52643
I203
sg52644
VIL-13
p58155
sg52646
I5
sg52674
VP35225
p58156
sg52649
I1
sa(dp58157
g52643
I210
sg52644
VTNF-Alfa
p58158
sg52646
I8
sg52674
VP01375
p58159
sg52649
I1
sa(dp58160
g52643
I121
sg52644
Vgranulocyte macrophage colony-stimulating factor
p58161
sg52646
I48
sg52674
VP04141
p58162
sg52649
I4
sa(dp58163
g52643
I171
sg52644
Vinterleukin (IL)-1
p58164
sg52646
I18
sg52674
VP60568
p58165
sg52649
I2
sa(dp58166
g52643
I191
sg52644
g58146
sg52646
I4
sg52674
VP05231
p58167
sg52649
I1
sasg52640
(lp58168
(dp58169
g52643
I34
sg52644
g58147
sg52646
I4
sg52647
VC0206180
p58170
sg52649
I1
sasa(dp58171
g52636
VWe examined B7-H1 expression in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) and found that it was constitutively expressed in both clinical samples and cell lines.
p58172
sg52638
(lp58173
(dp58174
g52643
I12
sg52644
VB7-H1
p58175
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58176
(dp58177
g52643
I92
sg52644
VHL
p58178
sg52646
I2
sg52647
VC0019829
p58179
sg52649
I1
sa(dp58180
g52643
I74
sg52644
VHodgkin lymphoma
p58181
sg52646
I16
sg52647
VC0019829
p58182
sg52649
I2
sa(dp58183
g52643
I32
sg52644
Vanaplastic large cell lymphoma
p58184
sg52646
I30
sg52647
VC0206180
p58185
sg52649
I4
sa(dp58186
g52643
I64
sg52644
VALCL
p58187
sg52646
I4
sg52647
VC0206180
p58188
sg52649
I1
sasa(dp58189
g135
(dp58190
(VERK
p58191
Vanaplastic lymphoma
p58192
tp58193
I00
ssg52636
VIn anaplastic lymphoma kinase-positive (ALK(+)) ALCL cells, B7-H1 expression was suppressed by the blocking of extracellular signal-regulated kinase (ERK) signaling and upregulated by the augmentation of ERK activity by phorbol 13-myristate 12-acetate stimulation, suggesting that B7-H1 expression is regulated by ERK signaling pathway in ALCL.
p58194
sg52638
(lp58195
(dp58196
g52643
I150
sg52644
VERK
p58197
sg52646
I3
sg52674
VP29323
p58198
sg52649
I1
sa(dp58199
g52643
I60
sg52644
VB7-H1
p58200
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58201
g52643
I111
sg52644
Vextracellular signal-regulated kinase
p58202
sg52646
I37
sg52674
VP53779
p58203
sg52649
I3
sa(dp58204
g52643
I150
sg52644
VERK
p58205
sg52646
I3
sg52674
VP29323
p58206
sg52649
I1
sa(dp58207
g52643
I150
sg52644
g58191
sg52646
I3
sg52674
VP29323
p58208
sg52649
I1
sa(dp58209
g52643
I60
sg52644
VB7-H1
p58210
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58211
(dp58212
g52643
I48
sg52644
VALCL
p58213
sg52646
I4
sg52647
VC0206180
p58214
sg52649
I1
sa(dp58215
g52643
I99
sg52644
Vblocking
p58216
sg52646
I8
sg52647
VC0233660
p58217
sg52649
I1
sa(dp58218
g52643
I48
sg52644
VALCL
p58219
sg52646
I4
sg52647
VC0206180
p58220
sg52649
I1
sa(dp58221
g52643
I3
sg52644
g58192
sg52646
I19
sg52647
VC1321546
p58222
sg52649
I2
sasa(dp58223
g135
(dp58224
(VERK
p58225
VALCL
p58226
tp58227
I00
ssg52636
VERK is one of the downstream mediators of nucleophosmin (NPM)/ALK signaling in ALK(+)ALCL, and pharmacological inhibition of ALK was shown to dephosphorylate ERK and down-regulate B7-H1.
p58228
sg52638
(lp58229
(dp58230
g52643
I62
sg52644
VALK
p58231
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp58232
g52643
I62
sg52644
VALK
p58233
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp58234
g52643
I0
sg52644
VERK
p58235
sg52646
I3
sg52674
VP29323
p58236
sg52649
I1
sa(dp58237
g52643
I180
sg52644
VB7-H1
p58238
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58239
g52643
I0
sg52644
g58225
sg52646
I3
sg52674
VP29323
p58240
sg52649
I1
sasg52640
(lp58241
(dp58242
g52643
I85
sg52644
g58226
sg52646
I4
sg52647
VC0206180
p58243
sg52649
I1
sasa(dp58244
g52636
VThe involvement of NPM/ALK in B7-H1 expression was also demonstrated by introducing the construct into human non-ALCL lymphoid cell lines, which resulted in B7-H1 expression.
p58245
sg52638
(lp58246
(dp58247
g52643
I30
sg52644
VB7-H1
p58248
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58249
g52643
I30
sg52644
VB7-H1
p58250
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58251
g52643
I19
sg52644
VNPM
p58252
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp58253
g52643
I23
sg52644
VALK
p58254
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp58255
(dp58256
g52643
I113
sg52644
VALCL
p58257
sg52646
I4
sg52647
VC0206180
p58258
sg52649
I1
sasa(dp58259
g135
(dp58260
(VERK
p58261
VALCL
p58262
tp58263
I00
ssg52636
VThese results suggest that B7-H1 expression is controlled by common ERK signaling pathways in ALCL and HL cells.
p58264
sg52638
(lp58265
(dp58266
g52643
I68
sg52644
g58261
sg52646
I3
sg52674
VP29323
p58267
sg52649
I1
sa(dp58268
g52643
I27
sg52644
VB7-H1
p58269
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58270
(dp58271
g52643
I94
sg52644
g58262
sg52646
I4
sg52647
VC0206180
p58272
sg52649
I1
sasa(dp58273
g135
(dp58274
(VMYH9
p58275
VHippel Lindau syndrome
p58276
tp58277
I00
ssg52636
VThe applicability of clinical genetics in nephrology is due to the fact that many kidney diseases are characterized by genetic mutations (e.g., von-Hippel Lindau syndrome, MYH9 related disorders, Fabry's syndrome, Liddle's and Bartter's Syndrome, and others).
p58278
sg52638
(lp58279
(dp58280
g52643
I172
sg52644
g58275
sg52646
I4
sg52674
VP35579
p58281
sg52649
I1
sasg52640
(lp58282
(dp58283
g52643
I204
sg52644
Vsyndrome, Liddle
p58284
sg52646
I16
sg52647
VC0221043
p58285
sg52649
I2
sa(dp58286
g52643
I227
sg52644
VBartter's Syndrome
p58287
sg52646
I18
sg52647
VC0004775
p58288
sg52649
I2
sa(dp58289
g52643
I82
sg52644
Vkidney diseases
p58290
sg52646
I15
sg52647
VC0022658
p58291
sg52649
I2
sa(dp58292
g52643
I148
sg52644
g58276
sg52646
I22
sg52647
VC0019562
p58293
sg52649
I3
sasa(dp58294
g135
(dp58295
(VMYH9 gene
p58296
Vtype 2 diabetes
p58297
tp58298
I00
ssg52636
VIn this study, we tested the hypothesis that a common single nucleotide polymorphism rs16996677 in the MYH9 gene may contribute to the etiology of DN in type 2 diabetes (T2D) in a Taiwanese population with T2D.
p58299
sg52638
(lp58300
(dp58301
g52643
I103
sg52644
g58296
sg52646
I9
sg52674
VP35579
p58302
sg52649
I2
sasg52640
(lp58303
(dp58304
g52643
I170
sg52644
VT2D
p58305
sg52646
I3
sg52647
VC0011860
p58306
sg52649
I1
sa(dp58307
g52643
I170
sg52644
VT2D
p58308
sg52646
I3
sg52647
VC0011860
p58309
sg52649
I1
sa(dp58310
g52643
I153
sg52644
g58297
sg52646
I15
sg52647
VC0011860
p58311
sg52649
I3
sasa(dp58312
g52636
VIt has been demonstrated that Wnt signaling through the secretion of Wnt inhibitors, such as DKK1, sFRP-2, and sFRP-3, plays a key role in the decreased osteoblast activity associated with multiple myeloma (MM) bone disease.
p58313
sg52638
(lp58314
(dp58315
g52643
I111
sg52644
VsFRP-3
p58316
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp58317
g52643
I99
sg52644
VsFRP-2
p58318
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp58319
g52643
I93
sg52644
VDKK1
p58320
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp58321
(dp58322
g52643
I211
sg52644
Vbone disease
p58323
sg52646
I12
sg52647
VC0005940
p58324
sg52649
I2
sa(dp58325
g52643
I189
sg52644
Vmultiple myeloma
p58326
sg52646
I16
sg52647
VC0026764
p58327
sg52649
I2
sasa(dp58328
g135
(dp58329
(VJUNB
p58330
VAPC
p58331
tp58332
I00
ssg52636
VThe authors studied the methylation status of CDKN2A, CDKN2B, XAF1, CDH13, JUNB and a panel of soluble Wnt inhibitors including WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in 31 bone marrow and 21 peripheral blood samples of patients with essential thrombocythaemia.
p58333
sg52638
(lp58334
(dp58335
g52643
I54
sg52644
VCDKN2B
p58336
sg52646
I6
sg52674
VP42772
p58337
sg52649
I1
sa(dp58338
g52643
I62
sg52644
VXAF1
p58339
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58340
g52643
I128
sg52644
VWIF1
p58341
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58342
g52643
I134
sg52644
VDKK3
p58343
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58344
g52643
I159
sg52644
VSFRP4
p58345
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58346
g52643
I169
sg52644
VSFRP5
p58347
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58348
g52643
I145
sg52644
VSFRP1
p58349
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58350
g52643
I140
sg52644
VAPC
p58351
sg52646
I3
sg52674
VP25054
p58352
sg52649
I1
sa(dp58353
g52643
I68
sg52644
VCDH13
p58354
sg52646
I5
sg52674
VP55290
p58355
sg52649
I1
sa(dp58356
g52643
I46
sg52644
VCDKN2A
p58357
sg52646
I6
sg52674
VP42771
p58358
sg52649
I1
sa(dp58359
g52643
I152
sg52644
VSFRP2
p58360
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58361
g52643
I75
sg52644
g58330
sg52646
I4
sg52674
VP17275
p58362
sg52649
I1
sasg52640
(lp58363
(dp58364
g52643
I270
sg52644
Vessential thrombocythaemia
p58365
sg52646
I26
sg52647
VC0040028
p58366
sg52649
I2
sa(dp58367
g52643
I140
sg52644
g58331
sg52646
I3
sg52647
VC0033036
p58368
sg52649
I1
sasa(dp58369
g135
(dp58370
(VAPC
p58371
VAPC
p58372
tp58373
I00
ssg52636
VWe studied the activity of Wnt signaling and the methylation status of WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-specific PCR in myeloma cell lines and primary myeloma samples.
p58374
sg52638
(lp58375
(dp58376
g52643
I71
sg52644
VWIF1
p58377
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58378
g52643
I88
sg52644
VSFRP1
p58379
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58380
g52643
I102
sg52644
VSFRP4
p58381
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58382
g52643
I77
sg52644
VDKK3
p58383
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58384
g52643
I112
sg52644
VSFRP5
p58385
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58386
g52643
I95
sg52644
VSFRP2
p58387
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58388
g52643
I83
sg52644
g58371
sg52646
I3
sg52674
VP25054
p58389
sg52649
I1
sasg52640
(lp58390
(dp58391
g52643
I149
sg52644
Vmyeloma
p58392
sg52646
I7
sg52647
VC0026764
p58393
sg52649
I1
sa(dp58394
g52643
I149
sg52644
Vmyeloma
p58395
sg52646
I7
sg52647
VC0026764
p58396
sg52649
I1
sa(dp58397
g52643
I83
sg52644
g58372
sg52646
I3
sg52647
VC0033036
p58398
sg52649
I1
sasa(dp58399
g52636
VOn the other hand, myeloma cells suppress osteoblast function by the secretion of osteoblast inhibiting factors, e.g., the Wnt inhibitors DKK-1 and sFRP-2.
p58400
sg52638
(lp58401
(dp58402
g52643
I138
sg52644
VDKK-1
p58403
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58404
g52643
I148
sg52644
VsFRP-2
p58405
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp58406
(dp58407
g52643
I19
sg52644
Vmyeloma
p58408
sg52646
I7
sg52647
VC0026764
p58409
sg52649
I1
sasa(dp58410
g52636
VHedgehog signaling is frequently activated in esophageal cancer, gastric cancer and pancreatic cancer due to transcriptional upregulation of Hedgehog ligands and epigenetic silencing of HHIP1/HHIP gene, encoding the Hedgehog inhibitor.
p58411
sg52638
(lp58412
(dp58413
g52643
I192
sg52644
VHHIP gene
p58414
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp58415
(dp58416
g52643
I65
sg52644
Vgastric cancer
p58417
sg52646
I14
sg52647
VC0024623
p58418
sg52649
I2
sa(dp58419
g52643
I84
sg52644
Vpancreatic cancer
p58420
sg52646
I17
sg52647
VC0235974
p58421
sg52649
I2
sa(dp58422
g52643
I46
sg52644
Vesophageal cancer
p58423
sg52646
I17
sg52647
VC0014859
p58424
sg52649
I2
sasa(dp58425
g52636
VSel-1-like (SEL1L) is a putative tumor suppressor gene that is significantly downregulated in human pancreatic ductal adenocarcinoma (PDA).
p58426
sg52638
(lp58427
(dp58428
g52643
I0
sg52644
VSel-1-like
p58429
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp58430
g52643
I12
sg52644
VSEL1L
p58431
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58432
(dp58433
g52643
I134
sg52644
VPDA
p58434
sg52646
I3
sg52647
VC0013274
p58435
sg52649
I1
sa(dp58436
g52643
I33
sg52644
Vtumor
p58437
sg52646
I5
sg52647
VC0027651
p58438
sg52649
I1
sa(dp58439
g52643
I100
sg52644
Vpancreatic ductal adenocarcinoma
p58440
sg52646
I32
sg52647
VC1335302
p58441
sg52649
I3
sasa(dp58442
g52636
VSEL1L is a putative tumor suppressor gene that is frequently down-regulated in pancreatic ductal adenocarcinoma (PDA).
p58443
sg52638
(lp58444
(dp58445
g52643
I0
sg52644
VSEL1L
p58446
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58447
(dp58448
g52643
I20
sg52644
Vtumor
p58449
sg52646
I5
sg52647
VC0027651
p58450
sg52649
I1
sa(dp58451
g52643
I79
sg52644
Vpancreatic ductal adenocarcinoma
p58452
sg52646
I32
sg52647
VC1335302
p58453
sg52649
I3
sa(dp58454
g52643
I113
sg52644
VPDA
p58455
sg52646
I3
sg52647
VC0013274
p58456
sg52649
I1
sasa(dp58457
g135
(dp58458
(VTNC
p58459
Vpancreatic tumor
p58460
tp58461
I00
ssg52636
VUsing a functional genomic approach, we identified a seven-gene panel (TNC, TFPI, TGFBI, SEL-1L, L1CAM, WWTR1, and CDC42BPA) that was differentially expressed across three different expression platforms, including pancreatic tumor/normal samples.
p58462
sg52638
(lp58463
(dp58464
g52643
I76
sg52644
VTFPI
p58465
sg52646
I4
sg52674
VP10646
p58466
sg52649
I1
sa(dp58467
g52643
I97
sg52644
VL1CAM
p58468
sg52646
I5
sg52674
VP32004
p58469
sg52649
I1
sa(dp58470
g52643
I71
sg52644
g58459
sg52646
I3
sg52674
VP63316
p58471
sg52649
I1
sa(dp58472
g52643
I89
sg52644
VSEL-1L
p58473
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp58474
g52643
I104
sg52644
VWWTR1
p58475
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58476
(dp58477
g52643
I214
sg52644
g58460
sg52646
I16
sg52647
VC0030297
p58478
sg52649
I2
sasa(dp58479
g52636
VPreviously, it was reported that SEL1L is able to decrease the aggressive behavior of human pancreatic tumor cells both in vitro and in vivo.
p58480
sg52638
(lp58481
(dp58482
g52643
I33
sg52644
VSEL1L
p58483
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58484
(dp58485
g52643
I63
sg52644
Vaggressive behavior
p58486
sg52646
I19
sg52647
VC0001807
p58487
sg52649
I2
sa(dp58488
g52643
I92
sg52644
Vpancreatic tumor
p58489
sg52646
I16
sg52647
VC0030297
p58490
sg52649
I2
sasa(dp58491
g52636
VTo gain insights into the involvement of SEL1L in tumor invasion, we performed gene expression analysis on the pancreatic cancer cell line Suit-2 subjected to two complementary strategies: upregulation and downregulation of SEL1L expression by stable transfection of the entire cDNA under an inducible promoter and by RNA-mediated interference.
p58492
sg52638
(lp58493
(dp58494
g52643
I41
sg52644
VSEL1L
p58495
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58496
g52643
I41
sg52644
VSEL1L
p58497
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58498
(dp58499
g52643
I50
sg52644
Vtumor
p58500
sg52646
I5
sg52647
VC0027651
p58501
sg52649
I1
sa(dp58502
g52643
I56
sg52644
Vinvasion
p58503
sg52646
I8
sg52647
VC2699153
p58504
sg52649
I1
sa(dp58505
g52643
I111
sg52644
Vpancreatic cancer
p58506
sg52646
I17
sg52647
VC0235974
p58507
sg52649
I2
sasa(dp58508
g52636
VThe gene SEL1L is involved both in human breast and pancreatic cancer progression.
p58509
sg52638
(lp58510
(dp58511
g52643
I4
sg52644
Vgene SEL1L
p58512
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp58513
(dp58514
g52643
I63
sg52644
Vcancer progression
p58515
sg52646
I18
sg52647
VC0178874
p58516
sg52649
I2
sasa(dp58517
g52636
VRecent data suggest that SEL1L may play an important role in pancreatic carcinoma, similar to breast cancer, where the expression of SEL1L has been associated with a reduction in both proliferative activity in vitro and clinical tumor aggressiveness.
p58518
sg52638
(lp58519
(dp58520
g52643
I25
sg52644
VSEL1L
p58521
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58522
g52643
I25
sg52644
VSEL1L
p58523
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58524
(dp58525
g52643
I94
sg52644
Vbreast cancer
p58526
sg52646
I13
sg52647
VC0678222
p58527
sg52649
I2
sa(dp58528
g52643
I229
sg52644
Vtumor
p58529
sg52646
I5
sg52647
VC0027651
p58530
sg52649
I1
sa(dp58531
g52643
I61
sg52644
Vpancreatic carcinoma
p58532
sg52646
I20
sg52647
VC0235974
p58533
sg52649
I2
sa(dp58534
g52643
I235
sg52644
Vaggressiveness
p58535
sg52646
I14
sg52647
VC0001807
p58536
sg52649
I1
sa(dp58537
g52643
I184
sg52644
Vproliferative
p58538
sg52646
I13
sg52647
VC0334094
p58539
sg52649
I1
sasa(dp58540
g52636
VTo investigate this possibility, we examined the expression of Sel1L in a series of primary pancreatic carcinomas by immunohistochemistry and characterized the effects of Sel1L overexpression both in vitro and in vivo.
p58541
sg52638
(lp58542
(dp58543
g52643
I63
sg52644
VSel1L
p58544
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58545
g52643
I63
sg52644
VSel1L
p58546
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58547
(dp58548
g52643
I103
sg52644
Vcarcinomas
p58549
sg52646
I10
sg52647
VC0007097
p58550
sg52649
I1
sasa(dp58551
g52636
VIn 74 pancreatic cancers analysed, 36% lacked Sel1L expression, although there was no significant correlation between the expression of Sel1L and any clinicopathologic parameter, including survival.
p58552
sg52638
(lp58553
(dp58554
g52643
I46
sg52644
VSel1L
p58555
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58556
g52643
I46
sg52644
VSel1L
p58557
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58558
(dp58559
g52643
I6
sg52644
Vpancreatic cancers
p58560
sg52646
I18
sg52647
VC0346647
p58561
sg52649
I2
sasa(dp58562
g135
(dp58563
(Vactivin A
p58564
Vpancreatic cancer
p58565
tp58566
I00
ssg52636
VOverexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4.
p58567
sg52638
(lp58568
(dp58569
g52643
I208
sg52644
VSMAD4
p58570
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58571
g52643
I194
sg52644
g58564
sg52646
I9
sg52674
VP08476
p58572
sg52649
I2
sa(dp58573
g52643
I18
sg52644
VSEL1L
p58574
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58575
(dp58576
g52643
I46
sg52644
g58565
sg52646
I17
sg52647
VC0235974
p58577
sg52649
I2
sasa(dp58578
g52636
VThus, it can be hypothesized that Sel1L plays an important function in the growth and aggressiveness of pancreatic carcinoma.
p58579
sg52638
(lp58580
(dp58581
g52643
I34
sg52644
VSel1L
p58582
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp58583
(dp58584
g52643
I86
sg52644
Vaggressiveness
p58585
sg52646
I14
sg52647
VC0001807
p58586
sg52649
I1
sa(dp58587
g52643
I104
sg52644
Vpancreatic carcinoma
p58588
sg52646
I20
sg52647
VC0235974
p58589
sg52649
I2
sasa(dp58590
g135
(dp58591
(Vangiogenin and VEGF
p58592
VNSCLC
p58593
tp58594
I00
ssg52636
VLevels of angiogenic markers bFGF, angiogenin and VEGF in EBC significantly discriminated between 17 individuals with newly detected NSCLC versus stable and exacerbated chronic obstructive pulmonary disease (COPD) patients as well as healthy volunteers.
p58595
sg52638
(lp58596
(dp58597
g52643
I29
sg52644
VbFGF
p58598
sg52646
I4
sg52674
VP53370
p58599
sg52649
I1
sa(dp58600
g52643
I35
sg52644
g58592
sg52646
I19
sg52674
VP03950
p58601
sg52649
I3
sasg52640
(lp58602
(dp58603
g52643
I169
sg52644
Vchronic obstructive pulmonary disease
p58604
sg52646
I37
sg52647
VC0024117
p58605
sg52649
I4
sa(dp58606
g52643
I208
sg52644
VCOPD
p58607
sg52646
I4
sg52647
VC0024117
p58608
sg52649
I1
sa(dp58609
g52643
I133
sg52644
g58593
sg52646
I5
sg52647
VC0007131
p58610
sg52649
I1
sasa(dp58611
g52636
VHereditary amyloidosis of the Finnish type (HAF, or familial amyloid polyneuropathy type IV) is an autosomal dominant disease that has been described most commonly in the Finnish population but has also been found in some other countries.
p58612
sg52638
(lp58613
sg52640
(lp58614
(dp58615
g52643
I0
sg52644
VHereditary amyloidosis
p58616
sg52646
I22
sg52647
VC0206246
p58617
sg52649
I2
sa(dp58618
g52643
I52
sg52644
Vfamilial amyloid polyneuropathy
p58619
sg52646
I31
sg52647
VC0206245
p58620
sg52649
I3
sasa(dp58621
g135
(dp58622
(VC4BP
p58623
Vmetastatic colorectal cancer
p58624
tp58625
I00
ssg52636
VPlasma fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI and FXII activity levels and C4BP concentrations were determined in 73 patients with non-metastatic colorectal cancer (48 colon and 25 rectum) and in 67 matched control subjects.
p58626
sg52638
(lp58627
(dp58628
g52643
I34
sg52644
VFVIII
p58629
sg52646
I5
sg52674
VP00451
p58630
sg52649
I1
sa(dp58631
g52643
I7
sg52644
Vfibrinogen
p58632
sg52646
I10
sg52674
VP22087
p58633
sg52649
I1
sa(dp58634
g52643
I58
sg52644
VFXII
p58635
sg52646
I4
sg52674
VP00748
p58636
sg52649
I1
sa(dp58637
g52643
I50
sg52644
VFXI
p58638
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp58639
g52643
I41
sg52644
VFIX
p58640
sg52646
I3
sg52674
VP00740
p58641
sg52649
I1
sa(dp58642
g52643
I83
sg52644
g58623
sg52646
I4
sg52674
VP04003
p58643
sg52649
I1
sasg52640
(lp58644
(dp58645
g52643
I143
sg52644
g58624
sg52646
I28
sg52647
VC0948380
p58646
sg52649
I3
sasa(dp58647
g135
(dp58648
(Vfibrinogen
p58649
Vcolorectal cancer
p58650
tp58651
I00
ssg52636
VMean plasma concentrations of fibrinogen (functional and antigen), FVIII, FIX, FV and C4BP were significantly higher in colorectal cancer patients than in control subjects, while FVII and FXII levels were significantly decreased.
p58652
sg52638
(lp58653
(dp58654
g52643
I86
sg52644
VC4BP
p58655
sg52646
I4
sg52674
VP04003
p58656
sg52649
I1
sa(dp58657
g52643
I74
sg52644
VFIX
p58658
sg52646
I3
sg52674
VP00740
p58659
sg52649
I1
sa(dp58660
g52643
I67
sg52644
VFVIII
p58661
sg52646
I5
sg52674
VP00451
p58662
sg52649
I1
sa(dp58663
g52643
I188
sg52644
VFXII
p58664
sg52646
I4
sg52674
VP00748
p58665
sg52649
I1
sa(dp58666
g52643
I30
sg52644
g58649
sg52646
I10
sg52674
VP22087
p58667
sg52649
I1
sasg52640
(lp58668
(dp58669
g52643
I120
sg52644
g58650
sg52646
I17
sg52647
VC1527249
p58670
sg52649
I2
sasa(dp58671
g135
(dp58672
(VFXII
p58673
Vcolorectal cancer
p58674
tp58675
I00
ssg52636
VIn colorectal cancer patients high plasma fibrinogen, FVIII and FIX levels might represent further risk factors for venous thrombotic complications in the immediate post-surgery period, while decreased FVII and FXII concentrations may be an index of intravascular coagulation activation, still in a subclinical phase.
p58676
sg52638
(lp58677
(dp58678
g52643
I42
sg52644
Vfibrinogen, FVIII and FIX
p58679
sg52646
I25
sg52674
VP00451
p58680
sg52649
I4
sa(dp58681
g52643
I211
sg52644
g58673
sg52646
I4
sg52674
VP00748
p58682
sg52649
I1
sasg52640
(lp58683
(dp58684
g52643
I3
sg52644
g58674
sg52646
I17
sg52647
VC1527249
p58685
sg52649
I2
sasa(dp58686
g52636
VComplications of PPROM include prematurity, chorioamnionitis, neonatal sepsis, limb position defects, respiratory distress syndrome, pulmonary hypoplasia chronic lung disease, periventricular leukomalacia and intraventricular haemorrhage.A number of different sealing techniques have been employed which aim to restore a physical barrier against infection and encourage the re-accumulation of amniotic fluid.
p58687
sg52638
(lp58688
sg52640
(lp58689
(dp58690
g52643
I62
sg52644
Vneonatal sepsis
p58691
sg52646
I15
sg52647
VC0456103
p58692
sg52649
I2
sa(dp58693
g52643
I102
sg52644
Vrespiratory distress syndrome
p58694
sg52646
I29
sg52647
VC0035220
p58695
sg52649
I3
sa(dp58696
g52643
I133
sg52644
Vpulmonary hypoplasia
p58697
sg52646
I20
sg52647
VC0265783
p58698
sg52649
I2
sa(dp58699
g52643
I209
sg52644
Vintraventricular haemorrhage
p58700
sg52646
I28
sg52647
VC0240059
p58701
sg52649
I2
sa(dp58702
g52643
I44
sg52644
Vchorioamnionitis
p58703
sg52646
I16
sg52647
VC0008495
p58704
sg52649
I1
sa(dp58705
g52643
I17
sg52644
VPPROM
p58706
sg52646
I5
sg52647
VC0729264
p58707
sg52649
I1
sa(dp58708
g52643
I154
sg52644
Vchronic lung disease
p58709
sg52646
I20
sg52647
VC0746102
p58710
sg52649
I3
sa(dp58711
g52643
I346
sg52644
Vinfection
p58712
sg52646
I9
sg52647
VC0009450
p58713
sg52649
I1
sa(dp58714
g52643
I176
sg52644
Vperiventricular leukomalacia
p58715
sg52646
I28
sg52647
VC0023529
p58716
sg52649
I2
sasa(dp58717
g52636
VNL infants were unexposed to PPROM or maternal hypertension, had highest requirement for surfactant, did not develop IVH and periventricular leukomalacia (PVL) and none of them were Caucasian.
p58718
sg52638
(lp58719
sg52640
(lp58720
(dp58721
g52643
I29
sg52644
VPPROM
p58722
sg52646
I5
sg52647
VC0729264
p58723
sg52649
I1
sa(dp58724
g52643
I125
sg52644
Vperiventricular leukomalacia
p58725
sg52646
I28
sg52647
VC0023529
p58726
sg52649
I2
sa(dp58727
g52643
I155
sg52644
VPVL
p58728
sg52646
I3
sg52647
VC0023529
p58729
sg52649
I1
sa(dp58730
g52643
I38
sg52644
Vmaternal hypertension
p58731
sg52646
I21
sg52647
VC0565599
p58732
sg52649
I2
sasa(dp58733
g52636
VMolecular analysis indicated that the livers of BDNF mutants fed HFD contained elevated levels of peroxisome proliferator-activated receptor alpha (Pparalpha or Ppara as listed in the MGI Database) and fibroblast growth factor 21 (Fgf21) transcripts compared with WTs.
p58734
sg52638
(lp58735
(dp58736
g52643
I48
sg52644
VBDNF mutants
p58737
sg52646
I12
sg52674
g12
sg52649
I2
sa(dp58738
g52643
I98
sg52644
Vperoxisome proliferator-activated receptor alpha
p58739
sg52646
I48
sg52674
g12
sg52649
I4
sa(dp58740
g52643
I148
sg52644
VPparalpha
p58741
sg52646
I9
sg52674
g12
sg52649
I1
sasg52640
(lp58742
(dp58743
g52643
I264
sg52644
VWTs
p58744
sg52646
I3
sg52647
VC1839736
p58745
sg52649
I1
sasa(dp58746
g135
(dp58747
(Vtumor necrosis factor
p58748
Vtumor necrosis
p58749
tp58750
I00
ssg52636
VWe measured the cerebrospinal fluid (CSF) and plasma concentrations of interleukin (IL)-1Alfa, IL-1Beta, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-Alfa, TNF-Beta, interferon (IFN)-Gamma, the IL-1 receptor antagonist, and soluble IL-4 receptor (sIL-4r) by ELISA in 12 patients each with acute, monosymptomatic, idiopathic optic neuritis (ON), ON as part of MS, other attack forms of MS, and in neurological control subjects.
p58751
sg52638
(lp58752
(dp58753
g52643
I105
sg52644
VIL-2
p58754
sg52646
I4
sg52674
VP60568
p58755
sg52649
I1
sa(dp58756
g52643
I95
sg52644
VIL-1Beta
p58757
sg52646
I8
sg52674
VP01584
p58758
sg52649
I1
sa(dp58759
g52643
I117
sg52644
VIL-6
p58760
sg52646
I4
sg52674
VP05231
p58761
sg52649
I1
sa(dp58762
g52643
I164
sg52644
VTNF-Beta
p58763
sg52646
I8
sg52674
VP01375
p58764
sg52649
I1
sa(dp58765
g52643
I153
sg52644
VTNF
p58766
sg52646
I3
sg52674
VP01375
p58767
sg52649
I1
sa(dp58768
g52643
I111
sg52644
VIL-4
p58769
sg52646
I4
sg52674
VP05112
p58770
sg52649
I1
sa(dp58771
g52643
I174
sg52644
Vinterferon
p58772
sg52646
I10
sg52674
VP01563
p58773
sg52649
I1
sa(dp58774
g52643
I255
sg52644
VsIL-4r
p58775
sg52646
I6
sg52674
VP40967
p58776
sg52649
I1
sa(dp58777
g52643
I232
sg52644
Vsoluble IL-4 receptor
p58778
sg52646
I21
sg52674
VP40967
p58779
sg52649
I3
sa(dp58780
g52643
I71
sg52644
Vinterleukin (IL)-1Alfa
p58781
sg52646
I22
sg52674
VP60568
p58782
sg52649
I2
sa(dp58783
g52643
I130
sg52644
g58748
sg52646
I21
sg52674
VP01375
p58784
sg52649
I3
sa(dp58785
g52643
I186
sg52644
VIFN
p58786
sg52646
I3
sg52674
VP01562
p58787
sg52649
I1
sa(dp58788
g52643
I202
sg52644
VIL-1 receptor
p58789
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp58790
(dp58791
g52643
I348
sg52644
VON
p58792
sg52646
I2
sg52647
VC0029134
p58793
sg52649
I1
sa(dp58794
g52643
I255
sg52644
VsIL
p58795
sg52646
I3
sg52647
VC0333873
p58796
sg52649
I1
sa(dp58797
g52643
I348
sg52644
VON
p58798
sg52646
I2
sg52647
VC0029134
p58799
sg52649
I1
sa(dp58800
g52643
I332
sg52644
Voptic neuritis
p58801
sg52646
I14
sg52647
VC0029134
p58802
sg52649
I2
sa(dp58803
g52643
I130
sg52644
g58749
sg52646
I14
sg52647
VC0333516
p58804
sg52649
I2
sasa(dp58805
g135
(dp58806
(VIL-4
p58807
Vdemyelination
p58808
tp58809
I00
ssg52636
VWe have reported previously that ocular infection of different strains of mice with recombinant herpes simplex virus 1 (HSV-1) constitutively expressing interleukin-2 (IL-2) provokes central nervous system (CNS) demyelination and optic neuropathy, as determined by changes in visual evoked cortical potentials and pathological changes in the optic nerve and CNS, whereas recombinant viruses expressing IL-4, gamma interferon, IL-12p35, IL-12p40, or IL-12p70 do not induce this neuropathy.
p58810
sg52638
(lp58811
(dp58812
g52643
I168
sg52644
VIL-2
p58813
sg52646
I4
sg52674
VP60568
p58814
sg52649
I1
sa(dp58815
g52643
I153
sg52644
Vinterleukin-2
p58816
sg52646
I13
sg52674
VP60568
p58817
sg52649
I1
sa(dp58818
g52643
I408
sg52644
Vgamma interferon
p58819
sg52646
I16
sg52674
VP01579
p58820
sg52649
I2
sa(dp58821
g52643
I402
sg52644
g58807
sg52646
I4
sg52674
VP05112
p58822
sg52649
I1
sasg52640
(lp58823
(dp58824
g52643
I33
sg52644
Vocular infection
p58825
sg52646
I16
sg52647
VC0015403
p58826
sg52649
I2
sa(dp58827
g52643
I230
sg52644
Voptic neuropathy
p58828
sg52646
I16
sg52647
VC0029132
p58829
sg52649
I2
sa(dp58830
g52643
I236
sg52644
Vneuropathy
p58831
sg52646
I10
sg52647
VC0442874
p58832
sg52649
I1
sa(dp58833
g52643
I96
sg52644
Vherpes simplex
p58834
sg52646
I14
sg52647
VC0019348
p58835
sg52649
I2
sa(dp58836
g52643
I191
sg52644
Vnervous
p58837
sg52646
I7
sg52647
VC0027769
p58838
sg52649
I1
sa(dp58839
g52643
I212
sg52644
g58808
sg52646
I13
sg52647
VC0011304
p58840
sg52649
I1
sasa(dp58841
g135
(dp58842
(VIL-4
p58843
Vencephalomyelitis
p58844
tp58845
I00
ssg52636
VThe objective of this study was to detect interleukin-17 (IL-17), interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and forkhead/winged helix transcription factor p3 (Foxp3) protein and gene expression of the optic nerve and to further explore the role of T helper cell subsets such as Th1, Th2, Th17 and Treg in the pathogenesis of optic neuritis in experimental autoimmune encephalomyelitis (EAE).
p58846
sg52638
(lp58847
(dp58848
g52643
I42
sg52644
Vinterleukin-17
p58849
sg52646
I14
sg52674
VP60568
p58850
sg52649
I1
sa(dp58851
g52643
I121
sg52644
Vforkhead/winged helix transcription factor p3
p58852
sg52646
I45
sg52674
g12
sg52649
I5
sa(dp58853
g52643
I58
sg52644
VIL-17
p58854
sg52646
I5
sg52674
VP60568
p58855
sg52649
I1
sa(dp58856
g52643
I168
sg52644
VFoxp3
p58857
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp58858
g52643
I84
sg52644
VIFN-gamma
p58859
sg52646
I9
sg52674
VP01579
p58860
sg52649
I1
sa(dp58861
g52643
I96
sg52644
Vinterleukin-4
p58862
sg52646
I13
sg52674
VP05112
p58863
sg52649
I1
sa(dp58864
g52643
I66
sg52644
Vinterferon-gamma
p58865
sg52646
I16
sg52674
VP01579
p58866
sg52649
I1
sa(dp58867
g52643
I111
sg52644
g58843
sg52646
I4
sg52674
VP05112
p58868
sg52649
I1
sasg52640
(lp58869
(dp58870
g52643
I334
sg52644
Voptic neuritis
p58871
sg52646
I14
sg52647
VC0029134
p58872
sg52649
I2
sa(dp58873
g52643
I395
sg52644
VEAE
p58874
sg52646
I3
sg52647
VC0014070
p58875
sg52649
I1
sa(dp58876
g52643
I318
sg52644
Vpathogenesis
p58877
sg52646
I12
sg52647
VC0699748
p58878
sg52649
I1
sa(dp58879
g52643
I365
sg52644
Vautoimmune
p58880
sg52646
I10
sg52647
VC0443146
p58881
sg52649
I1
sa(dp58882
g52643
I376
sg52644
g58844
sg52646
I17
sg52647
VC0014070
p58883
sg52649
I1
sasa(dp58884
g135
(dp58885
(VTGF-beta
p58886
Voptic neuritis
p58887
tp58888
I00
ssg52636
VIn MS and optic neuritis, IL-4 mRNA expressing cells predominated, followed by TGF-beta- and IFN-gamma-positive cells.
p58889
sg52638
(lp58890
(dp58891
g52643
I26
sg52644
VIL-4 mRNA
p58892
sg52646
I9
sg52674
VP05112
p58893
sg52649
I2
sa(dp58894
g52643
I93
sg52644
VIFN-gamma
p58895
sg52646
I9
sg52674
VP01579
p58896
sg52649
I1
sa(dp58897
g52643
I79
sg52644
g58886
sg52646
I8
sg52674
VP18075
p58898
sg52649
I1
sasg52640
(lp58899
(dp58900
g52643
I10
sg52644
g58887
sg52646
I14
sg52647
VC0029134
p58901
sg52649
I2
sasa(dp58902
g135
(dp58903
(Vtrefoil factors
p58904
Vadenocarcinomas
p58905
tp58906
I00
ssg52636
VGKN1, GKN2, and the trefoil factors TFF1 and TFF3 were examined in tissue microarrays from 155 distal gastric adenocarcinomas.
p58907
sg52638
(lp58908
(dp58909
g52643
I36
sg52644
VTFF1
p58910
sg52646
I4
sg52674
VP04155
p58911
sg52649
I1
sa(dp58912
g52643
I6
sg52644
VGKN2
p58913
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58914
g52643
I20
sg52644
g58904
sg52646
I15
sg52674
VP19883
p58915
sg52649
I2
sa(dp58916
g52643
I45
sg52644
VTFF3
p58917
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58918
g52643
I0
sg52644
VGKN1
p58919
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp58920
(dp58921
g52643
I110
sg52644
g58905
sg52646
I15
sg52647
VC0001418
p58922
sg52649
I1
sasa(dp58923
g52636
VLoss of GKN1 and GKN2 expression occurs frequently in gastric adenocarcinomas, especially in the diffuse subtype.
p58924
sg52638
(lp58925
(dp58926
g52643
I17
sg52644
VGKN2
p58927
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp58928
g52643
I8
sg52644
VGKN1
p58929
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp58930
(dp58931
g52643
I62
sg52644
Vadenocarcinomas
p58932
sg52646
I15
sg52647
VC0001418
p58933
sg52649
I1
sasa(dp58934
g52636
VSince RIs significantly correlate with renal function, they have been proposed to be independent risk factors for CKD progression, besides proteinuria, low GFR and arterial hypertension.
p58935
sg52638
(lp58936
sg52640
(lp58937
(dp58938
g52643
I164
sg52644
Varterial hypertension
p58939
sg52646
I21
sg52647
VC0020538
p58940
sg52649
I2
sasa(dp58941
g52636
VHigh uterine artery Doppler resistance indexes (RIs) are predictive of placental complications of pregnancy, such as preeclampsia, fetal growth restriction, and stillbirth.
p58942
sg52638
(lp58943
sg52640
(lp58944
(dp58945
g52643
I117
sg52644
Vpreeclampsia
p58946
sg52646
I12
sg52647
VC0032914
p58947
sg52649
I1
sa(dp58948
g52643
I131
sg52644
Vfetal growth restriction
p58949
sg52646
I24
sg52647
VC0015934
p58950
sg52649
I3
sa(dp58951
g52643
I161
sg52644
Vstillbirth
p58952
sg52646
I10
sg52647
VC0595939
p58953
sg52649
I1
sa(dp58954
g52643
I81
sg52644
Vcomplications of pregnancy
p58955
sg52646
I26
sg52647
VC0032962
p58956
sg52649
I3
sasa(dp58957
g52636
VPatients with hypertension or diabetes mellitus showed higher RIs (p &lt; 0.05) than those without the ailments.
p58958
sg52638
(lp58959
sg52640
(lp58960
(dp58961
g52643
I30
sg52644
Vdiabetes mellitus
p58962
sg52646
I17
sg52647
VC0011849
p58963
sg52649
I2
sa(dp58964
g52643
I14
sg52644
Vhypertension
p58965
sg52646
I12
sg52647
VC0020538
p58966
sg52649
I1
sasa(dp58967
g52636
VMyelodysplastic syndrome (MDS) and myeloproliferative disorders are rare in children; they are divided into low-grade MDS (refractory cytopenia of childhood [RCC]), advanced MDS (refractory anemia with excess blasts in transformation), and juvenile myelomonocytic leukemia (JMML), each with different characteristics and management strategies.
p58968
sg52638
(lp58969
sg52640
(lp58970
(dp58971
g52643
I274
sg52644
VJMML
p58972
sg52646
I4
sg52647
VC0349639
p58973
sg52649
I1
sa(dp58974
g52643
I35
sg52644
Vmyeloproliferative disorders
p58975
sg52646
I28
sg52647
VC0027022
p58976
sg52649
I2
sa(dp58977
g52643
I123
sg52644
Vrefractory cytopenia of childhood
p58978
sg52646
I33
sg52647
VC2826323
p58979
sg52649
I4
sa(dp58980
g52643
I26
sg52644
VMDS
p58981
sg52646
I3
sg52647
VC0265219
p58982
sg52649
I1
sa(dp58983
g52643
I240
sg52644
Vjuvenile myelomonocytic leukemia
p58984
sg52646
I32
sg52647
VC0349639
p58985
sg52649
I3
sa(dp58986
g52643
I158
sg52644
VRCC
p58987
sg52646
I3
sg52647
VC0007134
p58988
sg52649
I1
sa(dp58989
g52643
I179
sg52644
Vrefractory anemia with excess blasts in transformation
p58990
sg52646
I54
sg52647
VC0280028
p58991
sg52649
I7
sa(dp58992
g52643
I0
sg52644
VMyelodysplastic syndrome
p58993
sg52646
I24
sg52647
VC3463824
p58994
sg52649
I2
sa(dp58995
g52643
I26
sg52644
VMDS
p58996
sg52646
I3
sg52647
VC0265219
p58997
sg52649
I1
sa(dp58998
g52643
I26
sg52644
VMDS
p58999
sg52646
I3
sg52647
VC0265219
p59000
sg52649
I1
sasa(dp59001
g135
(dp59002
(VPten loss
p59003
Vsevere anemia
p59004
tp59005
I00
ssg52636
VThus, genetic ablation or pharmacologic inhibition of Shp2 suppresses the leukemogenic effect of Pten loss, yet simultaneously induces severe anemia in mice with Pten deficiency in blood cells.
p59006
sg52638
(lp59007
(dp59008
g52643
I97
sg52644
VPten
p59009
sg52646
I4
sg52674
VP60484
p59010
sg52649
I1
sa(dp59011
g52643
I97
sg52644
g59003
sg52646
I9
sg52674
VP60484
p59012
sg52649
I2
sa(dp59013
g52643
I54
sg52644
VShp2
p59014
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp59015
(dp59016
g52643
I97
sg52644
VPten loss
p59017
sg52646
I9
sg52647
VC3272693
p59018
sg52649
I2
sa(dp59019
g52643
I135
sg52644
g59004
sg52646
I13
sg52647
VC0238644
p59020
sg52649
I2
sasa(dp59021
g135
(dp59022
(VPten and Shp2
p59023
Vanemia
p59024
tp59025
I01
ssg52636
VSurprisingly, the Shp2 and Pten double-knockout mice suffered lethal anemia, a phenotype that reveals previously unappreciated cooperative roles of Pten and Shp2 in erythropoiesis.
p59026
sg52638
(lp59027
(dp59028
g52643
I27
sg52644
VPten
p59029
sg52646
I4
sg52674
VP60484
p59030
sg52649
I1
sa(dp59031
g52643
I18
sg52644
VShp2
p59032
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp59033
g52643
I148
sg52644
g59023
sg52646
I13
sg52674
VP60484
p59034
sg52649
I3
sasg52640
(lp59035
(dp59036
g52643
I53
sg52644
Vsuffered
p59037
sg52646
I8
sg52647
VC0683278
p59038
sg52649
I1
sa(dp59039
g52643
I69
sg52644
g59024
sg52646
I6
sg52647
VC0002871
p59040
sg52649
I1
sasa(dp59041
g52636
VConsistently, treatment of Pten-deficient mice with a specific Shp2 inhibitor suppressed myeloproliferative neoplasm while causing anemia.
p59042
sg52638
(lp59043
(dp59044
g52643
I63
sg52644
VShp2
p59045
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp59046
(dp59047
g52643
I89
sg52644
Vmyeloproliferative neoplasm
p59048
sg52646
I27
sg52647
VC1292778
p59049
sg52649
I2
sa(dp59050
g52643
I131
sg52644
Vanemia
p59051
sg52646
I6
sg52647
VC0002871
p59052
sg52649
I1
sasa(dp59053
g52636
VInfants with non-metabolic disorders (n = 34); 10 (three neuroblastoma [NBL], three brain tumor, two acute meylogenous leukemia [AML], one rhabdomyosarcoma, and one retinoblastoma) received auto HSCT, and 24 (eight hemophagocytic lymphohistiocytosis [HLH], four juvenile meylomonocytic leukemia [JMML], four Wiscott-Aldrych Syndrome [WAS], three acute lymphoblastic leukemia [ALL], two AML, one severe aplastic anemia [SAA], one chronic granulomatous disease [CGD], and one amegakaryocytic thrombocytopenia) received allo HSCT.
p59054
sg52638
(lp59055
sg52640
(lp59056
(dp59057
g52643
I395
sg52644
Vsevere aplastic anemia
p59058
sg52646
I22
sg52647
VC1883018
p59059
sg52649
I3
sa(dp59060
g52643
I474
sg52644
Vamegakaryocytic thrombocytopenia
p59061
sg52646
I32
sg52647
VC0398639
p59062
sg52649
I2
sa(dp59063
g52643
I215
sg52644
Vhemophagocytic lymphohistiocytosis
p59064
sg52646
I34
sg52647
VC0024291
p59065
sg52649
I2
sa(dp59066
g52643
I324
sg52644
VSyndrome
p59067
sg52646
I8
sg52647
VC0039082
p59068
sg52649
I1
sa(dp59069
g52643
I460
sg52644
VCGD
p59070
sg52646
I3
sg52647
VC0018203
p59071
sg52649
I1
sa(dp59072
g52643
I129
sg52644
VAML
p59073
sg52646
I3
sg52647
VC0023467
p59074
sg52649
I1
sa(dp59075
g52643
I346
sg52644
Vacute lymphoblastic leukemia
p59076
sg52646
I28
sg52647
VC1961102
p59077
sg52649
I3
sa(dp59078
g52643
I139
sg52644
Vrhabdomyosarcoma
p59079
sg52646
I16
sg52647
VC0035412
p59080
sg52649
I1
sa(dp59081
g52643
I17
sg52644
Vmetabolic disorders
p59082
sg52646
I19
sg52647
VC0025517
p59083
sg52649
I2
sa(dp59084
g52643
I119
sg52644
Vleukemia
p59085
sg52646
I8
sg52647
VC0023418
p59086
sg52649
I1
sa(dp59087
g52643
I84
sg52644
Vbrain tumor
p59088
sg52646
I11
sg52647
VC0006118
p59089
sg52649
I2
sa(dp59090
g52643
I119
sg52644
Vleukemia
p59091
sg52646
I8
sg52647
VC0023418
p59092
sg52649
I1
sa(dp59093
g52643
I165
sg52644
Vretinoblastoma
p59094
sg52646
I14
sg52647
VC0035335
p59095
sg52649
I1
sa(dp59096
g52643
I429
sg52644
Vchronic granulomatous disease
p59097
sg52646
I29
sg52647
VC0018203
p59098
sg52649
I3
sa(dp59099
g52643
I129
sg52644
VAML
p59100
sg52646
I3
sg52647
VC0023467
p59101
sg52649
I1
sa(dp59102
g52643
I296
sg52644
VJMML
p59103
sg52646
I4
sg52647
VC0349639
p59104
sg52649
I1
sa(dp59105
g52643
I57
sg52644
Vneuroblastoma
p59106
sg52646
I13
sg52647
VC0027819
p59107
sg52649
I1
sa(dp59108
g52643
I251
sg52644
VHLH
p59109
sg52646
I3
sg52647
VC0024291
p59110
sg52649
I1
sasa(dp59111
g135
(dp59112
(Vchoroideremia-like
p59113
Vchoroideremia
p59114
tp59115
I00
ssg52636
VThe human choroideremia-like (CHML) gene and a locus for Usher syndrome type 2 (USH2) were recently mapped to the 1q31-qter region employing physical mapping and genetic linkage studies, respectively.
p59116
sg52638
(lp59117
(dp59118
g52643
I57
sg52644
VUsher syndrome type 2
p59119
sg52646
I21
sg52674
g12
sg52649
I4
sa(dp59120
g52643
I80
sg52644
VUSH2
p59121
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp59122
g52643
I30
sg52644
VCHML
p59123
sg52646
I4
sg52674
VP26374
p59124
sg52649
I1
sa(dp59125
g52643
I10
sg52644
g59113
sg52646
I18
sg52674
VP26374
p59126
sg52649
I1
sasg52640
(lp59127
(dp59128
g52643
I57
sg52644
VUsher syndrome type 2
p59129
sg52646
I21
sg52647
VC0339534
p59130
sg52649
I4
sa(dp59131
g52643
I80
sg52644
VUSH2
p59132
sg52646
I4
sg52647
VC0339534
p59133
sg52649
I1
sa(dp59134
g52643
I10
sg52644
g59114
sg52646
I13
sg52647
VC0008525
p59135
sg52649
I1
sasa(dp59136
g52636
VTo investigate a possible role of the CHML gene in the pathogenesis of USH2, we investigated 10 Dutch and 9 Danish USH2 patients for point mutations in the open reading frame of the CHML gene.
p59137
sg52638
(lp59138
(dp59139
g52643
I71
sg52644
VUSH2
p59140
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp59141
g52643
I38
sg52644
VCHML gene
p59142
sg52646
I9
sg52674
VP26374
p59143
sg52649
I2
sa(dp59144
g52643
I38
sg52644
VCHML gene
p59145
sg52646
I9
sg52674
VP26374
p59146
sg52649
I2
sasg52640
(lp59147
(dp59148
g52643
I55
sg52644
Vpathogenesis
p59149
sg52646
I12
sg52647
VC0699748
p59150
sg52649
I1
sasa(dp59151
g52636
VThese results suggest that CHML is not involved in the pathogenesis of USH2.
p59152
sg52638
(lp59153
(dp59154
g52643
I27
sg52644
VCHML
p59155
sg52646
I4
sg52674
VP26374
p59156
sg52649
I1
sa(dp59157
g52643
I71
sg52644
VUSH2
p59158
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp59159
(dp59160
g52643
I55
sg52644
Vpathogenesis
p59161
sg52646
I12
sg52647
VC0699748
p59162
sg52649
I1
sasa(dp59163
g52636
VWe hypothesized that the Hrad17 may be expressed in thymoma, especially in invasive thymoma.
p59164
sg52638
(lp59165
(dp59166
g52643
I25
sg52644
VHrad17
p59167
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp59168
(dp59169
g52643
I75
sg52644
Vinvasive thymoma
p59170
sg52646
I16
sg52647
VC0278846
p59171
sg52649
I2
sa(dp59172
g52643
I52
sg52644
Vthymoma
p59173
sg52646
I7
sg52647
VC0040100
p59174
sg52649
I1
sasa(dp59175
g52636
VWe attempted to determine the influence of Hrad17 expression on clinicopathological features for patients with thymoma who had undergone surgery.
p59176
sg52638
(lp59177
(dp59178
g52643
I43
sg52644
VHrad17
p59179
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp59180
(dp59181
g52643
I111
sg52644
Vthymoma
p59182
sg52646
I7
sg52647
VC0040100
p59183
sg52649
I1
sasa(dp59184
g52636
VExpression of Hrad17 messenger ribonucleic acid (RNA) was evaluated by reverse transcription-polymerase chain reaction using a LightCycler in 38 thymomas and 10 adjacent histologically normal thymus samples from patients for whom follow-up data was available.
p59185
sg52638
(lp59186
(dp59187
g52643
I14
sg52644
VHrad17 messenger
p59188
sg52646
I16
sg52674
g12
sg52649
I2
sasg52640
(lp59189
(dp59190
g52643
I145
sg52644
Vthymomas
p59191
sg52646
I8
sg52647
VC0040100
p59192
sg52649
I1
sasa(dp59193
g52636
VNo relationship was seen between Hrad17 gene expression and age, gender, or pathological thymoma subtypes.
p59194
sg52638
(lp59195
(dp59196
g52643
I33
sg52644
VHrad17 gene
p59197
sg52646
I11
sg52674
g12
sg52649
I2
sasg52640
(lp59198
(dp59199
g52643
I89
sg52644
Vthymoma
p59200
sg52646
I7
sg52647
VC0040100
p59201
sg52649
I1
sasa(dp59202
g52636
VHrad17 mRNA expression in invasive thymomas (stage II-IV, 10.067 +/- 5.293) was significantly higher than that in stage I thymomas (5.193 +/- 4.485, p = 0.0168).
p59203
sg52638
(lp59204
(dp59205
g52643
I0
sg52644
VHrad17 mRNA
p59206
sg52646
I11
sg52674
g12
sg52649
I2
sasg52640
(lp59207
(dp59208
g52643
I35
sg52644
Vthymomas
p59209
sg52646
I8
sg52647
VC0040100
p59210
sg52649
I1
sa(dp59211
g52643
I35
sg52644
Vthymomas
p59212
sg52646
I8
sg52647
VC0040100
p59213
sg52649
I1
sasa(dp59214
g52636
VImmunohistochemistry showed that Hrad17 protein was highly expressed in invasive thymoma tumor tissue but not within the normal thymus tissue.
p59215
sg52638
(lp59216
(dp59217
g52643
I33
sg52644
VHrad17 protein
p59218
sg52646
I14
sg52674
g12
sg52649
I2
sasg52640
(lp59219
(dp59220
g52643
I72
sg52644
Vinvasive thymoma
p59221
sg52646
I16
sg52647
VC0278846
p59222
sg52649
I2
sa(dp59223
g52643
I89
sg52644
Vtumor
p59224
sg52646
I5
sg52647
VC0027651
p59225
sg52649
I1
sasa(dp59226
g52636
VHrad17 was highly expressed in invasive thymoma.
p59227
sg52638
(lp59228
(dp59229
g52643
I0
sg52644
VHrad17
p59230
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp59231
(dp59232
g52643
I31
sg52644
Vinvasive thymoma
p59233
sg52646
I16
sg52647
VC0278846
p59234
sg52649
I2
sasa(dp59235
g135
(dp59236
(VLDHA
p59237
Vapical periodontitis
p59238
tp59239
I00
ssg52636
VIn induced apical periodontitis, osteoblastic expression of SIRT6 was significantly suppressed (P = 0.001) which was associated with significantly elevated levels of LDHA (P = 0.003) and 8-OHdG (P = 0.004) and significantly enhanced recruitment of macrophages (P = 0.004).
p59240
sg52638
(lp59241
(dp59242
g52643
I166
sg52644
g59237
sg52646
I4
sg52674
VP00338
p59243
sg52649
I1
sasg52640
(lp59244
(dp59245
g52643
I233
sg52644
Vrecruitment
p59246
sg52646
I11
sg52647
VC0271510
p59247
sg52649
I1
sa(dp59248
g52643
I11
sg52644
g59238
sg52646
I20
sg52647
VC0031030
p59249
sg52649
I2
sasa(dp59250
g135
(dp59251
(Vlactate dehydrogenase A
p59252
Vcolorectal cancer
p59253
tp59254
I00
ssg52636
VThe main objective of this work was to evaluate a new therapeutic strategy against a colitis-related colorectal cancer in vivo and in vitro by targeting mTOR-signaling and lactate dehydrogenase A.
p59255
sg52638
(lp59256
(dp59257
g52643
I85
sg52644
Vcolitis-related colorectal cancer
p59258
sg52646
I33
sg52674
VP31749
p59259
sg52649
I3
sa(dp59260
g52643
I153
sg52644
VmTOR
p59261
sg52646
I4
sg52674
VP42345
p59262
sg52649
I1
sa(dp59263
g52643
I172
sg52644
g59252
sg52646
I23
sg52674
VP49366
p59264
sg52649
I3
sasg52640
(lp59265
(dp59266
g52643
I85
sg52644
Vcolitis
p59267
sg52646
I7
sg52647
VC0009319
p59268
sg52649
I1
sa(dp59269
g52643
I101
sg52644
g59253
sg52646
I17
sg52647
VC1527249
p59270
sg52649
I2
sasa(dp59271
g52636
VThere were striking laboratory abnormalities in the groups diagnosed with toxic hepatitis (mean peak values: AST 775 +/- 464 U/L, ALT 400 +/- 447 U/L, ALP 767 +/- 408 U/L, LDH 1,469 +/- 779 U/L).
p59272
sg52638
(lp59273
(dp59274
g52643
I172
sg52644
VLDH 1
p59275
sg52646
I5
sg52674
g12
sg52649
I2
sasg52640
(lp59276
(dp59277
g52643
I80
sg52644
Vhepatitis
p59278
sg52646
I9
sg52647
VC0019159
p59279
sg52649
I1
sasa(dp59280
g135
(dp59281
(VLactate Dehydrogenase Activity
p59282
Vperiodontal disease
p59283
tp59284
I00
ssg52636
VTo determine Lactate Dehydrogenase Activity (LDHA) in whole saliva in individuals with periodontal disease and the effect of ultrasonic scaling on this enzyme activity.
p59285
sg52638
(lp59286
(dp59287
g52643
I45
sg52644
VLDHA
p59288
sg52646
I4
sg52674
VP00338
p59289
sg52649
I1
sa(dp59290
g52643
I13
sg52644
g59282
sg52646
I30
sg52674
VP00338
p59291
sg52649
I3
sasg52640
(lp59292
(dp59293
g52643
I87
sg52644
g59283
sg52646
I19
sg52647
VC0031090
p59294
sg52649
I2
sasa(dp59295
g52636
VLDH-1 activity was detected to be significantly higher in the sterile cirrhotic ascites when compared with spontaneous bacterial peritonitis, malignant ascites, tuberculous ascites and congestive heart failure-related ascites.
p59296
sg52638
(lp59297
(dp59298
g52643
I0
sg52644
VLDH-1
p59299
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp59300
(dp59301
g52643
I107
sg52644
Vspontaneous bacterial peritonitis
p59302
sg52646
I33
sg52647
VC0275551
p59303
sg52649
I3
sa(dp59304
g52643
I62
sg52644
Vsterile
p59305
sg52646
I7
sg52647
VC0678108
p59306
sg52649
I1
sa(dp59307
g52643
I185
sg52644
Vcongestive heart failure
p59308
sg52646
I24
sg52647
VC0018802
p59309
sg52649
I3
sa(dp59310
g52643
I142
sg52644
Vmalignant ascites
p59311
sg52646
I17
sg52647
VC0220656
p59312
sg52649
I2
sa(dp59313
g52643
I161
sg52644
Vtuberculous ascites
p59314
sg52646
I19
sg52647
VC0275919
p59315
sg52649
I2
sasa(dp59316
g135
(dp59317
(VHirudin variants
p59318
Vstomatitis
p59319
tp59320
I00
ssg52636
VHirudin variants (HV1 and HV2) were produced in infected insect cells as secreted proteins by joining their coding sequences to the leader peptide sequence of the vescicular stomatitis virus G protein.
p59321
sg52638
(lp59322
(dp59323
g52643
I18
sg52644
VHV1
p59324
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp59325
g52643
I0
sg52644
g59318
sg52646
I16
sg52674
VP26640
p59326
sg52649
I2
sasg52640
(lp59327
(dp59328
g52643
I174
sg52644
g59319
sg52646
I10
sg52647
VC0038362
p59329
sg52649
I1
sasa(dp59330
g52636
VMacrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in systemic, autoimmune, and inflammatory diseases, such as obesity, rheumatoid arthritis, and systemic lupus erythematosus.
p59331
sg52638
(lp59332
sg52640
(lp59333
(dp59334
g52643
I144
sg52644
Vobesity
p59335
sg52646
I7
sg52647
VC0028754
p59336
sg52649
I1
sa(dp59337
g52643
I97
sg52644
Vautoimmune
p59338
sg52646
I10
sg52647
VC0443146
p59339
sg52649
I1
sa(dp59340
g52643
I179
sg52644
Vsystemic lupus erythematosus
p59341
sg52646
I28
sg52647
VC0024141
p59342
sg52649
I3
sa(dp59343
g52643
I153
sg52644
Vrheumatoid arthritis
p59344
sg52646
I20
sg52647
VC0003873
p59345
sg52649
I2
sasa(dp59346
g135
(dp59347
(VMIF gene
p59348
Vrheumatoid arthritis
p59349
tp59350
I00
ssg52636
VTo systematically review evidence regarding the relationship between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis (RA), and the association between MIF gene polymorphisms and RA susceptibility.
p59351
sg52638
(lp59352
(dp59353
g52643
I192
sg52644
g59348
sg52646
I8
sg52674
VP05109
p59354
sg52649
I2
sasg52640
(lp59355
(dp59356
g52643
I159
sg52644
VRA
p59357
sg52646
I2
sg52647
VC0003873
p59358
sg52649
I1
sa(dp59359
g52643
I159
sg52644
VRA
p59360
sg52646
I2
sg52647
VC0003873
p59361
sg52649
I1
sa(dp59362
g52643
I137
sg52644
g59349
sg52646
I20
sg52647
VC0003873
p59363
sg52649
I2
sasa(dp59364
g52636
VTo investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS).
p59365
sg52638
(lp59366
sg52640
(lp59367
(dp59368
g52643
I95
sg52644
Vankylosing spondylitis
p59369
sg52646
I22
sg52647
VC0038013
p59370
sg52649
I2
sa(dp59371
g52643
I79
sg52644
Vpathogenesis
p59372
sg52646
I12
sg52647
VC0699748
p59373
sg52649
I1
sa(dp59374
g52643
I119
sg52644
VAS
p59375
sg52646
I2
sg52647
VC0038013
p59376
sg52649
I1
sasa(dp59377
g135
(dp59378
(VMIF
p59379
Vosteoarthritis
p59380
tp59381
I00
ssg52636
VRheumatoid SAAT secreted more adiponectin and macrophage migration inhibitory factor (MIF) than respective osteoarthritis tissue.
p59382
sg52638
(lp59383
(dp59384
g52643
I86
sg52644
g59379
sg52646
I3
sg52674
VP05109
p59385
sg52649
I1
sa(dp59386
g52643
I30
sg52644
Vadiponectin and macrophage migration inhibitory factor
p59387
sg52646
I54
sg52674
g12
sg52649
I6
sasg52640
(lp59388
(dp59389
g52643
I107
sg52644
g59380
sg52646
I14
sg52647
VC0029408
p59390
sg52649
I1
sasa(dp59391
g52636
VMacrophage migration inhibitory factor (MIF) has emerged as a promising drug target in diseases including sepsis, rheumatoid arthritis, and cancer.
p59392
sg52638
(lp59393
sg52640
(lp59394
(dp59395
g52643
I114
sg52644
Vrheumatoid arthritis
p59396
sg52646
I20
sg52647
VC0003873
p59397
sg52649
I2
sa(dp59398
g52643
I140
sg52644
Vcancer
p59399
sg52646
I6
sg52647
VC0006826
p59400
sg52649
I1
sa(dp59401
g52643
I106
sg52644
Vsepsis
p59402
sg52646
I6
sg52647
VC0243026
p59403
sg52649
I1
sasa(dp59404
g135
(dp59405
(Vanti-CCP
p59406
VCCP
p59407
tp59408
I01
ssg52636
VMacrophage migration inhibitory factor (MIF) and vascular endothelial growth factor (VEGF), as crucial parameters of angiogenesis and inflammation, were evaluated to identify the role of cyclic citrullinated peptide antibodies (anti-CCP) during angiogenesis in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
p59409
sg52638
(lp59410
(dp59411
g52643
I49
sg52644
Vvascular endothelial growth factor
p59412
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp59413
g52643
I228
sg52644
g59406
sg52646
I8
sg52674
VP07320
p59414
sg52649
I1
sa(dp59415
g52643
I85
sg52644
VVEGF
p59416
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp59417
(dp59418
g52643
I261
sg52644
Vrheumatoid arthritis
p59419
sg52646
I20
sg52647
VC0003873
p59420
sg52649
I2
sa(dp59421
g52643
I134
sg52644
Vinflammation
p59422
sg52646
I12
sg52647
VC0021368
p59423
sg52649
I1
sa(dp59424
g52643
I283
sg52644
VRA
p59425
sg52646
I2
sg52647
VC0003873
p59426
sg52649
I1
sa(dp59427
g52643
I312
sg52644
VPsA
p59428
sg52646
I3
sg52647
VC1519176
p59429
sg52649
I1
sa(dp59430
g52643
I291
sg52644
Vpsoriatic arthritis
p59431
sg52646
I19
sg52647
VC0003872
p59432
sg52649
I2
sa(dp59433
g52643
I233
sg52644
g59407
sg52646
I3
sg52647
VC1832526
p59434
sg52649
I1
sasa(dp59435
g52636
VThe aim of this study was to search for any difference between the serum levels of OPG, FGF-23, and vitamin D in patients with hypogonadism and the healthy controls.
p59436
sg52638
(lp59437
(dp59438
g52643
I83
sg52644
VOPG
p59439
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp59440
g52643
I88
sg52644
VFGF-23
p59441
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp59442
(dp59443
g52643
I127
sg52644
Vhypogonadism
p59444
sg52646
I12
sg52647
VC0020619
p59445
sg52649
I1
sasa(dp59446
g135
(dp59447
(VFGF3
p59448
Vspinocerebellar ataxia
p59449
tp59450
I00
ssg52636
VThese include FGF3 in Michel aplasia; FGF8 in cleft lip/palate and in hypogonadotropic hypogonadism; FGF9 in carcinoma; FGF10 in the lacrimal/salivary glands aplasia, and lacrimo-auriculo-dento-digital syndrome; FGF14 in spinocerebellar ataxia; FGF20 in Parkinson disease; and FGF23 in tumoral calcinosis and hypophosphatemic rickets.
p59451
sg52638
(lp59452
(dp59453
g52643
I120
sg52644
VFGF10
p59454
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp59455
g52643
I277
sg52644
VFGF23
p59456
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp59457
g52643
I38
sg52644
VFGF8
p59458
sg52646
I4
sg52674
VP55075
p59459
sg52649
I1
sa(dp59460
g52643
I212
sg52644
VFGF14
p59461
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp59462
g52643
I101
sg52644
VFGF9
p59463
sg52646
I4
sg52674
VP31371
p59464
sg52649
I1
sa(dp59465
g52643
I14
sg52644
g59448
sg52646
I4
sg52674
VP11487
p59466
sg52649
I1
sasg52640
(lp59467
(dp59468
g52643
I254
sg52644
VParkinson disease
p59469
sg52646
I17
sg52647
VC0030567
p59470
sg52649
I2
sa(dp59471
g52643
I29
sg52644
Vaplasia
p59472
sg52646
I7
sg52647
VC0243065
p59473
sg52649
I1
sa(dp59474
g52643
I171
sg52644
Vlacrimo-auriculo-dento-digital syndrome
p59475
sg52646
I39
sg52647
VC0265269
p59476
sg52649
I2
sa(dp59477
g52643
I46
sg52644
Vcleft lip/palate
p59478
sg52646
I16
sg52647
VC0158646
p59479
sg52649
I2
sa(dp59480
g52643
I309
sg52644
Vhypophosphatemic rickets
p59481
sg52646
I24
sg52647
VC1704375
p59482
sg52649
I2
sa(dp59483
g52643
I286
sg52644
Vtumoral calcinosis
p59484
sg52646
I18
sg52647
VC0263628
p59485
sg52649
I2
sa(dp59486
g52643
I109
sg52644
Vcarcinoma
p59487
sg52646
I9
sg52647
VC0007097
p59488
sg52649
I1
sa(dp59489
g52643
I29
sg52644
Vaplasia
p59490
sg52646
I7
sg52647
VC0243065
p59491
sg52649
I1
sa(dp59492
g52643
I70
sg52644
Vhypogonadotropic hypogonadism
p59493
sg52646
I29
sg52647
VC0022735
p59494
sg52649
I2
sa(dp59495
g52643
I221
sg52644
g59449
sg52646
I22
sg52647
VC0087012
p59496
sg52649
I2
sasa(dp59497
g52636
VRecent studies using genetically modified mice, such as FGF23-/- and Klotho-/- mice that exhibit altered mineral homeostasis due to a high vitamin D activity showed features of premature aging that include retarded growth, osteoporosis, atherosclerosis, ectopic calcification, immunological deficiency, skin and general organ atrophy, hypogonadism and short lifespan.
p59498
sg52638
(lp59499
(dp59500
g52643
I56
sg52644
VFGF23
p59501
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp59502
(dp59503
g52643
I326
sg52644
Vatrophy
p59504
sg52646
I7
sg52647
VC0333641
p59505
sg52649
I1
sa(dp59506
g52643
I335
sg52644
Vhypogonadism
p59507
sg52646
I12
sg52647
VC0020619
p59508
sg52649
I1
sa(dp59509
g52643
I206
sg52644
Vretarded growth
p59510
sg52646
I15
sg52647
VC0151686
p59511
sg52649
I2
sa(dp59512
g52643
I223
sg52644
Vosteoporosis
p59513
sg52646
I12
sg52647
VC0029456
p59514
sg52649
I1
sa(dp59515
g52643
I237
sg52644
Vatherosclerosis
p59516
sg52646
I15
sg52647
VC0004153
p59517
sg52649
I1
sa(dp59518
g52643
I177
sg52644
Vpremature aging
p59519
sg52646
I15
sg52647
VC0231341
p59520
sg52649
I2
sasa(dp59521
g52636
VMoreover, Fgf23(-/-)/klotho(-/-) mice show soft tissue and vascular calcification, severe muscle wasting, hypogonadism, pulmonary emphysema, distention of intestinal wall, and skin atrophy, all of which are also seen in Fgf23(-/-) and klotho(-/-) mice.
p59522
sg52638
(lp59523
sg52640
(lp59524
(dp59525
g52643
I176
sg52644
Vskin atrophy
p59526
sg52646
I12
sg52647
VC0151514
p59527
sg52649
I2
sa(dp59528
g52643
I141
sg52644
Vdistention
p59529
sg52646
I10
sg52647
VC0012359
p59530
sg52649
I1
sa(dp59531
g52643
I120
sg52644
Vpulmonary emphysema
p59532
sg52646
I19
sg52647
VC0034067
p59533
sg52649
I2
sa(dp59534
g52643
I59
sg52644
Vvascular calcification
p59535
sg52646
I22
sg52647
VC0342649
p59536
sg52649
I2
sa(dp59537
g52643
I90
sg52644
Vmuscle wasting
p59538
sg52646
I14
sg52647
VC0026846
p59539
sg52649
I2
sa(dp59540
g52643
I106
sg52644
Vhypogonadism
p59541
sg52646
I12
sg52647
VC0020619
p59542
sg52649
I1
sasa(dp59543
g52636
VRecent studies using genetically altered mouse models, such as in Fgf-23(-/-) and klotho mutant mice, that exhibit altered mineral ion metabolism due to high vitamin D activities showed features of premature aging that include atherosclerosis, emphysema, osteopenia/osteoporosis, hypogonadism, soft tissue calcifications and generalized atrophy of organs; the pathologic effects of vitamin D in these mouse models are obvious, as diminution or genetic ablation of the vitamin D pathway ameliorated most of the above-mentioned phenotypes, by reversing mineral ion metabolism, and the resultant effect being prolonged survival of the mutant mice.
p59544
sg52638
(lp59545
sg52640
(lp59546
(dp59547
g52643
I89
sg52644
Vmutant
p59548
sg52646
I6
sg52647
VC0596988
p59549
sg52649
I1
sa(dp59550
g52643
I244
sg52644
Vemphysema
p59551
sg52646
I9
sg52647
VC0013990
p59552
sg52649
I1
sa(dp59553
g52643
I280
sg52644
Vhypogonadism
p59554
sg52646
I12
sg52647
VC0020619
p59555
sg52649
I1
sa(dp59556
g52643
I89
sg52644
Vmutant
p59557
sg52646
I6
sg52647
VC0596988
p59558
sg52649
I1
sa(dp59559
g52643
I255
sg52644
Vosteopenia/osteoporosis
p59560
sg52646
I23
sg52647
VC0262586
p59561
sg52649
I1
sa(dp59562
g52643
I337
sg52644
Vatrophy
p59563
sg52646
I7
sg52647
VC0333641
p59564
sg52649
I1
sa(dp59565
g52643
I227
sg52644
Vatherosclerosis
p59566
sg52646
I15
sg52647
VC0004153
p59567
sg52649
I1
sa(dp59568
g52643
I198
sg52644
Vpremature aging
p59569
sg52646
I15
sg52647
VC0231341
p59570
sg52649
I2
sasa(dp59571
g52636
VClinical, cytogenetic and molecular features of acute myeloid leukemia with a MLL-SEPT5 fusion gene are reviewed.
p59572
sg52638
(lp59573
(dp59574
g52643
I82
sg52644
VSEPT5
p59575
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp59576
g52643
I78
sg52644
VMLL
p59577
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp59578
(dp59579
g52643
I48
sg52644
Vacute myeloid leukemia
p59580
sg52646
I22
sg52647
VC0023467
p59581
sg52649
I3
sasa(dp59582
g135
(dp59583
(VAF1p
p59584
Vleukemia
p59585
tp59586
I00
ssg52636
VThe MLL-LCX fusion protein lacked a CXXC domain of LCX, but retained an alpha-helical coiled-coil region at the COOH terminus, similar to MLL-SEPTING, MLL-CDCREL1, MLL-AF1p/Eps15, and MLL-AF6, which suggests that these fusion proteins are involved in the pathogenesis of 11q23-associated leukemia through similar mechanisms.
p59587
sg52638
(lp59588
(dp59589
g52643
I4
sg52644
VMLL-LCX fusion protein
p59590
sg52646
I22
sg52674
g12
sg52649
I3
sa(dp59591
g52643
I173
sg52644
VEps15
p59592
sg52646
I5
sg52674
VP42566
p59593
sg52649
I1
sa(dp59594
g52643
I155
sg52644
VCDCREL1
p59595
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp59596
g52643
I4
sg52644
VMLL
p59597
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp59598
g52643
I4
sg52644
VMLL
p59599
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp59600
g52643
I188
sg52644
VAF6
p59601
sg52646
I3
sg52674
VP55196
p59602
sg52649
I1
sa(dp59603
g52643
I138
sg52644
VMLL-SEPTING
p59604
sg52646
I11
sg52674
g12
sg52649
I1
sa(dp59605
g52643
I168
sg52644
g59584
sg52646
I4
sg52674
VP42566
p59606
sg52649
I1
sa(dp59607
g52643
I4
sg52644
VMLL
p59608
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp59609
(dp59610
g52643
I255
sg52644
Vpathogenesis
p59611
sg52646
I12
sg52647
VC0699748
p59612
sg52649
I1
sa(dp59613
g52643
I288
sg52644
g59585
sg52646
I8
sg52647
VC0023418
p59614
sg52649
I1
sasa(dp59615
g52636
VWe also investigated TG101348 activity against feeder cells and observed that STAT5 phosphorylation, granulocyte macrophage colony-stimulating factor, and interleukin 6 levels decreased, indicating reduced cytokine production in HS-5 cells treated with TG101348.
p59616
sg52638
(lp59617
(dp59618
g52643
I155
sg52644
Vinterleukin 6
p59619
sg52646
I13
sg52674
VP05231
p59620
sg52649
I2
sa(dp59621
g52643
I101
sg52644
Vgranulocyte macrophage colony-stimulating factor
p59622
sg52646
I48
sg52674
VP04141
p59623
sg52649
I4
sa(dp59624
g52643
I78
sg52644
VSTAT5
p59625
sg52646
I5
sg52674
VP42229
p59626
sg52649
I1
sasg52640
(lp59627
sa(dp59628
g52636
VIn the present study, we examined the impact of cytoplasmic/mitochondrial localization of p33ING1b in oral squamous cell carcinoma (OSCC) patient samples and explored the therapeutic potential of adenovirally-overexpressed p33ING1b in OSCC cell lines in combination with ionizing radiation (IR) treatment.
p59629
sg52638
(lp59630
sg52640
(lp59631
(dp59632
g52643
I102
sg52644
Voral squamous cell carcinoma
p59633
sg52646
I28
sg52647
VC0007137
p59634
sg52649
I4
sa(dp59635
g52643
I132
sg52644
VOSCC
p59636
sg52646
I4
sg52647
VC0007137
p59637
sg52649
I1
sa(dp59638
g52643
I132
sg52644
VOSCC
p59639
sg52646
I4
sg52647
VC0007137
p59640
sg52649
I1
sasa(dp59641
g52636
VIn contrast with previous reports, we found that p33ING1b protein and mRNA levels are higher in OSCC compared to normal epithelial cells.
p59642
sg52638
(lp59643
sg52640
(lp59644
sa(dp59645
g52636
VIn OSCC patient samples, higher levels of intra-tumoral cytoplasmic p33ING1b correlated with increased apoptotic markers and significantly better patient survival.
p59646
sg52638
(lp59647
sg52640
(lp59648
sa(dp59649
g52636
VIR treatment induced p33ING1b translocation to the mitochondria and adenoviral-p33ING1b synergized with IR to kill OSCC cells.
p59650
sg52638
(lp59651
sg52640
(lp59652
(dp59653
g52643
I30
sg52644
Vtranslocation
p59654
sg52646
I13
sg52647
VC0040715
p59655
sg52649
I1
sasa(dp59656
g52636
VOur results identify a novel functional relationship between cytoplasmic p33ING1b and patient survival and highlight the potential for the use of p33ING1b as a therapeutic agent in combination with adjuvant radiotherapy in OSCC.
p59657
sg52638
(lp59658
sg52640
(lp59659
sa(dp59660
g52636
VSince loss of heterozygosity at 13q34 has been reported in squamous cell carcinoma of head and neck, we screened for mutations in ING1 by polymerase chain reaction-single strand conformation polymorphism in 71 oral squamous cell carcinomas (OSCC) from India, 15 of which were known to harbor p53 mutations.
p59661
sg52638
(lp59662
(dp59663
g52643
I292
sg52644
Vp53 mutations
p59664
sg52646
I13
sg52674
VP42771
p59665
sg52649
I2
sasg52640
(lp59666
(dp59667
g52643
I215
sg52644
Vsquamous cell carcinomas
p59668
sg52646
I24
sg52647
VC0007137
p59669
sg52649
I3
sa(dp59670
g52643
I59
sg52644
Vsquamous cell carcinoma of head and neck
p59671
sg52646
I40
sg52647
VC1168401
p59672
sg52649
I7
sasa(dp59673
g52636
VThese results suggest that ING1 is not a target for mutational inactivation in OSCC of Indians.
p59674
sg52638
(lp59675
sg52640
(lp59676
(dp59677
g52643
I63
sg52644
Vinactivation
p59678
sg52646
I12
sg52647
VC0544461
p59679
sg52649
I1
sasa(dp59680
g135
(dp59681
(VTSP
p59682
VHAM
p59683
tp59684
I00
ssg52636
VThe incidence of human T cell lymphotropic virus type 1 (HLTV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is not well defined in the literature.
p59685
sg52638
(lp59686
(dp59687
g52643
I117
sg52644
VHAM
p59688
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp59689
g52643
I121
sg52644
g59682
sg52646
I3
sg52674
VP07996
p59690
sg52649
I1
sasg52640
(lp59691
(dp59692
g52643
I76
sg52644
Vmyelopathy
p59693
sg52646
I10
sg52647
VC0037928
p59694
sg52649
I1
sa(dp59695
g52643
I87
sg52644
Vtropical spastic paraparesis
p59696
sg52646
I28
sg52647
VC0030481
p59697
sg52649
I3
sa(dp59698
g52643
I117
sg52644
g59683
sg52646
I3
sg52647
VC0030481
p59699
sg52649
I1
sasa(dp59700
g52636
VFollowing adult T cell leukemia/lymphoma and HLTV-1-associated myelopathy/tropical spastic paraparesis, HTLV-1 uveitis (HU) has been established as a distinct clinical entity caused by HTLV-1 based on seroepidemiological, clinical, and virological studies.
p59701
sg52638
(lp59702
sg52640
(lp59703
(dp59704
g52643
I10
sg52644
Vadult T cell leukemia
p59705
sg52646
I21
sg52647
VC0023492
p59706
sg52649
I4
sa(dp59707
g52643
I74
sg52644
Vtropical spastic paraparesis
p59708
sg52646
I28
sg52647
VC0030481
p59709
sg52649
I3
sa(dp59710
g52643
I32
sg52644
Vlymphoma
p59711
sg52646
I8
sg52647
VC0024299
p59712
sg52649
I1
sa(dp59713
g52643
I63
sg52644
Vmyelopathy
p59714
sg52646
I10
sg52647
VC0037928
p59715
sg52649
I1
sa(dp59716
g52643
I111
sg52644
Vuveitis
p59717
sg52646
I7
sg52647
VC0042164
p59718
sg52649
I1
sasa(dp59719
g52636
VThis is a study of the early identification of a new case of tropical spastic paraparesis/HLTV-1-associated myelopathy in a Spanish patient not previously reported on.
p59720
sg52638
(lp59721
sg52640
(lp59722
(dp59723
g52643
I108
sg52644
Vmyelopathy
p59724
sg52646
I10
sg52647
VC0037928
p59725
sg52649
I1
sa(dp59726
g52643
I61
sg52644
Vtropical spastic paraparesis
p59727
sg52646
I28
sg52647
VC0030481
p59728
sg52649
I3
sasa(dp59729
g52636
VMyxoid liposarcoma (MLS) is a soft tissue sarcoma characterized by a recurrent t(12;16) translocation.
p59730
sg52638
(lp59731
sg52640
(lp59732
(dp59733
g52643
I88
sg52644
Vtranslocation
p59734
sg52646
I13
sg52647
VC0040715
p59735
sg52649
I1
sa(dp59736
g52643
I0
sg52644
VMyxoid liposarcoma
p59737
sg52646
I18
sg52647
VC0206634
p59738
sg52649
I2
sa(dp59739
g52643
I20
sg52644
VMLS
p59740
sg52646
I3
sg52647
VC0796070
p59741
sg52649
I1
sa(dp59742
g52643
I30
sg52644
Vsoft tissue sarcoma
p59743
sg52646
I19
sg52647
VC1261473
p59744
sg52649
I3
sasa(dp59745
g52636
VAlthough myxoid liposarcomas (MLS) are the most common type of soft-tissue sarcomas in adults, their primary location in the superficial tissues is rare.
p59746
sg52638
(lp59747
sg52640
(lp59748
(dp59749
g52643
I20
sg52644
Vsarcomas
p59750
sg52646
I8
sg52647
VC1261473
p59751
sg52649
I1
sa(dp59752
g52643
I30
sg52644
VMLS
p59753
sg52646
I3
sg52647
VC0796070
p59754
sg52649
I1
sa(dp59755
g52643
I9
sg52644
Vmyxoid liposarcomas
p59756
sg52646
I19
sg52647
VC0206634
p59757
sg52649
I2
sasa(dp59758
g135
(dp59759
(VCHOP
p59760
Vmyxoid liposarcoma
p59761
tp59762
I00
ssg52636
VPRG4 is one of the downstream molecules of the myxoid liposarcoma (MLS)-specific fusion oncoproteins TLS-CHOP and EWS-CHOP.
p59763
sg52638
(lp59764
(dp59765
g52643
I101
sg52644
VTLS
p59766
sg52646
I3
sg52674
VP35637
p59767
sg52649
I1
sa(dp59768
g52643
I114
sg52644
VEWS
p59769
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp59770
g52643
I105
sg52644
VCHOP
p59771
sg52646
I4
sg52674
VP35638
p59772
sg52649
I1
sa(dp59773
g52643
I0
sg52644
VPRG4
p59774
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp59775
g52643
I105
sg52644
g59760
sg52646
I4
sg52674
VP35638
p59776
sg52649
I1
sasg52640
(lp59777
(dp59778
g52643
I67
sg52644
VMLS
p59779
sg52646
I3
sg52647
VC0796070
p59780
sg52649
I1
sa(dp59781
g52643
I47
sg52644
g59761
sg52646
I18
sg52647
VC0206634
p59782
sg52649
I2
sasa(dp59783
g52636
VThe SUV max values of the low-grade thymomas, high-grade thymomas, TCs and MLs were 3.14 +/- 0.73, 4.34 +/- 1.49, 8.59 +/- 3.05, and 10.08 +/- 2.53, respectively, with significant differences between the low- and high-grade thymomas, and between TCs and MLs.
p59784
sg52638
(lp59785
sg52640
(lp59786
(dp59787
g52643
I75
sg52644
VMLs
p59788
sg52646
I3
sg52647
VC0796070
p59789
sg52649
I1
sa(dp59790
g52643
I36
sg52644
Vthymomas
p59791
sg52646
I8
sg52647
VC0040100
p59792
sg52649
I1
sa(dp59793
g52643
I75
sg52644
VMLs
p59794
sg52646
I3
sg52647
VC0796070
p59795
sg52649
I1
sa(dp59796
g52643
I67
sg52644
VTCs
p59797
sg52646
I3
sg52647
VC0242387
p59798
sg52649
I1
sa(dp59799
g52643
I36
sg52644
Vthymomas
p59800
sg52646
I8
sg52647
VC0040100
p59801
sg52649
I1
sa(dp59802
g52643
I36
sg52644
Vthymomas
p59803
sg52646
I8
sg52647
VC0040100
p59804
sg52649
I1
sa(dp59805
g52643
I67
sg52644
VTCs
p59806
sg52646
I3
sg52647
VC0242387
p59807
sg52649
I1
sasa(dp59808
g135
(dp59809
(VPDGFRA
p59810
Vcarcinosarcoma
p59811
tp59812
I01
ssg52636
VOf 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease).
p59813
sg52638
(lp59814
(dp59815
g52643
I134
sg52644
VPIK3CA
p59816
sg52646
I6
sg52674
VP42336
p59817
sg52649
I1
sa(dp59818
g52643
I360
sg52644
VBRAF
p59819
sg52646
I4
sg52674
VP15056
p59820
sg52649
I1
sa(dp59821
g52643
I445
sg52644
VERBB2
p59822
sg52646
I5
sg52674
VP04626
p59823
sg52649
I1
sa(dp59824
g52643
I278
sg52644
g59810
sg52646
I6
sg52674
VP16234
p59825
sg52649
I1
sasg52640
(lp59826
(dp59827
g52643
I463
sg52644
Vesophageal adenocarcinoma
p59828
sg52646
I25
sg52647
VC0279628
p59829
sg52649
I2
sa(dp59830
g52643
I199
sg52644
Vtracheal squamous cell carcinoma
p59831
sg52646
I32
sg52647
VC0345946
p59832
sg52649
I4
sa(dp59833
g52643
I407
sg52644
Vprogressive disease
p59834
sg52646
I19
sg52647
VC0677932
p59835
sg52649
I2
sa(dp59836
g52643
I388
sg52644
Vadnexal carcinoma
p59837
sg52646
I17
sg52647
VC0206697
p59838
sg52649
I2
sa(dp59839
g52643
I407
sg52644
Vprogressive disease
p59840
sg52646
I19
sg52647
VC0677932
p59841
sg52649
I2
sa(dp59842
g52643
I312
sg52644
Vadenocarcinoma
p59843
sg52646
I14
sg52647
VC0001418
p59844
sg52649
I1
sa(dp59845
g52643
I161
sg52644
g59811
sg52646
I14
sg52647
VC0007140
p59846
sg52649
I1
sasa(dp59847
g135
(dp59848
(VHER2
p59849
Vcarcinosarcoma
p59850
tp59851
I00
ssg52636
VThe objective of this study was to determine the efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma.
p59852
sg52638
(lp59853
(dp59854
g52643
I91
sg52644
g59849
sg52646
I4
sg52674
VP04626
p59855
sg52649
I1
sasg52640
(lp59856
(dp59857
g52643
I106
sg52644
g59850
sg52646
I14
sg52647
VC0007140
p59858
sg52649
I1
sasa(dp59859
g135
(dp59860
(VHER2
p59861
Vcarcinosarcoma
p59862
tp59863
I00
ssg52636
VThe efficacy of neratinib in the treatment of HER2 amplified carcinosarcoma was determined in vitro using seven primary carcinosarcoma cell lines with differential expression of HER2/neu.
p59864
sg52638
(lp59865
(dp59866
g52643
I183
sg52644
Vneu
p59867
sg52646
I3
sg52674
VP04626
p59868
sg52649
I1
sa(dp59869
g52643
I46
sg52644
VHER2
p59870
sg52646
I4
sg52674
VP04626
p59871
sg52649
I1
sa(dp59872
g52643
I46
sg52644
g59861
sg52646
I4
sg52674
VP04626
p59873
sg52649
I1
sasg52640
(lp59874
(dp59875
g52643
I61
sg52644
Vcarcinosarcoma
p59876
sg52646
I14
sg52647
VC0007140
p59877
sg52649
I1
sa(dp59878
g52643
I61
sg52644
g59862
sg52646
I14
sg52647
VC0007140
p59879
sg52649
I1
sasa(dp59880
g52636
VThe efficacy of neratinib was determined in treating mice harboring HER2 amplified carcinosarcoma xenografts.
p59881
sg52638
(lp59882
sg52640
(lp59883
(dp59884
g52643
I83
sg52644
Vcarcinosarcoma
p59885
sg52646
I14
sg52647
VC0007140
p59886
sg52649
I1
sasa(dp59887
g135
(dp59888
(Vneu
p59889
Vcarcinosarcoma
p59890
tp59891
I00
ssg52636
VTwo of seven (28.5%) carcinosarcoma cell lines were HER2/neu amplified.
p59892
sg52638
(lp59893
(dp59894
g52643
I52
sg52644
VHER2
p59895
sg52646
I4
sg52674
VP04626
p59896
sg52649
I1
sa(dp59897
g52643
I57
sg52644
g59889
sg52646
I3
sg52674
VP04626
p59898
sg52649
I1
sasg52640
(lp59899
(dp59900
g52643
I21
sg52644
g59890
sg52646
I14
sg52647
VC0007140
p59901
sg52649
I1
sasa(dp59902
g135
(dp59903
(VHER2
p59904
VSEM
p59905
tp59906
I00
ssg52636
VHER2/neu amplified cell lines SARARK6 and SARARK9 were significantly more sensitive to neratinib than the five non-HER2/neu amplified carcinosarcoma cell lines (mean+/-SEM IC50:0.014myM+/-0.004vs.0.164myM+/-0.019 p=0.0003).
p59907
sg52638
(lp59908
(dp59909
g52643
I5
sg52644
Vneu
p59910
sg52646
I3
sg52674
VP04626
p59911
sg52649
I1
sa(dp59912
g52643
I5
sg52644
Vneu
p59913
sg52646
I3
sg52674
VP04626
p59914
sg52649
I1
sa(dp59915
g52643
I0
sg52644
VHER2
p59916
sg52646
I4
sg52674
VP04626
p59917
sg52649
I1
sa(dp59918
g52643
I0
sg52644
g59904
sg52646
I4
sg52674
VP04626
p59919
sg52649
I1
sasg52640
(lp59920
(dp59921
g52643
I134
sg52644
Vcarcinosarcoma
p59922
sg52646
I14
sg52647
VC0007140
p59923
sg52649
I1
sa(dp59924
g52643
I168
sg52644
g59905
sg52646
I3
sg52647
VC0432222
p59925
sg52649
I1
sasa(dp59926
g52636
VNeratinib inhibited tumor growth (p=0.012) and prolonged survival in mice harboring HER2 amplified carcinosarcoma xenografts (p=0.0039).
p59927
sg52638
(lp59928
sg52640
(lp59929
(dp59930
g52643
I20
sg52644
Vtumor growth
p59931
sg52646
I12
sg52647
VC0598934
p59932
sg52649
I2
sa(dp59933
g52643
I99
sg52644
Vcarcinosarcoma
p59934
sg52646
I14
sg52647
VC0007140
p59935
sg52649
I1
sasa(dp59936
g135
(dp59937
(VHER2
p59938
Vcarcinosarcoma
p59939
tp59940
I00
ssg52636
VNeratinib inhibits HER2 amplified carcinosarcoma proliferation, signaling, cell cycle progression and tumor growth in vitro.
p59941
sg52638
(lp59942
(dp59943
g52643
I19
sg52644
g59938
sg52646
I4
sg52674
VP04626
p59944
sg52649
I1
sasg52640
(lp59945
(dp59946
g52643
I49
sg52644
Vproliferation
p59947
sg52646
I13
sg52647
VC0334094
p59948
sg52649
I1
sa(dp59949
g52643
I34
sg52644
g59939
sg52646
I14
sg52647
VC0007140
p59950
sg52649
I1
sa(dp59951
g52643
I102
sg52644
Vtumor growth
p59952
sg52646
I12
sg52647
VC0598934
p59953
sg52649
I2
sasa(dp59954
g135
(dp59955
(VERBB2
p59956
Vcarcinosarcoma
p59957
tp59958
I00
ssg52636
VNumerous correlative scientific investigations have demonstrated that the HER2 (ERBB2) gene is amplified in 17%-33% of carcinosarcoma, uterine serous carcinoma, and a subset of high-grade endometrioid endometrial tumors.
p59959
sg52638
(lp59960
(dp59961
g52643
I74
sg52644
VHER2
p59962
sg52646
I4
sg52674
VP04626
p59963
sg52649
I1
sa(dp59964
g52643
I80
sg52644
g59956
sg52646
I5
sg52674
VP04626
p59965
sg52649
I1
sasg52640
(lp59966
(dp59967
g52643
I143
sg52644
Vserous carcinoma
p59968
sg52646
I16
sg52647
VC0206701
p59969
sg52649
I2
sa(dp59970
g52643
I213
sg52644
Vtumors
p59971
sg52646
I6
sg52647
VC0027651
p59972
sg52649
I1
sa(dp59973
g52643
I119
sg52644
g59957
sg52646
I14
sg52647
VC0007140
p59974
sg52649
I1
sasa(dp59975
g135
(dp59976
(Vp65
p59977
VGBM
p59978
tp59979
I01
ssg52636
VThe analysis of human datasets and GBM tumors revealed higher expression of p65 in GBM-associated CD68+ macrophages compared to neighboring stroma.
p59980
sg52638
(lp59981
(dp59982
g52643
I76
sg52644
g59977
sg52646
I3
sg52674
VP21579
p59983
sg52649
I1
sa(dp59984
g52643
I83
sg52644
VGBM-associated CD68+
p59985
sg52646
I20
sg52674
g12
sg52649
I2
sasg52640
(lp59986
(dp59987
g52643
I39
sg52644
Vtumors
p59988
sg52646
I6
sg52647
VC0027651
p59989
sg52649
I1
sa(dp59990
g52643
I35
sg52644
VGBM
p59991
sg52646
I3
sg52647
VC0017636
p59992
sg52649
I1
sa(dp59993
g52643
I35
sg52644
g59978
sg52646
I3
sg52647
VC0017636
p59994
sg52649
I1
sasa(dp59995
g135
(dp59996
(VCD68
p59997
VATRX
p59998
tp59999
I00
ssg52636
VOf paramount importance in the recognition of oligodendroglial and astrocytic tumor cells were the double immunostainings for ATRX/GFAP, ATRX/IDH1R132H, ATRX/Iba-1 and ATRX/CD68.
p60000
sg52638
(lp60001
(dp60002
g52643
I173
sg52644
g59997
sg52646
I4
sg52674
VP34810
p60003
sg52649
I1
sasg52640
(lp60004
(dp60005
g52643
I126
sg52644
VATRX
p60006
sg52646
I4
sg52647
VC1845055
p60007
sg52649
I1
sa(dp60008
g52643
I126
sg52644
VATRX
p60009
sg52646
I4
sg52647
VC1845055
p60010
sg52649
I1
sa(dp60011
g52643
I126
sg52644
VATRX
p60012
sg52646
I4
sg52647
VC1845055
p60013
sg52649
I1
sa(dp60014
g52643
I67
sg52644
Vastrocytic tumor
p60015
sg52646
I16
sg52647
VC0004114
p60016
sg52649
I2
sa(dp60017
g52643
I126
sg52644
g59998
sg52646
I4
sg52647
VC1845055
p60018
sg52649
I1
sasa(dp60019
g52636
VTherefore, Dan-gua Fang might be an ideal drug for comprehensive intervention for glucose and lipid metabolism disorders in type 2 diabetes mellitus.
p60020
sg52638
(lp60021
(dp60022
g52643
I11
sg52644
VDan-gua Fang
p60023
sg52646
I12
sg52674
VP41271
p60024
sg52649
I2
sasg52640
(lp60025
(dp60026
g52643
I124
sg52644
Vtype 2 diabetes mellitus
p60027
sg52646
I24
sg52647
VC0011860
p60028
sg52649
I4
sa(dp60029
g52643
I94
sg52644
Vlipid metabolism disorders
p60030
sg52646
I26
sg52647
VC0154251
p60031
sg52649
I3
sasa(dp60032
g52636
VAn electrochemical study of the oxidation of 8-hydroxyguanine (8-OH-Gua) at gold nanoparticles attached to single walled carbon nanotube modified edge plane pyrolytic graphite electrode (AuNP-SWCNT/EPPGE) has been carried out to develop a method for the self diagnosis of diabetes.
p60033
sg52638
(lp60034
sg52640
(lp60035
(dp60036
g52643
I272
sg52644
Vdiabetes
p60037
sg52646
I8
sg52647
VC0011849
p60038
sg52649
I1
sasa(dp60039
g52636
VConsequently, Metformin - the biguanide drug of choice orally administered for diabetes type II - is anticipated to see a spike in production.
p60040
sg52638
(lp60041
sg52640
(lp60042
(dp60043
g52643
I79
sg52644
Vdiabetes type II
p60044
sg52646
I16
sg52647
VC0011860
p60045
sg52649
I3
sasa(dp60046
g52636
VTo study the toxicity features of high glucose on the endothelial cell cycle and the influence of Dan Gua-Fang, a Chinese herbal compound prescription, on the reproductive cycle of vascular endothelial cells cultivated under a high glucose condition; to reveal the partial mechanisms of Dan Gua-Fang in the prevention and treatment of endothelial injury caused by hyperglycemia in diabetes mellitus (DM); and offer a reference for dealing with the vascular complications of DM patients with long-term high blood glucose.
p60047
sg52638
(lp60048
(dp60049
g52643
I98
sg52644
VDan Gua
p60050
sg52646
I7
sg52674
VP41271
p60051
sg52649
I2
sasg52640
(lp60052
(dp60053
g52643
I240
sg52644
Vcondition
p60054
sg52646
I9
sg52647
VC0012634
p60055
sg52649
I1
sa(dp60056
g52643
I381
sg52644
Vdiabetes mellitus
p60057
sg52646
I17
sg52647
VC0011849
p60058
sg52649
I2
sa(dp60059
g52643
I400
sg52644
VDM
p60060
sg52646
I2
sg52647
VC0011849
p60061
sg52649
I1
sa(dp60062
g52643
I400
sg52644
VDM
p60063
sg52646
I2
sg52647
VC0011849
p60064
sg52649
I1
sa(dp60065
g52643
I364
sg52644
Vhyperglycemia
p60066
sg52646
I13
sg52647
VC0020456
p60067
sg52649
I1
sasa(dp60068
g52636
VTo study the effect of anticolchicine cytotoxicity of Dan Gua-Fang, a Chinesea Chinese), a Chinese herbal compound prescription on endothelial cells of vein (ECV304) cultivated in mediums of different glucose concentrations as well as the proliferation of those cells in the same conditions, in order to reveal the value of Dan Gua-Fang in preventing and treating endothelial damage caused by hyperglycemia in diabetes mellitus.
p60069
sg52638
(lp60070
(dp60071
g52643
I54
sg52644
VDan Gua-Fang
p60072
sg52646
I12
sg52674
VP41271
p60073
sg52649
I2
sasg52640
(lp60074
(dp60075
g52643
I239
sg52644
Vproliferation
p60076
sg52646
I13
sg52647
VC0334094
p60077
sg52649
I1
sa(dp60078
g52643
I410
sg52644
Vdiabetes mellitus
p60079
sg52646
I17
sg52647
VC0011849
p60080
sg52649
I2
sa(dp60081
g52643
I38
sg52644
Vcytotoxicity
p60082
sg52646
I12
sg52647
VC0596402
p60083
sg52649
I1
sa(dp60084
g52643
I393
sg52644
Vhyperglycemia
p60085
sg52646
I13
sg52647
VC0020456
p60086
sg52649
I1
sasa(dp60087
g52636
V(1) Dan Gua-Fang at all concentrations reduced the floating cell population of ECV304 cultivated in hyperglycemia mediums.
p60088
sg52638
(lp60089
sg52640
(lp60090
(dp60091
g52643
I100
sg52644
Vhyperglycemia
p60092
sg52646
I13
sg52647
VC0020456
p60093
sg52649
I1
sasa(dp60094
g52636
V(2) Dan Gua-Fang at all concentrations and hyperglycemia both had a function of promoting "pseudopod-like" structure formation in cultivated ECV304, but the function was not superimposed in mediums containing both hyperglycemia and Dan Gua-Fang.
p60095
sg52638
(lp60096
sg52640
(lp60097
(dp60098
g52643
I43
sg52644
Vhyperglycemia
p60099
sg52646
I13
sg52647
VC0020456
p60100
sg52649
I1
sa(dp60101
g52643
I43
sg52644
Vhyperglycemia
p60102
sg52646
I13
sg52647
VC0020456
p60103
sg52649
I1
sasa(dp60104
g52636
V(3) Colchicine reduced and even vanished the "pseudopod-like" structure of the endotheliocyte apparently cultivated in mediums of hyperglycemia or with Dan Gua-Fang.
p60105
sg52638
(lp60106
sg52640
(lp60107
(dp60108
g52643
I130
sg52644
Vhyperglycemia
p60109
sg52646
I13
sg52647
VC0020456
p60110
sg52649
I1
sasa(dp60111
g52636
VThe "pseudopod-like" structure of the endotheliocyte emerged quickly in Dan Gua-Fang groups after colchicine was removed, but it was not the case in hyperglycemia only without Dan Gua-Fang groups.
p60112
sg52638
(lp60113
sg52640
(lp60114
(dp60115
g52643
I149
sg52644
Vhyperglycemia
p60116
sg52646
I13
sg52647
VC0020456
p60117
sg52649
I1
sasa(dp60118
g52636
VThe spinodal point concentration of statistical significance of hyperglycemia cytotoxicity is 22.2 mmol/l; 1/300 Dan Gua can reverse the endothelia cytotoxicity in different concentrations of hyperglycemia.
p60119
sg52638
(lp60120
sg52640
(lp60121
(dp60122
g52643
I78
sg52644
Vcytotoxicity
p60123
sg52646
I12
sg52647
VC0596402
p60124
sg52649
I1
sa(dp60125
g52643
I64
sg52644
Vhyperglycemia
p60126
sg52646
I13
sg52647
VC0020456
p60127
sg52649
I1
sa(dp60128
g52643
I78
sg52644
Vcytotoxicity
p60129
sg52646
I12
sg52647
VC0596402
p60130
sg52649
I1
sa(dp60131
g52643
I64
sg52644
Vhyperglycemia
p60132
sg52646
I13
sg52647
VC0020456
p60133
sg52649
I1
sasa(dp60134
g52636
VPatients with resected stage III colon cancer who were 18 years of age or older, with an Eastern Cooperative Oncology Group performance status of 0 or 1, from four randomised controlled trials (NSABP C-08, XELOXA, X-ACT, and AVANT; 8734 patients in total) were pooled and analysed.
p60135
sg52638
(lp60136
sg52640
(lp60137
(dp60138
g52643
I23
sg52644
Vstage III colon cancer
p60139
sg52646
I22
sg52647
VC3146254
p60140
sg52649
I4
sasa(dp60141
g52636
VBased on the results of the X-ACT study, capecitabine has become one of the standard postoperative adjuvant chemotherapies for colon cancer.
p60142
sg52638
(lp60143
sg52640
(lp60144
(dp60145
g52643
I127
sg52644
Vcolon cancer
p60146
sg52646
I12
sg52647
VC0699790
p60147
sg52649
I2
sasa(dp60148
g52636
VIn the adjuvant setting, the Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial demonstrated that capecitabine as a single agent led to improvement in relapse-free survival (hazard ratio: 0.86, 95% confidence interval: 0.74-0.99, P = 0.04) and was associated with significantly fewer adverse events than 5-FU plus leucovorin (LV, folinic acid).
p60149
sg52638
(lp60150
sg52640
(lp60151
(dp60152
g52643
I48
sg52644
VColon Cancer
p60153
sg52646
I12
sg52647
VC0699790
p60154
sg52649
I2
sa(dp60155
g52643
I154
sg52644
Vrelapse
p60156
sg52646
I7
sg52647
VC0277556
p60157
sg52649
I1
sasa(dp60158
g52636
VOn the basis of the X-ACT trial, capecitabine was approved by the United States Food and Drug Administration, the National Institute for Clinical Excellence, and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.
p60159
sg52638
(lp60160
sg52640
(lp60161
(dp60162
g52643
I241
sg52644
Vstage III colon cancer
p60163
sg52646
I22
sg52647
VC3146254
p60164
sg52649
I4
sasa(dp60165
g52636
VThe Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) study confirmed that capecitabine (Xeloda) is at least as effective and is less toxic than a bolus 5-FU and leucovorin regimen for patients with stage III colon cancer.
p60166
sg52638
(lp60167
sg52640
(lp60168
(dp60169
g52643
I23
sg52644
VColon Cancer
p60170
sg52646
I12
sg52647
VC0699790
p60171
sg52649
I2
sa(dp60172
g52643
I197
sg52644
Vstage III colon cancer
p60173
sg52646
I22
sg52647
VC3146254
p60174
sg52649
I4
sasa(dp60175
g52636
VIn the recent X-ACT (Xeloda in Adjuvant Colon cancer Therapy) trial, oral capecitabine (Xeloda) demonstrated superior efficacy and an improved safety profile compared with infused fluorouracil + leucovorin (folinic acid) [FU+LV] in patients with Dukes' C colorectal cancer.
p60176
sg52638
(lp60177
sg52640
(lp60178
(dp60179
g52643
I255
sg52644
Vcolorectal cancer
p60180
sg52646
I17
sg52647
VC1527249
p60181
sg52649
I2
sa(dp60182
g52643
I40
sg52644
VColon cancer
p60183
sg52646
I12
sg52647
VC0699790
p60184
sg52649
I2
sasa(dp60185
g52636
VThe X-ACT trial (Xeloda in Adjuvant Colon Cancer Therapy) compared traditional bolus 5-FU/LV (as per the Mayo Clinic regimen) with capecitabine, in the adjuvant treatment of 1987 stage III colon cancer patients.
p60186
sg52638
(lp60187
sg52640
(lp60188
(dp60189
g52643
I179
sg52644
Vstage III colon cancer
p60190
sg52646
I22
sg52647
VC3146254
p60191
sg52649
I4
sa(dp60192
g52643
I36
sg52644
VColon Cancer
p60193
sg52646
I12
sg52647
VC0699790
p60194
sg52649
I2
sasa(dp60195
g52636
VOn the basis of the X-ACT trial, capecitabine was approved by the US FDA, the National Institute for Clinical Excellence and the Scottish Medicines Consortium as monotherapy for the adjuvant treatment of stage III colon cancer.
p60196
sg52638
(lp60197
sg52640
(lp60198
(dp60199
g52643
I204
sg52644
Vstage III colon cancer
p60200
sg52646
I22
sg52647
VC3146254
p60201
sg52649
I4
sasa(dp60202
g52636
VIn order to specifically target GD2 overexpressed on the surface of neuroblastoma stNB-V1 cells, anti-GD2 was conjugated to chitosan modified GNRs (CGNRs).
p60203
sg52638
(lp60204
sg52640
(lp60205
(dp60206
g52643
I68
sg52644
Vneuroblastoma
p60207
sg52646
I13
sg52647
VC0027819
p60208
sg52649
I1
sasa(dp60209
g52636
VOur results illustrated that anti-GD2-conjugated CGNRs were extensively endocytosed by GD2+ stNB-V1 neuroblastoma cells via antibody-mediated endocytosis.
p60210
sg52638
(lp60211
sg52640
(lp60212
(dp60213
g52643
I100
sg52644
Vneuroblastoma
p60214
sg52646
I13
sg52647
VC0027819
p60215
sg52649
I1
sasa(dp60216
g52636
VIn order to specifically target disialoganglioside (GD2) overexpressed on the surface of neuroblastoma stNB-V1 cells, GD2 monoclonal antibody (anti-GD2) was conjugated to acidified CNTs.
p60217
sg52638
(lp60218
sg52640
(lp60219
(dp60220
g52643
I89
sg52644
Vneuroblastoma
p60221
sg52646
I13
sg52647
VC0027819
p60222
sg52649
I1
sasa(dp60223
g135
(dp60224
(Vglial fibrillary acidic protein
p60225
VCreutzfeldt-Jakob disease
p60226
tp60227
I00
ssg52636
VIn addition to the well-known increase in glial fibrillary acidic protein and other proteins in reactive astrocytes, astrocytopathy is evidenced by deposition of abnormal proteins such as Beta-amyloid, hyper-phosphorylated tau, abnormal Alfa-synuclein, mutated huntingtin, phosphorylated TDP-43 and mutated SOD1, and PrPres , in Alzheimer's disease, tauopathies, Lewy body diseases, Huntington's disease, amyotrophic lateral sclerosis and Creutzfeldt-Jakob disease, respectively.
p60228
sg52638
(lp60229
(dp60230
g52643
I299
sg52644
Vmutated SOD1
p60231
sg52646
I12
sg52674
VP00441
p60232
sg52649
I2
sa(dp60233
g52643
I273
sg52644
Vphosphorylated TDP-43
p60234
sg52646
I21
sg52674
g12
sg52649
I2
sa(dp60235
g52643
I237
sg52644
VAlfa-synuclein
p60236
sg52646
I14
sg52674
VP37840
p60237
sg52649
I1
sa(dp60238
g52643
I253
sg52644
Vmutated huntingtin
p60239
sg52646
I18
sg52674
VP42858
p60240
sg52649
I2
sa(dp60241
g52643
I42
sg52644
g60225
sg52646
I31
sg52674
VP05230
p60242
sg52649
I4
sasg52640
(lp60243
(dp60244
g52643
I193
sg52644
Vamyloid
p60245
sg52646
I7
sg52647
VC0011560
p60246
sg52649
I1
sa(dp60247
g52643
I329
sg52644
VAlzheimer's disease
p60248
sg52646
I19
sg52647
VC1521724
p60249
sg52649
I2
sa(dp60250
g52643
I405
sg52644
Vamyotrophic lateral sclerosis
p60251
sg52646
I29
sg52647
VC0002736
p60252
sg52649
I3
sa(dp60253
g52643
I350
sg52644
Vtauopathies
p60254
sg52646
I11
sg52647
VC0949664
p60255
sg52649
I1
sa(dp60256
g52643
I383
sg52644
VHuntington's disease
p60257
sg52646
I20
sg52647
VC0020179
p60258
sg52649
I2
sa(dp60259
g52643
I439
sg52644
g60226
sg52646
I25
sg52647
VC0022336
p60260
sg52649
I2
sasa(dp60261
g135
(dp60262
(VSOD1
p60263
Vneurodegenerative disorders
p60264
tp60265
I00
ssg52636
VInterestingly, BAG3-mediated selective macroautophagy is also involved in the clearance of aggregated proteins associated with age-related neurodegenerative disorders, like Alzheimer's disease (tau-protein), Huntington's disease (mutated huntingtin/polyQ proteins), and amyotrophic lateral sclerosis (mutated SOD1).
p60266
sg52638
(lp60267
(dp60268
g52643
I249
sg52644
VpolyQ proteins
p60269
sg52646
I14
sg52674
VP02649
p60270
sg52649
I2
sa(dp60271
g52643
I15
sg52644
VBAG3
p60272
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp60273
g52643
I238
sg52644
Vhuntingtin
p60274
sg52646
I10
sg52674
VP42858
p60275
sg52649
I1
sa(dp60276
g52643
I309
sg52644
g60263
sg52646
I4
sg52674
VP00441
p60277
sg52649
I1
sasg52640
(lp60278
(dp60279
g52643
I173
sg52644
VAlzheimer's disease
p60280
sg52646
I19
sg52647
VC1521724
p60281
sg52649
I2
sa(dp60282
g52643
I270
sg52644
Vamyotrophic lateral sclerosis
p60283
sg52646
I29
sg52647
VC0002736
p60284
sg52649
I3
sa(dp60285
g52643
I208
sg52644
VHuntington's disease
p60286
sg52646
I20
sg52647
VC0020179
p60287
sg52649
I2
sa(dp60288
g52643
I139
sg52644
g60264
sg52646
I27
sg52647
VC0524851
p60289
sg52649
I2
sasa(dp60290
g52636
VThis report is the first successful generation of neural cells using iPSCs from sleep bruxism patients with 5-HT2A polymorphism, which has the potential to elucidate the etiology and underlying mechanism of SB.
p60291
sg52638
(lp60292
(dp60293
g52643
I110
sg52644
VHT2A
p60294
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp60295
(dp60296
g52643
I80
sg52644
Vsleep bruxism
p60297
sg52646
I13
sg52647
VC0751771
p60298
sg52649
I2
sasa(dp60299
g135
(dp60300
(Vinterleukin-6
p60301
Vobstructive sleep apnea-hypopnea syndrome
p60302
tp60303
I00
ssg52636
VAt present, variants of the 5-hydroxytryptamine receptor 2A (5-HTR2A) and interleukin-6 (IL-6) genes may be susceptible markers to develop for obstructive sleep apnea-hypopnea syndrome (OSAHS).
p60304
sg52638
(lp60305
(dp60306
g52643
I89
sg52644
VIL-6
p60307
sg52646
I4
sg52674
VP05231
p60308
sg52649
I1
sa(dp60309
g52643
I74
sg52644
g60301
sg52646
I13
sg52674
VP05231
p60310
sg52649
I1
sasg52640
(lp60311
(dp60312
g52643
I186
sg52644
VOSAHS
p60313
sg52646
I5
sg52647
VC0520679
p60314
sg52649
I1
sa(dp60315
g52643
I143
sg52644
g60302
sg52646
I41
sg52647
VC0520679
p60316
sg52649
I4
sasa(dp60317
g135
(dp60318
(V5-HTR2A
p60319
VOSAS
p60320
tp60321
I00
ssg52636
VThe results of our study showed that tumor necrosis factor-Alfa (TNF-Alfa) -308 G/A (OR = 3.70, 95 % CI = 1.39-9.83), gene-linked polymorphic region (LPR) (OR = 0.57, 95 % CI = 0.41-0.79), and variable number tandem repeat (VNTR) of the 5-hydroxytryptamine transporter gene (5-HTT) (OR = 3.44, 95 % CI = 1.49-7.95) polymorphisms were associated with OSAS risk in the Chinese population, while there was no significant association between 5-hydroxytryptamine 2A receptor (5-HTR2A) 102C/T, 5-HTR2A A1438G, angiotensin-converting enzyme (ACE) insertion (I)/deletion (D), or leptin receptor (LEPR)-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p60322
sg52638
(lp60323
(dp60324
g52643
I237
sg52644
V5-hydroxytryptamine transporter gene
p60325
sg52646
I36
sg52674
VP31645
p60326
sg52649
I3
sa(dp60327
g52643
I488
sg52644
V5-HTR2A A1438G
p60328
sg52646
I14
sg52674
VP28223
p60329
sg52649
I2
sa(dp60330
g52643
I588
sg52644
VLEPR
p60331
sg52646
I4
sg52674
VP48357
p60332
sg52649
I1
sa(dp60333
g52643
I535
sg52644
VACE
p60334
sg52646
I3
sg52674
VP12821
p60335
sg52649
I1
sa(dp60336
g52643
I37
sg52644
Vtumor necrosis factor-Alfa
p60337
sg52646
I26
sg52674
VP01375
p60338
sg52649
I3
sa(dp60339
g52643
I504
sg52644
Vangiotensin-converting enzyme
p60340
sg52646
I29
sg52674
VP12821
p60341
sg52649
I2
sa(dp60342
g52643
I65
sg52644
VTNF-Alfa
p60343
sg52646
I8
sg52674
VP01375
p60344
sg52649
I1
sa(dp60345
g52643
I571
sg52644
Vleptin receptor
p60346
sg52646
I15
sg52674
VP48357
p60347
sg52649
I2
sa(dp60348
g52643
I438
sg52644
V5-hydroxytryptamine 2A receptor
p60349
sg52646
I31
sg52674
VP34969
p60350
sg52649
I3
sa(dp60351
g52643
I275
sg52644
V5-HTT
p60352
sg52646
I5
sg52674
VP31645
p60353
sg52649
I1
sa(dp60354
g52643
I471
sg52644
g60319
sg52646
I7
sg52674
VP28223
p60355
sg52649
I1
sasg52640
(lp60356
(dp60357
g52643
I350
sg52644
VOSAS
p60358
sg52646
I4
sg52647
VC0520679
p60359
sg52649
I1
sa(dp60360
g52643
I37
sg52644
Vtumor necrosis
p60361
sg52646
I14
sg52647
VC0333516
p60362
sg52649
I2
sa(dp60363
g52643
I193
sg52644
Vvariable number tandem repeat
p60364
sg52646
I29
sg52647
VC1710347
p60365
sg52649
I4
sa(dp60366
g52643
I224
sg52644
VVNTR
p60367
sg52646
I4
sg52647
VC1710347
p60368
sg52649
I1
sa(dp60369
g52643
I350
sg52644
g60320
sg52646
I4
sg52647
VC0520679
p60370
sg52649
I1
sasa(dp60371
g135
(dp60372
(V5-HTR2A 102C
p60373
VOSAS
p60374
tp60375
I00
ssg52636
VOur study demonstrated that TNF-Alfa 308 G/A, 5-HTT LPR, and 5-HTT-VNTR polymorphisms were associated with OSAS risk, whereas little association was observed between 5-HTR2A 102C/T, 5-HTR2A A1438G, ACE I/D, or LEPR-Gln 223Arg polymorphism and risk of OSAS in the Chinese population.
p60376
sg52638
(lp60377
(dp60378
g52643
I198
sg52644
VACE I/D
p60379
sg52646
I7
sg52674
VP12821
p60380
sg52649
I2
sa(dp60381
g52643
I28
sg52644
VTNF
p60382
sg52646
I3
sg52674
VP01375
p60383
sg52649
I1
sa(dp60384
g52643
I182
sg52644
V5-HTR2A A1438G
p60385
sg52646
I14
sg52674
VP28223
p60386
sg52649
I2
sa(dp60387
g52643
I166
sg52644
g60373
sg52646
I12
sg52674
VP28223
p60388
sg52649
I2
sasg52640
(lp60389
(dp60390
g52643
I107
sg52644
VOSAS
p60391
sg52646
I4
sg52647
VC0520679
p60392
sg52649
I1
sa(dp60393
g52643
I107
sg52644
g60374
sg52646
I4
sg52647
VC0520679
p60394
sg52649
I1
sasa(dp60395
g135
(dp60396
(V5-HTT
p60397
VOSAS
p60398
tp60399
I00
ssg52636
VWe performed a meta-analysis to better evaluate the associations between 5-HT2A, 5-HTT, and LEPR polymorphisms, and OSAS.
p60400
sg52638
(lp60401
(dp60402
g52643
I75
sg52644
VHT2A
p60403
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp60404
g52643
I81
sg52644
g60397
sg52646
I5
sg52674
VP31645
p60405
sg52649
I1
sasg52640
(lp60406
(dp60407
g52643
I116
sg52644
g60398
sg52646
I4
sg52647
VC0520679
p60408
sg52649
I1
sasa(dp60409
g135
(dp60410
(V5-HTT
p60411
VOSAS
p60412
tp60413
I00
ssg52636
V5-HT2A, 5-HTT, and LEPR polymorphisms and OSAS were identified in PubMed and EMBASE.
p60414
sg52638
(lp60415
(dp60416
g52643
I2
sg52644
VHT2A
p60417
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp60418
g52643
I8
sg52644
g60411
sg52646
I5
sg52674
VP31645
p60419
sg52649
I1
sasg52640
(lp60420
(dp60421
g52643
I42
sg52644
g60412
sg52646
I4
sg52647
VC0520679
p60422
sg52649
I1
sasa(dp60423
g52636
VThe -1438 "A" allele of 5-HT2A was identified as a candidate genetic risk factor for OSAS (OR: 2.33, 95%CI 1.49-3.66).
p60424
sg52638
(lp60425
(dp60426
g52643
I26
sg52644
VHT2A
p60427
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp60428
(dp60429
g52643
I85
sg52644
VOSAS
p60430
sg52646
I4
sg52647
VC0520679
p60431
sg52649
I1
sasa(dp60432
g135
(dp60433
(V5-HT2A 102C
p60434
VOSAS
p60435
tp60436
I00
ssg52636
VThere was no significant association between 5-HT2A 102C/T and OSAS risk, using any model.
p60437
sg52638
(lp60438
(dp60439
g52643
I45
sg52644
g60434
sg52646
I11
sg52674
VP28223
p60440
sg52649
I2
sasg52640
(lp60441
(dp60442
g52643
I63
sg52644
g60435
sg52646
I4
sg52647
VC0520679
p60443
sg52649
I1
sasa(dp60444
g135
(dp60445
(V5-HTR2A gene
p60446
VOSAS
p60447
tp60448
I00
ssg52636
VEight studies were finally included in the meta-analysis of the association between 5-HTR2A gene variants (including 102T/C and 1438G/A), 5-HTT gene polymorphisms (including 5-HTT gene-linked promoter region (5-HTTLRP), and serotonin transporter intron 2 variable number tandem repeat (STin2VNTR) and OSAS risk.
p60449
sg52638
(lp60450
(dp60451
g52643
I224
sg52644
Vserotonin transporter
p60452
sg52646
I21
sg52674
VP31645
p60453
sg52649
I2
sa(dp60454
g52643
I138
sg52644
V5-HTT gene
p60455
sg52646
I10
sg52674
VP31645
p60456
sg52649
I2
sa(dp60457
g52643
I84
sg52644
g60446
sg52646
I12
sg52674
VP28223
p60458
sg52649
I2
sasg52640
(lp60459
(dp60460
g52643
I301
sg52644
g60447
sg52646
I4
sg52647
VC0520679
p60461
sg52649
I1
sa(dp60462
g52643
I255
sg52644
Vvariable number tandem repeat
p60463
sg52646
I29
sg52647
VC1710347
p60464
sg52649
I4
sasa(dp60465
g135
(dp60466
(VOSAS susceptibility
p60467
VOSAS
p60468
tp60469
I00
ssg52636
VThe G allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR were shown to increase OSAS susceptibility, with ORs of 2.33 (A vs. G, 95% CI 1.48-3.66), 1.24 (L vs. S, 95% CI: 1.04-1.49), and 2.87 (10 vs. 12, 95% CI: 1.38-5.97), respectively.
p60470
sg52638
(lp60471
(dp60472
g52643
I4
sg52644
VG allele of 5-HTR2A 1438G/A, long 5-HTTLPR, and 10-tandem-repeats STin2VNTR
p60473
sg52646
I75
sg52674
VP28223
p60474
sg52649
I10
sa(dp60475
g52643
I103
sg52644
g60467
sg52646
I19
sg52674
VP27986
p60476
sg52649
I2
sasg52640
(lp60477
(dp60478
g52643
I103
sg52644
g60468
sg52646
I4
sg52647
VC0520679
p60479
sg52649
I1
sasa(dp60480
g135
(dp60481
(V5-HTR2A 1438G
p60482
VOSAS
p60483
tp60484
I00
ssg52636
VOf the 5-HTR2A 1438G/A gene polymorphism, the AA genotype increased the OSAS risk, with an OR of 4.21 (95% CI: 2.83-6.25) in a recessive model in male OSAS patients, but no significant association was found in females.
p60485
sg52638
(lp60486
(dp60487
g52643
I7
sg52644
g60482
sg52646
I13
sg52674
VP28223
p60488
sg52649
I2
sasg52640
(lp60489
(dp60490
g52643
I72
sg52644
VOSAS
p60491
sg52646
I4
sg52647
VC0520679
p60492
sg52649
I1
sa(dp60493
g52643
I72
sg52644
g60483
sg52646
I4
sg52647
VC0520679
p60494
sg52649
I1
sasa(dp60495
g135
(dp60496
(V5-HTR2A 1438G
p60497
VOSAS
p60498
tp60499
I00
ssg52636
VOur meta-analysis demonstrated that polymorphisms in the 5-HTR2A 1438G/A and 5-HTT genes contributed to susceptibility to OSAS.
p60500
sg52638
(lp60501
(dp60502
g52643
I77
sg52644
V5-HTT genes
p60503
sg52646
I11
sg52674
VP31645
p60504
sg52649
I2
sa(dp60505
g52643
I57
sg52644
g60497
sg52646
I13
sg52674
VP28223
p60506
sg52649
I2
sasg52640
(lp60507
(dp60508
g52643
I122
sg52644
g60498
sg52646
I4
sg52647
VC0520679
p60509
sg52649
I1
sasa(dp60510
g52636
VThe serotonin 2A (5-HT2A) receptor has been implicated in obstructive sleep apnea (OSA).
p60511
sg52638
(lp60512
(dp60513
g52643
I4
sg52644
Vserotonin 2A
p60514
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp60515
(dp60516
g52643
I83
sg52644
VOSA
p60517
sg52646
I3
sg52647
VC0520679
p60518
sg52649
I1
sa(dp60519
g52643
I58
sg52644
Vobstructive sleep apnea
p60520
sg52646
I23
sg52647
VC0520679
p60521
sg52649
I3
sasa(dp60522
g135
(dp60523
(VEPO
p60524
Vchronic kidney disease
p60525
tp60526
I00
ssg52636
VOur findings suggest that upregulated functional TRPC5 gene may be one cause of EPO-induced hypertension in patients with chronic kidney disease.
p60527
sg52638
(lp60528
(dp60529
g52643
I49
sg52644
VTRPC5 gene
p60530
sg52646
I10
sg52674
g12
sg52649
I2
sa(dp60531
g52643
I80
sg52644
g60524
sg52646
I3
sg52674
VP01588
p60532
sg52649
I1
sasg52640
(lp60533
(dp60534
g52643
I92
sg52644
Vhypertension
p60535
sg52646
I12
sg52647
VC0020538
p60536
sg52649
I1
sa(dp60537
g52643
I122
sg52644
g60525
sg52646
I22
sg52647
VC1561643
p60538
sg52649
I3
sasa(dp60539
g135
(dp60540
(Vtransthyretin
p60541
Vamyloidosis
p60542
tp60543
I00
ssg52636
VTTR (transthyretin) gene could be a possible candidate for lumbosacral stenosis in Labrador retrievers based on previous human studies that have reported an association between human lumbar spinal stenosis and transthyretin protein amyloidosis.
p60544
sg52638
(lp60545
(dp60546
g52643
I0
sg52644
VTTR
p60547
sg52646
I3
sg52674
VP02766
p60548
sg52649
I1
sa(dp60549
g52643
I5
sg52644
Vtransthyretin
p60550
sg52646
I13
sg52674
VP02766
p60551
sg52649
I1
sa(dp60552
g52643
I5
sg52644
g60541
sg52646
I13
sg52674
VP02766
p60553
sg52649
I1
sasg52640
(lp60554
(dp60555
g52643
I59
sg52644
Vlumbosacral stenosis
p60556
sg52646
I20
sg52647
VC1299881
p60557
sg52649
I2
sa(dp60558
g52643
I183
sg52644
Vlumbar spinal stenosis
p60559
sg52646
I22
sg52647
VC0158288
p60560
sg52649
I3
sa(dp60561
g52643
I232
sg52644
g60542
sg52646
I11
sg52647
VC0002726
p60562
sg52649
I1
sasa(dp60563
g135
(dp60564
(VWild-type ATTR
p60565
Vamyloidosis
p60566
tp60567
I00
ssg52636
VWild-type ATTR amyloidosis mainly involves the heart, although the reported occurrence of bilateral carpal tunnel syndrome, spinal stenosis and biceps tendon rupture in these patients speaks to more generalized protein deposition.
p60568
sg52638
(lp60569
(dp60570
g52643
I0
sg52644
g60565
sg52646
I14
sg52674
VP02766
p60571
sg52649
I2
sasg52640
(lp60572
(dp60573
g52643
I100
sg52644
Vcarpal tunnel syndrome
p60574
sg52646
I22
sg52647
VC0007286
p60575
sg52649
I3
sa(dp60576
g52643
I124
sg52644
Vspinal stenosis
p60577
sg52646
I15
sg52647
VC0037944
p60578
sg52649
I2
sa(dp60579
g52643
I211
sg52644
Vprotein deposition
p60580
sg52646
I18
sg52647
VC0333584
p60581
sg52649
I2
sa(dp60582
g52643
I15
sg52644
g60566
sg52646
I11
sg52647
VC0002726
p60583
sg52649
I1
sasa(dp60584
g52636
VIn all groups, but the HBD group, the livers were pretreated with FK506 and prostaglandin I2 analogue, and were preserved in University of Wisconsin solution after cardiac arrest.
p60585
sg52638
(lp60586
sg52640
(lp60587
(dp60588
g52643
I23
sg52644
VHBD
p60589
sg52646
I3
sg52647
VC1840321
p60590
sg52649
I1
sa(dp60591
g52643
I164
sg52644
Vcardiac arrest
p60592
sg52646
I14
sg52647
VC0018790
p60593
sg52649
I2
sasa(dp60594
g52636
VWe used a new vasodilator, TTC-909 (a prostaglandin I2 analog incorporated in lipid microspheres), which produced marked reduction in the pulmonary arterial pressure and resistance in an infant with primary pulmonary hypertension.
p60595
sg52638
(lp60596
sg52640
(lp60597
(dp60598
g52643
I199
sg52644
Vprimary pulmonary hypertension
p60599
sg52646
I30
sg52647
VC0152171
p60600
sg52649
I3
sasa(dp60601
g52636
VA prostaglandin I2 (PGI2) was administered before cardiac arrest by St. Thomas solution.
p60602
sg52638
(lp60603
sg52640
(lp60604
(dp60605
g52643
I50
sg52644
Vcardiac arrest
p60606
sg52646
I14
sg52647
VC0018790
p60607
sg52649
I2
sasa(dp60608
g52636
VRecently, with the introduction of prostacyclin (Prostaglandin I2, epoprostenon) as a potent vasodilator, several reports have shown a positive effect in primary pulmonary hypertension.
p60609
sg52638
(lp60610
sg52640
(lp60611
(dp60612
g52643
I154
sg52644
Vprimary pulmonary hypertension
p60613
sg52646
I30
sg52647
VC0152171
p60614
sg52649
I3
sasa(dp60615
g135
(dp60616
(VGLI3
p60617
Vglioma
p60618
tp60619
I00
ssg52636
VFurthermore, the involvement of functional GREM1 in the epithelial-mesenchymal transition (EMT) process of glioma was investigated by detecting the expression levels of glioma-associated oncogene homologue 3 (GLI3) and EMT-related molecules.
p60620
sg52638
(lp60621
(dp60622
g52643
I219
sg52644
VEMT-related molecules
p60623
sg52646
I21
sg52674
g12
sg52649
I2
sa(dp60624
g52643
I43
sg52644
VGREM1
p60625
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp60626
g52643
I169
sg52644
Vglioma-associated oncogene homologue 3
p60627
sg52646
I38
sg52674
VP08151
p60628
sg52649
I4
sa(dp60629
g52643
I209
sg52644
g60617
sg52646
I4
sg52674
VP10071
p60630
sg52649
I1
sasg52640
(lp60631
(dp60632
g52643
I91
sg52644
VEMT
p60633
sg52646
I3
sg52647
VC0599156
p60634
sg52649
I1
sa(dp60635
g52643
I91
sg52644
VEMT
p60636
sg52646
I3
sg52647
VC0599156
p60637
sg52649
I1
sa(dp60638
g52643
I107
sg52644
Vglioma
p60639
sg52646
I6
sg52647
VC0017638
p60640
sg52649
I1
sa(dp60641
g52643
I56
sg52644
Vepithelial-mesenchymal transition
p60642
sg52646
I33
sg52647
VC0599156
p60643
sg52649
I2
sa(dp60644
g52643
I107
sg52644
g60618
sg52646
I6
sg52647
VC0017638
p60645
sg52649
I1
sasa(dp60646
g135
(dp60647
(VGLI3 repressor mutant
p60648
VGBM
p60649
tp60650
I00
ssg52636
VSuppression of GLI1/GLI2 functions by a C-terminus truncated GLI3 repressor mutant (GLI3R), or by GANT61, a pharmacological inhibitor of GLI1/GLI2, reduced hTERT protein expression in human colon cancer, prostate cancer and Glioblastoma multiforme (GBM) cell lines.
p60651
sg52638
(lp60652
(dp60653
g52643
I20
sg52644
VGLI2
p60654
sg52646
I4
sg52674
VP10070
p60655
sg52649
I1
sa(dp60656
g52643
I156
sg52644
VhTERT protein
p60657
sg52646
I13
sg52674
g12
sg52649
I2
sa(dp60658
g52643
I84
sg52644
VGLI3R
p60659
sg52646
I5
sg52674
VP10071
p60660
sg52649
I1
sa(dp60661
g52643
I15
sg52644
VGLI1
p60662
sg52646
I4
sg52674
VP08151
p60663
sg52649
I1
sa(dp60664
g52643
I20
sg52644
VGLI2
p60665
sg52646
I4
sg52674
VP10070
p60666
sg52649
I1
sa(dp60667
g52643
I15
sg52644
VGLI1
p60668
sg52646
I4
sg52674
VP08151
p60669
sg52649
I1
sa(dp60670
g52643
I61
sg52644
g60648
sg52646
I21
sg52674
VP10071
p60671
sg52649
I3
sasg52640
(lp60672
(dp60673
g52643
I196
sg52644
Vcancer, prostate
p60674
sg52646
I16
sg52647
VC0376358
p60675
sg52649
I2
sa(dp60676
g52643
I196
sg52644
Vcancer
p60677
sg52646
I6
sg52647
VC0006826
p60678
sg52649
I1
sa(dp60679
g52643
I224
sg52644
VGlioblastoma multiforme
p60680
sg52646
I23
sg52647
VC1621958
p60681
sg52649
I2
sa(dp60682
g52643
I249
sg52644
g60649
sg52646
I3
sg52647
VC1621958
p60683
sg52649
I1
sa(dp60684
g52643
I76
sg52644
Vmutant
p60685
sg52646
I6
sg52647
VC0596988
p60686
sg52649
I1
sa(dp60687
g52643
I0
sg52644
VSuppression
p60688
sg52646
I11
sg52647
VC0221103
p60689
sg52649
I1
sasa(dp60690
g135
(dp60691
(VInhibitor of DNA binding protein-1
p60692
VGBM
p60693
tp60694
I00
ssg52636
VInhibitor of DNA binding protein-1 (ID1) has been shown to maintain the self-renewal capacity of neural stem cells and might be involved in the therapeutic resistance of GBM.
p60695
sg52638
(lp60696
(dp60697
g52643
I36
sg52644
VID1
p60698
sg52646
I3
sg52674
VP29372
p60699
sg52649
I1
sa(dp60700
g52643
I0
sg52644
g60692
sg52646
I34
sg52674
VP29372
p60701
sg52649
I5
sasg52640
(lp60702
(dp60703
g52643
I170
sg52644
g60693
sg52646
I3
sg52647
VC0017636
p60704
sg52649
I1
sasa(dp60705
g135
(dp60706
(Vhistone deacetylase
p60707
VGBM
p60708
tp60709
I01
ssg52636
VIn glioblastoma neurosphere cultures that contain cancer stem cells (GBM-CSCs), the bHLH family member inhibitors of DNA binding protein 2 and 4 (Id2 and Id4) were found to be upregulated during the differentiation of GBM-CSCs in response to histone deacetylase inhibitors.
p60710
sg52638
(lp60711
(dp60712
g52643
I84
sg52644
VbHLH family
p60713
sg52646
I11
sg52674
g12
sg52649
I2
sa(dp60714
g52643
I154
sg52644
VId4
p60715
sg52646
I3
sg52674
VP47928
p60716
sg52649
I1
sa(dp60717
g52643
I242
sg52644
g60707
sg52646
I19
sg52674
VP56524
p60718
sg52649
I2
sa(dp60719
g52643
I117
sg52644
VDNA binding protein 2 and 4
p60720
sg52646
I27
sg52674
VP51523
p60721
sg52649
I6
sa(dp60722
g52643
I146
sg52644
VId2
p60723
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp60724
(dp60725
g52643
I69
sg52644
VGBM
p60726
sg52646
I3
sg52647
VC0017636
p60727
sg52649
I1
sa(dp60728
g52643
I50
sg52644
Vcancer
p60729
sg52646
I6
sg52647
VC0006826
p60730
sg52649
I1
sa(dp60731
g52643
I3
sg52644
Vglioblastoma
p60732
sg52646
I12
sg52647
VC0017636
p60733
sg52649
I1
sa(dp60734
g52643
I69
sg52644
g60708
sg52646
I3
sg52647
VC0017636
p60735
sg52649
I1
sasa(dp60736
g52636
VThe improvement in mitral regurgitation was greater for the mitral repair group (-2.1 +/- 0.3 vs -1.1 +/- 0.8, P &lt; .0001), and mitral regurgitation remained significantly lower on follow-up at 6 months or more (0.6 +/- 0.4 0.9 +/- 0.2, P = .002).
p60737
sg52638
(lp60738
sg52640
(lp60739
(dp60740
g52643
I19
sg52644
Vmitral regurgitation
p60741
sg52646
I20
sg52647
VC0026266
p60742
sg52649
I2
sa(dp60743
g52643
I19
sg52644
Vmitral regurgitation
p60744
sg52646
I20
sg52647
VC0026266
p60745
sg52649
I2
sasa(dp60746
g135
(dp60747
(Vtransforming growth factor-beta1
p60748
Vcataract
p60749
tp60750
I00
ssg52636
VThis study was undertaken to examine changes in 1-cysPrx expression in human cataract samples, human lens epithelial (HLE B3) cell line, and rat organ-cultured lenses in response to oxidative insult induced by H2O2 or transforming growth factor-beta1 (TGF-beta1).
p60751
sg52638
(lp60752
(dp60753
g52643
I252
sg52644
VTGF-beta1
p60754
sg52646
I9
sg52674
VP01137
p60755
sg52649
I1
sa(dp60756
g52643
I218
sg52644
g60748
sg52646
I32
sg52674
VP01137
p60757
sg52649
I3
sasg52640
(lp60758
(dp60759
g52643
I77
sg52644
g60749
sg52646
I8
sg52647
VC0086543
p60760
sg52649
I1
sasa(dp60761
g52636
VIn a functional analysis, transient cotransfections in nonerythroid NIH/3T3 cells of SP1, SP3, BKLF, or EKLF and HS2 epsilony promoter-luciferase constructs, with or without coactivators (p300, CREB-binding protein [CBP], or p300/CBP-associated factor [PCAF]) and SCFAs, were performed.
p60762
sg52638
(lp60763
(dp60764
g52643
I230
sg52644
VCBP-associated factor [PCAF]
p60765
sg52646
I28
sg52674
g12
sg52649
I3
sa(dp60766
g52643
I85
sg52644
VSP1
p60767
sg52646
I3
sg52674
VP08047
p60768
sg52649
I1
sa(dp60769
g52643
I113
sg52644
VHS2 epsilony promoter-luciferase constructs
p60770
sg52646
I43
sg52674
VP11277
p60771
sg52649
I4
sa(dp60772
g52643
I95
sg52644
VBKLF
p60773
sg52646
I4
sg52674
VP57682
p60774
sg52649
I1
sa(dp60775
g52643
I194
sg52644
VCREB-binding protein [CBP]
p60776
sg52646
I26
sg52674
g12
sg52649
I3
sa(dp60777
g52643
I90
sg52644
VSP3
p60778
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp60779
g52643
I188
sg52644
Vp300
p60780
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp60781
g52643
I188
sg52644
Vp300
p60782
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp60783
g52643
I104
sg52644
VEKLF
p60784
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp60785
sa(dp60786
g52636
VUsing our newly created Ngb overexpressing transgenic (Ngb-Tg) mice, we measured brain infarction on day 1 and day 14 after transient focal cerebral ischemia and performed neurobehavioral assessments in sensorimotor deficits on days 1, 3, 7, and 14.
p60787
sg52638
(lp60788
(dp60789
g52643
I24
sg52644
VNgb
p60790
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp60791
g52643
I24
sg52644
VNgb
p60792
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp60793
(dp60794
g52643
I140
sg52644
Vcerebral ischemia
p60795
sg52646
I17
sg52647
VC0917798
p60796
sg52649
I2
sa(dp60797
g52643
I81
sg52644
Vbrain infarction
p60798
sg52646
I16
sg52647
VC0751955
p60799
sg52649
I2
sasa(dp60800
g52636
VCompared with wild-type controls, brain infarction volumes 1 day and 14 days after transient focal cerebral ischemia were significantly reduced in Ngb-Tg mice.
p60801
sg52638
(lp60802
(dp60803
g52643
I147
sg52644
VNgb
p60804
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp60805
(dp60806
g52643
I34
sg52644
Vbrain infarction
p60807
sg52646
I16
sg52647
VC0751955
p60808
sg52649
I2
sa(dp60809
g52643
I99
sg52644
Vcerebral ischemia
p60810
sg52646
I17
sg52647
VC0917798
p60811
sg52649
I2
sasa(dp60812
g52636
VEvidence includes the observations that neuronal hypoxia and cerebral ischemia induce Ngb expression, that enhancing Ngb expression reduces--and knocking down Ngb expression increases--hypoxic neuronal injury in vitro and ischemic cerebral injury in vivo, and that Ngb-overexpressing transgenic mice are resistant to cerebral infarction.
p60813
sg52638
(lp60814
(dp60815
g52643
I86
sg52644
VNgb
p60816
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp60817
g52643
I86
sg52644
VNgb
p60818
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp60819
g52643
I86
sg52644
VNgb
p60820
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp60821
g52643
I86
sg52644
VNgb
p60822
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp60823
(dp60824
g52643
I61
sg52644
Vcerebral ischemia
p60825
sg52646
I17
sg52647
VC0917798
p60826
sg52649
I2
sa(dp60827
g52643
I317
sg52644
Vcerebral infarction
p60828
sg52646
I19
sg52647
VC0038454
p60829
sg52649
I2
sa(dp60830
g52643
I185
sg52644
Vhypoxic
p60831
sg52646
I7
sg52647
VC0242184
p60832
sg52649
I1
sa(dp60833
g52643
I49
sg52644
Vhypoxia
p60834
sg52646
I7
sg52647
VC0242184
p60835
sg52649
I1
sasa(dp60836
g52636
VSono stati presentati i casi di un effetto paradosso di aggressivita sotto la possibile influenza di acepromazina e un protocollo modificato per il trattamento di un avvelenamento da permetrina nei gatti.
p60837
sg52638
(lp60838
sg52640
(lp60839
(dp60840
g52643
I88
sg52644
Vinfluenza
p60841
sg52646
I9
sg52647
VC0021400
p60842
sg52649
I1
sasa(dp60843
g52636
VADRP and perilipin localized to the phagosomal membrane, which contains M. leprae in skin biopsy specimens of lepromatous leprosy.
p60844
sg52638
(lp60845
(dp60846
g52643
I9
sg52644
Vperilipin
p60847
sg52646
I9
sg52674
g12
sg52649
I1
sa(dp60848
g52643
I0
sg52644
VADRP
p60849
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp60850
(dp60851
g52643
I110
sg52644
Vlepromatous leprosy
p60852
sg52646
I19
sg52647
VC0023348
p60853
sg52649
I2
sasa(dp60854
g52636
VIn this work, two novel exonic BCKDK mutations, c.520C&gt;G/p.R174G and c.1166T&gt;C/p.L389P, were identified at the homozygous state in two unrelated children with persistently reduced body fluid levels of branched-chain amino acids (BCAAs), developmental delay, microcephaly, and neurobehavioral abnormalities.
p60855
sg52638
(lp60856
(dp60857
g52643
I31
sg52644
VBCKDK
p60858
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp60859
(dp60860
g52643
I264
sg52644
Vmicrocephaly
p60861
sg52646
I12
sg52647
VC0025958
p60862
sg52649
I1
sa(dp60863
g52643
I243
sg52644
Vdevelopmental delay
p60864
sg52646
I19
sg52647
VC0424605
p60865
sg52649
I2
sasa(dp60866
g135
(dp60867
(VHSP90
p60868
VHIV
p60869
tp60870
I00
ssg52636
VAR-12-stimulated the co-localization of Influenza, EBV and HIV virus proteins with LC3 in autophagosomes and reduced viral protein association with the chaperones HSP90, HSP70, and GRP78.
p60871
sg52638
(lp60872
(dp60873
g52643
I83
sg52644
VLC3
p60874
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp60875
g52643
I170
sg52644
VHSP70
p60876
sg52646
I5
sg52674
VP34932
p60877
sg52649
I1
sa(dp60878
g52643
I181
sg52644
VGRP78
p60879
sg52646
I5
sg52674
VP11021
p60880
sg52649
I1
sa(dp60881
g52643
I163
sg52644
g60868
sg52646
I5
sg52674
VP07900
p60882
sg52649
I1
sasg52640
(lp60883
(dp60884
g52643
I40
sg52644
VInfluenza
p60885
sg52646
I9
sg52647
VC0021400
p60886
sg52649
I1
sa(dp60887
g52643
I59
sg52644
g60869
sg52646
I3
sg52647
VC0019693
p60888
sg52649
I1
sasa(dp60889
g135
(dp60890
(VHSP70c fusion protein
p60891
Vinfluenza
p60892
tp60893
I00
ssg52636
VHence, in agreement with heat shock protein 70 (HSP70) acting as Th1 cytokine-like adjuvant, an Escherichia coli-expressed r4M2e.HSP70c fusion protein comprising C-terminus of Mycobacterium tuberculosis HSP70 genetically fused to four tandem repeats of influenza A virus M2e was constructed.
p60894
sg52638
(lp60895
(dp60896
g52643
I48
sg52644
VHSP70
p60897
sg52646
I5
sg52674
VP34932
p60898
sg52649
I1
sa(dp60899
g52643
I25
sg52644
Vheat shock protein 70
p60900
sg52646
I21
sg52674
VP34932
p60901
sg52649
I4
sa(dp60902
g52643
I48
sg52644
VHSP70
p60903
sg52646
I5
sg52674
VP34932
p60904
sg52649
I1
sa(dp60905
g52643
I253
sg52644
Vinfluenza A virus M2e
p60906
sg52646
I21
sg52674
g12
sg52649
I4
sa(dp60907
g52643
I129
sg52644
g60891
sg52646
I21
sg52674
VP35637
p60908
sg52649
I3
sasg52640
(lp60909
(dp60910
g52643
I190
sg52644
Vtuberculosis
p60911
sg52646
I12
sg52647
VC0041296
p60912
sg52649
I1
sa(dp60913
g52643
I253
sg52644
g60892
sg52646
I9
sg52647
VC0021400
p60914
sg52649
I1
sasa(dp60915
g52636
VFurthermore, a virus challenge experiment revealed that mice vaccinated with r4M2e.HSP70c limited the severity of influenza A disease by 100% survival rate, less sever body weight loss and delaying the onset of morbidity in mice for 2days rather than other control groups.
p60916
sg52638
(lp60917
sg52640
(lp60918
(dp60919
g52643
I114
sg52644
Vinfluenza
p60920
sg52646
I9
sg52647
VC0021400
p60921
sg52649
I1
sasa(dp60922
g135
(dp60923
(VLeishmania major HSP70
p60924
VInfluenza
p60925
tp60926
I00
ssg52636
VTo prepare an effective vaccine against influenza A viruses, a chimerical DNA plasmid encoding Influenza virus M2 protein and Leishmania major HSP70 was constructed.
p60927
sg52638
(lp60928
(dp60929
g52643
I126
sg52644
g60924
sg52646
I22
sg52674
VP34932
p60930
sg52649
I3
sasg52640
(lp60931
(dp60932
g52643
I40
sg52644
Vinfluenza
p60933
sg52646
I9
sg52647
VC0021400
p60934
sg52649
I1
sa(dp60935
g52643
I95
sg52644
g60925
sg52646
I9
sg52647
VC0021400
p60936
sg52649
I1
sasa(dp60937
g52636
VOur previous study have shown that a prime-boost administration of recombinant 4xM2e.HSP70c (r4M2e/H70c) fusion protein compared to conventional HA-based influenza vaccines provided full protection against lethal dose of influenza A viruses in mice.
p60938
sg52638
(lp60939
sg52640
(lp60940
(dp60941
g52643
I154
sg52644
Vinfluenza
p60942
sg52646
I9
sg52647
VC0021400
p60943
sg52649
I1
sa(dp60944
g52643
I154
sg52644
Vinfluenza
p60945
sg52646
I9
sg52647
VC0021400
p60946
sg52649
I1
sasa(dp60947
g52636
VThe data reported herein show that protection against H9N2 viral challenge was significantly increased in chickens by injection of r4M2e/H70c compared with injection of conventional HA-based influenza vaccine adjuvanted with MF59 or recombinant 4xM2e (r4M2e) without HSP70c.
p60948
sg52638
(lp60949
sg52640
(lp60950
(dp60951
g52643
I191
sg52644
Vinfluenza
p60952
sg52646
I9
sg52647
VC0021400
p60953
sg52649
I1
sasa(dp60954
g135
(dp60955
(VIFN-Gamma
p60956
Vinfluenza
p60957
tp60958
I00
ssg52636
VThis protective immunity might be attributed to enhanced cell-mediated immunity, which is interpreted as increased lymphocytes proliferation, increased levels of Th1-type (IFN-Gamma) and Th2-type (IL-4) cytokines production and increased CD4(+) to CD8(+) ratios, resulting from the injection of four tandem repeats of the ectodomain of the conserved influenza matrix protein M2 (4xM2e) genetically fused to C-terminus of Mycobacterium tuberculosis HSP70 (mHSP70c).
p60959
sg52638
(lp60960
(dp60961
g52643
I448
sg52644
VHSP70
p60962
sg52646
I5
sg52674
VP34932
p60963
sg52649
I1
sa(dp60964
g52643
I248
sg52644
VCD8
p60965
sg52646
I3
sg52674
VP01732
p60966
sg52649
I1
sa(dp60967
g52643
I238
sg52644
VCD4
p60968
sg52646
I3
sg52674
VP01730
p60969
sg52649
I1
sa(dp60970
g52643
I172
sg52644
g60956
sg52646
I9
sg52674
VP01579
p60971
sg52649
I1
sasg52640
(lp60972
(dp60973
g52643
I435
sg52644
Vtuberculosis
p60974
sg52646
I12
sg52647
VC0041296
p60975
sg52649
I1
sa(dp60976
g52643
I350
sg52644
g60957
sg52646
I9
sg52647
VC0021400
p60977
sg52649
I1
sa(dp60978
g52643
I127
sg52644
Vproliferation
p60979
sg52646
I13
sg52647
VC0334094
p60980
sg52649
I1
sasa(dp60981
g135
(dp60982
(VHsp70
p60983
Vinfluenza
p60984
tp60985
I00
ssg52636
VHeat shock protein 70 (Hsp70) was identified as a cellular interaction partner of the influenza virus ribonucleoprotein (RNP) complex.
p60986
sg52638
(lp60987
(dp60988
g52643
I0
sg52644
VHeat shock protein 70
p60989
sg52646
I21
sg52674
VP34932
p60990
sg52649
I4
sa(dp60991
g52643
I23
sg52644
g60983
sg52646
I5
sg52674
VP34932
p60992
sg52649
I1
sasg52640
(lp60993
(dp60994
g52643
I86
sg52644
g60984
sg52646
I9
sg52647
VC0021400
p60995
sg52649
I1
sasa(dp60996
g135
(dp60997
(VHsp70
p60998
Vinfluenza
p60999
tp61000
I00
ssg52636
VHere we demonstrated that Hsp70 was involved in the regulation of influenza A viral transcription and replication.
p61001
sg52638
(lp61002
(dp61003
g52643
I26
sg52644
g60998
sg52646
I5
sg52674
VP34932
p61004
sg52649
I1
sasg52640
(lp61005
(dp61006
g52643
I66
sg52644
g60999
sg52646
I9
sg52647
VC0021400
p61007
sg52649
I1
sasa(dp61008
g135
(dp61009
(VHsp70
p61010
Vinfluenza
p61011
tp61012
I00
ssg52636
VFurthermore, delivered Hsp70 could inhibit the replication of influenza A virus in mice.
p61013
sg52638
(lp61014
(dp61015
g52643
I23
sg52644
g61010
sg52646
I5
sg52674
VP34932
p61016
sg52649
I1
sasg52640
(lp61017
(dp61018
g52643
I62
sg52644
g61011
sg52646
I9
sg52647
VC0021400
p61019
sg52649
I1
sasa(dp61020
g135
(dp61021
(Vhuman antigen-specific CD4
p61022
Vinfluenza
p61023
tp61024
I00
ssg52636
VIn this study, antigenic peptides from tetanus toxin and influenza hemagglutinin complexed to human stress-inducible Hsp70 were found to enhance the proliferation and cytokine production of human antigen-specific CD4(+) T cells.
p61025
sg52638
(lp61026
(dp61027
g52643
I117
sg52644
VHsp70
p61028
sg52646
I5
sg52674
VP34932
p61029
sg52649
I1
sa(dp61030
g52643
I190
sg52644
g61022
sg52646
I26
sg52674
VP14209
p61031
sg52649
I3
sasg52640
(lp61032
(dp61033
g52643
I57
sg52644
g61023
sg52646
I9
sg52647
VC0021400
p61034
sg52649
I1
sa(dp61035
g52643
I39
sg52644
Vtetanus
p61036
sg52646
I7
sg52647
VC0039614
p61037
sg52649
I1
sa(dp61038
g52643
I149
sg52644
Vproliferation
p61039
sg52646
I13
sg52647
VC0334094
p61040
sg52649
I1
sasa(dp61041
g135
(dp61042
(VHSP70(359-610)
p61043
Vtuberculosis
p61044
tp61045
I00
ssg52636
VHerein, to construct a recombinant M2e-based vaccine candidate with the appropriate structural conformation and immunogenicity the corresponding nucleotide sequence from an H9N2 influenza strain was fused to the N-terminus of the truncated Mycobacterium tuberculosis HSP70(359-610), as a potent adjuvant, and following its cloning into the pPICZ alpha A plasmid the fusion gene was expressed in Pichia pastoris KM71H yeast.
p61046
sg52638
(lp61047
(dp61048
g52643
I267
sg52644
g61043
sg52646
I14
sg52674
VP34932
p61049
sg52649
I1
sasg52640
(lp61050
(dp61051
g52643
I178
sg52644
Vinfluenza
p61052
sg52646
I9
sg52647
VC0021400
p61053
sg52649
I1
sa(dp61054
g52643
I254
sg52644
g61044
sg52646
I12
sg52647
VC0041296
p61055
sg52649
I1
sasa(dp61056
g135
(dp61057
(VHSP70(359-610)
p61058
Vinfluenza
p61059
tp61060
I00
ssg52636
VAccording to previous reports, this study was designed to produce a novel influenza A virus recombinant fusion protein consisted of M2e, a potent immunogenic protein from influenza A virus, fused to C-terminal domain of mycobacterium tuberculosis HSP70, HSP70(359-610), as a carrier and adjuvant.
p61061
sg52638
(lp61062
(dp61063
g52643
I247
sg52644
VHSP70
p61064
sg52646
I5
sg52674
VP34932
p61065
sg52649
I1
sa(dp61066
g52643
I254
sg52644
g61058
sg52646
I14
sg52674
VP34932
p61067
sg52649
I1
sasg52640
(lp61068
(dp61069
g52643
I234
sg52644
Vtuberculosis
p61070
sg52646
I12
sg52647
VC0041296
p61071
sg52649
I1
sa(dp61072
g52643
I74
sg52644
Vinfluenza
p61073
sg52646
I9
sg52647
VC0021400
p61074
sg52649
I1
sa(dp61075
g52643
I74
sg52644
g61059
sg52646
I9
sg52647
VC0021400
p61076
sg52649
I1
sasa(dp61077
g135
(dp61078
(VATPase family AAA-domain containing protein 3A
p61079
Vdevelopmental delay
p61080
tp61081
I00
ssg52636
VDe novo mutations in ATAD3A (ATPase family AAA-domain containing protein 3A) were recently found to cause a neurological syndrome with developmental delay, hypotonia, spasticity, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
p61082
sg52638
(lp61083
(dp61084
g52643
I21
sg52644
VATAD3A
p61085
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp61086
g52643
I29
sg52644
g61079
sg52646
I46
sg52674
VP38606
p61087
sg52649
I6
sasg52640
(lp61088
(dp61089
g52643
I194
sg52644
Vaxonal neuropathy
p61090
sg52646
I17
sg52647
VC0270921
p61091
sg52649
I2
sa(dp61092
g52643
I156
sg52644
Vhypotonia
p61093
sg52646
I9
sg52647
VC0026827
p61094
sg52649
I1
sa(dp61095
g52643
I121
sg52644
Vsyndrome
p61096
sg52646
I8
sg52647
VC0039082
p61097
sg52649
I1
sa(dp61098
g52643
I179
sg52644
Voptic atrophy
p61099
sg52646
I13
sg52647
VC0029124
p61100
sg52649
I2
sa(dp61101
g52643
I167
sg52644
Vspasticity
p61102
sg52646
I10
sg52647
VC0026838
p61103
sg52649
I1
sa(dp61104
g52643
I43
sg52644
VAAA
p61105
sg52646
I3
sg52647
VC0162871
p61106
sg52649
I1
sa(dp61107
g52643
I217
sg52644
Vhypertrophic cardiomyopathy
p61108
sg52646
I27
sg52647
VC0007194
p61109
sg52649
I2
sa(dp61110
g52643
I135
sg52644
g61080
sg52646
I19
sg52647
VC0424605
p61111
sg52649
I2
sasa(dp61112
g52636
VWe identified a recurrent de novo ATAD3A c.1582C&gt;T (p.Arg528Trp) variant by whole-exome sequencing (WES) in five unrelated individuals with a core phenotype of global developmental delay, hypotonia, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
p61113
sg52638
(lp61114
(dp61115
g52643
I34
sg52644
VATAD3A c.1582C
p61116
sg52646
I14
sg52674
g12
sg52649
I2
sasg52640
(lp61117
(dp61118
g52643
I217
sg52644
Vaxonal neuropathy
p61119
sg52646
I17
sg52647
VC0270921
p61120
sg52649
I2
sa(dp61121
g52643
I240
sg52644
Vhypertrophic cardiomyopathy
p61122
sg52646
I27
sg52647
VC0007194
p61123
sg52649
I2
sa(dp61124
g52643
I202
sg52644
Voptic atrophy
p61125
sg52646
I13
sg52647
VC0029124
p61126
sg52649
I2
sa(dp61127
g52643
I163
sg52644
Vglobal developmental delay
p61128
sg52646
I26
sg52647
VC0557874
p61129
sg52649
I3
sa(dp61130
g52643
I191
sg52644
Vhypotonia
p61131
sg52646
I9
sg52647
VC0026827
p61132
sg52649
I1
sasa(dp61133
g135
(dp61134
(VANT
p61135
VAAA
p61136
tp61137
I00
ssg52636
VImmunoblot and mass spectrometry analyses revealed that the 800-kDa complex contained the OMM translocator protein (18-kDa) and VDAC along with IMM CYP11A1, ATPase family AAA domain-containing protein 3A (ATAD3A), and optic atrophy type 1 proteins, but not ANT.
p61138
sg52638
(lp61139
(dp61140
g52643
I144
sg52644
VIMM CYP11A1
p61141
sg52646
I11
sg52674
VP05108
p61142
sg52649
I2
sa(dp61143
g52643
I157
sg52644
VATPase family AAA domain-containing protein 3A
p61144
sg52646
I46
sg52674
g12
sg52649
I6
sa(dp61145
g52643
I257
sg52644
g61135
sg52646
I3
sg52674
VP12235
p61146
sg52649
I1
sa(dp61147
g52643
I90
sg52644
VOMM translocator protein
p61148
sg52646
I24
sg52674
VP30536
p61149
sg52649
I3
sa(dp61150
g52643
I205
sg52644
VATAD3A
p61151
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp61152
(dp61153
g52643
I218
sg52644
Voptic atrophy type 1
p61154
sg52646
I20
sg52647
VC0338508
p61155
sg52649
I4
sa(dp61156
g52643
I171
sg52644
g61136
sg52646
I3
sg52647
VC0162871
p61157
sg52649
I1
sasa(dp61158
g135
(dp61159
(VANT
p61160
Voptic atrophy type 1
p61161
tp61162
I00
ssg52636
VKnockdown of ATAD3A, but not ANT or optic atrophy type 1, in Leydig cells resulted in a significant decrease in hormone-induced, but not 22R-hydroxycholesterol-supported, steroid production.
p61163
sg52638
(lp61164
(dp61165
g52643
I29
sg52644
g61160
sg52646
I3
sg52674
VP12235
p61166
sg52649
I1
sa(dp61167
g52643
I13
sg52644
VATAD3A
p61168
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp61169
(dp61170
g52643
I36
sg52644
g61161
sg52646
I20
sg52647
VC0338508
p61171
sg52649
I4
sasa(dp61172
g135
(dp61173
(Vserotonergic (5HT2A) receptor
p61174
Vschizophrenia
p61175
tp61176
I00
ssg52636
VSo, we attempted to evaluate the association between dopamine D2 (DRD2) receptor, serotonergic (5HT2A) receptor and CYP2D6 gene polymorphisms and response to treatment with risperidone in persons with schizophrenia from North India.
p61177
sg52638
(lp61178
(dp61179
g52643
I53
sg52644
Vdopamine D2 (DRD2) receptor
p61180
sg52646
I27
sg52674
VP14416
p61181
sg52649
I4
sa(dp61182
g52643
I116
sg52644
VCYP2D6 gene
p61183
sg52646
I11
sg52674
VP10635
p61184
sg52649
I2
sa(dp61185
g52643
I82
sg52644
g61174
sg52646
I29
sg52674
VP28223
p61186
sg52649
I3
sasg52640
(lp61187
(dp61188
g52643
I201
sg52644
g61175
sg52646
I13
sg52647
VC0036341
p61189
sg52649
I1
sasa(dp61190
g52636
VWe identified 60 miRNAs that were significantly increased in recurrent serous ovarian carcinoma compared with primary tumor tissue, including miR-630, miR-370, and miR-575.
p61191
sg52638
(lp61192
(dp61193
g52643
I142
sg52644
VmiR-630
p61194
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61195
g52643
I151
sg52644
VmiR-370
p61196
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp61197
(dp61198
g52643
I110
sg52644
Vprimary tumor
p61199
sg52646
I13
sg52647
VC0677930
p61200
sg52649
I2
sa(dp61201
g52643
I78
sg52644
Vovarian carcinoma
p61202
sg52646
I17
sg52647
VC0029925
p61203
sg52649
I2
sasa(dp61204
g52636
VThree other miRNAs, miR-19b, miR-433, and miR-370 were associated with lymph node metastasis, decreased curvature, and poorly differentiated carcinoma.
p61205
sg52638
(lp61206
(dp61207
g52643
I29
sg52644
VmiR-433
p61208
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61209
g52643
I42
sg52644
VmiR-370
p61210
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61211
g52643
I20
sg52644
VmiR-19b
p61212
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp61213
(dp61214
g52643
I71
sg52644
Vlymph node metastasis
p61215
sg52646
I21
sg52647
VC0686619
p61216
sg52649
I3
sa(dp61217
g52643
I119
sg52644
Vpoorly differentiated carcinoma
p61218
sg52646
I31
sg52647
VC0741899
p61219
sg52649
I3
sasa(dp61220
g52636
VA preliminary screening study suggested that down-regulation of miR-370 occurs in oral squamous cell carcinoma (OSCC) tissue.
p61221
sg52638
(lp61222
(dp61223
g52643
I64
sg52644
VmiR-370
p61224
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp61225
(dp61226
g52643
I87
sg52644
Vsquamous cell carcinoma
p61227
sg52646
I23
sg52647
VC0007137
p61228
sg52649
I3
sasa(dp61229
g52636
VSquamous cell carcinoma tissues with perineural invasion had lowered miR-370 expression compared with contrasting OSCC.
p61230
sg52638
(lp61231
(dp61232
g52643
I69
sg52644
VmiR-370
p61233
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp61234
(dp61235
g52643
I48
sg52644
Vinvasion
p61236
sg52646
I8
sg52647
VC2699153
p61237
sg52649
I1
sa(dp61238
g52643
I0
sg52644
VSquamous cell carcinoma
p61239
sg52646
I23
sg52647
VC0007137
p61240
sg52649
I3
sasa(dp61241
g52636
VExpression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues.
p61242
sg52638
(lp61243
(dp61244
g52643
I36
sg52644
VmiR-30d
p61245
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61246
g52643
I57
sg52644
VmiR-370
p61247
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61248
g52643
I27
sg52644
VmiR-30c
p61249
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61250
g52643
I45
sg52644
VmiR-30e-3p
p61251
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp61252
(dp61253
g52643
I102
sg52644
Vcarcinoma
p61254
sg52646
I9
sg52647
VC0007097
p61255
sg52649
I1
sa(dp61256
g52643
I102
sg52644
Vcarcinomas
p61257
sg52646
I10
sg52647
VC0007097
p61258
sg52649
I1
sasa(dp61259
g135
(dp61260
(VMPO
p61261
VPruritus
p61262
tp61263
I00
ssg52636
VPruritus was assessed by the number of scratching bouts, whilst skin inflammation was evaluated by the extravascular accumulation of intravenously injected 125I-albumin (plasma extravasation) and myeloperoxidase (MPO) activity (neutrophil recruitment).
p61264
sg52638
(lp61265
(dp61266
g52643
I196
sg52644
Vmyeloperoxidase
p61267
sg52646
I15
sg52674
VP05164
p61268
sg52649
I1
sa(dp61269
g52643
I161
sg52644
Valbumin
p61270
sg52646
I7
sg52674
VP00441
p61271
sg52649
I1
sa(dp61272
g52643
I213
sg52644
g61261
sg52646
I3
sg52674
VP05164
p61273
sg52649
I1
sasg52640
(lp61274
(dp61275
g52643
I239
sg52644
Vrecruitment
p61276
sg52646
I11
sg52647
VC0271510
p61277
sg52649
I1
sa(dp61278
g52643
I64
sg52644
Vskin inflammation
p61279
sg52646
I17
sg52647
VC0011603
p61280
sg52649
I2
sa(dp61281
g52643
I0
sg52644
g61262
sg52646
I8
sg52647
VC0033774
p61282
sg52649
I1
sa(dp61283
g52643
I177
sg52644
Vextravasation
p61284
sg52646
I13
sg52647
VC0015376
p61285
sg52649
I1
sasa(dp61286
g135
(dp61287
(VVPAC1
p61288
Vcongenital thrombocytopenia
p61289
tp61290
I00
ssg52636
VThe neuropeptide PACAP and VPAC1 were previously found to negatively regulate megakaryopoiesis, and inhibition of their physiological pathway was found to have a thrombopoietic effect in conditions where megakaryopoiesis and thrombopoiesis were impaired, such as chemotherapy-induced thrombocytopenia and congenital thrombocytopenia.
p61291
sg52638
(lp61292
(dp61293
g52643
I27
sg52644
g61288
sg52646
I5
sg52674
VP32241
p61294
sg52649
I1
sa(dp61295
g52643
I17
sg52644
VPACAP
p61296
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61297
(dp61298
g52643
I305
sg52644
g61289
sg52646
I27
sg52647
VC0272278
p61299
sg52649
I2
sa(dp61300
g52643
I245
sg52644
Vimpaired
p61301
sg52646
I8
sg52647
VC0684336
p61302
sg52649
I1
sasa(dp61303
g135
(dp61304
(VVPAC1
p61305
Vimmune thrombocytopenia
p61306
tp61307
I00
ssg52636
VThe present study explored the thrombopoietic effect of VPAC1 inhibition in a murine model of syngeneic bone marrow transplantation (BMT) and in passive immune thrombocytopenia.
p61308
sg52638
(lp61309
(dp61310
g52643
I56
sg52644
g61305
sg52646
I5
sg52674
VP32241
p61311
sg52649
I1
sasg52640
(lp61312
(dp61313
g52643
I153
sg52644
g61306
sg52646
I23
sg52647
VC0272286
p61314
sg52649
I2
sasa(dp61315
g52636
VRheumatoid arthritis (RA) is an autoimmune disease which may lead to severe disabilities due to structural joint damage and extraarticular manifestations The dendritic cell marker CD83 belongs to the immunoglobulin superfamily and has previously been associated with autoimmune diseases.
p61316
sg52638
(lp61317
(dp61318
g52643
I180
sg52644
VCD83
p61319
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp61320
g52643
I200
sg52644
Vimmunoglobulin superfamily
p61321
sg52646
I26
sg52674
g12
sg52649
I2
sasg52640
(lp61322
(dp61323
g52643
I32
sg52644
Vautoimmune disease
p61324
sg52646
I18
sg52647
VC0004364
p61325
sg52649
I2
sa(dp61326
g52643
I267
sg52644
Vautoimmune diseases
p61327
sg52646
I19
sg52647
VC0004364
p61328
sg52649
I2
sa(dp61329
g52643
I22
sg52644
VRA
p61330
sg52646
I2
sg52647
VC0003873
p61331
sg52649
I1
sa(dp61332
g52643
I0
sg52644
VRheumatoid arthritis
p61333
sg52646
I20
sg52647
VC0003873
p61334
sg52649
I2
sasa(dp61335
g52636
VPatients with PLCH displayed a normal expression of the maturity marker CD83 on BALF myeloid DCs.
p61336
sg52638
(lp61337
(dp61338
g52643
I72
sg52644
VCD83
p61339
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp61340
(dp61341
g52643
I93
sg52644
VDCs
p61342
sg52646
I3
sg52647
VC0268238
p61343
sg52649
I1
sasa(dp61344
g135
(dp61345
(VBRAF
p61346
VLCH
p61347
tp61348
I00
ssg52636
VTo the differentiation-related markers, the BRAF/MAP2K1-mut LCH expressed CD14 but rarely expressed CD83 or CD86 (P &lt; .001).
p61349
sg52638
(lp61350
(dp61351
g52643
I56
sg52644
Vmut
p61352
sg52646
I3
sg52674
VP22033
p61353
sg52649
I1
sa(dp61354
g52643
I100
sg52644
VCD83
p61355
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp61356
g52643
I49
sg52644
VMAP2K1
p61357
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp61358
g52643
I74
sg52644
VCD14
p61359
sg52646
I4
sg52674
VP08571
p61360
sg52649
I1
sa(dp61361
g52643
I108
sg52644
VCD86
p61362
sg52646
I4
sg52674
VP42081
p61363
sg52649
I1
sa(dp61364
g52643
I44
sg52644
g61346
sg52646
I4
sg52674
VP15056
p61365
sg52649
I1
sasg52640
(lp61366
(dp61367
g52643
I60
sg52644
g61347
sg52646
I3
sg52647
VC0019621
p61368
sg52649
I1
sasa(dp61369
g135
(dp61370
(VCD86
p61371
VLCH
p61372
tp61373
I00
ssg52636
VOn the contrary, BRAF/MAP2K1-wt LCH cells rarely expressed CD14 but expressed CD86, and some also expressed CD83 (P &lt; .001).
p61374
sg52638
(lp61375
(dp61376
g52643
I108
sg52644
VCD83
p61377
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp61378
g52643
I59
sg52644
VCD14
p61379
sg52646
I4
sg52674
VP08571
p61380
sg52649
I1
sa(dp61381
g52643
I17
sg52644
VBRAF
p61382
sg52646
I4
sg52674
VP15056
p61383
sg52649
I1
sa(dp61384
g52643
I22
sg52644
VMAP2K1
p61385
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp61386
g52643
I78
sg52644
g61371
sg52646
I4
sg52674
VP42081
p61387
sg52649
I1
sasg52640
(lp61388
(dp61389
g52643
I32
sg52644
g61372
sg52646
I3
sg52647
VC0019621
p61390
sg52649
I1
sasa(dp61391
g52636
VThe protein phosphatase 1-like gene (PPM1l) was identified as causal gene for obesity and metabolic abnormalities in mice.
p61392
sg52638
(lp61393
(dp61394
g52643
I4
sg52644
Vprotein phosphatase 1-like gene
p61395
sg52646
I31
sg52674
g12
sg52649
I4
sa(dp61396
g52643
I37
sg52644
VPPM1l
p61397
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61398
(dp61399
g52643
I78
sg52644
Vobesity
p61400
sg52646
I7
sg52647
VC0028754
p61401
sg52649
I1
sasa(dp61402
g135
(dp61403
(Vlipoprotein lipase
p61404
Vmetabolic disease
p61405
tp61406
I00
ssg52636
VThree genes in this network, lipoprotein lipase (Lpl), lactamase beta (Lactb) and protein phosphatase 1-like (Ppm1l), are validated as previously unknown obesity genes, strengthening the association between this network and metabolic disease traits.
p61407
sg52638
(lp61408
(dp61409
g52643
I110
sg52644
VPpm1l
p61410
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp61411
g52643
I71
sg52644
VLactb
p61412
sg52646
I5
sg52674
VP83111
p61413
sg52649
I1
sa(dp61414
g52643
I49
sg52644
VLpl
p61415
sg52646
I3
sg52674
VP06858
p61416
sg52649
I1
sa(dp61417
g52643
I55
sg52644
Vlactamase beta
p61418
sg52646
I14
sg52674
VP83111
p61419
sg52649
I2
sa(dp61420
g52643
I29
sg52644
g61404
sg52646
I18
sg52674
VP06858
p61421
sg52649
I2
sa(dp61422
g52643
I82
sg52644
Vprotein phosphatase 1-like
p61423
sg52646
I26
sg52674
g12
sg52649
I3
sasg52640
(lp61424
(dp61425
g52643
I154
sg52644
Vobesity
p61426
sg52646
I7
sg52647
VC0028754
p61427
sg52649
I1
sa(dp61428
g52643
I224
sg52644
g61405
sg52646
I17
sg52647
VC0025517
p61429
sg52649
I2
sasa(dp61430
g135
(dp61431
(Vphosphatidylinositol-3-kinase
p61432
Vosteoporosis
p61433
tp61434
I00
ssg52636
VBased on previous research, we hypothesized that RES regulates FoxO1 transcriptional activity through the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway to achieve an antioxidative effect on osteoporosis and then we confirmed this hypothesis in the present study.
p61435
sg52638
(lp61436
(dp61437
g52643
I137
sg52644
VPI3K
p61438
sg52646
I4
sg52674
VP42336
p61439
sg52649
I1
sa(dp61440
g52643
I106
sg52644
g61432
sg52646
I29
sg52674
VP33981
p61441
sg52649
I1
sa(dp61442
g52643
I143
sg52644
VAKT
p61443
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp61444
(dp61445
g52643
I203
sg52644
g61433
sg52646
I12
sg52647
VC0029456
p61446
sg52649
I1
sasa(dp61447
g52636
VFoxO1 is a major action target of RES to confer anti-osteoporosis function, and whose effect stems from its power to improve redox balance.
p61448
sg52638
(lp61449
(dp61450
g52643
I0
sg52644
VFoxO1
p61451
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61452
(dp61453
g52643
I53
sg52644
Vosteoporosis
p61454
sg52646
I12
sg52647
VC0029456
p61455
sg52649
I1
sasa(dp61456
g52636
VBut whether FoxO1 is involved in the oxidative damage during osteoporosis is largely unknown.
p61457
sg52638
(lp61458
(dp61459
g52643
I12
sg52644
VFoxO1
p61460
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61461
(dp61462
g52643
I61
sg52644
Vosteoporosis
p61463
sg52646
I12
sg52647
VC0029456
p61464
sg52649
I1
sasa(dp61465
g135
(dp61466
(VTNF-Alfa
p61467
Vosteoporosis
p61468
tp61469
I00
ssg52636
VIn conclusion, our study revealed that the decline of FoxO1 is an important etiology factor of osteoporosis and unclosed a novel mechanism of FoxO1 regulation by TNF-Alfa.
p61470
sg52638
(lp61471
(dp61472
g52643
I162
sg52644
g61467
sg52646
I8
sg52674
VP01375
p61473
sg52649
I1
sa(dp61474
g52643
I54
sg52644
VFoxO1
p61475
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp61476
g52643
I54
sg52644
VFoxO1
p61477
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61478
(dp61479
g52643
I95
sg52644
g61468
sg52646
I12
sg52647
VC0029456
p61480
sg52649
I1
sasa(dp61481
g135
(dp61482
(VIL5-IL13 region
p61483
Vasthma
p61484
tp61485
I00
ssg52636
VIn addition, several new PheWAS findings were identified including a cluster of association near the NDFIP1 gene for mental retardation (best SNP rs10057309, p = 4.33 x 10(-7), OR = 1.70, 95%CI = 1.38 - 2.09); association near PLCL1 gene for developmental delays and speech disorder [best SNP rs1595825, p = 1.13 x 10(-8), OR = 0.65(0.57 - 0.76)]; a cluster of associations in the IL5-IL13 region with Eosinophilic Esophagitis (EoE) [best at rs12653750, p = 3.03 x 10(-9), OR = 1.73 95%CI = (1.44 - 2.07)], previously implicated in asthma, allergy, and eosinophilia; and association of variants in GCKR and JAZF1 with allergic rhinitis in our pediatric cohorts [best SNP rs780093, p = 2.18 x 10(-5), OR = 1.39, 95%CI = (1.19 - 1.61)], previously demonstrated in metabolic disease and diabetes in adults.
p61486
sg52638
(lp61487
(dp61488
g52643
I101
sg52644
VNDFIP1 gene
p61489
sg52646
I11
sg52674
g12
sg52649
I2
sa(dp61490
g52643
I227
sg52644
VPLCL1 gene
p61491
sg52646
I10
sg52674
g12
sg52649
I2
sa(dp61492
g52643
I598
sg52644
VGCKR
p61493
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp61494
g52643
I607
sg52644
VJAZF1
p61495
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp61496
g52643
I381
sg52644
g61483
sg52646
I15
sg52674
VP05113
p61497
sg52649
I2
sasg52640
(lp61498
(dp61499
g52643
I428
sg52644
VEoE
p61500
sg52646
I3
sg52647
VC0341106
p61501
sg52649
I1
sa(dp61502
g52643
I762
sg52644
Vmetabolic disease
p61503
sg52646
I17
sg52647
VC0025517
p61504
sg52649
I2
sa(dp61505
g52643
I784
sg52644
Vdiabetes
p61506
sg52646
I8
sg52647
VC0011849
p61507
sg52649
I1
sa(dp61508
g52643
I553
sg52644
Veosinophilia
p61509
sg52646
I12
sg52647
VC0014457
p61510
sg52649
I1
sa(dp61511
g52643
I267
sg52644
Vspeech disorder
p61512
sg52646
I15
sg52647
VC0037822
p61513
sg52649
I2
sa(dp61514
g52643
I540
sg52644
Vallergy
p61515
sg52646
I7
sg52647
VC0020517
p61516
sg52649
I1
sa(dp61517
g52643
I117
sg52644
Vmental retardation
p61518
sg52646
I18
sg52647
VC0025362
p61519
sg52649
I2
sa(dp61520
g52643
I618
sg52644
Vallergic rhinitis
p61521
sg52646
I17
sg52647
VC2607914
p61522
sg52649
I2
sa(dp61523
g52643
I402
sg52644
VEosinophilic Esophagitis
p61524
sg52646
I24
sg52647
VC0341106
p61525
sg52649
I2
sa(dp61526
g52643
I532
sg52644
g61484
sg52646
I6
sg52647
VC0004096
p61527
sg52649
I1
sasa(dp61528
g135
(dp61529
(VMAX = myc-associated factor X
p61530
Vhypoxia
p61531
tp61532
I00
ssg52636
V177Lu-DOTATATE = lutetium octreotate; ACO = aconitase; Ad = adenine; AD = autosomal dominant; ATRX = ATRX chromatin remodeler; ccRCC = clear cell renal cell carcinoma; c-MYC = MYC proto oncognene; CoA = coenzyme A; COMT = catechol-O-methyl transferase; CPE = carboxypeptidase E; CS = citrate synthase; CT = computed tomography; DH = pyruvate dehydrogenase; DOTATATE = DOTA-octreotate; EGLN1/2 = egl-9 family hypoxia inducible factor 1/2; EGLN2/PHD1 = egl-9 family hypoxia inducible factor 2; elF-4E = eukaryotic initiation factor 4E; EMT = epithelial-to-mesenchymal transition; EPAS1/HIF2A = endothelial PAS domain protein 2/hypoxia-inducible factor 2Alfa; ERK = extracellular signal-regulated kinase; FH = fumarate hydroxylase; GSH = glutathione; H3F3A = histone 3.3 encoding gene; HIFs = Hypoxia-inducible factors; HIF-Alfa = hypoxia-inducible factor alpha; HNPGLs = head and neck paragangliomas; HRAS = HRas protooncogene; IDH = isocitrate dehydrogenase; IGF-1R = growth factor 1 receptor; KIF1B = kinesin family member 1B; MAX = myc-associated factor X; MDH2 = malate dehydrogenase; MN = metanephrine; MRI = magnetic resonance imaging; mTORC1 = mammalian target of rapamycin complex 1; MTY = methoxytyramine; NAd = nicotinamide adenine dinucleotide; NETs = neuroendocrine tumors; NF1 = neurofibromin 1; NMN = normetanephrine; OPLS-DA = orthogonal partial least square discriminant analysis; PFS = progression free survival; PHD = prolyl hydroxylase domain protein; PPGLs = Pheochromocytoma and Paragangliomas; PRRT = peptide receptor radionuclide therapy; Pvhl = von Hippel-Lindau protein; Raptor = regulatory associated protein of mTOR; RAS = rat sarcoma oncogene; RET = rearranged during transfection proto-oncogene; ROS = reactive oxygen species; S6K = S6 kinase; SDH = succinate dehydrogenase; SDHA, -B, -C, -D, = succinate dehydrogenase subunits A, B, C, D; SDHAF2 = succinate dehydrogenase complex assembly factor 2; SDHB, C, D = succinate dehydrogenase subunits B, C, D; SDHx = succinate dehydrogenase subunits; SSTRs = somatostatin receptors; SUCLG = succinyl-CoA synthase; TERRA = Telomeric Repeat-containing RNA; TET = ten-eleven-translocation methylcytosine dioxygenase; TMEM127 = transmembrane protein 127; VEGF = vascular endothelial growth factor; VHL = von Hippel-Lindau; Alfa-KGDH = alpha-ketoglutarate dehydrogenase.
p61533
sg52638
(lp61534
(dp61535
g52643
I1876
sg52644
Vsuccinate dehydrogenase complex assembly factor 2
p61536
sg52646
I49
sg52674
VP49366
p61537
sg52649
I6
sa(dp61538
g52643
I1927
sg52644
VSDHB
p61539
sg52646
I4
sg52674
VP21912
p61540
sg52649
I1
sa(dp61541
g52643
I1771
sg52644
VSDH
p61542
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp61543
g52643
I2023
sg52644
VSSTRs = somatostatin receptors
p61544
sg52646
I30
sg52674
VP61278
p61545
sg52649
I4
sa(dp61546
g52643
I438
sg52644
VEGLN2
p61547
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp61548
g52643
I2266
sg52644
VVHL
p61549
sg52646
I3
sg52674
VP40337
p61550
sg52649
I1
sa(dp61551
g52643
I1802
sg52644
VSDHA
p61552
sg52646
I4
sg52674
VP31040
p61553
sg52649
I1
sa(dp61554
g52643
I1760
sg52644
VS6 kinase
p61555
sg52646
I9
sg52674
VP33981
p61556
sg52649
I2
sa(dp61557
g52643
I578
sg52644
VEPAS1
p61558
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp61559
g52643
I1434
sg52644
Vprolyl hydroxylase domain protein
p61560
sg52646
I33
sg52674
VP13674
p61561
sg52649
I4
sa(dp61562
g52643
I2303
sg52644
Valpha-ketoglutarate dehydrogenase
p61563
sg52646
I33
sg52674
VP49366
p61564
sg52649
I2
sa(dp61565
g52643
I464
sg52644
Vhypoxia inducible factor 2
p61566
sg52646
I26
sg52674
g12
sg52649
I4
sa(dp61567
g52643
I1140
sg52644
VmTOR
p61568
sg52646
I4
sg52674
VP42345
p61569
sg52649
I1
sa(dp61570
g52643
I1754
sg52644
VS6K
p61571
sg52646
I3
sg52674
VP62753
p61572
sg52649
I1
sa(dp61573
g52643
I592
sg52644
Vendothelial PAS domain protein 2
p61574
sg52646
I32
sg52674
g12
sg52649
I5
sa(dp61575
g52643
I492
sg52644
VelF
p61576
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp61577
g52643
I584
sg52644
VHIF2A
p61578
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp61579
g52643
I2063
sg52644
Vsuccinyl-CoA synthase
p61580
sg52646
I21
sg52674
g12
sg52649
I2
sa(dp61581
g52643
I231
sg52644
VO-methyl transferase
p61582
sg52646
I20
sg52674
VP31947
p61583
sg52649
I2
sa(dp61584
g52643
I958
sg52644
VIGF-1R = growth factor 1 receptor
p61585
sg52646
I33
sg52674
g12
sg52649
I6
sa(dp61586
g52643
I1777
sg52644
Vsuccinate dehydrogenase
p61587
sg52646
I23
sg52674
VP49366
p61588
sg52649
I2
sa(dp61589
g52643
I926
sg52644
VIDH = isocitrate dehydrogenase
p61590
sg52646
I30
sg52674
VP48735
p61591
sg52649
I4
sa(dp61592
g52643
I748
sg52644
VH3F3A
p61593
sg52646
I5
sg52674
VP84243
p61594
sg52649
I1
sa(dp61595
g52643
I900
sg52644
VRAS
p61596
sg52646
I3
sg52674
VP01116
p61597
sg52649
I1
sa(dp61598
g52643
I1058
sg52644
VMDH2 = malate dehydrogenase
p61599
sg52646
I27
sg52674
VP49366
p61600
sg52649
I4
sa(dp61601
g52643
I385
sg52644
VEGLN1/2
p61602
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61603
g52643
I253
sg52644
VCPE = carboxypeptidase E
p61604
sg52646
I24
sg52674
VP16870
p61605
sg52649
I4
sa(dp61606
g52643
I1001
sg52644
Vkinesin
p61607
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61608
g52643
I756
sg52644
Vhistone 3.3 encoding gene
p61609
sg52646
I25
sg52674
VP62805
p61610
sg52649
I4
sa(dp61611
g52643
I625
sg52644
Vhypoxia-inducible factor 2Alfa
p61612
sg52646
I30
sg52674
g12
sg52649
I3
sa(dp61613
g52643
I1648
sg52644
Vrat sarcoma oncogene
p61614
sg52646
I20
sg52674
VP35125
p61615
sg52649
I3
sa(dp61616
g52643
I1670
sg52644
VRET
p61617
sg52646
I3
sg52674
VP07949
p61618
sg52649
I1
sa(dp61619
g52643
I657
sg52644
VERK
p61620
sg52646
I3
sg52674
VP29323
p61621
sg52649
I1
sa(dp61622
g52643
I1027
sg52644
g61530
sg52646
I29
sg52674
VP61244
p61623
sg52649
I5
sa(dp61624
g52643
I408
sg52644
Vhypoxia inducible factor 1/2
p61625
sg52646
I28
sg52674
g12
sg52649
I4
sa(dp61626
g52643
I2230
sg52644
Vvascular endothelial growth factor
p61627
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp61628
g52643
I444
sg52644
VPHD1
p61629
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp61630
(dp61631
g52643
I1771
sg52644
VSDH
p61632
sg52646
I3
sg52647
VC0018946
p61633
sg52649
I1
sa(dp61634
g52643
I1261
sg52644
Vneuroendocrine tumors
p61635
sg52646
I21
sg52647
VC0206754
p61636
sg52649
I2
sa(dp61637
g52643
I1477
sg52644
VPheochromocytoma
p61638
sg52646
I16
sg52647
VC0031511
p61639
sg52649
I1
sa(dp61640
g52643
I1648
sg52644
Vrat sarcoma
p61641
sg52646
I11
sg52647
VC1882848
p61642
sg52649
I2
sa(dp61643
g52643
I408
sg52644
Vhypoxia
p61644
sg52646
I7
sg52647
VC0242184
p61645
sg52649
I1
sa(dp61646
g52643
I790
sg52644
VHypoxia
p61647
sg52646
I7
sg52647
VC0242184
p61648
sg52649
I1
sa(dp61649
g52643
I1213
sg52644
VNAd
p61650
sg52646
I3
sg52647
VC1850380
p61651
sg52649
I1
sa(dp61652
g52643
I94
sg52644
VATRX
p61653
sg52646
I4
sg52647
VC1845055
p61654
sg52649
I1
sa(dp61655
g52643
I197
sg52644
VCoA
p61656
sg52646
I3
sg52647
VC2678439
p61657
sg52649
I1
sa(dp61658
g52643
I1498
sg52644
VParagangliomas
p61659
sg52646
I14
sg52647
VC0030421
p61660
sg52649
I1
sa(dp61661
g52643
I883
sg52644
Vparagangliomas
p61662
sg52646
I14
sg52647
VC0030421
p61663
sg52649
I1
sa(dp61664
g52643
I408
sg52644
Vhypoxia
p61665
sg52646
I7
sg52647
VC0242184
p61666
sg52649
I1
sa(dp61667
g52643
I1284
sg52644
VNF1
p61668
sg52646
I3
sg52647
VC0027831
p61669
sg52649
I1
sa(dp61670
g52643
I408
sg52644
Vhypoxia
p61671
sg52646
I7
sg52647
VC0242184
p61672
sg52649
I1
sa(dp61673
g52643
I2266
sg52644
VVHL
p61674
sg52646
I3
sg52647
VC0019562
p61675
sg52649
I1
sa(dp61676
g52643
I729
sg52644
VGSH
p61677
sg52646
I3
sg52647
VC1260386
p61678
sg52649
I1
sa(dp61679
g52643
I135
sg52644
Vclear cell renal cell carcinoma
p61680
sg52646
I31
sg52647
VC0279702
p61681
sg52649
I5
sa(dp61682
g52643
I566
sg52644
Vtransition
p61683
sg52646
I10
sg52647
VC0599156
p61684
sg52649
I1
sa(dp61685
g52643
I94
sg52644
VATRX
p61686
sg52646
I4
sg52647
VC1845055
p61687
sg52649
I1
sa(dp61688
g52643
I2144
sg52644
Vtranslocation
p61689
sg52646
I13
sg52647
VC0040715
p61690
sg52649
I1
sa(dp61691
g52643
I197
sg52644
VCoA
p61692
sg52646
I3
sg52647
VC2678439
p61693
sg52649
I1
sa(dp61694
g52643
I408
sg52644
g61531
sg52646
I7
sg52647
VC0242184
p61695
sg52649
I1
sasa(dp61696
g52636
VWe report a case of MAX-associated renal cell carcinoma and confirm the role of TMEM127 mutations with renal cell carcinoma predisposition.
p61697
sg52638
(lp61698
sg52640
(lp61699
(dp61700
g52643
I35
sg52644
Vrenal cell carcinoma
p61701
sg52646
I20
sg52647
VC0007134
p61702
sg52649
I3
sa(dp61703
g52643
I35
sg52644
Vrenal cell carcinoma
p61704
sg52646
I20
sg52647
VC0007134
p61705
sg52649
I3
sasa(dp61706
g135
(dp61707
(Vvon Hippel-Lindau
p61708
VPGLs
p61709
tp61710
I00
ssg52636
VAlterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.
p61711
sg52638
(lp61712
(dp61713
g52643
I40
sg52644
Vsuccinate dehydrogenase
p61714
sg52646
I23
sg52674
VP49366
p61715
sg52649
I2
sa(dp61716
g52643
I34
sg52644
VVHL
p61717
sg52646
I3
sg52674
VP40337
p61718
sg52649
I1
sa(dp61719
g52643
I76
sg52644
VTMEM127
p61720
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61721
g52643
I15
sg52644
g61708
sg52646
I17
sg52674
VP40337
p61722
sg52649
I2
sasg52640
(lp61723
(dp61724
g52643
I129
sg52644
Vpheochromocytomas
p61725
sg52646
I17
sg52647
VC0031511
p61726
sg52649
I1
sa(dp61727
g52643
I15
sg52644
Vvon Hippel-Lindau
p61728
sg52646
I17
sg52647
VC0019562
p61729
sg52649
I2
sa(dp61730
g52643
I148
sg52644
VPCs
p61731
sg52646
I3
sg52647
VC1864389
p61732
sg52649
I1
sa(dp61733
g52643
I157
sg52644
Vparagangliomas
p61734
sg52646
I14
sg52647
VC0030421
p61735
sg52649
I1
sa(dp61736
g52643
I34
sg52644
VVHL
p61737
sg52646
I3
sg52647
VC0019562
p61738
sg52649
I1
sa(dp61739
g52643
I227
sg52644
Vrenal neoplasms
p61740
sg52646
I15
sg52647
VC0022665
p61741
sg52649
I2
sa(dp61742
g52643
I173
sg52644
g61709
sg52646
I4
sg52647
VC0030421
p61743
sg52649
I1
sasa(dp61744
g135
(dp61745
(VSDHB
p61746
VRCCs
p61747
tp61748
I00
ssg52636
VImmunohistochemistry for SDHB and mutation analysis for TMEM127 was performed, in addition to analysis of The Cancer Genome Atlas datasets for SDHX and TMEM127 mutated renal cell carcinomas (RCCs).
p61749
sg52638
(lp61750
(dp61751
g52643
I25
sg52644
g61746
sg52646
I4
sg52674
VP21912
p61752
sg52649
I1
sa(dp61753
g52643
I56
sg52644
VTMEM127
p61754
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp61755
(dp61756
g52643
I110
sg52644
VCancer
p61757
sg52646
I6
sg52647
VC0006826
p61758
sg52649
I1
sa(dp61759
g52643
I168
sg52644
Vrenal cell carcinomas
p61760
sg52646
I21
sg52647
VC0007134
p61761
sg52649
I3
sa(dp61762
g52643
I191
sg52644
g61747
sg52646
I4
sg52647
VC0007134
p61763
sg52649
I1
sasa(dp61764
g135
(dp61765
(VSDHA
p61766
Vparagangliomas
p61767
tp61768
I00
ssg52636
VThe expanding etiology for hereditary pheochromocytomas and paragangliomas has recently included SDHA, TMEM127, MAX, and SDHAF2 as susceptibility genes.
p61769
sg52638
(lp61770
(dp61771
g52643
I103
sg52644
VTMEM127
p61772
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61773
g52643
I121
sg52644
VSDHAF2
p61774
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp61775
g52643
I97
sg52644
g61766
sg52646
I4
sg52674
VP31040
p61776
sg52649
I1
sasg52640
(lp61777
(dp61778
g52643
I38
sg52644
Vpheochromocytomas
p61779
sg52646
I17
sg52647
VC0031511
p61780
sg52649
I1
sa(dp61781
g52643
I60
sg52644
g61767
sg52646
I14
sg52647
VC0030421
p61782
sg52649
I1
sasa(dp61783
g135
(dp61784
(VSDHA
p61785
VPheochromocytoma
p61786
tp61787
I00
ssg52636
VThis study analyzed the prospective, longitudinally followed up European-American-Asian Pheochromocytoma-Paraganglioma Registry for prevalence of SDHA, TMEM127, MAX, and SDHAF2 germline mutation carriers from 1993 to 2016.
p61788
sg52638
(lp61789
(dp61790
g52643
I146
sg52644
g61785
sg52646
I4
sg52674
VP31040
p61791
sg52649
I1
sa(dp61792
g52643
I170
sg52644
VSDHAF2
p61793
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp61794
g52643
I152
sg52644
VTMEM127
p61795
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp61796
(dp61797
g52643
I177
sg52644
Vgermline mutation
p61798
sg52646
I17
sg52647
VC1705427
p61799
sg52649
I2
sa(dp61800
g52643
I105
sg52644
VParaganglioma
p61801
sg52646
I13
sg52647
VC0030421
p61802
sg52649
I1
sa(dp61803
g52643
I88
sg52644
g61786
sg52646
I16
sg52647
VC0031511
p61804
sg52649
I1
sasa(dp61805
g52636
VOf 972 unrelated registrants without mutations in the classic pheochromocytoma- and paraganglioma-associated genes (632 female [65.0%] and 340 male [35.0%]; age range, 8-80; mean [SD] age, 41.0 [13.3] years), 58 (6.0%) carried germline mutations of interest, including 29 SDHA, 20 TMEM127, 8 MAX, and 1 SDHAF2.
p61806
sg52638
(lp61807
sg52640
(lp61808
(dp61809
g52643
I62
sg52644
Vpheochromocytoma
p61810
sg52646
I16
sg52647
VC0031511
p61811
sg52649
I1
sa(dp61812
g52643
I84
sg52644
Vparaganglioma
p61813
sg52646
I13
sg52647
VC0030421
p61814
sg52649
I1
sasa(dp61815
g52636
VNewly uncovered are 7 of 63 (11%) malignant pheochromocytomas and paragangliomas in SDHA and TMEM127 disease.
p61816
sg52638
(lp61817
sg52640
(lp61818
(dp61819
g52643
I44
sg52644
Vpheochromocytomas
p61820
sg52646
I17
sg52647
VC0031511
p61821
sg52649
I1
sa(dp61822
g52643
I66
sg52644
Vparagangliomas
p61823
sg52646
I14
sg52647
VC0030421
p61824
sg52649
I1
sasa(dp61825
g135
(dp61826
(VSDHA
p61827
Vpheochromocytoma
p61828
tp61829
I00
ssg52636
VThe SDHA, TMEM127, MAX, and SDHAF2 genes may contribute to hereditary pheochromocytoma and paraganglioma.
p61830
sg52638
(lp61831
(dp61832
g52643
I4
sg52644
g61827
sg52646
I4
sg52674
VP31040
p61833
sg52649
I1
sa(dp61834
g52643
I28
sg52644
VSDHAF2 genes
p61835
sg52646
I12
sg52674
g12
sg52649
I2
sa(dp61836
g52643
I10
sg52644
VTMEM127
p61837
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp61838
(dp61839
g52643
I91
sg52644
Vparaganglioma
p61840
sg52646
I13
sg52647
VC0030421
p61841
sg52649
I1
sa(dp61842
g52643
I70
sg52644
g61828
sg52646
I16
sg52647
VC0031511
p61843
sg52649
I1
sasa(dp61844
g135
(dp61845
(Vsuccinate dehydrogenase
p61846
Vneurofibromatosis type 1
p61847
tp61848
I00
ssg52636
V3-MT = 3-methoxytyramine; EPAS1 = endothelial pas domain protein 1; FH = fumarate hydratase; HIF2A = hypoxia inducible factor type 2A; MEN2 = multiple endocrine neoplasia type 2; NF1 = neurofibromatosis type 1; PNMT = phenylethanolamine N-methyltransferase; PPGL = pheochromocytoma and paraganglioma; RET = rearranged during transfection; SDH = succinate dehydrogenase; SDHAF2 = succinate dehydrogenase complex assembly factor 2; TCA = tricarboxylic acid; TH = tyrosine hydroxylase; TMEM127 = transmembrane protein 127; VHL = von Hippel-Lindau.
p61849
sg52638
(lp61850
(dp61851
g52643
I370
sg52644
VSDHAF2
p61852
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp61853
g52643
I93
sg52644
VHIF2A
p61854
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp61855
g52643
I101
sg52644
Vhypoxia inducible factor type 2A
p61856
sg52646
I32
sg52674
g12
sg52649
I5
sa(dp61857
g52643
I483
sg52644
VTMEM127
p61858
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp61859
g52643
I456
sg52644
VTH = tyrosine hydroxylase
p61860
sg52646
I25
sg52674
VP07101
p61861
sg52649
I4
sa(dp61862
g52643
I339
sg52644
VSDH
p61863
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp61864
g52643
I345
sg52644
Vsuccinate dehydrogenase
p61865
sg52646
I23
sg52674
VP49366
p61866
sg52649
I2
sa(dp61867
g52643
I345
sg52644
g61846
sg52646
I23
sg52674
VP49366
p61868
sg52649
I2
sasg52640
(lp61869
(dp61870
g52643
I265
sg52644
Vpheochromocytoma
p61871
sg52646
I16
sg52647
VC0031511
p61872
sg52649
I1
sa(dp61873
g52643
I286
sg52644
Vparaganglioma
p61874
sg52646
I13
sg52647
VC0030421
p61875
sg52649
I1
sa(dp61876
g52643
I179
sg52644
VNF1
p61877
sg52646
I3
sg52647
VC0027831
p61878
sg52649
I1
sa(dp61879
g52643
I520
sg52644
VVHL
p61880
sg52646
I3
sg52647
VC0019562
p61881
sg52649
I1
sa(dp61882
g52643
I142
sg52644
Vmultiple endocrine neoplasia type 2
p61883
sg52646
I35
sg52647
VC0025268
p61884
sg52649
I5
sa(dp61885
g52643
I101
sg52644
Vhypoxia
p61886
sg52646
I7
sg52647
VC0242184
p61887
sg52649
I1
sa(dp61888
g52643
I339
sg52644
VSDH
p61889
sg52646
I3
sg52647
VC0018946
p61890
sg52649
I1
sa(dp61891
g52643
I185
sg52644
g61847
sg52646
I24
sg52647
VC0027831
p61892
sg52649
I3
sasa(dp61893
g52636
VThis study assessed the effects of leukemia-related protein 16 (LRP16) on the regulation of pancreatic functions in mouse insulinoma (MIN6) cells.
p61894
sg52638
(lp61895
(dp61896
g52643
I35
sg52644
Vleukemia-related protein 16
p61897
sg52646
I27
sg52674
g12
sg52649
I3
sa(dp61898
g52643
I64
sg52644
VLRP16
p61899
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61900
(dp61901
g52643
I35
sg52644
Vleukemia
p61902
sg52646
I8
sg52647
VC0023418
p61903
sg52649
I1
sa(dp61904
g52643
I116
sg52644
Vmouse insulinoma
p61905
sg52646
I16
sg52647
VC1522248
p61906
sg52649
I2
sasa(dp61907
g52636
VOur recent studies have shown that a selective ABHD6 inhibitor WWL70 has anti-inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis.
p61908
sg52638
(lp61909
(dp61910
g52643
I47
sg52644
VABHD6
p61911
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61912
(dp61913
g52643
I166
sg52644
Vmultiple sclerosis
p61914
sg52646
I18
sg52647
VC0026769
p61915
sg52649
I2
sasa(dp61916
g52636
VIn this study, we investigated the role of targeting ABHD6 in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
p61917
sg52638
(lp61918
(dp61919
g52643
I53
sg52644
VABHD6
p61920
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp61921
(dp61922
g52643
I105
sg52644
VEAE
p61923
sg52646
I3
sg52647
VC0014070
p61924
sg52649
I1
sa(dp61925
g52643
I86
sg52644
Vencephalomyelitis
p61926
sg52646
I17
sg52647
VC0014070
p61927
sg52649
I1
sa(dp61928
g52643
I150
sg52644
VMS
p61929
sg52646
I2
sg52647
VC0026769
p61930
sg52649
I1
sa(dp61931
g52643
I130
sg52644
Vmultiple sclerosis
p61932
sg52646
I18
sg52647
VC0026769
p61933
sg52649
I2
sa(dp61934
g52643
I75
sg52644
Vautoimmune
p61935
sg52646
I10
sg52647
VC0443146
p61936
sg52649
I1
sasa(dp61937
g52636
VExpression of clusterin correlates with tumor progression and therapeutic response in several human malignancies, including breast cancer.
p61938
sg52638
(lp61939
sg52640
(lp61940
(dp61941
g52643
I100
sg52644
Vmalignancies
p61942
sg52646
I12
sg52647
VC0006826
p61943
sg52649
I1
sa(dp61944
g52643
I40
sg52644
Vtumor progression
p61945
sg52646
I17
sg52647
VC0178874
p61946
sg52649
I2
sa(dp61947
g52643
I124
sg52644
Vbreast cancer
p61948
sg52646
I13
sg52647
VC0678222
p61949
sg52649
I2
sasa(dp61950
g52636
VThe objective of this explorative study was to determine whether clusterin expression in breast cancer correlated with clinical pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy (NAC).
p61951
sg52638
(lp61952
sg52640
(lp61953
(dp61954
g52643
I89
sg52644
Vbreast cancer
p61955
sg52646
I13
sg52647
VC0678222
p61956
sg52649
I2
sasa(dp61957
g135
(dp61958
(Vclusterin
p61959
Vbreast cancers
p61960
tp61961
I00
ssg52636
VWe determined the clusterin expression pattern in 72 triple negative breast cancers (TNBC) treated with NAC before surgery.
p61962
sg52638
(lp61963
(dp61964
g52643
I18
sg52644
g61959
sg52646
I9
sg52674
VP10909
p61965
sg52649
I1
sasg52640
(lp61966
(dp61967
g52643
I69
sg52644
g61960
sg52646
I14
sg52647
VC0006142
p61968
sg52649
I2
sasa(dp61969
g135
(dp61970
(VClusterin
p61971
Vbreast cancer
p61972
tp61973
I00
ssg52636
VClusterin was present at higher levels in both fractions of patients with early and intermediate stages of breast cancer.
p61974
sg52638
(lp61975
(dp61976
g52643
I0
sg52644
g61971
sg52646
I9
sg52674
VP10909
p61977
sg52649
I1
sasg52640
(lp61978
(dp61979
g52643
I107
sg52644
g61972
sg52646
I13
sg52647
VC0678222
p61980
sg52649
I2
sasa(dp61981
g135
(dp61982
(VPEG-SMR-Clu peptide
p61983
Vbreast cancer
p61984
tp61985
I00
ssg52636
VDiscovery and development of a novel anticancer PEG-SMR-Clu peptide to prevent breast cancer metastasis.
p61986
sg52638
(lp61987
(dp61988
g52643
I48
sg52644
g61983
sg52646
I19
sg52674
VP09466
p61989
sg52649
I2
sasg52640
(lp61990
(dp61991
g52643
I93
sg52644
Vmetastasis
p61992
sg52646
I10
sg52647
VC0027627
p61993
sg52649
I1
sa(dp61994
g52643
I79
sg52644
g61984
sg52646
I13
sg52647
VC0678222
p61995
sg52649
I2
sasa(dp61996
g135
(dp61997
(VClu
p61998
Vbreast cancer
p61999
tp62000
I00
ssg52636
VPEG-SMRwt-Clu and PEG-SMRwt peptides inhibited the growth of both of MCF-7 (estrogen responsive, ER+) and MDA-MD-231 (estrogen non-responsive, ER-) human breast cancer cells in a dose and time-dependent manner, without inducing cytotoxic effects.
p62001
sg52638
(lp62002
(dp62003
g52643
I18
sg52644
VPEG-SMRwt peptides
p62004
sg52646
I18
sg52674
VP09466
p62005
sg52649
I2
sa(dp62006
g52643
I0
sg52644
VPEG
p62007
sg52646
I3
sg52674
VP09466
p62008
sg52649
I1
sa(dp62009
g52643
I10
sg52644
g61998
sg52646
I3
sg52674
VP10909
p62010
sg52649
I1
sasg52640
(lp62011
(dp62012
g52643
I154
sg52644
g61999
sg52646
I13
sg52647
VC0678222
p62013
sg52649
I2
sasa(dp62014
g135
(dp62015
(VPEG-SMRwt-CLU peptides
p62016
Vbreast cancer
p62017
tp62018
I00
ssg52636
VPEG-SMRwt-CLU peptides inhibited the growth of human breast cancer cells and blocked tumor exosome release in vitro.
p62019
sg52638
(lp62020
(dp62021
g52643
I0
sg52644
g62016
sg52646
I22
sg52674
VP09466
p62022
sg52649
I2
sasg52640
(lp62023
(dp62024
g52643
I53
sg52644
g62017
sg52646
I13
sg52647
VC0678222
p62025
sg52649
I2
sa(dp62026
g52643
I85
sg52644
Vtumor
p62027
sg52646
I5
sg52647
VC0027651
p62028
sg52649
I1
sasa(dp62029
g135
(dp62030
(VCD68
p62031
Vbreast cancer
p62032
tp62033
I00
ssg52636
VClinically, breast cancer patients possess sCLU expression only in mature CD68(+) macrophages but not in immature CD33(+) immunosuppressive myeloid cells infiltrating the tumors.
p62034
sg52638
(lp62035
(dp62036
g52643
I74
sg52644
g62031
sg52646
I4
sg52674
VP34810
p62037
sg52649
I1
sasg52640
(lp62038
(dp62039
g52643
I35
sg52644
Vpossess
p62040
sg52646
I7
sg52647
VC0850310
p62041
sg52649
I1
sa(dp62042
g52643
I154
sg52644
Vinfiltrating
p62043
sg52646
I12
sg52647
VC0332448
p62044
sg52649
I1
sa(dp62045
g52643
I12
sg52644
g62032
sg52646
I13
sg52647
VC0678222
p62046
sg52649
I2
sa(dp62047
g52643
I171
sg52644
Vtumors
p62048
sg52646
I6
sg52647
VC0027651
p62049
sg52649
I1
sasa(dp62050
g135
(dp62051
(Vannexin A1
p62052
Vbreast cancer
p62053
tp62054
I00
ssg52636
VImmunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and Alfa1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.
p62055
sg52638
(lp62056
(dp62057
g52643
I224
sg52644
Vceruloplasmin
p62058
sg52646
I13
sg52674
VP00450
p62059
sg52649
I1
sa(dp62060
g52643
I208
sg52644
VCO9
p62061
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp62062
g52643
I173
sg52644
VSAP3
p62063
sg52646
I4
sg52674
VP17900
p62064
sg52649
I1
sa(dp62065
g52643
I134
sg52644
Vretinol-binding protein 4
p62066
sg52646
I25
sg52674
VP02753
p62067
sg52649
I3
sa(dp62068
g52643
I213
sg52644
Vclusterin
p62069
sg52646
I9
sg52674
VP10909
p62070
sg52649
I1
sa(dp62071
g52643
I243
sg52644
VAlfa1-antitrypsin
p62072
sg52646
I17
sg52674
g12
sg52649
I1
sa(dp62073
g52643
I185
sg52644
Vgelsolin
p62074
sg52646
I8
sg52674
VP06396
p62075
sg52649
I1
sa(dp62076
g52643
I195
sg52644
Vkininogen 1
p62077
sg52646
I11
sg52674
VP01042
p62078
sg52649
I2
sa(dp62079
g52643
I102
sg52644
Vzinc-alpha2-glycoprotein
p62080
sg52646
I24
sg52674
VP36222
p62081
sg52649
I1
sa(dp62082
g52643
I161
sg52644
g62052
sg52646
I10
sg52674
VP04083
p62083
sg52649
I2
sasg52640
(lp62084
(dp62085
g52643
I326
sg52644
g62053
sg52646
I13
sg52647
VC0678222
p62086
sg52649
I2
sasa(dp62087
g52636
VExportin 4 (XPO4) is a novel identified candidate tumour-suppressor gene involved in the pathogenesis of hepatocellular carcinoma (HCC).
p62088
sg52638
(lp62089
(dp62090
g52643
I12
sg52644
VXPO4
p62091
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62092
g52643
I0
sg52644
VExportin 4
p62093
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp62094
(dp62095
g52643
I105
sg52644
Vhepatocellular carcinoma
p62096
sg52646
I24
sg52647
VC2239176
p62097
sg52649
I2
sa(dp62098
g52643
I131
sg52644
VHCC
p62099
sg52646
I3
sg52647
VC2239176
p62100
sg52649
I1
sa(dp62101
g52643
I89
sg52644
Vpathogenesis
p62102
sg52646
I12
sg52647
VC0699748
p62103
sg52649
I1
sa(dp62104
g52643
I50
sg52644
Vtumour
p62105
sg52646
I6
sg52647
VC0027651
p62106
sg52649
I1
sasa(dp62107
g135
(dp62108
(VTGFBeta
p62109
VHCC
p62110
tp62111
I00
ssg52636
VTo evaluate potential biomarkers in HCC, we employed multiple methods in this study, including qPCR, immunostaining methods and tissue microarrays (TMAs), as well as histological and pathological analysis, to assess TGFBeta, XPO4, elF5A2 and ANGPTL4 in cancerous and paracancerous liver tissues from 280 patients suffering from liver cancer.
p62112
sg52638
(lp62113
(dp62114
g52643
I225
sg52644
VXPO4
p62115
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62116
g52643
I216
sg52644
g62109
sg52646
I7
sg52674
VP01137
p62117
sg52649
I1
sa(dp62118
g52643
I242
sg52644
VANGPTL4
p62119
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp62120
(dp62121
g52643
I313
sg52644
Vsuffering
p62122
sg52646
I9
sg52647
VC0683278
p62123
sg52649
I1
sa(dp62124
g52643
I328
sg52644
Vliver cancer
p62125
sg52646
I12
sg52647
VC0345904
p62126
sg52649
I2
sa(dp62127
g52643
I36
sg52644
g62110
sg52646
I3
sg52647
VC2239176
p62128
sg52649
I1
sasa(dp62129
g52636
VXPO4 in cancerous liver tissue and TGFBeta1 in paracancerous liver tissue were positively correlated with tumor differentiation.
p62130
sg52638
(lp62131
(dp62132
g52643
I0
sg52644
VXPO4
p62133
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp62134
(dp62135
g52643
I106
sg52644
Vtumor
p62136
sg52646
I5
sg52647
VC0027651
p62137
sg52649
I1
sasa(dp62138
g52636
VAdditionally, higher levels of XPO4 in cancerous liver tissue suggested that the patient would have a better prognosis and survival rate.
p62139
sg52638
(lp62140
(dp62141
g52643
I31
sg52644
VXPO4
p62142
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp62143
sa(dp62144
g52636
VHowever, higher production of XPO4 in paracancerous liver tissue suggested a worse prognosis.
p62145
sg52638
(lp62146
(dp62147
g52643
I30
sg52644
VXPO4
p62148
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp62149
sa(dp62150
g135
(dp62151
(VTGFBeta1
p62152
Vliver cancer
p62153
tp62154
I00
ssg52636
VAll the results above provide new insights into better understanding biological indicators, such as XPO4, TGFBeta1, ANGPTL4 and elF5A2, in the prediction and evaluation of liver cancer, as well as signaling pathways in the control of liver cancer.
p62155
sg52638
(lp62156
(dp62157
g52643
I106
sg52644
g62152
sg52646
I8
sg52674
VP01137
p62158
sg52649
I1
sa(dp62159
g52643
I116
sg52644
VANGPTL4
p62160
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp62161
g52643
I100
sg52644
VXPO4
p62162
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp62163
(dp62164
g52643
I172
sg52644
Vliver cancer
p62165
sg52646
I12
sg52647
VC0345904
p62166
sg52649
I2
sa(dp62167
g52643
I172
sg52644
g62153
sg52646
I12
sg52647
VC0345904
p62168
sg52649
I2
sasa(dp62169
g135
(dp62170
(VTGFBeta1
p62171
Vliver cancer
p62172
tp62173
I00
ssg52636
VXPO4 and TGFBeta1 may serve as useful markers to evaluate the size and prognosis of liver cancer.
p62174
sg52638
(lp62175
(dp62176
g52643
I9
sg52644
g62171
sg52646
I8
sg52674
VP01137
p62177
sg52649
I1
sa(dp62178
g52643
I0
sg52644
VXPO4
p62179
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp62180
(dp62181
g52643
I84
sg52644
g62172
sg52646
I12
sg52647
VC0345904
p62182
sg52649
I2
sasa(dp62183
g52636
VExportin 4 (XPO4) is a recently-discovered candidate tumor-suppressor gene identified in a liver cancer mouse model.
p62184
sg52638
(lp62185
(dp62186
g52643
I12
sg52644
VXPO4
p62187
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62188
g52643
I0
sg52644
VExportin 4
p62189
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp62190
(dp62191
g52643
I91
sg52644
Vliver cancer
p62192
sg52646
I12
sg52647
VC0345904
p62193
sg52649
I2
sa(dp62194
g52643
I53
sg52644
Vtumor
p62195
sg52646
I5
sg52647
VC0027651
p62196
sg52649
I1
sasa(dp62197
g52636
VTo investigate the role of XPO4 in hepatocellular carcinoma (HCC) pathogenesis, we determined XPO4 expression and its correlation to prognosis in human primary HCC.
p62198
sg52638
(lp62199
(dp62200
g52643
I27
sg52644
VXPO4
p62201
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62202
g52643
I27
sg52644
VXPO4
p62203
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp62204
(dp62205
g52643
I66
sg52644
Vpathogenesis
p62206
sg52646
I12
sg52647
VC0699748
p62207
sg52649
I1
sa(dp62208
g52643
I61
sg52644
VHCC
p62209
sg52646
I3
sg52647
VC2239176
p62210
sg52649
I1
sa(dp62211
g52643
I61
sg52644
VHCC
p62212
sg52646
I3
sg52647
VC2239176
p62213
sg52649
I1
sa(dp62214
g52643
I35
sg52644
Vhepatocellular carcinoma
p62215
sg52646
I24
sg52647
VC2239176
p62216
sg52649
I2
sasa(dp62217
g52636
VOne gene, XPO4, encodes a nuclear export protein whose substrate, EIF5A2, is amplified in human tumors, is required for proliferation of XPO4-deficient tumor cells, and promotes hepatocellular carcinoma in mice.
p62218
sg52638
(lp62219
(dp62220
g52643
I10
sg52644
VXPO4
p62221
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62222
g52643
I10
sg52644
VXPO4
p62223
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62224
g52643
I66
sg52644
VEIF5A2
p62225
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp62226
(dp62227
g52643
I120
sg52644
Vproliferation
p62228
sg52646
I13
sg52647
VC0334094
p62229
sg52649
I1
sa(dp62230
g52643
I96
sg52644
Vtumor
p62231
sg52646
I5
sg52647
VC0027651
p62232
sg52649
I1
sa(dp62233
g52643
I96
sg52644
Vtumors
p62234
sg52646
I6
sg52647
VC0027651
p62235
sg52649
I1
sa(dp62236
g52643
I178
sg52644
Vhepatocellular carcinoma
p62237
sg52646
I24
sg52647
VC1512411
p62238
sg52649
I2
sasa(dp62239
g52636
VIn a population of 159 patients on renal replacement therapy (RDT) we performed a 1-yr prospective observational study, with common parameters to indicate cardiovascular pathologies (PAS, LVMI), calcium-phosphorous metabolism (Ca, PO 4 , Ca x PO 4 ), dialytic adequacy (Kt/V, URR%), nutritional status (nPCR, Alb, K), and anemia (hemoglobin (Hb)).
p62240
sg52638
(lp62241
(dp62242
g52643
I330
sg52644
Vhemoglobin
p62243
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp62244
g52643
I276
sg52644
VURR
p62245
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp62246
g52643
I309
sg52644
VAlb
p62247
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp62248
(dp62249
g52643
I322
sg52644
Vanemia
p62250
sg52646
I6
sg52647
VC0002871
p62251
sg52649
I1
sa(dp62252
g52643
I62
sg52644
VRDT
p62253
sg52646
I3
sg52647
VC0206743
p62254
sg52649
I1
sasa(dp62255
g52636
VBased on serial mortality rates for the general population of England and Wales, significantly increased mortality was shown for cancers of the pharynx (observed (Obs) 4, expected (Exp) 0.7, standardised mortality ratio (SMR) 559, p&lt;0.05), non-malignant diseases of the respiratory system (Obs 61, Exp 43.0, SMR 142, p&lt;0.05), and non-malignant diseases of the genitourinary system (Obs 10, Exp 4.1, SMR 243, p&lt;0.05).
p62256
sg52638
(lp62257
sg52640
(lp62258
(dp62259
g52643
I350
sg52644
Vdiseases of the genitourinary system
p62260
sg52646
I36
sg52647
VC0080276
p62261
sg52649
I5
sa(dp62262
g52643
I129
sg52644
Vcancers
p62263
sg52646
I7
sg52647
VC0006826
p62264
sg52649
I1
sa(dp62265
g52643
I257
sg52644
Vdiseases of the respiratory system
p62266
sg52646
I34
sg52647
VC0035204
p62267
sg52649
I5
sasa(dp62268
g135
(dp62269
(VObs 9
p62270
Vlung cancer
p62271
tp62272
I00
ssg52636
VNon-significantly increased SMRs were shown for lung cancer (Obs 45, Exp 40.7, SMR 111) and cancer of the prostate (Obs 9, Exp 7.5, SMR 116).
p62273
sg52638
(lp62274
(dp62275
g52643
I79
sg52644
VSMR 111
p62276
sg52646
I7
sg52674
g12
sg52649
I2
sa(dp62277
g52643
I116
sg52644
g62270
sg52646
I5
sg52674
VP41159
p62278
sg52649
I2
sa(dp62279
g52643
I123
sg52644
VExp 7
p62280
sg52646
I5
sg52674
g12
sg52649
I2
sasg52640
(lp62281
(dp62282
g52643
I92
sg52644
Vcancer of the prostate
p62283
sg52646
I22
sg52647
VC0600139
p62284
sg52649
I4
sa(dp62285
g52643
I48
sg52644
g62271
sg52646
I11
sg52647
VC0684249
p62286
sg52649
I2
sasa(dp62287
g135
(dp62288
(VCHRNA5-CHRNA3-CHRNB4 genes
p62289
Vnicotine dependence
p62290
tp62291
I00
ssg52636
VIn this largest-ever GWAS meta-analysis for nicotine dependence and the largest-ever cross-ancestry GWAS meta-analysis for any smoking phenotype, we reconfirmed the well-known CHRNA5-CHRNA3-CHRNB4 genes and further yielded a novel association in the DNA methyltransferase gene DNMT3B.
p62292
sg52638
(lp62293
(dp62294
g52643
I250
sg52644
VDNA methyltransferase gene DNMT3B
p62295
sg52646
I33
sg52674
g12
sg52649
I4
sa(dp62296
g52643
I176
sg52644
g62289
sg52646
I26
sg52674
VP30532
p62297
sg52649
I2
sasg52640
(lp62298
(dp62299
g52643
I44
sg52644
g62290
sg52646
I19
sg52647
VC0028043
p62300
sg52649
I2
sasa(dp62301
g135
(dp62302
(VCHRNB4
p62303
Vnicotine dependence
p62304
tp62305
I00
ssg52636
VThe relationship of HTR4 (rs3995090), HTR2A (rs6313), GRIK5 (rs8099939), GRIN2B (rs2268132), and CHRNB4 (rs1948) gene polymorphisms and COPD, as well as the contribution of these polymorphisms to the variations in quantitative characteristics that describe respiratory function, smoking behavior, and nicotine dependence was assessed in an ethnically homogeneous Tatar population.
p62306
sg52638
(lp62307
(dp62308
g52643
I38
sg52644
VHTR2A
p62309
sg52646
I5
sg52674
VP28223
p62310
sg52649
I1
sa(dp62311
g52643
I97
sg52644
g62303
sg52646
I6
sg52674
VP30926
p62312
sg52649
I1
sa(dp62313
g52643
I73
sg52644
VGRIN2B
p62314
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp62315
g52643
I54
sg52644
VGRIK5
p62316
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62317
(dp62318
g52643
I136
sg52644
VCOPD
p62319
sg52646
I4
sg52647
VC0024117
p62320
sg52649
I1
sa(dp62321
g52643
I301
sg52644
g62304
sg52646
I19
sg52647
VC0028043
p62322
sg52649
I2
sasa(dp62323
g135
(dp62324
(VCHRNA3
p62325
Vnicotine dependence
p62326
tp62327
I00
ssg52636
VGenome-wide association studies (GWASs) have identified associations between the CHRNA5-CHRNA3-CHRNB4 gene cluster and smoking heaviness and nicotine dependence.
p62328
sg52638
(lp62329
(dp62330
g52643
I81
sg52644
VCHRNA5
p62331
sg52646
I6
sg52674
VP30532
p62332
sg52649
I1
sa(dp62333
g52643
I95
sg52644
VCHRNB4
p62334
sg52646
I6
sg52674
VP30926
p62335
sg52649
I1
sa(dp62336
g52643
I88
sg52644
g62325
sg52646
I6
sg52674
VP32297
p62337
sg52649
I1
sasg52640
(lp62338
(dp62339
g52643
I141
sg52644
g62326
sg52646
I19
sg52647
VC0028043
p62340
sg52649
I2
sasa(dp62341
g135
(dp62342
(VCHRNA5-CHRNA3-CHRNB4 gene cluster
p62343
Vnicotine dependence
p62344
tp62345
I00
ssg52636
VPolymorphisms in the CHRNA5-CHRNA3-CHRNB4 gene cluster (Chr15q25) have been robustly associated with nicotine dependence, including genome-wide studies, as well as with cognitive and neuropsychological measures.
p62346
sg52638
(lp62347
(dp62348
g52643
I21
sg52644
g62343
sg52646
I33
sg52674
VP30532
p62349
sg52649
I3
sasg52640
(lp62350
(dp62351
g52643
I101
sg52644
g62344
sg52646
I19
sg52647
VC0028043
p62352
sg52649
I2
sasa(dp62353
g135
(dp62354
(VCHRNA5-CHRNA3-CHRNB4 gene cluster
p62355
VADHD
p62356
tp62357
I00
ssg52636
VHere, we evaluated the effect of polymorphisms in CHRNA5-CHRNA3-CHRNB4 gene cluster and their interaction with tobacco smoking status on cognition in patients with Attention Deficit/Hyperactivity Disorder (ADHD).
p62358
sg52638
(lp62359
(dp62360
g52643
I50
sg52644
g62355
sg52646
I33
sg52674
VP30532
p62361
sg52649
I3
sasg52640
(lp62362
(dp62363
g52643
I164
sg52644
VAttention Deficit/Hyperactivity Disorder
p62364
sg52646
I40
sg52647
VC1263846
p62365
sg52649
I3
sa(dp62366
g52643
I206
sg52644
g62356
sg52646
I4
sg52647
VC1263846
p62367
sg52649
I1
sasa(dp62368
g135
(dp62369
(VCHRNA3
p62370
VADHD
p62371
tp62372
I00
ssg52636
VEight SNPs from the CHRNA5-CHRNA3-CHRNB4 gene cluster were evaluated on a clinical sample of 403 adults with ADHD.
p62373
sg52638
(lp62374
(dp62375
g52643
I34
sg52644
VCHRNB4
p62376
sg52646
I6
sg52674
VP30926
p62377
sg52649
I1
sa(dp62378
g52643
I20
sg52644
VCHRNA5
p62379
sg52646
I6
sg52674
VP30532
p62380
sg52649
I1
sa(dp62381
g52643
I27
sg52644
g62370
sg52646
I6
sg52674
VP32297
p62382
sg52649
I1
sasg52640
(lp62383
(dp62384
g52643
I109
sg52644
g62371
sg52646
I4
sg52647
VC1263846
p62385
sg52649
I1
sasa(dp62386
g135
(dp62387
(VCHRNA5-CHRNA3-CHRNB4 variants
p62388
VNicotine Dependence
p62389
tp62390
I00
ssg52636
VThe associations between CHRNA5-CHRNA3-CHRNB4 variants and cigarettes per day (CPD), the Fagerstroem Test for Nicotine Dependence (FTND), and craving were analyzed in data from 662 lifetime smokers from an Israeli adult Jewish household sample.
p62391
sg52638
(lp62392
(dp62393
g52643
I25
sg52644
g62388
sg52646
I29
sg52674
VP30532
p62394
sg52649
I2
sasg52640
(lp62395
(dp62396
g52643
I110
sg52644
g62389
sg52646
I19
sg52647
VC0028043
p62397
sg52649
I2
sasa(dp62398
g135
(dp62399
(VVCAM-1
p62400
Vadhesion
p62401
tp62402
I00
ssg52636
VWe found a significant increase in levels of adhesion molecules (VCAM-1) and selectins (E-selectin) in parallel with increased severity of diabetic retinopathy, with a significant difference of inflammatory markers between stages of retinopathy.
p62403
sg52638
(lp62404
(dp62405
g52643
I88
sg52644
VE-selectin
p62406
sg52646
I10
sg52674
VP16581
p62407
sg52649
I1
sa(dp62408
g52643
I65
sg52644
g62400
sg52646
I6
sg52674
VP19320
p62409
sg52649
I1
sasg52640
(lp62410
(dp62411
g52643
I148
sg52644
Vretinopathy
p62412
sg52646
I11
sg52647
VC0035309
p62413
sg52649
I1
sa(dp62414
g52643
I139
sg52644
Vdiabetic retinopathy
p62415
sg52646
I20
sg52647
VC0011884
p62416
sg52649
I2
sa(dp62417
g52643
I45
sg52644
g62401
sg52646
I8
sg52647
VC0001511
p62418
sg52649
I1
sasa(dp62419
g135
(dp62420
(VE-selectin
p62421
Vdiabetic retinopathy
p62422
tp62423
I00
ssg52636
VOur aim was to investigate the role of soluble E-selectin in the formation of diabetic retinopathy.
p62424
sg52638
(lp62425
(dp62426
g52643
I47
sg52644
g62421
sg52646
I10
sg52674
VP16581
p62427
sg52649
I1
sasg52640
(lp62428
(dp62429
g52643
I78
sg52644
g62422
sg52646
I20
sg52647
VC0011884
p62430
sg52649
I2
sasa(dp62431
g135
(dp62432
(VE-selectin
p62433
Vdiabetic retinopathy
p62434
tp62435
I00
ssg52636
VAn elevated E-selectin level can play a role in the development of diabetic retinopathy, but it does not seem to alter disease severity.
p62436
sg52638
(lp62437
(dp62438
g52643
I12
sg52644
g62433
sg52646
I10
sg52674
VP16581
p62439
sg52649
I1
sasg52640
(lp62440
(dp62441
g52643
I67
sg52644
g62434
sg52646
I20
sg52647
VC0011884
p62442
sg52649
I2
sasa(dp62443
g135
(dp62444
(VE-selectin
p62445
Vdiabetic retinopathy
p62446
tp62447
I00
ssg52636
VHowever, glycemic control and the reduction of cardiovascular risk factors may also alter the level of E-selectin that might play a role in the prevention of diabetic retinopathy.
p62448
sg52638
(lp62449
(dp62450
g52643
I103
sg52644
g62445
sg52646
I10
sg52674
VP16581
p62451
sg52649
I1
sasg52640
(lp62452
(dp62453
g52643
I158
sg52644
g62446
sg52646
I20
sg52647
VC0011884
p62454
sg52649
I2
sasa(dp62455
g135
(dp62456
(Vplasma soluble E-selectin
p62457
Vretinal detachment
p62458
tp62459
I00
ssg52636
VTo evaluate efficacy of the treatment, the progression of the disease (number of laser treatments, number of bevacizumab treatments, and incidence of retinal detachment) was evaluated by serial ophthalmologic examinations, and plasma soluble E-selectin levels were measured weekly.
p62460
sg52638
(lp62461
(dp62462
g52643
I227
sg52644
g62457
sg52646
I25
sg52674
VP16581
p62463
sg52649
I3
sasg52640
(lp62464
(dp62465
g52643
I150
sg52644
g62458
sg52646
I18
sg52647
VC0035305
p62466
sg52649
I2
sasa(dp62467
g135
(dp62468
(Vtumor necrosis factor-Alfa
p62469
Vproliferative DR
p62470
tp62471
I01
ssg52636
VAfter adjusting for age, glycemic control, and other potential confounders, baseline plasma levels of E-selectin were associated significantly with progression of DR, E-selectin and tumor necrosis factor-Alfa (TNF-Alfa) levels with incidence of proliferative DR (PDR), and soluble intercellular adhesion molecule-1 (sICAM-1) and TNF-Alfa levels with incidence of macular edema (ME).
p62472
sg52638
(lp62473
(dp62474
g52643
I210
sg52644
VTNF-Alfa
p62475
sg52646
I8
sg52674
VP01375
p62476
sg52649
I1
sa(dp62477
g52643
I210
sg52644
VTNF-Alfa
p62478
sg52646
I8
sg52674
VP01375
p62479
sg52649
I1
sa(dp62480
g52643
I102
sg52644
VE-selectin
p62481
sg52646
I10
sg52674
VP16581
p62482
sg52649
I1
sa(dp62483
g52643
I102
sg52644
VE-selectin
p62484
sg52646
I10
sg52674
VP16581
p62485
sg52649
I1
sa(dp62486
g52643
I281
sg52644
Vintercellular adhesion molecule-1
p62487
sg52646
I33
sg52674
VP05362
p62488
sg52649
I3
sa(dp62489
g52643
I182
sg52644
g62469
sg52646
I26
sg52674
VP01375
p62490
sg52649
I3
sasg52640
(lp62491
(dp62492
g52643
I263
sg52644
VPDR
p62493
sg52646
I3
sg52647
VC1845050
p62494
sg52649
I1
sa(dp62495
g52643
I363
sg52644
Vmacular edema
p62496
sg52646
I13
sg52647
VC0271051
p62497
sg52649
I2
sa(dp62498
g52643
I182
sg52644
Vtumor necrosis
p62499
sg52646
I14
sg52647
VC0333516
p62500
sg52649
I2
sa(dp62501
g52643
I295
sg52644
Vadhesion
p62502
sg52646
I8
sg52647
VC0001511
p62503
sg52649
I1
sa(dp62504
g52643
I378
sg52644
VME
p62505
sg52646
I2
sg52647
VC0271051
p62506
sg52649
I1
sa(dp62507
g52643
I245
sg52644
g62470
sg52646
I16
sg52647
VC1845050
p62508
sg52649
I2
sasa(dp62509
g52636
VThe 6-HT was administrated by perfusion and ejection in "brain slices" of hippocampus, inducing epileptic activity after its administration; the toxin was not able to block the epileptogenic crisis observed in the chronic model of the epilepsy, suggesting that 6-HT did not block the overactive GluRs responsible for this epileptic activity.
p62510
sg52638
(lp62511
sg52640
(lp62512
(dp62513
g52643
I96
sg52644
Vepileptic
p62514
sg52646
I9
sg52647
VC0014544
p62515
sg52649
I1
sa(dp62516
g52643
I96
sg52644
Vepileptic
p62517
sg52646
I9
sg52647
VC0014544
p62518
sg52649
I1
sa(dp62519
g52643
I235
sg52644
Vepilepsy
p62520
sg52646
I8
sg52647
VC0014544
p62521
sg52649
I1
sasa(dp62522
g135
(dp62523
(Vinterferon
p62524
VSSc
p62525
tp62526
I00
ssg52636
VIn patients with systemic sclerosis (SSc), the relationship between innate immune activation, represented by increased expression of interferon (IFN)-regulated genes, and vascular injury/activation, manifest by increased endothelin-1 (ET-1), endothelin converting enzyme-1 (ECE1) and intercellular adhesion molecule-1, is uncertain.
p62527
sg52638
(lp62528
(dp62529
g52643
I274
sg52644
VECE1
p62530
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62531
g52643
I145
sg52644
VIFN
p62532
sg52646
I3
sg52674
VP01562
p62533
sg52649
I1
sa(dp62534
g52643
I235
sg52644
VET-1
p62535
sg52646
I4
sg52674
VP05305
p62536
sg52649
I1
sa(dp62537
g52643
I221
sg52644
Vendothelin-1
p62538
sg52646
I12
sg52674
VP20800
p62539
sg52649
I1
sa(dp62540
g52643
I242
sg52644
Vendothelin converting enzyme-1
p62541
sg52646
I30
sg52674
g12
sg52649
I3
sa(dp62542
g52643
I284
sg52644
Vintercellular adhesion molecule-1
p62543
sg52646
I33
sg52674
VP05362
p62544
sg52649
I3
sa(dp62545
g52643
I133
sg52644
g62524
sg52646
I10
sg52674
VP01563
p62546
sg52649
I1
sasg52640
(lp62547
(dp62548
g52643
I298
sg52644
Vadhesion
p62549
sg52646
I8
sg52647
VC0001511
p62550
sg52649
I1
sa(dp62551
g52643
I17
sg52644
Vsystemic sclerosis
p62552
sg52646
I18
sg52647
VC0036421
p62553
sg52649
I2
sa(dp62554
g52643
I37
sg52644
g62525
sg52646
I3
sg52647
VC0036421
p62555
sg52649
I1
sasa(dp62556
g52636
VRecent findings indicate that the level of SR-BI expression correlate with aggressiveness and poor survival in breast and prostate cancer.
p62557
sg52638
(lp62558
(dp62559
g52643
I43
sg52644
VSR-BI
p62560
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62561
(dp62562
g52643
I75
sg52644
Vaggressiveness
p62563
sg52646
I14
sg52647
VC0001807
p62564
sg52649
I1
sa(dp62565
g52643
I122
sg52644
Vprostate cancer
p62566
sg52646
I15
sg52647
VC0600139
p62567
sg52649
I2
sasa(dp62568
g135
(dp62569
(VmTOR
p62570
Vprostate cancer
p62571
tp62572
I00
ssg52636
VFurthermore, we performed immunohistochemistry analysis on human primary prostate cancer tissue sections derived from patients to investigate the correlation of SR-BI with clinicopathological parameters and the mTOR target pS6.
p62573
sg52638
(lp62574
(dp62575
g52643
I211
sg52644
g62570
sg52646
I4
sg52674
VP42345
p62576
sg52649
I1
sa(dp62577
g52643
I161
sg52644
VSR-BI
p62578
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62579
(dp62580
g52643
I73
sg52644
g62571
sg52646
I15
sg52647
VC0600139
p62581
sg52649
I2
sasa(dp62582
g135
(dp62583
(VLDLR
p62584
Vprostate cancers
p62585
tp62586
I00
ssg52636
VIn contrast to LDLR, we identified SR-BI mRNA and protein expression to be induced in high Gleason grade primary prostate cancers.
p62587
sg52638
(lp62588
(dp62589
g52643
I15
sg52644
g62584
sg52646
I4
sg52674
VP01130
p62590
sg52649
I1
sa(dp62591
g52643
I35
sg52644
VSR-BI mRNA
p62592
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp62593
(dp62594
g52643
I113
sg52644
g62585
sg52646
I16
sg52647
VC0376358
p62595
sg52649
I2
sasa(dp62596
g52636
VWe identified SR-BI to indicate human prostate cancer formation, suggesting that increased levels of SR-BI may be involved in the generation of a castration-resistant phenotype.
p62597
sg52638
(lp62598
(dp62599
g52643
I14
sg52644
VSR-BI
p62600
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp62601
g52643
I14
sg52644
VSR-BI
p62602
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62603
(dp62604
g52643
I38
sg52644
Vprostate cancer
p62605
sg52646
I15
sg52647
VC0600139
p62606
sg52649
I2
sasa(dp62607
g52636
VSilencing of SR-BI may impact the ability of prostate cancer cells, particularly those of castration-resistant state, to maintain the intracellular supply of androgens by removing a supply of cholesterol.
p62608
sg52638
(lp62609
(dp62610
g52643
I13
sg52644
VSR-BI
p62611
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62612
(dp62613
g52643
I45
sg52644
Vprostate cancer
p62614
sg52646
I15
sg52647
VC0600139
p62615
sg52649
I2
sasa(dp62616
g135
(dp62617
(VHDL
p62618
VPSA
p62619
tp62620
I00
ssg52636
VThe down-regulation of SR-BI significantly impacts PSA production of prostate cancer cells, as well as the viability of C4-2 cells in the presence and absence of HDL.
p62621
sg52638
(lp62622
(dp62623
g52643
I51
sg52644
VPSA
p62624
sg52646
I3
sg52674
VP55786
p62625
sg52649
I1
sa(dp62626
g52643
I23
sg52644
VSR-BI
p62627
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp62628
g52643
I162
sg52644
g62618
sg52646
I3
sg52674
VP28845
p62629
sg52649
I1
sasg52640
(lp62630
(dp62631
g52643
I69
sg52644
Vprostate cancer
p62632
sg52646
I15
sg52647
VC0600139
p62633
sg52649
I2
sa(dp62634
g52643
I51
sg52644
g62619
sg52646
I3
sg52647
VC1519176
p62635
sg52649
I1
sasa(dp62636
g52636
VThis may indicate a deficiency in cholesterol availability to the androgen synthesis pathway or may implicate a role for SR-BI in prostate cancer signal transduction pathways.
p62637
sg52638
(lp62638
(dp62639
g52643
I121
sg52644
VSR-BI
p62640
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62641
(dp62642
g52643
I130
sg52644
Vprostate cancer
p62643
sg52646
I15
sg52647
VC0600139
p62644
sg52649
I2
sasa(dp62645
g135
(dp62646
(VpPROM
p62647
Vpreterm premature rupture of membranes
p62648
tp62649
I01
ssg52636
Vplay roles in preterm labor and preterm premature rupture of membranes (pPROM); 3) integrated aspects of maternal and fetal host responses (inflammation, altered immune adaptations, endocrine and paracrine mechanisms) play increasingly understood roles in premature activation of parturition; and 4) identification and systemic treatment of common genitourinary infections, most importantly bacterial vaginosis (BV), reduce the risks of preterm delivery and PROM.
p62650
sg52638
(lp62651
(dp62652
g52643
I72
sg52644
g62647
sg52646
I5
sg52674
VP50454
p62653
sg52649
I1
sasg52640
(lp62654
(dp62655
g52643
I391
sg52644
Vbacterial vaginosis
p62656
sg52646
I19
sg52647
VC0085166
p62657
sg52649
I2
sa(dp62658
g52643
I437
sg52644
Vpreterm delivery
p62659
sg52646
I16
sg52647
VC0151526
p62660
sg52649
I2
sa(dp62661
g52643
I14
sg52644
Vpreterm labor
p62662
sg52646
I13
sg52647
VC0022876
p62663
sg52649
I2
sa(dp62664
g52643
I362
sg52644
Vinfections
p62665
sg52646
I10
sg52647
VC0021311
p62666
sg52649
I1
sa(dp62667
g52643
I0
sg52644
Vplay roles
p62668
sg52646
I10
sg52647
VC0699820
p62669
sg52649
I2
sa(dp62670
g52643
I72
sg52644
VpPROM
p62671
sg52646
I5
sg52647
VC0729264
p62672
sg52649
I1
sa(dp62673
g52643
I140
sg52644
Vinflammation
p62674
sg52646
I12
sg52647
VC0021368
p62675
sg52649
I1
sa(dp62676
g52643
I32
sg52644
g62648
sg52646
I38
sg52647
VC0729264
p62677
sg52649
I5
sasa(dp62678
g52636
VUnivariate analysis showed the following to be significant predictors of PPROM at &lt; 35 weeks: a past history of PTD between 25 and 30 weeks (P &lt; 0.008), cerclage in the current pregnancy (P &lt; 0.0001), bacterial vaginosis (P &lt; 0.011), CL &lt; 25 mm (P &lt; 0.0001) and CF &gt; 25% (P &lt; 0.0001).
p62679
sg52638
(lp62680
sg52640
(lp62681
(dp62682
g52643
I73
sg52644
VPPROM
p62683
sg52646
I5
sg52647
VC0729264
p62684
sg52649
I1
sa(dp62685
g52643
I210
sg52644
Vbacterial vaginosis
p62686
sg52646
I19
sg52647
VC0085166
p62687
sg52649
I2
sa(dp62688
g52643
I115
sg52644
VPTD
p62689
sg52646
I3
sg52647
VC0266006
p62690
sg52649
I1
sasa(dp62691
g52636
VIn this study, localization of gelatinase activities in six cases of glioblastoma, two cases of anaplastic astrocytoma, and six cases of low-grade astrocytomas was investigated by film in situ zymography (FIZ).
p62692
sg52638
(lp62693
sg52640
(lp62694
(dp62695
g52643
I147
sg52644
Vastrocytomas
p62696
sg52646
I12
sg52647
VC0004114
p62697
sg52649
I1
sa(dp62698
g52643
I96
sg52644
Vanaplastic astrocytoma
p62699
sg52646
I22
sg52647
VC0334579
p62700
sg52649
I2
sa(dp62701
g52643
I69
sg52644
Vglioblastoma
p62702
sg52646
I12
sg52647
VC0017636
p62703
sg52649
I1
sasa(dp62704
g52636
VIn situ hybridization of the null cell line HLN-STL-C established from an adult T-cell leukemia patient showed that 100% of the cells contained both EBERs and LMP1 mRNA and about 0.1% of the cells contained gp350/220 mRNA, indicating that a few of the null cells which carried the EBV genome spontaneously entered the late EBV replication cycle.
p62705
sg52638
(lp62706
(dp62707
g52643
I159
sg52644
VLMP1 mRNA
p62708
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp62709
(dp62710
g52643
I74
sg52644
Vadult T-cell leukemia
p62711
sg52646
I21
sg52647
VC0023492
p62712
sg52649
I3
sasa(dp62713
g52636
VIQ and CELF-3 performance were highly interrelated regardless of whether subjects had autism or were controls.
p62714
sg52638
(lp62715
sg52640
(lp62716
(dp62717
g52643
I86
sg52644
Vautism
p62718
sg52646
I6
sg52647
VC0004352
p62719
sg52649
I1
sasa(dp62720
g52636
VBoth IQ and CELF-3 ability were positively correlated with STG in controls, but a different pattern was observed in subjects with autism.
p62721
sg52638
(lp62722
sg52640
(lp62723
(dp62724
g52643
I130
sg52644
Vautism
p62725
sg52646
I6
sg52647
VC0004352
p62726
sg52649
I1
sasa(dp62727
g52636
VIn controls, left STG gray matter was significantly (r = .42, p &lt; or = .05) related to receptive language on the CELF-3; in contrast, a zero order correlation was found with autism.
p62728
sg52638
(lp62729
(dp62730
g52643
I116
sg52644
VCELF-3
p62731
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp62732
(dp62733
g52643
I177
sg52644
Vautism
p62734
sg52646
I6
sg52647
VC0004352
p62735
sg52649
I1
sasa(dp62736
g135
(dp62737
(VERK1/2
p62738
Vdextran sodium sulphate
p62739
tp62740
I01
ssg52636
VHere, we showed that DUSP10 knockout (KO) mice had increased intestinal epithelial cell (IEC) proliferation and migration and developed less severe colitis than wild-type (WT) mice in response to dextran sodium sulphate (DSS) treatment, which is associated with increased ERK1/2 activation and Kruppel-like factor 5 (KLF5) expression in IEC.
p62741
sg52638
(lp62742
(dp62743
g52643
I272
sg52644
g62738
sg52646
I6
sg52674
VP27361
p62744
sg52649
I1
sa(dp62745
g52643
I294
sg52644
VKruppel-like factor 5
p62746
sg52646
I21
sg52674
g12
sg52649
I3
sa(dp62747
g52643
I317
sg52644
VKLF5
p62748
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp62749
g52643
I21
sg52644
VDUSP10
p62750
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp62751
(dp62752
g52643
I221
sg52644
VDSS
p62753
sg52646
I3
sg52647
VC0011195
p62754
sg52649
I1
sa(dp62755
g52643
I148
sg52644
Vcolitis
p62756
sg52646
I7
sg52647
VC0009319
p62757
sg52649
I1
sa(dp62758
g52643
I196
sg52644
g62739
sg52646
I23
sg52647
VC0011195
p62759
sg52649
I3
sa(dp62760
g52643
I94
sg52644
Vproliferation
p62761
sg52646
I13
sg52647
VC0334094
p62762
sg52649
I1
sasa(dp62763
g52636
VModels of painful small-fiber sensory neuropathy were developed and several laboratories have progressed in the conception of TRPV1 agonists and antagonists.
p62764
sg52638
(lp62765
(dp62766
g52643
I126
sg52644
VTRPV1
p62767
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62768
(dp62769
g52643
I30
sg52644
Vsensory neuropathy
p62770
sg52646
I18
sg52647
VC0151313
p62771
sg52649
I2
sa(dp62772
g52643
I10
sg52644
Vpainful
p62773
sg52646
I7
sg52647
VC0030193
p62774
sg52649
I1
sasa(dp62775
g52636
VTRPV1 is involved in oxidant stress-induced pain and in neuronal injury, contributing to diabetic sensory neuropathy.
p62776
sg52638
(lp62777
(dp62778
g52643
I0
sg52644
VTRPV1
p62779
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp62780
(dp62781
g52643
I98
sg52644
Vsensory neuropathy
p62782
sg52646
I18
sg52647
VC0151313
p62783
sg52649
I2
sasa(dp62784
g52636
VDespite the impediments posed by phenotypic and genetic heterogeneity among women with PCOS, investigation into one locus, the DENND1A gene, is providing insight into the ovarian steroidogenesis.
p62785
sg52638
(lp62786
(dp62787
g52643
I127
sg52644
VDENND1A gene
p62788
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp62789
(dp62790
g52643
I87
sg52644
VPCOS
p62791
sg52646
I4
sg52647
VC0032460
p62792
sg52649
I1
sasa(dp62793
g52636
VWe conducted a meta-analysis to evaluate the rs10818854, rs2479106, and rs10986105 polymorphism in DENND1A gene with PCOS susceptibility.
p62794
sg52638
(lp62795
(dp62796
g52643
I99
sg52644
VDENND1A gene
p62797
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp62798
(dp62799
g52643
I117
sg52644
VPCOS
p62800
sg52646
I4
sg52647
VC0032460
p62801
sg52649
I1
sasa(dp62802
g52636
VIn conclusion, the DENND1A gene variant is likely to have influence on PCOS risk.
p62803
sg52638
(lp62804
(dp62805
g52643
I19
sg52644
VDENND1A gene
p62806
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp62807
(dp62808
g52643
I71
sg52644
VPCOS
p62809
sg52646
I4
sg52647
VC0032460
p62810
sg52649
I1
sasa(dp62811
g52636
VPCOS has a strong genetic component, and genome-wide association studies have identified several candidate genes, notably DENND1A, which encodes connecdenn 1, involved in trafficking of endosomes.
p62812
sg52638
(lp62813
(dp62814
g52643
I145
sg52644
Vconnecdenn 1
p62815
sg52646
I12
sg52674
g12
sg52649
I2
sa(dp62816
g52643
I122
sg52644
VDENND1A
p62817
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp62818
(dp62819
g52643
I0
sg52644
VPCOS
p62820
sg52646
I4
sg52647
VC0032460
p62821
sg52649
I1
sasa(dp62822
g52636
VFurthermore, overexpression of DENND1A variant 2 in normal theca cells resulted in a PCOS phenotype with increased androgen production.
p62823
sg52638
(lp62824
(dp62825
g52643
I31
sg52644
VDENND1A variant 2
p62826
sg52646
I17
sg52674
g12
sg52649
I3
sasg52640
(lp62827
(dp62828
g52643
I85
sg52644
VPCOS
p62829
sg52646
I4
sg52647
VC0032460
p62830
sg52649
I1
sasa(dp62831
g135
(dp62832
(Vepidermal growth factor
p62833
VPCOS
p62834
tp62835
I00
ssg52636
VIn addition, GWAS have suggested that DENND1A, epidermal growth factor signaling, and DNA repair pathways play a role in PCOS pathogenesis.
p62836
sg52638
(lp62837
(dp62838
g52643
I47
sg52644
g62833
sg52646
I23
sg52674
VP01133
p62839
sg52649
I3
sa(dp62840
g52643
I38
sg52644
VDENND1A
p62841
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp62842
(dp62843
g52643
I126
sg52644
Vpathogenesis
p62844
sg52646
I12
sg52647
VC0699748
p62845
sg52649
I1
sa(dp62846
g52643
I121
sg52644
g62834
sg52646
I4
sg52647
VC0032460
p62847
sg52649
I1
sasa(dp62848
g52636
VThe rs2479106 and rs10818854 polymorphisms in the DENND1A gene have been reported to be extensively associated with risk of polycystic ovary syndrome (PCOS).
p62849
sg52638
(lp62850
(dp62851
g52643
I50
sg52644
VDENND1A gene
p62852
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp62853
(dp62854
g52643
I151
sg52644
VPCOS
p62855
sg52646
I4
sg52647
VC0032460
p62856
sg52649
I1
sa(dp62857
g52643
I124
sg52644
Vpolycystic ovary syndrome
p62858
sg52646
I25
sg52647
VC0032460
p62859
sg52649
I3
sasa(dp62860
g52636
VOverall, significant increase of PCOS risk was found between DENND1A-rs10818854 and PCOS susceptibility.
p62861
sg52638
(lp62862
(dp62863
g52643
I61
sg52644
VDENND1A
p62864
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp62865
(dp62866
g52643
I33
sg52644
VPCOS
p62867
sg52646
I4
sg52647
VC0032460
p62868
sg52649
I1
sa(dp62869
g52643
I33
sg52644
VPCOS
p62870
sg52646
I4
sg52647
VC0032460
p62871
sg52649
I1
sasa(dp62872
g52636
VThis meta-analysis suggested that rs2479106 and rs10818854 polymorphisms in the DENND1A gene were associated with increased risk of PCOS.
p62873
sg52638
(lp62874
(dp62875
g52643
I80
sg52644
VDENND1A gene
p62876
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp62877
(dp62878
g52643
I132
sg52644
VPCOS
p62879
sg52646
I4
sg52647
VC0032460
p62880
sg52649
I1
sasa(dp62881
g52636
VVariant 2 of the DENND1A gene was found overexpressed in PCOS theca cells and confirmed to enhance androgen production.
p62882
sg52638
(lp62883
(dp62884
g52643
I17
sg52644
VDENND1A gene
p62885
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp62886
(dp62887
g52643
I57
sg52644
VPCOS
p62888
sg52646
I4
sg52647
VC0032460
p62889
sg52649
I1
sasa(dp62890
g135
(dp62891
(VLHCGR
p62892
VPCOS
p62893
tp62894
I00
ssg52636
VOur previous research had identified three susceptibility loci (rs2479106, DENND1A; rs13405728, LHCGR; rs13429458, THADA) for PCOS in Han Chinese women.
p62895
sg52638
(lp62896
(dp62897
g52643
I75
sg52644
VDENND1A
p62898
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp62899
g52643
I96
sg52644
g62892
sg52646
I5
sg52674
VP22888
p62900
sg52649
I1
sasg52640
(lp62901
(dp62902
g52643
I126
sg52644
g62893
sg52646
I4
sg52647
VC0032460
p62903
sg52649
I1
sasa(dp62904
g135
(dp62905
(VYAP1
p62906
VPCOS
p62907
tp62908
I00
ssg52636
VThree of the eleven variants associated with PCOS in the Han Chinese genome-wide association studies were also associated with PCOS in at least one European population when corrected for multiple testing (DENND1A, THADA and YAP1).
p62909
sg52638
(lp62910
(dp62911
g52643
I224
sg52644
g62906
sg52646
I4
sg52674
VP46937
p62912
sg52649
I1
sa(dp62913
g52643
I205
sg52644
VDENND1A
p62914
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp62915
(dp62916
g52643
I45
sg52644
VPCOS
p62917
sg52646
I4
sg52647
VC0032460
p62918
sg52649
I1
sa(dp62919
g52643
I45
sg52644
g62907
sg52646
I4
sg52647
VC0032460
p62920
sg52649
I1
sasa(dp62921
g52636
VMicroRNA-106a-5p (MiR-106a-5p), a small non-coding RNA, has been reported to be downregulated in astrocytoma, osteosarcoma and colorectal cancer.
p62922
sg52638
(lp62923
(dp62924
g52643
I0
sg52644
VMicroRNA-106a-5p
p62925
sg52646
I16
sg52674
g12
sg52649
I1
sa(dp62926
g52643
I18
sg52644
VMiR-106a-5p
p62927
sg52646
I11
sg52674
g12
sg52649
I1
sasg52640
(lp62928
(dp62929
g52643
I127
sg52644
Vcolorectal cancer
p62930
sg52646
I17
sg52647
VC1527249
p62931
sg52649
I2
sa(dp62932
g52643
I97
sg52644
Vastrocytoma
p62933
sg52646
I11
sg52647
VC0004114
p62934
sg52649
I1
sa(dp62935
g52643
I110
sg52644
Vosteosarcoma
p62936
sg52646
I12
sg52647
VC0029463
p62937
sg52649
I1
sasa(dp62938
g52636
VThe study aimed to evaluate the effects of miR-106a on prostate cancer cells and the underlying molecular mechanism.
p62939
sg52638
(lp62940
(dp62941
g52643
I43
sg52644
VmiR-106a
p62942
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp62943
(dp62944
g52643
I55
sg52644
Vprostate cancer
p62945
sg52646
I15
sg52647
VC0600139
p62946
sg52649
I2
sasa(dp62947
g135
(dp62948
(VPTEN
p62949
Vprostate cancer
p62950
tp62951
I00
ssg52636
VMiR-106a as an oncogene could promote proliferation and metastasis of prostate cancer cells by directly targeting PTEN in vivo and in vitro.
p62952
sg52638
(lp62953
(dp62954
g52643
I114
sg52644
g62949
sg52646
I4
sg52674
VP60484
p62955
sg52649
I1
sa(dp62956
g52643
I0
sg52644
VMiR-106a
p62957
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp62958
(dp62959
g52643
I38
sg52644
Vproliferation
p62960
sg52646
I13
sg52647
VC0334094
p62961
sg52649
I1
sa(dp62962
g52643
I56
sg52644
Vmetastasis
p62963
sg52646
I10
sg52647
VC0027627
p62964
sg52649
I1
sa(dp62965
g52643
I70
sg52644
g62950
sg52646
I15
sg52647
VC0600139
p62966
sg52649
I2
sasa(dp62967
g135
(dp62968
(VCXCL1
p62969
Vbreast cancer
p62970
tp62971
I00
ssg52636
VCXCL1 secreted by hAdSCs downregulated miR-106a expression in triple negative breast cancer, and resulted in ABCG2 upregulation and doxorubicin resistance.
p62972
sg52638
(lp62973
(dp62974
g52643
I39
sg52644
VmiR-106a
p62975
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp62976
g52643
I0
sg52644
g62969
sg52646
I5
sg52674
VP09341
p62977
sg52649
I1
sasg52640
(lp62978
(dp62979
g52643
I78
sg52644
g62970
sg52646
I13
sg52647
VC0678222
p62980
sg52649
I2
sasa(dp62981
g135
(dp62982
(VCXCL1
p62983
Vbreast cancer
p62984
tp62985
I00
ssg52636
VOur findings suggest that CXCL1 secreted by hAdSCs elicits doxorubicin resistance through miR-106a-mediated ABCG2 upregulation in triple negative breast cancer.
p62986
sg52638
(lp62987
(dp62988
g52643
I90
sg52644
VmiR-106a
p62989
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp62990
g52643
I26
sg52644
g62983
sg52646
I5
sg52674
VP09341
p62991
sg52649
I1
sasg52640
(lp62992
(dp62993
g52643
I146
sg52644
g62984
sg52646
I13
sg52647
VC0678222
p62994
sg52649
I2
sasa(dp62995
g52636
VPrevious studies have revealed that miR-106a is abnormally expressed in various cancers.
p62996
sg52638
(lp62997
(dp62998
g52643
I36
sg52644
VmiR-106a
p62999
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp63000
(dp63001
g52643
I80
sg52644
Vcancers
p63002
sg52646
I7
sg52647
VC0006826
p63003
sg52649
I1
sasa(dp63004
g135
(dp63005
(VSOX2
p63006
Vinvasive carcinoma
p63007
tp63008
I00
ssg52636
VCopy number gains in SOX2 in the region of 3q26-28 occur in 94% of SQCCs, and appear to act both early and late in disease progression by stabilizing the initial squamous injury response in stem cells and promoting growth of invasive carcinoma.
p63009
sg52638
(lp63010
(dp63011
g52643
I21
sg52644
g63006
sg52646
I4
sg52674
VP48431
p63012
sg52649
I1
sasg52640
(lp63013
(dp63014
g52643
I225
sg52644
g63007
sg52646
I18
sg52647
VC1334274
p63015
sg52649
I2
sa(dp63016
g52643
I115
sg52644
Vdisease progression
p63017
sg52646
I19
sg52647
VC0242656
p63018
sg52649
I2
sasa(dp63019
g135
(dp63020
(VPRKCI
p63021
Vovarian carcinoma
p63022
tp63023
I01
ssg52636
VA key feature of high-grade serous ovarian carcinoma (HGSOC) is frequent amplification of the 3q26 locus harboring PRKC-l (PRKCI).
p63024
sg52638
(lp63025
(dp63026
g52643
I115
sg52644
VPRKC-l
p63027
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp63028
g52643
I123
sg52644
g63021
sg52646
I5
sg52674
VP41743
p63029
sg52649
I1
sasg52640
(lp63030
(dp63031
g52643
I73
sg52644
Vamplification
p63032
sg52646
I13
sg52647
VC1705759
p63033
sg52649
I1
sa(dp63034
g52643
I35
sg52644
g63022
sg52646
I17
sg52647
VC0029925
p63035
sg52649
I2
sasa(dp63036
g52636
VFour loci, 5p15.33 (TERT), 6p21.3 (BTNL2), 3q28 (TP63) and 17q24.2 (BPTF), previously shown to be strongly associated with overall lung adenocarcinoma risk in East Asians, were re-discovered as loci associated with a higher susceptibility to EGFR mutation-positive lung adenocarcinoma.
p63037
sg52638
(lp63038
sg52640
(lp63039
(dp63040
g52643
I131
sg52644
Vlung adenocarcinoma
p63041
sg52646
I19
sg52647
VC0152013
p63042
sg52649
I2
sa(dp63043
g52643
I131
sg52644
Vlung adenocarcinoma
p63044
sg52646
I19
sg52647
VC0152013
p63045
sg52649
I2
sasa(dp63046
g52636
VChromosome 3q26-28 is a critical region of genomic amplification in non-small cell lung cancer (NSCLC), particularly lung squamous cell carcinomas (SCCs).
p63047
sg52638
(lp63048
sg52640
(lp63049
(dp63050
g52643
I96
sg52644
VNSCLC
p63051
sg52646
I5
sg52647
VC0007131
p63052
sg52649
I1
sa(dp63053
g52643
I68
sg52644
Vnon-small cell lung cancer
p63054
sg52646
I26
sg52647
VC0007131
p63055
sg52649
I4
sa(dp63056
g52643
I51
sg52644
Vamplification
p63057
sg52646
I13
sg52647
VC1705759
p63058
sg52649
I1
sa(dp63059
g52643
I148
sg52644
VSCCs
p63060
sg52646
I4
sg52647
VC0007137
p63061
sg52649
I1
sa(dp63062
g52643
I122
sg52644
Vsquamous cell carcinomas
p63063
sg52646
I24
sg52647
VC0007137
p63064
sg52649
I3
sasa(dp63065
g135
(dp63066
(VPIK3CA gene
p63067
Vsquamous cell carcinoma of the lung
p63068
tp63069
I00
ssg52636
VThe PIK3CA gene at chromosome 3q26.32 was found to be amplified in up to 45% of patients with squamous cell carcinoma of the lung.
p63070
sg52638
(lp63071
(dp63072
g52643
I4
sg52644
g63067
sg52646
I11
sg52674
VP42336
p63073
sg52649
I2
sasg52640
(lp63074
(dp63075
g52643
I94
sg52644
g63068
sg52646
I35
sg52647
VC0149782
p63076
sg52649
I6
sasa(dp63077
g135
(dp63078
(VTNFRSF1A
p63079
Vcolon cancer
p63080
tp63081
I01
ssg52636
VAspirin/NSAID interacted with MAP3K7 (colon cancer) and with MAPK14, NFAT5, and TRAF2 (rectal cancer); smoking cigarettes interacted with NFAM1 and NFAT2 (colon cancer) and MAPK8, NFAT5, and TNFRSF1A (rectal cancer); BMI interacted with NFAM1 and NFAT5 (colon cancer) and with MAPK8 and TNFRSF1A (rectal cancer).
p63082
sg52638
(lp63083
(dp63084
g52643
I148
sg52644
VNFAT2 (colon cancer)
p63085
sg52646
I20
sg52674
g12
sg52649
I3
sa(dp63086
g52643
I191
sg52644
VTNFRSF1A
p63087
sg52646
I8
sg52674
VP19438
p63088
sg52649
I1
sa(dp63089
g52643
I69
sg52644
VNFAT5
p63090
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63091
g52643
I138
sg52644
VNFAM1
p63092
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63093
g52643
I69
sg52644
VNFAT5
p63094
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63095
g52643
I30
sg52644
VMAP3K7 (colon cancer)
p63096
sg52646
I21
sg52674
g12
sg52649
I3
sa(dp63097
g52643
I80
sg52644
VTRAF2
p63098
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63099
g52643
I173
sg52644
VMAPK8
p63100
sg52646
I5
sg52674
VP45983
p63101
sg52649
I1
sa(dp63102
g52643
I138
sg52644
VNFAM1
p63103
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63104
g52643
I247
sg52644
VNFAT5 (colon cancer)
p63105
sg52646
I20
sg52674
g12
sg52649
I3
sa(dp63106
g52643
I173
sg52644
VMAPK8
p63107
sg52646
I5
sg52674
VP45983
p63108
sg52649
I1
sa(dp63109
g52643
I61
sg52644
VMAPK14
p63110
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp63111
g52643
I191
sg52644
g63079
sg52646
I8
sg52674
VP19438
p63112
sg52649
I1
sasg52640
(lp63113
(dp63114
g52643
I87
sg52644
Vrectal cancer
p63115
sg52646
I13
sg52647
VC0007113
p63116
sg52649
I2
sa(dp63117
g52643
I87
sg52644
Vrectal cancer
p63118
sg52646
I13
sg52647
VC0007113
p63119
sg52649
I2
sa(dp63120
g52643
I38
sg52644
Vcolon cancer
p63121
sg52646
I12
sg52647
VC0699790
p63122
sg52649
I2
sa(dp63123
g52643
I38
sg52644
Vcolon cancer
p63124
sg52646
I12
sg52647
VC0699790
p63125
sg52649
I2
sa(dp63126
g52643
I87
sg52644
Vrectal cancer
p63127
sg52646
I13
sg52647
VC0007113
p63128
sg52649
I2
sa(dp63129
g52643
I38
sg52644
g63080
sg52646
I12
sg52647
VC0699790
p63130
sg52649
I2
sasa(dp63131
g52636
VPreviously, we have cloned the cDNAs for the meningioma expressed antigen 6 (MGEA6) and its splice variant MGEA11.
p63132
sg52638
(lp63133
sg52640
(lp63134
(dp63135
g52643
I45
sg52644
Vmeningioma
p63136
sg52646
I10
sg52647
VC0025286
p63137
sg52649
I1
sasa(dp63138
g52636
VHere, we show that antibodies against recombinantly expressed MGEA6/11 are found in 41.7% (10/24) of the sera from meningioma patients and in 2/8 sera of glioblastoma patients, whereas no response was seen in 12 sera from healthy persons.
p63139
sg52638
(lp63140
(dp63141
g52643
I62
sg52644
VMGEA6/11
p63142
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp63143
(dp63144
g52643
I154
sg52644
Vglioblastoma
p63145
sg52646
I12
sg52647
VC0017636
p63146
sg52649
I1
sa(dp63147
g52643
I115
sg52644
Vmeningioma
p63148
sg52646
I10
sg52647
VC0025286
p63149
sg52649
I1
sasa(dp63150
g52636
VThe immune response to MGEA6/11 is frequent in both meningioma and glioma patients and may likely be attributed to overexpression of the MGEA6/11 protein in the tumor cells.
p63151
sg52638
(lp63152
(dp63153
g52643
I137
sg52644
VMGEA6/11 protein
p63154
sg52646
I16
sg52674
g12
sg52649
I2
sa(dp63155
g52643
I23
sg52644
VMGEA6/11
p63156
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp63157
(dp63158
g52643
I161
sg52644
Vtumor
p63159
sg52646
I5
sg52647
VC0027651
p63160
sg52649
I1
sa(dp63161
g52643
I67
sg52644
Vglioma
p63162
sg52646
I6
sg52647
VC0017638
p63163
sg52649
I1
sa(dp63164
g52643
I52
sg52644
Vmeningioma
p63165
sg52646
I10
sg52647
VC0025286
p63166
sg52649
I1
sasa(dp63167
g52636
VThe meningioma expressed antigen-6 (MGEA6) was originally identified as an immunogenic antigen in meningioma patients.
p63168
sg52638
(lp63169
(dp63170
g52643
I4
sg52644
Vmeningioma expressed antigen-6
p63171
sg52646
I30
sg52674
g12
sg52649
I3
sa(dp63172
g52643
I36
sg52644
VMGEA6
p63173
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp63174
(dp63175
g52643
I4
sg52644
Vmeningioma
p63176
sg52646
I10
sg52647
VC0025286
p63177
sg52649
I1
sa(dp63178
g52643
I4
sg52644
Vmeningioma
p63179
sg52646
I10
sg52647
VC0025286
p63180
sg52649
I1
sasa(dp63181
g52636
VThe clones were sequenced, and sequence comparison revealed that the seven clones represent five different genes, providing evidence that meningiomas express a spectrum of immunoreactive antigens, which were termed meningioma expressed antigens (MGEAs).
p63182
sg52638
(lp63183
sg52640
(lp63184
(dp63185
g52643
I138
sg52644
Vmeningioma
p63186
sg52646
I10
sg52647
VC0025286
p63187
sg52649
I1
sa(dp63188
g52643
I138
sg52644
Vmeningiomas
p63189
sg52646
I11
sg52647
VC0025286
p63190
sg52649
I1
sasa(dp63191
g52636
VThese data suggest that the newly identified MGEA genes may be useful for diagnosis and possibly therapy of meningioma.
p63192
sg52638
(lp63193
(dp63194
g52643
I45
sg52644
VMGEA genes
p63195
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp63196
(dp63197
g52643
I108
sg52644
Vmeningioma
p63198
sg52646
I10
sg52647
VC0025286
p63199
sg52649
I1
sasa(dp63200
g52636
VThe longest open reading frame was found to be 2412 bp encoding an immunoreactive antigen termed meningioma expressed antigen 6 (MEA6).
p63201
sg52638
(lp63202
sg52640
(lp63203
(dp63204
g52643
I97
sg52644
Vmeningioma
p63205
sg52646
I10
sg52647
VC0025286
p63206
sg52649
I1
sasa(dp63207
g52636
VUsing the keywords [St John's Wort OR Hypericum perforatum OR hypericin OR hyperforin OR johanniskraut OR] AND [depression OR antidepressant OR SSRI], a preliminary search (without language restriction) on the PubMed, Ovid, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group, Cochrane Field for Complementary Medicine, China National Knowledge Infrastructure and WanFang database yielded 5428 papers between 1-Jan-1960 and 1-May-2016.
p63208
sg52638
(lp63209
sg52640
(lp63210
(dp63211
g52643
I303
sg52644
VNeurosis
p63212
sg52646
I8
sg52647
VC0027932
p63213
sg52649
I1
sa(dp63214
g52643
I112
sg52644
Vdepression
p63215
sg52646
I10
sg52647
VC0011581
p63216
sg52649
I1
sa(dp63217
g52643
I279
sg52644
VDepression
p63218
sg52646
I10
sg52647
VC0011581
p63219
sg52649
I1
sasa(dp63220
g52636
VThere is evidence to suggest that caregivers of patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD) symptoms.
p63221
sg52638
(lp63222
sg52640
(lp63223
(dp63224
g52643
I108
sg52644
Vpost-traumatic stress disorder
p63225
sg52646
I30
sg52647
VC0038436
p63226
sg52649
I3
sa(dp63227
g52643
I140
sg52644
VPTSD
p63228
sg52646
I4
sg52647
VC0038436
p63229
sg52649
I1
sa(dp63230
g52643
I62
sg52644
Vhead and neck cancer
p63231
sg52646
I20
sg52647
VC0278996
p63232
sg52649
I4
sa(dp63233
g52643
I84
sg52644
VHNC
p63234
sg52646
I3
sg52647
VC0278996
p63235
sg52649
I1
sasa(dp63236
g52636
VEvidence suggests that patients with head and neck cancer (HNC) are susceptible to post-traumatic stress disorder (PTSD).
p63237
sg52638
(lp63238
sg52640
(lp63239
(dp63240
g52643
I83
sg52644
Vpost-traumatic stress disorder
p63241
sg52646
I30
sg52647
VC0038436
p63242
sg52649
I3
sa(dp63243
g52643
I115
sg52644
VPTSD
p63244
sg52646
I4
sg52647
VC0038436
p63245
sg52649
I1
sa(dp63246
g52643
I59
sg52644
VHNC
p63247
sg52646
I3
sg52647
VC0278996
p63248
sg52649
I1
sa(dp63249
g52643
I37
sg52644
Vhead and neck cancer
p63250
sg52646
I20
sg52647
VC0278996
p63251
sg52649
I4
sasa(dp63252
g52636
VAmong distressed HNC survivors, higher PTG was associated with lower tumor stage, absence of an anxiety disorder, absence of an alcohol use disorder, and better social functioning.
p63253
sg52638
(lp63254
sg52640
(lp63255
(dp63256
g52643
I69
sg52644
Vtumor
p63257
sg52646
I5
sg52647
VC0027651
p63258
sg52649
I1
sa(dp63259
g52643
I96
sg52644
Vanxiety disorder
p63260
sg52646
I16
sg52647
VC0003469
p63261
sg52649
I2
sa(dp63262
g52643
I6
sg52644
Vdistressed
p63263
sg52646
I10
sg52647
VC0700361
p63264
sg52649
I1
sa(dp63265
g52643
I128
sg52644
Valcohol use disorder
p63266
sg52646
I20
sg52647
VC0001956
p63267
sg52649
I3
sasa(dp63268
g52636
VAlthough lysyl oxidase-like 1 (LOXL1) is known as the principal genetic risk factor for pseudoexfoliation (PEX) syndrome, a major cause of glaucoma and cardiovascular complications, no functional variants have been identified to date.
p63269
sg52638
(lp63270
(dp63271
g52643
I31
sg52644
VLOXL1
p63272
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63273
g52643
I9
sg52644
Vlysyl oxidase-like 1
p63274
sg52646
I20
sg52674
g12
sg52649
I3
sasg52640
(lp63275
(dp63276
g52643
I112
sg52644
Vsyndrome
p63277
sg52646
I8
sg52647
VC0039082
p63278
sg52649
I1
sa(dp63279
g52643
I139
sg52644
Vglaucoma
p63280
sg52646
I8
sg52647
VC0017601
p63281
sg52649
I1
sasa(dp63282
g52636
VRecent studies have shed new light on the genetic factors underlying pseudoexfoliation syndrome, growing our understanding of the role of the lysyl oxidase-like 1 (LOXL1) gene and its various polymorphisms as well as identifying new genetic associations.
p63283
sg52638
(lp63284
(dp63285
g52643
I142
sg52644
Vlysyl oxidase-like 1
p63286
sg52646
I20
sg52674
g12
sg52649
I3
sa(dp63287
g52643
I164
sg52644
VLOXL1
p63288
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp63289
(dp63290
g52643
I69
sg52644
Vpseudoexfoliation syndrome
p63291
sg52646
I26
sg52647
VC0206368
p63292
sg52649
I2
sasa(dp63293
g135
(dp63294
(Vutrophin
p63295
Vchronic lymphocytic leukemia
p63296
tp63297
I00
ssg52636
VWe found that TAPP2, syntrophin, and utrophin are coexpressed in normal human B cells and B-chronic lymphocytic leukemia (B-CLL) cells.
p63298
sg52638
(lp63299
(dp63300
g52643
I37
sg52644
g63295
sg52646
I8
sg52674
VP46939
p63301
sg52649
I1
sa(dp63302
g52643
I14
sg52644
VTAPP2
p63303
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp63304
(dp63305
g52643
I124
sg52644
VCLL
p63306
sg52646
I3
sg52647
VC0023434
p63307
sg52649
I1
sa(dp63308
g52643
I92
sg52644
g63296
sg52646
I28
sg52647
VC0023434
p63309
sg52649
I3
sasa(dp63310
g135
(dp63311
(VRFC3
p63312
Vacute myeloid leukemia
p63313
tp63314
I01
ssg52636
VCREB1 expression, which was activated by E2F, was coupled with RFC3 expression during the G1/S progression in the KG-1 acute myeloid leukemia (AML) cell line.
p63315
sg52638
(lp63316
(dp63317
g52643
I0
sg52644
VCREB1
p63318
sg52646
I5
sg52674
VP16220
p63319
sg52649
I1
sa(dp63320
g52643
I63
sg52644
g63312
sg52646
I4
sg52674
VP40938
p63321
sg52649
I1
sasg52640
(lp63322
(dp63323
g52643
I143
sg52644
VAML
p63324
sg52646
I3
sg52647
VC0023467
p63325
sg52649
I1
sa(dp63326
g52643
I119
sg52644
g63313
sg52646
I22
sg52647
VC0023467
p63327
sg52649
I3
sasa(dp63328
g52636
VThe National Reference Center for equine infectious anemia (EIA) validated a commercial ELISA (Eradikit(R) EIAV Indirect ELISA, In3diagnostic(R), Turin, Italy) employing a chimeric recombinant gag and env peptide for the detection of EIA virus antibodies, following the guidelines of the World Organization for Animal Health.
p63329
sg52638
(lp63330
(dp63331
g52643
I172
sg52644
Vchimeric recombinant gag
p63332
sg52646
I24
sg52674
VP87889
p63333
sg52649
I3
sa(dp63334
g52643
I201
sg52644
Venv
p63335
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp63336
(dp63337
g52643
I60
sg52644
VEIA
p63338
sg52646
I3
sg52647
VC0014661
p63339
sg52649
I1
sa(dp63340
g52643
I60
sg52644
VEIA
p63341
sg52646
I3
sg52647
VC0014661
p63342
sg52649
I1
sa(dp63343
g52643
I34
sg52644
Vequine infectious anemia
p63344
sg52646
I24
sg52647
VC0014661
p63345
sg52649
I3
sasa(dp63346
g52636
VThe development of anaemia in feline leukaemia virus (FeLV)-infected cats is associated with the emergence of a novel viral subgroup, FeLV-C. FeLV-C arises from the subgroup that is transmitted, FeLV-A, through alterations in the amino acid sequence of the receptor binding domain (RBD) of the envelope glycoprotein that result in a shift in the receptor usage and the cell tropism of the virus.
p63347
sg52638
(lp63348
(dp63349
g52643
I294
sg52644
Venvelope glycoprotein
p63350
sg52646
I21
sg52674
g12
sg52649
I2
sasg52640
(lp63351
(dp63352
g52643
I37
sg52644
Vleukaemia
p63353
sg52646
I9
sg52647
VC0023418
p63354
sg52649
I1
sa(dp63355
g52643
I19
sg52644
Vanaemia
p63356
sg52646
I7
sg52647
VC0002871
p63357
sg52649
I1
sa(dp63358
g52643
I182
sg52644
Vtransmitted
p63359
sg52646
I11
sg52647
VC0242781
p63360
sg52649
I1
sasa(dp63361
g135
(dp63362
(Vsf-Stk
p63363
Vpolycythemia
p63364
tp63365
I00
ssg52636
VThese results suggest that the interaction between sf-Stk and the envelope proteins of the polycythemia- and anemia-inducing variants of SFFV is architecturally different.
p63366
sg52638
(lp63367
(dp63368
g52643
I66
sg52644
Venvelope
p63369
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp63370
g52643
I51
sg52644
g63363
sg52646
I6
sg52674
VP52823
p63371
sg52649
I1
sasg52640
(lp63372
(dp63373
g52643
I109
sg52644
Vanemia
p63374
sg52646
I6
sg52647
VC0002871
p63375
sg52649
I1
sa(dp63376
g52643
I91
sg52644
g63364
sg52646
I12
sg52647
VC0032461
p63377
sg52649
I1
sasa(dp63378
g52636
VWe conclude that the common clinical features of patients with an isolated mutation of ZRSR2 are a macrocytic anemia without leukopenia, thrombocytopenia or an increase in marrow blast percentage.
p63379
sg52638
(lp63380
(dp63381
g52643
I87
sg52644
VZRSR2
p63382
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp63383
(dp63384
g52643
I99
sg52644
Vmacrocytic anemia
p63385
sg52646
I17
sg52647
VC0002886
p63386
sg52649
I2
sa(dp63387
g52643
I125
sg52644
Vleukopenia
p63388
sg52646
I10
sg52647
VC0023530
p63389
sg52649
I1
sasa(dp63390
g52636
VRecent studies have shown that recombinant human thrombomodulin (rhTM) improves exacerbation and clinical outcome of idiopathic pulmonary fibrosis, but the mechanism remains unknown.
p63391
sg52638
(lp63392
(dp63393
g52643
I31
sg52644
Vrecombinant human thrombomodulin
p63394
sg52646
I32
sg52674
VP07204
p63395
sg52649
I3
sa(dp63396
g52643
I65
sg52644
VrhTM
p63397
sg52646
I4
sg52674
VP07204
p63398
sg52649
I1
sasg52640
(lp63399
(dp63400
g52643
I117
sg52644
Vidiopathic pulmonary fibrosis
p63401
sg52646
I29
sg52647
VC3161101
p63402
sg52649
I3
sasa(dp63403
g52636
VThis furthers our understanding of the regulatory mechanism of cardiac sarcomere assembly in both physiologic and pathologic contexts, and uncovers a potential novel pathway to cardiomyopathy through modulating the Stk38/Rbm24 protein activity.
p63404
sg52638
(lp63405
(dp63406
g52643
I215
sg52644
VStk38
p63407
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63408
g52643
I221
sg52644
VRbm24 protein
p63409
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp63410
(dp63411
g52643
I177
sg52644
Vcardiomyopathy
p63412
sg52646
I14
sg52647
VC0878544
p63413
sg52649
I1
sasa(dp63414
g52636
VThis study uncovers a potential novel pathway to cardiomyopathy through down-regulation of the RBP Rbm24.
p63415
sg52638
(lp63416
(dp63417
g52643
I95
sg52644
VRBP Rbm24
p63418
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp63419
(dp63420
g52643
I49
sg52644
Vcardiomyopathy
p63421
sg52646
I14
sg52647
VC0878544
p63422
sg52649
I1
sasa(dp63423
g52636
VNsp3 proteins of Semliki Forest (SFV), Sindbis (SINV), and Chikungunya viruses all showed avid and SH3-dependent binding to amphiphysins.
p63424
sg52638
(lp63425
(dp63426
g52643
I0
sg52644
VNsp3 proteins
p63427
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp63428
(dp63429
g52643
I59
sg52644
VChikungunya
p63430
sg52646
I11
sg52647
VC0008055
p63431
sg52649
I1
sasa(dp63432
g135
(dp63433
(VMPO
p63434
VColitis
p63435
tp63436
I00
ssg52636
VColitis severity was assessed by body weight, colonoscopy, colon length, histological score, cytokine mRNA expression, and myeloperoxidase (MPO) activity.
p63437
sg52638
(lp63438
(dp63439
g52643
I123
sg52644
Vmyeloperoxidase
p63440
sg52646
I15
sg52674
VP05164
p63441
sg52649
I1
sa(dp63442
g52643
I140
sg52644
g63434
sg52646
I3
sg52674
VP05164
p63443
sg52649
I1
sasg52640
(lp63444
(dp63445
g52643
I0
sg52644
g63435
sg52646
I7
sg52647
VC0009319
p63446
sg52649
I1
sasa(dp63447
g135
(dp63448
(Vinsulin
p63449
Vinsulin-dependent diabetes mellitus
p63450
tp63451
I00
ssg52636
VPigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) is associated with recessive mutations in SLC29A3, encoding the equilibrative nucleoside transporter hENT3 expressed in mitochondria, causing PHID and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy-plus syndrome.
p63452
sg52638
(lp63453
(dp63454
g52643
I45
sg52644
g63449
sg52646
I7
sg52674
VP01308
p63455
sg52649
I1
sa(dp63456
g52643
I166
sg52644
Vnucleoside transporter hENT3
p63457
sg52646
I28
sg52674
g12
sg52649
I3
sasg52640
(lp63458
(dp63459
g52643
I82
sg52644
VPHID
p63460
sg52646
I4
sg52647
VC1864445
p63461
sg52649
I1
sa(dp63462
g52643
I241
sg52644
Vsyndrome
p63463
sg52646
I8
sg52647
VC0039082
p63464
sg52649
I1
sa(dp63465
g52643
I11
sg52644
Vhypertrichosis
p63466
sg52646
I14
sg52647
VC0020555
p63467
sg52649
I1
sa(dp63468
g52643
I288
sg52644
Vhistiocytosis
p63469
sg52646
I13
sg52647
VC0019618
p63470
sg52649
I1
sa(dp63471
g52643
I34
sg52644
Vautoimmune
p63472
sg52646
I10
sg52647
VC0443146
p63473
sg52649
I1
sa(dp63474
g52643
I241
sg52644
Vsyndromes
p63475
sg52646
I9
sg52647
VC0039082
p63476
sg52649
I1
sa(dp63477
g52643
I82
sg52644
VPHID
p63478
sg52646
I4
sg52647
VC1864445
p63479
sg52649
I1
sa(dp63480
g52643
I261
sg52644
VRosai-Dorfman disease
p63481
sg52646
I21
sg52647
VC0019625
p63482
sg52649
I2
sa(dp63483
g52643
I45
sg52644
g63450
sg52646
I35
sg52647
VC0011854
p63484
sg52649
I3
sasa(dp63485
g135
(dp63486
(Vinsulin
p63487
Vhypertrichosis
p63488
tp63489
I00
ssg52636
VThe patients share many of the characteristics previously reported with H syndrome, including hyperpigmentation, hypertrichosis, short stature, insulin-dependent diabetes, arthritis and systemic inflammation, as well as some novel features, including selective IgG subclass deficiency and autoimmune hepatitis.
p63490
sg52638
(lp63491
(dp63492
g52643
I144
sg52644
g63487
sg52646
I7
sg52674
VP01308
p63493
sg52649
I1
sasg52640
(lp63494
(dp63495
g52643
I172
sg52644
Varthritis
p63496
sg52646
I9
sg52647
VC0003864
p63497
sg52649
I1
sa(dp63498
g52643
I251
sg52644
Vselective IgG subclass deficiency
p63499
sg52646
I33
sg52647
VC0162539
p63500
sg52649
I4
sa(dp63501
g52643
I129
sg52644
Vshort stature
p63502
sg52646
I13
sg52647
VC0013336
p63503
sg52649
I2
sa(dp63504
g52643
I195
sg52644
Vinflammation
p63505
sg52646
I12
sg52647
VC0021368
p63506
sg52649
I1
sa(dp63507
g52643
I94
sg52644
Vhyperpigmentation
p63508
sg52646
I17
sg52647
VC0162834
p63509
sg52649
I1
sa(dp63510
g52643
I72
sg52644
VH syndrome
p63511
sg52646
I10
sg52647
VC1864445
p63512
sg52649
I2
sa(dp63513
g52643
I289
sg52644
Vautoimmune hepatitis
p63514
sg52646
I20
sg52647
VC0241910
p63515
sg52649
I2
sa(dp63516
g52643
I144
sg52644
Vinsulin-dependent diabetes
p63517
sg52646
I26
sg52647
VC0011854
p63518
sg52649
I2
sa(dp63519
g52643
I113
sg52644
g63488
sg52646
I14
sg52647
VC0020555
p63520
sg52649
I1
sasa(dp63521
g135
(dp63522
(Vinsulin
p63523
VPHID
p63524
tp63525
I00
ssg52636
VLoss of function recessive mutations in the SLC29A3 gene that encodes human equilibrative nucleoside transporter 3 (ENT3) have been identified in patients with pigmented hypertrichotic dermatosis with insulin-dependent diabetes (PHID).
p63526
sg52638
(lp63527
(dp63528
g52643
I70
sg52644
Vhuman equilibrative nucleoside transporter 3
p63529
sg52646
I44
sg52674
g12
sg52649
I5
sa(dp63530
g52643
I201
sg52644
g63523
sg52646
I7
sg52674
VP01308
p63531
sg52649
I1
sasg52640
(lp63532
(dp63533
g52643
I160
sg52644
Vpigmented hypertrichotic dermatosis with insulin-dependent diabetes
p63534
sg52646
I67
sg52647
VC1864445
p63535
sg52649
I6
sa(dp63536
g52643
I229
sg52644
g63524
sg52646
I4
sg52647
VC1864445
p63537
sg52649
I1
sasa(dp63538
g135
(dp63539
(Vinsulin
p63540
Vinsulin-dependent diabetes
p63541
tp63542
I00
ssg52636
VThus, apoptotic loss of islet Beta-cells may contribute to the occurrence of autoantibody-negative insulin-dependent diabetes in individuals with non-functional ENT3 mutations.
p63543
sg52638
(lp63544
(dp63545
g52643
I99
sg52644
g63540
sg52646
I7
sg52674
VP01308
p63546
sg52649
I1
sasg52640
(lp63547
(dp63548
g52643
I99
sg52644
g63541
sg52646
I26
sg52647
VC0011854
p63549
sg52649
I2
sasa(dp63550
g135
(dp63551
(Vinsulin
p63552
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p63553
tp63554
I00
ssg52636
VH syndrome and pigmented hypertrichosis with insulin-dependent diabetes mellitus (PHID) had been described as two autosomal recessive disorders.
p63555
sg52638
(lp63556
(dp63557
g52643
I45
sg52644
g63552
sg52646
I7
sg52674
VP01308
p63558
sg52649
I1
sasg52640
(lp63559
(dp63560
g52643
I82
sg52644
VPHID
p63561
sg52646
I4
sg52647
VC1864445
p63562
sg52649
I1
sa(dp63563
g52643
I0
sg52644
VH syndrome
p63564
sg52646
I10
sg52647
VC1864445
p63565
sg52649
I2
sa(dp63566
g52643
I15
sg52644
g63553
sg52646
I65
sg52647
VC1864445
p63567
sg52649
I6
sasa(dp63568
g52636
VThe term H syndrome was coined to denote the major clinical findings which include hyperpigmentation, hypertrichosis, hearing loss, hepatosplenomegaly, hypogonadism, hyperglycemia/diabetes mellitus and hallux valgus/flexion contractures.
p63569
sg52638
(lp63570
sg52640
(lp63571
(dp63572
g52643
I202
sg52644
Vhallux valgus
p63573
sg52646
I13
sg52647
VC0018536
p63574
sg52649
I2
sa(dp63575
g52643
I152
sg52644
Vhypogonadism
p63576
sg52646
I12
sg52647
VC0020619
p63577
sg52649
I1
sa(dp63578
g52643
I180
sg52644
Vdiabetes mellitus
p63579
sg52646
I17
sg52647
VC0011849
p63580
sg52649
I2
sa(dp63581
g52643
I118
sg52644
Vhearing loss
p63582
sg52646
I12
sg52647
VC0011053
p63583
sg52649
I2
sa(dp63584
g52643
I9
sg52644
VH syndrome
p63585
sg52646
I10
sg52647
VC1864445
p63586
sg52649
I2
sa(dp63587
g52643
I132
sg52644
Vhepatosplenomegaly
p63588
sg52646
I18
sg52647
VC0019214
p63589
sg52649
I1
sa(dp63590
g52643
I166
sg52644
Vhyperglycemia
p63591
sg52646
I13
sg52647
VC0020456
p63592
sg52649
I1
sa(dp63593
g52643
I51
sg52644
Vclinical findings
p63594
sg52646
I17
sg52647
VC0037088
p63595
sg52649
I2
sa(dp63596
g52643
I83
sg52644
Vhyperpigmentation
p63597
sg52646
I17
sg52647
VC0162834
p63598
sg52649
I1
sa(dp63599
g52643
I216
sg52644
Vflexion contractures
p63600
sg52646
I20
sg52647
VC0333068
p63601
sg52649
I2
sa(dp63602
g52643
I102
sg52644
Vhypertrichosis
p63603
sg52646
I14
sg52647
VC0020555
p63604
sg52649
I1
sasa(dp63605
g135
(dp63606
(Vinsulin
p63607
VRosai-Dorfman disease
p63608
tp63609
I00
ssg52636
VMutations in SLC29A3 lead to pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) and H syndromes, familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy plus syndrome.
p63610
sg52638
(lp63611
(dp63612
g52643
I74
sg52644
g63607
sg52646
I7
sg52674
VP01308
p63613
sg52649
I1
sasg52640
(lp63614
(dp63615
g52643
I63
sg52644
Vautoimmune
p63616
sg52646
I10
sg52647
VC0443146
p63617
sg52649
I1
sa(dp63618
g52643
I74
sg52644
Vinsulin-dependent diabetes mellitus
p63619
sg52646
I35
sg52647
VC0011854
p63620
sg52649
I3
sa(dp63621
g52643
I170
sg52644
Vhistiocytosis-lymphadenopathy plus syndrome
p63622
sg52646
I43
sg52647
VC1864445
p63623
sg52649
I3
sa(dp63624
g52643
I123
sg52644
Vsyndromes
p63625
sg52646
I9
sg52647
VC0039082
p63626
sg52649
I1
sa(dp63627
g52643
I111
sg52644
VPHID
p63628
sg52646
I4
sg52647
VC1864445
p63629
sg52649
I1
sa(dp63630
g52643
I40
sg52644
Vhypertrichosis
p63631
sg52646
I14
sg52647
VC0020555
p63632
sg52649
I1
sa(dp63633
g52643
I143
sg52644
g63608
sg52646
I21
sg52647
VC0019625
p63634
sg52649
I2
sasa(dp63635
g135
(dp63636
(Vinsulin
p63637
Vinsulin-dependent diabetes
p63638
tp63639
I00
ssg52636
VThis report describes an insulin-dependent diabetes patient with a syndromic presentation in whom a homozygous SLC29A3 mutation was identified.
p63640
sg52638
(lp63641
(dp63642
g52643
I25
sg52644
g63637
sg52646
I7
sg52674
VP01308
p63643
sg52649
I1
sasg52640
(lp63644
(dp63645
g52643
I25
sg52644
g63638
sg52646
I26
sg52647
VC0011854
p63646
sg52649
I2
sasa(dp63647
g135
(dp63648
(Vinsulin
p63649
VPHID
p63650
tp63651
I00
ssg52636
VThese clinical features overlapped with pigmented hypertrichosis with insulin-dependent diabetes (PHID), H syndrome, Faisalabad histiocytosis and sinus histiocytosis with massive lymphadenopathy (SHML), all of which are also caused by SLC29A3 mutations.
p63652
sg52638
(lp63653
(dp63654
g52643
I70
sg52644
g63649
sg52646
I7
sg52674
VP01308
p63655
sg52649
I1
sasg52640
(lp63656
(dp63657
g52643
I146
sg52644
Vsinus histiocytosis with massive lymphadenopathy
p63658
sg52646
I48
sg52647
VC0019625
p63659
sg52649
I5
sa(dp63660
g52643
I105
sg52644
VH syndrome
p63661
sg52646
I10
sg52647
VC1864445
p63662
sg52649
I2
sa(dp63663
g52643
I40
sg52644
Vpigmented hypertrichosis with insulin-dependent diabetes
p63664
sg52646
I56
sg52647
VC1864445
p63665
sg52649
I5
sa(dp63666
g52643
I117
sg52644
VFaisalabad histiocytosis
p63667
sg52646
I24
sg52647
VC1864445
p63668
sg52649
I2
sa(dp63669
g52643
I196
sg52644
VSHML
p63670
sg52646
I4
sg52647
VC1864445
p63671
sg52649
I1
sa(dp63672
g52643
I98
sg52644
g63650
sg52646
I4
sg52647
VC1864445
p63673
sg52649
I1
sasa(dp63674
g135
(dp63675
(Vinsulin
p63676
Vpigmented hypertrichosis with insulin-dependent diabetes mellitus
p63677
tp63678
I00
ssg52636
VGermline mutations in the SLC29A3 gene result in a range of recessive, clinically related syndromes: H syndrome, pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome, Faisalabad histiocytosis, and sinus histiocytosis with massive lymphadenopathy.
p63679
sg52638
(lp63680
(dp63681
g52643
I143
sg52644
g63676
sg52646
I7
sg52674
VP01308
p63682
sg52649
I1
sasg52640
(lp63683
(dp63684
g52643
I101
sg52644
VH syndrome
p63685
sg52646
I10
sg52647
VC1864445
p63686
sg52649
I2
sa(dp63687
g52643
I219
sg52644
Vsinus histiocytosis with massive lymphadenopathy
p63688
sg52646
I48
sg52647
VC0019625
p63689
sg52649
I5
sa(dp63690
g52643
I189
sg52644
VFaisalabad histiocytosis
p63691
sg52646
I24
sg52647
VC1864445
p63692
sg52649
I2
sa(dp63693
g52643
I90
sg52644
Vsyndrome
p63694
sg52646
I8
sg52647
VC0039082
p63695
sg52649
I1
sa(dp63696
g52643
I113
sg52644
g63677
sg52646
I65
sg52647
VC1864445
p63697
sg52649
I6
sa(dp63698
g52643
I90
sg52644
Vsyndromes
p63699
sg52646
I9
sg52647
VC0039082
p63700
sg52649
I1
sasa(dp63701
g52636
VCharacteristic ADC map features were identified for protrusion, extrusion and sequester types of lumbar disk herniations, spondylolisthesis, reactive Modic endplate changes, Pfirrmann grades of IVD degeneration, and compromised spinal nerves.
p63702
sg52638
(lp63703
sg52640
(lp63704
(dp63705
g52643
I122
sg52644
Vspondylolisthesis
p63706
sg52646
I17
sg52647
VC0038017
p63707
sg52649
I1
sa(dp63708
g52643
I52
sg52644
Vprotrusion
p63709
sg52646
I10
sg52647
VC0333056
p63710
sg52649
I1
sa(dp63711
g52643
I198
sg52644
Vdegeneration
p63712
sg52646
I12
sg52647
VC0011164
p63713
sg52649
I1
sa(dp63714
g52643
I109
sg52644
Vherniations
p63715
sg52646
I11
sg52647
VC0019270
p63716
sg52649
I1
sasa(dp63717
g52636
VWe measured T2 relaxation time of the intervertebral discs (IVD) and facet joints (FJ) in patients with degenerative spondylolisthesis (DS) and no spondylolisthesis (NS) and investigated the characteristics of these parts in DS.
p63718
sg52638
(lp63719
sg52640
(lp63720
(dp63721
g52643
I136
sg52644
VDS
p63722
sg52646
I2
sg52647
VC0264184
p63723
sg52649
I1
sa(dp63724
g52643
I117
sg52644
Vspondylolisthesis
p63725
sg52646
I17
sg52647
VC0038017
p63726
sg52649
I1
sa(dp63727
g52643
I104
sg52644
Vdegenerative spondylolisthesis
p63728
sg52646
I30
sg52647
VC0264184
p63729
sg52649
I2
sa(dp63730
g52643
I136
sg52644
VDS
p63731
sg52646
I2
sg52647
VC0264184
p63732
sg52649
I1
sasa(dp63733
g52636
VEarly stages of scoliosis and spondylolisthesis entail changes in the intervertebral disc (IVD) structure and biochemistry.
p63734
sg52638
(lp63735
sg52640
(lp63736
(dp63737
g52643
I30
sg52644
Vspondylolisthesis
p63738
sg52646
I17
sg52647
VC0038017
p63739
sg52649
I1
sa(dp63740
g52643
I16
sg52644
Vscoliosis
p63741
sg52646
I9
sg52647
VC0700208
p63742
sg52649
I1
sasa(dp63743
g52636
VTherefore, this study aims to develop the AMRSID (analysis of MR signal intensity distribution) method to analyze the 3D distribution of the MR signal intensity within the IVD and to evaluate their sensitivity to scoliosis and spondylolisthesis and their severities.
p63744
sg52638
(lp63745
sg52640
(lp63746
(dp63747
g52643
I227
sg52644
Vspondylolisthesis
p63748
sg52646
I17
sg52647
VC0038017
p63749
sg52649
I1
sa(dp63750
g52643
I213
sg52644
Vscoliosis
p63751
sg52646
I9
sg52647
VC0700208
p63752
sg52649
I1
sasa(dp63753
g52636
VIVDs were collected from patients with lumbar fracture, vertebral tumor, disc herniation or spondylolisthesis.
p63754
sg52638
(lp63755
sg52640
(lp63756
(dp63757
g52643
I92
sg52644
Vspondylolisthesis
p63758
sg52646
I17
sg52647
VC0038017
p63759
sg52649
I1
sa(dp63760
g52643
I66
sg52644
Vtumor
p63761
sg52646
I5
sg52647
VC0027651
p63762
sg52649
I1
sa(dp63763
g52643
I78
sg52644
Vherniation
p63764
sg52646
I10
sg52647
VC0019270
p63765
sg52649
I1
sasa(dp63766
g52636
V"Pedra hume caa" is the common name of five species of Myrcia genus used as traditional medicine for the treatment of diabetes mellitus.
p63767
sg52638
(lp63768
sg52640
(lp63769
(dp63770
g52643
I12
sg52644
Vcaa
p63771
sg52646
I3
sg52647
VC1842937
p63772
sg52649
I1
sa(dp63773
g52643
I118
sg52644
Vdiabetes mellitus
p63774
sg52646
I17
sg52647
VC0011849
p63775
sg52649
I2
sasa(dp63776
g135
(dp63777
(Vinsulin
p63778
Vdiabetes
p63779
tp63780
I00
ssg52636
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p63781
sg52638
(lp63782
(dp63783
g52643
I112
sg52644
g63778
sg52646
I7
sg52674
VP01308
p63784
sg52649
I1
sasg52640
(lp63785
(dp63786
g52643
I84
sg52644
Vcaa
p63787
sg52646
I3
sg52647
VC1842937
p63788
sg52649
I1
sa(dp63789
g52643
I84
sg52644
Vcaa
p63790
sg52646
I3
sg52647
VC1842937
p63791
sg52649
I1
sa(dp63792
g52643
I183
sg52644
g63779
sg52646
I8
sg52647
VC0011849
p63793
sg52649
I1
sasa(dp63794
g135
(dp63795
(Vinsulin
p63796
Vdiabetes
p63797
tp63798
I00
ssg52636
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p63799
sg52638
(lp63800
(dp63801
g52643
I112
sg52644
g63796
sg52646
I7
sg52674
VP01308
p63802
sg52649
I1
sasg52640
(lp63803
(dp63804
g52643
I84
sg52644
Vcaa
p63805
sg52646
I3
sg52647
VC1842937
p63806
sg52649
I1
sa(dp63807
g52643
I84
sg52644
Vcaa
p63808
sg52646
I3
sg52647
VC1842937
p63809
sg52649
I1
sa(dp63810
g52643
I183
sg52644
g63797
sg52646
I8
sg52647
VC0011849
p63811
sg52649
I1
sasa(dp63812
g135
(dp63813
(Vinsulin
p63814
Vdiabetes
p63815
tp63816
I00
ssg52636
VSome of the species are used in folk medicine, such as a group known as "pedra-hume-caa" or "pedra-ume-caa" or "insulina vegetal" (insulin plant) that it is used for the treatment of diabetes.
p63817
sg52638
(lp63818
(dp63819
g52643
I112
sg52644
g63814
sg52646
I7
sg52674
VP01308
p63820
sg52649
I1
sasg52640
(lp63821
(dp63822
g52643
I84
sg52644
Vcaa
p63823
sg52646
I3
sg52647
VC1842937
p63824
sg52649
I1
sa(dp63825
g52643
I84
sg52644
Vcaa
p63826
sg52646
I3
sg52647
VC1842937
p63827
sg52649
I1
sa(dp63828
g52643
I183
sg52644
g63815
sg52646
I8
sg52647
VC0011849
p63829
sg52649
I1
sasa(dp63830
g135
(dp63831
(Vinsulin
p63832
Vglucose intolerance
p63833
tp63834
I00
ssg52636
VAdult Tshz1(+/-) mice display glucose intolerance due to defects in glucose-stimulated insulin secretion associated with reduced Pdx1 and Clec16a expression in Tshz1(+/-) islets.
p63835
sg52638
(lp63836
(dp63837
g52643
I138
sg52644
VClec16a
p63838
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp63839
g52643
I129
sg52644
VPdx1
p63840
sg52646
I4
sg52674
VP52945
p63841
sg52649
I1
sa(dp63842
g52643
I6
sg52644
VTshz1
p63843
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp63844
g52643
I87
sg52644
g63832
sg52646
I7
sg52674
VP01308
p63845
sg52649
I1
sasg52640
(lp63846
(dp63847
g52643
I30
sg52644
g63833
sg52646
I19
sg52647
VC0271650
p63848
sg52649
I2
sasa(dp63849
g52636
VLastly, we demonstrate that TSHZ1 levels are reduced in human islets of donors with type 2 diabetes.
p63850
sg52638
(lp63851
(dp63852
g52643
I28
sg52644
VTSHZ1
p63853
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp63854
(dp63855
g52643
I84
sg52644
Vtype 2 diabetes
p63856
sg52646
I15
sg52647
VC0011860
p63857
sg52649
I3
sasa(dp63858
g52636
VThus, we position Tshz1 in the transcriptional network of maturing Beta-cells and suggest that its dysregulation could contribute to the islet phenotype of human type 2 diabetes.
p63859
sg52638
(lp63860
(dp63861
g52643
I18
sg52644
VTshz1
p63862
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp63863
(dp63864
g52643
I162
sg52644
Vtype 2 diabetes
p63865
sg52646
I15
sg52647
VC0011860
p63866
sg52649
I3
sasa(dp63867
g52636
VMaterial e Metodos: Revisao bibliografica, atraves da Medline e PubMed, utilizando como palavras-chave: 'borderline personality disorder', 'cognitive-behavioral therapy', 'efficacy'.
p63868
sg52638
(lp63869
sg52640
(lp63870
(dp63871
g52643
I104
sg52644
V'borderline personality disorder
p63872
sg52646
I32
sg52647
VC0006012
p63873
sg52649
I3
sasa(dp63874
g52636
V#\u76ee#\u7684#\uff1a #\u7814#\u7a76#\u963b#\u585e#\u6027#\u7761#\u7720#\u547c#\u5438#\u6682#\u505c#\u4f4e#\u901a#\u6c14#\u7efc#\u5408#\u5f81(obstructive sleep apnea hypopnea syndrome, OSAHS)#\u5408#\u5e76#\u96be#\u6cbb#\u6027#\u9ad8#\u8840#\u538b(resistant hypertension, RH)#\u60a3#\u8005#\u4e2d, OSAHS#\u7684#\u6cbb#\u7597#\u5bf9#\u8840#\u538b#\u63a7#\u5236#\u7684#\u610f#\u4e49#\u3002 #\u65b9#\u6cd5#\uff1a 80#\u4f8bOSAHS#\u5408#\u5e76RH#\u60a3#\u8005[#\u81f3#\u5c113#\u79cd#\u6297#\u9ad8#\u8840#\u538b#\u836f(#\u5305#\u62ec#\u5229#\u5c3f#\u5242)#\u6cbb#\u7597, #\u4ecd#\u4e0d#\u80fd#\u5c06#\u6536#\u7f29#\u538b#\u548c#\u8212#\u5f20#\u538b#\u63a7#\u5236#\u5728#\u76ee#\u6807#\u6c34#\u5e73(140/90 mmHg, 1 mmHg=0.133 kPa)]#\u884c#\u624b#\u672f#\u6216#\u6301#\u7eed#\u6b63#\u538b#\u901a#\u6c14#\u6cbb#\u7597, #\u6cbb#\u7597#\u524d#\u53ca#\u6cbb#\u75976#\u4e2a#\u6708#\u540e#\u884c#\u591a#\u9053#\u7761#\u7720#\u76d1#\u6d4b#\u548c#\u52a8#\u6001#\u8840#\u538b#\u76d1#\u6d4b, #\u8bb0#\u5f55#\u547c#\u5438#\u6682#\u505c#\u4f4e#\u901a#\u6c14#\u6307#\u6570(apnea hypopnea index, AHI)#\u3001#\u6700#\u4f4e#\u8840#\u6c27#\u9971#\u548c#\u5ea6(SaO(2))#\u3001#\u8840#\u538b#\u3001#\u591c#\u95f4#\u8840#\u538b#\u4e0b#\u964d#\u7387, #\u6bd4#\u8f83#\u6cbb#\u7597#\u524d#\u540e#\u964d#\u538b#\u836f#\u7269#\u79cd#\u7c7b#\u7684#\u53d8#\u5316#\u3002 #\u7ed3#\u679c#\uff1a #\u6cbb#\u7597#\u540e, AHI#\u7531(32.9+/-10.8)#\u6b21/h(x+/-s, #\u4e0b#\u540c)#\u964d#\u81f3(9.4+/-6.5)#\u6b21/h, #\u6700#\u4f4eSaO(2)#\u7531(0.682+/-0.062)#\u589e#\u81f3(0.884+/-0.056), #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a18.863#\u300126.614, P#\u503c#\u5747&lt;0.001)#\u3002#\u5168#\u5929#\u6536#\u7f29#\u538b#\u7531(150.5+/-9.8) mmHg#\u964d#\u81f3(140.7+/-6.8) mmHg, #\u8212#\u5f20#\u538b#\u7531(97.8+/-7.3) mmHg#\u964d#\u81f3(88.6+/-6.3) mmHg#\uff1b#\u65e5#\u95f4#\u6536#\u7f29#\u538b#\u7531(154.3+/-8.9) mmHg#\u964d#\u81f3(144.8+/-5.8) mmHg, #\u8212#\u5f20#\u538b#\u7531(100.6+/-7.4) mmHg#\u964d#\u81f3(91.3+/-5.5) mmHg#\uff1b#\u591c#\u95f4#\u6536#\u7f29#\u538b#\u7531(145.5+/-8.8) mmHg#\u964d#\u81f3(135.8+/-5.7) mmHg, #\u8212#\u5f20#\u538b#\u7531(93.8+/-6.4) mmHg#\u964d#\u81f3(84.6+/-5.9) mmHg, #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a7.832#\u30016.903#\u30017.005#\u30016.848#\u30018.025#\u30017.554, P#\u503c#\u5747&lt;0.001)#\u3002#\u591c#\u95f4#\u6536#\u7f29#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(11.5+/-2.2)mmHg#\u3001#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(10.2+/-3.1)mmHg, #\u65e5#\u95f4#\u6536#\u7f29#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(9.0+/-2.8)mmHg#\u3001#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u503c#\u4e3a(7.9+/-3.5)mmHg, #\u591c#\u95f4#\u6536#\u7f29#\u538b#\u53ca#\u8212#\u5f20#\u538b#\u4e0b#\u964d#\u8f83#\u65e5#\u95f4#\u66f4#\u660e#\u663e, #\u5dee#\u5f02#\u5747#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t#\u503c#\u5206#\u522b#\u4e3a9.732#\u30016.936, P#\u503c#\u5747&lt;0.001)#\u3002#\u591c#\u95f4#\u8840#\u538b#\u4e0b#\u964d#\u7387&lt;10%#\u7684#\u60a3#\u8005#\u6bd4#\u4f8b#\u7531#\u6cbb#\u7597#\u524d#\u768475.0%#\u964d#\u4e3a#\u6cbb#\u7597#\u540e#\u768437.5%, #\u5dee#\u5f02#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(X(2)=22.857, P&lt;0.01), #\u63d0#\u793a#\u8840#\u538b#\u663c#\u591c#\u8282#\u5f8b#\u53d8#\u5316#\u60c5#\u51b5#\u597d#\u8f6c#\u300245#\u4f8b#\u60a3#\u8005#\u670d#\u7528#\u7684#\u964d#\u538b#\u836f#\u7269#\u79cd#\u7c7b#\u51cf#\u5c11, #\u7531#\u6cbb#\u7597#\u524d#\u7684(3.2+/-0.4)#\u79cd#\u51cf#\u4e3a#\u6cbb#\u7597#\u540e#\u7684(2.6+/-0.5)#\u79cd, #\u5dee#\u5f02#\u6709#\u7edf#\u8ba1#\u5b66#\u610f#\u4e49(t=9.276, P&lt;0.01)#\u3002 #\u7ed3#\u8bba#\uff1a OSAHS#\u5408#\u5e76RH#\u60a3#\u8005#\u4e2d, #\u6cbb#\u7597OSAHS#\u80fd#\u6709#\u6548#\u6539#\u5584#\u8840#\u538b#\u63a7#\u5236#\u6c34#\u5e73, #\u6539#\u5584#\u8840#\u538b#\u663c#\u591c#\u8282#\u5f8b, #\u51cf#\u5c11#\u964d#\u538b#\u836f#\u7269#\u7684#\u4f7f#\u7528#\u3002.
p63875
sg52638
(lp63876
sg52640
(lp63877
(dp63878
g52643
I85
sg52644
VOSAHS
p63879
sg52646
I5
sg52647
VC0520679
p63880
sg52649
I1
sa(dp63881
g52643
I118
sg52644
Vhypertension
p63882
sg52646
I12
sg52647
VC0020538
p63883
sg52649
I1
sa(dp63884
g52643
I85
sg52644
VOSAHS
p63885
sg52646
I5
sg52647
VC0520679
p63886
sg52649
I1
sa(dp63887
g52643
I42
sg52644
Vobstructive sleep apnea
p63888
sg52646
I23
sg52647
VC0520679
p63889
sg52649
I3
sa(dp63890
g52643
I66
sg52644
Vhypopnea syndrome
p63891
sg52646
I17
sg52647
VC2748060
p63892
sg52649
I2
sa(dp63893
g52643
I60
sg52644
Vapnea
p63894
sg52646
I5
sg52647
VC0003578
p63895
sg52649
I1
sa(dp63896
g52643
I85
sg52644
VOSAHS
p63897
sg52646
I5
sg52647
VC0520679
p63898
sg52649
I1
sasa(dp63899
g52636
VIn case of coronary atherosclerosis the organism reaction to expressed CMC is manifested basically by intensified synthesis of cathodic complement-C3-similar autoprecipitin, but in case of endocarditis--by consumption of one with formation of anodic autoprecipitin and by intensified synthesis of autoprecipitating immunoglobulin G. These membranotropic autoimmune reactions are identical with the organism reactions to alien (heterologous) agents and differentially participate in development both of basic disease and perioperational complications after cardiac operations using trans- and implants, hence, they should be taken into account during membrane-stabilising and immunocorrecting therapy of recipients.
p63900
sg52638
(lp63901
(dp63902
g52643
I315
sg52644
Vimmunoglobulin G
p63903
sg52646
I16
sg52674
g12
sg52649
I2
sa(dp63904
g52643
I127
sg52644
Vcathodic complement-C3
p63905
sg52646
I22
sg52674
g12
sg52649
I2
sasg52640
(lp63906
(dp63907
g52643
I354
sg52644
Vautoimmune reactions
p63908
sg52646
I20
sg52647
VC0443146
p63909
sg52649
I2
sa(dp63910
g52643
I11
sg52644
Vcoronary atherosclerosis
p63911
sg52646
I24
sg52647
VC2733225
p63912
sg52649
I2
sa(dp63913
g52643
I189
sg52644
Vendocarditis
p63914
sg52646
I12
sg52647
VC0014118
p63915
sg52649
I1
sasa(dp63916
g135
(dp63917
(VTNF-Alfa
p63918
Vhepatoma
p63919
tp63920
I00
ssg52636
VIn cultured rat hepatoma (H4IIE) cells, TNF-Alfa significantly increased hemopexin mRNA accumulation.
p63921
sg52638
(lp63922
(dp63923
g52643
I73
sg52644
Vhemopexin mRNA
p63924
sg52646
I14
sg52674
VP02790
p63925
sg52649
I2
sa(dp63926
g52643
I40
sg52644
g63918
sg52646
I8
sg52674
VP01375
p63927
sg52649
I1
sasg52640
(lp63928
(dp63929
g52643
I16
sg52644
g63919
sg52646
I8
sg52647
VC0023903
p63930
sg52649
I1
sasa(dp63931
g135
(dp63932
(VA2M
p63933
Vhepatocellular carcinoma
p63934
tp63935
I00
ssg52636
VThis analytical method was applied to an in vitro diagnostic multivariate index assay where a panel of hepatocellular carcinoma (HCC) biomarkers comprising alpha-fetoprotein, hemopexin, and alpha-2-macroglobulin (A2M) was examined in terms of the serum level and their fuco-fractions.
p63936
sg52638
(lp63937
(dp63938
g52643
I175
sg52644
Vhemopexin
p63939
sg52646
I9
sg52674
VP02790
p63940
sg52649
I1
sa(dp63941
g52643
I156
sg52644
Valpha-fetoprotein
p63942
sg52646
I17
sg52674
VP02771
p63943
sg52649
I1
sa(dp63944
g52643
I190
sg52644
Valpha-2-macroglobulin
p63945
sg52646
I21
sg52674
VP01023
p63946
sg52649
I1
sa(dp63947
g52643
I213
sg52644
g63933
sg52646
I3
sg52674
VP01023
p63948
sg52649
I1
sasg52640
(lp63949
(dp63950
g52643
I129
sg52644
VHCC
p63951
sg52646
I3
sg52647
VC2239176
p63952
sg52649
I1
sa(dp63953
g52643
I103
sg52644
g63934
sg52646
I24
sg52647
VC2239176
p63954
sg52649
I2
sasa(dp63955
g52636
VThe aim of this study was to identify new target genes for microRNA polymorphisms (miR-146aC&gt;G and miR-196a2T&gt;C) in primary ovarian insufficiency (POI).
p63956
sg52638
(lp63957
(dp63958
g52643
I-1
sg52644
VmiR-196a2T>C
p63959
sg52646
I12
sg52674
g12
sg52649
I1
sa(dp63960
g52643
I83
sg52644
VmiR-146aC
p63961
sg52646
I9
sg52674
g12
sg52649
I1
sasg52640
(lp63962
(dp63963
g52643
I153
sg52644
VPOI
p63964
sg52646
I3
sg52647
VC0041408
p63965
sg52649
I1
sa(dp63966
g52643
I122
sg52644
Vprimary ovarian insufficiency
p63967
sg52646
I29
sg52647
VC0041408
p63968
sg52649
I3
sasa(dp63969
g52636
VIn addition, several specific miRNAs (miR-23a, miR-27a, miR-22-3p, miR-146a, miR-196a, miR-290-295, miR-423, and miR-608) related to POI are also examined in order to highlight the issues that deserve further investigation.
p63970
sg52638
(lp63971
(dp63972
g52643
I67
sg52644
VmiR-146a
p63973
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp63974
g52643
I47
sg52644
VmiR-27a
p63975
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp63976
g52643
I56
sg52644
VmiR-22-3p
p63977
sg52646
I9
sg52674
g12
sg52649
I1
sa(dp63978
g52643
I113
sg52644
VmiR-608
p63979
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp63980
g52643
I77
sg52644
VmiR-196a
p63981
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp63982
g52643
I38
sg52644
VmiR-23a
p63983
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp63984
sa(dp63985
g52636
V(2) Expand sample size to 14 cases for endometriosis group and 16 cases for control group.Reverse transcription (RT)-PCR technique was utilized to detect the expression of miR- 142- 5p, miR- 146a- 5p and miR- 543 in endometrial tissues, and verify miRNA microarray results.
p63986
sg52638
(lp63987
(dp63988
g52643
I186
sg52644
VmiR- 146a- 5p
p63989
sg52646
I13
sg52674
g12
sg52649
I3
sa(dp63990
g52643
I172
sg52644
VmiR- 142- 5p
p63991
sg52646
I12
sg52674
g12
sg52649
I3
sa(dp63992
g52643
I204
sg52644
VmiR- 543
p63993
sg52646
I8
sg52674
g12
sg52649
I2
sasg52640
(lp63994
(dp63995
g52643
I39
sg52644
Vendometriosis
p63996
sg52646
I13
sg52647
VC0014175
p63997
sg52649
I1
sasa(dp63998
g52636
V(1) miRNA and mRNA microarray screening results showed that, among the endometrial tissues of patients with endometriosis infertility and with implantation window phase, 6 differentially expressed miRNA were indentified, among which miR-142-5p, miR-146a-5p, miR-1281, miR-940, miR-4634 showed significantly enhanced expression and miR- 543 showed significantly inhibited expression.
p63999
sg52638
(lp64000
(dp64001
g52643
I233
sg52644
VmiR-142-5p
p64002
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp64003
g52643
I268
sg52644
VmiR-940
p64004
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp64005
g52643
I277
sg52644
VmiR-4634
p64006
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp64007
g52643
I245
sg52644
VmiR-146a-5p
p64008
sg52646
I11
sg52674
g12
sg52649
I1
sa(dp64009
g52643
I258
sg52644
VmiR-1281
p64010
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp64011
g52643
I331
sg52644
VmiR- 543
p64012
sg52646
I8
sg52674
g12
sg52649
I2
sasg52640
(lp64013
(dp64014
g52643
I122
sg52644
Vinfertility
p64015
sg52646
I11
sg52647
VC0021359
p64016
sg52649
I1
sa(dp64017
g52643
I108
sg52644
Vendometriosis
p64018
sg52646
I13
sg52647
VC0014175
p64019
sg52649
I1
sasa(dp64020
g52636
V(2) RT- PCR test showed that the average levels of expression of miR-142-5p and miR-146a-5p in implantation window phase endometrium in endometriosis group were 8.3+/-10.6 and 1.9+/-0.8 respectively; the average levels of that in control group were 1.1+/-0.6 and 0.9+/-0.4, respectively.
p64021
sg52638
(lp64022
(dp64023
g52643
I80
sg52644
VmiR-146a-5p
p64024
sg52646
I11
sg52674
g12
sg52649
I1
sa(dp64025
g52643
I65
sg52644
VmiR-142-5p
p64026
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp64027
(dp64028
g52643
I136
sg52644
Vendometriosis
p64029
sg52646
I13
sg52647
VC0014175
p64030
sg52649
I1
sasa(dp64031
g52636
VThere are multiple differential expressions of miRNA in the implantation window phase endometrium tissues of endometriosis infertility patients, among which miR-142-5p and miR-146a-5p show significantly enhanced expression and may affect embryo implantation by acting on a variety of endometrial receptivity marker molecules.
p64032
sg52638
(lp64033
(dp64034
g52643
I172
sg52644
VmiR-146a-5p
p64035
sg52646
I11
sg52674
g12
sg52649
I1
sa(dp64036
g52643
I157
sg52644
VmiR-142-5p
p64037
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp64038
(dp64039
g52643
I123
sg52644
Vinfertility
p64040
sg52646
I11
sg52647
VC0021359
p64041
sg52649
I1
sa(dp64042
g52643
I109
sg52644
Vendometriosis
p64043
sg52646
I13
sg52647
VC0014175
p64044
sg52649
I1
sasa(dp64045
g135
(dp64046
(VRhoA
p64047
Vasthma
p64048
tp64049
I01
ssg52636
VWe also analyze the ezrin-meditated regulation of critical pathways associated with asthma, such as the RhoA, Rho-associated protein kinase (ROCK), and protein kinase A (cAMP/PKA) pathways.
p64050
sg52638
(lp64051
(dp64052
g52643
I141
sg52644
VROCK
p64053
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64054
g52643
I170
sg52644
VcAMP/PKA
p64055
sg52646
I8
sg52674
VP49913
p64056
sg52649
I1
sa(dp64057
g52643
I110
sg52644
VRho-associated protein kinase
p64058
sg52646
I29
sg52674
VP08100
p64059
sg52649
I3
sa(dp64060
g52643
I152
sg52644
Vprotein kinase A
p64061
sg52646
I16
sg52674
VP17612
p64062
sg52649
I3
sa(dp64063
g52643
I104
sg52644
g64047
sg52646
I4
sg52674
VP61586
p64064
sg52649
I1
sasg52640
(lp64065
(dp64066
g52643
I84
sg52644
g64048
sg52646
I6
sg52647
VC0004096
p64067
sg52649
I1
sasa(dp64068
g52636
VPneumothorax is a well-recognized complication of central venous line insertion (CVL).
p64069
sg52638
(lp64070
sg52640
(lp64071
(dp64072
g52643
I34
sg52644
Vcomplication
p64073
sg52646
I12
sg52647
VC0009566
p64074
sg52649
I1
sa(dp64075
g52643
I0
sg52644
VPneumothorax
p64076
sg52646
I12
sg52647
VC0032326
p64077
sg52649
I1
sasa(dp64078
g135
(dp64079
(VSLC9A3-SLC9A3R1/2-EZR complex
p64080
Vlung disease
p64081
tp64082
I00
ssg52636
VWe identify and replicate an association between the constituents of the apical plasma membrane and CF lung disease (p = 0.0099 and p = 0.0180, respectively) and highlight a role for the SLC9A3-SLC9A3R1/2-EZR complex in contributing to CF lung disease.
p64083
sg52638
(lp64084
(dp64085
g52643
I187
sg52644
g64080
sg52646
I29
sg52674
VP48764
p64086
sg52649
I2
sasg52640
(lp64087
(dp64088
g52643
I103
sg52644
Vlung disease
p64089
sg52646
I12
sg52647
VC0024115
p64090
sg52649
I2
sa(dp64091
g52643
I103
sg52644
g64081
sg52646
I12
sg52647
VC0024115
p64092
sg52649
I2
sasa(dp64093
g135
(dp64094
(VSti1
p64095
VAld
p64096
tp64097
I00
ssg52636
VThe BrGR-expressing yeast strain induced the activation of metabolic enzymes (Hxt, G6PDH, GAPDH and Ald), antioxidant systems (Gpx, Trx2, Trx3, Trr1, Tsa1 and porin) and molecular chaperones (Hsp104, Hsp90, Hsp70, Hsp42, Hsp26, Grp, Sti1 and Zpr1), which led to lower oxidative protein damage after a reduction in the level of cellular ROS in the BrGR-expressing yeast strain exposed to H(2)O(2) than in the wild-type yeast strain.
p64098
sg52638
(lp64099
(dp64100
g52643
I100
sg52644
VAld
p64101
sg52646
I3
sg52674
VP33897
p64102
sg52649
I1
sa(dp64103
g52643
I127
sg52644
VGpx
p64104
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp64105
g52643
I228
sg52644
VGrp
p64106
sg52646
I3
sg52674
VP07492
p64107
sg52649
I1
sa(dp64108
g52643
I90
sg52644
VGAPDH
p64109
sg52646
I5
sg52674
VP04406
p64110
sg52649
I1
sa(dp64111
g52643
I159
sg52644
Vporin
p64112
sg52646
I5
sg52674
VP21796
p64113
sg52649
I1
sa(dp64114
g52643
I132
sg52644
VTrx2
p64115
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64116
g52643
I150
sg52644
VTsa1
p64117
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64118
g52643
I207
sg52644
VHsp70
p64119
sg52646
I5
sg52674
VP34932
p64120
sg52649
I1
sa(dp64121
g52643
I242
sg52644
VZpr1
p64122
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64123
g52643
I83
sg52644
VG6PDH
p64124
sg52646
I5
sg52674
VP11413
p64125
sg52649
I1
sa(dp64126
g52643
I200
sg52644
VHsp90
p64127
sg52646
I5
sg52674
VP07900
p64128
sg52649
I1
sa(dp64129
g52643
I78
sg52644
VHxt
p64130
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp64131
g52643
I233
sg52644
g64095
sg52646
I4
sg52674
VP31948
p64132
sg52649
I1
sasg52640
(lp64133
(dp64134
g52643
I100
sg52644
g64096
sg52646
I3
sg52647
VC0162309
p64135
sg52649
I1
sasa(dp64136
g52636
VIn this review, we focus on the use of these agents in children to treat inflammatory skin diseases other than psoriasis, including atopic dermatitis, hidradenitis suppurativa, pemphigus vulgaris, bullous pemphigoid, and toxic epidermal necrolysis, with an emphasis on the use of etanercept, infliximab, rituximab, omalizumab, and ustekinumab.
p64137
sg52638
(lp64138
sg52640
(lp64139
(dp64140
g52643
I177
sg52644
Vpemphigus vulgaris
p64141
sg52646
I18
sg52647
VC0030809
p64142
sg52649
I2
sa(dp64143
g52643
I111
sg52644
Vpsoriasis
p64144
sg52646
I9
sg52647
VC0033860
p64145
sg52649
I1
sa(dp64146
g52643
I151
sg52644
Vhidradenitis suppurativa
p64147
sg52646
I24
sg52647
VC0162836
p64148
sg52649
I2
sa(dp64149
g52643
I221
sg52644
Vtoxic epidermal necrolysis
p64150
sg52646
I26
sg52647
VC0014518
p64151
sg52649
I3
sa(dp64152
g52643
I197
sg52644
Vbullous pemphigoid
p64153
sg52646
I18
sg52647
VC0030805
p64154
sg52649
I2
sa(dp64155
g52643
I132
sg52644
Vatopic dermatitis
p64156
sg52646
I17
sg52647
VC0011615
p64157
sg52649
I2
sa(dp64158
g52643
I86
sg52644
Vskin diseases
p64159
sg52646
I13
sg52647
VC0037274
p64160
sg52649
I2
sasa(dp64161
g52636
VThe addition of distamycin A enhanced the double-strand DNA cleavage at the 5'-CCT-3'/3'-GGA-5' and 5'-CCA-3'/3'-GGT-5' sequences, with a two-nucleotide 3'-stagger of the cleaved residues.
p64162
sg52638
(lp64163
sg52640
(lp64164
(dp64165
g52643
I79
sg52644
VCCT
p64166
sg52646
I3
sg52647
VC2752078
p64167
sg52649
I1
sa(dp64168
g52643
I103
sg52644
VCCA
p64169
sg52646
I3
sg52647
VC0220668
p64170
sg52649
I1
sasa(dp64171
g135
(dp64172
(VCOX6A1
p64173
VCMT2K
p64174
tp64175
I00
ssg52636
VBesides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).
p64176
sg52638
(lp64177
(dp64178
g52643
I133
sg52644
VCMT2B1
p64179
sg52646
I6
sg52674
VP02545
p64180
sg52649
I1
sa(dp64181
g52643
I112
sg52644
VCMT2A2
p64182
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp64183
g52643
I140
sg52644
VLMNA
p64184
sg52646
I4
sg52674
VP02545
p64185
sg52649
I1
sa(dp64186
g52643
I127
sg52644
VMFN2
p64187
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64188
g52643
I214
sg52644
VLRSAM1
p64189
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp64190
g52643
I195
sg52644
VCMT2K
p64191
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64192
g52643
I235
sg52644
VCMT2S
p64193
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64194
g52643
I294
sg52644
VGAN
p64195
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp64196
g52643
I449
sg52644
VSPG15
p64197
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64198
g52643
I439
sg52644
VSPG7
p64199
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64200
g52643
I294
sg52644
VGAN
p64201
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp64202
g52643
I483
sg52644
VFA2H
p64203
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64204
g52643
I455
sg52644
VZFYVE26
p64205
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp64206
g52643
I241
sg52644
VIGHMBP2
p64207
sg52646
I7
sg52674
VP38935
p64208
sg52649
I1
sa(dp64209
g52643
I256
sg52644
VHSJ1
p64210
sg52646
I4
sg52674
VP25686
p64211
sg52649
I1
sa(dp64212
g52643
I444
sg52644
VPGN
p64213
sg52646
I3
sg52674
VP00747
p64214
sg52649
I1
sa(dp64215
g52643
I228
sg52644
VTRIM2
p64216
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64217
g52643
I153
sg52644
VMED25
p64218
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64219
g52643
I495
sg52644
VGBA2
p64220
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp64221
g52643
I167
sg52644
VNEFL
p64222
sg52646
I4
sg52674
VP07196
p64223
sg52649
I1
sa(dp64224
g52643
I285
sg52644
VHINT
p64225
sg52646
I4
sg52674
VP49773
p64226
sg52649
I1
sa(dp64227
g52643
I507
sg52644
VC12orf65
p64228
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp64229
g52643
I470
sg52644
VACP33
p64230
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64231
g52643
I520
sg52644
VSPG56/CYP2U1
p64232
sg52646
I12
sg52674
g12
sg52649
I1
sa(dp64233
g52643
I201
sg52644
VGDAP1
p64234
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64235
g52643
I119
sg52644
VHMSN2A2
p64236
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp64237
g52643
I464
sg52644
VSPG21
p64238
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64239
g52643
I269
sg52644
g64173
sg52646
I6
sg52674
VP12074
p64240
sg52649
I1
sasg52640
(lp64241
(dp64242
g52643
I208
sg52644
VCMT2P
p64243
sg52646
I5
sg52647
VC3280797
p64244
sg52649
I1
sa(dp64245
g52643
I146
sg52644
VCMT2B2
p64246
sg52646
I6
sg52647
VC1854150
p64247
sg52649
I1
sa(dp64248
g52643
I294
sg52644
VGAN
p64249
sg52646
I3
sg52647
VC1850386
p64250
sg52649
I1
sa(dp64251
g52643
I449
sg52644
VSPG15
p64252
sg52646
I5
sg52647
VC1849128
p64253
sg52649
I1
sa(dp64254
g52643
I439
sg52644
VSPG7
p64255
sg52646
I4
sg52647
VC1846564
p64256
sg52649
I1
sa(dp64257
g52643
I133
sg52644
VCMT2B1
p64258
sg52646
I6
sg52647
VC1854154
p64259
sg52649
I1
sa(dp64260
g52643
I294
sg52644
VGAN
p64261
sg52646
I3
sg52647
VC1850386
p64262
sg52649
I1
sa(dp64263
g52643
I83
sg52644
VCharcot-Marie-Tooth disease
p64264
sg52646
I27
sg52647
VC0007959
p64265
sg52649
I2
sa(dp64266
g52643
I112
sg52644
VCMT2A2
p64267
sg52646
I6
sg52647
VC1836485
p64268
sg52649
I1
sa(dp64269
g52643
I119
sg52644
VHMSN2A2
p64270
sg52646
I7
sg52647
VC1836485
p64271
sg52649
I1
sa(dp64272
g52643
I409
sg52644
Vaxonal peripheral neuropathy
p64273
sg52646
I28
sg52647
VC1263857
p64274
sg52649
I3
sa(dp64275
g52643
I181
sg52644
VdHMN2B
p64276
sg52646
I6
sg52647
VC2608087
p64277
sg52649
I1
sa(dp64278
g52643
I610
sg52644
Vagenesis of the corpus callosum
p64279
sg52646
I31
sg52647
VC0175754
p64280
sg52649
I5
sa(dp64281
g52643
I464
sg52644
VSPG21
p64282
sg52646
I5
sg52647
VC1855346
p64283
sg52649
I1
sa(dp64284
g52643
I329
sg52644
Vautosomal recessive hereditary spastic paraplegia
p64285
sg52646
I49
sg52647
VC0751603
p64286
sg52649
I5
sa(dp64287
g52643
I416
sg52644
Vperipheral neuropathy
p64288
sg52646
I21
sg52647
VC0031117
p64289
sg52649
I2
sa(dp64290
g52643
I195
sg52644
g64174
sg52646
I5
sg52647
VC1842983
p64291
sg52649
I1
sasa(dp64292
g52636
VPlasmacytomas often present as a collection of findings known as POEMS-syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein spike, and Skin changes).
p64293
sg52638
(lp64294
sg52640
(lp64295
(dp64296
g52643
I71
sg52644
Vsyndrome
p64297
sg52646
I8
sg52647
VC0039082
p64298
sg52649
I1
sa(dp64299
g52643
I111
sg52644
VEndocrinopathy
p64300
sg52646
I14
sg52647
VC0014130
p64301
sg52649
I1
sa(dp64302
g52643
I0
sg52644
VPlasmacytomas
p64303
sg52646
I13
sg52647
VC0032131
p64304
sg52649
I1
sa(dp64305
g52643
I81
sg52644
VPolyneuropathy
p64306
sg52646
I14
sg52647
VC0152025
p64307
sg52649
I1
sasa(dp64308
g135
(dp64309
(VM protein
p64310
Vmyeloma
p64311
tp64312
I00
ssg52636
VPOEMS (acronym for polyneuropathy, organomegaly, endocrinopathy, M protein myeloma and skin changes), is a rare disease which occurs in the setting of plasma cell dyscrasias.
p64313
sg52638
(lp64314
(dp64315
g52643
I65
sg52644
g64310
sg52646
I9
sg52674
VP54296
p64316
sg52649
I2
sasg52640
(lp64317
(dp64318
g52643
I107
sg52644
Vrare disease
p64319
sg52646
I12
sg52647
VC0678236
p64320
sg52649
I2
sa(dp64321
g52643
I49
sg52644
Vendocrinopathy
p64322
sg52646
I14
sg52647
VC0014130
p64323
sg52649
I1
sa(dp64324
g52643
I19
sg52644
Vpolyneuropathy
p64325
sg52646
I14
sg52647
VC0152025
p64326
sg52649
I1
sa(dp64327
g52643
I151
sg52644
Vplasma cell dyscrasias
p64328
sg52646
I22
sg52647
VC1136084
p64329
sg52649
I3
sa(dp64330
g52643
I75
sg52644
g64311
sg52646
I7
sg52647
VC0026764
p64331
sg52649
I1
sasa(dp64332
g135
(dp64333
(Vanti-myelin-associated glycoprotein (MAG) antibody
p64334
Vpolyneuropathy
p64335
tp64336
I00
ssg52636
VPrevious case reports and studies have shown that anti-myelin-associated glycoprotein (MAG) antibody can be detected in patients with polyneuropathy without any detectable M-protein.
p64337
sg52638
(lp64338
(dp64339
g52643
I50
sg52644
g64334
sg52646
I50
sg52674
VP20916
p64340
sg52649
I4
sasg52640
(lp64341
(dp64342
g52643
I134
sg52644
g64335
sg52646
I14
sg52647
VC0152025
p64343
sg52649
I1
sasa(dp64344
g52636
VPolyneuropathy, Organomegaly, Endocrinopathy, M protein and Skin changes (POEMS) syndrome is rare plasma cell dyscrasia with multisystem involvement.
p64345
sg52638
(lp64346
sg52640
(lp64347
(dp64348
g52643
I81
sg52644
Vsyndrome
p64349
sg52646
I8
sg52647
VC0039082
p64350
sg52649
I1
sa(dp64351
g52643
I98
sg52644
Vplasma cell dyscrasia
p64352
sg52646
I21
sg52647
VC1136084
p64353
sg52649
I3
sa(dp64354
g52643
I30
sg52644
VEndocrinopathy
p64355
sg52646
I14
sg52647
VC0014130
p64356
sg52649
I1
sa(dp64357
g52643
I0
sg52644
VPolyneuropathy
p64358
sg52646
I14
sg52647
VC0152025
p64359
sg52649
I1
sasa(dp64360
g52636
VThe name comes from the five characteristic features: Polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes.
p64361
sg52638
(lp64362
sg52640
(lp64363
(dp64364
g52643
I84
sg52644
Vendocrinopathy
p64365
sg52646
I14
sg52647
VC0014130
p64366
sg52649
I1
sa(dp64367
g52643
I54
sg52644
VPolyneuropathy
p64368
sg52646
I14
sg52647
VC0152025
p64369
sg52649
I1
sasa(dp64370
g52636
VPolyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome and monoclonal gammopathy of undetermined significance (MGUS) are paraproteinemic disorders that can cause demyelinating polyneuropathy.
p64371
sg52638
(lp64372
sg52640
(lp64373
(dp64374
g52643
I82
sg52644
Vsyndrome
p64375
sg52646
I8
sg52647
VC0039082
p64376
sg52649
I1
sa(dp64377
g52643
I95
sg52644
Vmonoclonal gammopathy of undetermined significance
p64378
sg52646
I50
sg52647
VC0026470
p64379
sg52649
I5
sa(dp64380
g52643
I147
sg52644
VMGUS
p64381
sg52646
I4
sg52647
VC0026470
p64382
sg52649
I1
sa(dp64383
g52643
I198
sg52644
Vdemyelinating polyneuropathy
p64384
sg52646
I28
sg52647
VC0270922
p64385
sg52649
I2
sa(dp64386
g52643
I30
sg52644
Vendocrinopathy
p64387
sg52646
I14
sg52647
VC0014130
p64388
sg52649
I1
sa(dp64389
g52643
I0
sg52644
VPolyneuropathy
p64390
sg52646
I14
sg52647
VC0152025
p64391
sg52649
I1
sasa(dp64392
g52636
VPolyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome, a form of osteosclerotic myeloma, is a multisystem disease related to a monoclonal plasma cell proliferative disorder.
p64393
sg52638
(lp64394
sg52640
(lp64395
(dp64396
g52643
I82
sg52644
Vsyndrome
p64397
sg52646
I8
sg52647
VC0039082
p64398
sg52649
I1
sa(dp64399
g52643
I102
sg52644
Vosteosclerotic myeloma
p64400
sg52646
I22
sg52647
VC1510415
p64401
sg52649
I2
sa(dp64402
g52643
I187
sg52644
Vproliferative
p64403
sg52646
I13
sg52647
VC0334094
p64404
sg52649
I1
sa(dp64405
g52643
I30
sg52644
Vendocrinopathy
p64406
sg52646
I14
sg52647
VC0014130
p64407
sg52649
I1
sa(dp64408
g52643
I0
sg52644
VPolyneuropathy
p64409
sg52646
I14
sg52647
VC0152025
p64410
sg52649
I1
sasa(dp64411
g52636
VShe had been treated with cyclophosphamide, melphalan, lenalidomide and corticosteroids for POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy or edema, M protein, skin changes).
p64412
sg52638
(lp64413
sg52640
(lp64414
(dp64415
g52643
I138
sg52644
Vendocrinopathy
p64416
sg52646
I14
sg52647
VC0014130
p64417
sg52649
I1
sa(dp64418
g52643
I156
sg52644
Vedema
p64419
sg52646
I5
sg52647
VC0013604
p64420
sg52649
I1
sa(dp64421
g52643
I108
sg52644
Vpolyneuropathy
p64422
sg52646
I14
sg52647
VC0152025
p64423
sg52649
I1
sa(dp64424
g52643
I92
sg52644
VPOEMS syndrome
p64425
sg52646
I14
sg52647
VC0085404
p64426
sg52649
I2
sasa(dp64427
g52636
VPolyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome is a rare cause of demyelinating neuropathy, with multi-organ involvement characterised by plasma cell dyscrasia and VEGF overproduction.
p64428
sg52638
(lp64429
sg52640
(lp64430
(dp64431
g52643
I110
sg52644
Vdemyelinating neuropathy
p64432
sg52646
I24
sg52647
VC0270922
p64433
sg52649
I2
sa(dp64434
g52643
I82
sg52644
Vsyndrome
p64435
sg52646
I8
sg52647
VC0039082
p64436
sg52649
I1
sa(dp64437
g52643
I30
sg52644
Vendocrinopathy
p64438
sg52646
I14
sg52647
VC0014130
p64439
sg52649
I1
sa(dp64440
g52643
I182
sg52644
Vplasma cell dyscrasia
p64441
sg52646
I21
sg52647
VC1136084
p64442
sg52649
I3
sa(dp64443
g52643
I0
sg52644
VPolyneuropathy
p64444
sg52646
I14
sg52647
VC0152025
p64445
sg52649
I1
sasa(dp64446
g52636
VAs a consequence, leukemia induction and leukemia maintenance were severely impaired in Inca1-/- bone marrow cells.
p64447
sg52638
(lp64448
sg52640
(lp64449
(dp64450
g52643
I18
sg52644
Vleukemia
p64451
sg52646
I8
sg52647
VC0023418
p64452
sg52649
I1
sa(dp64453
g52643
I18
sg52644
Vleukemia
p64454
sg52646
I8
sg52647
VC0023418
p64455
sg52649
I1
sa(dp64456
g52643
I76
sg52644
Vimpaired
p64457
sg52646
I8
sg52647
VC0684336
p64458
sg52649
I1
sasa(dp64459
g135
(dp64460
(VBCL2
p64461
Vleukemia
p64462
tp64463
I00
ssg52636
VThe re-initiation of leukemia was also significantly inhibited in absence of Inca1-/- in MLL-AF9- and c-myc/BCL2-positive leukemia mouse models.
p64464
sg52638
(lp64465
(dp64466
g52643
I102
sg52644
Vc-myc
p64467
sg52646
I5
sg52674
VP12524
p64468
sg52649
I1
sa(dp64469
g52643
I93
sg52644
VAF9
p64470
sg52646
I3
sg52674
VP42568
p64471
sg52649
I1
sa(dp64472
g52643
I108
sg52644
g64461
sg52646
I4
sg52674
VP10415
p64473
sg52649
I1
sa(dp64474
g52643
I77
sg52644
VInca1-/- in MLL
p64475
sg52646
I15
sg52674
g12
sg52649
I3
sasg52640
(lp64476
(dp64477
g52643
I21
sg52644
Vleukemia
p64478
sg52646
I8
sg52647
VC0023418
p64479
sg52649
I1
sa(dp64480
g52643
I21
sg52644
g64462
sg52646
I8
sg52647
VC0023418
p64481
sg52649
I1
sasa(dp64482
g52636
VThese findings indicate distinct functional properties of Inca1 in normal hematopoietic cells compared to leukemia initiating cells.
p64483
sg52638
(lp64484
(dp64485
g52643
I58
sg52644
VInca1
p64486
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64487
(dp64488
g52643
I106
sg52644
Vleukemia
p64489
sg52646
I8
sg52647
VC0023418
p64490
sg52649
I1
sasa(dp64491
g135
(dp64492
(VCCNA1
p64493
Vnasopharyngeal carcinoma
p64494
tp64495
I01
ssg52636
VThis preliminary study indicated the tumor suppressing roles of miR-372 in cell cycle progression of TW01 cells, possibly via the down-regulation of CDK2 and CCNA1 as well as the up-regulation of CDKN1A and INCA1.Key Words: apoptosis, microRNA, nasopharyngeal carcinoma, miR-372, CDK2, CCNA1.
p64496
sg52638
(lp64497
(dp64498
g52643
I158
sg52644
VCCNA1
p64499
sg52646
I5
sg52674
VP78396
p64500
sg52649
I1
sa(dp64501
g52643
I196
sg52644
VCDKN1A
p64502
sg52646
I6
sg52674
VP38936
p64503
sg52649
I1
sa(dp64504
g52643
I149
sg52644
VCDK2
p64505
sg52646
I4
sg52674
VP24941
p64506
sg52649
I1
sa(dp64507
g52643
I149
sg52644
VCDK2
p64508
sg52646
I4
sg52674
VP24941
p64509
sg52649
I1
sa(dp64510
g52643
I158
sg52644
g64493
sg52646
I5
sg52674
VP78396
p64511
sg52649
I1
sa(dp64512
g52643
I207
sg52644
VINCA1
p64513
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64514
(dp64515
g52643
I245
sg52644
g64494
sg52646
I24
sg52647
VC2931822
p64516
sg52649
I2
sa(dp64517
g52643
I37
sg52644
Vtumor
p64518
sg52646
I5
sg52647
VC0027651
p64519
sg52649
I1
sasa(dp64520
g52636
VFurthermore, blasts from acute lymphoid leukemia and acute myeloid leukemia patients expressed significantly reduced INCA1 levels highlighting its relevance for growth control in vivo.
p64521
sg52638
(lp64522
(dp64523
g52643
I117
sg52644
VINCA1
p64524
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64525
(dp64526
g52643
I25
sg52644
Vacute lymphoid leukemia
p64527
sg52646
I23
sg52647
VC1961102
p64528
sg52649
I3
sa(dp64529
g52643
I53
sg52644
Vacute myeloid leukemia
p64530
sg52646
I22
sg52647
VC0023467
p64531
sg52649
I3
sasa(dp64532
g52636
VOur objectives were (i) to assess the current prevalence of childhood overweight (including obesity) (OWOB) in France and its relationship with comprehensive socioeconomic status (SES) indicators and (ii) to examine trends in OWOB prevalence and changes in energy intake (EI) and sedentary behavior (SED) based on the previous INCA 1 (Individuelle Nationale des Consommations Alimentaires) data (1998-1999).
p64533
sg52638
(lp64534
(dp64535
g52643
I327
sg52644
VINCA 1
p64536
sg52646
I6
sg52674
g12
sg52649
I2
sasg52640
(lp64537
(dp64538
g52643
I92
sg52644
Vobesity
p64539
sg52646
I7
sg52647
VC0028754
p64540
sg52649
I1
sa(dp64541
g52643
I70
sg52644
Voverweight
p64542
sg52646
I10
sg52647
VC0497406
p64543
sg52649
I1
sa(dp64544
g52643
I358
sg52644
Vdes
p64545
sg52646
I3
sg52647
VC0394006
p64546
sg52649
I1
sasa(dp64547
g135
(dp64548
(VERalpha
p64549
Vischemia
p64550
tp64551
I00
ssg52636
VBoth estradiol and global ischemia markedly increased ERalpha, but not ERbeta, protein in CA1.
p64552
sg52638
(lp64553
(dp64554
g52643
I54
sg52644
g64549
sg52646
I7
sg52674
VP03372
p64555
sg52649
I1
sasg52640
(lp64556
(dp64557
g52643
I26
sg52644
g64550
sg52646
I8
sg52647
VC0022116
p64558
sg52649
I1
sasa(dp64559
g52636
VIt has been reported that BMPR2 is associated with chondrosarcoma.
p64560
sg52638
(lp64561
(dp64562
g52643
I26
sg52644
VBMPR2
p64563
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64564
(dp64565
g52643
I51
sg52644
Vchondrosarcoma
p64566
sg52646
I14
sg52647
VC0008479
p64567
sg52649
I1
sasa(dp64568
g52636
VMoreover, the detection of BMPR2 is more frequent in dedifferentiated chondrosarcomas (DDCS) than in conventional chondrosarcomas (CCS).
p64569
sg52638
(lp64570
(dp64571
g52643
I27
sg52644
VBMPR2
p64572
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64573
(dp64574
g52643
I131
sg52644
VCCS
p64575
sg52646
I3
sg52647
VC0008479
p64576
sg52649
I1
sa(dp64577
g52643
I70
sg52644
Vchondrosarcomas
p64578
sg52646
I15
sg52647
VC0008479
p64579
sg52649
I1
sa(dp64580
g52643
I70
sg52644
Vchondrosarcomas
p64581
sg52646
I15
sg52647
VC0008479
p64582
sg52649
I1
sasa(dp64583
g135
(dp64584
(VpSMAD1/5
p64585
Vchondrosarcoma
p64586
tp64587
I00
ssg52636
VBMPR2, phospho-SMAD1/5 (pSMAD1/5), and runt-related transcription factor 2 (RUNX2) expressions were found to be associated with the pathological grades of chondrosarcoma and could be a promising target of treatment outcome.
p64588
sg52638
(lp64589
(dp64590
g52643
I76
sg52644
VRUNX2
p64591
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64592
g52643
I0
sg52644
VBMPR2
p64593
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64594
g52643
I7
sg52644
Vphospho-SMAD1/5
p64595
sg52646
I15
sg52674
VP41250
p64596
sg52649
I1
sa(dp64597
g52643
I24
sg52644
g64585
sg52646
I8
sg52674
VP41250
p64598
sg52649
I1
sasg52640
(lp64599
(dp64600
g52643
I39
sg52644
Vrunt
p64601
sg52646
I4
sg52647
VC0013336
p64602
sg52649
I1
sa(dp64603
g52643
I155
sg52644
g64586
sg52646
I14
sg52647
VC0008479
p64604
sg52649
I1
sasa(dp64605
g52636
VIt has been demonstrated that more prevalent expression of bone morphogenetic protein receptor 2 (BMPR2) has been detected in dedifferentiated chondrosarcomas than conventional chondrosarcomas.
p64606
sg52638
(lp64607
(dp64608
g52643
I98
sg52644
VBMPR2
p64609
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64610
g52643
I59
sg52644
Vbone morphogenetic protein receptor 2
p64611
sg52646
I37
sg52674
g12
sg52649
I5
sasg52640
(lp64612
(dp64613
g52643
I143
sg52644
Vchondrosarcomas
p64614
sg52646
I15
sg52647
VC0008479
p64615
sg52649
I1
sa(dp64616
g52643
I143
sg52644
Vchondrosarcomas
p64617
sg52646
I15
sg52647
VC0008479
p64618
sg52649
I1
sasa(dp64619
g52636
VHere, we find that BMPR2 inhibition induces apoptosis and autophagy of chondrosarcoma.
p64620
sg52638
(lp64621
(dp64622
g52643
I19
sg52644
VBMPR2
p64623
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64624
(dp64625
g52643
I71
sg52644
Vchondrosarcoma
p64626
sg52646
I14
sg52647
VC0008479
p64627
sg52649
I1
sasa(dp64628
g52636
VWe found that BMPR2 expression was correlated with the clinicopathological features of chondrosarcomas, and could predict the treatment outcome.
p64629
sg52638
(lp64630
(dp64631
g52643
I14
sg52644
VBMPR2
p64632
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64633
(dp64634
g52643
I87
sg52644
Vchondrosarcomas
p64635
sg52646
I15
sg52647
VC0008479
p64636
sg52649
I1
sasa(dp64637
g52636
VKnockdown of BMPR2 by small interfering RNA results in growth inhibition in chondrosarcoma cells.
p64638
sg52638
(lp64639
(dp64640
g52643
I13
sg52644
VBMPR2
p64641
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64642
(dp64643
g52643
I76
sg52644
Vchondrosarcoma
p64644
sg52646
I14
sg52647
VC0008479
p64645
sg52649
I1
sasa(dp64646
g135
(dp64647
(VX-linked inhibitor of apoptosis protein
p64648
Vchondrosarcoma
p64649
tp64650
I00
ssg52636
VSilencing BMPR2 promoted G2/M cell cycle arrest, induced chondrosarcoma cell apoptosis through caspase-3-dependent pathway via repression of X-linked inhibitor of apoptosis protein (XIAP) and induced autophagy of chondrosarcoma cells via XIAP-Mdm2-p53 pathway.
p64651
sg52638
(lp64652
(dp64653
g52643
I248
sg52644
Vp53
p64654
sg52646
I3
sg52674
VP42771
p64655
sg52649
I1
sa(dp64656
g52643
I95
sg52644
Vcaspase-3
p64657
sg52646
I9
sg52674
VP42574
p64658
sg52649
I1
sa(dp64659
g52643
I182
sg52644
VXIAP
p64660
sg52646
I4
sg52674
VP98170
p64661
sg52649
I1
sa(dp64662
g52643
I10
sg52644
VBMPR2
p64663
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64664
g52643
I182
sg52644
VXIAP
p64665
sg52646
I4
sg52674
VP98170
p64666
sg52649
I1
sa(dp64667
g52643
I141
sg52644
g64648
sg52646
I39
sg52674
VP98170
p64668
sg52649
I5
sasg52640
(lp64669
(dp64670
g52643
I57
sg52644
Vchondrosarcoma
p64671
sg52646
I14
sg52647
VC0008479
p64672
sg52649
I1
sa(dp64673
g52643
I57
sg52644
g64649
sg52646
I14
sg52647
VC0008479
p64674
sg52649
I1
sasa(dp64675
g52636
VInhibition of autophagy induced by BMPR2 small interfering RNA (siBMPR2) sensitized chondrosarcoma cells to siBMPR2-induced apoptotic cell death, suggesting that autophagy has a protective role for chondrosarcoma cells in context of siBMPR2-induced apoptotic cell death.
p64676
sg52638
(lp64677
(dp64678
g52643
I35
sg52644
VBMPR2 small interfering RNA
p64679
sg52646
I27
sg52674
g12
sg52649
I4
sasg52640
(lp64680
(dp64681
g52643
I84
sg52644
Vchondrosarcoma
p64682
sg52646
I14
sg52647
VC0008479
p64683
sg52649
I1
sa(dp64684
g52643
I84
sg52644
Vchondrosarcoma
p64685
sg52646
I14
sg52647
VC0008479
p64686
sg52649
I1
sasa(dp64687
g52636
VTaken together, our results suggest that BMPR2 has a significant role in the tumorigenesis of chondrosarcoma, and could be an important prognostic marker for chondrosarcoma.
p64688
sg52638
(lp64689
(dp64690
g52643
I41
sg52644
VBMPR2
p64691
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64692
(dp64693
g52643
I94
sg52644
Vchondrosarcoma
p64694
sg52646
I14
sg52647
VC0008479
p64695
sg52649
I1
sa(dp64696
g52643
I77
sg52644
Vtumorigenesis
p64697
sg52646
I13
sg52647
VC0007621
p64698
sg52649
I1
sa(dp64699
g52643
I94
sg52644
Vchondrosarcoma
p64700
sg52646
I14
sg52647
VC0008479
p64701
sg52649
I1
sasa(dp64702
g52636
VBMPR2 inhibition could eventually provide a promising therapy for chondrosarcoma treatment.
p64703
sg52638
(lp64704
(dp64705
g52643
I0
sg52644
VBMPR2
p64706
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp64707
(dp64708
g52643
I66
sg52644
Vchondrosarcoma
p64709
sg52646
I14
sg52647
VC0008479
p64710
sg52649
I1
sasa(dp64711
g135
(dp64712
(VBeta-defensin-1
p64713
Vasthma
p64714
tp64715
I00
ssg52636
VThe role of Beta-defensin-1 in asthma and chronic obstructive pulmonary disease (COPD) remains unclear.
p64716
sg52638
(lp64717
(dp64718
g52643
I12
sg52644
g64713
sg52646
I15
sg52674
VP60022
p64719
sg52649
I1
sasg52640
(lp64720
(dp64721
g52643
I81
sg52644
VCOPD
p64722
sg52646
I4
sg52647
VC0024117
p64723
sg52649
I1
sa(dp64724
g52643
I42
sg52644
Vchronic obstructive pulmonary disease
p64725
sg52646
I37
sg52647
VC0024117
p64726
sg52649
I4
sa(dp64727
g52643
I31
sg52644
g64714
sg52646
I6
sg52647
VC0004096
p64728
sg52649
I1
sasa(dp64729
g135
(dp64730
(Vbeta-defensin-1
p64731
Vchronic obstructive pulmonary disease
p64732
tp64733
I00
ssg52636
VIn Japanese and Chinese populations, two different beta-defensin-1 polymorphisms have been associated with chronic obstructive pulmonary disease phenotypes.
p64734
sg52638
(lp64735
(dp64736
g52643
I51
sg52644
g64731
sg52646
I15
sg52674
VP60022
p64737
sg52649
I1
sasg52640
(lp64738
(dp64739
g52643
I107
sg52644
g64732
sg52646
I37
sg52647
VC0024117
p64740
sg52649
I4
sasa(dp64741
g135
(dp64742
(VSCAE
p64743
VPDC
p64744
tp64745
I00
ssg52636
VThe autosomal recessive ataxias are separated into Friedreich ataxia, ataxia due to vitamin E deficiency, ataxia due to Abeta-lipoproteinemia, Refsum disease, late-onset Tay-Sachs disease, cerebrotendineous xanthomatosis, spinocerebellar ataxia with axonal neuropathy, ataxia telangiectasia, ataxia telangiectasia-like disorder, ataxia with oculomotor apraxia 1 and 2, spastic ataxia of Charlevoix-Saguenay, Cayman ataxia, Marinesco-Sjoegren syndrome, and autosomal recessive mitochondrial ataxias (AR-CPEO, SANDO, SCAE, AHS, IOSCA, MEMSA, LBSL CoQ-deficiency, PDC-deficiency).
p64746
sg52638
(lp64747
(dp64748
g52643
I120
sg52644
VAbeta
p64749
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64750
g52643
I526
sg52644
VIOSCA
p64751
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp64752
g52643
I508
sg52644
VSANDO
p64753
sg52646
I5
sg52674
VP54098
p64754
sg52649
I1
sa(dp64755
g52643
I561
sg52644
VPDC
p64756
sg52646
I3
sg52674
VP20941
p64757
sg52649
I1
sa(dp64758
g52643
I521
sg52644
VAHS
p64759
sg52646
I3
sg52674
VP02765
p64760
sg52649
I1
sa(dp64761
g52643
I540
sg52644
VLBSL CoQ
p64762
sg52646
I8
sg52674
g12
sg52649
I2
sa(dp64763
g52643
I515
sg52644
g64743
sg52646
I4
sg52674
VP54098
p64764
sg52649
I1
sasg52640
(lp64765
(dp64766
g52643
I269
sg52644
Vataxia telangiectasia
p64767
sg52646
I21
sg52647
VC0004135
p64768
sg52649
I2
sa(dp64769
g52643
I508
sg52644
VSANDO
p64770
sg52646
I5
sg52647
VC1843851
p64771
sg52649
I1
sa(dp64772
g52643
I369
sg52644
Vspastic ataxia of Charlevoix-Saguenay
p64773
sg52646
I37
sg52647
VC1849140
p64774
sg52649
I4
sa(dp64775
g52643
I24
sg52644
Vataxias
p64776
sg52646
I7
sg52647
VC0004134
p64777
sg52649
I1
sa(dp64778
g52643
I515
sg52644
VSCAE
p64779
sg52646
I4
sg52647
VC1843852
p64780
sg52649
I1
sa(dp64781
g52643
I51
sg52644
VFriedreich ataxia
p64782
sg52646
I17
sg52647
VC0016719
p64783
sg52649
I2
sa(dp64784
g52643
I222
sg52644
Vspinocerebellar ataxia
p64785
sg52646
I22
sg52647
VC0087012
p64786
sg52649
I2
sa(dp64787
g52643
I207
sg52644
Vxanthomatosis
p64788
sg52646
I13
sg52647
VC0043325
p64789
sg52649
I1
sa(dp64790
g52643
I143
sg52644
VRefsum disease
p64791
sg52646
I14
sg52647
VC0034960
p64792
sg52649
I2
sa(dp64793
g52643
I526
sg52644
VIOSCA
p64794
sg52646
I5
sg52647
VC1849096
p64795
sg52649
I1
sa(dp64796
g52643
I250
sg52644
Vaxonal neuropathy
p64797
sg52646
I17
sg52647
VC0270921
p64798
sg52649
I2
sa(dp64799
g52643
I24
sg52644
Vataxia
p64800
sg52646
I6
sg52647
VC0004134
p64801
sg52649
I1
sa(dp64802
g52643
I341
sg52644
Voculomotor apraxia
p64803
sg52646
I18
sg52647
VC0271270
p64804
sg52649
I2
sa(dp64805
g52643
I84
sg52644
Vvitamin E deficiency
p64806
sg52646
I20
sg52647
VC0042875
p64807
sg52649
I3
sa(dp64808
g52643
I502
sg52644
VCPEO
p64809
sg52646
I4
sg52647
VC0162674
p64810
sg52649
I1
sa(dp64811
g52643
I170
sg52644
VTay-Sachs disease
p64812
sg52646
I17
sg52647
VC0039373
p64813
sg52649
I2
sa(dp64814
g52643
I442
sg52644
Vsyndrome
p64815
sg52646
I8
sg52647
VC0039082
p64816
sg52649
I1
sa(dp64817
g52643
I24
sg52644
Vataxia
p64818
sg52646
I6
sg52647
VC0004134
p64819
sg52649
I1
sa(dp64820
g52643
I24
sg52644
Vataxia
p64821
sg52646
I6
sg52647
VC0004134
p64822
sg52649
I1
sa(dp64823
g52643
I269
sg52644
Vataxia telangiectasia
p64824
sg52646
I21
sg52647
VC0004135
p64825
sg52649
I2
sa(dp64826
g52643
I24
sg52644
Vataxia
p64827
sg52646
I6
sg52647
VC0004134
p64828
sg52649
I1
sa(dp64829
g52643
I540
sg52644
VLBSL
p64830
sg52646
I4
sg52647
VC1970180
p64831
sg52649
I1
sa(dp64832
g52643
I24
sg52644
Vataxias
p64833
sg52646
I7
sg52647
VC0004134
p64834
sg52649
I1
sa(dp64835
g52643
I561
sg52644
g64744
sg52646
I3
sg52647
VC1869117
p64836
sg52649
I1
sasa(dp64837
g135
(dp64838
(VPOLG
p64839
Vmotor peripheral neuropathy
p64840
tp64841
I00
ssg52636
VOnly patients presenting PEO as part of their clinical phenotype had POLG mutations, in seven of them together with myopathic signs and in one with a sensori-motor peripheral neuropathy.
p64842
sg52638
(lp64843
(dp64844
g52643
I69
sg52644
g64839
sg52646
I4
sg52674
VP54098
p64845
sg52649
I1
sasg52640
(lp64846
(dp64847
g52643
I158
sg52644
g64840
sg52646
I27
sg52647
VC0235025
p64848
sg52649
I3
sasa(dp64849
g52636
VMoreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate.
p64850
sg52638
(lp64851
(dp64852
g52643
I197
sg52644
V5-HT3 receptors
p64853
sg52646
I15
sg52674
g12
sg52649
I2
sa(dp64854
g52643
I44
sg52644
V5-HT3 and 5-HT4 receptors
p64855
sg52646
I25
sg52674
g12
sg52649
I4
sa(dp64856
g52643
I54
sg52644
V5-HT4 receptors
p64857
sg52646
I15
sg52674
g12
sg52649
I2
sa(dp64858
g52643
I54
sg52644
V5-HT4 receptors
p64859
sg52646
I15
sg52674
g12
sg52649
I2
sasg52640
(lp64860
(dp64861
g52643
I105
sg52644
Vmotion sickness
p64862
sg52646
I15
sg52647
VC0026603
p64863
sg52649
I2
sa(dp64864
g52643
I284
sg52644
Vemesis
p64865
sg52646
I6
sg52647
VC0042963
p64866
sg52649
I1
sa(dp64867
g52643
I157
sg52644
Vblocking
p64868
sg52646
I8
sg52647
VC0233660
p64869
sg52649
I1
sa(dp64870
g52643
I284
sg52644
Vemesis
p64871
sg52646
I6
sg52647
VC0042963
p64872
sg52649
I1
sasa(dp64873
g52636
VTherefore, we used Biolog GN2 microplates to analyze the ability of 103 clinical, predominantly diarrheal, isolates of Aeromonas to use various carbon sources, and we verified whether, among the substrates metabolized by these strains, there were some endogenous to the human intestine.
p64874
sg52638
(lp64875
sg52640
(lp64876
sa(dp64877
g52636
VRP30 was one of these strains that was randomly selected and analysed by using a morphological, physiological and biochemical plate, Biolog GN2 Microplate System and API 20E system.
p64878
sg52638
(lp64879
(dp64880
g52643
I0
sg52644
VRP30
p64881
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp64882
(dp64883
g52643
I0
sg52644
VRP30
p64884
sg52646
I4
sg52647
VC1842816
p64885
sg52649
I1
sasa(dp64886
g135
(dp64887
(VIgA nephropathy 3
p64888
VIgA nephropathy
p64889
tp64890
I01
ssg52636
VHistological and clinical diagnoses of the 14 patients were as follows: IgA nephropathy 3, non-IgA GN 2, and asymptomatic significant microscopic hematuria [more than 100 red blood cells per high-power field (x400)] with or without proteinuria 9.
p64891
sg52638
(lp64892
(dp64893
g52643
I91
sg52644
Vnon-IgA GN 2
p64894
sg52646
I12
sg52674
g12
sg52649
I3
sa(dp64895
g52643
I72
sg52644
g64888
sg52646
I17
sg52674
VP11912
p64896
sg52649
I3
sasg52640
(lp64897
(dp64898
g52643
I134
sg52644
Vmicroscopic hematuria
p64899
sg52646
I21
sg52647
VC0239937
p64900
sg52649
I2
sa(dp64901
g52643
I72
sg52644
g64889
sg52646
I15
sg52647
VC0017661
p64902
sg52649
I2
sasa(dp64903
g52636
VThe incidence of membranous form of glomerulonephritis was high (34 out of 44 kidney biopsy cases, 77%), the rest of patients showing mesangiocapillary GN-8 (18%) and mesangial proliferative GN-2 (5%).
p64904
sg52638
(lp64905
sg52640
(lp64906
(dp64907
g52643
I36
sg52644
Vglomerulonephritis
p64908
sg52646
I18
sg52647
VC0017658
p64909
sg52649
I1
sa(dp64910
g52643
I177
sg52644
Vproliferative
p64911
sg52646
I13
sg52647
VC0334094
p64912
sg52649
I1
sasa(dp64913
g52636
VIn organ cultures, nephrosis-producing IBV strains (GN-2 and M-41) were slightly more ciliostatic and respiratory strains (Beaudette and Kita-1/Tokushima) less ciliostatic at 40.5 degrees C than at 37 degrees C. Mortality of chicken embryos infected with the GN-2, M-41 and Kita-1/Tokushima strains was greater at 40.5 degrees C than at 37 degrees C, while the reverse was true of the Beaudette strain which caused no embryo mortality at 40.5 degrees C. The Beaudette strain of IBV was the only one which could not be recovered from the kidneys of young chickens four days after infection.
p64914
sg52638
(lp64915
(dp64916
g52643
I52
sg52644
VGN-2
p64917
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp64918
(dp64919
g52643
I19
sg52644
Vnephrosis
p64920
sg52646
I9
sg52647
VC0027720
p64921
sg52649
I1
sa(dp64922
g52643
I579
sg52644
Vinfection
p64923
sg52646
I9
sg52647
VC0009450
p64924
sg52649
I1
sasa(dp64925
g52636
VIn addition, in Alzheimer's disease we found simple gangliosides (GN2, GM3) to be elevated in the frontal and parietal cortex, which might correlate accelerated lysosomal degradation of gangliosides and/or astrogliosis occurring during neuronal death.
p64926
sg52638
(lp64927
sg52640
(lp64928
(dp64929
g52643
I16
sg52644
VAlzheimer's disease
p64930
sg52646
I19
sg52647
VC1521724
p64931
sg52649
I2
sa(dp64932
g52643
I206
sg52644
Vastrogliosis
p64933
sg52646
I12
sg52647
VC0017639
p64934
sg52649
I1
sasa(dp64935
g135
(dp64936
(Vcathepsin-G
p64937
Vcutaneous mastocytosis
p64938
tp64939
I00
ssg52636
VThe aim of this study was to investigate the immunoreactivity to tryptase and to cathepsin-G of MC from human cutaneous mastocytosis and to compare their number in normal skin and cutaneous mastocytosis.
p64940
sg52638
(lp64941
(dp64942
g52643
I81
sg52644
g64937
sg52646
I11
sg52674
VP25774
p64943
sg52649
I1
sasg52640
(lp64944
(dp64945
g52643
I110
sg52644
Vcutaneous mastocytosis
p64946
sg52646
I22
sg52647
VC1136033
p64947
sg52649
I2
sa(dp64948
g52643
I110
sg52644
g64938
sg52646
I22
sg52647
VC1136033
p64949
sg52649
I2
sasa(dp64950
g135
(dp64951
(Vcathepsin-G
p64952
Vcutaneous mastocytosis
p64953
tp64954
I00
ssg52636
VMorphometric evaluation of MC number demostrated that the number of both tryptase- and cathepsin-G-positive MC was significantly higher in cutaneous mastocytosis as compared to normal skin and that in both conditions the number of tryptase-positive MC was significantly higher as compared to the number of cathepsin-G-positive MC.
p64955
sg52638
(lp64956
(dp64957
g52643
I87
sg52644
Vcathepsin-G
p64958
sg52646
I11
sg52674
VP25774
p64959
sg52649
I1
sa(dp64960
g52643
I87
sg52644
g64952
sg52646
I11
sg52674
VP25774
p64961
sg52649
I1
sasg52640
(lp64962
(dp64963
g52643
I139
sg52644
g64953
sg52646
I22
sg52647
VC1136033
p64964
sg52649
I2
sasa(dp64965
g135
(dp64966
(Vcathepsin-G
p64967
Vcutaneous mastocytosis
p64968
tp64969
I00
ssg52636
VIn conclusion, in this study, for the first time we have demonstrated the presence of MC with immunoreactivity to cathepsin-G in human cutaneous mastocytosis, as well as the co-localization of tryptase and cathepsin-G in MC secretory granules.
p64970
sg52638
(lp64971
(dp64972
g52643
I114
sg52644
Vcathepsin-G
p64973
sg52646
I11
sg52674
VP25774
p64974
sg52649
I1
sa(dp64975
g52643
I114
sg52644
g64967
sg52646
I11
sg52674
VP25774
p64976
sg52649
I1
sasg52640
(lp64977
(dp64978
g52643
I135
sg52644
g64968
sg52646
I22
sg52647
VC1136033
p64979
sg52649
I2
sasa(dp64980
g52636
VThe aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab.
p64981
sg52638
(lp64982
(dp64983
g52643
I97
sg52644
VmiR-664-3p
p64984
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp64985
g52643
I82
sg52644
VmiR-126-5p
p64986
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp64987
g52643
I70
sg52644
VmiR-126-3p
p64988
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp64989
(dp64990
g52643
I164
sg52644
Vmetastatic colorectal cancer
p64991
sg52646
I28
sg52647
VC0948380
p64992
sg52649
I3
sa(dp64993
g52643
I108
sg52644
Vtumour
p64994
sg52646
I6
sg52647
VC0027651
p64995
sg52649
I1
sasa(dp64996
g52636
VIn the present study, we investigated the role of miR-126-5p and Bcl2l2 in cervical cancer cells.
p64997
sg52638
(lp64998
(dp64999
g52643
I65
sg52644
VBcl2l2
p65000
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp65001
g52643
I50
sg52644
VmiR-126-5p
p65002
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp65003
(dp65004
g52643
I75
sg52644
Vcervical cancer
p65005
sg52646
I15
sg52647
VC0302592
p65006
sg52649
I2
sasa(dp65007
g52636
VFirst, miR-126-5p expression was aberrantly downregulated in human cervical cancer tumor tissues in comparison with normal tissues, as evaluated by RT-PCR.
p65008
sg52638
(lp65009
(dp65010
g52643
I7
sg52644
VmiR-126-5p
p65011
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp65012
(dp65013
g52643
I83
sg52644
Vtumor
p65014
sg52646
I5
sg52647
VC0027651
p65015
sg52649
I1
sa(dp65016
g52643
I67
sg52644
Vcervical cancer
p65017
sg52646
I15
sg52647
VC0302592
p65018
sg52649
I2
sasa(dp65019
g52636
VConsistently, the levels of miR-126-5p were also significantly reduced in cervical cancer cell lines when compared to normal cervical epithelial cells.
p65020
sg52638
(lp65021
(dp65022
g52643
I28
sg52644
VmiR-126-5p
p65023
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp65024
(dp65025
g52643
I74
sg52644
Vcervical cancer
p65026
sg52646
I15
sg52647
VC0302592
p65027
sg52649
I2
sasa(dp65028
g52636
VFlow cytometric analysis showed that the rate of apoptosis of cervical cancer cells was significantly increased by miR-126-5p overexpression but inhibited by miR-126-5p inhibitor.
p65029
sg52638
(lp65030
(dp65031
g52643
I115
sg52644
VmiR-126-5p
p65032
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp65033
g52643
I115
sg52644
VmiR-126-5p
p65034
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp65035
(dp65036
g52643
I62
sg52644
Vcervical cancer
p65037
sg52646
I15
sg52647
VC0302592
p65038
sg52649
I2
sasa(dp65039
g135
(dp65040
(Vprotein caspase 3
p65041
Vcervical cancer
p65042
tp65043
I00
ssg52636
VA similar change pattern was observed in the expression of apoptosis-regulated protein caspase 3 in cervical cancer cells transfected with miR-126-5p mimic or inhibitor.
p65044
sg52638
(lp65045
(dp65046
g52643
I139
sg52644
VmiR-126-5p
p65047
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp65048
g52643
I79
sg52644
g65041
sg52646
I17
sg52674
VP42574
p65049
sg52649
I3
sasg52640
(lp65050
(dp65051
g52643
I100
sg52644
g65042
sg52646
I15
sg52647
VC0302592
p65052
sg52649
I2
sasa(dp65053
g52636
VBy bioinformatic prediction with online databases and verification using luciferase reporter assay, we then identified that Bcl2l2 is a direct target of miR-126-5p in cervical cancer cells.
p65054
sg52638
(lp65055
(dp65056
g52643
I124
sg52644
VBcl2l2
p65057
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp65058
g52643
I153
sg52644
VmiR-126-5p
p65059
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp65060
(dp65061
g52643
I167
sg52644
Vcervical cancer
p65062
sg52646
I15
sg52647
VC0302592
p65063
sg52649
I2
sasa(dp65064
g52636
VThe expression of Bcl2l2 was strongly downregulated by the miR-126-5p mimic but upregulated by the miR-126-5p inhibitor in cervical cancer cells, and Bcl2l2 expression was significantly increased in human cervical cancer tumor tissues, which was negatively correlated with miR-126-5p levels.
p65065
sg52638
(lp65066
(dp65067
g52643
I18
sg52644
VBcl2l2
p65068
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp65069
g52643
I59
sg52644
VmiR-126-5p
p65070
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp65071
g52643
I59
sg52644
VmiR-126-5p
p65072
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp65073
g52643
I18
sg52644
VBcl2l2
p65074
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp65075
(dp65076
g52643
I123
sg52644
Vcervical cancer
p65077
sg52646
I15
sg52647
VC0302592
p65078
sg52649
I2
sa(dp65079
g52643
I123
sg52644
Vcervical cancer
p65080
sg52646
I15
sg52647
VC0302592
p65081
sg52649
I2
sa(dp65082
g52643
I221
sg52644
Vtumor
p65083
sg52646
I5
sg52647
VC0027651
p65084
sg52649
I1
sasa(dp65085
g52636
VFurthermore, we confirmed that the rate of apoptosis was significantly increased by Bcl2l2 silencing in cervical cancer cells, which was not affected by the miR-126-5p inhibitor.
p65086
sg52638
(lp65087
(dp65088
g52643
I84
sg52644
VBcl2l2
p65089
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp65090
g52643
I157
sg52644
VmiR-126-5p
p65091
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp65092
(dp65093
g52643
I104
sg52644
Vcervical cancer
p65094
sg52646
I15
sg52647
VC0302592
p65095
sg52649
I2
sasa(dp65096
g52636
VIn summary, miR-126-5p plays an inhibitory role in human cervical cancer progression, regulating the apoptosis of cancer cells via directly targeting Bcl2l2.
p65097
sg52638
(lp65098
(dp65099
g52643
I12
sg52644
VmiR-126-5p
p65100
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp65101
g52643
I150
sg52644
VBcl2l2
p65102
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp65103
(dp65104
g52643
I66
sg52644
Vcancer
p65105
sg52646
I6
sg52647
VC0006826
p65106
sg52649
I1
sa(dp65107
g52643
I66
sg52644
Vcancer progression
p65108
sg52646
I18
sg52647
VC0178874
p65109
sg52649
I2
sasa(dp65110
g52636
VPatients with miR-126*low myelodysplastic syndrome had significantly lower response rates (P = 0.04) and higher relapse rates (P = 0.03), as well as shorter progression-free (PFS; P = 0.004) and overall survival (OS; P = 0.004).
p65111
sg52638
(lp65112
sg52640
(lp65113
(dp65114
g52643
I26
sg52644
Vmyelodysplastic syndrome
p65115
sg52646
I24
sg52647
VC0033027
p65116
sg52649
I2
sa(dp65117
g52643
I112
sg52644
Vrelapse
p65118
sg52646
I7
sg52647
VC0277556
p65119
sg52649
I1
sasa(dp65120
g52636
VIn the present study, the relationship between miR-126-5p/3p expression levels and overall survival in 109 patients with acute myeloid leukemia (AML) who received intensive therapy were evaluated.
p65121
sg52638
(lp65122
(dp65123
g52643
I47
sg52644
VmiR-126-5p/3p
p65124
sg52646
I13
sg52674
g12
sg52649
I1
sasg52640
(lp65125
(dp65126
g52643
I121
sg52644
Vacute myeloid leukemia
p65127
sg52646
I22
sg52647
VC0023467
p65128
sg52649
I3
sa(dp65129
g52643
I145
sg52644
VAML
p65130
sg52646
I3
sg52647
VC0023467
p65131
sg52649
I1
sasa(dp65132
g135
(dp65133
(VXBP-1
p65134
VBurkitt's lymphoma
p65135
tp65136
I00
ssg52636
VThe presence of XBP-1s, the active form of XBP-1, after administration of anti-Ig to Akata Burkitt's lymphoma cells is consistent with a role for this factor in reactivation of the EBV lytic cycle, although signalling through MEF2D was quantitatively much more significant in activation of Zp.
p65137
sg52638
(lp65138
(dp65139
g52643
I16
sg52644
VXBP-1s
p65140
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp65141
g52643
I226
sg52644
VMEF2D
p65142
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65143
g52643
I16
sg52644
g65134
sg52646
I5
sg52674
VP17861
p65144
sg52649
I1
sasg52640
(lp65145
(dp65146
g52643
I185
sg52644
Vlytic
p65147
sg52646
I5
sg52647
VC0024348
p65148
sg52649
I1
sa(dp65149
g52643
I91
sg52644
g65135
sg52646
I18
sg52647
VC0006413
p65150
sg52649
I2
sasa(dp65151
g135
(dp65152
(VBCL2
p65153
VB-cell lymphoma
p65154
tp65155
I00
ssg52636
VAs expected, markers of neuronal differentiation such as anti-apoptotic protein B-cell lymphoma 2 (BCL2), myocyte enhancer factor-2D (MEF2D) and zipper protein kinase (MAP3K12; aka ZPK/MUK/DLK) were each up-regulated in response to differentiation.
p65156
sg52638
(lp65157
(dp65158
g52643
I189
sg52644
VDLK
p65159
sg52646
I3
sg52674
VP80370
p65160
sg52649
I1
sa(dp65161
g52643
I99
sg52644
g65153
sg52646
I4
sg52674
VP10415
p65162
sg52649
I1
sa(dp65163
g52643
I134
sg52644
VMEF2D
p65164
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65165
g52643
I168
sg52644
VMAP3K12
p65166
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp65167
g52643
I185
sg52644
VMUK
p65168
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp65169
g52643
I145
sg52644
Vzipper protein kinase
p65170
sg52646
I21
sg52674
g12
sg52649
I3
sa(dp65171
g52643
I106
sg52644
Vmyocyte enhancer factor-2D
p65172
sg52646
I26
sg52674
g12
sg52649
I3
sa(dp65173
g52643
I177
sg52644
Vaka ZPK
p65174
sg52646
I7
sg52674
g12
sg52649
I2
sa(dp65175
g52643
I57
sg52644
Vanti-apoptotic protein B-cell lymphoma 2
p65176
sg52646
I40
sg52674
g12
sg52649
I5
sasg52640
(lp65177
(dp65178
g52643
I80
sg52644
g65154
sg52646
I15
sg52647
VC0079731
p65179
sg52649
I2
sasa(dp65180
g52636
VThe decrease in T-Shc and T1 were less obvious in mucinous adenocarcinoma and not observed in serous or endometrioid adenocarcinoma.
p65181
sg52638
(lp65182
sg52640
(lp65183
(dp65184
g52643
I104
sg52644
Vendometrioid adenocarcinoma
p65185
sg52646
I27
sg52647
VC1569637
p65186
sg52649
I2
sa(dp65187
g52643
I50
sg52644
Vmucinous adenocarcinoma
p65188
sg52646
I23
sg52647
VC0007130
p65189
sg52649
I2
sasa(dp65190
g52636
VOverexpression of the signalling adaptor protein ShcD in melanoma was found to be a prerequisite for melanoma migration and invasion.
p65191
sg52638
(lp65192
(dp65193
g52643
I49
sg52644
VShcD
p65194
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp65195
(dp65196
g52643
I124
sg52644
Vinvasion
p65197
sg52646
I8
sg52647
VC2699153
p65198
sg52649
I1
sa(dp65199
g52643
I57
sg52644
Vmelanoma
p65200
sg52646
I8
sg52647
VC0025202
p65201
sg52649
I1
sa(dp65202
g52643
I57
sg52644
Vmelanoma
p65203
sg52646
I8
sg52647
VC0025202
p65204
sg52649
I1
sasa(dp65205
g52636
VWe have further demonstrated that ShcD accumulates in the nucleus upon hydrogen peroxide treatment in FLAG-ShcD expressing HEK293 cells, as well as 518.A2 melanoma cells.
p65206
sg52638
(lp65207
(dp65208
g52643
I34
sg52644
VShcD
p65209
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65210
g52643
I34
sg52644
VShcD
p65211
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp65212
(dp65213
g52643
I155
sg52644
Vmelanoma
p65214
sg52646
I8
sg52647
VC0025202
p65215
sg52649
I1
sasa(dp65216
g52636
VWe suggest that ShcD nuclear translocation might provide melanoma cells with a mechanism that enables them to resist DNA damage due to oxidative stress.
p65217
sg52638
(lp65218
(dp65219
g52643
I16
sg52644
VShcD
p65220
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp65221
(dp65222
g52643
I135
sg52644
Voxidative stress
p65223
sg52646
I16
sg52647
VC0242606
p65224
sg52649
I2
sa(dp65225
g52643
I57
sg52644
Vmelanoma
p65226
sg52646
I8
sg52647
VC0025202
p65227
sg52649
I1
sa(dp65228
g52643
I117
sg52644
VDNA damage
p65229
sg52646
I10
sg52647
VC0012860
p65230
sg52649
I2
sa(dp65231
g52643
I29
sg52644
Vtranslocation
p65232
sg52646
I13
sg52647
VC0040715
p65233
sg52649
I1
sasa(dp65234
g135
(dp65235
(VRai like protein
p65236
Vmetastatic melanoma
p65237
tp65238
I00
ssg52636
VRai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target.
p65239
sg52638
(lp65240
(dp65241
g52643
I46
sg52644
VSrc homology 2 domain containing (Shc) family member
p65242
sg52646
I52
sg52674
VP12931
p65243
sg52649
I8
sa(dp65244
g52643
I18
sg52644
VRaLP
p65245
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65246
g52643
I0
sg52644
g65236
sg52646
I16
sg52674
VP13489
p65247
sg52649
I3
sasg52640
(lp65248
(dp65249
g52643
I132
sg52644
Vtransition
p65250
sg52646
I10
sg52647
VC0599156
p65251
sg52649
I1
sa(dp65252
g52643
I157
sg52644
Vmelanoma
p65253
sg52646
I8
sg52647
VC0025202
p65254
sg52649
I1
sa(dp65255
g52643
I146
sg52644
g65237
sg52646
I19
sg52647
VC0278883
p65256
sg52649
I2
sasa(dp65257
g52636
VMutations in ABHD5 gene are associated with the onset of Chanarin-Dorfman syndrome (CDS), a rare autosomal recessive lipid storage disorder, characterized by non-bullous congenital ichthyosiform erythroderma (NCIE), hepatomegaly and liver steatosis.
p65258
sg52638
(lp65259
(dp65260
g52643
I13
sg52644
VABHD5 gene
p65261
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp65262
(dp65263
g52643
I216
sg52644
Vhepatomegaly
p65264
sg52646
I12
sg52647
VC0019209
p65265
sg52649
I1
sa(dp65266
g52643
I209
sg52644
VNCIE
p65267
sg52646
I4
sg52647
VC1855792
p65268
sg52649
I1
sa(dp65269
g52643
I57
sg52644
VChanarin-Dorfman syndrome
p65270
sg52646
I25
sg52647
VC0268238
p65271
sg52649
I2
sa(dp65272
g52643
I158
sg52644
Vnon-bullous congenital ichthyosiform erythroderma
p65273
sg52646
I49
sg52647
VC1855792
p65274
sg52649
I4
sa(dp65275
g52643
I233
sg52644
Vliver steatosis
p65276
sg52646
I15
sg52647
VC0015695
p65277
sg52649
I2
sa(dp65278
g52643
I84
sg52644
VCDS
p65279
sg52646
I3
sg52647
VC0268238
p65280
sg52649
I1
sasa(dp65281
g52636
VIt is an autosomal recessive disease caused by mutations in the ABHD5 gene.
p65282
sg52638
(lp65283
(dp65284
g52643
I64
sg52644
VABHD5 gene
p65285
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp65286
sa(dp65287
g52636
VMutations of comparative gene identification 58 (CGI-58) in humans cause Chanarin-Dorfman syndrome, a rare autosomal recessive disease in which excess triacylglycerol (TAG) accumulates in multiple tissues.
p65288
sg52638
(lp65289
sg52640
(lp65290
(dp65291
g52643
I151
sg52644
Vtriacylglycerol
p65292
sg52646
I15
sg52647
VC0037293
p65293
sg52649
I1
sa(dp65294
g52643
I168
sg52644
VTAG
p65295
sg52646
I3
sg52647
VC0037293
p65296
sg52649
I1
sa(dp65297
g52643
I73
sg52644
VChanarin-Dorfman syndrome
p65298
sg52646
I25
sg52647
VC0268238
p65299
sg52649
I2
sasa(dp65300
g52636
VThe case histories of two children (aged two months) affected by myocarditis showing an atypical band of serum creatine kinase (EC 2.7.3.2; CK) in the CK isoenzyme electrophoretic pattern are reported.
p65301
sg52638
(lp65302
(dp65303
g52643
I105
sg52644
Vserum creatine kinase
p65304
sg52646
I21
sg52674
VP12532
p65305
sg52649
I3
sasg52640
(lp65306
(dp65307
g52643
I65
sg52644
Vmyocarditis
p65308
sg52646
I11
sg52647
VC0027059
p65309
sg52649
I1
sasa(dp65310
g135
(dp65311
(Vbovine serum albumin
p65312
Vimmune complex glomerulonephritis
p65313
tp65314
I00
ssg52636
VThe objective of this study was to evaluate the nephroprotective potential of resveratrol and piperine at same dose on cationic bovine serum albumin (cBSA) induced immune complex glomerulonephritis (ICGN) in BALB/c mice.
p65315
sg52638
(lp65316
(dp65317
g52643
I128
sg52644
g65312
sg52646
I20
sg52674
VP49639
p65318
sg52649
I3
sasg52640
(lp65319
(dp65320
g52643
I199
sg52644
VICGN
p65321
sg52646
I4
sg52647
VC0744421
p65322
sg52649
I1
sa(dp65323
g52643
I164
sg52644
g65313
sg52646
I33
sg52647
VC0744421
p65324
sg52649
I3
sasa(dp65325
g135
(dp65326
(Vcationic bovine serum albumin
p65327
Vimmune-complex glomerulonephritis
p65328
tp65329
I00
ssg52636
VThe object of the present study was to investigate the effects of VA, alone and in combination with methylprednisolone (MP), on cationic bovine serum albumin (cBSA induced immune-complex glomerulonephritis in female BALB/c mice.
p65330
sg52638
(lp65331
(dp65332
g52643
I128
sg52644
g65327
sg52646
I29
sg52674
VP49639
p65333
sg52649
I4
sasg52640
(lp65334
(dp65335
g52643
I172
sg52644
g65328
sg52646
I33
sg52647
VC0744421
p65336
sg52649
I2
sasa(dp65337
g135
(dp65338
(VBovine serum albumin
p65339
Vimmune complex glomerulonephritis
p65340
tp65341
I00
ssg52636
VBovine serum albumin (BSA) glomerulonephritis is a type of immune complex glomerulonephritis that is characterized by a large number of leukocytes infiltrating the kidney.
p65342
sg52638
(lp65343
(dp65344
g52643
I22
sg52644
VBSA
p65345
sg52646
I3
sg52674
VP49639
p65346
sg52649
I1
sa(dp65347
g52643
I0
sg52644
g65339
sg52646
I20
sg52674
VP49639
p65348
sg52649
I3
sasg52640
(lp65349
(dp65350
g52643
I27
sg52644
Vglomerulonephritis
p65351
sg52646
I18
sg52647
VC0017658
p65352
sg52649
I1
sa(dp65353
g52643
I147
sg52644
Vinfiltrating
p65354
sg52646
I12
sg52647
VC0332448
p65355
sg52649
I1
sa(dp65356
g52643
I59
sg52644
g65340
sg52646
I33
sg52647
VC0744421
p65357
sg52649
I3
sasa(dp65358
g52636
VThe aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.
p65359
sg52638
(lp65360
sg52640
(lp65361
(dp65362
g52643
I90
sg52644
Vhospital discharge records
p65363
sg52646
I26
sg52647
VC1840333
p65364
sg52649
I3
sa(dp65365
g52643
I118
sg52644
VHDRs
p65366
sg52646
I4
sg52647
VC1840333
p65367
sg52649
I1
sasa(dp65368
g52636
VThe aim of this study is to show the results of the retrospective analysis (2010-2012) on hospital discharge records (HDRs) related to diseases potentially due to S. pneumoniae, using a selection of ICD9-CM codes.
p65369
sg52638
(lp65370
sg52640
(lp65371
(dp65372
g52643
I90
sg52644
Vhospital discharge records
p65373
sg52646
I26
sg52647
VC1840333
p65374
sg52649
I3
sa(dp65375
g52643
I118
sg52644
VHDRs
p65376
sg52646
I4
sg52647
VC1840333
p65377
sg52649
I1
sasa(dp65378
g135
(dp65379
(VGATA3
p65380
Vinfluenza
p65381
tp65382
I01
ssg52636
VGATA binding protein 3 (GATA3) and suppressors of cytokine signalling3 mRNA were differentially regulated in HDM and influenza-stimulated cultures+/-IFN-Beta.
p65383
sg52638
(lp65384
(dp65385
g52643
I149
sg52644
VIFN-Beta
p65386
sg52646
I8
sg52674
VP01574
p65387
sg52649
I1
sa(dp65388
g52643
I0
sg52644
VGATA binding protein 3
p65389
sg52646
I22
sg52674
VP23771
p65390
sg52649
I4
sa(dp65391
g52643
I24
sg52644
g65380
sg52646
I5
sg52674
VP23771
p65392
sg52649
I1
sasg52640
(lp65393
(dp65394
g52643
I117
sg52644
g65381
sg52646
I9
sg52647
VC0021400
p65395
sg52649
I1
sasa(dp65396
g52636
VIn this article we review the current available evidence describing the effects of allopurinol in hypertension, kidney disease, and coronary heart disease, highlighting unresolved issues surrounding allopurinol use for uric acid lowering in individuals without gout.
p65397
sg52638
(lp65398
sg52640
(lp65399
(dp65400
g52643
I98
sg52644
Vhypertension
p65401
sg52646
I12
sg52647
VC0020538
p65402
sg52649
I1
sa(dp65403
g52643
I261
sg52644
Vgout
p65404
sg52646
I4
sg52647
VC0018099
p65405
sg52649
I1
sa(dp65406
g52643
I112
sg52644
Vkidney disease
p65407
sg52646
I14
sg52647
VC0022658
p65408
sg52649
I2
sa(dp65409
g52643
I132
sg52644
Vcoronary heart disease
p65410
sg52646
I22
sg52647
VC0010054
p65411
sg52649
I3
sasa(dp65412
g135
(dp65413
(VITGA2
p65414
VDR
p65415
tp65416
I00
ssg52636
VMany epidemiological studies have evaluated associations of platelet glycoprotein receptor alpha2beta1 integrin (ITGA2) and glycoprotein IIIa (ITGB3) gene polymorphisms with diabetic retinopathy (DR), but the published data are inconclusive.
p65417
sg52638
(lp65418
(dp65419
g52643
I124
sg52644
Vglycoprotein IIIa
p65420
sg52646
I17
sg52674
VP05106
p65421
sg52649
I2
sa(dp65422
g52643
I60
sg52644
Vplatelet glycoprotein receptor alpha2beta1 integrin
p65423
sg52646
I51
sg52674
VP14770
p65424
sg52649
I5
sa(dp65425
g52643
I143
sg52644
VITGB3
p65426
sg52646
I5
sg52674
VP05106
p65427
sg52649
I1
sa(dp65428
g52643
I113
sg52644
g65414
sg52646
I5
sg52674
VP17301
p65429
sg52649
I1
sasg52640
(lp65430
(dp65431
g52643
I174
sg52644
Vdiabetic retinopathy
p65432
sg52646
I20
sg52647
VC0011884
p65433
sg52649
I2
sa(dp65434
g52643
I196
sg52644
g65415
sg52646
I2
sg52647
VC0011884
p65435
sg52649
I1
sasa(dp65436
g135
(dp65437
(VGPIIIa
p65438
Vmyocardial infarction
p65439
tp65440
I00
ssg52636
VGenetic polymorphisms of the alpha2beta1 integrin and glycoprotein IIIa (GPIIIa) have been associated with myocardial infarction, stroke, and diabetic retinopathy.
p65441
sg52638
(lp65442
(dp65443
g52643
I29
sg52644
Valpha2beta1 integrin and glycoprotein IIIa
p65444
sg52646
I42
sg52674
VP05106
p65445
sg52649
I5
sa(dp65446
g52643
I73
sg52644
g65438
sg52646
I6
sg52674
VP05106
p65447
sg52649
I1
sasg52640
(lp65448
(dp65449
g52643
I130
sg52644
Vstroke
p65450
sg52646
I6
sg52647
VC0038454
p65451
sg52649
I1
sa(dp65452
g52643
I142
sg52644
Vdiabetic retinopathy
p65453
sg52646
I20
sg52647
VC0011884
p65454
sg52649
I2
sa(dp65455
g52643
I107
sg52644
g65439
sg52646
I21
sg52647
VC0027051
p65456
sg52649
I2
sasa(dp65457
g135
(dp65458
(VCD14
p65459
Vadhesion
p65460
tp65461
I00
ssg52636
VImmunostaining procedures were used to seek for the expression of the following 30 membrane antigens related to the immune system, using dendriform cells obtained in conjunctival specimens from 80 normal subjects and 105 with chronic conjunctivitis: class II antigens HLADR and DQ, CD1a (T6) and CD5, which usually mark Langerhans cells, macrophage markers CD14, CD36 and CD63, various lymphocyte antigens (CD2, CD4 and CD8), receptor to interleukin 2 (CD25), adhesion molecules and integrins (CD11a, CD11b, CD11c, CD18, CD29, CD41, CD61), the selectin CD62, ICAM-1 (CD54), ICAM-3 (CD50) and ELAM-1, CD45RO, related to activation of immune cells, and its ligand CD22, receptors to immunoglobulins (CD23 and CD32) and complement (CD21), transferrin receptor CD71, tryptase and vimentin, were thus investigated.
p65462
sg52638
(lp65463
(dp65464
g52643
I592
sg52644
VELAM-1
p65465
sg52646
I6
sg52674
VP16581
p65466
sg52649
I1
sa(dp65467
g52643
I296
sg52644
VCD5
p65468
sg52646
I3
sg52674
VP06127
p65469
sg52649
I1
sa(dp65470
g52643
I420
sg52644
VCD8
p65471
sg52646
I3
sg52674
VP01732
p65472
sg52649
I1
sa(dp65473
g52643
I527
sg52644
VCD41
p65474
sg52646
I4
sg52674
VP08514
p65475
sg52649
I1
sa(dp65476
g52643
I508
sg52644
VCD11c
p65477
sg52646
I5
sg52674
VP20702
p65478
sg52649
I1
sa(dp65479
g52643
I372
sg52644
VCD63
p65480
sg52646
I4
sg52674
VP08962
p65481
sg52649
I1
sa(dp65482
g52643
I494
sg52644
VCD11a
p65483
sg52646
I5
sg52674
VP20701
p65484
sg52649
I1
sa(dp65485
g52643
I438
sg52644
Vinterleukin 2
p65486
sg52646
I13
sg52674
VP60568
p65487
sg52649
I2
sa(dp65488
g52643
I501
sg52644
VCD11b
p65489
sg52646
I5
sg52674
VP11215
p65490
sg52649
I1
sa(dp65491
g52643
I707
sg52644
VCD32
p65492
sg52646
I4
sg52674
VP12318
p65493
sg52649
I1
sa(dp65494
g52643
I453
sg52644
VCD25
p65495
sg52646
I4
sg52674
VP01589
p65496
sg52649
I1
sa(dp65497
g52643
I412
sg52644
VCD4
p65498
sg52646
I3
sg52674
VP01730
p65499
sg52649
I1
sa(dp65500
g52643
I574
sg52644
VICAM-3
p65501
sg52646
I6
sg52674
VP32942
p65502
sg52649
I1
sa(dp65503
g52643
I698
sg52644
VCD23
p65504
sg52646
I4
sg52674
VP06734
p65505
sg52649
I1
sa(dp65506
g52643
I736
sg52644
Vtransferrin receptor CD71
p65507
sg52646
I25
sg52674
VP02787
p65508
sg52649
I3
sa(dp65509
g52643
I567
sg52644
VCD54
p65510
sg52646
I4
sg52674
VP05362
p65511
sg52649
I1
sa(dp65512
g52643
I515
sg52644
VCD18
p65513
sg52646
I4
sg52674
VP05107
p65514
sg52649
I1
sa(dp65515
g52643
I533
sg52644
VCD61
p65516
sg52646
I4
sg52674
VP05106
p65517
sg52649
I1
sa(dp65518
g52643
I559
sg52644
VICAM-1
p65519
sg52646
I6
sg52674
VP05362
p65520
sg52649
I1
sa(dp65521
g52643
I407
sg52644
VCD2
p65522
sg52646
I3
sg52674
VP06729
p65523
sg52649
I1
sa(dp65524
g52643
I282
sg52644
VCD1a
p65525
sg52646
I4
sg52674
VP15813
p65526
sg52649
I1
sa(dp65527
g52643
I681
sg52644
Vimmunoglobulins
p65528
sg52646
I15
sg52674
g12
sg52649
I1
sa(dp65529
g52643
I386
sg52644
Vlymphocyte antigens
p65530
sg52646
I19
sg52674
VP30486
p65531
sg52649
I2
sa(dp65532
g52643
I582
sg52644
VCD50
p65533
sg52646
I4
sg52674
VP32942
p65534
sg52649
I1
sa(dp65535
g52643
I729
sg52644
VCD21
p65536
sg52646
I4
sg52674
VP20023
p65537
sg52649
I1
sa(dp65538
g52643
I250
sg52644
Vclass II
p65539
sg52646
I8
sg52674
g12
sg52649
I2
sa(dp65540
g52643
I553
sg52644
VCD62
p65541
sg52646
I4
sg52674
VP16109
p65542
sg52649
I1
sa(dp65543
g52643
I357
sg52644
g65459
sg52646
I4
sg52674
VP08571
p65544
sg52649
I1
sasg52640
(lp65545
(dp65546
g52643
I226
sg52644
Vchronic conjunctivitis
p65547
sg52646
I22
sg52647
VC0155145
p65548
sg52649
I2
sa(dp65549
g52643
I460
sg52644
g65460
sg52646
I8
sg52647
VC0001511
p65550
sg52649
I1
sasa(dp65551
g135
(dp65552
(VLTA
p65553
VAAA
p65554
tp65555
I00
ssg52636
VIn order to elucidate the involvement of adhesion mechanisms in the process of megakaryocyte-dependent fibroblast growth, we applied BSA-coupled polymers of glucose, galactose, fucose, mannose, and several lectins (AAA, LCA, LTA, UEA-I) to cocultures of CD61 -positive (CD61+)/MACS-enriched megakaryocytes and human bone marrow fibroblasts.
p65556
sg52638
(lp65557
(dp65558
g52643
I254
sg52644
VCD61 -positive
p65559
sg52646
I14
sg52674
VP05106
p65560
sg52649
I2
sa(dp65561
g52643
I270
sg52644
VCD61+
p65562
sg52646
I5
sg52674
VP05106
p65563
sg52649
I1
sa(dp65564
g52643
I215
sg52644
VAAA
p65565
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp65566
g52643
I133
sg52644
VBSA
p65567
sg52646
I3
sg52674
VP49639
p65568
sg52649
I1
sa(dp65569
g52643
I220
sg52644
VLCA
p65570
sg52646
I3
sg52674
VP09496
p65571
sg52649
I1
sa(dp65572
g52643
I225
sg52644
g65553
sg52646
I3
sg52674
VP10515
p65573
sg52649
I1
sasg52640
(lp65574
(dp65575
g52643
I41
sg52644
Vadhesion
p65576
sg52646
I8
sg52647
VC0001511
p65577
sg52649
I1
sa(dp65578
g52643
I220
sg52644
VLCA
p65579
sg52646
I3
sg52647
VC0339527
p65580
sg52649
I1
sa(dp65581
g52643
I215
sg52644
g65554
sg52646
I3
sg52647
VC0162871
p65582
sg52649
I1
sasa(dp65583
g52636
VComplications included pyogenic granuloma (10 patients, 24.4%), exposure keratopathy (7 patients, 17.1%) lagophthalmos (5 patients, 12.2%), ectropion (6 patients, 14.6%), lateral canthal dystopia (2 cases, 4.9%), eyelid notch (2 cases, 4.9%) and trichiasis (4 cases, 9.8%).
p65584
sg52638
(lp65585
sg52640
(lp65586
(dp65587
g52643
I23
sg52644
Vpyogenic granuloma
p65588
sg52646
I18
sg52647
VC0085653
p65589
sg52649
I2
sa(dp65590
g52643
I246
sg52644
Vtrichiasis
p65591
sg52646
I10
sg52647
VC0221259
p65592
sg52649
I1
sa(dp65593
g52643
I105
sg52644
Vlagophthalmos
p65594
sg52646
I13
sg52647
VC0152226
p65595
sg52649
I1
sa(dp65596
g52643
I64
sg52644
Vexposure keratopathy
p65597
sg52646
I20
sg52647
VC0339295
p65598
sg52649
I2
sa(dp65599
g52643
I140
sg52644
Vectropion
p65600
sg52646
I9
sg52647
VC0013592
p65601
sg52649
I1
sasa(dp65602
g52636
VComplications included eyelid margin notch (3 cases), persistent canthal dystopia (3 cases), trichiasis (2 cases), pyogenic granuloma (2 cases), eyelid margin nodule (1 case), lower eyelid elevation of 1 mm (1 case), and mild resolving medial lagophthalmos (1 case).
p65603
sg52638
(lp65604
sg52640
(lp65605
(dp65606
g52643
I159
sg52644
Vnodule
p65607
sg52646
I6
sg52647
VC0028259
p65608
sg52649
I1
sa(dp65609
g52643
I93
sg52644
Vtrichiasis
p65610
sg52646
I10
sg52647
VC0221259
p65611
sg52649
I1
sa(dp65612
g52643
I115
sg52644
Vpyogenic granuloma
p65613
sg52646
I18
sg52647
VC0085653
p65614
sg52649
I2
sa(dp65615
g52643
I243
sg52644
Vlagophthalmos
p65616
sg52646
I13
sg52647
VC0152226
p65617
sg52649
I1
sasa(dp65618
g52636
VAfter operation slight entropion occurred in 8 cases, slight ectropion in 3 cases, lagophthalmos for 2 -- 3 mm in 7 cases, notch of the palpebral margin in 5 cases and thinness of the donor tarsal plates in 4 cases, but the functional and aesthetic results were normal.
p65619
sg52638
(lp65620
sg52640
(lp65621
(dp65622
g52643
I23
sg52644
Ventropion
p65623
sg52646
I9
sg52647
VC0014390
p65624
sg52649
I1
sa(dp65625
g52643
I83
sg52644
Vlagophthalmos
p65626
sg52646
I13
sg52647
VC0152226
p65627
sg52649
I1
sa(dp65628
g52643
I61
sg52644
Vectropion
p65629
sg52646
I9
sg52647
VC0013592
p65630
sg52649
I1
sasa(dp65631
g52636
VWe screened the exons of RAY1/ST7 and ST7OT1-3 for sequence variants in 90 unrelated autism probands and identified several rare variants, including a Ile361Val substitution.
p65632
sg52638
(lp65633
(dp65634
g52643
I30
sg52644
VST7
p65635
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp65636
g52643
I25
sg52644
VRAY1
p65637
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp65638
(dp65639
g52643
I85
sg52644
Vautism
p65640
sg52646
I6
sg52647
VC0004352
p65641
sg52649
I1
sasa(dp65642
g135
(dp65643
(VSTAT5 protein
p65644
VNAD
p65645
tp65646
I00
ssg52636
VSeveral signaling systems downstream of G-CSFR have been identified that are defective or hyperactivated in myeloid cells of patients with congenital neutropenia: severely reduced expression of myeloid-specific transcription factors LEF-1 and C/EBPAlfa, severely reduced expression and functions of HCLS1 protein, severely reduced expression of neutrophil elastase protein, dramatic compensatory up-regulation of the NAMPT/NAD(+)/SIRT pathway leading to continuous activation of emergency granulopoiesis via the transcription factor C/EBPBeta, and hyperactivation of STAT5 protein by tyrosine phosphorylation.
p65647
sg52638
(lp65648
(dp65649
g52643
I40
sg52644
VG-CSFR
p65650
sg52646
I6
sg52674
VP07333
p65651
sg52649
I1
sa(dp65652
g52643
I345
sg52644
Vneutrophil elastase
p65653
sg52646
I19
sg52674
VP08246
p65654
sg52649
I2
sa(dp65655
g52643
I299
sg52644
VHCLS1 protein
p65656
sg52646
I13
sg52674
VP14317
p65657
sg52649
I2
sa(dp65658
g52643
I512
sg52644
Vtranscription factor C/EBPBeta
p65659
sg52646
I30
sg52674
VP35398
p65660
sg52649
I3
sa(dp65661
g52643
I194
sg52644
Vmyeloid-specific transcription factors LEF-1
p65662
sg52646
I44
sg52674
g12
sg52649
I4
sa(dp65663
g52643
I567
sg52644
g65644
sg52646
I13
sg52674
VP42229
p65664
sg52649
I2
sasg52640
(lp65665
(dp65666
g52643
I139
sg52644
Vcongenital neutropenia
p65667
sg52646
I22
sg52647
VC0340970
p65668
sg52649
I2
sa(dp65669
g52643
I479
sg52644
Vemergency
p65670
sg52646
I9
sg52647
VC2745965
p65671
sg52649
I1
sa(dp65672
g52643
I423
sg52644
g65645
sg52646
I3
sg52647
VC1850380
p65673
sg52649
I1
sasa(dp65674
g52636
VWe observed spontaneous osteoclastogenesis with a significant increase in OC formation and bone resorbing activity in late-stage CKD and HD patients when compared with early-stage CKD patients and healthy donors, likely due to an increased expression of RANKL and LIGHT (homologous to Lymphotoxins exhibiting Inducible expression and competing with herpes simplex virus Glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) in PBMCs.
p65675
sg52638
(lp65676
(dp65677
g52643
I264
sg52644
VLIGHT
p65678
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65679
g52643
I254
sg52644
VRANKL
p65680
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp65681
(dp65682
g52643
I349
sg52644
Vherpes simplex
p65683
sg52646
I14
sg52647
VC0019348
p65684
sg52649
I2
sa(dp65685
g52643
I349
sg52644
Vherpes
p65686
sg52646
I6
sg52647
VC0019340
p65687
sg52649
I1
sasa(dp65688
g52636
VHealthy individuals of African ancestry have neutropenia that has been linked with the variant rs2814778(G) of the gene encoding atypical chemokine receptor 1 (ACKR1).
p65689
sg52638
(lp65690
(dp65691
g52643
I115
sg52644
Vgene encoding atypical chemokine receptor 1
p65692
sg52646
I43
sg52674
VP61073
p65693
sg52649
I6
sasg52640
(lp65694
sa(dp65695
g52636
VHere we describe an unexpected fundamental role for ACKR1 in hematopoiesis and provide the mechanism that links its absence with neutropenia.
p65696
sg52638
(lp65697
sg52640
(lp65698
sa(dp65699
g52636
VThe absence of erythroid ACKR1 altered mouse hematopoiesis including stem and progenitor cells, which ultimately gave rise to phenotypically distinct neutrophils that readily left the circulation, causing neutropenia.
p65700
sg52638
(lp65701
(dp65702
g52643
I15
sg52644
Verythroid ACKR1
p65703
sg52646
I15
sg52674
VP22557
p65704
sg52649
I2
sasg52640
(lp65705
sa(dp65706
g135
(dp65707
(VDetection of Apoptotic Retinal Cells
p65708
Vocular hypertension
p65709
tp65710
I00
ssg52636
VIn vivo studies in Adult Dark Agouti (DA) rats with unilateral surgically-induced ocular hypertension (OHT) treated with either CoQ10/TPGS micelles or TPGS vehicle twice daily for three weeks were performed, following which retinal cell health was assessed in vivo using DARC (Detection of Apoptotic Retinal Cells) and post-mortem with Brn3a histological assessment on whole retinal mounts.
p65711
sg52638
(lp65712
(dp65713
g52643
I271
sg52644
VDARC
p65714
sg52646
I4
sg52674
VP55283
p65715
sg52649
I1
sa(dp65716
g52643
I277
sg52644
g65708
sg52646
I36
sg52674
VP55283
p65717
sg52649
I5
sa(dp65718
g52643
I336
sg52644
VBrn3a
p65719
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp65720
(dp65721
g52643
I103
sg52644
VOHT
p65722
sg52646
I3
sg52647
VC0028840
p65723
sg52649
I1
sa(dp65724
g52643
I82
sg52644
g65709
sg52646
I19
sg52647
VC0028840
p65725
sg52649
I2
sasa(dp65726
g52636
VAfter correction for multiple testing, DARC polymorphism rs3027012 in 5'-UTR was associated with higher risk of low absolute phagocyte count (APC&lt;500 and &lt;1000 cells per microliter, P=0.001 and P&lt;0.0005, respectively) and hospitalization due to febrile neutropenia (P=0.002).
p65727
sg52638
(lp65728
sg52640
(lp65729
(dp65730
g52643
I254
sg52644
Vfebrile neutropenia
p65731
sg52646
I19
sg52647
VC0746883
p65732
sg52649
I2
sa(dp65733
g52643
I142
sg52644
VAPC
p65734
sg52646
I3
sg52647
VC0033036
p65735
sg52649
I1
sasa(dp65736
g52636
VWe examined the effects of PR and EZ on NPC1L1, ABCG5, and ABCG8 expression in human hepatoma HepG2 cells and the murine small intestine.
p65737
sg52638
(lp65738
(dp65739
g52643
I40
sg52644
VNPC1L1
p65740
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp65741
g52643
I48
sg52644
VABCG5
p65742
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65743
g52643
I59
sg52644
VABCG8
p65744
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp65745
(dp65746
g52643
I85
sg52644
Vhepatoma
p65747
sg52646
I8
sg52647
VC0023903
p65748
sg52649
I1
sasa(dp65749
g52636
VIn addition, knockdown of epigenetic regulator UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) in RIP3-null cancer cells reduces the methylation level of the Rip3 promoter.
p65750
sg52638
(lp65751
(dp65752
g52643
I115
sg52644
VRIP3
p65753
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65754
g52643
I175
sg52644
VRip3 promoter
p65755
sg52646
I13
sg52674
g12
sg52649
I2
sa(dp65756
g52643
I81
sg52644
VPHD
p65757
sg52646
I3
sg52674
VP20941
p65758
sg52649
I1
sa(dp65759
g52643
I54
sg52644
Vubiquitin
p65760
sg52646
I9
sg52674
VP62979
p65761
sg52649
I1
sa(dp65762
g52643
I47
sg52644
VUHRF1
p65763
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp65764
(dp65765
g52643
I125
sg52644
Vcancer
p65766
sg52646
I6
sg52647
VC0006826
p65767
sg52649
I1
sasa(dp65768
g52636
VA previous study revealed that ubiquitin-like with PHD and RING finger domains 1 (UHRF1) promoted cell proliferation and was a potential biomarker in medulloblastoma (MB).
p65769
sg52638
(lp65770
(dp65771
g52643
I82
sg52644
VUHRF1
p65772
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65773
g52643
I31
sg52644
Vubiquitin-like with PHD and RING finger domains 1
p65774
sg52646
I49
sg52674
g12
sg52649
I8
sasg52640
(lp65775
(dp65776
g52643
I150
sg52644
Vmedulloblastoma
p65777
sg52646
I15
sg52647
VC0025149
p65778
sg52649
I1
sa(dp65779
g52643
I103
sg52644
Vproliferation
p65780
sg52646
I13
sg52647
VC0334094
p65781
sg52649
I1
sa(dp65782
g52643
I167
sg52644
VMB
p65783
sg52646
I2
sg52647
VC0025149
p65784
sg52649
I1
sasa(dp65785
g135
(dp65786
(VSOX2-OT
p65787
Vlung cancer
p65788
tp65789
I00
ssg52636
VThree lncRNAs, sex determining region Y-box 2 overlapping transcript (SOX2-OT), NCBP2 antisense RNA 2 (NCBP2-AS2) and ubiquitin like with PHD and ring finger domains 1 (UHRF1), were predicted to be associated with lung cancer; RT-qPCR confirmed that SOX2-OT and NCBP2-AS2 were associated with lung cancer.
p65790
sg52638
(lp65791
(dp65792
g52643
I118
sg52644
Vubiquitin like with PHD and ring finger domains 1
p65793
sg52646
I49
sg52674
g12
sg52649
I9
sa(dp65794
g52643
I169
sg52644
VUHRF1
p65795
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65796
g52643
I103
sg52644
VNCBP2-AS2
p65797
sg52646
I9
sg52674
VP52298
p65798
sg52649
I1
sa(dp65799
g52643
I70
sg52644
VSOX2-OT
p65800
sg52646
I7
sg52674
VP48431
p65801
sg52649
I1
sa(dp65802
g52643
I103
sg52644
VNCBP2-AS2
p65803
sg52646
I9
sg52674
VP52298
p65804
sg52649
I1
sa(dp65805
g52643
I80
sg52644
VNCBP2 antisense RNA 2
p65806
sg52646
I21
sg52674
VP52298
p65807
sg52649
I4
sa(dp65808
g52643
I15
sg52644
Vsex determining region Y-box 2 overlapping transcript
p65809
sg52646
I53
sg52674
VP48431
p65810
sg52649
I7
sa(dp65811
g52643
I70
sg52644
g65787
sg52646
I7
sg52674
VP48431
p65812
sg52649
I1
sasg52640
(lp65813
(dp65814
g52643
I214
sg52644
Vlung cancer
p65815
sg52646
I11
sg52647
VC0684249
p65816
sg52649
I2
sa(dp65817
g52643
I214
sg52644
g65788
sg52646
I11
sg52647
VC0684249
p65818
sg52649
I2
sasa(dp65819
g52636
VUHRF1 (ubiquitin-like, with PHD and RING finger domains 1) plays a crucial role in DNA methylation, chromatin remodeling and gene expression and is aberrantly upregulated in various types of human cancers.
p65820
sg52638
(lp65821
(dp65822
g52643
I28
sg52644
VPHD
p65823
sg52646
I3
sg52674
VP20941
p65824
sg52649
I1
sa(dp65825
g52643
I7
sg52644
Vubiquitin-like
p65826
sg52646
I14
sg52674
VP62979
p65827
sg52649
I1
sa(dp65828
g52643
I0
sg52644
VUHRF1
p65829
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp65830
(dp65831
g52643
I197
sg52644
Vcancers
p65832
sg52646
I7
sg52647
VC0006826
p65833
sg52649
I1
sasa(dp65834
g52636
VUHRF1 (ubiquitin-like with PHD and RING finger domains 1) is a critical regulator for DNA methylation, and its frequent overexpression in human cancers has been associated with tumor-promoting effects.
p65835
sg52638
(lp65836
(dp65837
g52643
I0
sg52644
VUHRF1
p65838
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65839
g52643
I7
sg52644
Vubiquitin-like with PHD and RING finger domains 1
p65840
sg52646
I49
sg52674
VP20941
p65841
sg52649
I8
sasg52640
(lp65842
(dp65843
g52643
I177
sg52644
Vtumor
p65844
sg52646
I5
sg52647
VC0027651
p65845
sg52649
I1
sa(dp65846
g52643
I144
sg52644
Vcancers
p65847
sg52646
I7
sg52647
VC0006826
p65848
sg52649
I1
sasa(dp65849
g52636
VThe lower level of PHRF1 mRNA was observed in human lung cancer tissues than that in paracancerous tissues.
p65850
sg52638
(lp65851
(dp65852
g52643
I19
sg52644
VPHRF1 mRNA
p65853
sg52646
I10
sg52674
g12
sg52649
I2
sasg52640
(lp65854
(dp65855
g52643
I52
sg52644
Vlung cancer
p65856
sg52646
I11
sg52647
VC0684249
p65857
sg52649
I2
sasa(dp65858
g52636
VIn conclusion, our findings suggest that overexpression of PHRF1 attenuated the proliferation and tumorigenicity of non-small cell lung cancer cell line of H1299.
p65859
sg52638
(lp65860
(dp65861
g52643
I59
sg52644
VPHRF1
p65862
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp65863
(dp65864
g52643
I98
sg52644
Vtumorigenicity
p65865
sg52646
I14
sg52647
VC1519697
p65866
sg52649
I1
sa(dp65867
g52643
I80
sg52644
Vproliferation
p65868
sg52646
I13
sg52647
VC0334094
p65869
sg52649
I1
sa(dp65870
g52643
I116
sg52644
Vnon-small cell lung cancer
p65871
sg52646
I26
sg52647
VC0007131
p65872
sg52649
I4
sasa(dp65873
g52636
VRecessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
p65874
sg52638
(lp65875
(dp65876
g52643
I35
sg52644
VORC6
p65877
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65878
g52643
I49
sg52644
VCDC6
p65879
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65880
g52643
I23
sg52644
VORC1
p65881
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65882
g52643
I41
sg52644
VCDT1
p65883
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65884
g52643
I29
sg52644
VORC4
p65885
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp65886
(dp65887
g52643
I181
sg52644
Vmicrocephaly
p65888
sg52646
I12
sg52647
VC0025958
p65889
sg52649
I1
sa(dp65890
g52643
I135
sg52644
Vimpaired
p65891
sg52646
I8
sg52647
VC0684336
p65892
sg52649
I1
sa(dp65893
g52643
I82
sg52644
VMeier-Gorlin syndrome
p65894
sg52646
I21
sg52647
VC1868684
p65895
sg52649
I2
sa(dp65896
g52643
I105
sg52644
VMGS
p65897
sg52646
I3
sg52647
VC1969653
p65898
sg52649
I1
sa(dp65899
g52643
I163
sg52644
Vshort stature
p65900
sg52646
I13
sg52647
VC0013336
p65901
sg52649
I2
sasa(dp65902
g52636
VMutations in ORC1, ORC4, ORC6, CDT1, and CDC6, which encode proteins required for DNA replication origin licensing, cause Meier-Gorlin syndrome (MGS), a disorder conferring microcephaly, primordial dwarfism, underdeveloped ears, and skeletal abnormalities.
p65903
sg52638
(lp65904
(dp65905
g52643
I41
sg52644
VCDC6
p65906
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65907
g52643
I31
sg52644
VCDT1
p65908
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65909
g52643
I25
sg52644
VORC6
p65910
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65911
g52643
I13
sg52644
VORC1
p65912
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65913
g52643
I19
sg52644
VORC4
p65914
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp65915
(dp65916
g52643
I145
sg52644
VMGS
p65917
sg52646
I3
sg52647
VC1969653
p65918
sg52649
I1
sa(dp65919
g52643
I187
sg52644
Vprimordial dwarfism
p65920
sg52646
I19
sg52647
VC0013336
p65921
sg52649
I2
sa(dp65922
g52643
I173
sg52644
Vmicrocephaly
p65923
sg52646
I12
sg52647
VC0025958
p65924
sg52649
I1
sa(dp65925
g52643
I122
sg52644
VMeier-Gorlin syndrome
p65926
sg52646
I21
sg52647
VC1868684
p65927
sg52649
I2
sasa(dp65928
g135
(dp65929
(VHMGB1
p65930
Vallergic rhinitis
p65931
tp65932
I00
ssg52636
VSignificantly higher concentrations of HMGB1 were found in nasal secretions from patients with chronic rhinosinusitis with nasal polyp or allergic rhinitis compared with the control subjects.
p65933
sg52638
(lp65934
(dp65935
g52643
I39
sg52644
g65930
sg52646
I5
sg52674
VP09429
p65936
sg52649
I1
sasg52640
(lp65937
(dp65938
g52643
I123
sg52644
Vnasal polyp
p65939
sg52646
I11
sg52647
VC0027430
p65940
sg52649
I2
sa(dp65941
g52643
I95
sg52644
Vchronic rhinosinusitis
p65942
sg52646
I22
sg52647
VC0149516
p65943
sg52649
I2
sa(dp65944
g52643
I138
sg52644
g65931
sg52646
I17
sg52647
VC2607914
p65945
sg52649
I2
sasa(dp65946
g135
(dp65947
(VHMGB1
p65948
Vallergic rhinitis
p65949
tp65950
I00
ssg52636
VPrevious studies have shown that HMGB1 is elevated in the nasal lavage fluids (NLF) of children suffering from allergic rhinitis (AR) and is associated with the severity of this disease.
p65951
sg52638
(lp65952
(dp65953
g52643
I33
sg52644
g65948
sg52646
I5
sg52674
VP09429
p65954
sg52649
I1
sasg52640
(lp65955
(dp65956
g52643
I96
sg52644
Vsuffering
p65957
sg52646
I9
sg52647
VC0683278
p65958
sg52649
I1
sa(dp65959
g52643
I130
sg52644
VAR
p65960
sg52646
I2
sg52647
VC2607914
p65961
sg52649
I1
sa(dp65962
g52643
I111
sg52644
g65949
sg52646
I17
sg52647
VC2607914
p65963
sg52649
I2
sasa(dp65964
g52636
VThe major cystinosis mutation is a 57 kb deletion on human chromosome 17p13 that removes the majority of CTNS and the entire adjacent gene, CARKL/SHPK.
p65965
sg52638
(lp65966
(dp65967
g52643
I140
sg52644
VCARKL
p65968
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65969
g52643
I146
sg52644
VSHPK
p65970
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp65971
(dp65972
g52643
I105
sg52644
VCTNS
p65973
sg52646
I4
sg52647
VC0015624
p65974
sg52649
I1
sa(dp65975
g52643
I10
sg52644
Vcystinosis
p65976
sg52646
I10
sg52647
VC0010690
p65977
sg52649
I1
sasa(dp65978
g52636
VThe most common mutation in the nephropathic cystinosis (CTNS) gene is a homozygous 57-kb deletion that also includes an adjacent gene carbohydrate kinase-like (CARKL).
p65979
sg52638
(lp65980
(dp65981
g52643
I161
sg52644
VCARKL
p65982
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65983
g52643
I135
sg52644
Vcarbohydrate kinase-like
p65984
sg52646
I24
sg52674
g12
sg52649
I2
sasg52640
(lp65985
(dp65986
g52643
I57
sg52644
VCTNS
p65987
sg52646
I4
sg52647
VC0015624
p65988
sg52649
I1
sa(dp65989
g52643
I32
sg52644
Vnephropathic cystinosis
p65990
sg52646
I23
sg52647
VC0015624
p65991
sg52649
I2
sasa(dp65992
g52636
VAnalysis of the resulting data revealed a number of interesting features about this genomic region, including the long-range organization of CTNS, insight about the breakpoints and intervening DNA associated with the common cystinosis-causing deletion, and structural information about five genes neighboring CTNS (human ortholog of rat vanilloid receptor subtype 1 gene, CARKL, TIP-1, P2X5, and HUMINAE).
p65993
sg52638
(lp65994
(dp65995
g52643
I141
sg52644
VCTNS
p65996
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp65997
g52643
I372
sg52644
VCARKL
p65998
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp65999
g52643
I379
sg52644
VTIP-1
p66000
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp66001
g52643
I386
sg52644
VP2X5
p66002
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66003
g52643
I333
sg52644
Vrat vanilloid receptor subtype 1 gene
p66004
sg52646
I37
sg52674
g12
sg52649
I6
sasg52640
(lp66005
(dp66006
g52643
I141
sg52644
VCTNS
p66007
sg52646
I4
sg52647
VC0015624
p66008
sg52649
I1
sa(dp66009
g52643
I224
sg52644
Vcystinosis
p66010
sg52646
I10
sg52647
VC0010690
p66011
sg52649
I1
sa(dp66012
g52643
I141
sg52644
VCTNS
p66013
sg52646
I4
sg52647
VC0015624
p66014
sg52649
I1
sasa(dp66015
g52636
VIn particular, sequence analysis detected the presence of a novel gene (CARKL) residing within the most common cystinosis-causing deletion.
p66016
sg52638
(lp66017
(dp66018
g52643
I72
sg52644
VCARKL
p66019
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp66020
(dp66021
g52643
I111
sg52644
Vcystinosis
p66022
sg52646
I10
sg52647
VC0010690
p66023
sg52649
I1
sasa(dp66024
g52636
VInterestingly, both CTNS and CARKL are absent in nearly half of all cystinosis patients (i.e., those homozygous for the common deletion).
p66025
sg52638
(lp66026
(dp66027
g52643
I20
sg52644
VCTNS
p66028
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66029
g52643
I29
sg52644
VCARKL
p66030
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp66031
(dp66032
g52643
I68
sg52644
Vcystinosis
p66033
sg52646
I10
sg52647
VC0010690
p66034
sg52649
I1
sa(dp66035
g52643
I20
sg52644
VCTNS
p66036
sg52646
I4
sg52647
VC0015624
p66037
sg52649
I1
sasa(dp66038
g52636
VThere is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).
p66039
sg52638
(lp66040
sg52640
(lp66041
(dp66042
g52643
I187
sg52644
VCOPD
p66043
sg52646
I4
sg52647
VC0024117
p66044
sg52649
I1
sa(dp66045
g52643
I68
sg52644
Vdys
p66046
sg52646
I3
sg52647
VC0013364
p66047
sg52649
I1
sa(dp66048
g52643
I148
sg52644
Vchronic obstructive pulmonary disease
p66049
sg52646
I37
sg52647
VC0024117
p66050
sg52649
I4
sasa(dp66051
g52636
VBackground There is limited evidence regarding interactions between pulmonary (dys)function, posture, and mobility of the upper body quadrant in patients with chronic obstructive pulmonary disease (COPD).
p66052
sg52638
(lp66053
sg52640
(lp66054
(dp66055
g52643
I79
sg52644
Vdys
p66056
sg52646
I3
sg52647
VC0013364
p66057
sg52649
I1
sa(dp66058
g52643
I198
sg52644
VCOPD
p66059
sg52646
I4
sg52647
VC0024117
p66060
sg52649
I1
sa(dp66061
g52643
I159
sg52644
Vchronic obstructive pulmonary disease
p66062
sg52646
I37
sg52647
VC0024117
p66063
sg52649
I4
sasa(dp66064
g52636
VRecent progress in our understanding of the developmental regulation of this tissue, the differentiation pathways, recognition of pathogens and antimicrobial responses is now exploited to help understand how epithelial cell function and dysfunction contributes to the pathogenesis of a variety of inflammatory lung diseases.
p66065
sg52638
(lp66066
sg52640
(lp66067
(dp66068
g52643
I310
sg52644
Vlung diseases
p66069
sg52646
I13
sg52647
VC0024115
p66070
sg52649
I2
sa(dp66071
g52643
I268
sg52644
Vpathogenesis
p66072
sg52646
I12
sg52647
VC0699748
p66073
sg52649
I1
sasa(dp66074
g52636
VHerein, advances in our knowledge of the biology of airway epithelium, as well as its role and (dys)function in asthma, chronic obstructive pulmonary fibrosis and cystic fibrosis will be discussed.
p66075
sg52638
(lp66076
sg52640
(lp66077
(dp66078
g52643
I163
sg52644
Vcystic fibrosis
p66079
sg52646
I15
sg52647
VC0010674
p66080
sg52649
I2
sa(dp66081
g52643
I96
sg52644
Vdys
p66082
sg52646
I3
sg52647
VC0013364
p66083
sg52649
I1
sa(dp66084
g52643
I112
sg52644
Vasthma
p66085
sg52646
I6
sg52647
VC0004096
p66086
sg52649
I1
sa(dp66087
g52643
I140
sg52644
Vpulmonary fibrosis
p66088
sg52646
I18
sg52647
VC0034069
p66089
sg52649
I2
sasa(dp66090
g52636
VManaging neurogenic dysphagia with effective protection of the airway passages and prompt treatment of aspiration pneumonias is necessary to prevent respiratory failure.
p66091
sg52638
(lp66092
sg52640
(lp66093
(dp66094
g52643
I103
sg52644
Vaspiration pneumonias
p66095
sg52646
I21
sg52647
VC0032290
p66096
sg52649
I2
sa(dp66097
g52643
I9
sg52644
Vneurogenic dysphagia
p66098
sg52646
I20
sg52647
VC1955520
p66099
sg52649
I2
sa(dp66100
g52643
I149
sg52644
Vrespiratory failure
p66101
sg52646
I19
sg52647
VC1145670
p66102
sg52649
I2
sasa(dp66103
g52636
VMultivariate analysis identified four independent risk factors for mortality in patients with severe sepsis and septic shock: three or more organ dysfunctions (OR, 3.212; 95% CI, 1.585-6.506; p&lt;0.001), acute respiratory failure (OR, 2.649 95% CI, 1.327-5.287; p=0.006), positive blood culture (OR, 2.708; 95% CI, 1.289-5.689; p=0.009) and chronic heart failure (OR, 2.112; 95% CI, 1.036-4.308; p=0.040).
p66104
sg52638
(lp66105
sg52640
(lp66106
(dp66107
g52643
I112
sg52644
Vseptic shock
p66108
sg52646
I12
sg52647
VC0036983
p66109
sg52649
I2
sa(dp66110
g52643
I205
sg52644
Vacute respiratory failure
p66111
sg52646
I25
sg52647
VC0264490
p66112
sg52649
I3
sa(dp66113
g52643
I342
sg52644
Vchronic heart failure
p66114
sg52646
I21
sg52647
VC0264716
p66115
sg52649
I3
sa(dp66116
g52643
I94
sg52644
Vsevere sepsis
p66117
sg52646
I13
sg52647
VC1719672
p66118
sg52649
I2
sasa(dp66119
g52636
VOur results highlight the importance of three or more organ dys-functions, acute respiratory failure, positive blood culture and chronic heart failure as independent risk factors for mortality in the first 24 hours after admission in patients with severe sepsis and septic shock.
p66120
sg52638
(lp66121
sg52640
(lp66122
(dp66123
g52643
I248
sg52644
Vsevere sepsis
p66124
sg52646
I13
sg52647
VC1719672
p66125
sg52649
I2
sa(dp66126
g52643
I266
sg52644
Vseptic shock
p66127
sg52646
I12
sg52647
VC0036983
p66128
sg52649
I2
sa(dp66129
g52643
I75
sg52644
Vacute respiratory failure
p66130
sg52646
I25
sg52647
VC0264490
p66131
sg52649
I3
sa(dp66132
g52643
I129
sg52644
Vchronic heart failure
p66133
sg52646
I21
sg52647
VC0264716
p66134
sg52649
I3
sa(dp66135
g52643
I60
sg52644
Vdys
p66136
sg52646
I3
sg52647
VC0013364
p66137
sg52649
I1
sasa(dp66138
g135
(dp66139
(Vdys
p66140
Vlung disease
p66141
tp66142
I00
ssg52636
VThis review briefly touches on CF genetics as it applies to lung disease and will focus on the current hypotheses of CFTR (dys)function and its impact on pulmonary fluid homeostasis.
p66143
sg52638
(lp66144
(dp66145
g52643
I117
sg52644
VCFTR
p66146
sg52646
I4
sg52674
VP13569
p66147
sg52649
I1
sa(dp66148
g52643
I123
sg52644
g66140
sg52646
I3
sg52674
VP11532
p66149
sg52649
I1
sasg52640
(lp66150
(dp66151
g52643
I123
sg52644
Vdys
p66152
sg52646
I3
sg52647
VC0013364
p66153
sg52649
I1
sa(dp66154
g52643
I60
sg52644
g66141
sg52646
I12
sg52647
VC0024115
p66155
sg52649
I2
sasa(dp66156
g135
(dp66157
(VABL
p66158
Vchronic myeloid leukemia
p66159
tp66160
I00
ssg52636
VTo investigate the expression of the CDH13 gene and BCR/ABL fusion gene in chronic myeloid leukemia(CML) patients at different stages and explore their relationship.
p66161
sg52638
(lp66162
(dp66163
g52643
I52
sg52644
VBCR
p66164
sg52646
I3
sg52674
VP11274
p66165
sg52649
I1
sa(dp66166
g52643
I37
sg52644
VCDH13 gene
p66167
sg52646
I10
sg52674
VP55290
p66168
sg52649
I2
sa(dp66169
g52643
I56
sg52644
g66158
sg52646
I3
sg52674
VP55157
p66170
sg52649
I1
sasg52640
(lp66171
(dp66172
g52643
I100
sg52644
VCML
p66173
sg52646
I3
sg52647
VC0023473
p66174
sg52649
I1
sa(dp66175
g52643
I56
sg52644
VABL
p66176
sg52646
I3
sg52647
VC0000744
p66177
sg52649
I1
sa(dp66178
g52643
I75
sg52644
g66159
sg52646
I24
sg52647
VC0023473
p66179
sg52649
I3
sasa(dp66180
g135
(dp66181
(Vp15
p66182
Vleukemia
p66183
tp66184
I00
ssg52636
VWe performed genomewide screening for methylated CpG islands and identified 8 genes frequently methylated in leukemia cell lines and in patients with acute myeloid leukemia (AML): NOR1, CDH13, p15, NPM2, OLIG2, PGR, HIN1, and SLC26A4.
p66185
sg52638
(lp66186
(dp66187
g52643
I198
sg52644
VNPM2
p66188
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66189
g52643
I204
sg52644
VOLIG2
p66190
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp66191
g52643
I180
sg52644
VNOR1
p66192
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66193
g52643
I186
sg52644
VCDH13
p66194
sg52646
I5
sg52674
VP55290
p66195
sg52649
I1
sa(dp66196
g52643
I226
sg52644
VSLC26A4
p66197
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp66198
g52643
I216
sg52644
VHIN1
p66199
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66200
g52643
I211
sg52644
VPGR
p66201
sg52646
I3
sg52674
VP06401
p66202
sg52649
I1
sa(dp66203
g52643
I193
sg52644
g66182
sg52646
I3
sg52674
VP53999
p66204
sg52649
I1
sasg52640
(lp66205
(dp66206
g52643
I150
sg52644
Vacute myeloid leukemia
p66207
sg52646
I22
sg52647
VC0023467
p66208
sg52649
I3
sa(dp66209
g52643
I174
sg52644
VAML
p66210
sg52646
I3
sg52647
VC0023467
p66211
sg52649
I1
sa(dp66212
g52643
I109
sg52644
g66183
sg52646
I8
sg52647
VC0023418
p66213
sg52649
I1
sasa(dp66214
g135
(dp66215
(VCDH13
p66216
Vchronic myeloid leukemia
p66217
tp66218
I01
ssg52636
VAlthough defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease.
p66219
sg52638
(lp66220
(dp66221
g52643
I123
sg52644
g66216
sg52646
I5
sg52674
VP55290
p66222
sg52649
I1
sasg52640
(lp66223
(dp66224
g52643
I38
sg52644
Vadhesion
p66225
sg52646
I8
sg52647
VC0001511
p66226
sg52649
I1
sa(dp66227
g52643
I105
sg52644
VCML
p66228
sg52646
I3
sg52647
VC0023473
p66229
sg52649
I1
sa(dp66230
g52643
I79
sg52644
g66217
sg52646
I24
sg52647
VC0023473
p66231
sg52649
I3
sasa(dp66232
g135
(dp66233
(VpIgR
p66234
Vpancreatic ductal adenocarcinoma
p66235
tp66236
I00
ssg52636
VRecent work from our laboratory suggested pIgR may be upregulated in pancreatic ductal adenocarcinoma (PDAC).
p66237
sg52638
(lp66238
(dp66239
g52643
I42
sg52644
g66234
sg52646
I4
sg52674
VP01833
p66240
sg52649
I1
sasg52640
(lp66241
(dp66242
g52643
I103
sg52644
VPDAC
p66243
sg52646
I4
sg52647
VC1335302
p66244
sg52649
I1
sa(dp66245
g52643
I69
sg52644
g66235
sg52646
I32
sg52647
VC1335302
p66246
sg52649
I3
sasa(dp66247
g52636
VIn this work we investigated the expression of the SERCA3-type calcium pump in choroid plexus epithelial cells grown in vitro, and in normal and hyperplastic choroid plexus tissue, in choroid plexus papillomas displaying various degrees of atypia, and in choroid plexus carcinoma by immunohistochemistry in situ.
p66248
sg52638
(lp66249
sg52640
(lp66250
(dp66251
g52643
I255
sg52644
Vchoroid plexus carcinoma
p66252
sg52646
I24
sg52647
VC0431109
p66253
sg52649
I3
sa(dp66254
g52643
I145
sg52644
Vhyperplastic
p66255
sg52646
I12
sg52647
VC0020507
p66256
sg52649
I1
sa(dp66257
g52643
I184
sg52644
Vchoroid plexus papillomas
p66258
sg52646
I25
sg52647
VC0205770
p66259
sg52649
I3
sasa(dp66260
g52636
VWhereas normal choroid plexus epithelial cells express SERCA3 abundantly, SERCA3 expression is strongly decreased in papillomas, and is absent in choroid plexus carcinoma, while expression in hyperplastic epithelium is high, similarly to normal epithelium.
p66261
sg52638
(lp66262
sg52640
(lp66263
(dp66264
g52643
I117
sg52644
Vpapillomas
p66265
sg52646
I10
sg52647
VC0030354
p66266
sg52649
I1
sa(dp66267
g52643
I192
sg52644
Vhyperplastic
p66268
sg52646
I12
sg52647
VC0020507
p66269
sg52649
I1
sa(dp66270
g52643
I146
sg52644
Vchoroid plexus carcinoma
p66271
sg52646
I24
sg52647
VC0431109
p66272
sg52649
I3
sasa(dp66273
g135
(dp66274
(VRho
p66275
VGBM
p66276
tp66277
I00
ssg52636
VDue to the inverse interaction of Rac1 and Ras homolog family member A (RhoA) signaling in the transition between mesenchymal and amoeboid morphology, simultaneous treatment of NSC23766 and Y27632 (selective Rho associated coiled-coil containing protein kinase 1 inhibitor), abolished U87 GBM cell migration through inhibiting MAT and amoeboid-mesenchymal transition.
p66278
sg52638
(lp66279
(dp66280
g52643
I285
sg52644
VU87 GBM
p66281
sg52646
I7
sg52674
g12
sg52649
I2
sa(dp66282
g52643
I327
sg52644
VMAT
p66283
sg52646
I3
sg52674
VP24752
p66284
sg52649
I1
sa(dp66285
g52643
I43
sg52644
VRas homolog family member A
p66286
sg52646
I27
sg52674
VP01116
p66287
sg52649
I5
sa(dp66288
g52643
I34
sg52644
VRac1
p66289
sg52646
I4
sg52674
VP63000
p66290
sg52649
I1
sa(dp66291
g52643
I72
sg52644
VRhoA
p66292
sg52646
I4
sg52674
VP61586
p66293
sg52649
I1
sa(dp66294
g52643
I223
sg52644
Vcoiled-coil containing protein kinase 1
p66295
sg52646
I39
sg52674
VP38432
p66296
sg52649
I5
sa(dp66297
g52643
I72
sg52644
g66275
sg52646
I3
sg52674
VP08100
p66298
sg52649
I1
sasg52640
(lp66299
(dp66300
g52643
I289
sg52644
g66276
sg52646
I3
sg52647
VC0017636
p66301
sg52649
I1
sa(dp66302
g52643
I95
sg52644
Vtransition
p66303
sg52646
I10
sg52647
VC0599156
p66304
sg52649
I1
sa(dp66305
g52643
I95
sg52644
Vtransition
p66306
sg52646
I10
sg52647
VC0599156
p66307
sg52649
I1
sasa(dp66308
g135
(dp66309
(VRac1
p66310
VGBM
p66311
tp66312
I00
ssg52636
VThe combined inhibition of Rac1 and RhoA signaling would be a promising strategy to suppress GBM invasion.
p66313
sg52638
(lp66314
(dp66315
g52643
I36
sg52644
VRhoA
p66316
sg52646
I4
sg52674
VP61586
p66317
sg52649
I1
sa(dp66318
g52643
I27
sg52644
g66310
sg52646
I4
sg52674
VP63000
p66319
sg52649
I1
sasg52640
(lp66320
(dp66321
g52643
I97
sg52644
Vinvasion
p66322
sg52646
I8
sg52647
VC2699153
p66323
sg52649
I1
sa(dp66324
g52643
I93
sg52644
g66311
sg52646
I3
sg52647
VC0017636
p66325
sg52649
I1
sasa(dp66326
g135
(dp66327
(VRac1
p66328
Vlupus nephritis
p66329
tp66330
I00
ssg52636
VSpecifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities.
p66331
sg52638
(lp66332
(dp66333
g52643
I44
sg52644
VTLR7
p66334
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66335
g52643
I257
sg52644
VRhoA
p66336
sg52646
I4
sg52674
VP61586
p66337
sg52649
I1
sa(dp66338
g52643
I266
sg52644
g66328
sg52646
I4
sg52674
VP63000
p66339
sg52649
I1
sasg52640
(lp66340
(dp66341
g52643
I88
sg52644
g66329
sg52646
I15
sg52647
VC0024143
p66342
sg52649
I2
sasa(dp66343
g135
(dp66344
(VAP2S1
p66345
Vprimary hyperparathyroidism
p66346
tp66347
I00
ssg52636
VWe hypothesized that mutations in AP2S1 and GNA11 are causative in Danish patients with suspected FHH and that these mutations are not found in patients with primary hyperparathyroidism (PHPT), which is the main differential diagnostic disorder.
p66348
sg52638
(lp66349
(dp66350
g52643
I44
sg52644
VGNA11
p66351
sg52646
I5
sg52674
VP29992
p66352
sg52649
I1
sa(dp66353
g52643
I34
sg52644
g66345
sg52646
I5
sg52674
VP53680
p66354
sg52649
I1
sasg52640
(lp66355
(dp66356
g52643
I187
sg52644
VPHPT
p66357
sg52646
I4
sg52647
VC0221002
p66358
sg52649
I1
sa(dp66359
g52643
I158
sg52644
g66346
sg52646
I27
sg52647
VC0221002
p66360
sg52649
I2
sasa(dp66361
g135
(dp66362
(VAP2S1 genes
p66363
VFamilial hypocalciuric hypercalcemia
p66364
tp66365
I00
ssg52636
VFamilial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous condition resembling primary hyperparathyroidism (PHPT) but not curable by surgery; FHH types 1, 2, and 3 are due to loss-of-function mutations of the CASR, GNA11, or AP2S1 genes, respectively.
p66366
sg52638
(lp66367
(dp66368
g52643
I225
sg52644
VCASR
p66369
sg52646
I4
sg52674
VP41180
p66370
sg52649
I1
sa(dp66371
g52643
I231
sg52644
VGNA11
p66372
sg52646
I5
sg52674
VP29992
p66373
sg52649
I1
sa(dp66374
g52643
I241
sg52644
g66363
sg52646
I11
sg52674
VP53680
p66375
sg52649
I2
sasg52640
(lp66376
(dp66377
g52643
I124
sg52644
VPHPT
p66378
sg52646
I4
sg52647
VC0221002
p66379
sg52649
I1
sa(dp66380
g52643
I74
sg52644
Vcondition
p66381
sg52646
I9
sg52647
VC0012634
p66382
sg52649
I1
sa(dp66383
g52643
I38
sg52644
VFHH
p66384
sg52646
I3
sg52647
VC0342637
p66385
sg52649
I1
sa(dp66386
g52643
I38
sg52644
VFHH
p66387
sg52646
I3
sg52647
VC0342637
p66388
sg52649
I1
sa(dp66389
g52643
I95
sg52644
Vprimary hyperparathyroidism
p66390
sg52646
I27
sg52647
VC0221002
p66391
sg52649
I2
sa(dp66392
g52643
I0
sg52644
g66364
sg52646
I36
sg52647
VC0342637
p66393
sg52649
I3
sasa(dp66394
g135
(dp66395
(VFHH
p66396
Vprimary hyperparathyroidism
p66397
tp66398
I00
ssg52636
VThe aim of this study was to analyse prevalence and pathogenicity of CaSR, GNA11 and AP2S1 mutations in patients with an FHH phenotype and to compare them with a sample of patients with primary hyperparathyroidism (PHPT) in order to identify the most useful laboratory parameter for a differential diagnosis.
p66399
sg52638
(lp66400
(dp66401
g52643
I85
sg52644
VAP2S1
p66402
sg52646
I5
sg52674
VP53680
p66403
sg52649
I1
sa(dp66404
g52643
I69
sg52644
VCaSR
p66405
sg52646
I4
sg52674
VP41180
p66406
sg52649
I1
sa(dp66407
g52643
I75
sg52644
VGNA11
p66408
sg52646
I5
sg52674
VP29992
p66409
sg52649
I1
sa(dp66410
g52643
I121
sg52644
g66396
sg52646
I3
sg52674
VP41180
p66411
sg52649
I1
sasg52640
(lp66412
(dp66413
g52643
I215
sg52644
VPHPT
p66414
sg52646
I4
sg52647
VC0221002
p66415
sg52649
I1
sa(dp66416
g52643
I186
sg52644
g66397
sg52646
I27
sg52647
VC0221002
p66417
sg52649
I2
sasa(dp66418
g52636
VTripartite motif-containing protein 37 (TRIM37), a new member of the RING-B-box-coiled-coil (RBCC) subfamily of zinc finger proteins, was found to be involved in the development and progression of several cancers.
p66419
sg52638
(lp66420
(dp66421
g52643
I112
sg52644
Vzinc finger proteins
p66422
sg52646
I20
sg52674
g12
sg52649
I3
sa(dp66423
g52643
I40
sg52644
VTRIM37
p66424
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp66425
g52643
I69
sg52644
VRING-B-box-coiled-coil
p66426
sg52646
I22
sg52674
VP38432
p66427
sg52649
I1
sa(dp66428
g52643
I93
sg52644
VRBCC
p66429
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66430
g52643
I0
sg52644
VTripartite motif-containing protein 37
p66431
sg52646
I38
sg52674
g12
sg52649
I4
sasg52640
(lp66432
(dp66433
g52643
I205
sg52644
Vcancers
p66434
sg52646
I7
sg52647
VC0006826
p66435
sg52649
I1
sasa(dp66436
g135
(dp66437
(VHMGB1 B
p66438
Vbreast cancer
p66439
tp66440
I00
ssg52636
VIn the present work, we clearly demonstrate that HMGB1 secreted by cancer cells is N-glycosylated at Asn37, which facilitates monocytic (M)-MDSC differentiation from bone marrow via the p38/NFKB/Erk1/2 pathway and also contributes to conversion of monocytes into MDSC-like cells; HMGB1 blockade by a monoclonal antibody against the HMGB1 B box obviously reduced the accumulation of M-MDSC in tumor-bearing mice, delaying tumor growth and development; additionally, MDSC expansion and HMGB1 up-regulation were also found in breast cancer patients.
p66441
sg52638
(lp66442
(dp66443
g52643
I195
sg52644
VErk1/2
p66444
sg52646
I6
sg52674
VP27361
p66445
sg52649
I1
sa(dp66446
g52643
I49
sg52644
VHMGB1
p66447
sg52646
I5
sg52674
VP09429
p66448
sg52649
I1
sa(dp66449
g52643
I190
sg52644
VNFKB
p66450
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66451
g52643
I49
sg52644
VHMGB1
p66452
sg52646
I5
sg52674
VP09429
p66453
sg52649
I1
sa(dp66454
g52643
I186
sg52644
Vp38
p66455
sg52646
I3
sg52674
VP46108
p66456
sg52649
I1
sa(dp66457
g52643
I49
sg52644
VHMGB1
p66458
sg52646
I5
sg52674
VP09429
p66459
sg52649
I1
sa(dp66460
g52643
I332
sg52644
g66438
sg52646
I7
sg52674
VP09429
p66461
sg52649
I2
sasg52640
(lp66462
(dp66463
g52643
I67
sg52644
Vcancer
p66464
sg52646
I6
sg52647
VC0006826
p66465
sg52649
I1
sa(dp66466
g52643
I523
sg52644
g66439
sg52646
I13
sg52647
VC0678222
p66467
sg52649
I2
sa(dp66468
g52643
I421
sg52644
Vtumor growth
p66469
sg52646
I12
sg52647
VC0598934
p66470
sg52649
I2
sa(dp66471
g52643
I392
sg52644
Vtumor
p66472
sg52646
I5
sg52647
VC0027651
p66473
sg52649
I1
sasa(dp66474
g135
(dp66475
(VCOMT Val158Met
p66476
Vconversion disorder
p66477
tp66478
I00
ssg52636
VWe examined a possible association between the COMT Val158Met polymorphism and conversion disorder in a study of 48 patients with conversion disorder and 48 control patients.
p66479
sg52638
(lp66480
(dp66481
g52643
I47
sg52644
g66476
sg52646
I14
sg52674
VP21964
p66482
sg52649
I2
sasg52640
(lp66483
(dp66484
g52643
I79
sg52644
Vconversion disorder
p66485
sg52646
I19
sg52647
VC0009946
p66486
sg52649
I2
sa(dp66487
g52643
I79
sg52644
g66477
sg52646
I19
sg52647
VC0009946
p66488
sg52649
I2
sasa(dp66489
g135
(dp66490
(VCOMT Val158Met genotype
p66491
Vconversion disorder
p66492
tp66493
I00
ssg52636
VWe conclude that the COMT Val158Met genotype is quite common in Turkey and that it is not a risk factor for conversion disorder in the Turkish population.
p66494
sg52638
(lp66495
(dp66496
g52643
I21
sg52644
g66491
sg52646
I23
sg52674
VP21964
p66497
sg52649
I3
sasg52640
(lp66498
(dp66499
g52643
I108
sg52644
g66492
sg52646
I19
sg52647
VC0009946
p66500
sg52649
I2
sasa(dp66501
g135
(dp66502
(Vserine protease
p66503
Vthrombosis
p66504
tp66505
I00
ssg52636
VFactor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer.
p66506
sg52638
(lp66507
(dp66508
g52643
I0
sg52644
VFactor VII (FVII) activating protease
p66509
sg52646
I37
sg52674
VP08709
p66510
sg52649
I5
sa(dp66511
g52643
I39
sg52644
VFSAP
p66512
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66513
g52643
I62
sg52644
g66503
sg52646
I15
sg52674
VP57727
p66514
sg52649
I2
sasg52640
(lp66515
(dp66516
g52643
I150
sg52644
Vstroke
p66517
sg52646
I6
sg52647
VC0038454
p66518
sg52649
I1
sa(dp66519
g52643
I158
sg52644
Vatherosclerosis
p66520
sg52646
I15
sg52647
VC0004153
p66521
sg52649
I1
sa(dp66522
g52643
I175
sg52644
Vliver fibrosis
p66523
sg52646
I14
sg52647
VC0239946
p66524
sg52649
I2
sa(dp66525
g52643
I206
sg52644
Vcancer
p66526
sg52646
I6
sg52647
VC0006826
p66527
sg52649
I1
sa(dp66528
g52643
I191
sg52644
g66504
sg52646
I10
sg52647
VC0040053
p66529
sg52649
I1
sasa(dp66530
g135
(dp66531
(Vlipoprotein (alpha)
p66532
Vatherosclerosis
p66533
tp66534
I00
ssg52636
VWith purpose to study content of alpha-defensins (1-3) and synthesis and liberation of other proteins and peptides by neutrophils the concentrations of alpha-defensins, lipoprotein (alpha), C-reactive protein, precursor of cerebral natriuretic peptide, coagulation factor VII and von Willebrand factor were determined in supernatants of leukocytal cultures in patients with exertional angina pectoris and atherosclerosis of lower extremities.
p66535
sg52638
(lp66536
(dp66537
g52643
I280
sg52644
Vvon Willebrand factor
p66538
sg52646
I21
sg52674
VP04275
p66539
sg52649
I3
sa(dp66540
g52643
I190
sg52644
VC-reactive protein
p66541
sg52646
I18
sg52674
VP02741
p66542
sg52649
I2
sa(dp66543
g52643
I223
sg52644
Vcerebral natriuretic peptide
p66544
sg52646
I28
sg52674
VP16860
p66545
sg52649
I3
sa(dp66546
g52643
I33
sg52644
Valpha-defensins
p66547
sg52646
I15
sg52674
VP59665
p66548
sg52649
I1
sa(dp66549
g52643
I253
sg52644
Vcoagulation factor VII
p66550
sg52646
I22
sg52674
VP08709
p66551
sg52649
I3
sa(dp66552
g52643
I169
sg52644
g66532
sg52646
I19
sg52674
VP02652
p66553
sg52649
I2
sasg52640
(lp66554
(dp66555
g52643
I374
sg52644
Vexertional angina
p66556
sg52646
I17
sg52647
VC0577698
p66557
sg52649
I2
sa(dp66558
g52643
I405
sg52644
g66533
sg52646
I15
sg52647
VC0004153
p66559
sg52649
I1
sasa(dp66560
g52636
VThe frequency of HLA-DR4 was increased in patients with optic neuritis alone compared to controls and to patients with multiple sclerosis, but further studies are required to confirm this finding.
p66561
sg52638
(lp66562
(dp66563
g52643
I17
sg52644
VHLA-DR4
p66564
sg52646
I7
sg52674
VP30486
p66565
sg52649
I1
sasg52640
(lp66566
(dp66567
g52643
I56
sg52644
Voptic neuritis
p66568
sg52646
I14
sg52647
VC0029134
p66569
sg52649
I2
sa(dp66570
g52643
I119
sg52644
Vmultiple sclerosis
p66571
sg52646
I18
sg52647
VC0026769
p66572
sg52649
I2
sasa(dp66573
g52636
VThe MS profiling by PGC-LC also revealed several glycan structural isomers that corresponded to LacdiNAc-type (GalNAcBeta1-4GlcNAc) motifs that were unique to the serous ovarian cancers and that correlated with elevated gene expression of B4GALNT3 and B4GALNT4 in patients with serous cancer.
p66574
sg52638
(lp66575
(dp66576
g52643
I252
sg52644
VB4GALNT4
p66577
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp66578
g52643
I239
sg52644
VB4GALNT3
p66579
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp66580
(dp66581
g52643
I178
sg52644
Vcancer
p66582
sg52646
I6
sg52647
VC0006826
p66583
sg52649
I1
sa(dp66584
g52643
I170
sg52644
Vovarian cancers
p66585
sg52646
I15
sg52647
VC1140680
p66586
sg52649
I2
sasa(dp66587
g52636
VWe previously showed that B4GALNT3 overexpression enhances colon cancer cell malignant phenotypes in vitro and in vivo.
p66588
sg52638
(lp66589
(dp66590
g52643
I26
sg52644
VB4GALNT3
p66591
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp66592
(dp66593
g52643
I59
sg52644
Vcolon cancer
p66594
sg52646
I12
sg52647
VC0699790
p66595
sg52649
I2
sasa(dp66596
g52636
VHowever, the role of B4GALNT3 in cancer stemness remains unclear.
p66597
sg52638
(lp66598
(dp66599
g52643
I21
sg52644
VB4GALNT3
p66600
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp66601
(dp66602
g52643
I33
sg52644
Vcancer
p66603
sg52646
I6
sg52647
VC0006826
p66604
sg52649
I1
sasa(dp66605
g52636
VWe found that B4GALNT3 expression was positively correlated with advanced stages and poor survival in colorectal cancer patients.
p66606
sg52638
(lp66607
(dp66608
g52643
I14
sg52644
VB4GALNT3
p66609
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp66610
(dp66611
g52643
I102
sg52644
Vcolorectal cancer
p66612
sg52646
I17
sg52647
VC1527249
p66613
sg52649
I2
sasa(dp66614
g52636
VKnockdown of B4GALNT3 using small interfering (si) RNAs in colon cancer cell lines (HCT116, SW480, HCT15, and HT29 cells) decreased sphere formation and the expression of stem cell markers, OCT4 and NANOG.
p66615
sg52638
(lp66616
(dp66617
g52643
I199
sg52644
VNANOG
p66618
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp66619
(dp66620
g52643
I59
sg52644
Vcolon cancer
p66621
sg52646
I12
sg52647
VC0699790
p66622
sg52649
I2
sasa(dp66623
g52636
VTaken together, these data suggest B4GALNT3 regulates cancer stemness and the invasive properties of colon cancer cells through modifying EGFR glycosylation and signaling.
p66624
sg52638
(lp66625
(dp66626
g52643
I35
sg52644
VB4GALNT3
p66627
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp66628
(dp66629
g52643
I54
sg52644
Vcancer
p66630
sg52646
I6
sg52647
VC0006826
p66631
sg52649
I1
sa(dp66632
g52643
I101
sg52644
Vcolon cancer
p66633
sg52646
I12
sg52647
VC0699790
p66634
sg52649
I2
sasa(dp66635
g52636
VIn this study, we investigated the expression and role of B4GALNT3 in human neuroblastoma (NB).
p66636
sg52638
(lp66637
(dp66638
g52643
I58
sg52644
VB4GALNT3
p66639
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp66640
(dp66641
g52643
I91
sg52644
VNB
p66642
sg52646
I2
sg52647
VC0027819
p66643
sg52649
I1
sa(dp66644
g52643
I76
sg52644
Vneuroblastoma
p66645
sg52646
I13
sg52647
VC0027819
p66646
sg52649
I1
sasa(dp66647
g135
(dp66648
(VIL-7
p66649
VPOAG
p66650
tp66651
I00
ssg52636
VDetection rates were as follows: IL-7: NVG higher than POAG; IL-10: POAG lower than cataract or NVG; and GM-CSF: cataract higher than POAG or NVG.
p66652
sg52638
(lp66653
(dp66654
g52643
I105
sg52644
VGM-CSF
p66655
sg52646
I6
sg52674
VP04141
p66656
sg52649
I1
sa(dp66657
g52643
I33
sg52644
g66649
sg52646
I4
sg52674
VP13232
p66658
sg52649
I1
sasg52640
(lp66659
(dp66660
g52643
I55
sg52644
VPOAG
p66661
sg52646
I4
sg52647
VC0339573
p66662
sg52649
I1
sa(dp66663
g52643
I84
sg52644
Vcataract
p66664
sg52646
I8
sg52647
VC0086543
p66665
sg52649
I1
sa(dp66666
g52643
I55
sg52644
VPOAG
p66667
sg52646
I4
sg52647
VC0339573
p66668
sg52649
I1
sa(dp66669
g52643
I84
sg52644
Vcataract
p66670
sg52646
I8
sg52647
VC0086543
p66671
sg52649
I1
sa(dp66672
g52643
I55
sg52644
g66650
sg52646
I4
sg52647
VC0339573
p66673
sg52649
I1
sasa(dp66674
g52636
VSixty-four vitreous samples (40 RVO, 24 controls with idiopathic floaters) were analyzed in this retrospective case series using LC/MS for LPAs 16:0, 18:0, 18:1, 20:4, and ELISA kits or Luminex technology for ATX, angiopoetin-1 (ANG-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), pigment epithelium-derived factor (PEDF), and vascular endothelial growth factor (VEGF).
p66675
sg52638
(lp66676
(dp66677
g52643
I274
sg52644
VIL-7
p66678
sg52646
I4
sg52674
VP13232
p66679
sg52649
I1
sa(dp66680
g52643
I393
sg52644
Vvascular endothelial growth factor
p66681
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp66682
g52643
I237
sg52644
Vinterleukin-6
p66683
sg52646
I13
sg52674
VP05231
p66684
sg52649
I1
sa(dp66685
g52643
I259
sg52644
Vinterleukin-7
p66686
sg52646
I13
sg52674
VP13232
p66687
sg52649
I1
sa(dp66688
g52643
I339
sg52644
VMCP-1
p66689
sg52646
I5
sg52674
VP41597
p66690
sg52649
I1
sa(dp66691
g52643
I209
sg52644
VATX
p66692
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp66693
g52643
I229
sg52644
VANG-1
p66694
sg52646
I5
sg52674
VP03950
p66695
sg52649
I1
sa(dp66696
g52643
I214
sg52644
Vangiopoetin-1
p66697
sg52646
I13
sg52674
VP03950
p66698
sg52649
I1
sa(dp66699
g52643
I252
sg52644
VIL-6
p66700
sg52646
I4
sg52674
VP05231
p66701
sg52649
I1
sa(dp66702
g52643
I429
sg52644
VVEGF
p66703
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66704
g52643
I281
sg52644
Vinterleukin-8
p66705
sg52646
I13
sg52674
VP60568
p66706
sg52649
I1
sa(dp66707
g52643
I303
sg52644
Vmonocyte chemoattractant protein-1
p66708
sg52646
I34
sg52674
VP41597
p66709
sg52649
I3
sa(dp66710
g52643
I296
sg52644
VIL-8
p66711
sg52646
I4
sg52674
VP60568
p66712
sg52649
I1
sasg52640
(lp66713
sa(dp66714
g135
(dp66715
(VIL-7
p66716
Vdacryoadenitis
p66717
tp66718
I00
ssg52636
VPoly I:C induces IL-7 production, early inflammatory responses, and characteristic pathologies of SS-like dacryoadenitis in non-autoimmune-prone C57BL/6 mice.
p66719
sg52638
(lp66720
(dp66721
g52643
I17
sg52644
g66716
sg52646
I4
sg52674
VP13232
p66722
sg52649
I1
sasg52640
(lp66723
(dp66724
g52643
I40
sg52644
Vinflammatory responses
p66725
sg52646
I22
sg52647
VC1155266
p66726
sg52649
I2
sa(dp66727
g52643
I106
sg52644
g66717
sg52646
I14
sg52647
VC0155223
p66728
sg52649
I1
sa(dp66729
g52643
I128
sg52644
Vautoimmune
p66730
sg52646
I10
sg52647
VC0443146
p66731
sg52649
I1
sasa(dp66732
g52636
VDiagnosis of AIDS-NHL was preceded by a significantly elevated frequency of activated/germinal center-like CD19CD10CD71CD86AID B cells (P = 0.0072), elevated serum prevalence of the TLR2 ligand, and significantly elevated B-cell TLR2 expression (P = 0.0015), positively correlating with the frequency of activated/germinal center-like B cells (rho = 0.7273, P = 0.0144).
p66733
sg52638
(lp66734
(dp66735
g52643
I222
sg52644
VB-cell TLR2
p66736
sg52646
I11
sg52674
g12
sg52649
I2
sa(dp66737
g52643
I182
sg52644
VTLR2 ligand
p66738
sg52646
I11
sg52674
g12
sg52649
I2
sasg52640
(lp66739
(dp66740
g52643
I18
sg52644
VNHL
p66741
sg52646
I3
sg52647
VC0024305
p66742
sg52649
I1
sasa(dp66743
g52636
VTLR2-stimulated purified B cells exhibited the activated B-cell phenotype observed in HIV+ subjects before AIDS-NHL diagnosis.
p66744
sg52638
(lp66745
(dp66746
g52643
I0
sg52644
VTLR2
p66747
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp66748
(dp66749
g52643
I112
sg52644
VNHL
p66750
sg52646
I3
sg52647
VC0024305
p66751
sg52649
I1
sasa(dp66752
g52636
VThese results indicate that an elevated fraction of B cells display an activated/germinal center phenotype in those HIV+ subjects who go on to develop AIDS-NHL and suggest that TLR2-mediated activation may play a role in HIV infection-associated B-cell activation, potentially contributing to the genesis of AIDS-NHL.
p66753
sg52638
(lp66754
(dp66755
g52643
I177
sg52644
VTLR2
p66756
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp66757
(dp66758
g52643
I156
sg52644
VNHL
p66759
sg52646
I3
sg52647
VC0024305
p66760
sg52649
I1
sa(dp66761
g52643
I221
sg52644
VHIV infection
p66762
sg52646
I13
sg52647
VC0019693
p66763
sg52649
I2
sa(dp66764
g52643
I156
sg52644
VNHL
p66765
sg52646
I3
sg52647
VC0024305
p66766
sg52649
I1
sasa(dp66767
g135
(dp66768
(VAVP
p66769
Vdepression
p66770
tp66771
I00
ssg52636
VThe regulatory role of AVP on the hypothalamic-pituitary-adrenal (HPA) axis suggests potential uses for AVP receptor modulators in various CNS indications, including depression, anxiety and post-traumatic stress disorder.
p66772
sg52638
(lp66773
(dp66774
g52643
I104
sg52644
VAVP receptor
p66775
sg52646
I12
sg52674
VP01185
p66776
sg52649
I2
sa(dp66777
g52643
I23
sg52644
g66769
sg52646
I3
sg52674
VP01185
p66778
sg52649
I1
sasg52640
(lp66779
(dp66780
g52643
I190
sg52644
Vpost-traumatic stress disorder
p66781
sg52646
I30
sg52647
VC0038436
p66782
sg52649
I3
sa(dp66783
g52643
I166
sg52644
g66770
sg52646
I10
sg52647
VC0011581
p66784
sg52649
I1
sasa(dp66785
g135
(dp66786
(Vhomologous recombination factors BRCA1
p66787
VFANCJ
p66788
tp66789
I00
ssg52636
VWhen POLN was ectopically overexpressed in human cells, it specifically coimmunoprecipitated with the homologous recombination factors BRCA1 and FANCJ, but not with previously suggested interaction partners (HELQ and members of the Fanconi anemia core complex).
p66790
sg52638
(lp66791
(dp66792
g52643
I208
sg52644
VHELQ
p66793
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp66794
g52643
I232
sg52644
VFanconi anemia core complex
p66795
sg52646
I27
sg52674
VP51587
p66796
sg52649
I4
sa(dp66797
g52643
I145
sg52644
VFANCJ
p66798
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp66799
g52643
I102
sg52644
g66787
sg52646
I38
sg52674
VP19883
p66800
sg52649
I4
sasg52640
(lp66801
(dp66802
g52643
I232
sg52644
VFanconi anemia
p66803
sg52646
I14
sg52647
VC3469521
p66804
sg52649
I2
sa(dp66805
g52643
I145
sg52644
g66788
sg52646
I5
sg52647
VC1836860
p66806
sg52649
I1
sasa(dp66807
g52636
VMoreover, we obtained evidence for physical and functional interaction of POLN with factors belonging to the Fanconi anemia pathway, a master regulator of cross-link repair.
p66808
sg52638
(lp66809
(dp66810
g52643
I74
sg52644
VPOLN
p66811
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp66812
(dp66813
g52643
I109
sg52644
VFanconi anemia
p66814
sg52646
I14
sg52647
VC3469521
p66815
sg52649
I2
sasa(dp66816
g52636
VThe results indicate that the Pol n I component MV is an allergen for human beings as well as for mice, and useful as a diagnostic tool for chironomid allergy.
p66817
sg52638
(lp66818
(dp66819
g52643
I30
sg52644
VPol n I component MV
p66820
sg52646
I20
sg52674
VP10266
p66821
sg52649
I5
sasg52640
(lp66822
(dp66823
g52643
I151
sg52644
Vallergy
p66824
sg52646
I7
sg52647
VC0020517
p66825
sg52649
I1
sasa(dp66826
g52636
VPrevalence of service receipt was highest among women in the highest family income category (&gt;400% of federal poverty level [FPL]) and among women with insurance coverage for each of the following: contraceptive services among women at risk for unintended pregnancy; medical services beyond advice to help achieve pregnancy; vaccinations (hepatitis B and human papillomavirus [HPV], ever; tetanus, past 10 years; influenza, past year); discussions with a health care professional about improving health before pregnancy and taking vitamins with folic acid; blood pressure and diabetes screening; discussions with a health care professional in the past year about diet, among those with obesity; discussions with a health care professional in the past year about smoking, among current smokers; Pap tests within the past 3 years; and mammograms within the past 2 years.
p66827
sg52638
(lp66828
sg52640
(lp66829
(dp66830
g52643
I689
sg52644
Vobesity
p66831
sg52646
I7
sg52647
VC0028754
p66832
sg52649
I1
sa(dp66833
g52643
I416
sg52644
Vinfluenza
p66834
sg52646
I9
sg52647
VC0021400
p66835
sg52649
I1
sa(dp66836
g52643
I797
sg52644
VPap
p66837
sg52646
I3
sg52647
VC1863340
p66838
sg52649
I1
sa(dp66839
g52643
I342
sg52644
Vhepatitis B
p66840
sg52646
I11
sg52647
VC0019163
p66841
sg52649
I2
sa(dp66842
g52643
I579
sg52644
Vdiabetes
p66843
sg52646
I8
sg52647
VC0011849
p66844
sg52649
I1
sa(dp66845
g52643
I392
sg52644
Vtetanus
p66846
sg52646
I7
sg52647
VC0039614
p66847
sg52649
I1
sasa(dp66848
g135
(dp66849
(VLMNA gene
p66850
Vdyslipidemia
p66851
tp66852
I00
ssg52636
VHerein we describe a new phenotype associated with a mutation in exon 11 of the LMNA gene: hypertrophic cardiomyopathy, atrioventricular block, severe dyslipidemia and diabetes.
p66853
sg52638
(lp66854
(dp66855
g52643
I80
sg52644
g66850
sg52646
I9
sg52674
VP02545
p66856
sg52649
I2
sasg52640
(lp66857
(dp66858
g52643
I168
sg52644
Vdiabetes
p66859
sg52646
I8
sg52647
VC0011849
p66860
sg52649
I1
sa(dp66861
g52643
I91
sg52644
Vhypertrophic cardiomyopathy
p66862
sg52646
I27
sg52647
VC0007194
p66863
sg52649
I2
sa(dp66864
g52643
I120
sg52644
Vatrioventricular block
p66865
sg52646
I22
sg52647
VC0004245
p66866
sg52649
I2
sa(dp66867
g52643
I151
sg52644
g66851
sg52646
I12
sg52647
VC0242339
p66868
sg52649
I1
sasa(dp66869
g135
(dp66870
(VLMNA variants
p66871
Vtype 2 diabetes
p66872
tp66873
I00
ssg52636
VIndependent analysis of LMNA variants via the type 2 diabetes (T2D) Knowledge Portal showed that variant p.G602S associated significantly with type 2 diabetes (p = 0.02; odds ratio = 4.58), and was more frequent in African Americans (allele frequency 0.297%).
p66874
sg52638
(lp66875
(dp66876
g52643
I24
sg52644
g66871
sg52646
I13
sg52674
VP02545
p66877
sg52649
I2
sasg52640
(lp66878
(dp66879
g52643
I63
sg52644
VT2D
p66880
sg52646
I3
sg52647
VC0011860
p66881
sg52649
I1
sa(dp66882
g52643
I46
sg52644
Vtype 2 diabetes
p66883
sg52646
I15
sg52647
VC0011860
p66884
sg52649
I3
sa(dp66885
g52643
I46
sg52644
g66872
sg52646
I15
sg52647
VC0011860
p66886
sg52649
I3
sasa(dp66887
g135
(dp66888
(Vinsulin
p66889
VLipodystrophy
p66890
tp66891
I01
ssg52636
VLipodystrophy is a rare disorder characterized by the complete or partial loss of subcutaneous adipose tissue, insulin resistance, diabetes mellitus and hyperlipidemia.Proteinuric renal disease is a prevalent feature of generalized lipodystrophy but rare in familial partial lipodystrophy.Patients carrying the c.1045C &gt; T missense LMNA mutation (p.R349W) may present with familial partial lipodystrophy, proteinuric nephropathy, cardiomyopathy and atypical myopathy.
p66892
sg52638
(lp66893
(dp66894
g52643
I111
sg52644
g66889
sg52646
I7
sg52674
VP01308
p66895
sg52649
I1
sasg52640
(lp66896
(dp66897
g52643
I220
sg52644
Vgeneralized lipodystrophy
p66898
sg52646
I25
sg52647
VC0221032
p66899
sg52649
I2
sa(dp66900
g52643
I131
sg52644
Vdiabetes mellitus
p66901
sg52646
I17
sg52647
VC0011849
p66902
sg52649
I2
sa(dp66903
g52643
I258
sg52644
Vfamilial partial lipodystrophy
p66904
sg52646
I30
sg52647
VC0271694
p66905
sg52649
I3
sa(dp66906
g52643
I439
sg52644
Vmyopathy
p66907
sg52646
I8
sg52647
VC0026848
p66908
sg52649
I1
sa(dp66909
g52643
I420
sg52644
Vnephropathy
p66910
sg52646
I11
sg52647
VC0022658
p66911
sg52649
I1
sa(dp66912
g52643
I433
sg52644
Vcardiomyopathy
p66913
sg52646
I14
sg52647
VC0878544
p66914
sg52649
I1
sa(dp66915
g52643
I153
sg52644
Vhyperlipidemia
p66916
sg52646
I14
sg52647
VC0020473
p66917
sg52649
I1
sa(dp66918
g52643
I180
sg52644
Vrenal disease
p66919
sg52646
I13
sg52647
VC0022658
p66920
sg52649
I2
sa(dp66921
g52643
I111
sg52644
Vinsulin resistance
p66922
sg52646
I18
sg52647
VC0021655
p66923
sg52649
I2
sa(dp66924
g52643
I19
sg52644
Vrare disorder
p66925
sg52646
I13
sg52647
VC0678236
p66926
sg52649
I2
sa(dp66927
g52643
I258
sg52644
Vfamilial partial lipodystrophy
p66928
sg52646
I30
sg52647
VC0271694
p66929
sg52649
I3
sa(dp66930
g52643
I0
sg52644
g66890
sg52646
I13
sg52647
VC0023787
p66931
sg52649
I1
sasa(dp66932
g135
(dp66933
(VEPI 5'-deiodinase
p66934
Vhypothyroidism
p66935
tp66936
I00
ssg52636
VBAT 5'-deiodinase activity was unaffected by propylthiouracil (PTU) and was elevated in hypothyroid rats, whereas EPI 5'-deiodinase was totally inhibited by PTU and was depressed in hypothyroidism.
p66937
sg52638
(lp66938
(dp66939
g52643
I114
sg52644
g66934
sg52646
I17
sg52674
VP10646
p66940
sg52649
I2
sa(dp66941
g52643
I0
sg52644
VBAT 5'-deiodinase
p66942
sg52646
I17
sg52674
g12
sg52649
I2
sasg52640
(lp66943
(dp66944
g52643
I88
sg52644
Vhypothyroid
p66945
sg52646
I11
sg52647
VC0020676
p66946
sg52649
I1
sa(dp66947
g52643
I114
sg52644
VEPI
p66948
sg52646
I3
sg52647
VC0267963
p66949
sg52649
I1
sa(dp66950
g52643
I182
sg52644
g66935
sg52646
I14
sg52647
VC0020676
p66951
sg52649
I1
sasa(dp66952
g52636
VHere, we report a novel mutation in ERCC8 gene in a 16-year-old boy who suffers from poor weight gain, short stature, microcephaly, intellectual disability, and photosensitivity.
p66953
sg52638
(lp66954
(dp66955
g52643
I36
sg52644
VERCC8 gene
p66956
sg52646
I10
sg52674
VP01243
p66957
sg52649
I2
sasg52640
(lp66958
(dp66959
g52643
I85
sg52644
Vpoor weight gain
p66960
sg52646
I16
sg52647
VC0231246
p66961
sg52649
I3
sa(dp66962
g52643
I161
sg52644
Vphotosensitivity
p66963
sg52646
I16
sg52647
VC0393720
p66964
sg52649
I1
sa(dp66965
g52643
I72
sg52644
Vsuffers
p66966
sg52646
I7
sg52647
VC0683278
p66967
sg52649
I1
sa(dp66968
g52643
I118
sg52644
Vmicrocephaly
p66969
sg52646
I12
sg52647
VC0025958
p66970
sg52649
I1
sa(dp66971
g52643
I132
sg52644
Vintellectual disability
p66972
sg52646
I23
sg52647
VC0025362
p66973
sg52649
I2
sa(dp66974
g52643
I18
sg52644
Vnovel mutation
p66975
sg52646
I14
sg52647
VC2985438
p66976
sg52649
I2
sa(dp66977
g52643
I103
sg52644
Vshort stature
p66978
sg52646
I13
sg52647
VC0013336
p66979
sg52649
I2
sasa(dp66980
g135
(dp66981
(VCSB
p66982
Vdevelopmental delay
p66983
tp66984
I00
ssg52636
VCockayne syndrome is caused by biallelic ERCC8 (CSA) or ERCC6 (CSB) mutations and is characterized by growth restriction, microcephaly, developmental delay, and premature pathological aging.
p66985
sg52638
(lp66986
(dp66987
g52643
I41
sg52644
VERCC8 (CSA)
p66988
sg52646
I11
sg52674
VP01243
p66989
sg52649
I2
sa(dp66990
g52643
I56
sg52644
VERCC6
p66991
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp66992
g52643
I63
sg52644
g66982
sg52646
I3
sg52674
VP35548
p66993
sg52649
I1
sasg52640
(lp66994
(dp66995
g52643
I122
sg52644
Vmicrocephaly
p66996
sg52646
I12
sg52647
VC0025958
p66997
sg52649
I1
sa(dp66998
g52643
I0
sg52644
VCockayne syndrome
p66999
sg52646
I17
sg52647
VC0009207
p67000
sg52649
I2
sa(dp67001
g52643
I48
sg52644
VCSA
p67002
sg52646
I3
sg52647
VC0751039
p67003
sg52649
I1
sa(dp67004
g52643
I63
sg52644
VCSB
p67005
sg52646
I3
sg52647
VC1858160
p67006
sg52649
I1
sa(dp67007
g52643
I21
sg52644
Vcaused by biallelic ERCC8
p67008
sg52646
I25
sg52647
VC0751039
p67009
sg52649
I4
sa(dp67010
g52643
I136
sg52644
g66983
sg52646
I19
sg52647
VC0424605
p67011
sg52649
I2
sasa(dp67012
g52636
VThis study included 54 beta-thalassemia major patients divided into 2 groups; group A consisted of 28 patients who have thrombocytosis secondary to a previous splenectomy and group B comprised of 26 patients who did not have a splenectomy with normal platelet count, as well as a control group of 30 healthy individuals.
p67013
sg52638
(lp67014
sg52640
(lp67015
(dp67016
g52643
I28
sg52644
Vthalassemia major
p67017
sg52646
I17
sg52647
VC0002875
p67018
sg52649
I2
sa(dp67019
g52643
I120
sg52644
Vthrombocytosis
p67020
sg52646
I14
sg52647
VC0836924
p67021
sg52649
I1
sa(dp67022
g52643
I175
sg52644
Vgroup B
p67023
sg52646
I7
sg52647
VC0348801
p67024
sg52649
I2
sasa(dp67025
g135
(dp67026
(Vclaudin-10
p67027
Vlung adenocarcinoma
p67028
tp67029
I00
ssg52636
VA microarray analysis of the B-1 lymphocytes revealed that IL-10 deficiency is associated with down-regulation of the genes that code for claudin-10, a protein that is involved in cell-to-cell contact and that has been linked to lung adenocarcinoma.
p67030
sg52638
(lp67031
(dp67032
g52643
I138
sg52644
g67027
sg52646
I10
sg52674
VP78369
p67033
sg52649
I1
sasg52640
(lp67034
(dp67035
g52643
I229
sg52644
g67028
sg52646
I19
sg52647
VC0152013
p67036
sg52649
I2
sasa(dp67037
g135
(dp67038
(Vclaudin-10
p67039
Vaggressive
p67040
tp67041
I00
ssg52636
VThus, our findings suggest that the axis IL-10/claudin-10 is a promising target for the development of therapeutic agents against aggressive melanoma.
p67042
sg52638
(lp67043
(dp67044
g52643
I47
sg52644
g67039
sg52646
I10
sg52674
VP78369
p67045
sg52649
I1
sasg52640
(lp67046
(dp67047
g52643
I141
sg52644
Vmelanoma
p67048
sg52646
I8
sg52647
VC0025202
p67049
sg52649
I1
sa(dp67050
g52643
I130
sg52644
g67040
sg52646
I10
sg52647
VC0001807
p67051
sg52649
I1
sasa(dp67052
g135
(dp67053
(VE-cadherin
p67054
Vgastric cancer
p67055
tp67056
I00
ssg52636
VTo explore the expression distinction of the cell adhesion proteins claudin-10,-14,-17 and E-cadherin in the adjacent non-neoplastic tissues and gastric cancer tissues, 50 gastric cancer tissues and 50 samples of adjacent non-neoplastic tissues adjacent to the tumors were examined for expression of claudin-10,-14,-17 and E-cadherin by streptavidin-perosidase immunohistochemical staining method.
p67057
sg52638
(lp67058
(dp67059
g52643
I68
sg52644
Vclaudin-10,-14,-17
p67060
sg52646
I18
sg52674
VP78369
p67061
sg52649
I1
sa(dp67062
g52643
I337
sg52644
Vstreptavidin-perosidase
p67063
sg52646
I23
sg52674
g12
sg52649
I1
sa(dp67064
g52643
I68
sg52644
Vclaudin-10,-14,-17
p67065
sg52646
I18
sg52674
VP78369
p67066
sg52649
I1
sa(dp67067
g52643
I91
sg52644
VE-cadherin
p67068
sg52646
I10
sg52674
VP12830
p67069
sg52649
I1
sa(dp67070
g52643
I91
sg52644
g67054
sg52646
I10
sg52674
VP12830
p67071
sg52649
I1
sasg52640
(lp67072
(dp67073
g52643
I145
sg52644
Vgastric cancer
p67074
sg52646
I14
sg52647
VC0024623
p67075
sg52649
I2
sa(dp67076
g52643
I261
sg52644
Vtumors
p67077
sg52646
I6
sg52647
VC0027651
p67078
sg52649
I1
sa(dp67079
g52643
I50
sg52644
Vadhesion
p67080
sg52646
I8
sg52647
VC0001511
p67081
sg52649
I1
sa(dp67082
g52643
I145
sg52644
g67055
sg52646
I14
sg52647
VC0024623
p67083
sg52649
I2
sasa(dp67084
g135
(dp67085
(Vclaudin-10
p67086
Vgastric cancer
p67087
tp67088
I00
ssg52636
VThe positive expression rates of claudin-10 in gastric cancer tissues and adjacent non-neoplastic tissues were 24% and 72% respectively (P &lt; 0.01).
p67089
sg52638
(lp67090
(dp67091
g52643
I33
sg52644
g67086
sg52646
I10
sg52674
VP78369
p67092
sg52649
I1
sasg52640
(lp67093
(dp67094
g52643
I47
sg52644
g67087
sg52646
I14
sg52647
VC0024623
p67095
sg52649
I2
sasa(dp67096
g135
(dp67097
(Vclaudin-10
p67098
Vgastric cancer
p67099
tp67100
I00
ssg52636
VIn contrast, the positive expression rates of claudin-14 in gastric cancer tissues and adjacent non-neoplastic tissues were 58% and 24% respectively (P = 0.015 &lt; 0.05) Thus in our study, the expression of E-cadherin, claudin-10, and claudin-17 was down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated.
p67101
sg52638
(lp67102
(dp67103
g52643
I46
sg52644
Vclaudin-14
p67104
sg52646
I10
sg52674
g12
sg52649
I1
sa(dp67105
g52643
I208
sg52644
VE-cadherin
p67106
sg52646
I10
sg52674
VP12830
p67107
sg52649
I1
sa(dp67108
g52643
I236
sg52644
Vclaudin-17
p67109
sg52646
I10
sg52674
VP56750
p67110
sg52649
I1
sa(dp67111
g52643
I220
sg52644
g67098
sg52646
I10
sg52674
VP78369
p67112
sg52649
I1
sasg52640
(lp67113
(dp67114
g52643
I60
sg52644
Vgastric cancer
p67115
sg52646
I14
sg52647
VC0024623
p67116
sg52649
I2
sa(dp67117
g52643
I60
sg52644
g67099
sg52646
I14
sg52647
VC0024623
p67118
sg52649
I2
sasa(dp67119
g135
(dp67120
(Vclaudin-10
p67121
Vlymphatic metastasis
p67122
tp67123
I00
ssg52636
VOur study reveals that the expression of E-cadherin, claudin-10, and claudin-17 were down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated and correlation between claudins and E-cadherin expression with lymphatic metastasis were observed.
p67124
sg52638
(lp67125
(dp67126
g52643
I69
sg52644
Vclaudin-17
p67127
sg52646
I10
sg52674
VP56750
p67128
sg52649
I1
sa(dp67129
g52643
I41
sg52644
VE-cadherin
p67130
sg52646
I10
sg52674
VP12830
p67131
sg52649
I1
sa(dp67132
g52643
I41
sg52644
VE-cadherin
p67133
sg52646
I10
sg52674
VP12830
p67134
sg52649
I1
sa(dp67135
g52643
I53
sg52644
g67121
sg52646
I10
sg52674
VP78369
p67136
sg52649
I1
sasg52640
(lp67137
(dp67138
g52643
I103
sg52644
Vgastric cancer
p67139
sg52646
I14
sg52647
VC0024623
p67140
sg52649
I2
sa(dp67141
g52643
I241
sg52644
g67122
sg52646
I20
sg52647
VC0024232
p67142
sg52649
I2
sasa(dp67143
g135
(dp67144
(VCLDN10
p67145
Vlung adenocarcinoma
p67146
tp67147
I00
ssg52636
VFour genes (MMP-2, c-fos, claudin 1 (CLDN1) and claudin 10(CLDN10)) were correlated with the results of microarray and real time RT-PCR analyses for the gene-expression data in samples from 41 patients with lung adenocarcinoma.
p67148
sg52638
(lp67149
(dp67150
g52643
I12
sg52644
VMMP-2
p67151
sg52646
I5
sg52674
VP08253
p67152
sg52649
I1
sa(dp67153
g52643
I48
sg52644
Vclaudin 10
p67154
sg52646
I10
sg52674
VP78369
p67155
sg52649
I2
sa(dp67156
g52643
I19
sg52644
Vc-fos
p67157
sg52646
I5
sg52674
VP01100
p67158
sg52649
I1
sa(dp67159
g52643
I26
sg52644
Vclaudin 1
p67160
sg52646
I9
sg52674
g12
sg52649
I2
sa(dp67161
g52643
I37
sg52644
VCLDN1
p67162
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp67163
g52643
I59
sg52644
g67145
sg52646
I6
sg52674
VP78369
p67164
sg52649
I1
sasg52640
(lp67165
(dp67166
g52643
I207
sg52644
g67146
sg52646
I19
sg52647
VC0152013
p67167
sg52649
I2
sasa(dp67168
g135
(dp67169
(VCLDN10
p67170
Vlung adenocarcinoma
p67171
tp67172
I00
ssg52636
VImmunohistochemical staining for these genes in samples from 81 cases of lung adenocarcinoma demonstrated the expressions of CLDN1 and CLDN10 were correlated with overall survival of patients with lung adenocarcinoma.
p67173
sg52638
(lp67174
(dp67175
g52643
I135
sg52644
g67170
sg52646
I6
sg52674
VP78369
p67176
sg52649
I1
sa(dp67177
g52643
I125
sg52644
VCLDN1
p67178
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp67179
(dp67180
g52643
I73
sg52644
Vlung adenocarcinoma
p67181
sg52646
I19
sg52647
VC0152013
p67182
sg52649
I2
sa(dp67183
g52643
I73
sg52644
g67171
sg52646
I19
sg52647
VC0152013
p67184
sg52649
I2
sasa(dp67185
g135
(dp67186
(VCLDN10
p67187
Vlung adenocarcinoma
p67188
tp67189
I00
ssg52636
VOverexpression of CLDN1 and CLDN10 indicates a favorable prognosis for overall survival in some patients with lung adenocarcinoma.
p67190
sg52638
(lp67191
(dp67192
g52643
I18
sg52644
VCLDN1
p67193
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp67194
g52643
I28
sg52644
g67187
sg52646
I6
sg52674
VP78369
p67195
sg52649
I1
sasg52640
(lp67196
(dp67197
g52643
I110
sg52644
g67188
sg52646
I19
sg52647
VC0152013
p67198
sg52649
I2
sasa(dp67199
g52636
VFurthermore, circadian regulation of Gnaz was disturbed in the db/db mouse, a model of diabetic retinopathy.
p67200
sg52638
(lp67201
sg52640
(lp67202
(dp67203
g52643
I87
sg52644
Vdiabetic retinopathy
p67204
sg52646
I20
sg52647
VC0011884
p67205
sg52649
I2
sasa(dp67206
g135
(dp67207
(VGNAZ
p67208
Vmelanoma
p67209
tp67210
I01
ssg52636
VThe highest rates of somatic, non-synonymous mutations were found in GNG10 and GNAZ, neither of which has been previously reported to be mutated in melanoma.
p67211
sg52638
(lp67212
(dp67213
g52643
I69
sg52644
VGNG10
p67214
sg52646
I5
sg52674
VP50151
p67215
sg52649
I1
sa(dp67216
g52643
I79
sg52644
g67208
sg52646
I4
sg52674
VP19086
p67217
sg52649
I1
sasg52640
(lp67218
(dp67219
g52643
I148
sg52644
g67209
sg52646
I8
sg52647
VC0025202
p67220
sg52649
I1
sasa(dp67221
g135
(dp67222
(VRGS4
p67223
VWFS1
p67224
tp67225
I00
ssg52636
VVarious other protein products of genes associated with bipolar disorder either bind to or are affected by phosphatidyl-inositol phosphate products of this pathway (ADBRK2, HIP1R, KCNQ2, RGS4, WFS1), are associated with its constituent elements (BCR, DUSP6, FAT, GNAZ) or are downstream targets of this signalling cascade (DPYSL2, DRD3, GAD1, G6PD, GCH1, KCNQ2, NOS3, SLC6A3, SLC6A4, SST, TH, TIMELESS).
p67226
sg52638
(lp67227
(dp67228
g52643
I343
sg52644
VG6PD
p67229
sg52646
I4
sg52674
VP11441
p67230
sg52649
I1
sa(dp67231
g52643
I193
sg52644
VWFS1
p67232
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67233
g52643
I384
sg52644
VSST
p67234
sg52646
I3
sg52674
VP61278
p67235
sg52649
I1
sa(dp67236
g52643
I251
sg52644
VDUSP6
p67237
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp67238
g52643
I263
sg52644
VGNAZ
p67239
sg52646
I4
sg52674
VP19086
p67240
sg52649
I1
sa(dp67241
g52643
I337
sg52644
VGAD1
p67242
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67243
g52643
I258
sg52644
VFAT
p67244
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp67245
g52643
I323
sg52644
VDPYSL2
p67246
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp67247
g52643
I349
sg52644
VGCH1
p67248
sg52646
I4
sg52674
VP30793
p67249
sg52649
I1
sa(dp67250
g52643
I393
sg52644
VTIMELESS
p67251
sg52646
I8
sg52674
VP60174
p67252
sg52649
I1
sa(dp67253
g52643
I362
sg52644
VNOS3
p67254
sg52646
I4
sg52674
VP60323
p67255
sg52649
I1
sa(dp67256
g52643
I376
sg52644
VSLC6A4
p67257
sg52646
I6
sg52674
VP31645
p67258
sg52649
I1
sa(dp67259
g52643
I368
sg52644
VSLC6A3
p67260
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp67261
g52643
I246
sg52644
VBCR
p67262
sg52646
I3
sg52674
VP11274
p67263
sg52649
I1
sa(dp67264
g52643
I180
sg52644
VKCNQ2
p67265
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp67266
g52643
I331
sg52644
VDRD3
p67267
sg52646
I4
sg52674
VP35462
p67268
sg52649
I1
sa(dp67269
g52643
I173
sg52644
VHIP1R
p67270
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp67271
g52643
I187
sg52644
g67223
sg52646
I4
sg52674
VP49798
p67272
sg52649
I1
sa(dp67273
g52643
I180
sg52644
VKCNQ2
p67274
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp67275
(dp67276
g52643
I56
sg52644
Vbipolar disorder
p67277
sg52646
I16
sg52647
VC0005586
p67278
sg52649
I2
sa(dp67279
g52643
I193
sg52644
g67224
sg52646
I4
sg52647
VC0043207
p67280
sg52649
I1
sasa(dp67281
g135
(dp67282
(VDHFR gene
p67283
Vunilateral retinoblastoma
p67284
tp67285
I00
ssg52636
VIn a recent study we found that the risk for unilateral retinoblastoma in offspring is 4 fold higher in women that are homozygotes for the 19 bp deletion in the DHFR gene and took folic acid supplement during pregnancy.
p67286
sg52638
(lp67287
(dp67288
g52643
I161
sg52644
g67283
sg52646
I9
sg52674
VP00374
p67289
sg52649
I2
sasg52640
(lp67290
(dp67291
g52643
I45
sg52644
g67284
sg52646
I25
sg52647
VC0854915
p67292
sg52649
I2
sasa(dp67293
g135
(dp67294
(Vdihydrofolate reductase
p67295
VRetinoblastoma
p67296
tp67297
I00
ssg52636
VRetinoblastoma protein (pRb) was highly phosphorylated but p107 was upregulated, and the expression of E2f target genes was dysregulated as shown by upregulation of Cdc6 but downregulation of cyclin E, dihydrofolate reductase (dhfr), Cdc25a and B-Myb in chondrocytes of K6(H)/D1(H) mice.
p67298
sg52638
(lp67299
(dp67300
g52643
I103
sg52644
VE2f target genes
p67301
sg52646
I16
sg52674
VP01893
p67302
sg52649
I3
sa(dp67303
g52643
I192
sg52644
Vcyclin E
p67304
sg52646
I8
sg52674
VP24864
p67305
sg52649
I2
sa(dp67306
g52643
I234
sg52644
VCdc25a
p67307
sg52646
I6
sg52674
VP30304
p67308
sg52649
I1
sa(dp67309
g52643
I227
sg52644
Vdhfr
p67310
sg52646
I4
sg52674
VP00374
p67311
sg52649
I1
sa(dp67312
g52643
I0
sg52644
VRetinoblastoma protein
p67313
sg52646
I22
sg52674
g12
sg52649
I2
sa(dp67314
g52643
I245
sg52644
VB-Myb
p67315
sg52646
I5
sg52674
VP10244
p67316
sg52649
I1
sa(dp67317
g52643
I24
sg52644
VpRb
p67318
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp67319
g52643
I165
sg52644
VCdc6
p67320
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67321
g52643
I59
sg52644
Vp107
p67322
sg52646
I4
sg52674
VP28749
p67323
sg52649
I1
sa(dp67324
g52643
I202
sg52644
g67295
sg52646
I23
sg52674
VP00374
p67325
sg52649
I2
sasg52640
(lp67326
(dp67327
g52643
I0
sg52644
g67296
sg52646
I14
sg52647
VC0035335
p67328
sg52649
I1
sasa(dp67329
g135
(dp67330
(Vfolate-metabolizing genes methylenetetrahydrofolate reductase
p67331
Vretinoblastoma
p67332
tp67333
I00
ssg52636
VThe authors used a case-control study design to examine the association between retinoblastoma risk and maternal variations in the folate-metabolizing genes methylenetetrahydrofolate reductase (MTHFR) (a cytosine-to-thymine substitution at nucleotide 677 [MTHFR677C-&gt;T]; reference single nucleotide polymorphism rs1801133) and dihydrofolate reductase (DHFR) (a 19-base-pair deletion of intron 1a [DHFR19bpdel]; rs70991108).
p67334
sg52638
(lp67335
(dp67336
g52643
I330
sg52644
Vdihydrofolate reductase
p67337
sg52646
I23
sg52674
VP00374
p67338
sg52649
I2
sa(dp67339
g52643
I355
sg52644
VDHFR
p67340
sg52646
I4
sg52674
VP00374
p67341
sg52649
I1
sa(dp67342
g52643
I194
sg52644
VMTHFR
p67343
sg52646
I5
sg52674
VP42898
p67344
sg52649
I1
sa(dp67345
g52643
I131
sg52644
g67331
sg52646
I61
sg52674
VP42898
p67346
sg52649
I4
sasg52640
(lp67347
(dp67348
g52643
I80
sg52644
g67332
sg52646
I14
sg52647
VC0035335
p67349
sg52649
I1
sasa(dp67350
g52636
VThe risk of having a child with unilateral retinoblastoma was associated with maternal homozygosity for DHFR19bpdel (odds ratio, 3.78; 95% confidence interval, 1.89-7.55; P = .0002), even after controlling for the child's DHFR19bpdel genotype (odds ratio, 2.81; 95% confidence interval, 1.32-5.99; P = .0073).
p67351
sg52638
(lp67352
sg52640
(lp67353
(dp67354
g52643
I32
sg52644
Vunilateral retinoblastoma
p67355
sg52646
I25
sg52647
VC0854915
p67356
sg52649
I2
sasa(dp67357
g135
(dp67358
(VDHFR gene
p67359
Vretinoblastoma
p67360
tp67361
I00
ssg52636
VMaternal homozygosity for a polymorphism in the DHFR gene necessary for converting synthetic folic acid into biologic folate was associated with an increased risk for retinoblastoma.
p67362
sg52638
(lp67363
(dp67364
g52643
I48
sg52644
g67359
sg52646
I9
sg52674
VP00374
p67365
sg52649
I2
sasg52640
(lp67366
(dp67367
g52643
I167
sg52644
g67360
sg52646
I14
sg52647
VC0035335
p67368
sg52649
I1
sasa(dp67369
g52636
VTo explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients.
p67370
sg52638
(lp67371
(dp67372
g52643
I23
sg52644
VMajor Vault Protein
p67373
sg52646
I19
sg52674
g12
sg52649
I3
sa(dp67374
g52643
I44
sg52644
VMVP
p67375
sg52646
I3
sg52674
g12
sg52649
I1
sasg52640
(lp67376
(dp67377
g52643
I23
sg52644
VMajor Vault Protein
p67378
sg52646
I19
sg52647
VC0026267
p67379
sg52649
I3
sa(dp67380
g52643
I44
sg52644
VMVP
p67381
sg52646
I3
sg52647
VC0026267
p67382
sg52649
I1
sa(dp67383
g52643
I52
sg52644
Voral cavity squamous cell carcinoma
p67384
sg52646
I35
sg52647
VC0585362
p67385
sg52649
I5
sasa(dp67386
g135
(dp67387
(VGYS2 gene
p67388
Vhypoglycemia
p67389
tp67390
I00
ssg52636
VMolecular analysis of the GYS2 gene was not feasible, but this particular gene was included in the panel of hypoglycemia of whole exome sequencing (WES) which was at our disposal.
p67391
sg52638
(lp67392
(dp67393
g52643
I26
sg52644
g67388
sg52646
I9
sg52674
VP54840
p67394
sg52649
I2
sasg52640
(lp67395
(dp67396
g52643
I108
sg52644
g67389
sg52646
I12
sg52647
VC0020615
p67397
sg52649
I1
sasa(dp67398
g135
(dp67399
(VGYS2 gene
p67400
Vketotic hypoglycaemia
p67401
tp67402
I00
ssg52636
VTo understand the frequency of GSD0 in patients presenting with ketotic hypoglycaemia and to report a novel mutation in the GYS2 gene.
p67403
sg52638
(lp67404
(dp67405
g52643
I124
sg52644
g67400
sg52646
I9
sg52674
VP54840
p67406
sg52649
I2
sasg52640
(lp67407
(dp67408
g52643
I64
sg52644
g67401
sg52646
I21
sg52647
VC0271713
p67409
sg52649
I2
sa(dp67410
g52643
I102
sg52644
Vnovel mutation
p67411
sg52646
I14
sg52647
VC2985438
p67412
sg52649
I2
sasa(dp67413
g135
(dp67414
(VGYS2 gene
p67415
Vketotic hypoglycaemia
p67416
tp67417
I00
ssg52636
VThe GYS2 gene was sequenced in 50 patients diagnosed with ketotic hypoglycaemia.
p67418
sg52638
(lp67419
(dp67420
g52643
I4
sg52644
g67415
sg52646
I9
sg52674
VP54840
p67421
sg52649
I2
sasg52640
(lp67422
(dp67423
g52643
I58
sg52644
g67416
sg52646
I21
sg52647
VC0271713
p67424
sg52649
I2
sasa(dp67425
g135
(dp67426
(VGYS2 gene
p67427
Vhyperglycaemia
p67428
tp67429
I00
ssg52636
VSequencing of the GYS2 gene is more likely to be positive in patients with fasting ketotic hypoglycaemia and concomitant postprandial hyperglycaemia with hyperlactataemia.
p67430
sg52638
(lp67431
(dp67432
g52643
I18
sg52644
g67427
sg52646
I9
sg52674
VP54840
p67433
sg52649
I2
sasg52640
(lp67434
(dp67435
g52643
I83
sg52644
Vketotic hypoglycaemia
p67436
sg52646
I21
sg52647
VC0271713
p67437
sg52649
I2
sa(dp67438
g52643
I134
sg52644
g67428
sg52646
I14
sg52647
VC0020456
p67439
sg52649
I1
sasa(dp67440
g135
(dp67441
(VGYS2 gene
p67442
Vfasting hypoglycemia
p67443
tp67444
I00
ssg52636
VBiochemical evaluation as well as direct sequencing of exons and exon-intron boundary regions of the GYS2 gene were performed in a patient presenting fasting hypoglycemia and postprandial hyperglycemia and her parents.
p67445
sg52638
(lp67446
(dp67447
g52643
I101
sg52644
g67442
sg52646
I9
sg52674
VP54840
p67448
sg52649
I2
sasg52640
(lp67449
(dp67450
g52643
I188
sg52644
Vhyperglycemia
p67451
sg52646
I13
sg52647
VC0020456
p67452
sg52649
I1
sa(dp67453
g52643
I150
sg52644
g67443
sg52646
I20
sg52647
VC0271708
p67454
sg52649
I2
sasa(dp67455
g135
(dp67456
(VGS
p67457
Vgrowth retardation
p67458
tp67459
I00
ssg52636
VA 7 year-old boy presenting with growth retardation, fasting hypoglycemia and ketoacidosis was diagnosed as having both idiopathic growth hormone (GH) deficiency and hepatic glycogen synthase (GS) deficiency caused by a homozygous mutation in exon 5 of the liver glycogen synthase gene (GYS-2).
p67460
sg52638
(lp67461
(dp67462
g52643
I120
sg52644
Vidiopathic growth hormone
p67463
sg52646
I25
sg52674
VP01242
p67464
sg52649
I3
sa(dp67465
g52643
I287
sg52644
VGYS-2
p67466
sg52646
I5
sg52674
VP13807
p67467
sg52649
I1
sa(dp67468
g52643
I263
sg52644
Vglycogen synthase gene
p67469
sg52646
I22
sg52674
VP13807
p67470
sg52649
I3
sa(dp67471
g52643
I193
sg52644
g67457
sg52646
I2
sg52674
VP15104
p67472
sg52649
I1
sa(dp67473
g52643
I166
sg52644
Vhepatic glycogen synthase
p67474
sg52646
I25
sg52674
g12
sg52649
I3
sasg52640
(lp67475
(dp67476
g52643
I53
sg52644
Vfasting hypoglycemia
p67477
sg52646
I20
sg52647
VC0271708
p67478
sg52649
I2
sa(dp67479
g52643
I78
sg52644
Vketoacidosis
p67480
sg52646
I12
sg52647
VC0220982
p67481
sg52649
I1
sa(dp67482
g52643
I33
sg52644
g67458
sg52646
I18
sg52647
VC0151686
p67483
sg52649
I2
sasa(dp67484
g52636
VGPB dosed at 6 mL BID lowered fasting ammonia levels in cirrhotic patients with HE as compared with baseline, was better tolerated than 9 mL BID, and is appropriate for further evaluation in patients with cirrhosis and episodic HE.
p67485
sg52638
(lp67486
sg52640
(lp67487
(dp67488
g52643
I205
sg52644
Vcirrhosis
p67489
sg52646
I9
sg52647
VC0023890
p67490
sg52649
I1
sasa(dp67491
g52636
VGPB reduced HE events as well as ammonia in patients with cirrhosis and HE and its safety profile was similar to placebo.
p67492
sg52638
(lp67493
sg52640
(lp67494
(dp67495
g52643
I58
sg52644
Vcirrhosis
p67496
sg52646
I9
sg52647
VC0023890
p67497
sg52649
I1
sasa(dp67498
g52636
VIn vitro and clinical studies have been performed to assess GPB digestion, safety, and pharmacology in healthy adults and individuals with cirrhosis.
p67499
sg52638
(lp67500
sg52640
(lp67501
(dp67502
g52643
I139
sg52644
Vcirrhosis
p67503
sg52646
I9
sg52647
VC0023890
p67504
sg52649
I1
sasa(dp67505
g135
(dp67506
(Vlipases
p67507
Vcirrhosis
p67508
tp67509
I00
ssg52636
VGPB exhibits delayed release characteristics, presumably reflecting gradual PBA release by pancreatic lipases, and is well tolerated in adults with cirrhosis, suggesting that further clinical testing for HE is warranted.
p67510
sg52638
(lp67511
(dp67512
g52643
I0
sg52644
VGPB
p67513
sg52646
I3
sg52674
VP06028
p67514
sg52649
I1
sa(dp67515
g52643
I102
sg52644
g67507
sg52646
I7
sg52674
VP04118
p67516
sg52649
I1
sasg52640
(lp67517
(dp67518
g52643
I148
sg52644
g67508
sg52646
I9
sg52647
VC0023890
p67519
sg52649
I1
sasa(dp67520
g135
(dp67521
(VS1PR1
p67522
Vacute myeloid leukemia
p67523
tp67524
I00
ssg52636
VHowever, the role of S1PR1 in the progression of human acute myeloid leukemia (AML) remains to be fully elucidated.
p67525
sg52638
(lp67526
(dp67527
g52643
I21
sg52644
g67522
sg52646
I5
sg52674
VP21453
p67528
sg52649
I1
sasg52640
(lp67529
(dp67530
g52643
I79
sg52644
VAML
p67531
sg52646
I3
sg52647
VC0023467
p67532
sg52649
I1
sa(dp67533
g52643
I55
sg52644
g67523
sg52646
I22
sg52647
VC0023467
p67534
sg52649
I3
sasa(dp67535
g135
(dp67536
(VS1PR1
p67537
Vmyeloid leukemia
p67538
tp67539
I00
ssg52636
VUsing overexpression and RNA interference knockdown assays, it was shown that the expression of S1PR1 in several human myeloid leukemia cell lines contributed to the suppression of cell apoptosis and promotion of cell proliferation.
p67540
sg52638
(lp67541
(dp67542
g52643
I96
sg52644
g67537
sg52646
I5
sg52674
VP21453
p67543
sg52649
I1
sasg52640
(lp67544
(dp67545
g52643
I218
sg52644
Vproliferation
p67546
sg52646
I13
sg52647
VC0334094
p67547
sg52649
I1
sa(dp67548
g52643
I166
sg52644
Vsuppression
p67549
sg52646
I11
sg52647
VC0221103
p67550
sg52649
I1
sa(dp67551
g52643
I119
sg52644
g67538
sg52646
I16
sg52647
VC0023470
p67552
sg52649
I2
sasa(dp67553
g135
(dp67554
(VCXCR4
p67555
VCLL
p67556
tp67557
I00
ssg52636
VCirculating chronic lymphocytic leukemia (CLL) cells display an abnormal increase in the surface levels of the homing receptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression.
p67558
sg52638
(lp67559
(dp67560
g52643
I128
sg52644
VCCR7
p67561
sg52646
I4
sg52674
VP32248
p67562
sg52649
I1
sa(dp67563
g52643
I164
sg52644
VS1P receptor 1
p67564
sg52646
I14
sg52674
g12
sg52649
I3
sa(dp67565
g52643
I137
sg52644
g67555
sg52646
I5
sg52674
VP61073
p67566
sg52649
I1
sa(dp67567
g52643
I180
sg52644
VS1P1
p67568
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp67569
(dp67570
g52643
I12
sg52644
Vchronic lymphocytic leukemia
p67571
sg52646
I28
sg52647
VC0023434
p67572
sg52649
I3
sa(dp67573
g52643
I42
sg52644
g67556
sg52646
I3
sg52647
VC0023434
p67574
sg52649
I1
sasa(dp67575
g135
(dp67576
(Vkeratin 17
p67577
Vcervical squamous cell carcinoma
p67578
tp67579
I01
ssg52636
VPrevious work in our laboratory identified keratin 17 (K17) as a specific and sensitive biomarker for high-grade squamous intraepithelial lesions and cervical squamous cell carcinoma (SCC).
p67580
sg52638
(lp67581
(dp67582
g52643
I55
sg52644
VK17
p67583
sg52646
I3
sg52674
VP02533
p67584
sg52649
I1
sa(dp67585
g52643
I43
sg52644
g67577
sg52646
I10
sg52674
VP02533
p67586
sg52649
I2
sasg52640
(lp67587
(dp67588
g52643
I150
sg52644
g67578
sg52646
I32
sg52647
VC0279671
p67589
sg52649
I4
sasa(dp67590
g135
(dp67591
(VKIP1
p67592
Vcervical cancer
p67593
tp67594
I00
ssg52636
VIn this study, we show that high expression of keratin-17 (K17) predicts poor outcome in patients with cervical cancer, at early or late stages of disease, surpassing in accuracy either tumor staging or loss of p27(KIP1) as a negative prognostic marker in this setting.
p67595
sg52638
(lp67596
(dp67597
g52643
I47
sg52644
Vkeratin-17
p67598
sg52646
I10
sg52674
VP02533
p67599
sg52649
I1
sa(dp67600
g52643
I211
sg52644
Vp27
p67601
sg52646
I3
sg52674
VP40305
p67602
sg52649
I1
sa(dp67603
g52643
I59
sg52644
VK17
p67604
sg52646
I3
sg52674
VP02533
p67605
sg52649
I1
sa(dp67606
g52643
I215
sg52644
g67592
sg52646
I4
sg52674
VP46527
p67607
sg52649
I1
sasg52640
(lp67608
(dp67609
g52643
I103
sg52644
g67593
sg52646
I15
sg52647
VC0302592
p67610
sg52649
I2
sa(dp67611
g52643
I186
sg52644
Vtumor
p67612
sg52646
I5
sg52647
VC0027651
p67613
sg52649
I1
sasa(dp67614
g135
(dp67615
(VKRT4
p67616
Vsquamous cell carcinoma
p67617
tp67618
I00
ssg52636
VIn summary, both KRT4 and KRT17 expressions are related to the histopathology of the cervical squamous mucosa; KRT17 is highly overexpressed in immature squamous metaplasia, in HSIL, and in squamous cell carcinoma and the level of KRT17 in squamous cell carcinoma may help to identify patients who are at greatest risk for cervical cancer mortality.
p67619
sg52638
(lp67620
(dp67621
g52643
I17
sg52644
g67616
sg52646
I4
sg52674
VP19013
p67622
sg52649
I1
sasg52640
(lp67623
(dp67624
g52643
I323
sg52644
Vcervical cancer
p67625
sg52646
I15
sg52647
VC0302592
p67626
sg52649
I2
sa(dp67627
g52643
I153
sg52644
Vsquamous metaplasia
p67628
sg52646
I19
sg52647
VC0025570
p67629
sg52649
I2
sa(dp67630
g52643
I177
sg52644
VHSIL
p67631
sg52646
I4
sg52647
VC0333875
p67632
sg52649
I1
sa(dp67633
g52643
I190
sg52644
Vsquamous cell carcinoma
p67634
sg52646
I23
sg52647
VC0007137
p67635
sg52649
I3
sa(dp67636
g52643
I190
sg52644
g67617
sg52646
I23
sg52647
VC0007137
p67637
sg52649
I3
sasa(dp67638
g52636
VP2X4 receptors in microglia are up-regulated in epilepsy and in neuropathic pain; that is to say, their total and/or PM expression levels increase.
p67639
sg52638
(lp67640
(dp67641
g52643
I0
sg52644
VP2X4 receptors
p67642
sg52646
I14
sg52674
g12
sg52649
I2
sasg52640
(lp67643
(dp67644
g52643
I48
sg52644
Vepilepsy
p67645
sg52646
I8
sg52647
VC0014544
p67646
sg52649
I1
sa(dp67647
g52643
I64
sg52644
Vneuropathic pain
p67648
sg52646
I16
sg52647
VC0027796
p67649
sg52649
I2
sasa(dp67650
g52636
VExpression of several members of the family including P2X2, P2X4, and P2X7 receptors has been reported to be altered in the hippocampus following status epilepticus.
p67651
sg52638
(lp67652
(dp67653
g52643
I70
sg52644
VP2X7 receptors
p67654
sg52646
I14
sg52674
g12
sg52649
I2
sasg52640
(lp67655
(dp67656
g52643
I146
sg52644
Vstatus epilepticus
p67657
sg52646
I18
sg52647
VC0038220
p67658
sg52649
I2
sasa(dp67659
g52636
VRecent work also found altered neuronal injury and inflammation after status epilepticus in mice lacking the P2X4 receptor.
p67660
sg52638
(lp67661
(dp67662
g52643
I109
sg52644
VP2X4 receptor
p67663
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp67664
(dp67665
g52643
I70
sg52644
Vstatus epilepticus
p67666
sg52646
I18
sg52647
VC0038220
p67667
sg52649
I2
sa(dp67668
g52643
I51
sg52644
Vinflammation
p67669
sg52646
I12
sg52647
VC0021368
p67670
sg52649
I1
sasa(dp67671
g52636
VIn this study, we investigated the potential involvement of P2X4R in microglial functions in a model of kainate (KA)-induced status epilepticus (SE).
p67672
sg52638
(lp67673
(dp67674
g52643
I60
sg52644
VP2X4R
p67675
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp67676
(dp67677
g52643
I125
sg52644
Vstatus epilepticus
p67678
sg52646
I18
sg52647
VC0038220
p67679
sg52649
I2
sa(dp67680
g52643
I145
sg52644
VSE
p67681
sg52646
I2
sg52647
VC0038220
p67682
sg52649
I1
sasa(dp67683
g52636
VHere we show that, in the seizure-sensitive (SS) gerbil hippocampus, a recognized genetic epilepsy model, the expressions of both P2X2 and P2X4 receptors are markedly decreased as compared with that in the seizure-resistant (SR) gerbil.
p67684
sg52638
(lp67685
(dp67686
g52643
I139
sg52644
VP2X4 receptors
p67687
sg52646
I14
sg52674
g12
sg52649
I2
sasg52640
(lp67688
(dp67689
g52643
I26
sg52644
Vseizure
p67690
sg52646
I7
sg52647
VC0036572
p67691
sg52649
I1
sa(dp67692
g52643
I26
sg52644
Vseizure
p67693
sg52646
I7
sg52647
VC0036572
p67694
sg52649
I1
sa(dp67695
g52643
I90
sg52644
Vepilepsy
p67696
sg52646
I8
sg52647
VC0014544
p67697
sg52649
I1
sasa(dp67698
g52636
VIn addition to pathogen recognition, DCIR has been shown to be pivotal in preventing autoimmune disease by controlling dendritic cell proliferation.
p67699
sg52638
(lp67700
(dp67701
g52643
I37
sg52644
VDCIR
p67702
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp67703
(dp67704
g52643
I134
sg52644
Vproliferation
p67705
sg52646
I13
sg52647
VC0334094
p67706
sg52649
I1
sa(dp67707
g52643
I85
sg52644
Vautoimmune disease
p67708
sg52646
I18
sg52647
VC0004364
p67709
sg52649
I2
sasa(dp67710
g52636
VThis study was aimed to further investigate whether DCIR polymorphisms are novel susceptibility factors for other autoimmune diseases, i.e.
p67711
sg52638
(lp67712
sg52640
(lp67713
(dp67714
g52643
I114
sg52644
Vautoimmune diseases
p67715
sg52646
I19
sg52647
VC0004364
p67716
sg52649
I2
sasa(dp67717
g52636
VTubulointerstitial nephritis and uveitis syndrome, HLA-B27-associated uveitis, inflammatory bowel disease, and Kawasaki disease each made up fewer than 5% of diagnoses.
p67718
sg52638
(lp67719
(dp67720
g52643
I51
sg52644
VHLA-B27
p67721
sg52646
I7
sg52674
VP30486
p67722
sg52649
I1
sasg52640
(lp67723
(dp67724
g52643
I0
sg52644
VTubulointerstitial nephritis and uveitis syndrome
p67725
sg52646
I49
sg52647
VC1639520
p67726
sg52649
I5
sa(dp67727
g52643
I79
sg52644
Vinflammatory bowel disease
p67728
sg52646
I26
sg52647
VC0021390
p67729
sg52649
I3
sa(dp67730
g52643
I33
sg52644
Vuveitis
p67731
sg52646
I7
sg52647
VC0042164
p67732
sg52649
I1
sa(dp67733
g52643
I111
sg52644
VKawasaki disease
p67734
sg52646
I16
sg52647
VC0026691
p67735
sg52649
I2
sasa(dp67736
g135
(dp67737
(VIGFII
p67738
VHGF
p67739
tp67740
I00
ssg52636
VStromal tissue was isolated from epithelial cells with laser capture microdissection (LCMD) and analyzed by cDNA array for the expression of TGFalpha, TGF-beta1, HGF, PDGF-alpha, IGFII, bFGF, aFGF, VEGFC, and VEGF.
p67741
sg52638
(lp67742
(dp67743
g52643
I151
sg52644
VTGF-beta1
p67744
sg52646
I9
sg52674
VP01137
p67745
sg52649
I1
sa(dp67746
g52643
I192
sg52644
VaFGF
p67747
sg52646
I4
sg52674
VP05230
p67748
sg52649
I1
sa(dp67749
g52643
I198
sg52644
VVEGFC
p67750
sg52646
I5
sg52674
VP49767
p67751
sg52649
I1
sa(dp67752
g52643
I141
sg52644
VTGFalpha
p67753
sg52646
I8
sg52674
VP01135
p67754
sg52649
I1
sa(dp67755
g52643
I167
sg52644
VPDGF-alpha
p67756
sg52646
I10
sg52674
VP04085
p67757
sg52649
I1
sa(dp67758
g52643
I162
sg52644
VHGF
p67759
sg52646
I3
sg52674
VP05231
p67760
sg52649
I1
sa(dp67761
g52643
I186
sg52644
VbFGF
p67762
sg52646
I4
sg52674
VP53370
p67763
sg52649
I1
sa(dp67764
g52643
I179
sg52644
g67738
sg52646
I5
sg52674
VP01344
p67765
sg52649
I1
sasg52640
(lp67766
(dp67767
g52643
I162
sg52644
g67739
sg52646
I3
sg52647
VC0399440
p67768
sg52649
I1
sasa(dp67769
g135
(dp67770
(VSTAT3
p67771
Vglioma
p67772
tp67773
I00
ssg52636
VHere, we demonstrate that Inositol Polyphosphate-5-Phosphatase F (INPP5F), one of the polyphosphoinositide phosphatases, is differentially expressed in GSCs from glioma patients, and is identified as an inhibitor of STAT3 signaling via interaction with STAT3 and inhibition of its phosphorylation.
p67774
sg52638
(lp67775
(dp67776
g52643
I66
sg52644
VINPP5F
p67777
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp67778
g52643
I216
sg52644
VSTAT3
p67779
sg52646
I5
sg52674
VP40763
p67780
sg52649
I1
sa(dp67781
g52643
I216
sg52644
g67771
sg52646
I5
sg52674
VP40763
p67782
sg52649
I1
sa(dp67783
g52643
I26
sg52644
VInositol Polyphosphate-5-Phosphatase F
p67784
sg52646
I38
sg52674
g12
sg52649
I3
sasg52640
(lp67785
(dp67786
g52643
I162
sg52644
g67772
sg52646
I6
sg52647
VC0017638
p67787
sg52649
I1
sasa(dp67788
g52636
VIn addition, loss of INPP5F gene in gliomas is significantly correlated with lower overall patient survivals.
p67789
sg52638
(lp67790
(dp67791
g52643
I21
sg52644
VINPP5F gene
p67792
sg52646
I11
sg52674
g12
sg52649
I2
sasg52640
(lp67793
(dp67794
g52643
I36
sg52644
Vgliomas
p67795
sg52646
I7
sg52647
VC0017638
p67796
sg52649
I1
sasa(dp67797
g135
(dp67798
(VSTAT3
p67799
Vgliomas
p67800
tp67801
I00
ssg52636
VThese findings suggest that INPP5F is a potential tumor suppressor in gliomas via inhibition of STAT3 pathway, and that deregulation of INPP5F may lead to contribution to gliomagenesis.
p67802
sg52638
(lp67803
(dp67804
g52643
I28
sg52644
VINPP5F
p67805
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp67806
g52643
I96
sg52644
g67799
sg52646
I5
sg52674
VP40763
p67807
sg52649
I1
sa(dp67808
g52643
I28
sg52644
VINPP5F
p67809
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp67810
(dp67811
g52643
I70
sg52644
g67800
sg52646
I7
sg52647
VC0017638
p67812
sg52649
I1
sa(dp67813
g52643
I50
sg52644
Vtumor
p67814
sg52646
I5
sg52647
VC0027651
p67815
sg52649
I1
sasa(dp67816
g52636
VThe patient and his identical twin show a retinal dystrophy that, based on clinical appearance, visual fields, amd electrophysiology, is most likely autosomal recessive retinitis pigmentosa.
p67817
sg52638
(lp67818
sg52640
(lp67819
(dp67820
g52643
I42
sg52644
Vretinal dystrophy
p67821
sg52646
I17
sg52647
VC0854723
p67822
sg52649
I2
sa(dp67823
g52643
I149
sg52644
Vautosomal recessive retinitis pigmentosa
p67824
sg52646
I40
sg52647
VC0339526
p67825
sg52649
I4
sa(dp67826
g52643
I111
sg52644
Vamd
p67827
sg52646
I3
sg52647
VC0242383
p67828
sg52649
I1
sasa(dp67829
g52636
VAlthough Gln supplementation had no effect on the loss of the tight junction protein occludin, the increased portal endotoxin and fasting glucose concentrations found in WSD-fed mice, markers of liver damage (e.g., nonalcoholic fatty liver disease activity score and number of neutrophils in the liver) were significantly lower in the WSD+Gln group than in the WSD group (~47% and ~60% less, respectively; P &lt; 0.05).
p67830
sg52638
(lp67831
(dp67832
g52643
I109
sg52644
Vportal endotoxin
p67833
sg52646
I16
sg52674
g12
sg52649
I2
sasg52640
(lp67834
(dp67835
g52643
I215
sg52644
Vnonalcoholic fatty liver disease
p67836
sg52646
I32
sg52647
VC0400966
p67837
sg52649
I4
sa(dp67838
g52643
I195
sg52644
Vliver damage
p67839
sg52646
I12
sg52647
VC0151763
p67840
sg52649
I2
sasa(dp67841
g52636
VThe purpose of this Evidence-Based Practice (EBP) paper is to answer PICOT questions by a review the effectiveness of chronotherapeutics interventions on depressive symptoms with depression and the depressive episode in the course of bipolar disorder.
p67842
sg52638
(lp67843
sg52640
(lp67844
(dp67845
g52643
I179
sg52644
Vdepression
p67846
sg52646
I10
sg52647
VC0011581
p67847
sg52649
I1
sa(dp67848
g52643
I234
sg52644
Vbipolar disorder
p67849
sg52646
I16
sg52647
VC0005586
p67850
sg52649
I2
sa(dp67851
g52643
I154
sg52644
Vdepressive symptoms
p67852
sg52646
I19
sg52647
VC0086132
p67853
sg52649
I2
sa(dp67854
g52643
I198
sg52644
Vdepressive episode
p67855
sg52646
I18
sg52647
VC0349217
p67856
sg52649
I2
sasa(dp67857
g52636
VWe evaluated whether post-bronchiolitis asthma was associated with polymorphisms in the TLR3 rs3775291, TLR4 rs4986790, TLR7 rs179008, TLR8 rs2407992, TLR9 rs187084, and TLR10 rs4129009 genes.
p67858
sg52638
(lp67859
(dp67860
g52643
I151
sg52644
VTLR9 rs187084
p67861
sg52646
I13
sg52674
g12
sg52649
I2
sa(dp67862
g52643
I170
sg52644
VTLR10 rs4129009 genes
p67863
sg52646
I21
sg52674
g12
sg52649
I3
sa(dp67864
g52643
I135
sg52644
VTLR8 rs2407992
p67865
sg52646
I14
sg52674
g12
sg52649
I2
sa(dp67866
g52643
I88
sg52644
VTLR3 rs3775291
p67867
sg52646
I14
sg52674
g12
sg52649
I2
sa(dp67868
g52643
I120
sg52644
VTLR7 rs179008
p67869
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp67870
(dp67871
g52643
I40
sg52644
Vasthma
p67872
sg52646
I6
sg52647
VC0004096
p67873
sg52649
I1
sa(dp67874
g52643
I26
sg52644
Vbronchiolitis
p67875
sg52646
I13
sg52647
VC0006271
p67876
sg52649
I1
sasa(dp67877
g52636
VThere were no significant associations between TLR3, TLR4, TLR8, or TLR9 polymorphisms and post-bronchiolitis asthma.
p67878
sg52638
(lp67879
(dp67880
g52643
I68
sg52644
VTLR9
p67881
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67882
g52643
I59
sg52644
VTLR8
p67883
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67884
g52643
I47
sg52644
VTLR3
p67885
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp67886
(dp67887
g52643
I110
sg52644
Vasthma
p67888
sg52646
I6
sg52647
VC0004096
p67889
sg52649
I1
sa(dp67890
g52643
I96
sg52644
Vbronchiolitis
p67891
sg52646
I13
sg52647
VC0006271
p67892
sg52649
I1
sasa(dp67893
g135
(dp67894
(VCC-chemokine ligand 2
p67895
Vatopic asthma
p67896
tp67897
I01
ssg52636
VSignificant associations with SAFS compared with atopic asthma included Toll-like receptor 3 (TLR3) (p = .009), TLR9 (p = .025), C-type lectin domain family seven member A (dectin-1) (p = .043), interleukin-10 (IL-10) (p = .0010), mannose-binding lectin (MBL2) (p = .007), CC-chemokine ligand 2 (CCL2) (2 SNPs, p = .025 and .041), CCL17 (p = .002), plasminogen (p = .049) and adenosine A2a receptor (p = .024).
p67898
sg52638
(lp67899
(dp67900
g52643
I211
sg52644
VIL-10
p67901
sg52646
I5
sg52674
VP22301
p67902
sg52649
I1
sa(dp67903
g52643
I94
sg52644
VTLR3
p67904
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67905
g52643
I129
sg52644
VC-type lectin domain family seven member A
p67906
sg52646
I42
sg52674
g12
sg52649
I7
sa(dp67907
g52643
I195
sg52644
Vinterleukin-10
p67908
sg52646
I14
sg52674
VP22301
p67909
sg52649
I1
sa(dp67910
g52643
I376
sg52644
Vadenosine A2a receptor
p67911
sg52646
I22
sg52674
VP29274
p67912
sg52649
I3
sa(dp67913
g52643
I349
sg52644
Vplasminogen
p67914
sg52646
I11
sg52674
VP00747
p67915
sg52649
I1
sa(dp67916
g52643
I112
sg52644
VTLR9
p67917
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67918
g52643
I72
sg52644
VToll-like receptor 3
p67919
sg52646
I20
sg52674
g12
sg52649
I3
sa(dp67920
g52643
I255
sg52644
VMBL2
p67921
sg52646
I4
sg52674
VP11226
p67922
sg52649
I1
sa(dp67923
g52643
I331
sg52644
VCCL17
p67924
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp67925
g52643
I296
sg52644
VCCL2
p67926
sg52646
I4
sg52674
VP13500
p67927
sg52649
I1
sa(dp67928
g52643
I231
sg52644
Vmannose-binding lectin
p67929
sg52646
I22
sg52674
VP11226
p67930
sg52649
I2
sa(dp67931
g52643
I273
sg52644
g67895
sg52646
I21
sg52674
VP51671
p67932
sg52649
I3
sasg52640
(lp67933
(dp67934
g52643
I49
sg52644
g67896
sg52646
I13
sg52647
VC0155877
p67935
sg52649
I2
sasa(dp67936
g52636
VAsthmatics had significantly lower circulating HPC expressing TLR-2 and TLR-9 with a similar trend for TLR-4.
p67937
sg52638
(lp67938
(dp67939
g52643
I47
sg52644
VHPC
p67940
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp67941
g52643
I62
sg52644
VTLR-2
p67942
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp67943
g52643
I72
sg52644
VTLR-9
p67944
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp67945
(dp67946
g52643
I47
sg52644
VHPC
p67947
sg52646
I3
sg52647
VC0238339
p67948
sg52649
I1
sa(dp67949
g52643
I0
sg52644
VAsthmatics
p67950
sg52646
I10
sg52647
VC0004096
p67951
sg52649
I1
sasa(dp67952
g52636
VThe endosomal TLRs have been shown to be associated with the induction of asthmatic inflammation (TLR3), and with disease exacerbations (TLR7, TLR8 and TLR9).
p67953
sg52638
(lp67954
(dp67955
g52643
I137
sg52644
VTLR7
p67956
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67957
g52643
I152
sg52644
VTLR9
p67958
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67959
g52643
I143
sg52644
VTLR8
p67960
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp67961
g52643
I98
sg52644
VTLR3
p67962
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp67963
(dp67964
g52643
I84
sg52644
Vinflammation
p67965
sg52646
I12
sg52647
VC0021368
p67966
sg52649
I1
sa(dp67967
g52643
I74
sg52644
Vasthmatic
p67968
sg52646
I9
sg52647
VC0004096
p67969
sg52649
I1
sasa(dp67970
g52636
VA defect in the P-protein component of the glycine cleavage system has been the most frequent abnormality found in patients with glycine encephalopathy (NKH).
p67971
sg52638
(lp67972
sg52640
(lp67973
(dp67974
g52643
I153
sg52644
VNKH
p67975
sg52646
I3
sg52647
VC0751748
p67976
sg52649
I1
sa(dp67977
g52643
I129
sg52644
Vglycine encephalopathy
p67978
sg52646
I22
sg52647
VC0751748
p67979
sg52649
I2
sasa(dp67980
g135
(dp67981
(VVWF
p67982
Vtumor necrosis
p67983
tp67984
I00
ssg52636
VSoluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin-1 receptor antagonist (IL-1Ra), von Willebrand factor (VWF), and osteoprotegerin (OPG) were measured in schizophrenia (n = 69) and affective (n = 55) spectrum patients at baseline and at one-year follow-up, and compared to healthy controls (HC) (n = 92) with analysis of covariance.
p67985
sg52638
(lp67986
(dp67987
g52643
I96
sg52644
Vvon Willebrand factor
p67988
sg52646
I21
sg52674
VP04275
p67989
sg52649
I3
sa(dp67990
g52643
I129
sg52644
Vosteoprotegerin
p67991
sg52646
I15
sg52674
g12
sg52649
I1
sa(dp67992
g52643
I52
sg52644
Vinterleukin-1 receptor antagonist
p67993
sg52646
I33
sg52674
VP18510
p67994
sg52649
I3
sa(dp67995
g52643
I0
sg52644
VSoluble tumor necrosis factor receptor 1
p67996
sg52646
I40
sg52674
g12
sg52649
I6
sa(dp67997
g52643
I146
sg52644
VOPG
p67998
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp67999
g52643
I87
sg52644
VIL-1Ra
p68000
sg52646
I6
sg52674
VP18510
p68001
sg52649
I1
sa(dp68002
g52643
I119
sg52644
g67982
sg52646
I3
sg52674
VP04275
p68003
sg52649
I1
sa(dp68004
g52643
I42
sg52644
VsTNF-R1
p68005
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp68006
(dp68007
g52643
I168
sg52644
Vschizophrenia
p68008
sg52646
I13
sg52647
VC0036341
p68009
sg52649
I1
sa(dp68010
g52643
I8
sg52644
g67983
sg52646
I14
sg52647
VC0333516
p68011
sg52649
I2
sasa(dp68012
g52636
VSerum sTNFR1 was significantly higher in patients with acute-stage schizophrenia compared to matched controls while no significant group differences were observed for the other markers.
p68013
sg52638
(lp68014
sg52640
(lp68015
(dp68016
g52643
I67
sg52644
Vschizophrenia
p68017
sg52646
I13
sg52647
VC0036341
p68018
sg52649
I1
sasa(dp68019
g135
(dp68020
(Vvon Willebrand factor
p68021
Vschizophrenia
p68022
tp68023
I01
ssg52636
VPlasma levels of soluble tumor necrosis factor receptor 1 (sTNF-R1), interleukin 1 receptor antagonist (IL-1Ra), osteoprotegerin (OPG), and von Willebrand factor (vWf) were measured in patients (n=992) with schizophrenia spectrum (SCZ, n=584), schizoaffective disorder (SA, n=93), affective spectrum disorders (AFF, n=315), and healthy controls (HC, n=638).
p68024
sg52638
(lp68025
(dp68026
g52643
I163
sg52644
VvWf
p68027
sg52646
I3
sg52674
VP04275
p68028
sg52649
I1
sa(dp68029
g52643
I17
sg52644
Vsoluble tumor necrosis factor receptor 1
p68030
sg52646
I40
sg52674
g12
sg52649
I6
sa(dp68031
g52643
I104
sg52644
VIL-1Ra
p68032
sg52646
I6
sg52674
VP18510
p68033
sg52649
I1
sa(dp68034
g52643
I130
sg52644
VOPG
p68035
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp68036
g52643
I59
sg52644
VsTNF-R1
p68037
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp68038
g52643
I69
sg52644
Vinterleukin 1 receptor antagonist
p68039
sg52646
I33
sg52674
VP18510
p68040
sg52649
I4
sa(dp68041
g52643
I140
sg52644
g68021
sg52646
I21
sg52674
VP04275
p68042
sg52649
I3
sa(dp68043
g52643
I113
sg52644
Vosteoprotegerin
p68044
sg52646
I15
sg52674
g12
sg52649
I1
sasg52640
(lp68045
(dp68046
g52643
I244
sg52644
Vschizoaffective disorder
p68047
sg52646
I24
sg52647
VC0036337
p68048
sg52649
I2
sa(dp68049
g52643
I25
sg52644
Vtumor necrosis
p68050
sg52646
I14
sg52647
VC0333516
p68051
sg52649
I2
sa(dp68052
g52643
I270
sg52644
VSA
p68053
sg52646
I2
sg52647
VC0036337
p68054
sg52649
I1
sa(dp68055
g52643
I207
sg52644
g68022
sg52646
I13
sg52647
VC0036341
p68056
sg52649
I1
sasa(dp68057
g52636
VMIS includes 10 components: dry weight changes, dietary intake, functional capacity, comorbidity, muscle wasting and loss of subcutaneous fat as well as body mass index (BMI), serum albumin level and total iron binding capacity (TIBC).
p68058
sg52638
(lp68059
(dp68060
g52643
I176
sg52644
Vserum albumin
p68061
sg52646
I13
sg52674
g12
sg52649
I2
sasg52640
(lp68062
(dp68063
g52643
I98
sg52644
Vmuscle wasting
p68064
sg52646
I14
sg52647
VC0026846
p68065
sg52649
I2
sasa(dp68066
g135
(dp68067
(Valbumin
p68068
Vmalnourished
p68069
tp68070
I01
ssg52636
VThis study suggests that consecutive PNC contributed to the improvement of the protein intake, serum levels of albumin, cholesterol and to the delay of muscle wasting, which could also have a positive impact on the nutritional status, particularly in malnourished patients receiving HD treatment.
p68071
sg52638
(lp68072
(dp68073
g52643
I111
sg52644
g68068
sg52646
I7
sg52674
VP00441
p68074
sg52649
I1
sasg52640
(lp68075
(dp68076
g52643
I152
sg52644
Vmuscle wasting
p68077
sg52646
I14
sg52647
VC0026846
p68078
sg52649
I2
sa(dp68079
g52643
I251
sg52644
g68069
sg52646
I12
sg52647
VC0162429
p68080
sg52649
I1
sasa(dp68081
g135
(dp68082
(VInsulin
p68083
Vhyperglycemia
p68084
tp68085
I00
ssg52636
VGCs = glucocorticoids; HDG = high-dose glucocorticoids; A1C = Hemoglobin A1C; GA = Glycated Albumin; FBG = fasting blood glucose; IG = interstitial glucose; BG = blood glucose; GIH = Glucocorticoids-induced hyperglycemia; HOMA-IR = Homeostasis Model Assessment-Insulin Resistance; CGMS = continuous glucose monitoring system; AUC = the area under the curve; MODD = absolute means of daily differences; LAGE = the largest amplitude of glycemic excursions; BMI = body mass index; DM = diabetes mellitus; SLE = systemic lupus erythematosus; IQR = interquartile range; HR = hazard ratio; PUMCH = Peking Union Medical College Hospital.
p68086
sg52638
(lp68087
(dp68088
g52643
I261
sg52644
g68083
sg52646
I7
sg52674
VP01308
p68089
sg52649
I1
sa(dp68090
g52643
I62
sg52644
VHemoglobin
p68091
sg52646
I10
sg52674
g12
sg52649
I1
sasg52640
(lp68092
(dp68093
g52643
I502
sg52644
VSLE
p68094
sg52646
I3
sg52647
VC0024141
p68095
sg52649
I1
sa(dp68096
g52643
I508
sg52644
Vsystemic lupus erythematosus
p68097
sg52646
I28
sg52647
VC0024141
p68098
sg52649
I3
sa(dp68099
g52643
I483
sg52644
Vdiabetes mellitus
p68100
sg52646
I17
sg52647
VC0011849
p68101
sg52649
I2
sa(dp68102
g52643
I261
sg52644
VInsulin Resistance
p68103
sg52646
I18
sg52647
VC0021655
p68104
sg52649
I2
sa(dp68105
g52643
I207
sg52644
g68084
sg52646
I13
sg52647
VC0020456
p68106
sg52649
I1
sasa(dp68107
g135
(dp68108
(Valbumin
p68109
Vosteoarthritis
p68110
tp68111
I01
ssg52636
VObjective To evaluate the presence and localization of folate receptor expressing macrophages in the rat groove model of osteoarthritis and determine the suitability of a new folate conjugate with albumin-binding entity (cm09) for in vivo SPECT (single-photon emission computed tomography) analysis.
p68112
sg52638
(lp68113
(dp68114
g52643
I55
sg52644
Vfolate receptor
p68115
sg52646
I15
sg52674
VP15328
p68116
sg52649
I2
sa(dp68117
g52643
I197
sg52644
g68109
sg52646
I7
sg52674
VP00441
p68118
sg52649
I1
sasg52640
(lp68119
(dp68120
g52643
I121
sg52644
g68110
sg52646
I14
sg52647
VC0029408
p68121
sg52649
I1
sasa(dp68122
g135
(dp68123
(Valbumin
p68124
Vosteoarthritis
p68125
tp68126
I01
ssg52636
VResults In vivo SPECT/CT imaging of the new folate conjugate (cm09) was as useful as a folate conjugate without albumin-binding entity in the groove model of osteoarthritis with less renal accumulation.
p68127
sg52638
(lp68128
(dp68129
g52643
I112
sg52644
g68124
sg52646
I7
sg52674
VP00441
p68130
sg52649
I1
sasg52640
(lp68131
(dp68132
g52643
I158
sg52644
g68125
sg52646
I14
sg52647
VC0029408
p68133
sg52649
I1
sasa(dp68134
g52636
VHowever, the effects of agonistic anti-4-1BB Abs have not been examined in an experimental mouse model of psoriasis.
p68135
sg52638
(lp68136
sg52640
(lp68137
(dp68138
g52643
I106
sg52644
Vpsoriasis
p68139
sg52646
I9
sg52647
VC0033860
p68140
sg52649
I1
sasa(dp68141
g52636
VTherefore, we investigated the protective effects of agonistic anti-4-1BB Abs, using imiquimod (IMQ)-induced psoriasis-like dermatitis in mice, a condition histologically and clinically similar to human psoriasis.
p68142
sg52638
(lp68143
sg52640
(lp68144
(dp68145
g52643
I109
sg52644
Vpsoriasis
p68146
sg52646
I9
sg52647
VC0033860
p68147
sg52649
I1
sa(dp68148
g52643
I109
sg52644
Vpsoriasis
p68149
sg52646
I9
sg52647
VC0033860
p68150
sg52649
I1
sa(dp68151
g52643
I146
sg52644
Vcondition
p68152
sg52646
I9
sg52647
VC0012634
p68153
sg52649
I1
sa(dp68154
g52643
I124
sg52644
Vdermatitis
p68155
sg52646
I10
sg52647
VC0011603
p68156
sg52649
I1
sasa(dp68157
g52636
VWe found that administration of agonistic anti-4-1BB Abs (10mg/kg) significantly alleviated the severity of IMQ-induced psoriasis-like skin inflammation in mice, with reduced histologic symptoms, including inflammatory infiltration, parakeratosis, and hyperkeratosis.
p68158
sg52638
(lp68159
sg52640
(lp68160
(dp68161
g52643
I252
sg52644
Vhyperkeratosis
p68162
sg52646
I14
sg52647
VC0870082
p68163
sg52649
I1
sa(dp68164
g52643
I233
sg52644
Vparakeratosis
p68165
sg52646
I13
sg52647
VC0030436
p68166
sg52649
I1
sa(dp68167
g52643
I206
sg52644
Vinflammatory infiltration
p68168
sg52646
I25
sg52647
VC0302158
p68169
sg52649
I2
sa(dp68170
g52643
I135
sg52644
Vskin inflammation
p68171
sg52646
I17
sg52647
VC0011603
p68172
sg52649
I2
sa(dp68173
g52643
I120
sg52644
Vpsoriasis
p68174
sg52646
I9
sg52647
VC0033860
p68175
sg52649
I1
sasa(dp68176
g52636
VTaken together, our data provide evidence that agonistic anti-4-1BB Abs possesses immunosuppressive properties in IMQ-induced psoriasis-like skin inflammation, providing insight into the immunomodulatory effect of agonistic anti-4-1BB Abs for psoriasis immunotherapy.
p68177
sg52638
(lp68178
sg52640
(lp68179
(dp68180
g52643
I126
sg52644
Vpsoriasis
p68181
sg52646
I9
sg52647
VC0033860
p68182
sg52649
I1
sa(dp68183
g52643
I72
sg52644
Vpossesses
p68184
sg52646
I9
sg52647
VC0850310
p68185
sg52649
I1
sa(dp68186
g52643
I141
sg52644
Vskin inflammation
p68187
sg52646
I17
sg52647
VC0011603
p68188
sg52649
I2
sa(dp68189
g52643
I126
sg52644
Vpsoriasis
p68190
sg52646
I9
sg52647
VC0033860
p68191
sg52649
I1
sasa(dp68192
g135
(dp68193
(VTNFAIP3
p68194
Vpsoriasis
p68195
tp68196
I00
ssg52636
VAmong identified psoriasis risk variants, three were more strongly associated with PsC than PsA (rs12189871 near HLA-C, p = 5.0 x 10(-19); rs4908742 near TNFRSF9, p = 0.00020; rs10888503 near LCE3A, p = 0.0014), and two were more strongly associated with PsA than PsC (rs12044149 near IL23R, p = 0.00018; rs9321623 near TNFAIP3, p = 0.00022).
p68197
sg52638
(lp68198
(dp68199
g52643
I192
sg52644
VLCE3A
p68200
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp68201
g52643
I154
sg52644
VTNFRSF9
p68202
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp68203
g52643
I320
sg52644
g68194
sg52646
I7
sg52674
VP21580
p68204
sg52649
I1
sa(dp68205
g52643
I113
sg52644
VHLA
p68206
sg52646
I3
sg52674
VP30486
p68207
sg52649
I1
sasg52640
(lp68208
(dp68209
g52643
I83
sg52644
VPsC
p68210
sg52646
I3
sg52647
VC0566602
p68211
sg52649
I1
sa(dp68212
g52643
I92
sg52644
VPsA
p68213
sg52646
I3
sg52647
VC1519176
p68214
sg52649
I1
sa(dp68215
g52643
I83
sg52644
VPsC
p68216
sg52646
I3
sg52647
VC0566602
p68217
sg52649
I1
sa(dp68218
g52643
I92
sg52644
VPsA
p68219
sg52646
I3
sg52647
VC1519176
p68220
sg52649
I1
sa(dp68221
g52643
I17
sg52644
g68195
sg52646
I9
sg52647
VC0033860
p68222
sg52649
I1
sasa(dp68223
g52636
VInteratrial electromechanical delay (IA-EMD) and intra-left atrial electromechanical delay (ILA-EMD) were significantly longer in the psoriasis group compared with controls.
p68224
sg52638
(lp68225
(dp68226
g52643
I49
sg52644
Vintra-left atrial electromechanical delay
p68227
sg52646
I41
sg52674
g12
sg52649
I4
sa(dp68228
g52643
I92
sg52644
VILA-EMD
p68229
sg52646
I7
sg52674
g12
sg52649
I1
sasg52640
(lp68230
(dp68231
g52643
I40
sg52644
VEMD
p68232
sg52646
I3
sg52647
VC0340861
p68233
sg52649
I1
sa(dp68234
g52643
I134
sg52644
Vpsoriasis
p68235
sg52646
I9
sg52647
VC0033860
p68236
sg52649
I1
sa(dp68237
g52643
I40
sg52644
VEMD
p68238
sg52646
I3
sg52647
VC0340861
p68239
sg52649
I1
sasa(dp68240
g135
(dp68241
(Vorphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA
p68242
Voral lichen planus
p68243
tp68244
I00
ssg52636
VTo investigate the expression of the peripheral blood retinoid-related orphan receptor gamma t (RORgamma t) and 4-1BB/4-1BBL mRNA in oral lichen planus (OLP) patients.
p68245
sg52638
(lp68246
(dp68247
g52643
I71
sg52644
g68242
sg52646
I58
sg52674
VP25106
p68248
sg52649
I9
sasg52640
(lp68249
(dp68250
g52643
I153
sg52644
VOLP
p68251
sg52646
I3
sg52647
VC0206139
p68252
sg52649
I1
sa(dp68253
g52643
I133
sg52644
g68243
sg52646
I18
sg52647
VC0206139
p68254
sg52649
I3
sasa(dp68255
g135
(dp68256
(VIgE
p68257
VIgE
p68258
tp68259
I01
ssg52636
VBlood and tissue eosinophils from patients with IgE-mediated allergic responses (atopic dermatitis, extrinsic asthma) express CD137.
p68260
sg52638
(lp68261
(dp68262
g52643
I126
sg52644
VCD137
p68263
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp68264
g52643
I48
sg52644
g68257
sg52646
I3
sg52674
VP01854
p68265
sg52649
I1
sasg52640
(lp68266
(dp68267
g52643
I81
sg52644
Vatopic dermatitis
p68268
sg52646
I17
sg52647
VC0011615
p68269
sg52649
I2
sa(dp68270
g52643
I100
sg52644
Vextrinsic asthma
p68271
sg52646
I16
sg52647
VC0155877
p68272
sg52649
I2
sa(dp68273
g52643
I48
sg52644
g68258
sg52646
I3
sg52647
VC0270850
p68274
sg52649
I1
sasa(dp68275
g135
(dp68276
(VTPI1
p68277
VPARK7
p68278
tp68279
I00
ssg52636
VProteomic analysis revealed 14 statistically significant differentially expressed proteins, with nine showing increased expression (PDIA3, VIM/HEXA, SELENBP1, ENO1, CAPZA1, ERP29, TPI1, PARK7, and FABP3) and five showing decreased expression (EIF2S, PSMA3, RPSA, TUBB, and TUBA1B) in uveal melanomas that subsequently metastasized compared with those that did not.
p68280
sg52638
(lp68281
(dp68282
g52643
I165
sg52644
VCAPZA1
p68283
sg52646
I6
sg52674
VP52907
p68284
sg52649
I1
sa(dp68285
g52643
I149
sg52644
VSELENBP1
p68286
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp68287
g52643
I132
sg52644
VPDIA3
p68288
sg52646
I5
sg52674
VP30101
p68289
sg52649
I1
sa(dp68290
g52643
I143
sg52644
VHEXA
p68291
sg52646
I4
sg52674
VP06865
p68292
sg52649
I1
sa(dp68293
g52643
I273
sg52644
VTUBA1B
p68294
sg52646
I6
sg52674
VP68363
p68295
sg52649
I1
sa(dp68296
g52643
I197
sg52644
VFABP3
p68297
sg52646
I5
sg52674
VP05413
p68298
sg52649
I1
sa(dp68299
g52643
I173
sg52644
VERP29
p68300
sg52646
I5
sg52674
VP30040
p68301
sg52649
I1
sa(dp68302
g52643
I250
sg52644
VPSMA3
p68303
sg52646
I5
sg52674
VP25788
p68304
sg52649
I1
sa(dp68305
g52643
I263
sg52644
VTUBB
p68306
sg52646
I4
sg52674
VP04350
p68307
sg52649
I1
sa(dp68308
g52643
I180
sg52644
g68277
sg52646
I4
sg52674
VP60174
p68309
sg52649
I1
sa(dp68310
g52643
I186
sg52644
VPARK7
p68311
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp68312
(dp68313
g52643
I318
sg52644
Vmetastasized
p68314
sg52646
I12
sg52647
VC0027627
p68315
sg52649
I1
sa(dp68316
g52643
I290
sg52644
Vmelanomas
p68317
sg52646
I9
sg52647
VC0025202
p68318
sg52649
I1
sa(dp68319
g52643
I186
sg52644
g68278
sg52646
I5
sg52647
VC1853445
p68320
sg52649
I1
sasa(dp68321
g135
(dp68322
(VLDHA
p68323
Vliver cancer
p68324
tp68325
I01
ssg52636
VAmong these, 14 genes (FTL, K-ALPHA1, LDHA, RPL4, ENO1, ANXA2, RPL9, RPL10, RPL13A, GNB2L1, AMBP, GC, A1BG, and SERPINC1), in addition to previously well-known liver cancer related genes, were confirmed to be differentially expressed in seven liver cancer cell lines and 17 HCC tissues by semi-quantitative RT-PCR.
p68326
sg52638
(lp68327
(dp68328
g52643
I69
sg52644
VRPL10
p68329
sg52646
I5
sg52674
VP61313
p68330
sg52649
I1
sa(dp68331
g52643
I56
sg52644
VANXA2
p68332
sg52646
I5
sg52674
VP07355
p68333
sg52649
I1
sa(dp68334
g52643
I28
sg52644
VK-ALPHA1
p68335
sg52646
I8
sg52674
VP25100
p68336
sg52649
I1
sa(dp68337
g52643
I92
sg52644
VAMBP
p68338
sg52646
I4
sg52674
VP02760
p68339
sg52649
I1
sa(dp68340
g52643
I76
sg52644
VRPL13A
p68341
sg52646
I6
sg52674
VP40429
p68342
sg52649
I1
sa(dp68343
g52643
I102
sg52644
VA1BG
p68344
sg52646
I4
sg52674
VP04217
p68345
sg52649
I1
sa(dp68346
g52643
I63
sg52644
VRPL9
p68347
sg52646
I4
sg52674
VP32969
p68348
sg52649
I1
sa(dp68349
g52643
I44
sg52644
VRPL4
p68350
sg52646
I4
sg52674
VP36578
p68351
sg52649
I1
sa(dp68352
g52643
I23
sg52644
VFTL
p68353
sg52646
I3
sg52674
VP02792
p68354
sg52649
I1
sa(dp68355
g52643
I84
sg52644
VGNB2L1
p68356
sg52646
I6
sg52674
VP63244
p68357
sg52649
I1
sa(dp68358
g52643
I38
sg52644
g68323
sg52646
I4
sg52674
VP00338
p68359
sg52649
I1
sasg52640
(lp68360
(dp68361
g52643
I160
sg52644
Vliver cancer
p68362
sg52646
I12
sg52647
VC0345904
p68363
sg52649
I2
sa(dp68364
g52643
I274
sg52644
VHCC
p68365
sg52646
I3
sg52647
VC2239176
p68366
sg52649
I1
sa(dp68367
g52643
I160
sg52644
g68324
sg52646
I12
sg52647
VC0345904
p68368
sg52649
I2
sasa(dp68369
g135
(dp68370
(VHMBS
p68371
Vbladder cancer
p68372
tp68373
I00
ssg52636
VExpression profiles of the 9 genes ACTB, ALAS1, G6PD, GAPD, HMBS, HPRT1, K-ALPHA-1, SDHA and TBP were established in matched malignant and nonmalignant tissue specimens from 14 patients with bladder cancer.
p68374
sg52638
(lp68375
(dp68376
g52643
I73
sg52644
VK-ALPHA-1
p68377
sg52646
I9
sg52674
VP68363
p68378
sg52649
I1
sa(dp68379
g52643
I41
sg52644
VALAS1
p68380
sg52646
I5
sg52674
VP13196
p68381
sg52649
I1
sa(dp68382
g52643
I66
sg52644
VHPRT1
p68383
sg52646
I5
sg52674
VP55884
p68384
sg52649
I1
sa(dp68385
g52643
I93
sg52644
VTBP
p68386
sg52646
I3
sg52674
VP20226
p68387
sg52649
I1
sa(dp68388
g52643
I48
sg52644
VG6PD
p68389
sg52646
I4
sg52674
VP11441
p68390
sg52649
I1
sa(dp68391
g52643
I54
sg52644
VGAPD
p68392
sg52646
I4
sg52674
VP04406
p68393
sg52649
I1
sa(dp68394
g52643
I35
sg52644
VACTB
p68395
sg52646
I4
sg52674
VP63261
p68396
sg52649
I1
sa(dp68397
g52643
I84
sg52644
VSDHA
p68398
sg52646
I4
sg52674
VP31040
p68399
sg52649
I1
sa(dp68400
g52643
I60
sg52644
g68371
sg52646
I4
sg52674
VP08397
p68401
sg52649
I1
sasg52640
(lp68402
(dp68403
g52643
I191
sg52644
g68372
sg52646
I14
sg52647
VC0699885
p68404
sg52649
I2
sasa(dp68405
g135
(dp68406
(VALAS1
p68407
VHRPT1
p68408
tp68409
I00
ssg52636
VThe use of HPRT1 alone as a reference gene shown in our study was sufficient, but the normalization factors generated from two (HRPT1, ALAS1) or all three genes (HRPT1, ALAS1, K-ALPHA-1) should be considered for an improved reliability of normalization in gene profiling studies of prostate cancer.
p68410
sg52638
(lp68411
(dp68412
g52643
I128
sg52644
VHRPT1
p68413
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp68414
g52643
I176
sg52644
VK-ALPHA-1
p68415
sg52646
I9
sg52674
VP68363
p68416
sg52649
I1
sa(dp68417
g52643
I128
sg52644
VHRPT1
p68418
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp68419
g52643
I11
sg52644
VHPRT1
p68420
sg52646
I5
sg52674
VP55884
p68421
sg52649
I1
sa(dp68422
g52643
I135
sg52644
VALAS1
p68423
sg52646
I5
sg52674
VP13196
p68424
sg52649
I1
sa(dp68425
g52643
I135
sg52644
g68407
sg52646
I5
sg52674
VP13196
p68426
sg52649
I1
sasg52640
(lp68427
(dp68428
g52643
I128
sg52644
VHRPT1
p68429
sg52646
I5
sg52647
VC1840402
p68430
sg52649
I1
sa(dp68431
g52643
I282
sg52644
Vprostate cancer
p68432
sg52646
I15
sg52647
VC0600139
p68433
sg52649
I2
sa(dp68434
g52643
I128
sg52644
g68408
sg52646
I5
sg52647
VC1840402
p68435
sg52649
I1
sasa(dp68436
g135
(dp68437
(Vplasma albumin
p68438
Vmarasmus
p68439
tp68440
I00
ssg52636
VWe show that glucose clearance rates are affected in both children with marasmus as well as kwashiorkor, which correlate with plasma albumin concentrations.
p68441
sg52638
(lp68442
(dp68443
g52643
I126
sg52644
g68438
sg52646
I14
sg52674
VP00441
p68444
sg52649
I2
sasg52640
(lp68445
(dp68446
g52643
I92
sg52644
Vkwashiorkor
p68447
sg52646
I11
sg52647
VC0022806
p68448
sg52649
I1
sa(dp68449
g52643
I72
sg52644
g68439
sg52646
I8
sg52647
VC0086588
p68450
sg52649
I1
sasa(dp68451
g52636
VAlthough marasmus is characterized by clinical wasting, kwashiorkor is associated with peripheral edema, oxidative stress, hypoalbuminemia, and hypoglycemia.
p68452
sg52638
(lp68453
sg52640
(lp68454
(dp68455
g52643
I47
sg52644
Vwasting
p68456
sg52646
I7
sg52647
VC0235394
p68457
sg52649
I1
sa(dp68458
g52643
I56
sg52644
Vkwashiorkor
p68459
sg52646
I11
sg52647
VC0022806
p68460
sg52649
I1
sa(dp68461
g52643
I105
sg52644
Voxidative stress
p68462
sg52646
I16
sg52647
VC0242606
p68463
sg52649
I2
sa(dp68464
g52643
I98
sg52644
Vedema
p68465
sg52646
I5
sg52647
VC0013604
p68466
sg52649
I1
sa(dp68467
g52643
I9
sg52644
Vmarasmus
p68468
sg52646
I8
sg52647
VC0086588
p68469
sg52649
I1
sa(dp68470
g52643
I144
sg52644
Vhypoglycemia
p68471
sg52646
I12
sg52647
VC0020615
p68472
sg52649
I1
sasa(dp68473
g135
(dp68474
(Valbumin
p68475
Vmarasmus
p68476
tp68477
I00
ssg52636
VTotal proteins, albumin and transferrin were all significantly lower in children with edema than in those with marasmus.
p68478
sg52638
(lp68479
(dp68480
g52643
I28
sg52644
Vtransferrin
p68481
sg52646
I11
sg52674
VP02787
p68482
sg52649
I1
sa(dp68483
g52643
I16
sg52644
g68475
sg52646
I7
sg52674
VP00441
p68484
sg52649
I1
sasg52640
(lp68485
(dp68486
g52643
I86
sg52644
Vedema
p68487
sg52646
I5
sg52647
VC0013604
p68488
sg52649
I1
sa(dp68489
g52643
I111
sg52644
g68476
sg52646
I8
sg52647
VC0086588
p68490
sg52649
I1
sasa(dp68491
g135
(dp68492
(VsPLA2
p68493
Vtumor necrosis
p68494
tp68495
I00
ssg52636
VIn this condition, 8CR inhibited edema and myonecrosis induced by the sPLA2 activity of Crotalus durissus terrificus in a dose-dependent manner by decreasing interleukin-1Beta (IL-1Beta), tumor necrosis factor Alfa (TNF-Alfa), prostaglandin E2 (PGE2), and lipid peroxidation.
p68496
sg52638
(lp68497
(dp68498
g52643
I216
sg52644
VTNF-Alfa
p68499
sg52646
I8
sg52674
VP01375
p68500
sg52649
I1
sa(dp68501
g52643
I177
sg52644
VIL-1Beta
p68502
sg52646
I8
sg52674
VP01584
p68503
sg52649
I1
sa(dp68504
g52643
I158
sg52644
Vinterleukin-1Beta
p68505
sg52646
I17
sg52674
VP01584
p68506
sg52649
I1
sa(dp68507
g52643
I188
sg52644
Vtumor necrosis factor Alfa
p68508
sg52646
I26
sg52674
VP01375
p68509
sg52649
I4
sa(dp68510
g52643
I70
sg52644
g68493
sg52646
I5
sg52674
VP14555
p68511
sg52649
I1
sasg52640
(lp68512
(dp68513
g52643
I8
sg52644
Vcondition
p68514
sg52646
I9
sg52647
VC0012634
p68515
sg52649
I1
sa(dp68516
g52643
I43
sg52644
Vmyonecrosis
p68517
sg52646
I11
sg52647
VC0235957
p68518
sg52649
I1
sa(dp68519
g52643
I33
sg52644
Vedema
p68520
sg52646
I5
sg52647
VC0013604
p68521
sg52649
I1
sa(dp68522
g52643
I188
sg52644
g68494
sg52646
I14
sg52647
VC0333516
p68523
sg52649
I2
sasa(dp68524
g135
(dp68525
(VsPLA2
p68526
Voxidative stress
p68527
tp68528
I00
ssg52636
VIn addition, it was shown that Crotalus durissus terrificus sPLA2 increases cell oxidative stress during edema and myonecrosis, and the antioxidant properties of the polyphenolic compound may be significant in mitigating the pharmacological effect induced by sPLA2 and other snake venom toxins.
p68529
sg52638
(lp68530
(dp68531
g52643
I60
sg52644
g68526
sg52646
I5
sg52674
VP14555
p68532
sg52649
I1
sasg52640
(lp68533
(dp68534
g52643
I115
sg52644
Vmyonecrosis
p68535
sg52646
I11
sg52647
VC0235957
p68536
sg52649
I1
sa(dp68537
g52643
I105
sg52644
Vedema
p68538
sg52646
I5
sg52647
VC0013604
p68539
sg52649
I1
sa(dp68540
g52643
I81
sg52644
g68527
sg52646
I16
sg52647
VC0242606
p68541
sg52649
I2
sasa(dp68542
g52636
VMoreover, 5CQA significantly decreased the enzymatic activity and the oedema and myonecrosis induced by native sPLA2.
p68543
sg52638
(lp68544
sg52640
(lp68545
(dp68546
g52643
I70
sg52644
Voedema
p68547
sg52646
I6
sg52647
VC0013604
p68548
sg52649
I1
sa(dp68549
g52643
I81
sg52644
Vmyonecrosis
p68550
sg52646
I11
sg52647
VC0235957
p68551
sg52649
I1
sasa(dp68552
g52636
VThis flavonoid was able to decrease enzymatic activity and some pharmacological effects, such as myonecrosis, platelet aggregation, and neurotoxic activity caused by sPLA2, however, the inflammatory effect was not affected by naringin.
p68553
sg52638
(lp68554
sg52640
(lp68555
(dp68556
g52643
I97
sg52644
Vmyonecrosis
p68557
sg52646
I11
sg52647
VC0235957
p68558
sg52649
I1
sasa(dp68559
g52636
VUnder the conditions tested, we observed that both Boc-5 and Boc-10 strongly decreased edema, myonecrosis, and neurotoxicity induced by native sPLA2.
p68560
sg52638
(lp68561
(dp68562
g52643
I51
sg52644
VBoc-5
p68563
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp68564
g52643
I61
sg52644
VBoc-10
p68565
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp68566
(dp68567
g52643
I94
sg52644
Vmyonecrosis
p68568
sg52646
I11
sg52647
VC0235957
p68569
sg52649
I1
sa(dp68570
g52643
I87
sg52644
Vedema
p68571
sg52646
I5
sg52647
VC0013604
p68572
sg52649
I1
sasa(dp68573
g135
(dp68574
(VGi-proteins
p68575
Vpertussis
p68576
tp68577
I00
ssg52636
VIncubation with pertussis toxin prior to the addition of either sPLA2 or LPA only showed abrogation of the response to LPA, thus suggesting the involvement of pertussis-sensitive Gi-proteins in the case of LPA.
p68578
sg52638
(lp68579
(dp68580
g52643
I64
sg52644
VsPLA2
p68581
sg52646
I5
sg52674
VP14555
p68582
sg52649
I1
sa(dp68583
g52643
I16
sg52644
Vpertussis toxin
p68584
sg52646
I15
sg52674
g12
sg52649
I2
sa(dp68585
g52643
I179
sg52644
g68575
sg52646
I11
sg52674
VP63096
p68586
sg52649
I1
sasg52640
(lp68587
(dp68588
g52643
I16
sg52644
Vpertussis
p68589
sg52646
I9
sg52647
VC0043167
p68590
sg52649
I1
sa(dp68591
g52643
I16
sg52644
g68576
sg52646
I9
sg52647
VC0043167
p68592
sg52649
I1
sasa(dp68593
g52636
VIn contrast, all of the four classical CMNs tested were negative, as were cases of Wilms' tumor and clear cell sarcoma of the kidney.
p68594
sg52638
(lp68595
sg52640
(lp68596
(dp68597
g52643
I100
sg52644
Vclear cell sarcoma of the kidney
p68598
sg52646
I32
sg52647
VC0334488
p68599
sg52649
I6
sa(dp68600
g52643
I83
sg52644
VWilms' tumor
p68601
sg52646
I12
sg52647
VC0027708
p68602
sg52649
I2
sasa(dp68603
g52636
VThe aspirates were from 16 cases of classical Wilms' tumor (WT), one anaplastic WT, 2 clear cell sarcomas of the kidney (CCSK), 2 malignant rhabdoid tumors of the kidney (MRTK) and 6 congenital mesoblastic nephromas (CMNs).
p68604
sg52638
(lp68605
sg52640
(lp68606
(dp68607
g52643
I60
sg52644
VWT
p68608
sg52646
I2
sg52647
VC0027708
p68609
sg52649
I1
sa(dp68610
g52643
I46
sg52644
VWilms' tumor
p68611
sg52646
I12
sg52647
VC0027708
p68612
sg52649
I2
sa(dp68613
g52643
I183
sg52644
Vcongenital mesoblastic nephromas
p68614
sg52646
I32
sg52647
VC1332965
p68615
sg52649
I3
sa(dp68616
g52643
I60
sg52644
VWT
p68617
sg52646
I2
sg52647
VC0027708
p68618
sg52649
I1
sa(dp68619
g52643
I86
sg52644
Vclear cell sarcomas
p68620
sg52646
I19
sg52647
VC0206651
p68621
sg52649
I3
sa(dp68622
g52643
I140
sg52644
Vrhabdoid tumors
p68623
sg52646
I15
sg52647
VC0206743
p68624
sg52649
I2
sa(dp68625
g52643
I217
sg52644
VCMNs
p68626
sg52646
I4
sg52647
VC1332965
p68627
sg52649
I1
sasa(dp68628
g135
(dp68629
(VHPL
p68630
VMFHs
p68631
tp68632
I00
ssg52636
VArchival tissue from 38 patients with superficial smooth muscle cell and so-called fibrohistiocytic tumors (8 benign fibrous histiocytomas (BFHs), 6 dermatofibrosarcoma protuberans (DFPT), 9 malignant fibrous histiocytomas (MFHs), 9 leiomyomas (LMs) and 6 leiomyosarcomas (LMSs)) were immunostained with antibodies against SMA, HCD, CALP, PLAP and HPL.
p68633
sg52638
(lp68634
(dp68635
g52643
I323
sg52644
VSMA
p68636
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp68637
g52643
I339
sg52644
VPLAP
p68638
sg52646
I4
sg52674
VP51003
p68639
sg52649
I1
sa(dp68640
g52643
I348
sg52644
g68630
sg52646
I3
sg52674
VP09382
p68641
sg52649
I1
sa(dp68642
g52643
I328
sg52644
VHCD
p68643
sg52646
I3
sg52674
VP0C7U2
p68644
sg52649
I1
sa(dp68645
g52643
I333
sg52644
VCALP
p68646
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp68647
(dp68648
g52643
I110
sg52644
Vbenign fibrous histiocytomas
p68649
sg52646
I28
sg52647
VC0206644
p68650
sg52649
I3
sa(dp68651
g52643
I233
sg52644
Vleiomyomas
p68652
sg52646
I10
sg52647
VC0023267
p68653
sg52649
I1
sa(dp68654
g52643
I100
sg52644
Vtumors
p68655
sg52646
I6
sg52647
VC0027651
p68656
sg52649
I1
sa(dp68657
g52643
I191
sg52644
Vmalignant fibrous histiocytomas
p68658
sg52646
I31
sg52647
VC0334463
p68659
sg52649
I3
sa(dp68660
g52643
I256
sg52644
Vleiomyosarcomas
p68661
sg52646
I15
sg52647
VC0023269
p68662
sg52649
I1
sa(dp68663
g52643
I323
sg52644
VSMA
p68664
sg52646
I3
sg52647
VC0026847
p68665
sg52649
I1
sa(dp68666
g52643
I328
sg52644
VHCD
p68667
sg52646
I3
sg52647
VC0235833
p68668
sg52649
I1
sa(dp68669
g52643
I245
sg52644
VLMs
p68670
sg52646
I3
sg52647
VC1851710
p68671
sg52649
I1
sa(dp68672
g52643
I149
sg52644
Vdermatofibrosarcoma protuberans
p68673
sg52646
I31
sg52647
VC0392784
p68674
sg52649
I2
sa(dp68675
g52643
I273
sg52644
VLMSs
p68676
sg52646
I4
sg52647
VC0023269
p68677
sg52649
I1
sa(dp68678
g52643
I224
sg52644
g68631
sg52646
I4
sg52647
VC0334463
p68679
sg52649
I1
sasa(dp68680
g135
(dp68681
(Vcalponin
p68682
Vleiomyosarcoma
p68683
tp68684
I00
ssg52636
VIn cell culture, d12.CALP at low multiplicity of infection (0.001 plaque-forming unit/cell) selectively killed calponin-positive human synovial sarcoma, leiomyosarcoma, and osteosarcoma cells.
p68685
sg52638
(lp68686
(dp68687
g52643
I111
sg52644
g68682
sg52646
I8
sg52674
VP51911
p68688
sg52649
I1
sasg52640
(lp68689
(dp68690
g52643
I49
sg52644
Vinfection
p68691
sg52646
I9
sg52647
VC0009450
p68692
sg52649
I1
sa(dp68693
g52643
I66
sg52644
Vplaque
p68694
sg52646
I6
sg52647
VC0011389
p68695
sg52649
I1
sa(dp68696
g52643
I173
sg52644
Vosteosarcoma
p68697
sg52646
I12
sg52647
VC0029463
p68698
sg52649
I1
sa(dp68699
g52643
I135
sg52644
Vsynovial sarcoma
p68700
sg52646
I16
sg52647
VC0039101
p68701
sg52649
I2
sa(dp68702
g52643
I153
sg52644
g68683
sg52646
I14
sg52647
VC0023269
p68703
sg52649
I1
sasa(dp68704
g135
(dp68705
(Vinterleukin-8
p68706
Vperiodontal disease
p68707
tp68708
I01
ssg52636
VTo investigate the possible role of beta-defensins in gingival health and periodontal disease, we examined the effect of several stimuli on the expression of interleukin-8 (IL-8), human beta-defensin-1, -2, -3, and -4 (hBD) in primary human diseased gingival epithelial (HGE) cell cultures from periodontitis patients by quantitative TaqMan reverse transcription polymerase chain reaction (RT-PCR).
p68709
sg52638
(lp68710
(dp68711
g52643
I219
sg52644
VhBD
p68712
sg52646
I3
sg52674
VP02042
p68713
sg52649
I1
sa(dp68714
g52643
I36
sg52644
Vbeta-defensins
p68715
sg52646
I14
sg52674
g12
sg52649
I1
sa(dp68716
g52643
I173
sg52644
VIL-8
p68717
sg52646
I4
sg52674
VP60568
p68718
sg52649
I1
sa(dp68719
g52643
I158
sg52644
g68706
sg52646
I13
sg52674
VP60568
p68720
sg52649
I1
sasg52640
(lp68721
(dp68722
g52643
I219
sg52644
VhBD
p68723
sg52646
I3
sg52647
VC1840321
p68724
sg52649
I1
sa(dp68725
g52643
I295
sg52644
Vperiodontitis
p68726
sg52646
I13
sg52647
VC0031099
p68727
sg52649
I1
sa(dp68728
g52643
I74
sg52644
g68707
sg52646
I19
sg52647
VC0031090
p68729
sg52649
I2
sasa(dp68730
g52636
VHuman gingival epithelial cells (HGE) express two antimicrobial peptides of the beta-defensin family, human beta-defensin 1 (hBD-1) and hBD-2, as well as cytokines and chemokines that contribute to innate immunity.
p68731
sg52638
(lp68732
(dp68733
g52643
I125
sg52644
VhBD-1
p68734
sg52646
I5
sg52674
VP60022
p68735
sg52649
I1
sa(dp68736
g52643
I136
sg52644
VhBD-2
p68737
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp68738
g52643
I102
sg52644
Vhuman beta-defensin 1
p68739
sg52646
I21
sg52674
VP60022
p68740
sg52649
I3
sa(dp68741
g52643
I80
sg52644
Vbeta-defensin family
p68742
sg52646
I20
sg52674
VP59861
p68743
sg52649
I2
sasg52640
(lp68744
(dp68745
g52643
I125
sg52644
VhBD
p68746
sg52646
I3
sg52647
VC1840321
p68747
sg52649
I1
sa(dp68748
g52643
I125
sg52644
VhBD
p68749
sg52646
I3
sg52647
VC1840321
p68750
sg52649
I1
sasa(dp68751
g52636
VSSKcnj16-/- rats exhibited hypokalemia and reduced blood pressure, and when fed a high-salt diet (4% NaCl), experienced 100% mortality within a few days triggered by salt wasting and severe hypokalemia.
p68752
sg52638
(lp68753
sg52640
(lp68754
(dp68755
g52643
I171
sg52644
Vwasting
p68756
sg52646
I7
sg52647
VC0235394
p68757
sg52649
I1
sasa(dp68758
g52636
VHence, patients with HNF1Beta mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.
p68759
sg52638
(lp68760
(dp68761
g52643
I57
sg52644
VKir5.1
p68762
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp68763
g52643
I21
sg52644
VHNF1Beta mutations
p68764
sg52646
I18
sg52674
VP35680
p68765
sg52649
I2
sasg52640
(lp68766
sa(dp68767
g52636
VThe Kir5.1(-/-) mice displayed hypokalemic, hyperchloremic metabolic acidosis with hypercalciuria.
p68768
sg52638
(lp68769
(dp68770
g52643
I4
sg52644
VKir5.1
p68771
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp68772
(dp68773
g52643
I83
sg52644
Vhypercalciuria
p68774
sg52646
I14
sg52647
VC0020438
p68775
sg52649
I1
sa(dp68776
g52643
I59
sg52644
Vmetabolic acidosis
p68777
sg52646
I18
sg52647
VC0220981
p68778
sg52649
I2
sasa(dp68779
g52636
VIn conclusion, disruption of Kcnj16 induces a severe renal phenotype that, apart from hypokalemia, is the opposite of the phenotype seen in SeSAME/EAST syndrome.
p68780
sg52638
(lp68781
(dp68782
g52643
I29
sg52644
VKcnj16
p68783
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp68784
(dp68785
g52643
I147
sg52644
VEAST syndrome
p68786
sg52646
I13
sg52647
VC2748572
p68787
sg52649
I2
sasa(dp68788
g52636
VWe found that Kir5.1(-/-) mice presented with persistent metabolic acidosis and a clear respiratory phenotype.
p68789
sg52638
(lp68790
(dp68791
g52643
I14
sg52644
VKir5.1
p68792
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp68793
(dp68794
g52643
I57
sg52644
Vmetabolic acidosis
p68795
sg52646
I18
sg52647
VC0220981
p68796
sg52649
I2
sasa(dp68797
g52636
VDespite metabolic acidosis, ventilation at rest and in hyperoxic hypercapnia were similar in wild-type and Kir5.1(-/-) mice.
p68798
sg52638
(lp68799
sg52640
(lp68800
(dp68801
g52643
I8
sg52644
Vmetabolic acidosis
p68802
sg52646
I18
sg52647
VC0220981
p68803
sg52649
I2
sa(dp68804
g52643
I65
sg52644
Vhypercapnia
p68805
sg52646
I11
sg52647
VC0020440
p68806
sg52649
I1
sasa(dp68807
g52636
VWe suggest that this compensatory modulation of the peripheral chemosensory inputs develops in Kir5.1(-/-) mice in order to counteract the effect of continuing metabolic acidosis on the activity of the peripheral chemoreceptors.
p68808
sg52638
(lp68809
(dp68810
g52643
I95
sg52644
VKir5.1
p68811
sg52646
I6
sg52674
g12
sg52649
I1
sasg52640
(lp68812
(dp68813
g52643
I160
sg52644
Vmetabolic acidosis
p68814
sg52646
I18
sg52647
VC0220981
p68815
sg52649
I2
sasa(dp68816
g135
(dp68817
(VCYP2E1*6
p68818
VNSCLC
p68819
tp68820
I00
ssg52636
VIn this study, CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in 137 advanced stage NSCLC patients were investigated.
p68821
sg52638
(lp68822
(dp68823
g52643
I36
sg52644
VCYP2E1*7B
p68824
sg52646
I9
sg52674
VP05181
p68825
sg52649
I1
sa(dp68826
g52643
I15
sg52644
VCYP2E1*5B
p68827
sg52646
I9
sg52674
VP05181
p68828
sg52649
I1
sa(dp68829
g52643
I47
sg52644
VGSTO1 (A140D), and TP53
p68830
sg52646
I23
sg52674
VP78417
p68831
sg52649
I4
sa(dp68832
g52643
I26
sg52644
g68818
sg52646
I8
sg52674
VP05181
p68833
sg52649
I1
sasg52640
(lp68834
(dp68835
g52643
I175
sg52644
g68819
sg52646
I5
sg52647
VC0007131
p68836
sg52649
I1
sasa(dp68837
g135
(dp68838
(VGSTO1-1
p68839
Vtransitional cell carcinoma
p68840
tp68841
I00
ssg52636
VGSTO1-1 expression pattern has not been studied in transitional cell carcinoma (TCC), as yet.
p68842
sg52638
(lp68843
(dp68844
g52643
I0
sg52644
g68839
sg52646
I7
sg52674
VP78417
p68845
sg52649
I1
sasg52640
(lp68846
(dp68847
g52643
I80
sg52644
VTCC
p68848
sg52646
I3
sg52647
VC1861305
p68849
sg52649
I1
sa(dp68850
g52643
I51
sg52644
g68840
sg52646
I27
sg52647
VC0007138
p68851
sg52649
I3
sasa(dp68852
g135
(dp68853
(VGSTO1-1
p68854
VTCC
p68855
tp68856
I00
ssg52636
VIncreased GSTO1-1 expression might contribute to TCC development and/or progression supporting the notion that GSTO1-1 may be a promising novel cancer target.
p68857
sg52638
(lp68858
(dp68859
g52643
I10
sg52644
VGSTO1-1
p68860
sg52646
I7
sg52674
VP78417
p68861
sg52649
I1
sa(dp68862
g52643
I10
sg52644
g68854
sg52646
I7
sg52674
VP78417
p68863
sg52649
I1
sasg52640
(lp68864
(dp68865
g52643
I49
sg52644
g68855
sg52646
I3
sg52647
VC1861305
p68866
sg52649
I1
sa(dp68867
g52643
I144
sg52644
Vcancer
p68868
sg52646
I6
sg52647
VC0006826
p68869
sg52649
I1
sasa(dp68870
g52636
VGlutathione S-transferase omega 1 (GSTO1) is an atypical GST isoform that is overexpressed in several cancers and has been implicated in drug resistance.
p68871
sg52638
(lp68872
(dp68873
g52643
I0
sg52644
VGlutathione S-transferase omega 1
p68874
sg52646
I33
sg52674
VP78417
p68875
sg52649
I4
sa(dp68876
g52643
I35
sg52644
VGST
p68877
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp68878
g52643
I35
sg52644
VGSTO1
p68879
sg52646
I5
sg52674
VP78417
p68880
sg52649
I1
sasg52640
(lp68881
(dp68882
g52643
I102
sg52644
Vcancers
p68883
sg52646
I7
sg52647
VC0006826
p68884
sg52649
I1
sasa(dp68885
g52636
VHere we show that silencing of GSTO1 with siRNA significantly impairs cancer cell viability, validating GSTO1 as a potential new target in oncology.
p68886
sg52638
(lp68887
(dp68888
g52643
I31
sg52644
VGSTO1
p68889
sg52646
I5
sg52674
VP78417
p68890
sg52649
I1
sa(dp68891
g52643
I31
sg52644
VGSTO1
p68892
sg52646
I5
sg52674
VP78417
p68893
sg52649
I1
sasg52640
(lp68894
(dp68895
g52643
I70
sg52644
Vcancer
p68896
sg52646
I6
sg52647
VC0006826
p68897
sg52649
I1
sasa(dp68898
g135
(dp68899
(VGSTO1
p68900
Vcolon cancer
p68901
tp68902
I00
ssg52636
VThese potent GSTO1 inhibitors suppress cancer cell growth, enhance the cytotoxic effects of cisplatin and inhibit tumour growth in colon cancer models as single agent.
p68903
sg52638
(lp68904
(dp68905
g52643
I13
sg52644
g68900
sg52646
I5
sg52674
VP78417
p68906
sg52649
I1
sasg52640
(lp68907
(dp68908
g52643
I114
sg52644
Vtumour
p68909
sg52646
I6
sg52647
VC0027651
p68910
sg52649
I1
sa(dp68911
g52643
I131
sg52644
g68901
sg52646
I12
sg52647
VC0699790
p68912
sg52649
I2
sa(dp68913
g52643
I39
sg52644
Vcancer cell growth
p68914
sg52646
I18
sg52647
VC1516170
p68915
sg52649
I3
sasa(dp68916
g135
(dp68917
(VGSTO1
p68918
Vcolorectal cancer
p68919
tp68920
I00
ssg52636
VOur findings demonstrate the therapeutic utility of GSTO1 inhibitors as anticancer agents and identify the novel cellular pathways under GSTO1 regulation in colorectal cancer.
p68921
sg52638
(lp68922
(dp68923
g52643
I52
sg52644
g68918
sg52646
I5
sg52674
VP78417
p68924
sg52649
I1
sasg52640
(lp68925
(dp68926
g52643
I157
sg52644
g68919
sg52646
I17
sg52647
VC1527249
p68927
sg52649
I2
sasa(dp68928
g52636
VTo explore the relationship between angiogenin-1/2 (Ang-1/2) and clinical parameters of idiopathic pulmonary fibrosis (IPF), and to assess the value of Ang-1/2 in predicting the prognosis of patients with IPF.
p68929
sg52638
(lp68930
(dp68931
g52643
I36
sg52644
Vangiogenin-1/2
p68932
sg52646
I14
sg52674
VP03950
p68933
sg52649
I1
sa(dp68934
g52643
I52
sg52644
VAng-1/2
p68935
sg52646
I7
sg52674
VP03950
p68936
sg52649
I1
sa(dp68937
g52643
I52
sg52644
VAng-1/2
p68938
sg52646
I7
sg52674
VP03950
p68939
sg52649
I1
sasg52640
(lp68940
(dp68941
g52643
I119
sg52644
VIPF
p68942
sg52646
I3
sg52647
VC3161101
p68943
sg52649
I1
sa(dp68944
g52643
I88
sg52644
Vidiopathic pulmonary fibrosis
p68945
sg52646
I29
sg52647
VC3161101
p68946
sg52649
I3
sa(dp68947
g52643
I119
sg52644
VIPF
p68948
sg52646
I3
sg52647
VC3161101
p68949
sg52649
I1
sasa(dp68950
g52636
VPreterm infants exposed to oxygen and mechanical ventilation are at risk for bronchopulmonary dysplasia (BPD), a multifactorial chronic lung disorder characterized by arrested alveolar development and nonsprouting, dysmorphic microvascular angiogenesis.
p68951
sg52638
(lp68952
sg52640
(lp68953
(dp68954
g52643
I77
sg52644
Vbronchopulmonary dysplasia
p68955
sg52646
I26
sg52647
VC0006287
p68956
sg52649
I2
sa(dp68957
g52643
I128
sg52644
Vchronic lung disorder
p68958
sg52646
I21
sg52647
VC0746102
p68959
sg52649
I3
sa(dp68960
g52643
I167
sg52644
Varrested
p68961
sg52646
I8
sg52647
VC0018790
p68962
sg52649
I1
sa(dp68963
g52643
I105
sg52644
VBPD
p68964
sg52646
I3
sg52647
VC0006012
p68965
sg52649
I1
sasa(dp68966
g135
(dp68967
(VAP-1
p68968
Vheart disease
p68969
tp68970
I00
ssg52636
VMany genes previously known to be affected by BPA and involved in obesity, hypertension, or heart disease were altered following these treatments, and AP-1, EGR1, and EGFR were key hubs affected by BPA and/or overfeeding.
p68971
sg52638
(lp68972
(dp68973
g52643
I157
sg52644
VEGR1
p68974
sg52646
I4
sg52674
VP18146
p68975
sg52649
I1
sa(dp68976
g52643
I151
sg52644
g68968
sg52646
I4
sg52674
VP01100
p68977
sg52649
I1
sasg52640
(lp68978
(dp68979
g52643
I66
sg52644
Vobesity
p68980
sg52646
I7
sg52647
VC0028754
p68981
sg52649
I1
sa(dp68982
g52643
I75
sg52644
Vhypertension
p68983
sg52646
I12
sg52647
VC0020538
p68984
sg52649
I1
sa(dp68985
g52643
I92
sg52644
g68969
sg52646
I13
sg52647
VC0018799
p68986
sg52649
I2
sasa(dp68987
g135
(dp68988
(VPAH
p68989
VPAH
p68990
tp68991
I00
ssg52636
VUsing immunohistochemistry, we studied Egr-1 expression specifically in a wide morphologic spectrum of pulmonary arteries in the lung tissue of 72 patients with different forms and stages of PAH, specifically idiopathic PAH (n = 18), advanced-stage congenital heart disease-associated PAH (PAH-CHD) (n = 21), early-stage PAH-CHD (n = 19) and non-neointimal hypoxic pulmonary hypertension (PH) (n = 4), and controls (n = 10).
p68992
sg52638
(lp68993
(dp68994
g52643
I290
sg52644
VPAH-CHD
p68995
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp68996
g52643
I191
sg52644
VPAH
p68997
sg52646
I3
sg52674
VP00439
p68998
sg52649
I1
sa(dp68999
g52643
I39
sg52644
VEgr-1
p69000
sg52646
I5
sg52674
VP18146
p69001
sg52649
I1
sa(dp69002
g52643
I191
sg52644
g68989
sg52646
I3
sg52674
VP00439
p69003
sg52649
I1
sasg52640
(lp69004
(dp69005
g52643
I389
sg52644
VPH
p69006
sg52646
I2
sg52647
VC0020542
p69007
sg52649
I1
sa(dp69008
g52643
I365
sg52644
Vpulmonary hypertension
p69009
sg52646
I22
sg52647
VC0020542
p69010
sg52649
I2
sa(dp69011
g52643
I191
sg52644
VPAH
p69012
sg52646
I3
sg52647
VC0152171
p69013
sg52649
I1
sa(dp69014
g52643
I191
sg52644
VPAH
p69015
sg52646
I3
sg52647
VC0152171
p69016
sg52649
I1
sa(dp69017
g52643
I191
sg52644
VPAH
p69018
sg52646
I3
sg52647
VC0152171
p69019
sg52649
I1
sa(dp69020
g52643
I191
sg52644
VPAH
p69021
sg52646
I3
sg52647
VC0152171
p69022
sg52649
I1
sa(dp69023
g52643
I357
sg52644
Vhypoxic
p69024
sg52646
I7
sg52647
VC0242184
p69025
sg52649
I1
sa(dp69026
g52643
I249
sg52644
Vcongenital heart disease
p69027
sg52646
I24
sg52647
VC0152021
p69028
sg52649
I3
sa(dp69029
g52643
I191
sg52644
g68990
sg52646
I3
sg52647
VC0152171
p69030
sg52649
I1
sasa(dp69031
g135
(dp69032
(VAlfa-synuclein
p69033
VParkinson's disease
p69034
tp69035
I00
ssg52636
VParkin substrates include two septins; SEPT4/CDCrel-2 which coaggregates with Alfa-synuclein as Lewy bodies in Parkinson's disease, and its closest homolog SEPT5/CDCrel-1/PNUTL1 whose overload with viral vector can rapidly eliminate dopamine neurons in rats.
p69036
sg52638
(lp69037
(dp69038
g52643
I156
sg52644
VSEPT5
p69039
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp69040
g52643
I30
sg52644
Vseptins
p69041
sg52646
I7
sg52674
g12
sg52649
I1
sa(dp69042
g52643
I171
sg52644
VPNUTL1
p69043
sg52646
I6
sg52674
g12
sg52649
I1
sa(dp69044
g52643
I78
sg52644
g69033
sg52646
I14
sg52674
VP37840
p69045
sg52649
I1
sa(dp69046
g52643
I39
sg52644
VSEPT4
p69047
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp69048
g52643
I162
sg52644
VCDCrel-1
p69049
sg52646
I8
sg52674
g12
sg52649
I1
sa(dp69050
g52643
I45
sg52644
VCDCrel-2
p69051
sg52646
I8
sg52674
g12
sg52649
I1
sasg52640
(lp69052
(dp69053
g52643
I111
sg52644
g69034
sg52646
I19
sg52647
VC0030567
p69054
sg52649
I2
sasa(dp69055
g135
(dp69056
(VAlfa-synuclein
p69057
Vneurodegenerative disease
p69058
tp69059
I00
ssg52636
VAfter validation by Western blot and quantitative real-time PCR, the expressions of three proteins related to neurodegenerative disease, septin 5, Alfa-internexin, and Alfa-synuclein, were identified to be altered by MCLR exposure.
p69060
sg52638
(lp69061
(dp69062
g52643
I168
sg52644
g69057
sg52646
I14
sg52674
VP37840
p69063
sg52649
I1
sa(dp69064
g52643
I137
sg52644
Vseptin 5
p69065
sg52646
I8
sg52674
g12
sg52649
I2
sasg52640
(lp69066
(dp69067
g52643
I110
sg52644
g69058
sg52646
I25
sg52647
VC0524851
p69068
sg52649
I2
sasa(dp69069
g52636
VInterestingly, Septin 5, one of the genes isolated from HPAI H5N1-infected brain tissues has been reported to participate in the pathogenic process of Parkinson's disease.
p69070
sg52638
(lp69071
(dp69072
g52643
I15
sg52644
VSeptin 5
p69073
sg52646
I8
sg52674
g12
sg52649
I2
sasg52640
(lp69074
(dp69075
g52643
I61
sg52644
VH5N1
p69076
sg52646
I4
sg52647
VC0016627
p69077
sg52649
I1
sa(dp69078
g52643
I151
sg52644
VParkinson's disease
p69079
sg52646
I19
sg52647
VC0030567
p69080
sg52649
I2
sasa(dp69081
g52636
VA previous study successfully developed and validated a self-report BPD measure, the Minnesota Borderline Personality Disorder Scale (MBPD).
p69082
sg52638
(lp69083
sg52640
(lp69084
(dp69085
g52643
I68
sg52644
VBPD
p69086
sg52646
I3
sg52647
VC0006012
p69087
sg52649
I1
sa(dp69088
g52643
I95
sg52644
VBorderline Personality Disorder
p69089
sg52646
I31
sg52647
VC0006012
p69090
sg52649
I3
sasa(dp69091
g52636
VA previous study successfully developed and validated a BPD measure embedded within a normal trait measure, the Minnesota Borderline Personality Disorder Scale (MBPD).
p69092
sg52638
(lp69093
sg52640
(lp69094
(dp69095
g52643
I122
sg52644
VBorderline Personality Disorder
p69096
sg52646
I31
sg52647
VC0006012
p69097
sg52649
I3
sa(dp69098
g52643
I56
sg52644
VBPD
p69099
sg52646
I3
sg52647
VC0006012
p69100
sg52649
I1
sasa(dp69101
g135
(dp69102
(VHSP70
p69103
VCOPD
p69104
tp69105
I01
ssg52636
VThis study was to investigate HSP70 expression in the peripheral lung tissues of chronic obstructive pulmonary disease (COPD) patients and in human bronchial epithelial cells (16-HBE) exposed to cigarette smoke extract (CSE).
p69106
sg52638
(lp69107
(dp69108
g52643
I30
sg52644
g69103
sg52646
I5
sg52674
VP34932
p69109
sg52649
I1
sasg52640
(lp69110
(dp69111
g52643
I220
sg52644
VCSE
p69112
sg52646
I3
sg52647
VC1832855
p69113
sg52649
I1
sa(dp69114
g52643
I81
sg52644
Vchronic obstructive pulmonary disease
p69115
sg52646
I37
sg52647
VC0024117
p69116
sg52649
I4
sa(dp69117
g52643
I195
sg52644
Vcigarette smoke extract
p69118
sg52646
I23
sg52647
VC1832855
p69119
sg52649
I3
sa(dp69120
g52643
I120
sg52644
g69104
sg52646
I4
sg52647
VC0024117
p69121
sg52649
I1
sasa(dp69122
g52636
VSequencing analysis of the endogenous E2F4 gene in a series of colorectal cancer cell lines showed that the microsatellite-unstable cell line SW48 exhibited a serine deletion in this gene.
p69123
sg52638
(lp69124
(dp69125
g52643
I38
sg52644
VE2F4 gene
p69126
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp69127
(dp69128
g52643
I63
sg52644
Vcolorectal cancer
p69129
sg52646
I17
sg52647
VC1527249
p69130
sg52649
I2
sasa(dp69131
g52636
VIn conclusion, our data demonstrate that cancer-associated E2F4 mutations enhance the capacity of colorectal cancer cells to grow without anchorage, thereby contributing to tumor progression.
p69132
sg52638
(lp69133
(dp69134
g52643
I59
sg52644
VE2F4
p69135
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp69136
(dp69137
g52643
I41
sg52644
Vcancer
p69138
sg52646
I6
sg52647
VC0006826
p69139
sg52649
I1
sa(dp69140
g52643
I173
sg52644
Vtumor progression
p69141
sg52646
I17
sg52647
VC0178874
p69142
sg52649
I2
sa(dp69143
g52643
I98
sg52644
Vcolorectal cancer
p69144
sg52646
I17
sg52647
VC1527249
p69145
sg52649
I2
sasa(dp69146
g52636
VThe inverse immunohistochemical relationship between E2F1 and E2F4 indicates a possible mechanistic interlink in colorectal cancer.
p69147
sg52638
(lp69148
(dp69149
g52643
I62
sg52644
VE2F4
p69150
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69151
g52643
I53
sg52644
VE2F1
p69152
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp69153
(dp69154
g52643
I113
sg52644
Vcolorectal cancer
p69155
sg52646
I17
sg52647
VC1527249
p69156
sg52649
I2
sasa(dp69157
g52636
VIn an attempt to identify the role of E2F-4 as a potential mediator of cell proliferation, differentiation, tumorigenesis, and apoptosis in colorectal mucosa comparing with that of E2F-1, the authors examine 20 patients with human colon cancer and their corresponding histologically healthy mucosa by using immunohistochemical methods, computerized quantitative image analysis, and immunoblot analysis.
p69158
sg52638
(lp69159
(dp69160
g52643
I38
sg52644
VE2F-4
p69161
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp69162
g52643
I181
sg52644
VE2F-1
p69163
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp69164
(dp69165
g52643
I108
sg52644
Vtumorigenesis
p69166
sg52646
I13
sg52647
VC0007621
p69167
sg52649
I1
sa(dp69168
g52643
I76
sg52644
Vproliferation
p69169
sg52646
I13
sg52647
VC0334094
p69170
sg52649
I1
sa(dp69171
g52643
I231
sg52644
Vcolon cancer
p69172
sg52646
I12
sg52647
VC0699790
p69173
sg52649
I2
sasa(dp69174
g52636
VEighteen colorectal cancer (CRC) patients from 13 kindreds meeting the Amsterdam criteria for HNPCC were analyzed and compared to sporadic CRC patients with MSI-H. We detected mutations of E2F-4 at the same repeat sequence in HNPCC.
p69175
sg52638
(lp69176
(dp69177
g52643
I189
sg52644
VE2F-4
p69178
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp69179
(dp69180
g52643
I28
sg52644
VCRC
p69181
sg52646
I3
sg52647
VC1527249
p69182
sg52649
I1
sa(dp69183
g52643
I157
sg52644
VMSI
p69184
sg52646
I3
sg52647
VC0920269
p69185
sg52649
I1
sa(dp69186
g52643
I9
sg52644
Vcolorectal cancer
p69187
sg52646
I17
sg52647
VC1527249
p69188
sg52649
I2
sa(dp69189
g52643
I28
sg52644
VCRC
p69190
sg52646
I3
sg52647
VC1527249
p69191
sg52649
I1
sa(dp69192
g52643
I94
sg52644
VHNPCC
p69193
sg52646
I5
sg52647
VC1333990
p69194
sg52649
I1
sa(dp69195
g52643
I94
sg52644
VHNPCC
p69196
sg52646
I5
sg52647
VC1333990
p69197
sg52649
I1
sasa(dp69198
g52636
VAlthough the implication of vascular endothelial growth factor, angiopoietin-2, and C-X-C motif chemokine 10 has been suggested, the pathogenesis of systemic capillary leak syndrome remains unclear.
p69199
sg52638
(lp69200
(dp69201
g52643
I64
sg52644
Vangiopoietin-2
p69202
sg52646
I14
sg52674
g12
sg52649
I1
sa(dp69203
g52643
I28
sg52644
Vvascular endothelial growth factor
p69204
sg52646
I34
sg52674
g12
sg52649
I4
sasg52640
(lp69205
(dp69206
g52643
I149
sg52644
Vsystemic capillary leak syndrome
p69207
sg52646
I32
sg52647
VC0343084
p69208
sg52649
I4
sa(dp69209
g52643
I133
sg52644
Vpathogenesis
p69210
sg52646
I12
sg52647
VC0699748
p69211
sg52649
I1
sasa(dp69212
g135
(dp69213
(Vfibrin
p69214
Vseptic shock
p69215
tp69216
I00
ssg52636
VMicrovascular dysfunction under septic shock is related to: increased capillary permeability that manifests as a breakdown of the microvascular endothelial barrier (factors which may contribute to capillary leak syndrome include endogenous proinflammatory cytokines, angiopoietin 2, vascular endothelial growth factor); arteriolar hyporesponsiveness to vasoconstrictors and vasodilators, the loss of adrenergic sensitivity and tone of smooth muscle cells lining the arterioles; loss of the anti-adhesive function of endothelial surfaces; decreased density of perfused capillaries (due to several contributing factors: decreased deformability of erythrocytes and neutrophils; activation of the clotting cascade with fibrin deposition and the formation of microthrombi; dysfunction of vascular autoregulatory mechanisms by nitric oxide; enhanced functional arteriovenous shunting of the microcirculation).
p69217
sg52638
(lp69218
(dp69219
g52643
I283
sg52644
Vvascular endothelial growth factor
p69220
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp69221
g52643
I267
sg52644
Vangiopoietin 2
p69222
sg52646
I14
sg52674
g12
sg52649
I2
sa(dp69223
g52643
I715
sg52644
g69214
sg52646
I6
sg52674
VP22087
p69224
sg52649
I1
sasg52640
(lp69225
(dp69226
g52643
I113
sg52644
Vbreakdown
p69227
sg52646
I9
sg52647
VC1265875
p69228
sg52649
I1
sa(dp69229
g52643
I715
sg52644
Vfibrin deposition
p69230
sg52646
I17
sg52647
VC0333565
p69231
sg52649
I2
sa(dp69232
g52643
I197
sg52644
Vcapillary leak syndrome
p69233
sg52646
I23
sg52647
VC0343084
p69234
sg52649
I3
sa(dp69235
g52643
I32
sg52644
g69215
sg52646
I12
sg52647
VC0036983
p69236
sg52649
I2
sasa(dp69237
g52636
VFurther investigations of AL-1 as a promising new agent for treatment and/or prevention of diabetes are warranted.
p69238
sg52638
(lp69239
sg52640
(lp69240
(dp69241
g52643
I91
sg52644
Vdiabetes
p69242
sg52646
I8
sg52647
VC0011849
p69243
sg52649
I1
sasa(dp69244
g52636
VIn established cardiac ATTR amyloidosis, T1 elevation was not as high as in AL amyloidosis (AL 1,130 +/- 68 ms; p = 0.01).
p69245
sg52638
(lp69246
sg52640
(lp69247
(dp69248
g52643
I28
sg52644
Vamyloidosis
p69249
sg52646
I11
sg52647
VC0002726
p69250
sg52649
I1
sa(dp69251
g52643
I76
sg52644
VAL amyloidosis
p69252
sg52646
I14
sg52647
VC0268381
p69253
sg52649
I2
sasa(dp69254
g52636
VWe previously reported that EphA5 receptor-ephrinA5 interactions within the ventromedial hypothalamus (VMH) influence counterregulatory hormone responses during acute hypoglycemia in nondiabetic rats.
p69255
sg52638
(lp69256
(dp69257
g52643
I28
sg52644
VEphA5 receptor
p69258
sg52646
I14
sg52674
VP54756
p69259
sg52649
I2
sasg52640
(lp69260
(dp69261
g52643
I161
sg52644
Vacute hypoglycemia
p69262
sg52646
I18
sg52647
VC0745150
p69263
sg52649
I2
sasa(dp69264
g135
(dp69265
(VVMH EphA5 receptors
p69266
Vhypoglycemia
p69267
tp69268
I00
ssg52636
VIn this study, we examined whether recurrent hypoglycemia alters the capacity of the ephrinA5 ligand to activate VMH EphA5 receptors, and if so, whether these changes could contribute to pathogenesis of defective glucose counterregulation in response to a standard hypoglycemic stimulus.
p69269
sg52638
(lp69270
(dp69271
g52643
I85
sg52644
VephrinA5 ligand
p69272
sg52646
I15
sg52674
g12
sg52649
I2
sa(dp69273
g52643
I113
sg52644
g69266
sg52646
I19
sg52674
VP54756
p69274
sg52649
I3
sasg52640
(lp69275
(dp69276
g52643
I187
sg52644
Vpathogenesis
p69277
sg52646
I12
sg52647
VC0699748
p69278
sg52649
I1
sa(dp69279
g52643
I45
sg52644
g69267
sg52646
I12
sg52647
VC0020615
p69280
sg52649
I1
sasa(dp69281
g135
(dp69282
(VEphA5 receptors
p69283
Vhypoglycemia
p69284
tp69285
I00
ssg52636
VThe expression of ephrinA5, but not EphA5 receptors within the VMH, was reduced by antecedent recurrent hypoglycemia.
p69286
sg52638
(lp69287
(dp69288
g52643
I36
sg52644
g69283
sg52646
I15
sg52674
VP54756
p69289
sg52649
I2
sasg52640
(lp69290
(dp69291
g52643
I104
sg52644
g69284
sg52646
I12
sg52647
VC0020615
p69292
sg52649
I1
sasa(dp69293
g135
(dp69294
(VVMH EphA5 receptors
p69295
Vhypoglycemia
p69296
tp69297
I00
ssg52636
VActivation of VMH EphA5 receptors via targeted microinjection of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduction in the glucose infusion rate in nondiabetic rats exposed to recurrent hypoglycemia.
p69298
sg52638
(lp69299
(dp69300
g52643
I14
sg52644
g69295
sg52646
I19
sg52674
VP54756
p69301
sg52649
I3
sasg52640
(lp69302
(dp69303
g52643
I217
sg52644
g69296
sg52646
I12
sg52647
VC0020615
p69304
sg52649
I1
sasa(dp69305
g135
(dp69306
(Vglucagon
p69307
Vhypoglycemia
p69308
tp69309
I00
ssg52636
VThese data suggest that changes in ephrinA5/EphA5 interactions and synaptic plasticity within the VMH, a key glucose-sensing region in the brain, may contribute to the impairment in glucagon secretion and counterregulatory responses caused by recurrent hypoglycemia.
p69310
sg52638
(lp69311
(dp69312
g52643
I44
sg52644
VEphA5
p69313
sg52646
I5
sg52674
VP54756
p69314
sg52649
I1
sa(dp69315
g52643
I182
sg52644
g69307
sg52646
I8
sg52674
VP01275
p69316
sg52649
I1
sasg52640
(lp69317
(dp69318
g52643
I253
sg52644
g69308
sg52646
I12
sg52647
VC0020615
p69319
sg52649
I1
sa(dp69320
g52643
I168
sg52644
Vimpairment
p69321
sg52646
I10
sg52647
VC0684336
p69322
sg52649
I1
sasa(dp69323
g135
(dp69324
(Vinsulin
p69325
Vhypoglycemia
p69326
tp69327
I00
ssg52636
VActivation of Beta-cell EphA5 receptors by its ligand ephrinA5 from adjacent Beta-cells has been reported to decrease insulin secretion during hypoglycemia.
p69328
sg52638
(lp69329
(dp69330
g52643
I14
sg52644
VBeta-cell EphA5 receptors
p69331
sg52646
I25
sg52674
VP54756
p69332
sg52649
I3
sa(dp69333
g52643
I118
sg52644
g69325
sg52646
I7
sg52674
VP01308
p69334
sg52649
I1
sasg52640
(lp69335
(dp69336
g52643
I143
sg52644
g69326
sg52646
I12
sg52647
VC0020615
p69337
sg52649
I1
sasa(dp69338
g135
(dp69339
(VEphA5
p69340
Vhypoglycemia
p69341
tp69342
I00
ssg52636
VGiven the similarities between islet and ventromedial hypothalamus (VMH) glucose sensing, we tested the hypothesis that the EphA5/ephrinA5 system might function within the VMH during hypoglycemia to stimulate counterregulatory hormone release as well.
p69343
sg52638
(lp69344
(dp69345
g52643
I124
sg52644
g69340
sg52646
I5
sg52674
VP54756
p69346
sg52649
I1
sasg52640
(lp69347
(dp69348
g52643
I183
sg52644
g69341
sg52646
I12
sg52647
VC0020615
p69349
sg52649
I1
sasa(dp69350
g135
(dp69351
(VVMH EphA5 receptors
p69352
Vhypoglycemia
p69353
tp69354
I00
ssg52636
VLocal stimulation of VMH EphA5 receptors by ephrinA5-Fc or ephrinA5 overexpression increased, whereas knockdown of VMH ephrinA5 reduced counterregulatory responses during hypoglycemia.
p69355
sg52638
(lp69356
(dp69357
g52643
I21
sg52644
g69352
sg52646
I19
sg52674
VP54756
p69358
sg52649
I3
sasg52640
(lp69359
(dp69360
g52643
I171
sg52644
g69353
sg52646
I12
sg52647
VC0020615
p69361
sg52649
I1
sasa(dp69362
g52636
VOverexpression of VMH ephrinA5 transiently increased local glutamate concentrations, whereas ephrinA5 knockdown produced profound suppression of VMH interstitial fluid glutamine concentrations in the basal state and during hypoglycemia.
p69363
sg52638
(lp69364
(dp69365
g52643
I93
sg52644
VephrinA5 knockdown
p69366
sg52646
I18
sg52674
g12
sg52649
I2
sasg52640
(lp69367
(dp69368
g52643
I223
sg52644
Vhypoglycemia
p69369
sg52646
I12
sg52647
VC0020615
p69370
sg52649
I1
sa(dp69371
g52643
I130
sg52644
Vsuppression
p69372
sg52646
I11
sg52647
VC0221103
p69373
sg52649
I1
sasa(dp69374
g52636
VChanges in ephrinA5/EphA5 interactions within the VMH, a key brain glucose-sensing region, act in concert with islets to restore glucose homeostasis during acute hypoglycemia, and its effect on counterregulation may be mediated by changes in glutamate/glutamine cycling.
p69375
sg52638
(lp69376
(dp69377
g52643
I20
sg52644
VEphA5
p69378
sg52646
I5
sg52674
VP54756
p69379
sg52649
I1
sasg52640
(lp69380
(dp69381
g52643
I156
sg52644
Vacute hypoglycemia
p69382
sg52646
I18
sg52647
VC0745150
p69383
sg52649
I2
sasa(dp69384
g135
(dp69385
(VpME
p69386
VdcmA
p69387
tp69388
I00
ssg52636
VFractionation of dichloromethane (DCM) molecules with different chlorine isotopes by aerobic methylobacteria Methylobacterium dichloromethanicum DM4 and Albibacter nethylovorans DM10; cell-free extract of strain DM4; and transconjugant Methylobacterium evtorquens Al1/pME 8220, expressing the dcmA gene for DCM dehalogenase but unable to grow on DCM, was studied.
p69389
sg52638
(lp69390
(dp69391
g52643
I268
sg52644
g69386
sg52646
I3
sg52674
VP04080
p69392
sg52649
I1
sa(dp69393
g52643
I293
sg52644
VdcmA gene
p69394
sg52646
I9
sg52674
g12
sg52649
I2
sasg52640
(lp69395
(dp69396
g52643
I268
sg52644
VpME
p69397
sg52646
I3
sg52647
VC0751785
p69398
sg52649
I1
sa(dp69399
g52643
I293
sg52644
g69387
sg52646
I4
sg52647
VC1857776
p69400
sg52649
I1
sasa(dp69401
g135
(dp69402
(VTFE3
p69403
VRCC
p69404
tp69405
I00
ssg52636
VWe also describe the first RCC with a DVL2-TFE3 gene fusion, in addition to an extrarenal pigmented PEComa with a NONO-TFE3 gene fusion.
p69406
sg52638
(lp69407
(dp69408
g52643
I43
sg52644
VTFE3
p69409
sg52646
I4
sg52674
VP19532
p69410
sg52649
I1
sa(dp69411
g52643
I114
sg52644
VNONO
p69412
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69413
g52643
I38
sg52644
VDVL2
p69414
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69415
g52643
I43
sg52644
g69403
sg52646
I4
sg52674
VP19532
p69416
sg52649
I1
sasg52640
(lp69417
(dp69418
g52643
I48
sg52644
Vgene fusion
p69419
sg52646
I11
sg52647
VC1705736
p69420
sg52649
I2
sa(dp69421
g52643
I100
sg52644
VPEComa
p69422
sg52646
I6
sg52647
VC1300127
p69423
sg52649
I1
sa(dp69424
g52643
I48
sg52644
Vgene fusion
p69425
sg52646
I11
sg52647
VC1705736
p69426
sg52649
I2
sa(dp69427
g52643
I27
sg52644
g69404
sg52646
I3
sg52647
VC0007134
p69428
sg52649
I1
sasa(dp69429
g135
(dp69430
(VTFE3
p69431
VRCCs
p69432
tp69433
I00
ssg52636
VFurthermore, among neoplasms with the SFPQ-TFE3, NONO-TFE3, DVL2-TFE3, and ASPL-TFE3 gene fusions, the RCCs are almost always PAX8 positive, cathepsin K negative by immunohistochemistry, whereas the mesenchymal counterparts (Xp11 translocation PEComas, melanotic Xp11 translocation renal cancers, and alveolar soft part sarcoma) are PAX8 negative, cathepsin K positive.
p69434
sg52638
(lp69435
(dp69436
g52643
I225
sg52644
VXp11 translocation PEComas
p69437
sg52646
I26
sg52674
g12
sg52649
I3
sa(dp69438
g52643
I49
sg52644
VNONO
p69439
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69440
g52643
I38
sg52644
VSFPQ
p69441
sg52646
I4
sg52674
VP23246
p69442
sg52649
I1
sa(dp69443
g52643
I43
sg52644
VTFE3
p69444
sg52646
I4
sg52674
VP19532
p69445
sg52649
I1
sa(dp69446
g52643
I126
sg52644
VPAX8
p69447
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69448
g52643
I43
sg52644
VTFE3
p69449
sg52646
I4
sg52674
VP19532
p69450
sg52649
I1
sa(dp69451
g52643
I141
sg52644
Vcathepsin K
p69452
sg52646
I11
sg52674
VP43235
p69453
sg52649
I2
sa(dp69454
g52643
I75
sg52644
VASPL
p69455
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69456
g52643
I253
sg52644
Vmelanotic Xp11 translocation renal cancers
p69457
sg52646
I42
sg52674
g12
sg52649
I5
sa(dp69458
g52643
I43
sg52644
VTFE3
p69459
sg52646
I4
sg52674
VP19532
p69460
sg52649
I1
sa(dp69461
g52643
I126
sg52644
VPAX8
p69462
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69463
g52643
I60
sg52644
VDVL2
p69464
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69465
g52643
I141
sg52644
Vcathepsin K
p69466
sg52646
I11
sg52674
VP43235
p69467
sg52649
I2
sa(dp69468
g52643
I43
sg52644
g69431
sg52646
I4
sg52674
VP19532
p69469
sg52649
I1
sasg52640
(lp69470
(dp69471
g52643
I244
sg52644
VPEComas
p69472
sg52646
I7
sg52647
VC1300127
p69473
sg52649
I1
sa(dp69474
g52643
I19
sg52644
Vneoplasms
p69475
sg52646
I9
sg52647
VC0027651
p69476
sg52649
I1
sa(dp69477
g52643
I230
sg52644
Vtranslocation
p69478
sg52646
I13
sg52647
VC0040715
p69479
sg52649
I1
sa(dp69480
g52643
I230
sg52644
Vtranslocation
p69481
sg52646
I13
sg52647
VC0040715
p69482
sg52649
I1
sa(dp69483
g52643
I282
sg52644
Vrenal cancers
p69484
sg52646
I13
sg52647
VC0740457
p69485
sg52649
I2
sa(dp69486
g52643
I301
sg52644
Valveolar soft part sarcoma
p69487
sg52646
I26
sg52647
VC0206657
p69488
sg52649
I4
sa(dp69489
g52643
I103
sg52644
g69432
sg52646
I4
sg52647
VC0007134
p69490
sg52649
I1
sasa(dp69491
g52636
VThe compound was further tested in vitro for acetylation of histone H4 and other non-histone proteins, and in vivo in a colon carcinoma model, showing significant proapoptotic and antitumor activities.
p69492
sg52638
(lp69493
(dp69494
g52643
I81
sg52644
Vnon-histone proteins
p69495
sg52646
I20
sg52674
VP62805
p69496
sg52649
I2
sa(dp69497
g52643
I60
sg52644
Vhistone H4
p69498
sg52646
I10
sg52674
VP62805
p69499
sg52649
I2
sasg52640
(lp69500
(dp69501
g52643
I120
sg52644
Vcolon carcinoma
p69502
sg52646
I15
sg52647
VC0699790
p69503
sg52649
I2
sasa(dp69504
g135
(dp69505
(Vcytochrome C
p69506
Vcolon carcinoma
p69507
tp69508
I00
ssg52636
VAs a proof-of-principle, we have identified cytochrome C and Histone H4 as two of the predominant protein species in the 3D colon carcinoma cultures.
p69509
sg52638
(lp69510
(dp69511
g52643
I44
sg52644
g69506
sg52646
I12
sg52674
VP99999
p69512
sg52649
I2
sa(dp69513
g52643
I61
sg52644
VHistone H4
p69514
sg52646
I10
sg52674
VP62805
p69515
sg52649
I2
sasg52640
(lp69516
(dp69517
g52643
I124
sg52644
g69507
sg52646
I15
sg52647
VC0699790
p69518
sg52649
I2
sasa(dp69519
g52636
VDouble 2-mm core tissue microarrays were made from 261 paraffin-embedded gastric adenocarcinoma samples and examined by immunohistochemistry for histone H3 lysine 9 (H3K9) acetylation and trimethylation, histone H4 lysine 16 acetylation, and histone H4 lysine 20 trimethylation.
p69520
sg52638
(lp69521
(dp69522
g52643
I145
sg52644
Vhistone H3 lysine 9
p69523
sg52646
I19
sg52674
g12
sg52649
I4
sa(dp69524
g52643
I204
sg52644
Vhistone H4
p69525
sg52646
I10
sg52674
VP62805
p69526
sg52649
I2
sa(dp69527
g52643
I204
sg52644
Vhistone H4 lysine 16
p69528
sg52646
I20
sg52674
VP62805
p69529
sg52649
I4
sasg52640
(lp69530
(dp69531
g52643
I73
sg52644
Vgastric adenocarcinoma
p69532
sg52646
I22
sg52647
VC0278701
p69533
sg52649
I2
sasa(dp69534
g52636
VThis study aimed to investigate the expression of NOR1 in hepatocellular carcinoma (HCC) tissue and its relationship with prognosis.
p69535
sg52638
(lp69536
(dp69537
g52643
I50
sg52644
VNOR1
p69538
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp69539
(dp69540
g52643
I84
sg52644
VHCC
p69541
sg52646
I3
sg52647
VC2239176
p69542
sg52649
I1
sa(dp69543
g52643
I58
sg52644
Vhepatocellular carcinoma
p69544
sg52646
I24
sg52647
VC2239176
p69545
sg52649
I2
sasa(dp69546
g52636
VOxidored-nitro domain-containing protein 1 (NOR1) expression levels are greater in hepatitis, cirrhosis and hepatocellular carcinoma samples compared with from normal liver samples.
p69547
sg52638
(lp69548
(dp69549
g52643
I44
sg52644
VNOR1
p69550
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69551
g52643
I0
sg52644
VOxidored-nitro domain-containing protein 1
p69552
sg52646
I42
sg52674
g12
sg52649
I4
sasg52640
(lp69553
(dp69554
g52643
I94
sg52644
Vcirrhosis
p69555
sg52646
I9
sg52647
VC0023890
p69556
sg52649
I1
sa(dp69557
g52643
I108
sg52644
Vhepatocellular carcinoma
p69558
sg52646
I24
sg52647
VC1512411
p69559
sg52649
I2
sa(dp69560
g52643
I83
sg52644
Vhepatitis
p69561
sg52646
I9
sg52647
VC0019159
p69562
sg52649
I1
sasa(dp69563
g52636
VIn conclusion, these results indicate that NOR1 may be involved in the progression of HCC and thus may be a potential target for the treatment of liver cancer.
p69564
sg52638
(lp69565
(dp69566
g52643
I43
sg52644
VNOR1
p69567
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp69568
(dp69569
g52643
I86
sg52644
VHCC
p69570
sg52646
I3
sg52647
VC2239176
p69571
sg52649
I1
sa(dp69572
g52643
I146
sg52644
Vliver cancer
p69573
sg52646
I12
sg52647
VC0345904
p69574
sg52649
I2
sasa(dp69575
g52636
VTo date, several studies have revealed that gene mutations of the transporters are likely to be associated with some diseases; however, there are no data concerning the genetic polymorphism of the hOSCP1 gene in Japanese patients with non-viral liver carcinoma (LC).
p69576
sg52638
(lp69577
(dp69578
g52643
I197
sg52644
VhOSCP1 gene
p69579
sg52646
I11
sg52674
g12
sg52649
I2
sasg52640
(lp69580
(dp69581
g52643
I245
sg52644
Vliver carcinoma
p69582
sg52646
I15
sg52647
VC2239176
p69583
sg52649
I2
sa(dp69584
g52643
I262
sg52644
VLC
p69585
sg52646
I2
sg52647
VC2239176
p69586
sg52649
I1
sasa(dp69587
g135
(dp69588
(Vnitroreductase oxidored-nitro domain containing protein 1
p69589
Vnasopharyngeal carcinoma
p69590
tp69591
I00
ssg52636
VThe nitroreductase oxidored-nitro domain containing protein 1 (NOR1) gene may be involved in the chemical carcinogenesis of hepatic cancer and nasopharyngeal carcinoma (NPC).
p69592
sg52638
(lp69593
(dp69594
g52643
I63
sg52644
VNOR1
p69595
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69596
g52643
I4
sg52644
g69589
sg52646
I57
sg52674
VP14222
p69597
sg52649
I6
sasg52640
(lp69598
(dp69599
g52643
I124
sg52644
Vhepatic cancer
p69600
sg52646
I14
sg52647
VC0345904
p69601
sg52649
I2
sa(dp69602
g52643
I97
sg52644
Vchemical carcinogenesis
p69603
sg52646
I23
sg52647
VC0596321
p69604
sg52649
I2
sa(dp69605
g52643
I169
sg52644
VNPC
p69606
sg52646
I3
sg52647
VC2931822
p69607
sg52649
I1
sa(dp69608
g52643
I143
sg52644
g69590
sg52646
I24
sg52647
VC2931822
p69609
sg52649
I2
sasa(dp69610
g135
(dp69611
(Vgrowth factor receptor-bound protein 2
p69612
Vhepatocellular carcinoma
p69613
tp69614
I00
ssg52636
VUsing cDNA microarrays and quantitative real-time PCR, we previously discovered that NOR1 increases the expression of growth factor receptor-bound protein 2 (Grb2) mRNA by 4.8-fold in the human hepatocellular carcinoma cell line HepG2.
p69615
sg52638
(lp69616
(dp69617
g52643
I158
sg52644
VGrb2
p69618
sg52646
I4
sg52674
VP62993
p69619
sg52649
I1
sa(dp69620
g52643
I85
sg52644
VNOR1
p69621
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69622
g52643
I118
sg52644
g69612
sg52646
I38
sg52674
VP62993
p69623
sg52649
I5
sasg52640
(lp69624
(dp69625
g52643
I194
sg52644
g69613
sg52646
I24
sg52647
VC1512411
p69626
sg52649
I2
sasa(dp69627
g52636
VIn addition, expression of human NOR1 protein in different normal and cancerous human tissues was analyzed via search of the human RNA and protein databases; the data showed that although most malignant cells weakly stained or were negative for NOR1 expression, the liver cancer cells displayed moderate to strong expression of NOR1.
p69628
sg52638
(lp69629
(dp69630
g52643
I33
sg52644
VNOR1
p69631
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69632
g52643
I27
sg52644
Vhuman NOR1 protein
p69633
sg52646
I18
sg52674
g12
sg52649
I3
sa(dp69634
g52643
I33
sg52644
VNOR1
p69635
sg52646
I4
sg52674
g12
sg52649
I1
sasg52640
(lp69636
(dp69637
g52643
I266
sg52644
Vliver cancer
p69638
sg52646
I12
sg52647
VC0345904
p69639
sg52649
I2
sasa(dp69640
g52636
VThese data suggested that NOR1 might serve as a cancer/testis/brain antigen in cells, and that altered NOR1 expression in liver cancer may help us to elucidate the functions of NOR1 protein in liver carcinogenesis.
p69641
sg52638
(lp69642
(dp69643
g52643
I26
sg52644
VNOR1
p69644
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69645
g52643
I26
sg52644
VNOR1
p69646
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69647
g52643
I177
sg52644
VNOR1 protein
p69648
sg52646
I12
sg52674
g12
sg52649
I2
sasg52640
(lp69649
(dp69650
g52643
I48
sg52644
Vcancer
p69651
sg52646
I6
sg52647
VC0006826
p69652
sg52649
I1
sa(dp69653
g52643
I122
sg52644
Vliver cancer
p69654
sg52646
I12
sg52647
VC0345904
p69655
sg52649
I2
sa(dp69656
g52643
I193
sg52644
Vliver carcinogenesis
p69657
sg52646
I20
sg52647
VC1512409
p69658
sg52649
I2
sasa(dp69659
g52636
VSignificant allelic associations with SLE were detected in European Americans (EA) and African Americans (AA), which could be attributed to an intronic CFH SNP (rs6677604, in intron 11, P(meta) = 6.6x10(-8), OR = 1.18) and an intergenic SNP between CFHR1 and CFHR4 (rs16840639, P(meta) = 2.9x10(-7), OR = 1.17) rather than to previously identified disease-associated CFH exonic SNPs, including I62V, Y402H, A474A, and D936E.
p69660
sg52638
(lp69661
(dp69662
g52643
I152
sg52644
VCFH SNP
p69663
sg52646
I7
sg52674
g12
sg52649
I2
sa(dp69664
g52643
I249
sg52644
VCFHR1
p69665
sg52646
I5
sg52674
g12
sg52649
I1
sa(dp69666
g52643
I259
sg52644
VCFHR4
p69667
sg52646
I5
sg52674
g12
sg52649
I1
sasg52640
(lp69668
(dp69669
g52643
I38
sg52644
VSLE
p69670
sg52646
I3
sg52647
VC0014060
p69671
sg52649
I1
sasa(dp69672
g52636
VGastroschisis and omphalocele are the most common fetal abdominal wall defects (AWDs).
p69673
sg52638
(lp69674
sg52640
(lp69675
(dp69676
g52643
I0
sg52644
VGastroschisis
p69677
sg52646
I13
sg52647
VC0265706
p69678
sg52649
I1
sa(dp69679
g52643
I18
sg52644
Vomphalocele
p69680
sg52646
I11
sg52647
VC0795690
p69681
sg52649
I1
sasa(dp69682
g52636
VAWDs were identified through gastroschisis and omphalocele checkboxes from publicly available US Natality data (2006 to 2010).
p69683
sg52638
(lp69684
sg52640
(lp69685
(dp69686
g52643
I47
sg52644
Vomphalocele
p69687
sg52646
I11
sg52647
VC0795690
p69688
sg52649
I1
sa(dp69689
g52643
I29
sg52644
Vgastroschisis
p69690
sg52646
I13
sg52647
VC0265706
p69691
sg52649
I1
sasa(dp69692
g135
(dp69693
(Vprokineticin1 (PROK1) proteins
p69694
Vcolorectal cancer
p69695
tp69696
I00
ssg52636
VThe angiogenic proteins vascular endothelial growth factor (VEGF) and prokineticin1 (PROK1) proteins are considered important in colorectal cancer, the relationship between their simultaneous expression and prognosis was investigated in the present study.
p69697
sg52638
(lp69698
(dp69699
g52643
I60
sg52644
VVEGF
p69700
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69701
g52643
I24
sg52644
Vvascular endothelial growth factor
p69702
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp69703
g52643
I70
sg52644
g69694
sg52646
I30
sg52674
VP58294
p69704
sg52649
I3
sasg52640
(lp69705
(dp69706
g52643
I129
sg52644
g69695
sg52646
I17
sg52647
VC1527249
p69707
sg52649
I2
sasa(dp69708
g135
(dp69709
(VPROK1
p69710
Vcolorectal cancer
p69711
tp69712
I00
ssg52636
VVEGF and PROK1 expression in 620 primary human colorectal cancer lesions was confirmed via immunohistochemical staining with anti-VEGF and anti-PROK1 antibodies, and the correlation between the expression of these 2 proteins and recurrence/prognosis were investigated.
p69713
sg52638
(lp69714
(dp69715
g52643
I139
sg52644
Vanti-PROK1 antibodies
p69716
sg52646
I21
sg52674
VP58294
p69717
sg52649
I2
sa(dp69718
g52643
I9
sg52644
g69710
sg52646
I5
sg52674
VP58294
p69719
sg52649
I1
sasg52640
(lp69720
(dp69721
g52643
I229
sg52644
Vrecurrence
p69722
sg52646
I10
sg52647
VC1458156
p69723
sg52649
I1
sa(dp69724
g52643
I47
sg52644
g69711
sg52646
I17
sg52647
VC1527249
p69725
sg52649
I2
sasa(dp69726
g135
(dp69727
(VPROK1
p69728
Vcolorectal cancers
p69729
tp69730
I00
ssg52636
VThe prognosis was poorer in colorectal cancers that expressed both PROK1 and VEGF relative to the cases that expressed only 1 protein, and the expression of both proteins was found to be an independent prognostic factor.
p69731
sg52638
(lp69732
(dp69733
g52643
I67
sg52644
g69728
sg52646
I5
sg52674
VP58294
p69734
sg52649
I1
sasg52640
(lp69735
(dp69736
g52643
I28
sg52644
g69729
sg52646
I18
sg52647
VC1527249
p69737
sg52649
I2
sasa(dp69738
g135
(dp69739
(VPROK1
p69740
Vmetastasis
p69741
tp69742
I01
ssg52636
VTwo angiogenic growth factors, in particular, Vascular endothelial growth factor (VEGF) and Prokineticin1(PROK1), are considered to have an important role in hematogenous metastasis of colorectal cancer.
p69743
sg52638
(lp69744
(dp69745
g52643
I4
sg52644
Vangiogenic growth factors
p69746
sg52646
I25
sg52674
VP19883
p69747
sg52649
I3
sa(dp69748
g52643
I82
sg52644
VVEGF
p69749
sg52646
I4
sg52674
g12
sg52649
I1
sa(dp69750
g52643
I46
sg52644
VVascular endothelial growth factor
p69751
sg52646
I34
sg52674
g12
sg52649
I4
sa(dp69752
g52643
I106
sg52644
g69740
sg52646
I5
sg52674
VP58294
p69753
sg52649
I1
sasg52640
(lp69754
(dp69755
g52643
I185
sg52644
Vcolorectal cancer
p69756
sg52646
I17
sg52647
VC1527249
p69757
sg52649
I2
sa(dp69758
g52643
I171
sg52644
g69741
sg52646
I10
sg52647
VC0027627
p69759
sg52649
I1
sasa(dp69760
g135
(dp69761
(VPROK1
p69762
Vcolorectal cancer
p69763
tp69764
I00
ssg52636
VAccordingly, we report our findings on the importance of the anti-tumor efffect by inhibiting these two factors in human colorectal cancer.When the culture fluid of Colorectal cancer cell lines(DLD-1, HCT116, and LoVo) with high levels of VEGF/PROK1 expression was injected subcutaneously into mice, the culture fluid increased subcutaneous angiogenesis.
p69765
sg52638
(lp69766
(dp69767
g52643
I194
sg52644
VDLD-1
p69768
sg52646
I5
sg52674
VP98173
p69769
sg52649
I1
sa(dp69770
g52643
I244
sg52644
g69762
sg52646
I5
sg52674
VP58294
p69771
sg52649
I1
sasg52640
(lp69772
(dp69773
g52643
I66
sg52644
Vtumor
p69774
sg52646
I5
sg52647
VC0027651
p69775
sg52649
I1
sa(dp69776
g52643
I165
sg52644
VColorectal cancer
p69777
sg52646
I17
sg52647
VC1527249
p69778
sg52649
I2
sa(dp69779
g52643
I121
sg52644
g69763
sg52646
I17
sg52647
VC1527249
p69780
sg52649
I2
sasa(dp69781
g135
(dp69782
(VPROK1
p69783
Vcolorectal cancer
p69784
tp69785
I00
ssg52636
VAlso, tumor masses were produced in mice by subcutaneously embedding colorectal cancer cells with high levels VEGF/PROK1 expression.
p69786
sg52638
(lp69787
(dp69788
g52643
I115
sg52644
g69783
sg52646
I5
sg52674
VP58294
p69789
sg52649
I1
sasg52640
(lp69790
(dp69791
g52643
I6
sg52644
Vtumor
p69792
sg52646
I5
sg52647
VC0027651
p69793
sg52649
I1
sa(dp69794
g52643
I69
sg52644
g69784
sg52646
I17
sg52647
VC1527249
p69795
sg52649
I2
sasa(dp69796
g135
(dp69797
(Vangiogenic growth factors
p69798
Vcolorectal cancer
p69799
tp69800
I00
ssg52636
VWhen both anti-PROK1 and anti-VEGF antibodies were simultaneously applied, tumor formation and peritumoral angiogenesis were strongly suppressed, compared with when either anti-PROK1 antibody or anti-VEGF antibody was applied alone.Simultaneous targeting of both angiogenic growth factors (VEGF/PROK1) may prove more useful in colorectal cancer.
p69801
sg52638
(lp69802
(dp69803
g52643
I15
sg52644
VPROK1
p69804
sg52646
I5
sg52674
VP58294
p69805
sg52649
I1
sa(dp69806
g52643
I172
sg52644
Vanti-PROK1 antibody
p69807
sg52646
I19
sg52674
VP58294
p69808
sg52649
I2
sa(dp69809
g52643
I10
sg52644
Vanti-PROK1
p69810
sg52646
I10
sg52674
VP58294
p69811
sg52649
I1
sa(dp69812
g52643
I263
sg52644
g69798
sg52646
I25
sg52674
VP19883
p69813
sg52649
I3
sasg52640
(lp69814
(dp69815
g52643
I327
sg52644
g69799
sg52646
I17
sg52647
VC1527249
p69816
sg52649
I2
sa(dp69817
g52643
I75
sg52644
Vtumor
p69818
sg52646
I5
sg52647
VC0027651
p69819
sg52649
I1
sasa(dp69820
g135
(dp69821
(VPROK1 protein
p69822
Vcolorectal cancer
p69823
tp69824
I00
ssg52636
VThe current study established the anti-PROK1 monoclonal antibody (mAb) and examined the relationship between the expression of PROK1 protein and human colorectal cancer.
p69825
sg52638
(lp69826
(dp69827
g52643
I34
sg52644
Vanti-PROK1 monoclonal antibody
p69828
sg52646
I30
sg52674
VP58294
p69829
sg52649
I3
sa(dp69830
g52643
I127
sg52644
g69822
sg52646
I13
sg52674
VP58294
p69831
sg52649
I2
sasg52640
(lp69832
(dp69833
g52643
I151
sg52644
g69823
sg52646
I17
sg52647
VC1527249
p69834
sg52649
I2
sasa(dp69835
g135
(dp69836
(Vhuman PROK1 mAb
p69837
Vcolorectal cancer
p69838
tp69839
I00
ssg52636
VThe expression of PROK1 protein was assessed in 620 resected sporadic colorectal cancer tissue samples by immunohistochemical staining with in-house-developed human PROK1 mAb to investigate the relationship of PROK1 expression to clinicopathologic factors, recurrence, and survival rate and to evaluate its prognostic significance.
p69840
sg52638
(lp69841
(dp69842
g52643
I18
sg52644
VPROK1 protein
p69843
sg52646
I13
sg52674
VP58294
p69844
sg52649
I2
sa(dp69845
g52643
I18
sg52644
VPROK1
p69846
sg52646
I5
sg52674
VP58294
p69847
sg52649
I1
sa(dp69848
g52643
I159
sg52644
g69837
sg52646
I15
sg52674
VP58294
p69849
sg52649
I3
sasg52640
(lp69850
(dp69851
g52643
I70
sg52644
g69838
sg52646
I17
sg52647
VC1527249
p69852
sg52649
I2
sa(dp69853
g52643
I257
sg52644
Vrecurrence
p69854
sg52646
I10
sg52647
VC1458156
p69855
sg52649
I1
sasa(dp69856
g135
(dp69857
(VPROK1 protein
p69858
Vcolorectal cancer
p69859
tp69860
I00
ssg52636
VThe expression of PROK1 protein was detected in 36 % (223/620) of human primary colorectal cancer lesions but no in the healthy mucosa adjacent to the colorectal cancer lesions.
p69861
sg52638
(lp69862
(dp69863
g52643
I18
sg52644
g69858
sg52646
I13
sg52674
VP58294
p69864
sg52649
I2
sasg52640
(lp69865
(dp69866
g52643
I80
sg52644
Vcolorectal cancer
p69867
sg52646
I17
sg52647
VC1527249
p69868
sg52649
I2
sa(dp69869
g52643
I80
sg52644
g69859
sg52646
I17
sg52647
VC1527249
p69870
sg52649
I2
sasa(dp69871
g135
(dp69872
(VPROK1 protein
p69873
Vcolorectal cancer
p69874
tp69875
I00
ssg52636
VThe expression of PROK1 protein was identified for the first time as a new prognostic factor in colorectal cancer.
p69876
sg52638
(lp69877
(dp69878
g52643
I18
sg52644
g69873
sg52646
I13
sg52674
VP58294
p69879
sg52649
I2
sasg52640
(lp69880
(dp69881
g52643
I96
sg52644
g69874
sg52646
I17
sg52647
VC1527249
p69882
sg52649
I2
sasa(dp69883
g135
(dp69884
(VPROK1
p69885
Vcolorectal cancer
p69886
tp69887
I00
ssg52636
VHere we investigated how the anti-PROK1 monoclonal antibody (mAb; established by our department) would affect the high-PROK1-expressing colorectal cancer (CRC) cells in vitro and vivo.
p69888
sg52638
(lp69889
(dp69890
g52643
I29
sg52644
Vanti-PROK1 monoclonal antibody
p69891
sg52646
I30
sg52674
VP58294
p69892
sg52649
I3
sa(dp69893
g52643
I34
sg52644
g69885
sg52646
I5
sg52674
VP58294
p69894
sg52649
I1
sasg52640
(lp69895
(dp69896
g52643
I155
sg52644
VCRC
p69897
sg52646
I3
sg52647
VC1527249
p69898
sg52649
I1
sa(dp69899
g52643
I136
sg52644
g69886
sg52646
I17
sg52647
VC1527249
p69900
sg52649
I2
sasa(dp69901
g135
(dp69902
(VPROK1
p69903
Vgastric cancer
p69904
tp69905
I00
ssg52636
VPROK1 expression was not observed in healthy gastrointestinal mucosa, but was observed in the primary lesions in 23 out of 98 (31.6%) patients with colorectal cancer, 19 out of 55 (34.5%) patients with gastric cancer, and 5 of 10 (50%) patients with cancer of the small intestine.
p69906
sg52638
(lp69907
(dp69908
g52643
I0
sg52644
g69903
sg52646
I5
sg52674
VP58294
p69909
sg52649
I1
sasg52640
(lp69910
(dp69911
g52643
I148
sg52644
Vcolorectal cancer
p69912
sg52646
I17
sg52647
VC1527249
p69913
sg52649
I2
sa(dp69914
g52643
I202
sg52644
g69904
sg52646
I14
sg52647
VC0024623
p69915
sg52649
I2
sa(dp69916
g52643
I159
sg52644
Vcancer
p69917
sg52646
I6
sg52647
VC0006826
p69918
sg52649
I1
sasa(dp69919
g135
(dp69920
(VEG-VEGF
p69921
Vcolon cancer
p69922
tp69923
I00
ssg52636
VEndocrine gland-derived vascular endothelial growth factor (EG-VEGF) has             recently been identified as one of the vascular endothelial growth factors, and             it is considered that the overexpression of EG-VEGF in colon cancer is related             to hepatic metastasis.
p69924
sg52638
(lp69925
(dp69926
g52643
I60
sg52644
VEG-VEGF
p69927
sg52646
I7
sg52674
VP58294
p69928
sg52649
I1
sa(dp69929
g52643
I124
sg52644
Vvascular endothelial growth factors
p69930
sg52646
I35
sg52674
VP19883
p69931
sg52649
I4
sa(dp69932
g52643
I0
sg52644
VEndocrine gland-derived vascular endothelial growth factor
p69933
sg52646
I58
sg52674
VP58294
p69934
sg52649
I6
sa(dp69935
g52643
I60
sg52644
g69921
sg52646
I7
sg52674
VP58294
p69936
sg52649
I1
sasg52640
(lp69937
(dp69938
g52643
I271
sg52644
Vhepatic metastasis
p69939
sg52646
I18
sg52647
VC0494165
p69940
sg52649
I2
sa(dp69941
g52643
I232
sg52644
g69922
sg52646
I12
sg52647
VC0699790
p69942
sg52649
I2
sasa(dp69943
g135
(dp69944
(VEG-VEGF
p69945
Vcolon cancer
p69946
tp69947
I00
ssg52636
VIn this study, we report our recent novel findings of the             involvement of EG-VEGF in cell invasion of colon cancer cells.
p69948
sg52638
(lp69949
(dp69950
g52643
I85
sg52644
g69945
sg52646
I7
sg52674
VP58294
p69951
sg52649
I1
sasg52640
(lp69952
(dp69953
g52643
I113
sg52644
g69946
sg52646
I12
sg52647
VC0699790
p69954
sg52649
I2
sa(dp69955
g52643
I96
sg52644
Vcell invasion
p69956
sg52646
I13
sg52647
VC2699153
p69957
sg52649
I2
sasa(dp69958
g135
(dp69959
(VEG-VEGF receptor
p69960
Vcolon cancer
p69961
tp69962
I00
ssg52636
VFinally, the EG-VEGF receptor on the colon cancer cell membrane             was blocked by anti-PK-R1 and -PK-R2 antibodies to study whether cell invasion             ability would be altered.
p69963
sg52638
(lp69964
(dp69965
g52643
I13
sg52644
g69960
sg52646
I16
sg52674
VP58294
p69966
sg52649
I2
sa(dp69967
g52643
I91
sg52644
Vanti-PK-R1 and -PK-R2 antibodies
p69968
sg52646
I32
sg52674
g12
sg52649
I4
sasg52640
(lp69969
(dp69970
g52643
I141
sg52644
Vcell invasion
p69971
sg52646
I13
sg52647
VC2699153
p69972
sg52649
I2
sa(dp69973
g52643
I37
sg52644
g69961
sg52646
I12
sg52647
VC0699790
p69974
sg52649
I2
sasa(dp69975
g135
(dp69976
(VEG-VEGF
p69977
Vcolon cancer
p69978
tp69979
I00
ssg52636
VIn colon cancer cell lines where the expression of PK-R1             and 2 was confirmed, stimulation with EG-VEGF increased cell invasion a maximum             of ~3-5 times.
p69980
sg52638
(lp69981
(dp69982
g52643
I107
sg52644
g69977
sg52646
I7
sg52674
VP58294
p69983
sg52649
I1
sasg52640
(lp69984
(dp69985
g52643
I3
sg52644
g69978
sg52646
I12
sg52647
VC0699790
p69986
sg52649
I2
sa(dp69987
g52643
I125
sg52644
Vcell invasion
p69988
sg52646
I13
sg52647
VC2699153
p69989
sg52649
I2
sasa(dp69990
g135
(dp69991
(VMMP-2, -7
p69992
Vcolon cancer
p69993
tp69994
I00
ssg52636
VThe study showed that the EG-VEGF             protein may act on MMP-2, -7 and -9 via PK-R2 to strengthen cell invasion ability             in colon cancer cell lines.
p69995
sg52638
(lp69996
(dp69997
g52643
I26
sg52644
VEG-VEGF
p69998
sg52646
I7
sg52674
VP58294
p69999
sg52649
I1
sa(dp70000
g52643
I65
sg52644
g69992
sg52646
I9
sg52674
VP08253
p70001
sg52649
I2
sasg52640
(lp70002
(dp70003
g52643
I143
sg52644
g69993
sg52646
I12
sg52647
VC0699790
p70004
sg52649
I2
sa(dp70005
g52643
I106
sg52644
Vcell invasion
p70006
sg52646
I13
sg52647
VC2699153
p70007
sg52649
I2
sasa(dp70008
g135
(dp70009
(VEG-VEGF
p70010
Vhepatocellular carcinoma
p70011
tp70012
I00
ssg52636
VTo study the implication of prokineticin 1 (PK1/EG-VEGF) and prokineticin 2 (PK2/Bv8) in hepatocellular carcinoma angiogenesis.
p70013
sg52638
(lp70014
(dp70015
g52643
I28
sg52644
Vprokineticin 1
p70016
sg52646
I14
sg52674
VP58294
p70017
sg52649
I2
sa(dp70018
g52643
I77
sg52644
VPK2
p70019
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp70020
g52643
I81
sg52644
VBv8
p70021
sg52646
I3
sg52674
g12
sg52649
I1
sa(dp70022
g52643
I61
sg52644
Vprokineticin 2
p70023
sg52646
I14
sg52674
g12
sg52649
I2
sa(dp70024
g52643
I44
sg52644
VPK1
p70025
sg52646
I3
sg52674
VP58294
p70026
sg52649
I1
sa(dp70027
g52643
I48
sg52644
g70010
sg52646
I7
sg52674
VP58294
p70028
sg52649
I1
sasg52640
(lp70029
(dp70030
g52643
I89
sg52644
g70011
sg52646
I24
sg52647
VC1512411
p70031
sg52649
I2
sasa(dp70032
g135
(dp70033
(VEG-VEGF
p70034
Vcolorectal cancer
p70035
tp70036
I00
ssS'line'
p70037
VIn this study, we investigated the expression of EG-VEGF in colorectal cancer, the relationship between its expression and clinicopathological factors, and the in vitro activity of EG-VEGF transfectants.
p70038
sS'genes'
p70039
(lp70040
(dp70041
S'index'
p70042
I49
sS'name'
p70043
VEG-VEGF
p70044
sS'lengthInChars'
p70045
I7
sS'uniprot'
p70046
VP58294
p70047
sS'lengthInWords'
p70048
I1
sa(dp70049
g70042
I49
sg70043
g70034
sg70045
I7
sg70046
VP58294
p70050
sg70048
I1
sasS'diseases'
p70051
(lp70052
(dp70053
g70042
I60
sg70043
g70035
sg70045
I17
sS'cui'
p70054
VC1527249
p70055
sg70048
I2
sasa(dp70056
g135
(dp70057
(VEG-VEGF
p70058
Vcolorectal cancers
p70059
tp70060
I00
ssg70037
VWe determined expression levels of EG-VEGF in 113 advanced colorectal cancers resected in our hospital by quantitative PCR, and compared the expression levels and clinicopathological findings by multivariate analyses.
p70061
sg70039
(lp70062
(dp70063
g70042
I35
sg70043
g70058
sg70045
I7
sg70046
VP58294
p70064
sg70048
I1
sasg70051
(lp70065
(dp70066
g70042
I59
sg70043
g70059
sg70045
I18
sg70054
VC1527249
p70067
sg70048
I2
sasa(dp70068
g135
(dp70069
(VEG-VEGF gene
p70070
Vcolorectal cancers
p70071
tp70072
I00
ssg70037
VWe speculate that, in colorectal cancers, the EG-VEGF gene functions as an important factor in angiogenesis in primary and metastatic lesions, and consider that it is useful as a novel prognostic factor.
p70073
sg70039
(lp70074
(dp70075
g70042
I46
sg70043
g70070
sg70045
I12
sg70046
VP58294
p70076
sg70048
I2
sasg70051
(lp70077
(dp70078
g70042
I22
sg70043
g70071
sg70045
I18
sg70054
VC1527249
p70079
sg70048
I2
sasa(dp70080
g135
(dp70081
(Vendocrine gland-derived vascular endothelial growth factor
p70082
Vhepatocellular carcinoma
p70083
tp70084
I00
ssg70037
VThe aim of the present study was to detect the correlation between the expression of vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2), ephrinB2 and endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and carcinogenesis or portal vein tumor thrombus (PVTT) formation in human hepatocellular carcinoma (HCC).
p70085
sg70039
(lp70086
(dp70087
g70042
I128
sg70043
Vangiopoietin 2
p70088
sg70045
I14
sg70046
g12
sg70048
I2
sa(dp70089
g70042
I85
sg70043
Vvascular endothelial growth factor
p70090
sg70045
I34
sg70046
g12
sg70048
I4
sa(dp70091
g70042
I151
sg70043
VephrinB2
p70092
sg70045
I8
sg70046
VP52799
p70093
sg70048
I1
sa(dp70094
g70042
I224
sg70043
VEG-VEGF
p70095
sg70045
I7
sg70046
VP58294
p70096
sg70048
I1
sa(dp70097
g70042
I164
sg70043
g70082
sg70045
I58
sg70046
VP58294
p70098
sg70048
I6
sa(dp70099
g70042
I144
sg70043
VAng2
p70100
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp70101
g70042
I121
sg70043
VVEGF
p70102
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp70103
(dp70104
g70042
I334
sg70043
VHCC
p70105
sg70045
I3
sg70054
VC2239176
p70106
sg70048
I1
sa(dp70107
g70042
I237
sg70043
Vcarcinogenesis
p70108
sg70045
I14
sg70054
VC0596263
p70109
sg70048
I1
sa(dp70110
g70042
I267
sg70043
Vtumor thrombus
p70111
sg70045
I14
sg70054
VC3163918
p70112
sg70048
I2
sa(dp70113
g70042
I308
sg70043
g70083
sg70045
I24
sg70054
VC2239176
p70114
sg70048
I2
sasa(dp70115
g70037
VA recent genome-wide association study (GWA) reported a significant association between single nucleotide polymorphisms (SNPs) at the PCDH11X gene and late-onset Alzheimer's disease (LOAD).
p70116
sg70039
(lp70117
sg70051
(lp70118
(dp70119
g70042
I162
sg70043
VAlzheimer's disease
p70120
sg70045
I19
sg70054
VC1521724
p70121
sg70048
I2
sasa(dp70122
g70037
VProtocadherin 11X (Pcdh11X) has been suspected to be associated with Alzheimer's disease through participating in the metabolism of PP1Alfa and Beta-catenin or by altering the synaptic functions.
p70123
sg70039
(lp70124
(dp70125
g70042
I144
sg70043
VBeta-catenin
p70126
sg70045
I12
sg70046
VP35222
p70127
sg70048
I1
sa(dp70128
g70042
I0
sg70043
VProtocadherin 11X
p70129
sg70045
I17
sg70046
g12
sg70048
I2
sa(dp70130
g70042
I19
sg70043
VPcdh11X
p70131
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp70132
(dp70133
g70042
I69
sg70043
VAlzheimer's disease
p70134
sg70045
I19
sg70054
VC1521724
p70135
sg70048
I2
sasa(dp70136
g70037
VA recent genome-wide association study reported that a common single nucleotide polymorphism (SNP, rs5984894) in the gene encoding Pcdh11X was associated with susceptibility to late-onset Alzheimer's disease (LOAD) in Caucasians.
p70137
sg70039
(lp70138
sg70051
(lp70139
(dp70140
g70042
I188
sg70043
VAlzheimer's disease
p70141
sg70045
I19
sg70054
VC1521724
p70142
sg70048
I2
sasa(dp70143
g70037
VA recent genome-wide study on late-onset Alzheimer's disease identified a SNP (rs5984894) on Xq21.3 in the PCDH11X gene strongly associated with LOAD individuals of European descent from the United States.
p70144
sg70039
(lp70145
sg70051
(lp70146
(dp70147
g70042
I41
sg70043
VAlzheimer's disease
p70148
sg70045
I19
sg70054
VC1521724
p70149
sg70048
I2
sasa(dp70150
g70037
VBy analyzing late-onset Alzheimer's disease (LOAD) in a genome-wide association study (313,504 SNPs, three series, 844 cases and 1,255 controls) and evaluating the 25 SNPs with the most significant allelic association in four additional series (1,547 cases and 1,209 controls), we identified a SNP (rs5984894) on Xq21.3 in PCDH11X that is strongly associated with LOAD in individuals of European descent from the United States.
p70151
sg70039
(lp70152
sg70051
(lp70153
(dp70154
g70042
I45
sg70043
VLOAD
p70155
sg70045
I4
sg70054
VC1521724
p70156
sg70048
I1
sa(dp70157
g70042
I13
sg70043
Vlate-onset Alzheimer's disease
p70158
sg70045
I30
sg70054
VC1521724
p70159
sg70048
I3
sa(dp70160
g70042
I45
sg70043
VLOAD
p70161
sg70045
I4
sg70054
VC1521724
p70162
sg70048
I1
sasa(dp70163
g70037
VIn this study, we investigated the effect of Bim-1 siRNA on cell proliferation, cell cycle, cell apoptosis and migration of human esophageal carcinoma EC9706 cells, and explored its potential mechanisms.
p70164
sg70039
(lp70165
sg70051
(lp70166
(dp70167
g70042
I65
sg70043
Vproliferation
p70168
sg70045
I13
sg70054
VC0334094
p70169
sg70048
I1
sa(dp70170
g70042
I130
sg70043
Vesophageal carcinoma
p70171
sg70045
I20
sg70054
VC0152018
p70172
sg70048
I2
sasa(dp70173
g70037
VIn the present study, 4-mm samples of BIM (n=31) and CIM (n=9) were selected from esophagectomy specimens that had been resected for esophageal cancer.
p70174
sg70039
(lp70175
(dp70176
g70042
I53
sg70043
VCIM
p70177
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp70178
(dp70179
g70042
I133
sg70043
Vesophageal cancer
p70180
sg70045
I17
sg70054
VC0014859
p70181
sg70048
I2
sasa(dp70182
g135
(dp70183
(Vcaspase 3
p70184
Vmyeloid leukemia
p70185
tp70186
I01
ssg70037
VMechanistically, HCMV upregulated two specific cellular antiapoptotic proteins, myeloid leukemia sequence 1 (Mcl-1) and heat shock protein 27 (HSP27), to block the two proteolytic cleavages necessary for the formation of fully active caspase 3 and the subsequent initiation of apoptosis.
p70187
sg70039
(lp70188
(dp70189
g70042
I120
sg70043
Vheat shock protein 27
p70190
sg70045
I21
sg70046
VP34931
p70191
sg70048
I4
sa(dp70192
g70042
I109
sg70043
VMcl-1
p70193
sg70045
I5
sg70046
VP07954
p70194
sg70048
I1
sa(dp70195
g70042
I234
sg70043
g70184
sg70045
I9
sg70046
VP42574
p70196
sg70048
I2
sa(dp70197
g70042
I143
sg70043
VHSP27
p70198
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70199
(dp70200
g70042
I109
sg70043
VMcl
p70201
sg70045
I3
sg70054
VC1708350
p70202
sg70048
I1
sa(dp70203
g70042
I80
sg70043
g70185
sg70045
I16
sg70054
VC0023470
p70204
sg70048
I2
sasa(dp70205
g135
(dp70206
(VHeat shock protein 27
p70207
Vleukemia
p70208
tp70209
I01
ssg70037
VHeat shock protein 27 (HSP27) has been reported to promote the development of leukemia by protecting tumor cells from apoptosis through various mechanisms.
p70210
sg70039
(lp70211
(dp70212
g70042
I0
sg70043
g70207
sg70045
I21
sg70046
VP34931
p70213
sg70048
I4
sa(dp70214
g70042
I23
sg70043
VHSP27
p70215
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70216
(dp70217
g70042
I101
sg70043
Vtumor
p70218
sg70045
I5
sg70054
VC0027651
p70219
sg70048
I1
sa(dp70220
g70042
I78
sg70043
g70208
sg70045
I8
sg70054
VC0023418
p70221
sg70048
I1
sasa(dp70222
g70037
VThe present study investigated the effects of small hairpin (sh)RNA-mediated HSP27 knockdown on the anti-cancer effects of quercetin in U937 human leukemia cells.
p70223
sg70039
(lp70224
(dp70225
g70042
I77
sg70043
VHSP27
p70226
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70227
(dp70228
g70042
I105
sg70043
Vcancer
p70229
sg70045
I6
sg70054
VC0006826
p70230
sg70048
I1
sa(dp70231
g70042
I147
sg70043
Vleukemia
p70232
sg70045
I8
sg70054
VC0023418
p70233
sg70048
I1
sasa(dp70234
g70037
VTherefore, these findings collectively suggested that suppression of HSP27 expression amplified the anti-cancer effects of quercetin in U937 human leukemia cells, and that quercetin in combination with shHSP27 represents a promising therapeutic strategy for human leukemia.
p70235
sg70039
(lp70236
(dp70237
g70042
I69
sg70043
VHSP27
p70238
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70239
(dp70240
g70042
I105
sg70043
Vcancer
p70241
sg70045
I6
sg70054
VC0006826
p70242
sg70048
I1
sa(dp70243
g70042
I147
sg70043
Vleukemia
p70244
sg70045
I8
sg70054
VC0023418
p70245
sg70048
I1
sa(dp70246
g70042
I54
sg70043
Vsuppression
p70247
sg70045
I11
sg70054
VC0221103
p70248
sg70048
I1
sa(dp70249
g70042
I147
sg70043
Vleukemia
p70250
sg70045
I8
sg70054
VC0023418
p70251
sg70048
I1
sasa(dp70252
g135
(dp70253
(Vsorcin
p70254
Vmyelogenous leukemia
p70255
tp70256
I00
ssg70037
VAmong these proteins, enolase, aldolase, HSP70 and sorcin were up-regulated in doxorubicin-resistant myelogenous leukemia cell line, whereas HSP27 was down-regulated.
p70257
sg70039
(lp70258
(dp70259
g70042
I22
sg70043
Venolase
p70260
sg70045
I7
sg70046
VP13929
p70261
sg70048
I1
sa(dp70262
g70042
I31
sg70043
Valdolase
p70263
sg70045
I8
sg70046
VP05062
p70264
sg70048
I1
sa(dp70265
g70042
I41
sg70043
VHSP70
p70266
sg70045
I5
sg70046
VP34932
p70267
sg70048
I1
sa(dp70268
g70042
I141
sg70043
VHSP27
p70269
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70270
g70042
I51
sg70043
g70254
sg70045
I6
sg70046
VP30626
p70271
sg70048
I1
sasg70051
(lp70272
(dp70273
g70042
I101
sg70043
g70255
sg70045
I20
sg70054
VC0023470
p70274
sg70048
I2
sasa(dp70275
g70037
VHowever, the role of Hsp27 in the pathogenesis of pediatric acute             leukemia (AL) remains unknown.
p70276
sg70039
(lp70277
(dp70278
g70042
I21
sg70043
VHsp27
p70279
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70280
(dp70281
g70042
I78
sg70043
Vleukemia
p70282
sg70045
I8
sg70054
VC0023418
p70283
sg70048
I1
sa(dp70284
g70042
I34
sg70043
Vpathogenesis
p70285
sg70045
I12
sg70054
VC0699748
p70286
sg70048
I1
sasa(dp70287
g70037
VIn this study, we evaluated the expression levels             of Hsp27 in bone marrow samples from 94 children with newly diagnosed acute lymphoblastic             leukemia (ALL), acute myeloid leukemia (AML) and 5 leukemia cell lines.
p70288
sg70039
(lp70289
(dp70290
g70042
I65
sg70043
VHsp27
p70291
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70292
(dp70293
g70042
I164
sg70043
Vleukemia
p70294
sg70045
I8
sg70054
VC0023418
p70295
sg70048
I1
sa(dp70296
g70042
I164
sg70043
Vleukemia
p70297
sg70045
I8
sg70054
VC0023418
p70298
sg70048
I1
sa(dp70299
g70042
I180
sg70043
Vacute myeloid leukemia
p70300
sg70045
I22
sg70054
VC0023467
p70301
sg70048
I3
sa(dp70302
g70042
I204
sg70043
VAML
p70303
sg70045
I3
sg70054
VC0023467
p70304
sg70048
I1
sasa(dp70305
g70037
VAdditionally,             we transfected a target-specific siRNA duplex against Hsp27 into leukemia cells,             and examined the chemosensitivity and cell apoptosis in the response to antitumor             drugs.
p70306
sg70039
(lp70307
(dp70308
g70042
I80
sg70043
VHsp27
p70309
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70310
(dp70311
g70042
I91
sg70043
Vleukemia
p70312
sg70045
I8
sg70054
VC0023418
p70313
sg70048
I1
sasa(dp70314
g135
(dp70315
(VAML
p70316
VAML
p70317
tp70318
I00
ssg70037
VHsp27 was abundantly expressed in newly diagnosed AML-M4/M5 bone marrow             mononuclear cells (BMMCs) and THP-1, OCI/AML-3 leukemia cell lines.
p70319
sg70039
(lp70320
(dp70321
g70042
I50
sg70043
g70316
sg70045
I3
sg70046
VP41212
p70322
sg70048
I1
sa(dp70323
g70042
I0
sg70043
VHsp27
p70324
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70325
(dp70326
g70042
I131
sg70043
Vleukemia
p70327
sg70045
I8
sg70054
VC0023418
p70328
sg70048
I1
sa(dp70329
g70042
I50
sg70043
VAML
p70330
sg70045
I3
sg70054
VC0023467
p70331
sg70048
I1
sa(dp70332
g70042
I50
sg70043
g70317
sg70045
I3
sg70054
VC0023467
p70333
sg70048
I1
sasa(dp70334
g70037
VKnockdown of Hsp27 expression increased the chemosensitivity of             leukemia cells and the anticancer drug-induced apoptosis.
p70335
sg70039
(lp70336
(dp70337
g70042
I13
sg70043
VHsp27
p70338
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70339
(dp70340
g70042
I76
sg70043
Vleukemia
p70341
sg70045
I8
sg70054
VC0023418
p70342
sg70048
I1
sasa(dp70343
g70037
VTherefore, Hsp27 may be exploited as a new target for enhancing the             efficacy of chemotherapeutic drugs against leukemia.
p70344
sg70039
(lp70345
(dp70346
g70042
I11
sg70043
VHsp27
p70347
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70348
(dp70349
g70042
I123
sg70043
Vleukemia
p70350
sg70045
I8
sg70054
VC0023418
p70351
sg70048
I1
sasa(dp70352
g70037
VIt was: xS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M-G-D-N-F-S-K-D-E-V-R-Q-T-W-K-E-A-P-I-A-G-G-K-V-D-Y-N-A-F-V-S-K-I- K- G-K-E-Q-D-D-A.
p70353
sg70039
(lp70354
(dp70355
g70042
I8
sg70043
VxS-D-D-K-K-A-K-A-A-T-S-S-V-L-T-K-F-T-Q-N-Q-I-Q-E-M-K-E-A-F-T-M-I-D-Q-N-R -D-G-L- I-D-V-S-D-L-K-E-M-Y-S-N-L-G-T-A-P-Q-D-S-V-L-Q-A-M-V-K-E-A-P-Q-M-N-F-T-G- F-L-S-L- F-S-E-K-M-S-G-T-D-P-E-E-T-L-R-N-A-F-Q-M-F-D-S-D-N-T-G-Y-I-P-E-E-Y-M-K-D- L- L-E-N-M
p70356
sg70045
I246
sg70046
g12
sg70048
I7
sasg70051
(lp70357
sa(dp70358
g135
(dp70359
(VIntegrin alpha 8
p70360
Vneurodegenerative disease
p70361
tp70362
I00
ssg70037
VIntegrin alpha 8 (ITGA8) encodes the alpha 8 subunit of the integrin alpha8beta1 protein and has recently been suggested as a new candidate gene for Parkinson's disease, an age related neurodegenerative disease with unknown etiology.
p70363
sg70039
(lp70364
(dp70365
g70042
I18
sg70043
VITGA8
p70366
sg70045
I5
sg70046
VP53708
p70367
sg70048
I1
sa(dp70368
g70042
I0
sg70043
g70360
sg70045
I16
sg70046
VP53708
p70369
sg70048
I3
sasg70051
(lp70370
(dp70371
g70042
I149
sg70043
VParkinson's disease
p70372
sg70045
I19
sg70054
VC0030567
p70373
sg70048
I2
sa(dp70374
g70042
I185
sg70043
g70361
sg70045
I25
sg70054
VC0524851
p70375
sg70048
I2
sasa(dp70376
g135
(dp70377
(VITGA8
p70378
VParkinson's disease
p70379
tp70380
I00
ssg70037
VScreen a Swedish case control material for rs7077361, a genetic variant in ITGA8, in order to investigate its possible implication in Parkinson's disease in Sweden.
p70381
sg70039
(lp70382
(dp70383
g70042
I75
sg70043
g70378
sg70045
I5
sg70046
VP53708
p70384
sg70048
I1
sasg70051
(lp70385
(dp70386
g70042
I134
sg70043
g70379
sg70045
I19
sg70054
VC0030567
p70387
sg70048
I2
sasa(dp70388
g135
(dp70389
(VITGA8
p70390
VParkinson's disease
p70391
tp70392
I00
ssg70037
VOur results do not support the hypothesis of ITGA8 as a candidate gene for Parkinson's disease in Sweden.
p70393
sg70039
(lp70394
(dp70395
g70042
I45
sg70043
g70390
sg70045
I5
sg70046
VP53708
p70396
sg70048
I1
sasg70051
(lp70397
(dp70398
g70042
I75
sg70043
g70391
sg70045
I19
sg70054
VC0030567
p70399
sg70048
I2
sasa(dp70400
g135
(dp70401
(VBP2
p70402
VPWS
p70403
tp70404
I00
ssg70037
VCYFIP1 maps to the interval between proximal breakpoint 1 (BP1) and breakpoint 2 (BP2) of chromosomal 15q11-q13 deletions that are implicated in the Angelman (AS) and Prader-Willi syndrome (PWS).
p70405
sg70039
(lp70406
(dp70407
g70042
I82
sg70043
g70402
sg70045
I3
sg70046
VP18065
p70408
sg70048
I1
sa(dp70409
g70042
I45
sg70043
Vbreakpoint 1 (BP1) and breakpoint 2
p70410
sg70045
I35
sg70046
g12
sg70048
I6
sa(dp70411
g70042
I0
sg70043
VCYFIP1
p70412
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp70413
(dp70414
g70042
I167
sg70043
VPrader-Willi syndrome
p70415
sg70045
I21
sg70054
VC0032897
p70416
sg70048
I2
sa(dp70417
g70042
I190
sg70043
g70403
sg70045
I3
sg70054
VC0032897
p70418
sg70048
I1
sasa(dp70419
g135
(dp70420
(VKCNE1
p70421
Vmental retardation
p70422
tp70423
I00
ssg70037
VWe found copy number variants in PDE10A (phosphodiesterase 10A), CYFIP1 [cytoplasmic FMR1 (Fragile X mental retardation 1)-interacting protein 1], K(+) channel genes KCNE1 and KCNE2, the Down's syndrome critical region 1 gene RCAN1 (regulator of calcineurin 1), cell-recognition protein CHL1 (cell adhesion molecule with homology with L1CAM), the transcription factor SP4 (specificity protein 4) and histone deacetylase HDAC9, among others (see http://www.genes2cognition.org/SCZ-CNV).
p70424
sg70039
(lp70425
(dp70426
g70042
I335
sg70043
VL1CAM
p70427
sg70045
I5
sg70046
VP32004
p70428
sg70048
I1
sa(dp70429
g70042
I33
sg70043
VPDE10A
p70430
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70431
g70042
I166
sg70043
g70421
sg70045
I5
sg70046
VP15382
p70432
sg70048
I1
sa(dp70433
g70042
I176
sg70043
VKCNE2
p70434
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70435
g70042
I41
sg70043
Vphosphodiesterase 10A
p70436
sg70045
I21
sg70046
g12
sg70048
I2
sa(dp70437
g70042
I400
sg70043
Vhistone deacetylase HDAC9
p70438
sg70045
I25
sg70046
g12
sg70048
I3
sa(dp70439
g70042
I287
sg70043
VCHL1 (cell adhesion molecule
p70440
sg70045
I28
sg70046
g12
sg70048
I4
sasg70051
(lp70441
(dp70442
g70042
I298
sg70043
Vadhesion
p70443
sg70045
I8
sg70054
VC0001511
p70444
sg70048
I1
sa(dp70445
g70042
I187
sg70043
VDown's syndrome
p70446
sg70045
I15
sg70054
VC0013080
p70447
sg70048
I2
sa(dp70448
g70042
I101
sg70043
g70422
sg70045
I18
sg70054
VC0025362
p70449
sg70048
I2
sasa(dp70450
g70037
VWe describe nine cases with a microdeletion at 15q11.2 between BP1-BP2, thus having a haploinsufficiency for TUBGCP5, NIPA1, NIPA2, and CYFIP1 without Prader-Willi/Angelman syndrome.
p70451
sg70039
(lp70452
(dp70453
g70042
I63
sg70043
VBP1-BP2
p70454
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp70455
g70042
I118
sg70043
VNIPA1
p70456
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70457
g70042
I109
sg70043
VTUBGCP5
p70458
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp70459
g70042
I136
sg70043
VCYFIP1
p70460
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70461
g70042
I125
sg70043
VNIPA2
p70462
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70463
(dp70464
g70042
I164
sg70043
VAngelman syndrome
p70465
sg70045
I17
sg70054
VC0162635
p70466
sg70048
I2
sasa(dp70467
g70037
VAltered expression of CYFIP1 is seen in other developmental disabilities, including 15q disorders, and haploinsufficiency of CYFIP1 in Type I PWS cases may be associated with age-related phenotypic effects.
p70468
sg70039
(lp70469
(dp70470
g70042
I22
sg70043
VCYFIP1
p70471
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70472
g70042
I22
sg70043
VCYFIP1
p70473
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp70474
(dp70475
g70042
I142
sg70043
VPWS
p70476
sg70045
I3
sg70054
VC0032897
p70477
sg70048
I1
sa(dp70478
g70042
I46
sg70043
Vdevelopmental disabilities
p70479
sg70045
I26
sg70054
VC0008073
p70480
sg70048
I2
sasa(dp70481
g70037
VExpression analysis of cultured human cells and brain tissues from PWS patients indicates that CYFIP1 and NIPA2 are biallelically expressed.
p70482
sg70039
(lp70483
(dp70484
g70042
I95
sg70043
VCYFIP1
p70485
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70486
g70042
I106
sg70043
VNIPA2
p70487
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70488
(dp70489
g70042
I67
sg70043
VPWS
p70490
sg70045
I3
sg70054
VC0032897
p70491
sg70048
I1
sasa(dp70492
g70037
VFour genes (NIPA1, NIPA2, CYFIP1, and GCP5) have been identified in the chromosomal region between breakpoints 1 and 2 and are implicated in compulsive behavior and lower intellectual ability observed in individuals with Prader-Willi syndrome with TI versus TII deletions.
p70493
sg70039
(lp70494
(dp70495
g70042
I38
sg70043
VGCP5
p70496
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp70497
g70042
I19
sg70043
VNIPA2
p70498
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70499
g70042
I26
sg70043
VCYFIP1
p70500
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70501
g70042
I12
sg70043
VNIPA1
p70502
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70503
(dp70504
g70042
I141
sg70043
Vcompulsive behavior
p70505
sg70045
I19
sg70054
VC0600104
p70506
sg70048
I2
sa(dp70507
g70042
I221
sg70043
VPrader-Willi syndrome
p70508
sg70045
I21
sg70054
VC0032897
p70509
sg70048
I2
sasa(dp70510
g70037
VMessenger RNA from NIPA1, NIPA2, CYFIP1, and GCP5 was reduced but detectable in the subjects with Prader-Willi syndrome with the TI deletion, supporting biallelic expression.
p70511
sg70039
(lp70512
(dp70513
g70042
I26
sg70043
VNIPA2
p70514
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70515
g70042
I45
sg70043
VGCP5
p70516
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp70517
g70042
I33
sg70043
VCYFIP1
p70518
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70519
g70042
I19
sg70043
VNIPA1
p70520
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70521
(dp70522
g70042
I98
sg70043
VPrader-Willi syndrome
p70523
sg70045
I21
sg70054
VC0032897
p70524
sg70048
I2
sasa(dp70525
g135
(dp70526
(VCD16
p70527
Vatopic
p70528
tp70529
I00
ssg70037
VTherefore, we recruited 50 untreated house dust mite-sensitive allergic rhinitis patients and 29 non-atopic healthy individuals and performed comprehensive simultaneous flow cytometric analysis of mutual correlations between levels of CD14, CD16, CD163, CD206, CD124 (IL-4R), CD210 (IL-10R) and CD25, CD124, CD127 (IL-7R), CD210, ICOS expression on monocytes and CD4+ T cells, respectively.
p70530
sg70039
(lp70531
(dp70532
g70042
I254
sg70043
VCD206
p70533
sg70045
I5
sg70046
VP22897
p70534
sg70048
I1
sa(dp70535
g70042
I363
sg70043
VCD4+
p70536
sg70045
I4
sg70046
VP01730
p70537
sg70048
I1
sa(dp70538
g70042
I295
sg70043
VCD25
p70539
sg70045
I4
sg70046
VP01589
p70540
sg70048
I1
sa(dp70541
g70042
I283
sg70043
VIL-10R
p70542
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70543
g70042
I247
sg70043
VCD163
p70544
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70545
g70042
I235
sg70043
VCD14
p70546
sg70045
I4
sg70046
VP08571
p70547
sg70048
I1
sa(dp70548
g70042
I241
sg70043
g70527
sg70045
I4
sg70046
VP08637
p70549
sg70048
I1
sasg70051
(lp70550
(dp70551
g70042
I63
sg70043
Vallergic rhinitis
p70552
sg70045
I17
sg70054
VC2607914
p70553
sg70048
I2
sa(dp70554
g70042
I101
sg70043
g70528
sg70045
I6
sg70054
VC0392707
p70555
sg70048
I1
sasa(dp70556
g70037
VWe did not observe any statistically significant differences between healthy and diabetic children in mRNA expression for FoxP3, IL-7R (CD127), IL-8RA, IL-10RA, IL-12A, IL-2RA (CD25), IL-21, STAT1, STAT3, SOCS2, SOCS3, TGF-beta1-R1, TGF-beta-R2 and TBX-21 genes.
p70557
sg70039
(lp70558
(dp70559
g70042
I191
sg70043
VSTAT1
p70560
sg70045
I5
sg70046
VP42224
p70561
sg70048
I1
sa(dp70562
g70042
I198
sg70043
VSTAT3
p70563
sg70045
I5
sg70046
VP40763
p70564
sg70048
I1
sa(dp70565
g70042
I184
sg70043
VIL-21
p70566
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70567
g70042
I122
sg70043
VFoxP3
p70568
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70569
g70042
I177
sg70043
VCD25
p70570
sg70045
I4
sg70046
VP01589
p70571
sg70048
I1
sa(dp70572
g70042
I205
sg70043
VSOCS2
p70573
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70574
g70042
I161
sg70043
VIL-12A
p70575
sg70045
I6
sg70046
VP29459
p70576
sg70048
I1
sa(dp70577
g70042
I233
sg70043
VTGF-beta-R2
p70578
sg70045
I11
sg70046
VP18075
p70579
sg70048
I1
sa(dp70580
g70042
I212
sg70043
VSOCS3
p70581
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70582
g70042
I219
sg70043
VTGF-beta1-R1
p70583
sg70045
I12
sg70046
VP01137
p70584
sg70048
I1
sasg70051
(lp70585
sa(dp70586
g135
(dp70587
(VB-Cell Lymphoma 6
p70588
VB-Cell Lymphoma
p70589
tp70590
I00
ssg70037
VExpression of the Growth Hormone (GH)-stimulated gene Socs2 (Suppressor of Cytokine Signaling 2) is mediated by the transcription activator STAT5 (Signal Transducer and Activator of Transcription 5) and the transcription repressor BCL6 (B-Cell Lymphoma 6).
p70591
sg70039
(lp70592
(dp70593
g70042
I18
sg70043
VGrowth Hormone
p70594
sg70045
I14
sg70046
VP01242
p70595
sg70048
I2
sa(dp70596
g70042
I140
sg70043
VSTAT5
p70597
sg70045
I5
sg70046
VP42229
p70598
sg70048
I1
sa(dp70599
g70042
I34
sg70043
VGH
p70600
sg70045
I2
sg70046
VP01242
p70601
sg70048
I1
sa(dp70602
g70042
I54
sg70043
VSocs2
p70603
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70604
g70042
I61
sg70043
VSuppressor of Cytokine Signaling 2
p70605
sg70045
I34
sg70046
g12
sg70048
I5
sa(dp70606
g70042
I231
sg70043
VBCL6
p70607
sg70045
I4
sg70046
VP41182
p70608
sg70048
I1
sa(dp70609
g70042
I147
sg70043
VSignal Transducer and Activator of Transcription 5
p70610
sg70045
I50
sg70046
VP42229
p70611
sg70048
I7
sa(dp70612
g70042
I237
sg70043
g70588
sg70045
I17
sg70046
VP41182
p70613
sg70048
I3
sasg70051
(lp70614
(dp70615
g70042
I237
sg70043
g70589
sg70045
I15
sg70054
VC0079731
p70616
sg70048
I2
sasa(dp70617
g135
(dp70618
(VMAPK1
p70619
Vfollicular lymphoma
p70620
tp70621
I01
ssg70037
VGene expression analysis revealed increased expression of MAPK1, AKT1, PRKCE, IL4R and DROSHA and decreased expression of CDKN1A/p21, SOCS2, CHEK1, RAD51, KLF4, BLIMP1 and IRF4 in follicular lymphoma.
p70622
sg70039
(lp70623
(dp70624
g70042
I141
sg70043
VCHEK1
p70625
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70626
g70042
I129
sg70043
Vp21
p70627
sg70045
I3
sg70046
VP42857
p70628
sg70048
I1
sa(dp70629
g70042
I161
sg70043
VBLIMP1
p70630
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70631
g70042
I155
sg70043
VKLF4
p70632
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp70633
g70042
I172
sg70043
VIRF4
p70634
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp70635
g70042
I87
sg70043
VDROSHA
p70636
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp70637
g70042
I122
sg70043
VCDKN1A
p70638
sg70045
I6
sg70046
VP38936
p70639
sg70048
I1
sa(dp70640
g70042
I148
sg70043
VRAD51
p70641
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70642
g70042
I134
sg70043
VSOCS2
p70643
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70644
g70042
I65
sg70043
VAKT1
p70645
sg70045
I4
sg70046
VP31749
p70646
sg70048
I1
sa(dp70647
g70042
I58
sg70043
g70619
sg70045
I5
sg70046
VP28482
p70648
sg70048
I1
sa(dp70649
g70042
I71
sg70043
VPRKCE
p70650
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70651
(dp70652
g70042
I180
sg70043
g70620
sg70045
I19
sg70054
VC0024301
p70653
sg70048
I2
sasa(dp70654
g135
(dp70655
(VCDKN1A
p70656
Vfollicular lymphoma
p70657
tp70658
I01
ssg70037
VmiR-20a/b and miR-194 target CDKN1A and SOCS2 in follicular lymphoma, potentially contributing to tumor cell proliferation and survival.
p70659
sg70039
(lp70660
(dp70661
g70042
I40
sg70043
VSOCS2
p70662
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp70663
g70042
I0
sg70043
VmiR-20a/b
p70664
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp70665
g70042
I29
sg70043
g70656
sg70045
I6
sg70046
VP38936
p70666
sg70048
I1
sa(dp70667
g70042
I14
sg70043
VmiR-194
p70668
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp70669
(dp70670
g70042
I98
sg70043
Vtumor
p70671
sg70045
I5
sg70054
VC0027651
p70672
sg70048
I1
sa(dp70673
g70042
I49
sg70043
g70657
sg70045
I19
sg70054
VC0024301
p70674
sg70048
I2
sa(dp70675
g70042
I109
sg70043
Vproliferation
p70676
sg70045
I13
sg70054
VC0334094
p70677
sg70048
I1
sasa(dp70678
g70037
VNuclear factors such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR), as well as transporters and conjugation enzymes involved in the detoxification of lithocholic acid (LCA), also showed higher expression in SPF mice.
p70679
sg70039
(lp70680
(dp70681
g70042
I24
sg70043
Vpregnane X receptor
p70682
sg70045
I19
sg70046
g12
sg70048
I3
sa(dp70683
g70042
I45
sg70043
VPXR
p70684
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp70685
(dp70686
g70042
I54
sg70043
Vconstitutive androstane receptor
p70687
sg70045
I32
sg70054
VC2607929
p70688
sg70048
I3
sa(dp70689
g70042
I88
sg70043
VCAR
p70690
sg70045
I3
sg70054
VC2607929
p70691
sg70048
I1
sa(dp70692
g70042
I176
sg70043
Vlithocholic acid
p70693
sg70045
I16
sg70054
VC0339527
p70694
sg70048
I2
sa(dp70695
g70042
I194
sg70043
VLCA
p70696
sg70045
I3
sg70054
VC0339527
p70697
sg70048
I1
sasa(dp70698
g70037
VIn this study, using transgenic mice bearing conditional expression of the activated constitutive androstane receptor (CAR), we demonstrate that activation of CAR is both necessary and sufficient to confer resistance to the hepatotoxicity of lithocholic acid (LCA).
p70699
sg70039
(lp70700
sg70051
(lp70701
(dp70702
g70042
I119
sg70043
VCAR
p70703
sg70045
I3
sg70054
VC2607929
p70704
sg70048
I1
sa(dp70705
g70042
I260
sg70043
VLCA
p70706
sg70045
I3
sg70054
VC0339527
p70707
sg70048
I1
sa(dp70708
g70042
I119
sg70043
VCAR
p70709
sg70045
I3
sg70054
VC2607929
p70710
sg70048
I1
sa(dp70711
g70042
I85
sg70043
Vconstitutive androstane receptor
p70712
sg70045
I32
sg70054
VC2607929
p70713
sg70048
I3
sa(dp70714
g70042
I242
sg70043
Vlithocholic acid
p70715
sg70045
I16
sg70054
VC0339527
p70716
sg70048
I2
sasa(dp70717
g135
(dp70718
(VCA VI
p70719
Vdental caries
p70720
tp70721
I01
ssg70037
VThese results support the conclusion that dental caries is highly affected by the activity of CA VI in saliva as well as by the salivary flow rate.
p70722
sg70039
(lp70723
(dp70724
g70042
I94
sg70043
g70719
sg70045
I5
sg70046
VP23280
p70725
sg70048
I2
sasg70051
(lp70726
(dp70727
g70042
I42
sg70043
g70720
sg70045
I13
sg70054
VC0333519
p70728
sg70048
I2
sasa(dp70729
g135
(dp70730
(Vbeta defensin 1 and lysozyme-like protein
p70731
Vdental caries
p70732
tp70733
I00
ssg70037
VEleven articles found a consistent association between salivary protein polymorphisms and risk of dental caries, for proteins related to antimicrobial activity (beta defensin 1 and lysozyme-like protein), pH control (carbonic anhydrase VI), and bacterial colonization/adhesion (lactotransferrin, mucin, and proline-rich protein Db).
p70734
sg70039
(lp70735
(dp70736
g70042
I217
sg70043
Vcarbonic anhydrase VI
p70737
sg70045
I21
sg70046
VP23280
p70738
sg70048
I3
sa(dp70739
g70042
I161
sg70043
g70731
sg70045
I41
sg70046
VP60022
p70740
sg70048
I6
sa(dp70741
g70042
I296
sg70043
Vmucin
p70742
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70743
(dp70744
g70042
I268
sg70043
Vadhesion
p70745
sg70045
I8
sg70054
VC0001511
p70746
sg70048
I1
sa(dp70747
g70042
I98
sg70043
g70732
sg70045
I13
sg70054
VC0333519
p70748
sg70048
I2
sasa(dp70749
g135
(dp70750
(VCA VI
p70751
Vdental caries
p70752
tp70753
I01
ssg70037
VThe rs17032907 genetic variant and the haplotype (ACA) of CA VI may be associated with dental caries susceptibility.
p70754
sg70039
(lp70755
(dp70756
g70042
I58
sg70043
g70751
sg70045
I5
sg70046
VP23280
p70757
sg70048
I2
sasg70051
(lp70758
(dp70759
g70042
I87
sg70043
g70752
sg70045
I13
sg70054
VC0333519
p70760
sg70048
I2
sasa(dp70761
g135
(dp70762
(VCA
p70763
Vdental caries
p70764
tp70765
I00
ssg70037
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p70766
sg70039
(lp70767
(dp70768
g70042
I110
sg70043
Vcarbonic anhydrase
p70769
sg70045
I18
sg70046
VP35218
p70770
sg70048
I2
sa(dp70771
g70042
I130
sg70043
g70763
sg70045
I2
sg70046
VP35218
p70772
sg70048
I1
sasg70051
(lp70773
(dp70774
g70042
I48
sg70043
g70764
sg70045
I13
sg70054
VC0333519
p70775
sg70048
I2
sasa(dp70776
g135
(dp70777
(VBeta-class carbonic anhydrase
p70778
Vdental caries
p70779
tp70780
I00
ssg70037
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p70781
sg70039
(lp70782
(dp70783
g70042
I101
sg70043
g70778
sg70045
I29
sg70046
VP35218
p70784
sg70048
I3
sasg70051
(lp70785
(dp70786
g70042
I62
sg70043
g70779
sg70045
I13
sg70054
VC0333519
p70787
sg70048
I2
sasa(dp70788
g135
(dp70789
(Vparvalbumin
p70790
Vautism
p70791
tp70792
I01
ssg70037
VWe used mice lacking the CNTNAP2 gene, which has been implicated in autism, and achieved a temporally precise reduction in E:I balance in the medial prefrontal cortex (mPFC) either by optogenetically increasing the excitability of inhibitory parvalbumin (PV) neurons or decreasing the excitability of excitatory pyramidal neurons.
p70793
sg70039
(lp70794
(dp70795
g70042
I255
sg70043
VPV
p70796
sg70045
I2
sg70046
VP20472
p70797
sg70048
I1
sa(dp70798
g70042
I242
sg70043
g70790
sg70045
I11
sg70046
VP20472
p70799
sg70048
I1
sa(dp70800
g70042
I25
sg70043
VCNTNAP2 gene
p70801
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp70802
(dp70803
g70042
I215
sg70043
Vexcitability
p70804
sg70045
I12
sg70054
VC0235169
p70805
sg70048
I1
sa(dp70806
g70042
I68
sg70043
g70791
sg70045
I6
sg70054
VC0004352
p70807
sg70048
I1
sa(dp70808
g70042
I215
sg70043
Vexcitability
p70809
sg70045
I12
sg70054
VC0235169
p70810
sg70048
I1
sasa(dp70811
g135
(dp70812
(VPV
p70813
Vautism spectrum disorders
p70814
tp70815
I00
ssg70037
VPost-mortem analyses have demonstrated a selective reduction in the expression of parvalbumin (PV) in GABAergic interneurons in the frontal rather than the sensory cortex of patients with neuropsychiatric disorders such as schizophrenia, autism spectrum disorders, and bipolar disorders.
p70816
sg70039
(lp70817
(dp70818
g70042
I82
sg70043
Vparvalbumin
p70819
sg70045
I11
sg70046
VP20472
p70820
sg70048
I1
sa(dp70821
g70042
I95
sg70043
g70813
sg70045
I2
sg70046
VP20472
p70822
sg70048
I1
sasg70051
(lp70823
(dp70824
g70042
I223
sg70043
Vschizophrenia
p70825
sg70045
I13
sg70054
VC0036341
p70826
sg70048
I1
sa(dp70827
g70042
I269
sg70043
Vbipolar disorders
p70828
sg70045
I17
sg70054
VC0005586
p70829
sg70048
I2
sa(dp70830
g70042
I238
sg70043
g70814
sg70045
I25
sg70054
VC1510586
p70831
sg70048
I3
sasa(dp70832
g135
(dp70833
(Vparvalbumin
p70834
VASD
p70835
tp70836
I00
ssg70037
VRecent neuropathology studies in human brains indicate that several areas of the prefrontal cortex have decreased numbers of parvalbumin interneurons or decreased parvalbumin expression in Autism Spectrum disorders (ASD) [Hashemi, Ariza, Rogers, Noctor, &amp; Martinez-Cerdeno, 2017; Zikopoulos &amp; Barbas, ].
p70837
sg70039
(lp70838
(dp70839
g70042
I125
sg70043
Vparvalbumin
p70840
sg70045
I11
sg70046
VP20472
p70841
sg70048
I1
sa(dp70842
g70042
I125
sg70043
g70834
sg70045
I11
sg70046
VP20472
p70843
sg70048
I1
sasg70051
(lp70844
(dp70845
g70042
I189
sg70043
VAutism Spectrum disorders
p70846
sg70045
I25
sg70054
VC1510586
p70847
sg70048
I3
sa(dp70848
g70042
I216
sg70043
g70835
sg70045
I3
sg70054
VC1510586
p70849
sg70048
I1
sa(dp70850
g70042
I7
sg70043
Vneuropathology
p70851
sg70045
I14
sg70054
VC1540677
p70852
sg70048
I1
sasa(dp70853
g135
(dp70854
(Vparvalbumin gene
p70855
Vautism
p70856
tp70857
I01
ssg70037
VIn view of the documented association between parvalbumin-expressing neurons and autism, the objective of the present study was to determine if parvalbumin gene expression is also altered in Purkinje neurons of the cerebellum.
p70858
sg70039
(lp70859
(dp70860
g70042
I46
sg70043
Vparvalbumin
p70861
sg70045
I11
sg70046
VP20472
p70862
sg70048
I1
sa(dp70863
g70042
I144
sg70043
g70855
sg70045
I16
sg70046
VP20472
p70864
sg70048
I2
sasg70051
(lp70865
(dp70866
g70042
I81
sg70043
g70856
sg70045
I6
sg70054
VC0004352
p70867
sg70048
I1
sasa(dp70868
g135
(dp70869
(Vparvalbumin
p70870
VAutism
p70871
tp70872
I01
ssg70037
VOur hypothesis is that parvalbumin, a molecule that controls and coordinate many cellular brain functions, contributes to the excitatory/inhibitory imbalance in Autism.
p70873
sg70039
(lp70874
(dp70875
g70042
I23
sg70043
g70870
sg70045
I11
sg70046
VP20472
p70876
sg70048
I1
sasg70051
(lp70877
(dp70878
g70042
I148
sg70043
Vimbalance
p70879
sg70045
I9
sg70054
VC1397014
p70880
sg70048
I1
sa(dp70881
g70042
I161
sg70043
g70871
sg70045
I6
sg70054
VC0004352
p70882
sg70048
I1
sasa(dp70883
g135
(dp70884
(Vparvalbumin
p70885
Vautism
p70886
tp70887
I01
ssg70037
VWe report that parvalbumin expression is depressed in Purkinje cells of the cerebellum in autism.
p70888
sg70039
(lp70889
(dp70890
g70042
I15
sg70043
g70885
sg70045
I11
sg70046
VP20472
p70891
sg70048
I1
sasg70051
(lp70892
(dp70893
g70042
I90
sg70043
g70886
sg70045
I6
sg70054
VC0004352
p70894
sg70048
I1
sasa(dp70895
g70037
VFor children less than 32 weeks, FVL homozygosity may be associated with an increase in the risk of developing quadriplegia (OR 9.12, 95% CI 0.86-53.71).
p70896
sg70039
(lp70897
sg70051
(lp70898
(dp70899
g70042
I111
sg70043
Vquadriplegia
p70900
sg70045
I12
sg70054
VC0034372
p70901
sg70048
I1
sasa(dp70902
g70037
VIn the myocardium activation of NFATc3 down-regulates the expression of voltage-gated K(+) (Kv) channels after myocardial infarction (MI).
p70903
sg70039
(lp70904
(dp70905
g70042
I32
sg70043
VNFATc3
p70906
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp70907
(dp70908
g70042
I134
sg70043
VMI
p70909
sg70045
I2
sg70054
VC0027051
p70910
sg70048
I1
sa(dp70911
g70042
I111
sg70043
Vmyocardial infarction
p70912
sg70045
I21
sg70054
VC0027051
p70913
sg70048
I2
sasa(dp70914
g70037
VKnockdown of NFAT4 suppresses mitochondrial fission and protects cardiomyocyte from apoptosis and myocardial infarction.
p70915
sg70039
(lp70916
(dp70917
g70042
I13
sg70043
VNFAT4
p70918
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp70919
(dp70920
g70042
I98
sg70043
Vmyocardial infarction
p70921
sg70045
I21
sg70054
VC0027051
p70922
sg70048
I2
sasa(dp70923
g135
(dp70924
(VWNT3A
p70925
Vcolon cancer
p70926
tp70927
I00
ssg70037
VThe expression pattern of WNT3A is consistent with BRG1 in colon cancer tissues and WNT3A expression was inhibited in BRG1 knockdown cells.
p70928
sg70039
(lp70929
(dp70930
g70042
I51
sg70043
VBRG1
p70931
sg70045
I4
sg70046
VP51532
p70932
sg70048
I1
sa(dp70933
g70042
I26
sg70043
VWNT3A
p70934
sg70045
I5
sg70046
VP56704
p70935
sg70048
I1
sa(dp70936
g70042
I51
sg70043
VBRG1 in colon cancer tissues
p70937
sg70045
I28
sg70046
VP51532
p70938
sg70048
I5
sa(dp70939
g70042
I26
sg70043
g70925
sg70045
I5
sg70046
VP56704
p70940
sg70048
I1
sasg70051
(lp70941
(dp70942
g70042
I59
sg70043
g70926
sg70045
I12
sg70054
VC0699790
p70943
sg70048
I2
sasa(dp70944
g135
(dp70945
(VBRG1
p70946
Vcancer progression
p70947
tp70948
I00
ssg70037
VIn this study, we demonstrate that BRG1 may contribute to colon cancer progression through upregulating WNT3A expression.
p70949
sg70039
(lp70950
(dp70951
g70042
I104
sg70043
VWNT3A
p70952
sg70045
I5
sg70046
VP56704
p70953
sg70048
I1
sa(dp70954
g70042
I35
sg70043
g70946
sg70045
I4
sg70046
VP51532
p70955
sg70048
I1
sasg70051
(lp70956
(dp70957
g70042
I64
sg70043
g70947
sg70045
I18
sg70054
VC0178874
p70958
sg70048
I2
sasa(dp70959
g135
(dp70960
(VBeta-catenin
p70961
Vcolon cancer
p70962
tp70963
I00
ssg70037
VVM-positive colon cancer samples showed increased Wnt3a expression (p &lt; 0.001) and Beta-catenin nuclear expression (p &lt; 0.001) compared with the VM-negative samples.
p70964
sg70039
(lp70965
(dp70966
g70042
I50
sg70043
VWnt3a
p70967
sg70045
I5
sg70046
VP56704
p70968
sg70048
I1
sa(dp70969
g70042
I86
sg70043
g70961
sg70045
I12
sg70046
VP35222
p70970
sg70048
I1
sasg70051
(lp70971
(dp70972
g70042
I12
sg70043
g70962
sg70045
I12
sg70054
VC0699790
p70973
sg70048
I2
sasa(dp70974
g135
(dp70975
(VWnt3a
p70976
Vcolon cancer
p70977
tp70978
I00
ssg70037
VIn vitro, over-regulated Wnt3a expression in HT29 colon cancer cells promoted the capacity to form tube-like structures in the three-dimensional (3-D) culture together with increased expression of endothelial phenotype-associated proteins such as VEGFR2 and VE-cadherin.
p70979
sg70039
(lp70980
(dp70981
g70042
I258
sg70043
VVE-cadherin
p70982
sg70045
I11
sg70046
VP33151
p70983
sg70048
I1
sa(dp70984
g70042
I247
sg70043
VVEGFR2
p70985
sg70045
I6
sg70046
VP35968
p70986
sg70048
I1
sa(dp70987
g70042
I25
sg70043
g70976
sg70045
I5
sg70046
VP56704
p70988
sg70048
I1
sasg70051
(lp70989
(dp70990
g70042
I50
sg70043
g70977
sg70045
I12
sg70054
VC0699790
p70991
sg70048
I2
sasa(dp70992
g135
(dp70993
(VWnt3a
p70994
Vcancer progression
p70995
tp70996
I00
ssg70037
VHowever, the roles of Wnt3a, the representative canonical Wnt ligand, in EMT and colon cancer progression have not yet been fully explored.
p70997
sg70039
(lp70998
(dp70999
g70042
I58
sg70043
VWnt ligand
p71000
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp71001
g70042
I22
sg70043
g70994
sg70045
I5
sg70046
VP56704
p71002
sg70048
I1
sa(dp71003
g70042
I73
sg70043
VEMT
p71004
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp71005
(dp71006
g70042
I87
sg70043
g70995
sg70045
I18
sg70054
VC0178874
p71007
sg70048
I2
sasa(dp71008
g135
(dp71009
(VWnt3a
p71010
Vcolon cancer
p71011
tp71012
I00
ssg70037
VThe expression levels of Wnt3a and EMT-associated proteins (E-cadherin, vimentin, and Beta-catenin) were assessed by immunohistochemistry in human colon cancer tissues to evaluate the clinicopathological significance of Wnt3a, as well as the correlation between Wnt3a and EMT.
p71013
sg70039
(lp71014
(dp71015
g70042
I25
sg70043
VWnt3a
p71016
sg70045
I5
sg70046
VP56704
p71017
sg70048
I1
sa(dp71018
g70042
I35
sg70043
VEMT-associated proteins
p71019
sg70045
I23
sg70046
g12
sg70048
I2
sa(dp71020
g70042
I60
sg70043
VE-cadherin
p71021
sg70045
I10
sg70046
VP12830
p71022
sg70048
I1
sa(dp71023
g70042
I86
sg70043
VBeta-catenin
p71024
sg70045
I12
sg70046
VP35222
p71025
sg70048
I1
sa(dp71026
g70042
I35
sg70043
VEMT
p71027
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp71028
g70042
I25
sg70043
VWnt3a
p71029
sg70045
I5
sg70046
VP56704
p71030
sg70048
I1
sa(dp71031
g70042
I25
sg70043
g71010
sg70045
I5
sg70046
VP56704
p71032
sg70048
I1
sasg70051
(lp71033
(dp71034
g70042
I147
sg70043
g71011
sg70045
I12
sg70054
VC0699790
p71035
sg70048
I2
sasa(dp71036
g135
(dp71037
(VBeta-catenin
p71038
Vcolon cancer
p71039
tp71040
I00
ssg70037
VWe then upregulated Wnt3a expression in HCT116 colon cancer cells, established a nude mouse xenograft model, detected the expression of EMT and Wnt/Beta-catenin signaling-associated proteins, and observed invasion and clone-initiating abilities.
p71041
sg70039
(lp71042
(dp71043
g70042
I20
sg70043
VWnt3a
p71044
sg70045
I5
sg70046
VP56704
p71045
sg70048
I1
sa(dp71046
g70042
I136
sg70043
VEMT
p71047
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp71048
g70042
I148
sg70043
g71038
sg70045
I12
sg70046
VP35222
p71049
sg70048
I1
sasg70051
(lp71050
(dp71051
g70042
I47
sg70043
g71039
sg70045
I12
sg70054
VC0699790
p71052
sg70048
I2
sa(dp71053
g70042
I205
sg70043
Vinvasion
p71054
sg70045
I8
sg70054
VC2699153
p71055
sg70048
I1
sasa(dp71056
g135
(dp71057
(VWnt3a
p71058
Vcolon cancer
p71059
tp71060
I00
ssg70037
VIn 203 human colon cancer tissue samples, Wnt3a protein overexpression was related to colon cancer histological differentiation (P = 0.004), clinical stage (P = 0.008), presence of metastasis and recurrence (P = 0.036), and survival time (P = 0.007) of colon cancer patients.
p71061
sg70039
(lp71062
(dp71063
g70042
I42
sg70043
g71058
sg70045
I5
sg70046
VP56704
p71064
sg70048
I1
sasg70051
(lp71065
(dp71066
g70042
I181
sg70043
Vmetastasis
p71067
sg70045
I10
sg70054
VC0027627
p71068
sg70048
I1
sa(dp71069
g70042
I13
sg70043
Vcolon cancer
p71070
sg70045
I12
sg70054
VC0699790
p71071
sg70048
I2
sa(dp71072
g70042
I13
sg70043
Vcolon cancer
p71073
sg70045
I12
sg70054
VC0699790
p71074
sg70048
I2
sa(dp71075
g70042
I13
sg70043
g71059
sg70045
I12
sg70054
VC0699790
p71076
sg70048
I2
sa(dp71077
g70042
I196
sg70043
Vrecurrence
p71078
sg70045
I10
sg70054
VC1458156
p71079
sg70048
I1
sasa(dp71080
g135
(dp71081
(VWnt3a
p71082
Vcancer progression
p71083
tp71084
I00
ssg70037
VWnt3a expression was associated with EMT and promoted colon cancer progression.
p71085
sg70039
(lp71086
(dp71087
g70042
I37
sg70043
VEMT
p71088
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp71089
g70042
I0
sg70043
g71082
sg70045
I5
sg70046
VP56704
p71090
sg70048
I1
sasg70051
(lp71091
(dp71092
g70042
I60
sg70043
g71083
sg70045
I18
sg70054
VC0178874
p71093
sg70048
I2
sasa(dp71094
g70037
VDisruption of 11-cis-RDHs causes a slowly developing cone dystrophy caused by inefficient cone pigment regeneration.
p71095
sg70039
(lp71096
(dp71097
g70042
I14
sg70043
V11-cis-RDHs
p71098
sg70045
I11
sg70046
g12
sg70048
I1
sasg70051
(lp71099
(dp71100
g70042
I53
sg70043
Vcone dystrophy
p71101
sg70045
I14
sg70054
VC0730290
p71102
sg70048
I2
sa(dp71103
g70042
I17
sg70043
Vcis
p71104
sg70045
I3
sg70054
VC0007099
p71105
sg70048
I1
sasa(dp71106
g135
(dp71107
(VGH-releasing hormone
p71108
Vhypothalamic amenorrhea
p71109
tp71110
I00
ssg70037
VTo evaluate the GH-releasing hormone (GH-RH)-induced response of GH in patients affected by hypothalamic amenorrhea.
p71111
sg70039
(lp71112
(dp71113
g70042
I38
sg70043
VGH-RH
p71114
sg70045
I5
sg70046
VP01286
p71115
sg70048
I1
sa(dp71116
g70042
I16
sg70043
g71108
sg70045
I20
sg70046
VP01286
p71117
sg70048
I2
sasg70051
(lp71118
(dp71119
g70042
I92
sg70043
g71109
sg70045
I23
sg70054
VC0341862
p71120
sg70048
I2
sasa(dp71121
g70037
VThe amenorrheic condition associated with reduced BMI changes the GH-RH--induced GH response in hypothalamic amenorrhea, supporting a GH and a IGF-I disregulation in weight-loss--related amenorrhea.
p71122
sg70039
(lp71123
(dp71124
g70042
I143
sg70043
VIGF-I
p71125
sg70045
I5
sg70046
VP01343
p71126
sg70048
I1
sasg70051
(lp71127
(dp71128
g70042
I109
sg70043
Vamenorrhea
p71129
sg70045
I10
sg70054
VC0002453
p71130
sg70048
I1
sa(dp71131
g70042
I96
sg70043
Vhypothalamic amenorrhea
p71132
sg70045
I23
sg70054
VC0341862
p71133
sg70048
I2
sa(dp71134
g70042
I16
sg70043
Vcondition
p71135
sg70045
I9
sg70054
VC0012634
p71136
sg70048
I1
sasa(dp71137
g135
(dp71138
(VGnRH
p71139
Vshort stature
p71140
tp71141
I00
ssg70037
VWe report the case of a 17-year-old girl presenting short stature (height 149 cm, below the 3rd percentile), obesity (weight 83.5 kg, body mass index 37 kg/m2) and secondary amenorrhea, in whom endocrinological evaluation disclosed an absolute lack of GH responsiveness to both suprapituitary challenges and repetitive growth hormone releasing hormone administration together with failure of plasma gonadotropins and PRL, low under basal conditions, to rise in response to GnRH and insulin-hypoglycemia, respectively.
p71142
sg70039
(lp71143
(dp71144
g70042
I319
sg70043
Vgrowth hormone
p71145
sg70045
I14
sg70046
VP01242
p71146
sg70048
I2
sa(dp71147
g70042
I482
sg70043
Vinsulin
p71148
sg70045
I7
sg70046
VP01308
p71149
sg70048
I1
sa(dp71150
g70042
I417
sg70043
VPRL
p71151
sg70045
I3
sg70046
VP01236
p71152
sg70048
I1
sa(dp71153
g70042
I473
sg70043
g71139
sg70045
I4
sg70046
VP01148
p71154
sg70048
I1
sasg70051
(lp71155
(dp71156
g70042
I164
sg70043
Vsecondary amenorrhea
p71157
sg70045
I20
sg70054
VC0232940
p71158
sg70048
I2
sa(dp71159
g70042
I109
sg70043
Vobesity
p71160
sg70045
I7
sg70054
VC0028754
p71161
sg70048
I1
sa(dp71162
g70042
I490
sg70043
Vhypoglycemia
p71163
sg70045
I12
sg70054
VC0020615
p71164
sg70048
I1
sa(dp71165
g70042
I52
sg70043
g71140
sg70045
I13
sg70054
VC0013336
p71166
sg70048
I2
sasa(dp71167
g135
(dp71168
(VJag1
p71169
Vneuroblastoma
p71170
tp71171
I00
ssg70037
VCommon genes include Jagged 1 (Jag1), Tetraspanin 2 (Tspan2), neuroblastoma, suppression of tumourigenicity 1 (Nbl1) and N-myc downstream regulated gene 2 (Ndrg2).
p71172
sg70039
(lp71173
(dp71174
g70042
I21
sg70043
VJagged 1
p71175
sg70045
I8
sg70046
VP78504
p71176
sg70048
I2
sa(dp71177
g70042
I121
sg70043
VN-myc
p71178
sg70045
I5
sg70046
VP04198
p71179
sg70048
I1
sa(dp71180
g70042
I38
sg70043
VTetraspanin 2
p71181
sg70045
I13
sg70046
g12
sg70048
I2
sa(dp71182
g70042
I31
sg70043
g71169
sg70045
I4
sg70046
VP78504
p71183
sg70048
I1
sa(dp71184
g70042
I53
sg70043
VTspan2
p71185
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp71186
(dp71187
g70042
I62
sg70043
g71170
sg70045
I13
sg70054
VC0027819
p71188
sg70048
I1
sa(dp71189
g70042
I77
sg70043
Vsuppression
p71190
sg70045
I11
sg70054
VC0221103
p71191
sg70048
I1
sasa(dp71192
g70037
VWhile vincristine was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, etoposide was assessed ineffective as a single agent in all of the 3 xenografts used.
p71193
sg70039
(lp71194
sg70051
(lp71195
(dp71196
g70042
I48
sg70043
Vneuroblastoma
p71197
sg70045
I13
sg70054
VC0027819
p71198
sg70048
I1
sasa(dp71199
g135
(dp71200
(Vsomatostatin receptor-2
p71201
Vneuroblastoma
p71202
tp71203
I00
ssg70037
VThe purpose of this study was to evaluate the correlation of somatostatin receptor-2 (SSTR2) expression with 68Ga-DOTA-TATE uptake and 177Lu-DOTA-TATE therapy in neuroblastoma (NB) xenograft models.
p71204
sg70039
(lp71205
(dp71206
g70042
I86
sg70043
VSSTR2
p71207
sg70045
I5
sg70046
VP30874
p71208
sg70048
I1
sa(dp71209
g70042
I61
sg70043
g71201
sg70045
I23
sg70046
VP61278
p71210
sg70048
I2
sasg70051
(lp71211
(dp71212
g70042
I177
sg70043
VNB
p71213
sg70045
I2
sg70054
VC0027819
p71214
sg70048
I1
sa(dp71215
g70042
I162
sg70043
g71202
sg70045
I13
sg70054
VC0027819
p71216
sg70048
I1
sasa(dp71217
g135
(dp71218
(VSomatostatin Receptor
p71219
VNeuroblastoma
p71220
tp71221
I00
ssg70037
VNeuroblastoma may be treated with molecular radiotherapy, 131I meta-Iodobenzylguanidine and 177Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2), respectively.
p71222
sg70039
(lp71223
(dp71224
g70042
I225
sg70043
VSSTR2
p71225
sg70045
I5
sg70046
VP30874
p71226
sg70048
I1
sa(dp71227
g70042
I202
sg70043
g71219
sg70045
I21
sg70046
VP61278
p71228
sg70048
I2
sasg70051
(lp71229
(dp71230
g70042
I0
sg70043
g71220
sg70045
I13
sg70054
VC0027819
p71231
sg70048
I1
sasa(dp71232
g135
(dp71233
(VNAT
p71234
Vneuroblastoma
p71235
tp71236
I00
ssg70037
VTissue bank samples of formalin fixed paraffin embedded neuroblastoma tissue from patients for whom clinical outcome data were available were sectioned and stained with haematoxylin and eosin, and monoclonal antibodies directed against NAT and SSTR2.
p71237
sg70039
(lp71238
(dp71239
g70042
I244
sg70043
VSSTR2
p71240
sg70045
I5
sg70046
VP30874
p71241
sg70048
I1
sa(dp71242
g70042
I236
sg70043
g71234
sg70045
I3
sg70046
VP18440
p71243
sg70048
I1
sasg70051
(lp71244
(dp71245
g70042
I56
sg70043
g71235
sg70045
I13
sg70054
VC0027819
p71246
sg70048
I1
sasa(dp71247
g135
(dp71248
(Vsomatostatin receptor 2
p71249
Vmeningioma
p71250
tp71251
I01
ssg70037
V68Ga-DOTATATE PET/CT enables detection of meningioma tissue based on somatostatin receptor 2 expression.
p71252
sg70039
(lp71253
(dp71254
g70042
I69
sg70043
g71249
sg70045
I23
sg70046
VP61278
p71255
sg70048
I3
sasg70051
(lp71256
(dp71257
g70042
I42
sg70043
g71250
sg70045
I10
sg70054
VC0025286
p71258
sg70048
I1
sasa(dp71259
g135
(dp71260
(VEMA
p71261
Vepithelial membrane antigen
p71262
tp71263
I00
ssg70037
VImmunohistochemistry for the meningioma markers EMA and SSTR2A raised the possibility of intraosseous meningioma, as all 3 lesions were convincingly positive for epithelial membrane antigen (EMA) and 1 lesion was convincingly positive for the somatostatin receptor subtype 2A (SSTR2A); weak, questionable positivity for SSTR2 was present in the remaining 2 cases.
p71264
sg70039
(lp71265
(dp71266
g70042
I56
sg70043
VSSTR2A
p71267
sg70045
I6
sg70046
VP61278
p71268
sg70048
I1
sa(dp71269
g70042
I162
sg70043
Vepithelial membrane antigen
p71270
sg70045
I27
sg70046
VP12830
p71271
sg70048
I3
sa(dp71272
g70042
I48
sg70043
VEMA
p71273
sg70045
I3
sg70046
VP13804
p71274
sg70048
I1
sa(dp71275
g70042
I56
sg70043
VSSTR2
p71276
sg70045
I5
sg70046
VP30874
p71277
sg70048
I1
sa(dp71278
g70042
I56
sg70043
VSSTR2A
p71279
sg70045
I6
sg70046
VP61278
p71280
sg70048
I1
sa(dp71281
g70042
I243
sg70043
Vsomatostatin receptor subtype 2A
p71282
sg70045
I32
sg70046
VP61278
p71283
sg70048
I4
sa(dp71284
g70042
I48
sg70043
g71261
sg70045
I3
sg70046
VP12830
p71285
sg70048
I1
sasg70051
(lp71286
(dp71287
g70042
I29
sg70043
Vmeningioma
p71288
sg70045
I10
sg70054
VC0025286
p71289
sg70048
I1
sa(dp71290
g70042
I48
sg70043
VEMA
p71291
sg70045
I3
sg70054
VC0268596
p71292
sg70048
I1
sa(dp71293
g70042
I29
sg70043
Vmeningioma
p71294
sg70045
I10
sg70054
VC0025286
p71295
sg70048
I1
sa(dp71296
g70042
I48
sg70043
VEMA
p71297
sg70045
I3
sg70054
VC0268596
p71298
sg70048
I1
sa(dp71299
g70042
I162
sg70043
g71262
sg70045
I27
sg70054
VC0268596
p71300
sg70048
I3
sasa(dp71301
g135
(dp71302
(VSSTR2
p71303
VNB
p71304
tp71305
I00
ssg70037
VSomatostatine receptors subtype 2 (SSTR2) are regarded as a potential target in neuroblastoma (NB) for imaging and promising therapeutic approaches.
p71306
sg70039
(lp71307
(dp71308
g70042
I0
sg70043
VSomatostatine receptors subtype 2
p71309
sg70045
I33
sg70046
g12
sg70048
I4
sa(dp71310
g70042
I35
sg70043
g71303
sg70045
I5
sg70046
VP30874
p71311
sg70048
I1
sasg70051
(lp71312
(dp71313
g70042
I80
sg70043
Vneuroblastoma
p71314
sg70045
I13
sg70054
VC0027819
p71315
sg70048
I1
sa(dp71316
g70042
I95
sg70043
g71304
sg70045
I2
sg70054
VC0027819
p71317
sg70048
I1
sasa(dp71318
g135
(dp71319
(VSSTR 2
p71320
Vneuroblastoma
p71321
tp71322
I00
ssg70037
VGaTATE PET was positive in a high proportion of patients with refractory neuroblastoma, correlating with SSTR 2 on IHC, with additional disease identified compared with MIBG imaging.
p71323
sg70039
(lp71324
(dp71325
g70042
I105
sg70043
g71320
sg70045
I6
sg70046
VP31391
p71326
sg70048
I2
sasg70051
(lp71327
(dp71328
g70042
I73
sg70043
g71321
sg70045
I13
sg70054
VC0027819
p71329
sg70048
I1
sasa(dp71330
g135
(dp71331
(VSSTR2
p71332
Vmeningiomas
p71333
tp71334
I00
ssg70037
VPET using the SSTR2 analog (68)Ga-DOTATATE has recently been introduced for imaging of meningiomas.
p71335
sg70039
(lp71336
(dp71337
g70042
I14
sg70043
g71332
sg70045
I5
sg70046
VP30874
p71338
sg70048
I1
sasg70051
(lp71339
(dp71340
g70042
I87
sg70043
g71333
sg70045
I11
sg70054
VC0025286
p71341
sg70048
I1
sasa(dp71342
g135
(dp71343
(VSSTR2
p71344
Vmeningioma
p71345
tp71346
I00
ssg70037
V(68)Ga-DOTATATE uptake correlates with SSTR2 expression and offers high diagnostic accuracy to delineate meningioma from tumor-free tissue even in recurrent tumors after previous therapy.
p71347
sg70039
(lp71348
(dp71349
g70042
I39
sg70043
g71344
sg70045
I5
sg70046
VP30874
p71350
sg70048
I1
sasg70051
(lp71351
(dp71352
g70042
I105
sg70043
g71345
sg70045
I10
sg70054
VC0025286
p71353
sg70048
I1
sa(dp71354
g70042
I121
sg70043
Vtumor
p71355
sg70045
I5
sg70054
VC0027651
p71356
sg70048
I1
sa(dp71357
g70042
I157
sg70043
Vtumors
p71358
sg70045
I6
sg70054
VC0027651
p71359
sg70048
I1
sasa(dp71360
g135
(dp71361
(VSSTR2
p71362
Vperineuriomas
p71363
tp71364
I00
ssg70037
VWe aimed to compare the frequency of perineurial marker expression in these two entities, and to determine whether somatostatin receptor 2 (SSTR2) and progesterone receptor (PR), both expressed frequently in meningiomas, are also expressed in perineuriomas.
p71365
sg70039
(lp71366
(dp71367
g70042
I115
sg70043
Vsomatostatin receptor 2
p71368
sg70045
I23
sg70046
VP61278
p71369
sg70048
I3
sa(dp71370
g70042
I151
sg70043
Vprogesterone receptor
p71371
sg70045
I21
sg70046
VP06401
p71372
sg70048
I2
sa(dp71373
g70042
I174
sg70043
VPR
p71374
sg70045
I2
sg70046
VP06401
p71375
sg70048
I1
sa(dp71376
g70042
I140
sg70043
g71362
sg70045
I5
sg70046
VP30874
p71377
sg70048
I1
sasg70051
(lp71378
(dp71379
g70042
I208
sg70043
Vmeningiomas
p71380
sg70045
I11
sg70054
VC0025286
p71381
sg70048
I1
sa(dp71382
g70042
I243
sg70043
g71363
sg70045
I13
sg70054
VC0751691
p71383
sg70048
I1
sasa(dp71384
g135
(dp71385
(VEMA
p71386
VEMA
p71387
tp71388
I00
ssg70037
VAll tumours were stained using five antibodies against antigens that are known to be expressed in perineuriomas or meningiomas: epithelial membrane antigen (EMA), claudin-1, GLUT-1 (glucose transporter-1), SSTR2, and PR.
p71389
sg70039
(lp71390
(dp71391
g70042
I174
sg70043
VGLUT-1
p71392
sg70045
I6
sg70046
VP11166
p71393
sg70048
I1
sa(dp71394
g70042
I128
sg70043
Vepithelial membrane antigen
p71395
sg70045
I27
sg70046
VP12830
p71396
sg70048
I3
sa(dp71397
g70042
I182
sg70043
Vglucose transporter-1
p71398
sg70045
I21
sg70046
VP11166
p71399
sg70048
I2
sa(dp71400
g70042
I206
sg70043
VSSTR2
p71401
sg70045
I5
sg70046
VP30874
p71402
sg70048
I1
sa(dp71403
g70042
I157
sg70043
g71386
sg70045
I3
sg70046
VP13804
p71404
sg70048
I1
sa(dp71405
g70042
I163
sg70043
Vclaudin-1
p71406
sg70045
I9
sg70046
g12
sg70048
I1
sasg70051
(lp71407
(dp71408
g70042
I98
sg70043
Vperineuriomas
p71409
sg70045
I13
sg70054
VC0751691
p71410
sg70048
I1
sa(dp71411
g70042
I115
sg70043
Vmeningiomas
p71412
sg70045
I11
sg70054
VC0025286
p71413
sg70048
I1
sa(dp71414
g70042
I128
sg70043
Vepithelial membrane antigen
p71415
sg70045
I27
sg70054
VC0268596
p71416
sg70048
I3
sa(dp71417
g70042
I4
sg70043
Vtumours
p71418
sg70045
I7
sg70054
VC0027651
p71419
sg70048
I1
sa(dp71420
g70042
I157
sg70043
g71387
sg70045
I3
sg70054
VC0268596
p71421
sg70048
I1
sasa(dp71422
g70037
VOf the meningiomas, EMA was expressed in 59 of 61, claudin-1 in five of 63, GLUT-1 in 19 of 62, SSTR2 in 59 of 68, and PR in 44 of 62.
p71423
sg70039
(lp71424
(dp71425
g70042
I51
sg70043
Vclaudin-1
p71426
sg70045
I9
sg70046
g12
sg70048
I1
sasg70051
(lp71427
(dp71428
g70042
I7
sg70043
Vmeningiomas
p71429
sg70045
I11
sg70054
VC0025286
p71430
sg70048
I1
sa(dp71431
g70042
I20
sg70043
VEMA
p71432
sg70045
I3
sg70054
VC0268596
p71433
sg70048
I1
sasa(dp71434
g135
(dp71435
(VSSTR2
p71436
Vperineuriomas
p71437
tp71438
I00
ssg70037
VThe SSTR2-positive/PR-positive phenotype was detected in 42 of 60 meningiomas, but in none of 20 perineuriomas.
p71439
sg70039
(lp71440
(dp71441
g70042
I4
sg70043
g71436
sg70045
I5
sg70046
VP30874
p71442
sg70048
I1
sasg70051
(lp71443
(dp71444
g70042
I66
sg70043
Vmeningiomas
p71445
sg70045
I11
sg70054
VC0025286
p71446
sg70048
I1
sa(dp71447
g70042
I97
sg70043
g71437
sg70045
I13
sg70054
VC0751691
p71448
sg70048
I1
sasa(dp71449
g135
(dp71450
(VSSTR2
p71451
Vmeningioma
p71452
tp71453
I00
ssg70037
VSSTR2 and PR are highly sensitive and, in this context, specific meningioma markers.
p71454
sg70039
(lp71455
(dp71456
g70042
I0
sg70043
g71451
sg70045
I5
sg70046
VP30874
p71457
sg70048
I1
sasg70051
(lp71458
(dp71459
g70042
I65
sg70043
g71452
sg70045
I10
sg70054
VC0025286
p71460
sg70048
I1
sasa(dp71461
g135
(dp71462
(VcPLA2 alpha
p71463
Vmultiple sclerosis
p71464
tp71465
I01
ssg70037
VWe utilized inhibitors of cPLA2 alpha, COX-1/2 and 5-LO to determine the potential roles of these enzymes in development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
p71466
sg70039
(lp71467
(dp71468
g70042
I39
sg70043
VCOX-1/2
p71469
sg70045
I7
sg70046
VP00395
p71470
sg70048
I1
sa(dp71471
g70042
I26
sg70043
g71463
sg70045
I11
sg70046
VP47712
p71472
sg70048
I2
sasg70051
(lp71473
(dp71474
g70042
I167
sg70043
VEAE
p71475
sg70045
I3
sg70054
VC0014070
p71476
sg70048
I1
sa(dp71477
g70042
I212
sg70043
VMS
p71478
sg70045
I2
sg70054
VC0026769
p71479
sg70048
I1
sa(dp71480
g70042
I148
sg70043
Vencephalomyelitis
p71481
sg70045
I17
sg70054
VC0014070
p71482
sg70048
I1
sa(dp71483
g70042
I192
sg70043
g71464
sg70045
I18
sg70054
VC0026769
p71484
sg70048
I2
sa(dp71485
g70042
I137
sg70043
Vautoimmune
p71486
sg70045
I10
sg70054
VC0443146
p71487
sg70048
I1
sasa(dp71488
g135
(dp71489
(VHBx
p71490
VHCC
p71491
tp71492
I00
ssg70037
VThis study aimed to better understand the role of miR-200a-3p and its correlation with HBx in HBV-induced hepatocellular carcinoma (HCC).
p71493
sg70039
(lp71494
(dp71495
g70042
I87
sg70043
g71490
sg70045
I3
sg70046
VP24821
p71496
sg70048
I1
sa(dp71497
g70042
I50
sg70043
VmiR-200a-3p
p71498
sg70045
I11
sg70046
g12
sg70048
I1
sasg70051
(lp71499
(dp71500
g70042
I106
sg70043
Vhepatocellular carcinoma
p71501
sg70045
I24
sg70054
VC2239176
p71502
sg70048
I2
sa(dp71503
g70042
I94
sg70043
VHBV
p71504
sg70045
I3
sg70054
VC0019163
p71505
sg70048
I1
sa(dp71506
g70042
I132
sg70043
g71491
sg70045
I3
sg70054
VC2239176
p71507
sg70048
I1
sasa(dp71508
g135
(dp71509
(VZEB1
p71510
Vhepatocellular carcinoma
p71511
tp71512
I00
ssg70037
VFurther study suggested that lncRNA-PE downregulated miR-200a/b by repressing the primary transcript expression, enhanced ZEB1 expression, and promoted epithelial-mesenchymal transition of hepatocellular carcinoma cells.
p71513
sg70039
(lp71514
(dp71515
g70042
I53
sg70043
VmiR-200a/b
p71516
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp71517
g70042
I29
sg70043
VlncRNA-PE
p71518
sg70045
I9
sg70046
VP48147
p71519
sg70048
I1
sa(dp71520
g70042
I122
sg70043
g71510
sg70045
I4
sg70046
VP37275
p71521
sg70048
I1
sasg70051
(lp71522
(dp71523
g70042
I175
sg70043
Vtransition
p71524
sg70045
I10
sg70054
VC0599156
p71525
sg70048
I1
sa(dp71526
g70042
I189
sg70043
g71511
sg70045
I24
sg70054
VC1512411
p71527
sg70048
I2
sasa(dp71528
g135
(dp71529
(VZEB1
p71530
Vhepatocellular carcinoma
p71531
tp71532
I00
ssg70037
VAll these data imply that lncRNA-PE might play an important role in hepatocellular carcinoma development via the miR-200a/b-ZEB1 pathway.
p71533
sg70039
(lp71534
(dp71535
g70042
I26
sg70043
VlncRNA-PE
p71536
sg70045
I9
sg70046
VP48147
p71537
sg70048
I1
sa(dp71538
g70042
I124
sg70043
g71530
sg70045
I4
sg70046
VP37275
p71539
sg70048
I1
sa(dp71540
g70042
I113
sg70043
VmiR-200a
p71541
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp71542
(dp71543
g70042
I68
sg70043
g71531
sg70045
I24
sg70054
VC1512411
p71544
sg70048
I2
sasa(dp71545
g70037
VHerein, we found that hepatocellular carcinoma cells shed more microvesicles than normal hepatocytes and miR-200a were shown to inhibit the release of microvesicles in hepatocellular carcinoma cells.
p71546
sg70039
(lp71547
(dp71548
g70042
I105
sg70043
VmiR-200a
p71549
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp71550
(dp71551
g70042
I22
sg70043
Vhepatocellular carcinoma
p71552
sg70045
I24
sg70054
VC1512411
p71553
sg70048
I2
sa(dp71554
g70042
I22
sg70043
Vhepatocellular carcinoma
p71555
sg70045
I24
sg70054
VC1512411
p71556
sg70048
I2
sasa(dp71557
g70037
VCollectively, our findings indicate that miR-200a regulated the microvesicle biogenesis involved in the hepatocellular carcinoma progression.
p71558
sg70039
(lp71559
(dp71560
g70042
I41
sg70043
VmiR-200a
p71561
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp71562
(dp71563
g70042
I104
sg70043
Vhepatocellular carcinoma
p71564
sg70045
I24
sg70054
VC1512411
p71565
sg70048
I2
sasa(dp71566
g70037
VConclusions: These findings indicate that miR-200a regulates the proliferation, migration and invasion of HCC cells by targeting Foxa2, suggesting that miR-200a may function as a potential therapeutic molecular for the diagnosis and treatment of the liver cancer.
p71567
sg70039
(lp71568
(dp71569
g70042
I129
sg70043
VFoxa2
p71570
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp71571
g70042
I42
sg70043
VmiR-200a
p71572
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp71573
g70042
I42
sg70043
VmiR-200a
p71574
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp71575
(dp71576
g70042
I65
sg70043
Vproliferation
p71577
sg70045
I13
sg70054
VC0334094
p71578
sg70048
I1
sa(dp71579
g70042
I94
sg70043
Vinvasion
p71580
sg70045
I8
sg70054
VC2699153
p71581
sg70048
I1
sa(dp71582
g70042
I250
sg70043
Vliver cancer
p71583
sg70045
I12
sg70054
VC0345904
p71584
sg70048
I2
sa(dp71585
g70042
I106
sg70043
VHCC
p71586
sg70045
I3
sg70054
VC2239176
p71587
sg70048
I1
sasa(dp71588
g135
(dp71589
(Vtransforming growth factor beta
p71590
Vhepatocellular carcinoma
p71591
tp71592
I00
ssg70037
VLong noncoding RNAs (lncRNAs)-activated by transforming growth factor beta (lncRNA-ATB) is known to be involved in the invasion of hepatocellular carcinoma by regulating target genes of miR-200a.
p71593
sg70039
(lp71594
(dp71595
g70042
I186
sg70043
VmiR-200a
p71596
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp71597
g70042
I76
sg70043
VlncRNA-ATB
p71598
sg70045
I10
sg70046
VP00325
p71599
sg70048
I1
sa(dp71600
g70042
I43
sg70043
g71590
sg70045
I31
sg70046
VP18075
p71601
sg70048
I4
sasg70051
(lp71602
(dp71603
g70042
I119
sg70043
Vinvasion
p71604
sg70045
I8
sg70054
VC2699153
p71605
sg70048
I1
sa(dp71606
g70042
I131
sg70043
g71591
sg70045
I24
sg70054
VC1512411
p71607
sg70048
I2
sasa(dp71608
g70037
VIn this study, we determined that miR-200a was downregulated in hepatocellular carcinoma (HCC) tissues and cell lines, consistent with the results of our previous study.
p71609
sg70039
(lp71610
(dp71611
g70042
I34
sg70043
VmiR-200a
p71612
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp71613
(dp71614
g70042
I90
sg70043
VHCC
p71615
sg70045
I3
sg70054
VC2239176
p71616
sg70048
I1
sa(dp71617
g70042
I64
sg70043
Vhepatocellular carcinoma
p71618
sg70045
I24
sg70054
VC2239176
p71619
sg70048
I2
sasa(dp71620
g135
(dp71621
(VPlek
p71622
Vmultiple sclerosis
p71623
tp71624
I00
ssg70037
VOur data indicate that nine distinct genes associated with multiple sclerosis risk, Bach2, Il2ra, Irf8, Mertk, Odf3b, Plek, Rgs1, Slc30a7 and Thada, can be confirmed to be differentially regulated in pathogenic CD4(+) T cells.
p71625
sg70039
(lp71626
(dp71627
g70042
I111
sg70043
VOdf3b
p71628
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp71629
g70042
I98
sg70043
VIrf8
p71630
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp71631
g70042
I91
sg70043
VIl2ra
p71632
sg70045
I5
sg70046
VP01589
p71633
sg70048
I1
sa(dp71634
g70042
I104
sg70043
VMertk
p71635
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp71636
g70042
I211
sg70043
VCD4
p71637
sg70045
I3
sg70046
VP01730
p71638
sg70048
I1
sa(dp71639
g70042
I84
sg70043
VBach2
p71640
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp71641
g70042
I130
sg70043
VSlc30a7
p71642
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp71643
g70042
I124
sg70043
VRgs1
p71644
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp71645
g70042
I118
sg70043
g71622
sg70045
I4
sg70046
VP08567
p71646
sg70048
I1
sasg70051
(lp71647
(dp71648
g70042
I59
sg70043
g71623
sg70045
I18
sg70054
VC0026769
p71649
sg70048
I2
sasa(dp71650
g135
(dp71651
(Vtranscription factor BACH2
p71652
Vasthma
p71653
tp71654
I00
ssg70037
VGenetic polymorphisms within a single locus encoding the transcription factor BACH2 are associated with numerous autoimmune and allergic diseases including asthma, Crohn's disease, coeliac disease, vitiligo, multiple sclerosis and type 1 diabetes.
p71655
sg70039
(lp71656
(dp71657
g70042
I57
sg70043
g71652
sg70045
I26
sg70046
VP35398
p71658
sg70048
I3
sasg70051
(lp71659
(dp71660
g70042
I208
sg70043
Vmultiple sclerosis
p71661
sg70045
I18
sg70054
VC0026769
p71662
sg70048
I2
sa(dp71663
g70042
I164
sg70043
VCrohn's disease
p71664
sg70045
I15
sg70054
VC0010346
p71665
sg70048
I2
sa(dp71666
g70042
I113
sg70043
Vautoimmune
p71667
sg70045
I10
sg70054
VC0443146
p71668
sg70048
I1
sa(dp71669
g70042
I181
sg70043
Vcoeliac disease
p71670
sg70045
I15
sg70054
VC0007570
p71671
sg70048
I2
sa(dp71672
g70042
I231
sg70043
Vtype 1 diabetes
p71673
sg70045
I15
sg70054
VC0011854
p71674
sg70048
I3
sa(dp71675
g70042
I198
sg70043
Vvitiligo
p71676
sg70045
I8
sg70054
VC0042900
p71677
sg70048
I1
sa(dp71678
g70042
I156
sg70043
g71653
sg70045
I6
sg70054
VC0004096
p71679
sg70048
I1
sasa(dp71680
g135
(dp71681
(Vsmall leucine-rich proteoglycans
p71682
VPACD
p71683
tp71684
I00
ssg70037
VHowever, array-based copy number analysis and qPCR were used to detect a hemizygous deletion in the PACD linkage interval containing 4 genes encoding small leucine-rich proteoglycans (SLRPs): KERA, LUM, DCN, and EPYC.
p71685
sg70039
(lp71686
(dp71687
g70042
I192
sg70043
VKERA
p71688
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp71689
g70042
I212
sg70043
VEPYC
p71690
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp71691
g70042
I198
sg70043
VLUM
p71692
sg70045
I3
sg70046
VP51884
p71693
sg70048
I1
sa(dp71694
g70042
I203
sg70043
VDCN
p71695
sg70045
I3
sg70046
VP07585
p71696
sg70048
I1
sa(dp71697
g70042
I184
sg70043
VSLRPs
p71698
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp71699
g70042
I150
sg70043
g71682
sg70045
I32
sg70046
VP30740
p71700
sg70048
I3
sasg70051
(lp71701
(dp71702
g70042
I100
sg70043
g71683
sg70045
I4
sg70054
VC2748502
p71703
sg70048
I1
sasa(dp71704
g135
(dp71705
(VLUM
p71706
VPACD
p71707
tp71708
I00
ssg70037
VThe authors performed clinical evaluation of a previously unreported pedigree with PACD, light and electron microscopic examination of an excised corneal button, genomewide linkage analysis, fine mapping linkage and haplotype analysis, and screening of four candidate genes (KERA, LUM, DCN, and EPYC).
p71709
sg70039
(lp71710
(dp71711
g70042
I295
sg70043
VEPYC
p71712
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp71713
g70042
I286
sg70043
VDCN
p71714
sg70045
I3
sg70046
VP07585
p71715
sg70048
I1
sa(dp71716
g70042
I275
sg70043
VKERA
p71717
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp71718
g70042
I281
sg70043
g71706
sg70045
I3
sg70046
VP51884
p71719
sg70048
I1
sasg70051
(lp71720
(dp71721
g70042
I83
sg70043
g71707
sg70045
I4
sg70054
VC2748502
p71722
sg70048
I1
sasa(dp71723
g70037
VEmerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer.
p71724
sg70039
(lp71725
(dp71726
g70042
I42
sg70043
VCD164
p71727
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71728
(dp71729
g70042
I150
sg70043
Vlung cancer
p71730
sg70045
I11
sg70054
VC0684249
p71731
sg70048
I2
sa(dp71732
g70042
I89
sg70043
Vmetastasis
p71733
sg70045
I10
sg70054
VC0027627
p71734
sg70048
I1
sa(dp71735
g70042
I78
sg70043
Vaggressive
p71736
sg70045
I10
sg70054
VC0001807
p71737
sg70048
I1
sasa(dp71738
g70037
VHowever, no data are available regarding the clinical significance of CD164 expression in lung cancer.
p71739
sg70039
(lp71740
(dp71741
g70042
I70
sg70043
VCD164
p71742
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71743
(dp71744
g70042
I90
sg70043
Vlung cancer
p71745
sg70045
I11
sg70054
VC0684249
p71746
sg70048
I2
sasa(dp71747
g70037
VUsing tissue microarrays, we determine that CD164 expression is correlated with clinicopathological characteristics in human lung cancer.
p71748
sg70039
(lp71749
(dp71750
g70042
I44
sg70043
VCD164
p71751
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71752
(dp71753
g70042
I125
sg70043
Vlung cancer
p71754
sg70045
I11
sg70054
VC0684249
p71755
sg70048
I2
sasa(dp71756
g70037
VTherefore, identification of CD164 as a cancer stem cell therapeutic marker may develop an effective therapy in patients with chemoresistant lung cancer.
p71757
sg70039
(lp71758
(dp71759
g70042
I29
sg70043
VCD164
p71760
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71761
(dp71762
g70042
I40
sg70043
Vcancer
p71763
sg70045
I6
sg70054
VC0006826
p71764
sg70048
I1
sa(dp71765
g70042
I141
sg70043
Vlung cancer
p71766
sg70045
I11
sg70054
VC0684249
p71767
sg70048
I2
sasa(dp71768
g70037
VCluster of differentiation 164 (CD164), a sialomucin, has been demonstrated to be involved in the regulation of proliferation, apoptosis, adhesion and differentiation in multiple cancers.
p71769
sg70039
(lp71770
(dp71771
g70042
I42
sg70043
Vsialomucin
p71772
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp71773
g70042
I0
sg70043
VCluster of differentiation 164
p71774
sg70045
I30
sg70046
g12
sg70048
I4
sa(dp71775
g70042
I32
sg70043
VCD164
p71776
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71777
(dp71778
g70042
I138
sg70043
Vadhesion
p71779
sg70045
I8
sg70054
VC0001511
p71780
sg70048
I1
sa(dp71781
g70042
I112
sg70043
Vproliferation
p71782
sg70045
I13
sg70054
VC0334094
p71783
sg70048
I1
sa(dp71784
g70042
I179
sg70043
Vcancers
p71785
sg70045
I7
sg70054
VC0006826
p71786
sg70048
I1
sasa(dp71787
g70037
VHowever, the involvement of CD164 in human glioma proliferation and apoptosis remains unknown.
p71788
sg70039
(lp71789
(dp71790
g70042
I28
sg70043
VCD164
p71791
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71792
(dp71793
g70042
I43
sg70043
Vglioma
p71794
sg70045
I6
sg70054
VC0017638
p71795
sg70048
I1
sa(dp71796
g70042
I50
sg70043
Vproliferation
p71797
sg70045
I13
sg70054
VC0334094
p71798
sg70048
I1
sasa(dp71799
g70037
VThe aim of the present study was to investigate the expression and oncogenic function of CD164 in normal human astrocytes (NHA) and glioma cells in vitro and in vivo.
p71800
sg70039
(lp71801
(dp71802
g70042
I89
sg70043
VCD164
p71803
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71804
(dp71805
g70042
I132
sg70043
Vglioma
p71806
sg70045
I6
sg70054
VC0017638
p71807
sg70048
I1
sasa(dp71808
g70037
VThe results of the present study demonstrated that CD164 mRNA and protein levels were significantly increased in human glioma cell lines and tissue samples.
p71809
sg70039
(lp71810
(dp71811
g70042
I51
sg70043
VCD164 mRNA
p71812
sg70045
I10
sg70046
g12
sg70048
I2
sasg70051
(lp71813
(dp71814
g70042
I119
sg70043
Vglioma
p71815
sg70045
I6
sg70054
VC0017638
p71816
sg70048
I1
sasa(dp71817
g70037
VKnockdown of CD164 inhibited cell proliferation and promoted apoptosis of the U87 human glioma cell line in vitro and in vivo.
p71818
sg70039
(lp71819
(dp71820
g70042
I13
sg70043
VCD164
p71821
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71822
(dp71823
g70042
I88
sg70043
Vglioma
p71824
sg70045
I6
sg70054
VC0017638
p71825
sg70048
I1
sa(dp71826
g70042
I34
sg70043
Vproliferation
p71827
sg70045
I13
sg70054
VC0334094
p71828
sg70048
I1
sasa(dp71829
g135
(dp71830
(VPTEN
p71831
Vglioma
p71832
tp71833
I00
ssg70037
VThe results suggest that CD164 expression may have affected the proliferation and apoptosis of human glioma cells via the PTEN/phosphoinositide 3-kinase/AKT pathway, and may therefore present a potential target for the diagnosis and treatment of glioma.
p71834
sg70039
(lp71835
(dp71836
g70042
I127
sg70043
Vphosphoinositide 3-kinase
p71837
sg70045
I25
sg70046
g12
sg70048
I2
sa(dp71838
g70042
I122
sg70043
g71831
sg70045
I4
sg70046
VP60484
p71839
sg70048
I1
sa(dp71840
g70042
I153
sg70043
VAKT
p71841
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp71842
g70042
I25
sg70043
VCD164
p71843
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71844
(dp71845
g70042
I64
sg70043
Vproliferation
p71846
sg70045
I13
sg70054
VC0334094
p71847
sg70048
I1
sa(dp71848
g70042
I101
sg70043
Vglioma
p71849
sg70045
I6
sg70054
VC0017638
p71850
sg70048
I1
sa(dp71851
g70042
I101
sg70043
g71832
sg70045
I6
sg70054
VC0017638
p71852
sg70048
I1
sasa(dp71853
g135
(dp71854
(VCD4+
p71855
VSezary syndrome
p71856
tp71857
I01
ssg70037
VWe recently demonstrated the high expression of CD164 on CD4+ T cells from Sezary syndrome patients with a wide range of circulating tumor burdens.
p71858
sg70039
(lp71859
(dp71860
g70042
I48
sg70043
VCD164
p71861
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp71862
g70042
I57
sg70043
g71855
sg70045
I4
sg70046
VP01730
p71863
sg70048
I1
sasg70051
(lp71864
(dp71865
g70042
I133
sg70043
Vtumor
p71866
sg70045
I5
sg70054
VC0027651
p71867
sg70048
I1
sa(dp71868
g70042
I75
sg70043
g71856
sg70045
I15
sg70054
VC0036920
p71869
sg70048
I2
sasa(dp71870
g70037
VOur results suggest that miR-124 function as a tumor suppressor miRNA and suppress tumor proliferation and aggression by directly targeting oncogenic CD164 signaling pathway in NSCLC.
p71871
sg70039
(lp71872
(dp71873
g70042
I150
sg70043
VCD164
p71874
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71875
(dp71876
g70042
I47
sg70043
Vtumor
p71877
sg70045
I5
sg70054
VC0027651
p71878
sg70048
I1
sa(dp71879
g70042
I47
sg70043
Vtumor
p71880
sg70045
I5
sg70054
VC0027651
p71881
sg70048
I1
sa(dp71882
g70042
I177
sg70043
VNSCLC
p71883
sg70045
I5
sg70054
VC0007131
p71884
sg70048
I1
sa(dp71885
g70042
I107
sg70043
Vaggression
p71886
sg70045
I10
sg70054
VC0001807
p71887
sg70048
I1
sa(dp71888
g70042
I89
sg70043
Vproliferation
p71889
sg70045
I13
sg70054
VC0334094
p71890
sg70048
I1
sasa(dp71891
g135
(dp71892
(VCD4+
p71893
VSezary syndrome
p71894
tp71895
I01
ssg70037
VIn a cohort of patients with Sezary syndrome, CD164 expression on total CD4+ lymphocytes was significantly upregulated compared with healthy controls.
p71896
sg70039
(lp71897
(dp71898
g70042
I72
sg70043
g71893
sg70045
I4
sg70046
VP01730
p71899
sg70048
I1
sa(dp71900
g70042
I46
sg70043
VCD164
p71901
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71902
(dp71903
g70042
I29
sg70043
g71894
sg70045
I15
sg70054
VC0036920
p71904
sg70048
I2
sasa(dp71905
g70037
VIncreased expression of CD164 may be a promising diagnostic parameter and a potential target for a CD164-linked therapeutic approach in Sezary syndrome.
p71906
sg70039
(lp71907
(dp71908
g70042
I24
sg70043
VCD164
p71909
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp71910
g70042
I24
sg70043
VCD164
p71911
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71912
(dp71913
g70042
I136
sg70043
VSezary syndrome
p71914
sg70045
I15
sg70054
VC0036920
p71915
sg70048
I2
sasa(dp71916
g70037
VThese results indicate that miR-219 suppresses the proliferation, migration and invasion of medulloblastoma cells by targeting CD164.
p71917
sg70039
(lp71918
(dp71919
g70042
I127
sg70043
VCD164
p71920
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp71921
(dp71922
g70042
I80
sg70043
Vinvasion
p71923
sg70045
I8
sg70054
VC2699153
p71924
sg70048
I1
sa(dp71925
g70042
I51
sg70043
Vproliferation
p71926
sg70045
I13
sg70054
VC0334094
p71927
sg70048
I1
sa(dp71928
g70042
I92
sg70043
Vmedulloblastoma
p71929
sg70045
I15
sg70054
VC0025149
p71930
sg70048
I1
sasa(dp71931
g135
(dp71932
(VHirschsprung disease
p71933
VHirschsprung disease
p71934
tp71935
I00
ssg70037
VDespite the known engagement of the AFAP1-AS in several human diseases, its biological function in Hirschsprung disease (HSCR) remains elusive.
p71936
sg70039
(lp71937
(dp71938
g70042
I36
sg70043
VAFAP1-AS
p71939
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp71940
g70042
I121
sg70043
VHSCR
p71941
sg70045
I4
sg70046
VP14138
p71942
sg70048
I1
sa(dp71943
g70042
I99
sg70043
g71933
sg70045
I20
sg70046
VP14138
p71944
sg70048
I2
sasg70051
(lp71945
(dp71946
g70042
I121
sg70043
VHSCR
p71947
sg70045
I4
sg70054
VC2931876
p71948
sg70048
I1
sa(dp71949
g70042
I99
sg70043
g71934
sg70045
I20
sg70054
VC0019569
p71950
sg70048
I2
sasa(dp71951
g70037
VThis prospective observational study included 47 patients (mean age 29 years, range 3-50) with different resistant generalized epilepsy syndromes: idiopathic generalized syndromes (IGE) 15 patients, (juvenile myoclonic epilepsy four, absence epilepsy four, myoclonic absence two, unclassified IGE five), progressive myoclonic epilepsy type 1 (PME1) four, severe myoclonic epilepsy of infancy (SMEI) three, borderline SMEI three, Lennox-Gastaut syndrome/secondary generalized epileptic encephalopties 23 patients.
p71952
sg70039
(lp71953
(dp71954
g70042
I304
sg70043
Vprogressive myoclonic epilepsy type 1
p71955
sg70045
I37
sg70046
g12
sg70048
I5
sa(dp71956
g70042
I343
sg70043
VPME1
p71957
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp71958
(dp71959
g70042
I115
sg70043
Vgeneralized epilepsy
p71960
sg70045
I20
sg70054
VC0014548
p71961
sg70048
I2
sa(dp71962
g70042
I147
sg70043
Vidiopathic generalized syndromes
p71963
sg70045
I32
sg70054
VC0270850
p71964
sg70048
I3
sa(dp71965
g70042
I393
sg70043
VSMEI
p71966
sg70045
I4
sg70054
VC0751122
p71967
sg70048
I1
sa(dp71968
g70042
I304
sg70043
Vprogressive myoclonic epilepsy
p71969
sg70045
I30
sg70054
VC0751778
p71970
sg70048
I3
sa(dp71971
g70042
I234
sg70043
Vabsence epilepsy
p71972
sg70045
I16
sg70054
VC0014553
p71973
sg70048
I2
sa(dp71974
g70042
I393
sg70043
VSMEI
p71975
sg70045
I4
sg70054
VC0751122
p71976
sg70048
I1
sa(dp71977
g70042
I355
sg70043
Vsevere myoclonic epilepsy of infancy
p71978
sg70045
I36
sg70054
VC0751122
p71979
sg70048
I5
sa(dp71980
g70042
I181
sg70043
VIGE
p71981
sg70045
I3
sg70054
VC0270850
p71982
sg70048
I1
sa(dp71983
g70042
I475
sg70043
Vepileptic
p71984
sg70045
I9
sg70054
VC0014544
p71985
sg70048
I1
sa(dp71986
g70042
I200
sg70043
Vjuvenile myoclonic epilepsy
p71987
sg70045
I27
sg70054
VC0270853
p71988
sg70048
I3
sa(dp71989
g70042
I429
sg70043
VLennox-Gastaut syndrome
p71990
sg70045
I23
sg70054
VC0238111
p71991
sg70048
I2
sa(dp71992
g70042
I181
sg70043
VIGE
p71993
sg70045
I3
sg70054
VC0270850
p71994
sg70048
I1
sa(dp71995
g70042
I136
sg70043
Vsyndromes
p71996
sg70045
I9
sg70054
VC0039082
p71997
sg70048
I1
sasa(dp71998
g70037
VThe International League Against Epilepsy (ILAE) classification recognizes 2 forms of myoclonic epilepsy with a good prognosis: benign myoclonic epilepsy of infancy (BMEI) and juvenile myoclonic epilepsy (JME); recent studies confirm the efficacy of levetiracetam (LEV) in treating idiopathic generalized epilepsies (IGE) in patients with myoclonic seizures.
p71999
sg70039
(lp72000
sg70051
(lp72001
(dp72002
g70042
I86
sg70043
Vmyoclonic epilepsy
p72003
sg70045
I18
sg70054
VC0014550
p72004
sg70048
I2
sa(dp72005
g70042
I339
sg70043
Vmyoclonic seizures
p72006
sg70045
I18
sg70054
VC0014550
p72007
sg70048
I2
sa(dp72008
g70042
I317
sg70043
VIGE
p72009
sg70045
I3
sg70054
VC0270850
p72010
sg70048
I1
sa(dp72011
g70042
I86
sg70043
Vmyoclonic epilepsy
p72012
sg70045
I18
sg70054
VC0014550
p72013
sg70048
I2
sa(dp72014
g70042
I205
sg70043
VJME
p72015
sg70045
I3
sg70054
VC0270853
p72016
sg70048
I1
sa(dp72017
g70042
I33
sg70043
VEpilepsy
p72018
sg70045
I8
sg70054
VC0014544
p72019
sg70048
I1
sa(dp72020
g70042
I176
sg70043
Vjuvenile myoclonic epilepsy
p72021
sg70045
I27
sg70054
VC0270853
p72022
sg70048
I3
sa(dp72023
g70042
I282
sg70043
Vidiopathic generalized epilepsies
p72024
sg70045
I33
sg70054
VC0270850
p72025
sg70048
I3
sasa(dp72026
g70037
VWe evaluated 35 patients (21 female, mean age 24.7 years) with different types of generalised epilepsies (juvenile myoclonic epilepsy (JME), severe myoclonic epilepsy of infancy (SMEI), Lennox-Gastaut syndrome (LGS), myoclonic-astatic epilepsy (MAE), myoclonic absences (MA), benign myoclonic epilepsy in infancy (BMEI) and 4 patients had unspecified epileptic syndromes).
p72027
sg70039
(lp72028
sg70051
(lp72029
(dp72030
g70042
I211
sg70043
VLGS
p72031
sg70045
I3
sg70054
VC0023003
p72032
sg70048
I1
sa(dp72033
g70042
I125
sg70043
Vepilepsy
p72034
sg70045
I8
sg70054
VC0014544
p72035
sg70048
I1
sa(dp72036
g70042
I314
sg70043
VBMEI
p72037
sg70045
I4
sg70054
VC0751120
p72038
sg70048
I1
sa(dp72039
g70042
I135
sg70043
VJME
p72040
sg70045
I3
sg70054
VC0270853
p72041
sg70048
I1
sa(dp72042
g70042
I276
sg70043
Vbenign myoclonic epilepsy in infancy
p72043
sg70045
I36
sg70054
VC0751120
p72044
sg70048
I5
sa(dp72045
g70042
I179
sg70043
VSMEI
p72046
sg70045
I4
sg70054
VC0751122
p72047
sg70048
I1
sa(dp72048
g70042
I361
sg70043
Vsyndromes
p72049
sg70045
I9
sg70054
VC0039082
p72050
sg70048
I1
sa(dp72051
g70042
I141
sg70043
Vsevere myoclonic epilepsy of infancy
p72052
sg70045
I36
sg70054
VC0751122
p72053
sg70048
I5
sa(dp72054
g70042
I186
sg70043
VLennox-Gastaut syndrome
p72055
sg70045
I23
sg70054
VC0238111
p72056
sg70048
I2
sa(dp72057
g70042
I106
sg70043
Vjuvenile myoclonic epilepsy
p72058
sg70045
I27
sg70054
VC0270853
p72059
sg70048
I3
sa(dp72060
g70042
I351
sg70043
Vepileptic
p72061
sg70045
I9
sg70054
VC0014544
p72062
sg70048
I1
sa(dp72063
g70042
I94
sg70043
Vepilepsies
p72064
sg70045
I10
sg70054
VC0014544
p72065
sg70048
I1
sasa(dp72066
g70037
VThe electroclinical features suggested juvenile myoclonic epilepsy in 14 patients, progressive myoclonus epilepsy in three, progressive familial cerebellar ataxia with myoclonus in two, and severe myoclonic epilepsy of infancy in one.
p72067
sg70039
(lp72068
sg70051
(lp72069
(dp72070
g70042
I83
sg70043
Vprogressive myoclonus epilepsy
p72071
sg70045
I30
sg70054
VC0751778
p72072
sg70048
I3
sa(dp72073
g70042
I190
sg70043
Vsevere myoclonic epilepsy of infancy
p72074
sg70045
I36
sg70054
VC0751122
p72075
sg70048
I5
sa(dp72076
g70042
I136
sg70043
Vfamilial cerebellar ataxia
p72077
sg70045
I26
sg70054
VC0270749
p72078
sg70048
I3
sa(dp72079
g70042
I39
sg70043
Vjuvenile myoclonic epilepsy
p72080
sg70045
I27
sg70054
VC0270853
p72081
sg70048
I3
sa(dp72082
g70042
I95
sg70043
Vmyoclonus
p72083
sg70045
I9
sg70054
VC0027066
p72084
sg70048
I1
sasa(dp72085
g70037
VIn the idiopathic generalized epilepsies we consider the benign myoclonic epilepsy of infancy and its reflex variant, juvenile myoclonic epilepsy and palpebral myoclonias with absences.
p72086
sg70039
(lp72087
sg70051
(lp72088
(dp72089
g70042
I118
sg70043
Vjuvenile myoclonic epilepsy
p72090
sg70045
I27
sg70054
VC0270853
p72091
sg70048
I3
sa(dp72092
g70042
I18
sg70043
Vgeneralized epilepsies
p72093
sg70045
I22
sg70054
VC0014548
p72094
sg70048
I2
sa(dp72095
g70042
I64
sg70043
Vmyoclonic epilepsy
p72096
sg70045
I18
sg70054
VC0014550
p72097
sg70048
I2
sasa(dp72098
g70037
VGroup 5 comprises the true myoclonic epilepsies, differentiating syndromes recognized as idiopathic--such as "Benign myoclonic epilepsy of infancy" and "Juvenile myoclonic epilepsy"--from those which are cryptogenic and carry a more cautious prognosis--as "Cryptogenic myoclonic and myoclonoastatic epilepsies" and "Severe myoclonic epilepsy of infancy".
p72099
sg70039
(lp72100
sg70051
(lp72101
(dp72102
g70042
I117
sg70043
Vmyoclonic epilepsy
p72103
sg70045
I18
sg70054
VC0014550
p72104
sg70048
I2
sa(dp72105
g70042
I27
sg70043
Vmyoclonic epilepsies
p72106
sg70045
I20
sg70054
VC0014550
p72107
sg70048
I2
sa(dp72108
g70042
I37
sg70043
Vepilepsies
p72109
sg70045
I10
sg70054
VC0014544
p72110
sg70048
I1
sa(dp72111
g70042
I153
sg70043
VJuvenile myoclonic epilepsy
p72112
sg70045
I27
sg70054
VC0270853
p72113
sg70048
I3
sa(dp72114
g70042
I316
sg70043
VSevere myoclonic epilepsy of infancy
p72115
sg70045
I36
sg70054
VC0751122
p72116
sg70048
I5
sa(dp72117
g70042
I65
sg70043
Vsyndromes
p72118
sg70045
I9
sg70054
VC0039082
p72119
sg70048
I1
sasa(dp72120
g70037
VInteraction studies also showed that CEP78 binds to FAM161A, another ciliary protein associated with retinal degeneration.
p72121
sg70039
(lp72122
(dp72123
g70042
I52
sg70043
VFAM161A
p72124
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp72125
g70042
I37
sg70043
VCEP78
p72126
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp72127
(dp72128
g70042
I101
sg70043
Vretinal degeneration
p72129
sg70045
I20
sg70054
VC0035304
p72130
sg70048
I2
sasa(dp72131
g70037
VAltogether, our data strongly suggest that mutations in CEP78 cause a previously undescribed clinical entity of a ciliary nature characterized by blindness and deafness but clearly distinct from Usher syndrome, a condition for which visual impairment is due to retinitis pigmentosa.
p72132
sg70039
(lp72133
(dp72134
g70042
I56
sg70043
VCEP78
p72135
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp72136
(dp72137
g70042
I261
sg70043
Vretinitis pigmentosa
p72138
sg70045
I20
sg70054
VC0035334
p72139
sg70048
I2
sa(dp72140
g70042
I195
sg70043
VUsher syndrome
p72141
sg70045
I14
sg70054
VC0271097
p72142
sg70048
I2
sa(dp72143
g70042
I160
sg70043
Vdeafness
p72144
sg70045
I8
sg70054
VC0011053
p72145
sg70048
I1
sa(dp72146
g70042
I233
sg70043
Vvisual impairment
p72147
sg70045
I17
sg70054
VC3489703
p72148
sg70048
I2
sa(dp72149
g70042
I213
sg70043
Vcondition
p72150
sg70045
I9
sg70054
VC0012634
p72151
sg70048
I1
sa(dp72152
g70042
I146
sg70043
Vblindness
p72153
sg70045
I9
sg70054
VC0456909
p72154
sg70048
I1
sasa(dp72155
g70037
VMethods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed treatment (not including endocrine therapy) 2 months to 5 years previously, were age &gt; 18 years, and had scores above the clinical cutoff on the FCR Inventory (FCRI) severity subscale at screening.
p72156
sg70039
(lp72157
sg70051
(lp72158
(dp72159
g70042
I49
sg70043
Vcolorectal cancer
p72160
sg70045
I17
sg70054
VC1527249
p72161
sg70048
I2
sa(dp72162
g70042
I70
sg70043
Vmelanoma
p72163
sg70045
I8
sg70054
VC0025202
p72164
sg70048
I1
sasa(dp72165
g135
(dp72166
(VFCRI
p72167
Vpsychological distress
p72168
tp72169
I00
ssg70037
VConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P &lt; .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total).
p72170
sg70039
(lp72171
(dp72172
g70042
I122
sg70043
VFCRI
p72173
sg70045
I4
sg70046
VP12314
p72174
sg70048
I1
sa(dp72175
g70042
I122
sg70043
g72167
sg70045
I4
sg70046
VP12314
p72176
sg70048
I1
sasg70051
(lp72177
(dp72178
g70042
I353
sg70043
g72168
sg70045
I22
sg70054
VC0815107
p72179
sg70048
I2
sa(dp72180
g70042
I422
sg70043
Vcancer
p72181
sg70045
I6
sg70054
VC0006826
p72182
sg70048
I1
sasa(dp72183
g70037
VDifferences in FCRI psychological distress and cancer-specific distress (total) remained significantly different at T3.
p72184
sg70039
(lp72185
sg70051
(lp72186
(dp72187
g70042
I20
sg70043
Vpsychological distress
p72188
sg70045
I22
sg70054
VC0815107
p72189
sg70048
I2
sa(dp72190
g70042
I47
sg70043
Vcancer
p72191
sg70045
I6
sg70054
VC0006826
p72192
sg70048
I1
sasa(dp72193
g70037
VGanoderic acid interacts and modulates the signaling network in IR, IGFR-1, IGFR-2, VEGFR-1, VEFGR-2, and EGFR in cancer signaling pathways.
p72194
sg70039
(lp72195
(dp72196
g70042
I68
sg70043
VIGFR-1
p72197
sg70045
I6
sg70046
VP08069
p72198
sg70048
I1
sa(dp72199
g70042
I84
sg70043
VVEGFR-1
p72200
sg70045
I7
sg70046
VP17948
p72201
sg70048
I1
sa(dp72202
g70042
I76
sg70043
VIGFR-2
p72203
sg70045
I6
sg70046
VP08069
p72204
sg70048
I1
sasg70051
(lp72205
(dp72206
g70042
I114
sg70043
Vcancer
p72207
sg70045
I6
sg70054
VC0006826
p72208
sg70048
I1
sasa(dp72209
g135
(dp72210
(VCD14 IND
p72211
Vbacterial infection
p72212
tp72213
I00
ssg70037
VSixty-four patients with hematological tumors were selected and divided into the group complicated with bacterial infection (infection group, 33 cases) and the non-infection group (31 cases), the flow cytometry was be used to detect the related peripheral blood markers CD64 and CD14, the nCD64 IND and CD14 IND were calculated, and the peripheral blood WBC count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were determined at the same time.
p72214
sg70039
(lp72215
(dp72216
g70042
I406
sg70043
VC-reactive protein
p72217
sg70045
I18
sg70046
VP02741
p72218
sg70048
I2
sa(dp72219
g70042
I279
sg70043
VCD14
p72220
sg70045
I4
sg70046
VP08571
p72221
sg70048
I1
sa(dp72222
g70042
I426
sg70043
VCRP
p72223
sg70045
I3
sg70046
VP02741
p72224
sg70048
I1
sa(dp72225
g70042
I270
sg70043
VCD64
p72226
sg70045
I4
sg70046
VP12314
p72227
sg70048
I1
sa(dp72228
g70042
I303
sg70043
g72211
sg70045
I8
sg70046
VP08571
p72229
sg70048
I2
sasg70051
(lp72230
(dp72231
g70042
I25
sg70043
Vhematological tumors
p72232
sg70045
I20
sg70054
VC0376545
p72233
sg70048
I2
sa(dp72234
g70042
I104
sg70043
g72212
sg70045
I19
sg70054
VC0004623
p72235
sg70048
I2
sa(dp72236
g70042
I114
sg70043
Vinfection
p72237
sg70045
I9
sg70054
VC0009450
p72238
sg70048
I1
sa(dp72239
g70042
I114
sg70043
Vinfection
p72240
sg70045
I9
sg70054
VC0009450
p72241
sg70048
I1
sasa(dp72242
g70037
VThe study objectives are to translate the FCRI in Dutch, and to explore the factor structure and the psychometric qualities of the Dutch translation of the Fear of Cancer Recurrence Inventory (FCRI-NL).
p72243
sg70039
(lp72244
sg70051
(lp72245
(dp72246
g70042
I164
sg70043
VCancer Recurrence
p72247
sg70045
I17
sg70054
VC0920420
p72248
sg70048
I2
sa(dp72249
g70042
I156
sg70043
VFear of Cancer
p72250
sg70045
I14
sg70054
VC0233705
p72251
sg70048
I3
sasa(dp72252
g70037
VThe Severity subscale (FCRI-SF-NL) may be a valuable screening tool for fear of cancer recurrence severity in clinical care.
p72253
sg70039
(lp72254
sg70051
(lp72255
(dp72256
g70042
I80
sg70043
Vcancer recurrence
p72257
sg70045
I17
sg70054
VC0920420
p72258
sg70048
I2
sa(dp72259
g70042
I72
sg70043
Vfear of cancer
p72260
sg70045
I14
sg70054
VC0233705
p72261
sg70048
I3
sasa(dp72262
g135
(dp72263
(VCD34
p72264
VAPL
p72265
tp72266
I00
ssg70037
VFCI features, with single-tube 8-color combination using CD45, CD34, HAL-DR, CD11b, CD13, CD33, and CD117 and CD64, were compared for the 30 consecutive APL and 30 non-APL acute myeloid leukemia (AML) cases which morphologically mimicked an APL.
p72267
sg70039
(lp72268
(dp72269
g70042
I100
sg70043
VCD117
p72270
sg70045
I5
sg70046
VP10721
p72271
sg70048
I1
sa(dp72272
g70042
I57
sg70043
VCD45
p72273
sg70045
I4
sg70046
VP08575
p72274
sg70048
I1
sa(dp72275
g70042
I90
sg70043
VCD33
p72276
sg70045
I4
sg70046
VP20138
p72277
sg70048
I1
sa(dp72278
g70042
I84
sg70043
VCD13
p72279
sg70045
I4
sg70046
VP15144
p72280
sg70048
I1
sa(dp72281
g70042
I77
sg70043
VCD11b
p72282
sg70045
I5
sg70046
VP11215
p72283
sg70048
I1
sa(dp72284
g70042
I69
sg70043
VHAL-DR
p72285
sg70045
I6
sg70046
VP42357
p72286
sg70048
I1
sa(dp72287
g70042
I110
sg70043
VCD64
p72288
sg70045
I4
sg70046
VP12314
p72289
sg70048
I1
sa(dp72290
g70042
I63
sg70043
g72264
sg70045
I4
sg70046
VP28906
p72291
sg70048
I1
sasg70051
(lp72292
(dp72293
g70042
I196
sg70043
VAML
p72294
sg70045
I3
sg70054
VC0023467
p72295
sg70048
I1
sa(dp72296
g70042
I153
sg70043
VAPL
p72297
sg70045
I3
sg70054
VC0023487
p72298
sg70048
I1
sa(dp72299
g70042
I172
sg70043
Vacute myeloid leukemia
p72300
sg70045
I22
sg70054
VC0023467
p72301
sg70048
I3
sa(dp72302
g70042
I153
sg70043
VAPL
p72303
sg70045
I3
sg70054
VC0023487
p72304
sg70048
I1
sa(dp72305
g70042
I153
sg70043
g72265
sg70045
I3
sg70054
VC0023487
p72306
sg70048
I1
sasa(dp72307
g70037
VThis study aimed to confirm the cultural equivalence, reliability, and validity of the Korean version of Fear of Cancer Recurrence Inventory (K-FCRI).
p72308
sg70039
(lp72309
sg70051
(lp72310
(dp72311
g70042
I113
sg70043
VCancer Recurrence
p72312
sg70045
I17
sg70054
VC0920420
p72313
sg70048
I2
sa(dp72314
g70042
I105
sg70043
VFear of Cancer
p72315
sg70045
I14
sg70054
VC0233705
p72316
sg70048
I3
sasa(dp72317
g70037
VThe psychometric property of the K-FCRI was then validated in 444 survivors from cancers at various sites.
p72318
sg70039
(lp72319
(dp72320
g70042
I33
sg70043
VK-FCRI
p72321
sg70045
I6
sg70046
VP12314
p72322
sg70048
I1
sasg70051
(lp72323
(dp72324
g70042
I81
sg70043
Vcancers
p72325
sg70045
I7
sg70054
VC0006826
p72326
sg70048
I1
sasa(dp72327
g70037
VThe K-FCRI had significant correlations with the Korean version of Fear of Progression Questionnaire, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0, Hospital Anxiety and Depression Scale, and Fatigue Severity Score, supporting the good construct validity and psychometric properties of K-FCRI.
p72328
sg70039
(lp72329
sg70051
(lp72330
(dp72331
g70042
I154
sg70043
VCancer
p72332
sg70045
I6
sg70054
VC0006826
p72333
sg70048
I1
sa(dp72334
g70042
I247
sg70043
VFatigue
p72335
sg70045
I7
sg70054
VC0015672
p72336
sg70048
I1
sa(dp72337
g70042
I225
sg70043
VDepression
p72338
sg70045
I10
sg70054
VC0011581
p72339
sg70048
I1
sasa(dp72340
g70037
VThe K-FCRI was confirmed as a valid and reliable psychometric test for measuring FCR of Korean survivors from cancers at various sites.
p72341
sg70039
(lp72342
(dp72343
g70042
I4
sg70043
VK-FCRI
p72344
sg70045
I6
sg70046
VP12314
p72345
sg70048
I1
sasg70051
(lp72346
(dp72347
g70042
I110
sg70043
Vcancers
p72348
sg70045
I7
sg70054
VC0006826
p72349
sg70048
I1
sasa(dp72350
g70037
VRecently, CLPB deficiency has been shown to cause a genetic syndrome with cataracts, neutropenia, and 3-methylglutaconic aciduria.
p72351
sg70039
(lp72352
(dp72353
g70042
I10
sg70043
VCLPB
p72354
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp72355
(dp72356
g70042
I102
sg70043
V3-methylglutaconic aciduria
p72357
sg70045
I27
sg70054
VC0342727
p72358
sg70048
I2
sa(dp72359
g70042
I52
sg70043
Vgenetic syndrome
p72360
sg70045
I16
sg70054
VC0567439
p72361
sg70048
I2
sa(dp72362
g70042
I74
sg70043
Vcataracts
p72363
sg70045
I9
sg70054
VC0521707
p72364
sg70048
I1
sasa(dp72365
g70037
VCLPB deficiency should be considered in neonates with absence of voluntary movements, respiratory insufficiency and swallowing problems, especially if associated with 3-methylglutaconic aciduria, neutropenia and cataracts.
p72366
sg70039
(lp72367
sg70051
(lp72368
(dp72369
g70042
I167
sg70043
V3-methylglutaconic aciduria
p72370
sg70045
I27
sg70054
VC0342727
p72371
sg70048
I2
sa(dp72372
g70042
I86
sg70043
Vrespiratory insufficiency
p72373
sg70045
I25
sg70054
VC0035229
p72374
sg70048
I2
sa(dp72375
g70042
I212
sg70043
Vcataracts
p72376
sg70045
I9
sg70054
VC0521707
p72377
sg70048
I1
sa(dp72378
g70042
I116
sg70043
Vswallowing problems
p72379
sg70045
I19
sg70054
VC0392678
p72380
sg70048
I2
sasa(dp72381
g70037
VMutations in CLPB, SERAC1, TAZ genes were identified in neonates with 3-methylglutaconic aciduria (3-MGA) as a discriminative feature.
p72382
sg70039
(lp72383
(dp72384
g70042
I27
sg70043
VTAZ genes
p72385
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp72386
g70042
I19
sg70043
VSERAC1
p72387
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp72388
(dp72389
g70042
I99
sg70043
V3-MGA
p72390
sg70045
I5
sg70054
VC0342727
p72391
sg70048
I1
sa(dp72392
g70042
I70
sg70043
V3-methylglutaconic aciduria
p72393
sg70045
I27
sg70054
VC0342727
p72394
sg70048
I2
sasa(dp72395
g70037
VAltogether, our study suggests that disruption of CLPB causes a novel form of neonatal encephalopathy associated with 3-methylglutaconic aciduria.
p72396
sg70039
(lp72397
(dp72398
g70042
I50
sg70043
VCLPB
p72399
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp72400
(dp72401
g70042
I78
sg70043
Vneonatal encephalopathy
p72402
sg70045
I23
sg70054
VC0235820
p72403
sg70048
I2
sa(dp72404
g70042
I118
sg70043
V3-methylglutaconic aciduria
p72405
sg70045
I27
sg70054
VC0342727
p72406
sg70048
I2
sasa(dp72407
g70037
VTaken together, mutations in CLPB define a syndrome with intellectual disability, congenital neutropenia, progressive brain atrophy, movement disorder, cataracts, and 3-methylglutaconic aciduria.
p72408
sg70039
(lp72409
sg70051
(lp72410
(dp72411
g70042
I152
sg70043
Vcataracts
p72412
sg70045
I9
sg70054
VC0521707
p72413
sg70048
I1
sa(dp72414
g70042
I57
sg70043
Vintellectual disability
p72415
sg70045
I23
sg70054
VC0025362
p72416
sg70048
I2
sa(dp72417
g70042
I167
sg70043
V3-methylglutaconic aciduria
p72418
sg70045
I27
sg70054
VC0342727
p72419
sg70048
I2
sa(dp72420
g70042
I82
sg70043
Vcongenital neutropenia
p72421
sg70045
I22
sg70054
VC0340970
p72422
sg70048
I2
sa(dp72423
g70042
I133
sg70043
Vmovement disorder
p72424
sg70045
I17
sg70054
VC0026650
p72425
sg70048
I2
sa(dp72426
g70042
I43
sg70043
Vsyndrome
p72427
sg70045
I8
sg70054
VC0039082
p72428
sg70048
I1
sa(dp72429
g70042
I118
sg70043
Vbrain atrophy
p72430
sg70045
I13
sg70054
VC0235946
p72431
sg70048
I2
sasa(dp72432
g70037
VWe conclude that accumulation of protein aggregates underlies the development of cataracts and nephrocalcinosis in CLPB deficiency, which is a novel genetic cause of 3-methylglutaconic aciduria.
p72433
sg70039
(lp72434
sg70051
(lp72435
(dp72436
g70042
I95
sg70043
Vnephrocalcinosis
p72437
sg70045
I16
sg70054
VC0027709
p72438
sg70048
I1
sa(dp72439
g70042
I81
sg70043
Vcataracts
p72440
sg70045
I9
sg70054
VC0521707
p72441
sg70048
I1
sa(dp72442
g70042
I166
sg70043
V3-methylglutaconic aciduria
p72443
sg70045
I27
sg70054
VC0342727
p72444
sg70048
I2
sasa(dp72445
g70037
VWe now propose that perturbation of the mitochondrial membranes by abnormal protein aggregates leads to 3-methylglutaconic aciduria in CLPB deficiency.
p72446
sg70039
(lp72447
sg70051
(lp72448
(dp72449
g70042
I104
sg70043
V3-methylglutaconic aciduria
p72450
sg70045
I27
sg70054
VC0342727
p72451
sg70048
I2
sasa(dp72452
g70037
VHere, we present mechanistic details about the Hsp100 chaperone inhibition by GdmCl using the Hsp104 homolog ClpB from Thermus thermophilus.
p72453
sg70039
(lp72454
(dp72455
g70042
I94
sg70043
VHsp104 homolog ClpB
p72456
sg70045
I19
sg70046
g12
sg70048
I3
sasg70051
(lp72457
sa(dp72458
g70037
VWe present a crystal structure of ClpB NBD1 in complex with GdmCl and ADP, showing that the Gdm(+) ion binds specifically to the active site of NBD1.
p72459
sg70039
(lp72460
(dp72461
g70042
I34
sg70043
VClpB NBD1
p72462
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp72463
(dp72464
g70042
I60
sg70043
VGdm
p72465
sg70045
I3
sg70054
VC0085207
p72466
sg70048
I1
sasa(dp72467
g135
(dp72468
(Vsecretin
p72469
Vnesidioblastosis
p72470
tp72471
I00
ssg70037
VOne patient with nesidioblastosis had no response to secretin, indicating that the pathophysiology of this entity is distinct from that of other forms of islet hyperplasia.
p72472
sg70039
(lp72473
(dp72474
g70042
I53
sg70043
g72469
sg70045
I8
sg70046
VP09683
p72475
sg70048
I1
sasg70051
(lp72476
(dp72477
g70042
I160
sg70043
Vhyperplasia
p72478
sg70045
I11
sg70054
VC0020507
p72479
sg70048
I1
sa(dp72480
g70042
I17
sg70043
g72470
sg70045
I16
sg70054
VC0027773
p72481
sg70048
I1
sasa(dp72482
g135
(dp72483
(Vsecretin
p72484
Vadenomas
p72485
tp72486
I00
ssg70037
VIn addition, the ability to respond to secretin appears to be lost in patients with single insulinomas and nesidioblastosis, but not in those with multiple B-cell adenomas and hyperplasia.
p72487
sg70039
(lp72488
(dp72489
g70042
I39
sg70043
g72484
sg70045
I8
sg70046
VP09683
p72490
sg70048
I1
sasg70051
(lp72491
(dp72492
g70042
I176
sg70043
Vhyperplasia
p72493
sg70045
I11
sg70054
VC0020507
p72494
sg70048
I1
sa(dp72495
g70042
I91
sg70043
Vinsulinomas
p72496
sg70045
I11
sg70054
VC0021670
p72497
sg70048
I1
sa(dp72498
g70042
I107
sg70043
Vnesidioblastosis
p72499
sg70045
I16
sg70054
VC0027773
p72500
sg70048
I1
sa(dp72501
g70042
I163
sg70043
g72485
sg70045
I8
sg70054
VC0001430
p72502
sg70048
I1
sasa(dp72503
g135
(dp72504
(VHLXB9
p72505
Vacute myeloid leukemia
p72506
tp72507
I00
ssg70037
VIn addition, HLXB9 is recurrently rearranged in young children with acute myeloid leukemia characterized by a chromosomal translocation t(7;12)-HLXB9/TEL and concomitant high expression of the unrearranged, wild-type HLXB9 allele.
p72508
sg70039
(lp72509
(dp72510
g70042
I13
sg70043
VHLXB9
p72511
sg70045
I5
sg70046
VP50219
p72512
sg70048
I1
sa(dp72513
g70042
I207
sg70043
Vwild-type HLXB9 allele
p72514
sg70045
I22
sg70046
VP50219
p72515
sg70048
I3
sa(dp72516
g70042
I150
sg70043
VTEL
p72517
sg70045
I3
sg70046
VP41212
p72518
sg70048
I1
sa(dp72519
g70042
I13
sg70043
g72505
sg70045
I5
sg70046
VP50219
p72520
sg70048
I1
sasg70051
(lp72521
(dp72522
g70042
I110
sg70043
Vchromosomal translocation
p72523
sg70045
I25
sg70054
VC0040715
p72524
sg70048
I2
sa(dp72525
g70042
I68
sg70043
g72506
sg70045
I22
sg70054
VC0023467
p72526
sg70048
I3
sasa(dp72527
g135
(dp72528
(VHLXB9
p72529
Vacute myeloid leukemia
p72530
tp72531
I00
ssg70037
VHerein, we report the clinical course of an 8-month-old patient with acute myeloid leukemia, M2 subtype and with a HLXB9/TEL rearrangement.
p72532
sg70039
(lp72533
(dp72534
g70042
I121
sg70043
VTEL
p72535
sg70045
I3
sg70046
VP41212
p72536
sg70048
I1
sa(dp72537
g70042
I115
sg70043
g72529
sg70045
I5
sg70046
VP50219
p72538
sg70048
I1
sasg70051
(lp72539
(dp72540
g70042
I69
sg70043
g72530
sg70045
I22
sg70054
VC0023467
p72541
sg70048
I3
sasa(dp72542
g135
(dp72543
(VEN2
p72544
Vacute myeloid leukemia
p72545
tp72546
I00
ssg70037
VUsing RT-PCR, we screened members of the EHG family of homeobox genes, comprising EN1 (at 2q14), GBX2 (at 2q36), and EN2, GBX1, and HLXB9 (at 7q36), for dysregulation in acute myeloid leukemia (AML) cell lines indicated by chromosomal breakpoints at these sites.
p72547
sg70039
(lp72548
(dp72549
g70042
I55
sg70043
Vhomeobox genes
p72550
sg70045
I14
sg70046
VP52954
p72551
sg70048
I2
sa(dp72552
g70042
I97
sg70043
VGBX2
p72553
sg70045
I4
sg70046
VP52951
p72554
sg70048
I1
sa(dp72555
g70042
I122
sg70043
VGBX1
p72556
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72557
g70042
I132
sg70043
VHLXB9
p72558
sg70045
I5
sg70046
VP50219
p72559
sg70048
I1
sa(dp72560
g70042
I117
sg70043
g72544
sg70045
I3
sg70046
VP41208
p72561
sg70048
I1
sasg70051
(lp72562
(dp72563
g70042
I194
sg70043
VAML
p72564
sg70045
I3
sg70054
VC0023467
p72565
sg70048
I1
sa(dp72566
g70042
I170
sg70043
g72545
sg70045
I22
sg70054
VC0023467
p72567
sg70048
I3
sasa(dp72568
g135
(dp72569
(VRAS
p72570
Vadenomas
p72571
tp72572
I00
ssg70037
VPreviously, we showed that KLF5 is a mediator of RAS/MAPK and WNT signaling pathways under homeostatic conditions and that it promotes their tumorigenic functions during the development and progression of intestinal adenomas.
p72573
sg70039
(lp72574
(dp72575
g70042
I27
sg70043
VKLF5
p72576
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72577
g70042
I53
sg70043
VMAPK
p72578
sg70045
I4
sg70046
VP53779
p72579
sg70048
I1
sa(dp72580
g70042
I49
sg70043
g72570
sg70045
I3
sg70046
VP01116
p72581
sg70048
I1
sasg70051
(lp72582
(dp72583
g70042
I216
sg70043
g72571
sg70045
I8
sg70054
VC0001430
p72584
sg70048
I1
sasa(dp72585
g135
(dp72586
(VBeta-catenin
p72587
Vadenomas
p72588
tp72589
I00
ssg70037
VMoreover, production of lethal adenomas and carcinomas by specific expression of an oncogenic mutant of Beta-catenin in Lgr5(+) stem cells was suppressed completely by Klf5 deletion in the same cells.
p72590
sg70039
(lp72591
(dp72592
g70042
I168
sg70043
VKlf5 deletion
p72593
sg70045
I13
sg70046
g12
sg70048
I2
sa(dp72594
g70042
I120
sg70043
VLgr5
p72595
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72596
g70042
I104
sg70043
g72587
sg70045
I12
sg70046
VP35222
p72597
sg70048
I1
sasg70051
(lp72598
(dp72599
g70042
I31
sg70043
g72588
sg70045
I8
sg70054
VC0001430
p72600
sg70048
I1
sa(dp72601
g70042
I44
sg70043
Vcarcinomas
p72602
sg70045
I10
sg70054
VC0007097
p72603
sg70048
I1
sa(dp72604
g70042
I94
sg70043
Vmutant
p72605
sg70045
I6
sg70054
VC0596988
p72606
sg70048
I1
sasa(dp72607
g70037
VElevated levels of two particular Fbxw7 substrates, Klf5 and Tgif1, were found in normal intestine and adenomas of R482Q/+, R482Q/R482Q and Fbxw7(-/-) mice, but not Fbxw7(+/-) animals.
p72608
sg70039
(lp72609
(dp72610
g70042
I52
sg70043
VKlf5
p72611
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72612
g70042
I61
sg70043
VTgif1
p72613
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp72614
g70042
I34
sg70043
VFbxw7
p72615
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp72616
g70042
I34
sg70043
VFbxw7
p72617
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp72618
g70042
I34
sg70043
VFbxw7
p72619
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp72620
(dp72621
g70042
I103
sg70043
Vadenomas
p72622
sg70045
I8
sg70054
VC0001430
p72623
sg70048
I1
sasa(dp72624
g70037
VHere we investigated the in vivo effect of Klf5 heterozygosity on the propensity of ApcMin/KRASV12 double transgenic mice to develop intestinal tumors.
p72625
sg70039
(lp72626
(dp72627
g70042
I43
sg70043
VKlf5
p72628
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp72629
(dp72630
g70042
I133
sg70043
Vintestinal tumors
p72631
sg70045
I17
sg70054
VC0021841
p72632
sg70048
I2
sasa(dp72633
g135
(dp72634
(VApc
p72635
VApc
p72636
tp72637
I00
ssg70037
VTo determine whether KLF5 contributes to intestinal adenoma formation, we examined tumor burdens in Apc(Min/+) mice and Apc(Min/+)/Klf5(+/-) mice.
p72638
sg70039
(lp72639
(dp72640
g70042
I100
sg70043
VApc
p72641
sg70045
I3
sg70046
VP25054
p72642
sg70048
I1
sa(dp72643
g70042
I100
sg70043
g72635
sg70045
I3
sg70046
VP25054
p72644
sg70048
I1
sa(dp72645
g70042
I21
sg70043
VKLF5
p72646
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72647
g70042
I131
sg70043
VKlf5
p72648
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp72649
(dp72650
g70042
I41
sg70043
Vintestinal adenoma
p72651
sg70045
I18
sg70054
VC1142339
p72652
sg70048
I2
sa(dp72653
g70042
I83
sg70043
Vtumor
p72654
sg70045
I5
sg70054
VC0027651
p72655
sg70048
I1
sa(dp72656
g70042
I100
sg70043
VApc
p72657
sg70045
I3
sg70054
VC0033036
p72658
sg70048
I1
sa(dp72659
g70042
I100
sg70043
g72636
sg70045
I3
sg70054
VC0033036
p72660
sg70048
I1
sasa(dp72661
g135
(dp72662
(VApc
p72663
VApc
p72664
tp72665
I00
ssg70037
VCompared with Apc(Min/+) mice, Apc(Min/+)/Klf5(+/-) mice had a 96% reduction in the number of intestinal adenomas.
p72666
sg70039
(lp72667
(dp72668
g70042
I14
sg70043
VApc
p72669
sg70045
I3
sg70046
VP25054
p72670
sg70048
I1
sa(dp72671
g70042
I42
sg70043
VKlf5
p72672
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72673
g70042
I14
sg70043
g72663
sg70045
I3
sg70046
VP25054
p72674
sg70048
I1
sasg70051
(lp72675
(dp72676
g70042
I14
sg70043
VApc
p72677
sg70045
I3
sg70054
VC0033036
p72678
sg70048
I1
sa(dp72679
g70042
I105
sg70043
Vadenomas
p72680
sg70045
I8
sg70054
VC0001430
p72681
sg70048
I1
sa(dp72682
g70042
I14
sg70043
g72664
sg70045
I3
sg70054
VC0033036
p72683
sg70048
I1
sasa(dp72684
g135
(dp72685
(VApc
p72686
VApc
p72687
tp72688
I00
ssg70037
VThus, KLF5 is necessary for the tumor-initiating activity of beta-catenin during intestinal adenoma formation in Apc(Min/+) mice, and reduced expression of KLF5 offsets the tumor-initiating activity of the Apc(Min) mutation by reducing the nuclear localization and activity of beta-catenin.
p72689
sg70039
(lp72690
(dp72691
g70042
I6
sg70043
VKLF5
p72692
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72693
g70042
I61
sg70043
Vbeta-catenin
p72694
sg70045
I12
sg70046
VP35222
p72695
sg70048
I1
sa(dp72696
g70042
I113
sg70043
VApc
p72697
sg70045
I3
sg70046
VP25054
p72698
sg70048
I1
sa(dp72699
g70042
I6
sg70043
VKLF5
p72700
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72701
g70042
I61
sg70043
Vbeta-catenin
p72702
sg70045
I12
sg70046
VP35222
p72703
sg70048
I1
sa(dp72704
g70042
I113
sg70043
g72686
sg70045
I3
sg70046
VP25054
p72705
sg70048
I1
sasg70051
(lp72706
(dp72707
g70042
I113
sg70043
VApc
p72708
sg70045
I3
sg70054
VC0033036
p72709
sg70048
I1
sa(dp72710
g70042
I81
sg70043
Vintestinal adenoma
p72711
sg70045
I18
sg70054
VC1142339
p72712
sg70048
I2
sa(dp72713
g70042
I32
sg70043
Vtumor
p72714
sg70045
I5
sg70054
VC0027651
p72715
sg70048
I1
sa(dp72716
g70042
I113
sg70043
g72687
sg70045
I3
sg70054
VC0033036
p72717
sg70048
I1
sa(dp72718
g70042
I32
sg70043
Vtumor
p72719
sg70045
I5
sg70054
VC0027651
p72720
sg70048
I1
sasa(dp72721
g135
(dp72722
(VKRAS
p72723
Vcolorectal cancers
p72724
tp72725
I00
ssg70037
VKLF5 expression was examined in intestinal tumors derived from transgenic mice expressing KRAS(V12G) under villin promoter and in human colorectal cancers with mutated KRAS.
p72726
sg70039
(lp72727
(dp72728
g70042
I90
sg70043
VKRAS
p72729
sg70045
I4
sg70046
VP01116
p72730
sg70048
I1
sa(dp72731
g70042
I107
sg70043
Vvillin promoter
p72732
sg70045
I15
sg70046
VP09327
p72733
sg70048
I2
sa(dp72734
g70042
I0
sg70043
VKLF5
p72735
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72736
g70042
I90
sg70043
g72723
sg70045
I4
sg70046
VP01116
p72737
sg70048
I1
sasg70051
(lp72738
(dp72739
g70042
I32
sg70043
Vintestinal tumors
p72740
sg70045
I17
sg70054
VC0021841
p72741
sg70048
I2
sa(dp72742
g70042
I136
sg70043
g72724
sg70045
I18
sg70054
VC1527249
p72743
sg70048
I2
sasa(dp72744
g135
(dp72745
(VKRAS
p72746
Vcolorectal cancers
p72747
tp72748
I00
ssg70037
VIn vivo, both intestinal tumors derived from mice transgenic for villin-KRAS(V12G) and human primary colorectal cancers with mutated KRAS contained high levels of KLF5 and increased staining of the proliferative marker Ki67.
p72749
sg70039
(lp72750
(dp72751
g70042
I65
sg70043
Vvillin
p72752
sg70045
I6
sg70046
VP09327
p72753
sg70048
I1
sa(dp72754
g70042
I72
sg70043
VKRAS
p72755
sg70045
I4
sg70046
VP01116
p72756
sg70048
I1
sa(dp72757
g70042
I72
sg70043
g72746
sg70045
I4
sg70046
VP01116
p72758
sg70048
I1
sa(dp72759
g70042
I163
sg70043
VKLF5
p72760
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp72761
(dp72762
g70042
I198
sg70043
Vproliferative
p72763
sg70045
I13
sg70054
VC0334094
p72764
sg70048
I1
sa(dp72765
g70042
I14
sg70043
Vintestinal tumors
p72766
sg70045
I17
sg70054
VC0021841
p72767
sg70048
I2
sa(dp72768
g70042
I101
sg70043
g72747
sg70045
I18
sg70054
VC1527249
p72769
sg70048
I2
sasa(dp72770
g135
(dp72771
(VKRAS
p72772
Vintestinal tumors
p72773
tp72774
I00
ssg70037
VElevated levels of KLF5 protein are strongly correlated with activating KRAS mutations in intestinal tumors in vitro and in vivo.
p72775
sg70039
(lp72776
(dp72777
g70042
I19
sg70043
VKLF5 protein
p72778
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp72779
g70042
I72
sg70043
g72772
sg70045
I4
sg70046
VP01116
p72780
sg70048
I1
sasg70051
(lp72781
(dp72782
g70042
I90
sg70043
g72773
sg70045
I17
sg70054
VC0021841
p72783
sg70048
I2
sasa(dp72784
g135
(dp72785
(VRas
p72786
Vintestinal tumors
p72787
tp72788
I00
ssg70037
VRas-transformation also markedly down-regulated KLF5; further analysis indicated that reduced expression of KLF5 mRNA and destabilization of KLF5 protein occur in intestinal tumors.
p72789
sg70039
(lp72790
(dp72791
g70042
I141
sg70043
VKLF5 protein
p72792
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp72793
g70042
I108
sg70043
VKLF5 mRNA
p72794
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp72795
g70042
I48
sg70043
VKLF5
p72796
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72797
g70042
I0
sg70043
g72786
sg70045
I3
sg70046
VP01116
p72798
sg70048
I1
sasg70051
(lp72799
(dp72800
g70042
I163
sg70043
g72787
sg70045
I17
sg70054
VC0021841
p72801
sg70048
I2
sa(dp72802
g70042
I4
sg70043
Vtransformation
p72803
sg70045
I14
sg70054
VC1510411
p72804
sg70048
I1
sasa(dp72805
g70037
VReduced levels of KLF5 mRNA were also detected in APC(min) mouse and human familial adenomatous polyposis adenomas compared with normal crypt epithelium, indicating that down-regulation of KLF5 is an early event in intestinal tumorigenesis in vivo.
p72806
sg70039
(lp72807
(dp72808
g70042
I18
sg70043
VKLF5
p72809
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72810
g70042
I18
sg70043
VKLF5 mRNA
p72811
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp72812
(dp72813
g70042
I75
sg70043
Vfamilial adenomatous polyposis
p72814
sg70045
I30
sg70054
VC0032580
p72815
sg70048
I3
sa(dp72816
g70042
I106
sg70043
Vadenomas
p72817
sg70045
I8
sg70054
VC0001430
p72818
sg70048
I1
sa(dp72819
g70042
I226
sg70043
Vtumorigenesis
p72820
sg70045
I13
sg70054
VC0007621
p72821
sg70048
I1
sa(dp72822
g70042
I50
sg70043
VAPC
p72823
sg70045
I3
sg70054
VC0033036
p72824
sg70048
I1
sasa(dp72825
g70037
VCollectively, these data indicate that intestinal tumor progression is associated with a change in the growth-related functions of KLF5 and that intestinal tumors down-regulate KLF5 expression by multiple mechanisms.
p72826
sg70039
(lp72827
(dp72828
g70042
I131
sg70043
VKLF5
p72829
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp72830
g70042
I131
sg70043
VKLF5
p72831
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp72832
(dp72833
g70042
I145
sg70043
Vintestinal tumors
p72834
sg70045
I17
sg70054
VC0021841
p72835
sg70048
I2
sa(dp72836
g70042
I50
sg70043
Vtumor progression
p72837
sg70045
I17
sg70054
VC0178874
p72838
sg70048
I2
sasa(dp72839
g135
(dp72840
(VTNF
p72841
Vtumor necrosis
p72842
tp72843
I00
ssg70037
VVariable major lipoprotein (Vmp) is a major tumor necrosis factor (TNF)-inducing component of Borrelia recurrentis, the agent of louse-borne relapsing fever.
p72844
sg70039
(lp72845
(dp72846
g70042
I44
sg70043
Vtumor necrosis factor
p72847
sg70045
I21
sg70046
VP01375
p72848
sg70048
I3
sa(dp72849
g70042
I67
sg70043
g72841
sg70045
I3
sg70046
VP01375
p72850
sg70048
I1
sasg70051
(lp72851
(dp72852
g70042
I94
sg70043
VBorrelia
p72853
sg70045
I8
sg70054
VC0024198
p72854
sg70048
I1
sa(dp72855
g70042
I129
sg70043
Vlouse-borne relapsing fever
p72856
sg70045
I27
sg70054
VC0152061
p72857
sg70048
I3
sa(dp72858
g70042
I44
sg70043
g72842
sg70045
I14
sg70054
VC0333516
p72859
sg70048
I2
sasa(dp72860
g135
(dp72861
(Vtumor necrosis factor
p72862
VBorrelia
p72863
tp72864
I01
ssg70037
VLouse-borne relapsing fever, caused by Borrelia recurrentis, provides one of the best documented examples of the causative role of tumor necrosis factor (TNF) in the pathology of severe infection in humans.
p72865
sg70039
(lp72866
(dp72867
g70042
I154
sg70043
VTNF
p72868
sg70045
I3
sg70046
VP01375
p72869
sg70048
I1
sa(dp72870
g70042
I131
sg70043
g72862
sg70045
I21
sg70046
VP01375
p72871
sg70048
I3
sasg70051
(lp72872
(dp72873
g70042
I186
sg70043
Vinfection
p72874
sg70045
I9
sg70054
VC0009450
p72875
sg70048
I1
sa(dp72876
g70042
I166
sg70043
Vpathology
p72877
sg70045
I9
sg70054
VC0677042
p72878
sg70048
I1
sa(dp72879
g70042
I0
sg70043
VLouse-borne relapsing fever
p72880
sg70045
I27
sg70054
VC0152061
p72881
sg70048
I3
sa(dp72882
g70042
I131
sg70043
Vtumor necrosis
p72883
sg70045
I14
sg70054
VC0333516
p72884
sg70048
I2
sa(dp72885
g70042
I39
sg70043
g72863
sg70045
I8
sg70054
VC0024198
p72886
sg70048
I1
sasa(dp72887
g135
(dp72888
(Vinterleukin 8
p72889
Vtumour necrosis
p72890
tp72891
I00
ssg70037
VSevere Jarisch Herxheimer reaction (J-HR) precipitated by antibiotic treatment of louse-borne relapsing fever (LBRF) is associated with a transient, marked rise in circulating tumour necrosis factor alpha (TNF alpha), interleukin 6 (IL-6) and interleukin 8 (IL-8).
p72892
sg70039
(lp72893
(dp72894
g70042
I206
sg70043
VTNF alpha
p72895
sg70045
I9
sg70046
VP01375
p72896
sg70048
I2
sa(dp72897
g70042
I258
sg70043
VIL-8
p72898
sg70045
I4
sg70046
VP60568
p72899
sg70048
I1
sa(dp72900
g70042
I218
sg70043
Vinterleukin 6
p72901
sg70045
I13
sg70046
VP05231
p72902
sg70048
I2
sa(dp72903
g70042
I233
sg70043
VIL-6
p72904
sg70045
I4
sg70046
VP05231
p72905
sg70048
I1
sa(dp72906
g70042
I176
sg70043
Vtumour necrosis factor alpha
p72907
sg70045
I28
sg70046
VP01375
p72908
sg70048
I4
sa(dp72909
g70042
I243
sg70043
g72889
sg70045
I13
sg70046
VP60568
p72910
sg70048
I2
sasg70051
(lp72911
(dp72912
g70042
I111
sg70043
VLBRF
p72913
sg70045
I4
sg70054
VC0152061
p72914
sg70048
I1
sa(dp72915
g70042
I82
sg70043
Vlouse-borne relapsing fever
p72916
sg70045
I27
sg70054
VC0152061
p72917
sg70048
I3
sa(dp72918
g70042
I176
sg70043
g72890
sg70045
I15
sg70054
VC0333516
p72919
sg70048
I2
sasa(dp72920
g135
(dp72921
(Vtumor necrosis factor alpha
p72922
Vrigors
p72923
tp72924
I00
ssg70037
VIn patients with louse-borne relapsing fever (Borrelia recurrentis infection), antimicrobial treatment is often followed by sudden fever, rigors, and persistent hypotension (Jarisch-Herxheimer reactions) that are associated with increases in plasma concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-6, and interleukin-8.
p72925
sg70039
(lp72926
(dp72927
g70042
I296
sg70043
VTNF-alpha
p72928
sg70045
I9
sg70046
VP01375
p72929
sg70048
I1
sa(dp72930
g70042
I327
sg70043
Vinterleukin-8
p72931
sg70045
I13
sg70046
VP60568
p72932
sg70048
I1
sa(dp72933
g70042
I308
sg70043
Vinterleukin-6
p72934
sg70045
I13
sg70046
VP05231
p72935
sg70048
I1
sa(dp72936
g70042
I267
sg70043
g72922
sg70045
I27
sg70046
VP01375
p72937
sg70048
I4
sasg70051
(lp72938
(dp72939
g70042
I267
sg70043
Vtumor necrosis
p72940
sg70045
I14
sg70054
VC0333516
p72941
sg70048
I2
sa(dp72942
g70042
I17
sg70043
Vlouse-borne relapsing fever
p72943
sg70045
I27
sg70054
VC0152061
p72944
sg70048
I3
sa(dp72945
g70042
I46
sg70043
VBorrelia recurrentis infection
p72946
sg70045
I30
sg70054
VC0857817
p72947
sg70048
I3
sa(dp72948
g70042
I138
sg70043
g72923
sg70045
I6
sg70054
VC0424790
p72949
sg70048
I1
sasa(dp72950
g135
(dp72951
(Vanti-TNF-alpha Fab
p72952
Vsepsis
p72953
tp72954
I00
ssg70037
VPretreatment with sheep anti-TNF-alpha Fab suppresses Jarisch-Herxheimer reactions that occur after penicillin treatment for louse-borne relapsing fever, reduces the associated increases in plasma concentrations of interleukin-6 and interleukin-8, and may be useful in other forms of sepsis.
p72955
sg70039
(lp72956
(dp72957
g70042
I233
sg70043
Vinterleukin-8
p72958
sg70045
I13
sg70046
VP60568
p72959
sg70048
I1
sa(dp72960
g70042
I215
sg70043
Vinterleukin-6
p72961
sg70045
I13
sg70046
VP05231
p72962
sg70048
I1
sa(dp72963
g70042
I24
sg70043
g72952
sg70045
I18
sg70046
VP01375
p72964
sg70048
I2
sasg70051
(lp72965
(dp72966
g70042
I125
sg70043
Vlouse-borne relapsing fever
p72967
sg70045
I27
sg70054
VC0152061
p72968
sg70048
I3
sa(dp72969
g70042
I284
sg70043
g72953
sg70045
I6
sg70054
VC0243026
p72970
sg70048
I1
sasa(dp72971
g70037
VA frail 84-year old lady with situs inversus totalis and symptomatic aortic stenosis underwent a successful transcatheter aortic valve implantation (TAVI) after extensive diagnostic work-up.
p72972
sg70039
(lp72973
sg70051
(lp72974
(dp72975
g70042
I57
sg70043
Vsymptomatic aortic stenosis
p72976
sg70045
I27
sg70054
VC0741183
p72977
sg70048
I3
sa(dp72978
g70042
I30
sg70043
Vsitus inversus
p72979
sg70045
I14
sg70054
VC0037221
p72980
sg70048
I2
sasa(dp72981
g70037
VHere, we report the first known case of Marfan's syndrome, combined with situs inversus totalis with dextrocardia and discrete subaortic stenosis and aortic insufficiency in a 22-year-old woman.
p72982
sg70039
(lp72983
sg70051
(lp72984
(dp72985
g70042
I101
sg70043
Vdextrocardia
p72986
sg70045
I12
sg70054
VC0011813
p72987
sg70048
I1
sa(dp72988
g70042
I118
sg70043
Vdiscrete subaortic stenosis
p72989
sg70045
I27
sg70054
VC0012628
p72990
sg70048
I3
sa(dp72991
g70042
I73
sg70043
Vsitus inversus
p72992
sg70045
I14
sg70054
VC0037221
p72993
sg70048
I2
sa(dp72994
g70042
I40
sg70043
VMarfan's syndrome
p72995
sg70045
I17
sg70054
VC0024796
p72996
sg70048
I2
sa(dp72997
g70042
I150
sg70043
Vaortic insufficiency
p72998
sg70045
I20
sg70054
VC0003504
p72999
sg70048
I2
sasa(dp73000
g70037
VLow-frequency artifacts that plague traditional TIE methods can be suppressed without an excessive number of captured images.
p73001
sg70039
(lp73002
sg70051
(lp73003
(dp73004
g70042
I29
sg70043
Vplague
p73005
sg70045
I6
sg70054
VC0032064
p73006
sg70048
I1
sasa(dp73007
g135
(dp73008
(VFGF9
p73009
VHCC
p73010
tp73011
I00
ssg70037
VThe FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.
p73012
sg70039
(lp73013
(dp73014
g70042
I4
sg70043
VFGF9 subfamily
p73015
sg70045
I14
sg70046
VP31371
p73016
sg70048
I2
sa(dp73017
g70042
I4
sg70043
g73009
sg70045
I4
sg70046
VP31371
p73018
sg70048
I1
sa(dp73019
g70042
I36
sg70043
VFGF16
p73020
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp73021
g70042
I47
sg70043
VFGF20
p73022
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73023
(dp73024
g70042
I169
sg70043
Vhepatocellular carcinoma
p73025
sg70045
I24
sg70054
VC2239176
p73026
sg70048
I2
sa(dp73027
g70042
I195
sg70043
g73010
sg70045
I3
sg70054
VC2239176
p73028
sg70048
I1
sa(dp73029
g70042
I127
sg70043
Vproliferation
p73030
sg70045
I13
sg70054
VC0334094
p73031
sg70048
I1
sasa(dp73032
g70037
VFGF16 promoted proliferation and invasion behavior of SKOV-3 ovarian cancer cells, whose function may be similar in lung cancer.
p73033
sg70039
(lp73034
(dp73035
g70042
I0
sg70043
VFGF16
p73036
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73037
(dp73038
g70042
I61
sg70043
Vovarian cancer
p73039
sg70045
I14
sg70054
VC1140680
p73040
sg70048
I2
sa(dp73041
g70042
I33
sg70043
Vinvasion
p73042
sg70045
I8
sg70054
VC2699153
p73043
sg70048
I1
sa(dp73044
g70042
I116
sg70043
Vlung cancer
p73045
sg70045
I11
sg70054
VC0684249
p73046
sg70048
I2
sa(dp73047
g70042
I15
sg70043
Vproliferation
p73048
sg70045
I13
sg70054
VC0334094
p73049
sg70048
I1
sasa(dp73050
g70037
VThis finding indicated possible involvement of FGF16 in ovarian cancer progression.
p73051
sg70039
(lp73052
(dp73053
g70042
I47
sg70043
VFGF16
p73054
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73055
(dp73056
g70042
I64
sg70043
Vcancer progression
p73057
sg70045
I18
sg70054
VC0178874
p73058
sg70048
I2
sasa(dp73059
g70037
VWe observed that FGF16 stimulates the proliferation of human ovarian adenocarcinoma cells, SKOV-3 and OAW-42.
p73060
sg70039
(lp73061
(dp73062
g70042
I17
sg70043
VFGF16
p73063
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73064
(dp73065
g70042
I61
sg70043
Vovarian adenocarcinoma
p73066
sg70045
I22
sg70054
VC0948216
p73067
sg70048
I2
sa(dp73068
g70042
I38
sg70043
Vproliferation
p73069
sg70045
I13
sg70054
VC0334094
p73070
sg70048
I1
sasa(dp73071
g70037
VTaken together, our findings indicate that FGF16 in conjunction with Wnt pathway contributes to the cancer phenotype of ovarian cells and suggests that modulation of its expression in ovarian cells might be a promising therapeutic strategy for the treatment of invasive ovarian cancers.
p73072
sg70039
(lp73073
(dp73074
g70042
I43
sg70043
VFGF16
p73075
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73076
(dp73077
g70042
I270
sg70043
Vovarian cancers
p73078
sg70045
I15
sg70054
VC1140680
p73079
sg70048
I2
sa(dp73080
g70042
I100
sg70043
Vcancer
p73081
sg70045
I6
sg70054
VC0006826
p73082
sg70048
I1
sasa(dp73083
g70037
VLoss-of-function mutations in the UBR1 gene cause Johanson-Blizzard syndrome, which involves pancreatic exocrine insufficiency.
p73084
sg70039
(lp73085
(dp73086
g70042
I34
sg70043
VUBR1 gene
p73087
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp73088
(dp73089
g70042
I50
sg70043
VJohanson-Blizzard syndrome
p73090
sg70045
I26
sg70054
VC0175692
p73091
sg70048
I2
sasa(dp73092
g70037
VJohanson-Blizzard syndrome (JBS) is considered as an infrequent, but clinically easily recognizable autosomal recessive entity by the pathognomonic combination of congenital exocrine pancreatic insufficiency and hypoplastic alae nasi, in addition to other distinctive findings such as scalp defects, hypothyroidism, and rectourogenital malformations.
p73093
sg70039
(lp73094
sg70051
(lp73095
(dp73096
g70042
I336
sg70043
Vmalformations
p73097
sg70045
I13
sg70054
VC0000768
p73098
sg70048
I1
sa(dp73099
g70042
I0
sg70043
VJohanson-Blizzard syndrome
p73100
sg70045
I26
sg70054
VC0175692
p73101
sg70048
I2
sa(dp73102
g70042
I300
sg70043
Vhypothyroidism
p73103
sg70045
I14
sg70054
VC0020676
p73104
sg70048
I1
sa(dp73105
g70042
I28
sg70043
VJBS
p73106
sg70045
I3
sg70054
VC0175692
p73107
sg70048
I1
sa(dp73108
g70042
I174
sg70043
Vexocrine pancreatic insufficiency
p73109
sg70045
I33
sg70054
VC0267963
p73110
sg70048
I3
sasa(dp73111
g70037
VThere are few reports of patients with JBS in association with facial clefting, referring all to types 2 to 6 of Tessier's classification that can be characterized properly as oblique facial clefts (OFCs).
p73112
sg70039
(lp73113
sg70051
(lp73114
(dp73115
g70042
I199
sg70043
VOFCs
p73116
sg70045
I4
sg70054
VC1838348
p73117
sg70048
I1
sa(dp73118
g70042
I176
sg70043
Voblique facial clefts
p73119
sg70045
I21
sg70054
VC1838348
p73120
sg70048
I3
sa(dp73121
g70042
I39
sg70043
VJBS
p73122
sg70045
I3
sg70054
VC0795841
p73123
sg70048
I1
sasa(dp73124
g70037
VWe describe the clinical aspects in four patients with JBS and extensive OFCs.
p73125
sg70039
(lp73126
sg70051
(lp73127
(dp73128
g70042
I55
sg70043
VJBS
p73129
sg70045
I3
sg70054
VC0795841
p73130
sg70048
I1
sasa(dp73131
g70037
VIn all of them, the diagnosis of JBS was confirmed by the demonstration of homozygous or compound-heterozygous mutations in the UBR1 gene.
p73132
sg70039
(lp73133
(dp73134
g70042
I128
sg70043
VUBR1 gene
p73135
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp73136
(dp73137
g70042
I33
sg70043
VJBS
p73138
sg70045
I3
sg70054
VC0795841
p73139
sg70048
I1
sasa(dp73140
g70037
VAdditionally, we review three previously reported cases of JBS with OFCs.
p73141
sg70039
(lp73142
sg70051
(lp73143
(dp73144
g70042
I59
sg70043
VJBS
p73145
sg70045
I3
sg70054
VC0795841
p73146
sg70048
I1
sasa(dp73147
g70037
VTaking into account a number of approximately 100 individuals affected by JBS that have been published in the literature we estimate that the frequency of OFCs in JBS is between 5% and 10%.
p73148
sg70039
(lp73149
sg70051
(lp73150
(dp73151
g70042
I74
sg70043
VJBS
p73152
sg70045
I3
sg70054
VC0795841
p73153
sg70048
I1
sa(dp73154
g70042
I74
sg70043
VJBS
p73155
sg70045
I3
sg70054
VC0795841
p73156
sg70048
I1
sasa(dp73157
g70037
VThis report emphasizes that extensive OFCs may be the severe end of the spectrum of facial malformations occurring in JBS.
p73158
sg70039
(lp73159
sg70051
(lp73160
(dp73161
g70042
I84
sg70043
Vfacial malformations
p73162
sg70045
I20
sg70054
VC0266617
p73163
sg70048
I2
sa(dp73164
g70042
I118
sg70043
VJBS
p73165
sg70045
I3
sg70054
VC0795841
p73166
sg70048
I1
sasa(dp73167
g70037
VJohanson-Blizzard Syndrome (JBS) (MIM #243800) is a rare autosomal recessive genetic disorder characterized by exocrine pancreatic insufficiency, abnormal facial appearance and varying degrees of mental retardation.
p73168
sg70039
(lp73169
sg70051
(lp73170
(dp73171
g70042
I0
sg70043
VJohanson-Blizzard Syndrome
p73172
sg70045
I26
sg70054
VC0175692
p73173
sg70048
I2
sa(dp73174
g70042
I77
sg70043
Vgenetic disorder
p73175
sg70045
I16
sg70054
VC0019247
p73176
sg70048
I2
sa(dp73177
g70042
I28
sg70043
VJBS
p73178
sg70045
I3
sg70054
VC0175692
p73179
sg70048
I1
sa(dp73180
g70042
I196
sg70043
Vmental retardation
p73181
sg70045
I18
sg70054
VC0025362
p73182
sg70048
I2
sa(dp73183
g70042
I111
sg70043
Vexocrine pancreatic insufficiency
p73184
sg70045
I33
sg70054
VC0267963
p73185
sg70048
I3
sasa(dp73186
g70037
VHere, we report a 3 year-old mentally normal JBS girl.
p73187
sg70039
(lp73188
sg70051
(lp73189
(dp73190
g70042
I45
sg70043
VJBS
p73191
sg70045
I3
sg70054
VC0795841
p73192
sg70048
I1
sasa(dp73193
g70037
VWith these findings, JBS diagnosis was established clinically.
p73194
sg70039
(lp73195
sg70051
(lp73196
(dp73197
g70042
I21
sg70043
VJBS
p73198
sg70045
I3
sg70054
VC0795841
p73199
sg70048
I1
sasa(dp73200
g70037
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive syndrome characterized by dysmorphic nasal alae, ectodermal abnormalities, exocrine pancreatic insufficiency and early growth failure.
p73201
sg70039
(lp73202
sg70051
(lp73203
(dp73204
g70042
I138
sg70043
Vexocrine pancreatic insufficiency
p73205
sg70045
I33
sg70054
VC0267963
p73206
sg70048
I3
sa(dp73207
g70042
I0
sg70043
VJohanson-Blizzard syndrome
p73208
sg70045
I26
sg70054
VC0175692
p73209
sg70048
I2
sa(dp73210
g70042
I28
sg70043
VJBS
p73211
sg70045
I3
sg70054
VC0175692
p73212
sg70048
I1
sa(dp73213
g70042
I182
sg70043
Vgrowth failure
p73214
sg70045
I14
sg70054
VC0878787
p73215
sg70048
I2
sa(dp73216
g70042
I18
sg70043
Vsyndrome
p73217
sg70045
I8
sg70054
VC0039082
p73218
sg70048
I1
sasa(dp73219
g70037
VNonsense, frame shift and splice-site mutations of the ubiquitin ligase gene (UBR1) lead to early loss of acinar cells in individuals with JBS.
p73220
sg70039
(lp73221
(dp73222
g70042
I55
sg70043
Vubiquitin ligase gene
p73223
sg70045
I21
sg70046
g12
sg70048
I3
sa(dp73224
g70042
I78
sg70043
VUBR1
p73225
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp73226
(dp73227
g70042
I139
sg70043
VJBS
p73228
sg70045
I3
sg70054
VC0795841
p73229
sg70048
I1
sasa(dp73230
g70037
VThis case illustrates that the phenotypic variability of pancreatic involvement in JBS may be subtle and may not manifest until the second decade of life.
p73231
sg70039
(lp73232
(dp73233
g70042
I83
sg70043
VJBS
p73234
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp73235
(dp73236
g70042
I83
sg70043
VJBS
p73237
sg70045
I3
sg70054
VC0795841
p73238
sg70048
I1
sasa(dp73239
g70037
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive disorder resulting from loss-of-function mutations in the UBR1 gene.
p73240
sg70039
(lp73241
(dp73242
g70042
I121
sg70043
VUBR1 gene
p73243
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp73244
(dp73245
g70042
I0
sg70043
VJohanson-Blizzard syndrome
p73246
sg70045
I26
sg70054
VC0175692
p73247
sg70048
I2
sa(dp73248
g70042
I28
sg70043
VJBS
p73249
sg70045
I3
sg70054
VC0175692
p73250
sg70048
I1
sasa(dp73251
g70037
VJBS can be easily recognized by its unique clinical presentation (including exocrine pancreatic insufficiency, hypoplasia/aplasia of the alae nasi, congenital scalp defects, sensorineural hearing loss, growth retardation, psychomotor retardation, and anal and genitourinary anomalies).
p73252
sg70039
(lp73253
sg70051
(lp73254
(dp73255
g70042
I174
sg70043
Vsensorineural hearing loss
p73256
sg70045
I26
sg70054
VC0018784
p73257
sg70048
I3
sa(dp73258
g70042
I76
sg70043
Vexocrine pancreatic insufficiency
p73259
sg70045
I33
sg70054
VC0267963
p73260
sg70048
I3
sa(dp73261
g70042
I202
sg70043
Vgrowth retardation
p73262
sg70045
I18
sg70054
VC0151686
p73263
sg70048
I2
sa(dp73264
g70042
I122
sg70043
Vaplasia
p73265
sg70045
I7
sg70054
VC0243065
p73266
sg70048
I1
sa(dp73267
g70042
I0
sg70043
VJBS
p73268
sg70045
I3
sg70054
VC0795841
p73269
sg70048
I1
sa(dp73270
g70042
I111
sg70043
Vhypoplasia
p73271
sg70045
I10
sg70054
VC0243069
p73272
sg70048
I1
sasa(dp73273
g70037
VThe objective of this study is to report on the first familial case of gender-discordant twins presenting JBS and a novel mutation in the UBR1 gene.
p73274
sg70039
(lp73275
(dp73276
g70042
I138
sg70043
VUBR1 gene
p73277
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp73278
(dp73279
g70042
I116
sg70043
Vnovel mutation
p73280
sg70045
I14
sg70054
VC2985438
p73281
sg70048
I2
sa(dp73282
g70042
I106
sg70043
VJBS
p73283
sg70045
I3
sg70054
VC0795841
p73284
sg70048
I1
sasa(dp73285
g70037
VWe also review literature describing molecularly confirmed cases of JBS.
p73286
sg70039
(lp73287
sg70051
(lp73288
(dp73289
g70042
I68
sg70043
VJBS
p73290
sg70045
I3
sg70054
VC0795841
p73291
sg70048
I1
sasa(dp73292
g70037
VBoth patients presented typical clinical features of JBS.
p73293
sg70039
(lp73294
sg70051
(lp73295
(dp73296
g70042
I53
sg70043
VJBS
p73297
sg70045
I3
sg70054
VC0795841
p73298
sg70048
I1
sasa(dp73299
g70037
VSevere presentation of JBS usually involves deleterious (nonsense, frameshift, or splice-site) mutations in the UBR1 gene that are thought to completely abolish the expression of a functional protein product, as in this familial case; however, milder presentation of JBS has occasionally been observed with missense mutations in at least 1 of the 2 copies of UBR1, in which there may be residual activity of the product of this gene.
p73300
sg70039
(lp73301
(dp73302
g70042
I112
sg70043
VUBR1 gene
p73303
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp73304
g70042
I112
sg70043
VUBR1
p73305
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp73306
(dp73307
g70042
I23
sg70043
VJBS
p73308
sg70045
I3
sg70054
VC0795841
p73309
sg70048
I1
sa(dp73310
g70042
I23
sg70043
VJBS
p73311
sg70045
I3
sg70054
VC0795841
p73312
sg70048
I1
sa(dp73313
g70042
I67
sg70043
Vframeshift
p73314
sg70045
I10
sg70054
VC0079380
p73315
sg70048
I1
sasa(dp73316
g70037
VJohanson-Blizzard syndrome (JBS) is a rare, autosomal recessive disorder characterized by exocrine pancreatic insufficiency, typical facial features, dental anomalies, hypothyroidism, sensorineural hearing loss, scalp defects, urogenital and anorectal anomalies, short stature, and cognitive impairment of variable degree.
p73317
sg70039
(lp73318
sg70051
(lp73319
(dp73320
g70042
I168
sg70043
Vhypothyroidism
p73321
sg70045
I14
sg70054
VC0020676
p73322
sg70048
I1
sa(dp73323
g70042
I28
sg70043
VJBS
p73324
sg70045
I3
sg70054
VC0175692
p73325
sg70048
I1
sa(dp73326
g70042
I0
sg70043
VJohanson-Blizzard syndrome
p73327
sg70045
I26
sg70054
VC0175692
p73328
sg70048
I2
sa(dp73329
g70042
I242
sg70043
Vanorectal anomalies
p73330
sg70045
I19
sg70054
VC2974527
p73331
sg70048
I2
sa(dp73332
g70042
I282
sg70043
Vcognitive impairment
p73333
sg70045
I20
sg70054
VC0338656
p73334
sg70048
I2
sa(dp73335
g70042
I90
sg70043
Vexocrine pancreatic insufficiency
p73336
sg70045
I33
sg70054
VC0267963
p73337
sg70048
I3
sa(dp73338
g70042
I263
sg70043
Vshort stature
p73339
sg70045
I13
sg70054
VC0013336
p73340
sg70048
I2
sa(dp73341
g70042
I184
sg70043
Vsensorineural hearing loss
p73342
sg70045
I26
sg70054
VC0018784
p73343
sg70048
I3
sasa(dp73344
g70037
VMutation types include nonsense, frameshift, splice site, missense, and small in-frame deletions consistent with the hypothesis that loss of UBR1 protein function is the molecular basis of JBS.
p73345
sg70039
(lp73346
(dp73347
g70042
I141
sg70043
VUBR1 protein
p73348
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp73349
(dp73350
g70042
I33
sg70043
Vframeshift
p73351
sg70045
I10
sg70054
VC0079380
p73352
sg70048
I1
sa(dp73353
g70042
I189
sg70043
VJBS
p73354
sg70045
I3
sg70054
VC0795841
p73355
sg70048
I1
sasa(dp73356
g70037
VThe review of clinical data of a large number of molecularly confirmed JBS cases allows us to define minimal clinical criteria for the diagnosis of JBS.
p73357
sg70039
(lp73358
sg70051
(lp73359
(dp73360
g70042
I71
sg70043
VJBS
p73361
sg70045
I3
sg70054
VC0795841
p73362
sg70048
I1
sa(dp73363
g70042
I71
sg70043
VJBS
p73364
sg70045
I3
sg70054
VC0795841
p73365
sg70048
I1
sasa(dp73366
g70037
VJohanson-Blizzard syndrome (JBS) is a rare autosomal recessive disease characterized by exocrine pancreatic insufficiency, hypoplastic or aplastic nasal alae, cutis aplasia on the scalp, and other features including developmental delay, failure to thrive, hearing loss, mental retardation, hypothyroidism, dental abnormalities, and anomalies in cardiac and genitourinary systems.
p73367
sg70039
(lp73368
sg70051
(lp73369
(dp73370
g70042
I159
sg70043
Vcutis aplasia
p73371
sg70045
I13
sg70054
VC0282160
p73372
sg70048
I2
sa(dp73373
g70042
I256
sg70043
Vhearing loss
p73374
sg70045
I12
sg70054
VC0011053
p73375
sg70048
I2
sa(dp73376
g70042
I88
sg70043
Vexocrine pancreatic insufficiency
p73377
sg70045
I33
sg70054
VC0267963
p73378
sg70048
I3
sa(dp73379
g70042
I28
sg70043
VJBS
p73380
sg70045
I3
sg70054
VC0175692
p73381
sg70048
I1
sa(dp73382
g70042
I0
sg70043
VJohanson-Blizzard syndrome
p73383
sg70045
I26
sg70054
VC0175692
p73384
sg70048
I2
sa(dp73385
g70042
I216
sg70043
Vdevelopmental delay
p73386
sg70045
I19
sg70054
VC0424605
p73387
sg70048
I2
sa(dp73388
g70042
I237
sg70043
Vfailure to thrive
p73389
sg70045
I17
sg70054
VC0015544
p73390
sg70048
I3
sa(dp73391
g70042
I270
sg70043
Vmental retardation
p73392
sg70045
I18
sg70054
VC0025362
p73393
sg70048
I2
sa(dp73394
g70042
I290
sg70043
Vhypothyroidism
p73395
sg70045
I14
sg70054
VC0020676
p73396
sg70048
I1
sasa(dp73397
g70037
VWe describe the case of a male infant with typical symptoms of JBS.
p73398
sg70039
(lp73399
sg70051
(lp73400
(dp73401
g70042
I63
sg70043
VJBS
p73402
sg70045
I3
sg70054
VC0795841
p73403
sg70048
I1
sasa(dp73404
g70037
VJohanson-Blizzard syndrome (JBS; OMIM 243800) is an autosomal recessive disorder that includes congenital exocrine pancreatic insufficiency, facial dysmorphism with the characteristic nasal wing hypoplasia, multiple malformations, and frequent mental retardation.
p73405
sg70039
(lp73406
sg70051
(lp73407
(dp73408
g70042
I216
sg70043
Vmalformations
p73409
sg70045
I13
sg70054
VC0000768
p73410
sg70048
I1
sa(dp73411
g70042
I195
sg70043
Vhypoplasia
p73412
sg70045
I10
sg70054
VC0243069
p73413
sg70048
I1
sa(dp73414
g70042
I28
sg70043
VJBS
p73415
sg70045
I3
sg70054
VC0175692
p73416
sg70048
I1
sa(dp73417
g70042
I106
sg70043
Vexocrine pancreatic insufficiency
p73418
sg70045
I33
sg70054
VC0267963
p73419
sg70048
I3
sa(dp73420
g70042
I244
sg70043
Vmental retardation
p73421
sg70045
I18
sg70054
VC0025362
p73422
sg70048
I2
sa(dp73423
g70042
I0
sg70043
VJohanson-Blizzard syndrome
p73424
sg70045
I26
sg70054
VC0175692
p73425
sg70048
I2
sa(dp73426
g70042
I141
sg70043
Vfacial dysmorphism
p73427
sg70045
I18
sg70054
VC0266617
p73428
sg70048
I2
sasa(dp73429
g135
(dp73430
(VE3 ubiquitin ligases
p73431
VJBS
p73432
tp73433
I00
ssg70037
VOur previous work has shown that JBS is caused by mutations in human UBR1, which encodes one of the E3 ubiquitin ligases of the N-end rule pathway.
p73434
sg70039
(lp73435
(dp73436
g70042
I63
sg70043
Vhuman UBR1
p73437
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp73438
g70042
I33
sg70043
VJBS
p73439
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73440
g70042
I100
sg70043
g73431
sg70045
I20
sg70046
VP62979
p73441
sg70048
I3
sasg70051
(lp73442
(dp73443
g70042
I33
sg70043
g73432
sg70045
I3
sg70054
VC0795841
p73444
sg70048
I1
sasa(dp73445
g70037
VMost JBS-causing alterations of UBR1 are nonsense, frameshift or splice-site mutations that abolish UBR1 activity.
p73446
sg70039
(lp73447
(dp73448
g70042
I32
sg70043
VUBR1
p73449
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp73450
g70042
I32
sg70043
VUBR1
p73451
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp73452
(dp73453
g70042
I51
sg70043
Vframeshift
p73454
sg70045
I10
sg70054
VC0079380
p73455
sg70048
I1
sa(dp73456
g70042
I5
sg70043
VJBS
p73457
sg70045
I3
sg70054
VC0795841
p73458
sg70048
I1
sasa(dp73459
g70037
VWe report here missense mutations of human UBR1 in patients with milder variants of JBS.
p73460
sg70039
(lp73461
(dp73462
g70042
I37
sg70043
Vhuman UBR1
p73463
sg70045
I10
sg70046
g12
sg70048
I2
sasg70051
(lp73464
(dp73465
g70042
I84
sg70043
VJBS
p73466
sg70045
I3
sg70054
VC0795841
p73467
sg70048
I1
sasa(dp73468
g70037
VTaking advantage of this conservation, we constructed alleles of the yeast Saccharomyces cerevisiae UBR1 that were counterparts of missense JBS-UBR1 alleles.
p73469
sg70039
(lp73470
(dp73471
g70042
I140
sg70043
VJBS
p73472
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73473
g70042
I69
sg70043
Vyeast Saccharomyces cerevisiae UBR1
p73474
sg70045
I35
sg70046
g12
sg70048
I4
sa(dp73475
g70042
I100
sg70043
VUBR1
p73476
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp73477
(dp73478
g70042
I140
sg70043
VJBS
p73479
sg70045
I3
sg70054
VC0795841
p73480
sg70048
I1
sasa(dp73481
g70037
VAmong these yeast Ubr1 mutants, one of them (H160R) was inactive in yeast-based activity assays, the other one (Q1224E) had a detectable but weak activity, and the third one (V146L) exhibited a decreased but significant activity, in agreement with manifestations of JBS in the corresponding JBS patients.
p73482
sg70039
(lp73483
(dp73484
g70042
I18
sg70043
VUbr1 mutants
p73485
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp73486
(dp73487
g70042
I266
sg70043
VJBS
p73488
sg70045
I3
sg70054
VC0795841
p73489
sg70048
I1
sa(dp73490
g70042
I266
sg70043
VJBS
p73491
sg70045
I3
sg70054
VC0795841
p73492
sg70048
I1
sasa(dp73493
g70037
VThese results, made possible by modeling defects of a human ubiquitin ligase in its yeast counterpart, verified and confirmed the relevance of specific missense UBR1 alleles to JBS, and suggested that a residual activity of a missense allele is causally associated with milder variants of JBS.
p73494
sg70039
(lp73495
(dp73496
g70042
I54
sg70043
Vhuman ubiquitin ligase
p73497
sg70045
I22
sg70046
g12
sg70048
I3
sa(dp73498
g70042
I161
sg70043
VUBR1 alleles
p73499
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp73500
(dp73501
g70042
I177
sg70043
VJBS
p73502
sg70045
I3
sg70054
VC0795841
p73503
sg70048
I1
sa(dp73504
g70042
I177
sg70043
VJBS
p73505
sg70045
I3
sg70054
VC0795841
p73506
sg70048
I1
sasa(dp73507
g70037
VWe report on a triplet pregnancy of consanguineous parents with one fetus being affected by recurrent Johanson-Blizzard syndrome (JBS).
p73508
sg70039
(lp73509
sg70051
(lp73510
(dp73511
g70042
I130
sg70043
VJBS
p73512
sg70045
I3
sg70054
VC0175692
p73513
sg70048
I1
sa(dp73514
g70042
I15
sg70043
Vtriplet pregnancy
p73515
sg70045
I17
sg70054
VC0152151
p73516
sg70048
I2
sa(dp73517
g70042
I102
sg70043
VJohanson-Blizzard syndrome
p73518
sg70045
I26
sg70054
VC0175692
p73519
sg70048
I2
sasa(dp73520
g70037
VIn addition to the lack of exocrine acini as the characteristic feature of JBS, the pancreas revealed a resorptive inflammatory reaction with infiltration by eosinophilic granulocytes that focally dispersed onto islets of Langerhans, thus favoring a progressive destructive rather than primary dysplastic process and possibly explaining the occurrence of diabetes mellitus in later life.
p73521
sg70039
(lp73522
sg70051
(lp73523
(dp73524
g70042
I142
sg70043
Vinfiltration
p73525
sg70045
I12
sg70054
VC0332448
p73526
sg70048
I1
sa(dp73527
g70042
I355
sg70043
Vdiabetes mellitus
p73528
sg70045
I17
sg70054
VC0011849
p73529
sg70048
I2
sa(dp73530
g70042
I115
sg70043
Vinflammatory reaction
p73531
sg70045
I21
sg70054
VC0021368
p73532
sg70048
I2
sa(dp73533
g70042
I294
sg70043
Vdysplastic
p73534
sg70045
I10
sg70054
VC0334044
p73535
sg70048
I1
sa(dp73536
g70042
I75
sg70043
VJBS
p73537
sg70045
I3
sg70054
VC0795841
p73538
sg70048
I1
sasa(dp73539
g70037
VJBS maps to chromosome 15q15-q21.1 and is associated with mutations in the UBR1 gene.
p73540
sg70039
(lp73541
(dp73542
g70042
I0
sg70043
VJBS
p73543
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73544
g70042
I75
sg70043
VUBR1 gene
p73545
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp73546
(dp73547
g70042
I0
sg70043
VJBS
p73548
sg70045
I3
sg70054
VC0795841
p73549
sg70048
I1
sasa(dp73550
g70037
VJohanson-Blizzard syndrome is a rare autosomal recessive multisystem disorder, it is characterized by the association of congenital exocrine pancreatic insufficiency and hypoplasia or aplasia of the nasal wings, and can be diagnosed by clinical characteristics and UBR1 gene analysis.
p73551
sg70039
(lp73552
(dp73553
g70042
I265
sg70043
VUBR1 gene
p73554
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp73555
(dp73556
g70042
I0
sg70043
VJohanson-Blizzard syndrome
p73557
sg70045
I26
sg70054
VC0175692
p73558
sg70048
I2
sa(dp73559
g70042
I57
sg70043
Vmultisystem disorder
p73560
sg70045
I20
sg70054
VC0559758
p73561
sg70048
I2
sa(dp73562
g70042
I184
sg70043
Vaplasia
p73563
sg70045
I7
sg70054
VC0243065
p73564
sg70048
I1
sa(dp73565
g70042
I170
sg70043
Vhypoplasia
p73566
sg70045
I10
sg70054
VC0243069
p73567
sg70048
I1
sa(dp73568
g70042
I132
sg70043
Vexocrine pancreatic insufficiency
p73569
sg70045
I33
sg70054
VC0267963
p73570
sg70048
I3
sasa(dp73571
g135
(dp73572
(VatpB
p73573
VIGS
p73574
tp73575
I00
ssg70037
V* Sixteen distinct haplotypes were detected from 258 individuals in the C. conica complex inferred from the cpDNA sequences of intergenic spacer (IGS) between atpB and rbcL, IGS between trnT and trnL, trnL intron, and IGS between trnL and trnF.
p73576
sg70039
(lp73577
(dp73578
g70042
I146
sg70043
VIGS
p73579
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73580
g70042
I186
sg70043
VtrnT
p73581
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp73582
g70042
I201
sg70043
VtrnL intron
p73583
sg70045
I11
sg70046
VP49184
p73584
sg70048
I2
sa(dp73585
g70042
I146
sg70043
VIGS
p73586
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73587
g70042
I195
sg70043
VtrnL
p73588
sg70045
I4
sg70046
VP49184
p73589
sg70048
I1
sa(dp73590
g70042
I159
sg70043
g73573
sg70045
I4
sg70046
VP05026
p73591
sg70048
I1
sa(dp73592
g70042
I195
sg70043
VtrnL
p73593
sg70045
I4
sg70046
VP49184
p73594
sg70048
I1
sasg70051
(lp73595
(dp73596
g70042
I146
sg70043
VIGS
p73597
sg70045
I3
sg70054
VC1306856
p73598
sg70048
I1
sa(dp73599
g70042
I146
sg70043
VIGS
p73600
sg70045
I3
sg70054
VC1306856
p73601
sg70048
I1
sa(dp73602
g70042
I146
sg70043
g73574
sg70045
I3
sg70054
VC1306856
p73603
sg70048
I1
sasa(dp73604
g135
(dp73605
(VpsbA-trnH igs
p73606
Vigs
p73607
tp73608
I00
ssg70037
VMaximum parsimony and Bayesian inference analyses of DNA sequence data of the plastid (the trnT-L igs, the trnL intron, two parts of the trnK intron, and the psbA-trnH igs) and nuclear genome (ITS1, 5.8S, and ITS2) showed these markers to be suitable to assess the species composition of sect.
p73609
sg70039
(lp73610
(dp73611
g70042
I158
sg70043
g73606
sg70045
I13
sg70046
VP40306
p73612
sg70048
I2
sa(dp73613
g70042
I107
sg70043
VtrnL intron
p73614
sg70045
I11
sg70046
VP49184
p73615
sg70048
I2
sa(dp73616
g70042
I91
sg70043
VtrnT-L igs
p73617
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp73618
g70042
I137
sg70043
VtrnK intron
p73619
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp73620
(dp73621
g70042
I98
sg70043
Vigs
p73622
sg70045
I3
sg70054
VC1306856
p73623
sg70048
I1
sa(dp73624
g70042
I98
sg70043
g73607
sg70045
I3
sg70054
VC1306856
p73625
sg70048
I1
sasa(dp73626
g135
(dp73627
(Vchloroplast trnD-trnT intron
p73628
VIGS
p73629
tp73630
I00
ssg70037
VHowever, the primers for amplification of chloroplast trnD-trnT intron and rRNA IGS failed to amplify the respective region in Elymus species.
p73631
sg70039
(lp73632
(dp73633
g70042
I42
sg70043
g73628
sg70045
I28
sg70046
VP27708
p73634
sg70048
I3
sasg70051
(lp73635
(dp73636
g70042
I25
sg70043
Vamplification
p73637
sg70045
I13
sg70054
VC1705759
p73638
sg70048
I1
sa(dp73639
g70042
I80
sg70043
g73629
sg70045
I3
sg70054
VC1306856
p73640
sg70048
I1
sasa(dp73641
g70037
VNew primer pairs were designed and successfully amplified the cpDNA trnD-trnT intron and rRNA IGS region in Elymus species.
p73642
sg70039
(lp73643
(dp73644
g70042
I73
sg70043
VtrnT
p73645
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp73646
(dp73647
g70042
I94
sg70043
VIGS
p73648
sg70045
I3
sg70054
VC1306856
p73649
sg70048
I1
sasa(dp73650
g135
(dp73651
(VEphrinB2
p73652
Vcolorectal cancer
p73653
tp73654
I01
ssg70037
VIn the present study, we investigated the effect of taspine derivative 12k on human colorectal cancer targeted at EphrinB2 and its PDZ.
p73655
sg70039
(lp73656
(dp73657
g70042
I114
sg70043
g73652
sg70045
I8
sg70046
VP52799
p73658
sg70048
I1
sasg70051
(lp73659
(dp73660
g70042
I84
sg70043
g73653
sg70045
I17
sg70054
VC1527249
p73661
sg70048
I2
sasa(dp73662
g70037
VIn this study, we investigated the mechanism of chemoresistance and epithelial-to-mesenchymal transition (EMT) in colorectal cancer involving the gain-of-function (GOF) mutant p53/ephrin-B2 signaling axis.
p73663
sg70039
(lp73664
(dp73665
g70042
I176
sg70043
Vp53
p73666
sg70045
I3
sg70046
VP42771
p73667
sg70048
I1
sasg70051
(lp73668
(dp73669
g70042
I169
sg70043
Vmutant
p73670
sg70045
I6
sg70054
VC0596988
p73671
sg70048
I1
sa(dp73672
g70042
I94
sg70043
Vtransition
p73673
sg70045
I10
sg70054
VC0599156
p73674
sg70048
I1
sa(dp73675
g70042
I114
sg70043
Vcolorectal cancer
p73676
sg70045
I17
sg70054
VC1527249
p73677
sg70048
I2
sasa(dp73678
g135
(dp73679
(Vextracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility
p73680
VB-cell Lymphoma
p73681
tp73682
I00
ssg70037
VTwenty proteins from different signaling pathways (epidermal growth factor receptor [EGFR], phosphorylated extracellular signal regulated kinase [pERK], receptor for hyalouronic acid mediated motility [RHAMM], Raf-1 kinase inhibitor protein [RKIP], Beta-catenin, E-cadherin, phosphorylated AK transforming [pAKT], p16, p21, Ki-67, B-cell Lymphoma-2 [BCL2], vascular endothelial growth factor, apoptosis protease activating factor 1 [APAF-1], mucin1 [MUC1], ephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7], phosphorylated mothers against decapentaplegic 2 [pSMAD2], caudal type homeobox transcription factor 2 [CDX2], Laminin5Gamma2, and mammalian sterile 20-like kinase 1 [MST1]) involved in colorectal cancer progression were studied immunohistochemically on 220 well-characterized patients using a multiple-punch tissue microarray including 437 and 430 samples from the tumor center and the invasive front, respectively.
p73683
sg70039
(lp73684
(dp73685
g70042
I223
sg70043
Vinhibitor protein [RKIP]
p73686
sg70045
I24
sg70046
VP30086
p73687
sg70048
I3
sa(dp73688
g70042
I210
sg70043
VRaf-1 kinase
p73689
sg70045
I12
sg70046
VP04049
p73690
sg70048
I2
sa(dp73691
g70042
I51
sg70043
Vepidermal growth factor receptor
p73692
sg70045
I32
sg70046
VP01133
p73693
sg70048
I4
sa(dp73694
g70042
I201
sg70043
V[RHAMM]
p73695
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp73696
g70042
I249
sg70043
VBeta-catenin
p73697
sg70045
I12
sg70046
VP35222
p73698
sg70048
I1
sa(dp73699
g70042
I263
sg70043
VE-cadherin
p73700
sg70045
I10
sg70046
VP12830
p73701
sg70048
I1
sa(dp73702
g70042
I579
sg70043
Vcaudal type homeobox transcription factor 2 [CDX2]
p73703
sg70045
I50
sg70046
g12
sg70048
I7
sa(dp73704
g70042
I357
sg70043
Vvascular endothelial growth factor
p73705
sg70045
I34
sg70046
g12
sg70048
I4
sa(dp73706
g70042
I314
sg70043
Vp16
p73707
sg70045
I3
sg70046
VP42771
p73708
sg70048
I1
sa(dp73709
g70042
I393
sg70043
Vapoptosis protease activating factor 1
p73710
sg70045
I38
sg70046
VP63123
p73711
sg70048
I5
sa(dp73712
g70042
I324
sg70043
VKi-67
p73713
sg70045
I5
sg70046
VP46013
p73714
sg70048
I1
sa(dp73715
g70042
I319
sg70043
Vp21
p73716
sg70045
I3
sg70046
VP42857
p73717
sg70048
I1
sa(dp73718
g70042
I669
sg70043
V20-like kinase 1
p73719
sg70045
I16
sg70046
VP27361
p73720
sg70048
I3
sa(dp73721
g70042
I275
sg70043
Vphosphorylated AK
p73722
sg70045
I17
sg70046
VP55263
p73723
sg70048
I2
sa(dp73724
g70042
I457
sg70043
Vephrin B2 receptor [EphB2], matrix metalloproteinase 7 [MMP7]
p73725
sg70045
I61
sg70046
VP52799
p73726
sg70048
I8
sa(dp73727
g70042
I331
sg70043
VB-cell Lymphoma-2 [BCL2]
p73728
sg70045
I24
sg70046
VP10415
p73729
sg70048
I3
sa(dp73730
g70042
I687
sg70043
VMST1
p73731
sg70045
I4
sg70046
VP26927
p73732
sg70048
I1
sa(dp73733
g70042
I107
sg70043
g73680
sg70045
I93
sg70046
VP53778
p73734
sg70048
I11
sasg70051
(lp73735
(dp73736
g70042
I717
sg70043
Vcancer progression
p73737
sg70045
I18
sg70054
VC0178874
p73738
sg70048
I2
sa(dp73739
g70042
I886
sg70043
Vtumor
p73740
sg70045
I5
sg70054
VC0027651
p73741
sg70048
I1
sa(dp73742
g70042
I661
sg70043
Vsterile
p73743
sg70045
I7
sg70054
VC0678108
p73744
sg70048
I1
sa(dp73745
g70042
I331
sg70043
g73681
sg70045
I15
sg70054
VC0079731
p73746
sg70048
I2
sasa(dp73747
g135
(dp73748
(VIFN-Gamma
p73749
VDM
p73750
tp73751
I00
ssg70037
VAbundant expression of IFN-Gamma-inducible protein 10 (IP-10) was observed on macrophages and in T cells in perimysial infiltrates of dermatomyositis (DM), and strong chemokine (C-X-C motif) receptor (CXCR)3 expression was observed on the majority of T cells in DM.
p73752
sg70039
(lp73753
(dp73754
g70042
I23
sg70043
g73749
sg70045
I9
sg70046
VP01579
p73755
sg70048
I1
sasg70051
(lp73756
(dp73757
g70042
I151
sg70043
VDM
p73758
sg70045
I2
sg70054
VC0221056
p73759
sg70048
I1
sa(dp73760
g70042
I119
sg70043
Vinfiltrates
p73761
sg70045
I11
sg70054
VC0332448
p73762
sg70048
I1
sa(dp73763
g70042
I134
sg70043
Vdermatomyositis
p73764
sg70045
I15
sg70054
VC0221056
p73765
sg70048
I1
sa(dp73766
g70042
I151
sg70043
g73750
sg70045
I2
sg70054
VC0221056
p73767
sg70048
I1
sasa(dp73768
g70037
VAbundant expression of IP-10 was observed on macrophages and T cells surrounding and invading non-necrotic muscle fibers in polymyositis and sporadic inclusion body myositis and in T cells in perimysial infiltrates of dermatomyositis.
p73769
sg70039
(lp73770
sg70051
(lp73771
(dp73772
g70042
I141
sg70043
Vsporadic inclusion body myositis
p73773
sg70045
I32
sg70054
VC0751713
p73774
sg70048
I4
sa(dp73775
g70042
I218
sg70043
Vdermatomyositis
p73776
sg70045
I15
sg70054
VC0221056
p73777
sg70048
I1
sa(dp73778
g70042
I203
sg70043
Vinfiltrates
p73779
sg70045
I11
sg70054
VC0332448
p73780
sg70048
I1
sa(dp73781
g70042
I124
sg70043
Vpolymyositis
p73782
sg70045
I12
sg70054
VC0085655
p73783
sg70048
I1
sasa(dp73784
g70037
VDORs were colocalized in tissue slices and synaptosomes from the canine right atrium and SA node along with cholinergic and adrenergic markers, vesicular acetylcholine transporter (VAChT), and tyrosine hydroxylase (TH).
p73785
sg70039
(lp73786
(dp73787
g70042
I144
sg70043
Vvesicular acetylcholine transporter
p73788
sg70045
I35
sg70046
g12
sg70048
I3
sa(dp73789
g70042
I181
sg70043
VVAChT
p73790
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp73791
g70042
I193
sg70043
Vtyrosine hydroxylase
p73792
sg70045
I20
sg70046
VP07101
p73793
sg70048
I2
sa(dp73794
g70042
I215
sg70043
VTH
p73795
sg70045
I2
sg70046
VP07101
p73796
sg70048
I1
sasg70051
(lp73797
sa(dp73798
g135
(dp73799
(VMsx2
p73800
Vsyndactyly
p73801
tp73802
I00
ssg70037
VFurthermore, the lack of interdigital programmed cell death and associated syndactyly was related to down-regulated gene expression of Bmp2, Bmp7, Msx1, and Msx2, which are known to promote apoptosis in the interdigital mesenchyme.
p73803
sg70039
(lp73804
(dp73805
g70042
I135
sg70043
VBmp2
p73806
sg70045
I4
sg70046
VP12643
p73807
sg70048
I1
sa(dp73808
g70042
I147
sg70043
VMsx1
p73809
sg70045
I4
sg70046
VP28360
p73810
sg70048
I1
sa(dp73811
g70042
I141
sg70043
VBmp7
p73812
sg70045
I4
sg70046
VP18075
p73813
sg70048
I1
sa(dp73814
g70042
I157
sg70043
g73800
sg70045
I4
sg70046
VP35548
p73815
sg70048
I1
sasg70051
(lp73816
(dp73817
g70042
I75
sg70043
g73801
sg70045
I10
sg70054
VC0039075
p73818
sg70048
I1
sasa(dp73819
g70037
VIn this context, ERdj3 suppression may eliminate the toxic gain of function associated with polymerization of ZAAT, thus providing a potential new therapeutic approach to the treatment of AATD-related liver disease.
p73820
sg70039
(lp73821
(dp73822
g70042
I17
sg70043
VERdj3
p73823
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73824
(dp73825
g70042
I201
sg70043
Vliver disease
p73826
sg70045
I13
sg70054
VC0023895
p73827
sg70048
I2
sa(dp73828
g70042
I23
sg70043
Vsuppression
p73829
sg70045
I11
sg70054
VC0221103
p73830
sg70048
I1
sa(dp73831
g70042
I188
sg70043
VAATD
p73832
sg70045
I4
sg70054
VC0221757
p73833
sg70048
I1
sasa(dp73834
g135
(dp73835
(VGPT
p73836
Vneuromuscular diseases
p73837
tp73838
I00
ssg70037
VThe CPK, aldolase, GOT, GPT, and LDH concentrations in the serum and lumbar CSF of 80 patients with neuromuscular diseases and 20 controls were measured.
p73839
sg70039
(lp73840
(dp73841
g70042
I33
sg70043
VLDH
p73842
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73843
g70042
I9
sg70043
Valdolase
p73844
sg70045
I8
sg70046
VP05062
p73845
sg70048
I1
sa(dp73846
g70042
I69
sg70043
Vlumbar CSF
p73847
sg70045
I10
sg70046
VP04141
p73848
sg70048
I2
sa(dp73849
g70042
I4
sg70043
VCPK
p73850
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73851
g70042
I24
sg70043
g73836
sg70045
I3
sg70046
VP24298
p73852
sg70048
I1
sasg70051
(lp73853
(dp73854
g70042
I100
sg70043
g73837
sg70045
I22
sg70054
VC0027868
p73855
sg70048
I2
sasa(dp73856
g135
(dp73857
(Valdolase
p73858
Vneuromuscular diseases
p73859
tp73860
I00
ssg70037
VIn 60 cases of various neuromuscular diseases, serum CA-III, CPK and aldolase were measured.
p73861
sg70039
(lp73862
(dp73863
g70042
I53
sg70043
VCA-III
p73864
sg70045
I6
sg70046
VP07451
p73865
sg70048
I1
sa(dp73866
g70042
I69
sg70043
g73858
sg70045
I8
sg70046
VP05062
p73867
sg70048
I1
sa(dp73868
g70042
I61
sg70043
VCPK
p73869
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp73870
(dp73871
g70042
I23
sg70043
g73859
sg70045
I22
sg70054
VC0027868
p73872
sg70048
I2
sasa(dp73873
g70037
VTogether, our results show that P. gingivalis activates the ERK1/2-Ets1, p38/HSP27, and PAR2/NF-kB pathways to induce proMMP9 expression, after which the proenzyme is activated by gingipains to promote cellular invasion of OSCC cell lines.
p73874
sg70039
(lp73875
(dp73876
g70042
I88
sg70043
VPAR2
p73877
sg70045
I4
sg70046
VP55085
p73878
sg70048
I1
sa(dp73879
g70042
I60
sg70043
VERK1/2
p73880
sg70045
I6
sg70046
VP27361
p73881
sg70048
I1
sa(dp73882
g70042
I77
sg70043
VHSP27
p73883
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp73884
g70042
I73
sg70043
Vp38
p73885
sg70045
I3
sg70046
VP46108
p73886
sg70048
I1
sa(dp73887
g70042
I67
sg70043
VEts1
p73888
sg70045
I4
sg70046
VP14921
p73889
sg70048
I1
sasg70051
(lp73890
(dp73891
g70042
I211
sg70043
Vinvasion
p73892
sg70045
I8
sg70054
VC2699153
p73893
sg70048
I1
sasa(dp73894
g135
(dp73895
(Vets-1 proteins
p73896
Vsquamous cell carcinoma
p73897
tp73898
I01
ssg70037
VTissue sections ranging from normal mucosa to moderately-differentiated oral squamous cell carcinoma were studied using monoclonal antibodies against N-ras and ets-1 proteins.
p73899
sg70039
(lp73900
(dp73901
g70042
I152
sg70043
Vras
p73902
sg70045
I3
sg70046
VP01116
p73903
sg70048
I1
sa(dp73904
g70042
I160
sg70043
g73896
sg70045
I14
sg70046
VP14921
p73905
sg70048
I2
sasg70051
(lp73906
(dp73907
g70042
I77
sg70043
g73897
sg70045
I23
sg70054
VC0007137
p73908
sg70048
I3
sasa(dp73909
g70037
VIn a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations.
p73910
sg70039
(lp73911
(dp73912
g70042
I300
sg70043
VFGF23
p73913
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73914
(dp73915
g70042
I50
sg70043
Vdyslipidemia
p73916
sg70045
I12
sg70054
VC0242339
p73917
sg70048
I1
sasa(dp73918
g135
(dp73919
(VG-protein coupled receptor
p73920
Vdyslipidemia
p73921
tp73922
I00
ssg70037
VThe use of nicotinic acid to treat dyslipidemia is limited by induction of a "flushing" response, mediated in part by the interaction of prostaglandin D(2) (PGD(2)) with its G-protein coupled receptor, DP1 (Ptgdr).
p73923
sg70039
(lp73924
(dp73925
g70042
I174
sg70043
g73920
sg70045
I26
sg70046
VP32247
p73926
sg70048
I3
sa(dp73927
g70042
I202
sg70043
VDP1
p73928
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp73929
g70042
I207
sg70043
VPtgdr
p73930
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp73931
(dp73932
g70042
I78
sg70043
Vflushing
p73933
sg70045
I8
sg70054
VC0016382
p73934
sg70048
I1
sa(dp73935
g70042
I35
sg70043
g73921
sg70045
I12
sg70054
VC0242339
p73936
sg70048
I1
sasa(dp73937
g70037
VWe performed a post hoc data analysis of serum phosphorus concentrations that had been determined serially (at baseline and weeks 4, 8, 12, 18, and 24) among 1547 patients who had dyslipidemia and were randomly assigned in a 3:2:1 ratio to treatment with extended release niacin (ERN; 1 g/d for 4 weeks and dose advanced to 2 g/d for 20 weeks) combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (L; n = 761), ERN alone (n = 518), or placebo (n = 268).
p73938
sg70039
(lp73939
sg70051
(lp73940
(dp73941
g70042
I180
sg70043
Vdyslipidemia
p73942
sg70045
I12
sg70054
VC0242339
p73943
sg70048
I1
sasa(dp73944
g135
(dp73945
(Vepithelial sodium channel genes
p73946
Vpseudohypoaldosteronism type 2
p73947
tp73948
I00
ssg70037
VApart from primary aldosteronism, mineralocorticoid excess can be caused by congenital adrenal hyperplasia (CAH) due to mutations of the 11beta-hydroxylase and 17alpha-hydroxylase genes, by inactivating mutations of the glucocorticoid receptor gene (Chrousos syndrome), endogenous hypercortisolism (Cushing's syndrome), by mutations of the 11beta-hydroxysteroid dehydrogenase type 2 gene (apparent mineralocorticoid excess/AME) or licorice/carbenoxolone intake, mutations of the epithelial sodium channel genes (Liddle syndrome), mutations of the mineralocorticoid receptor gene (Geller syndrome), and by mutations in the WNK1, WNK4, KLHL3, CUL3 genes (pseudohypoaldosteronism type 2 or Gordon syndrome).
p73949
sg70039
(lp73950
(dp73951
g70042
I340
sg70043
V11beta-hydroxysteroid dehydrogenase type 2 gene
p73952
sg70045
I47
sg70046
VP49366
p73953
sg70048
I5
sa(dp73954
g70042
I220
sg70043
Vglucocorticoid receptor gene
p73955
sg70045
I28
sg70046
VP04150
p73956
sg70048
I3
sa(dp73957
g70042
I641
sg70043
VCUL3 genes
p73958
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp73959
g70042
I622
sg70043
VWNK1
p73960
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp73961
g70042
I160
sg70043
V17alpha-hydroxylase genes
p73962
sg70045
I25
sg70046
VP01893
p73963
sg70048
I2
sa(dp73964
g70042
I547
sg70043
Vmineralocorticoid receptor gene
p73965
sg70045
I31
sg70046
VP08235
p73966
sg70048
I3
sa(dp73967
g70042
I634
sg70043
VKLHL3
p73968
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp73969
g70042
I628
sg70043
VWNK4
p73970
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp73971
g70042
I479
sg70043
g73946
sg70045
I31
sg70046
VP12830
p73972
sg70048
I4
sasg70051
(lp73973
(dp73974
g70042
I11
sg70043
Vprimary aldosteronism
p73975
sg70045
I21
sg70054
VC1384514
p73976
sg70048
I2
sa(dp73977
g70042
I259
sg70043
Vsyndrome
p73978
sg70045
I8
sg70054
VC0039082
p73979
sg70048
I1
sa(dp73980
g70042
I281
sg70043
Vhypercortisolism
p73981
sg70045
I16
sg70054
VC0010481
p73982
sg70048
I1
sa(dp73983
g70042
I259
sg70043
Vsyndrome
p73984
sg70045
I8
sg70054
VC0039082
p73985
sg70048
I1
sa(dp73986
g70042
I76
sg70043
Vcongenital adrenal hyperplasia
p73987
sg70045
I30
sg70054
VC0001627
p73988
sg70048
I3
sa(dp73989
g70042
I687
sg70043
VGordon syndrome
p73990
sg70045
I15
sg70054
VC0220666
p73991
sg70048
I2
sa(dp73992
g70042
I299
sg70043
VCushing's syndrome
p73993
sg70045
I18
sg70054
VC0010481
p73994
sg70048
I2
sa(dp73995
g70042
I108
sg70043
VCAH
p73996
sg70045
I3
sg70054
VC0520463
p73997
sg70048
I1
sa(dp73998
g70042
I389
sg70043
Vapparent mineralocorticoid excess
p73999
sg70045
I33
sg70054
VC2936861
p74000
sg70048
I3
sa(dp74001
g70042
I512
sg70043
VLiddle syndrome
p74002
sg70045
I15
sg70054
VC0221043
p74003
sg70048
I2
sa(dp74004
g70042
I653
sg70043
g73947
sg70045
I30
sg70054
VC1449844
p74005
sg70048
I3
sasa(dp74006
g70037
VWe provide an overview and diagnostic approach to apparent mineralocorticoid excess, glucocorticoid remediable aldosteronism, familial hyperaldosteronism type 2, Liddle's syndrome, Gordon's syndrome, activating mutations of the mineralocorticoid receptor, generalized glucocorticoid resistance and hypertensive forms of congenital adrenal hyperplasia.
p74007
sg70039
(lp74008
sg70051
(lp74009
(dp74010
g70042
I181
sg70043
VGordon's syndrome
p74011
sg70045
I17
sg70054
VC0220666
p74012
sg70048
I2
sa(dp74013
g70042
I162
sg70043
VLiddle's syndrome
p74014
sg70045
I17
sg70054
VC0221043
p74015
sg70048
I2
sa(dp74016
g70042
I320
sg70043
Vcongenital adrenal hyperplasia
p74017
sg70045
I30
sg70054
VC0001627
p74018
sg70048
I3
sa(dp74019
g70042
I135
sg70043
Vhyperaldosteronism
p74020
sg70045
I18
sg70054
VC0020428
p74021
sg70048
I1
sa(dp74022
g70042
I268
sg70043
Vglucocorticoid resistance
p74023
sg70045
I25
sg70054
VC1841971
p74024
sg70048
I2
sa(dp74025
g70042
I50
sg70043
Vapparent mineralocorticoid excess
p74026
sg70045
I33
sg70054
VC2936861
p74027
sg70048
I3
sa(dp74028
g70042
I111
sg70043
Valdosteronism
p74029
sg70045
I13
sg70054
VC0020428
p74030
sg70048
I1
sasa(dp74031
g70037
VAs chronic pancreatitis (CP) is characterized by tissue infiltration of inflammatory cells, fibrosis, pancreatic neuritis and severe pain, the roles of fractalkine and CX3CR1 were investigated in CP (n=61) and normal pancreas (NP, n=21) by QRT-PCR, western blot and immunohistochemistry analyses.
p74032
sg70039
(lp74033
sg70051
(lp74034
(dp74035
g70042
I49
sg70043
Vtissue infiltration
p74036
sg70045
I19
sg70054
VC0332448
p74037
sg70048
I2
sa(dp74038
g70042
I92
sg70043
Vfibrosis
p74039
sg70045
I8
sg70054
VC0016059
p74040
sg70048
I1
sa(dp74041
g70042
I126
sg70043
Vsevere pain
p74042
sg70045
I11
sg70054
VC0278140
p74043
sg70048
I2
sa(dp74044
g70042
I113
sg70043
Vneuritis
p74045
sg70045
I8
sg70054
VC0027813
p74046
sg70048
I1
sa(dp74047
g70042
I3
sg70043
Vchronic pancreatitis
p74048
sg70045
I20
sg70054
VC0149521
p74049
sg70048
I2
sa(dp74050
g70042
I25
sg70043
VCP
p74051
sg70045
I2
sg70054
VC0149521
p74052
sg70048
I1
sa(dp74053
g70042
I25
sg70043
VCP
p74054
sg70045
I2
sg70054
VC0149521
p74055
sg70048
I1
sasa(dp74056
g135
(dp74057
(VCX3CR1
p74058
Vneuritis
p74059
tp74060
I00
ssg70037
VNeuro-immunoreactivity for fractalkine and CX3CR1 was strongest in patients suffering from severe pain and pancreatic neuritis.
p74061
sg70039
(lp74062
(dp74063
g70042
I43
sg70043
g74058
sg70045
I6
sg70046
VP78423
p74064
sg70048
I1
sasg70051
(lp74065
(dp74066
g70042
I76
sg70043
Vsuffering
p74067
sg70045
I9
sg70054
VC0683278
p74068
sg70048
I1
sa(dp74069
g70042
I91
sg70043
Vsevere pain
p74070
sg70045
I11
sg70054
VC0278140
p74071
sg70048
I2
sa(dp74072
g70042
I118
sg70043
g74059
sg70045
I8
sg70054
VC0027813
p74073
sg70048
I1
sasa(dp74074
g70037
VOur data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a promising treatment option for patients with retinitis pigmentosa.
p74075
sg70039
(lp74076
sg70051
(lp74077
(dp74078
g70042
I120
sg70043
Vretinitis pigmentosa
p74079
sg70045
I20
sg70054
VC0035334
p74080
sg70048
I2
sasa(dp74081
g135
(dp74082
(VNRL gene
p74083
VOPMD
p74084
tp74085
I00
ssg70037
VThe index patients were homozygotes for both a dominant mutation of the PABPN1 gene, (GCN)13, and a recessive mutation of the NRL gene, p.R31X, on chromosome 14q11.1, leading to early-onset OPMD accompanied by night blindness and reduced visual acuity.
p74086
sg70039
(lp74087
(dp74088
g70042
I126
sg70043
g74083
sg70045
I8
sg70046
VP54845
p74089
sg70048
I2
sa(dp74090
g70042
I72
sg70043
VPABPN1 gene
p74091
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp74092
(dp74093
g70042
I210
sg70043
Vnight blindness
p74094
sg70045
I15
sg70054
VC0028077
p74095
sg70048
I2
sa(dp74096
g70042
I190
sg70043
g74084
sg70045
I4
sg70054
VC0270952
p74097
sg70048
I1
sasa(dp74098
g135
(dp74099
(VNRL mutation
p74100
VESCS
p74101
tp74102
I00
ssg70037
VHomozygosity for the recessive NRL mutation described here appears to be associated with a distinct retinal phenotype, demonstrating ERG characteristics similar to those of ESCS patients.
p74103
sg70039
(lp74104
(dp74105
g70042
I31
sg70043
g74100
sg70045
I12
sg70046
VP54845
p74106
sg70048
I2
sasg70051
(lp74107
(dp74108
g70042
I173
sg70043
g74101
sg70045
I4
sg70054
VC1849394
p74109
sg70048
I1
sasa(dp74110
g135
(dp74111
(VNRL
p74112
VOPMD
p74113
tp74114
I00
ssg70037
VThis report expands the spectrum of NRL recessive mutations, as well as the genetic spectrum of ESCS, and indicates a new syndrome of OPMD with an ESCS-like phenotype.
p74115
sg70039
(lp74116
(dp74117
g70042
I96
sg70043
VESCS
p74118
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74119
g70042
I36
sg70043
g74112
sg70045
I3
sg70046
VP54845
p74120
sg70048
I1
sa(dp74121
g70042
I147
sg70043
VESCS-like
p74122
sg70045
I9
sg70046
g12
sg70048
I1
sasg70051
(lp74123
(dp74124
g70042
I96
sg70043
VESCS
p74125
sg70045
I4
sg70054
VC1849394
p74126
sg70048
I1
sa(dp74127
g70042
I122
sg70043
Vsyndrome
p74128
sg70045
I8
sg70054
VC0039082
p74129
sg70048
I1
sa(dp74130
g70042
I96
sg70043
VESCS
p74131
sg70045
I4
sg70054
VC1849394
p74132
sg70048
I1
sa(dp74133
g70042
I134
sg70043
g74113
sg70045
I4
sg70054
VC0270952
p74134
sg70048
I1
sasa(dp74135
g135
(dp74136
(VNrl(-/-)
p74137
Vedema
p74138
tp74139
I00
ssg70037
VBlue light exposure of the R91W;Nrl(-/-) mouse could therefore be used to study molecular events preceding edema formation in a cone-rich environment, and thus potentially help to develop treatment strategies for edema-based complications in macular degenerations.
p74140
sg70039
(lp74141
(dp74142
g70042
I32
sg70043
g74137
sg70045
I8
sg70046
VP54845
p74143
sg70048
I1
sasg70051
(lp74144
(dp74145
g70042
I107
sg70043
Vedema
p74146
sg70045
I5
sg70054
VC0013604
p74147
sg70048
I1
sa(dp74148
g70042
I242
sg70043
Vmacular degenerations
p74149
sg70045
I21
sg70054
VC0242383
p74150
sg70048
I2
sa(dp74151
g70042
I107
sg70043
g74138
sg70045
I5
sg70054
VC0013604
p74152
sg70048
I1
sasa(dp74153
g135
(dp74154
(VCXCL2
p74155
Vcolon cancer
p74156
tp74157
I01
ssg70037
VCXCL6 and CXCL2 enhanced angiogenesis by HUVECs when cultured with fibroblast cells and colon cancer cells (P &lt; 0.01).
p74158
sg70039
(lp74159
(dp74160
g70042
I0
sg70043
VCXCL6
p74161
sg70045
I5
sg70046
VP80162
p74162
sg70048
I1
sa(dp74163
g70042
I10
sg70043
g74155
sg70045
I5
sg70046
VP19875
p74164
sg70048
I1
sasg70051
(lp74165
(dp74166
g70042
I88
sg70043
g74156
sg70045
I12
sg70054
VC0699790
p74167
sg70048
I2
sasa(dp74168
g135
(dp74169
(VCXCL2
p74170
Vcolorectal cancer
p74171
tp74172
I00
ssg70037
VAfter quality and quantity measurements, gene expression analysis of a colorectal cancer-specific marker set with 11 genes (CA7, COL12A1, CXCL1, CXCL2, CHI3L1, GREM1, IL1B, IL1RN, IL8, MMP3, SLC5A7) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler480 System (Roche).
p74173
sg70039
(lp74174
(dp74175
g70042
I167
sg70043
VIL1B
p74176
sg70045
I4
sg70046
VP01584
p74177
sg70048
I1
sa(dp74178
g70042
I173
sg70043
VIL1RN
p74179
sg70045
I5
sg70046
VP18510
p74180
sg70048
I1
sa(dp74181
g70042
I152
sg70043
VCHI3L1
p74182
sg70045
I6
sg70046
VP36222
p74183
sg70048
I1
sa(dp74184
g70042
I160
sg70043
VGREM1
p74185
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp74186
g70042
I124
sg70043
VCA7
p74187
sg70045
I3
sg70046
VP43166
p74188
sg70048
I1
sa(dp74189
g70042
I138
sg70043
VCXCL1
p74190
sg70045
I5
sg70046
VP09341
p74191
sg70048
I1
sa(dp74192
g70042
I185
sg70043
VMMP3
p74193
sg70045
I4
sg70046
VP08254
p74194
sg70048
I1
sa(dp74195
g70042
I145
sg70043
g74170
sg70045
I5
sg70046
VP19875
p74196
sg70048
I1
sa(dp74197
g70042
I129
sg70043
VCOL12A1
p74198
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74199
g70042
I191
sg70043
VSLC5A7
p74200
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp74201
(dp74202
g70042
I71
sg70043
g74171
sg70045
I17
sg70054
VC1527249
p74203
sg70048
I2
sasa(dp74204
g135
(dp74205
(VCXCL2
p74206
Vcolon cancer
p74207
tp74208
I01
ssg70037
VThese observations indicate a crucial role for TANs in the initiation and progression of CAC and suggest that the CXCL2-CXCR2 axis might be useful in reducing the risk of UC-associated colon cancer.
p74209
sg70039
(lp74210
(dp74211
g70042
I120
sg70043
VCXCR2
p74212
sg70045
I5
sg70046
VP25025
p74213
sg70048
I1
sa(dp74214
g70042
I114
sg70043
g74206
sg70045
I5
sg70046
VP19875
p74215
sg70048
I1
sasg70051
(lp74216
(dp74217
g70042
I185
sg70043
g74207
sg70045
I12
sg70054
VC0699790
p74218
sg70048
I2
sasa(dp74219
g135
(dp74220
(VCXCL1
p74221
Vcolorectal cancer
p74222
tp74223
I00
ssg70037
VGene expression analysis of a colorectal cancer-specific marker set (with 7 genes: COL12A1, CXCL1, CXCL2, GREM1, IL1B, IL8, SLC7A5) was performed with array real-time PCR using Transcriptor First Strand cDNA Synthesis Kit (Roche) and RealTime ready assays on LightCycler(R) 480 System (Roche).
p74224
sg70039
(lp74225
(dp74226
g70042
I99
sg70043
VCXCL2
p74227
sg70045
I5
sg70046
VP19875
p74228
sg70048
I1
sa(dp74229
g70042
I83
sg70043
VCOL12A1
p74230
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74231
g70042
I124
sg70043
VSLC7A5
p74232
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74233
g70042
I113
sg70043
VIL1B
p74234
sg70045
I4
sg70046
VP01584
p74235
sg70048
I1
sa(dp74236
g70042
I92
sg70043
g74221
sg70045
I5
sg70046
VP09341
p74237
sg70048
I1
sa(dp74238
g70042
I106
sg70043
VGREM1
p74239
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp74240
(dp74241
g70042
I30
sg70043
g74222
sg70045
I17
sg70054
VC1527249
p74242
sg70048
I2
sasa(dp74243
g70037
VIt is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis.
p74244
sg70039
(lp74245
sg70051
(lp74246
(dp74247
g70042
I211
sg70043
Vaxial spondyloarthritis
p74248
sg70045
I23
sg70054
VC3203547
p74249
sg70048
I2
sa(dp74250
g70042
I236
sg70043
Vplaque psoriasis
p74251
sg70045
I16
sg70054
VC0406317
p74252
sg70048
I2
sa(dp74253
g70042
I107
sg70043
Varthritis
p74254
sg70045
I9
sg70054
VC0003864
p74255
sg70048
I1
sa(dp74256
g70042
I236
sg70043
Vplaque psoriasis
p74257
sg70045
I16
sg70054
VC0406317
p74258
sg70048
I2
sa(dp74259
g70042
I107
sg70043
Varthritis, juvenile idiopathic
p74260
sg70045
I30
sg70054
VC0553662
p74261
sg70048
I3
sa(dp74262
g70042
I138
sg70043
Varthritis, psoriatic
p74263
sg70045
I20
sg70054
VC0003872
p74264
sg70048
I2
sa(dp74265
g70042
I170
sg70043
Vankylosing spondylitis
p74266
sg70045
I22
sg70054
VC0038013
p74267
sg70048
I2
sasa(dp74268
g70037
VWe describe the case of a boy with a TUBA1A mutation presenting with microphthalmia and congenital cataracts in addition to microcephaly and severe brain malformation.
p74269
sg70039
(lp74270
(dp74271
g70042
I37
sg70043
VTUBA1A
p74272
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp74273
(dp74274
g70042
I69
sg70043
Vmicrophthalmia
p74275
sg70045
I14
sg70054
VC0026010
p74276
sg70048
I1
sa(dp74277
g70042
I148
sg70043
Vbrain malformation
p74278
sg70045
I18
sg70054
VC0266449
p74279
sg70048
I2
sa(dp74280
g70042
I88
sg70043
Vcongenital cataracts
p74281
sg70045
I20
sg70054
VC0009691
p74282
sg70048
I2
sa(dp74283
g70042
I124
sg70043
Vmicrocephaly
p74284
sg70045
I12
sg70054
VC0025958
p74285
sg70048
I1
sasa(dp74286
g135
(dp74287
(Vubiquitin
p74288
Vglomerulonephritis
p74289
tp74290
I00
ssg70037
VWe previously showed that Decorin--a leucine-rich proteoglycan inhibiting the progression of glomerulonephritis and glomerular sclerosis--can be degraded by the ubiquitin-proteasome pathway and deubiquitinated and stabilized by ubiquitin-specific processing protease 2-69(Usp2-69).
p74291
sg70039
(lp74292
(dp74293
g70042
I26
sg70043
VDecorin
p74294
sg70045
I7
sg70046
VP07585
p74295
sg70048
I1
sa(dp74296
g70042
I161
sg70043
g74288
sg70045
I9
sg70046
VP62979
p74297
sg70048
I1
sa(dp74298
g70042
I228
sg70043
Vubiquitin-specific processing protease 2-69
p74299
sg70045
I43
sg70046
g12
sg70048
I4
sa(dp74300
g70042
I272
sg70043
VUsp2-69
p74301
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp74302
(dp74303
g70042
I116
sg70043
Vglomerular sclerosis
p74304
sg70045
I20
sg70054
VC0178664
p74305
sg70048
I2
sa(dp74306
g70042
I93
sg70043
g74289
sg70045
I18
sg70054
VC0017658
p74307
sg70048
I1
sasa(dp74308
g135
(dp74309
(VDecorin
p74310
Vnephritis
p74311
tp74312
I00
ssg70037
VHere, we explored the effect of Usp2-69 on MC proliferation and ECM deposition by transfecting Usp2-69 plasmid into rat anti-Thy1.1 nephritis model and into cultured MCs, as well as detected Usp2-69 and Decorin in rat anti-Thy1.1 nephritis model by western blot.
p74313
sg70039
(lp74314
(dp74315
g70042
I32
sg70043
VUsp2-69
p74316
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74317
g70042
I32
sg70043
VUsp2-69
p74318
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74319
g70042
I116
sg70043
Vrat anti-Thy1
p74320
sg70045
I13
sg70046
VP04216
p74321
sg70048
I2
sa(dp74322
g70042
I203
sg70043
g74310
sg70045
I7
sg70046
VP07585
p74323
sg70048
I1
sa(dp74324
g70042
I32
sg70043
VUsp2-69
p74325
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp74326
(dp74327
g70042
I166
sg70043
VMCs
p74328
sg70045
I3
sg70054
VC0036221
p74329
sg70048
I1
sa(dp74330
g70042
I132
sg70043
Vnephritis
p74331
sg70045
I9
sg70054
VC0027697
p74332
sg70048
I1
sa(dp74333
g70042
I46
sg70043
Vproliferation
p74334
sg70045
I13
sg70054
VC0334094
p74335
sg70048
I1
sa(dp74336
g70042
I132
sg70043
g74311
sg70045
I9
sg70054
VC0027697
p74337
sg70048
I1
sasa(dp74338
g135
(dp74339
(Vanti-Thy1.1
p74340
Vnephritis
p74341
tp74342
I00
ssg70037
VOverexpressing Usp2-69 at the early stage, but not advanced stage, of anti-Thy1.1 nephritis alleviated cell proliferation and ECM deposition, which was shown by decreased Ki-67, Collagen IV and Fibronectin detected by immunohistochemistry.
p74343
sg70039
(lp74344
(dp74345
g70042
I15
sg70043
VUsp2-69
p74346
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74347
g70042
I171
sg70043
VKi-67
p74348
sg70045
I5
sg70046
VP46013
p74349
sg70048
I1
sa(dp74350
g70042
I70
sg70043
g74340
sg70045
I11
sg70046
VP04216
p74351
sg70048
I1
sasg70051
(lp74352
(dp74353
g70042
I82
sg70043
g74341
sg70045
I9
sg70054
VC0027697
p74354
sg70048
I1
sa(dp74355
g70042
I108
sg70043
Vproliferation
p74356
sg70045
I13
sg70054
VC0334094
p74357
sg70048
I1
sasa(dp74358
g135
(dp74359
(Vrat anti-Thy1.1
p74360
Vnephritis
p74361
tp74362
I00
ssg70037
VIn conclusion, our findings suggest that Usp2-69 overexpression alleviates the progression of rat anti-Thy1.1 nephritis and, therefore, that exogenous plasmid injection via the renal artery enhanced by electrotransfer technology could be a promising avenue for glomerular disease research.
p74363
sg70039
(lp74364
(dp74365
g70042
I94
sg70043
g74360
sg70045
I15
sg70046
VP04216
p74366
sg70048
I2
sa(dp74367
g70042
I41
sg70043
VUsp2-69
p74368
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp74369
(dp74370
g70042
I261
sg70043
Vglomerular disease
p74371
sg70045
I18
sg70054
VC0268731
p74372
sg70048
I2
sa(dp74373
g70042
I110
sg70043
g74361
sg70045
I9
sg70054
VC0027697
p74374
sg70048
I1
sasa(dp74375
g135
(dp74376
(VIgAN
p74377
Vminimal change disease
p74378
tp74379
I00
ssg70037
VThe proportion of USP2-69 positive area in the glomeruli was 3.90% in normal kidney, 4.96% in minimal change disease, and 4.39% in membranous glomerulonephritides, while it was 14.84% in IgA nephropathy (IgAN) (mesangial proliferative type), 16.18% in lupus nephritis (LN; diffuse proliferative type) and 15.54% in acute proliferative glomerulonephritides (APGN); the difference of the percentages between IgAN, LN (IV subtype) and APGN and normal kidney were statistically significant (P &lt; 0.05).
p74380
sg70039
(lp74381
(dp74382
g70042
I187
sg70043
VIgA nephropathy
p74383
sg70045
I15
sg70046
VP11912
p74384
sg70048
I2
sa(dp74385
g70042
I204
sg70043
VIgAN
p74386
sg70045
I4
sg70046
VP11912
p74387
sg70048
I1
sa(dp74388
g70042
I18
sg70043
VUSP2-69
p74389
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74390
g70042
I204
sg70043
g74377
sg70045
I4
sg70046
VP11912
p74391
sg70048
I1
sasg70051
(lp74392
(dp74393
g70042
I187
sg70043
VIgA nephropathy
p74394
sg70045
I15
sg70054
VC0017661
p74395
sg70048
I2
sa(dp74396
g70042
I269
sg70043
VLN
p74397
sg70045
I2
sg70054
VC0024143
p74398
sg70048
I1
sa(dp74399
g70042
I357
sg70043
VAPGN
p74400
sg70045
I4
sg70054
VC0017658
p74401
sg70048
I1
sa(dp74402
g70042
I221
sg70043
Vproliferative
p74403
sg70045
I13
sg70054
VC0334094
p74404
sg70048
I1
sa(dp74405
g70042
I269
sg70043
VLN
p74406
sg70045
I2
sg70054
VC0024143
p74407
sg70048
I1
sa(dp74408
g70042
I131
sg70043
Vmembranous glomerulonephritides
p74409
sg70045
I31
sg70054
VC0017665
p74410
sg70048
I2
sa(dp74411
g70042
I252
sg70043
Vlupus nephritis
p74412
sg70045
I15
sg70054
VC0024143
p74413
sg70048
I2
sa(dp74414
g70042
I204
sg70043
VIgAN
p74415
sg70045
I4
sg70054
VC0017661
p74416
sg70048
I1
sa(dp74417
g70042
I315
sg70043
Vacute proliferative glomerulonephritides
p74418
sg70045
I40
sg70054
VC0017658
p74419
sg70048
I3
sa(dp74420
g70042
I357
sg70043
VAPGN
p74421
sg70045
I4
sg70054
VC0017658
p74422
sg70048
I1
sa(dp74423
g70042
I221
sg70043
Vproliferative
p74424
sg70045
I13
sg70054
VC0334094
p74425
sg70048
I1
sa(dp74426
g70042
I204
sg70043
VIgAN
p74427
sg70045
I4
sg70054
VC0017661
p74428
sg70048
I1
sa(dp74429
g70042
I94
sg70043
g74378
sg70045
I22
sg70054
VC1704320
p74430
sg70048
I3
sasa(dp74431
g135
(dp74432
(VGIRK2
p74433
VParkinson's disease
p74434
tp74435
I00
ssg70037
VWe analysed surviving human SN DA neurons from patients with Parkinson's disease and from controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson's disease.
p74436
sg70039
(lp74437
(dp74438
g70042
I167
sg70043
g74433
sg70045
I5
sg70046
VP48051
p74439
sg70048
I1
sasg70051
(lp74440
(dp74441
g70042
I61
sg70043
VParkinson's disease
p74442
sg70045
I19
sg70054
VC0030567
p74443
sg70048
I2
sa(dp74444
g70042
I61
sg70043
g74434
sg70045
I19
sg70054
VC0030567
p74445
sg70048
I2
sasa(dp74446
g135
(dp74447
(VGIRK2
p74448
VParkinson's disease
p74449
tp74450
I00
ssg70037
VThus, our findings provide a novel homeostatic functional link in SN DA neurons between Cav1.3- L-type-Ca(2+) channels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Cav1.3/NCS-1/D2/GIRK2) is also active in human SN DA neurons, and contributes to Parkinson's disease pathology.
p74451
sg70039
(lp74452
(dp74453
g70042
I88
sg70043
VCav1.3- L
p74454
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp74455
g70042
I222
sg70043
VCav1.3/NCS-1
p74456
sg70045
I12
sg70046
VP62166
p74457
sg70048
I1
sa(dp74458
g70042
I238
sg70043
g74448
sg70045
I5
sg70046
VP48051
p74459
sg70048
I1
sasg70051
(lp74460
(dp74461
g70042
I323
sg70043
Vpathology
p74462
sg70045
I9
sg70054
VC0677042
p74463
sg70048
I1
sa(dp74464
g70042
I303
sg70043
g74449
sg70045
I19
sg70054
VC0030567
p74465
sg70048
I2
sasa(dp74466
g70037
VIn conclusion, sera from AIH-1 patients reacted with the amino acids in the sequence 33-37 (PQDGS) of the N-terminal of UGT1A6.
p74467
sg70039
(lp74468
(dp74469
g70042
I120
sg70043
VUGT1A6
p74470
sg70045
I6
sg70046
VP35504
p74471
sg70048
I1
sasg70051
(lp74472
sa(dp74473
g135
(dp74474
(VAKT1
p74475
Vmultiple myeloma
p74476
tp74477
I00
ssg70037
VSeveral proapoptotic genes (AKT1 and AKT2) were down-regulated and antiapoptotic genes (APAF1 and BCL2L1) were up-regulated in multiple myeloma, both symptomatic and asymptomatic, compared to monoclonal gammopathy of undetermined significance.
p74478
sg70039
(lp74479
(dp74480
g70042
I98
sg70043
VBCL2L1
p74481
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74482
g70042
I37
sg70043
VAKT2
p74483
sg70045
I4
sg70046
VP31751
p74484
sg70048
I1
sa(dp74485
g70042
I28
sg70043
g74475
sg70045
I4
sg70046
VP31749
p74486
sg70048
I1
sasg70051
(lp74487
(dp74488
g70042
I192
sg70043
Vmonoclonal gammopathy of undetermined significance
p74489
sg70045
I50
sg70054
VC0026470
p74490
sg70048
I5
sa(dp74491
g70042
I127
sg70043
g74476
sg70045
I16
sg70054
VC0026764
p74492
sg70048
I2
sasa(dp74493
g135
(dp74494
(Vp14
p74495
Vmultiple myeloma
p74496
tp74497
I00
ssg70037
VTo study the role of gene promoter hypermethylation of the putative tumour suppressor genes involved in the death-associated protein (DAP) kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma (MM).
p74498
sg70039
(lp74499
(dp74500
g70042
I155
sg70043
Vp53
p74501
sg70045
I3
sg70046
VP42771
p74502
sg70048
I1
sa(dp74503
g70042
I134
sg70043
VDAP
p74504
sg70045
I3
sg70046
VP51397
p74505
sg70048
I1
sa(dp74506
g70042
I108
sg70043
Vdeath-associated protein
p74507
sg70045
I24
sg70046
VP51397
p74508
sg70048
I2
sa(dp74509
g70042
I146
sg70043
g74495
sg70045
I3
sg70046
VP03971
p74510
sg70048
I1
sasg70051
(lp74511
(dp74512
g70042
I187
sg70043
g74496
sg70045
I16
sg70054
VC0026764
p74513
sg70048
I2
sa(dp74514
g70042
I68
sg70043
Vtumour
p74515
sg70045
I6
sg70054
VC0027651
p74516
sg70048
I1
sasa(dp74517
g135
(dp74518
(Vsynaptophysin
p74519
Vspermatocytic seminoma
p74520
tp74521
I00
ssg70037
VThe other was a spermatocytic seminoma with focal primitive neuroectodermal differentiation: formation of Homer-Wright rosettes and perivascular pseudorosettes, with immunoreactivity for S-100 protein, neuron-specific enolase, synaptophysin, neurofilament-68 kDa, microtubule-associated protein 2, and vimentin.
p74522
sg70039
(lp74523
(dp74524
g70042
I264
sg70043
Vmicrotubule-associated protein 2
p74525
sg70045
I32
sg70046
VP11137
p74526
sg70048
I3
sa(dp74527
g70042
I187
sg70043
VS-100 protein
p74528
sg70045
I13
sg70046
VP04271
p74529
sg70048
I2
sa(dp74530
g70042
I202
sg70043
Vneuron-specific enolase
p74531
sg70045
I23
sg70046
VP09104
p74532
sg70048
I2
sa(dp74533
g70042
I227
sg70043
g74519
sg70045
I13
sg70046
VP08247
p74534
sg70048
I1
sasg70051
(lp74535
(dp74536
g70042
I16
sg70043
g74520
sg70045
I22
sg70054
VC0334517
p74537
sg70048
I2
sasa(dp74538
g135
(dp74539
(Vubiquinol-cytochrome c reductase core protein I
p74540
Vovarian cancer
p74541
tp74542
I01
ssg70037
VIn addition to Rett syndrome and breast/ovarian cancer observed in other studies, we report evidence for the first time, to our knowledge, that overexpression of ubiquinol-cytochrome c reductase core protein I might affect mitochondrial morphology and/or physiology and lead to development of obesity and related conditions.
p74543
sg70039
(lp74544
(dp74545
g70042
I162
sg70043
g74540
sg70045
I47
sg70046
VP99999
p74546
sg70048
I6
sasg70051
(lp74547
(dp74548
g70042
I293
sg70043
Vobesity
p74549
sg70045
I7
sg70054
VC0028754
p74550
sg70048
I1
sa(dp74551
g70042
I15
sg70043
VRett syndrome
p74552
sg70045
I13
sg70054
VC0035372
p74553
sg70048
I2
sa(dp74554
g70042
I40
sg70043
g74541
sg70045
I14
sg70054
VC1140680
p74555
sg70048
I2
sasa(dp74556
g135
(dp74557
(VKRAS
p74558
Vcolitis
p74559
tp74560
I00
ssg70037
VFrom the therapeutic standpoint, colitis-associated cancers are associated with a lower prevalence of KRAS mutations than the sporadic variant.
p74561
sg70039
(lp74562
(dp74563
g70042
I102
sg70043
g74558
sg70045
I4
sg70046
VP01116
p74564
sg70048
I1
sasg70051
(lp74565
(dp74566
g70042
I33
sg70043
g74559
sg70045
I7
sg70054
VC0009319
p74567
sg70048
I1
sa(dp74568
g70042
I52
sg70043
Vcancers
p74569
sg70045
I7
sg70054
VC0006826
p74570
sg70048
I1
sasa(dp74571
g135
(dp74572
(Vtransferrin
p74573
Vsystemic candidiasis
p74574
tp74575
I00
ssg70037
VIn a murine acute systemic candidiasis model, C albicans strongly stimulated hepcidin, accompanied by a major reduction in transferrin saturation.
p74576
sg70039
(lp74577
(dp74578
g70042
I123
sg70043
g74573
sg70045
I11
sg70046
VP02787
p74579
sg70048
I1
sasg70051
(lp74580
(dp74581
g70042
I18
sg70043
g74574
sg70045
I20
sg70054
VC0153252
p74582
sg70048
I2
sasa(dp74583
g135
(dp74584
(Vtransferrin
p74585
Vcandidiasis
p74586
tp74587
I00
ssg70037
VOn the other hand, iron overload (iron saturated transferrin) is a serious risk factor for candidiasis in newborn and in leukemic patients.
p74588
sg70039
(lp74589
(dp74590
g70042
I49
sg70043
g74585
sg70045
I11
sg70046
VP02787
p74591
sg70048
I1
sasg70051
(lp74592
(dp74593
g70042
I19
sg70043
Viron overload
p74594
sg70045
I13
sg70054
VC0282193
p74595
sg70048
I2
sa(dp74596
g70042
I91
sg70043
g74586
sg70045
I11
sg70054
VC0006840
p74597
sg70048
I1
sasa(dp74598
g135
(dp74599
(VNHE1
p74600
VAF
p74601
tp74602
I00
ssg70037
VIt has been suggested that blockade of the Na+/H+ exchanger (NHE1) can prevent atrial fibrillation (AF)-induced electrical remodeling and the development of AF.
p74603
sg70039
(lp74604
(dp74605
g70042
I61
sg70043
g74600
sg70045
I4
sg70046
VP19634
p74606
sg70048
I1
sasg70051
(lp74607
(dp74608
g70042
I79
sg70043
Vatrial fibrillation
p74609
sg70045
I19
sg70054
VC0004238
p74610
sg70048
I2
sa(dp74611
g70042
I100
sg70043
VAF
p74612
sg70045
I2
sg70054
VC0232197
p74613
sg70048
I1
sa(dp74614
g70042
I100
sg70043
g74601
sg70045
I2
sg70054
VC0232197
p74615
sg70048
I1
sasa(dp74616
g70037
VThe case of a 13-year-old boy is presented and the diagnostic process discussed especially the differentiation between trance states and epilepsy.
p74617
sg70039
(lp74618
sg70051
(lp74619
(dp74620
g70042
I137
sg70043
Vepilepsy
p74621
sg70045
I8
sg70054
VC0014544
p74622
sg70048
I1
sa(dp74623
g70042
I119
sg70043
Vtrance
p74624
sg70045
I6
sg70054
VC0855240
p74625
sg70048
I1
sasa(dp74626
g135
(dp74627
(VT-B+NK+ SCID
p74628
VSCID
p74629
tp74630
I00
ssg70037
VThe phenotype is usually T-B+NK+ SCID with lymphopenia where the clinical findings may be mild (CD3Gamma) or severe (CD3Delta, Epsilon, Zeta) owing to the underlying molecular defect.
p74631
sg70039
(lp74632
(dp74633
g70042
I25
sg70043
g74628
sg70045
I12
sg70046
VP31785
p74634
sg70048
I2
sasg70051
(lp74635
(dp74636
g70042
I43
sg70043
Vlymphopenia
p74637
sg70045
I11
sg70054
VC0024312
p74638
sg70048
I1
sa(dp74639
g70042
I65
sg70043
Vclinical findings
p74640
sg70045
I17
sg70054
VC0037088
p74641
sg70048
I2
sa(dp74642
g70042
I33
sg70043
g74629
sg70045
I4
sg70054
VC0085110
p74643
sg70048
I1
sasa(dp74644
g70037
VIn contrast, all reported human complete CD3delta (or CD3epsilon) deficiencies are in infants with life-threatening SCID and very severe alphabeta and gammadelta T lymphocytopenia.
p74645
sg70039
(lp74646
sg70051
(lp74647
(dp74648
g70042
I116
sg70043
VSCID
p74649
sg70045
I4
sg70054
VC0085110
p74650
sg70048
I1
sa(dp74651
g70042
I164
sg70043
Vlymphocytopenia
p74652
sg70045
I15
sg70054
VC0024312
p74653
sg70048
I1
sasa(dp74654
g70037
VAlthough clozapine, olanzapine, and other atypical antipsychotic drugs (APDs) have fewer extrapyramidal side effects, they have serious metabolic side effects such as substantial weight gain, intra-abdominal obesity, and type 2 diabetes mellitus.
p74655
sg70039
(lp74656
sg70051
(lp74657
(dp74658
g70042
I221
sg70043
Vtype 2 diabetes mellitus
p74659
sg70045
I24
sg70054
VC0011860
p74660
sg70048
I4
sa(dp74661
g70042
I198
sg70043
Vabdominal obesity
p74662
sg70045
I17
sg70054
VC0311277
p74663
sg70048
I2
sasa(dp74664
g70037
VGiven that most patients with mental disorders face chronic, even life-long, treatment with APDs, the risks of weight gain/obesity and other metabolic symptoms are major considerations for APD maintenance treatment.
p74665
sg70039
(lp74666
sg70051
(lp74667
(dp74668
g70042
I141
sg70043
Vmetabolic symptoms
p74669
sg70045
I18
sg70054
VC0476237
p74670
sg70048
I2
sa(dp74671
g70042
I47
sg70043
Vface
p74672
sg70045
I4
sg70054
VC3160739
p74673
sg70048
I1
sa(dp74674
g70042
I30
sg70043
Vmental disorders
p74675
sg70045
I16
sg70054
VC0004936
p74676
sg70048
I2
sa(dp74677
g70042
I123
sg70043
Vobesity
p74678
sg70045
I7
sg70054
VC0028754
p74679
sg70048
I1
sasa(dp74680
g70037
VAlthough offering many benefits for several psychiatric disorders, antipsychotic drugs (APDs) as a class have a major liability in their tendency to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population.
p74681
sg70039
(lp74682
sg70051
(lp74683
(dp74684
g70042
I168
sg70043
Vobesity
p74685
sg70045
I7
sg70054
VC0028754
p74686
sg70048
I1
sa(dp74687
g70042
I44
sg70043
Vpsychiatric disorders
p74688
sg70045
I21
sg70054
VC0004936
p74689
sg70048
I2
sa(dp74690
g70042
I157
sg70043
Vadiposity
p74691
sg70045
I9
sg70054
VC0028754
p74692
sg70048
I1
sasa(dp74693
g70037
VTo describe the association between obesity and the use of antipsychotic drugs (APDs) in adult outpatients followed-up on in five Primary Care settings.
p74694
sg70039
(lp74695
sg70051
(lp74696
(dp74697
g70042
I36
sg70043
Vobesity
p74698
sg70045
I7
sg70054
VC0028754
p74699
sg70048
I1
sasa(dp74700
g70037
VObesity was associated with the use of APDs [OR = 1.5 (CI: 1.3-1.8)], hypertension [OR = 2.4 (CI: 2.2-2.5)], diabetes [OR = 1.4 (CI: 1.3-1.5)] and dyslipidemia [OR = 1.3 (CI: 1.2-1.4)], p &lt; 0.0001 in all cases.
p74701
sg70039
(lp74702
sg70051
(lp74703
(dp74704
g70042
I0
sg70043
VObesity
p74705
sg70045
I7
sg70054
VC0028754
p74706
sg70048
I1
sa(dp74707
g70042
I147
sg70043
Vdyslipidemia
p74708
sg70045
I12
sg70054
VC0242339
p74709
sg70048
I1
sa(dp74710
g70042
I70
sg70043
Vhypertension
p74711
sg70045
I12
sg70054
VC0020538
p74712
sg70048
I1
sa(dp74713
g70042
I109
sg70043
Vdiabetes
p74714
sg70045
I8
sg70054
VC0011849
p74715
sg70048
I1
sasa(dp74716
g70037
VObesity was associated with the use of APDs, regardless of the type of drug, and with the presence of hypertension, diabetes and dyslipidemia.
p74717
sg70039
(lp74718
sg70051
(lp74719
(dp74720
g70042
I0
sg70043
VObesity
p74721
sg70045
I7
sg70054
VC0028754
p74722
sg70048
I1
sa(dp74723
g70042
I116
sg70043
Vdiabetes
p74724
sg70045
I8
sg70054
VC0011849
p74725
sg70048
I1
sa(dp74726
g70042
I129
sg70043
Vdyslipidemia
p74727
sg70045
I12
sg70054
VC0242339
p74728
sg70048
I1
sa(dp74729
g70042
I102
sg70043
Vhypertension
p74730
sg70045
I12
sg70054
VC0020538
p74731
sg70048
I1
sasa(dp74732
g135
(dp74733
(VDARs
p74734
VDAR
p74735
tp74736
I00
ssg70037
VHigher DARs were associated with lower rates of moderate or severe paravalvular aortic regurgitation: DAR &lt;=10%, 17.6%; DAR 10% to 15%, 9.9%; DAR 15% to 20%, 6.3%; and DAR &gt;20%, 4.9%; P&lt;0.001.
p74737
sg70039
(lp74738
(dp74739
g70042
I7
sg70043
g74734
sg70045
I4
sg70046
VP14868
p74740
sg70048
I1
sasg70051
(lp74741
(dp74742
g70042
I7
sg70043
VDAR
p74743
sg70045
I3
sg70054
VC0022595
p74744
sg70048
I1
sa(dp74745
g70042
I7
sg70043
VDAR
p74746
sg70045
I3
sg70054
VC0022595
p74747
sg70048
I1
sa(dp74748
g70042
I80
sg70043
Vaortic regurgitation
p74749
sg70045
I20
sg70054
VC0003504
p74750
sg70048
I2
sa(dp74751
g70042
I7
sg70043
VDAR
p74752
sg70045
I3
sg70054
VC0022595
p74753
sg70048
I1
sa(dp74754
g70042
I7
sg70043
g74735
sg70045
I3
sg70054
VC0022595
p74755
sg70048
I1
sasa(dp74756
g70037
VIn 1990, Hopkins and Ruiz-Riben stated that the target date o f the end o f 1995 for the eradication of dracunculiasis is unrealistic only if it is judged to be unimportant.
p74757
sg70039
(lp74758
sg70051
(lp74759
(dp74760
g70042
I104
sg70043
Vdracunculiasis
p74761
sg70045
I14
sg70054
VC0013100
p74762
sg70048
I1
sasa(dp74763
g70037
VDLL1 influence drug resistance of small cell lung cancer through activating transcription of downstream genes HES1 and HEY1.
p74764
sg70039
(lp74765
(dp74766
g70042
I119
sg70043
VHEY1
p74767
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74768
g70042
I110
sg70043
VHES1
p74769
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74770
g70042
I0
sg70043
VDLL1
p74771
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp74772
(dp74773
g70042
I34
sg70043
Vsmall cell lung cancer
p74774
sg70045
I22
sg70054
VC0149925
p74775
sg70048
I4
sasa(dp74776
g135
(dp74777
(VJagged1
p74778
Vlung cancer
p74779
tp74780
I00
ssg70037
VIn this study, we showed that a high percentage of lung cancer lines expressed Jagged1, Notch receptors, and their transcriptional target genes (HES1, Hey1), suggesting that the Notch pathway plays an important role in lung cancer biology.
p74781
sg70039
(lp74782
(dp74783
g70042
I145
sg70043
VHES1
p74784
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74785
g70042
I79
sg70043
g74778
sg70045
I7
sg70046
VP78504
p74786
sg70048
I1
sa(dp74787
g70042
I151
sg70043
VHey1
p74788
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74789
g70042
I88
sg70043
VNotch receptors
p74790
sg70045
I15
sg70046
g12
sg70048
I2
sasg70051
(lp74791
(dp74792
g70042
I51
sg70043
Vlung cancer
p74793
sg70045
I11
sg70054
VC0684249
p74794
sg70048
I2
sa(dp74795
g70042
I51
sg70043
g74779
sg70045
I11
sg70054
VC0684249
p74796
sg70048
I2
sasa(dp74797
g135
(dp74798
(VALPs
p74799
VALPs
p74800
tp74801
I00
ssg70037
VALPs easily insert in the outer leaflet of the plasma membrane and cross the membrane via an ATP-dependent CDC50a-containing 'flippase' complex (in carcinoma cells), or are internalized by lipid raft-dependent endocytosis (in lymphoma/leukemic cells).
p74802
sg70039
(lp74803
(dp74804
g70042
I107
sg70043
VCDC50a
p74805
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74806
g70042
I125
sg70043
V'flippase
p74807
sg70045
I9
sg70046
VP98196
p74808
sg70048
I1
sa(dp74809
g70042
I0
sg70043
g74799
sg70045
I4
sg70046
VP03973
p74810
sg70048
I1
sasg70051
(lp74811
(dp74812
g70042
I148
sg70043
Vcarcinoma
p74813
sg70045
I9
sg70054
VC0007097
p74814
sg70048
I1
sa(dp74815
g70042
I226
sg70043
Vlymphoma
p74816
sg70045
I8
sg70054
VC0024299
p74817
sg70048
I1
sa(dp74818
g70042
I0
sg70043
g74800
sg70045
I4
sg70054
VC1328840
p74819
sg70048
I1
sasa(dp74820
g135
(dp74821
(Vplasma membrane proteins
p74822
Vprostate cancer
p74823
tp74824
I00
ssg70037
VLevels of 27 transcripts were investigated as potential novel markers for prostate cancer, including genes encoding plasma membrane proteins (ADAM2, ELOVL5, MARCKSL1, RAMP1, TMEM30A, and TMEM66); secreted proteins (SPON2, TMEM30A, TMEM66, and truncated TMEFF2 (called POP4)); intracellular proteins (CAMK2N1, DHCR24, GLO1, NGFRAP1, PGK1, PSMA7, SBDS, and YWHAQ); and noncoding transcripts (POP1 (100 kb) from mRNA AK000023), POP2 (4 kb from mRNA AL832227), POP3 (50 kb from EST CFI40309), POP5 (intron of NCAM2, accession DO668384), POP6 (intron of FHIT), POP7 (intron of TNFAIP8), POP8 (intron of EFNA5), POP9 (intron of DSTN), POP10 (intron of ADAM2, accession DO668396), POP11 (87kb from EST BG194644), and POP12 (intron of EST BQ226050)).
p74825
sg70039
(lp74826
(dp74827
g70042
I489
sg70043
VPOP5
p74828
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74829
g70042
I149
sg70043
VELOVL5
p74830
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74831
g70042
I332
sg70043
VPGK1
p74832
sg70045
I4
sg70046
VP00558
p74833
sg70048
I1
sa(dp74834
g70042
I174
sg70043
VTMEM30A
p74835
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74836
g70042
I582
sg70043
VPOP8 (intron of EFNA5)
p74837
sg70045
I22
sg70046
VP52803
p74838
sg70048
I4
sa(dp74839
g70042
I157
sg70043
VMARCKSL1
p74840
sg70045
I8
sg70046
VP49006
p74841
sg70048
I1
sa(dp74842
g70042
I142
sg70043
VADAM2
p74843
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp74844
g70042
I309
sg70043
VDHCR24
p74845
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74846
g70042
I300
sg70043
VCAMK2N1
p74847
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74848
g70042
I317
sg70043
VGLO1
p74849
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74850
g70042
I142
sg70043
VADAM2
p74851
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp74852
g70042
I187
sg70043
VTMEM66
p74853
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74854
g70042
I323
sg70043
VNGFRAP1
p74855
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74856
g70042
I556
sg70043
VPOP7 (intron of TNFAIP8)
p74857
sg70045
I24
sg70046
g12
sg70048
I4
sa(dp74858
g70042
I533
sg70043
VPOP6 (intron of FHIT)
p74859
sg70045
I21
sg70046
VP49789
p74860
sg70048
I4
sa(dp74861
g70042
I505
sg70043
VNCAM2
p74862
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp74863
g70042
I167
sg70043
VRAMP1
p74864
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp74865
g70042
I268
sg70043
VPOP4
p74866
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp74867
g70042
I457
sg70043
VPOP3 (50 kb from EST CFI40309
p74868
sg70045
I29
sg70046
VP49888
p74869
sg70048
I6
sa(dp74870
g70042
I174
sg70043
VTMEM30A
p74871
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74872
g70042
I187
sg70043
VTMEM66
p74873
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74874
g70042
I116
sg70043
g74822
sg70045
I24
sg70046
VP35968
p74875
sg70048
I3
sa(dp74876
g70042
I338
sg70043
VPSMA7
p74877
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp74878
g70042
I215
sg70043
VSPON2
p74879
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp74880
g70042
I390
sg70043
VPOP1 (100 kb) from mRNA AK000023
p74881
sg70045
I32
sg70046
g12
sg70048
I6
sasg70051
(lp74882
(dp74883
g70042
I74
sg70043
g74823
sg70045
I15
sg70054
VC0600139
p74884
sg70048
I2
sasa(dp74885
g70037
VLevels of CAMK2N1, GLO1, SDBS, and TMEM30A transcripts tended to be increased in primary prostate cancer from patients who later had biochemical failure.
p74886
sg70039
(lp74887
(dp74888
g70042
I10
sg70043
VCAMK2N1
p74889
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp74890
g70042
I35
sg70043
VTMEM30A transcripts
p74891
sg70045
I19
sg70046
g12
sg70048
I2
sa(dp74892
g70042
I19
sg70043
VGLO1
p74893
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp74894
(dp74895
g70042
I89
sg70043
Vprostate cancer
p74896
sg70045
I15
sg70054
VC0600139
p74897
sg70048
I2
sasa(dp74898
g70037
VHuman CDC50A mRNA was expressed in embryonic stem (ES) cells, placenta, brain and chondrosarcoma, while CDC50B mRNA was expressed in pancreatic islet, kidney, prostate as well as in lung carcinoid, parathyroid tumor, bladder tumor, meningioma and pancreatic cancer.
p74899
sg70039
(lp74900
(dp74901
g70042
I0
sg70043
VHuman CDC50A mRNA
p74902
sg70045
I17
sg70046
g12
sg70048
I3
sa(dp74903
g70042
I104
sg70043
VCDC50B mRNA
p74904
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp74905
(dp74906
g70042
I198
sg70043
Vparathyroid tumor
p74907
sg70045
I17
sg70054
VC0030521
p74908
sg70048
I2
sa(dp74909
g70042
I247
sg70043
Vpancreatic cancer
p74910
sg70045
I17
sg70054
VC0235974
p74911
sg70048
I2
sa(dp74912
g70042
I232
sg70043
Vmeningioma
p74913
sg70045
I10
sg70054
VC0025286
p74914
sg70048
I1
sa(dp74915
g70042
I217
sg70043
Vbladder tumor
p74916
sg70045
I13
sg70054
VC0005695
p74917
sg70048
I2
sa(dp74918
g70042
I82
sg70043
Vchondrosarcoma
p74919
sg70045
I14
sg70054
VC0008479
p74920
sg70048
I1
sa(dp74921
g70042
I187
sg70043
Vcarcinoid
p74922
sg70045
I9
sg70054
VC0007095
p74923
sg70048
I1
sasa(dp74924
g135
(dp74925
(Vephrin-B2
p74926
Vcorneal neovascularization
p74927
tp74928
I00
ssg70037
VFinally, ephrin-B2/Fc promoted angiogenesis in vivo in corneal neovascularization and Matrigel plug assays in adult mice, whereas LY294002 reduced angiogenesis in Matrigel that was induced by ephrin-B2/Fc.
p74929
sg70039
(lp74930
(dp74931
g70042
I9
sg70043
g74926
sg70045
I9
sg70046
VP52799
p74932
sg70048
I1
sasg70051
(lp74933
(dp74934
g70042
I55
sg70043
g74927
sg70045
I26
sg70054
VC0085109
p74935
sg70048
I2
sasa(dp74936
g70037
VMutations of SYNGAP1 have been frequently linked to brain disorders including intellectual disability, autisms, and seizure.
p74937
sg70039
(lp74938
(dp74939
g70042
I13
sg70043
VSYNGAP1
p74940
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp74941
(dp74942
g70042
I116
sg70043
Vseizure
p74943
sg70045
I7
sg70054
VC0036572
p74944
sg70048
I1
sa(dp74945
g70042
I103
sg70043
Vautisms
p74946
sg70045
I7
sg70054
VC0004352
p74947
sg70048
I1
sa(dp74948
g70042
I52
sg70043
Vbrain disorders
p74949
sg70045
I15
sg70054
VC0006111
p74950
sg70048
I2
sa(dp74951
g70042
I78
sg70043
Vintellectual disability
p74952
sg70045
I23
sg70054
VC0025362
p74953
sg70048
I2
sasa(dp74954
g135
(dp74955
(VDlg4
p74956
Vautism spectrum disorder
p74957
tp74958
I00
ssg70037
VFurthermore, the LTP-regulated phosphoproteins, which included the scaffold proteins Shank3, Syngap1, Dlgap1, and Dlg4, represented the "PSD risk" for schizophrenia and autism spectrum disorder, such that without these proteins in the analysis, the association with the PSD and these two psychiatric diseases was not present.
p74959
sg70039
(lp74960
(dp74961
g70042
I102
sg70043
VDlgap1
p74962
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74963
g70042
I114
sg70043
g74956
sg70045
I4
sg70046
VP78352
p74964
sg70048
I1
sa(dp74965
g70042
I137
sg70043
VPSD
p74966
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp74967
g70042
I85
sg70043
VShank3
p74968
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp74969
g70042
I93
sg70043
VSyngap1
p74970
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp74971
(dp74972
g70042
I151
sg70043
Vschizophrenia
p74973
sg70045
I13
sg70054
VC0036341
p74974
sg70048
I1
sa(dp74975
g70042
I169
sg70043
g74957
sg70045
I24
sg70054
VC1510586
p74976
sg70048
I3
sasa(dp74977
g70037
VDevelopmental delay was the first manifestation of SYNGAP1-related encephalopathy; intellectual disability became progressively obvious and was associated with autistic behaviours in eight patients.
p74978
sg70039
(lp74979
(dp74980
g70042
I51
sg70043
VSYNGAP1
p74981
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp74982
(dp74983
g70042
I0
sg70043
VDevelopmental delay
p74984
sg70045
I19
sg70054
VC0424605
p74985
sg70048
I2
sa(dp74986
g70042
I83
sg70043
Vintellectual disability
p74987
sg70045
I23
sg70054
VC0025362
p74988
sg70048
I2
sa(dp74989
g70042
I160
sg70043
Vautistic
p74990
sg70045
I8
sg70054
VC0004352
p74991
sg70048
I1
sa(dp74992
g70042
I67
sg70043
Vencephalopathy
p74993
sg70045
I14
sg70054
VC0085584
p74994
sg70048
I1
sasa(dp74995
g135
(dp74996
(VFlt1
p74997
Vmetabolic syndromes
p74998
tp74999
I00
ssg70037
VThe only two genes upregulated across all transcriptome-wide PE analyses to date (microarray, RNA-Seq and PAS-Seq) are NRIP1 (RIP140), a transcriptional co-regulator linked to metabolic syndromes associated with obesity, and Flt1.
p75000
sg70039
(lp75001
(dp75002
g70042
I126
sg70043
VRIP140
p75003
sg70045
I6
sg70046
VP48552
p75004
sg70048
I1
sa(dp75005
g70042
I106
sg70043
VPAS-Seq
p75006
sg70045
I7
sg70046
VP05165
p75007
sg70048
I1
sa(dp75008
g70042
I119
sg70043
VNRIP1
p75009
sg70045
I5
sg70046
VP48552
p75010
sg70048
I1
sa(dp75011
g70042
I225
sg70043
g74997
sg70045
I4
sg70046
VP17948
p75012
sg70048
I1
sasg70051
(lp75013
(dp75014
g70042
I212
sg70043
Vobesity
p75015
sg70045
I7
sg70054
VC0028754
p75016
sg70048
I1
sa(dp75017
g70042
I176
sg70043
g74998
sg70045
I19
sg70054
VC0524620
p75018
sg70048
I2
sasa(dp75019
g135
(dp75020
(VVEGFB
p75021
Vobesity
p75022
tp75023
I00
ssg70037
VFurthermore, endothelial Flt1 gene deletion enhanced the effect of VEGFB, activating the thermogenic program in subcutaneous adipose tissue, which increased the basal metabolic rate, thus preventing diet-induced obesity and related metabolic complications.
p75024
sg70039
(lp75025
(dp75026
g70042
I25
sg70043
VFlt1
p75027
sg70045
I4
sg70046
VP17948
p75028
sg70048
I1
sa(dp75029
g70042
I67
sg70043
g75021
sg70045
I5
sg70046
VP49765
p75030
sg70048
I1
sasg70051
(lp75031
(dp75032
g70042
I212
sg70043
g75022
sg70045
I7
sg70054
VC0028754
p75033
sg70048
I1
sa(dp75034
g70042
I30
sg70043
Vgene deletion
p75035
sg70045
I13
sg70054
VC1442161
p75036
sg70048
I2
sasa(dp75037
g135
(dp75038
(Vactivating VEGFR2
p75039
Vobesity
p75040
tp75041
I00
ssg70037
V(2016) demonstrate that VEGF-B, by displacing VEGF-A from VEGFR1 and activating VEGFR2, increases adipose tissue vascularity, improves insulin sensitivity, diminishes obesity, and alleviates metabolic syndrome.
p75042
sg70039
(lp75043
(dp75044
g70042
I135
sg70043
Vinsulin
p75045
sg70045
I7
sg70046
VP01308
p75046
sg70048
I1
sa(dp75047
g70042
I58
sg70043
VVEGFR1
p75048
sg70045
I6
sg70046
VP17948
p75049
sg70048
I1
sa(dp75050
g70042
I24
sg70043
VVEGF-B
p75051
sg70045
I6
sg70046
VP49765
p75052
sg70048
I1
sa(dp75053
g70042
I69
sg70043
g75039
sg70045
I17
sg70046
VP35968
p75054
sg70048
I2
sasg70051
(lp75055
(dp75056
g70042
I135
sg70043
Vinsulin sensitivity
p75057
sg70045
I19
sg70054
VC0920563
p75058
sg70048
I2
sa(dp75059
g70042
I191
sg70043
Vmetabolic syndrome
p75060
sg70045
I18
sg70054
VC0524620
p75061
sg70048
I2
sa(dp75062
g70042
I167
sg70043
g75040
sg70045
I7
sg70054
VC0028754
p75063
sg70048
I1
sasa(dp75064
g135
(dp75065
(VVEGFR-1
p75066
VTAM
p75067
tp75068
I00
ssg70037
VHere, we hypothesized that increased activity of PlGF/VEGFR-1 signaling mediates obesity-induced tumor progression by augmenting tumor angiogenesis and TAM recruitment/activity.
p75069
sg70039
(lp75070
(dp75071
g70042
I49
sg70043
VPlGF
p75072
sg70045
I4
sg70046
VP49763
p75073
sg70048
I1
sa(dp75074
g70042
I54
sg70043
g75066
sg70045
I7
sg70046
VP17948
p75075
sg70048
I1
sasg70051
(lp75076
(dp75077
g70042
I81
sg70043
Vobesity
p75078
sg70045
I7
sg70054
VC0028754
p75079
sg70048
I1
sa(dp75080
g70042
I156
sg70043
Vrecruitment
p75081
sg70045
I11
sg70054
VC0271510
p75082
sg70048
I1
sa(dp75083
g70042
I97
sg70043
Vtumor progression
p75084
sg70045
I17
sg70054
VC0178874
p75085
sg70048
I2
sa(dp75086
g70042
I129
sg70043
Vtumor angiogenesis
p75087
sg70045
I18
sg70054
VC1519670
p75088
sg70048
I2
sa(dp75089
g70042
I152
sg70043
g75067
sg70045
I3
sg70054
VC1834582
p75090
sg70048
I1
sasa(dp75091
g135
(dp75092
(VVEGFR-1
p75093
Vobesity
p75094
tp75095
I01
ssg70037
VAblation of VEGFR-1 signaling prevented obesity-induced tumor progression and shifted the tumor immune environment toward an antitumor phenotype.
p75096
sg70039
(lp75097
(dp75098
g70042
I12
sg70043
g75093
sg70045
I7
sg70046
VP17948
p75099
sg70048
I1
sasg70051
(lp75100
(dp75101
g70042
I56
sg70043
Vtumor
p75102
sg70045
I5
sg70054
VC0027651
p75103
sg70048
I1
sa(dp75104
g70042
I56
sg70043
Vtumor progression
p75105
sg70045
I17
sg70054
VC0178874
p75106
sg70048
I2
sa(dp75107
g70042
I40
sg70043
g75094
sg70045
I7
sg70054
VC0028754
p75108
sg70048
I1
sasa(dp75109
g135
(dp75110
(VPlGF
p75111
Vobesity
p75112
tp75113
I00
ssg70037
VTargeting PlGF/VEGFR-1 signaling reprograms the tumor immune microenvironment and inhibits obesity-induced acceleration of tumor progression.
p75114
sg70039
(lp75115
(dp75116
g70042
I15
sg70043
VVEGFR-1
p75117
sg70045
I7
sg70046
VP17948
p75118
sg70048
I1
sa(dp75119
g70042
I10
sg70043
g75111
sg70045
I4
sg70046
VP49763
p75120
sg70048
I1
sasg70051
(lp75121
(dp75122
g70042
I123
sg70043
Vtumor progression
p75123
sg70045
I17
sg70054
VC0178874
p75124
sg70048
I2
sa(dp75125
g70042
I91
sg70043
g75112
sg70045
I7
sg70054
VC0028754
p75126
sg70048
I1
sa(dp75127
g70042
I48
sg70043
Vtumor
p75128
sg70045
I5
sg70054
VC0027651
p75129
sg70048
I1
sasa(dp75130
g70037
VIn a group of unmedicated patients with major depressive disorder matched for age with normal control group, we found a significant increase in 5-HT (100 microM)-induced accumulation of IP-1 (150 +/- 7% of basal for depressed patients, 132 +/- 3% for controls).
p75131
sg70039
(lp75132
sg70051
(lp75133
(dp75134
g70042
I40
sg70043
Vmajor depressive disorder
p75135
sg70045
I25
sg70054
VC1269683
p75136
sg70048
I3
sasa(dp75137
g135
(dp75138
(VFGFR1
p75139
Vlymphoma
p75140
tp75141
I00
ssg70037
VIt is hoped that the same will happen in other MPN with specific genetic alterations: polycythemia vera (JAK2 V617F and other JAK2 mutations), essential thrombocythemia (JAK2V617F and MPL515 mutations), primary myelofibrosis (JAK2 V617F and MPL515 mutations), systemic mastocytosis (KITD816V and other KIT mutations) and stem cell leukaemia/lymphoma (ZNF198-FGFR1 and other FGFR1 fusion genes).
p75142
sg70039
(lp75143
(dp75144
g70042
I126
sg70043
VJAK2 mutations
p75145
sg70045
I14
sg70046
g12
sg70048
I2
sa(dp75146
g70042
I302
sg70043
VKIT mutations
p75147
sg70045
I13
sg70046
VP10721
p75148
sg70048
I2
sa(dp75149
g70042
I374
sg70043
VFGFR1 fusion genes
p75150
sg70045
I18
sg70046
VP35637
p75151
sg70048
I3
sa(dp75152
g70042
I105
sg70043
VJAK2 V617F
p75153
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp75154
g70042
I105
sg70043
VJAK2 V617F
p75155
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp75156
g70042
I358
sg70043
g75139
sg70045
I5
sg70046
VP20930
p75157
sg70048
I1
sasg70051
(lp75158
(dp75159
g70042
I321
sg70043
Vstem cell leukaemia
p75160
sg70045
I19
sg70054
VC1378511
p75161
sg70048
I3
sa(dp75162
g70042
I203
sg70043
Vprimary myelofibrosis
p75163
sg70045
I21
sg70054
VC0001815
p75164
sg70048
I2
sa(dp75165
g70042
I143
sg70043
Vessential thrombocythemia
p75166
sg70045
I25
sg70054
VC0040028
p75167
sg70048
I2
sa(dp75168
g70042
I260
sg70043
Vsystemic mastocytosis
p75169
sg70045
I21
sg70054
VC0221013
p75170
sg70048
I2
sa(dp75171
g70042
I86
sg70043
Vpolycythemia vera
p75172
sg70045
I17
sg70054
VC0032463
p75173
sg70048
I2
sa(dp75174
g70042
I341
sg70043
g75140
sg70045
I8
sg70054
VC0024299
p75175
sg70048
I1
sasa(dp75176
g70037
VWe show that stimulation of B-cells with the TLR9 ligands CpG-oligodeoxynucleotides (CpG-ODN) prevents spontaneous and irradiation-induced death of normal peripheral blood B-cells, and of B-cells from patients diagnosed with Common variable immunodeficiency (CVID).
p75177
sg70039
(lp75178
(dp75179
g70042
I45
sg70043
VTLR9
p75180
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp75181
(dp75182
g70042
I259
sg70043
VCVID
p75183
sg70045
I4
sg70054
VC0009447
p75184
sg70048
I1
sa(dp75185
g70042
I225
sg70043
VCommon variable immunodeficiency
p75186
sg70045
I32
sg70054
VC0009447
p75187
sg70048
I3
sasa(dp75188
g70037
VDecreased IFN-Alfa secretion induced by TLR7/TLR8 activation was observed in CVID, which was recovered with TLR9 signaling.
p75189
sg70039
(lp75190
(dp75191
g70042
I45
sg70043
VTLR8
p75192
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75193
g70042
I108
sg70043
VTLR9
p75194
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75195
g70042
I40
sg70043
VTLR7
p75196
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75197
g70042
I10
sg70043
VIFN-Alfa
p75198
sg70045
I8
sg70046
VP01562
p75199
sg70048
I1
sasg70051
(lp75200
(dp75201
g70042
I77
sg70043
VCVID
p75202
sg70045
I4
sg70054
VC0009447
p75203
sg70048
I1
sasa(dp75204
g70037
VOur findings revealed that TLR9 activation has an adjuvant effect on the altered type I response in CVID.
p75205
sg70039
(lp75206
(dp75207
g70042
I27
sg70043
VTLR9
p75208
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp75209
(dp75210
g70042
I100
sg70043
VCVID
p75211
sg70045
I4
sg70054
VC0009447
p75212
sg70048
I1
sasa(dp75213
g135
(dp75214
(Vanti-IgM
p75215
VCVID
p75216
tp75217
I00
ssg70037
VWe activated purified CVID B-cells with surrogate T-dependent (anti-CD40), T-independent (TLR-9 ligand) stimuli or through B-cell receptor engagement (anti-IgM) with or without IL-21.
p75218
sg70039
(lp75219
(dp75220
g70042
I123
sg70043
VB-cell receptor engagement
p75221
sg70045
I26
sg70046
g12
sg70048
I3
sa(dp75222
g70042
I151
sg70043
g75215
sg70045
I8
sg70046
VP29965
p75223
sg70048
I1
sasg70051
(lp75224
(dp75225
g70042
I22
sg70043
g75216
sg70045
I4
sg70054
VC0009447
p75226
sg70048
I1
sasa(dp75227
g135
(dp75228
(Vinterleukin-12
p75229
VDCs
p75230
tp75231
I00
ssg70037
VMoreover, studies at the single cell level showed that DCs from CVID patients and healthy controls produced similar amounts of interferon-Alfa or interleukin-12 and expressed similar levels of activation markers in response to human cytomegalovirus and ligands for TLR-7 and TLR-9.
p75232
sg70039
(lp75233
(dp75234
g70042
I127
sg70043
Vinterferon-Alfa
p75235
sg70045
I15
sg70046
VP01563
p75236
sg70048
I1
sa(dp75237
g70042
I146
sg70043
g75229
sg70045
I14
sg70046
VP60568
p75238
sg70048
I1
sa(dp75239
g70042
I265
sg70043
VTLR-7
p75240
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp75241
g70042
I275
sg70043
VTLR-9
p75242
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp75243
(dp75244
g70042
I64
sg70043
VCVID
p75245
sg70045
I4
sg70054
VC0009447
p75246
sg70048
I1
sa(dp75247
g70042
I55
sg70043
g75230
sg70045
I3
sg70054
VC0268238
p75248
sg70048
I1
sasa(dp75249
g70037
VIn conclusion, it seems unlikely that CVID is secondary to insufficient production of naturally occurring DCs or a defect in their signalling through TLR-7 or TLR-9.
p75250
sg70039
(lp75251
(dp75252
g70042
I150
sg70043
VTLR-7
p75253
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp75254
g70042
I159
sg70043
VTLR-9
p75255
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp75256
(dp75257
g70042
I38
sg70043
VCVID
p75258
sg70045
I4
sg70054
VC0009447
p75259
sg70048
I1
sa(dp75260
g70042
I106
sg70043
VDCs
p75261
sg70045
I3
sg70054
VC0268238
p75262
sg70048
I1
sasa(dp75263
g70037
VGiven the established link between vitamin A deficiency and increased susceptibility to infections, we investigated the ability of the vitamin A metabolite all-trans retinoic acid (RA) to restore the defective immune responses in CVID-derived B cells activated through the TLRs TLR9 and RP105.
p75264
sg70039
(lp75265
(dp75266
g70042
I273
sg70043
VTLRs TLR9
p75267
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp75268
g70042
I287
sg70043
VRP105
p75269
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp75270
(dp75271
g70042
I88
sg70043
Vinfections
p75272
sg70045
I10
sg70054
VC0021311
p75273
sg70048
I1
sa(dp75274
g70042
I35
sg70043
Vvitamin A deficiency
p75275
sg70045
I20
sg70054
VC0042842
p75276
sg70048
I3
sa(dp75277
g70042
I230
sg70043
VCVID
p75278
sg70045
I4
sg70054
VC0009447
p75279
sg70048
I1
sasa(dp75280
g70037
VThis can be explained by impaired RA-mediated isotype switching in TLR9/RP105-stimulated CVID-derived B cells owing to reduced induction of activation-induced deaminase.
p75281
sg70039
(lp75282
(dp75283
g70042
I72
sg70043
VRP105
p75284
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp75285
g70042
I67
sg70043
VTLR9
p75286
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp75287
(dp75288
g70042
I89
sg70043
VCVID
p75289
sg70045
I4
sg70054
VC0009447
p75290
sg70048
I1
sa(dp75291
g70042
I25
sg70043
Vimpaired
p75292
sg70045
I8
sg70054
VC0684336
p75293
sg70048
I1
sasa(dp75294
g70037
VThe ability of RA to improve critical immune parameters in CVID-derived B cells stimulated through TLR9 and RP105 support the possibility of combining RA with TLR stimulation for the treatment of CVID.
p75295
sg70039
(lp75296
(dp75297
g70042
I99
sg70043
VTLR9
p75298
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75299
g70042
I108
sg70043
VRP105
p75300
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp75301
(dp75302
g70042
I59
sg70043
VCVID
p75303
sg70045
I4
sg70054
VC0009447
p75304
sg70048
I1
sa(dp75305
g70042
I59
sg70043
VCVID
p75306
sg70045
I4
sg70054
VC0009447
p75307
sg70048
I1
sasa(dp75308
g135
(dp75309
(VBCR
p75310
VHIV
p75311
tp75312
I00
ssg70037
VThe CD21(low) V(H)1-69(+) B cells of MC patients, like those of CVID and HIV patients, are anergic to BCR and TLR9 stimulation and display deregulation of several anergy-related genes; proliferative anergy is also observed in CD21(high) MZ-like V(H)1-69(+) B cells, that over-express the antiproliferative transcriptional repressor Stra13.
p75313
sg70039
(lp75314
(dp75315
g70042
I4
sg70043
VCD21(low) V(H)1-69
p75316
sg70045
I18
sg70046
VP20023
p75317
sg70048
I2
sa(dp75318
g70042
I226
sg70043
VCD21(high) MZ-like V(H)1-69
p75319
sg70045
I27
sg70046
VP20023
p75320
sg70048
I3
sa(dp75321
g70042
I332
sg70043
VStra13
p75322
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75323
g70042
I102
sg70043
g75310
sg70045
I3
sg70046
VP11274
p75324
sg70048
I1
sa(dp75325
g70042
I110
sg70043
VTLR9
p75326
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp75327
(dp75328
g70042
I185
sg70043
Vproliferative
p75329
sg70045
I13
sg70054
VC0334094
p75330
sg70048
I1
sa(dp75331
g70042
I64
sg70043
VCVID
p75332
sg70045
I4
sg70054
VC0009447
p75333
sg70048
I1
sa(dp75334
g70042
I73
sg70043
g75311
sg70045
I3
sg70054
VC0019693
p75335
sg70048
I1
sasa(dp75336
g135
(dp75337
(VCFTR
p75338
VCF
p75339
tp75340
I01
ssg70037
VThe secretion of glucagon by islet Alfa cells is normally suppressed by high blood glucose, but this suppressibility is impaired in patients with diabetes or cystic fibrosis (CF), a disease caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate-activated Cl- channel.
p75341
sg70039
(lp75342
(dp75343
g70042
I17
sg70043
Vglucagon
p75344
sg70045
I8
sg70046
VP01275
p75345
sg70048
I1
sa(dp75346
g70042
I231
sg70043
VCF transmembrane conductance regulator
p75347
sg70045
I38
sg70046
g12
sg70048
I4
sa(dp75348
g70042
I271
sg70043
g75338
sg70045
I4
sg70046
VP13569
p75349
sg70048
I1
sasg70051
(lp75350
(dp75351
g70042
I175
sg70043
VCF
p75352
sg70045
I2
sg70054
VC0016059
p75353
sg70048
I1
sa(dp75354
g70042
I158
sg70043
Vcystic fibrosis
p75355
sg70045
I15
sg70054
VC0010674
p75356
sg70048
I2
sa(dp75357
g70042
I146
sg70043
Vdiabetes
p75358
sg70045
I8
sg70054
VC0011849
p75359
sg70048
I1
sa(dp75360
g70042
I120
sg70043
Vimpaired
p75361
sg70045
I8
sg70054
VC0684336
p75362
sg70048
I1
sa(dp75363
g70042
I175
sg70043
g75339
sg70045
I2
sg70054
VC0016059
p75364
sg70048
I1
sasa(dp75365
g135
(dp75366
(Vglucagon
p75367
Vdiabetes
p75368
tp75369
I00
ssg70037
VThe results reveal that by potentiating KATP channels, CFTR acts as a glucose-sensing negative regulator of glucagon secretion in Alfa cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes.
p75370
sg70039
(lp75371
(dp75372
g70042
I55
sg70043
VCFTR
p75373
sg70045
I4
sg70046
VP13569
p75374
sg70048
I1
sa(dp75375
g70042
I108
sg70043
g75367
sg70045
I8
sg70046
VP01275
p75376
sg70048
I1
sasg70051
(lp75377
(dp75378
g70042
I178
sg70043
Vglucose intolerance
p75379
sg70045
I19
sg70054
VC0271650
p75380
sg70048
I2
sa(dp75381
g70042
I223
sg70043
g75368
sg70045
I8
sg70054
VC0011849
p75382
sg70048
I1
sasa(dp75383
g135
(dp75384
(VCFTR
p75385
VCF
p75386
tp75387
I00
ssg70037
VAlthough Beta-cell dysfunction in cystic fibrosis (CF) leads to diabetes, the mechanism by which the cystic fibrosis transmembrane conductance regulator (CFTR) channel influences islet insulin secretion remains debated.
p75388
sg70039
(lp75389
(dp75390
g70042
I101
sg70043
Vcystic fibrosis transmembrane conductance regulator
p75391
sg70045
I51
sg70046
VP13569
p75392
sg70048
I5
sa(dp75393
g70042
I9
sg70043
VBeta-cell dysfunction in cystic fibrosis (CF)
p75394
sg70045
I45
sg70046
VP13569
p75395
sg70048
I6
sa(dp75396
g70042
I185
sg70043
Vinsulin
p75397
sg70045
I7
sg70046
VP01308
p75398
sg70048
I1
sa(dp75399
g70042
I154
sg70043
g75385
sg70045
I4
sg70046
VP13569
p75400
sg70048
I1
sasg70051
(lp75401
(dp75402
g70042
I64
sg70043
Vdiabetes
p75403
sg70045
I8
sg70054
VC0011849
p75404
sg70048
I1
sa(dp75405
g70042
I34
sg70043
Vcystic fibrosis
p75406
sg70045
I15
sg70054
VC0010674
p75407
sg70048
I2
sa(dp75408
g70042
I34
sg70043
Vcystic fibrosis
p75409
sg70045
I15
sg70054
VC0010674
p75410
sg70048
I2
sa(dp75411
g70042
I51
sg70043
g75386
sg70045
I2
sg70054
VC0010674
p75412
sg70048
I1
sasa(dp75413
g135
(dp75414
(VF508del-CFTR 6
p75415
VMRSA
p75416
tp75417
I00
ssg70037
VBaseline estimated cost in 2008 for a hypothetical underweight, homozygous F508del-CFTR 6-year-old female without chronic Pseudomonas aeruginosa/Staphylococcus aureus, CF-related diabetes (CFRD) or methicillin-resistant S. aureus (MRSA), and with a poor percent predicted forced expiratory volume in 1 s (ppFEV1) was Euro10,113, and was Euro21,082 in a 25-year-old with the same hypothetical profile.
p75418
sg70039
(lp75419
(dp75420
g70042
I75
sg70043
g75415
sg70045
I14
sg70046
VP13569
p75421
sg70048
I2
sasg70051
(lp75422
(dp75423
g70042
I179
sg70043
Vdiabetes
p75424
sg70045
I8
sg70054
VC0011849
p75425
sg70048
I1
sa(dp75426
g70042
I231
sg70043
g75416
sg70045
I4
sg70054
VC0343401
p75427
sg70048
I1
sasa(dp75428
g135
(dp75429
(Vmegalin
p75430
Vcystic fibrosis
p75431
tp75432
I00
ssg70037
VThe goal of this work was to evaluate renal function and the expression of megalin, cubilin, CFTR (cystic fibrosis transmembrane conductance regulator), and ClC-5 in the proximal tubule and renal cortex of rats with type 1 diabetes.
p75433
sg70039
(lp75434
(dp75435
g70042
I157
sg70043
VClC-5
p75436
sg70045
I5
sg70046
VP51795
p75437
sg70048
I1
sa(dp75438
g70042
I84
sg70043
Vcubilin
p75439
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75440
g70042
I75
sg70043
g75430
sg70045
I7
sg70046
VP54317
p75441
sg70048
I1
sasg70051
(lp75442
(dp75443
g70042
I216
sg70043
Vtype 1 diabetes
p75444
sg70045
I15
sg70054
VC0011854
p75445
sg70048
I3
sa(dp75446
g70042
I99
sg70043
g75431
sg70045
I15
sg70054
VC0010674
p75447
sg70048
I2
sasa(dp75448
g70037
VMean values in lichen ruber planus were Zn 784 micrograms/l, RBP 5.26 mg/dl and Vit A 656 ng/ml; in leukoplakia Zn 696 micrograms/l, RBP 5.30 mg/dl and Vit A 652 ng/ml; and in OSCC Zn 659 micrograms/l, RBP 5.00 mg/dl and Vit A 617 ng/ml.
p75449
sg70039
(lp75450
sg70051
(lp75451
(dp75452
g70042
I100
sg70043
Vleukoplakia
p75453
sg70045
I11
sg70054
VC0023531
p75454
sg70048
I1
sa(dp75455
g70042
I15
sg70043
Vlichen ruber planus
p75456
sg70045
I19
sg70054
VC0023646
p75457
sg70048
I3
sasa(dp75458
g135
(dp75459
(Vgalectin-3
p75460
Vautoimmunity
p75461
tp75462
I00
ssg70037
VThese observations indicate that HYA and PIIINP mainly reflect expansive synovitis proliferation while galectin-3 is more closely linked to autoimmunity, smoking and joint destructive processes.
p75463
sg70039
(lp75464
(dp75465
g70042
I103
sg70043
g75460
sg70045
I10
sg70046
VP17931
p75466
sg70048
I1
sasg70051
(lp75467
(dp75468
g70042
I73
sg70043
Vsynovitis
p75469
sg70045
I9
sg70054
VC0039103
p75470
sg70048
I1
sa(dp75471
g70042
I83
sg70043
Vproliferation
p75472
sg70045
I13
sg70054
VC0334094
p75473
sg70048
I1
sa(dp75474
g70042
I140
sg70043
g75461
sg70045
I12
sg70054
VC0004368
p75475
sg70048
I1
sasa(dp75476
g135
(dp75477
(Vgalectin-3
p75478
Vbone marrow edema
p75479
tp75480
I00
ssg70037
VIn the entire UA cohort, galectin-3 correlated with the MRI bone marrow edema score, while PIIANP correlated with the MRI erosion score, and HYA with the synovitis and erosion scores.
p75481
sg70039
(lp75482
(dp75483
g70042
I25
sg70043
g75478
sg70045
I10
sg70046
VP17931
p75484
sg70048
I1
sasg70051
(lp75485
(dp75486
g70042
I122
sg70043
Verosion
p75487
sg70045
I7
sg70054
VC1959609
p75488
sg70048
I1
sa(dp75489
g70042
I154
sg70043
Vsynovitis
p75490
sg70045
I9
sg70054
VC0039103
p75491
sg70048
I1
sa(dp75492
g70042
I60
sg70043
g75479
sg70045
I17
sg70054
VC0948162
p75493
sg70048
I3
sa(dp75494
g70042
I122
sg70043
Verosion
p75495
sg70045
I7
sg70054
VC1959609
p75496
sg70048
I1
sasa(dp75497
g135
(dp75498
(VGalectin-3
p75499
Vsynovitis
p75500
tp75501
I00
ssg70037
VPrevious studies have reported overexpression of Galectin-3 in RA synovitis and increased levels in synovial fluid and serum in long-standing RA compared with osteoarthritis and healthy controls.
p75502
sg70039
(lp75503
(dp75504
g70042
I49
sg70043
g75499
sg70045
I10
sg70046
VP17931
p75505
sg70048
I1
sasg70051
(lp75506
(dp75507
g70042
I159
sg70043
Vosteoarthritis
p75508
sg70045
I14
sg70054
VC0029408
p75509
sg70048
I1
sa(dp75510
g70042
I66
sg70043
g75500
sg70045
I9
sg70054
VC0039103
p75511
sg70048
I1
sasa(dp75512
g135
(dp75513
(Vmyeloperoxidase
p75514
Vsynovitis
p75515
tp75516
I00
ssg70037
VWe defined by immunohistology the infiltrating cells and examined the in situ expression of plausible protagonists in synovitis of FMF: myeloperoxidase, lysozyme, galectin 1, galectin 3, p65 (RelA)/nuclear factor KB, inducible nitric-oxide synthase, cyclooxygenase 2, and cleaved caspase 3.
p75517
sg70039
(lp75518
(dp75519
g70042
I192
sg70043
VRelA
p75520
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75521
g70042
I187
sg70043
Vp65
p75522
sg70045
I3
sg70046
VP21579
p75523
sg70048
I1
sa(dp75524
g70042
I131
sg70043
VFMF
p75525
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp75526
g70042
I153
sg70043
Vlysozyme
p75527
sg70045
I8
sg70046
VP61626
p75528
sg70048
I1
sa(dp75529
g70042
I280
sg70043
Vcaspase 3
p75530
sg70045
I9
sg70046
VP42574
p75531
sg70048
I2
sa(dp75532
g70042
I163
sg70043
Vgalectin 1
p75533
sg70045
I10
sg70046
VP09382
p75534
sg70048
I2
sa(dp75535
g70042
I198
sg70043
Vnuclear factor KB
p75536
sg70045
I17
sg70046
VP01160
p75537
sg70048
I3
sa(dp75538
g70042
I175
sg70043
Vgalectin 3
p75539
sg70045
I10
sg70046
VP17931
p75540
sg70048
I2
sa(dp75541
g70042
I250
sg70043
Vcyclooxygenase 2
p75542
sg70045
I16
sg70046
VP35354
p75543
sg70048
I2
sa(dp75544
g70042
I227
sg70043
Vnitric-oxide synthase
p75545
sg70045
I21
sg70046
VP29475
p75546
sg70048
I2
sa(dp75547
g70042
I136
sg70043
g75514
sg70045
I15
sg70046
VP05164
p75548
sg70048
I1
sasg70051
(lp75549
(dp75550
g70042
I131
sg70043
VFMF
p75551
sg70045
I3
sg70054
VC0031069
p75552
sg70048
I1
sa(dp75553
g70042
I34
sg70043
Vinfiltrating
p75554
sg70045
I12
sg70054
VC0332448
p75555
sg70048
I1
sa(dp75556
g70042
I118
sg70043
g75515
sg70045
I9
sg70054
VC0039103
p75557
sg70048
I1
sasa(dp75558
g70037
VOnly one of these, pFLJ2, was mobilized by the IncP plasmids RP4, pRK231 and R702, but not by plasmids pSa, R40a, R387, pN3 or R16.
p75559
sg70039
(lp75560
sg70051
(lp75561
(dp75562
g70042
I103
sg70043
VpSa
p75563
sg70045
I3
sg70054
VC1519176
p75564
sg70048
I1
sa(dp75565
g70042
I61
sg70043
VRP4
p75566
sg70045
I3
sg70054
VC3151001
p75567
sg70048
I1
sasa(dp75568
g135
(dp75569
(VAGT
p75570
Vmetabolic syndrome
p75571
tp75572
I00
ssg70037
VChanges in the frequencies of genotypes and mutant alleles of ACE, AGTR1, AGT, and ITGB3 genes were analyzed in patients with arterial hypertension coupled with metabolic syndrome (N=15) and compared with population data and corresponding parameters in patients with isolated hypertension (N=15).
p75573
sg70039
(lp75574
(dp75575
g70042
I67
sg70043
VAGTR1
p75576
sg70045
I5
sg70046
VP30556
p75577
sg70048
I1
sa(dp75578
g70042
I62
sg70043
VACE
p75579
sg70045
I3
sg70046
VP12821
p75580
sg70048
I1
sa(dp75581
g70042
I83
sg70043
VITGB3 genes
p75582
sg70045
I11
sg70046
VP05106
p75583
sg70048
I2
sa(dp75584
g70042
I67
sg70043
g75570
sg70045
I3
sg70046
VP21549
p75585
sg70048
I1
sasg70051
(lp75586
(dp75587
g70042
I126
sg70043
Varterial hypertension
p75588
sg70045
I21
sg70054
VC0020538
p75589
sg70048
I2
sa(dp75590
g70042
I135
sg70043
Vhypertension
p75591
sg70045
I12
sg70054
VC0020538
p75592
sg70048
I1
sa(dp75593
g70042
I44
sg70043
Vmutant
p75594
sg70045
I6
sg70054
VC0596988
p75595
sg70048
I1
sa(dp75596
g70042
I161
sg70043
g75571
sg70045
I18
sg70054
VC0524620
p75597
sg70048
I2
sasa(dp75598
g135
(dp75599
(VHDL-c
p75600
Vhypertension
p75601
tp75602
I00
ssg70037
VWe examined associations between 15 single nucleotide polymorphisms (SNPs) across ITGB3 and five CVD-related traits in the Hutterites: plasma levels of high density lipoprotein-cholesterol (HDL-c), triglycerides (TG), low density lipoprotein-cholesterol (LDL-c), and lipoprotein(a) [Lp(a)] and blood pressure or hypertension.
p75603
sg70039
(lp75604
(dp75605
g70042
I218
sg70043
Vlow density lipoprotein-cholesterol
p75606
sg70045
I35
sg70046
VP02652
p75607
sg70048
I3
sa(dp75608
g70042
I255
sg70043
VLDL-c
p75609
sg70045
I5
sg70046
VP02652
p75610
sg70048
I1
sa(dp75611
g70042
I152
sg70043
Vhigh density lipoprotein-cholesterol
p75612
sg70045
I36
sg70046
VP28845
p75613
sg70048
I3
sa(dp75614
g70042
I267
sg70043
Vlipoprotein(a)
p75615
sg70045
I14
sg70046
VP02652
p75616
sg70048
I1
sa(dp75617
g70042
I190
sg70043
g75600
sg70045
I5
sg70046
VP28845
p75618
sg70048
I1
sasg70051
(lp75619
(dp75620
g70042
I97
sg70043
VCVD
p75621
sg70045
I3
sg70054
VC0007222
p75622
sg70048
I1
sa(dp75623
g70042
I312
sg70043
g75601
sg70045
I12
sg70054
VC0020538
p75624
sg70048
I1
sasa(dp75625
g135
(dp75626
(VMMP-9
p75627
Vtympanosclerosis
p75628
tp75629
I00
ssg70037
VThe present study was performed to investigate the expressions of transforming growth factor Beta1 (TGF-Beta1) and matrix metalloproteinase-9 (MMP-9) in an experimental model of tympanosclerosis and their possible roles in the formation of this disorder.
p75630
sg70039
(lp75631
(dp75632
g70042
I66
sg70043
Vtransforming growth factor Beta1
p75633
sg70045
I32
sg70046
VP01137
p75634
sg70048
I4
sa(dp75635
g70042
I100
sg70043
VTGF-Beta1
p75636
sg70045
I9
sg70046
VP01137
p75637
sg70048
I1
sa(dp75638
g70042
I115
sg70043
Vmatrix metalloproteinase-9
p75639
sg70045
I26
sg70046
VP14780
p75640
sg70048
I2
sa(dp75641
g70042
I143
sg70043
g75627
sg70045
I5
sg70046
VP14780
p75642
sg70048
I1
sasg70051
(lp75643
(dp75644
g70042
I178
sg70043
g75628
sg70045
I16
sg70054
VC0395887
p75645
sg70048
I1
sasa(dp75646
g135
(dp75647
(VNDST1
p75648
VGBM
p75649
tp75650
I00
ssg70037
VRT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.
p75651
sg70039
(lp75652
(dp75653
g70042
I157
sg70043
VHS3ST2
p75654
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75655
g70042
I115
sg70043
VEXT2
p75656
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75657
g70042
I195
sg70043
VHPSE
p75658
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75659
g70042
I181
sg70043
VSULF1
p75660
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp75661
g70042
I128
sg70043
VNDST2
p75662
sg70045
I5
sg70046
VP52849
p75663
sg70048
I1
sa(dp75664
g70042
I141
sg70043
VHS2ST1
p75665
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75666
g70042
I121
sg70043
g75648
sg70045
I5
sg70046
VP52848
p75667
sg70048
I1
sa(dp75668
g70042
I135
sg70043
VGLCE
p75669
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75670
g70042
I109
sg70043
VEXT1
p75671
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75672
g70042
I149
sg70043
VHS3ST1
p75673
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75674
g70042
I165
sg70043
VHS6ST1
p75675
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75676
g70042
I188
sg70043
VSULF2
p75677
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp75678
(dp75679
g70042
I115
sg70043
VEXT2
p75680
sg70045
I4
sg70054
VC1851413
p75681
sg70048
I1
sa(dp75682
g70042
I245
sg70043
Vglioma
p75683
sg70045
I6
sg70054
VC0017638
p75684
sg70048
I1
sa(dp75685
g70042
I245
sg70043
Vglioma
p75686
sg70045
I6
sg70054
VC0017638
p75687
sg70048
I1
sa(dp75688
g70042
I300
sg70043
Vglioblastoma multiforme
p75689
sg70045
I23
sg70054
VC1621958
p75690
sg70048
I2
sa(dp75691
g70042
I109
sg70043
VEXT1
p75692
sg70045
I4
sg70054
VC0015306
p75693
sg70048
I1
sa(dp75694
g70042
I325
sg70043
g75649
sg70045
I3
sg70054
VC1621958
p75695
sg70048
I1
sasa(dp75696
g70037
VThis study aimed to analyze the expression and function of HS6ST3 in breast cancer.
p75697
sg70039
(lp75698
(dp75699
g70042
I59
sg70043
VHS6ST3
p75700
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp75701
(dp75702
g70042
I69
sg70043
Vbreast cancer
p75703
sg70045
I13
sg70054
VC0678222
p75704
sg70048
I2
sasa(dp75705
g70037
VHS6ST3 was found up-regulated in T47D, MCF7 and MDA-MB231 breast cancer cell lines.
p75706
sg70039
(lp75707
(dp75708
g70042
I0
sg70043
VHS6ST3
p75709
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp75710
(dp75711
g70042
I58
sg70043
Vbreast cancer
p75712
sg70045
I13
sg70054
VC0678222
p75713
sg70048
I2
sasa(dp75714
g70037
VSilencing HS6ST3 diminished tumor cell growth, migration and invasion, but enhanced cell adhesion and apoptosis in breast cancer.
p75715
sg70039
(lp75716
sg70051
(lp75717
(dp75718
g70042
I28
sg70043
Vtumor
p75719
sg70045
I5
sg70054
VC0027651
p75720
sg70048
I1
sa(dp75721
g70042
I115
sg70043
Vbreast cancer
p75722
sg70045
I13
sg70054
VC0678222
p75723
sg70048
I2
sa(dp75724
g70042
I61
sg70043
Vinvasion
p75725
sg70045
I8
sg70054
VC2699153
p75726
sg70048
I1
sa(dp75727
g70042
I89
sg70043
Vadhesion
p75728
sg70045
I8
sg70054
VC0001511
p75729
sg70048
I1
sasa(dp75730
g135
(dp75731
(VIGF1R
p75732
Vbreast cancer
p75733
tp75734
I00
ssg70037
VGene microarray analysis revealed that silencing HS6ST3 significantly changed the expression of IGF1R and XAF1 in breast cancer cells.
p75735
sg70039
(lp75736
(dp75737
g70042
I96
sg70043
g75732
sg70045
I5
sg70046
VP08069
p75738
sg70048
I1
sa(dp75739
g70042
I49
sg70043
VHS6ST3
p75740
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75741
g70042
I106
sg70043
VXAF1
p75742
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp75743
(dp75744
g70042
I114
sg70043
g75733
sg70045
I13
sg70054
VC0678222
p75745
sg70048
I2
sasa(dp75746
g135
(dp75747
(VIGF1R
p75748
Vbreast cancer
p75749
tp75750
I00
ssg70037
VFurther functional studies showed that the cellular processes were mediated by IGF1R and XAF1 after silencing HS6ST3 in breast cancer cells.
p75751
sg70039
(lp75752
(dp75753
g70042
I89
sg70043
VXAF1
p75754
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp75755
g70042
I79
sg70043
g75748
sg70045
I5
sg70046
VP08069
p75756
sg70048
I1
sa(dp75757
g70042
I110
sg70043
VHS6ST3
p75758
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp75759
(dp75760
g70042
I120
sg70043
g75749
sg70045
I13
sg70054
VC0678222
p75761
sg70048
I2
sasa(dp75762
g70037
VTogether these results indicate that HS6ST3 might be involved in the tumorigenesis of breast cancer and it could be a promising target in breast cancer therapy.
p75763
sg70039
(lp75764
(dp75765
g70042
I37
sg70043
VHS6ST3
p75766
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp75767
(dp75768
g70042
I86
sg70043
Vbreast cancer
p75769
sg70045
I13
sg70054
VC0678222
p75770
sg70048
I2
sa(dp75771
g70042
I69
sg70043
Vtumorigenesis
p75772
sg70045
I13
sg70054
VC0007621
p75773
sg70048
I1
sa(dp75774
g70042
I86
sg70043
Vbreast cancer
p75775
sg70045
I13
sg70054
VC0678222
p75776
sg70048
I2
sasa(dp75777
g70037
VWe aimed to examine the relationship between the preoperative GSA index [uptake ratio of the liver to the liver plus heart at 15 min (LHL15) to uptake ratio of the heart at 15 min to that at 3 min (HH15) ratio] calculated from 99mTc-labeled diethylene triamine pentaacetate-galactosyl human serum albumin (99mTc-GSA) scintigraphy and background liver fibrosis and to investigate whether the GSA index can be a useful predictor in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) patients treated with surgical resection (SR).
p75778
sg70039
(lp75779
(dp75780
g70042
I285
sg70043
Vhuman serum albumin
p75781
sg70045
I19
sg70046
g12
sg70048
I3
sasg70051
(lp75782
(dp75783
g70042
I462
sg70043
Vhepatocellular carcinoma
p75784
sg70045
I24
sg70054
VC2239176
p75785
sg70048
I2
sa(dp75786
g70042
I345
sg70043
Vliver fibrosis
p75787
sg70045
I14
sg70054
VC0239946
p75788
sg70048
I2
sa(dp75789
g70042
I430
sg70043
Vhepatitis C
p75790
sg70045
I11
sg70054
VC0019196
p75791
sg70048
I2
sa(dp75792
g70042
I488
sg70043
VHCC
p75793
sg70045
I3
sg70054
VC2239176
p75794
sg70048
I1
sasa(dp75795
g135
(dp75796
(VHS-dependent HB-EGF
p75797
Vcancer angiogenesis
p75798
tp75799
I00
ssg70037
VHere we demonstrate that HS 6-O-sulfotransferases 1 and 2 (HS6ST-1 and HS6ST-2), which perform sulfation at 6-O position in glucosamine in HS, impact ovarian cancer angiogenesis through the HS-dependent HB-EGF/EGFR axis that subsequently modulates the expression of multiple angiogenic cytokines.
p75800
sg70039
(lp75801
(dp75802
g70042
I190
sg70043
g75797
sg70045
I19
sg70046
VP19525
p75803
sg70048
I2
sa(dp75804
g70042
I59
sg70043
VHS6ST-1
p75805
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75806
g70042
I25
sg70043
VHS 6-O-sulfotransferases 1 and 2
p75807
sg70045
I32
sg70046
g12
sg70048
I5
sa(dp75808
g70042
I71
sg70043
VHS6ST-2
p75809
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp75810
(dp75811
g70042
I158
sg70043
g75798
sg70045
I19
sg70054
VC1536999
p75812
sg70048
I2
sasa(dp75813
g135
(dp75814
(VIL-6
p75815
Vovarian cancer
p75816
tp75817
I00
ssg70037
VDown-regulation of HS6ST-1 or HS6ST-2 in human ovarian cancer cell lines results in 30-50% reduction in glucosamine 6-O-sulfate levels in HS, impairing HB-EGF-dependent EGFR signaling and diminishing FGF2, IL-6, and IL-8 mRNA and protein levels in cancer cells.
p75818
sg70039
(lp75819
(dp75820
g70042
I19
sg70043
VHS6ST-1
p75821
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75822
g70042
I30
sg70043
VHS6ST-2
p75823
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75824
g70042
I152
sg70043
VHB-EGF-dependent EGFR
p75825
sg70045
I21
sg70046
g12
sg70048
I2
sa(dp75826
g70042
I206
sg70043
g75815
sg70045
I4
sg70046
VP05231
p75827
sg70048
I1
sa(dp75828
g70042
I200
sg70043
VFGF2
p75829
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp75830
(dp75831
g70042
I55
sg70043
Vcancer
p75832
sg70045
I6
sg70054
VC0006826
p75833
sg70048
I1
sa(dp75834
g70042
I47
sg70043
g75816
sg70045
I14
sg70054
VC1140680
p75835
sg70048
I2
sasa(dp75836
g135
(dp75837
(VEGF
p75838
Vovarian cancer
p75839
tp75840
I00
ssg70037
VOur results show that in addition to the critical role that 6-O-sulfate moieties play in angiogenic cytokine activation, HS 6-O-sulfation level, determined by the expression of HS6ST isoforms in ovarian cancer cells, is a major regulator of angiogenic program in ovarian cancer cells impacting HB-EGF signaling and subsequent expression of angiogenic cytokines by cancer cells.
p75841
sg70039
(lp75842
(dp75843
g70042
I340
sg70043
Vangiogenic cytokines
p75844
sg70045
I20
sg70046
VP01374
p75845
sg70048
I2
sa(dp75846
g70042
I297
sg70043
g75838
sg70045
I3
sg70046
VP01133
p75847
sg70048
I1
sa(dp75848
g70042
I177
sg70043
VHS6ST isoforms
p75849
sg70045
I14
sg70046
g12
sg70048
I2
sasg70051
(lp75850
(dp75851
g70042
I195
sg70043
Vovarian cancer
p75852
sg70045
I14
sg70054
VC1140680
p75853
sg70048
I2
sa(dp75854
g70042
I203
sg70043
Vcancer
p75855
sg70045
I6
sg70054
VC0006826
p75856
sg70048
I1
sa(dp75857
g70042
I195
sg70043
g75839
sg70045
I14
sg70054
VC1140680
p75858
sg70048
I2
sasa(dp75859
g70037
VWe have investigated whether the expression of HS6STs and SULFs changes during chondrosarcoma progression and have determined 6O-sulphation levels in two chondrosarcoma cell lines.
p75860
sg70039
(lp75861
(dp75862
g70042
I47
sg70043
VHS6STs
p75863
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp75864
(dp75865
g70042
I79
sg70043
Vchondrosarcoma
p75866
sg70045
I14
sg70054
VC0008479
p75867
sg70048
I1
sa(dp75868
g70042
I79
sg70043
Vchondrosarcoma
p75869
sg70045
I14
sg70054
VC0008479
p75870
sg70048
I1
sasa(dp75871
g70037
VImmunohistochemistry on tissue microarrays of chondrosarcomas showed that HS6ST3 and SULF1 were highly expressed in most chondrosarcomas, whereas SULF2 expression was absent in most cases.
p75872
sg70039
(lp75873
(dp75874
g70042
I85
sg70043
VSULF1
p75875
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp75876
g70042
I74
sg70043
VHS6ST3
p75877
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75878
g70042
I146
sg70043
VSULF2
p75879
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp75880
(dp75881
g70042
I46
sg70043
Vchondrosarcomas
p75882
sg70045
I15
sg70054
VC0008479
p75883
sg70048
I1
sa(dp75884
g70042
I46
sg70043
Vchondrosarcomas
p75885
sg70045
I15
sg70054
VC0008479
p75886
sg70048
I1
sasa(dp75887
g70037
VHS6ST1 and HS6ST2 expression are significantly increased during chondrosarcoma progression, which suggest that 6O-sulphation is increased during progression.
p75888
sg70039
(lp75889
(dp75890
g70042
I0
sg70043
VHS6ST1
p75891
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp75892
(dp75893
g70042
I64
sg70043
Vchondrosarcoma
p75894
sg70045
I14
sg70054
VC0008479
p75895
sg70048
I1
sasa(dp75896
g70037
VIn conclusion, our results show increased HS6ST1 and HS6ST2 expression during chondrosarcoma progression and increased HS 6O-sulphation in vitro.
p75897
sg70039
(lp75898
(dp75899
g70042
I42
sg70043
VHS6ST1
p75900
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp75901
(dp75902
g70042
I78
sg70043
Vchondrosarcoma
p75903
sg70045
I14
sg70054
VC0008479
p75904
sg70048
I1
sasa(dp75905
g70037
VAs 6O-sulphation plays an important role in signal transduction, altered HS6ST expression might be associated with changes in signal transduction pathways in chondrosarcoma progression.
p75906
sg70039
(lp75907
(dp75908
g70042
I73
sg70043
VHS6ST
p75909
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp75910
(dp75911
g70042
I158
sg70043
Vchondrosarcoma
p75912
sg70045
I14
sg70054
VC0008479
p75913
sg70048
I1
sasa(dp75914
g135
(dp75915
(VCXCR3
p75916
Vosteoarthritis
p75917
tp75918
I01
ssg70037
VThus, neutrophils and NK cells act as important disease-promoting immune cells in experimental osteoarthritis and their functional interaction is promoted by the CXCL10/CXCR3 axis.
p75919
sg70039
(lp75920
(dp75921
g70042
I162
sg70043
VCXCL10
p75922
sg70045
I6
sg70046
VP02778
p75923
sg70048
I1
sa(dp75924
g70042
I169
sg70043
g75916
sg70045
I5
sg70046
VP49682
p75925
sg70048
I1
sasg70051
(lp75926
(dp75927
g70042
I95
sg70043
g75917
sg70045
I14
sg70054
VC0029408
p75928
sg70048
I1
sasa(dp75929
g70037
VOvarian cancer cell line OC316 was reverse transfected with a miR-223 mimic and relative expression levels of miR-223 and SMARCD1 were quantified by RT-PCR; protein expression of SMARCD1 was evaluated by Western Blot.
p75930
sg70039
(lp75931
(dp75932
g70042
I122
sg70043
VSMARCD1
p75933
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75934
g70042
I122
sg70043
VSMARCD1
p75935
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75936
g70042
I62
sg70043
VmiR-223
p75937
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp75938
(dp75939
g70042
I0
sg70043
VOvarian cancer
p75940
sg70045
I14
sg70054
VC1140680
p75941
sg70048
I2
sasa(dp75942
g70037
VmiR-223 expression was upregulated in high grade ovarian serous carcinoma samples (median RQ=4.8881, P=.0045), whilst SMARCD1 was down-regulated (median RQ=0.5107, P=.0492).
p75943
sg70039
(lp75944
(dp75945
g70042
I118
sg70043
VSMARCD1
p75946
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp75947
(dp75948
g70042
I49
sg70043
Vovarian serous carcinoma
p75949
sg70045
I24
sg70054
VC1335177
p75950
sg70048
I3
sasa(dp75951
g135
(dp75952
(VSWI
p75953
Vbreast cancer
p75954
tp75955
I00
ssg70037
VIt was indicated that SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily D, member 1, dihydropyrimidinase-like 2, RMND5A and ANGPTL1 were potential prognostic markers in breast cancer, and the cell cycle may be involved in the regulation of breast cancer.
p75956
sg70039
(lp75957
(dp75958
g70042
I186
sg70043
Vchromatin, subfamily D, member 1, dihydropyrimidinase-like 2
p75959
sg70045
I60
sg70046
g12
sg70048
I7
sa(dp75960
g70042
I259
sg70043
VANGPTL1
p75961
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75962
g70042
I248
sg70043
VRMND5A
p75963
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp75964
g70042
I22
sg70043
VSWI
p75965
sg70045
I3
sg70046
VP28370
p75966
sg70048
I1
sa(dp75967
g70042
I26
sg70043
VSNF
p75968
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp75969
g70042
I26
sg70043
VSNF
p75970
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp75971
g70042
I87
sg70043
Vchromatin, subfamily D, member 1
p75972
sg70045
I32
sg70046
g12
sg70048
I5
sa(dp75973
g70042
I22
sg70043
g75953
sg70045
I3
sg70046
VP28370
p75974
sg70048
I1
sasg70051
(lp75975
(dp75976
g70042
I304
sg70043
Vbreast cancer
p75977
sg70045
I13
sg70054
VC0678222
p75978
sg70048
I2
sa(dp75979
g70042
I304
sg70043
g75954
sg70045
I13
sg70054
VC0678222
p75980
sg70048
I2
sasa(dp75981
g135
(dp75982
(Vcyclin D1
p75983
Vepithelial ovarian cancer
p75984
tp75985
I00
ssg70037
VMiR-490-3p plays a tumour suppressor role in epithelial ovarian cancer by targeting CDK1 regulation and influencing SMARCD1 and cyclin D1 (CCND1) expressions.
p75986
sg70039
(lp75987
(dp75988
g70042
I84
sg70043
VCDK1
p75989
sg70045
I4
sg70046
VP06493
p75990
sg70048
I1
sa(dp75991
g70042
I139
sg70043
VCCND1
p75992
sg70045
I5
sg70046
VP24385
p75993
sg70048
I1
sa(dp75994
g70042
I116
sg70043
VSMARCD1
p75995
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp75996
g70042
I0
sg70043
VMiR-490-3p
p75997
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp75998
g70042
I128
sg70043
g75983
sg70045
I9
sg70046
VP24385
p75999
sg70048
I2
sasg70051
(lp76000
(dp76001
g70042
I19
sg70043
Vtumour
p76002
sg70045
I6
sg70054
VC0027651
p76003
sg70048
I1
sa(dp76004
g70042
I45
sg70043
g75984
sg70045
I25
sg70054
VC0677886
p76005
sg70048
I3
sasa(dp76006
g70037
VHepatocyte-specific inactivation of Baf60a reduced bile acid production and cholesterol absorption, and attenuated diet-induced hypercholesterolemia and atherosclerosis in mice.
p76007
sg70039
(lp76008
(dp76009
g70042
I36
sg70043
VBaf60a
p76010
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76011
(dp76012
g70042
I128
sg70043
Vhypercholesterolemia
p76013
sg70045
I20
sg70054
VC0020443
p76014
sg70048
I1
sa(dp76015
g70042
I153
sg70043
Vatherosclerosis
p76016
sg70045
I15
sg70054
VC0004153
p76017
sg70048
I1
sa(dp76018
g70042
I20
sg70043
Vinactivation
p76019
sg70045
I12
sg70054
VC0544461
p76020
sg70048
I1
sasa(dp76021
g70037
VmiR-7 expression reduced SMARCD1 protein expression in lung cancer cell lines.
p76022
sg70039
(lp76023
(dp76024
g70042
I25
sg70043
VSMARCD1 protein
p76025
sg70045
I15
sg70046
g12
sg70048
I2
sa(dp76026
g70042
I0
sg70043
VmiR-7
p76027
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp76028
(dp76029
g70042
I55
sg70043
Vlung cancer
p76030
sg70045
I11
sg70054
VC0684249
p76031
sg70048
I2
sasa(dp76032
g70037
VWe found that although SMARCD1 sensitized lung cancer cells to chemotherapy drug-induced apoptosis, miR-7 enhanced the drug resistance potential of lung cancer cells against chemotherapy drugs.
p76033
sg70039
(lp76034
(dp76035
g70042
I100
sg70043
VmiR-7
p76036
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp76037
g70042
I23
sg70043
VSMARCD1
p76038
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp76039
(dp76040
g70042
I42
sg70043
Vlung cancer
p76041
sg70045
I11
sg70054
VC0684249
p76042
sg70048
I2
sa(dp76043
g70042
I42
sg70043
Vlung cancer
p76044
sg70045
I11
sg70054
VC0684249
p76045
sg70048
I2
sasa(dp76046
g70037
VSMARCD1 was down-regulated in patients with non-small cell lung cancer and lung adenocarcinoma cell lines, and SMARCD1 and miR-7 expression levels were negatively correlated in clinical samples.
p76047
sg70039
(lp76048
(dp76049
g70042
I0
sg70043
VSMARCD1
p76050
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp76051
g70042
I0
sg70043
VSMARCD1
p76052
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp76053
g70042
I123
sg70043
VmiR-7
p76054
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp76055
(dp76056
g70042
I75
sg70043
Vlung adenocarcinoma
p76057
sg70045
I19
sg70054
VC0152013
p76058
sg70048
I2
sa(dp76059
g70042
I44
sg70043
Vnon-small cell lung cancer
p76060
sg70045
I26
sg70054
VC0007131
p76061
sg70048
I4
sasa(dp76062
g135
(dp76063
(VSWI
p76064
Vlung cancer
p76065
tp76066
I00
ssg70037
VOur investigation into the involvement of the EGFR-regulated microRNA pathway in the SWI/SNF chromatin remodeling complex suggests that EGFR-mediated miR-7 suppresses the coupling of the chromatin remodeling factor SMARCD1 with p53, resulting in increased chemo-resistance of lung cancer cells.
p76067
sg70039
(lp76068
(dp76069
g70042
I187
sg70043
Vchromatin remodeling factor
p76070
sg70045
I27
sg70046
g12
sg70048
I3
sa(dp76071
g70042
I85
sg70043
g76064
sg70045
I3
sg70046
VP28370
p76072
sg70048
I1
sa(dp76073
g70042
I89
sg70043
VSNF
p76074
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp76075
g70042
I150
sg70043
VmiR-7
p76076
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp76077
g70042
I215
sg70043
VSMARCD1
p76078
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp76079
g70042
I228
sg70043
Vp53
p76080
sg70045
I3
sg70046
VP42771
p76081
sg70048
I1
sasg70051
(lp76082
(dp76083
g70042
I276
sg70043
g76065
sg70045
I11
sg70054
VC0684249
p76084
sg70048
I2
sasa(dp76085
g135
(dp76086
(VSWI
p76087
Vmetastasis
p76088
tp76089
I01
ssg70037
VmiR-490-3p exerted growth- and metastasis-suppressive effects on gastric cancer cells through directly targeting SMARCD1, a SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex subunit.
p76090
sg70039
(lp76091
(dp76092
g70042
I159
sg70043
VSNF
p76093
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp76094
g70042
I124
sg70043
g76087
sg70045
I3
sg70046
VP28370
p76095
sg70048
I1
sa(dp76096
g70042
I0
sg70043
VmiR-490-3p
p76097
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp76098
g70042
I113
sg70043
VSMARCD1
p76099
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp76100
(dp76101
g70042
I65
sg70043
Vgastric cancer
p76102
sg70045
I14
sg70054
VC0024623
p76103
sg70048
I2
sa(dp76104
g70042
I31
sg70043
g76088
sg70045
I10
sg70054
VC0027627
p76105
sg70048
I1
sasa(dp76106
g70037
VKnockdown of SMARCD1 significantly attenuated the protumorigenic effects of miR-490-3p inhibitor, whereas enforced expression of SMARCD1 promoted in vitro and in vivo oncogenic phenotypes of gastric cancer cells.
p76107
sg70039
(lp76108
(dp76109
g70042
I13
sg70043
VSMARCD1
p76110
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp76111
g70042
I13
sg70043
VSMARCD1
p76112
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp76113
g70042
I76
sg70043
VmiR-490-3p
p76114
sg70045
I10
sg70046
g12
sg70048
I1
sasg70051
(lp76115
(dp76116
g70042
I191
sg70043
Vgastric cancer
p76117
sg70045
I14
sg70054
VC0024623
p76118
sg70048
I2
sasa(dp76119
g70037
VSMARCD1 was markedly upregulated in gastric cancer in which its high expression was associated with shortened patients' survival independent of TNM staging.
p76120
sg70039
(lp76121
(dp76122
g70042
I144
sg70043
VTNM
p76123
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp76124
g70042
I0
sg70043
VSMARCD1
p76125
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp76126
(dp76127
g70042
I36
sg70043
Vgastric cancer
p76128
sg70045
I14
sg70054
VC0024623
p76129
sg70048
I2
sasa(dp76130
g70037
ViTD, nTD, and ECLNI were all significant independent adverse factors for RFS in rectal cancer, and were all associated with pT, pN, and LN ratio.
p76131
sg70039
(lp76132
(dp76133
g70042
I5
sg70043
VnTD
p76134
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp76135
(dp76136
g70042
I73
sg70043
VRFS
p76137
sg70045
I3
sg70054
VC0015624
p76138
sg70048
I1
sa(dp76139
g70042
I80
sg70043
Vrectal cancer
p76140
sg70045
I13
sg70054
VC0007113
p76141
sg70048
I2
sasa(dp76142
g135
(dp76143
(VErk
p76144
VCCM3
p76145
tp76146
I00
ssg70037
VSilencing CCM3 by siRNA stimulated endothelial proliferation, migration and sprouting accompanied by significant downregulation of the core components of Notch signalling including DLL4, Notch4, HEY2 and HES1 and by activation of VEGF and Erk pathways.
p76147
sg70039
(lp76148
(dp76149
g70042
I204
sg70043
VHES1
p76150
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp76151
g70042
I195
sg70043
VHEY2
p76152
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp76153
g70042
I181
sg70043
VDLL4
p76154
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp76155
g70042
I10
sg70043
VCCM3
p76156
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp76157
g70042
I239
sg70043
g76144
sg70045
I3
sg70046
VP29323
p76158
sg70048
I1
sa(dp76159
g70042
I187
sg70043
VNotch4
p76160
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76161
(dp76162
g70042
I10
sg70043
g76145
sg70045
I4
sg70054
VC1864040
p76163
sg70048
I1
sa(dp76164
g70042
I47
sg70043
Vproliferation
p76165
sg70045
I13
sg70054
VC0334094
p76166
sg70048
I1
sasa(dp76167
g70037
VThe aim was to assess the efficacy of glucomannan (GNN) as a sole treatment for functional constipation.
p76168
sg70039
(lp76169
sg70051
(lp76170
(dp76171
g70042
I80
sg70043
Vfunctional constipation
p76172
sg70045
I23
sg70054
VC0401146
p76173
sg70048
I2
sasa(dp76174
g70037
VChildren aged 3-16 years with functional constipation according to Rome III criteria were randomly assigned to receive GNN (2.52 g/d) or placebo for 4 weeks.
p76175
sg70039
(lp76176
sg70051
(lp76177
(dp76178
g70042
I30
sg70043
Vfunctional constipation
p76179
sg70045
I23
sg70054
VC0401146
p76180
sg70048
I2
sasa(dp76181
g70037
VInterestingly, using Affymetrix gene expression data of a cohort of 285 patients with acute myeloid leukemia (AML), we found that GNN/TU12B1-TY expression was specifically increased in two AML clusters.
p76182
sg70039
(lp76183
(dp76184
g70042
I130
sg70043
VGNN
p76185
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp76186
(dp76187
g70042
I110
sg70043
VAML
p76188
sg70045
I3
sg70054
VC0023467
p76189
sg70048
I1
sa(dp76190
g70042
I110
sg70043
VAML
p76191
sg70045
I3
sg70054
VC0023467
p76192
sg70048
I1
sa(dp76193
g70042
I86
sg70043
Vacute myeloid leukemia
p76194
sg70045
I22
sg70054
VC0023467
p76195
sg70048
I3
sasa(dp76196
g70037
VThe present results indicate that reduced function of TU12B1-TY may contribute to the development and/or progression of human pancreatic cancer.
p76197
sg70039
(lp76198
(dp76199
g70042
I54
sg70043
VTU12B1-TY
p76200
sg70045
I9
sg70046
g12
sg70048
I1
sasg70051
(lp76201
(dp76202
g70042
I126
sg70043
Vpancreatic cancer
p76203
sg70045
I17
sg70054
VC0235974
p76204
sg70048
I2
sasa(dp76205
g70037
VTo characterize morphologic alterations in the retina of the visual mutant zebrafish gantenbein (gnn) and to examine whether these alterations correlate with those present in human hereditary eye diseases.
p76206
sg70039
(lp76207
(dp76208
g70042
I61
sg70043
Vvisual mutant zebrafish gantenbein
p76209
sg70045
I34
sg70046
g12
sg70048
I4
sa(dp76210
g70042
I97
sg70043
Vgnn
p76211
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp76212
(dp76213
g70042
I181
sg70043
Vhereditary eye diseases
p76214
sg70045
I23
sg70054
VC0015398
p76215
sg70048
I3
sa(dp76216
g70042
I68
sg70043
Vmutant
p76217
sg70045
I6
sg70054
VC0596988
p76218
sg70048
I1
sasa(dp76219
g70037
VThus, the early developmental morphology of gnn exhibits similarities to cone dystrophies most commonly seen in age-related macular degeneration (AMD) among humans, whereas the later stages of degeneration in gnn resemble RPE alterations in retinitis pigmentosa (RP) in humans.
p76220
sg70039
(lp76221
(dp76222
g70042
I44
sg70043
Vgnn
p76223
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp76224
(dp76225
g70042
I78
sg70043
Vdystrophies
p76226
sg70045
I11
sg70054
VC0333606
p76227
sg70048
I1
sa(dp76228
g70042
I132
sg70043
Vdegeneration
p76229
sg70045
I12
sg70054
VC0011164
p76230
sg70048
I1
sa(dp76231
g70042
I222
sg70043
VRP
p76232
sg70045
I2
sg70054
VC0035334
p76233
sg70048
I1
sa(dp76234
g70042
I112
sg70043
Vage-related macular degeneration
p76235
sg70045
I32
sg70054
VC0242383
p76236
sg70048
I3
sa(dp76237
g70042
I241
sg70043
Vretinitis pigmentosa
p76238
sg70045
I20
sg70054
VC0035334
p76239
sg70048
I2
sa(dp76240
g70042
I146
sg70043
VAMD
p76241
sg70045
I3
sg70054
VC0242383
p76242
sg70048
I1
sasa(dp76243
g70037
VThe gnn zebrafish mutant may therefore be a useful model for examining the possible interplay and connection between cone dystrophy and RPE degeneration.
p76244
sg70039
(lp76245
(dp76246
g70042
I4
sg70043
Vgnn zebrafish mutant
p76247
sg70045
I20
sg70046
g12
sg70048
I3
sasg70051
(lp76248
(dp76249
g70042
I117
sg70043
Vcone dystrophy
p76250
sg70045
I14
sg70054
VC0730290
p76251
sg70048
I2
sa(dp76252
g70042
I18
sg70043
Vmutant
p76253
sg70045
I6
sg70054
VC0596988
p76254
sg70048
I1
sa(dp76255
g70042
I140
sg70043
Vdegeneration
p76256
sg70045
I12
sg70054
VC0011164
p76257
sg70048
I1
sasa(dp76258
g135
(dp76259
(Vmelanoma risk factors
p76260
Vmelanoma
p76261
tp76262
I00
ssg70037
VOur goal was to assess the patterns of familial aggregation of three melanoma risk factors: great number of naevi (GNN), light phototype (LP) and high degree of sun exposure (HDSE).
p76263
sg70039
(lp76264
(dp76265
g70042
I69
sg70043
g76260
sg70045
I21
sg70046
VP19883
p76266
sg70048
I3
sasg70051
(lp76267
(dp76268
g70042
I69
sg70043
g76261
sg70045
I8
sg70054
VC0025202
p76269
sg70048
I1
sasa(dp76270
g70037
VTwenty-five patients were divided into the following groups: (1) chronic glomerulonephritis with normal renal function (GNN) (2) chronic glomerulonephritis with moderate renal insufficiency (GNI) (3) severe chronic renal failure undergoing maintenance dialysis (CRF) (4) acute renal failure during oliguric phase (ARF) (5) normal control without renal suffering (NC).
p76271
sg70039
(lp76272
sg70051
(lp76273
(dp76274
g70042
I65
sg70043
Vchronic glomerulonephritis
p76275
sg70045
I26
sg70054
VC0152451
p76276
sg70048
I2
sa(dp76277
g70042
I170
sg70043
Vrenal insufficiency
p76278
sg70045
I19
sg70054
VC0035078
p76279
sg70048
I2
sa(dp76280
g70042
I271
sg70043
Vacute renal failure during oliguric phase
p76281
sg70045
I41
sg70054
VC0022660
p76282
sg70048
I6
sa(dp76283
g70042
I262
sg70043
VCRF
p76284
sg70045
I3
sg70054
VC0022661
p76285
sg70048
I1
sa(dp76286
g70042
I314
sg70043
VARF
p76287
sg70045
I3
sg70054
VC0022660
p76288
sg70048
I1
sa(dp76289
g70042
I352
sg70043
Vsuffering
p76290
sg70045
I9
sg70054
VC0683278
p76291
sg70048
I1
sa(dp76292
g70042
I207
sg70043
Vchronic renal failure undergoing maintenance dialysis
p76293
sg70045
I53
sg70054
VC0022661
p76294
sg70048
I6
sa(dp76295
g70042
I65
sg70043
Vchronic glomerulonephritis
p76296
sg70045
I26
sg70054
VC0152451
p76297
sg70048
I2
sasa(dp76298
g135
(dp76299
(Vbeta-actin mRNA
p76300
VCRF
p76301
tp76302
I00
ssg70037
VThe levels of PTH/PTHrP receptor mRNA (corrected by beta-actin mRNA) in the kidney of GNN, GNI, CRF and ARF patients was markedly decreased by up to 35.7%, 68.5%, 77.9% and 92.2%, respectively.
p76303
sg70039
(lp76304
(dp76305
g70042
I86
sg70043
VGNN
p76306
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp76307
g70042
I96
sg70043
VCRF
p76308
sg70045
I3
sg70046
VP06850
p76309
sg70048
I1
sa(dp76310
g70042
I14
sg70043
VPTH
p76311
sg70045
I3
sg70046
VP01270
p76312
sg70048
I1
sa(dp76313
g70042
I18
sg70043
VPTHrP receptor mRNA
p76314
sg70045
I19
sg70046
VP12272
p76315
sg70048
I3
sa(dp76316
g70042
I52
sg70043
g76300
sg70045
I15
sg70046
VP63261
p76317
sg70048
I2
sa(dp76318
g70042
I104
sg70043
VARF
p76319
sg70045
I3
sg70046
VP42771
p76320
sg70048
I1
sasg70051
(lp76321
(dp76322
g70042
I104
sg70043
VARF
p76323
sg70045
I3
sg70054
VC0264490
p76324
sg70048
I1
sa(dp76325
g70042
I96
sg70043
g76301
sg70045
I3
sg70054
VC0022661
p76326
sg70048
I1
sasa(dp76327
g70037
VHere, we tested whether rhMG53 protein can improve membrane repair in a dysferlin-deficient mouse model of LGMD2B (B6.129-Dysftm1Kcam/J).
p76328
sg70039
(lp76329
sg70051
(lp76330
(dp76331
g70042
I107
sg70043
VLGMD2B
p76332
sg70045
I6
sg70054
VC1850889
p76333
sg70048
I1
sasa(dp76334
g135
(dp76335
(Vcaveolin-3
p76336
Vlimb girdle muscular dystrophy
p76337
tp76338
I00
ssg70037
VThree interacting partners of dysferlin are also implicated in membrane resealing: caveolin-3 (in limb girdle muscular dystrophy type 1C), annexin A1, and the newly identified protein mitsugumin 53 (MG53).
p76339
sg70039
(lp76340
(dp76341
g70042
I139
sg70043
Vannexin A1
p76342
sg70045
I10
sg70046
VP04083
p76343
sg70048
I2
sa(dp76344
g70042
I83
sg70043
g76336
sg70045
I10
sg70046
VP56539
p76345
sg70048
I1
sasg70051
(lp76346
(dp76347
g70042
I98
sg70043
g76337
sg70045
I30
sg70054
VC0686353
p76348
sg70048
I4
sasa(dp76349
g70037
VLatency and amplitude of the visual P300 and N270 were examined in patients with transient ischemic attack (TIA) and in age-matched healthy control subjects to investigate the feasibility of N270 as a clinical examination method to evaluate the cognitive status of patients with TIA.
p76350
sg70039
(lp76351
sg70051
(lp76352
(dp76353
g70042
I81
sg70043
Vtransient ischemic attack
p76354
sg70045
I25
sg70054
VC0007787
p76355
sg70048
I3
sa(dp76356
g70042
I108
sg70043
VTIA
p76357
sg70045
I3
sg70054
VC0007787
p76358
sg70048
I1
sa(dp76359
g70042
I108
sg70043
VTIA
p76360
sg70045
I3
sg70054
VC0007787
p76361
sg70048
I1
sasa(dp76362
g70037
VWe applied multichannel recording of P300 in 28 patients (68.3 +/- 8.1 years; 15 asymptomatic, 13 with a history of transient ischemic attack (TIA)) and compared them with an age- and sex-matched control group.
p76363
sg70039
(lp76364
sg70051
(lp76365
(dp76366
g70042
I116
sg70043
Vtransient ischemic attack
p76367
sg70045
I25
sg70054
VC0007787
p76368
sg70048
I3
sa(dp76369
g70042
I143
sg70043
VTIA
p76370
sg70045
I3
sg70054
VC0007787
p76371
sg70048
I1
sasa(dp76372
g70037
VPrevious studies have implicated the roles of NT and NTR1 in the etiology or expression of schizophrenia.
p76373
sg70039
(lp76374
(dp76375
g70042
I53
sg70043
VNTR1
p76376
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp76377
(dp76378
g70042
I91
sg70043
Vschizophrenia
p76379
sg70045
I13
sg70054
VC0036341
p76380
sg70048
I1
sasa(dp76381
g70037
VThis case-control study examined the associations between schizophrenia and three NTR1 gene polymorphisms (rs6090453C/G, rs6011914C/G, and rs2427422A/G) previously linked to working memory performance in a Han Chinese population.
p76382
sg70039
(lp76383
(dp76384
g70042
I82
sg70043
VNTR1 gene
p76385
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp76386
(dp76387
g70042
I58
sg70043
Vschizophrenia
p76388
sg70045
I13
sg70054
VC0036341
p76389
sg70048
I1
sasa(dp76390
g70037
VThis suggested that nonpeptide agonist mimetics acting at the NTR1 might be helpful in the treatment of Parkinson's disease and schizophrenia.
p76391
sg70039
(lp76392
(dp76393
g70042
I62
sg70043
VNTR1
p76394
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp76395
(dp76396
g70042
I104
sg70043
VParkinson's disease
p76397
sg70045
I19
sg70054
VC0030567
p76398
sg70048
I2
sa(dp76399
g70042
I128
sg70043
Vschizophrenia
p76400
sg70045
I13
sg70054
VC0036341
p76401
sg70048
I1
sasa(dp76402
g135
(dp76403
(VIgE
p76404
VIgE
p76405
tp76406
I01
ssg70037
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p76407
sg70039
(lp76408
(dp76409
g70042
I164
sg70043
g76404
sg70045
I3
sg70046
VP01854
p76410
sg70048
I1
sasg70051
(lp76411
(dp76412
g70042
I219
sg70043
VABPA
p76413
sg70045
I4
sg70054
VC0004031
p76414
sg70048
I1
sa(dp76415
g70042
I144
sg70043
Veosinophilia
p76416
sg70045
I12
sg70054
VC0014457
p76417
sg70048
I1
sa(dp76418
g70042
I164
sg70043
g76405
sg70045
I3
sg70054
VC0270850
p76419
sg70048
I1
sasa(dp76420
g135
(dp76421
(VIgE
p76422
VIgE
p76423
tp76424
I01
ssg70037
VThe patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA).
p76425
sg70039
(lp76426
(dp76427
g70042
I164
sg70043
g76422
sg70045
I3
sg70046
VP01854
p76428
sg70048
I1
sasg70051
(lp76429
(dp76430
g70042
I219
sg70043
VABPA
p76431
sg70045
I4
sg70054
VC0004031
p76432
sg70048
I1
sa(dp76433
g70042
I144
sg70043
Veosinophilia
p76434
sg70045
I12
sg70054
VC0014457
p76435
sg70048
I1
sa(dp76436
g70042
I164
sg70043
g76423
sg70045
I3
sg70054
VC0270850
p76437
sg70048
I1
sasa(dp76438
g135
(dp76439
(Vsph1
p76440
Vsph1
p76441
tp76442
I00
ssg70037
Vsph1- and spa2-deleted cells possess defects in mating projection morphology and pseudohyphal growth.
p76443
sg70039
(lp76444
(dp76445
g70042
I0
sg70043
g76440
sg70045
I4
sg70046
VP16157
p76446
sg70048
I1
sa(dp76447
g70042
I10
sg70043
Vspa2
p76448
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp76449
(dp76450
g70042
I29
sg70043
Vpossess
p76451
sg70045
I7
sg70054
VC0850310
p76452
sg70048
I1
sa(dp76453
g70042
I0
sg70043
g76441
sg70045
I4
sg70054
VC2674218
p76454
sg70048
I1
sasa(dp76455
g135
(dp76456
(Vsph1(Delta) spa2(Delta) double mutants
p76457
Vsph1
p76458
tp76459
I00
ssg70037
Vsph1(Delta) spa2(Delta) double mutants also exhibit a strong haploid invasive growth defect and an exacerbated mating projection defect relative to either sph1(Delta) or spa2(Delta) single mutants.
p76460
sg70039
(lp76461
(dp76462
g70042
I170
sg70043
Vspa2(Delta) single mutants
p76463
sg70045
I26
sg70046
g12
sg70048
I3
sa(dp76464
g70042
I0
sg70043
Vsph1(Delta)
p76465
sg70045
I11
sg70046
VP16157
p76466
sg70048
I1
sa(dp76467
g70042
I0
sg70043
g76457
sg70045
I38
sg70046
VP16157
p76468
sg70048
I4
sasg70051
(lp76469
(dp76470
g70042
I0
sg70043
Vsph1
p76471
sg70045
I4
sg70054
VC2674218
p76472
sg70048
I1
sa(dp76473
g70042
I0
sg70043
g76458
sg70045
I4
sg70054
VC2674218
p76474
sg70048
I1
sa(dp76475
g70042
I69
sg70043
Vinvasive growth
p76476
sg70045
I15
sg70054
VC1156244
p76477
sg70048
I2
sasa(dp76478
g135
(dp76479
(VSPH1
p76480
VSPH1
p76481
tp76482
I00
ssg70037
VSPH1, which is similar to SPA2, is required for bipolar budding and plays a role in shmoo formation.
p76483
sg70039
(lp76484
(dp76485
g70042
I0
sg70043
g76480
sg70045
I4
sg70046
VP16157
p76486
sg70048
I1
sa(dp76487
g70042
I26
sg70043
VSPA2
p76488
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp76489
(dp76490
g70042
I0
sg70043
g76481
sg70045
I4
sg70054
VC2674218
p76491
sg70048
I1
sasa(dp76492
g70037
VOutcomes were best in patients with ovarian cancer (MS 15.9 months) and colorectal cancer (MS 14.3 months) and worst in patients with lung (MS 2.4 months) and pancreas (MS 1.9 months) cancers.
p76493
sg70039
(lp76494
sg70051
(lp76495
(dp76496
g70042
I184
sg70043
Vcancers
p76497
sg70045
I7
sg70054
VC0006826
p76498
sg70048
I1
sa(dp76499
g70042
I72
sg70043
Vcolorectal cancer
p76500
sg70045
I17
sg70054
VC1527249
p76501
sg70048
I2
sa(dp76502
g70042
I36
sg70043
Vovarian cancer
p76503
sg70045
I14
sg70054
VC1140680
p76504
sg70048
I2
sasa(dp76505
g135
(dp76506
(VADAM8
p76507
Vhepatoma
p76508
tp76509
I00
ssg70037
VThis study was undertaken to evaluate the effect of ADAM8 on the proliferation and apoptosis of hepatocytes and hepatoma carcinoma cells during hepatocellular carcinoma (HCC) progression.
p76510
sg70039
(lp76511
(dp76512
g70042
I52
sg70043
g76507
sg70045
I5
sg70046
VP78325
p76513
sg70048
I1
sasg70051
(lp76514
(dp76515
g70042
I170
sg70043
VHCC
p76516
sg70045
I3
sg70054
VC2239176
p76517
sg70048
I1
sa(dp76518
g70042
I65
sg70043
Vproliferation
p76519
sg70045
I13
sg70054
VC0334094
p76520
sg70048
I1
sa(dp76521
g70042
I121
sg70043
Vcarcinoma
p76522
sg70045
I9
sg70054
VC0007097
p76523
sg70048
I1
sa(dp76524
g70042
I144
sg70043
Vhepatocellular carcinoma
p76525
sg70045
I24
sg70054
VC2239176
p76526
sg70048
I2
sa(dp76527
g70042
I112
sg70043
g76508
sg70045
I8
sg70054
VC2239176
p76528
sg70048
I1
sasa(dp76529
g135
(dp76530
(VADAM8
p76531
VHCC
p76532
tp76533
I00
ssg70037
VIn conclusion, our study suggested that ADAM8 could promote the proliferation of normal hepatocytes and render hepatoma carcinoma cells more resistant to apoptosis to play important roles during the progression of HCC.
p76534
sg70039
(lp76535
(dp76536
g70042
I40
sg70043
g76531
sg70045
I5
sg70046
VP78325
p76537
sg70048
I1
sasg70051
(lp76538
(dp76539
g70042
I64
sg70043
Vproliferation
p76540
sg70045
I13
sg70054
VC0334094
p76541
sg70048
I1
sa(dp76542
g70042
I111
sg70043
Vhepatoma
p76543
sg70045
I8
sg70054
VC2239176
p76544
sg70048
I1
sa(dp76545
g70042
I120
sg70043
Vcarcinoma
p76546
sg70045
I9
sg70054
VC0007097
p76547
sg70048
I1
sa(dp76548
g70042
I214
sg70043
g76532
sg70045
I3
sg70054
VC2239176
p76549
sg70048
I1
sasa(dp76550
g135
(dp76551
(VADAM8
p76552
Vpancreatic cancer
p76553
tp76554
I01
ssg70037
VThus, our data integrate ADAM8 in pancreatic cancer signalling and validate ADAM8 as a target for PDAC therapy.
p76555
sg70039
(lp76556
(dp76557
g70042
I25
sg70043
VADAM8
p76558
sg70045
I5
sg70046
VP78325
p76559
sg70048
I1
sa(dp76560
g70042
I25
sg70043
g76552
sg70045
I5
sg70046
VP78325
p76561
sg70048
I1
sasg70051
(lp76562
(dp76563
g70042
I34
sg70043
g76553
sg70045
I17
sg70054
VC0235974
p76564
sg70048
I2
sasa(dp76565
g135
(dp76566
(Vdisintegrin and metalloproteinase 8 (ADAM8)
p76567
VHCC
p76568
tp76569
I00
ssg70037
VThis study focuses on investigating the concrete role of a disintegrin and metalloproteinase 8 (ADAM8) in the progression of hepatocellular carcinoma (HCC).
p76570
sg70039
(lp76571
(dp76572
g70042
I59
sg70043
g76567
sg70045
I43
sg70046
VP78325
p76573
sg70048
I5
sasg70051
(lp76574
(dp76575
g70042
I125
sg70043
Vhepatocellular carcinoma
p76576
sg70045
I24
sg70054
VC2239176
p76577
sg70048
I2
sa(dp76578
g70042
I151
sg70043
g76568
sg70045
I3
sg70054
VC2239176
p76579
sg70048
I1
sasa(dp76580
g135
(dp76581
(VADAM8 association in colorectal cancer (CRC)
p76582
Vcolorectal cancer
p76583
tp76584
I01
ssg70037
VHowever, no studies have examined ADAM8 association in colorectal cancer (CRC).
p76585
sg70039
(lp76586
(dp76587
g70042
I34
sg70043
g76582
sg70045
I44
sg70046
VP78325
p76588
sg70048
I6
sasg70051
(lp76589
(dp76590
g70042
I74
sg70043
VCRC
p76591
sg70045
I3
sg70054
VC1527249
p76592
sg70048
I1
sa(dp76593
g70042
I55
sg70043
g76583
sg70045
I17
sg70054
VC1527249
p76594
sg70048
I2
sasa(dp76595
g135
(dp76596
(VADAM8
p76597
Vcolon cancer
p76598
tp76599
I00
ssg70037
VSubgroup analysis showed that 5-year OS of colon cancer, T3-T4 stage and N0 stage was worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p76600
sg70039
(lp76601
(dp76602
g70042
I110
sg70043
g76597
sg70045
I5
sg70046
VP78325
p76603
sg70048
I1
sasg70051
(lp76604
(dp76605
g70042
I125
sg70043
Vtumors
p76606
sg70045
I6
sg70054
VC0027651
p76607
sg70048
I1
sa(dp76608
g70042
I43
sg70043
g76598
sg70045
I12
sg70054
VC0699790
p76609
sg70048
I2
sa(dp76610
g70042
I125
sg70043
Vtumors
p76611
sg70045
I6
sg70054
VC0027651
p76612
sg70048
I1
sasa(dp76613
g135
(dp76614
(VADAM8
p76615
Vcolon cancer
p76616
tp76617
I00
ssg70037
VThe 5-year DFS in colon cancer, T3-T4 stage, N0 stage, TNM stage II, adenocarcinoma, moderate differentiation and male patient subgroups was also worse for patients with ADAM8-positive tumors than those with ADAM8-negative tumors (p &lt; 0.05).
p76618
sg70039
(lp76619
(dp76620
g70042
I170
sg70043
g76615
sg70045
I5
sg70046
VP78325
p76621
sg70048
I1
sa(dp76622
g70042
I55
sg70043
VTNM stage II
p76623
sg70045
I12
sg70046
g12
sg70048
I3
sasg70051
(lp76624
(dp76625
g70042
I69
sg70043
Vadenocarcinoma
p76626
sg70045
I14
sg70054
VC0001418
p76627
sg70048
I1
sa(dp76628
g70042
I18
sg70043
g76616
sg70045
I12
sg70054
VC0699790
p76629
sg70048
I2
sa(dp76630
g70042
I185
sg70043
Vtumors
p76631
sg70045
I6
sg70054
VC0027651
p76632
sg70048
I1
sa(dp76633
g70042
I185
sg70043
Vtumors
p76634
sg70045
I6
sg70054
VC0027651
p76635
sg70048
I1
sasa(dp76636
g135
(dp76637
(Vdisintegrin and metalloproteinase 8 (ADAM8)
p76638
Vpancreatic cancer
p76639
tp76640
I01
ssg70037
VThe aim of this study was to examine the role of the inflammatory cells in the invasion of pancreatic cancer cells, focusing on the involvement of a disintegrin and metalloproteinase 8 (ADAM8) and matrix metalloproteinase 9 (MMP9) proteins.
p76641
sg70039
(lp76642
(dp76643
g70042
I197
sg70043
Vmatrix metalloproteinase 9 (MMP9) proteins
p76644
sg70045
I42
sg70046
VP14780
p76645
sg70048
I5
sa(dp76646
g70042
I149
sg70043
g76638
sg70045
I43
sg70046
VP78325
p76647
sg70048
I5
sasg70051
(lp76648
(dp76649
g70042
I91
sg70043
g76639
sg70045
I17
sg70054
VC0235974
p76650
sg70048
I2
sa(dp76651
g70042
I79
sg70043
Vinvasion
p76652
sg70045
I8
sg70054
VC2699153
p76653
sg70048
I1
sasa(dp76654
g135
(dp76655
(VADAM8
p76656
Vpancreatic cancer
p76657
tp76658
I01
ssg70037
VADAM8 expression is associated with worse survival of pancreatic cancer patients.
p76659
sg70039
(lp76660
(dp76661
g70042
I0
sg70043
g76656
sg70045
I5
sg70046
VP78325
p76662
sg70048
I1
sasg70051
(lp76663
(dp76664
g70042
I54
sg70043
g76657
sg70045
I17
sg70054
VC0235974
p76665
sg70048
I2
sasa(dp76666
g135
(dp76667
(VADAM8
p76668
Vpancreatic cancer
p76669
tp76670
I01
ssg70037
VAnti-inflammatory macrophages increase pancreatic cancer cell migration rate in basement membrane matrix by inducing ADAM8 and MMP9 expression in cancer cells, thereby possibly enhancing the invasiveness of cancer.
p76671
sg70039
(lp76672
(dp76673
g70042
I127
sg70043
VMMP9
p76674
sg70045
I4
sg70046
VP14780
p76675
sg70048
I1
sa(dp76676
g70042
I117
sg70043
g76668
sg70045
I5
sg70046
VP78325
p76677
sg70048
I1
sasg70051
(lp76678
(dp76679
g70042
I39
sg70043
g76669
sg70045
I17
sg70054
VC0235974
p76680
sg70048
I2
sa(dp76681
g70042
I50
sg70043
Vcancer
p76682
sg70045
I6
sg70054
VC0006826
p76683
sg70048
I1
sa(dp76684
g70042
I50
sg70043
Vcancer
p76685
sg70045
I6
sg70054
VC0006826
p76686
sg70048
I1
sasa(dp76687
g135
(dp76688
(VADAM8
p76689
VHCC
p76690
tp76691
I00
ssg70037
VIn this study,we investigated the ADAM8 expression in hepatocellular carcinoma (HCC) and its correlation with clinicopathologic features,including the survival of patients with HCC.
p76692
sg70039
(lp76693
(dp76694
g70042
I34
sg70043
g76689
sg70045
I5
sg70046
VP78325
p76695
sg70048
I1
sasg70051
(lp76696
(dp76697
g70042
I54
sg70043
Vhepatocellular carcinoma
p76698
sg70045
I24
sg70054
VC2239176
p76699
sg70048
I2
sa(dp76700
g70042
I80
sg70043
VHCC
p76701
sg70045
I3
sg70054
VC2239176
p76702
sg70048
I1
sa(dp76703
g70042
I80
sg70043
g76690
sg70045
I3
sg70054
VC2239176
p76704
sg70048
I1
sasa(dp76705
g135
(dp76706
(VADAM8
p76707
Vhepatocellular carcinoma
p76708
tp76709
I00
ssg70037
VOther studies have demonstrated overexpression of some ADAM family proteins in a variety of human tumors, but no report is available on the actual expression of ADAM8 and the correlation between clinicopathologic features and prognosis of hepatocellular carcinoma (HCC) patients.
p76710
sg70039
(lp76711
(dp76712
g70042
I55
sg70043
VADAM family proteins
p76713
sg70045
I20
sg70046
VP02649
p76714
sg70048
I3
sa(dp76715
g70042
I161
sg70043
g76707
sg70045
I5
sg70046
VP78325
p76716
sg70048
I1
sasg70051
(lp76717
(dp76718
g70042
I98
sg70043
Vtumors
p76719
sg70045
I6
sg70054
VC0027651
p76720
sg70048
I1
sa(dp76721
g70042
I265
sg70043
VHCC
p76722
sg70045
I3
sg70054
VC2239176
p76723
sg70048
I1
sa(dp76724
g70042
I239
sg70043
g76708
sg70045
I24
sg70054
VC2239176
p76725
sg70048
I2
sasa(dp76726
g135
(dp76727
(VADAM8
p76728
Vhepatocellular carcinoma
p76729
tp76730
I00
ssg70037
VTo evaluate the association between ADAM8 tissue expression and patient prognosis in hepatocellular carcinoma (HCC).
p76731
sg70039
(lp76732
(dp76733
g70042
I36
sg70043
g76728
sg70045
I5
sg70046
VP78325
p76734
sg70048
I1
sasg70051
(lp76735
(dp76736
g70042
I111
sg70043
VHCC
p76737
sg70045
I3
sg70054
VC2239176
p76738
sg70048
I1
sa(dp76739
g70042
I85
sg70043
g76729
sg70045
I24
sg70054
VC2239176
p76740
sg70048
I2
sasa(dp76741
g135
(dp76742
(VALDH2
p76743
Vgout
p76744
tp76745
I00
ssg70037
VSome of the previously reported gout associated loci (except ALDH16A1), including ABCG2, SLC2A9, GCKR, ALDH2 and CNIH2, were replicated.
p76746
sg70039
(lp76747
(dp76748
g70042
I113
sg70043
VCNIH2
p76749
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp76750
g70042
I89
sg70043
VSLC2A9
p76751
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp76752
g70042
I103
sg70043
g76743
sg70045
I5
sg70046
VP05091
p76753
sg70048
I1
sa(dp76754
g70042
I61
sg70043
VALDH16A1
p76755
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp76756
g70042
I97
sg70043
VGCKR
p76757
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp76758
(dp76759
g70042
I32
sg70043
g76744
sg70045
I4
sg70054
VC0018099
p76760
sg70048
I1
sasa(dp76761
g135
(dp76762
(VABCG2 variants
p76763
Vgout
p76764
tp76765
I00
ssg70037
VThe aim of this study was to examine the role of SLC2A9 and ABCG2 variants in tophaceous disease in people with gout.
p76766
sg70039
(lp76767
(dp76768
g70042
I49
sg70043
VSLC2A9
p76769
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp76770
g70042
I60
sg70043
g76763
sg70045
I14
sg70046
VP26640
p76771
sg70048
I2
sasg70051
(lp76772
(dp76773
g70042
I112
sg70043
g76764
sg70045
I4
sg70054
VC0018099
p76774
sg70048
I1
sasa(dp76775
g70037
VThe main objective of this study is to elucidate the clinical significance of the SLC2A9/GLUT9 rs11722228 polymorphism among male gout patients.
p76776
sg70039
(lp76777
(dp76778
g70042
I89
sg70043
VGLUT9
p76779
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp76780
g70042
I82
sg70043
VSLC2A9
p76781
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76782
(dp76783
g70042
I130
sg70043
Vgout
p76784
sg70045
I4
sg70054
VC0018099
p76785
sg70048
I1
sasa(dp76786
g70037
VThe genotypic frequencies of SLC2A9/GLUT9 rs1172228 did not differ significantly between the gout cases and the healthy controls.
p76787
sg70039
(lp76788
(dp76789
g70042
I29
sg70043
VSLC2A9
p76790
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp76791
g70042
I36
sg70043
VGLUT9
p76792
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp76793
(dp76794
g70042
I93
sg70043
Vgout
p76795
sg70045
I4
sg70054
VC0018099
p76796
sg70048
I1
sasa(dp76797
g70037
VThe genotypic distribution of SLC2A9/GLUT9 rs1172228 in male gout patients did not differ significantly from that of healthy male controls.
p76798
sg70039
(lp76799
(dp76800
g70042
I37
sg70043
VGLUT9 rs1172228
p76801
sg70045
I15
sg70046
g12
sg70048
I2
sa(dp76802
g70042
I30
sg70043
VSLC2A9
p76803
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76804
(dp76805
g70042
I61
sg70043
Vgout
p76806
sg70045
I4
sg70054
VC0018099
p76807
sg70048
I1
sasa(dp76808
g70037
VThe relationship between the SLC2A9 (solute carrier family 2, member 9) gene polymorphisms and gout was still inconsistent among the individual genetic association studies.
p76809
sg70039
(lp76810
(dp76811
g70042
I37
sg70043
Vsolute carrier family 2
p76812
sg70045
I23
sg70046
g12
sg70048
I4
sa(dp76813
g70042
I29
sg70043
VSLC2A9
p76814
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76815
(dp76816
g70042
I95
sg70043
Vgout
p76817
sg70045
I4
sg70054
VC0018099
p76818
sg70048
I1
sasa(dp76819
g70037
VTherefore, this present research was aimed to systematically evaluate the association between SLC2A9 gene polymorphisms and gout susceptibility.
p76820
sg70039
(lp76821
(dp76822
g70042
I94
sg70043
VSLC2A9 gene
p76823
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp76824
(dp76825
g70042
I124
sg70043
Vgout
p76826
sg70045
I4
sg70054
VC0018099
p76827
sg70048
I1
sasa(dp76828
g70037
VThis study demonstrated that the genetic susceptibility for gout is associated with the SLC2A9 gene polymorphisms.
p76829
sg70039
(lp76830
(dp76831
g70042
I88
sg70043
VSLC2A9 gene
p76832
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp76833
(dp76834
g70042
I60
sg70043
Vgout
p76835
sg70045
I4
sg70054
VC0018099
p76836
sg70048
I1
sasa(dp76837
g70037
VEight variants of ABCG2, SLC2A9, SLC22A12, SLC22A11 and SLC17A3 were genotyped in male individuals in a case-control study with 157 gout (33% tophi), 106 asymptomatic hyperuricaemia and 295 control subjects from Taiwan.
p76838
sg70039
(lp76839
(dp76840
g70042
I33
sg70043
VSLC22A12
p76841
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp76842
g70042
I43
sg70043
VSLC22A11
p76843
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp76844
g70042
I25
sg70043
VSLC2A9
p76845
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp76846
g70042
I56
sg70043
VSLC17A3
p76847
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp76848
(dp76849
g70042
I142
sg70043
Vtophi
p76850
sg70045
I5
sg70054
VC0221248
p76851
sg70048
I1
sa(dp76852
g70042
I132
sg70043
Vgout
p76853
sg70045
I4
sg70054
VC0018099
p76854
sg70048
I1
sa(dp76855
g70042
I167
sg70043
Vhyperuricaemia
p76856
sg70045
I14
sg70054
VC0740394
p76857
sg70048
I1
sasa(dp76858
g70037
VABCG2 Q141K (T), SLC2A9 rs1014290 (A) and SLC22A12 rs475688 (C) under an additive model and alcohol use independently predicted the risk of gout (respective odds ratio for each factor=2.48, 2.03, 1.95 and 2.48).
p76859
sg70039
(lp76860
(dp76861
g70042
I17
sg70043
VSLC2A9 rs1014290
p76862
sg70045
I16
sg70046
g12
sg70048
I2
sa(dp76863
g70042
I42
sg70043
VSLC22A12
p76864
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp76865
(dp76866
g70042
I140
sg70043
Vgout
p76867
sg70045
I4
sg70054
VC0018099
p76868
sg70048
I1
sasa(dp76869
g70037
VThe aim of this study was to determine whether polymorphisms in solute carrier family 2 and facilitated glucose transporter member 9 (SLC2A9) are associated with susceptibility to gout.
p76870
sg70039
(lp76871
(dp76872
g70042
I134
sg70043
VSLC2A9
p76873
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp76874
g70042
I64
sg70043
Vsolute carrier family 2 and facilitated glucose transporter member 9
p76875
sg70045
I68
sg70046
g12
sg70048
I10
sasg70051
(lp76876
(dp76877
g70042
I180
sg70043
Vgout
p76878
sg70045
I4
sg70054
VC0018099
p76879
sg70048
I1
sasa(dp76880
g70037
VA meta-analysis was conducted on associations between the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 and gout susceptibility using fixed and random effects models.
p76881
sg70039
(lp76882
(dp76883
g70042
I113
sg70043
VSLC2A9
p76884
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76885
(dp76886
g70042
I124
sg70043
Vgout
p76887
sg70045
I4
sg70054
VC0018099
p76888
sg70048
I1
sasa(dp76889
g70037
VThis meta-analysis shows that the rs12510549, rs16890979, and rs1014290 polymorphisms of SLC2A9 protect against the development of gout in Caucasians and/or Asians.
p76890
sg70039
(lp76891
sg70051
(lp76892
(dp76893
g70042
I131
sg70043
Vgout
p76894
sg70045
I4
sg70054
VC0018099
p76895
sg70048
I1
sasa(dp76896
g70037
VWe investigated the association of polymorphisms in the ABCG2 and SLC2A9 genes with gout in Korean patients and healthy individuals.
p76897
sg70039
(lp76898
(dp76899
g70042
I66
sg70043
VSLC2A9 genes
p76900
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp76901
(dp76902
g70042
I84
sg70043
Vgout
p76903
sg70045
I4
sg70054
VC0018099
p76904
sg70048
I1
sasa(dp76905
g70037
VWe demonstrated a significant association between rs2231142 in the ABCG2 gene and gout and identified novel SNPs, c.881A&gt;G and c.1002+78G&gt;A, in the SLC2A9 gene that may be associated with gout in a Korean population.
p76906
sg70039
(lp76907
(dp76908
g70042
I154
sg70043
VSLC2A9 gene
p76909
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp76910
(dp76911
g70042
I82
sg70043
Vgout
p76912
sg70045
I4
sg70054
VC0018099
p76913
sg70048
I1
sa(dp76914
g70042
I82
sg70043
Vgout
p76915
sg70045
I4
sg70054
VC0018099
p76916
sg70048
I1
sasa(dp76917
g70037
VSLC2A9 and ZNF518B may play a role in gout progression in different populations, but no studies have focused on the Tibetan Chinese population.
p76918
sg70039
(lp76919
(dp76920
g70042
I11
sg70043
VZNF518B
p76921
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp76922
g70042
I0
sg70043
VSLC2A9
p76923
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76924
(dp76925
g70042
I38
sg70043
Vgout
p76926
sg70045
I4
sg70054
VC0018099
p76927
sg70048
I1
sasa(dp76928
g70037
VWe detected 6 single nucleotide polymorphisms in SLC2A9 and ZNF518B in 319 Chinese Tibetan gout patients.
p76929
sg70039
(lp76930
(dp76931
g70042
I49
sg70043
VSLC2A9
p76932
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp76933
g70042
I60
sg70043
VZNF518B
p76934
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp76935
(dp76936
g70042
I91
sg70043
Vgout
p76937
sg70045
I4
sg70054
VC0018099
p76938
sg70048
I1
sasa(dp76939
g70037
VPolymorphisms in SLC2A9 and ZNF518B affected multiple risk factors related to gout development.
p76940
sg70039
(lp76941
(dp76942
g70042
I17
sg70043
VSLC2A9
p76943
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp76944
g70042
I28
sg70043
VZNF518B
p76945
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp76946
(dp76947
g70042
I78
sg70043
Vgout
p76948
sg70045
I4
sg70054
VC0018099
p76949
sg70048
I1
sasa(dp76950
g70037
VThis study is the first to investigate and identify positive correlations between SLC2A9 and ZNF518B gene polymorphisms and metabolic indices in Tibetan gout patients.
p76951
sg70039
(lp76952
(dp76953
g70042
I93
sg70043
VZNF518B gene
p76954
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp76955
g70042
I82
sg70043
VSLC2A9
p76956
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp76957
(dp76958
g70042
I153
sg70043
Vgout
p76959
sg70045
I4
sg70054
VC0018099
p76960
sg70048
I1
sasa(dp76961
g70037
VIn conclusion, two patients who developed hypercalcemia associated with bone metastasis after surgery for HCC were treated with alendronate and they experienced alleviation of the pain due to bone metastasis, improvement of their quality of life and a marked decrease in AFP levels with tumor regression.
p76962
sg70039
(lp76963
sg70051
(lp76964
(dp76965
g70042
I42
sg70043
Vhypercalcemia
p76966
sg70045
I13
sg70054
VC0020437
p76967
sg70048
I1
sa(dp76968
g70042
I72
sg70043
Vbone metastasis
p76969
sg70045
I15
sg70054
VC0153690
p76970
sg70048
I2
sa(dp76971
g70042
I287
sg70043
Vtumor
p76972
sg70045
I5
sg70054
VC0027651
p76973
sg70048
I1
sa(dp76974
g70042
I106
sg70043
VHCC
p76975
sg70045
I3
sg70054
VC2239176
p76976
sg70048
I1
sa(dp76977
g70042
I72
sg70043
Vbone metastasis
p76978
sg70045
I15
sg70054
VC0153690
p76979
sg70048
I2
sasa(dp76980
g70037
VColoboma-like optic discs might be an additional feature observed in patients with SPTAN1 mutations.
p76981
sg70039
(lp76982
sg70051
(lp76983
(dp76984
g70042
I0
sg70043
VColoboma
p76985
sg70045
I8
sg70054
VC0009363
p76986
sg70048
I1
sasa(dp76987
g70037
VA newly described autoantibody to alpha-fodrin found in other neurodegenerative diseases such as Alzheimer's, further implicate a role for autoimmunity and the neurodegenerative processes in glaucoma.
p76988
sg70039
(lp76989
sg70051
(lp76990
(dp76991
g70042
I62
sg70043
Vneurodegenerative diseases
p76992
sg70045
I26
sg70054
VC0524851
p76993
sg70048
I2
sa(dp76994
g70042
I191
sg70043
Vglaucoma
p76995
sg70045
I8
sg70054
VC0017601
p76996
sg70048
I1
sa(dp76997
g70042
I139
sg70043
Vautoimmunity
p76998
sg70045
I12
sg70054
VC0004368
p76999
sg70048
I1
sasa(dp77000
g70037
VIn a similar experiment, ocular hypertension was induced in four eyes pre-treated with an intravitreal injection of AAV-BIRC4 to assess alpha-fodrin cleavage.
p77001
sg70039
(lp77002
sg70051
(lp77003
(dp77004
g70042
I25
sg70043
Vocular hypertension
p77005
sg70045
I19
sg70054
VC0028840
p77006
sg70048
I2
sasa(dp77007
g70037
VComparison of the Zrs z-scores between the healthy children and the health groups found significant differences in children with asthma, current wheeze and respiratory symptoms, but not in children born preterm or with early-life wheeze.
p77008
sg70039
(lp77009
sg70051
(lp77010
(dp77011
g70042
I156
sg70043
Vrespiratory symptoms
p77012
sg70045
I20
sg70054
VC0037090
p77013
sg70048
I2
sa(dp77014
g70042
I145
sg70043
Vwheeze
p77015
sg70045
I6
sg70054
VC0043144
p77016
sg70048
I1
sa(dp77017
g70042
I145
sg70043
Vwheeze
p77018
sg70045
I6
sg70054
VC0043144
p77019
sg70048
I1
sa(dp77020
g70042
I129
sg70043
Vasthma
p77021
sg70045
I6
sg70054
VC0004096
p77022
sg70048
I1
sasa(dp77023
g70037
VThe aim of this retrospective study was to assess responses to a bronchodilator by forced oscillation technique (FOT) and to relate the results of respiratory impedance (Zrs) to spirometric parameters in patients with chronic obstructive pulmonary disease (COPD).
p77024
sg70039
(lp77025
sg70051
(lp77026
(dp77027
g70042
I218
sg70043
Vchronic obstructive pulmonary disease
p77028
sg70045
I37
sg70054
VC0024117
p77029
sg70048
I4
sa(dp77030
g70042
I257
sg70043
VCOPD
p77031
sg70045
I4
sg70054
VC0024117
p77032
sg70048
I1
sasa(dp77033
g70037
VThe diagnostic efficiency of Zrs, R5 and X35 when diagnosis asthma, expressed by ROC curve parameters, was as follows: AUC (0.721, 0.710, 0.695), sensitivity (62%, 72%, 53%) and specificity (72%, 61%, 76%), respectively.
p77034
sg70039
(lp77035
sg70051
(lp77036
(dp77037
g70042
I60
sg70043
Vasthma
p77038
sg70045
I6
sg70054
VC0004096
p77039
sg70048
I1
sasa(dp77040
g70037
VAnd R5, X35 and Zrs may provide useful IOS parameters for asthma.
p77041
sg70039
(lp77042
(dp77043
g70042
I16
sg70043
VZrs
p77044
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp77045
(dp77046
g70042
I58
sg70043
Vasthma
p77047
sg70045
I6
sg70054
VC0004096
p77048
sg70048
I1
sasa(dp77049
g70037
VBirth weight less than 3,000 g was associated with larger exercise-induced changes in Zrs and Rrs at 5 Hz, and in reactance (Xrs) at 5 Hz, than those with birth weight more than 3,000 g. Preliminary evidence was found that obesity may be associated with airway obstruction, but not with bronchial hyper-reactivity.
p77050
sg70039
(lp77051
sg70051
(lp77052
(dp77053
g70042
I223
sg70043
Vobesity
p77054
sg70045
I7
sg70054
VC0028754
p77055
sg70048
I1
sa(dp77056
g70042
I94
sg70043
VRrs
p77057
sg70045
I3
sg70054
VC1849334
p77058
sg70048
I1
sa(dp77059
g70042
I254
sg70043
Vairway obstruction
p77060
sg70045
I18
sg70054
VC0001883
p77061
sg70048
I2
sasa(dp77062
g135
(dp77063
(Vuromodulin (UM) gene
p77064
Vmultiple myeloma
p77065
tp77066
I00
ssg70037
VTo investigate the nature of mutations in exons 4 and 5 of the uromodulin (UM) gene, including in the area encoding the domain of 8 cysteines (D8C), in patients with multiple myeloma (MM) with the secretion of monoclonal light chains (LC) in cast nephropathy (CN) and without kidney injury.
p77067
sg70039
(lp77068
(dp77069
g70042
I63
sg70043
g77064
sg70045
I20
sg70046
VP07911
p77070
sg70048
I3
sasg70051
(lp77071
(dp77072
g70042
I247
sg70043
Vnephropathy
p77073
sg70045
I11
sg70054
VC0022658
p77074
sg70048
I1
sa(dp77075
g70042
I166
sg70043
g77065
sg70045
I16
sg70054
VC0026764
p77076
sg70048
I2
sasa(dp77077
g135
(dp77078
(Vuromodulin
p77079
Vaggressiveness
p77080
tp77081
I00
ssg70037
VThe aim of the study was to investigate the association of the uromodulin (UMOD) genotype with patient health status and with renal cell carcinoma (RCC) aggressiveness.
p77082
sg70039
(lp77083
(dp77084
g70042
I75
sg70043
VUMOD
p77085
sg70045
I4
sg70046
VP07911
p77086
sg70048
I1
sa(dp77087
g70042
I63
sg70043
g77079
sg70045
I10
sg70046
VP07911
p77088
sg70048
I1
sasg70051
(lp77089
(dp77090
g70042
I148
sg70043
VRCC
p77091
sg70045
I3
sg70054
VC0007134
p77092
sg70048
I1
sa(dp77093
g70042
I126
sg70043
Vrenal cell carcinoma
p77094
sg70045
I20
sg70054
VC0007134
p77095
sg70048
I3
sa(dp77096
g70042
I153
sg70043
g77080
sg70045
I14
sg70054
VC0001807
p77097
sg70048
I1
sasa(dp77098
g135
(dp77099
(Vuromodulin
p77100
Vrenal cell carcinoma
p77101
tp77102
I00
ssg70037
VIn patients diagnosed with renal cell carcinoma and treated with surgery, uromodulin homozygous genotype is associated with more aggressive renal cell carcinoma clinical and pathological characteristics.
p77103
sg70039
(lp77104
(dp77105
g70042
I74
sg70043
g77100
sg70045
I10
sg70046
VP07911
p77106
sg70048
I1
sasg70051
(lp77107
(dp77108
g70042
I129
sg70043
Vaggressive
p77109
sg70045
I10
sg70054
VC0001807
p77110
sg70048
I1
sa(dp77111
g70042
I27
sg70043
Vrenal cell carcinoma
p77112
sg70045
I20
sg70054
VC0007134
p77113
sg70048
I3
sa(dp77114
g70042
I27
sg70043
g77101
sg70045
I20
sg70054
VC0007134
p77115
sg70048
I3
sasa(dp77116
g135
(dp77117
(VUMOD
p77118
Vprimary aldosteronism
p77119
tp77120
I00
ssg70037
VCYP11B2 was sequenced if the aldosterone level was high (primary aldosteronism phenotype); SCNN1B, NEDD4L, GRK4, UMOD, and NPPA genes were sequenced if the aldosterone level was low (Liddle phenotype).
p77121
sg70039
(lp77122
(dp77123
g70042
I91
sg70043
VSCNN1B
p77124
sg70045
I6
sg70046
VP51168
p77125
sg70048
I1
sa(dp77126
g70042
I0
sg70043
VCYP11B2
p77127
sg70045
I7
sg70046
VP19099
p77128
sg70048
I1
sa(dp77129
g70042
I123
sg70043
VNPPA genes
p77130
sg70045
I10
sg70046
VP01160
p77131
sg70048
I2
sa(dp77132
g70042
I113
sg70043
g77118
sg70045
I4
sg70046
VP07911
p77133
sg70048
I1
sasg70051
(lp77134
(dp77135
g70042
I57
sg70043
g77119
sg70045
I21
sg70054
VC1384514
p77136
sg70048
I2
sasa(dp77137
g135
(dp77138
(VMT2A gene
p77139
Vcolon cancer
p77140
tp77141
I01
ssg70037
VMT1F, MT1G, MT1X, and MT2A gene expression was significantly downregulated in colon cancer tissue (p&lt;0.05).
p77142
sg70039
(lp77143
(dp77144
g70042
I12
sg70043
VMT1X
p77145
sg70045
I4
sg70046
VP80297
p77146
sg70048
I1
sa(dp77147
g70042
I6
sg70043
VMT1G
p77148
sg70045
I4
sg70046
VP04733
p77149
sg70048
I1
sa(dp77150
g70042
I0
sg70043
VMT1F
p77151
sg70045
I4
sg70046
VP04733
p77152
sg70048
I1
sa(dp77153
g70042
I22
sg70043
g77139
sg70045
I9
sg70046
VP02795
p77154
sg70048
I2
sasg70051
(lp77155
(dp77156
g70042
I78
sg70043
g77140
sg70045
I12
sg70054
VC0699790
p77157
sg70048
I2
sasa(dp77158
g135
(dp77159
(Vmetallothionein 1X gene
p77160
Vcolorectal cancer
p77161
tp77162
I00
ssg70037
VHere, we describe the discovery of a new MSI marker for colorectal cancer located in the 3'-untranslated region (3'UTR, T20 mononucleotide repeat) of the metallothionein 1X gene (MT1XT20).
p77163
sg70039
(lp77164
(dp77165
g70042
I154
sg70043
g77160
sg70045
I23
sg70046
VP80297
p77166
sg70048
I3
sasg70051
(lp77167
(dp77168
g70042
I41
sg70043
VMSI
p77169
sg70045
I3
sg70054
VC0920269
p77170
sg70048
I1
sa(dp77171
g70042
I56
sg70043
g77161
sg70045
I17
sg70054
VC1527249
p77172
sg70048
I2
sasa(dp77173
g70037
VIndeed, MT1XT20 instability was detected in 36 out of 37 cases (97.3%) of MSI-high colorectal cancers, whereas no MT1XT20 alterations were observed in 254 MSS or in 46 MSI-low cases.
p77174
sg70039
(lp77175
sg70051
(lp77176
(dp77177
g70042
I74
sg70043
VMSI
p77178
sg70045
I3
sg70054
VC0920269
p77179
sg70048
I1
sa(dp77180
g70042
I155
sg70043
VMSS
p77181
sg70045
I3
sg70054
VC0024814
p77182
sg70048
I1
sa(dp77183
g70042
I74
sg70043
VMSI
p77184
sg70045
I3
sg70054
VC0920269
p77185
sg70048
I1
sa(dp77186
g70042
I83
sg70043
Vcolorectal cancers
p77187
sg70045
I18
sg70054
VC1527249
p77188
sg70048
I2
sasa(dp77189
g135
(dp77190
(Vepidermal growth factor receptor
p77191
VFas
p77192
tp77193
I00
ssg70037
VHNF-1Beta regulates tissue-specific gene expression in endometriosis, as well as the expression of several genes, including CD44v9, which binds several molecules, including hyaluronan, epidermal growth factor receptor (EGFR), leukemia-associated Rho-guanine nucleotide exchange factor (LARG), IQ motif containing GTPase activating protein 1 (IQGAP1), macrophage migration inhibitory factor (MIF), major histocompatibility complex, class II invariant chain (CD74), cystine transporter subunit (xCT), Fas and extracellular matrix (ECM) proteins.
p77194
sg70039
(lp77195
(dp77196
g70042
I342
sg70043
VIQGAP1
p77197
sg70045
I6
sg70046
VP46940
p77198
sg70048
I1
sa(dp77199
g70042
I286
sg70043
VLARG
p77200
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp77201
g70042
I0
sg70043
VHNF-1Beta
p77202
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp77203
g70042
I507
sg70043
Vextracellular matrix (ECM) proteins
p77204
sg70045
I35
sg70046
g12
sg70048
I4
sa(dp77205
g70042
I293
sg70043
VIQ motif containing GTPase activating protein 1
p77206
sg70045
I47
sg70046
VP46940
p77207
sg70048
I7
sa(dp77208
g70042
I226
sg70043
Vleukemia-associated Rho-guanine nucleotide exchange factor
p77209
sg70045
I58
sg70046
g12
sg70048
I5
sa(dp77210
g70042
I219
sg70043
VEGFR
p77211
sg70045
I4
sg70046
VP01133
p77212
sg70048
I1
sa(dp77213
g70042
I499
sg70043
VFas
p77214
sg70045
I3
sg70046
VP48023
p77215
sg70048
I1
sa(dp77216
g70042
I457
sg70043
VCD74
p77217
sg70045
I4
sg70046
VP04233
p77218
sg70048
I1
sa(dp77219
g70042
I397
sg70043
Vmajor histocompatibility complex, class II invariant chain
p77220
sg70045
I58
sg70046
VP18464
p77221
sg70048
I7
sa(dp77222
g70042
I464
sg70043
Vcystine transporter subunit
p77223
sg70045
I27
sg70046
g12
sg70048
I3
sa(dp77224
g70042
I185
sg70043
g77191
sg70045
I32
sg70046
VP01133
p77225
sg70048
I4
sa(dp77226
g70042
I493
sg70043
VxCT
p77227
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp77228
(dp77229
g70042
I226
sg70043
Vleukemia
p77230
sg70045
I8
sg70054
VC0023418
p77231
sg70048
I1
sa(dp77232
g70042
I55
sg70043
Vendometriosis
p77233
sg70045
I13
sg70054
VC0014175
p77234
sg70048
I1
sa(dp77235
g70042
I499
sg70043
g77192
sg70045
I3
sg70054
VC0015923
p77236
sg70048
I1
sasa(dp77237
g70037
VWe sought to determine whether oxidative stress or a relative deficit of l-arginine plays a role in reducing cutaneous vasodilation in response to local heating in chronic kidney disease (CKD).
p77238
sg70039
(lp77239
sg70051
(lp77240
(dp77241
g70042
I62
sg70043
Vdeficit
p77242
sg70045
I7
sg70054
VC0162429
p77243
sg70048
I1
sa(dp77244
g70042
I164
sg70043
Vchronic kidney disease
p77245
sg70045
I22
sg70054
VC1561643
p77246
sg70048
I3
sa(dp77247
g70042
I188
sg70043
VCKD
p77248
sg70045
I3
sg70054
VC1561643
p77249
sg70048
I1
sa(dp77250
g70042
I119
sg70043
Vvasodilation
p77251
sg70045
I12
sg70054
VC0595862
p77252
sg70048
I1
sa(dp77253
g70042
I31
sg70043
Voxidative stress
p77254
sg70045
I16
sg70054
VC0242606
p77255
sg70048
I2
sasa(dp77256
g70037
VEight patients with stage 3-4 CKD and eight age- and sex-matched healthy control (HC) subjects were instrumented with four microdialysis (MD) fibers for the local delivery of 1) Ringers solution (R), 2) 20 mM ascorbic acid (AA), 3) 10 mM l-arginine (l-Arg), and 4) 10 mM N(G)-nitro-l-arginine methyl ester (l-NAME).
p77257
sg70039
(lp77258
sg70051
(lp77259
sa(dp77260
g70037
VThe plateau %CVC(max) in the CKD group was significantly greater at the AA and l-Arg sites compared with R (AA: 89 +/- 2; l-Arg: 90 +/- 1; R: 76 +/- 4; P &lt; 0.05) and did not differ from HC.
p77261
sg70039
(lp77262
sg70051
(lp77263
sa(dp77264
g70037
VInitial peak %CVC(max) was also significantly attenuated at the R and l-Arg sites in CKD (P &lt; 0.05) but did not differ at the AA site.
p77265
sg70039
(lp77266
sg70051
(lp77267
sa(dp77268
g70037
VThese results suggest that cutaneous microvascular function is impaired in stage 3-4 CKD and that oxidative stress and a deficit of l-arginine play a role in this impairment.
p77269
sg70039
(lp77270
sg70051
(lp77271
(dp77272
g70042
I163
sg70043
Vimpairment
p77273
sg70045
I10
sg70054
VC0684336
p77274
sg70048
I1
sa(dp77275
g70042
I63
sg70043
Vimpaired
p77276
sg70045
I8
sg70054
VC0684336
p77277
sg70048
I1
sa(dp77278
g70042
I121
sg70043
Vdeficit
p77279
sg70045
I7
sg70054
VC0162429
p77280
sg70048
I1
sa(dp77281
g70042
I98
sg70043
Voxidative stress
p77282
sg70045
I16
sg70054
VC0242606
p77283
sg70048
I2
sasa(dp77284
g135
(dp77285
(Vchronic renal failure
p77286
VCRF
p77287
tp77288
I00
ssg70037
VIf true, plasma L-arg should be severely reduced in chronic renal failure (CRF); however, plasma L-arg is frequently unchanged in CRF.
p77289
sg70039
(lp77290
(dp77291
g70042
I75
sg70043
VCRF
p77292
sg70045
I3
sg70046
VP06850
p77293
sg70048
I1
sa(dp77294
g70042
I52
sg70043
g77286
sg70045
I21
sg70046
VP06850
p77295
sg70048
I3
sasg70051
(lp77296
(dp77297
g70042
I75
sg70043
VCRF
p77298
sg70045
I3
sg70054
VC0022661
p77299
sg70048
I1
sa(dp77300
g70042
I52
sg70043
Vchronic renal failure
p77301
sg70045
I21
sg70054
VC0022661
p77302
sg70048
I3
sa(dp77303
g70042
I75
sg70043
g77287
sg70045
I3
sg70054
VC0022661
p77304
sg70048
I1
sasa(dp77305
g70037
Vl-arg, by its cytoprotective effect, maintained the thiol status, thereby preserving the activities of the membrane bound ATPases and preventing proteinuria and subsequent weight loss in EG-treated rats.
p77306
sg70039
(lp77307
(dp77308
g70042
I122
sg70043
VATPases
p77309
sg70045
I7
sg70046
VP05026
p77310
sg70048
I1
sasg70051
(lp77311
sa(dp77312
g135
(dp77313
(Venkephalinase
p77314
Vanalgesia
p77315
tp77316
I00
ssg70037
VAs expected, a physiological analgesia is produced by administration of inhibitors, especially kelatorphan and analogues, demonstrating unambiguously the implication of enkephalinase and aminopeptidase M in enkephalin metabolism.
p77317
sg70039
(lp77318
(dp77319
g70042
I187
sg70043
Vaminopeptidase M
p77320
sg70045
I16
sg70046
VP15144
p77321
sg70048
I2
sa(dp77322
g70042
I169
sg70043
g77314
sg70045
I13
sg70046
VP08473
p77323
sg70048
I1
sasg70051
(lp77324
(dp77325
g70042
I29
sg70043
g77315
sg70045
I9
sg70054
VC0344307
p77326
sg70048
I1
sasa(dp77327
g135
(dp77328
(Vanti-dipeptidylpeptidase IV
p77329
Vautism
p77330
tp77331
I01
ssg70037
VAssociated with antigliadin and anti-HSP antibodies, children with autism and patients with autoimmune disease developed anti-dipeptidylpeptidase I (DPP I), anti-dipeptidylpeptidase IV (DPP IV [or CD26]) and anti-aminopeptidase N (CD13) autoantibodies.
p77332
sg70039
(lp77333
(dp77334
g70042
I32
sg70043
Vanti-HSP antibodies
p77335
sg70045
I19
sg70046
g12
sg70048
I2
sa(dp77336
g70042
I149
sg70043
VDPP I
p77337
sg70045
I5
sg70046
g12
sg70048
I2
sa(dp77338
g70042
I121
sg70043
Vanti-dipeptidylpeptidase I
p77339
sg70045
I26
sg70046
g12
sg70048
I2
sa(dp77340
g70042
I208
sg70043
Vanti-aminopeptidase N
p77341
sg70045
I21
sg70046
VP15144
p77342
sg70048
I2
sa(dp77343
g70042
I231
sg70043
VCD13
p77344
sg70045
I4
sg70046
VP15144
p77345
sg70048
I1
sa(dp77346
g70042
I186
sg70043
VDPP IV
p77347
sg70045
I6
sg70046
VP27487
p77348
sg70048
I2
sa(dp77349
g70042
I157
sg70043
g77329
sg70045
I27
sg70046
VP27487
p77350
sg70048
I2
sasg70051
(lp77351
(dp77352
g70042
I92
sg70043
Vautoimmune disease
p77353
sg70045
I18
sg70054
VC0004364
p77354
sg70048
I2
sa(dp77355
g70042
I37
sg70043
VHSP
p77356
sg70045
I3
sg70054
VC0034152
p77357
sg70048
I1
sa(dp77358
g70042
I67
sg70043
g77330
sg70045
I6
sg70054
VC0004352
p77359
sg70048
I1
sasa(dp77360
g70037
VWe therefore investigated plasma ApN in anorexia nervosa (AN).
p77361
sg70039
(lp77362
sg70051
(lp77363
(dp77364
g70042
I58
sg70043
VAN
p77365
sg70045
I2
sg70054
VC0003125
p77366
sg70048
I1
sa(dp77367
g70042
I40
sg70043
Vanorexia nervosa
p77368
sg70045
I16
sg70054
VC0003125
p77369
sg70048
I2
sasa(dp77370
g70037
VThe observed ocular comorbidities included nystagmus (36.7%, 18/49), vitreous opacity (28.6%, 14/49), foveal hypoplasia (20.4%, 10/49), ametropia (12.2%, 6/49), exotropia (12.2%, 6/49), congenital glaucoma (12.2%, 6/49), esotropia (4.1%, 2/49), congenital ptosis (4.1%, 2/49), lens ectopia (4.1%, 2/49), scleral staphyloma (2.0%, 1/49) and pigmentary degeneration of retina (2.0%, 1/49).
p77371
sg70039
(lp77372
sg70051
(lp77373
(dp77374
g70042
I351
sg70043
Vdegeneration of retina
p77375
sg70045
I22
sg70054
VC0035304
p77376
sg70048
I3
sa(dp77377
g70042
I186
sg70043
Vcongenital glaucoma
p77378
sg70045
I19
sg70054
VC0020302
p77379
sg70048
I2
sa(dp77380
g70042
I340
sg70043
Vpigmentary degeneration
p77381
sg70045
I23
sg70054
VC0333446
p77382
sg70048
I2
sa(dp77383
g70042
I245
sg70043
Vcongenital ptosis
p77384
sg70045
I17
sg70054
VC0266573
p77385
sg70048
I2
sa(dp77386
g70042
I161
sg70043
Vexotropia
p77387
sg70045
I9
sg70054
VC0015310
p77388
sg70048
I1
sa(dp77389
g70042
I109
sg70043
Vhypoplasia
p77390
sg70045
I10
sg70054
VC0243069
p77391
sg70048
I1
sa(dp77392
g70042
I221
sg70043
Vesotropia
p77393
sg70045
I9
sg70054
VC0014877
p77394
sg70048
I1
sa(dp77395
g70042
I136
sg70043
Vametropia
p77396
sg70045
I9
sg70054
VC1527310
p77397
sg70048
I1
sa(dp77398
g70042
I43
sg70043
Vnystagmus
p77399
sg70045
I9
sg70054
VC0028738
p77400
sg70048
I1
sa(dp77401
g70042
I78
sg70043
Vopacity
p77402
sg70045
I7
sg70054
VC1265876
p77403
sg70048
I1
sa(dp77404
g70042
I304
sg70043
Vscleral staphyloma
p77405
sg70045
I18
sg70054
VC0155359
p77406
sg70048
I2
sa(dp77407
g70042
I282
sg70043
Vectopia
p77408
sg70045
I7
sg70054
VC1562630
p77409
sg70048
I1
sasa(dp77410
g70037
VThe common eye disorders for which genetic testing is commonly requested are briefly discussed - anophthalmia, microphthalmia, coloboma, anterior segment dysgenesis, corneal dystrophies, cataracts, optic atrophy, congenital glaucoma, congenital amaurosis, retinitis pigmentosa, color blindness, juvenile retinoshisis, retinoblastoma etc.
p77411
sg70039
(lp77412
(dp77413
g70042
I318
sg70043
Vretinoblastoma etc
p77414
sg70045
I18
sg70046
g12
sg70048
I2
sasg70051
(lp77415
(dp77416
g70042
I97
sg70043
Vanophthalmia
p77417
sg70045
I12
sg70054
VC0003119
p77418
sg70048
I1
sa(dp77419
g70042
I318
sg70043
Vretinoblastoma
p77420
sg70045
I14
sg70054
VC0035335
p77421
sg70048
I1
sa(dp77422
g70042
I256
sg70043
Vretinitis pigmentosa
p77423
sg70045
I20
sg70054
VC0035334
p77424
sg70048
I2
sa(dp77425
g70042
I137
sg70043
Vanterior segment dysgenesis
p77426
sg70045
I27
sg70054
VC0266525
p77427
sg70048
I3
sa(dp77428
g70042
I245
sg70043
Vamaurosis
p77429
sg70045
I9
sg70054
VC0376288
p77430
sg70048
I1
sa(dp77431
g70042
I166
sg70043
Vcorneal dystrophies
p77432
sg70045
I19
sg70054
VC0010036
p77433
sg70048
I2
sa(dp77434
g70042
I187
sg70043
Vcataracts
p77435
sg70045
I9
sg70054
VC0521707
p77436
sg70048
I1
sa(dp77437
g70042
I198
sg70043
Voptic atrophy
p77438
sg70045
I13
sg70054
VC0029124
p77439
sg70048
I2
sa(dp77440
g70042
I224
sg70043
Vglaucoma, congenital
p77441
sg70045
I20
sg70054
VC0020302
p77442
sg70048
I2
sa(dp77443
g70042
I111
sg70043
Vmicrophthalmia
p77444
sg70045
I14
sg70054
VC0026010
p77445
sg70048
I1
sa(dp77446
g70042
I278
sg70043
Vcolor blindness
p77447
sg70045
I15
sg70054
VC0242225
p77448
sg70048
I2
sa(dp77449
g70042
I127
sg70043
Vcoloboma
p77450
sg70045
I8
sg70054
VC0009363
p77451
sg70048
I1
sa(dp77452
g70042
I11
sg70043
Veye disorders
p77453
sg70045
I13
sg70054
VC0015397
p77454
sg70048
I2
sasa(dp77455
g70037
VThe anatomical causes of blindness include optic nerve disorders in 75 (24.8%) cases, retinal disorders in 55 (18.2%), corneal disorders in 47 (15.6%), lens-related disorders in 39 (12.9%), congenital anomalies in 11 (3.6%), and congenital glaucoma in 20 (6.6%) cases.
p77456
sg70039
(lp77457
sg70051
(lp77458
(dp77459
g70042
I86
sg70043
Vretinal disorders
p77460
sg70045
I17
sg70054
VC0035309
p77461
sg70048
I2
sa(dp77462
g70042
I190
sg70043
Vcongenital anomalies
p77463
sg70045
I20
sg70054
VC0000768
p77464
sg70048
I2
sa(dp77465
g70042
I119
sg70043
Vcorneal disorders
p77466
sg70045
I17
sg70054
VC0010034
p77467
sg70048
I2
sa(dp77468
g70042
I229
sg70043
Vcongenital glaucoma
p77469
sg70045
I19
sg70054
VC0020302
p77470
sg70048
I2
sa(dp77471
g70042
I25
sg70043
Vblindness
p77472
sg70045
I9
sg70054
VC0456909
p77473
sg70048
I1
sa(dp77474
g70042
I43
sg70043
Voptic nerve disorders
p77475
sg70045
I21
sg70054
VC0029132
p77476
sg70048
I3
sasa(dp77477
g70037
VAmong conditions causing blindness, optic atrophy seen in 73 (24.17%) cases was the most common, followed by retinal dystrophy in 44 (14.56%), corneal scarring in 35 (11.59%), cataract in 22 (7.28%), and congenital glaucoma in 20 (6.6%) cases.
p77478
sg70039
(lp77479
sg70051
(lp77480
(dp77481
g70042
I36
sg70043
Voptic atrophy
p77482
sg70045
I13
sg70054
VC0029124
p77483
sg70048
I2
sa(dp77484
g70042
I151
sg70043
Vscarring
p77485
sg70045
I8
sg70054
VC0008767
p77486
sg70048
I1
sa(dp77487
g70042
I204
sg70043
Vcongenital glaucoma
p77488
sg70045
I19
sg70054
VC0020302
p77489
sg70048
I2
sa(dp77490
g70042
I176
sg70043
Vcataract
p77491
sg70045
I8
sg70054
VC0086543
p77492
sg70048
I1
sa(dp77493
g70042
I109
sg70043
Vretinal dystrophy
p77494
sg70045
I17
sg70054
VC0854723
p77495
sg70048
I2
sa(dp77496
g70042
I25
sg70043
Vblindness
p77497
sg70045
I9
sg70054
VC0456909
p77498
sg70048
I1
sasa(dp77499
g70037
VOther abnormalities included vitreous hemorrhage (n=1), congenital glaucoma (n=2), uveal coloboma (n=2), retinopathy mimicking retinopathy of prematurity (n=2), and cystic fovea (n=3).
p77500
sg70039
(lp77501
sg70051
(lp77502
(dp77503
g70042
I29
sg70043
Vvitreous hemorrhage
p77504
sg70045
I19
sg70054
VC0042909
p77505
sg70048
I2
sa(dp77506
g70042
I89
sg70043
Vcoloboma
p77507
sg70045
I8
sg70054
VC0009363
p77508
sg70048
I1
sa(dp77509
g70042
I105
sg70043
Vretinopathy
p77510
sg70045
I11
sg70054
VC0035309
p77511
sg70048
I1
sa(dp77512
g70042
I56
sg70043
Vcongenital glaucoma
p77513
sg70045
I19
sg70054
VC0020302
p77514
sg70048
I2
sa(dp77515
g70042
I127
sg70043
Vretinopathy of prematurity
p77516
sg70045
I26
sg70054
VC0035344
p77517
sg70048
I3
sasa(dp77518
g70037
VPrimary congenital glaucoma (PCG) is isolated, non-syndromic glaucoma that occurs in the first three years of life and is a major cause of childhood blindness.
p77519
sg70039
(lp77520
sg70051
(lp77521
(dp77522
g70042
I19
sg70043
Vglaucoma
p77523
sg70045
I8
sg70054
VC0017601
p77524
sg70048
I1
sa(dp77525
g70042
I149
sg70043
Vblindness
p77526
sg70045
I9
sg70054
VC0456909
p77527
sg70048
I1
sa(dp77528
g70042
I0
sg70043
VPrimary congenital glaucoma
p77529
sg70045
I27
sg70054
VC1533041
p77530
sg70048
I3
sa(dp77531
g70042
I29
sg70043
VPCG
p77532
sg70045
I3
sg70054
VC1533041
p77533
sg70048
I1
sasa(dp77534
g70037
VThe purpose of the present study is to investigate the association between the polymorphisms in AXIN1 with susceptibility to clear cell renal cell carcinoma (ccRCC).
p77535
sg70039
(lp77536
(dp77537
g70042
I96
sg70043
VAXIN1
p77538
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp77539
(dp77540
g70042
I158
sg70043
VccRCC
p77541
sg70045
I5
sg70054
VC0279702
p77542
sg70048
I1
sa(dp77543
g70042
I125
sg70043
Vclear cell renal cell carcinoma
p77544
sg70045
I31
sg70054
VC0279702
p77545
sg70048
I5
sasa(dp77546
g135
(dp77547
(VBeta-catenin
p77548
Vmelanoma
p77549
tp77550
I00
ssg70037
VIn both cultured melanoma cell lines and in vivo in melanoma cell-derived tumor xenografts, 1-benzyl-I3C disrupted canonical Wnt/Beta-catenin signaling that resulted in the down regulation of Beta-catenin protein levels with a concomitant increase in levels of the Beta-catenin destruction complex components GSK3Beta and Axin.
p77551
sg70039
(lp77552
(dp77553
g70042
I192
sg70043
VBeta-catenin protein
p77554
sg70045
I20
sg70046
VP35222
p77555
sg70048
I2
sa(dp77556
g70042
I129
sg70043
g77548
sg70045
I12
sg70046
VP35222
p77557
sg70048
I1
sa(dp77558
g70042
I322
sg70043
VAxin
p77559
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp77560
(dp77561
g70042
I74
sg70043
Vtumor
p77562
sg70045
I5
sg70054
VC0027651
p77563
sg70048
I1
sa(dp77564
g70042
I17
sg70043
Vmelanoma
p77565
sg70045
I8
sg70054
VC0025202
p77566
sg70048
I1
sa(dp77567
g70042
I17
sg70043
g77549
sg70045
I8
sg70054
VC0025202
p77568
sg70048
I1
sasa(dp77569
g70037
VHere, we showed that SKL2001, which has been identified as an activator for Wnt signaling by disrupting the Axin/Beta-Catenin complex, negatively regulates growth of colon cancer spheroids cultured in the 3D condition that simulates tumor microenvironment in vivo.
p77570
sg70039
(lp77571
(dp77572
g70042
I108
sg70043
VAxin
p77573
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp77574
(dp77575
g70042
I233
sg70043
Vtumor
p77576
sg70045
I5
sg70054
VC0027651
p77577
sg70048
I1
sa(dp77578
g70042
I166
sg70043
Vcolon cancer
p77579
sg70045
I12
sg70054
VC0699790
p77580
sg70048
I2
sa(dp77581
g70042
I208
sg70043
Vcondition
p77582
sg70045
I9
sg70054
VC0012634
p77583
sg70048
I1
sasa(dp77584
g70037
VDefective lysosomal function defines many neurodegenerative diseases, such as neuronal ceroid lipofuscinoses (NCL) and Niemann-Pick type C (NPC), and is implicated in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD-TDP) with progranulin (PGRN) deficiency.
p77585
sg70039
(lp77586
(dp77587
g70042
I140
sg70043
VNPC
p77588
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp77589
g70042
I119
sg70043
VNiemann-Pick type C
p77590
sg70045
I19
sg70046
g12
sg70048
I3
sasg70051
(lp77591
(dp77592
g70042
I231
sg70043
VFTLD
p77593
sg70045
I4
sg70054
VC0751072
p77594
sg70048
I1
sa(dp77595
g70042
I167
sg70043
VAlzheimer's disease
p77596
sg70045
I19
sg70054
VC1521724
p77597
sg70048
I2
sa(dp77598
g70042
I110
sg70043
VNCL
p77599
sg70045
I3
sg70054
VC0027877
p77600
sg70048
I1
sa(dp77601
g70042
I140
sg70043
VNPC
p77602
sg70045
I3
sg70054
VC2931822
p77603
sg70048
I1
sa(dp77604
g70042
I188
sg70043
VAD
p77605
sg70045
I2
sg70054
VC1521724
p77606
sg70048
I1
sa(dp77607
g70042
I196
sg70043
Vfrontotemporal lobar degeneration
p77608
sg70045
I33
sg70054
VC0751072
p77609
sg70048
I3
sa(dp77610
g70042
I119
sg70043
VNiemann-Pick type C
p77611
sg70045
I19
sg70054
VC2931822
p77612
sg70048
I3
sa(dp77613
g70042
I78
sg70043
Vneuronal ceroid lipofuscinoses
p77614
sg70045
I30
sg70054
VC0027877
p77615
sg70048
I3
sa(dp77616
g70042
I42
sg70043
Vneurodegenerative diseases
p77617
sg70045
I26
sg70054
VC0524851
p77618
sg70048
I2
sasa(dp77619
g70037
VMoreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease.
p77620
sg70039
(lp77621
sg70051
(lp77622
(dp77623
g70042
I117
sg70043
Vpathology
p77624
sg70045
I9
sg70054
VC0677042
p77625
sg70048
I1
sa(dp77626
g70042
I80
sg70043
Vneurodegenerative disorders
p77627
sg70045
I27
sg70054
VC0524851
p77628
sg70048
I2
sa(dp77629
g70042
I138
sg70043
VAlzheimer's disease
p77630
sg70045
I19
sg70054
VC1521724
p77631
sg70048
I2
sasa(dp77632
g70037
VTogether, these critical roles in the CNS suggest that PGRN has the potential to be an important therapeutic target for the treatment of various neurodegenerative disorders, particularly Alzheimer's disease (AD).
p77633
sg70039
(lp77634
sg70051
(lp77635
(dp77636
g70042
I187
sg70043
VAlzheimer's disease
p77637
sg70045
I19
sg70054
VC1521724
p77638
sg70048
I2
sa(dp77639
g70042
I145
sg70043
Vneurodegenerative disorders
p77640
sg70045
I27
sg70054
VC0524851
p77641
sg70048
I2
sa(dp77642
g70042
I208
sg70043
VAD
p77643
sg70045
I2
sg70054
VC1521724
p77644
sg70048
I1
sasa(dp77645
g70037
VPathological examination revealed Alzheimer's disease in three cases (all LPA), pathological PSP in two cases (one clinical PSP and one PNFA) and corticobasal degeneration in one case (PNFA).
p77646
sg70039
(lp77647
sg70051
(lp77648
(dp77649
g70042
I93
sg70043
VPSP
p77650
sg70045
I3
sg70054
VC0038868
p77651
sg70048
I1
sa(dp77652
g70042
I34
sg70043
VAlzheimer's disease
p77653
sg70045
I19
sg70054
VC1521724
p77654
sg70048
I2
sa(dp77655
g70042
I146
sg70043
Vcorticobasal degeneration
p77656
sg70045
I25
sg70054
VC0393570
p77657
sg70048
I2
sa(dp77658
g70042
I93
sg70043
VPSP
p77659
sg70045
I3
sg70054
VC0038868
p77660
sg70048
I1
sasa(dp77661
g70037
VGranulin mutations were initially found in tau-negative patients, though recent findings indicate that these mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease and corticobasal degeneration.
p77662
sg70039
(lp77663
sg70051
(lp77664
(dp77665
g70042
I182
sg70043
Vpathology
p77666
sg70045
I9
sg70054
VC0677042
p77667
sg70048
I1
sa(dp77668
g70042
I227
sg70043
Vcorticobasal degeneration
p77669
sg70045
I25
sg70054
VC0393570
p77670
sg70048
I2
sa(dp77671
g70042
I145
sg70043
Vneurodegenerative disorders
p77672
sg70045
I27
sg70054
VC0524851
p77673
sg70048
I2
sa(dp77674
g70042
I203
sg70043
VAlzheimer's disease
p77675
sg70045
I19
sg70054
VC1521724
p77676
sg70048
I2
sasa(dp77677
g135
(dp77678
(VCEBPG
p77679
Vlung cancer
p77680
tp77681
I00
ssg70037
VInter-individual variation in CCAAT/enhancer binding protein gamma (CEBPG) transcript expression in normal human bronchial epithelial cells (NBEC) is associated with predisposition to lung cancer.
p77682
sg70039
(lp77683
(dp77684
g70042
I30
sg70043
VCCAAT/enhancer binding protein gamma
p77685
sg70045
I36
sg70046
g12
sg70048
I4
sa(dp77686
g70042
I68
sg70043
g77679
sg70045
I5
sg70046
VP53567
p77687
sg70048
I1
sasg70051
(lp77688
(dp77689
g70042
I184
sg70043
g77680
sg70045
I11
sg70054
VC0684249
p77690
sg70048
I2
sasa(dp77691
g135
(dp77692
(VRNA polymerase II
p77693
Vdisequilibrium
p77694
tp77695
I00
ssg70037
VThese data support the hypothesis that genetic variation in linkage disequilibrium with rs2772 influences regulation of CEBPG transcript expression through a trans-effect downstream of RNA polymerase II transcription and confirm that cis-acting genetic variation contributes to inter-individual variation in CEBPG transcript expression in NBEC, which is associated with variation in lung cancer risk.
p77696
sg70039
(lp77697
(dp77698
g70042
I120
sg70043
VCEBPG transcript
p77699
sg70045
I16
sg70046
VP53567
p77700
sg70048
I2
sa(dp77701
g70042
I120
sg70043
VCEBPG transcript
p77702
sg70045
I16
sg70046
VP53567
p77703
sg70048
I2
sa(dp77704
g70042
I185
sg70043
g77693
sg70045
I17
sg70046
VP19388
p77705
sg70048
I3
sasg70051
(lp77706
(dp77707
g70042
I383
sg70043
Vlung cancer
p77708
sg70045
I11
sg70054
VC0684249
p77709
sg70048
I2
sa(dp77710
g70042
I234
sg70043
Vcis
p77711
sg70045
I3
sg70054
VC0007099
p77712
sg70048
I1
sa(dp77713
g70042
I68
sg70043
g77694
sg70045
I14
sg70054
VC0394006
p77714
sg70048
I1
sasa(dp77715
g135
(dp77716
(VGPX1
p77717
Vlung cancer
p77718
tp77719
I00
ssg70037
VIn an effort to develop a biomarker for lung cancer risk, we evaluated the transcript expressions of 14 antioxidant, DNA repair, and transcription factor genes in normal bronchial epithelial cells (HUGO names CAT, CEBPG, E2F1, ERCC4, ERCC5, GPX1, GPX3, GSTM3, GSTP1, GSTT1, GSTZ1, MGST1, SOD1, and XRCC1).
p77720
sg70039
(lp77721
(dp77722
g70042
I227
sg70043
VERCC4
p77723
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77724
g70042
I209
sg70043
VCAT
p77725
sg70045
I3
sg70046
VP04040
p77726
sg70048
I1
sa(dp77727
g70042
I234
sg70043
VERCC5
p77728
sg70045
I5
sg70046
VP28715
p77729
sg70048
I1
sa(dp77730
g70042
I274
sg70043
VGSTZ1
p77731
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77732
g70042
I214
sg70043
VCEBPG
p77733
sg70045
I5
sg70046
VP53567
p77734
sg70048
I1
sa(dp77735
g70042
I221
sg70043
VE2F1
p77736
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp77737
g70042
I267
sg70043
VGSTT1
p77738
sg70045
I5
sg70046
VP30711
p77739
sg70048
I1
sa(dp77740
g70042
I260
sg70043
VGSTP1
p77741
sg70045
I5
sg70046
VP09211
p77742
sg70048
I1
sa(dp77743
g70042
I288
sg70043
VSOD1
p77744
sg70045
I4
sg70046
VP00441
p77745
sg70048
I1
sa(dp77746
g70042
I298
sg70043
VXRCC1
p77747
sg70045
I5
sg70046
VP18887
p77748
sg70048
I1
sa(dp77749
g70042
I253
sg70043
VGSTM3
p77750
sg70045
I5
sg70046
VP21266
p77751
sg70048
I1
sa(dp77752
g70042
I281
sg70043
VMGST1
p77753
sg70045
I5
sg70046
VP10620
p77754
sg70048
I1
sa(dp77755
g70042
I247
sg70043
VGPX3
p77756
sg70045
I4
sg70046
VP22352
p77757
sg70048
I1
sa(dp77758
g70042
I241
sg70043
g77717
sg70045
I4
sg70046
VP07203
p77759
sg70048
I1
sasg70051
(lp77760
(dp77761
g70042
I40
sg70043
g77718
sg70045
I11
sg70054
VC0684249
p77762
sg70048
I2
sasa(dp77763
g70037
VWe sought to review English language research articles examining the presence, clinical significance, and/or pathophysiology of MM in Parkinson's disease (PD), corticobasal syndrome (CBS), essential tremor (ET), focal hand dystonia, Creutzfeldt-Jakob's disease (CJD), and Huntington's disease.
p77764
sg70039
(lp77765
sg70051
(lp77766
(dp77767
g70042
I155
sg70043
VPD
p77768
sg70045
I2
sg70054
VC0030567
p77769
sg70048
I1
sa(dp77770
g70042
I262
sg70043
VCJD
p77771
sg70045
I3
sg70054
VC0022336
p77772
sg70048
I1
sa(dp77773
g70042
I207
sg70043
VET
p77774
sg70045
I2
sg70054
VC0270736
p77775
sg70048
I1
sa(dp77776
g70042
I189
sg70043
Vessential tremor
p77777
sg70045
I16
sg70054
VC0270736
p77778
sg70048
I2
sa(dp77779
g70042
I272
sg70043
VHuntington's disease
p77780
sg70045
I20
sg70054
VC0020179
p77781
sg70048
I2
sa(dp77782
g70042
I173
sg70043
Vsyndrome
p77783
sg70045
I8
sg70054
VC0039082
p77784
sg70048
I1
sa(dp77785
g70042
I212
sg70043
Vfocal hand dystonia
p77786
sg70045
I19
sg70054
VC3267192
p77787
sg70048
I3
sa(dp77788
g70042
I134
sg70043
VParkinson's disease
p77789
sg70045
I19
sg70054
VC0030567
p77790
sg70048
I2
sa(dp77791
g70042
I233
sg70043
VCreutzfeldt-Jakob's disease
p77792
sg70045
I27
sg70054
VC0022336
p77793
sg70048
I2
sasa(dp77794
g70037
VWe report a patient that presented with the corticobasal syndrome (CBS), including progressive dementia, asymmetric parkinsonism associated with constructional and ideomotor apraxia, action myoclonus and focal hand dystonia.
p77795
sg70039
(lp77796
sg70051
(lp77797
(dp77798
g70042
I83
sg70043
Vprogressive dementia
p77799
sg70045
I20
sg70054
VC0743039
p77800
sg70048
I2
sa(dp77801
g70042
I204
sg70043
Vfocal hand dystonia
p77802
sg70045
I19
sg70054
VC3267192
p77803
sg70048
I3
sa(dp77804
g70042
I116
sg70043
Vparkinsonism
p77805
sg70045
I12
sg70054
VC0242422
p77806
sg70048
I1
sa(dp77807
g70042
I183
sg70043
Vaction myoclonus
p77808
sg70045
I16
sg70054
VC0751354
p77809
sg70048
I2
sa(dp77810
g70042
I164
sg70043
Videomotor apraxia
p77811
sg70045
I17
sg70054
VC0234523
p77812
sg70048
I2
sa(dp77813
g70042
I57
sg70043
Vsyndrome
p77814
sg70045
I8
sg70054
VC0039082
p77815
sg70048
I1
sasa(dp77816
g135
(dp77817
(VPTPRC
p77818
VSezary syndrome
p77819
tp77820
I00
ssg70037
VFifteen rearrangements detected in Sezary syndrome patients and SeAx resulted in an expression of new fusion transcripts, nine of them were in frame (EHD1-CAPN12, TMEM66-BAIAP2, MBD4-PTPRC, PTPRC-CPN2, MYB-MBNL1, TFG-GPR128, MAP4K3-FIGLA, DCP1A-CCL27, MBNL1-KIAA2018) and five resulted in ectopic expression of fragments of genes not expressed in normal T-cells (BAIAP2, CPN2, GPR128, CAPN12, FIGLA).
p77821
sg70039
(lp77822
(dp77823
g70042
I150
sg70043
VEHD1
p77824
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp77825
g70042
I163
sg70043
VTMEM66
p77826
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77827
g70042
I190
sg70043
VPTPRC-CPN2
p77828
sg70045
I10
sg70046
VP08575
p77829
sg70048
I1
sa(dp77830
g70042
I232
sg70043
VFIGLA
p77831
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77832
g70042
I217
sg70043
VGPR128
p77833
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77834
g70042
I155
sg70043
VCAPN12
p77835
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77836
g70042
I252
sg70043
VMBNL1-KIAA2018
p77837
sg70045
I14
sg70046
g12
sg70048
I1
sa(dp77838
g70042
I217
sg70043
VGPR128
p77839
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77840
g70042
I178
sg70043
VMBD4
p77841
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp77842
g70042
I232
sg70043
VFIGLA
p77843
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77844
g70042
I155
sg70043
VCAPN12
p77845
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77846
g70042
I225
sg70043
VMAP4K3
p77847
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77848
g70042
I206
sg70043
VMBNL1
p77849
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77850
g70042
I170
sg70043
VBAIAP2
p77851
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77852
g70042
I213
sg70043
VTFG
p77853
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp77854
g70042
I170
sg70043
VBAIAP2
p77855
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77856
g70042
I196
sg70043
VCPN2
p77857
sg70045
I4
sg70046
VP15538
p77858
sg70048
I1
sa(dp77859
g70042
I202
sg70043
VMYB
p77860
sg70045
I3
sg70046
VP10243
p77861
sg70048
I1
sa(dp77862
g70042
I239
sg70043
VDCP1A
p77863
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77864
g70042
I245
sg70043
VCCL27
p77865
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77866
g70042
I183
sg70043
g77818
sg70045
I5
sg70046
VP08575
p77867
sg70048
I1
sasg70051
(lp77868
(dp77869
g70042
I35
sg70043
g77819
sg70045
I15
sg70054
VC0036920
p77870
sg70048
I2
sasa(dp77871
g135
(dp77872
(VNF1
p77873
VNF1
p77874
tp77875
I00
ssg70037
VIn addition, we found eleven potential cancer-related genes with mutations (EZH1, SPOP, NF1, TCF12, IGF2BP3, KMT2C, CNOT1, BRIP1, KDM5C, STAG2 and MAP4K3) that have not been reported in thyroid follicular tumors.
p77876
sg70039
(lp77877
(dp77878
g70042
I123
sg70043
VBRIP1
p77879
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77880
g70042
I82
sg70043
VSPOP
p77881
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp77882
g70042
I137
sg70043
VSTAG2
p77883
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77884
g70042
I109
sg70043
VKMT2C
p77885
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77886
g70042
I130
sg70043
VKDM5C
p77887
sg70045
I5
sg70046
VP41229
p77888
sg70048
I1
sa(dp77889
g70042
I88
sg70043
g77873
sg70045
I3
sg70046
VP21359
p77890
sg70048
I1
sa(dp77891
g70042
I93
sg70043
VTCF12
p77892
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp77893
g70042
I76
sg70043
VEZH1
p77894
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp77895
g70042
I147
sg70043
VMAP4K3
p77896
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77897
g70042
I100
sg70043
VIGF2BP3
p77898
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp77899
(dp77900
g70042
I194
sg70043
Vfollicular tumors
p77901
sg70045
I17
sg70054
VC0474808
p77902
sg70048
I2
sa(dp77903
g70042
I39
sg70043
Vcancer
p77904
sg70045
I6
sg70054
VC0006826
p77905
sg70048
I1
sa(dp77906
g70042
I88
sg70043
g77874
sg70045
I3
sg70054
VC0027831
p77907
sg70048
I1
sasa(dp77908
g135
(dp77909
(VGLK
p77910
VNSCLC
p77911
tp77912
I00
ssg70037
VSince GLK (also named MAP4K3) induces activation of NF-KB, which contributes to tumor progression, we investigated the role of GLK in NSCLC.
p77913
sg70039
(lp77914
(dp77915
g70042
I6
sg70043
VGLK
p77916
sg70045
I3
sg70046
VP35557
p77917
sg70048
I1
sa(dp77918
g70042
I22
sg70043
VMAP4K3
p77919
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77920
g70042
I6
sg70043
g77910
sg70045
I3
sg70046
VP35557
p77921
sg70048
I1
sasg70051
(lp77922
(dp77923
g70042
I80
sg70043
Vtumor progression
p77924
sg70045
I17
sg70054
VC0178874
p77925
sg70048
I2
sa(dp77926
g70042
I134
sg70043
g77911
sg70045
I5
sg70054
VC0007131
p77927
sg70048
I1
sasa(dp77928
g135
(dp77929
(VGLK
p77930
Vstage III NSCLC
p77931
tp77932
I00
ssg70037
VGLK protein levels of 190 samples from pulmonary tissue arrays and 58 pulmonary resection samples from stage I to stage III NSCLC patients were studied using immunohistochemistry or immunoblotting.
p77933
sg70039
(lp77934
(dp77935
g70042
I0
sg70043
g77930
sg70045
I3
sg70046
VP35557
p77936
sg70048
I1
sasg70051
(lp77937
(dp77938
g70042
I114
sg70043
g77931
sg70045
I15
sg70054
VC0278506
p77939
sg70048
I3
sasa(dp77940
g135
(dp77941
(VGLK proteins
p77942
VNSCLC
p77943
tp77944
I00
ssg70037
VHigh levels of GLK proteins were detected in pulmonary tissues from NSCLC patients.
p77945
sg70039
(lp77946
(dp77947
g70042
I15
sg70043
g77942
sg70045
I12
sg70046
VP35557
p77948
sg70048
I2
sasg70051
(lp77949
(dp77950
g70042
I68
sg70043
g77943
sg70045
I5
sg70054
VC0007131
p77951
sg70048
I1
sasa(dp77952
g135
(dp77953
(VGLK protein
p77954
VNSCLC
p77955
tp77956
I00
ssg70037
VElevated GLK protein levels were correlated with increased recurrence risks and poor recurrence-free survival rates in NSCLC patients after adjusting for pathologic stage, smoking status, alcohol status, and EGFR levels.
p77957
sg70039
(lp77958
(dp77959
g70042
I9
sg70043
g77954
sg70045
I11
sg70046
VP35557
p77960
sg70048
I2
sasg70051
(lp77961
(dp77962
g70042
I59
sg70043
Vrecurrence
p77963
sg70045
I10
sg70054
VC1458156
p77964
sg70048
I1
sa(dp77965
g70042
I59
sg70043
Vrecurrence
p77966
sg70045
I10
sg70054
VC1458156
p77967
sg70048
I1
sa(dp77968
g70042
I119
sg70043
g77955
sg70045
I5
sg70054
VC0007131
p77969
sg70048
I1
sasa(dp77970
g135
(dp77971
(VGLK
p77972
VNSCLC
p77973
tp77974
I00
ssg70037
VThus, GLK is a novel prognostic biomarker for NSCLC recurrence.
p77975
sg70039
(lp77976
(dp77977
g70042
I6
sg70043
g77972
sg70045
I3
sg70046
VP35557
p77978
sg70048
I1
sasg70051
(lp77979
(dp77980
g70042
I46
sg70043
g77973
sg70045
I5
sg70054
VC0007131
p77981
sg70048
I1
sa(dp77982
g70042
I52
sg70043
Vrecurrence
p77983
sg70045
I10
sg70054
VC1458156
p77984
sg70048
I1
sasa(dp77985
g135
(dp77986
(VAkt1
p77987
VNf2
p77988
tp77989
I00
ssg70037
VRNA fusion-based CISs were identified corresponding to both DNA-based CISs (Cdkn2a, Mycl1, Nf2, Pten, Sema6d, and Rere) and additional regions strongly associated with cancer that were not observed by LM-PCR (Myc, Akt1, Pth, Csf1r, Fgfr2, Wisp1, Map3k5, and Map4k3).
p77990
sg70039
(lp77991
(dp77992
g70042
I84
sg70043
VMyc
p77993
sg70045
I3
sg70046
VP12524
p77994
sg70048
I1
sa(dp77995
g70042
I258
sg70043
VMap4k3
p77996
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp77997
g70042
I84
sg70043
VMycl1
p77998
sg70045
I5
sg70046
VP12524
p77999
sg70048
I1
sa(dp78000
g70042
I96
sg70043
VPten
p78001
sg70045
I4
sg70046
VP60484
p78002
sg70048
I1
sa(dp78003
g70042
I225
sg70043
VCsf1r
p78004
sg70045
I5
sg70046
VP09619
p78005
sg70048
I1
sa(dp78006
g70042
I220
sg70043
VPth
p78007
sg70045
I3
sg70046
VP01270
p78008
sg70048
I1
sa(dp78009
g70042
I76
sg70043
VCdkn2a
p78010
sg70045
I6
sg70046
VP42771
p78011
sg70048
I1
sa(dp78012
g70042
I239
sg70043
VWisp1
p78013
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp78014
g70042
I17
sg70043
VCISs
p78015
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp78016
g70042
I214
sg70043
g77987
sg70045
I4
sg70046
VP31749
p78017
sg70048
I1
sa(dp78018
g70042
I246
sg70043
VMap3k5
p78019
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp78020
(dp78021
g70042
I168
sg70043
Vcancer
p78022
sg70045
I6
sg70054
VC0006826
p78023
sg70048
I1
sa(dp78024
g70042
I91
sg70043
g77988
sg70045
I3
sg70054
VC0027832
p78025
sg70048
I1
sasa(dp78026
g135
(dp78027
(VPTPRF
p78028
Vbreast cancer
p78029
tp78030
I00
ssg70037
VComputationally, PTPRF, PRKAR2B, MAP4K3, and RICTOR were calculated as highly drug-targetable genes for breast cancer.
p78031
sg70039
(lp78032
(dp78033
g70042
I24
sg70043
VPRKAR2B
p78034
sg70045
I7
sg70046
VP31323
p78035
sg70048
I1
sa(dp78036
g70042
I33
sg70043
VMAP4K3
p78037
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp78038
g70042
I17
sg70043
g78028
sg70045
I5
sg70046
VP10586
p78039
sg70048
I1
sa(dp78040
g70042
I45
sg70043
VRICTOR
p78041
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp78042
(dp78043
g70042
I104
sg70043
g78029
sg70045
I13
sg70054
VC0678222
p78044
sg70048
I2
sasa(dp78045
g70037
VIn the GeparTrio FFPE training cohort, a significant linear correlation between TMSB15A expression and pCR was apparent in triple-negative breast cancer (TNBC) (n=61, P=0.040).
p78046
sg70039
(lp78047
(dp78048
g70042
I80
sg70043
VTMSB15A
p78049
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp78050
(dp78051
g70042
I139
sg70043
Vbreast cancer
p78052
sg70045
I13
sg70054
VC0678222
p78053
sg70048
I2
sasa(dp78054
g70037
VIn normal human prostate and prostate cancer tissues, TMSB15A was the predominant isoform expressed.
p78055
sg70039
(lp78056
sg70051
(lp78057
(dp78058
g70042
I29
sg70043
Vprostate cancer
p78059
sg70045
I15
sg70054
VC0600139
p78060
sg70048
I2
sasa(dp78061
g70037
VIn contrast, normal colon and colon cancer tissue expressed predominantly TMSB15B.
p78062
sg70039
(lp78063
(dp78064
g70042
I74
sg70043
VTMSB15B
p78065
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp78066
(dp78067
g70042
I30
sg70043
Vcolon cancer
p78068
sg70045
I12
sg70054
VC0699790
p78069
sg70048
I2
sasa(dp78070
g135
(dp78071
(Vtransforming growth factor beta 1
p78072
Vbreast cancer
p78073
tp78074
I00
ssg70037
VTreatment of MCF-7 breast cancer cells with transforming growth factor beta 1 repressed TMSB15A expression but had no effect on TMSB15B.
p78075
sg70039
(lp78076
(dp78077
g70042
I88
sg70043
VTMSB15A
p78078
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78079
g70042
I128
sg70043
VTMSB15B
p78080
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78081
g70042
I44
sg70043
g78072
sg70045
I33
sg70046
VP01137
p78082
sg70048
I5
sasg70051
(lp78083
(dp78084
g70042
I19
sg70043
g78073
sg70045
I13
sg70054
VC0678222
p78085
sg70048
I2
sasa(dp78086
g135
(dp78087
(Vepidermal growth factor
p78088
Vprostate cancer
p78089
tp78090
I00
ssg70037
VsiRNA specific to the TMSB15B isoform suppressed cell migration of prostate cancer cells to epidermal growth factor, suggesting a functional role for this second isoform.
p78091
sg70039
(lp78092
(dp78093
g70042
I92
sg70043
g78088
sg70045
I23
sg70046
VP01133
p78094
sg70048
I3
sasg70051
(lp78095
(dp78096
g70042
I67
sg70043
g78089
sg70045
I15
sg70054
VC0600139
p78097
sg70048
I2
sasa(dp78098
g70037
VWe showed earlier that human beta-thymosin 15 (Tb15) is up-regulated in prostate cancer, confirming studies from others that propagated Tb15 as a prostate cancer biomarker.
p78099
sg70039
(lp78100
(dp78101
g70042
I18
sg70043
Vthat human beta-thymosin 15
p78102
sg70045
I27
sg70046
g12
sg70048
I4
sa(dp78103
g70042
I47
sg70043
VTb15
p78104
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp78105
g70042
I47
sg70043
VTb15
p78106
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp78107
(dp78108
g70042
I72
sg70043
Vprostate cancer
p78109
sg70045
I15
sg70054
VC0600139
p78110
sg70048
I2
sa(dp78111
g70042
I72
sg70043
Vprostate cancer
p78112
sg70045
I15
sg70054
VC0600139
p78113
sg70048
I2
sasa(dp78114
g70037
VTb15r is present also in mouse prostate cancer cell lines.
p78115
sg70039
(lp78116
sg70051
(lp78117
(dp78118
g70042
I31
sg70043
Vprostate cancer
p78119
sg70045
I15
sg70054
VC0600139
p78120
sg70048
I2
sasa(dp78121
g70037
VIn those patients with isolated adenopathy the following diagnoses were reached; sarcoidosis 23, TB 15, lymphoma 4, carcinoma 4, no diagnosis 1.
p78122
sg70039
(lp78123
sg70051
(lp78124
(dp78125
g70042
I81
sg70043
Vsarcoidosis
p78126
sg70045
I11
sg70054
VC0036202
p78127
sg70048
I1
sa(dp78128
g70042
I116
sg70043
Vcarcinoma
p78129
sg70045
I9
sg70054
VC0007097
p78130
sg70048
I1
sa(dp78131
g70042
I104
sg70043
Vlymphoma
p78132
sg70045
I8
sg70054
VC0024299
p78133
sg70048
I1
sasa(dp78134
g70037
VHowever, in this report we provide evidence that TbNB, initially identified in human neuroblastoma, is the only Tb isoform upregulated in human prostate cancer and that the Tb15 sequence is not present herein.
p78135
sg70039
(lp78136
(dp78137
g70042
I49
sg70043
VTbNB
p78138
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp78139
g70042
I173
sg70043
VTb15 sequence
p78140
sg70045
I13
sg70046
g12
sg70048
I2
sasg70051
(lp78141
(dp78142
g70042
I144
sg70043
Vprostate cancer
p78143
sg70045
I15
sg70054
VC0600139
p78144
sg70048
I2
sa(dp78145
g70042
I85
sg70043
Vneuroblastoma
p78146
sg70045
I13
sg70054
VC0027819
p78147
sg70048
I1
sasa(dp78148
g135
(dp78149
(Vbeta-thymosin
p78150
Vneuroblastoma
p78151
tp78152
I00
ssg70037
VHuman NB thymosin beta is a beta-thymosin originally found in neuroblastoma.
p78153
sg70039
(lp78154
(dp78155
g70042
I0
sg70043
VHuman NB thymosin beta
p78156
sg70045
I22
sg70046
VP20962
p78157
sg70048
I4
sa(dp78158
g70042
I28
sg70043
g78150
sg70045
I13
sg70046
VP20962
p78159
sg70048
I1
sasg70051
(lp78160
(dp78161
g70042
I62
sg70043
g78151
sg70045
I13
sg70054
VC0027819
p78162
sg70048
I1
sasa(dp78163
g70037
VOur studies provide the first evidence that Upk1b is directly associated with the development of congenital anomalies of the urinary tract (CAKUT), spontaneous age-dependent hydronephrosis, and dysplastic urothelia.
p78164
sg70039
(lp78165
(dp78166
g70042
I44
sg70043
VUpk1b
p78167
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp78168
(dp78169
g70042
I97
sg70043
Vcongenital anomalies
p78170
sg70045
I20
sg70054
VC0000768
p78171
sg70048
I2
sa(dp78172
g70042
I140
sg70043
VCAKUT
p78173
sg70045
I5
sg70054
VC1968949
p78174
sg70048
I1
sa(dp78175
g70042
I194
sg70043
Vdysplastic
p78176
sg70045
I10
sg70054
VC0334044
p78177
sg70048
I1
sa(dp78178
g70042
I174
sg70043
Vhydronephrosis
p78179
sg70045
I14
sg70054
VC0020295
p78180
sg70048
I1
sasa(dp78181
g135
(dp78182
(VRFP
p78183
Vhydronephrosis
p78184
tp78185
I00
ssg70037
VUpk1b(RFP/RFP) mice developed age-dependent progressive hydronephrosis.
p78186
sg70039
(lp78187
(dp78188
g70042
I0
sg70043
VUpk1b
p78189
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp78190
g70042
I6
sg70043
VRFP
p78191
sg70045
I3
sg70046
VP25090
p78192
sg70048
I1
sa(dp78193
g70042
I6
sg70043
g78183
sg70045
I3
sg70046
VP25090
p78194
sg70048
I1
sasg70051
(lp78195
(dp78196
g70042
I56
sg70043
g78184
sg70045
I14
sg70054
VC0020295
p78197
sg70048
I1
sasa(dp78198
g70037
VThe aim of the present study was to investigate the role of serotonin (5-hydroxytryptamine) in the rostral ventromedial medulla (RVM) and spinal cord in pain sensory abnormalities in a 6-hydroxydopamine-treated rat model of Parkinson's disease.
p78199
sg70039
(lp78200
sg70051
(lp78201
(dp78202
g70042
I145
sg70043
Vcord
p78203
sg70045
I4
sg70054
VC0035334
p78204
sg70048
I1
sa(dp78205
g70042
I224
sg70043
VParkinson's disease
p78206
sg70045
I19
sg70054
VC0030567
p78207
sg70048
I2
sasa(dp78208
g70037
VConclusions These results suggest that the decreased 5-hydroxytryptamine contents in the rostral ventromedial medulla and spinal dorsal horn may be involved in hyperalgesia in the 6-hydroxydopamine-induced rat model of Parkinson's disease.
p78209
sg70039
(lp78210
sg70051
(lp78211
(dp78212
g70042
I219
sg70043
VParkinson's disease
p78213
sg70045
I19
sg70054
VC0030567
p78214
sg70048
I2
sa(dp78215
g70042
I160
sg70043
Vhyperalgesia
p78216
sg70045
I12
sg70054
VC0020429
p78217
sg70048
I1
sasa(dp78218
g135
(dp78219
(Vserotonin7 (5-HT7) receptors
p78220
Vdepression
p78221
tp78222
I00
ssg70037
VThe role of serotonin7 (5-HT7) receptors in the regulation of depression is poorly understood, particularly in Parkinson's disease-associated depression.
p78223
sg70039
(lp78224
(dp78225
g70042
I12
sg70043
g78220
sg70045
I28
sg70046
VP34969
p78226
sg70048
I3
sasg70051
(lp78227
(dp78228
g70042
I62
sg70043
Vdepression
p78229
sg70045
I10
sg70054
VC0011581
p78230
sg70048
I1
sa(dp78231
g70042
I111
sg70043
VParkinson's disease
p78232
sg70045
I19
sg70054
VC0030567
p78233
sg70048
I2
sa(dp78234
g70042
I62
sg70043
g78221
sg70045
I10
sg70054
VC0011581
p78235
sg70048
I1
sasa(dp78236
g70037
VThe expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4).
p78237
sg70039
(lp78238
(dp78239
g70042
I75
sg70043
VmiR-27a
p78240
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78241
g70042
I148
sg70043
VmiR-221
p78242
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78243
g70042
I67
sg70043
VmiR-21
p78244
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp78245
g70042
I58
sg70043
VmiR-20a
p78246
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78247
g70042
I139
sg70043
VmiR-155
p78248
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78249
g70042
I102
sg70043
VmiR-29c
p78250
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78251
g70042
I93
sg70043
VmiR-29a
p78252
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78253
g70042
I111
sg70043
VmiR-92a
p78254
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78255
g70042
I157
sg70043
VmiR-222
p78256
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78257
g70042
I129
sg70043
VmiR-146a
p78258
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp78259
g70042
I84
sg70043
VmiR-27b
p78260
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78261
g70042
I120
sg70043
VmiR-122
p78262
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp78263
(dp78264
g70042
I21
sg70043
Vfibrosis
p78265
sg70045
I8
sg70054
VC0016059
p78266
sg70048
I1
sa(dp78267
g70042
I253
sg70043
VCHB
p78268
sg70045
I3
sg70054
VC0151517
p78269
sg70048
I1
sa(dp78270
g70042
I21
sg70043
Vfibrosis
p78271
sg70045
I8
sg70054
VC0016059
p78272
sg70048
I1
sa(dp78273
g70042
I316
sg70043
Vcirrhosis
p78274
sg70045
I9
sg70054
VC0023890
p78275
sg70048
I1
sasa(dp78276
g70037
VFor this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples.
p78277
sg70039
(lp78278
(dp78279
g70042
I60
sg70043
VmiR-92a-3p
p78280
sg70045
I10
sg70046
g12
sg70048
I1
sasg70051
(lp78281
(dp78282
g70042
I359
sg70043
VHCC
p78283
sg70045
I3
sg70054
VC2239176
p78284
sg70048
I1
sa(dp78285
g70042
I319
sg70043
VHBV
p78286
sg70045
I3
sg70054
VC0019163
p78287
sg70048
I1
sa(dp78288
g70042
I319
sg70043
VHBV
p78289
sg70045
I3
sg70054
VC0019163
p78290
sg70048
I1
sa(dp78291
g70042
I298
sg70043
Vchronic hepatitis B
p78292
sg70045
I19
sg70054
VC0524909
p78293
sg70048
I3
sa(dp78294
g70042
I332
sg70043
Vcirrhosis
p78295
sg70045
I9
sg70054
VC0023890
p78296
sg70048
I1
sasa(dp78297
g135
(dp78298
(VPFC
p78299
VADHD
p78300
tp78301
I00
ssg70037
VConsistently, Bhlhb2 expression was significantly higher in PFC of ADHD model SHR than control.
p78302
sg70039
(lp78303
(dp78304
g70042
I67
sg70043
VADHD model SHR
p78305
sg70045
I14
sg70046
g12
sg70048
I3
sa(dp78306
g70042
I14
sg70043
VBhlhb2
p78307
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp78308
g70042
I60
sg70043
g78299
sg70045
I3
sg70046
VP27918
p78309
sg70048
I1
sasg70051
(lp78310
(dp78311
g70042
I67
sg70043
g78300
sg70045
I4
sg70054
VC1263846
p78312
sg70048
I1
sasa(dp78313
g135
(dp78314
(VLDHA
p78315
VWTs
p78316
tp78317
I00
ssg70037
VWe examined ANG expression in WTs, human fetal kidney (FK) and childhood kidney (NK) samples and studied its relationship with microvascular density (MVD) and with three other hypoxia-induced angiogenic factors: lactate dehydrogenase A (LDHA), vascular endothelial growth factor (VEGFA) and BHLHE40 (basic helix-loop-helix transcription factor E40).
p78318
sg70039
(lp78319
(dp78320
g70042
I244
sg70043
Vvascular endothelial growth factor
p78321
sg70045
I34
sg70046
g12
sg70048
I4
sa(dp78322
g70042
I291
sg70043
VBHLHE40
p78323
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp78324
g70042
I280
sg70043
VVEGFA
p78325
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp78326
g70042
I212
sg70043
Vlactate dehydrogenase A
p78327
sg70045
I23
sg70046
VP49366
p78328
sg70048
I3
sa(dp78329
g70042
I237
sg70043
g78315
sg70045
I4
sg70046
VP00338
p78330
sg70048
I1
sa(dp78331
g70042
I300
sg70043
Vbasic helix-loop-helix transcription factor E40
p78332
sg70045
I47
sg70046
g12
sg70048
I5
sasg70051
(lp78333
(dp78334
g70042
I176
sg70043
Vhypoxia
p78335
sg70045
I7
sg70054
VC0242184
p78336
sg70048
I1
sa(dp78337
g70042
I30
sg70043
g78316
sg70045
I3
sg70054
VC1839736
p78338
sg70048
I1
sasa(dp78339
g135
(dp78340
(VANG
p78341
VWTs
p78342
tp78343
I00
ssg70037
VANG, CD31, VEGFA and BHLHE40 mRNA levels were significantly lower in 15 WTs compared with matched-paired NKs.
p78344
sg70039
(lp78345
(dp78346
g70042
I0
sg70043
g78341
sg70045
I3
sg70046
VP03950
p78347
sg70048
I1
sa(dp78348
g70042
I5
sg70043
VCD31
p78349
sg70045
I4
sg70046
VP69905
p78350
sg70048
I1
sa(dp78351
g70042
I21
sg70043
VBHLHE40 mRNA
p78352
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp78353
(dp78354
g70042
I72
sg70043
g78342
sg70045
I3
sg70054
VC1839736
p78355
sg70048
I1
sasa(dp78356
g70037
VMutations in the SLC5A5 gene encoding NIS that result in a non-functional protein lead to congenital hypothyroidism due to I- transport defect (ITD).
p78357
sg70039
(lp78358
(dp78359
g70042
I17
sg70043
VSLC5A5 gene encoding NIS
p78360
sg70045
I24
sg70046
g12
sg70048
I4
sasg70051
(lp78361
(dp78362
g70042
I90
sg70043
Vcongenital hypothyroidism
p78363
sg70045
I25
sg70054
VC0342200
p78364
sg70048
I2
sasa(dp78365
g70037
VThyroid concentrates radioactive iodine by sodium-iodide symporter; this is used for treating hyperthyroidism and thyroid cancer.
p78366
sg70039
(lp78367
sg70051
(lp78368
(dp78369
g70042
I94
sg70043
Vhyperthyroidism
p78370
sg70045
I15
sg70054
VC0020550
p78371
sg70048
I1
sa(dp78372
g70042
I114
sg70043
Vthyroid cancer
p78373
sg70045
I14
sg70054
VC0007115
p78374
sg70048
I2
sasa(dp78375
g70037
VIn this study, we investigated the relationship between iodine content and sodium iodide symporter (NIS) expression by using the clinical specimens from patients with nodular goiter and explored the pathogenesis triggered by iodine deficiency in nodular goiter.
p78376
sg70039
(lp78377
(dp78378
g70042
I100
sg70043
VNIS
p78379
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp78380
g70042
I75
sg70043
Vsodium iodide symporter
p78381
sg70045
I23
sg70046
g12
sg70048
I3
sasg70051
(lp78382
(dp78383
g70042
I167
sg70043
Vnodular goiter
p78384
sg70045
I14
sg70054
VC1318500
p78385
sg70048
I2
sa(dp78386
g70042
I167
sg70043
Vnodular goiter
p78387
sg70045
I14
sg70054
VC1318500
p78388
sg70048
I2
sa(dp78389
g70042
I225
sg70043
Viodine deficiency
p78390
sg70045
I17
sg70054
VC0342199
p78391
sg70048
I2
sa(dp78392
g70042
I199
sg70043
Vpathogenesis
p78393
sg70045
I12
sg70054
VC0699748
p78394
sg70048
I1
sasa(dp78395
g135
(dp78396
(Vtumor necrosis factor-Alfa
p78397
Vtumor necrosis
p78398
tp78399
I00
ssg70037
VThe same technique was used for the assays of the hepatic levels of FGF-21, silent information regulator (SIRT1), malondialdehyde (MDA),IL-10, tumor necrosis factor-Alfa (TNF-Alfa) as well as the apoptotic markers; caspase-3 and B-cell lymphoma (Bcl-2).
p78400
sg70039
(lp78401
(dp78402
g70042
I68
sg70043
VFGF-21
p78403
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp78404
g70042
I171
sg70043
VTNF-Alfa
p78405
sg70045
I8
sg70046
VP01375
p78406
sg70048
I1
sa(dp78407
g70042
I215
sg70043
Vcaspase-3
p78408
sg70045
I9
sg70046
VP42574
p78409
sg70048
I1
sa(dp78410
g70042
I106
sg70043
VSIRT1
p78411
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp78412
g70042
I143
sg70043
g78397
sg70045
I26
sg70046
VP01375
p78413
sg70048
I3
sasg70051
(lp78414
(dp78415
g70042
I229
sg70043
VB-cell lymphoma
p78416
sg70045
I15
sg70054
VC0079731
p78417
sg70048
I2
sa(dp78418
g70042
I143
sg70043
g78398
sg70045
I14
sg70054
VC0333516
p78419
sg70048
I2
sasa(dp78420
g135
(dp78421
(VFUS gene
p78422
VALS
p78423
tp78424
I00
ssg70037
VWe report here the case of a 25-year-old woman with a bulbar onset ALS that progressed in less than 12 months to invasive ventilation due to respiratory failure; Genetic screening identified a new mutation in the FUS gene that lies within the last codon.
p78425
sg70039
(lp78426
(dp78427
g70042
I213
sg70043
g78422
sg70045
I8
sg70046
VP35637
p78428
sg70048
I2
sasg70051
(lp78429
(dp78430
g70042
I141
sg70043
Vrespiratory failure
p78431
sg70045
I19
sg70054
VC1145670
p78432
sg70048
I2
sa(dp78433
g70042
I193
sg70043
Vnew mutation
p78434
sg70045
I12
sg70054
VC2985439
p78435
sg70048
I2
sa(dp78436
g70042
I67
sg70043
g78423
sg70045
I3
sg70054
VC0002736
p78437
sg70048
I1
sasa(dp78438
g135
(dp78439
(VGrb2-associated binding 2
p78440
VRCC
p78441
tp78442
I00
ssg70037
VThe expression and biological function of Grb2-associated binding 2 (Gab2) in renal cell carcinoma (RCC) cells was tested here.
p78443
sg70039
(lp78444
(dp78445
g70042
I69
sg70043
VGab2
p78446
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp78447
g70042
I42
sg70043
g78440
sg70045
I25
sg70046
VP62993
p78448
sg70048
I3
sasg70051
(lp78449
(dp78450
g70042
I78
sg70043
Vrenal cell carcinoma
p78451
sg70045
I20
sg70054
VC0007134
p78452
sg70048
I3
sa(dp78453
g70042
I100
sg70043
g78441
sg70045
I3
sg70054
VC0007134
p78454
sg70048
I1
sasa(dp78455
g135
(dp78456
(VRas
p78457
Vbladder cancer
p78458
tp78459
I00
ssg70037
VHowever, the significance of Grb2 and Sos proteins, which is related to EGF-triggered Ras activation, has not been elucidated in human bladder cancer.
p78460
sg70039
(lp78461
(dp78462
g70042
I72
sg70043
VEGF
p78463
sg70045
I3
sg70046
VP01133
p78464
sg70048
I1
sa(dp78465
g70042
I29
sg70043
VGrb2
p78466
sg70045
I4
sg70046
VP62993
p78467
sg70048
I1
sa(dp78468
g70042
I86
sg70043
g78457
sg70045
I3
sg70046
VP01116
p78469
sg70048
I1
sa(dp78470
g70042
I38
sg70043
VSos proteins
p78471
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp78472
(dp78473
g70042
I135
sg70043
g78458
sg70045
I14
sg70054
VC0699885
p78474
sg70048
I2
sasa(dp78475
g135
(dp78476
(VGrb2
p78477
Vbladder cancer
p78478
tp78479
I01
ssg70037
VOn the other hand, expression of Grb2 and Sos proteins was substantially increased in all human bladder cancer cell lines examined in comparison with cultured normal urothelial cells, whether codon 12 of H-ras was mutated or not.
p78480
sg70039
(lp78481
(dp78482
g70042
I42
sg70043
VSos proteins
p78483
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp78484
g70042
I204
sg70043
VH-ras
p78485
sg70045
I5
sg70046
VP01112
p78486
sg70048
I1
sa(dp78487
g70042
I33
sg70043
g78477
sg70045
I4
sg70046
VP62993
p78488
sg70048
I1
sasg70051
(lp78489
(dp78490
g70042
I96
sg70043
g78478
sg70045
I14
sg70054
VC0699885
p78491
sg70048
I2
sasa(dp78492
g135
(dp78493
(VGrb2
p78494
Vcarcinogenesis
p78495
tp78496
I00
ssg70037
VThese results suggest that the amplification of both Grb2 and SOS proteins plays an important role in the carcinogenesis of human bladder cancer.
p78497
sg70039
(lp78498
(dp78499
g70042
I62
sg70043
VSOS proteins
p78500
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp78501
g70042
I53
sg70043
g78494
sg70045
I4
sg70046
VP62993
p78502
sg70048
I1
sasg70051
(lp78503
(dp78504
g70042
I31
sg70043
Vamplification
p78505
sg70045
I13
sg70054
VC1705759
p78506
sg70048
I1
sa(dp78507
g70042
I130
sg70043
Vbladder cancer
p78508
sg70045
I14
sg70054
VC0699885
p78509
sg70048
I2
sa(dp78510
g70042
I106
sg70043
g78495
sg70045
I14
sg70054
VC0596263
p78511
sg70048
I1
sasa(dp78512
g70037
VIn the 32 patients studied, bladder cancer was diagnosed as pTaG1-2 in 8 cases, pT1G2 in 6, pT1G3 in 7, pT2G2-3 in 7, pT3G2-3 in 3 and pT4 in 1 patient.
p78513
sg70039
(lp78514
sg70051
(lp78515
(dp78516
g70042
I28
sg70043
Vbladder cancer
p78517
sg70045
I14
sg70054
VC0699885
p78518
sg70048
I2
sasa(dp78519
g70037
VIn this study, we investigated whether silencing Wnt2B expression could inhibit the invasiveness of ovarian cancer cells and reduce drug resistance.
p78520
sg70039
(lp78521
(dp78522
g70042
I49
sg70043
VWnt2B
p78523
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp78524
(dp78525
g70042
I100
sg70043
Vovarian cancer
p78526
sg70045
I14
sg70054
VC1140680
p78527
sg70048
I2
sasa(dp78528
g70037
VThese data suggest that Wnt2B indeed plays an important role in ovarian cancer metastasis and drug resistance.
p78529
sg70039
(lp78530
(dp78531
g70042
I24
sg70043
VWnt2B
p78532
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp78533
(dp78534
g70042
I64
sg70043
Vovarian cancer
p78535
sg70045
I14
sg70054
VC1140680
p78536
sg70048
I2
sa(dp78537
g70042
I79
sg70043
Vmetastasis
p78538
sg70045
I10
sg70054
VC0027627
p78539
sg70048
I1
sasa(dp78540
g70037
VWNT2B is expressed in several types of human cancer, such as basal cell carcinoma, gastric cancer, breast cancer, head/neck squamous cell carcinoma, cervical cancer and leukemia.
p78541
sg70039
(lp78542
(dp78543
g70042
I0
sg70043
VWNT2B
p78544
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp78545
(dp78546
g70042
I45
sg70043
Vcancer
p78547
sg70045
I6
sg70054
VC0006826
p78548
sg70048
I1
sa(dp78549
g70042
I149
sg70043
Vcervical cancer
p78550
sg70045
I15
sg70054
VC0302592
p78551
sg70048
I2
sa(dp78552
g70042
I91
sg70043
Vcancer, breast
p78553
sg70045
I14
sg70054
VC0006142
p78554
sg70048
I2
sa(dp78555
g70042
I124
sg70043
Vsquamous cell carcinoma
p78556
sg70045
I23
sg70054
VC0007137
p78557
sg70048
I3
sa(dp78558
g70042
I45
sg70043
Vcancer
p78559
sg70045
I6
sg70054
VC0006826
p78560
sg70048
I1
sa(dp78561
g70042
I61
sg70043
Vbasal cell carcinoma
p78562
sg70045
I20
sg70054
VC0007117
p78563
sg70048
I3
sa(dp78564
g70042
I169
sg70043
Vleukemia
p78565
sg70045
I8
sg70054
VC0023418
p78566
sg70048
I1
sasa(dp78567
g70037
VAmong various cancer cell lines, the Wnt-13 mRNA was detected in HeLa (cervical cancer), MKN28 and MKN74 (gastric cancer).
p78568
sg70039
(lp78569
(dp78570
g70042
I37
sg70043
VWnt-13 mRNA
p78571
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp78572
(dp78573
g70042
I14
sg70043
Vcancer
p78574
sg70045
I6
sg70054
VC0006826
p78575
sg70048
I1
sa(dp78576
g70042
I71
sg70043
Vcervical cancer
p78577
sg70045
I15
sg70054
VC0302592
p78578
sg70048
I2
sa(dp78579
g70042
I106
sg70043
Vgastric cancer
p78580
sg70045
I14
sg70054
VC0024623
p78581
sg70048
I2
sasa(dp78582
g70037
VThe receptor protein tyrosine phosphatase PTPRG has been genetically associated with psychiatric disorders and is a ligand for members of the contactin family, which are themselves linked to autism spectrum disorders.
p78583
sg70039
(lp78584
(dp78585
g70042
I142
sg70043
Vcontactin family
p78586
sg70045
I16
sg70046
g12
sg70048
I2
sa(dp78587
g70042
I4
sg70043
Vreceptor protein tyrosine phosphatase PTPRG
p78588
sg70045
I43
sg70046
g12
sg70048
I5
sasg70051
(lp78589
(dp78590
g70042
I191
sg70043
Vautism spectrum disorders
p78591
sg70045
I25
sg70054
VC1510586
p78592
sg70048
I3
sa(dp78593
g70042
I85
sg70043
Vpsychiatric disorders
p78594
sg70045
I21
sg70054
VC0004936
p78595
sg70048
I2
sasa(dp78596
g135
(dp78597
(VPTPRG
p78598
Vschizophrenia
p78599
tp78600
I00
ssg70037
VBased on our finding of a phosphatase-null de novo mutation in PTPRG associated with a case of sporadic schizophrenia, we used PTPRG knockout (KO) mice to model the effect of a loss-of-function mutation.
p78601
sg70039
(lp78602
(dp78603
g70042
I63
sg70043
g78598
sg70045
I5
sg70046
VP23470
p78604
sg70048
I1
sasg70051
(lp78605
(dp78606
g70042
I43
sg70043
Vde novo mutation
p78607
sg70045
I16
sg70054
VC2985439
p78608
sg70048
I3
sa(dp78609
g70042
I104
sg70043
g78599
sg70045
I13
sg70054
VC0036341
p78610
sg70048
I1
sasa(dp78611
g135
(dp78612
(VPTPRG gene
p78613
Vschizophrenia
p78614
tp78615
I00
ssg70037
VThe most notable behavioral consequences of PTPRG gene inactivation were reduced immobilization in the forced swim test, suggestive of some negative symptoms of schizophrenia.
p78616
sg70039
(lp78617
(dp78618
g70042
I44
sg70043
g78613
sg70045
I10
sg70046
VP23470
p78619
sg70048
I2
sasg70051
(lp78620
(dp78621
g70042
I161
sg70043
g78614
sg70045
I13
sg70054
VC0036341
p78622
sg70048
I1
sa(dp78623
g70042
I55
sg70043
Vinactivation
p78624
sg70045
I12
sg70054
VC0544461
p78625
sg70048
I1
sasa(dp78626
g135
(dp78627
(VPTPRG
p78628
VARMS
p78629
tp78630
I00
ssg70037
VThe subgroups significantly differed in important features, including specific working memory deficits for PTPRG (n=5); severe negative symptoms, global cognitive deficits and poor educational attainment, suggesting a developmental disorder, for SLC39A13 (n=4); slow processing speed, childhood attention deficit disorder and milder symptoms for TGM5 (n=4); and global cognitive deficits with good educational attainment suggesting neurodegeneration for ARMS/KIDINS220 (n=5).
p78631
sg70039
(lp78632
(dp78633
g70042
I246
sg70043
VSLC39A13
p78634
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp78635
g70042
I346
sg70043
VTGM5
p78636
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp78637
g70042
I107
sg70043
g78628
sg70045
I5
sg70046
VP23470
p78638
sg70048
I1
sa(dp78639
g70042
I459
sg70043
VKIDINS220
p78640
sg70045
I9
sg70046
g12
sg70048
I1
sasg70051
(lp78641
(dp78642
g70042
I432
sg70043
Vneurodegeneration
p78643
sg70045
I17
sg70054
VC0027746
p78644
sg70048
I1
sa(dp78645
g70042
I153
sg70043
Vcognitive deficits
p78646
sg70045
I18
sg70054
VC0679466
p78647
sg70048
I2
sa(dp78648
g70042
I87
sg70043
Vmemory deficits
p78649
sg70045
I15
sg70054
VC0233794
p78650
sg70048
I2
sa(dp78651
g70042
I295
sg70043
Vattention deficit disorder
p78652
sg70045
I26
sg70054
VC0339002
p78653
sg70048
I3
sa(dp78654
g70042
I153
sg70043
Vcognitive deficits
p78655
sg70045
I18
sg70054
VC0679466
p78656
sg70048
I2
sa(dp78657
g70042
I218
sg70043
Vdevelopmental disorder
p78658
sg70045
I22
sg70054
VC0008073
p78659
sg70048
I2
sa(dp78660
g70042
I454
sg70043
g78629
sg70045
I4
sg70054
VC0206655
p78661
sg70048
I1
sasa(dp78662
g135
(dp78663
(VPTPRG
p78664
Vschizophrenia
p78665
tp78666
I00
ssg70037
VFirst, whole exome sequencing was conducted to identify disruptive de novo mutations in 14 complete parent-offspring trios with sporadic schizophrenia from Jerusalem, which identified 5 sporadic cases with de novo gene mutations in 5 different genes (PTPRG, TGM5, SLC39A13, BTK, CDKN3).
p78667
sg70039
(lp78668
(dp78669
g70042
I258
sg70043
VTGM5
p78670
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp78671
g70042
I264
sg70043
VSLC39A13
p78672
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp78673
g70042
I251
sg70043
g78664
sg70045
I5
sg70046
VP23470
p78674
sg70048
I1
sa(dp78675
g70042
I274
sg70043
VBTK
p78676
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp78677
(dp78678
g70042
I137
sg70043
g78665
sg70045
I13
sg70054
VC0036341
p78679
sg70048
I1
sasa(dp78680
g70037
VNext, targeted exome capture of these genes was conducted in 48 well-characterized, unrelated, ethnically diverse schizophrenia cases, recruited and characterized by the same research team in New York (NY sample), which demonstrated extremely rare and potentially damaging variants in three of the five genes (MAF&lt;0.01) in 12/48 cases (25%); including PTPRG (5 cases), SCL39A13 (4 cases) and TGM5 (4 cases), a higher number than usually identified by whole exome sequencing.
p78681
sg70039
(lp78682
sg70051
(lp78683
(dp78684
g70042
I114
sg70043
Vschizophrenia
p78685
sg70045
I13
sg70054
VC0036341
p78686
sg70048
I1
sasa(dp78687
g70037
VActivated astrocytes were found to be strongly positive for RPTPGamma also in a mice model of Alzheimer's disease.
p78688
sg70039
(lp78689
(dp78690
g70042
I60
sg70043
VRPTPGamma
p78691
sg70045
I9
sg70046
VP23470
p78692
sg70048
I1
sasg70051
(lp78693
(dp78694
g70042
I94
sg70043
VAlzheimer's disease
p78695
sg70045
I19
sg70054
VC1521724
p78696
sg70048
I2
sasa(dp78697
g135
(dp78698
(VCXCL12
p78699
Vtumor necrosis
p78700
tp78701
I00
ssg70037
VAqueous humor (AH) samples from 14 patients with presumed tuberculous uveitis (PTU), and 30 control patients were assayed for the proinflammatory cytokines interleukin IL-4, IL-12, IL-15, IL-17, interferon (IFN)-Gamma, and tumor necrosis factor (TNF)-Alfa, the immunosuppressive cytokine IL-10, and the chemokines GRO-Alfa/CXCL1, IL-8/CXCL8, MIG/CXCL9, IP-10/CXCL10 and SDF-1/CXCL12 with the use of a multiplex assay.
p78702
sg70039
(lp78703
(dp78704
g70042
I342
sg70043
VMIG
p78705
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp78706
g70042
I353
sg70043
VIP-10
p78707
sg70045
I5
sg70046
VP02778
p78708
sg70048
I1
sa(dp78709
g70042
I370
sg70043
VSDF-1
p78710
sg70045
I5
sg70046
VP48061
p78711
sg70048
I1
sa(dp78712
g70042
I314
sg70043
VGRO
p78713
sg70045
I3
sg70046
VP09341
p78714
sg70048
I1
sa(dp78715
g70042
I207
sg70043
VIFN
p78716
sg70045
I3
sg70046
VP01562
p78717
sg70048
I1
sa(dp78718
g70042
I195
sg70043
Vinterferon
p78719
sg70045
I10
sg70046
VP01563
p78720
sg70048
I1
sa(dp78721
g70042
I346
sg70043
VCXCL9
p78722
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp78723
g70042
I156
sg70043
Vinterleukin IL-4
p78724
sg70045
I16
sg70046
VP05112
p78725
sg70048
I2
sa(dp78726
g70042
I223
sg70043
Vtumor necrosis factor (TNF)-Alfa
p78727
sg70045
I32
sg70046
VP01375
p78728
sg70048
I4
sa(dp78729
g70042
I181
sg70043
VIL-15
p78730
sg70045
I5
sg70046
VP40933
p78731
sg70048
I1
sa(dp78732
g70042
I359
sg70043
VCXCL10
p78733
sg70045
I6
sg70046
VP02778
p78734
sg70048
I1
sa(dp78735
g70042
I323
sg70043
VCXCL1
p78736
sg70045
I5
sg70046
VP09341
p78737
sg70048
I1
sa(dp78738
g70042
I376
sg70043
g78699
sg70045
I6
sg70046
VP48061
p78739
sg70048
I1
sasg70051
(lp78740
(dp78741
g70042
I0
sg70043
VAqueous humor
p78742
sg70045
I13
sg70054
VC0595936
p78743
sg70048
I2
sa(dp78744
g70042
I15
sg70043
VAH
p78745
sg70045
I2
sg70054
VC0595936
p78746
sg70048
I1
sa(dp78747
g70042
I58
sg70043
Vtuberculous uveitis
p78748
sg70045
I19
sg70054
VC1281935
p78749
sg70048
I2
sa(dp78750
g70042
I223
sg70043
g78700
sg70045
I14
sg70054
VC0333516
p78751
sg70048
I2
sasa(dp78752
g135
(dp78753
(VCXCL10
p78754
VBD
p78755
tp78756
I00
ssg70037
VAqueous humor (AH) samples from patients with Behcet's disease (BD) (n=29), Vogt-Koyanagi-Harada (VKH) disease (n=21), and HLA-B27-associated uveitis (n=8), and 42 control patients were assayed for the neutrophil chemoattractants CXCL1/GRO-Alfa and CXCL8/IL-8 and the lymphocyte chemoattractants CXCL9/MIG, CXCL10/IP-10 and CXCL12/SDF-1 with the use of a multiplex chemokine assay.
p78757
sg70039
(lp78758
(dp78759
g70042
I331
sg70043
VSDF-1
p78760
sg70045
I5
sg70046
VP48061
p78761
sg70048
I1
sa(dp78762
g70042
I236
sg70043
VGRO
p78763
sg70045
I3
sg70046
VP09341
p78764
sg70048
I1
sa(dp78765
g70042
I314
sg70043
VIP-10
p78766
sg70045
I5
sg70046
VP02778
p78767
sg70048
I1
sa(dp78768
g70042
I296
sg70043
VCXCL9
p78769
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp78770
g70042
I324
sg70043
VCXCL12
p78771
sg70045
I6
sg70046
VP48061
p78772
sg70048
I1
sa(dp78773
g70042
I123
sg70043
VHLA-B27
p78774
sg70045
I7
sg70046
VP30486
p78775
sg70048
I1
sa(dp78776
g70042
I302
sg70043
VMIG
p78777
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp78778
g70042
I230
sg70043
VCXCL1
p78779
sg70045
I5
sg70046
VP09341
p78780
sg70048
I1
sa(dp78781
g70042
I307
sg70043
g78754
sg70045
I6
sg70046
VP02778
p78782
sg70048
I1
sasg70051
(lp78783
(dp78784
g70042
I0
sg70043
VAqueous humor
p78785
sg70045
I13
sg70054
VC0595936
p78786
sg70048
I2
sa(dp78787
g70042
I15
sg70043
VAH
p78788
sg70045
I2
sg70054
VC0595936
p78789
sg70048
I1
sa(dp78790
g70042
I46
sg70043
VBehcet's disease
p78791
sg70045
I16
sg70054
VC0004943
p78792
sg70048
I2
sa(dp78793
g70042
I142
sg70043
Vuveitis
p78794
sg70045
I7
sg70054
VC0042164
p78795
sg70048
I1
sa(dp78796
g70042
I64
sg70043
g78755
sg70045
I2
sg70054
VC0004943
p78797
sg70048
I1
sasa(dp78798
g135
(dp78799
(VGRO-Alfa
p78800
Vuveitis
p78801
tp78802
I00
ssg70037
VIn patients with the same disease activity, AH levels of GRO-Alfa and IP-10 were significantly higher in patients with BD than in patients with VKH disease and HLA-B27-associated uveitis (p=0.0474; p&lt;0.001, respectively).
p78803
sg70039
(lp78804
(dp78805
g70042
I160
sg70043
VHLA-B27
p78806
sg70045
I7
sg70046
VP30486
p78807
sg70048
I1
sa(dp78808
g70042
I70
sg70043
VIP-10
p78809
sg70045
I5
sg70046
VP02778
p78810
sg70048
I1
sa(dp78811
g70042
I57
sg70043
g78800
sg70045
I8
sg70046
VP09341
p78812
sg70048
I1
sasg70051
(lp78813
(dp78814
g70042
I179
sg70043
g78801
sg70045
I7
sg70054
VC0042164
p78815
sg70048
I1
sasa(dp78816
g135
(dp78817
(VIP-10
p78818
Vuveitis
p78819
tp78820
I00
ssg70037
VThese data suggest that GRO-Alfa and IP-10 are the predominant CXC chemokines involved in neutrophil and activated T lymphocyte chemoattraction in endogenous uveitis, particularly in BD.
p78821
sg70039
(lp78822
(dp78823
g70042
I24
sg70043
VGRO
p78824
sg70045
I3
sg70046
VP09341
p78825
sg70048
I1
sa(dp78826
g70042
I37
sg70043
g78818
sg70045
I5
sg70046
VP02778
p78827
sg70048
I1
sasg70051
(lp78828
(dp78829
g70042
I158
sg70043
g78819
sg70045
I7
sg70054
VC0042164
p78830
sg70048
I1
sasa(dp78831
g135
(dp78832
(VGRO
p78833
Vuveitis
p78834
tp78835
I00
ssg70037
VThe purpose of this study was to investigate the role and regulation of the CXC chemokine GRO and the interaction between GRO and IL-8 in LPS-induced uveitis in rabbits.
p78836
sg70039
(lp78837
(dp78838
g70042
I90
sg70043
g78833
sg70045
I3
sg70046
VP09341
p78839
sg70048
I1
sasg70051
(lp78840
(dp78841
g70042
I138
sg70043
VLPS
p78842
sg70045
I3
sg70054
VC0175697
p78843
sg70048
I1
sa(dp78844
g70042
I150
sg70043
g78834
sg70045
I7
sg70054
VC0042164
p78845
sg70048
I1
sasa(dp78846
g135
(dp78847
(VGRO
p78848
VLPS
p78849
tp78850
I00
ssg70037
VTaken together, our results suggest that GRO is an essential mediator for neutrophil infiltration in LPS-induced uveitis in rabbits.
p78851
sg70039
(lp78852
(dp78853
g70042
I41
sg70043
g78848
sg70045
I3
sg70046
VP09341
p78854
sg70048
I1
sasg70051
(lp78855
(dp78856
g70042
I113
sg70043
Vuveitis
p78857
sg70045
I7
sg70054
VC0042164
p78858
sg70048
I1
sa(dp78859
g70042
I101
sg70043
g78849
sg70045
I3
sg70054
VC0175697
p78860
sg70048
I1
sa(dp78861
g70042
I85
sg70043
Vinfiltration
p78862
sg70045
I12
sg70054
VC0332448
p78863
sg70048
I1
sasa(dp78864
g135
(dp78865
(VNa(+)K(+)ATPase
p78866
VMeniere's disease
p78867
tp78868
I00
ssg70037
VNa(+)K(+)ATPase, NKCC1, and alpha-syntrophin were expressed within sensory epithelia and were unaltered in Meniere's disease specimens.
p78869
sg70039
(lp78870
(dp78871
g70042
I17
sg70043
VNKCC1
p78872
sg70045
I5
sg70046
VP55011
p78873
sg70048
I1
sa(dp78874
g70042
I28
sg70043
Valpha-syntrophin
p78875
sg70045
I16
sg70046
g12
sg70048
I1
sa(dp78876
g70042
I0
sg70043
g78866
sg70045
I15
sg70046
VP38606
p78877
sg70048
I1
sasg70051
(lp78878
(dp78879
g70042
I107
sg70043
g78867
sg70045
I17
sg70054
VC0025281
p78880
sg70048
I2
sasa(dp78881
g135
(dp78882
(VHbAc1
p78883
Vdigestive cancer
p78884
tp78885
I00
ssg70037
VAlthough an elevated hemoglobin A1c (HbAc1) level is an independent predictor of worse survival in patients with both digestive cancer and diabetes mellitus, its relationship to short-term prognosis in these patients has not been addressed.
p78886
sg70039
(lp78887
(dp78888
g70042
I37
sg70043
g78883
sg70045
I5
sg70046
VP40145
p78889
sg70048
I1
sa(dp78890
g70042
I21
sg70043
Vhemoglobin A1c
p78891
sg70045
I14
sg70046
g12
sg70048
I2
sasg70051
(lp78892
(dp78893
g70042
I139
sg70043
Vdiabetes mellitus
p78894
sg70045
I17
sg70054
VC0011849
p78895
sg70048
I2
sa(dp78896
g70042
I118
sg70043
g78884
sg70045
I16
sg70054
VC0685938
p78897
sg70048
I2
sasa(dp78898
g135
(dp78899
(VADCY3
p78900
Vadenoma
p78901
tp78902
I00
ssg70037
VWe identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution.
p78903
sg70039
(lp78904
(dp78905
g70042
I163
sg70043
VLAMA1
p78906
sg70045
I5
sg70046
VP25391
p78907
sg70048
I1
sa(dp78908
g70042
I175
sg70043
VAkt
p78909
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp78910
g70042
I112
sg70043
VGPCR
p78911
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp78912
g70042
I170
sg70043
VPI3K
p78913
sg70045
I4
sg70046
VP42336
p78914
sg70048
I1
sa(dp78915
g70042
I105
sg70043
VOR1B1
p78916
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp78917
g70042
I237
sg70043
VCRC
p78918
sg70045
I3
sg70046
VP31749
p78919
sg70048
I1
sa(dp78920
g70042
I202
sg70043
g78900
sg70045
I5
sg70046
VP40145
p78921
sg70048
I1
sasg70051
(lp78922
(dp78923
g70042
I59
sg70043
Vadenoma
p78924
sg70045
I7
sg70054
VC0001430
p78925
sg70048
I1
sa(dp78926
g70042
I237
sg70043
VCRC
p78927
sg70045
I3
sg70054
VC1527249
p78928
sg70048
I1
sa(dp78929
g70042
I59
sg70043
g78901
sg70045
I7
sg70054
VC0001430
p78930
sg70048
I1
sa(dp78931
g70042
I71
sg70043
Vcancer
p78932
sg70045
I6
sg70054
VC0006826
p78933
sg70048
I1
sasa(dp78934
g135
(dp78935
(VNeurofibromatosis type 1
p78936
Vbrain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma
p78937
tp78938
I00
ssg70037
VRecently, we provided human validation for a cooperating oncogenic role for cAMP in brain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma (brain tumor) risk in individuals with Neurofibromatosis type 1 (NF1).
p78939
sg70039
(lp78940
(dp78941
g70042
I230
sg70043
VNF1
p78942
sg70045
I3
sg70046
VP21359
p78943
sg70048
I1
sa(dp78944
g70042
I131
sg70043
VADCY8
p78945
sg70045
I5
sg70046
VP40145
p78946
sg70048
I1
sa(dp78947
g70042
I204
sg70043
g78936
sg70045
I24
sg70046
VP21359
p78948
sg70048
I3
sasg70051
(lp78949
(dp78950
g70042
I230
sg70043
VNF1
p78951
sg70045
I3
sg70054
VC0027831
p78952
sg70048
I1
sa(dp78953
g70042
I84
sg70043
Vbrain tumor
p78954
sg70045
I11
sg70054
VC0006118
p78955
sg70048
I2
sa(dp78956
g70042
I204
sg70043
VNeurofibromatosis type 1
p78957
sg70045
I24
sg70054
VC0027831
p78958
sg70048
I3
sa(dp78959
g70042
I84
sg70043
g78937
sg70045
I80
sg70054
VC0006118
p78960
sg70048
I13
sasa(dp78961
g135
(dp78962
(VADCY8
p78963
Vglioma
p78964
tp78965
I01
ssg70037
VHowever, the cAMP pathway is well-known to be sexually dimorphic, and SNPs in ADCY8 affected glioma risk in a sex-specific fashion, elevating the risk for females while protecting males.
p78966
sg70039
(lp78967
(dp78968
g70042
I78
sg70043
g78963
sg70045
I5
sg70046
VP40145
p78969
sg70048
I1
sasg70051
(lp78970
(dp78971
g70042
I93
sg70043
g78964
sg70045
I6
sg70054
VC0017638
p78972
sg70048
I1
sasa(dp78973
g135
(dp78974
(VNF1
p78975
VNF1
p78976
tp78977
I00
ssg70037
VHere, we report genetic polymorphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that correlate with glioma risk in NF1 in a sex-specific manner, elevating risk in females while reducing risk in males.
p78978
sg70039
(lp78979
(dp78980
g70042
I95
sg70043
VADCY8
p78981
sg70045
I5
sg70046
VP40145
p78982
sg70048
I1
sa(dp78983
g70042
I45
sg70043
Vhuman adenylate cyclase gene adenylate cyclase 8
p78984
sg70045
I48
sg70046
g12
sg70048
I7
sa(dp78985
g70042
I137
sg70043
g78975
sg70045
I3
sg70046
VP21359
p78986
sg70048
I1
sasg70051
(lp78987
(dp78988
g70042
I122
sg70043
Vglioma
p78989
sg70045
I6
sg70054
VC0017638
p78990
sg70048
I1
sa(dp78991
g70042
I137
sg70043
g78976
sg70045
I3
sg70054
VC0027831
p78992
sg70048
I1
sasa(dp78993
g135
(dp78994
(VADCY8
p78995
Vglioma
p78996
tp78997
I01
ssg70037
VOverall, our results establish a sex-specific role for cAMP regulation in human gliomagenesis, specifically identifying ADCY8 as a modifier of glioma risk in NF1.
p78998
sg70039
(lp78999
(dp79000
g70042
I158
sg70043
VNF1
p79001
sg70045
I3
sg70046
VP21359
p79002
sg70048
I1
sa(dp79003
g70042
I120
sg70043
g78995
sg70045
I5
sg70046
VP40145
p79004
sg70048
I1
sasg70051
(lp79005
(dp79006
g70042
I158
sg70043
VNF1
p79007
sg70045
I3
sg70054
VC0027831
p79008
sg70048
I1
sa(dp79009
g70042
I80
sg70043
g78996
sg70045
I6
sg70054
VC0017638
p79010
sg70048
I1
sasa(dp79011
g135
(dp79012
(Vinsulin
p79013
Vhepatoma
p79014
tp79015
I00
ssg70037
VThe effect of insulin on the oxidative desaturation of 1-14C palmitic acid to palmitoleic acid (delta 9 desaturase) 1-14C linoleic acid to alpha-linolenic acid (delta 6 desaturase) on rat liver microsomes and 1-14C eicosa-8,11,14-trienoic acid to arachidonic acid (delta 5 desaturase) on rat liver microsomes and hepatoma tissue culture (HTC) cells was studied.
p79016
sg70039
(lp79017
(dp79018
g70042
I265
sg70043
Vdelta 5 desaturase
p79019
sg70045
I18
sg70046
VP28072
p79020
sg70048
I3
sa(dp79021
g70042
I161
sg70043
Vdelta 6 desaturase
p79022
sg70045
I18
sg70046
VP28072
p79023
sg70048
I3
sa(dp79024
g70042
I14
sg70043
g79013
sg70045
I7
sg70046
VP01308
p79025
sg70048
I1
sasg70051
(lp79026
(dp79027
g70042
I313
sg70043
g79014
sg70045
I8
sg70054
VC0023903
p79028
sg70048
I1
sasa(dp79029
g135
(dp79030
(VDAPK1
p79031
VADC
p79032
tp79033
I00
ssg70037
VMethylation of CALCA, CDH1, DAPK1, and EVX2 was more common in squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC).
p79034
sg70039
(lp79035
(dp79036
g70042
I39
sg70043
VEVX2
p79037
sg70045
I4
sg70046
VP55085
p79038
sg70048
I1
sa(dp79039
g70042
I22
sg70043
VCDH1
p79040
sg70045
I4
sg70046
VP12830
p79041
sg70048
I1
sa(dp79042
g70042
I28
sg70043
g79031
sg70045
I5
sg70046
VP53355
p79043
sg70048
I1
sasg70051
(lp79044
(dp79045
g70042
I89
sg70043
VSCC
p79046
sg70045
I3
sg70054
VC0007137
p79047
sg70048
I1
sa(dp79048
g70042
I63
sg70043
Vsquamous cell carcinomas
p79049
sg70045
I24
sg70054
VC0007137
p79050
sg70048
I3
sa(dp79051
g70042
I106
sg70043
Vadenocarcinomas
p79052
sg70045
I15
sg70054
VC0001418
p79053
sg70048
I1
sa(dp79054
g70042
I123
sg70043
g79032
sg70045
I3
sg70054
VC0001418
p79055
sg70048
I1
sasa(dp79056
g135
(dp79057
(VTIMP3
p79058
VAPC
p79059
tp79060
I00
ssg70037
VOverall, CALCA, DAPK, ESR1, TIMP3, APC and RAR-beta2 promoters were significantly more often hypermethylated in cancers than in controls, while adenocarcinomas were more often hypermethylated above the highest control ratio for APC, TIMP3 and RASSF1A promoters.
p79061
sg70039
(lp79062
(dp79063
g70042
I28
sg70043
VTIMP3
p79064
sg70045
I5
sg70046
VP35625
p79065
sg70048
I1
sa(dp79066
g70042
I35
sg70043
VAPC
p79067
sg70045
I3
sg70046
VP25054
p79068
sg70048
I1
sa(dp79069
g70042
I9
sg70043
VCALCA
p79070
sg70045
I5
sg70046
VP06881
p79071
sg70048
I1
sa(dp79072
g70042
I16
sg70043
VDAPK
p79073
sg70045
I4
sg70046
VP53355
p79074
sg70048
I1
sa(dp79075
g70042
I22
sg70043
VESR1
p79076
sg70045
I4
sg70046
VP03372
p79077
sg70048
I1
sa(dp79078
g70042
I43
sg70043
VRAR-beta2 promoters
p79079
sg70045
I19
sg70046
VP10276
p79080
sg70048
I2
sa(dp79081
g70042
I35
sg70043
VAPC
p79082
sg70045
I3
sg70046
VP25054
p79083
sg70048
I1
sa(dp79084
g70042
I28
sg70043
g79058
sg70045
I5
sg70046
VP35625
p79085
sg70048
I1
sasg70051
(lp79086
(dp79087
g70042
I112
sg70043
Vcancers
p79088
sg70045
I7
sg70054
VC0006826
p79089
sg70048
I1
sa(dp79090
g70042
I144
sg70043
Vadenocarcinomas
p79091
sg70045
I15
sg70054
VC0001418
p79092
sg70048
I1
sa(dp79093
g70042
I35
sg70043
VAPC
p79094
sg70045
I3
sg70054
VC0033036
p79095
sg70048
I1
sa(dp79096
g70042
I35
sg70043
g79059
sg70045
I3
sg70054
VC0033036
p79097
sg70048
I1
sasa(dp79098
g135
(dp79099
(VESR1
p79100
Vpapilloma
p79101
tp79102
I01
ssg70037
VCombining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).
p79103
sg70039
(lp79104
(dp79105
g70042
I26
sg70043
VDAPK
p79106
sg70045
I4
sg70046
VP53355
p79107
sg70048
I1
sa(dp79108
g70042
I19
sg70043
VCALCA
p79109
sg70045
I5
sg70046
VP06881
p79110
sg70048
I1
sa(dp79111
g70042
I0
sg70043
VCombining 4 genes
p79112
sg70045
I17
sg70046
VP01893
p79113
sg70048
I3
sa(dp79114
g70042
I41
sg70043
VAPC
p79115
sg70045
I3
sg70046
VP25054
p79116
sg70048
I1
sa(dp79117
g70042
I32
sg70043
g79100
sg70045
I4
sg70046
VP03372
p79118
sg70048
I1
sasg70051
(lp79119
(dp79120
g70042
I41
sg70043
VAPC
p79121
sg70045
I3
sg70054
VC0033036
p79122
sg70048
I1
sa(dp79123
g70042
I85
sg70043
Vadenocarcinomas
p79124
sg70045
I15
sg70054
VC0001418
p79125
sg70048
I1
sa(dp79126
g70042
I164
sg70043
g79101
sg70045
I9
sg70054
VC0030354
p79127
sg70048
I1
sasa(dp79128
g135
(dp79129
(Vcarcinoembryonic antigen
p79130
Vthyroid tumor
p79131
tp79132
I00
ssg70037
VThe thyroid tumor was diagnosed as metastasis to the thyroid from lung adenocarcinoma, because it showed mucin production, positive immunoreactivity for carcinoembryonic antigen and negative immunoreactivities for thyroglobulin and calcitonin.
p79133
sg70039
(lp79134
(dp79135
g70042
I153
sg70043
g79130
sg70045
I24
sg70046
VP40198
p79136
sg70048
I2
sa(dp79137
g70042
I214
sg70043
Vthyroglobulin
p79138
sg70045
I13
sg70046
g12
sg70048
I1
sa(dp79139
g70042
I105
sg70043
Vmucin
p79140
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp79141
g70042
I232
sg70043
Vcalcitonin
p79142
sg70045
I10
sg70046
VP06881
p79143
sg70048
I1
sasg70051
(lp79144
(dp79145
g70042
I66
sg70043
Vlung adenocarcinoma
p79146
sg70045
I19
sg70054
VC0152013
p79147
sg70048
I2
sa(dp79148
g70042
I4
sg70043
g79131
sg70045
I13
sg70054
VC0040136
p79149
sg70048
I2
sa(dp79150
g70042
I35
sg70043
Vmetastasis to the thyroid
p79151
sg70045
I25
sg70054
VC0347023
p79152
sg70048
I4
sasa(dp79153
g135
(dp79154
(VOct 31
p79155
Vrelapsing-remitting multiple sclerosis
p79156
tp79157
I00
ssg70037
VWe searched Medline for clinical trials that assessed disease-modifying drugs for relapsing-remitting multiple sclerosis published from Sept 1, 2008, to Oct 31, 2012.
p79158
sg70039
(lp79159
(dp79160
g70042
I153
sg70043
g79155
sg70045
I6
sg70046
VP00480
p79161
sg70048
I2
sasg70051
(lp79162
(dp79163
g70042
I82
sg70043
g79156
sg70045
I38
sg70054
VC0751967
p79164
sg70048
I3
sasa(dp79165
g70037
VSEPT1, SEPT4, and SEPT2 have been found in deposits known as neurofibrillary tangles and glial fibrils in Alzheimer's disease.
p79166
sg70039
(lp79167
(dp79168
g70042
I7
sg70043
VSEPT4
p79169
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp79170
g70042
I0
sg70043
VSEPT1
p79171
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp79172
g70042
I18
sg70043
VSEPT2
p79173
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp79174
(dp79175
g70042
I61
sg70043
Vneurofibrillary tangles
p79176
sg70045
I23
sg70054
VC0085400
p79177
sg70048
I2
sa(dp79178
g70042
I106
sg70043
VAlzheimer's disease
p79179
sg70045
I19
sg70054
VC1521724
p79180
sg70048
I2
sasa(dp79181
g135
(dp79182
(VHcrt-1
p79183
VCRF
p79184
tp79185
I00
ssg70037
VFinally, we evaluated the effect of the pro-arousal neuropeptides CRF and Hcrt-1/Ox-A in NPSR-deficient mice.
p79186
sg70039
(lp79187
(dp79188
g70042
I74
sg70043
g79183
sg70045
I6
sg70046
VP50336
p79189
sg70048
I1
sasg70051
(lp79190
(dp79191
g70042
I66
sg70043
g79184
sg70045
I3
sg70054
VC0022661
p79192
sg70048
I1
sasa(dp79193
g135
(dp79194
(VCRF
p79195
VCRF
p79196
tp79197
I00
ssg70037
VThe administration of CRF and Hcrt-1/Ox-A, two classic pro-arousal peptides, elicited the same effects in both NPSR(-/-) and wild type mice, ruling out the possibility that adaptive mechanisms occurring at the level of these two systems could have occurred during NPSR(-/-) development to compensate for the lack of NPSR receptors.
p79198
sg70039
(lp79199
(dp79200
g70042
I30
sg70043
VHcrt-1
p79201
sg70045
I6
sg70046
VP50336
p79202
sg70048
I1
sa(dp79203
g70042
I316
sg70043
VNPSR receptors
p79204
sg70045
I14
sg70046
g12
sg70048
I2
sa(dp79205
g70042
I22
sg70043
g79195
sg70045
I3
sg70046
VP06850
p79206
sg70048
I1
sasg70051
(lp79207
(dp79208
g70042
I22
sg70043
g79196
sg70045
I3
sg70054
VC0022661
p79209
sg70048
I1
sasa(dp79210
g135
(dp79211
(VHcrt-1
p79212
VCRF
p79213
tp79214
I00
ssg70037
VMoreover, we demonstrated that the deletion of NPSR did not lead to compensatory changes in the vigilance-promoting effects of the CRF and Hcrt-1/Ox-A systems.
p79215
sg70039
(lp79216
(dp79217
g70042
I131
sg70043
VCRF
p79218
sg70045
I3
sg70046
VP06850
p79219
sg70048
I1
sa(dp79220
g70042
I139
sg70043
g79212
sg70045
I6
sg70046
VP50336
p79221
sg70048
I1
sasg70051
(lp79222
(dp79223
g70042
I131
sg70043
g79213
sg70045
I3
sg70054
VC0022661
p79224
sg70048
I1
sasa(dp79225
g70037
VWe included all RCTs of any calcimimetic agent, cinacalcet HCl (AMG-073, Sensipar), NPS R-467 or NPS R-568 administered to patients with CKD for the treatment of SHPT.
p79226
sg70039
(lp79227
sg70051
(lp79228
(dp79229
g70042
I84
sg70043
VNPS
p79230
sg70045
I3
sg70054
VC0027341
p79231
sg70048
I1
sa(dp79232
g70042
I84
sg70043
VNPS
p79233
sg70045
I3
sg70054
VC0027341
p79234
sg70048
I1
sasa(dp79235
g70037
VRenal osteodystrophy (RO) due to secondary hyperparathyroidism (HPT) in chronic renal failure was an obvious target for studying the effects of NPS R-568.
p79236
sg70039
(lp79237
sg70051
(lp79238
(dp79239
g70042
I33
sg70043
Vsecondary hyperparathyroidism
p79240
sg70045
I29
sg70054
VC0020503
p79241
sg70048
I2
sa(dp79242
g70042
I22
sg70043
VRO
p79243
sg70045
I2
sg70054
VC0035086
p79244
sg70048
I1
sa(dp79245
g70042
I144
sg70043
VNPS
p79246
sg70045
I3
sg70054
VC0027341
p79247
sg70048
I1
sa(dp79248
g70042
I0
sg70043
VRenal osteodystrophy
p79249
sg70045
I20
sg70054
VC0035086
p79250
sg70048
I2
sa(dp79251
g70042
I72
sg70043
Vchronic renal failure
p79252
sg70045
I21
sg70054
VC0022661
p79253
sg70048
I3
sasa(dp79254
g70037
VChanges in BIS (bispectral index) VISTA bilateral monitoring system associated with intraoperative episodes of generalized and focal seizures, during total intravenous anesthesia for resection of a left frontal parasagittal meningioma, are herein described.
p79255
sg70039
(lp79256
sg70051
(lp79257
(dp79258
g70042
I211
sg70043
Vparasagittal meningioma
p79259
sg70045
I23
sg70054
VC0751304
p79260
sg70048
I2
sa(dp79261
g70042
I127
sg70043
Vfocal seizures
p79262
sg70045
I14
sg70054
VC0751495
p79263
sg70048
I2
sa(dp79264
g70042
I168
sg70043
Vanesthesia
p79265
sg70045
I10
sg70054
VC0278134
p79266
sg70048
I1
sasa(dp79267
g135
(dp79268
(VmTOR
p79269
VFanconi's anemia
p79270
tp79271
I01
ssg70037
VPrevious studies identified a variety of putative target genes from several pathways associated with DNA damage repair, chromatin remodeling complex, PI3K-AKT-mTOR signaling, Notch signaling, cell cycle checkpoint signaling, BRCA-associated complex and Fanconi's anemia susceptibility genes that could be used as biomarkers or therapeutic targets for PARP inhibition.
p79272
sg70039
(lp79273
(dp79274
g70042
I155
sg70043
VAKT
p79275
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp79276
g70042
I351
sg70043
VPARP
p79277
sg70045
I4
sg70046
VP09874
p79278
sg70048
I1
sa(dp79279
g70042
I150
sg70043
VPI3K
p79280
sg70045
I4
sg70046
VP42336
p79281
sg70048
I1
sa(dp79282
g70042
I159
sg70043
g79269
sg70045
I4
sg70046
VP42345
p79283
sg70048
I1
sasg70051
(lp79284
(dp79285
g70042
I101
sg70043
VDNA damage
p79286
sg70045
I10
sg70054
VC0012860
p79287
sg70048
I2
sa(dp79288
g70042
I253
sg70043
g79270
sg70045
I16
sg70054
VC0015625
p79289
sg70048
I2
sasa(dp79290
g135
(dp79291
(VPARP
p79292
Vanemia
p79293
tp79294
I00
ssg70037
VHematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied.
p79295
sg70039
(lp79296
(dp79297
g70042
I106
sg70043
g79292
sg70045
I4
sg70046
VP09874
p79298
sg70048
I1
sasg70051
(lp79299
(dp79300
g70042
I69
sg70043
g79293
sg70045
I6
sg70054
VC0002871
p79301
sg70048
I1
sa(dp79302
g70042
I87
sg70043
Vadverse effects
p79303
sg70045
I15
sg70054
VC0879626
p79304
sg70048
I2
sasa(dp79305
g70037
VA total of 2,479 patients from 12 RCTs revealed that the incidence of PARPi-associated severe hematologic toxicities was, respectively: neutropenia: 32.9% (95% CI, 20.5%-48.3%); thrombocytopenia: 15.9% (95% CI, 9.5%-25.4%), and anemia: 9.1% (95% CI, 5.1%-15.7%).
p79306
sg70039
(lp79307
sg70051
(lp79308
(dp79309
g70042
I228
sg70043
Vanemia
p79310
sg70045
I6
sg70054
VC0002871
p79311
sg70048
I1
sasa(dp79312
g135
(dp79313
(Vadrenocorticotropic hormone
p79314
VCushing's syndrome
p79315
tp79316
I00
ssg70037
VExamples of endocrine syndromes are classical carcinoid syndrome caused by serotonin (measured in the urine as its metabolite 5-HIAA), insulinoma syndrome caused by insulin or proinsulin, Zollinger-Ellison syndrome resulting from gastrin secretion, glucagonoma syndrome caused by glucagon, WDHA syndrome caused by vasoactive intestinal peptide, or Cushing's syndrome resulting from ectopic production of adrenocorticotropic hormone or corticotropin-releasing hormone.
p79317
sg70039
(lp79318
(dp79319
g70042
I230
sg70043
Vgastrin
p79320
sg70045
I7
sg70046
VP01350
p79321
sg70048
I1
sa(dp79322
g70042
I176
sg70043
Vproinsulin
p79323
sg70045
I10
sg70046
VP01308
p79324
sg70048
I1
sa(dp79325
g70042
I435
sg70043
Vcorticotropin-releasing hormone
p79326
sg70045
I31
sg70046
VP06850
p79327
sg70048
I2
sa(dp79328
g70042
I135
sg70043
Vinsulin
p79329
sg70045
I7
sg70046
VP01308
p79330
sg70048
I1
sa(dp79331
g70042
I249
sg70043
Vglucagon
p79332
sg70045
I8
sg70046
VP01275
p79333
sg70048
I1
sa(dp79334
g70042
I404
sg70043
g79314
sg70045
I27
sg70046
VP01189
p79335
sg70048
I2
sasg70051
(lp79336
(dp79337
g70042
I135
sg70043
Vinsulinoma
p79338
sg70045
I10
sg70054
VC0021670
p79339
sg70048
I1
sa(dp79340
g70042
I22
sg70043
Vsyndrome
p79341
sg70045
I8
sg70054
VC0039082
p79342
sg70048
I1
sa(dp79343
g70042
I188
sg70043
VZollinger-Ellison syndrome
p79344
sg70045
I26
sg70054
VC0043515
p79345
sg70048
I2
sa(dp79346
g70042
I22
sg70043
Vsyndromes
p79347
sg70045
I9
sg70054
VC0039082
p79348
sg70048
I1
sa(dp79349
g70042
I46
sg70043
Vcarcinoid syndrome
p79350
sg70045
I18
sg70054
VC0024586
p79351
sg70048
I2
sa(dp79352
g70042
I249
sg70043
Vglucagonoma syndrome
p79353
sg70045
I20
sg70054
VC0017689
p79354
sg70048
I2
sa(dp79355
g70042
I290
sg70043
VWDHA syndrome
p79356
sg70045
I13
sg70054
VC0086768
p79357
sg70048
I2
sa(dp79358
g70042
I348
sg70043
g79315
sg70045
I18
sg70054
VC0010481
p79359
sg70048
I2
sasa(dp79360
g135
(dp79361
(Vvasoactive intestinal peptide
p79362
VCushing's disease
p79363
tp79364
I00
ssg70037
VWe have previously reported and confirmed that vasoactive intestinal peptide (VIP) is a significant stimulator of ACTH and cortisol secretion in at least some patients with Cushing's disease.
p79365
sg70039
(lp79366
(dp79367
g70042
I78
sg70043
VVIP
p79368
sg70045
I3
sg70046
VP01282
p79369
sg70048
I1
sa(dp79370
g70042
I114
sg70043
VACTH
p79371
sg70045
I4
sg70046
VP01189
p79372
sg70048
I1
sa(dp79373
g70042
I47
sg70043
g79362
sg70045
I29
sg70046
VP01282
p79374
sg70048
I3
sasg70051
(lp79375
(dp79376
g70042
I173
sg70043
g79363
sg70045
I17
sg70054
VC0221406
p79377
sg70048
I2
sasa(dp79378
g135
(dp79379
(VVIP
p79380
VCushing's disease
p79381
tp79382
I00
ssg70037
VWe have also found that the hormonal responses to corticotropin-releasing hormone (CRH) in VIP-responsive patients with Cushing's disease were higher than those in VIP non-responders, which suggested a linkage between the actions of CRH and VIP in this disorder.
p79383
sg70039
(lp79384
(dp79385
g70042
I83
sg70043
VCRH
p79386
sg70045
I3
sg70046
VP06850
p79387
sg70048
I1
sa(dp79388
g70042
I50
sg70043
Vcorticotropin-releasing hormone
p79389
sg70045
I31
sg70046
VP06850
p79390
sg70048
I2
sa(dp79391
g70042
I83
sg70043
VCRH
p79392
sg70045
I3
sg70046
VP06850
p79393
sg70048
I1
sa(dp79394
g70042
I91
sg70043
g79380
sg70045
I3
sg70046
VP01282
p79395
sg70048
I1
sasg70051
(lp79396
(dp79397
g70042
I120
sg70043
g79381
sg70045
I17
sg70054
VC0221406
p79398
sg70048
I2
sasa(dp79399
g135
(dp79400
(VCRH
p79401
VCushing's disease
p79402
tp79403
I00
ssg70037
VThis study is the first to demonstrate the parallel inhibition by DEX of ACTH and cortisol responses to CRH and VIP in Cushing's disease.
p79404
sg70039
(lp79405
(dp79406
g70042
I73
sg70043
VACTH
p79407
sg70045
I4
sg70046
VP01189
p79408
sg70048
I1
sa(dp79409
g70042
I112
sg70043
VVIP
p79410
sg70045
I3
sg70046
VP01282
p79411
sg70048
I1
sa(dp79412
g70042
I104
sg70043
g79401
sg70045
I3
sg70046
VP06850
p79413
sg70048
I1
sasg70051
(lp79414
(dp79415
g70042
I119
sg70043
g79402
sg70045
I17
sg70054
VC0221406
p79416
sg70048
I2
sasa(dp79417
g135
(dp79418
(VACTH
p79419
VCushing's disease
p79420
tp79421
I00
ssg70037
VOf the patients with Cushing's disease, 9 (75%) were responsive to hCRH, 5 (42%) were to VIP, and 3 (25%) were to PHM, showing significant increases in both ACTH and cortisol.
p79422
sg70039
(lp79423
(dp79424
g70042
I89
sg70043
VVIP
p79425
sg70045
I3
sg70046
VP01282
p79426
sg70048
I1
sa(dp79427
g70042
I157
sg70043
g79419
sg70045
I4
sg70046
VP01189
p79428
sg70048
I1
sasg70051
(lp79429
(dp79430
g70042
I21
sg70043
g79420
sg70045
I17
sg70054
VC0221406
p79431
sg70048
I2
sasa(dp79432
g135
(dp79433
(VACTH
p79434
VCushing's disease
p79435
tp79436
I00
ssg70037
VIn addition, in the patients with Cushing's disease the coadministration of hCRH with PHM or VIP produced additive increases in both ACTH and cortisol.
p79437
sg70039
(lp79438
(dp79439
g70042
I93
sg70043
VVIP
p79440
sg70045
I3
sg70046
VP01282
p79441
sg70048
I1
sa(dp79442
g70042
I133
sg70043
g79434
sg70045
I4
sg70046
VP01189
p79443
sg70048
I1
sasg70051
(lp79444
(dp79445
g70042
I34
sg70043
g79435
sg70045
I17
sg70054
VC0221406
p79446
sg70048
I2
sasa(dp79447
g135
(dp79448
(VCRH
p79449
VCushing's disease
p79450
tp79451
I00
ssg70037
VAbnormalities in hypothalamic-pituitary adrenal axis function were demonstrated by measuring plasma adrenocorticotropin abnormal concentrations following Vasoactive Intestinal Peptide (VIP) and Corticotropin Releasing Hormone (CRH) administration during a phase of remission of Cushing's disease in a 45-year-old female patient.
p79452
sg70039
(lp79453
(dp79454
g70042
I194
sg70043
VCorticotropin Releasing Hormone
p79455
sg70045
I31
sg70046
VP06850
p79456
sg70048
I3
sa(dp79457
g70042
I100
sg70043
Vadrenocorticotropin
p79458
sg70045
I19
sg70046
VP01189
p79459
sg70048
I1
sa(dp79460
g70042
I185
sg70043
VVIP
p79461
sg70045
I3
sg70046
VP01282
p79462
sg70048
I1
sa(dp79463
g70042
I154
sg70043
VVasoactive Intestinal Peptide
p79464
sg70045
I29
sg70046
VP01282
p79465
sg70048
I3
sa(dp79466
g70042
I227
sg70043
g79449
sg70045
I3
sg70046
VP06850
p79467
sg70048
I1
sasg70051
(lp79468
(dp79469
g70042
I278
sg70043
g79450
sg70045
I17
sg70054
VC0221406
p79470
sg70048
I2
sa(dp79471
g70042
I265
sg70043
Vremission
p79472
sg70045
I9
sg70054
VC0687702
p79473
sg70048
I1
sasa(dp79474
g135
(dp79475
(VVIP
p79476
VCushing's disease
p79477
tp79478
I00
ssg70037
VWe conclude that the study of ACTH and cortisol response to VIP and CRH may be useful in revealing Cushing's disease even during a remission phase of the disorder.
p79479
sg70039
(lp79480
(dp79481
g70042
I68
sg70043
VCRH
p79482
sg70045
I3
sg70046
VP06850
p79483
sg70048
I1
sa(dp79484
g70042
I30
sg70043
VACTH
p79485
sg70045
I4
sg70046
VP01189
p79486
sg70048
I1
sa(dp79487
g70042
I60
sg70043
g79476
sg70045
I3
sg70046
VP01282
p79488
sg70048
I1
sasg70051
(lp79489
(dp79490
g70042
I131
sg70043
Vremission
p79491
sg70045
I9
sg70054
VC0687702
p79492
sg70048
I1
sa(dp79493
g70042
I99
sg70043
g79477
sg70045
I17
sg70054
VC0221406
p79494
sg70048
I2
sasa(dp79495
g70037
VHere we introduce a cell culture model of EAD propagation consisting of monolayers of cultured neonatal rat ventricular myocytes treated with anthopleurin-A (AP-A).
p79496
sg70039
(lp79497
(dp79498
g70042
I142
sg70043
Vanthopleurin-A
p79499
sg70045
I14
sg70046
g12
sg70048
I1
sa(dp79500
g70042
I158
sg70043
VAP-A
p79501
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp79502
(dp79503
g70042
I42
sg70043
VEAD
p79504
sg70045
I3
sg70054
VC1864233
p79505
sg70048
I1
sasa(dp79506
g70037
VThe present study provides evidence in support of the hypothesis that AP-A-induced ventricular tachyarrhythmias are due to bradycardia-dependent EAD and triggered activity.
p79507
sg70039
(lp79508
(dp79509
g70042
I70
sg70043
VAP-A
p79510
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp79511
(dp79512
g70042
I145
sg70043
VEAD
p79513
sg70045
I3
sg70054
VC1864233
p79514
sg70048
I1
sa(dp79515
g70042
I123
sg70043
Vbradycardia
p79516
sg70045
I11
sg70054
VC0428977
p79517
sg70048
I1
sasa(dp79518
g135
(dp79519
(Vbradycardia dependent long QTU, EADs
p79520
Vbradycardia
p79521
tp79522
I00
ssg70037
VTU alternans was investigated by MAP recordings in six normal dogs, following the administration of anthopleurin-A (AP-A), a drug shown to delay sodium inactivation and to induce bradycardia dependent long QTU, EADs, and TdP.
p79523
sg70039
(lp79524
(dp79525
g70042
I179
sg70043
g79520
sg70045
I36
sg70046
VP19525
p79526
sg70048
I5
sa(dp79527
g70042
I100
sg70043
Vanthopleurin-A
p79528
sg70045
I14
sg70046
g12
sg70048
I1
sa(dp79529
g70042
I116
sg70043
VAP-A
p79530
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp79531
(dp79532
g70042
I179
sg70043
g79521
sg70045
I11
sg70054
VC0428977
p79533
sg70048
I1
sa(dp79534
g70042
I152
sg70043
Vinactivation
p79535
sg70045
I12
sg70054
VC0544461
p79536
sg70048
I1
sasa(dp79537
g70037
VMoreover, a series of recent studies have genetically and functionally linked kalirin signaling to several disorders, including schizophrenia and Alzheimer's disease.
p79538
sg70039
(lp79539
(dp79540
g70042
I78
sg70043
Vkalirin
p79541
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp79542
(dp79543
g70042
I128
sg70043
Vschizophrenia
p79544
sg70045
I13
sg70054
VC0036341
p79545
sg70048
I1
sa(dp79546
g70042
I146
sg70043
VAlzheimer's disease
p79547
sg70045
I19
sg70054
VC1521724
p79548
sg70048
I2
sasa(dp79549
g70037
VA series of recent studies has improved our understanding of spine dynamics by establishing kalirin-7 as an important regulator of dendritic spine development as well as structural and functional plasticity, providing a model for the molecular control of structural plasticity and implicating kalirin-7 in synaptic pathology in several disorders including schizophrenia and Alzheimer's disease.
p79550
sg70039
(lp79551
(dp79552
g70042
I92
sg70043
Vkalirin-7
p79553
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp79554
g70042
I92
sg70043
Vkalirin-7
p79555
sg70045
I9
sg70046
g12
sg70048
I1
sasg70051
(lp79556
(dp79557
g70042
I356
sg70043
Vschizophrenia
p79558
sg70045
I13
sg70054
VC0036341
p79559
sg70048
I1
sa(dp79560
g70042
I374
sg70043
VAlzheimer's disease
p79561
sg70045
I19
sg70054
VC1521724
p79562
sg70048
I2
sa(dp79563
g70042
I315
sg70043
Vpathology
p79564
sg70045
I9
sg70054
VC0677042
p79565
sg70048
I1
sasa(dp79566
g135
(dp79567
(VCdk9
p79568
VEKC
p79569
tp79570
I00
ssg70037
VHere, we report that inhibition of the cell cycle-dependent kinase 9 (Cdk9) by RNA interference, or the compound flavopiridol, blocked infections with HAdV-C2/5, EKC-causing HAdV-D8/37, and progeny formation in human corneal epithelial and cancer cells.
p79571
sg70039
(lp79572
(dp79573
g70042
I44
sg70043
Vcycle-dependent kinase 9
p79574
sg70045
I24
sg70046
VP19525
p79575
sg70048
I3
sa(dp79576
g70042
I70
sg70043
g79568
sg70045
I4
sg70046
VP50750
p79577
sg70048
I1
sasg70051
(lp79578
(dp79579
g70042
I240
sg70043
Vcancer
p79580
sg70045
I6
sg70054
VC0006826
p79581
sg70048
I1
sa(dp79582
g70042
I135
sg70043
Vinfections
p79583
sg70045
I10
sg70054
VC0021311
p79584
sg70048
I1
sa(dp79585
g70042
I162
sg70043
g79569
sg70045
I3
sg70054
VC0014493
p79586
sg70048
I1
sasa(dp79587
g135
(dp79588
(VCdk9
p79589
Vadenovirus
p79590
tp79591
I00
ssg70037
VThe study identifies Cdk9 as a postexposure drug target against adenovirus infections in vitro and suggests that the clinically tested anticancer drug flavopiridol is a candidate for treating adenoviral EKC or adenovirus emergence upon immune suppression.
p79592
sg70039
(lp79593
(dp79594
g70042
I21
sg70043
g79589
sg70045
I4
sg70046
VP50750
p79595
sg70048
I1
sasg70051
(lp79596
(dp79597
g70042
I64
sg70043
Vadenovirus infections
p79598
sg70045
I21
sg70054
VC0001486
p79599
sg70048
I2
sa(dp79600
g70042
I236
sg70043
Vimmune suppression
p79601
sg70045
I18
sg70054
VC1840264
p79602
sg70048
I2
sa(dp79603
g70042
I203
sg70043
VEKC
p79604
sg70045
I3
sg70054
VC0014493
p79605
sg70048
I1
sa(dp79606
g70042
I64
sg70043
g79590
sg70045
I10
sg70054
VC0001486
p79607
sg70048
I1
sasa(dp79608
g70037
VWe conclude that: 1) synthetic non-thiazolidinediones can serve as ligands of PPARgamma and PPARdelta; 2) ligand-dependent activation of PPARdelta involves an apparent conformational change and association of the receptor ligand binding domain with CREB-binding protein; 3) PPARgamma activation (but not PPARdelta or PPARalpha activation) is sufficient to potentiate preadipocyte differentiation; 4) non-thiazolidinedione PPARgamma agonists improve hyperglycemia and hypertriglyceridemia in vivo; 5) although PPARalpha activation is sufficient to affect triglyceride metabolism, PPARdelta activation does not appear to modulate glucose or triglyceride levels.
p79609
sg70039
(lp79610
(dp79611
g70042
I92
sg70043
VPPARdelta
p79612
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp79613
g70042
I92
sg70043
VPPARdelta
p79614
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp79615
g70042
I92
sg70043
VPPARdelta
p79616
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp79617
g70042
I317
sg70043
VPPARalpha
p79618
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp79619
g70042
I249
sg70043
VCREB-binding protein
p79620
sg70045
I20
sg70046
g12
sg70048
I2
sa(dp79621
g70042
I92
sg70043
VPPARdelta
p79622
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp79623
g70042
I317
sg70043
VPPARalpha
p79624
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp79625
g70042
I213
sg70043
Vreceptor ligand binding domain
p79626
sg70045
I30
sg70046
g12
sg70048
I4
sasg70051
(lp79627
(dp79628
g70042
I449
sg70043
Vhyperglycemia
p79629
sg70045
I13
sg70054
VC0020456
p79630
sg70048
I1
sasa(dp79631
g70037
VAt present, four loci associated with non-syndromic auditory neuropathy have been mapped: Autosomal recessive deafness-9 [DFNB9; the otoferlin (OTOF) gene] and autosomal recessive deafness-59 [DFNB59; the pejvakin (PJVK) gene], associated with autosomal recessive inheritance; the autosomal dominant auditory neuropathy gene [AUNA1; the diaphanous-3 (DIAPH3) gene]; and AUNX1, linked to chromosome X.
p79632
sg70039
(lp79633
(dp79634
g70042
I122
sg70043
VDFNB9
p79635
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp79636
(dp79637
g70042
I370
sg70043
VAUNX1
p79638
sg70045
I5
sg70054
VC1845095
p79639
sg70048
I1
sa(dp79640
g70042
I110
sg70043
Vdeafness
p79641
sg70045
I8
sg70054
VC0011053
p79642
sg70048
I1
sa(dp79643
g70042
I122
sg70043
VDFNB9
p79644
sg70045
I5
sg70054
VC1832828
p79645
sg70048
I1
sa(dp79646
g70042
I110
sg70043
Vdeafness
p79647
sg70045
I8
sg70054
VC0011053
p79648
sg70048
I1
sa(dp79649
g70042
I193
sg70043
VDFNB59
p79650
sg70045
I6
sg70054
VC1857744
p79651
sg70048
I1
sa(dp79652
g70042
I326
sg70043
VAUNA1
p79653
sg70045
I5
sg70054
VC1836743
p79654
sg70048
I1
sa(dp79655
g70042
I52
sg70043
Vauditory neuropathy
p79656
sg70045
I19
sg70054
VC1852271
p79657
sg70048
I2
sa(dp79658
g70042
I52
sg70043
Vauditory neuropathy
p79659
sg70045
I19
sg70054
VC1852271
p79660
sg70048
I2
sasa(dp79661
g135
(dp79662
(VCarP-Fib
p79663
VArthritis
p79664
tp79665
I00
ssg70037
VPresence of antibodies to carbamylated fetal calf serum (CarP-FCS) and fibrinogen (CarP-Fib) was determined by inhouse ELISAs among RA cases in the Leiden Early Arthritis Clinic (n=846) and in the Swedish Epidemiological Investigation of Rheumatoid Arthritis (n=1985) cohorts.
p79666
sg70039
(lp79667
(dp79668
g70042
I57
sg70043
VCarP-FCS
p79669
sg70045
I8
sg70046
VP35219
p79670
sg70048
I1
sa(dp79671
g70042
I71
sg70043
Vfibrinogen
p79672
sg70045
I10
sg70046
VP22087
p79673
sg70048
I1
sa(dp79674
g70042
I83
sg70043
g79663
sg70045
I8
sg70046
VP35219
p79675
sg70048
I1
sasg70051
(lp79676
(dp79677
g70042
I57
sg70043
VCarP
p79678
sg70045
I4
sg70054
VC0263385
p79679
sg70048
I1
sa(dp79680
g70042
I238
sg70043
VRheumatoid Arthritis
p79681
sg70045
I20
sg70054
VC0003873
p79682
sg70048
I2
sa(dp79683
g70042
I57
sg70043
VCarP
p79684
sg70045
I4
sg70054
VC0263385
p79685
sg70048
I1
sa(dp79686
g70042
I161
sg70043
g79664
sg70045
I9
sg70054
VC0003864
p79687
sg70048
I1
sasa(dp79688
g135
(dp79689
(Vhuman fibrinogen
p79690
VRA
p79691
tp79692
I00
ssg70037
VTo detect the antibodies against human fibrinogen (FIB) Beta67-77 peptide and citrullinated human FIB Beta67-77 peptide in rheumatoid arthritis (RA) and examine their diagnostic values in RA.
p79693
sg70039
(lp79694
(dp79695
g70042
I92
sg70043
Vhuman FIB Beta67-77 peptide
p79696
sg70045
I27
sg70046
VP22087
p79697
sg70048
I4
sa(dp79698
g70042
I51
sg70043
VFIB
p79699
sg70045
I3
sg70046
VP22087
p79700
sg70048
I1
sa(dp79701
g70042
I56
sg70043
VBeta67-77 peptide
p79702
sg70045
I17
sg70046
g12
sg70048
I2
sa(dp79703
g70042
I33
sg70043
g79690
sg70045
I16
sg70046
VP22087
p79704
sg70048
I2
sasg70051
(lp79705
(dp79706
g70042
I123
sg70043
Vrheumatoid arthritis
p79707
sg70045
I20
sg70054
VC0003873
p79708
sg70048
I2
sa(dp79709
g70042
I145
sg70043
VRA
p79710
sg70045
I2
sg70054
VC0003873
p79711
sg70048
I1
sa(dp79712
g70042
I145
sg70043
g79691
sg70045
I2
sg70054
VC0003873
p79713
sg70048
I1
sasa(dp79714
g70037
VPolymyositis/dermatomyositis, systemic lupus erythematosus and Addison's disease, three conditions regulated by the HLA-B8-DR3 haplotype, were most strongly associated with MG, especially early-onset disease.
p79715
sg70039
(lp79716
(dp79717
g70042
I116
sg70043
VHLA-B8-DR3 haplotype
p79718
sg70045
I20
sg70046
VP30486
p79719
sg70048
I2
sasg70051
(lp79720
(dp79721
g70042
I30
sg70043
Vsystemic lupus erythematosus
p79722
sg70045
I28
sg70054
VC0024141
p79723
sg70048
I3
sa(dp79724
g70042
I63
sg70043
VAddison's disease
p79725
sg70045
I17
sg70054
VC0001403
p79726
sg70048
I2
sa(dp79727
g70042
I0
sg70043
VPolymyositis
p79728
sg70045
I12
sg70054
VC0085655
p79729
sg70048
I1
sa(dp79730
g70042
I13
sg70043
Vdermatomyositis
p79731
sg70045
I15
sg70054
VC0221056
p79732
sg70048
I1
sasa(dp79733
g70037
VThe prevalence of sporadic inclusion body myositis (sIBM) was correlated with the frequency of HLA-DR3.
p79734
sg70039
(lp79735
(dp79736
g70042
I95
sg70043
VHLA-DR3
p79737
sg70045
I7
sg70046
VP30486
p79738
sg70048
I1
sasg70051
(lp79739
(dp79740
g70042
I18
sg70043
Vsporadic inclusion body myositis
p79741
sg70045
I32
sg70054
VC0751713
p79742
sg70048
I4
sa(dp79743
g70042
I52
sg70043
VsIBM
p79744
sg70045
I4
sg70054
VC0751713
p79745
sg70048
I1
sasa(dp79746
g70037
VThe B8-DR3 haplotype fragment conferred the strongest susceptibility (OR 2.9, 95% CI 1.8-4.6), and the B-DR region of other ancestral haplotypes was associated with myositis subgroups.
p79747
sg70039
(lp79748
sg70051
(lp79749
(dp79750
g70042
I165
sg70043
Vmyositis
p79751
sg70045
I8
sg70054
VC0027121
p79752
sg70048
I1
sasa(dp79753
g70037
VMost gastric IFPs were associated with chronic atrophic gastritis while only one ileal polyp was associated with Meckels diverticulum.
p79754
sg70039
(lp79755
(dp79756
g70042
I13
sg70043
VIFPs
p79757
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp79758
(dp79759
g70042
I87
sg70043
Vpolyp
p79760
sg70045
I5
sg70054
VC0032584
p79761
sg70048
I1
sa(dp79762
g70042
I113
sg70043
VMeckels diverticulum
p79763
sg70045
I20
sg70054
VC0025037
p79764
sg70048
I2
sa(dp79765
g70042
I39
sg70043
Vchronic atrophic gastritis
p79766
sg70045
I26
sg70054
VC0017154
p79767
sg70048
I3
sasa(dp79768
g135
(dp79769
(VHMGN1
p79770
VDown syndrome
p79771
tp79772
I00
ssg70037
VCBR1, DYRK1A, HMGN1, ITSN1, RCAN1, SON, TMEM50B, and TTC3 were each up-regulated two-fold in Down syndrome samples compared to normal samples; of these, SON and TTC3 were newly reported.
p79773
sg70039
(lp79774
(dp79775
g70042
I21
sg70043
VITSN1
p79776
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp79777
g70042
I40
sg70043
VTMEM50B
p79778
sg70045
I7
sg70046
VP56557
p79779
sg70048
I1
sa(dp79780
g70042
I0
sg70043
VCBR1
p79781
sg70045
I4
sg70046
VP16152
p79782
sg70048
I1
sa(dp79783
g70042
I6
sg70043
VDYRK1A
p79784
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp79785
g70042
I14
sg70043
g79770
sg70045
I5
sg70046
VP05114
p79786
sg70048
I1
sasg70051
(lp79787
(dp79788
g70042
I93
sg70043
g79771
sg70045
I13
sg70054
VC0013080
p79789
sg70048
I2
sasa(dp79790
g70037
VIn this report we show that high levels of the TTC3 protein, encoded by one of the genes of the Down Syndrome Critical Region (DCR), prevent neurite extension and disrupt Golgi compactness in differentiating primary neurons.
p79791
sg70039
(lp79792
sg70051
(lp79793
(dp79794
g70042
I96
sg70043
VDown Syndrome Critical Region
p79795
sg70045
I29
sg70054
VC1860787
p79796
sg70048
I4
sa(dp79797
g70042
I127
sg70043
VDCR
p79798
sg70045
I3
sg70054
VC1860787
p79799
sg70048
I1
sasa(dp79800
g70037
VTTC3 contains a canonical RING finger motif, a pair of tetratricopeptide motifs, a putative Akt phosphorylation site, and nuclear localization signals, and is encoded by a gene within the Down syndrome (DS) critical region on chromosome 21.
p79801
sg70039
(lp79802
(dp79803
g70042
I92
sg70043
VAkt
p79804
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp79805
(dp79806
g70042
I203
sg70043
VDS
p79807
sg70045
I2
sg70054
VC0013080
p79808
sg70048
I1
sa(dp79809
g70042
I188
sg70043
VDown syndrome
p79810
sg70045
I13
sg70054
VC0013080
p79811
sg70048
I2
sasa(dp79812
g135
(dp79813
(VDSCR5
p79814
Vmemory impairment
p79815
tp79816
I00
ssg70037
VNonchimeric polytransgenic 152F7 mice encompassing four human chromosome 21 genes (DSCR3, DSCR5, TTC3, and DYRK1A) within the Down syndrome critical region present with learning and memory impairment.
p79817
sg70039
(lp79818
(dp79819
g70042
I90
sg70043
g79814
sg70045
I5
sg70046
VP57054
p79820
sg70048
I1
sa(dp79821
g70042
I107
sg70043
VDYRK1A
p79822
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp79823
g70042
I83
sg70043
VDSCR3
p79824
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp79825
(dp79826
g70042
I126
sg70043
VDown syndrome critical region
p79827
sg70045
I29
sg70054
VC1860787
p79828
sg70048
I4
sa(dp79829
g70042
I182
sg70043
g79815
sg70045
I17
sg70054
VC0233794
p79830
sg70048
I2
sasa(dp79831
g135
(dp79832
(Vplasma VWF Ag
p79833
VARDS
p79834
tp79835
I00
ssg70037
VMultivariate regression analysis revealed that plasma VWF Ag level is an independent predictor of mortality in ARDS pediatric patients.
p79836
sg70039
(lp79837
(dp79838
g70042
I47
sg70043
g79833
sg70045
I13
sg70046
VP04275
p79839
sg70048
I3
sasg70051
(lp79840
(dp79841
g70042
I111
sg70043
g79834
sg70045
I4
sg70054
VC0035222
p79842
sg70048
I1
sasa(dp79843
g135
(dp79844
(VPlasma VWF Ag
p79845
VARDS
p79846
tp79847
I00
ssg70037
VPlasma VWF Ag level is an excellent predictive marker for outcome in children with ALI/ARDS.
p79848
sg70039
(lp79849
(dp79850
g70042
I0
sg70043
g79845
sg70045
I13
sg70046
VP04275
p79851
sg70048
I3
sasg70051
(lp79852
(dp79853
g70042
I87
sg70043
g79846
sg70045
I4
sg70054
VC0035222
p79854
sg70048
I1
sasa(dp79855
g135
(dp79856
(Vvon Willebrand factor antigen
p79857
Vinflammation
p79858
tp79859
I00
ssg70037
VIn the multicenter study, patients with direct ARDS also had lower levels of von Willebrand factor antigen and IL-6 and IL-8, markers of endothelial injury and inflammation, respectively.
p79860
sg70039
(lp79861
(dp79862
g70042
I111
sg70043
VIL-6
p79863
sg70045
I4
sg70046
VP05231
p79864
sg70048
I1
sa(dp79865
g70042
I77
sg70043
g79857
sg70045
I29
sg70046
VP04275
p79866
sg70048
I4
sasg70051
(lp79867
(dp79868
g70042
I47
sg70043
VARDS
p79869
sg70045
I4
sg70054
VC0035222
p79870
sg70048
I1
sa(dp79871
g70042
I160
sg70043
g79858
sg70045
I12
sg70054
VC0021368
p79872
sg70048
I1
sasa(dp79873
g135
(dp79874
(Vendothelial cell mediators, E-selectin
p79875
Vacute pancreatitis
p79876
tp79877
I00
ssg70037
VTo investigate the role of endothelial cell mediators, E-selectin (ES), intercellular adhesion molecule-1 (ICAM-1), tissue factor (TF), and von Willebrand factor (vWF), in the early phase of severe acute pancreatitis (SAP) complicated with respiratory failure [pancreatitis-associated lung injury (PALI)].
p79878
sg70039
(lp79879
(dp79880
g70042
I72
sg70043
Vintercellular adhesion molecule-1
p79881
sg70045
I33
sg70046
VP05362
p79882
sg70048
I3
sa(dp79883
g70042
I140
sg70043
Vvon Willebrand factor
p79884
sg70045
I21
sg70046
VP04275
p79885
sg70048
I3
sa(dp79886
g70042
I163
sg70043
VvWF
p79887
sg70045
I3
sg70046
VP04275
p79888
sg70048
I1
sa(dp79889
g70042
I107
sg70043
VICAM-1
p79890
sg70045
I6
sg70046
VP05362
p79891
sg70048
I1
sa(dp79892
g70042
I27
sg70043
g79875
sg70045
I38
sg70046
VP16581
p79893
sg70048
I4
sasg70051
(lp79894
(dp79895
g70042
I86
sg70043
Vadhesion
p79896
sg70045
I8
sg70054
VC0001511
p79897
sg70048
I1
sa(dp79898
g70042
I240
sg70043
Vrespiratory failure
p79899
sg70045
I19
sg70054
VC1145670
p79900
sg70048
I2
sa(dp79901
g70042
I204
sg70043
Vpancreatitis
p79902
sg70045
I12
sg70054
VC0030305
p79903
sg70048
I1
sa(dp79904
g70042
I198
sg70043
g79876
sg70045
I18
sg70054
VC0001339
p79905
sg70048
I2
sasa(dp79906
g135
(dp79907
(VCLC-2
p79908
Vprimary open-angle glaucoma
p79909
tp79910
I00
ssg70037
VThus, CLC-2 may be a promising and potential novel therapeutic strategy for combating primary open-angle glaucoma.
p79911
sg70039
(lp79912
(dp79913
g70042
I6
sg70043
g79908
sg70045
I5
sg70046
VP51788
p79914
sg70048
I1
sasg70051
(lp79915
(dp79916
g70042
I86
sg70043
g79909
sg70045
I27
sg70054
VC0339573
p79917
sg70048
I3
sasa(dp79918
g135
(dp79919
(Valbumin
p79920
VCKD
p79921
tp79922
I01
ssg70037
VIn type 2 diabetes mellitus (T2DM) patients, chronic kidney disease (CKD) progression may occur without detectable changes in urinary albumin excretion (UAE) rate.
p79923
sg70039
(lp79924
(dp79925
g70042
I134
sg70043
g79920
sg70045
I7
sg70046
VP00441
p79926
sg70048
I1
sasg70051
(lp79927
(dp79928
g70042
I45
sg70043
Vchronic kidney disease
p79929
sg70045
I22
sg70054
VC1561643
p79930
sg70048
I3
sa(dp79931
g70042
I3
sg70043
Vtype 2 diabetes mellitus
p79932
sg70045
I24
sg70054
VC0011860
p79933
sg70048
I4
sa(dp79934
g70042
I29
sg70043
VT2DM
p79935
sg70045
I4
sg70054
VC0011860
p79936
sg70048
I1
sa(dp79937
g70042
I69
sg70043
g79921
sg70045
I3
sg70054
VC1561643
p79938
sg70048
I1
sasa(dp79939
g70037
VTo investigate, for the first time, the impact of systolic pulmonary arterial pressure (PASP) on maximal exercise capacity in adults with mild-to-moderate cystic fibrosis, without PH at rest.
p79940
sg70039
(lp79941
sg70051
(lp79942
(dp79943
g70042
I155
sg70043
Vcystic fibrosis
p79944
sg70045
I15
sg70054
VC0010674
p79945
sg70048
I2
sasa(dp79946
g135
(dp79947
(Vcarboxypeptidase B-like
p79948
Vdeficiency of carboxypeptidase B
p79949
tp79950
I00
ssg70037
VAssays of carboxypeptidase B-like activity and C3 in serum from patients with cystic fibrosis and appropriate control subjects failed to demonstrate a deficiency of carboxypeptidase B-like activity or a consistent increase in C3, as was suggested by Conover and associates.
p79951
sg70039
(lp79952
(dp79953
g70042
I10
sg70043
Vcarboxypeptidase B-like
p79954
sg70045
I23
sg70046
VP15086
p79955
sg70048
I2
sa(dp79956
g70042
I10
sg70043
g79948
sg70045
I23
sg70046
VP15086
p79957
sg70048
I2
sasg70051
(lp79958
(dp79959
g70042
I78
sg70043
Vcystic fibrosis
p79960
sg70045
I15
sg70054
VC0010674
p79961
sg70048
I2
sa(dp79962
g70042
I151
sg70043
g79949
sg70045
I32
sg70054
VC0398782
p79963
sg70048
I4
sasa(dp79964
g135
(dp79965
(Vserum carboxypeptidase B
p79966
Vcystic fibrosis
p79967
tp79968
I00
ssg70037
VDifferences between men and women with cystic fibrosis were apparent, in that women with cystic fibrosis had higher concentrations of both serum carboxypeptidase B-like activity and C3 than either men with cystic fibrosis or control subjects.
p79969
sg70039
(lp79970
(dp79971
g70042
I139
sg70043
g79966
sg70045
I24
sg70046
VP15086
p79972
sg70048
I3
sasg70051
(lp79973
(dp79974
g70042
I39
sg70043
Vcystic fibrosis
p79975
sg70045
I15
sg70054
VC0010674
p79976
sg70048
I2
sa(dp79977
g70042
I39
sg70043
Vcystic fibrosis
p79978
sg70045
I15
sg70054
VC0010674
p79979
sg70048
I2
sa(dp79980
g70042
I39
sg70043
g79967
sg70045
I15
sg70054
VC0010674
p79981
sg70048
I2
sasa(dp79982
g135
(dp79983
(Vcystic fibrosis enzyme
p79984
Vcystic fibrosis
p79985
tp79986
I00
ssg70037
VThe properties and lysosomal distribution of the enzyme indicated that it was a carboxypeptidase B. Substrate affinity, thermolability, pH stability, the fall and rise in activity with subculture, the cyclical pattern of activity through serial passage and the level of activity were similar for the control and cystic fibrosis enzyme.
p79987
sg70039
(lp79988
(dp79989
g70042
I80
sg70043
Vcarboxypeptidase B
p79990
sg70045
I18
sg70046
VP15086
p79991
sg70048
I2
sa(dp79992
g70042
I312
sg70043
g79984
sg70045
I22
sg70046
VP13569
p79993
sg70048
I3
sasg70051
(lp79994
(dp79995
g70042
I312
sg70043
g79985
sg70045
I15
sg70054
VC0010674
p79996
sg70048
I2
sasa(dp79997
g70037
VIn this review the roles identified for different selenoproteins in these steps and how they may promote or inhibit metastatic cancers is discussed.
p79998
sg70039
(lp79999
sg70051
(lp80000
(dp80001
g70042
I127
sg70043
Vcancers
p80002
sg70045
I7
sg70054
VC0006826
p80003
sg70048
I1
sasa(dp80004
g135
(dp80005
(Vselenoproteins
p80006
VDNA damage
p80007
tp80008
I00
ssg70037
VIndeed, many selenoproteins have antioxidant activity which can attenuate cancer development by minimizing oxidative insult and resultant DNA damage.
p80009
sg70039
(lp80010
(dp80011
g70042
I13
sg70043
g80006
sg70045
I14
sg70046
VP55073
p80012
sg70048
I1
sasg70051
(lp80013
(dp80014
g70042
I138
sg70043
g80007
sg70045
I10
sg70054
VC0012860
p80015
sg70048
I2
sa(dp80016
g70042
I74
sg70043
Vcancer
p80017
sg70045
I6
sg70054
VC0006826
p80018
sg70048
I1
sasa(dp80019
g135
(dp80020
(Vselenoproteins
p80021
Vtumorigenesis
p80022
tp80023
I00
ssg70037
VIn this review, we discuss what is currently known about selenoproteins in tumorigenesis with a focus on their contextual roles in cancer development, growth, and progression.
p80024
sg70039
(lp80025
(dp80026
g70042
I57
sg70043
g80021
sg70045
I14
sg70046
VP55073
p80027
sg70048
I1
sasg70051
(lp80028
(dp80029
g70042
I75
sg70043
g80022
sg70045
I13
sg70054
VC0007621
p80030
sg70048
I1
sa(dp80031
g70042
I131
sg70043
Vcancer
p80032
sg70045
I6
sg70054
VC0006826
p80033
sg70048
I1
sasa(dp80034
g135
(dp80035
(Vselenoproteins
p80036
Vbreast cancer
p80037
tp80038
I00
ssg70037
VNew aspects of Se actions in breast cancer have emerged such as the impact of genetic polymorphisms on Se metabolism and response, new functions of selenoproteins, epigenetic modulation of gene expression, and long-term influence of early-life exposure on disease risk.
p80039
sg70039
(lp80040
(dp80041
g70042
I148
sg70043
g80036
sg70045
I14
sg70046
VP55073
p80042
sg70048
I1
sasg70051
(lp80043
(dp80044
g70042
I29
sg70043
g80037
sg70045
I13
sg70054
VC0678222
p80045
sg70048
I2
sasa(dp80046
g70037
VWe observed that both SelS and C99 were colocalized in the membrane fraction of mouse neuroblastoma Neuro2a (N2a) cells.
p80047
sg70039
(lp80048
(dp80049
g70042
I22
sg70043
VSelS
p80050
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp80051
(dp80052
g70042
I80
sg70043
Vmouse neuroblastoma
p80053
sg70045
I19
sg70054
VC1524043
p80054
sg70048
I2
sasa(dp80055
g135
(dp80056
(VNPY-NPY Y1 receptor
p80057
Vdepression
p80058
tp80059
I00
ssg70037
VThe results suggest that decreased NPY expression in the extended amygdala might be causally linked with the depression induced following type 2 diabetes and that the antidepressant action of imipramine in diabetic mice might be mediated by NPY-NPY Y1 receptor system.
p80060
sg70039
(lp80061
(dp80062
g70042
I35
sg70043
VNPY
p80063
sg70045
I3
sg70046
VP25929
p80064
sg70048
I1
sa(dp80065
g70042
I241
sg70043
g80057
sg70045
I19
sg70046
VP25929
p80066
sg70048
I3
sasg70051
(lp80067
(dp80068
g70042
I138
sg70043
Vtype 2 diabetes
p80069
sg70045
I15
sg70054
VC0011860
p80070
sg70048
I3
sa(dp80071
g70042
I109
sg70043
g80058
sg70045
I10
sg70054
VC0011581
p80072
sg70048
I1
sasa(dp80073
g135
(dp80074
(Vneuropeptide Y
p80075
Vobesity
p80076
tp80077
I00
ssg70037
VNumerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact, a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so, in large part, via signaling through the CNS NPY Y1 receptor.
p80078
sg70039
(lp80079
(dp80080
g70042
I301
sg70043
VCNS NPY Y1 receptor
p80081
sg70045
I19
sg70046
VP25929
p80082
sg70048
I4
sa(dp80083
g70042
I116
sg70043
VNPY
p80084
sg70045
I3
sg70046
VP25929
p80085
sg70048
I1
sa(dp80086
g70042
I116
sg70043
VNPY
p80087
sg70045
I3
sg70046
VP25929
p80088
sg70048
I1
sa(dp80089
g70042
I100
sg70043
g80075
sg70045
I14
sg70046
VP01303
p80090
sg70048
I2
sasg70051
(lp80091
(dp80092
g70042
I31
sg70043
Vdiabetes
p80093
sg70045
I8
sg70054
VC0011849
p80094
sg70048
I1
sa(dp80095
g70042
I19
sg70043
g80076
sg70045
I7
sg70054
VC0028754
p80096
sg70048
I1
sa(dp80097
g70042
I79
sg70043
Vnervous
p80098
sg70045
I7
sg70054
VC0027769
p80099
sg70048
I1
sasa(dp80100
g70037
VWe investigated whether annexin A8 (A-A8), a Ca-binding protein overexpressed in pancreatic cancer, plays a role in cell growth and migration and investigated its association with pancreatic cancer prognosis.
p80101
sg70039
(lp80102
(dp80103
g70042
I45
sg70043
VCa-binding protein
p80104
sg70045
I18
sg70046
g12
sg70048
I2
sasg70051
(lp80105
(dp80106
g70042
I81
sg70043
Vpancreatic cancer
p80107
sg70045
I17
sg70054
VC0235974
p80108
sg70048
I2
sa(dp80109
g70042
I81
sg70043
Vpancreatic cancer
p80110
sg70045
I17
sg70054
VC0235974
p80111
sg70048
I2
sasa(dp80112
g70037
VAlthough Annexin A8 (ANXA8), a member of a superfamily of calcium and phospholipid binding proteins, is physiologically expressed in a tissue-specific manner, recent microarray studies reported that ANXA8 was also ectopically expressed in pancreatic cancers.
p80113
sg70039
(lp80114
(dp80115
g70042
I21
sg70043
VANXA8
p80116
sg70045
I5
sg70046
VP13928
p80117
sg70048
I1
sa(dp80118
g70042
I21
sg70043
VANXA8
p80119
sg70045
I5
sg70046
VP13928
p80120
sg70048
I1
sa(dp80121
g70042
I9
sg70043
VAnnexin A8
p80122
sg70045
I10
sg70046
VP13928
p80123
sg70048
I2
sasg70051
(lp80124
(dp80125
g70042
I239
sg70043
Vpancreatic cancers
p80126
sg70045
I18
sg70054
VC0346647
p80127
sg70048
I2
sasa(dp80128
g70037
VWe investigated the molecular mechanism of expression of ANXA8 in cancer cells and its functional role in pancreatic cancer cells.
p80129
sg70039
(lp80130
(dp80131
g70042
I57
sg70043
VANXA8
p80132
sg70045
I5
sg70046
VP13928
p80133
sg70048
I1
sasg70051
(lp80134
(dp80135
g70042
I66
sg70043
Vcancer
p80136
sg70045
I6
sg70054
VC0006826
p80137
sg70048
I1
sa(dp80138
g70042
I106
sg70043
Vpancreatic cancer
p80139
sg70045
I17
sg70054
VC0235974
p80140
sg70048
I2
sasa(dp80141
g135
(dp80142
(Vinsulin-like growth factor 2 messenger RNA binding protein 3
p80143
Vductal adenocarcinoma of the pancreas
p80144
tp80145
I00
ssg70037
VTo investigate the utility of 26 immunohistochemical markers (CAM 5.2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas.
p80146
sg70039
(lp80147
(dp80148
g70042
I135
sg70043
VMUC6
p80149
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp80150
g70042
I220
sg70043
VS100P
p80151
sg70045
I5
sg70046
VP25815
p80152
sg70048
I1
sa(dp80153
g70042
I328
sg70043
Vclaudin 18
p80154
sg70045
I10
sg70046
VP56856
p80155
sg70048
I2
sa(dp80156
g70042
I91
sg70043
VCK20
p80157
sg70045
I4
sg70046
VP35900
p80158
sg70048
I1
sa(dp80159
g70042
I151
sg70043
VSMAD4
p80160
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80161
g70042
I158
sg70043
VCDX2
p80162
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp80163
g70042
I317
sg70043
Vclaudin 4
p80164
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp80165
g70042
I227
sg70043
VIMP-3
p80166
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80167
g70042
I115
sg70043
VMUC2
p80168
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp80169
g70042
I164
sg70043
VpVHL
p80170
sg70045
I4
sg70046
VP40337
p80171
sg70048
I1
sa(dp80172
g70042
I402
sg70043
VCEA
p80173
sg70045
I3
sg70046
VP40198
p80174
sg70048
I1
sa(dp80175
g70042
I352
sg70043
Vfascin
p80176
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp80177
g70042
I395
sg70043
VMOC31
p80178
sg70045
I5
sg70046
VP16422
p80179
sg70048
I1
sa(dp80180
g70042
I340
sg70043
Vannexin A8
p80181
sg70045
I10
sg70046
VP13928
p80182
sg70048
I2
sa(dp80183
g70042
I360
sg70043
VPSCA
p80184
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp80185
g70042
I62
sg70043
VCAM 5.2
p80186
sg70045
I7
sg70046
VP01768
p80187
sg70048
I2
sa(dp80188
g70042
I297
sg70043
Vmaspin
p80189
sg70045
I6
sg70046
VP36952
p80190
sg70048
I1
sa(dp80191
g70042
I141
sg70043
Vp53
p80192
sg70045
I3
sg70046
VP42771
p80193
sg70048
I1
sa(dp80194
g70042
I234
sg70043
g80143
sg70045
I60
sg70046
VP01308
p80195
sg70048
I9
sa(dp80196
g70042
I71
sg70043
VCK [cytokeratin] 7
p80197
sg70045
I18
sg70046
g12
sg70048
I3
sa(dp80198
g70042
I146
sg70043
VDPC4
p80199
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp80200
(dp80201
g70042
I446
sg70043
Vcancer
p80202
sg70045
I6
sg70054
VC0006826
p80203
sg70048
I1
sa(dp80204
g70042
I62
sg70043
VCAM
p80205
sg70045
I3
sg70054
VC1861821
p80206
sg70048
I1
sa(dp80207
g70042
I488
sg70043
g80144
sg70045
I37
sg70054
VC1335302
p80208
sg70048
I5
sa(dp80209
g70042
I188
sg70043
Vtumor
p80210
sg70045
I5
sg70054
VC0027651
p80211
sg70048
I1
sasa(dp80212
g135
(dp80213
(VClaudin 18
p80214
Vadenocarcinomas
p80215
tp80216
I00
ssg70037
VClaudin 18 and annexin A8 are frequently highly overexpressed in infiltrating ductal adenocarcinomas when compared with normal reactive ducts, suggesting a role for these molecules in pancreatic ductal adenocarcinomas.
p80217
sg70039
(lp80218
(dp80219
g70042
I15
sg70043
Vannexin A8
p80220
sg70045
I10
sg70046
VP13928
p80221
sg70048
I2
sa(dp80222
g70042
I0
sg70043
g80214
sg70045
I10
sg70046
VP56856
p80223
sg70048
I2
sasg70051
(lp80224
(dp80225
g70042
I85
sg70043
Vadenocarcinomas
p80226
sg70045
I15
sg70054
VC0001418
p80227
sg70048
I1
sa(dp80228
g70042
I85
sg70043
g80215
sg70045
I15
sg70054
VC0001418
p80229
sg70048
I1
sa(dp80230
g70042
I65
sg70043
Vinfiltrating
p80231
sg70045
I12
sg70054
VC0332448
p80232
sg70048
I1
sasa(dp80233
g70037
VMultivariate analysis further confirmed that miR-340-low/ROCK1-high expression was an independent prognostic factor of unfavorable survival in pediatric osteosarcoma (for overall survival: p = 0.006, for progression-free survival: p = 0.008).
p80234
sg70039
(lp80235
(dp80236
g70042
I57
sg70043
VROCK1
p80237
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80238
g70042
I45
sg70043
VmiR-340-low
p80239
sg70045
I11
sg70046
g12
sg70048
I1
sasg70051
(lp80240
(dp80241
g70042
I143
sg70043
Vpediatric osteosarcoma
p80242
sg70045
I22
sg70054
VC1332986
p80243
sg70048
I2
sasa(dp80244
g70037
VOur data offer convincing evidence, for the first time, that the combined miR-340 downregulation and ROCK1 upregulation may be linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
p80245
sg70039
(lp80246
(dp80247
g70042
I101
sg70043
VROCK1
p80248
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp80249
(dp80250
g70042
I180
sg70043
Vpediatric osteosarcoma
p80251
sg70045
I22
sg70054
VC1332986
p80252
sg70048
I2
sa(dp80253
g70042
I137
sg70043
Vtumor progression
p80254
sg70045
I17
sg70054
VC0178874
p80255
sg70048
I2
sasa(dp80256
g70037
VWe analyzed the effects of 3 war components-combat exposure (CES), observation of abusive violence (OBS), and participation in abusive violence (PARTC)-and sense of coherence (SOC) on the development of both posttraumatic stress disorder (PTSD) and depression among a sample of war veterans.
p80257
sg70039
(lp80258
sg70051
(lp80259
(dp80260
g70042
I61
sg70043
VCES
p80261
sg70045
I3
sg70054
VC0265493
p80262
sg70048
I1
sa(dp80263
g70042
I90
sg70043
Vviolence
p80264
sg70045
I8
sg70054
VC0042693
p80265
sg70048
I1
sa(dp80266
g70042
I208
sg70043
Vposttraumatic stress disorder
p80267
sg70045
I29
sg70054
VC0038436
p80268
sg70048
I3
sa(dp80269
g70042
I249
sg70043
Vdepression
p80270
sg70045
I10
sg70054
VC0011581
p80271
sg70048
I1
sa(dp80272
g70042
I90
sg70043
Vviolence
p80273
sg70045
I8
sg70054
VC0042693
p80274
sg70048
I1
sa(dp80275
g70042
I239
sg70043
VPTSD
p80276
sg70045
I4
sg70054
VC0038436
p80277
sg70048
I1
sa(dp80278
g70042
I33
sg70043
Vcomponents-combat exposure
p80279
sg70045
I26
sg70054
VC0265493
p80280
sg70048
I2
sasa(dp80281
g70037
VThe expression levels of miR-155 in 38 pairs of cancer tissues and adjacent normal tissues from breast cancer patients were detected using quantitative real-time PCR.
p80282
sg70039
(lp80283
sg70051
(lp80284
(dp80285
g70042
I48
sg70043
Vcancer
p80286
sg70045
I6
sg70054
VC0006826
p80287
sg70048
I1
sa(dp80288
g70042
I96
sg70043
Vbreast cancer
p80289
sg70045
I13
sg70054
VC0678222
p80290
sg70048
I2
sasa(dp80291
g70037
VSoft agar colony formation assay and tumor xenografts showed inhibition of miR-155 could significantly reduce proliferation of cancer cells in vivo and vitro, which confirmed that miR-155 is an effective therapeutic target of breast cancer.
p80292
sg70039
(lp80293
(dp80294
g70042
I75
sg70043
VmiR-155
p80295
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80296
g70042
I75
sg70043
VmiR-155
p80297
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp80298
(dp80299
g70042
I37
sg70043
Vtumor
p80300
sg70045
I5
sg70054
VC0027651
p80301
sg70048
I1
sa(dp80302
g70042
I127
sg70043
Vcancer
p80303
sg70045
I6
sg70054
VC0006826
p80304
sg70048
I1
sa(dp80305
g70042
I226
sg70043
Vbreast cancer
p80306
sg70045
I13
sg70054
VC0678222
p80307
sg70048
I2
sa(dp80308
g70042
I110
sg70043
Vproliferation
p80309
sg70045
I13
sg70054
VC0334094
p80310
sg70048
I1
sasa(dp80311
g70037
VOur results underscore the importance of miR-155 as a therapeutic target and combination of Doxorubicinol and miR-155-silencing would be a potential way to cure breast cancer.
p80312
sg70039
(lp80313
sg70051
(lp80314
(dp80315
g70042
I161
sg70043
Vbreast cancer
p80316
sg70045
I13
sg70054
VC0678222
p80317
sg70048
I2
sasa(dp80318
g70037
VWe have quantified expression of seven oncomiRs, namely miR-17/92 cluster (miR-17, miR-18a, miR-19a and miR-20a), miR-21, miR-27a and miR-155, in plasma of 137 breast cancer (BC) patients.
p80319
sg70039
(lp80320
(dp80321
g70042
I134
sg70043
VmiR-155
p80322
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80323
g70042
I92
sg70043
VmiR-19a
p80324
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80325
g70042
I56
sg70043
VmiR-17
p80326
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp80327
g70042
I83
sg70043
VmiR-18a
p80328
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80329
g70042
I104
sg70043
VmiR-20a
p80330
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80331
g70042
I122
sg70043
VmiR-27a
p80332
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80333
g70042
I56
sg70043
VmiR-17/92 cluster
p80334
sg70045
I17
sg70046
g12
sg70048
I2
sasg70051
(lp80335
(dp80336
g70042
I175
sg70043
VBC
p80337
sg70045
I2
sg70054
VC0678222
p80338
sg70048
I1
sa(dp80339
g70042
I160
sg70043
Vbreast cancer
p80340
sg70045
I13
sg70054
VC0678222
p80341
sg70048
I2
sasa(dp80342
g70037
VOur results suggested that MIAT acted as a competing endogenous RNA (ceRNA) to regulate the expression of dual specificity phosphatase 7 (DUSP7) by taking up miR-155-5p in breast cancer.
p80343
sg70039
(lp80344
(dp80345
g70042
I158
sg70043
VmiR-155-5p
p80346
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp80347
g70042
I138
sg70043
VDUSP7
p80348
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80349
g70042
I106
sg70043
Vdual specificity phosphatase 7
p80350
sg70045
I30
sg70046
g12
sg70048
I4
sasg70051
(lp80351
(dp80352
g70042
I172
sg70043
Vbreast cancer
p80353
sg70045
I13
sg70054
VC0678222
p80354
sg70048
I2
sasa(dp80355
g70037
VWe conclude that MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p in breast cancer.
p80356
sg70039
(lp80357
(dp80358
g70042
I92
sg70043
VDUSP7
p80359
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80360
g70042
I121
sg70043
VmiR-155-5p
p80361
sg70045
I10
sg70046
g12
sg70048
I1
sasg70051
(lp80362
(dp80363
g70042
I31
sg70043
Vbreast cancer
p80364
sg70045
I13
sg70054
VC0678222
p80365
sg70048
I2
sa(dp80366
g70042
I38
sg70043
Vcancer progression
p80367
sg70045
I18
sg70054
VC0178874
p80368
sg70048
I2
sasa(dp80369
g70037
VFour oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high- and low-risk early breast cancer (EBC) and reflect the surgical tumor removal and adjuvant therapy.
p80370
sg70039
(lp80371
(dp80372
g70042
I35
sg70043
VmiR-19a
p80373
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80374
g70042
I44
sg70043
VmiR-181b
p80375
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp80376
g70042
I58
sg70043
VmiR-24
p80377
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp80378
(dp80379
g70042
I170
sg70043
Vbreast cancer
p80380
sg70045
I13
sg70054
VC0678222
p80381
sg70048
I2
sa(dp80382
g70042
I74
sg70043
Vtumor
p80383
sg70045
I5
sg70054
VC0027651
p80384
sg70048
I1
sa(dp80385
g70042
I74
sg70043
Vtumor
p80386
sg70045
I5
sg70054
VC0027651
p80387
sg70048
I1
sasa(dp80388
g70037
VThe present study determined the role of postoperative wound fluids (WFs) from patients diagnosed with breast cancer subsequent to breast conserving surgery or breast conserving surgery followed by IORT on the expression of three microRNAs (miRNAs), consisting of miR-21, miR-155 and miR-221, in distinct breast cancer cell lines that represent the general subtypes of breast cancer.
p80389
sg70039
(lp80390
sg70051
(lp80391
(dp80392
g70042
I103
sg70043
Vbreast cancer
p80393
sg70045
I13
sg70054
VC0678222
p80394
sg70048
I2
sa(dp80395
g70042
I103
sg70043
Vbreast cancer
p80396
sg70045
I13
sg70054
VC0678222
p80397
sg70048
I2
sa(dp80398
g70042
I55
sg70043
Vwound fluids
p80399
sg70045
I12
sg70054
VC0043207
p80400
sg70048
I2
sa(dp80401
g70042
I103
sg70043
Vbreast cancer
p80402
sg70045
I13
sg70054
VC0678222
p80403
sg70048
I2
sa(dp80404
g70042
I69
sg70043
VWFs
p80405
sg70045
I3
sg70054
VC0043207
p80406
sg70048
I1
sasa(dp80407
g70037
VAdditionally, it was indicated that both WFs and RT-WF strongly downregulated the expression of miR-21, miR-155 and miR-221 in basal/epithelial and luminal subtypes of breast cancer.
p80408
sg70039
(lp80409
(dp80410
g70042
I41
sg70043
VWFs
p80411
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp80412
(dp80413
g70042
I41
sg70043
VWFs
p80414
sg70045
I3
sg70054
VC0043207
p80415
sg70048
I1
sa(dp80416
g70042
I168
sg70043
Vbreast cancer
p80417
sg70045
I13
sg70054
VC0678222
p80418
sg70048
I2
sasa(dp80419
g70037
VThe expression of three different microRNAs (miR-9, miR-21, and miR-155) in 52 formalin-fixed paraffin-embedded (FFPE) primary cervical cancer tissue samples and 50 FFPE normal cervical tissue samples were evaluated.
p80420
sg70039
(lp80421
sg70051
(lp80422
(dp80423
g70042
I127
sg70043
Vcervical cancer
p80424
sg70045
I15
sg70054
VC0302592
p80425
sg70048
I2
sasa(dp80426
g70037
VMiR-9, miR-21, and miR-155 were significantly overexpressed in cervical cancer tissues compared to normal tissues (P &lt; 0.001).
p80427
sg70039
(lp80428
(dp80429
g70042
I0
sg70043
VMiR-9
p80430
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp80431
(dp80432
g70042
I63
sg70043
Vcervical cancer
p80433
sg70045
I15
sg70054
VC0302592
p80434
sg70048
I2
sasa(dp80435
g70037
VMiR-21 and miR-155 expression combined with the HPV E6/E7 mRNA assay in HPV E6/E7 negative cervical cancer showed increased AUC of 0.7267 and 0.7000, respectively (P = 0.01, P = 0.04), demonstrating their potential as diagnostic tools.
p80436
sg70039
(lp80437
sg70051
(lp80438
(dp80439
g70042
I91
sg70043
Vcervical cancer
p80440
sg70045
I15
sg70054
VC0302592
p80441
sg70048
I2
sasa(dp80442
g70037
VMoreover, miR-21 and miR-155 were predictors showing a 7 fold and 10.3 fold higher risk for HPV E6/E7 negative patients with cervical cancer (P = 0.024 and P = 0.017, respectively) while miR-155 was a predictor showing a 27.9 fold higher risk for HPV E6/E7 positive patients with cervical cancer (P &lt; 0.0001).
p80443
sg70039
(lp80444
sg70051
(lp80445
(dp80446
g70042
I125
sg70043
Vcervical cancer
p80447
sg70045
I15
sg70054
VC0302592
p80448
sg70048
I2
sa(dp80449
g70042
I125
sg70043
Vcervical cancer
p80450
sg70045
I15
sg70054
VC0302592
p80451
sg70048
I2
sasa(dp80452
g70037
VMiR-21 and miR-155 may be helpful in the prediction of both HPV positive and HPV negative cases of cervical cancer.
p80453
sg70039
(lp80454
(dp80455
g70042
I0
sg70043
VMiR-21
p80456
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp80457
g70042
I11
sg70043
VmiR-155
p80458
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp80459
(dp80460
g70042
I99
sg70043
Vcervical cancer
p80461
sg70045
I15
sg70054
VC0302592
p80462
sg70048
I2
sasa(dp80463
g70037
VThe purpose of this study was to analyze the clinicopathologic significance of expression of EMT-related miRNAs, miR-9 and miR-155, in triple-negative breast cancers (TNBCs).
p80464
sg70039
(lp80465
(dp80466
g70042
I113
sg70043
VmiR-9
p80467
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80468
g70042
I123
sg70043
VmiR-155
p80469
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp80470
g70042
I93
sg70043
VEMT-related miRNAs
p80471
sg70045
I18
sg70046
g12
sg70048
I2
sasg70051
(lp80472
(dp80473
g70042
I151
sg70043
Vbreast cancers
p80474
sg70045
I14
sg70054
VC0006142
p80475
sg70048
I2
sasa(dp80476
g70037
VThen, based on the experimentally validated miRNA regulations to target genes, 4 candidate miRNAs (miR-24-3p, miR-192-5p, miR-139-5p and miR-155-5p) were identified to potentially contribute to ovarian cancer cell chemoresistance to CDDP through mediating OVCAR-8R cell CDDP resistance-related gene modules, which participated in functions that were closely related to "apoptosis", "cell cycle" and "adhesion".
p80477
sg70039
(lp80478
(dp80479
g70042
I137
sg70043
VmiR-155-5p
p80480
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp80481
g70042
I122
sg70043
VmiR-139-5p
p80482
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp80483
g70042
I99
sg70043
VmiR-24-3p
p80484
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp80485
g70042
I110
sg70043
VmiR-192-5p
p80486
sg70045
I10
sg70046
g12
sg70048
I1
sasg70051
(lp80487
(dp80488
g70042
I400
sg70043
Vadhesion
p80489
sg70045
I8
sg70054
VC0001511
p80490
sg70048
I1
sa(dp80491
g70042
I194
sg70043
Vovarian cancer
p80492
sg70045
I14
sg70054
VC1140680
p80493
sg70048
I2
sasa(dp80494
g70037
VThe renal involvement may present with symptoms arising from interstitial nephritis, mainly distal renal tubular acidosis.
p80495
sg70039
(lp80496
sg70051
(lp80497
(dp80498
g70042
I92
sg70043
Vdistal renal tubular acidosis
p80499
sg70045
I29
sg70054
VC1704380
p80500
sg70048
I4
sa(dp80501
g70042
I61
sg70043
Vinterstitial nephritis
p80502
sg70045
I22
sg70054
VC0027707
p80503
sg70048
I2
sasa(dp80504
g70037
VIn a 29-year-old female patient, with bilateral nephrolithiasis, the diagnosis of primary Sjoegren's syndrome, tubulo-interstitial nephritis, distal renal tubular acidosis, and hypokalemia were established.
p80505
sg70039
(lp80506
sg70051
(lp80507
(dp80508
g70042
I90
sg70043
VSjoegren's syndrome
p80509
sg70045
I19
sg70054
VC1527336
p80510
sg70048
I2
sa(dp80511
g70042
I48
sg70043
Vnephrolithiasis
p80512
sg70045
I15
sg70054
VC0392525
p80513
sg70048
I1
sa(dp80514
g70042
I111
sg70043
Vtubulo-interstitial nephritis
p80515
sg70045
I29
sg70054
VC0041349
p80516
sg70048
I2
sa(dp80517
g70042
I142
sg70043
Vdistal renal tubular acidosis
p80518
sg70045
I29
sg70054
VC1704380
p80519
sg70048
I4
sasa(dp80520
g70037
VTubulo-interstitial nephritis constitutes the most frequent renal lesion and distal tubular acidosis (Type 1) is the most important clinical manifestation of this tubular dysfunction, although the occurrence of chronic renal insufficiency is not an uncommon finding in the presence of distal renal tubular acidosis.
p80521
sg70039
(lp80522
sg70051
(lp80523
(dp80524
g70042
I211
sg70043
Vchronic renal insufficiency
p80525
sg70045
I27
sg70054
VC0022661
p80526
sg70048
I3
sa(dp80527
g70042
I0
sg70043
VTubulo-interstitial nephritis
p80528
sg70045
I29
sg70054
VC0041349
p80529
sg70048
I2
sa(dp80530
g70042
I92
sg70043
Vacidosis
p80531
sg70045
I8
sg70054
VC0001122
p80532
sg70048
I1
sa(dp80533
g70042
I285
sg70043
Vdistal renal tubular acidosis
p80534
sg70045
I29
sg70054
VC1704380
p80535
sg70048
I4
sasa(dp80536
g70037
VRight atrial thrombosis is classified as two type: A (mobile, thin) and B (non mobile and attached to atrial wall) that they are probably of cardiac origin due to local pathology, indwelling catheter, atrial fibrillation, stasis, rheumatological or hematological disease like protein C or S deficiency.
p80537
sg70039
(lp80538
(dp80539
g70042
I276
sg70043
Vprotein C
p80540
sg70045
I9
sg70046
VP02810
p80541
sg70048
I2
sasg70051
(lp80542
(dp80543
g70042
I169
sg70043
Vpathology
p80544
sg70045
I9
sg70054
VC0677042
p80545
sg70048
I1
sa(dp80546
g70042
I222
sg70043
Vstasis
p80547
sg70045
I6
sg70054
VC0333138
p80548
sg70048
I1
sa(dp80549
g70042
I6
sg70043
Vatrial thrombosis
p80550
sg70045
I17
sg70054
VC0340517
p80551
sg70048
I2
sa(dp80552
g70042
I201
sg70043
Vatrial fibrillation
p80553
sg70045
I19
sg70054
VC0004238
p80554
sg70048
I2
sa(dp80555
g70042
I249
sg70043
Vhematological disease
p80556
sg70045
I21
sg70054
VC0018939
p80557
sg70048
I2
sasa(dp80558
g135
(dp80559
(Vantithrombin III
p80560
Vhypercoagulability
p80561
tp80562
I00
ssg70037
VVenous stasis (e.g., immobilization, congestive heart failure, acute myocardial infarction, obesity), hypercoagulability (e.g., malignancy, inflammatory bowel disease, hyperhomocysteinemia, protein C resistance, antithrombin III, protein C or S deficiency) and endothelial trauma (e.g., surgical trauma, venous trauma, in-dwelling venous instrumentation) are risk factors.
p80563
sg70039
(lp80564
(dp80565
g70042
I212
sg70043
g80560
sg70045
I16
sg70046
VP05546
p80566
sg70048
I2
sa(dp80567
g70042
I190
sg70043
Vprotein C
p80568
sg70045
I9
sg70046
VP02810
p80569
sg70048
I2
sasg70051
(lp80570
(dp80571
g70042
I0
sg70043
VVenous stasis
p80572
sg70045
I13
sg70054
VC0277919
p80573
sg70048
I2
sa(dp80574
g70042
I140
sg70043
Vinflammatory bowel disease
p80575
sg70045
I26
sg70054
VC0021390
p80576
sg70048
I3
sa(dp80577
g70042
I168
sg70043
Vhyperhomocysteinemia
p80578
sg70045
I20
sg70054
VC0598608
p80579
sg70048
I1
sa(dp80580
g70042
I37
sg70043
Vcongestive heart failure
p80581
sg70045
I24
sg70054
VC0018802
p80582
sg70048
I3
sa(dp80583
g70042
I92
sg70043
Vobesity
p80584
sg70045
I7
sg70054
VC0028754
p80585
sg70048
I1
sa(dp80586
g70042
I63
sg70043
Vacute myocardial infarction
p80587
sg70045
I27
sg70054
VC0155626
p80588
sg70048
I3
sa(dp80589
g70042
I128
sg70043
Vmalignancy
p80590
sg70045
I10
sg70054
VC0006826
p80591
sg70048
I1
sa(dp80592
g70042
I102
sg70043
g80561
sg70045
I18
sg70054
VC0398623
p80593
sg70048
I1
sasa(dp80594
g70037
VTo evaluate the use of selective vs. non-selective cyclo-oxygenase inhibitors (COXIs) for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.
p80595
sg70039
(lp80596
(dp80597
g70042
I51
sg70043
Vcyclo-oxygenase
p80598
sg70045
I15
sg70046
VP23219
p80599
sg70048
I1
sasg70051
(lp80600
(dp80601
g70042
I147
sg70043
Vscleritis and episcleritis
p80602
sg70045
I26
sg70054
VC1971635
p80603
sg70048
I3
sa(dp80604
g70042
I119
sg70043
Vinfectious
p80605
sg70045
I10
sg70054
VC0009450
p80606
sg70048
I1
sasa(dp80607
g70037
VSixty-nine patients with scleritis and episcleritis treated for &gt;=2 months with COXIs were included.
p80608
sg70039
(lp80609
sg70051
(lp80610
(dp80611
g70042
I25
sg70043
Vscleritis and episcleritis
p80612
sg70045
I26
sg70054
VC1971635
p80613
sg70048
I3
sasa(dp80614
g70037
VInitial inflammation control was achieved in 78-81% of scleritis patients and 73-80% episcleritis patients on COXIs (p &gt; .05).
p80615
sg70039
(lp80616
sg70051
(lp80617
(dp80618
g70042
I8
sg70043
Vinflammation
p80619
sg70045
I12
sg70054
VC0021368
p80620
sg70048
I1
sa(dp80621
g70042
I85
sg70043
Vepiscleritis
p80622
sg70045
I12
sg70054
VC0014583
p80623
sg70048
I1
sa(dp80624
g70042
I55
sg70043
Vscleritis
p80625
sg70045
I9
sg70054
VC0036416
p80626
sg70048
I1
sasa(dp80627
g70037
VSelective vs. non-selective COXIs were equally efficacious for the treatment of chronic non-infectious, non-necrotizing scleritis and episcleritis.
p80628
sg70039
(lp80629
sg70051
(lp80630
(dp80631
g70042
I92
sg70043
Vinfectious
p80632
sg70045
I10
sg70054
VC0009450
p80633
sg70048
I1
sa(dp80634
g70042
I120
sg70043
Vscleritis and episcleritis
p80635
sg70045
I26
sg70054
VC1971635
p80636
sg70048
I3
sasa(dp80637
g135
(dp80638
(VGEF
p80639
Vfaciogenital dysplasia
p80640
tp80641
I00
ssg70037
VHere we show that KIAA0793, containing substantial sequence homology with the catalytic Dbl homology domain of the faciogenital dysplasia gene product (FGD1), is a specific GEF for Cdc42.
p80642
sg70039
(lp80643
(dp80644
g70042
I181
sg70043
VCdc42
p80645
sg70045
I5
sg70046
VP60953
p80646
sg70048
I1
sa(dp80647
g70042
I152
sg70043
VFGD1
p80648
sg70045
I4
sg70046
VP98174
p80649
sg70048
I1
sa(dp80650
g70042
I173
sg70043
g80639
sg70045
I3
sg70046
VP10911
p80651
sg70048
I1
sa(dp80652
g70042
I78
sg70043
Vcatalytic Dbl homology domain
p80653
sg70045
I29
sg70046
g12
sg70048
I4
sasg70051
(lp80654
(dp80655
g70042
I152
sg70043
VFGD1
p80656
sg70045
I4
sg70054
VC1859974
p80657
sg70048
I1
sa(dp80658
g70042
I115
sg70043
g80640
sg70045
I22
sg70054
VC0175701
p80659
sg70048
I2
sasa(dp80660
g135
(dp80661
(VCDC42-specific GEF
p80662
Vfaciogenital dysplasia
p80663
tp80664
I01
ssg70037
VThe faciogenital dysplasia gene product, FGD1, is a Dbl family member that has recently been shown to function as a CDC42-specific GEF.
p80665
sg70039
(lp80666
(dp80667
g70042
I52
sg70043
VDbl family member
p80668
sg70045
I17
sg70046
VP10911
p80669
sg70048
I3
sa(dp80670
g70042
I41
sg70043
VFGD1
p80671
sg70045
I4
sg70046
VP98174
p80672
sg70048
I1
sa(dp80673
g70042
I116
sg70043
g80662
sg70045
I18
sg70046
VP60953
p80674
sg70048
I2
sasg70051
(lp80675
(dp80676
g70042
I41
sg70043
VFGD1
p80677
sg70045
I4
sg70054
VC1859974
p80678
sg70048
I1
sa(dp80679
g70042
I4
sg70043
g80663
sg70045
I22
sg70054
VC0175701
p80680
sg70048
I2
sasa(dp80681
g135
(dp80682
(VFGD1
p80683
VFGD1
p80684
tp80685
I00
ssg70037
VThe majority of proteins that contain a DH (Dbl homology) domain were isolated as oncogenes in transfection assays, but two members of the DH family, FGD1 (the product of the faciogenital dysplasia or Aarskog-Scott syndrome locus) and Vav, have been shown to be essential for normal embryonic development.
p80686
sg70039
(lp80687
(dp80688
g70042
I44
sg70043
VDbl
p80689
sg70045
I3
sg70046
VP10911
p80690
sg70048
I1
sa(dp80691
g70042
I235
sg70043
VVav
p80692
sg70045
I3
sg70046
VP15498
p80693
sg70048
I1
sa(dp80694
g70042
I150
sg70043
g80683
sg70045
I4
sg70046
VP98174
p80695
sg70048
I1
sasg70051
(lp80696
(dp80697
g70042
I201
sg70043
VAarskog-Scott syndrome
p80698
sg70045
I22
sg70054
VC0175701
p80699
sg70048
I2
sa(dp80700
g70042
I175
sg70043
Vfaciogenital dysplasia
p80701
sg70045
I22
sg70054
VC0175701
p80702
sg70048
I2
sa(dp80703
g70042
I150
sg70043
g80684
sg70045
I4
sg70054
VC1859974
p80704
sg70048
I1
sasa(dp80705
g135
(dp80706
(VFGD1
p80707
VAarskog-Scott syndrome
p80708
tp80709
I00
ssg70037
VHere we have examined the role of a Dbl-like molecule, the faciogenital dysplasia gene product (FGD1), which when mutated in its Dbl homology domain, cosegregates with the developmental disease Aarskog-Scott syndrome.
p80710
sg70039
(lp80711
(dp80712
g70042
I129
sg70043
VDbl homology domain
p80713
sg70045
I19
sg70046
VP10911
p80714
sg70048
I3
sa(dp80715
g70042
I36
sg70043
VDbl-like molecule
p80716
sg70045
I17
sg70046
VP10911
p80717
sg70048
I2
sa(dp80718
g70042
I96
sg70043
g80707
sg70045
I4
sg70046
VP98174
p80719
sg70048
I1
sasg70051
(lp80720
(dp80721
g70042
I59
sg70043
Vfaciogenital dysplasia
p80722
sg70045
I22
sg70054
VC0175701
p80723
sg70048
I2
sa(dp80724
g70042
I96
sg70043
VFGD1
p80725
sg70045
I4
sg70054
VC1859974
p80726
sg70048
I1
sa(dp80727
g70042
I194
sg70043
g80708
sg70045
I22
sg70054
VC0175701
p80728
sg70048
I2
sasa(dp80729
g70037
VNon-survivors (n=29) versus survivors (n=46) were: older (77+/-9.8 vs 68+/-14, p=0.006), had higher New York Heart Association (NYHA) class (2.7+/-0.8 vs 2.3+/-0.8, p=0.037), higher brain natriuretic peptide (1157+/-717 vs 427+/-502 pg/mL, p=0.024, n=18), more coronary artery disease (61% vs 35%, p=0.031), more frequent left ventricular ejection fraction &lt;50% (20.7% vs 4.3%, p=0.026), more functional MR (41% vs 22%, p=0.069), higher mitral E/E(') (12.7+/-4.6 vs 9.8+/-4, p=0.008), higher pulmonary artery systolic pressure (PASP; 52.6+/-18.7 vs 36.7+/-14, p &lt;0.001), more &gt;=3+ tricuspid regurgitation (28% vs 4%, p=0.005) and more right ventricular dysfunction (26% vs 6%, p=0.035).
p80730
sg70039
(lp80731
sg70051
(lp80732
(dp80733
g70042
I261
sg70043
Vcoronary artery disease
p80734
sg70045
I23
sg70054
VC1956346
p80735
sg70048
I3
sa(dp80736
g70042
I644
sg70043
Vright ventricular dysfunction
p80737
sg70045
I29
sg70054
VC0242707
p80738
sg70048
I3
sa(dp80739
g70042
I590
sg70043
Vtricuspid regurgitation
p80740
sg70045
I23
sg70054
VC0040961
p80741
sg70048
I2
sasa(dp80742
g70037
VThe presence of RBBB, IVCD, PASP &gt;= 40 mmHg, left atrium diameter and NYHA functional class were independent predictors of all-cause mortality in DCM patients.
p80743
sg70039
(lp80744
sg70051
(lp80745
(dp80746
g70042
I16
sg70043
VRBBB
p80747
sg70045
I4
sg70054
VC0085615
p80748
sg70048
I1
sa(dp80749
g70042
I22
sg70043
VIVCD
p80750
sg70045
I4
sg70054
VC1882112
p80751
sg70048
I1
sasa(dp80752
g70037
VThe goals of therapy, which should be highlighted in follow-up imaging, include not only reduction of PASP, decrease in pulmonary vascular resistance, and improvements in right ventricular function, cardiac output, and tricuspid regurgitation.
p80753
sg70039
(lp80754
sg70051
(lp80755
(dp80756
g70042
I219
sg70043
Vtricuspid regurgitation
p80757
sg70045
I23
sg70054
VC0040961
p80758
sg70048
I2
sasa(dp80759
g135
(dp80760
(VIL-10
p80761
Vsquamous cell carcinoma
p80762
tp80763
I00
ssg70037
VThe objective of this study was to determine the prognostic significance of CD163(+) cells, interleukin-10 (IL-10), and interferon-gamma (IFN-Gamma) in oral lesions associated with oral squamous cell carcinoma (OSCC).
p80764
sg70039
(lp80765
(dp80766
g70042
I92
sg70043
Vinterleukin-10
p80767
sg70045
I14
sg70046
VP22301
p80768
sg70048
I1
sa(dp80769
g70042
I120
sg70043
Vinterferon-gamma
p80770
sg70045
I16
sg70046
VP01579
p80771
sg70048
I1
sa(dp80772
g70042
I76
sg70043
VCD163
p80773
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80774
g70042
I138
sg70043
VIFN-Gamma
p80775
sg70045
I9
sg70046
VP01579
p80776
sg70048
I1
sa(dp80777
g70042
I108
sg70043
g80761
sg70045
I5
sg70046
VP22301
p80778
sg70048
I1
sasg70051
(lp80779
(dp80780
g70042
I186
sg70043
g80762
sg70045
I23
sg70054
VC0007137
p80781
sg70048
I3
sasa(dp80782
g135
(dp80783
(Vinterferon-gamma
p80784
Vtumor necrosis
p80785
tp80786
I01
ssg70037
Vbeta-defensin expression was quantitatively assessed using real-time polymerase chain reactions in OSCC and control cell lines after exposure to interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma.
p80787
sg70039
(lp80788
(dp80789
g70042
I0
sg70043
Vbeta-defensin
p80790
sg70045
I13
sg70046
VP59861
p80791
sg70048
I1
sa(dp80792
g70042
I145
sg70043
Vinterleukin-1beta
p80793
sg70045
I17
sg70046
VP01584
p80794
sg70048
I1
sa(dp80795
g70042
I164
sg70043
Vtumor necrosis factor-alpha
p80796
sg70045
I27
sg70046
VP01375
p80797
sg70048
I3
sa(dp80798
g70042
I197
sg70043
g80784
sg70045
I16
sg70046
VP01579
p80799
sg70048
I1
sasg70051
(lp80800
(dp80801
g70042
I164
sg70043
g80785
sg70045
I14
sg70054
VC0333516
p80802
sg70048
I2
sasa(dp80803
g135
(dp80804
(VOCT-2
p80805
Vdiffuse large B-cell lymphoma
p80806
tp80807
I01
ssg70037
VWe investigated the utility of J chain and MEF2B in the diagnosis of CHL, NLPHL, PMBL, T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL), and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL (BCLU, DLBCL/CHL) compared to OCT-2 and BOB.1.
p80808
sg70039
(lp80809
(dp80810
g70042
I292
sg70043
VBOB.1
p80811
sg70045
I5
sg70046
VP49685
p80812
sg70048
I1
sa(dp80813
g70042
I282
sg70043
g80805
sg70045
I5
sg70046
VP09086
p80814
sg70048
I1
sasg70051
(lp80815
(dp80816
g70042
I87
sg70043
VT-cell/histiocyte-rich large B-cell lymphoma
p80817
sg70045
I44
sg70054
VC1321547
p80818
sg70048
I4
sa(dp80819
g70042
I74
sg70043
VNLPHL
p80820
sg70045
I5
sg70054
VC1334968
p80821
sg70048
I1
sa(dp80822
g70042
I116
sg70043
VB-cell lymphoma
p80823
sg70045
I15
sg70054
VC0079731
p80824
sg70048
I2
sa(dp80825
g70042
I133
sg70043
VTCRLBL
p80826
sg70045
I6
sg70054
VC1321547
p80827
sg70048
I1
sa(dp80828
g70042
I214
sg70043
g80806
sg70045
I29
sg70054
VC0079744
p80829
sg70048
I4
sasa(dp80830
g135
(dp80831
(VOCT-2
p80832
VNLPHL
p80833
tp80834
I01
ssg70037
VJ chain and MEF2B are highly sensitive and specific markers of NLPHL versus CHL, are particularly useful in highlighting LP cells, and, with rare exception, are of greater utility than OCT-2 and BOB.1 in differentiating CHL from NLPHL and other large B-cell lymphomas.
p80835
sg70039
(lp80836
(dp80837
g70042
I12
sg70043
VMEF2B
p80838
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80839
g70042
I195
sg70043
VBOB.1
p80840
sg70045
I5
sg70046
VP49685
p80841
sg70048
I1
sa(dp80842
g70042
I185
sg70043
g80832
sg70045
I5
sg70046
VP09086
p80843
sg70048
I1
sasg70051
(lp80844
(dp80845
g70042
I251
sg70043
VB-cell lymphomas
p80846
sg70045
I16
sg70054
VC0079731
p80847
sg70048
I2
sa(dp80848
g70042
I63
sg70043
VNLPHL
p80849
sg70045
I5
sg70054
VC1334968
p80850
sg70048
I1
sa(dp80851
g70042
I63
sg70043
g80833
sg70045
I5
sg70054
VC1334968
p80852
sg70048
I1
sasa(dp80853
g135
(dp80854
(VC-X-C motif chemokine ligand 17
p80855
Vgastric cancer
p80856
tp80857
I00
ssg70037
VWe identified several consensus differentially expressed genes and these genes were further confirmed with literature mining; at last, two genes, that is, immunoglobulin J chain and C-X-C motif chemokine ligand 17, were screened as novel gastric cancer associated genes.
p80858
sg70039
(lp80859
(dp80860
g70042
I155
sg70043
Vimmunoglobulin J chain
p80861
sg70045
I22
sg70046
VP01591
p80862
sg70048
I3
sa(dp80863
g70042
I182
sg70043
g80855
sg70045
I31
sg70046
VP55773
p80864
sg70048
I5
sasg70051
(lp80865
(dp80866
g70042
I238
sg70043
g80856
sg70045
I14
sg70054
VC0024623
p80867
sg70048
I2
sasa(dp80868
g70037
VA discovery/validation study on RR-MS responsive to glatiramer acetate identified 8 differentially expressed genes: ITGA2B, ITGB3, CD177, IGJ, IL5RA, MMP8, P2RY12, and S100Beta.
p80869
sg70039
(lp80870
(dp80871
g70042
I143
sg70043
VIL5RA
p80872
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80873
g70042
I168
sg70043
VS100Beta
p80874
sg70045
I8
sg70046
VP04271
p80875
sg70048
I1
sa(dp80876
g70042
I150
sg70043
VMMP8
p80877
sg70045
I4
sg70046
VP22894
p80878
sg70048
I1
sa(dp80879
g70042
I138
sg70043
VIGJ
p80880
sg70045
I3
sg70046
VP01591
p80881
sg70048
I1
sa(dp80882
g70042
I131
sg70043
VCD177
p80883
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp80884
g70042
I124
sg70043
VITGB3
p80885
sg70045
I5
sg70046
VP05106
p80886
sg70048
I1
sa(dp80887
g70042
I116
sg70043
VITGA2B
p80888
sg70045
I6
sg70046
VP08514
p80889
sg70048
I1
sa(dp80890
g70042
I156
sg70043
VP2RY12
p80891
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp80892
sa(dp80893
g135
(dp80894
(VIGL family
p80895
Vneuroblastoma
p80896
tp80897
I00
ssg70037
VFor the transcriptome analysis, we found some genes related to Alzheimer's disease (LRP1), an insulin-like growth factor receptor (IGF2R), immunity genes (IGL family and IGJ), two genes related to inflammatory reaction (CXCL5 and CCL3), one gene related to maintenance of cellular morphology (NHS), one gene considered to be a strong apoptosis inductor (LGALS14), and several transcripts of the neuroblastoma breakpoint family (NBPF).
p80898
sg70039
(lp80899
(dp80900
g70042
I220
sg70043
VCXCL5
p80901
sg70045
I5
sg70046
VP42830
p80902
sg70048
I1
sa(dp80903
g70042
I170
sg70043
VIGJ
p80904
sg70045
I3
sg70046
VP01591
p80905
sg70048
I1
sa(dp80906
g70042
I230
sg70043
VCCL3
p80907
sg70045
I4
sg70046
VP10147
p80908
sg70048
I1
sa(dp80909
g70042
I428
sg70043
VNBPF
p80910
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp80911
g70042
I395
sg70043
Vneuroblastoma breakpoint family
p80912
sg70045
I31
sg70046
g12
sg70048
I3
sa(dp80913
g70042
I131
sg70043
VIGF2R
p80914
sg70045
I5
sg70046
VP11717
p80915
sg70048
I1
sa(dp80916
g70042
I94
sg70043
Vinsulin-like growth factor receptor
p80917
sg70045
I35
sg70046
VP01308
p80918
sg70048
I4
sa(dp80919
g70042
I84
sg70043
VLRP1
p80920
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp80921
g70042
I155
sg70043
g80895
sg70045
I10
sg70046
VP15814
p80922
sg70048
I2
sasg70051
(lp80923
(dp80924
g70042
I63
sg70043
VAlzheimer's disease
p80925
sg70045
I19
sg70054
VC1521724
p80926
sg70048
I2
sa(dp80927
g70042
I197
sg70043
Vinflammatory reaction
p80928
sg70045
I21
sg70054
VC0021368
p80929
sg70048
I2
sa(dp80930
g70042
I293
sg70043
VNHS
p80931
sg70045
I3
sg70054
VC0796085
p80932
sg70048
I1
sa(dp80933
g70042
I395
sg70043
g80896
sg70045
I13
sg70054
VC0027819
p80934
sg70048
I1
sasa(dp80935
g135
(dp80936
(Vapolipoprotein A-I
p80937
Vlymphoma
p80938
tp80939
I00
ssg70037
VUsing principal components analysis, spots containing immunoglobulin J chain, apolipoprotein A-I, procollagen C-endopeptidase enhancer-1 and complement C4-A were associated with lymphoma development (P &lt; 0.0001).
p80940
sg70039
(lp80941
(dp80942
g70042
I54
sg70043
Vimmunoglobulin J chain
p80943
sg70045
I22
sg70046
VP01591
p80944
sg70048
I3
sa(dp80945
g70042
I98
sg70043
Vprocollagen C-endopeptidase enhancer-1
p80946
sg70045
I38
sg70046
g12
sg70048
I3
sa(dp80947
g70042
I141
sg70043
Vcomplement C4-A
p80948
sg70045
I15
sg70046
g12
sg70048
I2
sa(dp80949
g70042
I78
sg70043
g80937
sg70045
I18
sg70046
VP02647
p80950
sg70048
I2
sasg70051
(lp80951
(dp80952
g70042
I37
sg70043
Vspots
p80953
sg70045
I5
sg70054
VC0015230
p80954
sg70048
I1
sa(dp80955
g70042
I178
sg70043
g80938
sg70045
I8
sg70054
VC0024299
p80956
sg70048
I1
sasa(dp80957
g70037
VThe relationship between combined temperature factors showed a linear impact until reaching high temperatures limiting malaria incidence, with a lag 3.25 months.
p80958
sg70039
(lp80959
sg70051
(lp80960
(dp80961
g70042
I119
sg70043
Vmalaria
p80962
sg70045
I7
sg70054
VC0024530
p80963
sg70048
I1
sasa(dp80964
g135
(dp80965
(VPD-1
p80966
Vmalaria
p80967
tp80968
I00
ssg70037
VExperimental models of malaria have shown that the regulatory molecules, cytotoxic T-lymphocyte attenuator-4 (CTLA-4), lymphocyte activation gene-3 (LAG-3), and programmed death-1 (PD-1) are involved in the functional impairment of T cells during infection.
p80969
sg70039
(lp80970
(dp80971
g70042
I119
sg70043
Vlymphocyte activation gene-3
p80972
sg70045
I28
sg70046
VP05154
p80973
sg70048
I3
sa(dp80974
g70042
I110
sg70043
VCTLA-4
p80975
sg70045
I6
sg70046
VP16410
p80976
sg70048
I1
sa(dp80977
g70042
I149
sg70043
VLAG-3
p80978
sg70045
I5
sg70046
VP16949
p80979
sg70048
I1
sa(dp80980
g70042
I161
sg70043
Vprogrammed death-1
p80981
sg70045
I18
sg70046
VP18621
p80982
sg70048
I2
sa(dp80983
g70042
I73
sg70043
Vcytotoxic T-lymphocyte attenuator-4
p80984
sg70045
I35
sg70046
VP16410
p80985
sg70048
I3
sa(dp80986
g70042
I181
sg70043
g80966
sg70045
I4
sg70046
VP18621
p80987
sg70048
I1
sasg70051
(lp80988
(dp80989
g70042
I23
sg70043
g80967
sg70045
I7
sg70054
VC0024530
p80990
sg70048
I1
sa(dp80991
g70042
I218
sg70043
Vimpairment
p80992
sg70045
I10
sg70054
VC0684336
p80993
sg70048
I1
sa(dp80994
g70042
I247
sg70043
Vinfection
p80995
sg70045
I9
sg70054
VC0009450
p80996
sg70048
I1
sasa(dp80997
g135
(dp80998
(VHLA-G
p80999
VChagas disease
p81000
tp81001
I00
ssg70037
VWe evaluated the HLA-G 3' untranslated region (3'UTR) polymorphic sites (associated with mRNA stability and target for microRNA binding) and HLA-G tissue expression (heart, colon, and esophagus) in patients presenting Chagas disease, stratified according to the major clinical variants.
p81002
sg70039
(lp81003
(dp81004
g70042
I17
sg70043
g80999
sg70045
I5
sg70046
VP17693
p81005
sg70048
I1
sasg70051
(lp81006
(dp81007
g70042
I218
sg70043
g81000
sg70045
I14
sg70054
VC0041234
p81008
sg70048
I2
sasa(dp81009
g135
(dp81010
(VHLA-G 3'UTR susceptibility
p81011
VChagas disease
p81012
tp81013
I00
ssg70037
VChagas disease patients exhibited differential HLA-G 3'UTR susceptibility allele/genotype/haplotype patterns, according to the major clinical variant (digestive/cardiac/mixed/indeterminate).
p81014
sg70039
(lp81015
(dp81016
g70042
I47
sg70043
g81011
sg70045
I26
sg70046
VP17693
p81017
sg70048
I3
sasg70051
(lp81018
(dp81019
g70042
I0
sg70043
g81012
sg70045
I14
sg70054
VC0041234
p81020
sg70048
I2
sasa(dp81021
g70037
VWe studied the arthritis association and the spliceo-transcriptome of four different Ltab-Ncr3 haplotypes and showed that higher Ltb and Ncr3 expression, lower Lst1 expression, and the expression of a shorter splice variant of Lst1 correlate with reduced arthritis severity in rats.
p81022
sg70039
(lp81023
(dp81024
g70042
I160
sg70043
VLst1
p81025
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp81026
g70042
I129
sg70043
VLtb
p81027
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp81028
g70042
I160
sg70043
VLst1
p81029
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp81030
(dp81031
g70042
I15
sg70043
Varthritis
p81032
sg70045
I9
sg70054
VC0003864
p81033
sg70048
I1
sa(dp81034
g70042
I15
sg70043
Varthritis
p81035
sg70045
I9
sg70054
VC0003864
p81036
sg70048
I1
sasa(dp81037
g135
(dp81038
(VGNB3
p81039
Vessential hypertension
p81040
tp81041
I00
ssg70037
VThe C825T polymorphism (rs5443) of the Guanine Nucleotide-Binding protein subunit Beta3 (GNB3) gene has been associated with obesity, essential hypertension, atherosclerosis, coronary diseases, and cerebrovascular events, but with some sex-specific effects.
p81042
sg70039
(lp81043
(dp81044
g70042
I39
sg70043
VGuanine Nucleotide-Binding protein subunit Beta3
p81045
sg70045
I48
sg70046
VP09471
p81046
sg70048
I5
sa(dp81047
g70042
I89
sg70043
g81039
sg70045
I4
sg70046
VP16520
p81048
sg70048
I1
sasg70051
(lp81049
(dp81050
g70042
I125
sg70043
Vobesity
p81051
sg70045
I7
sg70054
VC0028754
p81052
sg70048
I1
sa(dp81053
g70042
I158
sg70043
Vatherosclerosis, coronary
p81054
sg70045
I25
sg70054
VC0010054
p81055
sg70048
I2
sa(dp81056
g70042
I134
sg70043
g81040
sg70045
I22
sg70054
VC0085580
p81057
sg70048
I2
sasa(dp81058
g135
(dp81059
(VGNB3
p81060
VEH
p81061
tp81062
I00
ssg70037
VThe guanine nucleotide-binding protein beta polypeptide 3 (GNB3) 825T allele encodes a product that enhances the activation of heterotrimeric G proteins, which is associated with the occurrence of the splice variant GBeta3 s that could play a role in vascular reactivity and hyperproliferation of smooth muscle cells, that makes such proteins attractive candidate gene products for susceptibility to essential hypertension (EH).
p81063
sg70039
(lp81064
(dp81065
g70042
I201
sg70043
Vsplice variant GBeta3 s
p81066
sg70045
I23
sg70046
VP26640
p81067
sg70048
I4
sa(dp81068
g70042
I4
sg70043
Vguanine nucleotide-binding protein beta polypeptide 3
p81069
sg70045
I53
sg70046
VP09471
p81070
sg70048
I6
sa(dp81071
g70042
I127
sg70043
Vheterotrimeric G proteins
p81072
sg70045
I25
sg70046
g12
sg70048
I3
sa(dp81073
g70042
I59
sg70043
g81060
sg70045
I4
sg70046
VP16520
p81074
sg70048
I1
sasg70051
(lp81075
(dp81076
g70042
I400
sg70043
Vessential hypertension
p81077
sg70045
I22
sg70054
VC0085580
p81078
sg70048
I2
sa(dp81079
g70042
I424
sg70043
g81061
sg70045
I2
sg70054
VC0085580
p81080
sg70048
I1
sasa(dp81081
g135
(dp81082
(VAng II
p81083
Vinflammation
p81084
tp81085
I00
ssg70037
VIn our investigation of how Ang II signals are converted by the AT1R from physiological to pathological outputs, we found that the purinergic P2Y6 receptor (P2Y6R), an inflammation-inducible G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR), promoted Ang II-induced hypertension in mice.
p81086
sg70039
(lp81087
(dp81088
g70042
I28
sg70043
VAng II
p81089
sg70045
I6
sg70046
VP01019
p81090
sg70048
I2
sa(dp81091
g70042
I64
sg70043
VAT1R
p81092
sg70045
I4
sg70046
VP30556
p81093
sg70048
I1
sa(dp81094
g70042
I271
sg70043
VGPCR
p81095
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp81096
g70042
I28
sg70043
g81083
sg70045
I6
sg70046
VP01019
p81097
sg70048
I2
sa(dp81098
g70042
I131
sg70043
Vpurinergic P2Y6 receptor
p81099
sg70045
I24
sg70046
g12
sg70048
I3
sa(dp81100
g70042
I191
sg70043
VG protein
p81101
sg70045
I9
sg70046
g12
sg70048
I2
sasg70051
(lp81102
(dp81103
g70042
I302
sg70043
Vhypertension
p81104
sg70045
I12
sg70054
VC0020538
p81105
sg70048
I1
sa(dp81106
g70042
I168
sg70043
g81084
sg70045
I12
sg70054
VC0021368
p81107
sg70048
I1
sasa(dp81108
g135
(dp81109
(Vheterotrimeric guanine nucleotide-binding protein
p81110
Vpreeclampsia
p81111
tp81112
I00
ssg70037
VWe identified the role of regulator of G protein (heterotrimeric guanine nucleotide-binding protein) signaling 5 (RGS5) in blood pressure regulation during pregnancy and preeclampsia.
p81113
sg70039
(lp81114
(dp81115
g70042
I114
sg70043
VRGS5
p81116
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp81117
g70042
I39
sg70043
VG protein
p81118
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp81119
g70042
I50
sg70043
g81110
sg70045
I49
sg70046
VP09471
p81120
sg70048
I4
sasg70051
(lp81121
(dp81122
g70042
I170
sg70043
g81111
sg70045
I12
sg70054
VC0032914
p81123
sg70048
I1
sasa(dp81124
g70037
VHere, we investigated the expression and function of NR6A1 and its underlying mechanisms in prostate cancer (PCa) patients who underwent radical prostatectomy.
p81125
sg70039
(lp81126
(dp81127
g70042
I53
sg70043
VNR6A1
p81128
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp81129
(dp81130
g70042
I92
sg70043
Vprostate cancer
p81131
sg70045
I15
sg70054
VC0600139
p81132
sg70048
I2
sa(dp81133
g70042
I109
sg70043
VPCa
p81134
sg70045
I3
sg70054
VC0268398
p81135
sg70048
I1
sasa(dp81136
g70037
VA total of 303 cases of prostate cancer after radical prostatectomy were analysed in a tissue microarray (TMA) for NR6A1 immunohistochemistry-based protein expression.
p81137
sg70039
(lp81138
(dp81139
g70042
I115
sg70043
VNR6A1 immunohistochemistry-based protein
p81140
sg70045
I40
sg70046
g12
sg70048
I3
sasg70051
(lp81141
(dp81142
g70042
I24
sg70043
Vprostate cancer
p81143
sg70045
I15
sg70054
VC0600139
p81144
sg70048
I2
sasa(dp81145
g70037
VKnockdown of NR6A1 by small interfering RNA mediated gene silencing and overexpression of NR6A1 through lentivirus were utilized to investigate its potential role in prostate cancer cells.
p81146
sg70039
(lp81147
(dp81148
g70042
I13
sg70043
VNR6A1
p81149
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp81150
g70042
I13
sg70043
VNR6A1
p81151
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp81152
(dp81153
g70042
I166
sg70043
Vprostate cancer
p81154
sg70045
I15
sg70054
VC0600139
p81155
sg70048
I2
sasa(dp81156
g70037
VIn addition, gene silencing of NR6A1 resulted in G0/G1 phase cell cycle arrest, and decreased metastatic and invasive potential of prostate cancer cells DU145 and PC3.
p81157
sg70039
(lp81158
(dp81159
g70042
I31
sg70043
VNR6A1
p81160
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp81161
(dp81162
g70042
I131
sg70043
Vprostate cancer
p81163
sg70045
I15
sg70054
VC0600139
p81164
sg70048
I2
sasa(dp81165
g70037
VIn contrast, overexpression of NR6A1 reduced G0/G1 phase cell cycle arrest, and promoted metastatic and invasive potential of prostate cancer cells 22RV1.
p81166
sg70039
(lp81167
(dp81168
g70042
I31
sg70043
VNR6A1
p81169
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp81170
(dp81171
g70042
I126
sg70043
Vprostate cancer
p81172
sg70045
I15
sg70054
VC0600139
p81173
sg70048
I2
sasa(dp81174
g70037
VThe increasing age and number of RTR is likely to be paralleled by an increase of prostate cancer (PCa) incidence.
p81175
sg70039
(lp81176
(dp81177
g70042
I33
sg70043
VRTR
p81178
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp81179
(dp81180
g70042
I82
sg70043
Vprostate cancer
p81181
sg70045
I15
sg70054
VC0600139
p81182
sg70048
I2
sa(dp81183
g70042
I99
sg70043
VPCa
p81184
sg70045
I3
sg70054
VC0268398
p81185
sg70048
I1
sasa(dp81186
g70037
VWe conducted a multicenter retrospective study and reviewed the charts and records of 20 RTRs who had undergone RRP for localized prostate cancer at four French renal transplant centers belonging to the Renal Transplantation Committee of the French Urological Association from April 1996 to April 2007.
p81187
sg70039
(lp81188
(dp81189
g70042
I112
sg70043
VRRP
p81190
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp81191
(dp81192
g70042
I130
sg70043
Vprostate cancer
p81193
sg70045
I15
sg70054
VC0600139
p81194
sg70048
I2
sasa(dp81195
g70037
VIn our study, RRP was a safe procedure to treat localized prostate cancer in RTRs.
p81196
sg70039
(lp81197
sg70051
(lp81198
(dp81199
g70042
I58
sg70043
Vprostate cancer
p81200
sg70045
I15
sg70054
VC0600139
p81201
sg70048
I2
sasa(dp81202
g70037
VIn this study, we examine the expression of RTR in murine placenta and several human placental choriocarcinoma cell lines.
p81203
sg70039
(lp81204
(dp81205
g70042
I44
sg70043
VRTR
p81206
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp81207
(dp81208
g70042
I85
sg70043
Vplacental choriocarcinoma
p81209
sg70045
I25
sg70054
VC0855173
p81210
sg70048
I2
sasa(dp81211
g70037
VRTR mRNA was also expressed in rat choriocarcinoma Rcho-1 cells and in the human placental choriocarcinoma cell lines BeWo, JAR, and JEG-3.
p81212
sg70039
(lp81213
(dp81214
g70042
I0
sg70043
VRTR mRNA
p81215
sg70045
I8
sg70046
g12
sg70048
I2
sasg70051
(lp81216
(dp81217
g70042
I31
sg70043
Vrat choriocarcinoma
p81218
sg70045
I19
sg70054
VC1882624
p81219
sg70048
I2
sa(dp81220
g70042
I81
sg70043
Vplacental choriocarcinoma
p81221
sg70045
I25
sg70054
VC0855173
p81222
sg70048
I2
sasa(dp81223
g135
(dp81224
(VPSA nadir
p81225
VPSA
p81226
tp81227
I00
ssg70037
VTo evaluate the prognostic significance of PSA nadir (nPSA) and the time to nadir in disease free of recurrence (DFR) in localized carcinoma of prostate treated with radical radiotherapy (RTR).
p81228
sg70039
(lp81229
(dp81230
g70042
I43
sg70043
g81225
sg70045
I9
sg70046
VP55786
p81231
sg70048
I2
sasg70051
(lp81232
(dp81233
g70042
I101
sg70043
Vrecurrence
p81234
sg70045
I10
sg70054
VC1458156
p81235
sg70048
I1
sa(dp81236
g70042
I131
sg70043
Vcarcinoma of prostate
p81237
sg70045
I21
sg70054
VC0600139
p81238
sg70048
I3
sa(dp81239
g70042
I43
sg70043
g81226
sg70045
I3
sg70054
VC1519176
p81240
sg70048
I1
sasa(dp81241
g135
(dp81242
(VPC1
p81243
VPC1
p81244
tp81245
I00
ssg70037
VThe present study was aimed to determine the effect of steviol on PC1, CFTR, and Beta-catenin levels in renal epithelial cells with defective PC1 biogenesis and expression (Prkcsh-/- cell) and postnatal Pkd1 homozygous cell (Pkd1-/- cells).
p81246
sg70039
(lp81247
(dp81248
g70042
I71
sg70043
VCFTR
p81249
sg70045
I4
sg70046
VP13569
p81250
sg70048
I1
sa(dp81251
g70042
I203
sg70043
VPkd1 homozygous cell
p81252
sg70045
I20
sg70046
VP98161
p81253
sg70048
I3
sa(dp81254
g70042
I203
sg70043
VPkd1
p81255
sg70045
I4
sg70046
VP98161
p81256
sg70048
I1
sa(dp81257
g70042
I81
sg70043
VBeta-catenin
p81258
sg70045
I12
sg70046
VP35222
p81259
sg70048
I1
sa(dp81260
g70042
I66
sg70043
g81243
sg70045
I3
sg70046
VP98161
p81261
sg70048
I1
sasg70051
(lp81262
(dp81263
g70042
I203
sg70043
VPkd1
p81264
sg70045
I4
sg70054
VC3149841
p81265
sg70048
I1
sa(dp81266
g70042
I203
sg70043
VPkd1
p81267
sg70045
I4
sg70054
VC3149841
p81268
sg70048
I1
sa(dp81269
g70042
I66
sg70043
VPC1
p81270
sg70045
I3
sg70054
VC1706595
p81271
sg70048
I1
sa(dp81272
g70042
I66
sg70043
g81244
sg70045
I3
sg70054
VC1706595
p81273
sg70048
I1
sasa(dp81274
g135
(dp81275
(VBeta-catenin protein
p81276
VPC1
p81277
tp81278
I00
ssg70037
VUsing western blot analysis, it was found that steviol treatment at 100myM for 24-48h substantially enhanced and stabilized PC1 C-terminal expression, while decreasing CFTR and Beta-catenin protein expression in both Prkcsh-/- and Pkd1-/- cells.
p81279
sg70039
(lp81280
(dp81281
g70042
I231
sg70043
VPkd1
p81282
sg70045
I4
sg70046
VP98161
p81283
sg70048
I1
sa(dp81284
g70042
I124
sg70043
VPC1 C
p81285
sg70045
I5
sg70046
VP98161
p81286
sg70048
I2
sa(dp81287
g70042
I168
sg70043
VCFTR
p81288
sg70045
I4
sg70046
VP13569
p81289
sg70048
I1
sa(dp81290
g70042
I177
sg70043
g81276
sg70045
I20
sg70046
VP35222
p81291
sg70048
I2
sasg70051
(lp81292
(dp81293
g70042
I231
sg70043
VPkd1
p81294
sg70045
I4
sg70054
VC3149841
p81295
sg70048
I1
sa(dp81296
g70042
I124
sg70043
g81277
sg70045
I3
sg70054
VC1706595
p81297
sg70048
I1
sasa(dp81298
g135
(dp81299
(VPkd1-null
p81300
Vcellular proliferation
p81301
tp81302
I00
ssg70037
VKPT-9274 can attenuate cellular proliferation and induce apoptosis associated with a decrease in active (phosphorylated) PAK4 and Beta-catenin in several Pkd1-null murine cell lines, with a less pronounced effect on the corresponding phenotypically normal cells.
p81303
sg70039
(lp81304
(dp81305
g70042
I130
sg70043
VBeta-catenin
p81306
sg70045
I12
sg70046
VP35222
p81307
sg70048
I1
sa(dp81308
g70042
I121
sg70043
VPAK4
p81309
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp81310
g70042
I154
sg70043
g81300
sg70045
I9
sg70046
VP98161
p81311
sg70048
I1
sasg70051
(lp81312
(dp81313
g70042
I154
sg70043
VPkd1
p81314
sg70045
I4
sg70054
VC3149841
p81315
sg70048
I1
sa(dp81316
g70042
I23
sg70043
g81301
sg70045
I22
sg70054
VC0020507
p81317
sg70048
I2
sasa(dp81318
g135
(dp81319
(VPKD1
p81320
VPKD1
p81321
tp81322
I00
ssg70037
VGiven the fundamental role of Beta-catenin signaling in intestinal epithelial cell proliferation and the growth-promoting function of protein kinase D1 (PKD1) in these cells, we hypothesized that PKDs mediate cross talk with Beta-catenin signaling.
p81323
sg70039
(lp81324
(dp81325
g70042
I134
sg70043
Vprotein kinase D1
p81326
sg70045
I17
sg70046
g12
sg70048
I3
sa(dp81327
g70042
I30
sg70043
VBeta-catenin
p81328
sg70045
I12
sg70046
VP35222
p81329
sg70048
I1
sa(dp81330
g70042
I196
sg70043
VPKDs
p81331
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp81332
g70042
I30
sg70043
VBeta-catenin
p81333
sg70045
I12
sg70046
VP35222
p81334
sg70048
I1
sa(dp81335
g70042
I153
sg70043
g81320
sg70045
I4
sg70046
VP98161
p81336
sg70048
I1
sasg70051
(lp81337
(dp81338
g70042
I134
sg70043
Vprotein kinase D1
p81339
sg70045
I17
sg70054
VC3149841
p81340
sg70048
I3
sa(dp81341
g70042
I83
sg70043
Vproliferation
p81342
sg70045
I13
sg70054
VC0334094
p81343
sg70048
I1
sa(dp81344
g70042
I153
sg70043
g81321
sg70045
I4
sg70054
VC3149841
p81345
sg70048
I1
sasa(dp81346
g135
(dp81347
(VPKD1
p81348
VPKD1
p81349
tp81350
I00
ssg70037
VGPCR stimulation also induced the formation of a complex between PKD1 and Beta-catenin, as shown by coimmunoprecipitation that depended on PKD1 catalytic activation, as it was abrogated by cell treatment with PKD family inhibitors.
p81351
sg70039
(lp81352
(dp81353
g70042
I74
sg70043
VBeta-catenin
p81354
sg70045
I12
sg70046
VP35222
p81355
sg70048
I1
sa(dp81356
g70042
I209
sg70043
VPKD family
p81357
sg70045
I10
sg70046
VP98161
p81358
sg70048
I2
sa(dp81359
g70042
I0
sg70043
VGPCR
p81360
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp81361
g70042
I65
sg70043
VPKD1
p81362
sg70045
I4
sg70046
VP98161
p81363
sg70048
I1
sa(dp81364
g70042
I65
sg70043
g81348
sg70045
I4
sg70046
VP98161
p81365
sg70048
I1
sasg70051
(lp81366
(dp81367
g70042
I65
sg70043
VPKD
p81368
sg70045
I3
sg70054
VC1868682
p81369
sg70048
I1
sa(dp81370
g70042
I65
sg70043
VPKD1
p81371
sg70045
I4
sg70054
VC3149841
p81372
sg70048
I1
sa(dp81373
g70042
I65
sg70043
g81349
sg70045
I4
sg70054
VC3149841
p81374
sg70048
I1
sasa(dp81375
g135
(dp81376
(VPKD1 protein
p81377
VPKD1
p81378
tp81379
I00
ssg70037
VUsing transgenic mice that express elevated PKD1 protein in the intestinal epithelium, we detected a marked increase in the localization of Beta-catenin in the nucleus of crypt epithelial cells in the ileum of PKD1 transgenic mice, compared with nontransgenic littermates.
p81380
sg70039
(lp81381
(dp81382
g70042
I44
sg70043
VPKD1
p81383
sg70045
I4
sg70046
VP98161
p81384
sg70048
I1
sa(dp81385
g70042
I140
sg70043
VBeta-catenin
p81386
sg70045
I12
sg70046
VP35222
p81387
sg70048
I1
sa(dp81388
g70042
I44
sg70043
g81377
sg70045
I12
sg70046
VP98161
p81389
sg70048
I2
sasg70051
(lp81390
(dp81391
g70042
I44
sg70043
VPKD1
p81392
sg70045
I4
sg70054
VC3149841
p81393
sg70048
I1
sa(dp81394
g70042
I44
sg70043
g81378
sg70045
I4
sg70054
VC3149841
p81395
sg70048
I1
sasa(dp81396
g135
(dp81397
(VKRT6B
p81398
VPachyonychia congenita
p81399
tp81400
I00
ssg70037
VPachyonychia congenita subjects were sampled who exhibited a mutation in KRT6A, KRT6B, KRT6C, KRT16 or KRT17, and the proteins were digested and analyzed by tandem mass spectrometry.
p81401
sg70039
(lp81402
(dp81403
g70042
I73
sg70043
VKRT6A
p81404
sg70045
I5
sg70046
VP02538
p81405
sg70048
I1
sa(dp81406
g70042
I94
sg70043
VKRT16
p81407
sg70045
I5
sg70046
VP08779
p81408
sg70048
I1
sa(dp81409
g70042
I87
sg70043
VKRT6C
p81410
sg70045
I5
sg70046
VP48668
p81411
sg70048
I1
sa(dp81412
g70042
I80
sg70043
g81398
sg70045
I5
sg70046
VP08779
p81413
sg70048
I1
sasg70051
(lp81414
(dp81415
g70042
I0
sg70043
g81399
sg70045
I22
sg70054
VC0265334
p81416
sg70048
I2
sasa(dp81417
g135
(dp81418
(Vkeratin 16
p81419
Vhyperplasia
p81420
tp81421
I00
ssg70037
VWe thus performed extensive biomarker measures in these compartments using univariate and multivariate approaches to correlate disease biomarkers with SCORAD and with a combined hyperplasia score [thickness and keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD patients.
p81422
sg70039
(lp81423
(dp81424
g70042
I223
sg70043
VK16
p81425
sg70045
I3
sg70046
VP04264
p81426
sg70048
I1
sa(dp81427
g70042
I211
sg70043
g81419
sg70045
I10
sg70046
VP04264
p81428
sg70048
I2
sasg70051
(lp81429
(dp81430
g70042
I178
sg70043
g81420
sg70045
I11
sg70054
VC0020507
p81431
sg70048
I1
sasa(dp81432
g135
(dp81433
(VKRT16
p81434
VCRPS
p81435
tp81436
I00
ssg70037
VIn addition to increased abundance, KRT16 demonstrated autoantigenicity, since sera from both fracture mice and CRPS patients showed increased autoantibody binding to recombinant kRT16 protein.
p81437
sg70039
(lp81438
(dp81439
g70042
I167
sg70043
Vrecombinant kRT16 protein
p81440
sg70045
I25
sg70046
VP08779
p81441
sg70048
I3
sa(dp81442
g70042
I36
sg70043
g81434
sg70045
I5
sg70046
VP08779
p81443
sg70048
I1
sasg70051
(lp81444
(dp81445
g70042
I112
sg70043
g81435
sg70045
I4
sg70054
VC0458219
p81446
sg70048
I1
sasa(dp81447
g135
(dp81448
(VKRT16
p81449
VCRPS
p81450
tp81451
I00
ssg70037
VThe identification of autoantibodies against KRT16 as a biomarker in mice and in humans is a critical step towards these goals, and towards redefining CRPS as having an autoimmune etiology.
p81452
sg70039
(lp81453
(dp81454
g70042
I45
sg70043
g81449
sg70045
I5
sg70046
VP08779
p81455
sg70048
I1
sasg70051
(lp81456
(dp81457
g70042
I169
sg70043
Vautoimmune
p81458
sg70045
I10
sg70054
VC0443146
p81459
sg70048
I1
sa(dp81460
g70042
I151
sg70043
g81450
sg70045
I4
sg70054
VC0458219
p81461
sg70048
I1
sasa(dp81462
g135
(dp81463
(VBcl-2 family
p81464
Vpancreatitis
p81465
tp81466
I00
ssg70037
VThese findings were associated with upregulation of mitochondrial Bak and Bcl-2/Bcl-xL, proapoptotic and prosurvival members in the Bcl-2 family, respectively, as well as increased mitochondrial cytochrome c release, caspase activation, and apoptosis in pancreatitis in PKCEpsilon knockout mice.
p81467
sg70039
(lp81468
(dp81469
g70042
I181
sg70043
Vmitochondrial cytochrome c release
p81470
sg70045
I34
sg70046
VP99999
p81471
sg70048
I4
sa(dp81472
g70042
I66
sg70043
VBak
p81473
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp81474
g70042
I80
sg70043
VBcl-xL
p81475
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp81476
g70042
I74
sg70043
VBcl-2
p81477
sg70045
I5
sg70046
VP10415
p81478
sg70048
I1
sa(dp81479
g70042
I217
sg70043
Vcaspase
p81480
sg70045
I7
sg70046
VP39880
p81481
sg70048
I1
sa(dp81482
g70042
I132
sg70043
g81464
sg70045
I12
sg70046
VP10415
p81483
sg70048
I2
sasg70051
(lp81484
(dp81485
g70042
I254
sg70043
g81465
sg70045
I12
sg70054
VC0030305
p81486
sg70048
I1
sasa(dp81487
g135
(dp81488
(Vlactate dehydrogenase
p81489
Vhypoglycemia
p81490
tp81491
I00
ssg70037
VWe then microinjected a GABAA receptor antagonist, an inhibitor of lactate transport (4CIN), or an inhibitor of lactate dehydrogenase, oxamate (OX), into the VMH prior to inducing hypoglycemia.
p81492
sg70039
(lp81493
(dp81494
g70042
I24
sg70043
VGABAA receptor
p81495
sg70045
I14
sg70046
g12
sg70048
I2
sa(dp81496
g70042
I112
sg70043
g81489
sg70045
I21
sg70046
VP49366
p81497
sg70048
I2
sasg70051
(lp81498
(dp81499
g70042
I180
sg70043
g81490
sg70045
I12
sg70054
VC0020615
p81500
sg70048
I1
sasa(dp81501
g70037
VTo assess whether lactate contributes to raising GABA in RH and diabetes, we injected 4CIN or OX into the VMH of RH and diabetic rats before inducing hypoglycemia.
p81502
sg70039
(lp81503
sg70051
(lp81504
(dp81505
g70042
I64
sg70043
Vdiabetes
p81506
sg70045
I8
sg70054
VC0011849
p81507
sg70048
I1
sa(dp81508
g70042
I150
sg70043
Vhypoglycemia
p81509
sg70045
I12
sg70054
VC0020615
p81510
sg70048
I1
sasa(dp81511
g135
(dp81512
(VBcl-2
p81513
Vpancreatitis
p81514
tp81515
I00
ssg70037
VMechanistically, we show that the protective effect of IL-22 on pancreatitis was mediated via the induction of Bcl-2 and Bcl-X(L), which bind to Beclin-1 and subsequently inhibit autophagosome formation to ameliorate pancreatitis.
p81516
sg70039
(lp81517
(dp81518
g70042
I111
sg70043
g81513
sg70045
I5
sg70046
VP10415
p81519
sg70048
I1
sa(dp81520
g70042
I55
sg70043
VIL-22
p81521
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp81522
g70042
I145
sg70043
VBeclin-1
p81523
sg70045
I8
sg70046
g12
sg70048
I1
sa(dp81524
g70042
I121
sg70043
VBcl-X(L)
p81525
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp81526
(dp81527
g70042
I64
sg70043
Vpancreatitis
p81528
sg70045
I12
sg70054
VC0030305
p81529
sg70048
I1
sa(dp81530
g70042
I64
sg70043
g81514
sg70045
I12
sg70054
VC0030305
p81531
sg70048
I1
sasa(dp81532
g135
(dp81533
(VMYL4
p81534
Vcardiomyopathy
p81535
tp81536
I00
ssg70037
VWe used genetically modified rat models to investigate the role of MYL4 in atrial cardiomyopathy.
p81537
sg70039
(lp81538
(dp81539
g70042
I67
sg70043
g81534
sg70045
I4
sg70046
VP12829
p81540
sg70048
I1
sasg70051
(lp81541
(dp81542
g70042
I82
sg70043
g81535
sg70045
I14
sg70054
VC0878544
p81543
sg70048
I1
sasa(dp81544
g135
(dp81545
(VMYL4
p81546
Vcardiomyopathy
p81547
tp81548
I00
ssg70037
VExome sequencing and systematic bioinformatic analyses identified a rare missense variant of MYL4 (c.31G&gt;A [p.E11K]) in a large multiplex atrial cardiomyopathy family pedigree.
p81549
sg70039
(lp81550
(dp81551
g70042
I93
sg70043
g81546
sg70045
I4
sg70046
VP12829
p81552
sg70048
I1
sasg70051
(lp81553
(dp81554
g70042
I148
sg70043
g81547
sg70045
I14
sg70054
VC0878544
p81555
sg70048
I1
sasa(dp81556
g135
(dp81557
(VMYL4
p81558
Vcardiomyopathy
p81559
tp81560
I00
ssg70037
VMYL4 knockout rats showed a similar atrial cardiomyopathy phenotype, whereas rats with an adjacent 4-amino-acid deletion showed no phenotype.
p81561
sg70039
(lp81562
(dp81563
g70042
I0
sg70043
g81558
sg70045
I4
sg70046
VP12829
p81564
sg70048
I1
sasg70051
(lp81565
(dp81566
g70042
I43
sg70043
g81559
sg70045
I14
sg70054
VC0878544
p81567
sg70048
I1
sasa(dp81568
g135
(dp81569
(VMYL4 gene variants
p81570
Vcardiomyopathy
p81571
tp81572
I00
ssg70037
VLoss-of-function MYL4 gene variants cause progressive atrial cardiomyopathy in humans and rats.
p81573
sg70039
(lp81574
(dp81575
g70042
I17
sg70043
g81570
sg70045
I18
sg70046
VP12829
p81576
sg70048
I3
sasg70051
(lp81577
(dp81578
g70042
I61
sg70043
g81571
sg70045
I14
sg70054
VC0878544
p81579
sg70048
I1
sasa(dp81580
g135
(dp81581
(VMYH6
p81582
VAF
p81583
tp81584
I00
ssg70037
VGenome-wide association studies (GWAS) have yielded variants at &gt;30 loci that associate with atrial fibrillation (AF), including rare coding mutations in the sarcomere genes MYH6 and MYL4.
p81585
sg70039
(lp81586
(dp81587
g70042
I186
sg70043
VMYL4
p81588
sg70045
I4
sg70046
VP12829
p81589
sg70048
I1
sa(dp81590
g70042
I177
sg70043
g81582
sg70045
I4
sg70046
VP13533
p81591
sg70048
I1
sasg70051
(lp81592
(dp81593
g70042
I96
sg70043
Vatrial fibrillation
p81594
sg70045
I19
sg70054
VC0004238
p81595
sg70048
I2
sa(dp81596
g70042
I117
sg70043
g81583
sg70045
I2
sg70054
VC0004238
p81597
sg70048
I1
sasa(dp81598
g135
(dp81599
(Vthyroid-stimulating hormone
p81600
Vliver diseases
p81601
tp81602
I00
ssg70037
VWe imputed these variants into 104,220 individuals down to a minor allele frequency of 0.1% and found a recessive frameshift mutation in MYL4 that causes early-onset atrial fibrillation, several mutations in ABCB4 that increase risk of liver diseases and an intronic variant in GNAS associating with increased thyroid-stimulating hormone levels when maternally inherited.
p81603
sg70039
(lp81604
(dp81605
g70042
I137
sg70043
VMYL4
p81606
sg70045
I4
sg70046
VP12829
p81607
sg70048
I1
sa(dp81608
g70042
I208
sg70043
VABCB4
p81609
sg70045
I5
sg70046
VP21439
p81610
sg70048
I1
sa(dp81611
g70042
I310
sg70043
g81600
sg70045
I27
sg70046
VP01222
p81612
sg70048
I2
sasg70051
(lp81613
(dp81614
g70042
I166
sg70043
Vatrial fibrillation
p81615
sg70045
I19
sg70054
VC0004238
p81616
sg70048
I2
sa(dp81617
g70042
I236
sg70043
g81601
sg70045
I14
sg70054
VC0023895
p81618
sg70048
I2
sa(dp81619
g70042
I114
sg70043
Vframeshift mutation
p81620
sg70045
I19
sg70054
VC0079380
p81621
sg70048
I2
sasa(dp81622
g135
(dp81623
(VNDUFV2
p81624
Vencephalopathy
p81625
tp81626
I00
ssg70037
VThe aim of this study is to examine the mitochondrial targeting of NDUFV2 and dissect the pathogenetic mechanism of one human deletion mutation present in patients with early-onset hypertrophic cardiomyopathy and encephalopathy.
p81627
sg70039
(lp81628
(dp81629
g70042
I67
sg70043
g81624
sg70045
I6
sg70046
VP19404
p81630
sg70048
I1
sasg70051
(lp81631
(dp81632
g70042
I181
sg70043
Vhypertrophic cardiomyopathy
p81633
sg70045
I27
sg70054
VC0007194
p81634
sg70048
I2
sa(dp81635
g70042
I213
sg70043
g81625
sg70045
I14
sg70054
VC0085584
p81636
sg70048
I1
sasa(dp81637
g135
(dp81638
(VNDUFV2
p81639
Vencephalopathy
p81640
tp81641
I00
ssg70037
VThe deletion mutant mimicking the human early-onset hypertrophic cardiomyopathy and encephalopathy lacked 19-40 residues in NDUFV2 and exhibited a significant reduction in its mitochondrial targeting ability.
p81642
sg70039
(lp81643
(dp81644
g70042
I124
sg70043
g81639
sg70045
I6
sg70046
VP19404
p81645
sg70048
I1
sasg70051
(lp81646
(dp81647
g70042
I13
sg70043
Vmutant
p81648
sg70045
I6
sg70054
VC0596988
p81649
sg70048
I1
sa(dp81650
g70042
I52
sg70043
Vhypertrophic cardiomyopathy
p81651
sg70045
I27
sg70054
VC0007194
p81652
sg70048
I2
sa(dp81653
g70042
I84
sg70043
g81640
sg70045
I14
sg70054
VC0085584
p81654
sg70048
I1
sasa(dp81655
g135
(dp81656
(VNDUFV2
p81657
Vhypertrophic cardiomyopathy
p81658
tp81659
I00
ssg70037
VThe results of human disease cell model established that the impairment of mitochondrial localization of NDUFV2 as a mechanistic basis for early-onset hypertrophic cardiomyopathy and encephalopathy.
p81660
sg70039
(lp81661
(dp81662
g70042
I105
sg70043
g81657
sg70045
I6
sg70046
VP19404
p81663
sg70048
I1
sasg70051
(lp81664
(dp81665
g70042
I61
sg70043
Vimpairment
p81666
sg70045
I10
sg70054
VC0684336
p81667
sg70048
I1
sa(dp81668
g70042
I183
sg70043
Vencephalopathy
p81669
sg70045
I14
sg70054
VC0085584
p81670
sg70048
I1
sa(dp81671
g70042
I151
sg70043
g81658
sg70045
I27
sg70054
VC0007194
p81672
sg70048
I2
sasa(dp81673
g135
(dp81674
(Vhuman NDUFV2 (IVS2+5_+8delGTAA)
p81675
Vhypertrophic cardiomyopathy
p81676
tp81677
I00
ssg70037
VA small deletion in the second intron of human NDUFV2 (IVS2+5_+8delGTAA) has been shown to cause hypertrophic cardiomyopathy and encephalomyopathy [Benit, P., Beugnot, R., Chretien, D., Giurgea, I., de Lonlay-Debeney, P., Issartel, J.P., Kerscher, S., Rustin, P., Roetig, A.
p81678
sg70039
(lp81679
(dp81680
g70042
I41
sg70043
g81675
sg70045
I31
sg70046
VP19404
p81681
sg70048
I3
sasg70051
(lp81682
(dp81683
g70042
I97
sg70043
g81676
sg70045
I27
sg70054
VC0007194
p81684
sg70048
I2
sasa(dp81685
g135
(dp81686
(VNDUFV2
p81687
Vcardiomyopathy
p81688
tp81689
I00
ssg70037
VWhile mutations in the NDUFS3 gene thus result in Leigh syndrome, a dissimilar clinical phenotype is observed in mutations in the NDUFV2 and NDUFS2 genes, resulting in encephalomyopathy and cardiomyopathy.
p81690
sg70039
(lp81691
(dp81692
g70042
I141
sg70043
VNDUFS2 genes
p81693
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp81694
g70042
I130
sg70043
g81687
sg70045
I6
sg70046
VP19404
p81695
sg70048
I1
sa(dp81696
g70042
I23
sg70043
VNDUFS3 gene
p81697
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp81698
(dp81699
g70042
I50
sg70043
VLeigh syndrome
p81700
sg70045
I14
sg70054
VC0023264
p81701
sg70048
I2
sa(dp81702
g70042
I190
sg70043
g81688
sg70045
I14
sg70054
VC0878544
p81703
sg70048
I1
sasa(dp81704
g135
(dp81705
(VNDUFV2 gene
p81706
Vcomplex I deficiency
p81707
tp81708
I01
ssg70037
VCombination of denaturing high performance liquid chromatography and sequence analysis allowed us to show that a 4-bp deletion in intron 2 (IVS2+5_+8delGTAA) of the NDUFV2 gene (encoding NADH dehydrogenase ubiquinone flavoprotein 2) causes complex I deficiency and early onset hypertrophic cardiomyopathy with trunk hypotonia in three affected sibs of a consanguineous family.
p81709
sg70039
(lp81710
(dp81711
g70042
I187
sg70043
VNADH dehydrogenase ubiquinone flavoprotein 2
p81712
sg70045
I44
sg70046
VP49366
p81713
sg70048
I5
sa(dp81714
g70042
I165
sg70043
g81706
sg70045
I11
sg70046
VP19404
p81715
sg70048
I2
sasg70051
(lp81716
(dp81717
g70042
I316
sg70043
Vhypotonia
p81718
sg70045
I9
sg70054
VC0026827
p81719
sg70048
I1
sa(dp81720
g70042
I277
sg70043
Vhypertrophic cardiomyopathy
p81721
sg70045
I27
sg70054
VC0007194
p81722
sg70048
I2
sa(dp81723
g70042
I240
sg70043
g81707
sg70045
I20
sg70054
VC0342776
p81724
sg70048
I3
sasa(dp81725
g135
(dp81726
(VNDUFV2
p81727
Vcardiomyopathy
p81728
tp81729
I00
ssg70037
VWhile mutation in a number of genes encoding complex I subunits essentially result in neurological symptoms, this first mutation in NDUFV2 is strikingly associated with cardiomyopathy, as previously observed in the unique case of NDFUS2 mutations.
p81730
sg70039
(lp81731
(dp81732
g70042
I132
sg70043
g81727
sg70045
I6
sg70046
VP19404
p81733
sg70048
I1
sasg70051
(lp81734
(dp81735
g70042
I86
sg70043
Vneurological symptoms
p81736
sg70045
I21
sg70054
VC0235031
p81737
sg70048
I2
sa(dp81738
g70042
I169
sg70043
g81728
sg70045
I14
sg70054
VC0878544
p81739
sg70048
I1
sasa(dp81740
g70037
VMice were fed a high fat diet to cause diet-induced obesity (DIO) and then administered GALP intranasally for 2 weeks (experimental), or vehicle (control).
p81741
sg70039
(lp81742
sg70051
(lp81743
(dp81744
g70042
I52
sg70043
Vobesity
p81745
sg70045
I7
sg70054
VC0028754
p81746
sg70048
I1
sasa(dp81747
g135
(dp81748
(VGAL
p81749
Vobesity
p81750
tp81751
I01
ssg70037
VGAL and GALP concentrations may be taken as potential biomarkers to predict development of obesity.
p81752
sg70039
(lp81753
(dp81754
g70042
I0
sg70043
g81749
sg70045
I3
sg70046
VP16278
p81755
sg70048
I1
sa(dp81756
g70042
I8
sg70043
VGALP
p81757
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp81758
(dp81759
g70042
I91
sg70043
g81750
sg70045
I7
sg70054
VC0028754
p81760
sg70048
I1
sasa(dp81761
g70037
VGalanin-like peptide (GALP) has an anti-obesity effect in rats and mice.
p81762
sg70039
(lp81763
(dp81764
g70042
I0
sg70043
VGalanin-like peptide
p81765
sg70045
I20
sg70046
g12
sg70048
I2
sa(dp81766
g70042
I22
sg70043
VGALP
p81767
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp81768
(dp81769
g70042
I40
sg70043
Vobesity
p81770
sg70045
I7
sg70054
VC0028754
p81771
sg70048
I1
sasa(dp81772
g70037
VThese results suggest that intranasal administration is an effective route whereby GALP can exert its effect as an anti-obesity drug.
p81773
sg70039
(lp81774
sg70051
(lp81775
(dp81776
g70042
I120
sg70043
Vobesity
p81777
sg70045
I7
sg70054
VC0028754
p81778
sg70048
I1
sasa(dp81779
g70037
VThese results show that GALP stimulates fatty acid Beta-oxidation in liver and lipolysis in adipose tissue, and suggest that the anti-obesity effect of GALP may be due to anorexigenic actions and improvement of lipid metabolism in peripheral tissues via the sympathetic nervous system.
p81780
sg70039
(lp81781
(dp81782
g70042
I24
sg70043
VGALP
p81783
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp81784
g70042
I24
sg70043
VGALP
p81785
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp81786
(dp81787
g70042
I270
sg70043
Vnervous
p81788
sg70045
I7
sg70054
VC0027769
p81789
sg70048
I1
sa(dp81790
g70042
I134
sg70043
Vobesity
p81791
sg70045
I7
sg70054
VC0028754
p81792
sg70048
I1
sasa(dp81793
g70037
VWe conclude that GALP may be of therapeutic value for obesity and life-style-related diseases in the near future.
p81794
sg70039
(lp81795
(dp81796
g70042
I17
sg70043
VGALP
p81797
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp81798
(dp81799
g70042
I54
sg70043
Vobesity
p81800
sg70045
I7
sg70054
VC0028754
p81801
sg70048
I1
sasa(dp81802
g70037
VGalanin-like peptide (GALP) shows potential as a therapeutic in the treatment of obesity and related conditions.
p81803
sg70039
(lp81804
(dp81805
g70042
I0
sg70043
VGalanin-like peptide
p81806
sg70045
I20
sg70046
g12
sg70048
I2
sa(dp81807
g70042
I22
sg70043
VGALP
p81808
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp81809
(dp81810
g70042
I81
sg70043
Vobesity
p81811
sg70045
I7
sg70054
VC0028754
p81812
sg70048
I1
sasa(dp81813
g70037
VVariations within the gene locus encoding SHP-2 have been associated with increased susceptibility to develop ulcerative colitis and gastric atrophy.
p81814
sg70039
(lp81815
(dp81816
g70042
I42
sg70043
VSHP-2
p81817
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp81818
(dp81819
g70042
I133
sg70043
Vgastric atrophy
p81820
sg70045
I15
sg70054
VC0017154
p81821
sg70048
I2
sa(dp81822
g70042
I110
sg70043
Vulcerative colitis
p81823
sg70045
I18
sg70054
VC0009324
p81824
sg70048
I2
sasa(dp81825
g135
(dp81826
(VPGC rs4711690-PGC rs6912200-PTPN11 rs12229892
p81827
Vgastric cancer
p81828
tp81829
I00
ssg70037
VWhen we considered the host genetic effects alone, gene-gene interactions consistently decreased the risks of gastric cancer and/or atrophic gastritis, including three two-way interactions: PGC rs6912200-PTPN11 rs12229892, PGC rs4711690-IL1B rs1143623 and PTPN11 rs12229892-IL1B rs1143623 and a three-way interaction: PGC rs4711690-PGC rs6912200-PTPN11 rs12229892.
p81830
sg70039
(lp81831
(dp81832
g70042
I190
sg70043
VPGC rs6912200-PTPN11 rs12229892
p81833
sg70045
I31
sg70046
VP20142
p81834
sg70048
I3
sa(dp81835
g70042
I223
sg70043
VPGC rs4711690-IL1B rs1143623
p81836
sg70045
I28
sg70046
VP20142
p81837
sg70048
I3
sa(dp81838
g70042
I318
sg70043
g81827
sg70045
I45
sg70046
VP20142
p81839
sg70048
I4
sa(dp81840
g70042
I256
sg70043
VPTPN11 rs12229892-IL1B rs1143623
p81841
sg70045
I32
sg70046
g12
sg70048
I3
sasg70051
(lp81842
(dp81843
g70042
I132
sg70043
Vatrophic gastritis
p81844
sg70045
I18
sg70054
VC0017154
p81845
sg70048
I2
sa(dp81846
g70042
I110
sg70043
g81828
sg70045
I14
sg70054
VC0024623
p81847
sg70048
I2
sasa(dp81848
g70037
VInconsistency of reported associations of the G/A polymorphism (rs2301756) in the PTPN11 gene and gastric atrophy prompted us to undertake a meta-analysis.
p81849
sg70039
(lp81850
(dp81851
g70042
I82
sg70043
VPTPN11 gene
p81852
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp81853
(dp81854
g70042
I98
sg70043
Vgastric atrophy
p81855
sg70045
I15
sg70054
VC0017154
p81856
sg70048
I2
sasa(dp81857
g70037
VAssociations of PTPN11 polymorphism with gastric atrophy in H. pylori (-) and (+) subjects are more readily interpreted in the homozygous and recessive models given that the dominant codominant effects skirted null associations.
p81858
sg70039
(lp81859
(dp81860
g70042
I16
sg70043
VPTPN11
p81861
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp81862
(dp81863
g70042
I41
sg70043
Vgastric atrophy
p81864
sg70045
I15
sg70054
VC0017154
p81865
sg70048
I2
sasa(dp81866
g70037
VEvidence of overall and subgroup decreased risks, strong in seropositive subjects, demonstrates protective effects of the PTPN11 G/A polymorphism from gastric atrophy.
p81867
sg70039
(lp81868
(dp81869
g70042
I122
sg70043
VPTPN11 G/A
p81870
sg70045
I10
sg70046
g12
sg70048
I2
sasg70051
(lp81871
(dp81872
g70042
I151
sg70043
Vgastric atrophy
p81873
sg70045
I15
sg70054
VC0017154
p81874
sg70048
I2
sasa(dp81875
g135
(dp81876
(VcagA
p81877
Vgastric cancer
p81878
tp81879
I00
ssg70037
VThe interaction between Src homology 2 domain-containing protein tyrosine phosphatase (SHP-2) of gastric epithelial cells and cagA from H. pylori plays a crucial role in developments of gastric atrophy and gastric cancer.
p81880
sg70039
(lp81881
(dp81882
g70042
I24
sg70043
VSrc homology 2 domain-containing protein tyrosine phosphatase
p81883
sg70045
I61
sg70046
VP12931
p81884
sg70048
I7
sa(dp81885
g70042
I126
sg70043
g81877
sg70045
I4
sg70046
VP05109
p81886
sg70048
I1
sa(dp81887
g70042
I87
sg70043
VSHP-2
p81888
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp81889
(dp81890
g70042
I186
sg70043
Vgastric atrophy
p81891
sg70045
I15
sg70054
VC0017154
p81892
sg70048
I2
sa(dp81893
g70042
I206
sg70043
g81878
sg70045
I14
sg70054
VC0024623
p81894
sg70048
I2
sasa(dp81895
g70037
VThis study aimed to investigate the association of haplotype tagging SNPs (htSNPs) in the PTPN11 gene encoding SHP-2 with gastric atrophy and gastric cancer in Chinese population.
p81896
sg70039
(lp81897
(dp81898
g70042
I111
sg70043
VSHP-2
p81899
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp81900
g70042
I90
sg70043
VPTPN11 gene
p81901
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp81902
(dp81903
g70042
I122
sg70043
Vgastric atrophy
p81904
sg70045
I15
sg70054
VC0017154
p81905
sg70048
I2
sa(dp81906
g70042
I142
sg70043
Vgastric cancer
p81907
sg70045
I14
sg70054
VC0024623
p81908
sg70048
I2
sasa(dp81909
g70037
VOur study provides the first evidence that rs12423190 polymorphism of the PTPN11 gene is significantly associated with an increased risk of gastric atrophy in H. pylori infected Chinese Han population, suggesting that rs12423190 polymorphism could be used as a useful marker of genetic susceptibility to gastric atrophy among H. pylori infected subjects.
p81910
sg70039
(lp81911
(dp81912
g70042
I74
sg70043
VPTPN11 gene
p81913
sg70045
I11
sg70046
g12
sg70048
I2
sasg70051
(lp81914
(dp81915
g70042
I140
sg70043
Vgastric atrophy
p81916
sg70045
I15
sg70054
VC0017154
p81917
sg70048
I2
sa(dp81918
g70042
I140
sg70043
Vgastric atrophy
p81919
sg70045
I15
sg70054
VC0017154
p81920
sg70048
I2
sasa(dp81921
g135
(dp81922
(VGRP78
p81923
Vadhesion
p81924
tp81925
I00
ssg70037
VThe present study indicated that overexpression of GRP78 in colon cancer cells could promote cell-matrix adhesion through the upregulation of fibronectin, integrin-Beta1 and phosphorylated FAK.
p81926
sg70039
(lp81927
(dp81928
g70042
I189
sg70043
VFAK
p81929
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp81930
g70042
I51
sg70043
g81923
sg70045
I5
sg70046
VP11021
p81931
sg70048
I1
sasg70051
(lp81932
(dp81933
g70042
I60
sg70043
Vcolon cancer
p81934
sg70045
I12
sg70054
VC0699790
p81935
sg70048
I2
sa(dp81936
g70042
I105
sg70043
g81924
sg70045
I8
sg70054
VC0001511
p81937
sg70048
I1
sasa(dp81938
g135
(dp81939
(VAMPK
p81940
Vcolon cancer
p81941
tp81942
I00
ssg70037
VCollectively, our results suggest that berberine-induced AMPK activation inhibits the metastatic potential of colon cancer cells by decreasing integrin Beta1 protein levels and downstream signaling.
p81943
sg70039
(lp81944
(dp81945
g70042
I57
sg70043
g81940
sg70045
I4
sg70046
VP54646
p81946
sg70048
I1
sasg70051
(lp81947
(dp81948
g70042
I110
sg70043
g81941
sg70045
I12
sg70054
VC0699790
p81949
sg70048
I2
sasa(dp81950
g135
(dp81951
(VMx1
p81952
Vhepatitis C
p81953
tp81954
I00
ssg70037
VOn multivariate analysis, the independent predictors of gene expression were hepatitis C (Mx1, OAS2, PKR and IFI16), donor age (IFI16) and recipient gender (IRF7A) (P &lt; .05 for all).
p81955
sg70039
(lp81956
(dp81957
g70042
I101
sg70043
VPKR
p81958
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp81959
g70042
I95
sg70043
VOAS2
p81960
sg70045
I4
sg70046
VP29728
p81961
sg70048
I1
sa(dp81962
g70042
I90
sg70043
g81952
sg70045
I3
sg70046
VP20591
p81963
sg70048
I1
sa(dp81964
g70042
I157
sg70043
VIRF7A
p81965
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp81966
(dp81967
g70042
I77
sg70043
g81953
sg70045
I11
sg70054
VC0019196
p81968
sg70048
I2
sasa(dp81969
g70037
VNo significant difference was observed in the expression of ERRbeta mRNA between endometrial carcinoma (23%, 0.21 +/- 0.16) and normal endometrium (22%, 0.27 +/- 0.15; P &gt; 0.05).
p81970
sg70039
(lp81971
(dp81972
g70042
I60
sg70043
VERRbeta mRNA
p81973
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp81974
(dp81975
g70042
I81
sg70043
Vendometrial carcinoma
p81976
sg70045
I21
sg70054
VC0476089
p81977
sg70048
I2
sasa(dp81978
g70037
VPatients undergoing major open vascular surgery (open abdominal aortic aneurysm [oAAA] repair, aortofemoral bypass, and lower extremity infrainguinal bypass [LEB]) were identified using the Michigan Surgical Quality Collaborative (MSQC) between July 2012 and June 2015.
p81979
sg70039
(lp81980
sg70051
(lp81981
(dp81982
g70042
I54
sg70043
Vabdominal aortic aneurysm
p81983
sg70045
I25
sg70054
VC0162871
p81984
sg70048
I3
sasa(dp81985
g70037
VBeta blocker utilization (&lt;1 month preoperative versus chronic) and POMI rates were prospectively collected for patients undergoing open abdominal aortic aneurysm (AAA) repair (n = 926) and lower extremity bypass (LEB; n = 2,123) from 2003 through 2008.
p81986
sg70039
(lp81987
sg70051
(lp81988
(dp81989
g70042
I167
sg70043
VAAA
p81990
sg70045
I3
sg70054
VC0162871
p81991
sg70048
I1
sa(dp81992
g70042
I140
sg70043
Vabdominal aortic aneurysm
p81993
sg70045
I25
sg70054
VC0162871
p81994
sg70048
I3
sasa(dp81995
g70037
VWe studied 10,081 patients who underwent nonemergent carotid endarterectomy (CEA; n = 5293), lower extremity bypass (LEB; n = 2673), endovascular abdominal aortic aneurysm repair (EVAR; n = 1005), and open infrarenal abdominal aortic aneurysm repair (OAAA; n = 1,110) within the VSGNE from 2003 to 2008.
p81996
sg70039
(lp81997
sg70051
(lp81998
(dp81999
g70042
I146
sg70043
Vabdominal aortic aneurysm
p82000
sg70045
I25
sg70054
VC0162871
p82001
sg70048
I3
sa(dp82002
g70042
I146
sg70043
Vabdominal aortic aneurysm
p82003
sg70045
I25
sg70054
VC0162871
p82004
sg70048
I3
sasa(dp82005
g70037
VWe mailed a survey to the directors of the 8 Canadian vascular surgery training programs, to ascertain the yearly operative volumes of their 3 most recent trainees with respect to 6 index operations: carotid endarterectomy (CEA), types I-IV thoracoabdominal aortic aneurysm (TAA) repair, elective open infrarenal aortic aneurysm (eAAA) repair, ruptured abdominal aortic aneurysm (rAAA) repair, endovascular abdominal aortic aneurysm repair (EVAR) and lower extremity arterial bypass (LEB).
p82006
sg70039
(lp82007
sg70051
(lp82008
(dp82009
g70042
I380
sg70043
VrAAA
p82010
sg70045
I4
sg70054
VC0265012
p82011
sg70048
I1
sa(dp82012
g70042
I344
sg70043
Vruptured abdominal aortic aneurysm
p82013
sg70045
I34
sg70054
VC0265012
p82014
sg70048
I4
sa(dp82015
g70042
I248
sg70043
Vabdominal aortic aneurysm
p82016
sg70045
I25
sg70054
VC0162871
p82017
sg70048
I3
sa(dp82018
g70042
I241
sg70043
Vthoracoabdominal aortic aneurysm
p82019
sg70045
I32
sg70054
VC0340630
p82020
sg70048
I3
sa(dp82021
g70042
I258
sg70043
Vaortic aneurysm
p82022
sg70045
I15
sg70054
VC0003486
p82023
sg70048
I2
sa(dp82024
g70042
I275
sg70043
VTAA
p82025
sg70045
I3
sg70054
VC0162872
p82026
sg70048
I1
sasa(dp82027
g70037
VBetween 1999 and 2002, vascular surgery trainees in Canadian training programs were exposed to the following yearly clinical volumes (expressed as mean [and standard deviation]): CEA 55.4 (33.9), TAA 6.2 (3.8), eAAA 63.8 (30.0), rAAA 13.5 (9.4), EVAR 14.9 (9.6) and LEB 74.5 (34.5).
p82028
sg70039
(lp82029
sg70051
(lp82030
(dp82031
g70042
I196
sg70043
VTAA
p82032
sg70045
I3
sg70054
VC0162872
p82033
sg70048
I1
sasa(dp82034
g70037
VThe range of yearly clinical volumes were: CEA 21-124, TAA 1-18, eAAA 30-133, rAAA 3-45, EVAR 0-34 and LEB 20-143.
p82035
sg70039
(lp82036
sg70051
(lp82037
(dp82038
g70042
I55
sg70043
VTAA
p82039
sg70045
I3
sg70054
VC0162872
p82040
sg70048
I1
sasa(dp82041
g70037
VRisk-adjustment models have not been developed for elective abdominal aortic aneurysm repair (AAA), lower extremity bypass revascularization (LEB), or lower extremity amputation (AMP).
p82042
sg70039
(lp82043
sg70051
(lp82044
(dp82045
g70042
I60
sg70043
Vabdominal aortic aneurysm
p82046
sg70045
I25
sg70054
VC0162871
p82047
sg70048
I3
sa(dp82048
g70042
I94
sg70043
VAAA
p82049
sg70045
I3
sg70054
VC0162871
p82050
sg70048
I1
sa(dp82051
g70042
I70
sg70043
Vaortic aneurysm repair
p82052
sg70045
I22
sg70054
VC0162871
p82053
sg70048
I3
sasa(dp82054
g70037
VPostoperative ileus is accompanied by activation of CGRP, NGF-TrkA, and PAR-2 in DRGs.
p82055
sg70039
(lp82056
(dp82057
g70042
I72
sg70043
VPAR-2
p82058
sg70045
I5
sg70046
VP55085
p82059
sg70048
I1
sa(dp82060
g70042
I58
sg70043
VNGF
p82061
sg70045
I3
sg70046
VP01138
p82062
sg70048
I1
sa(dp82063
g70042
I52
sg70043
VCGRP
p82064
sg70045
I4
sg70046
VP80511
p82065
sg70048
I1
sa(dp82066
g70042
I62
sg70043
VTrkA
p82067
sg70045
I4
sg70046
VP06753
p82068
sg70048
I1
sasg70051
(lp82069
(dp82070
g70042
I0
sg70043
VPostoperative ileus
p82071
sg70045
I19
sg70054
VC0400877
p82072
sg70048
I2
sasa(dp82073
g135
(dp82074
(VTrkA
p82075
Vcolitis
p82076
tp82077
I00
ssg70037
VThe present study by examining the mRNA and/or protein levels of TrkA and TrkB in the distal colon and in colonic primary afferent neurons in the dorsal root ganglia (DRG) during colitis demonstrated that colitis elicited location-specific changes in the mRNA and protein levels of TrkA and TrkB in colonic primary sensory pathways.
p82078
sg70039
(lp82079
(dp82080
g70042
I65
sg70043
VTrkA
p82081
sg70045
I4
sg70046
VP06753
p82082
sg70048
I1
sa(dp82083
g70042
I74
sg70043
VTrkB
p82084
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82085
g70042
I65
sg70043
g82075
sg70045
I4
sg70046
VP06753
p82086
sg70048
I1
sa(dp82087
g70042
I74
sg70043
VTrkB
p82088
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp82089
(dp82090
g70042
I179
sg70043
Vcolitis
p82091
sg70045
I7
sg70054
VC0009319
p82092
sg70048
I1
sa(dp82093
g70042
I179
sg70043
g82076
sg70045
I7
sg70054
VC0009319
p82094
sg70048
I1
sasa(dp82095
g135
(dp82096
(VTrkA
p82097
Vcolitis
p82098
tp82099
I00
ssg70037
VIn colitis both the TrkA and TrkB protein levels were increased in the L1 and S1 DRGs in a time-dependent manner; however, the level of TrkB mRNA but not TrkA mRNA was increased in these DRGs.
p82100
sg70039
(lp82101
(dp82102
g70042
I29
sg70043
VTrkB protein
p82103
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp82104
g70042
I154
sg70043
VTrkA mRNA
p82105
sg70045
I9
sg70046
VP06753
p82106
sg70048
I2
sa(dp82107
g70042
I136
sg70043
VTrkB mRNA
p82108
sg70045
I9
sg70046
g12
sg70048
I2
sa(dp82109
g70042
I20
sg70043
g82097
sg70045
I4
sg70046
VP06753
p82110
sg70048
I1
sa(dp82111
g70042
I78
sg70043
VS1 DRGs
p82112
sg70045
I7
sg70046
g12
sg70048
I2
sasg70051
(lp82113
(dp82114
g70042
I3
sg70043
g82098
sg70045
I7
sg70054
VC0009319
p82115
sg70048
I1
sasa(dp82116
g135
(dp82117
(VTrkA protein
p82118
Vcolitis
p82119
tp82120
I00
ssg70037
VFurther experiments showed that colitis facilitated a retrograde transport of TrkA protein toward and an anterograde transport of TrkA mRNA away from the DRG, which may contribute to the increased TrkA mRNA level in the distal colon during colitis.
p82121
sg70039
(lp82122
(dp82123
g70042
I130
sg70043
VTrkA mRNA
p82124
sg70045
I9
sg70046
VP06753
p82125
sg70048
I2
sa(dp82126
g70042
I130
sg70043
VTrkA mRNA
p82127
sg70045
I9
sg70046
VP06753
p82128
sg70048
I2
sa(dp82129
g70042
I78
sg70043
g82118
sg70045
I12
sg70046
VP06753
p82130
sg70048
I2
sasg70051
(lp82131
(dp82132
g70042
I32
sg70043
Vcolitis
p82133
sg70045
I7
sg70054
VC0009319
p82134
sg70048
I1
sa(dp82135
g70042
I32
sg70043
g82119
sg70045
I7
sg70054
VC0009319
p82136
sg70048
I1
sasa(dp82137
g135
(dp82138
(VTrkA
p82139
Vcolitis
p82140
tp82141
I00
ssg70037
VDouble staining showed that the expression of TrkA but not TrkB was increased in the specifically labeled colonic afferent neurons in the L1 and S1 DRGs during colitis; this increase in TrkA level was attenuated by pretreatment with resiniferatoxin.
p82142
sg70039
(lp82143
(dp82144
g70042
I46
sg70043
VTrkA
p82145
sg70045
I4
sg70046
VP06753
p82146
sg70048
I1
sa(dp82147
g70042
I145
sg70043
VS1 DRGs
p82148
sg70045
I7
sg70046
g12
sg70048
I2
sa(dp82149
g70042
I59
sg70043
VTrkB
p82150
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82151
g70042
I46
sg70043
g82139
sg70045
I4
sg70046
VP06753
p82152
sg70048
I1
sasg70051
(lp82153
(dp82154
g70042
I160
sg70043
g82140
sg70045
I7
sg70054
VC0009319
p82155
sg70048
I1
sasa(dp82156
g135
(dp82157
(VTrkA
p82158
Vcolitis
p82159
tp82160
I00
ssg70037
VThese results suggested that colitis-induced primary afferent activation involved retrograde transport of TrkA but not TrkB from the distal colon to primary afferent neurons in DRG.
p82161
sg70039
(lp82162
(dp82163
g70042
I106
sg70043
g82158
sg70045
I4
sg70046
VP06753
p82164
sg70048
I1
sa(dp82165
g70042
I119
sg70043
VTrkB
p82166
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp82167
(dp82168
g70042
I29
sg70043
g82159
sg70045
I7
sg70054
VC0009319
p82169
sg70048
I1
sasa(dp82170
g135
(dp82171
(VHSCR
p82172
VCIPA
p82173
tp82174
I00
ssg70037
VIn fact, receptor rearrangements or point mutations convert RET and NTRK1 in dominantly acting transforming genes leading to thyroid tumors, whereas inactivating mutations, associated with Hirschsprung's disease (HSCR) and congenital insensitivity to pain with anhidrosis (CIPA), impair RET and NTRK1 functions, respectively.
p82175
sg70039
(lp82176
(dp82177
g70042
I60
sg70043
VRET
p82178
sg70045
I3
sg70046
VP07949
p82179
sg70048
I1
sa(dp82180
g70042
I60
sg70043
VRET
p82181
sg70045
I3
sg70046
VP07949
p82182
sg70048
I1
sa(dp82183
g70042
I189
sg70043
VHirschsprung's disease
p82184
sg70045
I22
sg70046
VP14138
p82185
sg70048
I2
sa(dp82186
g70042
I213
sg70043
g82172
sg70045
I4
sg70046
VP14138
p82187
sg70048
I1
sasg70051
(lp82188
(dp82189
g70042
I223
sg70043
Vcongenital insensitivity to pain with anhidrosis
p82190
sg70045
I48
sg70054
VC0020074
p82191
sg70048
I6
sa(dp82192
g70042
I189
sg70043
VHirschsprung's disease
p82193
sg70045
I22
sg70054
VC0019569
p82194
sg70048
I2
sa(dp82195
g70042
I125
sg70043
Vthyroid tumors
p82196
sg70045
I14
sg70054
VC0040136
p82197
sg70048
I2
sa(dp82198
g70042
I213
sg70043
VHSCR
p82199
sg70045
I4
sg70054
VC2931876
p82200
sg70048
I1
sa(dp82201
g70042
I273
sg70043
g82173
sg70045
I4
sg70054
VC0020074
p82202
sg70048
I1
sasa(dp82203
g135
(dp82204
(VCCR5
p82205
VChagas disease
p82206
tp82207
I00
ssg70037
VThus, our results corroborate that therapeutic strategies based on the modulation of CCR1/CCR5-mediated cell migration and/or effector function may contribute to cardiac tissue damage limitation during chronic Chagas disease.
p82208
sg70039
(lp82209
(dp82210
g70042
I85
sg70043
VCCR1
p82211
sg70045
I4
sg70046
VP32246
p82212
sg70048
I1
sa(dp82213
g70042
I90
sg70043
g82205
sg70045
I4
sg70046
VP32302
p82214
sg70048
I1
sasg70051
(lp82215
(dp82216
g70042
I210
sg70043
g82206
sg70045
I14
sg70054
VC0041234
p82217
sg70048
I2
sasa(dp82218
g135
(dp82219
(VHDAC4
p82220
Vrheumatoid arthritis
p82221
tp82222
I00
ssg70037
VThe results of integrated analysis explored 3 OA-related pathways (rheumatoid arthritis, osteoclast differentiation and ECM-receptor interaction) and 4 candidate genes of OA (BST2, HDAC4, ITGB2 and VCAM1) that may be therapeutic targets.
p82223
sg70039
(lp82224
(dp82225
g70042
I188
sg70043
VITGB2
p82226
sg70045
I5
sg70046
VP05107
p82227
sg70048
I1
sa(dp82228
g70042
I175
sg70043
VBST2
p82229
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82230
g70042
I198
sg70043
VVCAM1
p82231
sg70045
I5
sg70046
VP19320
p82232
sg70048
I1
sa(dp82233
g70042
I120
sg70043
VECM-receptor
p82234
sg70045
I12
sg70046
g12
sg70048
I1
sa(dp82235
g70042
I181
sg70043
g82220
sg70045
I5
sg70046
VP56524
p82236
sg70048
I1
sasg70051
(lp82237
(dp82238
g70042
I67
sg70043
g82221
sg70045
I20
sg70054
VC0003873
p82239
sg70048
I2
sasa(dp82240
g135
(dp82241
(VCD18
p82242
Vsystemic lupus erythematosus
p82243
tp82244
I00
ssg70037
VThe patient showed moderate expression of CD18 in neutrophils with a homozygous splice mutation with c.41_c.58+2dup20 of ITGB2 and experienced recurrent severe infections complicated with systemic lupus erythematosus.
p82245
sg70039
(lp82246
(dp82247
g70042
I101
sg70043
Vc.41_c.58+2dup20 of ITGB2
p82248
sg70045
I25
sg70046
VP05107
p82249
sg70048
I3
sa(dp82250
g70042
I42
sg70043
g82242
sg70045
I4
sg70046
VP05107
p82251
sg70048
I1
sasg70051
(lp82252
(dp82253
g70042
I188
sg70043
g82243
sg70045
I28
sg70054
VC0024141
p82254
sg70048
I3
sa(dp82255
g70042
I160
sg70043
Vinfections
p82256
sg70045
I10
sg70054
VC0021311
p82257
sg70048
I1
sasa(dp82258
g135
(dp82259
(Vmutation of ITGB2
p82260
Vsystemic lupus erythematosus
p82261
tp82262
I00
ssg70037
VShe received hematopoietic stem cell transplantation from a matched elder brother with heterozygous mutation of ITGB2, and has since remained free of infection and systemic lupus erythematosus symptoms without immunosuppression therapy.
p82263
sg70039
(lp82264
(dp82265
g70042
I100
sg70043
g82260
sg70045
I17
sg70046
VP05107
p82266
sg70048
I3
sasg70051
(lp82267
(dp82268
g70042
I150
sg70043
Vinfection
p82269
sg70045
I9
sg70054
VC0009450
p82270
sg70048
I1
sa(dp82271
g70042
I164
sg70043
g82261
sg70045
I28
sg70054
VC0024141
p82272
sg70048
I3
sasa(dp82273
g135
(dp82274
(Vheterodimeric adhesion molecules
p82275
Vadhesion
p82276
tp82277
I00
ssg70037
VUsing mice deficient in all beta2 integrins (CD18 null mice), we demonstrate that expression of these heterodimeric adhesion molecules is critical for arthritis induction in the K/B x N serum transfer model.
p82278
sg70039
(lp82279
(dp82280
g70042
I45
sg70043
VCD18 null
p82281
sg70045
I9
sg70046
VP05107
p82282
sg70048
I2
sa(dp82283
g70042
I102
sg70043
g82275
sg70045
I32
sg70046
VP01185
p82284
sg70048
I3
sasg70051
(lp82285
(dp82286
g70042
I151
sg70043
Varthritis
p82287
sg70045
I9
sg70054
VC0003864
p82288
sg70048
I1
sa(dp82289
g70042
I116
sg70043
g82276
sg70045
I8
sg70054
VC0001511
p82290
sg70048
I1
sasa(dp82291
g135
(dp82292
(VCD11a
p82293
Varthritis
p82294
tp82295
I01
ssg70037
VUsing null-allele mice and blocking mAbs, we demonstrate specifically that CD11a/CD18 (LFA-1) is absolutely required for the development of arthritis in this model.
p82296
sg70039
(lp82297
(dp82298
g70042
I87
sg70043
VLFA-1
p82299
sg70045
I5
sg70046
VP20701
p82300
sg70048
I1
sa(dp82301
g70042
I81
sg70043
VCD18
p82302
sg70045
I4
sg70046
VP05107
p82303
sg70048
I1
sa(dp82304
g70042
I75
sg70043
g82293
sg70045
I5
sg70046
VP20701
p82305
sg70048
I1
sasg70051
(lp82306
(dp82307
g70042
I27
sg70043
Vblocking
p82308
sg70045
I8
sg70054
VC0233660
p82309
sg70048
I1
sa(dp82310
g70042
I140
sg70043
g82294
sg70045
I9
sg70054
VC0003864
p82311
sg70048
I1
sasa(dp82312
g135
(dp82313
(VTau
p82314
VAlzheimer Disease
p82315
tp82316
I00
ssg70037
VThus, key proteins in Alzheimer Disease and Amyotrophic lateral sclerosis (ALS), including amyloid-Beta precursor protein, Tau and superoxide dismutase 1 (SOD1), spread to adjacent cells in their misfolded aggregated forms and exhibit template-directed misfolding to induce further misfolding, disruptions to proteostasis and toxicity.
p82317
sg70039
(lp82318
(dp82319
g70042
I155
sg70043
VSOD1
p82320
sg70045
I4
sg70046
VP00441
p82321
sg70048
I1
sa(dp82322
g70042
I91
sg70043
Vamyloid-Beta precursor protein
p82323
sg70045
I30
sg70046
VP17342
p82324
sg70048
I3
sa(dp82325
g70042
I131
sg70043
Vsuperoxide dismutase 1
p82326
sg70045
I22
sg70046
VP00441
p82327
sg70048
I3
sa(dp82328
g70042
I123
sg70043
g82314
sg70045
I3
sg70046
VP49768
p82329
sg70048
I1
sasg70051
(lp82330
(dp82331
g70042
I44
sg70043
VAmyotrophic lateral sclerosis
p82332
sg70045
I29
sg70054
VC0002736
p82333
sg70048
I3
sa(dp82334
g70042
I75
sg70043
VALS
p82335
sg70045
I3
sg70054
VC0002736
p82336
sg70048
I1
sa(dp82337
g70042
I22
sg70043
g82315
sg70045
I17
sg70054
VC0002395
p82338
sg70048
I2
sa(dp82339
g70042
I91
sg70043
Vamyloid
p82340
sg70045
I7
sg70054
VC0011560
p82341
sg70048
I1
sasa(dp82342
g70037
VThe method is useful for identifying the defective APP-mRNA isoform in LND patients, and in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease, and may pave the way for new strategies applicable to rational antisense drugs design.
p82343
sg70039
(lp82344
(dp82345
g70042
I156
sg70043
VAPP gene
p82346
sg70045
I8
sg70046
g12
sg70048
I2
sa(dp82347
g70042
I51
sg70043
VAPP-mRNA
p82348
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp82349
(dp82350
g70042
I245
sg70043
Vamyotrophic lateral sclerosis
p82351
sg70045
I29
sg70054
VC0002736
p82352
sg70048
I3
sa(dp82353
g70042
I184
sg70043
Vpathogenesis
p82354
sg70045
I12
sg70054
VC0699748
p82355
sg70048
I1
sa(dp82356
g70042
I225
sg70043
Vfragile X syndrome
p82357
sg70045
I18
sg70054
VC0016667
p82358
sg70048
I3
sa(dp82359
g70042
I280
sg70043
VAlzheimer's disease
p82360
sg70045
I19
sg70054
VC1521724
p82361
sg70048
I2
sa(dp82362
g70042
I217
sg70043
Vautism
p82363
sg70045
I6
sg70054
VC0004352
p82364
sg70048
I1
sa(dp82365
g70042
I115
sg70043
Vneurodegenerative disorders
p82366
sg70045
I27
sg70054
VC0524851
p82367
sg70048
I2
sasa(dp82368
g135
(dp82369
(Vamyloid precursor protein
p82370
Vmotor neuron disease
p82371
tp82372
I00
ssg70037
VSeveral findings suggest that the amyloid precursor protein (APP) and the amyloid cascade may play a role in motor neuron disease (MND).
p82373
sg70039
(lp82374
(dp82375
g70042
I34
sg70043
g82370
sg70045
I25
sg70046
VP17342
p82376
sg70048
I3
sa(dp82377
g70042
I61
sg70043
VAPP
p82378
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp82379
(dp82380
g70042
I131
sg70043
VMND
p82381
sg70045
I3
sg70054
VC0085084
p82382
sg70048
I1
sa(dp82383
g70042
I34
sg70043
Vamyloid
p82384
sg70045
I7
sg70054
VC0011560
p82385
sg70048
I1
sa(dp82386
g70042
I109
sg70043
g82371
sg70045
I20
sg70054
VC0085084
p82387
sg70048
I3
sa(dp82388
g70042
I34
sg70043
Vamyloid
p82389
sg70045
I7
sg70054
VC0011560
p82390
sg70048
I1
sasa(dp82391
g70037
VConsidering that dementia is one of the most frequent non-motor symptoms in amyotrophic lateral sclerosis (ALS) and that hippocampus is one of the brain areas with greater presence of amyloid-related changes in neurodegenerative diseases, our aim was to analyze the molecular markers of the amyloid cascade of APP in pathology studies of the hippocampus of autopsied patients with ALS and ALS-frontotemporal dementia (FTD).
p82392
sg70039
(lp82393
sg70051
(lp82394
(dp82395
g70042
I76
sg70043
Vamyotrophic lateral sclerosis
p82396
sg70045
I29
sg70054
VC0002736
p82397
sg70048
I3
sa(dp82398
g70042
I184
sg70043
Vamyloid
p82399
sg70045
I7
sg70054
VC0011560
p82400
sg70048
I1
sa(dp82401
g70042
I17
sg70043
Vdementia
p82402
sg70045
I8
sg70054
VC0497327
p82403
sg70048
I1
sa(dp82404
g70042
I107
sg70043
VALS
p82405
sg70045
I3
sg70054
VC0002736
p82406
sg70048
I1
sa(dp82407
g70042
I58
sg70043
Vmotor symptoms
p82408
sg70045
I14
sg70054
VC0426980
p82409
sg70048
I2
sa(dp82410
g70042
I389
sg70043
VALS-frontotemporal dementia
p82411
sg70045
I27
sg70054
VC0338451
p82412
sg70048
I2
sa(dp82413
g70042
I418
sg70043
VFTD
p82414
sg70045
I3
sg70054
VC0338451
p82415
sg70048
I1
sa(dp82416
g70042
I184
sg70043
Vamyloid
p82417
sg70045
I7
sg70054
VC0011560
p82418
sg70048
I1
sa(dp82419
g70042
I317
sg70043
Vpathology
p82420
sg70045
I9
sg70054
VC0677042
p82421
sg70048
I1
sa(dp82422
g70042
I211
sg70043
Vneurodegenerative diseases
p82423
sg70045
I26
sg70054
VC0524851
p82424
sg70048
I2
sa(dp82425
g70042
I107
sg70043
VALS
p82426
sg70045
I3
sg70054
VC0002736
p82427
sg70048
I1
sasa(dp82428
g135
(dp82429
(Vpho-TAU
p82430
VALS
p82431
tp82432
I00
ssg70037
VImmunohistochemical studies and confocal microscopy were used to analyze the expression of APP, TDP-43, pho-TDP-43, ABeta, APP intracellular cytoplasmatic domain (AICD) peptide, Fe65 protein, and pho-TAU in the hippocampus of seven patients with ALS, two patients with ALS-FTD, and four controls.
p82433
sg70039
(lp82434
(dp82435
g70042
I104
sg70043
Vpho-TDP-43
p82436
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp82437
g70042
I196
sg70043
g82430
sg70045
I7
sg70046
VP49768
p82438
sg70048
I1
sa(dp82439
g70042
I91
sg70043
VAPP
p82440
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp82441
g70042
I141
sg70043
Vcytoplasmatic domain (AICD) peptide
p82442
sg70045
I35
sg70046
g12
sg70048
I4
sa(dp82443
g70042
I91
sg70043
VAPP
p82444
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp82445
g70042
I178
sg70043
VFe65 protein
p82446
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp82447
g70042
I96
sg70043
VTDP-43
p82448
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp82449
g70042
I116
sg70043
VABeta
p82450
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82451
(dp82452
g70042
I273
sg70043
VFTD
p82453
sg70045
I3
sg70054
VC0338451
p82454
sg70048
I1
sa(dp82455
g70042
I246
sg70043
VALS
p82456
sg70045
I3
sg70054
VC0002736
p82457
sg70048
I1
sa(dp82458
g70042
I246
sg70043
g82431
sg70045
I3
sg70054
VC0002736
p82459
sg70048
I1
sasa(dp82460
g70037
VThese results suggest that Sidt2(-/-) mice had spontaneous nonalcoholic fatty liver disease (NAFLD) accompanied by ERS.
p82461
sg70039
(lp82462
sg70051
(lp82463
(dp82464
g70042
I115
sg70043
VERS
p82465
sg70045
I3
sg70054
VC0403549
p82466
sg70048
I1
sa(dp82467
g70042
I59
sg70043
Vnonalcoholic fatty liver disease
p82468
sg70045
I32
sg70054
VC0400966
p82469
sg70048
I4
sa(dp82470
g70042
I93
sg70043
VNAFLD
p82471
sg70045
I5
sg70054
VC0400966
p82472
sg70048
I1
sasa(dp82473
g135
(dp82474
(Vserum insulin
p82475
Vglucose intolerance
p82476
tp82477
I00
ssg70037
VIntraperitoneal and oral glucose tolerance tests in Sidt2 knockout mice indicated glucose intolerance and decreased serum insulin level.
p82478
sg70039
(lp82479
(dp82480
g70042
I116
sg70043
g82475
sg70045
I13
sg70046
VP01308
p82481
sg70048
I2
sasg70051
(lp82482
(dp82483
g70042
I33
sg70043
Vtolerance
p82484
sg70045
I9
sg70054
VC0020963
p82485
sg70048
I1
sa(dp82486
g70042
I82
sg70043
g82476
sg70045
I19
sg70054
VC0271650
p82487
sg70048
I2
sasa(dp82488
g135
(dp82489
(VCDH15
p82490
Vschizophrenia
p82491
tp82492
I00
ssg70037
VFor example, CDH15 and PCDH19 are associated with cognitive impairment; CDH5, CDH8, CDH9, CDH10, CDH13, CDH15, PCDH10, PCDH19 and PCDHb4 with autism; CDH7, CDH12, CDH18, PCDH12 and FAT with bipolar disease and schizophrenia; and CDH11, CDH12 and CDH13 with methamphetamine and alcohol dependency.
p82493
sg70039
(lp82494
(dp82495
g70042
I13
sg70043
VCDH15
p82496
sg70045
I5
sg70046
VP55291
p82497
sg70048
I1
sa(dp82498
g70042
I90
sg70043
VCDH10
p82499
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82500
g70042
I78
sg70043
VCDH8
p82501
sg70045
I4
sg70046
VP55286
p82502
sg70048
I1
sa(dp82503
g70042
I130
sg70043
VPCDHb4
p82504
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp82505
g70042
I229
sg70043
VCDH11
p82506
sg70045
I5
sg70046
VP55287
p82507
sg70048
I1
sa(dp82508
g70042
I156
sg70043
VCDH12
p82509
sg70045
I5
sg70046
VP55289
p82510
sg70048
I1
sa(dp82511
g70042
I156
sg70043
VCDH12
p82512
sg70045
I5
sg70046
VP55289
p82513
sg70048
I1
sa(dp82514
g70042
I163
sg70043
VCDH18
p82515
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82516
g70042
I23
sg70043
VPCDH19
p82517
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp82518
g70042
I170
sg70043
VPCDH12
p82519
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp82520
g70042
I97
sg70043
VCDH13
p82521
sg70045
I5
sg70046
VP55290
p82522
sg70048
I1
sa(dp82523
g70042
I23
sg70043
VPCDH19
p82524
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp82525
g70042
I72
sg70043
VCDH5
p82526
sg70045
I4
sg70046
VP33151
p82527
sg70048
I1
sa(dp82528
g70042
I150
sg70043
VCDH7
p82529
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82530
g70042
I97
sg70043
VCDH13
p82531
sg70045
I5
sg70046
VP55290
p82532
sg70048
I1
sa(dp82533
g70042
I84
sg70043
VCDH9
p82534
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82535
g70042
I111
sg70043
VPCDH10
p82536
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp82537
g70042
I13
sg70043
g82490
sg70045
I5
sg70046
VP55291
p82538
sg70048
I1
sasg70051
(lp82539
(dp82540
g70042
I142
sg70043
Vautism
p82541
sg70045
I6
sg70054
VC0004352
p82542
sg70048
I1
sa(dp82543
g70042
I277
sg70043
Valcohol dependency
p82544
sg70045
I18
sg70054
VC0001973
p82545
sg70048
I2
sa(dp82546
g70042
I50
sg70043
Vcognitive impairment
p82547
sg70045
I20
sg70054
VC0338656
p82548
sg70048
I2
sa(dp82549
g70042
I210
sg70043
g82491
sg70045
I13
sg70054
VC0036341
p82550
sg70048
I1
sasa(dp82551
g70037
VThe UCNs emitting UV/blue and green/red multiband light were used to activate the photoresponsive Azo and photosensitizer RB molecules; The mesoporous silica shell offered the possibilities to load anticancer drug and conjugate the light triggers; As there are strong charge interaction and hydrogen bonds between Dox and surface silanols of mesoporous silica, the azobenzene molecules worked as "gatekeeper" and "molecular stirrer" to precisely trap and propel the release of Dox under the external stimuli.
p82552
sg70039
(lp82553
sg70051
(lp82554
sa(dp82555
g70037
VUCN1 is significantly reduced in endometrial adenocarcinoma compared to healthy controls.
p82556
sg70039
(lp82557
(dp82558
g70042
I0
sg70043
VUCN1
p82559
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp82560
(dp82561
g70042
I33
sg70043
Vendometrial adenocarcinoma
p82562
sg70045
I26
sg70054
VC1153706
p82563
sg70048
I2
sasa(dp82564
g70037
VUCN1 suppressed migration of endometrial cancer cells in vitro.
p82565
sg70039
(lp82566
sg70051
(lp82567
(dp82568
g70042
I29
sg70043
Vendometrial cancer
p82569
sg70045
I18
sg70054
VC0476089
p82570
sg70048
I2
sasa(dp82571
g70037
VWe demonstrate that UCN1 significantly suppresses the migration of endometrial cancer cells but has no effect on their proliferation.
p82572
sg70039
(lp82573
(dp82574
g70042
I20
sg70043
VUCN1
p82575
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp82576
(dp82577
g70042
I119
sg70043
Vproliferation
p82578
sg70045
I13
sg70054
VC0334094
p82579
sg70048
I1
sa(dp82580
g70042
I67
sg70043
Vendometrial cancer
p82581
sg70045
I18
sg70054
VC0476089
p82582
sg70048
I2
sasa(dp82583
g70037
VThus, loss of UCN1 in endometrial cancer may promote invasion and metastatic spread.
p82584
sg70039
(lp82585
(dp82586
g70042
I14
sg70043
VUCN1
p82587
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp82588
(dp82589
g70042
I53
sg70043
Vinvasion
p82590
sg70045
I8
sg70054
VC2699153
p82591
sg70048
I1
sa(dp82592
g70042
I22
sg70043
Vendometrial cancer
p82593
sg70045
I18
sg70054
VC0476089
p82594
sg70048
I2
sasa(dp82595
g70037
VSeven pathogenic variants leading to NSHL have so far been reported on two mitochondrial genes: MT-RNR1 encoding 12SrRNA and MT-TS1 encoding tRNA for Ser((UCN)) .
p82596
sg70039
(lp82597
(dp82598
g70042
I96
sg70043
VMT-RNR1 encoding 12SrRNA
p82599
sg70045
I24
sg70046
VP43354
p82600
sg70048
I3
sasg70051
(lp82601
sa(dp82602
g70037
VThis study examines the role of FcgammaRIIB in the initiation of allergic rhinitis in mice.
p82603
sg70039
(lp82604
(dp82605
g70042
I32
sg70043
VFcgammaRIIB
p82606
sg70045
I11
sg70046
VP31994
p82607
sg70048
I1
sasg70051
(lp82608
(dp82609
g70042
I65
sg70043
Vallergic rhinitis
p82610
sg70045
I17
sg70054
VC2607914
p82611
sg70048
I2
sasa(dp82612
g70037
VThese results suggest that FcgammaRIIB plays a regulatory role in the initiation of allergic rhinitis that is independent of either mouse strain or type of sensitization.
p82613
sg70039
(lp82614
(dp82615
g70042
I27
sg70043
VFcgammaRIIB
p82616
sg70045
I11
sg70046
VP31994
p82617
sg70048
I1
sasg70051
(lp82618
(dp82619
g70042
I84
sg70043
Vallergic rhinitis
p82620
sg70045
I17
sg70054
VC2607914
p82621
sg70048
I2
sasa(dp82622
g70037
VThis study evaluated the interaction of radiation therapy (RT) and radiofrequency kyphoplasty (RFK) in the treatment of myeloma associated VCF.
p82623
sg70039
(lp82624
sg70051
(lp82625
(dp82626
g70042
I120
sg70043
Vmyeloma
p82627
sg70045
I7
sg70054
VC0026764
p82628
sg70048
I1
sasa(dp82629
g70037
VEighty-six myeloma patients with VCF were treated with RFK followed by radiation therapy (RFK group) or vice versa (RT group).
p82630
sg70039
(lp82631
sg70051
(lp82632
(dp82633
g70042
I11
sg70043
Vmyeloma
p82634
sg70045
I7
sg70054
VC0026764
p82635
sg70048
I1
sasa(dp82636
g70037
VRFK is an effective method for treating VCF in myeloma patients independent of treatment order with regard to radiation therapy.
p82637
sg70039
(lp82638
(dp82639
g70042
I0
sg70043
VRFK
p82640
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp82641
(dp82642
g70042
I47
sg70043
Vmyeloma
p82643
sg70045
I7
sg70054
VC0026764
p82644
sg70048
I1
sasa(dp82645
g70037
VWe investigated the involvement of RFK in cisplatin resistance using human prostate cancer PC3 cells.
p82646
sg70039
(lp82647
(dp82648
g70042
I35
sg70043
VRFK
p82649
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp82650
(dp82651
g70042
I75
sg70043
Vprostate cancer
p82652
sg70045
I15
sg70054
VC0600139
p82653
sg70048
I2
sasa(dp82654
g70037
VThe present study suggests that RFK expression is involved not only in cellular protection from oxidative stress but also in malignant progression of prostate cancer.
p82655
sg70039
(lp82656
(dp82657
g70042
I32
sg70043
VRFK
p82658
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp82659
(dp82660
g70042
I135
sg70043
Vprogression of prostate cancer
p82661
sg70045
I30
sg70054
VC1739135
p82662
sg70048
I4
sa(dp82663
g70042
I96
sg70043
Voxidative stress
p82664
sg70045
I16
sg70054
VC0242606
p82665
sg70048
I2
sasa(dp82666
g70037
VThe anti-cancer effect of ATF-Fc (alone and in combination with trastuzumab) on tumor cells and in a nude mouse tumor model was evaluated by detecting the expression of uPA, urokinase plasminogen activator receptor (uPAR) and HER-2.
p82667
sg70039
(lp82668
(dp82669
g70042
I169
sg70043
VuPA
p82670
sg70045
I3
sg70046
VP00749
p82671
sg70048
I1
sa(dp82672
g70042
I226
sg70043
VHER-2
p82673
sg70045
I5
sg70046
VP04626
p82674
sg70048
I1
sa(dp82675
g70042
I174
sg70043
Vurokinase plasminogen activator receptor
p82676
sg70045
I40
sg70046
VP00747
p82677
sg70048
I4
sa(dp82678
g70042
I216
sg70043
VuPAR
p82679
sg70045
I4
sg70046
VP00747
p82680
sg70048
I1
sa(dp82681
g70042
I26
sg70043
VATF
p82682
sg70045
I3
sg70046
VP00749
p82683
sg70048
I1
sasg70051
(lp82684
(dp82685
g70042
I80
sg70043
Vtumor
p82686
sg70045
I5
sg70054
VC0027651
p82687
sg70048
I1
sa(dp82688
g70042
I80
sg70043
Vtumor
p82689
sg70045
I5
sg70054
VC0027651
p82690
sg70048
I1
sa(dp82691
g70042
I9
sg70043
Vcancer
p82692
sg70045
I6
sg70054
VC0006826
p82693
sg70048
I1
sasa(dp82694
g135
(dp82695
(Vplasminogen activator system
p82696
Vcancer progression
p82697
tp82698
I00
ssg70037
VThe ability of HMGA1 to regulate the plasminogen activator system may constitute an important mechanism by which HMGA1 promotes cancer progression.
p82699
sg70039
(lp82700
(dp82701
g70042
I15
sg70043
VHMGA1
p82702
sg70045
I5
sg70046
VP17096
p82703
sg70048
I1
sa(dp82704
g70042
I15
sg70043
VHMGA1
p82705
sg70045
I5
sg70046
VP17096
p82706
sg70048
I1
sa(dp82707
g70042
I37
sg70043
g82696
sg70045
I28
sg70046
VP00747
p82708
sg70048
I3
sasg70051
(lp82709
(dp82710
g70042
I128
sg70043
g82697
sg70045
I18
sg70054
VC0178874
p82711
sg70048
I2
sasa(dp82712
g135
(dp82713
(VKCNJ1
p82714
Vdiabetes
p82715
tp82716
I00
ssg70037
VKCNJ1 variation is associated with multiple diseases, such as antenatal Bartter syndrome and diabetes.
p82717
sg70039
(lp82718
(dp82719
g70042
I0
sg70043
g82714
sg70045
I5
sg70046
VP48048
p82720
sg70048
I1
sasg70051
(lp82721
(dp82722
g70042
I72
sg70043
VBartter syndrome
p82723
sg70045
I16
sg70054
VC0004775
p82724
sg70048
I2
sa(dp82725
g70042
I93
sg70043
g82715
sg70045
I8
sg70054
VC0011849
p82726
sg70048
I1
sasa(dp82727
g135
(dp82728
(VKir1.1
p82729
Vdiabetes mellitus
p82730
tp82731
I00
ssg70037
VNeither diabetes mellitus nor Tempol altered Kir1.1, Kir2.1, Kir6.1, or SUR2B protein levels in renal cortical microvessels.
p82732
sg70039
(lp82733
(dp82734
g70042
I53
sg70043
VKir2.1
p82735
sg70045
I6
sg70046
VP63252
p82736
sg70048
I1
sa(dp82737
g70042
I72
sg70043
VSUR2B protein
p82738
sg70045
I13
sg70046
g12
sg70048
I2
sa(dp82739
g70042
I61
sg70043
VKir6.1
p82740
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp82741
g70042
I45
sg70043
g82729
sg70045
I6
sg70046
VP48048
p82742
sg70048
I1
sasg70051
(lp82743
(dp82744
g70042
I8
sg70043
g82730
sg70045
I17
sg70054
VC0011849
p82745
sg70048
I2
sasa(dp82746
g135
(dp82747
(VKir1.1
p82748
Voxidative stress
p82749
tp82750
I00
ssg70037
VTo the extent that the effects of Tempol reflect its antioxidant actions, our observations indicate that oxidative stress contributes to the exaggerated impact of Kir1.1, Kir2.1, and K(ATP) channels on afferent arteriolar tone during diabetes mellitus and that this phenomenon involves posttranslational modulation of channel function.
p82751
sg70039
(lp82752
(dp82753
g70042
I171
sg70043
VKir2.1
p82754
sg70045
I6
sg70046
VP63252
p82755
sg70048
I1
sa(dp82756
g70042
I163
sg70043
g82748
sg70045
I6
sg70046
VP48048
p82757
sg70048
I1
sasg70051
(lp82758
(dp82759
g70042
I234
sg70043
Vdiabetes mellitus
p82760
sg70045
I17
sg70054
VC0011849
p82761
sg70048
I2
sa(dp82762
g70042
I105
sg70043
g82749
sg70045
I16
sg70054
VC0242606
p82763
sg70048
I2
sasa(dp82764
g70037
VFurthermore, results suggested that co-exposure exacerbated the activation of TRPV1 signal pathways, with an enhancement in substance P and calcitonin gene-related peptide production, which contributed to inflammation in asthma by neurogenic inflammation.
p82765
sg70039
(lp82766
(dp82767
g70042
I140
sg70043
Vcalcitonin gene
p82768
sg70045
I15
sg70046
VP06881
p82769
sg70048
I2
sa(dp82770
g70042
I78
sg70043
VTRPV1
p82771
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82772
(dp82773
g70042
I221
sg70043
Vasthma
p82774
sg70045
I6
sg70054
VC0004096
p82775
sg70048
I1
sa(dp82776
g70042
I205
sg70043
Vinflammation
p82777
sg70045
I12
sg70054
VC0021368
p82778
sg70048
I1
sa(dp82779
g70042
I205
sg70043
Vinflammation
p82780
sg70045
I12
sg70054
VC0021368
p82781
sg70048
I1
sasa(dp82782
g70037
VIt is concluded that co-exposure to PM2.5 and FA exacerbated allergic asthma through oxidative stress and enhanced TRPV1 activation.
p82783
sg70039
(lp82784
(dp82785
g70042
I115
sg70043
VTRPV1
p82786
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82787
(dp82788
g70042
I85
sg70043
Voxidative stress
p82789
sg70045
I16
sg70054
VC0242606
p82790
sg70048
I2
sa(dp82791
g70042
I61
sg70043
Vallergic asthma
p82792
sg70045
I15
sg70054
VC0155877
p82793
sg70048
I2
sasa(dp82794
g135
(dp82795
(VTRPM2
p82796
Vlung fibrosis
p82797
tp82798
I00
ssg70037
VIn this review we will summarize recent evidence for an involvement of TRP channels (TRPA1, TRPC4, TRPC6, TRPV1, TRPV4, TRPM2 and TRPM8) expressed in the lung in pathways of toxin sensing and as mediators of lung inflammation and associated diseases like asthma, COPD, lung fibrosis and edema formation.
p82799
sg70039
(lp82800
(dp82801
g70042
I71
sg70043
VTRP channels
p82802
sg70045
I12
sg70046
VP13686
p82803
sg70048
I2
sa(dp82804
g70042
I120
sg70043
g82796
sg70045
I5
sg70046
VP10909
p82805
sg70048
I1
sa(dp82806
g70042
I130
sg70043
VTRPM8
p82807
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82808
g70042
I99
sg70043
VTRPC6
p82809
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82810
g70042
I92
sg70043
VTRPC4
p82811
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82812
g70042
I106
sg70043
VTRPV1
p82813
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82814
g70042
I85
sg70043
VTRPA1
p82815
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82816
(dp82817
g70042
I208
sg70043
Vlung inflammation
p82818
sg70045
I17
sg70054
VC0032285
p82819
sg70048
I2
sa(dp82820
g70042
I255
sg70043
Vasthma
p82821
sg70045
I6
sg70054
VC0004096
p82822
sg70048
I1
sa(dp82823
g70042
I263
sg70043
VCOPD
p82824
sg70045
I4
sg70054
VC0024117
p82825
sg70048
I1
sa(dp82826
g70042
I287
sg70043
Vedema
p82827
sg70045
I5
sg70054
VC0013604
p82828
sg70048
I1
sa(dp82829
g70042
I269
sg70043
g82797
sg70045
I13
sg70054
VC0034069
p82830
sg70048
I2
sasa(dp82831
g70037
VOur purpose was to investigate the regulatory mechanism of TRPV1 and related cytokines on children bronchial asthma.
p82832
sg70039
(lp82833
(dp82834
g70042
I59
sg70043
VTRPV1
p82835
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82836
(dp82837
g70042
I99
sg70043
Vbronchial asthma
p82838
sg70045
I16
sg70054
VC0004096
p82839
sg70048
I2
sasa(dp82840
g135
(dp82841
(VIL-5
p82842
VEOS
p82843
tp82844
I00
ssg70037
VLogistic regression analysis further demonstrated that TRPV1 mRNA level, EOS, IL-4 and IL-5 may be risk factors for children bronchial asthma.
p82845
sg70039
(lp82846
(dp82847
g70042
I78
sg70043
VIL-4
p82848
sg70045
I4
sg70046
VP05112
p82849
sg70048
I1
sa(dp82850
g70042
I87
sg70043
g82842
sg70045
I4
sg70046
VP05113
p82851
sg70048
I1
sa(dp82852
g70042
I55
sg70043
VTRPV1 mRNA
p82853
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp82854
g70042
I73
sg70043
VEOS
p82855
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp82856
(dp82857
g70042
I125
sg70043
Vbronchial asthma
p82858
sg70045
I16
sg70054
VC0004096
p82859
sg70048
I2
sa(dp82860
g70042
I73
sg70043
g82843
sg70045
I3
sg70054
VC1836122
p82861
sg70048
I1
sasa(dp82862
g70037
VThe preliminary regulatory network of TRPV1 and related cytokines on children bronchial asthma established in this study provides certain theoretical basis for pathogenesis and treatment of children bronchial asthma.
p82863
sg70039
(lp82864
(dp82865
g70042
I38
sg70043
VTRPV1
p82866
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82867
(dp82868
g70042
I78
sg70043
Vbronchial asthma
p82869
sg70045
I16
sg70054
VC0004096
p82870
sg70048
I2
sa(dp82871
g70042
I160
sg70043
Vpathogenesis
p82872
sg70045
I12
sg70054
VC0699748
p82873
sg70048
I1
sa(dp82874
g70042
I78
sg70043
Vbronchial asthma
p82875
sg70045
I16
sg70054
VC0004096
p82876
sg70048
I2
sasa(dp82877
g70037
Voleoylethanolamide, sphingosine-1-phosphate, N-palmitoyltaurine) were postulated to be involved in activating the transient receptor potential vanilloid type 1 (TRPV1) receptor, driving TRPV1-dependent pathogenesis in asthma.Our findings suggest that asthma is characterised by a modest systemic metabolic shift in a disease severity-dependent manner, and that steroid treatment significantly affects metabolism.
p82878
sg70039
(lp82879
(dp82880
g70042
I161
sg70043
VTRPV1
p82881
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82882
g70042
I114
sg70043
Vtransient receptor potential vanilloid type 1 (TRPV1) receptor
p82883
sg70045
I62
sg70046
g12
sg70048
I8
sasg70051
(lp82884
(dp82885
g70042
I218
sg70043
Vasthma
p82886
sg70045
I6
sg70054
VC0004096
p82887
sg70048
I1
sa(dp82888
g70042
I218
sg70043
Vasthma
p82889
sg70045
I6
sg70054
VC0004096
p82890
sg70048
I1
sa(dp82891
g70042
I202
sg70043
Vpathogenesis
p82892
sg70045
I12
sg70054
VC0699748
p82893
sg70048
I1
sasa(dp82894
g70037
VTo investigate the effects of particulate matter &lt;= 2.5 microns (PM2.5) on asthma-related phenotypes and on lung expression of TRPA1 and TRPV1 proteins in a mouse model of asthma.
p82895
sg70039
(lp82896
(dp82897
g70042
I140
sg70043
VTRPV1 proteins
p82898
sg70045
I14
sg70046
g12
sg70048
I2
sa(dp82899
g70042
I130
sg70043
VTRPA1
p82900
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82901
(dp82902
g70042
I78
sg70043
Vasthma
p82903
sg70045
I6
sg70054
VC0004096
p82904
sg70048
I1
sa(dp82905
g70042
I78
sg70043
Vasthma
p82906
sg70045
I6
sg70054
VC0004096
p82907
sg70048
I1
sasa(dp82908
g70037
VPM2.5 exacerbates effects of asthma in this model, possibly by regulating TRPA1 and TRPV1 and the relevant neurokines.
p82909
sg70039
(lp82910
(dp82911
g70042
I74
sg70043
VTRPA1
p82912
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp82913
g70042
I84
sg70043
VTRPV1
p82914
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp82915
(dp82916
g70042
I29
sg70043
Vasthma
p82917
sg70045
I6
sg70054
VC0004096
p82918
sg70048
I1
sasa(dp82919
g70037
VOur results show that CM Tln2 is essential for proper Beta1D-integrin expression and that Tln1 can substitute for Tln2 in preserving heart function, but that loss of all Tln forms from the heart-muscle cell leads to myocyte instability and a dilated cardiomyopathy.
p82920
sg70039
(lp82921
(dp82922
g70042
I25
sg70043
VTln2
p82923
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82924
g70042
I90
sg70043
VTln1
p82925
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82926
g70042
I22
sg70043
VCM Tln2
p82927
sg70045
I7
sg70046
g12
sg70048
I2
sasg70051
(lp82928
(dp82929
g70042
I242
sg70043
Vdilated cardiomyopathy
p82930
sg70045
I22
sg70054
VC0007193
p82931
sg70048
I2
sasa(dp82932
g135
(dp82933
(VCYP1A2 mRNA transcripts
p82934
Vhsa
p82935
tp82936
I00
ssg70037
VThe levels of two miRNAs, hsa-miR-132-5p and hsa-miR-221-5p, were inversely correlated with the expression of CYP1A2 mRNA transcripts in normal human liver tissue samples represented in The Cancer Genome Atlas (TCGA) dataset.
p82937
sg70039
(lp82938
(dp82939
g70042
I26
sg70043
Vhsa-miR-132-5p
p82940
sg70045
I14
sg70046
g12
sg70048
I1
sa(dp82941
g70042
I110
sg70043
g82934
sg70045
I23
sg70046
VP05177
p82942
sg70048
I3
sa(dp82943
g70042
I45
sg70043
Vhsa-miR-221-5p
p82944
sg70045
I14
sg70046
g12
sg70048
I1
sasg70051
(lp82945
(dp82946
g70042
I190
sg70043
VCancer
p82947
sg70045
I6
sg70054
VC0006826
p82948
sg70048
I1
sa(dp82949
g70042
I26
sg70043
Vhsa
p82950
sg70045
I3
sg70054
VC0393754
p82951
sg70048
I1
sa(dp82952
g70042
I26
sg70043
g82935
sg70045
I3
sg70054
VC0393754
p82953
sg70048
I1
sasa(dp82954
g70037
VIn situ hybridization and functional experiments in a panel of colorectal cancer cell lines and xenografts further clarified the role of clinical relevant miRNAs.Results: Six miRNAs (miR-92b-3p, miR-188-3p, miR-221-5p, miR-331-3p, miR-425-3p, and miR-497-5p) were identified as strong predictors of survival in the screening cohort.
p82955
sg70039
(lp82956
(dp82957
g70042
I195
sg70043
VmiR-188-3p
p82958
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp82959
g70042
I231
sg70043
VmiR-425-3p
p82960
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp82961
g70042
I183
sg70043
VmiR-92b-3p
p82962
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp82963
g70042
I247
sg70043
VmiR-497-5p
p82964
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp82965
g70042
I219
sg70043
VmiR-331-3p
p82966
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp82967
g70042
I207
sg70043
VmiR-221-5p
p82968
sg70045
I10
sg70046
g12
sg70048
I1
sasg70051
(lp82969
(dp82970
g70042
I63
sg70043
Vcolorectal cancer
p82971
sg70045
I17
sg70054
VC1527249
p82972
sg70048
I2
sasa(dp82973
g135
(dp82974
(VCLN1
p82975
VCLN2
p82976
tp82977
I00
ssg70037
VParticularly, CLN1, CLN2 and CLN3 were obtained by adding derivatives C1, C2 or C3 during nanoparticles preparation, while CLN2-Pt were obtained by treating preformed CLN2 with Pt(II).
p82978
sg70039
(lp82979
(dp82980
g70042
I20
sg70043
VCLN2
p82981
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82982
g70042
I20
sg70043
VCLN2
p82983
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82984
g70042
I29
sg70043
VCLN3
p82985
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp82986
g70042
I123
sg70043
VCLN2-Pt
p82987
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp82988
g70042
I14
sg70043
g82975
sg70045
I4
sg70046
VP50897
p82989
sg70048
I1
sasg70051
(lp82990
(dp82991
g70042
I20
sg70043
VCLN2
p82992
sg70045
I4
sg70054
VC1876161
p82993
sg70048
I1
sa(dp82994
g70042
I20
sg70043
VCLN2
p82995
sg70045
I4
sg70054
VC1876161
p82996
sg70048
I1
sa(dp82997
g70042
I29
sg70043
VCLN3
p82998
sg70045
I4
sg70054
VC2931674
p82999
sg70048
I1
sa(dp83000
g70042
I14
sg70043
VCLN1
p83001
sg70045
I4
sg70054
VC1850451
p83002
sg70048
I1
sa(dp83003
g70042
I20
sg70043
g82976
sg70045
I4
sg70054
VC1876161
p83004
sg70048
I1
sasa(dp83005
g70037
VAs determined by ICP-OES, a content of P and Pt 2.2-fold and 2.5-fold higher in CLN2-Pt than in CLN3 was evidenced.
p83006
sg70039
(lp83007
(dp83008
g70042
I80
sg70043
VCLN2-Pt
p83009
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp83010
g70042
I96
sg70043
VCLN3
p83011
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83012
g70042
I17
sg70043
VICP-OES
p83013
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp83014
(dp83015
g70042
I21
sg70043
VOES
p83016
sg70045
I3
sg70054
VC1838329
p83017
sg70048
I1
sa(dp83018
g70042
I80
sg70043
VCLN2
p83019
sg70045
I4
sg70054
VC1876161
p83020
sg70048
I1
sa(dp83021
g70042
I96
sg70043
VCLN3
p83022
sg70045
I4
sg70054
VC2931674
p83023
sg70048
I1
sa(dp83024
g70042
I17
sg70043
VICP
p83025
sg70045
I3
sg70054
VC0268318
p83026
sg70048
I1
sasa(dp83027
g70037
VIn fact, the antiproliferative activity shown by CLN3, CLN2-Pt on the three model cancer cell lines was substantially similar and comparable to that of complex C3 in dmso solution.
p83028
sg70039
(lp83029
(dp83030
g70042
I55
sg70043
VCLN2-Pt
p83031
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp83032
g70042
I49
sg70043
VCLN3
p83033
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp83034
(dp83035
g70042
I55
sg70043
VCLN2
p83036
sg70045
I4
sg70054
VC1876161
p83037
sg70048
I1
sa(dp83038
g70042
I49
sg70043
VCLN3
p83039
sg70045
I4
sg70054
VC2931674
p83040
sg70048
I1
sa(dp83041
g70042
I82
sg70043
Vcancer
p83042
sg70045
I6
sg70054
VC0006826
p83043
sg70048
I1
sasa(dp83044
g70037
VSeparate prediction models which could predict consumption of each blood component in intra and postoperative phase of LDLT were derived from among the preoperative Hb, Hct, model for end-stage liver disease (MELD) score, body surface area (BSA), Plt, T. proteins, S. creatinine, B. urea, INR, and serum sodium and chloride.
p83045
sg70039
(lp83046
(dp83047
g70042
I247
sg70043
VPlt
p83048
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp83049
(dp83050
g70042
I194
sg70043
Vliver disease
p83051
sg70045
I13
sg70054
VC0023895
p83052
sg70048
I2
sasa(dp83053
g135
(dp83054
(VMECL1 gene
p83055
Vvitiligo
p83056
tp83057
I00
ssg70037
VNo association with vitiligo was found for the MECL1 gene, which encodes a third immunoproteasome subunit and is unlinked to the MHC class II region.
p83058
sg70039
(lp83059
(dp83060
g70042
I129
sg70043
VMHC class II region
p83061
sg70045
I19
sg70046
VP13747
p83062
sg70048
I4
sa(dp83063
g70042
I47
sg70043
g83055
sg70045
I10
sg70046
VP40313
p83064
sg70048
I2
sasg70051
(lp83065
(dp83066
g70042
I20
sg70043
g83056
sg70045
I8
sg70054
VC0042900
p83067
sg70048
I1
sasa(dp83068
g135
(dp83069
(VACTH
p83070
VACTH deficiency
p83071
tp83072
I00
ssg70037
VWe report a novel LHX3 mutation, which is associated with combined pituitary hormone deficiency including ACTH deficiency, short neck, and sensorineural hearing loss.
p83073
sg70039
(lp83074
(dp83075
g70042
I58
sg70043
Vcombined pituitary hormone
p83076
sg70045
I26
sg70046
VP18509
p83077
sg70048
I3
sa(dp83078
g70042
I18
sg70043
VLHX3
p83079
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83080
g70042
I106
sg70043
g83070
sg70045
I4
sg70046
VP01189
p83081
sg70048
I1
sasg70051
(lp83082
(dp83083
g70042
I139
sg70043
Vsensorineural hearing loss
p83084
sg70045
I26
sg70054
VC0018784
p83085
sg70048
I3
sa(dp83086
g70042
I77
sg70043
Vhormone deficiency
p83087
sg70045
I18
sg70054
VC0599750
p83088
sg70048
I2
sa(dp83089
g70042
I106
sg70043
g83071
sg70045
I15
sg70054
VC0342388
p83090
sg70048
I2
sasa(dp83091
g135
(dp83092
(Vadrenocorticotropic hormone
p83093
Vmotion sickness
p83094
tp83095
I00
ssg70037
VSo-called stress hormones, like adrenocorticotropic hormone, cortisol, and antidiuretic hormone, are released concomitant with nausea and vomiting in motion sickness, but do not seem to be involved in the aetiology of motion sickness.
p83096
sg70039
(lp83097
(dp83098
g70042
I32
sg70043
g83093
sg70045
I27
sg70046
VP01189
p83099
sg70048
I2
sasg70051
(lp83100
(dp83101
g70042
I150
sg70043
Vmotion sickness
p83102
sg70045
I15
sg70054
VC0026603
p83103
sg70048
I2
sa(dp83104
g70042
I127
sg70043
Vnausea and vomiting
p83105
sg70045
I19
sg70054
VC0027498
p83106
sg70048
I3
sa(dp83107
g70042
I150
sg70043
g83094
sg70045
I15
sg70054
VC0026603
p83108
sg70048
I2
sasa(dp83109
g135
(dp83110
(VMMP-1
p83111
VUIP
p83112
tp83113
I01
ssg70037
VMMP-1/7 serum levels were measured using Luminex xMAP technology in 139 patients- 47 IPF, 36 non-IPF Usual Interstitial Pneumonia (UIP), 14 idiopathic Nonspecific Interstitial Pneumonia (iNSIP), 29 secondary NSIP (secNSIP), 13 stage IV sarcoidosis- and 20 healthy controls, and compared using the Mann-Whitney U test.
p83114
sg70039
(lp83115
(dp83116
g70042
I0
sg70043
g83111
sg70045
I5
sg70046
VP03956
p83117
sg70048
I1
sasg70051
(lp83118
(dp83119
g70042
I101
sg70043
VUsual Interstitial Pneumonia
p83120
sg70045
I28
sg70054
VC0085786
p83121
sg70048
I3
sa(dp83122
g70042
I151
sg70043
VNonspecific Interstitial Pneumonia
p83123
sg70045
I34
sg70054
VC1290344
p83124
sg70048
I3
sa(dp83125
g70042
I236
sg70043
Vsarcoidosis
p83126
sg70045
I11
sg70054
VC0036202
p83127
sg70048
I1
sa(dp83128
g70042
I131
sg70043
g83112
sg70045
I3
sg70054
VC0085786
p83129
sg70048
I1
sasa(dp83130
g135
(dp83131
(Vcystatin C
p83132
Vchronic obstructive lung disease
p83133
tp83134
I01
ssg70037
VThis activity is regulated by such inhibitors as metalloprvteinase 1 tissue inhibitor and cystatin C. The comparative analysis was applied concerning matrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor and cystatin C--indicators of conditions of the "proteolysis-antiproteolysis" system in the bronchoalveolar secretion of patients with chronic obstructive lung disease, bronchial asthma and pneumonia.
p83135
sg70039
(lp83136
(dp83137
g70042
I90
sg70043
Vcystatin C
p83138
sg70045
I10
sg70046
VP01034
p83139
sg70048
I2
sa(dp83140
g70042
I150
sg70043
Vmatrix metalloproteinase 1 precursor; metalloproteinase I tissue inhibitor
p83141
sg70045
I74
sg70046
VP03956
p83142
sg70048
I8
sa(dp83143
g70042
I90
sg70043
g83132
sg70045
I10
sg70046
VP01034
p83144
sg70048
I2
sasg70051
(lp83145
(dp83146
g70042
I394
sg70043
Vbronchial asthma
p83147
sg70045
I16
sg70054
VC0004096
p83148
sg70048
I2
sa(dp83149
g70042
I415
sg70043
Vpneumonia
p83150
sg70045
I9
sg70054
VC0032285
p83151
sg70048
I1
sa(dp83152
g70042
I360
sg70043
g83133
sg70045
I32
sg70054
VC0024117
p83153
sg70048
I4
sasa(dp83154
g135
(dp83155
(VTIMP-1
p83156
Vvirus infection
p83157
tp83158
I00
ssg70037
VTo observe the effects of Dureping Injection on the contents of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in the lung tissue of mice with pneumonia of influenza virus infection.
p83159
sg70039
(lp83160
(dp83161
g70042
I64
sg70043
Vmatrix metalloproteinase-9
p83162
sg70045
I26
sg70046
VP14780
p83163
sg70048
I2
sa(dp83164
g70042
I92
sg70043
VMMP-9
p83165
sg70045
I5
sg70046
VP14780
p83166
sg70048
I1
sa(dp83167
g70042
I103
sg70043
Vtissue inhibitor of matrix metalloproteinase-1
p83168
sg70045
I46
sg70046
VP01033
p83169
sg70048
I5
sa(dp83170
g70042
I151
sg70043
g83156
sg70045
I6
sg70046
VP01033
p83171
sg70048
I1
sasg70051
(lp83172
(dp83173
g70042
I204
sg70043
Vinfluenza
p83174
sg70045
I9
sg70054
VC0021400
p83175
sg70048
I1
sa(dp83176
g70042
I191
sg70043
Vpneumonia
p83177
sg70045
I9
sg70054
VC0032285
p83178
sg70048
I1
sa(dp83179
g70042
I214
sg70043
g83157
sg70045
I15
sg70054
VC0042769
p83180
sg70048
I2
sasa(dp83181
g70037
VWe developed a Korean version of the NPI-Q (KNPI-Q) and compared subitems with those of the Korean version of the NPI (KNPI) in 63 dementia patients; 47 patients had been diagnosed with Alzheimer's disease with dementia, 8 with vascular dementia, and 8 with dementia with Lewy body disease.
p83182
sg70039
(lp83183
(dp83184
g70042
I44
sg70043
VKNPI-Q
p83185
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp83186
g70042
I15
sg70043
VKorean version of the NPI-Q
p83187
sg70045
I27
sg70046
g12
sg70048
I5
sasg70051
(lp83188
(dp83189
g70042
I131
sg70043
Vdementia
p83190
sg70045
I8
sg70054
VC0497327
p83191
sg70048
I1
sa(dp83192
g70042
I186
sg70043
VAlzheimer's disease
p83193
sg70045
I19
sg70054
VC1521724
p83194
sg70048
I2
sa(dp83195
g70042
I131
sg70043
Vdementia
p83196
sg70045
I8
sg70054
VC0497327
p83197
sg70048
I1
sa(dp83198
g70042
I131
sg70043
Vdementia
p83199
sg70045
I8
sg70054
VC0497327
p83200
sg70048
I1
sa(dp83201
g70042
I272
sg70043
VLewy body disease
p83202
sg70045
I17
sg70054
VC0752347
p83203
sg70048
I3
sa(dp83204
g70042
I228
sg70043
Vvascular dementia
p83205
sg70045
I17
sg70054
VC0011269
p83206
sg70048
I2
sasa(dp83207
g70037
VAll patients received the Korean version of the Mini-Mental State Examination and the Clinical Dementia Rating within 1 month of the KNPI-Q.
p83208
sg70039
(lp83209
(dp83210
g70042
I133
sg70043
VKNPI-Q
p83211
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp83212
(dp83213
g70042
I95
sg70043
VDementia
p83214
sg70045
I8
sg70054
VC0497327
p83215
sg70048
I1
sasa(dp83216
g70037
VThe KNPI-Q is a reliable and brief instrument that can be employed for screening in the evaluation of neuropsychiatric symptoms of dementia and associated caregiver distress.
p83217
sg70039
(lp83218
(dp83219
g70042
I4
sg70043
VKNPI-Q
p83220
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp83221
(dp83222
g70042
I131
sg70043
Vdementia
p83223
sg70045
I8
sg70054
VC0497327
p83224
sg70048
I1
sasa(dp83225
g135
(dp83226
(VClinical Dementia Rating Sum of Box
p83227
Vdepressive symptoms
p83228
tp83229
I00
ssg70037
VThe cognitive function of each sub-domain, functional impairments, depressive symptoms, and caregiver burden were assessed using the dementia version of Seoul Neuropsychological Screening Battery (SNSB-D), Barthel Index for Daily Living Activities (ADL), Seoul-Instrumental Activities of Daily Living (S-IADL), the Clinical Dementia Rating Sum of Box (CDR-SB), the Global Deterioration Scale (GDS), the Korean version of the Neuropsychiatric Inventory (K-NPI), and the 15-item Geriatric Depression Scale.
p83230
sg70039
(lp83231
(dp83232
g70042
I352
sg70043
VCDR-SB
p83233
sg70045
I6
sg70046
VP51861
p83234
sg70048
I1
sa(dp83235
g70042
I315
sg70043
g83227
sg70045
I35
sg70046
VP51861
p83236
sg70048
I6
sasg70051
(lp83237
(dp83238
g70042
I324
sg70043
VDementia
p83239
sg70045
I8
sg70054
VC0497327
p83240
sg70048
I1
sa(dp83241
g70042
I133
sg70043
Vdementia
p83242
sg70045
I8
sg70054
VC0497327
p83243
sg70048
I1
sa(dp83244
g70042
I487
sg70043
VDepression
p83245
sg70045
I10
sg70054
VC0011581
p83246
sg70048
I1
sa(dp83247
g70042
I67
sg70043
g83228
sg70045
I19
sg70054
VC0086132
p83248
sg70048
I2
sasa(dp83249
g70037
VOur primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI).
p83250
sg70039
(lp83251
sg70051
(lp83252
(dp83253
g70042
I117
sg70043
VDementia
p83254
sg70045
I8
sg70054
VC0497327
p83255
sg70048
I1
sasa(dp83256
g70037
VThe patients were also evaluated using the Korean version of the Severe Impairment Battery (SIB-Ko), Clinical Dementia Rating (CDR), Global Deterioration Scale (GDS), Barthel Activities of Daily Living (B-ADL), the Korean version of the Instrumental Activities of Daily Living (K-IADL), the Korean version of the Neuropsychiatric Inventory (K-NPI) and the Functional Assessment Staging (FAST).
p83257
sg70039
(lp83258
sg70051
(lp83259
(dp83260
g70042
I72
sg70043
VImpairment
p83261
sg70045
I10
sg70054
VC0684336
p83262
sg70048
I1
sa(dp83263
g70042
I110
sg70043
VDementia
p83264
sg70045
I8
sg70054
VC0497327
p83265
sg70048
I1
sasa(dp83266
g70037
VThe aim of this study is to develop the Korean version of the NPI (K-NPI) and to test its reliability and usefulness in dementia patients.
p83267
sg70039
(lp83268
sg70051
(lp83269
(dp83270
g70042
I120
sg70043
Vdementia
p83271
sg70045
I8
sg70054
VC0497327
p83272
sg70048
I1
sasa(dp83273
g70037
VTotal K-NPI scores correlated positively with dementia severity assessed with the Korean Mini-Mental State Examination.
p83274
sg70039
(lp83275
sg70051
(lp83276
(dp83277
g70042
I46
sg70043
Vdementia
p83278
sg70045
I8
sg70054
VC0497327
p83279
sg70048
I1
sasa(dp83280
g70037
VThe K-NPI, whose reliability and competency are comparable to those of the original version, may be a reliable and useful tool for measuring neuropsychiatric disturbances in Korean dementia patients.
p83281
sg70039
(lp83282
sg70051
(lp83283
(dp83284
g70042
I181
sg70043
Vdementia
p83285
sg70045
I8
sg70054
VC0497327
p83286
sg70048
I1
sasa(dp83287
g135
(dp83288
(Vadenylyl cyclase
p83289
VCED
p83290
tp83291
I00
ssg70037
VBone and cartilage and their disorders are addressed under the following headings: functions of bone; normal and abnormal bone remodeling; osteopetrosis and osteoporosis; epithelial-mesenchymal interaction, condensation and differentiation; osteoblasts, markers of bone formation, osteoclasts, components of bone, and pathology of bone; chondroblasts, markers of cartilage formation, secondary cartilage, components of cartilage, and pathology of cartilage; intramembranous and endochondral bone formation; RUNX genes and cleidocranial dysplasia (CCD); osterix; histone deacetylase 4 and Runx2; Ligand to receptor activator of NFkappaB (RANKL), RANK, osteoprotegerin, and osteoimmunology; WNT signaling, LRP5 mutations, and beta-catenin; the role of leptin in bone remodeling; collagens, collagenopathies, and osteogenesis imperfecta; FGFs/FGFRs, FGFR3 skeletal dysplasias, craniosynostosis, and other disorders; short limb chondrodysplasias; molecular control of the growth plate in endochondral bone formation and genetic disorders of IHH and PTHR1; ANKH, craniometaphyseal dysplasia, and chondrocalcinosis; transforming growth factor beta, Camurati-Engelmann disease (CED), and Marfan syndrome, types I and II; an ACVR1 mutation and fibrodysplasia ossificans progressiva; MSX1 and MSX2: biology, mutations, and associated disorders; G protein, activation of adenylyl cyclase, GNAS1 mutations, McCune-Albright syndrome, fibrous dysplasia, and Albright hereditary osteodystrophy; FLNA and associated disorders; and morphological development of teeth and their genetic mutations.
p83292
sg70039
(lp83293
(dp83294
g70042
I562
sg70043
Vhistone deacetylase 4
p83295
sg70045
I21
sg70046
VP56524
p83296
sg70048
I3
sa(dp83297
g70042
I704
sg70043
VLRP5
p83298
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83299
g70042
I1217
sg70043
VACVR1
p83300
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83301
g70042
I1284
sg70043
VMSX2
p83302
sg70045
I4
sg70046
VP35548
p83303
sg70048
I1
sa(dp83304
g70042
I1045
sg70043
VPTHR1
p83305
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83306
g70042
I1037
sg70043
VIHH
p83307
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp83308
g70042
I627
sg70043
VNFkappaB
p83309
sg70045
I8
sg70046
VP19838
p83310
sg70048
I1
sa(dp83311
g70042
I1275
sg70043
VMSX1
p83312
sg70045
I4
sg70046
VP28360
p83313
sg70048
I1
sa(dp83314
g70042
I1379
sg70043
VGNAS1
p83315
sg70045
I5
sg70046
VP84996
p83316
sg70048
I1
sa(dp83317
g70042
I1171
sg70043
VCED
p83318
sg70045
I3
sg70046
VP01137
p83319
sg70048
I1
sa(dp83320
g70042
I588
sg70043
VRunx2
p83321
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83322
g70042
I847
sg70043
VFGFR3
p83323
sg70045
I5
sg70046
VP22607
p83324
sg70048
I1
sa(dp83325
g70042
I1052
sg70043
VANKH
p83326
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83327
g70042
I1143
sg70043
VCamurati-Engelmann disease
p83328
sg70045
I26
sg70046
VP01137
p83329
sg70048
I2
sa(dp83330
g70042
I1110
sg70043
Vtransforming growth factor beta
p83331
sg70045
I31
sg70046
VP18075
p83332
sg70048
I4
sa(dp83333
g70042
I750
sg70043
Vleptin
p83334
sg70045
I6
sg70046
VP41159
p83335
sg70048
I1
sa(dp83336
g70042
I724
sg70043
Vbeta-catenin
p83337
sg70045
I12
sg70046
VP35222
p83338
sg70048
I1
sa(dp83339
g70042
I1361
sg70043
g83289
sg70045
I16
sg70046
VP51828
p83340
sg70048
I2
sa(dp83341
g70042
I651
sg70043
Vosteoprotegerin
p83342
sg70045
I15
sg70046
g12
sg70048
I1
sa(dp83343
g70042
I637
sg70043
VRANKL
p83344
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83345
(dp83346
g70042
I1016
sg70043
Vgenetic disorders
p83347
sg70045
I17
sg70054
VC0019247
p83348
sg70048
I2
sa(dp83349
g70042
I157
sg70043
Vosteoporosis
p83350
sg70045
I12
sg70054
VC0029456
p83351
sg70048
I1
sa(dp83352
g70042
I862
sg70043
Vdysplasias
p83353
sg70045
I10
sg70054
VC0334044
p83354
sg70048
I1
sa(dp83355
g70042
I522
sg70043
Vcleidocranial dysplasia
p83356
sg70045
I23
sg70054
VC0008928
p83357
sg70048
I2
sa(dp83358
g70042
I1422
sg70043
Vfibrous dysplasia
p83359
sg70045
I17
sg70054
VC0259779
p83360
sg70048
I2
sa(dp83361
g70042
I810
sg70043
Vosteogenesis imperfecta
p83362
sg70045
I23
sg70054
VC0029434
p83363
sg70048
I2
sa(dp83364
g70042
I547
sg70043
VCCD
p83365
sg70045
I3
sg70054
VC0008928
p83366
sg70048
I1
sa(dp83367
g70042
I1058
sg70043
Vcraniometaphyseal dysplasia
p83368
sg70045
I27
sg70054
VC0265292
p83369
sg70048
I2
sa(dp83370
g70042
I1091
sg70043
Vchondrocalcinosis
p83371
sg70045
I17
sg70054
VC0553730
p83372
sg70048
I1
sa(dp83373
g70042
I318
sg70043
Vpathology
p83374
sg70045
I9
sg70054
VC0677042
p83375
sg70048
I1
sa(dp83376
g70042
I1445
sg70043
VAlbright hereditary osteodystrophy
p83377
sg70045
I34
sg70054
VC2931404
p83378
sg70048
I3
sa(dp83379
g70042
I1037
sg70043
VIHH
p83380
sg70045
I3
sg70054
VC0342384
p83381
sg70048
I1
sa(dp83382
g70042
I1143
sg70043
VCamurati-Engelmann disease
p83383
sg70045
I26
sg70054
VC0011989
p83384
sg70048
I2
sa(dp83385
g70042
I139
sg70043
Vosteopetrosis
p83386
sg70045
I13
sg70054
VC0029454
p83387
sg70048
I1
sa(dp83388
g70042
I1396
sg70043
VMcCune-Albright syndrome
p83389
sg70045
I24
sg70054
VC0242292
p83390
sg70048
I2
sa(dp83391
g70042
I318
sg70043
Vpathology
p83392
sg70045
I9
sg70054
VC0677042
p83393
sg70048
I1
sa(dp83394
g70042
I207
sg70043
Vcondensation
p83395
sg70045
I12
sg70054
VC0233656
p83396
sg70048
I1
sa(dp83397
g70042
I924
sg70043
Vchondrodysplasias
p83398
sg70045
I17
sg70054
VC0343284
p83399
sg70048
I1
sa(dp83400
g70042
I1236
sg70043
Vfibrodysplasia ossificans progressiva
p83401
sg70045
I37
sg70054
VC0016037
p83402
sg70048
I3
sa(dp83403
g70042
I1181
sg70043
VMarfan syndrome
p83404
sg70045
I15
sg70054
VC0024796
p83405
sg70048
I2
sa(dp83406
g70042
I874
sg70043
Vcraniosynostosis
p83407
sg70045
I16
sg70054
VC0010278
p83408
sg70048
I1
sa(dp83409
g70042
I1171
sg70043
g83290
sg70045
I3
sg70054
VC0011989
p83410
sg70048
I1
sasa(dp83411
g70037
VGenome-wide analysis showed an association of asthma in Russians with the polymorphic loci of gene MUC19 (12q12) encoding gel-forming mucin 19.
p83412
sg70039
(lp83413
(dp83414
g70042
I122
sg70043
Vgel-forming mucin 19
p83415
sg70045
I20
sg70046
g12
sg70048
I3
sa(dp83416
g70042
I94
sg70043
Vgene MUC19 (12q12)
p83417
sg70045
I18
sg70046
g12
sg70048
I3
sasg70051
(lp83418
(dp83419
g70042
I46
sg70043
Vasthma
p83420
sg70045
I6
sg70054
VC0004096
p83421
sg70048
I1
sasa(dp83422
g70037
VSeven polymorphic loci of gene MUC19 (rs1492313, rs2588401, rs2588402, rs2638863, rs2638864, rs1352940, and rs2933373), which are in close linkage disequilibrium among themselves and rs2933346, are associated with asthma with the same p-value (p = 4.96 x 10(-6)).
p83423
sg70039
(lp83424
(dp83425
g70042
I31
sg70043
VMUC19
p83426
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83427
(dp83428
g70042
I214
sg70043
Vasthma
p83429
sg70045
I6
sg70054
VC0004096
p83430
sg70048
I1
sa(dp83431
g70042
I147
sg70043
Vdisequilibrium
p83432
sg70045
I14
sg70054
VC0394006
p83433
sg70048
I1
sasa(dp83434
g70037
VAccording to our data, the association of polymorphic variants of gene MUC19 with asthma has not been previously identified in any study.
p83435
sg70039
(lp83436
(dp83437
g70042
I71
sg70043
VMUC19
p83438
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83439
(dp83440
g70042
I82
sg70043
Vasthma
p83441
sg70045
I6
sg70054
VC0004096
p83442
sg70048
I1
sasa(dp83443
g70037
VOur results indicate the important role of polymorphic variants of gene MUC19 in the formation of a predisposition to the development of asthma in individuals of Russian ethnicity.
p83444
sg70039
(lp83445
(dp83446
g70042
I72
sg70043
VMUC19
p83447
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83448
(dp83449
g70042
I137
sg70043
Vasthma
p83450
sg70045
I6
sg70054
VC0004096
p83451
sg70048
I1
sasa(dp83452
g135
(dp83453
(VMUC18
p83454
Vnasal polyps
p83455
tp83456
I00
ssg70037
VTo detect the mucin gene (MUC2, MUC5AC, MUC5B, MUC18 and MUC19) expression in the nasal polyps, allergic rhinitis (AR) and the normal nasal mucosa in human.
p83457
sg70039
(lp83458
(dp83459
g70042
I26
sg70043
VMUC2
p83460
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83461
g70042
I47
sg70043
g83454
sg70045
I5
sg70046
VP43121
p83462
sg70048
I1
sa(dp83463
g70042
I14
sg70043
Vmucin gene
p83464
sg70045
I10
sg70046
g12
sg70048
I2
sa(dp83465
g70042
I57
sg70043
VMUC19
p83466
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83467
(dp83468
g70042
I96
sg70043
Vallergic rhinitis
p83469
sg70045
I17
sg70054
VC2607914
p83470
sg70048
I2
sa(dp83471
g70042
I115
sg70043
VAR
p83472
sg70045
I2
sg70054
VC2607914
p83473
sg70048
I1
sa(dp83474
g70042
I82
sg70043
g83455
sg70045
I12
sg70054
VC0027430
p83475
sg70048
I2
sasa(dp83476
g70037
VIt indicates that the secretion of MUC19 in allergic rhinitis was on high level.
p83477
sg70039
(lp83478
(dp83479
g70042
I35
sg70043
VMUC19
p83480
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83481
(dp83482
g70042
I44
sg70043
Vallergic rhinitis
p83483
sg70045
I17
sg70054
VC2607914
p83484
sg70048
I2
sasa(dp83485
g135
(dp83486
(Vhypocretin
p83487
Vnarcolepsy
p83488
tp83489
I00
ssg70037
VWe aimed to assess the impact of hypocretin deficiency on attentional functioning by comparing performances on the attention network test (ANT) of narcoleptic patients with hypocretin deficiency (narcolepsy type 1-NT1) versus patients without hypocretin deficiency (narcolepsy type 2-NT2) and healthy controls.
p83490
sg70039
(lp83491
(dp83492
g70042
I33
sg70043
Vhypocretin
p83493
sg70045
I10
sg70046
VP50336
p83494
sg70048
I1
sa(dp83495
g70042
I33
sg70043
Vhypocretin
p83496
sg70045
I10
sg70046
VP50336
p83497
sg70048
I1
sa(dp83498
g70042
I33
sg70043
g83487
sg70045
I10
sg70046
VP50336
p83499
sg70048
I1
sasg70051
(lp83500
(dp83501
g70042
I196
sg70043
Vnarcolepsy
p83502
sg70045
I10
sg70054
VC0027404
p83503
sg70048
I1
sa(dp83504
g70042
I196
sg70043
g83488
sg70045
I10
sg70054
VC0027404
p83505
sg70048
I1
sasa(dp83506
g135
(dp83507
(Vgastrin
p83508
Vtype 1 diabetes
p83509
tp83510
I01
ssg70037
VA randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.
p83511
sg70039
(lp83512
(dp83513
g70042
I173
sg70043
g83508
sg70045
I7
sg70046
VP01350
p83514
sg70048
I1
sa(dp83515
g70042
I227
sg70043
VReg receptor
p83516
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp83517
(dp83518
g70042
I21
sg70043
Vblind
p83519
sg70045
I5
sg70054
VC0456909
p83520
sg70048
I1
sa(dp83521
g70042
I64
sg70043
g83509
sg70045
I15
sg70054
VC0011854
p83522
sg70048
I3
sasa(dp83523
g135
(dp83524
(Vinsulin
p83525
VCVT
p83526
tp83527
I00
ssg70037
VIn the A(1)AR agonist area, clinical candidates have been discovered for the following conditions: atrial arrhythmias (tecadenoson, selodenoson and PJ-875); Type II diabetes and insulin sensitizing agents (GR79236, ARA, RPR-749, and CVT-3619); and angina (BAY 68-4986).
p83528
sg70039
(lp83529
(dp83530
g70042
I178
sg70043
g83525
sg70045
I7
sg70046
VP01308
p83531
sg70048
I1
sasg70051
(lp83532
(dp83533
g70042
I99
sg70043
Vatrial arrhythmias
p83534
sg70045
I18
sg70054
VC0085611
p83535
sg70048
I2
sa(dp83536
g70042
I157
sg70043
VType II diabetes
p83537
sg70045
I16
sg70054
VC0011860
p83538
sg70048
I3
sa(dp83539
g70042
I248
sg70043
Vangina
p83540
sg70045
I6
sg70054
VC0002962
p83541
sg70048
I1
sa(dp83542
g70042
I233
sg70043
g83526
sg70045
I3
sg70054
VC0240912
p83543
sg70048
I1
sasa(dp83544
g70037
VThe treatment of type II diabetes using A(1)AR agonists in the clinic has met with limited success due to cardiovascular side effects and a well-defined desensitization of full agonists in human trials (GR79236, ARA, and RPR 749).
p83545
sg70039
(lp83546
sg70051
(lp83547
(dp83548
g70042
I17
sg70043
Vtype II diabetes
p83549
sg70045
I16
sg70054
VC0011860
p83550
sg70048
I3
sasa(dp83551
g135
(dp83552
(VReg protein
p83553
Vdiabetes
p83554
tp83555
I00
ssg70037
VReg protein acts as an autocrine/paracrine growth factor to induce beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p83556
sg70039
(lp83557
(dp83558
g70042
I97
sg70043
VReg receptor
p83559
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp83560
g70042
I0
sg70043
g83553
sg70045
I11
sg70046
VP05451
p83561
sg70048
I2
sasg70051
(lp83562
(dp83563
g70042
I139
sg70043
g83554
sg70045
I8
sg70054
VC0011849
p83564
sg70048
I1
sasa(dp83565
g135
(dp83566
(VREG
p83567
Vdiabetes
p83568
tp83569
I00
ssg70037
VWe have demonstrated in vitro and in vivo that the exogenous addition of rat and human Reg gene products, Reg/REG proteins, induced beta-cell replication via the Reg receptor and thereby ameliorated experimental diabetes.
p83570
sg70039
(lp83571
(dp83572
g70042
I87
sg70043
VReg
p83573
sg70045
I3
sg70046
VP05451
p83574
sg70048
I1
sa(dp83575
g70042
I81
sg70043
Vhuman Reg gene products
p83576
sg70045
I23
sg70046
VP05451
p83577
sg70048
I4
sa(dp83578
g70042
I162
sg70043
VReg receptor
p83579
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp83580
g70042
I110
sg70043
g83567
sg70045
I3
sg70046
VP05451
p83581
sg70048
I1
sasg70051
(lp83582
(dp83583
g70042
I212
sg70043
g83568
sg70045
I8
sg70054
VC0011849
p83584
sg70048
I1
sasa(dp83585
g135
(dp83586
(VReg
p83587
Vdiabetes
p83588
tp83589
I00
ssg70037
VFrom the regenerating islet-derived cDNA library we isolated Reg (Regenerating Gene) and demonstrated that Reg protein induces beta-cell replication via the Reg receptor and ameliorates experimental diabetes.
p83590
sg70039
(lp83591
(dp83592
g70042
I107
sg70043
VReg protein
p83593
sg70045
I11
sg70046
VP05451
p83594
sg70048
I2
sa(dp83595
g70042
I61
sg70043
g83587
sg70045
I3
sg70046
VP05451
p83596
sg70048
I1
sa(dp83597
g70042
I157
sg70043
VReg receptor
p83598
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp83599
(dp83600
g70042
I199
sg70043
g83588
sg70045
I8
sg70054
VC0011849
p83601
sg70048
I1
sasa(dp83602
g135
(dp83603
(Vpituitary specific transcription factors
p83604
Vhypopituitarism
p83605
tp83606
I00
ssg70037
VGenomic DNA was isolated from patients with hypopituitarism to amplify and sequence eight pituitary specific transcription factors (HESX1, LHX3, LHX4, OTX2, PITX2, POU1F1, PROP1, and SIX6).
p83607
sg70039
(lp83608
(dp83609
g70042
I132
sg70043
VHESX1
p83610
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83611
g70042
I172
sg70043
VPROP1
p83612
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83613
g70042
I145
sg70043
VLHX4
p83614
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83615
g70042
I164
sg70043
VPOU1F1
p83616
sg70045
I6
sg70046
VP28069
p83617
sg70048
I1
sa(dp83618
g70042
I151
sg70043
VOTX2
p83619
sg70045
I4
sg70046
VP32243
p83620
sg70048
I1
sa(dp83621
g70042
I157
sg70043
VPITX2
p83622
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83623
g70042
I139
sg70043
VLHX3
p83624
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83625
g70042
I183
sg70043
VSIX6
p83626
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp83627
g70042
I90
sg70043
g83604
sg70045
I40
sg70046
VP19883
p83628
sg70048
I4
sasg70051
(lp83629
(dp83630
g70042
I44
sg70043
g83605
sg70045
I15
sg70054
VC0020635
p83631
sg70048
I1
sasa(dp83632
g135
(dp83633
(VRat insulinoma INS-1E
p83634
Vinsulinoma
p83635
tp83636
I00
ssg70037
VRat insulinoma INS-1E cells and mouse beta-TC3 cells stably expressing Gadd45b were generated.
p83637
sg70039
(lp83638
(dp83639
g70042
I0
sg70043
g83634
sg70045
I21
sg70046
VP01308
p83640
sg70048
I3
sa(dp83641
g70042
I71
sg70043
VGadd45b
p83642
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp83643
(dp83644
g70042
I15
sg70043
VINS
p83645
sg70045
I3
sg70054
VC1533172
p83646
sg70048
I1
sa(dp83647
g70042
I4
sg70043
g83635
sg70045
I10
sg70054
VC0021670
p83648
sg70048
I1
sasa(dp83649
g70037
VTo define the genetic landscape of amyotrophic lateral sclerosis (ALS) and assess the contribution of possible oligogenic inheritance, we aimed to comprehensively sequence 17 known ALS genes in 391 ALS patients from the United States.
p83650
sg70039
(lp83651
sg70051
(lp83652
(dp83653
g70042
I66
sg70043
VALS
p83654
sg70045
I3
sg70054
VC0002736
p83655
sg70048
I1
sa(dp83656
g70042
I66
sg70043
VALS
p83657
sg70045
I3
sg70054
VC0002736
p83658
sg70048
I1
sa(dp83659
g70042
I35
sg70043
Vamyotrophic lateral sclerosis
p83660
sg70045
I29
sg70054
VC0002736
p83661
sg70048
I3
sa(dp83662
g70042
I66
sg70043
VALS
p83663
sg70045
I3
sg70054
VC0002736
p83664
sg70048
I1
sasa(dp83665
g135
(dp83666
(VHigh nuclear ATF2
p83667
Vperipheral nerve sheath tumor
p83668
tp83669
I00
ssg70037
VHigh nuclear ATF2 expression was mainly observed in translocation-associated and/or spindle cell sarcomas including synovial sarcoma, desmoplastic small round cell tumor, endometrial stromal sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, and solitary fibrous tumor.
p83670
sg70039
(lp83671
(dp83672
g70042
I0
sg70043
g83667
sg70045
I17
sg70046
VP15336
p83673
sg70048
I3
sasg70051
(lp83674
(dp83675
g70042
I134
sg70043
Vdesmoplastic small round cell tumor
p83676
sg70045
I35
sg70054
VC0281508
p83677
sg70048
I5
sa(dp83678
g70042
I171
sg70043
Vendometrial stromal sarcoma
p83679
sg70045
I27
sg70054
VC0206630
p83680
sg70048
I3
sa(dp83681
g70042
I84
sg70043
Vspindle cell sarcomas
p83682
sg70045
I21
sg70054
VC0205945
p83683
sg70048
I3
sa(dp83684
g70042
I116
sg70043
Vsynovial sarcoma
p83685
sg70045
I16
sg70054
VC0039101
p83686
sg70048
I2
sa(dp83687
g70042
I277
sg70043
Vsolitary fibrous tumor
p83688
sg70045
I22
sg70054
VC1266119
p83689
sg70048
I3
sa(dp83690
g70042
I52
sg70043
Vtranslocation
p83691
sg70045
I13
sg70054
VC0040715
p83692
sg70048
I1
sa(dp83693
g70042
I200
sg70043
Vgastrointestinal stromal tumor, malignant
p83694
sg70045
I41
sg70054
VC3179349
p83695
sg70048
I4
sa(dp83696
g70042
I242
sg70043
g83668
sg70045
I29
sg70054
VC0751689
p83697
sg70048
I4
sasa(dp83698
g70037
VSIRT1 immunoreactivity was reviewed in a series of 164 soft tissue tumors including alveolar soft part sarcoma, angiomyolipoma, clear cell sarcoma, desmoid/fibromatosis, desmoplastic small round cell tumor, Ewing sarcoma, gastrointestinal stromal tumor, glomus tumor, leiomyoma, leiomyosarcoma, lipoma, liposarcoma, malignant peripheral nerve sheath tumor, nodular fasciitis, osteosarcoma, rhabdomyosarcoma, schwannoma, solitary fibrous tumor, synovial sarcoma, undifferentiated pleomorphic sarcoma, and Wilms tumor.
p83699
sg70039
(lp83700
(dp83701
g70042
I0
sg70043
VSIRT1
p83702
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83703
(dp83704
g70042
I444
sg70043
Vsynovial sarcoma
p83705
sg70045
I16
sg70054
VC0039101
p83706
sg70048
I2
sa(dp83707
g70042
I420
sg70043
Vsolitary fibrous tumor
p83708
sg70045
I22
sg70054
VC1266119
p83709
sg70048
I3
sa(dp83710
g70042
I462
sg70043
Vundifferentiated pleomorphic sarcoma
p83711
sg70045
I36
sg70054
VC1704218
p83712
sg70048
I3
sa(dp83713
g70042
I390
sg70043
Vrhabdomyosarcoma
p83714
sg70045
I16
sg70054
VC0035412
p83715
sg70048
I1
sa(dp83716
g70042
I408
sg70043
Vschwannoma
p83717
sg70045
I10
sg70054
VC0027809
p83718
sg70048
I1
sa(dp83719
g70042
I254
sg70043
Vglomus tumor
p83720
sg70045
I12
sg70054
VC0017653
p83721
sg70048
I2
sa(dp83722
g70042
I268
sg70043
Vleiomyoma
p83723
sg70045
I9
sg70054
VC0023267
p83724
sg70048
I1
sa(dp83725
g70042
I156
sg70043
Vfibromatosis
p83726
sg70045
I12
sg70054
VC0016048
p83727
sg70048
I1
sa(dp83728
g70042
I207
sg70043
VEwing sarcoma
p83729
sg70045
I13
sg70054
VC0553580
p83730
sg70048
I2
sa(dp83731
g70042
I112
sg70043
Vangiomyolipoma
p83732
sg70045
I14
sg70054
VC0206633
p83733
sg70048
I1
sa(dp83734
g70042
I376
sg70043
Vosteosarcoma
p83735
sg70045
I12
sg70054
VC0029463
p83736
sg70048
I1
sa(dp83737
g70042
I128
sg70043
Vclear cell sarcoma
p83738
sg70045
I18
sg70054
VC0206651
p83739
sg70048
I3
sa(dp83740
g70042
I148
sg70043
Vdesmoid
p83741
sg70045
I7
sg70054
VC0079218
p83742
sg70048
I1
sa(dp83743
g70042
I120
sg70043
Vlipoma
p83744
sg70045
I6
sg70054
VC3489413
p83745
sg70048
I1
sa(dp83746
g70042
I303
sg70043
Vliposarcoma
p83747
sg70045
I11
sg70054
VC0023827
p83748
sg70048
I1
sa(dp83749
g70042
I170
sg70043
Vdesmoplastic small round cell tumor
p83750
sg70045
I35
sg70054
VC0281508
p83751
sg70048
I5
sa(dp83752
g70042
I84
sg70043
Valveolar soft part sarcoma
p83753
sg70045
I26
sg70054
VC0206657
p83754
sg70048
I4
sa(dp83755
g70042
I222
sg70043
Vgastrointestinal stromal tumor
p83756
sg70045
I30
sg70054
VC0238198
p83757
sg70048
I3
sa(dp83758
g70042
I55
sg70043
Vsoft tissue tumors
p83759
sg70045
I18
sg70054
VC0037579
p83760
sg70048
I3
sa(dp83761
g70042
I504
sg70043
VWilms tumor
p83762
sg70045
I11
sg70054
VC0027708
p83763
sg70048
I2
sa(dp83764
g70042
I279
sg70043
Vleiomyosarcoma
p83765
sg70045
I14
sg70054
VC0023269
p83766
sg70048
I1
sa(dp83767
g70042
I357
sg70043
Vnodular fasciitis
p83768
sg70045
I17
sg70054
VC0410005
p83769
sg70048
I2
sa(dp83770
g70042
I316
sg70043
Vmalignant peripheral nerve sheath tumor
p83771
sg70045
I39
sg70054
VC0751690
p83772
sg70048
I5
sasa(dp83773
g135
(dp83774
(VCD117-negative GISTs
p83775
VGISTs
p83776
tp83777
I00
ssg70037
VPathologic diagnosis of CD117-negative GISTs can be facilitated with the application of a panel of immunohistochemical markers, including DOG-1 and WT-1.
p83778
sg70039
(lp83779
(dp83780
g70042
I138
sg70043
VDOG-1
p83781
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83782
g70042
I24
sg70043
g83775
sg70045
I20
sg70046
VP10721
p83783
sg70048
I2
sasg70051
(lp83784
(dp83785
g70042
I39
sg70043
g83776
sg70045
I5
sg70054
VC0238198
p83786
sg70048
I1
sasa(dp83787
g70037
VIn this study, WT-1 immunoreactivity was explored in 97 gastrointestinal stromal tumours (GISTs).
p83788
sg70039
(lp83789
sg70051
(lp83790
(dp83791
g70042
I56
sg70043
Vgastrointestinal stromal tumours
p83792
sg70045
I32
sg70054
VC0238198
p83793
sg70048
I3
sa(dp83794
g70042
I90
sg70043
VGISTs
p83795
sg70045
I5
sg70054
VC0238198
p83796
sg70048
I1
sasa(dp83797
g135
(dp83798
(VGIST
p83799
VGIST
p83800
tp83801
I00
ssg70037
VThe expression of WT-1 was compared with other immunohistochemical markers of GIST and the association with clinicopathological features was also evaluated.
p83802
sg70039
(lp83803
(dp83804
g70042
I78
sg70043
g83799
sg70045
I4
sg70046
VP10721
p83805
sg70048
I1
sasg70051
(lp83806
(dp83807
g70042
I78
sg70043
g83800
sg70045
I4
sg70054
VC1847319
p83808
sg70048
I1
sasa(dp83809
g70037
VAll 97 GISTs were positive for WT-1 and the staining intensity was strong in 59 (60.8%), moderate in 28 (28.9%) and weak in 10 cases (10.3%).
p83810
sg70039
(lp83811
sg70051
(lp83812
(dp83813
g70042
I7
sg70043
VGISTs
p83814
sg70045
I5
sg70054
VC0238198
p83815
sg70048
I1
sasa(dp83816
g70037
VAlthough the biological roles of WT-1 in GIST are still unknown, our findings might provide a rationale for immunotherapy targeting WT-1 and a therapeutic solution to the challenge of imatinib-resistant GISTs.
p83817
sg70039
(lp83818
sg70051
(lp83819
(dp83820
g70042
I203
sg70043
VGISTs
p83821
sg70045
I5
sg70054
VC0238198
p83822
sg70048
I1
sa(dp83823
g70042
I41
sg70043
VGIST
p83824
sg70045
I4
sg70054
VC0238198
p83825
sg70048
I1
sasa(dp83826
g70037
VWT-1 immunoreactivity in gastrointestinal stromal tumor (GIST) was currently not known.
p83827
sg70039
(lp83828
sg70051
(lp83829
(dp83830
g70042
I57
sg70043
VGIST
p83831
sg70045
I4
sg70054
VC0238198
p83832
sg70048
I1
sa(dp83833
g70042
I25
sg70043
Vgastrointestinal stromal tumor
p83834
sg70045
I30
sg70054
VC0238198
p83835
sg70048
I3
sasa(dp83836
g70037
VWe, therefore, investigated the expression of WT-1 in GIST in comparison to other soft tissue tumors by immunohistochemistry and Western blot analysis.
p83837
sg70039
(lp83838
sg70051
(lp83839
(dp83840
g70042
I54
sg70043
VGIST
p83841
sg70045
I4
sg70054
VC1847319
p83842
sg70048
I1
sa(dp83843
g70042
I82
sg70043
Vsoft tissue tumors
p83844
sg70045
I18
sg70054
VC0037579
p83845
sg70048
I3
sasa(dp83846
g135
(dp83847
(VGIST
p83848
VGIST
p83849
tp83850
I00
ssg70037
VWe found that all 28 cases (100%) of GIST are positive for WT-1, diffusely (&gt;75%, 3+) in 13 (46.4%) cases, moderately (26% to 75%, 2+) in 13 (46.4%) cases, and focally (5% to 25%, 1+) in 2 (7.2%) cases.
p83851
sg70039
(lp83852
(dp83853
g70042
I37
sg70043
g83848
sg70045
I4
sg70046
VP10721
p83854
sg70048
I1
sasg70051
(lp83855
(dp83856
g70042
I37
sg70043
g83849
sg70045
I4
sg70054
VC1847319
p83857
sg70048
I1
sasa(dp83858
g70037
VThe significance of cytoplasmic expression of WT-1 in GIST and some smooth muscle tumors is unclear and warrant further investigation.
p83859
sg70039
(lp83860
sg70051
(lp83861
(dp83862
g70042
I68
sg70043
Vsmooth muscle tumors
p83863
sg70045
I20
sg70054
VC0206658
p83864
sg70048
I3
sa(dp83865
g70042
I54
sg70043
VGIST
p83866
sg70045
I4
sg70054
VC1847319
p83867
sg70048
I1
sasa(dp83868
g70037
VThe potential roles of WT-1 in the diagnosis and treatment of GIST were discussed.
p83869
sg70039
(lp83870
sg70051
(lp83871
(dp83872
g70042
I62
sg70043
VGIST
p83873
sg70045
I4
sg70054
VC1847319
p83874
sg70048
I1
sasa(dp83875
g135
(dp83876
(Vras
p83877
Vdermatofibrosarcoma protuberans
p83878
tp83879
I00
ssg70037
VThis review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.
p83880
sg70039
(lp83881
(dp83882
g70042
I69
sg70043
Vtyrosine kinase
p83883
sg70045
I15
sg70046
VP29401
p83884
sg70048
I2
sa(dp83885
g70042
I367
sg70043
g83877
sg70045
I3
sg70046
VP01116
p83886
sg70048
I1
sasg70051
(lp83887
(dp83888
g70042
I39
sg70043
Vsarcoma
p83889
sg70045
I7
sg70054
VC1261473
p83890
sg70048
I1
sa(dp83891
g70042
I172
sg70043
Vcongenital fibrosarcoma
p83892
sg70045
I23
sg70054
VC0334459
p83893
sg70048
I2
sa(dp83894
g70042
I200
sg70043
Vmesoblastic nephroma
p83895
sg70045
I20
sg70054
VC0206628
p83896
sg70048
I2
sa(dp83897
g70042
I380
sg70043
Vneurofibromatosis
p83898
sg70045
I17
sg70054
VC0162678
p83899
sg70048
I1
sa(dp83900
g70042
I104
sg70043
Vgastrointestinal stromal tumor
p83901
sg70045
I30
sg70054
VC0238198
p83902
sg70048
I3
sa(dp83903
g70042
I39
sg70043
Vsarcoma
p83904
sg70045
I7
sg70054
VC1261473
p83905
sg70048
I1
sa(dp83906
g70042
I323
sg70043
Vsyndrome
p83907
sg70045
I8
sg70054
VC0039082
p83908
sg70048
I1
sa(dp83909
g70042
I259
sg70043
Vdesmoplastic small round cell tumor
p83910
sg70045
I35
sg70054
VC0281508
p83911
sg70048
I5
sa(dp83912
g70042
I136
sg70043
Vinflammatory myofibroblastic tumor
p83913
sg70045
I34
sg70054
VC0334121
p83914
sg70048
I3
sa(dp83915
g70042
I222
sg70043
g83878
sg70045
I31
sg70054
VC0392784
p83916
sg70048
I2
sasa(dp83917
g70037
VAn additional 80 endometrial cancer patients were studied for RAB32 methylation and MSI status.
p83918
sg70039
(lp83919
(dp83920
g70042
I62
sg70043
VRAB32
p83921
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83922
(dp83923
g70042
I84
sg70043
VMSI
p83924
sg70045
I3
sg70054
VC0920269
p83925
sg70048
I1
sa(dp83926
g70042
I17
sg70043
Vendometrial cancer
p83927
sg70045
I18
sg70054
VC0476089
p83928
sg70048
I2
sasa(dp83929
g70037
VIn contrast, RAB32 methylation occurred in only 1 of 80 endometrial cancers, including 20 MSI-H, 8 MSI-L and 52 MSS tumors.
p83930
sg70039
(lp83931
(dp83932
g70042
I13
sg70043
VRAB32
p83933
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83934
(dp83935
g70042
I112
sg70043
VMSS
p83936
sg70045
I3
sg70054
VC0024814
p83937
sg70048
I1
sa(dp83938
g70042
I116
sg70043
Vtumors
p83939
sg70045
I6
sg70054
VC0027651
p83940
sg70048
I1
sa(dp83941
g70042
I90
sg70043
VMSI
p83942
sg70045
I3
sg70054
VC0920269
p83943
sg70048
I1
sa(dp83944
g70042
I56
sg70043
Vendometrial cancers
p83945
sg70045
I19
sg70054
VC0476089
p83946
sg70048
I2
sa(dp83947
g70042
I90
sg70043
VMSI
p83948
sg70045
I3
sg70054
VC0920269
p83949
sg70048
I1
sasa(dp83950
g135
(dp83951
(VhMLH1
p83952
Vadenocarcinomas
p83953
tp83954
I00
ssg70037
VWe conclude that although RAB32 methylation is rare in endometrial cancers, it is strongly associated with hMLH1 hypermethylation and MSI in gastric adenocarcinomas.
p83955
sg70039
(lp83956
(dp83957
g70042
I107
sg70043
g83952
sg70045
I5
sg70046
VP40692
p83958
sg70048
I1
sa(dp83959
g70042
I26
sg70043
VRAB32
p83960
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp83961
(dp83962
g70042
I134
sg70043
VMSI
p83963
sg70045
I3
sg70054
VC0920269
p83964
sg70048
I1
sa(dp83965
g70042
I55
sg70043
Vendometrial cancers
p83966
sg70045
I19
sg70054
VC0476089
p83967
sg70048
I2
sa(dp83968
g70042
I149
sg70043
g83953
sg70045
I15
sg70054
VC0001418
p83969
sg70048
I1
sasa(dp83970
g135
(dp83971
(VFGF12
p83972
VVHL
p83973
tp83974
I00
ssg70037
VPanel, consisting of 16 new potential markers for early and differentiated diagnosis of prostatic gland cancer, was identified: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY and LRRC58.
p83975
sg70039
(lp83976
(dp83977
g70042
I177
sg70043
VLOC440944
p83978
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp83979
g70042
I199
sg70043
VCLCN2
p83980
sg70045
I5
sg70046
VP51788
p83981
sg70048
I1
sa(dp83982
g70042
I245
sg70043
VMAP4
p83983
sg70045
I4
sg70046
VP27816
p83984
sg70048
I1
sa(dp83985
g70042
I238
sg70043
VCAND2
p83986
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83987
g70042
I222
sg70043
VLMCD1
p83988
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83989
g70042
I229
sg70043
VFAM19A4
p83990
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp83991
g70042
I162
sg70043
VCTDSPL
p83992
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp83993
g70042
I128
sg70043
VBHLHE40
p83994
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp83995
g70042
I187
sg70043
VSETD5
p83996
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp83997
g70042
I258
sg70043
VLRRC58
p83998
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp83999
g70042
I137
sg70043
VFOXP1
p84000
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp84001
g70042
I194
sg70043
VVHL
p84002
sg70045
I3
sg70046
VP40337
p84003
sg70048
I1
sa(dp84004
g70042
I206
sg70043
VOSBPL10
p84005
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp84006
g70042
I170
sg70043
g83972
sg70045
I5
sg70046
VP61328
p84007
sg70048
I1
sa(dp84008
g70042
I155
sg70043
VITGA9
p84009
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp84010
g70042
I214
sg70043
VZNF860
p84011
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp84012
(dp84013
g70042
I104
sg70043
Vcancer
p84014
sg70045
I6
sg70054
VC0006826
p84015
sg70048
I1
sa(dp84016
g70042
I194
sg70043
g83973
sg70045
I3
sg70054
VC0019562
p84017
sg70048
I1
sasa(dp84018
g70037
VHowever, there is little information about the involvement of MAP4 in human cancer.
p84019
sg70039
(lp84020
(dp84021
g70042
I62
sg70043
VMAP4
p84022
sg70045
I4
sg70046
VP27816
p84023
sg70048
I1
sasg70051
(lp84024
(dp84025
g70042
I76
sg70043
Vcancer
p84026
sg70045
I6
sg70054
VC0006826
p84027
sg70048
I1
sasa(dp84028
g70037
VHere we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells.
p84029
sg70039
(lp84030
(dp84031
g70042
I18
sg70043
VMAP4
p84032
sg70045
I4
sg70046
VP27816
p84033
sg70048
I1
sasg70051
(lp84034
(dp84035
g70042
I48
sg70043
Vinvasion
p84036
sg70045
I8
sg70054
VC2699153
p84037
sg70048
I1
sa(dp84038
g70042
I94
sg70043
Vcancer
p84039
sg70045
I6
sg70054
VC0006826
p84040
sg70048
I1
sasa(dp84041
g70037
VThe fusion between echinoderm microtubule-associated protein 4 (EML4) and anaplastic lymphatic tumor kinase (ALK) rearrangement is present in approximately 5% of non-small cell lung cancer (NSCLC) patients.
p84042
sg70039
(lp84043
(dp84044
g70042
I74
sg70043
Vanaplastic lymphatic tumor kinase
p84045
sg70045
I33
sg70046
g12
sg70048
I4
sa(dp84046
g70042
I19
sg70043
Vechinoderm microtubule-associated protein 4
p84047
sg70045
I43
sg70046
g12
sg70048
I4
sa(dp84048
g70042
I64
sg70043
VEML4
p84049
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp84050
g70042
I109
sg70043
VALK
p84051
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp84052
(dp84053
g70042
I162
sg70043
Vnon-small cell lung cancer
p84054
sg70045
I26
sg70054
VC0007131
p84055
sg70048
I4
sa(dp84056
g70042
I190
sg70043
VNSCLC
p84057
sg70045
I5
sg70054
VC0007131
p84058
sg70048
I1
sa(dp84059
g70042
I95
sg70043
Vtumor
p84060
sg70045
I5
sg70054
VC0027651
p84061
sg70048
I1
sasa(dp84062
g135
(dp84063
(Vras
p84064
VNSCLC
p84065
tp84066
I00
ssg70037
V#\u80cc#\u666f#\u4e0e#\u76ee#\u7684 #\u68d8#\u76ae#\u52a8#\u7269#\u5fae#\u7ba1#\u76f8#\u5173#\u86cb#\u767d4 (echinoderm microtubule-associated protein 4, EML4) #\u4e0e#\u95f4#\u53d8#\u6027#\u6dcb#\u5df4#\u7624#\u6fc0#\u9176 (anaplastic lymphatic tumor kinase, ALK) #\u91cd#\u6392#\u5f62#\u6210#\u7684#\u878d#\u5408#\u57fa#\u56e0#\u5b58#\u5728#\u4e8e#\u5927#\u7ea65%#\u7684#\u975e#\u5c0f#\u7ec6#\u80de#\u80ba#\u764c (non-small cell lung cancer, NSCLC) #\u60a3#\u8005#\u4e2d, #\u662f#\u7ee7#\u8868#\u76ae#\u751f#\u957f#\u56e0#\u5b50#\u53d7#\u4f53 (epidermal growth factor receptor, EGFR) #\u3001K-ras#\u4e4b#\u540e#\u53c8#\u4e00#\u65b0#\u578b#\u9776#\u70b9#\u57fa#\u56e0#\u3002#\u6709#\u6570#\u636e#\u663e#\u793a#\u643a#\u5e26EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684NSCLC#\u60a3#\u8005#\u63a5#\u53d7ALK#\u6291#\u5236#\u5242#\u6cbb#\u7597#\u540e, #\u5176#\u75be#\u75c5#\u63a7#\u5236#\u7684#\u6709#\u6548#\u7387#\u53ef#\u8fbe80%, #\u63a2#\u7d22#\u548c#\u5efa#\u7acb#\u80fd#\u591f#\u51c6#\u786e#\u5feb#\u901f#\u68c0#\u6d4b#\u51faNSCLC#\u60a3#\u8005EML4-ALK#\u878d#\u5408#\u7a81#\u53d8#\u7684#\u65b9#\u6cd5, #\u662f#\u7b5b#\u9009#\u51fa#\u9002#\u5408#\u6cbb#\u7597#\u7684#\u4f18#\u52bf#\u4eba#\u7fa4#\u7684#\u5173#\u952e#\u3002#\u672c#\u7814#\u7a76#\u5206#\u6790#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5 (immunohistochemistry, IHC) #\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7a81#\u53d8#\u7684#\u654f#\u611f#\u5ea6#\u4e0e#\u7279#\u5f02#\u5ea6, #\u8bc4#\u4ef7#\u8be5#\u65b9#\u6cd5#\u51c6#\u786e#\u6027#\u53ca#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c, #\u4ece#\u800c#\u4e3a#\u80ba#\u764c#\u60a3#\u8005"#\u4e2a#\u4f53#\u5316#\u5206#\u5b50#\u6cbb#\u7597"#\u63d0#\u4f9b#\u4f9d#\u636e#\u3002#\u65b9#\u6cd5 #\u901a#\u8fc7Pubmed#\u6570#\u636e#\u5e93#\u68c0#\u7d22#\u6240#\u6709#\u7b26#\u5408#\u68c0#\u7d22#\u6761#\u4ef6#\u7684#\u6587#\u732e, #\u672b#\u6b21#\u68c0#\u7d22#\u65e5#\u671f#\u4e3a2015#\u5e742#\u670825#\u65e5, #\u6839#\u636e#\u7eb3#\u5165#\u548c#\u6392#\u9664#\u6807#\u51c6#\u8fdb#\u884c#\u8fdb#\u4e00#\u6b65#\u7b5b#\u9009, #\u91c7#\u7528#\u8bca#\u65ad#\u8bd5#\u9a8cmeta#\u5206#\u6790#\u65b9#\u6cd5, #\u6bd4#\u8f83#\u7279#\u5f02#\u6027#\u6297#\u4f53#\u514d#\u75ab#\u7ec4#\u5316#\u6cd5#\u4e0e"#\u91d1#\u6807#\u51c6"#\u8367#\u5149#\u539f#\u4f4d#\u6742#\u4ea4 (fluorescence in situ hybridization, FISH) #\u6cd5#\u7684#\u654f#\u611f#\u5ea6#\u3001#\u7279#\u5f02#\u5ea6, #\u4ee5#\u660e#\u786e#\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u4f5c#\u4e3a#\u7b5b#\u67e5#\u65b9#\u6cd5#\u7684#\u53ef#\u884c#\u6027#\u3002#\u7ed3#\u679c #\u672c#\u658711#\u7bc7#\u6587#\u732e#\u7eb3#\u5165meta#\u5206#\u6790, EML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u514d#\u75ab#\u7ec4#\u5316#\u7d2f#\u8ba1#\u75c5#\u4f8b3,234#\u4f8b, #\u8bca#\u65ad#\u6bd4#\u503c#\u6bd4 (diagnositic odds ratio, DOR) #\u4e3a1,135.00 (95%CI: 337.10-3,821.46) #\uff1b#\u7efc#\u5408#\u53d7#\u8bd5#\u8005#\u5de5#\u4f5c#\u7279#\u5f81#\u66f2#\u7ebf  (summary receiver operating characteristic curve, SROC) #\u4e0b#\u9762#\u79ef#\u4e3a0.992,3 (SEAUC=0.003,2) , Q*#\u7edf#\u8ba1#\u91cf#\u4e3a0.964,4 (SEQ*=0.008,7) #\u3002#\u7ed3#\u8bba #\u7279#\u5f02#\u6027#\u6297#\u4f53IHC#\u6cd5#\u68c0#\u6d4bEML4-ALK#\u878d#\u5408#\u57fa#\u56e0#\u7684#\u65b9#\u6cd5#\u53ef#\u884c, #\u5177#\u6709#\u9ad8#\u7279#\u5f02#\u5ea6#\u548c#\u654f#\u611f#\u5ea6, #\u53ef#\u4f5c#\u4e3a#\u4e00#\u79cd#\u7b80#\u5355#\u5feb#\u901f#\u7684#\u7b5b#\u67e5#\u65b9#\u6cd5, #\u5177#\u6709#\u4e34#\u5e8a#\u5e94#\u7528#\u4ef7#\u503c#\u3002.
p84067
sg70039
(lp84068
(dp84069
g70042
I256
sg70043
Vepidermal growth factor receptor
p84070
sg70045
I32
sg70046
VP01133
p84071
sg70048
I4
sa(dp84072
g70042
I45
sg70043
Vmicrotubule-associated protein 4
p84073
sg70045
I32
sg70046
VP27816
p84074
sg70048
I3
sa(dp84075
g70042
I79
sg70043
VEML4
p84076
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp84077
g70042
I140
sg70043
VALK
p84078
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84079
g70042
I79
sg70043
VEML4
p84080
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp84081
g70042
I140
sg70043
VALK
p84082
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84083
g70042
I140
sg70043
VALK
p84084
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84085
g70042
I140
sg70043
VALK
p84086
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84087
g70042
I300
sg70043
g84064
sg70045
I3
sg70046
VP01116
p84088
sg70048
I1
sa(dp84089
g70042
I140
sg70043
VALK
p84090
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84091
g70042
I140
sg70043
VALK
p84092
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp84093
(dp84094
g70042
I191
sg70043
Vnon-small cell lung cancer
p84095
sg70045
I26
sg70054
VC0007131
p84096
sg70048
I4
sa(dp84097
g70042
I126
sg70043
Vtumor
p84098
sg70045
I5
sg70054
VC0027651
p84099
sg70048
I1
sa(dp84100
g70042
I219
sg70043
g84065
sg70045
I5
sg70054
VC0007131
p84101
sg70048
I1
sasa(dp84102
g135
(dp84103
(VMAP4
p84104
VVHL
p84105
tp84106
I00
ssg70037
VBased on these data, we proposed the set of potential biomarkers for detection of prostate cancer and discrimination between prostate tumors with different malignancy and aggressiveness: BHLHE40, FOXP1, LOC285205, ITGA9, CTDSPL, FGF12, LOC440944/SETD5, VHL, CLCN2, OSBPL10/ZNF860, LMCD1, FAM19A4, CAND2, MAP4, KY, and LRRC58.
p84107
sg70039
(lp84108
(dp84109
g70042
I258
sg70043
VCLCN2
p84110
sg70045
I5
sg70046
VP51788
p84111
sg70048
I1
sa(dp84112
g70042
I318
sg70043
VLRRC58
p84113
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp84114
g70042
I281
sg70043
VLMCD1
p84115
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp84116
g70042
I187
sg70043
VBHLHE40
p84117
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp84118
g70042
I196
sg70043
VFOXP1
p84119
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp84120
g70042
I253
sg70043
VVHL
p84121
sg70045
I3
sg70046
VP40337
p84122
sg70048
I1
sa(dp84123
g70042
I246
sg70043
VSETD5
p84124
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp84125
g70042
I288
sg70043
VFAM19A4
p84126
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp84127
g70042
I229
sg70043
VFGF12
p84128
sg70045
I5
sg70046
VP61328
p84129
sg70048
I1
sa(dp84130
g70042
I221
sg70043
VCTDSPL
p84131
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp84132
g70042
I304
sg70043
g84104
sg70045
I4
sg70046
VP27816
p84133
sg70048
I1
sa(dp84134
g70042
I214
sg70043
VITGA9
p84135
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp84136
g70042
I265
sg70043
VOSBPL10
p84137
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp84138
g70042
I297
sg70043
VCAND2
p84139
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp84140
g70042
I273
sg70043
VZNF860
p84141
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp84142
g70042
I236
sg70043
VLOC440944
p84143
sg70045
I9
sg70046
g12
sg70048
I1
sasg70051
(lp84144
(dp84145
g70042
I82
sg70043
Vprostate cancer
p84146
sg70045
I15
sg70054
VC0600139
p84147
sg70048
I2
sa(dp84148
g70042
I125
sg70043
Vprostate tumors
p84149
sg70045
I15
sg70054
VC0033578
p84150
sg70048
I2
sa(dp84151
g70042
I171
sg70043
Vaggressiveness
p84152
sg70045
I14
sg70054
VC0001807
p84153
sg70048
I1
sa(dp84154
g70042
I156
sg70043
Vmalignancy
p84155
sg70045
I10
sg70054
VC0006826
p84156
sg70048
I1
sa(dp84157
g70042
I253
sg70043
g84105
sg70045
I3
sg70054
VC0019562
p84158
sg70048
I1
sasa(dp84159
g135
(dp84160
(VMAP4
p84161
Vbladder cancer
p84162
tp84163
I01
ssg70037
VWe also analyzed gene expression of MAP4 in 34 patients with bladder cancer using immunohistochemical staining assay.
p84164
sg70039
(lp84165
(dp84166
g70042
I36
sg70043
g84161
sg70045
I4
sg70046
VP27816
p84167
sg70048
I1
sasg70051
(lp84168
(dp84169
g70042
I61
sg70043
g84162
sg70045
I14
sg70054
VC0699885
p84170
sg70048
I2
sasa(dp84171
g135
(dp84172
(VMAP4
p84173
Vbladder cancer
p84174
tp84175
I01
ssg70037
VWe used cAMP elevators and small interfering RNA of MAP4 here, found that both of them can potently inhibit the invasion and the migration of bladder cancer cells by disrupting microtubule (MT) cytoskeleton.
p84176
sg70039
(lp84177
(dp84178
g70042
I52
sg70043
g84173
sg70045
I4
sg70046
VP27816
p84179
sg70048
I1
sasg70051
(lp84180
(dp84181
g70042
I112
sg70043
Vinvasion
p84182
sg70045
I8
sg70054
VC2699153
p84183
sg70048
I1
sa(dp84184
g70042
I142
sg70043
g84174
sg70045
I14
sg70054
VC0699885
p84185
sg70048
I2
sasa(dp84186
g135
(dp84187
(VMAP4
p84188
Vbladder cancer
p84189
tp84190
I01
ssg70037
VConsistently, the bladder cancer grade is positively correlated with the protein level of MAP4.
p84191
sg70039
(lp84192
(dp84193
g70042
I90
sg70043
g84188
sg70045
I4
sg70046
VP27816
p84194
sg70048
I1
sasg70051
(lp84195
(dp84196
g70042
I18
sg70043
g84189
sg70045
I14
sg70054
VC0699885
p84197
sg70048
I2
sasa(dp84198
g135
(dp84199
(VPKA
p84200
Vbladder cancer
p84201
tp84202
I00
ssg70037
VOur results indicated that the cAMP/PKA signaling pathway might inhibit bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics, which could be exploited for the therapy of invasive bladder cancer.
p84203
sg70039
(lp84204
(dp84205
g70042
I114
sg70043
VMAP4
p84206
sg70045
I4
sg70046
VP27816
p84207
sg70048
I1
sa(dp84208
g70042
I36
sg70043
g84200
sg70045
I3
sg70046
VP17612
p84209
sg70048
I1
sasg70051
(lp84210
(dp84211
g70042
I87
sg70043
Vcell invasion
p84212
sg70045
I13
sg70054
VC2699153
p84213
sg70048
I2
sa(dp84214
g70042
I72
sg70043
g84201
sg70045
I14
sg70054
VC0699885
p84215
sg70048
I2
sa(dp84216
g70042
I195
sg70043
Vinvasive bladder cancer
p84217
sg70045
I23
sg70054
VC0859917
p84218
sg70048
I3
sasa(dp84219
g70037
VIrritable bowel syndrome symptoms consistently improved after 3 weeks of LFD, and significantly more participants reported symptom relief in response to placebo (80%) than FOS (30%).
p84220
sg70039
(lp84221
sg70051
(lp84222
(dp84223
g70042
I25
sg70043
Vsymptom
p84224
sg70045
I7
sg70054
VC1457887
p84225
sg70048
I1
sa(dp84226
g70042
I0
sg70043
VIrritable bowel syndrome
p84227
sg70045
I24
sg70054
VC0022104
p84228
sg70048
I3
sasa(dp84229
g70037
VChildren with congenital esophageal atresia (EA) and tracheoesophageal fistula (TEF) have chronic respiratory symptoms including recurrent pneumonia, wheezing and persistent cough.
p84230
sg70039
(lp84231
sg70051
(lp84232
(dp84233
g70042
I25
sg70043
Vesophageal atresia
p84234
sg70045
I18
sg70054
VC0014850
p84235
sg70048
I2
sa(dp84236
g70042
I163
sg70043
Vpersistent cough
p84237
sg70045
I16
sg70054
VC0562483
p84238
sg70048
I2
sa(dp84239
g70042
I80
sg70043
VTEF
p84240
sg70045
I3
sg70054
VC0040588
p84241
sg70048
I1
sa(dp84242
g70042
I129
sg70043
Vrecurrent pneumonia
p84243
sg70045
I19
sg70054
VC0694550
p84244
sg70048
I2
sa(dp84245
g70042
I45
sg70043
VEA
p84246
sg70045
I2
sg70054
VC0014850
p84247
sg70048
I1
sa(dp84248
g70042
I150
sg70043
Vwheezing
p84249
sg70045
I8
sg70054
VC0043144
p84250
sg70048
I1
sa(dp84251
g70042
I53
sg70043
Vtracheoesophageal fistula
p84252
sg70045
I25
sg70054
VC0040588
p84253
sg70048
I2
sa(dp84254
g70042
I98
sg70043
Vrespiratory symptoms
p84255
sg70045
I20
sg70054
VC0037090
p84256
sg70048
I2
sasa(dp84257
g70037
VAdult patients experiencing symptoms of cough and recurrent aspiration pneumonia should be evaluated for congenital TEF.
p84258
sg70039
(lp84259
sg70051
(lp84260
(dp84261
g70042
I50
sg70043
Vrecurrent aspiration pneumonia
p84262
sg70045
I30
sg70054
VC0747651
p84263
sg70048
I3
sa(dp84264
g70042
I40
sg70043
Vcough
p84265
sg70045
I5
sg70054
VC0010200
p84266
sg70048
I1
sasa(dp84267
g70037
VOur patient underwent primary repair of OA/TEF malformations, which was later complicated by pneumonia and a recurrent TEF.
p84268
sg70039
(lp84269
sg70051
(lp84270
(dp84271
g70042
I93
sg70043
Vpneumonia
p84272
sg70045
I9
sg70054
VC0032285
p84273
sg70048
I1
sa(dp84274
g70042
I47
sg70043
Vmalformations
p84275
sg70045
I13
sg70054
VC0000768
p84276
sg70048
I1
sasa(dp84277
g135
(dp84278
(VTNF
p84279
Vpneumonia
p84280
tp84281
I00
ssg70037
VThese findings suggest that a relatively small increase in plasma TNF-Alfa, and decreases in urine TNF-Alfa, GM-CSF, and IL-15 from just before to just after the diagnosis of pneumonia could be markers for an increased risk of PUs in individuals with pneumonia after traumatic SCI.
p84282
sg70039
(lp84283
(dp84284
g70042
I121
sg70043
VIL-15
p84285
sg70045
I5
sg70046
VP40933
p84286
sg70048
I1
sa(dp84287
g70042
I93
sg70043
Vurine TNF-Alfa
p84288
sg70045
I14
sg70046
VP01375
p84289
sg70048
I2
sa(dp84290
g70042
I109
sg70043
VGM-CSF
p84291
sg70045
I6
sg70046
VP04141
p84292
sg70048
I1
sa(dp84293
g70042
I66
sg70043
g84279
sg70045
I3
sg70046
VP01375
p84294
sg70048
I1
sasg70051
(lp84295
(dp84296
g70042
I175
sg70043
Vpneumonia
p84297
sg70045
I9
sg70054
VC0032285
p84298
sg70048
I1
sa(dp84299
g70042
I175
sg70043
g84280
sg70045
I9
sg70054
VC0032285
p84300
sg70048
I1
sasa(dp84301
g135
(dp84302
(VIL-15
p84303
Vviral bronchiolitis
p84304
tp84305
I00
ssg70037
VThe study aimed to investigate the innate cytokine interleukin-15 (IL-15) as a marker of disease severity.A prospective single-centre observational study was conducted in a university-affiliated paediatric teaching hospital, comparing children (0-18 months) hospitalised for viral bronchiolitis, those admitted to the paediatric intensive care unit with severe disease and healthy age-matched controls.
p84306
sg70039
(lp84307
(dp84308
g70042
I67
sg70043
g84303
sg70045
I5
sg70046
VP40933
p84309
sg70048
I1
sa(dp84310
g70042
I42
sg70043
Vcytokine interleukin-15
p84311
sg70045
I23
sg70046
VP13236
p84312
sg70048
I2
sasg70051
(lp84313
(dp84314
g70042
I275
sg70043
g84304
sg70045
I19
sg70054
VC0006274
p84315
sg70048
I2
sasa(dp84316
g135
(dp84317
(Vblood mononuclear cell (PBMC) IL-15 mRNA
p84318
Vbronchiolitis
p84319
tp84320
I01
ssg70037
VPeripheral blood mononuclear cell (PBMC) IL-15 mRNA expression was significantly higher in those with moderate severity bronchiolitis compared with controls and those with severe disease.
p84321
sg70039
(lp84322
(dp84323
g70042
I11
sg70043
g84318
sg70045
I40
sg70046
VP40933
p84324
sg70048
I6
sasg70051
(lp84325
(dp84326
g70042
I120
sg70043
g84319
sg70045
I13
sg70054
VC0006271
p84327
sg70048
I1
sasa(dp84328
g135
(dp84329
(VSTAT5A
p84330
Vbronchiolitis
p84331
tp84332
I00
ssg70037
VTargets of de-regulated miRNA were differentially expressed in bronchiolitis, including JAK3, STAT5A and NFKB1 on the IL-15 signalling pathway.IL-15 is associated with disease severity in children hospitalised with viral bronchiolitis.
p84333
sg70039
(lp84334
(dp84335
g70042
I88
sg70043
VJAK3
p84336
sg70045
I4
sg70046
VP52333
p84337
sg70048
I1
sa(dp84338
g70042
I118
sg70043
VIL-15 signalling pathway.IL-15
p84339
sg70045
I30
sg70046
VP40933
p84340
sg70048
I3
sa(dp84341
g70042
I105
sg70043
VNFKB1
p84342
sg70045
I5
sg70046
VP19838
p84343
sg70048
I1
sa(dp84344
g70042
I94
sg70043
g84330
sg70045
I6
sg70046
VP42229
p84345
sg70048
I1
sasg70051
(lp84346
(dp84347
g70042
I215
sg70043
Vviral bronchiolitis
p84348
sg70045
I19
sg70054
VC0006274
p84349
sg70048
I2
sa(dp84350
g70042
I63
sg70043
g84331
sg70045
I13
sg70054
VC0006271
p84351
sg70048
I1
sasa(dp84352
g135
(dp84353
(VIL-15
p84354
VCOPD
p84355
tp84356
I01
ssg70037
VThe present study aimed to investigate the role of Interleukin 15 (IL-15) in protein degradation in skeletal muscle mediated by the ubiquitin-proteasome pathway (UPP) in a rat model of chronic obstructive pulmonary disease (COPD).
p84357
sg70039
(lp84358
(dp84359
g70042
I132
sg70043
Vubiquitin
p84360
sg70045
I9
sg70046
VP62979
p84361
sg70048
I1
sa(dp84362
g70042
I51
sg70043
VInterleukin 15
p84363
sg70045
I14
sg70046
VP40933
p84364
sg70048
I2
sa(dp84365
g70042
I67
sg70043
g84354
sg70045
I5
sg70046
VP40933
p84366
sg70048
I1
sasg70051
(lp84367
(dp84368
g70042
I185
sg70043
Vchronic obstructive pulmonary disease
p84369
sg70045
I37
sg70054
VC0024117
p84370
sg70048
I4
sa(dp84371
g70042
I224
sg70043
g84355
sg70045
I4
sg70054
VC0024117
p84372
sg70048
I1
sasa(dp84373
g70037
VPatients with SWA were older at seizure diagnosis than those with SA (p=0.04), were less often referred for evaluation of seizures or epilepsy (p=0.04), and were referred faster for VEM, despite SWA were significantly less likely to include motor manifestations (p=0.0004).
p84374
sg70039
(lp84375
sg70051
(lp84376
(dp84377
g70042
I122
sg70043
Vseizures
p84378
sg70045
I8
sg70054
VC0036572
p84379
sg70048
I1
sa(dp84380
g70042
I32
sg70043
Vseizure
p84381
sg70045
I7
sg70054
VC0036572
p84382
sg70048
I1
sa(dp84383
g70042
I134
sg70043
Vepilepsy
p84384
sg70045
I8
sg70054
VC0014544
p84385
sg70048
I1
sa(dp84386
g70042
I241
sg70043
Vmotor manifestations
p84387
sg70045
I20
sg70054
VC1334804
p84388
sg70048
I2
sasa(dp84389
g70037
VWe suggest that patients with SWA have a unique epilepsy syndrome.
p84390
sg70039
(lp84391
sg70051
(lp84392
(dp84393
g70042
I57
sg70043
Vsyndrome
p84394
sg70045
I8
sg70054
VC0039082
p84395
sg70048
I1
sa(dp84396
g70042
I48
sg70043
Vepilepsy
p84397
sg70045
I8
sg70054
VC0014544
p84398
sg70048
I1
sasa(dp84399
g70037
VAchilles tendon (T) and Hoffmann (H) reflexes were evoked during spike and wave activity (SWA) in 6 patients with generalized epilepsy, selected on the basis of their photosensitivity.
p84400
sg70039
(lp84401
sg70051
(lp84402
(dp84403
g70042
I167
sg70043
Vphotosensitivity
p84404
sg70045
I16
sg70054
VC0393720
p84405
sg70048
I1
sa(dp84406
g70042
I114
sg70043
Vgeneralized epilepsy
p84407
sg70045
I20
sg70054
VC0014548
p84408
sg70048
I2
sasa(dp84409
g70037
VPartial epilepsy after shunting manifested itself in 15 patients, but this did not correlate with the side of the shunt or with the side of the SWA in the EEG.
p84410
sg70039
(lp84411
sg70051
(lp84412
(dp84413
g70042
I0
sg70043
VPartial epilepsy
p84414
sg70045
I16
sg70054
VC0014547
p84415
sg70048
I2
sasa(dp84416
g70037
VWe hypothesized that the NDI may be due to of severe hypokalemia induced tubular dysfunction.
p84417
sg70039
(lp84418
sg70051
(lp84419
(dp84420
g70042
I25
sg70043
VNDI
p84421
sg70045
I3
sg70054
VC1563705
p84422
sg70048
I1
sasa(dp84423
g135
(dp84424
(VV2R mRNA
p84425
Vmetabolic acidosis
p84426
tp84427
I00
ssg70037
VPreviously, we reported an increase of V1aR mRNA and a decrease of V2R mRNA in the collecting ducts under chronic metabolic acidosis.
p84428
sg70039
(lp84429
(dp84430
g70042
I39
sg70043
VV1aR mRNA
p84431
sg70045
I9
sg70046
VP37288
p84432
sg70048
I2
sa(dp84433
g70042
I67
sg70043
g84425
sg70045
I8
sg70046
VP30518
p84434
sg70048
I2
sasg70051
(lp84435
(dp84436
g70042
I114
sg70043
g84426
sg70045
I18
sg70054
VC0220981
p84437
sg70048
I2
sasa(dp84438
g70037
VPatients with moderate to severe nonproliferative diabetic retinopathy (NPDR) had POBF 18% higher than the control (mean OBF, 943 microL/min).
p84439
sg70039
(lp84440
sg70051
(lp84441
(dp84442
g70042
I26
sg70043
Vsevere nonproliferative diabetic retinopathy
p84443
sg70045
I44
sg70054
VC0730278
p84444
sg70048
I4
sasa(dp84445
g70037
VAmong PRP-treated subjects with PDR, ocular blood flow was 22% below the control (mean OBF, 619 microL/min), and 34% less than moderate to severe nonproliferative diabetic retinopathy.
p84446
sg70039
(lp84447
(dp84448
g70042
I6
sg70043
VPRP
p84449
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp84450
(dp84451
g70042
I139
sg70043
Vsevere nonproliferative diabetic retinopathy
p84452
sg70045
I44
sg70054
VC0730278
p84453
sg70048
I4
sa(dp84454
g70042
I32
sg70043
VPDR
p84455
sg70045
I3
sg70054
VC1845050
p84456
sg70048
I1
sasa(dp84457
g70037
VDiabetic patients with no retinopathy or mild NPDR had OBF indistinguishable from the control (785 vs. 797 microL/min).
p84458
sg70039
(lp84459
sg70051
(lp84460
(dp84461
g70042
I26
sg70043
Vretinopathy
p84462
sg70045
I11
sg70054
VC0035309
p84463
sg70048
I1
sasa(dp84464
g70037
VPOBF is unaffected early in diabetic retinopathy, but increases significantly in eyes with moderate to severe NPDR.
p84465
sg70039
(lp84466
sg70051
(lp84467
(dp84468
g70042
I28
sg70043
Vdiabetic retinopathy
p84469
sg70045
I20
sg70054
VC0011884
p84470
sg70048
I2
sa(dp84471
g70042
I103
sg70043
Vsevere NPDR
p84472
sg70045
I11
sg70054
VC0730278
p84473
sg70048
I2
sasa(dp84474
g70037
VThese experimental data represent the largest published assessment of POBF in NPDR.
p84475
sg70039
(lp84476
sg70051
(lp84477
sa(dp84478
g70037
VPOBF in the patients with non-exudative and exudative age related macular degeneration (AMD) was investigated.
p84479
sg70039
(lp84480
sg70051
(lp84481
(dp84482
g70042
I88
sg70043
VAMD
p84483
sg70045
I3
sg70054
VC0242383
p84484
sg70048
I1
sa(dp84485
g70042
I54
sg70043
Vage related macular degeneration
p84486
sg70045
I32
sg70054
VC0242383
p84487
sg70048
I4
sasa(dp84488
g70037
VThe POBF increased but was still below normal levels at the NPDR stage, and then increased to an above normal level in the PPDR/PDR stage of diabetic retinopathy.
p84489
sg70039
(lp84490
sg70051
(lp84491
(dp84492
g70042
I141
sg70043
Vdiabetic retinopathy
p84493
sg70045
I20
sg70054
VC0011884
p84494
sg70048
I2
sa(dp84495
g70042
I61
sg70043
VPDR
p84496
sg70045
I3
sg70054
VC1845050
p84497
sg70048
I1
sasa(dp84498
g70037
VRight before and one month after this fourth vaccine dose, the avidity of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn) was determined using 1.5 M ammonium thiocyanate as dissociating agent.
p84499
sg70039
(lp84500
(dp84501
g70042
I209
sg70043
VPrn
p84502
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84503
g70042
I198
sg70043
Vpertactin
p84504
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp84505
g70042
I115
sg70043
VDT
p84506
sg70045
I2
sg70046
g12
sg70048
I1
sa(dp84507
g70042
I140
sg70043
Vpertussis toxin
p84508
sg70045
I15
sg70046
g12
sg70048
I2
sa(dp84509
g70042
I97
sg70043
Vdiphtheria toxin
p84510
sg70045
I16
sg70046
g12
sg70048
I2
sa(dp84511
g70042
I157
sg70043
VPT
p84512
sg70045
I2
sg70046
g12
sg70048
I1
sasg70051
(lp84513
(dp84514
g70042
I162
sg70043
Vfilamentous hemagglutinin
p84515
sg70045
I25
sg70054
VC1704429
p84516
sg70048
I2
sa(dp84517
g70042
I189
sg70043
VFHA
p84518
sg70045
I3
sg70054
VC1704429
p84519
sg70048
I1
sa(dp84520
g70042
I140
sg70043
Vpertussis
p84521
sg70045
I9
sg70054
VC0043167
p84522
sg70048
I1
sa(dp84523
g70042
I120
sg70043
Vtetanus
p84524
sg70045
I7
sg70054
VC0039614
p84525
sg70048
I1
sa(dp84526
g70042
I97
sg70043
Vdiphtheria
p84527
sg70045
I10
sg70054
VC0012546
p84528
sg70048
I1
sasa(dp84529
g70037
VImmunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT), and diphtheria toxoid (DT) were measured using commercially available enzyme-linked immunosorbent assays (ELISA).
p84530
sg70039
(lp84531
(dp84532
g70042
I18
sg70043
VIgG
p84533
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84534
g70042
I97
sg70043
Vpertactin
p84535
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp84536
g70042
I108
sg70043
VPrn
p84537
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84538
g70042
I0
sg70043
VImmunoglobulin G
p84539
sg70045
I16
sg70046
g12
sg70048
I2
sa(dp84540
g70042
I59
sg70043
VPT
p84541
sg70045
I2
sg70046
g12
sg70048
I1
sa(dp84542
g70042
I42
sg70043
Vpertussis toxin
p84543
sg70045
I15
sg70046
g12
sg70048
I2
sasg70051
(lp84544
(dp84545
g70042
I42
sg70043
Vpertussis
p84546
sg70045
I9
sg70054
VC0043167
p84547
sg70048
I1
sa(dp84548
g70042
I64
sg70043
Vfilamentous hemagglutinin
p84549
sg70045
I25
sg70054
VC1704429
p84550
sg70048
I2
sa(dp84551
g70042
I114
sg70043
Vtetanus
p84552
sg70045
I7
sg70054
VC0039614
p84553
sg70048
I1
sa(dp84554
g70042
I139
sg70043
Vdiphtheria
p84555
sg70045
I10
sg70054
VC0012546
p84556
sg70048
I1
sa(dp84557
g70042
I91
sg70043
VFHA
p84558
sg70045
I3
sg70054
VC1704429
p84559
sg70048
I1
sasa(dp84560
g70037
VWe have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn).
p84561
sg70039
(lp84562
(dp84563
g70042
I185
sg70043
VPT
p84564
sg70045
I2
sg70046
g12
sg70048
I1
sa(dp84565
g70042
I237
sg70043
VPrn
p84566
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84567
g70042
I143
sg70043
VDT
p84568
sg70045
I2
sg70046
g12
sg70048
I1
sa(dp84569
g70042
I226
sg70043
Vpertactin
p84570
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp84571
g70042
I168
sg70043
Vpertussis toxin
p84572
sg70045
I15
sg70046
g12
sg70048
I2
sa(dp84573
g70042
I125
sg70043
Vdiphtheria toxin
p84574
sg70045
I16
sg70046
g12
sg70048
I2
sasg70051
(lp84575
(dp84576
g70042
I148
sg70043
Vtetanus
p84577
sg70045
I7
sg70054
VC0039614
p84578
sg70048
I1
sa(dp84579
g70042
I190
sg70043
Vfilamentous hemagglutinin
p84580
sg70045
I25
sg70054
VC1704429
p84581
sg70048
I2
sa(dp84582
g70042
I168
sg70043
Vpertussis
p84583
sg70045
I9
sg70054
VC0043167
p84584
sg70048
I1
sa(dp84585
g70042
I217
sg70043
VFHA
p84586
sg70045
I3
sg70054
VC1704429
p84587
sg70048
I1
sa(dp84588
g70042
I125
sg70043
Vdiphtheria
p84589
sg70045
I10
sg70054
VC0012546
p84590
sg70048
I1
sasa(dp84591
g70037
VImmunoglobulin G (IgG) antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxoid (TT) and diphtheria toxoid (DT) were measured using commercially available ELISA tests.
p84592
sg70039
(lp84593
(dp84594
g70042
I18
sg70043
VIgG
p84595
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84596
g70042
I97
sg70043
Vpertactin
p84597
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp84598
g70042
I108
sg70043
VPrn
p84599
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84600
g70042
I0
sg70043
VImmunoglobulin G
p84601
sg70045
I16
sg70046
g12
sg70048
I2
sa(dp84602
g70042
I59
sg70043
VPT
p84603
sg70045
I2
sg70046
g12
sg70048
I1
sa(dp84604
g70042
I42
sg70043
Vpertussis toxin
p84605
sg70045
I15
sg70046
g12
sg70048
I2
sasg70051
(lp84606
(dp84607
g70042
I42
sg70043
Vpertussis
p84608
sg70045
I9
sg70054
VC0043167
p84609
sg70048
I1
sa(dp84610
g70042
I64
sg70043
Vfilamentous hemagglutinin
p84611
sg70045
I25
sg70054
VC1704429
p84612
sg70048
I2
sa(dp84613
g70042
I114
sg70043
Vtetanus
p84614
sg70045
I7
sg70054
VC0039614
p84615
sg70048
I1
sa(dp84616
g70042
I138
sg70043
Vdiphtheria
p84617
sg70045
I10
sg70054
VC0012546
p84618
sg70048
I1
sa(dp84619
g70042
I91
sg70043
VFHA
p84620
sg70045
I3
sg70054
VC1704429
p84621
sg70048
I1
sasa(dp84622
g70037
VAntibody geometric mean concentrations (GMCs) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (Prn) were measured with commercial ELISA tests in samples taken preceding maternal vaccination and one month afterwards, at delivery and from the cord blood, and in infants before and 1 month after the primary series of 3 pertussis containing hexavalent vaccines.
p84623
sg70039
(lp84624
(dp84625
g70042
I155
sg70043
VPrn
p84626
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84627
g70042
I144
sg70043
Vpertactin
p84628
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp84629
g70042
I85
sg70043
Vpertussis toxin
p84630
sg70045
I15
sg70046
g12
sg70048
I2
sa(dp84631
g70042
I102
sg70043
VPT
p84632
sg70045
I2
sg70046
g12
sg70048
I1
sasg70051
(lp84633
(dp84634
g70042
I301
sg70043
Vcord
p84635
sg70045
I4
sg70054
VC0035334
p84636
sg70048
I1
sa(dp84637
g70042
I135
sg70043
VFHA
p84638
sg70045
I3
sg70054
VC1704429
p84639
sg70048
I1
sa(dp84640
g70042
I85
sg70043
Vpertussis
p84641
sg70045
I9
sg70054
VC0043167
p84642
sg70048
I1
sa(dp84643
g70042
I85
sg70043
Vpertussis
p84644
sg70045
I9
sg70054
VC0043167
p84645
sg70048
I1
sa(dp84646
g70042
I68
sg70043
Vdiphtheria
p84647
sg70045
I10
sg70054
VC0012546
p84648
sg70048
I1
sa(dp84649
g70042
I54
sg70043
Vtetanus
p84650
sg70045
I7
sg70054
VC0039614
p84651
sg70048
I1
sa(dp84652
g70042
I107
sg70043
Vfilamentous haemagglutinin
p84653
sg70045
I26
sg70054
VC1704429
p84654
sg70048
I2
sa(dp84655
g70042
I63
sg70043
VTT
p84656
sg70045
I2
sg70054
VC0039614
p84657
sg70048
I1
sa(dp84658
g70042
I80
sg70043
VDT
p84659
sg70045
I2
sg70054
VC0012546
p84660
sg70048
I1
sasa(dp84661
g70037
VImmunoglobulin G (IgG) against tetanus (TT), diphtheria (DT), pertussis toxin (PT), filamentous hemaglutinin (FHA) and pertactin (Prn) were measured using commercial ELISA tests, at baseline, 1 month after maternal vaccination, at delivery, and in infants from cord blood and before and after the primary series (EPI: month 2-3-4) of a pertussis containing vaccine.
p84662
sg70039
(lp84663
(dp84664
g70042
I18
sg70043
VIgG
p84665
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84666
g70042
I79
sg70043
VPT
p84667
sg70045
I2
sg70046
g12
sg70048
I1
sa(dp84668
g70042
I0
sg70043
VImmunoglobulin G
p84669
sg70045
I16
sg70046
g12
sg70048
I2
sa(dp84670
g70042
I62
sg70043
Vpertussis toxin
p84671
sg70045
I15
sg70046
g12
sg70048
I2
sa(dp84672
g70042
I119
sg70043
Vpertactin
p84673
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp84674
g70042
I130
sg70043
VPrn
p84675
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp84676
(dp84677
g70042
I62
sg70043
Vpertussis
p84678
sg70045
I9
sg70054
VC0043167
p84679
sg70048
I1
sa(dp84680
g70042
I45
sg70043
Vdiphtheria
p84681
sg70045
I10
sg70054
VC0012546
p84682
sg70048
I1
sa(dp84683
g70042
I62
sg70043
Vpertussis
p84684
sg70045
I9
sg70054
VC0043167
p84685
sg70048
I1
sa(dp84686
g70042
I57
sg70043
VDT
p84687
sg70045
I2
sg70054
VC0012546
p84688
sg70048
I1
sa(dp84689
g70042
I31
sg70043
Vtetanus
p84690
sg70045
I7
sg70054
VC0039614
p84691
sg70048
I1
sa(dp84692
g70042
I84
sg70043
Vfilamentous hemaglutinin
p84693
sg70045
I24
sg70054
VC1704429
p84694
sg70048
I2
sa(dp84695
g70042
I110
sg70043
VFHA
p84696
sg70045
I3
sg70054
VC1704429
p84697
sg70048
I1
sa(dp84698
g70042
I261
sg70043
Vcord
p84699
sg70045
I4
sg70054
VC0035334
p84700
sg70048
I1
sa(dp84701
g70042
I40
sg70043
VTT
p84702
sg70045
I2
sg70054
VC0039614
p84703
sg70048
I1
sa(dp84704
g70042
I313
sg70043
VEPI
p84705
sg70045
I3
sg70054
VC0267963
p84706
sg70048
I1
sasa(dp84707
g70037
VAnti-Pertussis Toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), tetanus toxin (TT) and diphtheria toxin (DT) antibodies were measured by ELISA.
p84708
sg70039
(lp84709
(dp84710
g70042
I100
sg70043
Vdiphtheria toxin (DT) antibodies
p84711
sg70045
I32
sg70046
g12
sg70048
I4
sa(dp84712
g70042
I22
sg70043
VPT
p84713
sg70045
I2
sg70046
g12
sg70048
I1
sa(dp84714
g70042
I71
sg70043
VPrn
p84715
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84716
g70042
I60
sg70043
Vpertactin
p84717
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp84718
g70042
I0
sg70043
VAnti-Pertussis Toxin
p84719
sg70045
I20
sg70046
g12
sg70048
I2
sasg70051
(lp84720
(dp84721
g70042
I5
sg70043
VPertussis
p84722
sg70045
I9
sg70054
VC0043167
p84723
sg70048
I1
sa(dp84724
g70042
I54
sg70043
VFHA
p84725
sg70045
I3
sg70054
VC1704429
p84726
sg70048
I1
sa(dp84727
g70042
I77
sg70043
Vtetanus
p84728
sg70045
I7
sg70054
VC0039614
p84729
sg70048
I1
sa(dp84730
g70042
I27
sg70043
Vfilamentous hemagglutinin
p84731
sg70045
I25
sg70054
VC1704429
p84732
sg70048
I2
sa(dp84733
g70042
I100
sg70043
Vdiphtheria
p84734
sg70045
I10
sg70054
VC0012546
p84735
sg70048
I1
sasa(dp84736
g70037
VGeometric mean titers were not different after prebiotic supplementation at 5 months, Ptx (37/44 EU/ml), FHA (78/96 EU/ml), Prn (78/80 EU/ml), Diphtheria (0.40/0.57 IU/ml), Tetanus (0.74/0.99 IU/ml) and Hib (0.35/0.63 myg/ml), and at 12 months Ptx (55/66 EU/ml), FHA (122/119 EU/ml), Prn (116/106 Eu/ml), Diphtheria (0.88/1.11 IU/ml), Tetanus (1.64/1.79 IU/ml) and Hib (2.91/2.55 myg/ml).
p84737
sg70039
(lp84738
(dp84739
g70042
I124
sg70043
VPrn
p84740
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp84741
(dp84742
g70042
I173
sg70043
VTetanus
p84743
sg70045
I7
sg70054
VC0039614
p84744
sg70048
I1
sa(dp84745
g70042
I105
sg70043
VFHA
p84746
sg70045
I3
sg70054
VC1704429
p84747
sg70048
I1
sa(dp84748
g70042
I105
sg70043
VFHA
p84749
sg70045
I3
sg70054
VC1704429
p84750
sg70048
I1
sa(dp84751
g70042
I173
sg70043
VTetanus
p84752
sg70045
I7
sg70054
VC0039614
p84753
sg70048
I1
sa(dp84754
g70042
I143
sg70043
VDiphtheria
p84755
sg70045
I10
sg70054
VC0012546
p84756
sg70048
I1
sa(dp84757
g70042
I143
sg70043
VDiphtheria
p84758
sg70045
I10
sg70054
VC0012546
p84759
sg70048
I1
sasa(dp84760
g135
(dp84761
(Vcombined fimbria type 2 and 3 antigens
p84762
Vfilamentous hemagglutinin
p84763
tp84764
I00
ssg70037
VThis multiplex immunoassay (MIA) can simultaneously determine levels of specific mouse serum IgG antibodies to P antigens P.69 pertactin (P.69 Prn), filamentous hemagglutinin (FHA), pertussis toxin (Ptx), and combined fimbria type 2 and 3 antigens (Fim2/3) and to diphtheria toxin (Dtx) and tetanus toxin (TT) in a single well.
p84765
sg70039
(lp84766
(dp84767
g70042
I199
sg70043
VPtx
p84768
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84769
g70042
I249
sg70043
VFim2/3
p84770
sg70045
I6
sg70046
VP07333
p84771
sg70048
I1
sa(dp84772
g70042
I138
sg70043
VP.69 Prn
p84773
sg70045
I8
sg70046
g12
sg70048
I2
sa(dp84774
g70042
I81
sg70043
Vmouse serum IgG antibodies
p84775
sg70045
I26
sg70046
g12
sg70048
I4
sa(dp84776
g70042
I111
sg70043
VP antigens P.69 pertactin
p84777
sg70045
I25
sg70046
VP01893
p84778
sg70048
I4
sa(dp84779
g70042
I264
sg70043
Vdiphtheria toxin
p84780
sg70045
I16
sg70046
g12
sg70048
I2
sa(dp84781
g70042
I209
sg70043
g84762
sg70045
I38
sg70046
VP01893
p84782
sg70048
I7
sa(dp84783
g70042
I282
sg70043
VDtx
p84784
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84785
g70042
I182
sg70043
Vpertussis toxin
p84786
sg70045
I15
sg70046
g12
sg70048
I2
sasg70051
(lp84787
(dp84788
g70042
I182
sg70043
Vpertussis
p84789
sg70045
I9
sg70054
VC0043167
p84790
sg70048
I1
sa(dp84791
g70042
I264
sg70043
Vdiphtheria
p84792
sg70045
I10
sg70054
VC0012546
p84793
sg70048
I1
sa(dp84794
g70042
I176
sg70043
VFHA
p84795
sg70045
I3
sg70054
VC1704429
p84796
sg70048
I1
sa(dp84797
g70042
I149
sg70043
g84763
sg70045
I25
sg70054
VC1704429
p84798
sg70048
I2
sa(dp84799
g70042
I291
sg70043
Vtetanus
p84800
sg70045
I7
sg70054
VC0039614
p84801
sg70048
I1
sasa(dp84802
g135
(dp84803
(VG protein Gamma2 subunit
p84804
Vmalignant melanoma
p84805
tp84806
I01
ssg70037
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p84807
sg70039
(lp84808
(dp84809
g70042
I63
sg70043
VGNG2
p84810
sg70045
I4
sg70046
VP59768
p84811
sg70048
I1
sa(dp84812
g70042
I58
sg70043
VGng2
p84813
sg70045
I4
sg70046
VP59768
p84814
sg70048
I1
sa(dp84815
g70042
I32
sg70043
g84804
sg70045
I24
sg70046
VP59768
p84816
sg70048
I4
sasg70051
(lp84817
(dp84818
g70042
I90
sg70043
g84805
sg70045
I18
sg70054
VC0025202
p84819
sg70048
I2
sasa(dp84820
g135
(dp84821
(VGNG2
p84822
Vmalignant melanoma
p84823
tp84824
I01
ssg70037
VOur recent study also showed that reduced GNG2 alone augmented proliferation of malignant melanoma cells.
p84825
sg70039
(lp84826
(dp84827
g70042
I42
sg70043
g84822
sg70045
I4
sg70046
VP59768
p84828
sg70048
I1
sasg70051
(lp84829
(dp84830
g70042
I80
sg70043
g84823
sg70045
I18
sg70054
VC0025202
p84831
sg70048
I2
sa(dp84832
g70042
I63
sg70043
Vproliferation
p84833
sg70045
I13
sg70054
VC0334094
p84834
sg70048
I1
sasa(dp84835
g135
(dp84836
(VGNG2
p84837
Vmalignant melanoma
p84838
tp84839
I01
ssg70037
VTo our knowledge, however, there is no evidence showing an effect of Gng2/GNG2 alone on metastasis of any cancers including malignant melanoma.
p84840
sg70039
(lp84841
(dp84842
g70042
I69
sg70043
VGng2
p84843
sg70045
I4
sg70046
VP59768
p84844
sg70048
I1
sa(dp84845
g70042
I74
sg70043
g84837
sg70045
I4
sg70046
VP59768
p84846
sg70048
I1
sasg70051
(lp84847
(dp84848
g70042
I106
sg70043
Vcancers
p84849
sg70045
I7
sg70054
VC0006826
p84850
sg70048
I1
sa(dp84851
g70042
I88
sg70043
Vmetastasis
p84852
sg70045
I10
sg70054
VC0027627
p84853
sg70048
I1
sa(dp84854
g70042
I124
sg70043
g84838
sg70045
I18
sg70054
VC0025202
p84855
sg70048
I2
sasa(dp84856
g135
(dp84857
(VGNG2 protein
p84858
Vmalignant melanoma
p84859
tp84860
I01
ssg70037
VIn his study, we first prepared GNG2-overexpressed SK-Mel28 human malignant melanoma cells, in which GNG2 protein expression level was undetectably low.
p84861
sg70039
(lp84862
(dp84863
g70042
I32
sg70043
VGNG2
p84864
sg70045
I4
sg70046
VP59768
p84865
sg70048
I1
sa(dp84866
g70042
I101
sg70043
g84858
sg70045
I12
sg70046
VP59768
p84867
sg70048
I2
sasg70051
(lp84868
(dp84869
g70042
I66
sg70043
g84859
sg70045
I18
sg70054
VC0025202
p84870
sg70048
I2
sasa(dp84871
g135
(dp84872
(VGNG2
p84873
Vadhesion
p84874
tp84875
I00
ssg70037
VMigration and invasion activities of the GNG2-overexpressed malignant melanoma cells were suppressed up to 1/10th, with decreased activity of focal adhesion kinase (FAK).
p84876
sg70039
(lp84877
(dp84878
g70042
I165
sg70043
VFAK
p84879
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84880
g70042
I142
sg70043
Vfocal adhesion kinase
p84881
sg70045
I21
sg70046
g12
sg70048
I3
sa(dp84882
g70042
I41
sg70043
g84873
sg70045
I4
sg70046
VP59768
p84883
sg70048
I1
sasg70051
(lp84884
(dp84885
g70042
I60
sg70043
Vmalignant melanoma
p84886
sg70045
I18
sg70054
VC0025202
p84887
sg70048
I2
sa(dp84888
g70042
I120
sg70043
Vdecreased activity
p84889
sg70045
I18
sg70054
VC0086439
p84890
sg70048
I2
sa(dp84891
g70042
I14
sg70043
Vinvasion
p84892
sg70045
I8
sg70054
VC2699153
p84893
sg70048
I1
sa(dp84894
g70042
I148
sg70043
g84874
sg70045
I8
sg70054
VC0001511
p84895
sg70048
I1
sasa(dp84896
g135
(dp84897
(VGNG2
p84898
Vmalignant melanoma
p84899
tp84900
I01
ssg70037
VTaken together, our results suggest that overexpression of GNG2 alone inhibits metastasis in human malignant melanoma cells with decreased FAK activity.
p84901
sg70039
(lp84902
(dp84903
g70042
I139
sg70043
VFAK
p84904
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp84905
g70042
I59
sg70043
g84898
sg70045
I4
sg70046
VP59768
p84906
sg70048
I1
sasg70051
(lp84907
(dp84908
g70042
I79
sg70043
Vmetastasis
p84909
sg70045
I10
sg70054
VC0027627
p84910
sg70048
I1
sa(dp84911
g70042
I99
sg70043
g84899
sg70045
I18
sg70054
VC0025202
p84912
sg70048
I2
sasa(dp84913
g135
(dp84914
(VGNG2
p84915
Vmalignant melanoma
p84916
tp84917
I01
ssg70037
VThus, GNG2 might be a candidate of molecular targets of prevention and therapy for metastasis of malignant melanoma.
p84918
sg70039
(lp84919
(dp84920
g70042
I6
sg70043
g84915
sg70045
I4
sg70046
VP59768
p84921
sg70048
I1
sasg70051
(lp84922
(dp84923
g70042
I83
sg70043
Vmetastasis
p84924
sg70045
I10
sg70054
VC0027627
p84925
sg70048
I1
sa(dp84926
g70042
I97
sg70043
g84916
sg70045
I18
sg70054
VC0025202
p84927
sg70048
I2
sasa(dp84928
g135
(dp84929
(VG protein Gamma2 subunit
p84930
Vmalignant melanoma
p84931
tp84932
I01
ssg70037
VOur recent study showed reduced G protein Gamma2 subunit (Gng2/GNG2) expression levels in malignant melanoma cells compared with those in benign melanocytic cells in both mice and humans.
p84933
sg70039
(lp84934
(dp84935
g70042
I63
sg70043
VGNG2
p84936
sg70045
I4
sg70046
VP59768
p84937
sg70048
I1
sa(dp84938
g70042
I58
sg70043
VGng2
p84939
sg70045
I4
sg70046
VP59768
p84940
sg70048
I1
sa(dp84941
g70042
I32
sg70043
g84930
sg70045
I24
sg70046
VP59768
p84942
sg70048
I4
sasg70051
(lp84943
(dp84944
g70042
I90
sg70043
g84931
sg70045
I18
sg70054
VC0025202
p84945
sg70048
I2
sasa(dp84946
g70037
VAt present, however, there is no evidence showing an effect of Gng2/GNG2 alone on cancer biology.
p84947
sg70039
(lp84948
(dp84949
g70042
I68
sg70043
VGNG2
p84950
sg70045
I4
sg70046
VP59768
p84951
sg70048
I1
sa(dp84952
g70042
I63
sg70043
VGng2
p84953
sg70045
I4
sg70046
VP59768
p84954
sg70048
I1
sasg70051
(lp84955
(dp84956
g70042
I82
sg70043
Vcancer
p84957
sg70045
I6
sg70054
VC0006826
p84958
sg70048
I1
sasa(dp84959
g135
(dp84960
(VGNG2
p84961
Vmalignant melanoma
p84962
tp84963
I01
ssg70037
VThe purpose of this study was to examine the biological significance of GNG2 in human malignant melanoma cells.
p84964
sg70039
(lp84965
(dp84966
g70042
I72
sg70043
g84961
sg70045
I4
sg70046
VP59768
p84967
sg70048
I1
sasg70051
(lp84968
(dp84969
g70042
I86
sg70043
g84962
sg70045
I18
sg70054
VC0025202
p84970
sg70048
I2
sasa(dp84971
g135
(dp84972
(VGNG2
p84973
Vmalignant melanoma
p84974
tp84975
I01
ssg70037
VLevels of proliferation and activities of signal transduction molecules were examined in both GNG2-overexpressed and -depleted human malignant melanoma cells.
p84976
sg70039
(lp84977
(dp84978
g70042
I94
sg70043
g84973
sg70045
I4
sg70046
VP59768
p84979
sg70048
I1
sasg70051
(lp84980
(dp84981
g70042
I10
sg70043
Vproliferation
p84982
sg70045
I13
sg70054
VC0334094
p84983
sg70048
I1
sa(dp84984
g70042
I133
sg70043
g84974
sg70045
I18
sg70054
VC0025202
p84985
sg70048
I2
sasa(dp84986
g135
(dp84987
(Vp21
p84988
Vmalignant melanoma
p84989
tp84990
I00
ssg70037
VProliferation of GNG2-overexpressed SK-Mel28 human malignant melanoma cells was suppressed with decreased c-SRC and AKT activities and increased p21(Cip/WAF1) expression level in vitro.
p84991
sg70039
(lp84992
(dp84993
g70042
I153
sg70043
VWAF1
p84994
sg70045
I4
sg70046
VP38936
p84995
sg70048
I1
sa(dp84996
g70042
I106
sg70043
Vc-SRC
p84997
sg70045
I5
sg70046
VP12931
p84998
sg70048
I1
sa(dp84999
g70042
I17
sg70043
VGNG2
p85000
sg70045
I4
sg70046
VP59768
p85001
sg70048
I1
sa(dp85002
g70042
I116
sg70043
VAKT
p85003
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp85004
g70042
I145
sg70043
g84988
sg70045
I3
sg70046
VP42857
p85005
sg70048
I1
sa(dp85006
g70042
I149
sg70043
VCip
p85007
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp85008
(dp85009
g70042
I51
sg70043
g84989
sg70045
I18
sg70054
VC0025202
p85010
sg70048
I2
sa(dp85011
g70042
I0
sg70043
VProliferation
p85012
sg70045
I13
sg70054
VC0334094
p85013
sg70048
I1
sasa(dp85014
g135
(dp85015
(VGNG2
p85016
Vmalignant melanoma
p85017
tp85018
I01
ssg70037
VIn contrast, proliferation of GNG2-depleted A375P human malignant melanoma cells was enhanced with increased c-SRC and AKT activities and decreased p21(Cip/WAF1) expression level in vitro.
p85019
sg70039
(lp85020
(dp85021
g70042
I152
sg70043
VCip
p85022
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp85023
g70042
I156
sg70043
VWAF1
p85024
sg70045
I4
sg70046
VP38936
p85025
sg70048
I1
sa(dp85026
g70042
I109
sg70043
Vc-SRC
p85027
sg70045
I5
sg70046
VP12931
p85028
sg70048
I1
sa(dp85029
g70042
I119
sg70043
VAKT
p85030
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp85031
g70042
I148
sg70043
Vp21
p85032
sg70045
I3
sg70046
VP42857
p85033
sg70048
I1
sa(dp85034
g70042
I30
sg70043
g85016
sg70045
I4
sg70046
VP59768
p85035
sg70048
I1
sasg70051
(lp85036
(dp85037
g70042
I13
sg70043
Vproliferation
p85038
sg70045
I13
sg70054
VC0334094
p85039
sg70048
I1
sa(dp85040
g70042
I56
sg70043
g85017
sg70045
I18
sg70054
VC0025202
p85041
sg70048
I2
sasa(dp85042
g135
(dp85043
(VGNG2
p85044
Vmalignant melanoma
p85045
tp85046
I01
ssg70037
VWe demonstrated for the first time that increased protein expression level of GNG2 alone inhibits proliferation of malignant melanoma cells in vitro and in vivo, suggesting that GNG2 could be a novel molecular target for malignant melanoma therapy.
p85047
sg70039
(lp85048
(dp85049
g70042
I78
sg70043
VGNG2
p85050
sg70045
I4
sg70046
VP59768
p85051
sg70048
I1
sa(dp85052
g70042
I78
sg70043
g85044
sg70045
I4
sg70046
VP59768
p85053
sg70048
I1
sasg70051
(lp85054
(dp85055
g70042
I115
sg70043
Vmalignant melanoma
p85056
sg70045
I18
sg70054
VC0025202
p85057
sg70048
I2
sa(dp85058
g70042
I98
sg70043
Vproliferation
p85059
sg70045
I13
sg70054
VC0334094
p85060
sg70048
I1
sa(dp85061
g70042
I115
sg70043
g85045
sg70045
I18
sg70054
VC0025202
p85062
sg70048
I2
sasa(dp85063
g135
(dp85064
(VGng2 transcript
p85065
Vmalignant melanoma
p85066
tp85067
I01
ssg70037
VGng2 transcript expression levels in a malignant melanoma were less than 1/10 of the level in a benign tumor.
p85068
sg70039
(lp85069
(dp85070
g70042
I0
sg70043
g85065
sg70045
I15
sg70046
VP59768
p85071
sg70048
I2
sasg70051
(lp85072
(dp85073
g70042
I96
sg70043
Vbenign tumor
p85074
sg70045
I12
sg70054
VC0086692
p85075
sg70048
I2
sa(dp85076
g70042
I39
sg70043
g85066
sg70045
I18
sg70054
VC0025202
p85077
sg70048
I2
sasa(dp85078
g135
(dp85079
(VGng2 transcript
p85080
Vmalignant melanomas
p85081
tp85082
I01
ssg70037
VThe difference in Gng2 transcript expression levels between benign tumors and malignant melanomas was greatest among all of the G protein Gamma subunits examined in this study.
p85083
sg70039
(lp85084
(dp85085
g70042
I18
sg70043
g85080
sg70045
I15
sg70046
VP59768
p85086
sg70048
I2
sa(dp85087
g70042
I128
sg70043
VG protein Gamma subunits
p85088
sg70045
I24
sg70046
g12
sg70048
I4
sasg70051
(lp85089
(dp85090
g70042
I60
sg70043
Vbenign tumors
p85091
sg70045
I13
sg70054
VC0086692
p85092
sg70048
I2
sa(dp85093
g70042
I78
sg70043
g85081
sg70045
I19
sg70054
VC0025202
p85094
sg70048
I2
sasa(dp85095
g135
(dp85096
(VGng2
p85097
Vmalignant melanomas
p85098
tp85099
I01
ssg70037
VMoreover, protein expression levels of Gng2 were decreased in malignant melanomas compared with those in benign melanocytic tumors in RET-mice.
p85100
sg70039
(lp85101
(dp85102
g70042
I39
sg70043
g85097
sg70045
I4
sg70046
VP59768
p85103
sg70048
I1
sasg70051
(lp85104
(dp85105
g70042
I124
sg70043
Vtumors
p85106
sg70045
I6
sg70054
VC0027651
p85107
sg70048
I1
sa(dp85108
g70042
I62
sg70043
g85098
sg70045
I19
sg70054
VC0025202
p85109
sg70048
I2
sasa(dp85110
g135
(dp85111
(VGNG2 protein
p85112
Vmalignant melanoma
p85113
tp85114
I01
ssg70037
VAnalysis of human malignant melanomas also showed reduced GNG2 protein expression levels in five human malignant melanoma cell lines compared with the expression levels in normal human epithelial melanocytes (NHEM).
p85115
sg70039
(lp85116
(dp85117
g70042
I58
sg70043
g85112
sg70045
I12
sg70046
VP59768
p85118
sg70048
I2
sasg70051
(lp85119
(dp85120
g70042
I18
sg70043
Vmalignant melanomas
p85121
sg70045
I19
sg70054
VC0025202
p85122
sg70048
I2
sa(dp85123
g70042
I18
sg70043
g85113
sg70045
I18
sg70054
VC0025202
p85124
sg70048
I2
sasa(dp85125
g135
(dp85126
(VGNG2
p85127
Vmalignant melanoma
p85128
tp85129
I01
ssg70037
VThus, we demonstrated for the first time that Gng2/GNG2 expression levels are reduced in malignant melanoma, suggesting that GNG2 could be a novel biomarker for malignant melanoma.
p85130
sg70039
(lp85131
(dp85132
g70042
I46
sg70043
VGng2
p85133
sg70045
I4
sg70046
VP59768
p85134
sg70048
I1
sa(dp85135
g70042
I51
sg70043
VGNG2
p85136
sg70045
I4
sg70046
VP59768
p85137
sg70048
I1
sa(dp85138
g70042
I51
sg70043
g85127
sg70045
I4
sg70046
VP59768
p85139
sg70048
I1
sasg70051
(lp85140
(dp85141
g70042
I89
sg70043
Vmalignant melanoma
p85142
sg70045
I18
sg70054
VC0025202
p85143
sg70048
I2
sa(dp85144
g70042
I89
sg70043
g85128
sg70045
I18
sg70054
VC0025202
p85145
sg70048
I2
sasa(dp85146
g135
(dp85147
(VAPE1
p85148
VPKs
p85149
tp85150
I00
ssg70037
VSeveral DNA repair enzymes are essential for comprehensive neural repair mechanisms after stroke, including PolBeta and NEIL3 for neurogenesis, APE1 for white matter repair, Gadd45b for axonal regeneration, and DNA-PKs for neurovascular remodeling.
p85151
sg70039
(lp85152
(dp85153
g70042
I144
sg70043
g85148
sg70045
I4
sg70046
VP27695
p85154
sg70048
I1
sa(dp85155
g70042
I120
sg70043
VNEIL3
p85156
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp85157
g70042
I174
sg70043
VGadd45b
p85158
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp85159
g70042
I8
sg70043
VDNA repair enzymes
p85160
sg70045
I18
sg70046
g12
sg70048
I3
sa(dp85161
g70042
I211
sg70043
VDNA-PKs
p85162
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp85163
(dp85164
g70042
I90
sg70043
Vstroke
p85165
sg70045
I6
sg70054
VC0038454
p85166
sg70048
I1
sa(dp85167
g70042
I215
sg70043
g85149
sg70045
I3
sg70054
VC0265449
p85168
sg70048
I1
sasa(dp85169
g70037
VThe aims of this study are to determine the expression and the prognostic value of TFF3 in a large series of human endometrial cancer and its relation with ER.
p85170
sg70039
(lp85171
(dp85172
g70042
I83
sg70043
VTFF3
p85173
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85174
(dp85175
g70042
I115
sg70043
Vendometrial cancer
p85176
sg70045
I18
sg70054
VC0476089
p85177
sg70048
I2
sasa(dp85178
g70037
VWe evaluated 328 endometrial carcinomas using TFF3 and ER antibody on paraffin-embedded tissue.
p85179
sg70039
(lp85180
(dp85181
g70042
I46
sg70043
VTFF3
p85182
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85183
(dp85184
g70042
I17
sg70043
Vendometrial carcinomas
p85185
sg70045
I22
sg70054
VC0476089
p85186
sg70048
I2
sasa(dp85187
g70037
V1-TFF3 seems to be a novel pathway in the pathogenesis of type I endometrial carcinomas.
p85188
sg70039
(lp85189
(dp85190
g70042
I0
sg70043
V1-TFF3
p85191
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp85192
(dp85193
g70042
I42
sg70043
Vpathogenesis
p85194
sg70045
I12
sg70054
VC0699748
p85195
sg70048
I1
sa(dp85196
g70042
I65
sg70043
Vendometrial carcinomas
p85197
sg70045
I22
sg70054
VC0476089
p85198
sg70048
I2
sasa(dp85199
g70037
V2-The strong association of TFF3 and ER in the estrogen-dependent endometrioid carcinoma could explain the reason for its frequent expression by this tumor type.
p85200
sg70039
(lp85201
(dp85202
g70042
I28
sg70043
VTFF3
p85203
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85204
(dp85205
g70042
I66
sg70043
Vendometrioid carcinoma
p85206
sg70045
I22
sg70054
VC0206687
p85207
sg70048
I2
sa(dp85208
g70042
I150
sg70043
Vtumor
p85209
sg70045
I5
sg70054
VC0027651
p85210
sg70048
I1
sasa(dp85211
g70037
V3-TFF3(+) seems to forecast a good prognosis in type I endometrial carcinomas.
p85212
sg70039
(lp85213
(dp85214
g70042
I0
sg70043
V3-TFF3
p85215
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp85216
(dp85217
g70042
I55
sg70043
Vendometrial carcinomas
p85218
sg70045
I22
sg70054
VC0476089
p85219
sg70048
I2
sasa(dp85220
g70037
VBased on our data, TFF3 expression in endometrial cancer deserves further investigation.
p85221
sg70039
(lp85222
(dp85223
g70042
I19
sg70043
VTFF3
p85224
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85225
(dp85226
g70042
I38
sg70043
Vendometrial cancer
p85227
sg70045
I18
sg70054
VC0476089
p85228
sg70048
I2
sasa(dp85229
g135
(dp85230
(VPR
p85231
Vendometrial carcinomas
p85232
tp85233
I00
ssg70037
VWe evaluated 401 endometrial carcinomas cases by using four immunomarkers - oestrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor II mRNA - binding protein 3 (IMP3), and intestinal trefoil factor 3 (TFF3)-on a tissue microarray.
p85234
sg70039
(lp85235
(dp85236
g70042
I101
sg70043
Vprogesterone receptor
p85237
sg70045
I21
sg70046
VP06401
p85238
sg70048
I2
sa(dp85239
g70042
I129
sg70043
Vinsulin-like growth factor II mRNA - binding protein 3
p85240
sg70045
I54
sg70046
VP01344
p85241
sg70048
I9
sa(dp85242
g70042
I225
sg70043
VTFF3
p85243
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85244
g70042
I76
sg70043
Voestrogen receptor
p85245
sg70045
I18
sg70046
VP03372
p85246
sg70048
I2
sa(dp85247
g70042
I196
sg70043
Vintestinal trefoil factor 3
p85248
sg70045
I27
sg70046
g12
sg70048
I4
sa(dp85249
g70042
I185
sg70043
VIMP3
p85250
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85251
g70042
I124
sg70043
g85231
sg70045
I2
sg70046
VP06401
p85252
sg70048
I1
sasg70051
(lp85253
(dp85254
g70042
I17
sg70043
g85232
sg70045
I22
sg70054
VC0476089
p85255
sg70048
I2
sasa(dp85256
g70037
VWe recommend using an ER/PR/TFF3/IMP3 immunohistochemical panel in selected cases of endometrial carcinoma where the differential diagnosis is challenging.
p85257
sg70039
(lp85258
(dp85259
g70042
I28
sg70043
VTFF3
p85260
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85261
g70042
I33
sg70043
VIMP3
p85262
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85263
(dp85264
g70042
I85
sg70043
Vendometrial carcinoma
p85265
sg70045
I21
sg70054
VC0476089
p85266
sg70048
I2
sasa(dp85267
g70037
VBy RT-PCR we have confirmed complete FAM107A downregulation in laryngeal cancer cell lines (15/15) and primary tumors (21/21) and this finding was further supported by FAM107A protein immunohistochemistry (15/15).
p85268
sg70039
(lp85269
(dp85270
g70042
I37
sg70043
VFAM107A
p85271
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp85272
(dp85273
g70042
I63
sg70043
Vlaryngeal cancer
p85274
sg70045
I16
sg70054
VC0595989
p85275
sg70048
I2
sa(dp85276
g70042
I103
sg70043
Vprimary tumors
p85277
sg70045
I14
sg70054
VC0677930
p85278
sg70048
I2
sasa(dp85279
g70037
VDownregulated in renal cell carcinoma 1 (DRR1) has important roles in tumor cell growth, neuron survival and spine formation, and was recently shown to bind actin.
p85280
sg70039
(lp85281
(dp85282
g70042
I41
sg70043
VDRR1
p85283
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85284
g70042
I0
sg70043
VDownregulated in renal cell carcinoma 1
p85285
sg70045
I39
sg70046
g12
sg70048
I6
sasg70051
(lp85286
(dp85287
g70042
I17
sg70043
Vrenal cell carcinoma 1
p85288
sg70045
I22
sg70054
VC2931882
p85289
sg70048
I4
sa(dp85290
g70042
I70
sg70043
Vtumor
p85291
sg70045
I5
sg70054
VC0027651
p85292
sg70048
I1
sasa(dp85293
g135
(dp85294
(Vcyclin D1
p85295
Vneuroblastoma
p85296
tp85297
I00
ssg70037
VIn addition, DRR1 and COMMD1 suppressed the cyclin D1 expression, G1/S transition and cell proliferation of neuroblastoma cells.
p85298
sg70039
(lp85299
(dp85300
g70042
I13
sg70043
VDRR1
p85301
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85302
g70042
I22
sg70043
VCOMMD1
p85303
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp85304
g70042
I44
sg70043
g85295
sg70045
I9
sg70046
VP24385
p85305
sg70048
I2
sasg70051
(lp85306
(dp85307
g70042
I91
sg70043
Vproliferation
p85308
sg70045
I13
sg70054
VC0334094
p85309
sg70048
I1
sa(dp85310
g70042
I71
sg70043
Vtransition
p85311
sg70045
I10
sg70054
VC0599156
p85312
sg70048
I1
sa(dp85313
g70042
I108
sg70043
g85296
sg70045
I13
sg70054
VC0027819
p85314
sg70048
I1
sasa(dp85315
g70037
VConsistent with these facts, low expressions of DRR1 were associated with tumorigenesis of human neuroblastoma and its mouse model.
p85316
sg70039
(lp85317
(dp85318
g70042
I48
sg70043
VDRR1
p85319
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85320
(dp85321
g70042
I74
sg70043
Vtumorigenesis
p85322
sg70045
I13
sg70054
VC0007621
p85323
sg70048
I1
sa(dp85324
g70042
I97
sg70043
Vneuroblastoma
p85325
sg70045
I13
sg70054
VC0027819
p85326
sg70048
I1
sasa(dp85327
g70037
VThis study has thus revealed a novel nuclear complex of F-actin, DRR1 and COMMD1 that is involved in NF-KB degradation and cell cycle suppression in neuroblastoma cells.
p85328
sg70039
(lp85329
(dp85330
g70042
I65
sg70043
VDRR1
p85331
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85332
g70042
I74
sg70043
VCOMMD1
p85333
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp85334
(dp85335
g70042
I134
sg70043
Vsuppression
p85336
sg70045
I11
sg70054
VC0221103
p85337
sg70048
I1
sa(dp85338
g70042
I149
sg70043
Vneuroblastoma
p85339
sg70045
I13
sg70054
VC0027819
p85340
sg70048
I1
sasa(dp85341
g70037
VThe aim of the present study was to analyze the expression level of FAM107A gene, a TSG located in 3p21.1, in lung cancer tumors and in tumor adjacent normal lung samples.
p85342
sg70039
(lp85343
(dp85344
g70042
I68
sg70043
VFAM107A gene
p85345
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp85346
g70042
I84
sg70043
VTSG located in 3p21.1
p85347
sg70045
I21
sg70046
g12
sg70048
I4
sasg70051
(lp85348
(dp85349
g70042
I122
sg70043
Vtumors
p85350
sg70045
I6
sg70054
VC0027651
p85351
sg70048
I1
sa(dp85352
g70042
I110
sg70043
Vlung cancer
p85353
sg70045
I11
sg70054
VC0684249
p85354
sg70048
I2
sa(dp85355
g70042
I122
sg70043
Vtumor
p85356
sg70045
I5
sg70054
VC0027651
p85357
sg70048
I1
sasa(dp85358
g70037
VPromoter methylation of FAM107A gene was confirmed only in the minority of NSCLCs.
p85359
sg70039
(lp85360
(dp85361
g70042
I24
sg70043
VFAM107A gene
p85362
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp85363
sa(dp85364
g135
(dp85365
(Vglucocorticoid-regulated gene
p85366
Vrenal cell carcinoma
p85367
tp85368
I00
ssg70037
VWe recently characterized a stress and glucocorticoid-regulated gene, down-regulated in renal cell carcinoma - DRR1 (Fam107A).
p85369
sg70039
(lp85370
(dp85371
g70042
I117
sg70043
VFam107A
p85372
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp85373
g70042
I111
sg70043
VDRR1
p85374
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85375
g70042
I39
sg70043
g85366
sg70045
I29
sg70046
VP48506
p85376
sg70048
I2
sasg70051
(lp85377
(dp85378
g70042
I88
sg70043
g85367
sg70045
I20
sg70054
VC0007134
p85379
sg70048
I3
sasa(dp85380
g70037
VIn human, FAM107A termed TU3A/DRR1 has been reported as a candidate tumor suppressor gene which expression is downregulated in several types of cancer, however no studies have investigated the other family protein, FAM107B.
p85381
sg70039
(lp85382
(dp85383
g70042
I215
sg70043
VFAM107B
p85384
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp85385
g70042
I10
sg70043
VFAM107A
p85386
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp85387
g70042
I30
sg70043
VDRR1
p85388
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85389
g70042
I25
sg70043
VTU3A
p85390
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85391
(dp85392
g70042
I68
sg70043
Vtumor
p85393
sg70045
I5
sg70054
VC0027651
p85394
sg70048
I1
sa(dp85395
g70042
I144
sg70043
Vcancer
p85396
sg70045
I6
sg70054
VC0006826
p85397
sg70048
I1
sasa(dp85398
g70037
VDown-regulated in renal cell carcinoma 1 (DRR1) is mapped at 3p21.1, and is a candidate tumor suppressor gene.
p85399
sg70039
(lp85400
(dp85401
g70042
I0
sg70043
VDown-regulated in renal cell carcinoma 1
p85402
sg70045
I40
sg70046
g12
sg70048
I6
sa(dp85403
g70042
I42
sg70043
VDRR1
p85404
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85405
(dp85406
g70042
I88
sg70043
Vtumor
p85407
sg70045
I5
sg70054
VC0027651
p85408
sg70048
I1
sa(dp85409
g70042
I18
sg70043
Vrenal cell carcinoma 1
p85410
sg70045
I22
sg70054
VC2931882
p85411
sg70048
I4
sasa(dp85412
g70037
VDRR1 was poorly expressed in established cancer cell lines, including neuroblastoma cells, whereas strong expression was observed in normal cells.
p85413
sg70039
(lp85414
(dp85415
g70042
I0
sg70043
VDRR1
p85416
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85417
(dp85418
g70042
I41
sg70043
Vcancer
p85419
sg70045
I6
sg70054
VC0006826
p85420
sg70048
I1
sa(dp85421
g70042
I70
sg70043
Vneuroblastoma
p85422
sg70045
I13
sg70054
VC0027819
p85423
sg70048
I1
sasa(dp85424
g135
(dp85425
(VMYCN
p85426
Vhyperplasia
p85427
tp85428
I01
ssg70037
VA neuroblastoma model, MYCN transgenic mice, revealed that DRR1 protein was expressed in the celiac ganglion 2 weeks after birth when neuroblast hyperplasia was also observed; however, there was no longer any expression of DRR1 protein in tumors originating from the ganglion 8 weeks after birth.
p85429
sg70039
(lp85430
(dp85431
g70042
I59
sg70043
VDRR1 protein
p85432
sg70045
I12
sg70046
g12
sg70048
I2
sa(dp85433
g70042
I23
sg70043
g85426
sg70045
I4
sg70046
VP04198
p85434
sg70048
I1
sa(dp85435
g70042
I59
sg70043
VDRR1 protein
p85436
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp85437
(dp85438
g70042
I100
sg70043
Vganglion
p85439
sg70045
I8
sg70054
VC1258666
p85440
sg70048
I1
sa(dp85441
g70042
I2
sg70043
Vneuroblastoma
p85442
sg70045
I13
sg70054
VC0027819
p85443
sg70048
I1
sa(dp85444
g70042
I239
sg70043
Vtumors
p85445
sg70045
I6
sg70054
VC0027651
p85446
sg70048
I1
sa(dp85447
g70042
I100
sg70043
Vganglion
p85448
sg70045
I8
sg70054
VC1258666
p85449
sg70048
I1
sa(dp85450
g70042
I145
sg70043
g85427
sg70045
I11
sg70054
VC0020507
p85451
sg70048
I1
sasa(dp85452
g70037
VTogether, our data indicate that DRR1 protein is expressed in normal cells, particularly in the nervous system during embryogenesis, is involved in neuronal cell survival, and is downregulated during neuroblastoma carcinogenesis.
p85453
sg70039
(lp85454
(dp85455
g70042
I33
sg70043
VDRR1 protein
p85456
sg70045
I12
sg70046
g12
sg70048
I2
sasg70051
(lp85457
(dp85458
g70042
I214
sg70043
Vcarcinogenesis
p85459
sg70045
I14
sg70054
VC0596263
p85460
sg70048
I1
sa(dp85461
g70042
I96
sg70043
Vnervous
p85462
sg70045
I7
sg70054
VC0027769
p85463
sg70048
I1
sa(dp85464
g70042
I200
sg70043
Vneuroblastoma
p85465
sg70045
I13
sg70054
VC0027819
p85466
sg70048
I1
sasa(dp85467
g70037
VTU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC).
p85468
sg70039
(lp85469
(dp85470
g70042
I0
sg70043
VTU3A
p85471
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85472
(dp85473
g70042
I91
sg70043
Vrenal cell carcinoma
p85474
sg70045
I20
sg70054
VC0007134
p85475
sg70048
I3
sa(dp85476
g70042
I66
sg70043
Vtumor
p85477
sg70045
I5
sg70054
VC0027651
p85478
sg70048
I1
sa(dp85479
g70042
I113
sg70043
VRCC
p85480
sg70045
I3
sg70054
VC0007134
p85481
sg70048
I1
sasa(dp85482
g70037
VRecently, down-regulation of TU3A expression has been reported not only in RCC but also in other types of cancers.
p85483
sg70039
(lp85484
(dp85485
g70042
I29
sg70043
VTU3A
p85486
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85487
(dp85488
g70042
I106
sg70043
Vcancers
p85489
sg70045
I7
sg70054
VC0006826
p85490
sg70048
I1
sa(dp85491
g70042
I75
sg70043
VRCC
p85492
sg70045
I3
sg70054
VC0007134
p85493
sg70048
I1
sasa(dp85494
g70037
VFurthermore, we observed promoter hyper-methylation of TU3A in several types of cancer cell lines and primary cancers of the bladder and testis.
p85495
sg70039
(lp85496
(dp85497
g70042
I55
sg70043
VTU3A
p85498
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85499
(dp85500
g70042
I110
sg70043
Vcancers
p85501
sg70045
I7
sg70054
VC0006826
p85502
sg70048
I1
sa(dp85503
g70042
I80
sg70043
Vcancer
p85504
sg70045
I6
sg70054
VC0006826
p85505
sg70048
I1
sasa(dp85506
g70037
VTo our knowledge, the present study is the first to demonstrate the epigenetic inactivation of TU3A in human cancers.
p85507
sg70039
(lp85508
(dp85509
g70042
I95
sg70043
VTU3A
p85510
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85511
(dp85512
g70042
I109
sg70043
Vcancers
p85513
sg70045
I7
sg70054
VC0006826
p85514
sg70048
I1
sa(dp85515
g70042
I79
sg70043
Vinactivation
p85516
sg70045
I12
sg70054
VC0544461
p85517
sg70048
I1
sasa(dp85518
g70037
VThe findings of this study warrant further study to investigate the role of TU3A methylation in cancer development.
p85519
sg70039
(lp85520
(dp85521
g70042
I76
sg70043
VTU3A
p85522
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp85523
(dp85524
g70042
I96
sg70043
Vcancer
p85525
sg70045
I6
sg70054
VC0006826
p85526
sg70048
I1
sasa(dp85527
g135
(dp85528
(VGCK
p85529
Vgestational diabetes
p85530
tp85531
I00
ssg70037
VThe aim of this study was to examine the association between GCK, GCKR, FADS1, DGKB/TMEM195 and CDKAL1 gene polymorphisms and the development of gestational diabetes.
p85532
sg70039
(lp85533
(dp85534
g70042
I66
sg70043
VGCKR
p85535
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp85536
g70042
I84
sg70043
VTMEM195
p85537
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp85538
g70042
I96
sg70043
VCDKAL1 gene
p85539
sg70045
I11
sg70046
g12
sg70048
I2
sa(dp85540
g70042
I61
sg70043
g85529
sg70045
I3
sg70046
VP35557
p85541
sg70048
I1
sasg70051
(lp85542
(dp85543
g70042
I145
sg70043
g85530
sg70045
I20
sg70054
VC0085207
p85544
sg70048
I2
sasa(dp85545
g135
(dp85546
(Vneuronal voltage-gated sodium channel gene SCN1A
p85547
VFamilial hemiplegic migraine
p85548
tp85549
I00
ssg70037
VBackground Familial hemiplegic migraine type 3 is a monogenic subtype of migraine caused by missense mutations in the neuronal voltage-gated sodium channel gene SCN1A, with 10 different mutations reported so far.
p85550
sg70039
(lp85551
(dp85552
g70042
I118
sg70043
g85547
sg70045
I48
sg70046
VP29475
p85553
sg70048
I6
sasg70051
(lp85554
(dp85555
g70042
I31
sg70043
Vmigraine
p85556
sg70045
I8
sg70054
VC0149931
p85557
sg70048
I1
sa(dp85558
g70042
I11
sg70043
g85548
sg70045
I28
sg70054
VC0338484
p85559
sg70048
I3
sasa(dp85560
g135
(dp85561
(VSCN1A mutation p.F1499L
p85562
Vfamilial hemiplegic migraine
p85563
tp85564
I00
ssg70037
VResults In both pedigrees, we identified SCN1A mutation p.F1499L, which has been previously associated with familial hemiplegic migraine type 3 and elicited repetitive daily blindness.
p85565
sg70039
(lp85566
(dp85567
g70042
I41
sg70043
g85562
sg70045
I23
sg70046
VP35498
p85568
sg70048
I3
sasg70051
(lp85569
(dp85570
g70042
I174
sg70043
Vblindness
p85571
sg70045
I9
sg70054
VC0456909
p85572
sg70048
I1
sa(dp85573
g70042
I108
sg70043
g85563
sg70045
I28
sg70054
VC0338484
p85574
sg70048
I3
sasa(dp85575
g135
(dp85576
(VSCN1A
p85577
Vfamilial hemiplegic migraine
p85578
tp85579
I00
ssg70037
VConclusion Like a substantial proportion of other familial hemiplegic migraine type 3 mutations, p.F1499L affects the intracellular linker between domains III and IV of SCN1A, which seems to be a mutational hot-spot.
p85580
sg70039
(lp85581
(dp85582
g70042
I169
sg70043
g85577
sg70045
I5
sg70046
VP35498
p85583
sg70048
I1
sasg70051
(lp85584
(dp85585
g70042
I50
sg70043
g85578
sg70045
I28
sg70054
VC0338484
p85586
sg70048
I3
sasa(dp85587
g135
(dp85588
(VCACNA1A genes
p85589
Vepilepsy
p85590
tp85591
I00
ssg70037
VA genetic link between these two diseases is particularly evident in familial hemiplegic migraine: mutations of ATP1A2, SCN1A and CACNA1A genes, identified in this disease, have also been involved in different types of epilepsy and febrile seizures.
p85592
sg70039
(lp85593
(dp85594
g70042
I112
sg70043
VATP1A2
p85595
sg70045
I6
sg70046
VP50993
p85596
sg70048
I1
sa(dp85597
g70042
I120
sg70043
VSCN1A
p85598
sg70045
I5
sg70046
VP35498
p85599
sg70048
I1
sa(dp85600
g70042
I130
sg70043
g85589
sg70045
I13
sg70046
VP01893
p85601
sg70048
I2
sasg70051
(lp85602
(dp85603
g70042
I232
sg70043
Vfebrile seizures
p85604
sg70045
I16
sg70054
VC0009952
p85605
sg70048
I2
sa(dp85606
g70042
I69
sg70043
Vfamilial hemiplegic migraine
p85607
sg70045
I28
sg70054
VC0338484
p85608
sg70048
I3
sa(dp85609
g70042
I219
sg70043
g85590
sg70045
I8
sg70054
VC0014544
p85610
sg70048
I1
sasa(dp85611
g70037
VMutations in three genes (CACNA1A, ATP1A2, and SCN1A) have been found to cause FHM.
p85612
sg70039
(lp85613
(dp85614
g70042
I35
sg70043
VATP1A2
p85615
sg70045
I6
sg70046
VP50993
p85616
sg70048
I1
sa(dp85617
g70042
I47
sg70043
VSCN1A
p85618
sg70045
I5
sg70046
VP35498
p85619
sg70048
I1
sasg70051
(lp85620
(dp85621
g70042
I79
sg70043
VFHM
p85622
sg70045
I3
sg70054
VC1832894
p85623
sg70048
I1
sasa(dp85624
g135
(dp85625
(VSCN1A gene
p85626
VFHM3
p85627
tp85628
I00
ssg70037
VAmong these, nine SCN1A gene mutations were reported to cause familial hemiplegic migraine type 3 (FHM3).
p85629
sg70039
(lp85630
(dp85631
g70042
I62
sg70043
Vfamilial hemiplegic migraine type 3
p85632
sg70045
I35
sg70046
VP35498
p85633
sg70048
I5
sa(dp85634
g70042
I99
sg70043
VFHM3
p85635
sg70045
I4
sg70046
VP35498
p85636
sg70048
I1
sa(dp85637
g70042
I18
sg70043
g85626
sg70045
I10
sg70046
VP35498
p85638
sg70048
I2
sasg70051
(lp85639
(dp85640
g70042
I62
sg70043
Vfamilial hemiplegic migraine type 3
p85641
sg70045
I35
sg70054
VC1864987
p85642
sg70048
I5
sa(dp85643
g70042
I99
sg70043
g85627
sg70045
I4
sg70054
VC1864987
p85644
sg70048
I1
sasa(dp85645
g70037
VMethod The clinical manifestations of a Chinese FHM family were recorded and all coding exons and flanking intronic regions of the CACNA1A, ATP1A2, and SCN1A genes were tested for mutations.
p85646
sg70039
(lp85647
(dp85648
g70042
I140
sg70043
VATP1A2
p85649
sg70045
I6
sg70046
VP50993
p85650
sg70048
I1
sa(dp85651
g70042
I152
sg70043
VSCN1A genes
p85652
sg70045
I11
sg70046
VP35498
p85653
sg70048
I2
sasg70051
(lp85654
(dp85655
g70042
I48
sg70043
VFHM
p85656
sg70045
I3
sg70054
VC1832894
p85657
sg70048
I1
sasa(dp85658
g70037
VConclusion The identification of a novel mutation in the SCN1A gene in the Chinese population may further aid in the understanding of FHM genetics.
p85659
sg70039
(lp85660
(dp85661
g70042
I57
sg70043
VSCN1A gene
p85662
sg70045
I10
sg70046
VP35498
p85663
sg70048
I2
sasg70051
(lp85664
(dp85665
g70042
I134
sg70043
VFHM
p85666
sg70045
I3
sg70054
VC1832894
p85667
sg70048
I1
sa(dp85668
g70042
I35
sg70043
Vnovel mutation
p85669
sg70045
I14
sg70054
VC2985438
p85670
sg70048
I2
sasa(dp85671
g135
(dp85672
(VATPase
p85673
Vfamilial hemiplegic migraine
p85674
tp85675
I00
ssg70037
VMutations in four genes have been identified in familial hemiplegic migraine (FHM), from which CACNA1A (FHM type 1) and SCN1A (FHM type 3) code for neuronal voltage-gated calcium or sodium channels, respectively, while ATP1A2 (FHM type 2) encodes the Alfa2 isoform of the Na(+),K(+)-ATPase's catalytic subunit, thus classifying FHM primarily as an ion channel/ion transporter pathology.
p85676
sg70039
(lp85677
(dp85678
g70042
I219
sg70043
VATP1A2
p85679
sg70045
I6
sg70046
VP50993
p85680
sg70048
I1
sa(dp85681
g70042
I120
sg70043
VSCN1A
p85682
sg70045
I5
sg70046
VP35498
p85683
sg70048
I1
sa(dp85684
g70042
I283
sg70043
g85673
sg70045
I6
sg70046
VP38606
p85685
sg70048
I1
sasg70051
(lp85686
(dp85687
g70042
I78
sg70043
VFHM
p85688
sg70045
I3
sg70054
VC1832894
p85689
sg70048
I1
sa(dp85690
g70042
I78
sg70043
VFHM
p85691
sg70045
I3
sg70054
VC1832894
p85692
sg70048
I1
sa(dp85693
g70042
I376
sg70043
Vpathology
p85694
sg70045
I9
sg70054
VC0677042
p85695
sg70048
I1
sa(dp85696
g70042
I78
sg70043
VFHM
p85697
sg70045
I3
sg70054
VC1832894
p85698
sg70048
I1
sa(dp85699
g70042
I48
sg70043
g85674
sg70045
I28
sg70054
VC0338484
p85700
sg70048
I3
sa(dp85701
g70042
I78
sg70043
VFHM
p85702
sg70045
I3
sg70054
VC1832894
p85703
sg70048
I1
sa(dp85704
g70042
I78
sg70043
VFHM
p85705
sg70045
I3
sg70054
VC1832894
p85706
sg70048
I1
sasa(dp85707
g135
(dp85708
(VATP1A2
p85709
Vfamilial hemiplegic migraine
p85710
tp85711
I00
ssg70037
VMoreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura.
p85712
sg70039
(lp85713
(dp85714
g70042
I44
sg70043
VSCN1A
p85715
sg70045
I5
sg70046
VP35498
p85716
sg70048
I1
sa(dp85717
g70042
I32
sg70043
g85709
sg70045
I6
sg70046
VP50993
p85718
sg70048
I1
sasg70051
(lp85719
(dp85720
g70042
I134
sg70043
VFHM
p85721
sg70045
I3
sg70054
VC1832894
p85722
sg70048
I1
sa(dp85723
g70042
I160
sg70043
Vmigraine with aura
p85724
sg70045
I18
sg70054
VC0154723
p85725
sg70048
I3
sa(dp85726
g70042
I104
sg70043
g85710
sg70045
I28
sg70054
VC0338484
p85727
sg70048
I3
sasa(dp85728
g135
(dp85729
(VFHM3 subtype
p85730
VFHM3
p85731
tp85732
I00
ssg70037
VThe FHM3 subtype is caused by mutations in SCN1A, which is also the most frequent epilepsy gene encoding the voltage-gated Na+ channel NaV1.1.
p85733
sg70039
(lp85734
(dp85735
g70042
I123
sg70043
VNa+ channel NaV1.1
p85736
sg70045
I18
sg70046
VP37088
p85737
sg70048
I3
sa(dp85738
g70042
I43
sg70043
VSCN1A
p85739
sg70045
I5
sg70046
VP35498
p85740
sg70048
I1
sa(dp85741
g70042
I4
sg70043
g85730
sg70045
I12
sg70046
VP35498
p85742
sg70048
I2
sasg70051
(lp85743
(dp85744
g70042
I82
sg70043
Vepilepsy
p85745
sg70045
I8
sg70054
VC0014544
p85746
sg70048
I1
sa(dp85747
g70042
I4
sg70043
g85731
sg70045
I4
sg70054
VC1864987
p85748
sg70048
I1
sasa(dp85749
g135
(dp85750
(VFHM3 family
p85751
VFHM3
p85752
tp85753
I00
ssg70037
VThe aim of this study was to explore the clinical, genetic and pathogenetic features of a pure FHM3 family.
p85754
sg70039
(lp85755
(dp85756
g70042
I95
sg70043
g85751
sg70045
I11
sg70046
VP35498
p85757
sg70048
I2
sasg70051
(lp85758
(dp85759
g70042
I95
sg70043
g85752
sg70045
I4
sg70054
VC1864987
p85760
sg70048
I1
sasa(dp85761
g70037
VResults and conclusions We identified a novel SCN1A (p.Leu1624Pro) mutation in a pure FHM family with notably early-onset attacks at mean age of 7.
p85762
sg70039
(lp85763
(dp85764
g70042
I46
sg70043
VSCN1A
p85765
sg70045
I5
sg70046
VP35498
p85766
sg70048
I1
sasg70051
(lp85767
(dp85768
g70042
I86
sg70043
VFHM
p85769
sg70045
I3
sg70054
VC1832894
p85770
sg70048
I1
sasa(dp85771
g135
(dp85772
(VFHM3
p85773
VFHM3
p85774
tp85775
I00
ssg70037
VL1624P locates in S3 of domain IV, the same domain as two of four known pure FHM3 mutations.
p85776
sg70039
(lp85777
(dp85778
g70042
I77
sg70043
g85773
sg70045
I4
sg70046
VP35498
p85779
sg70048
I1
sasg70051
(lp85780
(dp85781
g70042
I77
sg70043
g85774
sg70045
I4
sg70054
VC1864987
p85782
sg70048
I1
sasa(dp85783
g135
(dp85784
(VFHM3 mutations
p85785
VFHM3
p85786
tp85787
I00
ssg70037
VSimilar to the known FHM3 mutations, this novel mutation predicts hyperexcitability of GABAergic inhibitory neurons.
p85788
sg70039
(lp85789
(dp85790
g70042
I21
sg70043
g85785
sg70045
I14
sg70046
VP35498
p85791
sg70048
I2
sasg70051
(lp85792
(dp85793
g70042
I21
sg70043
g85786
sg70045
I4
sg70054
VC1864987
p85794
sg70048
I1
sa(dp85795
g70042
I42
sg70043
Vnovel mutation
p85796
sg70045
I14
sg70054
VC2985438
p85797
sg70048
I2
sasa(dp85798
g135
(dp85799
(VATP1A2
p85800
Vmigraine with aura
p85801
tp85802
I00
ssg70037
VSixty patients with migraine without aura (MO) or with different types of migraine with aura (MA), including sporadic hemiplegic, familial hemiplegic, and probable familial hemiplegic, were screened for mutations in the four genes previously linked with different types of migraine (ATP1A2, CACNA1A, SCN1A, and KCNK18).
p85803
sg70039
(lp85804
(dp85805
g70042
I300
sg70043
VSCN1A
p85806
sg70045
I5
sg70046
VP35498
p85807
sg70048
I1
sa(dp85808
g70042
I283
sg70043
g85800
sg70045
I6
sg70046
VP50993
p85809
sg70048
I1
sa(dp85810
g70042
I311
sg70043
VKCNK18
p85811
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp85812
(dp85813
g70042
I94
sg70043
VMA
p85814
sg70045
I2
sg70054
VC0154723
p85815
sg70048
I1
sa(dp85816
g70042
I20
sg70043
Vmigraine without aura
p85817
sg70045
I21
sg70054
VC0338480
p85818
sg70048
I3
sa(dp85819
g70042
I20
sg70043
Vmigraine
p85820
sg70045
I8
sg70054
VC0149931
p85821
sg70048
I1
sa(dp85822
g70042
I43
sg70043
VMO
p85823
sg70045
I2
sg70054
VC0338480
p85824
sg70048
I1
sa(dp85825
g70042
I74
sg70043
g85801
sg70045
I18
sg70054
VC0154723
p85826
sg70048
I3
sasa(dp85827
g70037
VOne novel mutation in SCN1A, encoding Alfa subunit of sodium channel, causing amino acid change M1500V localized to a region encoding inactivation loop between transmembrane domains III and IV of the channel, was detected in a female FHM patient.
p85828
sg70039
(lp85829
(dp85830
g70042
I22
sg70043
VSCN1A
p85831
sg70045
I5
sg70046
VP35498
p85832
sg70048
I1
sasg70051
(lp85833
(dp85834
g70042
I234
sg70043
VFHM
p85835
sg70045
I3
sg70054
VC1832894
p85836
sg70048
I1
sa(dp85837
g70042
I134
sg70043
Vinactivation
p85838
sg70045
I12
sg70054
VC0544461
p85839
sg70048
I1
sa(dp85840
g70042
I4
sg70043
Vnovel mutation
p85841
sg70045
I14
sg70054
VC2985438
p85842
sg70048
I2
sasa(dp85843
g70037
VThe presence of SCN1A mutations and absence of mutations in ATP1A2 or CACNA1A suggest that the Polish patients represent FHM type 3.
p85844
sg70039
(lp85845
(dp85846
g70042
I16
sg70043
VSCN1A mutations
p85847
sg70045
I15
sg70046
VP35498
p85848
sg70048
I2
sa(dp85849
g70042
I60
sg70043
VATP1A2
p85850
sg70045
I6
sg70046
VP50993
p85851
sg70048
I1
sasg70051
(lp85852
(dp85853
g70042
I121
sg70043
VFHM
p85854
sg70045
I3
sg70054
VC1832894
p85855
sg70048
I1
sasa(dp85856
g135
(dp85857
(VSCN1A
p85858
Vfamilial hemiplegic migraine
p85859
tp85860
I00
ssg70037
VMutations of the voltage gated Na(+) channel Na(V)1.1 (SCN1A) are important causes of different genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III).
p85861
sg70039
(lp85862
(dp85863
g70042
I55
sg70043
g85858
sg70045
I5
sg70046
VP35498
p85864
sg70048
I1
sasg70051
(lp85865
(dp85866
g70042
I104
sg70043
Vepilepsies
p85867
sg70045
I10
sg70054
VC0014544
p85868
sg70048
I1
sa(dp85869
g70042
I164
sg70043
VFHM-III
p85870
sg70045
I7
sg70054
VC0338484
p85871
sg70048
I1
sa(dp85872
g70042
I134
sg70043
g85859
sg70045
I28
sg70054
VC0338484
p85873
sg70048
I3
sasa(dp85874
g135
(dp85875
(VFHM3
p85876
VFHM3
p85877
tp85878
I00
ssg70037
VA mutation causing FHM type 3 (FHM3) has been identified in SCN1A encoding the Nav1.1 Na(+) channel.
p85879
sg70039
(lp85880
(dp85881
g70042
I60
sg70043
VSCN1A
p85882
sg70045
I5
sg70046
VP35498
p85883
sg70048
I1
sa(dp85884
g70042
I19
sg70043
VFHM type 3
p85885
sg70045
I10
sg70046
VP35498
p85886
sg70048
I3
sa(dp85887
g70042
I79
sg70043
VNav1.1 Na(+)
p85888
sg70045
I12
sg70046
VP35498
p85889
sg70048
I2
sa(dp85890
g70042
I31
sg70043
g85876
sg70045
I4
sg70046
VP35498
p85891
sg70048
I1
sasg70051
(lp85892
(dp85893
g70042
I19
sg70043
VFHM type 3
p85894
sg70045
I10
sg70054
VC1864987
p85895
sg70048
I3
sa(dp85896
g70042
I31
sg70043
g85877
sg70045
I4
sg70054
VC1864987
p85897
sg70048
I1
sasa(dp85898
g135
(dp85899
(VFHM3
p85900
Vdepression
p85901
tp85902
I00
ssg70037
VIn particular, we investigate the dynamical repertoire from normal spiking (milliseconds) to spreading depression and anoxic depolarization (tens of seconds) and show that FHM3 mutations render gray matter tissue more vulnerable to spreading depression despite opposing effects associated with action potential generation.
p85903
sg70039
(lp85904
(dp85905
g70042
I172
sg70043
g85900
sg70045
I4
sg70046
VP35498
p85906
sg70048
I1
sasg70051
(lp85907
(dp85908
g70042
I172
sg70043
VFHM3
p85909
sg70045
I4
sg70054
VC1864987
p85910
sg70048
I1
sa(dp85911
g70042
I103
sg70043
Vdepression
p85912
sg70045
I10
sg70054
VC0011581
p85913
sg70048
I1
sa(dp85914
g70042
I103
sg70043
g85901
sg70045
I10
sg70054
VC0011581
p85915
sg70048
I1
sasa(dp85916
g135
(dp85917
(VIL-1Beta
p85918
Vgastritis
p85919
tp85920
I00
ssg70037
VPAR2 gene expression correlated positively with transcript levels of IL-8, IL-1Beta as well mucosal SLPI levels in H. pylori-infected patients (r: 0.47-0.84; p &lt; .0001), whereas no correlation was found with the degree of gastritis.
p85921
sg70039
(lp85922
(dp85923
g70042
I0
sg70043
VPAR2
p85924
sg70045
I4
sg70046
VP55085
p85925
sg70048
I1
sa(dp85926
g70042
I75
sg70043
g85918
sg70045
I8
sg70046
VP01584
p85927
sg70048
I1
sasg70051
(lp85928
(dp85929
g70042
I225
sg70043
g85919
sg70045
I9
sg70054
VC0017152
p85930
sg70048
I1
sasa(dp85931
g70037
VMucosal levels of Secretory Leukocyte Protease Inhibitor (SLPI) are specifically reduced in relation to H. pylori-induced gastritis.
p85932
sg70039
(lp85933
sg70051
(lp85934
(dp85935
g70042
I122
sg70043
Vgastritis
p85936
sg70045
I9
sg70054
VC0017152
p85937
sg70048
I1
sasa(dp85938
g70037
VIn contrast to other diseases, SLPI seems not to have a regulatory role for Progranulin in H. pylori-mediated gastritis.
p85939
sg70039
(lp85940
sg70051
(lp85941
(dp85942
g70042
I110
sg70043
Vgastritis
p85943
sg70045
I9
sg70054
VC0017152
p85944
sg70048
I1
sasa(dp85945
g135
(dp85946
(VSLPI
p85947
Vgastritis
p85948
tp85949
I01
ssg70037
VSLPI expression is generally induced during inflammation; however, Helicobacter pylori-mediated gastritis is associated with significantly decreased antral SLPI levels.
p85950
sg70039
(lp85951
(dp85952
g70042
I0
sg70043
g85947
sg70045
I4
sg70046
VP03973
p85953
sg70048
I1
sasg70051
(lp85954
(dp85955
g70042
I44
sg70043
Vinflammation
p85956
sg70045
I12
sg70054
VC0021368
p85957
sg70048
I1
sa(dp85958
g70042
I96
sg70043
g85948
sg70045
I9
sg70054
VC0017152
p85959
sg70048
I1
sasa(dp85960
g70037
VSLPI expression was retrospectively analysed by immunohistochemistry in 85 paraffin-embedded samples: H. pylori-induced (n=13), non-steroidal anti-inflammatory drug (NSAID)-enhanced (n=18), autoimmune (n=11), lymphocytic gastritis (n=26) and H. pylori-negative controls (n=17).
p85961
sg70039
(lp85962
sg70051
(lp85963
(dp85964
g70042
I190
sg70043
Vautoimmune
p85965
sg70045
I10
sg70054
VC0443146
p85966
sg70048
I1
sa(dp85967
g70042
I209
sg70043
Vlymphocytic gastritis
p85968
sg70045
I21
sg70054
VC1283271
p85969
sg70048
I2
sasa(dp85970
g135
(dp85971
(Vepithelial SLPI
p85972
Vautoimmune gastritis
p85973
tp85974
I01
ssg70037
VIn comparison with the control group, the SLPI expression of antral mucosa in H. pylori-mediated and lymphocytic gastritis was significantly lower (P&lt;0.001), whereas epithelial SLPI expression was not affected in NSAID-enhanced and autoimmune gastritis either in the antrum or corpus, respectively.
p85975
sg70039
(lp85976
(dp85977
g70042
I42
sg70043
VSLPI
p85978
sg70045
I4
sg70046
VP03973
p85979
sg70048
I1
sa(dp85980
g70042
I169
sg70043
g85972
sg70045
I15
sg70046
VP12830
p85981
sg70048
I2
sasg70051
(lp85982
(dp85983
g70042
I101
sg70043
Vlymphocytic gastritis
p85984
sg70045
I21
sg70054
VC1283271
p85985
sg70048
I2
sa(dp85986
g70042
I235
sg70043
g85973
sg70045
I20
sg70054
VC0017154
p85987
sg70048
I2
sasa(dp85988
g135
(dp85989
(VSLPI
p85990
Vautoimmune gastritis
p85991
tp85992
I00
ssg70037
VBoth the H. pylori-mediated and lymphocytic gastritis revealed a significantly lower expression of SLPI in infiltrating immune cells (P&lt;0.01), whereas immune cells infiltrating the corpus in autoimmune gastritis showed higher SLPI levels than the immune cells of other groups (P&lt;0.03).
p85993
sg70039
(lp85994
(dp85995
g70042
I99
sg70043
g85990
sg70045
I4
sg70046
VP03973
p85996
sg70048
I1
sasg70051
(lp85997
(dp85998
g70042
I32
sg70043
Vlymphocytic gastritis
p85999
sg70045
I21
sg70054
VC1283271
p86000
sg70048
I2
sa(dp86001
g70042
I194
sg70043
g85991
sg70045
I20
sg70054
VC0017154
p86002
sg70048
I2
sa(dp86003
g70042
I107
sg70043
Vinfiltrating
p86004
sg70045
I12
sg70054
VC0332448
p86005
sg70048
I1
sa(dp86006
g70042
I107
sg70043
Vinfiltrating
p86007
sg70045
I12
sg70054
VC0332448
p86008
sg70048
I1
sasa(dp86009
g70037
VAntral SLPI levels were inversely correlated with inflammatory scores of antrum-predominant gastritis.
p86010
sg70039
(lp86011
sg70051
(lp86012
(dp86013
g70042
I92
sg70043
Vgastritis
p86014
sg70045
I9
sg70054
VC0017152
p86015
sg70048
I1
sasa(dp86016
g135
(dp86017
(VTGF-Beta1
p86018
Vrenal fibrosis
p86019
tp86020
I00
ssg70037
VPharmacological inhibition of different signaling pathways and genetic knockdown of Notch-2 further revealed JNK as an upstream effector of Notch-2 in TGF-Beta1-mediated renal fibrosis.
p86021
sg70039
(lp86022
(dp86023
g70042
I109
sg70043
VJNK
p86024
sg70045
I3
sg70046
VP53779
p86025
sg70048
I1
sa(dp86026
g70042
I151
sg70043
g86018
sg70045
I9
sg70046
VP01137
p86027
sg70048
I1
sa(dp86028
g70042
I84
sg70043
VNotch-2
p86029
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86030
g70042
I84
sg70043
VNotch-2
p86031
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp86032
(dp86033
g70042
I170
sg70043
g86019
sg70045
I14
sg70054
VC0151650
p86034
sg70048
I2
sasa(dp86035
g135
(dp86036
(VJNK
p86037
Vrenal fibrosis
p86038
tp86039
I00
ssg70037
VConsistently, we also demonstrated that administration of TSA or a Gamma-secretase inhibitor RO4929097 in the mouse model of unilateral ureteral obstruction significantly ameliorated renal fibrosis through suppression of the JNK/Notch-2 signaling activation.
p86040
sg70039
(lp86041
(dp86042
g70042
I229
sg70043
VNotch-2
p86043
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86044
g70042
I225
sg70043
g86037
sg70045
I3
sg70046
VP53779
p86045
sg70048
I1
sasg70051
(lp86046
(dp86047
g70042
I136
sg70043
Vureteral obstruction
p86048
sg70045
I20
sg70054
VC0041956
p86049
sg70048
I2
sa(dp86050
g70042
I183
sg70043
g86038
sg70045
I14
sg70054
VC0151650
p86051
sg70048
I2
sa(dp86052
g70042
I206
sg70043
Vsuppression
p86053
sg70045
I11
sg70054
VC0221103
p86054
sg70048
I1
sasa(dp86055
g70037
VAlthough, renal abnormalities are considered an integral part of the HJCYS, published reports on ESRD are scarce.
p86056
sg70039
(lp86057
sg70051
(lp86058
(dp86059
g70042
I69
sg70043
VHJCYS
p86060
sg70045
I5
sg70054
VC0917715
p86061
sg70048
I1
sa(dp86062
g70042
I97
sg70043
VESRD
p86063
sg70045
I4
sg70054
VC0022661
p86064
sg70048
I1
sasa(dp86065
g70037
VHere we show that Notch2 prevents podocyte loss and nephrosis.
p86066
sg70039
(lp86067
(dp86068
g70042
I18
sg70043
VNotch2
p86069
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp86070
(dp86071
g70042
I52
sg70043
Vnephrosis
p86072
sg70045
I9
sg70054
VC0027720
p86073
sg70048
I1
sasa(dp86074
g70037
VAdministration of a Notch2 agonistic monoclonal antibody ameliorates proteinuria and glomerulosclerosis in a mouse model of nephrosis and focal segmental glomerulosclerosis.
p86075
sg70039
(lp86076
(dp86077
g70042
I20
sg70043
VNotch2
p86078
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp86079
(dp86080
g70042
I138
sg70043
Vfocal segmental glomerulosclerosis
p86081
sg70045
I34
sg70054
VC0017668
p86082
sg70048
I3
sa(dp86083
g70042
I85
sg70043
Vglomerulosclerosis
p86084
sg70045
I18
sg70054
VC0178664
p86085
sg70048
I1
sa(dp86086
g70042
I124
sg70043
Vnephrosis
p86087
sg70045
I9
sg70054
VC0027720
p86088
sg70048
I1
sasa(dp86089
g70037
VHence, specific activation of Notch2 rescues damaged podocytes and activating Notch2 may represent a novel clinical strategy for the amelioration of nephrosis and glomerulosclerosis.
p86090
sg70039
(lp86091
(dp86092
g70042
I30
sg70043
VNotch2
p86093
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp86094
g70042
I30
sg70043
VNotch2
p86095
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp86096
(dp86097
g70042
I149
sg70043
Vnephrosis
p86098
sg70045
I9
sg70054
VC0027720
p86099
sg70048
I1
sa(dp86100
g70042
I163
sg70043
Vglomerulosclerosis
p86101
sg70045
I18
sg70054
VC0178664
p86102
sg70048
I1
sasa(dp86103
g70037
VTo investigate the effect of both fermented Cordyceps powder (CS) and prednisone on the Notch2/hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy (AAAN).
p86104
sg70039
(lp86105
(dp86106
g70042
I95
sg70043
Vhes-1
p86107
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp86108
g70042
I88
sg70043
VNotch2
p86109
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp86110
(dp86111
g70042
I95
sg70043
Vhes
p86112
sg70045
I3
sg70054
VC0206141
p86113
sg70048
I1
sa(dp86114
g70042
I181
sg70043
Vnephropathy
p86115
sg70045
I11
sg70054
VC0022658
p86116
sg70048
I1
sasa(dp86117
g135
(dp86118
(VJAG1
p86119
VAlagille syndrome
p86120
tp86121
I00
ssg70037
VThe role of NOTCH2 and JAG1 in formation of proximal nephron structures and podocytes might explain the observed phenotypes of renal dysplasia and proteinuria in patients with Alagille syndrome, and renal tubular acidosis may be the result of JAG1 expression in the collecting ducts.
p86122
sg70039
(lp86123
(dp86124
g70042
I12
sg70043
VNOTCH2
p86125
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp86126
g70042
I23
sg70043
VJAG1
p86127
sg70045
I4
sg70046
VP78504
p86128
sg70048
I1
sa(dp86129
g70042
I23
sg70043
g86119
sg70045
I4
sg70046
VP78504
p86130
sg70048
I1
sasg70051
(lp86131
(dp86132
g70042
I127
sg70043
Vrenal dysplasia
p86133
sg70045
I15
sg70054
VC0266313
p86134
sg70048
I2
sa(dp86135
g70042
I199
sg70043
Vrenal tubular acidosis
p86136
sg70045
I22
sg70054
VC0001126
p86137
sg70048
I3
sa(dp86138
g70042
I176
sg70043
g86120
sg70045
I17
sg70054
VC0085280
p86139
sg70048
I2
sasa(dp86140
g135
(dp86141
(VCA
p86142
Vdental caries
p86143
tp86144
I00
ssg70037
VThe oral pathogenic bacterium involved in human dental caries formation Streptococcus mutans, encodes for two carbonic anhydrase (CA, EC 4.2.1.1) one belonging to the Alfa- and the other one to the Beta-class.
p86145
sg70039
(lp86146
(dp86147
g70042
I110
sg70043
Vcarbonic anhydrase
p86148
sg70045
I18
sg70046
VP35218
p86149
sg70048
I2
sa(dp86150
g70042
I130
sg70043
g86142
sg70045
I2
sg70046
VP35218
p86151
sg70048
I1
sasg70051
(lp86152
(dp86153
g70042
I48
sg70043
g86143
sg70045
I13
sg70054
VC0333519
p86154
sg70048
I2
sasa(dp86155
g135
(dp86156
(VBeta-class carbonic anhydrase
p86157
Vdental caries
p86158
tp86159
I00
ssg70037
VStreptococcus mutans, the oral pathogenic bacterium provoking dental caries formation, encodes for a Beta-class carbonic anhydrase (CA, EC 4.2.1.1), SmuCA.
p86160
sg70039
(lp86161
(dp86162
g70042
I101
sg70043
g86157
sg70045
I29
sg70046
VP35218
p86163
sg70048
I3
sasg70051
(lp86164
(dp86165
g70042
I62
sg70043
g86158
sg70045
I13
sg70054
VC0333519
p86166
sg70048
I2
sasa(dp86167
g135
(dp86168
(Vcarbonic anhydrase
p86169
Vperiodontitis
p86170
tp86171
I00
ssg70037
VA carbonic anhydrase (CA, EC 4.2.1.1) denominated PgiCA, belonging to the Gamma-class, from the oral pathogenic bacteria Porphyromonas gingivalis, the main causative agent of periodontitis, was investigated for its inhibition profile with sulfonamides and one sulfamate.
p86172
sg70039
(lp86173
(dp86174
g70042
I22
sg70043
VCA
p86175
sg70045
I2
sg70046
VP35218
p86176
sg70048
I1
sa(dp86177
g70042
I2
sg70043
g86169
sg70045
I18
sg70046
VP35218
p86178
sg70048
I2
sasg70051
(lp86179
(dp86180
g70042
I175
sg70043
g86170
sg70045
I13
sg70054
VC0031099
p86181
sg70048
I1
sasa(dp86182
g135
(dp86183
(VTFIIH
p86184
VXPB
p86185
tp86186
I01
ssg70037
VRecently, an interaction between FIR (FUSE-Binding Protein-Interacting Repressor) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and so might be important for suppressing tumor formation.
p86187
sg70039
(lp86188
(dp86189
g70042
I130
sg70043
Vc-myc
p86190
sg70045
I5
sg70046
VP12524
p86191
sg70048
I1
sa(dp86192
g70042
I96
sg70043
VXPB helicase
p86193
sg70045
I12
sg70046
VP19447
p86194
sg70048
I2
sa(dp86195
g70042
I86
sg70043
g86184
sg70045
I5
sg70046
VP32780
p86196
sg70048
I1
sasg70051
(lp86197
(dp86198
g70042
I192
sg70043
Vtumor
p86199
sg70045
I5
sg70054
VC0027651
p86200
sg70048
I1
sa(dp86201
g70042
I96
sg70043
g86185
sg70045
I3
sg70054
VC0268136
p86202
sg70048
I1
sasa(dp86203
g135
(dp86204
(VTFIIH
p86205
VXPB
p86206
tp86207
I01
ssg70037
VIn XPB cells carrying mutant TFIIH, loop formation failed and the serum response was abnormal; RNAi depletion of FIR similarly disabled c-myc regulation.
p86208
sg70039
(lp86209
(dp86210
g70042
I113
sg70043
VFIR
p86211
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp86212
g70042
I136
sg70043
Vc-myc
p86213
sg70045
I5
sg70046
VP12524
p86214
sg70048
I1
sa(dp86215
g70042
I29
sg70043
g86205
sg70045
I5
sg70046
VP32780
p86216
sg70048
I1
sasg70051
(lp86217
(dp86218
g70042
I3
sg70043
g86206
sg70045
I3
sg70054
VC0268136
p86219
sg70048
I1
sa(dp86220
g70042
I22
sg70043
Vmutant
p86221
sg70045
I6
sg70054
VC0596988
p86222
sg70048
I1
sasa(dp86223
g135
(dp86224
(VTFIIH
p86225
VXPB
p86226
tp86227
I01
ssg70037
VRecently, an interaction between FUSE-binding protein-interacting repressor (FIR) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and might be important for suppressing tumor formation.
p86228
sg70039
(lp86229
(dp86230
g70042
I130
sg70043
Vc-myc
p86231
sg70045
I5
sg70046
VP12524
p86232
sg70048
I1
sa(dp86233
g70042
I77
sg70043
VFIR
p86234
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp86235
g70042
I96
sg70043
VXPB helicase
p86236
sg70045
I12
sg70046
VP19447
p86237
sg70048
I2
sa(dp86238
g70042
I86
sg70043
g86225
sg70045
I5
sg70046
VP32780
p86239
sg70048
I1
sa(dp86240
g70042
I33
sg70043
VFUSE-binding protein-interacting repressor
p86241
sg70045
I42
sg70046
g12
sg70048
I3
sasg70051
(lp86242
(dp86243
g70042
I189
sg70043
Vtumor
p86244
sg70045
I5
sg70054
VC0027651
p86245
sg70048
I1
sa(dp86246
g70042
I96
sg70043
g86226
sg70045
I3
sg70054
VC0268136
p86247
sg70048
I1
sasa(dp86248
g135
(dp86249
(VXPD
p86250
VXPB
p86251
tp86252
I01
ssg70037
VHere, XPB and XPD mutations are shown to block transcription activation by the FUSE Binding Protein (FBP), a regulator of c-myc expression, and repression by the FBP Interacting Repressor (FIR).
p86253
sg70039
(lp86254
(dp86255
g70042
I189
sg70043
VFIR
p86256
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp86257
g70042
I101
sg70043
VFBP
p86258
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp86259
g70042
I122
sg70043
Vc-myc
p86260
sg70045
I5
sg70046
VP12524
p86261
sg70048
I1
sa(dp86262
g70042
I6
sg70043
VXPB
p86263
sg70045
I3
sg70046
VP19447
p86264
sg70048
I1
sa(dp86265
g70042
I14
sg70043
g86250
sg70045
I3
sg70046
VP18074
p86266
sg70048
I1
sa(dp86267
g70042
I79
sg70043
VFUSE Binding Protein
p86268
sg70045
I20
sg70046
g12
sg70048
I3
sa(dp86269
g70042
I162
sg70043
VFBP Interacting Repressor
p86270
sg70045
I25
sg70046
g12
sg70048
I3
sasg70051
(lp86271
(dp86272
g70042
I14
sg70043
VXPD
p86273
sg70045
I3
sg70054
VC0268138
p86274
sg70048
I1
sa(dp86275
g70042
I6
sg70043
g86251
sg70045
I3
sg70054
VC0268136
p86276
sg70048
I1
sasa(dp86277
g135
(dp86278
(VTFIIH
p86279
VXPB
p86280
tp86281
I01
ssg70037
VThe repression domain of FIR targeted only TFIIH's p89/XPB helicase, required at several stages in transcription, but not factors required for promoter selection.
p86282
sg70039
(lp86283
(dp86284
g70042
I55
sg70043
VXPB helicase
p86285
sg70045
I12
sg70046
VP19447
p86286
sg70048
I2
sa(dp86287
g70042
I25
sg70043
VFIR
p86288
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp86289
g70042
I43
sg70043
g86279
sg70045
I5
sg70046
VP32780
p86290
sg70048
I1
sasg70051
(lp86291
(dp86292
g70042
I55
sg70043
g86280
sg70045
I3
sg70054
VC0268136
p86293
sg70048
I1
sasa(dp86294
g70037
VTo investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD).
p86295
sg70039
(lp86296
sg70051
(lp86297
(dp86298
g70042
I243
sg70043
VAD
p86299
sg70045
I2
sg70054
VC0011615
p86300
sg70048
I1
sa(dp86301
g70042
I210
sg70043
Vpsoriasis
p86302
sg70045
I9
sg70054
VC0033860
p86303
sg70048
I1
sa(dp86304
g70042
I195
sg70043
Vskin diseases
p86305
sg70045
I13
sg70054
VC0037274
p86306
sg70048
I2
sa(dp86307
g70042
I224
sg70043
Vatopic dermatitis
p86308
sg70045
I17
sg70054
VC0011615
p86309
sg70048
I2
sasa(dp86310
g70037
VIL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis.
p86311
sg70039
(lp86312
sg70051
(lp86313
(dp86314
g70042
I132
sg70043
Vpsoriasis
p86315
sg70045
I9
sg70054
VC0033860
p86316
sg70048
I1
sasa(dp86317
g135
(dp86318
(VIL32 mRNA
p86319
Vskin diseases
p86320
tp86321
I01
ssg70037
VUsing skin samples from patients with mycosis fungoides (n = 21), healthy volunteers (n = 17), and individuals with atopic dermatitis (n = 17) and psoriasis (n = 9), we found IL32 mRNA expression significantly higher in mycosis fungoides samples than in samples from benign inflammatory skin diseases, and its expression increases with disease progression.
p86322
sg70039
(lp86323
(dp86324
g70042
I175
sg70043
g86319
sg70045
I9
sg70046
VP24001
p86325
sg70048
I2
sasg70051
(lp86326
(dp86327
g70042
I116
sg70043
Vatopic dermatitis
p86328
sg70045
I17
sg70054
VC0011615
p86329
sg70048
I2
sa(dp86330
g70042
I38
sg70043
Vmycosis fungoides
p86331
sg70045
I17
sg70054
VC0026948
p86332
sg70048
I2
sa(dp86333
g70042
I336
sg70043
Vdisease progression
p86334
sg70045
I19
sg70054
VC0242656
p86335
sg70048
I2
sa(dp86336
g70042
I147
sg70043
Vpsoriasis
p86337
sg70045
I9
sg70054
VC0033860
p86338
sg70048
I1
sa(dp86339
g70042
I38
sg70043
Vmycosis fungoides
p86340
sg70045
I17
sg70054
VC0026948
p86341
sg70048
I2
sa(dp86342
g70042
I287
sg70043
g86320
sg70045
I13
sg70054
VC0037274
p86343
sg70048
I2
sasa(dp86344
g70037
VImmunofluorescence staining demonstrated that IL-32 was expressed in AD lesional skin, whereas it was present in neither skin biopsy specimens from healthy donors nor in lesional skin from patients with psoriasis.
p86345
sg70039
(lp86346
sg70051
(lp86347
(dp86348
g70042
I203
sg70043
Vpsoriasis
p86349
sg70045
I9
sg70054
VC0033860
p86350
sg70048
I1
sasa(dp86351
g70037
VIn this study, the expression profile of ASPP2 in choriocarcinoma was examined in comparison with normal placentas and hydatidiform moles, the latter being a type of GTD that carries malignant potential.
p86352
sg70039
(lp86353
(dp86354
g70042
I41
sg70043
VASPP2
p86355
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp86356
(dp86357
g70042
I50
sg70043
Vchoriocarcinoma
p86358
sg70045
I15
sg70054
VC0008497
p86359
sg70048
I1
sa(dp86360
g70042
I119
sg70043
Vhydatidiform moles
p86361
sg70045
I18
sg70054
VC0020217
p86362
sg70048
I2
sasa(dp86363
g70037
VDownregulation of ASPP2 messenger RNA and protein was demonstrated in choriocarcinoma by quantitative PCR and immunohistochemistry.
p86364
sg70039
(lp86365
(dp86366
g70042
I18
sg70043
VASPP2 messenger RNA and protein
p86367
sg70045
I31
sg70046
g12
sg70048
I5
sasg70051
(lp86368
(dp86369
g70042
I70
sg70043
Vchoriocarcinoma
p86370
sg70045
I15
sg70054
VC0008497
p86371
sg70048
I1
sasa(dp86372
g135
(dp86373
(VTdT
p86374
Vchoriocarcinoma
p86375
tp86376
I00
ssg70037
VASPP2-transfected choriocarcinoma cells (JEG-3 and JAR) showed an increase in apoptosis and a decrease in cell migration as detected by TdT-mediated dUTP nick end labeling and wound healing assays, respectively, illustrating the complex action of ASPP2 on cell functions other than programmed cell death.
p86377
sg70039
(lp86378
(dp86379
g70042
I0
sg70043
VASPP2
p86380
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp86381
g70042
I0
sg70043
VASPP2
p86382
sg70045
I5
sg70046
g12
sg70048
I1
sa(dp86383
g70042
I136
sg70043
g86374
sg70045
I3
sg70046
VP04053
p86384
sg70048
I1
sasg70051
(lp86385
(dp86386
g70042
I18
sg70043
g86375
sg70045
I15
sg70054
VC0008497
p86387
sg70048
I1
sasa(dp86388
g70037
VTaken together, we demonstrated a loss of tumor-suppressive ASPP2 in choriocarcinoma with effects on cell migration and apoptosis.
p86389
sg70039
(lp86390
(dp86391
g70042
I60
sg70043
VASPP2
p86392
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp86393
(dp86394
g70042
I69
sg70043
Vchoriocarcinoma
p86395
sg70045
I15
sg70054
VC0008497
p86396
sg70048
I1
sa(dp86397
g70042
I42
sg70043
Vtumor
p86398
sg70045
I5
sg70054
VC0027651
p86399
sg70048
I1
sasa(dp86400
g135
(dp86401
(Valpha-ETK
p86402
VESRD
p86403
tp86404
I00
ssg70037
VNo correlation between erythrocyte TDP concentration and transketolase activity and/or alpha-ETK was observed in ESRD patients, either before or 10 h after administration.
p86405
sg70039
(lp86406
(dp86407
g70042
I57
sg70043
Vtransketolase
p86408
sg70045
I13
sg70046
VP29401
p86409
sg70048
I1
sa(dp86410
g70042
I87
sg70043
g86402
sg70045
I9
sg70046
VP51813
p86411
sg70048
I1
sasg70051
(lp86412
(dp86413
g70042
I113
sg70043
g86403
sg70045
I4
sg70054
VC0022661
p86414
sg70048
I1
sasa(dp86415
g135
(dp86416
(VSLPI
p86417
Vchondropathy
p86418
tp86419
I00
ssg70037
VScores for VEGF, TIMP-1, TIMP-3, SLPI and PAI-1 were all increased in OA compared with PM, and higher scores were associated with greater chondropathy.
p86420
sg70039
(lp86421
(dp86422
g70042
I42
sg70043
VPAI-1
p86423
sg70045
I5
sg70046
VP05121
p86424
sg70048
I1
sa(dp86425
g70042
I25
sg70043
VTIMP-3
p86426
sg70045
I6
sg70046
VP35625
p86427
sg70048
I1
sa(dp86428
g70042
I17
sg70043
VTIMP-1
p86429
sg70045
I6
sg70046
VP01033
p86430
sg70048
I1
sa(dp86431
g70042
I33
sg70043
g86417
sg70045
I4
sg70046
VP03973
p86432
sg70048
I1
sasg70051
(lp86433
(dp86434
g70042
I138
sg70043
g86418
sg70045
I12
sg70054
VC0007302
p86435
sg70048
I1
sasa(dp86436
g135
(dp86437
(VPAI-2
p86438
Vrheumatoid arthritis
p86439
tp86440
I00
ssg70037
VConcentrations of the plasminogen activators pro-urokinase, tissue plasminogen activator, plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), plasminogen, and fibrin split product D-dimer in synovial fluid (SF) and blood plasma of 29 patients with rheumatoid arthritis (RA) were compared with the concentrations of 18 patients with spondyloarthropathy (SpA).
p86441
sg70039
(lp86442
(dp86443
g70042
I132
sg70043
VPAI-1
p86444
sg70045
I5
sg70046
VP05121
p86445
sg70048
I1
sa(dp86446
g70042
I60
sg70043
Vtissue plasminogen activator
p86447
sg70045
I28
sg70046
VP00747
p86448
sg70048
I3
sa(dp86449
g70042
I22
sg70043
Vplasminogen
p86450
sg70045
I11
sg70046
VP00747
p86451
sg70048
I1
sa(dp86452
g70042
I22
sg70043
Vplasminogen activators pro-urokinase
p86453
sg70045
I36
sg70046
VP00747
p86454
sg70048
I3
sa(dp86455
g70042
I90
sg70043
Vplasminogen activator inhibitors 1 and 2
p86456
sg70045
I40
sg70046
VP00747
p86457
sg70048
I6
sa(dp86458
g70042
I167
sg70043
Vfibrin
p86459
sg70045
I6
sg70046
VP22087
p86460
sg70048
I1
sa(dp86461
g70042
I142
sg70043
g86438
sg70045
I5
sg70046
VP05120
p86462
sg70048
I1
sasg70051
(lp86463
(dp86464
g70042
I278
sg70043
VRA
p86465
sg70045
I2
sg70054
VC0003873
p86466
sg70048
I1
sa(dp86467
g70042
I361
sg70043
VSpA
p86468
sg70045
I3
sg70054
VC0949691
p86469
sg70048
I1
sa(dp86470
g70042
I340
sg70043
Vspondyloarthropathy
p86471
sg70045
I19
sg70054
VC0949691
p86472
sg70048
I1
sa(dp86473
g70042
I256
sg70043
g86439
sg70045
I20
sg70054
VC0003873
p86474
sg70048
I2
sasa(dp86475
g135
(dp86476
(VMPO
p86477
VAML
p86478
tp86479
I00
ssg70037
VBesides myeloperoxidase (MPO), which was used as the gold standard in differentiating AML from other type of ALs, the most specific markers for AML in our study were CD14 and CD64 (99.5 and 95.6%).
p86480
sg70039
(lp86481
(dp86482
g70042
I8
sg70043
Vmyeloperoxidase
p86483
sg70045
I15
sg70046
VP05164
p86484
sg70048
I1
sa(dp86485
g70042
I166
sg70043
VCD14
p86486
sg70045
I4
sg70046
VP08571
p86487
sg70048
I1
sa(dp86488
g70042
I25
sg70043
g86477
sg70045
I3
sg70046
VP05164
p86489
sg70048
I1
sasg70051
(lp86490
(dp86491
g70042
I86
sg70043
VAML
p86492
sg70045
I3
sg70054
VC0023467
p86493
sg70048
I1
sa(dp86494
g70042
I109
sg70043
VALs
p86495
sg70045
I3
sg70054
VC0002736
p86496
sg70048
I1
sa(dp86497
g70042
I86
sg70043
g86478
sg70045
I3
sg70054
VC0023467
p86498
sg70048
I1
sasa(dp86499
g135
(dp86500
(VMPO
p86501
Vhearing loss
p86502
tp86503
I00
ssg70037
VThey were characterized as follows: (1) disease onset with initial signs/symptoms due to intractable otitis media with effusion or granulation, which did not respond to ordinary treatments such as antibiotics and insertion of tympanic ventilation tubes, followed by progressive hearing loss; (2) predominantly female (73%) and older (median age: 68 years); (3) predominantly myeloperoxidase (MPO)-ANCA-positive (60%), followed by proteinase 3 (PR3)-ANCA-positive (19%) and both ANCAs-negative (16%); (4) frequently observed accompanying facial palsy (36%) and hypertrophic pachymeningitis (28%); and (5) disease often involving lung (35%) and kidney (26%) lesions.
p86504
sg70039
(lp86505
(dp86506
g70042
I430
sg70043
Vproteinase 3
p86507
sg70045
I12
sg70046
VP63123
p86508
sg70048
I2
sa(dp86509
g70042
I444
sg70043
VPR3
p86510
sg70045
I3
sg70046
VP63123
p86511
sg70048
I1
sa(dp86512
g70042
I375
sg70043
Vmyeloperoxidase
p86513
sg70045
I15
sg70046
VP05164
p86514
sg70048
I1
sa(dp86515
g70042
I392
sg70043
g86501
sg70045
I3
sg70046
VP05164
p86516
sg70048
I1
sasg70051
(lp86517
(dp86518
g70042
I537
sg70043
Vfacial palsy
p86519
sg70045
I12
sg70054
VC0015469
p86520
sg70048
I2
sa(dp86521
g70042
I101
sg70043
Votitis media with effusion
p86522
sg70045
I26
sg70054
VC0029883
p86523
sg70048
I4
sa(dp86524
g70042
I278
sg70043
g86502
sg70045
I12
sg70054
VC0011053
p86525
sg70048
I2
sa(dp86526
g70042
I560
sg70043
Vhypertrophic pachymeningitis
p86527
sg70045
I28
sg70054
VC0948402
p86528
sg70048
I2
sasa(dp86529
g70037
VEffects of zolpidem were wide ranging (eg, improvement on the JFK Coma Recovery Scale-Revised, the Unified Parkinson Disease Rating Scale, and the Burke-Fahn-Marsden Dystonia Rating Scale) and generally lasted 1 to 4 hours before the participant returned to baseline.
p86530
sg70039
(lp86531
sg70051
(lp86532
(dp86533
g70042
I66
sg70043
VComa
p86534
sg70045
I4
sg70054
VC0009421
p86535
sg70048
I1
sa(dp86536
g70042
I166
sg70043
VDystonia
p86537
sg70045
I8
sg70054
VC0393593
p86538
sg70048
I1
sa(dp86539
g70042
I107
sg70043
VParkinson Disease
p86540
sg70045
I17
sg70054
VC0030567
p86541
sg70048
I2
sasa(dp86542
g135
(dp86543
(VHSD3B2
p86544
Vendometriosis
p86545
tp86546
I01
ssg70037
VThe altered tissue steroid concentrations in endometriosis were in line with the expression of various steroidogenic enzymes in the lesions, of which HSD3B2 showed constantly high expression, whereas CYP11A1 expression was low.
p86547
sg70039
(lp86548
(dp86549
g70042
I200
sg70043
VCYP11A1
p86550
sg70045
I7
sg70046
VP05108
p86551
sg70048
I1
sa(dp86552
g70042
I150
sg70043
g86544
sg70045
I6
sg70046
VP26439
p86553
sg70048
I1
sasg70051
(lp86554
(dp86555
g70042
I45
sg70043
g86545
sg70045
I13
sg70054
VC0014175
p86556
sg70048
I1
sasa(dp86557
g135
(dp86558
(Vinsulin
p86559
Vautoimmune haemolytic anaemia
p86560
tp86561
I00
ssg70037
VType III groups together 10 autoimmune diseases (autoimmune thyroid disease, myasthenia and/or thymoma, Sjoegren's syndrome, pernicious anaemia, idiopathic thrombocytopaenic purpura, Addison's disease, insulin-dependent diabetes, vitiligo, autoimmune haemolytic anaemia, systemic lupus erythematosus) for which a genetic predisposition (phenotype HLA B8 and/or DR3 or DR5) seems to be an important factor.
p86562
sg70039
(lp86563
(dp86564
g70042
I202
sg70043
g86559
sg70045
I7
sg70046
VP01308
p86565
sg70048
I1
sasg70051
(lp86566
(dp86567
g70042
I49
sg70043
Vautoimmune thyroid disease
p86568
sg70045
I26
sg70054
VC0178468
p86569
sg70048
I3
sa(dp86570
g70042
I271
sg70043
Vsystemic lupus erythematosus
p86571
sg70045
I28
sg70054
VC0024141
p86572
sg70048
I3
sa(dp86573
g70042
I183
sg70043
VAddison's disease
p86574
sg70045
I17
sg70054
VC0001403
p86575
sg70048
I2
sa(dp86576
g70042
I202
sg70043
Vinsulin-dependent diabetes
p86577
sg70045
I26
sg70054
VC0011854
p86578
sg70048
I2
sa(dp86579
g70042
I230
sg70043
Vvitiligo
p86580
sg70045
I8
sg70054
VC0042900
p86581
sg70048
I1
sa(dp86582
g70042
I95
sg70043
Vthymoma
p86583
sg70045
I7
sg70054
VC0040100
p86584
sg70048
I1
sa(dp86585
g70042
I28
sg70043
Vautoimmune diseases
p86586
sg70045
I19
sg70054
VC0004364
p86587
sg70048
I2
sa(dp86588
g70042
I77
sg70043
Vmyasthenia
p86589
sg70045
I10
sg70054
VC0947912
p86590
sg70048
I1
sa(dp86591
g70042
I104
sg70043
VSjoegren's syndrome
p86592
sg70045
I19
sg70054
VC1527336
p86593
sg70048
I2
sa(dp86594
g70042
I156
sg70043
Vthrombocytopaenic purpura
p86595
sg70045
I25
sg70054
VC0857305
p86596
sg70048
I2
sa(dp86597
g70042
I125
sg70043
Vpernicious anaemia
p86598
sg70045
I18
sg70054
VC0002892
p86599
sg70048
I2
sa(dp86600
g70042
I240
sg70043
g86560
sg70045
I29
sg70054
VC0002880
p86601
sg70048
I3
sasa(dp86602
g70037
VA significant increase in the frequency of HLA DR5 antigen was observed in patients with ARC mainly in purpura thrombocytopenic patients.
p86603
sg70039
(lp86604
(dp86605
g70042
I43
sg70043
VHLA DR5 antigen
p86606
sg70045
I15
sg70046
VP30486
p86607
sg70048
I3
sasg70051
(lp86608
(dp86609
g70042
I103
sg70043
Vpurpura thrombocytopenic
p86610
sg70045
I24
sg70054
VC0857305
p86611
sg70048
I2
sa(dp86612
g70042
I89
sg70043
VARC
p86613
sg70045
I3
sg70054
VC0001857
p86614
sg70048
I1
sasa(dp86615
g70037
VGenome-wide pathway analysis with the dysregulated genes after overexpression of either of the two miRs in MCF-7 breast cancer cell identified the "Cancer"- and "Cell signaling"-related pathway as the top pathway for miR-204 and miR-211, respectively.
p86616
sg70039
(lp86617
(dp86618
g70042
I217
sg70043
VmiR-204
p86619
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86620
g70042
I229
sg70043
VmiR-211
p86621
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp86622
(dp86623
g70042
I148
sg70043
VCancer
p86624
sg70045
I6
sg70054
VC0006826
p86625
sg70048
I1
sa(dp86626
g70042
I113
sg70043
Vbreast cancer
p86627
sg70045
I13
sg70054
VC0678222
p86628
sg70048
I2
sasa(dp86629
g70037
VIn addition, a high association was observed between miR-204 and miR-211 expression in breast cancer tissue.
p86630
sg70039
(lp86631
(dp86632
g70042
I53
sg70043
VmiR-204
p86633
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86634
g70042
I65
sg70043
VmiR-211
p86635
sg70045
I7
sg70046
g12
sg70048
I1
sasg70051
(lp86636
(dp86637
g70042
I87
sg70043
Vbreast cancer
p86638
sg70045
I13
sg70054
VC0678222
p86639
sg70048
I2
sasa(dp86640
g70037
VTo shed light on their roles of miR-211 in breast cancer, the expression of miR-211 was examined by real-time RT-PCR in breast cancer and normal tissues.
p86641
sg70039
(lp86642
sg70051
(lp86643
(dp86644
g70042
I43
sg70043
Vbreast cancer
p86645
sg70045
I13
sg70054
VC0678222
p86646
sg70048
I2
sa(dp86647
g70042
I43
sg70043
Vbreast cancer
p86648
sg70045
I13
sg70054
VC0678222
p86649
sg70048
I2
sasa(dp86650
g70037
VMiR-211 is significantly downregulated in breast cancer.
p86651
sg70039
(lp86652
(dp86653
g70042
I0
sg70043
VMiR
p86654
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp86655
(dp86656
g70042
I42
sg70043
Vbreast cancer
p86657
sg70045
I13
sg70054
VC0678222
p86658
sg70048
I2
sasa(dp86659
g70037
VMiR-211 re-expression suppressed cell growth, cell cycle, migration, and invasion in triple-negative breast cancer (TNBC) cell line MDA-MB231.
p86660
sg70039
(lp86661
(dp86662
g70042
I0
sg70043
VMiR
p86663
sg70045
I3
sg70046
g12
sg70048
I1
sasg70051
(lp86664
(dp86665
g70042
I101
sg70043
Vbreast cancer
p86666
sg70045
I13
sg70054
VC0678222
p86667
sg70048
I2
sa(dp86668
g70042
I73
sg70043
Vinvasion
p86669
sg70045
I8
sg70054
VC2699153
p86670
sg70048
I1
sasa(dp86671
g70037
VThe expression and the functional role of several miRNAs (miR-206, miR-31, miR-27a/b, miR-21, miR-92a, miR-205, miR-125a/b, miR-10b, miR-155, miR-146a/b, miR-335, miR-204, miR-211, miR-7, miR-22, miR-126, and miR-17) in breast cancer has been identified.
p86672
sg70039
(lp86673
(dp86674
g70042
I94
sg70043
VmiR-92a
p86675
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86676
g70042
I124
sg70043
VmiR-10b
p86677
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86678
g70042
I103
sg70043
VmiR-205
p86679
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86680
g70042
I86
sg70043
VmiR-21
p86681
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp86682
g70042
I142
sg70043
VmiR-146a/b
p86683
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp86684
g70042
I58
sg70043
VmiR-206
p86685
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86686
g70042
I188
sg70043
VmiR-22
p86687
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp86688
g70042
I75
sg70043
VmiR-27a/b
p86689
sg70045
I9
sg70046
g12
sg70048
I1
sa(dp86690
g70042
I154
sg70043
VmiR-335
p86691
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86692
g70042
I172
sg70043
VmiR-211
p86693
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86694
g70042
I67
sg70043
VmiR-31
p86695
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp86696
g70042
I163
sg70043
VmiR-204
p86697
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86698
g70042
I112
sg70043
VmiR-125a/b
p86699
sg70045
I10
sg70046
g12
sg70048
I1
sa(dp86700
g70042
I209
sg70043
VmiR-17
p86701
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp86702
g70042
I133
sg70043
VmiR-155
p86703
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86704
g70042
I196
sg70043
VmiR-126
p86705
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86706
g70042
I181
sg70043
VmiR-7
p86707
sg70045
I5
sg70046
g12
sg70048
I1
sasg70051
(lp86708
(dp86709
g70042
I220
sg70043
Vbreast cancer
p86710
sg70045
I13
sg70054
VC0678222
p86711
sg70048
I2
sasa(dp86712
g70037
VQuantitative RT-PCR analysis confirmed that miR-135b, miR-192, miR-194 and miR-211 were significantly up-regulated in radiation-induced mammary cancer compared with spontaneous cancer and normal mammary tissue.
p86713
sg70039
(lp86714
(dp86715
g70042
I54
sg70043
VmiR-192
p86716
sg70045
I7
sg70046
g12
sg70048
I1
sa(dp86717
g70042
I44
sg70043
VmiR-135b
p86718
sg70045
I8
sg70046
g12
sg70048
I1
sasg70051
(lp86719
(dp86720
g70042
I144
sg70043
Vcancer
p86721
sg70045
I6
sg70054
VC0006826
p86722
sg70048
I1
sa(dp86723
g70042
I144
sg70043
Vcancer
p86724
sg70045
I6
sg70054
VC0006826
p86725
sg70048
I1
sasa(dp86726
g70037
VThe HBD/LD ratio in the measles patients two to three days after the onset of rash was significantly lower than that in control subjects (P less than 0.001).
p86727
sg70039
(lp86728
sg70051
(lp86729
(dp86730
g70042
I78
sg70043
Vrash
p86731
sg70045
I4
sg70054
VC0015230
p86732
sg70048
I1
sa(dp86733
g70042
I24
sg70043
Vmeasles
p86734
sg70045
I7
sg70054
VC0025007
p86735
sg70048
I1
sa(dp86736
g70042
I4
sg70043
VHBD
p86737
sg70045
I3
sg70054
VC1840321
p86738
sg70048
I1
sasa(dp86739
g135
(dp86740
(VIFN-Gamma
p86741
Vcorneal neovascularization
p86742
tp86743
I00
ssg70037
VUC treatment obviously reduced the expression levels of IL-2, IFN-Gamma, NF-KBp65, ICAM-1 and VEGF and increased inhibitory kappa B alpha (IKB-Alfa) expression in the grafts, where no obvious inflammatory cell infiltration or corneal neovascularization was found.
p86744
sg70039
(lp86745
(dp86746
g70042
I56
sg70043
VIL-2
p86747
sg70045
I4
sg70046
VP60568
p86748
sg70048
I1
sa(dp86749
g70042
I83
sg70043
VICAM-1
p86750
sg70045
I6
sg70046
VP05362
p86751
sg70048
I1
sa(dp86752
g70042
I139
sg70043
VIKB-Alfa
p86753
sg70045
I8
sg70046
VP25963
p86754
sg70048
I1
sa(dp86755
g70042
I62
sg70043
g86741
sg70045
I9
sg70046
VP01579
p86756
sg70048
I1
sasg70051
(lp86757
(dp86758
g70042
I192
sg70043
Vinflammatory cell infiltration
p86759
sg70045
I30
sg70054
VC0302158
p86760
sg70048
I3
sa(dp86761
g70042
I226
sg70043
g86742
sg70045
I26
sg70054
VC0085109
p86762
sg70048
I2
sasa(dp86763
g70037
VIn contrast, none of other patients with MFM had necklace CBs except for one patient with reducing body myopathy.
p86764
sg70039
(lp86765
sg70051
(lp86766
(dp86767
g70042
I104
sg70043
Vmyopathy
p86768
sg70045
I8
sg70054
VC0026848
p86769
sg70048
I1
sasa(dp86770
g70037
VAmong the serums assessed, MMA levels showed a positive correlation to TNSr and KNPQ in the IPD patients with peripheral neuropathy (TNSr r = 0.882, p &lt; 0.001, KNPQ r = 0.710, p = 0.004), while Vitamin B12 and homocysteine showed no statistically significant correlation.
p86771
sg70039
(lp86772
sg70051
(lp86773
(dp86774
g70042
I27
sg70043
VMMA
p86775
sg70045
I3
sg70054
VC0276096
p86776
sg70048
I1
sa(dp86777
g70042
I110
sg70043
Vperipheral neuropathy
p86778
sg70045
I21
sg70054
VC0031117
p86779
sg70048
I2
sasa(dp86780
g70037
VThe serum MMA positively correlated with the severity of neuropathic pain and this can be used as a useful marker in assessment of peripheral neuropathy in Parkinson's disease.
p86781
sg70039
(lp86782
sg70051
(lp86783
(dp86784
g70042
I10
sg70043
VMMA
p86785
sg70045
I3
sg70054
VC0276096
p86786
sg70048
I1
sa(dp86787
g70042
I131
sg70043
Vperipheral neuropathy
p86788
sg70045
I21
sg70054
VC0031117
p86789
sg70048
I2
sa(dp86790
g70042
I57
sg70043
Vneuropathic pain
p86791
sg70045
I16
sg70054
VC0027796
p86792
sg70048
I2
sa(dp86793
g70042
I156
sg70043
VParkinson's disease
p86794
sg70045
I19
sg70054
VC0030567
p86795
sg70048
I2
sasa(dp86796
g70037
VFunctional vitamin B12 deficiency, defined by elevated levels of the B12-dependent metabolites, methylmalonic acid (MMA), and/or homocysteine, despite normal B12 values, may cause neuropathy and is associated with disorders linked to increased oxidative stress.
p86797
sg70039
(lp86798
sg70051
(lp86799
(dp86800
g70042
I244
sg70043
Voxidative stress
p86801
sg70045
I16
sg70054
VC0242606
p86802
sg70048
I2
sa(dp86803
g70042
I11
sg70043
Vvitamin B12 deficiency
p86804
sg70045
I22
sg70054
VC0042847
p86805
sg70048
I3
sa(dp86806
g70042
I116
sg70043
VMMA
p86807
sg70045
I3
sg70054
VC0276096
p86808
sg70048
I1
sa(dp86809
g70042
I180
sg70043
Vneuropathy
p86810
sg70045
I10
sg70054
VC0442874
p86811
sg70048
I1
sa(dp86812
g70042
I96
sg70043
Vmethylmalonic acid
p86813
sg70045
I18
sg70054
VC0276096
p86814
sg70048
I2
sasa(dp86815
g135
(dp86816
(VGDF-9
p86817
Vchronic cholecystitis
p86818
tp86819
I00
ssg70037
VCDC6 and GDF-9 expressions in 108 gallbladder adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues were detected using immunohistochemistry (IHC).
p86820
sg70039
(lp86821
(dp86822
g70042
I0
sg70043
VCDC6
p86823
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp86824
g70042
I9
sg70043
g86817
sg70045
I5
sg70046
VP09466
p86825
sg70048
I1
sasg70051
(lp86826
(dp86827
g70042
I66
sg70043
Vgallbladder polyps
p86828
sg70045
I18
sg70054
VC0262493
p86829
sg70048
I2
sa(dp86830
g70042
I46
sg70043
Vadenocarcinomas
p86831
sg70045
I15
sg70054
VC0001418
p86832
sg70048
I1
sa(dp86833
g70042
I89
sg70043
g86818
sg70045
I21
sg70054
VC0085694
p86834
sg70048
I2
sasa(dp86835
g135
(dp86836
(VGDF-9
p86837
Vadenocarcinomas
p86838
tp86839
I01
ssg70037
VWe demonstrated that positive CDC6 and GDF-9 expressions were significantly higher in adenocarcinomas than that in peritumoral tissues, polyps, and chronic cholecystitis (p &lt; 0.01).
p86840
sg70039
(lp86841
(dp86842
g70042
I30
sg70043
VCDC6
p86843
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp86844
g70042
I39
sg70043
g86837
sg70045
I5
sg70046
VP09466
p86845
sg70048
I1
sasg70051
(lp86846
(dp86847
g70042
I148
sg70043
Vchronic cholecystitis
p86848
sg70045
I21
sg70054
VC0085694
p86849
sg70048
I2
sa(dp86850
g70042
I136
sg70043
Vpolyps
p86851
sg70045
I6
sg70054
VC0032584
p86852
sg70048
I1
sa(dp86853
g70042
I86
sg70043
g86838
sg70045
I15
sg70054
VC0001418
p86854
sg70048
I1
sasa(dp86855
g135
(dp86856
(VMFAP4
p86857
Vhepatitis C
p86858
tp86859
I00
ssg70037
VPreviously, we identified MFAP4 as a serum biomarker candidate for hepatic fibrosis and cirrhosis in hepatitis C patients.
p86860
sg70039
(lp86861
(dp86862
g70042
I26
sg70043
g86857
sg70045
I5
sg70046
VP55083
p86863
sg70048
I1
sasg70051
(lp86864
(dp86865
g70042
I67
sg70043
Vhepatic fibrosis
p86866
sg70045
I16
sg70054
VC0239946
p86867
sg70048
I2
sa(dp86868
g70042
I88
sg70043
Vcirrhosis
p86869
sg70045
I9
sg70054
VC0023890
p86870
sg70048
I1
sa(dp86871
g70042
I101
sg70043
g86858
sg70045
I11
sg70054
VC0019196
p86872
sg70048
I2
sasa(dp86873
g135
(dp86874
(VMFAP4
p86875
Vfibrosis
p86876
tp86877
I00
ssg70037
VThe aim of the present study was to elucidate the potential of MFAP4 as biomarker for hepatic fibrosis with a focus on the differentiation of no to moderate (F0-F2) and severe fibrosis stages and cirrhosis (F3 and F4, Desmet-Scheuer scoring system).
p86878
sg70039
(lp86879
(dp86880
g70042
I63
sg70043
g86875
sg70045
I5
sg70046
VP55083
p86881
sg70048
I1
sasg70051
(lp86882
(dp86883
g70042
I196
sg70043
Vcirrhosis
p86884
sg70045
I9
sg70054
VC0023890
p86885
sg70048
I1
sa(dp86886
g70042
I86
sg70043
Vhepatic fibrosis
p86887
sg70045
I16
sg70054
VC0239946
p86888
sg70048
I2
sa(dp86889
g70042
I94
sg70043
g86876
sg70045
I8
sg70054
VC0016059
p86890
sg70048
I1
sasa(dp86891
g70037
VLinear and logistic multivariate regression analyses were performed and nonparametric receiver operating characteristic-curves for cirrhosis were used to estimate cut-off points for pMFAP4.
p86892
sg70039
(lp86893
sg70051
(lp86894
(dp86895
g70042
I131
sg70043
Vcirrhosis
p86896
sg70045
I9
sg70054
VC0023890
p86897
sg70048
I1
sasa(dp86898
g135
(dp86899
(VMFAP4
p86900
Vhepatic cirrhosis
p86901
tp86902
I00
ssg70037
VMicrofibrillar-associated protein 4 (MFAP4) is a systemic biomarker that is significantly elevated in samples from patients suffering from hepatic cirrhosis.
p86903
sg70039
(lp86904
(dp86905
g70042
I0
sg70043
VMicrofibrillar-associated protein 4
p86906
sg70045
I35
sg70046
VP55083
p86907
sg70048
I3
sa(dp86908
g70042
I37
sg70043
g86900
sg70045
I5
sg70046
VP55083
p86909
sg70048
I1
sasg70051
(lp86910
(dp86911
g70042
I124
sg70043
Vsuffering
p86912
sg70045
I9
sg70054
VC0683278
p86913
sg70048
I1
sa(dp86914
g70042
I139
sg70043
g86901
sg70045
I17
sg70054
VC0023890
p86915
sg70048
I2
sasa(dp86916
g135
(dp86917
(VTropomyosin
p86918
Vhepatic cirrhosis
p86919
tp86920
I00
ssg70037
VTropomyosin and MFAP-4 demonstrated high serum levels in patients with hepatic cirrhosis of different causes.
p86921
sg70039
(lp86922
(dp86923
g70042
I0
sg70043
g86918
sg70045
I11
sg70046
VP07951
p86924
sg70048
I1
sasg70051
(lp86925
(dp86926
g70042
I71
sg70043
g86919
sg70045
I17
sg70054
VC0023890
p86927
sg70048
I2
sasa(dp86928
g70037
VA quantitative analysis of MFAP-4 serum levels in a large number of patients showed MFAP-4 as novel candidate biomarker with high diagnostic accuracy for prediction of nondiseased liver versus cirrhosis [area under receiver operating characteristic curve (AUC) = 0.97, P &lt; 0.0001] as well as stage 0 versus stage 4 fibrosis (AUC = 0.84, P &lt; 0.0001), and stages 0 to 3 versus stage 4 fibrosis (AUC = 0.76, P &lt; 0.0001).
p86929
sg70039
(lp86930
sg70051
(lp86931
(dp86932
g70042
I318
sg70043
Vfibrosis
p86933
sg70045
I8
sg70054
VC0016059
p86934
sg70048
I1
sa(dp86935
g70042
I318
sg70043
Vfibrosis
p86936
sg70045
I8
sg70054
VC0016059
p86937
sg70048
I1
sa(dp86938
g70042
I193
sg70043
Vcirrhosis
p86939
sg70045
I9
sg70054
VC0023890
p86940
sg70048
I1
sasa(dp86941
g135
(dp86942
(VCRF
p86943
Voverweight and obesity
p86944
tp86945
I00
ssg70037
VLow CRF had PARs of 9.3% and 10.5% for cancer mortality in subjects who had overweight and obesity, respectively.
p86946
sg70039
(lp86947
(dp86948
g70042
I4
sg70043
g86943
sg70045
I3
sg70046
VP06850
p86949
sg70048
I1
sasg70051
(lp86950
(dp86951
g70042
I4
sg70043
VCRF
p86952
sg70045
I3
sg70054
VC0022661
p86953
sg70048
I1
sa(dp86954
g70042
I39
sg70043
Vcancer
p86955
sg70045
I6
sg70054
VC0006826
p86956
sg70048
I1
sa(dp86957
g70042
I76
sg70043
g86944
sg70045
I22
sg70054
VC1561826
p86958
sg70048
I3
sasa(dp86959
g70037
VThe population attributable risks (PARs) were 0.41, 0.40 and 0.38 for total, CVD and cancer mortality, accordingly.
p86960
sg70039
(lp86961
sg70051
(lp86962
(dp86963
g70042
I85
sg70043
Vcancer
p86964
sg70045
I6
sg70054
VC0006826
p86965
sg70048
I1
sa(dp86966
g70042
I77
sg70043
VCVD
p86967
sg70045
I3
sg70054
VC0007222
p86968
sg70048
I1
sasa(dp86969
g70037
VMean EARs for lung cancer were 17.5 cases per 10,000 persons per year (PY) and 10.1 PY.
p86970
sg70039
(lp86971
sg70051
(lp86972
(dp86973
g70042
I14
sg70043
Vlung cancer
p86974
sg70045
I11
sg70054
VC0684249
p86975
sg70048
I2
sasa(dp86976
g70037
VMean EARs for breast cancer were 8.2 PY and 2.8 PY.
p86977
sg70039
(lp86978
sg70051
(lp86979
(dp86980
g70042
I14
sg70043
Vbreast cancer
p86981
sg70045
I13
sg70054
VC0678222
p86982
sg70048
I2
sasa(dp86983
g70037
VIn addition, through activation of G-protein-coupled protease activated receptors (PARs) TF induces cell signaling that is related to cancer, angiogenesis and inflammation.
p86984
sg70039
(lp86985
(dp86986
g70042
I83
sg70043
VPARs
p86987
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp86988
g70042
I35
sg70043
VG-protein-coupled protease activated receptors
p86989
sg70045
I46
sg70046
VP63123
p86990
sg70048
I4
sasg70051
(lp86991
(dp86992
g70042
I134
sg70043
Vcancer
p86993
sg70045
I6
sg70054
VC0006826
p86994
sg70048
I1
sa(dp86995
g70042
I159
sg70043
Vinflammation
p86996
sg70045
I12
sg70054
VC0021368
p86997
sg70048
I1
sasa(dp86998
g70037
VPARs are implicated in a wide range of diseases, such as cancer and inflammation.
p86999
sg70039
(lp87000
(dp87001
g70042
I0
sg70043
VPARs
p87002
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp87003
(dp87004
g70042
I57
sg70043
Vcancer
p87005
sg70045
I6
sg70054
VC0006826
p87006
sg70048
I1
sa(dp87007
g70042
I68
sg70043
Vinflammation
p87008
sg70045
I12
sg70054
VC0021368
p87009
sg70048
I1
sasa(dp87010
g135
(dp87011
(VThrombin
p87012
Vinflammation
p87013
tp87014
I00
ssg70037
VThrombin-induced activation of protease-activated receptors (PARs) represents a link between inflammation and cancer.
p87015
sg70039
(lp87016
(dp87017
g70042
I61
sg70043
VPARs
p87018
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp87019
g70042
I31
sg70043
Vprotease-activated receptors
p87020
sg70045
I28
sg70046
VP63123
p87021
sg70048
I2
sa(dp87022
g70042
I0
sg70043
g87012
sg70045
I8
sg70046
VP00734
p87023
sg70048
I1
sasg70051
(lp87024
(dp87025
g70042
I93
sg70043
g87013
sg70045
I12
sg70054
VC0021368
p87026
sg70048
I1
sa(dp87027
g70042
I110
sg70043
Vcancer
p87028
sg70045
I6
sg70054
VC0006826
p87029
sg70048
I1
sasa(dp87030
g135
(dp87031
(VAQP1
p87032
Vvaginalis
p87033
tp87034
I00
ssg70037
VFrozen tunica vaginalis specimens from patients with adult-onset primary hydrocele testis and control male nonhydrocele patients were subjected to Western blot analysis for the detection of AQP1 and AQP3 proteins.
p87035
sg70039
(lp87036
(dp87037
g70042
I190
sg70043
g87032
sg70045
I4
sg70046
VP29972
p87038
sg70048
I1
sa(dp87039
g70042
I199
sg70043
VAQP3 proteins
p87040
sg70045
I13
sg70046
g12
sg70048
I2
sasg70051
(lp87041
(dp87042
g70042
I73
sg70043
Vhydrocele testis
p87043
sg70045
I16
sg70054
VC1720771
p87044
sg70048
I2
sa(dp87045
g70042
I14
sg70043
g87033
sg70045
I9
sg70054
VC0750103
p87046
sg70048
I1
sasa(dp87047
g135
(dp87048
(VAQP1
p87049
Vhydrocele testis
p87050
tp87051
I00
ssg70037
VAQP1 protein expression in the tunica vaginalis was significantly higher in patients with adult-onset hydrocele testis than in the controls.
p87052
sg70039
(lp87053
(dp87054
g70042
I0
sg70043
g87049
sg70045
I4
sg70046
VP29972
p87055
sg70048
I1
sasg70051
(lp87056
(dp87057
g70042
I38
sg70043
Vvaginalis
p87058
sg70045
I9
sg70054
VC0750103
p87059
sg70048
I1
sa(dp87060
g70042
I102
sg70043
g87050
sg70045
I16
sg70054
VC1720771
p87061
sg70048
I2
sasa(dp87062
g135
(dp87063
(VAQP1
p87064
Vhydrocele
p87065
tp87066
I00
ssg70037
VThe densities of AQP1-expressing capillaries and lymphatic vessels were similar between the tunica vaginalis of the controls and those of hydrocele patients.
p87067
sg70039
(lp87068
(dp87069
g70042
I17
sg70043
g87064
sg70045
I4
sg70046
VP29972
p87070
sg70048
I1
sasg70051
(lp87071
(dp87072
g70042
I99
sg70043
Vvaginalis
p87073
sg70045
I9
sg70054
VC0750103
p87074
sg70048
I1
sa(dp87075
g70042
I138
sg70043
g87065
sg70045
I9
sg70054
VC1720771
p87076
sg70048
I1
sasa(dp87077
g135
(dp87078
(VAQP1 protein
p87079
Vvaginalis
p87080
tp87081
I00
ssg70037
VIn conclusion, overexpression of the AQP1 protein in individual capillary endothelial cells of the tunica vaginalis may contribute to the development of adult-onset primary noncommunicating hydrocele testis as another aquaporin-related disease.
p87082
sg70039
(lp87083
(dp87084
g70042
I218
sg70043
Vaquaporin
p87085
sg70045
I9
sg70046
VP30301
p87086
sg70048
I1
sa(dp87087
g70042
I37
sg70043
g87079
sg70045
I12
sg70046
VP29972
p87088
sg70048
I2
sasg70051
(lp87089
(dp87090
g70042
I190
sg70043
Vhydrocele testis
p87091
sg70045
I16
sg70054
VC1720771
p87092
sg70048
I2
sa(dp87093
g70042
I106
sg70043
g87080
sg70045
I9
sg70054
VC0750103
p87094
sg70048
I1
sasa(dp87095
g70037
VThere are very few reports in the published literature of abdominal aortic aneurysm in patient with situs inversus totalis, all of whom underwent open aneurysm repair.
p87096
sg70039
(lp87097
sg70051
(lp87098
(dp87099
g70042
I100
sg70043
Vsitus inversus
p87100
sg70045
I14
sg70054
VC0037221
p87101
sg70048
I2
sa(dp87102
g70042
I58
sg70043
Vabdominal aortic aneurysm
p87103
sg70045
I25
sg70054
VC0162871
p87104
sg70048
I3
sa(dp87105
g70042
I75
sg70043
Vaneurysm
p87106
sg70045
I8
sg70054
VC0002940
p87107
sg70048
I1
sasa(dp87108
g70037
VThe authors describe a case of successfully repaired abdominal aortic aneurysm with a false aneurysm of the right external iliac artery in situs inversus totalis.
p87109
sg70039
(lp87110
sg70051
(lp87111
(dp87112
g70042
I139
sg70043
Vsitus inversus
p87113
sg70045
I14
sg70054
VC0037221
p87114
sg70048
I2
sa(dp87115
g70042
I53
sg70043
Vabdominal aortic aneurysm
p87116
sg70045
I25
sg70054
VC0162871
p87117
sg70048
I3
sa(dp87118
g70042
I86
sg70043
Vfalse aneurysm
p87119
sg70045
I14
sg70054
VC1510412
p87120
sg70048
I2
sasa(dp87121
g70037
VThe surgical management of patients with abdominal aortic aneurysm in situs inversus totalis is discussed.
p87122
sg70039
(lp87123
sg70051
(lp87124
(dp87125
g70042
I41
sg70043
Vabdominal aortic aneurysm
p87126
sg70045
I25
sg70054
VC0162871
p87127
sg70048
I3
sa(dp87128
g70042
I70
sg70043
Vsitus inversus
p87129
sg70045
I14
sg70054
VC0037221
p87130
sg70048
I2
sasa(dp87131
g135
(dp87132
(VTGF-Beta
p87133
VMLNs
p87134
tp87135
I00
ssg70037
VCollectively, the MLN CD11b- CD103+ PD-L1High DC subset probably takes up luminal antigens in the intestine, migrates to MLNs, and highly induces regulatory T cells through TGF-Beta activation.
p87136
sg70039
(lp87137
(dp87138
g70042
I121
sg70043
VMLNs
p87139
sg70045
I4
sg70046
VP12872
p87140
sg70048
I1
sa(dp87141
g70042
I18
sg70043
VMLN CD11b- CD103+ PD-L1High
p87142
sg70045
I27
sg70046
VP12872
p87143
sg70048
I4
sa(dp87144
g70042
I173
sg70043
g87133
sg70045
I8
sg70046
VP18075
p87145
sg70048
I1
sasg70051
(lp87146
(dp87147
g70042
I121
sg70043
g87134
sg70045
I4
sg70054
VC0026691
p87148
sg70048
I1
sasa(dp87149
g135
(dp87150
(VCCR7
p87151
VDCs
p87152
tp87153
I00
ssg70037
VFurthermore, Ye were found exclusively associated with CD103(+) DCs in the MLNs from wild-type mice, but not from CCR7(-/-) mice, demonstrating a CCR7 dependent transport of Ye by CD103(+) DCs from LP to the MLNs.
p87154
sg70039
(lp87155
(dp87156
g70042
I55
sg70043
VCD103(+) DCs
p87157
sg70045
I12
sg70046
VP38570
p87158
sg70048
I2
sa(dp87159
g70042
I55
sg70043
VCD103(+) DCs
p87160
sg70045
I12
sg70046
VP38570
p87161
sg70048
I2
sa(dp87162
g70042
I114
sg70043
VCCR7
p87163
sg70045
I4
sg70046
VP32248
p87164
sg70048
I1
sa(dp87165
g70042
I114
sg70043
g87151
sg70045
I4
sg70046
VP32248
p87166
sg70048
I1
sasg70051
(lp87167
(dp87168
g70042
I75
sg70043
VMLNs
p87169
sg70045
I4
sg70054
VC0026691
p87170
sg70048
I1
sa(dp87171
g70042
I75
sg70043
VMLNs
p87172
sg70045
I4
sg70054
VC0026691
p87173
sg70048
I1
sa(dp87174
g70042
I64
sg70043
VDCs
p87175
sg70045
I3
sg70054
VC0268238
p87176
sg70048
I1
sa(dp87177
g70042
I64
sg70043
g87152
sg70045
I3
sg70054
VC0268238
p87178
sg70048
I1
sasa(dp87179
g70037
VAlthough extensive studies have demonstrated the importance of the mesenteric lymph nodes (MLNs) and intestinal CD103(+) dendritic cells (DCs) in driving small intestinal tolerance to protein antigen, the structural and immunological basis of colonic tolerance remain poorly understood.
p87180
sg70039
(lp87181
sg70051
(lp87182
(dp87183
g70042
I171
sg70043
Vtolerance
p87184
sg70045
I9
sg70054
VC0020963
p87185
sg70048
I1
sa(dp87186
g70042
I67
sg70043
Vmesenteric lymph nodes
p87187
sg70045
I22
sg70054
VC0026691
p87188
sg70048
I3
sa(dp87189
g70042
I138
sg70043
VDCs
p87190
sg70045
I3
sg70054
VC0268238
p87191
sg70048
I1
sa(dp87192
g70042
I91
sg70043
VMLNs
p87193
sg70045
I4
sg70054
VC0026691
p87194
sg70048
I1
sa(dp87195
g70042
I171
sg70043
Vtolerance
p87196
sg70045
I9
sg70054
VC0020963
p87197
sg70048
I1
sa(dp87198
g70042
I121
sg70043
Vdendritic cells
p87199
sg70045
I15
sg70054
VC0268238
p87200
sg70048
I2
sasa(dp87201
g135
(dp87202
(VCD103(+)CD11b(+) DCs
p87203
VMLNs
p87204
tp87205
I00
ssg70037
VDespite tolerance development, CD103(+)CD11b(+) DCs, which are the major migratory DC population in the MLNs, and the tolerance-related retinoic acid-generating enzyme RALDH2 were virtually absent from the ILNs.
p87206
sg70039
(lp87207
(dp87208
g70042
I168
sg70043
VRALDH2
p87209
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp87210
g70042
I31
sg70043
g87203
sg70045
I20
sg70046
VP38570
p87211
sg70048
I2
sasg70051
(lp87212
(dp87213
g70042
I8
sg70043
Vtolerance
p87214
sg70045
I9
sg70054
VC0020963
p87215
sg70048
I1
sa(dp87216
g70042
I48
sg70043
VDCs
p87217
sg70045
I3
sg70054
VC0268238
p87218
sg70048
I1
sa(dp87219
g70042
I8
sg70043
Vtolerance
p87220
sg70045
I9
sg70054
VC0020963
p87221
sg70048
I1
sa(dp87222
g70042
I104
sg70043
g87204
sg70045
I4
sg70054
VC0026691
p87223
sg70048
I1
sasa(dp87224
g135
(dp87225
(VCD103(+)CD11b(-)
p87226
Vdendritic cells
p87227
tp87228
I00
ssg70037
VHere, we demonstrate that GVHD markedly enhances alloantigen presentation within the mesenteric lymph nodes (mLNs), mediated by donor CD103(+)CD11b(-) dendritic cells (DCs) that migrate from the colon under the influence of CCR7.
p87229
sg70039
(lp87230
(dp87231
g70042
I224
sg70043
VCCR7
p87232
sg70045
I4
sg70046
VP32248
p87233
sg70048
I1
sa(dp87234
g70042
I134
sg70043
g87226
sg70045
I16
sg70046
VP38570
p87235
sg70048
I1
sasg70051
(lp87236
(dp87237
g70042
I85
sg70043
Vmesenteric lymph nodes
p87238
sg70045
I22
sg70054
VC0026691
p87239
sg70048
I3
sa(dp87240
g70042
I168
sg70043
VDCs
p87241
sg70045
I3
sg70054
VC0268238
p87242
sg70048
I1
sa(dp87243
g70042
I26
sg70043
VGVHD
p87244
sg70045
I4
sg70054
VC0018133
p87245
sg70048
I1
sa(dp87246
g70042
I109
sg70043
VmLNs
p87247
sg70045
I4
sg70054
VC0026691
p87248
sg70048
I1
sa(dp87249
g70042
I151
sg70043
g87227
sg70045
I15
sg70054
VC0268238
p87250
sg70048
I2
sasa(dp87251
g135
(dp87252
(VCD103
p87253
Vdendritic cells
p87254
tp87255
I00
ssg70037
VCD103(+) dendritic cells (DCs) continuously migrate from the intestine to the mesenteric lymph nodes (MLNs) and maintain tolerance by driving the development of regulatory T cells (Treg) in the gut.
p87256
sg70039
(lp87257
(dp87258
g70042
I0
sg70043
g87253
sg70045
I5
sg70046
VP38570
p87259
sg70048
I1
sasg70051
(lp87260
(dp87261
g70042
I26
sg70043
VDCs
p87262
sg70045
I3
sg70054
VC0268238
p87263
sg70048
I1
sa(dp87264
g70042
I78
sg70043
Vmesenteric lymph nodes
p87265
sg70045
I22
sg70054
VC0026691
p87266
sg70048
I3
sa(dp87267
g70042
I121
sg70043
Vtolerance
p87268
sg70045
I9
sg70054
VC0020963
p87269
sg70048
I1
sa(dp87270
g70042
I102
sg70043
VMLNs
p87271
sg70045
I4
sg70054
VC0026691
p87272
sg70048
I1
sa(dp87273
g70042
I9
sg70043
g87254
sg70045
I15
sg70054
VC0268238
p87274
sg70048
I2
sasa(dp87275
g135
(dp87276
(VCD103(+)CD11c
p87277
VMLNs
p87278
tp87279
I00
ssg70037
VTreatment with PBS followed by 1 single dose of VSL#3, 18 h before killing, was associated with a 2-fold increase in CD103(+)CD11c(+) dendritic cells in MLNs and PPs.
p87280
sg70039
(lp87281
(dp87282
g70042
I117
sg70043
g87277
sg70045
I13
sg70046
VP38570
p87283
sg70048
I1
sasg70051
(lp87284
(dp87285
g70042
I162
sg70043
VPPs
p87286
sg70045
I3
sg70054
VC0265259
p87287
sg70048
I1
sa(dp87288
g70042
I15
sg70043
VPBS
p87289
sg70045
I3
sg70054
VC1720830
p87290
sg70048
I1
sa(dp87291
g70042
I153
sg70043
g87278
sg70045
I4
sg70054
VC0026691
p87292
sg70048
I1
sasa(dp87293
g135
(dp87294
(VCD103
p87295
Vmesenteric lymph nodes
p87296
tp87297
I00
ssg70037
VReduced numbers of Th17 cells, suppressed interleukin (IL)-6 production by intestinal explants, and increased Tregs and CD103-positive regulatory dendritic cells in mesenteric lymph nodes (MLNs) were observed.
p87298
sg70039
(lp87299
(dp87300
g70042
I42
sg70043
Vinterleukin (IL)-6
p87301
sg70045
I18
sg70046
VP60568
p87302
sg70048
I2
sa(dp87303
g70042
I120
sg70043
g87295
sg70045
I5
sg70046
VP38570
p87304
sg70048
I1
sasg70051
(lp87305
(dp87306
g70042
I189
sg70043
VMLNs
p87307
sg70045
I4
sg70054
VC0026691
p87308
sg70048
I1
sa(dp87309
g70042
I165
sg70043
g87296
sg70045
I22
sg70054
VC0026691
p87310
sg70048
I3
sasa(dp87311
g135
(dp87312
(VCD103
p87313
VMLNs
p87314
tp87315
I00
ssg70037
VThus, oral administration of C. kefyr ameliorated EAE by altering the microflora, accompanied by increased Tregs and CD103-positive regulatory dendritic cells in MLNs and decreased Th17 cells in the intestinal lamina propria.
p87316
sg70039
(lp87317
(dp87318
g70042
I117
sg70043
g87313
sg70045
I5
sg70046
VP38570
p87319
sg70048
I1
sasg70051
(lp87320
(dp87321
g70042
I162
sg70043
g87314
sg70045
I4
sg70054
VC0026691
p87322
sg70048
I1
sasa(dp87323
g135
(dp87324
(VCD103 DCs
p87325
VMLNs
p87326
tp87327
I00
ssg70037
VThe proportion of CD103 DCs in PPs and MLNs and IL-10-expressing CD4 T cells of PPs and the LP increased after indomethacin treatment.
p87328
sg70039
(lp87329
(dp87330
g70042
I31
sg70043
VPPs
p87331
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp87332
g70042
I31
sg70043
VPPs
p87333
sg70045
I3
sg70046
g12
sg70048
I1
sa(dp87334
g70042
I48
sg70043
VIL-10-expressing CD4 T
p87335
sg70045
I22
sg70046
VP01730
p87336
sg70048
I3
sa(dp87337
g70042
I39
sg70043
VMLNs
p87338
sg70045
I4
sg70046
VP12872
p87339
sg70048
I1
sa(dp87340
g70042
I18
sg70043
g87325
sg70045
I9
sg70046
VP38570
p87341
sg70048
I2
sasg70051
(lp87342
(dp87343
g70042
I31
sg70043
VPPs
p87344
sg70045
I3
sg70054
VC0265259
p87345
sg70048
I1
sa(dp87346
g70042
I24
sg70043
VDCs
p87347
sg70045
I3
sg70054
VC0268238
p87348
sg70048
I1
sa(dp87349
g70042
I31
sg70043
VPPs
p87350
sg70045
I3
sg70054
VC0265259
p87351
sg70048
I1
sa(dp87352
g70042
I39
sg70043
g87326
sg70045
I4
sg70054
VC0026691
p87353
sg70048
I1
sasa(dp87354
g135
(dp87355
(VIL-10-expressing CD4 T
p87356
VDCs
p87357
tp87358
I00
ssg70037
VThe PP-null mice showed greater indomethacin-induced enteropathy, fewer CD103 DCs in their MLNs, and lower proportion of IL-10-expressing CD4 T cells of their LP than WT mice, regardless of commensal bacteria.
p87359
sg70039
(lp87360
(dp87361
g70042
I72
sg70043
VCD103 DCs
p87362
sg70045
I9
sg70046
VP38570
p87363
sg70048
I2
sa(dp87364
g70042
I121
sg70043
g87356
sg70045
I22
sg70046
VP01730
p87365
sg70048
I3
sasg70051
(lp87366
(dp87367
g70042
I53
sg70043
Venteropathy
p87368
sg70045
I11
sg70054
VC0021831
p87369
sg70048
I1
sa(dp87370
g70042
I91
sg70043
VMLNs
p87371
sg70045
I4
sg70054
VC0026691
p87372
sg70048
I1
sa(dp87373
g70042
I78
sg70043
g87357
sg70045
I3
sg70054
VC0268238
p87374
sg70048
I1
sasa(dp87375
g135
(dp87376
(VCD103 DCs
p87377
VDCs
p87378
tp87379
I00
ssg70037
VNaive splenic CD4 T cells co-cultured with CD103 DCs isolated from the MLNs of indomethacin-injected WT mice produced a higher amount of IL-10 compared with those co-cultured with CD103 DCs.
p87380
sg70039
(lp87381
(dp87382
g70042
I14
sg70043
VCD4
p87383
sg70045
I3
sg70046
VP01730
p87384
sg70048
I1
sa(dp87385
g70042
I43
sg70043
VCD103 DCs
p87386
sg70045
I9
sg70046
VP38570
p87387
sg70048
I2
sa(dp87388
g70042
I43
sg70043
g87377
sg70045
I9
sg70046
VP38570
p87389
sg70048
I2
sasg70051
(lp87390
(dp87391
g70042
I71
sg70043
VMLNs
p87392
sg70045
I4
sg70054
VC0026691
p87393
sg70048
I1
sa(dp87394
g70042
I49
sg70043
VDCs
p87395
sg70045
I3
sg70054
VC0268238
p87396
sg70048
I1
sa(dp87397
g70042
I49
sg70043
g87378
sg70045
I3
sg70054
VC0268238
p87398
sg70048
I1
sasa(dp87399
g135
(dp87400
(VPTH
p87401
Vrickets
p87402
tp87403
I00
ssg70037
VIn rickets, on the other hand, no PTH/PTHrP receptor gene expression was observed in the growth plate from day 8 of a vitamin D-deficient diet.
p87404
sg70039
(lp87405
(dp87406
g70042
I38
sg70043
VPTHrP receptor gene
p87407
sg70045
I19
sg70046
VP12272
p87408
sg70048
I3
sa(dp87409
g70042
I34
sg70043
g87401
sg70045
I3
sg70046
VP01270
p87410
sg70048
I1
sasg70051
(lp87411
(dp87412
g70042
I3
sg70043
g87402
sg70045
I7
sg70054
VC0035579
p87413
sg70048
I1
sasa(dp87414
g135
(dp87415
(VPTH
p87416
Vrickets
p87417
tp87418
I00
ssg70037
VThese results suggest that alterations in the PTH/PTHrP receptor gene expression are associated with rickets but not with TD.
p87419
sg70039
(lp87420
(dp87421
g70042
I50
sg70043
VPTHrP receptor gene
p87422
sg70045
I19
sg70046
VP12272
p87423
sg70048
I3
sa(dp87424
g70042
I46
sg70043
g87416
sg70045
I3
sg70046
VP01270
p87425
sg70048
I1
sasg70051
(lp87426
(dp87427
g70042
I101
sg70043
g87417
sg70045
I7
sg70054
VC0035579
p87428
sg70048
I1
sasa(dp87429
g135
(dp87430
(VPTH
p87431
Vrickets
p87432
tp87433
I00
ssg70037
VThe reduction in the PTH/PTHrP receptor gene expression in rickets may be due to the high plasma levels of PTH.
p87434
sg70039
(lp87435
(dp87436
g70042
I21
sg70043
VPTH
p87437
sg70045
I3
sg70046
VP01270
p87438
sg70048
I1
sa(dp87439
g70042
I25
sg70043
VPTHrP receptor gene
p87440
sg70045
I19
sg70046
VP12272
p87441
sg70048
I3
sa(dp87442
g70042
I21
sg70043
g87431
sg70045
I3
sg70046
VP01270
p87443
sg70048
I1
sasg70051
(lp87444
(dp87445
g70042
I59
sg70043
g87432
sg70045
I7
sg70054
VC0035579
p87446
sg70048
I1
sasa(dp87447
g70037
VWhat is more important is that the depressed-expression of Cav1.3 paralleled with enhanced-expression of Snapin was documented in atrial samples from atrial fibrillation (AF) patients.
p87448
sg70039
(lp87449
(dp87450
g70042
I105
sg70043
VSnapin
p87451
sg70045
I6
sg70046
g12
sg70048
I1
sa(dp87452
g70042
I59
sg70043
VCav1.3
p87453
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp87454
(dp87455
g70042
I171
sg70043
VAF
p87456
sg70045
I2
sg70054
VC0004238
p87457
sg70048
I1
sa(dp87458
g70042
I150
sg70043
Vatrial fibrillation
p87459
sg70045
I19
sg70054
VC0004238
p87460
sg70048
I2
sasa(dp87461
g70037
VFurthermore, inactivation of Cav1.3 channels promotes also atrial fibrillation and flutter in knockout mice suggesting that these channels can play a role in stabilizing atrial rhythm.
p87462
sg70039
(lp87463
(dp87464
g70042
I29
sg70043
VCav1.3 channels
p87465
sg70045
I15
sg70046
g12
sg70048
I2
sasg70051
(lp87466
(dp87467
g70042
I59
sg70043
Vatrial fibrillation and flutter
p87468
sg70045
I31
sg70054
VC0155709
p87469
sg70048
I4
sa(dp87470
g70042
I13
sg70043
Vinactivation
p87471
sg70045
I12
sg70054
VC0544461
p87472
sg70048
I1
sasa(dp87473
g70037
VThe significance of the tissue-specific expression of the channel is underpinned by our previous demonstration of atrial fibrillation in a Cav1.3 null mutant mouse model.
p87474
sg70039
(lp87475
(dp87476
g70042
I139
sg70043
VCav1.3
p87477
sg70045
I6
sg70046
g12
sg70048
I1
sasg70051
(lp87478
(dp87479
g70042
I151
sg70043
Vmutant
p87480
sg70045
I6
sg70054
VC0596988
p87481
sg70048
I1
sa(dp87482
g70042
I114
sg70043
Vatrial fibrillation
p87483
sg70045
I19
sg70054
VC0004238
p87484
sg70048
I2
sasa(dp87485
g70037
VMRS studies (MRI 1.5 T unit) were performed in 49 patients with schizophrenia (30 with auditory hallucinations and 19 without auditory hallucinations) and 37 controls.
p87486
sg70039
(lp87487
sg70051
(lp87488
(dp87489
g70042
I87
sg70043
Vauditory hallucinations
p87490
sg70045
I23
sg70054
VC0233762
p87491
sg70048
I2
sa(dp87492
g70042
I64
sg70043
Vschizophrenia
p87493
sg70045
I13
sg70054
VC0036341
p87494
sg70048
I1
sa(dp87495
g70042
I87
sg70043
Vauditory hallucinations
p87496
sg70045
I23
sg70054
VC0233762
p87497
sg70048
I2
sa(dp87498
g70042
I0
sg70043
VMRS
p87499
sg70045
I3
sg70054
VC0025235
p87500
sg70048
I1
sasa(dp87501
g135
(dp87502
(VOPN
p87503
VRD
p87504
tp87505
I00
ssg70037
VAs a first step towards understanding the role of OPN in retinal degeneration (RD), we examined changes in OPN expression in a mouse model of RD induced by exposure to a blue light-emitting diode (LED).
p87506
sg70039
(lp87507
(dp87508
g70042
I50
sg70043
g87503
sg70045
I3
sg70046
VP10451
p87509
sg70048
I1
sasg70051
(lp87510
(dp87511
g70042
I57
sg70043
Vretinal degeneration
p87512
sg70045
I20
sg70054
VC0035304
p87513
sg70048
I2
sa(dp87514
g70042
I79
sg70043
VRD
p87515
sg70045
I2
sg70054
VC0035304
p87516
sg70048
I1
sa(dp87517
g70042
I79
sg70043
g87504
sg70045
I2
sg70054
VC0035304
p87518
sg70048
I1
sasa(dp87519
g135
(dp87520
(Vosteopontin
p87521
Vretinal disease
p87522
tp87523
I00
ssg70037
VSimilarly, those who had retinal disease had higher osteopontin concentrations than those without (16.8+/-2 vs. 12.4+/-3 mg/L; p=0.005).
p87524
sg70039
(lp87525
(dp87526
g70042
I52
sg70043
g87521
sg70045
I11
sg70046
VP10451
p87527
sg70048
I1
sasg70051
(lp87528
(dp87529
g70042
I25
sg70043
g87522
sg70045
I15
sg70054
VC0035309
p87530
sg70048
I2
sasa(dp87531
g135
(dp87532
(VOPN
p87533
VPDR
p87534
tp87535
I00
ssg70037
VWe investigated the expression of S100A4 and correlated it with clinical disease activity as well as with the levels of osteopontin (OPN), soluble syndecan-1, and vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy (PDR).
p87536
sg70039
(lp87537
(dp87538
g70042
I199
sg70043
VVEGF
p87539
sg70045
I4
sg70046
g12
sg70048
I1
sa(dp87540
g70042
I34
sg70043
VS100A4
p87541
sg70045
I6
sg70046
VP26447
p87542
sg70048
I1
sa(dp87543
g70042
I163
sg70043
Vvascular endothelial growth factor
p87544
sg70045
I34
sg70046
g12
sg70048
I4
sa(dp87545
g70042
I120
sg70043
Vosteopontin
p87546
sg70045
I11
sg70046
VP10451
p87547
sg70048
I1
sa(dp87548
g70042
I147
sg70043
Vsyndecan-1
p87549
sg70045
I10
sg70046
VP18827
p87550
sg70048
I1
sa(dp87551
g70042
I133
sg70043
g87533
sg70045
I3
sg70046
VP10451
p87552
sg70048
I1
sasg70051
(lp87553
(dp87554
g70042
I208
sg70043
Vproliferative diabetic retinopathy
p87555
sg70045
I34
sg70054
VC0154830
p87556
sg70048
I3
sa(dp87557
g70042
I244
sg70043
g87534
sg70045
I3
sg70054
VC0154830
p87558
sg70048
I1
sasa(dp87559
g70037
VRecent studies show overexpressed ENAH in several cancer types, and ENAH correlates with tumor invasiveness.
p87560
sg70039
(lp87561
(dp87562
g70042
I34
sg70043
VENAH
p87563
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp87564
(dp87565
g70042
I50
sg70043
Vcancer
p87566
sg70045
I6
sg70054
VC0006826
p87567
sg70048
I1
sa(dp87568
g70042
I89
sg70043
Vtumor
p87569
sg70045
I5
sg70054
VC0027651
p87570
sg70048
I1
sasa(dp87571
g70037
VThis study aimed to investigate the expression and function of ENAH in primary gastric adenocarcinoma, and its prognostic significance.
p87572
sg70039
(lp87573
(dp87574
g70042
I63
sg70043
VENAH
p87575
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp87576
(dp87577
g70042
I79
sg70043
Vgastric adenocarcinoma
p87578
sg70045
I22
sg70054
VC0278701
p87579
sg70048
I2
sasa(dp87580
g70037
VWe found significantly increased mRNA (P = 0.0283) and protein (P = 0.0301) expression of ENAH in gastric cancer tissues.
p87581
sg70039
(lp87582
(dp87583
g70042
I90
sg70043
VENAH
p87584
sg70045
I4
sg70046
g12
sg70048
I1
sasg70051
(lp87585
(dp87586
g70042
I98
sg70043
Vgastric cancer
p87587
sg70045
I14
sg70054
VC0024623
p87588
sg70048
I2
sasa.